FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Tripathi, A
   Awasthi, P
   Rawat, KS
   Dwivedi, AP
   Singh, KB
   Sharma, K
   Prakash, R
   Singh, D
   Goel, A
AF Tripathi, Alok
   Awasthi, Pallavi
   Rawat, Kundan Singh
   Dwivedi, Atma P.
   Singh, Krishna Bhan
   Sharma, Kriti
   Prakash, Ravi
   Singh, Divya
   Goel, Atul
TI 3 PEP promotes bone regeneration by up regulating BCL 2 expression via
   ERK phosphorylation
SO JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
DE pterocarpan; bone regeneration; apoptosis; osteoporosis; PTH; ERK; BCL 2
ID POSTMENOPAUSAL WOMEN; PARATHYROID HORMONE; APOPTOSIS; CELLS;
   DIFFERENTIATION; OSTEOPOROSIS; RALOXIFENE; FRACTURES; KINASE; DEATH
AB Bone healing and regeneration is a complex process that recapitulates embryonic skeletal development and is delayed in diseases like osteoporosis. Bone healing therapies like recombinant bone morphogenetic 2 protein (rhBMP 2) and parathyroid hormone (PTH), an approved bone anabolic therapy reduces fracture risks but are fraught with high cost and several side effects. Thus, there is an unmet need for cost effective bone healing agents. In this study, we have synthesized 3 piperidinylethoxypterocarpan (3 PEP) which is a hybrid of bone supplement ipriflavone and anti resorptive drug raloxifene and evaluated its bone regeneration and healing potential. Prior to studies in animal models, the potency of 3 PEP was confirmed in calvarial osteoblast cells. Bromodeoxy uridine cell proliferation and cell viability assay revealed that 3 PEP at 100 pM concentration increased the proliferation and survival of osteoblasts simultaneously inhibiting the apoptosis by involving activation of BCL 2 by phosphorylation at Ser70 site through MEK ERK pathway. In vivo studies were conducted in estrogen deficient ovariectomized Balb/c mice and drill hole injury was generated in the mid diaphysis of the femur in all the animals. Treatment with 3 PEP commenced the next day onward and terminated at 7 and 15 days. Micro CT analysis and calcein labeling of newly generated bone at the drill hole injury site showed that 3 PEP promotes bone healing and new bone formation at a dose of 5 mg/kg at the injury site. These data were also corroborated in non ovariectomized Balb/c mice cortical defect model. Owing to the side effects associated with rhBMP 2 and PTH, along with the expenses involved, our study proposes an alternative therapeutic option for bone healing.
C1 [Tripathi, Alok; Singh, Krishna Bhan; Sharma, Kriti; Prakash, Ravi; Singh, Divya] CSIR Cent Drug Res Inst, Div Endocrinol, Lucknow 226031, India.
   [Tripathi, Alok; Awasthi, Pallavi; Rawat, Kundan Singh; Singh, Krishna Bhan; Sharma, Kriti; Singh, Divya; Goel, Atul] Acad Sci & Innovat Res AcSIR, Ghaziabad 201002, India.
   [Awasthi, Pallavi; Rawat, Kundan Singh; Dwivedi, Atma P.; Goel, Atul] CSIR Cent Drug Res Inst, Div Med & Proc Chem, Lucknow 226031, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); Academy of Scientific &
   Innovative Research (AcSIR); Council of Scientific & Industrial Research
   (CSIR)   India; CSIR   Central Drug Research Institute (CDRI)
RP Singh, D (通讯作者)，CSIR Cent Drug Res Inst, Div Endocrinol, Lucknow 226031, India.; Singh, D; Goel, A (通讯作者)，Acad Sci & Innovat Res AcSIR, Ghaziabad 201002, India.; Goel, A (通讯作者)，CSIR Cent Drug Res Inst, Div Med & Proc Chem, Lucknow 226031, India.
EM divya_singh@cdri.res.in; atul_goel@cdri.res.in
RI Prakash, Ravi/JYP 0200 2024; Rawat, Kundan Singh/KAL 8126 2024; Singh,
   Divya/IUM 7944 2023; Awasthi, Pallavi/NZO 0914 2025; SINGH,
   KRISHNA/C 2659 2019
OI Goel, Atul/0000 0003 2758 2461; 
FU Council of Scientific and Industrial Research, New Delhi; Department of
   Science and Technology, New Delhi [FBR MLP 2028]; Indian Council of
   Medical Research [GAP303]; CSIR Council of Scientific and Industrial
   Research; University Grants Commission; Department of Science and
   Technology, New Delhi
FX This study was funded by the Council of Scientific and Industrial
   Research, New Delhi, under project FBR MLP 2028 and Department of
   Science and Technology, New Delhi, under the project GAP303. The authors
   are thankful for the fellowship grants from Indian Council of Medical
   Research (A T and K B S), CSIR Council of Scientific and Industrial
   Research (P A), University Grants Commission (K S R, and R P), and
   Department of Science and Technology (K S), New Delhi.
CR Adhikary S, 2017, MENOPAUSE, V24, P686, DOI 10.1097/GME.0000000000000809
   Bhargavan B, 2009, J CELL BIOCHEM, V108, P388, DOI 10.1002/jcb.22264
   Boyce B.F., 2002, Principles of Bone Biology, VSecond, p151
   Cheng CY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155748
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cook SJ, 2017, FEBS J, V284, P4177, DOI 10.1111/febs.14122
   Endo I, 2008, BONE, V42, P1235, DOI 10.1016/j.bone.2008.02.014
   Fang JK, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1419 2
   Goel AK., 2014, U.S. Patent, Patent No. [8,686,028, 8686028]
   Head K A, 1999, Altern Med Rev, V4, P10
   Heringa M, 2003, INT J CLIN PHARM TH, V41, P331
   Kannan S, 2020, BIOL OPEN, V9, DOI 10.1242/bio.053280
   Levenson AS, 1998, CANCER RES, V58, P1872
   LIAN JB, 1992, CRIT REV ORAL BIOL M, V3, P269, DOI 10.1177/10454411920030030501
   Liang QH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033126
   Liu LJ, 2013, INT J ENDOCRINOL, V2013, DOI 10.1155/2013/786574
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Oryan A, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/1749 799X 9 18
   Pal S, 2019, BONE, V123, P28, DOI 10.1016/j.bone.2019.03.010
   Pandey R, 2010, MENOPAUSE, V17, P602, DOI 10.1097/gme.0b013e3181d0f7f0
   Ponnapakkam T, 2014, DRUG DISCOV TODAY, V19, P204, DOI 10.1016/j.drudis.2013.07.015
   Prakash R, 2021, CALCIFIED TISSUE INT, V109, P32, DOI 10.1007/s00223 021 00818 3
   Raghuvanshi A, 2017, MOL CELL ENDOCRINOL, V448, P41, DOI 10.1016/j.mce.2017.03.010
   Roberts RA, 2014, DRUG DISCOV TODAY, V19, P341, DOI 10.1016/j.drudis.2013.11.014
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Su PH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082343
   Subramanian M, 2007, J IMMUNOL, V179, P2330, DOI 10.4049/jimmunol.179.4.2330
   Sutherland MK, 2004, BONE, V35, P828, DOI 10.1016/j.bone.2004.05.023
   Tai CJ, 2013, ANN DIAGN PATHOL, V17, P165, DOI 10.1016/j.anndiagpath.2012.09.004
   Tasyriq M, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/765316
   Tyagi AM, 2010, MOL CELL ENDOCRINOL, V325, P101, DOI 10.1016/j.mce.2010.05.016
   Weinstein RS, 2000, AM J MED, V108, P153, DOI 10.1016/S0002 9343(99)00420 9
   Zara JN, 2011, TISSUE ENG PT A, V17, P1389, DOI [10.1089/ten.TEA.2010.0555, 10.1089/ten.tea.2010.0555]
   Zhang LY, 2011, BRAZ J MED BIOL RES, V44, P618, DOI 10.1590/S0100 879X2011007500078
   Zhou MJ, 2017, ONCOL REP, V38, P1742, DOI 10.3892/or.2017.5830
NR 39
TC 1
Z9 1
U1 0
U2 6
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA STARLING HOUSE, 1600 BRISTOL PARKWAY N, BRISTOL, ENGLAND
SN 0022 0795
EI 1479 6805
J9 J ENDOCRINOL
JI J. Endocrinol.
PD JUL 1
PY 2022
VL 254
IS 1
BP 51
EP 64
DI 10.1530/JOE 21 0439
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 6I4CB
UT WOS:000886073900005
PM 35702893
OA Bronze
DA 2025 08 17
ER

PT J
AU Khanka, S
   Somani, C
   Sharma, K
   Sharma, S
   Kumar, A
   Chattopadhyay, N
   Kanojiya, SK
   Yadav, DK
   Singh, D
AF Khanka, Sonu
   Somani, Charul
   Sharma, Kriti
   Sharma, Shivani
   Kumar, Akhilesh
   Chattopadhyay, Naibedya
   Kanojiya, Sanjeev K.
   Yadav, Dinesh Kumar
   Singh, Divya
TI Litsea glutinosa extract promotes fracture healing and prevents
   bone loss via BMP2/SMAD1 signaling
SO JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
DE Litsea glutinosaextract; fracture healing; osteoporosis; osteogenesis
   and BMP2/SDMA1 signaling
ID OSTEOPOROSIS; STRENGTH; MASS
AB Estrogen deficiency is one of the main causes for postmenopausal osteoporosis. Current osteoporotic therapies are of high cost and associated with serious side effects. So there is an urgent need for cost effective anti osteoporotic agents. Anti osteoporotic activity of Litsea glutinosa extract (LGE) is less explored. Moreover, its role in fracture healing and mechanism of action is still unknown. In the present study we explore the osteoprotective potential of LGE in osteoblast cells and fractured and ovariectomized (Ovx) mice models. Alkaline phosphatase (ALP), MTT (3 (4,5 dimethylthiazol 2 yl) 2,5 diphenyltetrazolium bromide) and mineralization assays revealed that LGE treatment increased osteoblast cell differentiation, viability and mineralization. LGE treatment at 0.01 mu g increased the expression of BMP2, PSMAD, RUNX2 and type 1 col. LGE also mitigated RANKL induced osteoclastogenesis. Next, drill hole injury Balb/C mice model was treated with LGE for 12 days. Micro CT analysis and Calcein labeling at the fracture site showed that LGE (20 mg/kg) enhanced new bone formation and bone regeneration, also increased expression of BMP2/SMAD1 signaling genes at fracture site. Ovx mice were treated with LGE for 1 month. mu CT analysis indicated that the treatment of LGE at 20 mg/kg dose prevented the alteration in bone microarchitecture and maintained bone mineral density and bone mineral content. Treatment also increased bone strength and restored the bone turnover markers. Furthermore, in bone samples, LGE increased osteogenesis by enhancing the expression of BMP2/SMAD1 signaling components and decreased osteoclast number and surface. We conclude that LGE promotes osteogenesis via modulating the BMP2/SMAD1 signaling pathway. The study advocates the therapeutic potential of LGE in osteoporosis treatment.
C1 [Khanka, Sonu; Sharma, Kriti; Sharma, Shivani; Chattopadhyay, Naibedya; Singh, Divya] CSIR Cent Drug Res Inst, Div Endocrinol, Lucknow, India.
   [Khanka, Sonu; Sharma, Kriti; Sharma, Shivani; Kumar, Akhilesh; Chattopadhyay, Naibedya; Kanojiya, Sanjeev K.; Singh, Divya] Acad Sci & Innovat Res AcSIR, Ghaziabad, Uttar Pradesh, India.
   [Somani, Charul; Yadav, Dinesh Kumar] Mohanlal Sukhadia Univ, Dept Chem, Udaipur, Rajasthan, India.
   [Kumar, Akhilesh; Kanojiya, Sanjeev K.] CSIR Cent Drug Res Inst, Sophisticated Analyt Instrument Facil & Res, Lucknow, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); Academy of Scientific &
   Innovative Research (AcSIR); Mohanlal Sukhadia University; Council of
   Scientific & Industrial Research (CSIR)   India; CSIR   Central Drug
   Research Institute (CDRI)
RP Singh, D (通讯作者)，CSIR Cent Drug Res Inst, Div Endocrinol, Lucknow, India.; Singh, D (通讯作者)，Acad Sci & Innovat Res AcSIR, Ghaziabad, Uttar Pradesh, India.; Yadav, DK (通讯作者)，Mohanlal Sukhadia Univ, Dept Chem, Udaipur, Rajasthan, India.
EM dineshkyadav@mlsu.ac.in; divya_singh@cdri.res.in
RI Sharma, Dr Shivani/LRT 9327 2024; Yadav, Dinesh/IYS 9870 2023;
   Chattopadhyay, Naibedya/AAF 2058 2019
OI Chattopadhyay, Naibedya/0000 0003 2473 0246
FU University Grants Commission; DST SERB; DST; Government of India
FX The authors are thankful to University Grants Commission (S Khanka, S
   Sharma and A Kumar), DST SERB (C Somani), DST (K Sharma) and Government
   of India for providing fellowships. The authors acknowledge SAIF
   division, CSIR CDRI, Lucknow, for various facilities and Mr G K Nagar
   and Mrs Rima R Sarkar for technical assistance. The CDRI communication
   number is 10768.
CR Agarwal K, 2021, BIOORG MED CHEM LETT, V50, DOI 10.1016/j.bmcl.2021.128340
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Changani H, 2022, J AYURVEDA INTEGR ME, V13, DOI 10.1016/j.jaim.2021.07.017
   Christiansen C, 1993, Int J Fertil Menopausal Stud, V38 Suppl 1, P45
   Conceiçao RS, 2020, PHYTOCHEM ANALYSIS, V31, P711, DOI 10.1002/pca.2935
   Curtis EM, 2016, BONE, V87, P19, DOI 10.1016/j.bone.2016.03.006
   Devi P., 2010, J. Pharm. Sci. Res, V2, P155
   Dixit M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144541
   Halloran D, 2020, J DEV BIOL, V8, DOI 10.3390/jdb8030019
   Hong H, 2019, CLINICS, V74, DOI 10.6061/clinics/2019/e800
   Jamaddar S, 2023, PHARMACEUTICALS BASE, V16, DOI 10.3390/ph16010003
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lane NE, 2002, OSTEOPOROSIS INT, V13, P816, DOI 10.1007/s001980200113
   Mc Donnell P, 2007, ANN BIOMED ENG, V35, P170, DOI 10.1007/s10439 006 9239 9
   Minisola S, 2019, THER ADV MUSCULOSKEL, V11, DOI 10.1177/1759720X19877994
   Naruphontjiralcul P, 2018, ACTA BIOMATER, V66, P67, DOI 10.1016/j.actbio.2017.11.008
   Okman Kilic T, 2015, Advances in osteoporosis, DOI [10.5772/59407, DOI 10.5772/59407]
   Pavone V, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00803
   Rai R, 2022, FREE RADICAL BIO MED, V190, P339, DOI 10.1016/j.freeradbiomed.2022.08.028
   Rai R, 2021, PHYTOMEDICINE, V93, DOI 10.1016/j.phymed.2021.153750
   Rangrez A.Y., 2011, PHARMACOLOGYONLINE, V1, P675
   Shahi M, 2017, REP BIOCHEM MOL BIOL, V5, P73
   Sharma Brijesh K., 2019, Journal of Drug Delivery and Therapeutics, V9, P1214, DOI 10.22270/jddt.v9i4 s.3939
   Sharma K, 2023, FREE RADICAL BIO MED, V194, P99, DOI 10.1016/j.freeradbiomed.2022.11.026
   Sharma K, 2022, J CELL BIOCHEM, V123, P1762, DOI 10.1002/jcb.30313
   Sharma S, 2022, FOOD FUNCT, V13, P2184, DOI [10.1039/d1fo03867b, 10.1039/D1FO03867B]
   Singh KB, 2022, BIOMED PHARMACOTHER, V145, DOI 10.1016/j.biopha.2021.112390
   Singh KB, 2017, BRIT J NUTR, V117, P1511, DOI 10.1017/S0007114517001556
   Stévigny C, 2004, RAPID COMMUN MASS SP, V18, P523, DOI 10.1002/rcm.1343
   Tan YF, 2021, PHARM BIOL, V59, P884, DOI 10.1080/13880209.2021.1944221
   Tripathi A, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.977347
   Tu Kristie N, 2018, P T, V43, P92
   Valenti MT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010041
   Vimalraj S, 2015, INT J BIOL MACROMOL, V78, P202, DOI 10.1016/j.ijbiomac.2015.04.008
   Wang QQ, 2020, J BONE MINER RES, V35, P1582, DOI 10.1002/jbmr.4025
NR 35
TC 2
Z9 2
U1 1
U2 8
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA STARLING HOUSE, 1600 BRISTOL PARKWAY N, BRISTOL, ENGLAND
SN 0022 0795
EI 1479 6805
J9 J ENDOCRINOL
JI J. Endocrinol.
PD MAY 1
PY 2024
VL 261
IS 2
AR e230351
DI 10.1530/JOE 23 0351
PG 17
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA QX6I4
UT WOS:001224202200005
PM 38492310
DA 2025 08 17
ER

PT J
AU Espinosa, JC
   Baamonde, AGD
   Herrero, FR
   Martin, EH
AF Cassinello Espinosa, Javier
   del Alba Baamonde, Aranzazu Gonzalez
   Rivera Herrero, Fernando
   Holgado Martin, Esther
TI SEOM guidelines for the treatment of bone metastases from solid tumours
SO CLINICAL & TRANSLATIONAL ONCOLOGY
LA English
DT Article
DE Bone metastasis; Prostate cancer; Breast cancer; Skeletal related events
   (SREs); Bisphosphonates; Zoledronic acid; Denosumab
ID PLACEBO CONTROLLED TRIAL; LONG TERM EFFICACY; ZOLEDRONIC ACID;
   BREAST CANCER; DOUBLE BLIND; SKELETAL COMPLICATIONS; THERAPY;
   CLODRONATE; SURVIVAL; WOMEN
AB Bone metastases are a common and distressing effect of cancer, being a major cause of morbidity in many patients with advanced stage cancer, in particular in breast and prostate cancer. Patients with bone metastases can experience complications known as skeletal related events (SREs) which may cause significant debilitation and have a negative impact on quality of life and functional independence. The current recommended systemic treatment for the prevention of SREs is based on the use of bisphosphonates: ibandronate, pamidronate and zoledronic acid the most potent one are approved in advanced breast cancer with bone metastases, whereas only zoledronic acid is indicated in advanced prostate cancer with bone metastases. The 2011 ASCO guidelines on breast cancer, recommend initiating bisphosphonate treatment only for patients with evidence of bone destruction due to bone metastases. Denosumab, a fully human antibody that specifically targets the RANK L, has been demonstrated in two phase III studies to be superior to zoledronic acid in preventing or delaying SREs in breast and prostate cancer and non inferior in other solid tumours and mieloma; it's convenient subcutaneous administration and the fact that does not require dose adjustment in cases of renal impairment, make this agent an attractive new therapeutic option in patients with bone metastases. Finally, in a phase III study against placebo, denosumab significantly increased the median metastasisfree survival in high risk non metastatic prostate cancer, arising the potential role of these bone modifying agents in preventing or delaying the development of bone metastases.
C1 [Cassinello Espinosa, Javier; Holgado Martin, Esther] Hosp Univ Guadalajara, Dept Med Oncol, ES 19002 Guadalajara, Spain.
   [del Alba Baamonde, Aranzazu Gonzalez] Hosp Univ Son Espases, Dept Med Oncol, Palma de Mallorca, Baleares, Spain.
   [Rivera Herrero, Fernando] Hosp Univ Marques de Valdecilla, Dept Med Oncol, Santander, Spain.
C3 Hospital Universitari Son Espases; Hospital Universitario Marques de
   Valdecilla (HUMV)
RP Espinosa, JC (通讯作者)，Hosp Univ Guadalajara, Dept Med Oncol, C Donante Sangre S N, ES 19002 Guadalajara, Spain.
EM jacaes@sescam.jccm.es
RI ; GONZALEZ DEL ALBA, ARANZAZU/ACR 8404 2022
OI GONZALEZ DEL ALBA BAAMONDE, ARANZAZU/0000 0001 6570 009X; 
CR [Anonymous], EUR J CANC
   Body JJ, 1998, J CLIN ONCOL, V16, P3890, DOI 10.1200/JCO.1998.16.12.3890
   Bristow AR, 2008, BREAST, V17, P98, DOI 10.1016/j.breast.2007.07.042
   Coleman R, 2008, CANCER TREAT REV, V34, P629, DOI 10.1016/j.ctrv.2008.05.001
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   DePuy V, 2007, SUPPORT CARE CANCER, V15, P869, DOI 10.1007/s00520 006 0203 x
   Eidtmann H, 2010, ANN ONCOL, V21, P2188, DOI 10.1093/annonc/mdq217
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   GALASKO CSB, 1980, CLIN NUCL MED, V5, P565
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Ha TC, 2007, BRIT J CANCER, V96, P1796, DOI 10.1038/sj.bjc.6603661
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hirsh Vera, 2004, Clin Lung Cancer, V6, P170, DOI 10.3816/CLC.2004.n.030
   Kohno N, 2005, J CLIN ONCOL, V23, P3314, DOI 10.1200/JCO.2005.05.116
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lipton A, 2010, EUR SOC MED ONC 8 12
   Mason MD, 2007, JNCI J NATL CANCER I, V99, P765, DOI 10.1093/jnci/djk178
   Moore MAS, 2001, BIOESSAYS, V23, P674, DOI 10.1002/bies.1095
   Patrick D, 2010, EUR SOC MED ONC MIL
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rosen LS, 2004, CANCER, V100, P36, DOI 10.1002/cncr.11892
   Rosen LS, 2004, CANCER, V100, P2613, DOI 10.1002/cncr.20308
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Smith MR, 2005, J CLIN ONCOL, V23, P2918, DOI 10.1200/JCO.2005.01.529
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Tatem AJ, 2011, LANCET, V377, P30, DOI 10.1016/S0140 6736(11)61226 9
   Van Poznak CH, 2012, AM SOC CLIN ONCOLOGY, DOI [10.1200/JCO.2010.23.5209, DOI 10.1200/JCO.2010.23.5209]
   Weinfurt KP, 2005, ANN ONCOL, V16, P579, DOI 10.1093/annonc/mdi122
   Yong M, 2011, BREAST CANCER RES TR, V129, P495, DOI 10.1007/s10549 011 1475 5
   Zarogoulidis K, 2009, INT J CANCER, V125, P1705, DOI 10.1002/ijc.24470
NR 32
TC 14
Z9 14
U1 0
U2 4
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH 6330, SWITZERLAND
SN 1699 048X
EI 1699 3055
J9 CLIN TRANSL ONCOL
JI Clin. Transl. Oncol.
PD JUL
PY 2012
VL 14
IS 7
BP 505
EP 511
DI 10.1007/s12094 012 0832 0
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 969NZ
UT WOS:000306063700004
PM 22721794
DA 2025 08 17
ER

PT J
AU Pisklakova, A
   Grigson, E
   Ozerova, M
   Chen, F
   Sullivan, DM
   Nefedova, Y
AF Pisklakova, Alexandra
   Grigson, Eileen
   Ozerova, Maria
   Chen, Feng
   Sullivan, Daniel M.
   Nefedova, Yulia
TI Anti myeloma effect of pharmacological inhibition of
   Notch/gamma secretase with RO4929097 is mediated by modulation of tumor
   microenvironment
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE Gamma secretase inhibitor; multiple myeloma; notch inhibitor; notch
   signaling; osteoclasts; RO4929097; TGF beta 1
ID BONE MARROW ANGIOGENESIS; GROWTH FACTOR BETA; MULTIPLE MYELOMA;
   PHASE II; OSTEOCLAST PRECURSORS; NOTCH; CELLS; DISEASE; TARGET; GENES
AB Multiple myeloma (MM), a blood cancer characterized by the uncontrolled proliferation of plasma cells, remains incurable by current therapy. Notch signaling has been implicated in the growth and chemoresistance of various cancer types including MM, and therefore we hypothesized that targeting the Notch pathway could be beneficial for the treatment of this disease. Here, we report an anti tumor effect of Notch/gamma secretase inhibitor RO4929097 in a pre clinical model of MM. We demonstrate that this effect was associated with decreased angiogenesis and significant down regulation of TGF beta 1. In addition, we also show that treatment with RO4929097 results in decreased number and functional activity of osteoclasts. Taken together, our data indicate that targeting Notch may be considered as a new strategy to be tested for MM therapy.
C1 [Pisklakova, Alexandra; Grigson, Eileen; Ozerova, Maria; Chen, Feng; Sullivan, Daniel M.; Nefedova, Yulia] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
   [Grigson, Eileen; Nefedova, Yulia] Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.
   [Chen, Feng] Capital Med Univ, Ctr Canc, Beijing Shijitan Hosp, Beijing, Peoples R China.
C3 H Lee Moffitt Cancer Center & Research Institute; The Wistar Institute;
   Capital Medical University
RP Nefedova, Y (通讯作者)，Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.
EM ynefedova@wistar.org
OI Nefedova, Yulia/0000 0002 5121 9294
FU NIH/NCI [R01CA130923]; Bankhead Coley Cancer Research TSA from the State
   of Florida; Wistar Institute; National Natural Science Foundation of
   China [81470139]
FX This work was supported in part by NIH/NCI grant R01CA130923 and
   Bankhead Coley Cancer Research TSA from the State of Florida. This work
   has been supported in part by the Flow Cytometry Core Facilities at the
   H. Lee Moffitt Cancer Center and the Wistar Institute. F.C. was
   supported by the grant from National Natural Science Foundation of China
   (No. 81470139).
CR Alexandrakis MG, 2015, MED ONCOL, V32, DOI 10.1007/s12032 015 0488 z
   Ashley JW, 2015, J CELL BIOCHEM, V116, P2598, DOI 10.1002/jcb.25205
   Bai S, 2008, J BIOL CHEM, V283, P6509, DOI 10.1074/jbc.M707000200
   Bertolini F, 2000, EXP HEMATOL, V28, P993, DOI 10.1016/S0301 472X(00)00508 7
   Blokzijl A, 2003, J CELL BIOL, V163, P723, DOI 10.1083/jcb.200305112
   Huynh C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025264
   Chen F, 2011, CELL ONCOL, V34, P545, DOI 10.1007/s13402 011 0060 6
   Colombo M, 2014, ONCOTARGET, V5, P10393, DOI 10.18632/oncotarget.2084
   Curry CL, 2006, LAB INVEST, V86, P842, DOI 10.1038/labinvest.3700442
   Dantas Barbosa C, 2015, ANTI CANCER DRUG, V26, P272, DOI 10.1097/CAD.0000000000000190
   De Jesus Acosta A, 2014, INVEST NEW DRUG, V32, P739, DOI 10.1007/s10637 014 0083 8
   Diaz Padilla I, 2015, GYNECOL ONCOL, V137, P216, DOI 10.1016/j.ygyno.2015.03.005
   Ding YR, 2015, BIOCHEM BIOPH RES CO, V467, P717, DOI 10.1016/j.bbrc.2015.10.076
   Doetzlhofer A, 2009, DEV CELL, V16, P58, DOI 10.1016/j.devcel.2008.11.008
   He W, 2011, MOL ONCOL, V5, P292, DOI 10.1016/j.molonc.2011.01.001
   Houde C, 2004, BLOOD, V104, P3697, DOI 10.1182/blood 2003 12 4114
   Jakob C, 2006, EUR J CANCER, V42, P1581, DOI 10.1016/j.ejca.2006.02.017
   JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0
   Jundt F, 2004, BLOOD, V103, P3511, DOI 10.1182/blood 2003 07 2254
   Jurczyszyn A, 2014, J CANCER, V5, P518, DOI 10.7150/jca.9266
   Kaiser M, 2008, EUR J HAEMATOL, V80, P490, DOI 10.1111/j.1600 0609.2008.01065.x
   Kangsamaksin T, 2014, BIOCHEM SOC T, V42, P1563, DOI 10.1042/BST20140233
   Kennard S, 2008, J BIOL CHEM, V283, P1324, DOI 10.1074/jbc.M706651200
   Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505
   Kopan R, 2000, GENE DEV, V14, P2799, DOI 10.1101/gad.836900
   Kurpinski K, 2010, STEM CELLS, V28, P734, DOI 10.1002/stem.319
   Lee SM, 2015, CANCER AM CANCER SOC, V121, P432, DOI 10.1002/cncr.29055
   Luistro L, 2009, CANCER RES, V69, P7672, DOI 10.1158/0008 5472.CAN 09 1843
   Maier MM, 2000, BIOCHEM BIOPH RES CO, V275, P652, DOI 10.1006/bbrc.2000.3354
   Mirandola L, 2013, LEUKEMIA, V27, P1558, DOI 10.1038/leu.2013.27
   Nakazaki H, 2008, DEV BIOL, V316, P510, DOI 10.1016/j.ydbio.2008.01.008
   Nefedova Y, 2004, BLOOD, V103, P3503, DOI 10.1182/blood 2003 07 2340
   Nefedova Y, 2008, BLOOD, V111, P2220, DOI 10.1182/blood 2007 07 102632
   Nyhan KC, 2010, BBA MOL CELL RES, V1803, P1386, DOI 10.1016/j.bbamcr.2010.09.001
   Osborne B, 1999, IMMUNITY, V11, P653, DOI 10.1016/S1074 7613(00)80140 5
   Pruneri G, 2002, BRIT J HAEMATOL, V118, P817, DOI 10.1046/j.1365 2141.2002.03654.x
   Rajkumar SV, 2002, CLIN CANCER RES, V8, P2210
   Richter S, 2014, INVEST NEW DRUG, V32, P243, DOI 10.1007/s10637 013 9965 4
   Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925 5934.2001
   Samon JB, 2008, BLOOD, V112, P1813, DOI 10.1182/blood 2008 03 144980
   Schwarzer R, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.37
   Schwarzer R, 2008, LEUKEMIA, V22, P2273, DOI 10.1038/leu.2008.138
   Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022
   Strosberg JR, 2012, EUR J CANCER, V48, P997, DOI 10.1016/j.ejca.2012.02.056
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Timmerman LA, 2004, GENE DEV, V18, P99, DOI 10.1101/gad.276304
   Urashima M, 1996, BLOOD, V87, P1928
   Vacca A, 2006, LEUKEMIA, V20, P193, DOI 10.1038/sj.leu.2404067
   van Stralen E, 2009, EXP HEMATOL, V37, P78, DOI 10.1016/j.exphem.2008.08.006
   WEIDNER N, 1992, JNCI J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875
   Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406
   Xu DH, 2012, BIOCHEM BIOPH RES CO, V428, P518, DOI 10.1016/j.bbrc.2012.10.071
   Yamada T, 2003, BLOOD, V101, P2227, DOI 10.1182/blood 2002 06 1740
   Yang GC, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/162410
   Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009
   Zhang ZY, 2010, AM J PATHOL, V177, P1459, DOI 10.2353/ajpath.2010.090476
NR 56
TC 8
Z9 10
U1 0
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538 4047
EI 1555 8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PY 2016
VL 17
IS 5
BP 477
EP 485
DI 10.1080/15384047.2016.1156261
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA DS1OP
UT WOS:000380366100003
PM 26934342
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Mainra, R
   Elder, GJ
AF Mainra, Rahul
   Elder, Grahame J.
TI Individualized Therapy to Prevent Bone Mineral Density Loss after Kidney
   and Kidney Pancreas Transplantation
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID RANDOMIZED PROSPECTIVE TRIAL; RENAL TRANSPLANTATION; LUNG
   TRANSPLANTATION; PARATHYROID HORMONE; RAPID LOSS; VITAMIN D; CALCITRIOL;
   RECIPIENTS; BISPHOSPHONATES; PAMIDRONATE
AB Background and objectives: Most patients who undergo kidney or kidney pancreas transplantation have renal osteodystrophy, and immediately after transplantation bone mineral density (BMD) commonly falls. Together, these abnormalities predispose to an increased fracture incidence. Bisphosphonate or calcitriol therapy can preserve BMD after transplantation, but although bisphosphonates may be more effective, they pose potential risks for adynamic bone.
   Design, setting, participants, & measurements: A total of 153 kidney (61%) and kidney pancreas (39%) transplant recipients were allocated to bisphosphonate (62%) or calcitriol (38%) therapy using an algorithm that incorporated BMD, prevalent vertebral fracture, biomarkers of bone turnover, and risk factor assessment. Patients received cholecalciferol and calcium as appropriate and were followed for 12 mo.
   Results: Patients who were treated with bisphosphonates had lower BMD at the lumbar spine and femoral neck and longer time on dialysis. Age and gender were similar between the groups. At 12 mo, bisphosphonate treated patients had significant BMD increases at the lumber spine and femoral neck and a negative trend at the wrist. Patients who were allocated to calcitriol, who were assessed to have lower baseline fracture risk, had no significant change in BMD at any site. At 1 yr, mean levels of bone turnover marker and intact parathyroid hormone normalized in both groups. incident fracture rates did not differ significantly.
   Conclusions: With targeted treatment, BMD levels were stable or improved and bone turnover markers normalized. This algorithm provides a guide to targeting therapy after transplantation that avoids BMD loss and may reduce suppression of bone turnover. Clin J Am Soc Nephrol 5: 117 124, 2010. doi: 10.2215/CJN.03770609
C1 [Mainra, Rahul; Elder, Grahame J.] Westmead Millennium Inst, Ctr Transplant & Renal Res, Westmead, NSW, Australia.
   [Elder, Grahame J.] Garvan Inst Med Res, Osteoporosis & Bone Biol Program, Sydney, NSW, Australia.
C3 University of Sydney; Westmead Institute for Medical Research; Garvan
   Institute of Medical Research
RP Elder, GJ (通讯作者)，Westmead Hosp, Dept Renal Med, Westmead, NSW 2145, Australia.
EM g.elder@garvan.unsw.edu.au
CR Akaberi S, 2008, AM J TRANSPLANT, V8, P2647, DOI 10.1111/j.1600 6143.2008.02423.x
   Brandenburg VM, 2004, TRANSPLANTATION, V77, P1566, DOI 10.1097/01.tp.0000131990.13277.28
   Casez JP, 2002, NEPHROL DIAL TRANSPL, V17, P1318, DOI 10.1093/ndt/17.7.1318
   Coco M, 2000, AM J KIDNEY DIS, V36, P1115, DOI 10.1053/ajkd.2000.19812
   Coco M, 2003, J AM SOC NEPHROL, V14, P2669, DOI 10.1097/01.ASN.0000087092.53894.80
   De Sévaux RGL, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000016082.70875.36
   El Agroudy AE, 2005, KIDNEY INT, V67, P2039, DOI 10.1111/j.1523 1755.2005.00306.x
   El Agroudy AE, 2003, J AM SOC NEPHROL, V14, P2975, DOI 10.1097/01.ASN.0000093255.56474.B4
   ELDER G, 2004, J BONE MINER RES, V19, pM553
   Elder GJ, 2006, J BONE MINER RES, V21, P1778, DOI 10.1359/JBMR.060803
   GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915
   Grotz W, 2001, J AM SOC NEPHROL, V12, P1530, DOI 10.1681/ASN.V1271530
   Henderson K, 2001, J BONE MINER RES, V16, P565, DOI 10.1359/jbmr.2001.16.3.565
   Jeffery JR, 2003, TRANSPLANTATION, V76, P1498, DOI 10.1097/01.TP.0000092523.30277.13
   Josephson MA, 2004, TRANSPLANTATION, V78, P1233, DOI 10.1097/01.TP.0000137937.44703.42
   JULIAN BA, 1991, NEW ENGL J MED, V325, P544, DOI 10.1056/NEJM199108223250804
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Kodras K, 2006, EUR J CLIN INVEST, V36, P63, DOI 10.1111/j.1365 2362.2006.01662.x
   MAINRA R, 2008, J BONE MINER RES, V23, pSA497
   Marcén R, 2006, TRANSPLANTATION, V81, P826, DOI 10.1097/01.tp.0000203557.36884.e3
   Mikuls TR, 2003, TRANSPLANTATION, V75, P49, DOI 10.1097/00007890 200301150 00009
   Miller PD, 2007, SEMIN DIALYSIS, V20, P186, DOI 10.1111/j.1525 139X.2007.00271.x
   Monier Faugere MC, 2000, J AM SOC NEPHROL, V11, P1093, DOI 10.1681/ASN.V1161093
   Nam JH, 2000, TRANSPLANT P, V32, P1876, DOI 10.1016/S0041 1345(00)01898 4
   Nayak B, 2007, TRANSPL P, V39, P750, DOI 10.1016/j.transproceed.2007.01.065
   Nowacka Cieciura E, 2006, TRANSPL P, V38, P165, DOI 10.1016/j.transproceed.2005.12.041
   Palmer SC, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005015.pub3
   Rojas E, 2003, KIDNEY INT, V63, P1915, DOI 10.1046/j.1523 1755.2003.00938.x
   Sambrook P, 2000, J BONE MINER RES, V15, P1818, DOI 10.1359/jbmr.2000.15.9.1818
   Torres A, 2004, KIDNEY INT, V65, P705, DOI 10.1111/j.1523 1755.2004.00432.x
   Trabulus S, 2008, TRANSPL P, V40, P160, DOI 10.1016/j.transproceed.2007.12.001
   Ugur A, 2000, TRANSPLANT P, V32, P556, DOI 10.1016/S0041 1345(00)00888 5
   US Renal Data System, 2004, USRDS 2004 ANN DAT R
   Walsh SB, 2009, AM J KIDNEY DIS, V53, P856, DOI 10.1053/j.ajkd.2008.11.036
   Weisinger JR, 2006, CLIN J AM SOC NEPHRO, V1, P1300, DOI 10.2215/CJN.01510506
NR 35
TC 27
Z9 31
U1 2
U2 4
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555 9041
EI 1555 905X
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD JAN
PY 2010
VL 5
IS 1
BP 117
EP 124
DI 10.2215/CJN.03770609
PG 8
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 545CN
UT WOS:000273710200018
PM 19965527
OA Green Published, Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Turner, RT
   Kalra, SP
   Wong, CP
   Philbrick, KA
   Lindenmaier, LB
   Boghossian, S
   Iwaniec, UT
AF Turner, Russell T.
   Kalra, Satya P.
   Wong, Carmen P.
   Philbrick, Kenneth A.
   Lindenmaier, Laurence B.
   Boghossian, Stephane
   Iwaniec, Urszula T.
TI Peripheral Leptin Regulates Bone Formation
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OB/OB; DB/DB; HYPOTHALAMUS; SKELETON
ID HUMAN OSTEOBLASTS; GENE THERAPY; EXPRESSION; MASS; RECEPTOR;
   DIFFERENTIATION; CELLS; PROLIFERATION; ABNORMALITIES; METABOLISM
AB Substantial evidence does not support the prevailing view that leptin, acting through a hypothalamic relay, decreases bone accrual by inhibiting bone formation. To clarify the mechanisms underlying regulation of bone architecture by leptin, we evaluated bone growth and turnover in wild type (WT) mice, leptin receptor deficient db/db mice, leptin deficient ob/ob mice, and ob/ob mice treated with leptin. We also performed hypothalamic leptin gene therapy to determine the effect of elevated hypothalamic leptin levels on osteoblasts. Finally, to determine the effects of loss of peripheral leptin signaling on bone formation and energy metabolism, we used bone marrow (BM) from WT or db/db donor mice to reconstitute the hematopoietic and mesenchymal stem cell compartments in lethally irradiated WT recipient mice. Decreases in bone growth, osteoblast lined bone perimeter and bone formation rate were observed in ob/ob mice and greatly increased in ob/ob mice following subcutaneous administration of leptin. Similarly, hypothalamic leptin gene therapy increased osteoblast lined bone perimeter in ob/ob mice. In spite of normal osteoclast lined bone perimeter, db/db mice exhibited a mild but generalized osteopetrotic like (calcified cartilage encased by bone) skeletal phenotype and greatly reduced serum markers of bone turnover. Tracking studies and histology revealed quantitative replacement of BM cells following BM transplantation. WT mice engrafted with db/db BM did not differ in energy homeostasis from untreated WT mice or WT mice engrafted with WT BM. Bone formation in WT mice engrafted with WT BM did not differ from WT mice, whereas bone formation in WT mice engrafted with db/db cells did not differ from the low rates observed in untreated db/db mice. In summary, our results indicate that leptin, acting primarily through peripheral pathways, increases osteoblast number and activity. (C) 2013 American Society for Bone and Mineral Research.
C1 [Turner, Russell T.; Philbrick, Kenneth A.; Lindenmaier, Laurence B.; Iwaniec, Urszula T.] Oregon State Univ, Sch Biol & Populat Hlth Sci, Skeletal Biol Lab, Corvallis, OR 97331 USA.
   [Kalra, Satya P.; Boghossian, Stephane] Univ Florida, Dept Neurosci, McKnight Brain Inst, Gainesville, FL 32610 USA.
   [Wong, Carmen P.] Oregon State Univ, Sch Biol & Populat Hlth Sci, Mol & Cellular Nutr Lab, Corvallis, OR 97331 USA.
C3 Oregon State University; State University System of Florida; University
   of Florida; Oregon State University
RP Iwaniec, UT (通讯作者)，Oregon State Univ, Sch Biol & Populat Hlth Sci, Skeletal Biol Lab, 108 Milam Hall, Corvallis, OR 97331 USA.
EM urszula.iwaniec@oregonstate.edu
OI Philbrick, Kenneth/0000 0003 1424 6987; Boghossian,
   stephane/0000 0002 5064 6024
FU National Institute of Health [AR 054609, AR 060913, DK 37273]
FX This work was supported by National Institute of Health grants AR 054609
   and AR 060913 (to UTI) and DK 37273 (to SPK). We thank Dr. Scott Mann
   for irradiating the mice.
CR Baek K, 2009, J BONE MINER RES, V24, P792, DOI [10.1359/JBMR.081241, 10.1359/jbmr.081241]
   Bartell SM, 2011, J BONE MINER RES, V26, P1710, DOI 10.1002/jbmr.406
   Beretta E, 2002, PEDIATR RES, V52, DOI 10.1203/00006450 200208000 00010
   Boghossian S, 2006, PEPTIDES, V27, P3245, DOI 10.1016/j.peptides.2006.07.022
   Burguera B, 2001, ENDOCRINOLOGY, V142, P3546, DOI 10.1210/en.142.8.3546
   Burguera B, 2006, MED SCI MONITOR, V12, pBR341
   Chauveau C, 2008, J RECEPT SIG TRANSD, V28, P347, DOI [10.1080/10799890802239762, 10.1080/10799890802239762 ]
   Chen BJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011056
   Cornish J, 2002, J ENDOCRINOL, V175, P405, DOI 10.1677/joe.0.1750405
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Ealey KN, 2006, REGUL PEPTIDES, V136, P9, DOI 10.1016/j.regpep.2006.04.013
   Enjuanes A, 2002, J BONE MINER RES, V17, P1135, DOI 10.1359/jbmr.2002.17.6.1135
   Erben RG., 2003, Handbook of Histology Methods for Bone and Cartilage, P99
   FOLDES J, 1992, INT J OBESITY, V16, P95
   Gat Yablonski G, 2004, ENDOCRINOLOGY, V145, P343, DOI 10.1210/en.2003 0910
   Gimble JM, 2011, J BONE MINER RES, V26, P1694, DOI 10.1002/jbmr.445
   Gordeladze JO, 2002, J CELL BIOCHEM, V85, P825, DOI 10.1002/jcb.10156
   Graham S, 2008, EXPERT OPIN INV DRUG, V17, P1281, DOI 10.1517/13543784.17.9.1281 
   Hamrick MW, 2004, J BONE MINER RES, V19, P1607, DOI 10.1359/JBMR.040712
   Hess R, 2005, J CELL BIOCHEM, V94, P50, DOI 10.1002/jcb.20330
   HILL EL, 1991, NEUROSCIENCE, V44, P747, DOI 10.1016/0306 4522(91)90094 5
   HOHMANN EL, 1986, SCIENCE, V232, P868, DOI 10.1126/science.3518059
   Hollung K, 2004, J CELL BIOCHEM, V92, P307, DOI 10.1002/jcb.20047
   Iwamoto I, 2004, GYNECOL ENDOCRINOL, V19, P97, DOI 10.1080/09513590412331284389
   Iwaniec UT, 2009, BONE, V44, P404, DOI 10.1016/j.bone.2008.10.058
   Iwaniec UT, 2007, PEPTIDES, V28, P1012, DOI 10.1016/j.peptides.2007.02.001
   Iwaniec UT, 2011, J BONE MINER RES, V26, P1506, DOI 10.1002/jbmr.365
   Iwaniec UT, 2009, J NUTR, V139, P1914, DOI 10.3945/jn.109.107201
   Iwaniec Urszula T., 2008, V447, P325, DOI 10.1007/978 1 59745 242 7_21
   Kajimura D, 2011, J EXP MED, V208, P841, DOI 10.1084/jem.20102608
   Kalra SP, 2009, PEPTIDES, V30, P967, DOI 10.1016/j.peptides.2009.01.020
   Kapur S, 2010, J BIOL CHEM, V285, P37607, DOI 10.1074/jbc.M110.169714
   Lamghari M, 2006, J CELL BIOCHEM, V98, P1123, DOI 10.1002/jcb.20853
   Lee YJ, 2002, FEBS LETT, V528, P43, DOI 10.1016/S0014 5793(02)02889 2
   Martin A, 2005, ENDOCRINOLOGY, V146, P3652, DOI 10.1210/en.2004 1509
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Reseland JE, 2001, J BONE MINER RES, V16, P1426, DOI 10.1359/jbmr.2001.16.8.1426
   Scheller EL, 2010, STEM CELLS, V28, P1071, DOI 10.1002/stem.432
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   TAKESHITA N, 1995, LIFE SCI, V56, P1095, DOI 10.1016/0024 3205(95)00046 9
   Thomas T, 1999, ENDOCRINOLOGY, V140, P1630, DOI 10.1210/en.140.4.1630
   Trivedi R, 2010, EXPERT OPIN INV DRUG, V19, P995, DOI 10.1517/13543784.2010.501077
   TURNER RT, 1994, ENDOCR REV, V15, P275, DOI 10.1210/er.15.3.275
   Wiedenhöft A, 1999, J CLIN ENDOCR METAB, V84, P3021, DOI 10.1210/jc.84.9.3021
   Williams GA, 2011, J BONE MINER RES, V26, P1698, DOI 10.1002/jbmr.367
   Wong IPL, 2008, SEMIN CELL DEV BIOL, V19, P452, DOI 10.1016/j.semcdb.2008.08.001
NR 46
TC 204
Z9 221
U1 0
U2 28
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JAN
PY 2013
VL 28
IS 1
BP 22
EP 34
DI 10.1002/jbmr.1734
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 092EY
UT WOS:000315103200004
PM 22887758
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Zhang, Y
   Wang, LR
   Feng, ZW
   Cheng, HZ
   McGuire, TF
   Ding, YH
   Cheng, T
   Gao, YD
   Xie, XQ
AF Zhang, Yu
   Wang, Lirong
   Feng, Zhiwei
   Cheng, Haizi
   McGuire, Terence Francis
   Ding, Yahui
   Cheng, Tao
   Gao, Yingdai
   Xie, Xiang Qun
TI StemCellCKB: An Integrated Stem Cell Specific Chemogenomics
   KnowledgeBase for Target Identification and Systems Pharmacology
   Research
SO JOURNAL OF CHEMICAL INFORMATION AND MODELING
LA English
DT Article
ID WNT SIGNALING PATHWAY; EX VIVO EXPANSION; DEFINITIVE ENDODERM;
   GENE EXPRESSION; SMALL MOLECULES; SELF RENEWAL; BETA CATENIN;
   BONE MARROW; DIFFERENTIATION; INHIBITOR
AB Given the capacity of self renewal and multilineage differentiation, stem cells are promising sources for use in regenerative medicines as well as in the clinical treatment of certain hematological malignancies and degenerative diseases. Complex networks of cellular signaling pathways largely determine stem cell fate and function. Small molecules that modulate these pathways can provide important biological and pharmacological insights. However, it is still challenging to identify the specific protein targets of these compounds, to explore the changes in stem cell phenotypes induced by compound treatment and to ascertain compound mechanisms of action. To facilitate stem cell related small molecule study and provide a better understanding of the associated signaling pathways, we have constructed a comprehensive domain specific chemogenomics resource, called StemCellCKB (http://www.cbligand.org/StemCellCKB/). This new cloud computing platform describes the chemical molecules, genes, proteins, and signaling pathways implicated in stem cell regulation. StemCellCKB is also implemented with web applications designed specifically to aid in the identification of stem cell relevant protein targets, including TargetHunter, a machine learning algorithm for predicting small molecule targets, based on molecular fingerprints, and HTDocking, a high throughput docking module for target prediction and systems pharmacology analyses. We have systematically tested StemCellCKB to verify data integrity. Target prediction accuracy has also been validated against the reported known target/compound associations. This proof of concept example demonstrates that StemCellCKB can (1) accurately predict the macromolecular targets of existing stem cell modulators and (2) identify novel small molecules capable of probing stem cell signaling mechanisms, for use in systems pharmacology studies. StemCellCKB facilitates the exploration and exchange of stem cell chemogenomics data among members of the broader research community.
C1 [Zhang, Yu; Wang, Lirong; Feng, Zhiwei; Cheng, Haizi; McGuire, Terence Francis; Xie, Xiang Qun] Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA 15260 USA.
   [Zhang, Yu; Wang, Lirong; Feng, Zhiwei; Cheng, Haizi; McGuire, Terence Francis; Xie, Xiang Qun] Univ Pittsburgh, Sch Pharm, Computat Chem Genom Screening Ctr, Pittsburgh, PA 15260 USA.
   [Zhang, Yu; Wang, Lirong; Feng, Zhiwei; Cheng, Haizi; McGuire, Terence Francis; Xie, Xiang Qun] Univ Pittsburgh, Natl Ctr Excellence Computat Drug Abuse Res, Pittsburgh, PA 15260 USA.
   [Zhang, Yu; Wang, Lirong; Feng, Zhiwei; Cheng, Haizi; McGuire, Terence Francis; Xie, Xiang Qun] Univ Pittsburgh, Drug Discovery Inst, Pittsburgh, PA 15260 USA.
   [Zhang, Yu; Wang, Lirong; Feng, Zhiwei; Cheng, Haizi; McGuire, Terence Francis; Xie, Xiang Qun] Univ Pittsburgh, Sch Med, Dept Computat Biol, Pittsburgh, PA 15260 USA.
   [Zhang, Yu; Wang, Lirong; Feng, Zhiwei; Cheng, Haizi; McGuire, Terence Francis; Xie, Xiang Qun] Univ Pittsburgh, Sch Med, Dept Biol Struct, Pittsburgh, PA 15260 USA.
   [Zhang, Yu; Ding, Yahui; Cheng, Tao; Gao, Yingdai] Chinese Acad Med Sci, Inst Hematol, Key Lab Expt Hematol, Tianjin 300020, Peoples R China.
   [Zhang, Yu; Ding, Yahui; Cheng, Tao; Gao, Yingdai] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin 300020, Peoples R China.
   [Zhang, Yu; Ding, Yahui; Cheng, Tao; Gao, Yingdai] Peking Union Med Coll, Tianjin 300020, Peoples R China.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Chinese Academy of
   Medical Sciences   Peking Union Medical College; Institute of Hematology
   & Blood Diseases Hospital   CAMS; Chinese Academy of Medical Sciences  
   Peking Union Medical College; Institute of Hematology & Blood Diseases
   Hospital   CAMS; Chinese Academy of Medical Sciences   Peking Union
   Medical College; Peking Union Medical College
RP Xie, XQ (通讯作者)，Univ Pittsburgh, Sch Pharm, 206 Salk Pavil, Pittsburgh, PA 15260 USA.; Gao, YD (通讯作者)，288 Nanjing Rd, Tianjin 300020, Peoples R China.
EM ydgao@ihcams.ac.cn; xix15@pitt.edu
RI ; Cheng, Haizi/L 9623 2019; Zhang, Yu/AAE 3574 2022; FENG,
   ZHIWEI/L 5072 2014
OI Cheng, Haizi/0000 0003 1525 0099; Cheng, Tao/0000 0002 5925 2769; FENG,
   ZHIWEI/0000 0001 6533 8932
FU NIH [R21HL109654, P30DA035778]; National Basic Research Program of China
   [2016YFA0100602, 2012CB966600]; National Natural Science Foundation of
   China (NSFC) [81421002, 81570100, 81500086, 81430004, 81600085]; key
   technologies R & D program of Tianjin [13RCGFSY19500]; China National
   Scholarship
FX Research reported in this publication was supported by the NIH grants
   R21HL109654 and P30DA035778, (X. Q.X.), the National Basic Research
   Program of China (nos. 2016YFA0100602 and 2012CB966600), the National
   Natural Science Foundation of China (NSFC 81421002, 81570100, 81500086,
   81430004, and 81600085), the key technologies R & D program of Tianjin
   (13RCGFSY19500), and the China National Scholarship.
CR Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Bari S, 2015, BIOL BLOOD MARROW TR, V21, P1008, DOI 10.1016/j.bbmt.2014.12.022
   Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596
   Bento AP, 2014, NUCLEIC ACIDS RES, V42, pD1083, DOI 10.1093/nar/gkt1031
   Berg S, 2012, J MED CHEM, V55, P9107, DOI 10.1021/jm201724m
   Boitano AE, 2010, SCIENCE, V329, P1345, DOI 10.1126/science.1191536
   Bone HK, 2011, J CELL SCI, V124, P1992, DOI 10.1242/jcs.081679
   Bone HK, 2009, CHEM BIOL, V16, P15, DOI 10.1016/j.chembiol.2008.11.003
   Cattelino A, 2003, J CELL BIOL, V162, P1111, DOI 10.1083/jcb.200212157
   Cheng T, 2008, GENE THER, V15, P67, DOI 10.1038/sj.gt.3303066
   Cheng T, 2001, BLOOD, V98, P3643, DOI 10.1182/blood.V98.13.3643
   Corrigan PM, 2009, STEM CELLS DEV, V18, P759, DOI 10.1089/scd.2008.0270
   Daley GQ, 2012, CELL STEM CELL, V10, P740, DOI 10.1016/j.stem.2012.05.010
   De Felice LD, 2005, CANCER RES, V65, P1505, DOI 10.1158/0008 5472.CAN 04 3063
   Dimmeler S, 2014, NAT MED, V20, P814, DOI 10.1038/nm.3627
   Doulatov S, 2012, CELL STEM CELL, V10, P120, DOI 10.1016/j.stem.2012.01.006
   Duncan AW, 2005, NAT IMMUNOL, V6, P314, DOI 10.1038/ni1164
   Ertl P, 2010, J CHEMINFORMATICS, V2, DOI 10.1186/1758 2946 2 1
   Feng ZW, 2014, J CHEM INF MODEL, V54, P2483, DOI 10.1021/ci5002718
   Gao YD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7328
   Hayakawa K, 2013, J BIOL CHEM, V288, P17099, DOI 10.1074/jbc.M113.455899
   Horwitz ME, 2015, CYTOTHERAPY, V17, P730, DOI 10.1016/j.jcyt.2015.02.004
   Hou PP, 2013, SCIENCE, V341, P651, DOI 10.1126/science.1239278
   Huang J, 2012, NAT MED, V18, P1778, DOI 10.1038/nm.2984
   Jaremko KL, 2013, STEM CELL RES, V10, P489, DOI 10.1016/j.scr.2012.04.002
   Kanehisa M, 2002, NUCLEIC ACIDS RES, V30, P42, DOI 10.1093/nar/30.1.42
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Katoh M, 2006, INT J MOL MED, V17, P681
   Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078 0432.CCR 06 2316
   Keiser MJ, 2007, NAT BIOTECHNOL, V25, P197, DOI 10.1038/nbt1284
   Ko KH, 2011, STEM CELLS, V29, P108, DOI 10.1002/stem.551
   Kuhn M, 2012, NUCLEIC ACIDS RES, V40, pD876, DOI 10.1093/nar/gkr1011
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Li J, 2015, MOL MED REP, V11, P815, DOI 10.3892/mmr.2014.2812
   Li WL, 2013, CELL STEM CELL, V13, P270, DOI 10.1016/j.stem.2013.08.002
   Lipinski CA, 2012, ADV DRUG DELIVER REV, V64, P4, DOI 10.1016/j.addr.2012.09.019
   Liu HB, 2014, J CHEM INF MODEL, V54, P1050, DOI 10.1021/ci500004h
   Luis TC, 2011, CELL STEM CELL, V9, P345, DOI 10.1016/j.stem.2011.07.017
   Lyssiotis CA, 2009, P NATL ACAD SCI USA, V106, P8912, DOI 10.1073/pnas.0903860106
   Ma C, 2013, J CHEM INF MODEL, V53, P11, DOI 10.1021/ci3003914
   Ma C, 2011, ACS COMB SCI, V13, P223, DOI 10.1021/co100033m
   Ma C, 2011, J CHEM INF MODEL, V51, P521, DOI 10.1021/ci100399j
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758 2946 3 33
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Patlewicz G, 2008, SAR QSAR ENVIRON RES, V19, P495, DOI 10.1080/10629360802083871
   Peled T, 2005, EXP HEMATOL, V33, P1092, DOI 10.1016/j.exphem.2005.06.015
   Peled T, 2012, EXP HEMATOL, V40, P342, DOI 10.1016/j.exphem.2011.12.005
   Pineault N, 2015, EXP HEMATOL, V43, P498, DOI 10.1016/j.exphem.2015.04.011
   Sandeep Gaddam, 2011, BMC Res Notes, V4, P445, DOI 10.1186/1756 0500 4 445
   Saraf S, 2015, TRANSFUSION, V55, P864, DOI 10.1111/trf.12904
   Sheng SJ, 2014, J ETHNOPHARMACOL, V154, P735, DOI 10.1016/j.jep.2014.04.048
   Shi Y, 2008, CELL STEM CELL, V3, P568, DOI 10.1016/j.stem.2008.10.004
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tenzen T, 2010, J CELL PHYSIOL, V222, P278, DOI 10.1002/jcp.21948
   THOMAS ED, 1957, NEW ENGL J MED, V257, P491, DOI 10.1056/NEJM195709122571102
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   van den Brink GR, 2004, NAT GENET, V36, P277, DOI 10.1038/ng1304
   Walasek MA, 2012, ANN NY ACAD SCI, V1266, P138, DOI 10.1111/j.1749 6632.2012.06549.x
   Wang L, 2013, AAPS J, V15, P53, DOI 10.1208/s12248 012 9413 y
   Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427
   Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958
   Xie XQ, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00003
   Xie XQ, 2003, PROTEINS, V53, P307, DOI 10.1002/prot.10511
   Xu T, 2013, STEM CELL TRANSL MED, V2, P355, DOI 10.5966/sctm.2012 0172
   Zhang Y, 2012, J CELL SCI, V125, P5609, DOI 10.1242/jcs.096032
   Zhou JX, 2010, STEM CELLS, V28, P1741, DOI 10.1002/stem.504
NR 68
TC 8
Z9 9
U1 1
U2 19
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1549 9596
EI 1549 960X
J9 J CHEM INF MODEL
JI J. Chem Inf. Model.
PD OCT
PY 2016
VL 56
IS 10
BP 1995
EP 2004
DI 10.1021/acs.jcim.5b00748
PG 10
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Computer Science,
   Information Systems; Computer Science, Interdisciplinary Applications
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Chemistry; Computer Science
GA EA0YH
UT WOS:000386315000010
PM 27643925
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Akshaya, N
   Srinaath, N
   Rohini, M
   Ilangovan, R
   Selvamurugan, N
AF Akshaya, N.
   Srinaath, N.
   Rohini, M.
   Ilangovan, R.
   Selvamurugan, N.
TI Parathyroid Hormone regulation of Runx2 by MiR 290 for Matrix
   Metalloproteinase 13 Expression in Rat Osteoblastic Cells
SO CURRENT MOLECULAR MEDICINE
LA English
DT Article
DE Osteoblasts; Parathyroid hormone; Runx2; Matrix metalloproteinase 13;
   miR 290; Bone remodeling
ID COLLAGENASE 3 PROMOTER; BONE; TARGET; MICRORNAS; DIFFERENTIATION;
   ACTIVATION; PREDICTION; PRECURSOR; DOMAIN; AP 1
AB Background: The dynamic changes that bone undergoes during the ensemble of remodeling are administered by vital factors like Runx2 (a bone transcription factor) and matrix metalloproteinases (MMPs). Aims: Parathyroid hormone (PTH), an FDA approved drug for bone related ailments, was seen to stimulate MMP 13 expression via Runx2 to ultimately aid in the bone remodeling process. MicroRNAs (miRNAs) have been shown to play a major role in controlling bone metabolism, and the use of miRNAs has recently become promising therapeutic avenues for the treatment of many diseases, including bone disorders. Thus, in this study, we attempted to investigate and evaluate the expression of MMP 13 via a miRNA profile targeting Runx2 under PTH regulation in rat osteoblastic cells. Methods: PTH stimulated the expression of MMP 13 mRNA significantly at 4 h in rat osteoblastic cells (UMR106 01). Runx2 was required for PTH stimulation of MMP 13 expression, in silico scrutiny generated 14 unique miRNAs targeting Runx2, and among these miRNAs, miR 290 was significantly downregulated by PTH treatment in UMR106 01 cells and in rat primary osteoblasts. Results: Overexpression of miR 290 decreased the expression of Runx2, the binding of Runx2 at the MMP 13 promoter, and the expression of MMP 13 mRNA in PTH treated UMR106 01 cells. A dual luciferase reporter assay identified the direct targeting of Runx2 mRNA by miR 290 in these cells. Conclusion: Our findings indicate that the PTH responsive miR 290 regulated Runx2 mediated MMP 13 expression in rat osteoblastic cells, suggesting miR 290 as a molecular marker or target in bone and bone related diseases.
C1 [Akshaya, N.; Srinaath, N.; Rohini, M.; Selvamurugan, N.] SRM Inst Sci & Technol, Coll Engn & Technol, Dept Biotechnol, Kattankulathur 603203, Tamil Nadu, India.
   [Ilangovan, R.] Univ Madras, Dr ALM PG Inst Basic Med Sci, Dept Endocrinol, Chennai, Tamil Nadu, India.
C3 SRM Institute of Science & Technology Chennai; University of Madras
RP Selvamurugan, N (通讯作者)，SRM Inst Sci & Technol, Coll Engn & Technol, Dept Biotechnol, Kattankulathur 603203, Tamil Nadu, India.
EM selvamun@srmist.edu.in
RI Selvamurugan, Nagarajan/P 7894 2016
OI Selvamurugan, Nagarajan/0000 0003 3713 1920
FU Department of Biotechnology, India [BT/PR15014/BRB/10/1481/2016]
FX This work was supported by the Department of Biotechnology, India (Grant
   No. BT/PR15014/BRB/10/1481/2016 to N. S).
CR Arumugam B, 2019, BIOCHIMIE, V158, P43, DOI 10.1016/j.biochi.2018.12.006
   Arumugam B, 2018, J CELL COMMUN SIGNAL, V12, P561, DOI 10.1007/s12079 018 0449 3
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bosson AD, 2014, MOL CELL, V56, P347, DOI 10.1016/j.molcel.2014.09.018
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Campbell EJ, 2015, EXPERT OPIN BIOL TH, V15, P119, DOI 10.1517/14712598.2015.977249
   Chandran SV, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 48429 1
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Feng QY, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180453
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Gan Lin, 2013, Microarrays (Basel), V2, P24, DOI 10.3390/microarrays2010024
   Gennari L, 2017, OSTEOPOROSIS INT, V28, P1191, DOI 10.1007/s00198 016 3847 5
   Gomathi K, 2020, LIFE SCI, V245, DOI 10.1016/j.lfs.2020.117389
   Griffiths Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112
   Jiménez MJG, 1999, MOL CELL BIOL, V19, P4431
   Johnson M, 2012, MAT METHODS, V2, P128, DOI [10.13070/mm.en.2.128, DOI 10.13070/MM.EN.2.128]
   Kanoria S, 2016, METHODS MOL BIOL, V1490, P73, DOI 10.1007/978 1 4939 6433 8_6
   Kennedy AM, 2005, J CLIN INVEST, V115, P2832, DOI 10.1172/JCI22900
   Knäuper V, 2002, FEBS LETT, V532, P127, DOI 10.1016/S0014 5793(02)03654 2
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Kotepui M, 2016, WSPOLCZESNA ONKOL, V20, P225, DOI 10.5114/wo.2016.61565
   Kudo Y, 2012, J BIOL CHEM, V287, P38716, DOI 10.1074/jbc.M112.373159
   Lee M, 2010, J BIOL CHEM, V285, P38014, DOI 10.1074/jbc.M110.142141
   Li P, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080791
   Liang H.P.H., 2016, Met Med, V3, P93, DOI DOI 10.2147/MNM.S92187
   Long D, 2007, NAT STRUCT MOL BIOL, V14, P287, DOI 10.1038/nsmb1226
   Long MW, 2001, BLOOD CELL MOL DIS, V27, P677, DOI 10.1006/bcmd.2001.0431
   Mackie EJ, 2008, INT J BIOCHEM CELL B, V40, P46, DOI 10.1016/j.biocel.2007.06.009
   Malavkia D, 2020, J CELL PHYSIOL, V235, P7996, DOI 10.1002/jcp.29454
   Miranda PJ, 2015, INT J BIOL MACROMOL, V72, P145, DOI 10.1016/j.ijbiomac.2014.07.051
   Mohamed AM, 2008, MALAYS J MED SCI, V15, P4
   Mohanakrishnan V, 2018, J CELL BIOCHEM, V119, P6181, DOI 10.1002/jcb.26827
   Mondry A, 2005, CURR MOL MED, V5, P489, DOI 10.2174/1566524054553531
   Mukherji S, 2011, NAT GENET, V43, P854, DOI 10.1038/ng.905
   Narayanan A, 2019, LIFE SCI, V232, DOI 10.1016/j.lfs.2019.116676
   Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27
   O'Hara AJ, 2008, BLOOD, V111, P2347, DOI 10.1182/blood 2007 08 104463
   Ortega N, 2004, TRENDS CELL BIOL, V14, P86, DOI 10.1016/j.tcb.2003.12.003
   Pivetta E, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3047
   Porte D, 1999, ONCOGENE, V18, P667, DOI 10.1038/sj.onc.1202333
   Qin L, 2003, J BIOL CHEM, V278, P19723, DOI 10.1074/jbc.M212226200
   Rohini M, 2019, INT J BIOL MACROMOL, V134, P954, DOI 10.1016/j.ijbiomac.2019.05.062
   Rohini M, 2018, BIOCHIMIE, V154, P10, DOI 10.1016/j.biochi.2018.07.023
   Saiganesh S, 2019, INT J BIOL MACROMOL, V132, P541, DOI 10.1016/j.ijbiomac.2019.04.003
   Saiganesh S, 2018, INT J BIOL MACROMOL, V109, P338, DOI 10.1016/j.ijbiomac.2017.12.091
   Sanjeev G, 2020, BIOORG MED CHEM LETT, V30, DOI 10.1016/j.bmcl.2020.127137
   Schmittgen TD, 2008, METHODS, V44, P31, DOI 10.1016/j.ymeth.2007.09.006
   Selvamurugan N, 2004, J BIOL CHEM, V279, P19327, DOI 10.1074/jbc.M314048200
   Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647
   Selvamurugan N, 2000, J BIOL CHEM, V275, P5037, DOI 10.1074/jbc.275.7.5037
   Selvamurugan N, 2006, J CELL BIOCHEM, V99, P545, DOI 10.1002/jcb.20878
   Selvamurugan N, 2009, FEBS LETT, V583, P1141, DOI 10.1016/j.febslet.2009.02.040
   Shu JM, 2012, RNA BIOL, V9, P1275, DOI 10.4161/rna.21998
   Srinaath N, 2019, BIOFACTORS, V45, P575, DOI 10.1002/biof.1515
   Sriram M, 2015, INT J BIOL MACROMOL, V74, P404, DOI 10.1016/j.ijbiomac.2014.12.034
   Takaishi H, 2008, CURR PHARM BIOTECHNO, V9, P47, DOI 10.2174/138920108783497659
   Tardif Ginette, 2004, Mod Rheumatol, V14, P197
   Vejnar CE, 2013, NUCLEIC ACIDS RES, V41, pW165, DOI 10.1093/nar/gkt430
   Vimalraj S, 2014, J CELL PHYSIOL, V229, P1236, DOI 10.1002/jcp.24557
   Vimalraj S, 2013, CURR ISSUES MOL BIOL, V15, P7
   Vishal M, 2017, J CELL PHYSIOL, V232, P371, DOI 10.1002/jcp.25434
   Wang XB, 2004, OSTEOARTHR CARTILAGE, V12, P963, DOI 10.1016/j.joca.2004.08.008
   Wong A, 2015, BONE, V81, P97, DOI 10.1016/j.bone.2015.07.002
   Zhang Y, 2010, BIOMATERIALS, V31, P3231, DOI 10.1016/j.biomaterials.2010.01.029
NR 64
TC 9
Z9 12
U1 0
U2 2
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566 5240
EI 1875 5666
J9 CURR MOL MED
JI Curr. Mol. Med.
PY 2022
VL 22
IS 6
BP 549
EP 561
DI 10.2174/1566524021666210830093232
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 2U8SS
UT WOS:000823425200008
PM 34463227
DA 2025 08 17
ER

PT J
AU Claro, T
   Widaa, A
   McDonnell, C
   Foster, TJ
   O'Brien, FJ
   Kerrigan, SW
AF Claro, Tania
   Widaa, Amro
   McDonnell, Cormac
   Foster, Timothy J.
   O'Brien, Fergal J.
   Kerrigan, Steven W.
TI Staphylococcus aureus protein A binding to osteoblast tumour
   necrosis factor receptor 1 results in activation of nuclear factor kappa
   B and release of interleukin 6 in bone infection
SO MICROBIOLOGY SGM
LA English
DT Article
ID EXPERIMENTAL MODEL; OSTEOMYELITIS; INTERNALIZATION; MECHANISMS
AB Staphylococcus aureus is the major pathogen among the staphylococci and the most common cause of bone infections. These infections are mainly characterized by bone destruction and inflammation, and are often debilitating and very difficult to treat. Previously we demonstrated that S. aureus protein A (SpA) can bind to osteoblasts, which results in inhibition of osteoblast proliferation and mineralization, apoptosis, and activation of osteoclasts. In this study we used small interfering RNA (siRNA) to demonstrate that osteoblast tumour necrosis factor receptor 1 (TNFR 1) is responsible for the recognition of and binding to SpA. TNFR 1 binding to SpA results in the activation of nuclear factor kappa B (NF kappa B). In turn, NF kappa B translocates to the nucleus of the osteoblast, which leads to release of interleukin 6 (IL 6). Silencing TNFR 1 in osteoblasts or disruption of the spa gene in S. aureus prevented both NF kappa B activation and IL 6 release. As well as playing a key role in proinflammatory reactions, IL 6 is also an important osteotropic factor. Release of IL 6 from osteoblasts results in the activation of the bone resorbing cells, the osteoclasts. Consistent with our results described above, both silencing TNFR 1 in osteoblasts and disruption of spa in S. aureus prevented osteoclast activation. These studies are the first to demonstrate the importance of the TNFR 1 SpA interaction in bone infection, and may help explain the mechanism through which osteoclasts become overactivated, leading to bone destruction. Anti inflammatory drug therapy could be used either alone or in conjunction with antibiotics to treat osteomyelitis or for prophylaxis in high risk patients.
C1 [Claro, Tania; Widaa, Amro; McDonnell, Cormac; Kerrigan, Steven W.] Royal Coll Surgeons Ireland, Microbial Infect Grp, Dublin 2, Ireland.
   [Foster, Timothy J.] Trinity Coll Dublin, Moyne Inst Prevent Med, Dept Microbiol, Dublin 2, Ireland.
   [Widaa, Amro; O'Brien, Fergal J.] Royal Coll Surgeons Ireland, Dept Anat, Dublin 2, Ireland.
   [O'Brien, Fergal J.] Trinity Coll Dublin, Trinity Ctr Bioengn, Dublin 2, Ireland.
   [Kerrigan, Steven W.] Royal Coll Surgeons Ireland, Sch Pharm, Dublin 2, Ireland.
C3 Royal College of Surgeons   Ireland; Trinity College Dublin; Royal
   College of Surgeons   Ireland; Trinity College Dublin; Royal College of
   Surgeons   Ireland
RP Kerrigan, SW (通讯作者)，Royal Coll Surgeons Ireland, Microbial Infect Grp, 123 St Stephens Green, Dublin 2, Ireland.
EM skerrigan@rcsi.ie
RI O'Brien, Fergal/F 9485 2011; Kerrigan, Steven/C 3922 2012
OI O'Brien, Fergal/0000 0003 2030 8005; McDonnell,
   Cormac/0000 0001 9854 1830; 
FU Science Foundation of Ireland [BMT/2008/1709]; Health Research Board of
   Ireland [RP/2006/2]
FX This work was supported by a grant from the Science Foundation of
   Ireland Research Frontiers Programme awarded to S. W. K. (no.
   BMT/2008/1709) and by Health Research Board of Ireland project grant
   RP/2006/2 to T. J. F.
CR Ahmed S, 2001, INFECT IMMUN, V69, P2872, DOI 10.1128/IAI.69.5.2872 2877.2001
   Berendt T, 2004, CLIN MED, V4, P510, DOI 10.7861/clinmedicine.4 6 510
   Bu RF, 2003, BONE, V33, P760, DOI 10.1016/j.bone.2003.07.006
   Carmody RJ, 2007, CELL MOL IMMUNOL, V4, P31
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Claro T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018748
   DUTHIE ES, 1952, J GEN MICROBIOL, V6, P95, DOI 10.1099/00221287 6 1 2 95
   Edwards CJ, 2010, OSTEOPOROSIS INT, V21, P1287, DOI 10.1007/s00198 010 1192 7
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Foster TJ, 2009, VET DERMATOL, V20, P456, DOI 10.1111/j.1365 3164.2009.00825.x
   García Alvarez F, 2009, BIOGERONTOLOGY, V10, P649, DOI 10.1007/s10522 008 9211 1
   Gómez MI, 2007, EMBO J, V26, P701, DOI 10.1038/sj.emboj.7601554
   Gómez MI, 2006, J BIOL CHEM, V281, P20190, DOI 10.1074/jbc.M601956200
   Guicciardi ME, 2009, FASEB J, V23, P1625, DOI 10.1096/fj.08 111005
   Have KLV, 2009, J PEDIATR ORTHOPED, V29, P927, DOI 10.1097/BPO.0b013e3181bd1e0c
   Hertzén E, 2010, J INNATE IMMUN, V2, P534, DOI 10.1159/000317635
   Hill P A, 1998, Br J Orthod, V25, P101
   ISHIMI Y, 1990, J IMMUNOL, V145, P3297
   Jazayeri JA, 2010, INT IMMUNOPHARMACOL, V10, P1, DOI 10.1016/j.intimp.2009.09.019
   Karsenty G, 2012, J ENDOCRINOL, V213, P107, DOI 10.1530/JOE 11 0452
   KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569
   Kriete A, 2009, EXP GERONTOL, V44, P250, DOI 10.1016/j.exger.2008.12.005
   Lew DP, 2004, LANCET, V364, P369, DOI 10.1016/S0140 6736(04)16727 5
   Marriott I, 2002, J INTERF CYTOK RES, V22, P1049, DOI 10.1089/107999002760624288
   MCDEVITT D, 1994, MOL MICROBIOL, V11, P237, DOI 10.1111/j.1365 2958.1994.tb00304.x
   Montanaro L, 2011, INT J ARTIF ORGANS, V34, P781, DOI 10.5301/ijao.5000052
   Ning RD, 2010, ACTA BIOCH BIOPH SIN, V42, P883, DOI 10.1093/abbs/gmq096
   OBrien L, 2002, MOL MICROBIOL, V44, P1033, DOI 10.1046/j.1365 2958.2002.02935.x
   Oviedo Boyso J, 2011, INFECT IMMUN, V79, P4569, DOI 10.1128/IAI.05303 11
   Panzer U, 2009, AM J PHYSIOL RENAL, V297, pF429, DOI 10.1152/ajprenal.90435.2008
   Rao NL, 2011, PLAST RECONSTR SURG, V127, p177S, DOI 10.1097/PRS.0b013e3182001f0f
   Scharf S, 2012, EXP LUNG RES, V38, P100, DOI 10.3109/01902148.2011.652802
   Sims NA, 2008, SEMIN CELL DEV BIOL, V19, P444, DOI 10.1016/j.semcdb.2008.07.016
   Sinha B, 1999, CELL MICROBIOL, V1, P101, DOI 10.1046/j.1462 5822.1999.00011.x
   Tucker KA, 2000, FEMS MICROBIOL LETT, V186, P151, DOI 10.1016/S0378 1097(00)00125 7
   Widaa A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040586
   Wright JA, 2010, INT J MED MICROBIOL, V300, P193, DOI 10.1016/j.ijmm.2009.10.003
   Yoshii T, 2002, CYTOKINE, V19, P59, DOI 10.1006/cyto.2002.1039
NR 38
TC 78
Z9 85
U1 1
U2 13
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 1350 0872
EI 1465 2080
J9 MICROBIOL SGM
JI Microbiology (UK)
PD JAN
PY 2013
VL 159
BP 147
EP 154
DI 10.1099/mic.0.063016 0
PN 1
PG 8
WC Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Microbiology
GA 098PK
UT WOS:000315561000015
PM 23154968
DA 2025 08 17
ER

PT J
AU Shim, KS
   Ma, CJ
   Kim, DS
   Ma, JY
AF Shim, Ki Shuk
   Ma, Choong Je
   Kim, Dong Seon
   Ma, Jin Yeul
TI Yukmijihwang tang Inhibits Receptor Activator for Nuclear
   Factor κB Ligand Induced Osteoclast Differentiation
SO JOURNAL OF MEDICINAL FOOD
LA English
DT Article
DE osteoclast differentiation; RAW264.7 cells; receptor activator for
   nuclear factor kappa B ligand; Yukmijihwang tang
ID RESISTANT ACID PHOSPHATASE; NECROSIS FACTOR RECEPTOR; BONE RESORPTION;
   GENE EXPRESSION; CATHEPSIN K; C FOS; SIGNALING PATHWAY; DERIVATIVES
   YMJD; PROTEIN KINASE; TRAF FAMILY
AB Yukmijihwang tang (YMT) is a traditional herbal medicine known to enhance memory in brain injury models. The aims of this study were to evaluate the inhibitory effect of YMT on osteoclast differentiation and to determine its molecular mechanism of action. YMT dose dependently inhibited receptor activator for nuclear factor kappa B (NF kappa B) ligand (RANKL) induced tartrate resistant acid phosphatase (TRAP) activity and the formation of multinucleated osteoclasts in RAW264.7 cells. In addition, quantitative reverse transcription polymerase chain reaction showed that YMT significantly decreased RANKL induced expression of osteoclast differentiation specific genes (TRAP, matrix metalloproteinase 9, cathepsin K, and the d2 isoform of vacuolar ATPase V(0) domain). Furthermore, YMT inhibited RANKL induced phosphorylation of mitogen activated protein kinases (extracellular signal regulated kinase, c Jun N terminal kinase, and p38), phosphorylation of I kappa B alpha, phosphorylation of NF kappa B p65, and the expression of transcription factors Fra 2 and nuclear factor of activated T cells, cytoplasmic 1. Furthermore, YMT inhibited the bone resorptive activity of differentiated osteoclasts, suggesting that YMT inhibits osteoclast differentiation by suppressing RANKL induced signaling molecules and transcription factors that affect the regulation of genes for osteoclast differentiation. As such, YMT may have therapeutic potential in bone diseases.
C1 [Shim, Ki Shuk; Kim, Dong Seon; Ma, Jin Yeul] Korea Inst Oriental Med, Ctr Herbal Med Improvement Res, Taejon 305811, South Korea.
   [Ma, Choong Je] Kangwon Natl Univ, Dept Biomat Engn, Chunchon, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM); Kangwon National University
RP Ma, JY (通讯作者)，Korea Inst Oriental Med, Ctr Herbal Med Improvement Res, Taejon 305811, South Korea.
EM jyma@kiom.re.kr
RI Je, Choong/H 9986 2013; Ma, Choong Je/H 9986 2013
OI Ma, Choong Je/0000 0001 8818 6396
FU Korea Institute of Oriental Medicine, Ministry of Education, Science and
   Technology, Korea [K11050]
FX This work was supported by a grant (K11050) from the Korea Institute of
   Oriental Medicine, Ministry of Education, Science and Technology, Korea.
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Battaglino R, 2002, J BONE MINER RES, V17, P763, DOI 10.1359/jbmr.2002.17.5.763
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Dong J, 2008, GENE DEV, V22, P1159, DOI 10.1101/gad.1657408
   Fleischmann A, 2000, GENE DEV, V14, P2695, DOI 10.1101/gad.187900
   Halleen JM, 1999, J BIOL CHEM, V274, P22907, DOI 10.1074/jbc.274.33.22907
   Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Ishibashi O, 2006, LIFE SCI, V79, P1657, DOI 10.1016/j.lfs.2006.05.024
   Jeong JC, 2003, INT IMMUNOPHARMACOL, V3, P1685, DOI 10.1016/j.intimp.2003.08.003
   Jin UH, 2006, J ETHNOPHARMACOL, V106, P333, DOI 10.1016/j.jep.2006.01.012
   KAMEDA T, 1993, P NATL ACAD SCI USA, V90, P9369, DOI 10.1073/pnas.90.20.9369
   Kang DG, 2006, J ETHNOPHARMACOL, V104, P47, DOI 10.1016/j.jep.2005.08.044
   Kang M, 2006, BIOL PHARM BULL, V29, P1431, DOI 10.1248/bpb.29.1431
   Kim HH, 1999, FEBS LETT, V443, P297, DOI 10.1016/S0014 5793(98)01731 1
   Kim JS, 2000, AM J CHINESE MED, V28, P343, DOI 10.1142/S0192415X00000404
   Kim MH, 2010, ARCH PHARM RES, V33, P457, DOI 10.1007/s12272 010 0316 0
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298
   Oh MS, 2007, REPROD TOXICOL, V24, P365, DOI 10.1016/j.reprotox.2007.05.007
   Pang M, 2007, GENE, V403, P151, DOI 10.1016/j.gene.2007.08.007
   Putnam SE, 2007, PHYTOTHER RES, V21, P99, DOI 10.1002/ptr.2030
   REDDY SV, 1995, J BONE MINER RES, V10, P601
   Rho S, 2005, BIOL PHARM BULL, V28, P87, DOI 10.1248/bpb.28.87
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Saftig P, 2000, ADV EXP MED BIOL, V477, P293
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   Srivastava S, 1999, J CLIN INVEST, V104, P503, DOI 10.1172/JCI7094
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Sundaram K, 2007, EXP CELL RES, V313, P168, DOI 10.1016/j.yexcr.2006.10.001
   Takatsuna H, 2005, J BONE MINER RES, V20, P653, DOI 10.1359/JBMR.041213
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Won JB, 2010, ARCH PHARM RES, V33, P619, DOI 10.1007/s12272 010 0417 9
   Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355
   Wu HP, 2009, J BONE MINER RES, V24, P871, DOI [10.1359/JBMR.081239, 10.1359/jbmr.081239]
   Yin J, 2008, PLANTA MED, V74, P1451, DOI 10.1055/s 2008 1081340
NR 47
TC 16
Z9 16
U1 0
U2 4
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096 620X
J9 J MED FOOD
JI J. Med. Food
PD NOV
PY 2011
VL 14
IS 11
BP 1439
EP 1447
DI 10.1089/jmf.2010.1502
PG 9
WC Chemistry, Medicinal; Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Food Science & Technology; Nutrition &
   Dietetics
GA 844LN
UT WOS:000296748800021
PM 21883017
DA 2025 08 17
ER

PT J
AU Rothea, R
   Sehulze, S
   Neuber, C
   Hausera, S
   Rammelt, S
   Pietzsch, J
AF Rothea, Rebecca
   Sehulze, Sabine
   Neuber, Christin
   Hausera, Sandra
   Rammelt, Stefan
   Pietzsch, Jens
TI Adjuvant drug assisted bone healing: Part I   Modulation of inflammation
SO CLINICAL HEMORHEOLOGY AND MICROCIRCULATION
LA English
DT Article
DE Biomaterials; critical size bone defects; cyclooxygenase 2; innate
   immunity; prostanoids; signaling; small molecules
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MESENCHYMAL STEM CELLS; SELECTIVE
   COX 2 INHIBITORS; PARATHYROID HORMONE; EP4 RECEPTOR; CRITICAL SIZE;
   MORPHOGENETIC PROTEIN 2; MOLECULAR MECHANISMS; CYCLOOXYGENASE 2
   INHIBITION; OSTEOBLAST DIFFERENTIATION
AB Critical size bone defects after compound fractures, infection, or tumor resection are challenging to treat. The same is true for fractures in patients with impaired bone healing due to metabolic diseases and cancer. Despite considerable progress over the last decade in surgical techniques, material design, and dedicated imaging approaches, these scenarios represent unsolved clinical problems. The high socioeconomic burden of such conditions justifies increasing interest in novel osteoinductive drugs for adjuvant therapeutic approaches. There is an increasing body of experimental and clinical literature on potentially promising effects of growth factors, anti resorptive, and anabolic agents. The true clinical efficacy of these, however, is discussed controversially. Therefore, we aimed to critically examine the hypothesis that targeted adjuvant therapies have the potential to enhance bone regeneration in critical size bone defects and under systemic conditions that impair bone healing. This first approach to the topic deals with small molecule drugs and compounds that influence the immune response and inflammatory processes. In particular, literature reporting on selective cyclooxygenase 2 inhibitors has been reviewed with respect to their local and systemic mode of action and to stimulate further research on bone healing under critical conditions.
C1 [Rothea, Rebecca; Neuber, Christin; Hausera, Sandra; Pietzsch, Jens] Helmholtz Zentrum Dresden Rossendorf, Inst Radiopharmaceut CancerRes, Dept Radiopharmaceut & Chem Biol, Bautzner Landstr 400, D 01328 Dresden, Germany.
   [Sehulze, Sabine; Rammelt, Stefan] Univ Hosp Carl Gustav Cams, Univ Ctr Orthopaed & Traumatol OUC, Dresden, Germany.
   [Sehulze, Sabine; Rammelt, Stefan] Tech Univ Dresden, Ctr Translat Bone Joint & Soft Tissue Res, Univ Hosp Carl Gustav Carus, Dresden, Germany.
   [Sehulze, Sabine; Rammelt, Stefan] Tech Univ Dresden, Fac Med, Dresden, Germany.
   [Rammelt, Stefan] CRTD, Dresden, Germany.
   [Pietzsch, Jens] Tech Univ Dresden, Sch Sci, Fac Chem & Food Chem, Dresden, Germany.
C3 Helmholtz Association; Helmholtz Zentrum Dresden Rossendorf (HZDR);
   Technische Universitat Dresden; Carl Gustav Carus University Hospital;
   Technische Universitat Dresden; Carl Gustav Carus University Hospital;
   Technische Universitat Dresden; Technische Universitat Dresden;
   Technische Universitat Dresden
RP Pietzsch, J (通讯作者)，Helmholtz Zentrum Dresden Rossendorf, Inst Radiopharmaceut CancerRes, Dept Radiopharmaceut & Chem Biol, Bautzner Landstr 400, D 01328 Dresden, Germany.; Rammelt, S (通讯作者)，Univ Hosp Carl Gustav Cams, Univ Ctr Orthopaed & Traumatol, Fetscherstr 74, D 01307 Dresden, Germany.
EM stefan.rammelt@uniklinikum dresden.de; j.pietzsch@hzdr.de
RI Pietzsch, Jens/O 5070 2017; Rammelt, Stefan/AAE 5863 2019
OI Pietzsch, Jens/0000 0002 1610 1493; Neuber,
   Christin/0000 0002 0646 5808; Hauser, Sandra/0000 0001 8206 6000;
   Rammelt, Stefan/0000 0003 1141 6493; Rothe, Rebecca/0000 0002 0615 1112
FU Deutsche Forschungsgemeinschaft (DFG) within the Collaborative Research
   Center Transregio 67 "Functional Biomaterials for Controlling Healing
   Processes in Bone und Skin   From Material Science to Clinical
   Application" [CRC/TRR 67/3]; Helmholtz Association through the Helmholtz
   Cross Programme Initiative "Technology and Medicine   Adaptive Systems"
FX We wish to apologize to those researchers whose works have not been
   mentioned due to restrictions in space. The authors are thankful to the
   Deutsche Forschungsgemeinschaft (DFG) for supporting this work within
   the Collaborative Research Center Transregio 67 "Functional Biomaterials
   for Controlling Healing Processes in Bone und Skin   From Material
   Science to Clinical Application" (CRC/TRR 67/3). The authors also thank
   the Helmholtz Association for funding a part of this work through the
   Helmholtz Cross Programme Initiative "Technology and Medicine   Adaptive
   Systems".
CR Ai Aql ZS, 2008, J DENT RES, V87, P107, DOI 10.1177/154405910808700215
   Akhter MP, 2001, BONE, V29, P121, DOI 10.1016/S8756 3282(01)00486 0
   Akman S, 2002, ADV THER, V19, P119, DOI 10.1007/BF02850267
   Akritopoulos P, 2009, ARCH ORTHOP TRAUM SU, V129, P1427, DOI 10.1007/s00402 008 0707 6
   Alkhiary YM, 2005, J BONE JOINT SURG AM, V87A, P731, DOI 10.2106/JBJS.D.02115
   [Anonymous], 1985, J APPL PHYSL, DOI DOI 10.1152/JAPPLPHYSI0L.00053.2013
   Aronin CEP, 2010, BIOMATERIALS, V31, P6417, DOI 10.1016/j.biomaterials.2010.04.061
   Arora N, 2018, CLIN HEMORHEOL MICRO, V69, P153, DOI 10.3233/CH 189109
   Aslan M, 2005, DENT TRAUMATOL, V21, P222, DOI 10.1111/j.1600 9657.2005.00300.x
   Aspenberg P, 2005, ACTA ORTHOP, V76, P741, DOI 10.1080/17453670510045318
   Atobe M, 2018, BIOORG MED CHEM LETT, V28, P2408, DOI 10.1016/j.bmcl.2018.06.022
   Bae MS, 2014, BONE, V59, P189, DOI 10.1016/j.bone.2013.11.019
   Bahney CS, 2019, J ORTHOP RES, V37, P35, DOI 10.1002/jor.24170
   Baht GS, 2018, CURR OSTEOPOROS REP, V16, P138, DOI 10.1007/s11914 018 0423 2
   Barnes GL, 2006, CLIN REV BONE MINER, V4, P269, DOI 10.1385/BMM:4:4:269
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Barry S, 2010, VET COMP ORTHOPAED, V23, P385, DOI 10.3415/VCOT 10 01 0017
   Bechmann N, 2015, BIOORG MED CHEM LETT, V25, P3295, DOI 10.1016/j.bmcl.2015.05.059
   Beck A, 2003, ARCH ORTHOP TRAUM SU, V123, P327, DOI 10.1007/s00402 003 0537 5
   Beck Alexander, 2005, Oper Orthop Traumatol, V17, P569, DOI 10.1007/s00064 005 1152 0
   Bergenstock M, 2005, J ORTHOP TRAUMA, V19, P717, DOI 10.1097/01.bot.0000184144.98071.5d
   Bhattacharyya T, 2005, ARTHRIT RHEUM ARTHR, V53, P364, DOI 10.1002/art.21170
   Bielby R, 2007, INJURY, V38, pS26, DOI 10.1016/j.injury.2007.02.007
   Blackwell KA, 2010, TRENDS ENDOCRIN MET, V21, P294, DOI 10.1016/j.tem.2009.12.004
   Borrelli J, 2012, J ORTHOP TRAUMA, V26, P708, DOI 10.1097/BOT.0b013e318274da8b
   Boursinos LA, 2009, J MUSCULOSKEL NEURON, V9, P44
   Caetano Lopes J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016947
   Cameron KO, 2009, BIOORG MED CHEM LETT, V19, P2075, DOI 10.1016/j.bmcl.2009.01.059
   Campana V, 2014, J MATER SCI MATER M, V25, P2445, DOI 10.1007/s10856 014 5240 2
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Canalis E, 2002, ANN NY ACAD SCI, V966, P73, DOI 10.1111/j.1749 6632.2002.tb04204.x
   Carbonare LD, 2001, J BONE MINER RES, V16, P97, DOI 10.1359/jbmr.2001.16.1.97
   Casanova Michele, 2014, Bonekey Rep, V3, P550, DOI 10.1038/bonekey.2014.45
   Cecchi S, 2016, J ORTHOP TRANSL, V4, P28, DOI 10.1016/j.jot.2015.08.001
   Chaparro O., 2016, Advanced Techniques in Bone Regeneration, P253, DOI [10.5772/61425, DOI 10.5772/61425]
   Chee Carolyn, 2014, Open Respir Med J, V8, P85, DOI 10.2174/1874306401408010085
   Chen MR, 2013, KNEE SURG SPORT TR A, V21, P540, DOI 10.1007/s00167 012 2095 2
   Chen Q, 2003, CALCIFIED TISSUE INT, V73, P387, DOI 10.1007/s00223 002 0009 x
   Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1
   Cooper GM, 2010, PLAST RECONSTR SURG, V125, P1685, DOI 10.1097/PRS.0b013e3181cb63a3
   Cottrell J, 2010, PHARMACEUTICALS, V3, P1668, DOI 10.3390/ph3051668
   Dahners LE, 2004, J AM ACAD ORTHOP SUR, V12, P139, DOI 10.5435/00124635 200405000 00001
   Datta NS, 2009, CELL SIGNAL, V21, P1245, DOI 10.1016/j.cellsig.2009.02.012
   Dean DB, 2010, J ANAT, V216, P625, DOI 10.1111/j.1469 7580.2010.01214.x
   Della Rocca GJ, 2010, J ORTHOP TRAUMA, V24, pS31, DOI 10.1097/BOT.0b013e3181cde5d1
   Deschaseaux F, 2009, TRENDS MOL MED, V15, P417, DOI 10.1016/j.molmed.2009.07.002
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Dimmen S, 2008, ACTA ORTHOP, V79, P438, DOI 10.1080/17453670710015373
   Dimmen S, 2009, CLIN ORTHOP RELAT R, V467, P1992, DOI 10.1007/s11999 009 0783 0
   Dittmer KE, 2017, J VET DIAGN INVEST, V29, P385, DOI 10.1177/1040638716679861
   Einhorn TA, 2002, J BONE MINER RES, V17, P977, DOI 10.1359/jbmr.2002.17.6.977
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Ellegaard M, 2010, CALCIFIED TISSUE INT, V87, P1, DOI 10.1007/s00223 010 9360 5
   Endo K, 2005, ACTA ORTHOP, V76, P470, DOI 10.1080/17453670510041439
   Endo Kenji, 2002, Journal of Physiological Anthropology and Applied Human Science, V21, P235, DOI 10.2114/jpa.21.235
   Endres S, 2011, CLIN HEMORHEOL MICRO, V48, P29, DOI 10.3233/CH 2011 1406
   Fader L, 2018, INJURY, V49, P2290, DOI 10.1016/j.injury.2018.09.024
   Fassbender M, 2014, INT J MOL SCI, V15, P8539, DOI 10.3390/ijms15058539
   Fazzalari NL, 2011, OSTEOPOROSIS INT, V22, P2003, DOI 10.1007/s00198 011 1611 4
   Fisher J, 2003, FUNCTIONAL TISSUE EN
   Förster Y, 2017, MAT SCI ENG C MATER, V71, P84, DOI 10.1016/j.msec.2016.09.071
   Förster Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159580
   Forster Yvonne, 2012, Biomatter, V2, P149, DOI 10.4161/biom.21563
   Frenkel B, 2015, ADV EXP MED BIOL, V872, P179, DOI 10.1007/978 1 4939 2895 8_8
   Fujino H, 2005, MOL PHARMACOL, V68, P251, DOI 10.1124/mol.105.011833
   Fujino H, 2003, J BIOL CHEM, V278, P12151, DOI 10.1074/jbc.M212665200
   Gajraj NM, 2003, REGION ANESTH PAIN M, V28, P456, DOI 10.1016/j.rapm.2003.09.001
   Ganesh T, 2014, J MED CHEM, V57, P4454, DOI 10.1021/jm401431x
   Gaston MS, 2007, J BONE JOINT SURG BR, V89B, P1553, DOI 10.1302/0301 620X.89B12
   Gelse K, 2011, ARTHRITIS RHEUM US, V63, P871, DOI 10.1002/art.30153
   Gerstenfeld LC, 2003, J ORTHOP RES, V21, P670, DOI 10.1016/S0736 0266(03)00003 2
   Gerstenfeld Louis C, 2004, Expert Opin Drug Saf, V3, P131, DOI 10.1517/14740338.3.2.131
   Geusens P, 2013, CURR OPIN RHEUMATOL, V25, P524, DOI 10.1097/BOR.0b013e32836200b8
   Ghiasi Mohammad S, 2017, Bone Rep, V6, P87, DOI 10.1016/j.bonr.2017.03.002
   Gibon E, 2017, J ORTHOP TRANSL, V10, P28, DOI 10.1016/j.jot.2017.04.002
   Giordano V, 2003, INJURY, V34, P85, DOI 10.1016/S0020 1383(02)00199 7
   Godoy Santos AL, 2017, INJURY, V48, pS27, DOI 10.1016/S0020 1383(17)30772 6
   Gomes S, 2012, PROG POLYM SCI, V37, P1, DOI 10.1016/j.progpolymsci.2011.07.003
   Goodman S, 2002, J ORTHOP RES, V20, P1164, DOI 10.1016/S0736 0266(02)00079 7
   Goodman SB, 2007, J AM ACAD ORTHOP SUR, V15, P450, DOI 10.5435/00124635 200708000 00002
   Graham S, 2009, EXPERT OPIN INV DRUG, V18, P749, DOI [10.1517/13543780902893051 , 10.1517/13543780902893051]
   Gregory LS, 2007, CALCIFIED TISSUE INT, V80, P176, DOI 10.1007/s00223 006 0170 8
   Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291
   Guo S, 2010, J DENT RES, V89, P219, DOI 10.1177/0022034509359125
   Gurgel Bruno César de Vasconcelos, 2005, Braz. oral res., V19, P312, DOI 10.1590/S1806 83242005000400014
   Hachemi Y, 2018, J MOL ENDOCRINOL, V61, pR75, DOI 10.1530/JME 18 0024
   Hagino H, 2005, BONE, V36, P444, DOI 10.1016/j.bone.2004.12.013
   Hak DJ, 2011, J ORTHOP SCI, V16, P93, DOI 10.1007/s00776 010 0016 0
   Hankenson KD, 2011, INJURY, V42, P556, DOI 10.1016/j.injury.2011.03.035
   Harada N, 2014, BIOMATERIALS, V35, P7800, DOI 10.1016/j.biomaterials.2014.05.052
   Harder AT, 2003, J CLIN PHARMACOL, V43, P807, DOI 10.1177/0091270003256061
   Haumer A, 2018, ADV DRUG DELIVER REV, V129, P285, DOI 10.1016/j.addr.2018.01.010
   Hauser S, 2017, TRENDS BIOTECHNOL, V35, P265, DOI 10.1016/j.tibtech.2016.09.007
   Hempel U, 2014, J CELL BIOCHEM, V115, P1561, DOI 10.1002/jcb.24814
   Hoff P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030583
   Huang HC, 2010, J BONE MINER RES, V25, P819, DOI 10.1359/jbmr.091019
   Inal S, 2014, INJURY, V45, P494, DOI 10.1016/j.injury.2013.10.002
   Janssen MPF, 2017, EUR CELLS MATER, V34, P202, DOI 10.22203/eCM.v034a13
   Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006 0459
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Kamolratanakul P, 2011, ARTHRITIS RHEUM US, V63, P1021, DOI 10.1002/art.30151
   Kanakaris NK, 2015, J ORTHOP TRAUMA, V29, pS10, DOI [10.1097/BOT.0000000000000286, 10.1097/BOT.0000000000000465]
   Karachalios T, 2007, J BONE JOINT SURG BR, V89B, P1253, DOI 10.1302/0301 620X.89B9.19050
   Katagiri W, 2015, IMPLANT DENT, V24, P657, DOI 10.1097/ID.0000000000000335
   Katzung BG., 2012, BASIC CLIN PHARM, P1227
   Kawai T, 2015, CYTOTHERAPY, V17, P369, DOI 10.1016/j.jcyt.2014.11.009
   Kay RM, 2010, J PEDIATR ORTHOPED, V30, P655, DOI 10.1097/BPO.0b013e3181efb8b4
   Ke HZ, 2006, J BONE MINER RES, V21, P565, DOI 10.1359/JBMR.051110
   Keila S, 2001, J ENDOCRINOL, V168, P131, DOI 10.1677/joe.0.1680131
   Kempen DHR, 2009, BIOMATERIALS, V30, P2816, DOI 10.1016/j.biomaterials.2009.01.031
   Kidd LJ, 2013, J ORTHOP RES, V31, P235, DOI 10.1002/jor.22203
   Kim CH, 2005, INT J BIOCHEM CELL B, V37, P375, DOI 10.1016/j.biocel.2004.07.013
   Koetz KR, 2012, J CLIN ENDOCR METAB, V97, P85, DOI 10.1210/jc.2011 2036
   Kolar P, 2010, TISSUE ENG PART B RE, V16, P427, DOI [10.1089/ten.teb.2009.0687, 10.1089/ten.TEB.2009.0687]
   Komatsu DE, 2010, J CELL BIOCHEM, V109, P302, DOI 10.1002/jcb.22418
   Komatsubara S, 2005, BONE, V36, P678, DOI 10.1016/j.bone.2005.02.002
   Kostenuik P, 2017, J ORTHOP RES, V35, P213, DOI 10.1002/jor.23460
   Krischak GD, 2007, ARCH ORTHOP TRAUM SU, V127, P453, DOI 10.1007/s00402 007 0288 9
   Krischak GD, 2007, ARCH ORTHOP TRAUM SU, V127, P3, DOI 10.1007/s00402 006 0202 x
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Kulkarni NH, 2005, J CELL BIOCHEM, V95, P1178, DOI 10.1002/jcb.20506
   Kwong FNK, 2008, J AM ACAD ORTHOP SUR, V16, P619, DOI 10.5435/00124635 200811000 00001
   Kyllönen L, 2015, ACTA BIOMATER, V11, P412, DOI 10.1016/j.actbio.2014.09.006
   Lane NE, 2006, J BONE MINER RES, V21, P466, DOI 10.1359/JBMR.051103
   Lau KHW, 2013, BONE, V53, P369, DOI 10.1016/j.bone.2013.01.003
   Laube M, 2016, ANTIOXIDANTS BASEL, V5, DOI 10.3390/antiox5020014
   Laube M, 2015, J ORG CHEM, V80, P5611, DOI 10.1021/acs.joc.5b00537
   Laube M, 2013, MOLECULES, V18, P6311, DOI 10.3390/molecules18066311
   Laurencin CT, 2014, DRUG DISCOV TODAY, V19, P794, DOI 10.1016/j.drudis.2014.01.012
   Lee SS, 2013, BIOMATERIALS, V34, P452, DOI 10.1016/j.biomaterials.2012.10.005
   Li M, 2007, INT ORTHOP, V31, P767, DOI 10.1007/s00264 007 0406 x
   Li M, 2005, BONE, V37, P46, DOI 10.1016/j.bone.2005.03.016
   Li M, 2003, J BONE MINER RES, V18, P2033, DOI 10.1359/jbmr.2003.18.11.2033
   Lieberman J.R., 2005, Bone regeneration and repair: Biology and clinical applications
   Linero I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107001
   Lisowska B, 2018, DRUG DES DEV THER, V12, P1809, DOI 10.2147/DDDT.S164565
   Lissenberg Thunnissen SN, 2011, INT ORTHOP, V35, P1271, DOI 10.1007/s00264 011 1301 z
   Lohmann P, 2017, BIOMATERIALS, V113, P158, DOI 10.1016/j.biomaterials.2016.10.039
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Lu LY, 2017, J ORTHOP RES, V35, P2378, DOI 10.1002/jor.23553
   Luppen CA, 2002, J BONE MINER RES, V17, P301, DOI 10.1359/jbmr.2002.17.2.301
   Marsell R, 2011, INJURY, V42, P551, DOI 10.1016/j.injury.2011.03.031
   Martin TJ, 2007, CLIN SCI, V112, P77, DOI 10.1042/CS20060046
   Martínez Vázquez FJ, 2015, ACTA BIOMATER, V15, P200, DOI 10.1016/j.actbio.2014.12.021
   Martins Márcia Valéria, 2005, Braz. Dent. J., V16, P207
   Matsumoto MA, 2008, J MOL HISTOL, V39, P381, DOI 10.1007/s10735 008 9176 z
   Meunier A, 2006, ARCH ORTHOP TRAUM SU, V126, P433, DOI 10.1007/s00402 006 0160 3
   Monfoulet LE, 2014, TISSUE ENG PT A, V20, P1827, DOI [10.1089/ten.TEA.2013.0500, 10.1089/ten.tea.2013.0500]
   Moreno Rubio J, 2010, ARTHRITIS RHEUM US, V62, P478, DOI 10.1002/art.27204
   Mosch B, 2010, J ONCOL, V2010, DOI 10.1155/2010/135285
   Mullis BH, 2006, INJURY, V37, P827, DOI 10.1016/j.injury.2005.12.018
   Murnaghan M, 2006, J BONE JOINT SURG AM, V88A, P140, DOI 10.2106/JBJS.F.00454
   Nagano A, 2017, J PHARMACOL SCI, V133, P18, DOI 10.1016/j.jphs.2016.11.003
   Naik AA, 2009, J BONE MINER RES, V24, P251, DOI [10.1359/jbmr.081002, 10.1359/JBMR.081002]
   Nair SK, 2010, TETRAHEDRON LETT, V51, P1451, DOI 10.1016/j.tetlet.2009.12.092
   Namas RA, 2015, ANTIOXID REDOX SIGN, V23, P1370, DOI 10.1089/ars.2015.6398
   Navarro M, 2008, J R SOC INTERFACE, V5, P1137, DOI 10.1098/rsif.2008.0151
   Nyangoga H, 2010, ACTA BIOMATER, V6, P3310, DOI 10.1016/j.actbio.2010.01.042
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   O'Connor J Patrick, 2014, Bonekey Rep, V3, P517, DOI 10.1038/bonekey.2014.12
   O'Connor JP, 2009, ACTA ORTHOP, V80, P597, DOI 10.3109/17453670903316769
   O'Connor JP, 2008, DRUG TODAY, V44, P693, DOI 10.1358/dot.2008.44.9.1251573
   O'Keefe RJ, 2006, ANN NY ACAD SCI, V1068, P532, DOI 10.1196/annals.1346.012
   Ogata K, 2015, BONE, V74, P95, DOI 10.1016/j.bone.2015.01.011
   Ono T, 2017, CURR OSTEOPOROS REP, V15, P367, DOI 10.1007/s11914 017 0381 0
   Pape HC, 2010, J ORTHOP TRAUMA, V24, P522, DOI 10.1097/BOT.0b013e3181ed1361
   Paralkar VM, 2003, P NATL ACAD SCI USA, V100, P6736, DOI 10.1073/pnas.1037343100
   Patel ZS, 2008, BONE, V43, P931, DOI 10.1016/j.bone.2008.06.019
   Peichl P, 2011, J BONE JOINT SURG AM, V93A, P1583, DOI 10.2106/JBJS.J.01379
   Persson PE, 2005, ACTA ORTHOP, V76, P465, DOI 10.1080/17453670510041420
   Potts JT, 2005, J ENDOCRINOL, V187, P311, DOI 10.1677/joe.1.06057
   Pountos I, 2008, INJURY, V39, P384, DOI 10.1016/j.injury.2007.10.035
   Pountos I, 2012, SCI WORLD J, DOI 10.1100/2012/606404
   Prystaz K, 2018, AM J PATHOL, V188, P474, DOI 10.1016/j.ajpath.2017.10.011
   Radi ZA, 2005, INFLAMM RES, V54, P358, DOI 10.1007/s00011 005 1367 4
   Rammelt S, 2005, J BIOMED MATER RES A, V73A, P284, DOI 10.1002/jbm.a.30263
   Rammelt S, 2016, EFORT OPEN REV, V1, P239, DOI 10.1302/2058 5241.1.000023
   Rao PNP, 2008, J PHARM PHARM SCI, V11, P81, DOI 10.18433/J3T886
   Rao R, 2007, J BIOL CHEM, V282, P16959, DOI 10.1074/jbc.M701214200
   Rapp AE, 2018, FASEB J, V32, P2235, DOI 10.1096/fj.201700459RR
   Rapp AE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147465
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Rehman Q, 2003, MED PEDIATR ONCOL, V41, P212, DOI 10.1002/mpo.10339
   Ren Q, 2018, BRAZ J MED BIOL RES, V51, DOI 10.1590/1414 431X20176520
   Reuben SS, 2007, CURR OPIN ANESTHESIO, V20, P440, DOI 10.1097/ACO.0b013e3282effb1d
   Robertson G, 2006, BONE, V39, P767, DOI 10.1016/j.bone.2006.04.006
   Rothe R, 2019, CLIN HEMORHEOL MICRO, V73, P409, DOI 10.3233/CH 199103
   Rothe R, 2019, CLIN HEMORHEOL MICRO, V73, P439, DOI 10.3233/CH 199104
   Rundle CH, 2008, J GENE MED, V10, P229, DOI 10.1002/jgm.1148
   Sansbury BE, 2016, CIRC RES, V119, P113, DOI 10.1161/CIRCRESAHA.116.307308
   Schindeler A, 2008, SEMIN CELL DEV BIOL, V19, P459, DOI 10.1016/j.semcdb.2008.07.004
   Schlundt C, 2018, BONE, V106, P78, DOI 10.1016/j.bone.2015.10.019
   Schmidt Bleek K, 2015, TISSUE ENG PART B RE, V21, P354, DOI [10.1089/ten.teb.2014.0677, 10.1089/ten.TEB.2014.0677]
   Schwarting T, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/926369
   Segar CE, 2013, CURR PHARM DESIGN, V19, P3403, DOI 10.2174/1381612811319190007
   Sen C, 2007, ARCH ORTHOP TRAUM SU, V127, P153, DOI 10.1007/s00402 006 0274 7
   Shrivats AR, 2014, DRUG DISCOV TODAY, V19, P781, DOI 10.1016/j.drudis.2014.04.010
   Sibai T, 2011, CLIN ORTHOP RELAT R, V469, P2215, DOI 10.1007/s11999 010 1722 9
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Simon AM, 2007, J BONE JOINT SURG AM, V89A, P500, DOI 10.2106/JBJS.F.00127
   Smith B, 2015, CURR REV MUSCULOSKE, V8, P193, DOI 10.1007/s12178 015 9265 z
   Spiro AS, 2010, J ORTHOP RES, V28, P785, DOI 10.1002/jor.21044
   Tanaka M, 2004, BONE, V34, P940, DOI 10.1016/j.bone.2004.01.002
   Tarantino U, 2009, CLIN CASES MINER BON, V6, P144
   Tatsuno I, 2009, J CLIN ENDOCR METAB, V94, P1671, DOI 10.1210/jc.2008 1578
   Thomas MV, 2011, J DENT RES, V90, P1052, DOI 10.1177/0022034510393967
   Tiseo Bruno C., 2006, Clinics, V61, P223, DOI 10.1590/S1807 59322006000300007
   Toyoda H, 2005, BONE, V37, P555, DOI 10.1016/j.bone.2005.04.042
   Tsiridis E, 2007, INJURY, V38, pS11, DOI 10.1016/j.injury.2007.02.006
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Vendégh Z, 2012, CLIN HEMORHEOL MICRO, V50, P279, DOI 10.3233/CH 2011 1436
   Virk MS, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4053
   Vuolteenaho K, 2008, BASIC CLIN PHARMACOL, V102, P10, DOI 10.1111/j.1742 7843.2007.00149.x
   Wagner AE, 2008, BIOCHEM BIOPH RES CO, V372, P336, DOI 10.1016/j.bbrc.2008.05.061
   Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809
   Wang T, 2017, J CELL PHYSIOL, V232, P913, DOI 10.1002/jcp.25641
   Wang WH, 2017, BIOACT MATER, V2, P224, DOI 10.1016/j.bioactmat.2017.05.007
   Waters RV, 2000, ACTA ORTHOP SCAND, V71, P316, DOI 10.1080/000164700317411951
   Weinreb M, 2004, BONE, V34, pS15
   Weinstein RS, 2010, AGING CELL, V9, P147, DOI 10.1111/j.1474 9726.2009.00545.x
   Wickerts L, 2011, MINERVA ANESTESIOL, V77, P1084
   Xie C, 2009, AM J PATHOL, V175, P772, DOI 10.2353/ajpath.2009.081099
   Yamada M, 2013, BIOMATERIALS, V34, P6147, DOI 10.1016/j.biomaterials.2013.04.064
   Yao W, 2008, ARTHRITIS RHEUM, V58, P3485, DOI 10.1002/art.23954
   Yoshida K, 2002, P NATL ACAD SCI USA, V99, P4580, DOI 10.1073/pnas.062053399
   Young S, 2009, TISSUE ENG PT A, V15, P2347, DOI 10.1089/ten.tea.2008.0510
   Zarghi A, 2011, IRAN J PHARM RES, V10, P655
   Zhang MJ, 2011, J BONE MINER RES, V26, P792, DOI 10.1002/jbmr.272
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
   Zhou W, 2017, CELL PHYSIOL BIOCHEM, V42, P551, DOI 10.1159/000477605
NR 231
TC 15
Z9 18
U1 0
U2 0
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1386 0291
EI 1875 8622
J9 CLIN HEMORHEOL MICRO
JI Clin. Hemorheol. Microcirc.
PY 2019
VL 73
IS 3
BP 381
EP 408
DI 10.3233/CH 199102
PG 28
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA KA3DN
UT WOS:000505678600002
PM 31177205
DA 2025 08 17
ER

PT J
AU Roser Page, S
   Vikulina, T
   Weiss, D
   Habib, MM
   Beck, GR
   Pacifici, R
   Lane, TF
   Weitzmann, MN
AF Roser Page, Susanne
   Vikulina, Tatyana
   Weiss, Daiana
   Habib, Mark M.
   Beck, George R., Jr.
   Pacifici, Roberto
   Lane, Timothy F.
   Weitzmann, M. Neale
TI CTLA 4Ig (abatacept) balances bone anabolic effects of T cells and
   Wnt 10b with antianabolic effects of osteoblastic sclerostin
SO ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Article
DE abatacept; CTLA 4Ig; T cells; osteoblasts; Wnt 10b
ID INTERMITTENT PTH TREATMENT; RHEUMATOID ARTHRITIS; ANTIGEN PRESENTATION;
   PARATHYROID HORMONE; IN VIVO; WNT10B; MASS; DEFICIENCY; ACTIVATION;
   EXPRESSION
AB Activated lymphocytes promote inflammation and bone destruction in rheumatoid arthritis (RA), making T cells and B cells therapeutic targets. Indeed, pharmacological blockade of CD28 costimulation using CTLA 4Ig (abatacept), approved for amelioration of RA, renders T cells dormant (anergic). CTLA 4Ig also promotes bone accretion in healthy mice; surprisingly, however, this effect is driven exclusively through upregulation of bone formation, rather than anti inflammatory effects on resorption. In the study presented here, we utilized T cell receptor gene and Wnt 10b gene knockout mice to investigate the roles of T cells and Wnt 10b in CTLA 4Ig induced bone anabolism. Ablation of either T cells or Wnt 10b not only abolished CTLA 4Ig induced bone anabolism but also, paradoxically, suppressed bone formation leading to bone loss. Stalled bone formation was accompanied by bone marrow stromal cell expression of the Wnt pathway inhibitor sclerostin. Our data suggest that an immunoskeletal pivot may promote or suppress bone formation, depending on the net outcome of CTLA 4Ig action directed independently on T cells and osteoblast linage cells that counter Wnt 10b induced bone anabolism, by secretion of sclerostin. While CTLA 4Ig action is tipped in favor of bone formation under physiological conditions, pathological immunodeficiency may lead to suppressed bone formation and skeletal damage.
C1 [Roser Page, Susanne; Vikulina, Tatyana; Habib, Mark M.; Beck, George R., Jr.; Weitzmann, M. Neale] Atlanta VA Med Ctr, Decatur, GA USA.
   [Vikulina, Tatyana; Weiss, Daiana; Habib, Mark M.; Beck, George R., Jr.; Pacifici, Roberto; Weitzmann, M. Neale] Emory Univ, Sch Med, Dept Med, Div Endocrinol & Metab & Lipids, Atlanta, GA USA.
   [Beck, George R., Jr.; Weitzmann, M. Neale] Emory Univ, Emory Winship Canc Inst, Atlanta, GA 30322 USA.
   [Pacifici, Roberto] Emory Univ, Immunol & Mol Pathogenesis Program, Atlanta, GA 30322 USA.
   [Lane, Timothy F.] Univ Calif Los Angeles, Dept Obstet & Gynecol, Los Angeles, CA 90024 USA.
   [Lane, Timothy F.] Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90024 USA.
   [Lane, Timothy F.] Univ Calif Los Angeles, Orthoped Hosp Res Ctr, Los Angeles, CA USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Atlanta VA Medical Center; Atlanta VA Health Care System; Emory
   University; Emory University; Emory University; University of California
   System; University of California Los Angeles; University of California
   System; University of California Los Angeles; University of California
   System; University of California Los Angeles
RP Weitzmann, MN (通讯作者)，Emory Univ Hosp, Sch Med, Div Endocrinol & Metab & Lipids, 101 Woodruff Circle,1305 WMB, Atlanta, GA 30322 USA.
EM mweitzm@emory.edu
RI Beck, George/AAO 2117 2020
OI Lane, Timothy F./0000 0002 0210 970X
FU Biomedical Laboratory Research & Development (BLRD) Service of the VA
   Office of Research and Development [5I01BX000105]; NIAMS [AR056090,
   AR059364, AR068157, AR070091]; NIA [AG040013]; BLRD [I01BX002363]; NIH
   [DK108842, AR054625, RR028009]
FX This work was supported by a grant from the Biomedical Laboratory
   Research & Development (BLRD) Service of the VA Office of Research and
   Development (5I01BX000105). M.N.W. was also supported, in part, by NIAMS
   Grants (AR056090, AR059364, AR068157, and AR070091) and NIA Grant
   AG040013. G.R.B. was supported by BLRD Grant number I01BX002363. R.P.
   was supported in part, by NIH Grants (DK108842, AR054625, and RR028009).
   The contents of this manuscript do not represent the views of the
   Department of Veterans Affairs, the National Institutes of Health, or
   the United States Government. M.N.W. designed the studies, interpreted
   the data, and wrote the manuscript. S.R P., T.V., D.W., M.M.H., and
   G.R.B. performed the research. R.P. and T.F.L. provided unique reagents
   necessary to undertake the studies. All authors read, provided
   intellectual input, and approved the final manuscript.
CR Axmann R, 2008, ANN RHEUM DIS, V67, P1603, DOI 10.1136/ard.2007.080713
   Bedi B, 2012, P NATL ACAD SCI USA, V109, pE725, DOI 10.1073/pnas.1120735109
   Bedi B, 2010, ANN NY ACAD SCI, V1192, P215, DOI 10.1111/j.1749 6632.2009.05216.x
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Bozec A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007764
   Camalier CE, 2013, J CELL PHYSIOL, V228, P1536, DOI 10.1002/jcp.24312
   Deodhar AA, 1996, BRIT J RHEUMATOL, V35, P309
   Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534
   Ernst B, 1999, IMMUNITY, V11, P173, DOI 10.1016/S1074 7613(00)80092 8
   Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092 8674(00)81109 5
   Fournier C, 2005, JOINT BONE SPINE, V72, P527, DOI 10.1016/j.jbspin.2004.12.012
   Gao Y, 2008, CELL METAB, V8, P132, DOI 10.1016/j.cmet.2008.07.001
   Grassi F, 2007, P NATL ACAD SCI USA, V104, P15087, DOI 10.1073/pnas.0703610104
   He XW, 2001, J RHEUMATOL, V28, P2168
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kates SL, 2007, INJURY, V38, P17, DOI 10.1016/j.injury.2007.08.007
   Klyushnenkova E, 2005, J BIOMED SCI, V12, P47, DOI 10.1007/s11373 004 8183 7
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kuek A, 2007, POSTGRAD MED J, V83, P251, DOI 10.1136/pgmj.2006.052688
   Li JY, 2014, J BONE MINER RES, V29, P43, DOI 10.1002/jbmr.2044
   Li Y, 2007, BLOOD, V109, P3839, DOI 10.1182/blood 2006 07 037994
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Reyes Botella C, 2000, J PERIODONTOL, V71, P614, DOI 10.1902/jop.2000.71.4.614
   Robinson JW, 2015, J BONE MINER RES, V30, P695, DOI 10.1002/jbmr.2394
   Roser Page S, 2014, ARTHRITIS RHEUMATOL, V66, P990, DOI 10.1002/art.38319
   Sayegh MH, 1999, J CLIN INVEST, V103, P1223, DOI 10.1172/JCI6952
   Stevens JR, 2010, J BONE MINER RES, V25, P2138, DOI 10.1002/jbmr.118
   Straub RH, 2015, SEMIN ARTHRITIS RHEU, V45, P220, DOI 10.1016/j.semarthrit.2015.04.014
   Terauchi M, 2009, CELL METAB, V10, P229, DOI 10.1016/j.cmet.2009.07.010
   Titanji K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004497
   Toraldo G, 2003, P NATL ACAD SCI USA, V100, P125, DOI 10.1073/pnas.0136772100
   Vertino AM, 2005, MOL BIOL CELL, V16, P2039, DOI 10.1091/mbc.E04 08 0720
   Vital Edward M, 2006, Ther Clin Risk Manag, V2, P365, DOI 10.2147/tcrm.2006.2.4.365
   Weitzmann MN, 2016, NAT REV ENDOCRINOL, V12, P518, DOI 10.1038/nrendo.2016.91
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Yanaba K, 2007, J IMMUNOL, V179, P1369, DOI 10.4049/jimmunol.179.2.1369
NR 37
TC 12
Z9 12
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0077 8923
EI 1749 6632
J9 ANN NY ACAD SCI
JI Ann. N.Y. Acad. Sci.
PD MAR
PY 2018
VL 1415
IS 1
SI SI
BP 21
EP 33
DI 10.1111/nyas.13643
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GA5DA
UT WOS:000428351100003
PM 29500936
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU McCarthy, TL
   Centrella, M
AF McCarthy, Thomas L.
   Centrella, Michael
TI Prostaglandin Dependent Control of an Endogenous Estrogen Receptor
   Agonist by Osteoblasts
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID BINDING PROTEIN DELTA; GROWTH FACTOR BETA; FACTOR I GENE; SUPPRESSED
   BONE TURNOVER; POSTMENOPAUSAL WOMEN; ADENYLYL CYCLASE; INDEPENDENT
   ACTIVATION; SELECTIVE INHIBITOR; PARATHYROID HORMONE; SIGNALING PATHWAYS
AB Estrogen receptor (ER) activation has complex effects on bone cells, and loss of circulating estradiol adversely affects skeletal status in women. Hormone replacement therapy effectively circumvents bone loss after menopause, but enhances disease risk in other tissues. Here we show that prostaglandin E2 (PGE2) augments the activity of an osteoblast derived selective ER modulator, ObSERM. The stimulatory effect of PGE2 is replicated in part by either the PG receptor EP3 agonist 17 phenyl trinor PGE2 or by the PG receptor FP agonist PGF2 Whereas activation of the various PG receptors induces multiple downstream signals, the response to PGE2 was mimicked by activators of protein kinase C, and suppressed by inhibition of protein kinase C but not by inhibition of protein kinase A. Moreover, inhibition of nitric oxide synthesis and activation of the PTH and Wnt pathways increases ObSERM activity. Our studies therefore reveal that ObSERM activity is controlled in distinct ways and revise our understanding of ER activation within bone by agents or events associated with PG expression. They also predict ways to sustain or improve bone formation, fracture repair, and surgical healing without adding the risk of disease in other tissues where ER activation also has important biological functions. J. Cell. Physiol. 230: 1104 1114, 2015. (c) 2014 Wiley Periodicals, Inc., A Wiley Company
C1 [McCarthy, Thomas L.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA.
   Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA.
C3 Yale University; Yale University
RP McCarthy, TL (通讯作者)，Yale Univ, Sch Med, Dept Pathol, LH109,330 Cedar St, New Haven, CT 06520 USA.
EM thomas.mccarthy@yale.edu; michael.centrella@yale.edu
FU NIH [AR39201, AR062764]
FX Contract grant sponsor: NIH;Contract grant numbers: AR39201, AR062764.
CR Agas D, 2013, J CELL PHYSIOL, V228, P25, DOI 10.1002/jcp.24117
   Armitage M, 2003, CLIN ENDOCRINOL, V59, P145, DOI 10.1046/j.1365 2265.2003.01815.x
   Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Berger K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004671
   Billiard J, 2001, J BIOL CHEM, V276, P15354, DOI 10.1074/jbc.M009973200
   Bogazzi F, 2011, J ENDOCRINOL INVEST, V34, pE200, DOI 10.3275/7228
   Byrns MC, 2008, BIOCHEM PHARMACOL, V75, P484, DOI 10.1016/j.bcp.2007.09.008
   CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885
   Carpenter TO, 1998, ENDOCRINOLOGY, V139, P35, DOI 10.1210/en.139.1.35
   CENTRELLA M, 1994, ENDOCRINOLOGY, V135, P1611, DOI 10.1210/en.135.4.1611
   Centrella M, 1996, ANN NY ACAD SCI, V785, P224, DOI 10.1111/j.1749 6632.1996.tb56267.x
   Centrella M, 2004, GENE, V342, P13, DOI 10.1016/j.gene.2004.06.036
   Centrella M, 2004, MOL ENDOCRINOL, V18, P1120, DOI 10.1210/me.2003 0491
   CENTRELLA M, 1987, J BIOL CHEM, V262, P2869
   CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273
   Centrella M, 2012, STEROIDS, V77, P174, DOI 10.1016/j.steroids.2011.10.016
   Chang WZ, 2005, GENE, V345, P225, DOI 10.1016/j.gene.2004.11.017
   Chang WZ, 2004, J BIOL CHEM, V279, P42438, DOI 10.1074/jbc.M405549200
   Chen Y, 1998, J CELL BIOCHEM, V71, P351, DOI 10.1002/(SICI)1097 4644(19981201)71:3<351::AID JCB4>3.0.CO;2 5
   Datta NS, 2011, WORLD J ORTHOP, V2, P67, DOI 10.5312/wjo.v2.i8.67
   Delmas PD, 2002, J CLIN ENDOCR METAB, V87, P3609, DOI 10.1210/jc.87.8.3609
   El Tanani M, 2001, J BIOL CHEM, V276, P41675, DOI 10.1074/jbc.M103966200
   Ensrud KE, 2008, J BONE MINER RES, V23, P112, DOI 10.1359/JBMR.070904
   Gao Q, 2009, BONE, V45, P98, DOI 10.1016/j.bone.2009.03.667
   Garcia Paramio P, 1998, BIOCHEM J, V333, P631, DOI 10.1042/bj3330631
   Genetos DC, 2009, J CELL BIOCHEM, V107, P233, DOI 10.1002/jcb.22119
   Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301 0082(01)00011 9
   Guo J, 2010, CELL METAB, V11, P161, DOI 10.1016/j.cmet.2009.12.007
   Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003
   Ji CH, 1997, J BIOL CHEM, V272, P21260, DOI 10.1074/jbc.272.34.21260
   Ji CH, 2003, MOL ENDOCRINOL, V17, P1834, DOI 10.1210/me.2002 0235
   Ji CH, 1998, J CELL BIOCHEM, V69, P353, DOI 10.1002/(SICI)1097 4644(19980601)69:3<353::AID JCB12>3.3.CO;2 W
   Ji CH, 2001, ENDOCRINOLOGY, V142, P3873, DOI 10.1210/en.142.9.3873
   Jones RL, 2009, BRIT J PHARMACOL, V158, P104, DOI 10.1111/j.1476 5381.2009.00317.x
   Kahlert S, 2000, J BIOL CHEM, V275, P18447, DOI 10.1074/jbc.M910345199
   Kharode Y, 2008, ENDOCRINOLOGY, V149, P6084, DOI 10.1210/en.2008 0817
   Kim KK, 2006, GENE, V379, P175, DOI 10.1016/j.gene.2006.05.005
   Kitase Y, 2010, J BONE MINER RES, V25, P2381, DOI 10.1002/jbmr.168
   Komm BS, 2012, THER ADV MUSCULOSKEL, V4, P21, DOI 10.1177/1759720X11422602
   LAURENZA A, 1989, TRENDS PHARMACOL SCI, V10, P442, DOI 10.1016/S0165 6147(89)80008 2
   Lemay Andre, 2002, J Obstet Gynaecol Can, V24, P711
   Lenart BA, 2008, NEW ENGL J MED, V358, P1304, DOI 10.1056/NEJMc0707493
   Li J, 2002, CALCIFIED TISSUE INT, V70, P320, DOI 10.1007/s00223 001 1025 y
   Liedtke AJ, 2013, J MED CHEM, V56, P2429, DOI 10.1021/jm3017656
   Lim K, 2008, CANCER RES, V68, P553, DOI 10.1158/0008 5472.CAN 07 2295
   LIPPINCOTTSCHWARTZ J, 1991, J CELL BIOL, V112, P567, DOI 10.1083/jcb.112.4.567
   LORENZO JA, 1988, ENDOCRINOLOGY, V123, P2194, DOI 10.1210/endo 123 5 2194
   MARUSIC A, 1991, J IMMUNOL, V146, P2633
   McCarthy TL, 2008, P NATL ACAD SCI USA, V105, P7022, DOI 10.1073/pnas.0800085105
   McCarthy TL, 2007, J BIOL CHEM, V282, P34003, DOI 10.1074/jbc.M707502200
   McCarthy TL, 2007, MOL ENDOCRINOL, V21, P2713, DOI 10.1210/me.2007 0210
   McCarthy TL, 2011, GENE, V479, P16, DOI 10.1016/j.gene.2011.02.002
   McCarthy TL, 2010, MOL ENDOCRINOL, V24, P587, DOI 10.1210/me.2009 0379
   McCarthy TL, 1996, J BIOL CHEM, V271, P6666, DOI 10.1074/jbc.271.12.6666
   MCCARTHY TL, 1990, J BIOL CHEM, V265, P15353
   McCarthy TL, 2000, ENDOCRINOLOGY, V141, P127, DOI 10.1210/en.141.1.127
   MCCARTHY TL, 1995, ENDOCRINOLOGY, V136, P3901, DOI 10.1210/en.136.9.3901
   McCarthy TL, 2000, J BIOL CHEM, V275, P21746, DOI 10.1074/jbc.M002291200
   McCarthy TL, 2003, J BIOL CHEM, V278, P43121, DOI 10.1074/jbc.M306531200
   McCarthy TL, 1997, J BIOL CHEM, V272, P18132, DOI 10.1074/jbc.272.29.18132
   McCarthy TL, 2000, CRIT REV ORAL BIOL M, V11, P409, DOI 10.1177/10454411000110040201
   MCCARTHY TL, 1988, J BONE MINER RES, V3, P401
   MCCARTHY TL, 1991, ENDOCRINOLOGY, V128, P2895, DOI 10.1210/endo 128 6 2895
   McCarthy TL, 2001, GROWTH HORM IGF RES, V11, P213, DOI 10.1054/ghir.2001.0236
   Minamizaki T, 2009, BONE, V44, P1177, DOI 10.1016/j.bone.2009.02.010
   MORRIS DI, 1991, J BIOL CHEM, V266, P13377
   MORRIS DI, 1994, MOL PHARMACOL, V46, P329
   MORRIS DI, 1991, BIOCHEMISTRY US, V30, P8371, DOI 10.1021/bi00098a014
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   RAWLINSON SCF, 1991, J BONE MINER RES, V6, P1345
   Rawlinson SCF, 2000, BONE, V27, P241, DOI 10.1016/S8756 3282(00)00323 9
   Russwurm Michael, 2013, Methods Mol Biol, V1020, P1, DOI 10.1007/978 1 62703 459 3_1
   Salminen A, 2010, CELL SIGNAL, V22, P573, DOI 10.1016/j.cellsig.2009.10.006
   Sambrook PN, 2004, J INTERN MED, V255, P503, DOI 10.1111/j.1365 2796.2004.01317.x
   Schmidt C, 2010, J NATL CANCER I, V102, P1690, DOI 10.1093/jnci/djq477
   Shao JY, 2005, J BIOL CHEM, V280, P26565, DOI 10.1074/jbc.M413056200
   Sunters A, 2010, J BIOL CHEM, V285, P8743, DOI 10.1074/jbc.M109.027086
   SUTKOWSKI EM, 1993, BIOCHEMISTRY US, V32, P2415, DOI 10.1021/bi00060a037
   Suzuki Yamamoto T, 1999, FEBS LETT, V462, P335, DOI 10.1016/S0014 5793(99)01551 3
   Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378 1119(01)00798 3
   Tang CH, 2005, J BIOL CHEM, V280, P22907, DOI 10.1074/jbc.M500130200
   Thomas MJ, 1996, J BIOL CHEM, V271, P21835, DOI 10.1074/jbc.271.36.21835
   TOULLEC D, 1991, J BIOL CHEM, V266, P15771
   Tsai LCL, 2011, CURR OPIN PHARMACOL, V11, P670, DOI 10.1016/j.coph.2011.09.003
   Umayahara Y, 1999, J BIOL CHEM, V274, P10609, DOI 10.1074/jbc.274.15.10609
   Umayahara Y, 1997, J BIOL CHEM, V272, P31793, DOI 10.1074/jbc.272.50.31793
   Visekruna M, 2008, J CLIN ENDOCR METAB, V93, P2948, DOI 10.1210/jc.2007 2803
   Wiren KM, 2002, J ENDOCRINOL, V175, P683, DOI 10.1677/joe.0.1750683
   Zaman G, 1997, J BONE MINER RES, V12, P769, DOI 10.1359/jbmr.1997.12.5.769
   Zaman G, 2010, BONE, V46, P628, DOI 10.1016/j.bone.2009.10.021
NR 91
TC 3
Z9 3
U1 1
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD MAY
PY 2015
VL 230
IS 5
BP 1104
EP 1114
DI 10.1002/jcp.24842
PG 11
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA CB0FL
UT WOS:000349301000015
PM 25292157
DA 2025 08 17
ER

PT J
AU Cha, PH
   Shin, W
   Zahoor, M
   Kim, HY
   Min, DS
   Choi, KY
AF Cha, Pu Hyeon
   Shin, Wookjin
   Zahoor, Muhammad
   Kim, Hyun Yi
   Min, Do Sik
   Choi, Kang Yell
TI Hovenia dulcis Thunb Extract and Its Ingredient Methyl Vanillate
   Activate Wnt/β Catenin Pathway and Increase Bone Mass in Growing or
   Ovariectomized Mice
SO PLOS ONE
LA English
DT Article
ID BETA CATENIN; VERTEBRAL FRACTURES; OSTEOPOROSIS; CONSTITUENTS;
   TERIPARATIDE; GROWTH; BISPHOSPHONATES; DIFFERENTIATION; OSTEOSARCOMAS;
   ALENDRONATE
AB The Wnt/beta catenin pathway is a potential target for development of anabolic agents to treat osteoporosis because of its role in osteoblast differentiation and bone formation. However, there is no clinically available anti osteoporosis drug that targets this Wnt/beta catenin pathway. In this study, we screened a library of aqueous extracts of 350 plants and identified Hovenia dulcis Thunb (HDT) extract as a Wnt/beta catenin pathway activator. HDT extract induced osteogenic differentiation of calvarial osteoblasts without cytotoxicity. In addition, HDT extract increased femoral bone mass without inducing significant weight changes in normal mice. In addition, thickness and area of femoral cortical bone were also significantly increased by the HDT extract. Methyl vanillate (MV), one of the ingredients in HDT, also activated the Wnt/beta catenin pathway and induced osteoblast differentiation in vitro. MV rescued trabecular or cortical femoral bone loss in the ovariectomized mice without inducing any significant weight changes or abnormality in liver tissue when administrated orally. Thus, natural HDT extract and its ingredient MV are potential anabolic agents for treating osteoporosis.
C1 [Cha, Pu Hyeon; Shin, Wookjin; Zahoor, Muhammad; Kim, Hyun Yi; Min, Do Sik; Choi, Kang Yell] Yonsei Univ, Coll Life Sci & Biotechnol, Translat Res Ctr Prot Funct Control, Seoul 120749, South Korea.
   [Cha, Pu Hyeon; Shin, Wookjin; Zahoor, Muhammad; Kim, Hyun Yi; Choi, Kang Yell] Yonsei Univ, Dept Biotechnol, Coll Life Sci & Biotechnol, Seoul 120749, South Korea.
   [Min, Do Sik] Pusan Natl Univ, Dept Mol Biol, Coll Nat Sci, Pusan 609735, South Korea.
C3 Yonsei University; Yonsei University; Pusan National University
RP Choi, KY (通讯作者)，Yonsei Univ, Coll Life Sci & Biotechnol, Translat Res Ctr Prot Funct Control, Seoul 120749, South Korea.
EM kychoi@yonsei.ac.kr
RI cha, puhyeon/ABA 7719 2020; Kim, Jong Yeup/ISA 2120 2023
FU National Research Foundation (NRF); Ministry of Future Creation and
   Science (MFCS) of Korea; Mid career Researcher Program
   [2012R1A2A1A01010285]; Translational Research Center for Protein
   Function Control; Stem Research Project [2010 0020235]; Ministry of
   Knowledge Economy through the Korea Research Institute of Chemical
   Technology [SI 095];  [2009 0083522]
FX This work was supported by grants from the National Research Foundation
   (NRF), funded by the Ministry of Future Creation and Science (MFCS) of
   Korea; Mid career Researcher Program (2012R1A2A1A01010285),
   Translational Research Center for Protein Function Control;
   (2009 0083522), and Stem Research Project (2010 0020235). This work was
   also partly supported by a grant from the Ministry of Knowledge Economy
   through the Korea Research Institute of Chemical Technology (SI 095).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Arioka M, 2013, BIOCHEM BIOPH RES CO
   Bilezikian JP, 2009, J BONE MINER RES, V24, P373, DOI [10.1359/JBMR.090105, 10.1359/jbmr.090105]
   Bouxsein ML, 2009, J BONE JOINT SURG AM, V91A, P1329, DOI 10.2106/JBJS.H.01030
   Cai YP, 2010, J PATHOL, V220, P24, DOI 10.1002/path.2628
   Chen Shao hong, 2006, Zhongguo Zhong Yao Za Zhi, V31, P1094
   Cheng MJ, 2008, J CHIL CHEM SOC, V53, P1631, DOI 10.4067/S0717 97072008000300019
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Ding L. S., 1997, Yaoxue Xuebao, V32, P600
   Finan B, 2012, NAT MED, V18, P1847, DOI 10.1038/nm.3009
   Gadelha APR, 2005, PARASITOL RES, V97, P399, DOI 10.1007/s00436 005 1476 6
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   HUSSAIN RA, 1990, J ETHNOPHARMACOL, V28, P103, DOI 10.1016/0378 8741(90)90067 4
   Hyun TK, 2010, PLANTA MED, V76, P943, DOI 10.1055/s 0030 1249776
   Iwaniec UT, 2007, J BONE MINER RES, V22, P394, DOI 10.1359/JBMR.061118
   Jeong WJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002242
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Khan AW, 2006, J OBSTET GYNAECOL CA, V28, P136, DOI 10.1016/S1701 2163(16)32063 1
   Khosla S, 2005, ENDOCRIN METAB CLIN, V34, P1015, DOI 10.1016/j.ecl.2005.07.009
   Kloen P, 1997, CANCER, V80, P2230
   Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784
   Li G, 2005, ARCH PHARM RES, V28, P804, DOI 10.1007/BF02977346
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Lories RJU, 2007, ARTHRITIS RHEUM US, V56, P4095, DOI 10.1002/art.23137
   Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98
   Massagué J, 2000, CELL, V103, P295, DOI 10.1016/S0092 8674(00)00121 5
   McGrath H, 1996, NEW ENGL J MED, V334, P734
   Pei SJ, 2001, PHARM BIOL, V39, P74, DOI [10.1076/phbi.39.s1.74.0005, 10.1076/phbi.39.7.74.5869]
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rodan GA, 1998, P NATL ACAD SCI USA, V95, P13361, DOI 10.1073/pnas.95.23.13361
   Saag KG, 2009, ARTHRITIS RHEUM US, V60, P3346, DOI 10.1002/art.24879
   Sawadogo WR, 2012, BIOCHEM PHARMACOL, V84, P1225, DOI 10.1016/j.bcp.2012.07.021
   Seeman E, 2009, CRIT REV EUKAR GENE, V19, P219, DOI 10.1615/CritRevEukarGeneExpr.v19.i3.40
   Sibai T, 2011, CLIN ORTHOP RELAT R, V469, P2215, DOI 10.1007/s11999 010 1722 9
   Tai A, 2012, BIOSCI BIOTECH BIOCH, V76, P314, DOI 10.1271/bbb.110700
   Tang DZ, 2010, J BONE MINER RES, V25, P1234, DOI 10.1002/jbmr.21
   Tashjian AH, 2006, J BONE MINER RES, V21, P354, DOI 10.1359/JBMR.051023
   Trivedi R, 2008, MOL CELL ENDOCRINOL, V289, P85, DOI 10.1016/j.mce.2008.02.027
   Vasudeva N, 2012, CHIN J INTEGR MED, V18, P473, DOI 10.1007/s11655 012 1120 0
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Yadav VK, 2010, NAT MED, V16, P308, DOI 10.1038/nm.2098
   Yang SP, 2012, ACTA PHARMACOL SIN, V33, P1147, DOI 10.1038/aps.2012.105
   YOSHIKAWA K, 1993, PHYTOCHEMISTRY, V34, P1431, DOI 10.1016/0031 9422(91)80044 2
   Yoshikawa M, 1997, YAKUGAKU ZASSHI, V117, P108, DOI 10.1248/yakushi1947.117.2_108
   Yun MS, 2005, J CELL SCI, V118, P313, DOI 10.1242/jcs.01601
   YUNCHOI HS, 1987, J NAT PROD, V50, P1059, DOI 10.1021/np50054a008
   Zhang JH, 2012, COMPLEMENT THER MED, V20, P100, DOI 10.1016/j.ctim.2011.09.004
NR 49
TC 32
Z9 36
U1 0
U2 24
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JAN 22
PY 2014
VL 9
IS 1
AR e85546
DI 10.1371/journal.pone.0085546
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 297VL
UT WOS:000330283100046
PM 24465596
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Xian, YS
   Gao, YJ
   Su, YJ
   Su, YA
   Lian, HY
   Feng, XL
   Liu, ZJ
   Zhao, JM
   Xu, JK
   Liu, Q
   Song, FM
AF Xian, Yansi
   Gao, Yijie
   Su, Yiji
   Su, Yuangang
   Lian, Haoyu
   Feng, Xiaoliang
   Liu, Zhijuan
   Zhao, Jinmin
   Xu, Jiake
   Liu, Qian
   Song, Fangming
TI Cichoric acid targets RANKL to inhibit osteoclastogenesis and prevent
   ovariectomy induced bone loss
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE cichoric acid; network pharmacology; osteoclast; RANKL
ID OSTEOPOROSIS
AB Background and Aim: Osteoporosis, a systemic metabolic bone disease, is characterized by the decline of bone mass and quality due to excessive osteoclast activity. Currently, drug targeting osteoclasts show promising therapy for osteoporosis. In this study, we investigated the effect of cichoric acid (CA) on receptor activator of nuclear kappa B ligand (RANKL) induced osteoclastogenesis and the bone loss induced by ovariectomy in mice. Experimental Procedure: Molecular docking technologies were employed to examine the interaction between CA and RANKL. CCK8 assay was used to evaluate the cell viability under CA treatment. TRAcP staining, podosome belt staining, and bone resorption assays were used to test the effect of CA on osteoclastogenesis and osteoclast function. Further, an OVX induced osteoporosis mice model was employed to identify the effect of CA on bone loss using micro CT scanning and histological examination. To investigate underlying mechanisms, network pharmacology was applied to predict the downstream signaling pathways, which were verified by Western blot and immunofluorescence staining. Key Results: The molecular docking analysis revealed that CA exhibited a specific binding affinity to RANKL, engaging multiple binding sites. CA inhibited RANKL induced osteoclastogenesis and bone resorption without cytotoxic effects. Mechanistically, CA suppressed RANKL induced intracellular reactive oxygen species, nuclear factor kappa B, and mitogen activated protein kinase pathways, followed by abrogated nuclear factor activated T cells 1 activity. Consistent with this finding, CA attenuated post ovariectomy induced osteoporosis by ameliorating osteoclastogenesis. Conclusions and Implications: CA inhibited osteoclast activity and bone loss by targeting RANKL. CA might represent a promising candidate for treating osteoclast related diseases, such as osteoporosis.
C1 [Xian, Yansi; Gao, Yijie; Su, Yiji; Su, Yuangang; Lian, Haoyu; Feng, Xiaoliang; Liu, Zhijuan; Zhao, Jinmin; Liu, Qian; Song, Fangming] Guangxi Med Univ, Affiliated Hosp 1, Guangxi Key Lab Regenerat Med Orthopaed Trauma & H, Nanning, Peoples R China.
   [Xian, Yansi; Gao, Yijie; Feng, Xiaoliang; Liu, Zhijuan; Zhao, Jinmin; Song, Fangming] Guangxi Med Univ, Collaborat Innovat Ctr Regenerat Med & Med BioReso, Dev & Applicat Coconstructed Prov Minist, Nanning, Peoples R China.
   [Xian, Yansi] Nanjing Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Med Sch,Dept Orthoped Surg,Div Sports Med & Adult, Nanjing, Peoples R China.
   [Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, Australia.
   [Xu, Jiake] Chinese Acad Sci, Shenzhen Inst Adv Technol, Shenzhen, Peoples R China.
   [Liu, Qian; Song, Fangming] Guangxi Med Univ, Affiliated Hosp 1, Guangxi Key Lab Regenerat Med Orthopaed Trauma & H, Nanning, Guangxi, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University; Nanjing
   University; University of Western Australia; Chinese Academy of
   Sciences; Shenzhen Institute of Advanced Technology, CAS; Guangxi
   Medical University
RP Xu, JK (通讯作者)，Univ Western Australia, Sch Biomed Sci, Perth, Australia.; Liu, Q; Song, FM (通讯作者)，Guangxi Med Univ, Affiliated Hosp 1, Guangxi Key Lab Regenerat Med Orthopaed Trauma & H, Nanning, Guangxi, Peoples R China.
EM jiake.xu@uwa.edu.au; liuqian@gxmu.edu.cn; songfangming@gxmu.edu.cn
RI zhao, jin/LBH 0351 2024; Su, Yuangang/KKU 6952 2024; Lian,
   Haoyu/W 3317 2017; Liu, Zhijuan/AEA 8412 2022
OI Xu, Jiake/0000 0003 2021 8309
FU Nanning Qingxiu District Science and Technology Bureau key research and
   development projects
FX No Statement Availabler No Statement Availabler No Statement Availabler
   No Statement Availabler No Statement Available
CR Bae S, 2023, CELL MOL IMMUNOL, V20, P94, DOI 10.1038/s41423 022 00959 x
   Bai JX, 2023, RESEARCH CHINA, V6, DOI 10.34133/research.0031
   Bai JX, 2020, BIOMATERIALS, V255, DOI 10.1016/j.biomaterials.2020.120197
   Chen DL, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104944
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Cotts KG, 2018, JAMA J AM MED ASSOC, V319, P1040, DOI 10.1001/jama.2017.21995
   Föger Samwald U, 2020, EXCLI J, V19, P1017, DOI 10.17179/excli2020 2591
   Hepworth EMW, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222212595
   Holmström KM, 2014, NAT REV MOL CELL BIO, V15, P411, DOI 10.1038/nrm3801
   Hong GJ, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.392
   Hu Y, 2021, EMBO REP, V22, DOI 10.15252/embr.202152481
   Ibáñez L, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23158551
   Idres AY, 2023, ANTIOXIDANTS BASEL, V12, DOI 10.3390/antiox12020340
   Iqbal Y, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10060932
   Kim MH, 2021, PHYTOMEDICINE, V80, DOI 10.1016/j.phymed.2020.153397
   Lee JM, 2021, J BONE MINER RES, V36, P553, DOI 10.1002/jbmr.4202
   Li B, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.824117
   Li YF, 2022, ACTA BIOMATER, V152, P406, DOI 10.1016/j.actbio.2022.08.054
   Liu C, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01273 4
   Liu JT, 2022, REDOX BIOL, V56, DOI 10.1016/j.redox.2022.102452
   Liu Y, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03939 7
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Mun SH, 2020, EXP MOL MED, V52, P1239
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976 0105.177703
   Ni S, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12882
   Qin YW, 2023, BIOMED PHARMACOTHER, V160, DOI 10.1016/j.biopha.2023.114347
   Ren J, 2023, FOOD CHEM, V427, DOI 10.1016/j.foodchem.2023.136707
   Sá Pessoa J, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 36629 3
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Sanada Y, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10030419
   Sarkar J, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 05343 1
   Sies H, 2020, NAT REV MOL CELL BIO, V21, P363, DOI 10.1038/s41580 020 0230 3
   Sun XW, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101309
   Tang CY, 2022, INT J BIOL SCI, V18, P2392, DOI 10.7150/ijbs.70620
   Tao HQ, 2021, PHARMACOL RES, V174, DOI 10.1016/j.phrs.2021.105967
   Thouverey C, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.80
   Trang NM, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12020256
   Uenaka M, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 28673 2
   Wang G, 2022, J CELL PHYSIOL, V237, P1790, DOI 10.1002/jcp.30642
   Wang H, 2022, ENVIRON POLLUT, V294, DOI 10.1016/j.envpol.2021.118659
   Wang LJ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00190 4
   Wang N, 2022, FOOD FUNCT, V13, P2019, DOI [10.1039/D1FO02216D, 10.1039/d1fo02216d]
   Wei LH, 2022, PHARMACOL RES, V184, DOI 10.1016/j.phrs.2022.106400
   Xian YS, 2021, BIOCHEM PHARMACOL, V193, DOI 10.1016/j.bcp.2021.114761
   Xu H, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392 023 01467 8
   Yu FY, 2022, INT J ORAL SCI, V14, DOI 10.1038/s41368 022 00159 3
   Zhang BY, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01543 1
   Zhang ZY, 2023, ADV HEALTHC MATER, V12, DOI 10.1002/adhm.202203195
   Zheng LM, 2021, INT J BIOL MACROMOL, V176, P13, DOI 10.1016/j.ijbiomac.2021.01.103
   Zhou Yan jiao, 2019, Nature Communications, V10, DOI [10.1038/s41467 019 12821 2, 10.1038/s41467 019 13698 x]
NR 51
TC 0
Z9 1
U1 7
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0951 418X
EI 1099 1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD APR
PY 2024
VL 38
IS 4
BP 1971
EP 1989
DI 10.1002/ptr.8141
EA FEB 2024
PG 19
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA NE8R6
UT WOS:001162792000001
PM 38358727
DA 2025 08 17
ER

PT J
AU Nelson, ER
   DuSell, CD
   Wang, XJ
   Howe, MK
   Evans, G
   Michalek, RD
   Umetani, M
   Rathmell, JC
   Khosla, S
   Gesty Palmer, D
   McDonnell, DP
AF Nelson, Erik R.
   DuSell, Carolyn D.
   Wang, Xiaojuan
   Howe, Matthew K.
   Evans, Glenda
   Michalek, Ryan D.
   Umetani, Michihisa
   Rathmell, Jeffrey C.
   Khosla, Sundeep
   Gesty Palmer, Diane
   McDonnell, Donald P.
TI The Oxysterol, 27 Hydroxycholesterol, Links Cholesterol Metabolism to
   Bone Homeostasis Through Its Actions on the Estrogen and Liver X
   Receptors
SO ENDOCRINOLOGY
LA English
DT Article
ID NECROSIS FACTOR ALPHA; OSTEOBLAST DIFFERENTIATION; OSTEOCLAST
   DIFFERENTIATION; POSTMENOPAUSAL WOMEN; GENE EXPRESSION; FAS LIGAND;
   IN VIVO; MACROPHAGES; ACTIVATION; REGULATOR
AB Osteoporosis and age related bone loss are important public health concerns. Therefore, there is a high level of interest in the development of medical interventions and lifestyle changes that reduce the incidence of osteoporosis and age related bone loss. Decreased bone mineral density is associated with high cholesterol, and patients on statins have increased bone mineral densities, strongly implicating cholesterol as a negative regulator of bone homeostasis. In this study, using both molecular and pharmacological approaches, we have been able to demonstrate that the primary cholesterol metabolite, 27 hydroxycholesterol, through its actions on both estrogen receptors and liver X receptors, decreases osteoblast differentiation and enhances osteoclastogenesis, resulting in increased bone resorbtion in mice. Induction of the short heterodimer partner protein by estrogens in osteoblasts can attenuate the liver X receptor mediated actions of 27 hydroxycholesterol in bone. These data establish a mechanistic link between cholesterol and bone quality, highlight an unexpected target of estrogens in osteoblasts, and define a signaling axis, the therapeutic exploitation of which is likely to yield novel antiosteoporotic drugs. (Endocrinology 152: 4691 4705, 2011)
C1 [Nelson, Erik R.; DuSell, Carolyn D.; Wang, Xiaojuan; Howe, Matthew K.; Michalek, Ryan D.; Rathmell, Jeffrey C.; Gesty Palmer, Diane; McDonnell, Donald P.] Duke Univ, Med Ctr, Durham, NC 27710 USA.
   [Evans, Glenda; Khosla, Sundeep] Mayo Clin, Coll Med, Endocrine Res Unit, Rochester, MN 55905 USA.
   [Umetani, Michihisa] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA.
   [Umetani, Michihisa] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA.
C3 Duke University; Mayo Clinic; University of Texas System; University of
   Texas Southwestern Medical Center; University of Texas System;
   University of Texas Southwestern Medical Center
RP McDonnell, DP (通讯作者)，Duke Univ, Med Ctr, POB 3813, Durham, NC 27710 USA.
EM donald.mcdonnell@duke.edu
RI Umetani, Michi/AAP 3964 2020; Nelson, Erik Russell/B 5158 2013; Khosla,
   Sundeep/AAE 6170 2020; Rathmell, Jeffrey/HCH 2318 2022; Nelson,
   Erik/U 2697 2019
OI Nelson, Erik Russell/0000 0002 8887 1905; Umetani,
   Michihisa/0000 0001 8474 7088; Khosla, Sundeep/0000 0002 2936 4372;
   Rathmell, Jeffrey/0000 0002 4106 3396; 
FU National Institutes of Health [R37DK048807, AG004875]; National
   Institute of Diabetes and Digestive and Kidney Diseases [1P30DK079328];
   Arthritis Foundation; Department of Defense [W81XWH 09 1 0613]
FX This work was supported by National Institutes of Health Grants
   R37DK048807 (to D.P.M.) and AG004875 (to S.K.), National Institute of
   Diabetes and Digestive and Kidney Diseases Grant 1P30DK079328 (to M.U.),
   the Arthritis Foundation (D.G. P.), and the Department of Defense
   Postdoctoral Award W81XWH 09 1 0613 (to E.R.N.).
CR Bodine PVN, 1998, ENDOCRINOLOGY, V139, P2048, DOI 10.1210/en.139.4.2048
   Castrillo A, 2003, J BIOL CHEM, V278, P10443, DOI 10.1074/jbc.M213071200
   Dai XY, 2007, INFLAMMATION, V30, P105, DOI 10.1007/s10753 007 9026 2
   Demigné C, 2006, EUR J NUTR, V45, P298, DOI 10.1007/s00394 006 0599 6
   DuSell CD, 2008, TRENDS PHARMACOL SCI, V29, P510, DOI 10.1016/j.tips.2008.07.003
   DuSell CD, 2008, MOL ENDOCRINOL, V22, P65, DOI 10.1210/me.2007 0383
   DuSell CD, 2010, ENDOCRINOLOGY, V151, P3675, DOI 10.1210/en.2010 0080
   Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200
   Gesty Palmer D, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000071
   Jeong BC, 2010, J BONE MINER RES, V25, P262, DOI 10.1359/jbmr.090718
   Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820
   Karuna R, 2011, ATHEROSCLEROSIS, V214, P448, DOI 10.1016/j.atherosclerosis.2010.10.042
   Kim WK, 2009, MOL ENDOCRINOL, V23, P1532, DOI 10.1210/me.2008 0453
   Krum SA, 2008, EMBO J, V27, P535, DOI 10.1038/sj.emboj.7601984
   Landis MS, 2002, J BIOL CHEM, V277, P4713, DOI 10.1074/jbc.M108807200
   Li YK, 2005, J BIOL CHEM, V280, P21763, DOI 10.1074/jbc.M501759200
   Li Hawkins J, 2000, J BIOL CHEM, V275, P16536, DOI 10.1074/jbc.M001811200
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Orozco P, 2004, EUR J EPIDEMIOL, V19, P1105, DOI 10.1007/s10654 004 1706 8
   Prawitt J, 2011, BONE, V48, P339, DOI 10.1016/j.bone.2010.08.018
   Robertson KM, 2006, J BONE MINER RES, V21, P1276, DOI 10.1359/JBMR.060503
   Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698
   Song C, 2000, ENDOCRINOLOGY, V141, P4180, DOI 10.1210/en.141.11.4180
   STANFORD CM, 1995, J BIOL CHEM, V270, P9420, DOI 10.1074/jbc.270.16.9420
   Tankó LB, 2003, BONE, V32, P8, DOI 10.1016/S8756 3282(02)00918 3
   Tarakida A, 2011, CLIMACTERIC, V14, P105, DOI 10.3109/13697137.2010.507888
   Töröcsik D, 2010, J IMMUNOL, V184, P5456, DOI 10.4049/jimmunol.0902399
   Umetani M, 2007, NAT MED, V13, P1185, DOI 10.1038/nm1641
   Voronov I, 2005, BIOCHEM PHARMACOL, V70, P300, DOI 10.1016/j.bcp.2005.04.028
   Wang YY, 2009, SHOCK, V32, P548, DOI 10.1097/SHK.0b013e3181a47f85
   Weivoda MM, 2011, ENDOCRINOLOGY, V152, P3113, DOI 10.1210/en.2011 0016
   Yamaguchi T, 2002, ENDOCR J, V49, P211, DOI 10.1507/endocrj.49.211
   Zuercher WJ, 2010, J MED CHEM, V53, P3412, DOI 10.1021/jm901797p
NR 34
TC 101
Z9 112
U1 0
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD DEC
PY 2011
VL 152
IS 12
BP 4691
EP 4705
DI 10.1210/en.2011 1298
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 852RZ
UT WOS:000297376500025
PM 21933863
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Zhong, JF
   Cao, H
   Chen, ZH
   Zhou, F
   Tan, XL
AF Zhong, Jingfei
   Cao, Hui
   Chen, Zhonghua
   Zhou, Fei
   Tan, Xiangling
TI Wnt signaling pathways participate in Astragalus injection induced
   differentiation of bone marrow mesenchymal stem cells
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE Bone marrow mesenchymal stem cells; Astragalus injection; Neuron like
   cells; Wnt signaling; Phospho GSK 3 beta
ID STROMAL CELLS; RAT; EXPRESSION; CATENIN; BIOLOGY
AB Bone marrow mesenchymal stem cells (MSCs) have the capacity for self renewal and multi directional differentiation, and MSCs can differentiate into neuron like cells under certain conditions. In this study, we used the traditional Chinese medicine Astragalus as an inducer. After 7 days of induction, the expression of specific markers was detected in each induced group by immunocytochemical staining. The results of real time quantitative PCR and Western blot confirmed the immunocytochemistry analysis. We also tested some key genes and proteins of the Wnt signaling pathway, and found that they were increased in Astragalus treated groups. After treatment with lithium chloride (LiCl), the protein expression of phospho GSK 3 beta and beta catenin was increased in each group compared to the corresponding group without LiCl. These findings demonstrate that Astragalus injection can induce differentiation of MSCs into neuron like cells and suggest that the process of differentiation might be mediated by activation of Wnt signaling pathways. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Zhong, Jingfei] Nantong Univ, Xinglin Coll, Nantong 226001, Jiangsu, Peoples R China.
   [Cao, Hui; Chen, Zhonghua; Zhou, Fei] Nantong Univ, Jiangsu Key Lab Neuroregenerat, Nantong 226001, Jiangsu, Peoples R China.
   [Tan, Xiangling] Nantong Univ, Sch Life Sci, Nantong 226001, Jiangsu, Peoples R China.
C3 Nantong University; Nantong University; Nantong University
RP Tan, XL (通讯作者)，Nantong Univ, Sch Life Sci, Nantong 226001, Jiangsu, Peoples R China.
EM research_young@126.com
CR Barnabé GF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005222
   Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   Bieback K, 2004, STEM CELLS, V22, P625, DOI 10.1634/stemcells.22 4 625
   Caplan AI, 2000, CLIN ORTHOP RELAT R, pS67
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Etheridge SL, 2004, STEM CELLS, V22, P849, DOI 10.1634/stemcells.22 5 849
   Fang WK, 2009, AM J CHINESE MED, V37, P945, DOI 10.1142/S0192415X09007363
   Fortier LA, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt50
   Hunter DD, 2004, MOL CELL NEUROSCI, V27, P477, DOI 10.1016/j.mcn.2004.08.003
   Hwang NS, 2007, J CELL PHYSIOL, V212, P281, DOI 10.1002/jcp.21052
   Jang S, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471 2121 11 25
   Kolf CM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2116
   Krampera M, 2007, BONE, V40, P382, DOI 10.1016/j.bone.2006.09.006
   Lange C, 2005, TRANSPL P, V37, P276, DOI 10.1016/j.transproceed.2004.11.087
   Ma L., 2005, J APPL CLIN PEDIAT, V106, P4227
   Miao ZN, 2006, CELL BIOL INT, V30, P681, DOI 10.1016/j.cellbi.2006.03.009
   Ojemann LM, 2006, EPILEPSY BEHAV, V8, P376, DOI 10.1016/j.yebeh.2005.12.009
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007 0637
   Rieger K, 2005, EXP HEMATOL, V33, P605, DOI 10.1016/j.exphem.2005.02.004
   Riekstina U, 2009, STEM CELL REV REP, V5, P378, DOI 10.1007/s12015 009 9094 9
   Sanchez Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389
   Tuan RS, 2003, ARTHRITIS RES THER, V5, P32, DOI 10.1186/ar614
   Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097 4547(20000815)61:4<364::AID JNR2>3.0.CO;2 C
   Yaccoby S, 2006, HAEMATOL HEMATOL J, V91, P192
   Zeng XY, 2013, EXP THER MED, V5, P193, DOI 10.3892/etm.2012.785
   Zhao H. n., 2005, MODERN J INTEGRATED, V5, P1
   Zheng JH, 2012, NEURAL REGEN RES, V7, P1370
   Zhou HF, 2005, NEUROBIOL DIS, V18, P441, DOI 10.1016/j.nbd.2004.12.005
NR 29
TC 6
Z9 8
U1 0
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304 3940
EI 1872 7972
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD OCT 11
PY 2013
VL 553
BP 29
EP 34
DI 10.1016/j.neulet.2013.08.007
PG 6
WC Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA 239FT
UT WOS:000326008700006
PM 23954827
DA 2025 08 17
ER

PT S
AU Blair, HC
   Carrington, JL
AF Blair, Harry C.
   Carrington, Jill L.
BE Zaidi, M
TI Bone cell precursors and the pathophysiology of bone loss
SO SKELETAL DEVELOPMENT AND REMODELING IN HEALTH, DISEASE, AND AGING
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT Conference on Skeletal Development and Remodeling in Health, Disease and
   Aging
CY MAY 18 21, 2005
CL New York, NY
SP NY Acad Sci, Alliance Better Bone Hlth, Procter & Gamble Pharmaceut, Sanofi Aventis, Novartis Pharmaceut Corp, Roche Pharmaceut, Merck & Co
DE stem cells; osteoblast; osteoclast; mesenchymal cells; aplastic anemia;
   autoimmunity; differentiation
ID GROWTH; PATHOGENESIS; DESTRUCTION; OSTEOBLASTS; MACROPHAGES; OSTEOCLASTS
AB In health, changes in bone formation and degradation rates are coupled and adequate cellular resources are available in the bone so that a change in bone formation rate occurs with an opposing change in resorption. On the other hand, the regulation of bone volume, particularly in pathological conditions, is dependent not only on the pathways that mediate terminal pathways of bone cell differentiation, but also on the availability of stem cells for allowing the differentiation to occur. Regulation of cell numbers in stem cell compartments and release of stem cells for differentiation of osteoblast or osteoclast precursors are not well understood, although it is clear that changes in stem cell numbers underlie pathological changes in bone mass. This may include effects of aging, fracture, metastatic disease, and autoimmune diseases on the precursor cell pools available for bone formation and degradation. Increases in osteoclast precursors or decreases in osteoblast precursors are common features of bone losing states; increases in precursors may conversely occur during growth or repair processes. Rational therapy based on modifying stem cell populations may, when the processes are better understood, help prevent chronic bone losing states and may also be of use in preventing or treating aplastic anemia and related conditions.
C1 Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA.
   Univ Pittsburgh, Dept Cell Biol, Pittsburgh, PA 15213 USA.
   VA Med Ctr, Pittsburgh, PA 15213 USA.
   NIA, Biol Aging Program, NIH, Bethesda, MD 20892 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; National Institutes of Health (NIH)  
   USA; NIH National Institute on Aging (NIA)
RP Blair, HC (通讯作者)，Univ Pittsburgh, Dept Pathol, 705 Scaife Hall, Pittsburgh, PA 15261 USA.
EM hcblair@imap.pitt.edu
FU NIAMS NIH HHS [AR47700] Funding Source: Medline; NIA NIH HHS [AG12951]
   Funding Source: Medline
CR Abe M, 2004, BLOOD, V104, P2484, DOI 10.1182/blood 2003 11 3839
   Bendre M, 2003, CLIN ORTHOP RELAT R, pS39, DOI 10.1097/01.blo.0000093844.72468.f4
   Blair HC, 1999, BIOCHEM BIOPH RES CO, V255, P778, DOI 10.1006/bbrc.1999.0260
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Cenci S, 2003, P NATL ACAD SCI USA, V100, P10405, DOI 10.1073/pnas.1533207100
   Choi SJ, 2000, BLOOD, V96, P671
   Dominici M, 2004, P NATL ACAD SCI USA, V101, P11761, DOI 10.1073/pnas.0404626101
   Eghbali Fatourechi GZ, 2005, NEW ENGL J MED, V352, P1959, DOI 10.1056/NEJMoa044264
   Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879
   Ferron M, 2005, GENESIS, V41, P138, DOI 10.1002/gene.20108
   Fujikawa Y, 1996, ENDOCRINOLOGY, V137, P4058, DOI 10.1210/en.137.9.4058
   Goldring SR, 2003, RHEUMATOLOGY, V42, P11, DOI 10.1093/rheumatology/keg327
   Kudo O, 2002, J PATHOL, V198, P220, DOI 10.1002/path.1190
   Kuznetsov SA, 2001, J CELL BIOL, V153, P1133, DOI 10.1083/jcb.153.5.1133
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Li P, 2004, J BONE MINER RES, V19, P207, DOI 10.1359/JBMR.0301233
   Lin Elaine Y, 2004, Novartis Found Symp, V256, P158
   LONG MW, 1995, J CLIN INVEST, V95, P881, DOI 10.1172/JCI117738
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Robak E, 2004, EUR CYTOKINE NETW, V15, P222
   Sherwood RI, 2004, STEM CELLS, V22, P1292, DOI 10.1634/stemcells.2004 0090
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood 2003 11 4011
NR 23
TC 8
Z9 13
U1 0
U2 1
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA
SN 0077 8923
BN 1 57331 583 4
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2006
VL 1068
BP 244
EP 249
DI 10.1196/annals.1346.028
PG 6
WC Multidisciplinary Sciences; Orthopedics
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Orthopedics
GA BFA92
UT WOS:000240548200026
PM 16831925
DA 2025 08 17
ER

PT J
AU Xu, XL
   Li, YX
   Shi, LF
   He, KY
   Sun, Y
   Ding, Y
   Meng, BY
   Zhang, JJ
   Xiang, L
   Dong, J
   Liu, M
   Zhang, JX
   Xiang, LW
   Xiang, GD
AF Xu, Xiaoli
   Li, Yixiang
   Shi, Lingfeng
   He, Kaiyue
   Sun, Ying
   Ding, Yan
   Meng, Biying
   Zhang, Jiajia
   Xiang, Lin
   Dong, Jing
   Liu, Min
   Zhang, Junxia
   Xiang, Lingwei
   Xiang, Guangda
TI Myeloid derived growth factor (MYDGF) protects bone mass through
   inhibiting osteoclastogenesis and promoting osteoblast differentiation
SO EMBO REPORTS
LA English
DT Article
DE bone marrow derived monocytes and macrophages; myeloid derived growth
   factor; osteoblast; osteoclast; osteoporosis
ID NF KAPPA B; OSTEOPOROSIS; GUIDELINES; DIAGNOSIS
AB Whether bone marrow regulates bone metabolism through endocrine and paracrine mechanism remains largely unknown. Here, we found that (i) myeloid cell specific myeloid derived growth factor (MYDGF) deficiency decreased bone mass and bone strength in young and aged mice; (ii) myeloid cell specific MYDGF restoration prevented decreases in bone mass and bone strength in MYDGF knockout mice; moreover, myeloid cell derived MYDGF improved the progress of bone defects healing, prevented ovariectomy (OVX) induced bone loss and age related osteoporosis; (iii) MYDGF inhibited osteoclastogenesis and promoted osteoblast differentiation in vivo and in vitro; and (iv) PKC beta NF kappa B and MAPK1/3 STAT3 pathways were involved in the regulation of MYDGF on bone metabolism. Thus, we concluded that myeloid cell derived MYDGF is a positive regulator of bone homeostasis by inhibiting bone resorption and promoting bone formation. MYDGF may become a potential novel therapeutic drug for osteoporosis, and bone marrow may become a potential therapeutic target for bone metabolic disorders.
C1 [Xu, Xiaoli; Shi, Lingfeng; He, Kaiyue; Sun, Ying; Ding, Yan; Meng, Biying; Zhang, Jiajia; Xiang, Lin; Dong, Jing; Liu, Min; Zhang, Junxia; Xiang, Guangda] Gen Hosp Cent Theater Command, Dept Endocrinol, Wuhan, Peoples R China.
   [Xu, Xiaoli; Shi, Lingfeng; He, Kaiyue; Ding, Yan; Meng, Biying; Zhang, Junxia; Xiang, Guangda] Southern Med Univ, Sch Clin Med 1, Guangzhou, Peoples R China.
   [Li, Yixiang] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA USA.
   [Xiang, Lingwei] Brigham & Womens Hosp, Ctr Surg, 75 Francis St, Boston, MA 02115 USA.
   [Xiang, Lingwei] Brigham & Womens Hosp, Ctr Publ Hlth, 75 Francis St, Boston, MA 02115 USA.
C3 Southern Medical University   China; Emory University; Harvard
   University; Harvard University Medical Affiliates; Brigham & Women's
   Hospital; Harvard University; Harvard University Medical Affiliates;
   Brigham & Women's Hospital
RP Zhang, JX; Xiang, GD (通讯作者)，Gen Hosp Cent Theater Command, Dept Endocrinol, Wuhan, Peoples R China.; Zhang, JX; Xiang, GD (通讯作者)，Southern Med Univ, Sch Clin Med 1, Guangzhou, Peoples R China.; Xiang, LW (通讯作者)，Brigham & Womens Hosp, Ctr Surg, 75 Francis St, Boston, MA 02115 USA.; Xiang, LW (通讯作者)，Brigham & Womens Hosp, Ctr Publ Hlth, 75 Francis St, Boston, MA 02115 USA.
EM zhangjx023@163.com; lxiang2@bwh.harvard.edu; guangda64@hotmail.com
RI Li, Yixiang/J 9407 2019
FU National Natural Science Foundation of China [NSFC 81870573, 81370896,
   81570730]; National Key Research and Development Program of China
   [2016YFC1305601]; Research Project of Health Commission of Hubei
   Province [WJ2017H0031]
FX This work was supported by grants from the National Natural Science
   Foundation of China (NSFC 81870573, 81370896, and 81570730), National
   Key Research and Development Program of China (2016YFC1305601), and
   Research Project of Health Commission of Hubei Province (WJ2017H0031).
CR Afridi I, 2003, J HYPERTENS, V21, P1983, DOI 10.1097/01.hjh.0000084751 37215.d2
   Bortnov V, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 13577 5
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Cheng XG, 2020, QUANT IMAG MED SURG, V10, P2066, DOI 10.21037/qims 2020 16
   Choi JY, 2018, J BONE MINER RES, V33, P2059, DOI 10.1002/jbmr.3549
   Curtis KJ, 2020, ANN NY ACAD SCI, V1460, P11, DOI 10.1111/nyas.14232
   Dwivedi RC, 2016, PROTEOM CLIN APPL, V10, P663, DOI 10.1002/prca.201500057
   Estell EG, 2021, NAT REV ENDOCRINOL, V17, P31, DOI 10.1038/s41574 020 00426 5
   Feng SM, 2009, BIOCHEM J, V417, P195, DOI 10.1042/BJ20081073
   Gruber R, 2015, WIEN MED WOCHENSCHR, V165, P48, DOI 10.1007/s10354 014 0310 0
   He MJ, 2020, DIABETOLOGIA, V63, P1916, DOI 10.1007/s00125 020 05197 2
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Ilich JZ, 2014, ARH HIG RADA TOKSIKO, V65, P139, DOI 10.2478/10004 1254 65 2014 2541
   Kim Jung Ha, 2020, Chonnam Med J, V56, P94
   Kim K, 2018, BONE, V113, P17, DOI 10.1016/j.bone.2018.05.009
   Korf Klingebiel M, 2015, NAT MED, V21, P140, DOI 10.1038/nm.3778
   Li CJ, 2018, J CLIN INVEST, V128, P5251, DOI 10.1172/JCI99044
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Liu WQ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12794
   Liu WQ, 2016, SCI REP UK, V6, DOI 10.1038/srep23041
   Liu XN, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22131 1
   Macías I, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051653
   Matsumoto Y, 2012, MOL CELL ENDOCRINOL, V350, P78, DOI 10.1016/j.mce.2011.11.023
   Mei W, 2016, MOL THER, V24, P1926, DOI 10.1038/mt.2016.160
   Meng BY, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe6903
   Miller PD, 2006, REV ENDOCR METAB DIS, V7, P75, DOI 10.1007/s11154 006 9006 0
   Minear S, 2010, J BONE MINER RES, V25, P1196, DOI 10.1002/jbmr.29
   Negishi Koga Takako, 2012, Bonekey Rep, V1, P183, DOI 10.1038/bonekey.2012.183
   Prideaux M, 2016, CURR OPIN PHARMACOL, V28, P24, DOI 10.1016/j.coph.2016.02.003
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Shi LF, 2022, CALCIFIED TISSUE INT, V110, P131, DOI 10.1007/s00223 021 00897 2
   Sims NA, 2020, EXP MOL MED, V52, P1185
   Sobacchi C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00629
   Wang L, 2020, ENDOCRINOLOGY, V161, DOI 10.1210/endocr/bqaa003
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xiong WC, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.586010
   Yang M, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12784
   Yang YL, 2019, J BIOL CHEM, V294, P15395, DOI 10.1074/jbc.RA119.010139
   Yao J, 2015, J CELL PHYSIOL, V230, P1235, DOI 10.1002/jcp.24858
   Yuan FL, 2015, BONE, V75, P128, DOI 10.1016/j.bone.2015.02.017
   Zhang JJ, 2018, DIABETES, V67, P2084, DOI 10.2337/db17 1583
   Zheng L, 2019, FASEB J, V33, P7667, DOI 10.1096/fj.201802364RR
   Zheng ZG, 2020, CELL DEATH DIFFER, V27, P2048, DOI 10.1038/s41418 019 0484 5
   Zhu B, 2020, EUR J PHARMACOL, V884, DOI 10.1016/j.ejphar.2020.173350
   Zhu B, 2019, AGING CELL, V18, DOI 10.1111/acel.12883
NR 45
TC 16
Z9 17
U1 0
U2 37
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1469 221X
EI 1469 3178
J9 EMBO REP
JI EMBO Rep.
PD FEB 3
PY 2022
VL 23
IS 3
AR e53509
DI 10.15252/embr.202153509
EA JAN 2022
PG 22
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA ZL1WI
UT WOS:000745878700001
PM 35068044
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Lee, YS
   Kim, YS
   Lee, SY
   Kim, GH
   Kim, BJ
   Lee, SH
   Lee, KU
   Kim, GS
   Kim, SW
   Koh, JM
AF Lee, Young Sun
   Kim, Yang Soon
   Lee, Sun Young
   Kim, Geun Hyang
   Kim, Beom Jun
   Lee, Seung Hun
   Lee, Ki Up
   Kim, Ghi Su
   Kim, Seung Whan
   Koh, Jung Min
TI AMP kinase acts as a negative regulator of RANKL in the differentiation
   of osteoclasts
SO BONE
LA English
DT Article
DE AMP kinase; Osteoclast; Bone resorption; RANKL
ID ACTIVATED PROTEIN KINASE; KAPPA B LIGAND; RECEPTOR ACTIVATOR;
   ENDOTHELIAL CELLS; EPITHELIAL CELLS; SKELETAL MUSCLE; IN VIVO;
   BERBERINE; PATHWAY; ALPHA
AB Introduction: AMP activated protein kinase (AMPK) has been reported to stimulate differentiation and proliferation of osteoblasts, but the role of AMPK in the physiology of osteoclasts has not been investigated.
   Method: Osteoclasts were differentiated from mouse BMM phi s. TRAP positive multinucleated cells were considered to be osteoclasts using TRAP staining, and resorption area was determined by incubation of cells on dentine discs. Signaling pathways were investigated using Western blotting and RT PCR.
   Results: RANKL induced phosphorylation/activation of AMPK alpha. in BMM phi s and stimulated formation of TRAP positive multinucleated cells. Pharmacological inhibition of AMPK with compound C and siRNA mediated knockdown of AMPK alpha, the predominant alpha subunit isoform in BMWs, increased RANKLinduced formation of TRAP positive multinucleated cells and bone resorption via activation of the downstream signaling elements p38, JNK, NF kappa B, Akt, CREB, kappa Fos, and NFATcl. STO 609, an inhibitor of CaMKK, completely blocked the RANKL induced activation of AMPK alpha, but KN 93, an inhibitor of CaMK, did not. siRNA mediated TAM knockdown also blocked RANKL induced activation of AMPK a. The AMPK activators metformin, ( ) epigallocatechin 3 gallate, berberine, resveratrol, and alpha lipoic acid dosedependently suppressed formation of TRAP positive multinucleated cells and bone resorption.
   Conclusion: AMPK negatively regulates RANKL, possibly by acting through CaMKK and TAK1. Thus, the development of AIVIPK activators may be a useful strategy for inhibiting the resorption of bone that is stimulated under RANKL activated conditions. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Kim, Beom Jun; Lee, Seung Hun; Lee, Ki Up; Kim, Ghi Su; Koh, Jung Min] Univ Ulsan, Coll Med, Div Endocrinol & Metab, Asan Med Ctr, Seoul 138736, South Korea.
   [Kim, Geun Hyang; Kim, Seung Whan] Univ Ulsan, Coll Med, Dept Pharmacol, Asan Med Ctr, Seoul 138736, South Korea.
   [Lee, Young Sun; Kim, Yang Soon; Lee, Sun Young] Asan Inst Life Sci, Seoul 138736, South Korea.
C3 University of Ulsan; Asan Medical Center; University of Ulsan; Asan
   Medical Center
RP Koh, JM (通讯作者)，Univ Ulsan, Coll Med, Div Endocrinol & Metab, Asan Med Ctr, 388 1 Poongnap2 Dong, Seoul 138736, South Korea.
EM swkim7@amc.seoul.kr; jmkoh@amc.seoul.kr
RI KIM, SUNJONG/JXN 0257 2024; Kim, Yong Won/AAA 2134 2022; KIM,
   SIWOUK/KCY 8510 2024; Kim, Hye/AAF 7609 2020
OI Kim, Seung Whan/0000 0001 6983 0481; Kim, Beom Jun/0000 0001 8591 1759
FU Korean Ministry of Education, Science and Technology [FPRO8B1 170];
   Ministry of Health & Welfare, Republic of Korea [A010252]; Ministry for
   Health, Welfare and Family Affairs [A080256]; Korean Government
   [313 2008 2 E00083]; Asan Institute for Life Sciences, Seoul, Korea
   [2007 347]
FX This work was supported by a grant from the Korean Ministry of
   Education, Science and Technology (FPRO8B1 170) of the 21C Frontier
   Functional Proteomics Program, a grant of the Korea Health 21 R&D
   Project, Ministry of Health & Welfare, Republic of Korea (Project No.:
   A010252), a grant of the Korea Healthcare technology R&D Project,
   Ministry for Health, Welfare and Family Affairs (Project No.: A080256),
   a grant (2007 347) from the Asan Institute for Life Sciences, Seoul,
   Korea, and National Research Foundation of Korea Grant funded by the
   Korean Government (313 2008 2 E00083).
CR Boissy P, 2005, CANCER RES, V65, P9943, DOI 10.1158/0008 5472.CAN 05 0651
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown D, 1996, J EXP BIOL, V199, P2345
   Collins QF, 2007, J BIOL CHEM, V282, P30143, DOI 10.1074/jbc.M702390200
   Feng YH, 2010, J CELL MOL MED
   Fisslthaler B, 2009, CIRC RES, V105, P114, DOI 10.1161/CIRCRESAHA.109.201590
   Fujii N, 2004, P NUTR SOC, V63, P205, DOI 10.1079/PNS2004340
   Guo DL, 2007, CIRC RES, V100, P564, DOI 10.1161/01.RES.0000259561.23876.c5
   Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540
   Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009
   Herrero Martín G, 2009, EMBO J, V28, P677, DOI 10.1038/emboj.2009.8
   Horike N, 2008, J BIOL CHEM, V283, P33902, DOI 10.1074/jbc.M802537200
   Hou XY, 2008, J BIOL CHEM, V283, P20015, DOI 10.1074/jbc.M802187200
   Jeong HW, 2009, AM J PHYSIOL ENDOC M, V296, pE955, DOI 10.1152/ajpendo.90599.2008
   Kim HJ, 2006, FREE RADICAL BIO MED, V40, P1483, DOI 10.1016/j.freeradbiomed.2005.10.066
   Kim MS, 2004, NAT MED, V10, P727, DOI 10.1038/nm1061
   Koh JM, 2005, J ENDOCRINOL, V185, P401, DOI 10.1677/joe.1.05995
   Kovacic S, 2003, J BIOL CHEM, V278, P39422, DOI 10.1074/jbc.M305371200
   Lee JH, 2010, MOL PHARMACOL, V77, P17, DOI 10.1124/mol.109.057877
   Li HY, 1999, BIOL PHARM BULL, V22, P391, DOI 10.1248/bpb.22.391
   Lin RW, 2009, BIOCHEM BIOPH RES CO, V379, P1033, DOI 10.1016/j.bbrc.2009.01.007
   Liu ZP, 2005, J MED FOOD, V8, P14, DOI 10.1089/jmf.2005.8.14
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Musi N, 2002, DIABETES, V51, P2074, DOI 10.2337/diabetes.51.7.2074
   Nagata D, 2003, J BIOL CHEM, V278, P31000, DOI 10.1074/jbc.M300643200
   Qin LP, 2008, J ETHNOPHARMACOL, V118, P271, DOI 10.1016/j.jep.2008.04.009
   Quinn JMW, 2010, FASEB J, V24, P275, DOI 10.1096/fj.09 137158
   Racioppi L, 2008, TRENDS IMMUNOL, V29, P600, DOI 10.1016/j.it.2008.08.005
   Sag D, 2008, J IMMUNOL, V181, P8633, DOI 10.4049/jimmunol.181.12.8633
   Sakamoto K, 2006, AM J PHYSIOL ENDOC M, V290, pE780, DOI 10.1152/ajpendo.00443.2005
   Sanders MJ, 2007, BIOCHEM J, V403, P139, DOI 10.1042/BJ20061520
   Sanz P, 2008, CURR PROTEIN PEPT SC, V9, P478, DOI 10.2174/138920308785915254
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Stahmann N, 2006, MOL CELL BIOL, V26, P5933, DOI 10.1128/MCB.00383 06
   Vestergaard P, 2005, DIABETOLOGIA, V48, P1292, DOI 10.1007/s00125 005 1786 3
   Winder WW, 1999, AM J PHYSIOL ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yin J, 2008, AM J PHYSIOL ENDOC M, V294, pE148, DOI 10.1152/ajpendo.00211.2007
   Young ME, 1996, FEBS LETT, V382, P43, DOI 10.1016/0014 5793(96)00129 9
   Zhang BB, 2009, CELL METAB, V9, P407, DOI 10.1016/j.cmet.2009.03.012
   Zhou G, 2009, ACTA PHYSIOL, V196, P175, DOI 10.1111/j.1748 1716.2009.01967.x
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505
NR 42
TC 128
Z9 141
U1 1
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD NOV
PY 2010
VL 47
IS 5
BP 926
EP 937
DI 10.1016/j.bone.2010.08.001
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 668PM
UT WOS:000283282000011
PM 20696287
DA 2025 08 17
ER

PT J
AU Tanwar, J
   Datta, A
   Tiwari, AK
   Thirumal, M
   Chuttani, K
   Mishra, AK
AF Tanwar, Jyoti
   Datta, Anupama
   Tiwari, Anjani Kumar
   Thirumal, Meganathan
   Chuttani, Krishna
   Mishra, Anil Kumar
TI Preclinical Evaluation of DO3P AME DO3P: A Polyazamacrocyclic Methylene
   Phosphonate for Diagnosis and Therapy of Skeletal Metastases
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID MRI CONTRAST AGENTS; BONE METASTASES; OSTEOCLAST DIFFERENTIATION;
   MACROCYCLIC LIGANDS; BREAST CANCER; COMPLEXES; RADIOPHARMACEUTICALS;
   IONS; BISPHOSPHONATES; PROTONATION
AB A phosphonate derivative 10' bis(acetamido) ethane bis [1,4,7] tri(methylene phosphonic acid)1,4,7,10 tetraazacyclododecane] (DO3P AME DO3P), was synthesized with 90% yield in high purity. It was labeled with Tc 99m in 97.5% efficiency and specific activity of 112 250 MBq/mu mol. The binding affinity of Tc 99m DO3P AME DO3P towards bone minerals was tested in vitro by using hydroxy apatite as a bone model with absorption of 93% during the first hour of the experiment. Receptor binding assay on human bone cell line SAOS 2 demonstrated K d value of 1.07 nM. Cell binding studies of DO3P AME DO3P on osteoblasts and osteoclasts cells performed in vitro displayed preferential affinity of the compound towards osteoclast (167.95 +/  3.56% dose/mg protein). The serum stability of Tc 99m complex was found to be 96.8% after 24 h. Blood kinetics of Tc 99m DO3P AME DO3P performed on normal rabbits showed fast clearance with t(1/2)(F) = 15 min +/  0.014 min and t(1/2)(S) = 4 h 3 min +/  0.09 min. Biodistribution studies carried out in normal BALB/c mice showed bone to blood ratio of 20 and bone to muscle ratio of 33. The bone tissue demonstrated highest concentration of bound radioactivity with 10.73% ID/g at 1 h post injection. The protonation and stability constants were determined by pH potentiornetry titrations. The stability constants of DO3P AME DO3P with Lu(III), Sm(III), and Ho(III) were 19.7, 21.8, and 20.2 determined by "out of cell" method. The excellent bone seeking properties of DO3P AME DO3P make it a candidate of choice for SPECT imaging and preferential uptake of the compound in osteoclasts in comparison to osteoblasts; BMM and BMC can be used to understand the pathway of pathogenesis of osteoporosis and skeletal metastases.
C1 [Tanwar, Jyoti; Datta, Anupama; Tiwari, Anjani Kumar; Chuttani, Krishna; Mishra, Anil Kumar] Def Res & Dev Org, Inst Nucl Med & Allied Sci, Div Cyclotron & Radiopharmaceut Sci, Delhi 54, India.
   [Tanwar, Jyoti; Thirumal, Meganathan] Univ Delhi, Dept Chem, Delhi 07, India.
C3 Defence Research & Development Organisation (DRDO); Institute of Nuclear
   Medicine & Allied Sciences (INMAS); University of Delhi
RP Datta, A (通讯作者)，Def Res & Dev Org, Inst Nucl Med & Allied Sci, Div Cyclotron & Radiopharmaceut Sci, Brig SK Mazumdar Rd, Delhi 54, India.
EM anupama@inmas.drdo.in; akmishra@inmas.drdo.in
RI TIWARI, ANJANI KUMAR/AAG 6558 2019; Mishra, Anil/J 9502 2013
OI Tiwari, Anjani Kumar/0000 0001 6271 3055; 
FU Defence Research and Development Organization, Ministry of Defence
   [INM 311.3.1]
FX We are thankful to Dr. R P. Tripathi, Director, Institute of Nuclear
   Medicine and Allied Sciences, Delhi for providing the necessary
   facilities. We wish to acknowledge Dr. Vinay K. Singh, University of
   Lucknow, India, for assistance in biological studies. This project was
   supported by Defence Research and Development Organization, Ministry of
   Defence, under R & D project INM 311.3.1. The authors declare that they
   have no conflict of interest.
CR AIME S, 1993, MAGN RESON MED, V30, P583, DOI 10.1002/mrm.1910300509
   Anderegg G, 2005, PURE APPL CHEM, V77, P1445, DOI 10.1351/pac200577081445
   Avecilla F, 2003, EUR J INORG CHEM, P4179, DOI 10.1002/ejic.200300312
   Bagi CM, 2005, ADV DRUG DELIVER REV, V57, P995, DOI 10.1016/j.addr.2004.12.014
   Bombardieri E, 2001, Q J NUCL MED, V45, P245
   Burai L, 2001, EUR J INORG CHEM, P813
   Chang CA, 2001, INORG CHEM, V40, P3448, DOI 10.1021/ic001325j
   Datta A, 2009, CANCER BIOTHER RADIO, V24, P123, DOI 10.1089/cbr.2008.0536
   DELGADO R, 1990, HELV CHIM ACTA, V73, P140, DOI 10.1002/hlca.19900730115
   Duarte LF, 2010, ARKIVOC, P117, DOI 10.3998/ark.5550190.0011.512
   El Mabhouh AA, 2008, EUR J NUCL MED MOL I, V35, P1240, DOI 10.1007/s00259 008 0728 y
   Försterová M, 2008, J INORG BIOCHEM, V102, P1531, DOI 10.1016/j.jinorgbio.2008.02.002
   Försterová M, 2007, DALTON T, P535, DOI 10.1039/b613404a
   Francis M. D., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P2
   FRANCIS MD, 1986, BONE SCANNING CLIN P, P7
   GERALDES CFGC, 1992, J MAGN RESON, V97, P290, DOI 10.1016/0022 2364(92)90314 W
   GERALDES CFGC, 1989, INORG CHEM, V28, P3336, DOI 10.1021/ic00316a018
   GERALDES CFGC, 1989, MAGN RESON MED, V9, P94, DOI 10.1002/mrm.1910090111
   Hamaoka T, 2004, J CLIN ONCOL, V22, P2942, DOI 10.1200/jco.2004.08.181
   Hassfjell S, 2001, NUCL MED BIOL, V28, P425, DOI 10.1016/S0969 8051(01)00202 5
   Houghton TJ, 2008, J MED CHEM, V51, P6955, DOI 10.1021/jm801007z
   Hsu WK, 2008, J NUCL MED, V49, P414, DOI 10.2967/jnumed.107.045666
   IZATT RM, 1995, CHEM REV, V95, P2529, DOI 10.1021/cr00039a010
   Kálmán FK, 2008, INORG CHEM, V47, P3851, DOI 10.1021/ic7024704
   Krakowiak KE, 2000, IND ENG CHEM RES, V39, P3499, DOI 10.1021/ie0004038
   Lam MGEH, 2009, EUR J NUCL MED MOL I, V36, P1425, DOI 10.1007/s00259 009 1119 8
   LAZAR I, 1992, INORG CHEM, V31, P4422, DOI 10.1021/ic00047a034
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Liu S, 2001, BIOCONJUGATE CHEM, V12, P7, DOI 10.1021/bc000070v
   Maini CL, 2004, EUR J NUCL MED MOL I, V31, pS171, DOI 10.1007/s00259 004 1540 y
   Máthé D, 2010, NUCL MED BIOL, V37, P215, DOI 10.1016/j.nucmedbio.2009.09.004
   MERRICK MV, 1975, BRIT J RADIOL, V48, P327, DOI 10.1259/0007 1285 48 569 327
   Mishra A, 2008, INORG CHEM, V47, P1370, DOI 10.1021/ic7017456
   Mitterhauser M, 2008, NUCL MED BIOL, V35, P817, DOI 10.1016/j.nucmedbio.2008.09.003
   Neale JR, 2009, BIOORG MED CHEM LETT, V19, P680, DOI 10.1016/j.bmcl.2008.12.051
   Ogawa K, 2009, NUCL MED BIOL, V36, P129, DOI 10.1016/j.nucmedbio.2008.11.007
   Panwar P, 2007, BIOORGAN MED CHEM, V15, P1138, DOI 10.1016/j.bmc.2006.10.005
   Panwar P, 2006, NUCL MED COMMUN, V27, P619, DOI 10.1097/00006231 200608000 00004
   Peterson JJ, 2003, CLIN ORTHOP RELAT R, pS120, DOI 10.1097/01.blo.0000093051.96273.7c
   Sherry AD, 1996, INORG CHEM, V35, P4604, DOI 10.1021/ic9600590
   Shukla G, 2009, CANCER BIOTHER RADIO, V24, P209, DOI 10.1089/cbr.2008.0551
   Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252
   THOM VJ, 1984, J AM CHEM SOC, V106, P5947, DOI 10.1021/ja00332a032
   Uehara T, 2007, NUCL MED BIOL, V34, P79, DOI 10.1016/j.nucmedbio.2006.10.001
   Verbeke K, 2002, BIOCONJUGATE CHEM, V13, P16, DOI 10.1021/bc0001600
   Volkert WA, 1999, CHEM REV, V99, P2269, DOI 10.1021/cr9804386
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Wang D, 2003, BIOCONJUGATE CHEM, V14, P853, DOI 10.1021/bc034090j
   Yasuda H, 1999, BONE, V25, P109, DOI 10.1016/S8756 3282(99)00121 0
NR 49
TC 22
Z9 24
U1 0
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043 1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD FEB
PY 2011
VL 22
IS 2
BP 244
EP 255
DI 10.1021/bc100382c
PG 12
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 720RE
UT WOS:000287297000018
PM 21222430
DA 2025 08 17
ER

PT J
AU Ma, JJ
   Ma, Y
   Liu, XQ
   Chen, S
   Liu, C
   Qin, A
   Fan, SW
AF Ma, Jianjun
   Ma, Yan
   Liu, Xuqiang
   Chen, Shuai
   Liu, Chao
   Qin, An
   Fan, Shunwu
TI Gambogic acid inhibits osteoclast formation and ovariectomy induced
   osteoporosis by suppressing the JNK, p38 and Akt signalling pathways
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE Akt; gambogic acid; JNK; osteoclasts; osteoporosis; p38
ID PARTICLE INDUCED OSTEOLYSIS; NF KAPPA B; BONE RESORPTION; INDUCED
   APOPTOSIS; IN VIVO; C FOS; DIFFERENTIATION; RANKL; CANCER;
   BISPHOSPHONATES
AB Excessive osteoclast formation and bone resorption are key causes of osteoporosis. Natural compounds can serve as alternative therapeutic agents for the prevention and treatment of osteoporosis, and some natural compounds may have advantages over traditional drugs. In the present paper, we report that the natural compound GBA (gambogic acid), which is bioavailable, effective and less toxic, inhibits osteoclast formation, thereby attenuating osteoclastic bone resorption in vitro. Further in vivo studies demonstrated that GBA prevented ovariectomy induced bone loss in a dose dependent manner. Moreover, we demonstrated that GBA suppressed RANKL (receptor activator of nuclear factor kappa B ligand) induced 2JNK (c Jun N terminal kinase), p38 and Akt phosphorylation. Taken together, our results demonstrate that GBA inhibits osteoclast formation in vitro and in vivo, suggesting that it is of potential value in the treatment of osteoclast related diseases.
C1 [Ma, Jianjun; Ma, Yan; Chen, Shuai; Liu, Chao; Fan, Shunwu] Zhejiang Univ, Sch Med, Dept Orthopaed, Sir Run Run Shaw Hosp, Hangzhou 310016, Zhejiang, Peoples R China.
   [Ma, Jianjun; Ma, Yan; Chen, Shuai; Liu, Chao; Fan, Shunwu] Zhejiang Univ, Sir Run Run Shaw Inst Clin Med, Hangzhou 310016, Zhejiang, Peoples R China.
   [Liu, Xuqiang; Qin, An] Shanghai Jiao Tong Univ, Sch Med, Dept Orthopaed, Shanghai Key Lab Orthopaed Implant,Shanghai Peopl, Shanghai 200011, Peoples R China.
C3 Zhejiang University; Zhejiang University; Shanghai Jiao Tong University
RP Qin, A (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Dept Orthopaed, Shanghai Key Lab Orthopaed Implant,Shanghai Peopl, Shanghai 200011, Peoples R China.
EM dr_qinan@163.com; orthopaedics2009@hotmail.com
RI Qin, An/J 2518 2019; Ma, Jianjun/O 8236 2015
FU National Nature Science Fund of China [81271971, 81271972, 31270997]
FX The study was sponsored by the National Nature Science Fund of China
   [grant numbers 81271971, 81271972 and 31270997]. No benefits in any form
   have or will be received from a commercial party related directly or
   indirectly to the subject of this study.
CR Bitto A, 2008, BRIT J PHARMACOL, V155, P896, DOI 10.1038/bjp.2008.305
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352
   Clohisy DR, 1998, J ORTHOPAED RES, V16, P660, DOI 10.1002/jor.1100160606
   Costa L, 2014, CURR OPIN SUPPORT PA, V8, P414, DOI 10.1097/SPC.0000000000000101
   Dempster DW, 2012, CLIN THER, V34, P521, DOI 10.1016/j.clinthera.2012.02.002
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Greenfield EM, 2002, J ORTHOPAED RES, V20, P1, DOI 10.1016/S0736 0266(01)00070 5
   Han QB, 2005, BIOL PHARM BULL, V28, P2335, DOI 10.1248/bpb.28.2335
   Hsieh TP, 2011, PHYTOMEDICINE, V18, P176, DOI 10.1016/j.phymed.2010.04.003
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Ikeda F, 2008, J BONE MINER RES, V23, P907, DOI 10.1359/JBMR.080211
   Jacobs C, 2014, CURR OPIN SUPPORT PA, V8, P420, DOI 10.1097/SPC.0000000000000084
   Kim KH, 2011, PHARM RES DORDR, V28, P597, DOI 10.1007/s11095 010 0311 7
   KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0
   Li HW, 2013, BIOCHEM BIOPH RES CO, V430, P951, DOI 10.1016/j.bbrc.2012.12.051
   Liu XQ, 2014, BIOMATERIALS, V35, P5721, DOI 10.1016/j.biomaterials.2014.04.006
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Ouyang ZX, 2014, BIOCHEM PHARMACOL, V90, P276, DOI 10.1016/j.bcp.2014.06.009
   Pandey MK, 2007, BLOOD, V110, P3517, DOI 10.1182/blood 2007 03 079616
   Pandey MK, 2014, EXP HEMATOL, V42, P883, DOI 10.1016/j.exphem.2014.07.261
   Qaseem A, 2008, ANN INTERN MED, V149, P404, DOI 10.7326/0003 4819 149 6 200809160 00007
   Qi Q, 2008, J ETHNOPHARMACOL, V117, P433, DOI 10.1016/j.jep.2008.02.027
   Qu XH, 2014, BIOCHEM BIOPH RES CO, V443, P658, DOI 10.1016/j.bbrc.2013.12.029
   ROODMAN GD, 1995, BONE, V17, pS57, DOI 10.1016/8756 3282(95)00179 H
   Salesi N, 2006, ANTICANCER RES, V26, P3111
   SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0
   Sato K, 2006, CURR OPIN RHEUMATOL, V18, P419, DOI 10.1097/01.bor.0000231912.24740.a5
   Suresh E, 2014, RHEUMATOLOGY, V53, P19, DOI 10.1093/rheumatology/ket236
   THOMPSON DD, 1995, BONE, V17, pS125, DOI 10.1016/8756 3282(95)00285 L
   Tyagi AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021216
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   Wang LH, 2014, CURR CANCER DRUG TAR, V14, P91, DOI 10.2174/1568009613666131113100634
   Wu ZQ, 2004, BIOL PHARM BULL, V27, P1769, DOI 10.1248/bpb.27.1769
   Wysowski DK, 2009, NEW ENGL J MED, V360, P89, DOI 10.1056/NEJMc0808738
   Xue LM, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/490843
NR 38
TC 31
Z9 36
U1 0
U2 23
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0264 6021
EI 1470 8728
J9 BIOCHEM J
JI Biochem. J.
PD AUG 1
PY 2015
VL 469
BP 399
EP 408
DI 10.1042/BJ20150151
PN 3
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA CR0ZW
UT WOS:000361053400007
PM 26205493
DA 2025 08 17
ER

PT J
AU Yi, Y
   Woo, YM
   Hwang, KH
   Kim, HS
   Lee, SH
AF Yi, Young
   Woo, Young Mi
   Hwang, Kyu Ho
   Kim, Hyun Sil
   Lee, Sang Hyeong
TI Niclosamide and Pyrvinium Are Both Potential Therapeutics for
   Osteosarcoma, Inhibiting Wnt Axin2 Snail Cascade
SO CANCERS
LA English
DT Article
DE osteosarcoma; epithelial mesenchymal transition; niclosamide; pyrvinium;
   Wnt; Snail; Axin2
ID TRANSCRIPTION FACTOR SNAIL; E CADHERIN; MESENCHYMAL TRANSITION; AXIN2
   EXPRESSION; GENE EXPRESSION; BETA CATENIN; WNT; REPRESSOR; PATHWAY;
   CELLS
AB Simple Summary Epithelial mesenchymal transition (EMT) regulated by Wnt signaling is known as a key mechanism of cancer progression. Although evidence has suggested that the oncogenic Wnt signaling pathway and EMT program are important in the progression of osteosarcoma, there is no known therapeutic drug targeting EMT for osteosarcoma. We investigated whether Axin2, an important EMT target, could be a suitable molecular target and biomarker for osteosarcoma. Furthermore, we showed that both niclosamide and pyrvinium target Axin2, and effectively induce EMT reversion in osteosarcoma cell lines. Our findings suggest an effective biomarker and potential EMT therapeutics for osteosarcoma patients. Osteosarcoma, the most common primary bone malignancy, is typically related to growth spurts during adolescence. Prognosis is very poor for patients with metastatic or recurrent osteosarcoma, with survival rates of only 20 30%. Epithelial mesenchymal transition (EMT) is a cellular mechanism that contributes to the invasion and metastasis of cancer cells, and Wnt signaling activates the EMT program by stabilizing Snail and beta catenin in tandem. Although the Wnt/Snail axis is known to play significant roles in the progression of osteosarcoma, and the anthelmintic agents, niclosamide and pyrvinium, have been studied as inhibitors of the Wnt pathway, their therapeutic effects and regulatory mechanisms in osteosarcoma remain unidentified. In this study, we show that both niclosamide and pyrvinium target Axin2, resulting in the suppression of EMT by the inhibition of the Wnt/Snail axis in osteosarcoma cells. Axin2 and Snail are abundant in patient samples and cell lines of osteosarcoma. The treatment of niclosamide and pyrvinium inhibits the migration of osteosarcoma cells at nanomolar concentrations. These results suggest that Axin2 and Snail are candidate therapeutic targets in osteosarcoma, and that anthelminthic agents, niclosamide and pyrvinium, may be effective for osteosarcoma patients.
C1 [Yi, Young] Inje Univ, Dept Orthoped, Seoul Paik Hosp, Seoul 04551, South Korea.
   [Woo, Young Mi; Hwang, Kyu Ho; Kim, Hyun Sil] Yonsei Univ, Oral Canc Res Inst, Dept Oral Pathol, Coll Dent, Seoul 03722, South Korea.
   [Lee, Sang Hyeong] Dongguk Univ, Dept Orthoped, Ilsan Hosp, Goyang Si 10326, Gyeonggi Do, South Korea.
C3 Inje University; Yonsei University; Yonsei University Health System;
   NHIS Ilsan Hospital; Dongguk University
RP Kim, HS (通讯作者)，Yonsei Univ, Oral Canc Res Inst, Dept Oral Pathol, Coll Dent, Seoul 03722, South Korea.; Lee, SH (通讯作者)，Dongguk Univ, Dept Orthoped, Ilsan Hosp, Goyang Si 10326, Gyeonggi Do, South Korea.
EM J5329@paik.ac.kr; marzol5th@hanmail.net; tinogo@yuhs.ac; khs@yuhs.ac;
   drlsh@dumc.or.kr
RI kim, sanghyo/G 8523 2012
OI Kim, Hyun Sil/0000 0003 3614 1764
FU National Research Foundation of Korea [NRF 2021R1A2C3003496]; Korean
   government (MSIP)
FX This work was supported by grants from the National Research Foundation
   of Korea (NRF 2021R1A2C3003496) funded by the Korean government (MSIP).
CR Ahn SY, 2017, ONCOTARGET, V8, P31842, DOI 10.18632/oncotarget.16252
   Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   Arend RC, 2014, GYNECOL ONCOL, V134, P112, DOI 10.1016/j.ygyno.2014.04.005
   Barrallo Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907
   Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034
   Cai Y, 2014, J CELL BIOCHEM, V115, P625, DOI 10.1002/jcb.24708
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Chen K, 2008, PEDIATR BLOOD CANCER, V51, P349, DOI 10.1002/pbc.21595
   Cho ES, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092064
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097 2765(01)00260 X
   Craig P, 2007, CURR OPIN INFECT DIS, V20, P524, DOI 10.1097/QCO.0b013e3282ef579e
   Dattilo R, 2020, CANCER RES, V80, P4087, DOI 10.1158/0008 5472.CAN 19 1184
   De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447
   Gill J, 2021, NAT REV CLIN ONCOL, V18, P609, DOI 10.1038/s41571 021 00519 8
   Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   Hoang BH, 2012, J AM ACAD ORTHOP SUR, V20, P58, DOI 10.5435/JAAOS 20 01 058
   Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389
   Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172 1183.2002
   Kang HE, 2021, CANCERS, V13, DOI 10.3390/cancers13143437
   Kim NH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14374
   Kim NH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001744
   Kim NH, 2011, J CELL BIOL, V195, P417, DOI 10.1083/jcb.201103097
   Klymkowsky MW, 2009, AM J PATHOL, V174, P1588, DOI 10.2353/ajpath.2009.080545
   Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200
   Li B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101969
   Lu WY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029290
   Ma YM, 2013, BIOCHEM BIOPH RES CO, V431, P274, DOI 10.1016/j.bbrc.2012.12.118
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Osada T, 2011, CANCER RES, V71, P4172, DOI 10.1158/0008 5472.CAN 10 3978
   Park SY, 2010, EMBO J, V29, P3787, DOI 10.1038/emboj.2010.254
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Pyun BJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.43
   Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025
   Sack U, 2011, JNCI J NATL CANCER I, V103, P1018, DOI 10.1093/jnci/djr190
   Wendt S, 2019, DTSCH ARZTEBL INT, V116, P213, DOI 10.3238/arztebl.2019.0213
   Wilkins RM, 2003, ANN SURG ONCOL, V10, P498, DOI 10.1245/ASO.2003.03.061
   Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498
   Yang GQ, 2013, MED ONCOL, V30, DOI 10.1007/s12032 013 0697 2
   Yang JH, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.202000683
   Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200
   Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508
   Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185
   Zhang X, 2017, ORAL ONCOL, V73, P48, DOI 10.1016/j.oraloncology.2017.08.004
   Zhang Y, 2018, ONCOL LETT, V16, P6228, DOI 10.3892/ol.2018.9434
   Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173
NR 50
TC 10
Z9 10
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD SEP
PY 2021
VL 13
IS 18
AR 4630
DI 10.3390/cancers13184630
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA UU8IS
UT WOS:000699039300001
PM 34572856
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Agajanian, MJ
   Potjewyd, FM
   Bowman, BM
   Solomon, S
   LaPak, KM
   Bhatt, DP
   Smith, JL
   Goldfarb, D
   Axtman, AD
   Major, MB
AF Agajanian, Megan J.
   Potjewyd, Frances M.
   Bowman, Brittany M.
   Solomon, Smaranda
   LaPak, Kyle M.
   Bhatt, Dhaval P.
   Smith, Jeffery L.
   Goldfarb, Dennis
   Axtman, Alison D.
   Major, Michael B.
TI Protein proximity networks and functional evaluation of the casein
   kinase 1 gamma family reveal unique roles for CK1?3 in WNT signaling
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID INTRINSICALLY DISORDERED REGIONS; PHOSPHORYLATION; LRP6; INHIBITION;
   ACTIVATION; REDUNDANCY; ELEMENTS; DOMAIN; CELLS; AXIN
AB Aberrant activation or suppression of WNT/beta catenin signaling contributes to cancer initiation and progression, neurodegeneration, and bone disease. However, despite great need and more than 40 years of research, targeted therapies for the WNT pathway have yet to be fully realized. Kinases are considered exceptionally druggable and occupy key nodes within the WNT signaling network, but several pathway relevant kinases remain understudied and "dark. " Here, we studied the function of the casein kinase 1 gamma (CSNK1 gamma) subfamily of human kinases and their roles in WNT signaling. miniTurbo based proximity biotinylation and mass spectrometry analysis of CSNK1 gamma 1, CSNK1 gamma 2, and CSNK1 gamma 3 revealed numerous components of the beta catenin dependent and beta catenin independent WNT pathways. In gain of function experiments, we found that CSNK1 gamma 3 but not CSNK1 gamma 1 or CSNK1 gamma 2 activated beta catenin dependent WNT signaling, with minimal effect on other signaling pathways. We also show that within the family, CSNK1 gamma 3 expression uniquely induced low density lipoprotein receptor related protein 6 phosphorylation, which mediates downstream WNT signaling transduction. Conversely, siRNA mediated silencing of CSNK1 gamma 3 alone had no impact on WNT signaling, though cosilencing of all three family members decreased WNT pathway activity. Finally, we characterized two moderately selective and potent small molecule inhibitors of the CSNK1 gamma family. We show that these inhibitors and a CSNK1 gamma 3 kinase  dead mutant suppressed but did not eliminate WNT driven low density lipoprotein receptor related protein 6 phosphorylation and beta catenin stabilization. Our data suggest that while CSNK1 gamma 3 expression uniquely drives pathway activity, potential functional redundancy within the family necessitates loss of all three family members to suppress the WNT signaling pathway.
C1 [Agajanian, Megan J.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA.
   [Agajanian, Megan J.] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27515 USA.
   [Agajanian, Megan J.; Bowman, Brittany M.; LaPak, Kyle M.; Bhatt, Dhaval P.; Goldfarb, Dennis; Major, Michael B.] Washington Univ, Dept Cell Biol & Physiol, St Louis, MO 63110 USA.
   [Potjewyd, Frances M.; Smith, Jeffery L.; Axtman, Alison D.] Univ N Carolina, UNC Eshelman Sch Pharm, Struct Genom Consortium, Div Chem Biol & Med Chem, Chapel Hill, NC 27515 USA.
   [Solomon, Smaranda; Goldfarb, Dennis] Washington Univ, Sch Med, Inst Informat, St Louis, MO USA.
   [Major, Michael B.] Washington Univ, Sch Med, Dept Otolaryngol, St Louis, MO 63110 USA.
   [Agajanian, Megan J.] Stanford Univ, Dept Dev Biol, Stanford, CA 94305 USA.
   [Bowman, Brittany M.] Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   Washington University (WUSTL); University of North Carolina; University
   of North Carolina Chapel Hill; Washington University (WUSTL); Washington
   University (WUSTL); Stanford University; University of Michigan System;
   University of Michigan
RP Major, MB (通讯作者)，Washington Univ, Dept Cell Biol & Physiol, St Louis, MO 63110 USA.; Major, MB (通讯作者)，Washington Univ, Sch Med, Dept Otolaryngol, St Louis, MO 63110 USA.
EM bmajor@wustl.edu
RI ; Bhatt, Dhaval/AAZ 9303 2020
OI Smith, Jeffery L/0000 0003 2189 0420; Solomon,
   Smaranda/0000 0003 1071 5360; Major, Michael/0000 0002 6753 8513;
   Bashore, Frances/0000 0003 4241 9873
FU HHMI Gilliam Fellowship; National Institutes of Health (NIH) National
   Cancer Institute Predoctoral to Postdoctoral Fellow Transition Award
   (F99/K00 Fellowship) [5F99CA245724 02]; NIH Illuminating the Druggable
   Genome Program [U24DK116204]; AbbVie; Bayer Pharma AG; Boehringer
   Ingelheim; Canada Foundation for Innovation; Eshelman Institute for
   Innovation; Genome Canada; Genentech; Innovative Medicines Initiative
   (EU/EFPIA) (ULTRA DD); Janssen; Merck KGaA Darmstadt Germany; MSD;
   Novartis Pharma AG; Ontario Ministry of Economic Development and
   Innovation; Pfizer [115766]; Sao Paulo Research Foundation FAPESP;
   Takeda; Wellcome; NC Biotechnology Center Institutional Support Grant;
   NIH;  [106169/ZZ14/Z];  [2018 IDG 1030];  [U54AG065187]; National Cancer
   Institute [T32CA009547] Funding Source: NIH RePORTER; NIH Office of the
   Director [U24DK116204] Funding Source: NIH RePORTER
FX M. J. A. was funded by HHMI Gilliam Fellowship and the National
   Institutes of Health (NIH) National Cancer Institute Predoctoral to
   Postdoctoral Fellow Transition Award (F99/K00 Fellowship
   [5F99CA245724 02] ) . This work was supported in part by a grant from
   the NIH Illuminating the Druggable Genome Program (U24DK116204) . The
   Structural Genomics Consortium is a registered charity (number 1097737)
   that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim,
   Canada Foundation for Innovation, Eshelman Institute for Innovation,
   Genome Canada, Genentech, Innovative Medicines Initiative (EU/EFPIA)
   (ULTRA DD grant no. 115766) , Janssen, Merck KGaA Darmstadt Germany,
   MSD, Novartis Pharma AG, Ontario Ministry of Economic Development and
   Innovation, Pfizer, Sao Paulo Research Foundation FAPESP, Takeda, and
   Wellcome (106169/ZZ14/Z) . Research reported in this publication was
   supported in part by the NC Biotechnology Center Institutional Support
   Grant 2018 IDG 1030, and NIH U54AG065187. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the NIH.
CR Agajanian MJ, 2019, CELL REP, V26, P79, DOI 10.1016/j.celrep.2018.12.023
   Akritopoulou Zanze I., 2007, US patent, Patent No. [US 9163007 B2, 9163007]
   Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   Babu MM, 2016, BIOCHEM SOC T, V44, P1185, DOI 10.1042/BST20160172
   Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049
   Berginski ME, 2021, NUCLEIC ACIDS RES, V49, pD529, DOI 10.1093/nar/gkaa853
   Beurel E, 2015, PHARMACOL THERAPEUT, V148, P114, DOI 10.1016/j.pharmthera.2014.11.016
   Biechele TL, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002274
   Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065
   Bosc N, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859 016 1413 y
   Branon TC, 2018, NAT BIOTECHNOL, V36, P880, DOI 10.1038/nbt.4201
   Chandrasekharan B, 2021, BIOCHEM BIOPH RES CO, V534, P720, DOI 10.1016/j.bbrc.2020.11.011
   Choi H, 2011, NAT METHODS, V8, P70, DOI 10.1038/NMETH.1541
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Cliffe A, 2003, CURR BIOL, V13, P960, DOI 10.1016/S0960 9822(03)00370 1
   Courbard JR, 2009, DEV BIOL, V333, P67, DOI 10.1016/j.ydbio.2009.06.024
   Cruciat CM, 2014, CURR OPIN CELL BIOL, V31, P46, DOI 10.1016/j.ceb.2014.08.003
   Daly CS, 2017, ONCOGENE, V36, P1793, DOI 10.1038/onc.2016.342
   Daulat AM, 2019, PROTEOMICS, V19, DOI 10.1002/pmic.201800487
   Davidson G, 2005, NATURE, V438, P867, DOI 10.1038/nature04170
   Davis MI, 2011, NAT BIOTECHNOL, V29, P1046, DOI 10.1038/nbt.1990
   DeBruine ZJ, 2017, BRIT J PHARMACOL, V174, P4564, DOI 10.1111/bph.14048
   del Valle Pérez B, 2011, MOL CELL BIOL, V31, P2877, DOI 10.1128/MCB.01466 10
   Doble BW, 2007, DEV CELL, V12, P957, DOI 10.1016/j.devcel.2007.04.001
   Du CX, 2021, FUTURE MED CHEM, V13, P505, DOI 10.4155/fmc 2020 0215
   Ferguson FM, 2018, NAT REV DRUG DISCOV, V17, P353, DOI 10.1038/nrd.2018.21
   Gammons MV, 2016, J CELL SCI, V129, P3892, DOI 10.1242/jcs.195685
   Hemmings BA, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011189
   Huang HB, 2012, ACS MED CHEM LETT, V3, P1059, DOI 10.1021/ml300278f
   Huang JQ, 2017, SCI REP UK, V7, DOI 10.1038/srep40716
   Huang XD, 2013, SCIENCE, V339, P1441, DOI 10.1126/science.1232253
   Huttlin EL, 2015, CELL, V162, P425, DOI 10.1016/j.cell.2015.06.043
   Jumper J, 2021, NATURE, V596, P583, DOI 10.1038/s41586 021 03819 2
   Kelly LK, 2016, CELL REP, V16, P344, DOI 10.1016/j.celrep.2016.06.010
   Lebensohn AM, 2016, ELIFE, V5, DOI 10.7554/eLife.21459
   Lee SY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2146 4
   Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011
   Li DR, 2020, ELIFE, V9, DOI 10.7554/eLife.61564
   Li S., 2020, J. Cell Biol., V219
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092 8674(02)00685 2
   Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273
   Madan B, 2016, P NATL ACAD SCI USA, V113, pE2945, DOI 10.1073/pnas.1605691113
   Major MB, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.2000037
   Metcalfe C, 2010, J CELL SCI, V123, P1588, DOI 10.1242/jcs.067546
   Moehlenkamp JD, 1999, ARCH BIOCHEM BIOPHYS, V363, P98, DOI 10.1006/abbi.1998.1046
   Mukai J, 2004, NAT GENET, V36, P725, DOI 10.1038/ng1375
   Niehrs C, 2010, CELL MOL LIFE SCI, V67, P2551, DOI 10.1007/s00018 010 0329 3
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Perez Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106
   Piao S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004046
   Proffitt KD, 2013, CANCER RES, V73, P502, DOI 10.1158/0008 5472.CAN 12 2258
   Rhee HW, 2013, SCIENCE, V339, P1328, DOI 10.1126/science.1230593
   Schittek B, 2014, MOL CANCER, V13, DOI 10.1186/1476 4598 13 231
   Schwarz Romond T, 2007, J CELL SCI, V120, P2402, DOI 10.1242/jcs.002956
   Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898
   Steinhart Z, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.146589
   Strassburger K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0198149
   Swarup S, 2015, DEVELOPMENT, V142, P1502, DOI 10.1242/dev.116715
   Tamir TY, 2020, J CELL SCI, V133, DOI 10.1242/jcs.241356
   Teo GC, 2014, J PROTEOMICS, V100, P37, DOI 10.1016/j.jprot.2013.10.023
   Tyanova S, 2016, NAT PROTOC, V11, P2301, DOI 10.1038/nprot.2016.136
   van der Lee R, 2014, CHEM REV, V114, P6589, DOI 10.1021/cr400525m
   Vasta JD, 2018, CELL CHEM BIOL, V25, P206, DOI 10.1016/j.chembiol.2017.10.010
   Walker MP, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005654
   Wall VE, 2014, METHODS MOL BIOL, V1116, P193, DOI 10.1007/978 1 62703 764 8_14
   Wang LM, 2009, MOL ENDOCRINOL, V23, P1455, DOI 10.1210/me.2009 0084
   Wang YT, 2014, J IMMUNOL, V192, P1855, DOI 10.4049/jimmunol.1302552
   Wells C, 2020, ACS MED CHEM LETT, V11, P340, DOI 10.1021/acsmedchemlett.9b00399
   Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097 2765(03)00427 1
   Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002
   Wu G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004926
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185
   Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304
NR 75
TC 6
Z9 6
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN
PY 2022
VL 298
IS 6
AR 101986
DI 10.1016/j.jbc.2022.101986
EA MAY 2022
PG 17
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 1X9OQ
UT WOS:000807778400006
PM 35487243
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Lv, ZY
   Wu, YZ
   Lin, JT
   Li, WT
   Weisbecker, H
   Wang, P
   Song, XR
   Sun, W
   Sun, ZY
   Xie, Y
   Meng, J
   Dong, J
   An, XY
   Chen, JQ
   Yang, SQ
   Yuan, T
   Jiang, H
   Sun, C
   Yang, XJ
   Qian, H
   Cai, HL
   Zhao, JN
   Bai, WB
   Shi, DQ
   Bao, NR
AF Lv, Zhongyang
   Wu, Yizhang
   Lin, Jintao
   Li, Weitong
   Weisbecker, Hannah
   Wang, Peng
   Song, Xueru
   Sun, Wei
   Sun, Ziying
   Xie, Ya
   Meng, Jia
   Dong, Jian
   An, Xueying
   Chen, Jiaqi
   Yang, Shaoqiang
   Yuan, Tao
   Jiang, Hui
   Sun, Chang
   Yang, Xiaojiang
   Qian, Hong
   Cai, Hongling
   Zhao, Jianning
   Bai, Wubin
   Shi, Dongquan
   Bao, Nirong
TI Schottky Heterojunction Facilitates Osteosarcoma Ferroptosis and
   Enhances Bone Formation in a Switchable Mode
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
DE bone regeneration; osteosarcoma; Schottky heterojunction; switchable
   therapy model
ID DIFFERENTIATION; STIMULATION
AB Effective antitumor agents with concurrent osteogenic properties are essential for comprehensive osteosarcoma (OS) treatment. However, the current clinical therapeutic strategies of OS fail to completely eradicate tumors while simultaneously encouraging bone formation. To address this issue, a switchable strategy for dynamic OS ablation and static bone regeneration is developed by integrating piezoelectric BaTiO3 (BTO) with atomic thin Ti3C2 (TC) through a Schottky heterojunction, resulting in the formation of TC@BTO. Under sequential ultrasound and near infrared irradiation, the optimized carrier transport of TC@BTO, based on Schottky heterojunction, exhibits excellent characteristics of photothermal conversion and reactive oxygen species generation. This results in ferroptosis of tumor cells and eventual elimination of OS. Moreover, in the static state, the interfacial Schottky heterojunction facilitates the carriers' directed transfer from the semiconductor to the metal. The Schottky heterojunction enhanced static electrical stimulation enhances the osteogenic differentiation of bone marrow derived mesenchymal stem cells and repair of bone defects. Furthermore, RNA sequencing analysis reveals that static TC@BTO promotes bone regeneration by activating Wnt signaling pathway, and remarkably, pharmacological inhibition of Wnt signaling suppresses the TC@BTO induced osteogenesis. Overall, this work broadens the biomedical potential of Schottky heterojunction based therapies and provides a comprehensive strategy for overall OS ablation and bone regeneration.
   Lv et al develop a Schottky heterojunction based multifunctional nano switch (TC@BTO) for the treatment of osteosarcoma. In dynamic state, under sequential ultrasound and near infrared irradiation, TC@BTO induces robust osteosarcoma elimination by generating reactive oxygen species and facilitating ferroptosis; in static state, without any irradiation, TC@BTO initiates osteogenic differentiation of BMSCs and repair of bone defects by activating Wnt signaling pathway.image
C1 [Lv, Zhongyang; Lin, Jintao; Sun, Ziying; Meng, Jia; Yang, Shaoqiang; Yuan, Tao; Jiang, Hui; Sun, Chang; Yang, Xiaojiang; Qian, Hong; Zhao, Jianning; Bao, Nirong] Nanjing Univ, Nanjing Jinling Hosp, Affiliated Hosp, Med Sch,Dept Orthoped, Nanjing 210002, Peoples R China.
   [Wu, Yizhang; Weisbecker, Hannah; Bai, Wubin] Univ North Carolina Chapel Hill, Dept Appl Phys Sci, Chapel Hill, NC 27514 USA.
   [Wu, Yizhang; Cai, Hongling] Nanjing Univ, Collaborat Innovat Ctr Adv Microstruct, Natl Lab Solid State Microstruct, Jiangsu Prov Key Lab Nanotechnol, Nanjing 210093, Peoples R China.
   [Li, Weitong; Wang, Peng; Xie, Ya; Dong, Jian; An, Xueying; Chen, Jiaqi; Shi, Dongquan] Nanjing Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Med Sch,Dept Orthoped Surg,Div Sports Med & Adult, Nanjing 210008, Peoples R China.
   [Li, Weitong; Xie, Ya] Nanjing Univ Chinese Med, Nanjing Drum Tower Hosp, Clin Coll Tradit Chinese & Western Med, Nanjing 210008, Jiangsu, Peoples R China.
   [Song, Xueru] Nanjing Univ, Nanjing Jinling Hosp, Affiliated Hosp, Med Sch,Dept Med Oncol, Nanjing 210002, Peoples R China.
   [Sun, Wei] Xuzhou Med Univ, Jiangyin Clin Coll, Dept Orthoped, Xuzhou 214400, Jiangyin, Peoples R China.
C3 Nanjing University; University of North Carolina; University of North
   Carolina Chapel Hill; University of North Carolina School of Medicine;
   Collaborative Innovation Center of Advanced Microstructures (CICAM);
   Nanjing University; Nanjing University; Nanjing University of Chinese
   Medicine; Nanjing University; Nanjing University; Xuzhou Medical
   University
RP Bao, NR (通讯作者)，Nanjing Univ, Nanjing Jinling Hosp, Affiliated Hosp, Med Sch,Dept Orthoped, Nanjing 210002, Peoples R China.; Wu, YZ; Bai, WB (通讯作者)，Univ North Carolina Chapel Hill, Dept Appl Phys Sci, Chapel Hill, NC 27514 USA.; Wu, YZ (通讯作者)，Nanjing Univ, Collaborat Innovat Ctr Adv Microstruct, Natl Lab Solid State Microstruct, Jiangsu Prov Key Lab Nanotechnol, Nanjing 210093, Peoples R China.; Shi, DQ (通讯作者)，Nanjing Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Med Sch,Dept Orthoped Surg,Div Sports Med & Adult, Nanjing 210008, Peoples R China.
EM yzwu@smail.nju.edu.cn; wbai@unc.edu; shidongquan@nju.edu.cn;
   bnrbnr@sina.com
RI shi, dongquan/ABH 3078 2021; jiaqi, chen/MIU 3630 2025; Wu,
   Yz/HDO 8387 2022; Bai, Wubin/MHQ 9006 2025; Cai, Hong ling/K 2855 2012;
   dong, jian/AFZ 7183 2022
OI Wu, Yizhang/0000 0001 6244 8458; Weisbecker, Hannah/0000 0002 3893 4891
FU This work was supported by the National Science Foundation of China
   (82325035, 82172481, and 32271409), The Scientific Research Project of
   Jiangsu Commission of Health (LKZ2022011), Project funded by the China
   Postdoctoral Science Foundation (2022M723892, [82325035, 82172481,
   32271409]; National Science Foundation of China [LKZ2022011]; Scientific
   Research Project of Jiangsu Commission of Health [2022M723892,
   2023M734292]; China Postdoctoral Science Foundation
FX This work was supported by the National Science Foundation of China
   (82325035, 82172481, and 32271409), The Scientific Research Project of
   Jiangsu Commission of Health (LKZ2022011), Project funded by the China
   Postdoctoral Science Foundation (2022M723892, 2023M734292). Several
   elements in the Scheme 1 were created with BioRender.com.
CR Alfareed TM, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 18306 5
   Bläsius F, 2022, CANCERS, V14, DOI 10.3390/cancers14112694
   Chang MY, 2021, ANGEW CHEM INT EDIT, V60, P12971, DOI 10.1002/anie.202101924
   Dong YX, 2021, NANOSCALE, V13, P14591, DOI 10.1039/d1nr03623h
   Gao WT, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 022 01046 3
   Genchi GG, 2016, ADV HEALTHC MATER, V5, P1808, DOI 10.1002/adhm.201600245
   Gong F, 2019, ADV MATER, V31, DOI 10.1002/adma.201900730
   He GP, 2023, BIOACT MATER, V19, P690, DOI 10.1016/j.bioactmat.2022.05.006
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Khare D, 2020, BIOMATERIALS, V258, DOI 10.1016/j.biomaterials.2020.120280
   Lee PS, 2022, ACTA BIOMATER, V149, P373, DOI 10.1016/j.actbio.2022.06.045
   Li L, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 25573 9
   Li XS, 2018, ANGEW CHEM INT EDIT, V57, P11522, DOI 10.1002/anie.201805138
   Li YJ, 2020, CHEM ENG J, V383, DOI 10.1016/j.cej.2019.123178
   Lv ZY, 2022, EBIOMEDICINE, V84, DOI 10.1016/j.ebiom.2022.104258
   Ma HY, 2022, ACS APPL MATER INTER, V14, P11937, DOI 10.1021/acsami.1c24686
   Ma L, 2020, MATER TODAY, V36, P48, DOI 10.1016/j.mattod.2019.12.005
   Ma SF, 2021, COMPOS PART A APPL S, V145, DOI 10.1016/j.compositesa.2021.106292
   Matsushita Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14029 w
   Meltzer PS, 2021, NEW ENGL J MED, V385, P2066, DOI 10.1056/NEJMra2103423
   Mo J, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI139807
   Moore CL, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010412
   Neffe AT, 2015, ADV MATER, V27, P1738, DOI 10.1002/adma.201404787
   Nie R, 2022, NANOSCALE, V14, P8112, DOI 10.1039/d2nr02176e
   Pan SS, 2020, ADV SCI, V7, DOI 10.1002/advs.201901511
   Shao JD, 2020, CHEM ENG J, V400, DOI 10.1016/j.cej.2020.126009
   Shen SD, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201700250
   Shuai CJ, 2020, COLLOID SURFACE B, V185, DOI 10.1016/j.colsurfb.2019.110587
   Smeland S, 2019, EUR J CANCER, V109, P36, DOI 10.1016/j.ejca.2018.11.027
   Son S, 2020, CHEM SOC REV, V49, P3244, DOI 10.1039/c9cs00648f
   Sun JL, 2021, REDOX BIOL, V41, DOI 10.1016/j.redox.2021.101942
   Tang DL, 2021, CELL RES, V31, P107, DOI 10.1038/s41422 020 00441 1
   Wang LY, 2021, ADV MATER, V33, DOI 10.1002/adma.202100150
   Wang YZ, 2019, SMALL, V15, DOI 10.1002/smll.201805435
   Wu H, 2023, BIOMATERIALS, V293, DOI 10.1016/j.biomaterials.2022.121990
   Wu Yizhang, 2022, Chemical Engineering Journal, DOI 10.1016/j.cej.2021.131925
   Wu YZ, 2023, SMALL, V19, DOI 10.1002/smll.202205053
   Wu YZ, 2021, NANO ENERGY, V90, DOI 10.1016/j.nanoen.2021.106532
   Wu YZ, 2021, SMALL, V17, DOI 10.1002/smll.202101705
   Wu YZ, 2020, APPL CATAL B ENVIRON, V269, DOI 10.1016/j.apcatb.2020.118848
   Xiao CR, 2022, ACS NANO, V16, P20770, DOI 10.1021/acsnano.2c07900
   Xu CF, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.672490
   Xu GL, 2022, CHINESE PHYS B, V31, DOI 10.1088/1674 1056/ac322e
   Xu QB, 2021, THERANOSTICS, V11, P1937, DOI 10.7150/thno.45511
   Yang C, 2021, ADV SCI, V8, DOI 10.1002/advs.202100894
   Yang ZB, 2022, ADV MATER, V34, DOI 10.1002/adma.202108908
   Yao JT, 2020, JACC BASIC TRANSL SC, V5, P53, DOI 10.1016/j.jacbts.2019.10.007
   Yoshida M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10991 7
   Yu C, 2022, J HAZARD MATER, V424, DOI 10.1016/j.jhazmat.2021.127440
   Yu QQ, 2018, ACS NANO, V12, P2695, DOI 10.1021/acsnano.7b08928
   Yuan HT, 2022, SMALL, V18, DOI 10.1002/smll.202202161
   Zhang K, 2014, SCI REP UK, V4, DOI 10.1038/srep05836
   Zhang Y, 2020, CHEM ENG J, V385, DOI 10.1016/j.cej.2019.123938
   Zhong HQ, 2015, REDOX BIOL, V4, P193, DOI 10.1016/j.redox.2014.12.011
NR 55
TC 12
Z9 12
U1 28
U2 145
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 301X
EI 1616 3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD MAR
PY 2024
VL 34
IS 10
DI 10.1002/adfm.202312032
EA NOV 2023
PG 17
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA KB0L7
UT WOS:001105305900001
DA 2025 08 17
ER

PT J
AU Saracino, S
   Canuto, RA
   Maggiora, M
   Oraldi, M
   Scoletta, M
   Ciuffreda, L
   Vandone, AM
   Carossa, S
   Mozzati, M
   Muzio, G
AF Saracino, S.
   Canuto, R. A.
   Maggiora, M.
   Oraldi, M.
   Scoletta, M.
   Ciuffreda, L.
   Vandone, A. M.
   Carossa, S.
   Mozzati, M.
   Muzio, G.
TI Exposing human epithelial cells to zoledronic acid can mediate
   osteonecrosis of jaw: an in vitro model
SO JOURNAL OF ORAL PATHOLOGY & MEDICINE
LA English
DT Article
DE cytokines; epithelial cells; osteonecrosis of the jaw; osteoblasts;
   zoledronic acid
ID BISPHOSPHONATES; NECROSIS
AB BACKGROUND: Osteonecrosis of the jaw (ONJ) is a chronic complication of bisphosphonate therapy, mainly when intravenous, in cancer patients with bone metastases and myeloma. Its pathophysiology is not yet fully elucidated; in particular, the molecular/cellular events triggering ONJ remain unclear. This complication could result from the effect of bisphosphonates released from bone into the soft tissues, or from osteolysis induced by soft tissues directly exposed to bisphosphonates. This research investigated the possibility that ONJ may be evocated by changes induced in osteoblast activity by factors released by soft tissue cells exposed to zoledronic acid.
   METHODS: An in vitro model was used, in which human osteoblast like MG 63 cells were grown in medium conditioned by human keratinocytes NCTC 2544, exposed or not to zoledronic acid (5 or 50 mu M); 5 mu M zoledronic acid was also directly administered to MG 63 cells.
   RESULTS: In NCTC 2544 cells, zoledronic acid decreased proliferation via decreased hydroxy 3 methyl glutaryl CoA reductase, suggesting that a decrease in healing capability can occur in case of injury. An increased pro inflammatory potential was also observed. Osteoblasts grown in medium conditioned in the presence of zoledronic acid showed decreased proliferation and osteogenic properties, and increased ability to induce osteoclast differentiation and inflammatory process. Zoledronic acid directly administered to MG 63 modulated only some parameters and in a lesser extent.
   CONCLUSIONS: The research evidenced, for the first time, the direct involvement of epithelial cells in zoledronic acid triggered molecular mechanisms leading to osteonecrosis of the jaw, by modulating both osteoblast and osteoclast properties. J Oral Pathol Med (2012) 41: 788 792
C1 [Saracino, S.; Canuto, R. A.; Maggiora, M.; Oraldi, M.; Muzio, G.] Univ Turin, Dept Expt Med & Oncol, I 10125 Turin, Italy.
   [Scoletta, M.; Carossa, S.; Mozzati, M.] Univ Turin, Dept Biomed Sci & Human Oncol, Dent Sect, Oral Surg Unit, I 10125 Turin, Italy.
   [Ciuffreda, L.; Vandone, A. M.] Osped San Giovanni Battista Torino, Ctr Oncoematol Subalpino, Turin, Italy.
C3 University of Turin; University of Turin; A.O.U. Citta della Salute e
   della Scienza di Torino; AOU San Giovanni Battista Molinette
RP Muzio, G (通讯作者)，Univ Turin, Dept Expt Med & Oncol, Corso Raffaello 30, I 10125 Turin, Italy.
EM giuliana.muzio@unito.it
RI Maggiora, Marco/D 4627 2011
OI Carossa, Stefano/0000 0002 4986 1798; Muzio,
   Giuliana/0000 0003 2730 1957
FU Regione Piemonte; University of Turin, Italy
FX The work was supported by grants from Regione Piemonte and University of
   Turin, Italy.
CR Allen MR, 2008, J ORAL MAXIL SURG, V66, P987, DOI 10.1016/j.joms.2008.01.038
   BARBIERO G, 1995, EXP CELL RES, V217, P410, DOI 10.1006/excr.1995.1104
   Hering S, 2001, EXP CLIN ENDOCR DIAB, V109, P217, DOI 10.1055/s 2001 15109
   Hess LM, 2008, AM J MED, V121, P475, DOI 10.1016/j.amjmed.2008.01.047
   KORNBERG A, 1955, METHOD ENZYMOL, V1, P441, DOI 10.1016/0076 6879(55)01072 0
   Landesberg R, 2008, J ORAL MAXIL SURG, V66, P839, DOI 10.1016/j.joms.2008.01.026
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Miziorko HM, 2011, ARCH BIOCHEM BIOPHYS, V505, P131, DOI 10.1016/j.abb.2010.09.028
   Morris M, 2010, EUR J ONCOL NURS, V14, P205, DOI 10.1016/j.ejon.2009.12.003
   Narongroeknawin P, 2010, SPEC CARE DENT, V30, P77, DOI 10.1111/j.1754 4505.2009.00128.x
   Pyper Sean R, 2010, Nucl Recept Signal, V8, pe002, DOI 10.1621/nrs.08002
   Reid IR, 2007, BONE, V41, P318, DOI 10.1016/j.bone.2007.04.196
   Reid IR, 2009, BONE, V44, P4, DOI 10.1016/j.bone.2008.09.012
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Scheper MA, 2010, FIBROGENESIS TISSUE, V3, DOI 10.1186/1755 1536 3 6
   Silverman SL, 2009, AM J MED, V122, P33, DOI 10.1016/j.amjmed.2008.12.005
   Wang J, 2003, J ORAL MAXIL SURG, V61, P1104, DOI 10.1016/S0278 2391(03)00328 8
NR 17
TC 23
Z9 25
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0904 2512
EI 1600 0714
J9 J ORAL PATHOL MED
JI J. Oral Pathol. Med.
PD NOV
PY 2012
VL 41
IS 10
BP 788
EP 792
DI 10.1111/j.1600 0714.2012.01173.x
PG 5
WC Dentistry, Oral Surgery & Medicine; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine; Pathology
GA 030WH
UT WOS:000310600300010
PM 22650360
DA 2025 08 17
ER

PT J
AU Park, KH
   Gu, DR
   Jin, SH
   Yoon, CS
   Ko, W
   Kim, YC
   Lee, SH
AF Park, Keun Ha
   Gu, Dong Ryun
   Jin, Su Hyun
   Yoon, Chi Su
   Ko, Wonmin
   Kim, Youn Chul
   Lee, Seoung Hoon
TI Pueraria lobate Inhibits RANKL Mediated Osteoclastogenesis Via
   Downregulation of CREB/PGC1β/c Fos/NFATc1 Signaling
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Pueraria lobate; Puerariae radix; Osteoclast; NFATc1; PGC1 beta; CREB;
   Bone Disease
ID PREVENTS BONE LOSS; HORMONE REPLACEMENT THERAPY; RANDOMIZED
   CONTROLLED TRIALS; OVARIECTOMIZED MICE; MINERAL DENSITY; POSTMENOPAUSAL
   WOMEN; RECEPTOR ACTIVATOR; SOY ISOFLAVONES; IN VITRO; PHYTOESTROGENS
AB Puerariae radix, the dried root of Pueraria lobate Ohwi, is known to prevent bone loss in ovariectomized mice; however, the precise molecular mechanisms are not understood. In this study, we investigated the effects and underlying mechanisms of action of Puerariae radix extract (PRE) on receptor activator of NF kappa B ligand (RANKL) induced osteoclastogenesis. PRE dose dependently inhibited osteoclast differentiation and formation, decreased the bone resorbing activity of osteoclasts, and downregulated the expression of osteoclast differentiation marker genes. The expression of osteoclastogenic factors produced by PRE treated osteoblasts such as RANKL, macrophage colony stimulating factor (M CSF), and osteoprotegerin (OPG) was comparable to that of untreated (control) cells. However, the formation of osteoclasts via bone marrow cell and calvaria derived osteoblast co cultures was suppressed by PRE treatment. Therefore, the inhibitory effects of PRE on osteoclastogenesis clearly targeted osteoclasts, but not osteoblasts. PRE treatment considerably reduced RANKL induced mitogen activated protein kinases (MAPKs) activity, especially c Jun N terminal kinase, in osteoclast precursor cells. In addition, PRE markedly suppressed cAMP response element binding protein (CREB) activation and the induction of peroxisome proliferator activated receptor gamma coactivator 1 beta (PGC1 beta), which stimulate osteoclastogenesis   an effect that was not observed for puerarin and 17 beta estradiol. Finally, PRE treatment significantly repressed the expression of c Fos and the nuclear factor of activated T cells cytoplasmic 1 (NFATc1), which is a master transcription factor for osteoclastogenesis in vitro and in vivo. Overall, these results strongly suggest that PRE is an effective inhibitor of RANKL induced osteoclastogenesis and may be a potent therapeutic agent for bone related diseases such as osteoporosis, rheumatoid arthritis, and periodontitis.
C1 [Park, Keun Ha; Gu, Dong Ryun; Lee, Seoung Hoon] Wonkwang Univ, Coll Dent, Dept Oral Microbiol & Immunol, 460 Iksandae Ro, Iksan 54538, Jeonbuk, South Korea.
   [Gu, Dong Ryun; Jin, Su Hyun; Lee, Seoung Hoon] Wonkwang Univ, CMFR, Sch Med, Iksan 54538, Jeonbuk, South Korea.
   [Yoon, Chi Su; Ko, Wonmin; Kim, Youn Chul] Wonkwang Univ, Inst Pharmaceut Res & Dev, Coll Pharm, Iksan 54538, Jeonbuk, South Korea.
   [Yoon, Chi Su; Ko, Wonmin; Kim, Youn Chul] Wonkwang Univ, Standardized Mat Bank New Bot Drugs, Coll Pharm, Iksan 54538, Jeonbuk, South Korea.
   [Lee, Seoung Hoon] Wonkwang Univ, Inst Biomat & Implant, Iksan 54538, Jeonbuk, South Korea.
C3 Wonkwang University; Wonkwang University; Wonkwang University; Wonkwang
   University; Wonkwang University
RP Lee, SH (通讯作者)，Wonkwang Univ, Coll Dent, Dept Oral Microbiol & Immunol, 460 Iksandae Ro, Iksan 54538, Jeonbuk, South Korea.
EM leesh2@wku.ac.kr
RI Kim, Sung/F 7292 2013; Yoon, Chi Su/MYQ 7181 2025
FU Wonkwang University
FX This paper was supported by Wonkwang University in 2015.
CR Alekel DL, 2010, AM J CLIN NUTR, V91, P218, DOI 10.3945/ajcn.2009.28306
   Arjmandi BH, 1998, AM J CLIN NUTR, V68, p1358S, DOI 10.1093/ajcn/68.6.1358S
   Beral Valerie, 2003, Lancet, V362, P419
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brandi ML, 1997, CALCIFIED TISSUE INT, V61, pS5, DOI 10.1007/s002239900376
   Clarkson TB, 1998, P SOC EXP BIOL MED, V217, P365
   FAN LL, 1982, CHINESE MED J PEKING, V95, P145
   Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910
   Ishimi Y, 2000, BIOCHEM BIOPH RES CO, V274, P697, DOI 10.1006/bbrc.2000.3175
   Jang WS, 2015, FOOD FUNCT, V6, P265, DOI 10.1039/c4fo00836g
   Jordan VC, 2004, CANCER CELL, V5, P207, DOI 10.1016/S1535 6108(04)00059 5
   Khosla S, 1997, J CLIN ENDOCR METAB, V82, P1522, DOI 10.1210/jc.82.5.1522
   Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978
   Lagari VS, 2010, CURR OPIN ENDOCRINOL, V17, P546, DOI 10.1097/MED.0b013e32833f4867
   Lim DW, 2013, NUTRIENTS, V5, P2734, DOI 10.3390/nu5072734
   Ma DF, 2008, CLIN NUTR, V27, P57, DOI 10.1016/j.clnu.2007.10.012
   Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385
   Martin LJ, 2009, MATURITAS, V64, P20, DOI 10.1016/j.maturitas.2009.07.009
   Mei J, 2001, J CLIN ENDOCR METAB, V86, P5217, DOI 10.1210/jc.86.11.5217
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Nelson HD, 2002, JAMA J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872
   Park KH, 2015, J DENT RES, V94, P1676, DOI 10.1177/0022034515604620
   Potter SM, 1998, AM J CLIN NUTR, V68, p1375S, DOI 10.1093/ajcn/68.6.1375S
   Pradhan AD, 2002, JAMA J AM MED ASSOC, V288, P980, DOI 10.1001/jama.288.8.980
   Prasain JK, 2003, J AGR FOOD CHEM, V51, P4213, DOI 10.1021/jf030174a
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Setchell KDR, 2003, AM J CLIN NUTR, V78, p593S, DOI 10.1093/ajcn/78.3.593S
   Shedd Wise KM, 2011, J CLIN DENSITOM, V14, P47, DOI 10.1016/j.jocd.2010.11.003
   Shumaker SA, 2003, JAMA J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651
   Srivastava S, 2001, J BIOL CHEM, V276, P8836, DOI 10.1074/jbc.M010764200
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Taku K, 2007, AM J CLIN NUTR, V85, P1148, DOI 10.1093/ajcn/85.4.1148
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Walsh MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00511
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Wang XX, 2005, METABOLISM, V54, P1536, DOI 10.1016/j.metabol.2005.05.022
   Wang XX, 2003, J BONE MINER METAB, V21, P268, DOI 10.1007/s00774 003 0420 z
   Wang Y, 2014, PHYTOMEDICINE, V21, P1032, DOI 10.1016/j.phymed.2014.04.012
   Wei W, 2010, CELL METAB, V11, P503, DOI 10.1016/j.cmet.2010.04.015
   Wiseman H, 2000, EXPERT OPIN INV DRUG, V9, P1829, DOI 10.1517/13543784.9.8.1829
   Wong KH, 2011, J ETHNOPHARMACOL, V134, P584, DOI 10.1016/j.jep.2011.02.001
   Wu J, 2003, J APPL PHYSIOL, V94, P335, DOI 10.1152/japplphysiol.00498.2002
   Yuan SY, 2016, CHIN J NAT MEDICINES, V14, P265, DOI 10.1016/S1875 5364(16)30026 7
   Zhang Y, 2016, BIOL PHARM BULL, V39, P2028, DOI 10.1248/bpb.b16 00522
NR 44
TC 33
Z9 37
U1 3
U2 19
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192 415X
EI 1793 6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PY 2017
VL 45
IS 8
BP 1725
EP 1744
DI 10.1142/S0192415X17500938
PG 20
WC Integrative & Complementary Medicine; Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; General & Internal Medicine
GA FP5YL
UT WOS:000417698800009
PM 29121799
DA 2025 08 17
ER

PT J
AU Patel, K
   Mangu, SVVSR
   Sukhdeo, SV
   Sharan, K
AF Patel, Kalpana
   Mangu, S. V. V. S. Ravi
   Sukhdeo, Shinde Vijay
   Sharan, Kunal
TI Ethanolic extract from the root and leaf of Sida
   cordifolia promotes osteoblast activity and prevents
   ovariectomy induced bone loss in mice
SO PHYTOMEDICINE
LA English
DT Article
DE Sida cordifolia; Polyphenols; Osteoblast; Ovariectomy; Postmenopausal
   bone loss; Osteoporosis
ID OXIDATIVE STRESS; MASS ACHIEVEMENT; MOUSE MODEL; IN VITRO;
   DIFFERENTIATION; QUERCETIN; OSTEOPOROSIS; ANTIOXIDANT; MECHANISMS;
   KAEMPFEROL
AB Background: Sida cordifolia is traditionally found in the Indian system of medicine, well known for its medicinal and nutritional properties among local natives.Purpose: The present study aims to investigate the osteo protective effect of root and leaf ethanolic extract of S. cordifolia (RE and LE) and its underlying mechanism.Methods: Antioxidant activity of RE and LE was assessed. Total phenolic and flavonoid content were determined. HPLC profiling of RE and LE was performed to examine the polyphenol content. The effect of RE and LE on osteoblast cells proliferation, differentiation, mineralization, and expression of the protein associated with osteogenesis were evaluated using primary calvarial osteoblast culture. Skeletal effects of RE and LE of S. cordifolia were investigated in C57BL/6J ovariectomized mice. Micro CT was employed to evaluate the alteration in trabecular and cortical bone microarchitecture. Histology studies were performed on the isolated vertebra. qPCR analysis and western blotting was done to check the key bone markers.Results: RE and LE showed a potent antioxidant activity, owing to a notable polyphenol content. Both RE and LE did not alter the cell viability but significantly increased the osteoblast cell proliferation, differentiation, and mineralization. Moreover, they enhanced the mRNA expression of osteogenic genes. Both RE and LE stimulated the activation of ERK, AKT, and CREB. Both RE and LE had no direct effect on osteoclastogenesis, but both increased Opg/ROl ratio expression in osteoblast cells. Both RE and LE at 750 mg/kg/day significantly improved the trabecular and cortical microarchitecture of femur and tibia by increasing bone mineral density, bone volume fraction, trabecular number, and trabecular thickness, and decreasing trabecular separation and structural model index in ovariectomized mice. Furthermore, vertebral histology of lumbar vertebrae revealed that RE and LE significantly enhance the vertebral bone mass and exert osteo protective effects by stimulating osteoblast function and inhibiting osteoclast function.Conclusion: In conclusion, both RE and LE stimulate osteoblast differentiation through activating ERK, AKT, and CREB signalling pathways and indirectly inhibits osteoclast differentiation. RE and LE also improve the
C1 [Patel, Kalpana; Mangu, S. V. V. S. Ravi; Sharan, Kunal] CSIR Cent Food Technol Res Inst, Dept Mol Nutr, Mysuru, India.
   [Patel, Kalpana; Mangu, S. V. V. S. Ravi; Sharan, Kunal] Acad Sci & Innovat Res AcSIR, Ghaziabad 201002, India.
   [Sukhdeo, Shinde Vijay] CSIR Cent Food Technol Res Inst, Dept Meat & Marine Sci, Mysuru, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Food Technological Research Institute (CFTRI); Academy of
   Scientific & Innovative Research (AcSIR); Council of Scientific &
   Industrial Research (CSIR)   India; CSIR   Central Food Technological
   Research Institute (CFTRI)
RP Sharan, K (通讯作者)，CSIR Cent Food Technol Res Inst, Dept Mol Nutr, Mysuru, India.
EM kunalsharan@cftri.res.in
RI Sharan, Kunal/C 9618 2012
OI Sharan, Kunal/0000 0003 2139 2544
CR Aghajanian P, 2015, J BONE MINER RES, V30, P1945, DOI 10.1002/jbmr.2709
   Ahmad N, 2017, BIOMED PHARMACOTHER, V88, P804, DOI 10.1016/j.biopha.2017.01.100
   Ali SJ, 2019, NEUROTOX RES, V36, P700, DOI 10.1007/s12640 019 00092 0
   Ali SJ, 2019, TOXICOL APPL PHARM, V363, P154, DOI 10.1016/j.taap.2018.12.003
   Almeida M, 2017, PHYSIOL REV, V97, P135, DOI 10.1152/physrev.00033.2015
   Altarejos JY, 2011, NAT REV MOL CELL BIO, V12, P141, DOI 10.1038/nrm3072
   Austermann K, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040871
   Baba SA, 2015, J TAIBAH UNIV SCI, V9, P449, DOI 10.1016/j.jtusci.2014.11.001
   Bachagol D, 2018, J NUTR BIOCHEM, V52, P18, DOI 10.1016/j.jnutbio.2017.09.023
   Bhattarai G, 2019, J PERIODONTAL RES, V54, P690, DOI 10.1111/jre.12678
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   BRAND WILLIAMS W, 1995, FOOD SCI TECHNOL LEB, V28, P25
   Burin VM, 2011, J CHROMATOGR SCI, V49, P647, DOI 10.1093/chrsci/49.8.647
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Ellur G, 2021, CELL MOL LIFE SCI, V78, P1729, DOI 10.1007/s00018 020 03608 6
   Franzotti EM, 2000, J ETHNOPHARMACOL, V72, P273, DOI 10.1016/S0378 8741(00)00205 1
   Galal A, 2015, CURR TRADIT MED, V1, P5, DOI 10.2174/2215083801666141226215639
   Gavva C, 2020, INT J BIOL MACROMOL, V145, P558, DOI 10.1016/j.ijbiomac.2019.12.189
   Isogai Y, 1996, J BONE MINER RES, V11, P1384
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Jung WW, 2014, INT J MOL MED, V33, P1327, DOI 10.3892/ijmm.2014.1666
   Kanth VR, 1999, PHYTOTHER RES, V13, P75, DOI 10.1002/(SICI)1099 1573(199902)13:1<75::AID PTR387>3.0.CO;2 F
   Kaur G, 2011, INDIAN J NAT PROD RE, V2, P428
   Kenkre JS, 2018, ANN CLIN BIOCHEM, V55, P308, DOI 10.1177/0004563218759371
   Khan K, 2012, MOL NUTR FOOD RES, V56, P1860, DOI 10.1002/mnfr.201200200
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Kubavat JB, 2009, J ETHNOPHARMACOL, V124, P162, DOI 10.1016/j.jep.2009.04.004
   Kyung TW, 2008, EXP MOL MED, V40, P52, DOI 10.3858/emm.2008.40.1.52
   Lane NE, 2002, OSTEOPOROSIS INT, V13, P816, DOI 10.1007/s001980200113
   Lepetsos P, 2016, BBA MOL BASIS DIS, V1862, P576, DOI 10.1016/j.bbadis.2016.01.003
   Lewis KE, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 09921 8
   Liu XW, 2021, EUR J HISTOCHEM, V65, DOI 10.4081/ejh.2021.3195
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Matsui TA, 2007, INT J ONCOL, V31, P915
   Mc Donnell P, 2007, ANN BIOMED ENG, V35, P170, DOI 10.1007/s10439 006 9239 9
   Medeiros IA, 2006, FITOTERAPIA, V77, P19, DOI 10.1016/j.fitote.2005.06.003
   Miyake M, 2003, BIOSCI BIOTECH BIOCH, V67, P1199, DOI 10.1271/bbb.67.1199
   Muzaffer A., 1991, INDIAN DRUGS, V28, P397
   OURSLER MJ, 1991, P NATL ACAD SCI USA, V88, P6613, DOI 10.1073/pnas.88.15.6613
   Pahwa H, 2020, MOL CELL BIOCHEM, V469, P109, DOI 10.1007/s11010 020 03732 8
   Palaska I, 2013, EUR J PHARMACOL, V720, P77, DOI 10.1016/j.ejphar.2013.10.047
   Pang XG, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4178021
   Pawar RS, 2013, INDIAN J PHARMACOL, V45, P474, DOI 10.4103/0253 7613.117759
   Prouillet C, 2004, BIOCHEM PHARMACOL, V67, P1307, DOI 10.1016/j.bcp.2003.11.009
   Ram S., AYURVEDA MED PLANT B
   RAO L., 2015, Phytochemicals   isolation, characterisation and role in human health, P247
   Reagan Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07 9574LSF
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rodríguez Carballo E, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00040
   Roman Garcia P., 2014, VITAMIN B
   Saeed N, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472 6882 12 221
   Sharan K, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12423
   Sharan K, 2011, J BONE MINER RES, V26, P2096, DOI 10.1002/jbmr.434
   Sharan K, 2009, CURR MED CHEM, V16, P1138, DOI 10.2174/092986709787581806
   Sharma AR, 2019, J NUTR BIOCHEM, V74, DOI 10.1016/j.jnutbio.2019.108228
   Silva Renata Lemos, 2006, Acta Cir. Bras., V21, P37, DOI 10.1590/S0102 86502006000700009
   Singh A., 2018, International Journal of Pharmaceutical and Clinical Research, V10, P16
   Singleton VL, 1999, METHOD ENZYMOL, V299, P152
   Srivastava S, 2014, J CELL PHYSIOL, V229, P2088, DOI 10.1002/jcp.24668
   STREWLER GJ, 1987, J CLIN INVEST, V80, P1803, DOI 10.1172/JCI113275
   Swarnkar G, 2011, EUR J PHARMACOL, V658, P65, DOI 10.1016/j.ejphar.2011.02.032
   Tahir AA, 2015, NUTR J, V14, DOI 10.1186/s12937 015 0015 2
   TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo 110 2 506
   Tanaka S, 2007, AM J NEPHROL, V27, P466, DOI 10.1159/000106484
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Trzeciakiewicz A, 2009, NUTR RES REV, V22, P68, DOI 10.1017/S095442240926402X
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   Wattel A, 2003, BIOCHEM PHARMACOL, V65, P35, DOI 10.1016/S0006 2952(02)01445 4
   Wauquier F, 2009, TRENDS MOL MED, V15, P468, DOI 10.1016/j.molmed.2009.08.004
   Woo JT, 2004, BIOL PHARM BULL, V27, P504, DOI 10.1248/bpb.27.504
   Yang SY, 2018, MOLECULES, V23, DOI 10.3390/molecules23020457
   Zhang MJ, 2016, BIOMED REP, V5, P57, DOI 10.3892/br.2016.679
NR 72
TC 9
Z9 9
U1 1
U2 8
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
EI 1618 095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD MAY
PY 2022
VL 99
AR 154024
DI 10.1016/j.phymed.2022.154024
EA MAR 2022
PG 12
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 1B2CL
UT WOS:000792248700005
PM 35263671
DA 2025 08 17
ER

PT J
AU Chen, H
   Song, FF
   Long, FX
AF Chen, Hong
   Song, Fangfang
   Long, Fanxin
TI WNT7B overexpression rescues bone loss caused by glucocorticoids in mice
SO FASEB JOURNAL
LA English
DT Article
DE bone; glucocorticoid; osteoblast; osteoporosis; WNT7B
ID SCLEROSTIN ANTIBODY; GENE EXPRESSION; OSTEOBLASTS; ACTIVATION;
   DIFFERENTIATION; TERIPARATIDE; ALENDRONATE; PREVALENCE; METABOLISM;
   DICKKOPF 1
AB Glucocorticoids, widely prescribed for anti inflammatory and immunosuppressive purposes, are the most common secondary cause for osteoporosis and related fractures. Current anti resorptive and anabolic therapies are insufficient for treating glucocorticoid induced osteoporosis due to contraindications or concerns of side effects. Glucocorticoids have been shown to disrupt Wnt signaling in osteoblast lineage cells, but the efficacy for Wnt proteins to restore bone mass after glucocorticoid therapy has not been examined. Here by using two mouse genetic models wherein WNT7B expression is temporally activated by either tamoxifen or doxycycline in osteoblast lineage cells, we show that WNT7B recovers bone mass following glucocorticoid induced bone loss, thanks to increased osteoblast number and function. However, WNT7B overexpression in bone either before or after glucocorticoid treatments does not ameliorate the abnormal accumulation of body fat. The study demonstrates a potent bone anabolic function for WNT7B in countering glucocorticoid induced bone loss.
C1 [Chen, Hong; Long, Fanxin] Washington Univ, Sch Med, Dept Orthoped Surg, St Louis, MO USA.
   [Chen, Hong] Chongqing Med Univ, Dept Orthoped, Affiliated Hosp 1, Chongqing, Peoples R China.
   [Song, Fangfang; Long, Fanxin] Childrens Hosp Philadelphia, Dept Surg, Translat Res Program Pediat Orthoped, Philadelphia, PA 19146 USA.
   [Song, Fangfang] Wuhan Univ, Sch & Hosp Stomatol, State Key Lab Breeding Base Basic Sci Stomatol, Wuhan, Peoples R China.
C3 Washington University (WUSTL); Chongqing Medical University; University
   of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of
   Philadelphia; Wuhan University
RP Long, FX (通讯作者)，Childrens Hosp Philadelphia, Dept Surg, Translat Res Program Pediat Orthoped, Philadelphia, PA 19146 USA.
EM longf1@chop.edu
FU HHS | NIH | National Institute of Arthritis and Musculoskeletal and Skin
   Diseases (NIAMS) [R01 AR060456, P30 AR057235]
FX HHS | NIH | National Institute of Arthritis and Musculoskeletal and Skin
   Diseases (NIAMS), Grant/Award Number: R01 AR060456 and P30 AR057235
CR Achiou Z, 2015, BONE, V81, P691, DOI 10.1016/j.bone.2015.09.010
   Arensman MD, 2014, ONCOGENE, V33, P899, DOI 10.1038/onc.2013.23
   Brennan Speranza TC, 2012, J CLIN INVEST, V122, P4172, DOI 10.1172/JCI63377
   Chen H, 2019, FASEB J, V33, P7810, DOI 10.1096/fj.201900201RR
   Chen JQ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004145
   Colditz J, 2019, J BONE MINER RES, V34, P1314, DOI 10.1002/jbmr.3702
   Compston J, 2018, ENDOCRINE, V61, P7, DOI 10.1007/s12020 018 1588 2
   Dimitriadis G, 1997, BIOCHEM J, V321, P707, DOI 10.1042/bj3210707
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   Fardet L, 2011, RHEUMATOLOGY, V50, P1982, DOI 10.1093/rheumatology/ker017
   File Elizabeth, 2009, Curr Rheumatol Rep, V11, P169
   Gasparini SJ, 2016, STEROIDS, V116, P76, DOI 10.1016/j.steroids.2016.10.008
   Hildebrandt S, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 26300 z
   Holguin N, 2016, J BONE MINER RES, V31, P2215, DOI 10.1002/jbmr.2900
   Joeng KS, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.4
   Karner CM, 2017, CELL MOL LIFE SCI, V74, P1649, DOI 10.1007/s00018 016 2425 5
   Karner CM, 2015, J CLIN INVEST, V125, P551, DOI 10.1172/JCI78470
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Ledford H, 2020, NATURE, V582, P469, DOI 10.1038/d41586 020 01824 5
   Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010
   Mak W, 2009, CALCIFIED TISSUE INT, V85, P538, DOI 10.1007/s00223 009 9303 1
   Malinauskas T, 2014, CURR OPIN STRUC BIOL, V29, P77, DOI 10.1016/j.sbi.2014.10.003
   Ohnaka K, 2004, BIOCHEM BIOPH RES CO, V318, P259, DOI 10.1016/j.bbrc.2004.04.025
   Overman RA, 2013, ARTHRIT CARE RES, V65, P294, DOI 10.1002/acr.21796
   Perl AKT, 2002, P NATL ACAD SCI USA, V99, P10482, DOI 10.1073/pnas.152238499
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Saag KG, 2009, ARTHRITIS RHEUM US, V60, P3346, DOI 10.1002/art.24879
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Shen LX, 2009, J CELL BIOCHEM, V106, P337, DOI 10.1002/jcb.22010
   Song DY, 2020, BONE RES, V8, DOI 10.1038/s41413 019 0081 8
   Thiele Sylvia, 2014, Bonekey Rep, V3, P552, DOI 10.1038/bonekey.2014.47
   Tu XL, 2007, DEV CELL, V12, P113, DOI 10.1016/j.devcel.2006.11.003
   Wang D, 2019, NAT REV DRUG DISCOV, V18, P358, DOI 10.1038/s41573 019 0012 9
   Wang FS, 2008, ENDOCRINOLOGY, V149, P1793, DOI 10.1210/en.2007 0910
   Yao W, 2016, OSTEOPOROSIS INT, V27, P283, DOI 10.1007/s00198 015 3308 6
   Yao W, 2008, ARTHRITIS RHEUM, V58, P1674, DOI 10.1002/art.23454
   Zheng DL, 2013, MOL CANCER RES, V11, P482, DOI 10.1158/1541 7786.MCR 12 0520
   Zhou H, 2008, J BIOL CHEM, V283, P1936, DOI 10.1074/jbc.M702687200
NR 39
TC 10
Z9 10
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD JUL
PY 2021
VL 35
IS 7
AR e21683
DI 10.1096/fj.202100151RR
PG 11
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA TB2YH
UT WOS:000667814100048
PM 34118078
DA 2025 08 17
ER

PT J
AU Wang, LN
   Zheng, SY
   Huang, GC
   Sun, J
   Pan, YL
   Si, YH
   Tu, PC
   Xu, GH
   Ma, Y
   Guo, Y
AF Wang, Lining
   Zheng, Suyang
   Huang, Guicheng
   Sun, Jie
   Pan, Yalan
   Si, Yuhao
   Tu, Pengcheng
   Xu, Guihua
   Ma, Yong
   Guo, Yang
TI Osthole loaded N octyl O sulfonyl chitosan micelles (NSC OST) inhibits
   RANKL induced osteoclastogenesis and prevents ovariectomy induced bone
   loss in rats
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE homology of medicine and food; mutual promotion; NFATc1; NSC OST;
   osteoclasts; osteoporosis
ID KAPPA B; NFATC1 ACTIVATION; NATURAL PRODUCTS; DIFFERENTIATION;
   OSTEOPOROSIS; CELLS; MECHANISMS; EXPRESSION; INJURY
AB Osthole (OST), a derivative of Fructus Cnidii, has been proved to have potential anti osteoporosis effects in our recent studies. However, its pharmacological effects are limited in the human body because of poor solubility and bioavailability. Under the guidance of the classical theory of Chinese medicine, Osthole loaded N octyl O sulfonyl chitosan micelles (NSC OST), which has not previously been reported in the literature, was synthesized in order to overcome the defects and obtain better efficacy. In this study, we found that NSC OST inhibited on the formation and resorption activity of osteoclasts through using a bone marrow macrophage (BMM) derived osteoclast culture system in vitro, rather than affecting the viability of cells. We also found that NSC OST inhibited osteoclast formation, hydroxyapatite resorption and RANKL induced osteoclast marker protein expression. In terms of mechanism, NSC OST suppressed the NFATc1 transcriptional activity and the activation of NF kappa B signalling pathway. In vivo, ovariectomized (OVX) rat models were established for further research. We found that NSC OST can attenuate bone loss in OVX rats through inhibiting osteoclastogenesis. Consistent with our hypothesis, NSC OST is more effective than OST in parts of the results. Taken together, our findings suggest that NSC OST can suppress RANKL induced osteoclastogenesis and prevents ovariectomy induced bone loss in rats and could be considered a safe and more effective anti osteoporosis drug than OST.
C1 [Wang, Lining; Zheng, Suyang; Huang, Guicheng; Sun, Jie; Pan, Yalan; Si, Yuhao; Tu, Pengcheng; Ma, Yong; Guo, Yang] Nanjing Univ Chinese Med, Inst Traumatol & Orthoped, Lab New Tech Restorat & Reconstruct, Xianlin St 138, Nanjing 210023, Peoples R China.
   [Huang, Guicheng; Ma, Yong] Nanjing Univ Chinese Med, Affiliated Hosp, Dept Traumatol & Orthoped, Nanjing, Peoples R China.
   [Pan, Yalan; Xu, Guihua] Nanjing Univ Chinese Med, TCM Nursing Intervent Lab, Chron Dis Key Lab, Nanjing, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine; Nanjing University of Chinese Medicine
RP Ma, Y; Guo, Y (通讯作者)，Nanjing Univ Chinese Med, Inst Traumatol & Orthoped, Lab New Tech Restorat & Reconstruct, Xianlin St 138, Nanjing 210023, Peoples R China.
EM zhongyi my@263.net; drguoyang@126.com
RI PAN, Misty/JRX 0528 2023; Zheng, Suyang/HNR 6545 2023; sun,
   Jay/HTL 9257 2023
OI Zheng, Suyang/0000 0001 8517 6002; Wang, Lining/0000 0001 6287 5724; 
FU Qing Lan Project of Jiangsu Province [(2018)12]; Third Phase Project of
   Advantage Discipline Construction in Jiangsu Universities, Su Degree
   Office [37]; National Natural Science Foundation of China [81473692]
FX Qing Lan Project of Jiangsu Province, Grant/Award Number: (2018)12;
   Third Phase Project of Advantage Discipline Construction in Jiangsu
   Universities, Grant/Award Number: No. 37, Su Degree Office, 2018;
   National Natural Science Foundation of China, Grant/Award Number:
   81473692
CR Alfaqeeh S, 2015, J DENT RES, V94, P1724, DOI 10.1177/0022034515608828
   An J, 2016, INT IMMUNOPHARMACOL, V36, P118, DOI 10.1016/j.intimp.2016.04.024
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Balagangadharan K, 2017, INT J BIOL MACROMOL, V104, P1372, DOI 10.1016/j.ijbiomac.2016.12.046
   Bar Shavit Z, 2007, J CELL BIOCHEM, V102, P1130, DOI 10.1002/jcb.21553
   Bernkop Schnürch A, 2012, EUR J PHARM BIOPHARM, V81, P463, DOI 10.1016/j.ejpb.2012.04.007
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cai Y, 2018, ACTA PHARMACOL SIN, V39, P74, DOI 10.1038/aps.2017.129
   Cappariello A, 2014, ARCH BIOCHEM BIOPHYS, V558, P70, DOI 10.1016/j.abb.2014.06.017
   Choi JH, 2017, J CELL BIOCHEM, V118, P860, DOI 10.1002/jcb.25763
   D'Amelio P, 2008, BONE, V43, P92, DOI 10.1016/j.bone.2008.02.017
   Feng HT, 2017, CELL ADHES MIGR, V11, P464, DOI 10.1080/19336918.2016.1259058
   Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020
   Jin HM, 2019, J CELL MOL MED, V23, P522, DOI 10.1111/jcmm.13955
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Kong LB, 2019, J CELL MOL MED, V23, P3077, DOI 10.1111/jcmm.14277
   Kuroda Y, 2008, P NATL ACAD SCI USA, V105, P8643, DOI 10.1073/pnas.0800642105
   Lagari VS, 2013, J CLIN DENSITOM, V16, P445, DOI 10.1016/j.jocd.2013.08.011
   Langdahl B, 2016, THER ADV MUSCULOSKEL, V8, P225, DOI 10.1177/1759720X16670154
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   Lin Y, 2019, LIFE SCI, V225, P117, DOI 10.1016/j.lfs.2019.04.004
   Liu FX, 2018, BIOMED PHARMACOTHER, V103, P1052, DOI 10.1016/j.biopha.2018.04.102
   Lorenzo J, 2017, J CLIN INVEST, V127, P2530, DOI 10.1172/JCI94606
   Lu XY, 2018, J CELL MOL MED, V22, P5029, DOI 10.1111/jcmm.13785
   Ma Y, 2019, J CELL BIOCHEM, V120, P16052, DOI 10.1002/jcb.28886
   Park JH, 2017, MOL CELLS, V40, P706
   Schweser KM, 2017, CURR REV MUSCULOSKE, V10, P265, DOI 10.1007/s12178 017 9410 y
   Sun L, 2016, RENAL FAILURE, V38, P276, DOI 10.3109/0886022X.2015.1120118
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Tang DZ, 2010, J BONE MINER RES, V25, P1234, DOI 10.1002/jbmr.21
   Troen BR, 2004, DRUG NEWS PERSPECT, V17, P19, DOI 10.1358/dnp.2004.17.1.829022
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Walker NJ, 2001, J BIOCHEM MOL TOXIC, V15, P121, DOI 10.1002/jbt.8
   Wang L, 2019, J Vis Exp., V147
   Wu SJ, 2015, J MED FOOD, V18, P972, DOI 10.1089/jmf.2014.3314
   Zeng XZ, 2016, ACTA PHARMACOL SIN, V37, P255, DOI 10.1038/aps.2015.85
   Zhang ZR, 2017, NUTRIENTS, V9, DOI 10.3390/nu9060588
   Zhao DF, 2018, MENOPAUSE, V25, P1459, DOI 10.1097/GME.0000000000001150
   Zheng SY, 2018, PHARMACOGN MAG, V14, P641, DOI 10.4103/pm.pm_591_17
NR 41
TC 19
Z9 21
U1 2
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD APR
PY 2020
VL 24
IS 7
BP 4105
EP 4117
DI 10.1111/jcmm.15064
PG 13
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA MJ1LE
UT WOS:000547854800024
PM 32126148
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Mediero, A
   Wilder, T
   Reddy, VSR
   Cheng, Q
   Tovar, N
   Coelho, PG
   Witek, L
   Whatling, C
   Cronstein, BN
AF Mediero, Aranzazu
   Wilder, Tuere
   Reddy, Vishnu S. R.
   Cheng, Qian
   Tovar, Nick
   Coelho, Paulo G.
   Witek, Lukasz
   Whatling, Carl
   Cronstein, Bruce N.
TI Ticagrelor regulates osteoblast and osteoclast function and promotes
   bone formation in vivo via an adenosine dependent mechanism
SO FASEB JOURNAL
LA English
DT Article
DE antiplatelet drugs; A(2A)R; bone regeneration; 3 D HA;  TCP scaffolds
ID ACTIVE METABOLITE; P2X7 RECEPTORS; A(2A) RECEPTOR; A2A RECEPTOR;
   PROTEIN 2; REGENERATION; INFLAMMATION; SUPPRESSION; ACTIVATION;
   EXPRESSION
AB As many as 10% of bone fractures heal poorly, and large bone defects resulting from trauma, tumor, or infection may not heal without surgical intervention. Activation of adenosine A(2A) receptors (A(2A)Rs) stimulates bone formation. Ticagrelor and dipyridamole inhibit platelet function by inhibiting P2Y(12) receptors and platelet phosphodiesterase, respectively, but share the capacity to inhibit cellular uptake of adenosine and thereby increase extracellular adenosine levels. Because dipyridamole promotes bone regeneration by an A(2A)R mediated mechanism we determined whether ticagrelor could regulate the cells involved in bone homeostasis and regeneration in a murine model and whether inhibition of P2Y(12) or indirect A(2A)R activation via adenosine was involved. Ticagrelor, dipyridamole and the active metabolite of clopidogrel (CAM), an alternative P2Y(12) antagonist, inhibited osteoclast differentiation and promoted osteoblast differentiation in vitro. A(2A)R blockade abrogated the effects of ticagrelor and dipyridamole on osteoclast and osteoblast differentiation whereas A(2B)R blockade abrogated the effects of CAM. Ticagrelor and CAM, when applied to a 3 dimentional printed resorbable calcium triphosphate/hydroxyapatite scaffold implanted in a calvarial bone defect, promoted significantly more bone regeneration than the scaffold alone and as much bone regeneration as BMP 2, a growth factor currently used to promote bone regeneration. These results suggest novel approaches to targeting adenosine receptors in the promotion of bone regeneration.Mediero, A., Wilder, T., Reddy, V. S. R., Cheng, Q., Tovar, N., Coelho, P. G., Witek, L., Whatling, C., Cronstein, B. N. Ticagrelor regulates osteoblast and osteoclast function and promotes bone formation in vivo via an adenosine dependent mechanism.
C1 [Mediero, Aranzazu] Univ Autonoma Madrid, Inst Invest Sanitaria, Bone & Joint Res Unit, Fdn Jimenez Diaz, Madrid, Spain.
   [Wilder, Tuere; Cheng, Qian; Cronstein, Bruce N.] NYU, Dept Med, Div Translat Med, Langone Med Ctr, 550 1St Ave, New York, NY 10016 USA.
   [Reddy, Vishnu S. R.; Tovar, Nick; Coelho, Paulo G.; Witek, Lukasz] NYU Coll Dent, Dept Biomat & Biomimet, New York, NY USA.
   [Whatling, Carl] AstraZeneca R&D, Cardiovasc & Metab Dis Innovat Med Unit, Translat Sci, Molndal, Sweden.
C3 Autonomous University of Madrid; Fundacion Jimenez Diaz; NYU Langone
   Medical Center; New York University; New York University; AstraZeneca
RP Cronstein, BN (通讯作者)，NYU Sch Med, Div Translat Med, Dept Med, 550 First Ave,MSB251, New York, NY 10016 USA.
EM bruce.cronstein@nyumc.org
RI ; Mediero, Aranzazu/AAA 8362 2020; Cronstein, Bruce/JTD 2507 2023;
   cheng, qian/KFR 1933 2024; Witek, Lukasz/AAU 5689 2020; Coelho,
   Paulo/B 2999 2014
OI Mediero, Aranzazu/0000 0002 5368 574X; Pintor,
   Jesus/0000 0002 9191 7679; Cronstein, Bruce/0000 0002 4295 7383; Witek,
   Lukasz/0000 0003 1458 6527
FU U.S. National Institutes of Health (NIH) National Institute of Arthritis
   and Musculoskeletal and Skin Diseases [AR56672, AR54897, AR046121]; NIH
   National Heart, Lung, and Blood Institute [RC1HL100815]; NYU HHC
   Clinical and Translational Science Institute [UL1TR000038]; NYU Georgia
   Family Support Program [9NIH/NCI 5 P30CA16087 310]; AstraZeneca
FX This work was supported by the U.S. National Institutes of Health (NIH)
   National Institute of Arthritis and Musculoskeletal and Skin Diseases
   (Grants AR56672, AR54897, and AR046121 to B.N.C.) and the NIH National
   Heart, Lung, and Blood Institute (Grant RC1HL100815 to B.N.C.); the
   NYU HHC Clinical and Translational Science Institute (Grant UL1TR000038
   to B.N.C.) and the NYU Georgia Family Support Program (Grant 9NIH/NCI 5
   P30CA16087 310 to B.N.C.); and by a grant from AstraZeneca. A.M. and
   B.N.C. have filed a patent on the use of adenosine A<INF>2A</INF>R
   agonists to prevent prosthesis loosening (pending) and a patent on the
   use of antibodies against Netrin 1 for the treatment of bone diseases.
   B.N.C. holds patents numbers 5,932,558; 6,020,321; 6,555,545; 7,795,427;
   adenosine A<INF>1</INF>R and A<INF>2B</INF>R antagonists to treat fatty
   liver (pending); adenosine A<INF>2A</INF>R agonists to prevent
   prosthesis loosening (pending). B.N.C. is a consultant for Bristol Myers
   Squibb, AstraZeneca, Novartis, CanFite Biopharmaceuticals, Cypress
   Laboratories, Regeneron (Westat, DSMB), Endocyte, Protalex, Allos, Inc.,
   Savient, Gismo Therapeutics, Antares Pharmaceutical, Medivector, King
   Pharmaceutical, Celizome, Tap Pharmaceuticals, Prometheus Laboratories,
   Sepracor, Amgen, Combinatorx, Kyowa Hakka, Hoffman LaRoche, and Avidimer
   Therapeutics. B.N.C. has stock in CanFite Biopharmaceuticals. The
   remaining authors declare no conflicts of interest.
CR Armstrong D, 2014, J CARDIOVASC PHARM T, V19, P209, DOI 10.1177/1074248413511693
   Bonello L, 2014, J AM COLL CARDIOL, V63, P872, DOI 10.1016/j.jacc.2013.09.067
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   Cattaneo M, 2014, J AM COLL CARDIOL, V63, P2503, DOI 10.1016/j.jacc.2014.03.031
   EINHORN TA, 1995, J BONE JOINT SURG AM, V77A, P940, DOI 10.2106/00004623 199506000 00016
   Elsalanty ME, 2009, CRANIOMAX TRAUM REC, V2, P125, DOI 10.1055/s 0029 1215875
   Gartland A, 2012, FRONT BIOSCI LANDMRK, V17, P16, DOI 10.2741/3912
   Gautschi OP, 2007, ANZ J SURG, V77, P626, DOI 10.1111/j.1445 2197.2007.04175.x
   Glassman SD, 2011, SPINE, V36, P1849, DOI 10.1097/BRS.0b013e3181d133d0
   Grol MW, 2009, PURINERG SIGNAL, V5, P205, DOI 10.1007/s11302 009 9139 1
   He WJ, 2013, FASEB J, V27, P3446, DOI 10.1096/fj.13 231233
   Husted S, 2009, CARDIOVASC THER, V27, P259, DOI 10.1111/j.1755 5922.2009.00096.x
   Ishack S, 2017, J BIOMED MATER RES B, V105, P366, DOI 10.1002/jbm.b.33561
   Kanakaris Nikolaos K, 2008, J Surg Orthop Adv, V17, P133
   Korcok J, 2004, J BONE MINER RES, V19, pS418
   Lee SS, 2013, BIOMATERIALS, V34, P452, DOI 10.1016/j.biomaterials.2012.10.005
   Mckay WF, 2007, INT ORTHOP, V31, P729, DOI 10.1007/s00264 007 0418 6
   Mediero A, 2015, FASEB J, V29, P1577, DOI 10.1096/fj.14 265066
   Mediero A, 2013, BRIT J PHARMACOL, V169, P1372, DOI 10.1111/bph.12227
   Mediero A, 2013, TRENDS ENDOCRIN MET, V24, P290, DOI 10.1016/j.tem.2013.02.001
   Mediero A, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003393
   Mediero A, 2012, AM J PATHOL, V180, P775, DOI 10.1016/j.ajpath.2011.10.017
   Michna S, 2005, BIOMATERIALS, V26, P5632, DOI 10.1016/j.biomaterials.2005.02.040
   Montesinos MC, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1914
   Moriyama K, 2010, J BIOL CHEM, V285, P39271, DOI 10.1074/jbc.M109.098293
   Noé L, 2010, CURR MED CHEM, V17, P2897, DOI 10.2174/092986710792065018
   Nylander S, 2013, J THROMB HAEMOST, V11, P1867, DOI 10.1111/jth.12360
   Oryan A, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/1749 799X 9 18
   Panupinthu N, 2008, J CELL BIOL, V181, P859, DOI 10.1083/jcb.200708037
   Pape HC, 2010, J ORTHOP TRAUMA, V24, P522, DOI 10.1097/BOT.0b013e3181ed1361
   Pereillo JM, 2002, DRUG METAB DISPOS, V30, P1288, DOI 10.1124/dmd.30.11.1288
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Riley EH, 1996, CLIN ORTHOP RELAT R, P39, DOI 10.1097/00003086 199603000 00006
   Savi P, 2000, THROMB HAEMOSTASIS, V84, P891, DOI 10.1055/s 0037 1614133
   SAVI P, 1992, BIOCHEM PHARMACOL, V44, P527, DOI 10.1016/0006 2952(92)90445 O
   Schindeler A, 2008, SEMIN CELL DEV BIOL, V19, P459, DOI 10.1016/j.semcdb.2008.07.004
   Siddiqui NA, 2013, CURR STEM CELL RES T, V8, P192
   Silva NRFA, 2011, J PROSTHODONT, V20, P93, DOI 10.1111/j.1532 849X.2010.00623.x
   Spiro AS, 2010, J ORTHOP RES, V28, P785, DOI 10.1002/jor.21044
   Sterling JA, 2014, CURR OSTEOPOROS REP, V12, P48, DOI 10.1007/s11914 014 0187 2
   Su XM, 2012, J CLIN INVEST, V122, P3579, DOI 10.1172/JCI38576
   Syberg S, 2012, J BONE MINER RES, V27, P2373, DOI 10.1002/jbmr.1690
   Szpalski C, 2012, J CRANIOFAC SURG, V23, P638, DOI 10.1097/SCS.0b013e31824db8d4
   Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio Thoracic Surgery (EACTS), 2010, Eur Heart J, V31, P2501, DOI 10.1093/eurheartj/ehq277
   Tsiridis E, 2007, INJURY, V38, pS11, DOI 10.1016/j.injury.2007.02.006
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   van Giezen JJJ, 2012, J CARDIOVASC PHARM T, V17, P164, DOI 10.1177/1074248411410883
   Wesselius A, 2011, FRONT BIOSCI LANDMRK, V16, P2572, DOI 10.2741/3873
   Wiebe SH, 1999, CELL PHYSIOL BIOCHEM, V9, P323, DOI 10.1159/000016326
   Witek L, 2013, J ADV CERAM, V2, P274, DOI 10.1007/s40145 013 0072 y
   Wittfeldt A, 2013, J AM COLL CARDIOL, V61, P723, DOI 10.1016/j.jacc.2012.11.032
   Yasuda H, 1999, BONE, V25, P109, DOI 10.1016/S8756 3282(99)00121 0
NR 52
TC 52
Z9 60
U1 0
U2 7
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3998 USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD NOV
PY 2016
VL 30
IS 11
BP 3887
EP 3900
DI 10.1096/fj.201600616R
PG 14
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA EA3BY
UT WOS:000386474700023
PM 27511945
OA Green Published
DA 2025 08 17
ER

PT J
AU Jang, Y
   Lee, H
   Cho, Y
   Choi, E
   Jo, S
   Sohn, HM
   Kim, BC
   Ko, YJ
   Lim, W
AF Jang, Yuria
   Lee, Hyeonjoon
   Cho, Yongjin
   Choi, Eunseo
   Jo, Suenghwan
   Sohn, Hong Moon
   Kim, Beom Chang
   Ko, Young Jong
   Lim, Wonbong
TI An LGR4 agonist activates the GSK 3β pathway to inhibit RANK RANKL
   signaling during osteoclastogenesis in bone marrow derived macrophages
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE leucine rich repeat containing G protein coupled receptor 4; receptor
   activator of nuclear factor kappa B ligand; osteoclast; osteoporosis;
   receptor activator of nuclear factor kappa B; glycogen synthase kinase 3
   beta
ID DENOSUMAB; RECEPTOR; DIFFERENTIATION; PREVENTION; MANAGEMENT
AB The binding between receptor activated nuclear factor kappa B (RANK) and the RANK ligand (RANKL) during osteoclast development is an important target for drugs that treat osteoporosis. The leucine rich repeat containing G protein coupled receptor 4 (LGR4) acts as a negative regulator of RANK RANKL that suppresses canonical RANK signaling during osteoclast differentiation. Therefore, LGR4 agonists may be useful in inhibiting osteoclastogenesis and effectively treating osteoporosis. In the present study, bone marrow derived macrophages and a mouse model of RANKL induced bone loss were used to investigate the effect of mutant RANKL (MT RANKL), which was previously developed based on the crystal structure of the RANKL complex. In the present study, the binding affinity of wild type (WT) RANKL and MT RANKL to RANK and LGR4 was determined using microscale thermophoresis analysis, and the effect of the ligands on the AKT glycogen synthase kinase 3 beta (GSK 3 beta) nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1 (NFATc1) signaling cascade was investigated using western blotting and confocal microscopy. In addition, the expression of LGR4 and the colocalization of LGR4 with MT RANKL were analyzed in a mouse model of RANKL induced bone loss. The results showed that in osteoclast precursor cells, MT RANKL bound with high affinity to LGR4 and increased GSK 3 beta phosphorylation independently of AKT, resulting in the inhibition of NFATc1 nuclear translocation. In the mouse model, MT RANKL colocalized with LGR4 and inhibited bone resorption. These results indicated that MT RANKL may inhibit RANKL induced osteoclastogenesis through an LGR4 dependent pathway and this could be exploited to develop new therapies for osteoporosis.
C1 [Jang, Yuria; Lee, Hyeonjoon; Cho, Yongjin; Jo, Suenghwan; Sohn, Hong Moon; Kim, Beom Chang; Ko, Young Jong; Lim, Wonbong] Chosun Univ Hosp, Lab Orthoped Res, Gwangju 61452, South Korea.
   [Jang, Yuria; Kim, Beom Chang; Ko, Young Jong; Lim, Wonbong] Chosun Univ, Coll Med, Dept Premed Sci, 146 Chosundaegil, Gwangju 61452, South Korea.
   [Lee, Hyeonjoon; Cho, Yongjin; Jo, Suenghwan; Sohn, Hong Moon; Lim, Wonbong] Chonnam Natl Univ, Coll Med, Dept Orthopaed Surg, Gwangju 61469, South Korea.
   [Choi, Eunseo] Chosun Univ, Dept Phys Educ, Gwangju 61452, South Korea.
C3 Chosun University; Chosun University; Chonnam National University;
   Chosun University
RP Lim, W (通讯作者)，Chosun Univ, Coll Med, Dept Premed Sci, 146 Chosundaegil, Gwangju 61452, South Korea.
EM wonbong@chosun.ac.kr
FU Chosun University
FX Not applicable.
CR Anastasilakis AD, 2021, J CLIN MED, V10, DOI 10.3390/jcm10010152
   Anastasilakis AD, 2020, J CLIN DENSITOM, V24, P338, DOI 10.1016/j.jocd.2020.10.014
   Anastasilakis AD, 2020, BONE REP, V12, DOI 10.1016/j.bonr.2020.100267
   Bartell SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4773
   Benlidayi IC, 2018, RHEUMATOL INT, V38, P1975, DOI 10.1007/s00296 018 4106 1
   Cadieux B, 2022, J BONE ONCOL, V33, DOI 10.1016/j.jbo.2022.100416
   Cao X, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0040 9
   Cipriani C, 2021, ENDOCRINE, V71, P199, DOI 10.1007/s12020 020 02483 2
   Cong F, 2017, GENE, V610, P1, DOI 10.1016/j.gene.2017.01.028
   Elango J, 2021, CYTOKINE, V144, DOI 10.1016/j.cyto.2021.155559
   Fan XQ, 2015, SCI REP UK, V5, DOI 10.1038/srep17732
   Gkoufa A, 2022, ANN PHARMACOTHER, V56, P853, DOI 10.1177/10600280211050216
   Gowen M, 2000, J CLIN INVEST, V105, P1595, DOI 10.1172/JCI9038
   Hanley DA, 2012, INT J CLIN PRACT, V66, P1139, DOI 10.1111/ijcp.12022
   Hofbauer L. C., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P268
   Jang Y, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010434
   Jin YY, 2016, SCI CHINA LIFE SCI, V59, P735, DOI 10.1007/s11427 016 5068 8
   Kim AS, 2022, CURR OSTEOPOROS REP, DOI 10.1007/s11914 022 00756 5
   Ko Y, 2020, OSTEOPOROSIS INT, V31, P983, DOI 10.1007/s00198 019 05200 6
   Ko YJ, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.368
   Lasco A, 2016, CALCIFIED TISSUE INT, V98, P123, DOI 10.1007/s00223 015 0075 5
   Law SM, 2022, ISCIENCE, V25, DOI 10.1016/j.isci.2022.104159
   Lee Y, 2013, BONE, V56, P383, DOI 10.1016/j.bone.2013.07.007
   Lei MM., 2022, Leuk Lymphoma, V63, P1
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Luo J, 2009, DEVELOPMENT, V136, P2747, DOI 10.1242/dev.033571
   Luo WJ, 2017, J BIOL CHEM, V292, P15525, DOI 10.1074/jbc.M116.771931
   Manolagas SC, 2010, TRENDS ENDOCRIN MET, V21, P369, DOI 10.1016/j.tem.2010.01.010
   Martin T John, 2014, J Bone Metab, V21, P8, DOI 10.11005/jbm.2014.21.1.8
   Miller Paul D, 2009, Curr Osteoporos Rep, V7, P18
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Pittman K, 2017, ASIA PAC J CLIN ONCO, V13, P266, DOI 10.1111/ajco.12517
   Romain M, 2020, BIO PROTOCOL, V10, DOI 10.21769/BioProtoc.3574
   Shi GX, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030564
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Takegahara N, 2022, BONE, V159, DOI 10.1016/j.bone.2022.116353
   Terpos E, 2019, J MED ECON, V22, P766, DOI 10.1080/13696998.2019.1606002
   Tokuyama Naoto, 2014, Clin Calcium, V24, P85, DOI CliCa14018591
   Wang LJ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00190 4
   Wang MM, 2022, J TRACE ELEM MED BIO, V73, DOI 10.1016/j.jtemb.2022.127025
   Yue ZY, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI144579
NR 42
TC 5
Z9 5
U1 1
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD JAN
PY 2024
VL 53
IS 1
AR 10
DI 10.3892/ijmm.2023.5334
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA CV5L8
UT WOS:001128023600001
PM 38063193
OA hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU Sambrook, PN
AF Sambrook, Philip N.
TI Glucocorticoid induced osteoporosis
SO INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
LA English
DT Article
DE bisphosphonates; bone mineral density; fracture; glucocorticoids;
   osteoporosis; parathyroid hormone; vitamin D
ID CORTICOSTEROID INDUCED OSTEOPOROSIS; LOW DOSE CORTICOSTEROIDS; VERTEBRAL
   FRACTURE RISK; RHEUMATOID ARTHRITIS; BONE LOSS; MINERAL DENSITY;
   THERAPY; ALENDRONATE; PREVENTION; CALCIUM
AB Introduction: Glucocorticoids have major effects on bone metabolism, leading to accelerated osteoporosis and fracture.
   Methods: This review will attempt to summarize current knowledge about their effects in light of new information and important remaining questions, especially with respect to management of this common clinical problem.
   Results: Glucocorticoids affect bone through multiple pathways, influencing both bone formation and bone resorption. Evidence from randomised trials suggests that postmenopausal women receiving glucocorticoids are at greatest risk of rapid bone loss and consequent fracture and should be actively considered for prophylaxis. Based upon available evidence, the rank order of choice for prophylaxis would be a bisphosphonate followed by vitamin D. For established glucocorticoid induced osteoporosis, parathyroid hormone followed by a bisphosphonate appears useful.
   Conclusions: Glucocorticoid induced bone loss can be effectively prevented or reversed.
C1 Univ Sydney, Inst Bone & Joint Res, Sydney, NSW 2006, Australia.
C3 University of Sydney
RP Sambrook, PN (通讯作者)，Univ Sydney, Inst Bone & Joint Res, Sydney, NSW 2006, Australia.
EM sambrook@med.usyd.edu.au
CR Adachi JD, 1997, NEW ENGL J MED, V337, P382, DOI 10.1056/NEJM199708073370603
   ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502
   Boutsen Y, 1997, CALCIFIED TISSUE INT, V61, P266, DOI 10.1007/s002239900334
   Buckley LM, 1996, ANN INTERN MED, V125, P961, DOI 10.7326/0003 4819 125 12 199612150 00004
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Carbonare LD, 2001, J BONE MINER RES, V16, P97, DOI 10.1359/jbmr.2001.16.1.97
   de Nijs RNJ, 2006, NEW ENGL J MED, V355, P675, DOI 10.1056/NEJMoa053569
   GOUGH AKS, 1994, LANCET, V344, P23, DOI 10.1016/S0140 6736(94)91049 9
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   LUENGO M, 1991, THORAX, V46, P803, DOI 10.1136/thx.46.11.803
   Naganathan V, 2000, ARCH INTERN MED, V160, P2917, DOI 10.1001/archinte.160.19.2917
   PEEL NFA, 1995, ANN RHEUM DIS, V54, P801, DOI 10.1136/ard.54.10.801
   Reginster JY, 1999, OSTEOPOROSIS INT, V9, P75, DOI 10.1007/s001980050118
   REID DM, 2008, SINGLE INFUSION ZOLE
   REID IR, 1990, ARCH INTERN MED, V150, P2545, DOI 10.1001/archinte.150.12.2545
   Ringe JD, 2003, OSTEOPOROSIS INT, V14, P801, DOI 10.1007/s00198 003 1425 0
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502
   SAMBROOK P, 1993, NEW ENGL J MED, V328, P1747, DOI 10.1056/NEJM199306173282404
   Sambrook PN, 2003, J BONE MINER RES, V18, P919, DOI 10.1359/jbmr.2003.18.5.919
   SAMBROOK PN, 1994, J HEART LUNG TRANSPL, V13, P116
   SAMBROOK PN, 1989, ANN RHEUM DIS, V48, P535, DOI 10.1136/ard.48.7.535
   SAMBROOK PN, 2006, GLUCOCORTICOID INDUC, P296
   van Rossum EFC, 2004, RECENT PROG HORM RES, V59, P333, DOI 10.1210/rp.59.1.333
   Van Staa TP, 2003, ARTHRITIS RHEUM, V48, P3224, DOI 10.1002/art.11283
   van Staa TP, 2001, J BONE MINER RES, V16, P581, DOI 10.1359/jbmr.2001.16.3.581
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   Wallach S, 2000, CALCIFIED TISSUE INT, V67, P277, DOI 10.1007/s002230001146
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Woolf AD, 2007, CURR OPIN RHEUMATOL, V19, P370
NR 30
TC 2
Z9 3
U1 0
U2 8
PU WILEY BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1756 1841
J9 INT J RHEUM DIS
JI Int. J. Rheum. Dis.
PY 2008
VL 11
IS 4
BP 381
EP 385
DI 10.1111/j.1756 185X.2008.00391.x
PG 5
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 450HO
UT WOS:000266391800010
DA 2025 08 17
ER

PT J
AU Andia, DC
   Nassar, CA
   Nassar, PO
   Guimaraes, MR
   Cerri, PS
   Spolidorio, LC
AF Andia, Denise Carleto
   Nassar, Carlos Augusto
   Nassar, Patricia Oehlmeyer
   Guimaraes, Morgana Rodrigues
   Cerri, Paulo Sergio
   Spolidorio, Luis Carlos
TI Treatment with tacrolimus enhances alveolar bone formation and decreases
   osteoclast number in the maxillae: A histomorphometric and
   ultrastructural study in rats
SO HISTOLOGY AND HISTOPATHOLOGY
LA English
DT Article
DE tacrolimus; osteoclasts; osteoblasts
ID CYCLOSPORINE A; MINERAL DENSITY; ORGAN TRANSPLANTATION; IN VIVO; FK506;
   CALCINEURIN; THERAPY; IMMUNOSUPPRESSION; DIFFERENTIATION; OSTEOBLASTS
AB Recent studies have suggested that tacrolimus monotherapy is a beneficial therapeutic alternative for the normalization of cyclosporin  induced bone loss in animal models and humans. The mechanism accounting for this action is unclear at present. In the present study, we attempted to determine the effect of tacrolimus monotherapy on alveolar bone using histological, histomorphometrical and transmission electron microscopy (TEM).
   Groups of rats (n= 10 each) were treated with either tacrolimus (1mg/ kg/ day, s.c.) or drug vehicle for 60 days. Fragments containing maxillary molars were processed for light microscopy to investigate the alveolar bone volume, trabecular separation, number of osteoclasts and osteoblasts, and transmission electron microscopy to investigate their ultrastructural basic phenotype.
   Treatment with tacrolimus monotherapy during 60 days may induce increases in alveolar bone volume (BV/ TV,%; P < 0.05) and a non  significant decrease in trabecular separation (Tb. Sp, mm; P > 0.05), represented by a decrease in osteoclast number (N. Oc/ BS; P < 0.05) and maintenance of osteoblast number (N. Ob/ BS; P > 0.05). Osteoblasts were often observed as a continuous layer of active cells on the bone surface. Osteoclasts appeared to be detached from the resorbed bone surface, which was often filled by active osteoblasts and collagen  rich matrix. Moreover, osteoclasts in the treated group were frequently observed as inactive cells (without ruffled border, clear zone and detached from the bone surface).
   Within the limits of the present study, we conclude that tacrolimus leads to an increase in alveolar bone formation, which probably exerts action on osteoclasts. Tacrolimus could, therefore, play a crucial role in the control of both early osteoclast differentiations from precursors, as well as in functional activation.
C1 [Andia, Denise Carleto; Nassar, Carlos Augusto; Nassar, Patricia Oehlmeyer; Guimaraes, Morgana Rodrigues] State Univ Sao Paulo, Dent Sch Araraquara, UNESP, Dept Periodont, Sao Paulo, Brazil.
   [Cerri, Paulo Sergio] State Univ Sao Paulo, Dent Sch Araraquara, UNESP, Dept Morphol, Sao Paulo, Brazil.
   [Spolidorio, Luis Carlos] State Univ Sao Paulo, Dent Sch Araraquara, UNESP, Dept Physiol & Pathol, Sao Paulo, Brazil.
C3 Universidade Estadual Paulista; Universidade Estadual Paulista;
   Universidade Estadual Paulista
RP Andia, DC (通讯作者)，State Univ Sao Paulo, Dent Sch Araraquara, UNESP, Dept Periodont, Sao Paulo, Brazil.
EM denise@andia.com.br
RI Andia, Denise/F 1080 2012; guimaraes, morgana/C 8966 2014; Cerri,
   Paulo/F 5338 2012; Spolidorio, Luis Carlos/G 1857 2012; STABILI,
   MORGANA/ABC 9852 2021; Nassar, Carlos/U 7076 2019; Cerri,
   Paulo/AAC 5797 2019; Spolidorio, Luís/G 1857 2012
OI Andia, Denise/0000 0002 0049 0201; guimaraes,
   morgana/0000 0002 1297 9717; Cerri, Paulo/0000 0001 5756 5828;
   Spolidorio, Luis Carlos/0000 0002 0592 542X; Nassar,
   Patricia/0000 0003 3791 0334; Nassar, Carlos Augusto/0000 0002 8647 413X
CR Aramburu J, 2000, CURR TOP CELL REGUL, V36, P237
   BARON R, 1989, ANAT RECORD, V224, P317, DOI 10.1002/ar.1092240220
   Bienemann K, 2007, ACTA PAEDIATR, V96, P312, DOI 10.1111/j.1651 2227.2007.00044.x
   Caffier PP, 2007, LARYNGOSCOPE, V117, P1046, DOI 10.1097/MLG.0b013e31804b1aad
   Cerri PS, 2005, ANAT REC PART A, V286A, P833, DOI 10.1002/ar.a.20220
   CVETKOVIC M, 1994, TRANSPLANTATION, V57, P1231, DOI 10.1097/00007890 199404270 00016
   Epstein S, 2003, J BONE MINER RES, V18, P2083, DOI 10.1359/jbmr.2003.18.12.2083
   Guimaraes MR, 2007, ARCH ORAL BIOL, V52, P882, DOI 10.1016/j.archoralbio.2007.02.004
   Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200
   Horslen S, 2007, AM J TRANSPLANT, V7, P1339, DOI 10.1111/j.1600 6143.2007.01780.x
   Huja SS, 2006, ANAT REC PART A, V288A, P1243, DOI 10.1002/ar.a.20396
   Igarashi K, 2004, BONE, V35, P47, DOI 10.1016/j.bone.2004.02.009
   JIANG H, 1991, TRANSPLANT P, V23, P540
   KINO T, 1987, J ANTIBIOT, V40, P1249, DOI 10.7164/antibiotics.40.1249
   Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270
   Krueger Gerald G, 2007, J Drugs Dermatol, V6, P185
   Li S, 2003, ANN THORAC SURG, V75, P257, DOI 10.1016/S0003 4975(02)04287 X
   Mackie EJ, 2003, INT J BIOCHEM CELL B, V35, P1301, DOI 10.1016/S1357 2725(03)00107 9
   Marcén R, 2006, TRANSPLANTATION, V81, P826, DOI 10.1097/01.tp.0000203557.36884.e3
   Misawa Y, 2007, ARCH ORAL BIOL, V52, P44, DOI 10.1016/j.archoralbio.2006.06.012
   Miyata S, 2005, INFLAMM RES, V54, P1, DOI 10.1007/s00011 004 1318 5
   Murakami Kosaku, 2007, Mod Rheumatol, V17, P167
   Nassar CA, 2008, ORAL DIS, V14, P67, DOI 10.1111/j.1601 0825.2006.01354.x
   PARFITT AM, 1988, BONE, V9, P67, DOI 10.1016/8756 3282(88)90029 4
   Sass DA, 1997, BONE, V21, P65, DOI 10.1016/S8756 3282(97)00071 9
   Scolapio JS, 2003, JPEN PARENTER ENTER, V27, P427, DOI 10.1177/0148607103027006427
   Scott LJ, 2003, DRUGS, V63, P1247, DOI 10.2165/00003495 200363120 00006
   Spolidorio LC, 2005, J PERIODONTOL, V76, P1520, DOI 10.1902/jop.2005.76.9.1520
   Spolidorio LC, 2004, J PERIODONTAL RES, V39, P257, DOI 10.1111/j.1600 0765.2004.00734.x
   Spolidorio LC, 2004, J PERIODONTOL, V75, P268, DOI 10.1902/jop.2004.75.2.268
   Spolidorio LC, 2007, CALCIFIED TISSUE INT, V81, P114, DOI 10.1007/s00223 007 9040 2
   Stempfle HU, 2002, TRANSPLANTATION, V73, P547, DOI 10.1097/00007890 200202270 00010
   Sun L, 2005, P NATL ACAD SCI USA, V102, P17130, DOI 10.1073/pnas.0508480102
   Sun L, 2007, AM J PHYSIOL RENAL, V292, pF285, DOI 10.1152/ajprenal.00415.2005
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Tamler R, 2006, ANN NY ACAD SCI, V1068, P284, DOI 10.1196/annals.1346.032
   Tang L, 2002, CELL BIOL INT, V26, P75, DOI 10.1006/cbir.2001.0812
   Taylor AL, 2005, CRIT REV ONCOL HEMAT, V56, P23, DOI 10.1016/j.critrevonc.2005.03.012
   Voggenreiter G, 2000, J BONE MINER RES, V15, P1825, DOI 10.1359/jbmr.2000.15.9.1825
   Yoshikawa T, 2005, TISSUE ENG, V11, P609, DOI 10.1089/ten.2005.11.609
   Yoshikawa T, 2000, J BONE MINER RES, V15, P1147, DOI 10.1359/jbmr.2000.15.6.1147
NR 41
TC 14
Z9 14
U1 0
U2 2
PU F HERNANDEZ
PI MURCIA
PA PLAZA FUENSANTA 2 7 C, 30008 MURCIA, SPAIN
SN 0213 3911
EI 1699 5848
J9 HISTOL HISTOPATHOL
JI Histol. Histopath.
PD OCT
PY 2008
VL 23
IS 10
BP 1177
EP 1184
PG 8
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Pathology
GA 332DW
UT WOS:000258063300002
PM 18712669
DA 2025 08 17
ER

PT J
AU Pore, SK
   Hahm, ER
   Kim, SH
   Singh, KB
   Nyiranshuti, L
   Latoche, JD
   Anderson, CJ
   Adamik, J
   Galson, DL
   Weiss, KR
   Watters, RJ
   Lee, B
   Kumta, PN
   Singh, SV
AF Pore, Subrata K.
   Hahm, Eun Ryeong
   Kim, Su Hyeong
   Singh, Krishna B.
   Nyiranshuti, Lea
   Latoche, Joseph D.
   Anderson, Carolyn J.
   Adamik, Juraj
   Galson, Deborah L.
   Weiss, Kurt R.
   Watters, Rebecca J.
   Lee, Boeun
   Kumta, Prashant N.
   Singh, Shivendra V.
TI A Novel Sulforaphane Regulated Gene Network in Suppression of Breast
   Cancer Induced Osteolytic Bone Resorption
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID OSTEOCLAST DIFFERENTIATION; RECEPTOR ACTIVATOR; RUNX2; BISPHOSPHONATES;
   METASTASIS; CELLS; EXPRESSION; MATRIX METALLOPROTEINASE 9;
   CHEMOPREVENTION; TIME
AB Bone is the most preferred site for colonization of metastatic breast cancer cells for each subtype of the disease. The standard of therapeutic care for breast cancer patients with bone metastasis includes bisphosphonates (e.g., zoledronic acid), which have poor oral bioavailability, and a humanized antibody (denosumab). However, these therapies are palliative, and a subset of patients still develop new bone lesions and/or experience serious adverse effects. Therefore, a safe and orally bioavailable intervention for therapy of osteolytic bone resorption is still a clinically unmet need. This study demonstrates suppression of breast cancer induced bone resorption by a small molecule (sulforaphane, SFN) that is safe clinically and orally bioavailable. In vitro osteoclast differentiation was inhibited in a dose dependent manner upon addition of conditioned media from SFN treated breast cancer cells representative of different sub types. Targeted microarrays coupled with interrogation of The Cancer Genome Atlas data set revealed a novel SFN regulated gene signature involving cross regulation of runt related transcription factor 2 (RUNX2) and nuclear factor kappa B and their downstream effectors. Both RUNX2 and p65/p50 expression were higher in human breast cancer tissues compared with normal mammary tissues. RUNX2 was recruited at the promotor of NFKB1. Inhibition of osteoclast differentiation by SFN was augmented by doxycycline inducible stable knockdown of RUNX2. Oral SFN administration significantly increased the percentage of bone volume/total volume of affected bones in the intracardiac MDA MB 231 Luc model indicating in vivo suppression of osteolytic bone resorption by SFN. These results indicate that SFN is a novel inhibitor of breast cancer induced osteolytic bone resorption in vitro and in vivo.
C1 [Pore, Subrata K.; Hahm, Eun Ryeong; Kim, Su Hyeong; Singh, Krishna B.; Singh, Shivendra V.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA.
   [Nyiranshuti, Lea; Latoche, Joseph D.; Anderson, Carolyn J.; Adamik, Juraj; Galson, Deborah L.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
   [Anderson, Carolyn J.; Galson, Deborah L.; Singh, Shivendra V.] Univ Pittsburgh, UPMC Hillman Canc Ctr, Pittsburgh, PA USA.
   [Anderson, Carolyn J.] Univ Pittsburgh, Dept Radiol, Pittsburgh, PA 15260 USA.
   [Weiss, Kurt R.; Watters, Rebecca J.] Univ Pittsburgh, Dept Orthoped Surg, Pittsburgh, PA USA.
   [Lee, Boeun; Kumta, Prashant N.] Univ Pittsburgh, Dept Bioengn, Swanson Sch Engn, Pittsburgh, PA USA.
   [Kumta, Prashant N.] Univ Pittsburgh, Dept Chem & Petr Engn, Swanson Sch Engn, Pittsburgh, PA 15261 USA.
   [Kumta, Prashant N.] Univ Pittsburgh, Dept Mech Engn & Mat Sci, Swanson Sch Engn, Pittsburgh, PA USA.
   [Pore, Subrata K.] Inst Adv Study Sci & Technol, Gauhati, India.
   [Nyiranshuti, Lea] Univ Calif Los Angeles, Dept Surg, Ahmanson Translat Imaging Div, Los Angeles, CA 90024 USA.
   [Adamik, Juraj] Parker Inst Canc Immunotherapy, San Francisco, CA USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Department of Science & Technology
   (India); Institute of Advanced Study in Science & Technology (IASST);
   University of California System; University of California Los Angeles
RP Singh, SV (通讯作者)，Univ Pittsburgh, Sch Med, 2 32A Hillman Canc Ctr Res Pavil,5117 Ctr Ave, Pittsburgh, PA 15213 USA.
EM singhs@upmc.edu
RI Galson, Deborah/E 9370 2010; Singh, Krishna/AAT 9496 2021
OI Galson, Deborah L./0000 0002 2045 8807; /0000 0002 4052 4373; Watters,
   Rebecca/0000 0001 7486 7510; Pore, Subrata/0000 0002 6324 6994
FU Hillman Foundation Pilot grant; NCI [R01 CA225716, R01 CA142604];
   National Institute of Arthritis and Musculoskeletal and Skin Diseases
   [R01 AR057310]; NCI at the NIH [P30 CA047904]
FX This study was supported in part by a Hillman Foundation Pilot grant
   (S.V. Singh), the NCI grants R01 CA225716 and R01 CA142604 (S.V. Singh),
   and the National Institute of Arthritis and Musculoskeletal and Skin
   Diseases grant R01 AR057310 (D.L. Galson). This study used the UPMC
   Hillman Cancer Center Core Facilities, including the Animal Facility,
   the In Vivo Imaging Facility, and the Tissue and Research Pathology
   Facility partly supported by the NCI at the NIH grant P30 CA047904. The
   funders had no role in the design of the study, data collection,
   analysis or interpretation of the data, manuscript preparation or
   decision to submit the manuscript for publication.
CR [Anonymous], BONE METASTASIS DIAG
   [Anonymous], ADV EXPT MED BIOL
   Atwell LL, 2015, CANCER PREV RES, V8, P1184, DOI 10.1158/1940 6207.CAPR 15 0119
   Bendre MS, 2005, CANCER RES, V65, P11001, DOI 10.1158/0008 5472.CAN 05 2630
   Bendre MS, 2003, BONE, V33, P28, DOI 10.1016/S8756 3282(03)00086 3
   Body JJ, 2015, EUR J CANCER, V51, P1812, DOI 10.1016/j.ejca.2015.05.016
   Bose C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193918
   Castro NP, 2019, CANCER PREV RES, V12, P147, DOI 10.1158/1940 6207.CAPR 18 0241
   Cipolla BG, 2015, CANCER PREV RES, V8, P712, DOI 10.1158/1940 6207.CAPR 14 0459
   Clézardin P, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2835
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Compston J, 2017, LANCET DIABETES ENDO, V5, P485, DOI 10.1016/S2213 8587(17)30178 X
   Cornblatt BS, 2007, CARCINOGENESIS, V28, P1485, DOI 10.1093/carcin/bgm049
   Cremers SCLM, 2005, CLIN PHARMACOKINET, V44, P551, DOI 10.2165/00003088 200544060 00001
   Enomoto H, 2003, J BIOL CHEM, V278, P23971, DOI 10.1074/jbc.M302457200
   Fingleton B, 2006, FRONT BIOSCI LANDMRK, V11, P479, DOI 10.2741/1811
   Fung PPL, 2017, ORAL DIS, V23, P477, DOI 10.1111/odi.12632
   Gül G, 2016, CURR MED RES OPIN, V32, P133, DOI 10.1185/03007995.2015.1105795
   Hahm ER, 2013, JNCI J NATL CANCER I, V105, P1111, DOI 10.1093/jnci/djt153
   Hartman ZC, 2013, CANCER RES, V73, P3470, DOI 10.1158/0008 5472.CAN 12 4524 T
   Kang H, 2012, J CELL BIOCHEM, V113, P2845, DOI 10.1002/jcb.24159
   Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Kim SJ, 2005, MOL CELLS, V20, P364
   Le Pape F, 2016, J BONE ONCOL, V5, P93, DOI 10.1016/j.jbo.2016.02.008
   Li YY, 2018, CANCER PREV RES, V11, P451, DOI 10.1158/1940 6207.CAPR 17 0423
   Liu J, 2018, DISCOV MED, V25, P211
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mathew A, 2015, INT J CANCER, V137, P753, DOI 10.1002/ijc.28965
   Matuoka JY, 2019, EUR J HEALTH ECON, V20, P487, DOI 10.1007/s10198 018 1011 1
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Ocak M, 2018, CANCER BIOTHER RADIO, V33, P74, DOI 10.1089/cbr.2017.2419
   Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581 8591.2005
   Siegel RL, 2019, CA CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Singh SV, 2012, CARCINOGENESIS, V33, P1833, DOI 10.1093/carcin/bgs216
   Singh SV, 2009, CANCER RES, V69, P2117, DOI 10.1158/0008 5472.CAN 08 3502
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Tahata S, 2018, CANCER PREV RES, V11, P429, DOI 10.1158/1940 6207.CAPR 17 0268
   Takagi T, 2017, BIOCHEM BIOPH RES CO, V483, P718, DOI 10.1016/j.bbrc.2016.12.075
   Thaler R, 2016, J BIOL CHEM, V291, P6754, DOI 10.1074/jbc.M115.678235
   Trotter TN, 2015, BLOOD, V125, P3598, DOI 10.1182/blood 2014 12 613968
   Van Acker HH, 2016, PHARMACOL THERAPEUT, V158, P24, DOI 10.1016/j.pharmthera.2015.11.008
   van der Deen M, 2012, J BIOL CHEM, V287, P4503, DOI 10.1074/jbc.M111.287771
   Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Wysokinski D, 2015, INT J MOL SCI, V16, P20969, DOI 10.3390/ijms160920969
   Xiao D, 2003, CARCINOGENESIS, V24, P891, DOI 10.1093/carcin/bgg023
NR 47
TC 9
Z9 10
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1535 7163
EI 1538 8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD FEB
PY 2020
VL 19
IS 2
BP 420
EP 431
DI 10.1158/1535 7163.MCT 19 0611
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA KK8TK
UT WOS:000513008800009
PM 31784454
OA Green Accepted, Green Submitted, Bronze
DA 2025 08 17
ER

PT J
AU Yan, DY
   Tang, JH
   Chen, L
   Wang, BZ
   Weng, SJ
   Xie, ZJ
   Wu, ZY
   Shen, ZJ
   Bai, BL
   Yang, L
AF Yan, De Yi
   Tang, Jiahao
   Chen, Liang
   Wang, Bingzhang
   Weng, Sheji
   Xie, Zhongjie
   Wu, Zong Yi
   Shen, Zijian
   Bai, Bingli
   Yang, Lei
TI Imperatorin promotes osteogenesis and suppresses osteoclast by
   activating AKT/GSK3 β/β catenin pathways
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE bone metabolism; osteoporosis; Wnt3a
ID OSTEOBLAST DIFFERENTIATION; BETA CATENIN; BONE; OSTEOPOROSIS; CELLS;
   DELIVERY
AB Osteoporosis is caused by disturbance in the dynamic balance of bone remodelling, a physiological process, vital for maintenance of healthy bone tissue in adult humans. In this process, a new bone is formed by osteoblasts and the pre existing bone matrix is resorbed by osteoclasts. Imperatorin, a widely available and inexpensive plant extract with antioxidative and apoptotic effects, is reported to treat osteoporosis. However, the underlying mechanism and specific effects on bone metabolism have not been elucidated. In this study, we used rat bone marrow derived mesenchymal stem cells and found that imperatorin can activate RUNX2, COL1A1 and osteocalcin by promoting the Ser9 phosphorylation of GSK3 beta and entry of beta catenin into the nucleus. Imperatorin also enhanced the production of phospho AKT (Ser473), an upstream factor that promotes the Ser9 phosphorylation of GSK3 beta. We used ipatasertib, a pan AKT inhibitor, to inhibit the osteogenic effect of imperatorin, and found that imperatorin promotes osteogenesis via AKT/GSK3 beta/beta catenin pathway. Next, we used rat bone marrow derived monocytes, to check whether imperatorin inhibits osteoclast differentiation via AKT/GSK3 beta/beta catenin pathway. Further, we removed the bilateral ovaries of rats to establish an osteoporotic model. Intragastric administration of imperatorin promoted osteogenesis and inhibited osteoclast in vivo. Our experiments showed that imperatorin is a potential drug for osteoporosis treatment.
C1 [Yan, De Yi; Tang, Jiahao; Chen, Liang; Wang, Bingzhang; Weng, Sheji; Xie, Zhongjie; Wu, Zong Yi; Shen, Zijian; Bai, Bingli; Yang, Lei] Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed Surg, Wenzhou, Zhejiang, Peoples R China.
   [Yan, De Yi; Tang, Jiahao; Chen, Liang; Wang, Bingzhang; Weng, Sheji; Xie, Zhongjie; Wu, Zong Yi; Shen, Zijian; Bai, Bingli; Yang, Lei] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Zhejiang, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University
RP Yang, L (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed Surg, Wenzhou, Zhejiang, Peoples R China.; Yang, L (通讯作者)，Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Zhejiang, Peoples R China.
EM yandeyi18367812991@163.com
FU National Natural Science Foundation of China [81772348]; Technology
   Department of Zhejiang Province [2016C37122]
FX National Natural Science Foundation of China, Grant/Award Number:
   81772348; Technology Department of Zhejiang Province, Grant/Award
   Number: 2016C37122
CR Bang YJ, 2019, EUR J CANCER, V108, P17, DOI 10.1016/j.ejca.2018.11.017
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen X, 2019, J CELL MOL MED, V23, P8269, DOI 10.1111/jcmm.14700
   Costa RLB, 2018, BREAST CANCER RES TR, V169, P397, DOI 10.1007/s10549 018 4697 y
   Doble BW, 2007, CELLS TISSUES ORGANS, V185, P73, DOI 10.1159/000101306
   Durao SF, 2014, OSTEOPOROSIS INT, V25, P1535, DOI 10.1007/s00198 014 2656 y
   Galli C, 2013, CLIN ORAL IMPLAN RES, V24, P921, DOI 10.1111/j.1600 0501.2012.02488.x
   GENANT HK, 1989, AM J OBSTET GYNECOL, V161, P1842, DOI 10.1016/S0002 9378(89)80004 3
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   He JY, 2007, EUR J PHARMACOL, V573, P170, DOI 10.1016/j.ejphar.2007.06.043
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Huang L, 2018, BIOMATERIALS, V182, P58, DOI 10.1016/j.biomaterials.2018.07.046
   Isaac J, 2014, CELL DEATH DIFFER, V21, P1365, DOI 10.1038/cdd.2014.82
   Jang HD, 2011, J BIOL CHEM, V286, P39043, DOI 10.1074/jbc.M111.256768
   Jia M, 2016, CHIN J NAT MEDICINES, V14, P413, DOI 10.1016/S1875 5364(16)30037 1
   Jin HM, 2019, J CELL MOL MED, V23, P8355, DOI 10.1111/jcmm.14713
   Jin HM, 2019, J CELL MOL MED, V23, P522, DOI 10.1111/jcmm.13955
   Johnell O, 2005, J BONE MINER RES, V20, P1185, DOI 10.1359/JBMR.050304
   Kartsogiannis V, 2004, MOL CELL ENDOCRINOL, V228, P79, DOI 10.1016/j.mce.2003.06.002
   Khrimian L, 2017, MOL METAB, V6, P1610, DOI 10.1016/j.molmet.2017.10.001
   Lee DJ, 2019, J TISSUE ENG, V10, DOI 10.1177/2041731419830427
   Li DJ, 2008, BLOOD, V111, P3522, DOI 10.1182/blood 2007 09 111518
   Li JP, 2017, EUR REV MED PHARMACO, V21, P4777
   Lienemann PS, 2012, ADV DRUG DELIVER REV, V64, P1078, DOI 10.1016/j.addr.2012.03.010
   Lin FX, 2018, CELL PHYSIOL BIOCHEM, V47, P161, DOI 10.1159/000489763
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Lv X, 2013, FOOD CHEM, V138, P2260, DOI 10.1016/j.foodchem.2012.11.138
   Mbalaviele G, 2005, J CELL BIOCHEM, V94, P403, DOI 10.1002/jcb.20253
   Migliario Mario, 2017, Dent J (Basel), V5, DOI 10.3390/dj5010013
   Modarresi R, 2009, AM J PATHOL, V174, P123, DOI 10.2353/ajpath.2009.080484
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Newman MR, 2016, CURR OPIN BIOTECH, V40, P125, DOI 10.1016/j.copbio.2016.02.029
   Qiang YW, 2010, BRIT J HAEMATOL, V148, P726, DOI 10.1111/j.1365 2141.2009.08009.x
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707
   Sarker SD, 2004, CURR MED CHEM, V11, P1479, DOI 10.2174/0929867043365189
   Schilcher J, 2015, ACTA ORTHOP, V86, P100, DOI 10.3109/17453674.2015.1004149
   Sigurdsson S, 2004, Z NATURFORSCH C, V59, P523
   Sims NA, 2012, CURR OSTEOPOROS REP, V10, P109, DOI 10.1007/s11914 012 0096 1
   Strom O, 2011, Arch Osteoporos, V6, P59, DOI 10.1007/s11657 011 0060 1
   THOMPSON DD, 1995, BONE, V17, pS125, DOI 10.1016/8756 3282(95)00285 L
   Wang J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.356
   Wei W, 2011, MOL CELL BIOL, V31, P4706, DOI 10.1128/MCB.05980 11
   Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002
   Wu HY, 2019, CANCER LETT, V456, P13, DOI 10.1016/j.canlet.2019.04.026
   Wu MR, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13700
   Yang YH, 2018, CLIN CANCER RES, V24, P834, DOI 10.1158/1078 0432.CCR 17 2006
NR 49
TC 45
Z9 46
U1 1
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD FEB
PY 2020
VL 24
IS 3
BP 2330
EP 2341
DI 10.1111/jcmm.14915
EA DEC 2019
PG 12
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA KJ9OQ
UT WOS:000504600600001
PM 31883297
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Erdogan, KE
   Deveci, MA
   Paydas, S
   Gonlusen, G
AF Erdogan, Kivilcim Eren
   Deveci, Mehmet Ali
   Paydas, Semra
   Gonlusen, Gulfiliz
TI MORPHOLOGIC EVALUATION OF THE EFFECT OF DENOSUMAB ON GIANT CELL TUMORS
   OF BONE AND A NEW GRADING SCHEME
SO POLISH JOURNAL OF PATHOLOGY
LA English
DT Article
DE denosumab; giant cell tumor of bone; pathology; grading; treatment;
   RANKL
ID EXPRESSION; EFFICACY; SAFETY
AB Giant cell tumor (GCT) is a rare, usually benign but locally aggressive neoplasm. Recent studies suggest new approaches in light of the elucidation of molecular pathways in bone. The osteolytic nature of GCT is caused by the receptor for activating nuclear factor kB ligand (RANKL) associated osteoclasts. Denosumab is a monoclonal antibody that affects GCT through RANKL and it prevents normal and neoplastic osteolysis. The aim of this study is to evaluate the histopathologic alterations due to denosumab treatment and the efficiency of this drug in GCT therapy.
   Ten patients had been treated with denosumab and were included in the study. Pretreatment biopsies were interpreted as conventional GCTs and posttreatment biopsies of the ten patients' GCTs were classified in accordance with the grading system. Only one patient had tumor remaining after treatment.
   There is limited data on histopathologic alterations that follow denosumab treatment. The bone pathologist should keep these changes in mind because they mimic different types of bone tumors. Furthermore, there is no widely accepted grading system to evaluate the effect of denosumab in GCT. Our study suggested a scheme that would be helpful to evaluate the efficiency of denosumab treatment in GCT.
C1 [Erdogan, Kivilcim Eren; Gonlusen, Gulfiliz] Cukurova Univ, Fac Med, Dept Pathol, TR 01330 Adana, Turkey.
   [Deveci, Mehmet Ali] Cukurova Univ, Fac Med, Dept Orthoped Surg, Adana, Turkey.
   [Paydas, Semra] Cukurova Univ, Fac Med, Dept Med Oncol, Adana, Turkey.
C3 Cukurova University; Cukurova University; Cukurova University
RP Erdogan, KE (通讯作者)，Cukurova Univ, Fac Med, Dept Pathol, TR 01330 Adana, Turkey.
EM kerdogan@cu.edu.tr
RI Gönlüşen, Gülfiliz/K 2244 2018; Erdogan, Kivilcim/D 3573 2016; Erdogan,
   Kıvılcım/D 3573 2016; Deveci, Mehmet/F 6429 2016; Paydas,
   Semra/F 3132 2018; deveci, mehmet ali/F 6429 2016
OI Erdogan, Kivilcim/0000 0002 4951 8703; deveci, mehmet
   ali/0000 0002 3670 3985
CR Agarwal A, 2013, CASE REP ONCOL MED, V2013, DOI 10.1155/2013/496351
   Anastasilakis AD, 2012, THER CLIN RISK MANAG, V8, P295, DOI 10.2147/TCRM.S24239
   Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078 0432.CCR 12 0578
   Chakarun CJ, 2013, RADIOGRAPHICS, V33, P197, DOI 10.1148/rg.331125089
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   Dietrich MF, 2014, J INVEST MED HIGH IM, V2, DOI 10.1177/2324709614560216
   Dorfman Howard D, 1997, BONE TUMORS, P56
   Girolami I, 2016, J CLIN PATHOL, V69, P240, DOI 10.1136/jclinpath 2015 203248
   Hakozaki M, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746 1596 9 111
   Hanley DA, 2012, INT J CLIN PRACT, V66, P1139, DOI 10.1111/ijcp.12022
   Huang L, 2000, AM J PATHOL, V156, P761, DOI 10.1016/S0002 9440(10)64942 5
   Lippuner K, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13624
   Matcuk GR, 2015, SKELETAL RADIOL, V44, P1027, DOI 10.1007/s00256 015 2117 5
   Mendenhall WM, 2006, AM J CLIN ONCOL CANC, V29, P96, DOI 10.1097/01.coc.0000195089.11620.b7
   Miller PD, 2011, THER ADV MUSCULOSKEL, V3, P271, DOI 10.1177/1759720X11424220
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Santosh N, 2016, APPL IMMUNOHISTO M M, V24, pE18, DOI 10.1097/PAI.0000000000000165
   Van Der Heijden L, 2015, ACTA ORTHOP, V86, P393, DOI 10.3109/17453674.2014.1002345
   Watanabe Naoto, 2014, BMC Res Notes, V7, P608, DOI 10.1186/1756 0500 7 608
NR 19
TC 9
Z9 9
U1 0
U2 2
PU VESALIUS UNIV MEDICAL PUBL
PI CRACOW
PA WISLISKO 1, CRACOW, 00000, POLAND
SN 1233 9687
J9 POL J PATHOL
JI Pol. J. Pathol.
PD DEC
PY 2016
VL 67
IS 4
BP 392
EP 397
DI 10.5114/PJP.2016.65873
PG 6
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA EK8VH
UT WOS:000394202200012
PM 28547968
OA gold
DA 2025 08 17
ER

PT J
AU Murthy, RK
   Morrow, PK
   Theriault, RL
AF Murthy, Rashmi K.
   Morrow, P. K.
   Theriault, Richard L.
TI Bone Biology and the Role of the RANK Ligand Pathway
SO ONCOLOGY NEW YORK
LA English
DT Article
ID AROMATASE INHIBITORS; PATHOPHYSIOLOGY; DISEASE; WOMEN; MEN;
   OSTEOPOROSIS; OSTEOCLAST; MECHANISMS; SURVIVAL; THERAPY
AB Bone biology and the molecular basis of normal bone remodeling are important for understanding bone health, particularly for medical professionals who are treating patients with skeletal complications. Key factors in bone remodeling include RANK ligand, which stimulates bone resorption, and osteoprotegerin (OPG), which inhibits bone resorption. The ratio between these two factors regulates osteoclast formation and activity. An imbalance in the expression of RANK ligand and OPG is an underlying mechanism in cancer treatment induced bone loss, in bone metastasis in patients with solid tumors, and in osteolysis in patients with multiple myeloma. In cancer induced bone disease, for example, RANK ligand overwhelms the effects of OPG, leading to imbalanced bone remodeling and the "vicious cycle" of metastatic disease. Experimental therapeutics that target RANK ligand are increasingly being studied and have shown promise for decreasing tumor related bone disease.
C1 [Murthy, Rashmi K.] Baylor Coll Med, Dept Internal Med, Houston, TX 77030 USA.
   [Morrow, P. K.; Theriault, Richard L.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Div Canc Med, Houston, TX 77030 USA.
C3 Baylor College of Medicine; University of Texas System; UTMD Anderson
   Cancer Center
RP Murthy, RK (通讯作者)，Baylor Coll Med, Dept Internal Med, Houston, TX 77030 USA.
OI Murthy, Rashmi/0000 0002 0103 4718
FU Amgen
FX This article was conceived of and fully funded by Amgen, and Amgen
   provided background direction for the article.
CR Akhtari M, 2008, CANCER BIOL THER, V7, P3, DOI 10.4161/cbt.7.1.5163
   [Anonymous], ONCOLOGY WILLISTON P
   [Anonymous], ONCOLOGY WILLISTON P
   [Anonymous], J CLIN ONCOL
   [Anonymous], ONCOLOGY WILLISTON P
   Bell NH, 2003, J CLIN INVEST, V111, P1120, DOI 10.1172/JCI200318358
   Berenson JR, 2006, CANCER BIOL THER, V5, P1082, DOI 10.4161/cbt.5.9.3307
   Blair JM, 2006, NAT CLIN PRACT ONCOL, V3, P41, DOI 10.1038/ncponc0381
   Burkiewicz JS, 2009, ANN PHARMACOTHER, V43, P1445, DOI 10.1345/aph.1M102
   Canon JR, 2008, CLIN EXP METASTAS, V25, P119, DOI 10.1007/s10585 007 9127 1
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Esteve FR, 2007, BEST PRACT RES CL HA, V20, P613, DOI 10.1016/j.beha.2007.08.003
   Gralow JR, 2009, J NATL COMPR CANC NE, V7, pS1, DOI 10.6004/jnccn.2009.0076
   Guise TA, 2006, ONCOLOGIST, V11, P1121, DOI 10.1634/theoncologist.11 10 1121
   Hadji P, 2008, ANN ONCOL, V19, P1407, DOI 10.1093/annonc/mdn164
   Heath DJ, 2007, CANCER RES, V67, P202, DOI 10.1158/0008 5472.CAN 06 1287
   Hillner BE, 2003, J CLIN ONCOL, V21, P4042, DOI 10.1200/JCO.2003.08.017
   Israeli RS, 2008, J UROLOGY, V179, P414, DOI 10.1016/j.juro.2007.09.028
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lonning PE, 2008, J CLIN ONCOL, V26, P4859, DOI 10.1200/JCO.2008.18.0851
   Mazzuoli G, 2002, BONE, V31, P718, DOI 10.1016/S8756 3282(02)00901 8
   Oefelein MG, 2002, J UROLOGY, V168, P1005, DOI 10.1016/S0022 5347(05)64561 2
   Perez EA, 2006, ONCOLOGY NY, V20, P1029
   Raisz LG, 1999, CLIN CHEM, V45, P1353
   Ramaswamy B, 2003, SEMIN ONCOL, V30, P763, DOI 10.1053/j.seminoncol.2003.08.028
   Roodman GD, 2009, LEUKEMIA, V23, P435, DOI 10.1038/leu.2008.336
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Satoh T, 2009, CANCER AM CANCER SOC, V115, P3468, DOI 10.1002/cncr.24404
   Shapiro CL, 2005, J CLIN ONCOL, V23, P4847, DOI 10.1200/JCO.2005.03.903
   Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197
NR 31
TC 11
Z9 14
U1 0
U2 2
PU UBM MEDICA
PI NORWALK
PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA
SN 0890 9091
J9 ONCOLOGY NY
JI Oncology NY
PD DEC
PY 2009
VL 23
IS 14
SU 5
BP 9
EP 15
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA V18QO
UT WOS:000208019500002
PM 20128323
DA 2025 08 17
ER

PT J
AU Cottone, L
   Ligammari, L
   Lee, HM
   Knowles, HJ
   Henderson, S
   Bianco, S
   Davies, C
   Strauss, S
   Amary, F
   Leite, AP
   Tirabosco, R
   Haendler, K
   Schultze, JL
   Herrero, J
   O'Donnell, P
   Grigoriadis, AE
   Salomoni, P
   Flanagan, AM
AF Cottone, Lucia
   Ligammari, Lorena
   Lee, Hang Mao
   Knowles, Helen J.
   Henderson, Stephen
   Bianco, Sara
   Davies, Christopher
   Strauss, Sandra
   Amary, Fernanda
   Leite, Ana Paula
   Tirabosco, Roberto
   Haendler, Kristian
   Schultze, Joachim L.
   Herrero, Javier
   O'Donnell, Paul
   Grigoriadis, Agamemnon E.
   Salomoni, Paolo
   Flanagan, Adrienne M.
TI Aberrant paracrine signalling for bone remodelling underlies the mutant
   histone driven giant cell tumour of bone
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article
ID PRC2 ACTIVITY; MUTATIONS; H3.3; DIFFERENTIATION; EXPRESSION; SCUBE3;
   PROGENITORS; PDGFRA; LIGAND; GROWTH
AB Oncohistones represent compelling evidence for a causative role of epigenetic perturbations in cancer. Giant cell tumours of bone (GCTs) are characterised by a mutated histone H3.3 as the sole genetic driver present in bone forming osteoprogenitor cells but absent from abnormally large bone resorbing osteoclasts which represent the hallmark of these neoplasms. While these striking features imply a pathogenic interaction between mesenchymal and myelomonocytic lineages during GCT development, the underlying mechanisms remain unknown. We show that the changes in the transcriptome and epigenome in the mesenchymal cells caused by the H3.3 G34W mutation contribute to increase osteoclast recruitment in part via reduced expression of the TGF beta like soluble factor, SCUBE3. Transcriptional changes in SCUBE3 are associated with altered histone marks and H3.3(G34W) enrichment at its enhancer regions. In turn, osteoclasts secrete unregulated amounts of SEMA4D which enhances proliferation of mutated osteoprogenitors arresting their maturation. These findings provide a mechanism by which GCTs undergo differentiation in response to denosumab, a drug that depletes the tumour of osteoclasts. In contrast, hTERT alterations, commonly found in malignant GCT, result in the histone mutated neoplastic cells being independent of osteoclasts for their proliferation, predicting unresponsiveness to denosumab. We provide a mechanism for the initiation of GCT, the basis of which is dysfunctional cross talk between bone forming and bone resorbing cells. The findings highlight the role of tumour/microenvironment bidirectional interactions in tumorigenesis and how this is exploited in the treatment of GCT.
C1 [Cottone, Lucia; Ligammari, Lorena; Bianco, Sara; Davies, Christopher; Leite, Ana Paula; Flanagan, Adrienne M.] UCL, UCL Canc Inst, Dept Pathol, London WC1E 6BT, England.
   [Lee, Hang Mao; Haendler, Kristian; Schultze, Joachim L.; Salomoni, Paolo] German Ctr Neurodegenerat Dis DZNE, D 53127 Bonn, Germany.
   [Knowles, Helen J.] Univ Oxford, Botnar Inst Musculoskeletal Sci, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford OX3 7LD, England.
   [Henderson, Stephen; Herrero, Javier] UCL, UCL Canc Inst, Bill Lyons Informat Ctr BLIC, London WC1 6BT, England.
   [Bianco, Sara; Leite, Ana Paula; Salomoni, Paolo] UCL, UCL Canc Inst, Dept Canc Biol, Samantha Dickson Brain Canc Unit, London WC1E 6BT, England.
   [Davies, Christopher; Amary, Fernanda; Tirabosco, Roberto; Flanagan, Adrienne M.] Royal Natl Orthopaed Hosp, Dept Histopathol, Stanmore HA7 4LP, Middx, England.
   [Strauss, Sandra] Univ Coll London Hosp Fdn Trust, London Sarcoma Serv, London WC1E 6DD, England.
   [Haendler, Kristian; Schultze, Joachim L.] DZNE, Platform Single Cell Genom & Epigen PRECISE, D 53127 Bonn, Germany.
   [Haendler, Kristian; Schultze, Joachim L.] Univ Bonn, D 53127 Bonn, Germany.
   [Haendler, Kristian] Univ Lubeck, Inst Human Genet, Lubeck, Germany.
   [Schultze, Joachim L.] Univ Bonn, Genom & Immunoregulat Life & Med Sci LIMES Inst, D 53115 Bonn, Germany.
   [O'Donnell, Paul] Royal Natl Orthopaed Hosp, Dept Radiol, Stanmore HA7 4LP, Middx, England.
   [Grigoriadis, Agamemnon E.] Kings Coll London, Guys Hosp, Ctr Craniofacial & Regenerat Biol, London SE1 9RT, England.
C3 University of London; University College London; Helmholtz Association;
   German Center for Neurodegenerative Diseases (DZNE); University of
   Oxford; University of London; University College London; University of
   London; University College London; University of London; University
   College London; Royal National Orthopaedic Hospital NHS Trust;
   University of London; University College London; Helmholtz Association;
   German Center for Neurodegenerative Diseases (DZNE); University of Bonn;
   University of Lubeck; University of Bonn; University of London;
   University College London; Royal National Orthopaedic Hospital NHS
   Trust; Guy's & St Thomas' NHS Foundation Trust; University of London;
   King's College London
RP Flanagan, AM (通讯作者)，UCL, UCL Canc Inst, Dept Pathol, London WC1E 6BT, England.; Salomoni, P (通讯作者)，German Ctr Neurodegenerat Dis DZNE, D 53127 Bonn, Germany.; Salomoni, P (通讯作者)，UCL, UCL Canc Inst, Dept Canc Biol, Samantha Dickson Brain Canc Unit, London WC1E 6BT, England.; Flanagan, AM (通讯作者)，Royal Natl Orthopaed Hosp, Dept Histopathol, Stanmore HA7 4LP, Middx, England.
EM Paolo.Salomoni@dzne.de; a.flanagan@ucl.ac.uk
RI Herrero, Javier/H 6971 2019; Amary, Fernanda/AAI 7339 2020; Knowles,
   Helen/JLL 7005 2023; Knowles, Helen/F 3857 2018; Schultze,
   Joachim/ABA 8176 2020; Salomoni, Paolo/LMN 4418 2024; Cottone,
   Lucia/W 4847 2019
OI Flanagan, Adrienne/0000 0002 2832 1303; Herrero,
   Javier/0000 0001 7313 717X; Henderson, Stephen/0000 0002 9032 3828;
   Knowles, Helen/0000 0002 9575 6067; Strauss, Sandra/0000 0001 8328 0260;
   Handler, Kristian/0000 0001 5273 5277
FU UK Medical Research Council [MR/M00094X/1]; PRECISE platform; Skeletal
   Action Trust UK; Tom Prince Cancer Trust; Royal National Orthopaedic
   Hospital NHS Trust RD Department; Rosetrees Trust [M46 F1, M456];
   Stoneygate Trust [M46 F1]; Bone Cancer Research Trust Infrastructure
   grant; Brain Tumour Charity; National Institute for Health Research;
   University College London Hospitals Biomedical Research Centre; Cancer
   Research UK University College London Experimental Cancer Medicine
   Centre; Cancer ERC Consolidator award until May 2019; Wilhelm Sander
   Stiftung; DFG under Germany's Excellence Strategy [EXC2151 390873048];
   Helmholtz Gemeinschaft Aging and Metabolic Programming (AMPro)
   Consortium; Arthritis Research UK [MP/19200]; Cancer Research
   UK University College London (CRUK UCL) Centre Award [C416/A25145]; UCL
   Cancer Institute Flow Cytometry Facility   CRUK UCL Centre Award
   [C416/A25145]; CRUK Cancer Immunotherapy Network Accelerator (CITA)
   Award [C33499/A20265]; CRUK Centre award [C16420/A18066]; UCL Biomedical
   Research Centre; MRC [MR/M00094X/1] Funding Source: UKRI; Medical
   Research Council [MR/M00094X/1] Funding Source: researchfish; Rosetrees
   [M46 F1, M456] Funding Source: researchfish; Austrian Science Fund (FWF)
   [M456] Funding Source: Austrian Science Fund (FWF)
FX Funding for this project was received from the UK Medical Research
   Council grant (MR/M00094X/1) (AMF and PS), PRECISE platform (PS), The
   Tom Prince Cancer Trust (AMF), Skeletal Action Trust UK (AMF), the Royal
   National Orthopaedic Hospital NHS Trust R&D Department, the Rosetrees
   and Stoneygate Trusts (M46 F1) (AMF), the Bone Cancer Research Trust
   Infrastructure grant (AMF), and the Brain Tumour Charity (PS). AMF, LC,
   PS and AL were supported by the National Institute for Health Research,
   the University College London Hospitals Biomedical Research Centre, and
   the Cancer Research UK University College London Experimental Cancer
   Medicine Centre. LC was supported by The Tom Prince Cancer Trust. PS was
   supported by the Cancer ERC Consolidator award until May 2019 and is
   currently supported by a project grant on histone variants from the
   Wilhelm Sander Stiftung, by the DFG under Germany's Excellence Strategy
   (Grant no. EXC2151 390873048; Excellence Cluster ImmunoSensation2) and
   the Helmholtz Gemeinschaft Aging and Metabolic Programming (AMPro)
   Consortium, along with other funding bodies. PS is a member of the Bonn
   International Graduate School of Neuroscience. HK is funded by Arthritis
   Research UK (MP/19200) and Rosetrees Trust (M456). SH was funded by the
   Cancer Research UK University College London (CRUK UCL) Centre Award
   [C416/A25145]. This work was also supported by the UCL Cancer Institute
   Flow Cytometry Facility, funded by the CRUK UCL Centre Award (Grant no.
   C416/A25145) and the CRUK Cancer Immunotherapy Network Accelerator
   (CITA) Award (grant no. C33499/A20265) as well as CRUK Centre award to
   Barts Cancer Centre (Grant no. C16420/A18066) and the UCL Biomedical
   Research Centre.
CR Abcam, HIST EXTR PROT
   Amary F, 2017, AM J SURG PATHOL, V41, P1059, DOI 10.1097/PAS.0000000000000859
   Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814
   Bjerke L, 2013, CANCER DISCOV, V3, P512, DOI 10.1158/2159 8290.CD 12 0426
   Bray NL, 2016, NAT BIOTECHNOL, V34, P888, DOI 10.1038/nbt0816 888d
   Chen CCL, 2020, CELL, V183, P1617, DOI 10.1016/j.cell.2020.11.012
   Correa Rodríguez M, 2018, INT J MED SCI, V15, P999, DOI 10.7150/ijms.25369
   Cottone L, 2020, J PATHOL CLIN RES, V6, P113, DOI 10.1002/cjp2.156
   Doolittle ML, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008805
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Editorial Board, 2020, WHO CLASS SOFT TISS
   Fittall MW, 2020, J PATHOL, V252, P433, DOI 10.1002/path.5537
   Forsyth RG, 2021, CANCERS, V13, DOI 10.3390/cancers13205119
   Fuchs H, 2016, G3 GENES GENOM GENET, V6, P4035, DOI 10.1534/g3.116.033670
   He YF, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 04161 1
   Hulley PA, 2017, J PATHOL, V242, P322, DOI 10.1002/path.4906
   Ignatiadis N, 2016, NAT METHODS, V13, P577, DOI [10.1038/NMETH.3885, 10.1038/nmeth.3885]
   Jain SU, 2020, P NATL ACAD SCI USA, V117, P27354, DOI 10.1073/pnas.2006076117
   Kato I, 2018, HISTOPATHOLOGY, V72, P914, DOI 10.1111/his.13448
   Kerr DA, 2021, AM J SURG PATHOL, V45, P93, DOI 10.1097/PAS.0000000000001555
   Khazaei S, 2020, CANCER DISCOV, V10, P1968, DOI 10.1158/2159 8290.CD 20 0461
   Krug B, 2019, CANCER CELL, V35, P782, DOI 10.1016/j.ccell.2019.04.004
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lampada A, 2017, CELL DEATH DIFFER, V24, P1045, DOI 10.1038/cdd.2017.41
   Lewis PW, 2013, SCIENCE, V340, P857, DOI 10.1126/science.1232245
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Lin YC, 2021, AM J HUM GENET, V108, P115, DOI 10.1016/j.ajhg.2020.11.015
   LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059 014 0550 8
   Lu C, 2016, SCIENCE, V352, P844, DOI 10.1126/science.aac7272
   Lutsik P, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18955 y
   Maganti HB, 2018, CANCER DISCOV, V8, P1376, DOI 10.1158/2159 8290.CD 17 0841
   Nacev BA, 2020, NAT REV CANCER, V20, P608, DOI 10.1038/s41568 020 0288 4
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Nielson CM, 2016, J BONE MINER RES, V31, P2085, DOI 10.1002/jbmr.2913
   Niu KY, 2018, BIO PROTOCOL, V8, DOI 10.21769/BioProtoc.2981
   Pathania M, 2017, CANCER CELL, V32, P684, DOI 10.1016/j.ccell.2017.09.014
   PromoCell GmbH, OST DIFF MIN
   Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
   Quinn JMW, 1998, CALCIFIED TISSUE INT, V62, P527, DOI 10.1007/s002239900473
   Raouf A, 2000, ONCOGENE, V19, P6455, DOI 10.1038/sj.onc.1204037
   Rivadeneira F, 2009, NAT GENET, V41, P1199, DOI 10.1038/ng.446
   Scheipl S, 2016, J PATHOL, V239, P320, DOI 10.1002/path.4729
   Schwartzentruber J, 2012, NATURE, V482, P226, DOI [10.1007/s13311 012 0137 6, 10.1038/nature10833]
   Shi LL, 2018, J MOL BIOL, V430, P1562, DOI 10.1016/j.jmb.2018.04.014
   Sims NA, 2020, ANNU REV PHYSIOL, V82, P507, DOI 10.1146/annurev physiol 021119 034425
   Soneson Charlotte, 2015, F1000Res, V4, P1521, DOI 10.12688/f1000research.7563.2
   Styrkarsdottir Unnur, 2008, N Engl J Med, V358, P2355, DOI 10.1056/NEJMoa0801197
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Voon HPJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05607 5
   Wagner EF, 2010, ANN RHEUM DIS, V69, P86, DOI 10.1136/ard.2009.119396
   Weber CM, 2014, GENE DEV, V28, P672, DOI 10.1101/gad.238873.114
   Wu BT, 2004, J BIOL CHEM, V279, P37485, DOI 10.1074/jbc.M405912200
   Wu YY, 2011, ONCOGENE, V30, P3682, DOI 10.1038/onc.2011.85
   Yen ML, 2007, STEM CELLS, V25, P125, DOI 10.1634/stemcells.2006 0295
   Yoshida K, 2019, MODERN PATHOL, V32, P1751, DOI 10.1038/s41379 019 0318 5
   Zhang L, 2014, HUM MOL GENET, V23, P1923, DOI 10.1093/hmg/ddt575
NR 56
TC 9
Z9 9
U1 1
U2 4
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1350 9047
EI 1476 5403
J9 CELL DEATH DIFFER
JI Cell Death Differ.
PD DEC
PY 2022
VL 29
IS 12
BP 2459
EP 2471
DI 10.1038/s41418 022 01031 x
EA AUG 2022
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA DA7E7
UT WOS:000856612100001
PM 36138226
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Nicolin, V
   Dal Piaz, F
   Norl, SL
   Narducci, P
   De Tommasi, N
AF Nicolin, V.
   Dal Piaz, F.
   Norl, S. L.
   Narducci, P.
   De Tommasi, N.
TI Inhibition of bone resorption by Tanshinone VI isolated from Salvia
   miltiorrhiza Bunge
SO EUROPEAN JOURNAL OF HISTOCHEMISTRY
LA English
DT Article
DE Tanshinone VI; osteoclastogenesis; receptor activator for nuclear factor
   kappa B ligand (RANKL)
ID OSTEOCLAST DIFFERENTIATION; IIA; OSTEOPROTEGERIN; COMPONENTS; SYSTEM;
   LIGAND; CELLS
AB During the last decade, a more detailed knowledge of molecular mechanisms involved in osteoclastogenesis has driven research efforts in the development and screening of compound libraries of several small molecules that specifically inhibit the pathway involved in the commitment of the osteoclast precursor cells. Natural compounds that suppress osteoclast differentiation may have therapeutic value in treating osteoporosis and other bone erosive diseases such as rheumatoid arthritis or metastasis associated with bone loss. In ongoing investigation into anti osteoporotic compounds from natural products we have analyzed the effect of Tanshinone VI on osteoclasts differentiation, using a physiologic three dimensional osteoblast/bone marrow model of cell co culture. Tanshinone VI is an abietane diterpene extracted from the root of Salvia miltiorrhiza Bunge (Labiatae), a Chinese traditional crude drug, "Tan Shen". Tashinone has been widely used in clinical practice for the prevention of cardiac diseases, arthritis and other inflammation related disorders based on its pharmacological actions in multiple tissues. Although Tanshinone VI A has been used as a medicinal agent in the treatment of many diseases, its role in osteoclast related bone diseases remains unknown. We showed previously that Tanshinone VI greatly inhibits osteoclast differentiation and suppresses bone resorption through disruption of the actin ring; subsequently, we intended to examine the precise inhibitory mechanism of Tanshinone VI on osteoclast differentiating factor. This study shows, for the first time, that Tanshinone VI prevents osteoclast differentiation by inhibiting RANKL expression and NFkB induction.
C1 [Nicolin, V.; Narducci, P.] Univ Trieste, Sch Med, Clin Dept Biomed, I 34138 Trieste, Italy.
   [Dal Piaz, F.; Norl, S. L.; De Tommasi, N.] Univ Salerno, Dept Pharmaceut Sci, I 84100 Salerno, Italy.
C3 University of Trieste; University of Salerno
RP Nicolin, V (通讯作者)，Univ Trieste, Sch Med, Clin Dept Biomed, Via Manzoni 16, I 34138 Trieste, Italy.
EM nicolin@units.it
RI ; Dal Piaz, Fabrizio/D 1843 2010; De Tommasi, Nunziatina/A 7768 2011
OI Nicolin, Vanessa/0000 0002 5665 6493; 
CR Bishop KA, 2009, MOL ENDOCRINOL, V23, P2095, DOI 10.1210/me.2009 0209
   Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02 07 0389
   Kim HK, 2008, IMMUNOPHARM IMMUNOT, V30, P347, DOI [10.1080/08923970801949133, 10.1080/08923970801949133 ]
   Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978
   Kwak HB, 2006, EXP MOL MED, V38, P256, DOI 10.1038/emm.2006.31
   Kwak HB, 2008, EUR J PHARMACOL, V601, P30, DOI 10.1016/j.ejphar.2008.10.034
   Lee SY, 2005, ARCH PHARM RES, V28, P909, DOI 10.1007/BF02973876
   Leibbrandt A, 2010, ADV EXP MED BIOL, V658, P77, DOI 10.1007/978 1 4419 1050 9_9
   Liu YR, 2007, J ETHNOPHARMACOL, V111, P573, DOI 10.1016/j.jep.2007.01.005
   Matsubara T, 2006, J BONE MINER METAB, V24, P368, DOI 10.1007/s00774 006 0701 4
   Mensah KA, 2010, J CELL PHYSIOL, V223, P76, DOI 10.1002/jcp.22012
   Narducci P, 2009, J RHEUMATOL, V36, P1837, DOI 10.3899/jrheum.081089
   Nicolin V, 2006, J MOL HISTOL, V37, P171, DOI 10.1007/s10735 006 9058 1
   Sharan K, 2009, CURR MED CHEM, V16, P1138, DOI 10.2174/092986709787581806
   Shiotani A, 2002, ANAT REC, V268, P137, DOI 10.1002/ar.10121
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   SOYSA NS, 2009, J BONE MINER RE 1019
   Vaira S, 2008, P NATL ACAD SCI USA, V105, P3897, DOI 10.1073/pnas.0708576105
NR 18
TC 20
Z9 24
U1 0
U2 19
PU PAGEPRESS PUBL
PI PAVIA
PA MEDITGROUP, VIA G BELLI, 4, PAVIA, 27100, ITALY
SN 1121 760X
EI 2038 8306
J9 EUR J HISTOCHEM
JI Eur. J. Histochem.
PD APR JUN
PY 2010
VL 54
IS 2
BP 104
EP 106
DI 10.4081/ejh.2010.e21
PG 3
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 614IV
UT WOS:000279051000008
PM 20558342
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Cheng, X
   Wei, JR
   Ge, Q
   Xing, DL
   Zhou, XF
   Qian, YZ
   Jiang, GQ
AF Cheng, Xi
   Wei, Jinrong
   Ge, Qi
   Xing, Danlei
   Zhou, Xuefeng
   Qian, Yunzhu
   Jiang, Guoqin
TI The optimized drug delivery systems of treating cancer bone metastatic
   osteolysis with nanomaterials
SO DRUG DELIVERY
LA English
DT Article
DE Osteolysis; cancer bone metastasis; drug delivery systems; nanomaterials
ID SKELETAL RELATED EVENTS; BREAST CANCER; ZOLEDRONIC ACID; IN VITRO;
   INDUCED OSTEOCLASTOGENESIS; LOCAL DELIVERY; GENE THERAPY; NANOPARTICLES;
   PROSTATE; CELLS
AB Some cancers such as human breast cancer, prostate cancer, and lung cancer easily metastasize to bone, leading to osteolysis and bone destruction accompanied by a complicated microenvironment. Systemic administration of bisphosphonates (BP) or denosumab is the routine therapy for osteolysis but with non negligible side effects such as mandibular osteonecrosis and hypocalcemia. Thus, it is imperative to exploit optimized drug delivery systems, and some novel nanotechnology and nanomaterials have opened new horizons for scientists. Targeted and local drug delivery systems can optimize biodistribution depending on nanoparticles (NPs) or microspheres (MS) and implantable biomaterials with the controllable property. Drug delivery kinetics can be optimized by smart and sustained/local drug delivery systems for responsive delivery and sustained delivery. These delicately fabricated drug delivery systems with special matrix, structure, morphology, and modification can minimize unexpected toxicity caused by systemic delivery and achieve desired effects through integrating multiple drugs or multiple functions. This review summarized recent studies about optimized drug delivery systems for the treatment of cancer metastatic osteolysis, aimed at giving some inspiration in designing efficient multifunctional drug delivery systems.
C1 [Cheng, Xi; Wei, Jinrong; Ge, Qi; Xing, Danlei; Jiang, Guoqin] Soochow Univ, Affiliated Hosp 2, Dept Surg, 1055 San Xiang Rd, Suzhou 215004, Peoples R China.
   [Zhou, Xuefeng] Southeast Univ, Sch Biol Sci & Med Engn, State Key Lab Bioelect, Jiangsu Key Lab Biomat & Devices, 2 Sipailou, Nanjing 210096, Peoples R China.
   [Qian, Yunzhu] Soochow Univ, Affiliated Hosp 2, Ctr Stomatol, 1055 Sanxiang Rd, Suzhou 215004, Peoples R China.
C3 Soochow University   China; Southeast University   China; Soochow
   University   China
RP Jiang, GQ (通讯作者)，Soochow Univ, Affiliated Hosp 2, Dept Surg, 1055 San Xiang Rd, Suzhou 215004, Peoples R China.; Zhou, XF (通讯作者)，Southeast Univ, Sch Biol Sci & Med Engn, State Key Lab Bioelect, Jiangsu Key Lab Biomat & Devices, 2 Sipailou, Nanjing 210096, Peoples R China.; Qian, YZ (通讯作者)，Soochow Univ, Affiliated Hosp 2, Ctr Stomatol, 1055 Sanxiang Rd, Suzhou 215004, Peoples R China.
EM zhouxuefeng@seu.edu.cn; yunzhu_qian@sina.com; jiang_guoqin@suda.edu.cn
RI Ge, Qi/B 2485 2015
FU National Natural Science Foundation of China [81873730, 81801025];
   Jiangsu Women and Children Health Key Discipline Program [FXK201758];
   Suzhou Health Planning Commission's Key Clinical Diagnosis and Treatment
   Program [LCZX201606]; Suzhou Science and Technology Development Project
   [SS2019062]; "National Tutor System" Training Program for Young Talents
   in Suzhou Health System
FX This work was supported by grants from the National Natural Science
   Foundation of China [81873730, 81801025 (Y. Q.)], Jiangsu Women and
   Children Health Key Discipline Program [FXK201758], Suzhou Health
   Planning Commission's Key Clinical Diagnosis and Treatment Program
   [LCZX201606], Suzhou Science and Technology Development Project
   [SS2019062 (Y. Q.)] and "National Tutor System" Training Program for
   Young Talents in Suzhou Health System (Y. Q.).
CR Abadeer NS, 2016, J PHYS CHEM C, V120, P4691, DOI 10.1021/acs.jpcc.5b11232
   Adjei IM, 2016, J CONTROL RELEASE, V232, P83, DOI 10.1016/j.jconrel.2016.04.019
   Ahangar P, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.04.41
   Ahangar P, 2018, MATERIALS, V11, DOI 10.3390/ma11091485
   Aluri S, 2009, ADV DRUG DELIVER REV, V61, P940, DOI 10.1016/j.addr.2009.07.002
   An SB, 2018, CELL PHYSIOL BIOCHEM, V50, P1100, DOI 10.1159/000494537
   Andrade K, 2017, SCI TRANSL MED, V9, P1, DOI 10.1126/scitranslmed.aai9338
   Assaraf YG, 2014, DRUG RESIST UPDATE, V17, P89, DOI 10.1016/j.drup.2014.10.002
   Au KM, 2016, BIOMATERIALS, V82, P178, DOI 10.1016/j.biomaterials.2015.12.018
   Bai SB, 2019, NANOMED NANOTECHNOL, V21, DOI 10.1016/j.nano.2019.102054
   Bellavia D, 2018, BBA GEN SUBJECTS, V1862, P1893, DOI 10.1016/j.bbagen.2018.06.003
   Chang Q, 2016, DRUG DELIV, V23, P3629, DOI 10.1080/10717544.2016.1214989
   Chen C, 2018, MOL THER NUCL ACIDS, V11, P508, DOI 10.1016/j.omtn.2018.04.003
   Chen JQ, 2019, PROG MATER SCI, V99, P1, DOI 10.1016/j.pmatsci.2018.07.005
   Chen LX, 2019, INT J NANOMED, V14, P149, DOI 10.2147/IJN.S188003
   Chen SH, 2020, J MATER CHEM B, V8, P3789, DOI 10.1039/d0tb00046a
   Chen SX, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201701024
   Chen XH, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012032
   Chen ZW, 2019, ACCOUNTS CHEM RES, V52, P1255, DOI 10.1021/acs.accounts.9b00079
   Chew SA, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201600766
   Chu CC, 2019, ANGEW CHEM INT EDIT, V58, P269, DOI 10.1002/anie.201812482
   Chu WJ, 2017, INT J PHARMACEUT, V516, P352, DOI 10.1016/j.ijpharm.2016.11.051
   Croucher PI, 2016, NAT REV CANCER, V16, P373, DOI 10.1038/nrc.2016.44
   Cruz Neves S, 2017, J BIOMED MATER RES A, V105, P2035, DOI 10.1002/jbm.a.36070
   Danaei M, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10020057
   De Felice M, 2016, MOL PAIN, V12, DOI 10.1177/1744806916643725
   de Miguel L, 2014, INT J PHARMACEUT, V460, P73, DOI 10.1016/j.ijpharm.2013.10.048
   Ding WM, 2016, DRUG DELIV, V23, P88, DOI 10.3109/10717544.2014.905651
   Dlamini N, 2019, MAT SCI ENG C MATER, V104, DOI 10.1016/j.msec.2019.109967
   Do AV, 2015, ADV HEALTHC MATER, V4, P1742, DOI 10.1002/adhm.201500168
   Dosio F, 2016, ADV DRUG DELIVER REV, V97, P204, DOI 10.1016/j.addr.2015.11.011
   Duong LT, 2014, MOL CANCER THER, V13, P2898, DOI 10.1158/1535 7163.MCT 14 0253
   Ell B, 2013, CANCER CELL, V24, P542, DOI 10.1016/j.ccr.2013.09.008
   Feng MX, 2016, SCI REP UK, V6, DOI 10.1038/srep19074
   Feng SS, 2019, ACS APPL MATER INTER, V11, P7357, DOI 10.1021/acsami.8b18820
   Fitzgerald KA, 2016, INT J PHARMACEUT, V511, P1058, DOI 10.1016/j.ijpharm.2016.07.079
   Forte L, 2017, J BIOMED MATER RES A, V105, P3293, DOI 10.1002/jbm.a.36192
   Futakuchi M, 2016, ADV DRUG DELIVER REV, V99, P206, DOI 10.1016/j.addr.2015.11.017
   Gdowski AS, 2019, ACS APPL NANO MATER, V2, P6249, DOI 10.1021/acsanm.9b01226
   Gdowski AS, 2017, NANOMEDICINE UK, V12, P2083, DOI 10.2217/nnm 2017 0190
   Ge YW, 2020, J CELL MOL MED, V24, P3203, DOI 10.1111/jcmm.14995
   George A, 2019, INT J PHARMACEUT, V561, P244, DOI 10.1016/j.ijpharm.2019.03.011
   Gilam A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12868
   Ginn SL, 2018, J GENE MED, V20, DOI 10.1002/jgm.3015
   Gül G, 2016, CURR MED RES OPIN, V32, P133, DOI 10.1185/03007995.2015.1105795
   Ha D, 2016, ACTA PHARM SIN B, V6, P287, DOI 10.1016/j.apsb.2016.02.001
   Hatami E, 2019, ACS BIOMATER SCI ENG, V5, P2343, DOI 10.1021/acsbiomaterials.9b00362
   Hirano Y, 2017, COLLOID SURFACE B, V153, P104, DOI 10.1016/j.colsurfb.2017.02.015
   Holzapfel BM, 2016, CANCER METAST REV, V35, P475, DOI 10.1007/s10555 016 9635 z
   Horne AM, 2018, CALCIFIED TISSUE INT, V103, P55, DOI 10.1007/s00223 018 0404 6
   Hsieh CJ, 2015, INT J ONCOL, V46, P555, DOI 10.3892/ijo.2014.2769
   Hu KF, 2017, CHIN J INTEGR MED, V23, P110, DOI 10.1007/s11655 016 2647 2
   Irelli A, 2016, BONE, V87, P169, DOI 10.1016/j.bone.2016.04.006
   Jain A, 2018, DRUG DELIV TRANSL RE, V8, P150, DOI 10.1007/s13346 017 0448 6
   Jie S, 2019, INT J NANOMED, V14, P7353, DOI 10.2147/IJN.S217974
   Kagiya T, 2015, J CLIN MED, V4, P1741, DOI 10.3390/jcm4091741
   Karimi M, 2016, CHEM SOC REV, V45, P1457, DOI 10.1039/c5cs00798d
   Kaur G, 2016, BIOMATERIALS, V101, P176, DOI 10.1016/j.biomaterials.2016.05.048
   Ke XZ, 2017, DRUG DELIV, V24, P1680, DOI 10.1080/10717544.2017.1396384
   Kim J, 2016, ADV DRUG DELIVER REV, V98, P99, DOI 10.1016/j.addr.2015.12.018
   Koto K, 2017, ONCOL LETT, V14, P1648, DOI 10.3892/ol.2017.6355
   Kozusko SD, 2018, J CRANIOFAC SURG, V29, P1788, DOI 10.1097/SCS.0000000000004909
   Kwakwa KA, 2017, CANCERS, V9, DOI 10.3390/cancers9070084
   Lee EU, 2016, CLIN ORAL IMPLAN RES, V27, pe91, DOI 10.1111/clr.12568
   Lee SK, 2015, CELL PHYSIOL BIOCHEM, V36, P1809, DOI 10.1159/000430152
   Li CY, 2017, ADV MATER, V29, DOI 10.1002/adma.201605754
   Li J, 2019, J CELL PHYSIOL, V234, P12663, DOI 10.1002/jcp.27875
   Li Z, 2012, CURR MOL MED, V12, P967, DOI 10.2174/156652412802480871
   Lima AC, 2019, EXPERT OPIN DRUG DEL, V16, P795, DOI 10.1080/17425247.2019.1635117
   Lipton A, 2016, EUR J CANCER, V53, P75, DOI 10.1016/j.ejca.2015.09.011
   Liu D, 2016, THERANOSTICS, V6, P1306, DOI 10.7150/thno.14858
   Liu T, 2019, MOL PHARMACEUT, V16, P2872, DOI 10.1021/acs.molpharmaceut.8b01343
   Liu YQ, 2016, SCI REP UK, V6, DOI 10.1038/srep32260
   Liu Y, 2018, CELL PHYSIOL BIOCHEM, V45, P1759, DOI 10.1159/000487784
   Liu YJ, 2019, CHEM SOC REV, V48, P2053, DOI 10.1039/c8cs00618k
   Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002
   Lu X, 2009, GENE DEV, V23, P1882, DOI 10.1101/gad.1824809
   Luo KW, 2015, J CANCER RES CLIN, V141, P1025, DOI 10.1007/s00432 014 1882 1
   Ma GT, 2018, CELL PHYSIOL BIOCHEM, V49, P1460, DOI 10.1159/000493449
   Macedo F, 2017, ONCOL REV, V11, P43, DOI 10.4081/oncol.2017.321
   Martin V, 2018, MAT SCI ENG C MATER, V82, P363, DOI 10.1016/j.msec.2017.04.038
   Müller WEG, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020427
   Newman MR, 2016, CURR OPIN BIOTECH, V40, P125, DOI 10.1016/j.copbio.2016.02.029
   Nooh A, 2017, J BONE ONCOL, V6, P8, DOI 10.1016/j.jbo.2017.01.001
   Norouzi M, 2016, DRUG DISCOV TODAY, V21, P1835, DOI 10.1016/j.drudis.2016.07.006
   O'Carrigan B, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub4
   Oledzka E, 2017, MOLECULES, V22, DOI 10.3390/molecules22071063
   Olthof MGL, 2018, J BIOMED MATER RES B, V106, P477, DOI 10.1002/jbm.b.33866
   Palamà IE, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 12824 3
   Pei XH., 2017, EVIDENCE BASED COMPL, V2017, P1
   Pérez Herrero E, 2015, EUR J PHARM BIOPHARM, V93, P52, DOI 10.1016/j.ejpb.2015.03.018
   Pore SK, 2018, CARCINOGENESIS, V39, P134, DOI 10.1093/carcin/bgx114
   Posadowska U, 2015, INT J PHARMACEUT, V485, P31, DOI 10.1016/j.ijpharm.2015.03.003
   Probert C, 2019, ONCOGENE, V38, P1751, DOI 10.1038/s41388 018 0540 5
   Qiao H, 2017, ACS NANO, V11, P7259, DOI 10.1021/acsnano.7b03197
   Rahmanian M, 2017, J CERAM SCI TECHNOL, V8, P505, DOI 10.4416/JCST2017 00029
   Rahmanian M, 2019, J TAIWAN INST CHEM E, V101, P214, DOI 10.1016/j.jtice.2019.04.028
   Robert J, 2015, B CANCER, V102, P297, DOI 10.1016/j.bulcan.2015.02.010
   Ross MH, 2017, CANCER RES, V77, P6299, DOI 10.1158/0008 5472.CAN 17 1225
   Rudnick Glick S, 2016, J NANOBIOTECHNOL, V14, DOI 10.1186/s12951 016 0233 6
   Ryu TK, 2016, J CONTROL RELEASE, V232, P152, DOI 10.1016/j.jconrel.2016.04.025
   Santini D, 2010, CANCER TREAT REV, V36, pS6, DOI 10.1016/S0305 7372(10)70013 X
   Santini D, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058 015 0634 8
   Saracino R, 2016, CURR DRUG TARGETS, V17, P303, DOI 10.2174/1389450116666150427154706
   Saravanakumar G, 2017, ADV SCI, V4, DOI 10.1002/advs.201600124
   Sarigol Calamak E, 2018, ADV EXP MED BIOL, V1078, P475, DOI 10.1007/978 981 13 0950 2_25
   Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022
   Shupp AB, 2018, CANCERS, V10, DOI 10.3390/cancers10060182
   Song R, 2018, DRUG DES DEV THER, V12, P3117, DOI 10.2147/DDDT.S165440
   Stapleton M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071345
   Stopeck AT, 2016, SUPPORT CARE CANCER, V24, P447, DOI 10.1007/s00520 015 2904 5
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Strazic Geljic I, 2016, BIOCHEM PHARMACOL, V116, P11, DOI 10.1016/j.bcp.2016.06.020
   Suk JS, 2016, ADV DRUG DELIVER REV, V99, P28, DOI 10.1016/j.addr.2015.09.012
   Sun WT, 2019, ACS NANO, V13, P7556, DOI 10.1021/acsnano.9b00097
   Sun WT, 2016, LANGMUIR, V32, P9237, DOI 10.1021/acs.langmuir.6b02228
   Sun XY, 2019, THERANOSTICS, V9, P5183, DOI 10.7150/thno.33376
   Sun Y, 2016, ACS APPL MATER INTER, V8, P25680, DOI 10.1021/acsami.6b06094
   Tan LL, 2016, J MATER CHEM B, V4, P135, DOI 10.1039/c5tb01789k
   Tang AM, 2016, NANOSCALE, V8, P10570, DOI 10.1039/c6nr00843g
   Thummuri D, 2015, PHARMACOL RES, V99, P63, DOI 10.1016/j.phrs.2015.05.006
   Turpin A, 2020, TRANSL ONCOL, V13, P308, DOI 10.1016/j.tranon.2019.10.012
   Ulbrich K, 2016, CHEM REV, V116, P5338, DOI 10.1021/acs.chemrev.5b00589
   Vanderburgh J, 2020, ACS NANO, V14, P311, DOI 10.1021/acsnano.9b04571
   Vanderburgh JP, 2019, J CONTROL RELEASE, V311, P257, DOI 10.1016/j.jconrel.2019.08.038
   Vinay R, 2016, DRUG DELIV, V23, P21, DOI 10.3109/10717544.2014.913325
   Wang BK, 2016, BIOMATERIALS, V78, P27, DOI 10.1016/j.biomaterials.2015.11.025
   Wang HK, 2015, BREAST CANCER RES TR, V149, P705, DOI 10.1007/s10549 015 3290 x
   Wang J, 2014, BIOMATERIALS, V35, P3080, DOI 10.1016/j.biomaterials.2013.12.025
   Wang KL, 2018, MOL PHARMACEUT, V15, P2764, DOI 10.1021/acs.molpharmaceut.8b00266
   Wang MM, 2018, ACS APPL MATER INTER, V10, P41003, DOI 10.1021/acsami.8b07527
   Wang Q, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0417 0
   Wang WY, 2016, TRENDS FOOD SCI TECH, V56, P21, DOI 10.1016/j.tifs.2016.07.004
   Wang YT, 2018, BIOMATERIALS, V183, P10, DOI 10.1016/j.biomaterials.2018.08.033
   Wang YH, 2020, MATER DESIGN, V186, DOI 10.1016/j.matdes.2019.108336
   Wei JR, 2017, MOL PAIN, V13, DOI 10.1177/1744806916688901
   Wu GY, 2004, J NUTR, V134, P489, DOI 10.1093/jn/134.10.2783S
   Wu W, 2018, DRUG DELIV, V25, P1642, DOI 10.1080/10717544.2018.1497105
   Wu XQ, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00076
   Xue YM, 2020, ACS NANO, V14, P442, DOI 10.1021/acsnano.9b06145
   Yan Y, 2019, ACS APPL MATER INTER, V11, P160, DOI 10.1021/acsami.8b15827
   Yang C, 2020, J CELL MOL MED, V24, P1553, DOI 10.1111/jcmm.14842
   Yu YX, 2016, RSC ADV, V6, P110557, DOI 10.1039/c6ra17718b
   Yuan GX, 2019, CANCER LETT, V443, P135, DOI 10.1016/j.canlet.2018.11.038
   Zeng YZ, 2019, ACTA BIOMATER, V93, P152, DOI 10.1016/j.actbio.2019.01.060
   Zhang K, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax6946
   Zhang LB, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20170961
   Zhang YY, 2019, PHARMACOL RES, V142, P140, DOI 10.1016/j.phrs.2019.02.015
   Zhao PP, 2020, CHEM ENG J, V381, DOI 10.1016/j.cej.2019.122694
   Zhao YP, 2017, NANOSCALE, V9, P6264, DOI 10.1039/c7nr00962c
   Zhou YQ, 2017, J PAIN, V18, P933, DOI 10.1016/j.jpain.2017.02.438
   Zhou ZX, 2017, ADV DRUG DELIVER REV, V115, P115, DOI 10.1016/j.addr.2017.07.021
   Zhu JH, 2018, NANOSCALE, V10, P18387, DOI 10.1039/c8nr03899f
NR 153
TC 32
Z9 32
U1 5
U2 135
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1071 7544
EI 1521 0464
J9 DRUG DELIV
JI Drug Deliv.
PD JAN 1
PY 2021
VL 28
IS 1
BP 37
EP 53
DI 10.1080/10717544.2020.1856225
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA PH5LZ
UT WOS:000600455200001
PM 33336610
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Sun, KQ
   Zhu, J
   Deng, Y
   Xu, XM
   Kong, FQ
   Sun, XF
   Huan, L
   Ren, CZ
   Sun, JC
   Shi, JG
AF Sun, Kaiqiang
   Zhu, Jian
   Deng, Yi
   Xu, Ximing
   Kong, Fanqi
   Sun, Xiaofei
   Huan, Le
   Ren, Changzhen
   Sun, Jingchuan
   Shi, Jiangang
TI Gamabufotalin Inhibits Osteoclastgenesis and Counteracts
   Estrogen Deficient Bone Loss in Mice by Suppressing RANKL Induced NF κB
   and ERK/MAPK Pathways
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE gamabufotalin; OVX model; osteoporosis; osteoclast; ERK; MAPK; receptor
   activator of nuclear factor kappa B ligand; TRAF6
AB Osteolytic bone disease is a condition of imbalanced bone homeostasis, characterized mainly by excessive bone resorptive activity, which could predispose these populations, such as the old and postmenopausal women, to developing high risk of skeletal fragility and fracture. The nature of bone homeostasis is the coordination between the osteoblasts (OBs) and osteoclasts (OCs). Abnormal activation of osteoclasts (OCs) could compromise the bone homeostasis, constantly followed by a clutch of osteolytic diseases, including postmenopausal osteoporosis, osteoarthritis, and rheumatoid arthritis. Thus, it is imperatively urgent to explore effective medical interventions for patients. The traditional Chinese medicine (TCM) gamabufotalin (CS 6) is a newly identified natural product from Chansu and has been utilized for oncologic therapies owing to its good clinical efficacy with less adverse events. Previous study suggested that CS 6 could be a novel anti osteoporotic agent. Nevertheless, whether CS 6 suppresses RANK (receptor activator of nuclear factor kappa B ligand)/TRAF6 (TNF receptor associated factor 6) mediated downstream signaling activation in OCs, as well as the effects of CS 6 on OC differentiation in vivo, remains elusive. Therefore, in this present study, we aimed to explore the biological effects of CS 6 on osteoclastogenesis and RANKL induced activation of related signaling pathways, and further to examine the potential therapeutic application in estrogen deficient bone loss in the mice model. The results of in vitro experiment showed that CS 6 can inhibit RANKL induced OC formation and the ability of bone resorption in a dose dependent manner at both the early and late stages of osteoclastogenesis. The gene expression of OC related key genes such as tartrate resistant acid phosphatase (TRAP), CTSK, DC STAMP, MMP9, and beta 3 integrin was evidently reduced. In addition, CS 6 could mitigate the systemic estrogen dependent bone loss and pro inframammary cytokines in mice in vivo. The molecular mechanism analysis suggested that CS 6 can suppress RANKL/TRAF6 induced early activation of NF kappa B and ERK/MAPK signaling pathways, which consequently suppressed the transcription activity of c Fos and NFATc1. Taken together, this present study provided ample evidence that CS 6 has the promise to become a therapeutic candidate in treating osteolytic conditions mediated by elevated OC formation and bone resorption.
C1 [Sun, Kaiqiang; Zhu, Jian; Xu, Ximing; Kong, Fanqi; Sun, Xiaofei; Huan, Le; Sun, Jingchuan; Shi, Jiangang] Naval Med Univ, Changzheng Hosp, Dept Spine Surg, Shanghai, Peoples R China.
   [Deng, Yi] Naval Med Univ, Changzheng Hosp, Dept Pharm, Shanghai, Peoples R China.
   [Ren, Changzhen] Naval Med Univ, Changzheng Hosp, Dept Cardiol, Shanghai, Peoples R China.
C3 Naval Medical University; Naval Medical University; Naval Medical
   University
RP Sun, JC; Shi, JG (通讯作者)，Naval Med Univ, Changzheng Hosp, Dept Spine Surg, Shanghai, Peoples R China.
EM sjchxc@foxmail.com; shijiangangspine@163.com
RI Kong, Fanqi/I 5419 2013; Xiaofei, Sun/AAN 2784 2021; Sun,
   Jingchuan/AAO 1220 2020
FU National Natural Science Foundation of China [81871828, 81802218,
   81702141]
FX The study is supported by the National Natural Science Foundation of
   China, Grant/Award Numbers: No. 81871828, No. 81802218, and No.
   81702141.
CR Banuls LMY, 2013, MOL CANCER, V12, DOI 10.1186/1476 4598 12 33
   Bertuglia A, 2016, OSTEOARTHR CARTILAGE, V24, P555, DOI 10.1016/j.joca.2015.10.008
   BISKOBING DM, 1995, J BONE MINER RES, V10, P1025
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen XZ, 2019, EXP CELL RES, V382, DOI 10.1016/j.yexcr.2019.06.015
   Chiu YH, 2016, J CELL PHYSIOL, V231, P2402, DOI 10.1002/jcp.25389
   Cho E, 2021, BONE, V142, DOI 10.1016/j.bone.2020.115707
   Collins FL, 2017, BONE, V97, P94, DOI 10.1016/j.bone.2017.01.002
   DiDonato J, 1996, MOL CELL BIOL, V16, P1295
   Feng W, 2017, SCI REP UK, V7, DOI 10.1038/srep41411
   Fleischmann A, 2000, GENE DEV, V14, P2695, DOI 10.1101/gad.187900
   Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128
   Han YJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0019 6
   He JB, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 016 0301 4
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   Hinchy NV, 2013, ORAL ONCOL, V49, P878, DOI 10.1016/j.oraloncology.2013.06.008
   Ji DX, 2017, N S ARCH PHARMACOL, V390, P1211, DOI 10.1007/s00210 017 1419 7
   Kim BJ, 2018, J CLIN INVEST, V128, P1429, DOI 10.1172/JCI91086
   Kim HS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01527 y
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lagasse E, 1997, CELL, V89, P1021, DOI 10.1016/S0092 8674(00)80290 1
   Lee SH, 2019, BONE, V129, DOI 10.1016/j.bone.2019.115056
   Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736
   Liao HJ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1353 3
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Lungu Andreea Elena, 2018, Clujul Med, V91, P209, DOI 10.15386/cjmed 838
   Meng ZQ, 2009, CANCER AM CANCER SOC, V115, P5309, DOI 10.1002/cncr.24602
   Mukherjee K, 2016, BIOCHEM PHARMACOL, V117, P10, DOI 10.1016/j.bcp.2016.04.010
   Negishi Koga Takako, 2012, Bonekey Rep, V1, P183, DOI 10.1038/bonekey.2012.183
   Nie Y, 2013, J ETHNOPHARMACOL, V147, P547, DOI 10.1016/j.jep.2013.03.066
   Park SH, 2020, AGING US, V12, P4727, DOI 10.18632/aging.102796
   Qi SS, 2019, MOLECULES, V24, DOI 10.3390/molecules24101871
   Qu XH, 2014, BIOCHEM BIOPH RES CO, V443, P658, DOI 10.1016/j.bbrc.2013.12.029
   Raynaud Messina B, 2019, BONE, V127, P315, DOI 10.1016/j.bone.2019.06.023
   Sapir Koren R, 2017, BONE, V103, P102, DOI 10.1016/j.bone.2017.06.020
   Shidara K, 2008, CALCIFIED TISSUE INT, V82, P278, DOI 10.1007/s00223 008 9127 4
   Sitara D, 2010, IMMUNOL REV, V233, P286, DOI 10.1111/j.0105 2896.2009.00849.x
   Sun XC, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00360
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Tang Ning, 2016, Oncotarget, V7, P3533, DOI 10.18632/oncotarget.6514
   Vaira S, 2008, P NATL ACAD SCI USA, V105, P3897, DOI 10.1073/pnas.0708576105
   Wagner EF, 2003, ANN RHEUM DIS, V62, P83, DOI 10.1136/ard.62.suppl_2.ii83
   Wang LJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14146 6
   Wang NN, 2019, J ETHNOPHARMACOL, V241, DOI 10.1016/j.jep.2019.111977
   Wu LL, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1500 x
   Wu ZQ, 2015, J ETHNOPHARMACOL, V164, P283, DOI 10.1016/j.jep.2015.02.016
   Xiong JH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05244 y
   Yu ZL, 2016, ONCOTARGET, V7, P15725, DOI 10.18632/oncotarget.7398
   Yu ZL, 2014, MOL CANCER, V13, DOI 10.1186/1476 4598 13 203
   Zhakeer Z, 2017, PHARMACOLOGY, V99, P179, DOI 10.1159/000450754
   Zhang K, 2018, INT IMMUNOPHARMACOL, V61, P150, DOI 10.1016/j.intimp.2018.05.030
   Zhang LY, 2016, ONCOTARGET, V7, P76551, DOI 10.18632/oncotarget.10388
   Zhang Y, 2017, J BONE MINER RES, V32, P1829, DOI 10.1002/jbmr.3172
   Zhao XD, 2019, J BONE MINER RES, V34, P911, DOI 10.1002/jbmr.3655
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
NR 57
TC 21
Z9 25
U1 0
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD APR 23
PY 2021
VL 12
AR 629968
DI 10.3389/fphar.2021.629968
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA RY7NW
UT WOS:000648094400001
PM 33967763
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU He, LH
   Liu, M
   He, Y
   Xiao, E
   Zhao, L
   Zhang, T
   Yang, HQ
   Zhang, Y
AF He, Lin Hai
   Liu, Meng
   He, Yang
   Xiao, E.
   Zhao, Lu
   Zhang, Ting
   Yang, Hua Qian
   Zhang, Yi
TI TRPV1 deletion impaired fracture healing and inhibited osteoclast and
   osteoblast differentiation
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CATHEPSIN K; PHARMACOLOGICAL INHIBITION; TERMINAL DIFFERENTIATION;
   T CELLS; BONE; OSTEOGENESIS; STIMULATION; ACTIVATION; INDUCTION; FUSION
AB Fracture healing, in which osteoclasts and osteoblasts play important roles, has drawn much clinical attention. Osteoclast deficiency or decreased osteoblast activity will impair fracture healing. TRPV1 is a member of the Ca2+ permeable cation channel subfamily, and pharmacological inhibition of TRPV1 prevents ovariectomy induced bone loss, which makes TRPV1 a potential target for osteoporosis. However, whether long term TRPV1 inhibition or TRPV1 deletion will affect the fracture healing process is unclear. In this study, we found that the wild type mice showed a well remodeled fracture callus, whereas TRPV1 knockout mice still had an obvious fracture gap with unresorbed soft callus 4 weeks post fracture. The number of osteoclasts was reduced in the TRPV1 knockout fracture callus, and osteoclast formation and resorption activity were also impaired in vitro. TRPV1 deletion decreased the calcium oscillation frequency and peak cytoplasmic concentration in osteoclast precursors, subsequently reducing the expression and nuclear translocation of NFATc1 and downregulating DC stamp, cathepsin K, and ATP6V. In addition, TRPV1 deletion caused reduced mRNA and protein expression of Runx2 and ALP in bone marrow stromal cells (BMSCs) and reduced calcium deposition in vitro. Our results suggest that TRPV1 deletion impairs fracture healing, and inhibited osteoclastogenesis and osteogenesis.
C1 [He, Lin Hai; Liu, Meng; He, Yang; Xiao, E.; Zhao, Lu; Zhang, Yi] Peking Univ, Beijing Key Lab Digital Stomatol, Natl Engn Lab Digital & Mat Technol Stomatol, Dept Oral & Maxillofacial Surg,Sch & Hosp Stomato, Beijing, Peoples R China.
   [Zhang, Ting] Peking Univ, Ctr Craniofacial Stem Cell Res & Regenerat, Natl Engn Lab Digital & Mat Technol Stomatol, Dept Orthodont,Sch & Hosp Stomatol,Beijing Key La, Beijing, Peoples R China.
   [Yang, Hua Qian] Peking Univ, Coll Life Sci, State Key Lab Biomembrane & Membrane Biotechnol, Beijing, Peoples R China.
C3 Peking University; Peking University; Peking University
RP Zhang, Y (通讯作者)，Peking Univ, Beijing Key Lab Digital Stomatol, Natl Engn Lab Digital & Mat Technol Stomatol, Dept Oral & Maxillofacial Surg,Sch & Hosp Stomato, Beijing, Peoples R China.
EM zhangyi2000@263.net
RI 贺, 阳/KMX 2254 2024; XIAO, E/AAA 7719 2020; Yang, Hua Qian/ABE 8167 2021
OI He, Linhai/0000 0002 2157 0630; Xiao, E/0000 0002 0527 1542
FU National Natural Science Foundation of China [81371117]; Beijing Natural
   Science Foundation [7152155]
FX This work was supported by a grant from the National Natural Science
   Foundation of China (No. 81371117) and the Beijing Natural Science
   Foundation (No. 7152155). The funders had no role in the design of the
   projects, performance of the experiments, analysis of results or
   preparation of the manuscript.
CR Balkan W, 2009, GENE, V446, P90, DOI 10.1016/j.gene.2009.06.013
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Colburn NT, 2009, ARTHRITIS RHEUM US, V60, P1694, DOI 10.1002/art.24520
   Daci E, 2000, J BONE MINER RES, V15, P1510, DOI 10.1359/jbmr.2000.15.8.1510
   Flick LM, 2003, J ORTHOP RES, V21, P676, DOI 10.1016/S0736 0266(03)00011 1
   Fromigué O, 2010, J BIOL CHEM, V285, P25251, DOI 10.1074/jbc.M110.110502
   Gentile MA, 2014, BONE, V66, P72, DOI 10.1016/j.bone.2014.04.032
   Gerstenfeld LC, 2003, J BONE MINER RES, V18, P1584, DOI 10.1359/jbmr.2003.18.9.1584
   Gerstenfeld LC, 2009, J BONE MINER RES, V24, P196, DOI 10.1359/JBMR.081113
   He LH, 2015, J DENT RES, V94, P1392, DOI 10.1177/0022034515599149
   Helfrich MH, 2003, MICROSC RES TECHNIQ, V61, P514, DOI 10.1002/jemt.10375
   Hwang SY, 2011, BBA MOL CELL RES, V1813, P979, DOI 10.1016/j.bbamcr.2010.11.002
   Idris AI, 2010, BONE, V46, P1089, DOI 10.1016/j.bone.2010.01.368
   Kajiya H, 2010, CELL CALCIUM, V48, P260, DOI 10.1016/j.ceca.2010.09.010
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Marsell R, 2011, INJURY, V42, P551, DOI 10.1016/j.injury.2011.03.031
   Masuyama R, 2008, CELL METAB, V8, P257, DOI 10.1016/j.cmet.2008.08.002
   Montell Craig, 2005, Sci STKE, V2005, pre3, DOI 10.1126/stke.2722005re3
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Orita S, 2010, SPINE, V35, P1974, DOI 10.1097/BRS.0b013e3181d5959e
   Ota N, 2009, ENDOCRINOLOGY, V150, P4823, DOI 10.1210/en.2009 0452
   Phillips A M, 2005, Injury, V36 Suppl 3, pS5, DOI 10.1016/j.injury.2005.07.027
   Phua YL, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12537
   Rossi F, 2014, BRIT J PHARMACOL, V171, P2621, DOI 10.1111/bph.12542
   Rossi F, 2009, BONE, V44, P476, DOI 10.1016/j.bone.2008.10.056
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Schindeler A, 2008, SEMIN CELL DEV BIOL, V19, P459, DOI 10.1016/j.semcdb.2008.07.004
   Soung DY, 2013, BONE, V55, P248, DOI 10.1016/j.bone.2013.02.010
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   van der Eerden BCJ, 2005, P NATL ACAD SCI USA, V102, P17507, DOI 10.1073/pnas.0505789102
   Winslow MM, 2006, DEV CELL, V10, P771, DOI 10.1016/j.devcel.2006.04.006
   Xiao E, 2015, STEM CELLS, V33, P615, DOI 10.1002/stem.1858
   Xiao E, 2013, J DENT RES, V92, P450, DOI 10.1177/0022034513483471
   Xu LL, 2015, FASEB J, V29, P1143, DOI 10.1096/fj.14 254169
   Yagi M, 2007, J BONE MINER RES, V22, P992, DOI 10.1359/JBMR.070401
   Yoshino K, 2014, YONSEI MED J, V55, P1600, DOI 10.3349/ymj.2014.55.6.1600
   ZAIDI M, 1993, CELL CALCIUM, V14, P271, DOI 10.1016/0143 4160(93)90048 B
   Zayzafoon M, 2006, J CELL BIOCHEM, V97, P56, DOI 10.1002/jcb.20675
NR 39
TC 67
Z9 73
U1 0
U2 20
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD FEB 22
PY 2017
VL 7
AR 42385
DI 10.1038/srep42385
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA EL6UZ
UT WOS:000394759200001
PM 28225019
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Hu, SJ
   Chen, SS
   Zeng, HZ
   Ruan, XY
   Lin, XY
   Vlashi, R
   Zhou, CH
   Wang, HD
   Chen, GQ
AF Hu, Sujie
   Chen, Sisi
   Zeng, Haozu
   Ruan, Xinyi
   Lin, Xinyi
   Vlashi, Rexhina
   Zhou, Chenhe
   Wang, Haidong
   Chen, Guiqian
TI Ap 213 regulates cranial osteogenic potential via the activation of
   Wnt/13 catenin signaling pathway
SO DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE Osteoblast differentiation; Ap 213; Wnt; 13 catenin signaling; Skull;
   Neural crest
ID TRANSCRIPTION FACTOR AP 2 GAMMA; CAUSE CHAR SYNDROME; NEURAL CREST
   CELLS; EXPRESSION PATTERN; GENE EXPRESSION; WNT; DIFFERENTIATION; ROLES;
   MUTATIONS; CARTILAGE
AB The skull is a fundamental bone that protects the development of brain and consists of several bony elements, such as the frontal and parietal bones. Frontal bone exhibited superior in osteogenic potential and regeneration of cranial defects compared to parietal bone. However, how this regional difference is regulated remains largely unknown. In this study, we identified an Ap 213 transcriptional factor with a higher expression in frontal bone, but its molecular function in osteoblasts needs to be elucidated. We found that Ap 213 knockdown in preosteoblasts leads to reduced proliferation, increased cell death and impaired differentiation. Through RNA seq analysis, we found that Ap 213 influences multiple signaling pathways including the Wnt pathway, and overexpression of Ap 213 showed increased nuclear 13 catenin and its target genes expressions in osteoblasts. Pharmacological activation of Wnt/13 catenin signaling using LiCl treatment cannot rescue the reduced luciferase activities of the 13 catenin/TCF/ LEF reporter in Ap 213 knockdown preosteoblasts. Besides, transient expression of Ap 213 via the lentivirus system could sufficiently rescue the inferior osteogenic potential in parietal osteoblasts, while Ap 213 knockdown in frontal osteoblasts resulted in reduced osteoblast activity, reduced active 13 catenin and target genes expressions. Taken together, our data demonstrated that Ap 213 modulates osteoblast proliferation and differentiation through the regulation of Wnt/13 catenin signaling pathway and plays an important role in regulating regional osteogenic potential in frontal and parietal bone.
C1 [Hu, Sujie; Chen, Sisi; Zeng, Haozu; Ruan, Xinyi; Lin, Xinyi; Vlashi, Rexhina; Chen, Guiqian] Zhejiang Sci Tech Univ, Coll Life Sci & Med, Dept Biopharm, Zhejiang Prov Key Lab Silkworm Bioreactor & Biomed, Hangzhou 310018, Peoples R China.
   [Zhou, Chenhe] Zhejiang Univ, Affiliated Hosp 2, Dept Orthoped Surg, Sch Med, Hangzhou, Zhejiang, Peoples R China.
   [Wang, Haidong] Jiaxing Hosp Tradit Chinese Med, Dept Orthoped, Jiaxing 314001, Peoples R China.
C3 Zhejiang Sci Tech University; Zhejiang University
RP Chen, GQ (通讯作者)，Zhejiang Sci Tech Univ, Coll Life Sci & Med, Dept Biopharm, Zhejiang Prov Key Lab Silkworm Bioreactor & Biomed, Hangzhou 310018, Peoples R China.; Wang, HD (通讯作者)，Jiaxing Hosp Tradit Chinese Med, Dept Orthoped, Jiaxing 314001, Peoples R China.
EM whd10086@163.com; gqchen@zstu.edu.cn
RI chen, sisi/KMA 2807 2024; Hu, Sujie/LZH 3373 2025; Lin,
   Xinyi/IXX 1194 2023; Zhou, Chenhe/AAI 9226 2020
OI Vlashi, Rexhina/0009 0001 4043 8790; 
FU Zhejiang Provincial Natural Science Foundation of China [LZ23H140001];
   Zhejiang Qianjiang Talent Program [21040040 E]; Zhejiang Sci Tech
   University [18042290 Y]; Fundamental Research Funds of Zhejiang Sci Tech
   University [2021Q031]; National Natural Science Foundation of China
   [81900806, 81400489, 82001461]
FX This work was supported by grants by Zhejiang Provincial Natural Science
   Foundation of China (No. LZ23H140001) , Zhejiang Qianjiang Talent
   Program (No. 21040040 E) , a startup grant from Zhejiang Sci Tech
   University (No. 18042290 Y) , the Fundamental Research Funds of Zhejiang
   Sci Tech University (No. 2021Q031) , funds from National Natural Science
   Foundation of China (No. 81900806, No. 81400489, No.82001461) . We
   apologize to the many researchers whose work could not be cited due to
   space limitations.
CR Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802
   Akiyama H, 2004, GENE DEV, V18, P1072, DOI 10.1101/gad.1171104
   Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717
   Beger M, 2001, J MOL MED, V79, P314, DOI 10.1007/s001090100211
   Bhukhai K, 2012, J BIOL CHEM, V287, P36168, DOI 10.1074/jbc.M112.344747
   Chazaud C, 1996, MECH DEVELOP, V54, P83, DOI 10.1016/0925 4773(95)00463 7
   Chen GQ, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00135
   Chen GQ, 2019, DEV DYNAM, V248, P1009, DOI 10.1002/dvdy.97
   Chiarito M, 2022, J ENDOCRINOL INVEST, V45, P1255, DOI 10.1007/s40618 022 01760 3
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Creaser PC, 1996, NUCLEIC ACIDS RES, V24, P2597, DOI 10.1093/nar/24.13.2597
   DuBuc TQ, 2020, SCIENCE, V367, P757, DOI 10.1126/science.aay6782
   Fabian P, 2023, SEMIN CELL DEV BIOL, V138, P45, DOI 10.1016/j.semcdb.2022.03.018
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Hayano S, 2015, DEVELOPMENT, V142, P1357, DOI 10.1242/dev.118802
   He GX, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.16
   Hoei Hansen CE, 2004, CLIN CANCER RES, V10, P8521, DOI 10.1158/1078 0432.CCR 04 1285
   Homayounfar N, 2015, ARCH ORAL BIOL, V60, P1450, DOI 10.1016/j.archoralbio.2015.06.008
   Hu B, 2017, CELL PHYSIOL BIOCHEM, V43, P2525, DOI 10.1159/000484496
   Huybrechts Y, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00165
   Jäger R, 2005, BREAST CANCER RES TR, V90, P273, DOI 10.1007/s10549 004 4815 x
   Jiang XB, 2002, DEV BIOL, V241, P106, DOI 10.1006/dbio.2001.0487
   Jin EJ, 2006, MOL CELLS, V22, P353
   Kegelman CD, 2018, FASEB J, V32, P2706, DOI 10.1096/fj.201700872R
   Kerber B, 2001, DEVELOPMENT, V128, P1231
   Kuratani S, 2005, ZOOLOGY, V108, P13, DOI 10.1016/j.zool.2004.12.001
   Li SL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138059
   Liao JG, 2022, CELL MOL LIFE SCI, V79, DOI 10.1007/s00018 022 04208 2
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Mani A, 2005, P NATL ACAD SCI USA, V102, P2975, DOI 10.1073/pnas.0409852102
   Maruyama T, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000727
   Morriss Kay GM, 2001, J ANAT, V199, P143
   Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938
   Moser M, 1997, DEV DYNAM, V208, P115, DOI 10.1002/(SICI)1097 0177(199701)208:1<115::AID AJA11>3.0.CO;2 5
   Moser M, 2003, LAB INVEST, V83, P571, DOI 10.1097/01.LAB.0000064703.92382.50
   Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260
   Pauls K, 2005, INT J CANCER, V115, P470, DOI 10.1002/ijc.20913
   Pfisterer P, 2002, J BIOL CHEM, V277, P6637, DOI 10.1074/jbc.M108578200
   Quarto N, 2010, J BONE MINER RES, V25, P1680, DOI 10.1359/jbmr.091116
   Quarto N, 2009, CELLS TISSUES ORGANS, V190, P158, DOI 10.1159/000202789
   Ren DN, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7906
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Satoda M, 2000, NAT GENET, V25, P42, DOI 10.1038/75578
   Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0
   Schupbach D, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115491
   Scott CC, 2018, ELIFE, V7, DOI 10.7554/eLife.36330
   Seo HS, 2009, DEV BIOL, V334, P481, DOI 10.1016/j.ydbio.2009.08.015
   Song DY, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 90324 1
   Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404 320
   Tejeda Muñoz N, 2015, IUBMB LIFE, V67, P914, DOI 10.1002/iub.1454
   Timberlake AT, 2019, P NATL ACAD SCI USA, V116, P15116, DOI 10.1073/pnas.1902041116
   Torimitsu S, 2015, FORENSIC SCI INT, V252, DOI 10.1016/j.forsciint.2015.04.029
   Van Otterloo E, 2022, ELIFE, V11, DOI 10.7554/eLife.70511
   Walker H, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168730
   Wang HV, 2004, DEV DYNAM, V231, P128, DOI 10.1002/dvdy.20119
   Wang YL, 2012, J CLIN INVEST, V122, P2153, DOI 10.1172/JCI62644
   Wenke AK, 2010, FEBS J, V277, P894, DOI 10.1111/j.1742 4658.2009.07509.x
   Werling U, 2002, MOL CELL BIOL, V22, P3149, DOI 10.1128/MCB.22.9.3149 3156.2002
   Wu TF, 2017, INT J DEV BIOL, V61, P495, DOI 10.1387/ijdb.170051gc
   Xu JQ, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm 21 174
   Xu Y, 2007, PLAST RECONSTR SURG, V120, P1783, DOI 10.1097/01.prs.0000279491.48283.51
   Yang BN, 2017, INT J BIOCHEM CELL B, V87, P104, DOI 10.1016/j.biocel.2017.04.007
   Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0
   Zhao F, 2003, GENE EXPR PATTERNS, V3, P213, DOI 10.1016/S1567 133X(02)00067 4
   Zhao F, 2001, AM J HUM GENET, V69, P695, DOI 10.1086/323410
NR 65
TC 12
Z9 12
U1 0
U2 17
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0012 1606
EI 1095 564X
J9 DEV BIOL
JI Dev. Biol.
PD SEP
PY 2023
VL 501
BP 81
EP 91
DI 10.1016/j.ydbio.2023.06.015
EA JUN 2023
PG 11
WC Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Developmental Biology
GA M9GX0
UT WOS:001033235100001
PM 37355029
OA Bronze
DA 2025 08 17
ER

PT J
AU Rufo, A
   Del Fattore, A
   Capulli, M
   Carvello, F
   De Pasquale, L
   Ferrari, S
   Pierroz, D
   Morandi, L
   De Simone, M
   Rucci, N
   Bertini, E
   Bianchi, ML
   De Benedetti, F
   Teti, A
AF Rufo, Anna
   Del Fattore, Andrea
   Capulli, Mattia
   Carvello, Francesco
   De Pasquale, Loredana
   Ferrari, Serge
   Pierroz, Dominique
   Morandi, Lucia
   De Simone, Michele
   Rucci, Nadia
   Bertini, Enrico
   Bianchi, Maria Luisa
   De Benedetti, Fabrizio
   Teti, Anna
TI Mechanisms Inducing Low Bone Density in Duchenne Muscular Dystrophy in
   Mice and Humans
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE DUCHENNE MUSCULAR DYSTROPHY; OSTEOCLAST; OSTEOBLAST; OSTEOPOROSIS;
   INTERLEUKIN 6
ID MESENCHYMAL STEM CELLS; MINERAL DENSITY; SKELETAL MUSCLE;
   MULTIPLE MYELOMA; INTERLEUKIN 6; DISEASE; PATHOPHYSIOLOGY;
   DIFFERENTIATION; EXPRESSION; DEFICIENT
AB Patients affected by Duchenne muscular dystrophy (DMD) and dystrophic MDX mice were investigated in this study for their bone phenotype and systemic regulators of bone turnover. Micro computed tomographic (mu CT) and histomorphometric analyses showed reduced bone mass and higher osteoclast and bone resorption parameters in MDX mice compared with wild type mice, whereas osteoblast parameters and mineral apposition rate were lower. In a panel of circulating pro osteoclastogenic cytokines evaluated in the MDX sera, interleukin 6 (IL 6) was increased compared with wild type mice. Likewise, DMD patients showed low bone mineral density (BMD) Z scores and high bone resorption marker and serum IL 6. Human primary osteoblasts from healthy donors incubated with 10% sera from DMD patients showed decreased nodule mineralization. Many osteogenic genes were downregulated in these cultures, including osterix and osteocalcin, by a mechanism blunted by an IL 6 neutralizing antibody. In contrast, the mRNAs of osteoclastogenic cytokines IL6, IL11, inhibin beta A, and TGF beta 2 were increased, although only IL 6 was found to be high in the circulation. Consistently, enhancement of osteoclastogenesis was noted in cultures of circulating mononuclear precursors from DMD patients or from healthy donors cultured in the presence of DMD sera or IL 6. Circulating IL 6 also played a dominant role in osteoclast formation because ex vivo wild type calvarial bones cultured with 10% sera of MDX mice showed increase osteoclast and bone resorption parameters that were dampen by treatment with an IL 6 antibody. These results point to IL 6 as an important mediator of bone loss in DMD and suggest that targeted anti IL 6 therapy may have a positive impact on the bone phenotype in these patients. (C) 2011 American Society for Bone and Mineral Research.
C1 [Rufo, Anna; Del Fattore, Andrea; Capulli, Mattia; Rucci, Nadia; Teti, Anna] Univ Aquila, Dept Expt Med, I 67100 Laquila, Italy.
   [Del Fattore, Andrea; Carvello, Francesco; De Pasquale, Loredana; Bertini, Enrico; De Benedetti, Fabrizio] Osped Pediat Bambino Gesu, Ist Ricovero & Cura Carattere Sci, Rome, Italy.
   [Ferrari, Serge; Pierroz, Dominique] Univ Hosp, Dept Rehabil & Geriatr, Geneva, Switzerland.
   [Morandi, Lucia] Ist Ricovero & Cura Carattere Sci, Ist Neurol C Besta, Muscle Pathol & Immunol Unit, Milan, Italy.
   [De Simone, Michele] Univ Hosp San Salvatore, Dept Internal Med, Laquila, Italy.
   [Bianchi, Maria Luisa] Ist Ricovero & Cura Carattere Sci, Ist Auxol Italiano, Metab Unit, Milan, Italy.
C3 University of L'Aquila; IRCCS Bambino Gesu; University of Geneva;
   Fondazione IRCCS Istituto Neurologico Carlo Besta; IRCCS Ca Granda
   Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore
   Policlinico; IRCCS Istituto Auxologico Italiano
RP Teti, A (通讯作者)，Univ Aquila, Dept Expt Med, Via Vetoio Coppito 2, I 67100 Laquila, Italy.
EM teti@univaq.it
RI Bianchi, Maria/AAC 2192 2019; de benedetti, fabrizio/J 9577 2018; De
   Benedetti, fabrizio/J 9577 2018; Capulli, Mattia/K 6604 2016; Del
   Fattore, Andrea/H 4409 2015; Ferrari, Serge/ABD 2730 2020; Bertini,
   Enrico/A 2284 2014
OI ferrari, serge/0000 0002 1372 4417; Teti, Anna
   Maria/0000 0002 5887 4419; De Benedetti, fabrizio/0000 0001 8749 8232;
   Capulli, Mattia/0000 0003 0449 6720; Del Fattore,
   Andrea/0000 0003 3848 412X; Rucci, Nadia/0000 0002 1371 8252; Bertini,
   Enrico/0000 0001 9276 4590
FU multicentricTelethon [GGP06119]; Telethon
FX We thank Dr Rita Di Massimo for her helpful assistance in the
   preparation of this manuscript and Dr Gianluca Gravina for providing
   biologic samples. This work was supported by multicentric Telethon Grant
   GGP06119 to FDB (coordinator), AT, MLB, and EB. AR was supported by a
   contract from the same Telethon grant.
CR BATAILLE R, 1992, ANN MED INTERNE, V143, P77
   Bianchi ML, 2003, OSTEOPOROSIS INT, V14, P761, DOI 10.1007/s00198 003 1443 y
   Bothwell JE, 2003, CLIN PEDIATR, V42, P353, DOI 10.1177/000992280304200408
   BULFIELD G, 1984, P NATL ACAD SCI BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189
   CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092 8674(95)90344 5
   CARTER DR, 1992, J BONE MINER RES, V7, P137
   Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321
   De Benedetti F, 2006, ARTHRITIS RHEUM, V54, P3551, DOI 10.1002/art.22175
   DEBENEDETTI F, 2010, ARTHRITIS RHEUM S10, V62, P596
   Deconinck N, 2007, PEDIATR NEUROL, V36, P1, DOI 10.1016/j.pediatrneurol.2006.09.016
   Devlin RD, 1996, J CLIN ENDOCR METAB, V81, P1893, DOI 10.1210/jc.81.5.1893
   Emery A E, 1991, Neuromuscul Disord, V1, P19, DOI 10.1016/0960 8966(91)90039 U
   ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809
   Febbraio MA, 2002, FASEB J, V16, P1335, DOI 10.1096/fj.01 0876rev
   Fischer CP, 2006, EXERC IMMUNOL REV, V12, P6
   GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130
   Goldring K, 2002, J CELL SCI, V115, P355
   Goldring S. R., 2003, Journal of Musculoskeletal & Neuronal Interactions, V3, P287
   Hayashi O, 2008, CALCIFIED TISSUE INT, V82, P238, DOI 10.1007/s00223 008 9112 y
   Heymann D, 2000, CYTOKINE, V12, P1455, DOI 10.1006/cyto.2000.0747
   Hu JCC, 2003, CRIT REV ORAL BIOL M, V14, P387, DOI 10.1177/154411130301400602
   Jacobs SCJM, 1996, J NEUROL, V243, P410, DOI 10.1007/BF00869001
   Karsenty G, 2008, ANNU REV GENOM HUM G, V9, P183, DOI 10.1146/annurev.genom.9.081307.164437
   KROGER H, 1992, BONE MINER, V17, P75, DOI 10.1016/0169 6009(92)90712 M
   Kumar A, 2004, FASEB J, V18, P102, DOI 10.1096/fj.03 0453com
   KUNKEL LM, 1989, CLIN CHEM, V35, pB21
   Kurek JB, 1996, MUSCLE NERVE, V19, P1291, DOI 10.1002/(SICI)1097 4598(199610)19:10<1291::AID MUS6>3.0.CO;2 9
   Larson CM, 2000, J PEDIATR ORTHOPED, V20, P71, DOI 10.1097/00004694 200001000 00016
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Marzia M, 2000, J CELL BIOL, V151, P311, DOI 10.1083/jcb.151.2.311
   McDonald DGM, 2002, DEV MED CHILD NEUROL, V44, P695
   MCDOUALL RM, 1990, J NEUROL SCI, V99, P199, DOI 10.1016/0022 510X(90)90156 H
   Montgomery E, 2005, ANAT REC PART A, V286A, P814, DOI 10.1002/ar.a.20224
   NAKAGAKI WR, 2010, BONE            0917
   Olney RC, 2009, HORM RES, V72, P30, DOI 10.1159/000229761
   Pandya S, 2005, NEUROMUSCULAR DISORD, V15, P687
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pearsall RS, 2008, P NATL ACAD SCI USA, V105, P7082, DOI 10.1073/pnas.0711263105
   Petrof BJ, 1998, MOL CELL BIOCHEM, V179, P111, DOI 10.1023/A:1006812004945
   Pfeilschifter J, 2002, ENDOCR REV, V23, P90, DOI 10.1210/er.23.1.90
   Porter JD, 2002, HUM MOL GENET, V11, P263, DOI 10.1093/hmg/11.3.263
   Raisz LG, 1999, CLIN CHEM, V45, P1353
   ROODMAN GD, 1992, J CLIN INVEST, V89, P46, DOI 10.1172/JCI115584
   Rucci N, 2009, J CELL BIOL, V187, P669, DOI 10.1083/jcb.200906014
   Rusinska A, 2005, ARCH IMMUNOL THER EX, V53, P257
   Söderpalm AC, 2007, NEUROMUSCULAR DISORD, V17, P919, DOI 10.1016/j.nmd.2007.05.008
   Souza LS, 2008, J RHEUMATOL, V35, P2265, DOI 10.3899/jrheum.080199
   Spencer MJ, 2001, NEUROMUSCULAR DISORD, V11, P556, DOI 10.1016/S0960 8966(01)00198 5
   Suresh S, 2005, J PAEDIATR CHILD H, V41, P500, DOI 10.1111/j.1440 1754.2005.00691.x
   Taranta A, 2004, J BONE MINER RES, V19, P1112, DOI 10.1359/JBMR.040319
   Tsangari H, 2006, BONE, V39, P1226, DOI 10.1016/j.bone.2006.06.019
   Vukicevic S, 2009, CYTOKINE GROWTH F R, V20, P441, DOI 10.1016/j.cytogfr.2009.10.020
   Wagner KR, 2007, BBA MOL BASIS DIS, V1772, P229, DOI 10.1016/j.bbadis.2006.06.009
   Wakayama Y, 2002, ARCH NEUROL CHICAGO, V59, P431, DOI 10.1001/archneur.59.3.431
   Wehling M, 2001, J CELL BIOL, V155, P123, DOI 10.1083/jcb.200105110
   Weldon D, 2009, ANN ALLERG ASTHMA IM, V103, P3, DOI 10.1016/S1081 1206(10)60135 4
   Wierzbowska A, 1999, BRIT J HAEMATOL, V105, P412, DOI 10.1046/j.1365 2141.1999.01350.x
NR 57
TC 123
Z9 135
U1 1
U2 14
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD AUG
PY 2011
VL 26
IS 8
BP 1891
EP 1903
DI 10.1002/jbmr.410
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 800RL
UT WOS:000293382600025
PM 21509823
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Cheng, YT
   Jin, WJ
   Zheng, L
   Huang, XL
   Luo, SS
   Hong, W
   Liao, J
   Samruajbenjakun, B
   Leethanakul, C
AF Cheng, Yuting
   Jin, Wenjun
   Zheng, Lin
   Huang, Xiaolin
   Luo, Shanshan
   Hong, Wei
   Liao, Jian
   Samruajbenjakun, Bancha
   Leethanakul, Chidchanok
TI The role of autophagy in SIM mediated anti inflammatory
   osteoclastogenesis through NLRP3 signaling pathway
SO IMMUNITY INFLAMMATION AND DISEASE
LA English
DT Article
DE autophagy; inflammatory bone resorption; NLRP3; osteoclast; Simvastatin
ID BONE LOSS; TNF ALPHA; LIPOPOLYSACCHARIDE; INFLAMMASOME; STATINS;
   EXPRESSION; PROTECTS; CELL
AB BackgroundInflammatory bone resorption is a prominent risk factor for implantation failure. Simvastatin (SIM) has anti inflammatory effects independent of cholesterol lowering and reduces osteoclastogenesis by decreasing both the number and activity of osteoclasts. However, the specific mechanism of inflammatory bone loss alleviation by SIM remains to be elucidated. We hypothesized that SIM relieves inflammatory bone loss by modulating autophagy and suppressing the NOD like receptor family pyrin domain containing protein 3 (NLRP3) signaling pathway.Methods and resultsRAW264.7 cells were stimulated by lipopolysaccharide (LPS) after being pretreated with various concentrations of SIM. Osteoclast (OC) differentiation, formation and activity were evaluated by tartrate resistant acid phosphatase staining, F actin ring staining and bone resorption pit assays, respectively. We observed autophagosomes by transmission electron microscopy. Then NLRP3 inhibitor MCC950 was used to further explore the corresponding molecular mechanism underlying anti inflammatory bone resorption, the expression of autophagy related proteins and NLRP3 signaling pathway factors in pre OCs were evaluated by western blot analysis, and the expression of OC specific molecules was analyzed using reverse transcription quantitative polymerase chain reaction. The results showed that SIM decreased the expression of tumor necrosis factor alpha, whereas increased Interleukin 10. In addition, SIM inhibited LPS induced OC differentiation, formation, bone resorption activity, the level of autophagosomes, and OC specific markers. Furthermore, SIM significantly suppressed autophagy by downregulating LC3II, Beclin1, ATG7, and NLRP3 related proteins expression while upregulating P62 under inflammatory conditions.ConclusionsSIM may reduce autophagy secretion to attenuate LPS induced osteoclastogenesis and the NLRP3 signaling pathway participates in this process, thus providing theoretical basis for the application of this drug in peri implantitis.
   Our research may provide a reference for evaluating the pharmacological effect of these statin products on bone tissue in an inflammatory state, as well as a direction for the application of these drugs in the regulation of bone metabolism in infectious bone disease.image
C1 [Cheng, Yuting; Samruajbenjakun, Bancha; Leethanakul, Chidchanok] Prince Songkla Univ, Fac Dent, Dept Stomatol, Hat Yai, Thailand.
   [Cheng, Yuting; Jin, Wenjun; Zheng, Lin; Luo, Shanshan; Liao, Jian] Guizhou Med Univ, Sch Hosp Stomatol, Guiyang, Peoples R China.
   [Huang, Xiaolin] Hosp Stomatol, Zhongshan, Guangdong, Peoples R China.
   [Hong, Wei] Guizhou Med Univ, Key Lab Endem & Ethn Dis, Minist Educ, Guiyang, Peoples R China.
   [Samruajbenjakun, Bancha; Leethanakul, Chidchanok] Prince Songkla Univ, Fac Dent, Hat Yai 90110, Songkla, Thailand.
C3 Prince of Songkla University; Guizhou Medical University; Guizhou
   Medical University; Prince of Songkla University
RP Samruajbenjakun, B; Leethanakul, C (通讯作者)，Prince Songkla Univ, Fac Dent, Hat Yai 90110, Songkla, Thailand.
EM samruaj@hotmail.com; chidchanok.l@psu.ac.th
RI ; Yuan, Yahong/KFB 9020 2024; cheng, yuting/HZL 7783 2023
OI Samruajbenjakun, Bancha/0000 0001 8429 9828; cheng,
   yuting/0000 0002 0300 9460; 
FU National Natural Science Foundation of China [82260198, 82060207];
   Natural Science Foundation of China [gzwkj2023 437]; Science and
   Technology Foundation of Guizhou Provincial Health Commission
   [GYKQKY2022 03]; Foundation of School/Hospital of Stomatology of Guizhou
   Medical University
FX The present study was supported by the Natural Science Foundation of
   China (Grant numbers 82260198 and 82060207), the Science and Technology
   Foundation of Guizhou Provincial Health Commission (grant no.
   gzwkj2023 437) and the Foundation of School/Hospital of Stomatology of
   Guizhou Medical University (grant no. GYKQKY2022 03).
CR Albrektsson T, 2014, CLIN IMPLANT DENT R, V16, P155, DOI 10.1111/cid.12142
   AlQranei MS, 2021, BMC IMMUNOL, V22, DOI 10.1186/s12865 021 00409 9
   Bai JX, 2020, BIOMATERIALS, V255, DOI 10.1016/j.biomaterials.2020.120197
   Biasizzo M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.591803
   Björnsson ES, 2017, LIVER INT, V37, P173, DOI 10.1111/liv.13308
   Bohannon JK, 2013, SHOCK, V40, P451, DOI 10.1097/SHK.0000000000000042
   Boyce Brendan F., 2005, Keio Journal of Medicine, V54, P127, DOI 10.2302/kjm.54.127
   Briot K, 2017, OSTEOPOROSIS INT, V28, P3301, DOI 10.1007/s00198 017 4189 7
   Chang YH, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031169
   Chen LL, 2020, BIOMED PHARMACOTHER, V126, DOI 10.1016/j.biopha.2020.110093
   Dai WY, 2021, INT J MOL MED, V47, P607, DOI 10.3892/ijmm.2020.4827
   Derks J, 2015, J CLIN PERIODONTOL, V42, pS158, DOI 10.1111/jcpe.12334
   Ferrari GL, 2011, CYTOKINE, V54, P144, DOI 10.1016/j.cyto.2011.02.005
   Gao XR, 2022, CELL SIGNAL, V95, DOI 10.1016/j.cellsig.2022.110353
   He SS, 2020, INFLAMMATION, V43, P220, DOI 10.1007/s10753 019 01111 0
   Hirata N, 2019, NUTRIENTS, V11, DOI 10.3390/nu11020368
   Hotokezaka H, 2007, J CELL BIOCHEM, V101, P122, DOI 10.1002/jcb.21167
   Ishida M, 2019, BIOMED PHARMACOTHER, V109, P242, DOI 10.1016/j.biopha.2018.10.052
   Islam S, 2007, BIOCHEM BIOPH RES CO, V360, P346, DOI 10.1016/j.bbrc.2007.06.023
   Jiang N, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.752546
   Jin J, 2014, J PERIODONTAL RES, V49, P518, DOI 10.1111/jre.12132
   Kotsakis GA, 2021, PERIODONTOL 2000, V86, P231, DOI 10.1111/prd.12372
   Leung PO, 2011, TOXICOL LETT, V207, P159, DOI 10.1016/j.toxlet.2011.09.004
   Li X, 2020, AGEING RES REV, V62, DOI 10.1016/j.arr.2020.101098
   Liu D, 2019, ANN ROY COLL SURG, V101, P328, DOI 10.1308/rcsann.2019.0021
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lupfer C, 2013, NAT IMMUNOL, V14, P480, DOI 10.1038/ni.2563
   McFarland AJ, 2018, TOXICOL APPL PHARM, V344, P56, DOI 10.1016/j.taap.2018.03.005
   Montaseri A, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10101398
   Moon HJ, 2011, EXP MOL MED, V43, P605, DOI 10.3858/emm.2011.43.11.067
   Murakami T, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23105365
   Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371 2380.1996
   Nakanishi Matsui M, 2012, BIOCHEM BIOPH RES CO, V425, P144, DOI 10.1016/j.bbrc.2012.07.050
   Ou XM, 2009, RESPIROLOGY, V14, P734, DOI 10.1111/j.1440 1843.2009.01549.x
   Paik S, 2021, CELL MOL IMMUNOL, V18, P1141, DOI 10.1038/s41423 021 00670 3
   Park HJ, 2018, BIOCHEM PHARMACOL, V151, P9, DOI 10.1016/j.bcp.2018.02.019
   Qu C, 2015, FASEB J, V29, P1269, DOI 10.1096/fj.14 264804
   Rathinam VAK, 2012, NAT IMMUNOL, V13, P333, DOI 10.1038/ni.2237
   Roccuzzo A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10051107
   Rokaya Dinesh, 2020, Eur J Dent, V14, P672, DOI 10.1055/s 0040 1715779
   Romandini M, 2021, CLIN ORAL IMPLAN RES, V32, P112, DOI 10.1111/clr.13684
   Sadowitz B, 2010, VASC ENDOVASC SURG, V44, P241, DOI 10.1177/1538574410362922
   Sendyk DI, 2016, J ORAL REHABIL, V43, P873, DOI 10.1111/joor.12438
   Stellaard F, 2017, CHOLESTEROL, DOI 10.1155/2017/5046294
   Sul OJ, 2017, MOL CELLS, V40, P880, DOI 10.14348/molcells.2017.0230
   Tong XS, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23179846
   Tseng HW, 2022, CURR OSTEOPOROS REP, V20, P170, DOI 10.1007/s11914 022 00729 8
   Valente NA, 2016, J PERIODONTAL IMPLAN, V46, P136, DOI 10.5051/jpis.2016.46.3.136
   Xiao Y, 2020, J CELL PHYSIOL, V235, P421, DOI 10.1002/jcp.28982
   Xu L., 2021, Mol Med Rep, V25, P25
   Yu CY, 2021, INFLAMMATION, V44, P434, DOI 10.1007/s10753 020 01357 z
   Yue XX, 2016, NANOTECHNOLOGY, V27, DOI 10.1088/0957 4484/27/11/115708
   Zhang XN, 2023, J ETHNOPHARMACOL, V309, DOI 10.1016/j.jep.2023.116304
   Zhong Z, 2016, CLIN EXP RHEUMATOL, V34, pS12
NR 54
TC 1
Z9 1
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2050 4527
J9 IMMUN INFLAMM DIS
JI IMMUN. INFLAMM. DIS.
PD JAN
PY 2024
VL 12
IS 1
AR e1145
DI 10.1002/iid3.1145
PG 15
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA EL6R7
UT WOS:001139127100001
PM 38270300
OA gold
DA 2025 08 17
ER

PT J
AU Kokufu, I
   Kohno, N
   Yamamoto, M
   Takao, S
AF Kokufu, Ikuo
   Kohno, Norio
   Yamamoto, Masayuki
   Takao, Shintaro
TI Adjuvant pamidronate therapy prevents the development of bone metastases
   in breast cancer patients with four or more positive nodes
SO ONCOLOGY LETTERS
LA English
DT Article
DE adjuvant therapy bisphosphonate; bone metastases; breast cancer;
   pamidronate
ID RANDOMIZED CONTROLLED TRIAL; CLODRONATE TREATMENT; FOLLOW UP; IN VITRO;
   BISPHOSPHONATES; APOPTOSIS; CELLS
AB Bisphosphonates are strongly efficacious in inhibiting osteoclast bone resorption and have beneficial effects on bone metastasis Due to their mechanism of action, bisphosphonates are expected to prevent the development of bone metastases in breast cancer patients Pamidronate is a potent inhibitor of osteoclast activity We examined whether pamidronate was able to prevent the development of bone metastases in breast cancer patients at high risk for bone metastasis Between 1997 and 2001, 90 patients with primary breast cancer with >= 4 positive nodes were assigned to receive 45 mg pamidronate 4 times every 2 weeks (33 patients) or standard follow up (57 patients) based on patient self preference Patients underwent surgery and adjuvant therapy The characteristics of the patients in the two groups were well balanced The median follow up period was 5 years Bone metastases were detected in 12 1% of patients in the pamidronate group and 404% in the control group (p=0 005) Distant metastases (36 4 vs 56 1%, p=0 071) and non osseous metastases (33 3 vs 52 6%, p=0 077) were detected at a lower frequency in the pamidronate group Thus, the rate of bone metastasis free survival was significantly higher in the pamidronate group (85 9 vs 640% at 5 years, p=0 023) Overall and disease free survival rates did not differ between the two groups In the pamidronate group, the incidence of bone metastases was significantly reduced and bone metastasis free survival was significantly higher Adjuvant pamidronate therapy therefore prevents the development of bone metastases in breast cancer patients with >= 4 positive nodes
C1 [Kohno, Norio] Tokyo Med Univ, Dept Breast Oncol, Shinjuku Ku, Tokyo 1600023, Japan.
   [Kokufu, Ikuo; Yamamoto, Masayuki] Itami City Hosp, Dept Surg, Itami, Hyogo 6648540, Japan.
   [Kohno, Norio; Takao, Shintaro] Hyogo Med Ctr Adults, Dept Breast Oncol, Akashi, Hyogo 6738558, Japan.
C3 Tokyo Medical University
RP Kohno, N (通讯作者)，Tokyo Med Univ, Dept Breast Oncol, Shinjuku Ku, 6 7 1 Nishi Shinjuku, Tokyo 1600023, Japan.
RI Kohno, Norio/Q 5594 2019
CR Colleoni M, 2000, J CLIN ONCOL, V18, P3925, DOI 10.1200/JCO.2000.18.23.3925
   Crohns CA, 2001, P AM SOC CLIN ONCOL, V20
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   DIEL IJ, 2000, P AM SOC CLIN ONCOL, V19
   GNANT M, 2008, J CLIN ONCOL, V26
   Goldhirsch A, 2007, ANN ONCOL, V18, P1133, DOI 10.1093/annonc/mdm271
   Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Jaschke A, 2004, J CLIN ONCOL, V22, p9S
   LEYVRAZ S, 1992, J NATL CANCER I, V84, P788, DOI 10.1093/jnci/84.10.788
   Michiqami T, 1997, J BONE MINER RES  S1, V12, ps106
   Paterson Alexander H. G., 2000, Cancer, V88, P3038, DOI 10.1002/1097 0142(20000615)88:12+<3038::AID CNCR21>3.0.CO;2 V
   Powles T, 2004, J CLIN ONCOL, V22, p9S
   Powles T, 2002, J CLIN ONCOL, V20, P3219, DOI 10.1200/JCO.2002.11.080
   Rodan GA., 1996, J Clin Invest, V97, P26922696
   Saarto T, 2004, J CLIN ONCOL, V22, p9S
   Saarto T, 2001, J CLIN ONCOL, V19, P10, DOI 10.1200/JCO.2001.19.1.10
   Santini D, 2003, ANN ONCOL, V14, P1468, DOI 10.1093/annonc/mdg401
   SASAKI A, 1995, CANCER RES, V55, P3551
   Teronen O, 1999, ANN NY ACAD SCI, V878, P453, DOI 10.1111/j.1749 6632.1999.tb07702.x
   vanderPluijm G, 1996, J CLIN INVEST, V98, P698, DOI 10.1172/JCI118841
NR 22
TC 6
Z9 9
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 1074
EI 1792 1082
J9 ONCOL LETT
JI Oncol. Lett.
PD MAR APR
PY 2010
VL 1
IS 2
BP 247
EP 252
DI 10.3892/ol_00000044
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 687TF
UT WOS:000284800100005
PM 22966289
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Park, JH
   Son, YJ
   Lee, CH
   Nho, CW
   Yoo, G
AF Park, Ji Hye
   Son, Yang Ju
   Lee, Chang Ho
   Nho, Chu Won
   Yoo, Gyhye
TI Circaea mollis Siebold & Zucc. Alleviates postmenopausal
   osteoporosis in a mouse model via the BMP 2/4/Runx2 pathway
SO BMC COMPLEMENTARY MEDICINE AND THERAPIES
LA English
DT Article
DE Circaea mollis Siebold & Zucc; Postmenopausal osteoporosis; Osteoblast
   differentiation; Runt related transcription factor 2; Bone morphogenetic
   protein 2/4
ID ESTROGEN RECEPTOR ALPHA; DIFFERENTIATION; OSTEOBLAST; EXPRESSION; CELLS;
   OSTEOCLASTS; PREVENTION; MECHANISMS; INDUCTION
AB Background: Circaea mollis Sieb. & Zucc. has been used as a traditional herbal medicine in Hani Ethnopharmacy and possesses anti arthritic activities. This study aimed to investigate the effect of Circaea mollis Siebold & Zucc on postmenopausal osteoporosis.
   Methods: For in vitro study, MCF7 breast cancer cells and MC3T3 E1 pre osteoblast cells were utilized to estimate estrogenic and osteogenic activity. Osteoblastic markers were measured by western blot and real time PCR. For in vivo study, female mature C57BL/6 mice were ovariectomized and oral administrated with 10 mg/kg and 40 mg/kg of EECM respectively.
   Results: EtOH extract of Circaea mollis Siebold & Zucc. (EECM) increased alkaline phosphatase activity and osteoblast marker levels at day 7 during differentiation of mouse preosteoblasts. EECM reduced osteoclast differentiation and bone resorption in an osteoblast osteoclast primary co culture system. In ovariectomized mice, EECM prevented the decrease in bone mineral density and recovered OSX and Runx2 via BMP2/4, Smad1/5/9 and p38.
   Conclusions: The results suggest that EECM may be effective in preventing bone loss, offering a promising alternative for the nutritional management of postmenopausal osteoporosis.
C1 [Park, Ji Hye; Son, Yang Ju; Nho, Chu Won; Yoo, Gyhye] Korea Inst Sci & Technol KIST, Gangneung Inst Nat Prod, Smart Farm Res Ctr, Nat Prod Res Ctr, Kangnung 25451, Gangwon Do, South Korea.
   [Park, Ji Hye; Lee, Chang Ho] Gangneung Wonju Natl Univ, Coll Biol, Kangnung 25457, South Korea.
C3 Korea Institute of Science & Technology (KIST); Gangneung Wonju National
   University
RP Yoo, G (通讯作者)，Korea Inst Sci & Technol KIST, Gangneung Inst Nat Prod, Smart Farm Res Ctr, Nat Prod Res Ctr, Kangnung 25451, Gangwon Do, South Korea.
EM loshell@kist.re.kr
OI Son, Yang Ju/0000 0002 7562 1915
FU Center Project for the Korea Mongolia Science and Technology Cooperation
   [2 U06170]
FX This work was supported by the Center Project for the Korea Mongolia
   Science and Technology Cooperation (Grant No. 2 U06170). The funding
   body had no role in the design of the study and collection and analysis
   of data and in writing manuscript.
CR Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Arpornmaeklong P, 2009, STEM CELLS DEV, V18, P955, DOI 10.1089/scd.2008.0310
   Barlas N, 2014, TOXICOL LETT, V226, P35, DOI 10.1016/j.toxlet.2014.01.030
   Black DM, 2016, NEW ENGL J MED, V374, P2096, DOI 10.1056/NEJMc1602599
   Che CT, 2016, MOLECULES, V21, DOI 10.3390/molecules21030239
   Corrado A, 2017, POSTGRAD MED, V129, P858, DOI 10.1080/00325481.2017.1362312
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   DUCY P, 1995, MOL CELL BIOL, V15, P1858
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   GENANT HK, 1989, AM J OBSTET GYNECOL, V161, P1842, DOI 10.1016/S0002 9378(89)80004 3
   Imai Y, 2010, MOL ENDOCRINOL, V24, P877, DOI 10.1210/me.2009 0238
   Ortuño MJ, 2013, BONE, V52, P548, DOI 10.1016/j.bone.2012.11.007
   Korea National Arboretum, 2016, NATURE
   Kousteni S, 2007, MOL CELL BIOL, V27, P1516, DOI 10.1128/MCB.01550 06
   Lagari VS, 2013, J CLIN DENSITOM, V16, P445, DOI 10.1016/j.jocd.2013.08.011
   Luo G, 2016, INT J CLIN EXP MED, V9, P1062
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Markaverich Barry M, 2011, Int J Biomed Sci, V7, P101
   Martin Millan M, 2010, MOL ENDOCRINOL, V24, P323, DOI 10.1210/me.2009 0354
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Riggs BL, 2000, J CLIN INVEST, V106, P1203, DOI 10.1172/JCI11468
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo 123 5 2600
   Tsurukai T, 2000, J BONE MINER METAB, V18, P177, DOI 10.1007/s007740070018
   TURNER CH, 1991, OSTEOPOROSIS INT, V2, P12, DOI 10.1007/BF01627073
   Zhang Q, 2018, J ETHNOPHARMACOL, V225, P359, DOI 10.1016/j.jep.2018.04.051
NR 26
TC 15
Z9 17
U1 0
U2 13
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2662 7671
J9 BMC COMPLEMENT MED
JI BMC Complement. Med. Ther.
PD APR 22
PY 2020
VL 20
IS 1
AR 123
DI 10.1186/s12906 020 02914 7
PG 11
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA MM7AH
UT WOS:000550305300001
PM 32321506
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Chen, XW
   Chen, XZ
   Zhou, ZH
   Qin, A
   Wang, YX
   Fan, BT
   Xu, WF
   Zhang, SY
AF Chen, Xinwei
   Chen, Xuzhuo
   Zhou, Zhihang
   Qin, An
   Wang, Yexin
   Fan, Baoting
   Xu, Weifeng
   Zhang, Shanyong
TI LY411575, a potent γ secretase inhibitor, suppresses osteoclastogenesis
   in vitro and LPS induced calvarial osteolysis in vivo
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE LY411575; Notch; osteoclast
ID KAPPA B PATHWAYS; NOTCH; DIFFERENTIATION; ACTIVATION; RESORPTION;
   INSIGHTS; TARGET; GENE
AB A series of osteolytic bone diseases are usually related to excessive bone resorption and osteoclast formation. Thus, agents or drugs which can target osteoclast development and attenuate bone loss are potentially considerable in preventing and treating of bone lytic diseases. In recent years, many studies have reported that Notch signaling has substantial impacts on the process of osteoclast differentiation, maturation, and bone destruction. In the present study, we showed that LY411575, a gamma secretase inhibitor, could potently suppress osteoclast differentiation, osteoclast specific gene expression, and bone resorption via suppressing Notch/HES1/MAPK (ERK and p38)/Akt mediated NFATc1 induction in vitro. Consistent with in vitro results, LY411575 exhibited protective effects in lipopolysaccharides induced calvarial bone destruction in vivo. Collectively, these results indicate that LY411575 may have therapeutic potential in the treatment of osteoclast mediated osteolytic bone diseases.
C1 [Chen, Xinwei; Chen, Xuzhuo; Zhou, Zhihang; Wang, Yexin; Fan, Baoting; Xu, Weifeng; Zhang, Shanyong] Shanghai Jiao Tong Univ, Dept Oral & Maxillofacial Surg, Peoples Hosp 9, Coll Stomatol,Sch Med,Shanghai Key Lab Stomatol, Shanghai, Peoples R China.
   [Chen, Xinwei; Chen, Xuzhuo; Zhou, Zhihang; Wang, Yexin; Fan, Baoting; Xu, Weifeng; Zhang, Shanyong] Shanghai Res Inst Stomatol, Shanghai, Peoples R China.
   [Qin, An] Shanghai Jiao Tong Univ, Dept Orthopaed, Shanghai Peoples Hosp 9, Shanghai Key Lab Orthopaed Implant,Sch Med, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Fan, BT; Xu, WF; Zhang, SY (通讯作者)，Shanghai Jiao Tong Univ, Dept Oral & Maxillofacial Surg, Shanghai Key Lab Stomatol,Peoples Hosp 9, Shanghai Res Inst Stomatol,Sch Med,Collage Stomat, 639 Zhi Zao Ju Rd, Shanghai 200011, Peoples R China.
EM 417163954@qq.com; 13122071968@163.com; zhangshanyong@126.com
RI ; Qin, An/J 2518 2019; Chen, Xuzhuo/ACC 3813 2022
OI chen, xuzhuo/0000 0002 1276 1662; 
FU National Natural Science Foundation of China [81671010, 81772373,
   81572167]; Shanghai Jiao Tong university school of medicine [JYLJ037];
   Science and Technology Commission of Shanghai Municipality
   [16441908800]; Shanghai Hospital Development Center [16CR3104B]
FX National Natural Science Foundation of China, Grant/Award Numbers:
   81671010, 81772373, 81572167; Clinical Research Program of 9th people's
   hospital, Shanghai Jiao Tong university school of medicine, Grant/Award
   Number: JYLJ037; Science and Technology Commission of Shanghai
   Municipality, Grant/Award Number: 16441908800; Shanghai Hospital
   Development Center, Grant/Award Number: 16CR3104B
CR Artavanis Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770
   Ashley JW, 2015, J CELL BIOCHEM, V116, P2598, DOI 10.1002/jcb.25205
   Bai S, 2008, J BIOL CHEM, V283, P6509, DOI 10.1074/jbc.M707000200
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009
   Chen S, 2014, CALCIFIED TISSUE INT, V94, P68, DOI 10.1007/s00223 013 9773 z
   Drissi H, 2016, J CELL BIOCHEM, V117, P1753, DOI 10.1002/jcb.25560
   Duan L, 2008, FRONT BIOSCI LANDMRK, V13, P7064, DOI 10.2741/3210
   Espinosa L, 2003, MOL BIOL CELL, V14, P491, DOI 10.1091/mbc.E02 07 0404
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Fukushima H, 2008, MOL CELL BIOL, V28, P6402, DOI 10.1128/MCB.00299 08
   Gil Henn H, 2007, J CELL BIOL, V178, P1053, DOI 10.1083/jcb.200701148
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   Hales EC, 2014, CELL SIGNAL, V26, P149, DOI 10.1016/j.cellsig.2013.09.021
   Haruki N, 2005, CANCER RES, V65, P3555, DOI 10.1158/0008 5472.CAN 04 3132
   Hienz SA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/615486
   Hirayama T, 2002, RHEUMATOLOGY, V41, P1232, DOI 10.1093/rheumatology/41.11.1232
   Ilagan Maria Xenia G, 2007, Cell, V128, P1246
   Islam S, 2007, BIOCHEM BIOPH RES CO, V360, P346, DOI 10.1016/j.bbrc.2007.06.023
   Jin WJ, 2016, CELL SIGNAL, V28, P357, DOI 10.1016/j.cellsig.2016.01.016
   Kim SH, 2013, EXPERT OPIN THER PAT, V23, P1591, DOI 10.1517/13543776.2013.842556
   Kimura K, 2012, FEMS IMMUNOL MED MIC, V64, P219, DOI 10.1111/j.1574 695X.2011.00888.x
   Lai EC, 2004, DEVELOPMENT, V131, P965, DOI 10.1242/dev.01074
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Nair P, 2003, J VIROL, V77, P7106, DOI 10.1128/JVI.77.12.7106 7112.2003
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Sekine C, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3758
   Shin HM, 2006, EMBO J, V25, P129, DOI 10.1038/sj.emboj.7600902
   Sims NA, 2008, SEMIN CELL DEV BIOL, V19, P444, DOI 10.1016/j.semcdb.2008.07.016
   Souilhol C, 2006, MOL CELL BIOL, V26, P4769, DOI 10.1128/MCB.00319 06
   Takito J, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19040984
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tremblay I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085502
   Vacca A, 2006, EMBO J, V25, P1000, DOI 10.1038/sj.emboj.7600996
   Wang ZW, 2010, CURR PROTEIN PEPT SC, V11, P398, DOI 10.2174/138920310791824039
   Wedemeyer C, 2007, CALCIFIED TISSUE INT, V81, P394, DOI 10.1007/s00223 007 9077 2
   Wei S, 2007, ADV ANAT PATHOL, V14, P42, DOI 10.1097/PAP.0b013e31802ef4f2
   Xie Z, 2018, J BONE MINER RES, V33, P667, DOI 10.1002/jbmr.3334
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhang J, 2015, INT ENDOD J, V48, P1077, DOI 10.1111/iej.12405
NR 45
TC 27
Z9 28
U1 1
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD NOV
PY 2019
VL 234
IS 11
BP 20944
EP 20956
DI 10.1002/jcp.28699
PG 13
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA IM5EX
UT WOS:000478018200158
PM 31020651
DA 2025 08 17
ER

PT J
AU Zhong, ML
   Wu, ZY
   Chen, ZX
   Ren, Q
   Zhou, JG
AF Zhong, Mingliang
   Wu, Zhenyu
   Chen, Zhixi
   Ren, Qun
   Zhou, Jianguo
TI Advances in the interaction between endoplasmic reticulum stress and
   osteoporosis
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Endoplasmic reticulum stress; Osteoblast; Osteoclast; Osteoporosis; Bone
   remodeling
ID UNFOLDED PROTEIN RESPONSE; INDUCED CELL APOPTOSIS; HIGH FAT DIET; ER
   STRESS; OSTEOBLAST DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION;
   PPAR GAMMA; IN VITRO; TRANSCRIPTION FACTOR; CYCLOSPORINE A
AB The endoplasmic reticulum (ER) is the main site for protein synthesis, folding, and secretion, and accumulation of the unfolded/misfolded proteins in the ER may induce ER stress. ER stress is an important participant in various intracellular signaling pathways. Prolonged  or high intensity ER stress may induce cell apoptosis. Osteoporosis, characterized by imbalanced bone remodeling, is a global disease caused by many factors, such as ER stress. ER stress stimulates osteoblast apoptosis, increases bone loss, and promotes osteoporosis development. Many factors, such as the drug's adverse effects, metabolic disorders, calcium ion imbalance, bad habits, and aging, have been reported to activate ER stress, resulting in the pathological development of osteoporosis. Increasing evidence shows that ER stress regulates osteogenic differentiation, osteoblast activity, and osteoclast formation and function. Various therapeutic agents have been developed to counteract ER stress and thereby suppress osteoporosis development. Thus, inhibition of ER stress has become a potential target for the therapeutic management of osteoporosis. However, the in depth understanding of ER stress in the pathogenesis of osteoporosis still needs more effort.
C1 [Zhong, Mingliang] Gannan Med Univ, Coll Rehabil, Ganzhou 341000, Peoples R China.
   [Wu, Zhenyu] Gannan Med Univ, Affiliated Hosp 1, Ganzhou 341000, Peoples R China.
   [Chen, Zhixi; Ren, Qun] Gannan Med Univ, Coll Pharm, Ganzhou 341000, Peoples R China.
   [Zhou, Jianguo] Ganzhou Peoples Hosp, Dept Joint Surg, Ganzhou 341000, Peoples R China.
C3 Gannan Medical University; Gannan Medical University; Gannan Medical
   University
RP Zhou, JG (通讯作者)，Ganzhou Peoples Hosp, Dept Joint Surg, Ganzhou 341000, Peoples R China.
EM zjg840818@163.com
RI Zhou, Jian Guo/AFK 7643 2022
FU National Natural Science Foundation of China [81960883]; Science and
   Technology Research Project of the Education Department of Jiangxi
   Province [GJJ211520]; Ganzhou Science and Technology Innovation Talent
   Plan [2022 RC1328]
FX Funding This research was funded by National Natural Science Foundation
   of China (81960883) ; the Science and Technology Research Project of the
   Education Department of Jiangxi Province (GJJ211520) , and the Ganzhou
   Science and Technology Innovation Talent Plan (2022 RC1328) .
CR Al Amin M, 2016, MOL CELLS, V39, P163, DOI 10.14348/molcells.2016.2298
   Amin U, 2023, WOMENS HEALTH, V19, DOI 10.1177/17455057231176655
   Anagnostis P, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031639
   Berman NK, 2022, OSTEOPOROSIS INT, V33, P1235, DOI 10.1007/s00198 021 05972 w
   Boonanantanasarn K, 2015, J CELL BIOCHEM, V116, P2849, DOI 10.1002/jcb.25231
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Briot K, 2018, JOINT BONE SPINE, V85, P519, DOI 10.1016/j.jbspin.2018.02.009
   Cao J, 2012, MOL CELL BIOCHEM, V364, P115, DOI 10.1007/s11010 011 1211 9
   Che JM, 2021, CELL SIGNAL, V84, DOI 10.1016/j.cellsig.2021.110024
   Chen SQ, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3524307
   Chen YC, 2017, MEDICINE, V96, DOI [10.1097/MD.0000000000009231, 10.1097/md.0000000000009231]
   Chen YP, 2013, CELL PHYSIOL BIOCHEM, V32, P743, DOI 10.1159/000354476
   Chen Y, 2020, J CELL MOL MED, V24, P12411, DOI 10.1111/jcmm.15753
   Cheng CH, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031376
   Cheng FZ, 2022, BIOCHEM BIOPH RES CO, V601, P45, DOI 10.1016/j.bbrc.2022.02.058
   Cheng SL, 2021, PHARMACOL RES PERSPE, V9, DOI 10.1002/prp2.791
   Cheng ZP, 2022, MOL MED, V28, DOI 10.1186/s10020 022 00448 x
   Cho H, 2022, J MOL HISTOL, V53, P75, DOI 10.1007/s10735 021 10034 w
   Chu SG, 2019, AM J RESP CELL MOL, V61, P737, DOI 10.1165/rcmb.2018 0324OC
   Clark AL, 2016, CURR OPIN IMMUNOL, V43, P60, DOI 10.1016/j.coi.2016.09.006
   Clynes MA, 2020, BRIT MED BULL, V133, P105, DOI 10.1093/bmb/ldaa005
   Compston J, 2018, ENDOCRINE, V61, P7, DOI 10.1007/s12020 018 1588 2
   Dennis EP, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24021496
   Desai BV, 2022, EUR J CLIN PHARMACOL, V78, P35, DOI 10.1007/s00228 021 03237 3
   Doroudgar S, 2009, J BIOL CHEM, V284, P29735, DOI 10.1074/jbc.M109.018036
   Duangchan T, 2021, LIFE SCI, V278, DOI 10.1016/j.lfs.2021.119628
   Evans Molina C, 2009, MOL CELL BIOL, V29, P2053, DOI 10.1128/MCB.01179 08
   Feng HS, 2021, TOXICOL IN VITRO, V77, DOI 10.1016/j.tiv.2021.105249
   Feng Y, 2023, NEUROL RES, V45, P590, DOI 10.1080/01616412.2023.2170905
   Fu ZR, 2019, J THORAC CARDIOV SUR, V158, P408, DOI 10.1016/j.jtcvs.2018.10.136
   Gao L, 2022, THERIOGENOLOGY, V189, P137, DOI 10.1016/j.theriogenology.2022.06.010
   Grey A, 2008, OSTEOPOROSIS INT, V19, P129, DOI 10.1007/s00198 007 0477 y
   Groenendyk J, 2021, INT REV CEL MOL BIO, V363, P1, DOI 10.1016/bs.ircmb.2021.03.003
   Guo FJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.194
   Guo H., 2022, ANTIOXIDANTS BASEL, V11
   Guo JC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 03046 z
   Guo YS, 2014, LAB INVEST, V94, P906, DOI 10.1038/labinvest.2014.63
   Guo YS, 2021, MOL BIOL REP, V48, P7841, DOI 10.1007/s11033 021 06806 y
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hamamura K, 2007, FEBS LETT, V581, P1769, DOI 10.1016/j.febslet.2007.03.063
   Hamamura K, 2015, CELL SIGNAL, V27, P353, DOI 10.1016/j.cellsig.2014.11.020
   Hamamura K, 2013, J BONE MINER METAB, V31, P618, DOI 10.1007/s00774 013 0450 0
   Han C, 2021, EXP CELL RES, V406, DOI 10.1016/j.yexcr.2021.112781
   Han D, 2009, CELL, V138, P562, DOI 10.1016/j.cell.2009.07.017
   Hayashi C, 2022, FRONT CELL DEV BIOL, V10, DOI [10.3389/icell.2022.1061216, 10.3389/fcell.2022.1061216]
   Hou WY, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1074574
   Hu H, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03083
   Hu XC, 2021, J CELL MOL MED, V25, P10454, DOI 10.1111/jcmm.16974
   Infante A, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0995 x
   Iyer S, 2020, FASEB BIOADV, V2, P207, DOI 10.1096/fba.2019 00032
   Jang WG, 2011, BMB REP, V44, P735, DOI 10.5483/BMBRep.2011.44.11.735
   Jang WG, 2012, J BIOL CHEM, V287, P905, DOI 10.1074/jbc.M111.253187
   Javed F, 2019, PERIODONTOL 2000, V81, P48, DOI 10.1111/prd.12282
   Jeon WJ, 2017, LIFE SCI, V178, P94, DOI 10.1016/j.lfs.2017.04.012
   Jia LN, 2023, ECOTOX ENVIRON SAFE, V251, DOI 10.1016/j.ecoenv.2023.114517
   Jin NQ, 2020, BIOMATER SCI UK, V8, P2840, DOI 10.1039/d0bm00424c
   Jing L, 2018, MOL MED REP, V17, P2415, DOI 10.3892/mmr.2017.8128
   Kan B, 2021, BMC MUSCULOSKEL DIS, V22, DOI 10.1186/s12891 021 04643 5
   Kassan M, 2012, ARTERIOSCL THROM VAS, V32, P1652, DOI 10.1161/ATVBAHA.112.249318
   Kawai M, 2010, NAT REV ENDOCRINOL, V6, P629, DOI 10.1038/nrendo.2010.155
   Keaveny TM, 2017, J BONE MINER RES, V32, P1956, DOI 10.1002/jbmr.3176
   Kiernan J, 2017, STEM CELL TRANSL MED, V6, P1930, DOI 10.1002/sctm.17 0054
   Kim JH, 2018, J IMMUNOL, V200, P1661, DOI 10.4049/jimmunol.1701036
   Krebs J, 2015, BIOCHEM BIOPH RES CO, V460, P114, DOI 10.1016/j.bbrc.2015.02.004
   Kureel J, 2016, MOL CELL BIOCHEM, V418, P71, DOI 10.1007/s11010 016 2734 x
   Kushchayeva Y, 2022, J CLIN MED, V11, DOI 10.3390/jcm11247477
   Lademann F, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.586031
   Lane NE, 2019, CURR OSTEOPOROS REP, V17, P1, DOI 10.1007/s11914 019 00498 x
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Lee EG, 2014, JOINT BONE SPINE, V81, P520, DOI 10.1016/j.jbspin.2014.04.012
   Lee HY, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1274 y
   Lee WS, 2018, CELL BIOL INT, V42, P393, DOI 10.1002/cbin.10861
   Leng B, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/5070415
   Lespessailles E, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms231810733
   Li F, 2022, J DRUG TARGET, V30, P1076, DOI 10.1080/1061186X.2022.2091577
   Li H, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01732 5
   Li HX, 2018, AUTOPHAGY, V14, P1726, DOI 10.1080/15548627.2018.1483807
   Li JY, 2022, CARDIOVASC RES, V118, P2018, DOI 10.1093/cvr/cvab243
   Li J, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2159 z
   Li J, 2017, BONE, V97, P2, DOI 10.1016/j.bone.2016.12.009
   Li K, 2018, CLIN INTERV AGING, V13, P2443, DOI 10.2147/CIA.S157523
   Li KD, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24065979
   Li LF, 2022, BIOCHEM BIOPH RES CO, V610, P70, DOI 10.1016/j.bbrc.2022.04.041
   Li XN, 2014, BIOL TRACE ELEM RES, V158, P113, DOI 10.1007/s12011 014 9897 7
   Li Y, 2017, INT J MOL MED, V39, P775, DOI 10.3892/ijmm.2017.2912
   Li YY, 2020, NEUROSCI BULL, V36, P134, DOI 10.1007/s12264 019 00411 7
   Liberman M, 2011, BIOCHEM BIOPH RES CO, V413, P436, DOI 10.1016/j.bbrc.2011.08.114
   Lin CH, 2018, J CELL MOL MED, V22, P786, DOI 10.1111/jcmm.13356
   Liu L, 2015, BIOL TRACE ELEM RES, V164, P64, DOI 10.1007/s12011 014 0192 4
   Liu MQ, 2016, ACTA PHARMACOL SIN, V37, P425, DOI 10.1038/aps.2015.145
   Liu Shengye, 2018, Oncotarget, V9, P11528, DOI 10.18632/oncotarget.23936
   Liu W, 2013, EXP THER MED, V5, P1289, DOI 10.3892/etm.2013.978
   Liu YL, 2023, J ETHNOPHARMACOL, V311, DOI 10.1016/j.jep.2023.116399
   Lu Y, 2021, J TRANSL MED, V19, DOI 10.1186/s12967 021 02836 z
   Martinez IKC, 2022, NICOTINE TOB RES, V24, P1921, DOI 10.1093/ntr/ntac144
   Meng XT, 2018, MOL MED REP, V17, P4817, DOI 10.3892/mmr.2018.8449
   Meng XT, 2018, INT J MOL MED, V41, P1003, DOI 10.3892/ijmm.2017.3300
   Merkel A, 2023, EUR CELLS MATER, V45, P14, DOI 10.22203/eCM.v045a02
   Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805 766
   Meyerovich K, 2016, J MOL ENDOCRINOL, V57, pR1, DOI 10.1530/JME 15 0306
   Nakamura S, 2013, INT J HEMATOL, V98, P66, DOI 10.1007/s12185 013 1367 z
   Nelson G, 2012, AGING CELL, V11, P345, DOI 10.1111/j.1474 9726.2012.00795.x
   Novack DV, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.MCHD 0011 2015
   Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011
   Oakes SA, 2015, ANNU REV PATHOL MECH, V10, P173, DOI 10.1146/annurev pathol 012513 104649
   Ohnaka K, 2005, BIOCHEM BIOPH RES CO, V329, P177, DOI 10.1016/j.bbrc.2005.01.117
   Omar Hmeadi M, 2021, CELL MOL LIFE SCI, V78, P1957, DOI 10.1007/s00018 020 03688 4
   Pallet N, 2008, AM J TRANSPLANT, V8, P2283, DOI 10.1111/j.1600 6143.2008.02396.x
   Park JK, 2014, BIOCHEM BIOPH RES CO, V443, P333, DOI 10.1016/j.bbrc.2013.11.121
   Passos E, 2022, J CELL BIOCHEM, V123, P1647, DOI 10.1002/jcb.30250
   Phetfong J, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658 016 0013 1
   Pluquet O, 2015, AM J PHYSIOL CELL PH, V308, pC415, DOI 10.1152/ajpcell.00334.2014
   Ponzetti M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136651
   Qadir A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010349
   Qiao J, 2021, FOOD FUNCT, V12, P963, DOI [10.1039/D0FO02664F, 10.1039/d0fo02664f]
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Raimondi L, 2020, CANCERS, V12, DOI 10.3390/cancers12082167
   Raven JF, 2008, J BIOL CHEM, V283, P3097, DOI 10.1074/jbc.M709677200
   Regunathan A, 2002, TOXICOL APPL PHARM, V185, P25, DOI 10.1006/taap.2002.9516
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Saito A, 2011, J BIOL CHEM, V286, P4809, DOI 10.1074/jbc.M110.152900
   Sato AY, 2016, J BONE MINER RES, V31, P1791, DOI 10.1002/jbmr.2869
   Sato AY, 2015, BONE, V73, P60, DOI 10.1016/j.bone.2014.12.012
   Sato Y, 2017, MOL GENET METAB REP, V10, P56, DOI 10.1016/j.ymgmr.2017.01.006
   Schiavi J, 2021, EXP CELL RES, V408, DOI 10.1016/j.yexcr.2021.112814
   Shafik MS, 2023, BIOMED PHARMACOTHER, V157, DOI 10.1016/j.biopha.2022.114042
   Shi MQ, 2021, BIOMED MATER, V16, DOI 10.1088/1748 605X/abbfee
   Shi MQ, 2017, ACTA BIOMATER, V54, P175, DOI 10.1016/j.actbio.2017.03.018
   Shin WY, 2000, YONSEI MED J, V41, P61, DOI 10.3349/ymj.2000.41.1.61
   Shoulders MD, 2013, CELL REP, V3, P1279, DOI 10.1016/j.celrep.2013.03.024
   Siddiqui JA, 2016, PHYSIOLOGY, V31, P233, DOI 10.1152/physiol.00061.2014
   Soliman E, 2019, LIFE SCI, V239, DOI 10.1016/j.lfs.2019.117047
   Son HE, 2020, MOL CELLS, V43, P58, DOI 10.14348/molcells.2019.0136
   Son HE, 2018, LIFE SCI, V193, P34, DOI 10.1016/j.lfs.2017.12.008
   Sozen E, 2017, REDOX BIOL, V12, P456, DOI 10.1016/j.redox.2017.02.025
   Straub DA, 2007, NUTR CLIN PRACT, V22, P286, DOI 10.1177/0115426507022003286
   Styner M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051613
   Su S, 2022, J BONE MINER METAB, V40, P422, DOI 10.1007/s00774 022 01313 x
   Suzuki R, 2020, J BONE MINER RES, V35, P1992, DOI 10.1002/jbmr.4053
   Tan J, 2022, ANN TRANSL MED, V10, DOI 10.21037/atm 22 6
   Tan J, 2016, J PERIODONTOL, V87, pE159, DOI 10.1902/jop.2016.150718
   Tanaka K, 2014, CALCIFIED TISSUE INT, V94, P454, DOI 10.1007/s00223 013 9828 1
   Tanaka K, 2013, BIOCHEM BIOPH RES CO, V438, P463, DOI 10.1016/j.bbrc.2013.07.126
   Tao SC, 2017, THERANOSTICS, V7, P733, DOI 10.7150/thno.17450
   Tao YM, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.856331
   Todd JA, 2003, POSTGRAD MED J, V79, P320, DOI 10.1136/pmj.79.932.320
   Tohmonda T, 2015, J CLIN INVEST, V125, P3269, DOI 10.1172/JCI76765
   Tohmonda T, 2011, EMBO REP, V12, P451, DOI 10.1038/embor.2011.34
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Varshney R, 2018, J NUTR BIOCHEM, V57, P212, DOI 10.1016/j.jnutbio.2018.02.017
   Wada C, 2006, J BONE MINER METAB, V24, P199, DOI 10.1007/s00774 005 0672 x
   Walker Bone K, 2012, NAT REV RHEUMATOL, V8, P480, DOI 10.1038/nrrheum.2012.93
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Wang KK, 2011, J MOL CELL BIOL, V3, P360, DOI 10.1093/jmcb/mjr021
   Wang XW, 2023, ALCOHOL ALCOHOLISM, V58, P375, DOI 10.1093/alcalc/agad026
   Watt J, 2015, TOXICOLOGY, V331, P66, DOI 10.1016/j.tox.2015.03.006
   Wei JW, 2008, J CELL PHYSIOL, V217, P693, DOI 10.1002/jcp.21543
   Wei X, 2022, FRONT CARDIOVASC MED, V9, DOI 10.3389/fcvm.2022.901786
   Wen CL, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.706768
   Wu D, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687551
   Wu HC, 2013, J CELL BIOCHEM, V114, P1969, DOI 10.1002/jcb.24534
   Wu JJ, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190304
   Wu JJ, 2019, J EXP MED, V216, P867, DOI 10.1084/jem.20182192
   Wu QH, 2018, FOOD CHEM TOXICOL, V118, P889, DOI 10.1016/j.fct.2018.06.054
   Wu Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.427
   Wu Y, 2015, BIOCHEM BIOPH RES CO, V464, P1275, DOI 10.1016/j.bbrc.2015.07.119
   Xiang ZC, 2021, ACS BIOMATER SCI ENG, V7, P3256, DOI 10.1021/acsbiomaterials.0c01802
   Xiao YS, 2022, J ETHNOPHARMACOL, V291, DOI 10.1016/j.jep.2022.115154
   Xie BC, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00411
   Yang JH, 2017, J BONE MINER METAB, V35, P366, DOI 10.1007/s00774 016 0778 3
   Yang L, 2018, CELL STRESS CHAPERON, V23, P1283, DOI 10.1007/s12192 018 0936 8
   Yang SS, 2021, CELL TRANSPLANT, V30, DOI 10.1177/09636897211035080
   Yang SY, 2016, CELL SIGNAL, V28, P880, DOI 10.1016/j.cellsig.2016.04.003
   Yang YY, 2022, J MOL MED, V100, P1191, DOI 10.1007/s00109 022 02233 z
   Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097 2765(00)00133 7
   Yoshida H, 2007, FEBS J, V274, P630, DOI 10.1111/j.1742 4658.2007.05639.x
   Zhang D, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 02037 3
   Zhang JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073086
   Zhang KF, 2019, AM J PHYSIOL ENDOC M, V316, pE590, DOI 10.1152/ajpendo.00371.2018
   Zhang L., 2017, BIOSCIENCE REP, V37
   Zhang L, 2018, BIOMED PHARMACOTHER, V104, P300, DOI 10.1016/j.biopha.2018.05.030
   Zhang YL, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/7382900
   Zhang Y, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/2297268
   Zhao XY, 2021, BIOCHEM BIOPH RES CO, V541, P8, DOI 10.1016/j.bbrc.2020.12.101
   Zheng LF, 2023, ACTA BIOCH BIOPH SIN, V55, P394, DOI 10.3724/abbs.2023043
   Zheng YZ, 2021, CELLS BASEL, V10, DOI 10.3390/cells10123424
   Zheng ZY, 2021, CELL DEATH DIFFER, V28, P2001, DOI 10.1038/s41418 020 00731 6
   Zhou RY, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.602307
NR 188
TC 16
Z9 18
U1 4
U2 41
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD SEP
PY 2023
VL 165
AR 115134
DI 10.1016/j.biopha.2023.115134
EA JUL 2023
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA N5CY4
UT WOS:001037202100001
PM 37437374
OA gold
DA 2025 08 17
ER

PT J
AU Rizzoli, R
   Kraenzlin, M
   Krieg, MA
   Mellinghoff, HU
   Lamy, O
   Lippuner, K
AF Rizzoli, Rene
   Kraenzlin, Marius
   Krieg, Marc Antoine
   Mellinghoff, Hans Ulrich
   Lamy, Olivier
   Lippuner, Kurt
TI Indications to teriparatide treatment in patients with osteoporosis
SO SWISS MEDICAL WEEKLY
LA English
DT Article
DE osteoporosis; fracture; risk; treatment; glucocorticoids;
   bisphosphonates
ID BONE MINERAL DENSITY; VERTEBRAL FRACTURE RISK; PARATHYROID HORMONE 1 34;
   POSTMENOPAUSAL WOMEN; ZOLEDRONIC ACID; NONVERTEBRAL FRACTURES;
   RANDOMIZED TRIAL; DOUBLE BLIND; ALENDRONATE; REDUCTION
AB To prevent osteoporotic fracture occurrence, a variety of treatment regimens with different mechanisms of action is available. The antiresorptive bisphosphonate drugs are currently the most commonly prescribed agents in the management of patients with osteoporosis. The recombinant amino terminal fragment of human parathyroid hormone (Teriparatide) is a bone anabolic agent which reduces fracture risk by increasing bone mass and improving bone microarchitecture. Teriparatide treatment reduces vertebral and non vertebral fracture risk markedly in women and men with idiopathic osteoporosis, or with glucocorticoid induced osteoporosis. Teriparatide should thus be considered as first line treatment for postmenopausal women and for men with severe osteoporosis.
C1 [Rizzoli, Rene] Univ Hosp Geneva, Serv Bone Dis, Dept Rehabil & Geriatr, CH 1211 Geneva, Switzerland.
   [Rizzoli, Rene] Fac Med Geneva, Geneva, Switzerland.
   [Kraenzlin, Marius] Univ Basel Hosp, Div Endocrinol Diabet & Clin Nutr, Basel, Switzerland.
   [Krieg, Marc Antoine] CHU Vaudois, Dept Muskuloskeletal Med, Lausanne, Switzerland.
   [Mellinghoff, Hans Ulrich] Kantonsspital St Gallen, Div Endocrinoloy Diabet & Osteol, Dept Med 1, St Gallen, Switzerland.
   [Lamy, Olivier] Univ Hosp Ctr, Dept Internal Med, Lausanne, Switzerland.
   [Lippuner, Kurt] Univ Hosp Bern, Osteoporosis Policlin, Inselspital, Bern, Switzerland.
   [Lippuner, Kurt] Univ Bern, CH 3012 Bern, Switzerland.
C3 University of Geneva; University of Geneva; University of Basel;
   University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV);
   Kantonsspital St. Gallen; University of Bern; University Hospital of
   Bern; University of Bern
RP Rizzoli, R (通讯作者)，Univ Hosp Geneva, Serv Bone Dis, Dept Rehabil & Geriatr, CH 1211 Geneva, Switzerland.
EM rene.rizzoli@unige.ch
RI Lamy, Olivier/E 5512 2013
OI Lippuner, Kurt/0000 0002 7195 3779
FU Eli Lilly company
FX This paper is based on discussions held during a meeting sponsored by
   the Eli Lilly company. None of the authors have received any financial
   support or paid fee for the writing of this review.
CR Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Boonen S, 2008, J CLIN ENDOCR METAB, V93, P852, DOI 10.1210/jc.2007 0711
   Cauley JA, 2007, JAMA J AM MED ASSOC, V298, P2761, DOI 10.1001/jama.298.23.2761
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Compston J, 2010, NAT REV RHEUMATOL, V6, P82, DOI 10.1038/nrrheum.2009.259
   Cosman F, 2011, J BONE MINER RES, V26, P503, DOI 10.1002/jbmr.238
   Cummings SR, 2002, JAMA J AM MED ASSOC, V288, P1889, DOI 10.1001/jama.288.15.1889
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Deal C, 2005, J BONE MINER RES, V20, P1905, DOI 10.1359/JBMR.050714
   Delmas PD, 2003, BONE, V33, P522, DOI 10.1016/S8756 3282(03)00241 2
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Finkelstein JS, 2010, J CLIN ENDOCR METAB, V95, P1838, DOI 10.1210/jc.2009 1703
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Johnell O, 2005, J BONE MINER RES, V20, P1185, DOI 10.1359/JBMR.050304
   Kanis JA, 2008, OSTEOPOROSIS INT, V19, P385, DOI 10.1007/s00198 007 0543 5
   Kanis JA, 2004, BONE, V35, P375, DOI 10.1016/j.bone.2004.03.024
   Kanis JA, 2001, OSTEOPOROSIS INT, V12, P989, DOI 10.1007/s001980170006
   Klotzbuecher CM, 2000, J BONE MINER RES, V15, P721, DOI 10.1359/jbmr.2000.15.4.721
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Lindsay R, 2004, ARCH INTERN MED, V164, P2024, DOI 10.1001/archinte.164.18.2024
   Lindsay R, 2001, JAMA J AM MED ASSOC, V285, P320, DOI 10.1001/jama.285.3.320
   Lippuner K, 2010, OSTEOPOROSIS INT, V21, P381, DOI 10.1007/s00198 009 0975 1
   Lippuner K, 2009, OSTEOPOROSIS INT, V20, P1131, DOI 10.1007/s00198 008 0779 8
   Lundkvist J, 2006, OSTEOPOROSIS INT, V17, P201, DOI 10.1007/s00198 005 1959 4
   Lunt M, 2003, BONE, V33, P505, DOI 10.1016/S8756 3282(03)00248 5
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nevitt MC, 2006, OSTEOPOROSIS INT, V17, P1630, DOI 10.1007/s00198 006 0177 z
   Nevitt MC, 1999, BONE, V25, P613, DOI 10.1016/S8756 3282(99)00202 1
   Obermayer Pietsch BM, 2008, J BONE MINER RES, V23, P1591, DOI 10.1359/JBMR.080506
   Prince R, 2005, J BONE MINER RES, V20, P1507, DOI 10.1359/JBMR.050501
   Puisto V, 2011, OSTEOPOROSIS INT, V22, P63, DOI 10.1007/s00198 010 1195 4
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Rizzoli R, 2011, QJM INT J MED, V104, P281, DOI 10.1093/qjmed/hcq259
   Rizzoli R, 2009, CURR MED RES OPIN, V25, P2373, DOI 10.1185/03007990903169262
   Roux C, 2007, OSTEOPOROSIS INT, V18, P1617, DOI 10.1007/s00198 007 0413 1
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Saag KG, 2009, ARTHRITIS RHEUM US, V60, P3346, DOI 10.1002/art.24879
   Silverman SL, 2008, J BONE MINER RES, V23, P1923, DOI 10.1359/JBMR.080710
   Siris ES, 2007, OSTEOPOROSIS INT, V18, P761, DOI 10.1007/s00198 006 0306 8
NR 47
TC 10
Z9 10
U1 0
U2 2
PU E M H SWISS MEDICAL PUBLISHERS LTD
PI MUTTENZ
PA FARNSBURGERSTR 8, CH 4132 MUTTENZ, SWITZERLAND
SN 1424 7860
EI 1424 3997
J9 SWISS MED WKLY
JI Swiss Med. Wkly.
PD NOV 7
PY 2011
VL 141
AR w13297
DI 10.4414/smw.2011.13297
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 844EU
UT WOS:000296731300001
PM 22057669
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Qin, QH
   Wang, YN
AF Qin, Qing Hua
   Wang, Ya Nan
TI A mathematical model of cortical bone remodeling at cellular level under
   mechanical stimulus
SO ACTA MECHANICA SINICA
LA English
DT Article
DE Cortical bone remodeling; Cell population dynamics; Mechanotransduction;
   Mechanosensitivity; Bone fracture energy; Bone mineral content
ID PARATHYROID HORMONE; NITRIC OXIDE; BIOMECHANICAL STRESS; GAP JUNCTIONS;
   FLUID FLOW; CELLS; RECEPTOR; MECHANOTRANSDUCTION; OSTEOCYTES; LIGAND
AB A bone cell population dynamics model for cortical bone remodeling under mechanical stimulus is developed in this paper. The external experiments extracted from the literature which have not been used in the creation of the model are used to test the validity of the model. Not only can the model compare reasonably well with these experimental results such as the increase percentage of final values of bone mineral content (BMC) and bone fracture energy (BFE) among different loading schemes (which proves the validity of the model), but also predict the realtime development pattern of BMC and BFE, as well as the dynamics of osteoblasts (OBA), osteoclasts (OCA), nitric oxide (NO) and prostaglandin E 2 (PGE(2)) for each loading scheme, which can hardly be monitored through experiment. In conclusion, the model is the first of its kind that is able to provide an insight into the quantitative mechanism of bone remodeling at cellular level by which bone cells are activated by mechanical stimulus in order to start resorption/formation of bone mass. More importantly, this model has laid a solid foundation based on which future work such as systemic control theory analysis of bone remodeling under mechanical stimulus can be investigated. The to be identified control mechanism will help to develop effective drugs and combined nonpharmacological therapies to combat bone loss pathologies. Also this deeper understanding of how mechanical forces quantitatively interact with skeletal tissue is essential for the generation of bone tissue for tissue replacement purposes in tissue engineering.
C1 [Qin, Qing Hua; Wang, Ya Nan] Australian Natl Univ, Res Sch Engn, Canberra, ACT 0200, Australia.
C3 Australian National University
RP Qin, QH (通讯作者)，Australian Natl Univ, Res Sch Engn, GPO Box 4, Canberra, ACT 0200, Australia.
EM qinghua.qin@anu.edu.au
RI Qin, Qinghua/A 4845 2008
OI Qin, Qinghua/0000 0003 0948 784X
CR Ajubi NE, 1996, BIOCHEM BIOPH RES CO, V225, P62, DOI 10.1006/bbrc.1996.1131
   Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254
   Alon U., 2007, INTRO SYSTEMS BIOL
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   ASCENZI A, 1967, ANAT RECORD, V158, P375, DOI 10.1002/ar.1091580403
   ASCENZI A, 1968, ANAT REC, V161, P377, DOI 10.1002/ar.1091610309
   Bacabac RG, 2004, BIOCHEM BIOPH RES CO, V315, P823, DOI 10.1016/j.bbrc.2004.01.138
   Bakker AD, 2001, J BIOMECH, V34, P671, DOI 10.1016/S0021 9290(00)00231 1
   Bass SL, 2002, J BONE MINER RES, V17, P2274, DOI 10.1359/jbmr.2002.17.12.2274
   Bergmann G., 2003, HIP JOINT FORCE MEAS
   BONEWALD LF, 1994, J CELL BIOCHEM, V55, P350, DOI 10.1002/jcb.240550312
   Burger EH, 1999, FASEB J, V13, pS101, DOI 10.1096/fasebj.13.9001.s101
   Burr DB, 2002, BONE, V30, P781, DOI 10.1016/S8756 3282(02)00707 X
   Burr DB, 2001, J BONE MINER RES, V16, P157, DOI 10.1359/jbmr.2001.16.1.157
   DOTY SB, 1981, CALCIFIED TISSUE INT, V33, P509, DOI 10.1007/BF02409482
   Ducher G, 2005, CAN J APPL PHYSIOL, V30, P3, DOI 10.1139/h05 101
   Fan X, 2004, ENDOCRINOLOGY, V145, P751, DOI 10.1210/en.2003 0726
   Frost H.M., 1963, BONE REMODELLING DYN, V59
   Frost HM., 1986, Intermediary Organization of the Skeleton
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hill AV, 1910, J PHYSIOL LONDON, V40, P389
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Klein Nulend J, 2005, PATHOL BIOL, V53, P576, DOI 10.1016/j.patbio.2004.12.005
   KLEINNULEND J, 1995, FASEB J, V9, P441, DOI 10.1096/fasebj.9.5.7896017
   Komarova SV, 2005, ENDOCRINOLOGY, V146, P3589, DOI 10.1210/en.2004 1642
   Komarova SV, 2003, BONE, V33, P206, DOI 10.1016/S8756 3282(03)00157 1
   Kroll MH, 2000, B MATH BIOL, V62, P163, DOI 10.1006/bulm.1999.0146
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Li I, 2007, DENT MATER, V23, P1073, DOI 10.1016/j.dental.2006.10.004
   Machwate M, 2001, MOL PHARMACOL, V60, P36, DOI 10.1124/mol.60.1.36
   Maldonado S., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P15
   Maldonado Solvey, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P3154
   Mullender M, 2004, MED BIOL ENG COMPUT, V42, P14, DOI 10.1007/BF02351006
   MULLENDER MG, 1994, J BIOMECH, V27, P1389, DOI 10.1016/0021 9290(94)90049 3
   Nijweide P.J., 2002, PRINCIPLES BONE BIOL
   Noble BS, 2003, AM J PHYSIOL CELL PH, V284, pC934, DOI 10.1152/ajpcell.00234.2002
   PARFITT AM, 1977, CLIN ORTHOP RELAT R, P236
   Pivonka P, 2008, BONE, V43, P249, DOI 10.1016/j.bone.2008.03.025
   Potter LK, 2005, BONE, V37, P159, DOI 10.1016/j.bone.2005.04.011
   Qin QH, 2005, BIOMATERIALS, V26, P6798, DOI 10.1016/j.biomaterials.2005.03.042
   Qin QH, 2004, INT J SOLIDS STRUCT, V41, P2447, DOI 10.1016/j.ijsolstr.2003.12.026
   Rattanakul C, 2003, BIOSYSTEMS, V70, P55, DOI 10.1016/S0303 2647(03)00040 6
   RIGGS CM, 1993, ANAT EMBRYOL, V187, P231
   Robling AG, 2002, J BONE MINER RES, V17, P1545, DOI 10.1359/jbmr.2002.17.8.1545
   Robling AG, 2001, J EXP BIOL, V204, P3389
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Rubin C, 2001, FASEB J, V15, P2225, DOI 10.1096/fj.01 0166com
   Ruimerman R, 2005, J BIOMECH, V38, P931, DOI 10.1016/j.jbiomech.2004.03.037
   Ruimerman R., 2001, COMPUT METHOD BIOMEC, V4, P433, DOI DOI 10.1080/10255840108908019
   Saxon LK, 2005, BONE, V36, P454, DOI 10.1016/j.bone.2004.12.001
   Schneider V, 1995, ACTA ASTRONAUT, V36, P463, DOI 10.1016/0094 5765(95)00131 X
   Schriefer JL, 2005, J BIOMECH, V38, P1838, DOI 10.1016/j.jbiomech.2004.08.017
   Shapiro F, 1997, CALCIFIED TISSUE INT, V61, P285, DOI 10.1007/s002239900337
   Tanaka E, 2000, JSME INT J C MECH SY, V43, P830, DOI 10.1299/jsmec.43.830
   Tate MLK, 2000, J EXP BIOL, V203, P2737
   TURNER CH, 1994, FASEB J, V8, P875, DOI 10.1096/fasebj.8.11.8070637
   Wang Yanan, 2009, Molecular & Cellular Biomechanics, V6, P101
   Warden SJ, 2004, BONE, V34, P261, DOI 10.1016/j.bone.2003.11.011
   WEINANS H, 1992, J BIOMECH, V25, P1425, DOI 10.1016/0021 9290(92)90056 7
   WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021 9290(94)90010 8
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zernicke R, 2006, APPL PHYSIOL NUTR ME, V31, P655, DOI 10.1139/h06 051
NR 64
TC 7
Z9 8
U1 0
U2 22
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 0567 7718
EI 1614 3116
J9 ACTA MECH SINICA PRC
JI Acta Mech. Sin.
PD DEC
PY 2012
VL 28
IS 6
BP 1678
EP 1692
DI 10.1007/s10409 012 0154 z
PG 15
WC Engineering, Mechanical; Mechanics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Mechanics
GA 064GK
UT WOS:000313061200019
DA 2025 08 17
ER

PT J
AU Shim, JH
   Greenblatt, MB
   Singh, A
   Brady, N
   Hu, D
   Drapp, R
   Ogawa, W
   Kasuga, M
   Noda, T
   Yang, SH
   Lee, SK
   Rebe, VI
   Glimcher, LH
AF Shim, Jae Hyuck
   Greenblatt, Matthew B.
   Singh, Anju
   Brady, Nicholas
   Hu, Dorothy
   Drapp, Rebecca
   Ogawa, Wataru
   Kasuga, Masato
   Noda, Tetsuo
   Yang, Sang Hwa
   Lee, Sang Kyou
   Rebe, Vivienne I.
   Glimcher, Laurie H.
TI Administration of BMP2/7 in utero partially reverses Rubinstein Taybi
   syndrome like skeletal defects induced by Pdk1 or Cbp
   mutations in mice
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID GROWTH FACTOR I; PROTEIN KINASE AKT/PKB; OSTEOBLAST DIFFERENTIATION;
   CLEIDOCRANIAL DYSPLASIA; REGULATORY TARGET; BONE DEVELOPMENT;
   COACTIVATOR CBP; CELL SIZE; CREB; TRANSCRIPTION
AB Mutations in the coactivator CREB binding protein (CBP) are a major cause of the human skeletal dysplasia Rubinstein Taybi syndrome (RTS); however, the mechanism by which these mutations affect skeletal mineralization and patterning is unknown. Here, we report the identification of 3 phosphoinositide dependent kinase 1 (PDK1) as a key regulator of CBP activity and demonstrate that its functions map to both osteoprogenitor cells and mature osteoblasts. In osteoblasts, PDK1 activated the CREB/CBP complex, which in turn controlled runt related transcription factor 2 (RUNX2) activation and expression of bone morphogenetic protein 2 (BMP2). These pathways also operated in vivo, as evidenced by recapitulation of RTS spectrum phenotypes with osteoblast specific Pdk1 deletion in mice (Pdk1(osx) mice) and by the genetic interactions observed in mice heterozygous for both osteoblast specific Pdk1 deletion and either Runx2 or Creb deletion. Finally, treatment of Pdk1(osx) and Cbp(+/ ) embryos with BMPs in utero partially reversed their skeletal anomalies at birth. These findings illustrate the in vivo function of the PDK1 AKT CREB/CBP pathway in bone formation and provide proof of principle for in utero growth factor supplementation as a potential therapy for skeletal dysplasias.
C1 [Shim, Jae Hyuck; Greenblatt, Matthew B.; Singh, Anju; Brady, Nicholas; Hu, Dorothy; Drapp, Rebecca; Glimcher, Laurie H.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
   [Greenblatt, Matthew B.; Glimcher, Laurie H.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
   [Ogawa, Wataru] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Diabet & Endocrinol, Kobe, Hyogo 657, Japan.
   [Kasuga, Masato] Natl Ctr Global Hlth & Med, Res Inst, Shinjuku Ku, Tokyo, Japan.
   [Noda, Tetsuo] Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Tokyo 170, Japan.
   [Yang, Sang Hwa; Lee, Sang Kyou] Yonsei Univ, Dept Biotechnol, Coll Life Sci & Biotechnol, Nanoparticles Ctr Inflammatory Response Modulat, Seoul 120749, South Korea.
   [Rebe, Vivienne I.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA.
C3 Harvard University; Harvard T.H. Chan School of Public Health; Harvard
   University; Harvard Medical School; Kobe University; Japan Institute for
   Health Security (JIHS); National Center for Global Health & Medicine  
   Japan; Japanese Foundation for Cancer Research; Yonsei University;
   University of Texas System; University of Texas Health Science Center at
   San Antonio
RP Glimcher, LH (通讯作者)，FXB Rm 205,651 Huntington Ave, Boston, MA 02115 USA.
EM jshim@hsph.harvard.edu; lglimche@hsph.harvard.edu
RI Yang, Sanghwa/HPF 1021 2023; OGAWA, Wataru/AAQ 9586 2020; Noda,
   Tetsuo/B 1667 2016; Brady, Nicholas/AAB 2888 2019
OI Shim, Jae Hyuck/0000 0002 4947 3293; Rebel,
   Vivienne/0000 0002 3862 3903; Yang, Sanghwa/0000 0002 4038 0947;
   Glimcher, Laurie/0000 0001 9537 3456; Brady,
   Nicholas/0000 0002 2928 0232; Lee, Sang Kyou/0000 0002 3272 9264
FU NIH [HD055601]; Arthritis Foundation
FX We would like to thank Sankar Ghosh and Sung Gyoo Park (Columbia
   University, New York, New York, USA) for providing Pdk1 foxed mice;
   Dorien J.M. Peters, Rachel H. Giles, Michael L. Cunningham, Ann Hwee
   Lee, Marc Wein, Henry Kronenberg, Dallas Jones, and Antonios Aliprantis
   for helpful discussions; and Chantel Lester, Heather De Rivera, Bella
   Hu, and Kirsten Sigrist for technical support. We also thank the many
   individuals who provided valuable reagents. This work was supported by
   NIH grant HD055601 (to L.H. Glimcher); J. H. Shim was supported by an
   Arthritis Foundation postdoctoral fellowship.
CR Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967
   Akune T, 2002, J CELL BIOL, V159, P147, DOI 10.1083/jcb.200204046
   Alarcón JM, 2004, NEURON, V42, P947, DOI 10.1016/j.neuron.2004.05.021
   Barco A, 2005, NEURON, V48, P123, DOI 10.1016/j.neuron.2005.09.005
   Bartsch O, 2010, AM J MED GENET A, V152A, P181, DOI 10.1002/ajmg.a.33153
   Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534 5807(04)00058 9
   Bleckmann SC, 2002, MOL CELL BIOL, V22, P1919, DOI 10.1128/MCB.22.6.1919 1925.2002
   Bloch Zupan A, 2007, AM J MED GENET A, V143A, P570, DOI 10.1002/ajmg.a.31622
   Borovecki F, 2004, NEPHRON EXP NEPHROL, V97, P26, DOI 10.1159/000077595
   BREUNING MH, 1993, AM J HUM GENET, V52, P249
   CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843
   Chan CKF, 2009, NATURE, V457, P490, DOI 10.1038/nature07547
   Choi KY, 2005, DEV DYNAM, V233, P115, DOI 10.1002/dvdy.20323
   CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0
   Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377
   Ferron M, 2010, CELL, V142, P296, DOI 10.1016/j.cell.2010.06.003
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Fulzele K, 2010, CELL, V142, P309, DOI 10.1016/j.cell.2010.06.002
   Gaide O, 2003, NAT MED, V9, P614, DOI 10.1038/nm861
   Ghosh Choudhury N, 2001, BIOCHEM BIOPH RES CO, V286, P101, DOI 10.1006/bbrc.2001.5351
   Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168 9525(98)01438 3
   Golan I, 2002, Orthod Craniofac Res, V5, P243, DOI 10.1034/j.1600 0544.2002.02206.x
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   HENNEKAM RCM, 1990, AM J MED GENET, P56
   HENNEKAM RCM, 1993, AM J HUM GENET, V52, P255
   Hildebrand TOR, 1997, Comput Methods Biomech Biomed Engin, V1, P15, DOI 10.1080/01495739708936692
   Inoue H, 2006, CELL METAB, V3, P267, DOI 10.1016/j.cmet.2006.02.009
   Israel DI, 1996, GROWTH FACTORS, V13, P291, DOI 10.3109/08977199609003229
   Jones DC, 2006, SCIENCE, V312, P1223, DOI 10.1126/science.1126313
   Kato S, 2007, BIOCHEM BIOPH RES CO, V354, P1061, DOI 10.1016/j.bbrc.2007.01.094
   Kawai M, 2009, PEDIATR NEPHROL, V24, P1277, DOI 10.1007/s00467 008 1040 6
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Kung AL, 2000, GENE DEV, V14, P272
   Langlois JA, 1998, J CLIN ENDOCR METAB, V83, P4257, DOI 10.1210/jc.83.12.4257
   Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387
   LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023
   Li XY, 2011, BIOCHEM BIOPH RES CO, V404, P711, DOI 10.1016/j.bbrc.2010.12.048
   LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092 8674(05)80084 4
   MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306
   Mukherjee A, 2010, MOL CELL BIOL, V30, P1018, DOI 10.1128/MCB.01401 09
   Mukherjee A, 2009, J CELL SCI, V122, P716, DOI 10.1242/jcs.042770
   Mundlos S, 1999, J MED GENET, V36, P177
   Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092 8674(00)80260 3
   Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092 8674(00)80119 1
   Ogata N, 2000, J CLIN INVEST, V105, P935, DOI 10.1172/JCI9017
   Oike Y, 1999, HUM MOL GENET, V8, P387, DOI 10.1093/hmg/8.3.387
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403
   Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523
   PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Roelfsema JH, 2005, AM J HUM GENET, V76, P572, DOI 10.1086/429130
   RUBINSTEIN JH, 1963, AM J DIS CHILD, V105, P588, DOI 10.1001/archpedi.1963.02080040590010
   Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481
   Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605
   Stevens CA, 1997, AM J MED GENET, V72, P188, DOI 10.1002/(SICI)1096 8628(19971017)72:2<188::AID AJMG12>3.0.CO;2 J
   Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Turgeman G, 2002, J CELL BIOCHEM, V86, P461, DOI 10.1002/jcb.10231
   Turner CH, 2000, J BONE MINER RES, V15, P1126, DOI 10.1359/jbmr.2000.15.6.1126
   Wang J, 2010, DEV CELL, V18, P114, DOI 10.1016/j.devcel.2009.10.023
   Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960 9822(00)00441 3
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Zhang RR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020780
NR 65
TC 17
Z9 21
U1 0
U2 6
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021 9738
EI 1558 8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JAN
PY 2012
VL 122
IS 1
BP 91
EP 106
DI 10.1172/JCI59466
PG 16
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 871WW
UT WOS:000298769400016
PM 22133875
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Huang, Y
   Chen, MW
   Shen, YD
   Shen, XK
   Li, MH
   Li, YA
   Liu, Y
   Cai, KY
   Luo, Z
   Hu, Y
AF Huang, Yan
   Chen, Maowen
   Shen, Yiding
   Shen, Xinkun
   Li, Menghuan
   Li, Yanan
   Liu, Yuan
   Cai, Kaiyong
   Luo, Zhong
   Hu, Yan
TI Bone targeting cell membrane engineered CaCO3 based nanoparticles
   restore local bone homeostasis for microenvironment responsive
   osteoporosis treatment
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE Nanomaterials; Bone  targeting; Osteoclast; Osteoporosis
ID SYNERGISTIC THERAPY; DELIVERY
AB Osteoporosis is a common bone disease characterized by the systemic disruption of hone homeostasis, where the imbalance between bone resorption and formation causes deterioration of bone structure and bone mass loss. Targeted restoration of bone hemostasis has thus become a promising strategy for osteoporosis treatment. For this purpose, we report a bone targeted nanoformulation based on CaCO3 nanomaterials, which could be acti vated in the acidic osteoporotic microenvironment and cooperatively regulate the activity of osteoclasts and osteoblasts to reverse bone deterioration. Herein, a clinical antiosteoporosis drug & beta; estradiol (E2) is first bio mineralized using CaCO3 to form physiologically stable nanocores. Meanwhile, azido groups are introduced onto MC3T3 E1 cells through incubation with AC4ManNAz. The azido tagged MC3T3 E1 cell membranes are extracted for the camouflaging of the CaCO3@E2 nanocores to enhance their in vivo stability and availability, while also enabling the surface modification of bone targeting dibenzocyclooctyne tagged alendronate moieties via copper free click reaction. After the selective deposition into acidic osteoporotic bone tissues, the CaCO3@E2 cores would be spontaneously degraded to release E2 and Ca2+ ions, which would systematically inhibit the activity of osteoclasts while promoting osteoblast mediated new bone formation, eventually ameliorating the osteoporosis symptoms. This study offers an effective approach for osteoporosis treatment in the clinics.
C1 [Huang, Yan; Chen, Maowen; Liu, Yuan; Cai, Kaiyong; Hu, Yan] Chongqing Univ, Coll Bioengn, Key Lab Biorheol Sci & Technol, Minist Educ, Chongqing 400044, Peoples R China.
   [Shen, Yiding; Shen, Xinkun; Li, Yanan] Wenzhou Med Univ, Ruian Peoples Hosp, Affiliated Hosp 3, Wenzhou 325016, Peoples R China.
   [Li, Menghuan; Luo, Zhong] Chongqing Univ, Sch Life Sci, Chongqing 400044, Peoples R China.
C3 Chongqing University; Wenzhou Medical University; Chongqing University
RP Hu, Y (通讯作者)，Chongqing Univ, Coll Bioengn, Key Lab Biorheol Sci & Technol, Minist Educ, Chongqing 400044, Peoples R China.; Shen, XK (通讯作者)，Wenzhou Med Univ, Ruian Peoples Hosp, Affiliated Hosp 3, Wenzhou 325016, Peoples R China.; Luo, Z (通讯作者)，Chongqing Univ, Sch Life Sci, Chongqing 400044, Peoples R China.
EM shenxinkun123@wmu.edu.cn; luozhong918@cqu.edu.cn; huyan303@cqu.edu.cn
RI Cai, Kaiyong/G 1233 2011
OI Cai, Kaiyong/0000 0001 9029 680X
FU National Key Research and Development Project of China [2022YFB3804400];
   Chongqing Science and Technology Commission [cstc2021jcyj cxttX0002,
   CSTB2022NSCQMSX0488]; National Natural Science Foundation of China
   [11832008, 32122048, 51825302, 92059107]; Chongqing Outstanding Young
   Talent Supporting Program [cstc2021ycjh  bgzxm0124]
FX This work was financially supported by National Key Research and
   Development Project of China (2022YFB3804400) , Chongqing Science and
   Technology Commission (cstc2021jcyj cxttX0002, CSTB2022NSCQMSX0488) ,
   National Natural Science Foundation of China (11832008, 32122048,
   51825302 and 92059107) , Chongqing Outstanding Young Talent Supporting
   Program (cstc2021ycjh  bgzxm0124) .
CR Arora S, 2018, IMMUNOBIOLOGY, V223, P383, DOI 10.1016/j.imbio.2017.11.001
   Binevski PV, 2019, COLLOID SURFACE B, V181, P437, DOI 10.1016/j.colsurfb.2019.05.077
   Cao HQ, 2016, ACS NANO, V10, P7738, DOI 10.1021/acsnano.6b03148
   Chen QC, 2018, ACS APPL MATER INTER, V10, P23700, DOI 10.1021/acsami.8b08606
   Cheng C, 2020, ANNU REV MED, V71, P277, DOI 10.1146/annurev med 052218 020620
   Dong ZL, 2018, J AM CHEM SOC, V140, P2165, DOI 10.1021/jacs.7b11036
   Du LH, 2017, ACS NANO, V11, P8930, DOI 10.1021/acsnano.7b03226
   Fang RH, 2018, ADV MATER, V30, DOI 10.1002/adma.201706759
   Filippini A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184525
   Guo YY, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 00976 4
   Hu CMJ, 2011, P NATL ACAD SCI USA, V108, P10980, DOI 10.1073/pnas.1106634108
   Huang YZ, 2020, CHEM ENG J, V395, DOI 10.1016/j.cej.2020.125098
   Kuyper CL, 2006, J AM CHEM SOC, V128, P3233, DOI 10.1021/ja057349c
   Li JC, 2018, ACS NANO, V12, P8520, DOI 10.1021/acsnano.8b04066
   Li YA, 2022, ACS NANO, V16, P3965, DOI 10.1021/acsnano.1c09480
   Li YL, 2021, BIOMATERIALS, V277, DOI 10.1016/j.biomaterials.2021.121080
   Lin XF, 2020, J AM CHEM SOC, V142, P17543, DOI 10.1021/jacs.0c07309
   Liu J, 2019, BIOMATER SCI UK, V7, P1463, DOI 10.1039/c8bm01611a
   Liu Y, 2019, NANO MICRO LETT, V11, DOI 10.1007/s40820 019 0330 9
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Mora Raimundo P, 2021, ADV SCI, V8, DOI 10.1002/advs.202101107
   Qiao JN, 2020, THERANOSTICS, V10, P5305, DOI 10.7150/thno.42445
   Ryu TK, 2016, J CONTROL RELEASE, V232, P152, DOI 10.1016/j.jconrel.2016.04.025
   Song SS, 2022, PHARMACOL THERAPEUT, V237, DOI 10.1016/j.pharmthera.2022.108168
   Tan C, 2022, ADV COLLOID INTERFAC, V309, DOI 10.1016/j.cis.2022.102791
   Tester CC, 2011, CRYSTENGCOMM, V13, P3975, DOI 10.1039/c1ce05153a
   Trushina DB, 2022, MATER TODAY ADV, V14, DOI 10.1016/j.mtadv.2022.100214
   Ueno Y, 2005, J CONTROL RELEASE, V103, P93, DOI 10.1016/j.jconrel.2004.11.015
   Veis DJ, 2023, ANNU REV PATHOL MECH, V18, P257, DOI 10.1146/annurev pathmechdis 031521 040919
   Wang JW, 2020, THERANOSTICS, V10, P8591, DOI 10.7150/thno.45142
   Wang LL, 2011, INT IMMUNOPHARMACOL, V11, P675, DOI 10.1016/j.intimp.2011.01.010
   Wu HH, 2019, J CONTROL RELEASE, V294, P102, DOI 10.1016/j.jconrel.2018.12.019
   Xiong K, 2016, ADV MATER, V28, P7929, DOI 10.1002/adma.201601643
   Xu CY, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201808146
   Ye CY, 2022, ADV HEALTHC MATER, V11, DOI 10.1002/adhm.202200787
   Yu B, 2016, TRENDS MOL MED, V22, P641, DOI 10.1016/j.molmed.2016.06.002
   Zhao Y, 2015, ANGEW CHEM INT EDIT, V54, P919, DOI 10.1002/anie.201408510
   Zheng LM, 2022, BIOACT MATER, V14, P250, DOI 10.1016/j.bioactmat.2021.11.012
   Zhou X, 2021, NANO LETT, V21, P7998, DOI 10.1021/acs.nanolett.1c02150
NR 39
TC 12
Z9 12
U1 13
U2 66
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385 8947
EI 1873 3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD AUG 15
PY 2023
VL 470
AR 144145
DI 10.1016/j.cej.2023.144145
EA JUN 2023
PG 12
WC Engineering, Environmental; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA N7XW4
UT WOS:001039107100001
DA 2025 08 17
ER

PT J
AU Yang, W
   Levine, AC
AF Yang, Wei
   Levine, Alice C.
TI Androgens and Prostate Cancer Bone Metastases: Effects on Both the Seed
   and the Soil
SO ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
LA English
DT Article
DE Androgens; Androgen receptor; Prostate cancer; Bone metastases
ID ENDOTHELIAL GROWTH FACTOR; EPITHELIAL MESENCHYMAL TRANSITION; TGF BETA;
   OSTEOBLASTIC LINEAGE; TUMOR PROGRESSION; STROMAL CELLS; SEX STEROIDS;
   KAPPA B; RECEPTOR; EXPRESSION
AB Androgens are essential for normal prostate development and are necessary, but not sufficient, for the development of prostate cancer (PCa). Androgen deprivation therapy has long been the mainstay of treatment for PCa bone metastases, providing palliation of symptoms in the majority of patients, followed by relapse and progression. The majority of published preclinical studies demonstrate a stimulatory effect of androgens and androgen receptor signaling on the multistep process of PCa bone metastases, including androgenic promotion of local PCa growth, angiogenesis, invasion, bone targeting, stimulation of PCa growth factors that enhance osteoclastogenesis, and enhancement of Wnt signaling in osteoblasts.
C1 [Yang, Wei; Levine, Alice C.] Mt Sinai Sch Med, Div Endocrinol Diabet & Bone Dis, Dept Med, New York, NY 10029 USA.
C3 Icahn School of Medicine at Mount Sinai
RP Levine, AC (通讯作者)，Mt Sinai Sch Med, Div Endocrinol Diabet & Bone Dis, Dept Med, 1 Gustave L Levy Pl,Box 1055, New York, NY 10029 USA.
EM alice.levine@mountsinai.org
OI Levine, Alice/0000 0002 0634 4133
CR ABRAMS HL, 1950, CANCER, V3, P74, DOI 10.1002/1097 0142(1950)3:1<74::AID CNCR2820030111>3.0.CO;2 7
   Akech J, 2010, ONCOGENE, V29, P811, DOI 10.1038/onc.2009.389
   Angelucci A, 2008, ENDOCR RELAT CANCER, V15, P91, DOI 10.1677/ERC 07 0100
   Baniwal SK, 2009, MOL ENDOCRINOL, V23, P1203, DOI 10.1210/me.2008 0470
   Bruckheimer EM, 2001, ENDOCRINOLOGY, V142, P2419, DOI 10.1210/en.142.6.2419
   Cai JA, 2010, TRANSL ONCOL, V3, P195, DOI 10.1593/tlo.09328
   Cardillo MR, 2000, ANAL QUANT CYTOL, V22, P1
   Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972
   Chen G, 2006, CANCER AM CANCER SOC, V107, P289, DOI 10.1002/cncr.21978
   Contreras HR, 2010, UROL ONCOL SEMIN ORI, V28, P534, DOI 10.1016/j.urolonc.2009.03.018
   CRAWFORD ED, 1989, NEW ENGL J MED, V321, P419, DOI 10.1056/NEJM198908173210702
   Derynck R, 2007, NAT CELL BIOL, V9, P1000, DOI 10.1038/ncb434
   FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18
   FIDLER IJ, 1970, JNCI J NATL CANCER I, V45, P773
   FOLKMAN J, 1990, JNCI J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4
   Franck Lissbrant I, 1998, ENDOCRINOLOGY, V139, P451, DOI 10.1210/en.139.2.451
   Frenkel B, 2010, J CELL PHYSIOL, V224, P305, DOI 10.1002/jcp.22159
   GABBIANI G, 1972, J EXP MED, V135, P719, DOI 10.1084/jem.135.4.719
   Geoffroy V, 2002, MOL CELL BIOL, V22, P6222, DOI 10.1128/MCB.22.17.6222 6233.2002
   Gerdes MJ, 1998, ENDOCRINOLOGY, V139, P3569, DOI 10.1210/en.139.8.3569
   Gerdes MJ, 2004, PROSTATE, V58, P299, DOI 10.1002/pros.10327
   Godoy A, 2008, ENDOCRINOLOGY, V149, P2959, DOI 10.1210/en.2007 1078
   Graham TR, 2010, CANCER SCI, V101, P103, DOI 10.1111/j.1349 7006.2009.01356.x
   Gregory CA, 2005, ANN NY ACAD SCI, V1049, P97, DOI 10.1196/annals.1334.010
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Henshall SM, 2001, CANCER RES, V61, P423
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001
   Huggins C, 1941, CANCER RES, V1, P293
   Huggins C, 1941, ARCH SURG CHICAGO, V43, P209, DOI 10.1001/archsurg.1941.01210140043004
   IMPERATO.J, 1974, SCIENCE, V186, P1213, DOI 10.1126/science.186.4170.1213
   Isaacs JT, 2004, NAT MED, V10, P26, DOI 10.1038/nm0104 26
   JACOBS SC, 1983, UROLOGY, V21, P337, DOI 10.1016/0090 4295(83)90147 4
   Joseph IBJK, 1997, CLIN CANCER RES, V3, P2507
   Josson S, 2010, SEMIN CELL DEV BIOL, V21, P26, DOI 10.1016/j.semcdb.2009.11.016
   Käkönen SM, 2003, CANCER AM CANCER SOC, V97, P834, DOI 10.1002/cncr.11132
   Kang HY, 2002, J BIOL CHEM, V277, P43749, DOI 10.1074/jbc.M205603200
   Kang HY, 2001, P NATL ACAD SCI USA, V98, P3018, DOI 10.1073/pnas.061305498
   Kawano H, 2003, P NATL ACAD SCI USA, V100, P9416, DOI 10.1073/pnas.1533500100
   Kirschenbaum A, 1997, Urol Oncol, V3, P3, DOI 10.1016/S1078 1439(97)00001 X
   Krupski TL, 2004, CANCER AM CANCER SOC, V101, P541, DOI 10.1002/cncr.20388
   Levine AC, 1998, ENDOCRINOLOGY, V139, P4672, DOI 10.1210/en.139.11.4672
   Liu XH, 2007, CANCER RES, V67, P5747, DOI 10.1158/0008 5472.CAN 07 0478
   Liu YN, 2008, MOL CELL BIOL, V28, P7096, DOI 10.1128/MCB.00449 08
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008 5472.CAN 08 0249
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Notini AJ, 2007, J BONE MINER RES, V22, P347, DOI 10.1359/JBMR.061117
   Odero Marah VA, 2008, CELL RES, V18, P858, DOI 10.1038/cr.2008.84
   Paget S., LANCET, V1, P571, DOI DOI 10.1016/S0140 6736(00)49915 0
   Pawlowski JE, 2002, J BIOL CHEM, V277, P20702, DOI 10.1074/jbc.M200545200
   Rennebeck G, 2005, CANCER RES, V65, P11230, DOI 10.1158/0008 5472.CAN 05 2763
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Sabbota AL, 2010, CANCER RES, V70, P5558, DOI 10.1158/0008 5472.CAN 09 4416
   Salm SN, 2000, J CELL PHYSIOL, V184, P70, DOI 10.1002/(SICI)1097 4652(200007)184:1<70::AID JCP7>3.0.CO;2 U
   Shibata Y, 2004, ENDOCRINOLOGY, V145, P4507, DOI 10.1210/en.2004 0288
   Smith MR, 2005, J CLIN ONCOL, V23, P7897, DOI 10.1200/JCO.2004.00.6908
   Taichman RS, 2002, CANCER RES, V62, P1832
   Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008 5472.CAN 10 1040
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Tuxhorn JA, 2002, CANCER RES, V62, P3298
   Verras M, 2004, CANCER RES, V64, P8860, DOI 10.1158/0008 5472.CAN 04 2370
   Wang JH, 2006, CANCER METAST REV, V25, P573, DOI 10.1007/s10555 006 9019 x
   Warg X, 2007, J CELL BIOCHEM, V102, P571, DOI 10.1002/jcb.21491
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Widmark A, 2009, LANCET, V373, P301, DOI 10.1016/S0140 6736(08)61815 2
   Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
   Zhu ML, 2010, FASEB J, V24, P769, DOI 10.1096/fj.09 136994
   Zhu ML, 2008, ENDOCR RELAT CANCER, V15, P841, DOI 10.1677/ERC 08 0084
   [No title captured]
NR 72
TC 3
Z9 6
U1 0
U2 4
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0889 8529
EI 1558 4410
J9 ENDOCRIN METAB CLIN
JI Endocrinol. Metabol. Clin. North Amer.
PD SEP
PY 2011
VL 40
IS 3
BP 643
EP +
DI 10.1016/j.ecl.2011.05.001
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 829RN
UT WOS:000295602100015
PM 21889726
DA 2025 08 17
ER

PT J
AU Kong, DP
   Ye, C
   Zhang, CX
   Sun, XC
   Wang, FB
   Chen, R
   Xiao, GA
   He, SP
   Xu, JR
   Rao, XW
   Ai, JZ
   Gao, X
   Li, H
   Su, L
AF Kong, Depei
   Ye, Chen
   Zhang, Chenxi
   Sun, Xiaochen
   Wang, Fubo
   Chen, Rui
   Xiao, Guangan
   He, Shipeng
   Xu, Jianrong
   Rao, Xiwu
   Ai, Jianzhong
   Gao, Xu
   Li, Hong
   Su, Li
TI Procoxacin bidirectionally inhibits osteoblastic and osteoclastic
   activity in bone and suppresses bone metastasis of prostate cancer
SO JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
LA English
DT Article
DE Osteoblast; Osteoclast; Prostate cancer; Metastasis; Drug screening;
   Procoxacin; Drug target
ID 14 3 3 PROTEINS; CELLS; BINDING; GROWTH
AB Background Bone is the most common site of metastasis of prostate cancer (PCa). PCa invasion leads to a disruption of osteogenic osteolytic balance and causes abnormal bone formation. The interaction between PCa and bone stromal cells, especially osteoblasts (OB), is considered essential for the disease progression. However, drugs that effectively block the cancer bone interaction and regulate the osteogenic osteolytic balance remain undiscovered.Methods A reporter gene system was constructed to screen compounds that could inhibit PCa induced OB activation from 631 compounds. Then, the pharmacological effects of a candidate drug, Procoxacin (Pro), on OBs, osteoclasts (OCs) and cancer bone interaction were studied in cellular models. Intratibial inoculation, micro CT and histological analysis were used to explore the effect of Pro on osteogenic and osteolytic metastatic lesions. Bioinformatic analysis and experiments including qPCR, western blotting and ELISA assay were used to identify the effector molecules of Pro in the cancer bone microenvironment. Virtual screening, molecular docking, surface plasmon resonance assay and RNA knockdown were utilized to identify the drug target of Pro. Experiments including co IP, western blotting and immunofluorescence were performed to reveal the role of Pro binding to its target. Intracardiac inoculation metastasis model and survival analysis were used to investigate the therapeutic effect of Pro on metastatic cancer.Results Luciferase reporter gene consisted of Runx2 binding sequence, OSE2, and Alp promotor could sensitively reflect the intensity of PCa OB interaction. Pro best matched the screening criteria among 631 compounds in drug screening. Further study demonstrated that Pro effectively inhibited the PCa induced osteoblastic changes without killing OBs or PCa cells and directly killed OCs or suppressed osteoclastic functions at very low concentrations. Mechanism study revealed that Pro broke the feedback loop of TGF beta/C Raf/MAPK pathway by sandwiching into 14 3 3 zeta/C Raf complex and prevented its disassociation. Pro treatment alleviated both osteogenic and osteolytic lesions in PCa involved bones and reduced the number of metastases of PCa in vivo.Conclusions In summary, our study provides a drug screening strategy based on the cancer host microenvironment and demonstrates that Pro effectively inhibits both osteoblastic and osteoclastic lesions in PCa involved bones, which makes it a promising therapeutic agent for PCa bone metastasis.
C1 [Kong, Depei; Ai, Jianzhong; Li, Hong] Sichuan Univ, West China Hosp, Inst Urol, Dept Urol, 88 South Keyuan Rd, Chengdu 610093, Peoples R China.
   [Kong, Depei; Zhang, Chenxi; Sun, Xiaochen; He, Shipeng; Su, Li] Shanghai Univ, Inst Translat Med, 99 Shangda Rd, Shanghai 200444, Peoples R China.
   [Ye, Chen; Chen, Rui; Xiao, Guangan; Gao, Xu] Second Mil Med Univ, Changhai Hosp, Dept Urol, Shanghai 200433, Peoples R China.
   [Wang, Fubo] Guangxi Med Univ, Ctr Genom & Personalized Med, Guangxi Collaborat Innovat Ctr Genom & Personalize, Guangxi Key Lab Genom & Personalized Med, 22 Shuangyong Rd, Nanning 530021, Peoples R China.
   [Xu, Jianrong] Shanghai Univ Tradit Chinese Med, Acad Integrat Med, 1200 Cailun Rd, Shanghai 201203, Peoples R China.
   [Xu, Jianrong] Shanghai Jiao Tong Univ, Sch Med, Dept Pharmacol & Chem Biol, 280 South Chongqing Rd, Shanghai 200025, Peoples R China.
   [Rao, Xiwu] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Canc Inst, Dept Med Oncol, Shanghai 200021, Peoples R China.
C3 Sichuan University; Shanghai University; Naval Medical University;
   Guangxi Medical University; Shanghai University of Traditional Chinese
   Medicine; Shanghai Jiao Tong University; Shanghai University of
   Traditional Chinese Medicine
RP Ai, JZ; Li, H (通讯作者)，Sichuan Univ, West China Hosp, Inst Urol, Dept Urol, 88 South Keyuan Rd, Chengdu 610093, Peoples R China.; Su, L (通讯作者)，Shanghai Univ, Inst Translat Med, 99 Shangda Rd, Shanghai 200444, Peoples R China.; Gao, X (通讯作者)，Second Mil Med Univ, Changhai Hosp, Dept Urol, Shanghai 200433, Peoples R China.
EM jianzhong.ai@wchscu.cn; gaoxu.changhai@foxmail.com;
   lihonghxhx@scu.edu.cn; suli1020@shu.edu.cn
RI Su, Li/JTV 1337 2023; wang, fubo/I 4093 2014; YE, Chen/KFR 3858 2024;
   Chen, Rui/ACB 1562 2022
OI Chen, Rui/0000 0003 3728 2577; Su, Li/0000 0002 4556 6863
FU National Natural Science Foundation of China [81981340417]; 1.3.5
   project for disciplines of excellence, West China Hospital, Sichuan
   University [ZYGD18011]; China Postdoctoral Science Foundation
   [2021M692301]; Postdoctoral Research Foundation of Sichuan University
   [2022SCU12037]
FX This study is supported by the National Natural Science Foundation of
   China 81981340417 (to LS), 1.3.5 project for disciplines of excellence,
   West China Hospital, Sichuan University ZYGD18011 (to HL), China
   Postdoctoral Science Foundation 2021M692301 (to DPK), Postdoctoral
   Research Foundation of Sichuan University 2022SCU12037 (to DPK).
CR Balunas MJ, 2005, LIFE SCI, V78, P431, DOI 10.1016/j.lfs.2005.09.012
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Calla B, 2020, INSECT MOL BIOL, V29, P112, DOI 10.1111/imb.12612
   Cau Y, 2018, CURR MED CHEM, V25, P5, DOI 10.2174/0929867324666170426095015
   Choi YJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030710
   Croucher PI, 2016, NAT REV CANCER, V16, P373, DOI 10.1038/nrc.2016.44
   Desai MM, 2022, JAMA NETW OPEN, V5, DOI 10.1001/jamanetworkopen.2022.2246
   DRUZGALA P, 1991, J STEROID BIOCHEM, V38, P149, DOI 10.1016/0960 0760(91)90120 T
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Ebhardt HA., 2018, ACM T INTEL SYST TEC, V4, P13
   Erin N, 2020, DRUG RESIST UPDATE, V53, DOI 10.1016/j.drup.2020.100715
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Ghosh A., 2015, WATER AIR SOIL POLL, V10
   Granger RE, 2005, BIOCHEM PHARMACOL, V69, P1101, DOI 10.1016/j.bcp.2005.01.002
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   Heinrich D, 2018, FUTURE ONCOL, V14, P2543, DOI 10.2217/fon 2018 0087
   Huynh DTN, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186656
   Iacovelli R, 2020, EXPERT REV MOL DIAGN, V20, P195, DOI 10.1080/14737159.2020.1707669
   Kelker MS, 2009, J MOL BIOL, V385, P11, DOI 10.1016/j.jmb.2008.10.053
   Kim KY, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051088
   Kirschenbaum A, 2011, ANN NY ACAD SCI, V1237, P64, DOI 10.1111/j.1749 6632.2011.06198.x
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Lage Vickers S, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003 020 01645 2
   Lee YC, 2015, MOL CELL PROTEOMICS, V14, P471, DOI 10.1074/mcp.M114.039909
   Lee YC, 2011, CANCER RES, V71, P5194, DOI 10.1158/0008 5472.CAN 10 4374
   Loberg RD, 2005, J CLIN ONCOL, V23, P8232, DOI 10.1200/JCO.2005.03.0841
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Maacha S, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 0965 7
   Mirzaei S, 2022, INT J BIOL MACROMOL, V206, P435, DOI 10.1016/j.ijbiomac.2022.02.094
   Molzan M, 2012, J MOL BIOL, V423, P486, DOI 10.1016/j.jmb.2012.08.009
   Morrison DK, 2009, TRENDS CELL BIOL, V19, P16, DOI 10.1016/j.tcb.2008.10.003
   Özdemir BC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114530
   Root A, 2018, MOL CANCER, V17, DOI 10.1186/s12943 018 0905 y
   Roudier MP, 2008, J UROLOGY, V180, P1154, DOI 10.1016/j.juro.2008.04.140
   Sandhu S, 2021, LANCET, V398, P1075, DOI 10.1016/S0140 6736(21)00950 8
   Siegel DA, 2020, MMWR MORBID MORTAL W, V69, P1473, DOI 10.15585/mmwr.mm6941a1
   Sung H, 2021, CA CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tewari D, 2019, FOOD CHEM TOXICOL, V123, P522, DOI 10.1016/j.fct.2018.11.041
   Mai TT, 2017, NAT CHEM, V9, P1025, DOI [10.1038/NCHEM.2778, 10.1038/nchem.2778]
   Trivedi T, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11111643
   Wang F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050638
   Wang JJ, 2009, FEBS LETT, V583, P643, DOI 10.1016/j.febslet.2009.01.030
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Xipell E, 2016, ONCOTARGET, V7, P30626, DOI [10.18632/oncotarget.8905, 10.16632/oncotarget.8905]
   Yang J, 2001, CANCER RES, V61, P5652
   Yun J, 2014, PHYTOMEDICINE, V21, P1287, DOI 10.1016/j.phymed.2014.07.003
   Zhao HD, 2020, INT IMMUNOPHARMACOL, V89, DOI 10.1016/j.intimp.2020.107101
   Zunich SM, 2012, MOL CANCER, V11, DOI 10.1186/1476 4598 11 30
NR 49
TC 6
Z9 8
U1 2
U2 27
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1756 9966
J9 J EXP CLIN CANC RES
JI J. Exp. Clin. Cancer Res.
PD FEB 9
PY 2023
VL 42
IS 1
AR 45
DI 10.1186/s13046 023 02610 7
PG 21
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 8X8AF
UT WOS:000932230400001
PM 36759880
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Hamdy, NAT
AF Hamdy, N. A. T.
TI Denosumab: RANKL inhibition in the management of bone loss
SO DRUGS OF TODAY
LA English
DT Article
ID KAPPA B LIGAND; GLUCOCORTICOID INDUCED OSTEOPOROSIS; HUMAN
   MONOCLONAL ANTIBODY; POSTMENOPAUSAL WOMEN; RECEPTOR ACTIVATOR;
   MULTIPLE MYELOMA; OSTEOCLAST DIFFERENTIATION; VASCULAR CALCIFICATION;
   OSTEOPROTEGERIN OPG; CELL SURFACE
AB Receptor activator of nuclear factor kappa B (RANK), its ligand (RANKL) and its decoy receptor osteoprotegerin (OPG) together play a key role in osteoclastogenesis. Alterations in the RANKL/OPG ratio are central in the pathogenesis of bone loss, from osteoporosis in all its forms to malignancy induced bone loss. This fact has led to the search for drugs capable of targeted RANKL inhibition in the management of skeletal disorders associated with bone loss. Promising preclinical data using OPG have paved the way for the development of the new agent denosumab, a high affinity, high specificity, fully human monoclonal antibody to RANKL, shown to be able to induce a close dependent, rapid, profound and sustained inhibition of bone resorption lasting for months after a single subcutaneous injection in healthy postmenopausal women, men and patients with multiple myeloma or metastatic breast cancer. Data from a phase II study in postmenopausal women with low bone mineral density (BMD) demonstrate that the sustained inhibition of bone resorption induced by three or six monthly subcutaneously administered denosumab was associated with significant increases in BMD for up to two years of treatment. Antifracture efficacy and long term skeletal and extraskeletal safety of denosumab are being addressed in ongoing phase III trials. The potential of denosumab to prevent bone loss has also been demonstrated in malignancy induced bone loss. Ongoing studies in rheumatoid arthritis are also promising. (c) 2008 Prous Science, S.A.U. or its licensors. All rights reserved.
C1 Leiden Univ, Med Ctr, Dept Endocrinol & Metab Dis, NL 2333 ZA Leiden, Netherlands.
C3 Leiden University; Leiden University Medical Center (LUMC); Leiden
   University   Excl LUMC
RP Hamdy, NAT (通讯作者)，Leiden Univ, Med Ctr, Dept Endocrinol & Metab Dis, Albinusdreef 2, NL 2333 ZA Leiden, Netherlands.
EM N.A.T.Hamdy@LUMC.nl
RI Hamdy, Neveen/AAL 9841 2021
CR Abu Amer Y, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2170
   Baron R, 2004, NAT MED, V10, P458, DOI 10.1038/nm0504 458
   Bekker PJ, 2001, J BONE MINER RES, V16, P348, DOI 10.1359/jbmr.2001.16.2.348
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Body JJ, 2003, CANCER AM CANCER SOC, V97, P887, DOI 10.1002/cncr.11138
   Boyce BF, 2006, CURR OPIN RHEUMATOL, V18, P427, DOI 10.1097/01.bor.0000231913.32364.32
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown JE, 2003, BRIT J CANCER, V89, P2031, DOI 10.1038/sj.bjc.6601437
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Capparelli C, 2003, J BONE MINER RES, V18, P852, DOI 10.1359/jbmr.2003.18.5.852
   CROUCHER P, 2005, CANC TREAT REV S1, V1, pS1
   Delmas PD, 2007, OSTEOPOROSIS INT, V18, pS189
   Dougau W, 2005, CANCER TREAT REV, V31, pS24
   Duong L T, 2001, Rev Endocr Metab Disord, V2, P95, DOI 10.1023/A:1010063225902
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363
   Franchimont N, 2004, CLIN EXP IMMUNOL, V138, P491, DOI 10.1111/j.1365 2249.2004.02643.x
   Hamdy NAT, 2007, CURR OPIN INVEST DR, V8, P299
   Hamdy Neveen A T, 2006, Curr Rheumatol Rep, V8, P50
   Heider U, 2004, J CANCER RES CLIN, V130, P469, DOI 10.1007/s00432 004 0578 3
   Heider U, 2003, CLIN CANCER RES, V9, P1436
   Hofbauer LC, 2007, OSTEOPOROSIS INT, V18, P251, DOI 10.1007/s00198 006 0282 z
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kostenuik PJ, 2004, J BONE MINER RES, V19, pS19
   Kostenuik PJ, 2001, ENDOCRINOLOGY, V142, P4295, DOI 10.1210/en.142.10.4295
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Martin TJ, 2007, CLIN SCI, V112, P77, DOI 10.1042/CS20060046
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Min H, 2000, J EXP MED, V192, P463, DOI 10.1084/jem.192.4.463
   Miranda Carús ME, 2006, ARTHRITIS RHEUM US, V54, P1151, DOI 10.1002/art.21731
   Morony S, 2001, J BONE MINER RES, V16, pS148
   Morony S, 2001, CANCER RES, V61, P4432
   Moschen AR, 2005, GUT, V54, P479, DOI 10.1136/gut.2004.044370
   Mundy GR, 2005, CANCER TREAT REV, V31, pS11
   Ominsky MS, 2007, OSTEOPOROSIS INT, V18, P1073, DOI 10.1007/s00198 007 0363 7
   *OST METH GROUP OS, 2002, ENDOCR REV, V4, P496
   Pacifici R, 1996, J BONE MINER RES, V11, P1043
   Peterson MC, 2005, BONE, V36, pS399
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Ritchlin CT, 2003, J CLIN INVEST, V111, P821, DOI 10.1172/JCI200316069
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Ross AB, 2001, J MATER SCI MATER M, V12, P583, DOI 10.1023/A:1011229324412
   Sasaki N, 2001, NEPHROL DIAL TRANSPL, V16, P479, DOI 10.1093/ndt/16.3.479
   Schwarz EM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2171
   Sezer O, 2003, BLOOD, V101, P2094, DOI 10.1182/blood 2002 09 2684
   Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sivagurunathan S, 2005, J BONE MINER RES, V20, P390, DOI 10.1359/JBMR.041233
   Stolina M, 2005, J BONE MINER RES, V20, P1756, DOI 10.1359/JBMR.050601
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179
   Teitelbaum SL, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1857
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Ulrich Vinther M, 2005, CALCIFIED TISSUE INT, V76, P280, DOI 10.1007/s00223 004 0126 9
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Whyte MP, 2006, NEW ENGL J MED, V354, P860, DOI 10.1056/NEJMe068003
NR 63
TC 33
Z9 46
U1 0
U2 3
PU PROUS SCIENCE, SAU THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 1699 3993
EI 1699 4019
J9 DRUG TODAY
JI Drugs Today
PD JAN
PY 2008
VL 44
IS 1
BP 7
EP 21
DI 10.1358/dot.2008.44.1.1178467
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 272VQ
UT WOS:000253889500002
PM 18301800
DA 2025 08 17
ER

PT J
AU Dai, G
   Zheng, D
   Wang, QL
   Yang, J
   Liu, GW
   Song, Q
   Sun, XG
   Tao, CJ
   Hu, QZ
   Gao, T
   Yu, L
   Guo, WC
AF Dai, Guo
   Zheng, Di
   Wang, Qianliang
   Yang, Jian
   Liu, Gaiwei
   Song, Qi
   Sun, Xiangran
   Tao, Chunjie
   Hu, Qingzhu
   Gao, Tian
   Yu, Ling
   Guo, Weichun
TI Baicalein inhibits progression of osteosarcoma cells through
   inactivation of the Wnt/β catenin signaling pathway
SO ONCOTARGET
LA English
DT Article
DE baicalein; osteosarcoma; proliferation; apoptosis; Wnt signaling pathway
ID TRADITIONAL CHINESE MEDICINE; BREAST CANCER; CYCLE ARREST; IN VITRO;
   SUPPRESSES; PROLIFERATION; EXPRESSION; GROWTH; METASTASIS; ACTIVATION
AB Osteosarcoma is a very common type of malignant bone tumor in children and young adults and aberrant activation of Wnt/beta catenin signaling pathway has been discovered in osteosarcoma. The traditional Chinese medicine baicalein was proved to have anti proliferative and anti metastatic properties in osteosarcoma, but the mechanism remained poorly understood. In the present study, we assessed the effects of baicalein on osteosarcoma and detected the potential molecular mechanism. We found that baicalein significantly suppressed the proliferation of osteosarcoma cells in a concentration and time dependent manner. In additional, baicalein could induce apoptosis and cell cycle arrest and reduce cell motility. Moreover, the level of beta catenin and its target genes, including c myc, cyclinD1, and survivin significantly decreased in baicalein treated osteosarcoma cells, whereas exogenous expression of beta catenin could reverse the anti proliferative and anti metastatic effects of baicalein. Subsequently, we established a 143B xenograft tumor model and found that baicalein treatment significantly inhibited tumor growth accompanied with inhibiting Wnt/beta catenin pathway. Thus, these findings suggest that baicalein may be a potentially effective Chinese herbal medicine for therapeutics of osteosarcoma and Wnt/beta catenin signaling pathway may serve as an efficient molecular marker or predictive target for osteosarcoma.
C1 [Dai, Guo; Zheng, Di; Yang, Jian; Liu, Gaiwei; Song, Qi; Sun, Xiangran; Tao, Chunjie; Hu, Qingzhu; Yu, Ling; Guo, Weichun] Wuhan Univ, Renmin Hosp, Dept Orthoped, Wuhan 430060, Hubei, Peoples R China.
   [Wang, Qianliang] Wuhan Univ, Renmin Hosp, Dept Urol Surg, Wuhan 430060, Hubei, Peoples R China.
   [Gao, Tian] Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ,Dept Orthoped Oncol, Beijing, Peoples R China.
C3 Wuhan University; Wuhan University; Peking University
RP Yu, L; Guo, WC (通讯作者)，Wuhan Univ, Renmin Hosp, Dept Orthoped, Wuhan 430060, Hubei, Peoples R China.
EM scaling@whu.edu.cn; guoweichun@aliyun.com
RI 叶, 佳/HGE 3966 2022
FU Natural Science Foundation of China [81341078, 81502575]; Fundamental
   Research Funds for the Central Universities [2042015kf0069,
   2042017kf0163]
FX This study was supported in part by Grants from the Natural Science
   Foundation of China (No. 81341078 and 81502575), and Fundamental
   Research Funds for the Central Universities (2042015kf0069 and
   2042017kf0163).
CR Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   [Anonymous], 2016, ELECT J DIFF EQU
   Bie BB, 2017, CELL PHYSIOL BIOCHEM, V41, P1519, DOI 10.1159/000470815
   Cai Y, 2014, J CELL BIOCHEM, V115, P625, DOI 10.1002/jcb.24708
   Chen CB, 2015, ONCOTARGET, V6, P17570, DOI 10.18632/oncotarget.4100
   Chen HJ, 2014, CANCER LETT, V354, P5, DOI 10.1016/j.canlet.2014.08.003
   Ganguly KK, 2013, CELL ADHES MIGR, V7, P251, DOI 10.4161/cam.23840
   Goldstein SD, 2016, ONCOTARGET, V7, P21114, DOI 10.18632/oncotarget.8522
   Gulappa T, 2013, CANCER LETT, V337, P177, DOI 10.1016/j.canlet.2013.05.014
   Hattinger CM, 2015, EXPERT OPIN EMERG DR, V20, P495, DOI 10.1517/14728214.2015.1051965
   He NB, 2015, MOL CELL BIOCHEM, V405, P187, DOI 10.1007/s11010 015 2410 6
   Herszényi L, 2012, INT J MOL SCI, V13, P13240, DOI 10.3390/ijms131013240
   Huang YJ, 2016, MOL CARCINOGEN, V55, P1598, DOI 10.1002/mc.22412
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Janeway KA, 2010, LANCET ONCOL, V11, P670, DOI 10.1016/S1470 2045(10)70062 0
   Jang GB, 2015, SCI REP UK, V5, DOI 10.1038/srep12465
   Kim SL, 2013, CANCER LETT, V335, P479, DOI 10.1016/j.canlet.2013.03.007
   Kim SD, 2014, BIOCHEM PHARMACOL, V92, P251, DOI 10.1016/j.bcp.2014.09.019
   Kiraz Y, 2016, TUMOR BIOL, V37, P8471, DOI 10.1007/s13277 016 5035 9
   Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389
   Li X, 2015, CANCER LETT, V357, P219, DOI 10.1016/j.canlet.2014.11.026
   Li Weber M, 2013, CANCER LETT, V332, P304, DOI 10.1016/j.canlet.2010.07.015
   Lin CH, 2014, ADV EXP MED BIOL, V804, P33, DOI 10.1007/978 3 319 04843 7_2
   Liu TY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114851
   Liu XP, 2016, ANN HEMATOL, V95, P1787, DOI 10.1007/s00277 016 2766 z
   Lu XS, 2017, ONCOTARGET, V8, P988, DOI 10.18632/oncotarget.13519
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Lv ZL, 2014, ONCOL REP, V31, P989, DOI 10.3892/or.2013.2931
   Ma YL, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046 015 0232 8
   Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602
   Maran A, 2013, J BIOMED MATER RES A, V101, P2491, DOI 10.1002/jbm.a.34550
   Martins Neves SR, 2016, CANCER LETT, V370, P286, DOI 10.1016/j.canlet.2015.11.013
   Mu JS, 2016, J CANCER, V7, P453, DOI 10.7150/jca.13548
   Radulescu S, 2013, ONCOGENE, V32, P2048, DOI 10.1038/onc.2012.224
   Sheppard KE, 2013, CLIN CANCER RES, V19, P5320, DOI 10.1158/1078 0432.CCR 13 0259
   Signore M, 2013, CANCER LETT, V332, P374, DOI 10.1016/j.canlet.2011.01.013
   Slusarz A, 2010, CANCER RES, V70, P3382, DOI 10.1158/0008 5472.CAN 09 3012
   Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61
   Tanaka M, 2009, BRIT J CANCER, V100, P1957, DOI 10.1038/sj.bjc.6605060
   Tang QL, 2011, CANCER LETT, V311, P113, DOI 10.1016/j.canlet.2011.07.016
   Teiten MH, 2012, CURR PHARM BIOTECHNO, V13, P245, DOI 10.2174/138920112798868593
   Tian J, 2014, TUMOR BIOL, V35, P9439, DOI 10.1007/s13277 014 2433 8
   Vijayamurugan N, 2014, EXPERT REV ANTICANC
   Wang CY, 2014, AM J CHINESE MED, V42, P543, DOI 10.1142/S0192415X14500359
   Wang CZ, 2015, INT J ONCOL, V47, P1749, DOI 10.3892/ijo.2015.3173
   Wang DZ, 2015, DRUG RES, V65, P597, DOI 10.1055/s 0034 1395597
   Wang L, 2010, CANCER LETT, V297, P42, DOI 10.1016/j.canlet.2010.04.022
   Wang W, 2015, INT J NANOMED, V10, P3737, DOI 10.2147/IJN.S80297
   Wang YJ, 2015, CANCER LETT, V358, P170, DOI 10.1016/j.canlet.2014.12.033
   Watson AL, 2013, CANCER DISCOV, V3, P674, DOI 10.1158/2159 8290.CD 13 0081
   Wunder JS, 2007, LANCET ONCOL, V8, P513, DOI 10.1016/S1470 2045(07)70169 9
   Xie T, 2016, INT J ONCOL, V48, P2098, DOI 10.3892/ijo.2016.3416
   Xu WP, 2017, ENVIRON TOXICOL PHAR, V49, P89, DOI 10.1016/j.etap.2016.12.002
   Yu L, 2016, ONCOTARGET, V7, P33055, DOI 10.18632/oncotarget.8849
   Zhang RX, 2016, INT J ONCOL, V49, P1973, DOI 10.3892/ijo.2016.3701
   Zhang SX, 2015, SCI REP UK, V5, DOI 10.1038/srep13626
   Zhang XH, 2014, CELL MOL BIOL, V60, P29
   Zhang YL, 2016, CANCER RES, V76, P4183, DOI 10.1158/0008 5472.CAN 15 2974
   Zheng YH, 2014, PHYTOTHER RES, V28, P1342, DOI 10.1002/ptr.5135
   Zhou RT, 2017, ONCOTARGET, V8, P56351, DOI 10.18632/oncotarget.16912
NR 60
TC 31
Z9 33
U1 2
U2 22
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 17
PY 2017
VL 8
IS 49
BP 86098
EP 86116
DI 10.18632/oncotarget.20987
PG 19
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA FJ9FN
UT WOS:000413077800125
PM 29156780
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Suominen, MI
   Mäki Jouppila, J
   Huhtinen, A
   Sjöholm, B
   Rissanen, JP
   Luostarinen, A
   Fagerlund, KM
   Alhoniemi, E
   Siemeister, G
   Mumberg, D
   Käkönen, SM
   Scholz, A
AF Suominen, Mari I.
   Maki Jouppila, Jenni
   Huhtinen, Anna
   Sjoholm, Birgitta
   Rissanen, Jukka P.
   Luostarinen, Anniina
   Fagerlund, Katja M.
   Alhoniemi, Esa
   Siemeister, Gerhard
   Mumberg, Dominik
   Kakonen, Sanna Maria
   Scholz, Arne
TI Additive Benefits of Radium 223 Dichloride and Bortezomib Combination in
   a Systemic Multiple Myeloma Mouse Model
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE multiple myeloma; bortezomib; radium 223; dexamethasone; myeloma bone
   disease; osteoblast; osteoclast; targeted alpha therapy; 5TGM1 mouse
   model; systemic model
ID PROTEASOME INHIBITORS; RA 223; AGENTS; CELLS; RESISTANCE; APPROVAL;
   THERAPY; GROWTH
AB Osteolytic bone disease is a hallmark of multiple myeloma (MM) mediated by MM cell proliferation, increased osteoclast activity, and suppressed osteoblast function. The proteasome inhibitor bortezomib targets MM cells and improves bone health in MM patients. Radium 223 dichloride (radium 223), the first targeted alpha therapy approved, specifically targets bone metastases, where it disrupts the activity of both tumor cells and tumor supporting bone cells in mouse models of breast and prostate cancer bone metastasis. We hypothesized that radium 223 and bortezomib combination treatment would have additive effects on MM. In vitro experiments revealed that the combination treatment inhibited MM cell proliferation and demonstrated additive efficacy. In the systemic, syngeneic 5TGM1 mouse MM model, both bortezomib and radium 223 decreased the osteolytic lesion area, and their combination was more effective than either monotherapy alone. Bortezomib decreased the number of osteoclasts at the tumor bone interface, and the combination therapy resulted in almost complete eradication of osteoclasts. Furthermore, the combination therapy improved the incorporation of radium 223 into MM bearing bone. Importantly, the combination therapy decreased tumor burden and restored body weights in MM mice. These results suggest that the combination of radium 223 with bortezomib could constitute a novel, effective therapy for MM and, in particular, myeloma bone disease.
C1 [Suominen, Mari I.; Maki Jouppila, Jenni; Rissanen, Jukka P.; Luostarinen, Anniina; Fagerlund, Katja M.] Pharmatest Serv Oy, Turku 20520, Finland.
   [Huhtinen, Anna; Sjoholm, Birgitta; Kakonen, Sanna Maria] Aurexel Life Sci Oy, Askainen 21240, Finland.
   [Alhoniemi, Esa] Vincit Oyj, Turku 20500, Finland.
   [Siemeister, Gerhard] Nuvisan ICB GmbH, Therapeut Oncol Res, D 13353 Berlin, Germany.
   [Mumberg, Dominik; Scholz, Arne] Bayer AG, Res & Dev, Pharmaceut, D 13353 Berlin, Germany.
   [Kakonen, Sanna Maria] Univ Turku, Fac Med, Dept Cell Biol & Anat, Turku 20014, Finland.
C3 Bayer AG; University of Turku
RP Scholz, A (通讯作者)，Bayer AG, Res & Dev, Pharmaceut, D 13353 Berlin, Germany.
EM mari.suominen@pharmatest.com; jenni.maki jouppila@pharmatest.com;
   anna.huhtinen@aurexel.com; birgitta.sjoholm@aurexel.com;
   jukka.rissanen@pharmatest.com; anniina.luostarinen@pharmatest.com;
   anna.huhtinen@aurexel.com; esa.alhoniemi@vincit.fi;
   gerhard.siemeister@nuvisan.com; dominik.mumberg@bayer.com;
   sanna.kakonen@aurexel.com; arne.scholz@bayer.com
RI ; Suominen, Mari/KHZ 4938 2024
OI , Gerhard/0000 0002 4712 0531; Kakonen, Sanna Maria/0000 0001 9393 6235;
   Suominen, Mari/0000 0002 8760 6595; 
FU Bayer AG
FX This research was funded by Bayer AG.
CR Accardi F, 2015, BIOMED RES INT UK, V2015, DOI 10.1155/2015/172458
   Alanazi F, 2020, DRUG DISCOV TODAY, V25, P367, DOI 10.1016/j.drudis.2019.11.008
   Anderson KC, 2016, CLIN CANCER RES, V22, P5419, DOI 10.1158/1078 0432.CCR 16 0625
   Asosingh K, 2000, Hematol J, V1, P351, DOI 10.1038/sj.thj.6200052
   Becker N, 2011, RECENT RESULTS CANC, V183, P25, DOI 10.1007/978 3 540 85772 3_2
   Bruland OS, 2006, CLIN CANCER RES, V12, p6250S, DOI 10.1158/1078 0432.CCR 06 0841
   Chari A, 2020, CL LYMPH MYELOM LEUK, V20, P8, DOI 10.1016/j.clml.2019.09.625
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Coleman R, 2016, SEMIN NUCL MED, V46, P99, DOI 10.1053/j.semnuclmed.2015.10.012
   Coleman R, 2014, BREAST CANCER RES TR, V145, P411, DOI 10.1007/s10549 014 2939 1
   Costa RP, 2019, CLIN TER, V170, pE1, DOI 10.7417/CT.2019.2100
   Dou QP, 2014, CURR CANCER DRUG TAR, V14, P517, DOI 10.2174/1568009614666140804154511
   Driscoll JJ, 2012, AM J THER, V19, P133, DOI 10.1097/MJT.0b013e3181ff7a9e
   Durer C, 2020, BLOOD REV, V39, DOI 10.1016/j.blre.2019.100616
   Edelman Martin J, 2005, Clin Lung Cancer, V7 Suppl 2, pS64, DOI 10.3816/CLC.2005.s.011
   Field Smith Antonia, 2006, Ther Clin Risk Manag, V2, P271, DOI 10.2147/tcrm.2006.2.3.271
   Garrett IR, 1997, BONE, V20, P515, DOI 10.1016/S8756 3282(97)00056 2
   Heider U, 2006, EUR J HAEMATOL, V77, P233, DOI 10.1111/j.1600 0609.2006.00692.x
   Henriksen G, 2003, J NUCL MED, V44, P252
   Henriksen G, 2001, RADIOCHIM ACTA, V89, P661, DOI 10.1524/ract.2001.89.10.661
   Hideshima T, 2001, CANCER RES, V61, P3071
   Kane RC, 2003, ONCOLOGIST, V8, P508, DOI 10.1634/theoncologist.8 6 508
   Kane RC, 2006, CLIN CANCER RES, V12, P2955, DOI 10.1158/1078 0432.CCR 06 0170
   Kyle RA, 2003, MAYO CLIN PROC, V78, P21, DOI 10.4065/78.1.21
   Makvandi M, 2018, TARGET ONCOL, V13, P189, DOI 10.1007/s11523 018 0550 9
   MANNING LS, 1992, BRIT J CANCER, V66, P1088, DOI 10.1038/bjc.1992.415
   Mitra R, 2011, PM&R, V3, P466, DOI 10.1016/j.pmrj.2011.02.017
   Mitsiades N, 2003, BLOOD, V101, P2377, DOI 10.1182/blood 2002 06 1768
   Moreau P, 2016, BLOOD, V127, P2569, DOI 10.1182/blood 2016 01 693580
   Moreau P, 2012, BLOOD, V120, P947, DOI 10.1182/blood 2012 04 403733
   Naymagon L, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045 016 0282 1
   NEUMAN WF, 1955, ANN NY ACAD SCI, V62, P125, DOI 10.1111/j.1749 6632.1955.tb35369.x
   Niewerth D, 2015, DRUG RESIST UPDATE, V18, P18, DOI 10.1016/j.drup.2014.12.001
   Orlowski RZ, 2016, CLIN CANCER RES, V22, P5443, DOI 10.1158/1078 0432.CCR 16 0861
   Oyajobi BO, 2007, MOL CANCER THER, V6, P1701, DOI 10.1158/1535 7163.MCT 07 0121
   Parker C, 2018, PROSTATE CANCER P D, V21, P37, DOI 10.1038/s41391 017 0020 y
   Parker C, 2013, NEW ENGL J MED, V369, P1659
   Qiang YW, 2012, SEMIN HEMATOL, V49, P243, DOI 10.1053/j.seminhematol.2012.04.011
   RADL J, 1988, AM J PATHOL, V132, P593
   Rajkumar SV, 2020, AM J HEMATOL, V95, P548, DOI 10.1002/ajh.25791
   Richardson PG, 2010, BLOOD, V116, P679, DOI 10.1182/blood 2010 02 268862
   Rossi Marco, 2018, Oncotarget, V9, P20119, DOI 10.18632/oncotarget.24614
   Siegel RL, 2020, CA CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Suominen MI, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163899
   Suominen MI, 2017, CLIN CANCER RES, V23, P4335, DOI 10.1158/1078 0432.CCR 16 2955
   Suominen MI, 2013, JNCI J NATL CANCER I, V105, P908, DOI 10.1093/jnci/djt116
   Takalkar Amol, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr 2015 211152
   Terpos E, 2019, BLOOD, V133, P1534, DOI 10.1182/blood 2018 11 852459
   Terpos E, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408 017 0037 4
   Terpos E, 2013, J CLIN ONCOL, V31, P2347, DOI 10.1200/JCO.2012.47.7901
   Weinstein RS, 2012, ENDOCRIN METAB CLIN, V41, P595, DOI 10.1016/j.ecl.2012.04.004
   Yong K, 2018, EUR J HAEMATOL, V101, P220, DOI 10.1111/ejh.13071
   Zangari M, 2016, BONE, V86, P131, DOI 10.1016/j.bone.2016.02.019
   Zangari M, 2012, CANCER TREAT REV, V38, P968, DOI 10.1016/j.ctrv.2011.12.007
   Zimmerman BE, 2015, J RES NATL INST STAN, V120, DOI 10.6028/jres.120.004
NR 55
TC 4
Z9 4
U1 0
U2 5
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUN
PY 2021
VL 22
IS 11
AR 5570
DI 10.3390/ijms22115570
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA SQ2YA
UT WOS:000660221800001
PM 34070363
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, CD
   Xiao, F
   Qu, XH
   Zhai, ZJ
   Hu, GL
   Chen, XD
   Zhang, XL
AF Wang, Chuandong
   Xiao, Fei
   Qu, Xinhua
   Zhai, Zanjing
   Hu, Guoli
   Chen, Xiaodong
   Zhang, Xiaoling
TI Sitagliptin, An Anti diabetic Drug, Suppresses Estrogen
   Deficiency Induced Osteoporosis In Vivo and Inhibits
   RANKL Induced Osteoclast Formation and Bone Resorption In Vitro
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE sitagliptin; osteoclast; osteoporosis; NFATc1; RANKL
ID PARTICLE INDUCED OSTEOLYSIS; OVARIECTOMIZED MICE; DIABETIC RATS; CRUCIAL
   ROLE; DIFFERENTIATION; ACTIVATION; METFORMIN; PATHWAY; ERK; AKT
AB Postmenopausal osteoporosis is a disease characterized by excessive osteoclastic bone resorption. Some anti diabetic drugs were demonstrated for anti osteoclastic bone loss effects. The present study investigated the skeletal effects of chronic administration of sitagliptin, a dipeptidyl peptidase IV (DPP IV) inhibitor that is increasingly used for type 2 diabetes treatments, in an estrogen deficiency induced osteoporosis and elucidated the associated mechanisms. This study indicated that sitagliptin effectively prevented ovariectomy induced bone loss and reduced osteoclast numbers in vivo. It was also indicated that sitagliptin suppressed receptor activator of nuclear factor kappa B ligand (RANKL) mediated osteoclast differentiation, bone resorption, and F actin ring formation in a manner of dose dependence. In addition, sitagliptin significantly reduced the expression of osteoclast specific markers in mouse bone marrow derived macrophages, including calcitonin receptor (Calcr), dendrite cell specific transmembrane protein (Dc stamp), c Fos, and nuclear factor of activated T cells cytoplasmic 1 (Nfatc1). Further study indicated that sitagliptin inhibited osteoclastogenesis by suppressing AKT and ERK signaling pathways, scavenging ROS activity, and suppressing the Ca2+ oscillation that consequently affects the expression and/or activity of the osteoclast specific transcription factors, c Fos and NFATc1. Collectively, these findings suggest that sitagliptin possesses beneficial effects on bone and the suppression of osteoclast number implies that the effect is exerted directly on osteoclastogenesis.
C1 [Wang, Chuandong; Xiao, Fei; Chen, Xiaodong; Zhang, Xiaoling] Shanghai Jiao Tong Univ, Sch Med, Xin Hua Hosp, Dept Orthoped Surg, Shanghai, Peoples R China.
   [Qu, Xinhua; Zhai, Zanjing] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Orthoped Implant, Dept Orthoped Surg,Shanghai Peoples Hosp 9, Shanghai, Peoples R China.
   [Hu, Guoli] Shanghai Jiao Tong Univ, Key Lab Stem Cell Biol, Inst Hlth Sci, Sch Med, Shanghai, Peoples R China.
   [Hu, Guoli] Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University; Chinese Academy of Sciences
RP Chen, XD; Zhang, XL (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Xin Hua Hosp, Dept Orthoped Surg, Shanghai, Peoples R China.
EM chenxiaodong@xinhuamed.com.cn; xlzhang@shsmu.edu.cn
RI Qu, Xinhua/Q 3950 2016; Zhang, Xiaoling/J 1666 2016; zhang,
   xuyang/GQH 3712 2022; Chen, Xiao Dong/ADG 8612 2022
OI Qu, Xinhua/0000 0002 8889 0890; Zhang, Xiaoling/0000 0002 0134 1347
FU Ministry of Science and Technology of China [2015DFG32200]; National
   Natural Science Foundation of China [81572123, 81401844]; National
   Natural Science Foundation for Youths [81401852]; Natural Science
   Foundation of Shanghai [14ZR1424000]; "Chen Guang" Project of the
   Shanghai Municipal Education Commission; Shanghai Education Development
   Foundation [14CG14]; Science and Technology Commission of Shanghai
   Municipality [14431900900, 15411951100, 16430723500]; Shanghai Municipal
   Education Commission Gaofeng Clinical Medicine Grant [20161314]; Xin Hua
   Hospital [009, 201601]
FX This work was supported by grants from the Ministry of Science and
   Technology of China (No. 2015DFG32200), National Natural Science
   Foundation of China (No. 81572123, 81401844), National Natural Science
   Foundation for Youths (Grant Nos. 81401852), the Natural Science
   Foundation of Shanghai (No. 14ZR1424000), "Chen Guang" Project of the
   Shanghai Municipal Education Commission and the Shanghai Education
   Development Foundation (No. 14CG14), Science and Technology Commission
   of Shanghai Municipality (No. 14431900900, 15411951100, 16430723500),
   Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant
   Support (No. 20161314) and Xin Hua Hospital affiliated to Shanghai Jiao
   Tong University School of Medicine (009&201601).
CR [Anonymous], 2014, J MAT
   Baek JM, 2016, INT J BIOL SCI, V12, P478, DOI 10.7150/ijbs.13815
   Baerts L, 2015, PHARMACOL RES, V100, P336, DOI 10.1016/j.phrs.2015.08.023
   Barnett A, 2006, INT J CLIN PRACT, V60, P1454, DOI 10.1111/j.1742 1241.2006.01178.x
   Bartell SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4773
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   DOLMETSCH RE, 1994, J GEN PHYSIOL, V103, P365, DOI 10.1085/jgp.103.3.365
   Dou C, 2016, OSTEOPOROSIS INT, V27, P2335, DOI 10.1007/s00198 016 3496 8
   El Sahar AE, 2015, LIFE SCI, V126, P81, DOI 10.1016/j.lfs.2015.01.030
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   Glorie L, 2014, AM J PHYSIOL ENDOC M, V307, pE447, DOI 10.1152/ajpendo.00217.2014
   Grassi F, 2007, P NATL ACAD SCI USA, V104, P15087, DOI 10.1073/pnas.0703610104
   Hegazy SK, 2015, J BONE MINER METAB, V33, P207, DOI 10.1007/s00774 014 0581 y
   Hwang SY, 2011, BBA MOL CELL RES, V1813, P979, DOI 10.1016/j.bbamcr.2010.11.002
   Kajiya H, 2012, ADV EXP MED BIOL, V740, P917, DOI 10.1007/978 94 007 2888 2_41
   Kharkwal G, 2012, J MOL ENDOCRINOL, V48, P261, DOI 10.1530/JME 11 0061
   Kim JY, 2015, J NAT PROD, V78, P2167, DOI 10.1021/acs.jnatprod.5b00233
   Kim JY, 2014, BONE, V60, P104, DOI 10.1016/j.bone.2013.12.013
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kyle KA, 2011, ENDOCRINOLOGY, V152, P457, DOI 10.1210/en.2010 1098
   Lean JM, 2003, J CLIN INVEST, V112, P915, DOI 10.1172/JCI200318859
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Mai QG, 2011, J CELL BIOCHEM, V112, P2902, DOI 10.1002/jcb.23206
   Mao DL, 2006, J CLIN INVEST, V116, P2869, DOI 10.1172/JCI28775
   Matsumoto T, 2011, ARTHRITIS RHEUM US, V63, P3908, DOI 10.1002/art.30646
   Meier C, 2016, BONE, V82, P93, DOI 10.1016/j.bone.2015.04.026
   Monami M, 2011, DIABETES CARE, V34, P2474, DOI 10.2337/dc11 1099
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Okawa Y, 2009, BLOOD, V113, P846, DOI 10.1182/blood 2008 04 151928
   Pereira M, 2015, BONE, V81, P459, DOI 10.1016/j.bone.2015.08.006
   Wilde JI, 2001, CELL SIGNAL, V13, P691, DOI 10.1016/S0898 6568(01)00191 7
   Wu CL, 2015, BIOCHEM PHARMACOL, V93, P59, DOI 10.1016/j.bcp.2014.10.019
   Xiao F, 2015, EXP CELL RES, V330, P91, DOI 10.1016/j.yexcr.2014.07.005
   Zaidi M, 2003, J BONE MINER RES, V18, P599, DOI 10.1359/jbmr.2003.18.4.599
   Zhai ZJ, 2014, BRIT J PHARMACOL, V171, P663, DOI 10.1111/bph.12463
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
   Zhu X, 2016, BIOCHEM PHARMACOL, V104, P118, DOI 10.1016/j.bcp.2016.02.013
   Zinman B, 2010, J CLIN ENDOCR METAB, V95, P134, DOI 10.1210/jc.2009 0572
NR 42
TC 40
Z9 45
U1 0
U2 22
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUN 30
PY 2017
VL 8
AR 407
DI 10.3389/fphar.2017.00407
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA EZ1PI
UT WOS:000404482900002
PM 28713268
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Bourebaba, L
   Michalak, I
   Baouche, M
   Kucharczyk, K
   Fal, AM
   Marycz, K
AF Bourebaba, Lynda
   Michalak, Izabela
   Baouche, Meriem
   Kucharczyk, Katarzyna
   Fal, Andrzej M.
   Marycz, Krzysztof
TI Cladophora glomerata enriched by biosorption with Mn(II)
   ions alleviates lipopolysaccharide induced osteomyelitis like model in
   MC3T3 E1, and 4B12 osteoclastogenesis
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE biosorption; Cladophora glomerata; LPS; manganese; osteoclast;
   osteomyelitis
ID MESENCHYMAL STEM CELLS; OSTEOBLAST DIFFERENTIATION; OSTEOGENIC
   DIFFERENTIATION; BONE RESORPTION; MOLECULAR MECHANISMS; INDUCED
   APOPTOSIS; LPS; ACTIVATION; EXPRESSION; MITOCHONDRIA
AB Chronic osteomyelitis, a bone infectious disease, is characterized by dysregulation of bone homeostasis, which results in excessive bone resorption. Lipopolysaccharide (LPS) which is a gram negative endotoxin was shown to inhibit osteoblast differentiation and to induce apoptosis and osteoclasts formation in vitro. While effective therapy against bacteria induced bone destruction is quite limited, the investigation of potential drugs that restore down regulated osteoblast function remains a major goal in the prevention of bone destruction in infective bone diseases. This investigation aimed to rescue LPS induced MC3T3 E1 pre osteoblastic cell line using the methanolic extract of Cladophora glomerata enriched with Mn(II) ions by biosorption. LPS induced MC3T3 E1 cultures supplemented with C. glomerata methanolic extract were tested for expression of the main genes and microRNAs involved in the osteogenesis pathway using RT PCR. Moreover, osteoclastogenesis of 4B12 cells was also investigated by tartrate resistant acid phosphatase (TRAP) assay. Treatment with algal extract significantly restored LPS suppressed bone mineralization and the mRNA expression levels of osteoblast specific genes such as runt related transcription factor 2 (Runx2), alkaline phosphatase (ALP) and osteocalcin (OCN), osteopontin (OPN), miR 27a and miR 29b. The extract also inhibited osteoblast apoptosis, significantly restored the down regulated expression of Bcl 2, and decreased the loss of MMP and reactive oxygen spices (ROS) production in MC3T3 E1 cells induced by LPS. Furthermore, pre treatment with algal extract strongly decreased the activation of osteoclast in MC3T3 E1 4B12 coculture system stimulated by LPS. Our findings suggest that C. glomerata enriched with Mn(II) ions may be a potential raw material for the development of drug for preventing abnormal bone loss induced by LPS in bacteria induced bone osteomyelitis.
C1 [Bourebaba, Lynda; Baouche, Meriem; Kucharczyk, Katarzyna; Marycz, Krzysztof] Wroclaw Univ Environm & Life Sci, Fac Biol & Anim Sci, Dept Expt Biol, Norwida 27B, PL 50375 Wroclaw, Poland.
   [Bourebaba, Lynda; Baouche, Meriem; Marycz, Krzysztof] Int Inst Translat Med, Wisznia Mala, Poland.
   [Michalak, Izabela] Wroclaw Univ Sci & Technol, Fac Chem, Dept Adv Mat Technol, Wroclaw, Poland.
   [Fal, Andrzej M.; Marycz, Krzysztof] Cardinal Stefan Wyszynski Univ UKSW, Coll Med, Inst Med Sci, Warsaw, Poland.
C3 Wroclaw University of Environmental & Life Sciences; Wroclaw University
   of Science & Technology; Cardinal Stefan Wyszynski University in Warsaw
RP Bourebaba, L (通讯作者)，Wroclaw Univ Environm & Life Sci, Fac Biol & Anim Sci, Dept Expt Biol, Norwida 27B, PL 50375 Wroclaw, Poland.
EM lynda.bourebaba@upwr.edu.pl
RI ; Fal, Andrzej/ABB 7181 2021; Bourebaba, Lynda/AAX 7613 2020; Baouche,
   Meriem/GQP 6178 2022; Michalak, Izabela/P 3770 2015
OI Lynda, Bourebaba/0000 0003 0660 8706; Baouche,
   Meriem/0000 0002 7344 1769; Fal, Andrzej/0000 0002 9675 7942; 
FU Narodowe Centrum Nauki [2015/18/E/NZ9/00607]
FX Narodowe Centrum Nauki, Grant/Award Number: 2015/18/E/NZ9/00607
CR Al Dhaheri Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109630
   Azadmanesh J, 2018, ANTIOXIDANTS BASEL, V7, DOI 10.3390/antiox7020025
   Bandow K, 2010, BIOCHEM BIOPH RES CO, V402, P755, DOI 10.1016/j.bbrc.2010.10.103
   Birt MC, 2017, J ORTHOP, V14, P45, DOI 10.1016/j.jor.2016.10.004
   Bourebaba L, 2019, BIOMED PHARMACOTHER, V111, P6, DOI 10.1016/j.biopha.2018.12.020
   Brodziak Dopierala B, 2013, J TRACE ELEM MED BIO, V27, P208, DOI 10.1016/j.jtemb.2012.12.005
   Carroll C, 2003, NATURE, V423, P337
   Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007 0509
   Clegg MS, 2013, EXP BIOL MED, V219, P41
   De Ugarte L, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920 015 0149 2
   Della Pepa G, 2016, CLIN CASES MINER BON, V13, P181, DOI 10.11138/ccmbm/2016.13.3.181
   Duan LJ, 2018, CELL PHYSIOL BIOCHEM, V51, P1087, DOI 10.1159/000495489
   El Gamal Ali A, 2010, Saudi Pharm J, V18, P1, DOI 10.1016/j.jsps.2009.12.001
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Fabrowska J, 2015, CHEMIK, V69, P495
   FARBER JL, 1994, ENVIRON HEALTH PERSP, V102, P17, DOI 10.2307/3432207
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Floriaczyk B, 2008, J PRECLIN CLIN RES, V2, P25
   Guo C, 2017, CELL PHYSIOL BIOCHEM, V43, P1547, DOI 10.1159/000481978
   Hong CY, 2004, J ORAL PATHOL MED, V33, P162, DOI 10.1111/j.0904 2512.2004.00045.x
   Hou GQ, 2013, INT J MOL MED, V32, P503, DOI 10.3892/ijmm.2013.1406
   Hsu HY, 2002, J BIOL CHEM, V277, P22131, DOI 10.1074/jbc.M111883200
   Hu WH, 2013, MOL MED REP, V7, P689, DOI 10.3892/mmr.2012.1207
   Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029
   Hudson JB, 1998, J APPL PHYCOL, V10, P427, DOI 10.1023/A:1008004117305
   Hunter R, 2017, NEUROSCI RES, V114, P62, DOI 10.1016/j.neures.2016.09.007
   Johnson CT, 2015, ANN BIOMED ENG, V43, P515, DOI 10.1007/s10439 014 1205 3
   Kapinas K, 2010, J BIOL CHEM, V285, P25221, DOI 10.1074/jbc.M110.116137
   Kim JH, 2016, INT J MOL MED, V37, P649, DOI 10.3892/ijmm.2016.2477
   Kim K, 2007, BLOOD, V109, P3253, DOI 10.1182/blood 2006 09 048249
   Kuwabara T, 2004, APOPTOSIS, V9, P467, DOI 10.1023/B:APPT.0000031453.90821.6a
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Li L, 2002, INFECT IMMUN, V70, P3915, DOI 10.1128/IAI.70.7.3915 3922.2002
   Li LM, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/7580707
   Li M, 2019, SCI REP UK, V9, DOI 10.1038/s41598 018 37091 8
   Li QQ, 2017, PROTEIN CELL, V8, P439, DOI 10.1007/s13238 017 0385 7
   Li XY, 2017, BIOCHEM BIOPH RES CO, V493, P928, DOI 10.1016/j.bbrc.2017.09.119
   Liu R, 2015, VET RES COMMUN, V39, P31, DOI 10.1007/s11259 015 9626 5
   Marycz K, 2017, MAR DRUGS, V15, DOI 10.3390/md15120385
   Michalak I, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205590
   Michalak I, 2013, APPL BIOCHEM BIOTECH, V170, P1389, DOI 10.1007/s12010 013 0269 0
   Michalak I, 2009, WORLD J MICROB BIOT, V25, P997, DOI 10.1007/s11274 009 9976 7
   Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371 2380.1996
   Nakashima T, 2011, ANN NY ACAD SCI, V1240, P13
   Panteli M, 2016, EFORT OPEN REV, V1, P128, DOI 10.1302/2058 5241.1.000017
   Peng SP, 2016, MOL MED REP, V14, P623, DOI 10.3892/mmr.2016.5335
   Rachek LI, 2007, ENDOCRINOLOGY, V148, P293, DOI 10.1210/en.2006 0998
   Sakuma Y, 2000, INFECT IMMUN, V68, P6819, DOI 10.1128/IAI.68.12.6819 6825.2000
   Sun WJ, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.15
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tang YZ, 2003, ADSORPT SCI TECHNOL, V21, P525, DOI 10.1260/026361703771953587
   Tsai PH, 2015, STEM CELLS DEV, V24, P2561, DOI 10.1089/scd.2015.0066
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   Wang MN, 2011, ANN NY ACAD SCI, V1240, P61, DOI 10.1111/j.1749 6632.2011.06258.x
   Wang TG, 2004, J NEUROCHEM, V88, P939, DOI 10.1046/j.1471 4159.2003.02242.x
   Witkowska Z, 2016, INT J ENVIRON SCI TE, V13, P1089, DOI 10.1007/s13762 016 0945 z
   Witkowska Z, 2013, ADSORPT SCI TECHNOL, V31, P421, DOI 10.1260/0263 6174.31.5.421
   Yavropoulou M. P., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P204
   Yu MJ, 2009, J BIOL CHEM, V284, P32968, DOI 10.1074/jbc.M109.001016
   Zhang W, 2018, DNA CELL BIOL, V37, P199, DOI 10.1089/dna.2017.3936
NR 60
TC 13
Z9 13
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JUL
PY 2020
VL 24
IS 13
BP 7282
EP 7300
DI 10.1111/jcmm.15294
EA JUN 2020
PG 19
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA MN5DL
UT WOS:000537593000001
PM 32497406
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Rezende, E
   Bradaschia Correa, V
   Siviero, F
   Ambrosio, LMB
   Arana Chavez, VE
AF Rezende, Eloiza
   Bradaschia Correa, Vivian
   Siviero, Fabio
   Ambrosio, Lucas M. B.
   Arana Chavez, Victor E.
TI Effects of bisphosphonates on osteogenesis and osteoclastogenesis
   signaling during the endochondral ossification of growing rats
SO CELL AND TISSUE RESEARCH
LA English
DT Article
DE Endochondral ossification; Bone development; Bisphosphonate;
   Alendronate; Etidronate
ID ALENDRONATE TREATED RATS; REAL TIME PCR; TOOTH ERUPTION; BONE FORMATION;
   ETHANE 1 HYDROXY 1,1 DIPHOSPHONATE EHDP; CALCIUM METABOLISM;
   GROWTH PLATE; RT PCR; 1 DIPHOSPHONATE; RESORPTION
AB Osteoclasts and chondroclasts are necessary, during endochondral ossification, for the resorption of primary bone and calcified cartilage septa, respectively. The bisphosphonates inhibit mineralized tissue resorption by various mechanisms according to the different types of this drug, which can affect bone remodeling during skeletal growth. The objective of the present study is to analyze the way that alendronate (ALN) and etidronate (ETN) can affect osteoclastogenesis and bone formation during endochondral ossification of the long bones of growing rats. Newborn Wistar rats were treated daily with ETN, ALN, or sterile saline solution (control) for 21 days. Their femur and tibiae epiphyses were radiographed and analyzed by light, scanning and transmission electron microscopy. The expression of genes related to osteogenesis and to osteoclast differentiation and activity were analyzed by real time quantitative polymerase chain reaction. The ETN group presented reduced body weight, disorganized growth plate and an extended area of cartilage in the ossification zone with little bone matrix; in the ALN group, this area was not altered. The ALN presented latent TRAP positive cells, whereas in the ETN group, they were activated. The expression of NF kappa B1 and 2, OPG, Spp1 and Runx2 in the ossification zone was reduced by both bisphosphonates. RANKL expression was reduced by ETN, whereas ALN decreased the expression of RANK. The results also indicated that, in addition to the anti resorptive effect of the drugs, disturbances in bone deposition occurred concomitantly with the reduced expression of osteogenesis related genes.
C1 [Rezende, Eloiza; Siviero, Fabio] Univ Sao Paulo, Inst Biomed Sci, Dept Cell & Dev Biol, Sao Paulo, Brazil.
   [Bradaschia Correa, Vivian; Ambrosio, Lucas M. B.; Arana Chavez, Victor E.] Univ Sao Paulo, Sch Dent, Dept Biomat & Oral Biol, BR 05508900 Sao Paulo, SP, Brazil.
C3 Universidade de Sao Paulo; Institute Biomed Science, University Sao
   Paulo; Universidade de Sao Paulo
RP Arana Chavez, VE (通讯作者)，Univ Sao Paulo, Sch Dent, Dept Biomat & Oral Biol, BR 05508900 Sao Paulo, SP, Brazil.
EM vearana@usp.br
RI Siviero, Fábio/C 9535 2012; Arana Chavez, V/G 4948 2012;
   Bradaschia Correa, Vivian/N 7452 2013; Siviero, Fabio/C 9535 2012
OI Siviero, Fabio/0000 0001 8998 9705
FU FAPESP [2010/07509 8, 2013/02240 9]; CNPq (Brazil); Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [13/02240 9, 10/07509 8]
   Funding Source: FAPESP; Swedish Research Council [2013 02240,
   2010 07509] Funding Source: Swedish Research Council
FX The authors thank Mr. Gaspar Lima for ultrathin sectioning. This work
   was supported by grants from FAPESP (2010/07509 8 and 2013/02240 9) and
   CNPq (Brazil).
CR Arana Chavez VE, 2009, INT J BIOCHEM CELL B, V41, P446, DOI 10.1016/j.biocel.2008.09.007
   Bachrach LK, 2009, J CLIN ENDOCR METAB, V94, P400, DOI 10.1210/jc.2008 1531
   Bianco P, 1998, MATRIX BIOL, V17, P185, DOI 10.1016/S0945 053X(98)90057 9
   Bozal CB, 2005, ARCH TOXICOL, V79, P475, DOI 10.1007/s00204 005 0649 5
   Bradaschia Correa V, 2012, Eur J Histochem, V56, pe24, DOI 10.4081/ejh.2012.24
   Bradaschia Correa V, 2007, CELL TISSUE RES, V330, P475, DOI 10.1007/s00441 007 0499 y
   Bradaschia Correa V, 2013, CELL TISSUE RES, V353, P79, DOI 10.1007/s00441 013 1623 9
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   D'Aoust P, 2000, CELL TISSUE RES, V302, P353, DOI 10.1007/s004419900165
   Ding M, 2008, CALCIFIED TISSUE INT, V82, P77, DOI 10.1007/s00223 007 9093 2
   Fisher JE, 2013, CALCIFIED TISSUE INT, V92, P531, DOI 10.1007/s00223 013 9711 0
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Kamoun Goldrat A, 2008, EUR J ORAL SCI, V116, P195, DOI 10.1111/j.1600 0722.2008.00529.x
   KATOH Y, 1991, BONE, V12, P59, DOI 10.1016/8756 3282(91)90001 Y
   Kim MS, 2009, ANAT HISTOL EMBRYOL, V38, P321, DOI 10.1111/j.1439 0264.2009.00938.x
   LARSSON A, 1978, ACTA PATH MICRO IM A, V86, P211
   Lerner UH, 2000, MATRIX BIOL, V19, P107, DOI 10.1016/S0945 053X(00)00052 4
   Li Yi, 2008, Journal of Medical and Dental Sciences, V55, P255
   Li ZP, 2006, BIOCHEM BIOPH RES CO, V343, P345, DOI 10.1016/j.bbrc.2006.02.147
   Maasalu K, 2003, ACTA PAEDIATR, V92, P452
   Mackie EJ, 2011, J ENDOCRINOL, V211, P109, DOI 10.1530/JOE 11 0048
   Marshall OJ, 2004, BIOINFORMATICS, V20, P2471, DOI 10.1093/bioinformatics/bth254
   Massa LF, 2000, EUR J ORAL SCI, V108, P74, DOI 10.1034/j.1600 0722.2000.00753.x
   Massa LF, 2006, J HISTOCHEM CYTOCHEM, V54, P713, DOI 10.1369/jhc.5A6853.2006
   MILLER SC, 1977, CALC TISS RES, V22, P243, DOI 10.1007/BF02010363
   MILLER SC, 1975, CALC TISS RES, V18, P215, DOI 10.1007/BF02546241
   Oyhanart SR, 2015, PEDIATR RES, V78, P618, DOI 10.1038/pr.2015.163
   Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Riminucci M, 1998, J BONE MINER RES, V13, P1852, DOI 10.1359/jbmr.1998.13.12.1852
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   SCHENK R, 1973, CALC TISS RES, V11, P196, DOI 10.1007/BF02547219
   Shaw NJ, 2005, ARCH DIS CHILD, V90, P206
   Shimizu E, 2012, J DENT RES, V91, P268, DOI 10.1177/0022034511432170
   Shirai T, 2011, J ORTHOP RES, V29, P1572, DOI 10.1002/jor.21394
   Sparidans RW, 1998, PHARM WORLD SCI, V20, P206, DOI 10.1023/A:1008626026484
   Takano Y, 1998, EUR J ORAL SCI, V106, P274, DOI 10.1111/j.1600 0722.1998.tb02187.x
   Turek J, 2012, CALCIFIED TISSUE INT, V90, P202, DOI 10.1007/s00223 012 9570 0
   Väänänen HK, 2000, J CELL SCI, V113, P377
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb 2002 3 7 research0034
   Yamamoto Silva FP, 2013, MICROSC RES TECHNIQ, V76, P633, DOI 10.1002/jemt.22210
NR 44
TC 12
Z9 12
U1 0
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0302 766X
EI 1432 0878
J9 CELL TISSUE RES
JI Cell Tissue Res.
PD MAY
PY 2017
VL 368
IS 2
BP 287
EP 300
DI 10.1007/s00441 017 2574 3
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA ES9YB
UT WOS:000399916800006
PM 28220293
DA 2025 08 17
ER

PT J
AU Sun, Z
   Luo, ZJ
AF Sun, Zhen
   Luo, Zhuo Jing
TI Osteoporosis therapies might lead to intervertebral disc degeneration
   via affecting cartilage endplate
SO MEDICAL HYPOTHESES
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; SPINE
AB Osteoporosis and intervertebral disc degeneration (IDD) are both age related diseases of the musculoskeletal system. With the average life expectancy longer than ever, the morbidity caused by these two diseases is increasing. Nowadays, treatment strategies for osteoporosis are mainly aimed at increasing the mineral density of the bone. Some of these therapies, including vitamin D, calcium, bisphosphonates, Wnt signal activators and parathyroid hormone regulators, have been suggested to be capable of causing calcification of the cartilage endplate in the intervertebral disc. This alteration could block nutrient and oxygen transportation to the center part of the disc, thus lead to intervertebral disc degeneration. Consequently, we hypothesize that osteoporosis therapies might be a potential risk for IDD. This assumption indicates that we should take the alterations of the cartilage endplate into consideration in further osteoporosis treatment to avoid IDD in the patient.
C1 [Sun, Zhen; Luo, Zhuo Jing] Fourth Mil Med Univ, Dept Orthoped, Xijing Hosp, West Changle Rd, Xian 710032, Shaanxi, Peoples R China.
C3 Air Force Medical University
RP Luo, ZJ (通讯作者)，Fourth Mil Med Univ, Dept Orthoped, Xijing Hosp, West Changle Rd, Xian 710032, Shaanxi, Peoples R China.
EM zhuojingluo@126.com
FU Xijing Hospital Foundation [XJZT18MJ17]
FX This work was funded by Xijing Hospital Foundation, XJZT18MJ17, China.
CR Aguilar EA, 2015, AM J MED SCI, V350, P357, DOI 10.1097/MAJ.0000000000000562
   Boos N, 2002, SPINE, V27, P2631, DOI 10.1097/00007632 200212010 00002
   Cairoli E, 2015, J ENDOCRINOL INVEST, V38, P303, DOI 10.1007/s40618 014 0236 9
   Chanchairujira K, 2004, RADIOLOGY, V230, P499, DOI 10.1148/radiol.2302011842
   Churchman SM, 2012, ARTHRITIS RHEUM US, V64, P2632, DOI 10.1002/art.34434
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Fitzpatrick LA, 2011, J CLIN ENDOCR METAB, V96, P2441, DOI 10.1210/jc.2010 2855
   Kageyama Goichi, 2015, Rinsho Byori, V63, P570
   Li XF, 2017, SPINE, V42, pE8, DOI 10.1097/BRS.0000000000001701
   Liou SF, 2015, J CELL PHYSIOL, V230, P2038, DOI 10.1002/jcp.24904
   Lockefeer J H, 1990, Ned Tijdschr Geneeskd, V134, P1931
   Luo Y, 2015, EUR SPINE J, V24, P1691, DOI 10.1007/s00586 014 3611 5
   Luo Y, 2013, BONE, V55, P439, DOI 10.1016/j.bone.2013.03.002
   Mäkitie RE, 2017, BONE, V101, P3, DOI 10.1016/j.bone.2017.04.001
   McClung MR, 2015, ENDOCRINOL METAB SEO
   Mirza S K, 1995, J Clin Laser Med Surg, V13, P131
   Narcisi R, 2015, STEM CELL REP, V4, P459, DOI 10.1016/j.stemcr.2015.01.017
   PETTIFOR JM, 1995, ANN INTERN MED, V122, P511, DOI 10.7326/0003 4819 122 7 199504010 00006
   Ravault P P, 1969, Rev Lyon Med, V18, P603
   Reginster JY, 2014, BEST PRACT RES CL EN, V28, P809, DOI 10.1016/j.beem.2014.09.003
   Renders GAP, 2014, CALCIFIED TISSUE INT, V95, P436, DOI 10.1007/s00223 014 9912 1
   Roberts S, 2006, J BONE JOINT SURG AM, V88A, P10, DOI 10.2106/JBJS.F.00019
   Saidak Z, 2015, J BIOL CHEM, V290, P6903, DOI 10.1074/jbc.M114.621219
   Tomaszewski KA, 2015, FOLIA MORPHOL, V74, P157, DOI 10.5603/FM.2015.0026
   Turgut M, 2003, NEUROSURG REV, V26, P133, DOI 10.1007/s10143 003 0259 8
   Urban JPG, 2004, SPINE, V29, P2700, DOI 10.1097/01.brs.0000146499.97948.52
   Wang L, 2014, ASIAN PAC J TROP MED, V7, P796, DOI 10.1016/S1995 7645(14)60139 5
   Xiao ZF, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1701 1
   Zhou Z, 2015, SPINE, V40, pE1073, DOI 10.1097/BRS.0000000000001092
NR 29
TC 20
Z9 23
U1 0
U2 17
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306 9877
EI 1532 2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD APR
PY 2019
VL 125
BP 5
EP 7
DI 10.1016/j.mehy.2019.02.003
PG 3
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA HR9FD
UT WOS:000463463700002
PM 30902151
DA 2025 08 17
ER

PT J
AU Lin, ZH
   Zhou, ZG
   Ye, JJ
   Wei, JF
   Chen, SZ
   Zhou, WY
   Bi, YH
   Zhou, ZB
   Xie, G
   Yuan, GX
   Yao, GF
AF Lin, Zihong
   Zhou, Zhigao
   Ye, Jiajie
   Wei, Jinfu
   Chen, Shaozhe
   Zhou, Wenyun
   Bi, Yonghao
   Zhou, Zibin
   Xie, Gang
   Yuan, Guixin
   Yao, Guanfeng
TI Trifolirhizin protects ovariectomy induced bone loss in mice by
   inhibiting osteoclast differentiation and bone resorption
SO HELIYON
LA English
DT Article
DE Trifolirhizin; Osteoclast differentiation; Osteoporosis; Osteoclast;
   MAPK NFAT signaling pathway
ID OSTEOPROTEGERIN; WOMEN
AB Background: Osteoporosis is a debilitating condition characterized by reduced bone density and microstructure, leading to increased susceptibility to fractures and increased mortality, particularly among older individuals. Despite the availability of drugs for osteoporosis treatment, the need for targeted and innovative agents with fewer adverse effects persists. Trifolirhizin, a natural pterostalin derived from the root of Sophora flavescens, has been previously studied for its effects on certain anticancer and antiinflammatory. The impact of trifolirhizin on the formation and function of osteoclasts remain unclear. Purpose: Herein, the possible roles of trifolirhizin the formation and function of osteoclasts and the underlying mechanism were explored. Methods: Bone marrow derived macrophages (BMMs) were employed to evaluate the roles of trifolirhizin on steoclastogenesis, bone absorption and the underlying mechanism in vitro. Bone loss model was established by ovariectomy(OVX) in mice in vivo. Results: Trifolirhizin repressed osteoclastogenesis, bone resorption induced by receptor activator of nuclear factor kappa B ligand (RANKL) in vitro. Mechanistically, trifolirhizin inhibits RANKLinduced MAPK signal transduction and NFATc1 expression. Moreover, trifolirhizin inhibited osteoclast marker gene expression, including NFATc1, CTSK, MMP9, DC STAMP, ACP5, and VATPase D2. Additionally, trifolirhizin was found to protect against ovariectomy(OVX) induced bone loss in mice.
C1 [Lin, Zihong; Zhou, Zhigao; Ye, Jiajie; Chen, Shaozhe; Zhou, Wenyun; Bi, Yonghao; Zhou, Zibin; Yuan, Guixin; Yao, Guanfeng] Shantou Univ, Affiliated Hosp 2, Med Coll, Dept Orthoped, Shantou 515000, Guangdong, Peoples R China.
   [Zhou, Zhigao; Ye, Jiajie; Wei, Jinfu; Chen, Shaozhe; Zhou, Wenyun; Bi, Yonghao; Zhou, Zibin; Xie, Gang] Shantou Univ, Med Coll, Shantou, Guangdong, Peoples R China.
   [Lin, Zihong] Dept Shantou Cent Hosp, Shantou, Guangdong, Peoples R China.
   [Wei, Jinfu] South China Univ Technol, Affiliated Hosp 6, Sch Med, Dept Orthoped, Foshan, Guangdong, Peoples R China.
C3 Shantou University; Shantou University; South China University of
   Technology
RP Yuan, GX; Yao, GF (通讯作者)，Shantou Univ, Affiliated Hosp 2, Med Coll, Dept Orthoped, Shantou 515000, Guangdong, Peoples R China.
EM gxyuan@stu.xmu.edu.cn; gfyao@stu.edu.cn
RI Yao, Guanfeng/JPA 5741 2023
FU National Natural Science Foundation of China [82103652]; Open Project of
   Guangxi Key Laboratory of Regenerative Medicine [GZZK201902]; Guangdong
   Province Science and Technology Special Fund [(2020) 53 122,
   2022KTSCX039]; Guangdong Provincial Natural Science Foundation
   [2024A1515013227]; Medical Science and Technology Research Fund project
   of Guangdong Province
FX This work was supported by the National Natural Science Foundation of
   China (grant number 82103652) ; Open Project of Guangxi Key Laboratory
   of Regenerative Medicine (GZZK201902) ; Guangdong Province Science and
   Technology Special Fund (No. ShanFuKe (2020) 53 122, 2022KTSCX039) ;
   Guangdong Provincial Natural Science Foundation (2024A1515013227) and
   Medical Science and Technology Research Fund project of Guangdong
   Province (No.B2021389) .
CR Adachi JD, 2001, OSTEOPOROSIS INT, V12, P903, DOI 10.1007/s001980170017
   Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   An YA, 2019, FASEB J, V33, P12515, DOI 10.1096/fj.201802805RR
   Bernard NJ, 2019, NAT REV RHEUMATOL, V15, P128, DOI 10.1038/s41584 019 0181 2
   Bessette L, 2008, OSTEOPOROSIS INT, V19, P79, DOI 10.1007/s00198 007 0426 9
   Ding D, 2022, INT J MOL MED, V49, DOI 10.3892/ijmm.2021.5059
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Guo JC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 03046 z
   Han JK, 2018, J CELL BIOCHEM, V119, P7310, DOI 10.1002/jcb.27028
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Ko WG, 2000, TOXICOL IN VITRO, V14, P429, DOI 10.1016/S0887 2333(00)00041 2
   Li ZN, 2019, BIOCHEM PHARMACOL, V163, P279, DOI 10.1016/j.bcp.2019.02.002
   Liu Y, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03939 7
   Looker AC, 1997, J BONE MINER RES, V12, P1761, DOI 10.1359/jbmr.1997.12.11.1761
   Nih T., 2001, JAMA, V285, P785, DOI [10.1001/jama.285.6.785, DOI 10.1001/JAMA.285.6.785]
   Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331
   Rahmani P, 2009, CAN MED ASSOC J, V181, P815, DOI 10.1503/cmaj.080709
   Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Sitara D, 2010, IMMUNOL REV, V233, P286, DOI 10.1111/j.0105 2896.2009.00849.x
   Sun DD, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392 020 00281 w
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   Yang X, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.664697
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zhou HP, 2009, J AGR FOOD CHEM, V57, P4580, DOI 10.1021/jf900340b
   Zhou T, 2019, REDOX REP, V24, P62, DOI 10.1080/13510002.2019.1658376
   Zou W, 2010, ANN NY ACAD SCI, V1192, P27, DOI 10.1111/j.1749 6632.2009.05245.x
NR 27
TC 2
Z9 2
U1 1
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2405 8440
J9 HELIYON
JI Heliyon
PD JUL 30
PY 2024
VL 10
IS 14
AR e34250
DI 10.1016/j.heliyon.2024.e34250
EA JUL 2024
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA ZI5K3
UT WOS:001274677700001
PM 39130482
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Bone, HG
   Bolognese, MA
   Yuen, CK
   Kendler, DL
   Miller, PD
   Yang, YC
   Grazette, L
   San Martin, J
   Gallagher, JC
AF Bone, Henry G.
   Bolognese, Michael A.
   Yuen, Chui Kin
   Kendler, David L.
   Miller, Paul D.
   Yang, Yu Ching
   Grazette, Luanda
   San Martin, Javier
   Gallagher, J. Christopher
TI Effects of Denosumab Treatment and Discontinuation on Bone Mineral
   Density and Bone Turnover Markers in Postmenopausal Women with Low Bone
   Mass
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID HORMONE REPLACEMENT THERAPY; FRACTURE RISK REDUCTION; ESTROGEN THERAPY;
   MEVALONATE PATHWAY; ALENDRONATE; OSTEOPOROSIS; BISPHOSPHONATES;
   WITHDRAWAL; TERIPARATIDE; COMBINATION
AB Context: Denosumab treatment for 24 months increased bone mineral density (BMD) and reduced bone turnover markers (BTM) in postmenopausal women.
   Objective: The aim was to determine the effects of prior denosumab or placebo injections on BMD, BTM, and safety over 24 months after treatment discontinuation.
   Design: We conducted an off treatment extension of a phase 3, randomized, double blind, parallel group study.
   Participants: A total of 256 postmenopausal women with a mean age of 59 yr and a mean lumbar spine T score of  1.61 at randomization participated in the study.
   Interventions: Participants received placebo or 60 mg denosumab every 6 months for 24 months, followed by 24 months off treatment.
   Main Outcome Measures: We measured the percentage changes in BMD and BTM, and evaluated safety.
   Results: Of the 256 participants enrolled in the posttreatment phase, 87% completed the study. During 24 months of denosumab treatment, BMD increased (lumbar spine, 6.4%; total hip, 3.6%; 1/3 radius, 1.4%), and BTM decreased (serum C terminal telopeptide of type 1 collagen, 63%; and N terminal propeptide of type 1 procollagen, 47%), compared with placebo. After discontinuation, BMD declined, but the previously treated denosumab group maintained higher BMD than the previously treated placebo group at these sites (P <= 0.05). Final BMD at month 48 strongly correlated with month 0 BMD. After denosumab discontinuation, BTM increased above baseline within 3 months (serum C terminal telopeptide of type 1 collagen) or 6 months (N terminal propeptide of type 1 procollagen) and returned to baseline by month 48. Adverse event rates during the off treatment phase were similar between groups.
   Conclusions: In postmenopausal women with low BMD, the effects of 60 mg denosumab treatment for 24 months on BMD and BTM are reversible upon discontinuation, reflecting its biological mechanism of action. Residual BMD measurements remained above those of the group previously treated with placebo. (J Clin Endocrinol Metab 96: 972 980, 2011)
C1 [Bone, Henry G.] Michigan Bone & Mineral Clin, Detroit, MI 48236 USA.
   [Bolognese, Michael A.] Bethesda Hlth Res Ctr, Bethesda, MD 20817 USA.
   [Yuen, Chui Kin] Univ Manitoba, Winnipeg, MB R3T 2N2, Canada.
   [Kendler, David L.] Clin Res Ctr, Vancouver, BC V6H 3X8, Canada.
   [Miller, Paul D.] Colorado Ctr Bone Res, Lakewood, CO 80227 USA.
   [Yang, Yu Ching; Grazette, Luanda; San Martin, Javier] Amgen Inc, Thousand Oaks, CA 91320 USA.
   [Gallagher, J. Christopher] Creighton Univ, Med Ctr, Omaha, NE 68131 USA.
C3 University of Manitoba; Colorado Center For Bone Research; Amgen;
   Creighton University
RP Bone, HG (通讯作者)，Michigan Bone & Mineral Clin, 22201 Moross Rd,Suite 260, Detroit, MI 48236 USA.
EM hgbone.md@att.net
RI ; Wang, Yuhui/JTT 7711 2023; Grazette, Luanda/AAJ 5965 2020
OI gallagher, john christopher/0000 0002 5129 9183; Kendler,
   David/0000 0001 7679 3965; 
FU Amgen Inc.; Eli Lilly; GSK; Novartis; Nycomed; Roche; Wyeth; Unigene
FX Disclosure Summary: Amgen Inc. sponsored this study. H. G. B. is an
   investigator, consultant, advisory board member, and/or speaker for
   Amgen Inc., Eli Lilly, GlaxoSmithKline (GSK), Merck, Nordic Bioscience,
   Novartis, and Zelos. M. A. B. is an investigator, advisory board member,
   and/or speaker for Amgen Inc., Eli Lilly, GSK, Novartis, Procter &
   Gamble, and Roche. C.K.Y. is an investigator for Amgen Inc. and an
   advisory board member for Amgen Canada, Novartis Canada, and Servier
   Canada. D. L. K. is an adviser and speaker and/or receives research
   grants from Amgen Inc., Eli Lilly, GSK, Novartis, Nycomed, Roche, and
   Wyeth. P. D. M. is an investigator, consultant, advisory board member,
   and/or speaker for Amgen Inc., Eli Lilly, GSK, Merck, Novartis,
   Procter&Gamble, Roche, and Sanofi/Aventis. Y. C.Y., L. G., and J.S.M.
   are employed by Amgen Inc. J.C.G. is a consultant for Wyeth, and
   receives research grants from Amgen Inc., Wyeth, and Unigene.
CR [Anonymous], 2003, World Health Organ Tech Rep Ser, V921, P1
   [Anonymous], 2004, Bone Health and Osteoporosis: A report of the Surgeon General
   Ascott Evans BH, 2003, ARCH INTERN MED, V163, P789, DOI 10.1001/archinte.163.7.789
   Banks E, 2004, JAMA J AM MED ASSOC, V291, P2212, DOI 10.1001/jama.291.18.2212
   Barrett Connor E, 2003, MENOPAUSE, V10, P412, DOI 10.1097/01.GME.0000086467.82759.DA
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Bone HG, 2008, J CLIN ENDOCR METAB, V93, P2149, DOI 10.1210/jc.2007 2814
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Ensrud KE, 2004, J BONE MINER RES, V19, P1259, DOI 10.1359/JBMR.040326
   ETTINGER B, 1993, NEW ENGL J MED, V329, P1192, DOI 10.1056/NEJM199310143291610
   FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Gallagher JC, 2002, J CLIN ENDOCR METAB, V87, P4914, DOI 10.1210/jc.2002 020727
   Greendale GA, 2002, ARCH INTERN MED, V162, P665, DOI 10.1001/archinte.162.6.665
   Greenspan SL, 2002, ANN INTERN MED, V137, P875, DOI 10.7326/0003 4819 137 11 200212030 00008
   Heiss G, 2008, JAMA J AM MED ASSOC, V299, P1036, DOI 10.1001/jama.299.9.1036
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lewiecki EM, 2007, J BONE MINER RES, V22, P1832, DOI 10.1359/JBMR.070809
   Lindsay R, 2004, ARCH INTERN MED, V164, P2024, DOI 10.1001/archinte.164.18.2024
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Neele SJM, 2002, BONE, V30, P599, DOI 10.1016/S8756 3282(01)00706 2
   Prince R, 2005, J BONE MINER RES, V20, P1507, DOI 10.1359/JBMR.050501
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Sornay Rendu E, 2003, BONE, V33, P159, DOI 10.1016/S8756 3282(03)00171 6
   Thomsen K, 1987, Gynecol Endocrinol, V1, P169, DOI 10.3109/09513598709030680
   Trémollieres FA, 2001, OSTEOPOROSIS INT, V12, P385, DOI 10.1007/s001980170107
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Wasnich Richard D, 2004, Menopause, V11, P622
   Watts NB, 2008, OSTEOPOROSIS INT, V19, P365, DOI 10.1007/s00198 007 0460 7
   Yates J, 2004, OBSTET GYNECOL, V103, P440, DOI 10.1097/01.AOG.0000114986.14806.37
NR 35
TC 443
Z9 465
U1 0
U2 19
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021 972X
EI 1945 7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD APR
PY 2011
VL 96
IS 4
BP 972
EP 980
DI 10.1210/jc.2010 1502
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 746JO
UT WOS:000289242800038
PM 21289258
OA Bronze
DA 2025 08 17
ER

PT J
AU Koide, M
   Kinugawa, S
   Ninomiya, T
   Mizoguchi, T
   Yamashita, T
   Maeda, K
   Yasuda, H
   Kobayashi, Y
   Nakamura, H
   Takahashi, N
   Udagawa, N
AF Koide, Masanori
   Kinugawa, Saya
   Ninomiya, Tadashi
   Mizoguchi, Toshihide
   Yamashita, Teruhito
   Maeda, Kazuhiro
   Yasuda, Hisataka
   Kobayashi, Yasuhiro
   Nakamura, Hiroaki
   Takahashi, Naoyuki
   Udagawa, Nobuyuki
TI Diphenylhydantoin Inhibits Osteoclast Differentiation and Function
   Through Suppression of NFATc1 Signaling
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE diphenylhydantoin; osteoclasts; nuclear factor of activated T cells c1;
   bone resorption; calcium channel
ID DRUG INDUCED OSTEOMALACIA; C FOS EXPRESSION; BONE RESORPTION; TERMINAL
   DIFFERENTIATION; IN VITRO; CYP24 EXPRESSION; MOUSE CALVARIA; PHENYTOIN;
   CELLS; OSTEOPROTEGERIN
AB Diphenylhydantoin (DPH) is widely used as an anticonvulsant drug. We examined the effects of DPH on osteoclast differentiation and function using in vivo and in vitro assay systems. Transgenic mice overexpressing a soluble form of RANKL (RANKL Tg) exhibited increased osteoclastic bone resorption. Injection of DPH into the subcutaneous tissue overlying calvaria of RANKL Tg mice suppressed the enhanced resorption in the calvaria. In co cultures of mouse osteoblasts and bone marrow cells, DPH inhibited lipopolysaccharide (LPS) induced osteoclast formation. DPH affected neither the mRNA expression of RANKL and osteoprotegerin nor the growth of mouse osteoblasts in culture. On the other hand, DPH inhibited the RANKL induced formation of osteoclasts in cultures of mouse bone marrow derived macrophages (BMM phi s) and of human peripheral blood derived CD14(+) cells. DPH concealed LPS induced bone resorption in mouse calvarial organ cultures and inhibited the pit forming activity of mouse osteoclasts cultured on dentine slices. DPH suppressed the RANKL induced calcium oscillation and expression of nuclear factor of activated T cells c1 (NFATc1) and c fos in BMM phi s. Moreover, DPH inhibited the RANKL induced nuclear localization and auto amplification of NFATc1. in mature osteoclasts. Both BMM phi s and osteoclasts expressed mRNA of a T type calcium channel, Cav3.2, a target of DPH. Blocking the expression of Cav3.2 by short hairpin RNAs significantly suppressed RANKL induced osteoclast differentiation. These results suggest that DPH inhibits osteoclast differentiation and function through suppression of NFATc1 signaling. The topical application of DPH may be a therapeutic treatment to prevent bone loss induced by local inflammation such as periodontitis. J Bone Miner Res 2009;24:1469 1480. Published online on March 16, 2009; doi: 10.1359/JBMR.090302
C1 [Udagawa, Nobuyuki] Matsumoto Dent Univ, Dept Biochem, Nagano 3990781, Japan.
   [Nakamura, Hiroaki] Matsumoto Dent Univ, Dept Oral Histol, Nagano 3990781, Japan.
   [Yasuda, Hisataka] Oriental Yeast Co, Nagahama Inst Biochem Sci, Shiga, Japan.
   [Koide, Masanori; Kinugawa, Saya; Ninomiya, Tadashi; Mizoguchi, Toshihide; Yamashita, Teruhito; Maeda, Kazuhiro; Kobayashi, Yasuhiro; Takahashi, Naoyuki; Udagawa, Nobuyuki] Matsumoto Dent Univ, Inst Oral Sci, Nagano 3990781, Japan.
C3 Matsumoto Dental University; Matsumoto Dental University; Oriental Yeast
   Co., Ltd.; Matsumoto Dental University
RP Udagawa, N (通讯作者)，Matsumoto Dent Univ, Dept Biochem, 1780 Hirooka Gobara, Nagano 3990781, Japan.
EM udagawa@po.mdu.ac.jp
RI ; Maeda, Kazuhiro/ABD 5762 2020; KOBAYASHI, YASUHIRO/AAU 4931 2021;
   Koide, Masanori/ABE 9670 2020
OI Koide, Masanori/0000 0002 6511 9999; Kobayashi,
   Yasuhiro/0000 0002 0903 3226; Yasuda, Hisataka/0000 0003 3511 609X
FU Ministry of Education, Culture, Sports, Science, and Technology of Japan
   [18791604, 18390495, 18390557, 18659618]; Grants in Aid for Scientific
   Research [21592378, 18390495, 18390557, 18659618, 18791604] Funding
   Source: KAKEN
FX This work was supported in part by Grants in Aid 18791604, 18390495,
   18390557, and 18659618 from the Ministry of Education, Culture, Sports,
   Science, and Technology of Japan.
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   CHAMBERS TJ, 1982, J PATHOL, V136, P27, DOI 10.1002/path.1711360104
   Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02 07 0389
   Gao ZY, 1998, EUR J NEUROSCI, V10, P2416, DOI 10.1046/j.1460 9568.1998.00252.x
   HAHN TJ, 1978, J CLIN INVEST, V62, P406, DOI 10.1172/JCI109142
   Hoenderop JGJ, 2003, J CLIN INVEST, V112, P1906, DOI 10.1172/JCI200319826
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Ikeda F, 2006, J IMMUNOL, V177, P2384, DOI 10.4049/jimmunol.177.4.2384
   Ikedo D, 1999, BONE, V25, P653, DOI 10.1016/S8756 3282(99)00222 7
   ISHIHARA Y, 1991, J PERIODONTAL RES, V26, P155, DOI 10.1111/j.1600 0765.1991.tb01639.x
   Kataoka M, 2005, BIOL PHARM BULL, V28, P1817, DOI 10.1248/bpb.28.1817
   Kohda M, 1996, J PHYSIOL LONDON, V492, P315, DOI 10.1113/jphysiol.1996.sp021311
   Komarova SV, 2005, P NATL ACAD SCI USA, V102, P2643, DOI 10.1073/pnas.0406874102
   Kuroda Y, 2008, P NATL ACAD SCI USA, V105, P8643, DOI 10.1073/pnas.0800642105
   Lee J, 2007, NEUROSCIENCE, V149, P602, DOI 10.1016/j.neuroscience.2007.08.013
   LERNER U, 1985, J ORAL PATHOL MED, V14, P644, DOI 10.1111/j.1600 0714.1985.tb00542.x
   Masuyama R, 2008, CELL METAB, V8, P257, DOI 10.1016/j.cmet.2008.08.002
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Mizuno A, 2002, J BONE MINER METAB, V20, P337, DOI 10.1007/s007740200049
   Nakade O, 1996, J BONE MINER RES, V11, P1880
   NAKAMURA I, 1995, FEBS LETT, V361, P79, DOI 10.1016/0014 5793(95)00153 Z
   Onodera K, 2001, CALCIFIED TISSUE INT, V69, P109, DOI 10.1007/s00223 001 0020 7
   Pascussi JM, 2005, J CLIN INVEST, V115, P177, DOI 10.1172/JCI200521867
   Saltel F, 2004, MOL BIOL CELL, V15, P5231, DOI 10.1091/mbc.E04 06 0522
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Suda K, 2004, J IMMUNOL, V172, P2504, DOI 10.4049/jimmunol.172.4.2504
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Suzuki H, 1996, ENDOCRINOLOGY, V137, P4685, DOI 10.1210/en.137.11.4685
   Takahashi A, 2000, JPN J PHARMACOL, V82, P82, DOI 10.1254/jjp.82.82
   Takahashi N, 2002, PRINCIPLES BONE BIOL, P109
   Takahashi Naoyuki, 2007, V135, P285
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Take I, 2005, ENDOCRINOLOGY, V146, P5204, DOI 10.1210/en.2005 0451
   Tarnawa Istvan, 2007, Recent Pat CNS Drug Discov, V2, P57, DOI 10.2174/157488907779561754
   Taubman MA, 2005, J PERIODONTOL, V76, P2033, DOI 10.1902/jop.2005.76.11 S.2033
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Todorovic SM, 2000, MOL PHARMACOL, V58, P98, DOI 10.1124/mol.58.1.98
   Tunnicliff G, 1996, GEN PHARMACOL, V27, P1091, DOI 10.1016/S0306 3623(96)00062 6
   Väänänen HK, 2000, J CELL SCI, V113, P377
   Valsamis HA, 2006, NUTR METABOLISM, V3, DOI 10.1186/1743 7075 3 36
   van der Eerden BCJ, 2005, P NATL ACAD SCI USA, V102, P17507, DOI 10.1073/pnas.0505789102
   YAARI Y, 1986, ANN NEUROL, V20, P171, DOI 10.1002/ana.410200202
   Yang SY, 2007, J BONE MINER RES, V22, P45, DOI 10.1359/JBMR.061007
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
   Zhao HB, 2006, J BONE MINER RES, V21, P456, DOI 10.1359/JBMR.051204
   Zhao RB, 2007, EUR J NEUROSCI, V25, P1127, DOI 10.1111/j.1460 9568.2007.05359.x
   Zhou CC, 2006, J CLIN INVEST, V116, P1703, DOI 10.1172/JCI27793
NR 49
TC 33
Z9 35
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD AUG
PY 2009
VL 24
IS 8
BP 1469
EP 1480
DI 10.1359/JBMR.090302
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 482CK
UT WOS:000268861300015
PM 19292614
OA Bronze
DA 2025 08 17
ER

PT J
AU Garcia Gomez, A
   De Las Rivas, J
   Ocio, EM
   Díaz Rodríguez, E
   Montero, JC
   Martín, M
   Blanco, JF
   Sanchez Guijo, FM
   Pandiella, A
   Miguel, JFS
   Garayoa, M
AF Garcia Gomez, Antonio
   De Las Rivas, Javier
   Ocio, Enrique M.
   Diaz Rodriguez, Elena
   Montero, Juan C.
   Martin, Montserrat
   Blanco, Juan F.
   Sanchez Guijo, Fermin M.
   Pandiella, Atanasio
   Miguel, Jesus F. San
   Garayoa, Mercedes
TI Transcriptomic profile induced in bone marrow mesenchymal stromal cells
   after interaction with multiple myeloma cells: implications in myeloma
   progression and myeloma bone disease
SO ONCOTARGET
LA English
DT Article
DE multiple myeloma; bone marrow mesenchymal stromal cells; tumor stroma
   interactions; gene expression profiling; co culture techniques; myeloma
   bone disease
ID STEM CELLS; CXC CHEMOKINES; OSTEOBLAST LINEAGE; GROWTH FACTORS;
   TUMOR CELLS; DIFFERENTIATION; EXPRESSION; MICROENVIRONMENT;
   PATHOGENESIS; ACTIVATION
AB Despite evidence about the implication of the bone marrow (BM) stromal microenvironment in multiple myeloma (MM) cell growth and survival, little is known about the effects of myelomatous cells on BM stromal cells. Mesenchymal stromal cells (MSCs) from healthy donors (dMSCs) or myeloma patients (pMSCs) were co cultured with the myeloma cell line MM.1S, and the transcriptomic profile of MSCs induced by this interaction was analyzed. Deregulated genes after co culture common to both d/pMSCs revealed functional involvement in tumor microenvironment crosstalk, myeloma growth induction and drug resistance, angiogenesis and signals for osteoclast activation and osteoblast inhibition. Additional genes induced by co culture were exclusively deregulated in pMSCs and predominantly associated to RNA processing, the ubiquitine proteasome pathway, cell cycle regulation, cellular stress and non canonical Wnt signaling. The upregulated expression of five genes after co culture (CXCL1, CXCL5 and CXCL6 in d/pMSCs, and Neuregulin 3 and Norrie disease protein exclusively in pMSCs) was confirmed, and functional in vitro assays revealed putative roles in MM pathophysiology. The transcriptomic profile of pMSCs co cultured with myeloma cells may better reflect that of MSCs in the BM of myeloma patients, and provides new molecular insights to the contribution of these cells to MM pathophysiology and to myeloma bone disease.
C1 [Garcia Gomez, Antonio; De Las Rivas, Javier; Ocio, Enrique M.; Diaz Rodriguez, Elena; Montero, Juan C.; Martin, Montserrat; Pandiella, Atanasio; Miguel, Jesus F. San; Garayoa, Mercedes] Univ Salamanca, IBMCC, CSIC, Ctr Invest Canc, E 37008 Salamanca, Spain.
   [Garcia Gomez, Antonio; Ocio, Enrique M.; Blanco, Juan F.; Sanchez Guijo, Fermin M.; Pandiella, Atanasio; Miguel, Jesus F. San; Garayoa, Mercedes] Hosp Univ Salamanca, IBSAL, Salamanca, Spain.
   [Garcia Gomez, Antonio; Martin, Montserrat; Sanchez Guijo, Fermin M.; Miguel, Jesus F. San; Garayoa, Mercedes] Ctr Red Med Regenerat & Terapia Celular Castilla, Salamanca, Spain.
C3 University of Salamanca; Consejo Superior de Investigaciones Cientificas
   (CSIC); CSIC USAL   Instituto de Biologia Molecular y Celular del Cancer
   de Salamanca (IBMCC)
RP Garayoa, M (通讯作者)，Univ Salamanca, IBMCC, CSIC, Ctr Invest Canc, E 37008 Salamanca, Spain.
EM mgarayoa@usal.es
RI ; Montero, Juan Carlos/AAO 1780 2020; San Miguel, Jesús/V 8977 2018;
   Pandiella, Atanasio/O 5180 2014; Garayoa, Mercedes/O 6039 2017; De Las
   Rivas, Javier/G 5936 2014; SAN MIGUEL, JESUS/V 8977 2018; Sanchez Guijo,
   Fermin/D 8542 2018; , Atanasio/O 5180 2014; Diaz Rodriguez,
   Elena/I 4784 2015; Blanco, Juan/AAI 5787 2021
OI Montero, Juan Carlos/0000 0003 4773 053X; Sanchez Guijo,
   Fermin/0000 0002 7076 7739; Garcia, Antonio/0000 0003 0527 7351;
   Garayoa, Mercedes/0000 0003 2194 2841; De Las Rivas,
   Javier/0000 0002 0984 9946; SAN MIGUEL, JESUS/0000 0002 9183 4857; ,
   Atanasio/0000 0002 4704 8971; Diaz Rodriguez, Elena/0000 0002 6240 6327;
   Ocio, Enrique M./0000 0002 5765 0085
FU Spanish MINECO ISCIII [PI12/02591, PI12/00624]; FEDER (European Funds
   for Regional Development); Centro en Red for Regenerative Medicine and
   Cellular Therapy from Castilla y Leon; Spanish Health Thematic Network
   of Cooperative Research in Cancer [RTICC RD12/0056/0058,
   RD12/0036/0003]; Spanish FIS [PS09/01897, PS09/00843]; Spanish Society
   of Hematology and Hemotherapy (SEHH); Spanish Association for Cancer
   Research (AECC)
FX This work was supported by grants from the Spanish MINECO ISCIII
   (PI12/02591, PI12/00624) and FEDER (European Funds for Regional
   Development); the Centro en Red for Regenerative Medicine and Cellular
   Therapy from Castilla y Leon; the Spanish Health Thematic Network of
   Cooperative Research in Cancer (RTICC RD12/0056/0058 and
   RD12/0036/0003), and Spanish FIS (PS09/01897 and PS09/00843). AG G
   received support from the Centro en Red for Regenerative Medicine and
   Cellular Therapy from Castilla y Leon and from the Spanish Society of
   Hematology and Hemotherapy (SEHH), and EDR from the Spanish Association
   for Cancer Research (AECC).
CR Aggarwal R, 2006, EXP HEMATOL, V34, P1289, DOI 10.1016/j.exphem.2006.06.017
   André T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059756
   Arnulf B, 2007, LEUKEMIA, V21, P158, DOI 10.1038/sj.leu.2404466
   Ayala F, 2009, LEUKEMIA, V23, P2233, DOI 10.1038/leu.2009.175
   Baksh D, 2007, J CELL BIOCHEM, V101, P1109, DOI 10.1002/jcb.21097
   Baksh D, 2007, J CELL PHYSIOL, V212, P817, DOI 10.1002/jcp.21080
   Basak GW, 2009, CURR PHARM BIOTECHNO, V10, P335, DOI 10.2174/138920109787847493
   Bendre MS, 2003, BONE, V33, P28, DOI 10.1016/S8756 3282(03)00086 3
   Bergfeld SA, 2010, CANCER METAST REV, V29, P249, DOI 10.1007/s10555 010 9222 7
   Bolzoni M, 2013, LEUKEMIA, V27, P451, DOI 10.1038/leu.2012.190
   Braunger BM, 2012, ADV EXP MED BIOL, V723, P679, DOI 10.1007/978 1 4614 0631 0_86
   Burger JA, 2011, HEMATOL AM SOC HEMAT, P96, DOI 10.1182/asheducation 2011.1.96
   Calabro A, 2002, BLOOD, V100, P2578, DOI 10.1182/blood 2002 01 0030
   Cao YR, 2010, EXP HEMATOL, V38, P860, DOI 10.1016/j.exphem.2010.06.012
   Chang J, 2007, J BIOL CHEM, V282, P30938, DOI 10.1074/jbc.M702391200
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Corre J, 2007, LEUKEMIA, V21, P1079, DOI 10.1038/sj.leu.2404621
   Corre J, 2012, CANCER RES, V72, P1395, DOI 10.1158/0008 5472.CAN 11 0188
   D'Souza S, 2012, BLOOD, V119, P1888, DOI 10.1182/blood 2011 11 393348
   D'Souza S, 2011, BLOOD, V118, P6871, DOI 10.1182/blood 2011 04 346775
   Danjo A, 2007, BIOCHEM BIOPH RES CO, V360, P199, DOI 10.1016/j.bbrc.2007.06.028
   Fontanillo C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024289
   Garayoa M, 2009, LEUKEMIA, V23, P1515, DOI 10.1038/leu.2009.65
   Garcia Gomez A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034914
   Garderet L, 2007, LEUKEMIA LYMPHOMA, V48, P2032, DOI 10.1080/10428190701593644
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Giuliani N, 2005, BLOOD, V106, P2472, DOI 10.1182/blood 2004 12 4986
   Giuliani N, 2008, CANCER RES, V68, P6840, DOI 10.1158/0008 5472.CAN 08 0402
   Giuliani N, 2011, CANCER MICROENVIRON, V4, P325, DOI 10.1007/s12307 011 0072 9
   Grassi F, 2003, HISTOCHEM CELL BIOL, V120, P391, DOI 10.1007/s00418 003 0587 3
   Grimes HL, 1996, MOL CELL BIOL, V16, P6263
   Groen RWJ, 2012, BLOOD, V120, pE9, DOI 10.1182/blood 2012 03 414920
   Guihard P, 2012, STEM CELLS, V30, P762, DOI 10.1002/stem.1040
   Guo J, 2008, BONE, V43, P961, DOI 10.1016/j.bone.2008.06.011
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092 8674(00)81683 9
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hatfield KJ, 2010, EUR CYTOKINE NETW, V21, P154, DOI 10.1684/ecn.2010.0204
   Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189
   Hojo H, 2012, J BIOL CHEM, V287, P17860, DOI 10.1074/jbc.M112.347716
   Huang DW, 2007, NUCLEIC ACIDS RES, V35, pW169, DOI 10.1093/nar/gkm415
   Kim J, 2012, BRIT J HAEMATOL, V158, P336, DOI 10.1111/j.1365 2141.2012.09154.x
   Kline M, 2007, LEUKEMIA RES, V31, P591, DOI 10.1016/j.leukres.2006.06.012
   Kulterer B, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 70
   Li BZ, 2010, ARCH MED RES, V41, P623, DOI 10.1016/j.arcmed.2010.11.008
   Li X, 2011, BLOOD, V118, P286
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   Mahtouk K, 2006, ONCOGENE, V25, P7180, DOI 10.1038/sj.onc.1209699
   Mahtouk K, 2007, CLIN CANCER RES, V13, P7289, DOI 10.1158/1078 0432.CCR 07 1758
   Mahtouk K, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 198
   Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602
   McMillin DW, 2010, NAT MED, V16, P483, DOI 10.1038/nm.2112
   Monroe DG, 2012, GENE, V492, P1, DOI 10.1016/j.gene.2011.10.044
   Nakamura T, 2010, CELL STRUCT FUNCT, V35, P53, DOI 10.1247/csf.10001
   Neri P, 2012, CURR CANCER DRUG TAR, V12, P776, DOI 10.2174/156800912802429337
   Pappa CA, 2011, CYTOKINE, V56, P616, DOI 10.1016/j.cyto.2011.08.034
   Pellegrino A, 2005, BRIT J HAEMATOL, V129, P248, DOI 10.1111/j.1365 2141.2005.05443.x
   Pennisi A, 2009, BLOOD, V114, P1803, DOI 10.1182/blood 2009 01 201954
   Pittenger Mark F., 2008, V449, P27, DOI 10.1007/978 1 60327 169 1_2
   Podar K, 2007, BEST PRACT RES CL HA, V20, P597, DOI 10.1016/j.beha.2007.08.002
   Qiang YW, 2008, BLOOD, V112, P374, DOI 10.1182/blood 2007 10 120253
   Ramsay AD, 2013, BRIT J HAEMATOL, V162, P15, DOI 10.1111/bjh.12344
   Reagan MR, 2012, CLIN CANCER RES, V18, P342, DOI 10.1158/1078 0432.CCR 11 2212
   Roccaro AM, 2013, J CLIN INVEST, V123, P1542, DOI 10.1172/JCI66517
   Roodman GD, 2009, LEUKEMIA, V23, P435, DOI 10.1038/leu.2008.336
   Rosmarin  AG, 2004, BLOOD CELL MOL DIS, V32, P143, DOI 10.1016/j.bcmd.2003.09.005
   STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348
   Su YY, 2008, MOL CELL, V32, P652, DOI 10.1016/j.molcel.2008.10.023
   Sugimura R, 2010, BIRTH DEFECTS RES C, V90, P243, DOI 10.1002/bdrc.20195
   Suh WK, 2004, P NATL ACAD SCI USA, V101, P12969, DOI 10.1073/pnas.0405259101
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Todoerti K, 2010, EXP HEMATOL, V38, P141, DOI 10.1016/j.exphem.2009.11.009
   Väänänen HK, 2008, ARCH BIOCHEM BIOPHYS, V473, P132, DOI 10.1016/j.abb.2008.03.037
   Vallet S, 2011, LEUKEMIA, V25, P1174, DOI 10.1038/leu.2011.43
   Vallet S, 2011, EXPERT OPIN THER TAR, V15, P1037, DOI 10.1517/14728222.2011.586634
   Wallace SR, 2001, CANCER AM CANCER SOC, V91, P1219, DOI 10.1002/1097 0142(20010401)91:7<1219::AID CNCR1122>3.0.CO;2 1
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Wuyts A, 1999, EUR J BIOCHEM, V260, P421, DOI 10.1046/j.1432 1327.1999.00166.x
   Xu S, 2012, STEM CELLS, V30, P266, DOI 10.1002/stem.787
   Yaccoby S, 2006, HAEMATOL HEMATOL J, V91, P192
   Yaccoby S, 2010, BRIT J HAEMATOL, V149, P311, DOI 10.1111/j.1365 2141.2010.08141.x
   Yeh LCC, 2002, J CELL BIOCHEM, V87, P292, DOI 10.1002/jcb.10315
   Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036
   Zanotti S, 2009, J ENDOCRINOL, V201, P263, DOI 10.1677/JOE 08 0514
   Zdzisinska B, 2008, LEUKEMIA RES, V32, P1763, DOI 10.1016/j.leukres.2008.04.001
NR 84
TC 46
Z9 48
U1 2
U2 14
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 30
PY 2014
VL 5
IS 18
BP 8284
EP 8305
DI 10.18632/oncotarget.2058
PG 22
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA AZ1YI
UT WOS:000348030900025
PM 25268740
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Cheon, YH
   Baek, JM
   Park, SH
   Ahn, SJ
   Lee, MS
   Oh, J
   Kim, JY
AF Cheon, Yoon Hee
   Baek, Jong Min
   Park, Sun Hyang
   Ahn, Sung Jun
   Lee, Myeung Su
   Oh, Jaemin
   Kim, Ju Young
TI Stauntonia hexaphylla (Lardizabalaceae) leaf methanol extract
   inhibits osteoclastogenesis and bone resorption activity via
   proteasome mediated degradation of c Fos protein and suppression of
   NFATc1 expression
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE Stauntonia hexaphylla; Osteoclast; c Fos; NFATc1; Bone resorption
ID NF KAPPA B; RECEPTOR ACTIVATOR; SIGNALING PATHWAYS; RANKL;
   DIFFERENTIATION; OSTEOPOROSIS; PLC GAMMA 2; CELLS
AB Background: Natural plants, including common vegetables and fruits, have been recognized as essential sources for drug discovery and the development of new, safe, and economical medicaments. Stauntonia hexaphylla (Lardizabalaceae) is widely distributed in Korea, Japan, and China, and is a popular herbal supplement in Korean and Chinese folk medicine owing to its analgesic, sedative, and diuretic properties. However, the exact pharmacological effects of S. hexaphylla extract, particularly its effect on osteoclastogenesis, are not known.
   Methods: Osteoclast differentiation and function were identified with tartrate resistant acid phosphatase (TRAP) staining and bone resorption assay, and the underling mechanisms were determined by real time RT PCR and western blot analysis.
   Results: S. hexaphylla was found to inhibit early stage receptor activator of nuclear factor kappa B (NF kappa B) ligand (RANKL) mediated osteoclast differentiation in bone marrow macrophages (BMMs) without cytotoxicity and bone resorbing activity in mature osteoclasts in a dose dependent manner. This S. hexaphylla mediated blockade of osteoclastogenesis involved abrogation of the NF kappa B, ERK, and c Src Btk PLC gamma 2 calcium signal pathways. Interestingly, we found that S. hexaphylla down regulated RANKL associated c Fos protein induction by suppressing its translation. Furthermore, ectopic overexpression of c Fos and NFATc1 rescued the inhibition of osteoclast differentiation by S. hexaphylla. Furthermore, S. hexaphylla inhibited the c Fos  and NFATc1 regulated expression of genes required for osteoclastogenesis, such as TRAP, OSCAR, beta 3 integrin, ATP6v0d2, and CtsK.
   Conclusions: These findings suggest that S. hexaphylla might be useful for the development of new anti osteoporosis agents.
C1 [Cheon, Yoon Hee; Baek, Jong Min; Park, Sun Hyang; Ahn, Sung Jun; Oh, Jaemin] Wonkwang Univ, Sch Med, Dept Anat, Iksan 570749, Jeonbuk, South Korea.
   [Cheon, Yoon Hee] Wonkwang Univ, Ctr Metab Funct Regulat, Iksan 570749, Jeonbuk, South Korea.
   [Lee, Myeung Su] Wonkwang Univ, Div Rheumatol, Iksan 570749, Jeonbuk, South Korea.
   [Lee, Myeung Su; Oh, Jaemin] Wonkwang Univ, Inst Skeletal Dis, Iksan 570749, Jeonbuk, South Korea.
   [Lee, Myeung Su; Oh, Jaemin; Kim, Ju Young] Wonkwang Univ, Imaging Sci Based Lung & Bone Dis Res Ctr, Iksan 570749, Jeonbuk, South Korea.
C3 Wonkwang University; Wonkwang University; Wonkwang University; Wonkwang
   University; Wonkwang University
RP Oh, J (通讯作者)，Wonkwang Univ, Sch Med, Dept Anat, Iksan 570749, Jeonbuk, South Korea.
EM jmoh@wku.ac.kr; kimjy1014@gmail.com
RI Lee, Sang Hoon/ABH 6210 2020
FU National Research Foundation of Korea (NRF)   Ministry of Education
   [NRF 2013R1A1A2059831]
FX This study was supported by a grant from Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Education (NRF 2013R1A1A2059831).
CR Arai A, 2012, J CELL SCI, V125, P2910, DOI 10.1242/jcs.099986
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Body JJ, 2002, BONE, V30, p75S
   BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen Z, 2015, CIRCULATION, V131, P805, DOI 10.1161/CIRCULATIONAHA.114.013675
   Eriksen EF, 2014, BONE, V58, P126, DOI 10.1016/j.bone.2013.09.023
   Faccio R, 2010, ANN NY ACAD SCI, V1192, P124, DOI 10.1111/j.1749 6632.2009.05217.x
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Kertész Z, 2012, EUR J CLIN INVEST, V42, P49, DOI 10.1111/j.1365 2362.2011.02556.x
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Mao DL, 2006, J CLIN INVEST, V116, P2869, DOI 10.1172/JCI28775
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Patterson RL, 2005, TRENDS BIOCHEM SCI, V30, P688, DOI 10.1016/j.tibs.2005.10.005
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Sipos W, 2008, CURR MED CHEM, V15, P127, DOI 10.2174/092986708783330638
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2002, ARTHRITIS RES THER, V4, pS227, DOI 10.1186/ar581
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   WANG HB, 1990, J NAT PROD, V53, P313, DOI 10.1021/np50068a007
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Zaidi M, 2003, J BONE MINER RES, V18, P599, DOI 10.1359/jbmr.2003.18.4.599
   Zheng H, 2006, J BIOL CHEM, V281, P15809, DOI 10.1074/jbc.M513225200
NR 30
TC 24
Z9 29
U1 0
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1472 6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD AUG 14
PY 2015
VL 15
AR 280
DI 10.1186/s12906 015 0801 6
PG 9
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA CO8YM
UT WOS:000359458100003
PM 26271279
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Schwendich, E
   Tejedor, LS
   Schmitz, G
   Rickert, M
   Steinmeyer, J
   Rehart, S
   Tsiami, S
   Braun, J
   Baraliakos, X
   Reinders, J
   Neumann, E
   Müller Ladner, U
   Capellino, S
AF Schwendich, Elena
   Tejedor, Laura Salinas
   Schmitz, Gernot
   Rickert, Markus
   Steinmeyer, Juergen
   Rehart, Stefan
   Tsiami, Styliani
   Braun, Juergen
   Baraliakos, Xenofon
   Reinders, Joerg
   Neumann, Elena
   Mueller Ladner, Ulf
   Capellino, Silvia
TI Modulation of Dopamine Receptors on Osteoblasts as a Possible
   Therapeutic Strategy for Inducing Bone Formation in Arthritis
SO CELLS
LA English
DT Article
DE rheumatoid arthritis; dopamine; osteoblast; osteoclasts; mineralization
ID RHEUMATOID ARTHRITIS; CELLS; DISEASE; NEUROBIOLOGY; EXPRESSION
AB Rheumatoid arthritis (RA) is associated with systemic osteoporosis, which leads to severe disability and low quality of life. Current therapies target osteoclasts to reduce bone degradation, but more treatment options would be required to promote bone protection by acting directly on osteoblasts (OB). Recently, the local production of dopamine in inflamed joints of RA has been observed. Thus, in this project, we aimed to determine the implication of the neurotransmitter dopamine in the bone formation process in RA. Dopamine receptors (DR) in the human bone tissue of RA or osteoarthritis (OA) patients were examined by immunohistochemistry. DR in isolated human osteoblasts (OB) was analyzed by flow cytometry, and dopamine content was evaluated by ELISA. Osteoclasts (OC) were differentiated from the PBMCs of healthy controls (HC) and RA patients. Isolated cells were treated with specific dopamine agonists. The effect of dopamine on mineralization was evaluated by Alizarin red staining. Cytokine release in supernatants was measured by ELISA. Osteoclastogenesis was evaluated with TRAP staining. OC markers were analyzed via real time PCR and bone resorption via staining of resorption pits with toluidine blue. All DR were observed in bone tissue, especially in the bone remodeling area. Isolated OB maintained DR expression, which allowed their study in vitro. Isolated OB expressed tyrosine hydroxylase, the rate limiting enzyme for dopamine production, and contained dopamine. The activation of D2 like DR significantly increased bone mineralization in RA osteoblasts and increased osteoclastogenesis but did not alter the expression of OC markers nor bone resorption. DR were found in the bone remodeling area of human bone tissue and dopamine can be produced by osteoblasts themselves, thus suggesting a local autocrine/paracrine pathway of dopamine in the bone. D2 like DRs are responsible for bone mineralization in osteoblasts from RA patients without an increase in bone resorption, thus suggesting the D2 like DR pathway as a possible future therapeutic target to counteract bone resorption in arthritis.
C1 [Schwendich, Elena; Tejedor, Laura Salinas; Schmitz, Gernot; Capellino, Silvia] IfADo Leibniz Res Ctr Working Environm & Human Fa, Dept Immunol, Project Grp Neuroimmunol, D 44139 Dortmund, Germany.
   [Rickert, Markus] Univ Hosp Giessen & Marburg UKGM, Dept Orthopaed & Orthopaed Surg, D 35392 Giessen, Germany.
   [Steinmeyer, Juergen] Justus Liebig Univ Giessen, Dept Orthopaed & Orthopaed Surg, Lab Expt Orthopaed, D 35392 Giessen, Germany.
   [Rehart, Stefan] Goethe Univ Frankfurt, Clin Orthoped & Trauma Surg, Agaplesion Markus Teaching Hosp, D 60431 Frankfurt, Germany.
   [Tsiami, Styliani; Braun, Juergen; Baraliakos, Xenofon] Ruhr Univ Bochum, Rheumazentrum Ruhrgebiet Herne, Claudiusstr 45, D 44649 Herne, Germany.
   [Reinders, Joerg] IfADo Leibniz Res Ctr Working Environm & Human Fa, Dept Toxicol, Analyt Chem, D 44139 Dortmund, Germany.
   [Neumann, Elena; Mueller Ladner, Ulf] Justus Liebig Univ Giessen, Rheumatol & Clin Immunol, Kerckhoff Klin GmbH, D 61231 Bad Nauheim, Germany.
C3 Dortmund University of Technology; Leibniz Association; Leibniz Institut
   for Arbeitsforschung an der TU Dortmund (IFADO); University Hospital of
   Giessen & Marburg; Justus Liebig University Giessen; Goethe University
   Frankfurt; Rheumazentrum Ruhrgebiet; Ruhr University Bochum; Dortmund
   University of Technology; Leibniz Association; Leibniz Institut for
   Arbeitsforschung an der TU Dortmund (IFADO); Kerckhoff Clinic; Justus
   Liebig University Giessen
RP Capellino, S (通讯作者)，IfADo Leibniz Res Ctr Working Environm & Human Fa, Dept Immunol, Project Grp Neuroimmunol, D 44139 Dortmund, Germany.
EM schwendich@ifado.de; salinastejedor.laura@gmail.com;
   gernot.schmitz@tu dortmund.de; markus.rickert@ortho.med.uni giessen.de;
   juergen.steinmeyer@ortho.med.uni giessen.de; stefan.rehart@fdk.info;
   styliani.tsiami@elisabethgruppe.de; juergen.braun@elisabethgruppe.de;
   xenofon.baraliakos@elisabethgruppe.de; reinders@ifado.de;
   e.neumann@kerckhoff klinik.de; u.mueller ladner@kerckhoff klinik.de;
   capellino@ifado.de
RI Baraliakos, Xenofon/AAF 7346 2019; Tejedor, Laura/W 5234 2018; Braun,
   Jochen/F 1370 2013; Capellino, Silvia/P 5888 2016; Steinmeyer, Prof.
   Dr./HMD 4154 2023; Neumann, Elena/A 1418 2011
OI Neumann, Elena/0000 0001 7609 5964; Reinders, Joerg/0000 0003 1025 7849;
   Baraliakos, Xenofon/0000 0002 9475 9362
FU European Union [703165]; IfADo Leibniz Research Center for Working
   Environment and Human Factors; Marie Curie Actions (MSCA) [703165]
   Funding Source: Marie Curie Actions (MSCA)
FX This project was funded from the European Union's Horizon 2020 program
   under the Marie Sklodowska Curie grant agreement No 703165 and by the
   IfADo Leibniz Research Center for Working Environment and Human Factors.
CR Alamanos Y, 2006, SEMIN ARTHRITIS RHEU, V36, P182, DOI 10.1016/j.semarthrit.2006.08.006
   [Anonymous], 2009, Rheumatoid arthritis. National clinical guideline for management ant treatmen in adults
   Backman CL, 2004, CURR OPIN RHEUMATOL, V16, P148, DOI 10.1097/00002281 200403000 00014
   Basu S, 2000, J NEUROIMMUNOL, V102, P113, DOI 10.1016/S0165 5728(99)00176 9
   Beaulieu JM, 2015, BRIT J PHARMACOL, V172, P1, DOI 10.1111/bph.12906
   Berner C, 2018, INT J RHEUMATOL, V2018, DOI 10.1155/2018/3756207
   Bliziotes M., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P291
   Broome ST, 2020, NEURAL REGEN RES, V15, P2173, DOI 10.4103/1673 5374.284976
   Capellino S, 2020, CELL MOL IMMUNOL, V17, P705, DOI 10.1038/s41423 020 0477 9
   Capellino S, 2014, ARTHRITIS RHEUMATOL, V66, P2685, DOI 10.1002/art.38746
   Capellino S, 2010, ANN RHEUM DIS, V69, P1853, DOI 10.1136/ard.2009.119701
   Corrado A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061272
   Cosentino M, 2007, BLOOD, V109, P632, DOI 10.1182/blood 2006 01 028423
   Cosentino M, 2013, J NEUROIMMUNE PHARM, V8, P163, DOI 10.1007/s11481 012 9410 z
   Crotti TN, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/281287
   David JP, 2010, CURR DIR AUTOIMMUN, V11, P135, DOI 10.1159/000289202
   Feng YF, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.663102
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Hanami K, 2013, BONE, V56, P1, DOI 10.1016/j.bone.2013.04.019
   Jenei Lanzl Z, 2015, BRAIN BEHAV IMMUN, V50, P266, DOI 10.1016/j.bbi.2015.07.020
   Junker S, 2017, MATRIX BIOL, V62, P75, DOI 10.1016/j.matbio.2016.11.005
   Kim H, 2016, ENDOCRINOL METAB, V31, P454, DOI 10.3803/EnM.2016.31.3.454
   Kleyer A, 2014, CURR OPIN RHEUMATOL, V26, P80, DOI 10.1097/BOR.0000000000000007
   Lee DJ, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.20
   Levite M, 2016, ACTA PHYSIOL, V216, P42, DOI 10.1111/apha.12476
   Liu B, 2021, WORLD NEUROSURG, V146, pE1202, DOI 10.1016/j.wneu.2020.11.132
   Marino F, 1999, EXP HEMATOL, V27, P489, DOI 10.1016/S0301 472X(98)00057 5
   Motyl KJ, 2017, BONE, V103, P168, DOI 10.1016/j.bone.2017.07.008
   Nakashioya H, 2011, MOD RHEUMATOL, V21, P260, DOI 10.1007/s10165 010 0387 2
   OLIVERIA SA, 1995, ARTHRITIS RHEUM, V38, P1134, DOI 10.1002/art.1780380817
   Perreault ML, 2014, NEUROPSYCHOPHARMACOL, V39, P156, DOI 10.1038/npp.2013.148
   Ritchlin C. T., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P276
   Sarkar C, 2010, BRAIN BEHAV IMMUN, V24, P525, DOI 10.1016/j.bbi.2009.10.015
   Sellgren C, 2014, SCHIZOPHRENIA BULL, V40, P1552, DOI 10.1093/schbul/sbu054
   SIBLEY DR, 1993, INT REV NEUROBIOL, V35, P391, DOI 10.1016/S0074 7742(08)60573 5
   Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1
   Steffen U, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01483
   Sun W, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 07626 8
   Swanberg M, 2010, BONE, V47, P424, DOI 10.1016/j.bone.2010.05.009
   Torsney KM, 2014, J NEUROL NEUROSUR PS, V85, P1159, DOI 10.1136/jnnp 2013 307307
   van Nie L, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 68836 z
   VIGNON E, 1990, BIOCHEM INT, V20, P251
   Wang CX, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 019 1529 x
   Wang TT, 2020, CURR DRUG TARGETS, V21, P213, DOI 10.2174/1389450120666190821161259
   Wei L, 2015, IMMUNOBIOLOGY, V220, P323, DOI 10.1016/j.imbio.2014.10.016
   Zerbini CAF, 2017, OSTEOPOROSIS INT, V28, P429, DOI 10.1007/s00198 016 3769 2
NR 46
TC 10
Z9 10
U1 0
U2 10
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD MAY
PY 2022
VL 11
IS 10
AR 1609
DI 10.3390/cells11101609
PG 20
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 1P9WU
UT WOS:000802352400001
PM 35626646
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Holen, I
   Walker, M
   Nutter, F
   Fowles, A
   Evans, CA
   Eaton, CL
   Ottewell, PD
AF Holen, I.
   Walker, M.
   Nutter, F.
   Fowles, A.
   Evans, C. A.
   Eaton, C. L.
   Ottewell, P. D.
TI Oestrogen receptor positive breast cancer metastasis to bone: inhibition
   by targeting the bone microenvironment in vivo
SO CLINICAL & EXPERIMENTAL METASTASIS
LA English
DT Article
DE ER plus ve; Breast cancer; Bone metastasis; Zoledronic acid; Estradiol
ID ZOLEDRONIC ACID; ANTITUMOR ACTIVITY; CELL INVASION; TUMOR GROWTH;
   BISPHOSPHONATES; DOXORUBICIN; THERAPY; MODELS; OSTEOCLASTS; INDUCTION
AB Clinical trials have shown that adjuvant Zoledronic acid (ZOL) reduces the development of bone metastases irrespective of ER status. However, post menopausal patients show anti tumour benefit with ZOL whereas pre menopausal patients do not. Here we have developed in vivo models of spontaneous ER+ve breast cancer metastasis to bone and investigated the effects of ZOL and oestrogen on tumour cell dissemination and growth. ER+ve (MCF7, T47D) or ER ve (MDA MB 231) cells were administered by inter mammary or inter cardiac injection into female nude mice +/  A estradiol. Mice were administered saline or 100 mu g/kg ZOL weekly. Tumour growth, dissemination of tumour cells in blood, bone and bone turnover were monitored by luciferase imaging, histology, flow cytometry, two photon microscopy, micro CT and TRAP/P1NP ELISA. Estradiol induced metastasis of ER+ve cells to bone in 80 100 % of animals whereas bone metastases from ER ve cells were unaffected. Administration of ZOL had no effect on tumour growth in the fat pad but significantly inhibited dissemination of ER+ve tumour cells to bone and frequency of bone metastasis. Estradiol and ZOL increased bone volume via different mechanisms: Estradiol increased activity of bone forming osteoblasts whereas administration of ZOL to estradiol supplemented mice decreased osteoclast activity and returned osteoblast activity to levels comparable to that of saline treated mice. ER ve cells require increased osteoclast activity to grow in bone whereas ER+ve cells do not. Zol does not affect ER+ve tumour growth in soft tissue, however, inhibition of bone turnover by ZOL reduced dissemination and growth of ER+ve breast cancer cells in bone.
C1 [Holen, I.; Walker, M.; Nutter, F.; Evans, C. A.; Ottewell, P. D.] Univ Sheffield, Sch Med, Dept Oncol, Acad Unit Clin Oncol, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
   [Fowles, A.; Eaton, C. L.] Univ Sheffield, Bone Biol, Dept Human Metab, Mellanby Ctr Bone Res, Sheffield S10 2RX, S Yorkshire, England.
C3 University of Sheffield; University of Sheffield
RP Ottewell, PD (通讯作者)，Univ Sheffield, Sch Med, Dept Oncol, Acad Unit Clin Oncol, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
EM p.d.ottewell@sheffield.ac.uk
OI Holen, Ingunn/0000 0002 8759 6913; Howard, Faith/0000 0001 9899 3079;
   Ottewell, Penelope/0000 0002 4826 0771
FU Yorkshire Cancer Research; Cancer Research UK; Weston Park Hospital
   Cancer Charity, UK; Cancer Research UK [11991] Funding Source:
   researchfish
FX The IVIS Lumina II system was purchased by an equipment grant from
   Yorkshire Cancer Research. Laboratory consumables were paid from by
   grants from Cancer Research UK and Weston Park Hospital Cancer Charity,
   UK.
CR Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200
   Benford HL, 2001, BONE, V28, P465, DOI 10.1016/S8756 3282(01)00412 4
   Boissier S, 2000, CANCER RES, V60, P2949
   Bosch Barrera J, 2011, CLIN TRANSL ONCOL, V13, P148, DOI 10.1007/s12094 011 0634 9
   Brown HK, 2009, CURR CANCER DRUG TAR, V9, P807, DOI 10.2174/156800909789760339
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Coleman R, 2013, ANN ONCOL, V24, P398, DOI 10.1093/annonc/mds277
   Coleman R, 2014, LANCET ONCOL, V15, P997, DOI 10.1016/S1470 2045(14)70302 X
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Daubiné F, 2007, J NATL CANCER I, V99, P322, DOI 10.1093/jnci/djk054
   Dedes PG, 2012, BIOCHIM BIOPHYS ACTA, V20, P1926
   Dieli F, 2003, BLOOD, V102, P2310, DOI 10.1182/blood 2003 05 1655
   Fleming JM, 2010, J CELL PHYSIOL, V224, P795, DOI 10.1002/jcp.22190
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500
   Green JR, 2011, CRIT REV ONCOL HEMAT, V77, pS3, DOI 10.1016/S1040 8428(11)70003 8
   Haider MT, 2014, BONE, V66, P240, DOI 10.1016/j.bone.2014.06.023
   Holen I, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3201
   Ibrahim T, 2012, CANCER CELL INT, V12, DOI 10.1186/1475 2867 12 48
   Insalaco L, 2012, J CELL MOL MED, V16, P2186, DOI 10.1111/j.1582 4934.2012.01527.x
   Khosla S, 2010, J CLIN ENDOCR METAB, V95, P3569, DOI 10.1210/jc.2010 0856
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Kousteni S, 2007, CELL METAB, V6, P254
   Kretschmann KL, 2012, CANCER METAST REV, V31, P579, DOI 10.1007/s10555 012 9378 4
   Miyagawa F, 2001, J IMMUNOL, V166, P5508, DOI 10.4049/jimmunol.166.9.5508
   Mönkkönen H, 2008, ANTI CANCER DRUG, V19, P391, DOI 10.1097/CAD.0b013e3282f632bf
   Muinelo Romay L, 2013, ANTICANCER RES, V33, P5295
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Novack DV, 2007, CELL METAB, V6, P254, DOI 10.1016/j.cmet.2007.09.007
   Ottewell PD, 2015, INT J CANC
   Ottewell PD, 2008, JNCI J NATL CANCER I, V100, P1167, DOI 10.1093/jnci/djn240
   Ottewell PD, 2008, CLIN CANCER RES, V14, P4658, DOI 10.1158/1078 0432.CCR 07 1545
   Ottewell PD, 2014, CLIN CANCER RES, V20, P2922, DOI 10.1158/1078 0432.CCR 13 1246
   Ottewell PD, 2012, BREAST CANCER RES TR, V133, P523, DOI 10.1007/s10549 011 1782 x
   Ottewell PD, 2010, INT J CANCER, V126, P522, DOI 10.1002/ijc.24756
   Rietkötter E, 2013, ONCOTARGET, V4, P1449, DOI 10.18632/oncotarget.1201
   Rogers MJ, 1997, CANCER, V80, P1652, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1652::AID CNCR15>3.0.CO;2 Z
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Steinman RA, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3223
   Tomkinson A, 1997, J CLIN ENDOCR METAB, V82, P3128, DOI 10.1210/jc.82.9.3128
   Zhang XHF, 2013, CLIN CANCER RES, V19, P6389, DOI 10.1158/1078 0432.CCR 13 0838
NR 42
TC 31
Z9 35
U1 0
U2 13
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0262 0898
EI 1573 7276
J9 CLIN EXP METASTAS
JI Clin. Exp. Metastasis
PD MAR
PY 2016
VL 33
IS 3
BP 211
EP 224
DI 10.1007/s10585 015 9770 x
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA DF8KS
UT WOS:000371607200001
PM 26585891
OA hybrid
DA 2025 08 17
ER

PT J
AU Ahlström, M
   Pekkinen, M
   Lamberg Allardt, C
AF Ahlstrom, Mikael
   Pekkinen, Minna
   Lamberg Allardt, Christel
TI Dexamethasone downregulates the expression of parathyroid
   hormone related protein (PTHrP) in mesenchymal stem cells
SO STEROIDS
LA English
DT Article
DE Parathyroid hormone related protein (PTHrP); Osteoblasts; Mesenchymal
   stem cells; Glucocorticoids; PTH1R
ID MESSENGER RNA EXPRESSION; OSTEOBLAST LIKE CELLS; GLUCOCORTICOID INDUCED
   OSTEOPOROSIS; MARROW STROMAL CELLS; OSTEOSARCOMA CELLS; OSTEOCALCIN
   GENE; ANABOLIC AGENT; PEPTIDE PTHRP; BONE; DIFFERENTIATION
AB Parathyroid hormone related protein (PTHrP) has been shown to have anabolic effects in women with postmenopausal osteoporosis, PTHrP promotes the recruitment of osteogenic cells and prevents apoptotic death of osteoblasts and osteocytes. The receptor responsible for the effects of PTHrP is the common PTH/PTHrP receptor (PTH1R). Glucocorticoids (GC) are commonly used as drugs to treat inflammatory diseases. Long term GC treatments are often associated with bone loss which can lead to GC induced osteoporosis. The aim of this work was to study the effects of the glucocorticoid dexamethasone (Dex) on the expression of PTHrP and PTH1R in adult human mesenchymal stem cells, the progenitor cells of osteoblasts.
   Adult human mesenchymal stem cells (hMSC) were Cultured and differentiated by standard methods. The expression of PTHrP and PTH1R mRNA was assayed by real time qPCR. The PTHrP release into the culture media was measured by an immunoradiometric assay.
   Treatment with Dex (10nM) resulted in an 80% drop in the PTHrP release within 6 h. A 24 h Dex treatment also reduced the expression of PTHrP mRNA by up to 90%. The expression of PTH1R receptor mRNA was simultaneously increased up to 20 fold by 10nM Dex. The effects of Dex on PTHrP and PTH1R were dose dependent and experiments with the GC receptor antagonist mifepristone showed an involvement of GC receptors in these effects. In addition to the Dex induced effects on PTHrP and PTH1R, Dex also increased mineralization and the expression of the osteoblast markets Runx2 and alkaline phosphatase. In Our studies, we show that dexamethasone decreases the expression of PTHrP and increases the expression of the PTH1R receptor. This could have an impact on PTHrP mediated anabolic actions on bone and could also affect the responsiveness of circulating PTH. The results indicate that glucocorticoids affect the signalling pathway of PTHrP by regulating both PTHrP and PTH1R expression and these mechanisms could be involved in glucocorticoid induced osteoporosis. (C) 2008 Elsevier Inc. All rights reserved,
C1 [Ahlstrom, Mikael; Pekkinen, Minna; Lamberg Allardt, Christel] Univ Helsinki, Calcium Res Unit, Dept Appl Chem & Microbiol, FIN 00014 Helsinki, Finland.
C3 University of Helsinki
RP Ahlström, M (通讯作者)，Univ Helsinki, Calcium Res Unit, Dept Appl Chem & Microbiol, POB 66, FIN 00014 Helsinki, Finland.
EM mikael.ahlstrom@helsinki.fi
OI Lamberg Allardt, Christel/0000 0001 7326 1904; Pekkinen,
   Minna/0000 0003 2947 4683
CR Ahlstrom M, 2008, BONE, V42, P483, DOI 10.1016/j.bone.2007.10.025
   ASA SL, 1990, J CLIN ENDOCR METAB, V71, P1112, DOI 10.1210/jcem 71 5 1112
   Bi LX, 1999, CALCIFIED TISSUE INT, V64, P63, DOI 10.1007/s002239900580
   Canalis E, 2002, ANN NY ACAD SCI, V966, P73, DOI 10.1111/j.1749 6632.2002.tb04204.x
   CANALIS E, 1990, ENDOCRINOLOGY, V126, P1806, DOI 10.1210/endo 126 4 1806
   Celic S, 1996, J ENDOCRINOL, V150, P299, DOI 10.1677/joe.0.1500299
   Chen HL, 2002, J BIOL CHEM, V277, P19374, DOI 10.1074/jbc.M108913200
   CHOUDHARY S, 2003, J BONE MINER RES, V18, P1530
   DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690
   Gennari C, 1986, Clin Rheum Dis, V12, P637
   Haller J, 2008, FRONT NEUROENDOCRIN, V29, P273, DOI 10.1016/j.yfrne.2007.10.004
   Haramoto N, 2007, ORAL DIS, V13, P23, DOI 10.1111/j.1601 0825.2006.01234.x
   Horwitz MJ, 2003, J CLIN ENDOCR METAB, V88, P569, DOI 10.1210/jc.2002 021122
   IIDAKLEIN A, 1995, MINER ELECTROL METAB, V21, P177
   Ito S, 2007, BONE, V40, P84, DOI 10.1016/j.bone.2006.07.012
   Jemtland R, 2003, BONE, V32, P611, DOI 10.1016/S8756 3282(03)00092 9
   Lanske B, 1998, CRIT REV EUKAR GENE, V8, P297, DOI 10.1615/CritRevEukarGeneExpr.v8.i3 4.40
   Lanske B, 1999, J CLIN INVEST, V104, P399, DOI 10.1172/JCI6629
   Lanske B, 1998, ENDOCRINOLOGY, V139, P5194, DOI 10.1210/en.139.12.5194
   MAO J, 1992, MOL CELL BIOCHEM, V109, P1
   Martin TJ, 1996, NEW ENGL J MED, V335, P736, DOI 10.1056/NEJM199609053351010
   Martin TJ, 2005, J CLIN INVEST, V115, P2322, DOI 10.1172/JCI26239
   Mazziotti G, 2006, TRENDS ENDOCRIN MET, V17, P144, DOI 10.1016/j.tem.2006.03.009
   MERCIER L, 1986, J STEROID BIOCHEM, V25, P11, DOI 10.1016/0022 4731(86)90275 X
   Miao DS, 2005, J CLIN INVEST, V115, P2402, DOI 10.1172/JCI24918
   Oshina H, 2007, BONE, V41, P575, DOI 10.1016/j.bone.2007.06.022
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   Pekkinen M, 2008, BONE, V43, P84, DOI 10.1016/j.bone.2008.02.021
   Porter RM, 2003, J CELL BIOCHEM, V90, P13, DOI 10.1002/jcb.10592
   Reid IR, 1997, EUR J ENDOCRINOL, V137, P209, DOI 10.1530/eje.0.1370209
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Stein GS, 1997, MOL BIOL REP, V24, P185, DOI 10.1023/A:1006803615430
   SUBRAMANIAM M, 1992, J CELL BIOCHEM, V50, P411, DOI 10.1002/jcb.240500410
   Suda N, 1996, J CELL PHYSIOL, V166, P94, DOI 10.1002/(SICI)1097 4652(199601)166:1<94::AID JCP11>3.0.CO;2 P
   Susperregui ARG, 2008, J CELL PHYSIOL, V216, P144, DOI 10.1002/jcp.21389
   Viereck V, 2002, J CELL BIOCHEM, V86, P348, DOI 10.1002/jcb.10220
   Yaghoobian J, 1998, NEPHROL DIAL TRANSPL, V13, P580, DOI 10.1093/ndt/13.3.580
   YAMAMOTO I, 1988, ENDOCRINOLOGY, V122, P1208, DOI 10.1210/endo 122 4 1208
   YAMAMOTO I, 1988, J BONE MINER RES, V3, P707
NR 39
TC 17
Z9 18
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0039 128X
J9 STEROIDS
JI Steroids
PD FEB
PY 2009
VL 74
IS 2
BP 277
EP 282
DI 10.1016/j.steroids.2008.12.002
PG 6
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 411BC
UT WOS:000263621400016
PM 19121329
DA 2025 08 17
ER

PT J
AU Ren, ZY
   Machuca Gayet, I
   Domenget, C
   Buchet, R
   Wu, YQ
   Jurdic, P
   Mebarek, S
AF Ren, Zhong Yuan
   Machuca Gayet, Irma
   Domenget, Chantal
   Buchet, Rene
   Wu, Yuqing
   Jurdic, Pierre
   Mebarek, Saida
TI Azanitrile Cathepsin K Inhibitors: Effects on Cell Toxicity,
   Osteoblast Induced Mineralization and Osteoclast Mediated Bone
   Resorption
SO PLOS ONE
LA English
DT Article
ID AZADIPEPTIDE NITRILE INHIBITORS; OSTEOPOROSIS; ODANACATIB; DESIGN;
   DENSITY; LIGAND; POTENT; ASSAYS; ACID; MICE
AB Aim
   The cysteine protease cathepsin K (CatK), abundantly expressed in osteoclasts, is responsible for the degradation of bone matrix proteins, including collagen type 1. Thus, CatK is an attractive target for new anti resorptive osteoporosis therapies, but the wider effects of CatK inhibitors on bone cells also need to be evaluated to assess their effects on bone. Therefore, we selected, among a series of synthetized isothiosemicarbazides, two molecules which are highly selective CatK inhibitors (CKIs) to test their effects on osteoblasts and osteoclasts.
   Research Design and Methods
   Cell viability upon treatment of CKIs were was assayed on human osteoblast like Saos 2, mouse monocyte cell line RAW 264.7 and mature mouse osteoclasts differentiated from bone marrow. Osteoblast induced mineralization in Saos 2 cells and in mouse primary osteoblasts from calvaria, with or without CKIs,; were was monitored by Alizarin Red staining and alkaline phosphatase activity, while osteoclast induced bone resorption was performed on bovine slices.
   Results
   Treatments with two CKIs, CKI 8 and CKI 13 in human osteoblast like Saos 2, murine RAW 264.7 macrophages stimulated with RANKL and mouse osteoclasts differentiated from bone marrow stimulated with RANKL and MCSF were found not to be toxic at doses of up to 100 nM. As probed by Alizarin Red staining, CKI 8 did not inhibit osteoblast induced mineralization in mouse primary osteoblasts as well as in osteoblast like Saos 2 cells. However, CKI 13 led to a reduction in mineralization of around 40% at 10 100 nM concentrations in osteoblast like Saos 2 cells while it did not in primary cells. After a 48 hour incubation, both CKI 8 and CKI 13 decreased bone resorption on bovine bone slices. CKI 13 was more efficient than the commercial inhibitor E 64 in inhibiting bone resorption induced by osteoclasts on bovine bone slices. Both CKI 8 and CKI 13 created smaller bone resorption pits on bovine bone slices, suggesting that the mobility of osteoclasts was slowed down by the addition of CKI 8 and CKI 13.
   Conclusion
   CKI 8 and CKI 13 screened here show promise as antiresorptive osteoporosis therapeutics but some off target effects on osteoblasts were found with CKI 13.
C1 [Ren, Zhong Yuan; Wu, Yuqing] Jilin Univ, State Key Lab Supramol Struct & Mat, Changchun 130012, Peoples R China.
   [Ren, Zhong Yuan; Machuca Gayet, Irma; Domenget, Chantal; Buchet, Rene; Jurdic, Pierre; Mebarek, Saida] Univ Lyon, F 69622 Villeurbanne, France.
   [Ren, Zhong Yuan; Machuca Gayet, Irma; Domenget, Chantal; Buchet, Rene; Jurdic, Pierre; Mebarek, Saida] Univ Lyon 1, F 69622 Villeurbanne, France.
   [Ren, Zhong Yuan; Buchet, Rene; Mebarek, Saida] CPE Lyon, F 69622 Villeurbanne, France.
   [Ren, Zhong Yuan; Buchet, Rene; Mebarek, Saida] Inst Natl Sci Appl, F 69622 Villeurbanne, France.
   [Ren, Zhong Yuan; Buchet, Rene; Mebarek, Saida] Inst Chim & Biochim Mol & Supramol, F 69622 Villeurbanne, France.
   [Ren, Zhong Yuan; Buchet, Rene; Mebarek, Saida] CNRS UMR 5246, F 69622 Villeurbanne, France.
   [Machuca Gayet, Irma; Domenget, Chantal; Jurdic, Pierre] Ecole Normale Super Lyon, F 69634 Lyon, France.
   [Machuca Gayet, Irma; Domenget, Chantal; Jurdic, Pierre] Inst Genom Fonct Lyon, F 69634 Lyon, France.
   [Machuca Gayet, Irma; Domenget, Chantal; Jurdic, Pierre] CNRS UMR3444, F 69634 Lyon, France.
C3 Jilin University; Universite Claude Bernard Lyon 1; Institut National
   des Sciences Appliquees de Lyon   INSA Lyon; Institut National des
   Sciences Appliquees de Lyon   INSA Lyon; Centre National de la Recherche
   Scientifique (CNRS); CNRS   Institute of Chemistry (INC); Institut
   National des Sciences Appliquees de Lyon   INSA Lyon; Ecole Normale
   Superieure de Lyon (ENS de LYON); CHU Lyon; Centre National de la
   Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de
   LYON); Universite Claude Bernard Lyon 1
RP Mebarek, S (通讯作者)，Univ Lyon, F 69622 Villeurbanne, France.
EM saida.youjil@univ lyon1.fr
RI ; Rene, Buchet/I 9781 2019; Mebarek, Saida/AAI 8237 2020
OI Buchet, Rene/0000 0002 7966 3856; Mebarek, Saida/0000 0001 8806 8904;
   Machuca  Gayet, irma/0000 0002 3010 9774; Ren,
   Zhongyuan/0000 0002 0300 7801; 
FU National Natural Science Foundation of China [21373101]
FX This work was supported by a grant from National Natural Science
   Foundation of China (No. 21373101) (YW). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Bone HG, 2015, OSTEOPOROSIS INT, V26, P699, DOI 10.1007/s00198 014 2944 6
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Boonen S, 2012, CURR OSTEOPOROS REP, V10, P73, DOI 10.1007/s11914 011 0085 9
   Chambers TJ, 2013, J CLIN ENDOCR METAB, V98, P4329, DOI 10.1210/jc.2013 2630
   Collin Osdoby P, 2012, METHODS MOL BIOL, V816, P187, DOI 10.1007/978 1 61779 415 5_13
   CYBORON GW, 1981, J BIOL CHEM, V256, P7262
   Delbeck M, 2012, Patent Application, Patent No. [A1, WO2012156311, 2012156311]
   Duong Le T, 2012, Bonekey Rep, V1, P67, DOI 10.1038/bonekey.2012.67
   Frizler M, 2011, CHEM EUR J, V17, P11419, DOI 10.1002/chem.201101350
   Frizler M, 2011, J MED CHEM, V54, P396, DOI 10.1021/jm101272p
   Fuller K, 2010, BONE, V46, P1400, DOI 10.1016/j.bone.2010.01.374
   Georgess D, 2014, MOL BIOL CELL, V25, P380, DOI 10.1091/mbc.E13 07 0363
   Gillette JM, 2004, J CELL SCI, V117, P441, DOI 10.1242/jcs.00909
   Henriksen K, 2009, BONE, V44, P1026, DOI 10.1016/j.bone.2009.03.671
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Kim MK, 2006, J PHARMACOL EXP THER, V318, P555, DOI 10.1124/jpet.106.102798
   Kiviranta R, 2001, J BONE MINER RES, V16, P1444, DOI 10.1359/jbmr.2001.16.8.1444
   Lems WF, 2014, CURR OPIN RHEUMATOL, V26, P245, DOI 10.1097/BOR.0000000000000057
   Li WA, 2010, ANAL BIOCHEM, V401, P91, DOI 10.1016/j.ab.2010.02.035
   Löser R, 2008, ANGEW CHEM INT EDIT, V47, P4331, DOI 10.1002/anie.200705858
   Loh YH, 2010, CHEM COMMUN, V46, P8407, DOI 10.1039/c0cc03738a
   Martin TJ, 2009, CRIT REV EUKAR GENE, V19, P73, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.40
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Nakamura T, 2014, OSTEOPOROSIS INT, V25, P367, DOI 10.1007/s00198 013 2398 2
   Ng KW, 2012, CLIN INTERV AGING, V7, P235, DOI 10.2147/CIA.S26729
   Novack DV, 2011, AGEING RES REV, V10, P54, DOI 10.1016/j.arr.2009.09.005
   Pennypacker B, 2009, BONE, V44, P199, DOI 10.1016/j.bone.2008.08.130
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Ren XF, 2013, ORG BIOMOL CHEM, V11, P1143, DOI 10.1039/c2ob26624e
   Rousselle AV, 2002, BONE, V30, P533, DOI 10.1016/S8756 3282(02)00672 5
   Schmitz J, 2014, ACS MED CHEM LETT, V5, P1076, DOI 10.1021/ml500238q
   STANFORD CM, 1995, J BIOL CHEM, V270, P9420, DOI 10.1074/jbc.270.16.9420
   Stoch SA, 2008, CLIN PHARMACOL THER, V83, P172, DOI 10.1038/sj.clpt.6100450
   Stoch SA, 2013, BRIT J CLIN PHARMACO, V75, P1240, DOI 10.1111/j.1365 2125.2012.04471.x
   Suda T, 1997, J BONE MINER RES, V12, P869, DOI 10.1359/jbmr.1997.12.6.869
   Thouverey C, 2009, J CELL BIOCHEM, V106, P127, DOI 10.1002/jcb.21992
   Vaingankar SM, 2004, AM J PHYSIOL CELL PH, V286, pC1177, DOI 10.1152/ajpcell.00320.2003
   Yamamoto A, 2002, J BONE MINER RES, V17, P612, DOI 10.1359/jbmr.2002.17.4.612
   Yang PY, 2012, CHEM EUR J, V18, P6528, DOI 10.1002/chem.201103322
   Yuan XY, 2013, ORG BIOMOL CHEM, V11, P5847, DOI 10.1039/c3ob41165f
NR 42
TC 11
Z9 12
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUL 13
PY 2015
VL 10
IS 7
AR e0132513
DI 10.1371/journal.pone.0132513
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CN1PW
UT WOS:000358193100049
PM 26168340
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Lin, XX
   Song, FM
   Zhou, L
   Wang, ZY
   Wei, CM
   Xu, JK
   Zhao, JM
   Liu, Q
AF Lin, Xixi
   Song, Fangming
   Zhou, Lin
   Wang, Ziyi
   Wei, Chengming
   Xu, Jiake
   Zhao, Jinmin
   Liu, Qian
TI Cepharanthine suppresses osteoclast formation by modulating the nuclear
   factor B and nuclear factor of activated T cell signaling pathways
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE cepharanthine; nuclear factor of activated T cell; nuclear factor B;
   osteoclast; receptor activator of nuclear factor B ligand
ID NF KAPPA B; RECEPTOR ACTIVATOR; EXPRESSION; NFATC1
AB The increased activation of osteoclasts is the major manifestation of several lytic bone diseases, including osteoporosis, rheumatoid arthritis, aseptic loosening of orthopedic implants, Paget disease and malignant bone diseases. One important bone protective therapy in these diseases focuses on the inhibition of osteoclast differentiation and resorptive function. Given that the deleterious side effects of currently available drugs, it is beneficial to search for effective and safe medications from natural compounds. Cepharanthine (CEP) is a compound extracted from Stephania japonica and has been found to have antioxidant and anti inflammatory effects. In this study, we found that CEP inhibited receptor activator of nuclear factor B (NF B) ligand (RANKL) induced osteoclast formation and bone resorbing activities using osteoclastogenesis and bone resorption assay. By polymerase chain reaction, we also found that CEP inhibited the expression of osteoclast differentiation marker genes including Ctsk, Calcr, Atp6v0d2, Mmp9 and Nfatc1. Mechanistic analyses including Western blot and luciferase reporter assay revealed that CEP inhibited RANKL induced activation of NF B and nuclear factor of activated T cell, which are essential for the formation of osteoclast. Collectively, these data suggested that CEP can potentially be used as an alternative therapy for preventing or treating osteolytic diseases.
C1 [Lin, Xixi; Song, Fangming; Wei, Chengming; Xu, Jiake; Zhao, Jinmin; Liu, Qian] Guangxi Med Univ, Affiliated Hosp 1, Res Ctr Regenerat Med, Dept Trauma Orthoped & Hand Surg, 22 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.
   [Lin, Xixi; Song, Fangming; Wei, Chengming; Zhao, Jinmin; Liu, Qian] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning, Guangxi, Peoples R China.
   [Song, Fangming; Zhou, Lin; Wang, Ziyi; Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia.
   [Zhou, Lin] Guangzhou Med Univ, Affiliated Hosp 1, Dept Endocrinol, Guangzhou, Guangdong, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University; University of
   Western Australia; Guangzhou Medical University
RP Zhao, JM; Liu, Q (通讯作者)，Guangxi Med Univ, Affiliated Hosp 1, Res Ctr Regenerat Med, Dept Trauma Orthoped & Hand Surg, 22 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.
EM zhaojinmin@126.com; luoboqian@hotmail.com
RI zhao, jin/LBH 0351 2024; xi, lin/JOK 1026 2023
OI Wang, Ziyi/0000 0002 1334 7287; Xu, Jiake/0000 0003 2021 8309; Zhao,
   Jinmin/0000 0002 1047 8820; Zhao, Jinmin/0000 0001 8423 0425; 
FU National Natural Science Foundation of China [81501910]; China
   Postdoctoral Science Foundation [2015M572421]; Guangxi Collaborative
   Innovation Center for Biomedicine talent cultivation [GCICB TC 2017001,
   GCICB TC 2017002]; Natural Science Foundation of Guangxi Province
   [2015GXNSFDA139019, 2015GXNSFCA414001]; Australian Health and Medical
   Research Council [APP1107828]
FX National Natural Science Foundation of China, Grant/Award Number:
   81501910; China Postdoctoral Science Foundation funded project,
   Grant/Award Number: 2015M572421; Guangxi Collaborative Innovation Center
   for Biomedicine talent cultivation, Grant/Award Number:
   GCICB TC 2017001, GCICB TC 2017002; Natural Science Foundation of
   Guangxi Province, Grant/Award Number: 2015GXNSFDA139019,
   2015GXNSFCA414001; Australian Health and Medical Research Council,
   Grant/Award Number: APP1107828
CR Ang E, 2009, J CELL PHYSIOL, V220, P450, DOI 10.1002/jcp.21787
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Cheng JW, 2018, J CELL PHYSIOL, V233, P2502, DOI 10.1002/jcp.26126
   Goltzman D, 2001, J CLIN INVEST, V107, P1219, DOI 10.1172/JCI13073
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Redlich K, 2002, ARTHRITIS RHEUM, V46, P785, DOI 10.1002/art.10097
   Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308
   Samra YA, 2016, LIFE SCI, V157, P187, DOI 10.1016/j.lfs.2016.06.002
   Sharma SM, 2007, J BIOL CHEM, V282, P15921, DOI 10.1074/jbc.M609723200
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wang C, 2003, J BONE MINER RES, V18, P2159, DOI 10.1359/jbmr.2003.18.12.2159
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Zhou ES, 2014, INFLAMMATION, V37, P331, DOI 10.1007/s10753 013 9744 6
NR 23
TC 15
Z9 16
U1 2
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD FEB
PY 2019
VL 120
IS 2
BP 1990
EP 1996
DI 10.1002/jcb.27495
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA HL6CW
UT WOS:000458822400089
PM 30426543
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Wiren, KM
   Semirale, AA
   Hashimoto, JG
   Zhang, XW
AF Wiren, Kristine M.
   Semirale, Anthony A.
   Hashimoto, Joel G.
   Zhang, Xiao Wei
TI Signaling pathways implicated in androgen regulation of endocortical
   bone
SO BONE
LA English
DT Article
DE Androgen; Androgen receptor; Osteoblast; Bone formation; BMP; TGF beta
ID GROWTH FACTOR BETA; DIFFERENTIATION IN VITRO; MESENCHYMAL STEM CELLS;
   ADRENAL ANDROGENS; OSTEOBLAST; RECEPTOR; EXPRESSION; MINERALIZATION;
   PROLIFERATION; RESORPTION
AB Periosteal expansion is a recognized response to androgen exposure during bone development and in profoundly hypogonadal adults. However, androgen also suppresses endocortical bone formation, indicating that its effects on bone are dichotomous and envelope specific. In fact, enhanced androgen signaling has been shown to have dramatic detrimental effects on whole bone biomechanical properties in two different transgenic models with skeletally targeted androgen receptor (AR) overexpression. As the mechanisms underlying this response are uncharacterized, we compared patterns of gene expression in periosteum free cortical bone samples derived from AR overexpressing transgenic male mice and their wild type counterparts. We then assessed direct androgen effects in both wild type and AR overexpressing osteoblasts in primary culture. Among Major Signaling pathways associated with bone formation, focused quantitative RT PCR (qPCR) array based analysis of endocortical bone gene expression from wild type vs. transgenic males identified the transforming growth factor beta (TGF beta) superfamily and bone morphogenetic protein (BMP) signaling as significantly altered by androgen in vivo. Bioinformatic analyses indicated proliferation, osteoblast differentiation and mineralization as major biological processes affected. Consistent with the in vivo array data and bioinformatic analyses, inhibition of differentiation observed with androgen exposure was reduced by exogenous BMP2 treatment of AR overexpressing cultures to stimulate BMP signaling, confirming array pathway analysis. In addition, nonaromatizable dihydrotestosterone (DHT) inhibited osteoblast proliferation, differentiation and several indices of mineralization, including mineral accumulation and mineralized nodule formation in primary cultures from both wild type and AR transgenic mice. These findings identify a molecular mechanism based on altered BMP signaling that contributes to androgen inhibition of osteoblast differentiation and mineralization. Such detrimental effects of androgen on osteoblast function May underlie the generally disappointing results of androgen therapy. Published by Elsevier Inc.
C1 [Wiren, Kristine M.; Semirale, Anthony A.; Hashimoto, Joel G.; Zhang, Xiao Wei] Portland VA Med Ctr, Bone & Mineral Res Unit, Portland, OR 97239 USA.
   [Wiren, Kristine M.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA.
   [Wiren, Kristine M.; Semirale, Anthony A.; Hashimoto, Joel G.; Zhang, Xiao Wei] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Portland VA Medical Center; Oregon Health & Science University; Oregon
   Health & Science University
RP Wiren, KM (通讯作者)，Portland VA Med Ctr, Bone & Mineral Res Unit, P3 R&D39,3710 SW Vet Hosp Rd, Portland, OR 97239 USA.
EM wirenk@ohsu.edu
OI Wiren, Kristine/0000 0002 6159 4450
FU United States Army Research Acquisition Activity Award
   [W81XWH 05 1 0086]; National Institute of Diabetes, Digestive Kidney
   Disease [R01 DK067541]
FX The authors would like to thank Dr. Robert Majeska (City College of New
   York) for helpful comments in the preparation of the manuscript. This
   publication was made possible by grants from the United States Army
   Research Acquisition Activity Award No. W81XWH 05 1 0086 (KMW) and the
   National Institute of Diabetes, Digestive & Kidney Disease R01 DK067541
   (KMW). The information contained in this publication does not
   necessarily reflect the position or the policy of the government, and no
   official endorsement should be inferred. All work was performed in
   facilities provided by the Department of Veterans Affairs.
CR Akilesh S, 2003, GENOME RES, V13, P1719, DOI 10.1101/gr.533003
   Bahamonde ME, 2001, J BONE JOINT SURG AM, V83A, pS56
   Bais MV, 2009, BONE, V45, P254, DOI 10.1016/j.bone.2009.04.239
   Balkan W, 2005, BIOCHEM BIOPH RES CO, V328, P783, DOI 10.1016/j.bbrc.2004.12.090
   Baniwal SK, 2009, MOL ENDOCRINOL, V23, P1203, DOI 10.1210/me.2008 0470
   Benito M, 2005, J BONE MINER RES, V20, P1785, DOI 10.1359/JBMR.050606
   BENZ DJ, 1991, ENDOCRINOLOGY, V128, P2723, DOI 10.1210/endo 128 6 2723
   BODINE PVN, 1995, J STEROID BIOCHEM, V52, P149, DOI 10.1016/0960 0760(94)00165 I
   Chiang C, 2009, J BONE MINER RES, V24, P621, DOI [10.1359/jbmr.081217, 10.1359/JBMR.081217]
   Diel P, 2008, J MOL ENDOCRINOL, V40, P231, DOI 10.1677/JME 07 0175
   Gaddy Dana, 2008, Curr Osteoporos Rep, V6, P51, DOI 10.1007/s11914 008 0009 5
   Gaddy Kurten D, 2002, ENDOCRINOLOGY, V143, P74, DOI 10.1210/en.143.1.74
   Goto K, 2007, J BIOL CHEM, V282, P20603, DOI 10.1074/jbc.M702100200
   GRAY C, 1992, J BONE MINER RES, V7, P41
   Haque T, 2008, BONE, V42, P1144, DOI 10.1016/j.bone.2008.01.028
   Hashimoto JG, 2004, BIOTECHNIQUES, V36, P54, DOI 10.2144/04361BM06
   Hofbauer LC, 1998, J CELL BIOCHEM, V71, P96, DOI 10.1002/(SICI)1097 4644(19981001)71:1<96::AID JCB10>3.0.CO;2 G
   Jiang JX, 2009, INT J GEOGR INF SCI, V23, P33, DOI 10.1080/13658810802577247
   Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15
   Kasperk CH, 1997, J BONE MINER RES, V12, P464, DOI 10.1359/jbmr.1997.12.3.464
   KASPERK CH, 1989, ENDOCRINOLOGY, V124, P1576, DOI 10.1210/endo 124 3 1576
   Katsuki Y, 2008, BIOCHEM BIOPH RES CO, V368, P808, DOI 10.1016/j.bbrc.2008.02.010
   Kitisin K., 2007, SCI STKE, DOI DOI 10.1126/STKE.3992007CM1
   Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935
   Lin IC, 2007, PLAST RECONSTR SURG, V120, P1137, DOI 10.1097/01.prs.0000279527.99734.bf
   Michael H, 2005, J BONE MINER RES, V20, P2224, DOI 10.1359/JBMR.050803
   Mishina Y, 2004, J BIOL CHEM, V279, P27560, DOI 10.1074/jbc.M404222200
   Notini AJ, 2007, J BONE MINER RES, V22, P347, DOI 10.1359/JBMR.061117
   Orwoll ES, 1996, TRENDS ENDOCRIN MET, V7, P77, DOI 10.1016/1043 2760(96)00024 0
   Patlas Natan, 2005, Odontology, V93, P16, DOI 10.1007/s10266 005 0051 z
   Pederson L, 1999, P NATL ACAD SCI USA, V96, P505, DOI 10.1073/pnas.96.2.505
   Petryk A, 2005, BONE, V36, P617, DOI 10.1016/j.bone.2005.01.018
   Raisz LG, 1996, J CLIN ENDOCR METAB, V81, P37, DOI 10.1210/jc.81.1.37
   Sabatakos G, 2008, J BONE MINER RES, V23, P584, DOI 10.1359/JBMR.080110
   Schaeffer EM, 2008, ONCOGENE, V27, P7180, DOI 10.1038/onc.2008.327
   Seeman E, 2006, OSTEOPOROSIS INT, V17, P1443, DOI 10.1007/s00198 006 0220 0
   Shi WB, 2007, J CELL SCI, V120, P1216, DOI 10.1242/jcs.03400
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092 8674(03)00432 X
   Singh R, 2009, ENDOCRINOLOGY, V150, P1259, DOI 10.1210/en.2008 0858
   Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369
   TAKEUCHI M, 1994, BIOCHEM BIOPH RES CO, V204, P905, DOI 10.1006/bbrc.1994.2545
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Wang C, 2004, J CLIN ENDOCR METAB, V89, P2085, DOI 10.1210/jc.2003 032006
   Wang XS, 1999, ENDOCRINE, V11, P13, DOI 10.1385/ENDO:11:1:13
   Wiren KM, 2002, J ENDOCRINOL, V175, P683, DOI 10.1677/joe.0.1750683
   Wiren KM, 2005, CURR OPIN PHARMACOL, V5, P626, DOI 10.1016/j.coph.2005.06.003
   Wiren KM, 2004, ENDOCRINOLOGY, V145, P3507, DOI 10.1210/en.2003 1016
   Wiren KM, 2004, J MOL ENDOCRINOL, V32, P209, DOI 10.1677/jme.0.0320209
   Wiren KM, 2008, BONE, V43, P440, DOI 10.1016/j.bone.2008.04.026
   Wiren KM, 2006, BONE, V38, P637, DOI 10.1016/j.bone.2005.10.029
   Wu M, 2009, BONE, V44, P528, DOI 10.1016/j.bone.2008.11.011
   Wu XB, 2003, J CLIN INVEST, V112, P924, DOI 10.1172/JCI200315543
   Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475
   Zhang FJ, 2009, J BONE MINER RES, V24, P1224, DOI [10.1359/jbmr.090204, 10.1359/JBMR.090204]
   Zhao J, 2008, BIOCHEM BIOPH RES CO, V369, P444, DOI 10.1016/j.bbrc.2008.02.054
NR 55
TC 17
Z9 19
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2010
VL 46
IS 3
BP 710
EP 723
DI 10.1016/j.bone.2009.10.039
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 564WJ
UT WOS:000275248600019
PM 19895913
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Imtiyaz, Z
   Lin, YT
   Liang, FY
   Chiou, WF
   Lee, MH
AF Imtiyaz, Zuha
   Lin, Yi Tzu
   Liang, Fang Yu
   Chiou, Wen Fei
   Lee, Mei Hsien
TI Compounds Isolated from Wikstroemia taiwanensis Regulate Bone
   Remodeling by Modulating Osteoblast and Osteoclast Activities
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE bone remodeling; osteoblasts; osteoclasts; Wikstroemia taiwanensis;
   astragalin; 3 O beta D apiofuranosyl (1  > 6) beta D glucopyranoside
ID FLAVONOID GLYCOSIDES; CELLS; SIALOPROTEIN; ASTRAGALIN; LEAVES
AB Bone remodeling, a dynamic process in which bone formation by osteoblast is preceded by bone resorption by osteoclast, is a vital physiological process for maintaining bone mass and strength, imbalances in which could precipitate osteoporosis. Due to the unilateral mechanism of the existing bone remodeling drugs, identifying compounds that could regulate the balance between osteoclast and osteoblast could improve the treatment of osteoporosis. Here, we show that compounds isolated from Wikstroemia taiwanensis modulate osteoclast and osteoblast activities. Specifically, astragalin (1) and kaempferol 3 O beta D apiofuranosyl (1  > 6) beta D glucopyranoside (2), besides increasing mineral deposition, increased alkaline phosphatase activity (137.2% for 1 and 115.8% for 2) and ESR alpha expression (112.8% for 1 and 122.5% for 2) in primary human osteoblasts. In contrast, compounds 1, 2, 3, and 5 inhibited tartrate resistant acid phosphatase (TRAP) activity in receptor activator of nuclear factor kappa B ligand induced osteoclasts by 40.8, 17.1, 25.9, and 14.5% and also decreased the number of TRAP positive cells by 51.6, 26.8, 20.5, and 18.6%, respectively. Our findings, therefore, showed that compounds isolated from W. taiwanensis could increase osteoblast activity while simultaneously decreasing osteoclast activity, and hence, warrant further evaluation for development as anti osteoporosis agents.
C1 [Imtiyaz, Zuha; Lin, Yi Tzu; Lee, Mei Hsien] Taipei Med Univ, Coll Pharm, Clin Drug Dev Herbal Med, Taipei, Taiwan.
   [Imtiyaz, Zuha] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA.
   [Lin, Yi Tzu] Acad Sinica, Inst Biol Chem, Taipei, Taiwan.
   [Liang, Fang Yu; Lee, Mei Hsien] Taipei Med Univ, Coll Pharm, Grad Inst Pharmacognosy, Taipei, Taiwan.
   [Chiou, Wen Fei] Minist Hlth & Welf, Natl Res Inst Chinese Med, Taipei, Taiwan.
   [Lee, Mei Hsien] Taipei Med Univ Hosp, Ctr Reprod Med Sci, Taipei, Taiwan.
C3 Taipei Medical University; University System of Maryland; University of
   Maryland Baltimore; Academia Sinica   Taiwan; Taipei Medical University;
   National Research Institute of Chinese Medicine; Taipei Medical
   University; Taipei Medical University Hospital
RP Lee, MH (通讯作者)，Taipei Med Univ, Coll Pharm, Clin Drug Dev Herbal Med, Taipei, Taiwan.; Lee, MH (通讯作者)，Taipei Med Univ, Coll Pharm, Grad Inst Pharmacognosy, Taipei, Taiwan.; Lee, MH (通讯作者)，Taipei Med Univ Hosp, Ctr Reprod Med Sci, Taipei, Taiwan.
EM lmh@tmu.edu.tw
OI Imtiyaz, Zuha/0000 0001 6927 8623
FU Ministry of Science and Technology, Taiwan [MOST106 2320 B 038 016 MY3]
FX The study was supported by the Ministry of Science and Technology,
   Taiwan under grant number MOST106 2320 B 038 016 MY3.
CR Adhikary S, 2018, NUTRITION, V53, P64, DOI 10.1016/j.nut.2017.12.003
   Aleebrahim Dehkordy E, 2017, INT J PREVENTIVE MED, V8, DOI 10.4103/ijpvm.IJPVM_4_17
   Baker ME, 2018, J STEROID BIOCHEM, V184, P29, DOI 10.1016/j.jsbmb.2018.07.001
   Blumer MJF, 2012, MECH DEVELOP, V129, P162, DOI 10.1016/j.mod.2012.04.003
   Burmistrova O, 2011, CANCER LETT, V309, P71, DOI 10.1016/j.canlet.2011.05.018
   Chen LY, 2012, INT J MOL SCI, V13, P1029, DOI 10.3390/ijms13011029
   Chen LZ, 2019, EUR J MED CHEM, V175, P114, DOI 10.1016/j.ejmech.2019.05.004
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Cho IH, 2014, BMC PULM MED, V14, DOI 10.1186/1471 2466 14 122
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   Deng SG, 2009, J CHROMATOGR B, V877, P2487, DOI 10.1016/j.jchromb.2009.06.026
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Foo LY, 2000, PHYTOCHEMISTRY, V54, P539, DOI 10.1016/S0031 9422(00)00124 2
   Haxaire C, 2016, AM J PATHOL, V186, P1598, DOI 10.1016/j.ajpath.2016.01.016
   Hsu FL, 2006, INT J FOOD MICROBIOL, V106, P32, DOI 10.1016/j.ijfoodmicro.2005.07.003
   Imtiyaz Z, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133119
   Ke M, 2012, BIO MED MATER ENG, V22, P113, DOI 10.3233/BME 2012 0696
   Khong A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039621
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Kim TY, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110697
   Korb Pap A, 2016, RHEUMATOLOGY, V55, P64, DOI 10.1093/rheumatology/kew347
   LEE M, 1992, MAGN RESON CHEM, V30, P1035, DOI 10.1002/mrc.1260301102
   Li HF, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4856761
   Li SF, 2018, PHYTOCHEMISTRY, V151, P17, DOI 10.1016/j.phytochem.2018.01.021
   Li YM, 2009, CURR PHARM BIOTECHNO, V10, P743, DOI 10.2174/138920109789978748
   Liu L, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00228
   Mao YW, 2014, J AGR FOOD CHEM, V62, P5581, DOI 10.1021/jf5012177
   Moyroud E, 1999, TETRAHEDRON, V55, P1277, DOI 10.1016/S0040 4020(98)01119 3
   Niedzwiedzki T, 2015, J MOL ENDOCRINOL, V55, pR23, DOI 10.1530/JME 15 0067
   Nowak B, 2017, PHARMACOL REP, V69, P1113, DOI 10.1016/j.pharep.2017.05.002
   Owen R, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00134
   Qian SJ, 2020, MITOCHONDRIAL DNA B, V5, P648, DOI 10.1080/23802359.2019.1711228
   Qu DX, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/8194690
   Suvarna V, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00981
   Weathers Pamela J, 2014, World J Pharmacol, V3, P39
   Wu B, 2007, CHEM PHARM BULL, V55, P815, DOI 10.1248/cpb.55.815
   Wu ZB, 2014, CHEM NAT COMPD+, V49, P1162, DOI 10.1007/s10600 014 0850 y
   Yan LL, 2019, ROY SOC OPEN SCI, V6, DOI 10.1098/rsos.190360
   Yang L, 2010, J CELL BIOCHEM, V110, P1342, DOI 10.1002/jcb.22649
   Yang LJ, 2011, J ETHNOPHARMACOL, V135, P553, DOI 10.1016/j.jep.2011.03.056
   Yao HK, 2019, NAT PROD RES, V33, P3450, DOI 10.1080/14786419.2018.1480019
   Yao HK, 2017, MOL MED REP, V16, P9197, DOI 10.3892/mmr.2017.7712
   You OH, 2017, PHYTOTHER RES, V31, P1614, DOI 10.1002/ptr.5895
   Zhao J, 2019, MOL MED REP, V20, P5197, DOI 10.3892/mmr.2019.10747
   Zurick KM, 2013, J BIOMED MATER RES A, V101, P1571, DOI 10.1002/jbm.a.34462
NR 45
TC 3
Z9 3
U1 1
U2 13
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUL 13
PY 2021
VL 12
AR 670254
DI 10.3389/fphar.2021.670254
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA TT3CS
UT WOS:000680228500001
PM 34349644
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Guillot, A
   Joly, C
   Barthélémy, P
   Meriaux, E
   Negrier, S
   Pouessel, D
   Chevreau, C
   Mahammedi, H
   Houede, N
   Roubaud, G
   Gravis, G
   Tartas, S
   Albiges, L
   Vassal, C
   Oriol, M
   Tinquaut, F
   Espenel, S
   Bouleftour, W
   Culine, S
   Fizazi, K
AF Guillot, Aline
   Joly, Charlotte
   Barthelemy, Philippe
   Meriaux, Emeline
   Negrier, Sylvie
   Pouessel, Damien
   Chevreau, Christine
   Mahammedi, Hakim
   Houede, Nadine
   Roubaud, Guilhem
   Gravis, Gwenaelle
   Tartas, Sophie
   Albiges, Laurence
   Vassal, Cecile
   Oriol, Mathieu
   Tinquaut, Fabien
   Espenel, Sophie
   Bouleftour, Wafa
   Culine, Stephane
   Fizazi, Karim
TI Denosumab Toxicity When Combined With Anti angiogenic Therapies on
   Patients With Metastatic Renal Cell Carcinoma: A GETUG Study
SO CLINICAL GENITOURINARY CANCER
LA English
DT Article
DE Anti angiogenic therapies; Bone metastasis; Desosumab; Metastatic renal
   cell carcinoma; Osteonecrosis of the jaw
ID SKELETAL RELATED EVENTS; BONE METASTASES; CANCER PATIENTS; ZOLEDRONIC
   ACID; FREE SURVIVAL; RISK FACTORS; OSTEONECROSIS; JAW; BISPHOSPHONATES;
   SUNITINIB
AB The aim of this multicenter retrospective study is to analyze the toxicity profile (mainly osteonecrosis of the jaw) of patients with metastatic renal cell carcinoma treated with denosumab and anti angiogenic combination. Of 41 patients enrolled in this study, 7 patients developed osteonecrosis of the jaw. This toxicity signal should warn physicians about this combination in the population with metastatic renal cell carcinoma.
   Background: About one third of patients with renal cell carcinoma (RCC) have detectable metastases at diagnosis. Among them, bone is the second most frequent metastatic site. Treatment of metastatic RCC mostly relies on anti angiogenic (AA) therapies and, more recently, immunotherapy. Skeletal related events (SREs) can be prevented with bone targeted therapies such as denosumab (Dmab), which has demonstrated superiority when compared with zoledronic acid in solid tumors. However, there is limited available data on Dmab toxicity in combination with AA therapies in patients with kidney cancer. The objective of this study was to retrospectively analyze the toxicity profile (mainly osteonecrosis of the jaw [ONJ] and hypocalcemia) in patients with metastatic renal cell carcinoma (mRCC) treated with Dmab and AA therapy combination. Patients and Methods: We conducted a multicenter retrospective study among centers from the French Groupe d'Etudes des Tumeurs Uro Genitales (GETUG). Patients with bone metastases who received concurrently or sequentially AA therapy and Dmab were included in this study. Results: A total of 41 patients with mRCC were enrolled. Although no patient presented with severe hypocalcemia, ONJ occurred in 7 (17%) of 41 patients. Interestingly, all patients with ONJ received the Dmab and AA combination in the first line of treatment; among these patients, 3 patients had no risk factor other than the Dmab and AA combination. Conclusion: The incidence of ONJ was high in this real life population of patients with mRCC treated with AA therapies combined with Dmab. This toxicity signal should warn physicians about this combination in the mRCC population. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Guillot, Aline; Vassal, Cecile; Oriol, Mathieu; Bouleftour, Wafa] Inst Cancerol Lucien Neuwirth, Dept Med Oncol, St Priest En Jarez, France.
   [Joly, Charlotte] Hop Henri Mondor, AP HP, Criteil, France.
   [Barthelemy, Philippe] Hop Univ Strasbourg, Strasbourg, France.
   [Meriaux, Emeline] Ctr Francois Baclesse, Caen, France.
   [Negrier, Sylvie] Ctr Leon Berard, Lyon, France.
   [Pouessel, Damien; Culine, Stephane] Hop St Louis, AP HP, Paris, France.
   [Chevreau, Christine] IUCT Oncopole, Ctr Jean Perrin, Toulouse, France.
   [Mahammedi, Hakim] Ctr Jean Perrin, Med Oncol, Clermont Ferrand, France.
   [Houede, Nadine] Inst Cancerol Gard, Nimes, France.
   [Roubaud, Guilhem] Inst Bergonie, Bordeaux, France.
   [Gravis, Gwenaelle] Inst Paoli Calmette, Marseille, France.
   [Tartas, Sophie] Hop Univ Lyon, Lyon, France.
   [Albiges, Laurence; Fizazi, Karim] Inst Gustave Roussy, Villejuif, France.
   [Tinquaut, Fabien] Inst Cancerol Lucien Neuwirth, Dept Biostat, St Priest En Jarez, France.
   [Espenel, Sophie] Inst Cancerol Lucien Neuwirth, Dept Radiotherapy, St Priest En Jarez, France.
C3 Institut de Cancerologie de la Loire; Assistance Publique Hopitaux Paris
   (APHP); Universite Paris Est Creteil Val de Marne (UPEC); Universites de
   Strasbourg Etablissements Associes; Universite de Strasbourg; CHU
   Strasbourg; UNICANCER; Centre Francois Baclesse; UNICANCER; Centre Leon
   Berard; Assistance Publique Hopitaux Paris (APHP); Universite Paris
   Cite; Hopital Universitaire Saint Louis   APHP; UNICANCER; Centre Jean
   Perrin; UNICANCER; Centre Jean Perrin; UNICANCER; Institut Bergonie;
   UNICANCER; Institut Paoli Calmette (IPC); CHU Lyon; UNICANCER; Gustave
   Roussy; Institut de Cancerologie de la Loire; Institut de Cancerologie
   de la Loire
RP Bouleftour, W (通讯作者)，Inst Cancerol Lucien Newirth, Dept Oncol Med, St Priest En Jarez, France.
EM wafa.bouleftour@icloire.fr
RI Albiges, Laurence/JOZ 9308 2023; Gravis, Gwenaelle/CAG 3019 2022;
   Chevreau, Christine/A 5565 2015
OI Bouleftour, Wafa/0000 0002 8485 9386; MAHAMMEDI,
   Hakim/0000 0002 7596 2357; Gravis, Gwenaelle/0000 0002 3127 1554;
   ALBIGES, Laurence/0000 0002 5734 3480
CR Aghaloo T, 2015, ORAL MAXIL SURG CLIN, V27, P489, DOI 10.1016/j.coms.2015.06.001
   Beuselinck B, 2012, BRIT J CANCER, V107, P1665, DOI 10.1038/bjc.2012.385
   Bianchi M, 2012, ANN ONCOL, V23, P973, DOI 10.1093/annonc/mdr362
   Body JJ, 2015, EUR J CANCER, V51, P1812, DOI 10.1016/j.ejca.2015.05.016
   Brunello A, 2009, BONE, V44, P173, DOI 10.1016/j.bone.2008.08.132
   Choueiri TK, 2015, NEW ENGL J MED, V373, P1814, DOI 10.1056/NEJMoa1510016
   Christodoulou C, 2009, ONCOLOGY BASEL, V76, P209, DOI 10.1159/000201931
   Colella G, 2009, J ORAL MAXIL SURG, V67, P2698, DOI 10.1016/j.joms.2009.07.097
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fusco V, 2015, CLIN GENITOURIN CANC, V13, P287, DOI 10.1016/j.clgc.2014.12.002
   Gilabert M, 2013, BRIT J CANCER, V109, P1750, DOI 10.1038/bjc.2013.516
   Goessl C, 2012, ANN NY ACAD SCI, V1263, P29, DOI 10.1111/j.1749 6632.2012.06674.x
   Guarneri V, 2010, BREAST CANCER RES TR, V122, P181, DOI 10.1007/s10549 010 0866 3
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hoff AO, 2008, J BONE MINER RES, V23, P826, DOI [10.1359/JBMR.080205, 10.1359/jbmr.080205]
   Keizman D, 2012, EUR J CANCER, V48, P1031, DOI 10.1016/j.ejca.2012.02.050
   Khan A, 2016, OSTEOPOROSIS INT, V27, P853, DOI 10.1007/s00198 015 3335 3
   Koch FP, 2011, ORAL MAXILLOFAC SURG, V15, P63, DOI 10.1007/s10006 010 0224 y
   Lipton A, 2016, EUR J CANCER, V53, P75, DOI 10.1016/j.ejca.2015.09.011
   Loyson T, 2018, ACTA CLIN BELG, V73, P100, DOI 10.1080/17843286.2017.1348001
   McKay RR, 2014, EUR UROL, V66, P502, DOI 10.1016/j.eururo.2014.02.040
   Mckay RR, 2014, EUR UROL, V65, P577, DOI 10.1016/j.eururo.2013.08.012
   Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293
   Qi WX, 2014, INT J CLIN ONCOL, V19, P403, DOI 10.1007/s10147 013 0561 6
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Sivolella S, 2013, ANTICANCER RES, V33, P1793
   Smidt Hansen T, 2013, J ORAL MAXIL SURG, V71, P1532, DOI 10.1016/j.joms.2013.03.019
   Smith MR, 2015, ANN ONCOL, V26, P368, DOI 10.1093/annonc/mdu519
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Wood SL, 2012, CANCER TREAT REV, V38, P284, DOI 10.1016/j.ctrv.2011.06.011
   Woodward E, 2011, BONE, V48, P160, DOI 10.1016/j.bone.2010.09.008
NR 33
TC 13
Z9 14
U1 0
U2 1
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219 3931 USA
SN 1558 7673
EI 1938 0682
J9 CLIN GENITOURIN CANC
JI Clin. Genitourin. Cancer
PD FEB
PY 2019
VL 17
IS 1
BP E38
EP E43
DI 10.1016/j.clgc.2018.08.006
PG 6
WC Oncology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Urology & Nephrology
GA HI3HP
UT WOS:000456341000033
PM 30279115
DA 2025 08 17
ER

PT J
AU Davidson, RK
   Himes, ER
   Takigawa, S
   Chen, A
   Horn, MR
   Meijome, T
   Wallace, JM
   Kacena, MA
   Yokota, H
   Nguyen, AV
   Li, JL
AF Davidson, Rebecca K.
   Himes, Evan R.
   Takigawa, Shinya
   Chen, Andy
   Horn, M. Ryne
   Meijome, Tomas
   Wallace, Joseph M.
   Kacena, Melissa A.
   Yokota, Hiroki
   Nguyen, Andrew, V
   Li, Jiliang
TI The loss of STAT3 in mature osteoclasts has detrimental effects on bone
   structure
SO PLOS ONE
LA English
DT Article
ID OSTEOBLASTIC CELLS; DIFFERENTIATION; RECEPTOR; EXPRESSION; OSTEOPOROSIS;
   INDUCTION; LIGAND; SUSCEPTIBILITY; INTERLEUKIN 6; DISRUPTION
AB Signal Transducer and Activator of Transcription 3 (STAT3) has recently been shown to be involved in bone development and has been implicated in bone diseases, such as Job's Syndrome. Bone growth and changes have been known for many years to differ between sexes with male bones tending to have higher bone mass than female bones and older females tending to lose bone mass at faster rates than older males. Previous studies using conditional knock mice withStat3specifically deleted from the osteoblasts showed both sexes exhibited decreased bone mineral density (BMD) and strength. Using the Cre Lox system with Cathepsin K promotor driving Cre to target the deletion of theStat3gene in mature osteoclasts (STAT3 cKO mice), we observed that 8 week old STAT3 cKO female femurs exhibited significantly lower BMD and bone mineral content (BMC) compared to littermate control (CN) females. There were no differences in BMD and BMC observed between male knock out and male CN femurs. However, micro computed tomography (mu CT) analysis showed that both male and female STAT3 cKO mice had significant decreases in bone volume/tissue volume (BV/TV). Bone histomorphometry analysis of the distal femur, further revealed a decrease in bone formation rate and mineralizing surface/bone surface (MS/BS) with a significant decrease in osteoclast surface in female, but not male, STAT3 cKO mice. Profiling gene expression in an osteoclastic cell line with a knockdown of STAT3 showed an upregulation of a number of genes that are directly regulated by estrogen receptors. These data collectively suggest that regulation of STAT3 differs in male and female osteoclasts and that inactivation of STAT3 in osteoclasts affects bone turnover more in females than males, demonstrating the complicated nature of STAT3 signaling pathways in osteoclastogenesis. Drugs targeting the STAT3 pathway may be used for treatment of diseases such as Job's Syndrome and osteoporosis.
C1 [Davidson, Rebecca K.; Himes, Evan R.; Li, Jiliang] Indiana Univ Purdue Univ, Dept Biol, Indianapolis, IN 46205 USA.
   [Takigawa, Shinya; Chen, Andy; Horn, M. Ryne; Wallace, Joseph M.; Yokota, Hiroki] Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46205 USA.
   [Meijome, Tomas; Kacena, Melissa A.] Indiana Univ Sch Med, Dept Orthopaed Surg, Indianapolis, IN 46205 USA.
   [Nguyen, Andrew, V] CUNY Queensborough Community Coll, Dept Biol Sci & Geol, Bayside, NY 11364 USA.
   [Takigawa, Shinya] Mie Univ, Dept Orthopaed Surg, Grad Sch Med, Tsu, Mie, Japan.
C3 Purdue University System; Purdue University; Purdue University in
   Indianapolis; Purdue University System; Purdue University; Purdue
   University in Indianapolis; Indiana University System; Indiana
   University Bloomington; City University of New York (CUNY) System; Mie
   University
RP Li, JL (通讯作者)，Indiana Univ Purdue Univ, Dept Biol, Indianapolis, IN 46205 USA.; Nguyen, AV (通讯作者)，CUNY Queensborough Community Coll, Dept Biol Sci & Geol, Bayside, NY 11364 USA.
EM anguyen@qcc.cuny.edu; jilili@iupui.edu
RI ; Wallace, Joseph/G 7906 2012; Nguyen, Andrew/JNR 4271 2023
OI Davidson, Rebecca/0000 0002 7337 9416; Horn,
   Michael/0000 0002 1066 6303; Wallace, Joseph/0000 0001 6077 8058; 
FU Biomechanics and Biomaterials Research Center; Release Time for Research
   2018; Research Support Funds Grant 2016; Indiana University Purdue
   University Indianapolis; PSC CUNY Grant
FX This study was supported by the research funds from Biomechanics and
   Biomaterials Research Center 2014 (JL), Release Time for Research 2018
   (JL) and Research Support Funds Grant 2016 (JL), Indiana University
   Purdue University Indianapolis (JL). AVN was supported by the PSC CUNY
   Grant (2018 2019).
CR Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138
   ARNOLD J. S., 1966, CLIN ORTHOP RELATED RES, V49, P17
   Bellido T, 2015, BASIC APPL BONE BIOL, P27
   Bivi N, 2012, J BONE MINER RES, V27, P374, DOI 10.1002/jbmr.548
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   BUCKLEY RH, 1972, PEDIATRICS, V49, P59
   Callewaert F, 2010, J ENDOCRINOL, V207, P127, DOI 10.1677/JOE 10 0209
   Callewaert F, 2010, J BONE MINER RES, V25, P124, DOI 10.1359/jbmr.091001
   Chabbi Achengli Y, 2012, P NATL ACAD SCI USA, V109, P2567, DOI 10.1073/pnas.1117792109
   Charles JF, 2012, BONE, V51, P902, DOI 10.1016/j.bone.2012.08.113
   Chiu WSM, 2004, GENESIS, V39, P178, DOI 10.1002/gene.20041
   Choi HK, 2013, CELL RES, V23, P524, DOI 10.1038/cr.2013.33
   Cirri P, 1997, BIOCHEM BIOPH RES CO, V239, P493, DOI 10.1006/bbrc.1997.7493
   Corry KA, 2019, BONE REP, V11, DOI 10.1016/j.bonr.2019.100218
   DAVIS SD, 1966, LANCET, V1, P1013
   Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195
   Freeman AF, 2008, IMMUNOL ALLERGY CLIN, V28, P277, DOI 10.1016/j.iac.2008.01.005
   Frost GI, 1997, BIOCHEM BIOPH RES CO, V236, P10, DOI 10.1006/bbrc.1997.6773
   GIMBLE JM, 1994, J CELL BIOCHEM, V54, P122, DOI 10.1002/jcb.240540113
   Goettsch C, 2011, ENDOCRINOLOGY, V152, P4915, DOI 10.1210/en.2011 1282
   Grimbacher B, 1999, NEW ENGL J MED, V340, P692, DOI 10.1056/NEJM199903043400904
   Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687
   Jules J, 2018, J BIOL CHEM, V293, P1480, DOI 10.1074/jbc.M116.736009
   Jules J, 2016, J BIOL CHEM, V291, P16390, DOI 10.1074/jbc.M115.674598
   Kim JH, 2016, SCI REP UK, V6, DOI 10.1038/srep38526
   Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978
   Kim T, 2010, BIOCHEM BIOPH RES CO, V403, P73, DOI 10.1016/j.bbrc.2010.10.117
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Li CH, 2013, BIOCHEM BIOPH RES CO, V435, P533, DOI 10.1016/j.bbrc.2013.04.084
   Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200
   Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Nicolaidou V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039871
   O'Brien CA, 1999, J BIOL CHEM, V274, P19301, DOI 10.1074/jbc.274.27.19301
   O'Brien CA, 2000, J CELL BIOCHEM, V79, P532, DOI 10.1002/1097 4644(20001215)79:4<532::AID JCB20>3.0.CO;2 U
   Panchanathan R, 2009, J IMMUNOL, V183, P7031, DOI 10.4049/jimmunol.0802665
   Pang MH, 2019, J CELL BIOCHEM, V120, P12382, DOI 10.1002/jcb.28504
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Park GB, 2019, NEOPLASIA, V21, P206, DOI 10.1016/j.neo.2018.12.005
   Pramanik R, 2004, J BIOL CHEM, V279, P16121, DOI 10.1074/jbc.M313140200
   Puissant E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165004
   Rybaczyk Leszek A, 2005, BMC Womens Health, V5, P12, DOI 10.1186/1472 6874 5 12
   Scarff KL, 2004, MOL CELL BIOL, V24, P4075, DOI 10.1128/MCB.24.9.4075 4082.2004
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924
   TROTTER M, 1970, AM J PHYS ANTHROPOL, V33, P313, DOI 10.1002/ajpa.1330330305
   UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461
   Wallace JM, 2010, ANN BIOMED ENG, V38, P1607, DOI 10.1007/s10439 009 9881 0
   Warden SJ, 2005, ENDOCRINOLOGY, V146, P685, DOI 10.1210/en.2004 1259
   Won HY, 2016, ARTHRITIS RHEUMATOL, V68, P1301, DOI 10.1002/art.39538
   Wu HP, 2009, J BONE MINER RES, V24, P871, DOI [10.1359/JBMR.081239, 10.1359/jbmr.081239]
   Yamada T, 2004, J BONE MINER RES, V19, P1452, DOI 10.1359/JBMR.040515
   Yang YL, 2019, J BIOL CHEM, V294, P15395, DOI 10.1074/jbc.RA119.010139
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   Yasuda H, 1999, BONE, V25, P109, DOI 10.1016/S8756 3282(99)00121 0
   Zhang ZY, 2005, BIOCHEM BIOPH RES CO, V328, P800, DOI 10.1016/j.bbrc.2005.01.019
   Zhou HK, 2011, BONE, V49, P404, DOI 10.1016/j.bone.2011.04.020
NR 57
TC 13
Z9 14
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUL 30
PY 2020
VL 15
IS 7
AR e0236891
DI 10.1371/journal.pone.0236891
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA MW2PD
UT WOS:000556884700057
PM 32730332
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Payne, KA
   Meszaros, LB
   Phillippi, JA
   Huard, J
AF Payne, Karin A.
   Meszaros, Laura B.
   Phillippi, Julie A.
   Huard, Johnny
TI Effect of Phosphatidyl Inositol 3 Kinase, Extracellular Signal Regulated
   Kinases 1/2, and p38 Mitogen Activated Protein Kinase Inhibition on
   Osteogenic Differentiation of Muscle Derived Stem Cells
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; SKELETAL MUSCLE; MAP KINASE; INDUCED
   CHONDROGENESIS; BONE; BETA; INVOLVEMENT; PATHWAYS; BMP 2; PROLIFERATION
AB Skeletal muscle derived stem cells (MDSCs) can undergo osteogenesis when treated with bone morphogenetic proteins (BMPs), making them a potential cell source for bone tissue engineering. The signaling pathways that regulate BMP4 induced osteogenesis in MDSCs are not well understood, although they may provide a means to better regulate differentiation during bone regeneration. The objective of this study was to characterize the signaling pathways involved in the BMP4 induced osteogenesis of MDSCs. Cells were treated with BMP4 and specific inhibitors to the extracellular signal regulated kinases 1/2 (ERK1/2), p38 mitogen activated protein kinase (MAPK), and phosphatidyl inositol 3 kinase (PI3K) pathways (PD98059, SB203580, and Ly294002, respectively). Cellular proliferation, expression of osteoblast related genes, alkaline phosphatase (ALP) activity, and tissue mineralization were measured to determine the role of each pathway in the osteogenic differentiation of MDSCs. Inhibition of the ERK1/2 pathway increased ALP activity and mineralization, whereas inhibition of the p38 MAPK pathway decreased osteogenesis, suggesting opposing roles of these pathways in the BMP4 induced osteogenesis of MDSCs. Inhibition of the PI3K pathway significantly increased mineralization by MDSCs. These findings highlight the involvement of the ERK1/2, p38 MAPK, and PI3K pathways in opposing capacities in MDSC differentiation and warrant further investigation, as it may identify novel therapeutic targets for the development of stem cell based therapies for bone tissue engineering.
C1 [Payne, Karin A.; Meszaros, Laura B.; Huard, Johnny] Childrens Hosp Pittsburgh, Stem Cell Res Ctr, Pittsburgh, PA 15219 USA.
   [Payne, Karin A.; Meszaros, Laura B.; Huard, Johnny] Univ Pittsburgh, Dept Orthopaed Surg, Pittsburgh, PA USA.
   [Meszaros, Laura B.; Huard, Johnny] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA.
   [Phillippi, Julie A.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA.
   [Huard, Johnny] Univ Pittsburgh, Dept Mol Genet & Biochem, Pittsburgh, PA USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh
RP Huard, J (通讯作者)，Childrens Hosp Pittsburgh, Stem Cell Res Ctr, 450 Technol Dr,Suite 206, Pittsburgh, PA 15219 USA.
EM jhuard@pitt.edu
RI Payne, Karin/AAU 8554 2020; Phillippi, Julie/AAW 3205 2021
OI Payne, Karin/0000 0003 2230 4497; 
FU National Institutes of Health [1 RO1 DE13420 06]; William F. and Jean W.
   Donaldson Chair at Children's Hospital of Pittsburgh; Henry J. Mankin
   Endowed Chair in Orthopaedic Surgery at the University of Pittsburgh
FX The authors thank Dr. Arvydas Usas for help with the microCT. This work
   was supported in part by a National Institutes of Health grant (1 RO1
   DE13420 06) to J. Huard. This work was also supported by the William F.
   and Jean W. Donaldson Chair at Children's Hospital of Pittsburgh and by
   the Henry J. Mankin Endowed Chair in Orthopaedic Surgery at the
   University of Pittsburgh.
CR ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489
   Ambrosino C, 2001, BIOL CELL, V93, P47, DOI 10.1016/S0248 4900(01)01124 8
   Billings PC, 2008, J BONE MINER RES, V23, P305, DOI 10.1359/JBMR.071030
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Cao BH, 2003, NAT CELL BIOL, V5, P640, DOI 10.1038/ncb1008
   Celil AB, 2005, J CELL BIOCHEM, V95, P518, DOI 10.1002/jcb.20429
   Collett GDM, 2007, CIRC RES, V100, P502, DOI 10.1161/01.RES.0000258854.03388.02
   Corsi KA, 2007, J BONE MINER RES, V22, P1592, DOI 10.1359/JBMR.070702
   Corsi KA, 2007, J ORTHOP RES, V25, P1261, DOI 10.1002/jor.20432
   CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014 5793(95)00357 F
   Dang ZC, 2004, J CELL BIOCHEM, V92, P525, DOI 10.1002/jcb.20087
   Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905
   Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264 6021:3510095
   Elia D, 2007, BBA MOL CELL RES, V1773, P1438, DOI 10.1016/j.bbamcr.2007.06.006
   Engel FB, 2005, GENE DEV, V19, P1175, DOI 10.1101/gad.1306705
   Fujita T, 2004, J CELL BIOCHEM, V93, P374, DOI 10.1002/jcb.20192
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756 3282(01)00415 X
   Gharaibeh B, 2008, NAT PROTOC, V3, P1501, DOI 10.1038/nprot.2008.142
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060
   Härtel FV, 2010, AM J PHYSIOL CELL PH, V298, pC1501, DOI 10.1152/ajpcell.00333.2009
   Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284
   Hidaka K, 2001, INT J BIOCHEM CELL B, V33, P1094, DOI 10.1016/S1357 2725(01)00067 X
   Hu YY, 2003, ENDOCRINOLOGY, V144, P2068, DOI 10.1210/en.2002 220863
   Jadlowiec J, 2004, J BIOL CHEM, V279, P53323, DOI 10.1074/jbc.M404934200
   Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146
   Kono SJ, 2007, BONE, V40, P68, DOI 10.1016/j.bone.2006.07.024
   Kozawa O, 2002, J CELL BIOCHEM, V84, P583, DOI 10.1002/jcb.10056.abs
   Kozawa O, 2001, J CELL BIOCHEM, V81, P430, DOI 10.1002/1097 4644(20010601)81:3<430::AID JCB1056>3.0.CO;2 G
   Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348
   Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959 437X(98)80069 5
   Kuroda R, 2006, ARTHRITIS RHEUM US, V54, P433, DOI 10.1002/art.21632
   Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200
   Lee JY, 2000, J CELL BIOL, V150, P1085, DOI 10.1083/jcb.150.5.1085
   Lund AW, 2009, STEM CELLS DEV, V18, P331, DOI 10.1089/scd.2008.0075
   Massagué J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753
   Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011
   Nöth U, 2003, EXP CELL RES, V291, P201, DOI 10.1016/S0014 4827(03)00386 0
   Osyczka AM, 2005, ENDOCRINOLOGY, V146, P3428, DOI 10.1210/en.2005 0303
   Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153
   Qu Petersen ZQ, 2002, J CELL BIOL, V157, P851, DOI 10.1083/jcb.200108150
   Sakaue H, 1998, J BIOL CHEM, V273, P28945, DOI 10.1074/jbc.273.44.28945
   Seib FP, 2009, EUR J CELL BIOL, V88, P257, DOI 10.1016/j.ejcb.2009.01.003
   Shoba LNN, 2003, J CELL BIOCHEM, V88, P1247, DOI 10.1002/jcb.10474
   Simmons CA, 2003, J BIOMECH, V36, P1087, DOI 10.1016/S0021 9290(03)00110 6
   Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582 4934.2005.tb00337.x
   Tazoe M, 2003, ARCH ORAL BIOL, V48, P615, DOI 10.1016/S0003 9969(03)00100 6
   Viñals F, 2002, FEBS LETT, V510, P99, DOI 10.1016/S0014 5793(01)03236 7
   VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241
   Wang XY, 2007, ENDOCRINOLOGY, V148, P1629, DOI 10.1210/en.2006 1000
   Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092 8674(00)81692 X
   Wright VJ, 2002, MOL THER, V6, P169, DOI 10.1006/mthe.2002.0654
   Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951 3964.2000
   Yuan Y, 2006, CHINESE MED J PEKING, V119, P324, DOI 10.1097/00029330 200602020 00010
NR 55
TC 31
Z9 36
U1 0
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD DEC
PY 2010
VL 16
IS 12
BP 3647
EP 3655
DI 10.1089/ten.tea.2009.0738
PG 9
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA 692HG
UT WOS:000285143300009
PM 20617875
OA Green Published, Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Hanna, R
   Agas, D
   Benedicenti, S
   Ferrando, S
   Laus, F
   Cuteri, V
   Lacava, G
   Sabbieti, MG
   Amaroli, A
AF Hanna, Reem
   Agas, Dimitrios
   Benedicenti, Stefano
   Ferrando, Sara
   Laus, Fulvio
   Cuteri, Vincenzo
   Lacava, Giovanna
   Sabbieti, Maria Giovanna
   Amaroli, Andrea
TI A Comparative Study Between the Effectiveness of 980 nm
   Photobiomodulation Delivered by Hand Piece With Gaussian vs. Flat Top
   Profiles on Osteoblasts Maturation
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE photobiomodulation; bone regeneration; osteoblast; Low Level Laser
   Therapy (LLLT); light therapy; cell proliferation
ID LOW LEVEL LASER; DIODE LASER; HIGHER FLUENCE; LIGHT THERAPY; TGF BETA;
   DIFFERENTIATION; IRRADIATION; CELLS; PROLIFERATION; PARAMECIUM
AB Photobiomodulation (PBM) is a clinically accepted tool in regenerative medicine and dentistry to improve tissue healing and repair and to restore the functional disability. The current in vitro study aimed to investigate the photobiomodulatory effects of 980 nm wavelength (the real energy at the target: similar to 0.9 W, similar to 0.9 W/cm(2) , 60 s, similar to 55 J/cm(2) and a single energy similar to 55J in CW) on MC3T3 E1 pre osteoblast, delivered with flattop profile in comparison to the standard profile. The laser groupings and their associated energies were: Group 1   once per week (total energy 110 J); Group 2   three times per week (alternate day) (total energy 330 J); Group 3   five times per week (total energy 550 J). The metabolic activity and the osteoblasts maturation were analyzed by alkaline phosphatase assay, alizarin red S histological staining, immunoblot and/or double immunolabeling analysis for Bcl2, Bax, Runx 2, Osx, Dlx5, osteocalcin, and collagen Type 1. Our data, for the first time, prove that laser irradiation of 980 nm wavelength with flat top beam profile delivery system, compared to standard Gaussian profile, has improved photobiomodulatory efficacy on pre osteoblastic cells differentiation. Mechanistically, the irradiation enhances the pre osteoblast differentiation through activation of Wnt signaling and activation of Smads 2/3 beta catenin pathway.
C1 [Hanna, Reem; Benedicenti, Stefano; Amaroli, Andrea] Univ Genoa, Laser Therapy Ctr, Dept Surg & Diagnost Sci, Genoa, Italy.
   [Hanna, Reem] Kings Coll Hosp NHS Fdn Trust, Dent Inst, Dept Oral Surg, London, England.
   [Agas, Dimitrios; Laus, Fulvio; Cuteri, Vincenzo; Lacava, Giovanna; Sabbieti, Maria Giovanna] Univ Camerino, Sch Biosci & Vet Med, Camerino, Italy.
   [Ferrando, Sara; Amaroli, Andrea] Univ Genoa, Dept Earth Environm & Life Sci, Lab New Model Organism NeMo LAB, Genoa, Italy.
C3 University of Genoa; King's College Hospital NHS Foundation Trust;
   University of Camerino; University of Genoa
RP Amaroli, A (通讯作者)，Univ Genoa, Laser Therapy Ctr, Dept Surg & Diagnost Sci, Genoa, Italy.; Amaroli, A (通讯作者)，Univ Genoa, Dept Earth Environm & Life Sci, Lab New Model Organism NeMo LAB, Genoa, Italy.
EM andrea.amaroli.71@gmail.com
RI ; Agas, Dimitrios/AAO 9214 2021; Ferrando, Sara/AAC 9934 2022; Hanna,
   Reem/AAP 6376 2020; Amaroli, Andrea/AAB 1932 2021
OI Sabbieti, Maria Giovanna/0000 0002 0838 5748; Hanna,
   Reem/0000 0003 2882 2156; Cuteri, Vincenzo/0000 0001 9536 3506;
   benedicenti, stefano/0000 0003 1302 3079; Amaroli,
   Andrea/0000 0002 0494 7942; Agas, Dimitrios/0000 0002 7809 3601; 
CR Agas D, 2013, J CELL PHYSIOL, V228, P2149, DOI 10.1002/jcp.24382
   Amaroli A, 2019, PHOTOCHEM PHOTOBIOL, V95, P455, DOI 10.1111/php.13032
   Amaroli A, 2019, LASER MED SCI, V34, P495, DOI 10.1007/s10103 018 2623 5
   Amaroli A, 2018, EUR J HISTOCHEM, V62, P51, DOI 10.4081/ejh.2018.2867
   Amaroli A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00123
   Amaroli A, 2017, PHOTOMED LASER SURG, V35, P127, DOI 10.1089/pho.2016.4136
   Amaroli A, 2016, PHOTOCHEM PHOTOBIOL, V92, P854, DOI 10.1111/php.12644
   Amaroli A, 2016, PHOTOMED LASER SURG, V34, P564, DOI 10.1089/pho.2015.4035
   Amaroli A, 2016, LASER MED SCI, V31, P741, DOI 10.1007/s10103 016 1901 3
   Amaroli A, 2015, PHOTOCHEM PHOTOBIOL, V91, P1150, DOI 10.1111/php.12486
   Amaroli A, 2015, PHOTOMED LASER SURG, V33, P35, DOI 10.1089/pho.2014.3829
   Amid R, 2014, J LASERS MED SCI, V5, P163
   Arany PR, 2016, J DENT RES, V95, P977, DOI 10.1177/0022034516648939
   Avci P, 2013, SEMIN CUTAN MED SURG, V32, P41
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bloise N, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.12.128006
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Chaparro O, 2016, ZORZI INTECHOPEN, V12, P253, DOI [10.5772/62523, DOI 10.5772/62523]
   Chellini F, 2010, LASER SURG MED, V42, P527, DOI 10.1002/lsm.20861
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Czerwinski M, 2010, PLAST RECONSTR SURG, V126, P181, DOI 10.1097/PRS.0b013e3181da87df
   Dang YY, 2011, LASER MED SCI, V26, P837, DOI 10.1007/s10103 011 0985 z
   de Freitas LF, 2016, IEEE J SEL TOP QUANT, V22, DOI 10.1109/JSTQE.2016.2561201
   Deana AM, 2018, LASER MED SCI, V33, P1147, DOI 10.1007/s10103 018 2486 9
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Hamblin MR, 2019, PHOTOCHEM PHOTOBIOL, V95, P126, DOI 10.1111/php.12951
   Hamblin MR, 2006, PROC SPIE, V6140, DOI 10.1117/12.646294
   He LH, 2017, SCI REP UK, V7, DOI 10.1038/srep42385
   Huang YY, 2011, DOSE RESPONSE, V9, P602, DOI 10.2203/dose response.11 009.Hamblin
   Jawad MM, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.12.128001
   Jenkins PA, 2011, PHOTOMED LASER SURG, V29, P785, DOI 10.1089/pho.2011.9895
   Kamali F, 2007, J PHOTOCH PHOTOBIO B, V88, P11, DOI 10.1016/j.jphotobiol.2007.04.010
   Kantarci A, 2016, FRONT ORAL BIOL, V18, P134, DOI [10.1159/isbn.978 3 318 05480 4, DOI 10.1159/ISBN.978 3 318 05480 4]
   Karu TI, 2010, IUBMB LIFE, V62, P607, DOI 10.1002/iub.359
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Huertas RM, 2014, BIOL RES NURS, V16, P191, DOI 10.1177/1099800413482695
   Moustakas A, 2009, DEVELOPMENT, V136, P3699, DOI 10.1242/dev.030338
   Muramatsu S, 2007, J BIOL CHEM, V282, P32158, DOI 10.1074/jbc.M706158200
   Nilius B, 2014, PHARMACOL REV, V66, P676, DOI 10.1124/pr.113.008268
   Niu YB, 2015, MOL MED REP, V11, P4468, DOI 10.3892/mmr.2015.3249
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Pandeshwar P, 2016, J INVESTIG CLIN DENT, V7, P114, DOI 10.1111/jicd.12148
   Passarella S, 2014, J PHOTOCH PHOTOBIO B, V140, P344, DOI 10.1016/j.jphotobiol.2014.07.021
   Pastore D, 2000, INT J RADIAT BIOL, V76, P863, DOI 10.1080/09553000050029020
   Petri Alice Dias, 2010, Braz. Dent. J., V21, P491, DOI 10.1590/S0103 64402010000600003
   Renno ACM, 2007, PHOTOMED LASER SURG, V25, P275, DOI 10.1089/pho.2007.2055
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Sabbieti MG, 2013, ENDOCRINOLOGY, V154, P2723, DOI 10.1210/en.2013 1025
   Sabbieti MG, 2010, J CELL PHYSIOL, V224, P465, DOI 10.1002/jcp.22143
   Saracino S, 2009, LASER SURG MED, V41, P298, DOI 10.1002/lsm.20762
   Sowa H, 2002, J BIOL CHEM, V277, P36024, DOI 10.1074/jbc.M206030200
   Stein A, 2005, PHOTOMED LASER SURG, V23, P161, DOI 10.1089/pho.2005.23.161
   Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277
   Wang M, 2011, OSTEOARTHR CARTILAGE, V19, P751, DOI 10.1016/j.joca.2011.03.004
   Wang YG, 2017, BBA GEN SUBJECTS, V1861, P441, DOI 10.1016/j.bbagen.2016.10.008
   Wang YG, 2016, SCI REP UK, V6, DOI 10.1038/srep33719
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Zhang C, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 37
NR 58
TC 65
Z9 65
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD FEB 20
PY 2019
VL 10
AR 92
DI 10.3389/fendo.2019.00092
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA HM0BJ
UT WOS:000459109800001
PM 30842754
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yao, BJ
   Gao, HW
   Liu, J
   Zhang, M
   Leng, XY
   Zhao, DQ
AF Yao, Baojin
   Gao, Hongwei
   Liu, Jia
   Zhang, Mei
   Leng, Xiangyang
   Zhao, Daqing
TI Identification of potential therapeutic targets of deer antler extract
   on bone regulation based on serum proteomic analysis
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Deer antler extract; Serum proteomics; iTRAQ; Bone regulation; Molecular
   mechanism
ID VELVET ANTLER; DYNAMICS; TROPOMYOSIN; GROWTH; ORGANIZATION; POPULATIONS;
   MIGRATION; SIGNALS; CANCER; MICE
AB Traditional Chinese medicine has been proven to be effective in treating human diseases according to a long term observation for more than 2000 years. However, the precise molecular mechanisms of a majority of the medications are still largely unknown. Deer antler has been clinically used as an effective animal medication in traditional Chinese medicine for many centuries. Previous studies have demonstrated that antler extracts play crucial roles in promoting bone and cartilage development, growth and repair. However, the underlying molecular mechanism remains to be elucidated. In the present study, we applied isobaric tags for relative and absolute quantitation (iTRAQ) technology and a systematic bioinformatics analysis accompanied with validation method to obtain a full spectrum of the serum protein profiles under deer antler extract treatment. We identified a complex interaction network formed by the positive regulation of Tropomyosins (Tpm1, 2 and 4), WD repeat containing protein 1 (Wdr1), Alpha actinin 1 (Actn1) and Destrin (Dstn) and the negative regulation of Alpha 2 macroglobulin (A2m), Serine protease inhibitor A3 N (Serpina3n) and Apolipoproteins (Apoh and Apof), which coordinately interact with multiple proteins and signaling pathways. Our results suggest that the therapeutic effects of deer antler extract on treating bone diseases might achieved though the regulation of bone formation and remodeling by controlling a series of serum proteins and signaling pathways that were essential for osteoblast and osteoclast activities. Thus, this study has greatly deepened the current knowledge about the molecular mechanism of therapeutic effects of deer antler extract on bone diseases such as osteoporosis.
C1 [Yao, Baojin; Zhao, Daqing] Changchun Univ Chinese Med, Jilin Ginseng Acad, Changchun 130117, Jilin, Peoples R China.
   [Gao, Hongwei; Leng, Xiangyang] Changchun Univ Chinese Med, Affiliated Hosp, Changchun 130117, Jilin, Peoples R China.
   [Liu, Jia] Changchun Univ Chinese Med, Coll Pharm, Changchun 130117, Jilin, Peoples R China.
   [Zhang, Mei] Changchun Univ Chinese Med, Innovat Practice Ctr, Changchun 130117, Jilin, Peoples R China.
C3 Changchun University of Chinese Medicine; Changchun University of
   Chinese Medicine; Changchun University of Chinese Medicine; Changchun
   University of Chinese Medicine
RP Zhao, DQ (通讯作者)，Changchun Univ Chinese Med, Jilin Ginseng Acad, Changchun 130117, Jilin, Peoples R China.; Leng, XY (通讯作者)，Changchun Univ Chinese Med, Affiliated Hosp, Changchun 130117, Jilin, Peoples R China.
EM leng_xiangyang@163.com; zhaodaqing1963@163.com
OI Zhao, Daqing/0000 0001 5678 7410; Leng, Xiangyang/0000 0001 5278 4001;
   Yao, Baojin/0000 0002 7542 1585; Zhang, Mei/0000 0001 9096 3852
FU National Key Research and Development Program of China [2018YFC1706605];
   TCM Clinical Research Centre for Bone diseases of Jilin Province
   [20180623048TC]; Science and Technology Development Project of Jilin
   Province [20170520044JH]
FX This work was supported by the National Key Research and Development
   Program of China (Grant No. 2018YFC1706605), the TCM Clinical Research
   Centre for Bone diseases of Jilin Province (Grant No. 20180623048TC) and
   the Science and Technology Development Project of Jilin Province (Grant
   No. 20170520044JH).
CR Ahn H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153886
   Aslam B, 2017, J CHROMATOGR SCI, V55, P182, DOI 10.1093/chromsci/bmw167
   Candotti F, 2002, J CLIN INVEST, V109, P1261, DOI 10.1172/JCI200215769
   Chandramouli Kondethimmanahalli, 2009, Hum Genomics Proteomics, V2009, DOI 10.4061/2009/239204
   Chen J, 2015, EVID BASED COMPL ALT, V2015
   Chiu WC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161950
   Cho WCS, 2007, AM J CHINESE MED, V35, P911, DOI 10.1142/S0192415X07005375
   Cruikshank WW, 2000, J LEUKOCYTE BIOL, V67, P757, DOI 10.1002/jlb.67.6.757
   Dallas SL, 2010, ANN NY ACAD SCI, V1192, P437, DOI 10.1111/j.1749 6632.2009.05246.x
   Dejaeger M, 2017, J BONE MINER RES, V32, P2087, DOI 10.1002/jbmr.3190
   Gateva G, 2017, CURR BIOL, V27, P705, DOI 10.1016/j.cub.2017.01.018
   Gavish H, 1997, BIOCHEMISTRY US, V36, P14883, DOI 10.1021/bi971670t
   Gomez Cambronero J, 2014, J BIOL CHEM, V289, P22557, DOI 10.1074/jbc.R114.574152
   Gunning PW, 2015, J CELL SCI, V128, P2965, DOI 10.1242/jcs.172502
   Hendershott MC, 2014, P NATL ACAD SCI USA, V111, P5860, DOI 10.1073/pnas.1404133111
   Hikiji H, 2009, P NATL ACAD SCI USA, V106, P21294, DOI 10.1073/pnas.0905209106
   Hong GJ, 2016, BIOMED REP, V4, P92, DOI 10.3892/br.2015.527
   Huang CC, 2014, MOLECULES, V19, P4669, DOI 10.3390/molecules19044669
   Ishida M, 2018, ENDOCRINOLOGY, V159, P3775, DOI 10.1210/en.2018 00639
   Ji Q, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/983139
   Kato A, 2008, BIOCHEM J, V414, P261, DOI 10.1042/BJ20071655
   Kim KS, 2004, INT IMMUNOPHARMACOL, V4, P963, DOI 10.1016/j.intimp.2004.04.010
   Kitaeva AB, 2016, NEW PHYTOL, V210, P168, DOI 10.1111/nph.13792
   Kotadiya P, 2008, BONE, V43, P951, DOI 10.1016/j.bone.2008.06.017
   Lao YZ, 2014, J ETHNOPHARMACOL, V155, P1, DOI 10.1016/j.jep.2014.05.022
   Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014 5793(01)03243 4
   Li S, 2014, ARTHRITIS RHEUMATOL, V66, P1854, DOI 10.1002/art.38521
   Luxenburg C, 2015, NAT CELL BIOL, V17, P592, DOI 10.1038/ncb3146
   McMichael BK, 2008, EXP CELL RES, V314, P564, DOI 10.1016/j.yexcr.2007.10.018
   McMichael BK, 2006, BONE, V39, P694, DOI 10.1016/j.bone.2006.04.031
   Menaa C, 2008, KIDNEY INT, V73, P1275, DOI 10.1038/ki.2008.100
   Moreau M, 2004, CAN VET J, V45, P133
   Munaron L, 2004, J CELL MOL MED, V8, P161, DOI 10.1111/j.1582 4934.2004.tb00271.x
   Onan D, 2009, ENDOCRINOLOGY, V150, P2244, DOI 10.1210/en.2008 1597
   Parsons JT, 2010, NAT REV MOL CELL BIO, V11, P633, DOI 10.1038/nrm2957
   Pauwels AM, 2017, TRENDS IMMUNOL, V38, P407, DOI 10.1016/j.it.2017.03.006
   Price J, 2004, PHILOS T R SOC B, V359, P809, DOI 10.1098/rstb.2004.1471
   Pu R, 2018, EXP THER MED, V15, P977, DOI 10.3892/etm.2017.5459
   Puri KD, 2013, INT REV IMMUNOL, V32, P397, DOI 10.3109/08830185.2013.818140
   Reagan Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07 9574LSF
   Ricklin D, 2013, J IMMUNOL, V190, P3831, DOI 10.4049/jimmunol.1203487
   Rueda JC, 2009, JCR J CLIN RHEUMATOL, V15, P130, DOI 10.1097/RHU.0b013e31819dbd20
   Schilling AF, 2005, J BONE MINER RES, V20, P274, DOI 10.1359/JBMR.041101
   Shi B, 2010, J ETHNOPHARMACOL, V127, P124, DOI 10.1016/j.jep.2009.09.036
   Shuang F, 2013, EUR J APPL PHYSIOL, V113, P403, DOI 10.1007/s00421 012 2451 4
   Sui ZG, 2014, J PHARMACEUT BIOMED, V87, P229, DOI 10.1016/j.jpba.2013.07.044
   Suo TC, 2016, EXPERT REV PROTEOMIC, V13, P873, DOI 10.1080/14789450.2016.1220837
   Sweeney SE, 2004, CURR OPIN RHEUMATOL, V16, P231, DOI 10.1097/00002281 200405000 00011
   Tristan C, 2011, CELL SIGNAL, V23, P317, DOI 10.1016/j.cellsig.2010.08.003
   Tseng SH, 2012, MOLECULES, V17, P10574, DOI 10.3390/molecules170910574
   Wiese S, 2007, PROTEOMICS, V7, P340, DOI 10.1002/pmic.200600422
   Wu SM, 2015, J CELL BIOCHEM, V116, P1419, DOI 10.1002/jcb.25102
   Xiao Y, 2017, J BIOL CHEM, V292, P1438, DOI 10.1074/jbc.M116.759886
   Yang JK, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/3290260
   Yao BJ, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9847286
   Yao BJ, 2018, IN VITRO CELL DEV AN, V54, P439, DOI 10.1007/s11626 018 0266 2
   Yuan BY, 2018, INT J BIOL SCI, V14, P1067, DOI 10.7150/ijbs.23845
   Zhang AH, 2013, APPL BIOCHEM BIOTECH, V170, P774, DOI 10.1007/s12010 013 0238 7
   Zhang LZ, 2013, J ETHNOPHARMACOL, V150, P181, DOI 10.1016/j.jep.2013.08.029
   Zhang ZY, 2017, EVID BASED COMPL ALT, V2017, DOI 10.1155/2017/3275096
   Zreiqat H, 2007, J MOL HISTOL, V38, P381, DOI 10.1007/s10735 007 9117 2
NR 61
TC 19
Z9 20
U1 1
U2 33
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301 4851
EI 1573 4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD OCT
PY 2019
VL 46
IS 5
BP 4861
EP 4872
DI 10.1007/s11033 019 04934 0
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA JL5SH
UT WOS:000495590600019
PM 31286391
DA 2025 08 17
ER

PT J
AU Xiao, YS
   Zhang, SS
   Ye, YJ
   Chen, JC
   Xu, YJ
AF Xiao, Yaosheng
   Zhang, Shanshan
   Ye, Yongjun
   Chen, Jincai
   Xu, Youjia
TI Geniposide suppressed OX LDL induced osteoblast apoptosis by regulating
   the NRF2/NF ?B signaling pathway
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article
DE Osteoporosis; Geniposide; Osteoblast; Apoptosis; NRF2/NF kappa B
ID OSTEOCLAST DIFFERENTIATION; OSTEOPOROSIS
AB Background Osteoporosis (OP), due to microarchitectural alterations, is associated with decreased bone mass, declined strength, and increased fracture risk. Increased osteoblast apoptosis contributes to the progression of OP. Natural compounds from herbs provide a rich resource for drug screening. Our previous investigation showed that geniposide (GEN), an effective compound from Eucommia ulmoides, could protect against the pathological development of OP induced by cholesterol accumulation.
   Methods The rat OP models were duplicated. Dual  energy X ray absorptiometry, hematoxylin and eosin staining, and immunohistochemistry were used to evaluate bone changes. TUNEL/DAPI staining assays were used for cell apoptosis detection. Protein expression was determined by western blotting assays.
   Results A high fat diet promoted OP development in vivo, and OX LDL stimulated osteoblast apoptosis in vitro. GEN exhibited protective activities against OX LDL induced osteoblast apoptosis by increasing the NRF2 pathway and decreasing the NF kappa B pathway. PDTC, an NF kappa B inhibitor, could further promote the biological functions of GEN. In contrast, ML385, an NRF2 inhibitor, might eliminate GEN's protection.
   Conclusion GEN suppressed OX LDL induced osteoblast apoptosis by regulating the NRF2/NF kappa B signaling pathway.
C1 [Xiao, Yaosheng] Soochow Univ, Med Coll, Suzhou 215123, Peoples R China.
   [Xiao, Yaosheng; Ye, Yongjun; Chen, Jincai] Gannan Med Univ, Dept Orthoped, Affiliated Hosp 1, Ganzhou 341000, Peoples R China.
   [Zhang, Shanshan] Gannan Med Univ, Coll Pharm, Ganzhou 341000, Peoples R China.
   [Xu, Youjia] Soochow Univ, Dept Orthopaed, Affiliated Hosp 2, Suzhou 215004, Peoples R China.
C3 Soochow University   China; Gannan Medical University; Gannan Medical
   University; Soochow University   China
RP Xu, YJ (通讯作者)，Soochow Univ, Dept Orthopaed, Affiliated Hosp 2, Suzhou 215004, Peoples R China.
EM xuyoujia@suda.edu.cn
RI zhang, shanshan/KCK 2173 2024; xiao, yaosheng/MIU 3357 2025
FU No applicable
FX No applicable
CR An YA, 2019, FASEB J, V33, P12515, DOI 10.1096/fj.201802805RR
   Anagnostis P, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031639
   Cao LL, 2022, FASEB J, V36, DOI 10.1096/fj.202200608RR
   Che YT, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23042020
   Chen SX, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.786599
   Chen TW, 2020, EBIOMEDICINE, V53, DOI 10.1016/j.ebiom.2020.102706
   Gao Shuya, 2022, Clin Sci (Lond), V136, P1711, DOI 10.1042/CS20220242
   Gill PK, 2022, CURR OPIN LIPIDOL, V33, P126, DOI 10.1097/MOL.0000000000000796
   Guo L, 2018, ARCH ORAL BIOL, V93, P149, DOI 10.1016/j.archoralbio.2018.06.007
   Ha H, 2003, ARCH PHARM RES, V26, P929, DOI 10.1007/BF02980202
   Han Biao, 2019, Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, V36, P421, DOI 10.7507/1001 5515.201801019
   Huang JS, 2022, BIOMED PHARMACOTHER, V155, DOI 10.1016/j.biopha.2022.113829
   Kosaka S, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9122563
   Lee CH, 2014, J PHARMACOL SCI, V124, P344, DOI 10.1254/jphs.13174FP
   Li JZ, 2019, MOL MED REP, V19, P2660, DOI 10.3892/mmr.2019.9922
   Li JL, 2020, EXP ANIM TOKYO, V69, P326, DOI 10.1538/expanim.19 0148
   Li N, 2022, NUTRIENTS, V14, DOI 10.3390/nu14183730
   Li YF, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0243108
   Liu SN, 2020, PSYCHOPHARMACOLOGY, V237, P465, DOI 10.1007/s00213 019 05379 w
   Liu SY, 2018, INT J MOL MED, V41, P2059, DOI 10.3892/ijmm.2018.3414
   Ma HD, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/9067610
   Malesza IJ, 2021, CELLS BASEL, V10, DOI 10.3390/cells10113164
   Oda Kawashima K, 2020, FEBS OPEN BIO, V10, P259, DOI 10.1002/2211 5463.12783
   Pei ZW, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/4878704
   Priddy C, 2021, BONE REP, V15, DOI 10.1016/j.bonr.2021.101149
   Sánchez de Diego C, 2021, REDOX BIOL, V40, DOI 10.1016/j.redox.2020.101845
   Sheng SR, 2023, PHYTOMEDICINE, V114, DOI 10.1016/j.phymed.2023.154739
   Shi Y, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.689092
   Si MD, 2022, PHARM BIOL, V60, P1960, DOI 10.1080/13880209.2022.2127153
   Su Fang Fang, 2019, Zhongguo Zhen Jiu, V39, P180, DOI 10.13703/j.0255 2930.2019.02.018
   Su Q, 2018, INFLAMMATION, V41, P1229, DOI 10.1007/s10753 018 0769 8
   Sun CC, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.575390
   Sun XW, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101309
   Tekin MB, 2019, INT J IMPLANT DENT, V5, DOI 10.1186/s40729 019 0170 x
   Tu YY, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/9247947
   Wang XY, 2021, LIPIDS HEALTH DIS, V20, DOI 10.1186/s12944 021 01601 x
   Wang YM, 2018, BIOCHEM BIOPH RES CO, V498, P981, DOI 10.1016/j.bbrc.2018.03.093
   Xiao PT, 2021, J ETHNOPHARMACOL, V264, DOI 10.1016/j.jep.2020.113380
   Xiao YS, 2022, J ETHNOPHARMACOL, V291, DOI 10.1016/j.jep.2022.115154
   Xie BC, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00411
   Xie R, 2023, J BIOCHEM MOL TOXIC, V37, DOI 10.1002/jbt.23251
   Xu L, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8284107
   Xu YL, 2020, AM J CHINESE MED, V48, P1821, DOI 10.1142/S0192415X20500913
   Yang H, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974 020 1731 x
   Yang L, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.772635
   Zhang Y, 2020, CHEM BIODIVERS, V17, DOI 10.1002/cbdv.201900479
   Zhang YF, 2021, PHARM BIOL, V59, P1556, DOI 10.1080/13880209.2021.1996614
   Zheng YZ, 2021, CELLS BASEL, V10, DOI 10.3390/cells10123424
   Zusso M, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974 019 1538 9
NR 49
TC 6
Z9 6
U1 3
U2 15
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD AUG 30
PY 2023
VL 18
IS 1
AR 641
DI 10.1186/s13018 023 04125 5
PG 11
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA Q6IT9
UT WOS:001058547200003
PM 37649066
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Kuehn, SC
   Koehne, T
   Cornils, K
   Markmann, S
   Riedel, C
   Pestka, JM
   Schweizer, M
   Baldauf, C
   Yorgan, TA
   Krause, M
   Keller, J
   Neven, M
   Breyer, S
   Stuecker, R
   Muschol, N
   Busse, B
   Braulke, T
   Fehse, B
   Amling, M
   Schinke, T
AF Kuehn, Sonja C.
   Koehne, Till
   Cornils, Kerstin
   Markmann, Sandra
   Riedel, Christoph
   Pestka, Jan M.
   Schweizer, Michaela
   Baldauf, Christina
   Yorgan, Timur A.
   Krause, Matthias
   Keller, Johannes
   Neven, Mona
   Breyer, Sandra
   Stuecker, Ralf
   Muschol, Nicole
   Busse, Bjoern
   Braulke, Thomas
   Fehse, Boris
   Amling, Michael
   Schinke, Thorsten
TI Impaired bone remodeling and its correction by combination therapy in a
   mouse model of mucopolysaccharidosis I
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID CELL TRANSPLANTATION; OSTEOCLAST; OSTEOPETROSIS; OSTEOCYTE; MARROW;
   HISTOMORPHOMETRY; MECHANISMS; PATHOLOGY; INSIGHTS; DISEASE
AB Mucopolysaccharidosis I (MPS I) is a lysosomal storage disease (LSD) caused by inactivating mutations of IDUA, encoding the glycosaminoglycan degrading enzyme alpha l iduronidase. Although MPS I is associated with skeletal abnormalities, the impact of IDUA deficiency on bone remodeling is poorly defined. Here we report that Idua deficient mice progressively develop a high bone mass phenotype with pathological lysosomal storage in cells of the osteoblast lineage. Histomorphometric quantification identified shortening of bone forming units and reduced osteoclast numbers per bone surface. This phenotype was not transferable into wild type mice by bone marrow transplantation (BMT). In contrast, the high bone mass phenotype of Idua deficient mice was prevented by BMT from wild type donors. At the cellular level, BMT did not only normalize defects of Idua deficient osteoblasts and osteocytes but additionally caused increased osteoclastogenesis. Based on clinical observations in an individual with MPS I, previously subjected to BMT and enzyme replacement therapy (ERT), we treated Idua deficient mice accordingly and found that combining both treatments normalized all histomorphometric parameters of bone remodeling. Our results demonstrate that BMT and ERT profoundly affect skeletal remodeling of Idua deficient mice, thereby suggesting that individuals with MPS I should be monitored for their bone remodeling status, before and after treatment, to avoid long term skeletal complications.
C1 [Kuehn, Sonja C.; Koehne, Till; Riedel, Christoph; Pestka, Jan M.; Baldauf, Christina; Yorgan, Timur A.; Krause, Matthias; Keller, Johannes; Neven, Mona; Busse, Bjoern; Amling, Michael; Schinke, Thorsten] Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, D 20246 Hamburg, Germany.
   [Koehne, Till] Univ Med Ctr Hamburg Eppendorf, Dept Orthodont, D 20246 Hamburg, Germany.
   [Cornils, Kerstin; Fehse, Boris] Univ Med Ctr Hamburg Eppendorf, Dept Stem Cell Transplantat, Res Dept Cell & Gene Therapy, D 20246 Hamburg, Germany.
   [Markmann, Sandra; Muschol, Nicole; Braulke, Thomas] Univ Med Ctr Hamburg Eppendorf, Childrens Hosp, Dept Biochem, D 20246 Hamburg, Germany.
   [Schweizer, Michaela] Univ Med Ctr Hamburg Eppendorf, Ctr Mol Neurobiol, D 20246 Hamburg, Germany.
   [Breyer, Sandra; Stuecker, Ralf] Univ Clin Hamburg, Dept Orthoped, Childrens Hosp Hamburg Altona, D 22763 Hamburg, Germany.
C3 University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Hamburg; University Medical Center Hamburg Eppendorf
RP Schinke, T (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, Martinistr 52, D 20246 Hamburg, Germany.
EM schinke@uke.de
RI ; Fehse, Boris/A 8721 2012; Koehne, Till/AAC 4458 2020; Braulke,
   Thomas/AAV 9121 2020; Busse, Björn/AAC 4033 2020
OI Fehse, Boris/0000 0001 9780 7211; Kohne, Till/0009 0000 8830 1964;
   Riedel, Christoph/0000 0001 8342 296X; Krause,
   Matthias/0000 0002 7345 6506; Busse, Bjorn/0000 0002 3099 8073; Keller,
   Johannes/0000 0002 8925 7288; Braulke, Thomas/0000 0002 2336 8532
FU European Community [602300]; Deutsche Forschungsgemeinschaft [AM
   103/25 1, SCHI 504 /8 1]
FX The research leading to these results has received funding from the
   European Community's Seventh Framework Programme under grant agreement
   no. 602300 (SYBIL) and from the Deutsche Forschungsgemeinschaft (AM
   103/25 1, SCHI 504 /8 1).
CR Aldenhoven M, 2009, ANN RHEUM DIS, V68, P1659, DOI 10.1136/ard.2008.095315
   Ballabio A, 2009, BBA MOL CELL RES, V1793, P684, DOI 10.1016/j.bbamcr.2008.12.001
   Bellido T, 2014, CALCIFIED TISSUE INT, V94, P25, DOI 10.1007/s00223 013 9774 y
   Campos D, 2012, METAB BRAIN DIS, V27, P121, DOI 10.1007/s11011 012 9302 1
   Clarke LA, 1997, HUM MOL GENET, V6, P503, DOI 10.1093/hmg/6.4.503
   Cornils K, 2009, MOL THER, V17, P131, DOI 10.1038/mt.2008.238
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   Dawson PA, 2010, J CLIN INVEST, V120, P706, DOI 10.1172/JCI31474
   de Ru MH, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750 1172 6 55
   Glorieux FH, 2000, BONE, V26, P103, DOI 10.1016/S8756 3282(99)00257 4
   Graupman P, 2004, J CRANIOFAC SURG, V15, P392, DOI 10.1097/00001665 200405000 00009
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Husain SM, 1999, ARCH DIS CHILD, V80, P370, DOI 10.1136/adc.80.4.370
   Kollmann K, 2012, BRAIN, V135, P2661, DOI 10.1093/brain/aws209
   Kollmann K, 2013, EMBO MOL MED, V5, P1871, DOI 10.1002/emmm.201302979
   Kubek DJ, 2010, MICROSC RES TECHNIQ, V73, P182, DOI 10.1002/jemt.20772
   Lamanna WC, 2011, J BIOL CHEM, V286, P6955, DOI 10.1074/jbc.M110.192062
   Lange C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014486
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Martin TJ, 2013, WORLD J ORTHOP, V4, P186, DOI 10.5312/wjo.v4.i4.186
   MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306
   Muenzer J, 2009, PEDIATRICS, V123, P19, DOI 10.1542/peds.2008 0416
   Nakashima T, 2011, ANN NY ACAD SCI, V1240, pE13, DOI 10.1111/j.1749 6632.2011.06373.x
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pastores GM, 2005, CURR OPIN RHEUMATOL, V17, P70, DOI 10.1097/01.bor.0000147283.40529.13
   Pievani A, 2015, BLOOD, V125, P1662, DOI 10.1182/blood 2014 06 581207
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rowan DJ, 2013, J INHERIT METAB DIS, V36, P235, DOI 10.1007/s10545 012 9522 x
   Russell C, 1998, CLIN GENET, V53, P349
   Saftig P, 2009, NAT REV MOL CELL BIO, V10, P623, DOI 10.1038/nrm2745
   Salbach Hirsch J, 2013, BIOMATERIALS, V34, P7653, DOI 10.1016/j.biomaterials.2013.06.053
   Scaramuzzo L, 2012, J BIOL REG HOMEOS AG, V26, P139
   Schinke T, 2009, NAT MED, V15, P674, DOI 10.1038/nm.1963
   Schulze J, 2011, J BONE MINER RES, V26, P704, DOI 10.1002/jbmr.269
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Stevenson DA, 2013, PEDIATR ENDOCR REV P, V10, P406
   Teitelbaum SL, 2011, ANN NY ACAD SCI, V1240, P14, DOI 10.1111/j.1749 6632.2011.06283.x
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   Valayannopoulos V, 2011, RHEUMATOLOGY, V50, pV49, DOI 10.1093/rheumatology/ker396
   Visigalli I, 2010, BLOOD, V116, P5130, DOI 10.1182/blood 2010 04 278234
   WALKER DG, 1975, SCIENCE, V190, P784, DOI 10.1126/science.1105786
   WALKER DG, 1975, SCIENCE, V190, P785, DOI 10.1126/science.1198094
   Weinert S, 2014, EMBO REP, V15, P784, DOI 10.15252/embr.201438553
   Weinert S, 2010, SCIENCE, V328, P1401, DOI 10.1126/science.1188072
   Wilson S, 2009, AM J PATHOL, V175, P2053, DOI 10.2353/ajpath.2009.090211
   Wraith JE, 2014, PEDIATR ENDOCR REV P, V12, P102
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
NR 47
TC 25
Z9 25
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964 6906
EI 1460 2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD DEC 15
PY 2015
VL 24
IS 24
BP 7075
EP 7086
DI 10.1093/hmg/ddv407
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA DB2WZ
UT WOS:000368372600017
PM 26427607
OA Bronze
DA 2025 08 17
ER

PT J
AU Kamoun Goldrat, A
   Ginisty, D
   Le Merrer, M
AF Kamoun Goldrat, Agnes
   Ginisty, Danielle
   Le Merrer, Martine
TI Effects of bisphosphonates on tooth eruption in children with
   osteogenesis imperfecta
SO EUROPEAN JOURNAL OF ORAL SCIENCES
LA English
DT Article
DE bone resorption; brittle bone disease; human; osteoclasts; teething
ID BONE RESORPTION; 1 HYDROXYETHYLIDENE 1,1 BISPHOSPHONATE HEBP; RAT;
   OSTEOPETROSIS; MOUSE; ABNORMALITIES; OSTEOCLASTS; METABOLISM;
   MECHANISMS; DENTITION
AB Bisphosphonates are currently used in the therapy of osteogenesis imperfecta (OI) to decrease the bone fragility observed in OI patients. Bisphosphonate therapy delays tooth eruption in rats. The aim of this study was to determine whether or not bisphosphonate therapy delays tooth eruption in children. The clinical emergence of teeth was observed and the calculated dental age and the number of delayed teeth were determined for 33 OI patients treated with bisphosphonates and for strictly gender  and age matched controls. There were significant differences between bisphosphonate treated patients and controls for calculated dental age and number of delayed teeth. Bisphosphonate therapy was associated with a mean delay of 1.67 yr in tooth eruption in children with OI.
C1 [Kamoun Goldrat, Agnes; Le Merrer, Martine] Paris Descartes Univ, INSERM, Hop Necker, Paris, France.
   [Ginisty, Danielle] Paris Descartes Univ, Hop Cochin St Vincent Paul, Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Necker Enfants Malades   APHP; Institut National
   de la Sante et de la Recherche Medicale (Inserm); Assistance Publique
   Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire
   Cochin   APHP
RP Kamoun Goldrat, A (通讯作者)，Tour Lavoisier Hop Necker Enfants Malades, INSERM, U781, F 75743 Paris 15, France.
EM agnes.kamoun@yahoo.fr
CR Alakangas A, 2002, CALCIFIED TISSUE INT, V70, P40, DOI 10.1007/s002230010047
   Alatli I, 1997, J DENT, V25, P313, DOI 10.1016/S0300 5712(96)00006 1
   ANDERSEN PE, 1989, CLIN GENET, V36, P250
   CARVALHO JC, 1989, J DENT RES, V68, P773, DOI 10.1177/00220345890680050401
   COTTON WR, 1974, P SOC EXP BIOL MED, V146, P554, DOI 10.3181/00379727 146 38146
   Engelbert RHH, 1998, ARCH PHYS MED REHAB, V79, P1590, DOI 10.1016/S0003 9993(98)90426 9
   FILIPSSON R, 1975, ANN HUM BIOL, V2, P13, DOI 10.1080/03014467500000521
   Fouda N, 1991, J Biol Buccale, V19, P106
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Grier RL, 1998, J DENT RES, V77, P8, DOI 10.1177/00220345980770011201
   HAGG U, 1985, ANGLE ORTHOD, V55, P93
   HURME V O, 1949, J Dent Child, V16, P11
   Lindau B, 1999, Int J Paediatr Dent, V9, P253, DOI 10.1111/j.1365 263X.1999.00143.x
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   LUKINMAA PL, 1987, J CRAN GENET DEV BIO, V7, P127
   Lund AM, 1998, J CRAN GENET DEV BIO, V18, P30
   LYSELL L., 1962, ODONTOL REVU, V13, P217
   Malmgren B, 2002, ACTA ODONTOL SCAND, V60, P65, DOI 10.1080/000163502753509446
   MARKS SC, 1995, INT J DEV BIOL, V39, P223
   MARKS SC, 1981, METAB BONE DIS RELAT, V3, P107, DOI 10.1016/0221 8747(81)90028 X
   MARKS SC, 1976, J HERED, V67, P11, DOI 10.1093/oxfordjournals.jhered.a108657
   MARKS SC, 1973, AM J ANAT, V138, P165, DOI 10.1002/aja.1001380204
   MOORREES CFA, 1978, ANN HUM BIOL, V5, P55, DOI 10.1080/03014467800002641
   O'Connell AC, 1999, ORAL SURG ORAL MED O, V87, P189, DOI 10.1016/S1079 2104(99)70272 6
   Papapoulos SE, 2006, BONE, V38, P613, DOI 10.1016/j.bone.2006.01.141
   PIPER K, 1994, CALCIFIED TISSUE INT, V54, P56, DOI 10.1007/BF00316291
   REITSMA PH, 1980, CALCIFIED TISSUE INT, V32, P145, DOI 10.1007/BF02408534
   Russell RGG, 1999, J BONE MINER RES, V14, P53, DOI 10.1002/jbmr.5650140212
   SCHWARTZ S, 1984, ORAL SURG ORAL MED O, V57, P161, DOI 10.1016/0030 4220(84)90206 8
   SEIFERT MF, 1988, AM J ANAT, V183, P158, DOI 10.1002/aja.1001830206
   SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101
   SYKES B, 1986, LANCET, V2, P69
   Tiffee JC, 1999, CALCIFIED TISSUE INT, V65, P53, DOI 10.1007/s002239900657
   WESSELINK PR, 1989, CALCIFIED TISSUE INT, V45, P104, DOI 10.1007/BF02561409
   WESSELINK PR, 1994, J CLIN PERIODONTOL, V21, P465, DOI 10.1111/j.1600 051X.1994.tb00409.x
NR 35
TC 61
Z9 66
U1 0
U2 8
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0909 8836
J9 EUR J ORAL SCI
JI Eur. J. Oral Sci.
PD JUN
PY 2008
VL 116
IS 3
BP 195
EP 198
DI 10.1111/j.1600 0722.2008.00529.x
PG 4
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 298QT
UT WOS:000255702900001
PM 18471236
DA 2025 08 17
ER

PT J
AU Yang, K
   Li, SY
   Wang, TQ
   Yan, XM
   He, Q
   Ning, RA
   Xu, X
   Yao, W
   Zhang, XF
   Yang, CH
   Jiang, M
   Deng, LF
AF Yang, Kai
   Li, Shunyao
   Wang, Tianqi
   Yan, Xueming
   He, Qian
   Ning, Ruonan
   Xu, Xing
   Yao, Wei
   Zhang, Xiaofei
   Yang, Chunhao
   Jiang, Min
   Deng, Lianfu
TI Development of an Orally Active Small Molecule Inhibitor of Receptor
   Activator of Nuclear Factor ?B Ligand
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID OSTEOCLAST DIFFERENTIATION; BONE RESORPTION; OSTEOPROTEGERIN; DENOSUMAB;
   RANKL; REGENERATION; ELUCIDATION; DISEASE; CANCER; WOMEN
AB Receptor activator of nuclear factor  KB (RANK) and its ligand, RANKL, play pivotal roles in bone remodeling. The monoclonal antibody denosumab successfully inhibited the maturation of osteoclasts (OCs) by binding to RANKL in the clinic. We continued our efforts to develop small molecule inhibitors of RANKL. In this work, 41 beta carboline derivatives were synthesized based on previously synthesized compound Y1599 to improve its drug like properties. Compound Y1693 was identified as a potent RANKL inhibitor that improved absorption  distribution metabolism excretion properties and effectively prevented RANKL induced osteoclastogenesis and bone resorption. Furthermore, Y1693 also suppressed the expression of OC marker genes. Moreover, Y1693 demonstrated good tolerability and efficacy in an orally administered mouse model of osteoporosis as well as the ability to rescue alveolar bone loss in vivo caused by periodontal disease. Collectively, the above findings may provide a valuable direction for the development of novel antiresorptive therapies that target RANKL.
C1 [Yang, Kai; Wang, Tianqi; Yan, Xueming; Ning, Ruonan; Xu, Xing; Jiang, Min; Deng, Lianfu] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Inst Traumatol & Orthopaed, Dept Orthopaed,Sch Med,Shanghai Key Lab Prevent &, Shanghai 200025, Peoples R China.
   [Li, Shunyao; He, Qian; Zhang, Xiaofei; Yang, Chunhao] Chinese Acad Sci, Shanghai Inst Mat Med, Dept Med Chem, State Key Lab Drug Res, Shanghai 201203, Peoples R China.
   [Yao, Wei] Univ Calif Davis, Ctr Musculoskeletal Hlth, Dept Internal Med, Med Ctr, Sacramento, CA 95817 USA.
C3 Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai
   Institute of Materia Medica, CAS; University of California System;
   University of California Davis
RP Jiang, M (通讯作者)，Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Inst Traumatol & Orthopaed, Dept Orthopaed,Sch Med,Shanghai Key Lab Prevent &, Shanghai 200025, Peoples R China.; Zhang, XF; Yang, CH (通讯作者)，Chinese Acad Sci, Shanghai Inst Mat Med, Dept Med Chem, State Key Lab Drug Res, Shanghai 201203, Peoples R China.
EM xiaofeizhang@simm.ac.cn; chyang@simm.ac.cn; jiangm263@163.com
RI Wang, Tianqi/KIC 1831 2024; Ning, Ruonan/IZP 7626 2023; Yang,
   Kai/JQW 2039 2023; zhang, xiaofei/GZB 2066 2022; Lei,
   Baiying/GQO 8422 2022; He, Qian/AAK 8732 2020
OI Jiang, Min/0000 0003 1530 6830; Zhang, Xiaofei/0000 0002 4805 9453;
   Yang, Kai/0000 0002 5544 7817; 
FU Shanghai Science and Technology Commission Project [19ZR1448200,
   21S11901500]; Shanghai Talent Development funding Scheme [2020093];
   Shanghai Municipal Health Bureau young scientific research project
   [201940149]; SKLDR/SIMM [SIMM2105KF 05]; National Research Center for
   Translational Medicine at Shanghai
FX This work was supported by grants from Shanghai Science and Technology
   Commission Project (no. 19ZR1448200, 21S11901500) , Shanghai Talent
   Development funding Scheme (no. 2020093) , Shanghai Municipal Health
   Bureau young scientific research project (no. 201940149) , and
   SKLDR/SIMM (SIMM2105KF 05) . Thanks are extended for the SPR technology
   support from the National Research Center for Translational Medicine at
   Shanghai.
CR Allard Chamard H, 2020, BONE REP, V12, DOI 10.1016/j.bonr.2020.100282
   Allgrove J., 2015, ENDOCR DEV, V28, P33
   Body JJ, 2003, CANCER AM CANCER SOC, V97, P887, DOI 10.1002/cncr.11138
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bussard KM, 2008, CANCER METAST REV, V27, P41, DOI 10.1007/s10555 007 9109 4
   Cao X, 2011, NAT MED, V17, P1344, DOI 10.1038/nm.2499
   Chen B, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/731039
   Cheng X, 2004, J BIOL CHEM, V279, P8269, DOI 10.1074/jbc.M309690200
   Cochran DL, 2008, J PERIODONTOL, V79, P1569, DOI 10.1902/jop.2008.080233
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Diab DL, 2014, EXPERT OPIN DRUG SAF, V13, P247, DOI 10.1517/14740338.2014.860133
   Feeley BT, 2006, J BONE MINER RES, V21, P1571, DOI 10.1359/JBMR.060706
   Haftcheshmeh SM, 2021, J CELL MOL MED, V25, P11333, DOI 10.1111/jcmm.17019
   He MM, 2005, SCIENCE, V310, P1022, DOI 10.1126/science.1116304
   Heath DJ, 2007, CANCER RES, V67, P202, DOI 10.1158/0008 5472.CAN 06 1287
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Jiang HW, 2015, FASEB J, V29, P2281, DOI 10.1096/fj.14 265744
   Jiang M, 2020, BMC PHARMACOL TOXICO, V21, DOI 10.1186/s40360 020 00454 x
   Jiang M, 2019, J MED CHEM, V62, P5370, DOI 10.1021/acs.jmedchem.8b02027
   Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Leguizamón ND, 2022, J DENT RES, V101, P216, DOI 10.1177/00220345211027811
   Lin XP, 2011, INFECT IMMUN, V79, P911, DOI 10.1128/IAI.00944 10
   Liu ZC, 2019, FASEB J, V33, P9828, DOI 10.1096/fj.201802242RR
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   Melagraki G, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005372
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Novello S, 2020, J PERIODONTAL RES, V55, P1, DOI 10.1111/jre.12684
   Ouchi T, 2020, REGEN THER, V14, P72, DOI 10.1016/j.reth.2019.12.011
   Park CH, 2007, J PERIODONTOL, V78, P273, DOI 10.1902/jop.2007.060252
   Rinotas V, 2020, J MED CHEM, V63, P12043, DOI 10.1021/acs.jmedchem.0c01316
   Seeman E, 2002, LANCET, V359, P1841, DOI 10.1016/S0140 6736(02)08706 8
   Sharif PS, 2011, RHEUMATOL INT, V31, P289, DOI 10.1007/s00296 010 1586 z
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Ta HM, 2010, P NATL ACAD SCI USA, V107, P20281, DOI 10.1073/pnas.1011686107
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Tanaka S, 2007, AM J NEPHROL, V27, P466, DOI 10.1159/000106484
   Watts NB, 2017, J BONE MINER RES, V32, P1481, DOI 10.1002/jbmr.3119
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   Zhang Z, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891 020 3184 x
NR 43
TC 13
Z9 14
U1 3
U2 27
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD AUG 25
PY 2022
VL 65
IS 16
BP 10992
EP 11009
DI 10.1021/acs.jmedchem.2c00081
EA AUG 2022
PG 18
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 4E7LT
UT WOS:000841501700001
PM 35960655
DA 2025 08 17
ER

PT J
AU Park, KR
   Leem, HH
   Kwon, YJ
   Kwon, I
   Hong, JT
   Yun, HM
AF Park, Kyung Ran
   Leem, Hyun Hee
   Kwon, Yoon Ju
   Kwon, Il Keun
   Hong, Jin Tae
   Yun, Hyung Mun
TI Sec O glucosylhamaudol promotes the osteogenesis of pre osteoblasts via
   BMP2 and Wnt3a signaling
SO JOURNAL OF FUNCTIONAL FOODS
LA English
DT Article
DE Wnt3a; SOGH; Saposhnikovia divaricata; Phytomedicine; Osteoblast; BMP2
ID ENDOTHELIAL GROWTH FACTOR; CHEMOTACTIC MIGRATION; MC3T3 E1 CELLS;
   DIFFERENTIATION; EXPRESSION; SUPPRESSION; INHIBITION; DIVARICATA;
   RECEPTORS; AUTOPHAGY
AB The perennial herb Saposhnikovia divaricata SCHISCHKIN, used as a source of traditional medicines, is known for its anti bone erosion, anti inflammatory, and analgesic effects. We examined the osteogenic properties of Sec Oglucosylhamaudol (SOGH) extracted from S. divaricata roots as a bone protective compound. We found that SOGH promoted osteoblast differentiation and mineralization and induced the expression of Bsp, Ocn, and Opn without any cytotoxic effects. SOGH also increased nuclear RUNX2 levels in pre osteoblasts via the BMP2 and Wnt3a signaling pathways, but it had no evident effects on the autophagic and necroptotic signaling pathways. Furthermore, SOGH promoted bone forming activities by inducing the adhesion and migration of osteoblasts and the expression of RUNX2 target proteins, including VEGF and MMP13. In sum, SOGH has osteogenic properties mediated via the BMP2 and Wnt3a signaling pathways and RUNX2 expression, indicating the bone protective potential of this compound in diseases such as periodontitis and osteoporosis.
C1 [Park, Kyung Ran; Yun, Hyung Mun] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, Seoul 02447, South Korea.
   [Park, Kyung Ran; Hong, Jin Tae] Chungbuk Natl Univ, Coll Pharm, Med Res Ctr, 194 31, Chungbuk, South Korea.
   [Leem, Hyun Hee; Kwon, Yoon Ju] Natl Dev Inst Korean Med, Gyongsan 38540, South Korea.
   [Kwon, Il Keun] Kyung Hee Univ, Sch Dent, Dept Dent Mat, 26 Kyungheedae Ro, Seoul 02447, South Korea.
   [Kwon, Il Keun] Kyung Hee Univ, Med Sci Res Inst, Med Device Res Ctr, Med Ctr, Seoul 02447, South Korea.
   [Yun, Hyung Mun] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, 26 Kyungheedae Ro, Seoul 02447, South Korea.
   [Hong, Jin Tae] Chungbuk Natl Univ, Coll Pharm, Med Res Ctr, Osongsaengmyeong 1 Ro 194 31, Cheongju 28160, Chungbuk, South Korea.
C3 Kyung Hee University; Chungbuk National University; Kyung Hee
   University; Kyung Hee University; Kyung Hee University; Chungbuk
   National University
RP Yun, HM (通讯作者)，Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, 26 Kyungheedae Ro, Seoul 02447, South Korea.; Hong, JT (通讯作者)，Chungbuk Natl Univ, Coll Pharm, Med Res Ctr, Osongsaengmyeong 1 Ro 194 31, Cheongju 28160, Chungbuk, South Korea.
EM jinthong@chungbuk.ac.kr; yunhm@khu.ac.kr
FU National Research Foundation of Korea [NRF]   Korea government (MSIP)
   (MRC) [2017R1A5A2015541, NRF 2022R1C1C1003491]; Bio & Medical Technology
   Development Program of the National Research Foundation (NRF)   Korean
   Government (MSIT) [2017M3A9E4048170]
FX This work was supported by the National Research Foundation of Korea
   [NRF] grant funded by the Korea government (MSIP) (MRC,
   2017R1A5A2015541; NRF 2022R1C1C1003491) . This work was supported by the
   Bio & Medical Technology Development Program of the National Research
   Foundation (NRF) funded by the Korean Government (MSIT) (No.
   2017M3A9E4048170) .
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Athanasopoulos AN, 2007, J BIOL CHEM, V282, P26746, DOI 10.1074/jbc.M705200200
   Broz A, 2017, J BIOMED MATER RES A, V105, P1469, DOI 10.1002/jbm.a.35969
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chin YW, 2011, B KOREAN CHEM SOC, V32, P2132, DOI 10.5012/bkcs.2011.32.6.2132
   Chun JM, 2016, EVID BASED COMPL ALT, V2016, DOI 10.1155/2016/1984238
   Deckers MML, 2000, ENDOCRINOLOGY, V141, P1667, DOI 10.1210/en.141.5.1667
   Duan J, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.724256
   Fakhry Maya, 2013, World J Stem Cells, V5, P136, DOI 10.4252/wjsc.v5.i4.136
   Fiedler J, 2005, BIOCHEM BIOPH RES CO, V334, P561, DOI 10.1016/j.bbrc.2005.06.116
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gui YG, 2011, J SEP SCI, V34, P520, DOI 10.1002/jssc.201000721
   Guo M, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/3027954
   Gupton SL, 2006, CELL, V125, P1361, DOI 10.1016/j.cell.2006.05.029
   Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200
   Huang RL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.101
   Infante A, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0995 x
   Javed A, 2005, P NATL ACAD SCI USA, V102, P1454, DOI 10.1073/pnas.0409121102
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kim MB, 2014, FITOTERAPIA, V98, P59, DOI 10.1016/j.fitote.2014.07.013
   Kim SH, 2017, KOREAN J PAIN, V30, P98, DOI 10.3344/kjp.2017.30.2.98
   Kong XY, 2013, J ETHNOPHARMACOL, V148, P842, DOI 10.1016/j.jep.2013.05.023
   Kreiner J, 2017, CHIN J NAT MEDICINES, V15, P255, DOI 10.1016/S1875 5364(17)30042 0
   Lee HS, 2011, PHYTOTHER RES, V25, P716, DOI 10.1002/ptr.3328
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Lee SH, 2012, J BIOL CHEM, V287, P14760, DOI 10.1074/jbc.M112.340232
   Liu F, 2013, J BONE MINER RES, V28, P2414, DOI 10.1002/jbmr.1971
   Liu G., 2020, Biosci. Rep., V40
   Mayr Wohlfart U, 2002, BONE, V30, P472, DOI 10.1016/S8756 3282(01)00690 1
   Mishra BB, 2011, EUR J MED CHEM, V46, P4769, DOI 10.1016/j.ejmech.2011.07.057
   Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148
   Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549
   Oh SH, 2021, KOREAN J PAIN, V34, P405, DOI 10.3344/kjp.2021.34.4.405
   Okuyama E, 2001, CHEM PHARM BULL, V49, P154, DOI 10.1248/cpb.49.154
   Palecek SP, 1997, NATURE, V388, P210, DOI 10.1038/40687
   Park KR, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111362
   Park KR, 2020, PHYTOMEDICINE, V79, DOI 10.1016/j.phymed.2020.153347
   Park KR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155332
   Pengjam Y, 2016, BIOMOL THER, V24, P123, DOI 10.4062/biomolther.2015.106
   Phan TCA, 2004, HISTOL HISTOPATHOL, V19, P1325, DOI 10.14670/HH 19.1325
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Reid IR, 2015, NAT REV ENDOCRINOL, V11, P418, DOI 10.1038/nrendo.2015.71
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Shi G, 2019, BRAZ J MED BIOL RES, V52, DOI [10.1590/1414 431X20187844, 10.1590/1414 431x20187844]
   Soelaiman IN, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/764701
   Su PH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082343
   Tai J, 2007, ONCOL REP, V18, P227
   Tian Q, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1295382
   Toriseva M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042596
   Uchihashi K, 2013, BONE, V56, P227, DOI 10.1016/j.bone.2013.06.001
   Yang M, 2020, CHIN J INTEGR MED, V26, P873, DOI 10.1007/s11655 020 3091 x
   Yang YQ, 2012, INT J ORAL SCI, V4, P64, DOI 10.1038/ijos.2012.33
   Zaragoza C, 2006, J CELL SCI, V119, P1896, DOI 10.1242/jcs.02895
   Zheng XG, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414 431X20187574, 10.1590/1414 431x20187574]
NR 55
TC 0
Z9 0
U1 1
U2 14
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1756 4646
EI 2214 9414
J9 J FUNCT FOODS
JI J. Funct. Food.
PD JUL
PY 2022
VL 94
AR 105112
DI 10.1016/j.jff.2022.105112
EA MAY 2022
PG 9
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA 1Z0ZG
UT WOS:000808561700007
OA gold
DA 2025 08 17
ER

PT J
AU Yuan, Y
   Yang, L
   Liu, T
   Zhang, H
   Lu, Q
AF Yuan, Ying
   Yang, Li
   Liu, Ting
   Zhang, Hong
   Lu, Qiong
TI Osteoclastogenesis inhibition by mutated IGSF23 results in human
   osteopetrosis
SO CELL PROLIFERATION
LA English
DT Article
DE IGSF23; mutation; osteopetrosis; peripheral blood mononuclear cells
ID BONE RESORPTION; EXPRESSION; RANKL; MICE; DIFFERENTIATION; PROMOTE; GENE
AB Objectives Osteopetrosis is a rare inherited skeletal disease characterized by increased bone mineral density due to the loss of osteoclast function or differentiation potential. Materials and Methods The study involved a Chinese patient with osteopetrosis (the proband) and her immediate family members and 180 controls without osteopetrosis. Bone density of the femoral neck, lumbar spine and total body was measured using dual energy x ray absorptiometry. Osteoclast differentiation by the participants' peripheral blood mononuclear cells (PBMCs) was investigated using tartrate resistant acid phosphatase (TRAP) staining. Osteoblast differentiation was examined with Alizarin Red S staining. Reverse transcription quantitative PCR was used to amplify immunoglobulin superfamily member 23 (IGSF23), c FOS and nuclear factor of activated T cells 1 (NFATC1). Results We found a homozygous mutation (c.295C>T) in the IGSF23 gene in two osteopetrosis samples. The mutation led to the formation of a stop codon, causing loss of the immunoglobulin like domain and the whole transmembrane domain. PBMCs from the proband (IGSF23( / )) exhibited poor ability for differentiating into mature osteoclasts in vitro. Overexpression of IGSF23 rescued the ability of IGSF23( / ) PBMCs to differentiate into osteoclasts. Moreover, knockdown of IGSF23 reversed the bone loss in OVX mice by injecting AAV shIGSF23 into mice femoral bone marrow cavity. Furthermore, we also found that the IGSF23 mutation led to decreased c Fos and NFATC1 expression levels by inhibiting the mitogen activated protein kinase signalling pathways. Conclusions IGSF23 mediated osteoclast differentiation of PBMCs may serve as a potential target in osteoporosis therapy.
C1 [Yuan, Ying; Liu, Ting; Zhang, Hong] Cent S Univ, Xiangya Hosp 2, Inst Endocrinol & Metab, Changsha, Hunan, Peoples R China.
   [Yang, Li] Hunan Prov Peoples Hosp, Dept Endocrinol, Changsha, Hunan, Peoples R China.
   [Lu, Qiong] Cent S Univ, Xiangya Hosp 2, Dept Pharm, 139 Middle Renmin Rd, Changsha 410011, Hunan, Peoples R China.
C3 Central South University; Central South University
RP Lu, Q (通讯作者)，Cent S Univ, Xiangya Hosp 2, Dept Pharm, 139 Middle Renmin Rd, Changsha 410011, Hunan, Peoples R China.
EM Christy_luq@csu.edu.cn
RI Liu, Ting/AHD 4687 2022
OI Lu, Qiong/0000 0002 0126 4978
FU National Natural Science Foundation of China from China [81500686,
   81601230]
FX This work was supported by National Natural Science Foundation of China
   (Grant NO. 81500686 and 81601230) from China
CR Abarrategi A, 2018, J EXP MED, V215, P729, DOI 10.1084/jem.20172139
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Booth FW, 2016, CELL METAB, V23, P961, DOI 10.1016/j.cmet.2016.05.016
   Cao HL, 2010, J CLIN INVEST, V120, P2755, DOI 10.1172/JCI42106
   Chong SZ, 2016, J EXP MED, V213, P2293, DOI 10.1084/jem.20160800
   de Vernejoul MC, 2010, ANN NY ACAD SCI, V1192, P269, DOI 10.1111/j.1749 6632.2009.05244.x
   Douni E, 2012, HUM MOL GENET, V21, P784, DOI 10.1093/hmg/ddr510
   Fan B, 2014, J CLIN DENSITOM, V17, P344, DOI 10.1016/j.jocd.2013.08.019
   Fan Y, 2017, CELL METAB, V25, P661, DOI 10.1016/j.cmet.2017.01.001
   Hayashi M, 2019, CELL METAB, V29, P627, DOI 10.1016/j.cmet.2018.12.021
   Huang J, 2018, THERANOSTICS, V8, P2435, DOI 10.7150/thno.22144
   Jin ZX, 2014, CELL METAB, V20, P483, DOI 10.1016/j.cmet.2014.07.011
   Kim H, 2013, CELL METAB, V17, P249, DOI 10.1016/j.cmet.2013.01.002
   Kiviranta R, 2013, J EXP MED, V210, P969, DOI 10.1084/jem.20121187
   Kondegowda NG, 2015, CELL METAB, V22, P77, DOI 10.1016/j.cmet.2015.05.021
   Leibbrandt A, 2008, ANN NY ACAD SCI, V1143, P123, DOI 10.1196/annals.1443.016
   Li CJ, 2018, J CLIN INVEST, V128, P5251, DOI 10.1172/JCI99044
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Li JY, 2015, CELL METAB, V22, P799, DOI 10.1016/j.cmet.2015.09.012
   Li SS, 2014, J CLIN INVEST, V124, P5057, DOI 10.1172/JCI71882
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lorenzo J, 2017, J CLIN INVEST, V127, P2530, DOI 10.1172/JCI94606
   Lu HW, 2018, MICROCHIM ACTA, V185, DOI 10.1007/s00604 018 3087 9
   Luo XH, 2006, J BONE MINER RES, V21, P1648, DOI 10.1359/JBMR.060707
   Luo YB, 2015, CELL METAB, V22, P886, DOI 10.1016/j.cmet.2015.08.020
   Malara A, 2019, J EXP MED, V216, P587, DOI 10.1084/jem.20181074
   Mansour A, 2012, J EXP MED, V209, P537, DOI 10.1084/jem.20110994
   MBALAVIELE G, 1995, J CLIN INVEST, V95, P2757, DOI 10.1172/JCI117979
   Mundy GR, 2007, CELL METAB, V6, P157, DOI 10.1016/j.cmet.2007.08.008
   Nakamura Ishizu A, 2015, J EXP MED, V212, P2323, DOI 10.1084/jem.2015005711172015c
   Nevius E, 2015, J EXP MED, V212, P1931, DOI 10.1084/jem.20150088
   Paloneva J, 2003, J EXP MED, V198, P669, DOI 10.1084/jem.20030027
   Pangrazio A, 2012, J BONE MINER RES, V27, P342, DOI 10.1002/jbmr.559
   RAISZ LG, 1977, J EXP MED, V145, P857, DOI 10.1084/jem.145.4.857
   Rydén M, 2015, CELL METAB, V22, P408, DOI 10.1016/j.cmet.2015.06.011
   Shen WC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10197 x
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Sponton CH, 2017, CELL METAB, V26, P285, DOI 10.1016/j.cmet.2017.07.018
   Wang XD, 2015, CELL METAB, V22, P811, DOI 10.1016/j.cmet.2015.09.010
   WIKTORJEDRZEJCZAK W, 1982, J EXP MED, V156, P1516, DOI 10.1084/jem.156.5.1516
   Xie H, 2011, J BONE MINER RES, V26, P156, DOI 10.1002/jbmr.169
   Yang M, 2019, J EXP MED, V216, P1944, DOI 10.1084/jem.20181554
   Yang M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16003
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
NR 44
TC 4
Z9 5
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0960 7722
EI 1365 2184
J9 CELL PROLIFERAT
JI Cell Prolif.
PD NOV
PY 2019
VL 52
IS 6
AR e12693
DI 10.1111/cpr.12693
EA SEP 2019
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA JR2PU
UT WOS:000487851900001
PM 31560140
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yuan, Y
   Chen, K
   Chen, X
   Wang, C
   Qiu, H
   Cao, Z
   Song, DZ
   Sun, YQ
   Guo, JM
   Tickner, J
   Xu, JK
   Zou, J
AF Yuan, Yu
   Chen, Kai
   Chen, Xi
   Wang, Chao
   Qiu, Heng
   Cao, Zhen
   Song, Dezhi
   Sun, Youqiang
   Guo, Jianmin
   Tickner, Jennifer
   Xu, Jiake
   Zou, Jun
TI Fumitremorgin C Attenuates Osteoclast Formation and Function via
   Suppressing RANKL Induced Signaling Pathways
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE fumitremorgin C; osteoclast; osteoporosis; NFATc1; MAPK
ID ACTIVATED PROTEIN KINASE; M CSF; INHIBITS OSTEOCLASTOGENESIS;
   MULTIDRUG RESISTANCE; INDUCED OSTEOPOROSIS; RECEPTOR ACTIVATOR; BONE;
   NFATC1; DIFFERENTIATION; EXPRESSION
AB Excessive bone resorption conducted by osteoclasts is considered as the main cause of osteoclast related bone diseases such as osteoporosis. Therefore, the suppression of excessive osteoclast formation and function is one of the strategies to treat osteoclast related bone diseases. Fumitremorgin C (Fum) is a mycotoxin extracted from Aspergillus fumigatus. It has been shown to have extensive pharmacological properties, but its role in the treatment of osteoclast related bone diseases remains unclear. In this study, we aim to find out whether Fum can inhibit the receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast formation and function. The results showed that Fum could significantly attenuate osteoclast formation and function at concentrations from 2.5 to 10 mu M. The protein expression of bone resorption factors such as NFATc1, cathepsin K, V ATPase d2, and c Fos was suppressed with the treatment of Fum at a concentration of 10 mu M. In addition, Fum was also shown to suppress the activity of NF kappa B, intracellular reactive oxygen species level, and MAPK pathway. Taken together, the present study showed that Fum could attenuate the formation and function of osteoclast via suppressing RANKL induced signaling pathways, suggesting that Fum might be a potential novel drug in the treatment of osteoclast related bone diseases.
C1 [Yuan, Yu; Guo, Jianmin; Zou, Jun] Shanghai Univ Sport, Sch Kinesiol, Shanghai, Peoples R China.
   [Yuan, Yu; Chen, Kai; Wang, Chao; Qiu, Heng; Cao, Zhen; Song, Dezhi; Guo, Jianmin; Tickner, Jennifer; Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia.
   [Yuan, Yu] South China Normal Univ, Sch Phys Educ & Sports Sci, Guangzhou, Peoples R China.
   [Chen, Kai] Wenzhou Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Wenzhou, Peoples R China.
   [Chen, Xi] Wenzhou Med Univ, Sch Sports Sci, Wenzhou, Peoples R China.
   [Sun, Youqiang] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Orthoped, Guangzhou, Peoples R China.
C3 Shanghai University of Sport; University of Western Australia; South
   China Normal University; Wenzhou Medical University; Wenzhou Medical
   University; Guangzhou University of Chinese Medicine
RP Zou, J (通讯作者)，Shanghai Univ Sport, Sch Kinesiol, Shanghai, Peoples R China.; Xu, JK (通讯作者)，Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia.
EM jiake.xu@uwa.edu.au; junzou@sus.edu.cn
RI ; Tickner, Jennifer/H 5965 2014; Yuan, Yu/HKN 3214 2023; Song,
   Dezhi/AAL 9799 2020; Zou, Jun/KYQ 8156 2024; GUO, Jianmin/NBX 6576 2025;
   Chen, KaiJie/A 1743 2016
OI Qiu, Heng/0000 0002 0864 317X; Tickner, Jennifer/0000 0002 5020 0671;
   Yuan, Yu/0000 0003 1032 6330; Xu, Jiake/0000 0003 2021 8309; Chen,
   Kai/0000 0001 6850 1723; 
FU Australian Health and Medical Research Council (NHMRC) [1107828,
   1127156, 1163933]; China Postdoctoral Science Foundation [2018M640792,
   2019T120739]; Shanghai Key Lab of Human Sport Competence Development and
   Maintenance (Shanghai University of Sport) [11DZ2261100]; National
   Natural Science Foundation of China [81572242]; National Health and
   Medical Research Council of Australia [1163933, 1127156] Funding Source:
   NHMRC
FX The present study was supported by grants from the Australian Health and
   Medical Research Council (NHMRC, Nos. 1107828, 1127156, and 1163933).
   The study was also supported by the China Postdoctoral Science
   Foundation funded project (Nos. 2018M640792 and 2019T120739), the
   Shanghai Key Lab of Human Sport Competence Development and Maintenance
   (Shanghai University of Sport) (No. 11DZ2261100), and the National
   Natural Science Foundation of China (No. 81572242).
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Boskey AL, 2009, CALCIFIED TISSUE INT, V84, P229, DOI 10.1007/s00223 008 9214 6
   Charles JF, 2012, BONE, V51, P902, DOI 10.1016/j.bone.2012.08.113
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Chen K, 2019, J CELL PHYSIOL, V234, P6477, DOI 10.1002/jcp.27385
   Cheng JW, 2018, J CELL PHYSIOL, V233, P2502, DOI 10.1002/jcp.26126
   De Vries TJ, 2015, J CELL PHYSIOL, V230, P210, DOI 10.1002/jcp.24702
   Dougall WC, 2012, CLIN CANCER RES, V18, P326, DOI 10.1158/1078 0432.CCR 10 2507
   Ghosh M, 2018, MOLECULES, V23, DOI 10.3390/molecules23030615
   González Lobato L, 2010, EUR J PHARMACOL, V644, P41, DOI 10.1016/j.ejphar.2010.07.016
   He J, 2012, CANCER RES, V72, P6393, DOI 10.1158/0008 5472.CAN 12 2664
   He L, 2013, CELL SIGNAL, V25, P552, DOI 10.1016/j.cellsig.2012.11.015
   Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041
   Karst M, 2004, J CELL PHYSIOL, V200, P99, DOI 10.1002/jcp.20036
   Ke QD, 2006, AM J PHYSIOL LUNG C, V291, pL257, DOI 10.1152/ajplung.00007.2006
   Kim JH, 2010, J BIOL CHEM, V285, P5224, DOI 10.1074/jbc.M109.042812
   Kim WS, 2013, EXP CELL RES, V319, P436, DOI 10.1016/j.yexcr.2012.12.004
   Kiviranta R, 2005, BONE, V36, P159, DOI 10.1016/j.bone.2004.09.020
   Kreja L, 2007, J MOL HISTOL, V38, P341, DOI 10.1007/s10735 007 9108 3
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Li XT, 2003, ENDOCRINOLOGY, V144, P4999, DOI 10.1210/en.2003 0166
   Liu H, 2006, INT J ONCOL, V29, P1237
   Liu Q, 2013, BIOCHEM PHARMACOL, V86, P1775, DOI 10.1016/j.bcp.2013.09.017
   Ma HY, 2006, PLANTA MED, V72, P387, DOI 10.1055/s 2005 916235
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955 0674(99)80030 1
   Narahara S, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 40240 2
   Oh JH, 2015, CELL SIGNAL, V27, P2325, DOI 10.1016/j.cellsig.2015.09.002
   Oh JH, 2015, MOL CELLS, V38, P279, DOI 10.14348/molcells.2015.2340
   Pang MH, 2019, J CELL BIOCHEM, V120, P12382, DOI 10.1002/jcb.28504
   Rabindran SK, 1998, CANCER RES, V58, P5850
   Rabindran SK, 2000, CANCER RES, V60, P47
   Song FM, 2016, J CELL PHYSIOL, V231, P1983, DOI 10.1002/jcp.25304
   Sun YQ, 2019, J CELL PHYSIOL, V234, P11792, DOI 10.1002/jcp.27868
   Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   Wang C, 2003, J BONE MINER RES, V18, P2159, DOI 10.1359/jbmr.2003.18.12.2159
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Yip KHM, 2005, J BONE MINER RES, V20, P1462, DOI 10.1359/JBMR.050324
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
NR 42
TC 12
Z9 13
U1 0
U2 16
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAR 10
PY 2020
VL 11
AR 238
DI 10.3389/fphar.2020.00238
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA LC0TX
UT WOS:000525044200001
PM 32210820
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Boufker, HI
   Lagneaux, L
   Najar, M
   Piccart, M
   Ghanem, G
   Body, JJ
   Journé, F
AF Boufker, Hichame Id
   Lagneaux, Laurence
   Najar, Mehdi
   Piccart, Martine
   Ghanem, Ghanem
   Body, Jean Jacques
   Journe, Fabrice
TI The Src inhibitor dasatinib accelerates the differentiation of human
   bone marrow derived mesenchymal stromal cells into osteoblasts
   (Publication with Expression of Concern. See vol. 25, 2025)
SO BMC CANCER
LA English
DT Article; Publication with Expression of Concern
ID STEM CELLS; OSTEOGENIC DIFFERENTIATION; KINASE INHIBITOR;
   PROSTATE CANCER; SUPPRESSES PROLIFERATION; MORPHOGENETIC PROTEIN 2;
   PARATHYROID HORMONE; IMATINIB MESYLATE; C SRC; BMS 354825
AB Background: The proto oncogene Src is an important non receptor protein tyrosine kinase involved in signaling pathways that control cell adhesion, growth, migration and differentiation. It negatively regulates osteoblast activity, and, as such, its inhibition is a potential means to prevent bone loss. Dasatinib is a new dual Src/Bcr Abl tyrosine kinase inhibitor initially developed for the treatment of chronic myeloid leukemia. It has also shown promising results in preclinical studies in various solid tumors. However, its effects on the differentiation of human osteoblasts have never been examined.
   Methods: We evaluated the effects of dasatinib on bone marrow derived mesenchymal stromal cells (MSC) differentiation into osteoblasts, in the presence or absence of a mixture of dexamethasone, ascorbic acid and beta glycerophosphate (DAG) for up to 21 days. The differentiation kinetics was assessed by evaluating mineralization of the extracellular matrix, alkaline phosphatase (ALP) activity, and expression of osteoblastic markers (receptor activator of nuclear factor kappa B ligand [RANKL], bone sialoprotein [BSP], osteopontin [OPN]).
   Results: Dasatinib significantly increased the activity of ALP and the level of calcium deposition in MSC cultured with DAG after, respectively, 7 and 14 days; it upregulated the expression of BSP and OPN genes independently of DAG; and it markedly downregulated the expression of RANKL gene and protein (decrease in RANKL/OPG ratio), the key factor that stimulates osteoclast differentiation and activity.
   Conclusions: Our results suggest a dual role for dasatinib in both (i) stimulating osteoblast differentiation leading to a direct increase in bone formation, and (ii) downregulating RANKL synthesis by osteoblasts leading to an indirect inhibition of osteoclastogenesis. Thus, dasatinib is a potentially interesting candidate drug for the treatment of osteolysis through its dual effect on bone metabolism.
C1 [Boufker, Hichame Id; Ghanem, Ghanem; Journe, Fabrice] Univ Libre Bruxelles, Inst Jules Bordet, Lab Oncol & Chirurg Expt, Brussels, Belgium.
   [Boufker, Hichame Id; Lagneaux, Laurence; Najar, Mehdi] Univ Libre Bruxelles, Inst Jules Bordet, Lab Hematol Expt, Brussels, Belgium.
   [Piccart, Martine] Univ Libre Bruxelles, Inst Jules Bordet, Clin Oncol Med, Brussels, Belgium.
   [Body, Jean Jacques] Univ Libre Bruxelles, CHU Brugmann, Med Serv, Brussels, Belgium.
C3 Institut Jules Bordet; Universite Libre de Bruxelles; Universite Libre
   de Bruxelles; Institut Jules Bordet; Universite Libre de Bruxelles;
   Institut Jules Bordet; Universite Libre de Bruxelles
RP Journé, F (通讯作者)，Univ Libre Bruxelles, Inst Jules Bordet, Lab Oncol & Chirurg Expt, Brussels, Belgium.
EM fabrice.journe@bordet.be
RI Body, Jean Jacques/G 9785 2015
OI JOURNE, Fabrice/0000 0001 5051 231X
FU Bristol Myers Squibb (Princeton, NJ, USA); Belgian Fund for Medical
   Scientific Research [3.4541.05]; Fondation Medic; Fondation
   Lambeau Marteaux; Les Amis de l'Institut Bordet; National Fund for
   Scientific Research [7.4528.05]
FX This study received financial support from Bristol Myers Squibb
   (Princeton, NJ, USA), from the Belgian Fund for Medical Scientific
   Research (grants n degrees 3.4541.05), from the "Fondation Medic", from
   the "Fondation Lambeau Marteaux" and from "Les Amis de l'Institut
   Bordet". Hichame Id Boufker is the recipient of a fellowship (grant n
   degrees 7.4528.05) from the National Fund for Scientific Research.
   Laurence Lagneaux is Senior Research Associate of the National Fund for
   Scientific Research.
CR Atkins GJ, 2003, J BONE MINER RES, V18, P1088, DOI 10.1359/jbmr.2003.18.6.1088
   Aubin JE, 1998, BIOCHEM CELL BIOL, V76, P899, DOI 10.1139/bcb 76 6 899
   Body JJ, 2002, BONE, V30, p75S
   Boyce BF, 2003, KIDNEY INT, V63, pS2, DOI 10.1046/j.1523 1755.63.s85.2.x
   Boyce BF, 2006, CLIN CANCER RES, V12, p6291S, DOI 10.1158/1078 0432.CCR 06 0991
   Brownlow N, 2009, LEUKEMIA, V23, P590, DOI 10.1038/leu.2008.237
   Chan GK, 2003, ENDOCRINOLOGY, V144, P5511, DOI 10.1210/en.2003 0273
   Chen ZM, 2006, MOL PHARMACOL, V69, P1527, DOI 10.1124/mol.105.020172
   Cho JY, 2006, GENE, V372, P71, DOI 10.1016/j.gene.2005.12.010
   Clines Gregory A., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000616
   Coelho MJ, 2000, BIOMATERIALS, V21, P1087, DOI 10.1016/S0142 9612(99)00284 7
   de Vries TJ, 2009, MOL CANCER RES, V7, P476, DOI 10.1158/1541 7786.MCR 08 0219
   ECAROTCHARRIER B, 1983, J CELL BIOL, V96, P639, DOI 10.1083/jcb.96.3.639
   Fierro F, 2007, CELL PROLIFERAT, V40, P355, DOI 10.1111/j.1365 2184.2007.00438.x
   Fitter S, 2008, BLOOD, V111, P2538, DOI 10.1182/blood 2007 07 104281
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Johnson FM, 2005, CLIN CANCER RES, V11, P6924, DOI 10.1158/1078 0432.CCR 05 0757
   Jönsson S, 2008, HAEMATOL HEMATOL J, V93, P1101, DOI 10.3324/haematol.12373
   Kha HT, 2004, J BONE MINER RES, V19, P830, DOI 10.1359/JBMR.040115
   Koreckij T, 2009, BRIT J CANCER, V101, P263, DOI 10.1038/sj.bjc.6605178
   Kumar A, 2010, TISSUE ENG PT A, V16, P983, DOI [10.1089/ten.tea.2009.0230, 10.1089/ten.TEA.2009.0230]
   Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097 4644(19990401)73:1<114::AID JCB13>3.3.CO;2 D
   Lee YC, 2010, ONCOGENE, V29, P3196, DOI 10.1038/onc.2010.73
   Leskelä HV, 2006, BONE, V39, P1026, DOI 10.1016/j.bone.2006.05.003
   Li BJ, 2000, NAT GENET, V24, P304, DOI 10.1038/73542
   Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a
   Majors AK, 1997, J ORTHOPAED RES, V15, P546, DOI 10.1002/jor.1100150410
   Marzia M, 2000, J CELL BIOL, V151, P311, DOI 10.1083/jcb.151.2.311
   Metcalf CA, 2002, CURR PHARM DESIGN, V8, P2049, DOI 10.2174/1381612023393323
   Moon JH, 2008, HUM REPROD, V23, P1760, DOI 10.1093/humrep/den202
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Nam S, 2005, CANCER RES, V65, P9185, DOI 10.1158/0008 5472.CAN 05 1731
   O'Hare T, 2005, CANCER RES, V65, P4500, DOI 10.1158/0008 5472.CAN 05 0259
   O'Sullivan S, 2007, J BONE MINER RES, V22, P1679, DOI 10.1359/JBMR.070719
   Reyes M, 2001, BLOOD, V98, P2615, DOI 10.1182/blood.V98.9.2615
   Roodman GD, 2005, J CLIN INVEST, V115, P200, DOI 10.1172/JCI200524281
   Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171
   Rucci N, 2008, ANTI CANCER AGENT ME, V8, P342, DOI 10.2174/187152008783961905
   Saad F, 2009, BJU INT, V103, P434, DOI 10.1111/j.1464 410X.2008.08249.x
   Salasznyk RM, 2004, J BIOMED BIOTECHNOL, P24, DOI 10.1155/S1110724304306017
   Sammons J, 2004, STEM CELLS DEV, V13, P273, DOI 10.1089/154732804323099208
   Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706
   Schecroun N, 2003, BONE, V32, P252, DOI 10.1016/S8756 3282(02)00970 5
   Shui CX, 2003, J BONE MINER RES, V18, P213, DOI 10.1359/jbmr.2003.18.2.213
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   THOMAS SM, 1997, ANNU REV CELL DEV BI, V513, P609
   Tibullo D, 2009, EXP HEMATOL, V37, P461, DOI 10.1016/j.exphem.2008.12.008
   Tondreau T, 2004, DIFFERENTIATION, V72, P319, DOI 10.1111/j.1432 0436.2004.07207003.x
   Trevino JG, 2006, AM J PATHOL, V168, P962, DOI 10.2353/ajpath.2006.050570
   Väänänen HK, 2005, ANN MED, V37, P469, DOI 10.1080/07853890500371957
   Vandyke K, 2009, LEUKEMIA, V23, P994, DOI 10.1038/leu.2008.356
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   Zaidi SK, 2004, EMBO J, V23, P790, DOI 10.1038/sj.emboj.7600073
   Zambuzzi WF, 2008, CELL PHYSIOL BIOCHEM, V22, P497, DOI 10.1159/000185506
   Zipori D, 2004, BLOOD CELL MOL DIS, V33, P211, DOI 10.1016/j.bcmd.2004.08.019
NR 55
TC 69
Z9 75
U1 0
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2407
J9 BMC CANCER
JI BMC Cancer
PD JUN 17
PY 2010
VL 10
AR 298
DI 10.1186/1471 2407 10 298
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 624DM
UT WOS:000279796400001
PM 20565769
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Cao, Y
   Wang, C
   Zhang, XL
   Xing, GC
   Lu, KF
   Gu, YQ
   He, FC
   Zhang, LQ
AF Cao, Yu
   Wang, Cheng
   Zhang, Xueli
   Xing, Guichun
   Lu, Kefeng
   Gu, Yongqing
   He, Fuchu
   Zhang, Lingqiang
TI Selective Small Molecule Compounds Increase BMP 2 Responsiveness by
   Inhibiting Smurf1 mediated Smad1/5 Degradation
SO SCIENTIFIC REPORTS
LA English
DT Article
ID UBIQUITIN LIGASE SMURF1; BONE MORPHOGENETIC PROTEIN; TGF BETA;
   OSTEOBLAST DIFFERENTIATION; PROTEASOMAL DEGRADATION; DRUG DISCOVERY;
   DOMAIN; WW; POLARITY; DOCKING
AB The ubiquitin ligase Smad ubiquitination regulatory factor 1 (Smurf1) negatively regulates bone morphogenetic protein (BMP) pathway by ubiquitinating certain signal components for degradation. Thus, it can be an eligible pharmacological target for increasing BMP signal responsiveness. We established a strategy to discover small molecule compounds that block the WW1 domain of Smurf1 from interacting with Smad1/5 by structure based virtual screening, molecular experimental examination and cytological efficacy evaluation. Our selected hits could reserve the protein level of Smad1/5 from degradation by interrupting Smurf1 Smad1/5 interaction and inhibiting Smurf1 mediated ubiquitination of Smad1/5. Further, these compounds increased BMP 2 signal responsiveness and the expression of certain downstream genes, enhanced the osteoblastic activity of myoblasts and osteoblasts. Our work indicates targeting Smurf1 for inhibition could be an accessible strategy to discover BMP sensitizers that might be applied in future clinical treatments of bone disorders such as osteopenia.
C1 [Cao, Yu; Wang, Cheng; Zhang, Xueli; Xing, Guichun; Lu, Kefeng; He, Fuchu; Zhang, Lingqiang] Beijing Proteome Res Ctr, Beijing Inst Radiat Med, Collaborat Innovat Ctr Canc Med, State Key Lab Prote, Beijing, Peoples R China.
   [Wang, Cheng; Gu, Yongqing] Shihezi Univ, Sch Med, Shihezi, Xinjiang Provin, Peoples R China.
   [Zhang, Lingqiang] Dalian Med Univ, Inst Canc Stem Cell, Dalian, Liaoning Provin, Peoples R China.
C3 Academy of Military Medical Sciences   China; Shihezi University; Dalian
   Medical University
RP Zhang, LQ (通讯作者)，Beijing Proteome Res Ctr, Beijing Inst Radiat Med, Collaborat Innovat Ctr Canc Med, State Key Lab Prote, Beijing, Peoples R China.
EM zhanglq@nic.bmi.ac.cn
RI ; He, FC/KGL 6713 2024; Lu, Kefeng/MIP 7558 2025; Zhang,
   Lingqiang/JBI 8606 2023
OI Gu, Yongqing/0000 0002 2211 8195; Lu, Kefeng/0000 0001 8200 9380; 
FU Chinese National Basic Research Programs [2012CB910304]; National Key
   Technologies R&D Program for New Drugs [2014ZX09J14106 04C]; ICGEB
   [CRP/CHN13 02]; Chinese National Natural Science Foundation Projects
   [81261160503, 31125010, 30960093, 31160183, 81221004]; Beijing Natural
   Science Foundation Project [7131012]
FX We thank Professor Zikuan Guo for his kind guidance on cell culturing
   and performing osteoblastic differentiation. We thank Fengjun Xiao for
   her technical support on flow cytometry and Wenjie Dai for her
   assistances on software operation. We thank Shengbo Fu for his kind
   support on writing the article. This work was supported by Chinese
   National Basic Research Programs (2012CB910304), The National Key
   Technologies R&D Program for New Drugs (2014ZX09J14106 04C), the ICGEB
   grant (CRP/CHN13 02), Chinese National Natural Science Foundation
   Projects (81261160503, 31125010, 30960093, 31160183 and 81221004) and
   Beijing Natural Science Foundation Project (7131012).
CR Ackerman SJ, 2002, SPINE, V27, pS94, DOI 10.1097/00007632 200208151 00017
   Aragón E, 2011, GENE DEV, V25, P1275, DOI 10.1101/gad.2060811
   Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   Boden SD, 2002, SPINE, V27, P2662, DOI 10.1097/00007632 200212010 00005
   Burnett JC, 2012, CHEM BIOL, V19, P60, DOI 10.1016/j.chembiol.2011.12.008
   Cao Y, 2013, CURR PHARM DESIGN, V19, P3226, DOI 10.2174/1381612811319180007
   Cao Y, 2013, CELL MOL LIFE SCI, V70, P2305, DOI 10.1007/s00018 012 1170 7
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Cheng XL, 2012, CHEM BIOL, V19, P1423, DOI 10.1016/j.chembiol.2012.09.008
   Cui Y, 2011, EMBO J, V30, P2675, DOI 10.1038/emboj.2011.155
   Eriksen EF, 2013, ACTA OBSTET GYN SCAN, V92, P620, DOI 10.1111/j.1600 0412.2012.01473.x
   Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018
   Gruendler C, 2001, J BIOL CHEM, V276, P46533, DOI 10.1074/jbc.M105500200
   Guo X, 2011, J BIOL CHEM, V286, P18037, DOI 10.1074/jbc.M111.225615
   Hadizadeh F, 2013, IRAN J BASIC MED SCI, V16, P910
   Hansch C, 2001, CHEM REV, V101, P619, DOI 10.1021/cr0000067
   Horiki M, 2004, J CELL BIOL, V165, P433, DOI 10.1083/jcb.200311015
   Jones DC, 2006, SCIENCE, V312, P1223, DOI 10.1126/science.1126313
   Kato S, 2011, MOL CELL BIOCHEM, V349, P97, DOI 10.1007/s11010 010 0664 6
   Li XN, 2008, J CELL BIOL, V181, P959, DOI 10.1083/jcb.200711044
   Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169 409X(96)00423 1
   Liu YL, 2011, STEM CELLS, V29, P1804, DOI 10.1002/stem.728
   Lu KF, 2008, NAT CELL BIOL, V10, P994, DOI 10.1038/ncb1760
   Lu KF, 2011, J BIOL CHEM, V286, P16861, DOI 10.1074/jbc.M110.211979
   Massagué J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705
   Morén A, 2005, J BIOL CHEM, V280, P22115, DOI 10.1074/jbc.M414027200
   Nie J, 2010, J BIOL CHEM, V285, P22816, DOI 10.1074/jbc.M110.126920
   Nie J, 2010, FEBS LETT, V584, P3005, DOI 10.1016/j.febslet.2010.05.033
   Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718
   Plewczynski D, 2011, J COMPUT CHEM, V32, P742, DOI 10.1002/jcc.21643
   Polly DW, 2003, ORTHOPEDICS, V26, P1027
   Ravitz O, 2011, J COMPUT AID MOL DES, V25, P1033, DOI 10.1007/s10822 011 9482 5
   Rosen CJ, 2012, NAT MED, V18, P202, DOI 10.1038/nm.2630
   Sapkota G, 2007, MOL CELL, V25, P441, DOI 10.1016/j.molcel.2007.01.006
   Taboureau O, 2012, CHEM BIOL, V19, P29, DOI 10.1016/j.chembiol.2011.12.007
   Tang LY, 2011, EMBO J, V30, P4777, DOI 10.1038/emboj.2011.393
   Wan LX, 2011, MOL CELL, V44, P721, DOI 10.1016/j.molcel.2011.09.024
   Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772
   Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035
   Ying SX, 2003, J BIOL CHEM, V278, P39029, DOI 10.1074/jbc.M301193200
   Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200
   Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200
   Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293
NR 45
TC 66
Z9 77
U1 2
U2 17
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD MAY 14
PY 2014
VL 4
AR 4965
DI 10.1038/srep04965
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AH0LY
UT WOS:000335812600002
PM 24828823
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Notomi, T
   Kuno, M
   Hiyama, A
   Ezura, Y
   Honma, M
   Ishizuka, T
   Ohura, K
   Yawo, H
   Noda, M
AF Notomi, Takuya
   Kuno, Miyuki
   Hiyama, Akiko
   Ezura, Yoichi
   Honma, Masashi
   Ishizuka, Toru
   Ohura, Kiyoshi
   Yawo, Hiromu
   Noda, Masaki
TI Membrane depolarization regulates intracellular RANKL transport in
   non excitable osteoblasts
SO BONE
LA English
DT Article
DE PTH; VD3; Osteoclast; Voltage gated Ca2+ channel; 1,25D(3) MARRS
   receptor
ID OSTEOCLAST DIFFERENTIATION; PARATHYROID HORMONE; CALCIUM CHANNELS; RAT
   OSTEOBLASTS; EXPRESSION; OSTEOPROTEGERIN; EXOCYTOSIS; RESPONSES; PTH
AB Parathyroid hormone (PTH) and 1 alpha,25 dihydroxyvitamin D 3 (VD3) are important factors in Ca2+ homeostasis, and promote osteoclastogenesis by modulating receptor activator of nuclear factor kappa B ligand (RANKL) mRNA expression. However, their contribution to RANKL. intracellular transport (RANKLiT), including the trigger for RANKL lysosomal vesicle (RANKL lv) fusion to the cell membrane, is unclear. In neurons, depolarization of membrane potential increases the intracellular Ca2+ level ([Ca2+](i)) and promotes neurotransmitter release via fusion of the synaptic vesicles to the cell membrane. To determine whether membrane depolarization also regulates cellular processes such as RANKLiT in MC3T3 E1 osteoblasts (OBs), we generated a light sensitive OB cell line and developed a system for altering their membrane potential via delivery of a blue light stimulus. In the membrane fraction of RANKL overexpressing OBs, PTH and VD3 increased the membrane bound RANKL (mbRANKL) level at 10 min after application without affecting the mRNA expression level, and depolarized the cell membrane while transiently increasing [Ca2+](i). In our novel OB line stably expressing the channelrhodopsin wide receiver, blue light induced depolarization increased the mbRANKL level, which was reversed by treatment of blockers for L type voltage gated Ca2+ channels and Ca2+ release from the endoplasmic reticulum. In co cultures of osteoclast precursor like RAW264.7 cells and light sensitive OBs overexpressing RANKL, light stimulation induced an increase in tartrate resistant acid phosphatase activity and promoted osteoclast differentiation. These results indicate that depolarization of the cell membrane is a trigger for RANKL lv fusion to the membrane and that membrane potential contributes to the function of OBs. In addition, the non genomic action of VD3 induced RANKL 1v fusion included the membrane bound VD3 receptor (1,25D(3) MARRS receptor). Elucidating the mechanism of RANKLiT regulation by PTH and VD3 will be useful for the development of drugs to prevent bone loss in osteoporosis and other bone diseases. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Notomi, Takuya; Hiyama, Akiko; Ohura, Kiyoshi] Osaka Dent Univ, Dept Pharmacol, Hirakata, Osaka 5731121, Japan.
   [Notomi, Takuya; Ezura, Yoichi; Noda, Masaki] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Pharmacol, Bunkyo Ku, Tokyo 1138510, Japan.
   [Notomi, Takuya; Noda, Masaki] Tokyo Med & Dent Univ, Global Ctr Excellence, Program Mol Sci Tooth & Bone Dis, Tokyo, Japan.
   [Notomi, Takuya; Kuno, Miyuki] Osaka City Univ, Grad Sch Med, Dept Physiol, Abeno, Osaka 5458585, Japan.
   [Honma, Masashi] Univ Tokyo, Tokyo Univ Hosp, Fac Med, Dept Pharm, Tokyo 1138655, Japan.
   [Ishizuka, Toru; Yawo, Hiromu] Tohoku Univ, Grad Sch Life Sci, Dept Dev Biol & Neurosci, Sendai, Miyagi 9808577, Japan.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Osaka Metropolitan University; University of Tokyo; Tohoku University
RP Notomi, T (通讯作者)，Osaka Dent Univ, Dept Pharmacol, 8 1 Kuzuhahanazono Cho, Hirakata, Osaka 5731121, Japan.
EM notomi@cc.osaka dent.ac.jp; noda.mph@mri.tmd.ac.jp
RI Ezura, Yoichi/L 9485 2016; Ishizuka, Toru/L 8191 2017; Yawo,
   Hiromu/I 4871 2015
OI Yawo, Hiromu/0000 0002 4299 3288
FU Ministry of Education, Science and Culture of Japan [25670638, 26282182,
   15K15558]; Grants in Aid for Scientific Research [15K08184, 26282182,
   15K15558, 25670638, 15H01413, 15K15025, 25250001] Funding Source: KAKEN
FX This work was supported by a Grant in Aid for Scientific Research from
   the Ministry of Education, Science and Culture of Japan [25670638]
   [26282182] [15K15558].
CR Atlas D, 2013, ANNU REV BIOCHEM, V82, P607, DOI 10.1146/annurev biochem 080411 121438
   Bergh JJ, 2006, AM J PHYSIOL CELL PH, V290, pC822, DOI 10.1152/ajpcell.00403.2005
   Bhangu PS, 2001, BONE, V29, P16, DOI 10.1016/S8756 3282(01)00482 3
   Bootman MD, 2002, CURR BIOL, V12, pR563, DOI 10.1016/S0960 9822(02)01055 2
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen JX, 2013, CELL SIGNAL, V25, P2362, DOI 10.1016/j.cellsig.2013.07.020
   Chen WK, 2010, J NEUROSCI, V30, P10360, DOI 10.1523/JNEUROSCI.1041 10.2010
   CHESNOYMARCHAIS D, 1988, J PHYSIOL LONDON, V398, P291, DOI 10.1113/jphysiol.1988.sp017043
   Dai SP, 2009, PHYSIOL REV, V89, P411, DOI 10.1152/physrev.00029.2007
   EDELMAN A, 1986, AM J PHYSIOL, V251, pC483, DOI 10.1152/ajpcell.1986.251.4.C483
   FRITSCH J, 1988, J BONE MINER RES, V3, P547
   Gu Y, 1999, PFLUG ARCH EUR J PHY, V438, P553, DOI 10.1007/s004240051075
   Horwood NJ, 1998, ENDOCRINOLOGY, V139, P4743, DOI 10.1210/en.139.11.4743
   Jahn R, 2006, NAT REV MOL CELL BIO, V7, P631, DOI 10.1038/nrm2002
   Kariya Y, 2011, J BONE MINER RES, V26, P689, DOI 10.1002/jbmr.268
   Kariya Y, 2009, J BONE MINER RES, V24, P1741, DOI [10.1359/JBMR.090409, 10.1359/jbmr.090409]
   Kim MH, 2013, J PHYSIOL LONDON, V591, P3167, DOI 10.1113/jphysiol.2012.249482
   Kohara K, 2014, NAT NEUROSCI, V17, P269, DOI 10.1038/nn.3614
   Kraus RL, 1998, J BIOL CHEM, V273, P27205, DOI 10.1074/jbc.273.42.27205
   Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552
   Li W, 1997, AM J PHYSIOL ENDOC M, V273, pE599, DOI 10.1152/ajpendo.1997.273.3.E599
   Matthews EA, 2007, EUR J NEUROSCI, V25, P3561, DOI 10.1111/j.1460 9568.2007.05605.x
   Nagel G, 2003, P NATL ACAD SCI USA, V100, P13940, DOI 10.1073/pnas.1936192100
   Nemere I, 2010, J BIOL CHEM, V285, P31859, DOI 10.1074/jbc.M110.116954
   Notomi T, 2004, J COMP NEUROL, V471, P241, DOI 10.1002/cne.11039
   Notomi T, 2012, J BIOL CHEM, V287, P35057, DOI 10.1074/jbc.M111.328930
   Pangalos M, 2011, J BIOENERG BIOMEMBR, V43, P311, DOI 10.1007/s10863 011 9354 7
   Sakai H, 2010, AM J PHYSIOL CELL PH, V299, pC570, DOI 10.1152/ajpcell.00486.2009
   Schultheis C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018766
   Seeman E, 2002, LANCET, V359, P1841, DOI 10.1016/S0140 6736(02)08706 8
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Sorensen JB, 2005, TRENDS NEUROSCI, V28, P453, DOI 10.1016/j.tins.2005.06.007
   Sun XH, 2012, BONE, V51, P860, DOI 10.1016/j.bone.2012.08.116
   Suzuki T, 2013, BONE, V54, P172, DOI 10.1016/j.bone.2013.01.001
   Tringham EW, 2008, J PHARMACOL EXP THER, V324, P806, DOI 10.1124/jpet.107.130641
   Uchida Yushi, 2010, Bull Tokyo Dent Coll, V51, P221, DOI 10.2209/tdcpublication.51.221
   van Driel M, 2004, CURR PHARM DESIGN, V10, P2535
   Veeraraghavan R, 2014, AM J PHYSIOL HEART C, V306, pH619, DOI 10.1152/ajpheart.00760.2013
   Wang HX, 2009, J BIOL CHEM, V284, P5685, DOI 10.1074/jbc.M807632200
   Wen L, 2012, BIOCHEM BIOPH RES CO, V424, P439, DOI 10.1016/j.bbrc.2012.06.128
   Wysolmerski J., 2008, PRINC BONE BIOL, P555
NR 41
TC 5
Z9 5
U1 1
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD DEC
PY 2015
VL 81
BP 306
EP 314
DI 10.1016/j.bone.2015.07.031
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CX0FR
UT WOS:000365372800038
PM 26211991
DA 2025 08 17
ER

PT J
AU Tripathi, G
   Raja, N
   Yun, HS
AF Tripathi, G.
   Raja, N.
   Yun, H. S.
TI Effect of direct loading of phytoestrogens into the calcium phosphate
   scaffold on osteoporotic bone tissue regeneration
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
ID MESENCHYMAL STEM CELLS; DRUG DELIVERY; NITRIC OXIDE; DIFFERENTIATION;
   MAGNESIUM; MECHANISMS; FABRICATION; ISOFLAVONE; STRONTIUM; RAT
AB 3D porous calcium deficient hydroxyapatite (CDHA) scaffolds with phytoestrogens were fabricated for osteoporotic bone tissue regeneration through a combination of 3D printing techniques and cement chemistry as a room temperature process. Quercetin, one of the major phytoestrogens isolated from onions and apples, was directly incorporated into CDHA for local administration in place of bisphosphonates (BPs) (which are recognized as standard treatment in osteoporosis), to avoid drug side effects. The CDHA scaffolds with quercetin (QC CDHA) showed favorable mechanical properties (compressive strength < 21 MPa) as well as pore morphology. Quercetin was steadily released with the biodegradation of CDHA scaffolds in vitro without any initial burst. The QC CDHA scaffolds greatly influenced both osteoblast and osteoclast cell activities. The QC CDHA scaffolds significantly increased pre osteoblast cell (MC3T3 E1) proliferation, differentiation, and mineralization, whereas osteoclast cell (RANK treated RAW 264.7) proliferation and differentiation were dramatically suppressed. The influence of quercetin on bone tissue regeneration was superior to alendronate, which is one of the most commonly administered BPs. All results indicated that quercetin in CDHA scaffolds plays an important role in both enhancing bone formation and suppressing bone resorption. Consequently, this technology promises great potential in osteoporotic bone tissue regeneration.
C1 [Tripathi, G.; Raja, N.; Yun, H. S.] KIMS, Powder & Ceram Div, Chang Won 641831, South Korea.
   [Raja, N.; Yun, H. S.] Korea Univ Sci & Technol UST, Taejon 305350, South Korea.
C3 Korea Institute of Materials Science (KIMS); University of Science &
   Technology (UST)
RP Yun, HS (通讯作者)，KIMS, Powder & Ceram Div, 797 Changwondero, Chang Won 641831, South Korea.
EM yuni@kims.re.kr
RI Raja, Naren/AAA 4156 2022
OI Raja, Naren/0000 0001 6321 1671
FU Mid Career Researcher Program through NRF grant   Korea Ministry of
   Education, Science, and Technology (MEST) [2011 0017572]
FX This work was supported by the Mid Career Researcher Program through an
   NRF grant funded by The Korea Ministry of Education, Science, and
   Technology (MEST) (Number 2011 0017572). Authors greatly thank Ms. Kim
   Seonyeon for her efforts and time to perform the real time PCR study and
   Dr Seong (Korea Food Research Institute) for valuable discussion
   concerning phytochemicals.
CR [Anonymous], ACS CANC TREATM INF
   Araújo CAC, 2001, MEM I OSWALDO CRUZ, V96, P723, DOI 10.1590/S0074 02762001000500026
   Baksh D, 2007, STEM CELLS, V25, P1384, DOI 10.1634/stemcells.2006 0709
   Ballanti P, 1997, OSTEOPOROSIS INT, V7, P39, DOI 10.1007/BF01623458
   Boanini E, 2008, BIOMATERIALS, V29, P790, DOI 10.1016/j.biomaterials.2007.10.040
   Bose S, 2012, ACTA BIOMATER, V8, P1401, DOI 10.1016/j.actbio.2011.11.017
   CARLISLE EM, 1970, SCIENCE, V167, P279, DOI 10.1126/science.167.3916.279
   Chen JS, 2012, NAT REV ENDOCRINOL, V8, P81, DOI 10.1038/nrendo.2011.146
   CHEN JK, 1992, J BONE MINER RES, V7, P987
   Chow LC, 2009, DENT MATER J, V28, P1
   Ehara A, 2003, BIOMATERIALS, V24, P831, DOI 10.1016/S0142 9612(02)00411 8
   Farag MM, 2014, MATER LETT, V132, P111, DOI 10.1016/j.matlet.2014.06.055
   Fröhlich M, 2008, CURR STEM CELL RES T, V3, P254, DOI 10.2174/157488808786733962
   Hohlweg Majert B, 2006, OSTEOPOROSIS INT, V17, P167, DOI 10.1007/s00198 005 1967 4
   Jindong Z., 2010, ORTHOPEDICS, V33, P11
   Jung HD, 2014, J BIOMED MATER RES B, V102, P913, DOI 10.1002/jbm.b.33072
   Kanno S, 2004, TOXICOLOGY, V196, P137, DOI 10.1016/j.tox.2003.12.002
   Kinoshita Y, 2013, SCI WORLD J, DOI 10.1155/2013/863157
   Kwun IS, 2010, BONE, V46, P732, DOI 10.1016/j.bone.2009.11.003
   Kyllönen L, 2015, ACTA BIOMATER, V11, P412, DOI 10.1016/j.actbio.2014.09.006
   Lee J, 2014, MAT SCI ENG C MATER, V36, P252, DOI 10.1016/j.msec.2013.12.007
   Marie PJ, 2001, CALCIFIED TISSUE INT, V69, P121, DOI 10.1007/s002230010055
   Marie PJ, 2006, BONE, V38, P10, DOI 10.1016/j.bone.2005.07.029
   Nakaya M, 2005, BIOCHEM PHARMACOL, V71, P108, DOI 10.1016/j.bcp.2005.10.002
   Patntirapong S, 2009, BIOMATERIALS, V30, P548, DOI 10.1016/j.biomaterials.2008.09.062
   Qu Q, 1998, BONE, V22, P201, DOI 10.1016/S8756 3282(97)00276 7
   Reichert JC, 2010, BIOMATERIALS, V31, P7928, DOI 10.1016/j.biomaterials.2010.06.055
   Reilly GC, 2007, BIOMATERIALS, V28, P4091, DOI 10.1016/j.biomaterials.2007.05.038
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Satue M, 2013, BIOCHEM PHARMACOL, V86, P1476, DOI 10.1016/j.bcp.2013.09.009
   Seeman E, 2003, J APPL PHYSIOL, V95, P2142, DOI 10.1152/japplphysiol.00564.2003
   Sheu SY, 2012, CHINESE MED J PEKING, V125, P3646, DOI 10.3760/cma.j.issn.0366 6999.2012.20.009
   Staiger MP, 2006, BIOMATERIALS, V27, P1728, DOI 10.1016/j.biomaterials.2005.10.003
   Sterling JA, 2014, CURR OSTEOPOROS REP, V12, P48, DOI 10.1007/s11914 014 0187 2
   Viereck V, 2002, J CELL BIOCHEM, V86, P348, DOI 10.1002/jcb.10220
   Wong R W K, 2008, Open Orthop J, V2, P27, DOI 10.2174/1874325000802010027
   Yamaguchi M, 2002, J HEALTH SCI, V48, P209, DOI 10.1248/jhs.48.209
   Yun HS, 2007, CHEM COMMUN, P2139, DOI 10.1039/b702103h
   Yun HS, 2011, INT J NANOMED, V6, P2521, DOI 10.2147/IJN.S25647
   Zreiqat H, 2002, J BIOMED MATER RES, V62, P175, DOI 10.1002/jbm.10270
NR 40
TC 35
Z9 35
U1 0
U2 59
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050 750X
EI 2050 7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PY 2015
VL 3
IS 44
BP 8694
EP 8703
DI 10.1039/c5tb01574j
PG 10
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA CV2RH
UT WOS:000364103600010
PM 32262726
DA 2025 08 17
ER

PT J
AU Sun, WT
   Ge, K
   Jin, Y
   Han, Y
   Zhang, HS
   Zhou, GQ
   Yang, XJ
   Liu, DD
   Liu, HF
   Liang, XJ
   Zhang, JC
AF Sun, Wentong
   Ge, Kun
   Jin, Yan
   Han, Yu
   Zhang, Haisong
   Zhou, Guoqiang
   Yang, Xinjian
   Liu, Dandan
   Liu, Huifang
   Liang, Xing Jie
   Zhang, Jinchao
TI Bone Targeted Nanoplatform Combining Zoledronate and Photothermal
   Therapy To Treat Breast Cancer Bone Metastasis
SO ACS NANO
LA English
DT Article
DE breast cancer bone metastasis; mesoporous silica nanoparticles; bone
   target; zoledronate; photothermal therapy
ID MESOPOROUS SILICA NANOPARTICLES; ACID; HYPERTHERMIA; MODELS; SYSTEM
AB Bone metastasis, a clinical complication of patients with advanced breast cancer, seriously reduces the quality of life. To avoid destruction of the bone matrix, current treatments focus on inhibiting the cancer cell growth and the osteoclast activity through combination therapy. Therefore, it could be beneficial to develop a bone targeted drug delivery system to treat bone metastasis. Here, a bone targeted nanoplatform was developed using gold nanorods enclosed inside mesoporous silica nanoparticles (Au@MSN5) which were then conjugated with zoledronic acid (ZOL). The nanoparticles (Au@MSNs ZOL) not only showed bone targeting ability in vivo but also inhibited the formation of osteoclast like cells and promoted osteoblast differentiation in vitro. The combination of Au@MSNs ZOL and photothermal therapy (PTT), triggered by near infrared irradiation, inhibited tumor growth both in vitro and in vivo and relieved pain and bone resorption in vivo by inducing apoptosis in cancer cells and improving the bone microenvironment. This single nanoplatform combines ZOL and PTT to provide an exciting strategy for treating breast cancer bone metastasis.
C1 [Sun, Wentong; Ge, Kun; Jin, Yan; Han, Yu; Zhou, Guoqiang; Yang, Xinjian; Liu, Dandan; Liu, Huifang; Zhang, Jinchao] Hebei Univ, Coll Chem & Environm Sci, Key Lab Med Chem & Mol Diag, Key Lab Chem Biol Hebei Prov,Minist Educ, Baoding 071002, Peoples R China.
   [Ge, Kun; Zhang, Haisong] Hebei Univ, Affiliated Hosp, Hebei Key Lab Chron Kidney Dis & Bone Metab, Baoding 071000, Peoples R China.
   [Liang, Xing Jie] Chinese Acad Sci, CAS Ctr Excellence Nanosci, Key Lab Biomed Effects Nanomat & Nanosafety, Natl Ctr Nanosci & Technol China, 11 First North Rd, Beijing 100190, Peoples R China.
C3 Hebei University; Hebei University; Chinese Academy of Sciences;
   National Center for Nanoscience & Technology, CAS; Key Laboratory for
   Biological Effects of Nanomaterials & Nanosafety, CAS
RP Ge, K; Zhang, JC (通讯作者)，Hebei Univ, Coll Chem & Environm Sci, Key Lab Med Chem & Mol Diag, Key Lab Chem Biol Hebei Prov,Minist Educ, Baoding 071002, Peoples R China.
EM kaqikun@163.com; jczhang6970@163.com
RI ; Sun, WT/JDN 1302 2023; Liang, Xingjie/ABF 2708 2021
OI Ge, Kun/0000 0001 8972 837X; 
FU National Natural Science Foundations of China [31470961, 21807023,
   31500812]; Basic Research Foundation of Education Ministry of Hebei
   Province [QN2018010]; Natural Science Key Foundation of Hebei Province
   [B2017201226]; Natural Science Foundation of Hebei Province
   [B2017201135]
FX This research was supported by the National Natural Science Foundations
   of China (31470961, 21807023, and 31500812), Basic Research Foundation
   of Education Ministry of Hebei Province (QN2018010), Natural Science Key
   Foundation of Hebei Province (B2017201226), and Natural Science
   Foundation of Hebei Province (B2017201135).
CR Au KM, 2016, BIOMATERIALS, V82, P178, DOI 10.1016/j.biomaterials.2015.12.018
   Berenson JR, 2005, ONCOLOGIST, V10, P52, DOI 10.1634/theoncologist.10 1 52
   Chaudhari KR, 2012, J CONTROL RELEASE, V158, P470, DOI 10.1016/j.jconrel.2011.11.020
   Chen SZ, 2016, J BIOMED NANOTECHNOL, V12, P1, DOI 10.1166/jbn.2016.2122
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Chen WH, 2015, ADV HEALTHC MATER, V4, P2247, DOI 10.1002/adhm.201500453
   Cleal K, 2013, CURR PHARM DESIGN, V19, P2878
   Currie GL, 2013, PAIN, V154, P917, DOI 10.1016/j.pain.2013.02.033
   Ge K, 2016, J NANOPART RES, V18, DOI 10.1007/s11051 016 3380 7
   Ge K, 2015, ACS APPL MATER INTER, V7, P10905, DOI 10.1021/acsami.5b02146
   Hildebrandt B, 2002, CRIT REV ONCOL HEMAT, V43, P33, DOI 10.1016/S1040 8428(01)00179 2
   Hortobagyi GN, 2017, JAMA ONCOL, V3, P906, DOI 10.1001/jamaoncol.2016.6316
   Huang YW, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122702
   Jafari S, 2019, BIOMED PHARMACOTHER, V109, P1100, DOI 10.1016/j.biopha.2018.10.167
   Kawatani M, 2009, CANCER SCI, V100, P1999, DOI 10.1111/j.1349 7006.2009.01294.x
   Kim YJ, 2013, ADV FUNCT MATER, V23, P5753, DOI 10.1002/adfm.201300746
   Kommalapati A, 2017, CRIT REV ONCOL HEMAT, V120, P217, DOI 10.1016/j.critrevonc.2017.09.003
   Kopp M, 2017, ACCOUNTS CHEM RES, V50, P1383, DOI 10.1021/acs.accounts.7b00051
   KOWAL CD, 1979, CANCER RES, V39, P2285
   Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375
   Li B, 2019, ACS APPL MATER INTER, V11, P7800, DOI 10.1021/acsami.8b21784
   Liu Hao, 2018, Biophys Rep, V4, P254, DOI 10.1007/s41048 018 0071 1
   Liu X, 2016, POLYM CHEM UK, V7, P1375, DOI 10.1039/c5py01807b
   Liverani C, 2014, BONE, V66, P214, DOI 10.1016/j.bone.2014.06.017
   Motevalli Seyed Mohammad, 2019, Biophysics Reports, V5, P19, DOI 10.1007/s41048 018 0079 6
   Pathi SP, 2011, BIOMATERIALS, V32, P5112, DOI 10.1016/j.biomaterials.2011.03.055
   Peng F, 2013, ANGEW CHEM INT EDIT, V52, P1457, DOI 10.1002/anie.201206737
   Qiao H, 2017, ACS NANO, V11, P7259, DOI 10.1021/acsnano.7b03197
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022
   Shane E, 2010, NEW ENGL J MED, V362, P1825, DOI 10.1056/NEJMe1003064
   Sun WT, 2016, LANGMUIR, V32, P9237, DOI 10.1021/acs.langmuir.6b02228
   Suvannasankha A, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058 014 0484 9
   Tian B, 2011, ACS NANO, V5, P7000, DOI 10.1021/nn201560b
   Valkenburg KC, 2013, CHIN J CANCER, V32, P380, DOI 10.5732/cjc.012.10218
   Wang BK, 2016, BIOMATERIALS, V78, P27, DOI 10.1016/j.biomaterials.2015.11.025
   Wang CP, 2015, SMALL, V11, P2080, DOI 10.1002/smll.201403315
   Wang C, 2016, ACS APPL MATER INTER, V8, P11262, DOI 10.1021/acsami.6b01103
   Wang FF, 2014, J CONTROL RELEASE, V196, P222, DOI 10.1016/j.jconrel.2014.10.012
   Wang HK, 2015, BIOCHEM BIOPH RES CO, V458, P268, DOI 10.1016/j.bbrc.2015.01.097
   Wang YT, 2017, BIOMATERIALS, V114, P97, DOI 10.1016/j.biomaterials.2016.11.010
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Xiong MH, 2012, J AM CHEM SOC, V134, P4355, DOI 10.1021/ja211279u
   Xue Xiangdong, 2015, Biophys Rep, V1, P61, DOI 10.1007/s41048 015 0002 3
   Yang PP, 2012, CHEM SOC REV, V41, P3679, DOI 10.1039/c2cs15308d
   Yang XJ, 2012, ADV MATER, V24, P2890, DOI 10.1002/adma.201104797
   Ye WL, 2015, SCI REP UK, V5, DOI 10.1038/srep14614
   Zhang PC, 2016, THERANOSTICS, V6, P948, DOI 10.7150/thno.15217
   Zhu JH, 2018, NANOSCALE, V10, P18387, DOI 10.1039/c8nr03899f
NR 49
TC 152
Z9 159
U1 9
U2 276
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936 0851
EI 1936 086X
J9 ACS NANO
JI ACS Nano
PD JUL
PY 2019
VL 13
IS 7
BP 7556
EP 7567
DI 10.1021/acsnano.9b00097
PG 12
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA IM1XY
UT WOS:000477786400022
PM 31259530
DA 2025 08 17
ER

PT J
AU Trichilo, S
   Scheiner, S
   Forwood, M
   Cooper, DML
   Pivonka, P
AF Trichilo, Silvia
   Scheiner, Stefan
   Forwood, Mark
   Cooper, David M. L.
   Pivonka, Peter
TI Computational model of the dual action of PTH   Application to a rat
   model of osteoporosis
SO JOURNAL OF THEORETICAL BIOLOGY
LA English
DT Article
DE Bone modelling; Bone remodelling; Intermittent administration of PTH;
   Rat model; Predictive simulation
ID PARATHYROID HORMONE; MATHEMATICAL MODEL; BONE FORMATION; OSTEOBLASTS;
   EXPRESSION; RANKL; SCLEROSTIN; MECHANISMS; APOPTOSIS; SYSTEM
AB This paper presents a pharmacokinetic/pharmacodynamic (PK/PD) model of the action of PTH(1 34) on bone modelling and remodelling, developed for quantitatively investigating the dose  and administration pattern dependency of the bone tissue response to this drug. Firstly, a PK model of PTH(1 34) was developed, accounting for administration via subcutaneous injections. Subsequently, the PK model was coupled to a (mechanistic) bone cell population model of bone modelling and remodelling, taking into account the effects of PTH(1 34) on the differentiation of lining cells into active osteoblasts, on the apoptosis of active osteoblasts, and on proliferation of osteoblast precursors, as well as on the key regulatory pathways of bone cell activities. Numerical simulations show that the coupled PK/PD model is able to distinguish between continuous and intermittent administration patterns of PTH(1 34), in terms of yielding both catabolic bone responses (if drug administration is carried out continuously) and anabolic bone responses (if drug administration is carried out intermittently). The model also features a non linear relation between bone gain and drug dose (as known from experiments); doubling the dose from 80 mu g/kg/day to 160 mu g/kg/day induced a 1.3 fold increase of the bone volume to total volume ratio. Furthermore, the model presented in this paper confirmed that bone modelling represents an essential mechanism of the anabolic response of bone to PTH(1 34) administration in rat models, and that the large amount of bone formation observed in such models cannot be explained via remodelling alone. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Trichilo, Silvia; Pivonka, Peter] Univ Melbourne, St Vincents Dept Surg, Clin Sci Bldg,29 Regent St, Fitzroy, Vic 3065, Australia.
   [Scheiner, Stefan] Vienna Univ Technol, TU Wien, Inst Mech Mat & Struct, Karlspl 13 202, A 1040 Vienna, Austria.
   [Forwood, Mark] Griffith Univ, Sch Med Sci, Gold Coast Campus,Parklands Dr, Southport, Qld 4222, Australia.
   [Cooper, David M. L.] Univ Saskatchewan, Dept Anat Physiol & Pharmacol, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.
   [Pivonka, Peter] Queensland Univ Technol, Sch Chem Phys & Mech Engn, 2 George St, Brisbane, Qld 4000, Australia.
C3 University of Melbourne; Technische Universitat Wien; Griffith
   University; Griffith University   Gold Coast Campus; University of
   Saskatchewan; Queensland University of Technology (QUT)
RP Pivonka, P (通讯作者)，Queensland Univ Technol, Sch Chem Phys & Mech Engn, 2 George St, Brisbane, Qld 4000, Australia.
RI Pivonka, Peter/AAL 1053 2021; Forwood, Mark/ABA 9040 2021
OI Pivonka, Peter/0000 0001 9183 530X; Forwood, Mark/0000 0002 9963 1616;
   Cooper, David/0000 0002 3175 9170; Scheiner, Stefan/0000 0003 1078 7807
FU University of Melbourne
FX Miss Silvia Trichilo acknowledges the support by The University of
   Melbourne, in the framework of the International PhD Scholarship
   Program.
CR [Anonymous], 2016, Williams textbook of endocrinology, DOI DOI 10.1016/C2013 0 15980 6
   Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   Buenzli PR, 2012, J THEOR BIOL, V307, P42, DOI 10.1016/j.jtbi.2012.04.019
   Cadigan KM, 2006, J CELL SCI, V119, P395, DOI 10.1242/jcs.02826
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Costa AG, 2012, CURR OSTEOPOROS REP, V10, P64, DOI 10.1007/s11914 011 0089 5
   Danhof M, 2007, ANNU REV PHARMACOL, V47, P357, DOI 10.1146/annurev.pharmtox.47.120505.105154
   Dempster D, 1993, ENDOCR REV, V14, P247
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Eli Lilly & Co, 2014, FORTEO TER RBE INJ
   European Medicines Agency, 2019, FORST PROD INF
   Fletcher PA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095613
   Fuerer C, 2008, EMBO REP, V9, P134, DOI 10.1038/sj.embor.7401159
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Hofbauer L. C., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P268
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Huang JC, 2004, J BONE MINER RES, V19, P235, DOI 10.1359/JBMR.0301226
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Kim SW, 2012, J BONE MINER RES, V27, P2075, DOI 10.1002/jbmr.1665
   Komarova SV, 2005, ENDOCRINOLOGY, V146, P3589, DOI 10.1210/en.2004 1642
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   LAUFFENBURGER DA, 1993, RECEPTORS MODELS BIN
   LEAFFER D, 1995, ENDOCRINOLOGY, V136, P3624, DOI 10.1210/en.136.8.3624
   Leder BZ, 2014, J CLIN ENDOCR METAB, V99, P1694, DOI 10.1210/jc.2013 4440
   Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Lerebours C, 2016, BIOMECH MODEL MECHAN, V15, P43, DOI 10.1007/s10237 015 0705 x
   Li X, 2007, J BIOL CHEM, V282, P33086, DOI 10.1074/jbc.M705194200
   LIU CC, 1990, J BONE MINER RES, V5, P973
   MCSHEEHY PMJ, 1986, ENDOCRINOLOGY, V118, P824, DOI 10.1210/endo 118 2 824
   Mundy GR, 1999, CLIN CHEM, V45, P1347
   Ogura Kenji, 2016, Bone Rep, V5, P7, DOI 10.1016/j.bonr.2016.01.002
   Pastrama MI, 2018, BONE, V107, P208, DOI 10.1016/j.bone.2017.11.009
   Peterson MC, 2010, BONE, V46, P49, DOI 10.1016/j.bone.2009.08.053
   Pivonka P, 2012, CELL INTERACTION INT, P169
   Pivonka P, 2008, BONE, V43, P249, DOI 10.1016/j.bone.2008.03.025
   Pivonka P, 2013, ENG STRUCT, V47, P134, DOI 10.1016/j.engstruct.2012.09.006
   Pivonka P, 2010, J THEOR BIOL, V262, P306, DOI 10.1016/j.jtbi.2009.09.021
   Poole KES, 2005, CURR OPIN PHARMACOL, V5, P612, DOI 10.1016/j.coph.2005.07.004
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Potter LK, 2005, BONE, V37, P159, DOI 10.1016/j.bone.2005.04.011
   Potts JT, 2005, J ENDOCRINOL, V187, P311, DOI 10.1677/joe.1.06057
   Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006
   Rattanakul C, 2003, BIOSYSTEMS, V70, P55, DOI 10.1016/S0303 2647(03)00040 6
   Satterwhite J, 2010, CALCIFIED TISSUE INT, V87, P485, DOI 10.1007/s00223 010 9424 6
   Scheiner S, 2013, COMPUT METHOD APPL M, V254, P181, DOI 10.1016/j.cma.2012.10.015
   Schnoke M, 2009, BONE, V45, P590, DOI 10.1016/j.bone.2009.05.006
   Sharma S, 2013, BIOCHEM BIOPH RES CO, V436, P607, DOI 10.1016/j.bbrc.2013.05.136
   Silva BC, 2015, CURR OPIN PHARMACOL, V22, P41, DOI 10.1016/j.coph.2015.03.005
   Stratford R, 2014, J PHARM SCI US, V103, P768, DOI 10.1002/jps.23843
   Trichilo S, 2018, CISM INT CTR MECH SC, V578, P61
   Tsai JN, 2015, J BONE MINER RES, V30, P39, DOI 10.1002/jbmr.2315
   U.S. Food and Drug Administration, 2019, APPR DRUG PROD THER
   WRONSKI TJ, 1993, ENDOCRINOLOGY, V132, P823, DOI 10.1210/en.132.2.823
   WRONSKI TJ, 1988, CALCIFIED TISSUE INT, V43, P179, DOI 10.1007/BF02571317
   Xiong JH, 2012, J BONE MINER RES, V27, P499, DOI 10.1002/jbmr.1547
NR 56
TC 13
Z9 14
U1 3
U2 10
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022 5193
EI 1095 8541
J9 J THEOR BIOL
JI J. Theor. Biol.
PD JUL 21
PY 2019
VL 473
BP 67
EP 79
DI 10.1016/j.jtbi.2019.04.020
PG 13
WC Biology; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Mathematical & Computational
   Biology
GA IA2RI
UT WOS:000469408400008
PM 31009612
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Lu, BW
   Liang, XZ
   Wen, MT
   Li, G
AF Lu, B.  W.
   Liang, X.  Z.
   Wen, M.  T.
   Li, G.
TI Exploration at the network pharmacology level of possible targeting
   mechanisms of Smilacis Glabrae Rhixoma for the treatment of osteoporosis
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Osteoporosis; Smilacis Glabrae Rhixoma; Molecular dynamics; CTSK; ADMET
ID OSTEOCLAST ACTIVATION; BONE LOSS; HIF1 ALPHA; CYTOSCAPE; DOCKING
AB OBJECTIVE: The aim of this study was to evaluate the therapeutic effect of Smila cis Glabrae Rhixoma (SGR) on osteoporosis at the level of network pharmacology, and to find new targets and mechanisms of SGR in the treat ment of osteoporosis, to better find new drugs and their clinical applications. MATERIALS AND METHODS: In the origi nal network pharmacology mode, we used an improved mode, such as screening the ingredi ents and targets of SGR through tools such as GEO database, Autodock Vina, and GROMACS. Through molecular docking, we conducted fur ther screening for the targets acting on the ef fective ingredients of SGR, and finally we per formed molecular dynamics simulation and consulted a large amount of related literature for the validation of the results. RESULTS: By screening and validating the da ta, we finally confirmed that there were mainly 10 active ingredients in SGR, which were isoerubo side b, smilagenin, diosgenin, stigmasterol, be ta sitosterol, sodium taurocholate, sitogluside, 4,7 dihydroxy 5 methoxy 6 methyl 8 formyl fla van, simiglaside B, and simiglaside E, and main ly acted on eleven targets. These targets main ly exert therapeutic effects on osteoporosis by regulating 20 signaling pathways including Th17 cell differentiation, HIF 1 signaling pathway, apoptosis, inflammatory bowel disease, and os teoclast differentiation. CONCLUSIONS: Our study successfully ex plains the effective mechanism by which SGR ameliorates osteoporosis while predicting the potential targets NFKB1 and CTSK of SGR for the treatment of osteoporosis, which provides a novel basis for investigating the mechanism of action of new Traditional Chinese medicines (TCMs) at the network pharmacology level and a great support for subsequent studies on oste oporosis.
C1 [Lu, B.  W.] Shandong Univ Tradit Chinese Med, Coll Tradit Chinese Med, Jinan, Shandong, Peoples R China.
   [Lu, B.  W.; Liang, X.  Z.; Wen, M.  T.; Li, G.] Shandong Univ Tradit Chinese Med, Coll Clin Med 1, Jinan, Shandong, Peoples R China.
   [Liang, X.  Z.; Li, G.] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Orthopaed Microsurg, Jinan, Shandong, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Shandong University
   of Traditional Chinese Medicine; Shandong University of Traditional
   Chinese Medicine
RP Li, G (通讯作者)，Shandong Univ Tradit Chinese Med, Coll Clin Med 1, Jinan, Shandong, Peoples R China.; Li, G (通讯作者)，Shandong Univ Tradit Chinese Med, Affiliated Hosp, Orthopaed Microsurg, Jinan, Shandong, Peoples R China.
EM sdszylg@163.com
RI LIANG, Xuezhen/HGA 4207 2022
FU National Natural Science Foundation of China [82205154, 82074453];
   National Natural Science Foundation of Shandong Province [ZR2021QH004,
   ZR2021LZY002]; Development Plan of Shandong Medical and Health
   Technology [2019WS577, 202104070600]; Development Plan of Shandong
   Traditional Chinese Medicine Science and Technology [2020Q009,
   2020Q130]; Innovation Program of Jinan Clinical Medicine Science and
   Technology [202019056]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 82205154 and No. 82074453) ; the National
   Natural Science Foundation of Shandong Province (No. ZR2021QH004 and No.
   ZR2021LZY002) ; the Development Plan of Shandong Medical and Health
   Technology (No. 2019WS577 and No. 202104070600) ; the Development Plan
   of Shandong Traditional Chinese Medicine Science and Technology (No.
   2020Q009 and No. 2020Q130) ; and the Innovation Program of Jinan
   Clinical Medicine Science and Technology (No. 202019056) .
CR Aminoshariae A, 2022, J AM DENT ASSOC, V153, P649, DOI 10.1016/j.adaj.2021.12.008
   Bauer Mehren A, 2010, BIOINFORMATICS, V26, P2924, DOI 10.1093/bioinformatics/btq538
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Cousins KR, 2011, J AM CHEM SOC, V133, P8388, DOI 10.1021/ja204075s
   Gao LH, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00048
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Lee WS, 2020, ARTHRITIS RHEUMATOL, V72, P1493, DOI 10.1002/art.41290
   Li SS, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.717065
   Long J, 2022, PSYCHIAT RES, V312, DOI 10.1016/j.psychres.2022.114588
   Matuszewska A, 2022, INT ORTHOP, V46, P1529, DOI 10.1007/s00264 022 05407 z
   Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110
   Morris GM, 1996, J COMPUT AID MOL DES, V10, P293, DOI 10.1007/BF00124499
   Nakamura H, 2013, J BONE MINER RES, V28, P1457, DOI 10.1002/jbmr.1866
   Rakhshani H, 2019, J MOL MODEL, V25, DOI 10.1007/s00894 019 4232 z
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Seeliger Daniel, 2010, J Comput Aided Mol Des, V24, P417, DOI 10.1007/s10822 010 9352 6
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Si L, 2015, OSTEOPOROSIS INT, V26, P1929, DOI 10.1007/s00198 015 3093 2
   Tando T, 2016, BIOCHEM BIOPH RES CO, V470, P391, DOI 10.1016/j.bbrc.2016.01.033
   Tang CY, 2022, INT J BIOL SCI, V18, P2392, DOI 10.7150/ijbs.70620
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wang YW, 2020, BMC CARDIOVASC DISOR, V20, DOI 10.1186/s12872 020 01568 0
   Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958
   Xiong GL, 2021, NUCLEIC ACIDS RES, V49, pW5, DOI 10.1093/nar/gkab255
   Zajic S, 2020, J PHARMACOKINET PHAR, V47, P473, DOI 10.1007/s10928 020 09699 9
   Zeng Q, 2019, J BONE MINER RES, V34, P1789, DOI 10.1002/jbmr.3757
   Zhang DD, 2022, COMPUT BIOL MED, V146, DOI 10.1016/j.compbiomed.2022.105549
NR 27
TC 1
Z9 1
U1 1
U2 5
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186 00165, ITALY
SN 1128 3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2023
VL 27
IS 8
BP 3681
EP 3698
PG 18
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA H4XI8
UT WOS:000996006000005
PM 37140318
DA 2025 08 17
ER

PT J
AU Kim, MH
   Kim, BT
   Min, YK
   Kim, SH
AF Kim, M. H.
   Kim, B. T.
   Min, Y. K.
   Kim, S. H.
TI Profiling signalling pathways of the receptor activator of NF κB
   ligand induced osteoclast formation in mouse monocyte cells, RAW264.7
SO AMINO ACIDS
LA English
DT Article
DE drug discovery; osteoclastogenesis; RAW264; 7 cells; receptor activator
   of NF kappa B ligand (RANKL); signal chemical genomics
ID EPIDERMAL GROWTH FACTOR; NITRIC OXIDE SYNTHASE; BONE RESORPTION; K+
   CHANNELS; FACTOR BETA; IN VITRO; DIFFERENTIATION; CHLORPROMAZINE;
   INHIBITION; EXPRESSION
AB Cell based signal chemical genomics can profile the signalling pathway for certain cellular events by using a target known chemical library. To ascertain its usefulness, the receptor activator of NF kappa B ligand (RANKL) induced osteoclastogenesis in mouse monocyte/macrophage cells RAW264.7 was used as an in vitro experimental model. Of 180 target known inhibitors/activators formatted in a 384 well plate, 8 chemicals were shown to inhibit the osteoclast formation, but 4 chemicals enhanced this process. A variety of references support, or possibly lead one to expect the effects of these 12 chemicals on the cellular process of osteoclastogenesis in RAW264.7 cells, but several signalling pathways were newly found in this study; for example, CA 074 Me inhibiting cathepsin B and nitrendipine blocking the calcium channel could have the potential to inhibit the osteoclast formation as well as bone resorption. This is a simple but very fast and powerful method of profiling the signalling pathway of certain cellular events. Signal chemical genomics could provide invaluable information for the exploration of new target signalling processes and further target based drug discovery strategies.
C1 [Kim, M. H.; Kim, B. T.; Min, Y. K.; Kim, S. H.] Korea Res Inst Chem Technol, Bioorgan Sci Div, Lab Chem Genom, Bioorgan Sci Team, Taejon 305600, South Korea.
   [Kim, M. H.] Chungnam Natl Univ, Dept Biochem, Taejon, South Korea.
C3 Korea Research Institute of Chemical Technology (KRICT); Chungnam
   National University
RP Kim, SH (通讯作者)，Korea Res Inst Chem Technol, Bioorgan Sci Div, Lab Chem Genom, Bioorgan Sci Team, POB 107, Taejon 305600, South Korea.
EM hwan@krict.re.kr
RI Kim, Seok/K 8263 2018; Kim, Seong/AAA 6086 2021; Kim,
   Myunghee/AAP 8425 2020
CR Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858
   BLEEKER MW, 1999, IMMUNOLOGY, V91, P548
   BUTTLE DJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P377, DOI 10.1016/0003 9861(92)90290 D
   CARON PR, 2004, CHEM GENOMICS, P1
   de Lima V, 2000, EUR J ORAL SCI, V108, P123, DOI 10.1034/j.1600 0722.2000.00766.x
   Fukunaga J, 2004, BONE, V34, P425, DOI 10.1016/j.bone.2003.05.003
   Garcia C, 1996, J BONE MINER RES, V11, P1619
   Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533
   Hall TJ, 1996, GEN PHARMACOL, V27, P845, DOI 10.1016/0306 3623(95)02109 4
   Han SY, 2005, BLOOD, V106, P1240, DOI 10.1182/blood 2004 12 4975
   HILL PA, 1994, J CELL BIOCHEM, V56, P118, DOI 10.1002/jcb.240560116
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   KON K, 1994, J PHARMACOL EXP THER, V271, P632
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   MARIE PJ, 1990, AM J PHYSIOL, V258, pE275, DOI 10.1152/ajpendo.1990.258.2.E275
   Nicolin V, 2005, ANAT REC PART A, V286A, P945, DOI 10.1002/ar.a.20239
   *NIH CHEM GEN CTR, 2006, ASS GUID MAN VERS 4
   Okahashi N, 2001, J CELL BIOCHEM, V80, P339, DOI 10.1002/1097 4644(20010301)80:3<339::AID JCB60>3.0.CO;2 #
   Okamoto F, 2001, JPN J PHYSIOL, V51, P501, DOI 10.2170/jjphysiol.51.501
   PALACIOS M, 1993, BIOCHEM BIOPH RES CO, V196, P280, DOI 10.1006/bbrc.1993.2246
   Persidis A, 1998, NAT BIOTECHNOL, V16, P1082, DOI 10.1038/3553
   Price JT, 2005, CANCER RES, V65, P4929, DOI 10.1158/0008 5472.CAN 04 4458
   Qiao M, 2006, J BIOL CHEM, V281, P7118, DOI 10.1074/jbc.M508162200
   RAISZ LG, 1980, ENDOCRINOLOGY, V107, P270, DOI 10.1210/endo 107 1 270
   RAVESLOOT JH, 1989, P NATL ACAD SCI USA, V86, P6821, DOI 10.1073/pnas.86.17.6821
   RITCHIE CK, 1994, ENDOCRINOLOGY, V135, P996, DOI 10.1210/en.135.3.996
   Russel K., 2004, Chemogenomics in drug discovery: a medicinal chemistry perspective, P69
   SHANKAR G, 1993, BONE, V14, P871, DOI 10.1016/8756 3282(93)90317 4
   Shui C, 2002, CALCIFIED TISSUE INT, V71, P437, DOI 10.1007/s00223 001 1138 3
   SHUTO T, 1994, ENDOCRINOLOGY, V134, P1121, DOI 10.1210/en.134.3.1121
   Take I, 2005, ENDOCRINOLOGY, V146, P5204, DOI 10.1210/en.2005 0451
   Takuma A, 2003, J BIOL CHEM, V278, P44667, DOI 10.1074/jbc.M300213200
   Traianedes K, 1998, ENDOCRINOLOGY, V139, P3178, DOI 10.1210/en.139.7.3178
   Wang K, 2004, J BIOL CHEM, V279, P53848, DOI 10.1074/jbc.M403114200
   Wartenberg M, 2002, BBA MOL CELL RES, V1589, P49, DOI 10.1016/S0167 4889(01)00185 9
   YONEDA T, 1993, J CLIN INVEST, V91, P2791, DOI 10.1172/JCI116521
   Zhang L, 2003, ENDOCRINOLOGY, V144, P4536, DOI 10.1210/en.2003 0147
NR 37
TC 6
Z9 6
U1 0
U2 3
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4 6, PO BOX 89, A 1201 WIEN, AUSTRIA
SN 0939 4451
EI 1438 2199
J9 AMINO ACIDS
JI Amino Acids
PD APR
PY 2008
VL 34
IS 3
BP 497
EP 506
DI 10.1007/s00726 006 0461 4
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 290GQ
UT WOS:000255111700015
PM 17086477
DA 2025 08 17
ER

PT J
AU Mukherjee, S
   Park, JP
   Yun, JW
AF Mukherjee, Sulagna
   Park, Jong Pil
   Yun, Jong Won
TI Carboxylesterase3 (Ces3) Interacts with Bone Morphogenetic Protein 11
   and Promotes Differentiation of Osteoblasts via Smad1/5/9 Pathway
SO BIOTECHNOLOGY AND BIOPROCESS ENGINEERING
LA English
DT Article
DE osteoblasts; Ces3; BMP11; differentiation; Smad 1; 5; 9
ID OBESITY; BMP; IDENTIFICATION; EXPRESSION; RECEPTOR; BETA; PROLIFERATION;
   METABOLISM; STEATOSIS; RUNX2
AB Ces3 is a lipolytic enzyme predominantly present in liver and adipocytes, with recent reports of its presence in skeletal muscles, as well. A cross linking study to understand the various interacting proteins involved in bone adipose axis could provide novel targets for drug development. We explored the functional role of Ces3 in osteoblasts and mesenchymal stem cells differentiating into osteoblast lineage using in vitro models. We also investigated the physiological functions of Ces3 by stable gene knockdown of Ces3 and exogenous Ces3 induction, and examined the interacting proteins by Co IP and in silico analysis. Data from our study suggests that Ces3 is highly expressed in osteoblasts and promotes proliferation of the cells by increasing the expressions of osteogenic marker proteins and genes. For the first time, our mechanistic studies revealed that Ces3 interacts with BMP11 protein for regulation of osteoblast differentiation and activates the ALK2 and BMP type II receptors via Smad 1/5/9 signaling pathways. In addition, we identified the various partner proteins linked to Ces3 and BMP11 which are also involved in the metabolic network of osteoblasts. In silico analysis revealed a direct and strong interaction between Ces3 and BMP11 which influences the growth and regulation of osteoblasts. Current data unveiled a hitherto unknown mechanism of Ces3 and BMP11 in the bone adipose axis, shedding light on Ces3 as a pharmacotherapeutic target to treat metabolic disorders.
C1 [Mukherjee, Sulagna; Yun, Jong Won] Daegu Univ, Dept Biotechnol, Gyongsan 38453, South Korea.
   [Park, Jong Pil] Chung Ang Univ, Dept Food Sci & Technol, Anseong 17546, South Korea.
C3 Daegu University; Chung Ang University
RP Yun, JW (通讯作者)，Daegu Univ, Dept Biotechnol, Gyongsan 38453, South Korea.
EM jwyun@daegu.ac.kr
RI ; Mukherjee, Sulagna/AAJ 6217 2021
OI Park, Jong Pil/0000 0002 4119 1574; Mukherjee,
   Sulagna/0000 0001 6595 4137; 
FU National Research Foundation of Korea (NRF)   Korean Government (MSIT)
   [2019R1A2C2002163]
FX This study was supported by a National Research Foundation of Korea
   (NRF) grant funded by the Korean Government (MSIT, No.
   2019R1A2C2002163).
CR Añón Hidalgo J, 2019, AGING US, V11, P1733, DOI 10.18632/aging.101865
   Berendsen AD, 2014, CELL MOL LIFE SCI, V71, P493, DOI 10.1007/s00018 013 1440 z
   Blair HC, 2017, TISSUE ENG PART B RE, V23, P268, DOI [10.1089/ten.teb.2016.0454, 10.1089/ten.TEB.2016.0454]
   Bridges D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042451
   Challa TD, 2015, DIABETES, V64, P4075, DOI 10.2337/db14 1932
   Chang J, 2014, DIABETOL METAB SYNDR, V6, DOI 10.1186/1758 5996 6 8
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen Q, 2013, J BONE MINER RES, V28, P1214, DOI 10.1002/jbmr.1851
   Di L, 2019, CURR DRUG METAB, V20, P91, DOI 10.2174/1389200219666180821094502
   Dimauro Ivan, 2012, BMC Res Notes, V5, P513, DOI 10.1186/1756 0500 5 513
   Dominguez E, 2014, NAT CHEM BIOL, V10, P113, DOI 10.1038/nchembio.1429
   Duhovny D, 2002, LECT NOTES COMPUT SC, V2452, P185
   Fitzpatrick LA, 2003, P NATL ACAD SCI USA, V100, P6027, DOI 10.1073/pnas.0934373100
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Garten A, 2009, TRENDS ENDOCRIN MET, V20, P130, DOI 10.1016/j.tem.2008.10.004
   Gómez Ambrosi J, 2008, OBES SURG, V18, P1134, DOI 10.1007/s11695 008 9548 1
   Gong K, 2016, BIOCHEM BIOPH RES CO, V478, P260, DOI 10.1016/j.bbrc.2016.07.057
   Hanna H, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0942 x
   Hu LF, 2018, J CELL PHYSIOL, V233, P1574, DOI 10.1002/jcp.26059
   Huang GJ, 2012, VITAM HORM, V88, P309, DOI 10.1016/B978 0 12 394622 5.00014 6
   Huntley R, 2019, BONE REP, V10, DOI 10.1016/j.bonr.2019.100207
   Imai Y, 2013, PHYSIOL REV, V93, P481, DOI 10.1152/physrev.00008.2012
   Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891 2905.2001
   Jensen ED, 2010, BIOFACTORS, V36, P25, DOI 10.1002/biof.72
   Jo I, 2007, BIOTECHNOL BIOPROC E, V12, P48, DOI 10.1007/BF02931803
   Joo JI, 2011, PROTEOMICS, V11, P1429, DOI 10.1002/pmic.201000515
   Katagiri T, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021899
   Knierim E, 2016, AM J HUM GENET, V98, P473, DOI 10.1016/j.ajhg.2016.01.006
   Kushwaha P, 2018, BONE, V115, P8, DOI 10.1016/j.bone.2017.08.024
   Laizure SC, 2013, PHARMACOTHERAPY, V33, P210, DOI 10.1002/phar.1194
   Lee BS, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8040157
   Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937
   Lezcano V, 2014, EXP CELL RES, V324, P30, DOI 10.1016/j.yexcr.2014.03.016
   Lian JH, 2018, PROTEIN CELL, V9, P178, DOI 10.1007/s13238 017 0437 z
   Lian JH, 2012, HEPATOLOGY, V56, P2154, DOI 10.1002/hep.25881
   Liu HB, 2012, J CELL PHYSIOL, V227, P952, DOI 10.1002/jcp.22802
   Lu Q, 2016, CALCIFIED TISSUE INT, V99, P500, DOI 10.1007/s00223 016 0173 z
   Luderer HF, 2008, EXP CELL RES, V314, P2884, DOI 10.1016/j.yexcr.2008.06.003
   Magnum LC., 2018, BIOCHEM J, V475, P621
   Mao M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0315 5
   Mukherjee S, 2020, BIOTECHNOL BIOPROC E, V25, P29, DOI 10.1007/s12257 020 0023 8
   Mukherjee S, 2019, APPL PHYSIOL NUTR ME, V44, P1089, DOI 10.1139/apnm 2018 0814
   Munson S, 2019, J ENDOCR SOC, V3, P1993, DOI 10.1210/js.2019 00171
   Muruganandan S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072277
   Okazaki H, 2006, DIABETES, V55, P2091, DOI 10.2337/db05 0585
   Pham HG, 2021, CELL BIOCHEM FUNCT, V39, P496, DOI 10.1002/cbf.3615
   Qiu WX, 2020, J CELL MOL MED, V24, P317, DOI 10.1111/jcmm.14729
   Quiroga AD, 2012, HEPATOLOGY, V56, P2188, DOI 10.1002/hep.25961
   Raichur S, 2010, NUCLEIC ACIDS RES, V38, P4296, DOI 10.1093/nar/gkq180
   Ross MK, 2010, J PESTIC SCI, V35, P257, DOI 10.1584/jpestics.R10 07
   Ruby MA, 2017, CELL REP, V18, P636, DOI 10.1016/j.celrep.2016.12.070
   Savopoulos C, 2011, HIPPOKRATIA, V15, P18
   Shalev M, 2019, BBA MOL CELL RES, V1866, P114, DOI 10.1016/j.bbamcr.2018.07.005
   Sharma D., 2017, PHARMATUTOR, V5, P18
   Shen GS, 2018, BBA MOL BASIS DIS, V1864, P3644, DOI 10.1016/j.bbadis.2018.09.015
   Shigunov P, 2012, STEM CELLS DEV, V21, P217, DOI 10.1089/scd.2011.0143
   Soni KG, 2004, J BIOL CHEM, V279, P40683, DOI 10.1074/jbc.M400541200
   Suh J, 2020, P NATL ACAD SCI USA, V117, P4910, DOI 10.1073/pnas.1916034117
   Tanaka N, 2014, BBA MOL CELL BIOL L, V1841, P1596, DOI 10.1016/j.bbalip.2014.08.015
   van Daalen KR, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00931
   Wang RN, 2014, GENES DIS, V1, P87, DOI 10.1016/j.gendis.2014.07.005
   Wang XW, 2017, DRUG METAB DISPOS, V45, P1149, DOI 10.1124/dmd.117.077669
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Yamaguchi A, 2008, JPN DENT SCI REV, V44, P48, DOI 10.1016/j.jdsr.2007.11.003
   Yang L, 2019, DIABETES, V68, P1178, DOI 10.2337/db18 1210
   Yang WG, 2013, INT J MOL MED, V32, P805, DOI 10.3892/ijmm.2013.1445
   Zhang C, 1997, J MOL BIOL, V267, P707, DOI 10.1006/jmbi.1996.0859
   Zhang C, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 37
   Zhang Q, 2016, BIOCHEM BIOPH RES CO, V476, P438, DOI 10.1016/j.bbrc.2016.05.141
   Zhang Y, 2015, GENE, V557, P209, DOI 10.1016/j.gene.2014.12.039
   Zhang YH, 2018, EXP THER MED, V15, P3495, DOI 10.3892/etm.2018.5861
   Zhang YH, 2017, ONCOTARGET, V8, P81604, DOI 10.18632/oncotarget.20258
   Zhao B, 2012, AM J PHYSIOL CELL PH, V303, pC427, DOI 10.1152/ajpcell.00103.2012
   Zhu M, 2009, J TISSUE ENG REGEN M, V3, P290, DOI 10.1002/term.165
NR 74
TC 9
Z9 10
U1 0
U2 5
PU KOREAN SOC BIOTECHNOLOGY & BIOENGINEERING
PI SEOUL
PA KOREAN SCIENCE TECHNOLOGY CENTER, #704 YEOGSAM DONG, KANGNAM KU, SEOUL
   135 703, SOUTH KOREA
SN 1226 8372
EI 1976 3816
J9 BIOTECHNOL BIOPROC E
JI Biotechnol. Bioprocess Eng.
PD FEB
PY 2022
VL 27
IS 1
BP 1
EP 16
DI 10.1007/s12257 021 0133 y
EA JAN 2022
PG 16
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology
GA ZN6PN
UT WOS:000748305500001
DA 2025 08 17
ER

PT J
AU Leucht, P
   Jiang, J
   Cheng, D
   Liu, B
   Dhamdhere, G
   Fang, MY
   Monica, SD
   Urena, JJ
   Cole, W
   Smith, LR
   Castillo, AB
   Longaker, MT
   Helms, JA
AF Leucht, Philipp
   Jiang, Jie
   Cheng, Du
   Liu, Bo
   Dhamdhere, Girija
   Fang, Mark Yang
   Monica, Stefanie D.
   Urena, Jonathan J.
   Cole, Whitney
   Smith, Lane R.
   Castillo, Alesha B.
   Longaker, Michael T.
   Helms, Jill A.
TI Wnt3a Reestablishes Osteogenic Capacity to Bone Grafts from Aged Animals
SO JOURNAL OF BONE AND JOINT SURGERY AMERICAN VOLUME
LA English
DT Article
ID MESENCHYMAL STEM CELLS; OSTEOBLAST DIFFERENTIATION; MORPHOGENETIC
   PROTEIN 2; CRITICAL SIZE; GENE THERAPY; MARROW FAT; TISSUE;
   ADIPOGENESIS; OSTEOPOROSIS; INHIBITION
AB Background: Age related fatty degeneration of the bone marrow contributes to delayed fracture healing and osteoporosis related fractures in the elderly. The mechanisms underlying this fatty change are unknown, but they may relate to the level of Wnt signaling within the aged marrow cavity.
   Methods: Transgenic mice were used in conjunction with a syngeneic bone graft model to follow the fates of cells involved in the engraftment. Immunohistochemistry along with quantitative assays were used to evaluate Wnt signaling and adipogenic and osteogenic gene expression in bone grafts from young and aged mice. Liposomal Wnt3a protein (L Wnt3a) was tested for its ability to restore osteogenic potential to aged bone grafts in critical size defect models created in mice and in rabbits. Radiography, microquantitative computed tomography (micro CT) reconstruction, histology, and histomorphometric measurements were used to quantify bone healing resulting from L Wnt3a or a control substance (liposomal phosphate buffered saline solution EL PBS]).
   Results: Expression profiling of cells in a bone graft demonstrated a shift away from an osteogenic gene profile and toward an adipogenic one with age. This age related adipogenic shift was accompanied by a significant reduction (p < 0.05) in Wnt signaling and a loss in osteogenic potential. In both large and small animal models, osteogenic competence was restored to aged bone grafts by a brief incubation with the stem cell factor Wnt3a. In addition, liposomal Wnt3a significantly reduced cell death in the bone graft, resulting in significantly more osseous regenerate in comparison with controls.
   Conclusions: Liposomal Wnt3a enhances cell survival and reestablishes the osteogenic capacity of bone grafts from aged animals.
   Clinical Relevance: We developed an effective, clinically applicable, regenerative medicine based strategy for revitalizing bone grafts from aged patients.
C1 [Leucht, Philipp] Stanford Sch Med, Dept Orthopaed Surg, Stanford, CA 94305 USA.
   Stanford Sch Med, Div Plast & Reconstruct Surg, Dept Surg, Stanford, CA 94305 USA.
C3 Stanford University; Stanford University
RP Leucht, P (通讯作者)，Stanford Sch Med, Dept Orthopaed Surg, Stanford, CA 94305 USA.
RI ; Leucht, Philipp/H 7238 2019; Castillo, Alesha/A 8728 2014; helms,
   jill/ISU 5419 2023; Ureña, Jesús/R 5385 2017; Castillo,
   Alesha/AAC 9961 2019
OI Leucht, Philipp/0000 0002 8409 8513; Cheng, Du/0000 0002 7851 1244;
   Helms, Jill/0000 0002 0463 396X; Castillo, Alesha/0000 0002 1371 7567;
   Jiang, Jie/0000 0001 6619 1936
FU California Institute for Regenerative Medicine (CIRM) [TR1 0219];
   Orthopaedic Research and Education Foundation (OREF) [10 006]; National
   Institutes of Health Ruth L. Kirschstein National Research Service Award
   (NRSA) [5F32AR57648 2]
FX Work was funded by the California Institute for Regenerative Medicine
   (CIRM) TR1 0219. R Leucht received funding from the Orthopaedic Research
   and Education Foundation (OREF) in the form of a Career Development
   Award in Total Joint and Trauma Surgery (OREF grant #10 006). J. Jiang
   was funded by a National Institutes of Health Ruth L. Kirschstein
   National Research Service Award (NRSA) 5F32AR57648 2. D. Cheng and W.
   Cole are California Institute for Regenerative Medicine (CIRM) Bridges
   to Stem Cell Research Certificate Program Scholars (TB1 01190 and
   TB1 01175). Neither the authors' employment at Stanford University nor
   any grants or patents pending played any role in the reporting of the
   study.
CR [Anonymous], 2004, Bone Health and Osteoporosis: A report of the Surgeon General
   Asciutti S, 2011, ONCOGENE, V30, P956, DOI 10.1038/onc.2010.475
   Asumda FZ, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471 2121 12 44
   Bauer TW, 2000, CLIN ORTHOP RELAT R, P10
   BIGELOW CL, 1984, ACTA ANAT, V118, P60
   Bouxsein ML, 1997, J BONE MINER RES, V12, P839, DOI 10.1359/jbmr.1997.12.5.839
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Carragee EJ, 2011, SPINE J, V11, P511, DOI 10.1016/j.spinee.2011.02.013
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   Cawthorn WP, 2012, BONE, V50, P477, DOI 10.1016/j.bone.2011.08.010
   Chan CKF, 2009, NATURE, V457, P490, DOI 10.1038/nature07547
   Christodoulides C, 2006, J CELL SCI, V119, P2613, DOI 10.1242/jcs.02975
   Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001
   Congdon KL, 2008, STEM CELLS, V26, P1202, DOI 10.1634/stemcells.2007 0768
   Cooper GM, 2010, PLAST RECONSTR SURG, V125, P1685, DOI 10.1097/PRS.0b013e3181cb63a3
   de Barros APDN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009093
   Dhamdhere GR, 2012, DRUGGING STEM UNPUB
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Duran Struuck R, 2009, J AM ASSOC LAB ANIM, V48, P11
   Eve FS, 1891, BMJ BRIT MED J, V5, P1194
   Glassman SD, 2011, SPINE J, V11, P522, DOI 10.1016/j.spinee.2010.05.016
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Greenwald AS, 2010, ORTHOPEDICS, V33, P626, DOI 10.3928/01477447 20100722 01
   Gregory CA, 2005, ANN NY ACAD SCI, V1049, P97, DOI 10.1196/annals.1334.010
   Hall MP, 2009, J AM ACAD ORTHOP SUR, V17, P602, DOI 10.5435/00124635 200910000 00002
   Ho AD, 2005, EMBO REP, V6, pS35, DOI 10.1038/sj.embor.7400436
   Ikawa T, 2010, SCIENCE, V329, P93, DOI 10.1126/science.1188995
   Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172 1183.2002
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894
   KIEFER F, 1991, BLOOD, V78, P2577
   Kirkland JL, 2002, EXP GERONTOL, V37, P757, DOI 10.1016/S0531 5565(02)00014 1
   Laudes M, 2011, J MOL ENDOCRINOL, V46, pR65, DOI 10.1530/JME 10 0169
   Lee SY, 2008, J ORTHOP RES, V26, P190, DOI 10.1002/jor.20412
   Leucht P, 2008, SEMIN CELL DEV BIOL, V19, P434, DOI 10.1016/j.semcdb.2008.09.002
   Li HX, 2008, MOL CELL ENDOCRINOL, V291, P116, DOI 10.1016/j.mce.2008.05.005
   LONG MW, 1990, J CLIN INVEST, V86, P1387, DOI 10.1172/JCI114852
   Longo KA, 2004, J BIOL CHEM, V279, P35503, DOI 10.1074/jbc.M402937200
   Lu CY, 2005, J ORTHOP RES, V23, P1300, DOI 10.1016/j.orthres.2005.04.003
   Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184 1193.2002
   Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108
   MEUNIER P, 1971, CLIN ORTHOP RELAT R, P147, DOI 10.1097/00003086 197110000 00021
   Minear S, 2010, J BONE MINER RES, V25, P1196, DOI 10.1002/jbmr.29
   Minear S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000231
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542
   Morrell NT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002930
   Muschler GE, 2004, J BONE JOINT SURG AM, V86A, P1541, DOI 10.2106/00004623 200407000 00029
   Neri M, 2011, STEM CELLS, V29, P1559, DOI 10.1002/stem.701
   Nishida S, 1999, J BONE MINER METAB, V17, P171, DOI 10.1007/s007740050081
   Nishikawa K, 2010, J CLIN INVEST, V120, P3455, DOI 10.1172/JCI42528
   Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014 5793(97)00313 X
   Oreffo Richard O C, 2004, Curr Opin Investig Drugs, V5, P419
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100
   Qiu WM, 2007, J BONE MINER RES, V22, P1720, DOI 10.1359/JBMR.070721
   Reinwald S, 2008, J BONE MINER RES, V23, P1353, DOI 10.1359/JBMR.080516
   Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101
   Rosen CJ, 2009, CRIT REV EUKAR GENE, V19, P109, DOI 10.1615/CritRevEukarGeneExpr.v19.i2.20
   Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950
   SCHMITZ JP, 1986, CLIN ORTHOP RELAT R, P299, DOI 10.1097/00003086 198604000 00036
   Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221
   Staal FJT, 2008, NAT REV IMMUNOL, V8, P581, DOI 10.1038/nri2360
   Suda T, 2008, CELL, V132, P729, DOI 10.1016/j.cell.2008.02.017
   Suire C, 2012, BLOOD, V119, pE86, DOI 10.1182/blood 2011 08 372334
   Syed Farhan A, 2010, Curr Osteoporos Rep, V8, P235, DOI 10.1007/s11914 010 0035 y
   Taichman RS, 2005, BLOOD, V105, P2631, DOI 10.1182/blood 2004 06 2480
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Takada R, 2006, DEV CELL, V11, P791, DOI 10.1016/j.devcel.2006.10.003
   Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117
   TANAKA Y, 1976, J GERONTOL, V31, P527, DOI 10.1093/geronj/31.5.527
   Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Trowbridge JJ, 2010, STEM CELLS, V28, P1379, DOI 10.1002/stem.457
   Trudel G, 2009, J APPL PHYSIOL, V107, P540, DOI 10.1152/japplphysiol.91530.2008
   Verma S, 2002, J CLIN PATHOL, V55, P693, DOI 10.1136/jcp.55.9.693
   Vescio RA, 2004, CURR CLIN O, P37
   Whitfield ML, 2006, NAT REV CANCER, V6, P99, DOI 10.1038/nrc1802
   Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611
   Yamamoto M, 2006, TISSUE ENG, V12, P1305, DOI 10.1089/ten.2006.12.1305
   Yin T, 2006, J CLIN INVEST, V116, P1195, DOI 10.1172/JCI28568
   Zhao L, 2009, METHOD ENZYMOL, V465, P331, DOI 10.1016/S0076 6879(09)65017 5
   Zhou S, 2008, AGING CELL, V7, P335, DOI 10.1111/j.1474 9726.2008.00377.x
   Zhu M, 2009, J TISSUE ENG REGEN M, V3, P290, DOI 10.1002/term.165
NR 85
TC 49
Z9 57
U1 0
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0021 9355
EI 1535 1386
J9 J BONE JOINT SURG AM
JI J. Bone Joint Surg. Am. Vol.
PD JUL 17
PY 2013
VL 95A
IS 14
BP 1278
EP 1288
DI 10.2106/JBJS.L01502
PG 11
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA 184JD
UT WOS:000321885000005
PM 23864176
DA 2025 08 17
ER

PT J
AU Siddiqi, MH
   Siddiqi, MZ
   Ahn, S
   Kim, YJ
   Yang, DC
AF Siddiqi, Muhammad Hanif
   Siddiqi, Muhammad Zubair
   Ahn, Sungeun
   Kim, Yeon Ju
   Yang, Deok Chun
TI Ginsenoside Rh1 induces mouse osteoblast growth and differentiation
   through the bone morphogenetic protein 2/runt related gene 2 signalling
   pathway
SO JOURNAL OF PHARMACY AND PHARMACOLOGY
LA English
DT Article
DE bone morphogenetic protein; runt related gene 2; differentiation;
   ginsenosides; MC3T3 E1 cells; osteoblast; Panax ginseng
ID OXIDATIVE STRESS; PANAX NOTOGINSENG; CELLS; MARROW; METABOLISM;
   EXPRESSION; RATS; PATHOPHYSIOLOGY; BIOAVAILABILITY; MINERALIZATION
AB ObjectivesThis study aimed to investigate the stimulative and pharmacological effects of ginsenoside Rh1 (hereinafter referred to as: Rh1) on differentiation and mineralization of osteoblast and its possible mechanism of action on the expression of bone morphogenetic protein 2 (BMP 2)/Runt related gene 2 (Runx2) signalling pathways using mouse preosteoblastic MC3T3 E1 cell line as in vitro model.
   MethodsAn in vitro stimulative activity of Rh1 was assessed by analyzing alkaline phosphatase activity (ALP), type I collagen (Coll I) synthesis, mineralization and glutathione content. Its antioxidant activity was measured by evaluating the reactive oxygen species (ROS) production in the presence of antimycin A (AMA), one of the mitochondrial dysfunction factors. The level of BMP 2/Runx2 signal regulated osteoblast specific proteins such as osteocalcin (OCN), Coll I and ALP were detected using Western blot analysis.
   Key findingsRh1 was capable to stimulate cell growth, ALP activity, Coll I synthesis, mineralization and glutathione content in the MC3T3 E1 cells. BMP 2 and Runx2 expression were also increased by Rh1 concentration dependently. Additionally, Rh1 also showed inhibitory action on the level of ROS production enhanced by AMA in MC3T3 E1 cells. Rh1 could increase the expression level of BMP 2/Runx2 signal regulated osteogenic markers such as ALP, Coll I and OCN.
   ConclusionsRh1, a protopanaxatriol type's active ingredients of Panax ginsengMeyer, possesses osteoblast differentiation, osteogenic stimulatory and anti oxidative activity.
C1 Kyung Hee Univ, Ginseng Genet Resource Bank, Grad Sch Biotechnol, Giheunggu Yonginsi 449701, Gyeonggido, South Korea.
   [Yang, Deok Chun] Kyung Hee Univ, Coll Life Sci, Giheunggu Yonginsi 449701, Gyeonggido, South Korea.
C3 Kyung Hee University; Kyung Hee University
RP Yang, DC (通讯作者)，Kyung Hee Univ, Ginseng Bank, Grad Sch Biotechnol, Giheunggu Yonginsi 449701, Gyeonggido, South Korea.
EM dcyang@khu.ac.kr
FU Korea Institute of Planning & Evaluation for Technology in Food,
   Agriculture, Forestry & Fisheries (KIPET) [309019 03 3 SB010]
FX The research funding was fully supported by the Korea Institute of
   Planning & Evaluation for Technology in Food, Agriculture, Forestry &
   Fisheries (KIPET 309019 03 3 SB010).
CR Abdallah BM, 2006, BONE, V39, P181, DOI 10.1016/j.bone.2005.12.082
   Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073
   Basu S, 2001, BIOCHEM BIOPH RES CO, V288, P275, DOI 10.1006/bbrc.2001.5747
   BOLANDER ME, 1992, P SOC EXP BIOL MED, V200, P165
   Cai ZW, 2003, ANAL CHIM ACTA, V492, P283, DOI 10.1016/S0003 2670(03)00719 0
   Cheung WMW, 2006, FEBS LETT, V580, P121, DOI 10.1016/j.febslet.2005.11.062
   Chiarugi P, 2004, ONCOGENE, V23, P3905, DOI 10.1038/sj.onc.1207508
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Garrett IR, 2007, CURR TOP DEV BIOL, V78, P127, DOI 10.1016/S0070 2153(06)78004 8
   Gu Y, 2009, FOOD CHEM TOXICOL, V47, P2257, DOI 10.1016/j.fct.2009.06.013
   Isomura H, 2004, TOXICOLOGY, V197, P93, DOI 10.1016/j.tox.2003.12.006
   Jiang SY, 2010, CELL PROLIFERAT, V43, P464, DOI 10.1111/j.1365 2184.2010.00696.x
   Jung JS, 2010, BIOCHEM BIOPH RES CO, V397, P323, DOI 10.1016/j.bbrc.2010.05.117
   Kang JK, 2002, REPROD TOXICOL, V16, P291, DOI 10.1016/S0890 6238(02)00021 7
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kim DY, 2012, FITOTERAPIA, V83, P215, DOI 10.1016/j.fitote.2011.10.017
   Kim DY, 2011, INT J MOL MED, V28, P753, DOI 10.3892/ijmm.2011.750
   Kim KW, 2008, J ETHNOPHARMACOL, V115, P42, DOI 10.1016/j.jep.2007.09.003
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kwak EJ, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/829650
   Lean JM, 2003, J CLIN INVEST, V112, P915, DOI 10.1172/JCI200318859
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Lee Y, 2003, J STEROID BIOCHEM, V84, P463, DOI 10.1016/S0960 0760(03)00067 0
   Lee YN, 1996, EUR J CANCER, V32A, P1420, DOI 10.1016/0959 8049(96)00102 5
   Li XY, 2007, BIOL PHARM BULL, V30, P847, DOI 10.1248/bpb.30.847
   Li XD, 2010, CELL PHYSIOL BIOCHEM, V26, P1081, DOI 10.1159/000323986
   Liu HF, 2009, DRUG METAB DISPOS, V37, P2290, DOI 10.1124/dmd.109.029819
   Maggio D, 2003, J CLIN ENDOCR METAB, V88, P1523, DOI 10.1210/jc.2002 021496
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119
   Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891 5849(01)00610 4
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Ning J, 2000, TOXICOL IN VITRO, V14, P329, DOI 10.1016/S0887 2333(00)00024 2
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   PARFITT AM, 1987, CLIN OBSTET GYNECOL, V30, P789, DOI 10.1097/00003081 198712000 00004
   Park EK, 2004, INT ARCH ALLERGY IMM, V133, P113, DOI 10.1159/000076383
   Prince M, 2001, J CELL BIOCHEM, V80, P424, DOI 10.1002/1097 4644(20010301)80:3<424::AID JCB160>3.0.CO;2 6
   RODAN GA, 1992, BONE, V13, pS3, DOI 10.1016/S8756 3282(09)80003 3
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698
   Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308
   SAMPATH TK, 1992, J BIOL CHEM, V267, P20352
   Tawab MA, 2003, DRUG METAB DISPOS, V31, P1065, DOI 10.1124/dmd.31.8.1065
   TIETZ NW, 1983, CLIN CHEM, V29, P751
   Tullberg Reinert H, 1999, HISTOCHEM CELL BIOL, V112, P271, DOI 10.1007/s004180050447
   Wang W, 2007, CANCER CHEMOTH PHARM, V59, P589, DOI 10.1007/s00280 006 0300 z
   Wang Y, 2000, ACTA PHARMACOL SIN, V21, P792
   Wang YZ, 2009, J PHARMACOL SCI, V109, P504, DOI 10.1254/jphs.08060FP
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Xu QF, 2003, J ETHNOPHARMACOL, V84, P187, DOI 10.1016/S0378 8741(02)00317 3
   YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681
   Yamaguchi A, 1996, BIOCHEM BIOPH RES CO, V220, P366, DOI 10.1006/bbrc.1996.0411
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
NR 55
TC 26
Z9 29
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3573
EI 2042 7158
J9 J PHARM PHARMACOL
JI J. Pharm. Pharmacol.
PD DEC
PY 2014
VL 66
IS 12
BP 1763
EP 1773
DI 10.1111/jphp.12306
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AU0KY
UT WOS:000345312800011
PM 25154440
OA Bronze
DA 2025 08 17
ER

PT J
AU Chen, CY
   Ke, CJ
   Yen, KC
   Hsieh, HC
   Sun, JS
   Lin, FH
AF Chen, Ching Yun
   Ke, Cherng Jyh
   Yen, Ko Chung
   Hsieh, Hui Chen
   Sun, Jui Sheng
   Lin, Feng Huei
TI 3D Porous Calcium Alginate Scaffolds Cell Culture System Improved Human
   Osteoblast Cell Clusters for Cell Therapy
SO THERANOSTICS
LA English
DT Article
DE Three dimensional culture; Preformed scaffolds; Bone like tissues;
   Perfusion; Auto grafts
ID MESENCHYMAL STEM CELLS; MARROW STROMAL CELLS; BONE; DIFFERENTIATION;
   RELEASE; PROLIFERATION; ENCAPSULATION; BIOREACTOR; HYDROGELS; PASSAGE
AB Age related orthopedic disorders and bone defects have become a critical public health issue, and cell based therapy is potentially a novel solution for issues surrounding bone tissue engineering and regenerative medicine. Long term cultures of primary bone cells exhibit phenotypic and functional degeneration; therefore, culturing cells or tissues suitable for clinical use remain a challenge. A platform consisting of human osteoblasts (hOBs), calcium alginate (Ca Alginate) scaffolds, and a self made bioreactor system was established for autologous transplantation of human osteoblast cell clusters. The Ca Alginate scaffold facilitated the growth and differentiation of human bone cell clusters, and the functionally closed process bioreactor system supplied the soluble nutrients and osteogenic signals required to maintain the cell viability. This system preserved the proliferative ability of cells and cell viability and up regulated bone related gene expression and biological apatite crystals formation. The bone like tissue generated could be extracted by removal of calcium ions via ethylenediaminetetraacetic acid (EDTA) chelation, and exhibited a size suitable for injection. The described strategy could be used in therapeutic application and opens new avenues for surgical interventions to correct skeletal defects.
C1 [Chen, Ching Yun; Yen, Ko Chung; Hsieh, Hui Chen; Lin, Feng Huei] Natl Taiwan Univ, Coll Med, Inst Biomed Engn, Taipei 10764, Taiwan.
   [Chen, Ching Yun; Yen, Ko Chung; Hsieh, Hui Chen; Lin, Feng Huei] Natl Taiwan Univ, Coll Engn, Taipei 10764, Taiwan.
   [Ke, Cherng Jyh] China Med Univ Hosp, Biomat Translat Res Ctr, Taichung, Taiwan.
   [Ke, Cherng Jyh; Sun, Jui Sheng] Natl Chiao Tung Univ, Translat Res Ctr, Dept Biomed Elect, Hsinchu, Taiwan.
   [Ke, Cherng Jyh; Sun, Jui Sheng] Natl Chiao Tung Univ, Biomimet Syst Res Ctr, Hsinchu, Taiwan.
   [Sun, Jui Sheng] Natl Taiwan Univ, Coll Med, Dept Orthoped, Taipei 10764, Taiwan.
   [Sun, Jui Sheng] Natl Taiwan Univ Hosp, Dept Orthoped Surg, Taipei, Taiwan.
   [Sun, Jui Sheng] Natl Taiwan Univ Hosp, Hsin Chu Branch, Dept Orthoped Surg, Hsinchu, Taiwan.
   [Lin, Feng Huei] Natl Hlth Res Inst, Inst Biomed Engn & Nanomed I BEN, Miaoli, Taiwan.
C3 National Taiwan University; National Taiwan University; China Medical
   University Taiwan; China Medical University Hospital   Taiwan; National
   Yang Ming Chiao Tung University; National Yang Ming Chiao Tung
   University; National Taiwan University; National Taiwan University;
   National Taiwan University Hospital; National Taiwan University;
   National Taiwan University Hospital; National Health Research Institutes
     Taiwan
RP Lin, FH (通讯作者)，Natl Taiwan Univ, Inst Biomed Engn, Taipei 10764, Taiwan.
EM double@ntu.edu.tw; drjs sun@gmail.com
RI ; SUN, Jus Sheng/ITU 1253 2023
OI Chen, Ching Yun/0000 0001 5218 5121; SUN, JUI SHENG/0000 0001 5142 8777
FU Ministry of Science and Technology, Taiwan, Republic of China [NSC
   100 2221 E 002 140]; Internal Ethical Committee of National Taiwan
   University Hospital, Taiwan (IRB) [201012057RB]
FX We thank Mr. Yu Tung Chen for schematic drawing. Also the authors
   acknowledge the staff of First Core Lab (Collage of Medicine, NTU) and
   many colleagues of the Second Core Lab (Department of Medical Research,
   NTUH) for technical support and helpful discussions. This work was
   supported by a grant from the Ministry of Science and Technology (NSC
   100 2221 E 002 140), Taiwan, Republic of China. The procedure in this
   study has been approved by the Internal Ethical Committee of National
   Taiwan University Hospital, Taiwan (IRB No. 201012057RB).
CR Awad HA, 2004, BIOMATERIALS, V25, P3211, DOI 10.1016/j.biomaterials.2003.10.045
   Brooks PM, 2006, CLIN RHEUMATOL, V25, P778, DOI 10.1007/s10067 006 0240 3
   Davey RB, 2000, BURNS, V26, P393, DOI 10.1016/S0305 4179(99)00140 0
   Draget K. I., 2005, Polysaccharides and polyamides in the food industry: properties, production, and patents, P1
   Frith JE, 2010, TISSUE ENG PART C ME, V16, P735, DOI [10.1089/ten.tec.2009.0432, 10.1089/ten.TEC.2009.0432]
   Glowacki J, 1998, CELL TRANSPLANT, V7, P319, DOI 10.1016/S0963 6897(98)00003 7
   Grellier M, 2009, BIOMATERIALS, V30, P3271, DOI 10.1016/j.biomaterials.2009.02.033
   Griffith LG, 2002, SCIENCE, V295, P1009, DOI 10.1126/science.1069210
   HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014 4827(65)90211 9
   Higuchi A, 2011, CHEM REV, V111, P3021, DOI 10.1021/cr1003612
   Huey DJ, 2012, SCIENCE, V338, P917, DOI 10.1126/science.1222454
   Hunt NC, 2010, ACTA BIOMATER, V6, P3649, DOI 10.1016/j.actbio.2010.03.026
   Hwang YS, 2009, BIOMATERIALS, V30, P499, DOI 10.1016/j.biomaterials.2008.07.028
   Ikeda E, 2009, P NATL ACAD SCI USA, V106, P13475, DOI 10.1073/pnas.0902944106
   Karageorgiou V, 2005, BIOMATERIALS, V26, P5474, DOI 10.1016/j.biomaterials.2005.02.002
   Khoo MLM, 2008, STEM CELLS DEV, V17, P883, DOI 10.1089/scd.2007.0185
   Kim K., 2005, TOP TISSUE ENG, V2, P1
   Kuo CK, 2001, BIOMATERIALS, V22, P511, DOI 10.1016/S0142 9612(00)00201 5
   LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529
   Lee CSD, 2010, BIOMATERIALS, V31, P4926, DOI 10.1016/j.biomaterials.2010.03.001
   Lee KY, 2012, PROG POLYM SCI, V37, P106, DOI 10.1016/j.progpolymsci.2011.06.003
   Leslie SK, 2013, BIOMATERIALS, V34, P8172, DOI 10.1016/j.biomaterials.2013.07.017
   Li JN, 2010, BIOMATERIALS, V31, P5782, DOI 10.1016/j.biomaterials.2010.04.023
   Liechty KW, 2000, NAT MED, V6, P1282, DOI 10.1038/81395
   Lin YJ, 2009, J BIOMED MATER RES A, V88A, P23, DOI 10.1002/jbm.a.31841
   Luckanagul J, 2012, BIOMACROMOLECULES, V13, P3949, DOI 10.1021/bm301180c
   Lund AW, 2009, TISSUE ENG PART B RE, V15, P371, DOI [10.1089/ten.teb.2009.0270, 10.1089/ten.TEB.2009.0270]
   Ma HL, 2005, J BIOMED MATER RES A, V74A, P439, DOI 10.1002/jbm.a.30314
   Majore I, 2011, STEM CELL REV REP, V7, P17, DOI 10.1007/s12015 010 9165 y
   Manolagas SC, 2013, J GERONTOL A BIOL, V68, P1195, DOI 10.1093/gerona/glt125
   Miron RJ, 2013, CLIN IMPLANT DENT R, V15, P481, DOI 10.1111/j.1708 8208.2012.00440.x
   Pawar SN, 2012, BIOMATERIALS, V33, P3279, DOI 10.1016/j.biomaterials.2012.01.007
   Pradel W, 2008, J PHYSIOL PHARMACOL, V59, P47
   Purnell B, 2008, SCIENCE, V322, P1489, DOI 10.1126/science.322.5907.1489
   Ratcliffe A, 2002, ANN NY ACAD SCI, V961, P210, DOI 10.1111/j.1749 6632.2002.tb03087.x
   Rauh J, 2011, TISSUE ENG PART B RE, V17, P263, DOI [10.1089/ten.teb.2010.0612, 10.1089/ten.TEB.2010.0612]
   Reichert JC, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003720
   Rowley JA, 1999, BIOMATERIALS, V20, P45, DOI 10.1016/S0142 9612(98)00107 0
   Schubert T, 2013, BIOMATERIALS, V34, P4428, DOI 10.1016/j.biomaterials.2013.02.053
   Shapiro L, 1997, BIOMATERIALS, V18, P583, DOI 10.1016/S0142 9612(96)00181 0
   Shull KR, 2012, NATURE, V489, P36, DOI 10.1038/489036a
   Sun JY, 2012, NATURE, V489, P133, DOI 10.1038/nature11409
   Sun JS, 2009, CLIN ORTHOP RELAT R, V467, P3156, DOI 10.1007/s11999 009 0864 0
   Walgenbach KJ, 2001, ANAT REC, V263, P372, DOI 10.1002/ar.1117
   Wang WJ, 2009, BIOMATERIALS, V30, P2705, DOI 10.1016/j.biomaterials.2009.01.030
   Yang Kisuk, 2012, Int J Stem Cells, V5, P1
   Zhang YB, 2011, J SURG RES, V169, pE37, DOI 10.1016/j.jss.2011.02.033
NR 47
TC 84
Z9 90
U1 0
U2 43
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838 7640
J9 THERANOSTICS
JI Theranostics
PY 2015
VL 5
IS 6
BP 643
EP 655
DI 10.7150/thno.11372
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA CG1VU
UT WOS:000353064200008
PM 25825603
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Wanachewin, O
   Boonmaleerat, K
   Pothacharoen, P
   Reutrakul, V
   Kongtawelert, P
AF Wanachewin, Orawan
   Boonmaleerat, Kanchanit
   Pothacharoen, Peraphan
   Reutrakul, Vichai
   Kongtawelert, Prachya
TI Sesamin stimulates osteoblast differentiation through p38 and ERK1/2
   MAPK signaling pathways
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID BONE MORPHOGENETIC PROTEINS; GENE EXPRESSION; OSTEOGENIC
   DIFFERENTIATION; CELL PROLIFERATION; STEM CELLS; GROWTH; BMP 2;
   MINERALIZATION; ACTIVATION; ASSAY
AB Background: Osteoporosis is a worldwide health problem predominantly affecting post menopausal women. Therapies aimed at increasing bone mass in osteoporetic patients lag behind comparable investigation of therapeutic strategies focusing on the bone resorption process. Sesamin, a major lignan compound found in Sesamun indicum Linn., has a variety of pharmacological effects, though its activity on bone cell function is unclear. Herein we examine the effect of this lignan on osteoblast differentiation and function.
   Method: Cell cytotoxicity and proliferative in hFOB1.19 were examined by MTT and alamar blue assay up to 96 h of treatment. Gene expression of COL1, ALP, BMP 2, Runx2, OC, RANKL and OPG were detected after 24 h of sesamin treatment. ALP activity was measured at day 7, 14 and 21 of cultured. For mineralized assay, ADSCs were cultured in the presence of osteogenic media supplement with or without sesamin for 21 days and then stained with Alizarin Red S. MAPK signaling pathway activation was observed by using western blotting.
   Results: Sesamin promoted the gene expression of COL1, ALP, OCN, BMP 2 and Runx2 in hFOB1.19. On the other hand, sesamin was able to up regulate OPG and down regulate RANKL gene expression. ALP activity also significantly increased after sesamin treatment. Interestingly, sesamin induced formation of mineralized nodules in adipose derived stem cells (ADSCs) as observed by Alizarin Red S staining; this implies that sesamin has anabolic effects both on progenitor and committed cell stages of osteoblasts. Western blotting data showed that sesamin activated phosphorylation of p38 and ERK1/2 in hFOB1.19.
   Conclusions: The data suggest that sesamin has the ability to trigger osteoblast differentiation by activation of the p38 and ERK MAPK signaling pathway and possibly indirectly regulate osteoclast development via the expression of OPG and RANKL in osteoblasts. Therefore, sesamin may be a promising phytochemical that could be developed for supplementation of osteoporotic therapy.
C1 [Wanachewin, Orawan; Boonmaleerat, Kanchanit; Pothacharoen, Peraphan; Kongtawelert, Prachya] Chiang Mai Univ, Fac Med, Dept Biochem, Thailand Excellence Ctr Tissue Engn & Stem Cells, Chiang Mai 50200, Thailand.
   [Reutrakul, Vichai] Mahidol Univ, Fac Sci, Dept Chem, Ctr Innovat Chem, Bangkok 10400, Thailand.
C3 Chiang Mai University; Mahidol University
RP Kongtawelert, P (通讯作者)，Chiang Mai Univ, Fac Med, Dept Biochem, Thailand Excellence Ctr Tissue Engn & Stem Cells, Chiang Mai 50200, Thailand.
EM prachya.kongtawelert@gmail.com
RI ; Pothacharoen, Peraphan/GZG 6521 2022
OI kongtawelert, prachya/0000 0002 5963 2796; Pothacharoen,
   Peraphan/0000 0002 8560 553X
FU program Strategic Scholarship for Frontier Research Network for the
   Ph.D. Program Thai Doctoral degree; Office of the Higher Education
   Commission; Graduate School of Chiang Mai University; Center for
   Innovation in Chemistry (PERCH CIC); Commission on Higher Education;
   Center of Excellence Grant of Chiang Mai University
FX This research was supported by grant under the program Strategic
   Scholarship for Frontier Research Network for the Ph.D. Program Thai
   Doctoral degree, the Office of the Higher Education Commission and the
   Graduate School of Chiang Mai University (to OW), Center for Innovation
   in Chemistry (PERCH CIC), Commission on Higher Education (to KB), and
   Center of Excellence Grant of Chiang Mai University (to PK).
CR Balcerzak M, 2003, ACTA BIOCHIM POL, V50, P1019
   Bekker PJ, 2001, J BONE MINER RES, V16, P348, DOI 10.1359/jbmr.2001.16.2.348
   Boulbaroud S, 2008, Pak J Biol Sci, V11, P1696, DOI 10.3923/pjbs.2008.1696.1701
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Celil AB, 2005, J BIOL CHEM, V280, P31353, DOI 10.1074/jbc.M503845200
   Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000
   Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756 3282(01)00415 X
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Gimble JM, 2007, CIRC RES, V100, P1249, DOI 10.1161/01.RES.0000265074.83288.09
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Jeng K., 2005, Curr Enzym Inhib, V1, P11, DOI [10.2174/1573408052952748, DOI 10.2174/1573408052952748]
   JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955 0674(94)90141 4
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Lecoeur L, 1997, BIOMATERIALS, V18, P989, DOI 10.1016/S0142 9612(97)00025 2
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lou J, 2000, BIOCHEM BIOPH RES CO, V268, P757, DOI 10.1006/bbrc.2000.2210
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Nakashima K, 2003, TRENDS GENET, V19, P458, DOI 10.1016/S0168 9525(03)00176 8
   Nöth U, 2003, EXP CELL RES, V291, P201, DOI 10.1016/S0014 4827(03)00386 0
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Reid IR, 2008, SEMIN CELL DEV BIOL, V19, P473, DOI 10.1016/j.semcdb.2008.08.002
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Schindeler A, 2006, J BONE MINER RES, V21, P1331, DOI 10.1359/JBMR.060603
   SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337
   Setzer B, 2009, BIOMATERIALS, V30, P979, DOI 10.1016/j.biomaterials.2008.10.054
   Sims NA, 2008, SEMIN CELL DEV BIOL, V19, P444, DOI 10.1016/j.semcdb.2008.07.016
   Singhatanadgit W, 2008, CELL BIOL INT, V32, P1362, DOI 10.1016/j.cellbi.2008.08.005
   Strem Brian M., 2005, Keio Journal of Medicine, V54, P132, DOI 10.2302/kjm.54.132
   Termaat MF, 2005, J BONE JOINT SURG AM, V87A, P1367, DOI 10.2106/JBJS.D.02585
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   Zhang W, 2002, CELL RES, V12, P9, DOI 10.1038/sj.cr.7290105
NR 39
TC 64
Z9 71
U1 0
U2 25
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1472 6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD MAY 30
PY 2012
VL 12
AR 71
DI 10.1186/1472 6882 12 71
PG 9
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA 031MW
UT WOS:000310646900001
PM 22646286
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Leightner, AC
   Meyers, CMG
   Evans, MD
   Mansky, KC
   Gopalakrishnan, R
   Jensen, ED
AF Leightner, Amanda C.
   Meyers, Carina Mello Guimaraes
   Evans, Michael D.
   Mansky, Kim C.
   Gopalakrishnan, Rajaram
   Jensen, Eric D.
TI Regulation of Osteoclast Differentiation at Multiple Stages by Protein
   Kinase D Family Kinases
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE osteoclasts; protein kinase D; cellular differentiation; actin
   cytoskeleton; bone resorption
ID ACTIVATION LOOP SER(744); NF KAPPA B; G(Q) COUPLED RECEPTORS;
   PROSTATE CANCER; NUCLEAR EXPORT; IN VITRO; BONE; PHOSPHORYLATION; PKD;
   JNK
AB Balanced osteoclast and osteoblast activity is necessary for skeletal health, whereas unbalanced osteoclast activity causes bone loss in many skeletal conditions. A better understanding of pathways that regulate osteoclast differentiation and activity is necessary for the development of new therapies to better manage bone resorption. The roles of Protein Kinase D (PKD) family of serine/threonine kinases in osteoclasts have not been well characterized. In this study we use immunofluorescence analysis to reveal that PKD2 and PKD3, the isoforms expressed in osteoclasts, are found in the nucleus and cytoplasm, the mitotic spindle and midbody, and in association with the actin belt. We show that PKD inhibitors CRT0066101 and CID755673 inhibit several distinct aspects of osteoclast formation. Treating bone marrow macrophages with lower doses of the PKD inhibitors had little effect on M CSF + RANKL dependent induction into committed osteoclast precursors, but inhibited their motility and subsequent differentiation into multinucleated mature osteoclasts, whereas higher doses of the PKD inhibitors induced apoptosis of the preosteoclasts. Treating post fusion multinucleated osteoclasts with the inhibitors disrupted the osteoclast actin belts and impaired their resorptive activity. In conclusion, these data implicate PKD kinases as positive regulators of osteoclasts, which are essential for multiple distinct processes throughout their formation and function.
C1 [Leightner, Amanda C.; Meyers, Carina Mello Guimaraes; Gopalakrishnan, Rajaram; Jensen, Eric D.] Univ Minnesota, Dept Diagnost & Biol Sci, Sch Dent, Minneapolis, MN 55455 USA.
   [Evans, Michael D.] Univ Minnesota, Clin & Translat Sci Inst, Minneapolis, MN 55455 USA.
   [Mansky, Kim C.] Univ Minnesota, Dept Dev & Surg Sci, Sch Dent, Minneapolis, MN 55455 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities
RP Jensen, ED (通讯作者)，Univ Minnesota, Dept Diagnost & Biol Sci, Sch Dent, Minneapolis, MN 55455 USA.
EM leightner.amanda@gmail.com; carinamgs@yahoo.com.br; evan0262@umn.edu;
   kmansky@umn.edu; gopal007@umn.edu; jens0709@umn.edu
RI Mansky, Kim/AAB 3592 2022; Jensen, Eric/HJI 9245 2023
OI Mansky, Kim/0000 0002 2826 5030; Jensen, Eric/0000 0003 0323 9706;
   Evans, Michael/0000 0001 7449 3993; 
FU NCATS NIH HHS [UL1 TR002494] Funding Source: Medline; NIAMS NIH HHS [R01
   AR061352] Funding Source: Medline; NIH HHS [R01AR061352, UL1TR002494,
   T32AR50938 9] Funding Source: Medline
CR Al Rashid M, 2015, ORTHOP CLIN N AM, V46, P577, DOI 10.1016/j.ocl.2015.06.008
   Bastea LI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030459
   Bernhart E, 2013, EXP CELL RES, V319, P2037, DOI 10.1016/j.yexcr.2013.03.029
   Borges S, 2015, MOL CANCER THER, V14, P1306, DOI 10.1158/1535 7163.MCT 14 0945
   Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Brändlin I, 2002, J BIOL CHEM, V277, P6490, DOI 10.1074/jbc.M106083200
   Brown JP, 2017, TOXICOL PATHOL, V45, P859, DOI 10.1177/0192623317737066
   Chu E, 2017, J SURG RES, V209, P191, DOI 10.1016/j.jss.2016.10.014
   Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02 07 0389
   Du C, 2010, CANCER RES, V70, P7810, DOI 10.1158/0008 5472.CAN 09 4481
   Eiseler T, 2012, J BIOL CHEM, V287, P32367, DOI 10.1074/jbc.M112.370999
   Eisenberg Lerner A, 2007, CELL DEATH DIFFER, V14, P1908, DOI 10.1038/sj.cdd.4402212
   Ellwanger K, 2013, IUBMB LIFE, V65, P98, DOI 10.1002/iub.1116
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Ford JJ, 2013, ENDOCRINOLOGY, V154, P4182, DOI 10.1210/en.2013 1376
   Fu Y, 2011, EMBO REP, V12, P785, DOI 10.1038/embor.2011.139
   Fukunaga T, 2014, J BIOL CHEM, V289, P13554, DOI 10.1074/jbc.M114.550731
   Gartrell BA, 2014, EUR UROL, V65, P278, DOI 10.1016/j.eururo.2013.05.015
   Georgess D, 2014, CELL ADHES MIGR, V8, P192, DOI 10.4161/cam.27840
   Hao F, 2017, MOL CANCER RES, V15, P929, DOI 10.1158/1541 7786.MCR 17 0023
   Harikumar KB, 2010, MOL CANCER THER, V9, P1136, DOI 10.1158/1535 7163.MCT 09 1145
   Hassan S, 2009, ONCOGENE, V28, P4386, DOI 10.1038/onc.2009.291
   Hausser A, 2001, FEBS LETT, V492, P39, DOI 10.1016/S0014 5793(01)02219 0
   Hienz SA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/615486
   Jacamo R, 2008, J BIOL CHEM, V283, P12877, DOI 10.1074/jbc.M800442200
   Jensen DD, 2016, J BIOL CHEM, V291, P11285, DOI 10.1074/jbc.M115.710681
   Lemonnier J, 2004, J BIOL CHEM, V279, P259, DOI 10.1074/jbc.M308665200
   Li S, 2017, SCI REP UK, V7, DOI [10.1038/srep40505, 10.1038/srep43956]
   Luxenburg C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000179
   Mansky KC, 2013, J BIOL CHEM, V288, P9826, DOI 10.1074/jbc.M112.444133
   Ni Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073149
   Olayioye MA, 2013, CELL SIGNAL, V25, P1739, DOI 10.1016/j.cellsig.2013.04.010
   Orriss IR, 2012, METHODS MOL BIOL, V816, P103, DOI 10.1007/978 1 61779 415 5_8
   Papazyan R, 2008, EXP CELL RES, V314, P3057, DOI 10.1016/j.yexcr.2008.07.014
   Parra M, 2005, J BIOL CHEM, V280, P13762, DOI 10.1074/jbc.M413396200
   Pereira M, 2018, J CELL SCI, V131, DOI 10.1242/jcs.216267
   Roy A., 2018, MOL CANC RES
   Roy A, 2017, BBA REV CANCER, V1868, P283, DOI 10.1016/j.bbcan.2017.05.008
   Rozengurt E, 2011, PHYSIOLOGY, V26, P23, DOI 10.1152/physiol.00037.2010
   Rykx A, 2003, FEBS LETT, V546, P81, DOI 10.1016/S0014 5793(03)00487 3
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Sinnett Smith J, 2007, J CELL PHYSIOL, V211, P781, DOI 10.1002/jcp.20984
   Sinnett Smith J, 2009, J BIOL CHEM, V284, P13434, DOI 10.1074/jbc.M806554200
   Stetler RA, 2012, J NEUROSCI, V32, P2667, DOI 10.1523/JNEUROSCI.5169 11.2012
   Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614 2626.2004
   Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Takito J, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19040984
   Torres Marquez E, 2010, BIOCHEM BIOPH RES CO, V391, P63, DOI 10.1016/j.bbrc.2009.11.002
   Vallet ME, 2016, J CELL BIOCHEM, V117, P289, DOI 10.1002/jcb.25291
   Vega RB, 2004, MOL CELL BIOL, V24, P8374, DOI 10.1128/MCB.24.19.8374 8385.2004
   Waldron RT, 2012, CELL SIGNAL, V24, P914, DOI 10.1016/j.cellsig.2011.12.014
   Waldron RT, 2003, J BIOL CHEM, V278, P154, DOI 10.1074/jbc.M208075200
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Xing LP, 2014, METHODS MOL BIOL, V1130, P307, DOI 10.1007/978 1 62703 989 5_23
   Yamamoto H, 2010, ONCOGENE, V29, P2036, DOI 10.1038/onc.2009.496
   Yamashita K, 2010, INT IMMUNOPHARMACOL, V10, P277, DOI 10.1016/j.intimp.2009.11.011
   Yuan J, 2008, J CELL BIOCHEM, V103, P648, DOI 10.1002/jcb.21439
   Yuan JZ, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.01014
   Zhang W, 2005, J BIOL CHEM, V280, P19036, DOI 10.1074/jbc.M414674200
NR 62
TC 8
Z9 10
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2020
VL 21
IS 3
AR 1056
DI 10.3390/ijms21031056
PG 20
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA KY4PQ
UT WOS:000522551606042
PM 32033440
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yang, KD
   Wang, XC
   Zhang, C
   Liu, D
   Tao, L
AF Yang, Keda
   Wang, Xiaochuan
   Zhang, Chi
   Liu, Dian
   Tao, Lin
TI Metformin improves HPRT1 targeted purine metabolism and repairs
   NR4A1 mediated autophagic flux by modulating FoxO1 nucleocytoplasmic
   shuttling to treat postmenopausal osteoporosis
SO CELL DEATH & DISEASE
LA English
DT Article
ID PHOSPHORYLATION; ACETYLATION
AB Osteoporosis is a major degenerative metabolic bone disease that threatens the life and health of postmenopausal women. Owing to limitations in detection methods and prevention strategy awareness, the purpose of osteoporosis treatment is more to delay further deterioration rather than to fundamentally correct bone mass. We aimed to clarify the pathogenesis of postmenopausal osteoporosis and optimize treatment plans. Our experiments were based on previous findings that oxidative stress mediates bone metabolism imbalance after oestrogen deficiency. Through energy metabolism targeted metabolomics, we revealed that purine metabolism disorder is the main mechanism involved in inducing oxidative damage in bone tissue, which was verified via the use of machine learning data from human databases. Xanthine and xanthine oxidase were used to treat osteoblasts to construct a purine metabolism disorder model. The activity and differentiation ability of osteoblasts decreased after X/XO treatment. Transcriptomic sequencing indicated that autophagic flux damage was involved in purine metabolism induced oxidative stress in osteoblasts. Additionally, we performed serum metabolomics combined with network pharmacology to determine the pharmacological mechanism of metformin in the treatment of postmenopausal osteoporosis. HPRT1 was the potential target filtered from the hub genes, and FoxO1 signalling was the key pathway mediating the effect of metformin in osteoblasts. We also revealed that SIRT3 mediated deacetylation promoted the nuclear localization of FoxO1 to increase the expression of HPRT1. HPRT1 upregulation promoted purine anabolism and prevented the accumulation of ROS caused by purine catabolism to reverse oxidative damage in osteoblasts. We propose that purine metabolism disorder induced oxidative stress is important for the pathogenesis of postmenopausal osteoporosis. The therapeutic mechanism of metformin should be confirmed through subsequent drug optimization and development studies to improve bone health in postmenopausal women.
C1 [Yang, Keda; Wang, Xiaochuan; Zhang, Chi; Liu, Dian; Tao, Lin] China Med Univ, Hosp 1, Dept Orthoped, Shenyang, Peoples R China.
C3 China Medical University
RP Tao, L (通讯作者)，China Med Univ, Hosp 1, Dept Orthoped, Shenyang, Peoples R China.
EM taolindr@163.com
OI Wang, Xiaochuan/0000 0001 8556 3301
FU National Science Fund for Distinguished Young Scholars [32200943];
   Shenyang Young and middle aged Innovative Talents Project [RC210171];
   China Postdoctoral Science Foundation [2022M723520]
FX Our study was supported by Project funded by the National Science Fund
   for Distinguished Young Scholars (32200943), Shenyang Young and
   middle aged Innovative Talents Project (RC210171), China Postdoctoral
   Science Foundation(2022M723520).
CR Abad Jiménez Z, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9090892
   Amorim R, 2024, BIOCHEM PHARMACOL, V219, DOI 10.1016/j.bcp.2023.115953
   Avgerinou C, 2023, OSTEOPOROSIS INT, V34, P1411, DOI 10.1007/s00198 023 06739 1
   Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788
   Buccellato FR, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10091353
   Cai YT, 2024, OSTEOPOROSIS INT, V35, P1089, DOI 10.1007/s00198 023 07013 0
   Chen LQ, 2020, CELL MOL BIOL LETT, V25, DOI 10.1186/s11658 020 00241 w
   Cheng WK, 2024, AGING CELL, V23, DOI 10.1111/acel.14072
   Gosset A, 2021, BEST PRACT RES CL EN, V35, DOI 10.1016/j.beem.2021.101551
   Guetta V, 1997, CIRCULATION, V96, P2795, DOI 10.1161/01.CIR.96.9.2795
   Kitamura YI, 2005, CELL METAB, V2, P153, DOI 10.1016/j.cmet.2005.08.004
   Lewiecki EM, 2023, J BONE MINER RES, V38, P1404, DOI 10.1002/jbmr.4877
   Li JY, 2022, NUTRIENTS, V14, DOI 10.3390/nu14112206
   Li X, 2022, BONE, V156, DOI 10.1016/j.bone.2021.116306
   Li Y, 2017, PROG LIPID RES, V66, P42, DOI 10.1016/j.plipres.2017.04.002
   Lian WS, 2024, ANTIOXIDANTS BASEL, V13, DOI 10.3390/antiox13040470
   Lin XX, 2024, PHYTOMEDICINE, V129, DOI 10.1016/j.phymed.2024.155559
   Liu F, 2021, REDOX BIOL, V43, DOI 10.1016/j.redox.2021.101963
   Ma MY, 2023, MOLECULES, V28, DOI 10.3390/molecules28186652
   Martin Montalvo A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3192
   Massimo G, 2023, REDOX BIOL, V67, DOI 10.1016/j.redox.2023.102864
   Matsuzaki H, 2005, P NATL ACAD SCI USA, V102, P11278, DOI 10.1073/pnas.0502738102
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Pryor R, 2019, CELL, V178, P1299, DOI 10.1016/j.cell.2019.08.003
   Qiang L, 2010, J BIOL CHEM, V285, P27396, DOI 10.1074/jbc.M110.140228
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Salvio G, 2023, ANTIOXIDANTS BASEL, V12, DOI 10.3390/antiox12101830
   Sarkar J, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 05343 1
   Shih YRV, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax1387
   Song MY, 2016, SCI REP UK, V6, DOI 10.1038/srep30321
   Song PJ, 2023, ANTIOXIDANTS BASEL, V12, DOI 10.3390/antiox12122123
   Tian R, 2022, ZOOL RES, V43, P241, DOI 10.24272/j.issn.2095 8137.2021.420
   Ukon Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102557
   Vinokurov AY, 2023, MOL NEUROBIOL, V60, P3147, DOI 10.1007/s12035 023 03266 2
   Wang YH, 2024, REDOX BIOL, V70, DOI 10.1016/j.redox.2023.103021
   Wei ZH, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12010041
   Yang KD, 2022, BIOMED PHARMACOTHER, V155, DOI 10.1016/j.biopha.2022.113784
   Yang KD, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.829830
   Yang KD, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10751
   Yoshida G, 2022, AUTOPHAGY, V18, P2323, DOI 10.1080/15548627.2021.2017587
   Zhang C, 2023, BIOMED PHARMACOTHER, V163, DOI 10.1016/j.biopha.2023.114834
   Zhang XH, 2002, J BIOL CHEM, V277, P45276, DOI 10.1074/jbc.M208063200
   Zhou QZ, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/7067984
NR 44
TC 5
Z9 5
U1 2
U2 5
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD NOV 6
PY 2024
VL 15
IS 11
AR 795
DI 10.1038/s41419 024 07177 5
PG 30
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA L0W9C
UT WOS:001348023700001
PM 39500875
OA gold
DA 2025 08 17
ER

PT J
AU An, JM
   Shahriar, SMS
   Hwang, YH
   Hwang, SR
   Lee, DY
   Cho, S
   Lee, YK
AF An, Jeong Man
   Shahriar, S. M. Shatil
   Hwang, Yong Hwa
   Hwang, Seung Rim
   Lee, Dong Yun
   Cho, Sungpil
   Lee, Yong kyu
TI Oral Delivery of Parathyroid Hormone Using a Triple Padlock Nanocarrier
   for Osteoporosis via an Enterohepatic Circulation Pathway
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE oral delivery; osteoporosis; parathyroid hormone; nanoparticle;
   enterohepatic recycling pathway
ID OSTEOBLAST DIFFERENTIATION; CHONDROITIN SULFATE; BILE ACID; INHIBITION;
   BONE; MAPK
AB Intermittent subcutaneous (S.C.) injection of teriparatide [PTH (1 34)] is one of the effective therapies to cure osteoporosis. However, a long term repeated administration of teriparatide by S.C. to the patients is highly challenging. Herein, a triple padlock nanocarrier prepared by a taurocholic acid conjugated chondroitin sulfate A (TCSA) is designed to develop an oral dosage form of recombinant human teriparatide (rhPTH). Oral administration of TCSA/rhPTH to the bilateral ovariectomized (OVX) rats resulted in the recovery of the bone marrow density and healthy serum bone parameters from the severe osteoporotic conditions. Also, it enhanced new bone formation in the osteoporotic tibias. This triple padlock oral delivery platform overcame the current barriers associated with teriparatide administration and exhibited a promising therapeutic effect against osteoporosis.
C1 [An, Jeong Man; Shahriar, S. M. Shatil; Lee, Yong kyu] Korea Natl Univ Transportat, Dept Chem & Biol Engn, Chungju 27469, South Korea.
   [An, Jeong Man] Hanyang Univ, Coll Engn, Dept Bioengn, Seoul 04763, South Korea.
   [Hwang, Yong Hwa; Lee, Yong kyu] KB Biomed Inc, Chungju 27469, South Korea.
   [Hwang, Seung Rim] Chosun Univ, Coll Pharm, Gwangju 61452, South Korea.
   [Lee, Dong Yun] Hanyang Univ, BK21 PLUS Future Biopharmaceut Human Resources Tr, Inst Nano Sci & Technol INST, Dept Bioengn,Coll Engn, Seoul 04763, South Korea.
   [Lee, Dong Yun] Hanyang Univ, Inst Nano Sci & Technol INST, Seoul 04763, South Korea.
   [Cho, Sungpil; Lee, Yong kyu] Korea Natl Univ Transportat, 4D Biomat Ctr, Chungju 27909, South Korea.
C3 Korea National University of Transportation; Hanyang University; Chosun
   University; Hanyang University; Hanyang University; Korea National
   University of Transportation
RP Lee, YK (通讯作者)，Korea Natl Univ Transportat, Dept Chem & Biol Engn, Chungju 27469, South Korea.; Lee, YK (通讯作者)，KB Biomed Inc, Chungju 27469, South Korea.; Cho, S; Lee, YK (通讯作者)，Korea Natl Univ Transportat, 4D Biomat Ctr, Chungju 27909, South Korea.
EM sungpilcho74@ut.ac.kr; leeyk@ut.ac.kr
RI ; Lee, Dong Yun/H 4989 2012
OI Lee, Dong Yun/0000 0001 7691 0447; 
FU National Research Foundation (NRF)   Korean government
   [2018R1D1A1A09083269, 2019R1A4A1024116]
FX This research was supported by the National Research Foundation (NRF)
   grant funded by the Korean government (2018R1D1A1A09083269,
   2019R1A4A1024116).
CR Alkhiary YM, 2005, J BONE JOINT SURG AM, V87A, P731, DOI 10.2106/JBJS.D.02115
   Aspenberg P, 2010, J BONE MINER RES, V25, P404, DOI 10.1359/jbmr.090731
   Bakker AD, 2012, METHODS MOL BIOL, V816, P19, DOI 10.1007/978 1 61779 415 5_2
   Bentley Lewis R., 2010, SCI TRANSL MED, V2
   Besschetnova T, 2019, BONE, V124, P148, DOI 10.1016/j.bone.2019.04.025
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brown EM, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.135pe40
   Cho SW, 2013, J BONE MINER RES, V28, P2109, DOI 10.1002/jbmr.1961
   FUKATSU T, 1988, BRIT J CANCER, V57, P74, DOI 10.1038/bjc.1988.12
   Gardner MJ, 2016, INJURY, V47, pS33, DOI 10.1016/S0020 1383(16)47006 3
   Guo C, 2017, CELL PHYSIOL BIOCHEM, V43, P1547, DOI 10.1159/000481978
   Hasan MN, 2020, ACS APPL MATER INTER, V12, P38925, DOI 10.1021/acsami.0c09814
   Kang SH, 2017, ACS NANO, V11, P10417, DOI 10.1021/acsnano.7b05547
   Kharode Yogendra P., 2008, V455, P111, DOI 10.1007/978 1 59745 104 8_8
   Khatun Z, 2013, J CONTROL RELEASE, V170, P74, DOI 10.1016/j.jconrel.2013.04.024
   Kim H W, 1999, Iowa Orthop J, V19, P71
   Kraenzlin ME, 2011, NAT REV ENDOCRINOL, V7, P647, DOI 10.1038/nrendo.2011.108
   Lai LP, 2009, CELL BIOCHEM FUNCT, V27, P269, DOI 10.1002/cbf.1568
   Lee C, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 50554 w
   Maji SK, 2009, SCIENCE, V325, P328, DOI 10.1126/science.1173155
   Narayanan D, 2013, MOL PHARMACEUT, V10, P4159, DOI 10.1021/mp400184v
   Nurunnabi M, 2017, J CONTROL RELEASE, V268, P305, DOI 10.1016/j.jconrel.2017.08.035
   Pecchi E, 2012, OSTEOARTHR CARTILAGE, V20, P127, DOI 10.1016/j.joca.2011.12.002
   Ren XY, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw4991
   Roberts SJ, 2018, CURR OSTEOPOROS REP, V16, P289, DOI 10.1007/s11914 018 0440 1
   Robinson LJ, 2012, LAB INVEST, V92, P1071, DOI 10.1038/labinvest.2012.72
   Schaap FG, 2014, NAT REV GASTRO HEPAT, V11, P55, DOI 10.1038/nrgastro.2013.151
   Seeman E, 2019, NAT REV RHEUMATOL, V15, P225, DOI 10.1038/s41584 019 0172 3
   Shahriar SMS, 2019, NANOMATERIALS BASEL, V9, DOI 10.3390/nano9040532
   Shih YRV, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax1387
   Singh AP, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392 019 0068 3
   Tamura T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13384
   Thomas C, 2008, NAT REV DRUG DISCOV, V7, P678, DOI 10.1038/nrd2619
   Tong G, 2017, MED SCI MONITOR, V23, P1896, DOI 10.12659/MSM.903699
   Wang ZM, 2017, NPG ASIA MATER, V9, DOI 10.1038/am.2017.171
   Wu Q, 2018, BIOMATERIALS, V162, P132, DOI 10.1016/j.biomaterials.2018.02.022
   Zou W., 2011, PROTOC EXCH, DOI [10.1038/protex.2011.242, DOI 10.1038/PROTEX.2011.242, 10.1038/protex.2011.243]
NR 37
TC 18
Z9 19
U1 1
U2 48
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD MAY 26
PY 2021
VL 13
IS 20
BP 23314
EP 23327
DI 10.1021/acsami.0c22170
EA FEB 2021
PG 14
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA SL8YT
UT WOS:000657202500002
PM 33587600
DA 2025 08 17
ER

PT J
AU Chen, X
   Wang, C
   Qiu, H
   Yuan, Y
   Chen, K
   Cao, Z
   Tan, RX
   Tickner, J
   Xu, JK
   Zou, J
AF Chen, Xi
   Wang, Chao
   Qiu, Heng
   Yuan, Yu
   Chen, Kai
   Cao, Zhen
   Tan, Ren Xiang
   Tickner, Jennifer
   Xu, Jiake
   Zou, Jun
TI Asperpyrone A attenuates RANKL induced osteoclast formation through
   inhibiting NFATc1, Ca<SUP>2+</SUP> signalling and oxidative stress
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE Asperpyrone A; Ca2+ signalling; osteoclast; osteoporosis; reactive
   oxygen species
ID NF KAPPA B; INDUCED BONE LOSS; RECEPTOR ACTIVATOR; ESTROGEN DEFICIENCY;
   GENE EXPRESSION; DIFFERENTIATION; OSTEOPOROSIS; RESORPTION; LIGAND;
   OSTEOPROTEGERIN
AB Imbalance of osteoblast and osteoclast in adult leads to a variety of bone related diseases, including osteoporosis. Thus, suppressing the activity of osteoclastic bone resorption becomes the main therapeutic strategy for osteoporosis. Asperpyrone A is a natural compound isolated from Aspergillus niger with various biological activities of antitumour, antimicrobial and antioxidant. The present study was designed to investigate the effects of Asperpyrone A on osteoclastogenesis and to explore its underlining mechanism. We found that Asperpyrone A inhibited RANKL induced osteoclastogenesis in a dose dependent manner when the concentration reached 1 mu m, and with no cytotoxicity until the concentration reached to 10 mu m. In addition, Asperpyrone A down regulated the mRNA and protein expression of NFATc1, c fos and V ATPase d2, as well as the mRNA expression of TRAcP and Ctsk. Furthermore, Asperpyrone A strongly attenuated the RNAKL induced intracellular Ca2+ oscillations and ROS (reactive oxygen species) production in the process of osteoclastogenesis and suppressed the activation of MAPK and NF kappa B signalling pathways. Collectively, Asperpyrone A attenuates RANKL induced osteoclast formation via suppressing NFATc1, Ca2+ signalling and oxidative stress, as well as MAPK and NF kappa B signalling pathways, indicating that this compound may become a potential candidate drug for the prevention or treatment of osteoporosis.
C1 [Chen, Xi] Wenzhou Med Univ, Sch Sports Sci, Wenzhou, Peoples R China.
   [Chen, Xi; Xu, Jiake; Zou, Jun] Shanghai Univ Sport, Sch Kinesiol, Changhai Rd 399, Shanghai 200438, Peoples R China.
   [Chen, Xi; Wang, Chao; Qiu, Heng; Yuan, Yu; Chen, Kai; Cao, Zhen; Tickner, Jennifer; Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia.
   [Yuan, Yu] South China Normal Univ, Sch Phys Educ & Sports Sci, Guangzhou, Guangdong, Peoples R China.
   [Tan, Ren Xiang] Nanjing Univ, Inst Funct Biomol, State Key Lab Pharmaceut Biotechnol, Nanjing, Jiangsu, Peoples R China.
C3 Wenzhou Medical University; Shanghai University of Sport; University of
   Western Australia; South China Normal University; Nanjing University
RP Xu, JK; Zou, J (通讯作者)，Shanghai Univ Sport, Sch Kinesiol, Changhai Rd 399, Shanghai 200438, Peoples R China.
EM jiake.xu@uwa.edu.au; zoujun777@126.com
RI Zou, Jun/KYQ 8156 2024; Tickner, Jennifer/H 5965 2014; Yuan,
   Yu/HKN 3214 2023; Chen, KaiJie/A 1743 2016; Chen, Xi/AGS 6702 2022
OI Tickner, Jennifer/0000 0002 5020 0671; Xu, Jiake/0000 0003 2021 8309;
   Yuan, Yu/0000 0003 1032 6330; Qiu, Heng/0000 0002 0864 317X; Chen,
   Xi/0000 0001 8374 8054; Chen, Kai/0000 0001 6850 1723; Zou,
   Jun/0000 0001 6036 8067
FU National Natural Science Foundation of China [81702235, 81871835];
   Australian National Health and Medical Research Council (NHMRC)
   [APP1107828, APP1127156, APP1163933]; University of Western Australia
   Research Collaboration Awards
FX This work was supported by grant from the National Natural Science
   Foundation of China (No. 81702235 and 81871835). This study was also
   supported in part by the Australian National Health and Medical Research
   Council (NHMRC, APP1107828, APP1127156, APP1163933) and University of
   Western Australia Research Collaboration Awards.
CR Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Altindag O, 2008, RHEUMATOL INT, V28, P317, DOI 10.1007/s00296 007 0452 0
   Balkan W, 2009, GENE, V446, P90, DOI 10.1016/j.gene.2009.06.013
   BAX BE, 1992, BIOCHEM BIOPH RES CO, V183, P1153, DOI 10.1016/S0006 291X(05)80311 0
   Bliuc D, 2015, J BONE MINER RES, V30, P637, DOI 10.1002/jbmr.2393
   Cai X, 2019, NAT PROD RES, V33, P1953, DOI 10.1080/14786419.2018.1481844
   Chen N, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00145
   Fang W, 2016, MOLECULES, V21, DOI 10.3390/molecules21070941
   Feng HT, 2009, J BIOL CHEM, V284, P14667, DOI 10.1074/jbc.M901670200
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   Hwang YH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072068
   Hwang YH, 2018, NUTRIENTS, V10, DOI 10.3390/nu10070901
   Hwang YH, 2018, MOLECULES, V23, DOI 10.3390/molecules23071598
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Kim H, 2017, J BONE MINER RES, V32, P397, DOI 10.1002/jbmr.2974
   Kim HJ, 2006, FREE RADICAL BIO MED, V40, P1483, DOI 10.1016/j.freeradbiomed.2005.10.066
   Kim HS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01527 y
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kuroda Y, 2008, P NATL ACAD SCI USA, V105, P8643, DOI 10.1073/pnas.0800642105
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   Liu Q, 2016, SCI REP UK, V6, DOI 10.1038/srep36662
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu SH, 2015, J NAT PROD, V78, P61, DOI 10.1021/np500663y
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Padhi S, 2020, NAT PROD RES, V34, P2573, DOI 10.1080/14786419.2018.1544982
   Rodan GA, 1998, P NATL ACAD SCI USA, V95, P13361, DOI 10.1073/pnas.95.23.13361
   Rosenfeld L, 2015, J BIOL CHEM, V290, P26180, DOI 10.1074/jbc.M115.671271
   Sharma SM, 2007, J BIOL CHEM, V282, P15921, DOI 10.1074/jbc.M609723200
   Song DZ, 2018, J CELL BIOCHEM, V119, P4826, DOI 10.1002/jcb.26682
   Song FM, 2016, J CELL PHYSIOL, V231, P1983, DOI 10.1002/jcp.25304
   Takayanag H, 2007, P JPN ACAD B PHYS, V83, P136, DOI 10.2183/pjab.83.136
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Wade SW, 2014, ARCH OSTEOPOROS, V9, DOI 10.1007/s11657 014 0182 3
   Wagner EF, 2003, ANN RHEUM DIS, V62, P83, DOI 10.1136/ard.62.suppl_2.ii83
   Wei CM, 2018, J CELL PHYSIOL, V233, P476, DOI 10.1002/jcp.25907
   Wu X, 2012, J BONE MINER RES, V27, P1298, DOI 10.1002/jbmr.1576
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Yip KHM, 2005, J BONE MINER RES, V20, P1462, DOI 10.1359/JBMR.050324
   Yuan FL, 2015, BONE, V75, P128, DOI 10.1016/j.bone.2015.02.017
   Zhang DW, 2010, METHODS MOL BIOL, V625, P41, DOI 10.1007/978 1 60761 579 8_5
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
   Zhou L, 2015, INT J MOL SCI, V16, P27087, DOI 10.3390/ijms161125998
NR 49
TC 17
Z9 21
U1 1
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD DEC
PY 2019
VL 23
IS 12
BP 8269
EP 8279
DI 10.1111/jcmm.14700
EA OCT 2019
PG 11
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA JL9PD
UT WOS:000489902200001
PM 31612613
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Mo, H
   Zhang, N
   Li, HF
   Li, F
   Pu, R
AF Mo, Hui
   Zhang, Ning
   Li, Huifu
   Li, Fan
   Pu, Rong
TI Beneficial effects of Cuscuta chinensis extract on
   glucocorticoid induced osteoporosis through modulation of RANKL/OPG
   signals
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE Dexamethasone; Oxidative status; Bone formation; Anti osteoporosis;
   RunX2
ID OXIDATIVE STRESS; OSTEOBLAST DIFFERENTIATION; BONE LOSS; IN VIVO;
   PROTECTS; HEALTH; CELLS
AB Cuscuta chinensis Lam. (Convolvulaceae) is an important herbal medicine widely used to improve sexual function, treat osteoporosis, and prevent aging, and has been reported to exhibit anti osteoporotic effects in vitro. However, the activity of Cuscuta chinensis Lam. on glucocorticoid induced osteoporosis still remains unclear. The present study aimed to assess the protective effect and the underlying mechanism of action of Cuscuta chinensis extract (CCE) against glucocorticoid induced osteoporosis in vivo. Sprague Dawley rats were randomly divided into four groups as follows: control group, osteoporosis group, and 2 CCE treated osteoporosis groups (100 mg . kg( 1) . day( 1) ). Blood samples and femur bones were collected for immunohistochemistry, biochemical, mRNA expression, and western blot analysis. HPLC analysis revealed that chlorogenic acid, quercetin, and hyperin were the major constituents of CCE. The results indicated that CCE increased bone length, bone weight, and bone mineral density and suppressed dexamethasone (DEX) induced reduction in body weight. In addition, TRAP staining indicated that CCE reduced osteoclasts in DEX induced osteoporosis rats. Mechanistically, CCE treatment alleviated the increase of bone resorption markers and the decline of osteogenic markers, which might be partially mediated by regulation of RANKL/OPG and RunX2 pathways. These results suggest that CCE showed promising effects in the protection against glucocorticoid induced osteoporosis through protecting osteoblasts and suppressing osteoclastogenesis.
C1 [Mo, Hui; Zhang, Ning; Li, Huifu; Li, Fan] Maoming Peoples Hosp, Dept Nucl Med, Maoming, Guangdong, Peoples R China.
   [Pu, Rong] Third Peoples Hosp Dongguan City, Clin Lab, Dongguan, Guangdong, Peoples R China.
RP Pu, R (通讯作者)，Third Peoples Hosp Dongguan City, Clin Lab, Dongguan, Guangdong, Peoples R China.
EM prong0325@163.com
CR Almeida M, 2011, J BIOL CHEM, V286, P44326, DOI 10.1074/jbc.M111.283481
   Brown JP, 2009, CLIN BIOCHEM, V42, P929, DOI 10.1016/j.clinbiochem.2009.04.001
   Buehring B, 2013, J ALLERGY CLIN IMMUN, V132, P1019, DOI 10.1016/j.jaci.2013.08.040
   Chen YY, 2015, SCI REP UK, V5, DOI 10.1038/srep11802
   Chen ZG, 2016, INT J MOL MED, V37, P329, DOI 10.3892/ijmm.2015.2432
   Compston J, 2018, ENDOCRINE, V61, P7, DOI 10.1007/s12020 018 1588 2
   D'Amelio P, 2008, BONE, V43, P1010, DOI 10.1016/j.bone.2008.08.107
   Donnapee S, 2014, J ETHNOPHARMACOL, V157, P292, DOI 10.1016/j.jep.2014.09.032
   Du KZ, 2018, J ANAL METHODS CHEM, V2018, DOI 10.1155/2018/6796720
   Fan SL, 2018, LIFE SCI, V207, P205, DOI 10.1016/j.lfs.2018.06.006
   Lucinda LMF, 2013, PHYTOTHER RES, V27, P515, DOI 10.1002/ptr.4747
   Hartmann K, 2016, PHYSIOL REV, V96, P409, DOI 10.1152/physrev.00011.2015
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Ishii M, 2013, BBA MOL CELL BIOL L, V1831, P223, DOI 10.1016/j.bbalip.2012.06.002
   Kerachian MA, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3062
   Kim JS, 2017, PHARM BIOL, V55, P1909, DOI 10.1080/13880209.2017.1340965
   KIRWAN JR, 1995, NEW ENGL J MED, V333, P142, DOI 10.1056/NEJM199507203330302
   Koromila T, 2014, J CELL BIOCHEM, V115, P27, DOI 10.1002/jcb.24646
   Lee AJ, 2000, ANN CLIN BIOCHEM, V37, P432, DOI 10.1258/0004563001899573
   Manolagas SC, 2010, TRENDS ENDOCRIN MET, V21, P369, DOI 10.1016/j.tem.2010.01.010
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891 5849(01)00610 4
   Park JA, 2008, LIFE SCI, V82, P1217, DOI 10.1016/j.lfs.2008.03.021
   Rizzoli R, 2015, NAT REV RHEUMATOL, V11, P98, DOI 10.1038/nrrheum.2014.188
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Sánchez Rodríguez MA, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471 2474 8 124
   Schürer C, 2015, DTSCH ARZTEBL INT, V112, P365, DOI 10.3238/arztebl.2015.0365
   Tolba MF, 2017, TOXICOL APPL PHARM, V324, P26, DOI 10.1016/j.taap.2017.03.021
   Wang CG, 2018, J NAT MED TOKYO, V72, P929, DOI 10.1007/s11418 018 1228 4
   Yang HM, 2009, J MED FOOD, V12, P85, DOI 10.1089/jmf.2007.0665
   Yang LJ, 2011, J ETHNOPHARMACOL, V135, P553, DOI 10.1016/j.jep.2011.03.056
   Yasuda H, 1999, BONE, V25, P109, DOI 10.1016/S8756 3282(99)00121 0
   Yen FL, 2007, J ETHNOPHARMACOL, V111, P123, DOI 10.1016/j.jep.2006.11.003
   Yoo HS, 2017, NUTRIENTS, V9, DOI 10.3390/nu9050504
   Yoon HY, 2012, J BONE MINER METAB, V30, P509, DOI 10.1007/s00774 012 0350 8
   Yuan Z, 2018, AM J TRANSL RES, V10, P4313
   Zhang S, 2015, CELL STRESS CHAPERON, V20, P621, DOI 10.1007/s12192 015 0585 0
   Zhang XN, 2016, CHEM BIOL INTERACT, V256, P188, DOI 10.1016/j.cbi.2016.07.003
   Zhou RP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166751
   Zhu YZ, 2016, TOXICOLOGY, V368, P183, DOI 10.1016/j.tox.2016.07.014
NR 40
TC 35
Z9 39
U1 0
U2 25
PU ASSOC BRAS DIVULG CIENTIFICA
PI RIBEIRAO PRETO
PA FACULDADE MEDICINA, CASA 10, 14049 RIBEIRAO PRETO, RIBEIRAO PRETO, SP
   14049, BRAZIL
SN 0100 879X
EI 1414 431X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PY 2019
VL 52
IS 12
AR e8754
DI 10.1590/1414 431X20198754
PG 9
WC Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Research & Experimental
   Medicine
GA JV3VA
UT WOS:000502292600001
PM 31826180
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Tao, S
   Chen, SQ
   Zhou, WT
   Yu, FY
   Bao, L
   Qiu, GX
   Qiao, Q
   Hu, FQ
   Wang, JW
   Yuan, H
AF Tao, Shan
   Chen, Shao qing
   Zhou, Wen tao
   Yu, Fang ying
   Bao, Lu
   Qiu, Guo xi
   Qiao, Qing
   Hu, Fu qiang
   Wang, Jian wei
   Yuan, Hong
TI A novel biocompatible, simvastatin loaded, bone targeting lipid
   nanocarrier for treating osteoporosis more effectively
SO RSC ADVANCES
LA English
DT Article
ID DRUG DELIVERY SYSTEM; OSTEOBLAST DIFFERENTIATION; IN VITRO; MINERAL
   DENSITY; NANOPARTICLES; CARRIERS; INHIBITION; SURFACES; THERAPY
AB An insufficient drug concentration at the target site and drug efflux resulting in poor efficacy are recognized as important obstacles in osteoporosis treatment. Simvastatin (SIM), which can treat osteoporosis by promoting osteoblast differentiation and mineralization through the bone morphogenetic proteins (BMP) Smad signaling pathway, has lower bioavailability, and less bone tissue distribution. Herein, novel lipid nanoparticles (LNPs) delivering SIM (SIM/LNPs) for osteoporosis therapy were developed with aspartic oligopeptide (ASP(n), here ASP(6)) based bone targeting moieties grafted to the nanoparticles (SIM/ASP(6) LNPs) in an attempt to increase the concentration of SIM in bones with a relatively low dose to minimize adverse effects. In vivo experiments indicated that the ASP(6) LNPs exhibited ideal bone targeting characteristics, and in vitro cell evaluation experiments showed LNPs have good biocompatibility with MC3T3 E1 cells. The cell mineralization experiment revealed that the SIM loaded LNPs induced osteoblast differentiation and the formation of mineralized nodules in MC3T3 E1 cells, achieving the same efficacy as that of SIM. Pharmacodynamic experiments revealed that SIM/ASP(6) LNPs improved the efficacy of SIM on the recovery of bone mineral density when compared to SIM/LNPs or to SIM alone. Therefore, SIM/ASP(6) LNPs may represent a potential bone targeting drug delivery system (DDS) that contributes to the development of a novel osteoporosis treatment.
C1 [Tao, Shan; Chen, Shao qing; Zhou, Wen tao; Yu, Fang ying; Bao, Lu; Qiu, Guo xi; Hu, Fu qiang; Yuan, Hong] Zhejiang Univ, Coll Pharmaceut Sci, 866 Yuhangtang Rd, Hangzhou 310058, Peoples R China.
   [Qiao, Qing] Zhejiang Univ, Anesthesia Dept, Sch Med, Sir Run Run Shaw Hosp, 3 Qingchun East Rd, Hangzhou 310016, Peoples R China.
   [Wang, Jian wei] Zhejiang Univ, Dept Orthopaed, Affiliated Hosp 2, Sch Med, 88 Jiefang Rd, Hangzhou 310009, Peoples R China.
C3 Zhejiang University; Zhejiang University; Zhejiang University
RP Yuan, H (通讯作者)，Zhejiang Univ, Coll Pharmaceut Sci, 866 Yuhangtang Rd, Hangzhou 310058, Peoples R China.; Wang, JW (通讯作者)，Zhejiang Univ, Dept Orthopaed, Affiliated Hosp 2, Sch Med, 88 Jiefang Rd, Hangzhou 310009, Peoples R China.
EM zjuwjw@zju.edu.cn; yuanhong70@zju.edu.cn
RI wentao, zhou/HHS 6331 2022
FU Zhejiang Natural Science Foundation [LY18H060002]; Project of Health
   Commission of Zhejiang Province [2016KYA115]; National Natural Science
   Foundation of China [81573366, 81773644]
FX This research was supported by Zhejiang Natural Science Foundation
   (LY18H060002), Project of Health Commission of Zhejiang Province
   (2016KYA115) and the National Natural Science Foundation of China under
   Contract No. 81573366, 81773644.
CR [Anonymous], ADV DRUG DELIVER REV
   Ansar M, 2013, ACS NANO, V7, P10597, DOI 10.1021/nn404719c
   BLUM CB, 1994, AM J CARDIOL, V73, pD3, DOI 10.1016/0002 9149(94)90626 2
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Heo DN, 2014, ACS NANO, V8, P12049, DOI 10.1021/nn504329u
   Hirose M, 2003, KEY ENG MAT, V240 2, P715, DOI 10.4028/www.scientific.net/KEM.240 242.715
   Kasugai S, 2000, J BONE MINER RES, V15, P936, DOI 10.1359/jbmr.2000.15.5.936
   Kawamoto T, 2003, ARCH HISTOL CYTOL, V66, P123, DOI 10.1679/aohc.66.123
   Li SJ, 2017, DRUG DELIV, V24, P402, DOI 10.1080/10717544.2016.1259369
   Low SA, 2012, ADV DRUG DELIVER REV, V64, P1189, DOI 10.1016/j.addr.2012.01.012
   Lu YM, 2014, BIOMATERIALS, V35, P530, DOI 10.1016/j.biomaterials.2013.09.093
   Maeda T, 2004, J CELL BIOCHEM, V92, P458, DOI 10.1002/jcb.20074
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   McClung M, 2013, AM J MED, V126, P13, DOI 10.1016/j.amjmed.2012.06.023
   Mehnert W, 2001, ADV DRUG DELIVER REV, V47, P165, DOI 10.1016/S0169 409X(01)00105 3
   Montagnani A, 2003, BONE, V32, P427, DOI 10.1016/S8756 3282(03)00034 6
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Murphy MB, 2007, BIOMACROMOLECULES, V8, P2237, DOI 10.1021/bm070121s
   Sekido T, 2001, J DRUG TARGET, V9, P111, DOI 10.3109/10611860108997922
   Tikiz C, 2005, CLIN RHEUMATOL, V24, P447, DOI 10.1007/s10067 004 1053 x
   Vennila Vijayasree, 2014, J Int Oral Health, V6, P115
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Wang H, 2015, INT J NANOMED, V10, P5671, DOI 10.2147/IJN.S88798
   Wang J, 2012, CURR DRUG METAB, V13, P447, DOI 10.2174/138920012800166553
   Wong HL, 2007, ADV DRUG DELIVER REV, V59, P491, DOI 10.1016/j.addr.2007.04.008
   Yamashita M, 2008, J ENDOCRINOL, V196, P601, DOI 10.1677/JOE 07 0532
   Yang F, 2011, ORAL SURG ORAL MED O, V111, P551, DOI 10.1016/j.tripleo.2010.06.018
   Yarbrough DK, 2010, CALCIFIED TISSUE INT, V86, P58, DOI 10.1007/s00223 009 9312 0
   Ye WL, 2015, J PHARM SCI US, V104, P2293, DOI 10.1002/jps.24476
   Yu Q, 2016, DRUG DELIV, V23, P1469, DOI 10.3109/10717544.2016.1153744
   Yu WL, 2017, SCI REP UK, V7, DOI 10.1038/srep44129
   Yue XX, 2016, NANOTECHNOLOGY, V27, DOI 10.1088/0957 4484/27/11/115708
   Zhai YJ, 2014, J CONTROL RELEASE, V193, P90, DOI 10.1016/j.jconrel.2014.05.054
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhang ZZ, 2019, EXP THER MED, V17, P79, DOI 10.3892/etm.2018.6947
NR 35
TC 22
Z9 24
U1 0
U2 19
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046 2069
J9 RSC ADV
JI RSC Adv.
PD JUN 1
PY 2020
VL 10
IS 35
BP 20445
EP 20459
DI 10.1039/d0ra00685h
PG 15
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA LY5CR
UT WOS:000540547000006
PM 35517758
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Goldeman, W
   Nasulewicz Goldeman, A
AF Goldeman, Waldemar
   Nasulewicz Goldeman, Anna
TI Synthesis and biological evaluation of aminomethylidenebisphosphonic
   derivatives of β arylethylamines
SO TETRAHEDRON
LA English
DT Article
DE Bisphosphonates; Bisphosphonic acids; Arylethylamines; Isocyanides;
   Isonitriles; Osteoclasts
ID SKELETAL RELATED EVENTS; BIFUNCTIONAL BISPHOSPHONATES; ANTIPROLIFERATIVE
   ACTIVITY; BONE; GROWTH; ACID; INHIBITION; TARGET; DRUGS
AB Addition of two equivalents of triethyl phosphite to beta arylethylisocyanides to synthesize tetraethyl aminomethylidenebisphosphonates in the presence of a stoichiometric amount of hydrogen chloride is reported. Acid hydrolysis of the tetraethyl esters gave the 2 arylethylaminomethylidenebisphosphonic acids in good yields. Additionally, the obtained bisphosphonates were evaluated for their anti proliferative effect against MCF 7 human breast cancer cells, J774E mouse macrophages and HL 60 human promyelocytic leukemia cells. beta Phenylphenethylamine derivative showed a selective activity towards J774E cells with IC50 values three times lower than Incadronate and twice as high as Zoledronate. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Goldeman, Waldemar] Wroclaw Univ Technol, Dept Organ Chem, PL 50370 Wroclaw, Poland.
   [Nasulewicz Goldeman, Anna] Polish Acad Sci, Inst Immunol & Expt Therapy, Dept Expt Oncol, PL 53114 Wroclaw, Poland.
C3 Wroclaw University of Science & Technology; Polish Academy of Sciences;
   Hirszfeld Institute of Immunology & Experimental Therapy of the Polish
   Academy of Sciences
RP Goldeman, W (通讯作者)，Wroclaw Univ Technol, Dept Organ Chem, Wybrzeze Wyspianskiego 27, PL 50370 Wroclaw, Poland.
EM waldemar.goldeman@pwr.edu.pl
FU National Science Center [N N204 122240]
FX This work was supported by National Science Center (grant No. N N204
   122240). W.G. would like to thank prof. Miroslaw Soroka for all the
   advice and helpful discussion, Mrs. Elzbieta Mroz for recording the FTIR
   spectra, Mrs. Gabriela Maciejewska for the recording the HRMS spectra
   and Mr. Pawel Dabrowski for help in recording the NMR spectra.
CR Abdou WM, 2009, ARKIVOC, P143, DOI 10.3998/ark.5550190.0010.910
   Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004
   Årstad E, 2003, J MED CHEM, V46, P3021, DOI 10.1021/jm021107v
   Arstad E., 2002, US Patent, Patent No. 20020042539
   Boduszek B, 1996, TETRAHEDRON, V52, P12483, DOI 10.1016/0040 4020(96)00727 2
   Demoro B, 2012, DALTON T, V41, P6468, DOI 10.1039/c2dt12179d
   Forlani G, 1996, PHOSPHORUS SULFUR, V109, P353
   Forlani G, 2007, J AGR FOOD CHEM, V55, P4340, DOI 10.1021/jf0701032
   Freeman S, 2002, EUR J MED CHEM, V37, P527, DOI 10.1016/S0223 5234(02)01382 X
   Gartrell BA, 2014, NAT REV CLIN ONCOL, V11, P335, DOI 10.1038/nrclinonc.2014.70
   Ghosh S, 2004, J MED CHEM, V47, P175, DOI 10.1021/jm030084x
   Goldeman W, 2014, BIOORG MED CHEM LETT, V24, P3475, DOI 10.1016/j.bmcl.2014.05.071
   Goldeman W, 2012, TETRAHEDRON LETT, V53, P5290, DOI 10.1016/j.tetlet.2012.07.085
   GROSS H, 1976, J PRAKT CHEM, V318, P116, DOI 10.1002/prac.19763180113
   Hudson HR, 2012, MINI REV MED CHEM, V12, P313, DOI 10.2174/138955712799829285
   Jobke B, 2014, BONE, V59, P37, DOI 10.1016/j.bone.2013.10.024
   Kafarski P, 1997, J PLANT GROWTH REGUL, V16, P153, DOI 10.1007/PL00006990
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Lecouvey M, 2000, HETEROATOM CHEM, V11, P556, DOI 10.1002/1098 1071(2000)11:7<556::AID HC15>3.0.CO;2 N
   Leon A, 2006, J MED CHEM, V49, P7331, DOI 10.1021/jm060492b
   Marcinkowska E, 1998, J STEROID BIOCHEM, V67, P71, DOI 10.1016/S0960 0760(98)00065 X
   MCKENNA CE, 1977, TETRAHEDRON LETT, P155
   Merlotti D, 2007, J BONE MINER RES, V22, P1510, DOI 10.1359/JBMR.070704
   Obojska A, 2004, J AGR FOOD CHEM, V52, P3337, DOI 10.1021/jf049843q
   Pecherstorfer M, 1996, J CLIN ONCOL, V14, P268, DOI 10.1200/JCO.1996.14.1.268
   Polyzos SA, 2011, EXP CLIN ENDOCR DIAB, V119, P519, DOI 10.1055/s 0031 1284365
   Poole KE, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e3211
   Rogers Maurice, 2011, Scottish Forestry, V65, P34
   Rogers TL, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 177
   Romanenko VD, 2012, ARKIVOC, P127, DOI 10.3998/ark.5550190.0013.411
   Sakamoto S., 1988, [No title captured], Patent No. [282320, EP 282320]
   Santosh K. S., 2008, BEILSTEIN J ORG CHEM, V4
   Senaratne SG, 2002, BREAST CANCER RES, V4, P18, DOI 10.1186/bcr412
   SKEHAN P, 1990, JNCI J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Suzuki F., 1979, DE Patent, Patent No. 2831578
   Suzuki F., 1979, JP Patent, Patent No. [4,135,724, 54135724]
   Suzuki F., 1978, JP Patent, Patent No. [53066431, 53,066,431]
   Szabo CM, 2002, J MED CHEM, V45, P2185, DOI 10.1021/jm010412y
   TAKEUCHI M, 1993, CHEM PHARM BULL, V41, P688
   Tang XD, 2010, INT J CANCER, V126, P90, DOI 10.1002/ijc.24710
   Tolia M, 2014, ANTICANCER RES, V34, P23
   UNTERSPANN S, 1976, EUR J NUCL MED, V1, P151
   UNTERSPANN S, 1981, EUR J NUCL MED, V6, P527
   Vrdoljak E, 2013, ANTI CANCER DRUG, V24, P431, DOI 10.1097/CAD.0b013e328360335f
   Wilkinson AN, 2008, BMJ BRIT MED J, V337, DOI 10.1136/bmj.a2041
   Yewle JN, 2013, BIOMATERIALS, V34, P3141, DOI 10.1016/j.biomaterials.2013.01.059
   Yewle JN, 2011, BIOCONJUGATE CHEM, V22, P2496, DOI 10.1021/bc2003132
NR 47
TC 11
Z9 13
U1 0
U2 29
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0040 4020
J9 TETRAHEDRON
JI Tetrahedron
PD MAY 27
PY 2015
VL 71
IS 21
BP 3282
EP 3289
DI 10.1016/j.tet.2015.03.112
PG 8
WC Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Chemistry
GA CI8OG
UT WOS:000355031000013
DA 2025 08 17
ER

PT J
AU Zhang, X
   Xu, XC
   Liu, XQ
   Mao, CY
   Qin, A
   Lu, EY
AF Zhang, Xi
   Xu, Xinchen
   Liu, Xuqiang
   Mao, Chuanyuan
   Qin, An
   Lu, Eryi
TI Bis enoxacin blocks alveolar bone resorption in rats with
   ovariectomy induced osteoporosis
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE bis enoxacin; ovariectomy; osteoporosis; alveolar bone resorption;
   osteoclast
ID POSTMENOPAUSAL; ALENDRONATE; PREVENTION; HEALTH; MASS
AB Postmenopausal osteoporosis is a common systemic skeletal disease that is associated with estrogen deficiency. Bone loss associated with bisphosphonates therapy can increase the risk of developing oral osteonecrosis. Recent studies have indicated that enoxacin may inhibit osteoclast formation and bone resorption via a different mechanism from that of bisphosphonates. Therefore, the authors hypothesized that the use of an enoxacin such as bis enoxacin (BE) in association with bisphosphonates may be effective in the treatment of postmenopausal osteoporosis associated alveolar bone resorption and reduce the risk of oral osteonecrosis by allowing the dose of bisphosphonates to be reduced. A total of 30 6 month old female Sprague Dawley rats were randomly assigned to five groups: The Sham, Vehicle, zoledronic acid (ZOL), low concentrations of BE (BE L) and high concentrations of BE (BE H) groups. The results demonstrated that the ZOL, BE L and BE H groups had an increased bone volume/tissue volume, trabecular thickness, mineral apposition rate, mineralizing surface/bone surface and a decreased trabecular separation when compared with the Vehicle group. The microscopic evaluation of histological sections clearly supported the results of the micro computed tomography. The number of tartrate resistant acid phosphatase positive osteoclasts was markedly decreased in the ZOL, BE L and BE H groups, indicating that BE may inhibit osteoclast formation. The anti resorptive effect in the BE H group was close to or better than that exhibited by the ZOL group; however, this effect was poorer in the BE L group. In conclusion, BE has the potential to block alveolar bone resorption resulting from ovariectomy induced osteoporosis in rats in a dose dependent manner.
C1 [Zhang, Xi; Xu, Xinchen; Mao, Chuanyuan; Lu, Eryi] Shanghai Jiao Tong Univ, Sch Med, Dept Stomatol, Renji Hosp, 1630 Dongfang Rd, Shanghai 200127, Peoples R China.
   [Xu, Xinchen] Xuzhou Cent Hosp, Dept Stomatol, Xuzhou 221009, Jiangsu, Peoples R China.
   [Liu, Xuqiang] Nanchang Univ, Dept Orthoped, Affiliated Hosp 1, Artificial Joint Engn & Technol Res Ctr Jiangxi P, Nanchang 330200, Jiangxi, Peoples R China.
   [Qin, An] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Orthoped Implants, Dept Orthoped,Shanghai Peoples Hosp 9, 639 Zhizaojiu Rd, Shanghai 200011, Peoples R China.
C3 Shanghai Jiao Tong University; Nanchang University; Shanghai Jiao Tong
   University
RP Lu, EY (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Dept Stomatol, Renji Hosp, 1630 Dongfang Rd, Shanghai 200127, Peoples R China.; Qin, A (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Orthoped Implants, Dept Orthoped,Shanghai Peoples Hosp 9, 639 Zhizaojiu Rd, Shanghai 200011, Peoples R China.
EM dr_qinan@163.com; lueryi222@126.com
RI Zhu, Xiao Dong/A 8197 2010; Qin, An/J 2518 2019
OI Lu, Eryi/0000 0002 0045 2571
FU Science and Technology Commission of Shanghai Municipality
   [17140903400]; Shanghai Municipal Commission of Health and Family
   Planning [M20170365]; Opening Project of Shanghai Key Laboratory of
   Orthopaedic Implant [KFKT2015002]; National Natural Science Foundation
   of China [81570948]
FX The present was supported by grants from the Science and Technology
   Commission of Shanghai Municipality (grant no. 17140903400), the
   Shanghai Municipal Commission of Health and Family Planning (grant no.
   M20170365), the Opening Project of Shanghai Key Laboratory of
   Orthopaedic Implant (grant no. KFKT2015002) and the National Natural
   Science Foundation of China (grant no. 81570948).
CR Al Habashneh R, 2016, OBES RES CLIN PRACT, V10, P15, DOI 10.1016/j.orcp.2015.03.010
   [Anonymous], 1994, World Health Organ Tech Rep Ser 843, V1
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336
   Cauley JA, 2003, JAMA J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729
   Chen H, 2015, BONE, V76, P141, DOI 10.1016/j.bone.2015.04.002
   Crandall CJ, 2014, ANN INTERN MED, V161, P711, DOI 10.7326/M14 0317
   Cummings SR, 2009, JNCI J NATL CANCER I, V101, P384, DOI 10.1093/jnci/djp018
   Dai QG, 2014, ORAL DIS, V20, P514, DOI 10.1111/odi.12166
   DEMPSTER DW, 1995, BONE, V16, P157, DOI 10.1016/8756 3282(95)80027 N
   Herczegh P, 2002, J MED CHEM, V45, P2338, DOI 10.1021/jm0105326
   Howson CP, 2000, J HUMAN VIROL, V3, P94
   Jeffcoat M K, 1998, Ann Periodontol, V3, P312, DOI 10.1902/annals.1998.3.1.312
   Khosla S, 2012, J CLIN ENDOCR METAB, V97, P2272, DOI 10.1210/jc.2012 1027
   KRIBBS PJ, 1990, J PROSTHET DENT, V63, P218, DOI 10.1016/0022 3913(90)90108 O
   KRIBBS PJ, 1989, J PROSTHET DENT, V62, P703, DOI 10.1016/0022 3913(89)90596 9
   Liu XQ, 2014, BIOMATERIALS, V35, P5721, DOI 10.1016/j.biomaterials.2014.04.006
   Mavropoulos A, 2007, J BONE MINER RES, V22, P403, DOI 10.1359/JBMR.061208
   McGrath C, 1999, Gerodontology, V16, P59, DOI 10.1111/j.1741 2358.1999.00059.x
   Ostrov DA, 2009, J MED CHEM, V52, P5144, DOI 10.1021/jm900277z
   Purdue PE, 2007, CLIN ORTHOP RELAT R, P251, DOI 10.1097/01.blo.0000238813.95035.1b
   Rivera MF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092119
   Salazar M, 2015, ARCH ORAL BIOL, V60, P776, DOI 10.1016/j.archoralbio.2015.02.003
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Sun W, 2014, J HUAZHONG U SCI MED, V34, P114, DOI 10.1007/s11596 014 1241 0
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   THOMPSON DD, 1995, BONE, V17, pS125, DOI 10.1016/8756 3282(95)00285 L
   Toro EJ, 2013, J DENT RES, V92, P925, DOI 10.1177/0022034513501876
   Tuck SP, 2002, POSTGRAD MED J, V78, P526, DOI 10.1136/pmj.78.923.526
   von Wowern N, 2001, Clin Oral Investig, V5, P71, DOI 10.1007/s007840100105
   Yang J, 2003, DENTOMAXILLOFAC RAD, V32, P247, DOI 10.1259/dmfr/12560890
NR 31
TC 8
Z9 9
U1 1
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD FEB
PY 2018
VL 17
IS 2
BP 3232
EP 3238
DI 10.3892/mmr.2017.8223
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA FT5WP
UT WOS:000423224300149
PM 29257280
OA Bronze
DA 2025 08 17
ER

PT J
AU D'Alimonte, I
   Lannutti, A
   Pipino, C
   Di Tomo, P
   Pierdomenico, L
   Cianci, E
   Antonucci, I
   Marchisio, M
   Romano, M
   Stuppia, L
   Caciagli, F
   Pandolfi, A
   Ciccarelli, R
AF D'Alimonte, Iolanda
   Lannutti, Angela
   Pipino, Caterina
   Di Tomo, Pamela
   Pierdomenico, Laura
   Cianci, Eleonora
   Antonucci, Ivana
   Marchisio, Marco
   Romano, Mario
   Stuppia, Liborio
   Caciagli, Francesco
   Pandolfi, Assunta
   Ciccarelli, Renata
TI Wnt Signaling Behaves as a "Master Regulator" in the Osteogenic and
   Adipogenic Commitment of Human Amniotic Fluid Mesenchymal Stem Cells
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article
DE Human amniotic fluids; Mesenchymal stem cells; Osteogenic/adipogenic
   differentiation; Wnt signaling
ID HUMAN BONE MARROW; CLINICAL APPLICATIONS; STROMAL CELLS;
   DIFFERENTIATION; GROWTH; PROLIFERATION; PLURIPOTENCY; EXPRESSION;
   OSTEOBLAST; FREQUENCY
AB Human amniotic fluid mesenchymal stem cells (huAFMSCs) are emerging as a promising therapeutic option in regenerative medicine. Here, we characterized huAFMSC phenotype and multipotentiality. When cultured in osteogenic medium, huAFMSC displayed a significant increase in: Alkaline Phosphatase (ALP) activity and mRNA expression, Alizarin Red S staining and Runx2 mRNA expression; whereas maintaining these cells in an adipogenic culture medium gave a time dependent increase in PPAR gamma and FABP4 mRNA expression, glycerol 3 phosphate dehydrogenase (GPDH) activity and positivity to Oil Red Oil staining. These results confirm that huAFMSCs can differentiate toward osteogenic and adipogenic phenotypes. The canonical Wnt/catenin signaling pathway appears to trigger huAFMSC osteoblastogenesis, since during early phases of osteogenic differentiation, the expression of Dishevelled 2 (Dvl 2), of the non phosphorylated form of  catenin, and the phosphorylation of glycogen synthase kinase 3 (GSK3) at serine 9 were upregulated. On the contrary, during adipogenic differentiation Dvl 2 expression decreased, whereas that of  catenin remained unchanged. This was associated with a late increase in GSK3 phosphorylation. Consistent with this scenario, huAFMSCs exposure to Dickkopf 1, a selective inhibitor of the Wnt signaling, abolished Runx2 and ALP mRNA upregulation during huAFMSC osteogenic differentiation, whereas it enhanced FABP4 expression in adipocyte differentiating cells. Taken together, these results unravel novel molecular determinants of huAFMSC commitment towards osteoblastogenesis, which may represent potential targets for directing the differentiation of these cells and improving their use in regenerative medicine.
C1 [D'Alimonte, Iolanda; Lannutti, Angela; Pipino, Caterina; Di Tomo, Pamela; Cianci, Eleonora; Romano, Mario; Caciagli, Francesco; Pandolfi, Assunta; Ciccarelli, Renata] Univ G dAnnunzio, Dept Expt & Clin Sci, Chieti, Italy.
   [Pierdomenico, Laura; Marchisio, Marco] Univ G dAnnunzio, Dept Med & Aging Sci, Chieti, Italy.
   [Antonucci, Ivana; Stuppia, Liborio] Univ G dAnnunzio, Dept Psychol Sci Humanities & Terr, Chieti, Italy.
   [D'Alimonte, Iolanda; Lannutti, Angela; Pipino, Caterina; Di Tomo, Pamela; Pierdomenico, Laura; Cianci, Eleonora; Antonucci, Ivana; Marchisio, Marco; Romano, Mario; Stuppia, Liborio; Pandolfi, Assunta; Ciccarelli, Renata] StemTeCh Grp, Chieti, Italy.
   [Pipino, Caterina; Di Tomo, Pamela; Pierdomenico, Laura; Cianci, Eleonora; Marchisio, Marco; Romano, Mario; Stuppia, Liborio; Caciagli, Francesco; Pandolfi, Assunta; Ciccarelli, Renata] Univ G dAnnunzio, Ctr Aging Sci Ce SI, Chieti, Italy.
   [Ciccarelli, Renata] Dept Expt & Clin Sci, Pharmacol Sect, I 66100 Chieti, Italy.
C3 G d'Annunzio University of Chieti Pescara; G d'Annunzio University of
   Chieti Pescara; G d'Annunzio University of Chieti Pescara; G d'Annunzio
   University of Chieti Pescara
RP Ciccarelli, R (通讯作者)，Dept Expt & Clin Sci, Pharmacol Sect, Via Vestini 29, I 66100 Chieti, Italy.
EM r.ciccarelli@unich.it
RI ; Pipino, Caterina/N 2078 2019; Ciccarelli, Renata/HTN 2298 2023;
   Romano, Mario/I 7986 2012; PANDOLFI, Assunta/K 4595 2016; pandolfi,
   assunta/K 4595 2016
OI Marchisio, Marco/0000 0003 3058 3422; CICCARELLI,
   Renata/0000 0003 1412 738X; ROMANO, Mario/0000 0001 8512 1458; Stuppia,
   Liborio/0000 0002 6232 0996; PIPINO, CATERINA/0000 0002 4350 8686;
   PANDOLFI, Assunta/0000 0003 4135 7631; 
FU StemTeCh Group from CARICHIETI Foundation; Italian Ministry of
   Education, University and Research (MIUR)
FX This study was partially supported by a grant to StemTeCh Group from
   CARICHIETI Foundation and also by funds to R.C. and F.C. from the
   Italian Ministry of Education, University and Research (MIUR).
CR Abdulrazzak H., 2012, CURRENT STEM CEL NOV
   Costa MA, 2011, J CELL PHYSIOL, V226, P1353, DOI 10.1002/jcp.22458
   Antonucci I, 2011, CELL TRANSPLANT, V20, P789, DOI 10.3727/096368910X539074
   Arnhold S, 2011, STEM CELLS INT, V2011, DOI 10.4061/2011/715341
   Bai J, 2012, CYTOTECHNOLOGY, V64, P577, DOI 10.1007/s10616 012 9441 6
   Baksh D, 2004, J CELL MOL MED, V8, P301, DOI 10.1111/j.1582 4934.2004.tb00320.x
   Bhattacharyya S, 2012, ACTA BIOCH BIOPH SIN, V44, P463, DOI 10.1093/abbs/gms027
   Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471 4914(01)02016 0
   Chen QA, 2010, ANAL SCI, V26, P1033, DOI 10.2116/analsci.26.1033
   Cho HH, 2006, TISSUE ENG, V12, P111, DOI 10.1089/ten.2006.12.111
   Christodoulides C, 2009, TRENDS ENDOCRIN MET, V20, P16, DOI 10.1016/j.tem.2008.09.002
   D'Alimonte I, 2011, J BIOL REG HOMEOS AG, V25, P57
   D'Alimonte I, 2007, NEUROSCI LETT, V418, P66, DOI 10.1016/j.neulet.2007.02.061
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   de Boer J, 2004, BONE, V34, P818, DOI 10.1016/j.bone.2004.01.016
   De Coppi P, 2007, NAT BIOTECHNOL, V25, P100, DOI 10.1038/nbt1274
   Ditadi A, 2009, BLOOD, V113, P3953, DOI 10.1182/blood 2008 10 182105
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Farmer SR, 2005, INT J OBESITY, V29, pS13, DOI 10.1038/sj.ijo.0802907
   Fedi P, 1999, J BIOL CHEM, V274, P19465, DOI 10.1074/jbc.274.27.19465
   Forde JE, 2007, CELL MOL LIFE SCI, V64, P1930, DOI 10.1007/s00018 007 7045 7
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Goldring SR, 2007, NAT MED, V13, P133, DOI 10.1038/nm0207 133
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955 0674(95)80104 9
   Hajra AK, 2000, J BIOL CHEM, V275, P9441, DOI 10.1074/jbc.275.13.9441
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Jones E, 2011, INJURY, V42, P562, DOI 10.1016/j.injury.2011.03.030
   Joo S, 2012, ARCH PHARM RES, V35, P271, DOI 10.1007/s12272 012 0207 7
   Kang NH, 2012, CANCER GENE THER, V19, P517, DOI 10.1038/cgt.2012.30
   Khojasteh A, 2012, J ORAL MAXIL SURG, V70, P972, DOI 10.1016/j.joms.2011.02.133
   Koch H, 2005, STEM CELLS DEV, V14, P621, DOI 10.1089/scd.2005.14.621
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Kugimiya F, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000837
   Laflamme C, 2010, ARCH ORAL BIOL, V55, P689, DOI 10.1016/j.archoralbio.2010.06.010
   Lanuti P, 2009, INT J IMMUNOPATH PH, V22, P689, DOI 10.1177/039463200902200314
   Lanuti P, 2012, NEUROBIOL AGING, V33, P2599, DOI 10.1016/j.neurobiolaging.2012.01.004
   Lanuti P, 2012, J IMMUNOL METHODS, V380, P16, DOI 10.1016/j.jim.2012.03.007
   Liu GZ, 2009, J CELL BIOL, V185, P67, DOI 10.1083/jcb.200810137
   Macsai CE, 2008, J CELL PHYSIOL, V215, P578, DOI 10.1002/jcp.21342
   Miranda Sayago JM, 2011, CYTOTHERAPY, V13, P572, DOI 10.3109/14653249.2010.547466
   Moorefield EC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026535
   Moschidou D, 2013, STEM CELLS DEV, V22, P444, DOI 10.1089/scd.2012.0267
   Moschidou D, 2012, MOL THER, V20, P1953, DOI 10.1038/mt.2012.117
   Phermthai T., 2012, STEM CELLS DEV  1218
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Poloni A, 2011, CELL TRANSPLANT, V20, P643, DOI 10.3727/096368910X536518
   Rao TP, 2010, CIRC RES, V106, P1798, DOI 10.1161/CIRCRESAHA.110.219840
   Rosner M, 2011, ONCOTARGET, V2, P705
   Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950
   Roubelakis MG, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/107836
   Scheller EL, 2008, J DENT RES, V87, P126, DOI 10.1177/154405910808700206
   Sessarego N, 2008, HAEMATOLOGICA, V93, P339, DOI 10.3324/haematol.11869
   Shekkeris AS, 2012, CURR STEM CELL RES T, V7, P127
   Sulpizio M, 2011, J CELL BIOCHEM, V112, P3797, DOI 10.1002/jcb.23310
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582 4934.2008.00569.x
   Tetè S, 2008, INT J IMMUNOPATH PH, V21, P309, DOI 10.1177/039463200802100207
   Tokalov SV, 2007, STEM CELLS DEV, V16, P439, DOI 10.1089/scd.2006.0078
   Wagner W, 2005, EXP HEMATOL, V33, P1402, DOI 10.1016/j.exphem.2005.07.003
   Wang SH, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756 8722 5 19
   YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960 9822(02)70716 1
   Yavropoulou Maria P, 2007, Hormones (Athens), V6, P279
   You Q, 2009, J INT MED RES, V37, P105, DOI 10.1177/147323000903700112
   Zaragosi LE, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471 2121 9 11
   Zheng YB, 2008, CELL BIOL INT, V32, P1439, DOI 10.1016/j.cellbi.2008.08.015
NR 67
TC 88
Z9 91
U1 0
U2 17
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2629 3269
EI 2629 3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
PD OCT
PY 2013
VL 9
IS 5
BP 642
EP 654
DI 10.1007/s12015 013 9436 5
PG 13
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 226JG
UT WOS:000325031100010
PM 23605563
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Li, TC
   Wang, H
   Jiang, YK
   Guan, YZ
   Chen, S
   Wu, ZP
   Zou, SJ
   Bonewald, LF
   Duan, PP
AF Li, Tiancheng
   Wang, Han
   Jiang, Yukun
   Guan, Yuzhe
   Chen, Shuo
   Wu, Zuping
   Zou, Shujuan
   Bonewald, Lynda Faye
   Duan, Peipei
TI Canonical Wnt/β catenin signaling has positive effects on osteogenesis,
   but can have negative effects on cementogenesis
SO JOURNAL OF PERIODONTOLOGY
LA English
DT Article
DE biomineralization; dental cementum; mice; transgenic; osteocytes; Wnt
   signaling pathway
ID CELL LINE; IN VITRO; WNT; DIFFERENTIATION; HOMEOSTASIS; PATHWAY;
   ACTIVATION; MICE
AB Background To date, therapeutic approaches for cementum regeneration are limited and outcomes remain unpredictable. A significant barrier to improve therapies for cementum regeneration is that the cementocyte and its intracellular signal transduction mechanisms remain poorly understood. This study aims to elucidate the regulatory mechanism of Wnt pathway in cementogenesis. Methods The effects of canonical Wnt signaling were compared in vitro using immortalized murine cementocyte cell line IDG CM6 and osteocyte cell line IDG SW3 by quantitative real time polymerase chain reaction, Western blot, confocal microscopy, alkaline phosphatase (ALP) assay, and Alizarin red S staining. In vivo, histological changes of cementum and bone formation were examined in transgenic mice in which constitutive activation of beta catenin is driven by Dmp1 promoter. Results Expression of components of the Wnt/beta catenin pathway were much greater in the IDG SW3 cells compared with the IDG CM6 cells resulting in much lower expression of Sost/sclerostin in the IDG SW3 cells. In the IDG CM6 cells, low dose Wnt3a (20 ng/ml) had a modest effect while high dose (200 ng/ml) inhibited runt related transcription factor 2, osterix, ALP, and osteopontin in contrast to the IDG SW3 cells where high dose Wnt3a dramatically increased mRNA expression of these same markers. However, high Wnt3a significantly increased mRNA for components of Wnt/beta catenin signaling pathway in both IDG CM6 and IDG SW3 cells. In vivo, constitutive activation of beta catenin in the Dmp1 lineage cells in mice leads to bone hyperplasia and cementum hypoplasia. Conclusion These findings indicate that Wnt signaling has distinct and different effects on the regulation of long bone as compared with cementum.
C1 [Li, Tiancheng; Wang, Han; Jiang, Yukun; Guan, Yuzhe; Chen, Shuo; Wu, Zuping; Zou, Shujuan; Duan, Peipei] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Sichuan, Peoples R China.
   [Li, Tiancheng; Wang, Han; Jiang, Yukun; Guan, Yuzhe; Chen, Shuo; Wu, Zuping; Zou, Shujuan; Duan, Peipei] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Chengdu, Sichuan, Peoples R China.
   [Li, Tiancheng; Wang, Han; Jiang, Yukun; Guan, Yuzhe; Chen, Shuo; Wu, Zuping; Zou, Shujuan; Duan, Peipei] Sichuan Univ, West China Hosp Stomatol, Dept Orthodont, 14,3rd Sect,Renmin South Rd, Chengdu 610041, Sichuan, Peoples R China.
   [Bonewald, Lynda Faye] Indiana Univ Sch Med, Indiana Ctr Musculoskeletal Hlth, Dept Anat, Indianapolis, IN 46202 USA.
   [Bonewald, Lynda Faye] Indiana Univ Sch Med, Indiana Ctr Musculoskeletal Hlth, Dept Cell Biol & Physiol, Indianapolis, IN 46202 USA.
   [Bonewald, Lynda Faye] Indiana Univ Sch Med, Indiana Ctr Musculoskeletal Hlth, Dept Orthopaed Surg, Indianapolis, IN 46202 USA.
C3 Sichuan University; Sichuan University; Sichuan University; Indiana
   University System; Indiana University Bloomington; Indiana University
   System; Indiana University Bloomington; Indiana University System;
   Indiana University Bloomington
RP Duan, PP (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Dept Orthodont, 14,3rd Sect,Renmin South Rd, Chengdu 610041, Sichuan, Peoples R China.
EM duanp@scu.edu.cn
RI Bonewald, Lynda/Q 3638 2019
OI Wang, Han/0000 0002 0104 7391
FU National Natural Science Foundation of China [81701005, 82071150];
   Science and Technology Department, Sichuan, China [2018JY0139]
FX National Natural Science Foundation of China, Grant/Award Numbers:
   81701005, 82071150; Science and Technology Department, Sichuan, China,
   Grant/Award Number: 2018JY0139
CR Aida Y, 2018, IN VITRO CELL DEV AN, V54, P468, DOI 10.1007/s11626 018 0265 3
   Alvarez Pérez MA, 2006, BONE, V38, P409, DOI 10.1016/j.bone.2005.09.009
   Aoki Koji, 2008, V468, P307, DOI 10.1007/978 1 59745 249 6_24
   Årtun J, 2009, AM J ORTHOD DENTOFAC, V135, P448, DOI 10.1016/j.ajodo.2007.06.012
   Azraq I, 2021, ANN ANAT, V234, DOI 10.1016/j.aanat.2020.151668
   Bao JQ, 2021, BIOMED PHARMACOTHER, V133, DOI 10.1016/j.biopha.2020.110935
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bosshardt DD, 2009, PERIODONTOL 2000, V51, P208, DOI 10.1111/j.1600 0757.2009.00317.x
   De Rossi A, 2016, J ENDODONT, V42, P1251, DOI 10.1016/j.joen.2016.05.009
   Han PP, 2015, J BONE MINER RES, V30, P1160, DOI 10.1002/jbmr.2445
   Han PP, 2012, BIOMATERIALS, V33, P6370, DOI 10.1016/j.biomaterials.2012.05.061
   Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931
   Hu YY, 2020, J CELL BIOCHEM, V121, P3700, DOI 10.1002/jcb.29509
   Huybrechts Y, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00165
   Khijmatgar S, 2021, J TISSUE ENG REGEN M, V15, P1069, DOI 10.1002/term.3250
   Kim SE, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.761418
   Kimura A, 2018, CURR PHARM DESIGN, V24, P3980, DOI 10.2174/1381612824666181116103514
   Ko FC, 2022, J ORTHOP RES, V40, P1834, DOI 10.1002/jor.25217
   Lerner UH, 2015, J INTERN MED, V277, P630, DOI 10.1111/joim.12368
   Li SG, 2016, MOL MED REP, V14, P4975, DOI 10.3892/mmr.2016.5909
   Lim WH, 2014, J PERIODONTAL RES, V49, P751, DOI 10.1111/jre.12158
   Lojk J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910840
   Maeda K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225525
   Maurel DB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158381
   Morgenthal A, 2021, J STRUCT BIOL, V213, DOI 10.1016/j.jsb.2021.107726
   Narita LE, 2021, MEDICINA LITHUANIA, V57, DOI 10.3390/medicina57101071
   Naruse H, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 99231 x
   Nemoto E, 2009, BONE, V44, P805, DOI 10.1016/j.bone.2008.12.029
   Nuñez J, 2010, J PERIODONTAL RES, V45, P809, DOI 10.1111/j.1600 0765.2010.01291.x
   Rooker SM, 2010, DEV DYNAM, V239, P140, DOI 10.1002/dvdy.22003
   Routledge D, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.176073
   Turkkahraman H, 2020, AM J ORTHOD DENTOFAC, V158, P16, DOI 10.1016/j.ajodo.2019.06.021
   Walker CG, 2008, EUR J ORAL SCI, V116, P312, DOI 10.1111/j.1600 0722.2008.00545.x
   Wang C, 2018, J PERIODONTAL RES, V53, P705, DOI 10.1111/jre.12554
   Wang H, 2020, BIOCHEM BIOPH RES CO, V523, P595, DOI 10.1016/j.bbrc.2020.01.003
   Wang X, 2017, J DENT RES, V96, P1430, DOI 10.1177/0022034517718790
   Wang Y, 2022, INFLAMMATION, V45, P780, DOI 10.1007/s10753 021 01583 z
   Woo SM, 2011, J BONE MINER RES, V26, P2634, DOI 10.1002/jbmr.465
   Xiao ZL, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006562
   Xie X, 2019, J DENT RES, V98, P1262, DOI 10.1177/0022034519871021
   Xu Y, 2019, J PERIODONTOL, V90, P1002, DOI 10.1002/JPER.18 0639
   Yamamoto T, 2019, J ORAL BIOSCI, V61, P105, DOI 10.1016/j.job.2019.03.006
   Zhao N, 2016, J DENT RES, V95, P734, DOI 10.1177/0022034516641898
   Zhao N, 2016, J BONE MINER RES, V31, P430, DOI 10.1002/jbmr.2690
   Zhatig Q, 2019, APPL MATER TODAY, V16, P375, DOI 10.1016/j.apmt.2019.06.011
   Zhong JX, 2019, J R SOC INTERFACE, V16, DOI 10.1098/rsif.2019.0108
NR 46
TC 6
Z9 6
U1 0
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3492
EI 1943 3670
J9 J PERIODONTOL
JI J. Periodont.
PD NOV
PY 2022
VL 93
IS 11
BP 1725
EP 1737
DI 10.1002/JPER.21 0599
EA AUG 2022
PG 13
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 6P5OY
UT WOS:000838440400001
PM 35642884
DA 2025 08 17
ER

PT J
AU Wu, QH
   Liang, HB
   Wang, CY
   Chen, YQ
   Yu, CX
   Luo, JT
   Cai, LQ
   Miao, JS
   Xu, JK
   Jin, HM
   Wang, XY
AF Wu, Qihang
   Liang, Haibo
   Wang, Chenyu
   Chen, Yiqi
   Yu, Chenxin
   Luo, Jiangtao
   Cai, Luqiong
   Miao, Jiansen
   Xu, Jiake
   Jin, Haiming
   Wang, Xiangyang
TI Tetrahydroberberine Prevents Ovariectomy Induced Bone Loss by Inhibiting
   RANKL Induced Osteoclastogenesis and Promoting Osteoclast Apoptosis
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE tetrahydroberberine; RANKL; osteoclast; estrogen deficiency; apoptosis
ID NUCLEAR FACTOR; OSTEOPOROSIS; ESTROGEN; CANADINE
AB Postmenopausal osteoporosis (PMOP) arises from the disruption in bone remodeling caused by estrogen deficiency, leading to a heightened susceptibility to osteoporotic fractures in aging women. Tetrahydroberberine (THB) is a chemical compound extracted from Corydalis yanhusuo, a member of the traditional Chinese medicine series "Zhejiang eight taste", possessing a variety of pharmacological functions such as lowering lipids and preventing muscle atrophy. However, the impact of THB on PMOP has not been systematically explored. In vitro experiments supported that THB suppresses osteoclast formation and resorption of bone concentration dependently. Further experiments confirmed that these inhibitory effects of THB were related to inhibition on expressions of osteoclast specific genes, the mitogen activated protein kinase (MAPK) pathway, and the nuclear factor kappa B (NF kappa B) pathway and an increased apoptosis level in mature osteoclasts. Additionally, THB treatment mitigated the ovariectomy induced bone loss and improved the skeletal microarchitecture in vivo. In conclusion, THB has such potential to improve the PMOP status.
C1 [Wu, Qihang; Liang, Haibo; Luo, Jiangtao; Miao, Jiansen; Xu, Jiake; Jin, Haiming; Wang, Xiangyang] Wenzhou Med Univ, Affiliated Hosp & Yuying Childrens Hosp 2, Dept Orthopaed, Wenzhou 325000, Peoples R China.
   [Wang, Chenyu; Chen, Yiqi] Wenzhou Med Univ, Sch Med 2, Wenzhou 325000, Peoples R China.
   [Yu, Chenxin; Cai, Luqiong] Wenzhou Med Univ, Affiliated Hosp & Yuying Childrens Hosp 2, Dept Endocrinol, Wenzhou 325000, Peoples R China.
   [Xu, Jiake] Chinese Acad Sci, Shenzhen Inst Adv Technol, Shenzhen 518055, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical
   University; Chinese Academy of Sciences; Shenzhen Institute of Advanced
   Technology, CAS
RP Xu, JK; Jin, HM; Wang, XY (通讯作者)，Wenzhou Med Univ, Affiliated Hosp & Yuying Childrens Hosp 2, Dept Orthopaed, Wenzhou 325000, Peoples R China.; Xu, JK (通讯作者)，Chinese Acad Sci, Shenzhen Inst Adv Technol, Shenzhen 518055, Peoples R China.
EM jiake.xu@siat.ac.cn; jinhaiming@wmu.edu.cn; xiangyangwang@wmu.edu.cn
RI Liang, Haibo/D 1730 2016; Jin, Haiming/LZE 3453 2025
OI Jin, Haiming/0000 0003 2666 8415; 
FU National Natural Science Foundation of China [82202757, 82172494,
   82350710800, 82374470]; "Pioneer" and "Leading Goose" R&D Program of
   Zhejiang [2022C013144]; Basic Scientific Research Project of Wenzhou
   [Y2023034]; Science and Technology Innovation Activity Plan and New
   Talents Plan for College Students in Zhejiang Province [2024R413A026];
   Shenzhen Medical Research Fund [B2302005]
FX This work was funded by the National Natural Science Foundation of China
   (82202757, 82172494, 82350710800, and 82374470), the "Pioneer" and
   "Leading Goose" R&D Program of Zhejiang (2022C013144), the Basic
   Scientific Research Project of Wenzhou (Y2023034), the Science and
   Technology Innovation Activity Plan and New Talents Plan for College
   Students in Zhejiang Province (2024R413A026) and Shenzhen Medical
   Research Fund (B2302005).
CR Bae S, 2023, CELL MOL IMMUNOL, V20, P94, DOI 10.1038/s41423 022 00959 x
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Clynes MA, 2021, RHEUMATOLOGY, V60, P529, DOI 10.1093/rheumatology/keaa755
   Correché ER, 2008, BIOORGAN MED CHEM, V16, P3641, DOI 10.1016/j.bmc.2008.02.015
   Cui YZ, 2024, SMALL, V20, DOI 10.1002/smll.202303494
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   He QM, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.983884
   Huang XL, 2022, MOL MED REP, V25, DOI 10.3892/mmr.2021.12575
   Kim BJ, 2019, CELL MOL LIFE SCI, V76, P1243, DOI 10.1007/s00018 018 2981 y
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Komori T, 2015, EUR J PHARMACOL, V759, P287, DOI 10.1016/j.ejphar.2015.03.028
   Lee H, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122748
   Liu CL, 2023, BIOMED PHARMACOTHER, V166, DOI 10.1016/j.biopha.2023.115392
   Manolagas SC, 2013, NAT REV ENDOCRINOL, V9, P699, DOI 10.1038/nrendo.2013.179
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Ryoo GH, 2020, BIOCHEM BIOPH RES CO, V531, P508, DOI 10.1016/j.bbrc.2020.07.083
   Stern PH, 2007, J CELL BIOCHEM, V101, P1087, DOI 10.1002/jcb.21311
   Tan CN, 2019, PHYTOMEDICINE, V54, P231, DOI 10.1016/j.phymed.2018.09.200
   Walker MD, 2023, NEW ENGL J MED, V389, P1979, DOI 10.1056/NEJMcp2307353
   Wang LT, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24065814
   Wang QQ, 2020, J BONE MINER RES, V35, P1582, DOI 10.1002/jbmr.4025
   Wei GL, 2024, EUR J PHARMACOL, V968, DOI 10.1016/j.ejphar.2024.176433
   Wei S, 2001, ENDOCRINOLOGY, V142, P1290, DOI 10.1210/en.142.3.1290
   Wu C, 2010, NEUROPHARMACOLOGY, V59, P567, DOI 10.1016/j.neuropharm.2010.08.018
   Zaheer S, 2015, EXPERT OPIN DRUG MET, V11, P461, DOI 10.1517/17425255.2015.1000860
   Zhu GC, 2022, INT J BIOL SCI, V18, P5522, DOI 10.7150/ijbs.72211
NR 30
TC 4
Z9 4
U1 4
U2 13
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021 8561
EI 1520 5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD SEP 5
PY 2024
VL 72
IS 37
BP 20383
EP 20395
DI 10.1021/acs.jafc.4c02982
EA SEP 2024
PG 13
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Agriculture; Chemistry; Food Science & Technology
GA G2U2E
UT WOS:001308683000001
PM 39238071
DA 2025 08 17
ER

PT J
AU Wang, LQ
   Wang, Y
   Chen, A
   Teli, M
   Kondo, R
   Jalali, A
   Fan, Y
   Liu, SZ
   Zhao, XY
   Siegel, A
   Minami, K
   Agarwal, M
   Li, BY
   Yokota, H
AF Wang, Luqi
   Wang, Yue
   Chen, Andy
   Teli, Meghana
   Kondo, Rika
   Jalali, Aydin
   Fan, Yao
   Liu, Shengzhi
   Zhao, Xinyu
   Siegel, Amanda
   Minami, Kazumasa
   Agarwal, Mangilal
   Li, Bai Yan
   Yokota, Hiroki
TI Pitavastatin slows tumor progression and alters urine derived volatile
   organic compounds through the mevalonate pathway
SO FASEB JOURNAL
LA English
DT Article
DE breast cancer; VOC; osteoclasts; bone metastasis
ID PROLIFERATOR ACTIVATED RECEPTOR; BREAST CANCER; CELL LINES; IN VITRO;
   STATINS; OSTEOCLASTOGENESIS; BISPHOSPHONATES; SUPPRESSION; MECHANISM;
   SNAIL
AB Bone is a frequent site of metastasis from breast cancer, and a desirable drug could suppress tumor growth as well as metastasis linked bone loss. Currently, no drug is able to cure breast cancer associated bone metastasis. In this study, we focused on statins that are known to inhibit cholesterol production and act as antitumor agents. After an initial potency screening of 7 U.S. Food and Drug Administration approved statins, we examined pitavastatin as a drug candidate for inhibiting tumor and tumor induced bone loss. In vitro analysis revealed that pitavastatin acted as an inhibitor of tumor progression by altering stress to the endoplasmic reticulum, down regulating peroxisome proliferator activated receptor gamma, and reducing Snail and matrix metalloproteinase 9. In bone homeostasis, it blocked osteoclast development by suppressing transcription factors c Fos and JunB, but stimulated osteoblast mineralization by regulating bone morphogenetic protein 2 and p53. In a mouse model, pitavastatin presented a dual role in tumor inhibition in the mammary fat pad, as well as in bone protection in the osteolytic tibia. In mass spectrometry based analysis, volatile organic compounds (VOCs) that were linked to lipid metabolism and cholesterol synthesis were elevated in mice from the tumor grown placebo group. Notably, pitavastatin treated mice reduced specific VOCs that are linked to lipid metabolites in the mevalonate pathway. Collectively, the results lay a foundation for further investigation of pitavastatin's therapeutic efficacy in tumor induced bone loss, as well as VOC based diagnosis of tumor progression and treatment efficacy.
C1 [Wang, Luqi; Wang, Yue; Fan, Yao; Li, Bai Yan; Yokota, Hiroki] Harbin Med Univ, Sch Pharm, Dept Pharmacol, 157 Baojian Rd, Harbin 150081, Peoples R China.
   [Wang, Luqi; Wang, Yue; Chen, Andy; Teli, Meghana; Kondo, Rika; Jalali, Aydin; Fan, Yao; Liu, Shengzhi; Zhao, Xinyu; Yokota, Hiroki] Indiana Univ Purdue Univ, Dept Biomed Engn, 723 West Michigan St,SL220, Indianapolis, IN 46202 USA.
   [Siegel, Amanda; Agarwal, Mangilal; Yokota, Hiroki] Indiana Univ Purdue Univ, Integrated Nanosyst Dev Inst, Indianapolis, IN 46202 USA.
   [Siegel, Amanda] Indiana Univ Purdue Univ, Dept Chem & Chem Biol, Indianapolis, IN 46202 USA.
   [Agarwal, Mangilal; Yokota, Hiroki] Indiana Univ Purdue Univ, Dept Mech Engn, Indianapolis, IN 46202 USA.
   [Kondo, Rika; Minami, Kazumasa] Osaka Univ, Grad Sch Med, Suita, Osaka, Japan.
   [Zhao, Xinyu] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing, Peoples R China.
   [Yokota, Hiroki] Indiana Univ Sch Med, Simon Canc Ctr, Indianapolis, IN 46202 USA.
   [Yokota, Hiroki] Indiana Univ Sch Med, Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN 46202 USA.
C3 Harbin Medical University; Purdue University System; Purdue University;
   Purdue University in Indianapolis; Purdue University System; Purdue
   University; Purdue University in Indianapolis; Purdue University System;
   Purdue University; Purdue University in Indianapolis; Purdue University
   System; Purdue University; Purdue University in Indianapolis; University
   of Osaka; Chinese Academy of Medical Sciences   Peking Union Medical
   College; Peking Union Medical College Hospital; Indiana University
   System; Indiana University Bloomington; Indiana University System;
   Indiana University Bloomington
RP Li, BY (通讯作者)，Harbin Med Univ, Sch Pharm, Dept Pharmacol, 157 Baojian Rd, Harbin 150081, Peoples R China.; Yokota, H (通讯作者)，Indiana Univ Purdue Univ, Dept Biomed Engn, 723 West Michigan St,SL220, Indianapolis, IN 46202 USA.
EM liby@ems.hrbmu.edu.cn; hyokota@iupui.edu
RI ; Siegel, Amanda/AAR 7871 2020
OI Jalali, Seyedaydin/0009 0008 8529 3629; Siegel,
   Amanda/0000 0003 4112 0212; 
FU 100 Voices of Hope; U.S. National Institutes of Health (NIH)/National
   Institute of Arthritis and Musculoskeletal and Skin Diseases
   [R01AR052144]; NIH/National Cancer Institute [R03CA238555]
FX The authors thank Ali Daneshkhah, Paul Grocki, and Mark Woollam (all
   from Indiana University Purdue University Indianapolis) for technical
   support, and Hisako Masuda (Indiana University, Kokomo, IN, USA) for
   data analysis. This study was supported, in part, by funds from 100
   Voices of Hope (to H.Y.) and the U.S. National Institutes of Health
   (NIH)/National Institute of Arthritis and Musculoskeletal and Skin
   Diseases (R01AR052144) and NIH/National Cancer Institute (R03CA238555 to
   H.Y.). The authors declare no conflicts of interest.
CR Ahern TP, 2014, LANCET ONCOL, V15, pE461, DOI 10.1016/S1470 2045(14)70119 6
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Brook N, 2018, INT J BIOCHEM CELL B, V96, P63, DOI 10.1016/j.biocel.2018.01.003
   Buhaescu I, 2007, CLIN BIOCHEM, V40, P575, DOI 10.1016/j.clinbiochem.2007.03.016
   CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661
   Catapano AL, 2012, CLIN LIPIDOL, V7, P3, DOI 10.2217/CLP.12.21
   Chiang YR, 2008, J BACTERIOL, V190, P905, DOI 10.1128/JB.01525 07
   Chimento A, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00807
   Chou R, 2016, JAMA J AM MED ASSOC, V316, P2008, DOI 10.1001/jama.2015.15629
   Coleman R E, 2000, Breast Cancer, V7, P361, DOI 10.1007/BF02966406
   Corsini A, 1999, PHARMACOL THERAPEUT, V84, P413, DOI 10.1016/S0163 7258(99)00045 5
   Davies Jonathan T, 2016, Lipid Insights, V9, P13
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Dunford JE, 2010, CURR PHARM DESIGN, V16, P2961
   Fan M, 2016, CELL PHYSIOL BIOCHEM, V38, P1319, DOI 10.1159/000443076
   Gago Dominguez M, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1628
   Garrett WS, 2015, SCIENCE, V348, P80, DOI 10.1126/science.aaa4972
   Ghavami S, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.61
   Göbel A, 2015, BREAST CANCER RES TR, V154, P623, DOI 10.1007/s10549 015 3624 8
   Hamamura K, 2015, CELL SIGNAL, V27, P353, DOI 10.1016/j.cellsig.2014.11.020
   Hamamura K, 2013, J BONE MINER METAB, V31, P618, DOI 10.1007/s00774 013 0450 0
   Han L, 2017, FUTUR CARDIOL, V13, DOI 10.2217/fca 2017 0019
   Iannelli F, 2018, RECENT PAT ANTI CANC, V13, P184, DOI 10.2174/1574892812666171129141211
   Iarrobino N. A., 2018, AM J CLIN ONCOL
   Jadhav SB, 2006, J PHARM PHARMACOL, V58, P3, DOI 10.1211/jpp.58.1.0002
   Jiang P, 2014, BRIT J CANCER, V111, P1562, DOI 10.1038/bjc.2014.431
   Kamiya Nobuhiro, 2012, Curr Mol Pharmacol, V5, P153
   Khalid T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143283
   Kobayashi Y, 2017, ONCOTARGET, V8, P72147, DOI 10.18632/oncotarget.20046
   Kodama H.A., 1981, J ORAL BIOL, V23, P899, DOI DOI 10.2330/JORALBIOSCI1965.23.899
   Kotta Loizou I, 2012, ANTI CANCER AGENT ME, V12, P1025, DOI 10.2174/187152012803529664
   Kwak J, 2012, PHYSIOL BEHAV, V107, P112, DOI 10.1016/j.physbeh.2012.06.008
   Lan CH, 2014, ENVIRON POLLUT, V193, P156, DOI 10.1016/j.envpol.2014.06.014
   Lavra L, 2015, SCI REP UK, V5, DOI 10.1038/srep13246
   Lelekakis M, 1999, CLIN EXP METASTAS, V17, P163, DOI 10.1023/A:1006689719505
   Liu SZ, 2018, CANCER RES, V78, P3865, DOI 10.1158/0008 5472.CAN 18 0056
   Liu YL, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471 2105 6 276
   Minami K, 2017, SCI REP UK, V7, DOI 10.1038/srep45686
   Miyazaki T, 2011, ANAL BIOCHEM, V410, P7, DOI 10.1016/j.ab.2010.11.014
   Murtagh F, 2012, WIRES DATA MIN KNOWL, V2, P86, DOI 10.1002/widm.53
   Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757
   Nomura S, 2006, J EXP CLIN CANC RES, V25, P443
   Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29
   RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092 8674(78)90101 0
   Rogers MJ, 2000, NAT MED, V6, P21, DOI 10.1038/71484
   Siegel AP, 2017, J BREATH RES, V11, DOI 10.1088/1752 7163/aa6ac6
   Sopková J, 2017, GEN PHYSIOL BIOPHYS, V36, P501, DOI 10.4149/gpb_2017045
   Summons RE, 2006, PHILOS T R SOC B, V361, P951, DOI 10.1098/rstb.2006.1837
   Wang CS, 2014, SCI REP UK, V4, DOI 10.1038/srep05383
   Wang HN, 2017, ONCOTARGET, V8, P88122, DOI 10.18632/oncotarget.21490
   Wang LQ, 2018, INT J ONCOL, V53, P1001, DOI 10.3892/ijo.2018.4481
   Whitaker M, 2012, NEW ENGL J MED, V366, P2048, DOI 10.1056/NEJMp1202619
   Wieczorek E, 2015, TUMOR BIOL, V36, P163, DOI 10.1007/s13277 014 2747 6
   Woollam M, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 38920 0
   Xu WX, 2015, CELL SIGNAL, V27, P2332, DOI 10.1016/j.cellsig.2015.08.014
   Zhang W, 2018, ONCOTARGET, V9, P3690, DOI [10.18632/oncotarget.24286, 10.18632/oncotarget.23196]
NR 56
TC 18
Z9 18
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD DEC
PY 2019
VL 33
IS 12
BP 13710
EP 13721
DI 10.1096/fj.201901388R
PG 12
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA KC9BO
UT WOS:000507466100052
PM 31585508
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Terpos, E
AF Terpos, Evangelos
TI Bisphosphonate Anticancer Activity in Multiple Myeloma
SO ANTI CANCER AGENTS IN MEDICINAL CHEMISTRY
LA English
DT Article
DE Bisphosphonate; Bone lesion; Clodronate; Ibandronate; Multiple myeloma;
   Pamidronate; Survival; Zoledronic acid
ID NITROGEN CONTAINING BISPHOSPHONATES; RANDOMIZED CONTROLLED TRIAL;
   ZOLEDRONIC ACID; BONE DISEASE; IN VIVO; CANCER PATIENTS; OSTEOLYTIC
   LESIONS; CLODRONIC ACID; TUMOR BURDEN; DOUBLE BLIND
AB Bisphosphonates inhibit osteoclast mediated bone resorption and have been used extensively to prevent skeletal related events in patients with bone lesions from multiple myeloma (MM). In addition, in vitro and in vivo preclinical data suggest that bisphosphonates also have antimyeloma properties that may induce myeloma cell apoptosis, activate an anticancer immune response, inhibit angiogenesis, and reduce tumor burden, supporting an expanded role for bisphosphonates. Signals for improved survival in the clinic first emerged in retrospective analyses of MM patient subgroups in larger clinical trials. Recently, improved progression free survival and overall survival with bisphosphonates have been reported in the overall populations of large scale randomized clinical trials. Several ongoing clinical trials will help further define the role of bisphosphonates during antimyeloma therapy. Overall, bisphosphonates appear to be well tolerated in patients with MM; the most common adverse events are mild and can be easily managed. However, emphasis on renal monitoring and preventive dentistry are necessary to reduce the risk of potential adverse events, and have become the standard of care for patients with MM.
C1 Univ Athens, Sch Med, Alexandra Gen Hosp, Dept Clin Therapeut, Athens 11528, Greece.
C3 Alexandra Hospital; National & Kapodistrian University of Athens
RP Terpos, E (通讯作者)，Univ Athens, Sch Med, Alexandra Gen Hosp, Dept Clin Therapeut, 80 Vas Sofias Ave, Athens 11528, Greece.
EM eterpos@med.uoa.gr
RI ; Terpos, Evangelos/AAD 3667 2019
OI Terpos, Evangelos/0000 0001 5133 1422; 
FU Novartis Pharmaceuticals Corporation
FX Financial support for medical editorial assistance was provided by
   Novartis Pharmaceuticals Corporation. We thank Michael Hobert, PhD, of
   ProEd Communications, Inc.(R), for his medical editorial assistance with
   this manuscript.
CR [Anonymous], NCCN CLIN PRACT GUID
   Avilés A, 2007, MED ONCOL, V24, P227, DOI 10.1007/BF02698044
   Badros A, 2008, J CLIN ONCOL, V26, P5904, DOI 10.1200/JCO.2008.16.9300
   BATAILLE R, 1995, BRIT J HAEMATOL, V90, P721, DOI 10.1111/j.1365 2141.1995.tb05609.x
   Berenson JR, 1998, J CLIN ONCOL, V16, P593, DOI 10.1200/JCO.1998.16.2.593
   Clézardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008 5472.CAN 05 0264
   Corso A, 2005, CANCER, V104, P118, DOI 10.1002/cncr.21104
   Croucher PI, 2003, CANCER AM CANCER SOC, V97, P818, DOI 10.1002/cncr.11125
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   Cruz JC, 2001, EXP HEMATOL, V29, P441, DOI 10.1016/S0301 472X(01)00618 X
   Dallas SL, 1999, BLOOD, V93, P1697, DOI 10.1182/blood.V93.5.1697.405a17_1697_1706
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Green JR, 2002, CURR OPIN ONCOL, V14, P609, DOI 10.1097/00001622 200211000 00004
   Guenther A, 2010, INT J CANCER, V126, P239, DOI 10.1002/ijc.24758
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hoff AO, 2008, J BONE MINER RES, V23, P826, DOI [10.1359/JBMR.080205, 10.1359/jbmr.080205]
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kavanagh KL, 2006, J BIOL CHEM, V281, P22004, DOI 10.1074/jbc.M602603200
   Koizumi M, 2007, EUR J HAEMATOL, V79, P382, DOI 10.1111/j.1600 0609.2007.00957.x
   Kunzmann V, 2000, BLOOD, V96, P384
   Kyle RA, 2007, J CLIN ONCOL, V25, P2464, DOI 10.1200/JCO.2007.12.1269
   Lipton A, 2007, CLIN LYMPHOMA MYELOM, V7, P346, DOI 10.3816/CLM.2007.n.011
   McCloskey EV, 2001, BRIT J HAEMATOL, V113, P1035, DOI 10.1046/j.1365 2141.2001.02851.x
   Mehrotra B., 2006, HEMATOL AM SOC HEMAT, P515
   Mehrotra Bhoomi, 2006, Hematology Am Soc Hematol Educ Program, P356
   Montefusco V, 2008, LEUKEMIA LYMPHOMA, V49, P2156, DOI 10.1080/10428190802483778
   Morgan GJ, 2011, LANCET ONCOL, V12, P743, DOI 10.1016/S1470 2045(11)70157 7
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Oshima T, 2005, BLOOD, V106, P3160, DOI 10.1182/blood 2004 12 4940
   RADL J, 1985, CANCER AM CANCER SOC, V55, P1030, DOI 10.1002/1097 0142(19850301)55:5<1030::AID CNCR2820550518>3.0.CO;2 Y
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Spencer Andrew, 2008, BMC Clin Pharmacol, V8, P2, DOI 10.1186/1472 6904 8 2
   Teoh G., 2009, BLOOD, P114
   Terpos E, 2005, ANN ONCOL, V16, P1223, DOI 10.1093/annonc/mdi235
   Terpos E, 2009, ANN ONCOL, V20, P1303, DOI 10.1093/annonc/mdn796
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Van den Wyngaert T, 2009, ANN ONCOL, V20, P331, DOI 10.1093/annonc/mdn630
   Weitzman R, 2007, CRIT REV ONCOL HEMAT, V62, P148, DOI 10.1016/j.critrevonc.2006.12.005
   Yaccoby S, 2002, BRIT J HAEMATOL, V116, P278, DOI 10.1046/j.1365 2141.2002.03257.x
NR 41
TC 7
Z9 9
U1 0
U2 5
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1871 5206
EI 1875 5992
J9 ANTI CANCER AGENT ME
JI Anti Cancer Agents Med. Chem.
PD FEB
PY 2012
VL 12
IS 2
BP 123
EP 128
DI 10.2174/187152012799014986
PG 6
WC Oncology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 936TK
UT WOS:000303612700005
PM 21864228
DA 2025 08 17
ER

PT J
AU Luther, J
   Yorgan, TA
   Rolvien, T
   Ulsamer, L
   Koehne, T
   Liao, NN
   Keller, D
   Vollersen, N
   Teufel, S
   Neven, M
   Peters, S
   Schweizer, M
   Trumpp, A
   Rosigkeit, S
   Bockamp, E
   Mundlos, S
   Kornak, U
   Oheim, R
   Amling, M
   Schinke, T
   David, JP
AF Luther, Julia
   Yorgan, Timur Alexander
   Rolvien, Tim
   Ulsamer, Lorenz
   Koehne, Till
   Liao, Nannan
   Keller, Daniela
   Vollersen, Nele
   Teufel, Stefan
   Neven, Mona
   Peters, Stephanie
   Schweizer, Michaela
   Trumpp, Andreas
   Rosigkeit, Sebastian
   Bockamp, Ernesto
   Mundlos, Stefan
   Kornak, Uwe
   Oheim, Ralf
   Amling, Michael
   Schinke, Thorsten
   David, Jean Pierre
TI Wnt1 is an Lrp5 independent bone anabolic Wnt ligand
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID PARATHYROID HORMONE 1 34; OSTEOGENESIS IMPERFECTA; LRP5 GENE; HR PQCT;
   MUTATIONS; MICE; OSTEOPOROSIS; OSTEOBLAST; MOUSE; RECEPTOR
AB WNT1 mutations in humans are associated with a new form of osteogenesis imperfecta and with early onset osteoporosis, suggesting a key role of WNT1 in bone mass regulation. However, the general mode of action and the therapeutic potential of Wnt1 in clinically relevant situations such as aging remain to be established. Here, we report the high prevalence of heterozygous WNT1 mutations in patients with early onset osteoporosis. We show that inactivation of Wnt1 in osteoblasts causes severe osteoporosis and spontaneous bone fractures in mice. In contrast, conditional Wnt1 expression in osteoblasts promoted rapid bone mass increase in developing young, adult, and aged mice by rapidly increasing osteoblast numbers and function. Contrary to current mechanistic models, loss of Lrp5, the co receptor thought to transmit extracellular WNT signals during bone mass regulation, did not reduce the bone anabolic effect of Wnt1, providing direct evidence that Wnt1 function does not require the LRP5 co receptor. The identification of Wnt1 as a regulator of bone formation and remodeling provides the basis for development of Wnt1 targeting drugs for the treatment of osteoporosis.
C1 [Luther, Julia; Yorgan, Timur Alexander; Rolvien, Tim; Ulsamer, Lorenz; Koehne, Till; Liao, Nannan; Keller, Daniela; Vollersen, Nele; Teufel, Stefan; Neven, Mona; Peters, Stephanie; Oheim, Ralf; Amling, Michael; Schinke, Thorsten; David, Jean Pierre] Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, D 20246 Hamburg, Germany.
   [Koehne, Till] Univ Med Ctr Hamburg Eppendorf, Dept Orthodont, D 20246 Hamburg, Germany.
   [Schweizer, Michaela] Univ Med Ctr Hamburg Eppendorf, Ctr Mol Neurobiol, D 20251 Hamburg, Germany.
   [Trumpp, Andreas] Deutsch Krebsforschungszentrum DKFZ, Div Stem Cells & Canc, D 69120 Heidelberg, Germany.
   [Rosigkeit, Sebastian; Bockamp, Ernesto] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Translat Immunol, D 55131 Mainz, Germany.
   [Rosigkeit, Sebastian; Bockamp, Ernesto] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Res Ctr Immunotherapy, D 55131 Mainz, Germany.
   [Mundlos, Stefan; Kornak, Uwe] Charite Univ Med Berlin, Inst Med Genet & Human Genet, D 13353 Berlin, Germany.
   [Keller, Daniela; Mundlos, Stefan; Kornak, Uwe] Charite Univ Med Berlin, Berlin Brandenburg Ctr Regenerat Therapies, D 13353 Berlin, Germany.
   [Mundlos, Stefan; Kornak, Uwe] Max Planck Inst Mol Genet, D 14195 Berlin, Germany.
   [Teufel, Stefan] Univ Munster, Med Fac, Inst Expt Musculoskeletal Med, D 48149 Munster, Germany.
C3 University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Hamburg; University Medical Center Hamburg Eppendorf;
   University of Hamburg; University Medical Center Hamburg Eppendorf;
   Helmholtz Association; German Cancer Research Center (DKFZ); Johannes
   Gutenberg University of Mainz; Johannes Gutenberg University of Mainz;
   Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin; Max Planck
   Society; University of Munster
RP Amling, M; Schinke, T; David, JP (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, D 20246 Hamburg, Germany.
EM amling@uke.de; schinke@uke.de; j.david@uke.de
RI Trumpp, Andreas/HDL 7232 2022; Mundlos, Stefan/ABH 9585 2020; Koehne,
   Till/AAC 4458 2020; Oheim, Ralf/KPA 2969 2024
OI Bockamp, Ernesto/0000 0002 6181 1734; Mundlos,
   Stefan/0000 0002 9788 3166; Trumpp, Andreas/0000 0002 6212 3466; Kohne,
   Till/0009 0000 8830 1964
FU DFG (Deutsche Forschungsgemeinschaft) [AM103/29, DA1067/5, SCHI 504/6];
   DFG [FOR 2165, FOR2033]; German Federal Ministry of Education and
   Research (BMBF) [1EC1402B]; FP7 EU [602300]
FX This work was supported by the DFG (Deutsche Forschungsgemeinschaft)
   grants AM103/29, DA1067/5, and SCHI 504/6 to J. P.D., M.A., and T.S.; by
   the DFG Research Unit FOR 2165 to U.K.; by DIMEOS (1EC1402B) from the
   German Federal Ministry of Education and Research (BMBF) and the FP7 EU
   grant agreement number 602300 (SYBIL) to T.S., M.A., U.K., and S.M.; and
   by the DFG Research Unit FOR2033 Nichen consortium to A.T.
CR Albers J, 2013, J CELL BIOL, V200, P537, DOI 10.1083/jcb.201207142
   Albers J, 2011, J CELL BIOL, V192, P1057, DOI 10.1083/jcb.201008012
   Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Brown JP, 2014, CAN FAM PHYSICIAN, V60, P324
   Burt LA, 2016, J BONE MINER RES, V31, P2041, DOI 10.1002/jbmr.2873
   Chang MK, 2014, J BONE MINER RES, V29, P29, DOI 10.1002/jbmr.2059
   Chen JS, 2012, NAT REV ENDOCRINOL, V8, P81, DOI 10.1038/nrendo.2011.146
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Fahiminiya S, 2013, J MED GENET, V50, P345, DOI 10.1136/jmedgenet 2013 101567
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gunther EJ, 2003, GENE DEV, V17, P488, DOI 10.1101/gad.1051603
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Holmen SL, 2004, J BONE MINER RES, V19, P2033, DOI 10.1359/JBMR.040907
   Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676
   Joeng KS, 2017, J CLIN INVEST, V127, P2678, DOI 10.1172/JCI92617
   Joeng KS, 2014, HUM MOL GENET, V23, P4035, DOI 10.1093/hmg/ddu117
   Joeng KS, 2011, DEV BIOL, V359, P222, DOI 10.1016/j.ydbio.2011.08.020
   Joiner DM, 2013, TRENDS ENDOCRIN MET, V24, P31, DOI 10.1016/j.tem.2012.10.003
   Kahler RA, 2003, J BIOL CHEM, V278, P11937, DOI 10.1074/jbc.M211443200
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Kedlaya R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006627
   Keupp K, 2013, AM J HUM GENET, V92, P565, DOI 10.1016/j.ajhg.2013.02.010
   Laine CM, 2013, NEW ENGL J MED, V368, P1809, DOI 10.1056/NEJMoa1215458
   Langdahl B, 2016, THER ADV MUSCULOSKEL, V8, P225, DOI 10.1177/1759720X16670154
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Macdonald HM, 2011, J BONE MINER RES, V26, P50, DOI 10.1002/jbmr.171
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   Mansour A, 2011, CELL RES, V21, P1102, DOI 10.1038/cr.2011.21
   Milovanovic P, 2015, J GERONTOL A BIOL, V70, P1269, DOI 10.1093/gerona/glv052
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092 8674(82)90409 3
   Priemel M, 2010, J BONE MINER RES, V25, P305, DOI 10.1359/jbmr.090728
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Riddle RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063323
   Schett G, 2010, NAT REV ENDOCRINOL, V6, P698, DOI 10.1038/nrendo.2010.190
   Scholtysek C, 2013, NAT MED, V19, P608, DOI 10.1038/nm.3146
   Shimomura Y, 2010, NATURE, V464, P1043, DOI 10.1038/nature08875
   Teufel S, 2014, J IMMUNOL, V193, P223, DOI 10.4049/jimmunol.1302713
   Tsai JN, 2013, LANCET, V382, P50, DOI 10.1016/S0140 6736(13)60856 9
   Tu XL, 2007, DEV CELL, V12, P113, DOI 10.1016/j.devcel.2006.11.003
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Välimäki VV, 2017, J CLIN ENDOCR METAB, V102, P535, DOI 10.1210/jc.2016 2423
   Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277
   Weivoda MM, 2016, J BONE MINER RES, V31, P76, DOI 10.1002/jbmr.2586
   Williams BO, 2016, AM J MED GENET C, V172, P24, DOI 10.1002/ajmg.c.31474
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
   Yorgan TA, 2015, J BONE MINER RES, V30, P1175, DOI 10.1002/jbmr.2461
   Yorgan Timur A, 2014, Mol Cell Ther, V2, P22
   Yu B, 2014, NAT MED, V20, P1009, DOI 10.1038/nm.3586
   Zhong ZD, 2012, J CELL BIOCHEM, V113, P31, DOI 10.1002/jcb.23324
NR 58
TC 73
Z9 77
U1 0
U2 16
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946 6234
EI 1946 6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD NOV 7
PY 2018
VL 10
IS 466
AR eaau7137
DI 10.1126/scitranslmed.aau7137
PG 12
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA GZ5MZ
UT WOS:000449468600005
PM 30404864
OA Green Published
DA 2025 08 17
ER

PT J
AU Miao, JS
   Tu, YT
   Jiang, JC
   Ren, RF
   Wu, QH
   Liang, HB
   Wang, TJ
   Lin, BH
   Wu, JT
   Pan, YJ
   Wang, XY
   Jin, HM
AF Miao, Jiansen
   Tu, Yiting
   Jiang, Junchen
   Ren, Rufeng
   Wu, Qihang
   Liang, Haibo
   Wang, Tengjie
   Lin, Binghao
   Wu, Jingtao
   Pan, Youjin
   Wang, Xiangyang
   Jin, Haiming
TI VSIG4 inhibits RANKL induced osteoclastogenesis by enhancing
   Nrf2 dependent antioxidant response against reactive oxygen species
   production
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Osteoporosis; Osteoclast; VSIG4; Nrf2; Reactive oxygen species; Keap1
ID OXIDATIVE STRESS; DIFFERENTIATION
AB Osteoporosis is a prevalent systemic skeletal disorder, particularly affecting postmenopausal women, primarily due to excessive production and activation of osteoclasts. However, the current anti osteoporotic drugs utilized in clinical practice may lead to certain side effects. Therefore, it is necessary to further unravel the potential mechanisms regulating the osteoclast differentiation and to identify novel targets for osteoporosis treatment. This study revealed the most significant decline in VSIG4 expression among the VSIG family members. VSIG4 overexpression significantly inhibited RANKL induced osteoclastogenesis and bone resorption function. Mechanistically, both western blot and immunofluorescence assay results demonstrated that VSIG4 overexpression attenuated the expression of osteoclast marker genes and dampened the activation of MAPK and NF kappa B signaling pathways. Furthermore, VSIG4 overexpression could inhibit the generation of reactive oxygen species (ROS) and stimulate the expression of Nrf2 along with its downstream antioxidant enzymes via interaction with Keap1. Notably, a potent Nrf2 inhibitor, ML385, could reverse the inhibitory effect of VSIG4 on osteoclast differentiation. In line with these findings, VSIG4 overexpression also mitigated bone loss induced by OVX and attenuated the activation of osteoclasts in vivo. In conclusion, our results suggest that VSIG4 holds promise as a novel target for addressing postmenopausal osteoporosis. This is achieved by suppressing osteoclast formation via enhancing Nrf2 dependent antioxidant response against reactive oxygen species production.
C1 [Miao, Jiansen; Tu, Yiting; Wu, Qihang; Liang, Haibo; Wang, Tengjie; Lin, Binghao; Wu, Jingtao; Wang, Xiangyang; Jin, Haiming] Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed, Wenzhou 325000, Peoples R China.
   [Miao, Jiansen; Tu, Yiting; Wu, Qihang; Liang, Haibo; Wang, Tengjie; Lin, Binghao; Wu, Jingtao; Pan, Youjin; Wang, Xiangyang; Jin, Haiming] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 325000, Peoples R China.
   [Miao, Jiansen; Tu, Yiting; Jiang, Junchen; Ren, Rufeng; Wu, Qihang; Liang, Haibo; Wang, Tengjie; Lin, Binghao; Wu, Jingtao; Pan, Youjin; Wang, Xiangyang; Jin, Haiming] Wenzhou Med Univ, Sch Med 2, Wenzhou 325000, Peoples R China.
   [Pan, Youjin] Wenzhou Med Univ, Affiliated Hosp 2, Dept Endocrinol, Wenzhou 325000, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical
   University; Wenzhou Medical University
RP Wang, XY; Jin, HM (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed, Wenzhou 325000, Peoples R China.; Pan, YJ; Wang, XY; Jin, HM (通讯作者)，Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 325000, Peoples R China.; Pan, YJ; Wang, XY; Jin, HM (通讯作者)，Wenzhou Med Univ, Sch Med 2, Wenzhou 325000, Peoples R China.; Pan, YJ (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 2, Dept Endocrinol, Wenzhou 325000, Peoples R China.
EM panyoujin@wmu.edu.cn; xiangyangwang@wmu.edu.cn; jinhaiming@wmu.edu.cn
RI Jin, Haiming/LZE 3453 2025; Liang, Haibo/D 1730 2016
OI Jin, Haiming/0000 0003 2666 8415; 
FU National Natural Science Foundation of China [82202757]; Natural Science
   Foundation of Zhejiang Province [TGD23H070002]; Wenzhou Municipal
   Science and Technology Bureau [Y2023034]; Innovation and
   Entrepreneurship Incubation Team of The Second Clinical Medical College
   of Wenzhou Medical University [WMLEFH2022003]
FX <BOLD>Funding</BOLD> This work was supported by the National Natural
   Science Foundation of China (82202757) , Natural Science Foundation of
   Zhejiang Province (TGD23H070002) , Wenzhou Municipal Science and
   Technology Bureau (Y2023034) , and Innovation and Entrepreneurship
   Incubation Team of The Second Clinical Medical College of Wenzhou
   Medical University (WMLEFH2022003) .
CR Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Bellezza I, 2018, BBA MOL CELL RES, V1865, P721, DOI 10.1016/j.bbamcr.2018.02.010
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Fang C, 2016, J IMMUNOL, V196, P4452, DOI 10.4049/jimmunol.1501466
   Gopinath V, 2023, MED CLIN N AM, V107, P213, DOI 10.1016/j.mcna.2022.10.013
   Gorgani NN, 2011, AM J PATHOL, V179, P1310, DOI 10.1016/j.ajpath.2011.05.021
   Huang XY, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau7426
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023
   Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Lee SW, 2003, BONE, V32, P217, DOI 10.1016/S8756 3282(02)00976 6
   Li JL, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01327 4
   Li Y, 2023, CYTOTHERAPY, V25, P561, DOI 10.1016/j.jcyt.2022.12.004
   Liu S, 2013, CELL DEATH DIFFER, V20, P456, DOI 10.1038/cdd.2012.141
   Ni S, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12882
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Perluigi M, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9090779
   Qin YW, 2023, BIOMED PHARMACOTHER, V160, DOI 10.1016/j.biopha.2023.114347
   Saha S, 2020, MOLECULES, V25, DOI 10.3390/molecules25225474
   Schröder K, 2019, FREE RADICAL BIO MED, V132, P67, DOI 10.1016/j.freeradbiomed.2018.08.036
   Sun XW, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101309
   Tan TT, 2023, INT IMMUNOPHARMACOL, V116, DOI 10.1016/j.intimp.2023.109745
   Tian S, 2023, BIOTECHNOL GENET ENG, V39, P1088, DOI 10.1080/02648725.2023.2167764
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Wang YA, 2022, PHYSIOL INT, V109, P356, DOI 10.1556/2060.2022.00055
   Wu LL, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1500 x
   Wu ZX, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.793087
   Xian YS, 2021, BIOCHEM PHARMACOL, V193, DOI 10.1016/j.bcp.2021.114761
   Xie XX, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.625808
   Yamaguchi Y, 2018, J CELL MOL MED, V22, P1138, DOI 10.1111/jcmm.13367
   Yoshida G, 2022, AUTOPHAGY, V18, P2323, DOI 10.1080/15548627.2021.2017587
   Zhang DZ, 2021, BRAIN RES BULL, V176, P67, DOI 10.1016/j.brainresbull.2021.08.008
   Zhang YT, 2022, BIOORG CHEM, V119, DOI 10.1016/j.bioorg.2021.105511
   Zhou X, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.938470
NR 36
TC 3
Z9 3
U1 3
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141 8130
EI 1879 0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD MAR
PY 2024
VL 260
AR 129357
DI 10.1016/j.ijbiomac.2024.129357
EA JAN 2024
PN 2
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA JL6H7
UT WOS:001173358100001
PM 38216011
DA 2025 08 17
ER

PT J
AU Wolf, M
   Jäger, A
   Abuduwali, N
   Götz, W
   Lossdörfer, S
AF Wolf, M.
   Jaeger, A.
   Abuduwali, N.
   Goetz, W.
   Lossdoerfer, S.
TI Continuous PTH modulates alkaline phosphatase activity in human PDL
   cells via protein kinase C dependent pathways in vitro
SO ANNALS OF ANATOMY ANATOMISCHER ANZEIGER
LA English
DT Article
DE Parathyroid hormone; Human PDL cells; Alkaline phosphatase activity;
   PKC; PKA; In vitro
ID PERIODONTAL LIGAMENT CELLS; PARATHYROID HORMONE; OSTEOBLASTIC
   DIFFERENTIATION; BONE FORMATION; ALVEOLAR BONE; ORAL CAVITY;
   REGENERATION; EXPRESSION; TISSUE; RAT
AB Periodontal ligament (PDL) cells, a major component of the tooth supporting apparatus, share osteoblastic characteristics including their responsiveness to parathyroid hormone (PTH). Clinical studies have already pointed to the benefit of PTH in supporting regenerative processes in the craniofacial region. However, those reports did not analyze which cells mediated the PTH effect on the alveolar bone. The aim of the present study has been to further elucidate the mechanism of action of continuous PTH application on human PDL cells mimicking a local bolus application and to analyze its intracellular signalling pathways to widen the theoretical basis for future development of reliable local PTH delivery protocols.
   Analyses of PDL of extracted human teeth as well as cultured human PDL cells demonstrated strong expression of PTH receptor 1 by immune fluorescencecytochemistry/histochemistry. To examine the effect of short time continuous PTH treatment on PDL cell osteogenic differentiation, PDL cells were stimulated for 48 h. Analyses for mRNA and protein expression of the early osteogenic marker alkaline phosphatase revealed an enhanced expression. Pathways analyses mediating the PTH effect resulted in a similar effect when PDL cells were stimulated with either the signal specific fragments lacking the PKA activating domain PTH(3 34), PTH(7 34), second messenger analogues PKC (PMA) or inhibitors for PICA (H8). Inhibition of the PKC dependent pathway by stimulation with PTH(1 31), PICA second messenger analogue (forskolin) or PICA inhibitor (RO 32 0432) abolished the PTH effect
   These data indicate abundant expression of PTH1R within the PDL and a stimulatory effect of short time continuous PTH on PDL cell differentiation towards an osteogenic phenotype and suggested local PTH application protocols as a possible treatment option in periodontal therapy. (C) 2013 Elsevier GmbH. All rights reserved.
C1 [Wolf, M.; Jaeger, A.; Abuduwali, N.; Goetz, W.; Lossdoerfer, S.] Univ Bonn, Dept Orthodont, Dent Clin, D 53111 Bonn, Germany.
C3 University of Bonn
RP Wolf, M (通讯作者)，Univ Bonn, Dept Orthodont, Dent Clin, Welschnonnenstr 17, D 53111 Bonn, Germany.
EM michael.wolf@uni bonn.de; andreas.jaeger@ukb.uni bonn.de;
   serk_omar@yahoo.com; wgoetz@uni bonn.de;
   stefan.lossdoerfer@ukb.uni bonn.de
FU Deutsche Forschungsgemeinschaft (DFG) [KFO 208, LO 1181/2 2]; Medical
   Faculty of the University of Bonn
FX The authors thank S. Nekum, M. Kobilay, D. Limmer and J. Marciniack for
   expert technical assistance. This research was supported by a research
   grant from the Deutsche Forschungsgemeinschaft (DFG, KFO 208;
   LO 1181/2 2) and by the Medical Faculty of the University of Bonn.
CR Akizuki T, 2005, J PERIODONTAL RES, V40, P245, DOI 10.1111/j.1600 0765.2005.00799.x
   AUKHIL I, 1990, Critical Reviews in Oral Biology and Medicine, V1, P101
   Barros SP, 2003, J DENT RES, V82, P791, DOI 10.1177/154405910308201006
   Basdra EK, 1997, EUR J ORTHODONT, V19, P615, DOI 10.1093/ejo/19.6.615
   Bashutski JD, 2010, NEW ENGL J MED, V363, P2396, DOI 10.1056/NEJMoa1005361
   Boguslawski G, 2000, J BIOL CHEM, V275, P999, DOI 10.1074/jbc.275.2.999
   Bretaudiere J. P., 1984, METHODS ENZYMATIC AN, V4, P75
   Datta NS, 2009, CELL SIGNAL, V21, P1245, DOI 10.1016/j.cellsig.2009.02.012
   Flores MG, 2008, J PERIODONTAL RES, V43, P364, DOI 10.1111/j.1600 0765.2007.01046.x
   Götz W, 2006, EUR J ORAL SCI, V114, P318
   Hasegawa M, 2005, TISSUE ENG, V11, P469, DOI 10.1089/ten.2005.11.469
   Isaka J, 2001, J PERIODONTOL, V72, P314, DOI 10.1902/jop.2001.72.3.314
   Ishizuya T, 1997, J CLIN INVEST, V99, P2961, DOI 10.1172/JCI119491
   Ivanovski S, 2001, J PERIODONTAL RES, V36, P131, DOI 10.1034/j.1600 0765.2001.360301.x
   Jung RE, 2007, CLIN ORAL IMPLAN RES, V18, P319, DOI 10.1111/j.1600 0501.2007.01342.x
   KANO J, 1994, BIOCHEM BIOPH RES CO, V199, P271, DOI 10.1006/bbrc.1994.1224
   Kraus D, 2012, J CELL PHYSIOL, V227, P994, DOI 10.1002/jcp.22808
   Lekic PC, 2001, ANAT REC, V262, P193
   Lossdörfer S, 2006, CELL TISSUE RES, V325, P469, DOI 10.1007/s00441 006 0198 0
   Lossdörfer S, 2011, J PERIODONTAL RES, V46, P318, DOI 10.1111/j.1600 0765.2011.01345.x
   Lossdörfer S, 2010, J PERIODONTAL RES, V45, P764, DOI 10.1111/j.1600 0765.2010.01297.x
   Lossdörfer S, 2011, CLIN ORAL INVEST, V15, P941, DOI 10.1007/s00784 010 0456 0
   Lossdörfer S, 2005, J DENT RES, V84, P634, DOI 10.1177/154405910508400710
   Ma YFL, 2001, ENDOCRINOLOGY, V142, P4047, DOI 10.1210/en.142.9.4047
   Nakahara T, 2004, TISSUE ENG, V10, P537, DOI 10.1089/107632704323061898
   Nohutcu RM, 1997, J PERIODONTOL, V68, P320, DOI 10.1902/jop.1997.68.4.320
   Ouyang HJ, 2000, ENDOCRINOLOGY, V141, P4671, DOI 10.1210/en.141.12.4671
   Padbury AD, 2006, J CLIN ENDOCR METAB, V91, P3439, DOI 10.1210/jc.2005 2282
   Patterson EK, 2007, BONE, V41, P603, DOI 10.1016/j.bone.2007.04.201
   Pettway GJ, 2008, BONE, V42, P806, DOI 10.1016/j.bone.2007.11.017
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006
   Robinson JA, 2006, J CELL BIOCHEM, V98, P1203, DOI 10.1002/jcb.20822
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Wolf M, 2013, CLIN ORAL INVEST, V17, P989, DOI 10.1007/s00784 012 0777 2
   Wolf M., 2012, CLIN ORAL INVES 0710
   Yang DH, 2006, BONE, V38, P485, DOI 10.1016/j.bone.2005.10.009
NR 37
TC 12
Z9 14
U1 0
U2 4
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0940 9602
EI 1618 0402
J9 ANN ANAT
JI Ann. Anat. Anat. Anz.
PY 2013
VL 195
IS 5
BP 455
EP 460
DI 10.1016/j.aanat.2013.04.006
PG 6
WC Anatomy & Morphology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anatomy & Morphology
GA 267JJ
UT WOS:000328093600011
PM 23742978
DA 2025 08 17
ER

PT J
AU Adhikari, A
   Davie, J
AF Adhikari, Abhinav
   Davie, Judith
TI JARID2 and the PRC2 complex regulate skeletal muscle differentiation
   through regulation of canonical Wnt signaling
SO EPIGENETICS & CHROMATIN
LA English
DT Article
DE jarid2; Ezh2; Wnt; Sfrp 1; MyoD
ID HISTONE METHYLTRANSFERASE ACTIVITY; STEM CELLS; GENE EXPRESSION; NOTCH1
   EXPRESSION; SELF RENEWAL; MYOD; MYOGENESIS; PROTEINS; THERAPY; JUMONJI
AB Background: JARID2 is a non catalytic member of the polycomb repressive complex 2 (PRC2), which is known to regulate developmental target genes in embryonic stem cells. Here, we provide mechanistic insight into the modulation of Wnt signaling by JARID2 during murine skeletal muscle differentiation.
   Results: We show that JARID2 is expressed in proliferating myoblasts, but downregulated upon muscle differentiation. Unexpectedly, depletion of JARID2 or the catalytic subunit of the PRC2 complex, EZH2, inhibited differentiation, suggesting that JARID2 and the PRC2 complex are required to initiate this process. Expression of the myogenic regulatory factors required to promote differentiation, MYOD and MYOG, was downregulated in the absence of JARID2, even though decreases in the methylation of histone H3 lysine 27 (H3K27(me3)) were observed on both promoters. We found that activation of the Wnt signaling pathway upregulated MYOD and restored differentiation. Activation of the Wnt pathway in JARID2 depleted cells caused beta catenin to translocate to the nucleus, where it bound to and activated the Myod1 promoter. We show that the Wnt antagonist SFRP1 is highly upregulated in the absence of JARID2 and is a direct target of JARID2 and the PRC2 complex. Ectopic expression of SFRP1 blocked MYOD and late muscle gene expression and inhibited the translocation of beta catenin to the nucleus. Finally, we show that JARID2 and SFRP1 are inversely correlated in melanoma, confirming that the JARID2 mediated repression of SFRP1 extends beyond skeletal muscle and has important implications in many cellular systems, including cancer.
   Conclusions: We show that JARID2 and the PRC2 complex regulate muscle differentiation by modulating Wnt signaling through the direct repression of Wnt antagonists.
C1 [Davie, Judith] Southern Illinois Univ, Sch Med, Dept Biochem & Mol Biol, Carbondale, IL 62901 USA.
   Southern Illinois Univ, Sch Med, Simmons Canc Inst, Carbondale, IL 62901 USA.
C3 Southern Illinois University System; Southern Illinois University;
   Southern Illinois University System; Southern Illinois University
RP Davie, J (通讯作者)，Southern Illinois Univ, Sch Med, Dept Biochem & Mol Biol, Carbondale, IL 62901 USA.
EM jdavie@siumed.edu
RI Adhikari, Abhinav/J 5224 2019
OI Adhikari, Abhinav/0000 0002 9228 480X
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases of
   the National Institutes of Health [RAR068622]
FX Research reported in this publication was supported by the National
   Institute of Arthritis and Musculoskeletal and Skin Diseases of the
   National Institutes of Health under Award Number RAR068622. The content
   is solely the responsibility of the authors and does not necessarily
   represent the official views of the National Institutes of Health.
CR Abraham ST, 2016, IN VITRO CELL DEV AN, V52, P935, DOI 10.1007/s11626 016 0058 5
   Anaya J, 2016, PEERJ COMPUT SCI, DOI 10.7717/peerj cs.67
   Annavarapu SR, 2013, LAB INVEST, V93, P1090, DOI 10.1038/labinvest.2013.97
   ASAKURA A, 1995, DEV BIOL, V171, P386, DOI 10.1006/dbio.1995.1290
   Asp P, 2011, P NATL ACAD SCI USA, V108, pE149, DOI 10.1073/pnas.1102223108
   Borello U, 2006, DEVELOPMENT, V133, P3723, DOI 10.1242/dev.02517
   Brack AS, 2008, CELL STEM CELL, V2, P50, DOI 10.1016/j.stem.2007.10.006
   Brunelli S, 2007, DEV BIOL, V304, P604, DOI 10.1016/j.ydbio.2007.01.006
   Cao J, 2017, MOL MED REP, V16, P3600, DOI 10.3892/mmr.2017.7024
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904
   Chen E, 2016, CURR DRUG TARGETS, V17, P1245, DOI 10.2174/1389450116666150630110625
   Cheng ASL, 2011, CANCER RES, V71, P4028, DOI 10.1158/0008 5472.CAN 10 3342
   Ciarapica R, 2014, BMC CANCER, V14, DOI 10.1186/1471 2407 14 139
   Conerly ML, 2011, GENE DEV, V25, P997, DOI 10.1101/gad.2054311
   Dennis S, 1999, J CELL SCI, V112, P3815
   GOLDHAMER DJ, 1992, SCIENCE, V256, P538, DOI 10.1126/science.1315077
   Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136
   Juan AH, 2011, GENE DEV, V25, P789, DOI 10.1101/gad.2027911
   Judson RN, 2018, CELL STEM CELL, V22, P177, DOI 10.1016/j.stem.2017.12.010
   Kephart JJG, 2015, CLIN CANCER RES, V21, P4868, DOI 10.1158/1078 0432.CCR 14 1797
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   Landeira D, 2015, CELL REP, V12, P573, DOI 10.1016/j.celrep.2015.06.060
   Lei X, 2016, ONCOTARGET, V7, P40266, DOI 10.18632/oncotarget.9733
   Li G, 2010, GENE DEV, V24, P368, DOI 10.1101/gad.1886410
   Liang DD, 2015, INT J CARDIOL, V201, P38, DOI 10.1016/j.ijcard.2015.06.163
   Londhe P, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004633
   Londhe P, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044 5040 1 14
   Lu JR, 1999, P NATL ACAD SCI USA, V96, P552, DOI 10.1073/pnas.96.2.552
   MacDonald BT, 2014, J BIOL CHEM, V289, P18122, DOI 10.1074/jbc.M114.575027
   MacQuarrie KL, 2013, SKELET MUSCLE, V3, DOI 10.1186/2044 5040 3 26
   Müller J, 2002, CELL, V111, P197, DOI 10.1016/S0092 8674(02)00976 5
   Mysliwiec MR, 2012, J BIOL CHEM, V287, P1235, DOI 10.1074/jbc.M111.315945
   Mysliwiec MR, 2011, J BIOL CHEM, V286, P17193, DOI 10.1074/jbc.M110.205146
   Nakajima K, 2011, DEVELOPMENT, V138, P1771, DOI 10.1242/dev.059295
   Palacios D, 2010, CELL STEM CELL, V7, P455, DOI 10.1016/j.stem.2010.08.013
   Pan YC, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20140177
   Pasini D, 2010, NATURE, V464, P306, DOI 10.1038/nature08788
   Peng JC, 2009, CELL, V139, P1290, DOI 10.1016/j.cell.2009.12.002
   RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275
   Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859
   Relaix F, 2005, NATURE, V435, P948, DOI 10.1038/nature03594
   Rudolf A, 2016, CELL REP, V15, P1277, DOI 10.1016/j.celrep.2016.04.022
   Shen XH, 2009, CELL, V139, P1303, DOI 10.1016/j.cell.2009.12.003
   Stojic L, 2011, EPIGENET CHROMATIN, V4, DOI 10.1186/1756 8935 4 16
   Tajbakhsh S, 1998, DEVELOPMENT, V125, P4155
   Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960 9822(03)00240 9
   Villanueva MT, 2017, NAT REV DRUG DISCOV, V16, P239, DOI 10.1038/nrd.2017.55
   von Maltzahn J, 2012, TRENDS CELL BIOL, V22, P602, DOI 10.1016/j.tcb.2012.07.008
   Walters ZS, 2014, ONCOGENE, V33, P1148, DOI 10.1038/onc.2013.46
   Wharton KA, 2001, DEV BIOL, V234, P93, DOI 10.1006/dbio.2001.0238
   Yamagishi M, 2017, CURR OPIN ONCOL, V29, P375, DOI 10.1097/CCO.0000000000000390
   Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304
   Zhang XQ, 2015, AM J CANCER RES, V5, P2344
   Zhu XX, 2017, ONCOTARGET, V8, P24483, DOI 10.18632/oncotarget.15522
NR 55
TC 24
Z9 36
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1756 8935
J9 EPIGENET CHROMATIN
JI Epigenetics Chromatin
PD AUG 17
PY 2018
VL 11
AR 46
DI 10.1186/s13072 018 0217 x
PG 20
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA GR0DJ
UT WOS:000442181500001
PM 30119689
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU You, L
   Chen, L
   Pan, L
   Chen, JY
AF You, Li
   Chen, Lin
   Pan, Ling
   Chen, Jin Yu
TI New insights into the gene function of osteoporosis
SO FRONTIERS IN BIOSCIENCE LANDMARK
LA English
DT Article
DE Osteoporosis; Fracture; Bone Mineral Density; Gene Therapy; Wnt; Review
ID BONE MINERAL DENSITY; VITAMIN D RECEPTOR; SP1 BINDING SITE; I ALPHA 1
   GENE; POSTMENOPAUSAL WOMEN; PREMENOPAUSAL WOMEN; IMMUNE RESPONSES;
   SEGMENTAL DEFECT; LUMBAR SPINE; STEM CELLS
AB Osteoporosis is a common disease characterized by low bone mass, microarchitectural deterioration of bone tissue and an increased risk of fracture. Population based and case control studies have identified polymorphisms in several candidate genes that have been associated with bone mass or osteoporotic fracture, including the vitamin D receptor (VDR), estrogen receptor (ER), oestrogen a receptor (ESR), transforming growth factor (TGF) beta, and type I collagen. The Wnt signaling and receptor activator of nuclear factor kappa B (RANK)/RANK ligand (RANK L)/osteoprotegerin (OPG) pathways have been shown to play critical roles in determining bone mass and strength. An important aim of future work will be to further clarify the mechanisms involved in the interaction between candidate genes and environmental variables leading to osteoporosis via signaling pathways in individual patients. Hence preventative therapy, particularly gene therapy, could be targeted in patients at greatest risk of osteoporosis.
C1 [You, Li; Chen, Lin; Pan, Ling; Chen, Jin Yu] Shanghai Jiao Tong Univ, Sch Med, Dept Endocrinol & Metab, Shanghai Peoples Hosp 1, Shanghai 200080, Peoples R China.
C3 Shanghai Jiao Tong University
RP You, L (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Dept Endocrinol & Metab, Shanghai Peoples Hosp 1, 100 Haining Rd, Shanghai 200080, Peoples R China.
EM youlisky2002@yeah.net
RI fang, li/JNS 8415 2023
CR Albagha OME, 2005, J MED GENET, V42, P240, DOI 10.1136/jmg.2004.023895
   Alden TD, 1999, HUM GENE THER, V10, P2245, DOI 10.1089/10430349950017220
   Alvarez L, 1999, CLIN CHEM, V45, P904
   Amado RG, 1999, SCIENCE, V285, P674, DOI 10.1126/science.285.5428.674
   Ames SK, 1999, J BONE MINER RES, V14, P740, DOI 10.1359/jbmr.1999.14.5.740
   [Anonymous], 2007, J BONE MINER RES S1, V22, pS2
   Arai H, 2001, J BONE MINER RES, V16, P1256, DOI 10.1359/jbmr.2001.16.7.1256
   Balemans W, 2007, ENDOCRINOLOGY, V148, P2622, DOI 10.1210/en.2006 1352
   Baltzer AWA, 2004, GENE THER, V11, P344, DOI 10.1038/sj.gt.3302195
   Baltzer AWA, 2000, GENE THER, V7, P734, DOI 10.1038/sj.gt.3301166
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Bland R, 2000, CLIN SCI, V98, P217, DOI 10.1042/CS19990252
   Bonadio J, 1999, NAT MED, V5, P753, DOI 10.1038/10473
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Chang SCN, 2003, GENE THER, V10, P2013, DOI 10.1038/sj.gt.3302106
   Chen Fang Ping, 2006, Taiwan J Obstet Gynecol, V45, P307
   CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281
   CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Ensrud KE, 1999, J BONE MINER RES, V14, P1637, DOI 10.1359/jbmr.1999.14.10.1637
   EVANS CH, 1995, J BONE JOINT SURG AM, V77A, P1103, DOI 10.2106/00004623 199507000 00021
   Fang JM, 1996, P NATL ACAD SCI USA, V93, P5753, DOI 10.1073/pnas.93.12.5753
   FERRARI S, 1995, LANCET, V345, P423, DOI 10.1016/S0140 6736(95)90404 2
   Franceschi RT, 2004, CELLS TISSUES ORGANS, V176, P95, DOI 10.1159/000075031
   Franceschi RT, 2000, J CELL BIOCHEM, V78, P476, DOI 10.1002/1097 4644(20000901)78:3<476::AID JCB12>3.0.CO;2 5
   Garcia Giralt N, 2002, J BONE MINER RES, V17, P384, DOI 10.1359/jbmr.2002.17.3.384
   Gardner JC, 2005, J CLIN ENDOCR METAB, V90, P6392, DOI 10.1210/jc.2005 1235
   GARNERO P, 1995, J BONE MINER RES, V10, P1283
   Gong G, 1999, OSTEOPOROSIS INT, V9, P55, DOI 10.1007/s001980050116
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Grant SFA, 1996, NAT GENET, V14, P203, DOI 10.1038/ng1096 203
   Gysin R, 2002, GENE THER, V9, P991, DOI 10.1038/sj.gt.3301772
   Harvey BG, 1999, HUM GENE THER, V10, P2823, DOI 10.1089/10430349950016555
   Harvey BG, 1999, J VIROL, V73, P6729, DOI 10.1128/JVI.73.8.6729 6742.1999
   Honma N., 2012, J BONE MINER METAB
   Hubacek Jaroslav A, 2006, Endocr Regul, V40, P107
   Hustmyer FG, 1999, OSTEOPOROSIS INT, V9, P346, DOI 10.1007/s001980050157
   Ioannidis JPA, 2004, JAMA J AM MED ASSOC, V292, P2105, DOI 10.1001/jama.292.17.2105
   Ito T, 2003, GENE THER, V10, P1623, DOI 10.1038/sj.gt.3302060
   Ivanova J, 2006, ENDOCRINE, V29, P413, DOI 10.1385/ENDO:29:3:413
   Johnson ML, 2004, J BONE MINER RES, V19, P1749, DOI 10.1359/JBMR.040816
   Khosla S, 2004, J CLIN ENDOCR METAB, V89, P1808, DOI 10.1210/jc.2003 031448
   Kobayashi S, 1996, J BONE MINER RES, V11, P306
   KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022
   KRALL EA, 1993, J BONE MINER RES, V8, P1
   Krebsbach PH, 2000, HUM GENE THER, V11, P1201, DOI 10.1089/10430340050015248
   Langdahl BL, 1998, J BONE MINER RES, V13, P1384, DOI 10.1359/jbmr.1998.13.9.1384
   Langdahl BL, 2002, J BONE MINER RES, V17, P1245, DOI 10.1359/jbmr.2002.17.7.1245
   Langdahl BL, 1997, BONE, V20, P289, DOI 10.1016/S8756 3282(96)00363 8
   Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017
   Lidén M, 1998, CALCIFIED TISSUE INT, V63, P293, DOI 10.1007/s002239900529
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Liu J, 2012, J BONE MINER RES, V27, P331, DOI 10.1002/jbmr.549
   Loots GG, 2012, BONE, V50, P663, DOI 10.1016/j.bone.2011.11.016
   Mann V, 2001, J CLIN INVEST, V107, P899, DOI 10.1172/JCI10347
   Mao X., 2012, INT J MOL MED
   Mbalaviele G, 2005, J CELL BIOCHEM, V94, P403, DOI 10.1002/jcb.20253
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Mencej Bedrac S, 2009, J MOL ENDOCRINOL, V42, P239, DOI 10.1677/JME 08 0108
   Mizunuma H, 1997, BONE, V21, P379, DOI 10.1016/S8756 3282(97)00178 6
   MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0
   Musgrave DS, 1999, BONE, V24, P541, DOI 10.1016/S8756 3282(99)00086 1
   Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263
   Ongphiphadhanakul B, 1998, J ENDOCRINOL INVEST, V21, P487, DOI 10.1007/BF03347333
   Park J, 2003, GENE THER, V10, P1089, DOI 10.1038/sj.gt.3301960
   PRESTWOOD KM, 1994, J CLIN ENDOCR METAB, V79, P366, DOI 10.1210/jc.79.2.366
   Qureshi AM, 2001, CALCIFIED TISSUE INT, V69, P67, DOI 10.1007/s002230010037
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24
   RIGGS BL, 1982, J CLIN INVEST, V70, P716, DOI 10.1172/JCI110667
   Roux C, 1998, ARTHRITIS RHEUM, V41, P187
   SANO M, 1995, BIOCHEM BIOPH RES CO, V217, P378, DOI 10.1006/bbrc.1995.2787
   Scaduto AA, 1999, ORTHOP CLIN N AM, V30, P625, DOI 10.1016/S0030 5898(05)70115 2
   Seeman E, 1996, AM J PHYSIOL ENDOC M, V270, pE320, DOI 10.1152/ajpendo.1996.270.2.E320
   Shoback D, 2007, J CLIN ENDOCR METAB, V92, P747, DOI 10.1210/jc.2007 0042
   Sims AM, 2008, J BONE MINER RES, V23, P499, DOI 10.1359/JBMR.071113
   SMITH DM, 1973, J CLIN INVEST, V52, P2800, DOI 10.1172/JCI107476
   SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604
   Sonobe J, 2004, HUM GENE THER, V15, P659, DOI 10.1089/1043034041361208
   Sowers M, 1999, J BONE MINER RES, V14, P1411, DOI 10.1359/jbmr.1999.14.8.1411
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Sugiyama O, 2005, MOL THER, V11, P390, DOI 10.1016/j.ymthe.2004.10.019
   Takada I, 2007, NAT CELL BIOL, V9, P1273, DOI 10.1038/ncb1647
   Torgerson DJ, 1996, J BONE MINER RES, V11, P293
   Tsuchida H, 2003, J ORTHOP RES, V21, P44, DOI 10.1016/S0736 0266(02)00108 0
   Uitterlinden AG, 1998, NEW ENGL J MED, V338, P1016, DOI 10.1056/NEJM199804093381502
   Uusitalo M, 1999, EXP CELL RES, V253, P336, DOI 10.1006/excr.1999.4710
   Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277
   Wang JC, 2003, J BONE JOINT SURG AM, V85A, P905, DOI 10.2106/00004623 200305000 00020
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59
   Xu XH, 2010, ENDOCR REV, V31, P447, DOI 10.1210/er.2009 0032
   Yamada Y, 1998, J BONE MINER RES, V13, P1569, DOI 10.1359/jbmr.1998.13.10.1569
   Yamada Y, 2001, J MOL MED JMM, V79, P149, DOI 10.1007/s001090100190
   Yoldemir T, 2011, CLIMACTERIC, V14, P384, DOI 10.3109/13697137.2010.550973
   Zhang XS, 2004, J GENE MED, V6, P4, DOI 10.1002/jgm.477
   Zmuda JM, 1999, OSTEOPOROSIS INT, V9, P214, DOI 10.1007/s001980050139
NR 99
TC 9
Z9 11
U1 0
U2 24
PU FRONTIERS IN BIOSCIENCE INC
PI IRVINE
PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA
SN 1093 9946
EI 1093 4715
J9 FRONT BIOSCI LANDMRK
JI Front. Biosci.
PD JUN 1
PY 2013
VL 18
BP 1088
EP 1097
DI 10.2741/4165
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 172OA
UT WOS:000321012500023
PM 23747869
OA Bronze
DA 2025 08 17
ER

PT J
AU Liu, Y
   Kou, XX
   Chen, C
   Yu, WJ
   Su, YY
   Kim, Y
   Shi, ST
   Liu, Y
AF Liu, Yao
   Kou, Xiaoxing
   Chen, Chider
   Yu, Wenjing
   Su, Yingying
   Kim, Yong
   Shi, Songtao
   Liu, Yi
TI Chronic High Dose Alcohol Induces Osteopenia via Activation of mTOR
   Signaling in Bone Marrow Mesenchymal Stem Cells
SO STEM CELLS
LA English
DT Article
DE Alcohol consumption; Osteoporosis; Bone marrow mesenchymal stem cells;
   Osteogenesis; Adipogenesis; Rapamycin
ID CHRONIC ETHANOL CONSUMPTION; MINERAL DENSITY; STROMAL CELLS;
   OSTEOBLASTIC DIFFERENTIATION; PARATHYROID HORMONE; RAPAMYCIN; DISEASE;
   PROLIFERATION; INHIBITION; LIGAND
AB Chronic consumption of excessive alcohol results in reduced bone mass, impaired bone structure, and increased risk of bone fracture. However, the mechanisms underlying alcohol induced osteoporosis are not fully understood. Here, we show that high dose chronic alcohol consumption reduces osteogenic differentiation and enhances adipogenic differentiation of bone marrow mesenchymal stem cells (BMMSCs), leading to osteopenia in a mouse model. Mechanistically, impaired osteo/adipogenic lineage differentiation of BMMSCs is due to activation of a phosphatidylinositide 3 kinase/AKT/mammalian target of rapamycin (mTOR) signaling cascade, resulting in downregulation of runt related transcription factor 2 and upregulation of peroxisome proliferator activated receptor gamma via activation of p70 ribosomal protein S6 kinase. Blockage of the mTOR pathway by rapamycin treatment ameliorates alcohol induced osteopenia by rescuing impaired osteo/adipogenic lineage differentiation of BMMSCs. In this study, we identify a previously unknown mechanism by which alcohol impairs BMMSC lineage differentiation and reveal a potential rapamycin based drug therapy for alcohol induced osteoporosis.
C1 [Liu, Yao] China Med Univ, Sch Stomatol, Dept Pediat Dent, 117 Nanjing North St, Shenyang 110002, Peoples R China.
   [Liu, Yao] Liaoning Prov Key Lab Oral Dis, Shenyang, Peoples R China.
   [Liu, Yao; Kou, Xiaoxing; Chen, Chider; Yu, Wenjing; Shi, Songtao] Univ Southern Calif, Ostrow Sch Dent, Ctr Craniofacial Mol Biol, Los Angeles, CA USA.
   [Kou, Xiaoxing; Chen, Chider; Yu, Wenjing; Shi, Songtao] Univ Penn, Sch Dent Med, Dept Anat & Cell Biol, Philadelphia, PA 19104 USA.
   [Su, Yingying; Liu, Yi] Capital Med Univ, Lab Tissue Regenerat & Immunol, Sch Stomatol, Beijing, Peoples R China.
   [Su, Yingying; Liu, Yi] Capital Med Univ, Dept Periodont, Sch Stomatol, Beijing Key Lab Tooth Regenerat & Funct Reconstru, Tian Tan Xi Li 4, Beijing 100050, Peoples R China.
   [Kim, Yong] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA.
C3 China Medical University; University of Southern California; University
   of Pennsylvania; Capital Medical University; Capital Medical University;
   University of California System; University of California Los Angeles
RP Liu, Y (通讯作者)，China Med Univ, Sch Stomatol, Dept Pediat Dent, 117 Nanjing North St, Shenyang 110002, Peoples R China.; Liu, Y (通讯作者)，Capital Med Univ, Dept Periodont, Sch Stomatol, Beijing Key Lab Tooth Regenerat & Funct Reconstru, Tian Tan Xi Li 4, Beijing 100050, Peoples R China.
EM yaoyao_517@hotmail.com; lililiuyi@163.com
RI Chen, Chider/L 9880 2016; Kou, Xiaoxing/IQS 3208 2023
OI Chen, Chider/0000 0003 2899 1208; Kou, Xiaoxing/0000 0001 9680 0077; Yu,
   Wenjing/0000 0002 6833 3528
FU National Natural Science Foundation of China [81470751, 81222011]; High
   Level Health Technical Personnel in Beijing Preferred Foundation;
   National Institute on Alcohol Abuse and Alcoholism, National Institutes
   of Health [R01AA021301]
FX This work was supported by grants from the National Natural Science
   Foundation of China (81470751, 81222011 to Y.L), and High Level Health
   Technical Personnel in Beijing Preferred Foundation (to Y.L.), the
   National Institute on Alcohol Abuse and Alcoholism, National Institutes
   of Health (R01AA021301 to Y.K. and S.S.).
CR Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483
   Akiyama K, 2012, CELL STEM CELL, V10, P544, DOI 10.1016/j.stem.2012.03.007
   Alvisa Negrín J, 2009, ALCOHOL ALCOHOLISM, V44, P468, DOI 10.1093/alcalc/agp038
   BADGER TM, 1993, J PHARMACOL EXP THER, V264, P438
   Bai S, 2008, J BIOL CHEM, V283, P6509, DOI 10.1074/jbc.M707000200
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   BARRAGRY JM, 1979, GUT, V20, P559, DOI 10.1136/gut.20.7.559
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   BIKLE DD, 1985, ANN INTERN MED, V103, P42, DOI 10.7326/0003 4819 103 1 42
   BLAZAR BR, 1994, BLOOD, V83, P600
   Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097 4644(199702)64:2<278::AID JCB11>3.0.CO;2 F
   Chakkalakal DA, 2005, ALCOHOL CLIN EXP RES, V29, P2077, DOI 10.1097/01.alc.0000192039.21305.55
   Chen C, 2015, J EXP MED, V212, P73, DOI 10.1084/jem.20140643
   Chen JR, 2008, J PHARMACOL EXP THER, V324, P50, DOI 10.1124/jpet.107.130351
   Chen JR, 2010, J BONE MINER RES, V25, P1117, DOI 10.1002/jbmr.7
   Chiang CY, 1999, INFECT IMMUN, V67, P4231, DOI 10.1128/IAI.67.8.4231 4236.1999
   Corrao G, 2000, ADDICTION, V95, P1505, DOI 10.1046/j.1360 0443.2000.951015056.x
   Criddle DN, 2015, PANCREATOLOGY, V15, pS6, DOI 10.1016/j.pan.2015.02.009
   Díez Ruiz A, 2010, ALCOHOL ALCOHOLISM, V45, P427, DOI 10.1093/alcalc/agq037
   Dimitri P, 2010, J BONE MINER RES, V25, P527, DOI 10.1359/jbmr.090823
   Duggal S, 2007, ALCOHOL CLIN EXP RES, V31, P104, DOI 10.1111/j.1530 0277.2006.00268.x
   FREUND G, 1982, ALCOHOL CLIN EXP RES, V6, P13, DOI 10.1111/j.1530 0277.1982.tb05377.x
   FRIDAY KE, 1991, METABOLISM, V40, P562, DOI 10.1016/0026 0495(91)90044 W
   FRIEDENSTEIN AJ, 1974, TRANSPLANTATION, V17, P331, DOI 10.1097/00007890 197404000 00001
   Friedenstein AJ., 1988, CIBA F SYMP, P42
   Gimble JM, 1996, BONE, V19, P421, DOI 10.1016/S8756 3282(96)00258 X
   Giuliani N, 1999, ALCOHOL CLIN EXP RES, V23, P381, DOI 10.1097/00000374 199902000 00028
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gong ZD, 2004, ALCOHOL CLIN EXP RES, V28, P468, DOI 10.1097/01.ALC.0000118315.58404.C1
   Hadji P, 2013, CRIT REV ONCOL HEMAT, V87, P101, DOI 10.1016/j.critrevonc.2013.05.015
   Howe KS, 2011, OSTEOPOROSIS INT, V22, P1175, DOI 10.1007/s00198 010 1304 4
   Islander U, 2011, MOL CELL ENDOCRINOL, V335, P14, DOI 10.1016/j.mce.2010.05.018
   Isomoto S, 2007, J ORTHOP SCI, V12, P83, DOI 10.1007/s00776 006 1079 9
   Jugdaohsingh R, 2006, P NUTR SOC, V65, P291, DOI 10.1079/PNS2006508
   Kawai M, 2010, NAT REV ENDOCRINOL, V6, P63, DOI 10.1038/nrendo.2009.249
   Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092 8674(02)00808 5
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140 6736(04)16104 7
   Lee KW, 2010, STEM CELLS DEV, V19, P557, DOI 10.1089/scd.2009.0147
   Martin SK, 2015, STEM CELLS, V33, P1359, DOI 10.1002/stem.1931
   Maurel DB, 2012, OSTEOPOROSIS INT, V23, P1, DOI 10.1007/s00198 011 1787 7
   Maurel DB, 2011, BONE, V49, P543, DOI 10.1016/j.bone.2011.06.001
   Miranda RC, 2010, ALCOHOL CLIN EXP RES, V34, P575, DOI 10.1111/j.1530 0277.2009.01126.x
   Mogi M, 2009, BIOCHEM BIOPH RES CO, V384, P82, DOI 10.1016/j.bbrc.2009.04.084
   Movérare Skrtic S, 2014, NAT MED, V20, P1279, DOI 10.1038/nm.3654
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Ogawa T, 1998, BIOCHEM BIOPH RES CO, V249, P226, DOI 10.1006/bbrc.1998.9118
   Pedrera Zamorano JD, 2009, NUTRITION, V25, P1057, DOI 10.1016/j.nut.2009.02.007
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014
   Ronis Martin J J, 2011, Curr Osteoporos Rep, V9, P53, DOI 10.1007/s11914 011 0049 0
   Shankar K, 2008, ENDOCRINOLOGY, V149, P1748, DOI 10.1210/en.2007 0903
   Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007
   Shi S, 2003, J BONE MINER RES, V18, P696, DOI 10.1359/jbmr.2003.18.4.696
   Shi ST, 2002, NAT BIOTECHNOL, V20, P587, DOI 10.1038/nbt0602 587
   Singha UK, 2008, J CELL BIOCHEM, V103, P434, DOI 10.1002/jcb.21411
   Song LG, 2012, J BONE MINER RES, V27, P2344, DOI 10.1002/jbmr.1694
   Sun LY, 2009, STEM CELLS, V27, P1421, DOI 10.1002/stem.68
   Tucker KL, 2009, AM J CLIN NUTR, V89, P1188, DOI 10.3945/ajcn.2008.26765
   Turner RT, 2000, ALCOHOL CLIN EXP RES, V24, P1693, DOI 10.1111/j.1530 0277.2000.tb01971.x
   Turner RT, 2010, BONE, V46, P806, DOI 10.1016/j.bone.2009.10.027
   Uccelli A, 2007, TRENDS IMMUNOL, V28, P219, DOI 10.1016/j.it.2007.03.001
   Uccelli A, 2010, CURR OPIN NEUROL, V23, P218, DOI 10.1097/WCO.0b013e328338b7ed
   Wang LH, 2003, P NATL ACAD SCI USA, V100, P11249, DOI 10.1073/pnas.1534805100
   Weinstein RS, 2010, BONE, V46, P564, DOI 10.1016/j.bone.2009.06.030
   Wezeman FH, 2004, ALCOHOL CLIN EXP RES, V28, P1091, DOI 10.1097/01.ALC.0000130808.49262.F5
   Xiong JH, 2012, J BONE MINER RES, V27, P499, DOI 10.1002/jbmr.1547
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yoon KH, 2009, ANN NY ACAD SCI, V1173, P752, DOI 10.1111/j.1749 6632.2009.04663.x
   Yu WH, 2008, MOL CELL BIOCHEM, V310, P11, DOI 10.1007/s11010 007 9661 9
   Zhang HH, 2009, PLOS ONE, V4, DOI [10.1371/journal.pone.0006189, 10.1371/journal.pone.0007826]
NR 74
TC 51
Z9 62
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD AUG
PY 2016
VL 34
IS 8
BP 2157
EP 2168
DI 10.1002/stem.2392
PG 12
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA DS4RD
UT WOS:000380767600014
PM 27145264
OA Bronze
DA 2025 08 17
ER

PT J
AU Glorieux, FH
AF Glorieux, Francis H.
TI Osteogenesis imperfecta
SO BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
LA English
DT Article
DE osteoporosis; bisphosphonates; type I collagen; osteogenesis imperfecta
ID GROWTH HORMONE TREATMENT; INTRAVENOUS PAMIDRONATE TREATMENT; HUMAN
   PARATHYROID HORMONE; COLLAGEN MESSENGER RNA; BRITTLE BONE DISEASE; X RAY
   ABSORPTIOMETRY; I COLLAGEN; BISPHOSPHONATE TREATMENT;
   EXTRACELLULAR MATRIX; HEARING LOSS
AB Osteogenesis Imperfecta is a heritable disorder characterized by bone fragility and low bone mass, with a wide spectrum of clinical expression. This review gives an update on its classification, the recent developments in the understanding of its pathophysiological mechanisms, and the current status of bisphosphonate therapy. Other therapeutic approaches and future directions of research are briefly discussed.
C1 McGill Univ, Shriners Hosp Children, Genet Unit, Montreal, PQ H3G 1A6, Canada.
C3 McGill University
RP Glorieux, FH (通讯作者)，McGill Univ, Shriners Hosp Children, Genet Unit, 1529 Cedar Ave, Montreal, PQ H3G 1A6, Canada.
EM glorieux@shriners.mcgill.ca
CR Adami S, 2003, J BONE MINER RES, V18, P126, DOI 10.1359/jbmr.2003.18.1.126
   AITCHISON K, 1988, HUM GENET, V78, P233, DOI 10.1007/BF00291667
   Antoniazzi F, 1996, J PEDIATR US, V129, P432, DOI 10.1016/S0022 3476(96)70077 X
   Arikoski P, 2004, BONE, V34, P539, DOI 10.1016/j.bone.2003.11.019
   Åström E, 2002, ARCH DIS CHILD, V86, P356, DOI 10.1136/adc.86.5.356
   Bank RA, 1999, P NATL ACAD SCI USA, V96, P1054, DOI 10.1073/pnas.96.3.1054
   BEIGHTON P, 1985, CLIN GENET, V28, P69
   Bianco P, 2000, J CLIN INVEST, V105, P1663, DOI 10.1172/JCI10413
   Bishop NJ, 1999, NAT MED, V5, P466, DOI 10.1038/8528
   Boyde A, 1999, CALCIFIED TISSUE INT, V64, P185, DOI 10.1007/s002239900600
   Byers PH, 2002, J CLIN INVEST, V109, P3, DOI 10.1172/JCI14841
   BYERS PH, 1992, ANNU REV MED, V43, P269, DOI 10.1146/annurev.med.43.1.269
   Byers PH, 2000, CURR OPIN PEDIATR, V12, P603, DOI 10.1097/00008480 200012000 00016
   Cabral WA, 2002, J BIOL CHEM, V277, P4215, DOI 10.1074/jbc.M109048200
   Cabral WA, 2001, MOL GENET METAB, V72, P326, DOI 10.1006/mgme.2001.3155
   Cabral WA, 2007, NAT GENET, V39, P359, DOI 10.1038/ng1968
   Cundy T, 2002, HUM MOL GENET, V11, P2119, DOI 10.1093/hmg/11.18.2119
   Dawson PA, 2000, NUCLEIC ACIDS RES, V28, P4013, DOI 10.1093/nar/28.20.4013
   DEVOGELAER JP, 1987, SKELETAL RADIOL, V16, P360, DOI 10.1007/BF00350961
   Dobrocky I, 1999, EUR RADIOL, V9, P665, DOI 10.1007/s003300050729
   Doudna JA, 2002, NATURE, V418, P222, DOI 10.1038/418222a
   Engelbert RHH, 1998, ARCH PHYS MED REHAB, V79, P1590, DOI 10.1016/S0003 9993(98)90426 9
   Fedarko NS, 1996, J BONE MINER RES, V11, P800
   FEDARKO NS, 1995, J BONE MINER RES, V10, P1122
   Fewtrell MS, 2003, ARCH DIS CHILD, V88, P795, DOI 10.1136/adc.88.9.795
   Forlino A, 2000, MOL GENET METAB, V71, P225, DOI 10.1006/mgme.2000.3039
   Galicka A, 2002, J PATHOL, V196, P235, DOI 10.1002/path.1030
   Gerber LH, 1998, ARCH PHYS MED REHAB, V79, P46, DOI 10.1016/S0003 9993(98)90207 6
   Gerson SL, 1999, NAT MED, V5, P262, DOI 10.1038/6470
   Glorieux FH, 2004, J BONE MINER RES, V19, pS12
   Glorieux FH, 2002, J BONE MINER RES, V17, P30, DOI 10.1359/jbmr.2002.17.1.30
   Glorieux FH, 2000, J BONE MINER RES, V15, P1650, DOI 10.1359/jbmr.2000.15.9.1650
   Glorieux FH, 1998, NEW ENGL J MED, V339, P947, DOI 10.1056/NEJM199810013391402
   GRZESIK WJ, 2002, J BIOL CHEM, V6, P6
   Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529
   Horwitz EM, 2001, BLOOD, V97, P1227, DOI 10.1182/blood.V97.5.1227
   Jepsen KJ, 1997, J BIOMECH, V30, P1141, DOI 10.1016/S0021 9290(97)00088 2
   Kadler KE, 1996, BIOCHEM J, V316, P1
   Körkkö J, 1998, AM J HUM GENET, V62, P98, DOI 10.1086/301689
   KRUSE HP, 1975, HORM METAB RES, V7, P488, DOI 10.1055/s 0028 1093710
   Kuijpers G, 2002, BRIT MED J, V324, P1218, DOI 10.1136/bmj.324.7347.1218
   Kuurila K, 2000, EUR J PEDIATR, V159, P515, DOI 10.1007/s004310051322
   Kuurila K, 2002, ANN OTO RHINOL LARYN, V111, P939, DOI 10.1177/000348940211101014
   Labuda M, 2002, BONE, V31, P19, DOI 10.1016/S8756 3282(02)00808 6
   Leonard MB, 2003, MED PEDIATR ONCOL, V41, P198, DOI 10.1002/mpo.10337
   Liu P, 2001, BONE, V29, P331, DOI 10.1016/S8756 3282(01)00590 7
   Lund AM, 1998, J CRAN GENET DEV BIO, V18, P30
   Lygidakis NA, 1996, ORAL SURG ORAL MED O, V81, P567, DOI 10.1016/S1079 2104(96)80048 5
   Maasalu K, 2003, ACTA PAEDIATR, V92, P452
   Malmgren B, 2002, ACTA ODONTOL SCAND, V60, P65, DOI 10.1080/000163502753509446
   Marini JC, 2003, J BONE MINER RES, V18, P237, DOI 10.1359/jbmr.2003.18.2.237
   Marini JC, 1999, NAT MED, V5, P466, DOI 10.1038/8326
   Marlowe A, 2002, J MED GENET, V39, P382, DOI 10.1136/jmg.39.6.382
   McAllion SJ, 1996, J CLIN PATHOL, V49, P627, DOI 10.1136/jcp.49.8.627
   McPherson E, 1997, AM J MED GENET, V70, P28, DOI 10.1002/(SICI)1096 8628(19970502)70:1<28::AID AJMG6>3.0.CO;2 N
   Miller ME, 1999, OSTEOPOROSIS INT, V9, P427, DOI 10.1007/s001980050167
   Millington Ward S, 2002, HUM MOL GENET, V11, P2201, DOI 10.1093/hmg/11.19.2201
   Moore M S, 1998, Am J Orthop (Belle Mead NJ), V27, P797
   Morello R, 2006, CELL, V127, P291, DOI 10.1016/j.cell.2006.08.039
   Mundlos S, 1996, J BIOL CHEM, V271, P21068, DOI 10.1074/jbc.271.35.21068
   Munns CFJ, 2005, J BONE MINER RES, V20, P1235, DOI 10.1359/JBMR.050213
   Munns CFJ, 2004, J BONE MINER RES, V19, P1779, DOI 10.1359/JBMR.040814
   Munns CFJ, 2004, J BONE MINER RES, V19, P1742, DOI 10.1359/JBMR.040711
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nimkin K, 2001, RADIOL CLIN N AM, V39, P843, DOI 10.1016/S0033 8389(05)70314 6
   Paterson CR, 1996, BRIT MED J, V312, P351
   Paterson CR, 2001, J LARYNGOL OTOL, V115, P280
   PEDERSEN U, 1984, SCAND AUDIOL, V13, P67, DOI 10.3109/01050398409043042
   Petersen K, 1998, J DENT CHILD, V65, P305
   PROCKOP DJ, 1993, J BONE MINER RES, V8, pS489
   Rauch F, 2006, J CLIN ENDOCR METAB, V91, P1268, DOI 10.1210/jc.2005 2413
   Rauch F, 2006, J CLIN ENDOCR METAB, V91, P511, DOI 10.1210/jc.2005 2036
   Rauch F, 2000, BONE, V26, P581, DOI 10.1016/S8756 3282(00)00269 6
   Rauch F, 2005, ANN MED, V37, P295, DOI 10.1080/07853890510007386
   Rauch F, 2004, J BONE MINER RES, V19, P1191, DOI 10.1359/JBMR.040303
   Rauch F, 2004, LANCET, V363, P1377, DOI 10.1016/S0140 6736(04)16051 0
   Rauch F, 2003, J BONE MINER RES, V18, P610, DOI 10.1359/jbmr.2003.18.4.610
   Rauch F, 2003, J CLIN ENDOCR METAB, V88, P986, DOI 10.1210/jc.2002 021371
   Rauch F, 2002, J CLIN INVEST, V110, P1293, DOI 10.1172/JCI200215952
   Rauch F, 2007, BONE, V40, P821, DOI 10.1016/j.bone.2006.11.020
   Rieker O, 1998, EUR RADIOL, V8, P1137, DOI 10.1007/s003300050521
   Sakkers R, 2004, LANCET, V363, P1427, DOI 10.1016/S0140 6736(04)16101 1
   Sarafova AP, 1998, HUM MUTAT, V11, P395, DOI 10.1002/(SICI)1098 1004(1998)11:5<395::AID HUMU7>3.3.CO;2 W
   Shapiro JR, 2003, CALCIFIED TISSUE INT, V72, P103, DOI 10.1007/s00223 001 1055 5
   SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101
   SMITH R, 1995, BRIT J RHEUMATOL, V34, P68
   Smith R, 2001, BRIT MED J, V322, P63, DOI 10.1136/bmj.322.7278.63
   Toudjarska I, 2001, ANTISENSE NUCLEIC A, V11, P341, DOI 10.1089/108729001753231722
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Vieira NE, 1999, BONE, V25, P501, DOI 10.1016/S8756 3282(99)00186 6
   WALLIS GA, 1993, J MED GENET, V30, P492, DOI 10.1136/jmg.30.6.492
   Ward C.E., 2002, Current Agriculture, Food Resource Issues, V3, P1
   WENSTRUP RJ, 1990, AM J HUM GENET, V46, P975
   Whyte MP, 2003, NEW ENGL J MED, V349, P457, DOI 10.1056/NEJMoa023110
   Whyte MP, 2002, NEW ENGL J MED, V347, P175, DOI 10.1056/NEJMoa013096
   Wilkinson JM, 1998, J BONE JOINT SURG BR, V80B, P999, DOI 10.1302/0301 620X.80B6.8667
   Willing MC, 1996, AM J HUM GENET, V59, P799
   Zeitlin L, 2003, PEDIATRICS, V111, P1030, DOI 10.1542/peds.111.5.1030
   Zeitlin L, 2003, J PEDIATR ORTHOP B, V12, P77, DOI 10.1097/01.bpb.0000049567.52224.fa
NR 99
TC 118
Z9 138
U1 1
U2 26
PU BAILLIERE TINDALL
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1521 6942
J9 BEST PRACT RES CL RH
JI Best Pract. Res. Clin. Rheumatol.
PD MAR
PY 2008
VL 22
IS 1
BP 85
EP 100
DI 10.1016/j.berh.2007.12.012
PG 16
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 288SD
UT WOS:000255005200008
PM 18328983
DA 2025 08 17
ER

PT J
AU Wu, FZ
   Li, BE
   Hu, XC
   Yu, FY
   Shi, Y
   Ye, L
AF Wu, Fanzi
   Li, Boer
   Hu, Xuchen
   Yu, Fanyuan
   Shi, Yu
   Ye, Ling
TI Wnt7b Inhibits Osteoclastogenesis via AKT Activation and Glucose
   Metabolic Rewiring
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE Wnt7b; osteoclastogenesis; AKT; glucose metabolism; osteoporosis
ID BONE; OSTEOBLAST; DIFFERENTIATION; OSTEOPOROSIS; EXCESS; LIGAND
AB The imbalance between bone formation and bone resorption causes osteoporosis, which leads to severe bone fractures. It is known that increases in osteoclast numbers and activities are the main reasons for increasing bone resorption. Although extensive studies have investigated the regulation of osteoclastogenesis of bone marrow macrophages (BMMs), new pharmacological avenues still need to be unveiled for clinical purpose. Wnt ligands have been widely demonstrated as stimulators of bone formation; however, the inhibitory effect of the Wnt pathway in osteoclastogenesis is largely unknown. Here, we demonstrate that Wnt7b, a potent Wnt ligand that enhances bone formation and increases bone mass, also abolishes osteoclastogenesis in vitro. Importantly, enforced expression of Wnt in bone marrow macrophage lineage cells significantly disrupts osteoclast formation and activity, which leads to a dramatic increase in bone mass. Mechanistically, Wnt7b impacts the glucose metabolic process and AKT activation during osteoclastogenesis. Thus, we demonstrate that Wnt7b diminishes osteoclast formation, which will be beneficial for osteoporosis therapy in the future.
C1 [Wu, Fanzi; Li, Boer; Hu, Xuchen; Yu, Fanyuan; Shi, Yu; Ye, Ling] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis, Chengdu, Peoples R China.
   [Li, Boer; Hu, Xuchen; Yu, Fanyuan; Ye, Ling] Sichuan Univ, West China Hosp Stomatol, Dept Endodont, Chengdu, Peoples R China.
C3 Sichuan University; Sichuan University
RP Ye, L (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis, Chengdu, Peoples R China.; Ye, L (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Dept Endodont, Chengdu, Peoples R China.
EM yeling@scu.edu.cn
RI ye, ling/AFP 0048 2022; Yu, Fanyuan/HHN 4701 2022
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Baron R, 2018, CURR OPIN PHARMACOL, V40, P134, DOI 10.1016/j.coph.2018.04.011
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Calejman CM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 14430 w
   Chen H, 2019, FASEB J, V33, P7810, DOI 10.1096/fj.201900201RR
   Chen JQ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004145
   Covarrubias AJ, 2016, ELIFE, V5, DOI 10.7554/eLife.11612
   Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Fong JE, 2013, BIOL OPEN, V2, P387, DOI 10.1242/bio.20133269
   Fu LJ, 2020, CALCIFIED TISSUE INT, V107, P60, DOI 10.1007/s00223 020 00687 2
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Hamamura K, 2014, CELL SIGNAL, V26, P2358, DOI 10.1016/j.cellsig.2014.07.018
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264
   Huybrechts Y, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00165
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055
   Kobayashi Yasuhiro, 2019, Clin Calcium, V29, P309, DOI 10.20837/4201903309
   Lecka Czernik B, 2015, J BONE MINER RES, V30, P1356, DOI 10.1002/jbmr.2574
   Lei S. F., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P36
   Li BE, 2020, FASEB J, V34, P11058, DOI 10.1096/fj.202000771R
   Liu W, 2015, MOL MED REP, V11, P3212, DOI 10.3892/mmr.2015.3152
   Maeda K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225525
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   Maupin KA, 2013, BONE RES, V1, DOI 10.4248/BR201301004
   Mizoguchi T, 2009, J CELL BIOL, V184, P541, DOI 10.1083/jcb.200806139
   Movérare Skrtic S, 2014, NAT MED, V20, P1279, DOI 10.1038/nm.3654
   Ren JG, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 04626 4
   Richards JB, 2008, LANCET, V371, P1505, DOI 10.1016/S0140 6736(08)60599 1
   Sui X, 2018, CELL PHYSIOL BIOCHEM, V48, P2091, DOI 10.1159/000492549
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Tiedemann K, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00054
   Tu XL, 2007, DEV CELL, V12, P113, DOI 10.1016/j.devcel.2006.11.003
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   van Amerongen R, 2009, DEVELOPMENT, V136, P3205, DOI 10.1242/dev.033910
   Weivoda MM, 2016, J BONE MINER RES, V31, P65, DOI 10.1002/jbmr.2599
   Xin YJ, 2020, CALCIFIED TISSUE INT, V106, P553, DOI 10.1007/s00223 020 00666 7
   Xu K, 2021, IMMUNITY, V54, P976, DOI 10.1016/j.immuni.2021.04.008
   Xu K, 2021, SCIENCE, V371, P405, DOI 10.1126/science.abb2683
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yu B, 2014, NAT MED, V20, P1009, DOI 10.1038/nm.3586
   Yu FY, 2020, STEM CELLS, V38, P1020, DOI 10.1002/stem.3192
   Zhang DD, 2016, ACS CHEM NEUROSCI, V7, P710, DOI 10.1021/acschemneuro.5b00306
NR 44
TC 6
Z9 8
U1 0
U2 13
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD NOV 22
PY 2021
VL 9
AR 771336
DI 10.3389/fcell.2021.771336
PG 13
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA XM6WD
UT WOS:000728963800001
PM 34881243
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Gallagher, JA
   Ranganath, LR
   Boyde, A
AF Gallagher, James A.
   Ranganath, Lakshminarayan R.
   Boyde, Alan
TI Lessons from rare diseases of cartilage and bone
SO CURRENT OPINION IN PHARMACOLOGY
LA English
DT Article
ID ARTICULAR CALCIFIED CARTILAGE; CATHEPSIN K; PROGRESSIVE ANKYLOSIS;
   MOLECULAR CLONING; SUBCHONDRAL BONE; OSTEOARTHRITIS; SCLEROSTIN;
   ALKAPTONURIA; CHONDRODYSPLASIA; BISPHOSPHONATES
AB Studying severe phenotypes of rare syndromes can elucidate disease mechanisms of more common disorders and identify potential therapeutic targets. Lessons from rare bone diseases contributed to the development of the most successful class of bone active agents, the bisphosphonates. More recent research on rare bone diseases has helped elucidate key pathways and identify new targets in bone resorption and bone formation including cathepsin K and sclerostin, for which drugs are now in clinical trials. By contrast, there has been much less focus on rare cartilage diseases and osteoarthritis (OA) remains a common disease with no effective therapy. Investigation of rare cartilage syndromes is identifying new potential targets in OA including GDF5 and lubricin. Research on the arthropathy of the ultra rare disease alkaptonuria has identified several new features of the OA phenotype, including high density mineralized protrusions (HDMPs) which constitute a newly identified mechanism of joint destruction.
C1 [Gallagher, James A.; Ranganath, Lakshminarayan R.] Univ Liverpool, Musculoskeletal Biol, Liverpool L69 3BX, Merseyside, England.
   [Ranganath, Lakshminarayan R.] Royal Liverpool Univ Hosp, Clin Biochem & Metab, Liverpool, Merseyside, England.
   [Boyde, Alan] QMUL, Barts & London Sch Med & Dent, Biophys Oral Growth & Dev, London, England.
C3 University of Liverpool; Royal Liverpool & Broadgreen University
   Hospitals NHS Trust; Royal Liverpool University Hospital; University of
   Liverpool; University of London; Queen Mary University London
RP Gallagher, JA (通讯作者)，Univ Liverpool, Musculoskeletal Biol, Liverpool L69 3BX, Merseyside, England.
EM jag1@liv.ac.uk
RI Hunt, John/G 6366 2012; Boyde, Alan/H 7053 2013
FU AKU Society; Rosetrees Foundation; Childwick Trust; Big Lottery
FX We are grateful to the AKU Society, the Rosetrees Foundation, the
   Childwick Trust and the Big Lottery for financial support. Drs Graham
   Davis, David Mills and Tomas Zikmund helped with our X ray
   microtomographic studies.
CR Abhishek A, 2011, NAT REV RHEUMATOL, V7, P96, DOI 10.1038/nrrheum.2010.182
   Ai M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116237
   [Anonymous], INBORN ERRORS METABO
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Balemans W, 2008, CALCIFIED TISSUE INT, V82, P445, DOI 10.1007/s00223 008 9130 9
   Bateson W., 1908, The Methods and Scope of Genetics: An Inaugural Lecture Delivered 23 October 1908
   Berenbaum F, 2011, ANN RHEUM DIS, V70, P1354, DOI 10.1136/ard.2010.146399
   Bertrand J, 2012, ANN RHEUM DIS, V71, P1249, DOI 10.1136/annrheumdis 2011 200892
   Bone HG, 2015, OSTEOPOROSIS INT, V26, P699, DOI 10.1007/s00198 014 2944 6
   Bouaziz W, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0540 6
   Boyde A, 2014, J ANAT, V225, P436, DOI 10.1111/joa.12226
   Boyde A, 2003, J ANAT, V203, P173, DOI 10.1046/j.1469 7580.2003.00213.x
   Boyde A, 2012, EUR CELLS MATER, V24, P154, DOI 10.22203/eCM.v024a11
   Boyde A, 2011, EUR CELLS MATER, V21, P470, DOI 10.22203/eCM.v021a35
   Cameron TL, 2015, OSTEOARTHR CARTILAGE, V23, P661, DOI 10.1016/j.joca.2015.01.001
   Chambers TJ, 2013, J CLIN ENDOCR METAB, V98, P4329, DOI 10.1210/jc.2013 2630
   Chan BY, 2011, OSTEOARTHR CARTILAGE, V19, P874, DOI 10.1016/j.joca.2011.04.014
   Cox TM, 2012, JIMD REP, V5, P49, DOI 10.1007/8904_2011_93
   Evangelou E, 2009, ARTHRITIS RHEUM US, V60, P1710, DOI 10.1002/art.24524
   FLEISCH H, 1966, P SOC EXP BIOL MED, V122, P317
   Gallagher JA., 2013, Brenner's Encyclopedia of Genetics, V2nd, P71, DOI [DOI 10.1002/JLAC.19626560106, 10.1002/jlac.19626560106]
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Graul Neumann LM, 2014, EUR J HUM GENET, V22, P726, DOI 10.1038/ejhg.2013.222
   Guo X, 2014, OSTEOARTHR CARTILAGE, V22, P1774, DOI 10.1016/j.joca.2014.07.023
   Hald JD, 2015, J BONE MINER RES, V30, P929, DOI 10.1002/jbmr.2410
   Harvey W., 1657, COMMUNICATION
   Helliwell TR, 2008, HISTOPATHOLOGY, V53, P503, DOI 10.1111/j.1365 2559.2008.03000.x
   Hirose J, 2011, ACTA HISTOCHEM, V113, P613, DOI 10.1016/j.acthis.2010.06.007
   INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013
   Kannu P, 2009, ARTHRITIS RHEUM US, V60, P325, DOI 10.1002/art.24251
   Karsdal MA, 2014, ANN RHEUM DIS, V73, P336, DOI 10.1136/annrheumdis 2013 204111
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Kung LHW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117016
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   LittlewoodEvans A, 1997, BONE, V20, P81, DOI 10.1016/S8756 3282(96)00351 1
   LittlewoodEvans AJ, 1997, CANCER RES, V57, P5386
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   Marcelino J, 1999, NAT GENET, V23, P319, DOI 10.1038/15496
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   McColm J, 2014, J BONE MINER RES, V29, P935, DOI 10.1002/jbmr.2092
   MORI S, 1993, ARCH PATHOL LAB MED, V117, P196
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Preston AJ, 2014, ANN RHEUM DIS, V73, P284, DOI 10.1136/annrheumdis 2012 202878
   Ratnayake M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086590
   Reginster JY, 2013, ANN RHEUM DIS, V72, P179, DOI 10.1136/annrheumdis 2012 202231
   Reynard LN, 2013, EXPERT REV MOL MED, V15, DOI 10.1017/erm.2013.4
   Rhee DK, 2005, J BIOL CHEM, V280, P31325, DOI 10.1074/jbc.M505401200
   Rosenthal AK, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4337
   Roudier M, 2013, ARTHRITIS RHEUM US, V65, P721, DOI 10.1002/art.37802
   Ruan MZC, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005409
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   RUSSELL RGG, 1965, LANCET, V2, P461
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   SOKOLOFF L, 1993, ARCH PATHOL LAB MED, V117, P191
   STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0
   SWEET HO, 1981, J HERED, V72, P87, DOI 10.1093/oxfordjournals.jhered.a109459
   Taylor AM, 2012, OSTEOARTHR CARTILAGE, V20, P880, DOI 10.1016/j.joca.2012.04.013
   Taylor AM, 2012, EUR CELLS MATER, V23, P300, DOI 10.22203/eCM.v023a23
   Taylor AM, 2011, ARTHRITIS RHEUM US, V63, P3887, DOI 10.1002/art.30606
   Taylor AM, 2010, RHEUMATOLOGY, V49, P1412, DOI 10.1093/rheumatology/keq027
   TEZUKA K, 1994, J BIOL CHEM, V269, P1106
   Thomas JT, 1996, NAT GENET, V12, P315, DOI 10.1038/ng0396 315
   Tinti L, 2011, RHEUMATOLOGY, V50, P271, DOI 10.1093/rheumatology/keq246
   Verzijl N, 2002, ARTHRITIS RHEUM, V46, P114, DOI 10.1002/1529 0131(200201)46:1<114::AID ART10025>3.0.CO;2 P
   Vogt A, 2015, APPL CLIN GENET, V8, P27, DOI 10.2147/TACG.S44315
   Walsh DA, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3448
   Whyte MP, 2010, ANN NY ACAD SCI, V1192, P190, DOI 10.1111/j.1749 6632.2010.05387.x
   Yan JY, 2014, OSTEOARTHR CARTILAGE, V22, P1869, DOI 10.1016/j.joca.2014.07.013
NR 70
TC 17
Z9 19
U1 0
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471 4892
EI 1471 4973
J9 CURR OPIN PHARMACOL
JI Curr. Opin. Pharmacol.
PD JUN
PY 2015
VL 22
BP 107
EP 114
DI 10.1016/j.coph.2015.04.002
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CL8MP
UT WOS:000357229100016
PM 25978274
DA 2025 08 17
ER

PT J
AU Nara, Y
   Kitaura, H
   Ogawa, S
   Shen, WR
   Qi, JW
   Ohori, F
   Noguchi, T
   Marahleh, A
   Pramusita, A
   Kinjo, R
   Mizoguchi, I
AF Nara, Yasuhiko
   Kitaura, Hideki
   Ogawa, Saika
   Shen, Wei Ren
   Qi, Jiawei
   Ohori, Fumitoshi
   Noguchi, Takahiro
   Marahleh, Aseel
   Pramusita, Adya
   Kinjo, Ria
   Mizoguchi, Itaru
TI Anti c fms Antibody Prevents Osteoclast Formation and Bone Resorption in
   Co Culture of Osteoblasts and Osteoclast Precursors In Vitro and in
   Ovariectomized Mice
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE osteoclast; OVX; anti c fms antibody; M CSF
ID M CSF; DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR; OSTEOPOROSIS; LIGAND;
   OSTEOPROTEGERIN; MODULATION; EXPRESSION; MANAGEMENT; CELLS
AB Osteoporosis morphology is characterized by bone resorption and decreases in micro architecture parameters. Anti osteoporosis therapy targets osteoclasts because bone resorption is a unique function of osteoclasts. Anti c fms antibodies against the receptor for macrophage colony stimulating factor (M CSF) inhibit osteoclast formation and bone resorption in vitro and in vivo. However, the effect of anti c fms antibodies on bone resorption in ovariectomized (OVX) mice is unknown. In this study, we evaluated the effect of anti c fms antibodies on osteoclast formation and bone resorption in osteoblast osteoclast precursor co culture in vitro and in OVX mice. Osteoblast and osteoclast precursor co cultures treated with anti c fms antibodies showed significantly inhibited osteoclast formation, while cultures without anti c fms antibody treatment showed osteoclast formation. However, anti c fms antibodies did not change the receptor activator of nuclear factor kappa B ligand (RANKL) or osteoprotegrin (OPG) expression during osteoblast and osteoclast differentiation in vitro. These results indicate that anti c fms antibodies directly affected osteoclast formation from osteoclast precursors in co culture. OVX mice were treated with intraperitoneal injections of anti c fms antibody. The trabecular bone structure of the femur was assessed by micro computer tomography. The anti c fms antibody inhibited osteoclast formation and bone loss compared with PBS treated OVX mice. These results indicate potential for the therapeutic application of anti c fms antibodies for postmenopausal osteoporosis.
C1 [Nara, Yasuhiko; Kitaura, Hideki; Ogawa, Saika; Shen, Wei Ren; Qi, Jiawei; Ohori, Fumitoshi; Noguchi, Takahiro; Marahleh, Aseel; Pramusita, Adya; Kinjo, Ria; Mizoguchi, Itaru] Tohoku Univ, Div Orthodont & Dentofacial Orthoped, Grad Sch Dent, Aoba Ku, Sendai, Miyagi 9808575, Japan.
C3 Tohoku University
RP Kitaura, H (通讯作者)，Tohoku Univ, Div Orthodont & Dentofacial Orthoped, Grad Sch Dent, Aoba Ku, Sendai, Miyagi 9808575, Japan.
EM yasuhiko.nara.q6@dc.tohoku.ac.jp; hideki.kitaura.b4@tohoku.ac.jp;
   saika.ogawa.a4@tohoku.ac.jp; shen.wei.ren.t5@dc.tohoku.ac.jp;
   qi.jiawei.p8@dc.tohoku.ac.jp; fumitoshi.ohori.t3@dc.tohoku.ac.jp;
   takahiro.noguchi.r4@dc.tohoku.ac.jp;
   marahleh.aseel.mahmoud.t6@dc.tohoku.ac.jp;
   adya.pramusita.q6@dc.tohoku.ac.jp; ria.kinjou.p5@dc.tohoku.ac.jp;
   mizo@tohoku.ac.jp
RI Marahleh, Aseel/AHA 5443 2022; Pramusita, Adya/AAR 9298 2020; Kitaura,
   Hideki/AAS 8064 2020; 齐, 地质环境承载力/HRB 5861 2023
OI Marahleh, Aseel/0000 0002 4324 3155; 
FU JSPS KAKENHI grants from the Japan Society for the Promotion of Science
   [19K10397, 18K09862]; Grants in Aid for Scientific Research [19K10397,
   18K09862] Funding Source: KAKEN
FX This work was supported in part by JSPS KAKENHI grants from the Japan
   Society for the Promotion of Science (No. 19K10397 to HK and No.
   18K09862 to IM).
CR Andersson N, 2005, J ENDOCRINOL, V187, P303, DOI 10.1677/joe.1.06181
   Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858
   Bakker AD, 2012, METHODS MOL BIOL, V816, P19, DOI 10.1007/978 1 61779 415 5_2
   Bettina A, 2016, J IMMUNOL, V196, P5047, DOI 10.4049/jimmunol.1600306
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cenci S, 2000, J CLIN INVEST, V105, P1279, DOI 10.1172/JCI8672
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Eastell R, 2019, J CLIN ENDOCR METAB, V104, P1595, DOI 10.1210/jc.2019 00221
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Fuller K, 2002, ENDOCRINOLOGY, V143, P1108, DOI 10.1210/en.143.3.1108
   Hikita A, 2006, J BIOL CHEM, V281, P36846, DOI 10.1074/jbc.M606656200
   Horwood NJ, 1998, ENDOCRINOLOGY, V139, P4743, DOI 10.1210/en.139.11.4743
   JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Khan M, 2017, ENDOCRIN METAB CLIN, V46, P181, DOI 10.1016/j.ecl.2016.09.009
   Kimura K, 2014, ORAL DIS, V20, P319, DOI 10.1111/odi.12117
   Kimura K, 2012, FEMS IMMUNOL MED MIC, V64, P219, DOI 10.1111/j.1574 695X.2011.00888.x
   Kishikawa A, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00157
   Kitaura H, 2008, J DENT RES, V87, P396, DOI 10.1177/154405910808700405
   Kitaura H, 2005, J CLIN INVEST, V115, P3418, DOI 10.1172/JCI26132
   Kitaura H, 2004, J IMMUNOL, V173, P4838, DOI 10.4049/jimmunol.173.8.4838
   Kitaura H, 2009, ANGLE ORTHOD, V79, P835, DOI 10.2319/080708 412.1
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Marahleh A, 2019, JOVE J VIS EXP, DOI 10.3791/59089
   Martínez Martínez A, 2020, PHARMACOL REP, V72, P1614, DOI 10.1007/s43440 020 00091 5
   Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379
   Ohori F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21031130
   Qi JW, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214260
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Shen WR, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/5783639
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Sudo T, 1995, ONCOGENE, V11, P2469
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Van Overmeire E, 2016, CANCER RES, V76, P35, DOI 10.1158/0008 5472.CAN 15 0869
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 42
TC 18
Z9 18
U1 0
U2 21
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2020
VL 21
IS 17
AR 6120
DI 10.3390/ijms21176120
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA NO7BY
UT WOS:000569644300001
PM 32854340
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU AlMuraikhi, N
   Ali, D
   Alshanwani, A
   Vishnubalaji, R
   Manikandan, M
   Atteya, M
   Siyal, A
   Alfayez, M
   Aldahmash, A
   Kassem, M
   Alajez, NM
AF AlMuraikhi, Nihal
   Ali, Dalia
   Alshanwani, Aliah
   Vishnubalaji, Radhakrishnan
   Manikandan, Muthurangan
   Atteya, Muhammad
   Siyal, Abdulaziz
   Alfayez, Musaad
   Aldahmash, Abdullah
   Kassem, Moustapha
   Alajez, Nehad M.
TI Stem cell library screen identified ruxolitinib as regulator of
   osteoblastic differentiation of human skeletal stem cells
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
ID BONE FORMATION; JAK1/2 INHIBITOR; SMALL MOLECULES; EXPRESSION; GENE;
   ACTIVATION; INCB018424; DISRUPTION; ROLES; JAK2
AB Background: Better understanding of the signaling pathways that regulate human bone marrow stromal stem cell (hBMSC) differentiation into bone forming osteoblasts is crucial for their clinical use in regenerative medicine. Chemical biology approaches using small molecules targeting specific signaling pathways are increasingly employed to manipulate stem cell differentiation fat.
   Methods: We employed alkaline phosphatase activity and staining assays to assess osteoblast differentiation and Alizarin R staining to assess mineralized matrix formation of cultured hBMSCs. Changes in gene expression were assessed using an Agilent microarray platform, and data normalization and bioinformatics were performed using GeneSpring software. For in vivo ectopic bone formation experiments, hMSCs were mixed with hydroxyapatite tricalcium phosphate granules and implanted subcutaneously into the dorsal surface of 8 week old female nude mice. Hematoxylin and eosin staining and Sirius Red staining were used to detect bone formation in vivo.
   Results: We identified several compounds which inhibited osteoblastic differentiation of hMSCs. In particular, we identified ruxolitinib (INCB018424) (3M), an inhibitor of JAK STAT signaling that inhibited osteoblastic differentiation and matrix mineralization of hMSCs in vitro and reduced ectopic bone formation in vivo. Global gene expression profiling of ruxolitinib treated cells identified 847 upregulated and 822 downregulated mRNA transcripts, compared to vehicle treated control cells. Bioinformatic analysis revealed differential regulation of multiple genetic pathways, including TGF and insulin signaling, endochondral ossification, and focal adhesion.
   Conclusions: We identified ruxolitinib as an important regulator of osteoblast differentiation of hMSCs. It is plausible that inhibition of osteoblast differentiation by ruxolitinib may represent a novel therapeutic strategy for the treatment of pathological conditions caused by accelerated osteoblast differentiation and mineralization.
C1 [AlMuraikhi, Nihal; Ali, Dalia; Vishnubalaji, Radhakrishnan; Manikandan, Muthurangan; Atteya, Muhammad; Siyal, Abdulaziz; Alfayez, Musaad; Aldahmash, Abdullah; Kassem, Moustapha; Alajez, Nehad M.] King Saud Univ, Coll Med, Dept Anat, Stem Cell Unit, Riyadh 11461, Saudi Arabia.
   [Ali, Dalia; Kassem, Moustapha] Odense Univ Hosp, Dept Endocrinol, Mol Endocrinol Unit KMEB, Odense, Denmark.
   [Ali, Dalia; Kassem, Moustapha] Univ Southern Denmark, Odense, Denmark.
   [Alshanwani, Aliah] King Saud Univ, Dept Physiol, Coll Med, Riyadh 11461, Saudi Arabia.
   [Atteya, Muhammad] Cairo Univ, Histol Dept, Fac Med, Cairo, Egypt.
   [Aldahmash, Abdullah] King Saud Univ, Prince Naif Hlth Res Ctr, Riyadh 11461, Saudi Arabia.
   [Kassem, Moustapha] Univ Copenhagen, Dept Cellular & Mol Med, Danish Stem Cell Ctr DanStem, DK 2200 Copenhagen, Denmark.
   [Alajez, Nehad M.] Hamad Bin Khalifa Univ, Qatar Biomed Res Inst, Qatar Fdn, Canc Res Ctr, Doha, Qatar.
C3 King Saud University; University of Southern Denmark; Odense University
   Hospital; University of Southern Denmark; King Saud University; Egyptian
   Knowledge Bank (EKB); Cairo University; King Saud University; University
   of Copenhagen; Qatar Foundation (QF); Hamad Bin Khalifa
   University Qatar; Qatar Biomedical Research Institute (QBRI)
RP Alajez, NM (通讯作者)，King Saud Univ, Coll Med, Dept Anat, Stem Cell Unit, Riyadh 11461, Saudi Arabia.; Alajez, NM (通讯作者)，Hamad Bin Khalifa Univ, Qatar Biomed Res Inst, Qatar Fdn, Canc Res Ctr, Doha, Qatar.
EM nalajez@hbku.edu.qa
RI Kassem, Moustapha/J 7688 2013; ALMURAIKHI, NIHAL/AAC 3894 2019;
   Aldahmash, Abdullah/D 4693 2015; Ali, Dalia/KEH 0488 2024; Alshanwani,
   Aliah/GVT 8158 2022; Hassan, Muhammad/AAZ 9974 2021; muthurangan,
   manikandan/GVU 5356 2022
OI Alajez, Nehad/0000 0002 1546 1091; Ali, Dalia/0000 0002 2852 5971;
   Atteya, Muhammad/0000 0002 4451 1449; muthurangan,
   manikandan/0000 0003 3057 1851
FU Deanship of Scientific Research at King Saud University Research Group
   [RG 1438 033]; Novo Nordisk Foundation Section for Basic Stem Cell
   Biology [Petersen Group] Funding Source: researchfish
FX This work was supported by the Deanship of Scientific Research at King
   Saud University Research Group No. RG 1438 033.
CR Abdallah Basem M., 2008, V455, P89, DOI 10.1007/978 1 59745 104 8_6
   Abdallah BM, 2005, BIOCHEM BIOPH RES CO, V326, P527, DOI 10.1016/j.bbrc.2004.11.059
   Abell K, 2005, CELL CYCLE, V4, P897, DOI 10.4161/cc.4.7.1837
   AKHURST RJ, 1992, MOL REPROD DEV, V32, P127, DOI 10.1002/mrd.1080320208
   Al Nbaheen M, 2013, STEM CELL REV REP, V9, P32, DOI 10.1007/s12015 012 9365 8
   Aldahmash A, 2012, ANN SAUDI MED, V32, P68, DOI 10.5144/0256 4947.2012.68
   Alessio N, 2015, ONCOTARGET, V6, P8155, DOI 10.18632/oncotarget.2692
   Ali D, 2016, STEM CELL TRANSL MED, V5, P1036, DOI 10.5966/sctm.2015 0331
   Augello A, 2010, HUM GENE THER, V21, P1226, DOI 10.1089/hum.2010.173
   Bottos A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12258
   Chen L, 2014, STEM CELLS, V32, P902, DOI 10.1002/stem.1615
   Ding S, 2004, NAT BIOTECHNOL, V22, P833, DOI 10.1038/nbt987
   Elsafadi M, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/6913594
   Fakhry Maya, 2013, World J Stem Cells, V5, P136, DOI 10.4252/wjsc.v5.i4.136
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Georgy SR, 2012, BONE, V50, P704, DOI 10.1016/j.bone.2011.11.023
   Hayrapetyan A, 2015, TISSUE ENG PART B RE, V21, P75, DOI [10.1089/ten.teb.2014.0119, 10.1089/ten.TEB.2014.0119]
   Itoh S, 2006, BONE, V39, P505, DOI 10.1016/j.bone.2006.02.074
   Jafari A, 2015, STEM CELLS, V33, P2219, DOI 10.1002/stem.2013
   LEHNERT SA, 1988, DEVELOPMENT, V104, P263
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu BS, 2014, DRUG DISCOV TODAY, V19, P801, DOI 10.1016/j.drudis.2013.11.011
   Luo J, 2009, DEVELOPMENT, V136, P2747, DOI 10.1242/dev.033571
   Ostojic A, 2011, FUTURE ONCOL, V7, P1035, DOI [10.2217/FON.11.81, 10.2217/fon.11.81]
   Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092 8674(00)81167 8
   PELTON RW, 1990, DEV BIOL, V141, P456, DOI 10.1016/0012 1606(90)90401 4
   Qiu WM, 2007, J BONE MINER RES, V22, P1720, DOI 10.1359/JBMR.070721
   Quintás Cardama A, 2010, BLOOD, V115, P3109, DOI 10.1182/blood 2009 04 214957
   Randhawa J, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756 8722 5 43
   Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092 8674(00)81166 6
   Saidak Z, 2015, J BIOL CHEM, V290, P6903, DOI 10.1074/jbc.M114.621219
   Salasznyk RM, 2007, EXP CELL RES, V313, P22, DOI 10.1016/j.yexcr.2006.09.013
   Schoen FJ, 2005, ANN THORAC SURG, V79, P1072, DOI 10.1016/j.athoracsur.2004.06.033
   Segar CE, 2013, CURR PHARM DESIGN, V19, P3403, DOI 10.2174/1381612811319190007
   Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602 592
   Stine RR, 2013, ADV EXP MED BIOL, V786, P247, DOI 10.1007/978 94 007 6621 1_14
   Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801
   Verstovsek S, 2010, NEW ENGL J MED, V363, P1117, DOI 10.1056/NEJMoa1002028
   Vishnubalaji Radhakrishnan, 2018, Oncotarget, V9, P13551, DOI 10.18632/oncotarget.24420
   Weiss WA, 2007, NAT CHEM BIOL, V3, P739, DOI 10.1038/nchembio1207 739
   Winston LA, 1996, CURR BIOL, V6, P668, DOI 10.1016/S0960 9822(09)00445 X
   WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0
   Zacharaki D, 2018, EUR J HAEMATOL, V101, P57, DOI 10.1111/ejh.13079
   Zhang Y, 2012, J CELL SCI, V125, P5609, DOI 10.1242/jcs.096032
   Zhou HK, 2011, BONE, V49, P404, DOI 10.1016/j.bone.2011.04.020
NR 45
TC 15
Z9 16
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD NOV 21
PY 2018
VL 9
AR 319
DI 10.1186/s13287 018 1068 x
PG 10
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA HB3MU
UT WOS:000450956400004
PM 30463599
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yue, F
   Jiang, WY
   Ku, AT
   Young, AIJ
   Zhang, WJ
   Souto, EP
   Gao, YK
   Yu, ZH
   Wang, Y
   Creighton, CJ
   Nagi, C
   Wang, T
   Hilsenbeck, SG
   Feng, XH
   Huang, SX
   Coarfa, C
   Zhang, XHF
   Liu, QY
   Lin, X
   Li, Y
AF Yue, Fei
   Jiang, Weiyu
   Ku, Amy T.
   Young, Adelaide I. J.
   Zhang, Weijie
   Souto, Eric P.
   Gao, Yankun
   Yu, Zihan
   Wang, Yi
   Creighton, Chad J.
   Nagi, Chandandeep
   Wang, Tao
   Hilsenbeck, Susan G.
   Feng, Xin Hua
   Huang, Shixia
   Coarfa, Cristian
   Zhang, Xiang H F
   Liu, Qingyun
   Lin, Xia
   Li, Yi
TI A Wnt Independent LGR4 EGFR Signaling Axis in Cancer Metastasis
SO CANCER RESEARCH
LA English
DT Article
ID GROWTH FACTOR RECEPTOR; STEM CELLS; WNT/BETA CATENIN; BONE METASTASIS;
   BREAST CANCER; OSTEOGENIC NICHE; DOWN REGULATION; HAIR FOLLICLE;
   BETA CATENIN; NULL MICE
AB Leucine rich repeat containing G protein coupled receptors 4, 5, and 6 (LGR4/5/6) play critical roles in development and cancer. The widely accepted mechanism is that these proteins, together with their R spondin ligands, stabilize Wnt receptors, thus potentiating Wnt signaling. Here we show that LGR4 enhanced breast cancer cell metastasis even when Wnt signaling was deactivated pharmacologically or genetically. Furthermore, LGR4 mutants that cannot potentiate Wnt signaling nevertheless promoted breast cancer cell migration and invasion in vitro and breast cancer metastasis in vivo. Multiomic screening identified EGFR as a crucial mediator of LGR4 activity in cancer progression. Mechanistically, LGR4 interacted with EGFR and blocked EGFR ubiquitination and degradation, resulting in persistent EGFR activation. Together, these data uncover a Wnt independent LGR4 EGFR signaling axis with broad implications for cancer progression and targeted therapy.
   Significance: This work demonstrates a Wnt independent mechanism by which LGR4 promotes cancer metastasis.
C1 [Yue, Fei; Jiang, Weiyu; Ku, Amy T.; Young, Adelaide I. J.; Zhang, Weijie; Souto, Eric P.; Nagi, Chandandeep; Hilsenbeck, Susan G.; Zhang, Xiang H F; Li, Yi] Baylor Coll Med, Lester & Sue Smith Breast Ctr, 1 Baylor Plaza, Houston, TX 77030 USA.
   [Gao, Yankun; Yu, Zihan; Wang, Yi] Natl Ctr Prot Sci Beijing, Beijing Proteome Res Ctr, Beijing Inst Life, State Key Lab Prote, Beijing, Peoples R China.
   [Creighton, Chad J.; Coarfa, Cristian] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
   [Creighton, Chad J.; Wang, Tao; Hilsenbeck, Susan G.; Huang, Shixia; Zhang, Xiang H F; Li, Yi] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA.
   [Nagi, Chandandeep] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA.
   [Feng, Xin Hua; Huang, Shixia; Coarfa, Cristian; Zhang, Xiang H F; Li, Yi] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
   [Feng, Xin Hua; Lin, Xia] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA.
   [Feng, Xin Hua] Zhejiang Univ, Inst Life Sci, Hangzhou, Zhejiang, Peoples R China.
   [Coarfa, Cristian] Baylor Coll Med, Ctr Precis Environm Hlth, Houston, TX 77030 USA.
   [Zhang, Xiang H F] Baylor Coll Med, McNair Med Inst, Houston, TX 77030 USA.
   [Liu, Qingyun] Univ Texas Hlth Sci Ctr Houston, Texas Therapeut Inst, Houston, TX 77030 USA.
   [Liu, Qingyun] Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med, Houston, TX 77030 USA.
   [Li, Yi] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.
C3 Baylor College of Medicine; Baylor College of Medicine; Baylor College
   of Medicine; Baylor College of Medicine; Baylor College of Medicine;
   Baylor College of Medicine; Zhejiang University; Baylor College of
   Medicine; Baylor College of Medicine; University of Texas System;
   University of Texas Health Science Center Houston; University of Texas
   System; University of Texas Health Science Center Houston; Baylor
   College of Medicine
RP Li, Y (通讯作者)，Baylor Coll Med, Lester & Sue Smith Breast Ctr, 1 Baylor Plaza, Houston, TX 77030 USA.
EM liyi@bcm.edu
RI ; Yu, Zihan/KVC 0494 2024; Li, Yi/A 7635 2009; Zhang,
   Weijie/AFS 0002 2022; Zhang, Xiang/B 1522 2008; Wang, Tao/AAT 3028 2020;
   jiang, weiyu/ACI 2707 2022; Yue, Fei/N 1891 2018
OI Yu, Zihan/0009 0002 4584 8331; Zhang, Xiang/0000 0002 5674 8670; Li,
   Yi/0000 0002 9976 518X; Fuqua, Suzanne/0000 0001 8886 5161; Zhang,
   Weijie/0000 0002 6462 6067; jiang, weiyu/0000 0001 6199 4289; Young,
   Adelaide/0000 0002 5714 0501; 
FU Rolanette and Berdon Lawrence Bone Disease Program of Texas; Baylor
   College of Medicine Center for Skeletal Biology and Medicine; NIH
   [R01CA204926]; DOD CDMRP [BC160240]; Lester and Sue Smith Breast Center
   [P50CA186784]; Dan L. Duncan Cancer Center [P30CA125123]; Cancer
   Prevention & Research Institute of Texas Proteomics and Metabolomics
   Core Facility Support Award [RP170005]; NCI Cancer Center Support Grant
   [P30CA125123]; NIH S10 instrument award [S10OD028648 01]; National
   Cancer Institute [R01CA204926] Funding Source: NIH RePORTER; CDMRP
   [917281, BC160240] Funding Source: Federal RePORTER
FX The authors thank Dr. Feng Cong for generous gifts of reagents. They
   also thank Ms. Myra Costello and Ms. Fuli Jia from the Baylor College of
   Medicine Antibody based Proteomics Core/Shared Resource for their
   technical assistance in performing Antibody Array experiments, as well
   as Dr. I wen Song for assistance on X ray imaging. The authors
   acknowledge the support from the Rolanette and Berdon Lawrence Bone
   Disease Program of Texas and the Baylor College of Medicine Center for
   Skeletal Biology andMedicine led by Dr. Brendan Lee. This work was
   supported in part by funds from NIH R01CA204926 (Y. Li) and DOD CDMRP
   BC160240 (Q. Liu and Y. Li), resources from the Lester and Sue Smith
   Breast Center (P50CA186784) and Dan L. Duncan Cancer Center
   (P30CA125123), Cancer Prevention & Research Institute of Texas
   Proteomics and Metabolomics Core Facility Support Award (RP170005, S.
   Huang), NCI Cancer Center Support Grant (P30CA125123, S. Huang), and NIH
   S10 instrument award (S10OD028648 01, S. Huang) to Antibody based
   Proteomics Core/Shared Resource (S. Huang).
CR Bänziger C, 2006, CELL, V125, P509, DOI 10.1016/j.cell.2006.02.049
   Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196
   Barker N, 2013, DEVELOPMENT, V140, P2484, DOI 10.1242/dev.083113
   Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602
   Bartscherer K, 2006, CELL, V125, P523, DOI 10.1016/j.cell.2006.04.009
   Blaas L, 2016, NAT CELL BIOL, V18, P1346, DOI 10.1038/ncb3434
   Carmon KS, 2017, J BIOL CHEM, V292, P14989, DOI 10.1074/jbc.M117.786798
   Carmon KS, 2014, P NATL ACAD SCI USA, V111, pE1221, DOI 10.1073/pnas.1323106111
   Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108
   Chen QH, 2012, J CELL SCI, V125, P2224, DOI 10.1242/jcs.098368
   Chen Y, 2019, J PROTEOME RES, V18, P3715, DOI 10.1021/acs.jproteome.9b00427
   de Lau W, 2011, NATURE, V476, P293, DOI 10.1038/nature10337
   Dharmat R, 2018, J CELL BIOL, V217, P2851, DOI 10.1083/jcb.201712117
   GalchevaGargova Z, 1995, ONCOGENE, V11, P2649
   Gao Y, 2006, CANCER RES, V66, P11623, DOI 10.1158/0008 5472.CAN 06 2629
   Geng AJ, 2020, ELIFE, V9, DOI 10.7554/eLife.56434
   Gingras MC, 2016, CELL REP, V14, P907, DOI 10.1016/j.celrep.2015.12.005
   Glinka A, 2011, EMBO REP, V12, P1055, DOI 10.1038/embor.2011.175
   Greicius G, 2018, P NATL ACAD SCI USA, V115, pE3173, DOI 10.1073/pnas.1713510115
   Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019
   Huang PY, 2017, NAT GENET, V49, P1624, DOI 10.1038/ng.3957
   Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555
   Jaks V, 2008, NAT GENET, V40, P1291, DOI 10.1038/ng.239
   Jin C, 2008, INVEST OPHTH VIS SCI, V49, P4245, DOI 10.1167/iovs.08 1860
   Kadowaki T, 1996, GENE DEV, V10, P3116, DOI 10.1101/gad.10.24.3116
   Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308
   Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593
   Lehoczky JA, 2015, P NATL ACAD SCI USA, V112, P13249, DOI 10.1073/pnas.1518874112
   Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663
   Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Luo WJ, 2017, J BIOL CHEM, V292, P15525, DOI 10.1074/jbc.M116.771931
   Mazerbourg S, 2004, MOL ENDOCRINOL, V18, P2241, DOI 10.1210/me.2004 0133
   Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586
   Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686
   Morita H, 2004, MOL CELL BIOL, V24, P9736, DOI 10.1128/MCB.24.22.9736 9743.2004
   Mustata RC, 2011, EMBO REP, V12, P558, DOI 10.1038/embor.2011.52
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Pan HJ, 2014, ENDOCRINOLOGY, V155, P3624, DOI 10.1210/en.2013 2183
   Park S, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aaz4051
   Peng WC, 2013, CELL REP, V3, P1885, DOI 10.1016/j.celrep.2013.06.009
   Proffitt KD, 2013, CANCER RES, V73, P502, DOI 10.1158/0008 5472.CAN 12 2258
   Richards MH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092159
   Ruffner H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040976
   Schlange T, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1769
   Snippert HJ, 2010, SCIENCE, V327, P1385, DOI 10.1126/science.1184733
   Styrkarsdottir U, 2013, NATURE, V497, P517, DOI 10.1038/nature12124
   Takahashi H, 2011, ANN SURG ONCOL, V18, P1166, DOI 10.1245/s10434 010 1373 9
   Tan XP, 2005, GASTROENTEROLOGY, V129, P285, DOI 10.1053/j.gastro.2005.04.013
   Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772
   TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092 8674(88)90220 6
   VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460 2075.1993.tb06225.x
   Wang H, 2018, CANCER CELL, V34, P823, DOI 10.1016/j.ccell.2018.10.002
   Wang H, 2015, CANCER CELL, V27, P193, DOI 10.1016/j.ccell.2014.11.017
   Wang Y, 2013, STEM CELLS, V31, P1921, DOI 10.1002/stem.1438
   Weng JS, 2008, P NATL ACAD SCI USA, V105, P6081, DOI 10.1073/pnas.0708257105
   Wu JH, 2013, CARCINOGENESIS, V34, P2861, DOI 10.1093/carcin/bgt229
   Yi J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078144
   Young AIJ, 2018, CELL ADHES MIGR, V12, P513, DOI 10.1080/19336918.2017.1393591
   Yu M, 2012, NATURE, V487, P510, DOI 10.1038/nature11217
   Yue ZY, 2018, FASEB J, V32, P2422, DOI 10.1096/fj.201700897R
   Zhang XHF, 2013, CELL, V154, P1060, DOI 10.1016/j.cell.2013.07.036
   Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017
   Zhou XL, 2017, CANCER RES, V77, P6589, DOI 10.1158/0008 5472.CAN 17 0219
   Zhuang XQ, 2017, NAT CELL BIOL, V19, P1274, DOI 10.1038/ncb3613
NR 65
TC 16
Z9 16
U1 0
U2 16
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 0008 5472
EI 1538 7445
J9 CANCER RES
JI Cancer Res.
PD SEP 1
PY 2021
VL 81
IS 17
BP 4441
EP 4454
DI 10.1158/0008 5472.CAN 21 1112
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA UL8RS
UT WOS:000692912800009
PM 34099494
OA Bronze, Green Accepted, Green Submitted
DA 2025 08 17
ER

PT J
AU Liu, YD
   Yang, T
   Chen, T
   Hao, J
   Gai, Y
   Zhang, WG
AF Liu, Yadong
   Yang, Tao
   Chen, Ting
   Hao, Jun
   Gai, Yu
   Zhang, Weiguo
TI (R) dehydroxyabscisic alcohol
   β D apiofuranosyl (1"→6′) β D glucopyranoside enhances the osteoblastic
   differentiation of ST2 cells via the BMP/WNT pathways
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE (R) dehydroxyabscisic alcohol  D apiofuranosyl (1 '' > 6
   ') beta D glucopyranoside; osteoblastic differentiation; ST2 cells; bone
   morphogenetic protein pathway; WNT pathway
ID BONE; BMP; OSTEOPOROSIS; EXPRESSION
AB Lonicera japonica has been used in traditional Chinese medicine as an important medicinal plant, with the ability to inhibit osteoclast development and bone loss. However, it is not clear which active ingredient exerts these effects. (R) dehydroxyabscisic alcohol  D apiofuranosy l (1?6')  D glucopyranoside (DAG) is an active constituent isolated from Lonicera japonica. In the present study, the ST2 bone marrow stromal cell line was treated by DAG at different concentrations and the osteoblastic differentiation was explored by ELISA assay, Von Kossa staining, Alizarin Red S staining, reverse transcription quantitative polymerase chain reaction and western blot analysis. The results revealed that DAG promoted osteoblastic differentiation, as evidenced by increasing mineralization and alkaline phosphatase (ALP) activity, as well as the expression of genes encoding bone differentiation markers, including Alp, osteopontin (Opn) and osteocalcin (Ocn). In addition, DAG upregulated the gene expression of bone morphogenetic protein (Bmp) 2, Bmp4, Wnt family member (Wnt) 1, Wnt3 and runt related transcription factor 2 (Runx2), as well as the protein expression of phosphorylated mothers against decapentaplegic homolog (Smad) 1, Smad5 Smad8,  catenin and Runx2 in ST2 cells. The osteogenic effects induced by DAG were attenuated by the BMP antagonist Noggin and the WNT signaling pathway inhibitor Dickkopf related protein 1. The data indicated that DAG promoted the osteoblastic differentiation of ST2 cells, at least partially through regulating the BMP/WNT signaling pathways. This provides scientific rationale for the development of DAG as a treatment for bone loss associated diseases, such as osteoporosis.
C1 [Liu, Yadong; Hao, Jun; Zhang, Weiguo] Dalian Med Univ, Dept Joint Surg, Affiliated Hosp 1, 222 Zhongshan Rd, Dalian 116011, Liaoning, Peoples R China.
   [Yang, Tao] Tianjin Union Med Ctr, Dept Joint Surg & Sports Med, Tianjin 300121, Peoples R China.
   [Chen, Ting] China Med Univ, Dept Orthoped, Shengjing Hosp, Shenyang 110004, Liaoning, Peoples R China.
   [Gai, Yu] Dalian Med Univ, Dept Pathol, Dalian Municipal Cent Hosp, Dalian 116033, Liaoning, Peoples R China.
C3 Dalian Medical University; China Medical University; Dalian Medical
   University
RP Zhang, WG (通讯作者)，Dalian Med Univ, Dept Joint Surg, Affiliated Hosp 1, 222 Zhongshan Rd, Dalian 116011, Liaoning, Peoples R China.
EM zhangweiguo_gk@163.com
CR Aubin JE, 1998, J CELL BIOCHEM, P73, DOI 10.1002/(SICI)1097 4644(1998)72:30/31+<73::AID JCB11>3.0.CO;2 L
   Augustine M, 2013, CURR OSTEOPOROS REP, V11, P400, DOI 10.1007/s11914 013 0171 2
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Jia TL, 2003, BIOCHEM PHARMACOL, V65, P709, DOI 10.1016/S0006 2952(02)01585 X
   Kamiya Nobuhiro, 2012, Curr Mol Pharmacol, V5, P153
   Kikuchi A, 2000, BIOCHEM BIOPH RES CO, V268, P243, DOI 10.1006/bbrc.1999.1860
   Kim MB, 2014, FITOTERAPIA, V98, P59, DOI 10.1016/j.fitote.2014.07.013
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Li Y, 2015, EURASIP J WIREL COMM, DOI 10.1186/s13638 015 0414 2
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lo YC, 2010, J AGR FOOD CHEM, V58, P6643, DOI 10.1021/jf904158k
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   MacDonald BT, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007880
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Mei W, 2005, BIOCHEM BIOPH RES CO, V328, P651, DOI 10.1016/j.bbrc.2004.11.067
   Otsuka E, 1999, AM J PHYSIOL CELL PH, V277, pC132, DOI 10.1152/ajpcell.1999.277.1.C132
   Pinzone JJ, 2009, BLOOD, V113, P517, DOI 10.1182/blood 2008 03 145169
   Rawadi G, 2005, EXPERT OPIN THER TAR, V9, P1063, DOI 10.1517/14728222.9.5.1063
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Seo BK, 2016, J ETHNOPHARMACOL, V193, P227, DOI 10.1016/j.jep.2016.07.022
   Skjodt MK, 2019, BRIT J CLIN PHARMACO, V85, P1063, DOI 10.1111/bcp.13759
   Xu JR, 2016, PHYTOCHEM LETT, V15, P98, DOI 10.1016/j.phytol.2015.11.016
   Yamaguchi A, 1996, BIOCHEM BIOPH RES CO, V220, P366, DOI 10.1006/bbrc.1996.0411
   Zhao M, 2002, J CELL BIOL, V157, P1049, DOI 10.1083/jcb.200109012
NR 26
TC 1
Z9 1
U1 0
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JAN
PY 2019
VL 19
IS 1
BP 461
EP 467
DI 10.3892/mmr.2018.9690
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA HF7PE
UT WOS:000454431000048
PM 30483786
OA hybrid, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Tanaka, K
   Hirai, T
   Ishibashi, Y
   Izumo, N
   Togari, A
AF Tanaka, Kenjiro
   Hirai, Takao
   Ishibashi, Yukiko
   Izumo, Nobuo
   Togari, Akifumi
TI Modulation of osteoblast differentiation and bone mass by
   5 HT2A receptor signaling in mice
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE 5 HT2A receptor; Osteoblast differentiation; Osterix; Bone mass; Bone
   formation; Serotonin
ID CELL FUNCTION; SEROTONIN; EXPRESSION; OSTERIX; ACTIVATION; PATHWAY;
   SYSTEM; GROWTH; MAPK; ERK
AB Recent studies reported that serotonin (5 hydroxytryptamine, 5 HT) may be an endogenous paracrine and/or autocrine factor that is used for intercellular communication in bone cells and between multiple organs regulating bone homeostasis. In the present study, we showed that the administration of MDL11939, a selective 5 HT2A receptor antagonist, reduced bone mass in mice. The loss of bone mass in MDL11939 treated mice was associated with impaired bone formation in vivo, as demonstrated by the lower expression of osterix (Osx) and osteocalcin than that in vehicle treated mice. On the other hand, no significant differences were observed in osteoclast numbers between MDL11939  and vehicle treated mice. The pharmacological blockade of 5 HT2A receptor signaling significantly decreased alkaline phosphatase activity in osteoblastic cells. In addition, the knockdown of the 5 HT2A receptor by a siRNA treatment decreased Osx, but not Runx2 gene expression in MC3T3 E1 cells. These results suggest that 5 HT2A receptor signaling mediated bone mass by regulating osteoblast differentiation. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Tanaka, Kenjiro; Hirai, Takao; Togari, Akifumi] Aichi Gakuin Univ, Sch Dent, Dept Pharmacol, Chikusa Ku, Nagoya, Aichi 4648650, Japan.
   [Ishibashi, Yukiko] Yokohama Coll Pharm, Fac Pharmaceut Sci, Dept Biochem, Totsuka Ku, Yokohama, Kanagawa 2450066, Japan.
   [Ishibashi, Yukiko] Kanazawa Univ, Div Dev Higher Brain Funct, United Grad Sch Child Dev, Univ Fukui,Osaka Univ, Fukui, Japan.
   [Ishibashi, Yukiko] Chiba Univ, Hamamatsu Univ Sch Med, Fukui, Japan.
   [Ishibashi, Yukiko] Univ Fukui, Fukui 910, Japan.
   [Izumo, Nobuo] Yokohama Coll Pharm, Fac Pharmaceut Sci, Dept Clin Pharmacol, Totsuka Ku, Yokohama, Kanagawa 2450066, Japan.
C3 Aichi Gakuin University; University of Fukui; Kanazawa University;
   University of Osaka; Chiba University; University of Fukui
RP Hirai, T (通讯作者)，Aichi Gakuin Univ, Sch Dent, Dept Pharmacol, Chikusa Ku, 1 100 Kusumoto Cho, Nagoya, Aichi 4648650, Japan.
EM t hirai@dpc.agu.ac.jp; togariaf@dpc.agu.ac.jp
FU Ministry of Education, Culture, Sports, Science, and Technology, Japan
   [26462827]; Grants in Aid for Scientific Research [26462827] Funding
   Source: KAKEN
FX This work was supported in part by Grants in Aid for Scientific Research
   to A.T. (26462827) from the Ministry of Education, Culture, Sports,
   Science, and Technology, Japan.
CR Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028 3908(99)00010 6
   Baudry A, 2010, J BIOL CHEM, V285, P26066, DOI 10.1074/jbc.M109.073791
   Bliziotes M, 2006, BONE, V39, P1313, DOI 10.1016/j.bone.2006.06.009
   Bliziotes MM, 2001, BONE, V29, P477, DOI 10.1016/S8756 3282(01)00593 2
   Celil AB, 2005, J BIOL CHEM, V280, P31353, DOI 10.1074/jbc.M503845200
   Celil AB, 2005, J CELL BIOCHEM, V95, P518, DOI 10.1002/jcb.20429
   Chabbi Achengli Y, 2012, P NATL ACAD SCI USA, V109, P2567, DOI 10.1073/pnas.1117792109
   Collet C, 2008, FASEB J, V22, P418, DOI 10.1096/fj.07 9209com
   Fujita T, 2001, JPN J PHARMACOL, V86, P86, DOI 10.1254/jjp.86.86
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Gershon MD, 2007, GASTROENTEROLOGY, V132, P397, DOI 10.1053/j.gastro.2006.11.002
   Gustafsson BI, 2006, J CELL BIOCHEM, V98, P139, DOI 10.1002/jcb.20734
   Hirai T, 2014, J CELL SCI, V127, P3711, DOI 10.1242/jcs.148148
   Hirai T, 2014, J BIOL CHEM, V289, P17174, DOI 10.1074/jbc.M113.546135
   Hirai T, 2010, BIOCHEM BIOPH RES CO, V396, P278, DOI 10.1016/j.bbrc.2010.04.078
   Hirai T, 2009, J PHARMACOL SCI, V109, P319, DOI 10.1254/jphs.08243SC
   Kondo H, 2011, CALCIFIED TISSUE INT, V88, P23, DOI 10.1007/s00223 010 9421 9
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Li XX, 2013, BIOCHEM BIOPH RES CO, V441, P809, DOI 10.1016/j.bbrc.2013.10.141
   Locker M, 2006, CELL SIGNAL, V18, P628, DOI 10.1016/j.cellsig.2005.06.006
   McLean PG, 2007, TRENDS NEUROSCI, V30, P9, DOI 10.1016/j.tins.2006.11.002
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Ramage AG, 2008, TRENDS PHARMACOL SCI, V29, P472, DOI 10.1016/j.tips.2008.06.009
   Sinha KM, 2013, J CELL BIOCHEM, V114, P975, DOI 10.1002/jcb.24439
   Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898 6568(96)00191 X
   Westbroek I, 2001, J BIOL CHEM, V276, P28961, DOI 10.1074/jbc.M101824200
   Yadav VK, 2009, CELL, V138, P976, DOI 10.1016/j.cell.2009.06.051
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
   Zhou X, 2010, P NATL ACAD SCI USA, V107, P12919, DOI 10.1073/pnas.0912855107
   Zofková I, 2014, PHYSIOL RES, V63, P421, DOI 10.33549/physiolres.932668
NR 30
TC 18
Z9 21
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD SEP 5
PY 2015
VL 762
BP 150
EP 157
DI 10.1016/j.ejphar.2015.05.048
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CP2ML
UT WOS:000359711100019
PM 26026645
DA 2025 08 17
ER

PT J
AU Ivanova, MM
   Dao, J
   Kasaci, N
   Friedman, A
   Noll, L
   Goker Alpan, O
AF Ivanova, Margarita M.
   Dao, Julia
   Kasaci, Neil
   Friedman, Andrew
   Noll, Lauren
   Goker Alpan, Ozlem
TI Wnt signaling pathway inhibitors, sclerostin and DKK 1, correlate with
   pain and bone pathology in patients with Gaucher disease
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE Gaucher disease; osteoporosis; pain; bone; SOST; DKK 1; Wnt
ID CATENIN; DIFFERENTIATION; MANIFESTATIONS; OSTEOPOROSIS; OSTEOCLASTS;
   EXPRESSION; DICKKOPF 1; CHILDREN; LEUKEMIA; CELLS
AB Patients with Gaucher disease (GD) have progressive bone involvement that clinically presents with debilitating bone pain, structural bone changes, bone marrow infiltration (BMI), Erlenmeyer (EM) flask deformity, and osteoporosis. Pain is referred by the majority of GD patients and continues to persist despite the type of therapy. The pain in GD is described as chronic deep penetrating pain; however, sometimes, patients experience severe acute pain. The source of bone pain is mainly debated as nociceptive pain secondary to bone pathology or neuropathic or inflammatory origins. Osteocytes constitute a significant source of secreted molecules that coordinate bone remodeling. Osteocyte markers, sclerostin (SOST) and Dickkopf 1 (DKK 1), inactivate the canonical Wnt signaling pathway and lead to the inhibition of bone formation. Thus, circulated sclerostin and DKK 1 are potential biomarkers of skeletal abnormalities. This study aimed to assess the circulating levels of sclerostin and DKK 1 in patients with GD and their correlation with clinical bone pathology parameters: pain, bone mineral density (BMD), and EM deformity. Thirty nine patients with GD were classified into cohorts based on the presence and severity of bone manifestations. The serum levels of sclerostin and DKK 1 were quantified by enzyme linked immunosorbent assays. The highest level of sclerostin was measured in GD patients with pain, BMI, and EM deformity. The multiparameter analysis demonstrated that 95% of GD patients with pain, BMI, and EM deformity had increased levels of sclerostin. The majority of patients with elevated sclerostin also have osteopenia or osteoporosis. Moreover, circulating sclerostin level increase with age, and GD patients have elevated sclerostin levels when compared with healthy control from the same age group. Pearson's linear correlation analysis showed a positive correlation between serum DKK 1 and sclerostin in healthy controls and GD patients with normal bone mineral density. However, the balance between sclerostin and DKK 1 waned in GD patients with osteopenia or osteoporosis. In conclusion, the osteocyte marker, sclerostin, when elevated, is associated with bone pain, BMI, and EM flask deformity in GD patients. The altered sclerostin/DKK 1 ratio correlates with the reduction of bone mineral density. These data confirm that the Wnt signaling pathway plays a role in GD associated bone disease. Sclerostin and bone pain could be used as biomarkers to assess patients with a high risk of BMI and EM flask deformities.
C1 [Ivanova, Margarita M.; Dao, Julia; Kasaci, Neil; Friedman, Andrew; Noll, Lauren; Goker Alpan, Ozlem] Lysosomal & Rare Disorders Res & Treatment Ctr, Translat Res, Fairfax, VA 22030 USA.
RP Ivanova, MM (通讯作者)，Lysosomal & Rare Disorders Res & Treatment Ctr, Translat Res, Fairfax, VA 22030 USA.
EM mivanova@ldrtc.org
RI ; Ivanova, Margarita/AAM 4510 2021
OI Ivanova, Margarita/0000 0002 6197 8606; Friedman,
   Andrew/0009 0008 1003 8826
FU Shire Pharmaceuticals USA [IISR 2019 104331, IISR 2020 104392]
FX This study received funding from an Investigator Initiated Award from
   Shire Pharmaceuticals USA, a member of the Takeda group IISR 2019 104331
   and IISR 2020 104392 to MI. The funder was not involved in the study
   design, collection, analysis, interpretation of data, the writing of
   this article, or the decision to submit it for publication.
CR Adusumilli G, 2021, SKELETAL RADIOL, V50, P361, DOI 10.1007/s00256 020 03561 2
   Altarescu G, 2005, CYTOKINE, V31, P149, DOI 10.1016/j.cyto.2005.03.006
   Arevalo NB, 2022, FRONT MOL NEUROSCI, V15, DOI 10.3389/fnmol.2022.934820
   Awad O, 2017, STEM CELL REP, V9, P1853, DOI 10.1016/j.stemcr.2017.10.029
   Baek K, 2014, J CELL PHYSIOL, V229, P640, DOI 10.1002/jcp.24487
   Bendikov Bar I, 2011, BLOOD CELL MOL DIS, V46, P4, DOI 10.1016/j.bcmd.2010.10.012
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   Coulson J, 2017, OSTEOPOROSIS INT, V28, P2683, DOI 10.1007/s00198 017 4104 2
   Delgado Calle J, 2017, BONE, V96, P29, DOI 10.1016/j.bone.2016.10.007
   Devigili G, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023 017 0700 7
   Fabre S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9113439
   Faden MA, 2009, AM J MED GENET A, V149A, P1334, DOI 10.1002/ajmg.a.32253
   Frost CO, 2016, CURR OPIN PHARMACOL, V28, P31, DOI 10.1016/j.coph.2016.02.007
   Gaudio A, 2012, J CLIN ENDOCR METAB, V97, P3744, DOI 10.1210/jc.2012 1901
   Gerosa L, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.623893
   Glass DA, 2006, CURR TOP DEV BIOL, V73, P43, DOI 10.1016/S0070 2153(05)73002 7
   Goker Alpan O, 2011, MOL GENET METAB, V104, P438, DOI 10.1016/j.ymgme.2011.08.004
   Gould NR, 2021, ELIFE, V10, DOI 10.7554/eLife.64393
   Grabowski GA, 2021, MOL GENET METAB, V132, P59, DOI 10.1016/j.ymgme.2020.12.291
   Hay E, 2016, GERONTOLOGY, V62, P618, DOI 10.1159/000446278
   Holdsworth G, 2019, J MOL ENDOCRINOL, V62, pR167, DOI 10.1530/JME 18 0176
   Hughes D, 2019, J BONE MINER RES, V34, P996, DOI 10.1002/jbmr.3734
   Itzchaki M, 2004, ACTA ORTHOP SCAND, V75, P641, DOI 10.1080/00016470410004003
   Ivanova M, 2021, J CLIN MED, V10, DOI 10.3390/jcm10102217
   Ivanova M, 2018, BLOOD CELL MOL DIS, V68, P100, DOI 10.1016/j.bcmd.2016.10.018
   Ivanova MM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210617
   Kaplan P, 2006, ARCH PEDIAT ADOL MED, V160, P603, DOI 10.1001/archpedi.160.6.603
   Kinghorn KJ, 2017, NEURAL REGEN RES, V12, P380, DOI 10.4103/1673 5374.202934
   Kitaura H, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031481
   Kitaura H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145169
   Kobayashi Y, 2016, J BIOCHEM, V159, P387, DOI 10.1093/jb/mvv124
   Lewiecki EM, 2014, THER ADV MUSCULOSKEL, V6, P48, DOI 10.1177/1759720X13510479
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Linari S, 2015, CLIN CASES MINER BON, V12, P157, DOI 10.11138/ccmbm/2015.12.2.157
   Lu K, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008082
   Maman E, 2007, J CHILD ORTHOP, V1, P63, DOI 10.1007/s11832 007 0013 9
   Mantyh PW, 2019, BRIT J CLIN PHARMACO, V85, P1103, DOI 10.1111/bcp.13801
   Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756
   Maor G, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750 1172 8 140
   Mucci JM, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/192761
   Masi L, 2015, CLIN CASES MINER BON, V12, P165, DOI 10.11138/ccmbm/2015.12.2.165
   Maupin KA, 2013, BONE RES, V1, DOI 10.4248/BR201301004
   Mehta A, 2019, INTERN MED J, V49, P578, DOI 10.1111/imj.14156
   Michelakakis H, 1996, BBA MOL BASIS DIS, V1317, P219, DOI 10.1016/S0925 4439(96)00056 7
   Mitchell SAT, 2018, CURR OSTEOPOROS REP, V16, P325, DOI 10.1007/s11914 018 0446 8
   Mödder UI, 2011, J BONE MINER RES, V26, P373, DOI 10.1002/jbmr.217
   Mucci JM, 2012, GENE, V509, P51, DOI 10.1016/j.gene.2012.07.071
   Ohori F, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/9716758
   Oliveri B, 2020, MEDICINA BUENOS AIRE, V80, P487
   Pandey Manoj Kumar, 2013, Critical Reviews in Oncogenesis, V18, P197
   Panicker LM, 2018, HUM MOL GENET, V27, P811, DOI 10.1093/hmg/ddx442
   Pastores GM, 2005, CURR OPIN RHEUMATOL, V17, P70, DOI 10.1097/01.bor.0000147283.40529.13
   Patel S, 2018, J BIOL CHEM, V293, P12149, DOI 10.1074/jbc.RA118.002918
   Pinzone JJ, 2009, BLOOD, V113, P517, DOI 10.1182/blood 2008 03 145169
   Polyzos SA, 2012, OSTEOPOROSIS INT, V23, P1171, DOI 10.1007/s00198 010 1525 6
   Rauner M, 2021, J CLIN MED, V10, DOI 10.3390/jcm10040787
   Reed M, 2013, BLOOD CELL MOL DIS, V51, P185, DOI 10.1016/j.bcmd.2013.04.006
   Reed MC, 2018, GENE, V678, P196, DOI 10.1016/j.gene.2018.08.045
   Reed MC, 2018, MOL GENET METAB, V124, P278, DOI 10.1016/j.ymgme.2018.06.007
   Roh J, 2022, J MOL MED, V100, P499, DOI 10.1007/s00109 021 02174 z
   Sakata H, 2014, ACUTE MED SURG, V1, P249, DOI 10.1002/ams2.46
   Sapir Koren R, 2014, OSTEOPOROSIS INT, V25, P2685, DOI 10.1007/s00198 014 2808 0
   Terpos E, 2012, INT J CANCER, V131, P1466, DOI 10.1002/ijc.27342
   Tian J, 2015, J HUAZHONG U SCI MED, V35, P212, DOI 10.1007/s11596 015 1413 6
   Tu XL, 2012, BONE, V50, P209, DOI 10.1016/j.bone.2011.10.025
   Ueland T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20122896
   Vincent C, 2009, J BONE MINER RES, V24, P1434, DOI [10.1359/JBMR.090305, 10.1359/jbmr.090305]
   Voskaridou E, 2012, HORM METAB RES, V44, P909, DOI 10.1055/s 0032 1312618
   Wenstrup RJ, 2002, BRIT J RADIOL, V75, pA2, DOI 10.1259/bjr.75.suppl_1.750002
   Xu Y, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00057
   Zancan I, 2015, HUM MOL GENET, V24, P1280, DOI 10.1093/hmg/ddu538
   Zha L, 2018, BIOMED PHARMACOTHER, V102, P369, DOI 10.1016/j.biopha.2018.03.080
NR 72
TC 12
Z9 12
U1 0
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD NOV 24
PY 2022
VL 13
AR 1029130
DI 10.3389/fendo.2022.1029130
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 6U1MA
UT WOS:000894132400001
PM 36506070
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zeng, LJ
   Gu, RL
   Li, W
   Shao, YZ
   Zhu, Y
   Xie, ZW
   Liu, H
   Zhou, YS
AF Zeng, Lijun
   Gu, Ranli
   Li, Wei
   Shao, Yuzi
   Zhu, Yuan
   Xie, Zhengwei
   Liu, Hao
   Zhou, Yongsheng
TI Ataluren prevented bone loss induced by ovariectomy and aging in mice
   through the BMP SMAD signaling pathway
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Ataluren; HBMMSC; Osteogenesis; Osteoporosis; BMP SMAD pathway
ID CONNECTIVITY MAP; OSTEOBLAST DIFFERENTIATION; PARATHYROID HORMONE; DRUG
   DISCOVERY; READ THROUGH; MUTATIONS; OSTEOPOROSIS; ESTROGEN; REVEALS;
   ANALOGS
AB Both estrogen deficiency and aging may lead to osteoporosis. Developing novel drugs for treating osteoporosis is a popular research direction. We screened several potential therapeutic agents through a new deep learning  based efficacy prediction system (DLEPS) using transcriptional profiles for osteoporosis. DLEPS screening led to a potential novel drug examinee, ataluren, for treating osteoporosis. Ataluren significantly reversed bone loss in ovariectomized mice. Next, ataluren significantly increased human bone marrow derived mesenchymal stem cell (hBMMSC) osteogenic differentiation without cytotoxicity, indicated by the high expression index of oste ogenic differentiation genes (OCN , BGLAP, ALP, COL1A, BMP2, RUNX2). Mechanistically, ataluren exerted its function through the BMP SMAD pathway. Furthermore, it activated SMAD phosphorylation but osteogenic differentiation was attenuated by BMP2 SMAD inhibitors or small interfering RNA of BMP2. Finally, ataluren significantly reversed bone loss in aged mice. In summary, our findings suggest that the DLEPS screened ataluren may be a therapeutic agent against osteoporosis by aiding hBMMSC osteogenic differentiation.
C1 [Zeng, Lijun; Gu, Ranli; Shao, Yuzi; Zhu, Yuan; Zhou, Yongsheng] Peking Univ, Sch & Hosp Stomatol, Dept Prosthodont, 22 Zhongguancun South Ave, Beijing 100081, Peoples R China.
   [Li, Wei] Peking Univ, Sch & Hosp Stomatol, Dept Oral Pathol, Beijing 100081, Peoples R China.
   [Xie, Zhengwei] Peking Univ, Int Canc Inst, Hlth Sci Ctr, 38 Xueyuan Lu, Beijing 100191, Peoples R China.
   [Liu, Hao] Peking Univ, Sch & Hosp Stomatol, Cent Lab, 22 Zhongguancun South Ave, Beijing 100081, Peoples R China.
   [Zeng, Lijun; Gu, Ranli; Li, Wei; Shao, Yuzi; Zhu, Yuan; Liu, Hao; Zhou, Yongsheng] Natl Ctr Stomatol, Beijing 100081, Peoples R China.
   [Zeng, Lijun; Gu, Ranli; Li, Wei; Shao, Yuzi; Zhu, Yuan; Liu, Hao; Zhou, Yongsheng] Natl Clin Res Ctr Oral Dis, Beijing 100081, Peoples R China.
   [Zeng, Lijun; Gu, Ranli; Li, Wei; Shao, Yuzi; Zhu, Yuan; Liu, Hao; Zhou, Yongsheng] Natl Engn Res Ctr Oral Biomat & Digital Med Device, Beijing 100081, Peoples R China.
   [Zeng, Lijun; Gu, Ranli; Li, Wei; Shao, Yuzi; Zhu, Yuan; Liu, Hao; Zhou, Yongsheng] Beijing Key Lab Digital Stomatol, Beijing 100081, Peoples R China.
   [Zeng, Lijun; Gu, Ranli; Li, Wei; Shao, Yuzi; Zhu, Yuan; Liu, Hao; Zhou, Yongsheng] Natl Hlth Commiss Key Lab Digital Technol Stomatol, Beijing 100081, Peoples R China.
   [Xie, Zhengwei] Peking Univ, Int Canc Inst, Hlth Sci Ctr, 38 Coll Rd, Beijing 100191, Peoples R China.
C3 Peking University; Peking University; Peking University; Peking
   University; Peking University
RP Zhou, YS (通讯作者)，Peking Univ, Sch & Hosp Stomatol, Dept Prosthodont, 22 Zhongguancun South Ave, Beijing 100081, Peoples R China.; Liu, H (通讯作者)，Peking Univ, Sch & Hosp Stomatol, Cent Lab, 22 Zhongguancun South Ave, Beijing 100081, Peoples R China.; Xie, ZW (通讯作者)，Peking Univ, Int Canc Inst, Hlth Sci Ctr, 38 Coll Rd, Beijing 100191, Peoples R China.
EM xiezhengwei@hsc.pku.edu.cn; kqliuhao@bjmu.edu.cn;
   kqzhouysh@hsc.pku.edu.cn
RI Xie, Zhengwei/AGW 2107 2022; Zhou, Yanheng/AFX 1820 2022; Li,
   Wei/C 4096 2011; GU, Ranlii/U 5392 2017
OI Zhou, Yongsheng/0000 0002 4332 0878; 
FU National Natural Science Foundation of China [81870742]; Beijing Natural
   Science Foundation [L222145, L182006]; Clinical Medicine Plus X Young
   Scholars Project, Peking University, the Fundamental Research Funds for
   the Central Universities [PKU2023LCXQ017]
FX This work was supported by the National Natural Science Foundation of
   China [grant number 81870742]; the Beijing Natural Science Foundation
   [grant numbers L222145, L182006]; Clinical Medicine Plus X Young
   Scholars Project, Peking University, the Fundamental Research Funds for
   the Central Universities [grant number PKU2023LCXQ017].
CR Antony Debré I, 2015, BLOOD, V125, P930, DOI 10.1182/blood 2014 06 585513
   Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468
   Aslam AA, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012040.pub2
   Aspray Terry J, 2019, Subcell Biochem, V91, P453, DOI 10.1007/978 981 13 3681 2_16
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bartolomeo R, 2013, J INHERIT METAB DIS, V36, P363, DOI 10.1007/s10545 012 9521 y
   Ben Shoham A, 2016, DEVELOPMENT, V143, P3933, DOI 10.1242/dev.139253
   Benisch P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045142
   Berger J, 2020, J CELL MOL MED, V24, P6680, DOI 10.1111/jcmm.15319
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Bray N.L., 2015, NEAR OPTIMAL RNA SEQ
   Brum AM, 2015, P NATL ACAD SCI USA, V112, P12711, DOI 10.1073/pnas.1501597112
   Bushby K, 2014, MUSCLE NERVE, V50, P477, DOI 10.1002/mus.24332
   Campbell C, 2020, J COMP EFFECT RES, V9, P973, DOI 10.2217/cer 2020 0095
   Carreira AC, 2014, ARCH BIOCHEM BIOPHYS, V561, P64, DOI 10.1016/j.abb.2014.07.011
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen WQ, 2021, NAT MICROBIOL, V6, P455, DOI 10.1038/s41564 020 00850 3
   Drake KM, 2013, AM J RESP CELL MOL, V49, P403, DOI 10.1165/rcmb.2013 0100OC
   Eriksen EF, 2013, ACTA OBSTET GYN SCAN, V92, P620, DOI 10.1111/j.1600 0412.2012.01473.x
   Ezzat A, 2019, BRIEF BIOINFORM, V20, P1337, DOI 10.1093/bib/bby002
   Feller L, 2011, SADJ, V66, P30
   Finkel RS, 2010, J CHILD NEUROL, V25, P1158, DOI 10.1177/0883073810371129
   Gan Q, 2023, BIOACT MATER, V24, P551, DOI 10.1016/j.bioactmat.2022.12.029
   Garber M, 2011, NAT METHODS, V8, P469, DOI [10.1038/NMETH.1613, 10.1038/nmeth.1613]
   Hajjo R, 2012, J MED CHEM, V55, P5704, DOI 10.1021/jm2011657
   Hanson NA, 2004, BONE, V35, P326, DOI 10.1016/j.bone.2004.02.019
   Hettiaratchi MH, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay1240
   Hirawat S, 2007, J CLIN PHARMACOL, V47, P430, DOI 10.1177/0091270006297140
   Hsu YH, 2019, J BONE MINER RES, V34, P1284, DOI 10.1002/jbmr.3698
   Jiang HM, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.474267
   Katagiri T, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021899
   Keiser MJ, 2009, NATURE, V462, P175, DOI 10.1038/nature08506
   Kidwai F, 2020, STEM CELLS, V38, P1107, DOI 10.1002/stem.3206
   Komori T, 2020, MOL CELLS, V43, P168, DOI 10.14348/molcells.2019.0244
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Kong RN, 2020, PHARMACOL RES PERSPE, V8, DOI 10.1002/prp2.576
   Kong R, 2020, DRUG METAB DISPOS, V48, P317, DOI 10.1124/dmd.119.089391
   Kusner MJ, 2017, PR MACH LEARN RES, V70
   Langdahl B, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115516
   Leder BZ, 2017, CURR OSTEOPOROS REP, V15, P110, DOI 10.1007/s11914 017 0353 4
   Lee EJ, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10071052
   Alpan AL, 2020, J CRANIOFAC SURG, V31, P1477, DOI 10.1097/SCS.0000000000006326
   Li MS, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 020 20713 z
   Lian N, 2012, J BIOL CHEM, V287, P35975, DOI 10.1074/jbc.M112.372458
   Liu XJ, 2021, STEM CELLS, V39, P1395, DOI 10.1002/stem.3428
   Long L, 2020, PULM CIRC, V10, DOI 10.1177/2045894020935783
   Lu JS, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075 021 02512 z
   Majidinia M, 2018, J CELL PHYSIOL, V233, P2937, DOI 10.1002/jcp.26042
   Migliorati CA, 2006, LANCET ONCOL, V7, P508, DOI 10.1016/S1470 2045(06)70726 4
   Milat F, 2009, MOL CELL ENDOCRINOL, V310, P52, DOI 10.1016/j.mce.2009.06.002
   Movérare Skrtic S, 2015, P NATL ACAD SCI USA, V112, P14972, DOI 10.1073/pnas.1520408112
   Nahorski S.R., 1990, Trends Pharmacol. Sci.
   Ng MY, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2020599118
   Porter JJ, 2021, WIRES RNA, V12, DOI 10.1002/wrna.1641
   Qu XYA, 2012, DRUG DISCOV TODAY, V17, P1289, DOI 10.1016/j.drudis.2012.07.017
   Ramasamy SK, 2014, NATURE, V507, P376, DOI 10.1038/nature13146
   Roy B, 2016, P NATL ACAD SCI USA, V113, P12508, DOI 10.1073/pnas.1605336113
   Saleem TH, 2018, INT J HEPATOL, V2018, DOI 10.1155/2018/7603437
   Sampath TK, 2020, BONE, V140, DOI 10.1016/j.bone.2020.115548
   Sharir A, 2011, DEVELOPMENT, V138, P3247, DOI 10.1242/dev.063768
   Short B, 2003, ARCH MED RES, V34, P565, DOI 10.1016/j.arcmed.2003.09.007
   Stevenson JC, 2001, MATURITAS, V38, P197, DOI 10.1016/S0378 5122(00)00219 X
   Stokes JM, 2020, CELL, V180, P688, DOI 10.1016/j.cell.2020.01.021
   Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049
   Tay D, 2018, BRIT J CLIN PHARMACO, V84, P252, DOI 10.1111/bcp.13455
   Tezuka K, 2002, J BONE MINER RES, V17, P231, DOI 10.1359/jbmr.2002.17.2.231
   Thielen NGM, 2019, CELLS BASEL, V8, DOI 10.3390/cells8090969
   Wang LJ, 2021, BONE RES, V9, DOI 10.1038/s41413 020 00129 7
   Wang R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18267 1
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Wu ZP, 2020, AGING US, V12, P26029, DOI 10.18632/aging.202252
   Yan J, 2016, P NATL ACAD SCI USA, V113, pE7554, DOI 10.1073/pnas.1607235113
   Yu GY, 2013, EUR J MED RES, V18, DOI 10.1186/2047 783X 18 5
   Zhao Pinghan, 2021, Alzheimers Dement, V17 Suppl 2, pe058716, DOI 10.1002/alz.058716
   Zhu J, 2021, NAT BIOTECHNOL, V39, P1444, DOI 10.1038/s41587 021 00946 z
NR 75
TC 2
Z9 2
U1 2
U2 19
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD OCT
PY 2023
VL 166
AR 115332
DI 10.1016/j.biopha.2023.115332
EA AUG 2023
PG 13
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA R1XN3
UT WOS:001062340700001
PM 37597324
OA gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Cook, B
   Walker, N
   Zhang, QS
   Chen, SB
   Evans, T
AF Cook, Brandoch
   Walker, Nicholas
   Zhang, Qisheng
   Chen, Shuibing
   Evans, Todd
TI The small molecule DIPQUO promotes osteogenic differentiation via
   inhibition of glycogen synthase kinase 3 beta signaling
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID DRUG TARGET ENGAGEMENT; OSTEOBLAST DIFFERENTIATION; BONE; TAU;
   PHOSPHORYLATION; DISEASE; PATHWAY; BETA
AB Bone fractures are common impact injuries typically resolved through natural processes of osteogenic regeneration and bone remodeling, restoring the biological and mechanical function. However, dysfunctionality in bone healing and repair often arises in the context of aging related chronic disorders, such as Alzheimer's disease (AD). There is unmet need for effective pharmacological modulators of osteogenic differentiation and an opportunity to probe the complex links between bone biology and cognitive disorders. We previously discovered the small molecule DIPQUO, which promotes osteoblast differentiation and bone mineralization in mouse and human cell culture models, and in zebrafish developmental and regenerative models. Here, we examined the detailed function of this molecule. First, we used kinase profiling, cellular thermal shift assays, and functional studies to identify glycogen synthase kinase 3 beta (GSK3 beta) inhibition as a mechanism of DIPQUO action. Treatment of mouse C2C12 myoblasts with DIPQUO promoted alkaline phosphatase expression and activity, which could be enhanced synergistically by treatment with other GSK3 beta inhibitors. Suppression of the expression or function of GSK3 beta attenuated DIPQUO dependent osteogenic differentiation. In addition, DIPQUO synergized with GSK3 beta inhibitors to stimulate expression of osteoblast genes in human multipotent progenitors. Accordingly, DIPQUO promoted accumulation and activation of beta catenin. Moreover, DIPQUO suppressed activation of tau microtubule associated protein, an AD related effector of GSK3 beta signaling. Therefore, DIPQUO has potential as both a lead candidate for bone therapeutic development and a pharmacological modulator of GSK3 beta signaling in cell culture and animal models of disorders including AD.
C1 [Cook, Brandoch; Walker, Nicholas; Chen, Shuibing; Evans, Todd] Weill Cornell Med, Dept Surg, New York, NY 10065 USA.
   [Walker, Nicholas] Weill Cornell Med, Program Physiol Biophys & Syst Biol, New York, NY USA.
   [Zhang, Qisheng] Univ North Carolina, Dept Pharmacol, Chapel Hill, NC 27515 USA.
C3 Cornell University; Weill Cornell Medicine; Cornell University; Weill
   Cornell Medicine; University of North Carolina; University of North
   Carolina Chapel Hill
RP Cook, B (通讯作者)，Weill Cornell Med, Dept Surg, New York, NY 10065 USA.
EM brc2018@med.cornell.edu
OI Walker, Nicholas/0000 0002 6054 8989; Chen, Shuibing/0000 0002 6294 5187
CR Beurel E, 2015, PHARMACOL THERAPEUT, V148, P114, DOI 10.1016/j.pharmthera.2014.11.016
   Bhat RV, 2018, J ALZHEIMERS DIS, V64, pS547, DOI 10.3233/JAD 179934
   Bradburn S, 2016, AGE AGEING, V45, P844, DOI 10.1093/ageing/afw137
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Cook B, 2019, CELL CHEM BIOL, V26, P926, DOI 10.1016/j.chembiol.2019.03.009
   Cornelius C, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00120
   Duan PP, 2016, INT J BIOCHEM CELL B, V77, P23, DOI 10.1016/j.biocel.2016.05.015
   Evans DB, 2000, J BIOL CHEM, V275, P24977, DOI 10.1074/jbc.M000808200
   Fei YR, 2011, J BIOL CHEM, V286, P40575, DOI 10.1074/jbc.M111.274910
   Freland L, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00014
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Gillespie JR, 2013, ENDOCRINOLOGY, V154, P3702, DOI 10.1210/en.2013 1155
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Hooper C, 2008, J NEUROCHEM, V104, P1433, DOI 10.1111/j.1471 4159.2007.05194.x
   Houschyar KS, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00170
   Jhang KA, 2017, J AGR FOOD CHEM, V65, P9626, DOI 10.1021/acs.jafc.7b03252
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Kimura T, 2018, FRONT NEUROSCI SWITZ, V12, DOI 10.3389/fnins.2018.00044
   Kimura T, 2014, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00065
   Li JJ, 2012, PHARMACOL BIOCHEM BE, V101, P564, DOI 10.1016/j.pbb.2012.03.002
   Li L, 2017, SCI REP UK, V7, DOI 10.1038/srep45204
   LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960 9822(00)00246 3
   Marsell R, 2012, BONE, V50, P619, DOI 10.1016/j.bone.2011.11.007
   Medina M, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00024
   Molina DM, 2016, ANNU REV PHARMACOL, V56, P141, DOI 10.1146/annurev pharmtox 010715 103715
   Molina DM, 2013, SCIENCE, V341, P84, DOI 10.1126/science.1233606
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Oishi T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056641
   Pan JX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 1123 7
   Pei JJ, 2006, FEBS LETT, V580, P107, DOI 10.1016/j.febslet.2005.11.059
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403
   Planel E, 2007, J NEUROSCI, V27, P13635, DOI 10.1523/JNEUROSCI.3949 07.2007
   Rodríguez Carballo E, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00040
   Roos PM, 2014, J TRACE ELEM MED BIO, V28, P418, DOI 10.1016/j.jtemb.2014.08.010
   Sisask G, 2013, BONE, V54, P126, DOI 10.1016/j.bone.2013.01.019
   Stepanov A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192519
   Thouverey C, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.80
   Valta MP, 2006, ENDOCRINOLOGY, V147, P2171, DOI 10.1210/en.2005 1502
   Wada MR, 2002, DEVELOPMENT, V129, P2987
   Wagner U, 1996, J CELL SCI, V109, P1537
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Yamauchi K, 2009, ARCH DERMATOL RES, V301, P357, DOI 10.1007/s00403 009 0929 7
   Ye SD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035892
   Yu K, 2003, DEVELOPMENT, V130, P3063, DOI 10.1242/dev.00491
   Zamani A, 2009, BONE, V44, P331, DOI 10.1016/j.bone.2008.10.001
NR 45
TC 10
Z9 11
U1 1
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JAN JUN
PY 2021
VL 296
AR 100696
DI 10.1016/j.jbc.2021.100696
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA TI5TQ
UT WOS:000672866400667
PM 33895139
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wang, YM
   Yan, ZQ
   Fan, WS
   Guo, CG
AF Wang, Yiming
   Yan, Zuoqin
   Fan, Wenshuai
   Guo, Changan
TI PTHrP/IHH Involvement in TGFβ and Bone Morphogenic Protein Cross Talk in
   the Growth Plate and In Vitro Cartilage Development to Prevent
   Hypertrophy of Mesenchymal Stromal/Stem Cells
SO JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING
LA English
DT Article
DE Chondrogenesis; Mesenchymal Stromal/Stem Cell; Hypertrophy; Endochondral
   Ossification; Signaling Pathway; Transforming Growth Factor beta; Bone
   Morphogenic Protein; Parathyroid Hormone Related Protein/Indian
   Hedgehog; Cross Talk; Feedback Mechanism
ID CHONDROGENIC DIFFERENTIATION; STEM CELLS; OSTEOGENIC DIFFERENTIATION;
   CHONDROCYTE MATURATION; JOINT FORMATION; PROLIFERATION; TRANSCRIPTION;
   PHOSPHORYLATION; CALCIFICATION; EXPRESSION
AB Mesenchymal stem/stromal cells (MSCs) serve as a promising candidate for tissue engineering based cartilage regeneration therapy because of their availability and multipotent capacity. However, premature hypertrophy is the main obstacle to the routine application of MSCs in the generation of stable cartilage. Transforming growth factor beta (TGF beta) is an anti hypertrophy signal, whereas bone morphogenic proteins (BMPs) have the opposite effect on bone formation. In addition, the parathyroid hormone related protein (PTHrP)/Indian hedgehog (IHH) signaling pathway is recognized as the most powerful pathway mediating chondrocyte hypertrophy. Understanding the cross talk between TGF beta, BMPs and PTHrP/IHH may thus provide insight to eliminate this undesirable phenomenon. This review elucidates these interactions during bone formation and compares them with those observed during MSCs hypertrophic processes in vitro, with the aim of facilitating cell based regeneration of functional and stable cartilage.
C1 [Wang, Yiming; Yan, Zuoqin; Fan, Wenshuai; Guo, Changan] Fudan Univ, Zhongshan Hosp, Dept Orthoped, Shanghai 200032, Peoples R China.
C3 Fudan University
RP Guo, CG (通讯作者)，Fudan Univ, Zhongshan Hosp, Dept Orthoped, Shanghai 200032, Peoples R China.
RI Yiming, Wang/JRW 6799 2023
CR Alvarez J, 2004, DEV DYNAM, V230, P685, DOI 10.1002/dvdy.20100
   Arnold MA, 2007, DEV CELL, V12, P377, DOI 10.1016/j.devcel.2007.02.004
   Augello A, 2010, HUM GENE THER, V21, P1226, DOI 10.1089/hum.2010.173
   Baksh D, 2004, J CELL MOL MED, V8, P301, DOI 10.1111/j.1582 4934.2004.tb00320.x
   Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104
   Beier F, 2001, MOL BIOL CELL, V12, P3852, DOI 10.1091/mbc.12.12.3852
   Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455
   Cucchiarini M, 2005, MOL THER, V12, P229, DOI 10.1016/j.ymthe.2005.03.012
   De Bari C, 2004, ARTHRITIS RHEUM US, V50, P142, DOI 10.1002/art.11450
   Dickhut A, 2009, J CELL PHYSIOL, V219, P219, DOI 10.1002/jcp.21673
   Filion TM, 2013, J BIOMATER TISS ENG, V3, P486, DOI 10.1166/jbt.2013.1103
   Fischer J, 2010, ARTHRITIS RHEUM US, V62, P2696, DOI 10.1002/art.27565
   Frisch J, 2014, HUM GENE THER, V25, P1050, DOI 10.1089/hum.2014.091
   Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019
   Grimsrud CD, 2001, J ORTHOPAED RES, V19, P18, DOI 10.1016/S0736 0266(00)00017 6
   Hellingman CA, 2011, TISSUE ENG PT A, V17, P1157, DOI [10.1089/ten.tea.2010.0043, 10.1089/ten.TEA.2010.0043]
   Hennig T, 2007, J CELL PHYSIOL, V211, P682, DOI 10.1002/jcp.20977
   Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355
   Ionescu AM, 2004, J CELL PHYSIOL, V198, P428, DOI 10.1002/jcp.10421
   Ionescu AM, 2003, EXP CELL RES, V288, P198, DOI 10.1016/S0014 4827(03)00181 2
   Karl A, 2014, TISSUE ENG PT A, V20, P178, DOI [10.1089/ten.tea.2013.0023, 10.1089/ten.TEA.2013.0023]
   Kawamura I, 2012, J BIOL CHEM, V287, P29101, DOI 10.1074/jbc.M112.349415
   Keller B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016421
   Kempf H, 2007, DEV DYNAM, V236, P1954, DOI 10.1002/dvdy.21205
   Kim YJ, 2008, BIOCHEM BIOPH RES CO, V373, P104, DOI 10.1016/j.bbrc.2008.05.183
   Kobayashi T, 2005, P NATL ACAD SCI USA, V102, P18023, DOI 10.1073/pnas.0503617102
   Kozhemyakina E, 2009, MOL CELL BIOL, V29, P5751, DOI 10.1128/MCB.00415 09
   Kronenberg HM, 2006, ANN NY ACAD SCI, V1068, P1, DOI 10.1196/annals.1346.002
   Kuo AC, 2006, OSTEOARTHR CARTILAGE, V14, P1126, DOI 10.1016/j.joca.2006.04.004
   Leboy PS, 2001, J BONE JOINT SURG AM, V83A, pS15
   Lee JM, 2012, BIOCHEM BIOPH RES CO, V421, P819, DOI 10.1016/j.bbrc.2012.04.096
   Li TF, 2006, J BONE MINER RES, V21, P4, DOI 10.1359/JBMR.050911
   Li TF, 2004, EXP CELL RES, V299, P128, DOI 10.1016/j.yexcr.2004.05.025
   Li YW, 2011, DEVELOPMENT, V138, P359, DOI 10.1242/dev.052324
   Ma RS, 2013, COMP BIOCHEM PHYS B, V166, P117, DOI 10.1016/j.cbpb.2013.07.010
   Mak KK, 2008, DEVELOPMENT, V135, P1947, DOI 10.1242/dev.018044
   Matsumoto K, 2009, DEVELOPMENT, V136, P2825, DOI 10.1242/dev.038505
   Mau E, 2007, DEV BIOL, V305, P28, DOI 10.1016/j.ydbio.2007.01.031
   Mehlhorn AT, 2007, CELL PROLIFERAT, V40, P809, DOI 10.1111/j.1365 2184.2007.00473.x
   Mueller MB, 2008, ARTHRITIS RHEUM US, V58, P1377, DOI 10.1002/art.23370
   Pathi S, 1999, DEV BIOL, V209, P239, DOI 10.1006/dbio.1998.9181
   Pelttari K, 2006, ARTHRITIS RHEUM US, V54, P3254, DOI 10.1002/art.22136
   Rodriguez L, 2005, ENDOCRINOLOGY, V146, P4597, DOI 10.1210/en.2005 0437
   Shen BJ, 2010, J CELL BIOCHEM, V109, P406, DOI 10.1002/jcb.22412
   Shen BJ, 2009, TISSUE ENG PT A, V15, P1311, DOI 10.1089/ten.tea.2008.0132
   Shimizu E, 2010, J BIOL CHEM, V285, P9616, DOI 10.1074/jbc.M109.094862
   Studer D, 2012, EUR CELLS MATER, V24, P118, DOI 10.22203/eCM.v024a09
   Weiss S, 2010, J CELL PHYSIOL, V223, P84, DOI 10.1002/jcp.22013
   Wrighton KH, 2009, J BIOL CHEM, V284, P9755, DOI 10.1074/jbc.M809223200
   Xu DL, 2006, GROWTH FACTORS, V24, P268, DOI 10.1080/08977190601075865
   Yang X, 2001, J CELL BIOL, V153, P35, DOI 10.1083/jcb.153.1.35
NR 51
TC 1
Z9 1
U1 1
U2 19
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381 0751 USA
SN 2157 9083
EI 2157 9091
J9 J BIOMATER TISS ENG
JI J. Biomater. Tissue Eng.
PD MAY
PY 2015
VL 5
IS 5
BP 391
EP 395
DI 10.1166/jbt.2015.1325
PG 5
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA CO8CA
UT WOS:000359391400007
DA 2025 08 17
ER

PT J
AU Koh, KS
   Kim, TY
   Kwak, YJ
   Kim, HJ
   Bae, MK
   Bae, SK
   Kim, DS
   Jang, HO
AF Koh, Kwang Soo
   Kim, Tae Young
   Kwak, Yeon Ju
   Kim, Hyung Joon
   Bae, Moon Kyoung
   Bae, Soo Kyung
   Kim, Da Sol
   Jang, Hye Ock
TI Natural Herb Mixture Extract Accelerates Osteogenic Differentiation of
   Human Bone Marrow Derived Mesenchymal Stem Cells by Activating the SMAD
   Pathway
SO JOURNAL OF MEDICINAL FOOD
LA English
DT Article
DE bone marrow mesenchymal stem cells; bone regeneration; cell signaling;
   natural herb mixture extract; regeneration medicine
ID TGF BETA; OSTEOPOROSIS
AB We aimed to analyze the effects and explore the molecular mechanisms of a natural herb mixture extract (NME) on osteoblasts during differentiation in human bone marrow derived mesenchymal stem cells (hBMSCs). We tried to confirm the regulation of osteogenic differentiation during NME treatment. Alkaline phosphatase assay and Alizarin red S staining were performed to evaluate the regulation of osteogenic differentiation. Real time polymerase chain reaction was performed to analyze the expression of osteoblast maker genes, and Western blot was used to verify the signaling pathway. Signaling pathway conformation, selective bone morphogenetic protein receptor inhibitor, and dorsomorphin homolog 1 were used as pretreatments before inducing osteogenic differentiation. We determined that MME (natural herb mixture extract) was a safe material and significantly increased osteoblast differentiation and that SMAD phosphorylation is a key signaling pathway that regulates osteogenic differentiation in hBMSCs.
C1 [Koh, Kwang Soo; Kim, Tae Young; Bae, Soo Kyung; Kim, Da Sol; Jang, Hye Ock] Pusan Natl Univ, Dept Dent Pharmacol, Sch Dent, Yangsan, South Korea.
   [Kim, Hyung Joon; Bae, Moon Kyoung] Pusan Natl Univ, Dept Oral Physiol, Sch Dent, Yangsan, South Korea.
   [Kim, Hyung Joon; Bae, Moon Kyoung; Bae, Soo Kyung; Kim, Da Sol] Pusan Natl Univ, Periodontal Dis Signaling Network Res Ctr MRC, Sch Dent, Yangsan, South Korea.
   [Kim, Hyung Joon; Bae, Moon Kyoung; Bae, Soo Kyung; Kim, Da Sol; Jang, Hye Ock] Pusan Natl Univ, Dent & Life Sci Inst, Sch Dent, Yangsan, South Korea.
   [Kwak, Yeon Ju] Agr Corp GAGOPA HEALING FOOD, Res Inst GH BioFarm, Chang Won, South Korea.
C3 Pusan National University; Pusan National University Hospital; Pusan
   National University; Pusan National University Hospital; Pusan National
   University; Pusan National University Hospital; Pusan National
   University; Pusan National University Hospital
RP Kim, DS; Jang, HO (通讯作者)，Pusan Natl Univ, Sch Dent, Dept Dent Pharmacol, Yangsan Si 50612, South Korea.
EM k201797801@pusan.ac.kr; jho9612@pusan.ac.kr
RI Kim, Hyung Joon/ABD 3143 2020
FU National Research Foundation of Korea [NRF 2019R1A6A3A01095696]
FX This work was supported by the National Research Foundation of Korea
   (NRF 2019R1A6A3A01095696).
CR Alam MR, 2006, AM J CHINESE MED, V34, P601, DOI 10.1142/S0192415X06004132
   Amaral R., 2019, Clinical Oncology (Royal College of Radiologist), V4, P1562
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   ANDERSON HC, 1989, LAB INVEST, V60, P320
   Augello A, 2010, HUM GENE THER, V21, P1226, DOI 10.1089/hum.2010.173
   BEERTSEN W, 1989, MATRIX, V9, P159, DOI 10.1016/S0934 8832(89)80035 6
   BELLOWS CG, 1991, BONE MINER, V14, P27, DOI 10.1016/0169 6009(91)90100 E
   Brekhman I, 2016, PHARM ORIENT PLANTS, V7, P97
   Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007 0197
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Fisher MB, 2013, TISSUE ENG PART B RE, V19, P1, DOI [10.1089/ten.TEB.2012.0723, 10.1089/ten.teb.2012.0723]
   Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284
   Heo J., DONGUIBOGAM
   Huang RL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0126 0
   Jiao F, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/2562105
   Kim DS, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2015.39
   Kim HJ, 2002, CALCIFIED TISSUE INT, V71, P88, DOI 10.1007/s00223 001 1080 4
   Kim JH, 2018, EVID BASED COMPL ALT, V2018, DOI 10.1155/2018/9837863
   Knippenberg M, 2006, BIOCHEM BIOPH RES CO, V342, P902, DOI 10.1016/j.bbrc.2006.02.052
   Liersch B., 1992, HAGERS HDB PHARM PRA, P54
   Min Kim Kyeong, 2017, [Journal of the Korean Society of Food Science and Nutrition, 한국식품영양과학회지], V46, P314
   Moon Eun jung, 2010, [Journal of Korea Academia Industrial cooperation Society, 한국산학기술학회논문지], V11, P3358
   Rao YV, 2006, FISH SHELLFISH IMMUN, V20, P263, DOI 10.1016/j.fsi.2005.04.006
   Saurabh Srivastav Saurabh Srivastav, 2011, Journal of Natural Product and Plant Resources, V1, P1
   Sun SC, 2019, BIOCHEM BIOPH RES CO, V516, P171, DOI 10.1016/j.bbrc.2019.06.029
   Yamaguchi Dean T, 2014, World J Stem Cells, V6, P94, DOI 10.4252/wjsc.v6.i2.94
NR 26
TC 1
Z9 1
U1 0
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096 620X
EI 1557 7600
J9 J MED FOOD
JI J. Med. Food
PD NOV 1
PY 2021
VL 24
IS 11
BP 1145
EP 1152
DI 10.1089/jmf.2021.K.0039
PG 8
WC Chemistry, Medicinal; Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Food Science & Technology; Nutrition &
   Dietetics
GA A4BH6
UT WOS:000954593400001
PM 34792394
DA 2025 08 17
ER

PT J
AU Liu, DF
   Ma, LY
   Zheng, JH
   Zhang, ZQ
   Zhang, NN
   Han, ZQ
   Wang, XJ
   Zhao, JY
   Lv, SQ
   Cui, HT
AF Liu, Defeng
   Ma, Lingyun
   Zheng, Jihui
   Zhang, Zhenqun
   Zhang, Nana
   Han, Zhongqian
   Wang, Xuejie
   Zhao, Jianyong
   Lv, Shuquan
   Cui, Huantian
TI Isopsoralen Improves Glucocorticoid induced Osteoporosis by Regulating
   Purine Metabolism and Promoting cGMP/PKG Pathway mediated Osteoblast
   Differentiation
SO CURRENT DRUG METABOLISM
LA English
DT Article
DE Isopsoralen; glucocorticoid induced osteoporosis (GIOP); purine
   metabolism; cyclic guanosine monophosphate (cGMP)/protein kinase G (PKG)
   pathway; osteoblast differentiation; non targeted metabolomics
ID IN VIVO; ACID; METABOLOMICS; ALENDRONATE; APOPTOSIS; PROTECTS; MASS
AB Background The effects of Isopsoralen (ISO) in promoting osteoblast differentiation and inhibiting osteoclast formation are well established, but the mechanism underlying ISO's improvement of Glucocorticoid Induced Osteoporosis (GIOP) by regulating metabolism remains unclear.Methods This study aims to elucidate the mechanism of ISO treatment for GIOP through non targeted metabolomics based on ISO's efficacy in GIOP. Initially, we established a GIOP female mouse model and assessed ISO's therapeutic effects using micro CT detection, biomechanical testing, serum calcium (Ca), and phosphorus (P) level detection, along with histological analyses using hematoxylin and eosin (HE), Masson, and tartrate resistant acidic phosphatase (TRAP) staining. Subsequently, non targeted metabolomics was employed to investigate ISO's impact on serum metabolites in GIOP mice. RT qPCR and Western blot analyses were conducted to measure the levels of enzymes associated with these metabolites. Building on the metabolomic results, we explored the effects of ISO on the cyclic Guanosine Monophosphate (cGMP)/Protein Kinase G (PKG) pathway and its role in mediating osteoblast differentiation.Results Our findings demonstrate that ISO intervention effectively enhances the bone microarchitecture and strength of GIOP mice. It mitigates pathological damage, such as structural damage in bone trabeculae, reduced collagen fibers, and increased osteoclasts, while improving serum Ca and P levels in GIOP mice. Non targeted metabolomics revealed purine metabolism as a common pathway between the Control and GIOP groups, as well as between the ISO high dose (ISOH) group and the GIOP group. ISO intervention upregulated inosine and adenosine levels, downregulated guanosine monophosphate levels, increased Adenosine Deaminase (ADA) expression, and decreased cGMP specific 3',5' cyclic phosphodiesterase (PDE5) expression. Additionally, ISO intervention elevated serum cGMP levels, upregulated PKGI and PKGII expression in bone tissues, as well as the expression of Runt related transcription factor 2 (Runx2) and Osterix, and increased serum Alkaline Phosphatase (ALP) activity.Conclusion In summary, ISO was able to enhance the bone microstructure and bone strength of GIOP mice and improve their Ca, P, and ALP levels, which may be related to ISO's regulation of purine metabolism and promotion of osteoblast differentiation mediated by the cGMP/PKG pathway. This suggests that ISO is a potential drug for treating GIOP. However, further research is still needed to explore the specific targets and clinical applications of ISO.
C1 [Liu, Defeng; Ma, Lingyun; Zheng, Jihui; Zhang, Nana; Han, Zhongqian; Wang, Xuejie; Zhao, Jianyong; Lv, Shuquan; Cui, Huantian] Hebei Univ Chinese Med, Cangzhou Hosp Integrated Tradit Chinese Med & West, Dept Endocrinol, Cangzhou, Peoples R China.
   [Zhang, Zhenqun] Hebei Univ Chinese Med, Dept Endocrinol, Cangzhou, Peoples R China.
   [Zhao, Jianyong; Lv, Shuquan; Cui, Huantian] Yunnan Univ Chinese Med, Fac Life Sci, Kunming, Peoples R China.
C3 Hebei University of Chinese Medicine; Hebei University of Chinese
   Medicine; Yunnan University of Chinese Medicine
RP Zhao, JY; Lv, SQ; Cui, HT (通讯作者)，Hebei Univ Chinese Med, Cangzhou Hosp Integrated Tradit Chinese Med & West, Dept Endocrinol, Cangzhou, Peoples R China.; Zhao, JY; Lv, SQ; Cui, HT (通讯作者)，Yunnan Univ Chinese Med, Fac Life Sci, Kunming, Peoples R China.
EM zhaojyvip@126.com; czlvshuquan@163.com; 1762316411@qq.com
RI wang, xuejie/HGW 1453 2022; Cui, Huantian/AAS 4283 2021
FU Hebei Key Laboratory of Integrated Traditional and Western Medicine in
   Osteoarthrosis Research [2024460]
FX Hebei Key Laboratory of Integrated Traditional and Western Medicine in
   Osteoarthrosis Research (Grant No. 2024460).
CR Alabed S, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005154.pub4
   Atif M, 2021, CELL REPROGRAM, V23, P57, DOI 10.1089/cell.2020.0087
   Chatterjee M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126559
   Chen M, 2023, CYTOKINE GROWTH F R, V70, P54, DOI 10.1016/j.cytogfr.2023.03.002
   Chen ZG, 2016, CLIN EXP PHARMACOL P, V43, P268, DOI 10.1111/1440 1681.12513
   Chopra B, 2013, FITOTERAPIA, V90, P44, DOI 10.1016/j.fitote.2013.06.016
   Compston J, 2018, ENDOCRINE, V61, P7, DOI 10.1007/s12020 018 1588 2
   Da WCL, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.675385
   Dewulf JP, 2022, MOL GENET METAB, V136, P190, DOI 10.1016/j.ymgme.2021.12.016
   Hu K, 2019, EXPERT REV ENDOCRINO, V14, P259, DOI 10.1080/17446651.2019.1617131
   Imai K, 2013, CLIN INTERV AGING, V8, P681, DOI 10.2147/CIA.S37199
   Jha SS, 2023, INDIAN J ORTHOP, V57, P181, DOI 10.1007/s43465 023 01037 8
   Kaster MP, 2013, PURINERG SIGNAL, V9, P481, DOI 10.1007/s11302 013 9361 8
   Kazemzadeh Narbat M, 2015, J DRUG TARGET, V23, P580, DOI 10.3109/1061186X.2015.1058803
   Kim SM, 2021, ANN NY ACAD SCI, V1487, P21, DOI 10.1111/nyas.14486
   Lane NE, 2019, CURR OSTEOPOROS REP, V17, P1, DOI 10.1007/s11914 019 00498 x
   Li Bo, 2022, Phytomedicine, V102, P154198, DOI 10.1016/j.phymed.2022.154198
   Li HJ, 2024, BIOMED CHROMATOGR, V38, DOI 10.1002/bmc.5763
   Li YP, 2019, EXP THER MED, V18, P1899, DOI 10.3892/etm.2019.7741
   Liang WD, 2020, EUR REV MED PHARMACO, V24, P9591, DOI 10.26355/eurrev_202009_23047
   Ling CW, 2021, J CLIN ENDOCR METAB, V106, pE3852, DOI 10.1210/clinem/dgab492
   Lu H., 2017, Chinese Gen. Prac, V20, P224
   Lu X, 2019, J PROTEOME RES, V18, P2065, DOI 10.1021/acs.jproteome.8b00936
   Ma WW, 2023, TRADIT MED RES, V8, DOI 10.53388/TMR20230704002
   Miyamoto K, 2021, METABOLITES, V11, DOI 10.3390/metabo11050278
   Miyazawa T, 2002, ENDOCRINOLOGY, V143, P3604, DOI 10.1210/en.2002 220307
   Newman H, 2023, CURR OPIN PHARMACOL, V70, DOI 10.1016/j.coph.2023.102378
   Pfeifer A, 2013, PHARMACOL THERAPEUT, V140, P81, DOI 10.1016/j.pharmthera.2013.06.001
   Qian C, 2025, J ADV RES, V70, P79, DOI 10.1016/j.jare.2024.05.003
   Schall N, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.135355
   Shen YW, 2023, PHYTOMEDICINE, V110, DOI 10.1016/j.phymed.2022.154607
   Shrivats AR, 2015, CLIN ORTHOP RELAT R, V473, P2139, DOI 10.1007/s11999 014 4073 0
   Si ZX, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00741
   Tolba MF, 2017, TOXICOL APPL PHARM, V324, P26, DOI 10.1016/j.taap.2017.03.021
   Wang J, 2017, INT J MOL MED, V39, P527, DOI 10.3892/ijmm.2017.2880
   Wang L, 2017, STEM CELLS DEV, V26, P419, DOI 10.1089/scd.2016.0233
   Wang T, 2020, MOLECULES, V25, DOI 10.3390/molecules25051165
   Xu YE, 2018, PHYTOMEDICINE, V51, P68, DOI 10.1016/j.phymed.2018.09.235
   Yanbeiy ZA, 2019, DRUG DES DEV THER, V13, P2843, DOI 10.2147/DDDT.S148654
   Yang KD, 2022, BIOMED PHARMACOTHER, V155, DOI 10.1016/j.biopha.2022.113784
   Yang Z, 2012, MENOPAUSE, V19, P1156, DOI 10.1097/gme.0b013e3182507e18
   Zhang XY, 2021, J BONE MINER RES, V36, P729, DOI 10.1002/jbmr.4240
   Zhou QY, 2022, AGING US, V14, P272, DOI 10.18632/aging.203729
NR 43
TC 2
Z9 2
U1 4
U2 9
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389 2002
EI 1875 5453
J9 CURR DRUG METAB
JI Curr. Drug Metab.
PY 2024
VL 25
IS 4
BP 288
EP 297
DI 10.2174/0113892002308141240628071541
PG 10
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA J2J8S
UT WOS:001335391300006
PM 39005121
DA 2025 08 17
ER

PT J
AU Santini, D
   Galluzzo, S
   Vincenzi, B
   Schiavon, G
   Fratto, E
   Pantano, F
   Tonini, G
AF Santini, D.
   Galluzzo, S.
   Vincenzi, B.
   Schiavon, G.
   Fratto, E.
   Pantano, F.
   Tonini, G.
TI New developments of aminobisphosphonates: the double face of Janus
SO ANNALS OF ONCOLOGY
LA English
DT Article; Proceedings Paper
CT 9th National GOIM Congress
CY JUN 17 19, 2007
CL Potenza, ITALY
SP GOIM
DE bisphosphonates; bone loss; bone metastases; survival; zoledronic acid
ID BISPHOSPHONATES INDUCE APOPTOSIS; BREAST CANCER CELLS; HUMAN MYELOMA
   CELLS; ZOLEDRONIC ACID; IN VITRO; BONE METASTASES; PROTEIN PRENYLATION;
   MEVALONATE PATHWAY; ADHESION; INHIBIT
AB Background: Bisphosphonate (BP) therapy has become a standard of therapy for patients with malignant bone disease. In vivo preclinical and preliminary clinical data indicate that BPS may prevent cancer treatment induced bone loss and the onset of malignant bone disease in patients with early stage cancer.
   Design: This review will describe the preclinical evidences of action of BPS on osteoclasts and tumor cells. In addition, the effects of principal BPS on skeletal disease progression in patients with breast cancer, prostate cancer, non small cell lung cancer and other cancers will be reported. The preliminary clinical data from retrospective trials on the effect of zoledronic acid (ZA) on survival will be described and the ongoing adjuvant phase III trial will be analyzed.
   Conclusions: This review will describe the preliminary clinical evidences from prospective studies on the effect of ZA treatment on the prevention of bone metastasis.
C1 Univ Campus Biomed, Dept Med Oncol, Rome, Italy.
C3 University Campus Bio Medico   Rome Italy
RP Santini, D (通讯作者)，Univ Campus Biomed, Dept Med Oncol, Rome, Italy.
EM d.santini@unicampus.it
RI ; Pantano, Francesco/D 8459 2012; Tonini, Giuseppe/ISA 1908 2023
OI Tonini, Giuseppe/0000 0003 4442 8677; Pantano,
   Francesco/0000 0002 2894 9686; Vincenzi, Bruno/0000 0001 8222 9025;
   Santini, Daniele/0000 0002 9118 3337
CR Aapro M, 2006, BREAST, V15, pS30, DOI 10.1016/j.breast.2006.01.005
   Algur E, 2005, INT J RADIAT ONCOL, V61, P535, DOI 10.1016/j.ijrobp.2004.09.065
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   Benford HL, 2001, BONE, V28, P465, DOI 10.1016/S8756 3282(01)00412 4
   Bezzi M, 2003, J BIOL CHEM, V278, P43603, DOI 10.1074/jbc.M308114200
   Boissier S, 2000, CANCER RES, V60, P2949
   Boissier S, 1997, CANCER RES, V57, P3890
   Brufsky A, 2007, J CLIN ONCOL, V25, P829, DOI 10.1200/JCO.2005.05.3744
   Brufsky A, 2006, SEMIN ONCOL, V33, pS13, DOI 10.1053/j.seminoncol.2006.03.022
   Caraglia M, 2005, FRONT BIOSCI, V10, P2566, DOI 10.2741/1720
   Clézardin P, 2002, SEMIN ONCOL, V29, P33, DOI 10.1053/sonc.2002.37420
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   Dieli F, 2003, BLOOD, V102, P2310, DOI 10.1182/blood 2003 05 1655
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Gouin F, 2006, INT J CANCER, V119, P980, DOI 10.1002/ijc.21951
   Hasmim M, 2007, J THROMB HAEMOST, V5, P166, DOI 10.1111/j.1538 7836.2006.02259.x
   Hiraga T, 2004, CLIN CANCER RES, V10, P4559, DOI 10.1158/1078 0432.CCR 03 0325
   Hiraga T, 2001, CANCER RES, V61, P4418
   Kimura S, 2004, INT J HEMATOL, V79, P37, DOI 10.1007/BF02983531
   Kunzmann V, 2000, BLOOD, V96, P384
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   Lipton A, 2004, ONCOLOGIST, V9, P38, DOI 10.1634/theoncologist.9 90004 38
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   Magnetto S, 1999, INT J CANCER, V83, P263, DOI 10.1002/(SICI)1097 0215(19991008)83:2<263::AID IJC19>3.0.CO;2 T
   Mystakidou K, 2005, MED ONCOL, V22, P195, DOI 10.1385/MO:22:2:195
   OLIFF A, 1999, BIOCHIM BIOPHYS ACTA, V1423, P19
   Russell RGG, 1999, J BONE MINER RES, V14, P53, DOI 10.1002/jbmr.5650140212
   Russell RGG, 1999, OSTEOPOROSIS INT, V9, P66, DOI 10.1007/PL00004164
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   Santini D, 2002, CLIN CANCER RES, V8, P1080
   Santini D, 2006, EXPERT OPIN BIOL TH, V6, P1333, DOI 10.1517/14712598.6.12.1333
   Selander KS, 1996, MOL PHARMACOL, V50, P1127
   Senaratne SG, 2002, BRIT J CANCER, V87, P1340, DOI 10.1038/sj.bjc.6600571
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Shipman CM, 1998, CANCER RES, V58, P5294
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Takahashi R, 2001, LEUKEMIA RES, V25, P77, DOI 10.1016/S0145 2126(00)00087 4
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   vanderPluijm G, 1996, J CLIN INVEST, V98, P698, DOI 10.1172/JCI118841
   Vincenzi B, 2005, J INTERF CYTOK RES, V25, P144, DOI 10.1089/jir.2005.25.144
   Woodward JKL, 2005, ANTI CANCER DRUG, V16, P845, DOI 10.1097/01.cad.0000175582.01446.6f
   Yaccoby S, 2002, BRIT J HAEMATOL, V116, P278, DOI 10.1046/j.1365 2141.2002.03257.x
   Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325
NR 45
TC 17
Z9 17
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923 7534
J9 ANN ONCOL
JI Ann. Oncol.
PY 2007
VL 18
SU 6
BP 164
EP 167
DI 10.1093/annonc/mdm249
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Oncology
GA 207WA
UT WOS:000249280600036
PM 17591815
DA 2025 08 17
ER

PT J
AU Phillips, WJ
   Saad, F
   Leigh, J
   Jooya, A
   Webber, C
   Morgan, S
   Macrae, R
   Bourque, JM
   Tanuseputro, P
   Ong, M
AF Phillips, William J.
   Saad, Fred
   Leigh, Jennifer
   Jooya, Alborz
   Webber, Colleen
   Morgan, Scott
   Macrae, Robert
   Bourque, Jean Marc
   Tanuseputro, Peter
   Ong, Michael
TI Real World Evaluation of Primary Versus Secondary Prevention of
   Skeletal Related Events in Metastatic Castration Resistant Prostate
   Cancer
SO ONCOLOGIST
LA English
DT Article
DE bone targeted agents; skeletal related events; prostate cancer;
   zoledronate; denosumab
ID BONE TARGETED THERAPIES; CLINICAL FEATURES; ZOLEDRONIC ACID; AGENTS;
   HEALTH; TRIAL; CARE; ABIRATERONE; EFFICACY; BREAST
AB Introduction Anti osteoclast treatment with denosumab or zoledronate is known to effectively reduce the need for radiotherapy to bone and other skeletal related events (SREs) in patients with metastatic castration resistant prostate cancer (mCRPC). In this study, we analyze primary versus secondary initiation of bone targeting agents (BTAs) relative to first palliative bone radiotherapy in patients dying of mCRPC.Methods Provincial administrative databases from Ontario, Canada identified patients with prostate cancer (2007 2018, n = 98 646) who received continuous androgen deprivation therapy (n = 29 453), died of prostate cancer (2013 2018, n = 3864), and received life prolonging therapy for mCRPC (n = 1850). Variables were collected looking back 3 years from death. Multivariable analysis explored the relationship between clinical variables and BTAs.Results Of the 58% (1066/1850) patients with mCRPC who received BTA, only 289 (25.4%) started BTA prior to first palliative bone radiotherapy as primary prevention. Eight hundred and forty eight (74.6%) patients either never received BTA before death (n = 447) or started BTA only after first bone radiotherapy (n = 401). More patients received denosumab (n = 825, 77%) than zoledronic acid (n = 241, 23%). 51.2% (582/1137) of palliative bone radiotherapy was initiated in the last 12 months of life. Factors associated with the use of BTA included elevated alkaline phosphatase (OR = 1.0, P = .023), de novo metastases (OR = 1.4, P = .005), medical oncologist involvement (OR = 2.0, P = .007), diagnosis 2012 2017 versus 2007 2011 (OR = 0.75, P = .034), and academic center (OR = 0.061, P = .007).Conclusion A majority of patients with mCRPC never receive BTAs prior to first SRE, despite universal access and availability of these agents in Ontario. These results highlight an opportunity to improve outcomes by emphasizing early introduction of BTA in patients with mCRPC being started on systemic therapy.
   Bone targeted agents (BTAs) are effective at preventing skeletal related events in patients with metastatic castration resistant prostate cancer (mCRPC). This study analyzed primary versus secondary initiation of BTAs relative to first palliative bone radiotherapy in patients dying of mCRPC.
C1 [Phillips, William J.; Leigh, Jennifer; Tanuseputro, Peter; Ong, Michael] Univ Ottawa, Dept Med, Div Med Oncol, Ottawa, ON, Canada.
   [Saad, Fred] Ctr Hosp Univ Montreal, Montreal, PQ, Canada.
   [Jooya, Alborz; Morgan, Scott; Macrae, Robert] Univ Ottawa, Dept Radiol Radiat Oncol & Med Phys, Ottawa, ON, Canada.
   [Webber, Colleen; Tanuseputro, Peter] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada.
   [Bourque, Jean Marc] Ctr Hosp Univ Montreal, Dept Radiat Oncol, Montreal, PQ, Canada.
   [Tanuseputro, Peter] Bruyere Res Inst, Ottawa, ON, Canada.
   [Ong, Michael] Ottawa Hosp Canc Ctr, 501 Smyth Rd, Ottawa, ON, Canada.
C3 University of Ottawa; Universite de Montreal; University of Ottawa;
   University of Ottawa; Ottawa Hospital Research Institute; Universite de
   Montreal; University of Ottawa; University of Ottawa; Ottawa Hospital
   Research Institute
RP Ong, M (通讯作者)，Ottawa Hosp Canc Ctr, 501 Smyth Rd, Ottawa, ON, Canada.
EM mong@toh.ca
RI ; Saad, Fred/ADN 9925 2022; Ong, Michael/AAS 5790 2020
OI Ong, Michael/0000 0002 0347 5541; Leigh, Jennifer/0000 0002 7431 3574
FU GUMOC Astellas Research Grant Program
FX This project was supported by the GUMOC Astellas Research Grant Program.
CR Alibhai SMH, 2017, CLIN ONCOL UK, V29, P348, DOI 10.1016/j.clon.2017.01.007
   Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095
   Body JJ, 2019, J BONE ONCOL, V14, DOI 10.1016/j.jbo.2018.100212
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Cho CKJ, 2019, PRACT RADIAT ONCOL, V9, pE274, DOI 10.1016/j.prro.2019.01.002
   Clemons M, 2021, EUR J CANCER, V142, P132, DOI 10.1016/j.ejca.2020.08.019
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   George DJ, 2020, CLIN GENITOURIN CANC, V18, P284, DOI [10.1016/j.clgc.2020.12.019, 10.1016/j.clgc.2019.12.019]
   Gillessen S, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.5002
   He J, 2012, ASIAN J ANDROL, V14, P505, DOI 10.1038/aja.2012.24
   Hong BY, 2016, CURR ONCOL, V23, pE77, DOI 10.3747/co.23.2913
   Ibrahim MFK, 2015, ANN ONCOL, V26, P2205, DOI 10.1093/annonc/mdv284
   Kawai AT, 2019, PROSTATE CANCER US, V2019, DOI 10.1155/2019/5971615
   Kim SY, 2022, JCO ONCOL PRACT, V18, P53, DOI 10.1200/OP.21.00206
   Liede A, 2018, CLIN THER, V40, P536, DOI 10.1016/j.clinthera.2017.12.015
   Lorente JA, 1996, J UROLOGY, V155, P1348, DOI 10.1016/S0022 5347(01)66263 3
   McDougall JA, 2016, ONCOLOGIST, V21, P320, DOI 10.1634/theoncologist.2015 0327
   Mollica V, 2022, CURR ONCOL, V29, P1709, DOI 10.3390/curroncol29030142
   Oudard S, 2017, J CLIN ONCOL, V35, P3189, DOI 10.1200/JCO.2016.72.1068
   Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Saad F, 2018, CUAJ CAN UROL ASSOC, V12, P370, DOI 10.5489/cuaj.5053
   Saad F, 2015, EUR UROL, V68, P570, DOI 10.1016/j.eururo.2015.04.032
   Santini D, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen 2019 000652
   Sathiakumar N, 2011, PROSTATE CANCER P D, V14, P177, DOI 10.1038/pcan.2011.7
   Saylor PJ, 2020, JCO ONCOL PRACT, V16, P389, DOI 10.1200/JOP.19.00778
   Smith M, 2019, LANCET ONCOL, V20, P408, DOI 10.1016/S1470 2045(18)30860 X
   So A, 2012, CUAJ CAN UROL ASSOC, V6, P465, DOI [10.5489/cuaj.12149, 10.5489/cuaj.117]
   Tatem AJ, 2011, LANCET, V377, P30, DOI 10.1016/S0140 6736(11)61226 9
   von Moos R, 2022, BONE, V154, DOI 10.1016/j.bone.2021.116243
   Weinfurt KP, 2005, ANN ONCOL, V16, P579, DOI 10.1093/annonc/mdi122
NR 33
TC 2
Z9 2
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1083 7159
EI 1549 490X
J9 ONCOLOGIST
JI Oncologist
PD MAR 25
PY 2024
VL 29
IS 10
BP 878
EP 886
DI 10.1093/oncolo/oyae036
EA MAR 2024
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA H7Z0L
UT WOS:001190036400001
PM 38527096
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Palmerini, CA
   Tartacca, F
   Mazzoni, M
   Granieri, L
   Goracci, L
   Scrascia, A
   Lepri, S
AF Palmerini, Carlo A.
   Tartacca, Francesco
   Mazzoni, Michela
   Granieri, Letizia
   Goracci, Laura
   Scrascia, Angela
   Lepri, Susan
TI Synthesis of new indole based bisphosphonates and evaluation of their
   chelating ability in PE/CA PJ15 cells
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Indole based bisphosphonate; Cytosolic calcium; Ene reaction; Chelating
   ability assessment
ID BONE DISEASE; SUSTAINED ACTIVATION; IN VITRO; CALCIUM; FLUORINE;
   DERIVATIVES; INHIBITION; MODULATION; PREDICTION; SURVIVAL
AB Bisphosphonates are the most important class of antiresorptive agents used against osteoclast mediated bone loss, and, more recently, in oncology. These compounds have high affinity for calcium ions (Ca2+) and therefore target bone mineral, where they appear to be internalized selectively by bone resorbing osteoclasts and inhibit osteoclast function. They are extensively used in healthcare, however they are affected by severe side effects; pharmacological properties of bisphosphonates depend on their molecular structure, which is frequently the cause of poor intestinal adsorption and low distribution. In this work we synthesized six novel bisphosphonate compounds having a variably substituted indole moiety to evaluate their extra  and intracellular calcium chelating ability in PE/CA PJ15 cells. Preliminary in silica and in vitro ADME studies were also performed and the results suggested that the indole moiety plays an important role in cell permeability and metabolism properties. (C) 2015 Elsevier Masson SAS. All rights reserved.
C1 [Palmerini, Carlo A.; Tartacca, Francesco; Mazzoni, Michela; Granieri, Letizia] Univ Perugia, Unit Res Biochem & Mol Biol, Dept Agr Food & Environm Sci, I 06125 Perugia, Italy.
   [Goracci, Laura; Scrascia, Angela; Lepri, Susan] Univ Perugia, Dept Chem Biol & Biotechnol, I 06123 Perugia, Italy.
C3 University of Perugia; University of Perugia
RP Lepri, S (通讯作者)，Univ Perugia, Dept Chem Biol & Biotechnol, Via Elce di Sotto 8, I 06123 Perugia, Italy.
EM susan@chemiome.chm.unipg.it
RI Goracci, Laura/G 3974 2014; Granieri, Letizia/AAC 2644 2019
OI Goracci, Laura/0000 0002 9282 9013; Lepri, Susan/0000 0003 1024 7368;
   Palmerini, Carlo Alberto/0000 0001 9179 7534; 
FU Molecular Discovery Ltd.
FX The authors would like to thank Prof. Renzo Ruzziconi for his scientific
   support and Molecular Discovery Ltd. for financial support. Dr.
   Cristiano Zuccaccia is kindly acknowledged for his contribution in the
   elucidation of NMR spectra.
CR Ascic E, 2015, J AM CHEM SOC, V137, P4666, DOI 10.1021/jacs.5b02316
   Bautista DM, 2004, J PHYSIOL LONDON, V556, P805, DOI 10.1113/jphysiol.2003.060004
   Bellezza F, 2008, J FLUORINE CHEM, V129, P97, DOI 10.1016/j.jfluchem.2007.09.003
   Bergman J, 2000, J CHEM SOC PERK T 1, P2609, DOI 10.1039/b004029k
   Bergner R, 2006, ONKOLOGIE, V29, P534, DOI 10.1159/000096056
   Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094
   Bezzi M, 2003, J BIOL CHEM, V278, P43603, DOI 10.1074/jbc.M308114200
   Broccatelli F, 2012, MOL PHARMACEUT, V9, P570, DOI 10.1021/mp2004302
   Caraglia M, 2007, INT J CANCER, V121, P2317, DOI 10.1002/ijc.22964
   Cerella Claudia, 2010, Int J Cell Biol, V2010, P546163, DOI 10.1155/2010/546163
   CharletFagnere C, 1996, B SOC CHIM FR, V133, P39
   Chiminazzo A, 2014, CHEMCATCHEM, V6, P2712, DOI 10.1002/cctc.201402346
   CLAPHAM DE, 1995, NATURE, V375, P634, DOI 10.1038/375634a0
   Clézardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008 5472.CAN 05 0264
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Couthon Gourvès H, 2006, SYNTHESIS STUTTGART, P81, DOI 10.1055/s 2005 921757
   Cruciani C, 2000, J MOL STRUC THEOCHEM, V503, P17, DOI 10.1016/S0166 1280(99)00360 7
   De Rosa G., 2013, J DRUG DELIV, V2013
   DEGENHARDT CR, 1986, J ORG CHEM, V51, P3488, DOI 10.1021/jo00368a017
   Denmeade SR, 2005, CANCER BIOL THER, V4, P14
   Diel Ingo J, 2007, J Support Oncol, V5, P475
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Fleisch H, 2003, EUR SPINE J, V12, pS142, DOI 10.1007/s00586 003 0622 z
   FLEISCH H, 1966, P SOC EXP BIOL MED, V122, P317
   FLEISCH HA, 1970, EUR J CLIN INVEST, V1, P12, DOI 10.1111/j.1365 2362.1970.tb00591.x
   Franz M, 2006, HISTOCHEM CELL BIOL, V126, P125, DOI 10.1007/s00418 005 0126 5
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   Hägele G, 2000, HETEROATOM CHEM, V11, P562
   Hagmann WK, 2008, J MED CHEM, V51, P4359, DOI 10.1021/jm800219f
   Krawczyk H, 2002, SYNTHESIS STUTTGART, P1351, DOI 10.1055/s 2002 33105
   Kulasekara KK, 2009, ARCH ORAL BIOL, V54, P924, DOI 10.1016/j.archoralbio.2009.07.004
   Ledoux D, 2006, ANTI CANCER DRUG, V17, P479, DOI 10.1097/01.cad.0000198909.52701.0f
   Lepri S, 2015, J FLUORINE CHEM, V171, P82, DOI 10.1016/j.jfluchem.2014.09.007
   Liu JG, 2014, BBA GEN SUBJECTS, V1840, P1051, DOI 10.1016/j.bbagen.2013.11.006
   Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968 0004(97)01143 2
   Milletti F, 2007, J CHEM INF MODEL, V47, P2172, DOI 10.1021/ci700018y
   Ory B, 2005, CANCER AM CANCER SOC, V104, P2522, DOI 10.1002/cncr.21530
   Purser S, 2008, CHEM SOC REV, V37, P320, DOI 10.1039/b610213c
   Ramachandran PV, 2009, FUTURE MED CHEM, V1, P771, DOI [10.4155/fmc.09.67, 10.4155/FMC.09.67]
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Ruzziconi R, 2003, J ORG CHEM, V68, P736, DOI 10.1021/jo0205154
   Shevchuk MV, 2011, SYNLETT, P1370, DOI 10.1055/s 0030 1260566
   Singh US, 2008, BIOORGAN MED CHEM, V16, P8482, DOI 10.1016/j.bmc.2008.08.024
   SMITH GF, 1961, J CHEM SOC, P940, DOI 10.1039/jr9610000940
   Townshend A., 1993, Dictionary of Analytical Reagents Chapman & Hall chemical database
   Vepsäläinen JJ, 2002, CURR MED CHEM, V9, P1201, DOI 10.2174/0929867023369998
   Webster MR, 2011, J MED CHEM, V54, P6647, DOI 10.1021/jm200521a
   Weisthal S, 2014, BBA MOL CELL RES, V1843, P2270, DOI 10.1016/j.bbamcr.2014.03.021
   Xu XL, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 303
NR 51
TC 11
Z9 11
U1 0
U2 17
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0223 5234
EI 1768 3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD SEP 18
PY 2015
VL 102
BP 403
EP 412
DI 10.1016/j.ejmech.2015.08.019
PG 10
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA CS2SS
UT WOS:000361922600036
PM 26301557
DA 2025 08 17
ER

PT J
AU Xie, Z
   Yu, HJ
   Sun, XW
   Tang, P
   Jie, ZW
   Chen, S
   Wang, JY
   Qin, A
   Fan, SW
AF Xie, Zi'ang
   Yu, Hejun
   Sun, Xuewu
   Tang, Pan
   Jie, Zhiwei
   Chen, Shuai
   Wang, Jiying
   Qin, An
   Fan, Shunwu
TI A Novel Diterpenoid Suppresses Osteoclastogenesis and Promotes
   Osteogenesis by Inhibiting Ifrd1 Mediated and IB Mediated p65 Nuclear
   Translocation
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE ORIDONIN; OSTEOPOROSIS; OSTEOCLASTOGENESIS; OSTEOGENESIS; IFRD1; NF ;
   THERAPEUTICS
ID NF KAPPA B; OVARIECTOMY INDUCED OSTEOPOROSIS; OSTEOBLAST
   DIFFERENTIATION; SIGNALING PATHWAY; IN VIVO; BONE FORMATION; CELLS;
   RUNX2; DEGRADATION; MECHANISMS
AB Osteoporosis develops because of impaired bone formation and/or excessive bone resorption. Although the pharmacological treatment of osteoporosis has been extensively developed, alternative treatments are still needed. Here, we showed that oridonin (ORI), a diterpenoid isolated from Rabdosia rubescens, can suppress osteoclastogenesis and enhance osteogenesis. ORI inhibited the receptor activator of nuclear factor B (NF B) ligand (RANKL) induced osteoclast formation and bone resorption through the inhibition of p65 nuclear translocation. ORI induced inhibition of this translocation led to an increase in osteoblast differentiation and mineralization through the promotion of Smad1/Smad5 phosphorylation. Further analyses demonstrated that the inhibition of p65 nuclear translocation is due to the suppression of IB phosphorylation and the induced proteasomal degradation of interferon related development regulator 1 (Ifrd1), a transcriptional corepressor that is involved in the suppression of NF B nuclear translocation. Moreover, mice treated with ORI at catabolic and anabolic windows showed a considerable attenuation of ovariectomy (OVX) induced osteoporosis. Taken together, our findings reveal that ORI protects against OVX induced bone loss via inhibiting osteoclastic bone resorption but enhancing osteoblastic bone formation through abolishing both Ifrd1 mediating and IB mediated p65 nuclear translocation. These results show the potential of ORI for treatment of osteoporosis and highlight Ifrd1 as a another novel promising target for anti osteoporotic drugs. (c) 2017 American Society for Bone and Mineral Research
C1 [Xie, Zi'ang; Yu, Hejun; Sun, Xuewu; Tang, Pan; Jie, Zhiwei; Chen, Shuai; Fan, Shunwu] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Orthopaed, Hangzhou, Zhejiang, Peoples R China.
   [Xie, Zi'ang; Sun, Xuewu; Tang, Pan; Jie, Zhiwei; Wang, Jiying] Key Lab Biotherapy Zhejiang Prov, Hangzhou, Zhejiang, Peoples R China.
   [Qin, An] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Orthopaed,Shanghai Key Lab Orthopaed Implant, Shanghai, Peoples R China.
C3 Zhejiang University; Shanghai Jiao Tong University
RP Fan, SW (通讯作者)，Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Orthopaed, Hangzhou, Zhejiang, Peoples R China.
EM dr_fanshunwu@163.com
RI Qin, An/J 2518 2019; Wang, Yijun/GXW 1763 2022; Tang, Pan/AIC 2118 2022
OI Jie, Zhiwei/0000 0002 9469 4490
FU National Natural Science Fund of China [81472064, 81572167, 81601924]
FX This study was sponsored by the National Natural Science Fund of China
   (81472064, 81572167, 81601924).
CR Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Cao X, 2011, NAT MED, V17, P1344, DOI 10.1038/nm.2499
   Chang J, 2013, P NATL ACAD SCI USA, V110, P9469, DOI 10.1073/pnas.1300532110
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Chen S, 2015, SCI REP UK, V5, DOI 10.1038/srep12853
   Choi YH, 2013, BBA MOL CELL RES, V1833, P69, DOI 10.1016/j.bbamcr.2012.10.018
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Du L, 2016, SCI REP UK, V6, DOI 10.1038/srep32261
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Gersbach CA, 2004, EXP CELL RES, V300, P406, DOI 10.1016/j.yexcr.2004.07.031
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092 8674(02)00703 1
   Grabowski P, 2009, ENDOCR DEV, V16, P32, DOI 10.1159/000223687
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Huang HL, 2012, MOL CANCER THER, V11, P1155, DOI 10.1158/1535 7163.MCT 12 0066
   Huang RL, 2014, STEM CELLS DEV, V23, P277, DOI 10.1089/scd.2013.0345
   Iezaki T, 2016, MOL CELL BIOL, V36, P2451, DOI 10.1128/MCB.01075 15
   Iezaki T, 2016, J BONE MINER RES, V31, P573, DOI 10.1002/jbmr.2720
   Ikezoe T, 2005, MOL CANCER THER, V4, P578, DOI 10.1158/1535 7163.MCT 04 0277
   Ito Y, 2001, J BONE MINER METAB, V19, P188, DOI 10.1007/s007740170041
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Keating SE, 2007, J BIOL CHEM, V282, P33435, DOI 10.1074/jbc.M705266200
   Kim JY, 2014, J BONE MINER RES, V29, P1541, DOI 10.1002/jbmr.2183
   Kim JH, 2009, J IMMUNOL, V183, P1862, DOI 10.4049/jimmunol.0803007
   Knopp Sihota JA, 2013, BMC GERIATR, V13, DOI 10.1186/1471 2318 13 36
   Ku CM, 2013, FOOD CHEM, V141, P1104, DOI 10.1016/j.foodchem.2013.04.044
   Kumar Y, 2015, J BIOL CHEM, V290, P30975, DOI 10.1074/jbc.M115.669531
   Le Henaff C, 2015, J BIOL CHEM, V290, P18009, DOI 10.1074/jbc.M115.646208
   Lee HW, 2008, J BONE MINER RES, V23, P1227, DOI 10.1359/JBMR.080325
   Li DH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091395
   Lietman SA, 2008, BIOCHEM BIOPH RES CO, V371, P644, DOI 10.1016/j.bbrc.2008.04.080
   Liu Y, 2014, INT J ONCOL, V45, P795, DOI 10.3892/ijo.2014.2456
   Ma JJ, 2015, BIOCHEM J, V469, P399, DOI 10.1042/BJ20150151
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Ninomiya Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465
   Ozes ON, 1999, NATURE, V401, P82
   Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083
   Shang YF, 2006, NAT REV CANCER, V6, P360, DOI 10.1038/nrc1879
   Sims NA, 2012, CURR OSTEOPOROS REP, V10, P109, DOI 10.1007/s11914 012 0096 1
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Xu Y, 2009, INT IMMUNOPHARMACOL, V9, P360, DOI 10.1016/j.intimp.2009.01.002
   Yang K, 2016, AM J CANCER RES, V6, P1302
   Yang XL, 2002, TRENDS MOL MED, V8, P340, DOI 10.1016/S1471 4914(02)02340 7
   Yasui T, 2011, J BONE MINER RES, V26, P1447, DOI 10.1002/jbmr.357
   Yu B, 2014, NAT MED, V20, P1009, DOI 10.1038/nm.3586
   Zhai ZJ, 2014, BRIT J PHARMACOL, V171, P663, DOI 10.1111/bph.12463
NR 49
TC 53
Z9 56
U1 0
U2 30
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR
PY 2018
VL 33
IS 4
BP 667
EP 678
DI 10.1002/jbmr.3334
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA GC3WF
UT WOS:000429713700014
PM 29091322
OA Bronze
DA 2025 08 17
ER

PT J
AU Li, SD
   Zou, DH
   Li, CH
   Meng, HX
   Sui, WW
   Feng, SZ
   Cheng, T
   Zhai, QL
   Qiu, LG
AF Li, Sidan
   Zou, Dehui
   Li, Changhong
   Meng, Hengxing
   Sui, Weiwei
   Feng, Sizhou
   Cheng, Tao
   Zhai, Qiongli
   Qiu, Lugui
TI Targeting stem cell niche can protect hematopoietic stem cells from
   chemotherapy and G CSF treatment
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
ID PARATHYROID HORMONE; BONE MARROW; PROGENITOR CELLS; MOBILIZATION;
   OSTEOIMMUNOLOGY; HOMEOSTASIS; MECHANISMS; APOPTOSIS
AB Introduction: Hematopoietic stem/progenitor cells (HSPCs) reside in a tightly controlled local microenvironment called bone marrow niche. The specialized microenvironment or niche not only provides a favorable habitat for HSPC maintenance and development but also governs stem cell function.
   Method: We investigated the effect of cytotoxic drugs on bone marrow niche. To mimic the multiple rounds of chemotherapy followed by autologous hematopoietic stem cells (HSCs) transplantation in a clinical setting, we further verified the hypothesis that targeting the niche might improve stem cell based therapies in mouse models.
   Results: We found that multiple rounds of cytotoxic drug treatment significantly disrupted niche and serum osteocalcin level was significantly reduced after treatment in autologous HSPCs transplanted patients (P = 0.01). In mouse models, the number of CD45( )Ter119( )OPN(+) osteoblasts was significantly reduced after multiple rounds of chemotherapies and granulocyte colony stimulating factor (G CSF) treatment (P < 0.01). Parathyroid hormone (PTH) or receptor activator of nuclear factor kappa B ligand (RANKL) treatment significantly increased the number of HSCs mobilized into peripheral blood (PB) for stem cell harvesting and protected stem cells from repeated exposure to cytotoxic chemotherapy. Treatments with G CSF and PTH significantly increased the preservation of the HSC pool (P < 0.05). Moreover, recipient mice transplanted with circulation HSPCs that were previously treated with PTH and RANKL showed robust myeloid and lymphatic cell engraftment compared to the mice transplanted with HSCs after chemotherapy or G CSF treatment.
   Conclusion: These data provide new evidence that the niche may be an important target for drug based stem cell therapy.
C1 [Li, Sidan; Zou, Dehui; Li, Changhong; Meng, Hengxing; Sui, Weiwei; Feng, Sizhou; Cheng, Tao; Qiu, Lugui] Chinese Acad Med Sci, Inst Hematol & Hosp Blood Dis, State Key Lab Expt Hematol, Tianjin 30020, Peoples R China.
   [Li, Sidan; Zou, Dehui; Li, Changhong; Meng, Hengxing; Sui, Weiwei; Feng, Sizhou; Cheng, Tao; Qiu, Lugui] Peking Union Med Coll, Tianjin 30020, Peoples R China.
   [Li, Sidan] Capital Med Univ, Beijing Childrens Hosp,Hematol Oncol Ctr, Beijing Key Lab Pediat Hematol Oncol, Minist Educ,Natl Key Discipline Pediat, Beijing, Peoples R China.
   [Zhai, Qiongli] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Pathol, Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China.
C3 Chinese Academy of Medical Sciences   Peking Union Medical College;
   Institute of Hematology & Blood Diseases Hospital   CAMS; Chinese
   Academy of Medical Sciences   Peking Union Medical College; Peking Union
   Medical College; Capital Medical University; Tianjin Medical University
RP Zhai, QL (通讯作者)，Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Pathol, Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China.
EM qionglizhai@hotmail.com; drqiu99@medmail.com.cn
RI ; Yang, Yong/GLQ 5561 2022
OI Cheng, Tao/0000 0002 5925 2769; 
FU National Natural Science Foundation of China [81300433, 81370632,
   81272361]; Beijing Municipal Natural Science Foundation [7144211];
   Specialized Research Fund for the Doctoral Program of Higher Education
   [20131107120008]; BCH Young Investigator Program [BCHYIPA 2013 06];
   Beijing Municipal Administration of Hospitals Clinical Medicine
   Development [ZY201404]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 81300433, No. 81370632 and No. 81272361), the
   Beijing Municipal Natural Science Foundation (No. 7144211), the
   Specialized Research Fund for the Doctoral Program of Higher Education
   (No. 20131107120008), the BCH Young Investigator Program
   (BCHYIPA 2013 06) and Beijing Municipal Administration of Hospitals
   Clinical Medicine Development of special funding support (No. ZY201404).
CR Adams GB, 2007, NAT BIOTECHNOL, V25, P238, DOI 10.1038/nbt1281
   [Anonymous], SCIENTIFICA CAIRO
   Arboleya L, 2013, REUMATOL CLIN, V9, P303, DOI [10.1016/j.reumae.2013.02.004, 10.1016/j.reuma.2013.02.008]
   Augustine M, 2013, CURR OSTEOPOROS REP, V11, P400, DOI 10.1007/s11914 013 0171 2
   Ballen KK, 2007, BIOL BLOOD MARROW TR, V13, P838, DOI 10.1016/j.bbmt.2007.03.007
   Bensinger W, 2009, BONE MARROW TRANSPL, V43, P181, DOI 10.1038/bmt.2008.410
   Bonig H, 2013, LEUKEMIA, V27, P24, DOI 10.1038/leu.2012.254
   Bonig Halvard, 2012, Methods Mol Biol, V904, P1, DOI 10.1007/978 1 61779 943 3_1
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Christopher MJ, 2008, J BONE MINER RES, V23, P1765, DOI 10.1359/JBMR.080612
   Dougall William C, 2014, Bonekey Rep, V3, P519, DOI 10.1038/bonekey.2014.14
   Feng W, 2014, FRONT BIOSCI LANDMRK, V19, P758, DOI 10.2741/4242
   Garrett RW, 2008, MOL CELL ENDOCRINOL, V288, P6, DOI 10.1016/j.mce.2008.02.022
   Hoggatt Jonathan, 2012, Methods Mol Biol, V904, P49, DOI 10.1007/978 1 61779 943 3_4
   Honma M, 2014, CURR OSTEOPOROS REP, V12, P115, DOI 10.1007/s11914 014 0189 0
   Huang Wenyang, 2014, Zhonghua Xue Ye Xue Za Zhi, V35, P332, DOI 10.3760/cma.j.issn.0253 2727.2014.04.018
   Inoue Daisuke, 2014, Clin Calcium, V24, P863, DOI CliCa1406863869
   Jin F, 2008, BONE MARROW TRANSPL, V42, P581, DOI 10.1038/bmt.2008.222
   Kollet O, 2006, NAT MED, V12, P657, DOI 10.1038/nm1417
   Kovacs CS, 2014, PHYSIOL REV, V94, P1143, DOI 10.1152/physrev.00014.2014
   Li SD, 2013, J CELL PHYSIOL, V228, P1002, DOI 10.1002/jcp.24246
   Liu Xin, 2014, Zhonghua Xue Ye Xue Za Zhi, V35, P250, DOI 10.3760/cma.j.issn.0253 2727.2014.03.018
   Martin TJ, 2013, WORLD J ORTHOP, V4, P186, DOI 10.5312/wjo.v4.i4.186
   Mayack SR, 2008, BLOOD, V112, P519, DOI 10.1182/blood 2008 01 133710
   Mendelson A, 2014, NAT MED, V20, P833, DOI 10.1038/nm.3647
   Mohty M, 2011, EXP HEMATOL, V39, P723, DOI 10.1016/j.exphem.2011.05.004
   Motabi IH, 2012, BLOOD REV, V26, P267, DOI 10.1016/j.blre.2012.09.003
   Pacifici R, 2013, AM J TRANSPLANT, V13, P2245, DOI 10.1111/ajt.12380
   Piccirillo N, 2012, TRANSFUS APHER SCI, V47, P217, DOI 10.1016/j.transci.2012.06.008
   Riether C, 2015, CELL DEATH DIFFER, V22, P187, DOI 10.1038/cdd.2014.89
   Semerad CL, 2005, BLOOD, V106, P3020, DOI 10.1182/blood 2004 01 0272
   Singh P, 2012, LEUKEMIA, V26, P2375, DOI 10.1038/leu.2012.117
   To LB, 2011, BLOOD, V118, P4530, DOI 10.1182/blood 2011 06 318220
   Winkler IG, 2012, LEUKEMIA, V26, P1594, DOI 10.1038/leu.2012.17
   Zou De hui, 2013, Zhonghua Xue Ye Xue Za Zhi, V34, P299, DOI 10.3760/cma.j.issn.0253 2727.2013.04.011
NR 36
TC 36
Z9 38
U1 0
U2 17
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD SEP 15
PY 2015
VL 6
AR 175
DI 10.1186/s13287 015 0164 4
PG 10
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA CR4DX
UT WOS:000361283100003
PM 26373707
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ou, L
   Kang, WQ
   Liang, ZY
   Gao, F
   Dong, TW
   Wei, PF
   Li, M
AF Ou, Li
   Kang, Wenqian
   Liang, Ziyi
   Gao, Feng
   Dong, Taiwei
   Wei, Peifeng
   Li, Min
TI Investigation of anti osteoporosis mechanisms of Rehmanniae Radix
   Preparata based on network pharmacology and experimental
   verification
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article
DE Rehmanniae Radix Preparata; Network pharmacology; Mechanism;
   Osteoporosis; Bone
ID OSTEOBLAST DIFFERENTIATION; BONE FORMATION
AB Background Rehmanniae Radix Preparata (RRP) can effectively improve the symptoms of osteoporosis, but its molecular mechanism for treating osteoporosis is still unclear. The objective of this study is to investigate the anti osteoporosis mechanisms of RRP through network pharmacology. Methods The overlapping targets of RRP and osteoporosis were screened out using online platforms. A visual network diagram of PPI was constructed and analyzed by Cytoscape 3.7.2 software. Molecular docking was used to evaluate the binding activity of ligands and receptors, and some key genes were verified through pharmacological experiments. Results According to topological analysis results, AKT1, MAPK1, ESR1, and SRC are critical genes for RRP to treat osteoporosis, and they have high binding activity with stigmasterol and sitosterol. The main signal pathways of RRP in the treatment of osteoporosis, including the estrogen signaling pathway, HIF 1 signal pathway, MAPK signal pathway, PI3K Akt signal pathway. Results of animal experiments showed that RRP could significantly increase the expression levels of Akt1, MAPK1, ESR1, and SRC1 mRNA in bone tissue to increase bone density. Conclusion This study explained the coordination between multiple components and multiple targets of RRP in the treatment of osteoporosis and provided new ideas for its clinical application and experimental research.
C1 [Ou, Li; Kang, Wenqian; Liang, Ziyi; Gao, Feng; Dong, Taiwei; Wei, Peifeng; Li, Min] Shaanxi Univ Chinese Med, Coll Pharm, Xianyang 712046, Peoples R China.
C3 Shaanxi University of Chinese Medicine
RP Ou, L (通讯作者)，Shaanxi Univ Chinese Med, Coll Pharm, Xianyang 712046, Peoples R China.
EM 23127438@qq.com
OI ou, li/0000 0001 8767 1322; kang, wenqian/0000 0003 1798 4504
FU National Natural Science Foundation of China [81903877]; Shaanxi
   Provincial Department of Science and Technology Project [2020JM 589];
   Shaanxi University of Traditional Chinese Medicine Innovation Team
   Project [2019 QN02]
FX This research was financially supported by the National Natural Science
   Foundation of China (No. 81903877), Shaanxi Provincial Department of
   Science and Technology Project (2020JM 589), and Shaanxi University of
   Traditional Chinese Medicine Innovation Team Project (No. 2019 QN02).
CR Burley SK, 2017, METHODS MOL BIOL, V1606, P627, DOI 10.1007/978 1 4939 7000 1_26
   Cagnacci A, 2019, MEDICINA LITHUANIA, V55, DOI 10.3390/medicina55090602
   Canalis E, 2010, ENDOCR PRACT, V16, P855, DOI 10.4158/EP10048.RA
   Coughlan T, 2014, CLIN MED, V14, P187, DOI 10.7861/clinmedicine.14 2 187
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   Doncheva NT, 2019, J PROTEOME RES, V18, P623, DOI 10.1021/acs.jproteome.8b00702
   Duan XC, 2016, MATRIX BIOL, V52 54, P127, DOI 10.1016/j.matbio.2016.02.005
   Farias Cisneros E, 2020, CLIMACTERIC, V23, P65, DOI 10.1080/13697137.2019.1627313
   Fu LJ, 2020, CALCIFIED TISSUE INT, V107, P60, DOI 10.1007/s00223 020 00687 2
   Gates BJ, 2011, MATURITAS, V69, P113, DOI 10.1016/j.maturitas.2011.03.009
   Guo C, 2017, CELL PHYSIOL BIOCHEM, V43, P1547, DOI 10.1159/000481978
   Hu GC., 2019, ZHEJIANG J TRADIT CH, V54, P232, DOI [10.13633/j.cnki.zjtcm.2019.03.056, DOI 10.13633/J.CNKI.ZJTCM.2019.03.056]
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Jafri MA, 2020, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00380
   Jiao XL, 2012, BIOINFORMATICS, V28, P1805, DOI 10.1093/bioinformatics/bts251
   Keiser MJ, 2007, NAT BIOTECHNOL, V25, P197, DOI 10.1038/nbt1284
   Li J, 2019, INTERDISCIP SCI, V11, P320, DOI 10.1007/s12539 019 00327 w
   Luo TT, 2020, CHIN J INTEGR MED, V26, P72, DOI 10.1007/s11655 019 3064 0
   Ma BC, 2020, BIOCHEM BIOPH RES CO, V524, P163, DOI 10.1016/j.bbrc.2020.01.060
   Ma YZ., 2019, CHIN J PRACT INT MED, V39, P38, DOI [10.19538/j.nk2019010109, DOI 10.19538/J.NK2019010109]
   Migliorini F, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02678 x
   Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110
   Mondockova V, 2018, BMC MED GENET, V19, DOI 10.1186/s12881 018 0684 8
   Mukherjee A, 2012, MOL CELL BIOL, V32, P490, DOI 10.1128/MCB.06361 11
   Piñero J, 2017, NUCLEIC ACIDS RES, V45, pD833, DOI 10.1093/nar/gkw943
   Shang DP, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15028106
   [沈华旦 Shen Huadan], 2018, [中草药, Chinese Traditional and Herbal Drugs], V49, P582
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Tanchuk VY, 2016, CHEM BIOL DRUG DES, V87, P618, DOI 10.1111/cbdd.12697
   Tao Y, 2012, CHIN J EXP TRADIT ME, V18, P249, DOI [10.13422/j.cnki.syfjx.2012.08.084, DOI 10.13422/J.CNKI.SYFJX.2012.08.084]
   Ulici V, 2009, BONE, V45, P1133, DOI 10.1016/j.bone.2009.08.003
   Wang X, 2017, NUCLEIC ACIDS RES, V45, pW356, DOI 10.1093/nar/gkx374
   Wang YX, 2020, NUCLEIC ACIDS RES, V48, pD1031, DOI 10.1093/nar/gkz981
   [魏秋实 Wei Qiushi], 2013, [生命科学, Chinese Bulletin of Life Sciences], V25, P694
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wu D., 2019, CLIN J TRADIT CHIN M, V31, P2038
   Xiang D, 2018, EUR REV MED PHARMACO, V22, P8084, DOI 10.26355/eurrev_201812_16498
   Zeng Q, 2019, J BONE MINER RES, V34, P1789, DOI 10.1002/jbmr.3757
   Zhang YQ, 2016, ONCOTARGET, V7, P51699, DOI 10.18632/oncotarget.10329
   Zhang YW, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010199
   [张云飞 Zhang Yunfei], 2019, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V25, P554
NR 42
TC 17
Z9 17
U1 1
U2 34
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD OCT 14
PY 2021
VL 16
IS 1
AR 599
DI 10.1186/s13018 021 02751 5
PG 12
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA WH0EZ
UT WOS:000707363600007
PM 34649566
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Zeng, HC
   Bae, Y
   Dawson, BC
   Chen, YQ
   Bertin, T
   Munivez, E
   Campeau, PM
   Tao, JN
   Chen, R
   Lee, BH
AF Zeng, Huan Chang
   Bae, Yangjin
   Dawson, Brian C.
   Chen, Yuqing
   Bertin, Terry
   Munivez, Elda
   Campeau, Philippe M.
   Tao, Jianning
   Chen, Rui
   Lee, Brendan H.
TI MicroRNA miR 23a cluster promotes osteocyte differentiation by
   regulating TGF β signalling in osteoblasts
SO NATURE COMMUNICATIONS
LA English
DT Article
ID GENE EXPRESSION; IN VIVO; PRDM16; MICE; OSTEOPOROSIS; MAINTENANCE;
   IMPERFECTA; PHENOTYPE; PROTEIN; TISSUE
AB Osteocytes are the terminally differentiated cell type of the osteoblastic lineage and have important functions in skeletal homeostasis. Although the transcriptional regulation of osteoblast differentiation has been well characterized, the factors that regulate differentiation of osteocytes from mature osteoblasts are poorly understood. Here we show that miR 23a similar to 27a similar to 24 2 (miR 23a cluster) promotes osteocyte differentiation. Osteoblast specific miR 23a cluster gain of function mice have low bone mass associated with decreased osteoblast but increased osteocyte numbers. By contrast, loss of function transgenic mice overexpressing microRNA decoys for either miR 23a or miR 27a, but not miR24 2, show decreased osteocyte numbers. Moreover, RNA sequencing analysis shows altered transforming growth factor beta (TGF beta) signalling. Prdm16, a negative regulator of the TGF beta pathway, is directly repressed by miR 27a with concomitant alteration of sclerostin expression, and pharmacological inhibition of TGF beta rescues the phenotypes observed in the gain of function transgenic mice. Taken together, the miR 23a cluster regulates osteocyte differentiation by modulating the TGF beta signalling pathway through targeting of Prdm16.
C1 [Zeng, Huan Chang; Chen, Rui; Lee, Brendan H.] Baylor Coll Med, Program Dev Biol, One Baylor Plaza, Houston, TX 77030 USA.
   [Bae, Yangjin; Dawson, Brian C.; Chen, Yuqing; Bertin, Terry; Munivez, Elda; Chen, Rui; Lee, Brendan H.] Baylor Coll Med, Dept Mol & Human Genet, One Baylor Plaza, Houston, TX 77030 USA.
   [Campeau, Philippe M.] Univ Montreal, Sainte Justine Hosp, Dept Pediat, Montreal, PQ H3T 1C5, Canada.
   [Tao, Jianning] Univ South Dakota, Dept Pediat, Sch Med, Vermillion, SD 57104 USA.
C3 Baylor College of Medicine; Baylor College of Medicine; Universite de
   Montreal; University of South Dakota
RP Lee, BH (通讯作者)，Baylor Coll Med, Program Dev Biol, One Baylor Plaza, Houston, TX 77030 USA.; Lee, BH (通讯作者)，Baylor Coll Med, Dept Mol & Human Genet, One Baylor Plaza, Houston, TX 77030 USA.
EM blee@bcm.edu
RI Tao, Jianning/U 5213 2017; Campeau, Philippe/J 8614 2015
OI Tao, Jianning/0000 0001 5678 9272; Campeau, Philippe/0000 0001 9713 7107
FU BCM Intellectual and Developmental Disabilities Research Center from the
   Eunice Kennedy Shriver National Institute of Child Health and Human
   Development [HD024064]; BCM Advanced Technology Cores; NIH [AI036211,
   CA125123, RR024574, HD70394]; Rolanette and Berdon Lawrence Bone Disease
   Program of Texas; BCM Center for Skeletal Medicine and Biology
FX We thank Drs Patrick Finn and Steven Ledbetter from the Genzyme Research
   Center (Framingham, Massachusetts, USA) for providing the anti TGF beta
   and control antibodies for our study. In addition, we also thank Dr
   Patricia Fonseca for editorial assistance, Megan Bagos and Carrie Jiang
   for assistance with the mu CT analyses. This work was supported by the
   BCM Intellectual and Developmental Disabilities Research Center
   (HD024064) from the Eunice Kennedy Shriver National Institute of Child
   Health and Human Development, the BCM Advanced Technology Cores with
   funding from the NIH (AI036211, CA125123 and RR024574), the Rolanette
   and Berdon Lawrence Bone Disease Program of Texas and the BCM Center for
   Skeletal Medicine and Biology. This work was supported by the NIH
   (HD70394 to B.H.L.).
CR Bae YJ, 2012, HUM MOL GENET, V21, P2991, DOI 10.1093/hmg/dds129
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Bjork BC, 2010, HUM MOL GENET, V19, P774, DOI 10.1093/hmg/ddp543
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Chuikov S, 2010, NAT CELL BIOL, V12, P999, DOI 10.1038/ncb2101
   Cohen P, 2014, CELL, V156, P304, DOI 10.1016/j.cell.2013.12.021
   Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079
   Eguchi T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058796
   Ely A, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp446
   Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195
   Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823
   Gaur T, 2010, DEV BIOL, V340, P10, DOI 10.1016/j.ydbio.2010.01.008
   Grafel I, 2014, NAT MED, V20, P670, DOI 10.1038/nm.3544
   Harms MJ, 2014, CELL METAB, V19, P593, DOI 10.1016/j.cmet.2014.03.007
   Hassan MQ, 2010, P NATL ACAD SCI USA, V107, P19879, DOI 10.1073/pnas.1007698107
   Kanazawa I, 2015, J BIOL CHEM, V290, P3910, DOI 10.1074/jbc.M114.629899
   Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375
   Lin AH, 2005, J IMMUNOL, V175, P547, DOI 10.4049/jimmunol.175.1.547
   Lin R, 2014, J CLIN INVEST, V124, P5352, DOI 10.1172/JCI76561
   Meerbrey KL, 2011, P NATL ACAD SCI USA, V108, P3665, DOI 10.1073/pnas.1019736108
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Napierala D, 2012, J BONE MINER RES, V27, P1735, DOI 10.1002/jbmr.1636
   Seale P, 2008, NATURE, V454, P961, DOI 10.1038/nature07182
   Sun L, 2014, METABOLISM, V63, P272, DOI 10.1016/j.metabol.2013.10.004
   Takahata M, 2009, J BIOL CHEM, V284, P3334, DOI 10.1074/jbc.M808989200
   Wang T, 2010, BIOCHEM BIOPH RES CO, V402, P186, DOI 10.1016/j.bbrc.2010.08.031
   Warner DR, 2007, BBA MOL CELL RES, V1773, P814, DOI 10.1016/j.bbamcr.2007.03.016
   Warner DR, 2013, CELL TISSUE RES, V351, P445, DOI 10.1007/s00441 012 1525 2
   Wei JW, 2012, J CELL BIOL, V197, P509, DOI 10.1083/jcb.201201057
   Wein Marc N, 2015, J Bone Miner Res, V30, P400, DOI 10.1002/jbmr.2381
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
NR 31
TC 93
Z9 109
U1 0
U2 30
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD APR 11
PY 2017
VL 8
AR 15000
DI 10.1038/ncomms15000
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA ER5IG
UT WOS:000398834500001
PM 28397831
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU El Safadi, M
   Shinwari, T
   Al Malki, S
   Manikandan, M
   Mahmood, A
   Aldahmash, A
   Alfayez, M
   Kassem, M
   Alajez, NM
AF El Safadi, Mona
   Shinwari, Tasneem
   Al Malki, Sami
   Manikandan, Muthurangan
   Mahmood, Amer
   Aldahmash, Abdullah
   Alfayez, Musaad
   Kassem, Moustapha
   Alajez, Nehad M.
TI Convergence of TGFβ and BMP signaling in regulating human bone marrow
   stromal cell differentiation
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MESENCHYMAL STEM CELLS; MORPHOGENETIC PROTEINS; OSTEOBLAST
   DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION; NOGGIN; EXPRESSION;
   MECHANISM; BIOLOGY; FATE; GENE
AB Targeting regulatory signaling pathways that control human bone marrow stromal (skeletal or mesenchymal) stem cell (hBMSC) differentiation and lineage fate determination is gaining momentum in the regenerative medicine field. Therefore, to identify the central regulatory mechanism of osteoblast differentiation of hBMSCs, the molecular phenotypes of two clonal hBMSC lines exhibiting opposite in vivo phenotypes, namely, bone forming (hBMSC(+bone)) and non bone forming (hBMSC( Bone)) cells, were studied. Global transcriptome analysis revealed significant downregulation of several TGF beta responsive genes, namely, TAGLN, TMP1, ACTA2, TGF beta 2, SMAD6, SMAD9, BMP2, and BMP4 in hBMSC( Bone) cells and upregulation on SERPINB2 and NOG. Transcriptomic data was associated with marked reduction in SMAD2 protein phosphorylation, which thereby implies the inactivation of TGF beta and BMP signaling in those cells. Concordantly, activation of TGF beta signaling in hBMSC( Bone) cells using either recombinant TGF beta 1 protein or knockdown of SERPINB2 TGF beta responsive gene partially restored their osteoblastic differentiation potential. Similarly, the activation of BMP signaling using exogenous BMP4 or via siRNA mediated knockdown of NOG partially restored the differentiation phenotype of hBMSC( Bone) cells. Concordantly, recombinant NOG impaired ex vivo osteoblastic differentiation of hBMSC(+Bone) cells, which was associated with SERBINB2 upregulation. Our data suggests the existence of reciprocal relationship between TGFB and BMP signaling that regulates hBMSC lineage commitment and differentiation, whilst provide a plausible strategy for generating osteoblastic committed cells from hBMSCs for clinical applications.
C1 [El Safadi, Mona; Shinwari, Tasneem; Manikandan, Muthurangan; Mahmood, Amer; Aldahmash, Abdullah; Alfayez, Musaad; Kassem, Moustapha] King Saud Univ, Dept Anat, Coll Med, Stem Cell Unit, Riyadh, Saudi Arabia.
   [Al Malki, Sami] King Saud Univ, Coll Agr, Riyadh, Saudi Arabia.
   [Aldahmash, Abdullah] King Saud Univ, Prince Naif Hlth Res Ctr, Riyadh 11461, Saudi Arabia.
   [Kassem, Moustapha] Univ Hosp Odense, Dept Endocrinol, KMEB, Odense, Denmark.
   [Kassem, Moustapha] Univ Southern Denmark, Odense, Denmark.
   [Alajez, Nehad M.] HBKU, Qatar Fdn, Qatar Biomed Res Inst, Canc Res Ctr, POB 34110, Doha, Qatar.
   [Alajez, Nehad M.] HBKU, Qatar Fdn, Coll Hlth & Life Sci, Doha, Qatar.
C3 King Saud University; King Saud University; King Saud University;
   University of Southern Denmark; Odense University Hospital; University
   of Southern Denmark; Qatar Foundation (QF); Hamad Bin Khalifa
   University Qatar; Qatar Biomedical Research Institute (QBRI); Qatar
   Foundation (QF); Hamad Bin Khalifa University Qatar
RP Alajez, NM (通讯作者)，HBKU, Qatar Fdn, Qatar Biomed Res Inst, Canc Res Ctr, POB 34110, Doha, Qatar.; Alajez, NM (通讯作者)，HBKU, Qatar Fdn, Coll Hlth & Life Sci, Doha, Qatar.
EM nalajez@hbku.edu.qa
RI Mahmood, Amer/A 9514 2011; Aldahmash, Abdullah/D 4693 2015; muthurangan,
   manikandan/GVU 5356 2022; Kassem, Moustapha/J 7688 2013
OI Alajez, Nehad/0000 0002 1546 1091; Mahmood, Amer/0000 0002 9199 0120;
   Elsafadi, Mona/0000 0002 7096 998X; muthurangan,
   manikandan/0000 0003 3057 1851; 
FU National Plan for science, Technology and Innovation (MAARIFAH), King
   Abdulaziz City for Science and Technology, Kingdom of Saudi Arabia
   [BIO1308 02]
FX This work was funded by National Plan for science, Technology and
   Innovation (MAARIFAH), King Abdulaziz City for Science and Technology,
   Kingdom of Saudi Arabia, Award Number (BIO1308 02).
CR Abdallah BM, 2008, GENE THER, V15, P109, DOI 10.1038/sj.gt.3303067
   Abdallah BM, 2017, J BONE MINER RES, V32, P913, DOI 10.1002/jbmr.3069
   Abdallah Basem M., 2008, V455, P89, DOI 10.1007/978 1 59745 104 8_6
   Abdallah BM, 2005, BIOCHEM BIOPH RES CO, V326, P527, DOI 10.1016/j.bbrc.2004.11.059
   Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663
   Al Nbaheen M, 2013, STEM CELL REV REP, V9, P32, DOI 10.1007/s12015 012 9365 8
   Ali D, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/2379546
   Ali D, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171252
   Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809
   Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002
   Capdevila J, 1998, DEV BIOL, V197, P205, DOI 10.1006/dbio.1997.8824
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   Devlin RD, 2003, ENDOCRINOLOGY, V144, P1972, DOI 10.1210/en.2002 220918
   Elsafadi M, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10983 x
   Elsafadi M, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9378081
   Fan JB, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0072474, 10.1371/journal.pone.0076701]
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Harris NLE, 2017, ONCOGENE, V36, P4288, DOI 10.1038/onc.2017.63
   HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527
   Hsieh HH, 2017, J CELL SCI, V130, P3272, DOI 10.1242/jcs.204974
   Jafari A, 2017, STEM CELL REP, V8, P373, DOI 10.1016/j.stemcr.2017.01.003
   Kassem M, 2011, AGING CELL, V10, P191, DOI 10.1111/j.1474 9726.2011.00669.x
   Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627
   Kristensen LP, 2012, MOL CELL PROTEOMICS, V11, P989, DOI 10.1074/mcp.M111.012138
   KRUITHOF EKO, 1995, BLOOD, V86, P4007, DOI 10.1182/blood.V86.11.4007.bloodjournal86114007
   Larsen KH, 2010, J BONE MINER RES, V25, P796, DOI 10.1359/jbmr.091018
   Lee JA, 2011, SEMIN THROMB HEMOST, V37, P395, DOI 10.1055/s 0031 1276589
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Reddi AH, 2001, J BONE JOINT SURG AM, V83A, pS1, DOI 10.2106/00004623 200100001 00001
   Ren GW, 2012, STEM CELL TRANSL MED, V1, P51, DOI 10.5966/sctm.2011 0019
   Rosen V, 2006, ANN NY ACAD SCI, V1068, P19, DOI 10.1196/annals.1346.005
   Serra Rosa, 2003, Birth Defects Research, V69, P333, DOI 10.1002/bdrc.10023
   Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602 592
   SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092 8674(92)90316 5
   Walsh DW, 2010, TRENDS CELL BIOL, V20, P244, DOI 10.1016/j.tcb.2010.01.008
   Wan DC, 2007, J BIOL CHEM, V282, P26450, DOI 10.1074/jbc.M703282200
   Watson L, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt439
   Wozney JM, 1998, CLIN ORTHOP RELAT R, P26
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Wu XB, 2003, J CLIN INVEST, V112, P924, DOI 10.1172/JCI200315543
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   Zaher W, 2014, ARCH TOXICOL, V88, P1069, DOI 10.1007/s00204 014 1232 8
   Zakin L, 2010, CURR BIOL, V20, pR89, DOI 10.1016/j.cub.2009.11.021
NR 44
TC 20
Z9 24
U1 1
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD MAR 21
PY 2019
VL 9
AR 4977
DI 10.1038/s41598 019 41543 0
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA HP7RH
UT WOS:000461885900017
PM 30899078
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU D'Amelio, P
   Grimaldi, A
   Cristofaro, MA
   Ravazzoli, M
   Molinatti, PA
   Pescarmona, GP
   Isaia, GC
AF D'Amelio, P.
   Grimaldi, A.
   Cristofaro, M. A.
   Ravazzoli, M.
   Molinatti, P. A.
   Pescarmona, G. P.
   Isaia, G. C.
TI Alendronate reduces osteoclast precursors in osteoporosis
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Alendronate; Osteoclast; Osteoclast precursors; Osteoporosis; RANKL
ID BLOOD MONONUCLEAR CELLS; BONE MINERAL DENSITY; IN VITRO;
   PERIPHERAL BLOOD; TNF ALPHA; T CELLS; POSTMENOPAUSAL OSTEOPOROSIS;
   PERIODONTITIS PATIENTS; MEVALONATE PATHWAY; CLINICAL EFFICACY
AB This study evaluates the effect of alendronate on osteoclastogenesis, cytokine production, and bone resorption in postmenopausal women. We suggest that it acts on mature bone resorbing osteoclasts after 3 months of treatment, whereas, after 1 year, it diminishes their formation by reducing their precursors and serum RANKL.
   Osteoclasts are the target cells of bisphosphonates, though the most drug sensitive steps of their formation and activity have not been determined. The present study evaluates the effect of alendronate on osteoclastogenesis, cytokine production, and bone resorption in postmenopausal women.
   The study was conducted on 35 osteoporotic women; 15 were pretreated with alendronate 70 mg/week, whereas, 20 were treated with calcium 1 g/day and vitamin D 800 IU/day. After 3 months, 30 received alendonate 70/mg, vitamin D 2800 IU/week, and calcium 1 g/day for 12 months (combined therapy), whereas, the other five patients remained on calcium 1 g/day and vitamin D 800 IU/day. The following parameters were assessed before and after therapy: changes in bone resorption markers, circulating osteoclast precursors, formation of osteoclasts in peripheral blood mononuclear cell cultures, their viability, and variations in cytokines production.
   After 3 months of alendronate, there was no significant reduction in the number of osteoclast precursors, osteoclast formation and viability, and cytokine levels, whereas, there was a significant reduction of bone resorption markers. One year of the combined therapy, on the other hand, reduced osteoclast precursors, osteoclast formation, and serum RANKL, whereas, calcium plus vitamin D alone had no effect.
   We suggest that alendronate mainly acts on mature bone resorbing osteoclasts in the short term, whereas, its long term administration diminishes their formation by reducing their precursors and serum RANKL.
C1 [D'Amelio, P.; Grimaldi, A.; Cristofaro, M. A.; Ravazzoli, M.; Molinatti, P. A.; Isaia, G. C.] Univ Turin, Gerontol Sect, Dept Surg & Med Disciplines, I 10126 Turin, Italy.
   [Pescarmona, G. P.] Hosp San Giovanni Battista, Ctr Expt Res & Med Studies, Turin, Italy.
   [Pescarmona, G. P.] Univ Turin, Dept Genet Biol & Biochem, I 10126 Turin, Italy.
C3 University of Turin; A.O.U. Citta della Salute e della Scienza di
   Torino; AOU San Giovanni Battista Molinette; University of Turin
RP D'Amelio, P (通讯作者)，Univ Turin, Gerontol Sect, Dept Surg & Med Disciplines, Corso Bramante 88 90, I 10126 Turin, Italy.
EM patrizia.damelio@unito.it
RI ; D'AMELIO, PATRIZIA/K 3042 2016
OI PESCARMONA, GIAN PIERO/0000 0003 2143 8901; D'AMELIO,
   PATRIZIA/0000 0002 4467 8337
FU Merck Sharp & Dohme SpA Italy; Fondazione Internazionale Ricerche
   Medicina Sperimentale (FIRMS) Compagnia San Paolo; Ministry for
   Education, University and Research (MIUR); Regione Piemonte
FX This work was supported by an unconditioned grant from the Merck Sharp &
   Dohme SpA Italy and a grant from the Fondazione Internazionale Ricerche
   Medicina Sperimentale (FIRMS) Compagnia San Paolo. M.A. Cristofaro was
   supported by a fellowship from the Ministry for Education, University
   and Research (MIUR); P. D'Amelio was supported by a fellowship from the
   Regione Piemonte. Alendronate and alendronate plus vitamin D were kindly
   provided by Merck Sharp & Dohme SpA Italy; calcium and vitamin D
   supplements were kindly provided by Procter & Gamble.
CR Amelio PD, 2008, J BONE MINER RES, V23, P373, DOI 10.1359/JBMR.071031
   Benford HL, 2001, BONE, V28, P465, DOI 10.1016/S8756 3282(01)00412 4
   BOONEKAMP PM, 1986, BONE MINER, V1, P27
   Brunetti G, 2005, J PERIODONTOL, V76, P1675, DOI 10.1902/jop.2005.76.10.1675
   CARANO A, 1990, J CLIN INVEST, V85, P456, DOI 10.1172/JCI114459
   CECCHINI MG, 1987, J BONE MINER RES, V2, P135
   Colucci S, 1998, CALCIFIED TISSUE INT, V63, P230, DOI 10.1007/s002239900519
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   D'Amelio P, 2004, FASEB J, V18, P410, DOI 10.1096/fj.04 2214fje
   D'Amelio P, 2008, BONE, V43, P92, DOI 10.1016/j.bone.2008.02.017
   Dalbeth N, 2008, ARTHRITIS RHEUM US, V58, P1854, DOI 10.1002/art.23488
   Deng X, 2007, INT IMMUNOPHARMACOL, V7, P152, DOI 10.1016/j.intimp.2006.09.009
   DEVRIES TJ, 2009, OSTEOCLAST FORMATION
   Dobnig H, 2006, OSTEOPOROSIS INT, V17, P693, DOI 10.1007/s00198 005 0035 4
   Faust J, 1999, J CELL BIOCHEM, V72, P67, DOI 10.1002/(SICI)1097 4644(19990101)72:1<67::AID JCB8>3.0.CO;2 A
   Gür A, 2003, YONSEI MED J, V44, P99
   Hewitt RE, 2005, CLIN EXP IMMUNOL, V139, P101, DOI 10.1111/j.1365 2249.2005.02665.x
   Hofbauer L. C., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P268
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200
   Massey HM, 1999, BRIT J HAEMATOL, V106, P167
   Matayoshi A, 1996, P NATL ACAD SCI USA, V93, P10785, DOI 10.1073/pnas.93.20.10785
   Mossetti G, 2005, BONE, V36, P549, DOI 10.1016/j.bone.2004.11.004
   Olivier BJ, 2008, HEPATOLOGY, V47, P259, DOI 10.1002/hep.21971
   Pan BQ, 2004, J BONE MINER RES, V19, P147, DOI 10.1359/jbmr.2004.19.1.147
   Papadaki HA, 2004, J BONE MINER METAB, V22, P577, DOI 10.1007/s00774 004 0526 y
   Pietschmann P, 1998, CALCIFIED TISSUE INT, V63, P325, DOI 10.1007/s002239900535
   Ramnaraine M, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.07.016
   Ritchlin CT, 2003, J CLIN INVEST, V111, P821, DOI 10.1172/JCI200316069
   Roato I, 2004, FASEB J, V18, P228, DOI 10.1096/fj.04 1823fje
   Roato I, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000124
   Rodan Gideon A., 2002, Current Molecular Medicine (Hilversum), V2, P571, DOI 10.2174/1566524023362104
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Rogers MJ, 1996, J BONE MINER RES, V11, P1482
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   SAHNI M, 1993, J CLIN INVEST, V91, P2004, DOI 10.1172/JCI116422
   Santini D, 2004, BIODRUGS, V18, P269, DOI 10.2165/00063030 200418040 00004
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Sauty A, 1996, BONE, V18, P133, DOI 10.1016/8756 3282(95)00448 3
   Shalhoub V, 2000, BRIT J HAEMATOL, V111, P501, DOI 10.1046/j.1365 2141.2000.02379.x
   Sudhoff H, 2003, ANN OTO RHINOL LARYN, V112, P780, DOI 10.1177/000348940311200907
   Thompson K, 2004, J BONE MINER RES, V19, P278, DOI 10.1359/JBMR.0301230
   Tjoa STS, 2008, J CLIN PERIODONTOL, V35, P568, DOI 10.1111/j.1600 051X.2008.01241.x
   Töyräs A, 2003, EUR J PHARM SCI, V19, P223, DOI 10.1016/S0928 0987(03)00108 8
   Van Beek ER, 2002, BONE, V30, P64, DOI 10.1016/S8756 3282(01)00655 X
   vanBeek ER, 1997, BONE, V20, P335, DOI 10.1016/S8756 3282(97)00006 9
   Vitte C, 1996, ENDOCRINOLOGY, V137, P2324, DOI 10.1210/en.137.6.2324
NR 48
TC 41
Z9 42
U1 3
U2 24
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD OCT
PY 2010
VL 21
IS 10
BP 1741
EP 1750
DI 10.1007/s00198 009 1129 1
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 646LX
UT WOS:000281543200012
PM 19949772
DA 2025 08 17
ER

PT J
AU Pelusi, L
   Mandatori, D
   Di Pietrantonio, N
   Del Pizzo, F
   Di Tomo, P
   Di Pietro, N
   Buda, R
   Genovese, S
   Epifano, F
   Pandolfi, A
   Fiorito, S
   Pipino, C
AF Pelusi, Letizia
   Mandatori, Domitilla
   Di Pietrantonio, Nadia
   Del Pizzo, Francesco
   Di Tomo, Pamela
   Di Pietro, Natalia
   Buda, Roberto
   Genovese, Salvatore
   Epifano, Francesco
   Pandolfi, Assunta
   Fiorito, Serena
   Pipino, Caterina
TI Estrogen Receptor 1 (ESR1) and the Wnt/β Catenin Pathway Mediate the
   Effect of the Coumarin Derivative Umbelliferon on Bone Mineralization
SO NUTRIENTS
LA English
DT Article
DE osteoblast; osteoclast; osteoporosis; coumarin derivatives;
   umbelliferon; bone mineralization; 3D culture
ID MICROGRAVITY; RESORPTION
AB Bone physiology is regulated by osteoblast and osteoclast activities, both involved in the bone remodeling process, through deposition and resorption mechanisms, respectively. The imbalance between these two phenomena contributes to the onset of bone diseases. Among these, osteoporosis is the most common metabolic bone disorder. The therapies currently used for its treatment include antiresorptive and anabolic agents associated with side effects. Therefore, alternative therapeutic approaches, including natural molecules such as coumarin and their derivatives, have recently shown positive results. Thus, our proposal was to investigate the effect of the coumarin derivative umbelliferon (UF) using an interesting model of human osteoblasts (hOBs) isolated from osteoporotic patients. UF significantly improved the activity of osteoporotic patient derived hOBs via estrogen receptor 1 (ESR1) and the downstream activation of beta catenin pathway. Additionally, hOBs were co cultured in microgravity with human osteoclasts (hOCs) using a 3D system bioreactor, able to reproduce the bone remodeling unit in bone loss conditions in vitro. Notably, UF exerted its anabolic role by reducing the multinucleated cells. Overall, our study confirms the potential efficacy of UF in bone health, and identified, for the first time, a prospective alternative natural compound useful to prevent/treat bone loss diseases such as osteoporosis.
C1 [Pelusi, Letizia; Mandatori, Domitilla; Di Pietrantonio, Nadia; Di Tomo, Pamela; Di Pietro, Natalia; Pandolfi, Assunta; Pipino, Caterina] Univ G dAnnunzio, Ctr Adv Studies & Technol CAST, Dept Med Oral & Biotechnol Sci, I 66100 Chieti, Italy.
   [Del Pizzo, Francesco] Univ G dAnnunzio, Ctr Adv Studies & Technol CAST, Dept Neurosci Imaging & Clin Sci, I 66100 Chieti, Italy.
   [Buda, Roberto] Univ G dAnnunzio, Dept Med & Aging Sci, I 66100 Chieti, Italy.
   [Genovese, Salvatore; Epifano, Francesco; Fiorito, Serena] Univ G dAnnunzio, Dept Pharm, I 66100 Chieti, Italy.
C3 G d'Annunzio University of Chieti Pescara; G d'Annunzio University of
   Chieti Pescara; G d'Annunzio University of Chieti Pescara; G d'Annunzio
   University of Chieti Pescara
RP Pipino, C (通讯作者)，Univ G dAnnunzio, Ctr Adv Studies & Technol CAST, Dept Med Oral & Biotechnol Sci, I 66100 Chieti, Italy.
EM caterina.pipino@unich.it
RI Pipino, Caterina/N 2078 2019; Buda, Roberto/T 4478 2019; Epifano,
   Francesco/AAC 6392 2021; Di Pietro, Natalia/K 1604 2016; pandolfi,
   assunta/K 4595 2016
OI Di Pietro, Natalia/0000 0001 9720 2116; 
FU PON MISE SustainableGrowth Funding DD27 September 2018 [21]; MIUR PON
   AIM "Attraction and International Mobility" Linea 2 (Attrazione dei
   ricercatori), profilo 2.1; Ministero della Sanita Programma di Ricerca
   Finalizzata 2019 [GR 2019 12369702]; PON R&I "Ricerca e innovazione"
   2014 2020
FX This researchwas founded by the PON MISE SustainableGrowth Funding DD27
   September 2018 (grant no. 21, ex 230). C.P. was supported by MIUR PON
   AIM "Attraction and International Mobility" Linea 2 (Attrazione dei
   ricercatori), profilo 2.1, and by the Ministero della Sanita Programma
   di Ricerca Finalizzata 2019 (GR 2019 12369702). D.M. was supported by
   PON R&I "Ricerca e innovazione" 2014 2020.
CR Abdallah BM, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929 019 0544 7
   Adami S, 2008, CURR MED RES OPIN, V24, P3259, DOI 10.1185/03007990802518130 
   Almeida M, 2017, PHYSIOL REV, V97, P135, DOI 10.1152/physrev.00033.2015
   Appelman Dijkstra NM, 2015, DRUGS, V75, P1049, DOI 10.1007/s40265 015 0417 7
   Bala Y, 2013, OSTEOPOROSIS INT, V24, P2153, DOI 10.1007/s00198 012 2228 y
   Behrens P., 2007, HDB BIOMINERALIZATIO
   Bilezikian JP, 2007, WOMENS HEALTH, V3, P243, DOI 10.2217/17455057.3.2.243
   Binder BYK, 2015, STEM CELL REV REP, V11, P387, DOI 10.1007/s12015 014 9555 7
   Chen JS, 2012, NAT REV ENDOCRINOL, V8, P81, DOI 10.1038/nrendo.2011.146
   D'Alimonte I, 2013, STEM CELL REV REP, V9, P642, DOI 10.1007/s12015 013 9436 5
   Di Tomo P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073816
   Dirckx N, 2019, NAT REV ENDOCRINOL, V15, P651, DOI 10.1038/s41574 019 0246 y
   Faraone I, 2021, PHYTOCHEMISTRY, V187, DOI 10.1016/j.phytochem.2021.112781
   Fiorito Serena, 2019, Prog Chem Org Nat Prod, V108, P143, DOI 10.1007/978 3 030 01099 7_2
   Fiorito S, 2018, EUR J MED CHEM, V152, P274, DOI 10.1016/j.ejmech.2018.04.051
   Gao YH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082436
   Kwak SC, 2019, INT J BIOL SCI, V15, P2427, DOI 10.7150/ijbs.28609
   Liang YD, 2021, PHYTOTHER RES, V35, P6131, DOI 10.1002/ptr.7221
   Ma Y, 2019, J CELL BIOCHEM, V120, P16052, DOI 10.1002/jcb.28886
   Mandatori D, 2021, NUTRIENTS, V13, DOI 10.3390/nu13082823
   Miranda LL, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/1296153
   Na WJ, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222212391
   Na W, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228581
   Nabavi N, 2011, BONE, V49, P965, DOI 10.1016/j.bone.2011.07.036
   Nagaraja MP, 2013, J CELL BIOCHEM, V114, P1001, DOI 10.1002/jcb.24454
   Park E, 2020, NUTRIENTS, V12, DOI 10.3390/nu12113565
   Pasqualetti S, 2012, J MOL HISTOL, V43, P589, DOI 10.1007/s10735 012 9425 z
   Peng XM, 2013, CURR PHARM DESIGN, V19, P3884, DOI 10.2174/1381612811319210013
   Preziuso F, 2020, MOLECULES, V25, DOI 10.3390/molecules25245923
   Putnam SE, 2007, PHYTOTHER RES, V21, P99, DOI 10.1002/ptr.2030
   Sarker SD, 2017, PROG CHEM ORG NAT PR, V106, P241, DOI 10.1007/978 3 319 59542 9_3
   Schiavi J, 2021, EXP CELL RES, V408, DOI 10.1016/j.yexcr.2021.112814
   Seeman E, 2019, NAT REV RHEUMATOL, V15, P225, DOI 10.1038/s41584 019 0172 3
   Shanmugam H, 2019, CHEM BIOL INTERACT, V310, DOI 10.1016/j.cbi.2019.108750
   Tavares SJS, 2021, FITOTERAPIA, V150, DOI 10.1016/j.fitote.2021.104842
   Skjodt MK, 2019, BRIT J CLIN PHARMACO, V85, P1063, DOI 10.1111/bcp.13759
   Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898
   Streicher C, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 06614 0
   Teti A, 2017, BONE, V102, P50, DOI 10.1016/j.bone.2017.02.002
   Xia HT, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.654714
   Zhang T, 2019, FASEB J, V33, P5399, DOI 10.1096/fj.201801797R
   Zhang TH, 2018, PHYTOCHEMISTRY, V152, P148, DOI 10.1016/j.phytochem.2018.05.010
   Zhu JJ, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/mnfr.201701073
NR 43
TC 10
Z9 10
U1 2
U2 10
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6643
J9 NUTRIENTS
JI Nutrients
PD AUG
PY 2022
VL 14
IS 15
AR 3209
DI 10.3390/nu14153209
PG 12
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA 3S7BF
UT WOS:000839746800001
PM 35956385
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Cong, W
   Zhou, C
   Yin, J
AF Cong, Wei
   Zhou, Chao
   Yin, Jun
TI Alpinumisoflavone inhibits osteoclast differentiation and exerts
   anti osteoporotic effect in ovariectomized mice
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Alpinumisoflavone Ovariectomy induced bone loss; c Fos; NFATc1
ID ERYTHRINA LYSISTEMON FABACEAE; BONE RESORPTION; OSTEOBLAST
   DIFFERENTIATION; KAPPA B; NATURAL PRODUCTS; ACTIVATION; CELLS;
   PROLIFERATION; MECHANISMS; FLAVONOIDS
AB Alpinumisoflavone (AIF), a naturally occurring flavonoid compound exacted from Derris eriocarpa, has been found to have a number of pharmacological activities. However, its role in bone disorder has not been investigated. The aim of this study is to evaluate the osteoprotective effect of AIF on ovariectomy induced bone loss in mice model and related underlying mechanisms. Our study provides experimental evidence that AIF could regulate the remodeling process of bone and exert osteoprotective effect against ovariectomy induced bone loss. Moreover, our results show that AIF suppresses osteoclast differentiation by attenuating RANKL induced activation of p38, ERK and JNK pathways and consequently represses the expression of c Fos and NFATc1. (C) 2017 Elsevier Masson SAS. All rights reserved.
C1 [Cong, Wei; Zhou, Chao; Yin, Jun] Shandong Univ, Qilu Hosp, Qingdao, Shandong, Peoples R China.
C3 Shandong University
RP Yin, J (通讯作者)，Shandong Univ, Qilu Hosp, Qingdao, Shandong, Peoples R China.
EM yinjunqdql@163.com
CR ADAMI HO, 1989, INT J CANCER, V44, P833, DOI 10.1002/ijc.2910440515
   An J, 2016, INT IMMUNOPHARMACOL, V36, P118, DOI 10.1016/j.intimp.2016.04.024
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Ang ESM, 2011, FEBS LETT, V585, P2755, DOI 10.1016/j.febslet.2011.07.046
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Babu S, 2015, WORLD J ORTHOP, V6, P457, DOI 10.5312/wjo.v6.i6.457
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chukwujekwu JC, 2011, PHYTOTHER RES, V25, P46, DOI 10.1002/ptr.3159
   Clavin M, 2007, J ETHNOPHARMACOL, V112, P585, DOI 10.1016/j.jep.2007.04.007
   Del Fattore A, 2008, ARCH BIOCHEM BIOPHYS, V473, P147, DOI 10.1016/j.abb.2008.01.011
   Edwards BJ, 2007, CLIN ORTHOP RELAT R, P226, DOI 10.1097/BLO.0b013e3180534269
   Guo JD, 2013, BRIT J PHARMACOL, V168, P1412, DOI 10.1111/bph.12036
   Han Y, 2016, AM J CANCER RES, V6, P2755
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   Hsieh TP, 2011, PHYTOMEDICINE, V18, P176, DOI 10.1016/j.phymed.2010.04.003
   Jeong Eun H, 2013, EUR J PHARMACOL, V698, P57, DOI 10.1016/j.ejphar.2012.08.013
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Kuete V, 2016, PHYTOMEDICINE, V23, P856, DOI 10.1016/j.phymed.2016.04.007
   Lee J, 2015, EXP CELL RES, V339, P380, DOI 10.1016/j.yexcr.2015.10.001
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Li LN, 2011, PHYTOMEDICINE, V18, P985, DOI 10.1016/j.phymed.2011.03.002
   Ma DF, 2008, EUR J CLIN NUTR, V62, P155, DOI 10.1038/sj.ejcn.1602748
   Miyamoto Takeshi, 2011, Keio Journal of Medicine, V60, P101
   Mvondo MA, 2012, PHYTOTHER RES, V26, P1029, DOI 10.1002/ptr.3685
   Mvondo MA, 2015, J PHARM PHARMACOL, V67, P990, DOI 10.1111/jphp.12386
   Namkoong S, 2011, BIOL PHARM BULL, V34, P203, DOI 10.1248/bpb.34.203
   Satue M, 2013, BIOCHEM PHARMACOL, V86, P1476, DOI 10.1016/j.bcp.2013.09.009
   Song LG, 2013, EUR J PHARMACOL, V714, P15, DOI 10.1016/j.ejphar.2013.05.039
   Takayanagi H, 2005, J PERIODONTAL RES, V40, P287, DOI 10.1111/j.1600 0765.2005.00814.x
   Uchino K, 2015, PHYTOTHER RES, V29, P1714, DOI 10.1002/ptr.5416
   Watanabe A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127158
   Yeon JT, 2012, BMB REP, V45, P171, DOI 10.5483/BMBRep.2012.45.3.171
   Yoshiko Y, 2003, ENDOCRINOLOGY, V144, P4134, DOI 10.1210/en.2003 0130
NR 33
TC 8
Z9 9
U1 0
U2 7
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD SEP
PY 2017
VL 93
BP 344
EP 351
DI 10.1016/j.biopha.2017.06.059
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FE0PU
UT WOS:000407923000037
PM 28651235
DA 2025 08 17
ER

PT J
AU Jin, ZF
   Li, HT
   Bi, FS
   Cao, HM
AF Jin, Zhefeng
   Li, Hongtao
   Bi, Fangshan
   Cao, Hongmei
TI The effects of Pinoresinol diglucoside on the differentiation and bone
   resorption of osteoclast RAW264.7
SO FOOD SCIENCE AND TECHNOLOGY
LA English
DT Article
DE Pinoresinol diglucoside; RAW264.7 cells; RNAKL/RANK; NF kappa B; AKT
ID OSTEOPOROSIS
AB The paper aimed to investigate the effect of Pinoresinol diglucoside on the differentiation and bone resorption of osteoclast RAW264.7, and to evaluate the effect of Pinoresinol diglucoside on osteoclasts.
   In order to study the effect of Pinoresinol diglucoside on osteoclast differentiation, RANKL was used to induce RAW264.7 cells to differentiate into osteoclasts, and different concentrations of Pinoresinol diglucoside was added to intervene. CCK 8 method was applied to detect cell viability. TRAP staining was employed to observe cell morphology. Annexin V/PI flow cytometry was used to detect cell apoptosis. Phalloidin was used to detect F actin formation of osteoclasts and to observe the effect on bone resorption. WB was employed to detect the effects of differentiation related proteins and RANKL/RANK signaling pathways, and immunofluorescence detection technology was used to measure the distribution and nuclear translocation of p65. Pinoresinol diglucoside can effectively inhibit RANKL induced osteoclast differentiation, especially in the early stage. The drug can inhibit the formation of F actin of osteoclasts and inhibit bone resorption. Through inhibiting the ubiquitination and degradation of the homologous phosphatase tensin (PTEN), the drug up regulated the viability of PTEN. The up regulated PTEN viability then inhibited the NF kappa B and AKT signaling pathways, resulting in a decrease in the expressions of nuclear factor c1 (NFATc1) in activated T cells. Pinoresinol diglucoside effectively inhibited the formation of F actin and bone resorption in mature osteoclasts. The mechanism is through inhibiting the expression levels of osteoclast related proteins NFATc1, c Fos, CSTK and TRAP and RNAKL/RANK signaling pathways, and also inhibiting the activation of NF kappa B and AKT signaling pathways.
C1 [Jin, Zhefeng] China Acad Chinese Med Sci, Wang Jing Hosp, Beijing, Peoples R China.
   [Li, Hongtao] China Acad Chinese Med Sci, Inst Informat Tradit Chinese Med, Beijing, Peoples R China.
   [Bi, Fangshan] Beijing Fengsheng Special Hosp Tradit Chinese Med, Beijing, Peoples R China.
   [Cao, Hongmei] Capitalbio Corp, Beijing, Peoples R China.
C3 China Academy of Chinese Medical Sciences; China Academy of Chinese
   Medical Sciences; Institute of Information on Traditional Chinese
   Medicine, CACMS; CapitalBio
RP Cao, HM (通讯作者)，Capitalbio Corp, Beijing, Peoples R China.
EM caohongmei437@sina.com
CR Anthamatten A, 2019, J MIDWIFERY WOM HEAL, V64, P265, DOI 10.1111/jmwh.12954
   Aspray Terry J, 2019, Subcell Biochem, V91, P453, DOI 10.1007/978 981 13 3681 2_16
   Choi YH, 2019, GEN PHYSIOL BIOPHYS, V38, P111, DOI 10.4149/gpb 2018044
   Jia YG, 2018, FASEB J, V32, P3398, DOI 10.1096/fj.201701148RR
   Khalifeh Soltani A, 2018, FASEB J, V32, P5927, DOI 10.1096/fj.201800109R
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim B, 2018, PHYTOMEDICINE, V51, P181, DOI 10.1016/j.phymed.2018.06.020
   Liu L, 2017, ONCOL LETT, V14, P3741, DOI 10.3892/ol.2017.6580
   Meng JH, 2019, J CELL MOL MED, V23, P6730, DOI 10.1111/jcmm.14551
   Shalev M, 2019, BBA MOL CELL RES, V1866, P114, DOI 10.1016/j.bbamcr.2018.07.005
   Tanaka S, 2019, EFORT OPEN REV, V4, P158, DOI 10.1302/2058 5241.4.180018
   Wu MR, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13700
   Xu Q, 2019, BIOCHEM BIOPH RES CO, V508, P902, DOI 10.1016/j.bbrc.2018.11.201
   Ye L, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0030 y
   Yu F, 2019, ARCH OSTEOPOROS, V14, DOI 10.1007/s11657 018 0549 y
NR 15
TC 1
Z9 1
U1 4
U2 17
PU SOC BRASILEIRA CIENCIA TECNOLOGIA ALIMENTOS
PI CAMPINAS
PA AV BRASIL 2880, CAXIA POSTAL 271 CEP 13001 970, CAMPINAS, SAO PAULO
   00000, BRAZIL
SN 0101 2061
EI 1678 457X
J9 FOOD SCI TECH BRAZIL
JI Food Sci. Technol.
PY 2022
VL 42
AR e89221
DI 10.1590/fst.89221
PG 6
WC Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology
GA 2Y7TF
UT WOS:000826093700113
OA gold
DA 2025 08 17
ER

PT J
AU Alshayeb, HM
   Josephson, MA
   Sprague, SM
AF Alshayeb, Hala M.
   Josephson, Michelle A.
   Sprague, Stuart M.
TI CKD Mineral and Bone Disorder Management in Kidney Transplant Recipients
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Posttransplantation bone disease; epidemiology; pathogenesis; screening;
   diagnosis; management
ID PERSISTENT SECONDARY HYPERPARATHYROIDISM; SUCCESSFUL
   RENAL TRANSPLANTATION; SOLID ORGAN TRANSPLANTATION; TERM FOLLOW UP;
   VITAMIN D; CYCLOSPORINE A; RISK FACTORS; PARATHYROID HORMONE; FRACTURE
   RISK; SINGLE CENTER
AB Kidney transplantation, the most effective treatment for the metabolic abnormalities of chronic kidney disease (CKD), only partially corrects CKD mineral and bone disorders. Posttransplantation bone disease, one of the major complications of kidney transplantation, is characterized by accelerated loss of bone mineral density and increased risk of fractures and osteonecrosis. The pathogenesis of posttransplantation bone disease is multifactorial and includes the persistent manifestations of pretransplantation CKD mineral and bone disorder, peritransplantation changes in the fibroblast growth factor 23 parathyroid hormone vitamin D axis, metabolic perturbations such as persistent hypophosphatemia and hypercalcemia, and the effects of immunosuppressive therapies. Posttransplantation fractures occur more commonly at peripheral than central sites. Although there is significant loss of bone density after transplantation, the evidence linking posttransplantation bone loss and subsequent fracture risk is circumstantial. Presently, there are no prospective clinical trials that define the optimal therapy for posttransplantation bone disease. Combined pharmacologic therapy that targets multiple components of the disordered pathways has been used. Although bisphosphonate or calcitriol therapy can preserve bone mineral density after transplantation, there is no evidence that these agents decrease fracture risk. Moreover, bisphosphonates pose potential risks for adynamic bone disease. Am J Kidney Dis. 61(2):310 325. (c) 2013 by the National Kidney Foundation, Inc.
C1 [Alshayeb, Hala M.; Josephson, Michelle A.] Univ Chicago, Dept Med, Nephrol Sect, Chicago, IL 60637 USA.
   [Sprague, Stuart M.] NorthShore Univ Hlth Syst, Dept Med, Nephrol Sect, Evanston, IL 60201 USA.
C3 University of Chicago; NorthShore University Health System
RP Sprague, SM (通讯作者)，NorthShore Univ Hlth Syst, Dept Med, Sect Nephrol & Hypertens, 2650 Ridge Ave, Evanston, IL 60201 USA.
EM stuartmsprague@gmail.com
CR Abbott KC, 2001, ANN EPIDEMIOL, V11, P450, DOI 10.1016/S1047 2797(01)00226 5
   Abediazar S, 2011, TRANSPL P, V43, P565, DOI 10.1016/j.transproceed.2011.01.025
   ADACHI JD, 1993, SEMIN ARTHRITIS RHEU, V22, P375, DOI 10.1016/S0049 0172(05)80029 0
   ALMOND MK, 1994, NEPHRON, V66, P52, DOI 10.1159/000187765
   Arlen DJ, 2001, TRANSPLANTATION, V71, P669, DOI 10.1097/00007890 200103150 00017
   Babarykin D, 1999, Ann Transplant, V4, P46
   Ball AM, 2002, JAMA J AM MED ASSOC, V288, P3014, DOI 10.1001/jama.288.23.3014
   Bates DW, 2002, JAMA J AM MED ASSOC, V288, P1898, DOI 10.1001/jama.288.15.1898
   Bergmann P, 2009, INT J CLIN PRACT, V63, P19, DOI 10.1111/j.1742 1241.2008.01911.x
   Bergua C, 2008, TRANSPLANTATION, V86, P413, DOI 10.1097/TP.0b013e31817c13e1
   Bertoni E, 2006, TRANSPL P, V38, P1024, DOI 10.1016/j.transproceed.2006.03.059
   BONOMINI V, 1984, ADV EXP MED BIOL, V178, P207
   Borchhardt K, 2007, AM J TRANSPLANT, V7, P2515, DOI 10.1111/j.1600 6143.2007.01950.x
   Boudville NC, 2006, NEPHROL DIAL TRANSPL, V21, P2621, DOI 10.1093/ndt/gfl201
   Brandenburg VM, 2005, OSTEOPOROSIS INT, V16, P1611, DOI 10.1007/s00198 005 1884 6
   Brandenburg VM, 2004, TRANSPLANTATION, V77, P1566, DOI 10.1097/01.tp.0000131990.13277.28
   Brandenburg VM, 2004, J NEPHROL, V17, P190
   Braun J, 1996, AM J KIDNEY DIS, V27, P394, DOI 10.1016/S0272 6386(96)90363 7
   Caravaca F, 1998, NEPHROL DIAL TRANSPL, V13, P2605, DOI 10.1093/ndt/13.10.2605
   Carlini RG, 1998, NEPHROL DIAL TRANSPL, V13, P103, DOI 10.1093/ndt/13.suppl_3.103
   Cejka D, 2008, AM J TRANSPLANT, V8, P1864, DOI 10.1111/j.1600 6143.2008.02327.x
   Cho ME, 2010, TRANSPL P, V42, P3554, DOI 10.1016/j.transproceed.2010.06.027
   Coco M, 2003, J AM SOC NEPHROL, V14, P2669, DOI 10.1097/01.ASN.0000087092.53894.80
   Collaud S, 2008, WORLD J SURG, V32, P1795, DOI 10.1007/s00268 008 9495 y
   Conley E, 2008, TRANSPLANTATION, V86, P231, DOI 10.1097/TP.0b013e318176b40f
   Copley JB, 2010, TRANSPL P, V42, P2503, DOI 10.1016/j.transproceed.2010.04.052
   Copley JB, 2011, CLIN TRANSPLANT, V25, P24, DOI 10.1111/j.1399 0012.2010.01287.x
   Courbebaisse M, 2012, AM J NEPHROL, V35, P341, DOI 10.1159/000337526
   Cruz EAS, 2004, AM J KIDNEY DIS, V44, P747, DOI 10.1053/j.ajkd.2004.06.022
   Cueto Manzano AM, 1999, KIDNEY INT, V55, P2021, DOI 10.1046/j.1523 1755.1999.00445.x
   Cueto Manzano AM, 2000, AM J KIDNEY DIS, V35, P227, DOI 10.1016/S0272 6386(00)70331 3
   CUNDY T, 1983, Q J MED, V52, P67
   D'Angelo A, 2000, CLIN NEPHROL, V53, pB19
   DAVIDSON JK, 1985, CLIN RADIOL, V36, P27, DOI 10.1016/S0009 9260(85)80012 X
   Dolgos S, 2009, SCAND J CLIN LAB INV, V69, P161, DOI 10.1080/00365510802449634
   Drakopoulos S, 2009, AM J SURG, V198, P178, DOI 10.1016/j.amjsurg.2008.08.017
   Durieux S, 2002, TRANSPLANTATION, V74, P496, DOI 10.1097/00007890 200208270 00011
   Ebeling PR, 2009, J CLIN ENDOCR METAB, V94, P1483, DOI 10.1210/jc.2009 0205
   Eckardt KU, 2009, AM J TRANSPLANT, V9, pS1, DOI 10.1111/j.1600 6143.2009.02834.x
   Economidou D, 2009, J TRANSPLANT, V2009, DOI 10.1155/2009/379082
   Edwards BJ, 2011, J OSTEOPOROS, V2011, DOI 10.4061/2011/591793
   El Agroudy AE, 2005, KIDNEY INT, V67, P2039, DOI 10.1111/j.1523 1755.2005.00306.x
   El Amm JM, 2007, TRANSPLANTATION, V83, P546, DOI 10.1097/01.tp.0000253429.33198.2f
   El Husseini AA, 2004, AM J TRANSPLANT, V4, P2052, DOI 10.1111/j.1600 6143.2004.00618.x
   ELMSTEDT E, 1981, ACTA ORTHOP SCAND, V52, P279, DOI 10.3109/17453678109050104
   Esposito L, 2007, CLIN NEPHROL, V68, P245
   Evenepoel P, 2005, NEPHROL DIAL TRANSPL, V20, P1714, DOI 10.1093/ndt/gfh892
   Evenepoel P, 2009, AM J TRANSPLANT, V9, P2470, DOI 10.1111/j.1600 6143.2009.02792.x
   Evenepoel P, 2008, CLIN J AM SOC NEPHRO, V3, P1829, DOI 10.2215/CJN.01310308
   Evenepoel P, 2007, NEPHROL DIAL TRANSPL, V22, P1730, DOI 10.1093/ndt/gfm044
   Fan SLS, 2003, KIDNEY INT, V63, P2275, DOI 10.1046/j.1523 1755.2003.00012.x
   Fan SLS, 2000, KIDNEY INT, V57, P684, DOI 10.1046/j.1523 1755.2000.00890.x
   Goffin E, 2002, TRANSPL INT, V15, P73, DOI 10.1007/s00147 001 0377 6
   Marqués GG, 2009, TRANSPL P, V41, P2139, DOI 10.1016/j.transproceed.2009.06.090
   Govindarajan S, 2011, Indian J Nephrol, V21, P85, DOI 10.4103/0971 4065.82140
   Grotz W, 2001, J AM SOC NEPHROL, V12, P1530, DOI 10.1681/ASN.V1271530
   GROTZ WH, 1995, TRANSPLANTATION, V59, P982, DOI 10.1097/00007890 199504150 00010
   GROTZ WH, 1994, TRANSPLANTATION, V58, P912, DOI 10.1097/00007890 199410270 00009
   Gwinner W, 2005, AM J TRANSPLANT, V5, P1934, DOI 10.1111/j.1600 6143.2005.00938.x
   Haas M, 2003, KIDNEY INT, V63, P1130, DOI 10.1046/j.1523 1755.2003.00816.x
   Hazzan M, 2009, NEPHROL THER, V5, pS355, DOI 10.1016/S1769 7255(09)73425 X
   Huang M, 2009, SEMIN NEPHROL, V29, P166, DOI 10.1016/j.semnephrol.2009.01.009
   Ing SW, 2011, CLIN TRANSPLANT, V25, pE113, DOI 10.1111/j.1399 0012.2010.01344.x
   Isoniemi H, 2001, J HEPATOL, V34, P299, DOI 10.1016/S0168 8278(00)00067 2
   Jamal SA, 2011, J BONE MINER RES, V26, P1829, DOI 10.1002/jbmr.403
   Jeffery JR, 2003, TRANSPLANTATION, V76, P1498, DOI 10.1097/01.TP.0000092523.30277.13
   Josephson MA, 2004, TRANSPLANTATION, V78, P1233, DOI 10.1097/01.TP.0000137937.44703.42
   Júnior JWRB, 2006, BRAZ J MED BIOL RES, V39, P137, DOI 10.1590/S0100 879X2006000100016
   Kanaan N, 2010, CLIN J AM SOC NEPHRO, V5, P1887, DOI 10.2215/CJN.00950110
   Kandil E, 2010, AM J MED SCI, V339, P420, DOI 10.1097/MAJ.0b013e3181d8b6ff
   KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200
   Karras D, 2012, J RHEUMATOL, V39, P600, DOI 10.3899/jrheum.110947
   Kasiske BL, 2010, KIDNEY INT, V77, P299, DOI 10.1038/ki.2009.377
   Kerby JD, 1998, ANN SURG, V227, P878, DOI 10.1097/00000658 199806000 00011
   KHALEELI AA, 1983, CLIN ENDOCRINOL, V18, P155, DOI 10.1111/j.1365 2265.1983.tb03198.x
   Kneissel M, 2004, BONE, V35, P1144, DOI 10.1016/j.bone.2004.07.013
   Koc M, 2002, TRANSPLANT P, V34, P2111, DOI 10.1016/S0041 1345(02)02872 5
   Kodras K, 2006, EUR J CLIN INVEST, V36, P63, DOI 10.1111/j.1365 2362.2006.01662.x
   Kruse AE, 2005, NEPHROL DIAL TRANSPL, V20, P1311, DOI 10.1093/ndt/gfh924
   Kruse AE, 2007, NEPHROL DIAL TRANSPL, V22, P2362, DOI 10.1093/ndt/gfm270
   Leca N, 2006, AM J TRANSPLANT, V6, P2391, DOI 10.1111/j.1600 6143.2006.01475.x
   Lehmann G, 2007, TRANSPL P, V39, P3153, DOI 10.1016/j.transproceed.2007.10.001
   Leonard N, 2006, NEPHROL DIAL TRANSPL, V21, P1736, DOI 10.1093/ndt/gfk018
   Leung P, 2011, BONE, V49, P623, DOI 10.1016/j.bone.2011.06.014
   LOBO PI, 1995, CLIN TRANSPLANT, V9, P277
   London GM, 2004, J AM SOC NEPHROL, V15, P1943, DOI 10.1097/01.asn.0000129337.50739.48
   Maalouf NM, 2005, J CLIN ENDOCR METAB, V90, P2456, DOI 10.1210/jc.2004 1978
   Mahajan A, 2009, HEMODIAL INT, V13, P547, DOI 10.1111/j.1542 4758.2009.00380.x
   Mainra R, 2010, CLIN J AM SOC NEPHRO, V5, P117, DOI 10.2215/CJN.03770609
   Malluche HH, 2011, J BONE MINER RES, V26, P1368, DOI 10.1002/jbmr.309
   Marcén R, 2007, TRANSPL P, V39, P2256, DOI 10.1016/j.transproceed.2007.07.073
   Maréchal C, 2012, AM J KIDNEY DIS, V59, P258, DOI 10.1053/j.ajkd.2011.07.019
   Messa P, 1998, KIDNEY INT, V54, P1704, DOI 10.1046/j.1523 1755.1998.00142.x
   Mikuls TR, 2003, TRANSPLANTATION, V75, P49, DOI 10.1097/00007890 200301150 00009
   Miller PD, 2007, SEMIN DIALYSIS, V20, P186, DOI 10.1111/j.1525 139X.2007.00271.x
   Miller PD, 2011, BONE, V49, P77, DOI 10.1016/j.bone.2010.12.024
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   Moe Sharon M, 2002, Clin Calcium, V12, P1417
   Monier Faugere MC, 2000, J AM SOC NEPHROL, V11, P1093, DOI 10.1681/ASN.V1161093
   Kulak CAM, 2010, ARQ BRAS ENDOCRINOL, V54, P143, DOI 10.1590/S0004 27302010000200009
   Moreira RO, 2009, MED SCI MONITOR, V15, pBR65
   Moreno A, 1999, TRANSPLANT P, V31, P2322, DOI 10.1016/S0041 1345(99)00360 7
   MOVSOWITZ C, 1988, ENDOCRINOLOGY, V123, P2571, DOI 10.1210/endo 123 5 2571
   Nam JH, 2000, TRANSPLANT P, V32, P1877, DOI 10.1016/S0041 1345(00)01472 X
   Nam JH, 2000, TRANSPLANT P, V32, P1876, DOI 10.1016/S0041 1345(00)01898 4
   Nassar CA, 2009, TRANSPL P, V41, P1871, DOI 10.1016/j.transproceed.2008.11.009
   Nikkel LE, 2012, AM J TRANSPLANT, V12, P649, DOI 10.1111/j.1600 6143.2011.03872.x
   Nikkel LE, 2009, TRANSPLANTATION, V87, P1846, DOI 10.1097/TP.0b013e3181a6bbda
   Nisbeth U, 1999, TRANSPLANTATION, V67, P1218, DOI 10.1097/00007890 199905150 00004
   Nogueira EL, 2011, TRANSPLANTATION, V92, P316, DOI 10.1097/TP.0b013e3182247b98
   Nowacka Cieciura E, 2006, TRANSPL P, V38, P165, DOI 10.1016/j.transproceed.2005.12.041
   O'Herrin JK, 2002, AM J NEPHROL, V22, P515, DOI 10.1159/000065289
   O'Shaughnessy EA, 2002, TRANSPLANTATION, V74, P362, DOI 10.1097/00007890 200208150 00012
   Opelz G, 2011, TRANSPLANTATION, V91, P65, DOI 10.1097/TP.0b013e3181fa94d6
   Oschatz E, 2006, AM J KIDNEY DIS, V48, P307, DOI 10.1053/j.ajkd.2006.04.066
   Ozel L, 2011, TRANSPL P, V43, P858, DOI 10.1016/j.transproceed.2011.02.075
   Palmer S, 2007, COCHRANE DB SYST REV, V3
   Pande S, 2006, NEPHRON PHYSIOL, V104, P23, DOI 10.1159/000093277
   Papapoulos S, 2012, J BONE MINER RES, V27, P694, DOI 10.1002/jbmr.1479
   Parker CR, 1999, J BONE MINER RES, V14, P1943, DOI 10.1359/jbmr.1999.14.11.1943
   Patel S, 2001, J BONE MINER RES, V16, P1863, DOI 10.1359/jbmr.2001.16.10.1863
   Peng LW, 2007, AM J MED, V120, pE7, DOI 10.1016/j.amjmed.2005.09.041
   Pereira S, 2010, TRANSPL P, V42, P555, DOI 10.1016/j.transproceed.2010.01.046
   Pichette V, 1996, AM J KIDNEY DIS, V28, P105, DOI 10.1016/S0272 6386(96)90138 9
   Ramezani M, 2007, TRANSPL P, V39, P1033, DOI 10.1016/j.transproceed.2007.03.025
   Ramsey Goldman R, 1999, J BONE MINER RES, V14, P456, DOI 10.1359/jbmr.1999.14.3.456
   Riella LV, 2011, AM J KIDNEY DIS, V57, P641, DOI 10.1053/j.ajkd.2010.11.024
   Rojas E, 2003, KIDNEY INT, V63, P1915, DOI 10.1046/j.1523 1755.2003.00938.x
   Rostand SG, 2008, CLIN J AM SOC NEPHRO, V3, P1534, DOI 10.2215/CJN.01130308
   Sahin G, 2008, RENAL FAILURE, V30, P992, DOI 10.1080/08860220802406369
   Sakhaee K, 2010, PEDIATR NEPHROL, V25, P213, DOI 10.1007/s00467 009 1252 4
   SCHLOSBERG M, 1989, ENDOCRINOLOGY, V124, P2179, DOI 10.1210/endo 124 5 2179
   Seikrit C, 2011, NAT REV NEPHROL, V7, P237, DOI 10.1038/nrneph.2010.169
   Serra AL, 2005, NEPHROL DIAL TRANSPL, V20, P1315, DOI 10.1093/ndt/gfh925
   Serra AL, 2007, NEPHROL DIAL TRANSPL, V22, P577, DOI 10.1093/ndt/gfl560
   Serra AL, 2008, AM J KIDNEY DIS, V52, P1151, DOI 10.1053/j.ajkd.2008.08.012
   Smets YFC, 2004, KIDNEY INT, V66, P2070, DOI 10.1111/j.1523 1755.2004.00986.x
   Sprague SM, 2000, SEMIN DIALYSIS, V13, P152, DOI 10.1046/j.1525 139x.2000.00042.x
   Sprague SM, 2004, SEMIN NEPHROL, V24, P82, DOI 10.1053/j.semnephrol.2003.08.012
   Srinivas TR, 2006, CLIN J AM SOC NEPHRO, V1, P323, DOI 10.2215/CJN.00500705
   Stehman Breen CO, 2000, KIDNEY INT, V58, P2200, DOI 10.1111/j.1523 1755.2000.00394.x
   Stein E, 2007, ENDOCRIN METAB CLIN, V36, P937, DOI 10.1016/j.ecl.2007.07.008
   Stein EM, 2011, J CLIN ENDOCR METAB, V96, P3457, DOI 10.1210/jc.2011 1448
   STEINER RW, 1993, TRANSPLANTATION, V56, P843, DOI 10.1097/00007890 199310000 00013
   Stempfle HU, 1999, TRANSPLANTATION, V68, P523, DOI 10.1097/00007890 199908270 00014
   STEWART PJ, 1989, HORM METAB RES, V21, P194, DOI 10.1055/s 2007 1009189
   STEWART PJ, 1989, CALCIFIED TISSUE INT, V45, P222, DOI 10.1007/BF02556041
   STRAFFEN AM, 1994, ANN CLIN BIOCHEM, V31, P125, DOI 10.1177/000456329403100202
   Szwarc I, 2006, TRANSPLANTATION, V82, P675, DOI 10.1097/01.tp.0000232452.80018.ad
   Torregrosa JV, 2007, TRANSPL INT, V20, P708, DOI 10.1111/j.1432 2277.2007.00501.x
   Torres A, 2004, KIDNEY INT, V65, P705, DOI 10.1111/j.1523 1755.2004.00432.x
   Trombetti A, 2011, EUR J ENDOCRINOL, V164, P839, DOI 10.1530/EJE 10 1150
   Uhlig K, 2010, AM J KIDNEY DIS, V55, P773, DOI 10.1053/j.ajkd.2010.02.340
   Unal A, 2010, TRANSPL P, V42, P3550, DOI 10.1016/j.transproceed.2010.07.106
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   Vautour LM, 2004, OSTEOPOROSIS INT, V15, P160, DOI 10.1007/s00198 003 1532 y
   VelasquezForero F, 1996, NEPHROL DIAL TRANSPL, V11, P58
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Westenfeld R, 2011, NEPHROL DIAL TRANSPL, V26, P4115, DOI 10.1093/ndt/gfr214
   WILKINS GE, 1995, J CLIN ENDOCR METAB, V80, P1628, DOI 10.1210/jc.80.5.1628
   Wissing KM, 2005, TRANSPLANTATION, V79, P108, DOI 10.1097/01.TP.0000149322.70295.A5
NR 161
TC 61
Z9 70
U1 0
U2 17
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0272 6386
EI 1523 6838
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD FEB
PY 2013
VL 61
IS 2
BP 310
EP 325
DI 10.1053/j.ajkd.2012.07.022
PG 16
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 071KP
UT WOS:000313591800019
PM 23102732
DA 2025 08 17
ER

PT J
AU Yu, AXD
   Xu, ML
   Yao, P
   Kwan, KKL
   Liu, YX
   Duan, R
   Dong, TTX
   Ko, RKM
   Tsim, KWK
AF Yu, Anna Xiao Dan
   Xu, Miranda Li
   Yao, Ping
   Kwan, Kenneth Kin Leung
   Liu, Yong Xiang
   Duan, Ran
   Dong, Tina Ting Xia
   Ko, Robert Kam Ming
   Tsim, Karl Wah Keung
TI Corylin, a flavonoid derived from Psoralea Fructus, induces osteoblastic
   differentiation via estrogen and Wnt/β catenin signaling pathways
SO FASEB JOURNAL
LA English
DT Article
DE bioenergetics; estrogen signaling; micromass; natural product;
   osteoblast; Wnt; beta catenin signaling
ID TRANSCRIPTION FACTOR; MICROMASS CULTURES; ENERGY METABOLISM;
   BONE DEVELOPMENT; CELL LINE; OSTEOPROTEGERIN; EXPRESSION; WNT;
   INHIBITION; MECHANISM
AB Corylin is a naturally occurring flavonoid isolated from the fruit of Psoralea corylifolia L. (Fabaceae), which is a Chinese medicinal herb in treating osteoporosis. Although a variety of pharmacological activities of corylin have been reported, its osteogenic action and the underlying mechanism in bone development remain unclear. In the present study, the involvement of bone specific genes in corylininduced differentiated osteoblasts was analyzed by RT PCR, promoter reporter assay, and Western blotting. In cultured osteoblasts, corylin induced cell differentiation and mineralization, as well as increased the expressions of vital biological markers for osteogenesis, such as Runx2, Osterix, Col1, and ALP. Corylin was proposed to have dual pathways in triggering the osteoblastic differentiation. First, the osteogenic function of corylin acted through the activation of Wnt/beta catenin signaling. The nuclear translocation of beta catenin of cultured osteoblasts, as determined by flow cytometry and confocal microscopy, was triggered by applied corylin, and which was blocked by DKK 1, an inhibitor of Wnt/beta catenin signaling. Second, the application of corylin induced estrogenic response in a dose dependent manner, and which was blocked by ICI 182 780, an antagonist of estrogen receptor. Furthermore, the activation of Runx2 promoter by corylin was abolished by both DKK 1 and ICI 182,780, indicating that the corylin exhibited its osteogenic effect via estrogen and Wnt/beta catenin signaling pathways. In addition, corylin regulated the metabolic profiles, as well as the membrane potential of mitochondria, in cultured osteoblasts. Corylin also stimulated the osteogenesis in bone micromass derived from mesenchymal progenitor cells. This study demonstrated the osteogenic activities of corylin in osteoblasts and micromass, suggesting that corylin has the potential to be developed as a novel pro osteogenic agent in targeting for the treatment of osteoblast mediated osteoporosis.
C1 [Yu, Anna Xiao Dan; Xu, Miranda Li; Yao, Ping; Kwan, Kenneth Kin Leung; Duan, Ran; Dong, Tina Ting Xia; Tsim, Karl Wah Keung] HKUST Shenzhen Res Inst, Shenzhen Key Lab Edible & Med Bioresources, Shenzhen, Peoples R China.
   [Yu, Anna Xiao Dan; Xu, Miranda Li; Yao, Ping; Kwan, Kenneth Kin Leung; Liu, Yong Xiang; Duan, Ran; Dong, Tina Ting Xia; Ko, Robert Kam Ming; Tsim, Karl Wah Keung] Hong Kong Univ Sci & Technol, Div Life Sci, Hong Kong, Peoples R China.
   [Yu, Anna Xiao Dan; Xu, Miranda Li; Yao, Ping; Kwan, Kenneth Kin Leung; Liu, Yong Xiang; Duan, Ran; Dong, Tina Ting Xia; Ko, Robert Kam Ming; Tsim, Karl Wah Keung] Hong Kong Univ Sci & Technol, Ctr Chinese Med, Hong Kong, Peoples R China.
C3 Shenzhen Research Institute, The Hong Kong University of Science &
   Technology; Hong Kong University of Science & Technology; Hong Kong
   University of Science & Technology; Hong Kong University of Science &
   Technology
RP Tsim, KWK (通讯作者)，HKUST Shenzhen Res Inst, Shenzhen Key Lab Edible & Med Bioresources, Shenzhen, Peoples R China.
EM botsim@ust.hk
RI Liu, Yongxiang/N 7163 2014; li, yan/GXH 7943 2022; Duan,
   Ran/IAO 3140 2023; YU, Xiaodan/MYQ 5304 2025
FU Shenzhen Science and Technology Innovation Committee
   [JCYJ20170413173747440, ZDSYS201707281432317, JCYJ20180306174903174];
   China Postdoctoral Science Foundation [2019M653087]; Guangzhou Science
   and Technology Committee Research [GZSTI16SC02, GZSTI17SC02]; Hong Kong
   RGC Theme based Research Scheme [T13 607/12R]; Hong Kong Innovation
   Technology Fund [UIM/340, UIM/385, ITS/500/18FP, TCPD/17 9]; Dr. Lau Wah
   Sham Foundation [PD18SC01, HMRF18SC06]
FX Shenzhen Science and Technology Innovation Committee, Grant/Award
   Number: JCYJ20170413173747440, ZDSYS201707281432317 and
   JCYJ20180306174903174; China Postdoctoral Science Foundation,
   Grant/Award Number: 2019M653087; Guangzhou Science and Technology
   Committee Research, Grant/Award Number: GZSTI16SC02 and GZSTI17SC02;
   Hong Kong RGC Theme based Research Scheme, Grant/Award Number:
   T13 607/12R; Hong Kong Innovation Technology Fund, Grant/Award Number:
   UIM/340, UIM/385, ITS/500/18FP and TCPD/17 9; Dr. Lau Wah Sham
   Foundation, Grant/Award Number: PD18SC01 and HMRF18SC06
CR Almeida M, 2013, J GERONTOL A BIOL, V68, P1197, DOI 10.1093/gerona/glt079
   Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081
   Bagan J, 2016, ORAL DIS, V22, P324, DOI 10.1111/odi.12447
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bobick BE, 2009, BIRTH DEFECTS RES C, V87, P351, DOI 10.1002/bdrc.20167
   Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756 3282(02)00953 5
   Boyce BF, 2005, CELL METAB, V2, P344, DOI 10.1016/j.cmet.2005.11.011
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Chazotte Brad, 2011, Cold Spring Harb Protoc, V2011, DOI 10.1101/pdb.prot065490
   Cong Q, 2016, STEM CELL REP, V6, P566, DOI 10.1016/j.stemcr.2016.02.001
   Dai J, 2003, J BONE MINER RES, V18, pS312
   Daniels K, 1996, METHOD CELL BIOL, V51, P237, DOI 10.1016/S0091 679X(08)60631 7
   Drake MT, 2015, CLIN THER, V37, P1837, DOI 10.1016/j.clinthera.2015.06.006
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Eggerschwiler B, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1170 8
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   Foster LJ, 2005, STEM CELLS, V23, P1367, DOI 10.1634/stemcells.2004 0372
   Franceschi RT, 2003, CONNECT TISSUE RES, V44, P109, DOI 10.1080/03008200390152188
   Garnero P, 2014, BONE, V66, P46, DOI 10.1016/j.bone.2014.05.016
   Greco KV, 2011, BIOCHEM PHARMACOL, V82, P1919, DOI 10.1016/j.bcp.2011.09.009
   Guo JM, 2005, FOOD CHEM, V91, P287, DOI 10.1016/j.foodchem.2004.04.029
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367
   Hung YL, 2017, SCI REP UK, V7, DOI 10.1038/srep46299
   Karner CM, 2017, CELL MOL LIFE SCI, V74, P1649, DOI 10.1007/s00018 016 2425 5
   Komarova SV, 2000, AM J PHYSIOL CELL PH, V279, pC1220, DOI 10.1152/ajpcell.2000.279.4.C1220
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Latha PG, 2000, FITOTERAPIA, V71, P223, DOI 10.1016/S0367 326X(99)00151 3
   Lee SW, 2012, PLANTA MED, V78, P903, DOI 10.1055/s 0031 1298482
   Li ZQ, 2018, INT J MED SCI, V15, P1415, DOI 10.7150/ijms.26741
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   McGrath JC, 2015, BRIT J PHARMACOL, V172, P3189, DOI 10.1111/bph.12955
   Miyazaki T, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.385369
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Onal M, 2013, J BIOL CHEM, V288, P17432, DOI 10.1074/jbc.M112.444190
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Papachristou DJ, 2005, HISTOCHEM CELL BIOL, V124, P215, DOI 10.1007/s00418 005 0026 8
   Park D, 2011, NATURE, V477, P220, DOI 10.1038/nature10340
   RAMP WK, 1994, BONE MINER, V24, P59, DOI 10.1016/S0169 6009(08)80131 6
   Riddle RC, 2014, J CLIN INVEST, V124, P1465, DOI 10.1172/JCI75554
   Seo E, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/897296
   Seo E, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/678028
   Shen CY, 2017, BRIT J PHARMACOL, V174, P1395, DOI 10.1111/bph.13631
   Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Thangaraj G, 2016, CHEM BIOL INTERACT, V259, P313, DOI 10.1016/j.cbi.2016.03.027
   Ucer S, 2017, J BONE MINER RES, V32, P560, DOI 10.1002/jbmr.3014
   Wang DW, 2001, PLANTA MED, V67, P748, DOI 10.1055/s 2001 18343
   Wang YP, 2014, FRONT BIOSCI LANDMRK, V19, P379, DOI 10.2741/4214
   Xu ML, 2017, J BIOL CHEM, V292, P12667, DOI 10.1074/jbc.M117.777581
   Yao QQ, 2017, BONE, V97, P175, DOI 10.1016/j.bone.2017.01.028
   Zhang XN, 2016, AM J CHINESE MED, V44, P35, DOI 10.1142/S0192415X16500038
   Zou P, 2012, FOOD CHEM TOXICOL, V50, P2831, DOI 10.1016/j.fct.2012.05.009
NR 54
TC 49
Z9 54
U1 1
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD MAR
PY 2020
VL 34
IS 3
BP 4311
EP 4328
DI 10.1096/fj.201902319RRR
EA JAN 2020
PG 18
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA KT7UL
UT WOS:000508585300001
PM 31965654
DA 2025 08 17
ER

PT J
AU Tai, TW
   Su, FC
   Chen, CY
   Jou, IM
   Lin, CF
AF Tai, Ta Wei
   Su, Fong Chin
   Chen, Ching Yu
   Jou, I Ming
   Lin, Chiou Feng
TI Activation of p38 MAPK regulated Bcl xL signaling increases survival
   against zoledronic acid induced apoptosis in osteoclast precursors
SO BONE
LA English
DT Article
DE Zoledronic acid; p38 MAPK; beta Catenin; Bcl xL; Osteoclast precursor;
   Osteoporosis
ID BONE MINERAL DENSITY; PROTEIN KINASE INHIBITOR; MONTHLY ORAL
   IBANDRONATE; FRACTURE TRIAL PFT; POSTMENOPAUSAL OSTEOPOROSIS; IN VITRO;
   BISPHOSPHONATE THERAPY; CELL SURVIVAL; CANCER CELLS; RESISTANCE
AB The nitrogen containing bisphosphonate zoledronic acid (ZA) induces apoptosis in osteoclasts and inhibits osteoclast mediated bone resorption. It is widely used to treat osteoporosis. However, some patients are less responsive to ZA treatment, and the mechanisms of resistance are still unclear. Here, we identified that murine osteoclast precursors may develop resistance to ZA induced apoptosis. These resistant cells survived the apoptotic effect of ZA following an increase in anti apoptotic Bcl xL. Pharmacologically inhibiting Bcl xL facilitated ZA induced apoptosis. Treatment with ZA activated p38 MAPK, increasing Bcl xL expression and cell survival. Nuclear import of beta catenin regulated by p38 MAPK determined Bcl xL mRNA expression and cell survival in response to ZA. ZA also inactivated glycogen synthase kinase (GSK) 3 beta, a negative upstream regulator of beta catenin, in a p38 MAPK mediated manner. Synergistic pharmacological inhibition of p38 MAPK with ZA attenuated receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast differentiation and facilitated ZA induced apoptosis. These results demonstrate that elevated Bcl xL expression mediated by p38 MAPK regulated GSK 3 beta/beta catenin signaling is required for cell survival of ZA induced apoptosis in both osteoclast precursors and osteoclasts. Finally, we demonstrated that inhibiting p38 MAPK mediated pathway enhanced ZA effect on increasing the bone mineral density of ovariectomized mice. This result suggests that targeting these pathways may represent a potential therapeutic strategy. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Tai, Ta Wei; Su, Fong Chin] Natl Cheng Kung Univ, Inst Biomed Engn, Tainan 701, Taiwan.
   [Tai, Ta Wei; Chen, Ching Yu; Jou, I Ming] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Orthopaed, Tainan 701, Taiwan.
   [Tai, Ta Wei] Tainan Hosp, Hsinhua Branch, Dept Orthopaed, Tainan, Taiwan.
   [Lin, Chiou Feng] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan 701, Taiwan.
   [Lin, Chiou Feng] Taipei Med Univ, Coll Med, Dept Microbiol & Immunol, Taipei 110, Taiwan.
C3 National Cheng Kung University; National Cheng Kung University; National
   Cheng Kung University Hospital; National Cheng Kung University; Taipei
   Medical University
RP Jou, IM (通讯作者)，Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Orthopaed, Tainan 701, Taiwan.
EM jming@mail.ncku.edu.tw; cflin@mail.ncku.edu.tw
RI SU, FONG CHIN/C 8094 2011
OI SU, FONG CHIN/0000 0002 3870 4842
FU National Science Council, Taiwan [NSC 96 2320 B 006 018 MY3, NSC
   101 2314 B 006 009 MY3]
FX This work was supported by grants NSC 96 2320 B 006 018 MY3 and NSC
   101 2314 B 006 009 MY3 from the National Science Council, Taiwan. We
   thank the Immunobiology Core, Research Center of Clinical Medicine,
   National Cheng Kung University Hospital, for providing services
   including training, technical support, and assistance with experimental
   design and data analysis using Flow Cytometry Core facilities.
CR Abe K, 2012, INT J MOL MED, V29, P1007, DOI 10.3892/ijmm.2012.952
   Basso FG, 2013, GERONTOLOGY, V59, P534, DOI 10.1159/000351194
   Bellido T, 2011, BONE, V49, P50, DOI 10.1016/j.bone.2010.08.008
   Benford HL, 2001, BONE, V28, P465, DOI 10.1016/S8756 3282(01)00412 4
   Bikkavilli RK, 2008, J CELL SCI, V121, P3598, DOI 10.1242/jcs.032854
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 2012, J BONE MINER RES, V27, P243, DOI 10.1002/jbmr.1494
   Bonnick S, 2006, J CLIN ENDOCR METAB, V91, P2631, DOI 10.1210/jc.2005 2602
   Breuil V, 2006, JOINT BONE SPINE, V73, P349, DOI 10.1016/j.jbspin.2005.10.019
   Busca A, 2012, J BIOL CHEM, V287, P15118, DOI 10.1074/jbc.M111.312660
   Carey JJ, 2005, CLEV CLIN J MED, V72, P1033, DOI 10.3949/ccjm.72.11.1033
   Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Ding Y, 2008, NAT MED, V14, P162, DOI 10.1038/nm1707
   Faust D, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478 811X 10 6
   Graham JA, 2010, J BIOL CHEM, V285, P32852, DOI 10.1074/jbc.M110.150904
   Greiner S, 2007, J BIOMED MATER RES A, V80A, P769, DOI 10.1002/jbm.a.30950
   Hochberg MC, 1999, ARTHRITIS RHEUM US, V42, P1246, DOI 10.1002/1529 0131(199906)42:6<1246::AID ANR22>3.0.CO;2 U
   Hsing CH, 2012, ANESTHESIOLOGY, V116, P868, DOI 10.1097/ALN.0b013e31824af68a
   Jacques RM, 2012, J BONE MINER RES, V27, P1627, DOI 10.1002/jbmr.1644
   Kanis JA, 2002, LANCET, V359, P1929, DOI 10.1016/S0140 6736(02)08761 5
   Kars MD, 2007, ANTICANCER RES, V27, P4031
   Kremer KN, 2013, J BIOL CHEM, V288, P22899, DOI 10.1074/jbc.M113.449926
   Kubo T, 2008, CANCER CHEMOTH PHARM, V62, P111, DOI 10.1007/s00280 007 0580 y
   Kuroda J, 2006, P NATL ACAD SCI USA, V103, P14907, DOI 10.1073/pnas.0606176103
   Lelovas PP, 2008, COMPARATIVE MED, V58, P424
   Lewiecki EM, 2003, J CLIN DENSITOM, V6, P307, DOI 10.1385/JCD:6:4:307
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Mbalaviele G, 2006, J PHARMACOL EXP THER, V317, P1044, DOI 10.1124/jpet.105.100362
   Medicherla S, 2006, J PHARMACOL EXP THER, V318, P132, DOI 10.1124/jpet.105.098020
   Merrell MA, 2007, EUR J PHARMACOL, V570, P27, DOI 10.1016/j.ejphar.2007.05.075
   Miller PD, 2005, J BONE MINER RES, V20, P1315, DOI 10.1359/JBMR.050313
   Milone MR, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.165
   Morii T, 2010, ANTICANCER RES, V30, P3565
   Nieto E, 2007, INT J INTERN MED, P7
   Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579
   Ory B, 2008, J CELL MOL MED, V12, P928, DOI 10.1111/j.1582 4934.2008.00141.x
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2008, J BONE MINER RES, V23, P1712, DOI [10.1359/jbmr.080617, 10.1359/JBMR.080617]
   Rabenda V, 2009, EXPERT OPIN PHARMACO, V10, P2303, DOI 10.1517/14656560903140533
   Recker RR, 2008, J BONE MINER RES, V23, P6, DOI 10.1359/JBMR.070906
   Reginster JY, 2006, ANN RHEUM DIS, V65, P654, DOI 10.1136/ard.2005.044958
   Ritchlin C. T., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P276
   Sebba AI, 2004, CURR MED RES OPIN, V20, P2031, DOI 10.1185/030079904X16768
   Sebba AI, 2008, CLIN THER, V30, P443, DOI 10.1016/j.clinthera.2008.03.008
   Shimizu S, 2010, J HEPATOL, V52, P698, DOI 10.1016/j.jhep.2009.12.024
   Shortt J, 2012, COLD SPRING HARBOR P, P4
   Sutherland KA, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2681
   Thornton TM, 2008, SCIENCE, V320, P667, DOI 10.1126/science.1156037
   Trosset JY, 2006, PROTEINS, V64, P60, DOI 10.1002/prot.20955
   Tseng PC, 2012, IMMUNOBIOLOGY, V217, P926, DOI 10.1016/j.imbio.2012.01.001
   Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389 3403.2002
   Wang X, 2011, FREE RADICAL BIO MED, V51, P539, DOI 10.1016/j.freeradbiomed.2011.04.019
   Watts NB, 2004, J CLIN DENSITOM, V7, P255, DOI 10.1385/JCD:7:3:255
   Xie HM, 2005, J IMMUNOL, V175, P7981, DOI 10.4049/jimmunol.175.12.7981
   Yamashita T, 2008, BIOCHEM BIOPH RES CO, V365, P252, DOI 10.1016/j.bbrc.2007.10.169
   Zhang N, 2011, CANCER CELL, V20, P427, DOI 10.1016/j.ccr.2011.08.016
   Zhang Q, 2005, ARTHRITIS RHEUM US, V52, P2708, DOI 10.1002/art.21236
   Zwerina J, 2006, ARTHRITIS RHEUM US, V54, P463, DOI 10.1002/art.21626
NR 60
TC 34
Z9 38
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2014
VL 67
BP 166
EP 174
DI 10.1016/j.bone.2014.07.003
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AO3KJ
UT WOS:000341227800021
PM 25016096
DA 2025 08 17
ER

PT J
AU Abe, K
   Yoshimura, Y
   Deyama, Y
   Kikuiri, T
   Hasegawa, T
   Tei, K
   Shinoda, H
   Suzuki, K
   Kitagawa, Y
AF Abe, Keigo
   Yoshimura, Yoshitaka
   Deyama, Yoshiaki
   Kikuiri, Takashi
   Hasegawa, Tomokazu
   Tei, Kanchu
   Shinoda, Hisashi
   Suzuki, Kuniaki
   Kitagawa, Yoshimasa
TI Effects of bisphosphonates on osteoclastogenesis in RAW264.7 cells
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE non nitrogen containing bisphosphonates; nitrogen containing
   bisphosphonates; osteoclast
ID MECHANICAL STRESS; DIFFERENTIATION; OSTEONECROSIS; THERAPY; FUSION; JAWS
AB Bisphosphonates are used as therapeutic agents for the management of osteoporosis and other bone diseases. However, the precise effects and mechanisms of bisphosphonates on osteoclastogenesis are unclear, as previous studies have reported contradictory findings and no studies have circumstantially assessed the effects of bisphosphonates on osteoclastogenesis. Therefore, the aim of this study was to determine the effects of bisphosphonates on osteoclastogenesis in RAW264.7 (RAW) cells. To examine the direct effects of bisphosphonates on osteoclast differentiation via receptor activator of nuclear factor kappa B (RANK) ligand (RANKL), RAW cells were cultured with bisphosphonates. Addition of bisphosphonates to RAW cells led to a significant decrease in the number of osteoclasts and large osteoclasts (>= 8 nuclei) in a bisphosphonate concentration dependent and time dependent manner. The cytotoxicity of non nitrogen containing bisphosphonates was specific to osteoclasts, while nitrogen containing bisphosphonates were cytotoxic and induced cell death in both osteoclasts and RAW cells. Resorption activity was significantly diminished by treatment with bisphosphonates, thus confirming that bisphosphonates impair the absorptive activity of osteoclasts. We also investigated the effects of bisphosphonates on the mRNA expression of genes associated with osteoclastogenesis, osteoclast specific markers and apoptosis related genes using quantitative real time PCR. The results suggest that bisphosphonates suppress osteoclast differentiation and infusion, and induce osteoclast apoptosis. With regard to osteoclast apoptosis induced by bisphosphonates, we further investigated the detection of DNA fragmentation and Caspase Glo 3/7 assay. DNA fragmentation was confirmed after treatment with bisphosphonates, while caspase 3/7 activity increased significantly when compared with controls. In conclusion, bisphosphonates directly inhibited RANKL stimulated osteoclast differentiation and fusion in RAW cells. It was confirmed that bisphosphonates impair osteoclast resorption activity and induce apoptosis. The effects of non nitrogen containing bisphosphonates were also specific to osteoclasts, while nitrogen containing bisphosphonates were cytotoxic and induced cell death in both osteoclasts and RAW cells.
C1 [Abe, Keigo; Yoshimura, Yoshitaka; Deyama, Yoshiaki; Suzuki, Kuniaki] Hokkaido Univ, Grad Sch Dent Med, Dept Mol Cell Pharmacol, Kita Ku, Sapporo, Hokkaido 0608586, Japan.
   [Abe, Keigo; Kitagawa, Yoshimasa] Hokkaido Univ, Grad Sch Dent Med, Dept Oral Diag & Oral Med, Kita Ku, Sapporo, Hokkaido 0608586, Japan.
   [Kikuiri, Takashi] Hokkaido Univ, Grad Sch Dent Med, Dept Pediat Dent, Kita Ku, Sapporo, Hokkaido 0608586, Japan.
   [Tei, Kanchu] Hokkaido Univ, Grad Sch Dent Med, Dept Oral & Maxillofacial Surg, Kita Ku, Sapporo, Hokkaido 0608586, Japan.
   [Hasegawa, Tomokazu] Univ Tokushima, Fac Dent, Dept Pediat Dent, Tokushima 7708504, Japan.
   [Shinoda, Hisashi] Tohoku Univ, Grad Sch Dent, Dept Appl Pharmacol, Sendai, Miyagi 9808575, Japan.
C3 Hokkaido University; Hokkaido University; Hokkaido University; Hokkaido
   University; Tokushima University; Tohoku University
RP Yoshimura, Y (通讯作者)，Hokkaido Univ, Grad Sch Dent Med, Dept Mol Cell Pharmacol, Kita Ku, Kita 13,Nishi 7, Sapporo, Hokkaido 0608586, Japan.
EM yoshi@den.hokudai.ac.jp
RI Yoshimura, Yoshitaka/F 9754 2012; Deyama, Yoshiaki/F 9447 2012; 智一,
   長谷川/ISS 1615 2023; Kitagawa, Yoshimasa/F 6909 2012
FU Japanese Society for the Promotion of Science [22592274, 21592584,
   23592910]; Grants in Aid for Scientific Research [22592059, 22592274,
   21592511, 21592584, 22592296, 23592910] Funding Source: KAKEN
FX We are grateful to Dr K. Shibata for technical advice and support. This
   study was supported in part by the Japanese Society for the Promotion of
   Science; Grants: Grant in Aid for Scientific Research (C) 22592274 to
   Y.Y., 21592584 to T.K. and 23592910 to K.T.
CR Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Clarke NW, 2006, EUR UROL SUPPL, V5, P871, DOI 10.1016/j.eursup.2006.06.019
   Dannemann C, 2007, BONE, V40, P828, DOI 10.1016/j.bone.2006.11.023
   Ferrara S, 2009, CURRENT PERSPECTIVES, P5
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460 2075.1992.tb05481.x
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kimachi K, 2011, N S ARCH PHARMACOL, V383, P297, DOI 10.1007/s00210 010 0596 4
   Kitami S, 2010, BIOCHIMIE, V92, P398, DOI 10.1016/j.biochi.2009.12.011
   Kwak HB, 2009, BIOL PHARM BULL, V32, P1193, DOI 10.1248/bpb.32.1193
   Lolli ML, 2010, BIOORGAN MED CHEM, V18, P2428, DOI 10.1016/j.bmc.2010.02.058
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Reginster JY, 2007, DRUG AGING, V24, P351, DOI 10.2165/00002512 200724050 00001
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Santini D, 2003, ANN ONCOL, V14, P1468, DOI 10.1093/annonc/mdg401
   Seo SW, 2010, INT ORTHOP, V34, P599, DOI 10.1007/s00264 009 0748 7
   Shibata K, 2011, INT J MOL MED, V28, P73, DOI 10.3892/ijmm.2011.675
   Shinoda H, 2008, J PHARMACOL SCI, V106, P555, DOI 10.1254/jphs.FM0070272
   Suzuki N, 2008, INT J MOL MED, V21, P291
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Urade M, 2011, J ORAL MAXIL SURG, V69, pE364, DOI 10.1016/j.joms.2011.03.051
   Väänänen HK, 2008, ARCH BIOCHEM BIOPHYS, V473, P132, DOI 10.1016/j.abb.2008.03.037
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
NR 26
TC 34
Z9 42
U1 0
U2 27
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD JUN
PY 2012
VL 29
IS 6
BP 1007
EP 1015
DI 10.3892/ijmm.2012.952
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 939CW
UT WOS:000303785700006
PM 22447156
OA Bronze
DA 2025 08 17
ER

PT J
AU Lin, JG
   Peng, Y
   Liu, QZ
   Li, K
   Lv, GC
   Seimbille, Y
   Huang, G
   Gao, F
   Qiu, L
AF Lin, Jianguo
   Peng, Ying
   Liu, Qingzhu
   Li, Ke
   Lv, Gaochao
   Seimbille, Yann
   Huang, Gang
   Gao, Feng
   Qiu, Ling
TI Pharmacological evaluation of imidazole derived bisphosphonates on
   receptor activator of nuclear factor κB ligand induced osteoclast
   differentiation and function
SO CHEMICAL BIOLOGY & DRUG DESIGN
LA English
DT Article
DE bisphosphonate; mechanism; osteoclastogenesis; pharmacology; RANKL
ID INTRAVENOUS ZOLEDRONIC ACID; CYTOSOLIC CA2+; CATHEPSIN K; BONE; RANKL;
   OSTEONECROSIS; EXPRESSION; NFATC1; OSTEOPOROSIS; INHIBITION
AB Bisphosphonates (BPs) have been commonly used in the treatment of osteolytic bone lesions, such as osteoporosis and osteogenesis imperfecta. However, serious side effects can occur during the therapy. To search for novel potent BPs with lower side effects, a series of imidazole containing BPs (zoledronic acid [ZOL]; ZOL derivatives by substitution of the hydrogen at the 2 position on the imidazole ring with a methyl [MIDP], ethyl [EIDP],n propyl [PIDP], orn butyl group [BIDP]) were developed and the effects on receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast differentiation were investigated using the murine macrophage RAW 264.7 cells at the protein, gene, and morphological and functional levels. Influences of these BPs on the cell growth and proliferation of RAW 264.7 were also studied in order to determine cytotoxicity. The results showed that PIDP significantly inhibited the RANKL induced osteoclast formation in a dose dependent fashion without inducing cytotoxicity under the concentration of 12.5 mu M. It exerted remarkable suppressive effects on the development of actin rings, the bone resorption, and the expressions of osteoclastogenesis related gene and protein markers. The down regulation of c Jun N terminal kinase (JNK), protein kinase B (Akt), and inhibitor of nuclear factor kappa B (I kappa B) phosphorylation in the early signaling event and subsequent inhibition of the expression of c Fos and nuclear factor of activated T cells (NFATc1) might be involved in these effects. All these results indicated that PIDP might be a promising drug to treat bone related disorders.
C1 [Lin, Jianguo; Peng, Ying; Liu, Qingzhu; Li, Ke; Lv, Gaochao; Qiu, Ling] Jiangsu Inst Nucl Med, NHC Key Lab Nucl Med, Jiangsu Key Lab Mol Nucl Med, Wuxi, Jiangsu, Peoples R China.
   [Lin, Jianguo; Qiu, Ling] Nanjing Med Univ, Sch Pharm, Dept Radiopharmaceut, Nanjing, Peoples R China.
   [Seimbille, Yann] Erasmus MC, Dept Radiol & Nucl Med, Univ Med Ctr Rotterdam, Rotterdam, Netherlands.
   [Huang, Gang] Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Shanghai, Peoples R China.
   [Gao, Feng] Nanjing Univ, Jinling Hosp, Dept Med Imaging, Med Sch, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Erasmus University Rotterdam; Erasmus MC;
   Shanghai University of Medicine & Health Sciences; Nanjing University
RP Qiu, L (通讯作者)，Jiangsu Inst Nucl Med, NHC Key Lab Nucl Med, Jiangsu Key Lab Mol Nucl Med, Wuxi, Jiangsu, Peoples R China.; Huang, G (通讯作者)，Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Shanghai, Peoples R China.; Gao, F (通讯作者)，Nanjing Univ, Jinling Hosp, Dept Med Imaging, Med Sch, Nanjing, Jiangsu, Peoples R China.
EM huanggang@sumhs.edu.cn; rggaofeng@hotmail.com; qiuling@jsinm.org
OI Seimbille, Yann/0000 0002 9736 5318
FU National Natural Science Foundation of China [81803586]; Natural Science
   Foundation of Jiangsu Province [BK20181128]; 333 Project of Jiangsu
   Province [BRA2016518, LGY2018086]; Jiangsu Provincial Medical Youth
   Talent [QNRC2016626, QNRC2016629]; Innovation Capacity Development Plan
   of Jiangsu Province [BM2018023 5]; Jiangsu Provincial Key Medical
   Discipline [ZDXKA2016017]
FX This work was supported by the National Natural Science Foundation of
   China (81803586), the Natural Science Foundation of Jiangsu Province
   (BK20181128), the 333 Project of Jiangsu Province (BRA2016518,
   LGY2018086), the Jiangsu Provincial Medical Youth Talent (QNRC2016626,
   QNRC2016629), Innovation Capacity Development Plan of Jiangsu Province
   (BM2018023 5), and Jiangsu Provincial Key Medical Discipline
   (ZDXKA2016017).
CR Arai A, 2012, J CELL SCI, V125, P2910, DOI 10.1242/jcs.099986
   Baykan EK, 2014, OSTEOPOROSIS INT, V25, P2221, DOI 10.1007/s00198 014 2752 z
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Broadhead ML, 2011, EXPERT OPIN THER TAR, V15, P169, DOI 10.1517/14728222.2011.546351
   Chamoux E, 2010, J BIOL CHEM, V285, P25354, DOI 10.1074/jbc.M109.075234
   Chen CQ, 2009, NUCL SCI TECH, V20, P302
   Cheng BB, 2012, FOOD CHEM TOXICOL, V50, P1610, DOI 10.1016/j.fct.2012.02.019
   Costa AG, 2011, NAT REV RHEUMATOL, V7, P447, DOI 10.1038/nrrheum.2011.77
   Crotti TN, 2008, J CELL PHYSIOL, V215, P636, DOI 10.1002/jcp.21344
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Fujisaki K, 2007, LIFE SCI, V80, P1311, DOI 10.1016/j.lfs.2006.12.037
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   Gough A, 1998, J RHEUMATOL, V25, P1282
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Hoefert S, 2016, CLIN ORAL INVEST, V20, P1043, DOI 10.1007/s00784 015 1584 3
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Ikeda F, 2008, J BONE MINER RES, V23, P907, DOI 10.1359/JBMR.080211
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Jurdic P, 2006, EUR J CELL BIOL, V85, P195, DOI 10.1016/j.ejcb.2005.09.008
   Kang B, 2013, J BONE MINER RES, V28, P1631, DOI 10.1002/jbmr.1894
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Knowles HJ, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00080
   Komarova SV, 2005, P NATL ACAD SCI USA, V102, P2643, DOI 10.1073/pnas.0406874102
   Komarova SV, 2003, J BIOL CHEM, V278, P8286, DOI 10.1074/jbc.M206421200
   Kong XY, 2015, J TRANSL MED, V13, DOI 10.1186/s12967 015 0440 1
   Krzeszinski JY, 2015, TRENDS PHARMACOL SCI, V36, P360, DOI [10.1016/J.tips.2015.04.006, 10.1016/j.tips.2015.04.006]
   Kwak HB, 2009, BIOL PHARM BULL, V32, P1193, DOI 10.1248/bpb.32.1193
   Lee CYS, 2015, IMPLANT DENT, V24, P227, DOI 10.1097/ID.0000000000000227
   Liu QZ, 2020, EUR J MED CHEM, V186, DOI 10.1016/j.ejmech.2019.111905
   Luo S., 2005, CHINESE J NUCL MED, V25, P341, DOI [10.3760/cma.j.issn.2095 2848.2005.06.006, DOI 10.3760/CMA.J.ISSN.2095 2848.2005.06.006]
   Lavado FM, 2017, J CLIN NEUROSCI, V44, P243, DOI 10.1016/j.jocn.2017.06.048
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Nakagawa T, 2015, ARCH ORAL BIOL, V60, P557, DOI 10.1016/j.archoralbio.2014.09.012
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Niu Guosai, 2008, Nuclear Techniques, V31, P698
   Odkhuu E, 2012, IMMUNOL LETT, V142, P34, DOI 10.1016/j.imlet.2011.12.001
   Pazianas M, 2011, JNCI J NATL CANCER I, V103, P232, DOI 10.1093/jnci/djq516
   Polascik TJ, 2008, DRUG DES DEV THER, V3, P27
   Qiu L, 2014, AUST J CHEM, V67, P192, DOI 10.1071/CH13194
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Ruza I, 2013, THER ADV MUSCULOSKEL, V5, P182, DOI 10.1177/1759720X13485829
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   Soysa NS, 2016, BIOCHEM BIOPH RES CO, V476, P115, DOI 10.1016/j.bbrc.2016.05.019
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tao HR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023199
   Teitelbaum SL, 2011, ANN NY ACAD SCI, V1240, P14, DOI 10.1111/j.1749 6632.2011.06283.x
   van Beek ER, 1998, BONE, V23, P437, DOI 10.1016/S8756 3282(98)00120 3
   Wagner EF, 2001, CURR OPIN GENET DEV, V11, P527, DOI 10.1016/S0959 437X(00)00228 8
   Wang Y., 2010, J JIANGNAN U, V9, P592
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i
   Xu XJ, 2017, J HUM GENET, V62, P205, DOI 10.1038/jhg.2016.109
   Yamanaka Y, 2013, J ORTHOP RES, V31, P67, DOI 10.1002/jor.22200
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
   Ziebart Thomas, 2016, Dent J (Basel), V4, DOI 10.3390/dj4040036
NR 55
TC 3
Z9 4
U1 0
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1747 0277
EI 1747 0285
J9 CHEM BIOL DRUG DES
JI Chem. Biol. Drug Des.
PD JAN
PY 2021
VL 97
IS 1
BP 121
EP 133
DI 10.1111/cbdd.13767
EA AUG 2020
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA PK7XJ
UT WOS:000555869000001
PM 32735740
DA 2025 08 17
ER

PT J
AU Deshmukh, V
   Hu, H
   Barroga, C
   Bossard, C
   Kc, S
   Dellamary, L
   Stewart, J
   Chiu, K
   Ibanez, M
   Pedraza, M
   Seo, T
   Do, L
   Cho, S
   Cahiwat, J
   Tam, B
   Tambiah, JRS
   Hood, J
   Lane, NE
   Yazici, Y
AF Deshmukh, V.
   Hu, H.
   Barroga, C.
   Bossard, C.
   Kc, S.
   Dellamary, L.
   Stewart, J.
   Chiu, K.
   Ibanez, M.
   Pedraza, M.
   Seo, T.
   Do, L.
   Cho, S.
   Cahiwat, J.
   Tam, B.
   Tambiah, J. R. S.
   Hood, J.
   Lane, N. E.
   Yazici, Y.
TI A small molecule inhibitor of the Wnt pathway (SM04690) as a potential
   disease modifying agent for the treatment of osteoarthritis of the knee
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE Osteoarthritis; Wnt signaling; Chondrocyte; ACLT; DMOAD; Small molecule
ID MESENCHYMAL STEM CELLS; SYNOVIAL FLUID INCREASE; CHONDROCYTE
   DIFFERENTIATION; ARTICULAR CARTILAGE; CHONDROGENESIS; EXPRESSION;
   PROTEIN; HISTOPATHOLOGY; OSTEOBLAST; MANAGEMENT
AB Objectives: Osteoarthritis (OA) is a degenerative disease characterized by loss of cartilage and increased subchondral bone within synovial joints. Wnt signaling affects the pathogenesis of OA as this pathway modulates both the differentiation of osteoblasts and chondrocytes, and production of catabolic proteases. A novel small molecule Wnt pathway inhibitor, SM04690, was evaluated in a series of in vitro and in vivo animal studies to determine its effects on chondrogenesis, cartilage protection and synovial lined joint pathology.
   Design: A high throughput screen was performed using a cell based reporter assay for Wnt pathway activity to develop a small molecule designated SM04690. Its properties were evaluated in bone marrow derived human mesenchymal stem cells (hMSCs) to assess chondrocyte differentiation and effects on cartilage catabolism by immunocytochemistry and gene expression, and glycosaminoglycan breakdown. In vivo effects of SM04690 on Wnt signaling, cartilage regeneration and protection were measured using biochemical and histopathological techniques in a rodent acute cruciate ligament tear and partial medial meniscectomy (ACLT thorn pMMx) OA model.
   Results: SM04690 induced hMSC differentiation into mature, functional chondrocytes and decreased cartilage catabolic marker levels compared to vehicle. A single SM04690 intra articular (IA) injection was efficacious in a rodent OA model, with increased cartilage thickness, evidence for cartilage regeneration, and protection from cartilage catabolism observed, resulting in significantly improved Osteoarthritis Research Society International (OARSI) histology scores and biomarkers, compared to vehicle.
   Conclusions: SM04690 induced chondrogenesis and appeared to inhibit joint destruction in a rat OA model, and is a candidate for a potential disease modifying therapy for OA. (c) 2017 The Author(s). Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
C1 [Deshmukh, V.; Hu, H.; Barroga, C.; Bossard, C.; Kc, S.; Dellamary, L.; Stewart, J.; Chiu, K.; Ibanez, M.; Pedraza, M.; Seo, T.; Do, L.; Cho, S.; Cahiwat, J.; Tam, B.; Tambiah, J. R. S.; Hood, J.; Yazici, Y.] Samumed LLC, 9381 Judicial Dr,Suite 160, San Diego, CA 92121 USA.
   [Lane, N. E.] Univ Calif Davis, Davis, CA 95616 USA.
C3 University of California System; University of California Davis
RP Yazici, Y (通讯作者)，Samumed LLC, 9381 Judicial Dr,Suite 160, San Diego, CA 92121 USA.
EM vishal@samumed.com; huyong21@gmail.com; charlene@samumed.com;
   carine@samumed.com; sunil@samumed.com; luis@samumed.com;
   josh@samumed.com; kevin@samumed.com; maureen@samumed.com;
   melinda@samumed.com; tim@samumed.com; long@samumed.com;
   shawn@samumed.com; joec@samumed.com; betty@samumed.com;
   jeymi@samumed.com; john@impactbiosciences.com; nelane@ucdavis.edu;
   yusuf@samumed.com
RI ; Tambiah, Jeyanesh/KDN 7427 2024
OI Do, Long/0000 0003 0911 1463; Tambiah, Jeyanesh/0000 0003 1451 1584
FU Samumed LLC
FX Financial support for this study and its publication was provided by
   Samumed LLC.
CR Åberg T, 2005, J HISTOCHEM CYTOCHEM, V53, P653, DOI 10.1369/jhc.4A6518.2005
   Altaf FM, 2006, EUR CELLS MATER, V12, P64, DOI 10.22203/eCM.v012a08
   Baker Lepain Julie C, 2012, Arthritis Rheum, V64, P1457, DOI 10.1002/art.34526
   Calich ALG, 2010, CLIN RHEUMATOL, V29, P451, DOI 10.1007/s10067 009 1352 3
   Chen BA, 2010, EXP MOL MED, V42, P684, DOI 10.3858/emm.2010.42.10.067
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012
   Dahlin RL, 2014, BIOMATERIALS, V35, P123, DOI 10.1016/j.biomaterials.2013.09.086
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Ge XP, 2009, ARTHRITIS RHEUM US, V60, P2714, DOI 10.1002/art.24779
   Glasson SS, 2010, OSTEOARTHR CARTILAGE, V18, pS17, DOI 10.1016/j.joca.2010.05.025
   Gonsalves FC, 2011, P NATL ACAD SCI USA, V108, P5954, DOI 10.1073/pnas.1017496108
   Hamilton CB, 2015, OSTEOARTHR CARTILAGE, V23, P1178, DOI 10.1016/j.joca.2015.03.001
   Handeli S, 2008, MOL CANCER THER, V7, P521, DOI 10.1158/1535 7163.MCT 07 2063
   Hayami T, 2006, BONE, V38, P234, DOI 10.1016/j.bone.2005.08.007
   HOWELL DS, 1986, AM J MED, V80, P24, DOI 10.1016/0002 9343(86)90075 6
   Johnson K, 2012, SCIENCE, V336, P717, DOI 10.1126/science.1215157
   Jones EA, 2008, ARTHRITIS RHEUM US, V58, P1731, DOI 10.1002/art.23485
   Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233
   Katz JN, 2010, ARTHRIT CARE RES, V62, P1220, DOI 10.1002/acr.20231
   Kim J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074342
   Lane NE, 2006, ARTHRITIS RHEUM US, V54, P1246, DOI 10.1002/art.21673
   Lawrence RC, 2008, ARTHRITIS RHEUM, V58, P26, DOI 10.1002/art.23176
   Leung VYL, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002356
   Li NG, 2011, CURR MED CHEM, V18, P977, DOI 10.2174/092986711794940905
   Matsukura Y, 2014, CLIN ORTHOP RELAT R, V472, P1357, DOI 10.1007/s11999 013 3418 4
   McAlindon TE, 2014, OSTEOARTHR CARTILAGE, V22, P363, DOI 10.1016/j.joca.2014.01.003
   Minami I, 2012, CELL REP, V2, P1448, DOI 10.1016/j.celrep.2012.09.015
   Murphy G, 2002, ARTHRITIS RES THER, V4, DOI 10.1186/ar572
   Pastoureau P, 2003, OSTEOARTHR CARTILAGE, V11, P412, DOI 10.1016/S1063 4584(03)00050 5
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Pritzker KPH, 2006, OSTEOARTHR CARTILAGE, V14, P13, DOI 10.1016/j.joca.2005.07.014
   Rousseau JC, 2004, OSTEOARTHR CARTILAGE, V12, P440, DOI 10.1016/j.joca.2004.02.004
   Sekiya I, 2012, J ORTHOP RES, V30, P943, DOI 10.1002/jor.22029
   Shu B, 2011, J CELL SCI, V124, P3428, DOI 10.1242/jcs.083659
   Stanton LA, 2003, DEV BIOL, V263, P165, DOI 10.1016/S0012 1606(03)00321 X
   Verma P, 2013, J ORTHOP RES, V31, P999, DOI 10.1002/jor.22324
   Voronkov A, 2013, CURR PHARM DESIGN, V19, P634, DOI 10.2174/138161213804581837
   Woods A, 2006, J BIOL CHEM, V281, P13134, DOI 10.1074/jbc.M509433200
   Wyles CC, 2015, STEM CELLS CLONING, V8, P117, DOI 10.2147/SCCAA.S68073
   Yang J, 2006, J BIOL CHEM, V281, P17751, DOI 10.1074/jbc.M600831200
   Yazici Y, 2017, OSTEOARTHR CARTILAGE, V25, P1598, DOI 10.1016/j.joca.2017.07.006
   Yoon HJ, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0599 x
   Zanotti S, 2012, J CELL BIOCHEM, V113, P449, DOI 10.1002/jcb.23365
   Zhang Y, 2007, BIOCHEM BIOPH RES CO, V363, P694, DOI 10.1016/j.bbrc.2007.09.030
   Zheng QP, 2003, J CELL BIOL, V162, P833, DOI 10.1083/jcb.200211089
NR 47
TC 177
Z9 207
U1 4
U2 76
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1063 4584
EI 1522 9653
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD JAN
PY 2018
VL 26
IS 1
BP 18
EP 27
DI 10.1016/j.joca.2017.08.015
PG 10
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA FU6MA
UT WOS:000423965500004
PM 28888902
OA hybrid
DA 2025 08 17
ER

PT J
AU Kedlaya, R
   Veera, S
   Horan, DJ
   Moss, RE
   Ayturk, UM
   Jacobsen, CM
   Bowen, ME
   Paszty, C
   Warman, ML
   Robling, AG
AF Kedlaya, Rajendra
   Veera, Shreya
   Horan, Daniel J.
   Moss, Rachel E.
   Ayturk, Ugur M.
   Jacobsen, Christina M.
   Bowen, Margot E.
   Paszty, Chris
   Warman, Matthew L.
   Robling, Alexander G.
TI Sclerostin Inhibition Reverses Skeletal Fragility in an Lrp5 Deficient
   Mouse Model of OPPG Syndrome
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID OSTEOPOROSIS PSEUDOGLIOMA SYNDROME; HIGH BONE MASS; MINERAL DENSITY;
   MICE DEFICIENT; LRP5 MUTATIONS; WNT; RECEPTOR; GENE; RESORPTION; BINDING
AB Osteoporosis pseudoglioma syndrome (OPPG) is a rare genetic disease that produces debilitating effects in the skeleton. OPPG is caused by mutations in LRP5, a WNT co receptor that mediates osteoblast activity. WNT signaling through LRP5, and also through the closely related receptor LRP6, is inhibited by the protein sclerostin (SOST). It is unclear whether OPPG patients might benefit from the anabolic action of sclerostin neutralization therapy (an approach currently being pursued in clinical trials for postmenopausal osteoporosis) in light of their LRP5 deficiency and consequent osteoblast impairment. To assess whether loss of sclerostin is anabolic in OPPG, we measured bone properties in a mouse model of OPPG (Lrp5( / )), a mouse model of sclerosteosis (Sost( / )), and in mice with both genes knocked out (Lrp5( / ); Sost( / )). Lrp5( / ); Sost( / ) mice have larger, denser, and stronger bones than do Lrp5( / ) mice, indicating that SOST deficiency can improve bone properties via pathways that do not require LRP5. Next, we determined whether the anabolic effects of sclerostin depletion in Lrp5( / ) mice are retained in adult mice by treating 17 week old Lrp5( / ) mice with a sclerostin antibody for 3 weeks. Lrp5(+/+) and Lrp5( / ) mice each exhibited osteoanabolic responses to antibody therapy, as indicated by increased bone mineral density, content, and formation rates. Collectively, our data show that inhibiting sclerostin can improve bone mass whether LRP5 is present or not. In the absence of LRP5, the anabolic effects of SOST depletion can occur via other receptors (such as LRP4/6). Regardless of the mechanism, our results suggest that humans with OPPG might benefit from sclerostin neutralization therapies.
C1 [Kedlaya, Rajendra; Veera, Shreya; Horan, Daniel J.; Moss, Rachel E.; Robling, Alexander G.] Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
   [Horan, Daniel J.; Robling, Alexander G.] Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA.
   [Ayturk, Ugur M.; Jacobsen, Christina M.; Bowen, Margot E.; Warman, Matthew L.] Boston Childrens Hosp, Dept Orthopaed Surg, Orthopaed Res Labs, Boston, MA 02115 USA.
   [Paszty, Chris] Amgen Inc, Dept Metab Disorders, Thousand Oaks, CA 91320 USA.
   [Warman, Matthew L.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
   [Warman, Matthew L.] Boston Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA.
   [Robling, Alexander G.] Purdue Univ, Indiana Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Indianapolis; US
   Department of Veterans Affairs; Veterans Health Administration (VHA);
   Richard L. Roudebush VA Medical Center; Harvard University; Harvard
   University Medical Affiliates; Boston Children's Hospital; Amgen;
   Harvard University; Harvard Medical School; Harvard University; Harvard
   University Medical Affiliates; Boston Children's Hospital; Howard Hughes
   Medical Institute; Purdue University System; Purdue University; Purdue
   University in Indianapolis
RP Robling, AG (通讯作者)，Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
EM arobling@iupui.edu
OI Moss, Rachel/0000 0002 2775 0309; Bowen, Margot/0000 0001 6391 5775
FU NIH [AR53237, AR62326]; Veterans Affairs grant [BX001478]; Howard Hughes
   Medical Institute; Osteogenesis Imperfecta Foundation
FX Funding: This work was supported by NIH grant AR53237 and Veterans
   Affairs grant BX001478 (to A. G. R.), NIH grant AR62326 and the Howard
   Hughes Medical Institute (to M. L. W.), and the Osteogenesis Imperfecta
   Foundation (to C.M.J.).
CR Arantes HP, 2011, J BONE MINER RES, V26, P2823, DOI 10.1002/jbmr.530
   Ayturk UM, 2013, J BONE MINER RES, V28, P2081, DOI 10.1002/jbmr.1946
   Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960
   Balemans W, 2008, CALCIFIED TISSUE INT, V82, P445, DOI 10.1007/s00223 008 9130 9
   Bayram F, 2006, J PEDIATR ENDOCR MET, V19, P275
   Becker David J, 2010, Curr Rheumatol Rep, V12, P186, DOI 10.1007/s11926 010 0097 y
   Bourhis E, 2011, STRUCTURE, V19, P1433, DOI 10.1016/j.str.2011.07.005
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Chang MK, 2014, J BONE MINER RES, V29, P29, DOI 10.1002/jbmr.2059
   Choi HY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007930
   Craig TA, 2010, BIOCHEM BIOPH RES CO, V402, P421, DOI 10.1016/j.bbrc.2010.10.048
   Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388
   Devarajan Ketha H, 2012, BIOCHEM BIOPH RES CO, V417, P830, DOI 10.1016/j.bbrc.2011.12.048
   Ellies DL, 2006, J BONE MINER RES, V21, P1738, DOI 10.1359/JBMR.060810
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Holdsworth G, 2012, J BIOL CHEM, V287, P26464, DOI 10.1074/jbc.M112.350108
   Holmen SL, 2004, J BONE MINER RES, V19, P2033, DOI 10.1359/JBMR.040907
   Iwaniec UT, 2007, J BONE MINER RES, V22, P394, DOI 10.1359/JBMR.061118
   Joeng KS, 2011, DEV BIOL, V359, P222, DOI 10.1016/j.ydbio.2011.08.020
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Kubota T, 2008, J BONE MINER RES, V23, P1661, DOI 10.1359/JBMR.080512
   Laine CM, 2011, EUR J HUM GENET, V19, P875, DOI 10.1038/ejhg.2011.42
   Leupin O, 2011, J BIOL CHEM, V286, P19489, DOI 10.1074/jbc.M110.190330
   Lev D, 2003, ISRAEL MED ASSOC J, V5, P419
   Li X., 2012, J BONE MINER RES S1, V27
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   MacDonald BT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023537
   McClung M. R., 2012, J BONE MINER RES S1, V27
   Niziolek PJ, 2011, BONE, V49, P1010, DOI 10.1016/j.bone.2011.07.034
   Ominsky MS, 2011, J BONE MINER RES, V26, P1012, DOI 10.1002/jbmr.307
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Robbins J, 2007, JAMA J AM MED ASSOC, V298, P2389, DOI 10.1001/jama.298.20.2389
   Robling AG, 2011, ENDOCRINOLOGY, V152, P2963, DOI 10.1210/en.2011 0049
   Saarinen A, 2010, CLIN ENDOCRINOL, V72, P481, DOI 10.1111/j.1365 2265.2009.03680.x
   Sawakami K, 2006, J BIOL CHEM, V281, P23698, DOI 10.1074/jbc.M601000200
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Semenov MV, 2006, J BIOL CHEM, V281, P38276, DOI 10.1074/jbc.M609509200
   Shahnazari M, 2012, CALCIFIED TISSUE INT, V91, P50, DOI 10.1007/s00223 012 9610 9
   Spatz JM, 2013, J BONE MINER RES, V28, P865, DOI 10.1002/jbmr.1807
   Streeten EA, 2008, BONE, V43, P584, DOI 10.1016/j.bone.2008.04.020
   Tian XY, 2011, BONE, V48, P197, DOI 10.1016/j.bone.2010.09.009
   Tian XY, 2010, BONE, V47, P529, DOI 10.1016/j.bone.2010.05.032
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   Tüysüz B, 2012, HORM RES PAEDIAT, V77, P115, DOI 10.1159/000336193
   van Lierop AH, 2013, J BONE MINER RES, V28, P848, DOI 10.1002/jbmr.1794
   Winkler DG, 2004, J BIOL CHEM, V279, P36293, DOI 10.1074/jbc.M400521200
   Winkler DG, 2005, J BIOL CHEM, V280, P2498, DOI 10.1074/jbc.M400524200
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
NR 51
TC 63
Z9 69
U1 0
U2 14
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946 6234
EI 1946 6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD NOV 13
PY 2013
VL 5
IS 211
AR 211ra158
DI 10.1126/scitranslmed.3006627
PG 10
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 252NN
UT WOS:000327012900005
PM 24225945
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Li, JC
   Liang, XZ
   Luo, D
   Yan, BZ
   Liu, JB
   Li, G
AF Li, Jia Cheng
   Liang, Xue Zhen
   Luo, Di
   Yan, Bo Zhao
   Liu, Jin Bao
   Li, Gang
TI Study on the molecular mechanism of BuShenHuoXue capsule in treatment of
   steroid induced osteonecrosis of the femoral head
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE BuShenHuoXue capsule (BSHXC); steroid induced osteonecrosis of the
   femoral head (SONFH); bioinformatics; molecular mechanisms of
   pharmacological action
ID GENE; PATHWAY
AB Background: Steroid induced osteonecrosis of the femoral head (SONFH) is the pathological process caused by the death of the active components of the head of the femur due to the high dose of hormones, which has become a common public health problem. BuShenHuoXue capsule (BSHXC) has been clinically proven to be effective against the SONFH, the main pharmacological action of BSHXC is tonifying kidney and promoting blood circulation, but the mechanism remains to be explored.
   Methods: We established a rat SONFH model by injecting Methylprednisolone (MPS) into the right gluteus muscle 30 mg/kg/d, 3 days of continuous injection every week, 4 weeks in total. According to the clinical dosage of BSHXC (Herba epimedium 3 g, Eucommia ulmoides 15 g, Salvia miltiorrhizae 30 g, Chuanxiong 15 g, Paeonia lactiflora Pall 15 g, Poria cocos 12 g, Achyranthes bidentata 12 g, antler gum 10 g, Cyperus rotundus L. Nine g and Radix Glycyrrhizae 9 g), it was converted into the equivalent dose of rats, and gavage was performed at the weight of 10 mL/kg, once per day. The BSHXC was subjected to experiments in vivo, SONFH pharmacodynamics, bioinformatics, and network of pharmacology to determine the active ingredients, and its protective role against SONFH, Enrichment analysis was performed to explore the possible mechanism of BSHXC, and cell experiments were undertaken to analyze the impact of BSHXC on the hormones associated with bone marrow mesenchymal stem cells (BMSCs) between osteogenesis and apoptosis.
   Results: Experiments confirmed that BSHXC could effectively reduce bone loss in SONFH rat models. From bioinformatics and a network constructed from 10 drugs 208 pharmacology 126 targets, the enrichment analysis showed that the core targets were inflammatory reaction, steroid hormones, estrogen receptors, osteoporosis, and adjustment of osteogenesis and osteoclast differentiation, among others. The cell proliferation and staining supported that the mechanism of BSHXC promoted osteogenesis and intervening in apoptosis.
   Conclusions: The BSHXC reduced the inflammatory response, changed steroid response, regulated estrogen receptors, delayed osteoporosis, regulated osteoblast and osteoclast differentiation by regulating related targets, and improved the local microenvironment by a multi component, multi target, and multilink process to delay or reverse the progression of SONFH.
C1 [Li, Jia Cheng; Liang, Xue Zhen; Yan, Bo Zhao; Liu, Jin Bao; Li, Gang] Shandong Univ Tradit Chinese Med, Clin Med Sch 1, Jinan, Peoples R China.
   [Luo, Di; Li, Gang] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Dept Orthoped, Jinan, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Shandong University
   of Traditional Chinese Medicine
RP Li, G (通讯作者)，Shandong Univ Tradit Chinese Med, Affiliated Hosp, 16369 Jingshi Rd, Jinan, Peoples R China.
EM sdszylg@163.com
RI tong, tongwei/HPH 7206 2023; LIANG, Xuezhen/HGA 4207 2022
FU National Natural Science Foundation of China [81774333]
FX This work was supported by a grant from the National Natural Science
   Foundation of China (81774333). Support from this grant contributed to
   the development of the study design, the collection, analysis and
   interpretation of data, writing of the report, and the decision to
   submit the article for publication.
CR Adapala NS, 2016, AM J PATHOL, V186, P2987, DOI 10.1016/j.ajpath.2016.06.024
   Altermann E, 2005, BMC GENOMICS, V6, DOI 10.1186/1471 2164 6 60
   Arai R, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 016 1379 y
   Cao F, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/1624074
   Chang C, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2020.102460
   Guo SG, 2016, BIOCHEM BIOPH RES CO, V471, P545, DOI 10.1016/j.bbrc.2016.02.036
   Jiang Y, 2014, J TRADITIONAL CHINES, P342
   Jin TB, 2019, MOL GENET GENOM MED, V7, DOI 10.1002/mgg3.563
   Kang PD, 2015, J MATER SCI MATER M, V26, DOI 10.1007/s10856 015 5402 x
   Li J, 2015, EXP BIOL MED, V240, P273, DOI 10.1177/1535370214553906
   Li JF, 2014, CONNECT TISSUE RES, V55, P322, DOI 10.3109/03008207.2014.941106
   Liu Hua, 2007, Zhongguo Shengwu Huaxue yu Fenzi Shengwu Xuebao, V23, P236
   Mont MA, 2004, J BONE JOINT SURG AM, V86A, P41, DOI 10.2106/00004623 200412002 00008
   Nozaki Y, 2012, ACTA ORTHOP, V83, P87, DOI 10.3109/17453674.2011.641103
   PIETROGRANDE V, 1953, Reumatismo, V5, P219
   Tao SC, 2017, THERANOSTICS, V7, P733, DOI 10.7150/thno.17450
   Tian L, 2014, J HUAZHONG U SCI MED, V34, P679, DOI 10.1007/s11596 014 1336 7
   Ulu MA, 2014, CHINESE MED J PEKING, V127, P2740, DOI 10.3760/cma.j.issn.0366 6999.20140367
   Wang Y, 2019, J BIOMED MATER RES B, V107, P149, DOI 10.1002/jbm.b.34105
   Xu XX, 2014, J MOL HISTOL, V45, P473, DOI 10.1007/s10735 014 9571 6
   Yang X, 2017, ONCOTARGET, V8, P97683, DOI 10.18632/oncotarget.18313
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang YL, 2016, INT J BIOL SCI, V12, P347, DOI 10.7150/ijbs.13269
NR 23
TC 11
Z9 13
U1 0
U2 11
PU AME PUBLISHING COMPANY
PI SHATIN
PA FLAT RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305 5839
EI 2305 5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD DEC
PY 2020
VL 8
IS 24
AR 1680
DI 10.21037/atm 20 7040
PG 17
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA PY9DB
UT WOS:000612339500009
PM 33490192
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhou, Y
   Guan, XX
   Liu, T
   Wang, XH
   Yu, MF
   Yang, GL
   Wang, HM
AF Zhou, Yi
   Guan, Xiaoxu
   Liu, Tie
   Wang, Xinhua
   Yu, Mengfei
   Yang, Guoli
   Wang, Huiming
TI Whole body vibration improves osseointegration by up regulating
   osteoblastic activity but down regulating osteoblast mediated
   osteoclastogenesis via ERK1/2 pathway
SO BONE
LA English
DT Article
DE Osteoporosis; Implant; Whole body vibration; Osseointegration;
   Osteoblast; Osteoclast precursors
ID BONE RESORPTION; OVARIECTOMIZED RATS; MECHANICAL STRAIN; IN VIVO;
   IMPLANT OSSEOINTEGRATION; FREQUENCY VIBRATION; STROMAL CELLS;
   DIFFERENTIATION; OSTEOPOROSIS; ACTIVATION
AB Due to the reduction in bone mass and deterioration in bone microarchitecture, osteoporosis is an important risk factor for impairing implant osseointegration. Recently, low magnitude, high frequency (LMHF) vibration (LM: <1 xg: HF: 20 90 Hz) has been shown to exhibit anabolic, but anti resorptive effects on skeletal homeostasis. Therefore, we hypothesized that LMHF loading, in terms of whole body vibration (WBV), may improve implant fixation under osteoporotic status. In the in vivo study, WBV treatment (magnitude: 0.3 g, frequency: 40 Hz, time: 30 min/12 h, 5 days/week) was applied after hydroxyapatite coated titanium implants were inserted in the bilateral tibiae of ovariectomized rats. The bone mass and the osteospecific gene expressions were measured at 12 weeks post implantation. In the in vitro study, the cellular and molecular mechanisms underlying osteoblastic and osteoclastic activities were fully investigated using various experimental assays. Micro CT examination showed that WBV could enhance osseointegration by improving microstructure parameters surrounding implants. WBV regulated gene levels in favor of bone formation over resorption may be the reason for the favorable adaptive bone remolding on bone implant surface. The in vitro study showed that vibration (magnitude: 0.3 g, frequency: 40 Hz, time: 30 min/12 h) up regulated osteoblast differentiation, matrix synthesis and mineralization. However, mechanically regulated osteoclastic activity Was mainly through the effect on osteoblastic cells producing osteoclastogenesis associated key soluble factors, including RANKL and M CSF. Osteoblasts were therefore the direct target cells during the mechanotransduction process. The ERK1/2 pathway was demonstrated to play an essential role in vibration induced enhancement of bone formation and decreased bone resorption. Our data suggests that WBV was a helpful non pharmacological intervention for improving osseointegration under osteoporosis. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Zhou, Yi; Guan, Xiaoxu; Liu, Tie; Wang, Xinhua; Yu, Mengfei; Yang, Guoli; Wang, Huiming] Zhejiang Univ, Coll Med, Affiliated Hosp Stomatol, Hangzhou 310000, Zhejiang, Peoples R China.
C3 Zhejiang University
RP Wang, HM (通讯作者)，Zhejiang Univ, Coll Med, Affiliated Hosp Stomatol, Yanan Rd 395, Hangzhou 310000, Zhejiang, Peoples R China.
EM huimingwang1960@163.com
FU Zhejiang Provincial Natural Science Foundation of China [LQ13H250001,
   LQ14H140004]; National Science Foundation of China [81400480]
FX We are grateful to Dr. Natalie Ward for the English editing. This study
   was financially supported by Zhejiang Provincial Natural Science
   Foundation of China (grant nos. LQ13H250001 and LQ14H140004) and the
   National Science Foundation of China (grant no. 81400480).
CR Ai LS, 2013, INT J CANCER, V133, P1074, DOI 10.1002/ijc.28116
   Akca Kivanc, 2007, Head Face Med, V3, P28, DOI 10.1186/1746 160X 3 28
   Asaba Y, 2009, J BONE MINER RES, V24, P241, DOI [10.1359/jbmr.081006, 10.1359/JBMR.081006]
   Bacabac RG, 2006, FASEB J, V20, P858, DOI 10.1096/fj.05 4966.com
   Brouwers JEM, 2010, J ORTHOP RES, V28, P62, DOI 10.1002/jor.20951
   Chen BL, 2012, J ORTHOP RES, V30, P733, DOI 10.1002/jor.22004
   Cicek M, 2007, CANCER RES, V67, P10106, DOI 10.1158/0008 5472.CAN 07 1362
   Damien E, 2000, J BONE MINER RES, V15, P2169, DOI 10.1359/jbmr.2000.15.11.2169
   Di Paola R, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/787159
   Duyck J, 2007, J CLIN PERIODONTOL, V34, P998, DOI 10.1111/j.1600 051X.2007.01135.x
   Gabet Y, 2006, BONE, V39, P276, DOI 10.1016/j.bone.2006.02.004
   Gao Y, 2009, BONE, V44, P225, DOI 10.1016/j.bone.2008.10.054
   Hawse JR, 2008, BONE, V42, P1025, DOI 10.1016/j.bone.2008.02.004
   Judex S, 2007, J BIOMECH, V40, P1333, DOI 10.1016/j.jbiomech.2006.05.014
   KLEINNULEND J, 1990, ARTHRITIS RHEUM US, V33, P66, DOI 10.1002/art.1780330108
   Lau E, 2011, J ORTHOP RES, V29, P1075, DOI 10.1002/jor.21334
   Lau E, 2010, BONE, V46, P1508, DOI 10.1016/j.bone.2010.02.031
   Ling L, 2010, J CELL BIOCHEM, V109, P1222, DOI 10.1002/jcb.22506
   Mazière C, 2010, BBA MOL BASIS DIS, V1802, P1013, DOI 10.1016/j.bbadis.2010.07.010
   Nishimura M, 2008, AM J ORTHOD DENTOFAC, V133, P572, DOI 10.1016/j.ajodo.2006.01.046
   Ogawa T, 2011, CLIN ORAL IMPLAN RES, V22, P302, DOI 10.1111/j.1600 0501.2010.02020.x
   Ogawa T, 2011, J CLIN PERIODONTOL, V38, P180, DOI 10.1111/j.1600 051X.2010.01637.x
   Otomo Corgel J, 2012, PERIODONTOL 2000, V59, P111, DOI 10.1111/j.1600 0757.2011.00435.x
   Park YD, 2012, CYTOKINE, V60, P284, DOI 10.1016/j.cyto.2012.05.021
   Prisby RD, 2008, AGEING RES REV, V7, P319, DOI 10.1016/j.arr.2008.07.004
   Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rubin C, 2002, BONE, V30, P445, DOI 10.1016/S8756 3282(01)00689 5
   Rubin C, 2003, SPINE, V28, P2621, DOI 10.1097/01.BRS.0000102682.61791.C9
   Rubin J, 2000, AM J PHYSIOL CELL PH, V278, pC1126, DOI 10.1152/ajpcell.2000.278.6.C1126
   Rucci N, 2007, J CELL BIOCHEM, V100, P464, DOI 10.1002/jcb.21059
   Ryu J, 2006, EMBO J, V25, P5840, DOI 10.1038/sj.emboj.7601430
   Santos A, 2009, OSTEOPOROSIS INT, V20, P1027, DOI 10.1007/s00198 009 0858 5
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Tanaka SM, 2003, J BIOMECH, V36, P73, DOI 10.1016/S0021 9290(02)00245 2
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Torcasio A, 2008, EUR CELLS MATER, V16, P56
   Wanachewin O, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472 6882 12 71
   Wauquier F, 2013, J BIOL CHEM, V288, P6542, DOI 10.1074/jbc.M112.429084
   Yoshida H, 2006, J BIOCHEM, V139, P583, DOI 10.1093/jb/mvj066
   You LD, 2008, BONE, V42, P172, DOI 10.1016/j.bone.2007.09.047
   Zhou Y, 2011, EUR CELLS MATER, V22, P12, DOI 10.22203/eCM.v022a02
   Zhou Y, 2009, MED HYPOTHESES, V73, P83, DOI 10.1016/j.mehy.2009.01.029
   Zou W, 2003, J BIOL CHEM, V278, P16732, DOI 10.1074/jbc.M212473200
NR 44
TC 44
Z9 55
U1 1
U2 38
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD FEB
PY 2015
VL 71
BP 17
EP 24
DI 10.1016/j.bone.2014.09.026
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AY7XU
UT WOS:000347770000003
PM 25304090
DA 2025 08 17
ER

PT J
AU Zhou, L
   Hong, GJ
   Li, SF
   Liu, Q
   Song, FM
   Zhao, JM
   Yuan, JB
   Tickner, J
   Xu, JK
AF Zhou, Lin
   Hong, Guoju
   Li, Shangfu
   Liu, Qian
   Song, Fangming
   Zhao, Jinmin
   Yuan, Jinbo
   Tickner, Jennifer
   Xu, Jiake
TI Fangchinoline protects against bone loss in OVX mice via inhibiting
   osteoclast formation, bone resorption and RANKL induced signaling
SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article
DE fangchinoline; RANKL; osteoclast; NF kappa B; NFATc1; MAPK
ID NF KAPPA B; RECEPTOR ACTIVATOR; RAT; DIFFERENTIATION; OSTEOPOROSIS
AB Osteoporosis is a disease characterized by abnormally increased formation and function of osteoclasts. Anti RANKL treatment using natural medicine is a potential therapy for osteoporosis. Here, we studied the effect of fangchinoline, which is extracted from the root of Stephania tetrandra S. Moore, on osteoclast formation and function. We found that fangchinoline inhibited osteoclastogenesis at doses of 0.5 and 1 mu M. In addition, we also examined the mechanism of the inhibitory effect of fangchinoline on osteoclasts. We found that fangchinoline down regulated NFATc1 activity and expression. However, fangchinoline did not affect IKB alpha degradation and MAPK pathways. In addition, we also found that fangchinoline could protect against bone loss in OVX mice. Taken together, fangchinoline may be a potential compound for osteoporosis.
C1 [Zhou, Lin; Hong, Guoju; Li, Shangfu; Liu, Qian; Song, Fangming; Yuan, Jinbo; Tickner, Jennifer; Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.
   [Zhou, Lin] Guangzhou Med Univ, Affiliated Hosp 5, Dept Endocrinol, Guangzhou 510700, Guangdong, Peoples R China.
   [Hong, Guoju] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Orthoped Dept, Guangzhou 510006, Guangdong, Peoples R China.
   [Li, Shangfu] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Spine Surg, Guangzhou 510630, Guangdong, Peoples R China.
   [Liu, Qian; Song, Fangming; Zhao, Jinmin] Guangxi Med Univ, Res Ctr Regenerat Med, Guangxi 530021, Peoples R China.
   [Liu, Qian; Song, Fangming; Zhao, Jinmin] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Guangxi 530021, Peoples R China.
C3 University of Western Australia; Guangzhou Medical University; Guangzhou
   University of Chinese Medicine; Sun Yat Sen University; Guangxi Medical
   University; Guangxi Medical University
RP Xu, JK (通讯作者)，Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.
EM jiake.xu@uwa.edu.au
RI ; Hong, Guoju/AAV 9433 2020; Tickner, Jennifer/H 5965 2014; zhao,
   jin/LBH 0351 2024
OI Xu, Jiake/0000 0003 2021 8309; Yuan, Jinbo/0000 0002 6240 9333; Tickner,
   Jennifer/0000 0002 5020 0671; 
FU Australian Health and Medical Research Council (NHMRC) [APP1107828,
   APP1127396, APP11271 56]; Arthritis Foundation of Australia (The H J&G J
   Mckenzie grant); Western Australia Medical & Health Research
   Infrastructure Fund; University of Western Australia Research
   Collaboration Awards; Nature Science Foundation of Guangxi
   [2015GXNSFDA139019]; Medical Scientific Research Foundation of Guangdong
   Province of China [A2019006]; Guangzhou Medical University Student
   Laboratory Open Project (2018); Young innovative talents project of
   Guangdong Province [2017KQNCX167]; Guangdong Natural Science Foundation
   [2018A030313248]; Fundamental Research Funds for the Central
   Universities in China [17ykpy49]
FX The authors acknowledge the support from Australian Health and Medical
   Research Council (NHMRC No. APP1107828, APP1127396, APP11271 56),
   Arthritis Foundation of Australia (The H J&G J Mckenzie grant), Western
   Australia Medical & Health Research Infrastructure Fund, University of
   Western Australia Research Collaboration Awards. This study was also
   funded in part by the Nature Science Foundation of Guangxi
   (2015GXNSFDA139019), Medical Scientific Research Foundation of Guangdong
   Province of China (A2019006), Guangzhou Medical University Student
   Laboratory Open Project (2018) and Young innovative talents project of
   Guangdong Province (2017KQNCX167). This study was also supported by
   grants from the Guangdong Natural Science Foundation (No.
   2018A030313248), the Fundamental Research Funds for the Central
   Universities in China (No.17ykpy49). The authors also acknowledge the
   facilities and technical assistance of the National Imaging Facility, a
   National Collaborative Research Infrastructure Strategy (NCRIS)
   capability, at the CMCA, The University of Western Australia (UWA). GH,
   SL, QL, and FS were visiting scholars to UWA.
CR Abu Ghefreh AA, 2009, INT IMMUNOPHARMACOL, V9, P313, DOI 10.1016/j.intimp.2008.12.002
   Bai S, 2016, ANAT REC, V299, P256, DOI 10.1002/ar.23293
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Choi HS, 2000, J ETHNOPHARMACOL, V69, P173, DOI 10.1016/S0378 8741(99)00141 5
   Feng HT, 2009, J BIOL CHEM, V284, P14667, DOI 10.1074/jbc.M901670200
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Gülçin I, 2010, J ENZYM INHIB MED CH, V25, P44, DOI 10.3109/14756360902932792
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Huang K.C., 1993, The Pharmacology of Chinese Herbs
   Hwang YP, 2010, BIOCHEM PHARMACOL, V79, P1714, DOI 10.1016/j.bcp.2010.02.003
   Jia Y, 2018, FASEB J OFFICIAL PUB
   Jimi E, 1999, J IMMUNOL, V163, P434
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Lelovas PP, 2008, COMPARATIVE MED, V58, P424
   Lin TY, 2009, NEUROCHEM INT, V54, P506, DOI 10.1016/j.neuint.2009.02.001
   Lippuner K, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13624
   Luo X, 2016, EXP THER MED, V11, P613, DOI 10.3892/etm.2015.2915
   McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905
   Pinkerton JV, 2013, CLIN OBSTET GYNECOL, V56, P711, DOI 10.1097/GRF.0b013e3182a9fb02
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rea SL, 2013, ENDOCR REV, V34, P501, DOI 10.1210/er.2012 1034
   Takahashi T, 2012, BIOL PHARM BULL, V35, P1765, DOI 10.1248/bpb.b12 00445
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   van der Kraan AGJ, 2013, BIOCHEM J, V451, P235, DOI 10.1042/BJ20121626
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wan ZT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039225
   Wang C, 2003, J BONE MINER RES, V18, P2159, DOI 10.1359/jbmr.2003.18.12.2159
   Wang CD, 2014, ASIAN PAC J CANCER P, V15, P769, DOI 10.7314/APJCP.2014.15.2.769
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Yavropoulou M. P., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P204
NR 33
TC 15
Z9 16
U1 0
U2 20
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449 2288
J9 INT J BIOL SCI
JI Int. J. Biol. Sci.
PY 2020
VL 16
IS 2
BP 309
EP 319
DI 10.7150/ijbs.37162
PG 11
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics
GA KA6PJ
UT WOS:000505918400011
PM 31929758
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Freise, C
   Kretzschmar, N
   Querfeld, U
AF Freise, Christian
   Kretzschmar, Nadja
   Querfeld, Uwe
TI Wnt signaling contributes to vascular calcification by induction of
   matrix metalloproteinases
SO BMC CARDIOVASCULAR DISORDERS
LA English
DT Article
DE Matrix metalloproteinases; Vascular calcification; Chronic kidney
   disease; Vascular smooth muscle cells; Wnt pathway; MOVAS 1
ID CHRONIC KIDNEY DISEASE; ARTERIAL CALCIFICATION; PROLIFERATION; CELLS;
   INVOLVEMENT; PHYSIOLOGY; PHOSPHATE; PROMOTES; CALCIUM; PATHWAY
AB Background: Vascular calcifications such as arteriosclerosis, which is characterized by a calcificiation of the tunica media, represent major comorbidities e.g. in patients with chronic kidney disease (CKD). An essential step during the development of arteriosclerosis is the transdifferentiation/calcification of vascular smooth muscle cells (VSMC) resembling osteogenesis. The matrix metalloproteinases (MMP) 2 and  9 were shown to promote these VSMC calcifications and their inhibition is of therapeutic value to prevent arteriosclerosis in preclinical studies. Aiming for an understanding of the underlying regulatory mechanisms of MMPs we here investigated, if the MMP mediated VSMC calcification involves altered signaling of the Wnt pathway, which is known to impact osteogenesis.
   Methods: We used an experimental in vitro model of vascular calcification. Transdifferentiation/calcification of murine VSMC was induced by elevated calcium and phosphorus levels. Calcification was assessed by calcium and alkaline phosphatase measurements. Activation/activity of the gelatinases MMP 2 and MMP 9 was assessed by conversion of fluorescence labelled substrates. Activation of the Wnt pathway was analysed by a reporter gene assay.
   Results: Besides pro calcifying culture conditions, also activation of Wnt signaling by a specific agonist (under normal culture conditions) stimulated VSMC calcification accompanied by enhanced expression and secretion of the gelatinases MMP 2 and  9. Vice versa, recombinant MMP 2 and  9 induced a time delayed activation of Wnt signaling after 72 h in VSMC but showed no direct effects after 24 48 h. These effects were blocked by pharmacological inhibition of MMPs or of Wnt signaling.
   Conclusions: Our study suggests that the pro calcifying environment in CKD induces Wnt signaling in VSMC which in turn contributes to the induction of MMPs which then foster the development of arteriosclerosis. Thus, besides MMP inhibition, the inhibition of Wnt signaling in VSMC might represent a therapeutic target for the prevention of vascular calcifications.
C1 [Freise, Christian; Kretzschmar, Nadja; Querfeld, Uwe] Charite, Cardiovasc Res Ctr, Campus Mitte,Hessische Str 3 4, D 10115 Berlin, Germany.
   [Freise, Christian; Kretzschmar, Nadja; Querfeld, Uwe] Charite, Dept Pediat Nephrol, Campus Virchow Clin, D 13353 Berlin, Germany.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin
RP Freise, C (通讯作者)，Charite, Cardiovasc Res Ctr, Campus Mitte,Hessische Str 3 4, D 10115 Berlin, Germany.; Freise, C (通讯作者)，Charite, Dept Pediat Nephrol, Campus Virchow Clin, D 13353 Berlin, Germany.
EM christian.freise@charite.de
RI Querfeld, Uwe/AAF 6330 2020; Freise, Christian/P 4285 2019
OI Querfeld, Uwe/0000 0001 6783 3822; Freise,
   Christian/0000 0003 2602 226X; 
FU Charite Funds for Research
FX Funding was provided by Charite Funds for Research.
CR Benyon RC, 1999, HEPATOLOGY, V30, P977, DOI 10.1002/hep.510300431
   Blacher J, 2001, HYPERTENSION, V38, P938, DOI 10.1161/hy1001.096358
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Demer LL, 2008, CIRCULATION, V117, P2938, DOI 10.1161/CIRCULATIONAHA.107.743161
   Dwivedi A, 2009, CARDIOVASC RES, V81, P178, DOI 10.1093/cvr/cvn278
   Freise C, 2012, EUR J MICROBIOL IMMU, V2, P186, DOI 10.1556/EuJMI.2.2012.3.3
   Freise C, 2014, PHARMACOL RES, V85, P6, DOI 10.1016/j.phrs.2014.04.013
   Hecht E, 2016, NEPHROL DIAL TRANSPL, V31, P789, DOI 10.1093/ndt/gfv321
   Keelan PC, 2001, CIRCULATION, V104, P412, DOI 10.1161/hc2901.093112
   Kumata C, 2011, THER APHER DIAL, V15, P18, DOI 10.1111/j.1744 9987.2011.00921.x
   Marinou K, 2012, TRENDS ENDOCRIN MET, V23, P628, DOI 10.1016/j.tem.2012.06.001
   Martínez Moreno JM, 2012, AM J PHYSIOL RENAL, V303, pF1136, DOI 10.1152/ajprenal.00684.2011
   Mizobuchi M, 2009, J AM SOC NEPHROL, V20, P1453, DOI 10.1681/ASN.2008070692
   Pai A, 2011, AM J PATHOL, V178, P764, DOI 10.1016/j.ajpath.2010.10.006
   Rong S, 2014, CELL PHYSIOL BIOCHEM, V34, P2049, DOI 10.1159/000366400
   Shanahan CM, 2013, NAT REV NEPHROL, V9, P661, DOI 10.1038/nrneph.2013.176
   Shanahan CM, 2011, CIRC RES, V109, P697, DOI 10.1161/CIRCRESAHA.110.234914
   Shanahan CM, 1999, CIRCULATION, V100, P2168, DOI 10.1161/01.CIR.100.21.2168
   Smiljanic K, 2014, MOL CELL BIOCHEM, V396, P147, DOI 10.1007/s11010 014 2151 y
   Thompson B, 2012, NAT REV ENDOCRINOL, V8, P529, DOI 10.1038/nrendo.2012.36
   Tölle M, 2015, EUR J CLIN INVEST, V45, P976, DOI 10.1111/eci.12493
   Wilson PWF, 2001, CIRCULATION, V103, P1529, DOI 10.1161/01.cir.103.11.1529
   Wu BB, 2007, IMMUNITY, V26, P227, DOI 10.1016/j.immuni.2006.12.007
NR 23
TC 34
Z9 39
U1 0
U2 11
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471 2261
J9 BMC CARDIOVASC DISOR
JI BMC Cardiovasc. Disord.
PD SEP 30
PY 2016
VL 16
AR 185
DI 10.1186/s12872 016 0362 8
PG 8
WC Cardiac & Cardiovascular Systems
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology
GA DZ3UC
UT WOS:000385774000001
PM 27716072
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Gong, SW
   Lang, S
   Wang, Y
   Li, XF
   Tian, AX
   Ma, JX
   Ma, XL
AF Gong, Shuwei
   Lang, Shuang
   Wang, Yan
   Li, Xiongfeng
   Tian, Aixian
   Ma, Jianxiong
   Ma, Xinlong
TI pH Responsive Mesoporous Silica Nanoparticles Loaded with Naringin for
   Targeted Osteoclast Inhibition and Bone Regeneration
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE mesoporous silica nanoparticles; naringin; chitosan; osteoclast;
   pH sensitive gated nano drug delivery system
ID RANKL INDUCED OSTEOCLASTOGENESIS; STEM CELLS; DRUG; MECHANISMS; HYDROGEL
AB Background: It is well  established that osteoclast activity is significantly influenced by fluctuations in intracellular pH. Consequently, a pH  sensitive gated nano  drug delivery system represents a promising therapeutic approach to mitigate osteoclast overactivity. Our prior research indicated that naringin, a natural flavonoid, effectively mitigates osteoclast activity. However, naringin showed low oral availability and short half life, which hinders its clinical application. We developed a drug delivery system wherein chitosan, as gatekeepers, coats mesoporous silica nanoparticles loaded with naringin (CS@MSNs Naringin). However, the inhibitory effects of CS@MSNs Naringin on osteoclasts and the underlying mechanisms remain unclear, warranting further research. Methods: First, we synthesized CS@MSNs Naringin and conducted a comprehensive characterization. We also measured drug release rates in a pH gradient solution and verified its biosafety. Subsequently, we investigated the impact of CS@MSNs Naringin on osteoclasts induced by bone marrow  derived macrophages, focusing on differentiation and bone resorption activity while exploring potential mechanisms. Finally, we established a rat model of bilateral critical  sized calvarial bone defects, in which CS@MSNsNaringin was dispersed in GelMA hydrogel to achieve in situ drug delivery. We observed the ability of CS@MSNs Naringin to promote bone regeneration and inhibit osteoclast activity in vivo. Results: CS@MSNs Naringin exhibited high uniformity and dispersity, low cytotoxicity (concentration <= 120 mu g/mL), and significant pH sensitivity. In vitro, compared to Naringin and MSNs Naringin, CS@MSNs Naringin more effectively inhibited the formation and bone resorption activity of osteoclasts. This effect was accompanied by decreased phosphorylation of key factors in the NF kappa B and MAPK signaling pathways, increased apoptosis levels, and a subsequent reduction in the production of osteoclast specific genes and proteins. In vivo, CS@MSNs Naringin outperformed Naringin and MSNs Naringin, promoting new bone formation while inhibiting osteoclast activity to a greater extent. Conclusion: Our research suggested that CS@MSNs Naringin exhibited the strikingly ability to anti osteoclasts in vitro and in vivo, moreover promoted bone regeneration in the calvarial bone defect.
C1 [Gong, Shuwei; Li, Xiongfeng] Zhejiang Univ, Huzhou Cent Hosp, Huzhou Hosp, Dept Orthoped, Huzhou 313000, Zhejiang, Peoples R China.
   [Lang, Shuang] Zhejiang Univ, Huzhou Cent Hosp, Huzhou Hosp, Dept Tradit Chinese Med, Huzhou 313000, Zhejiang, Peoples R China.
   [Wang, Yan; Tian, Aixian; Ma, Jianxiong; Ma, Xinlong] Tianjin Hosp, Orthoped Res Inst, Tianjin Key Lab Orthoped Biomech & Med Engn, 155 Munan Rd, Tianjin 300050, Peoples R China.
C3 Huzhou University; Zhejiang University; Huzhou University; Zhejiang
   University
RP Ma, JX; Ma, XL (通讯作者)，Tianjin Hosp, Orthoped Res Inst, Tianjin Key Lab Orthoped Biomech & Med Engn, 155 Munan Rd, Tianjin 300050, Peoples R China.
EM mjxtianjin@foxmail.com; maxinlong8686@126.com
FU National Natural Science Foundation of China [81871777, 81572154,
   11772226, 82304976]; Tianjin Science and Technology Plan Project
   [18PTLCSY00070, 16ZXZNGX00130]; Tianjin Science and Technology Plan Key
   Project [22JCZDJC00340]; National Key Research and Development Plan
   [2022YFC3601900]
FX <B>Funding</B> This work was supported by a grant from National Natural
   Science Foundation of China (No. 81871777, 81572154, 11772226, 82304976)
   , Tianjin Science and Technology Plan Project (No. 18PTLCSY00070,
   16ZXZNGX00130) , Tianjin Science and Technology Plan Key Project (No.
   22JCZDJC00340) , National Key Research and Development Plan (No.
   2022YFC3601900) .
CR Abou Saleh H, 2019, NANOMATERIALS BASEL, V9, DOI 10.3390/nano9010122
   Alam MA, 2014, ADV NUTR, V5, P404, DOI 10.3945/an.113.005603
   Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Andreev D, 2020, J CLIN INVEST, V130, P4811, DOI 10.1172/JCI134214
   Barati D, 2020, ANN BIOMED ENG, V48, P1971, DOI 10.1007/s10439 020 02522 z
   Blake J, 2021, MENOPAUSE, V28, P973, DOI 10.1097/GME.0000000000001831
   Bril M., 2022, Smart Materials in Medicine, V3, P257, DOI [10.1016/j.smaim.2022.01.010, DOI 10.1016/J.SMAIM.2022.01.010]
   Chen MW, 2019, J MATER CHEM B, V7, P2657, DOI 10.1039/c9tb00040b
   Cui Y, 2024, BIOACT MATER, V34, P436, DOI 10.1016/j.bioactmat.2024.01.001
   Da WCL, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.675385
   Gong SW, 2022, BIOSCI TRENDS, V16, P58, DOI 10.5582/bst.2021.01357
   Guo YF, 2021, J CELL PHYSIOL, V236, P4152, DOI 10.1002/jcp.30111
   Hu HX, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1778883
   Huang DM, 2005, FASEB J, V19, P2014, DOI 10.1096/fj.05 4288fje
   Huotari J, 2011, EMBO J, V30, P3481, DOI 10.1038/emboj.2011.286
   Jacome Galarza CE, 2019, NATURE, V568, P541, DOI 10.1038/s41586 019 1105 7
   Jafari S, 2019, BIOMED PHARMACOTHER, V109, P1100, DOI 10.1016/j.biopha.2018.10.167
   Jeong Eun H, 2013, EUR J PHARMACOL, V698, P57, DOI 10.1016/j.ejphar.2012.08.013
   Jiang GY, 2021, ACTA BIOMATER, V128, P150, DOI 10.1016/j.actbio.2021.04.010
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P801, DOI [10.1007/s00198 018 4704 5, 10.1007/s00198 020 05303 5, 10.1007/s00223 018 00512 x]
   Kempen PJ, 2015, THERANOSTICS, V5, P631, DOI 10.7150/thno.11389
   Kim HS, 2012, INT J MOL MED, V29, P169, DOI 10.3892/ijmm.2011.822
   Kim JM, 2007, CELL PHYSIOL BIOCHEM, V20, P935, DOI 10.1159/000110454
   Kim Ju Young, 2015, Bone Rep, V3, P83, DOI 10.1016/j.bonr.2015.10.003
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Li FB, 2014, BIOCHEM BIOPH RES CO, V452, P629, DOI 10.1016/j.bbrc.2014.08.117
   Liu WL, 2019, ACS APPL MATER INTER, V11, P9557, DOI 10.1021/acsami.8b20580
   Lohiya G, 2022, CARBOHYD POLYM, V277, DOI 10.1016/j.carbpol.2021.118822
   Ma XL, 2016, SCI REP UK, V6, DOI 10.1038/srep24562
   Mao SC, 2022, TISSUE ENG PT A, V28, P807, DOI [10.1089/ten.TEA.2022.0049, 10.1089/ten.tea.2022.0049]
   Marcoline FV, 2016, BONE, V93, P167, DOI 10.1016/j.bone.2016.09.007
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Park SH, 2016, PHYTOTHER RES, V30, P604, DOI 10.1002/ptr.5565
   Ramesh P, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.779638
   Rizeq BR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225776
   Shen YY, 2013, INT J NANOMED, V8, P119, DOI 10.2147/IJN.S38213
   Sun XY, 2019, THERANOSTICS, V9, P5183, DOI 10.7150/thno.33376
   Tang FQ, 2012, ADV MATER, V24, P1504, DOI 10.1002/adma.201104763
   Tang Y, 2021, BIOACT MATER, V6, P2039, DOI 10.1016/j.bioactmat.2020.12.025
   Tavares MT, 2020, ADV BIOSYST, V4, DOI 10.1002/adbi.202000123
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Wang CS, 2017, ADV DRUG DELIVER REV, V113, P87, DOI 10.1016/j.addr.2016.08.014
   Wang WQ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020487
   Wang YL, 2021, MICROCHIM ACTA, V188, DOI 10.1007/s00604 021 05054 y
   Wei S, 2020, CURR MED SCI, V40, P155, DOI 10.1007/s11596 020 2159 3
   Zhang JK, 2024, MATER HORIZ, V11, P12, DOI 10.1039/d3mh01260c
   Zhang Q, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01028
   Zhang SL, 2015, ACS NANO, V9, P8655, DOI 10.1021/acsnano.5b03184
   Zhou YX, 2018, ACTA PHARM SIN B, V8, P165, DOI 10.1016/j.apsb.2018.01.007
NR 49
TC 7
Z9 7
U1 11
U2 29
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2024
VL 19
BP 6337
EP 6358
DI 10.2147/IJN.S456545
PG 22
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA WE8K8
UT WOS:001253283100001
PM 38946884
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Shen, J
   Meyers, CA
   Shrestha, S
   Singh, A
   LaChaud, G
   Nguyen, V
   Asatrian, G
   Federman, N
   Bernthal, N
   Eilber, FC
   Dry, SM
   Ting, K
   Soo, C
   James, AW
AF Shen, Jia
   Meyers, Carolyn A.
   Shrestha, Swati
   Singh, Arun
   LaChaud, Greg
   Vi Nguyen
   Asatrian, Greg
   Federman, Noah
   Bernthal, Nicholas
   Eilber, Fritz C.
   Dry, Sarah M.
   Ting, Kang
   Soo, Chia
   James, Aaron W.
TI Sclerostin expression in skeletal sarcomas
SO HUMAN PATHOLOGY
LA English
DT Article
DE SOST; Wnt signaling; Sarcoma; Osteosarcoma; Enchondroma; Chondrosarcoma
ID OSTEOSARCOMA CELL LINES; WNT INHIBITORY FACTOR 1; LONG TERM SURVIVORS;
   METASTATIC PHENOTYPE; BONE FORMATION; ROMOSOZUMAB; ANTIBODY
AB Sclerostin (SOST) is an extracellular Wnt signaling antagonist which negatively regulates bone mass. Despite this, the expression and function of SOST in skeletal tumors remain poorly described. Here, we first describe the immunohistochemical staining pattern of SOST across benign and malignant skeletal tumors with bone or cartilage matrix (n = 68 primary tumors). Next, relative SOST expression was compared to markers of Wnt signaling activity and osteogenic differentiation across human osteosarcoma (OS) cell lines (n = 7 cell lines examined). Results showed immunohistochemical detection of SOST in most bone forming tumors (90.2%; 46/51) and all cartilage forming tumors (100%; 17/17). Among OSs, variable intensity and distribution of SOST expression were observed, which highly correlated with the presence and degree of neoplastic bone. Patchy SOST expression was observed in cartilage forming tumors, which did not distinguish between benign and malignant tumors or correlate with regional morphologic characteristics. Finally, SOST expression varied widely between OS cell lines, with more than 97 fold variation. Among OS cell lines, SOST expression positively correlated with the marker of osteogenic differentiation alkaline phosphatase and did not correlate well with markers of Wnt/beta catenin signaling activity. In summary, SOST is frequently expressed in skeletal bone  and cartilage forming tumors. The strong spatial correlation with bone formation and the in vitro expression patterns are in line with the known functions of SOST in nonneoplastic bone, as a feedback inhibitor on osteogenic differentiation. With anti SOST as a potential therapy for osteoporosis in the near future, its basic biologic and phenotypic consequences in skeletal tumors should not be overlooked. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Shen, Jia; LaChaud, Greg; Asatrian, Greg; Ting, Kang] Univ Calif Los Angeles, Sch Dent, Div Growth & Dev, Los Angeles, CA 90095 USA.
   [Shen, Jia; LaChaud, Greg; Asatrian, Greg; Ting, Kang] Univ Calif Los Angeles, Sch Dent, Sect Orthodont, Los Angeles, CA 90095 USA.
   [Shen, Jia; Meyers, Carolyn A.; Shrestha, Swati; LaChaud, Greg; Vi Nguyen; Asatrian, Greg; Dry, Sarah M.; James, Aaron W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
   [Singh, Arun] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Los Angeles, CA 90095 USA.
   [Federman, Noah] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA.
   [Bernthal, Nicholas; Soo, Chia; James, Aaron W.] Univ Calif Los Angeles, Los Angeles, CA 90095 USA.
   [Bernthal, Nicholas; Soo, Chia; James, Aaron W.] Orthoped Hosp, Dept Orthopaed Surg, Los Angeles, CA 90095 USA.
   [Bernthal, Nicholas; Soo, Chia; James, Aaron W.] Orthoped Hosp, Res Ctr, Los Angeles, CA 90095 USA.
   [Eilber, Fritz C.] Univ Calif Los Angeles, Div Surg Oncol, Los Angeles, CA 90095 USA.
   [Soo, Chia] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Plast & Reconstruct Surg, Los Angeles, CA 90095 USA.
   [James, Aaron W.] Johns Hopkins Univ, Dept Pathol, 720 Rutland Ave,Room 524A, Baltimore, MD 21205 USA.
C3 University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA; University of California System; University of California Los
   Angeles; University of California System; University of California Los
   Angeles; University of California System; University of California Los
   Angeles; University of California Los Angeles Medical Center; David
   Geffen School of Medicine at UCLA; Johns Hopkins University
RP James, AW (通讯作者)，Johns Hopkins Univ, Dept Pathol, 720 Rutland Ave,Room 524A, Baltimore, MD 21205 USA.
EM awjames@jhmi.ed
RI ; soo, chia/JOZ 6461 2023
OI Nguyen, Vi/0000 0003 4363 5009; Meyers, Carolyn/0000 0002 0734 029X
FU UCLA Department of Pathology and Laboratory Medicine; Translational
   Research Fund; UCLA Daljit S. and Elaine Sarkaria Fellowship award;
   Orthopedic Research and Education Foundation; Musculoskeletal Transplant
   Foundation; National Institutes of Health/National Institute of
   Arthritis; Musculoskeletal and Skin Diseases [K08 AR068316 01]
FX The present work was supported by the UCLA Department of Pathology and
   Laboratory Medicine, the Translational Research Fund, the UCLA Daljit S.
   and Elaine Sarkaria Fellowship award, the Orthopedic Research and
   Education Foundation with funding provided by the Musculoskeletal
   Transplant Foundation, and National Institutes of Health/National
   Institute of Arthritis, and Musculoskeletal and Skin Diseases K08
   AR068316 01.
CR Alaee F, 2014, J ORTHOP RES, V32, P197, DOI 10.1002/jor.22498
   Bruserud O, 2005, J CANCER RES CLIN, V131, P377, DOI 10.1007/s00432 004 0650 z
   Cai YP, 2010, J PATHOL, V220, P24, DOI 10.1002/path.2628
   Chen CB, 2015, ONCOTARGET, V6, P17570, DOI 10.18632/oncotarget.4100
   Chen K, 2008, PEDIATR BLOOD CANCER, V51, P349, DOI 10.1002/pbc.21595
   Chou CT, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0107869, 10.1371/journal.pone.0105414, 10.1371/journal.pone.0104899]
   Costa AG, 2014, EXPERT OPIN BIOL TH, V14, P697, DOI 10.1517/14712598.2014.895808
   Endo Munoz L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133592
   Gorska M, 2016, ANTICANCER RES, V36, P221
   Hoang BH, 2004, INT J CANCER, V109, P106, DOI 10.1002/ijc.11677
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   Holzer G, 2003, J BONE JOINT SURG BR, V85B, P231, DOI 10.1302/0301 620X.85B2.13257
   Inagaki Y, 2016, HISTOPATHOLOGY, V69, P470, DOI 10.1111/his.12953
   Jian YK, 2015, BIOCHEM BIOPH RES CO, V466, P356, DOI 10.1016/j.bbrc.2015.09.028
   Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175
   Lauvrak SU, 2013, BRIT J CANCER, V109, P2228, DOI 10.1038/bjc.2013.549
   Lee N, 2007, BRIT J CANCER, V97, P1552, DOI 10.1038/sj.bjc.6604069
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Lim JS, 2013, J PEDIAT HEMATOL ONC, V35, P54, DOI 10.1097/MPH.0b013e318275193b
   Mandal D, 2007, GENE, V386, P131, DOI 10.1016/j.gene.2006.08.030
   Martin T John, 2014, J Bone Metab, V21, P8, DOI 10.11005/jbm.2014.21.1.8
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Minisola S, 2014, EXPERT OPIN BIOL TH, V14, P1225, DOI 10.1517/14712598.2014.920815
   Mu XD, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00143
   Ominsky MS, 2014, J BONE MINER RES, V29, P1424, DOI 10.1002/jbmr.2152
   Ren L, 2015, ONCOTARGET, V6, P29469, DOI 10.18632/oncotarget.5177
   Rubin EM, 2010, MOL CANCER THER, V9, P731, DOI 10.1158/1535 7163.MCT 09 0147
   Shen J, 2012, J CELL BIOCHEM, V113, P3620, DOI 10.1002/jcb.24253
   Stolina M, 2014, BONE, V67, P305, DOI 10.1016/j.bone.2014.07.031
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Yao Q, 2014, CELL BIOCHEM BIOPHYS, V69, P229, DOI 10.1007/s12013 013 9787 1
   YOSHIKAWA H, 1988, CANCER AM CANCER SOC, V61, P569, DOI 10.1002/1097 0142(19880201)61:3<569::AID CNCR2820610324>3.0.CO;2 Z
NR 32
TC 8
Z9 8
U1 0
U2 9
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0046 8177
EI 1532 8392
J9 HUM PATHOL
JI Hum. Pathol.
PD DEC
PY 2016
VL 58
BP 24
EP 34
DI 10.1016/j.humpath.2016.07.016
PG 11
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA EE5YI
UT WOS:000389685100004
PM 27498059
OA Green Accepted, Green Submitted
DA 2025 08 17
ER

PT J
AU Liu, S
   Virdi, AS
   Sena, K
   Sumner, DR
AF Liu, Shuo
   Virdi, Amarjit S.
   Sena, Kotaro
   Sumner, Dale R.
TI Sclerostin Antibody Prevents Particle Induced Implant Loosening by
   Stimulating Bone Formation and Inhibiting Bone Resorption in a Rat Model
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID DEBRIS INDUCED OSTEOLYSIS; MICRO COMPUTED TOMOGRAPHY; WEAR DEBRIS;
   POLYETHYLENE PARTICLES; CONTINUOUS INFUSION; HUMAN OSTEOBLASTS; LOCAL
   INFUSION; DEFICIENT MICE; GENE THERAPY; MURINE MODEL
AB Objective. To assess the ability of sclerostin antibody therapy to blunt the negative effects of polyethylene particles on implant fixation and peri implant bone structure in a rat implant fixation model.
   Methods. Thirty six adult male rats received intramedullary titanium implants; 12 rats received vehicle injections only (control), and 24 rats received intraarticular injections of lipopolysaccharide doped polyethylene particles. Twelve of the rats that received particles also received sclerostin antibody treatment. The 3 groups of rats were maintained for 12 weeks in a pathogen free environment, at which time mechanical, micro computed tomography, and dynamic and static histomorphometry end points were assessed.
   Results. Sclerostin antibody treatment completely blocked the negative effect of the lipopolysaccharide doped polyethylene particles on implant fixation and peri implant bone volume by increasing the bone formation rate and depressing bone resorption.
   Conclusion. Anabolic agents targeting the Wnt signaling pathway are a promising new alternative for the prevention of periprosthetic osteolysis and aseptic loosening.
C1 [Sumner, Dale R.] Rush Univ, Dept Anat & Cell Biol, Med Ctr, Chicago, IL 60612 USA.
C3 Rush University
RP Sumner, DR (通讯作者)，Rush Univ, Dept Anat & Cell Biol, Med Ctr, 600 S Paulina St,Room 507, Chicago, IL 60612 USA.
EM rick_sumner@rush.edu
RI Sena, Kotaro/A 8033 2013
OI Sena, Kotaro/0000 0003 0612 1826; Sumner, Dale/0000 0001 9575 3862
FU Grainger Foundation
FX Supported by the Grainger Foundation. Amgen and UCB Pharma donated the
   sclerostin antibody.
CR Agholme F, 2010, J BONE MINER RES, V25, P2412, DOI 10.1002/jbmr.135
   Atkins GJ, 2009, BIOMATERIALS, V30, P3672, DOI 10.1016/j.biomaterials.2009.03.035
   BOBYN JD, 1995, CLIN ORTHOP RELAT R, P21
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Carmody EE, 2002, ARTHRITIS RHEUM US, V46, P1298, DOI 10.1002/art.10227
   Childs LM, 2001, J BONE JOINT SURG AM, V83A, P1789, DOI 10.2106/00004623 200112000 00004
   Choi Y, 2009, NAT REV RHEUMATOL, V5, P543, DOI 10.1038/nrrheum.2009.175
   Darowish M, 2009, BONE, V45, P661, DOI 10.1016/j.bone.2009.06.004
   Dong L, 2008, J ORTHOP RES, V26, P1114, DOI 10.1002/jor.20607
   Eddleston A, 2009, J BONE MINER RES, V24, P1662, DOI [10.1359/JBMR.090403, 10.1359/jbmr.090403]
   Epstein NJ, 2005, J ORTHOP RES, V23, P501, DOI 10.1016/j.orthres.2004.10.004
   GLANT TT, 1993, J BONE MINER RES, V8, P1071
   GOLDRING SR, 1983, J BONE JOINT SURG AM, V65, P575, DOI 10.2106/00004623 198365050 00001
   Goodman S, 2003, J BIOMED MATER RES A, V65A, P43, DOI 10.1002/jbm.a.10279
   Iwase M, 2002, J ORTHOPAED RES, V20, P499, DOI 10.1016/S0736 0266(01)00155 3
   Kamiya N, 2008, DEVELOPMENT, V135, P3801, DOI 10.1242/dev.025825
   Kim KJ, 1998, CLIN ORTHOP RELAT R, P46
   Kurtz S, 2007, J BONE JOINT SURG AM, V89A, P780, DOI 10.2106/JBJS.F.00222
   Landgraeber S, 2009, APOPTOSIS, V14, P173, DOI 10.1007/s10495 008 0297 3
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Lichtenstein GR, 2003, AM J GASTROENTEROL, V98, pS24, DOI 10.1016/j.amjgastroenterol.2003.11.003
   Liu S, 2012, J MICROSC OXFORD, V245, P34, DOI 10.1111/j.1365 2818.2011.03541.x
   Liu SO, 2012, J BIOMED MATER RES A, V100A, P918, DOI 10.1002/jbm.a.34029
   Ma T, 2006, J BIOMED MATER RES A, V79A, P740, DOI 10.1002/jbm.a.30949
   Markel DC, 2009, INFLAMM RES, V58, P413, DOI 10.1007/s00011 009 0007 9
   Millett PJ, 2002, J BONE JOINT SURG AM, V84A, P236, DOI 10.2106/00004623 200202000 00011
   Ominsky MS, 2011, J BONE MINER RES, V26, P1012, DOI 10.1002/jbmr.307
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Sacomen D, 1998, J BIOMED MATER RES, V43, P123, DOI 10.1002/(SICI)1097 4636(199822)43:2<123::AID JBM6>3.3.CO;2 F
   Shanbhag AS, 1997, CLIN ORTHOP RELAT R, P33
   Silvestrini G, 2008, J MOL HISTOL, V39, P237, DOI 10.1007/s10735 007 9158 6
   Smith RA, 2010, J BIOMED MATER RES A, V93A, P227, DOI 10.1002/jbm.a.32531
   Thadani PJ, 2002, ORTHOPEDICS, V25, P59
   Tian XY, 2010, BONE, V47, P529, DOI 10.1016/j.bone.2010.05.032
   Ulrich Vinther M, 2002, J BONE JOINT SURG AM, V84A, P1405, DOI 10.2106/00004623 200208000 00017
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Vermes C, 2000, J BONE MINER RES, V15, P1756, DOI 10.1359/jbmr.2000.15.9.1756
   Vincent C, 2009, J BONE MINER RES, V24, P1434, DOI [10.1359/JBMR.090305, 10.1359/jbmr.090305]
   Virdi AS, 2012, J BONE JOINT SURG AM, V94A, P1670, DOI 10.2106/JBJS.K.00344
   von Knoch F, 2005, J BIOMED MATER RES A, V75A, P288, DOI 10.1002/jbm.a.30441
   von Knoch F, 2005, BIOMATERIALS, V26, P3549, DOI 10.1016/j.biomaterials.2004.09.043
   von Knoch M, 2005, BIOMATERIALS, V26, P1803, DOI 10.1016/j.biomaterials.2004.06.010
   Wedemeyer C, 2007, CALCIFIED TISSUE INT, V80, P268, DOI 10.1007/s00223 007 9005 5
   Wedemeyer C, 2005, BIOMATERIALS, V26, P3719, DOI 10.1016/j.biomaterials.2004.09.026
   Wedemeyer C, 2007, J BONE MINER RES, V22, P1011, DOI 10.1359/JBMR.070408
   Wilkinson JM, 2011, BONE, V49, P95, DOI 10.1016/j.bone.2011.01.009
   WILLERT HG, 1990, CLIN ORTHOP RELAT R, P95
   Yang SY, 2004, GENE THER, V11, P483, DOI 10.1038/sj.gt.3302192
   Zhang T, 2009, BIOMATERIALS, V30, P6102, DOI 10.1016/j.biomaterials.2009.07.032
NR 50
TC 49
Z9 52
U1 0
U2 12
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0004 3591
J9 ARTHRITIS RHEUM US
JI Arthritis Rheum.
PD DEC
PY 2012
VL 64
IS 12
BP 4012
EP 4020
DI 10.1002/art.37697
PG 9
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 045ON
UT WOS:000311706300023
PM 23192793
DA 2025 08 17
ER

PT J
AU Chen, YQ
   Wei, ZY
   Shi, HX
   Wen, X
   Wang, YR
   Wei, R
AF Chen, Yuqi
   Wei, Zhiyong
   Shi, Hongxia
   Wen, Xin
   Wang, Yiran
   Wei, Rong
TI BushenHuoxue formula promotes osteogenic differentiation via affecting
   Hedgehog signaling pathway in bone marrow stem cells to improve
   osteoporosis symptoms
SO PLOS ONE
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; PROLIFERATION; RUNX2; EXPRESSION; MEDICINE;
   SKELETAL; MSCS
AB BackgroundThe BushenHuoxue formula (BSHX) has been previously demonstrated to ameliorate osteoporosis, but the mechanisms underlying this phenomenon are currently unclear. The present study aims at investigating the mechanisms that BSHX induces osteogenesis.MethodsWe established an osteoporosis model in rats by bilateral ovariectomy and then treated the rats with an osteogenic inducer (dexamethasone, beta sodium glycerophosphate and Vitamin C) and BSHX. After that, bone marrow density and histopathological bone examination were evaluated by using HE staining and immunohistochemistry, respectively. We also assessed the differentiation of bone marrow mesenchymal stem cells (BMSCs) into osteoblasts by using immunofluorescence staining. ALP, BMP, and COL1A1 levels were determined by ELISA. We identified genes involved in pathogenesis of osteoporosis through Gene Expression Omnibus (GEO) database and subsequently selected Hedgehog signaling related genes Shh, Ihh, Gli2, and Runx2 for assessment via qRT PCR and ELISA, Western blotting. Network pharmacology analysis was performed to identify bioactive metabolites of BSHX.ResultsBSHX treatment in osteoporosis model rats promoted tightening of the morphological structure of the trabecular bone and increased the bone mineral density (BMD). BSHX also increased levels of osteoblast makers ALP, BMP, and COL1A1. Additionally, bioinformatics analysis of the GEO dataset showed that Hedgehog signaling pathway was involved in pathogenesis of osteoporosis, especially related genes Shh, Ihh, Gli2, and Runx2. Remarkably, BHSX upregulated these genes indispensably involved in the osteogenesis related Hedgehog signaling pathway in both bone tissue and BMSCs. Importantly, we identified that quercetin was the active compounds that involved in the mechanism of BSHX improved OP via affecting Hedgehog related genes.ConclusionOur results indicate that BSHX promotes osteogenesis by improving BMSC differentiation into osteoblasts via increased expression of Hedgehog signaling related genes Shh, Ihh, Gli2, and Runx2, and quercetin was the bioactive compound of BSHX.
C1 [Chen, Yuqi; Wang, Yiran; Wei, Rong] Dept Peoples Hosp Suzhou New Dist, Suzhou, Peoples R China.
   [Wei, Zhiyong] Kuitun Hosp Xinjiang Prod & Construct Corps, Ili, Xinjiang Uygur, Peoples R China.
   [Shi, Hongxia; Wei, Rong] Xinjiang Med Univ, Affiliated Hosp 4, Urumqi, Peoples R China.
   [Wen, Xin] Urumqi Friendship Hosp, Urumqi, Peoples R China.
C3 Xinjiang Medical University
RP Wei, R (通讯作者)，Dept Peoples Hosp Suzhou New Dist, Suzhou, Peoples R China.; Wei, R (通讯作者)，Xinjiang Med Univ, Affiliated Hosp 4, Urumqi, Peoples R China.
EM 952257684@qq.com
RI Wei, Rong/AGX 0995 2022; Wang, Yiran/HDM 8015 2022; Wei,
   Zhiyong/C 5673 2012; Chen, Yuqi/JGD 8592 2023
FU National Natural Science Foundation grant [81460676]; Medical and Health
   science and Technology project of Suzhou High tech Zone [2019Z011]; 55th
   batch of funding for the China Postdoctoral Science Foundation Project
FX This work was supported by National Natural Science Foundation grant
   (No. 81460676) and Medical and Health science and Technology project of
   Suzhou High tech Zone(No. 2019Z011) and the 55th batch of funding for
   the China Postdoctoral Science Foundation Project.
CR Aljohani S, 2017, J CRANIO MAXILL SURG, V45, P1493, DOI 10.1016/j.jcms.2017.05.028
   Beloti MM, 2005, CELL BIOL INT, V29, P537, DOI 10.1016/j.cellbi.2005.02.007
   Benisch P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045142
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Cai JQ, 2012, CELL BIOL INT, V36, P349, DOI 10.1042/CBI20110284
   Chang HG, 2017, CELL DEATH DIS, V8, DOI 10.1038/s41419 017 0078 4
   Chen WK, 2020, FREE RADICAL BIO MED, V146, P92, DOI 10.1016/j.freeradbiomed.2019.10.412
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Donoso O, 2015, J CELL BIOCHEM, V116, P1267, DOI 10.1002/jcb.25082
   Fan JZ, 2014, MOL CELL BIOCHEM, V392, P85, DOI 10.1007/s11010 014 2021 7
   Gersbach CA, 2004, EXP CELL RES, V300, P406, DOI 10.1016/j.yexcr.2004.07.031
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   Huang YK, 2020, SCI CHINA LIFE SCI, V63, P429, DOI 10.1007/s11427 019 1555 9
   Huycke TR, 2012, DEVELOPMENT, V139, P2371, DOI 10.1242/dev.079806
   Jemtland R, 2003, BONE, V32, P611, DOI 10.1016/S8756 3282(03)00092 9
   Jiang TY, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1511 7
   Kim KI, 2017, KOREAN J INTERN MED, V32, P199, DOI 10.3904/kjim.2016.218
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Levi B, 2011, PLAST RECONSTR SURG, V127, P1182, DOI 10.1097/PRS.0b013e3182043a07
   Li KJ, 2018, BIOMED PHARMACOTHER, V99, P319, DOI 10.1016/j.biopha.2018.01.040
   Li L, 2015, INT J MOL MED, V35, P1641, DOI 10.3892/ijmm.2015.2172
   Li MX, 2018, ONCOTARGETS THER, V11, P4105, DOI 10.2147/OTT.S166567
   Liu HJ, 2015, EXP BIOL MED, V240, P1099, DOI 10.1177/1535370215591828
   Pino AM, 2012, BIOL RES, V45, P279, DOI 10.4067/S0716 97602012000300009
   Mo J, 2019, J NAT MED TOKYO, V73, P262, DOI 10.1007/s11418 018 1242 6
   Morsczeck C, 2017, MOL CELL BIOCHEM, V428, P79, DOI 10.1007/s11010 016 2918 4
   Mukwaya E, 2014, PHARM BIOL, V52, P1223, DOI 10.3109/13880209.2014.884606
   Ozturk S, 2023, J BONE MINER METAB, V41, P443, DOI 10.1007/s00774 023 01416 z
   Peng ZC, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.911326
   Pereira J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0074132
   Qiu N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015240
   Quaranta R, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.326
   Rimkus TK, 2016, CANCERS, V8, DOI 10.3390/cancers8020022
   Ringe JD, 2020, ARCH OSTEOPOROS, V15, DOI 10.1007/s11657 020 00842 0
   Shimoyama A, 2007, MOL BIOL CELL, V18, P2411, DOI 10.1091/mbc.E06 08 0743
   Sun LM, 2014, J CLIN ENDOCR METAB, V99, P4259, DOI 10.1210/jc.2014 2239
   Tian XD, 2016, J X RAY SCI TECHNOL, V24, P509, DOI 10.3233/XST 160567
   Tu XL, 2012, DEV BIOL, V362, P76, DOI 10.1016/j.ydbio.2011.11.013
   Veronesi F, 2011, CRIT REV EUKAR GENE, V21, P363, DOI 10.1615/CritRevEukarGeneExpr.v21.i4.60
   Wang DW, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/7532798
   Wei R., 2019, Chinese Journal of Tissue Engineering Research, V23, P691
   Wei R., 2018, Shi Zhen Guo Yi Guo Yao, V29, P1807
   Wu TZ, 2021, INNOVATION AMSTERDAM, V2, DOI 10.1016/j.xinn.2021.100141
   Xia CJ, 2023, J ORTHOP SURG RES, V18, DOI 10.1186/s13018 023 03696 7
   [许周媚 Xu Zhoumei], 2017, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V23, P534
   Yao E, 2015, J FORMOS MED ASSOC, V114, P569, DOI 10.1016/j.jfma.2015.01.005
   Yi W., 2017, Hunan J. Tradit. Chin. Med, V33, P116, DOI [10.16808/j.cnki.issn1003 7705.2017.02.060, DOI 10.16808/J.CNKI.ISSN1003 7705.2017.02.060]
   Yusuf AA, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657 018 0439 3
   Zhang Y, 2020, EXP MOL PATHOL, V113, DOI 10.1016/j.yexmp.2019.104366
   Zhong LN, 2019, J CELL BIOCHEM, V120, P19422, DOI 10.1002/jcb.29166
   Zhou J, 2016, AM J TRANSL RES, V8, P5354
NR 52
TC 6
Z9 6
U1 3
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD NOV 29
PY 2023
VL 18
IS 11
AR e0289912
DI 10.1371/journal.pone.0289912
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA EZ5S4
UT WOS:001142779200203
PM 38019761
OA gold
DA 2025 08 17
ER

PT J
AU Yan, LL
   Lu, LL
   Hu, FB
   Shetti, D
   Wei, K
AF Yan, Liuliu
   Lu, Lulu
   Hu, Fangbin
   Shetti, Dattatrya
   Wei, Kun
TI Piceatannol attenuates RANKL induced osteoclast differentiation and bone
   resorption by suppressing MAPK, NE κB and AKT signalling pathways and
   promotes Caspase3 mediated apoptosis of mature osteoclasts
SO ROYAL SOCIETY OPEN SCIENCE
LA English
DT Article
DE osteoclast; bone resorption; piceatannol; apoptosis; RANKL
ID ACTIVATION; MECHANISMS; CASPASE 3; DISEASES; CELLS; ACID
AB Osteoclasts are multinuclear giant cells that have unique ability to degrade bone. The search for new medicines that modulate the formation and function of osteoclasts is a potential approach for treating osteoclast related bone diseases. Piceatannol (PIC) is a natural organic polyphenolic stilbene compound found in diverse plants with a strong antioxidant and anti inflammatory effect. However, the effect of PIC on bone health has not been scrutinized systematically. In this study, we used RAW264.7, an osteoclast lineage of cells of murine macrophages, to investigate the effects and the underlying mechanisms of PIC on osteoclasts. Here, we demonstrated that PIC treatment ranging from 0 to 40 mu M strongly inhibited osteoclast formation and bone resorption in a dose dependent manner. Furthermore, the inhibitory effect of PIC was accompanied by the decrease of osteoclast specific genes. At the molecular level, PIC suppressed the phosphorylation of c Jun N terminal kinase (JNK), extracellular signal regulated kinase (ERK1/2), NF kappa B p65, I kappa B alpha and AKT. Besides, PIC promoted the apoptosis of mature osteoclasts by inducing caspase 3 expression. In conclusion, our results suggested that PIC inhibited RANKL induced osteoclastogenesis and bone resorption by suppressing MARK NP kappa B and AKT signalling pathways and promoted caspase3 mediated apoptosis of mature osteoclasts, which might contribute to the treatment of hone diseases characterized by excessive hone resorption.
C1 [Yan, Liuliu; Lu, Lulu; Hu, Fangbin; Shetti, Dattatrya; Wei, Kun] South China Univ Technol, Sch Biol & Biol Engn, Guangzhou 510006, Guangdong, Peoples R China.
C3 South China University of Technology
RP Shetti, D; Wei, K (通讯作者)，South China Univ Technol, Sch Biol & Biol Engn, Guangzhou 510006, Guangdong, Peoples R China.
EM dattakapilshetti@gmail.com; weikun@scut.edu.cn
FU Multi stage construction of high strength microsphere scaffolds and
   development of bone repair materials [2015A020214005]; International
   Cooperation Projects of Guangdong Provincial Science and Technology
   [2015A050502013]
FX This research was funded by Multi stage construction of high strength
   microsphere scaffolds and development of bone repair materials (grant
   no. 2015A020214005) and the International Cooperation Projects of
   Guangdong Provincial Science and Technology (grant no. 2015A050502013).
CR An J, 2016, INT IMMUNOPHARMACOL, V36, P118, DOI 10.1016/j.intimp.2016.04.024
   Ashikawa K, 2002, J IMMUNOL, V169, P6490, DOI 10.4049/jimmunol.169.11.6490
   Balogh E, 2018, PHARMACEUTICALS BASE, V11, DOI 10.3390/ph11040107
   Barman J, 2018, CURR PHARM BIOTECHNO, V19, P644, DOI 10.2174/1389201019666180821093239
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Bruzzaniti A, 2006, REV ENDOCR METAB DIS, V7, P123, DOI 10.1007/s11154 006 9009 x
   Chan Francis Ka Ming, 2013, Methods Mol Biol, V979, P65, DOI 10.1007/978 1 62703 290 2_7
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Chen YQ, 2018, LIFE SCI, V208, P305, DOI 10.1016/j.lfs.2018.07.048
   Chen YQ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091516
   Doss HM, 2018, LIFE SCI, V207, P284, DOI 10.1016/j.lfs.2018.06.013
   Dvorakova M, 2017, PHARMACOL RES, V124, P126, DOI 10.1016/j.phrs.2017.08.002
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   He LG, 2014, ACTA PHARMACOL SIN, V35, P203, DOI 10.1038/aps.2013.139
   Hubert PA, 2014, ANTIOXIDANTS BASEL, V3, P144, DOI 10.3390/antiox3010144
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Jayasooriya RGPT, 2013, ONCOL LETT, V5, P341, DOI 10.3892/ol.2012.968
   Jia YG, 2018, FASEB J, V32, P3398, DOI 10.1096/fj.201701148RR
   Jin CY, 2006, PHARMACOL RES, V54, P461, DOI 10.1016/j.phrs.2006.09.005
   Kasonga AE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125145
   Ke K, 2015, BONE, V81, P237, DOI 10.1016/j.bone.2015.07.006
   Kershaw J, 2017, J MED FOOD, V20, P427, DOI 10.1089/jmf.2017.3916
   Kim HJ, 2017, CELL SIGNAL, V29, P226, DOI 10.1016/j.cellsig.2016.11.007
   Ko YJ, 2013, INT J MOL MED, V31, P951, DOI 10.3892/ijmm.2013.1283
   Lee J, 2015, EXP CELL RES, V339, P380, DOI 10.1016/j.yexcr.2015.10.001
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lee WS, 2014, INFLAMMATION, V37, P1221, DOI 10.1007/s10753 014 9849 6
   Liu CY, 2017, EXP CELL RES, V352, P293, DOI 10.1016/j.yexcr.2017.02.018
   Lorenzo J, 2008, ENDOCR REV, V29, P403, DOI 10.1210/er.2007 0038
   Maurizi A, 2018, CANCERS, V10, DOI 10.3390/cancers10070218
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Shahnazari M, 2016, J NUTR BIOCHEM, V34, P73, DOI 10.1016/j.jnutbio.2016.04.007
   Shen CL, 2011, PHARMACOL RES, V64, P155, DOI 10.1016/j.phrs.2011.03.012
   Stern PH, 2007, J CELL BIOCHEM, V101, P1087, DOI 10.1002/jcb.21311
   Surh YJ, 2016, ADV EXP MED BIOL, V928, P185, DOI 10.1007/978 3 319 41334 1_9
   Szymczyk KH, 2006, J CELL PHYSIOL, V209, P836, DOI 10.1002/jcp.20770
   Torre E, 2017, PHYTOCHEM REV, V16, P1183, DOI 10.1007/s11101 017 9529 x
   van Heerden B, 2017, NUTRIENTS, V9, DOI 10.3390/nu9050441
   Viñas P, 2011, J CHROMATOGR A, V1218, P639, DOI 10.1016/j.chroma.2010.12.026
   Welch AA, 2014, CURR OSTEOPOROS REP, V12, P205, DOI 10.1007/s11914 014 0212 5
   Yan L, 2019, DRYAD DIGITAL REPOSI, DOI [10.5061/dryad.df19750, DOI 10.5061/DRYAD.DF19750]
NR 43
TC 24
Z9 26
U1 0
U2 15
PU ROYAL SOC
PI LONDON
PA 6 9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 2054 5703
J9 ROY SOC OPEN SCI
JI R. Soc. Open Sci.
PD JUN
PY 2019
VL 6
IS 6
AR 190360
DI 10.1098/rsos.190360
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA IG4TZ
UT WOS:000473797400035
PM 31312498
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Stanton, LA
   Beier, F
AF Stanton, Lee Anne
   Beier, Frank
TI Inhibition of p38 MAPK signaling in chondrocyte cultures results in
   enhanced osteogenic differentiation of perichondral cells
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE chondrocyte; Runx2/Cbfa 1; Ihh; osteocalcin; osterix; p38; perichondral
   cell; Ptch
ID ACTIVATED PROTEIN KINASE; ENDOCHONDRAL BONE DEVELOPMENT;
   INDIAN HEDGEHOG; OSTEOBLAST DIFFERENTIATION; TRANSCRIPTION FACTOR;
   HYPERTROPHIC CHONDROCYTE; SKELETAL DEVELOPMENT; GENE EXPRESSION; MATRIX
   PROTEINS; ATDC5 CELLS
AB Chondrocytes and osteoblasts originate from the same progenitor cell; however, both are characterized by distinct gene expression profiles once they are differentiated. Signals from differentiating chondrocytes, such as Indian hedgehog (Ihh), regulate the differentiation of osteoblast precursor cells. The MAPK pathways play important roles in controlling the differentiation of both chondrocytes and osteoblasts, with the p38 pathway being particularly relevant in skeletal cells. In the present study, we investigated the effects of p38 inhibition on osteoblastic marker gene expression in chondrocyte cultures. Using high density micromass cultures of mesenchymal cells as well as chondrocytes that had differentiated in vivo and were maintained in short term monolayer culture, we demonstrate elevated Runx2, Osterix and Osteocalcin transcript levels in chondrocyte cultures upon inhibition of p38 activity with the pharmacological inhibitor PD169316. Osteocalcin immunolocalization was restricted to perichondral/periosteal cells in micromass cultures, suggesting that inhibition of p38 results in increased periosteal osteogenesis. Coinciding with increased expression of these genes, we observed elevated levels of transcripts for Ihh and its target gene, Ptch, in response to p38 inhibition. Addition of recombinant hedgehog protein mimicked some effects of p38 inhibitors. We therefore suggest that p38 signaling regulates chondrocyte perichondral cell communication during skeletal development, partially through increased Ihh signaling. (c) 2006 Elsevier Inc. All rights reserved.
C1 Univ Western Ontario, Dept Physiol & Pharmacol, Grp Skeletal Dev & Remodeling, CIHR, London, ON N6A 5C1, Canada.
C3 Western University (University of Western Ontario)
RP Beier, F (通讯作者)，Univ Western Ontario, Dept Physiol & Pharmacol, Grp Skeletal Dev & Remodeling, CIHR, London, ON N6A 5C1, Canada.
EM fbeier@uwo.ca
RI Beier, Frank/G 4595 2013
OI Beier, Frank/0000 0002 8505 7537
CR Alsalameh S, 2004, ARTHRITIS RHEUM US, V50, P1522, DOI 10.1002/art.20269
   Chung UI, 2004, ENDOCR J, V51, P19, DOI 10.1507/endocrj.51.19
   Chung UI, 2001, J CLIN INVEST, V107, P295, DOI 10.1172/JCI11706
   Cohen MM, 2003, AM J MED GENET A, V123A, P5, DOI 10.1002/ajmg.a.20495
   Colnot C, 2005, DEVELOPMENT, V132, P1057, DOI 10.1242/dev.01649
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695
   Ferguson CM, 1998, ANN NY ACAD SCI, V857, P33, DOI 10.1111/j.1749 6632.1998.tb10105.x
   Fujita T, 2004, J CELL BIOCHEM, V93, P374, DOI 10.1002/jcb.20192
   Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756 3282(01)00415 X
   Gerstenfeld LC, 1996, J CELL BIOCHEM, V62, P1
   Halawani D, 2004, ONCOGENE, V23, P3726, DOI 10.1038/sj.onc.1207422
   Hu YY, 2003, ENDOCRINOLOGY, V144, P2068, DOI 10.1210/en.2002 220863
   IKEDA T, 1992, J HISTOCHEM CYTOCHEM, V40, P1079, DOI 10.1177/40.8.1619274
   Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097 0177(199904)214:4<279::AID AJA1>3.0.CO;2 W
   Iwasaki M, 1997, MECH DEVELOP, V69, P197, DOI 10.1016/S0925 4773(97)00145 7
   James CG, 2005, MOL BIOL CELL, V16, P5316, DOI 10.1091/mbc.E05 01 0084
   James CG, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471 2199 7 30
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925 4773(98)00210 X
   Kobayashi T, 2005, ENDOCRINOLOGY, V146, P1012, DOI 10.1210/en.2004 1343
   Komori T, 2000, BIOCHEM BIOPH RES CO, V276, P813, DOI 10.1006/bbrc.2000.3460
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2005, J CELL BIOCHEM, V95, P445, DOI 10.1002/jcb.20420
   Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657
   Lai LP, 2005, J CELL PHYSIOL, V203, P177, DOI 10.1002/jcp.20208
   Lefebvre Veronique, 2005, Birth Defects Research, V75, P200, DOI 10.1002/bdrc.20048
   LIAN JB, 1993, J CELL BIOCHEM, V52, P206, DOI 10.1002/jcb.240520212
   Long FX, 2004, DEVELOPMENT, V131, P1309, DOI 10.1242/dev.01006
   Mello MA, 1999, IN VITRO CELL DEV AN, V35, P262
   NAKASE T, 1994, BONE MINER, V26, P109, DOI 10.1016/S0169 6009(08)80056 6
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191
   Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898 6568(99)00071 6
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Qiao M, 2006, J BIOL CHEM, V281, P7118, DOI 10.1074/jbc.M508162200
   Razzaque MS, 2005, J PATHOL, V207, P453, DOI 10.1002/path.1870
   Shi Y, 2002, BIOL CHEM, V383, P1519, DOI 10.1515/BC.2002.173
   Sims NA, 1997, MOL ENDOCRINOL, V11, P1695, DOI 10.1210/me.11.11.1695
   Sommer B, 1996, BONE, V19, P371, DOI 10.1016/S8756 3282(96)00218 9
   St Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072
   Stanton LA, 2003, INT J EXP PATHOL, V84, P289, DOI 10.1111/j.0959 9673.2003.00365.x
   Stanton LA, 2003, DEV BIOL, V263, P165, DOI 10.1016/S0012 1606(03)00321 X
   Stanton LA, 2004, BIOCHEM J, V378, P53, DOI 10.1042/BJ20030874
   Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613
   Wang GY, 2005, J BONE MINER RES, V20, P1022, DOI 10.1359/JBMR.050113
   Wang GY, 2004, J BIOL CHEM, V279, P13205, DOI 10.1074/jbc.M311427200
   Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200
   Woods A, 2004, GENE, V342, P77, DOI 10.1016/j.gene.2004.07.026
   Woods A, 2006, J BIOL CHEM, V281, P13134, DOI 10.1074/jbc.M509433200
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   Yagi K, 2003, J CELL BIOCHEM, V88, P1077, DOI 10.1002/jcb.10467
   Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704
   Zhang R, 2006, P NATL ACAD SCI USA, V103, P365, DOI 10.1073/pnas.0507979103
   Zhen XC, 2001, J BIOL CHEM, V276, P4879, DOI 10.1074/jbc.M004990200
NR 55
TC 30
Z9 38
U1 0
U2 2
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0014 4827
J9 EXP CELL RES
JI Exp. Cell Res.
PD JAN 1
PY 2007
VL 313
IS 1
BP 146
EP 155
DI 10.1016/j.yexcr.2006.09.027
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA 123NS
UT WOS:000243303200013
PM 17067574
DA 2025 08 17
ER

PT J
AU Studer, D
   Millan, C
   Öztürk, E
   Maniura Weber, K
   Zenobi Wong, M
AF Studer, Deborah
   Millan, Christopher
   Oeztuerk, Ece
   Maniura Weber, Katharina
   Zenobi Wong, Marcy
TI MOLECULAR AND BIOPHYSICAL MECHANISMS REGULATING HYPERTROPHIC
   DIFFERENTIATION IN CHONDROCYTES AND MESENCHYMAL STEM CELLS
SO EUROPEAN CELLS & MATERIALS
LA English
DT Article
DE Hypertrophy; mesenchymal stem cells; chondrogenesis; biomaterials;
   epigenetics; hypoxia; coculture
ID GROWTH PLATE CHONDROCYTES; HUMAN ARTICULAR CHONDROCYTES; HORMONE RELATED
   PEPTIDE; PROMOTES CHONDROGENIC DIFFERENTIATION; TRANSCRIPTION FACTOR
   RUNX2; IN VITRO CHONDROGENESIS; REDUCED OXYGEN TENSION; GENE EXPRESSION;
   BONE MARROW; PARATHYROID HORMONE
AB Chondrocyte hypertrophy is one of the key physiological processes involved in the longitudinal growth of long bones, yet regulation of hypertrophy is becoming increasingly relevant for clinical application of mesenchymal stem cells (MSCs) and screening for drugs to treat hypertrophic osteoarthritis. The extraordinary cell volume increase during hypertrophy is accompanied by an up regulation of collagen X, matrix metalloproteinases (MMPs), and vascular endothelial growth factor (VEGF), all which are targets of the runt related transcription factor 2 (Runx2). Many pathways, including parathyroid hormone related protein (PTHrP)/Indian Hedgehog, Wingless/Int (Wnt)/beta catenin, and transforming growth factor beta (TGF beta)/Sma and Mad Related Family (Smad) pathways, can regulate hypertrophy, but factors as diverse as hypoxia, co culture, epigenetics and biomaterial composition can also potently affect Runx2 expression. Control of hypertrophic differentiation can be exploited both for cartilage repair, where a stable phenotype is desired, but also in bone regeneration, where hypertrophic cartilage could act as a template for endochondral bone formation. We hope this review will motivate the design of novel engineered microenvironments for skeletal regeneration applications.
C1 [Studer, Deborah; Millan, Christopher; Oeztuerk, Ece; Zenobi Wong, Marcy] ETH, Cartilage Engn Regenerat Lab, Dept Hlth Sci & Technol, CH 8092 Zurich, Switzerland.
   [Studer, Deborah; Maniura Weber, Katharina] Empa, Lab Mat Biol Interact, Swiss Fed Labs Mat Testing & Res, St Gallen, Switzerland.
C3 Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal
   Institutes of Technology Domain; Swiss Federal Laboratories for
   Materials Science & Technology (EMPA)
RP Zenobi Wong, M (通讯作者)，ETH, Cartilage Engn Regenerat Lab, Dept Hlth Sci & Technol, Gloriastr 35,ETZ F84, CH 8092 Zurich, Switzerland.
EM zmarcy@ethz.ch
RI ; Zenobi Wong, Marcy/J 5398 2013; Maniura, Katharina/N 2955 2016;
   Ozturk, Ece/JFK 6940 2023
OI Ozturk, Ece/0000 0001 8635 0279; Zenobi Wong, Marcy/0000 0002 8522 9909;
   Maniura, Katharina/0000 0001 7895 3563; 
FU Swiss National Science Foundation [CR23I2 130678/1]; European Union
   [NMP4 SL 2009 229292]; Swiss National Science Foundation (SNF)
   [CR23I2_130678] Funding Source: Swiss National Science Foundation (SNF)
FX This study was supported by the Swiss National Science Foundation
   (CR23I2 130678/1) to MZW and KMW and the European Union Seventh
   Framework Programme (FP7/2007 2013) under grant agreement no
   NMP4 SL 2009 229292 (Find&Bind). We acknowledge Markus Rottmar for
   carefully reviewing the manuscript.
CR Acharya C, 2012, J CELL PHYSIOL, V227, P88, DOI 10.1002/jcp.22706
   Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308
   Amling M, 1997, J CELL BIOL, V136, P205, DOI 10.1083/jcb.136.1.205
   Anderson H Clarke, 2003, Curr Rheumatol Rep, V5, P222, DOI 10.1007/s11926 003 0071 z
   Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717
   Arnold MA, 2007, DEV CELL, V12, P377, DOI 10.1016/j.devcel.2007.02.004
   Awad HA, 2004, BIOMATERIALS, V25, P3211, DOI 10.1016/j.biomaterials.2003.10.045
   Backs J, 2008, MOL CELL BIOL, V28, P3437, DOI 10.1128/MCB.01611 07
   Backs J, 2006, J CLIN INVEST, V116, P1853, DOI 10.1172/JCI27438
   Balcerzak M, 2003, ACTA BIOCHIM POL, V50, P1019
   Barry F, 2001, EXP CELL RES, V268, P189, DOI 10.1006/excr.2001.5278
   Barter MJ, 2012, OSTEOARTHR CARTILAGE, V20, P339, DOI 10.1016/j.joca.2011.12.012
   Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104
   BAWDEN JW, 1989, ANAT REC, V224, P226, DOI 10.1002/ar.1092240212
   Benton G, 2009, FASEB J, V23, P3884, DOI 10.1096/fj.08 128702
   BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092 8674(82)90027 7
   Beris AE, 2005, INJURY, V36, pS14, DOI 10.1016/j.injury.2005.10.007
   Betre H, 2006, BIOMATERIALS, V27, P91, DOI 10.1016/j.biomaterials.2005.05.071
   Bian L, 2011, TISSUE ENG PT A, V17, P1137, DOI [10.1089/ten.tea.2010.0531, 10.1089/ten.TEA.2010.0531]
   Bian LM, 2011, BIOMATERIALS, V32, P6425, DOI 10.1016/j.biomaterials.2011.05.033
   Böhrnsen F, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471 2121 10 92
   BONEN DK, 1991, J CELL BIOL, V115, P1171, DOI 10.1083/jcb.115.4.1171
   Bradley EW, 2010, MOL ENDOCRINOL, V24, P1581, DOI 10.1210/me.2010 0037
   BUCKWALTER JA, 1986, J BONE JOINT SURG AM, V68A, P243, DOI 10.2106/00004623 198668020 00010
   Bush PG, 2008, J CELL PHYSIOL, V214, P621, DOI 10.1002/jcp.21249
   Bush PG, 2010, J BONE MINER RES, V25, P1594, DOI 10.1002/jbmr.47
   Caporali E, 2011, VET CLIN MED
   Chang YH, 1999, ENDOCRINOLOGY, V140, P5883, DOI 10.1210/en.140.12.5883
   Chao PHG, 2006, AM J PHYSIOL CELL PH, V291, pC718, DOI 10.1152/ajpcell.00127.2005
   Chen ZX, 2011, J BIOL CHEM, V286, P18347, DOI 10.1074/jbc.R110.205286
   Cheung KSC, 2009, RHEUMATOL INT, V29, P525, DOI 10.1007/s00296 008 0744 z
   Choi KH, 2010, BIOMATERIALS, V31, P5355, DOI 10.1016/j.biomaterials.2010.03.053
   Choi SW, 2012, BIOCHEM J, V443, P789, DOI 10.1042/BJ20112062
   Clark AL, 2010, ARTHRITIS RHEUM US, V62, P2973, DOI 10.1002/art.27624
   Connelly JT, 2008, J CELL PHYSIOL, V217, P145, DOI 10.1002/jcp.21484
   Cooke ME, 2011, OSTEOARTHR CARTILAGE, V19, P1210, DOI 10.1016/j.joca.2011.07.005
   Crapo PM, 2011, BIOMATERIALS, V32, P3233, DOI 10.1016/j.biomaterials.2011.01.057
   Curran JM, 2005, BIOMATERIALS, V26, P7057, DOI 10.1016/j.biomaterials.2005.05.008
   D'Andrea P, 2000, BIORHEOLOGY, V37, P75
   D'Ippolito G, 2006, BONE, V39, P513, DOI 10.1016/j.bone.2006.02.061
   Dioum EM, 2009, SCIENCE, V324, P1289, DOI 10.1126/science.1169956
   Dong YF, 2006, J CELL PHYSIOL, V208, P77, DOI 10.1002/jcp.20656
   Dudek KA, 2010, J BIOL CHEM, V285, P24381, DOI 10.1074/jbc.M110.111328
   Dy P, 2012, DEV CELL, V22, P597, DOI 10.1016/j.devcel.2011.12.024
   El Serafi AT, 2011, DIFFERENTIATION, V81, P35, DOI 10.1016/j.diff.2010.09.183
   Elvenes J, 2009, J ORTHOP SCI, V14, P410, DOI 10.1007/s00776 009 1349 4
   Ezura Y, 2009, ARTHRITIS RHEUM, V60, P1416, DOI 10.1002/art.24472
   Farnum CE, 2002, BONE, V30, P574, DOI 10.1016/S8756 3282(01)00710 4
   Finan JD, 2009, ANN BIOMED ENG, V37, P477, DOI 10.1007/s10439 008 9618 5
   Fischer J, 2010, ARTHRITIS RHEUM US, V62, P2696, DOI 10.1002/art.27565
   Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014 5793(95)01539 6
   Freed LE, 2006, TISSUE ENG, V12, P3285, DOI 10.1089/ten.2006.12.3285
   Furumatsu T, 2005, J BIOL CHEM, V280, P8343, DOI 10.1074/jbc.M413913200
   Furumatsu T, 2010, ACTA MED OKAYAMA, V64, P155
   Gao L, 2010, STEM CELLS, V28, P564, DOI 10.1002/stem.308
   Giannoni P, 2009, J APPL BIOMATER BIOM, V7, P1
   GRANDOLFO M, 1992, BIOCHEM BIOPH RES CO, V182, P1429, DOI 10.1016/0006 291X(92)91893 U
   Grayson WL, 2006, J CELL PHYSIOL, V207, P331, DOI 10.1002/jcp.20571
   Guan YJ, 2011, FASEB J, V25, P4457, DOI 10.1096/fj.11 185132
   Guilak F, 1999, J ORTHOPAED RES, V17, P421, DOI 10.1002/jor.1100170319
   Guo J, 2002, DEV CELL, V3, P183, DOI 10.1016/S1534 5807(02)00218 6
   Hall BK, 2000, BIOESSAYS, V22, P138, DOI 10.1002/(SICI)1521 1878(200002)22:2<138::AID BIES5>3.0.CO;2 4
   Han JW, 2010, INT J MOL MED, V25, P377, DOI 10.3892/ijmm_00000355
   Haudenschild DR, 2010, ARTHRITIS RHEUM US, V62, P191, DOI 10.1002/art.25051
   He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219
   Hellingman CA, 2011, TISSUE ENG PT A, V17, P1157, DOI [10.1089/ten.tea.2010.0043, 10.1089/ten.TEA.2010.0043]
   Hendy GN, 2009, PROG MOL BIOL TRANSL, V89, P31, DOI 10.1016/S1877 1173(09)89003 0
   Hirao M, 2006, J BIOL CHEM, V281, P31079, DOI 10.1074/jbc.M602296200
   Hirsch MS, 1997, DEV DYNAM, V210, P249, DOI 10.1002/(SICI)1097 0177(199711)210:3<249::AID AJA6>3.3.CO;2 3
   Hoffmann A, 2002, J CELL SCI, V115, P769
   HOLTZER H, 1964, BIOPHYS J, V4, P239, DOI 10.1016/S0006 3495(64)86941 1
   Hoshiba T, 2010, EXPERT OPIN BIOL TH, V10, P1717, DOI 10.1517/14712598.2010.534079
   Huang J, 2010, STEM CELLS, V28, P357, DOI 10.1002/stem.288
   Huang WD, 2000, MOL CELL BIOL, V20, P7838, DOI 10.1128/MCB.20.20.7838 7838.2000
   Hunziker EB, 1999, HISTOCHEM CELL BIOL, V112, P115, DOI 10.1007/s004180050397
   Hutmacher DW, 2000, BIOMATERIALS, V21, P2529, DOI 10.1016/S0142 9612(00)00121 6
   IANNOTTI JP, 1989, J ORTHOP RES, V7, P511, DOI 10.1002/jor.1100070408
   IANNOTTI JP, 1994, CLIN ORTHOP RELAT R, P222
   Im GI, 2011, BIOTECHNOL LETT, V33, P1061, DOI 10.1007/s10529 010 0514 3
   Inada M, 2004, P NATL ACAD SCI USA, V101, P17192, DOI 10.1073/pnas.0407788101
   Jensen ED, 2009, J BIOL CHEM, V284, P2225, DOI 10.1074/jbc.M800586200
   Johnson KA, 2008, J CELL SCI, V121, P2256, DOI 10.1242/jcs.011262
   Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858
   Kafienah W, 2007, ARTHRITIS RHEUM, V56, P177, DOI 10.1002/art.22285
   Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729
   Kanichai M, 2008, J CELL PHYSIOL, V216, P708, DOI 10.1002/jcp.21446
   Kawato Y, 2011, BIOCHEM BIOPH RES CO, V416, P205, DOI 10.1016/j.bbrc.2011.11.026
   Kim YJ, 2008, BIOCHEM BIOPH RES CO, V376, P241, DOI 10.1016/j.bbrc.2008.08.133
   Kirsch T, 2003, MOL B INT U, P172
   Kobayashi T, 2002, DEVELOPMENT, V129, P2977
   Kozhemyakina E, 2009, MOL CELL BIOL, V29, P5751, DOI 10.1128/MCB.00415 09
   Kronenberg HM, 2006, ANN NY ACAD SCI, V1068, P1, DOI 10.1196/annals.1346.002
   Kuo CK, 2006, CURR OPIN RHEUMATOL, V18, P64, DOI 10.1097/01.bor.0000198005.88568.df
   Kwon HJ, 2010, ACTA BIOMATER, V6, P494, DOI 10.1016/j.actbio.2009.07.033
   Kwon TG, 2011, J CELL BIOCHEM, V112, P3582, DOI 10.1002/jcb.23289
   Lafont JE, 2007, ARTHRITIS RHEUM, V56, P3297, DOI 10.1002/art.22878
   Lamprecht SA, 2003, NAT REV CANCER, V3, P601, DOI 10.1038/nrc1144
   Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663
   Lee JM, 2012, BIOCHEM BIOPH RES CO, V421, P819, DOI 10.1016/j.bbrc.2012.04.096
   Lengner CJ, 2005, J BIOL CHEM, V280, P15872, DOI 10.1074/jbc.M411144200
   Lennon DP, 2001, J CELL PHYSIOL, V187, P345, DOI 10.1002/jcp.1081
   Li TF, 2004, EXP CELL RES, V299, P128, DOI 10.1016/j.yexcr.2004.05.025
   Li WJ, 2005, BIOMATERIALS, V26, P5158, DOI 10.1016/j.biomaterials.2005.01.002
   Li Y, 2011, BIOPHYS J, V100, P1902, DOI 10.1016/j.bpj.2011.03.008
   Li YW, 2011, DEVELOPMENT, V138, P359, DOI 10.1242/dev.052324
   Lin EA, 2009, J BIOL CHEM, V284, P11326, DOI 10.1074/jbc.M807709200
   Liu SQ, 2010, BIOMATERIALS, V31, P7298, DOI 10.1016/j.biomaterials.2010.06.001
   LOESER RF, 1995, EXP CELL RES, V217, P248, DOI 10.1006/excr.1995.1084
   Loeser RF, 2000, OSTEOARTHR CARTILAGE, V8, P96, DOI 10.1053/joca.1999.0277
   Lu ZF, 2008, BIOCHEM BIOPH RES CO, V372, P547, DOI 10.1016/j.bbrc.2008.05.063
   Luckman SP, 2003, BIOCHEM J, V372, P485, DOI 10.1042/BJ20021572
   Mackay AM, 1998, TISSUE ENG, V4, P415, DOI 10.1089/ten.1998.4.415
   Mackie EJ, 2011, J ENDOCRINOL, V211, P109, DOI 10.1530/JOE 11 0048
   MacRae VE, 2010, BONE, V46, P1146, DOI 10.1016/j.bone.2009.12.018
   Mak KK, 2008, DEVELOPMENT, V135, P1947, DOI 10.1242/dev.018044
   Maruyama T, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000727
   Mauck RL, 2006, OSTEOARTHR CARTILAGE, V14, P179, DOI 10.1016/j.joca.2005.09.002
   Mauck RL, 2011, TISSUE ENGINEERING: FROM LAB TO CLINIC, P493, DOI 10.1007/978 3 642 02824 3_23
   Mello MA, 1999, IN VITRO CELL DEV AN, V35, P262
   Merceron C, 2012, STEM CELLS, V30, P471, DOI 10.1002/stem.1686
   Millward Sadler SJ, 2004, ANN BIOMED ENG, V32, P435, DOI 10.1023/B:ABME.0000017538.72511.48
   Miyaki S, 2010, GENE DEV, V24, P1173, DOI 10.1101/gad.1915510
   Mo XT, 2009, BONE, V45, P42, DOI 10.1016/j.bone.2008.07.240
   Mohyeldin A, 2010, CELL STEM CELL, V7, P150, DOI 10.1016/j.stem.2010.07.007
   Mrugala D, 2009, CLONING STEM CELLS, V11, P61, DOI 10.1089/clo.2008.0070
   Mueller MB, 2008, ARTHRITIS RHEUM US, V58, P1377, DOI 10.1002/art.23370
   Murphy CL, 2010, CELL RES, V20, P977, DOI 10.1038/cr.2010.99
   Murphy CL, 2001, TISSUE ENG, V7, P791, DOI 10.1089/107632701753337735
   Murphy CL, 2004, J CELL PHYSIOL, V199, P451, DOI 10.1002/jcp.10481
   Mwale F, 2006, TISSUE ENG, V12, P2639, DOI 10.1089/ten.2006.12.2639
   Narcisi R, 2012, J CELL PHYSIOL, V227, P3282, DOI 10.1002/jcp.24024
   Negoro K, 2008, CLIN EXP RHEUMATOL, V26, P534
   Nesic D, 2006, ADV DRUG DELIVER REV, V58, P300, DOI 10.1016/j.addr.2006.01.012
   Nguyen LH, 2011, BIOMATERIALS, V32, P1327, DOI 10.1016/j.biomaterials.2010.10.009
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Ortega N, 2004, TRENDS CELL BIOL, V14, P86, DOI 10.1016/j.tcb.2003.12.003
   Park SH, 2011, TISSUE ENG PT A, V17, P1277, DOI [10.1089/ten.tea.2010.0337, 10.1089/ten.TEA.2010.0337]
   Pei M, 2009, DIFFERENTIATION, V78, P260, DOI 10.1016/j.diff.2009.08.001
   Pelttari K, 2006, ARTHRITIS RHEUM US, V54, P3254, DOI 10.1002/art.22136
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Provot S, 2006, DEVELOPMENT, V133, P651, DOI 10.1242/dev.02258
   Quintana L, 2009, TISSUE ENG PART B RE, V15, P29, DOI 10.1089/ten.teb.2008.0329
   Re'em T, 2012, BIOMATERIALS, V33, P751, DOI 10.1016/j.biomaterials.2011.10.007
   Reddi AH, 2000, TISSUE ENG, V6, P351, DOI 10.1089/107632700418074
   Richter K, 2007, J CELL SCI, V120, P1673, DOI 10.1242/jcs.03440
   Roach HI, 2005, ARTHRITIS RHEUM US, V52, P3110, DOI 10.1002/art.21300
   Robins JC, 2005, BONE, V37, P313, DOI 10.1016/j.bone.2005.04.040
   Rodriguez L, 2005, ENDOCRINOLOGY, V146, P4597, DOI 10.1210/en.2005 0437
   Ronzière MC, 2010, BIO MED MATER ENG, V20, P145, DOI 10.3233/BME 2010 0626
   Saito T, 2010, NAT MED, V16, P678, DOI 10.1038/nm.2146
   Sekiya I, 2002, P NATL ACAD SCI USA, V99, P4397, DOI 10.1073/pnas.052716199
   Shapiro Irving M., 2005, Birth Defects Research, V75, P330, DOI 10.1002/bdrc.20057
   Sheehy EJ, 2012, BIOCHEM BIOPH RES CO, V417, P305, DOI 10.1016/j.bbrc.2011.11.105
   Shen G, 2005, Orthod Craniofac Res, V8, P11, DOI 10.1111/j.1601 6343.2004.00308.x
   Shimizu E, 2010, J BIOL CHEM, V285, P9616, DOI 10.1074/jbc.M109.094862
   SOLURSH M, 1975, DEV BIOL, V44, P278, DOI 10.1016/0012 1606(75)90398 X
   Song JJ, 2011, TRENDS MOL MED, V17, P424, DOI 10.1016/j.molmed.2011.03.005
   Srinivas V, 2009, CELLS TISSUES ORGANS, V189, P88, DOI 10.1159/000151428
   Stanton LA, 2004, BIOCHEM J, V378, P53, DOI 10.1042/BJ20030874
   Ströbel S, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2942
   Suomi S, 2008, GENE REGUL SYST BIO, V2, P177
   Swieszkowski W, 2007, BIOMOL ENG, V24, P489, DOI 10.1016/j.bioeng.2007.07.014
   Swingler TE, 2012, ARTHRITIS RHEUM US, V64, P1909, DOI 10.1002/art.34314
   Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101
   Tamiya H, 2008, GENE, V416, P53, DOI 10.1016/j.gene.2008.03.003
   Tanaka K, 2007, MATRIX BIOL, V26, P409, DOI 10.1016/j.matbio.2007.04.005
   Thirunavukkarasu K, 2007, MOL BIOL REP, V34, P1, DOI 10.1007/s11033 006 9001 2
   Tomita M, 2002, J BIOL CHEM, V277, P42214, DOI 10.1074/jbc.C200504200
   Topol LL, 2009, J BIOL CHEM, V284, P3323, DOI 10.1074/jbc.M808048200
   Tuddenham L, 2006, FEBS LETT, V580, P4214, DOI 10.1016/j.febslet.2006.06.080
   van der Kraan PM, 2009, OSTEOARTHR CARTILAGE, V17, P1539, DOI 10.1016/j.joca.2009.06.008
   van der Windt AE, 2012, ARTHRITIS RHEUM US, V64, P1929, DOI 10.1002/art.34369
   van Donkelaar CC, 2007, BIOMECH MODEL MECHAN, V6, P55, DOI 10.1007/s10237 006 0035 0
   Varghese S, 2008, MATRIX BIOL, V27, P12, DOI 10.1016/j.matbio.2007.07.002
   Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024
   Verzi MP, 2007, DEV CELL, V12, P645, DOI 10.1016/j.devcel.2007.03.007
   Vinatier C, 2009, CURR STEM CELL RES T, V4, P318, DOI 10.2174/157488809789649205
   Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613
   Wang AH, 1999, MOL CELL BIOL, V19, P7816
   Wang F, 2011, J ORTHOP SCI, V16, P304, DOI 10.1007/s00776 011 0055 1
   Wang GY, 2005, J BONE MINER RES, V20, P1022, DOI 10.1359/JBMR.050113
   Wang GY, 2004, J BIOL CHEM, V279, P13205, DOI 10.1074/jbc.M311427200
   Weiss S, 2010, J CELL PHYSIOL, V223, P84, DOI 10.1002/jcp.22013
   Wienholds E, 2005, FEBS LETT, V579, P5911, DOI 10.1016/j.febslet.2005.07.070
   Williams R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013246
   Woodfield TBF, 2006, BIOMATERIALS, V27, P1043, DOI 10.1016/j.biomaterials.2005.07.032
   Woods A, 2006, J BIOL CHEM, V281, P13134, DOI 10.1074/jbc.M509433200
   Wu SF, 2004, FASEB J, V18, P143, DOI 10.1096/fj.03 0294fje
   Xu Y, 2007, TISSUE ENG, V13, P2981, DOI 10.1089/ten.2007.0050
   Yamashita S, 2009, EXP CELL RES, V315, P2231, DOI 10.1016/j.yexcr.2009.03.008
   Yang B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021679
   Yang S, 2010, NAT MED, V16, P687, DOI 10.1038/nm.2153
   Yang X, 2001, J CELL BIOL, V153, P35, DOI 10.1083/jcb.153.1.35
   Yoon BS, 2006, DEVELOPMENT, V133, P4667, DOI 10.1242/dev.02680
   Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704
   Zhang Y, 2011, P NATL ACAD SCI USA, V108, P9863, DOI 10.1073/pnas.1018493108
   Zhen XC, 2001, J BIOL CHEM, V276, P4879, DOI 10.1074/jbc.M004990200
   Zhou G, 2006, P NATL ACAD SCI USA, V103, P19004, DOI 10.1073/pnas.0605170103
   Zimmermann P, 2008, ARTHRITIS RHEUM, V58, P2743, DOI 10.1002/art.23736
   Zscharnack M, 2009, CELLS TISSUES ORGANS, V190, P81, DOI 10.1159/000178024
   Zuscik MJ, 2002, EXP CELL RES, V276, P310, DOI 10.1006/excr.2002.5527
NR 201
TC 163
Z9 205
U1 0
U2 81
PU AO RESEARCH INSTITUTE DAVOS ARI
PI DAVOS
PA CLAVADELERSTRASSE 8, DAVOS, CH 7270, SWITZERLAND
SN 1473 2262
J9 EUR CELLS MATER
JI Eur. Cells Mater.
PD JUL DEC
PY 2012
VL 24
BP 118
EP 135
DI 10.22203/eCM.v024a09
PG 18
WC Cell & Tissue Engineering; Engineering, Biomedical; Materials Science,
   Biomaterials; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science; Orthopedics
GA 989JJ
UT WOS:000307555800009
PM 22828990
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Stern, PH
AF Stern, Paula H.
TI Antiresorptive agents and osteoclast apoptosis
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE osteoclast; apoptosis; bone resorption
ID INHIBITS BONE RESORPTION; NF KAPPA B; NITROGEN CONTAINING
   BISPHOSPHONATES; SURVIVAL IN VITRO; CELL DEATH; CYCLOSPORINE A;
   GENE EXPRESSION; MEVALONATE PATHWAY; VITRONECTIN RECEPTOR; PROMOTES
   APOPTOSIS
AB Antiresorptive agents have proven to be effective therapies for the treatment of bone diseases associated with excessive osteoclast activity. Decreased osteoclast formation, inhibition of osteoclast actions, and reduced osteoclast survival represent mechanisms by which antiresorptive agents could act. The goals of this article are to present the evidence that antiresorptive agents can decrease osteoclast survival through apoptosis, to review the mechanisms by which they are thought to activate the apoptotic process, and to consider whether the actions on apoptosis fully account for the antiresorptive effects. As background, the apoptotic process will be briefly summarized together with the evidence that factors that promote osteoclast survival affect steps in the process. Following this, therapeutic agents that are both antiresorptive and can stimulate osteoclast apoptosis will be discussed. Other bone therapeutic agents that are either antiresorptive or apoptotic, but not both, will be described. Finally, newer antiresorptive compounds that elicit apoptosis and could represent potential therapeutic agents will be noted. J. Cell. Biochem. 101: 1087 1096, 2007. (C) 2007 Wiley Liss, Inc.
C1 Northwestern Univ, Dept Mol Pharmacol & Biol Chem S 215, Feinberg Sch Med, Chicago, IL 60611 USA.
C3 Northwestern University; Feinberg School of Medicine
RP Stern, PH (通讯作者)，Northwestern Univ, Dept Mol Pharmacol & Biol Chem S 215, Feinberg Sch Med, 308 E Chicago Ave, Chicago, IL 60611 USA.
EM p stern@northwestern.edu
CR ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756
   Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635
   Bredesen DE, 2006, NATURE, V443, P796, DOI 10.1038/nature05293
   Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318
   Chwieralski CE, 2006, APOPTOSIS, V11, P143, DOI 10.1007/s10495 006 3486 y
   CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0
   Cordes N, 2006, CANCER LETT, V242, P11, DOI 10.1016/j.canlet.2005.12.004
   Day CJ, 2004, J CELL BIOCHEM, V91, P303, DOI 10.1002/jcb.10780
   Dib IE, 2006, EUR J PHARMACOL, V551, P27, DOI 10.1016/j.ejphar.2006.09.007
   ENDRESEN PC, 1993, BIOCHEM PHARMACOL, V46, P1893, DOI 10.1016/0006 2952(93)90629 B
   Engelman VW, 1997, J CLIN INVEST, V99, P2284, DOI 10.1172/JCI119404
   Erben RG, 2003, ENDOCRINOLOGY, V144, P40, DOI 10.1210/en.2002 220513
   Fisher JE, 2000, ENDOCRINOLOGY, V141, P4793, DOI 10.1210/en.141.12.4793
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   FISHER JRA, 2006, ASBMR 28 ANN M
   Fornoni A, 2001, NEPHROL DIAL TRANSPL, V16, P500, DOI 10.1093/ndt/16.3.500
   GARDNER AM, 1993, J BIOL CHEM, V268, P17896
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693
   Halasy Nagy JM, 2001, BONE, V29, P553, DOI 10.1016/S8756 3282(01)00615 9
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   Hutchinson JH, 2003, J MED CHEM, V46, P4790, DOI 10.1021/jm030306r
   Igarashi K, 2004, BONE, V35, P47, DOI 10.1016/j.bone.2004.02.009
   Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092 8674(00)80153 1
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Ito M, 1999, BONE, V25, P447, DOI 10.1016/S8756 3282(99)00197 0
   Kameda T, 1997, J EXP MED, V186, P489, DOI 10.1084/jem.186.4.489
   Kanaoka K, 2000, ENDOCRINOLOGY, V141, P2995, DOI 10.1210/en.141.8.2995
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200
   KLAUSHOFER K, 1987, J PHARMACOL EXP THER, V243, P584
   Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270
   Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002 9440(10)64556 7
   Lark MW, 2001, J BONE MINER RES, V16, P319, DOI 10.1359/jbmr.2001.16.2.319
   Lark MW, 1999, J PHARMACOL EXP THER, V291, P612
   Lee SE, 2001, J BIOL CHEM, V276, P49343, DOI 10.1074/jbc.M103642200
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   LIU CC, 1991, ANAT REC, V229, P240, DOI 10.1002/ar.1092290211
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   Mackle PS, 2001, BRIT J CANCER, V84, P951, DOI 10.1054/bjoc.2000.1679
   MCCARTHY TJ, 1992, J CLIN PHARM THER, V17, P51, DOI 10.1111/j.1365 2710.1992.tb01265.x
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   MOVSOWITZ C, 1988, ENDOCRINOLOGY, V123, P2571, DOI 10.1210/endo 123 5 2571
   Murakami T, 1998, BIOCHEM BIOPH RES CO, V252, P747, DOI 10.1006/bbrc.1998.9723
   Murthy PSN, 2006, J STEROID BIOCHEM, V100, P117, DOI 10.1016/j.jsbmb.2006.03.009
   Nhan TQ, 2006, AM J PATHOL, V169, P729, DOI 10.2353/ajpath.2006.060105
   Niwa S, 2001, LIFE SCI, V70, P315, DOI 10.1016/S0024 3205(01)01386 8
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Okahashi N, 1997, J BONE MINER RES, V12, P1116, DOI 10.1359/jbmr.1997.12.7.1116
   Penolazzi L, 2006, INT J MOL MED, V18, P807
   Piva R, 2005, APOPTOSIS, V10, P1079, DOI 10.1007/s10495 005 0618 8
   Plotkin LI, 2006, BONE, V39, P443, DOI 10.1016/j.bone.2006.02.060
   PRYTZ PS, 1991, BIOCHEM PHARMACOL, V42, P1761, DOI 10.1016/0006 2952(91)90513 5
   Recchia I, 2004, BONE, V34, P65, DOI 10.1016/j.bone.2003.06.004
   Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967
   Rodino MA, 1998, AM J MED, V104, P459, DOI 10.1016/S0002 9343(98)00081 3
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Saintier D, 2006, J STEROID BIOCHEM, V99, P165, DOI 10.1016/j.jsbmb.2006.01.009
   Schafer ZT, 2006, DEV CELL, V10, P549, DOI 10.1016/j.devcel.2006.04.008
   Selander KS, 1996, MOL CELL ENDOCRINOL, V122, P119, DOI 10.1016/0303 7207(96)03870 1
   Selander KS, 1996, MOL PHARMACOL, V50, P1127
   STEWART PJ, 1986, J BONE MINER RES, V1, P285
   Sun L, 2005, P NATL ACAD SCI USA, V102, P17130, DOI 10.1073/pnas.0508480102
   Szymczyk KH, 2006, J CELL PHYSIOL, V209, P836, DOI 10.1002/jcp.20770
   Takai H, 1998, J BIOL CHEM, V273, P27091, DOI 10.1074/jbc.273.42.27091
   Tang L, 2002, CELL BIOL INT, V26, P75, DOI 10.1006/cbir.2001.0812
   Thiebaud D, 1996, EUR J CLIN INVEST, V26, P549, DOI 10.1046/j.1365 2362.1996.00170.x
   Thirunavukkarasu K, 2001, J BIOL CHEM, V276, P36241, DOI 10.1074/jbc.M104319200
   Uchiyama S, 2006, J CELL BIOCHEM, V98, P1185, DOI 10.1002/jcb.20824
   Villanova I, 1999, J BONE MINER RES, V14, P1867, DOI 10.1359/jbmr.1999.14.11.1867
   Willingham MC, 1999, J HISTOCHEM CYTOCHEM, V47, P1101, DOI 10.1177/002215549904700901
   Winslow MM, 2006, DEV CELL, V10, P771, DOI 10.1016/j.devcel.2006.04.006
   Woo JT, 2006, P NATL ACAD SCI USA, V103, P4729, DOI 10.1073/pnas.0505663103
   Woo JT, 2000, J BONE MINER RES, V15, P650, DOI 10.1359/jbmr.2000.15.4.650
   WU JG, 1993, J EXP MED, V178, P461, DOI 10.1084/jem.178.2.461
   Wu PL, 2006, J BIOL CHEM, V281, P7937, DOI 10.1074/jbc.M513035200
   Wu XJ, 2003, ENDOCRINOLOGY, V144, P5545, DOI 10.1210/en.2003 0296
   Yang Y, 1996, GENE THER, V3, P137
   YEO H, 2006, ASBMR 28 ANN M
   Zallone A, 2006, ANN NY ACAD SCI, V1068, P173, DOI 10.1196/annals.1346.019
   Zecchi Orlandini S, 1999, BIOCHEM BIOPH RES CO, V255, P680, DOI 10.1006/bbrc.1999.0215
   Zhao HB, 2005, MOL ENDOCRINOL, V19, P771, DOI 10.1210/me.2004 0161
NR 87
TC 33
Z9 38
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD AUG 1
PY 2007
VL 101
IS 5
BP 1087
EP 1096
DI 10.1002/jcb.21311
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 199KD
UT WOS:000248693800004
PM 17407157
DA 2025 08 17
ER

PT J
AU Cohn Schwartz, D
   Schary, Y
   Yalon, E
   Krut, Z
   Da, XY
   Schwarz, EM
   Gazit, D
   Pelled, G
   Gazit, Z
AF Cohn Schwartz, Doron
   Schary, Yeshai
   Yalon, Eran
   Krut, Zoe
   Da, Xiaoyu
   Schwarz, Edward M.
   Gazit, Dan
   Pelled, Gadi
   Gazit, Zulma
TI PTH Induced Bone Regeneration and Vascular Modulation Are Both Dependent
   on Endothelial Signaling
SO CELLS
LA English
DT Article
DE parathyroid hormone; fracture healing; angiogenesis; osteogenesis;
   allograft; calvarial bone repair
ID PARATHYROID HORMONE 1 34; PROTEIN RECEPTOR; ILIAC CREST; ALLOGRAFT;
   GRAFT; EXPRESSION; FRACTURES; NONUNION; CELLS; ARTERIOGENESIS
AB The use of a bone allograft presents a promising approach for healing nonunion fractures. We have previously reported that parathyroid hormone (PTH) therapy induced allograft integration while modulating angiogenesis at the allograft proximity. Here, we hypothesize that PTH induced vascular modulation and the osteogenic effect of PTH are both dependent on endothelial PTH receptor 1 (PTHR1) signaling. To evaluate our hypothesis, we used multiple transgenic mouse lines, and their wild type counterparts as a control. In addition to endothelial specific PTHR1 knock out mice, we used mice in which PTHR1 was engineered to be constitutively active in collagen 1 alpha+ osteoblasts, to assess the effect of PTH signaling activation exclusively in osteoprogenitors. To characterize resident cell recruitment and osteogenic activity, mice in which the Luciferase reporter gene is expressed under the Osteocalcin promoter (Oc Luc) were used. Mice were implanted with calvarial allografts and treated with either PTH or PBS. A micro computed tomography based structural analysis indicated that the induction of bone formation by PTH, as observed in wild type animals, was not maintained when PTHR1 was removed from endothelial cells. Furthermore, the induction of PTH signaling exclusively in osteoblasts resulted in significantly less bone formation compared to systemic PTH treatment, and significantly less osteogenic activity was measured by bioluminescence imaging of the Oc Luc mice. Deletion of the endothelial PTHR1 significantly decreased the PTH induced formation of narrow blood vessels, formerly demonstrated in wild type mice. However, the exclusive activation of PTH signaling in osteoblasts was sufficient to re establish the observed PTH effect. Collectively, our results show that endothelial PTHR1 signaling plays a key role in PTH induced osteogenesis and has implications in angiogenesis.
C1 [Cohn Schwartz, Doron] Rambam Healthcare Campus, Div Internal Med, Dept Internal Med B, IL 3109601 Haifa, Israel.
   [Cohn Schwartz, Doron; Schary, Yeshai; Yalon, Eran; Gazit, Dan; Pelled, Gadi; Gazit, Zulma] Hebrew Univ Jerusalem, Fac Dent Med, Skeletal Biotech Lab, IL 91120 Jerusalem, Israel.
   [Krut, Zoe; Gazit, Dan; Pelled, Gadi; Gazit, Zulma] Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA.
   [Krut, Zoe; Gazit, Dan; Pelled, Gadi; Gazit, Zulma] Cedars Sinai Med Ctr, Board Governors Regenerat Med Inst, Los Angeles, CA 90048 USA.
   [Da, Xiaoyu; Gazit, Dan; Pelled, Gadi] Cedars Sinai Med Ctr, Biomed Imaging Res Inst, Los Angeles, CA 90048 USA.
   [Schwarz, Edward M.] Univ Rochester, Ctr Musculoskeletal Res, Sch Med & Dent, Dept Orthpaed, Rochester, NY 14642 USA.
   [Gazit, Dan; Pelled, Gadi; Gazit, Zulma] Cedars Sinai Med Ctr, Dept Orthped, Los Angeles, CA 90048 USA.
C3 Rambam Health Care Campus; Hebrew University of Jerusalem; Cedars Sinai
   Medical Center; Cedars Sinai Medical Center; University of Rochester;
   Cedars Sinai Medical Center
RP Gazit, Z (通讯作者)，Hebrew Univ Jerusalem, Fac Dent Med, Skeletal Biotech Lab, IL 91120 Jerusalem, Israel.; Gazit, Z (通讯作者)，Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA.; Gazit, Z (通讯作者)，Cedars Sinai Med Ctr, Board Governors Regenerat Med Inst, Los Angeles, CA 90048 USA.; Gazit, Z (通讯作者)，Cedars Sinai Med Ctr, Dept Orthped, Los Angeles, CA 90048 USA.
EM d_cohnschwartz@rambam.health.gov.il; yeshaischary@mail.tau.ac.il;
   eran.yalon@mail.huji.ac.il; zoe.krut@cshs.org; xiaoyu.da@cshs.org;
   edward_schwarz@urmc.rochester.edu; dan.gazit@csmc.edu;
   gadi.pelled@cshs.org; zulma.gazit@csmc.edu
RI Gazit, Zulma/AAA 5790 2021; Pelled, Gadi/AAG 9728 2021
OI Schwarz, Edward/0000 0002 4854 9698; , Zulma/0000 0001 9176 0889; 
CR Andrzejowski P, 2019, J ORTHOP TRAUMATOL, V20, DOI 10.1186/s10195 019 0528 0
   Antebi Ben, 2016, Bioengineering Basel, V3, P6, DOI 10.3390/bioengineering3010006
   Berendsen AD, 2015, BONE, V80, P14, DOI 10.1016/j.bone.2015.04.035
   Bhatt RA, 2012, HAND CLIN, V28, P457, DOI 10.1016/j.hcl.2012.08.001
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296
   Cooper GM, 2010, PLAST RECONSTR SURG, V125, P1685, DOI 10.1097/PRS.0b013e3181cb63a3
   Costa G, 2012, DEVELOPMENT, V139, P1587, DOI 10.1242/dev.071282
   Curtis EM, 2016, BONE, V87, P19, DOI 10.1016/j.bone.2016.03.006
   Dhillon RS, 2013, J BONE MINER RES, V28, P586, DOI 10.1002/jbmr.1765
   Dimitriou R, 2011, INJURY, V42, pS3, DOI 10.1016/j.injury.2011.06.015
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Frölke JPM, 2007, INJURY, V38, pS19, DOI 10.1016/S0020 1383(07)80005 2
   Gambardella J, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9582319
   Hermenean A, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 16599 5
   Isales CM, 2000, AM J PHYSIOL ENDOC M, V279, pE654, DOI 10.1152/ajpendo.2000.279.3.E654
   Jiang BB, 1998, J CARDIOVASC PHARM, V31, pS142, DOI 10.1097/00005344 199800001 00042
   Jilka RL, 2010, J BONE MINER RES, V25, P2427, DOI 10.1002/jbmr.145
   Kallai I, 2011, NAT PROTOC, V6, P105, DOI 10.1038/nprot.2010.180
   Korhonen TK, 2019, J NEUROSURG, V130, P1672, DOI 10.3171/2017.12.JNS172013
   Lawton DM, 1997, J CLIN PATHOL MOL PA, V50, P194, DOI 10.1136/mp.50.4.194
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Manabe T, 2007, BONE, V40, P1475, DOI 10.1016/j.bone.2007.01.015
   Nazarian A, 2008, BONE, V43, P302, DOI 10.1016/j.bone.2008.04.009
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Prisby R, 2011, J BONE MINER RES, V26, P2583, DOI 10.1002/jbmr.459
   Qiu T, 2015, J BONE MINER RES, V30, P309, DOI 10.1002/jbmr.2327
   Rahman CV, 2014, J TISSUE ENG REGEN M, V8, P59, DOI 10.1002/term.1497
   Rashid G, 2007, NEPHROL DIAL TRANSPL, V22, P2831, DOI 10.1093/ndt/gfm269
   Rashid G, 2007, AM J PHYSIOL RENAL, V292, pF1215, DOI 10.1152/ajprenal.00406.2006
   Reynolds DG, 2011, BONE, V48, P562, DOI 10.1016/j.bone.2010.10.003
   Roche B, 2014, J BONE MINER RES, V29, P1608, DOI 10.1002/jbmr.2191
   Rodriguez Merchan EC, 2004, CLIN ORTHOP RELAT R, P4, DOI 10.1097/00003086 200402000 00003
   Schlundt C, 2018, CURR OSTEOPOROS REP, V16, P155, DOI 10.1007/s11914 018 0432 1
   Schwabe P, 2014, INT ORTHOP, V38, P2623, DOI 10.1007/s00264 014 2496 6
   Sen MK, 2007, INJURY, V38, pS75, DOI 10.1016/j.injury.2007.02.012
   Sheyn D, 2013, MOL PHARMACEUT, V10, P4462, DOI 10.1021/mp400292p
   Silva BC, 2015, CURR OPIN PHARMACOL, V22, P41, DOI 10.1016/j.coph.2015.03.005
   Szpalski C, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10201
   Takahata M, 2012, J BONE MINER RES, V27, P26, DOI 10.1002/jbmr.518
   Throckmorton D, 2002, PEPTIDES, V23, P79, DOI 10.1016/S0196 9781(01)00582 4
   Tomford William W., 2000, Cell and Tissue Banking, V1, P105, DOI 10.1023/A:1010158731885
   Wang LQ, 2019, J BONE MINER RES, V34, P520, DOI 10.1002/jbmr.3626
   Weng SJ, 2019, ENDOCRINE, V63, P376, DOI 10.1007/s12020 018 1761 7
   Yakubovich DC, 2017, BONE, V97, P192, DOI 10.1016/j.bone.2017.01.020
   Yakubovich DC, 2015, JOVE J VIS EXP, DOI 10.3791/53459
   Zhao S, 2021, CALCIFIED TISSUE INT, V108, P391, DOI 10.1007/s00223 020 00776 2
   Zura R, 2016, JAMA SURG, V151, DOI 10.1001/jamasurg.2016.2775
NR 48
TC 9
Z9 9
U1 0
U2 5
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD MAR
PY 2022
VL 11
IS 5
AR 897
DI 10.3390/cells11050897
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA ZT5HW
UT WOS:000769187800001
PM 35269519
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Higgs, JT
   Jarboe, JS
   Lee, JH
   Chanda, D
   Lee, CM
   Deivanayagam, C
   Ponnazhagan, S
AF Higgs, Jerome T.
   Jarboe, John S.
   Lee, Joo Hyoung
   Chanda, Diptiman
   Lee, Carnellia M.
   Deivanayagam, Champion
   Ponnazhagan, Selvarangan
TI Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone
   Remodeling in Osteolytic Malignancies
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID APOPTOSIS INDUCING LIGAND; NECROSIS FACTOR RECEPTOR; MESENCHYMAL
   STEM CELLS; OSTEOCLAST DIFFERENTIATION; CRYSTAL STRUCTURE;
   MULTIPLE MYELOMA; POSTMENOPAUSAL WOMEN; TUMOR GROWTH; DECOY RECEPTOR;
   MURINE MODEL
AB Osteolytic bone damage is a major cause of morbidity in several metastatic pathologies. Current therapies using bisphosphonates provide modest improvement, but cytotoxic side effects still occur prompting the need to develop more effective therapies to target aggressive osteoclastogenesis. Increased levels of receptor activator of NF kappa B ligand (TNFSF11/RANKL), leading to RANKL RANK signaling, remain the key axis for osteoclast activation and bone resorption. Osteoprotegerin (TNFRSF11B/OPG), a decoy receptor for RANKL, is significantly decreased in patients who present with bone lesions. Despite its potential in inhibiting osteoclast activation, OPG also binds to TNF related apoptosis inducing ligand (TNFSF10/TRAIL), making tumor cells resistant to apoptosis. Toward uncoupling the events of TRAIL binding of OPG and to improve its utility for bone remodeling without inducing tumor resistance to apoptosis, OPG mutants were developed by structural homology modeling based on interactive domain identification and by superimposing models of OPG, TRAIL, and its receptor DR5 (TNFRSF10B) to identify regions of OPG for rational design. The OPG mutants were purified and extensively characterized for their ability to decrease osteoclast damage without affecting tumor apoptosis pathway both in vitro and in vivo, confirming their potential in bone remodeling following cancer induced osteolytic damage. (C)2015 AACR.
C1 [Higgs, Jerome T.; Lee, Joo Hyoung; Chanda, Diptiman; Lee, Carnellia M.; Ponnazhagan, Selvarangan] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [Jarboe, John S.] Univ Alabama Birmingham, Dept Biochem, Birmingham, AL 35294 USA.
   [Jarboe, John S.] Univ Alabama Birmingham, Dept Radiat Oncol, Birmingham, AL 35294 USA.
   [Deivanayagam, Champion] Univ Alabama Birmingham, Dept Vision Sci, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Ponnazhagan, S (通讯作者)，Univ Alabama Birmingham, 1825 Univ Blvd,SHEL 814, Birmingham, AL 35294 USA.
EM pons@uab.edu
RI Lee, Joo/A 7713 2017
OI Deivanayagam, Champion/0000 0003 2972 1824
FU NIH [AR050251, AR560948, CA132077, CA133737, P30 AR046031, P30 AR48311];
   DoD grant [DoD BC101411]
FX This work was financially supported by NIH grants AR050251, AR560948,
   CA132077, CA133737, P30 AR046031, and P30 AR48311, and DoD grant
   DoD BC101411.
CR Body JJ, 2003, CANCER AM CANCER SOC, V97, P887, DOI 10.1002/cncr.11138
   Cha SS, 2000, J BIOL CHEM, V275, P31171, DOI 10.1074/jbc.M004414200
   Cha SS, 1999, IMMUNITY, V11, P253, DOI 10.1016/S1074 7613(00)80100 4
   Chanda D, 2010, J CELL BIOCHEM, V111, P249, DOI 10.1002/jcb.22701
   Corey E, 2005, CANCER RES, V65, P1710, DOI 10.1158/0008 5472.CAN 04 2033
   Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356
   Croucher PI, 2001, BLOOD, V98, P3534, DOI 10.1182/blood.V98.13.3534
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Doi T, 2011, CANCER CHEMOTH PHARM, V68, P733, DOI 10.1007/s00280 010 1544 1
   Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Gopal K, 2014, EXP BIOL MED, V239, P663, DOI 10.1177/1535370214530364
   Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367
   Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097 2765(00)80207 5
   Itonaga I, 2000, J PATHOL, V192, P97
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kitazawa S, 2002, J PATHOL, V198, P228, DOI 10.1002/path.1199
   Labrinidis A, 2009, CLIN CANCER RES, V15, P1998, DOI 10.1158/1078 0432.CCR 08 2444
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lam J, 2001, J CLIN INVEST, V108, P971, DOI 10.1172/JCI13890
   Maginn EN, 2011, BRIT J CANCER, V104, P281, DOI 10.1038/sj.bjc.6606035
   Mongkolsapaya J, 1999, NAT STRUCT BIOL, V6, P1048
   Morony S, 2001, CANCER RES, V61, P4432
   Naismith JH, 1996, STRUCTURE, V4, P1251, DOI 10.1016/S0969 2126(96)00134 7
   Nelson CA, 2012, STRUCTURE, V20, P1971, DOI 10.1016/j.str.2012.08.030
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Shipman CM, 2003, CANCER RES, V63, P912
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Szafran AA, 2009, CANCER BIOL THER, V8, P1109, DOI 10.4161/cbt.8.12.8327
   Takeda K, 2001, CELL IMMUNOL, V214, P194, DOI 10.1006/cimm.2001.1896
   Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171
   Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   Vanderkerken K, 2003, CANCER RES, V63, P287
   Vitovski S, 2007, J BIOL CHEM, V282, P31601, DOI 10.1074/jbc.M706078200
   Wittrant Y, 2004, BBA REV CANCER, V1704, P49, DOI 10.1016/j.bbcan.2004.05.002
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zerafa N, 2005, J IMMUNOL, V175, P5586, DOI 10.4049/jimmunol.175.9.5586
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
   Zhou ZY, 2014, INT J CLIN EXP PATHO, V7, P2113
   Zhu L, 2012, J CONTROL RELEASE, V163, P55, DOI 10.1016/j.jconrel.2012.05.044
   Zierhut ML, 2008, J PHARMACOKINET PHAR, V35, P379, DOI 10.1007/s10928 008 9093 5
NR 46
TC 8
Z9 8
U1 1
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1541 7786
EI 1557 3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD MAY
PY 2015
VL 13
IS 5
BP 819
EP 827
DI 10.1158/1541 7786.MCR 14 0492
PG 9
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA CM9VN
UT WOS:000358057500002
PM 25636966
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Joeng, KS
   Long, FX
AF Joeng, Kyu Sang
   Long, Fanxin
TI Constitutive Activation of Gli2 Impairs Bone Formation in Postnatal
   Growing Mice
SO PLOS ONE
LA English
DT Article
ID INDIAN HEDGEHOG; CHONDROCYTE DIFFERENTIATION; OSTEOBLAST
   DIFFERENTIATION; ENDOCHONDRAL OSSIFICATION; GROWTH PLATE; IHH;
   CARTILAGE; PROTEIN; PTHRP; PROLIFERATION
AB Indian hedgehog (Ihh) signaling is indispensable for osteoblast differentiation during endochondral bone development in the mouse embryo. We have previously shown that the Gli2 transcription activator critically mediates Ihh function in osteoblastogenesis. To explore the possibility that activation of Hedgehog (Hh) signaling may enhance bone formation, we generated mice that expressed a constitutively active form of Gli2 in the Osx lineage cells. Unexpectedly, these mice exhibited severe osteopenia due to a marked decrease in osteoblast number and function, although bone resorption was not affected. Quantitative analyses of the molecular markers indicated that osteoblast differentiation was impaired in the mutant mouse. However, the osteoblast lineage cells isolated from these mice exhibited more robust osteoblast differentiation than normal in vitro. Similarly, pharmacological stimulation of Hh signaling enhanced osteoblast differentiation from Osx expressing cells isolated from the wild type mouse. Thus, even though Hh signaling directly promotes osteoblast differentiation in vitro, constitutive activation of this pathway impairs bone formation in vivo, perhaps through an indirect mechanism.
C1 [Joeng, Kyu Sang; Long, Fanxin] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
   [Joeng, Kyu Sang; Long, Fanxin] Washington Univ, Sch Med, Div Biol & Biomed Sci, St Louis, MO 63110 USA.
   [Long, Fanxin] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63110 USA.
C3 Washington University (WUSTL); Washington University (WUSTL); Washington
   University (WUSTL)
RP Long, FX (通讯作者)，Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
EM flong@wustl.edu
FU National Institutes of Health [R01 DK065789]
FX The study is funded by National Institutes of Health R01 DK065789. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Chung UI, 2001, J CLIN INVEST, V107, P295, DOI 10.1172/JCI11706
   Davey RA, 2012, TRANSGENIC RES, V21, P885, DOI 10.1007/s11248 011 9581 z
   Heller E, 2012, CANCER RES, V72, P897, DOI 10.1158/0008 5472.CAN 11 2681
   Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716
   Hilton MJ, 2007, DEV BIOL, V308, P93, DOI 10.1016/j.ydbio.2007.05.011
   Hilton MJ, 2005, DEVELOPMENT, V132, P4339, DOI 10.1242/dev.02025
   Hojo H, 2012, J BIOL CHEM, V287, P17860, DOI 10.1074/jbc.M112.347716
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601
   Joeng KS, 2009, DEVELOPMENT, V136, P4177, DOI 10.1242/dev.041624
   Karp SJ, 2000, DEVELOPMENT, V127, P543
   Kesper DA, 2010, DEV DYNAM, V239, P1818, DOI 10.1002/dvdy.22301
   Kobayashi T, 2005, J CLIN INVEST, V115, P1734, DOI 10.1172/JCI24397
   Koziel L, 2005, DEVELOPMENT, V132, P5249, DOI 10.1242/dev.02097
   Long FX, 2004, DEVELOPMENT, V131, P1309, DOI 10.1242/dev.01006
   Long FX, 2001, DEVELOPMENT, V128, P5099
   Maeda Y, 2007, P NATL ACAD SCI USA, V104, P6382, DOI 10.1073/pnas.0608449104
   Mak KK, 2008, DEV CELL, V14, P674, DOI 10.1016/j.devcel.2008.02.003
   Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335
   Ohba S, 2008, DEV CELL, V14, P689, DOI 10.1016/j.devcel.2008.03.007
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   St Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072
   Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613
   Wu X, 2004, CHEM BIOL, V11, P1229, DOI 10.1016/j.chembiol.2004.06.010
NR 24
TC 8
Z9 11
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JAN 30
PY 2013
VL 8
IS 1
AR e55134
DI 10.1371/journal.pone.0055134
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 098QM
UT WOS:000315563800117
PM 23383082
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Gu, XH
   Fu, XJ
   Lu, JH
   Saijilafu
   Li, B
   Luo, ZP
   Chen, JQ
AF Gu, Xiaohui
   Fu, Xuejie
   Lu, Jihang
   Saijilafu
   Li, Bin
   Luo, Zong ping
   Chen, Jianquan
TI Pharmacological inhibition of S6K1 impairs self renewal and osteogenic
   differentiation of bone marrow stromal cells
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE BMSCs; LY2584702; osteogenic differentiation; S6K1; self renewal
ID SKELETAL GROWTH; OSTEOBLAST; PROLIFERATION; ACTIVATION; RECEPTOR
AB mTORC1 signaling not only plays important physiological roles in the regulation of proliferation and osteogenic differentiation of BMSCs, but also mediates exogenous Wnt induced protein anabolism and osteoblast differentiation. However, the downstream effectors of the mTORC1 signaling in the above processes are still poorly understood. In this study, we explored the specific role of S6K1, one of the major targets of the mTORC1 pathway, in BMSCs self renewal and osteogenic differentiation. We first found that S6K1 was active in primary mouse bone marrow stromal cells, and further activated upon osteogenic induction. We then determined the effects of S6K1 inhibition by LY2584702 Tosylate, a selective inhibitor of S6K1 (hereafter S6KI), using both primary mouse bone marrow stromal cells and ST2 cells. Colony Forming Unit Fibroblast (CFU F) assays showed that S6KI dramatically reduced the total number of colonies formed in primary BMSCs cultures. Under the basal osteogenic culture condition, S6KI significantly inhibited mRNA expression of osteoblast marker genes (Sp7, Bglap, Ibsp, and Col1a1), ALP activity and matrix mineralization. Upon Wnt3a treatments, S6KI inhibited Wnt3a induced osteoblast differentiation and expression of protein anabolism genes in ST2 cells, but to a much lesser degree than rapamycin (a specific inhibitor of mTORC1 signaling). Collectively, our findings have demonstrated that pharmacological inhibition of S6K1 impaired self renewal and osteogenic differentiation of BMSCs, but only partially suppressed exogenous Wnt3a induced osteoblast differentiation and protein anabolism.
C1 [Gu, Xiaohui] Zhejiang Prov Peoples Hosp, Dept Orthopaed, Hangzhou, Zhejiang, Peoples R China.
   [Gu, Xiaohui; Fu, Xuejie; Lu, Jihang; Saijilafu; Li, Bin; Luo, Zong ping; Chen, Jianquan] Soochow Univ, Inst Orthopaed, Affiliated Hosp 1, Dept Orthopaed, 708 Renmin Rd, Suzhou 215006, Jiangsu, Peoples R China.
C3 Hangzhou Medical College; Zhejiang Provincial People's Hospital; Soochow
   University   China
RP Luo, ZP; Chen, JQ (通讯作者)，Soochow Univ, Inst Orthopaed, Affiliated Hosp 1, Dept Orthopaed, 708 Renmin Rd, Suzhou 215006, Jiangsu, Peoples R China.
EM zongping_luo@yahoo.com; chenjianquan@suda.edu.cn
RI Saijilafu, Saijilafu/AAV 3704 2021; Li, Bin/B 7802 2012; Gu,
   Xiaohui/AAI 7507 2021
OI , Saijilafu/0000 0003 2290 9808; Li, Bin/0000 0001 8516 9953; 
FU National Key R&D Program of China [2016YFC1100203]; Priority Academic
   Program Development of Jiangsu High Education Institutions (PAPD);
   Zhejiang Provincial Health Commission; Chinese National Health
   Commission [WKJ2014 2 002]; Innovation and Entrepreneurship Program of
   Jiangsu Province; special fund of science and technology project of
   traditional Chinese medicine of Zhejiang Province
FX National Key R&D Program of China, Grant number: 2016YFC1100203; the
   Priority Academic Program Development of Jiangsu High Education
   Institutions (PAPD); the co building major project of Zhejiang
   Provincial Health Commission and Chinese National Health Commission,
   Grant number: WKJ2014 2 002; the Innovation and Entrepreneurship Program
   of Jiangsu Province; the special fund of science and technology project
   of traditional Chinese medicine of Zhejiang Province
CR Chen JQ, 2015, J BONE MINER RES, V30, P369, DOI 10.1002/jbmr.2348
   Chen JQ, 2014, DEVELOPMENT, V141, P2848, DOI 10.1242/dev.108811
   Chen JJ, 2014, SCI WORLD J, DOI 10.1155/2014/416530
   Cheng J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115339
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   Fitter S, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00668 16
   Ghosh J, 2016, J CLIN INVEST, V126, P2621, DOI 10.1172/JCI84565
   Hollebecque A, 2014, EUR J CANCER, V50, P876, DOI 10.1016/j.ejca.2013.12.006
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Jiang M, 2017, J CELL BIOCHEM, V118, P748, DOI 10.1002/jcb.25728
   Karner CM, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00253 16
   Karner CM, 2017, CELL MOL LIFE SCI, V74, P1649, DOI 10.1007/s00018 016 2425 5
   Karner CM, 2015, J CLIN INVEST, V125, P551, DOI 10.1172/JCI78470
   Koromila T, 2014, J CELL BIOCHEM, V115, P27, DOI 10.1002/jcb.24646
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Magnuson B, 2012, BIOCHEM J, V441, P1, DOI 10.1042/BJ20110892
   Rudnicki MA, 2015, BONE, V80, P60, DOI 10.1016/j.bone.2015.02.009
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Singha UK, 2008, J CELL BIOCHEM, V103, P434, DOI 10.1002/jcb.21411
   Tavares MR, 2015, LIFE SCI, V131, P1, DOI 10.1016/j.lfs.2015.03.001
   Tolcher A, 2014, EUR J CANCER, V50, P867, DOI 10.1016/j.ejca.2013.11.039
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   Yan B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11151
   Zhang H, 2017, OSTEOARTHR CARTILAGE, V25, P952, DOI 10.1016/j.joca.2016.12.024
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
NR 25
TC 13
Z9 15
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN
PY 2018
VL 119
IS 1
BP 1041
EP 1049
DI 10.1002/jcb.26272
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA FN5CO
UT WOS:000416024300101
PM 28853173
DA 2025 08 17
ER

PT J
AU Nováková, S
   Danchenko, M
   Okajceková, T
   Baranovicová, E
   Kovác, A
   Grendár, M
   Beke, G
   Pálesová, J
   Strnádel, J
   Janícková, M
   Halasová, E
   Skovierová, H
AF Novakova, Slavomira
   Danchenko, Maksym
   Okajcekova, Terezia
   Baranovicova, Eva
   Kovac, Andrej
   Grendar, Marian
   Beke, Gabor
   Palesova, Janka
   Strnadel, Jan
   Janickova, Maria
   Halasova, Erika
   Skovierova, Henrieta
TI Comparative Proteomic and Metabolomic Analysis of Human Osteoblasts,
   Differentiated from Dental Pulp Stem Cells, Hinted Crucial Signaling
   Pathways Promoting Osteogenesis
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE DPSCs; osteogenic differentiation; label free quantification; NMR; bone
   metabolism; mineralization phase; late osteoblast
ID ENERGY METABOLISM; BONE METABOLISM; VITAMIN D; TISSUE; PROLIFERATION;
   EXPRESSION; BETA; OSTEOPOROSIS; ACTIVATION; MECHANISMS
AB Population aging has been a global trend for the last decades, which increases the pressure to develop new cell based or drug based therapies, including those that may cure bone diseases. To understand molecular processes that underlie bone development and turnover, we followed osteogenic differentiation of human dental pulp stem cells (DPSCs) using a specific induction medium. The differentiation process imitating in vivo osteogenesis is triggered by various signaling pathways and is associated with massive proteome and metabolome changes. Proteome was profiled by ultrahigh performance liquid chromatography and comprehensively quantified by ion mobility enhanced mass spectrometry. From 2667 reproducibly quantified and identified proteins, 432 were differentially abundant by strict statistic criteria. Metabolome profiling was carried out by nuclear magnetic resonance. From 27 detected metabolites, 8 were differentially accumulated. KEGG and MetaboAnalyst hinted metabolic pathways that may be involved in the osteogenic process. Enrichment analysis of differentially abundant proteins highlighted PPAR, FoxO, JAK STAT, IL 17 signaling pathways, biosynthesis of thyroid hormones and steroids, mineral absorption, and fatty acid metabolism as processes with prominent impact on osteoinduction. In parallel, metabolomic data showed that aminoacyl tRNA biosynthesis, as well as specific amino acids, likely promote osteodifferentiation. Targeted immunoassays validated and complemented omic results. Our data underlined the complexity of the osteogenic mechanism. Finally, we proposed promising targets for future validation in patient samples, a step toward the treatment of bone defects.
C1 [Novakova, Slavomira; Okajcekova, Terezia; Baranovicova, Eva; Grendar, Marian; Palesova, Janka; Strnadel, Jan; Halasova, Erika; Skovierova, Henrieta] Comenius Univ Bratislava JFM CU, Jessenius Fac Med Martin, Biomed Ctr Martin, Mala Hora 4C, Martin 03601, Slovakia.
   [Danchenko, Maksym] Slovak Acad Sci, Plant Sci & Biodivers Ctr, Dubravska Cesta 9, Bratislava 84523, Slovakia.
   [Kovac, Andrej] Slovak Acad Sci, Inst Neuroimmunol, Dubravska Cesta 9, Bratislava 84510, Slovakia.
   [Beke, Gabor] Slovak Acad Sci, Inst Mol Biol, Dubravska Cesta 21, Bratislava 84551, Slovakia.
   [Janickova, Maria] Univ Hosp Martin & JFM CU, Dept Stomatol & Maxillofacial Surg, Kollarova 2, Martin 03601, Slovakia.
   [Janickova, Maria] JFM CU, Kollarova 2, Martin 03601, Slovakia.
   [Halasova, Erika] Comenius Univ Bratislava JFM CU, Jessenius Fac Med Martin, Dept Med Biol, Mala Hora 4C, Martin 03601, Slovakia.
C3 Comenius University Bratislava; Slovak Academy of Sciences; Plant
   Science & Biodiversity Centre, SAS; Slovak Academy of Sciences;
   Institute of Neuroimmunology, SAS; Slovak Academy of Sciences; Comenius
   University Bratislava; Comenius University Bratislava
RP Nováková, S; Skovierová, H (通讯作者)，Comenius Univ Bratislava JFM CU, Jessenius Fac Med Martin, Biomed Ctr Martin, Mala Hora 4C, Martin 03601, Slovakia.
EM slavomira.novakova@uniba.sk; maksym.danchenko@savba.sk;
   tereza.okj@gmail.com; eva.baranovicova@uniba.sk; andrej.kovac@savba.sk;
   marian.grendar@uniba.sk; gabor.beke@savba.sk; sopkova24@uniba.sk;
   jan.strnadel@uniba.sk; maria.janickova@uniba.sk;
   erika.halasova@uniba.sk; henrieta.skovierova@uniba.sk
RI Danchenko, Maksym/G 7793 2015; Janickova, Maria/X 6194 2018;
   Baranovicova, Eva/Y 1706 2018; Grendar, Marian/X 6032 2018; Strnadel,
   Jan/Y 5172 2018; Škovierová, Henrieta/Y 1751 2018
OI Danchenko, Maksym/0000 0002 3676 0728; Janickova,
   Maria/0000 0003 1819 7780; Kovac, Andrej/0000 0002 3223 8705;
   Baranovicova, Eva/0000 0003 1357 9368; Grendar,
   Marian/0000 0002 6712 3457; 
FU Scientific Grant Agency of the Ministry of Education, Science, Research
   and Sports of the Slovak Republic [VEGA 1/0310/21]; Slovak Academy of
   Sciences; Slovak Research and Development Agency [APVV 15 0217];
   Integrated Infrastructure Operational Program for the project: Systemic
   Public Research Infrastructure Biobank for Cancer and Rare diseases
   [ITMS: 313011AFG5]; European Regional Development Fund
FX This study was supported by projects VEGA 1/0310/21 of the Scientific
   Grant Agency of the Ministry of Education, Science, Research and Sports
   of the Slovak Republic and the Slovak Academy of Sciences and
   APVV 15 0217 from the Slovak Research and Development Agency. This
   publication also has been produced with the support of the Integrated
   Infrastructure Operational Program for the project: Systemic Public
   Research Infrastructure Biobank for Cancer and Rare diseases, ITMS:
   313011AFG5, co financed by the European Regional Development Fund.
CR Alekos NS, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.578194
   Almalki SG, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0393 1
   Alves RDAM, 2010, J PROTEOME RES, V9, P4688, DOI 10.1021/pr100400d
   Ambrogini E, 2010, CELL METAB, V11, P136, DOI 10.1016/j.cmet.2009.12.009
   Antebi B, 2014, CURR OSTEOPOROS REP, V12, P41, DOI 10.1007/s11914 013 0184 x
   Aspenberg P, 2005, ACTA ORTHOP, V76, P741, DOI 10.1080/17453670510045318
   Bassett JHD, 2016, ENDOCR REV, V37, P135, DOI 10.1210/er.2015 1106
   Bindal P, 2017, WOODH PUBL SER BIOM, P297, DOI 10.1016/B978 0 08 100961 1.00018 9
   Blair HC, 2016, LAB INVEST, V96, P763, DOI 10.1038/labinvest.2016.51
   Boyle EI, 2004, BIOINFORMATICS, V20, P3710, DOI 10.1093/bioinformatics/bth456
   Brun J, 2017, DIABETES, V66, P2541, DOI 10.2337/db17 0116
   Brylka LJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02182
   Campos JM, 2019, REGEN BIOMATER, V6, P49, DOI 10.1093/rb/rby025
   Campos JLO, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00784
   Cao CK, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.95512
   Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886
   Carluccio M, 2020, PURINERG SIGNAL, V16, P263, DOI 10.1007/s11302 020 09703 4
   Chau JFL, 2009, HISTOL HISTOPATHOL, V24, P1593, DOI 10.14670/HH 24.1593
   Chauhan N, 2021, MAT SCI ENG C MATER, V120, DOI 10.1016/j.msec.2020.111669
   Chen DJ, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12540
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen YY, 2016, INT J ORAL SCI, V8, P213, DOI 10.1038/ijos.2016.33
   Chong J, 2018, NUCLEIC ACIDS RES, V46, pW486, DOI 10.1093/nar/gky310
   d'Aquino R, 2009, EUR CELLS MATER, V18, P75, DOI 10.22203/eCM.v018a07
   de Paula FJA, 2013, BONE RES, V1, DOI 10.4248/BR201301005
   Della Pepa G, 2016, CLIN CASES MINER BON, V13, P181, DOI 10.11138/ccmbm/2016.13.3.181
   Distler U, 2016, NAT PROTOC, V11, P795, DOI 10.1038/nprot.2016.042
   Dyne KM, 1996, AM J MED GENET, V63, P161, DOI 10.1002/(SICI)1096 8628(19960503)63:1<161::AID AJMG28>3.0.CO;2 L
   El Refaey M, 2014, CALCIFIED TISSUE INT, V95, P174, DOI 10.1007/s00223 014 9878 z
   Feng YL, 2018, INT J MOL MED, V41, P202, DOI 10.3892/ijmm.2017.3208
   Fratzl Zelman N, 2003, CELL BIOL INT, V27, P459, DOI 10.1016/S1065 6995(03)00037 4
   Freist W, 1999, BIOL CHEM, V380, P623, DOI 10.1515/BC.1999.079
   Fritsche Guenther R, 2020, METABOLITES, V10, DOI 10.3390/metabo10010002
   Gaddy Kurten D, 2002, ENDOCRINOLOGY, V143, P74, DOI 10.1210/en.143.1.74
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Goedhart J, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 76603 3
   Gowda GAN, 2015, ANAL CHEM, V87, P706, DOI 10.1021/ac503651e
   Grygiel Górniak B, 2014, NUTR J, V13, DOI 10.1186/1475 2891 13 17
   Hayami T, 2008, MATRIX BIOL, V27, P682, DOI 10.1016/j.matbio.2008.07.005
   Hayrapetyan A, 2015, TISSUE ENG PART B RE, V21, P75, DOI [10.1089/ten.teb.2014.0119, 10.1089/ten.TEB.2014.0119]
   Hegde V, 2016, OSTEOPOROSIS INT, V27, P861, DOI 10.1007/s00198 015 3331 7
   Hoang Kim A, 2009, CLIN CASES MINER BON, V6, P136
   Holecek M, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030848
   Hu JJ, 2014, PROTEOME SCI, V12, DOI 10.1186/1477 5956 12 13
   Iaquinta MR, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00268
   Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617
   Iñiguez Ariza NM, 2015, MATURITAS, V82, P245, DOI 10.1016/j.maturitas.2015.07.003
   Izu Y, 2016, CELL TISSUE RES, V364, P623, DOI 10.1007/s00441 015 2345 y
   Jani PH, 2016, MATRIX BIOL, V52 54, P95, DOI 10.1016/j.matbio.2015.12.001
   Karbanová J, 2011, CELLS TISSUES ORGANS, V193, P344, DOI 10.1159/000321160
   Karbanova Jana, 2010, Acta Medica (Hradec Kralove), V53, P79
   Kim BC, 2012, TISSUE ENG PART B RE, V18, P235, DOI [10.1089/ten.teb.2011.0642, 10.1089/ten.TEB.2011.0642]
   Kim Jaehyun, 2021, J Bone Metab, V28, P1, DOI 10.11005/jbm.2021.28.1.1
   Kim JH, 2013, THER ADV MUSCULOSKEL, V5, P13, DOI 10.1177/1759720X12466608
   Kim SP, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92704
   Kim YH, 2019, BIOCHEM BIOPH RES CO, V520, P459, DOI 10.1016/j.bbrc.2019.10.048
   Kirkham G.R, GENES PROTEINS INVOL
   Klontzas ME, 2017, STEM CELLS DEV, V26, P723, DOI 10.1089/scd.2016.0315
   Koga T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147235
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kunimatsu R, 2018, BIOCHEM BIOPH RES CO, V501, P193, DOI 10.1016/j.bbrc.2018.04.213
   Laird E, 2010, NUTRIENTS, V2, P693, DOI 10.3390/nu2070693
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Lee Y, 2013, BMB REP, V46, P479, DOI 10.5483/BMBRep.2013.46.10.141
   Li Z, 2013, CELL PROLIFERAT, V46, P501, DOI 10.1111/cpr.12051
   Lin CY, 2011, J ENDODONT, V37, P211, DOI 10.1016/j.joen.2010.11.009
   Liu JJ, 2015, STEM CELLS, V33, P627, DOI 10.1002/stem.1909
   Liu MY, 2012, MOLECULES, V17, P1219, DOI 10.3390/molecules17021219
   Ma XL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030692
   MacDougall MJ, 2010, TOP BONE BIOL, V6, P183, DOI 10.1007/978 1 84882 822 3_11
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Manoli I, 2016, Transl Sci Rare Dis, V1, P91, DOI 10.3233/TRD 160009
   Maraldi T, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt203
   Matsuoka F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055082
   McGonnell Imelda M, 2012, Front Endocrinol (Lausanne), V3, P88, DOI 10.3389/fendo.2012.00088
   Meguid EA, 2018, J CELL PHYSIOL, V233, P1825, DOI 10.1002/jcp.25940
   Office of the Surgeon General, 2004, BONE HEAL OSTEOPOROS, P16
   Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29
   Okajcekova T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072280
   Okamoto M, 2014, SCI REP UK, V4, DOI 10.1038/srep04493
   Oryan A, 2017, CELLS TISSUES ORGANS, V204, P59, DOI 10.1159/000469704
   Pavone V, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00803
   Perez Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106
   Prabhu AV, 2016, J BIOL CHEM, V291, P8363, DOI 10.1074/jbc.M115.699546
   Pramojanee SN, 2014, ENDOCR RES, V39, P144, DOI 10.3109/07435800.2013.879168
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Redza Dutordoir M, 2016, BBA MOL CELL RES, V1863, P2977, DOI 10.1016/j.bbamcr.2016.09.012
   Reimand J, 2019, NAT PROTOC, V14, P482, DOI 10.1038/s41596 018 0103 9
   Sankaramanivel S., 2017, INT J CURR RES REV, V9, P54, DOI [10.7324/IJCRR.2017.91310, DOI 10.7324/IJCRR.2017.91310]
   Sanpaolo ER, 2020, MOL BIOL REP, V47, P9087, DOI 10.1007/s11033 020 05910 9
   Sapcariu SC, 2014, METHODSX, V1, P74, DOI 10.1016/j.mex.2014.07.002
   Sergi C, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00093
   Sharma V, 2021, ACTA BIOMATER, V120, P20, DOI 10.1016/j.actbio.2020.04.049
   Shum LC, 2016, STEM CELLS DEV, V25, P114, DOI 10.1089/scd.2015.0193
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Sun P, 2020, FEBS OPEN BIO, V10, P1503, DOI 10.1002/2211 5463.12906
   Tajima K, 2010, J ORTHOP RES, V28, P937, DOI 10.1002/jor.21086
   Testa G, 2015, J BIOL REG HOMEOS AG, V29, P729
   Teti G, 2013, EUR J HISTOCHEM, V57, P151, DOI 10.4081/ejh.2013.e23
   Trayhurn P., 2003, ENCY FOOD SCI NUTR, V2nd ed., P5762
   Tsai KS, 2010, J BIOMED MATER RES A, V94A, P673, DOI 10.1002/jbm.a.32693
   Tu Kristie N, 2018, P T, V43, P92
   van Gastel N, 2020, NATURE, V579, P111, DOI 10.1038/s41586 020 2050 1
   Verdelis K, 2008, BONE, V43, P983, DOI 10.1016/j.bone.2008.08.110
   Waddington R. J., 2003, European Cells & Materials, V6, P12
   Wang H, 2018, ARCH ORAL BIOL, V89, P9, DOI 10.1016/j.archoralbio.2018.01.015
   Wang ZY, 2016, MOL MED REP, V14, P4931, DOI 10.3892/mmr.2016.5867
   Wieczorek E, 2019, BBA GEN SUBJECTS, V1863, P313, DOI 10.1016/j.bbagen.2018.10.017
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD608, DOI 10.1093/nar/gkx1089
   Wu H, 2011, J BIOL CHEM, V286, P29462, DOI 10.1074/jbc.M110.194746
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Xu LJ, 2018, J CELL BIOCHEM, V119, P3819, DOI 10.1002/jcb.26332
   Yamagata K, 2008, MOL CELL, V32, P221, DOI 10.1016/j.molcel.2008.09.013
   YAMAGUCHI M, 1995, GEN PHARMACOL VASC S, V26, P1179, DOI 10.1016/0306 3623(95)00008 O
   Yamakoshi Y, 2014, J DENT RES, V93, P671, DOI 10.1177/0022034514534690
   Yamakoshi Y, 2018, JPN DENT SCI REV, V54, P183, DOI 10.1016/j.jdsr.2018.03.006
   Yang B, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00197
   Yang JH, 2010, CELL BIOCHEM FUNCT, V28, P334, DOI 10.1002/cbf.1668
   Yang YL, 2019, J BIOL CHEM, V294, P15395, DOI 10.1074/jbc.RA119.010139
   Yin WZ, 2019, NUTRIENTS, V11, DOI 10.3390/nu11061394
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zarjou A, 2010, J BONE MINER RES, V25, P164, DOI 10.1359/jbmr.091002
   Zhang SF, 2018, BIOCHEM BIOPH RES CO, V501, P968, DOI 10.1016/j.bbrc.2018.05.092
NR 123
TC 9
Z9 10
U1 1
U2 34
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2021
VL 22
IS 15
AR 7908
DI 10.3390/ijms22157908
PG 27
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA TV5UQ
UT WOS:000681788900001
PM 34360674
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Siddappa, R
   Martens, A
   Doorn, J
   Leusink, A
   Olivo, C
   Licht, R
   van Rijn, L
   Gaspar, C
   Fodde, R
   Janssen, F
   van Blitterswijk, C
   de Boer, J
AF Siddappa, Ramakrishnaiah
   Martens, Anton
   Doorn, Joyce
   Leusink, Anouk
   Olivo, Cristina
   Licht, Ruud
   van Rijn, Linda
   Gaspar, Claudia
   Fodde, Riccardo
   Janssen, Frank
   van Blitterswijk, Clemens
   de Boer, Jan
TI cAMP/PKA pathway activation in human mesenchymal stem cells in
   vitro results in robust bone formation in vivo
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE bone tissue engineering; osteogenesis; PKA signaling
ID MARROW STROMAL CELLS; TISSUE ENGINEERED BONE; OSTEOBLAST
   DIFFERENTIATION; SIGNALING PATHWAY; OSTEOGENIC DIFFERENTIATION;
   TELOMERASE EXPRESSION; GENE TRANSCRIPTION; PROTEIN KINASE;
   PROLIFERATION; MECHANISMS
AB Tissue engineering of large bone defects is approached through implantation of autologous osteogenic cells, generally referred to as multipotent stromal cells or mesenchymal stem cells (MSCs). Animal derived MSCs successfully bridge large bone defects, but models for ectopic bone formation as well as recent clinical trials demonstrate that bone formation by human MSCs (hMSCs) is inadequate. The expansion phase presents an attractive window to direct hMSCs by pharmacological manipulation, even though no profound effect on bone formation in vivo has been described so far using this approach. We report that activation of protein kinase A elicits an immediate response through induction of genes such as ID2 and FosB, followed by sustained secretion of bone related cytokines such as BMP 2, IGF 1, and IL 11. As a consequence, PKA activation results in robust in vivo bone formation by hMSCs derived from orthopedic patients.
C1 [Siddappa, Ramakrishnaiah; Doorn, Joyce; Leusink, Anouk; Licht, Ruud; van Rijn, Linda; Janssen, Frank; van Blitterswijk, Clemens; de Boer, Jan] Univ Twente, Inst Biomed Technol, Dept Tissue Regenerat, NL 7500 AE Enschede, Netherlands.
   [Martens, Anton; Olivo, Cristina] Univ Med Ctr, Dept Immunol, NL 3584 EA Utrecht, Netherlands.
   [Gaspar, Claudia; Fodde, Riccardo] Erasmus MC, Josephine Nefkens Inst, Dept Pathol, NL 3000 DR Rotterdam, Netherlands.
C3 University of Twente; Utrecht University; Utrecht University Medical
   Center; Erasmus University Rotterdam; Erasmus MC
RP de Boer, J (通讯作者)，Univ Twente, Inst Biomed Technol, Dept Tissue Regenerat, POB 217, NL 7500 AE Enschede, Netherlands.
EM j.deboer@tnw.utwente.nl
RI ; Janssen, Frank/ABD 7244 2020; Fodde, Riccardo/IIS 2405 2023; Gaspar,
   Claudia/I 6402 2013
OI van Blitterswijk, Clemens/0000 0003 2371 4615; Fodde,
   Riccardo/0000 0001 9839 4324; de Boer, Jan/0000 0001 9188 9324; Gaspar,
   Claudia/0000 0003 1051 0998
CR Bianco P, 2001, NATURE, V414, P118, DOI 10.1038/35102181
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Both SK, 2007, TISSUE ENG, V13, P3, DOI 10.1089/ten.2005.0513
   Braccini A, 2005, STEM CELLS, V23, P1066, DOI 10.1634/stemcells.2005 0002
   Cowan CM, 2004, NAT BIOTECHNOL, V22, P560, DOI 10.1038/nbt958
   de Boer J, 2004, BONE, V34, P818, DOI 10.1016/j.bone.2004.01.016
   De Boer J, 2004, TISSUE ENG, V10, P393, DOI 10.1089/107632704323061753
   De Boer J, 2006, TISSUE ENG, V12, P2927
   De Kok I J, 2006, J Oral Implantol, V32, P103, DOI 10.1563/760.1
   DELSAL G, 1995, MOL CELL BIOL, V15, P7152
   Dezawa M, 2005, SCIENCE, V309, P314, DOI 10.1126/science.1110364
   Ding S, 2004, NAT BIOTECHNOL, V22, P833, DOI 10.1038/nbt987
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Habibovic P, 2008, BIOMATERIALS, V29, P944, DOI 10.1016/j.biomaterials.2007.10.023
   Hughes FJ, 2006, PERIODONTOL 2000, V41, P48, DOI 10.1111/j.1600 0757.2006.00161.x
   Ionescu AM, 2004, J CELL PHYSIOL, V198, P428, DOI 10.1002/jcp.10421
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Janssen FW, 2006, BIOMATERIALS, V27, P315, DOI 10.1016/j.biomaterials.2005.07.044
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kim GS, 1997, J BONE MINER RES, V12, P896, DOI 10.1359/jbmr.1997.12.6.896
   Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627
   Kruyt MC, 2004, TRANSPLANTATION, V77, P359, DOI 10.1097/01.TP.0000102550.58160.39
   KURABAYASHI M, 1995, MOL CELL BIOL, V15, P6386
   Li TF, 2004, EXP CELL RES, V299, P128, DOI 10.1016/j.yexcr.2004.05.025
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lutolf MP, 2005, NAT BIOTECHNOL, V23, P47, DOI 10.1038/nbt1055
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   Meijer GJ, 2007, PLOS MED, V4, P260, DOI 10.1371/journal.pmed.0040009
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Petite H, 2000, NAT BIOTECHNOL, V18, P959, DOI 10.1038/79449
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Shi ST, 2002, NAT BIOTECHNOL, V20, P587, DOI 10.1038/nbt0602 587
   Siddappa Ramakrishnaiah, 2007, Curr Stem Cell Res Ther, V2, P209, DOI 10.2174/157488807781696267
   Siddappa R, 2007, J ORTHOP RES, V25, P1029, DOI 10.1002/jor.20402
   Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602 592
   Tezuka K, 2002, J BONE MINER RES, V17, P231, DOI 10.1359/jbmr.2002.17.2.231
   Tintut Y, 1998, J BIOL CHEM, V273, P7547, DOI 10.1074/jbc.273.13.7547
   TURKSEN K, 1990, J CELL PHYSIOL, V142, P61, DOI 10.1002/jcp.1041420109
   Umayahara Y, 1997, J BIOL CHEM, V272, P31793, DOI 10.1074/jbc.272.50.31793
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092 8674(04)00344 7
   Yuan HP, 2002, J MATER SCI MATER M, V13, P1271, DOI 10.1023/A:1021191432366
   Zhao YX, 2007, P NATL ACAD SCI USA, V104, P9673, DOI 10.1073/pnas.0703407104
NR 44
TC 201
Z9 226
U1 0
U2 25
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 20
PY 2008
VL 105
IS 20
BP 7281
EP 7286
DI 10.1073/pnas.0711190105
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 305FJ
UT WOS:000256162900033
PM 18490653
OA Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Yun, HM
   Park, KR
   Quang, TH
   Oh, H
   Hong, JT
   Kim, YC
   Kim, EC
AF Yun, H M
   Park, K R
   Quang, T. H.
   Oh, H.
   Hong, J. T.
   Kim, Y C
   Kim, E C
TI 2,4,5 Trimethoxyldalbergiquinol promotes osteoblastic differentiation
   and mineralization via the BMP and Wnt/β catenin pathway
SO CELL DEATH & DISEASE
LA English
DT Article
ID BONE MORPHOGENETIC PROTEIN 2; INHIBITS OSTEOCLAST DIFFERENTIATION;
   DALBERGIA ODORIFERA; SIGNALING PATHWAYS; HEME OXYGENASE 1; EXPRESSION;
   CELLS; ACTIVATION; HEARTWOOD; RUNX2
AB Dalbergia odorifera has been traditionally used as a medicine to treat many diseases. However, the role of 2,4,5 trimethoxyldalbergiquinol (TMDQ) isolated and extracted from D. odorifera in osteoblast function and the underlying molecular mechanisms remain poorly understood. The aim of this study was to investigate the effects and possible underlying mechanisms of TMDQ on osteoblastic differentiation of primary cultures of mouse osteoblasts as an in vitro assay system. TMDQ stimulated osteoblastic differentiation, as assessed by the alkaline phosphatase (ALP) activity, ALP staining, mineralized nodule formation, and the levels of mRNAs encoding the bone differentiation markers, including ALP, bone sialoprotein (BSP), osteopontin, and osteocalcin. TMDQ upregulated the expression of Bmp2 and Bmp4 genes, and increased the protein level of phospho Smad1/5/8. Furthermore, TMDQ treatment showed the increased mRNA expression of Wnt ligands, phosphorylation of GSK3, and the expression of beta catenin protein. The TMDQ induced osteogenic effects were abolished by Wnt inhibitor, Dickkopf 1 (DKK1), and bone morphogenetic protein (BMP) antagonist, noggin. TMDQ induced runt related transcription factor 2 (Runx2) expression was attenuatted by noggin and DKK1. These data suggest that TMDQ acts through the activation of BMP, Wnt/beta catenin, and Runx2 signaling to promote osteoblast differentiation, and we demonstrate that TMDQ could be a potential agent for the treatment of bone loss associated diseases such as osteoporosis.
C1 [Yun, H M; Park, K R; Kim, E C] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, Seoul 130701, South Korea.
   [Yun, H M; Park, K R; Kim, E C] Kyung Hee Univ, Res Ctr Tooth & Periodontal Regenerat MRC, Seoul 130701, South Korea.
   [Quang, T. H.; Oh, H.; Kim, Y C] Wonkwang Univ, Coll Pharm, Inst Pharmaceut Res & Dev, Dept Pharm, Iksan 570749, South Korea.
   [Hong, J. T.] Chungbuk Natl Univ, Coll Pharm, Dept Pharm, Cheongju 361763, South Korea.
   [Hong, J. T.] Chungbuk Natl Univ, Med Res Ctr, Cheongju 361763, South Korea.
C3 Kyung Hee University; Kyung Hee University; Wonkwang University;
   Chungbuk National University; Chungbuk National University
RP Kim, EC (通讯作者)，Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, 1 Heogi Dong, Seoul 130701, South Korea.
EM eckim@khu.ac.kr
RI Kim, Cheorl Ho/T 6753 2019
FU National Research Foundation of Korea (NRF) grant   Korea government
   (MEST) [2012R1A5A2051384]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MEST; No, 2012R1A5A2051384)
CR An RB, 2008, CHEM PHARM BULL, V56, P1722, DOI 10.1248/cpb.56.1722
   Augustine M, 2013, CURR OSTEOPOROS REP, V11, P400, DOI 10.1007/s11914 013 0171 2
   Bodine PVN, 2006, REV ENDOCR METAB DIS, V7, P33, DOI 10.1007/s11154 006 9002 4
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen Y, 2007, J BIOL CHEM, V282, P526, DOI 10.1074/jbc.M602700200
   Fukuda T, 2010, DIFFERENTIATION, V80, P46, DOI 10.1016/j.diff.2010.05.002
   Harris SE, 2003, FRONT BIOSCI, V8, pS1249, DOI 10.2741/1170
   Huang RL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.101
   Huang YF, 2012, J BONE MINER RES, V27, P1093, DOI 10.1002/jbmr.1548
   Im NK, 2013, BIOL PHARM BULL, V36, P796, DOI 10.1248/bpb.b12 00964
   Jia TL, 2003, BIOCHEM PHARMACOL, V65, P709, DOI 10.1016/S0006 2952(02)01585 X
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kim JY, 2014, INT IMMUNOPHARMACOL, V20, P213, DOI 10.1016/j.intimp.2014.03.001
   Kim MB, 2014, FITOTERAPIA, V98, P59, DOI 10.1016/j.fitote.2014.07.013
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   KULSHRES.SK, 1974, INDIAN J CHEM, V12, P10
   Kuo PL, 2005, J PHARMACOL EXP THER, V314, P1290, DOI 10.1124/jpet.105.085092
   Lee C, 2013, BIOORG MED CHEM LETT, V23, P4263, DOI 10.1016/j.bmcl.2013.04.032
   Lee DS, 2014, PHYTOTHER RES, V28, P1216, DOI 10.1002/ptr.5119
   Lee DS, 2013, INT IMMUNOPHARMACOL, V16, P114, DOI 10.1016/j.intimp.2013.03.026
   Lee DS, 2014, EUR J PHARMACOL, V728, P1, DOI 10.1016/j.ejphar.2013.12.041
   Lee HS, 2011, PHYTOTHER RES, V25, P716, DOI 10.1002/ptr.3328
   Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097 4644(19990401)73:1<114::AID JCB13>3.3.CO;2 D
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Lee MK, 2006, BIOORG MED CHEM LETT, V16, P2850, DOI 10.1016/j.binct.2006.03.018
   Lo YC, 2010, J AGR FOOD CHEM, V58, P6643, DOI 10.1021/jf904158k
   MacDonald B.T., 2012, PERSPECT BIOL, V4, P4, DOI DOI 10.1101/CSHPERSPECT.A007880
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549
   Qiu WM, 2007, J BONE MINER RES, V22, P1720, DOI 10.1359/JBMR.070721
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219
   Rodríguez Carballo E, 2011, J BONE MINER RES, V26, P718, DOI 10.1002/jbmr.260
   Wang Juan, 2013, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V29, P681
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Zhang JF, 2010, MOL CELL ENDOCRINOL, V314, P70, DOI 10.1016/j.mce.2009.08.012
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
   Zhao M, 2002, J CELL BIOL, V157, P1049, DOI 10.1083/jcb.200109012
   Zhao XB, 2011, MOLECULES, V16, P9775, DOI 10.3390/molecules16129775
NR 42
TC 79
Z9 83
U1 0
U2 19
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JUL
PY 2015
VL 6
AR e1819
DI 10.1038/cddis.2015.185
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA CN9SH
UT WOS:000358788800019
PM 26181200
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Farr, JN
   Roforth, MM
   Fujita, K
   Nicks, KM
   Cunningham, JM
   Atkinson, EJ
   Therneau, TM
   McCready, LK
   Peterson, JM
   Drake, MT
   Monroe, DG
   Khosla, S
AF Farr, Joshua N.
   Roforth, Matthew M.
   Fujita, Koji
   Nicks, Kristy M.
   Cunningham, Julie M.
   Atkinson, Elizabeth J.
   Therneau, Terry M.
   McCready, Louise K.
   Peterson, James M.
   Drake, Matthew T.
   Monroe, David G.
   Khosla, Sundeep
TI Effects of Age and Estrogen on Skeletal Gene Expression in Humans as
   Assessed by RNA Sequencing
SO PLOS ONE
LA English
DT Article
ID RECEPTOR RELATED PROTEIN 5; BONE MINERAL DENSITY; VAN BUCHEM DISEASE;
   POSTMENOPAUSAL WOMEN; EMBRYONIC LETHALITY; CIRCULATING SCLEROSTIN; SOST
   GENE; MICE; TURNOVER; NOTCH
AB Precise delineation of the specific genes and pathways altered with aging and estrogen (E) therapy may lead to new skeletal biomarkers and the development of novel bone therapeutics. Previous human bone studies, however, have been limited by only examining prespecified genes and pathways. High throughput RNA sequencing (RNAseq), on the other hand, offers an unbiased approach to examine the entire transcriptome. Here we present an RNAseq analysis of human bone samples, obtained from iliac crest needle biopsies, to yield the first in vivo interrogation of all genes and pathways that may be altered in bone with aging and E therapy in humans. 58 healthy women were studied, including 19 young women (mean age +/  SD, 30.3 +/  5.4 years), 19 old women (73.1 +/  6.6 years), and 20 old women treated with 3 weeks of E therapy (70.5 +/  5.2 years). Using generally accepted criteria (false discovery rate [q] < 0.10), aging altered a total of 678 genes and 12 pathways, including a subset known to regulate bone metabolism (e.g., Notch). Interestingly, the LEF1 transcription factor, which is a classical downstream target of the Wnt/beta catenin signaling pathway, was significantly downregulated in the bones from the old versus young women; consistent with this, LEF1 binding sites were significantly enriched in the promoter regions of the differentially expressed genes in the old versus young women, suggesting that aging was associated with alterations in Wnt signaling in bone. Further, of the 21 unique genes altered in bone by E therapy, the expression of INHBB (encoding for the inhibin, beta B polypeptide), which decreased with aging (by 0.6 fold), was restored to young adult levels in response to E therapy. In conclusion, our data demonstrate that aging alters a substantial portion of the skeletal transcriptome, whereas E therapy appears to have significant, albeit less wide ranging effects. These data provide a valuable resource for the potential identification of novel biomarkers associated with age related bone loss and also highlight potential pathways that could be targeted to treat osteoporosis.
C1 [Farr, Joshua N.; Roforth, Matthew M.; Fujita, Koji; Nicks, Kristy M.; McCready, Louise K.; Peterson, James M.; Drake, Matthew T.; Monroe, David G.; Khosla, Sundeep] Mayo Clin, Div Endocrinol, Dept Med, Coll Med, Rochester, MN 55905 USA.
   [Farr, Joshua N.; Roforth, Matthew M.; Fujita, Koji; Nicks, Kristy M.; Drake, Matthew T.; Monroe, David G.; Khosla, Sundeep] Mayo Clin, Robert & Arlene Kogod Ctr Aging, Coll Med, Rochester, MN 55905 USA.
   [Cunningham, Julie M.] Mayo Clin, Dept Expt Pathol & Lab Med, Coll Med, Rochester, MN 55905 USA.
   [Atkinson, Elizabeth J.; Therneau, Terry M.] Mayo Clin, Div Biomed Stat & Informat, Coll Med, Dept Hlth Sci Res, Rochester, MN 55905 USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic
RP Khosla, S (通讯作者)，Mayo Clin, Div Endocrinol, Dept Med, Coll Med, Rochester, MN 55905 USA.
EM khosla.sundeep@mayo.edu
RI Fujita, Koji/K 3905 2019; Khosla, Sundeep/AAE 6170 2020; Farr,
   Joshua/B 3355 2011; Cunningham, Julie/KII 0320 2024
OI Fujita, Koji/0000 0003 3733 0188; Khosla, Sundeep/0000 0002 2936 4372
FU NIH [P01 AG004875, UL1TR000135]; Merck
FX This research was supported by NIH Grant P01 AG004875, UL1TR000135, and
   an investigator initiated grant from Merck. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ayturk UM, 2013, J BONE MINER RES, V28, P2081, DOI 10.1002/jbmr.1946
   Baker DJ, 2013, CELL REP, V3, P1164, DOI 10.1016/j.celrep.2013.03.028
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108
   Chim CS, 2007, LEUKEMIA, V21, P2527, DOI 10.1038/sj.leu.2404939
   Clarke Bart L, 2013, Bonekey Rep, V2, P361, DOI 10.1038/bonekey.2013.95
   deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0
   Domenga V, 2004, GENE DEV, V18, P2730, DOI 10.1101/gad.308904
   Durosier C, 2013, J CLIN ENDOCR METAB, V98, P3873, DOI 10.1210/jc.2013 2113
   Fajardo RJ, 2010, BONE, V46, P64, DOI 10.1016/j.bone.2009.09.018
   Fatayerji D, 1999, J BONE MINER RES, V14, P1203, DOI 10.1359/jbmr.1999.14.7.1203
   Fujita K, 2014, OSTEOPOROSIS INT, V25, P887, DOI 10.1007/s00198 013 2529 9
   Fujita K, 2014, J CLIN ENDOCR METAB, V99, pE81, DOI 10.1210/jc.2013 3249
   Fukuda T, 2013, NATURE, V497, P490, DOI 10.1038/nature12115
   Gale NW, 2004, P NATL ACAD SCI USA, V101, P15949, DOI 10.1073/pnas.0407290101
   Garg V, 2005, NATURE, V437, P270, DOI 10.1038/nature03940
   GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Hamada Y, 1999, DEVELOPMENT, V126, P3415
   Hansen KD, 2012, BIOSTATISTICS, V13, P204, DOI 10.1093/biostatistics/kxr054
   Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092 8674(00)80303 7
   Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716
   Il Mödder U, 2011, J BONE MINER RES, V26, P27, DOI 10.1002/jbmr.128
   Jiang RL, 1998, GENE DEV, V12, P1046, DOI 10.1101/gad.12.7.1046
   Khosla S, 1998, J CLIN ENDOCR METAB, V83, P2266, DOI 10.1210/jc.83.7.2266
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Khosla S, 2013, J GERONTOL A BIOL, V68, P1226, DOI 10.1093/gerona/gls163
   Krebs LT, 2000, GENE DEV, V14, P1343
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb 2009 10 3 r25
   Levey AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003 4819 145 4 200608150 00004
   LIPS P, 1978, CALC TISS RES, V26, P13, DOI 10.1007/BF02013227
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Liu C, 2007, NATURE, V447, P477, DOI 10.1038/nature05767
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   Lotinun S., 2012, CURR MOL PHARMACOL, V5, P195, DOI [10.2174/1874467211205020195, DOI 10.2174/1874467211205020195]
   Lotinun S, 2010, BONE, V46, P1082, DOI 10.1016/j.bone.2010.01.370
   LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0
   Makanji Y, 2014, ENDOCR REV, V35, P747, DOI 10.1210/er.2014 1003
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Mödder UI, 2011, J BONE MINER RES, V26, P373, DOI 10.1002/jbmr.217
   Nicks KM, 2009, MOL CELL ENDOCRINOL, V310, P11, DOI 10.1016/j.mce.2009.07.001
   Pearsall RS, 2008, P NATL ACAD SCI USA, V105, P7082, DOI 10.1073/pnas.0711263105
   Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092 8674(00)81410 5
   Radonic A, 2004, BIOCHEM BIOPH RES CO, V313, P856, DOI 10.1016/j.bbrc.2003.11.177
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Roforth MM, 2014, BONE, V59, P1, DOI 10.1016/j.bone.2013.10.019
   Ruckle J, 2009, J BONE MINER RES, V24, P744, DOI 10.1359/JBMR.081208
   Salie R, 2010, BONE, V46, P680, DOI 10.1016/j.bone.2009.10.022
   St Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707
   Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120
   Tseng YH, 2014, AUTOPHAGY, V10, P20, DOI 10.4161/auto.26126
   Tu XL, 2015, P NATL ACAD SCI USA, V112, pE478, DOI 10.1073/pnas.1409857112
   van Lierop AH, 2010, EUR J ENDOCRINOL, V163, P833, DOI 10.1530/EJE 10 0699
   van Lierop AH, 2011, J BONE MINER RES, V26, P2804, DOI 10.1002/jbmr.474
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb 2002 3 7 research0034
   Wang LG, 2012, BIOINFORMATICS, V28, P2184, DOI 10.1093/bioinformatics/bts356
   Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441
   Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723
   Yi P, 2013, CELL, V153, P747, DOI 10.1016/j.cell.2013.04.008
   Zamurovic N, 2004, J BIOL CHEM, V279, P37704, DOI 10.1074/jbc.M403813200
   Zhao S, 2005, J COMPUT BIOL, V12, P1047, DOI 10.1089/cmb.2005.12.1047
NR 67
TC 55
Z9 61
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD SEP 24
PY 2015
VL 10
IS 9
AR e0138347
DI 10.1371/journal.pone.0138347
PG 22
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CS1BS
UT WOS:000361798100021
PM 26402159
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Iwatani, S
   Shono, A
   Yoshida, M
   Yamana, K
   Thwin, KKM
   Kuroda, J
   Kurokawa, D
   Koda, T
   Nishida, K
   Ikuta, T
   Fujioka, K
   Mizobuchi, M
   Taniguchi Ikeda, M
   Morioka, I
   Iijima, K
   Nishimura, N
AF Iwatani, Sota
   Shono, Akemi
   Yoshida, Makiko
   Yamana, Keiji
   Thwin, Khin Kyae Mon
   Kuroda, Jumpei
   Kurokawa, Daisuke
   Koda, Tsubasa
   Nishida, Kosuke
   Ikuta, Toshihiko
   Fujioka, Kazumichi
   Mizobuchi, Masami
   Taniguchi Ikeda, Mariko
   Morioka, Ichiro
   Iijima, Kazumoto
   Nishimura, Noriyuki
TI Involvement of WNT Signaling in the Regulation of Gestational
   Age Dependent Umbilical Cord Derived Mesenchymal Stem Cell Proliferation
SO STEM CELLS INTERNATIONAL
LA English
DT Article
ID BONE MARROW; STROMAL CELLS; DIFFERENTIATION; EXPRESSION; CATENIN;
   MECHANISMS; THERAPY; PATHWAY; REPAIR; ROLES
AB Mesenchymal stem cells (MSCs) are a heterogeneous cell population that is isolated initially from the bone marrow (BM) and subsequently almost all tissues including umbilical cord (UC). UC derived MSCs (UC MSCs) have attracted an increasing attention as a source for cell therapy against various degenerative diseases due to their vigorous proliferation and differentiation. Although the cell proliferation and differentiation of BM derived MSCs is known to decline with age, the functional difference between preterm and term UC MSCs is poorly characterized. In the present study, we isolated UC MSCs from 23 infants delivered at 22 40 weeks of gestation and analyzed their gene expression and cell proliferation. Microarray analysis revealed that global gene expression in preterm UC MSCs was distinct from term UC MSCs. WNT signaling impacts on a variety of tissue stem cell proliferation and differentiation, and its pathway genes were enriched in differentially expressed genes between preterm and term UC MSCs. Cell proliferation of preterm UC MSCs was significantly enhanced compared to term UC MSCs and counteracted by WNT signaling inhibitor XAV939. Furthermore, WNT2B expression in UC MSCs showed a significant negative correlation with gestational age (GA). These results suggest that WNT signaling is involved in the regulation of GAdependent UC MSC proliferation.
C1 [Iwatani, Sota; Shono, Akemi; Yamana, Keiji; Thwin, Khin Kyae Mon; Kurokawa, Daisuke; Nishida, Kosuke; Ikuta, Toshihiko; Fujioka, Kazumichi; Taniguchi Ikeda, Mariko; Morioka, Ichiro; Iijima, Kazumoto; Nishimura, Noriyuki] Kobe Univ, Grad Sch Med, Dept Pediat, Kobe, Hyogo 6500017, Japan.
   [Yoshida, Makiko] Kobe Childrens Hosp, Dept Pathol, Kobe, Hyogo 6500047, Japan.
   [Kuroda, Jumpei] Tokyo Metropolitan Childrens Med Ctr, Dept Neonatol, Fuchu, Tokyo 1838561, Japan.
   [Koda, Tsubasa] Hyogo Coll Med, Dept Pediat, Nishinomiya, Hyogo 6638181, Japan.
   [Mizobuchi, Masami] Shizuoka Childrens Hosp, Dept Dev Pediat, Shizuoka 4208660, Japan.
C3 Kobe University; Tokyo Metropolitan Children's Medical Center; Hyogo
   Medical University
RP Nishimura, N (通讯作者)，Kobe Univ, Grad Sch Med, Dept Pediat, Kobe, Hyogo 6500017, Japan.
EM nnishi@med.kobe u.ac.jp
RI Iwatani, Sota/F 2485 2018; Taniguchi Ikeda, Mariko/AGE 3152 2022;
   Fujioka, Kazumichi/O 3239 2019; KURODA, JUMPEI/ISV 0406 2023
OI Iwatani, Sota/0000 0002 2871 4000; FUJIOKA,
   KAZUMICHI/0000 0002 9913 6447; 
FU JSPS KAKENHI [25461644, 26860845]; Grants in Aid for Scientific Research
   [26860845, 17K10110, 25461644] Funding Source: KAKEN
FX This work was supported by Grants in Aid for Scientific Research (C)
   (Grant no. 25461644) and Young Scientists (B) (Grant no. 26860845) of
   JSPS KAKENHI. The authors thank Drs. Shohei Ohyama, Sachiyo Fukushima,
   Oshi Tokuda, Kaori Maeyama, and Miwako Nagasaka for collecting the
   umbilical cord samples.
CR Arutyunyan I, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/6901286
   Baarsma HA, 2013, PHARMACOL THERAPEUT, V138, P66, DOI 10.1016/j.pharmthera.2013.01.002
   Baksh D, 2007, STEM CELLS, V25, P1384, DOI 10.1634/stemcells.2006 0709
   Batsali AK, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0555 9
   Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002
   Bianco P, 2014, ANNU REV CELL DEV BI, V30, P677, DOI 10.1146/annurev cellbio 100913 013132
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Choumerianou DM, 2010, CYTOTHERAPY, V12, P881, DOI 10.3109/14653249.2010.501790
   Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Conconi M.T., 2011, The Open Tissue Engineering and Regenerative Medicine Journal, V4, P6, DOI [10.2174/1875043501104010006, DOI 10.2174/1875043501104010006]
   Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003
   DasGupta R, 1999, DEVELOPMENT, V126, P4557
   de Boer J, 2004, BONE, V34, P818, DOI 10.1016/j.bone.2004.01.016
   Ding DC, 2015, CELL TRANSPLANT, V24, P339, DOI 10.3727/096368915X686841
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Etheridge SL, 2004, STEM CELLS, V22, P849, DOI 10.1634/stemcells.22 5 849
   FRIEDENSTEIN AJ, 1968, TRANSPLANTATION, V6, P230, DOI 10.1097/00007890 196803000 00009
   Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092 8674(00)81631 1
   GERDES J, 1984, J IMMUNOL, V133, P1710
   Gregory CA, 2005, ANN NY ACAD SCI, V1049, P97, DOI 10.1196/annals.1334.010
   Hong SH, 2013, STEM CELLS DEV, V22, P2425, DOI 10.1089/scd.2012.0552
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Jain A, 2013, INDIAN J PEDIATR, V80, P375, DOI 10.1007/s12098 012 0844 3
   Javed MJ, 2008, PEDIATR RES, V64, P68, DOI 10.1203/PDR.0b013e31817445e9
   Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270
   Liu GZ, 2005, MOL CELL BIOL, V25, P3475, DOI 10.1128/MCB.25.9.3475 3482.2005
   Luo SM, 2013, BIOMED PHARMACOTHER, V67, P819, DOI 10.1016/j.biopha.2013.03.008
   Manochantr S, 2013, INTERN MED J, V43, P430, DOI 10.1111/imj.12044
   Mareschi K, 2006, J CELL BIOCHEM, V97, P744, DOI 10.1002/jcb.20681
   Mennan C, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/916136
   Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115
   Montemurro T, 2011, J CELL MOL MED, V15, P796, DOI 10.1111/j.1582 4934.2010.01047.x
   Nemeth MJ, 2007, P NATL ACAD SCI USA, V104, P15436, DOI 10.1073/pnas.0704747104
   Park JR, 2008, CELL PROLIFERAT, V41, P859, DOI 10.1111/j.1365 2184.2008.00565.x
   Subramanian A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127992
   Udartseva OO, 2015, DOKL BIOCHEM BIOPHYS, V465, P354, DOI 10.1134/S1607672915060046
   van Amerongen R, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.135re9
   Visweswaran M, 2015, INT J BIOCHEM CELL B, V68, P139, DOI 10.1016/j.biocel.2015.09.008
   Zhu DD, 2014, CYTOTHERAPY, V16, P1614, DOI 10.1016/j.jcyt.2014.06.004
NR 40
TC 14
Z9 15
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687 966X
EI 1687 9678
J9 STEM CELLS INT
JI Stem Cells Int.
PY 2017
VL 2017
AR 8749751
DI 10.1155/2017/8749751
PG 16
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA FG9SM
UT WOS:000410779700001
PM 29138639
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Yang, Y
   Mallampati, S
   Sun, BH
   Zhang, J
   Kim, SB
   Lee, JS
   Gong, Y
   Cai, Z
   Sun, XP
AF Yang, Yang
   Mallampati, Saradhi
   Sun, Baohua
   Zhang, Jing
   Kim, Sang Bae
   Lee, Ju Seog
   Gong, Yun
   Cai, Zhen
   Sun, Xiaoping
TI Wnt pathway contributes to the protection by bone marrow stromal cells
   of acute lymphoblastic leukemia cells and is a potential therapeutic
   target
SO CANCER LETTERS
LA English
DT Article
DE Acute lymphoblastic leukemia; Bone marrow stromal cells; Wnt pathway;
   Wnt pathway inhibitor; Chemotherapy resistance
ID BCL 2 EXPRESSION; B LINEAGE; KINASE; ACTIVATION; SURVIVAL;
   PROLIFERATION; ANTAGONISTS; INHIBITORS; DISEASE; GROWTH
AB Leukemia cells are protected by various components of their microenvironment, including marrow stromal cells (MSCs). To understand the molecular mechanisms underlying this protection, we cultured acute lymphoblastic leukemia (ALL) cells with MSCs and studied the effect of the latter on the molecular profiling of ALL cells at the mRNA and protein levels. Our results indicated that activated Wnt signaling in ALL cells is involved in MSC mediated drug resistance. Blocking the Wnt pathway sensitized the leukemia cells to chemotherapy and improved overall survival in a mouse model. Targeting the Wnt pathway may be an innovative approach to the treatment of ALL. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Yang, Yang; Zhang, Jing; Cai, Zhen] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Bone Marrow Transplant Ctr, Hangzhou 310003, Zhejiang, Peoples R China.
   [Yang, Yang; Mallampati, Saradhi; Sun, Baohua; Sun, Xiaoping] Univ Texas MD Anderson Canc Ctr, Dept Lab Med, Houston, TX 77030 USA.
   [Zhang, Jing; Gong, Yun] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
   [Kim, Sang Bae; Lee, Ju Seog] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.
C3 Zhejiang University; University of Texas System; UTMD Anderson Cancer
   Center; University of Texas System; UTMD Anderson Cancer Center;
   University of Texas System; UTMD Anderson Cancer Center
RP Cai, Z (通讯作者)，Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Bone Marrow Transplant Ctr, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China.
EM caizhen1@yahoo.com; xsun@mdanderson.org
RI Lee, Ju Seog/X 1786 2018
OI Lee, Ju Seog/0000 0002 5666 9753
FU American Cancer Society [119645 RSG 10 131 01 DDC]; Physician Scientist
   Program Award from MD Anderson; National Natural Science Foundation of
   China [81200385]; China Scholarship Council; High Level Health
   Technology Innovation of Elite Culture Program of Zhejiang Province; MD
   Anderson Support Grant [CA016672]
FX We thank Dr. J. G. Wen at Methodist Hospital, Houston, Texas, USA, for
   the human bone marrow MSC cell line HS; Dr. Patrick Zweidler McKay at MD
   Anderson for the human leukemia cell lines Reh, RS4;11, and SEMK2, Dr.
   Jan Burger at MD Anderson for the murine MSC line M2 10B4, and Dr. Roel
   Nusse at Stanford University for 7TGC reporter vector (obtained from
   Addgene; plasmid 24304). This work was supported in part by Research
   Scholar Grant 119645 RSG 10 131 01 DDC to X.S. from the American Cancer
   Society, a Physician Scientist Program Award to X.S. from MD Anderson, a
   scholarship award and National Natural Science Foundation of China (no.
   81200385) to Y.Y. from the China Scholarship Council, an award to Z.C.
   from the High Level Health Technology Innovation of Elite Culture
   Program of Zhejiang Province, and the MD Anderson Support Grant
   CA016672.
CR Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439
   Akiyama T, 2000, CYTOKINE GROWTH F R, V11, P273, DOI 10.1016/S1359 6101(00)00011 3
   Banker DE, 1998, LEUKEMIA RES, V22, P221, DOI 10.1016/S0145 2126(97)00174 4
   Cario G, 2005, BLOOD, V105, P821, DOI 10.1182/blood 2004 04 1552
   Chen YB, 2012, BLOOD
   Colmone A, 2008, SCIENCE, V322, P1861, DOI 10.1126/science.1164390
   Dutta Simmons J, 2009, BLOOD, V114, P2699, DOI 10.1182/blood 2008 12 194290
   Fielding AK, 2007, BLOOD, V109, P944, DOI 10.1182/blood 2006 05 018192
   Gaundar SS, 2009, CELL CYCLE, V8, P2975
   Gelebart P, 2008, BLOOD, V112, P5171, DOI 10.1182/blood 2008 02 139212
   Huang CL, 2008, EUR J CANCER, V44, P2680, DOI 10.1016/j.ejca.2008.08.004
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Juarez J, 2007, LEUKEMIA, V21, P1249, DOI 10.1038/sj.leu.2404684
   Kern W, 2003, HAEMATOLOGICA, V88, P646
   Khan NI, 2007, BRIT J HAEMATOL, V138, P338, DOI 10.1111/j.1365 2141.2007.06667.x
   Lee BH, 2005, J CELL BIOCHEM, V95, P1214, DOI 10.1002/jcb.20488
   LEMOINE FM, 1988, EXP HEMATOL, V16, P718
   MANABE A, 1992, BLOOD, V79, P2370
   Mudry RE, 2000, BLOOD, V96, P1926, DOI 10.1182/blood.V96.5.1926.h8001926_1926_1932
   Nishii K, 1999, BRIT J HAEMATOL, V105, P701, DOI 10.1046/j.1365 2141.1999.01380.x
   POCOCK CFE, 1995, BRIT J HAEMATOL, V90, P855, DOI 10.1111/j.1365 2141.1995.tb05207.x
   Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907
   ROECKLEIN BA, 1995, BLOOD, V85, P997, DOI 10.1182/blood.V85.4.997.bloodjournal854997
   ROSENFELD C, 1977, NATURE, V267, P841, DOI 10.1038/267841a0
   STONG RC, 1985, BLOOD, V65, P21, DOI 10.1182/blood.V65.1.21.21
   Tabe Y, 2007, CANCER RES, V67, P684, DOI 10.1158/0008 5472.CAN 06 3166
   Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535 7163.MCT 06 0334
   Valencia A, 2009, LEUKEMIA, V23, P1658, DOI 10.1038/leu.2009.86
   You A, 2011, J CANCER RES CLIN, V137, P621, DOI 10.1007/s00432 010 0916 6
   Zeng ZH, 2009, BLOOD, V113, P6215, DOI 10.1182/blood 2008 05 158311
   Zhu Y, 2009, LEUKEMIA, V23, P925, DOI 10.1038/leu.2008.384
NR 31
TC 67
Z9 76
U1 0
U2 19
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304 3835
EI 1872 7980
J9 CANCER LETT
JI Cancer Lett.
PD JUN 1
PY 2013
VL 333
IS 1
BP 9
EP 17
DI 10.1016/j.canlet.2012.11.056
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 136VC
UT WOS:000318390500002
PM 23333798
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Zhou, L
   Liu, Q
   Hong, GJ
   Song, FM
   Zhao, JM
   Yuan, JB
   Xu, J
   Tan, RX
   Tickner, J
   Gu, Q
   Xu, JK
AF Zhou, Lin
   Liu, Qian
   Hong, Guoju
   Song, Fangming
   Zhao, Jinmin
   Yuan, Jinbo
   Xu, Jun
   Tan, Ren Xiang
   Tickner, Jennifer
   Gu, Qiong
   Xu, Jiake
TI Cumambrin A prevents OVX induced osteoporosis via the inhibition
   of osteoclastogenesis, bone resorption, and RANKL signaling pathways
SO FASEB JOURNAL
LA English
DT Article
DE NF kappa B; NFATc1; ERK; osteolysis
ID NF KAPPA B; SESQUITERPENE LACTONES; DIFFERENTIATION; EXPRESSION; NFATC1;
   SUPPRESSION; ACTIVATION; REGULATOR; MEDICINE; SURVIVAL
AB Being the principal cells responsible for bone resorption and pathologic bone loss, osteoclasts have become the main target for antiresorptive treatment. Cumambrin A is a natural compound isolated from Chrysanthemum indicum L. and belongs to a member of the sesquiterpene lactone family. To date, the therapeutic effect of cumambrin A on osteoporosis and its mechanisms of action are not known. In this study, we found that cumambrin A can significantly inhibit osteoclast formation and bone resorption through the suppression of receptor activator of NF kappa B ligand (RANKL) induced NF kappa B and nuclear factor of activated T cell activity and ERK phosphorylation. Furthermore, cumambrin A inhibits the expression of osteoclast marker genes including cathepsin K, calcitonin receptor, and V ATPase d2. Using an in vivo ovariectomized mouse model, we showed that cumambrin A protects against estrogen withdrawal induced bone loss. Collectively, our results reveal that cumambrin A can suppress osteoclast formation, bone resorption, and RANKL induced signaling pathways, suggesting that cumambrin A is a potential therapeutic agent for the treatment of osteoporosis. Zhou, L., Liu, Q., Hong, G., Song, F., Zhao, J., Yuan, J., Xu, J., Tan, R. X., Tickner, J., Gu, Q., Xu, J. Cumambrin A prevents OVX induced osteoporosis via the inhibition of osteoclastogenesis, bone resorption, and RANKL signaling pathways.
C1 [Zhou, Lin; Liu, Qian; Hong, Guoju; Song, Fangming; Yuan, Jinbo; Tickner, Jennifer; Xu, Jiake] Univ Western Australia, Sch Biomed Sci, M504, Perth, WA 6009, Australia.
   [Zhou, Lin] Guangzhou Med Univ, Affiliated Hosp 5, Dept Endocrinol, Guangzhou, Guangdong, Peoples R China.
   [Liu, Qian; Song, Fangming; Zhao, Jinmin] Guangxi Med Univ, Res Ctr Regenerat Med, Nanning, Peoples R China.
   [Liu, Qian; Song, Fangming; Zhao, Jinmin] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning, Peoples R China.
   [Hong, Guoju] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Orthoped Dept, Guangzhou, Guangdong, Peoples R China.
   [Xu, Jun] Sun Yat Sen Univ, Res Ctr Drug Discovery, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China.
   [Tan, Ren Xiang; Gu, Qiong] Nanjing Univ, Inst Funct Biomol, State Key Lab Pharmaceut Biotechnol, Nanjing, Jiangsu, Peoples R China.
C3 University of Western Australia; Guangzhou Medical University; Guangxi
   Medical University; Guangxi Medical University; Guangzhou University of
   Chinese Medicine; Sun Yat Sen University; Nanjing University
RP Xu, JK (通讯作者)，Univ Western Australia, Sch Biomed Sci, M504, Perth, WA 6009, Australia.; Gu, Q (通讯作者)，Sun Yat Sen Univ, Res Ctr Drug Discovery, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China.
EM guqiong@sysu.edu.cn; jiake.xu@uwa.edu.au
RI Gu, Qiong/N 1653 2017; Tickner, Jennifer/H 5965 2014; zhao,
   jin/LBH 0351 2024; Hong, Guoju/AAV 9433 2020; Xu, Jun/A 3865 2010
OI Gu, Qiong/0000 0001 6011 3697; Zhao, Jinmin/0000 0001 8423 0425;
   Tickner, Jennifer/0000 0002 5020 0671; Xu, Jiake/0000 0003 2021 8309;
   Zhao, Jinmin/0000 0002 1047 8820; Yuan, Jinbo/0000 0002 6240 9333; 
FU Australian Health and Medical Research Council (NHMRC) [APP1107828,
   APP1127396, APP1127156]; Arthritis Foundation of Australia; Western
   Australia Medical and Health Research Infrastructure Fund; Young
   Innovative Talents Project of Guangdong Province [2017KQNCX167]; Nature
   Science Foundation of Guangxi [2015GXNSFDA139019]; National Natural
   Science Foundation of China [81573310]; China Scholarship Council;
   University of Western Australia Research Collaboration Awards
FX The authors acknowledge the support from Australian Health and Medical
   Research Council (NHMRC; APP1107828, APP1127396, APP1127156), Arthritis
   Foundation of Australia (The H.J. and G.J. Mckenzie Grant), Western
   Australia Medical and Health Research Infrastructure Fund, University of
   Western Australia Research Collaboration Awards, and Young Innovative
   Talents Project of Guangdong Province (2017KQNCX167). This study was
   also funded, in part, by the Nature Science Foundation of Guangxi
   (2015GXNSFDA139019) and the National Natural Science Foundation of China
   (81573310). L.Z. is a recipient of a scholarship from the China
   Scholarship Council. G.H., Q.L., and F.S. are visiting scholars to the
   University of Western Australia. The authors declare no conflicts of
   interest.
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Bakker AD, 2012, METHODS MOL BIOL, V816, P19, DOI 10.1007/978 1 61779 415 5_2
   Blair HC, 2004, HISTOL HISTOPATHOL, V19, P189, DOI 10.14670/HH 19.189
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown KD, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2457
   Deng SQ, 2017, JMIR RES PROTOC, V6, DOI 10.2196/resprot.7636
   Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092 8674(02)01166 2
   Feng HT, 2009, J BIOL CHEM, V284, P14667, DOI 10.1074/jbc.M901670200
   García Piñeres AJ, 2001, J BIOL CHEM, V276, P39713, DOI 10.1074/jbc.M101985200
   Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Jee W. S. S., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P193
   Jiang M, 2011, PLANTA MED, V77, P873, DOI 10.1055/s 0030 1270983
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Leibbrandt A., 2011, ENCY CANC, P3165
   Leibbrandt A, 2008, ANN NY ACAD SCI, V1143, P123, DOI 10.1196/annals.1443.016
   LEWELLEN TK, 1977, J NUCL MED, V18, P929
   Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508
   Mazor RL, 2000, CYTOKINE, V12, P239, DOI 10.1006/cyto.1999.0526
   Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174
   Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955 0674(99)80030 1
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Nakamura H, 2003, J BONE MINER RES, V18, P1198, DOI 10.1359/jbmr.2003.18.7.1198
   Rüngeler P, 1999, BIOORGAN MED CHEM, V7, P2343, DOI 10.1016/S0968 0896(99)00195 9
   Schmidt TJ, 1999, CURR ORG CHEM, V3, P577
   Soysa Niroshani Surangika, 2012, J Med Dent Sci, V59, P65
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Takayanagi Hiroshi, 2009, Rinsho Ketsueki, V50, P447
   Tarasov V.A., 1974, Chem. Nat. Compd, V10, P826, DOI [10.1007/BF00564023, DOI 10.1007/BF00564023]
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tomoyasu A, 1998, BIOCHEM BIOPH RES CO, V245, P382, DOI 10.1006/bbrc.1998.8443
   van der Kraan AGJ, 2013, BIOCHEM J, V451, P235, DOI 10.1042/BJ20121626
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang C, 2003, J BONE MINER RES, V18, P2159, DOI 10.1359/jbmr.2003.18.12.2159
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   Wang T, 2015, INT J MOL SCI, V16, P27470, DOI 10.3390/ijms161126039
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Yip KHM, 2004, J BONE MINER RES, V19, P1905, DOI 10.1359/JBMR.040919
   Zhu LL, 2005, BIOCHEM BIOPH RES CO, V326, P131, DOI 10.1016/j.bbrc.2004.10.212
   Zhu SP, 2018, BIOL REV, V93, P469, DOI 10.1111/brv.12353
   Zou W, 2010, ANN NY ACAD SCI, V1192, P27, DOI 10.1111/j.1749 6632.2009.05245.x
NR 46
TC 14
Z9 15
U1 0
U2 24
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3998 USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD JUN
PY 2019
VL 33
IS 6
BP 6726
EP 6735
DI 10.1096/fj.201800883RRR
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA IJ7YD
UT WOS:000476114200005
PM 30807230
OA Bronze
DA 2025 08 17
ER

PT J
AU Ruan, M
   Pederson, L
   Bradley, EW
   Bamberger, AM
   Oursler, MJ
AF Ruan, Ming
   Pederson, Larry
   Bradley, Elizabeth W.
   Bamberger, Ana Maria
   Oursler, Merry Jo
TI Transforming Growth Factor β Coordinately Induces Suppressor of Cytokine
   Signaling 3 and Leukemia Inhibitory Factor to Suppress Osteoclast
   Apoptosis
SO ENDOCRINOLOGY
LA English
DT Article
ID MESSENGER RNA EXPRESSION; TGF BETA; GENE EXPRESSION; SURVIVAL;
   ACTIVATION; INDUCTION; PATHWAYS; NEURONS; LIF; GLUCOCORTICOIDS
AB Local release of TGF beta during times of high bone turnover leads to elevated levels within the bone microenvironment, and we have shown that TGF beta suppresses osteoclast apoptosis. Therefore, understanding the influences of TGF beta on bone resorbing osteoclasts is critical to the design of therapies to reduce excess bone loss. Here we investigated the mechanisms by which TGF beta sustains suppression of osteoclast apoptosis. We found TGF beta rapidly increased leukemia inhibitory factor (LIF) expression and secretion by phosphorylated mothers against decapentaplegic dependent and  independent signaling pathways. TGF beta also induced suppressor of cytokine signaling 3 (SOCS3) expression, which was required for TGF beta or LIF to promote osteoclast survival by. Blocking LIF or SOCS3 blocked TGF beta promotion of osteoclast survival, confirming that LIF and SOCS3 expression are necessary for TGF beta mediated suppression of osteoclast apoptosis. Investigation of the mechanisms by which LIF promotes osteoclast survival revealed that LIF induced expression of Bcl X L and repressed Bcl 2 interacting domain expression by activating MAPK kinase, AKT, and nuclear factor kappa B pathways. Suppression of Janus kinase/signal transducer and activator of transcription signaling further increased Bcl X L expression and enhanced osteoclast survival, supporting that this pathway is not involved in prosurvival effects of TGF beta and LIF. These data show that TGF beta coordinately induces LIF and SOCS3 to promote prosurvival signaling. This alters the ratio of prosurvival Bcl2 family member Bcl X L to proapoptotic family member Bcl 2 interacting domain, leading to prolonged osteoclast survival. (Endocrinology 151: 1713 1722, 2010)
C1 [Ruan, Ming; Pederson, Larry; Oursler, Merry Jo] Mayo Clin, Endocrine Res Unit, Rochester, MN 55905 USA.
   [Bradley, Elizabeth W.; Oursler, Merry Jo] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.
   [Bamberger, Ana Maria] Univ Hosp Hamburg Eppendorf, Sect Endocrinol & Metab Aging, D 20249 Hamburg, Germany.
C3 Mayo Clinic; Mayo Clinic; University of Hamburg; University Medical
   Center Hamburg Eppendorf
RP Oursler, MJ (通讯作者)，Mayo Clin, Endocrine Res Unit, 200 1st St SW, Rochester, MN 55905 USA.
EM oursler.merryjo@mayo.edu
OI Bradley, Elizabeth/0000 0002 8814 5524
FU National Institutes of Health [R01 DE14680]; Mayo Foundation
FX This work was supported by National Institutes of Health Grant R01
   DE14680 (to M. J. O.) and the Mayo Foundation.
CR Abell K, 2005, NAT CELL BIOL, V7, P392, DOI 10.1038/ncb1242
   Abell K, 2005, CELL CYCLE, V4, P897, DOI 10.4161/cc.4.7.1837
   Auernhammer CJ, 2000, ENDOCR REV, V21, P313, DOI 10.1210/er.21.3.313
   Bamberger AM, 1997, MOL CELL ENDOCRINOL, V127, P71, DOI 10.1016/S0303 7207(96)03991 3
   Borton AJ, 2001, J BONE MINER RES, V16, P1754, DOI 10.1359/jbmr.2001.16.10.1754
   Bozec A, 2008, NATURE, V454, P221, DOI 10.1038/nature07019
   CAMPBELL IK, 1993, ARTHRITIS RHEUM US, V36, P790, DOI 10.1002/art.1780360608
   Carlson CD, 1996, J NEUROIMMUNOL, V70, P181, DOI 10.1016/S0165 5728(96)00115 4
   CARTER DA, 1995, J NEUROENDOCRINOL, V7, P623, DOI 10.1111/j.1365 2826.1995.tb00800.x
   Chabaud M, 1998, J IMMUNOL, V161, P409
   CHEEMA SS, 1994, J NEUROSCI RES, V37, P213, DOI 10.1002/jnr.490370207
   CHEEMA SS, 1994, NEUROREPORT, V5, P989, DOI 10.1097/00001756 199404000 00034
   DERIGS HG, 1993, LEUKEMIA, V7, P630
   Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006
   ELIAS JA, 1994, AM J PHYSIOL, V266, pL426, DOI 10.1152/ajplung.1994.266.4.L426
   Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018
   Fox SW, 2008, BIOCHEM BIOPH RES CO, V366, P123, DOI 10.1016/j.bbrc.2007.11.120
   Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484
   Futakuchi M, 2009, CANCER SCI, V100, P71, DOI 10.1111/j.1349 7006.2008.01012.x
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   Gingery A, 2008, EXP CELL RES, V314, P2725, DOI 10.1016/j.yexcr.2008.06.006
   Goltzman D, 2001, J CLIN INVEST, V107, P1219, DOI 10.1172/JCI13073
   Grosset C, 1999, CYTOKINE, V11, P29, DOI 10.1006/cyto.1998.0394
   GROSSET C, 1995, BLOOD, V86, P3763, DOI 10.1182/blood.V86.10.3763.bloodjournal86103763
   Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18
   HAMILTON JA, 1993, J IMMUNOL, V150, P1496
   Izumi M, 2006, J MOL CELL CARDIOL, V40, P224, DOI 10.1016/j.yjmcc.2005.11.007
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Johnsen SA, 2002, ONCOGENE, V21, P5783, DOI 10.1038/sj.onc.1205681
   Kanaan RA, 2006, MED SCI MONITOR, V12, pRA164
   Karst M, 2004, J CELL PHYSIOL, V200, P99, DOI 10.1002/jcp.20036
   Kurek JB, 1998, NEUROSCI LETT, V249, P1, DOI 10.1016/S0304 3940(98)00360 7
   Lentzsch S, 2004, LEUKEMIA, V18, P1883, DOI 10.1038/sj.leu.2403486
   Lu Y, 2006, J BIOL CHEM, V281, P36683, DOI 10.1074/jbc.M607374200
   Michigami T, 2001, CANCER RES, V61, P1637
   Mohammad KS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005275
   Moon C, 2009, J NEUROSCI RES, V87, P1098, DOI 10.1002/jnr.21919
   Morita Y, 1999, ENDOCRINOLOGY, V140, P941, DOI 10.1210/en.140.2.941
   Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554
   MURPHY M, 1993, DEVELOPMENT, V117, P1173
   Oberle S, 2006, J NEUROSCI, V26, P1823, DOI 10.1523/JNEUROSCI.4127 05.2006
   OURSLER MJ, 1994, J BONE MINER RES, V9, P443
   Park JI, 2003, MOL CELL BIOL, V23, P543, DOI 10.1128/MCB.23.2.543 554.2003
   Peñuelas S, 2009, CANCER CELL, V15, P315, DOI 10.1016/j.ccr.2009.02.011
   ROODMAN GD, 1995, BONE, V17, pS57, DOI 10.1016/8756 3282(95)00179 H
   Schweizer U, 2002, J CELL BIOL, V156, P287, DOI 10.1083/jcb.200107009
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092 8674(03)00432 X
   Slaets H, 2008, PROTEOMICS, V8, P1237, DOI 10.1002/pmic.200700641
   Stover DG, 2007, J CELL BIOCHEM, V101, P851, DOI 10.1002/jcb.21149
   Tanaka T, 2001, ARCH DERMATOL RES, V293, P18, DOI 10.1007/s004030000191
   Waterhouse NJ, 2006, IMMUNOL CELL BIOL, V84, P72, DOI 10.1111/j.1440 1711.2005.01416.x
   Whitlon DS, 2006, NEUROSCIENCE, V138, P653, DOI 10.1016/j.neuroscience.2005.11.030
   Winding B, 2000, J CANCER RES CLIN, V126, P631, DOI 10.1007/PL00008475
NR 53
TC 34
Z9 37
U1 0
U2 3
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD APR
PY 2010
VL 151
IS 4
BP 1713
EP 1722
DI 10.1210/en.2009 0813
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 572YL
UT WOS:000275874000037
PM 20181800
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Darcy, A
   Meltzer, M
   Miller, J
   Lee, S
   Chappell, S
   Donck, KV
   Montano, M
AF Darcy, Ariana
   Meltzer, Micah
   Miller, Joseph
   Lee, Steven
   Chappell, Scott
   Donck, Kris Ver
   Montano, Monty
TI A novel library screen identifies immunosuppressors that promote
   osteoblast differentiation
SO BONE
LA English
DT Article
DE High throughput screen; Osteoblast; Aging; Smad; Immune suppressors
ID GROWTH FACTOR BETA; TGF BETA; COLLAGEN SYNTHESIS; BONE FORMATION;
   STEM CELLS; RAPAMYCIN; MECHANISMS; RESVERATROL; PROTEINS; DENSITY
AB Bone homeostasis can be compromised by an increase in osteoclast mediated resorption and/or a decrease in osteoblast mediated bone deposition. While many efforts have focused on treating osteoclast resorption, there has been less emphasis on identifying strategies for promoting osteoblast function. Herein, we describe a high throughput screening assay to select for small molecules that augment bone morphogenetic protein 2 (BMP 2) mediated osteoblast lineage commitment. After an initial screen of 5405 compounds: consisting of FDA approved drugs, known bioactives, and compounds with novel chemical makeup, we identified 45 small molecules that promoted osteoblast commitment. Of the 45 candidates, there was a broad array of classes that included nine retinoid analogs/derivatives and four immunosuppressants, notably rapamycin and FK 506, which were chosen for further study. Treatment of osteoblast precursor cells with rapamycin or FK 506, either alone, or synergistically with BMP 2, increased levels of phospho Smad 1/5/8 protein and transcription of Runx 2, Osx and Smad 7, consistent with a role in promoting osteoblast differentiation. Only FK 506 was able to enhance osteocalcin transcripts and Alizarin Red staining, both late markers for differentiation. When osteoblast differentiation was suppressed with exogenous TGF beta 1 treatment, rapamycin (but not FK 506) was able to rescue expression of differentiation markers, indicating distinct but overlapping activity of these compounds. Collectively, these data add to an understanding of pathways engaged in osteoblastogenesis, support a role for non redundant immunosuppressant signaling, and provide a novel approach for the discovery of potentially therapeutic compounds that affect bone remodeling. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Darcy, Ariana; Meltzer, Micah; Miller, Joseph; Lee, Steven; Chappell, Scott; Montano, Monty] Boston Univ, Sch Med, Boston, MA 02118 USA.
   [Donck, Kris Ver] Digilab Inc, Holliston, MA 01746 USA.
C3 Boston University
RP Montano, M (通讯作者)，Boston Univ, Sch Med, Boston, MA 02118 USA.
EM mmontano@bu.edu
OI Montano, Monty/0000 0002 1473 887X
FU Boston OAIC Pepper Center; Boston University; National Institutes of
   Health [RO1 AR055115]
FX The authors would like to acknowledge the help of Dr. Sarah Haigh Molina
   and Ada Kane in the Boston University High Throughput Screening Core, as
   well as David Drapcho from Digilab. This research was in part funded by
   the Boston OAIC Pepper Center, the Boston University Ignition Award
   Program (MM.) and RO1 AR055115 from the National Institutes of Health
   (M.M.).
CR Andia DC, 2008, HISTOL HISTOPATHOL, V23, P1177, DOI 10.14670/HH 23.1177
   Arora Shitij, 2010, Curr Osteoporos Rep, V8, P219, DOI 10.1007/s11914 010 0036 x
   Astrinidis A, 2010, GENE CHROMOSOME CANC, V49, P282, DOI 10.1002/gcc.20739
   AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756 3282(95)00183 E
   Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200
   Cao K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002346
   Cazanave C, 2008, AIDS, V22, P395, DOI 10.1097/QAD.0b013e3282f423dd
   CENTRELLA M, 1987, J BIOL CHEM, V262, P2869
   CENTRELLA M, 1992, ENDOCRINOLOGY, V131, P2863, DOI 10.1210/en.131.6.2863
   Chambers TJ, 2000, J PATHOL, V192, P4
   Choo MK, 2009, BONE, V45, P579, DOI 10.1016/j.bone.2009.05.009
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dallas SL, 2010, ANN NY ACAD SCI, V1192, P437, DOI 10.1111/j.1749 6632.2009.05246.x
   Dolan SE, 2006, J CLIN ENDOCR METAB, V91, P2938, DOI 10.1210/jc.2006 0127
   Dumont FJ, 1995, LIFE SCI, V58, P373, DOI 10.1016/0024 3205(95)02233 3
   Edwards, 2010, J BONE MINER RES
   Ehnert S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014073
   Epstein Sol, 1995, Current Opinion in Rheumatology, V7, P255, DOI 10.1097/00002281 199505000 00018
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Giddings AM, 2010, J BIOMOL SCREEN, V15, P1204, DOI 10.1177/1087057110384612
   Hamawy MM, 2003, DRUG NEWS PERSPECT, V16, P277, DOI 10.1358/dnp.2003.16.5.829315
   Hoemann CD, 2009, PATHOL BIOL, V57, P318, DOI 10.1016/j.patbio.2008.06.004
   Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195
   Kaihara S, 2004, GENE THER, V11, P439, DOI 10.1038/sj.gt.3302176
   Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270
   Kugimiya F, 2005, BIOCHEM BIOPH RES CO, V338, P872, DOI 10.1016/j.bbrc.2005.10.024
   Lai CF, 2000, J BIOL CHEM, V275, P36400, DOI 10.1074/jbc.M002131200
   Lee KW, 2010, STEM CELLS DEV, V19, P557, DOI 10.1089/scd.2009.0147
   Li W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019313
   Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067
   Massagué J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051
   Matsumoto T, 2011, BONE, V48, P129, DOI 10.1016/j.bone.2010.05.036
   Miller RA, 2011, J GERONTOL A BIOL, V66, P191, DOI 10.1093/gerona/glq178
   Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Ogawa T, 1998, BIOCHEM BIOPH RES CO, V249, P226, DOI 10.1006/bbrc.1998.9118
   Ohdan H, CLIN PHARM THER, V87, P23
   Okamoto M, 2011, J BONE MINER RES, V26, P2511, DOI 10.1002/jbmr.477
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Rayalam S, 2011, MOL NUTR FOOD RES, V55, P1177, DOI 10.1002/mnfr.201000616
   ROMERO DF, 1995, J BONE MINER RES, V10, P760
   Rosen V, 2009, CYTOKINE GROWTH F R, V20, P475, DOI 10.1016/j.cytogfr.2009.10.018
   Rufo A, 2011, J BONE MINER RES, V26, P1891, DOI 10.1002/jbmr.410
   Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483
   Sehgal SN, 1998, CLIN BIOCHEM, V31, P335, DOI 10.1016/S0009 9120(98)00045 9
   SHIBATA Y, 1991, LIFE SCI, V49, P1103, DOI 10.1016/0024 3205(91)90598 6
   Singha UK, 2008, J CELL BIOCHEM, V103, P434, DOI 10.1002/jcb.21411
   Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593
   TAKUWA Y, 1991, BIOCHEM BIOPH RES CO, V174, P96, DOI 10.1016/0006 291X(91)90490 X
   Tamler R, 2006, ANN NY ACAD SCI, V1068, P284, DOI 10.1196/annals.1346.032
   Tanaka K, 2010, BONE, V47, P1006, DOI 10.1016/j.bone.2010.08.016
   Tang L, 2002, CELL BIOL INT, V26, P75, DOI 10.1006/cbir.2001.0812
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Taylor AL, 2005, CRIT REV ONCOL HEMAT, V56, P23, DOI 10.1016/j.critrevonc.2005.03.012
   Uysal T, 2011, ORTHOD CRANIOFAC RES, V14, P80, DOI 10.1111/j.1601 6343.2011.01511.x
   Viñals F, 2002, FEBS LETT, V510, P99, DOI 10.1016/S0014 5793(01)03236 7
   Wongdee K, 2011, WORLD J DIABETES, V2, P41, DOI 10.4239/wjd.v2.i3.41
   WRANA JL, 1988, J CELL BIOL, V106, P915, DOI 10.1083/jcb.106.3.915
   Xiang XX, 2011, ACTA BIOCH BIOPH SIN, V43, P501, DOI 10.1093/abbs/gmr041
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   Yeo H, 2007, BONE, V40, P1502, DOI 10.1016/j.bone.2007.02.017
   Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328
   Zhu L, 2001, CURR OPIN GENET DEV, V11, P91, DOI 10.1016/S0959 437X(00)00162 3
NR 65
TC 53
Z9 61
U1 0
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUN
PY 2012
VL 50
IS 6
BP 1294
EP 1303
DI 10.1016/j.bone.2012.03.001
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 948LC
UT WOS:000304503700012
PM 22421346
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Rizzoli, R
AF Rizzoli, Rene
TI A new drug: denosumab
SO EJHP PRACTICE
LA English
DT Article
ID LOW BONE MASS; POSTMENOPAUSAL WOMEN; THERAPY; FRACTURE; OSTEOPROTEGERIN;
   ADHERENCE; TURNOVER; DENSITY
AB A RANKL targeted monoclonal antibody, denosumab, has been evaluated as a novel antiresorptive treatment for osteoporosis. It has been shown to increase bone mineral density and decrease vertebral fracture risk significantly. This article reviews the efficacy of this new drug.
C1 [Rizzoli, Rene] Geneva Univ Hosp, Fac Med, Div Bone Dis, CH 1211 Geneva 14, Switzerland.
   [Rizzoli, Rene] Geneva Univ Hosp, Fac Med, Univ Dept Rehabil & Geriatr, CH 1211 Geneva 14, Switzerland.
C3 University of Geneva; University of Geneva
RP Rizzoli, R (通讯作者)，Geneva Univ Hosp, Fac Med, Div Bone Dis, 4 Rue Gabrielle Perret Gentil, CH 1211 Geneva 14, Switzerland.
CR Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Campagnuolo G, 2002, ARTHRITIS RHEUM US, V46, P1926, DOI 10.1002/art.10369
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Curtis JR, 2008, J BONE MINER RES, V23, P1435, DOI 10.1359/JBMR.080418
   Jamal SA, 2011, J BONE MINER RES, V26, P1829, DOI 10.1002/jbmr.403
   Kanis JA, 2008, OSTEOPOROSIS INT, V19, P385, DOI 10.1007/s00198 007 0543 5
   Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716
   Lippuner K, 2009, OSTEOPOROSIS INT, V20, P1131, DOI 10.1007/s00198 008 0779 8
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Miller PD, 2011, J CLIN ENDOCR METAB, V96, P394, DOI 10.1210/jc.2010 1805
   Rizzoli R, 2010, NAT REV DRUG DISCOV, V9, P591, DOI 10.1038/nrd3244
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Siris ES, 2006, MAYO CLIN PROC, V81, P1013, DOI 10.4065/81.8.1013
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
NR 16
TC 0
Z9 0
U1 0
U2 2
PU PHARMA PUBLISHING & MEDIA EUROPE PPM EUROPE
PI MOL
PA POSTBUS 10001, MOL, B 2400, BELGIUM
SN 1781 9989
EI 2030 3769
J9 EJHP PRACT
JI EJHP Pract.
PY 2011
VL 17
IS 4
BP 23
EP 25
PG 3
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 893HX
UT WOS:000300348100021
DA 2025 08 17
ER

PT J
AU Zhang, XN
   Chen, K
   Wei, B
   Liu, XW
   Lei, ZM
   Bai, XZ
AF Zhang, Xiaonan
   Chen, Kang
   Wei, Bo
   Liu, Xingwang
   Lei, Zeming
   Bai, Xizhuang
TI Ginsenosides Rg3 attenuates glucocorticoid induced osteoporosis through
   regulating BMP 2/BMPR1A/Runx2 signaling pathway
SO CHEMICO BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Ginsenosides Rg3; Glucocorticoid; Osteoporosis; Osteoblast; BMP 2
ID BONE MORPHOGENETIC PROTEIN; OSTEOCLAST DIFFERENTIATION; OSTEOBLAST
   DIFFERENTIATION; SECONDARY OSTEOPOROSIS; 20(S) GINSENOSIDE RG3;
   ALKALINE PHOSPHATASE; CONDITIONAL DELETION; MC3T3 E1 CELLS; FRACTURE;
   RATS
AB Glucocorticoid induced osteoporosis (GIOP) is the primary cause of secondary osteoporosis and the existing therapeutic strategies are limited. The aim of this study is to evaluate the effects of ginsenosides (GS) Rg3 on dexamethasone (DEX) induced osteoporosis in vivo and in vitro. GIOP rat was established by DEX injection for 5 weeks and treated by GS Rg3 10 or 20 mg/kg. Body weight and bone mineral density (BMD) of rats were measured at the beginning and the end of the experiment. Histological changes of femurs were observed using HE staining. The in vitro model was established on primary osteoblasts induced by DEX. CCK 8 assay was used to test the cell viability. Bone metabolism markers in serum or primary osteoblasts were detected using biochemical kits. Real time PCR and western blot were used to measure nuclear factor kappa B ligand (RANKL), osteoprotegerin (OPG), bone morphogenic protein 2 (BMP 2), BMP receptor 1A (BMPRIA) and Runx2 expression. The results demonstrated that GS Rg3 prevented DEX induced body weight and BMD reduction, enhanced secretion of bone formation markers and decreased bone resorption markers. In addition, GS Rg3 was found to prevent the suppression of BMP 2/BMPRIA/Runx2 signals induced by DEX both in GIOP rats and primary osteoblasts. Inhibition of BMP 2 by noggin completely blocked the bone alkaline phosphatase secretion promoted effect of GS Rg3 in vitro. These data suggest that GS Rg3 attenuates GIOP through regulating BMP 2 signaling pathway. This study provides a potential drug candidate for GIOP therapy. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Zhang, Xiaonan; Chen, Kang; Wei, Bo; Liu, Xingwang; Lei, Zeming] China Med Univ, Dept Sports Med & Joint Surg, Affiliated Hosp 1, Shenyang 110001, Peoples R China.
   [Bai, Xizhuang] China Med Univ, Dept Orthopaed Surg, Peoples Hosp, Shenyang 110016, Peoples R China.
C3 China Medical University; China Medical University
RP Bai, XZ (通讯作者)，China Med Univ, Dept Orthopaed Surg, Peoples Hosp, Shenyang 110016, Peoples R China.
EM Baixizh_65@163.com
RI liu, xingwang/KCY 1277 2024
FU Special Health Scientific Research Foundation of Liaoning Province
   [LNCCC A03 2014]; Science and Technology Project of Shenyang City
   [F16 206 9 21]
FX This study was supported by grants from the Special Health Scientific
   Research Foundation of Liaoning Province (No. LNCCC A03 2014) and the
   Science and Technology Project of Shenyang City (No.: F16 206 9 21).
CR Ahmed HH, 2012, EUR REV MED PHARMACO, V16, P1446
   Ahmed HH, 2012, EXP TOXICOL PATHOL, V64, P659, DOI 10.1016/j.etp.2011.01.004
   Attele AS, 1999, BIOCHEM PHARMACOL, V58, P1685, DOI 10.1016/S0006 2952(99)00212 9
   Bandyopadhyay A, 2006, PLOS GENET, V2, P2116, DOI 10.1371/journal.pgen.0020216
   Brown JP, 2009, CLIN BIOCHEM, V42, P929, DOI 10.1016/j.clinbiochem.2009.04.001
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Capeller B, 2003, ANTICANCER RES, V23, P1011
   Cauley JA, 2015, STEROIDS, V99, P11, DOI 10.1016/j.steroids.2014.12.010
   Chang G, 2015, J MAGN RESON IMAGING, V42, P1489, DOI 10.1002/jmri.24927
   CHARLES P, 1985, J CLIN INVEST, V76, P2254, DOI 10.1172/JCI112234
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Cheng LQ, 2008, PHYTOCHEMISTRY, V69, P218, DOI 10.1016/j.phytochem.2007.06.035
   Christensen LP, 2009, ADV FOOD NUTR RES, V55, P1, DOI 10.1016/S1043 4526(08)00401 4
   DELMAS PD, 1985, BONE, V6, P339, DOI 10.1016/8756 3282(85)90326 6
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   den Uyl D, 2011, CURR RHEUMATOL REP, V13, P233, DOI 10.1007/s11926 011 0173 y
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Feng M, 2014, J STEROID BIOCHEM, V144, P455, DOI 10.1016/j.jsbmb.2014.09.005
   Humphrey EL, 2006, BONE, V38, P652, DOI 10.1016/j.bone.2005.10.004
   Kamiya N, 2008, J BONE MINER RES, V23, P2007, DOI 10.1359/JBMR.080809
   Kano Y, 2005, ENDOCRINOLOGY, V146, P5332, DOI 10.1210/en.2005 0474
   Kim DY, 2012, FITOTERAPIA, V83, P215, DOI 10.1016/j.fitote.2011.10.017
   Kok C, 2009, BEST PRACT RES CL RH, V23, P769, DOI 10.1016/j.berh.2009.09.006
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee AJ, 2000, ANN CLIN BIOCHEM, V37, P432, DOI 10.1258/0004563001899573
   Liu Y, 2004, J BONE MINER RES, V19, P479, DOI 10.1359/JBMR.0301242
   Luppen CA, 2008, GROWTH FACTORS, V26, P226, DOI 10.1080/08977190802277880
   Mishina Y, 2004, J BIOL CHEM, V279, P27560, DOI 10.1074/jbc.M404222200
   Niu J, 2012, RAPID COMMUN MASS SP, V26, P2683, DOI 10.1002/rcm.6392
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Okamoto M, 2011, J BONE MINER RES, V26, P2511, DOI 10.1002/jbmr.477
   Orriss IR, 2006, BONE, V39, P300, DOI 10.1016/j.bone.2006.02.063
   Ovchinnikov DA, 2006, DEV BIOL, V295, P103, DOI 10.1016/j.ydbio.2006.03.013
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   Rao Subramaniam M, 2013, N Am J Med Sci, V5, P161, DOI 10.4103/1947 2714.109175
   Rizzoli R, 2012, CALCIFIED TISSUE INT, V91, P225, DOI 10.1007/s00223 012 9630 5
   Sengupta S, 2004, CIRCULATION, V110, P1219, DOI 10.1161/01.CIR.0000140676.88412.CF
   Shin YM, 2013, MOL BIOL REP, V40, P269, DOI 10.1007/s11033 012 2058 1
   Siddiqi M.H., 2015, PHYTOTHER RES, V8
   Siddiqi MH, 2014, J PHARM PHARMACOL, V66, P1763, DOI 10.1111/jphp.12306
   Siddiqi MH, 2014, PHYTOTHER RES, V28, P1447, DOI 10.1002/ptr.5146
   Siddiqi MZ, 2015, J MED FOOD, V18, P542, DOI 10.1089/jmf.2014.3251
   Song JM, 2015, J TRADIT CHIN MED, V35, P440, DOI 10.1016/S0254 6272(15)30122 9
   Tian JW, 2005, NEUROSCI LETT, V374, P92, DOI 10.1016/j.neulet.2004.10.030
   Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603
   Tsuji K, 2008, J BONE JOINT SURG AM, V90A, P14, DOI 10.2106/JBJS.G.01109
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Tsuji K, 2010, J ORTHOP RES, V28, P384, DOI 10.1002/jor.20996
   Urist MR, 1997, J BONE MINER RES, V12, P343, DOI 10.1359/jbmr.1997.12.3.343
   van Rossum EFC, 2004, RECENT PROG HORM RES, V59, P333, DOI 10.1210/rp.59.1.333
   Wang FS, 2008, ENDOCRINOLOGY, V149, P1793, DOI 10.1210/en.2007 0910
   Woolf AD, 2007, CURR OPIN RHEUMATOL, V19, P370
   Yasuda H, 1999, BONE, V25, P109, DOI 10.1016/S8756 3282(99)00121 0
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 54
TC 36
Z9 38
U1 1
U2 21
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009 2797
EI 1872 7786
J9 CHEM BIOL INTERACT
JI Chem. Biol. Interact.
PD AUG 25
PY 2016
VL 256
BP 188
EP 197
DI 10.1016/j.cbi.2016.07.003
PG 10
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA DU6RA
UT WOS:000382341100021
PM 27387537
DA 2025 08 17
ER

PT J
AU Pinna, A
   Baghbaderani, MT
   Hernández, VV
   Naruphontjirakul, P
   Li, SW
   McFarlane, T
   Hachim, D
   Stevens, MM
   Porter, AE
   Jones, JR
AF Pinna, Alessandra
   Baghbaderani, Mohammad Torki
   Hernandez, Victoria Vigil
   Naruphontjirakul, Parichart
   Li, Siwei
   McFarlane, Taneisha
   Hachim, Daniel
   Stevens, Molly M.
   Porter, Alexandra E.
   Jones, Julian R.
TI Nanoceria provides antioxidant and osteogenic properties to mesoporous
   silica nanoparticles for osteoporosis treatment
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Nanoparticles; Radical scavengers; Osteoporosis; Bioactive glass;
   Nanoceria
ID CERIUM OXIDE NANOPARTICLES; BONE MINERAL DENSITY; PRIMARY OSTEOBLASTS;
   OXIDATIVE STRESS; DIFFERENTIATION; BISPHOSPHONATES; CELLS; MECHANISM;
   GROWTH
AB Osteoporosis, a chronic metabolic bone disease, is the most common cause of fractures. Drugs for treating osteoporosis generally inhibit osteoclast (OC) activity, but are rarely aimed at encouraging new bone growth and often cause severe systemic side effects. Reactive oxygen species (ROS) are one of the key triggers of osteoporosis, by inducing osteoblast (OB) and osteocyte apoptosis and promoting osteoclastogenesis. Here we tested the capability of the ROS scavenger nanoceria encapsulated within mesoporous silica nanoparticles (Ce@MSNs) to treat osteoporosis using a pre osteoblast MC3T3 E1 cell monoculture in stressed and normal conditions. Ce@MSNs (diameter of 80 +/  10 nm) were synthesised following a scalable two step process involving sol gel and wet impregnation methods. The Ce@MSNs at concentration of 100 mu g mL( 1) induced a significant reduction in oxidative stress produced by t butyl hydroperoxide and did not alter cell viability significantly. Confocal microscopy showed that MSNs and Ce@MsNs were internalised into the cytoplasm of the pre osteoblasts after 24 h but were not in the nucleus, avoiding any DNA and RNA modifications. Ce@MSNs provoked mineralisation of the pre osteoablasts without osteogenic supplements, which did not occur when the cells were exposed to MSN without nanoceria. In a co culture system of MC3T3 E1 and RAW264.7 macrophages, the Ce@MSNs exhibited antioxidant capability and stimulated cell proliferation and osteogenic responses without adding osteogenic supplements to the culture. The work brings forward an effective platform based for facile synthesis of Ce@MSNs to interact with both OBs and OCs for treatment of osteoporosis.
   Statement of significance
   Current therapies that treat osteoporosis only target osteoclasts (OCs), using drugs, leading to side effects. Here, new multicomponent 80 nm spherical nanoparticles (Ce@MSNs) combine antioxidant, osteogenic and anti osteoclastogenic properties. Ce@MSNs interact with both osteoblast (OBs) and OCs in co culture of osteoblasts and macrophages. Ce@MSNs stimulated osteoblast cells to produce bone matrix and demonstrated antioxidant properties in a co culture cells without osteogenic supplements. Ce@MSNs have potential for treating osteoporosis and they could be adapted Ce@MSNs for the treatment of other diseases caused by oxidative stress. (C) 2020 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Pinna, Alessandra; Baghbaderani, Mohammad Torki; Hernandez, Victoria Vigil; Li, Siwei; McFarlane, Taneisha; Hachim, Daniel; Stevens, Molly M.; Porter, Alexandra E.; Jones, Julian R.] Imperial Coll London, Dept Mat, South Kensington Campus, London SW7 2AZ, England.
   [Naruphontjirakul, Parichart] King Mongkuts Univ Technol Thonburi, Biol Engn Program, Bangkok, Thailand.
   [Stevens, Molly M.] Imperial Coll London, Dept Bioengn, South Kensington Campus, London SW7 2AZ, England.
   [Stevens, Molly M.] Imperial Coll London, Inst Biomed Engn, South Kensington Campus, London SW7 2AZ, England.
C3 Imperial College London; King Mongkuts University of Technology
   Thonburi; Imperial College London; Imperial College London
RP Pinna, A; Jones, JR (通讯作者)，Imperial Coll London, Dept Mat, South Kensington Campus, London SW7 2AZ, England.
EM a.pinna@imperial.ac.uk; julian.r.jones@imperial.ac.uk
RI ; Jones, Julian/B 1007 2012; Stevens, Martin/J 6495 2013;
   Naruphontjirakul, Parichart/G 7577 2019; Li, Siwei/AHI 0154 2022
OI Pinna, Alessandra/0000 0002 4789 5898; McFarlane,
   Taneisha/0000 0002 8152 0504; Hachim, Daniel/0000 0002 6898 9009;
   Stevens, Molly/0000 0002 7335 266X; Li, Siwei/0000 0002 1042 0012; Torki
   Baghbaderani, Mohammad/0000 0001 7974 3904; naruphontjirakul,
   parichart/0000 0001 9998 6700; 
FU Marie Sklodowska Curie Actions (MSCA) Individual fellowship (IF) in
   Horizon 2020 program of the European Union; EPSRC [EP/M004414/1];
   Imperial College Research fellowship scheme (ICRF); Engineering and
   Physical Sciences Research Council [EP/M004414/1] Funding Source:
   researchfish; EPSRC [EP/M004414/1] Funding Source: UKRI
FX The research work has received funding by the Marie Sklodowska Curie
   Actions (MSCA) Individual fellowship (IF) in Horizon 2020 program of the
   European Union, the EPSRC (EP/M004414/1) and the Imperial College
   Research fellowship scheme (ICRF). Raw data is available on request from
   rdm enquiries@imperial.ac.uk.
CR Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Al Oweini R, 2009, J MOL STRUCT, V919, P140, DOI 10.1016/j.molstruc.2008.08.025
   Arakaki N, 2013, BIOMED RES TOKYO, V34, P161, DOI 10.2220/biomedres.34.161
   Asati A, 2011, ANAL CHEM, V83, P2547, DOI 10.1021/ac102826k
   Atkins GJ, 2003, J BONE MINER RES, V18, P1088, DOI 10.1359/jbmr.2003.18.6.1088
   Balas F, 2006, J AM CHEM SOC, V128, P8116, DOI 10.1021/ja062286z
   Ballesteros R., 2001, DESIGN APPL NOVEL TI
   Beck GR, 2012, NANOMED NANOTECHNOL, V8, P793, DOI 10.1016/j.nano.2011.11.003
   BOGUSH GH, 1991, J COLLOID INTERF SCI, V142, P19, DOI 10.1016/0021 9797(91)90030 C
   Callaway DA, 2015, J BONE MINER METAB, V33, P359, DOI 10.1007/s00774 015 0656 4
   Chang BS, 2013, CHEM MATER, V25, P574, DOI 10.1021/cm3037197
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Dowding JM, 2014, CELL DEATH DIFFER, V21, P1622, DOI 10.1038/cdd.2014.72
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Fielding GA, 2019, J FUNCT BIOMATER, V10, DOI 10.3390/jfb10040048
   Gao J, 2018, CELL DEATH DIFFER, V25, P229, DOI 10.1038/cdd.2017.144
   Gielen J, 2017, CRYSTALS, V7, P1
   Grecco STF, 2014, J BRAZIL CHEM SOC, V25, P2444, DOI 10.5935/0103 5053.20140271
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Janos P, 2017, ENVIRON SCI NANO, V4, P1283, DOI 10.1039/c7en00119c
   Karakoti AS, 2010, J MATER CHEM, V20, P8912, DOI 10.1039/c0jm01072c
   Kwon S, 2013, J TISSUE ENG, V4, DOI 10.1177/2041731413503357
   Labbaf S, 2011, BIOMATERIALS, V32, P1010, DOI 10.1016/j.biomaterials.2010.08.082
   Li XX, 2019, J GEODESY, V93, P749, DOI 10.1007/s00190 018 1195 2
   Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140 6736(97)02342 8
   Lv X, 2016, MICROPOR MESOPOR MAT, V225, P238, DOI 10.1016/j.micromeso.2015.12.024
   Martín Moldes Z, 2021, ACTA BIOMATER, V120, P203, DOI 10.1016/j.actbio.2020.10.043
   McClung M, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2167
   Naruphontjirakul P., 2016, BIOMEDICAL GLASSES, P72, DOI DOI 10.1515/BGLASS 2016 0009
   Naruphontjirakul P, 2019, ACTA BIOMATER, V90, P373, DOI 10.1016/j.actbio.2019.03.038
   Nicolini V, 2015, J PHYS CHEM B, V119, P4009, DOI 10.1021/jp511737b
   Pagliari F, 2012, ACS NANO, V6, P3767, DOI 10.1021/nn2048069
   Pal N, 2014, RSC ADV, V4, P9213, DOI 10.1039/c3ra47464j
   PARFITT AM, 1987, AM J MED, V82, P68, DOI 10.1016/0002 9343(87)90274 9
   Pinna A, 2015, RSC ADV, V5, P20432, DOI 10.1039/c4ra16265j
   Pinna A, 2013, ACS APPL MATER INTER, V5, P3168, DOI 10.1021/am4001024
   Pinna A, 2012, ACS APPL MATER INTER, V4, P3916, DOI 10.1021/am300732v
   Putz AM, 2012, INT J MOL SCI, V13, P15925, DOI 10.3390/ijms131215925
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Smietana MJ, 2010, BIOCHEM BIOPH RES CO, V403, P149, DOI 10.1016/j.bbrc.2010.11.006
   STOBER W, 1968, J COLLOID INTERF SCI, V26, P62, DOI 10.1016/0021 9797(68)90272 5
   Stürmer EK, 2006, J BONE MINER RES, V21, P89, DOI 10.1359/JBMR.050913
   Tarnuzzer RW, 2005, NANO LETT, V5, P2573, DOI 10.1021/nl052024f
   Tsigkou O, 2014, ADV HEALTHC MATER, V3, P115, DOI 10.1002/adhm.201300126
   Tsigkou O, 2009, BIOMATERIALS, V30, P3542, DOI 10.1016/j.biomaterials.2009.03.019
   Tu Kristie N, 2018, P T, V43, P92
   Vallet Regí M, 2008, PROG SOLID STATE CH, V36, P163, DOI 10.1016/j.progsolidstchem.2007.10.002
   Vazquez NI, 2017, BOL SOC ESP CERAM V, V56, P139, DOI 10.1016/j.bsecv.2017.03.002
   Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009 1947
   Wei L, 2014, OSTEOPOROSIS INT, V25, P2089, DOI 10.1007/s00198 014 2735 0
   Xu C, 2014, NPG ASIA MATER, V6, DOI 10.1038/am.2013.88
   Yan HJ, 2018, BIOMATERIALS, V161, P190, DOI 10.1016/j.biomaterials.2018.01.041
   Yaqin L, 2020, APPL MATER TODAY, V19, P1
   Zhou GQ, 2014, MICRO NANO LETT, V9, P91, DOI 10.1049/mnl.2013.0586
   Zhou GQ, 2013, BIOL TRACE ELEM RES, V153, P411, DOI 10.1007/s12011 013 9655 2
   Zhou XJ, 2015, ACS APPL MATER INTER, V7, P15777, DOI 10.1021/acsami.5b02636
NR 56
TC 69
Z9 72
U1 7
U2 95
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD MAR 1
PY 2021
VL 122
BP 365
EP 376
DI 10.1016/j.actbio.2020.12.029
EA FEB 2021
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA QK6IS
UT WOS:000620488200007
PM 33359295
DA 2025 08 17
ER

PT J
AU Biggin, A
   Munns, CF
AF Biggin, A.
   Munns, C. F.
TI Osteogenesis Imperfecta: Diagnosis and Treatment
SO CURRENT OSTEOPOROSIS REPORTS
LA English
DT Article
DE Osteogenesis imperfecta; Bisphosphonates; Bone fragility; Fractures
ID CYCLICAL INTRAVENOUS PAMIDRONATE; ZOLEDRONIC ACID; BISPHOSPHONATE
   TREATMENT; BONE HISTOMORPHOMETRY; MOUSE MODEL; CHILDREN; MUTATION;
   ADOLESCENTS; CHILDHOOD; IDENTIFICATION
AB Osteogenesis imperfecta (OI) is a genetic bone fragility disorder characterized by low bone mass, skeletal deformity, and variable short stature. OI is predominantly caused by dominant mutations affecting type 1 collagen synthesis, with a number of other genes implicated in OI over recent years. The clinical severity of OI can vary greatly, even within families who share a common mutation. Optimal management of OI requires a multidisciplinary approach involving pediatrician, endocrinologist (bone and mineral physician), rehabilitation specialist, orthopedic surgeon, dentist, geneticist, social worker/psychologist, physiotherapist, and occupational therapist. Bisphosphonate therapy remains the mainstay of medical treatment in OI and has been shown to decrease bone pain, enhance well being, improve muscle strength and mobility and decrease fracture incidence. Novel therapies are beginning to emerge as more is understood about the signaling pathways involved in bone formation. The following summarizes the diagnosis, genetic heterogeneity and management of OI in pediatric practice.
C1 [Biggin, A.; Munns, C. F.] Childrens Hosp Westmead, Inst Endocrinol & Diabet, Westmead, NSW 2145, Australia.
C3 University of Sydney; NSW Health; The Children's Hospital at Westmead;
   Sydney Childrens Hospitals Network
RP Biggin, A (通讯作者)，Childrens Hosp Westmead, Inst Endocrinol & Diabet, Locked Bag 4001, Westmead, NSW 2145, Australia.
EM andrew.biggin@health.nsw.gov.au
RI Munns, Craig/A 8719 2015
OI Munns, Craig/0000 0001 5898 5808; Biggin, Andrew/0000 0002 3443 9359
FU Sydney Medical School Foundation
FX The authors acknowledge the support of the Sydney Medical School
   Foundation.
CR Alcausin MB, 2013, HORM RES PAEDIAT, V79, P333, DOI 10.1159/000351374
   [Anonymous], BONE
   Åström E, 1998, ACTA PAEDIATR, V87, P64
   Bachrach LK, 2009, J CLIN ENDOCR METAB, V94, P400, DOI 10.1210/jc.2008 1531
   Barros ER, 2012, J PEDIATR ENDOCR MET, V25, P485, DOI 10.1515/jpem 2012 0016
   Becker J, 2011, AM J HUM GENET, V88, P362, DOI 10.1016/j.ajhg.2011.01.015
   Ben Amor IM, 2011, J OSTEOPOROS, V2011, DOI 10.4061/2011/540178
   Bhatt RN, 2014, AUST DENT J, V59, P9, DOI 10.1111/adj.12140
   Biggin A, 2014, HORM RES PAEDIAT, V81, P204, DOI 10.1159/000355111
   BINDER H, 1993, ARCH PHYS MED REHAB, V74, P386
   Birke O, 2011, J PEDIATR ORTHOPED, V31, P458, DOI 10.1097/BPO.0b013e31821bfb50
   Bishop N, 2013, LANCET, V382, P1424, DOI 10.1016/S0140 6736(13)61091 0
   BLECK EE, 1981, CLIN ORTHOP RELAT R, P111
   Byers P H, 1995, Connect Tissue Res, V31, P257, DOI 10.3109/03008209509010818
   Chahine C, 2008, J PEDIATR US, V153, P719, DOI 10.1016/j.jpeds.2008.05.003
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Cheung MS, 2007, J BONE MINER RES, V22, P1181, DOI 10.1359/jbmr.070418
   Chiasson R.M., 2004, INTERDISCIPLINARY TR
   Cho TJ, 2012, AM J HUM GENET, V91, P343, DOI 10.1016/j.ajhg.2012.06.005
   Christiansen HE, 2010, AM J HUM GENET, V86, P389, DOI 10.1016/j.ajhg.2010.01.034
   DEVOGELAER JP, 1987, SKELETAL RADIOL, V16, P360, DOI 10.1007/BF00350961
   Djokanovic N, 2008, J OBSTET GYNAECOL CA, V30, P1146, DOI 10.1016/S1701 2163(16)34026 9
   Engelbert RH, 2004, ARCH PHYS MED REHAB, V85, P772, DOI 10.1016/j.apmr.2003.08.085
   Esposito P, 2008, CURR OPIN PEDIATR, V20, P52, DOI 10.1097/MOP.0b013e3282f35f03
   Fahiminiya S, 2014, J BONE MINER RES, V29, P1805, DOI 10.1002/jbmr.2208
   Fahiminiya S, 2013, J MED GENET, V50, P345, DOI 10.1136/jmedgenet 2013 101567
   Forlino A, 2011, NAT REV ENDOCRINOL, V7, P540, DOI 10.1038/nrendo.2011.81
   Glorieux FH, 2002, J BONE MINER RES, V17, P30, DOI 10.1359/jbmr.2002.17.1.30
   Glorieux FH, 1998, NEW ENGL J MED, V339, P947, DOI 10.1056/NEJM199810013391402
   GREEN JR, 1994, J BONE MINER RES, V9, P745
   Ha Vinh R, 2004, AM J MED GENET A, V131A, P115, DOI 10.1002/ajmg.a.30231
   Janus GJM, 2000, EUR SPINE J, V9, P486, DOI 10.1007/s005860000165
   Kelley BP, 2011, J BONE MINER RES, V26, P666, DOI 10.1002/jbmr.250
   Land C, 2007, BONE, V40, P638, DOI 10.1016/j.bone.2006.10.010
   Lapunzina P, 2010, AM J HUM GENET, V87, P110, DOI 10.1016/j.ajhg.2010.05.016
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Martínez Glez V, 2012, HUM MUTAT, V33, P343, DOI 10.1002/humu.21647
   Millington Ward S, 2005, TRENDS MOL MED, V11, P299, DOI 10.1016/j.molmed.2005.04.006
   Misof K, 1997, J CLIN INVEST, V100, P40, DOI 10.1172/JCI119519
   Morello R, 2006, CELL, V127, P291, DOI 10.1016/j.cell.2006.08.039
   Munns CF, 2004, BONE, V35, P231, DOI 10.1016/j.bone.2004.03.008
   Munns CFJ, 2004, J BONE MINER RES, V19, P1779, DOI 10.1359/JBMR.040814
   Munns CFJ, 2004, J BONE MINER RES, V19, P1742, DOI 10.1359/JBMR.040711
   Pazianas M, 2011, BONE, V49, P103, DOI 10.1016/j.bone.2011.01.003
   Phillipi CA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005088.pub2
   Plotkin H, 2000, J CLIN ENDOCR METAB, V85, P1846, DOI 10.1210/jc.85.5.1846
   Rauch F, 2000, BONE, V26, P581, DOI 10.1016/S8756 3282(00)00269 6
   Rauch F, 2003, J CLIN ENDOCR METAB, V88, P986, DOI 10.1210/jc.2002 021371
   Rauch F, 2002, J CLIN INVEST, V110, P1293, DOI 10.1172/JCI200215952
   Rauch F, 2007, BONE, V40, P821, DOI 10.1016/j.bone.2006.11.020
   Rauch F, 2009, J BONE MINER RES, V24, P1282, DOI [10.1359/jbmr.090213, 10.1359/JBMR.090213]
   Robinson RE, 2004, PHARMACOTHERAPY, V24, P195, DOI 10.1592/phco.24.2.195.33143
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rossini M, 2012, J BONE MINER RES, V27, P227, DOI 10.1002/jbmr.521
   Ruck J, 2011, J CHILD ORTHOP, V5, P217, DOI 10.1007/s11832 011 0341 7
   RUSSELL RGG, 1970, LANCET, V2, P899, DOI 10.1016/S0140 6736(70)92070 2
   Sakkers R, 2004, LANCET, V363, P1427, DOI 10.1016/S0140 6736(04)16101 1
   Sawin PD, 1997, J NEUROSURG, V86, P950, DOI 10.3171/jns.1997.86.6.0950
   Semler O., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P77
   Semler O, 2012, J MUSCULOSKEL NEURON, V12, P183
   Shapiro JR, 2003, CALCIFIED TISSUE INT, V72, P103, DOI 10.1007/s00223 001 1055 5
   Sillence D O, 1995, Connect Tissue Res, V31, pS15, DOI 10.3109/03008209509116827
   SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101
   Sinder BP, 2013, J BONE MINER RES, V28, P73, DOI 10.1002/jbmr.1717
   Tanvetyanon T, 2006, ANN ONCOL, V17, P897, DOI 10.1093/annonc/mdj105
   van Dijk FS, 2009, AM J HUM GENET, V85, P521, DOI 10.1016/j.ajhg.2009.09.001
   Van Dijk FS, 2014, AM J MED GENET A, V8, P36545
   Volodarsky M, 2013, HUM MUTAT, V34, P582, DOI 10.1002/humu.22274
   Ward LM, 2011, J CLIN ENDOCR METAB, V96, P355, DOI 10.1210/jc.2010 0636
   Ward LM, 2002, BONE, V31, P12, DOI 10.1016/S8756 3282(02)00790 1
   Warman ML, 2011, AM J MED GENET A, V155A, P943, DOI 10.1002/ajmg.a.33909
   Whyte MP, 2003, NEW ENGL J MED, V349, P457, DOI 10.1056/NEJMoa023110
   Willaert A, 2009, J MED GENET, V46, P233, DOI 10.1136/jmg.2008.062729
   Zeitlin L, 2003, PEDIATRICS, V111, P1030, DOI 10.1542/peds.111.5.1030
NR 74
TC 42
Z9 54
U1 1
U2 18
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1544 1873
EI 1544 2241
J9 CURR OSTEOPOROS REP
JI Curr. Osteoporos. Rep.
PD SEP
PY 2014
VL 12
IS 3
BP 279
EP 288
DI 10.1007/s11914 014 0225 0
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AY0JZ
UT WOS:000347284200005
PM 24964776
DA 2025 08 17
ER

PT J
AU Nardi, A
   Ventura, L
   Cozzi, L
   Tonini, G
   Zennaro, R
   Celi, M
   Ramazzina, E
AF Nardi, A.
   Ventura, L.
   Cozzi, L.
   Tonini, G.
   Zennaro, R.
   Celi, M.
   Ramazzina, E.
TI The bone anabolic therapy
SO AGING CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Parathyroid hormone (PTH); Teriparatide (TPTD); Vertebral compression
   fractures (VCFs)
ID POSTMENOPAUSAL WOMEN; TERIPARATIDE; FRACTURES
AB Teriparatide (TPTD), the amino terminal parathyroid hormone recombinant peptide [PTH (1 34)], is a drug with a proven anabolic action on the bone, effective in preventing vertebral and non vertebral fragility fractures. Recent publications have investigated in great detail the TPTD action on the cortical bone, highlighting the increased strength in the critical zone of the hip with high risk of fracture in osteoporotic patients Poole (PLoS ONE 6:e16190, 2011). In November 2002, TPTD was approved by the FDA for use in post menopausal women and men with osteoporosis at high risk of fracture and in patients with glucocorticoid induced osteoporosis and, since then, has been used to treat more than 1 million patients worldwide (J Bone Miner Res 27(12):2429 2437, 2012). The unchanged safety profile and the well known mechanism of action of this drug have led doctors to explore the use of TPTD in other conditions such as delayed fracture healing, non union, osteonecrosis of the jaw, etc. The positive reports that have resulted from these studies are helping to hypothesize a new perspective on the wider use of this drug, but warrant further clinical investigation to consolidate these results.
C1 [Nardi, A.; Cozzi, L.; Tonini, G.] ULSS 18, Osteoarticolar Pathol Serv, Rovigo, Italy.
   [Ventura, L.] Azienda Osped Carlo Poma, Mantua, Italy.
   [Zennaro, R.] ULSS 19, Porto Viro, Italy.
   [Celi, M.] Univ Roma Tor Vergata, Policlinico Tor Vergata Fdn, Dept Orthopaed & Traumatol, I 00133 Rome, Italy.
   [Ramazzina, E.] ULSS 18, Rovigo, Italy.
C3 ULSS 5 Polesana; Hospital Carlo Poma; ULSS 5 Polesana; University of
   Rome Tor Vergata; ULSS 5 Polesana
RP Nardi, A (通讯作者)，ULSS 18, Osteoarticolar Pathol Serv, Rovigo, Italy.
EM dr.alfredo.nardi@gmail.com; monica.celi@uniroma2.it
CR Alkhiary YM, 2005, J BONE JOINT SURG AM, V87A, P731, DOI 10.2106/JBJS.D.02115
   Andrews EB, 2012, J BONE MINER RES, V27, P2429, DOI 10.1002/jbmr.1768
   Aspenberg P, 2010, J BONE MINER RES, V25, P404, DOI 10.1359/jbmr.090731
   Borggrefe J, 2010, J BONE MINER RES, V25, P472, DOI 10.1359/jbmr.090820
   Bouxsein ML, 2009, J BONE JOINT SURG AM, V91A, P1329, DOI 10.2106/JBJS.H.01030
   Chiang CY, 2013, BONE, V52, P360, DOI 10.1016/j.bone.2012.10.006
   Corradini C, 2010, OSTEOPOROSIS INT, V21, P177
   Gomberg SJ, 2011, J CLIN ENDOCR METAB, V96, P1627, DOI 10.1210/jc.2010 2520
   Graeff C, 2009, J BONE MINER RES, V24, P1672, DOI [10.1359/JBMR.090416, 10.1359/jbmr.090416]
   Kaback LA, 2008, J CELL BIOCHEM, V105, P219, DOI 10.1002/jcb.21816
   Kwon YD, 2012, OSTEOPOROSIS INT, V23, P2721, DOI 10.1007/s00198 011 1882 9
   Lee YK, 2012, OSTEOPOROSIS INT, V23, P2897, DOI 10.1007/s00198 012 2172 x
   Nardi A, 2011, CLIN CASES MINER BON, V8, P38
   Pietrogrande L, 2013, INJURY, V44, pS54, DOI 10.1016/S0020 1383(13)70013 5
   Poole KES, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016190
NR 15
TC 5
Z9 7
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1594 0667
EI 1720 8319
J9 AGING CLIN EXP RES
JI Aging Clin. Exp. Res.
PD OCT
PY 2013
VL 25
SU 1
BP S121
EP S124
DI 10.1007/s40520 013 0133 7
PG 4
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology
GA 257MW
UT WOS:000327389800033
PM 24078441
DA 2025 08 17
ER

PT J
AU Hesse, E
   Schröder, S
   Brandt, D
   Pamperin, J
   Saito, H
   Taipaleenmäki, H
AF Hesse, Eric
   Schroeder, Saskia
   Brandt, Diana
   Pamperin, Jenny
   Saito, Hiroaki
   Taipaleenmaeki, Hanna
TI Sclerostin inhibition alleviates breast cancer induced bone metastases
   and muscle weakness
SO JCI INSIGHT
LA English
DT Article
ID POSTMENOPAUSAL WOMEN; ROMOSOZUMAB TREATMENT; MOLECULAR MECHANISMS;
   SATELLITE CELLS; MASS; EXPRESSION; PREVENTION; RESISTANCE; MUTATIONS;
   MULTIPLE
AB Breast cancer bone metastases often cause a debilitating incurable condition with osteolytic lesions, muscle weakness, and a high mortality. Current treatment comprises chemotherapy, irradiation, surgery, and antiresorptive drugs that restrict but do not revert bone destruction. In hormone receptor negative breast cancer cell lines and human breast cancer tissue, we identified the expression of sclerostin, a soluble Wnt inhibitor that represses osteoblast differentiation and bone formation. In mice with breast cancer bone metastases, pharmacological inhibition of sclerostin using an anti sclerostin antibody (Scl Ab) reduced the metastatic burden. Furthermore, sclerostin inhibition prevented cancer induced bone destruction by augmenting osteoblast mediated bone formation and by reducing osteoclast dependent bone resorption. During advanced disease, NF kappa B and p38 signaling was increased in muscles in a TGF beta 1 dependent manner, causing muscle fiber atrophy, muscle weakness. and tissue regeneration with an increase in Pax7 positive satellite cells. Scl Ab treatment restored NF kappa B and p38 signaling, the abundance of Pax7 positive cells, and muscle function. These effects improved the health and expanded the life span of cancer bearing mice. Together, these results demonstrate that pharmacological inhibition of sclerostin reduces bone metastatic burden and muscle weakness, with a prolongation of survival time. This might provide novel options for treating musculoskeletal complications in breast cancer patients.
C1 [Hesse, Eric; Schroeder, Saskia; Brandt, Diana; Pamperin, Jenny; Saito, Hiroaki; Taipaleenmaeki, Hanna] Univ Med Ctr Hamburg Eppendorf, Mol Skeletal Biol Lab, Dept Trauma Hand & Reconstruct Surg, N27 Res Campus,Martinistr 52, D 20246 Hamburg, Germany.
   [Hesse, Eric] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
C3 University of Hamburg; University Medical Center Hamburg Eppendorf;
   Indiana University System; Indiana University Bloomington
RP Taipaleenmäki, H (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Mol Skeletal Biol Lab, Dept Trauma Hand & Reconstruct Surg, N27 Res Campus,Martinistr 52, D 20246 Hamburg, Germany.
EM h.taipaleenmaeki@uke.de
OI Saito, Hiroaki/0000 0002 8130 0624; Taipaleenmaki,
   Hanna/0000 0002 8254 9333
FU Deutsche Forschungsgemeinschaft [HE 5208/2 1, HE 5208/2 3, TA 1154/1 1]
FX We are indebted to Gudrun Arndt and Philipp Missberger for mouse
   husbandry and the University Medical Center Hamburg Eppendorf. We thank
   Antonio Virgilio Failla of the University Microscopy Imaging Facility
   (Umif) and Michael Horn Glander of the University Cancer Center Hamburg
   (UCCH) Core Facility In Vivo Optical Imaging (CF IVOI) for technical
   support. We are grateful to Michaela Kneissel and Ina Kramer (Novartis)
   for providing the Scl Ab and to Anthony Hall (Mereo BioPharma) for
   continued permission to use the antibody. EH acknowledges funding from
   the Deutsche Forschungsgemeinschaft (HE 5208/2 1, HE 5208/2 3). HT
   obtained funding from the Deutsche Forschungsgemeinschaft (TA 1154/1 1).
CR Aversa Z, 2017, THER ADV MED ONCOL, V9, P369, DOI 10.1177/1758834017698643
   Baracos VE, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2017.105
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Bonetto A, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.101
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Bu GJ, 2008, INT J CANCER, V123, P1034, DOI 10.1002/ijc.23625
   Chavez Kathryn J, 2010, Breast Dis, V32, P35, DOI 10.3233/BD 2010 0307
   Chen YC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2781
   Clines Gregory A., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000616
   Coleman RE, 2016, ONCOLOGY NY, V30, P695
   Coleman RE, 2010, CANCER TREAT REV, V36, P615, DOI 10.1016/j.ctrv.2010.04.003
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cosman F, 2017, NEW ENGL J MED, V376, P396, DOI 10.1056/NEJMc1615367
   Dai XF, 2017, J CANCER, V8, P3131, DOI 10.7150/jca.18457
   Delgado Calle J, 2017, LEUKEMIA, V31, P2686, DOI 10.1038/leu.2017.152
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Ferrari SL, 2018, NAT REV RHEUMATOL, V14, P128, DOI 10.1038/nrrheum.2018.5
   Forlino A, 2016, LANCET, V387, P1657, DOI 10.1016/S0140 6736(15)00728 X
   Galea GL, 2013, J BIOL CHEM, V288, P9035, DOI 10.1074/jbc.M112.405456
   Glorieux FH, 2017, J BONE MINER RES, V32, P1496, DOI 10.1002/jbmr.3143
   Gu GW, 2016, CURR OPIN PHARMACOL, V31, P97, DOI 10.1016/j.coph.2016.11.005
   Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534
   Jackman RW, 2013, EXP PHYSIOL, V98, P19, DOI 10.1113/expphysiol.2011.063321
   Jones NC, 2005, J CELL BIOL, V169, P105, DOI 10.1083/jcb.200408066
   Kurebayashi J, 1999, BRIT J CANCER, V79, P707, DOI 10.1038/sj.bjc.6690114
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   McDonald MM, 2017, BLOOD, V129, P3452, DOI 10.1182/blood 2017 03 773341
   Pannérec A, 2012, TRENDS MOL MED, V18, P599, DOI 10.1016/j.molmed.2012.07.004
   Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370
   Papatheodorou I, 2018, NUCLEIC ACIDS RES, V46, pD246, DOI 10.1093/nar/gkx1158
   Regan JN, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00358
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Sambasivan R, 2011, DEVELOPMENT, V138, P3647, DOI 10.1242/dev.067587
   Semenov MV, 2006, J BIOL CHEM, V281, P38276, DOI 10.1074/jbc.M609509200
   Solling ASK, 2018, THER ADV MUSCULOSKEL, V10, P105, DOI 10.1177/1759720X18775936
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Taipaleenmäki H, 2015, CANCER RES, V75, P1433, DOI 10.1158/0008 5472.CAN 14 1026
   Vallet S, 2010, CLIN CANCER RES, V16, P4084, DOI 10.1158/1078 0432.CCR 10 0600
   Wang YX, 2012, NAT REV MOL CELL BIO, V13, P127, DOI 10.1038/nrm3265
   Waning DL, 2015, NAT MED, V21, P1262, DOI 10.1038/nm.3961
   Waning DL, 2014, CLIN CANCER RES, V20, P3071, DOI 10.1158/1078 0432.CCR 13 1590
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Wijenayaka AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025900
   Wu Q, 2017, ONCOTARGET, V8, P27990, DOI 10.18632/oncotarget.15856
   Zhu MH, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 11913 7
   2013, J CLIN INVEST, V123, P4821, DOI DOI 10.1172/JCI68523
NR 49
TC 92
Z9 94
U1 0
U2 16
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
EI 2379 3708
J9 JCI INSIGHT
JI JCI Insight
PD MAY 2
PY 2019
VL 4
IS 9
AR e125543
DI 10.1172/jci.insight.125543
PG 17
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA HW6QC
UT WOS:000466814100010
PM 30965315
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Jiang, X
   Hou, SY
   Deng, XL
   Hu, LY
   Wang, J
   Hou, DC
AF Jiang, Xu
   Hou, Siyi
   Deng, Xiaolei
   Hu, Liyou
   Wang, Jian
   Hou, Decai
TI Sequential treatment from bisphosphonate to denosumab improves lumbar
   spine bone mineral density in postmenopausal osteoporosis patients: A
   meta analysis of randomized controlled trials
SO MEDICINE
LA English
DT Article
DE bisphosphonates; denosumab; meta analysis; osteoporosis; postmenopausal;
   sequential treatment
ID ZOLEDRONIC ACID; WOMEN; FRACTURE; RISEDRONATE; ALENDRONATE; EXTENSION;
   THERAPY; RISK; IBANDRONATE; MECHANISM
AB Background:Bisphosphonates are effective in the treatment of postmenopausal osteoporosis. However, their prolonged use induces adverse events and may lead to a rapid decline in bone mineral density (BMD) after discontinuation. Denosumab, a human monoclonal antibody, is a widely used antiresorptive agent that is more effective than bisphosphonates in improving bone density. Whether sequential treatment with denosumab after bisphosphonate therapy can maintain or further increase BMD at all sites has not been conclusively demonstrated. Thus, we performed a meta analysis of randomized controlled trials (RCTs) to assess the effects of this sequential therapy on BMD.Methods:We searched the PubMed, Embase, and Cochrane Library databases from December 1, 1986, to May 2, 2024, for all RCTs that assessed the efficacy of sequential therapy of bisphosphonate transition to denosumab in postmenopausal women with osteoporosis. BMD changes at the lumbar spine, femoral neck, and total hip were used as outcomes. We assessed methodological quality, extracted relevant data according to the Cochrane Handbook for Systematic Reviews of Interventions, applied random effects models for meta analyses, performed heterogeneity analyses, and assessed publication bias.Results:A total of 3290 patients from 4 RCTs were included in the meta analysis. Forest plot analysis showed that sequential treatment with bisphosphonate denosumab was associated with higher lumbar spine BMD gain than continuous bisphosphonate treatment [mean difference (MD) = 5.50, 95% confidence interval (CI) = 5.26 5.75, I2 = 32.88%). No risk of bias was observed for the 4 trials, but there was an increase in femoral neck and total hip BMD. Moreover, analyses could not be performed because of high heterogeneity (femoral neck BMD: MD = 3.85, 95% CI = 2.84 4.85, I2 = 97.88%; total hip BMD: MD = 5.65, 95% CI = 4.28 7.02, I2 = 97.91%).Conclusion:Sequential therapy that involves a transition from bisphosphonates to denosumab had a positive effect on lumbar spine bone density, and this type of therapy may be a potential treatment option for increasing lumbar spine bone density in postmenopausal women.
C1 [Jiang, Xu] Liaoning Univ Tradit Chinese Med, Clin Coll 1, Shenyang, Liaoning, Peoples R China.
   [Hou, Siyi] Liaoning Univ Tradit Chinese Med, Affiliated Hosp, Dept Geriatr, Shenyang, Liaoning, Peoples R China.
   [Deng, Xiaolei; Wang, Jian; Hou, Decai] Liaoning Univ Tradit Chinese Med, Affiliated Hosp, Dept Orthopaed 2, Shenyang, Liaoning, Peoples R China.
   [Hu, Liyou] Liaoning Univ Tradit Chinese Med, Grad Sch, Shenyang, Liaoning, Peoples R China.
C3 Liaoning University of Traditional Chinese Medicine; Liaoning University
   of Traditional Chinese Medicine; Liaoning University of Traditional
   Chinese Medicine; Liaoning University of Traditional Chinese Medicine
RP Hou, DC (通讯作者)，Liaoning Univ Tradit Chinese Med, Affiliated Hosp, Dept Orthopaed 2, Shenyang, Liaoning, Peoples R China.
EM jiangxu1004@163.com; lnzyhdc@126.com; lnzydxl@163.com;
   hlyshengzhongyi@126.com; lnzywj@126.com; lnzyhdc@126.com
RI Deng, Xiaolei/GLQ 7342 2022
FU Science and Technology Plan of Liaoning Province of China
   [2023JH2/101600029]; Shenyang City and Technology Plan Project
   [21 174 9 03]
FX This study was supported by funding from the Science and Technology Plan
   of Liaoning Province of China (no. 2023JH2/101600029) and the Shenyang
   City and Technology Plan Project (no. 21 174 9 03).
CR Adler RA, 2016, J BONE MINER RES, V31, P16, DOI 10.1002/jbmr.2708
   Alves C., 2023, Int J Clin Pharm, V46, P357
   Anagnostis P, 2017, MATURITAS, V101, P23, DOI 10.1016/j.maturitas.2017.04.008
   Anastasilakis AD, 2015, OSTEOPOROSIS INT, V26, P2521, DOI 10.1007/s00198 015 3174 2
   Anastasilakis AD, 2009, HORM METAB RES, V41, P721, DOI 10.1055/s 0029 1224109
   Barasch A, 2011, J DENT RES, V90, P439, DOI 10.1177/0022034510397196
   Bhatnagar A, 2022, CUREUS J MED SCIENCE, V14, DOI 10.7759/cureus.29367
   Billington E, 2024, BMJ BRIT MED J, V386, DOI 10.1136/bmj 2023 076898
   Black DM, 2012, J BONE MINER RES, V27, P243, DOI 10.1002/jbmr.1494
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Brown JP, 2014, OSTEOPOROSIS INT, V25, P1953, DOI 10.1007/s00198 014 2692 7
   Camacho PM, 2020, ENDOCR PRACT, V26, P564, DOI 10.4158/GL 2020 0524
   Cosman F, 2024, ENDOCR PRACT, V30, P490, DOI 10.1016/j.eprac.2024.01.014
   Cranney A, 2002, ENDOCR REV, V23, P508, DOI 10.1210/er.2001 2002
   Cranney A, 2002, ENDOCR REV, V23, P517, DOI 10.1210/er.2001 3002
   Dempster DW, 2012, CLIN THER, V34, P521, DOI 10.1016/j.clinthera.2012.02.002
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197 2456(86)90046 2
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Fontalis A, 2018, EXPERT OPIN DRUG SAF, V17, P413, DOI 10.1080/14740338.2018.1430764
   Gedmintas L, 2013, J BONE MINER RES, V28, P1729, DOI 10.1002/jbmr.1893
   Gehrke B, 2024, ARCH ENDOCRIN METAB, V68, P1, DOI 10.20945/2359 4292 2022 0334
   Han YX, 2024, ECLINICALMEDICINE, V68, DOI 10.1016/j.eclinm.2024.102425
   Hanley DA, 2012, INT J CLIN PRACT, V66, P1139, DOI 10.1111/ijcp.12022
   Hegazy AA., 2021, World J Gynecol Womens Health, V5, pe610
   Hegazy AA, 2020, INT J FERTIL STERIL, V13, P346, DOI 10.22074/ijfs.2020.5797
   Higgins JPT, 2003, BMJ BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, BMJ BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14 2385
   Lee S, 2015, FAM PRACT, V32, P276, DOI 10.1093/fampra/cmu088
   Licata AA, 2005, ANN PHARMACOTHER, V39, P668, DOI 10.1345/aph.1E357
   Lou SH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005496
   Lyu HC, 2019, J CLIN ENDOCR METAB, V104, P1753, DOI 10.1210/jc.2018 02236
   Meier RPH, 2012, ARCH INTERN MED, V172, P930, DOI 10.1001/archinternmed.2012.1796
   Miller PD, 2016, J CLIN ENDOCR METAB, V101, P3163, DOI 10.1210/jc.2016 1801
   Moslehi N, 2017, ADV NUTR, V8, P597, DOI [10.3945/an.116.014647, 10.3945/?an.116.014647]
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Recknor C, 2013, OBSTET GYNECOL, V121, P1291, DOI 10.1097/AOG.0b013e318291718c
   Rodan Gideon A., 2002, Current Molecular Medicine (Hilversum), V2, P571, DOI 10.2174/1566524023362104
   Roux C, 2014, BONE, V58, P48, DOI 10.1016/j.bone.2013.10.006
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Schousboe JT, 2016, J CLIN DENSITOM, V19, P8, DOI 10.1016/j.jocd.2015.08.004
   Seeman E, 2010, J BONE MINER RES, V25, P1886, DOI 10.1002/jbmr.81
   Sheik Ali Azizi, 2023, Cureus, V15, pe43031, DOI 10.7759/cureus.43031
   Wu JQ, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018 018 0865 3
NR 44
TC 1
Z9 1
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025 7974
EI 1536 5964
J9 MEDICINE
JI Medicine (Baltimore)
PD NOV 15
PY 2024
VL 103
IS 46
AR e40594
DI 10.1097/MD.0000000000040594
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA M6X7I
UT WOS:001358950000050
PM 39560527
OA gold
DA 2025 08 17
ER

PT J
AU Tsuruoka, S
   Kaneda, T
   Maeda, A
   Ioka, T
   Fujimura, A
AF Tsuruoka, Shuichi
   Kaneda, Tae
   Maeda, Akimitsu
   Ioka, Takashi
   Fujimura, Akio
TI Dosing time dependent variation of bone resorption by cyclosporin A in
   rats' femurs
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE chronopharmacology; cyclosporin A; osteoporosis; hypercalcemia; bone
   resorption
ID RENAL TUBULAR ACIDOSIS; NITRIC OXIDE; HEMODIALYSIS PATIENTS; CIRCADIAN
   VARIATION; ACTIVE VITAMIN D3; MINERAL DENSITY; DIURNAL RHYTHMS; CALCIUM;
   CHRONOTHERAPY; LIGHT
AB The dosing time dependent difference of bone resorption by cyclosporin A was determined in normal rats. Rats were kept in rooms with a 12 h light/dark cycle. Cyclosporin A (3 mg/kg, once a day) or vehicle was given at either 2 h after light on (2 HALO) or 8 HALO, 14 HALO, 20 HALO for 24 weeks. Serum and 4 h urine samples were obtained before and at 12 and 24 weeks after the treatment. Body weight, creatinine clearance, serum parathyroid hormone, the trough level of cyclosporin A in whole blood and urinary excretion of Ca and P were not changed by the drug at every any dosing time. Serum Ca and P concentrations by the vehicle treatment differed with the dosing time. Furthermore, increases of these two parameters by the drug varied with dosing time; most prominently at the 2 HALO dosing, and were not seen at the 8 and 14 HALO dosings. Degree of bone resorption of the femur determined by dual energy X ray absorption, also varied with dosing time, most prominently at 2 HALO and less prominently at 14 HALO. Increase of urine deoxypyridinoline excretion, a marker of osteoclast activity, by the drug was highest at 2 HALO and lowest at 14 HALO, however parathyroid hormone and osteocalcin concentrations after cyclosporin A treatment did not vary with dosing time. Reduction of urinary nitric oxide (NO) was most prominent at 2 HALO and negligible at 14 HALO. We concluded that cyclosporin A induced bone resorption and serum Ca and P increases were varied with dosing time. Sensitivity of osteoclasts by the drug was the major mechanisms of the phenomenon, while differences in pharmacokinetics, the parathyroid gland, osteoblasts and renal handling of Ca and P did not contribute to the phenomenon. (c) 2007 Elsevier B.V. All rights reserved.
C1 Jichi Med Univ, Dept Pharmacol, Div Clin Pharmacol, Shimotsuke, Tochigi 3290498, Japan.
C3 Jichi Medical University
RP Tsuruoka, S (通讯作者)，Jichi Med Univ, Dept Pharmacol, Div Clin Pharmacol, 3311 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.
EM tsuru@jichi.ac.jp
RI Tsuruoka, Shuichi/W 3322 2019
OI maeda, akimitsu/0000 0002 0709 3911
CR CALVO MS, 1991, J CLIN ENDOCR METAB, V72, P69, DOI 10.1210/jcem 72 1 69
   CONNERTY HV, 1966, AM J CLIN PATHOL, V45, P290
   Domrongkitchaiporn S, 2002, KIDNEY INT, V62, P2160, DOI 10.1046/j.1523 1755.2002.00656.x
   DREWES PA, 1972, CLIN CHIM ACTA, V39, P81, DOI 10.1016/0009 8981(72)90302 6
   Epstein S, 1996, J BONE MINER RES, V11, P1
   Fiore CE, 2000, EUR J PHARMACOL, V408, P323, DOI 10.1016/S0014 2999(00)00800 1
   Guerrero JM, 1996, NEUROCHEM INT, V29, P417, DOI 10.1016/0197 0186(95)00162 X
   MROSOVSKY N, 1987, NATURE, V330, P372, DOI 10.1038/330372a0
   Nishiki K, 2003, EUR J PHARMACOL, V460, P171, DOI 10.1016/S0014 2999(02)02921 7
   Provencher SJ, 2002, J PHARMACOL EXP THER, V303, P58, DOI 10.1124/jpet.102.035980
   SEYEDIN SM, 1993, J BONE MINER RES, V8, P635
   SHEN V, 1995, BONE, V16, P149, DOI 10.1016/8756 3282(95)80026 M
   SHINODA H, 1992, AM J PHYSIOL, V262, pR235, DOI 10.1152/ajpregu.1992.262.2.R235
   SHINODA H, 1985, MINER ELECTROL METAB, V11, P158
   TAKAHASHI JS, 1982, SCIENCE, V217, P1104, DOI 10.1126/science.6287576
   TAKAMURE M, 1991, PHYSIOL BEHAV, V50, P443, DOI 10.1016/0031 9384(91)90092 3
   Tsuruoka S, 2005, AM J NEPHROL, V25, P233, DOI 10.1159/000085969
   Tsuruoka S, 2004, EUR J PHARMACOL, V488, P239, DOI 10.1016/j.ejphar.2004.02.007
   Tsuruoka S, 2003, BRIT J CLIN PHARMACO, V55, P531, DOI 10.1046/j.1365 2125.2003.01809.x
   Tsuruoka S, 2002, LIFE SCI, V71, P1809, DOI 10.1016/S0024 3205(02)01940 9
   Tsuruoka S, 2003, J PHARMACOL EXP THER, V305, P840, DOI 10.1124/jpet.102.048207
   Tsuruoka S, 2001, EUR J PHARMACOL, V428, P287, DOI 10.1016/S0014 2999(01)01245 6
   Tsuruoka S, 1999, CLIN PHARMACOL THER, V66, P609, DOI 10.1053/cp.1999.v66.103169001
   Tsuruoka S, 2000, LIFE SCI, V68, P579, DOI 10.1016/S0024 3205(00)00964 4
   Tunçtan B, 2002, CHRONOBIOL INT, V19, P393, DOI 10.1081/CBI 120002915
   TUREK FW, 1985, ANNU REV PHYSIOL, V47, P49, DOI 10.1146/annurev.ph.47.030185.000405
   Wimalawansa S. M., 2000, Journal of Musculoskeletal & Neuronal Interactions, V1, P141
   Yamauchi H, 1998, CLIN EXP PHARMACOL P, V25, P435, DOI 10.1111/j.1440 1681.1998.tb02228.x
   YATSCOFF RW, 1990, CLIN CHEM, V36, P1969
NR 29
TC 7
Z9 9
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014 2999
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD JUN 14
PY 2007
VL 564
IS 1 3
BP 226
EP 231
DI 10.1016/j.ejphar.2007.02.007
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 175FP
UT WOS:000246998800030
PM 17362919
DA 2025 08 17
ER

PT J
AU Zhang, JF
   Li, G
   Chan, CY
   Meng, CL
   Lin, MCM
   Chen, YC
   He, ML
   Leung, PC
   Kung, HF
AF Zhang, Jin fang
   Li, Guo
   Chan, Chu yan
   Meng, Chun ling
   Lin, Marie Chia mi
   Chen, Yang chao
   He, Ming liang
   Leung, Ping chung
   Kung, Hsiang fu
TI Flavonoids of Herba Epimedii regulate osteogenesis of human
   mesenchymal stem cells through BMP and Wnt/β catenin signaling pathway
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE BMP signaling pathway; Wnt/beta catenin signaling pathway; Flavonoids of
   Herb Epidemium; Mesenchymal stem cells; Osteogenic differentiation
ID OSTEOBLAST DIFFERENTIATION; KOREANUM NAKAI; PROLIFERATION; SUPPRESSION;
   EXPRESSION; THERAPY; OSTERIX; GENE
AB Herba Epimedii is one of the most commonly used Chinese herbs for treating osteoporosis. In the present study, the flavonoids of Herba Epimedii (HEF) have shown to promote the osteogenic differentiation of human bone marrow derived mesenchymal stem cells. They were noted to enhance the mRNA expression of BMP 2, BMP 4, Runx2, beta catenin and cyclinD1, all of which are BMP or Wnt signaling pathway related regulators. The osteogenic effect was inhibited by the introduction of noggin and DKK 1, which is classical inhibitor of BMP and Wnt/beta catenin signaling, respectively. These results suggest that HEF exerts promoting effect on osteogenic differentiation, which plausibly functions via the BMP and Wnt/beta catenin signaling pathways. Considering the therapeutic efficiency and economical issues, HEF may be a potential candidate for promoting bone regeneration. On the other hand, osteogenic differentiation of MSCs may also be a promising and attractive tool to apply in bone repair. (C) 2009 Published by Elsevier Ireland Ltd.
C1 [Zhang, Jin fang] Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China.
   [Zhang, Jin fang; Kung, Hsiang fu] Tsinghua Univ, Grad Sch Shenzhen, Div Life Sci, Shenzhen 518055, Peoples R China.
   [Lin, Marie Chia mi] Univ Hong Kong, Dept Chem, Integrat Chem Biol Lab, Inst Mol Technol, Pokfulam, Hong Kong, Peoples R China.
   [Zhang, Jin fang; Li, Guo; Chan, Chu yan; Meng, Chun ling; Chen, Yang chao; He, Ming liang; Kung, Hsiang fu] Chinese Univ Hong Kong, Stanley Ho Ctr Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China.
   [Leung, Ping chung] Chinese Univ Hong Kong, Dept Orthopaed & Traumatol, Hong Kong, Hong Kong, Peoples R China.
C3 Tsinghua University; Tsinghua University; Tsinghua Shenzhen
   International Graduate School; University of Hong Kong; Chinese
   University of Hong Kong; Chinese University of Hong Kong
RP Kung, HF (通讯作者)，Chinese Univ Hong Kong, Stanley Ho Ctr Emerging Infect Dis, Room 511A,Li Basic Med Sci Bldg, Shatin, Hong Kong, Peoples R China.
EM b110473@mailserv.cuhk.edu.hk
RI HE, Ming Liang/AFK 4738 2022; Chen, Yangchao/AAG 2127 2019
OI HE, Mingliang/0000 0002 9942 9151; Chen, Yangchao/0000 0002 0249 3414
CR An SJ, 2000, CHIN J OSTEOPOROSIS, V6, P55
   Celil AB, 2005, J BIOL CHEM, V280, P31353, DOI 10.1074/jbc.M503845200
   Chen KM, 2004, PHARMAZIE, V59, P61
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Egermann M, 2005, OSTEOPOROSIS INT, V16, pS129, DOI 10.1007/s00198 005 1859 7
   Fitzpatrick Lorraine A., 2006, Arq Bras Endocrinol Metab, V50, P705, DOI 10.1590/S0004 27302006000400016
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Hamidouche Z, 2008, FASEB J, V22, P3813, DOI 10.1096/fj.08 106302
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Koga H, 2008, CELL TISSUE RES, V333, P207, DOI 10.1007/s00441 008 0633 5
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097 4644(19990401)73:1<114::AID JCB13>3.3.CO;2 D
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Licata AA, 2005, ANN PHARMACOTHER, V39, P668, DOI 10.1345/aph.1E357
   Meng FH, 2005, PHYTOMEDICINE, V12, P189, DOI 10.1016/j.phymed.2004.03.007
   Meng FH, 2005, PHARM BIOL, V43, P92, DOI 10.1080/13880200590903435
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nelson HD, 2002, JAMA J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872
   Nishio Y, 2006, GENE, V372, P62, DOI 10.1016/j.gene.2005.12.022
   Rodríguez JP, 2008, CURR STEM CELL RES T, V3, P208, DOI 10.2174/157488808785740325
   Pagani F, 2005, J Endocrinol Invest, V28, P8
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rotella DP, 2002, CURR OPIN DRUG DISC, V5, P477
   Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Wu H, 2003, PROG DRUG RES, V60, P1
   Yamaguchi A, 1996, BIOCHEM BIOPH RES CO, V220, P366, DOI 10.1006/bbrc.1996.0411
   Yin YX, 2007, CHINESE MED J PEKING, V120, P204, DOI 10.1097/00029330 200702010 00006
   Zhang DW, 2008, PHYTOMEDICINE, V15, P55, DOI 10.1016/j.phymed.2007.04.002
   Zhang JF, 2009, PHYTOMEDICINE, V16, P521, DOI 10.1016/j.phymed.2009.01.003
   Zhao J, 2008, BIOCHEM BIOPH RES CO, V369, P444, DOI 10.1016/j.bbrc.2008.02.054
NR 34
TC 118
Z9 147
U1 1
U2 41
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303 7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD JAN 15
PY 2010
VL 314
IS 1
BP 70
EP 74
DI 10.1016/j.mce.2009.08.012
PG 5
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA 523VC
UT WOS:000272101700008
PM 19703516
DA 2025 08 17
ER

PT J
AU Korff, C
   Adaway, M
   Atkinson, EG
   Klunk, A
   Silva, BS
   Bellido, T
   Plotkin, LI
   Robling, AG
   Bidwell, JP
AF Korff, Crystal
   Adaway, Michele
   Atkinson, Emily G.
   Klunk, Angela
   Silva, Brandy Suarez
   Bellido, Teresita
   Plotkin, Lilian I.
   Robling, Alexander G.
   Bidwell, Joseph P.
TI Loss of Nmp4 enhances bone gain from sclerostin antibody administration
SO BONE
LA English
DT Article
DE Bone anabolism; Osteoanabolics; Osteoporosis; Romosozumab aqqg
ID UNFOLDED PROTEIN RESPONSE; PARATHYROID HORMONE; POSTMENOPAUSAL WOMEN;
   TRANSCRIPTION FACTOR; FRACTURE PREVENTION; EXPRESSION; CELLS;
   DIFFERENTIATION; ROMOSOZUMAB; INCREASES
AB Severe osteoporosis is often treated with one of three Food and Drug Administration (FDA) approved osteoanabolics. These drugs act by (1) parathyroid hormone (PTH) receptor stimulation using analogues to PTH (teriparatide) or PTH related peptide (abaloparatide) or by (2) monoclonal antibody neutralization of sclerostin, an innate Wnt inhibitor (Scl mAb, romosozumab aqqg). The efficacies of both strategies wane over time. The transcription factor Nmp4 (Nuclear Matrix Protein 4) is expressed in all tissues yet mice lacking this gene are healthy and exhibit enhanced PTH induced bone formation. Conditional deletion of Nmp4 in mesenchymal stem progenitor cells (MSPCs) phenocopies the elevated response to PTH in global Nmp4 /  mice. However, targeted deletion in later osteoblast stages does not replicate this response. In this study we queried whether loss of Nmp4 improves Scl mAb potency. Experimental cohorts included global Nmp4 /  and Nmp4+/+ littermates and three conditional knockout models. Nmp4 floxed (Nmp4fl/fl) mice were crossed with mice harboring one of three Credrivers (i) Prx1Cre+ targeting MSPCs, (ii) BglapCre+ (mature osteocalcin expressing osteoblasts), and (iii) Dmp1Cre+ (osteocytes). Female mice were treated with Scl mAb or 0.9 % saline vehicle for 4 or 7 weeks from 10 weeks of age. Skeletal response was assessed using micro computed tomography, dual energy X ray absorptiometry, bone histomorphometry, and serum analysis. Global Nmp4 /  mice exhibited enhanced Scl mAbinduced increases in trabecular bone in the femur and spine and a heightened increase in whole body areal bone mineral density compared to global Nmp4+/+ controls. This improved Scl mAb potency was primarily driven by enhanced increases in bone formation. Nmp4fl/fl;PrxCre+ mice showed an exaggerated Scl mAbinduced increase in femoral bone but not in the spine since Prrx1 is not expressed in vertebra. The Nmp4fl/fl; BglapCre+ and Nmp4fl/fl;Dmp1Cre+ mice did not exhibit an improved Scl mAb response. We conclude that Nmp4 expression in MSPCs interferes with the bone anabolic response to anti sclerostin therapy.
C1 [Korff, Crystal] Indiana Univ Sch Med IUSM, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.
   [Adaway, Michele; Atkinson, Emily G.; Silva, Brandy Suarez; Plotkin, Lilian I.; Robling, Alexander G.; Bidwell, Joseph P.] Indiana Univ Sch Med IUSM, Dept Anat Cell Biol & Physiol, Indianapolis, IN 46202 USA.
   [Adaway, Michele; Plotkin, Lilian I.; Robling, Alexander G.] Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN USA.
   [Klunk, Angela] IUSM, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.
   [Bellido, Teresita] Univ Arkansas Med Sci UAMS, Dept Physiol & Cell Biol, Little Rock, AR 72205 USA.
   [Bellido, Teresita] Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA.
   [Plotkin, Lilian I.; Robling, Alexander G.; Bidwell, Joseph P.] Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN USA.
   [Bidwell, Joseph P.] Indiana Univ Sch Med, Dept Anat Cell Biol & Physiol, Indianapolis, IN 46202 USA.
   [Atkinson, Emily G.] IU Ventures 642 N Madison St,Suite 113, Bloomington, IN 47404 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Richard L. Roudebush VA Medical Center; University of Arkansas System;
   University of Arkansas Medical Sciences; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans
   Healthcare System; Indiana University System; Indiana University
   Bloomington
RP Bidwell, JP (通讯作者)，Indiana Univ Sch Med, Dept Anat Cell Biol & Physiol, Indianapolis, IN 46202 USA.
EM jbidwell@iupui.edu
RI Plotkin, Lilian/H 7188 2019
OI Bellido, Teresita/0000 0002 8203 7004
FU National Institutes of Health Grants (NIH) [1R01 AR073739, R01
   AR053237]; VA [I01 BX005861, IK6 BX 003783, R21 AG078861]; NIH [1I0
   1BX005154];  [T32 AR065971]
FX This work was supported by National Institutes of Health Grants (NIH)
   1R01 AR073739 to J.P.B. and R01 AR053237 to A.G.R.; VA grants I01
   BX005861 and IK6 BX 003783 to A.G.R.; and support from T32 AR065971 to
   E.G.A and C.K, and NIH R21 AG078861, VA 1I0 1BX005154 to L.I.P. We thank
   Alexander Jackson for his technical assistance with some aspects of this
   project. Sclerostin antibody was provided by Amgen Inc., (Thousand Oaks,
   CA) and UCB (Brussels, Belgium).
CR ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732
   Al Maskari M, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 32705 7
   Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717
   Atkinson EG, 2023, J BONE MINER RES, V38, P70, DOI 10.1002/jbmr.4732
   Balani DH, 2021, J BONE MINER RES, V36, P757, DOI 10.1002/jbmr.4238
   Bidwell J, 2022, CALCIFIED TISSUE INT, V110, P244, DOI 10.1007/s00223 021 00903 7
   Bivi N, 2012, J BONE MINER RES, V27, P374, DOI 10.1002/jbmr.548
   Chen JQ, 2013, J BONE MINER RES, V28, P1160, DOI 10.1002/jbmr.1834
   Childress P, 2015, MOL ENDOCRINOL, V29, P1269, DOI 10.1210/me.2014 1406
   Childress P, 2011, CALCIFIED TISSUE INT, V89, P74, DOI 10.1007/s00223 011 9496 y
   Conley RB, 2020, J BONE MINER RES, V35, P36, DOI 10.1002/jbmr.3877
   Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388
   Dekaney CM, 2019, CELL MOL GASTROENTER, V8, P549, DOI 10.1016/j.jcmgh.2019.07.003
   Deosthale P, 2022, BONE REP, V16, DOI 10.1016/j.bonr.2021.101164
   Fan Y, 2017, CELL METAB, V25, P661, DOI 10.1016/j.cmet.2017.01.001
   Fox Rebecca M, 2015, Front Biol (Beijing), V10, P28
   Gass JN, 2002, J BIOL CHEM, V277, P49047, DOI 10.1074/jbc.M205011200
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   He YZ, 2013, STEM CELLS DEV, V22, P492, DOI 10.1089/scd.2012.0308
   Hess DA, 2016, MOL CELL BIOL, V36, P2931, DOI 10.1128/MCB.00366 16
   Hino K, 2007, BONE, V40, P852, DOI 10.1016/j.bone.2006.03.019
   Huang WB, 2023, PHARMACOEPIDEM DR S, V32, P671, DOI 10.1002/pds.5594
   Iwakoshi NN, 2003, NAT IMMUNOL, V4, P321, DOI 10.1038/ni907
   Iwamoto R, 2021, J BONE MINER METAB, V39, P558, DOI 10.1007/s00774 021 01210 9
   Jiang M, 2016, MOL CELL BIOL, V36, P2945, DOI 10.1128/MCB.00370 16
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941
   Ke H.Z., 2020, Principles of Bone Biology, P1711
   Keaveny TM, 2017, J BONE MINER RES, V32, P1956, DOI 10.1002/jbmr.3176
   Khetchoumian K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 11894 3
   Kim SW, 2012, J BONE MINER RES, V27, P2075, DOI 10.1002/jbmr.1665
   Korff C, 2023, CALCIFIED TISSUE INT, V113, P110, DOI 10.1007/s00223 023 01088 x
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Lim KE, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115708
   Liu F, 2007, BONE, V40, P1135, DOI 10.1016/j.bone.2006.12.003
   Lo HYG, 2017, GENE DEV, V31, P154, DOI 10.1101/gad.285684.116
   Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092
   Lv F, 2020, BONE, V130, DOI 10.1016/j.bone.2019.115121
   MacDonald BT, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007880
   Martin TJ, 2021, ENDOCR REV, V42, P383, DOI 10.1210/endrev/bnab005
   Miao DS, 2005, J CLIN INVEST, V115, P2402, DOI 10.1172/JCI24918
   Migotsky N., 2023, bioRxiv, DOI [10.1101/2023.06.02.543484,2023.2006.2002.543484, DOI 10.1101/2023.06.02.543484,2023.2006.2002.543484]
   Mills JC, 2012, BIOESSAYS, V34, P10, DOI 10.1002/bies.201100089
   Nakamoto T, 2016, J CELL BIOCHEM, V117, P970, DOI 10.1002/jcb.25382
   Ominsky MS, 2015, BONE, V81, P380, DOI 10.1016/j.bone.2015.08.007
   Ominsky MS, 2014, J BONE MINER RES, V29, P1424, DOI 10.1002/jbmr.2152
   Padhi D, 2014, J CLIN PHARMACOL, V54, P168, DOI 10.1002/jcph.239
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Poole KES, 2022, J BONE MINER RES, V37, P256, DOI 10.1002/jbmr.4465
   Ramchand SK, 2020, HANDB EXP PHARMACOL, V262, P423, DOI 10.1007/164_2020_354
   Robling AG, 2011, ENDOCRINOLOGY, V152, P2963, DOI 10.1210/en.2011 0049
   Robling AG, 2009, J CELL PHYSIOL, V219, P734, DOI 10.1002/jcp.21717
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Shao Y, 2019, AM J PHYSIOL ENDOC M, V316, pE749, DOI 10.1152/ajpendo.00343.2018
   Shao Y, 2017, ENDOCRINOLOGY, V158, P2722, DOI 10.1210/en.2017 00355
   Sims NA, 2019, NAT REV RHEUMATOL, V15, P67, DOI 10.1038/s41584 018 0153 y
   Strom O, 2011, Arch Osteoporos, V6, P59, DOI 10.1007/s11657 011 0060 1
   Tabacco G, 2019, BRIT J CLIN PHARMACO, V85, P1084, DOI 10.1111/bcp.13766
   Tay D, 2018, BRIT J CLIN PHARMACO, V84, P252, DOI 10.1111/bcp.13455
   Thunyakitpisal P, 2001, J BONE MINER RES, V16, P10, DOI 10.1359/jbmr.2001.16.1.10
   Turishcheva E, 2022, BIOCHEMISTRY MOSCOW+, V87, P916, DOI 10.1134/S000629792209005X
   van Anken E, 2003, IMMUNITY, V18, P243, DOI 10.1016/S1074 7613(03)00024 4
   Wein MN, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031237
   Wijenayaka AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025900
   Yang D, 2007, BONE, V40, P1453, DOI 10.1016/j.bone.2007.02.001
   Yang SS, 2021, MUCOSAL IMMUNOL, V14, P209, DOI 10.1038/s41385 020 0280 z
   Young SK, 2016, J BIOL CHEM, V291, P13780, DOI 10.1074/jbc.M116.729830
   Yu SB, 2008, ENDOCRINOLOGY, V149, P1960, DOI 10.1210/en.2007 1573
   Zhang RR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020780
NR 70
TC 4
Z9 4
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD DEC
PY 2023
VL 177
AR 116891
DI 10.1016/j.bone.2023.116891
EA SEP 2023
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA W0RY1
UT WOS:001088801000001
PM 37660938
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Giannobile, WV
AF Giannobile, William V.
TI Host Response for Periodontal Therapeutics Diseases
SO JOURNAL OF PERIODONTOLOGY
LA English
DT Article; Proceedings Paper
CT Conference on Inflammation and Periodontal Diseases
CY JAN 29 30, 2008
CL Boston, MA
SP Amer Acad Periodontol
DE Bisphosphonates; bone resorption; matrix metalloproteinases;
   periodontitis
ID GINGIVAL CREVICULAR FLUID; MATRIX METALLOPROTEINASE INHIBITOR; ALVEOLAR
   BONE LOSS; DOSE DOXYCYCLINE; BISPHOSPHONATES; OSTEONECROSIS; BIOMARKERS;
   EFFICACY; IMPROVES; THERAPY
AB Periodontal diseases are initiated by Gram negative tooth associated microbial biofilms that elicit a host response, with resultant osseous and soft tissue destruction. In response to endotoxins derived from periodontal pathogens, several osteoclast related mediators target the destruction of alveolar bone and supporting connective tissues. Major drivers of this aggressive tissue destruction are matrix metalloproteinases (MMPs), cathepsins, and other osteoclast derived enzymes. This article focuses on the downstream factors of the osteoclast responsible for the degradation of bone and soft tissues around teeth and oral implants. Furthermore, therapeutic approaches that target MMP 2,  8, and  9 inhibition, such as MMP inhibitors, chemically modified tetracyclines, and sub antimicrobial formulations of tetracycline analogues, are discussed. The use of rapid, chair side tests of MMP activity, in particular for MMP 8 and bone collagen fragments, show strong potential as non invasive measures of tissue health or disease. In addition, studies using other agents for the preservation of bone mass, such as bisphosphonates that inhibit osteoclast recruitment, are highlighted. The application of these bone preservation strategies to periodontal management and treatment are discussed in the context of high risk patients susceptible to disease reactivation or disease complications. J Periodontol 2008;79:1592 1600.
C1 [Giannobile, William V.] Univ Michigan, Sch Dent, Michigan Ctr Oral Hlth Res, Dept Periodont & Oral Med, Ann Arbor, MI 48106 USA.
   [Giannobile, William V.] Univ Michigan, Coll Engn, Dept Biomed Engn, Ann Arbor, MI 48106 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan
RP Giannobile, WV (通讯作者)，Univ Michigan, Sch Dent, Michigan Ctr Oral Hlth Res, Dept Periodont & Oral Med, 24 Frank Lloyd Wright Dr,Lobby M,Box 422, Ann Arbor, MI 48106 USA.
EM wgiannob@umich.edu
OI Giannobile, William/0000 0002 7102 9746
FU NCRR NIH HHS [UL1 RR 024986, UL1 RR024986] Funding Source: Medline;
   NIDCR NIH HHS [U01 DE014961, U01 DE 14961] Funding Source: Medline
CR Albandar JM, 2002, PERIODONTOL 2000, V29, P31, DOI 10.1034/j.1600 0757.2002.290103.x
   *AM AC PER, 2005, AAP STAT BISPH
   Ashley RA, 1999, ANN NY ACAD SCI, V878, P335, DOI 10.1111/j.1749 6632.1999.tb07693.x
   Caton JG, 2000, J PERIODONTOL, V71, P521, DOI 10.1902/jop.2000.71.4.521
   Ciancio S, 1998, Adv Dent Res, V12, P27
   *EXP PAN REC PREV, DIAGN TREATM OST JAW
   Ficarra G, 2005, J CLIN PERIODONTOL, V32, P1123, DOI 10.1111/j.1600 051X.2005.00842.x
   Gapski R, 2004, J PERIODONTOL, V75, P441, DOI 10.1902/jop.2004.75.3.441
   Gill SE, 2008, INT J BIOCHEM CELL B, V40, P1334, DOI 10.1016/j.biocel.2007.10.024
   Golub L M, 1992, Curr Opin Dent, V2, P80
   Golub LM, 2006, J DENT RES, V85, P102, DOI 10.1177/154405910608500201
   Golub LM, 1997, INFLAMM RES, V46, P310, DOI 10.1007/s000110050193
   Golub LM, 2008, J PERIODONTOL, V79, P1409, DOI [10.1902/jop.2008.070623, 10.1902/jop.2008.070623 ]
   Herr AE, 2007, ANN NY ACAD SCI, V1098, P362, DOI 10.1196/annals.1384.004
   Herr AE, 2007, P NATL ACAD SCI USA, V104, P5268, DOI 10.1073/pnas.0607254104
   JEFFCOAT MK, 1996, BIOL MECH TOOTH MOVE, V1, P365
   Kamel HK, 2007, J AM MED DIR ASSOC, V8, P434, DOI 10.1016/j.jamda.2007.06.005
   Keller UAD, 2007, BIOL CHEM, V388, P1159, DOI 10.1515/BC.2007.146
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kinane DF, 2003, J PERIODONTAL RES, V38, P400, DOI 10.1034/j.1600 0765.2003.00663.x
   Kinney JS, 2007, ANN NY ACAD SCI, V1098, P230, DOI 10.1196/annals.1384.028
   Kirkwood KL, 2007, PERIODONTOL 2000, V43, P294, DOI 10.1111/j.1600 0757.2006.00166.x
   Lane N, 2005, J PERIODONTOL, V76, P1113, DOI 10.1902/jop.2005.76.7.1113
   López Otín C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228
   Nuti E, 2007, CURR PHARM DESIGN, V13, P2087
   Olsen NJ, 2004, NEW ENGL J MED, V350, P2167, DOI 10.1056/NEJMra032906
   Payne JB, 2007, J CLIN PERIODONTOL, V34, P776, DOI 10.1111/j.1600 051X.2007.01115.x
   Preshaw PM, 2008, J PERIODONTOL, V79, P440, DOI [10.1902/jop.2008.070375, 10.1902/jop.2008.070375 ]
   Pussinen PJ, 2007, CURR MED CHEM, V14, P2402, DOI 10.2174/092986707781745604
   Ra HJ, 2007, MATRIX BIOL, V26, P587, DOI 10.1016/j.matbio.2007.07.001
   Reddy Michael S, 2003, Ann Periodontol, V8, P12, DOI 10.1902/annals.2003.8.1.12
   Reinhardt RA, 2007, J CLIN PERIODONTOL, V34, P768, DOI 10.1111/j.1600 051X.2007.01114.x
   Rocha M, 2001, J PERIODONTOL, V72, P204, DOI 10.1902/jop.2001.72.2.204
   Sorsa T, 2006, ANN MED, V38, P306, DOI 10.1080/07853890600800103
   Takaishi Y, 2001, J INT MED RES, V29, P355, DOI 10.1177/147323000102900413
   Tenenbaum HC, 2002, J PERIODONTOL, V73, P813, DOI 10.1902/jop.2002.73.7.813
   Tester AM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000312
   Wang HL, 2007, J PERIODONTOL, V78, P584, DOI 10.1902/jop.2007.060239
   WILLIAMS RC, 1990, NEW ENGL J MED, V322, P373, DOI 10.1056/NEJM199002083220606
   Woodward JKL, 2007, BONE, V41, P912, DOI 10.1016/j.bone.2007.07.024
NR 40
TC 128
Z9 153
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3492
EI 1943 3670
J9 J PERIODONTOL
JI J. Periodont.
PD AUG
PY 2008
VL 79
IS 8
SU S
BP 1592
EP 1600
DI 10.1902/jop.2008.080174
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Dentistry, Oral Surgery & Medicine
GA 394IS
UT WOS:000262441000014
PM 18673015
OA Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Park, KR
   Kim, JY
   Hong, JT
   Yun, HM
AF Park, Kyung Ran
   Kim, Ji Youn
   Hong, Jin Tae
   Yun, Hyung Mun
TI A novel organosulfur compound, thiacremonone, regulates RANKL induced
   osteoclast differentiation
SO RSC ADVANCES
LA English
DT Article
ID OSTEOBLASTIC DIFFERENTIATION; BONE RESORPTION; MC3T3 E1 CELLS; C FOS;
   OSTEOPOROSIS; ACTIVATION; MINERALIZATION; PATHWAYS; RECEPTOR; SYSTEM
AB The medicinal properties of functionally active organosulfur compounds have received great attention for applications in treating various diseases. Thiacremonone (2,4 dihydroxy 2,5 dimethyl thiophene 3 one, THIA) is a novel organosulfur compound generated from high temperature high pressure treated garlic and has been reported to display pharmacological effects against various diseases. However, the role of THIA in bone resorbing cells was not reported. Herein, we have examined the pharmacological properties of THIA on osteoclast differentiation in primary cultured bone marrow macrophages (BMMs). Our results showed that THIA suppressed receptor activator of NF kappa B ligand (RANKL) induced gene expression (c Fos and NF ATc1) for osteoclast differentiation under no cytotoxicity condition. In addition, THIA significantly inhibited TRAP positive multinucleated osteoclasts and F actin ring formation during RANKL mediated osteoclastogenesis. However, in primary cultured calvarial pre osteoblasts, THIA did not influence the cytotoxicity and osteoblast differentiation, as assessed from the alkaline phosphatase (ALP) activity and mineralized nodule formation. Our findings have suggested that THIA can be considered as a potential agent for the therapeutics of bone diseases such as osteoporosis, alveolar bone resorption, and osteoarthritis.
C1 [Park, Kyung Ran] Kyung Hee Univ, Grad Sch, Dept Oral & Maxillofacial Regenerat, Seoul 130701, South Korea.
   [Kim, Ji Youn] Gachon Univ, Coll Hlth Sci, Dept Dent Hyg, Incheon 406799, South Korea.
   [Hong, Jin Tae] Chungbuk Natl Univ, Coll Pharm, Chungbuk 361763, South Korea.
   [Hong, Jin Tae] Chungbuk Natl Univ, Med Res Ctr, Chungbuk 361763, South Korea.
   [Yun, Hyung Mun] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, 1 Heogi Dong, Seoul 130701, South Korea.
C3 Kyung Hee University; Gachon University; Chungbuk National University;
   Chungbuk National University; Kyung Hee University
RP Yun, HM (通讯作者)，Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, 1 Heogi Dong, Seoul 130701, South Korea.
EM yunhm@khu.ac.kr
RI ; Kim, Ji Youn/A 5779 2017
OI Yun, Hyung Mun/0000 0001 6504 1610; 
FU National Research Foundation of Korea (NRF)   Korea government (MEST)
   (MRC) [20080062275, 2015R1D1A1A01059240]
FX This study was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MEST) (MRC, 20080062275;
   2015R1D1A1A01059240).
CR Augustine M, 2013, CURR OSTEOPOROS REP, V11, P400, DOI 10.1007/s11914 013 0171 2
   Ban JO, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2819
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chang EJ, 2008, NAT MED, V14, P966, DOI 10.1038/nm.1860
   Jo M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091508
   Khosla S, 2005, ENDOCRIN METAB CLIN, V34, P1015, DOI 10.1016/j.ecl.2005.07.009
   Kim MB, 2014, FITOTERAPIA, V98, P59, DOI 10.1016/j.fitote.2014.07.013
   Kim YR, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/974794
   Kwak HB, 2010, BONE, V46, P724, DOI 10.1016/j.bone.2009.10.042
   Lee HS, 2011, PHYTOTHER RES, V25, P716, DOI 10.1002/ptr.3328
   Lin GH, 2012, J ALZHEIMERS DIS, V29, P659, DOI 10.3233/JAD 2012 111709
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Monje P, 2005, J BIOL CHEM, V280, P35081, DOI 10.1074/jbc.C500353200
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2009, NAT REV RHEUMATOL, V5, P667, DOI 10.1038/nrrheum.2009.217
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Vondracek SF, 2008, CLIN INTERV AGING, V3, P315, DOI 10.2147/CIA.S2539
   Whitmarsh AJ, 1996, J MOL MED JMM, V74, P589, DOI 10.1007/s001090050063
   Yun HM, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.185
   Yun HM, 2017, ARCH PHARM RES, V40, P601, DOI 10.1007/s12272 017 0911 4
   Yun HM, 2016, SCI REP UK, V6, DOI 10.1038/srep30985
   Yun HM, 2016, MOL NEUROBIOL, V53, P2409, DOI 10.1007/s12035 015 9208 0
   Yun HM, 2014, PHARMACOL THERAPEUT, V142, P183, DOI 10.1016/j.pharmthera.2013.12.005
NR 27
TC 3
Z9 3
U1 0
U2 5
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046 2069
J9 RSC ADV
JI RSC Adv.
PY 2017
VL 7
IS 49
BP 30657
EP 30662
DI 10.1039/c7ra02049j
PG 6
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA EY0SQ
UT WOS:000403668900020
OA gold
DA 2025 08 17
ER

PT J
AU Xu, CY
   Wang, J
   Zhu, TJ
   Shen, Y
   Tang, XS
   Fang, L
   Xu, YZ
AF Xu, Chenyuan
   Wang, Jing
   Zhu, Tianjie
   Shen, Yun
   Tang, Xiaoshan
   Fang, Li
   Xu, Yuanzhi
TI Cross Talking Between PPAR and WNT Signaling and its Regulation in
   Mesenchymal Stem Cell Differentiation
SO CURRENT STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Adipogenesis; differentiation; mesenchymal stem cell; osteogenesis;
   PPAR; Wnt
ID ACTIVATED RECEPTOR GAMMA; BONE MARROW; BETA CATENIN; ADIPOCYTE
   DIFFERENTIATION; OSTEOBLAST DIFFERENTIATION; TYROSINE KINASE; PROTEIN 5
   LRP5; GROWTH FACTORS; ADIPOGENESIS; PATHWAY
AB The pluripotent mesenchymal stem cells (MSC) are common precursors to adipocytes and osteoblasts. Large numbers of extracellular and intracellular signals and transcription factors moderate adipogenesis and osteoblastogenesis. Importantly, between adipogenic and osteogenic lineage commitment and differentiation, differentiation of MSCs into one lineage will inhibit their differentiation toward the other lineage. This balance is regulated by numerous signaling pathways. As we know, the peroxisome proliferator activated receptor gamma (PPAR gamma) and Wnt/beta catenin pathway are regarded as the master moderators of adipogenesis and osteogenesis. Moreover, governing the differentiation of MSCs to adipogenesis and osteoblastogenesis has significant implications in diverse areas of human health, from obesity to regenerative medicine to osteoporosis. Rivalry roles have been reported of the two pathways since the downstream products activated by Wnt 5a repress PPAR gamma transactivation through the H3K9 histone methyltransferase protein complexes. This review will discuss the inductive and inhibitive role of PPAR gamma in adipogenesis and osteoblastogenesis respectively, as well as the canonical Wnt/beta catenin pathway.
C1 [Xu, Chenyuan; Wang, Jing; Shen, Yun; Tang, Xiaoshan; Fang, Li; Xu, Yuanzhi] Tongji Univ, Sch Med, Dept Stomatol, Shanghai Peoples Hosp 10, 301 Middle Yanchang Rd, Shanghai 200072, Peoples R China.
   [Zhu, Tianjie] Shanghai Xuhui Distict Dent Ctr, Dept Endodont, Shanghai, Peoples R China.
C3 Tongji University
RP Xu, YZ (通讯作者)，Tongji Univ, Sch Med, Dept Stomatol, Shanghai Peoples Hosp 10, 301 Middle Yanchang Rd, Shanghai 200072, Peoples R China.
EM amyxyz01@hotmail.com
RI ids, dw/HHN 4570 2022; xu, chenyuan/NXX 8817 2025
FU Natural Science Foundation of Shanghai [15ZR1432700]
FX This work was funded by the Natural Science Foundation of Shanghai
   (15ZR1432700).
CR Adami S, 2013, BONE RES, V1, P323, DOI 10.4248/BR201304003
   Adams M, 1997, J CLIN INVEST, V100, P3149, DOI 10.1172/JCI119870
   Adler RA, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.1
   Afzal AR, 2000, NAT GENET, V25, P419, DOI 10.1038/78107
   Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004 0735
   Arthur A, 2009, J CELL PHYSIOL, V218, P237, DOI 10.1002/jcp.21592
   Barker N, 2006, NAT REV DRUG DISCOV, V5, P997, DOI 10.1038/nrd2154
   Batsali AK, 2013, CURR STEM CELL RES T, V8, P144
   Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0
   Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018
   Berry R, 2013, NAT CELL BIOL, V15, P302, DOI 10.1038/ncb2696
   Berwick DC, 2012, BIOCHEM SOC T, V40, P1123, DOI 10.1042/BST20120122
   Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007 0197
   Chang J, 2007, J BIOL CHEM, V282, P30938, DOI 10.1074/jbc.M702391200
   Chen JQ, 2013, J BONE MINER RES, V28, P1160, DOI 10.1002/jbmr.1834
   Cock TA, 2004, EMBO REP, V5, P1007, DOI 10.1038/sj.embor.7400254
   Cristancho AG, 2011, NAT REV MOL CELL BIO, V12, P722, DOI 10.1038/nrm3198
   Crossno JT, 2006, J CLIN INVEST, V116, P3220, DOI 10.1172/JCI28510
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   DeChiara TM, 2000, NAT GENET, V24, P271, DOI 10.1038/73488
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   ECKENSTEIN FP, 1994, J NEUROBIOL, V25, P1467
   Etheridge SL, 2004, STEM CELLS, V22, P849, DOI 10.1634/stemcells.22 5 849
   Fu N, 2013, CELL PROLIFERAT, V46, P312, DOI 10.1111/cpr.12031
   Fujino T, 2003, P NATL ACAD SCI USA, V100, P229, DOI 10.1073/pnas.0133792100
   Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497
   Gatti D, 2012, J BONE MINER RES, V27, P2259, DOI 10.1002/jbmr.1681
   Gesta S, 2007, CELL, V131, P242, DOI 10.1016/j.cell.2007.10.004
   Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955 0674(97)80066 X
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653
   Grottkau BE, 2013, BONE RES, V1, DOI 10.4248/BR201302003
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Ho AD, 2008, CYTOTHERAPY, V10, P320, DOI 10.1080/14653240802217011
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Huang GTJ, 2009, J DENT RES, V88, P792, DOI 10.1177/0022034509340867
   Huang Y, 2010, CELL PROLIFERAT, V43, P147, DOI 10.1111/j.1365 2184.2009.00661.x
   ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0
   Jackson WM, 2012, STEM CELL TRANSL MED, V1, P44, DOI 10.5966/sctm.2011 0024
   Jumabay M, 2012, J MOL CELL CARDIOL, V53, P790, DOI 10.1016/j.yjmcc.2012.09.005
   Kanazawa A, 2005, BIOCHEM BIOPH RES CO, V330, P505, DOI 10.1016/j.bbrc.2005.03.007
   Kim W, 2013, BIOCHEM J, V450, P9, DOI 10.1042/BJ20121284
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kortenjann M, 2001, EUR J IMMUNOL, V31, P3580, DOI 10.1002/1521 4141(200112)31:12<3580::AID IMMU3580>3.0.CO;2 N
   Kucher U, 2014, INT J ORAL SCI, V6, P70, DOI 10.1038/ijos.2014.12
   Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663
   Lazarenko OP, 2006, BONE, V38, P74, DOI 10.1016/j.bone.2005.07.008
   Lecka Czernik B, 2002, ENDOCRINOLOGY, V143, P2376, DOI 10.1210/en.143.6.2376
   LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953
   Lehrke M, 2005, CELL, V123, P993, DOI 10.1016/j.cell.2005.11.026
   Li G, 2013, CELL PROLIFERAT, V46, P586, DOI 10.1111/cpr.12053
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Manolagas SC, 2007, MOL ENDOCRINOL, V21, P2605, DOI 10.1210/me.2007 0259
   Michalik L, 2008, PPAR RES, V2008, DOI 10.1155/2008/134059
   Mikkelsen TS, 2010, CELL, V143, P156, DOI 10.1016/j.cell.2010.09.006
   Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549
   Muruganandan S, 2009, CELL MOL LIFE SCI, V66, P236, DOI 10.1007/s00018 008 8429 z
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Neve A, 2011, CELL TISSUE RES, V343, P289, DOI 10.1007/s00441 010 1086 1
   Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Puetzer JL, 2010, TISSUE ENG PART B RE, V16, P435, DOI [10.1089/ten.teb.2009.0705, 10.1089/ten.TEB.2009.0705]
   Rosen ED, 2000, GENE DEV, V14, P1293
   Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066
   Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950
   Rzonca SO, 2004, ENDOCRINOLOGY, V145, P401, DOI 10.1210/en.2003 0746
   Salem HK, 2010, STEM CELLS, V28, P585, DOI 10.1002/stem.269
   Schwartz AV, 2006, J CLIN ENDOCR METAB, V91, P3349, DOI 10.1210/jc.2005 2226
   Schwarz S, 2014, INT J ORAL SCI, V6, P154, DOI 10.1038/ijos.2014.23
   Shen J, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.2
   Takada I, 2010, PPAR RES, V2010, DOI 10.1155/2010/341671
   Takada I, 2009, EXPERT OPIN THER TAR, V13, P593, DOI [10.1517/14728220902915310 , 10.1517/14728220902915310]
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Takeuchi S, 2000, GENES CELLS, V5, P71, DOI 10.1046/j.1365 2443.2000.00300.x
   Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117
   TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224
   Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829
   Tu XL, 2007, DEV CELL, V12, P113, DOI 10.1016/j.devcel.2006.11.003
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534 5807(03)00266 1
   Vroegrijk IOCM, 2013, OBESITY, V21, P2037, DOI 10.1002/oby.20354
   Walkey CJ, 2008, J BIOL CHEM, V283, P24290, DOI 10.1074/jbc.C800139200
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Watanabe Ken, 2009, Nihon Rinsho, V67, P879
   Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110
   Wei X, 2013, CELL PROLIFERAT, V46, P416, DOI 10.1111/cpr.12044
   White BD, 2012, GASTROENTEROLOGY, V142, P219, DOI 10.1053/j.gastro.2011.12.001
   Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097 4547(20000815)61:4<364::AID JNR2>3.0.CO;2 C
   Wu L, 2010, J CELL MOL MED, V14, P922, DOI 10.1111/j.1582 4934.2009.00709.x
   Yamaguchi TP, 1999, DEVELOPMENT, V126, P1211
   Zhang XR, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.15
NR 96
TC 84
Z9 94
U1 0
U2 46
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1574 888X
EI 2212 3946
J9 CURR STEM CELL RES T
JI Curr. Stem Cell Res. Ther.
PY 2016
VL 11
IS 3
BP 247
EP 254
DI 10.2174/1574888X10666150723145707
PG 8
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA DG8KS
UT WOS:000372333300009
PM 26201865
DA 2025 08 17
ER

PT J
AU Wiemer, AJ
   Tong, HX
   Swanson, KM
   Hohl, RJ
AF Wiemer, Andrew J.
   Tong, Huaxiang
   Swanson, Kelly M.
   Hohl, Raymond J.
TI Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE bisphosphonate; geranylgeranyl pyrophosphate synthase; farnesyl
   pyrophosphate synthase; isoprenoid; mevalonate; Prenylation; ras;
   zoledronate; digeranyl bisphosphonate
ID NITROGEN CONTAINING BISPHOSPHONATES; FARNESYL DIPHOSPHATE SYNTHASE;
   GTP BINDING PROTEINS; OSTEOCLAST FORMATION; MEVALONATE PATHWAY; SQUALENE
   SYNTHASE; BONE RESORPTION; IN VITRO; CELLS; ALENDRONATE
AB A primary cellular target of the clinical nitrogenous bisphosphonates is the isoprenoid biosynthetic pathway. Specifically these drugs inhibit the enzyme farnesyl pyrophosphate synthase and deplete cells of larger isoprenoids. Inhibition of this enzyme results in impaired processing of both farnesylated and geranylgeranylated proteins. We recently showed that isoprenoid containing bisphosphonates such as digeranyl bisphosphonate inhibit protein geranylgeranylation and not farnesylation. Here, we show that this impairment results from potent and specific inhibition of geranylgeranyl pyrophosphate synthase, which leads to enhanced depletion of intracellular geranylgeranyl pyrophosphate relative to the nitrogenous bisphosphonate zoledronate. (c) 2006 Elsevier Inc. All rights reserved.
C1 Univ Iowa, Mol & Cellular Biol Interdisciplinary Program, Iowa City, IA 52242 USA.
   Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA.
   Univ Iowa, Dept Pharmacol, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Iowa; University of Iowa
RP Wiemer, AJ (通讯作者)，Univ Iowa, Mol & Cellular Biol Interdisciplinary Program, Iowa City, IA 52242 USA.
EM Andrew Wiemer@uiowa.edu
RI Wiemer, Andrew/C 2257 2009
OI Wiemer, Andrew/0000 0002 3029 1780
CR AMIN D, 1992, J LIPID RES, V33, P1657
   Barrett J, 2004, J CLIN PHARMACOL, V44, P951, DOI 10.1177/0091270004267594
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Body JJ, 1998, J CLIN ONCOL, V16, P3890, DOI 10.1200/JCO.1998.16.12.3890
   Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092 8674(04)00003 0
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kavanagh KL, 2006, J BIOL CHEM, V281, P22004, DOI 10.1074/jbc.M602603200
   KRISANS SK, 1994, J BIOL CHEM, V269, P14165
   Kunzmann V, 2000, BLOOD, V96, P384
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Shull LW, 2006, BIOORGAN MED CHEM, V14, P4130, DOI 10.1016/j.bmc.2006.02.010
   STAMELLOS KD, 1993, J BIOL CHEM, V268, P12825
   Szabo CM, 2002, J MED CHEM, V45, P2185, DOI 10.1021/jm010412y
   Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153
   Tong HX, 2005, ANAL BIOCHEM, V336, P51, DOI 10.1016/j.ab.2004.09.024
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055
NR 23
TC 65
Z9 87
U1 0
U2 15
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD FEB 23
PY 2007
VL 353
IS 4
BP 921
EP 925
DI 10.1016/j.bbrc.2006.12.094
PG 5
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 131HL
UT WOS:000243859600013
PM 17208200
DA 2025 08 17
ER

PT J
AU Zhang, LY
   Li, XM
   Wan, CF
   Da, W
   Zhang, J
   Fan, LH
   Fu, Q
   Xing, SM
   Wang, YX
AF Zhang, Liyong
   Li, Xiaoming
   Wan, Chunfei
   Da, Weiwei
   Zhang, Jun
   Fan, Lihong
   Fu, Qiang
   Xing, Shunmin
   Wang, Yongxiang
TI Bioinformatics analysis identification of AKT3 and RAC1 as
   key genes in postmenopausal osteoporosis
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE postmenopausal osteoporosis; bioinformatics; bisphosphonates; AKT3;
   RAC1; osteoclast; peripheral blood mononuclear cells
ID CELLS; MECHANISMS
AB Postmenopausal osteoporosis (PMO) is an aging associated disease that manifests as degradation of bone tissue microstructure leading to decreased bone mass and increased bone fragility. Differentiation of peripheral blood mononuclear cells into osteoclasts is an important process in the development of PMO and identification of key genes that drive differentiation is essential to reveal the mechanism of PMO. The present study combined bioinformatics analysis of a Gene Expression Omnibus dataset of PMO and drug (bisphosphonate) target prediction using the STITCH database to identify hub genes in patients with PMO. Next, the expression of candidate hub genes was assessed in osteoclasts differentiated from THP 1 cells and small interfering RNA assays were performed to assess the function of selected hub genes. The present study identified 10 hub genes including WNT1, AKT3, disheveled segment polarity protein 1, cyclin D1, H2B clustered histone 17, JUN, EGFR, RAC1, actinin alpha 1 (ACTN1) and ACTN2. Among these, AKT3 and RAC1 were highly upregulated during osteoclast differentiation, and knockdown of AKT3 and RAC1 using small interfering RNA enhanced the inhibitory effect of bisphosphonates on osteoclast differentiation and apoptosis of monocytes as assessed by tartrate resistant acid phosphatase staining and flow cytometry examining Annexin V FITC/PI staining, respectively. In conclusion, AKT3 and RAC1 were key for development of PMO and inhibiting AKT3 and RAC1 may improve the therapeutic efficacy of bisphosphonates.
C1 [Zhang, Liyong; Wan, Chunfei; Da, Weiwei; Zhang, Jun; Fan, Lihong; Fu, Qiang] Yangzhou Univ, Yangzhou Hosp Tradit Chinese Med, Clin Tradit Chinese Med Coll, Dept Orthoped, Yangzhou 225012, Peoples R China.
   [Li, Xiaoming; Xing, Shunmin] 72nd Grp Mil Hosp, Dept Orthoped, Huzhou 313000, Zhejiang, Peoples R China.
   [Wang, Yongxiang] Yangzhou Univ, Subei Peoples Hosp Jiangsu Prov, Clin Med Coll, Dept Orthoped, Yangzhou 225001, Peoples R China.
   [Wang, Yongxiang] Yangzhou Univ, Subei Peoples Hosp Jiangsu Prov, Clin Med Coll, Dept Orthoped, 196 West Huayang Rd, Hanjiang, Yangzhou 225001, Peoples R China.
   [Xing, Shunmin] 72nd Grp Mil Hosp, Dept Orthoped, 9 Chezhan Rd, Huzhou 313000, Zhejiang, Peoples R China.
C3 Yangzhou University; Yangzhou University; Yangzhou University
RP Wang, YX (通讯作者)，Yangzhou Univ, Subei Peoples Hosp Jiangsu Prov, Clin Med Coll, Dept Orthoped, 196 West Huayang Rd, Hanjiang, Yangzhou 225001, Peoples R China.; Xing, SM (通讯作者)，72nd Grp Mil Hosp, Dept Orthoped, 9 Chezhan Rd, Huzhou 313000, Zhejiang, Peoples R China.
EM sm58_zhejiangx@126.com; wang_yx2011@yeah.net
RI Wang, Yongxiang/P 1045 2017
CR Abe S, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10101468
   Arceo Mendoza R, 2021, ENDOCRIN METAB CLIN, V50, P167, DOI 10.1016/j.ecl.2021.03.009
   Baccaro LF, 2015, CLIN INTERV AGING, V10, DOI 10.2147/CIA.S54614
   Castro Piedras Isabel, 2018, Oncotarget, V9, P35639, DOI 10.18632/oncotarget.26257
   Chen X, 2021, BMC MUSCULOSKEL DIS, V22, DOI 10.1186/s12891 020 03924 9
   COHENSOLAL ME, 1993, J CLIN ENDOCR METAB, V77, P1648, DOI 10.1210/jc.77.6.1648
   Dera AA, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/3189520
   Dutta P, 2020, BMC CANCER, V20, DOI 10.1186/s12885 020 6649 2
   Endo Y, 2020, YAKUGAKU ZASSHI, V140, P63, DOI 10.1248/yakushi.19 00125
   Fujikawa Y, 1996, ENDOCRINOLOGY, V137, P4058, DOI 10.1210/en.137.9.4058
   Gahankari A, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.704769
   Gao L, 2021, CURR DRUG TARGETS, V22, P1064, DOI 10.2174/1389450121666200925150446
   Guimaraes HIP, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8101482
   He YX, 2021, COMPUT MATH METHOD M, V2021, DOI 10.1155/2021/5548918
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Ihn HJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142201
   Jin HM, 2019, J CELL MOL MED, V23, P522, DOI 10.1111/jcmm.13955
   Korsic Mirko, 2006, Reumatizam, V53, P32
   Koyuturk M, 2004, NEUROSCI LETT, V370, P212, DOI 10.1016/j.neulet.2004.08.020
   Li J, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2159 z
   Li LY, 2018, ADV EXP MED BIOL, V1086, P199, DOI 10.1007/978 981 13 1117 8_13
   Lithgow KV, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00195 20
   Liu T, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm 21 3098
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Magalhaes JKRS, 2011, OSTEOPOROSIS INT, V22, P1481, DOI 10.1007/s00198 010 1355 6
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   McNamara LM, 2021, CURR OSTEOPOROS REP, V19, P592, DOI 10.1007/s11914 021 00702 x
   Peng W, 2021, REPROD BIOL ENDOCRIN, V19, DOI 10.1186/s12958 021 00733 0
   Salamanna F, 2016, J CELL PHYSIOL, V231, P521, DOI 10.1002/jcp.25134
   Sharma A, 2021, AM J DERMATOPATH, V43, pE141, DOI 10.1097/DAD.0000000000002060
   Song CY, 2022, J GENE MED, V24, DOI 10.1002/jgm.3409
   Wang J, 2020, MOL MED REP, V21, P685, DOI 10.3892/mmr.2019.10872
   Wang LJ, 2020, KAOHSIUNG J MED SCI, V36, P775, DOI 10.1002/kjm2.12236
   Wang YQ, 2008, J BONE MINER RES, V23, P260, DOI 10.1359/JBMR.071013
   Wang YQ, 2009, CALCIFIED TISSUE INT, V85, P257, DOI 10.1007/s00223 009 9274 2
   Wei W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.184
   Yang CG, 2019, MOL MED REP, V19, P1065, DOI 10.3892/mmr.2018.9752
   Yu T, 2020, AGING US, V12, P10473, DOI 10.18632/aging.103271
   Zhong Hang, 2017, Sichuan Da Xue Xue Bao Yi Xue Ban, V48, P862
NR 39
TC 5
Z9 6
U1 1
U2 12
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD NOV
PY 2022
VL 24
IS 5
AR 656
DI 10.3892/etm.2022.11592
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 5C8JM
UT WOS:000864500100001
PM 36168425
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kim, JY
   Ahn, SJ
   Baek, JM
   Yoon, KH
   Lee, MS
   Oh, J
AF Kim, Ju Young
   Ahn, Sung Jun
   Baek, Jong Min
   Yoon, Kwon Ha
   Lee, Myeung Su
   Oh, Jaemin
TI Ostericum koreanum Reduces LPS Induced Bone Loss Through
   Inhibition of Osteoclastogenesis
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Actin Ring; Bone Resorption; Bone Loss; Osteoclast Differentiation;
   Ostericum koreanum
ID TOLL LIKE RECEPTORS; SIGNALING PATHWAY; KAPPA B; DIFFERENTIATION; CELLS;
   LIPOPOLYSACCHARIDE; OSTEOPOROSIS; RESORPTION; OSTEOPROTEGERIN;
   PROSTAGLANDIN
AB The roots of Ostericum koreanum (OK) Maximowicz have traditionally been used to produce an herbal medicine reported to possess anti inflammatory, anti oxidant, antimicrobial, and antitumor activities; however, its effect on bone metabolism has not yet been reported. The present study examined the effects of OK extract on lipopolysaccharide (LPS) induced bone loss in mice by investigating bone structure and the levels of the receptor activator of nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) in serum and bone marrow fluid (BMF). The effects of OK extract on osteoclastogenesis were also investigated in mouse bone marrow macrophages by examining the formation of tartrate resistant acid phosphatase (TRAP) positive cells, the actin ring, and bone resorption activity. OK reduced LPS induced bone destruction in vivo via a decrease in the RANKL/OPG ratio. Furthermore, it suppressed the formation of TRAP positive cells and the actin ring, and reduced the bone resorbing activity of mature osteoclasts. OK also significantly down regulated the expression of various osteoclast specific genes. However, it did not affect osteoblast differentiation, or the expression of genes involved in this process. These results demonstrated that OK prevented LPS induced bone loss by decreasing the RANKL/OPG ratio in serum and BMF, and inhibited osteoclast differentiation and function, suggesting that OK represents a potential therapeutic drug for the treatment of osteoclast associated bone diseases.
C1 [Kim, Ju Young; Yoon, Kwon Ha; Lee, Myeung Su; Oh, Jaemin] Wonkwang Univ, Imaging Sci Based Lung & Bone Dis Res Ctr, Iksan 570749, Jeonbuk, South Korea.
   [Ahn, Sung Jun; Baek, Jong Min; Oh, Jaemin] Wonkwang Univ, Dept Anat, Iksan 570749, Jeonbuk, South Korea.
   [Ahn, Sung Jun; Baek, Jong Min; Oh, Jaemin] Wonkwang Univ, BK21plus Program, Iksan 570749, Jeonbuk, South Korea.
   [Ahn, Sung Jun; Baek, Jong Min; Oh, Jaemin] Wonkwang Univ, Dept Smart Life Care Convergence, Iksan 570749, Jeonbuk, South Korea.
   [Yoon, Kwon Ha] Wonkwang Univ, Dept Radiol, Iksan 570749, Jeonbuk, South Korea.
   [Lee, Myeung Su] Wonkwang Univ, Dept Rheumatol, Iksan 570749, Jeonbuk, South Korea.
   [Oh, Jaemin] Wonkwang Univ, Inst Skeletal Dis, Iksan 570749, Jeonbuk, South Korea.
C3 Wonkwang University; Wonkwang University; Wonkwang University; Wonkwang
   University; Wonkwang University; Wonkwang University; Wonkwang
   University
RP Oh, J (通讯作者)，Wonkwang Univ, Sch Med, Dept Anat, 344 2 Sinyong Dong, Iksan 570749, Jeonbuk, South Korea.
EM ckhlms@wku.ac.kr; jmoh@wku.ac.kr
RI Lee, Sang Hoon/ABH 6210 2020
FU Korean Health Technology R&D Project, Ministry of Health & Welfare,
   Republic of Korea [HI12C0110]
FX This study was supported by a grant from the Korean Health Technology
   R&D Project, Ministry of Health & Welfare, Republic of Korea
   (HI12C0110).
CR Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228
   Baek JM, 2014, MOLECULES, V19, P11628, DOI 10.3390/molecules190811628
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Body JJ, 2012, OSTEOPOROSIS INT, V23, pS1, DOI 10.1007/s00198 011 1891 8
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Gallagher JC, 2010, MATURITAS, V65, P301, DOI 10.1016/j.maturitas.2010.01.002
   Hamdy NAT, 2007, CURR OPIN INVEST DR, V8, P299
   ISHIHARA Y, 1991, J PERIODONTAL RES, V26, P155, DOI 10.1111/j.1600 0765.1991.tb01639.x
   Jun AY, 2012, FITOTERAPIA, V83, P1523, DOI 10.1016/j.fitote.2012.08.020
   Jung HW, 2011, ASIAN PAC J ALLERGY, V29, P338
   Jung HW, 2010, INT IMMUNOPHARMACOL, V10, P155, DOI 10.1016/j.intimp.2009.10.010
   Jurdic P, 2006, EUR J CELL BIOL, V85, P195, DOI 10.1016/j.ejcb.2005.09.008
   Kang TJ, 2009, ACTA ONCOL, V48, P895, DOI 10.1080/02841860902824925
   Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601 0825.2002.01829.x
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kondo T, 2004, J BONE MINER RES, V19, P1411, DOI 10.1359/JBMR.040604
   Koo HJ, 2014, J ETHNOPHARMACOL, V151, P951, DOI 10.1016/j.jep.2013.12.008
   Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529
   ORCEL P, 1993, AM J PHYSIOL, V264, pE391, DOI 10.1152/ajpendo.1993.264.3.E391
   Orija IB, 2003, CLIN ENDOCRINOL, V59, P657, DOI 10.1046/j.1365 2265.2003.01833.x
   Park YJ, 2007, CHEM PHARM BULL, V55, P1065, DOI 10.1248/cpb.55.1065
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Sakuma Y, 2000, INFECT IMMUN, V68, P6819, DOI 10.1128/IAI.68.12.6819 6825.2000
   Shin S, 2005, ARCH PHARM RES, V28, P765, DOI 10.1007/BF02977340
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tan KB, 1997, GENE, V204, P35, DOI 10.1016/S0378 1119(97)00509 X
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Woo KM, 2002, EXP MOL MED, V34, P347, DOI 10.1038/emm.2002.49
   Zou W, 2002, J BONE MINER RES, V17, P1211, DOI 10.1359/jbmr.2002.17.7.1211
NR 32
TC 7
Z9 7
U1 0
U2 1
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192 415X
EI 1793 6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PY 2015
VL 43
IS 3
BP 495
EP 512
DI 10.1142/S0192415X15500317
PG 18
WC Integrative & Complementary Medicine; Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; General & Internal Medicine
GA CI0FJ
UT WOS:000354411700007
PM 25967665
DA 2025 08 17
ER

PT J
AU Dai, LP
   Chen, XM
   Xiong, Y
   Chen, JH
   Li, J
   Li, DZ
   Zhou, GQ
   Zou, YH
   Liu, T
AF Dai, Luping
   Chen, Xuemei
   Xiong, Yu
   Chen, Junhui
   Li, Jun
   Li, Dezhi
   Zhou, Guangqian
   Zou, Yinghua
   Liu, Tao
TI Strontium gluconate potently promotes osteoblast development and
   restores bone formation in glucocorticoid induced osteoporosis rats
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Glucocorticoid induced osteoporosis; Dexamethasone (DEX); Strontium
   gluconate; Osteogenesis
AB Glucocorticoid induced osteoporosis (GIOP) has emerged as a challenge after long term glucocorticoid administration during the clinical therapy of diverse diseases. Although some candidates for GIOP treatment have been explored, there is still a lack of reliable drugs for GIOP prevention. In this study, rat bone marrow stem cells (rBMSCs) were utilized to investigate the feasibility of applying strontium gluconate (GluSr), which displays mild activity, easy absorption and good biocompatibility, for GIOP prevention. Thirty two SD rats were divided into 4 groups to explore the effects of GluSr on osteoporosis rescue in vivo. Our results suggested that GluSr markedly alleviated dexamethasone (DEX) induced apoptosis of osteoblast precursor cells and rBMSCs and enhanced rBMSC osteogenesis differentiation in vitro. GluSr also effectively promoted osteoblast survival, inhibited osteoclast differentiation and restored bone formation in GIOP rat models. Microarray analysis of the femora from GIOP rats treated with GluSr revealed that the signalling pathways of the glucocorticoid receptor (GR), oestrogen receptor gene (ESR) and vitamin D receptor (VDR) were involved in bone restoration by GluSr. In summary, our study proved that GluSr enhanced osteoblast differentiation and suppressed osteoclast activity both in vitro and in vivo. GluSr might function as a novel strontium reagent for GIOP prevention.
   (c) 2021 Elsevier Inc. All rights reserved.
C1 [Dai, Luping; Xiong, Yu; Chen, Junhui; Li, Dezhi] Peking Univ, Shenzhen Hosp, Intervent & Cell Therapy Ctr, Shenzhen, Guangdong, Peoples R China.
   [Chen, Xuemei; Liu, Tao] Shenzhen Univ, Affiliated Hosp 3, Shenzhen Luohu Peoples Hosp, Dept Oncol Rehabil, Shenzhen 518001, Guangdong, Peoples R China.
   [Dai, Luping; Zou, Yinghua] Peking Univ First Hosp, Dept Intervent Radiol & Vasc Surg, Beijing 100034, Peoples R China.
   [Li, Jun; Zhou, Guangqian] Shenzhen Univ, Dept Med Cell Biol & Genet, Guangdong Key Lab Genome Stabil & Dis Prevent, Shenzhen Key Lab Antiageing & Regenerat Med,Hlth, Shenzhen 518060, Peoples R China.
C3 Peking University; Shenzhen Luohu Hospital Group Luohu People's
   Hospital; Shenzhen University; Peking University; Shenzhen University
RP Liu, T (通讯作者)，Shenzhen Univ, Affiliated Hosp 3, Shenzhen Luohu Peoples Hosp, Dept Oncol Rehabil, Shenzhen 518001, Guangdong, Peoples R China.; Zou, YH (通讯作者)，Peking Univ First Hosp, Dept Intervent Radiol & Vasc Surg, Beijing 100034, Peoples R China.
EM cjr.zouyinghua@vip.163.com; tao2020@sohu.com
RI ; Chen, Junhui/HZJ 7077 2023
OI Li, Dezhi/0000 0003 4746 602X; Li, Jun/0000 0002 3257 9315; Chen,
   Xuemei/0000 0001 5187 9463
FU Shenzhen Science and Technology Innovation Committee
   [JCYJ20170412155231633, GJHZ20180928155604617]; National Key R&D Program
   of China [2017YFA0105200]
FX This work was funded by the Shenzhen Science and Technology Innovation
   Committee (Project No. JCYJ20170412155231633 and GJHZ20180928155604617)
   . In addition, National Key R&D Program of China (Grant/Award Number:
   2017YFA0105200) supported this work partially.
CR Anacker C, 2013, P NATL ACAD SCI USA, V110, P8708, DOI 10.1073/pnas.1300886110
   Baid SK, 2006, ORAL DIS, V12, P436, DOI 10.1111/j.1601 0825.2006.01290.x
   Bonnelye E, 2008, BONE, V42, P129, DOI 10.1016/j.bone.2007.08.043
   Buckley L, 2018, NEW ENGL J MED, V379, P2547, DOI 10.1056/NEJMcp1800214
   Chen F, 2019, J MOL MED, V97, P1169, DOI 10.1007/s00109 019 01807 8
   Choudhary S, 2007, J BONE MINER RES, V22, P1002, DOI 10.1359/JBMR.070321
   Henrotin Y, 2001, J BONE MINER RES, V16, P299, DOI 10.1359/jbmr.2001.16.2.299
   Hu PL, 2020, BIOL TRACE ELEM RES, V193, P422, DOI 10.1007/s12011 019 01711 9
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kraenzlin ME, 2011, NAT REV ENDOCRINOL, V7, P647, DOI 10.1038/nrendo.2011.108
   Lems WF, 2015, ENDOCRINE, V49, P628, DOI 10.1007/s12020 015 0639 1
   LIKHTAREV IA, 1975, HEALTH PHYS, V28, P49, DOI 10.1097/00004032 197501000 00008
   Lymperi S, 2008, BLOOD, V111, P1173, DOI 10.1182/blood 2007 03 082800
   MILSOM S, 1987, BMJ BRIT MED J, V295, P231, DOI 10.1136/bmj.295.6592.231
   Moghadam Kia S, 2010, INT J DERMATOL, V49, P239, DOI 10.1111/j.1365 4632.2009.04322.x
   Raterman HG, 2019, DRUGS, V79, P1065, DOI 10.1007/s40265 019 01145 6
   Reginster Jean Yves, 2005, Curr Osteoporos Rep, V3, P30
   Schakman O, 2013, INT J BIOCHEM CELL B, V45, P2163, DOI 10.1016/j.biocel.2013.05.036
   Sila Asna Monnipha, 2007, Kobe J Med Sci, V53, P25
   SKORYNA SC, 1981, CAN MED ASSOC J, V125, P703
   Tsourdi E, 2018, LANCET DIABETES ENDO, V6, P428, DOI 10.1016/S2213 8587(18)30097 4
   Vandewalle J, 2018, TRENDS ENDOCRIN MET, V29, P42, DOI 10.1016/j.tem.2017.10.010
   Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009 1947
   Yuan RS, 2016, ONCOTARGET, V7, P3692, DOI 10.18632/oncotarget.6923
   Zhang SK, 2018, MOL MED REP, V17, P4307, DOI 10.3892/mmr.2018.8461
NR 25
TC 7
Z9 8
U1 1
U2 50
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAY 21
PY 2021
VL 554
BP 33
EP 40
DI 10.1016/j.bbrc.2021.02.100
EA MAR 2021
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA RF6OX
UT WOS:000634962700006
PM 33774277
DA 2025 08 17
ER

PT J
AU Mbundi, L
   Meikle, ST
   Busquets, R
   Dowell, NG
   Cercignani, M
   Santin, M
AF Mbundi, Lubinda
   Meikle, Steve T.
   Busquets, Rosa
   Dowell, Nicholas G.
   Cercignani, Mara
   Santin, Matteo
TI Gadolinium Tagged Osteoprotegerin Mimicking Peptide: A Novel Magnetic
   Resonance Imaging Biospecific Contrast Agent for the Inhibition of
   Osteoclastogenesis and Osteoclast Activity
SO NANOMATERIALS
LA English
DT Article
DE osteoclastogenesis; RANK RANKL OPG; mimetic peptide; Gadolinium chelate;
   MRI
ID KAPPA B LIGAND; CRYSTAL STRUCTURE; RECEPTOR ACTIVATOR; EXTRACELLULAR
   DOMAIN; BONE RESORPTION; RANK LIGAND; COMPLEX; TOXICITY; HEALTH
AB The control of osteoblast/osteoclast cross talk is crucial in the bone remodelling process and provides a target mechanism in the development of drugs for bone metabolic diseases. Osteoprotegerin is a key molecule in this biosignalling pathway as it inhibits osteoclastogenesis and osteoclast activation to prevent run away bone resorption. This work reports the synthesis of a known osteoprotegerin peptide analogue, YCEIEFCYLIR (OP3 4), and its tagging with a gadolinium chelate, a standard contrast agent for magnetic resonance imaging. The resulting contrast agent allows the simultaneous imaging and treatment of metabolic bone diseases. The gadolinium tagged peptide was successfully synthesised, showing unaltered magnetic resonance imaging contrast agent properties, a lack of cytotoxicity, and dose dependent inhibition of osteoclastogenesis in vitro. These findings pave the way toward the development of biospecific and bioactive contrast agents for the early diagnosis, treatment, and follow up of metabolic bone diseases such as osteoporosis and osteosarcoma.
C1 [Mbundi, Lubinda] Univ Coll London, Northwick Pk Inst Med Res, Dept Surg Res, Northwick Pk Hosp, Watford Rd, Harrow HA1 3UJ, Middx, England.
   [Mbundi, Lubinda] Univ Coll London, Northwick Pk Inst Med Res, Dept Surg Res, St Marks Hosp, Watford Rd, Harrow HA1 3UJ, Middx, England.
   [Mbundi, Lubinda; Meikle, Steve T.; Santin, Matteo] Univ Brighton, Sch Pharm & Biomol Sci, Ctr Regenerat Med & Devices, Huxley Bldg,Lewes Rd, Brighton BN2 4GJ, E Sussex, England.
   [Busquets, Rosa] Kingston Univ, Fac Sci Engn & Comp, Penrhyn Rd, Kingston Upon Thames KT1 2EE, Surrey, England.
   [Dowell, Nicholas G.; Cercignani, Mara] Brighton & Sussex Med Sch, Ctr Regenerat Med & Devices, CISC, Lewes Rd, Brighton BN1 9RR, E Sussex, England.
C3 Imperial College London; University of London; University College
   London; University of London; University College London; Imperial
   College London; University of Brighton; Kingston University; University
   of Sussex; University of Brighton
RP Santin, M (通讯作者)，Univ Brighton, Sch Pharm & Biomol Sci, Ctr Regenerat Med & Devices, Huxley Bldg,Lewes Rd, Brighton BN2 4GJ, E Sussex, England.
EM l.mbundi@ucl.ac.uk; stevenmeikle@googlemail.com;
   r.busquets@kingston.ac.uk; N.G.Dowell@bsms.ac.uk;
   M.Cercignani@bsms.ac.uk; m.santin@brighton.ac.uk
RI Cercignani, Mara/LFU 0175 2024; Meikle, Steven/A 8268 2012
OI Mbundi, Lubinda/0000 0001 7034 6136; Dowell,
   Nicholas/0000 0002 1978 4779; Santin, Matteo/0000 0002 5260 7088;
   Busquets, Rosa/0000 0001 9033 4757; Cercignani, Mara/0000 0002 4550 2456
FU Orthopaedic Research UK, Furlong House, London , United Kingdom
FX This work was funded by the Orthopaedic Research UK, Furlong House, 10a
   Chandos Street, London W1G 9DQ, United Kingdom, www.oruk.org.
CR Alles N, 2009, EUR J PHARM SCI, V37, P83, DOI 10.1016/j.ejps.2009.01.002
   Anastasilakis AD, 2012, THER CLIN RISK MANAG, V8, P295, DOI 10.2147/TCRM.S24239
   Annesley TM, 2003, CLIN CHEM, V49, P1041, DOI 10.1373/49.7.1041
   [Anonymous], J CELL SCI
   Aoki K, 2006, J CLIN INVEST, V116, P1525, DOI 10.1172/JCI22513
   Appelman Dijkstra NM, 2015, DRUGS, V75, P1049, DOI 10.1007/s40265 015 0417 7
   Bagher Ebadian H, 2011, NEUROIMAGE, V54, pS176, DOI 10.1016/j.neuroimage.2010.05.032
   BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092 8674(93)90132 A
   Cheng X, 2004, J BIOL CHEM, V279, P8269, DOI 10.1074/jbc.M309690200
   Crockett JC, 2016, ADVANCES IN PATHOBIOLOGY AND MANAGEMENT OF PAGET'S DISEASE OF BONE, P71, DOI 10.1016/B978 0 12 805083 5.00006 3
   de Villiers TJ, 2009, BEST PRACT RES CL OB, V23, P73, DOI 10.1016/j.bpobgyn.2008.10.009
   Góngora Benítez M, 2011, BIOPOLYMERS, V96, P69, DOI 10.1002/bip.21480
   Hathout G, 2012, RADIOL RES PRACT, V2012, DOI 10.1155/2012/815729
   Henriksen K, 2011, ENDOCR REV, V32, P31, DOI 10.1210/er.2010 0006
   Hur J, 2016, MOL CELLS, V39, P316, DOI 10.14348/molcells.2016.2286
   Ilvesaro J, 2001, BONE, V28, pS165
   Ito S, 2002, J BIOL CHEM, V277, P6631, DOI 10.1074/jbc.M106525200
   Jansen IDC, 2012, CALCIFIED TISSUE INT, V90, P515, DOI 10.1007/s00223 012 9600 y
   JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0
   KARPUSAS M, 1995, STRUCTURE, V3, P1031, DOI 10.1016/S0969 2126(01)00239 8
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Kohli Sarvraj Singh, 2011, Indian J Endocrinol Metab, V15, P175, DOI 10.4103/2230 8210.83401
   Lam J, 2001, J CLIN INVEST, V108, P971, DOI 10.1172/JCI13890
   Li J, 2017, J ORTHOP TRANSL, V10, P42, DOI 10.1016/j.jot.2017.05.001
   Mbundi L., 2014, Patent No. [WO2014122431, 2014122431]
   Mongkolsapaya J, 1999, NAT STRUCT BIOL, V6, P1048
   Naismith JH, 1996, STRUCTURE, V4, P1251, DOI 10.1016/S0969 2126(96)00134 7
   Naismith JH, 1998, TRENDS BIOCHEM SCI, V23, P74, DOI 10.1016/S0968 0004(97)01164 X
   Noordin S, 2010, OSTEOARTHR CARTILAGE, V18, P964, DOI 10.1016/j.joca.2010.03.010
   Overoye Chan K, 2008, J AM CHEM SOC, V130, P6025, DOI 10.1021/ja800834y
   Perazella MA, 2009, CLIN J AM SOC NEPHRO, V4, P461, DOI 10.2215/CJN.06011108
   Rizzoli R, 2010, NAT REV DRUG DISCOV, V9, P591, DOI 10.1038/nrd3244
   Rogosnitzky M, 2016, BIOMETALS, V29, P365, DOI 10.1007/s10534 016 9931 7
   Shen YQ, 2015, INVEST RADIOL, V50, P330, DOI 10.1097/RLI.0000000000000132
   Shin J, 2008, MOL CELLS, V25, P352
   Sigl V, 2016, OSTEOIMMUNOLOGY: INTERACTIONS OF THE IMMUNE AND SKELETAL SYSTEMS, 2ND EDITION, P121, DOI 10.1016/B978 0 12 800571 2.00008 6
   STETTER H, 1976, ANGEW CHEM INT EDIT, V15, P686, DOI 10.1002/anie.197606861
   Susa Mira, 2004, J Transl Med, V2, P6, DOI 10.1186/1479 5876 2 6
   Svenson S, 2005, ADV DRUG DELIVER REV, V57, P2106, DOI 10.1016/j.addr.2005.09.018
   Ta HM, 2010, P NATL ACAD SCI USA, V107, P20281, DOI 10.1073/pnas.1011686107
   Varga Szemes A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149260
   Viola Villegas N, 2009, COORDIN CHEM REV, V253, P1906, DOI 10.1016/j.ccr.2009.03.013
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Weitzmann MN, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/125705
   Winther JR, 2014, BBA GEN SUBJECTS, V1840, P838, DOI 10.1016/j.bbagen.2013.03.031
   Zhou ZX, 2013, WIRES NANOMED NANOBI, V5, P1, DOI 10.1002/wnan.1198
NR 46
TC 4
Z9 4
U1 2
U2 17
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2079 4991
J9 NANOMATERIALS BASEL
JI Nanomaterials
PD JUN
PY 2018
VL 8
IS 6
AR 399
DI 10.3390/nano8060399
PG 15
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA GK8UO
UT WOS:000436505200044
PM 29865247
OA Green Published, Green Accepted, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Huang, JY
   Wang, X
   Zheng, JJ
   Jia, QY
   Wang, X
   Xie, ZR
   Ma, HR
AF Huang, Jinyong
   Wang, Xin
   Zheng, Jingjie
   Jia, Qiyu
   Wang, Xi
   Xie, Zengru
   Ma, Hairong
TI Mechanisms underlying the therapeutic effects of isoflavones isolated
   from chickpea sprouts in treating osteoporosis based on network
   pharmacology
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Chickpea sprouts isoflavone; Network pharmacology; Osteoporosis;
   Molecular docking
ID CICER ARIETINUM L.; ESTROGEN RECEPTOR; KAPPA B; OSTEOCLASTOGENESIS;
   DIFFERENTIATION; OSTEOBLASTS; BENEFITS; MAPK
AB Osteoporosis is a systemic bone disease that is caused by multiple factors that lead to an imbalance in bone metabolism. Isoflavones can prevent and treat osteoporosis by regulating bone metabolism through a variety of pathways. The germination of chickpeas can significantly increase their isoflavone contents. However, the use of isoflavones isolated from chickpea sprouts (ICS) to prevent and treat osteoporosis by regulating bone metabolism has not been widely studied. In vivo experimental studies in ovariectomized rats showed that ICS significantly improved femoral bone mineral density (BMD) and trabecular structure, with effects similar to raloxifene. Furthermore, the chemical composition of ICS as well as the targets and signalling pathways its regulates in the prevention and treatment of osteoporosis were predicted by network pharmacological studies. ICS with drug like properties were identified by Lipinski's 5 principles, and intersecting targets of isoflavones with osteoporosis were identified. The overlapping targets were analysed by PPI, GO and KEGG analyses, and the possible key targets, signalling pathways and biological processes by which ICS treats osteoporosis were predicted; the prediction results were verified by molecular docking technology. The results showed that ICS could play an important role in the treatment of osteoporosis through "multicomponent, multitarget and multipathway" mechanisms, and the MAKP, NF kB and ER related signalling pathways may be important pathways by which ICS regulates osteoporosis; these findings provide a new theoretical basis for further experimental studies.& COPY; 2023 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY NC license (http://creativecommons.org/licenses/by nc/4.0/).
C1 [Huang, Jinyong; Ma, Hairong] Xinjiang Med Univ, Affiliated Hosp 1, Clin Med Inst, State Key Lab Pathogenesis Prevent & Treatment Hig, Urumqi 830011, Xinjiang, Peoples R China.
   [Huang, Jinyong; Wang, Xin; Jia, Qiyu; Wang, Xi; Xie, Zengru] Xinjiang Med Univ, Affiliated Hosp 1, Dept Trauma Orthopaed, Urumqi 830011, Xinjiang, Peoples R China.
   [Zheng, Jingjie] Xinjiang Med Univ, Affiliated Hosp 1, Dept Joint Surg, Urumqi 830011, Xinjiang, Peoples R China.
   [Huang, Jinyong; Wang, Xin; Zheng, Jingjie; Jia, Qiyu; Wang, Xi; Xie, Zengru; Ma, Hairong] Xinjiang Med Univ, Key Lab High Incidence Dis Res Xinjiang, Minist Educ, Urumqi 830011, Xinjiang, Peoples R China.
   [Huang, Jinyong; Wang, Xin; Zheng, Jingjie; Jia, Qiyu; Wang, Xi; Xie, Zengru; Ma, Hairong] Xinjiang Clin Res Ctr Orthopaed, Urumqi 830011, Xinjiang, Peoples R China.
C3 Xinjiang Medical University; Xinjiang Medical University; Xinjiang
   Medical University; Xinjiang Medical University
RP Ma, HR (通讯作者)，Xinjiang Med Univ, Affiliated Hosp 1, Clin Med Inst, State Key Lab Pathogenesis Prevent & Treatment Hig, Urumqi 830011, Xinjiang, Peoples R China.; Xie, ZR (通讯作者)，Xinjiang Med Univ, Affiliated Hosp 1, Dept Trauma Orthopaed, Urumqi 830011, Xinjiang, Peoples R China.
EM xiezenru@126.com; mhrsj@163.com
RI ; Jia, Qiyu/JRX 6089 2023
OI Wang, Xi/0009 0006 3349 4125; Jia, Qiyu/0000 0003 1835 6665; Wang,
   Xin/0000 0001 8537 5300; Jia, Qiyu/0009 0003 7395 7663
FU National Natural Science Foundation of China [81860746,
   82060411,82260409]; Natural Science Foundation of Xinjiang Uygur
   Autonomous Region [2021D01D21, 2021D01D19]
FX This work was financially supported by the grants from the National
   Natural Science Foundation of China (81860746, 82060411,82260409) ,
   Natural Science Foundation of Xinjiang Uygur Autonomous Region
   (2021D01D21, 2021D01D19) .
CR Bilbrough T, 2022, CHEM SOC REV, V51, P5691, DOI 10.1039/d1cs00991e
   Clynes MA, 2020, BRIT MED BULL, V133, P105, DOI 10.1093/bmb/ldaa005
   Cui HQ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2723 6
   Dai J, 2013, INT J BIOL SCI, V9, P1089, DOI 10.7150/ijbs.7367
   Daina A, 2017, SCI REP UK, V7, DOI 10.1038/srep42717
   Fang YY, 2019, CELL BIOL INT, V43, P323, DOI 10.1002/cbin.11102
   Gao AG, 2018, EUR REV MED PHARMACO, V22, P4669, DOI 10.26355/eurrev_201807_15527
   Gao Y, 2015, J AGR FOOD CHEM, V63, P2701, DOI 10.1021/jf5057524
   Gautam J., BRIT J NUTR, V117
   Gupta RK, 2017, J AGR FOOD CHEM, V65, P6, DOI 10.1021/acs.jafc.6b02629
   Jukanti AK, 2012, BRIT J NUTR, V108, pS11, DOI 10.1017/S0007114512000797
   Katsuyama H, 2010, MOL MED REP, V3, P531, DOI 10.3892/mmr_00000293
   Krízová L, 2019, MOLECULES, V24, DOI 10.3390/molecules24061076
   LeBoff MS, 2022, OSTEOPOROSIS INT, V33, P2049, DOI 10.1007/s00198 021 05900 y
   Li N, 2020, MOL NUTR FOOD RES, V64, DOI 10.1002/mnfr.201900751
   Li S, 2013, CHIN J NAT MEDICINES, V11, P110, DOI [10.3724/SP.J.1009.2013.00110, 10.1016/S1875 5364(13)60037 0]
   Liao MH, 2014, BRIT J NUTR, V111, P55, DOI 10.1017/S0007114513002043
   Liu YF, 2016, MOL MED REP, V14, P955, DOI 10.3892/mmr.2016.5304
   Liu YH, 2020, J CELL MOL MED, V24, P12308, DOI 10.1111/jcmm.15647
   Ma HR, 2013, ACTA PHARMACOL SIN, V34, P380, DOI 10.1038/aps.2012.160
   Ma HR, 2013, PHYTOTHER RES, V27, P1237, DOI 10.1002/ptr.4858
   Matsubara T, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23105508
   Tan Y, 2022, CHIN MED UK, V17, DOI 10.1186/s13020 022 00653 0
   Tyagi AM, 2010, MOL CELL ENDOCRINOL, V325, P101, DOI 10.1016/j.mce.2010.05.016
   Vallejo Díaz J, 2019, TRENDS CANCER, V5, P233, DOI 10.1016/j.trecan.2019.02.009
   Wang PP, 2012, J ASIAN NAT PROD RES, V14, P897, DOI 10.1080/10286020.2012.702757
   Wang Y, 2017, J CELL PHYSIOL, V232, P2396, DOI 10.1002/jcp.25774
   Wu GJ, 2020, J AGR FOOD CHEM, V68, P10639, DOI 10.1021/acs.jafc.0c02830
   Wu ZY, 2012, J AGR FOOD CHEM, V60, P8606, DOI 10.1021/jf3021514
   Xiao L, 2020, AGING US, V12, P21706, DOI 10.18632/aging.103976
   Yu F, 2015, GENE, V573, P273, DOI 10.1016/j.gene.2015.07.054
   Zhu HT, 2021, COMPUT MATH METHOD M, V2021, DOI 10.1155/2021/2909454
NR 32
TC 7
Z9 7
U1 0
U2 25
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 3
PY 2023
VL 671
BP 26
EP 37
DI 10.1016/j.bbrc.2023.05.090
EA JUN 2023
PG 12
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA K7XA1
UT WOS:001018519800001
PM 37290281
OA hybrid
DA 2025 08 17
ER

PT J
AU Hendrix, AS
   Spoonmore, TJ
   Wilde, AD
   Putnam, NE
   Hammer, ND
   Snyder, DJ
   Guelcher, SA
   Skaar, EP
   Cassat, JE
AF Hendrix, Andrew S.
   Spoonmore, Thomas J.
   Wilde, Aimee D.
   Putnam, Nicole E.
   Hammer, Neal D.
   Snyder, Daniel J.
   Guelcher, Scott A.
   Skaar, Eric P.
   Cassat, James E.
TI Repurposing the Nonsteroidal Anti inflammatory Drug Diflunisal as an
   Osteoprotective, Antivirulence Therapy for Staphylococcus aureus
   Osteomyelitis
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID VIRULENCE; INFECTION; MECHANISMS; INHIBITORS; TRENDS
AB Staphylococcus aureus osteomyelitis is a common and debilitating invasive infection of bone. Treatment of osteomyelitis is confounded by widespread antimicrobial resistance and the propensity of bacteria to trigger pathological changes in bone remodeling that limit antimicrobial penetration to the infectious focus. Adjunctive therapies that limit pathogen induced bone destruction could therefore limit morbidity and enhance traditional antimicrobial therapies. In this study, we evaluate the efficacy of the U.S. Food and Drug Administration approved, nonsteroidal anti inflammatory (NSAID) compound diflunisal in limiting S. aureus cytotoxicity toward skeletal cells and in preventing bone destruction during staphylococcal osteomyelitis. Diflunisal is known to inhibit S. aureus virulence factor production by the accessory gene regulator (agr) locus, and we have previously demonstrated that the Agr system plays a substantial role in pathological bone remodeling during staphylococcal osteomyelitis. Consistent with these observations, we find that diflunisal potently inhibits osteoblast cytotoxicity caused by S. aureus secreted toxins independently of effects on bacterial growth. Compared to commonly used NSAIDs, diflunisal is uniquely potent in the inhibition of skeletal cell death in vitro. Moreover, local delivery of diflunisal by means of a drug eluting, bioresorbable foam significantly limits bone destruction during S. aureus osteomyelitis in vivo. Collectively, these data demonstrate that diflunisal potently inhibits skeletal cell death and bone destruction associated with S. aureus infection and may therefore be a useful adjunctive therapy for osteomyelitis.
C1 [Hendrix, Andrew S.; Wilde, Aimee D.; Putnam, Nicole E.; Snyder, Daniel J.; Cassat, James E.] Vanderbilt Univ, Med Ctr, Dept Pediat, Div Pediat Infect Dis, Nashville, TN 37232 USA.
   [Spoonmore, Thomas J.; Guelcher, Scott A.] Vanderbilt Univ, Dept Chem & Biomed Engn, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Wilde, Aimee D.; Putnam, Nicole E.; Hammer, Neal D.; Skaar, Eric P.; Cassat, James E.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Guelcher, Scott A.; Cassat, James E.] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Bone Biol, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Hammer, Neal D.] Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA.
   [Snyder, Daniel J.] Univ Pittsburgh, Dept Microbiol & Mol Genet, Pittsburgh, PA USA.
C3 Vanderbilt University; Vanderbilt University; Vanderbilt University;
   Vanderbilt University; Michigan State University; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh
RP Cassat, JE (通讯作者)，Vanderbilt Univ, Med Ctr, Dept Pediat, Div Pediat Infect Dis, Nashville, TN 37232 USA.; Cassat, JE (通讯作者)，Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37235 USA.; Cassat, JE (通讯作者)，Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Bone Biol, 221 Kirkland Hall, Nashville, TN 37235 USA.
EM jim.cassat@vanderbilt.edu
RI Cassat, James/KWU 8809 2024; Skaar, Eric/KLY 3672 2024; Putnam,
   Nicole/AAV 4297 2020
OI Skaar, Eric/0000 0001 5094 8105; Hammer, Neal/0000 0001 6148 7850;
   Potter, Aimee/0000 0003 1473 1149
FU Vanderbilt Center for Microbial Pathogenesis (Sabbatical Award); HHS \
   National Institutes of Health (NIH) [R01AR064772]; HHS \ NIH \ National
   Institute of Allergy and Infectious Diseases (NIAID) [K08AI113107, T32
   AI112541, R01AI069233, AI073843]; Burroughs Wellcome Fund (BWF) (Career
   Award for Medical Scientists); Cystic Fibrosis Foundation (CF
   Foundation) (Ann Weinberg Memorial Research Fellowship)
FX This work, including the efforts of Nicole E. Putnam, was funded by
   Vanderbilt Center for Microbial Pathogenesis (Sabbatical Award). This
   work, including the efforts of Scott A. Guelcher, was funded by HHS
   vertical bar National Institutes of Health (NIH) (R01AR064772). This
   work, including the efforts of James E. Cassat, was funded by HHS
   vertical bar NIH vertical bar National Institute of Allergy and
   Infectious Diseases (NIAID) (K08AI113107). This work, including the
   efforts of Aimee D. Wilde, was funded by HHS vertical bar NIH vertical
   bar National Institute of Allergy and Infectious Diseases (NIAID) (T32
   AI112541). This work, including the efforts of Eric P. Skaar, was funded
   by HHS vertical bar NIH vertical bar National Institute of Allergy and
   Infectious Diseases (NIAID) (R01AI069233). This work, including the
   efforts of Eric P. Skaar, was funded by HHS vertical bar NIH vertical
   bar National Institute of Allergy and Infectious Diseases (NIAID)
   (AI073843). This work, including the efforts of James E. Cassat, was
   funded by Burroughs Wellcome Fund (BWF) (Career Award for Medical
   Scientists). This work, including the efforts of Neal D. Hammer, was
   funded by Cystic Fibrosis Foundation (CF Foundation) (Ann Weinberg
   Memorial Research Fellowship).
CR Beenken KE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010790
   Beenken KE, 2003, INFECT IMMUN, V71, P4206, DOI 10.1128/IAI.71.7.4206 4211.2003
   Boles BR, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000052
   Boles BR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010146
   Cassat JE, 2013, CELL HOST MICROBE, V13, P759, DOI 10.1016/j.chom.2013.05.003
   Copley LAB, 2009, J AM ACAD ORTHOP SUR, V17, P618
   DUTHIE ES, 1952, J GEN MICROBIOL, V6, P95, DOI 10.1099/00221287 6 1 2 95
   George EA, 2008, J AM CHEM SOC, V130, P4914, DOI 10.1021/ja711126e
   Gerber JS, 2009, CLIN INFECT DIS, V49, P65, DOI 10.1086/599348
   Guelcher SA, 2006, TISSUE ENG, V12, P1247, DOI 10.1089/ten.2006.12.1247
   Guelcher SA, 2011, J ORTHOP TRAUMA, V25, P477, DOI 10.1097/BOT.0b013e31821f624c
   Hammer ND, 2014, CELL HOST MICROBE, V16, P531, DOI 10.1016/j.chom.2014.09.002
   Harder AT, 2003, J CLIN PHARMACOL, V43, P807, DOI 10.1177/0091270003256061
   Khodaverdian V, 2013, ANTIMICROB AGENTS CH, V57, P3645, DOI 10.1128/AAC.00269 13
   Kupferwasser LI, 2003, J CLIN INVEST, V112, P222, DOI 10.1172/JCI200316876
   Kupferwasser LI, 1999, CIRCULATION, V99, P2791, DOI 10.1161/01.CIR.99.21.2791
   Lew DP, 2004, LANCET, V364, P369, DOI 10.1016/S0140 6736(04)16727 5
   Liu Tang, 2011, Orthopedics, V34, pe363, DOI 10.3928/01477447 20110627 12
   Murray EJ, 2014, J MED CHEM, V57, P2813, DOI 10.1021/jm500215s
   Nielsen A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084992
   Palma M, 2006, J BACTERIOL, V188, P5896, DOI 10.1128/JB.01960 05
   Queck SY, 2008, MOL CELL, V32, P150, DOI 10.1016/j.molcel.2008.08.005
   SAWHNEY AS, 1990, J BIOMED MATER RES, V24, P1397, DOI 10.1002/jbm.820241011
   Sully EK, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004174
   Valour F, 2015, Clin Microbiol Infect, V21, DOI 10.1016/j.cmi.2015.01.026
   Wahbi AAM, 2009, PAK J PHARM SCI, V22, P8
   Wilde AD, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005341
NR 27
TC 52
Z9 53
U1 1
U2 19
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036 2904 USA
SN 0066 4804
EI 1098 6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD SEP
PY 2016
VL 60
IS 9
BP 5322
EP 5330
DI 10.1128/AAC.00834 16
PG 9
WC Microbiology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Microbiology; Pharmacology & Pharmacy
GA ED7OH
UT WOS:000389055400027
PM 27324764
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Hong, GJ
   Chen, ZQ
   Han, XR
   Zhou, L
   Pang, FX
   Wu, RS
   Shen, YS
   He, XM
   Hong, ZN
   Li, ZQ
   He, W
   Wei, QS
AF Hong, Guoju
   Chen, Zhenqiu
   Han, Xiaorui
   Zhou, Lin
   Pang, Fengxiang
   Wu, Rishana
   Shen, Yingshan
   He, Xiaoming
   Hong, Zhinan
   Li, Ziqi
   He, Wei
   Wei, Qiushi
TI A novel RANKL targeted flavonoid glycoside prevents osteoporosis through
   inhibiting NFATc1 and reactive oxygen species
SO CLINICAL AND TRANSLATIONAL MEDICINE
LA English
DT Article
DE NFAcT1; osteoclast; osteoporosis; RANKL; Robinin; ROS
ID NF KAPPA B; OSTEOCLAST DIFFERENTIATION; SIGNALING PATHWAY; OXIDATIVE
   STRESS; RECEPTOR ACTIVATOR; P38; LIGAND; EXPRESSION; MANAGEMENT;
   REGULATOR
AB Background and purpose Osteoporosis is characterized by excessive bone resorption due to enhanced osteoclast activation. Stimulation of nuclear factor of activated T cells 1 (NFATc1) and accumulation of reactive oxygen species (ROS) are important mechanisms underlying osteoclastogenesis. Robinin (Rob) is a flavonoid glycoside that has shown anti inflammatory and antioxidative effects in previous studies, but little is known about its effects on bone homeostasis. The purpose of our research was to investigate whether Rob could prevent bone resorption in ovariectomized (OVX) mice by suppressing osteoclast production through its underlying mechanisms.
   Methods The docking pose of Rob and RANKL was identified by protein ligand molecular docking. Rob was added to bone marrow macrophages (BMMs) stimulated by nuclear factor kappa B (NF kappa B) ligand (RANKL). The effects of Rob on osteoclastic activity were evaluated by positive tartrate resistant acid phosphatase (TRAcP) staining kit and hydroxyapatite resorption assay. RANKL induced ROS generation in osteoclasts was detected by H(2)DCFDA and MitoSox Red staining. The classic molecular cascades triggered by RANKL, such as NF kappa B, ROS, calcium oscillations, and NFATc1 mediated signaling pathways, were investigated using Fluo4 staining, western blot, and quantitative real time polymerase chain reaction. In addition, an OVX mouse model mimicking estrogen deficient osteoporosis was created to evaluate the therapeutic effects of Rob in vivo.
   Results Computational docking results showed that Rob could bind specifically to RANKL's predicted binding sites. In vitro, Rob inhibited RANKL mediated osteoclastogenesis dose dependently without obvious cytotoxicity at low concentrations. We also found that Rob attenuated RANKL induced mitochondrial ROS production or enhanced activities of ROS scavenging enzymes, and ultimately reduced intracellular ROS levels. Rob abrogated the RANKL induced mitogen activated protein kinase (MAPK) and NF kappa B signaling pathways, and subsequently blocked NFATc1 signaling and TRAcP expression. In addition, Rob inhibited osteoclast proliferation by downregulating the expression of osteoclast target genes (Acp5, Cathepsin K, Atp6v0d2, Nfact1, c Fos, and Mmp9) and reducing Ca2+ oscillations. Our in vivo results showed that Rob reduced bone resorption in OVX animal model by repressing osteoclast activity and function.
   Conclusions Rob inhibits the activation of osteoclasts by targeting RANKL and is therefore a potential osteoporosis drug.
C1 [Hong, Guoju] Univ Alberta, Div Orthopaed Surg, Edmonton, AB, Canada.
   [Hong, Guoju; Pang, Fengxiang; Wu, Rishana; Shen, Yingshan; He, Xiaoming; Hong, Zhinan; Li, Ziqi; He, Wei; Wei, Qiushi] Guangzhou Univ Chinese Med, Traumatol & Orthoped Inst, Guangzhou 510378, Guangdong, Peoples R China.
   [Chen, Zhenqiu] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Orthopaed, Guangzhou, Guangdong, Peoples R China.
   [Han, Xiaorui] South China Univ Technol, Sch Med, Div Bioengn, Guangzhou, Guangdong, Peoples R China.
   [Zhou, Lin] Guangzhou Med Univ, Affiliated Hosp 5, Dept Endocrinol, Guangzhou, Guangdong, Peoples R China.
   [Pang, Fengxiang; Wu, Rishana; Shen, Yingshan; He, Xiaoming] Guangzhou Univ Chinese Med, Clin Med Coll 1, Guangzhou, Guangdong, Peoples R China.
   [Hong, Zhinan; Li, Ziqi; He, Wei; Wei, Qiushi] Guangzhou Univ Chinese Med, Dept Orthopaed, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China.
C3 University of Alberta; Guangzhou University of Chinese Medicine;
   Guangzhou University of Chinese Medicine; South China University of
   Technology; Guangzhou Medical University; Guangzhou University of
   Chinese Medicine; Guangzhou University of Chinese Medicine
RP Wei, QS (通讯作者)，Guangzhou Univ Chinese Med, Traumatol & Orthoped Inst, Guangzhou 510378, Guangdong, Peoples R China.
EM weiqshi@126.com
RI Hong, Guoju/AFP 4180 2022; He, Wei/HTT 0020 2023; li, ziqi/JDC 9141 2023
FU Natural Science Foundation of Guangdong Province [2017A030313698,
   S2013040014927]; National Natural Science Foundation of China [81302994,
   81573996, 81873327, 81904226]; Science andTechnology Planning Project of
   Guangdong Province [2012A032500005, 2014A020221041, 2016A020226028]
FX Natural Science Foundation of Guangdong Province, Grant/AwardNumbers:
   2017A030313698, S2013040014927; NationalNatural Science Foundation of
   China, Grant/Award Numbers: 81302994, 81573996, 81873327, 81904226;
   Science andTechnology Planning Project of Guangdong Province,
   Grant/AwardNumbers: 2012A032500005, 2014A020221041, 2016A020226028
CR Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200
   Aquilano K, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00196
   Bai XC, 2005, J BIOL CHEM, V280, P17497, DOI 10.1074/jbc.M409332200
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown JP, 2014, CAN FAM PHYSICIAN, V60, P324
   Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031 10
   Chellaiah M, 2000, J CELL BIOL, V148, P665, DOI 10.1083/jcb.148.4.665
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Gambacciani M, 2014, MENOPAUSE REV, V13, P213, DOI 10.5114/pm.2014.44996
   Morais MLGD, 2019, REPROD BIOL, V19, P270, DOI 10.1016/j.repbio.2019.07.008
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   Hodge JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021462
   Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Ikeda F, 2008, J BONE MINER RES, V23, P907, DOI 10.1359/JBMR.080211
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Janeesh PA, 2014, BIOMED PHARMACOTHER, V68, P989, DOI 10.1016/j.biopha.2014.09.010
   Janeesh PA, 2014, INT IMMUNOPHARMACOL, V18, P191, DOI 10.1016/j.intimp.2013.11.023
   Jung YY, 2008, J BIOL CHEM, V283, P23863, DOI 10.1074/jbc.M803072200
   Kang IS, 2016, SCI REP UK, V6, DOI 10.1038/srep38014
   Kanzaki H, 2016, REDOX BIOL, V8, P186, DOI 10.1016/j.redox.2016.01.006
   Kim HJ, 2006, FREE RADICAL BIO MED, V40, P1483, DOI 10.1016/j.freeradbiomed.2005.10.066
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kozakowska M, 2014, ANTIOXID REDOX SIGN, V20, P1827, DOI 10.1089/ars.2013.5341
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Lindsay R, 2016, OSTEOPOROSIS INT, V27, P2395, DOI 10.1007/s00198 016 3534 6
   Nardone V, 2014, CLINICS, V69, P438, DOI 10.6061/clinics/2014(06)12
   Park JH, 2017, MOL CELLS, V40, P706
   Rodríguez Carballo E, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00040
   Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320 344.2004
   Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034
   Son Y, 2013, METHOD ENZYMOL, V528, P27, DOI 10.1016/B978 0 12 405881 1.00002 1
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Sundaram K, 2007, EXP CELL RES, V313, P168, DOI 10.1016/j.yexcr.2006.10.001
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Thouverey C, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.80
   Troen BR, 2006, ANN NY ACAD SCI, V1068, P165, DOI 10.1196/annals.1346.018
   Tsiklauri L, 2011, J PHARMACEUT BIOMED, V55, P109, DOI 10.1016/j.jpba.2010.12.021
   van der Kraan AGJ, 2013, BIOCHEM J, V451, P235, DOI 10.1042/BJ20121626
   Wang C, 2003, J BONE MINER RES, V18, P2159, DOI 10.1359/jbmr.2003.18.12.2159
   Xiao YL, 2017, BLOOD ADV, V1, P1993, DOI 10.1182/bloodadvances.2017008540
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Xu Q, 2016, J BIOL CHEM, V291, P20030, DOI 10.1074/jbc.M116.731216
   Zaheer S, 2015, EXPERT OPIN DRUG MET, V11, P461, DOI 10.1517/17425255.2015.1000860
NR 55
TC 55
Z9 59
U1 2
U2 45
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 2001 1326
J9 CLIN TRANSL MED
JI Clin. Transl. Med.
PD MAY
PY 2021
VL 11
IS 5
AR e392
DI 10.1002/ctm2.392
PG 23
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA SJ6CW
UT WOS:000655621800016
PM 34047464
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhou, L
   Wang, JQ
   Zhao, JL
   Kuai, F
   Yang, HL
AF Zhou, Liang
   Wang, Jiaqian
   Zhao, Jiali
   Kuai, Feng
   Yang, Huilin
TI Shikonin promotes osteogenesis and suppresses osteoclastogenesis in
   vitro
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Shikonin; mesenchymal stem cells; osteoporosis; Wnt; beta cantenin;
   RANKL; OPG
AB Shikonin, as a traditional Chinese herbal medicine with a role of anti cancer, anti inflammatory, antibacterial and other effects. However, there are few studies on the effect of shikonin on osteoporosis. Therefore, the purpose of this study aims to investigate the role and mechanism of shikonin on differentiation of BMSCs and BMMs into osteoblasts and osteoclasts formation. In our study, we treated the cells with different concentrations of shikonin, and then illuminated its effect on oteogenesis and osteoclast differentiation by ALP/alizarin red staining, ALP activity, qRT PCR, immunofluorescence, Western blot, and TRAP staining. The result showed that shikonin may promote BMSCs differentiate into osteoblasts through the Wnt/beta catenin signaling pathway. At the same time, it may also inhibit the formation of osteoclasts mediated by RANK/RANKL/OPG pathway in vitro. Our research explains excellently the mechanism of shikonin alleviating osteoporosis in vitro, which maybe contributing to the exploration of a new way to prevent osteoporosis.
C1 [Zhou, Liang] Lianshui Cty Peoples Hosp, Dept Orthoped, Huaian 223001, Jiangsu, Peoples R China.
   [Wang, Jiaqian; Yang, Huilin] Soochow Univ, Dept Orthoped, Affiliated Hosp 1, Suzhou 215006, Jiangsu, Peoples R China.
   [Zhao, Jiali] Xuzhou Med Univ, Dept Orthoped, Affiliated Huaian Hosp, Huaian 223002, Jiangsu, Peoples R China.
   [Zhao, Jiali] Second Peoples Hosp Huaian, Huaian 223002, Jiangsu, Peoples R China.
   [Kuai, Feng] Nantong Univ, Affiliated Hosp 4, Peoples Hosp Yancheng 1, Dept Geriatr, Yancheng 224001, Jiangsu, Peoples R China.
C3 Soochow University   China; Xuzhou Medical University; Nantong
   University
RP Yang, HL (通讯作者)，Soochow Univ, Dept Orthoped, Affiliated Hosp 1, Suzhou 215006, Jiangsu, Peoples R China.; Kuai, F (通讯作者)，Nantong Univ, Affiliated Hosp 4, Peoples Hosp Yancheng 1, Dept Geriatr, Yancheng 224001, Jiangsu, Peoples R China.
EM suzhouspine@163.com; yckf301415@163.com
RI ; Wang, Jiaqian/JTU 2870 2023
OI Wang, Jiaqian/0000 0003 4061 6574; 
CR Andújar I, 2013, PLANTA MED, V79, P1685, DOI 10.1055/s 0033 1350934
   Bandara N, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0442 9
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Barrett Connor E, 2005, ANNU REV PUBL HEALTH, V26, P115, DOI 10.1146/annurev.publhealth.26.021304.144637
   Boudin E, 2013, SEMIN ARTHRITIS RHEU, V43, P220, DOI 10.1016/j.semarthrit.2013.01.004
   Cai BZ, 2009, J MOL CELL CARDIOL, V47, P41, DOI 10.1016/j.yjmcc.2009.03.002
   Choi YH, 2016, INT J MOL MED, V38, P610, DOI 10.3892/ijmm.2016.2655
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101
   Fang T, 2016, MOL MED REP, V14, P1269, DOI 10.3892/mmr.2016.5363
   Kawai M, 2011, NAT REV DRUG DISCOV, V10, P141, DOI 10.1038/nrd3299
   Keating SE, 2007, J BIOL CHEM, V282, P33435, DOI 10.1074/jbc.M705266200
   Kim YO, 2010, KOREAN J PHYSIOL PHA, V14, P199, DOI 10.4196/kjpp.2010.14.4.199
   Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Liu J, 2016, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V30, P1626, DOI 10.13201/j.issn.1001 1781.2016.20.011
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nelson ER, 2013, BONE, V53, P42, DOI 10.1016/j.bone.2012.11.011
   Reid IR, 2015, NAT REV ENDOCRINOL, V11, P418, DOI 10.1038/nrendo.2015.71
   Wei W, 2011, MOL CELL BIOL, V31, P4706, DOI 10.1128/MCB.05980 11
   Xie Z, 2018, J BONE MINER RES, V33, P667, DOI 10.1002/jbmr.3334
   Yasui T, 2011, J BONE MINER RES, V26, P1447, DOI 10.1002/jbmr.357
   Zhong ZD, 2012, P NATL ACAD SCI USA, V109, pE2197, DOI 10.1073/pnas.1120407109
NR 24
TC 8
Z9 9
U1 0
U2 14
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943 8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2020
VL 12
IS 12
BP 8099
EP 8110
PG 12
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA PP0WF
UT WOS:000605590100003
PM 33437384
DA 2025 08 17
ER

PT J
AU Xu, Q
   Cao, ZY
   Xu, JQ
   Dai, M
   Zhang, B
   Lai, Q
   Liu, XQ
AF Xu, Qiang
   Cao, Zhiyou
   Xu, JiaQiang
   Dai, Min
   Zhang, Bin
   Lai, Qi
   Liu, Xuqiang
TI Effects and mechanisms of natural plant active compounds for the
   treatment of osteoclast mediated bone destructive diseases
SO JOURNAL OF DRUG TARGETING
LA English
DT Article
DE Bone metabolism; bone destructive diseases; osteoclast;
   osteoclastogenesis; natural products
ID NF KAPPA B; RANKL INDUCED OSTEOCLASTOGENESIS; SUPPRESSES RECEPTOR
   ACTIVATOR; PARTICLE INDUCED OSTEOLYSIS; DOWN REGULATING NFATC1;
   LIGAND INDUCED OSTEOCLASTOGENESIS; COLLAGEN INDUCED ARTHRITIS; INHIBITS
   OSTEOCLASTOGENESIS; IN VITRO; NUCLEAR FACTOR
AB Bone destructive diseases, caused by overdifferentiation of osteoclasts, reduce bone mass and quality, and disrupt bone microstructure, thereby causes osteoporosis, Paget's disease, osteolytic bone metastases, and rheumatoid arthritis. Osteoclasts, the only multinucleated cells with bone resorption function, are derived from haematopoietic progenitors of the monocyte/macrophage lineage. The regulation of osteoclast differentiation is considered an effective target for the treatment of bone destructive diseases. Natural plant derived products have received increasing attention in recent years due to their good safety profile, the preference of natural compounds over synthetic drugs, and their potential therapeutic and preventive activity against osteoclast mediated bone destructive diseases. In this study, we reviewed the research progress of the potential antiosteoclast active compounds extracted from medicinal plants and their molecular mechanisms. Active compounds from natural plants that inhibit osteoclast differentiation and functions include flavonoids, terpenoids, quinones, glucosides, polyphenols, alkaloids, coumarins, lignans, and limonoids. They inhibit bone destruction by downregulating the expression of osteoclast specific marker genes (CTSK, MMP 9, TRAP, OSCAR, DC STAMP, V ATPase d2, and integrin av3) and transcription factors (c Fos, NFATc1, and c Src), prevent the effects of local factors (ROS, LPS, and NO), and suppress the activation of various signalling pathways (MAPK, NF kappa B, Akt, and Ca2+). Therefore, osteoclast targeting natural products are of great value in the prevention and treatment of bone destructive diseases.
C1 [Xu, Qiang; Cao, Zhiyou; Xu, JiaQiang; Dai, Min; Zhang, Bin; Lai, Qi; Liu, Xuqiang] Nanchang Univ, Dept Orthoped, Affiliated Hosp 1, Nanchang 330006, Jiangxi, Peoples R China.
C3 Nanchang University
RP Lai, Q; Liu, XQ (通讯作者)，Nanchang Univ, Dept Orthoped, Affiliated Hosp 1, Nanchang 330006, Jiangxi, Peoples R China.
EM 961962914@qq.com; shliuxuqiang@163.com
RI DAI, M/GPS 8291 2022; Xu, Jiaqiang/A 9322 2013
FU National Natural Science Foundation of China [81860404, 81860405]
FX This research was supported by grants from National Natural Science
   Foundation of China [Grant Nos. 81860404 and 81860405].
CR Allen M, 2018, CURR OSTEOPOROS REP, V16, P198, DOI 10.1007/s11914 018 0430 3
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Ang ESM, 2011, FEBS LETT, V585, P2755, DOI 10.1016/j.febslet.2011.07.046
   Baek JM, 2015, BIOCHEM BIOPH RES CO, V461, P334, DOI 10.1016/j.bbrc.2015.04.034
   Baek JM, 2015, PHYTOMEDICINE, V22, P27, DOI 10.1016/j.phymed.2014.10.008
   Bao LL, 2011, CHEM BIOL INTERACT, V194, P97, DOI 10.1016/j.cbi.2011.08.013
   Beral Valerie, 2003, Lancet, V362, P419
   Boissy P, 2005, CANCER RES, V65, P9943, DOI 10.1158/0008 5472.CAN 05 0651
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cai BR, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/3153082
   Cappuzzo KA, 2004, ANN PHARMACOTHER, V38, P294, DOI 10.1345/aph.1D353
   Chen ST, 2019, MOLECULES, V24, DOI 10.3390/molecules24010156
   Chen X, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.394
   Cheng BB, 2012, FOOD CHEM TOXICOL, V50, P1610, DOI 10.1016/j.fct.2012.02.019
   Chiou WF, 2010, BRIT J PHARMACOL, V161, P321, DOI 10.1111/j.1476 5381.2010.00823.x
   Delitala AP, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041034
   Du NC, 2020, INT IMMUNOPHARMACOL, V83, DOI 10.1016/j.intimp.2020.106387
   Egusa H, 2011, BONE, V49, P264, DOI 10.1016/j.bone.2011.04.003
   Gan K, 2015, INT IMMUNOPHARMACOL, V24, P239, DOI 10.1016/j.intimp.2014.12.012
   Goto T, 2015, CYTOTECHNOLOGY, V67, P357, DOI 10.1007/s10616 014 9694 3
   Ha H, 2010, ARCH PHARM RES, V33, P625, DOI 10.1007/s12272 010 0418 8
   Ha J, 2009, INT IMMUNOPHARMACOL, V9, P774, DOI 10.1016/j.intimp.2009.03.001
   Han KY, 2007, BIOCHEM PHARMACOL, V74, P911, DOI 10.1016/j.bcp.2007.06.044
   Han SY, 2019, AM J CHINESE MED, V47, P439, DOI [10.1142/S0192415X19500228, 10.1142/s0192415x19500228]
   He L, 2012, BONE, V50, P1207, DOI 10.1016/j.bone.2012.03.022
   He Y, 2014, BIOCHEM BIOPH RES CO, V449, P344, DOI 10.1016/j.bbrc.2014.05.034
   He YQ, 2018, BIOCHEM BIOPH RES CO, V506, P927, DOI 10.1016/j.bbrc.2018.10.100
   Hsieh CJ, 2015, INT J ONCOL, V46, P555, DOI 10.3892/ijo.2014.2769
   Hu XY, 2017, ACTA BIOMATER, V48, P479, DOI 10.1016/j.actbio.2016.11.022
   Huang JB, 2015, MOL CELL ENDOCRINOL, V399, P346, DOI 10.1016/j.mce.2014.10.016
   Huang Q, 2015, BONE, V73, P132, DOI 10.1016/j.bone.2014.12.059
   Hung TY, 2010, J ETHNOPHARMACOL, V131, P70, DOI 10.1016/j.jep.2010.05.063
   Imangali N, 2021, J FISH BIOL, V98, P1018, DOI 10.1111/jfb.14317
   Jeong JC, 2004, TOXICOL IN VITRO, V18, P829, DOI 10.1016/j.tiv.2004.05.002
   Jeong Eun H, 2013, EUR J PHARMACOL, V698, P57, DOI 10.1016/j.ejphar.2012.08.013
   Jun AY, 2014, INVEST NEW DRUG, V32, P1, DOI 10.1007/s10637 013 9969 0
   Karsenty G, 2003, NATURE, V423, P316, DOI 10.1038/nature01654
   Kim AR, 2012, EUR J PHARMACOL, V682, P29, DOI 10.1016/j.ejphar.2012.02.026
   Kim HJ, 2018, BIOSCI TRENDS, V12, P257, DOI 10.5582/bst.2018.01107
   Kim HJ, 2014, EUR J PHARMACOL, V723, P473, DOI 10.1016/j.ejphar.2013.10.027
   Kim JY, 2015, J NAT PROD, V78, P2167, DOI 10.1021/acs.jnatprod.5b00233
   Kim JY, 2014, INT IMMUNOPHARMACOL, V20, P213, DOI 10.1016/j.intimp.2014.03.001
   Kim JY, 2014, BONE, V60, P104, DOI 10.1016/j.bone.2013.12.013
   Kim KJ, 2015, BONE, V81, P208, DOI 10.1016/j.bone.2015.07.023
   Kim MH, 2008, FOOD CHEM TOXICOL, V46, P3375, DOI 10.1016/j.fct.2008.08.016
   Kim SN, 2008, CELL BIOL INT, V32, P1064, DOI 10.1016/j.cellbi.2008.04.017
   Kim SN, 2009, PHYTOTHER RES, V23, P185, DOI 10.1002/ptr.2581
   Kim TH, 2011, J NUTR BIOCHEM, V22, P8, DOI 10.1016/j.jnutbio.2009.11.002
   Kimira Y, 2015, PHYTOMEDICINE, V22, P1120, DOI 10.1016/j.phymed.2015.08.013
   Ko SY, 2012, ARCH ORAL BIOL, V57, P1623, DOI 10.1016/j.archoralbio.2012.06.012
   Kunnurnakkara AB, 2007, BLOOD, V109, P5112, DOI 10.1182/blood 2007 01 067256
   Kwak SC, 2013, BIOL PHARM BULL, V36, P1779
   Lee JW, 2012, J NAT MED TOKYO, V66, P8, DOI 10.1007/s11418 011 0537 7
   Lee JH, 2010, MOL PHARMACOL, V77, P17, DOI 10.1124/mol.109.057877
   Lee SH, 2014, INT J MOL SCI, V15, P10605, DOI 10.3390/ijms150610605
   Lee SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080873
   Léotoing L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068388
   Li HW, 2013, BIOCHEM BIOPH RES CO, V430, P951, DOI 10.1016/j.bbrc.2012.12.051
   Li JX, 2007, MATURITAS, V58, P59, DOI 10.1016/j.maturitas.2007.06.001
   Li S.S., 2017, Sci Rep UK, V7
   Li XJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074274
   Liang XH, 2020, AM J TRANSL RES, V12, P800
   Liu YX, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005467.pub2
   Lu L, 2017, J CELL MOL MED, V21, P1361, DOI 10.1111/jcmm.13066
   Ma XJ, 2014, BIOCHEM BIOPH RES CO, V445, P282, DOI 10.1016/j.bbrc.2014.01.145
   Meng JH, 2018, AM J TRANSL RES, V10, P2901
   Meng Z, 2019, NUTR METAB, V16, DOI 10.1186/s12986 019 0354 7
   Mo H, 2019, BRAZ J MED BIOL RES, V52, DOI [10.1590/1414 431X20198754, 10.1590/1414 431x20198754]
   Moriwaki S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097177
   Mukai N, 2008, EXP CELL RES, V314, P430, DOI 10.1016/j.yexcr.2007.11.016
   Nagaoka M, 2019, ANTIOXIDANTS BASEL, V8, DOI 10.3390/antiox8090386
   Nepal M, 2013, EUR J PHARMACOL, V715, P96, DOI 10.1016/j.ejphar.2013.06.002
   Nie SB, 2016, BIOCHEM BIOPH RES CO, V470, P61, DOI 10.1016/j.bbrc.2015.12.115
   Nuti R, 2019, INTERN EMERG MED, V14, P85, DOI 10.1007/s11739 018 1874 2
   Ohnishi T, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094453
   Oka Y, 2012, J PHARMACOL SCI, V118, P55, DOI 10.1254/jphs.11082FP
   Park B, 2014, BIOCHIMIE, V105, P129, DOI 10.1016/j.biochi.2014.07.003
   Park CM, 2016, MOL CELLS, V39, P855, DOI 10.14348/molcells.2016.0111
   Park EK, 2004, BIOCHEM BIOPH RES CO, V325, P1472, DOI 10.1016/j.bbrc.2004.10.197
   Pinkerton JV, 2014, J STEROID BIOCHEM, V142, P142, DOI 10.1016/j.jsbmb.2013.12.011
   Ponnapakkam T, 2014, DRUG DISCOV TODAY, V19, P204, DOI 10.1016/j.drudis.2013.07.015
   Qiao H, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.11
   Qiao H, 2017, ACS NANO, V11, P7259, DOI 10.1021/acsnano.7b03197
   Qiu SX, 2007, CHEM BIOL, V14, P860, DOI 10.1016/j.chembiol.2007.06.010
   Qu XH, 2014, BIOCHEM BIOPH RES CO, V443, P658, DOI 10.1016/j.bbrc.2013.12.029
   Quan GH, 2015, INT J MOL SCI, V16, P29496, DOI 10.3390/ijms161226179
   Rantlha M, 2017, ARCH PHARM RES, V40, P79, DOI 10.1007/s12272 016 0790 0
   Reuter S, 2010, MOL CANCER RES, V8, P1425, DOI 10.1158/1541 7786.MCR 10 0141
   Ross RD, 2020, JBMR PLUS, V4, DOI 10.1002/jbm4.10344
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Sakai E, 2013, J PHARMACOL SCI, V121, P288, DOI 10.1254/jphs.12243FP
   Shim KS, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906 017 1986 7
   Shin DK, 2012, ACTA BIOMATER, V8, P3524, DOI 10.1016/j.actbio.2012.05.002
   Siddiqi MH, 2015, PHYTOTHER RES, V29, P1286, DOI 10.1002/ptr.5374
   Sujitha S, 2019, INT IMMUNOPHARMACOL, V74, DOI 10.1016/j.intimp.2019.105703
   Sun XY, 2019, THERANOSTICS, V9, P5183, DOI 10.7150/thno.33376
   Sun X, 2020, J CELL MOL MED, V24, P3692, DOI 10.1111/jcmm.15072
   Sung B, 2012, MOL CANCER THER, V11, P350, DOI 10.1158/1535 7163.MCT 11 0731
   Tanaka M, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1625 y
   Terruzzi I, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/5678548
   Thummuri D, 2015, PHARMACOL RES, V99, P63, DOI 10.1016/j.phrs.2015.05.006
   Tile L, 2020, THER ADV MUSCULOSKEL, V12, DOI 10.1177/1759720X20916983
   Tomomura M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130174
   Tsukamoto S, 2014, BIOORG MED CHEM LETT, V24, P5315, DOI 10.1016/j.bmcl.2014.09.043
   Ukon Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102557
   Uruno Y, 2015, BIOORG MED CHEM LETT, V25, P5357, DOI 10.1016/j.bmcl.2015.09.032
   Verron E, 2014, DRUG DISCOV TODAY, V19, P312, DOI 10.1016/j.drudis.2013.08.010
   Wanachewin O, 2017, ARCH PHARM RES, V40, P1186, DOI 10.1007/s12272 017 0926 x
   Wang HX, 2017, ONCOL REP, V38, P703, DOI 10.3892/or.2017.5767
   Wang W, 2020, NUTR METAB, V17, DOI 10.1186/s12986 020 00449 9
   Wang X, 2016, EUR J PHARMACOL, V774, P34, DOI 10.1016/j.ejphar.2016.01.008
   Wang YJ, 2015, INT IMMUNOPHARMACOL, V29, P513, DOI 10.1016/j.intimp.2015.10.004
   Wardhana Agung Satria, 2021, Eur J Dent, V15, P8, DOI 10.1055/s 0040 1714039
   Wei GJ, 2019, J CELL BIOCHEM, V120, P5367, DOI 10.1002/jcb.27815
   Wisutsitthiwong C, 2011, BIOCHEM BIOPH RES CO, V415, P361, DOI 10.1016/j.bbrc.2011.10.073
   Woolf AD, 2003, B WORLD HEALTH ORGAN, V81, P646
   Wu X, 2012, J BONE MINER RES, V27, P1298, DOI 10.1002/jbmr.1576
   Wu XW, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.919392
   Xie BP, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109045
   Xu HH, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/8048170
   Yeon JT, 2015, J NAT PROD, V78, P776, DOI 10.1021/np501017z
   Yeon JT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088974
   Yonezawa T, 2011, EUR J PHARMACOL, V650, P511, DOI 10.1016/j.ejphar.2010.10.048
   Yoon WJ, 2013, BIOCHEM BIOPH RES CO, V434, P892, DOI 10.1016/j.bbrc.2013.04.046
   Young MF, 2016, MATRIX BIOL, V52 54, P1, DOI 10.1016/j.matbio.2016.04.003
   Yu GY, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/7130653
   Yu KE, 2020, THER ADV MUSCULOSKEL, V12, DOI 10.1177/1759720X20966135
   Yu MX, 2014, BIOCHEM BIOPH RES CO, V447, P364, DOI 10.1016/j.bbrc.2014.04.009
   Yuan FL, 2015, BONE, V75, P128, DOI 10.1016/j.bone.2015.02.017
   Yuce HB, 2019, J PERIODONTOL, V90, P1481, DOI 10.1002/JPER.18 0584
   Zhai XH, 2013, MOL NUTR FOOD RES, V57, P249, DOI 10.1002/mnfr.201200536
   Zhai YK, 2017, EUR J PHARMACOL, V801, P62, DOI 10.1016/j.ejphar.2017.03.001
   Zhai ZJ, 2014, BRIT J PHARMACOL, V171, P663, DOI 10.1111/bph.12463
   Zhang DW, 2012, BIOCHIMIE, V94, P2514, DOI 10.1016/j.biochi.2012.06.033
   Zhang H, 2008, MATURITAS, V61, P334, DOI 10.1016/j.maturitas.2008.09.023
   Zhang X, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00201
   Zhao DF, 2018, J PHARMACOL SCI, V137, P76, DOI 10.1016/j.jphs.2018.03.007
   Zheng MX, 2014, INT ORTHOP, V38, P627, DOI 10.1007/s00264 013 2184 y
   Zhi X, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00022
   Zhou B, 2017, BIOMED PHARMACOTHER, V90, P835, DOI 10.1016/j.biopha.2017.03.084
   Zhou C, 2015, INT IMMUNOPHARMACOL, V25, P49, DOI 10.1016/j.intimp.2015.01.010
   Zhou F, 2017, BIOCHEM BIOPH RES CO, V484, P820, DOI 10.1016/j.bbrc.2017.01.179
NR 142
TC 21
Z9 24
U1 9
U2 54
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1061 186X
EI 1029 2330
J9 J DRUG TARGET
JI J. Drug Target.
PD APR 21
PY 2022
VL 30
IS 4
BP 394
EP 412
DI 10.1080/1061186X.2021.2013488
EA DEC 2021
PG 19
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA ZR1YZ
UT WOS:000730494000001
PM 34859718
DA 2025 08 17
ER

PT J
AU Lee, EG
   Sung, MS
   Yoo, HG
   Chae, HJ
   Kim, HR
   Yoo, WH
AF Lee, Eun Gyeong
   Sung, Myung Soon
   Yoo, Han Gyul
   Chae, Han Jung
   Kim, Hang Rae
   Yoo, Wan Hee
TI Increased RANKL mediated osteoclastogenesis by interleukin 1β and
   endoplasmic reticulum stress
SO JOINT BONE SPINE
LA English
DT Article
DE Endoplasmic reticulum stress; IL 1 beta; Osteoclast; 4 phenylbutyric
   acid; Thapsigargin
ID TUMOR NECROSIS FACTOR; RHEUMATOID ARTHRITIS; ER STRESS; PRECURSOR
   DIFFERENTIATION; SYNOVIAL FIBROBLASTS; ACTIVATION; RECEPTOR; PATHWAY;
   BONE; PROTEINS
AB Objective: The mechanism by which IL 1 beta and thapsigargin (TG) induced endoplasmic reticulum (ER) stress modulate the receptor activator of nuclear factor kappa B ligand (RANKL) mediated osteoclastogenesis remains elusive. Thus, we investigated the osteoclast specific and ER signals in osteoclastogenesis of bone marrow derived cells.
   Methods: Bone marrow cells (BMCs) were obtained from 5 week old male ICR mice and cultured to be differentiated into osteoclasts with M CSF and RANKL in the presence or absence of IL 1 beta, TG, or 4 phenylbutyric acid (PBA), an ER stress reducing drug. The formation of osteoclasts was evaluated by tartrate resistant acid phosphatase (TRAP) staining and resorption pit assay with a dentine slice. The molecular mechanism of IL 1 beta and ER stress in osteoclastogenesis was investigated in BMCs transfected with siRNA for GRP78, PERK and IRE1 using reverse transcription polymerase chain reaction and immunoblotting for osteoclast specific and ER stress signaling molecules.
   Results: IL 1 beta and ER stress induced by TG augmented the formation of osteoclasts, which was significantly inhibited by PBA and was mediated with osteoclast specific signals, including c Fos, NFATc1, and ER stress associated signaling pathways, such as PERK, IRE1, GRP78, and eIF2 alpha. siRNA mediated knockdown of ER stress signals inhibited the expression of NFATc1 and c Fos, thus reducing IL 1 beta and/or TG induced formation of osteoclasts.
   Conclusions: Osteoclastogenesis by IL 1 beta and/or ER stress is mainly associated with upregulation of eIF2 alpha, GRP78, PERK and IRE1. These results suggest that the signaling pathway of ER stress induced osteoclast formation might be a new therapeutic target to prevent inflammatory and destructive arthritic disease such as RA and diverse osteoporosis. (C) 2014 Societe francaise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.
C1 [Lee, Eun Gyeong; Sung, Myung Soon; Yoo, Wan Hee] Chonbuk Natl Univ, Sch Med, Dept Internal Med, Jeonju 561712, Jeonbuk, South Korea.
   [Lee, Eun Gyeong; Sung, Myung Soon; Yoo, Wan Hee] Chonbuk Natl Univ, Res Inst Clin Med, Jeonju 561712, Jeonbuk, South Korea.
   [Lee, Eun Gyeong; Sung, Myung Soon; Yoo, Wan Hee] Chonbuk Natl Univ Hosp, Jeonju 561712, Jeonbuk, South Korea.
   [Yoo, Han Gyul] Univ Rhode Isl, Coll Pharm, Dept Pharm Practice, Kingston, RI 02881 USA.
   [Chae, Han Jung] Chonbuk Natl Univ, Sch Med, Dept Pharmacol, Jeonju 561712, Jeonbuk, South Korea.
   [Kim, Hang Rae] Seoul Natl Univ, Coll Med, Dept Anat, Seoul 110799, South Korea.
C3 Jeonbuk National University; Jeonbuk National University; Jeonbuk
   National University; Jeonbuk National University Hospital; University of
   Rhode Island; Jeonbuk National University; Seoul National University
   (SNU)
RP Yoo, WH (通讯作者)，Chonbuk Natl Univ, Chonbuk Natl Univ Hosp, Sch Med, Dept Internal Med,Div Rheumatol, Jeonju 561180, Jeonbuk, South Korea.
EM ywhim@jbnu.ac.kr
RI Kim, Hang Rae/J 5448 2012
OI Kim, Hang Rae/0000 0002 3983 6193; Chae, Han Jung/0000 0003 4190 9889
FU Chonbuk National University Hospital Research Institute of Clinical
   Medicine
FX We thank all of the members of the Institute of Bone and Joint Diseases
   at Chonbuk National University. This paper was supported by Fund of
   Chonbuk National University Hospital Research Institute of Clinical
   Medicine.
CR AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679
   Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014
   Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161 10168.2004
   Diehl JA, 2011, GASTROENTEROLOGY, V141, P38, DOI 10.1053/j.gastro.2011.05.018
   Fouque Aubert A, 2008, JOINT BONE SPINE, V75, P5, DOI 10.1016/j.jbspin.2007.05.004
   Han MK, 2003, J LEUKOCYTE BIOL, V73, P525, DOI 10.1189/jlb.0502256
   Hino S, 2010, J BONE MINER METAB, V28, P131, DOI 10.1007/s00774 009 0117 z
   Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034
   Hu P, 2006, MOL CELL BIOL, V26, P3071, DOI 10.1128/MCB.26.8.3071 3084.2006
   Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211
   Kim GS, 2005, J BONE MINER RES, V20, P1342, DOI 10.1359/JBMR.050320
   Kim JH, 2009, J IMMUNOL, V183, P1862, DOI 10.4049/jimmunol.0803007
   Lee HY, 2006, ARTHRITIS RHEUM US, V54, P1747, DOI 10.1002/art.21873
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092 8674(00)80855 7
   Murdoch C, 2005, J IMMUNOL, V175, P6257, DOI 10.4049/jimmunol.175.10.6257
   Özcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294
   Okada Yosuke, 2007, Clin Calcium, V17, P1762
   Sawkar AR, 2002, P NATL ACAD SCI USA, V99, P15428, DOI 10.1073/pnas.192582899
   Shin YJ, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2921
   Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962 8924(98)01267 7
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2010, ANN NY ACAD SCI, V1192, P117, DOI 10.1111/j.1749 6632.2009.05303.x
   Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664
   van Vollenhoven RF, 2011, NAT REV RHEUMATOL, V7, P205, DOI 10.1038/nrrheum.2011.22
   Verma G, 2010, APOPTOSIS, V15, P864, DOI 10.1007/s10495 010 0498 4
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   Wang KK, 2011, J MOL CELL BIOL, V3, P360, DOI 10.1093/jmcb/mjr021
   Weber CK, 2010, RHEUMATOLOGY, V49, P2255, DOI 10.1093/rheumatology/keq272
   Yam GHT, 2007, INVEST OPHTH VIS SCI, V48, P1683, DOI 10.1167/iovs.06 0943
   Yamasaki S, 2005, ARTHRITIS RES THER, V7, P181, DOI 10.1186/ar1808
   Yamasaki S, 2006, INT J MOL MED, V18, P113
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yamazaki H, 2009, J IMMUNOL, V183, P1480, DOI 10.4049/jimmunol.0900017
   Yip KHM, 2005, J BONE MINER RES, V20, P1462, DOI 10.1359/JBMR.050324
   Yoshida H, 2007, FEBS J, V274, P630, DOI 10.1111/j.1742 4658.2007.05639.x
NR 36
TC 23
Z9 28
U1 1
U2 15
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 1297 319X
EI 1778 7254
J9 JOINT BONE SPINE
JI Joint Bone Spine
PD DEC
PY 2014
VL 81
IS 6
BP 520
EP 526
DI 10.1016/j.jbspin.2014.04.012
PG 7
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA AW7BF
UT WOS:000346418700010
PM 24956991
DA 2025 08 17
ER

PT J
AU Wu, CM
   Chen, PC
   Li, TM
   Fong, YC
   Tang, CH
AF Wu, Chi Ming
   Chen, Po Chun
   Li, Te Mao
   Fong, Yi Chin
   Tang, Chih Hsin
TI Si Wu tang extract stimulates bone formation through PI3K/Akt/NF κB
   signaling pathways in osteoblasts
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE SWT; Osteoblasts; Bone formation; Traditional Chinese medicine
ID MORPHOGENETIC PROTEIN 2 EXPRESSION; KAPPA B; TGF BETA; DIFFERENTIATION;
   ACTIVATION; MARROW; KINASE; P38; AKT; JUN
AB Background: Si Wu Tang (SWT), a Traditional Chinese Medicine (TCM) formula, is widely used for the treatment of gynopathies diseases such as menstrual discomfort, climacteric syndrome, dysmenorrhea, and other estrogen related diseases. Recent studies have shown that SWT can treat primary dysmenorrhea, have anti pruritic anti inflammatory effects, and protect against radiation induced bone marrow damage in an animal model. It has been reported that anti inflammatory and anti oxidant agents have the potential to treat osteoporosis by increasing bone formation and/or suppressing bone resorption. However, the effect of SWT on bone cell function has not yet been reported.
   Methods: Alkaline phosphatase (ALP), bone morphogenetic proteins (BMP) 2, and osteopontin (OPN) mRNA expression was analyzed by qPCR. The mechanism of action of SWT extract was investigated using western blotting. The in vivo anti osteoporotic effect of SWT extract was assessed in ovariectomized mice.
   Results: Here, we report that SWT increases ALP, BMP 2, and OPN expression as well as bone mineralization. In addition, we show that the PI3K, Akt, and NF kappa B signaling pathways may be involved in the SWT mediated increase in gene expression and bone mineralization. Notably, treatment of mice with SWT extract prevented bone loss induced by ovariectomy in vivo.
   Conclusion: SWT may be used to stimulate bone formation for the treatment of osteoporosis.
C1 [Wu, Chi Ming; Li, Te Mao; Fong, Yi Chin] China Med Univ, Sch Chinese Med, Taichung, Taiwan.
   [Chen, Po Chun] Natl Chung Hsing Univ, Dept Life Sci, Taichung 40227, Taiwan.
   [Fong, Yi Chin] China Med Univ Hosp, Dept Orthopaed, Taichung, Taiwan.
   [Tang, Chih Hsin] China Med Univ, Grad Inst Basic Med Sci, Taichung, Taiwan.
   [Tang, Chih Hsin] China Med Univ, Sch Med, Dept Pharmacol, Taichung, Taiwan.
   [Tang, Chih Hsin] Asia Univ, Dept Biotechnol, Coll Hlth Sci, Taichung, Taiwan.
C3 China Medical University Taiwan; National Chung Hsing University; China
   Medical University Taiwan; China Medical University Hospital   Taiwan;
   China Medical University Taiwan; China Medical University Taiwan; Asia
   University Taiwan
RP Tang, CH (通讯作者)，China Med Univ, Grad Inst Basic Med Sci, 91 Hsueh Shih Rd, Taichung, Taiwan.
EM chtang@mail.cmu.edu.tw
RI Yen, Ching/A 2771 2013; Chen, PoChun/KIG 7338 2024; Tang,
   Chih/O 5212 2015
FU National Science Council of Taiwan [NSC99 2320 B 039 003 MY3,
   100 2320 B 039 028 MY3]
FX This study was supported by grant from the National Science Council of
   Taiwan (NSC99 2320 B 039 003 MY3; 100 2320 B 039 028 MY3).
CR Alles N, 2010, ENDOCRINOLOGY, V151, P4626, DOI 10.1210/en.2010 0399
   Berg C, 2003, NAT REV DRUG DISCOV, V2, P257, DOI 10.1038/nrd1068
   Boyce BF, 2010, ANN NY ACAD SCI, V1192, P367, DOI 10.1111/j.1749 6632.2009.05315.x
   Canalis E, 2009, J CELL BIOCHEM, V108, P769, DOI 10.1002/jcb.22322
   Chang PJ, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/790474
   Dai Y, 2002, BIOL PHARM BULL, V25, P1175, DOI 10.1248/bpb.25.1175
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Goltzman D, 2002, NAT REV DRUG DISCOV, V1, P784, DOI 10.1038/nrd916
   Gupta SC, 2010, BBA GENE REGUL MECH, V1799, P775, DOI 10.1016/j.bbagrm.2010.05.004
   Hong CC, 2009, CYTOKINE GROWTH F R, V20, P409, DOI 10.1016/j.cytogfr.2009.10.021
   Hsu HY, 1996, J ETHNOPHARMACOL, V52, P113, DOI 10.1016/0378 8741(96)01400 6
   Huang CY, 2012, ARTHRITIS RHEUM US, V64, P3344, DOI 10.1002/art.34557
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Kapur S, 2004, BONE, V35, P525, DOI 10.1016/j.bone.2004.04.007
   Kim JL, 2012, J CELL BIOCHEM, V113, P247, DOI 10.1002/jcb.23351
   Lane NE, 2003, ARTHRITIS RES THER, V5, P214, DOI 10.1186/ar797
   Lee SE, 1999, AM J CHINESE MED, V27, P387, DOI 10.1142/S0192415X99000446
   Li TM, 2012, J PHARM PHARMACOL, V64, P897, DOI 10.1111/j.2042 7158.2012.01483.x
   Liu JF, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3815
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Nazrun AS, 2012, ADV PHARMACOL SCI, V2012, DOI 10.1155/2012/142702
   Pagani F, 2005, J Endocrinol Invest, V28, P8
   Qureshi HY, 2007, CELL SIGNAL, V19, P1643, DOI 10.1016/j.cellsig.2007.02.007
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rider CC, 2010, BIOCHEM J, V429, P1, DOI 10.1042/BJ20100305
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Ruland J, 2011, NAT IMMUNOL, V12, P709, DOI 10.1038/ni.2055
   Sharif PS, 2011, RHEUMATOL INT, V31, P289, DOI 10.1007/s00296 010 1586 z
   Styrkarsdottir U, 2003, PLOS BIOL, V1, P351, DOI 10.1371/journal.pbio.0000069
   Suzuki A, 1999, ENDOCRINOLOGY, V140, P3177, DOI 10.1210/en.140.7.3177
   Tang CH, 2008, EUR J PHARMACOL, V579, P40, DOI 10.1016/j.ejphar.2007.10.013
   Tang CH, 2007, J BIOL CHEM, V282, P2346, DOI 10.1074/jbc.M603070200
   Tang CH, 2006, MOL PHARMACOL, V69, P2047, DOI 10.1124/mol.105.022160
   Tang CH, 2010, ARTHRITIS RHEUM US, V62, P3615, DOI 10.1002/art.27755
   Thatcher JD, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3119tr4
   Wu JB, 2008, EUR J PHARMACOL, V588, P333, DOI 10.1016/j.ejphar.2008.04.030
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Zhang Y, 2007, PLANTA MED, V73, P341, DOI 10.1055/s 2007 967168
NR 38
TC 31
Z9 38
U1 2
U2 34
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1472 6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD OCT 24
PY 2013
VL 13
AR 277
DI 10.1186/1472 6882 13 277
PG 9
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA 271BF
UT WOS:000328364500001
PM 24156308
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhou, J
   Liu, HX
   Li, SH
   Gong, YS
   Zhou, MW
   Zhang, JH
   Zhu, GY
AF Zhou, J.
   Liu, H X
   Li, S H
   Gong, Y S
   Zhou, M W
   Zhang, J H
   Zhu, G Y
TI Effects of human umbilical cord mesenchymal stem cells derived exosomes
   on fracture healing in rats through the Wnt signaling pathway
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Human umbilical cord mesenchymal stem cells; Exosomes; Wnt signaling
   pathway; Fracture
ID EXTRACELLULAR VESICLES; REGENERATIVE MEDICINE; BONE; DIFFERENTIATION
AB OBJECTIVE: To investigate the role of human umbilical cord mesenchymal stem cell (hucMSC) derived exosomes in the Wnt signaling pathway and their effects on fracture healing in rats.
   MATERIALS AND METHODS: A total of 24 healthy male Sprague Dawley (SD) rats were randomly divided into 3 groups, of which the experimental groups were injected with Phosphate Buffered Saline (PBS) and hUCMSC derived exosomes, respectively, at the fracture site, and a blank control group was set. At 2 and 3 w after treatment, respectively, the healing condition at the fracture site in the rats was detected by micro computed tomography (CT). The protein expressions of beta catenin and Wnt3a of the Wnt signaling pathway in the bone tissue were measured via Western blotting (WB) assay. Quantitative Real Time fluorescence Polymerase Chain Reaction (qRT PCR) was performed to determine the expressions of osteogenic marker genes [collagen type I (COL 1), osteopontin (OPN) and runt related transcription factor 2 (RUNX2)].
   RESULTS: The results of the micro CT scan showed that the rats treated with exosomes had better apposition of the fracture site, and the appearance of cortical bone was continuous. The fracture sites in the blank control group and PBS injection group were not healed, and the appearance of cortical bone was discontinuous, with significant fracture lines. According to the WB results, the protein expression levels of beta catenin and Wnt3a in exosome treatment group were significantly higher than those in the blank control group and PBS injection group (p<0.01). The qRT PCR results indicated that the expression levels of COL 1, OPN and RUNX2 in exosome treatment group were increased evidently compared with those in the other two groups (p<0.01).
   CONCLUSIONS: HucMSC derived exosomes are probably involved in the repair of fracture in rats through the Wnt signaling pathway.
C1 [Zhou, J.; Liu, H X] Gansu Hosp Tradit Chinese Med, Dept Osteomyelitis, Lanzhou, Gansu, Peoples R China.
   [Li, S H] Gansu Hosp Tradit Chinese Med, Lanzhou, Gansu, Peoples R China.
   [Gong, Y S] Gansu Hosp Tradit Chinese Med, Dept Soft Tissue Injury, Lanzhou, Gansu, Peoples R China.
   [Zhou, M W] Gansu Hosp Tradit Chinese Med, Dept Orthoped, Lanzhou, Gansu, Peoples R China.
   [Zhang, J H; Zhu, G Y] Gansu Hosp Tradit Chinese Med, Dept Oncol, Lanzhou, Gansu, Peoples R China.
RP Zhu, GY (通讯作者)，Gansu Hosp Tradit Chinese Med, Dept Oncol, Lanzhou, Gansu, Peoples R China.
EM 375146748@qq.com
CR Beit Yannai E, 2018, J CELL MOL MED, V22, P2001, DOI 10.1111/jcmm.13479
   Bjorge IM, 2017, BIOMATER SCI UK, V6, P60, DOI 10.1039/c7bm00479f
   Borrelli DA, 2018, J CONTROL RELEASE, V273, P86, DOI 10.1016/j.jconrel.2018.01.022
   CHEN JK, 1993, MATRIX, V13, P113, DOI 10.1016/S0934 8832(11)80070 3
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Chen Y, 2009, J CELL BIOCHEM, V106, P353, DOI 10.1002/jcb.22020
   Church VL, 2002, INT J DEV BIOL, V46, P927
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   EL Andaloussi S, 2013, NAT REV DRUG DISCOV, V12, P348, DOI 10.1038/nrd3978
   Fischer L, 2002, J CELL BIOCHEM, V84, P816, DOI 10.1002/jcb.10091
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Hessvik NP, 2018, CELL MOL LIFE SCI, V75, P193, DOI 10.1007/s00018 017 2595 9
   Khan M, 2015, CIRC RES, V117, P52, DOI 10.1161/CIRCRESAHA.117.305990
   Leucht P, 2008, SEMIN CELL DEV BIOL, V19, P434, DOI 10.1016/j.semcdb.2008.09.002
   Lin KC, 2016, INT J CARDIOL, V216, P173, DOI 10.1016/j.ijcard.2016.04.061
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007
   Wehrle E, 2015, DIS MODEL MECH, V8, P93, DOI 10.1242/dmm.018622
   Wei JW, 2015, CELL, V161, P1576, DOI 10.1016/j.cell.2015.05.029
   Yin PB, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00336
   Zhang N, 2018, EUR REV MED PHARMACO, V22, P29, DOI 10.26355/eurrev_201807_15356
   Zhang X, 2013, CHINESE MED J PEKING, V126, P4758, DOI 10.3760/cma.j.issn.0366 6999.20120741
   Zhang Y, 2018, CELL PROLIFERAT, V52
   Zhou L, 2002, BIOTECHNIQUES, V33, P1126, DOI 10.2144/02335dd07
   Zhou Y, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt194
   Zuo R, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 018 1121 9
NR 27
TC 42
Z9 44
U1 2
U2 42
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186 00165, ITALY
SN 1128 3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD JUN
PY 2019
VL 23
IS 11
BP 4954
EP 4960
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA IE1WW
UT WOS:000472177500054
PM 31210331
DA 2025 08 17
ER

PT J
AU Huang, YP
   Liao, JG
   Vlashi, R
   Chen, GQ
AF Huang, Yuping
   Liao, Junguang
   Vlashi, Rexhina
   Chen, Guiqian
TI Focal adhesion kinase (FAK): its structure, characteristics, and
   signaling in skeletal system
SO CELLULAR SIGNALLING
LA English
DT Article
DE FAK; Mesenchymal stem cell; Osteoblast differentiation; Osteoarthritis;
   Osteosarcoma
ID INTENSITY PULSED ULTRASOUND; MESENCHYMAL STEM CELLS; ENHANCE OSTEOGENIC
   DIFFERENTIATION; HUMAN CHONDROSARCOMA CELLS; GTPASE ACTIVATING PROTEIN;
   GROWTH FACTOR; IN VITRO; ALPHA V BETA 3 INTEGRIN; TERMINAL DOMAIN;
   MIGRATION
AB Focal adhesion kinase (FAK) is a non receptor tyrosine kinase and distributes important regulatory functions in skeletal system. Mesenchymal stem cell (MSC) possesses significant migration and differentiation capacity, is an important source of distinctive bone cells production and a prominent bone development pathway. MSC has a wide range of applications in tissue bioengineering and regenerative medicine, and is frequently employed for hematopoietic support, immunological regulation, and defect repair, although current research is insufficient. FAK has been identified to cross link with many other keys signaling pathways in bone biology and is considered as a fundamental "crossroad" on the signal transduction pathway and a "node" in the signal network to mediate MSC lineage development in skeletal system. In this review, we summarized the structure, characteristics, cellular signaling, and the interactions of FAK with other signaling pathways in the skeletal system. The discovery of FAK and its mediated molecules will lead to a new knowledge of bone development and bone construction as well as considerable potential for therapeutic use in the treatment of bone related disorders such as osteoporosis, osteoarthritis, and osteosarcoma.
C1 [Huang, Yuping; Liao, Junguang; Vlashi, Rexhina; Chen, Guiqian] Zhejiang Sci Tech Univ, Coll Life Sci & Med, Zhejiang Prov Key Lab Silkworm Bioreactor & Biomed, Hangzhou 310018, Peoples R China.
   [Chen, Guiqian] Zhejiang Sci Tech Univ, Coll Life Sci & Med, Hangzhou 310018, Peoples R China.
C3 Zhejiang Sci Tech University; Zhejiang Sci Tech University
RP Chen, GQ (通讯作者)，Zhejiang Sci Tech Univ, Coll Life Sci & Med, Hangzhou 310018, Peoples R China.
EM gqchen@zstu.edu.cn
OI CHEN, GUIQIAN/0000 0001 6452 440X; Vlashi, Rexhina/0009 0001 4043 8790
FU Zhejiang Provincial Natural Science Foundation of China [LZ23H140001];
   Zhejiang Qianjiang Talent Program [21040040 E]; Zhejiang Sci Tech
   University [18042290 Y]; Fundamental Research Funds of Zhe jiang
   Sci Tech University [2021Q031]; National Natural Science Foundation of
   China [81900806, 81400489]; Jiaxing Science Technology Foundation
   [2020AY10001]
FX This work was supported by grants by Zhejiang Provincial Natural Science
   Foundation of China (LZ23H140001) , Zhejiang Qianjiang Talent Program
   (21040040 E) , a startup grant from Zhejiang Sci Tech University
   (18042290 Y) , the Fundamental Research Funds of Zhe jiang Sci Tech
   University (2021Q031) , funds from National Natural Science Foundation
   of China (81900806, 81400489) , Jiaxing Science Technology Foundation
   (2020AY10001) . We apologize to the many researchers whose work could
   not be cited due to space limitations.
CR Ali D, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171252
   Amano M, 2010, CYTOSKELETON, V67, P545, DOI 10.1002/cm.20472
   Arold ST, 2002, STRUCTURE, V10, P319, DOI 10.1016/S0969 2126(02)00717 7
   Bang OS, 2000, BIOCHEM BIOPH RES CO, V278, P522, DOI 10.1006/bbrc.2000.3831
   Bleyer A, 2008, NAT REV CANCER, V8, P288, DOI 10.1038/nrc2349
   Bosch Rué E, 2023, ACTA BIOMATER, V166, P14, DOI 10.1016/j.actbio.2023.06.001
   de Gusmao CVB, 2010, CLIN ORTHOP RELAT R, V468, P1149, DOI 10.1007/s11999 009 1146 6
   Cai XM, 2008, MOL CELL BIOL, V28, P201, DOI 10.1128/MCB.01324 07
   Cance WG, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.120pe22
   Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211
   Chandran SV, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 48429 1
   Chatzizacharias NA, 2010, HISTOL HISTOPATHOL, V25, P1039, DOI 10.14670/HH 25.1039
   Chen HJ, 2022, MOL NUTR FOOD RES, V66, DOI 10.1002/mnfr.202101088
   Chen JL, 2019, ARTIF CELL NANOMED B, V47, P3603, DOI 10.1080/21691401.2019.1657878
   Chen SY, 2006, MOL CELL BIOL, V26, P5155, DOI 10.1128/MCB.02186 05
   Chen X, 2023, GENES DIS, V10, P254, DOI 10.1016/j.gendis.2021.12.016
   Cheng K, 2014, ULTRASOUND MED BIOL, V40, P1609, DOI 10.1016/j.ultrasmedbio.2014.03.002
   Cheng SW, 2023, CHIN MED UK, V18, DOI 10.1186/s13020 023 00740 w
   Choi CH, 2013, J CELL BIOL, V202, P849, DOI 10.1083/jcb.201302131
   Crompton BD, 2013, CANCER RES, V73, P2873, DOI 10.1158/0008 5472.CAN 12 1944
   Cui Z, 2016, ANN RHEUM DIS, V75, P1714, DOI 10.1136/annrheumdis 2015 207923
   Deramaudt TB, 2011, MOL BIOL CELL, V22, P964, DOI 10.1091/mbc.E10 08 0725
   Dong W, 2022, BONE, V154, DOI 10.1016/j.bone.2021.116231
   Downey PA, 2006, PHYS THER, V86, P77, DOI 10.1093/ptj/86.1.77
   Elefteriou F, 2008, ARCH BIOCHEM BIOPHYS, V473, P231, DOI 10.1016/j.abb.2008.03.016
   Elefteriou F, 2011, BONE, V49, P1242, DOI 10.1016/j.bone.2011.08.021
   Fagard Remi, 2013, JAKSTAT, V2, pe22882, DOI 10.4161/jkst.22882
   Fan C., 2022, Int. J. Mol. Sci., V23
   Fang XQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107134
   Feng ST, 2015, ONCOL LETT, V9, P2670, DOI 10.3892/ol.2015.3131
   Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528
   Frame MC, 2010, NAT REV MOL CELL BIO, V11, P802, DOI 10.1038/nrm2996
   Garces CA, 2006, CANCER RES, V66, P1446, DOI 10.1158/0008 5472.CAN 05 1661
   Geletu Mulu, 2022, Exp Cell Res, V411, P112731, DOI 10.1016/j.yexcr.2021.112731
   Golubovskaya VM, 2011, ANTI CANCER AGENT ME, V11, P617
   Golubovskaya VM, 2005, J BIOL CHEM, V280, P25008, DOI 10.1074/jbc.M414172200
   Goñi GM, 2014, P NATL ACAD SCI USA, V111, pE3177, DOI 10.1073/pnas.1317022111
   Gu HJ, 2018, ONCOL LETT, V15, P6225, DOI 10.3892/ol.2018.8152
   Gunn SA, 2022, J BONE ONCOL, V34, DOI 10.1016/j.jbo.2022.100432
   Hall JE, 2011, INT REV CEL MOL BIO, V288, P185, DOI 10.1016/B978 0 12 386041 5.00005 4
   Hanks SK, 2003, FRONT BIOSCI LANDMRK, V8, pD982, DOI 10.2741/1114
   Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169
   Horikiri Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076785
   Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234
   Hsieh YH, 2021, PHARMACEUTICALS BASE, V14, DOI 10.3390/ph14030260
   Hu CZ, 2017, ONCOTARGET, V8, P75881, DOI 10.18632/oncotarget.17427
   Hu CZ, 2017, CANCER SCI, V108, P1347, DOI 10.1111/cas.13256
   Hu P, 2019, J DENT SCI, V14, P225, DOI 10.1016/j.jds.2019.03.001
   Hu SJ, 2023, DEV BIOL, V501, P81, DOI 10.1016/j.ydbio.2023.06.015
   Hu XY, 2011, AM J PHYSIOL CELL PH, V301, pC362, DOI 10.1152/ajpcell.00013.2010
   Hu YL, 2014, SCI REP UK, V4, DOI 10.1038/srep06024
   Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092 8674(02)00971 6
   Hyväri L, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/2190657
   Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0
   Jang KW, 2014, ULTRASOUND MED BIOL, V40, P1177, DOI 10.1016/j.ultrasmedbio.2013.12.007
   Jiang NN, 2020, MOL BIOL REP, V47, P4587, DOI 10.1007/s11033 020 05435 1
   Jin EJ, 2007, DEV BIOL, V308, P474, DOI 10.1016/j.ydbio.2007.06.003
   Kim JB, 2007, BONE, V41, P39, DOI 10.1016/j.bone.2007.01.024
   Korstjens CM, 2008, MED BIOL ENG COMPUT, V46, P1263, DOI 10.1007/s11517 008 0409 9
   Lawson C, 2012, J CELL BIOL, V196, P223, DOI 10.1083/jcb.201108078
   Lee JS, 2013, BIOCHEM BIOPH RES CO, V435, P696, DOI 10.1016/j.bbrc.2013.05.045
   Lee JW, 2003, J ORTHOP RES, V21, P1071, DOI 10.1016/S0736 0266(03)00101 3
   Lee SJ, 2022, CELL ADHES MIGR, V16, P72, DOI 10.1080/19336918.2022.2073002
   Legerstee K, 2021, BIOLOGY BASEL, V10, DOI 10.3390/biology10111189
   Li JF, 2021, J MATER CHEM B, V9, P7848, DOI 10.1039/d1tb01479j
   Li JJ, 2007, BIOCHEM BIOPH RES CO, V357, P648, DOI 10.1016/j.bbrc.2007.03.184
   Li Y, 2021, BIOMATERIALS, V275, DOI 10.1016/j.biomaterials.2021.120984
   Liang WW, 2013, CELL PHYSIOL BIOCHEM, V32, P915, DOI 10.1159/000354495
   Liao JG, 2022, CELL MOL LIFE SCI, V79, DOI 10.1007/s00018 022 04208 2
   Liao XL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072233
   Liao XL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042709
   Lietha D, 2007, CELL, V129, P1177, DOI 10.1016/j.cell.2007.05.041
   Lim ST, 2008, MOL CELL, V29, P9, DOI 10.1016/j.molcel.2007.11.031
   Lim Y, 2008, J CELL BIOL, V180, P187, DOI 10.1083/jcb.200708194
   Liu YH, 2002, MOL BIOL CELL, V13, P2147, DOI 10.1091/mbc.E02 01 0018
   Lohberger B, 2019, CELL SIGNAL, V56, P23, DOI 10.1016/j.cellsig.2018.12.010
   Lopes HB, 2020, J APPL ORAL SCI, V28, DOI 10.1590/1678 7757 2019 0156
   Lu KH, 2016, FOOD CHEM TOXICOL, V97, P177, DOI 10.1016/j.fct.2016.09.006
   Lu SQ, 2023, BMC CANCER, V23, DOI 10.1186/s12885 023 10731 7
   Lu XM, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/8178643
   Lu Y, 2020, J MED CHEM, V63, P14382, DOI 10.1021/acs.jmedchem.0c01248
   Ma XY, 2017, BIOMATER SCI UK, V6, P225, DOI 10.1039/c7bm00652g
   Mai W, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20193514
   Majidinia M, 2018, J CELL PHYSIOL, V233, P2937, DOI 10.1002/jcp.26042
   Martínez PT, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10020179
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   Mei P, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01361 5
   Mendoza Naranjo A, 2013, EMBO MOL MED, V5, P1087, DOI 10.1002/emmm.201202343
   Merino Casallo F, 2022, CELL ADHES MIGR, V16, P25, DOI 10.1080/19336918.2022.2055520
   Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549
   Moritake H, 2019, CANCER MED US, V8, P7809, DOI 10.1002/cam4.2647
   Murshed M, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031229
   Niu HY, 2017, ACS BIOMATER SCI ENG, V3, P3161, DOI 10.1021/acsbiomaterials.7b00315
   Ossovskaya V, 2008, FEBS LETT, V582, P2402, DOI 10.1016/j.febslet.2008.06.004
   Pala D, 2008, J BIOL CHEM, V283, P9239, DOI 10.1074/jbc.M705175200
   Panetti TS, 2002, FRONT BIOSCI LANDMRK, V7, pD143, DOI 10.2741/panetti
   Pang XJ, 2021, MOLECULES, V26, DOI 10.3390/molecules26144250
   Park GB, 2015, INT J ONCOL, V46, P185, DOI 10.3892/ijo.2014.2721
   Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877
   Peng X, 2011, CURR PROTEIN PEPT SC, V12, P52, DOI 10.2174/138920311795659452
   Petridou NI, 2013, DEVELOPMENT, V140, P4266, DOI 10.1242/dev.096073
   POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678
   Pomella S, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23041998
   Qi SQ, 2020, J BONE MINER RES, V35, P1798, DOI 10.1002/jbmr.4029
   Qu FN, 2019, NAT REV RHEUMATOL, V15, P167, DOI 10.1038/s41584 018 0151 0
   Rajshankar D, 2017, FASEB J, V31, P937, DOI 10.1096/fj.201600645R
   Reed DA, 2021, J ORAL MAXIL SURG, V79, DOI 10.1016/j.joms.2021.05.001
   Ren K, 2015, ONCOTARGET, V6, P31085, DOI 10.18632/oncotarget.5044
   Ritt M, 2013, J BIOL CHEM, V288, P8875, DOI 10.1074/jbc.M112.421164
   Sacitharan Pradeep Kumar, 2019, Subcell Biochem, V91, P123, DOI 10.1007/978 981 13 3681 2_6
   Salasznyk RM, 2007, J CELL BIOCHEM, V100, P499, DOI 10.1002/jcb.21074
   Salasznyk RM, 2007, EXP CELL RES, V313, P22, DOI 10.1016/j.yexcr.2006.09.013
   Sang F, 2021, CARTILAGE, V13, p196S, DOI 10.1177/1947603520912322
   SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192
   SCHLAEPFER DD, 1994, NATURE, V372, P786
   Schreiber C, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008216
   Serrels B, 2012, J CELL BIOL, V196, P185, DOI 10.1083/jcb.201112128
   Shao SJ, 2022, CANCER CELL INT, V22, DOI 10.1186/s12935 022 02591 1
   Shao SJ, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.774988
   Shin H, 2016, J CELL PHYSIOL, V231, P1822, DOI 10.1002/jcp.25290
   Short B, 2003, ARCH MED RES, V34, P565, DOI 10.1016/j.arcmed.2003.09.007
   Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517
   Sims NA, 2008, SEMIN CELL DEV BIOL, V19, P444, DOI 10.1016/j.semcdb.2008.07.016
   Soltanoff CS, 2009, CRIT REV EUKAR GENE, V19, P1, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.10
   Song B, 2007, DEV BIOL, V305, P202, DOI 10.1016/j.ydbio.2007.02.003
   Song J, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12453
   Steinestel K, 2020, MOL ONCOL, V14, P248, DOI 10.1002/1878 0261.12610
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Sun CH, 2016, J BONE MINER RES, V31, P2227, DOI 10.1002/jbmr.2908
   Sun XW, 2021, J BIOMED NANOTECHNOL, V17, P1058, DOI 10.1166/jbn.2021.3090
   Sun XW, 2020, J CELL PHYSIOL, V235, P4954, DOI 10.1002/jcp.29374
   Tan TW, 2009, J CELL BIOCHEM, V107, P345, DOI 10.1002/jcb.22132
   Tan TW, 2009, CARCINOGENESIS, V30, P258, DOI 10.1093/carcin/bgn284
   Urciuoli E, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249426
   Vlashi R, 2023, GENES DIS, V10, P1291, DOI 10.1016/j.gendis.2022.07.011
   Wang CQ, 2017, CANCER LETT, V385, P261, DOI 10.1016/j.canlet.2016.10.010
   Wang JL, 2014, TUMOR BIOL, V35, P1551, DOI 10.1007/s13277 013 1214 0
   Wang RX, 2020, BIOMATER SCI UK, V8, P4426, DOI 10.1039/d0bm00898b
   Wang S, 2019, CLIN CANCER RES, V25, P4552, DOI 10.1158/1078 0432.CCR 17 0375
   Ward Donald F. Jr., 2007, Molecular & Cellular Biomechanics, V4, P177
   Wen XZ, 2016, MOL MED REP, V13, P2885, DOI 10.3892/mmr.2016.4857
   Wu HT, 2020, J CELL PHYSIOL, V235, P8653, DOI 10.1002/jcp.29709
   Wu MH, 2012, J CELL PHYSIOL, V227, P3016, DOI 10.1002/jcp.23043
   Xia BJ, 2014, CALCIFIED TISSUE INT, V95, P495, DOI 10.1007/s00223 014 9917 9
   Xia P, 2015, J ULTRAS MED, V34, P1991, DOI 10.7863/ultra.14.10016
   Xie H, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030574
   Xu BY, 2014, J BIOSCI BIOENG, V117, P624, DOI 10.1016/j.jbiosc.2013.10.018
   Yang M, 2014, INT J CLIN EXP PATHO, V7, P7451
   Yang S, 2014, CELL BIOCHEM BIOPHYS, V70, P765, DOI 10.1007/s12013 014 9979 3
   Yanoshita M, 2020, ORAL DIS, V26, P1736, DOI 10.1111/odi.13494
   Yanoshita M, 2018, INFLAMMATION, V41, P1621, DOI 10.1007/s10753 018 0805 8
   Young SRL, 2009, J BONE MINER RES, V24, P411, DOI 10.1359/JBMR.081102
   Yun SP, 2011, J CELL PHYSIOL, V226, P683, DOI 10.1002/jcp.22383
   Zhai JB, 2003, J BIOL CHEM, V278, P24865, DOI 10.1074/jbc.M302381200
   Zhang CX, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 96348 x
   Zhang W, 2002, CELL RES, V12, P9, DOI 10.1038/sj.cr.7290105
   Zhang XR, 2019, J MATER CHEM B, V7, P2518, DOI 10.1039/c8tb02850h
   Zhang YC, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0883 4
   Zhao X, 2011, ADV DRUG DELIVER REV, V63, P610, DOI 10.1016/j.addr.2010.11.001
   Zheng WW, 2019, ARTIF CELL NANOMED B, V47, P2641, DOI 10.1080/21691401.2019.1631838
   Zou CY, 2013, CELL BIOCHEM BIOPHYS, V65, P455, DOI 10.1007/s12013 012 9449 8
NR 162
TC 26
Z9 26
U1 3
U2 30
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0898 6568
EI 1873 3913
J9 CELL SIGNAL
JI Cell. Signal.
PD NOV
PY 2023
VL 111
AR 110852
DI 10.1016/j.cellsig.2023.110852
EA AUG 2023
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA W6WB9
UT WOS:001093001300001
PM 37586468
DA 2025 08 17
ER

PT J
AU Henrotin, Y
   Pesesse, L
   Sanchez, C
AF Henrotin, Y.
   Pesesse, L.
   Sanchez, C.
TI Subchondral bone and osteoarthritis: biological and cellular aspects
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Cartilage; Cytokines; Osteoarthritis; Subchondral bone
ID PROSTAGLANDIN E 2; MARROW LESIONS; GROWTH FACTOR; GENE EXPRESSION;
   CARTILAGE LOSS; OSTEOBLASTS; INTERLEUKIN 6; METABOLISM; CELLS;
   INSULIN LIKE GROWTH FACTOR 1
AB The subchondral bone is involved in the patho physiology of osteoarthritis (OA), both by biochemical and mechanical pathways. Overloaded OA subchondral bone osteoblasts express a pro angiogenic and pro inflammatory phenotype which contributes to explain the structural changes (sclerosis and bone marrow lesion) visible in OA subchondral bone. Further, microfractures and conjonctivo vascular structures constitute exchange routes between bone and the overlying cartilage for mediators produced by osteoblasts. This narrative review describes these physiopathological mechanisms and identifies possible therapeutic targets for pharmacological modalities.
C1 [Henrotin, Y.; Pesesse, L.; Sanchez, C.] Univ Liege, Bone & Cartilage Res Unit, B 4000 Liege, Belgium.
   [Henrotin, Y.] Univ Liege, CHU Sart Tilman, Inst Pathol, B 4000 Liege, Belgium.
C3 University of Liege; University of Liege
RP Henrotin, Y (通讯作者)，Univ Liege, CHU Sart Tilman, Inst Pathol, Level 5, B 4000 Liege, Belgium.
EM yhenrotin@ulg.ac.be
OI sanchez, christelle/0000 0002 1005 8172; Henrotin,
   Yves/0000 0003 1073 449X
CR Agnello KA, 2005, AM J VET RES, V66, P1487, DOI 10.2460/ajvr.2005.66.1487
   Bailey AJ, 2002, INT J BIOCHEM CELL B, V34, P176, DOI 10.1016/S1357 2725(01)00107 8
   Bennell KL, 2010, ANN RHEUM DIS, V69, P1151, DOI 10.1136/ard.2009.118182
   Chan BY, 2011, OSTEOARTHR CARTILAGE, V19, P874, DOI 10.1016/j.joca.2011.04.014
   Chiba K, 2012, OSTEOPOROSIS INT, V23, P589, DOI 10.1007/s00198 011 1585 2
   Cox LGE, 2011, OSTEOARTHR CARTILAGE, V19, P676, DOI 10.1016/j.joca.2011.02.007
   Davies Tuck ML, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2873
   DUNCAN H, 1987, J BONE JOINT SURG AM, V69A, P1212, DOI 10.2106/00004623 198769080 00015
   Gosset M, 2008, ARTHRITIS RHEUM US, V58, P1399, DOI 10.1002/art.23431
   Griffin TM, 2009, ARTHRITIS RHEUM US, V60, P2935, DOI 10.1002/art.24854
   Grimston SK, 2006, ANN NY ACAD SCI, V1068, P214, DOI 10.1196/annals.1346.023
   GRYNPAS MD, 1991, CALCIFIED TISSUE INT, V49, P20, DOI 10.1007/BF02555898
   Hilal G, 1998, ARTHRITIS RHEUM, V41, P891, DOI 10.1002/1529 0131(199805)41:5<891::AID ART17>3.0.CO;2 X
   Hilal G, 2001, J BONE MINER RES, V16, P713, DOI 10.1359/jbmr.2001.16.4.713
   Hilal G, 1999, ARTHRITIS RHEUM, V42, P2112, DOI 10.1002/1529 0131(199910)42:10<2112::AID ANR11>3.0.CO;2 N
   Hopwood B, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2301
   Hunter DJ, 2006, ARTHRITIS RHEUM US, V54, P1529, DOI 10.1002/art.21789
   Imhof H, 2000, INVEST RADIOL, V35, P581, DOI 10.1097/00004424 200010000 00004
   Kadri A, 2010, ANN RHEUM DIS, V69, P1533, DOI 10.1136/ard.2009.124586
   Laslett LL, 2012, ANN RHEUM DIS, V71, P1322, DOI 10.1136/annrheumdis 2011 200970
   Liu XH, 2005, ENDOCRINOLOGY, V146, P1991, DOI 10.1210/en.2004 1167
   Liu XH, 2006, ANN NY ACAD SCI, V1068, P225, DOI 10.1196/annals.1346.047
   Mansell JP, 1998, J CLIN INVEST, V101, P1596, DOI 10.1172/JCI867
   Massicotte F, 2006, BONE, V38, P333, DOI 10.1016/j.bone.2005.09.007
   Mutabaruka MS, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2925
   Pesesse L, 2011, JOINT BONE SPINE, V78, P144, DOI 10.1016/j.jbspin.2010.07.001
   Podworny NV, 1999, J RHEUMATOL, V26, P1972
   Lamas JR, 2010, ANN RHEUM DIS, V69, P1880, DOI 10.1136/ard.2009.122564
   Reginster JY, 2012, OSTEOPOROSIS INT, V23, pS58
   Sakao K, 2009, J BONE MINER METAB, V27, P412, DOI 10.1007/s00774 009 0058 6
   Sanchez C, 2005, OSTEOARTHR CARTILAGE, V13, P988, DOI 10.1016/j.joca.2005.07.012
   Sanchez C, 2005, OSTEOARTHR CARTILAGE, V13, P979, DOI 10.1016/j.joca.2005.03.008
   Sanchez C, 2009, OSTEOARTHR CARTILAGE, V17, P473, DOI 10.1016/j.joca.2008.09.007
   Sanchez C, 2008, ARTHRITIS RHEUM US, V58, P442, DOI 10.1002/art.23159
   Sanchez C, 2012, ARTHRITIS RHEUM US, V64, P1193, DOI 10.1002/art.33445
   Strassle BW, 2010, OSTEOARTHR CARTILAGE, V18, P1319, DOI 10.1016/j.joca.2010.06.007
   Tat SK, 2011, BONE, V49, P559, DOI 10.1016/j.bone.2011.06.005
   Walsh DA, 2010, RHEUMATOLOGY, V49, P1852, DOI 10.1093/rheumatology/keq188
   Westacott CI, 1997, ARTHRITIS RHEUM, V40, P1282, DOI 10.1002/1529 0131(199707)40:7<1282::AID ART13>3.0.CO;2 E
NR 39
TC 99
Z9 109
U1 3
U2 41
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD DEC
PY 2012
VL 23
SU 8
BP S847
EP S851
DI 10.1007/s00198 012 2162 z
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 248TD
UT WOS:000326725200002
PM 23179567
DA 2025 08 17
ER

PT J
AU Suh, KS
   Chon, S
   Jung, WW
   Choi, EM
AF Suh, Kwang Sik
   Chon, Suk
   Jung, Woon Won
   Choi, Eun Mi
TI Crocin attenuates methylglyoxal induced osteoclast dysfunction by
   regulating glyoxalase, oxidative stress, and mitochondrial function
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
DE Crocin; Methylglyoxal; Osteoclastogenesis; Signaling pathway
ID SATIVUS L.; ISCHEMIA REPERFUSION; SAFFRON EXTRACT; RAT MODEL; KAPPA B;
   BONE; DAMAGE; PHOSPHORYLATION; DIFFERENTIATION; CONSTITUENTS
AB Methylglyoxal (MG), a highly reactive dicarbonyl compound, is a major cell permeant precursor of advanced glycation end products, which are associated with several conditions, including diabetes and degenerative diseases. Crocin, a constituent of saffron, is involved in many pharmacological activities. Recent studies have reported that crocin exerts protective effects against bone diseases. Osteoclasts are multinucleated cells derived from hematopoietic stem cells that are responsible for bone resorption. The up  or down regulation of their proliferation and differentiation is often associated with many bone related diseases. The present study aimed to investigate the effects of crocin on osteoclast differentiation and to clarify its mechanism of action in the presence of MG. We demonstrated that crocin reversed MG induced inhibition of tartrate resistant acid phosphatase activity and bone resorption activity in osteoclasts. Quantitative reverse transcription polymerase chain reaction analysis indicated that crocin treatment decreased the expression of TNF receptor associated factor 6 (TRAF6), Akt2, extracellular signal regulated kinase 1 (ERK1), osteopetrosis associated transmembrane protein 1 (OSTM1), and matrix metalloproteinase 9 (MMP 9) genes in the presence of MG. Crocin pretreatment also reversed MG induced changes in mitochondrial mass, mitochondrial membrane potential, mitochondrial superoxide, and glyoxalase I levels. Taken together, our data suggest that crocin may be a useful therapeutic agent for the treatment of diabetic bone disorders.
C1 [Suh, Kwang Sik; Chon, Suk; Choi, Eun Mi] Kyung Hee Univ, Sch Med, Dept Endocrinol & Metab, 1 Hoegi Dong, Seoul 02447, South Korea.
   [Jung, Woon Won] Cheongju Univ, Dept Biomed Lab Sci, Coll Hlth Sci, Cheongju 28503, Chungbuk, South Korea.
C3 Kyung Hee University; Cheongju University
RP Choi, EM (通讯作者)，Kyung Hee Univ, Sch Med, Dept Endocrinol & Metab, 1 Hoegi Dong, Seoul 02447, South Korea.
EM cheunmi@hanmail.net
RI Chon, Suk/AAV 3102 2020
FU Basic Science Research Program of the National Research Foundation of
   Korea (NRF)   Ministry of Education [NRF 2016R1D1A1B03930082]
FX This research was supported by the Basic Science Research Program of the
   National Research Foundation of Korea (NRF), which is funded by the
   Ministry of Education (NRF 2016R1D1A1B03930082).
CR Agalou S, 2003, BIOCHEM SOC T, V31, P1394
   Alavizadeh SH, 2014, FOOD CHEM TOXICOL, V64, P65, DOI 10.1016/j.fct.2013.11.016
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bakhtiary Zahra, 2014, Vet Res Forum, V5, P213
   Balemans W, 2005, CALCIFIED TISSUE INT, V77, P263, DOI 10.1007/s00223 005 0027 6
   Bandegi AR, 2014, ADV PHARM BULL, V4, P493, DOI 10.5681/apb.2014.073
   Biswas G, 2005, GENE, V354, P132, DOI 10.1016/j.gene.2005.03.028
   Cao PC, 2014, EVID BASED COMPL ALT, V2014, DOI 10.1155/2014/825181
   Han Y, 2007, MOL CELL BIOCHEM, V305, P123, DOI 10.1007/s11010 007 9535 1
   Hassani FV, 2014, DARU, V22, DOI 10.1186/2008 2231 22 16
   Hemshekhar M, 2012, BIOCHIMIE, V94, P2723, DOI 10.1016/j.biochi.2012.08.013
   Hosseinzadeh H, 2008, PHYTOMEDICINE, V15, P491, DOI 10.1016/j.phymed.2007.09.020
   Hosseinzadeh H, 2005, J PHARM PHARM SCI, V8, P387
   Hosseinzadeh H, 2005, FITOTERAPIA, V76, P722, DOI 10.1016/j.fitote.2005.07.008
   Hosseinzadeh H, 2013, PHYTOTHER RES, V27, P475, DOI 10.1002/ptr.4784
   Hosseinzadeh H, 2009, EVID BASED COMPL ALT, V6, P343, DOI 10.1093/ecam/nem125
   Jalili C, 2015, INT J PREVENTIVE MED, V6, DOI 10.4103/2008 7802.165203
   Kawatani M, 2008, P NATL ACAD SCI USA, V105, P11691, DOI 10.1073/pnas.0712239105
   Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978
   Kurra S, 2011, DIABETES METAB RES, V27, P430, DOI 10.1002/dmrr.1197
   Kusano K, 1998, ENDOCRINOLOGY, V139, P1338, DOI 10.1210/en.139.3.1338
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Liang W, 2011, EUR J PHARMACOL, V670, P317, DOI 10.1016/j.ejphar.2011.08.014
   LIN JK, 1986, CARCINOGENESIS, V7, P595, DOI 10.1093/carcin/7.4.595
   Liu B, 2003, J ORAL PATHOL MED, V32, P367, DOI 10.1034/j.1600 0714.2003.00126.x
   Macdonald R, 2001, MOL BRAIN RES, V90, P48, DOI 10.1016/S0169 328X(01)00086 9
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Martin TJ, 2008, BEST PRACT RES CL EN, V22, P701, DOI 10.1016/j.beem.2008.07.006
   Mehri S, 2012, CELL MOL NEUROBIOL, V32, P227, DOI 10.1007/s10571 011 9752 8
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Miyazaki Tsuyoshi, 2013, Clin Calcium, V23, P1577, DOI CliCa131115771583
   Nakamura H, 2003, J BONE MINER RES, V18, P1198, DOI 10.1359/jbmr.2003.18.7.1198
   Prabu SK, 2006, J BIOL CHEM, V281, P2061, DOI 10.1074/jbc.M507741200
   Rashedinia M, 2015, ACTA NEUROBIOL EXP, V75, P208, DOI 10.55782/ane 2015 2029
   Rousselle AV, 2002, BONE, V30, P533, DOI 10.1016/S8756 3282(02)00672 5
   Schroeder P, 2007, FREE RADICAL BIO MED, V43, P128, DOI 10.1016/j.freeradbiomed.2007.04.002
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Segovia Silvestre T, 2009, HUM GENET, V124, P561, DOI 10.1007/s00439 008 0583 8
   Suh KS, 2018, CHEM BIOL INTERACT, V296, P18, DOI 10.1016/j.cbi.2018.09.005
   Thornalley PJ, 1998, CHEM BIOL INTERACT, V112, P137, DOI 10.1016/S0009 2797(97)00157 9
   Xu GL, 2009, J AGR FOOD CHEM, V57, P8325, DOI 10.1021/jf901752f
NR 41
TC 24
Z9 24
U1 1
U2 18
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278 6915
EI 1873 6351
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD FEB
PY 2019
VL 124
BP 367
EP 373
DI 10.1016/j.fct.2018.12.031
PG 7
WC Food Science & Technology; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology; Toxicology
GA HL4SC
UT WOS:000458712400030
PM 30580027
DA 2025 08 17
ER

PT J
AU Cheung, FY
AF Cheung, Foon Yiu
TI Revisiting the role of bone modifying agents in the management of
   metastatic prostate cancer
SO ASIA PACIFIC JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article; Proceedings Paper
CT 3rd Annual Scientific Meeting of the Hong Kong Society Uro Oncology
   (HKSUO)
CY JAN 20, 2018
CL HONG KONG
SP Hong Kong Soc Uro Oncol
DE bone metastasis; castration resistant prostate cancer; denosumab;
   metastatic prostate cancer; zoledronic acid
ID SKELETAL RELATED EVENTS; ZOLEDRONIC ACID; TARGETED AGENTS;
   COMPLICATIONS; SURVIVAL; PLACEBO; MEN; GUIDELINES; DENOSUMAB; PHASE 3
AB Bone metastases are a hallmark of advanced prostate cancer and may drive the morbidity and mortality of the disease in patients with a poor prognosis. The pathogenesis of bone metastasis involves the interaction between cancer cells, normal bone cells and the bone microenvironment. Targeting the bone microenvironment has become a promising therapy for patients with advanced prostate cancer and bone metastasis. This article reviews the use of the antiresorptive bone targeted agents zoledronic acid and denosumab in the management of skeletal related events (SREs) in patients with metastatic castration resistant prostate cancer (mCRPC) and bone metastasis. In real world clinical practice, these agents have been widely prescribed as a concomitant medication to novel mCRPC therapies, such as abiraterone, enzalutamide and radium 223. International guidelines have recommended zoledronic acid or denosumab for the prevention of SREs in patients with bone metastasis from mCRPC. Although there is currently no consensus regarding the optimal sequencing between the bone targeted agents and novel anti cancer therapies, future optimal treatments for patients with bone metastasis from prostate cancer may involve the combination of these agents.
C1 [Cheung, Foon Yiu] Hong Kong Integrated Oncol Ctr, 4 F Champ Tower,3 Garden Rd, Hong Kong, Hong Kong, Peoples R China.
RP Cheung, FY (通讯作者)，Hong Kong Integrated Oncol Ctr, 4 F Champ Tower,3 Garden Rd, Hong Kong, Hong Kong, Peoples R China.
EM cheungfy@gmail.com
FU Amgen Asia Holding Limited
FX Amgen Asia Holding Limited
CR [Anonymous], NCCN GUID PROST CANC
   Body JJ, 2016, EUR UROL SUPPL, V15, pe771
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Espinosa JC, 2012, CLIN TRANSL ONCOL, V14, P505, DOI 10.1007/s12094 012 0832 0
   Cookson MS, 2015, J UROLOGY, V193, P491, DOI 10.1016/j.juro.2014.10.104
   Fizazi K, 2014, LANCET ONCOL, V15, P1147, DOI 10.1016/S1470 2045(14)70303 1
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Guise T, 2010, SEMIN ONCOL, V37, pS2, DOI 10.1053/j.seminoncol.2010.10.007
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Ibrahim A, 2003, CLIN CANCER RES, V9, P2394
   Lewiecki EM, 2006, EXPERT OPIN BIOL TH, V6, P1041, DOI 10.1517/14712598.6.10.1041
   Logothetis CJ, 2012, LANCET ONCOL, V13, P1210, DOI 10.1016/S1470 2045(12)70473 4
   Morgans AK, 2012, UROL CLIN N AM, V39, P533, DOI 10.1016/j.ucl.2012.07.009
   Parker C, 2015, ANN ONCOL, V26, pV69, DOI 10.1093/annonc/mdv222
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Poon DM, 2017, BJU INT
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Saad F, 2015, CUAJ CAN UROL ASSOC, V9, P90, DOI 10.5489/cuaj.2526
   Smith MR, 2007, UROLOGY, V70, P315, DOI 10.1016/j.urology.2007.03.071
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Vignani F, 2016, CANCER TREAT REV, V44, P61, DOI 10.1016/j.ctrv.2016.02.002
   Wong KW, 2016, HONG KONG MED J, V22, P106, DOI 10.12809/hkmj144449
NR 23
TC 6
Z9 7
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1743 7555
EI 1743 7563
J9 ASIA PAC J CLIN ONCO
JI Asia Pac. J. Clin. Oncol.
PD NOV
PY 2018
VL 14
SU 5
SI SI
BP 13
EP 15
DI 10.1111/ajco.13061
PG 3
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Oncology
GA HC1PR
UT WOS:000451573600004
PM 30489032
OA Bronze
DA 2025 08 17
ER

PT J
AU Zhang, YY
   Chen, X
   Xiao, Y
   Mei, YB
   Yang, T
   Li, DC
   Wang, XH
   Yang, H
   Huang, DG
   Hao, DJ
AF Zhang, Yuyang
   Chen, Xue
   Xiao, Yuan
   Mei, Yibo
   Yang, Tong
   Li, Dongchen
   Wang, Xiaohui
   Yang, Hao
   Huang, Dageng
   Hao, Dingjun
TI Elucidating the role of RBM5 in osteoclastogenesis: a novel potential
   therapeutic target for osteoporosis
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE RBM5; Osteoporosis; BMD; Osteoclasts differentiation; NFATc1; RAW264.7
ID TUMOR SUPPRESSOR; FRACTURE; PACKAGE; CELLS; WOMEN; MEN
AB Osteoporosis is a prevalent bone disease with multigene involved, and the molecular mechanisms of its pathogenesis are not entirely understood. This study aims to identify novel key genes involved in osteoporosis to discover potential pharmacological targets. We analyzed three microarray datasets and identified four differentially expressed genes. The LASSO model indicated that RNA binding motif protein 5 (RBM5) is associated with osteoporosis and is a potential drug target. We conducted the Spearman correlation analysis and found 52 genes that were significantly related to RBM5. Enrichment analysis showed that these genes were primarily involved in RNA splicing and osteoclast differentiation pathways. By using lentivirus based shRNA, we successfully knocked down RBM5 expression in RAW264.7 cell line, which showed that RBM5 knockdown significantly impaired their differentiation potential to mature osteoclasts and significantly inhibited bone resorbing activity. RT qPCR analyses revealed the expression of osteoclastogenesis marker genes was downregulated along with RBM5 expression. These findings suggest that RBM5 plays a crucial role in the pathogenesis of osteoporosis and provides a new potential pharmacological target.
C1 [Zhang, Yuyang; Xiao, Yuan; Yang, Tong; Wang, Xiaohui; Huang, Dageng; Hao, Dingjun] Xi An Jiao Tong Univ, Hlth Sci Ctr, Xian 710061, Peoples R China.
   [Zhang, Yuyang; Xiao, Yuan; Yang, Tong; Li, Dongchen; Wang, Xiaohui; Yang, Hao] Xi An Jiao Tong Univ, Hong Hui Hosp, Xian 710054, Peoples R China.
   [Chen, Xue] China Natl Petr Corp, Cent Hosp, Chengdu 610051, Peoples R China.
   [Mei, Yibo] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Urol, Xian 710061, Peoples R China.
   [Huang, Dageng; Hao, Dingjun] Xi An Jiao Tong Univ, Hong Hui Hosp, Dept Spine Surg, Xian 710054, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University; China National
   Petroleum Corporation; Xi'an Jiaotong University; Xi'an Jiaotong
   University
RP Huang, DG; Hao, DJ (通讯作者)，Xi An Jiao Tong Univ, Hlth Sci Ctr, Xian 710061, Peoples R China.; Huang, DG; Hao, DJ (通讯作者)，Xi An Jiao Tong Univ, Hong Hui Hosp, Dept Spine Surg, Xian 710054, Peoples R China.
EM huangdageng@mail.xjtu.edu.cn; haodingjun@mail.xjtu.edu.cn
OI Mei, Yibo/0000 0002 3969 8827; Zhang, Yuyang/0000 0002 3806 6094
FU National Natural Science Foundation of China
FX We unfeignedly thank all colleagues in Translational Medicine Center and
   all members of Hao Lab for generously help.
CR Antebi Yaron E, 2017, Curr Opin Syst Biol, V1, P16, DOI 10.1016/j.coisb.2016.12.003
   Ballane G, 2017, OSTEOPOROSIS INT, V28, P1531, DOI 10.1007/s00198 017 3909 3
   Center JR, 1999, LANCET, V353, P878, DOI 10.1016/S0140 6736(98)09075 8
   Huang YZ, 2018, EUR REV MED PHARMACO, V22, P5091, DOI 10.26355/eurrev_201808_15702
   Jackson TC, 2020, FRONT MOL NEUROSCI, V13, DOI 10.3389/fnmol.2020.00126
   Jacome Galarza CE, 2019, NATURE, V568, P541, DOI 10.1038/s41586 019 1105 7
   JONES G, 1994, OSTEOPOROSIS INT, V4, P277, DOI 10.1007/BF01623352
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim N, 2002, J EXP MED, V195, P201, DOI 10.1084/jem.20011681
   Kong LB, 2019, J CELL MOL MED, V23, P3077, DOI 10.1111/jcmm.14277
   Lampiasi N, 2021, BIOLOGY BASEL, V10, DOI 10.3390/biology10020117
   Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Martínez Limón A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21061913
   Nair A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133292
   Oh JJ, 2006, CANCER RES, V66, P3419, DOI 10.1158/0008 5472.CAN 05 1667
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Reimand J, 2007, NUCLEIC ACIDS RES, V35, pW193, DOI 10.1093/nar/gkm226
   Rintala Maki ND, 2004, APOPTOSIS, V9, P475, DOI 10.1023/B:APPT.0000031455.79352.57
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471 2105 12 77
   Sean D, 2007, BIOINFORMATICS, V23, P1846, DOI 10.1093/bioinformatics/btm254
   Shao C, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477 7819 10 160
   Simon N, 2011, J STAT SOFTW, V39, P1
   Sutherland LC, 2000, ONCOGENE, V19, P3774, DOI 10.1038/sj.onc.1203720
   Szklarczyk D, 2021, NUCLEIC ACIDS RES, V49, pD605, DOI 10.1093/nar/gkaa1074
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Walter W, 2015, BIOINFORMATICS, V31, P2912, DOI 10.1093/bioinformatics/btv300
   Wu TZ, 2021, INNOVATION AMSTERDAM, V2, DOI 10.1016/j.xinn.2021.100141
   Xu YL, 2019, ONCOL LETT, V17, P2013, DOI 10.3892/ol.2018.9818
   Xue Y, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750 1172 6 20
   Yang Y, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/352371
   Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257
   Zhang YP, 2019, FASEB J, V33, P10973, DOI 10.1096/fj.201900537R
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
NR 37
TC 0
Z9 0
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD NOV 29
PY 2023
VL 24
IS 1
AR 921
DI 10.1186/s12891 023 07002 8
PG 13
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA Z2VU0
UT WOS:001110711800001
PM 38031049
OA gold
DA 2025 08 17
ER

PT J
AU Uehara, H
   Takahashi, T
   Izumi, K
AF Uehara, Hisanori
   Takahashi, Tetsuyuki
   Izumi, Keisuke
TI Induction of retinol binding protein 4 and placenta specific 8
   expression in human prostate cancer cells remaining in bone following
   osteolytic tumor growth inhibition by osteoprotegerin
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE osteoprotegerin; retinol binding protein 4; placenta specific 8; bone
   metastasis; prostate cancer
ID BREAST CANCER; INSULIN RESISTANCE; SKELETAL METASTASES; ZOLEDRONIC ACID;
   SURVIVAL FACTOR; SOLID TUMORS; LUNG CANCER; PHASE II; DENOSUMAB;
   APOPTOSIS
AB New drugs that inhibit the osteoprotegerin (OPG)/receptor activator of NF kappa B ligand (RANKL)/RANK pathway have demonstrated efficacy for the treatment of bone metastasis. Toxicities induced by these drugs, however, including osteonecrosis of the jaw and hypocalcemia, may adversely affect therapy. The aim of this study was to identify additional therapeutic targets that can be combined with OPG/RANKL/RANK pathway inhibition in the treatment of prostate cancer bone metastasis. We established a stable transfectant that produces high levels of OPG mRNA and protein from PC 3 human prostate cancer cells (PC3 OPG). The culture medium of PC3 OPG cells significantly inhibited the differentiation of mouse monocytes into mature osteoclasts. Furthermore, when PC3 OPG cells were injected into the bones of nude mice, bone destruction and tumor induced osteoclast formation were reduced. Injection into bone of the mixtures containing equal amounts of green fluorescent protein (GFP) expressing PC 3 cells (PC3 GFP) and PC3 OPG cells also reduced bone destruction, compared to the control mixture. PC3 GFP cells were subsequently isolated from bone tumors and used for microarray analysis to assess changes in gene expression following osteolytic tumor growth inhibition by OPG. We selected the top 10 upregulated genes based on results from microarrays and confirmed mRNA expression of each gene by RT PCR. The expression patterns of retinol binding protein 4 (RBP4) and placenta specific 8 (PLAC8) were consistent with microarray results. Expression of these genes was also increased in the bone tumors of PC3 GFP/PC3 OPG injected mice. Knockdown of both RBP4 and PLAC8 by siRNA inhibited the growth of PC 3 cells in vitro. Thus, RBP4 and PLAC8 may become new therapeutic targets for prostate cancer bone metastasis, in combination with OPG/RANKL/RANK pathway inhibition.
C1 [Uehara, Hisanori; Takahashi, Tetsuyuki; Izumi, Keisuke] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Mol & Environm Pathol, Tokushima 7708503, Japan.
C3 Tokushima University
RP Uehara, H (通讯作者)，Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Mol & Environm Pathol, 3 18 15 Kuramoto Cho, Tokushima 7708503, Japan.
EM uehara.h@tokushima u.ac.jp
RI izumi, keisuke/L 3416 2013
CR Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575
   [Anonymous], CURR CANC DRUG TARGE
   [Anonymous], INT J PROTEOMICS
   Arah IN, 1998, ANTICANCER RES, V18, P1845
   Bao BY, 2004, ONCOGENE, V23, P3350, DOI 10.1038/sj.onc.1207461
   Brown JE, 2005, JNCI J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002
   Brown Glaberman U, 2012, BIOL TARGETS THER, V6, P89, DOI 10.2147/BTT.S20677
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Coleman R, 2012, JNCI J NATL CANCER I, V104, P1059, DOI 10.1093/jnci/djs263
   Corey E, 2005, CANCER RES, V65, P1710, DOI 10.1158/0008 5472.CAN 04 2033
   Demers LM, 2003, CANCER AM CANCER SOC, V97, P874, DOI 10.1002/cncr.11127
   Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009
   Fisher JL, 2006, CANCER RES, V66, P3620, DOI 10.1158/0008 5472.CAN 05 3119
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Flower DR, 1996, BIOCHEM J, V318, P1
   Ford JA, 2013, EUR J CANCER, V49, P416, DOI 10.1016/j.ejca.2012.07.016
   Freedland SJ, 2012, UROLOGY, V80, P293, DOI 10.1016/j.urology.2012.04.007
   Graham TE, 2006, NEW ENGL J MED, V354, P2552, DOI 10.1056/NEJMoa054862
   Holen I, 2002, CANCER RES, V62, P1619
   Kovacs P, 2007, DIABETES, V56, P3095, DOI 10.2337/db06 1647
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Li YJ, 2006, MOL CELL BIOL, V26, P3401, DOI 10.1128/MCB.26.9.3401 3413.2006
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   McGonigle JS, 2009, ANGIOGENESIS, V12, P35, DOI 10.1007/s10456 008 9127 z
   MUNDY GR, 1991, BONE, V12, pS1, DOI 10.1016/8756 3282(91)90057 P
   Newcomer ME, 2000, BBA PROTEIN STRUCT M, V1482, P57, DOI 10.1016/S0167 4838(00)00150 3
   Patz EF, 2007, J CLIN ONCOL, V25, P5578, DOI 10.1200/JCO.2007.13.5392
   Peddi P, 2013, CANCER TREAT REV, V39, P97, DOI 10.1016/j.ctrv.2012.07.002
   PERCIVAL RC, 1987, EUR J SURG ONCOL, V13, P41
   Rogulski K, 2005, ONCOGENE, V24, P7524, DOI 10.1038/sj.onc.1208897
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Shipman CM, 2003, CANCER RES, V63, P912
   Siegel R, 2011, CA CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Ting HJ, 2007, CANCER LETT, V247, P122, DOI 10.1016/j.canlet.2006.03.025
   TSUTSUMI C, 1992, J BIOL CHEM, V267, P1805
   Uehara H, 2003, J NATL CANCER I, V95, P458, DOI 10.1093/jnci/95.6.458
   Uemura H, 2012, INT J CLIN ONCOL
   Yang Q, 2005, NATURE, V436, P356, DOI 10.1038/nature03711
   Zhang J, 2003, CANCER RES, V63, P7883
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
NR 46
TC 25
Z9 31
U1 1
U2 9
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019 6439
J9 INT J ONCOL
JI Int. J. Oncol.
PD AUG
PY 2013
VL 43
IS 2
BP 365
EP 374
DI 10.3892/ijo.2013.1954
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 185AH
UT WOS:000321937100002
PM 23708710
OA hybrid, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Appelman Dijkstra, NM
   Papapoulos, SE
AF Appelman Dijkstra, Natasha M.
   Papapoulos, Socrates E.
TI Prevention of incident fractures in patients with prevalent fragility
   fractures: Current and future approaches
SO BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
LA English
DT Article
DE Fractures; Osteoporosis; Bisphosphonates; Denosumab; SERMs; PTH;
   Strontium ranelate; Cathepsin K; Sclerostin
ID BONE MINERAL DENSITY; CATHEPSIN K INHIBITORS; YEARLY ZOLEDRONIC ACID;
   VITAMIN D STATUS; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURE; NONVERTEBRAL
   FRACTURES; STRONTIUM RANELATE; SCLEROSTIN ANTIBODY; PARATHYROID HORMONE
AB Fragility fractures are a significant, independent risk factor for new fractures, but treatment uptake in subjects with prevalent fractures is disappointing. We addressed the question of the efficacy of pharmacological interventions in reducing the risk of incident fractures in patients with prevalent fragility fractures. For this, we reviewed randomised controlled trials (RCTs), pre planned and post hoc analyses of RCTs of approved agents for the treatment of osteoporosis. Results showed that a number of agents decrease the risk of incident vertebral and nonvertebral fractures in subjects with prevalent vertebral fractures, justifying the recommendation of treating such patients independently of the level of bone mineral density (BMD). By contrast, the evidence of antifracture efficacy of these agents in patients with prevalent nonvertebral fractures is limited. Advances in our understanding of the regulation of bone metabolism at the molecular level have identified targets for the development of new therapeutics for osteoporosis, some of which are currently in phase 3 clinical development. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Appelman Dijkstra, Natasha M.; Papapoulos, Socrates E.] Leiden Univ, Med Ctr, Ctr Bone Qual, NL 2333 ZA Leiden, Netherlands.
C3 Leiden University; Leiden University Medical Center (LUMC); Leiden
   University   Excl LUMC
RP Papapoulos, SE (通讯作者)，Leiden Univ, Med Ctr, Ctr Bone Qual C7Q, Albinusdreef 2, NL 2333 ZA Leiden, Netherlands.
EM m.v.iken@lumc.nl
RI ; Appelman Dijkstra, Natasha/V 7322 2018
OI Appelman Dijkstra, Natasha/0000 0001 5035 127X; 
FU Amgen; Eli Lilly; GSK; Merck Co.; Novartis; Pfizer; Roche; Warner
   Chilcott
FX Dr. Appelman has none. Dr. Papapoulos has received consulting/speaking
   fees from Amgen, Eli Lilly, GSK, Merck & Co., Novartis, Pfizer, Roche
   and Warner Chilcott.
CR Adami S, 2009, OSTEOPOROSIS INT, V20, P239, DOI 10.1007/s00198 008 0650 y
   ADAMI S, 2006, AM SOC BON MIN RES 2
   Åkesson K, 2013, OSTEOPOROSIS INT, V24, P2135, DOI 10.1007/s00198 013 2348 z
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Boonen S, 2012, CURR OSTEOPOROS REP, V10, P73, DOI 10.1007/s11914 011 0085 9
   Bouillon R, 2013, J CLIN ENDOCR METAB, V98, pE1283, DOI 10.1210/jc.2013 1195
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brumsen C, 2002, J BONE MINER RES, V17, P1057, DOI 10.1359/jbmr.2002.17.6.1057
   Cauley JA, 2008, ANN INTERN MED, V149, P242, DOI 10.7326/0003 4819 149 4 200808190 00005
   Center JR, 2011, J CLIN ENDOCR METAB, V96, P1006, DOI 10.1210/jc.2010 2730
   Chambers TJ, 2013, J CLIN ENDOCR METAB, V98, P4329, DOI 10.1210/jc.2013 2630
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Compston JE, 2007, BONE, V40, P1447, DOI 10.1016/j.bone.2006.09.008
   Cranney A, 2009, OSTEOPOROSIS INT, V20, P291, DOI 10.1007/s00198 008 0653 8
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Delmas PD, 2003, BONE, V33, P522, DOI 10.1016/S8756 3282(03)00241 2
   Eastell R, 2009, J CLIN ENDOCR METAB, V94, P3215, DOI 10.1210/jc.2008 2765
   Eisman JA, 2012, J BONE MINER RES, V27, P2039, DOI 10.1002/jbmr.1698
   Engelke K, 2013, J BONE MINER RES
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Fuller K, 2008, BONE, V42, P200, DOI 10.1016/j.bone.2007.09.044
   Gaugris S, 2005, QJM INT J MED, V98, P667, DOI 10.1093/qjmed/hci096
   Greenspan SL, 2007, ANN INTERN MED, V146, P326, DOI 10.7326/0003 4819 146 5 200703060 00005
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Holvik K, 2013, J CLIN ENDOCR METAB, V98, P3341, DOI 10.1210/jc.2013 1468
   Kanis JA, 2008, OSTEOPOROSIS INT, V19, P385, DOI 10.1007/s00198 007 0543 5
   Kanis JA, 2004, BONE, V35, P375, DOI 10.1016/j.bone.2004.03.024
   Ke HZ, 2012, ENDOCR REV, V33, P747, DOI 10.1210/er.2011 1060
   Kiviranta R, 2001, J BONE MINER RES, V16, P1444, DOI 10.1359/jbmr.2001.16.8.1444
   Langdahl B, 2012, J BONE MINER RES, V27, P2251, DOI 10.1002/jbmr.1695
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Lyles KW, 2007, N ENGL J MED, V357
   Masarachia PJ, 2012, J BONE MINER RES, V27, P509, DOI 10.1002/jbmr.1475
   Matsumoto T, 2009, OSTEOPOROSIS INT, V20, P1429, DOI 10.1007/s00198 008 0816 7
   McCloskey E, 2004, J BONE MINER RES, V19, P728, DOI 10.1359/JBMR.040116
   McClung MR, 2012, J BONE MINER RES, V27, P211, DOI 10.1002/jbmr.536
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   McLellan AR, 2011, OSTEOPOROSIS INT, V22, P2083, DOI 10.1007/s00198 011 1534 0
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Mithal A, 2013, OSTEOPOROSIS INT, V24, P1555, DOI 10.1007/s00198 012 2236 y
   Moester MJC, 2010, CALCIFIED TISSUE INT, V87, P99, DOI 10.1007/s00223 010 9372 1
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Ochi Y, 2011, BONE, V49, P1351, DOI 10.1016/j.bone.2011.09.041
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Papapoulos S.E., 2013, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, P412
   Papapoulos SE, 2011, ANN RHEUM DIS, V70, pI119, DOI 10.1136/ard.2010.141150
   Parfitt AM, 2008, OSTEOPOROSIS, VOLS I AND II, 3RD EDITION, P71
   Pazianas M, 2012, OSTEOPOROSIS INT, V23, P2693, DOI 10.1007/s00198 012 1902 4
   Pennypacker B, 2009, BONE, V44, P199, DOI 10.1016/j.bone.2008.08.130
   Rabenda V, 2008, J BONE JOINT SURG AM, V90A, P2142, DOI 10.2106/JBJS.G.00864
   Reginster JY, 2005, J CLIN ENDOCR METAB, V90, P2816, DOI 10.1210/jc.2004 1774
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Rizzoli R, 2011, CALCIFIED TISSUE INT, V89, P91, DOI 10.1007/s00223 011 9499 8
   Roerholt C, 2009, OSTEOPOROSIS INT, V20, P299, DOI 10.1007/s00198 008 0651 x
   Roux C, 2006, J BONE MINER RES, V21, P536, DOI 10.1359/JBMR.060101
   Sambrook PN, 2011, OSTEOPOROSIS INT, V22, P2551, DOI 10.1007/s00198 010 1444 6
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Segovia Silvestre T, 2009, HUM GENET, V124, P561, DOI 10.1007/s00439 008 0583 8
   Silverman SL, 2008, J BONE MINER RES, V23, P1923, DOI 10.1359/JBMR.080710
   Stroup GB, 2009, CALCIFIED TISSUE INT, V85, P344, DOI 10.1007/s00223 009 9279 x
   Svedbom A, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0137 0
NR 66
TC 6
Z9 6
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1521 6942
EI 1521 1770
J9 BEST PRACT RES CL RH
JI Best Pract. Res. Clin. Rheumatol.
PD DEC
PY 2013
VL 27
IS 6
BP 805
EP 820
DI 10.1016/j.berh.2014.01.010
PG 16
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA AI8VW
UT WOS:000337206100009
PM 24836337
DA 2025 08 17
ER

PT J
AU Oh, N
   Kim, S
   Hosoya, K
   Okumura, M
AF Oh, Namgil
   Kim, Sangho
   Hosoya, Kenji
   Okumura, Masahiro
TI Compensatory Cellular Reactions to Nonsteroidal Anti Inflammatory Drugs
   on Osteogenic Differentiation in Canine Bone Marrow Derived Mesenchymal
   Stem Cells
SO JOURNAL OF VETERINARY MEDICAL SCIENCE
LA English
DT Article
DE BMSCs; bone; canine; non steroidal anti inflammatory drug; osteoblast
   differentiation
ID PROSTAGLANDIN E 2 BIOSYNTHESIS; RECEPTOR AGONISTS; CYCLOOXYGENASE 2
   INHIBITION; ANABOLIC ACTIONS; IN VITRO; SYNTHASE; COX 2; STIMULATION;
   MECHANISMS; PREVENTION
AB The suppressive effects of nonsteroidal anti inflammatory drugs (NSAIDs) on the bone healing process have remained controversial, since no clinical data have clearly shown the relationship between NSAIDs and bone healing. The aim of this study was to assess the compensatory response of canine bone marrow derived mesenchymal stem cells (BMSCs) to several classes of NSAIDs, including carprofen, meloxicam, indomethacin and robenacoxib, on osteogenic differentiation. Each of the NSAIDs (10 mu M) was administered during 20 days of the osteogenic process with human recombinant IL 1 beta (1 ng/ml) as an inflammatory stimulator. Gene expression of osteoblast differentiation markers (alkaline phosphatase and osteocalcin), receptors of PGE(2) (EP2 and EP4) and enzymes for prostaglandin (PG) E2 synthesis (COX 1, COX 2, cPGES and mPGES 1) was measured by using quantitative reverse transcription polymerase chain reaction. Protein production levels of alkaline phosphatase, osteocalcin and PGE(2) were quantified using an alkaline phosphatase activity assay, osteocalcin immunoassay and PGE(2) immunoassay, respectively. Histologic analysis was performed using alkaline phosphatase staining, von Kossa staining and alizarin red staining. Alkaline phosphatase and calcium deposition were suppressed by all NSAIDs. However, osteocalcin production showed no significant suppression by NSAIDs. Gene expression levels of PGE(2) related receptors and enzymes were upregulated during continuous treatment with NSAIDs, while certain channels for PGE(2) synthesis were utilized differently depending on the kind of NSAIDs. These data suggest that canine BMSCs have a compensatory mechanism to restore PGE(2) synthesis, which would be an intrinsic regulator to maintain differentiation of osteoblasts under NSAID treatment.
C1 [Oh, Namgil; Kim, Sangho; Hosoya, Kenji; Okumura, Masahiro] Hokkaido Univ, Lab Vet Surg, Dept Vet Clin Sci, Grad Sch Vet Med, Sapporo, Hokkaido 0600818, Japan.
C3 Hokkaido University
RP Okumura, M (通讯作者)，Hokkaido Univ, Lab Vet Surg, Dept Vet Clin Sci, Grad Sch Vet Med, Sapporo, Hokkaido 0600818, Japan.
EM okumuram@vetmed.hokudai.ac.jp
RI Okumura, Masahiro/AAO 4766 2021
CR Alander CB, 2006, PROSTAG OTH LIPID M, V81, P178, DOI 10.1016/j.prostaglandins.2006.09.005
   Barry S, 2010, VET COMP ORTHOPAED, V23, P385, DOI 10.3415/VCOT 10 01 0017
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Cashman JN, 1996, DRUGS, V52, P13, DOI 10.2165/00003495 199600525 00004
   Cottrell J, 2010, PHARMACEUTICALS, V3, P1668, DOI 10.3390/ph3051668
   Einhorn TA, 2003, ARTHRITIS RES THER, V5, P5, DOI 10.1186/ar607
   FLANAGAN AM, 1992, ENDOCRINOLOGY, V130, P443, DOI 10.1210/en.130.1.443
   Gerstenfeld LC, 2007, J BONE JOINT SURG AM, V89A, P114, DOI 10.2106/JBJS.F.00495
   Grace R. F., 2000, Inflammopharmacology, V8, P43, DOI 10.1023/B:INFL.0000041131.54496.51
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Gregory LS, 2007, CALCIFIED TISSUE INT, V80, P176, DOI 10.1007/s00223 006 0170 8
   HUCKER HB, 1966, J PHARMACOL EXP THER, V153, P237
   Jung M, 2009, J VET PHARMACOL THER, V32, P41, DOI 10.1111/j.1365 2885.2008.01035.x
   Kidd BL, 2001, BRIT J ANAESTH, V87, P3, DOI 10.1093/bja/87.1.3
   Kirtikara K, 1998, J EXP MED, V187, P517, DOI 10.1084/jem.187.4.517
   Kulterer B, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 70
   Lascelles BDX, 1998, VET SURG, V27, P568, DOI 10.1111/j.1532 950X.1998.tb00533.x
   Minamizaki T, 2009, BONE, V44, P1177, DOI 10.1016/j.bone.2009.02.010
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Murakami M, 2003, J BIOL CHEM, V278, P37937, DOI 10.1074/jbc.M305108200
   Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200
   Nakamura A, 2009, TISSUE ENG PART C ME, V15, P169, DOI 10.1089/ten.tec.2007.0334
   Ochi H, 2011, AM J VET RES, V72, P634, DOI 10.2460/ajvr.72.5.634
   PILBEAM CC, 1995, J BONE MINER RES, V10, P406
   Raisz LG, 2003, PROSTAG OTH LIPID M, V71, P287, DOI 10.1016/S1098 8823(03)00049 2
   Ramirez Yanez GO, 2012, ARCH ORAL BIOL, V57, P1274, DOI 10.1016/j.archoralbio.2012.03.003
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449
   Sakuma Y, 2004, BONE, V34, P827, DOI 10.1016/j.bone.2003.12.007
   SCUTT A, 1995, J BONE MINER RES, V10, P474
   Shapiro F, 2008, EUR CELLS MATER, V15, P53, DOI 10.22203/eCM.v015a05
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Simon AM, 2007, J BONE JOINT SURG AM, V89A, P500, DOI 10.2106/JBJS.F.00127
   Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200
   Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97
   Vasileiadis GI, 2011, ORTHOPEDICS, V34, P467, DOI 10.3928/01477447 20110427 23
   Xie C, 2009, AM J PATHOL, V175, P772, DOI 10.2353/ajpath.2009.081099
   Yoon DS, 2010, STEM CELLS DEV, V19, P1523, DOI 10.1089/scd.2009.0393
   Yuan Y, 2009, ACTA PHARMACOL SIN, V30, P1060, DOI 10.1038/aps.2009.73
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 40
TC 8
Z9 10
U1 0
U2 13
PU JAPAN SOC VET SCI
PI TOKYO
PA UNIV TOKYO, 1 1 1 YAYOI, BUNKYO KU, TOKYO, 103, JAPAN
SN 0916 7250
EI 1347 7439
J9 J VET MED SCI
JI J. Vet. Med. Sci.
PD MAY
PY 2014
VL 76
IS 5
BP 629
EP 636
DI 10.1292/jvms.13 0482
PG 8
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA AI0BZ
UT WOS:000336512500002
PM 24419976
OA Green Published, hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU Adams, GB
   Martin, RP
   Alley, IR
   Chabner, KT
   Cohen, KS
   Calvi, LM
   Kronenberg, HM
   Scadden, DT
AF Adams, Gregor B.
   Martin, Roderick P.
   Alley, Ian R.
   Chabner, Karissa T.
   Cohen, Kenneth S.
   Calvi, Laura M.
   Kronenberg, Henry M.
   Scadden, David T.
TI Therapeutic targeting of a stem cell niche
SO NATURE BIOTECHNOLOGY
LA English
DT Article
ID UMBILICAL CORD BLOOD; HEMATOPOIETIC STEM; COMPETITIVE REPOPULATION;
   PARATHYROID HORMONE; PROGENITOR CELLS; G CSF; MARROW; CYCLOPHOSPHAMIDE;
   DIFFERENTIATION; QUIESCENCE
AB The specialized microenvironment or niche where stem cells reside provides regulatory input governing stem cell function. We tested the hypothesis that targeting the niche might improve stem cell based therapies using three mouse models that are relevant to clinical uses of hematopoietic stem ( HS) cells. We and others previously identified the osteoblast as a component of the adult HS cell niche and established that activation of the parathyroid hormone ( PTH) receptor on osteoblasts increases stem cell number(1 3). Here we show that pharmacologic use of PTH increases the number of HS cells mobilized into the peripheral blood for stem cell harvests, protects stem cells from repeated exposure to cytotoxic chemotherapy and expands stem cells in transplant recipients. These data provide evidence that the niche may be an attractive target for drug based stem cell therapeutics.
C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
   Univ Rochester, Sch Med, Rochester, NY 14642 USA.
   Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard Medical School; Harvard University; Harvard
   University Medical Affiliates; Massachusetts General Hospital; Harvard
   Medical School; University of Rochester; Harvard University
RP Scadden, DT (通讯作者)，Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Regenerat Med, 185 Cambridge St, Boston, MA 02114 USA.
EM scadden.david@mgh.harvard.edu
RI KRONENBERG, HENRY/MXK 0923 2025; Calvi, Laura/P 6988 2019
OI Calvi, Laura Maria/0000 0001 6969 239X
FU NIDDK NIH HHS [R21 DK069563] Funding Source: Medline
CR Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004
   Ballen KK, 2005, BLOOD, V105, P3786, DOI 10.1182/blood 2004 10 4125
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804
   Christensen JL, 2001, P NATL ACAD SCI USA, V98, P14541, DOI 10.1073/pnas.261562798
   Dallas MH, 2005, J EXP MED, V201, P1361, DOI 10.1084/jem.20042450
   Freedman A, 1997, BLOOD, V90, P4996, DOI 10.1182/blood.V90.12.4996.4996_4996_5001
   Gazitt Y, 1999, J HEMATOTHER, V8, P173, DOI 10.1089/106161299320442
   GONG JK, 1978, SCIENCE, V199, P1443, DOI 10.1126/science.75570
   HARRISON DE, 1993, EXP HEMATOL, V21, P206
   HARRISON DE, 1980, BLOOD, V55, P77
   HORNUNG RL, 1992, BLOOD, V80, P77
   Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026
   Laughlin MJ, 2001, NEW ENGL J MED, V344, P1815, DOI 10.1056/NEJM200106143442402
   LORD BI, 1975, BLOOD, V46, P65
   Matrosova VY, 2004, STEM CELLS, V22, P544, DOI 10.1634/stemcells.22 4 544
   MOORE MAS, 1992, BLOOD, V80, P3
   Nilsson SK, 2001, BLOOD, V97, P2293, DOI 10.1182/blood.V97.8.2293
   Qin L, 2003, J BIOL CHEM, V278, P19723, DOI 10.1074/jbc.M212226200
   SCHOFIELD R, 1978, BLOOD CELLS, V4, P7
   Semerad CL, 2005, BLOOD, V106, P3020, DOI 10.1182/blood 2004 01 0272
   SONNENBERG FA, 1989, BLOOD, V74, P2569
   Taichman RS, 1996, BLOOD, V87, P518, DOI 10.1182/blood.V87.2.518.bloodjournal872518
   TAICHMAN RS, 1994, J EXP MED, V179, P1677, DOI 10.1084/jem.179.5.1677
   van Os R, 1998, BLOOD, V92, P1950, DOI 10.1182/blood.V92.6.1950.418k21_1950_1956
   van Os R, 2000, STEM CELLS, V18, P120, DOI 10.1634/stemcells.18 2 120
   Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood 2003 11 4011
   Whitfield JF, 2006, CANCER LETT, V244, P8, DOI 10.1016/j.canlet.2006.02.006
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
NR 29
TC 233
Z9 257
U1 0
U2 13
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1087 0156
EI 1546 1696
J9 NAT BIOTECHNOL
JI Nat. Biotechnol.
PD FEB
PY 2007
VL 25
IS 2
BP 238
EP 243
DI 10.1038/nbt1281
PG 6
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology
GA 134DV
UT WOS:000244064000030
PM 17237769
DA 2025 08 17
ER

PT J
AU Wang, L
   Tran, AB
   Nociti, FH
   Thumbigere Math, V
   Foster, BL
   Krieger, CC
   Kantovitz, KR
   Novince, CM
   Koh, AJ
   McCauley, LK
   Somerman, MJ
AF Wang, L.
   Tran, A. B.
   Nociti, F. H., Jr.
   Thumbigere Math, V.
   Foster, B. L.
   Krieger, C. C.
   Kantovitz, K. R.
   Novince, C. M.
   Koh, A. J.
   McCauley, L. K.
   Somerman, M. J.
TI PTH and Vitamin D Repress DMP1 in Cementoblasts
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE parathyroid hormone; 1,25D; dentin matrix protein 1; mineral
   homeostasis; RNA sequencing; hormonal regulation
ID DENTIN MATRIX PROTEIN 1; OSTEOCLASTIC BONE RESORPTION;
   PARATHYROID HORMONE; GENE EXPRESSION; IN VITRO; FEEDBACK LOOP;
   OSTEOCYTES; FGF23; DIFFERENTIATION; CELLS
AB A complex feedback mechanism between parathyroid hormone (PTH), 1,25(OH)(2)D 3 (1,25D), and fibroblast growth factor 23 (FGF 23) maintains mineral homeostasis, in part by regulating calcium and phosphate absorption/reabsorption. Previously, we showed that 1,25D regulates mineral homeostasis by repressing dentin matrix protein 1 (DMP1) via the vitamin D receptor pathway. Similar to 1,25D, PTH may modulate DMP1, but the underlying mechanism remains unknown. Immortalized murine cementoblasts (OCCM.30), similar to osteoblasts and known to express DMP1, were treated with PTH (1 34). Real time quantitative polymerase chain reaction (PCR) and Western blot revealed that PTH decreased DMP1 gene transcription (85%) and protein expression (30%), respectively. PTH mediated the downregulation of DMP1 via the cAMP/protein kinase A (PKA) pathway. Immunohistochemistry confirmed the decreased localization of DMP1 in vivo in cellular cementum and alveolar bone of mice treated with a single dose (50 mu g/kg) of PTH (1 34). RNA seq was employed to further identify patterns of gene expression shared by PTH and 1,25D in regulating DMP1, as well as other factors involved in mineral homeostasis. PTH and 1,25D mutually upregulated 36 genes and mutually downregulated 27 genes by 2 fold expression (P 0.05). Many identified genes were linked with the regulation of bone/tooth homeostasis, cell growth and differentiation, calcium signaling, and DMP1 transcription. Validation of RNA seq results via PCR array confirmed a similar gene expression pattern in response to PTH and 1,25D treatment. Collectively, these results suggest that PTH and 1,25D share complementary effects in maintaining mineral homeostasis by mutual regulation of genes/proteins associated with calcium and phosphate metabolism while also exerting distinct roles on factors modulating mineral metabolism. Furthermore, PTH may modulate phosphate homeostasis by downregulating DMP1 expression via the cAMP/PKA pathway. Targeting genes/proteins mutually governed by PTH and 1,25D may be a viable approach for designing new therapies for preserving mineralized tissue health.
C1 [Wang, L.; Tran, A. B.; Nociti, F. H., Jr.; Thumbigere Math, V.; Foster, B. L.; Kantovitz, K. R.; Somerman, M. J.] Natl Inst Arthrit & Musculoskeletal & Skin Dis NI, NIH, Bethesda, MD 20892 USA.
   [Nociti, F. H., Jr.; Kantovitz, K. R.] Univ Estadual Campinas, Sch Dent, Div Periodont, Dept Prosthodont & Periodont, Piracicaba, SP, Brazil.
   [Krieger, C. C.] NIDDK, NIH, Bethesda, MD USA.
   [Novince, C. M.; Koh, A. J.; McCauley, L. K.] Univ Michigan, Sch Dent, Ann Arbor, MI 48109 USA.
   [Novince, C. M.] Med Univ S Carolina, Dept Oral Hlth Sci, Charleston, SC 29425 USA.
C3 National Institutes of Health (NIH)   USA; NIH National Institute of
   Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Universidade
   Estadual de Campinas; National Institutes of Health (NIH)   USA; NIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK);
   University of Michigan System; University of Michigan; Medical
   University of South Carolina
RP Wang, L (通讯作者)，Natl Inst Arthrit & Musculoskeletal & Skin Dis NI, NIH, Bldg 50 Room 4120, Bethesda, MD 20892 USA.
EM le.wang@nih.gov
RI McCauley, Laurie/G 4041 2012; Krieger, Christine/AAX 6822 2021;
   Kantovitz, Kamila/J 4567 2013; Nociti, Francisco/G 4907 2015
OI Krieger, Christine/0000 0002 1856 415X; Kantovitz,
   Kamila/0000 0003 2045 7924; Nociti, Francisco/0000 0001 6809 8866; 
FU Intramural Research Program of National Institute of Arthritis and
   Musculoskeletal and Skin Diseases; National Institute of Diabetes and
   Digestive and Kidney Diseases [R01DK53904]
FX This research was supported in part by the Intramural Research Program
   of the National Institute of Arthritis and Musculoskeletal and Skin
   Diseases (MJS) and the National Institute of Diabetes and Digestive and
   Kidney Diseases R01DK53904 (LKM). The authors thank Dr. Chunlin Qin
   (Baylor College of Dentistry) for providing the DMP1 antibody, Gustavo
   Gutierrez Cruz and Steve Brooks from the National Institute of Arthritis
   and Musculoskeletal and Skin Diseases (NIAMS) for RNA seq analysis, and
   Mudita Patel (NIAMS) for technical assistance. The authors declare no
   potential conflicts of interest with respect to the authorship and/or
   publication of this article.
CR Alos N, 2005, BONE, V37, P589, DOI 10.1016/j.bone.2005.05.006
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Bergwitz C, 2010, ANNU REV MED, V61, P91, DOI 10.1146/annurev.med.051308.111339
   BRITTO JM, 1994, ENDOCRINOLOGY, V134, P169, DOI 10.1210/en.134.1.169
   D'Errico JA, 2000, J PERIODONTOL, V71, P63, DOI 10.1902/jop.2000.71.1.63
   DSouza RN, 1997, J BONE MINER RES, V12, P2040, DOI 10.1359/jbmr.1997.12.12.2040
   Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905
   Feng JQ, 2002, J BONE MINER RES, V17, P1822, DOI 10.1359/jbmr.2002.17.10.1822
   Gooi JH, 2014, J ENDOCRINOL, V221, P181, DOI 10.1530/JOE 13 0524
   Haussler MR, 2013, CALCIFIED TISSUE INT, V92, P77, DOI 10.1007/s00223 012 9619 0
   He G, 2004, J BIOL CHEM, V279, P11649, DOI 10.1074/jbc.M309296200
   Huang BZ, 2008, CALCIFIED TISSUE INT, V82, P401, DOI 10.1007/s00223 008 9140 7
   Hunziker J, 2000, J DENT RES, V79, P1431, DOI 10.1177/00220345000790061301
   Komaba H, 2010, KIDNEY INT, V77, P292, DOI 10.1038/ki.2009.466
   Krajisnik T, 2007, J ENDOCRINOL, V195, P125, DOI 10.1677/JOE 07 0267
   Kuroshima S, 2013, J DENT RES, V92, P553, DOI 10.1177/0022034513487558
   Lanske B, 2014, KIDNEY INT, V86, P1071, DOI 10.1038/ki.2014.316
   Lavi Moshayoff V, 2010, AM J PHYSIOL RENAL, V299, pF882, DOI 10.1152/ajprenal.00360.2010
   Leupin O, 2007, J BONE MINER RES, V22, P1957, DOI 10.1359/JBMR.070804
   Lin H, 2013, J CELL PHYSIOL, V228, P2076, DOI 10.1002/jcp.24377
   Ling YF, 2005, J BONE MINER RES, V20, P2169, DOI 10.1359/JBMR.050815
   Liu H, 2013, J BIOL CHEM, V288, P9261, DOI 10.1074/jbc.M112.433730
   MacDougall M, 1998, J BONE MINER RES, V13, P422, DOI 10.1359/jbmr.1998.13.3.422
   Martin A, 2011, FASEB J, V25, P2551, DOI 10.1096/fj.10 177816
   MCSHEEHY PMJ, 1987, J CLIN INVEST, V80, P425, DOI 10.1172/JCI113089
   Miyazaki T, 2008, ARCH HISTOL CYTOL, V71, P131, DOI 10.1679/aohc.71.131
   Mundy GR, 1999, CLIN CHEM, V45, P1347
   Nociti FH, 2014, J DENT RES, V93, P148, DOI 10.1177/0022034513516344
   Novince CM, 2012, J BONE MINER RES, V27, P11, DOI 10.1002/jbmr.508
   Rowe PSN, 2012, CRIT REV EUKAR GENE, V22, P61, DOI 10.1615/CritRevEukarGeneExpr.v22.i1.50
   Siddappa R, 2008, P NATL ACAD SCI USA, V105, P7281, DOI 10.1073/pnas.0711190105
   St John HC, 2015, BONE, V72, P81, DOI 10.1016/j.bone.2014.11.010
   St John HC, 2014, MOL ENDOCRINOL, V28, P1150, DOI 10.1210/me.2014 1091
   Tfelt Hansen J, 2005, CRIT REV CL LAB SCI, V42, P35, DOI 10.1080/10408360590886606
   Wein MN, 2014, J BONE MINER RES, V30, P400
   Ye L, 2004, J BIOL CHEM, V279, P19141, DOI 10.1074/jbc.M400490200
   Zhang R, 2011, J BONE MINER RES, V26, P1047, DOI 10.1002/jbmr.294
NR 37
TC 14
Z9 17
U1 0
U2 14
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD OCT
PY 2015
VL 94
IS 10
BP 1408
EP 1416
DI 10.1177/0022034515599726
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA CS1JD
UT WOS:000361819400012
PM 26276370
OA Green Published
DA 2025 08 17
ER

PT J
AU Osada, M
   Jardine, L
   Misir, R
   Andl, T
   Millar, SE
   Pezzano, M
AF Osada, Masako
   Jardine, Logan
   Misir, Ruth
   Andl, Thomas
   Millar, Sarah E.
   Pezzano, Mark
TI DKK1 Mediated Inhibition of Wnt Signaling in Postnatal Mice Leads to
   Loss of TEC Progenitors and Thymic Degeneration
SO PLOS ONE
LA English
DT Article
ID HEMATOPOIETIC STEM CELL; MEDULLARY EPITHELIAL CELLS; BETA CATENIN;
   SELF RENEWAL; THYMOCYTE DEVELOPMENT; TRANSCRIPTION FACTORS;
   SMALL INTESTINE; EXPRESSION; P63; DIFFERENTIATION
AB Background: Thymic epithelial cell (TEC) microenvironments are essential for the recruitment of T cell precursors from the bone marrow, as well as the subsequent expansion and selection of thymocytes resulting in a mature self tolerant T cell repertoire. The molecular mechanisms, which control both the initial development and subsequent maintenance of these critical microenvironments, are poorly defined. Wnt signaling has been shown to be important to the development of several epithelial tissues and organs. Regulation of Wnt signaling has also been shown to impact both early thymocyte and thymic epithelial development. However, early blocks in thymic organogenesis or death of the mice have prevented analysis of a role of canonical Wnt signaling in the maintenance of TECs in the postnatal thymus.
   Methodology/Principal Findings: Here we demonstrate that tetracycline regulated expression of the canonical Wnt inhibitor DKK1 in TECs localized in both the cortex and medulla of adult mice, results in rapid thymic degeneration characterized by a loss of Delta NP63(+) Foxn1(+) and Aire(+) TECs, loss of K5K8DP TECs thought to represent or contain an immature TEC progenitor, decreased TEC proliferation and the development of cystic structures, similar to an aged thymus. Removal of DKK1 from DKK1 involuted mice results in full recovery, suggesting that canonical Wnt signaling is required for the differentiation or proliferation of TEC populations needed for maintenance of properly organized adult thymic epithelial microenvironments.
   Conclusions/Significance: Taken together, the results of this study demonstrate that canonical Wnt signaling within TECs is required for the maintenance of epithelial microenvironments in the postnatal thymus, possibly through effects on TEC progenitor/stem cell populations. Downstream targets of Wnt signaling, which are responsible for maintenance of these TEC progenitors may provide useful targets for therapies aimed at counteracting age associated thymic involution or the premature thymic degeneration associated with cancer therapy and bone marrow transplants.
C1 [Osada, Masako; Jardine, Logan; Misir, Ruth; Pezzano, Mark] CUNY City Coll, Dept Biol, New York, NY 10031 USA.
   [Andl, Thomas] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
   [Millar, Sarah E.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA.
   [Millar, Sarah E.] Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA.
C3 City University of New York (CUNY) System; City College of New York
   (CUNY); Vanderbilt University; University of Pennsylvania; University of
   Pennsylvania
RP Osada, M (通讯作者)，CUNY City Coll, Dept Biol, 138Th St & Convent Ave, New York, NY 10031 USA.
EM mpezzano@sci.ccny.cuny.edu
OI Millar, Sarah/0000 0001 8792 6890; Andl, Thomas/0000 0002 5555 468X
FU National Institutes of Health (NIH)/National Institute of Allergy and
   Infectious Diseases (NIAID) [1SC1AI081527]; NIH/NCI [1U56 CA96299, U54
   1U54CA137788 01, PSCREG 39 1051, RO1 AR47709, RO1 DE015342,
   RO1 HD053829]; National Center for Research Resources Research Centers
   in Minority Institutions [G12RR03060]
FX Funding: This work was supported by grants from National Institutes of
   Health (NIH)/National Institute of Allergy and Infectious Diseases
   (NIAID) 1SC1AI081527 NIH/NCI 1U56 CA96299, NIH/NCI U54 1U54CA137788 01
   and PSCREG 39 1051 to M. P. and RO1 AR47709, RO1 DE015342, RO1 HD053829
   to S. E. M. Infrastructure support for core facilities and technical
   staff was provided by a grant to The City College of New York from the
   National Center for Research Resources Research Centers in Minority
   Institutions program grant # G12RR03060. The funding agencies had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Akiyama T, 2008, IMMUNITY, V29, P423, DOI 10.1016/j.immuni.2008.06.015
   Anderson G, 2001, NAT REV IMMUNOL, V1, P31, DOI 10.1038/35095500
   Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958
   Andl T, 2002, DEV CELL, V2, P643, DOI 10.1016/S1534 5807(02)00167 3
   Aw D, 2008, AGING CELL, V7, P158, DOI 10.1111/j.1474 9726.2007.00365.x
   Baba Y, 2006, J IMMUNOL, V177, P2294, DOI 10.4049/jimmunol.177.4.2294
   Balciunaite G, 2002, NAT IMMUNOL, V3, P1102, DOI 10.1038/ni850
   BARCLAY AN, 1981, J EXP MED, V153, P1666, DOI 10.1084/jem.153.6.1666
   Blanpain C, 2009, NAT REV MOL CELL BIO, V10, P207, DOI 10.1038/nrm2636
   Candi E, 2007, P NATL ACAD SCI USA, V104, P11999, DOI 10.1073/pnas.0703458104
   Chilosi M, 2003, VIRCHOWS ARCH, V443, P175, DOI 10.1007/s00428 003 0857 4
   Chu EY, 2004, DEVELOPMENT, V131, P4819, DOI 10.1242/dev.01347
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Diamond I, 2000, J INVEST DERMATOL, V115, P788, DOI 10.1046/j.1523 1747.2000.00144.x
   Dooley J, 2008, J IMMUNOL, V181, P5225, DOI 10.4049/jimmunol.181.8.5225
   Dotto J, 2007, AM J CLIN PATHOL, V127, P415, DOI 10.1309/2GAYKPDDM85P2VEW
   FERRICK DA, 1989, CELL, V57, P483, DOI 10.1016/0092 8674(89)90923 9
   Fleming HE, 2008, CELL STEM CELL, V2, P274, DOI 10.1016/j.stem.2008.01.003
   Flores KG, 1999, J CLIN INVEST, V104, P1031, DOI 10.1172/JCI7558
   Gabor MJ, 1997, EUR J IMMUNOL, V27, P2010, DOI 10.1002/eji.1830270827
   Gillard GO, 2007, J IMMUNOL, V178, P3007, DOI 10.4049/jimmunol.178.5.3007
   Gillard GO, 2006, J IMMUNOL, V176, P5815, DOI 10.4049/jimmunol.176.10.5815
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Gotter J, 2004, J EXP MED, V199, P155, DOI 10.1084/jem.20031677
   Gray D, 2007, J EXP MED, V204, P2521, DOI 10.1084/jem.20070795
   Gray DHD, 2006, BLOOD, V108, P3777, DOI 10.1182/blood 2006 02 004531
   Grotewold L, 2002, INT J DEV BIOL, V46, P943
   Grotewold L, 2002, EMBO J, V21, P966, DOI 10.1093/emboj/21.5.966
   Hattori N, 1996, J EXP MED, V184, P1137, DOI 10.1084/jem.184.3.1137
   Hattori N, 1996, J EXP MED, V184, P1901, DOI 10.1084/jem.184.5.1901
   Heng TSP, 2005, J IMMUNOL, V175, P2982, DOI 10.4049/jimmunol.175.5.2982
   Hikosaka Y, 2008, IMMUNITY, V29, P438, DOI 10.1016/j.immuni.2008.06.018
   HIROKAWA K, 1994, IMMUNOL LETT, V40, P269, DOI 10.1016/0165 2478(94)00065 4
   Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092 8674(01)00336 1
   Ioannidis V, 2001, NAT IMMUNOL, V2, P691, DOI 10.1038/90623
   Irifune T, 2004, ARCH HISTOL CYTOL, V67, P149, DOI 10.1679/aohc.67.149
   Irla M, 2008, IMMUNITY, V29, P451, DOI 10.1016/j.immuni.2008.08.007
   Ito M, 2007, NATURE, V447, P316, DOI 10.1038/nature05766
   Itoi M, 2007, INT IMMUNOL, V19, P953, DOI 10.1093/intimm/dxm060
   Jenkinson WE, 2007, BLOOD, V109, P954, DOI 10.1182/blood 2006 05 023143
   Kikuchi T, 2004, INT IMMUNOL, V16, P831, DOI 10.1093/intimm/dxh087
   Klug DB, 1998, P NATL ACAD SCI USA, V95, P11822, DOI 10.1073/pnas.95.20.11822
   Klug DB, 2002, J IMMUNOL, V169, P2842, DOI 10.4049/jimmunol.169.6.2842
   Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270
   Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100
   Kuraguchi M, 2006, PLOS GENET, V2, P1362, DOI 10.1371/journal.pgen.0020146
   Kwack MH, 2008, J INVEST DERMATOL, V128, P262, DOI 10.1038/sj.jid.5700999
   Kyewski B, 2004, NAT REV IMMUNOL, V4, P688, DOI 10.1038/nri1436
   Laufer TM, 1996, NATURE, V383, P81, DOI 10.1038/383081a0
   Lee H, 2002, DEV CELL, V2, P607, DOI 10.1016/S1534 5807(02)00166 1
   Lena AM, 2008, CELL DEATH DIFFER, V15, P1187, DOI 10.1038/cdd.2008.69
   Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092 8674(00)81921 2
   Liston A, 2008, P NATL ACAD SCI USA, V105, P11903, DOI 10.1073/pnas.0801506105
   Liu F, 2007, NAT GENET, V39, P106, DOI 10.1038/ng1932
   Luis TC, 2009, BLOOD, V113, P546, DOI 10.1182/blood 2008 06 163774
   Millar JBA, 2002, GENOME BIOL, V3
   Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531
   Min D, 2007, BLOOD, V109, P2529, DOI 10.1182/blood 2006 08 043794
   Mukhopadhyay M, 2001, DEV CELL, V1, P423, DOI 10.1016/S1534 5807(01)00041 7
   Mulroy T, 2003, INT IMMUNOL, V15, P1485, DOI 10.1093/intimm/dxg146
   Mulroy T, 2002, EUR J IMMUNOL, V32, P967, DOI 10.1002/1521 4141(200204)32:4<967::AID IMMU967>3.3.CO;2 Y
   Niehrs C, 1999, TRENDS GENET, V15, P314, DOI 10.1016/S0168 9525(99)01767 9
   Osada M, 2006, CLIN DEV IMMUNOL, V13, P299, DOI 10.1080/17402520600935097
   Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523 1747.1999.00780.x
   Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098
   Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103
   Pongracz J, 2003, EUR J IMMUNOL, V33, P1949, DOI 10.1002/eji.200323564
   Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593
   Rossi SW, 2007, J EXP MED, V204, P1267, DOI 10.1084/jem.20062497
   Rossi SW, 2006, NATURE, V441, P988, DOI 10.1038/nature04813
   Savage PA, 2001, IMMUNITY, V14, P243, DOI 10.1016/S1074 7613(01)00106 6
   Scheller M, 2006, NAT IMMUNOL, V7, P1037, DOI 10.1038/ni1387
   Schilham MW, 1998, J IMMUNOL, V161, P3984
   Senoo M, 2007, CELL, V129, P523, DOI 10.1016/j.cell.2007.02.045
   Shakib S, 2009, J IMMUNOL, V182, P130, DOI 10.4049/jimmunol.182.1.130
   SHORES EW, 1991, EUR J IMMUNOL, V21, P1657, DOI 10.1002/eji.1830210711
   Shu WG, 2005, DEV BIOL, V283, P226, DOI 10.1016/j.ydbio.2005.04.014
   Staal FJT, 2001, EUR J IMMUNOL, V31, P285, DOI 10.1002/1521 4141(200101)31:1<285::AID IMMU285>3.3.CO;2 4
   Staal FJT, 2008, NAT REV IMMUNOL, V8, P581, DOI 10.1038/nri2360
   SURH CD, 1992, J EXP MED, V176, P611, DOI 10.1084/jem.176.2.611
   Takeoka Y, 1996, INT ARCH ALLERGY IMM, V111, P5, DOI 10.1159/000237337
   Truong AB, 2006, GENE DEV, V20, P3185, DOI 10.1101/gad.1463206
   UTSUYAMA M, 1995, MECH AGEING DEV, V81, P107, DOI 10.1016/0047 6374(95)01589 R
   van de Wetering M, 2002, CELL, V109, pS13, DOI 10.1016/S0092 8674(02)00709 2
   van Ewijk W, 2000, DEVELOPMENT, V127, P1583
   van Ewijk W, 1999, SEMIN IMMUNOL, V11, P57, DOI 10.1006/smim.1998.0158
   Weerkamp F, 2006, P NATL ACAD SCI USA, V103, P3322, DOI 10.1073/pnas.0511299103
   Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59
   Wu W, 2000, CURR BIOL, V10, P1611, DOI 10.1016/S0960 9822(00)00868 X
   Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539
   Yi R, 2008, NATURE, V452, P225, DOI 10.1038/nature06642
   Zhang Y, 2008, DEVELOPMENT, V135, P2161, DOI 10.1242/dev.017459
   Zuklys S, 2009, J IMMUNOL, V182, P2997, DOI 10.4049/jimmunol.0713723
NR 93
TC 48
Z9 56
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD FEB 8
PY 2010
VL 5
IS 2
AR e9062
DI 10.1371/journal.pone.0009062
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 554NU
UT WOS:000274442500002
PM 20161711
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Cai, J
   Shao, X
   Yan, ZD
   Liu, XY
   Yang, YQ
   Luo, EP
   Jing, D
AF Cai, Jing
   Shao, Xi
   Yan, Zedong
   Liu, Xiyu
   Yang, Yongqing
   Luo, Erping
   Jing, Da
TI Differential skeletal response in adult and aged rats to independent and
   combinatorial stimulation with pulsed electromagnetic fields and
   mechanical vibration
SO FASEB JOURNAL
LA English
DT Article
DE age related osteopenia; osteoporosis; bone anabolism; bone quality;
   canonical Wnt signaling; pulsed electromagnetic fields; whole body
   vibration
ID WHOLE BODY VIBRATION; PROMOTING BONE FORMATION; LOW MAGNITUDE; THERAPY;
   OSTEOPOROSIS; FRACTURE; STRENGTH; WOMEN; ACTIVATION; PREVENTION
AB Pulsed electromagnetic fields (PEMFs) and whole body vibration (WBV) are proved to partially preserve bone mass/strength in hindlimb unloaded and ovariectomized animals. However, the potential age dependent skeletal response to either PEMF or WBV has not been fully investigated. Moreover, whether the coupled "mechano electro magnetic" signals can induce greater osteogenic potential than single stimulation remains unknown. Herein, 5 month old or 20 month old rats were assigned to the Control, PEMF, WBV, and PEMF + WBV groups. After 8 week treatment, single PEMF/WBV enhanced bone mass, strength, and anabolism in 5 month old rats, but not in 20 month old rats. PEMF + WBV induced greater increase of bone quantity, quality, and anabolism than single PEMF/WBV in young adult rats. PEMF + WBV also inhibited bone loss in elderly rats by primarily improving osteoblast and osteocyte activity, but had no effects on bone resorption. PEMF + WBV upregulated the expression of various canonical Wnt ligands and downstream molecules (p GSK 3 beta and beta catenin), but had no impacts on noncanonical Wnt5a expression in aged skeleton, revealing the potential involvement of canonical Wnt signaling in bone anabolism of PEMF + WBV. This study not only reveals much weaker responsiveness of aged skeleton to single PEMF/WBV relative to young adult skeleton, but also presents a novel noninvasive approach based on combinatorial treatment with PEMF + WBV for improving bone health and preserving bone quantity/quality (especially for age related osteoporosis) with stronger anabolic effects.
C1 [Cai, Jing] Shaanxi Univ Chinese Med, Coll Basic Med, Xianyang, Peoples R China.
   [Cai, Jing; Shao, Xi; Yan, Zedong; Liu, Xiyu; Yang, Yongqing; Luo, Erping; Jing, Da] Fourth Mil Med Univ, Dept Biomed Engn, 169 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.
C3 Shaanxi University of Chinese Medicine; Air Force Medical University
RP Jing, D (通讯作者)，Fourth Mil Med Univ, Dept Biomed Engn, 169 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.
EM jingdaasq@126.com
RI Cai, Jing/JXM 0087 2024; Shao, Xi/H 9452 2016; Liu, xiyu/KEJ 2349 2024
FU National Natural Science Foundation of China [31500760, 51777211,
   11972366, 51907111]; Young Talent Supporting Project in Military
   Technology of China [17 JCJQ QT 038]; Shaanxi Provincial Natural Science
   Foundation of China [2018JQ8056]
FX National Natural Science Foundation of China, Grant/Award Number:
   31500760, 51777211, 11972366 and 51907111; Young Talent Supporting
   Project in Military Technology of China, Grant/Award Number:
   17 JCJQ QT 038; Shaanxi Provincial Natural Science Foundation of China,
   Grant/Award Number: 2018JQ8056
CR ANDERSON JC, 1970, NATURE, V227, P491, DOI 10.1038/227491a0
   Assiotis A, 2012, J ORTHOP SURG RES, V7, DOI 10.1186/1749 799X 7 24
   Bala Y, 2012, J BONE MINER RES, V27, P825, DOI 10.1002/jbmr.1501
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   BASSETT CAL, 1974, SCIENCE, V184, P575
   Benhaj K, 2006, ONCOL REP, V15, P701
   Blume SW, 2011, OSTEOPOROSIS INT, V22, P1835, DOI 10.1007/s00198 010 1419 7
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Cai J, 2018, OSTEOPOROSIS INT, V29, P1177, DOI 10.1007/s00198 018 4392 1
   Catalano A, 2018, BONE, V116, P42, DOI 10.1016/j.bone.2018.07.010
   Center JR, 1999, LANCET, V353, P878, DOI 10.1016/S0140 6736(98)09075 8
   Chan ME, 2013, CURR OSTEOPOROS REP, V11, P36, DOI 10.1007/s11914 012 0132 1
   Chan ME, 2012, FASEB J, V26, P4855, DOI 10.1096/fj.12 209841
   Clarke BL, 1996, J CLIN ENDOCR METAB, V81, P2264, DOI 10.1210/jc.81.6.2264
   De Laet CEDH, 2000, BEST PRACT RES CL EN, V14, P171, DOI 10.1053/beem.2000.0067
   Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905
   Ferguson VL, 2003, BONE, V33, P387, DOI 10.1016/S8756 3282(03)00199 6
   Gabel L, 2017, J BONE MINER RES, V32, P1525, DOI 10.1002/jbmr.3115
   Ganesan K, 2009, INDIAN J EXP BIOL, V47, P939
   Gao JZ, 2016, ANN BIOMED ENG, V44, P2489, DOI 10.1007/s10439 015 1532 z
   Gilsanz V, 2006, J BONE MINER RES, V21, P1464, DOI 10.1359/JBMR.060612
   Grace KLR, 1998, ORTHOPEDICS, V21, P297
   Gruntmanis U, 2007, AM J MED SCI, V333, P85, DOI 10.1097/00000441 200702000 00004
   Holguin N, 2016, J BONE MINER RES, V31, P2215, DOI 10.1002/jbmr.2900
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Jing D, 2011, OSTEOPOROSIS INT, V22, P1885, DOI 10.1007/s00198 010 1447 3
   Jing D, 2018, BONE, V106, P11, DOI 10.1016/j.bone.2017.10.001
   Jing D, 2016, J BONE MINER RES, V31, P1713, DOI 10.1002/jbmr.2837
   Jing D, 2014, J BONE MINER RES, V29, P2250, DOI 10.1002/jbmr.2260
   Jing D, 2014, FASEB J, V28, P1582, DOI 10.1096/fj.13 237578
   Jing D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079377
   Jing D, 2010, BONE, V46, P487, DOI 10.1016/j.bone.2009.09.021
   Khosla S, 2008, ENDOCR REV, V29, P441, DOI 10.1210/er.2008 0002
   Kiel DP, 2015, J BONE MINER RES, V30, P1319, DOI 10.1002/jbmr.2448
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lambert Jessica K, 2011, Curr Osteoporos Rep, V9, P229, DOI 10.1007/s11914 011 0066 z
   Li XD, 2010, J BONE MINER RES, V25, P2371, DOI 10.1002/jbmr.182
   Lynch MA, 2010, J ORTHOP RES, V28, P241, DOI 10.1002/jor.20965
   Mahavni V, 2001, CURR OPIN ONCOL, V13, P384, DOI 10.1097/00001622 200109000 00012
   Manolagas SC, 2010, TRENDS ENDOCRIN MET, V21, P369, DOI 10.1016/j.tem.2010.01.010
   Meakin LB, 2014, J BONE MINER RES, V29, P1859, DOI 10.1002/jbmr.2222
   Musette P, 2010, OSTEOPOROSIS INT, V21, P723, DOI 10.1007/s00198 009 1097 5
   Olivares Navarrete R, 2011, ACTA BIOMATER, V7, P2740, DOI 10.1016/j.actbio.2011.02.030
   OLIVER WC, 1992, J MATER RES, V7, P1564, DOI 10.1557/JMR.1992.1564
   Razi H, 2015, J BONE MINER RES, V30, P1864, DOI 10.1002/jbmr.2528
   Rizzoli R, 2011, CALCIFIED TISSUE INT, V89, P91, DOI 10.1007/s00223 011 9499 8
   Rubin C, 2001, FASEB J, V15, P2225, DOI 10.1096/fj.01 0166com
   Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122
   Rubin C, 2004, J BONE MINER RES, V19, P343, DOI 10.1359/JBMR.0301251
   Sañudo B, 2017, MENOPAUSE, V24, P1208, DOI 10.1097/GME.0000000000000872
   Sehmisch S, 2009, OSTEOPOROSIS INT, V20, P1999, DOI 10.1007/s00198 009 0892 3
   Shen WW, 2010, BIOELECTROMAGNETICS, V31, P113, DOI 10.1002/bem.20535
   Sherk VD, 2013, J CLIN DENSITOM, V16, P104, DOI 10.1016/j.jocd.2012.07.009
   Sinder BP, 2013, J BONE MINER RES, V28, P73, DOI 10.1002/jbmr.1717
   Tu XL, 2007, DEV CELL, V12, P113, DOI 10.1016/j.devcel.2006.11.003
   Vanleene M, 2013, BONE, V53, P507, DOI 10.1016/j.bone.2013.01.023
   Verschueren SMP, 2004, J BONE MINER RES, V19, P352, DOI 10.1359/JBMR.0301245
   Wang P, 2019, J CELL PHYSIOL, V234, P10588, DOI 10.1002/jcp.27734
   Wang T, 2019, OSTEOPOROSIS INT, V30, P267, DOI 10.1007/s00198 018 04822 6
   Zhai MM, 2016, BIOELECTROMAGNETICS, V37, P152, DOI 10.1002/bem.21961
   Zhu SY, 2017, BIOELECTROMAGNETICS, V38, P406, DOI 10.1002/bem.22065
NR 61
TC 18
Z9 18
U1 1
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD FEB
PY 2020
VL 34
IS 2
BP 3037
EP 3050
DI 10.1096/fj.201902779R
EA DEC 2019
PG 14
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA KN2HU
UT WOS:000504854800001
PM 31908035
DA 2025 08 17
ER

PT J
AU de Matos, IAF
   Fernandes, NAR
   Cirelli, G
   de Godoi, MA
   de Assis, LR
   Regasini, LO
   Rossa, C Jr
   Guimaraes Stabili, MR
AF de Matos, Iolanda Augusta Fernandes
   Fernandes, Natalie Aparecida Rodrigues
   Cirelli, Giovani
   de Godoi, Mariely Araujo
   de Assis, Leticia Ribeiro
   Regasini, Luis Octavio
   Rossa Junior, Carlos
   Guimaraes Stabili, Morgana Rodrigues
TI Chalcone T4 Inhibits RANKL Induced Osteoclastogenesis and Stimulates
   Osteogenesis In Vitro
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE chalcone; osteoclastogenesis; osteogenesis; intracellular signaling
ID PATHWAYS; THERAPY; EXPRESSION
AB Chalcones are phenolic compounds produced during the biosynthesis of flavonoids that have numerous biological activities, including anti inflammatory, antioxidant and anticancer. In this in vitro study, we investigate a newly synthesized chalcone (Chalcone T4) in the context of bone turnover, specifically on the modulation of osteoclast differentiation and activity and osteoblast differentiation. Murine macrophages (RAW 264.7) and pre osteoblasts (MC3T3 E1) were used as models of osteoclasts and osteoblasts, respectively. Differentiation and activity osteoclasts were induced by RANKL in the presence and absence of non cytotoxic concentrations of Chalcone T4, added in different periods during osteoclastogenesis. Osteoclast differentiation and activity were assessed by actin ring formation and resorption pit assay, respectively. Expression of osteoclast specific markers (Nfatc1, Oscar, Acp5, Mmp 9 and Ctsk) was determined by RT qPCR, and the activation status of relevant intracellular signaling pathways (MAPK, AKT and NF kB) by Western blot. Osteoblast differentiation and activity was induced by osteogenic culture medium in the presence and absence of the same concentrations of Chalcone T4. Outcomes assessed were the formation of mineralization nodules via alizarin red staining and the expression of osteoblast related genes (Alp e Runx2) by RT qPCR. Chalcone T4 reduced RANKL induced osteoclast differentiation and activity, suppressed Oscar, Acp5 and Mmp 9 expression, and decreased ERK and AKT activation in a dose dependent manner. Nfact1 expression and NF kB phosphorylation were not modulated by the compound. Mineralized matrix formation and the expression of Alp and Runx2 by MC3T3 E1 cells were markedly stimulated by Chalcone T4. Collectively, these results demonstrate that Chalcone T4 inhibits in osteoclast differentiation and activity and stimulates osteogenesis, which indicates a promising therapeutic potential in osteolytic diseases.
C1 [de Matos, Iolanda Augusta Fernandes; Fernandes, Natalie Aparecida Rodrigues; Cirelli, Giovani; de Godoi, Mariely Araujo; Rossa Junior, Carlos; Guimaraes Stabili, Morgana Rodrigues] Sao Paulo State Univ UNESP, Sch Dent Araraquara, Dept Diag & Surg, BR 14801385 Araraquara, SP, Brazil.
   [de Assis, Leticia Ribeiro; Regasini, Luis Octavio] Sao Paulo State Univ UNESP, Inst Biosci Humanities & Exact Sci, Dept Chem & Environm Sci, BR 15054000 Sao Jose Do Rio Preto, SP, Brazil.
C3 Universidade Estadual Paulista; Universidade Estadual Paulista
RP Guimaraes Stabili, MR (通讯作者)，Sao Paulo State Univ UNESP, Sch Dent Araraquara, Dept Diag & Surg, BR 14801385 Araraquara, SP, Brazil.
EM olanda.matos@unesp.br; natalie.fernandes@unesp.br;
   morgana.guimaraes@unesp.br
RI guimaraes, morgana/C 8966 2014; Regasini, Luis/B 1985 2012; Rossa Jr,
   Carlos/D 8328 2012; STABILI, MORGANA/ABC 9852 2021
OI guimaraes, morgana/0000 0002 1297 9717; Rossa Jr,
   Carlos/0000 0003 1705 5481; Ribeiro de Assis,
   Leticia/0000 0001 9869 8934; Rodrigues Fernandes, Natalie
   Aparecida/0000 0002 7157 527X
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [2018/17047 3]
FX Financial support was provided by Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (2018/17047 3) awarded to Guimaraes Stabili, MR.
CR Abdallah BM, 2020, MOLECULES, V25, DOI 10.3390/molecules25081885
   Ali AA, 2017, PHARMACOL REP, V69, P268, DOI 10.1016/j.pharep.2016.11.002
   Almelah E, 2016, ANTICANCER RES, V36, P6043, DOI 10.21873/anticanres.11193
   Batovska DI, 2010, CURR CLIN PHARMACOL, V5, P1, DOI 10.2174/157488410790410579
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Çetinkaya MB, 2002, J BONE MINER METAB, V20, P44, DOI 10.1007/s774 002 8446 8
   Chen X, 2018, BIOCHEM BIOPH RES CO, V496, P245, DOI 10.1016/j.bbrc.2017.11.159
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Fernandes NAR, 2021, J PERIODONTAL RES, V56, P569, DOI 10.1111/jre.12857
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   Golub LM, 2020, PERIODONTOL 2000, V82, P186, DOI 10.1111/prd.12315
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Hsieh HK, 2000, J PHARM PHARMACOL, V52, P163, DOI 10.1211/0022357001773814
   Jeong S, 2020, MOLECULES, V25, DOI 10.3390/molecules25173908
   Jimi E, 2019, CELLS BASEL, V8, DOI 10.3390/cells8121636
   Jung EG, 2015, ARCH PHARM RES, V38, P973, DOI 10.1007/s12272 015 0557 z
   Kim H, 2018, J MICROBIOL BIOTECHN, V28, P190, DOI 10.4014/jmb.1707.07042
   Kim SN, 2012, AMINO ACIDS, V42, P1455, DOI 10.1007/s00726 011 0901 7
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Komori T, 2018, HISTOCHEM CELL BIOL, V149, P313, DOI 10.1007/s00418 018 1640 6
   Leitao EPT, 2020, CURR PHARM DESIGN, V26, P2843, DOI 10.2174/1381612826666200403124259
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200
   Maurya SW, 2017, BIOORG MED CHEM LETT, V27, P1390, DOI 10.1016/j.bmcl.2017.02.004
   Nakamura S, 2018, PHARMACOLOGY, V101, P236, DOI 10.1159/000486599
   Rudrapal M, 2021, MOLECULES, V26, DOI 10.3390/molecules26237177
   Suh KS, 2013, FOOD CHEM TOXICOL, V62, P99, DOI 10.1016/j.fct.2013.08.047
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Tempone AG, 2022, CHEM BIOL INTERACT, V365, DOI 10.1016/j.cbi.2022.110086
   van de Laar L, 2012, BLOOD, V120, P4982, DOI 10.1182/blood 2012 02 413229
   Verron E, 2014, DRUG DISCOV TODAY, V19, P312, DOI 10.1016/j.drudis.2013.08.010
   Yang FC, 2006, J CLIN INVEST, V116, P2880, DOI 10.1172/JCI29092
   Zheng WH, 2017, INT IMMUNOPHARMACOL, V42, P1, DOI 10.1016/j.intimp.2016.11.009
NR 33
TC 0
Z9 0
U1 1
U2 7
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD APR
PY 2023
VL 24
IS 8
AR 7624
DI 10.3390/ijms24087624
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA E7XU9
UT WOS:000977636600001
PM 37108787
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Sabha, M
   Siaton, BC
   Hochberg, MC
AF Sabha, Marwa
   Siaton, Bernadette C.
   Hochberg, Marc C.
TI Lorecivivint, an intra articular potential disease modifying
   osteoarthritis drug
SO EXPERT OPINION ON INVESTIGATIONAL DRUGS
LA English
DT Article
DE Lorecivivint; osteoarthritis; knee osteoarthritis; wnt signaling;
   disease modifying osteoarthritis drug; dmoad; clinical trial
ID WNT PATHWAY INHIBITOR; BONE MARROW LESIONS; KNEE OSTEOARTHRITIS;
   ZOLEDRONIC ACID; UNITED STATES; PREVALENCE; ARTHRITIS; SM04690;
   DIFFERENTIATION; POPULATION
AB Introduction: Osteoarthritis (OA) is the most common form of arthritis. Knee OA is associated with joint pain, activity limitation, physical disability, reduced health related quality of life, and increased mortality. To date, all pharmacologic treatments for OA are directed toward pain management. Lorecivivint (LOR) is an investigational agent that has potential as a disease modifying osteoarthritis drug (DMOAD). It modulates the Wnt signaling pathway by inhibiting CDC like kinase 2 and dual specificity tyrosine phosphorylation regulated kinase 1 A which are molecular regulators in Wnt signaling, chondrogenesis, and inflammation.
   Areas covered: This paper discusses the current pharmacologic guidelines for the treatment of knee OA and illuminates the potential of a new agent, Lorecivivint, as a disease modifying osteoarthritis drug (DMOAD). Efficacy and safety and the challenges for this novel agent come under the spotlight.
   Expert opinion: LOR may be a potential DMOAD for the treatment of patients with knee OA. While the Phase 2A trial did not meet its primary endpoint, preplanned analyses did identify a target population for further evaluation of its potential as a DMOAD. Phase 3 trials are ongoing, but this intra articular drug is currently considered safe and well tolerated, with no significant reported systemic side effects.
C1 [Sabha, Marwa; Siaton, Bernadette C.; Hochberg, Marc C.] Univ Maryland, Sch Med, Dept Med, Div Rheumatol & Clin Immunol, Baltimore, MD 21201 USA.
   [Hochberg, Marc C.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Div Gerontol, Baltimore, MD 21201 USA.
C3 University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore
RP Hochberg, MC (通讯作者)，Univ Maryland, Sch Med, Med & Epidemiol & Publ Hlth, Baltimore, MD 21201 USA.; Hochberg, MC (通讯作者)，Univ Maryland, Sch Med, Div Rheumatol & Clin Immunol, Baltimore, MD 21201 USA.; Hochberg, MC (通讯作者)，Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA.
EM mhochber@som.umaryland.edu
OI Siaton, Bernadette/0000 0002 2170 8919
CR Agency for Healthcare Research and Quality, 2019, HCUP FAST STATS
   Arden NK, 2021, NAT REV RHEUMATOL, V17, P59, DOI 10.1038/s41584 020 00523 9
   Bannuru RR, 2019, OSTEOARTHR CARTILAGE, V27, P1578, DOI 10.1016/j.joca.2019.06.011
   Berra's Yogi, YOGIISMS QUOTATIONS
   Bruyère O, 2019, SEMIN ARTHRITIS RHEU, V49, P337, DOI 10.1016/j.semarthrit.2019.04.008
   Cai GQ, 2020, JAMA J AM MED ASSOC, V323, P1456, DOI 10.1001/jama.2020.2938
   Cisternas MG, 2016, ARTHRIT CARE RES, V68, P574, DOI 10.1002/acr.22721
   DALYs and HALE Collaborators, 2016, LANCET, V388
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   De Boer J, 2004, TISSUE ENG, V10, P393, DOI 10.1089/107632704323061753
   Derry S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007400.pub3
   Deshmukh V, 2019, OSTEOARTHR CARTILAGE, V27, P1347, DOI 10.1016/j.joca.2019.05.006
   Deshmukh V, 2018, OSTEOARTHR CARTILAGE, V26, P18, DOI 10.1016/j.joca.2017.08.015
   Dillon CF, 2006, J RHEUMATOL, V33, P2271
   Hawker GA, 2019, CLIN EXP RHEUMATOL, V37, P3
   Hayami T, 2006, BONE, V38, P234, DOI 10.1016/j.bone.2005.08.007
   Hochberg MC, 2019, JAMA J AM MED ASSOC, V322, P1360, DOI 10.1001/jama.2019.14735
   Hochberg MC, 2012, ARTHRIT CARE RES, V64, P465, DOI 10.1002/acr.21596
   Hochberg MC, 2019, OSTEOARTHRITIS
   Hootman JM, 2016, ARTHRITIS RHEUMATOL, V68, P1582, DOI 10.1002/art.39692
   Hunter DJ, 2019, LANCET, V393
   Kolasinski SL, 2020, ARTHRIT CARE RES, pNIL_1
   Kroon FPB, 2019, LANCET, V394, P1993, DOI 10.1016/S0140 6736(19)32489 4
   Kurtz SM, 2014, J BONE JOINT SURG AM, V96A, P624, DOI 10.2106/JBJS.M.00285
   Lane Nancy E, 2020, Trans Am Clin Climatol Assoc, V131, P55
   Laslett LL, 2012, ANN RHEUM DIS, V71, P1322, DOI 10.1136/annrheumdis 2011 200970
   Lories RJ, 2020, RHEUMATOL THER, V7, P259, DOI 10.1007/s40744 020 00205 8
   March L., 2016, Osteoarthritis: A Serious Disease: Submitted to the US Food and Drug Administration
   McAlindon TE, 2014, OSTEOARTHR CARTILAGE, V22, P363, DOI 10.1016/j.joca.2014.01.003
   Nelson AE, 2018, OSTEOARTHR CARTILAGE, V26, P319, DOI 10.1016/j.joca.2017.11.014
   Pincus T, 2019, CLIN EXP RHEUMATOL, V37, P7
   Rannou F, 2016, SEMIN ARTHRITIS RHEU, V45, pS18, DOI 10.1016/j.semarthrit.2015.11.007
   Reginster JY, 2014, ANN RHEUM DIS, V73, pE8, DOI 10.1136/annrheumdis 2013 204194
   Rutjes AWS, 2012, ANN INTERN MED, V157, P180, DOI 10.7326/0003 4819 157 3 201208070 00473
   Safiri S, 2020, ANN RHEUM DIS, V79, P819, DOI 10.1136/annrheumdis 2019 216515
   Samumed, 2019, SAMUMED LAUNCHES PHA
   Samumed, 2020, LORECIVIVINT SAMUMED
   Samumed, 2019, SAMUMED DOSES 1 SUBJ
   Samumed L., 2019, SAMUMED PRESENTS SAF
   SIMSEK I, 2020, OSTEOARTHR CARTILAGE, V28, pS37
   Stampella A, 2017, BEST PRACT RES CL RH, V31, P721, DOI 10.1016/j.berh.2018.03.004
   Usami Y, 2016, LAB INVEST, V96, P186, DOI 10.1038/labinvest.2015.142
   Veronese N, 2016, SEMIN ARTHRITIS RHEU, V46, P160, DOI 10.1016/j.semarthrit.2016.04.002
   Wang YM, 2019, INT J MOB COMMUN, V17, P1
   Yazici Y, 2017, OSTEOARTHR CARTILAGE, V25, P1598, DOI 10.1016/j.joca.2017.07.006
   Yazici Y, 2020, ARTHRITIS RHEUMATOL, V72, P1694, DOI 10.1002/art.41315
   Yazici Y, 2019, ANN RHEUM DIS, V78, P519, DOI 10.1136/annrheumdis 2019 eular.5045
   Zhang YQ, 2001, ARTHRITIS RHEUM, V44, P2065, DOI 10.1002/1529 0131(200109)44:9<2065::AID ART356>3.0.CO;2 Z
   Zhang YQ, 2010, CLIN GERIATR MED, V26, P355, DOI [10.1016/j.rdc.2012.10.004, 10.1016/j.cger.2010.03.001]
NR 49
TC 20
Z9 21
U1 0
U2 10
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1354 3784
EI 1744 7658
J9 EXPERT OPIN INV DRUG
JI Expert Opin. Investig. Drugs
PD DEC 1
PY 2020
VL 29
IS 12
BP 1339
EP 1345
DI 10.1080/13543784.2020.1842357
EA NOV 2020
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA PE3DP
UT WOS:000587523800001
PM 33096010
DA 2025 08 17
ER

PT S
AU Terpos, E
   Voskaridou, E
AF Terpos, Evangelos
   Voskaridou, Ersi
BE Vichinsky, EP
   Neufeld, EJ
TI Treatment options for thalassemia patients with osteoporosis
SO COOLEY'S ANEMIA: NINTH SYMPOSIUM
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT 9th Cooley's Anemia Symposium
CY OCT 21 24, 2009
CL New York Acad Sci, New York, NY
SP Cooleys Anemia Fdn, New York Acad Sci
HO New York Acad Sci
DE thalassemia; osteoporosis; bisphosphonates; therapy; pathogenesis
ID BONE MINERAL DENSITY; VITAMIN D RECEPTOR; BETA THALASSEMIA; ZOLEDRONIC
   ACID; REPLACEMENT THERAPY; MAJOR PATIENTS; YOUNG ADULTS; METABOLISM;
   GROWTH; OSTEOPROTEGERIN
AB Osteoporosis represents a prominent cause of morbidity in patients with thalassemia. The delay in sexual maturation, the presence of diabetes and hypothyroidism, the parathyroid gland dysfunction, the progressive marrow expansion, the iron toxicity on osteoblasts, the iron chelators, and the deficiency of growth hormone or insulin growth factors have been identified as major causes of osteoporosis in thalassemia. Adequate hormonal replacement, effective iron chelation, improvement of hemoglobin levels, calcium and vitamin D administration, physical activity, and smoking cessation are the main to date measures for the management of the disease. During the last decade, novel pathogenetic data suggest that the reduced osteoblastic activity, which is believed to be the basic mechanism of bone loss in thalassemia, is accompanied by a comparable or even greater increase in bone resorption. Therefore, the role of bisphosphonates, potent inhibitors of osteoclast activation, arises as a major factor in the management of osteoporosis in thalassemia patients.
C1 [Voskaridou, Ersi] Laikon Gen Hosp, Thalassemia Ctr, Athens, Greece.
   [Terpos, Evangelos] Univ Athens, Sch Med, Dept Clin Therapeut, GR 11527 Athens, Greece.
C3 Laiko General Hospital; National & Kapodistrian University of Athens
RP Terpos, E (通讯作者)，Univ Athens, Sch Med, Dept Clin Therapeut, Alexandra Gen Hosp, 80 Vas Sofias Ave, Athens 11528, Greece.
EM eterpos@hotmail.com
RI ; Terpos, Evangelos/AAD 3667 2019
OI Terpos, Evangelos/0000 0001 5133 1422; Voskaridou,
   Ersi/0000 0002 0979 5722
FU NOVARTIS
FX The authors have received research support and honoraria from NOVARTIS.
CR ANAPLIOTOU MLG, 1995, CLIN ENDOCRINOL, V42, P279, DOI 10.1111/j.1365 2265.1995.tb01876.x
   Angastiniotis M, 1998, J PEDIATR ENDOCR MET, V11, P779
   [Anonymous], 1994, World Health Organ Tech Rep Ser, V843, P1
   Berkovitch M, 2000, J PEDIATR ENDOCR MET, V13, P179
   BINKLEY NC, 2002, J CLIN DENSITOM, V5, P19
   CANATAN D, 1995, ACTA HAEMATOL BASEL, V93, P20
   Carmina E, 2004, CALCIFIED TISSUE INT, V74, P68, DOI 10.1007/s00223 002 1044 3
   DeSanctis V, 1996, EUR J PEDIATR, V155, P368, DOI 10.1007/BF01955263
   Domrongkitchaiporn S, 2003, J BONE MINER RES, V18, P1682, DOI 10.1359/jbmr.2003.18.9.1682
   Garofalo F, 1998, ANN NY ACAD SCI, V850, P475, DOI 10.1111/j.1749 6632.1998.tb10526.x
   Geusens PPMM, 2002, HORM RES, V58, P49, DOI 10.1159/000066483
   HATORI M, 1995, CALCIFIED TISSUE INT, V57, P229, DOI 10.1007/BF00310264
   Kosaryan Mehrnoosh, 2004, Pediatr Endocrinol Rev, V2 Suppl 2, P303
   Lasco A, 2001, OSTEOPOROSIS INT, V12, P570, DOI 10.1007/s001980170079
   LINDSAY R, 1993, LANCET, V341, P801, DOI 10.1016/0140 6736(93)90571 W
   Ma ESK, 2003, HAEMATOLOGICA, V88, P345
   Mahachoklertwattana P, 2003, J CLIN ENDOCR METAB, V88, P3966, DOI 10.1210/jc.2002 021548
   Michelson J, 1988, J Orthop Trauma, V2, P29, DOI 10.1097/00005131 198802000 00007
   Morabito N, 2004, J BONE MINER RES, V19, P722, DOI 10.1359/JBMR.040113
   Morabito N, 2002, OSTEOPOROSIS INT, V13, P644, DOI 10.1007/s001980200087
   Morabito N, 2007, BONE, V40, P1588, DOI 10.1016/j.bone.2007.02.020
   Olivieri NF, 1999, NEW ENGL J MED, V341, P99, DOI 10.1056/NEJM199907083410207
   Pennisi P, 2003, J BONE MINER METAB, V21, P402, DOI 10.1007/s00774 003 0435 5
   Perrotta S, 2000, BRIT J HAEMATOL, V111, P461, DOI 10.1046/j.1365 2141.2000.02382.x
   Pollak RD, 2000, BRIT J HAEMATOL, V111, P902
   Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763
   Rucker D, 2004, CLIN ENDOCRINOL, V60, P491, DOI 10.1111/j.1365 2265.2004.02006.x
   Soliman AT, 1998, METABOLISM, V47, P541, DOI 10.1016/S0026 0495(98)90237 2
   Uitterlinden AG, 2000, ARTHRITIS RHEUM US, V43, P1456, DOI 10.1002/1529 0131(200007)43:7<1456::AID ANR7>3.0.CO;2 M
   Uitterlinden AG, 2001, J BONE MINER RES, V16, P379, DOI 10.1359/jbmr.2001.16.2.379
   Voskaridou E, 2005, EUR J HAEMATOL, V74, P359, DOI 10.1111/j.1600 0609.2004.00395.x
   Voskaridou E, 2004, BRIT J HAEMATOL, V127, P127, DOI 10.1111/j.1365 2141.2004.05143.x
   Voskaridou E, 2003, BRIT J HAEMATOL, V123, P730, DOI 10.1046/j.1365 2141.2003.04657.x
   Voskaridou E, 2001, BRIT J HAEMATOL, V112, P36, DOI 10.1046/j.1365 2141.2001.02549.x
   Voskaridou E, 2008, HAEMATOL HEMATOL J, V93, P1588, DOI 10.3324/haematol.12849
   Voskaridou E, 2008, ACTA HAEMATOL BASEL, V119, P40, DOI 10.1159/000114869
   Voskaridou E, 2006, HAEMATOLOGICA, V91, P1193
   Voskaridou Ersi, 2008, Pediatr Endocrinol Rev, V6 Suppl 1, P86
   Voskaridou E, 2009, HAEMATOL HEMATOL J, V94, P725, DOI [10.3324/haematol.2008.000893, 10.3324/haema tol.2008.000893]
   Wonke B, 1998, J PEDIATR ENDOCR MET, V11, P795
NR 40
TC 51
Z9 51
U1 0
U2 3
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA
SN 0077 8923
BN 978 1 57331 782 5
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2010
VL 1202
BP 237
EP 243
DI 10.1111/j.1749 6632.2010.05542.x
PG 7
WC Hematology; Multidisciplinary Sciences
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Science & Technology   Other Topics
GA BRM50
UT WOS:000283099600036
PM 20712799
DA 2025 08 17
ER

PT J
AU Brommage, R
   Liu, J
   Vogel, P
   Mseeh, F
   Thompson, AY
   Potter, DG
   Shadoan, MK
   Hansen, GM
   Jeter Jones, S
   Cui, J
   Bright, D
   Bardenhagen, JP
   Doree, DD
   Movérare Skrtic, S
   Nilsson, KH
   Henning, P
   Lerner, UH
   Ohlsson, C
   Sands, AT
   Tarver, JE
   Powell, DR
   Zambrowicz, B
   Liu, QY
AF Brommage, Robert
   Liu, Jeff
   Vogel, Peter
   Mseeh, Faika
   Thompson, Andrea Y.
   Potter, David G.
   Shadoan, Melanie K.
   Hansen, Gwenn M.
   Jeter Jones, Sabrina
   Cui, Jie
   Bright, Dawn
   Bardenhagen, Jennifer P.
   Doree, Deon D.
   Moverare Skrtic, Sofia
   Nilsson, Karin H.
   Henning, Petra
   Lerner, Ulf H.
   Ohlsson, Claes
   Sands, Arthur T.
   Tarver, James E.
   Powell, David R.
   Zambrowicz, Brian
   Liu, Qingyun
TI NOTUM inhibition increases endocortical bone formation and bone strength
SO BONE RESEARCH
LA English
DT Article
ID NON VERTEBRAL FRACTURES; CORTICAL BONE; LINING CELLS; NON HIP;
   OSTEOCLASTOGENESIS; ROMOSOZUMAB; MUTATIONS; DYSPLASIA; FRAGILITY;
   DATABASE
AB The disability, mortality and costs caused by non vertebral osteoporotic fractures are enormous. Existing osteoporosis therapies are highly effective at reducing vertebral but not non vertebral fractures. Cortical bone is a major determinant of non vertebral bone strength. To identify novel osteoporosis drug targets, we phenotyped cortical bone of 3 366 viable mouse strains with global knockouts of druggable genes. Cortical bone thickness was substantially elevated in Notum( / ) mice. NOTUM is a secreted WNT lipase and we observed high NOTUM expression in cortical bone and osteoblasts but not osteoclasts. Three orally active small molecules and a neutralizing antibody inhibiting NOTUM lipase activity were developed. They increased cortical bone thickness and strength at multiple skeletal sites in both gonadal intact and ovariectomized rodents by stimulating endocortical bone formation. Thus, inhibition of NOTUM activity is a potential novel anabolic therapy for strengthening cortical bone and preventing non vertebral fractures.
C1 [Brommage, Robert; Liu, Jeff; Vogel, Peter; Mseeh, Faika; Thompson, Andrea Y.; Potter, David G.; Shadoan, Melanie K.; Hansen, Gwenn M.; Jeter Jones, Sabrina; Cui, Jie; Bright, Dawn; Bardenhagen, Jennifer P.; Doree, Deon D.; Sands, Arthur T.; Tarver, James E.; Powell, David R.; Zambrowicz, Brian; Liu, Qingyun] Lexicon Pharmaceut, The Woodlands, TX 77381 USA.
   [Moverare Skrtic, Sofia; Nilsson, Karin H.; Henning, Petra; Lerner, Ulf H.; Ohlsson, Claes] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Ctr Bone & Arthrit Res, Gothenburg, Sweden.
   [Brommage, Robert] Univ Gothenburg, Ctr Bone & Arthrit Res, Gothenburg, Sweden.
   [Liu, Jeff] Biogen Inc, 14 Cambridge Ctr, Cambridge, MA 02142 USA.
   [Vogel, Peter] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA.
   [Mseeh, Faika; Jeter Jones, Sabrina; Bardenhagen, Jennifer P.] MD Anderson Canc Ctr, Houston, TX USA.
   [Potter, David G.] Bethyl Labs, Montgomery, TX USA.
   [Shadoan, Melanie K.] Merck, Rahway, NJ USA.
   [Hansen, Gwenn M.; Sands, Arthur T.] Nurix, San Francisco, CA USA.
   [Cui, Jie] Wntrix, Houston, TX USA.
   [Doree, Deon D.] PRA Hlth Sci, Raleigh, NC USA.
   [Tarver, James E.] Univ Penn, Philadelphia, PA 19104 USA.
   [Zambrowicz, Brian] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.
   [Liu, Qingyun] Univ Texas Houston, Houston, TX USA.
C3 Lexicon Pharmaceuticals; University of Gothenburg; University of
   Gothenburg; Biogen; St Jude Children's Research Hospital; University of
   Texas System; UTMD Anderson Cancer Center; Merck & Company; University
   of Pennsylvania; Regeneron; University of Texas System; University of
   Texas Health Science Center Houston
RP Brommage, R (通讯作者)，Lexicon Pharmaceut, The Woodlands, TX 77381 USA.; Brommage, R (通讯作者)，Univ Gothenburg, Ctr Bone & Arthrit Res, Gothenburg, Sweden.
EM brommage@outlook.com
RI Vogel, Peter/N 2490 2018; Skrtic, Sofia/AAQ 1585 2020; Tarver,
   James/B 4323 2008; Ohlsson, Claes/HIR 6959 2022; Henning,
   Petra/KIL 4650 2024; Ohlsson, Claes/AGP 3544 2022
OI Brommage, Robert/0000 0002 9947 3822; Henning,
   Petra/0000 0002 9330 6265; Ohlsson, Claes/0000 0002 9633 2805; Lerner,
   Ulf/0000 0002 3579 1960; Hansen, Gwenn/0000 0003 2504 5849; 
FU Swedish Research Council; Swedish Government; Lundberg Foundation;
   Torsten Soderberg Foundation; Novo Nordisk Foundation; Swedish
   Foundation for Strategic Research; Knut and Alice Wallenberg Foundation;
   Novo Nordisk Fonden [NNF14OC0010513, NNF13OC0005785, NNF18OC0033898,
   NNF15OC0015080] Funding Source: researchfish
FX Victor Shen and Von Wright of Numira Biosciences performed bone breaking
   strength measurements. Lexicon's DMPK group provided key toxicology and
   pharmacokinetic data. Suma Gopinathan formulated LP compounds for oral
   administration to mice and rats. Thomas J. Wronski of the University of
   Florida performed the rat LV4 trabecular bone static histomorphometry
   measurements. Lexicon's Genome5000 (TM) KO mouse comprehensive
   phenotyping campaign involved hundreds of scientists, with Laurie Minze,
   Louis Frey and Zheng Zheng Shi, and others, focusing on skeletal
   analyses. Victoria K. Lombardo, Kenneth Carson, Joe Barbosa, Qiang Han,
   Praveen Pabba, Michael Gardyan, and Ashok Tunoori contributed to
   medicinal chemistry efforts. Xiao Feng and Bill Key contributed to
   antibody development. Thanks to Donald B. Kimmel and Hua Zhu (David) Ke
   for histomorphometry reviews and helpful discussions. The work in
   Gothenburg was supported by the Swedish Research Council and by grants
   from the Swedish Government (under the Avtal om Lakarutbildning och
   Medicinsk Forskning [Agreement for Medical Education and Research]), the
   Lundberg Foundation, the Torsten Soderberg Foundation, the Novo Nordisk
   Foundation, the Swedish Foundation for Strategic Research and the Knut
   and Alice Wallenberg Foundation.
CR Ashikov A, 2018, HUM MOL GENET, V27, P3029, DOI 10.1093/hmg/ddy213
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Binkley N, 2003, J BONE MINER RES, V18, P370, DOI 10.1359/jbmr.2003.18.2.370
   Boivin FJ, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00081
   Brommage R, 2000, CALCIFIED TISSUE INT, V67, P479, DOI 10.1007/s002230001187
   Brommage R, 2013, J BONE MINER RES  S1, V28, pS347
   Brommage R, 2018, BEST PRACT RES CL EN, V32, P329, DOI 10.1016/j.beem.2018.02.006
   Brommage R, 2015, J CELL BIOCHEM, V116, P2139, DOI 10.1002/jcb.25179
   Brommage R, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.34
   Burr DB, 2010, LANCET, V375, P1672, DOI 10.1016/S0140 6736(10)60444 8
   Chen YF, 2016, PROTEIN SCI, V25, P1942, DOI 10.1002/pro.3016
   Cooper DN, 2013, HUM GENET, V132, P1077, DOI 10.1007/s00439 013 1331 2
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Dickinson ME, 2016, NATURE, V537, P508, DOI 10.1038/nature19356
   Granholm S, 2013, BONE, V52, P83, DOI 10.1016/j.bone.2012.09.019
   Halt K, 2014, PEDIATR NEPHROL, V29, P737, DOI 10.1007/s00467 013 2733 z
   Han Q, 2016, BIOORG MED CHEM LETT, V26, P1184, DOI 10.1016/j.bmcl.2016.01.038
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   Holloway KL, 2016, OSTEOPOROSIS INT, V27, P905, DOI 10.1007/s00198 015 3322 8
   Hupkes M, 2014, BMC MOL BIOL, V15, DOI 10.1186/1471 2199 15 1
   Iida A, 2016, J MED GENET, V53, P568, DOI 10.1136/jmedgenet 2016 103756
   Janda CY, 2012, SCIENCE, V337, P59, DOI 10.1126/science.1222879
   Kakugawa S, 2015, NATURE, V519, P187, DOI 10.1038/nature14259
   KESHAWARZ NM, 1984, METAB BONE DIS RELAT, V5, P223, DOI 10.1016/0221 8747(84)90063 8
   Khosla S, 2017, NAT REV ENDOCRINOL, V13, P697, DOI 10.1038/nrendo.2017.136
   Kim SW, 2017, J BONE MINER RES, V32, P892, DOI 10.1002/jbmr.3038
   Kim SW, 2012, J BONE MINER RES, V27, P2075, DOI 10.1002/jbmr.1665
   Kiper POS, 2016, NEW ENGL J MED, V374, P2553, DOI 10.1056/NEJMoa1509342
   Langdahl B, 2016, THER ADV MUSCULOSKEL, V8, P225, DOI 10.1177/1759720X16670154
   Lerner UH, 2015, J INTERN MED, V277, P630, DOI 10.1111/joim.12368
   Mackey DC, 2011, J BONE MINER RES, V26, P2411, DOI 10.1002/jbmr.446
   MAZESS RB, 1990, CALCIFIED TISSUE INT, V47, P191, DOI 10.1007/BF02555918
   Movérare Skrtic S, 2014, NAT MED, V20, P1279, DOI 10.1038/nm.3654
   Ohlsson C, 2018, J ENDOCRINOL, V237, P113, DOI 10.1530/JOE 18 0020
   Ohlsson C, 2017, J CLIN ENDOCR METAB, V102, P516, DOI 10.1210/jc.2016 3177
   PEAD MJ, 1988, J BONE MINER RES, V3, P647
   Petryszak R, 2016, NUCLEIC ACIDS RES, V44, pD746, DOI 10.1093/nar/gkv1045
   Plewczynski D, 2009, J MOL MODEL, V15, P695, DOI 10.1007/s00894 008 0353 5
   Proffitt KD, 2012, J BIOL CHEM, V287, P34167, DOI 10.1074/jbc.M112.381970
   Reeve J, 2017, BONEKEY REP, V6, DOI 10.1038/bonekey.2016.82
   Russ AP, 2005, DRUG DISCOV TODAY, V10, P1607, DOI 10.1016/S1359 6446(05)03666 4
   Tarver JE, 2016, BIOORG MED CHEM LETT, V26, P1525, DOI 10.1016/j.bmcl.2016.02.021
   Tran T, 2017, J BONE MINER RES, V32, P1802, DOI 10.1002/jbmr.3118
   Torisu Y, 2008, CANCER SCI, V99, P1139, DOI 10.1111/j.1349 7006.2008.00814.x
   Vogel P, 2016, VET PATHOL, V53, P853, DOI 10.1177/0300985815626778
   Vogel P, 2012, VET PATHOL, V49, P998, DOI 10.1177/0300985812453177
   Wergedal JE, 2015, ENDOCRINOLOGY, V156, P1023, DOI 10.1210/en.2014 1702
   Whyte MP, 2017, J BONE MINER RES, V32, P757, DOI 10.1002/jbmr.3034
   Xing WR, 2013, J BONE MINER RES, V28, P1962, DOI 10.1002/jbmr.1935
   Yao W, 1999, BONE, V25, P697, DOI 10.1016/S8756 3282(99)00220 3
   Zambrowicz BP, 2003, NAT REV DRUG DISCOV, V2, P38, DOI 10.1038/nrd987
   Zebaze RMD, 2010, LANCET, V375, P1729, DOI 10.1016/S0140 6736(10)60320 0
   Zhang XJ, 2016, J BIOL CHEM, V291, P2435, DOI 10.1074/jbc.M115.677807
   Zhang XJ, 2015, DEV CELL, V32, P719, DOI 10.1016/j.devcel.2015.02.014
   Zheng HF, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002745
NR 56
TC 64
Z9 69
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095 4700
EI 2095 6231
J9 BONE RES
JI Bone Res.
PD JAN 8
PY 2019
VL 7
AR 2
DI 10.1038/s41413 018 0038 3
PG 12
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA HG7MC
UT WOS:000455174000001
PM 30622831
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Rolph, DN
   Deb, M
   Kanji, S
   Greene, CJ
   Das, M
   Joseph, M
   Aggarwal, R
   Leblebicioglu, B
   Das, H
AF Rolph, Daniela N.
   Deb, Moonmoon
   Kanji, Suman
   Greene, Carl J.
   Das, Manjusri
   Joseph, Matthew
   Aggarwal, Reeva
   Leblebicioglu, Binnaz
   Das, Hiranmoy
TI Ferutinin directs dental pulp derived stem cells towards the osteogenic
   lineage by epigenetically regulating canonical Wnt signaling
SO BIOCHIMICA ET BIOPHYSICA ACTA MOLECULAR BASIS OF DISEASE
LA English
DT Article
DE DPSC; Ferutinin; Osteogenic differentiation; Wnt/beta catenin;
   Epigenetic regulation
ID BREAST CANCER; BETA CATENIN; IN VITRO; BONE; PHYTOESTROGENS;
   METHYLATION; PATHWAY
AB Osteoporosis is a silent systemic disease that causes bone deterioration, and affects over 10 million people in the US alone. This study was undertaken to develop a potential stem cell therapy for osteoporosis. We have isolated and expanded human dental pulp derived stem cells (DPSCs), characterized them, and confirmed their multipotential differentiation abilities. Stem cells often remain quiescent and require activation to differentiate and function. Herein, we show that ferutinin activates DPSCs by modulating the Wnt/beta catenin signaling pathway and key osteoblast secreted proteins osteocalcin and collagen 1A1 both mRNA and protein levels. To confirm that ferutinin modulates the Wnt pathway, we inhibited glycogen synthase kinase 3 (GSK3) and found that protein expression patterns were similar to those found in ferutinin treated DPSCs. To evaluate the role of ferutinin in epigenetic regulation of canonical Wnt signaling, the pathway molecules Wnt3a and Dvl3 were analyzed using chromatin immunoprecipitation (ChIP) quantitative PCR approaches. We confirmed that active marks of both H3K9 acetylation and H3K4 trimethylation were significantly enhanced in the promoter sites of the WNT3A and DVL3 genes in DPSCs after addition of ferutinin. These data provide evidence that ferutinin activates and promotes osteogenic differentiation of DPSCs, and could be used as an inducer as a potentially effective stem cell therapy for osteoporosis.
C1 [Rolph, Daniela N.; Deb, Moonmoon; Kanji, Suman; Greene, Carl J.; Das, Hiranmoy] Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, ARB Suite 2116,1406 South Coulter St, Amarillo, TX 79106 USA.
   [Das, Manjusri; Joseph, Matthew; Aggarwal, Reeva; Das, Hiranmoy] Ohio State Univ, Dept Internal Med, Wexner Med Ctr, Columbus, OH 43210 USA.
   [Leblebicioglu, Binnaz] Ohio State Univ, Coll Dent, Div Periodontol, Columbus, OH 43210 USA.
C3 Texas Tech University System; Texas Tech University Health Sciences
   Center Amarillo; Texas Tech University Health Sciences Center Lubbock;
   University System of Ohio; Ohio State University; University System of
   Ohio; Ohio State University
RP Das, H (通讯作者)，Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, ARB Suite 2116,1406 South Coulter St, Amarillo, TX 79106 USA.
EM hiranmoy.das@ttuhsc.edu
RI Das, Hiranmoy/R 7452 2019
OI Das, Hiranmoy/0000 0002 3343 0096; Leblebicioglu,
   Binnaz/0000 0002 2303 7717
FU National Institutes of Health [R01AR068279]; STTR [1R41EY024217,
   1R41AG057242]
FX This work was supported in part by National Institutes of Health grants,
   R01AR068279 (NIAMS), STTR 1R41EY024217 (NEI) and STTR 1R41AG057242
   (NIA). The funders had no role in study design, data collection and
   analysis, decision to publish or preparation of the manuscript.
CR Aggarwal R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039365
   Akkouch A, 2014, J BIOMATER APPL, V28, P922, DOI 10.1177/0885328213486705
   [Anonymous], HLTH CONSMOK 50 YE
   Appendino G, 2002, J NAT PROD, V65, P1612, DOI 10.1021/np0201671
   Camacho PM, 2016, ENDOCR PRACT, V22, P1, DOI 10.4158/EP161435.GL
   Cawthorn WP, 2012, BONE, V50, P477, DOI 10.1016/j.bone.2011.08.010
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   d'Aquino R, 2007, CELL DEATH DIFFER, V14, P1162, DOI 10.1038/sj.cdd.4402121
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Ferretti M, 2010, J ANAT, V217, P48, DOI 10.1111/j.1469 7580.2010.01242.x
   Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092 8674(00)81631 1
   Gronthos S, 2002, J DENT RES, V81, P531, DOI 10.1177/154405910208100806
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Ikeda K, 2002, BIOCHEM BIOPH RES CO, V291, P354, DOI 10.1006/bbrc.2002.6446
   Iohara K, 2004, J DENT RES, V83, P590, DOI 10.1177/154405910408300802
   Itasaki N, 2010, DEV DYNAM, V239, P16, DOI 10.1002/dvdy.22009
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858
   Joseph M, 2014, BIOMATERIALS, V35, P8566, DOI 10.1016/j.biomaterials.2014.06.037
   Karmodiya K, 2012, BMC GENOMICS, V13, DOI 10.1186/1471 2164 13 424
   Kim JH, 2013, THER ADV MUSCULOSKEL, V5, P13, DOI 10.1177/1759720X12466608
   Komiya Yuko, 2008, Organogenesis, V4, P68
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Lindroos B, 2008, BIOCHEM BIOPH RES CO, V368, P329, DOI 10.1016/j.bbrc.2008.01.081
   Lizier NF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039885
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Neves VCM, 2017, SCI REP UK, V7, DOI 10.1038/srep39654
   Palumbo C, 2009, J BONE MINER METAB, V27, P538, DOI 10.1007/s00774 009 0070 x
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rice S, 2006, ENDOCR RELAT CANCER, V13, P995, DOI 10.1677/erc.1.01159
   Sengupta D, 2016, EXP CELL RES, V346, P176, DOI 10.1016/j.yexcr.2016.07.023
   Soares LM, 2017, MOL CELL, V68, P773, DOI 10.1016/j.molcel.2017.10.013
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Staal FJT, 2005, NAT REV IMMUNOL, V5, P21, DOI 10.1038/nri1529
   Wang YP, 2014, FRONT BIOSCI LANDMRK, V19, P379, DOI 10.2741/4214
   Watts Nelson B, 2010, Endocr Pract, V16, P1016
   Wei JW, 2015, REV ENDOCR METAB DIS, V16, P93, DOI 10.1007/s11154 014 9307 7
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Yang XC, 2009, TISSUE ENG PT A, V15, P367, DOI 10.1089/ten.tea.2008.0133
   Young MF, 2003, OSTEOPOROSIS INT, V14, pS35, DOI 10.1007/s00198 002 1342 7
NR 44
TC 39
Z9 39
U1 0
U2 14
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29a, 1043 NX AMSTERDAM, NETHERLANDS
SN 0925 4439
EI 1879 260X
J9 BBA MOL BASIS DIS
JI Biochim. Biophys. Acta Mol. Basis Dis.
PD APR 1
PY 2020
VL 1866
IS 4
SI SI
AR 165314
DI 10.1016/j.bbadis.2018.10.032
PG 9
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA KO0AY
UT WOS:000515209600002
PM 30412793
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Patntirapong, S
   Korjai, N
   Matchimapiro, M
   Sungkaruk, P
   Suthamporn, Y
AF Patntirapong, Somying
   Korjai, Nareerat
   Matchimapiro, Monticha
   Sungkaruk, Paphada
   Suthamporn, Yauwaluk
TI Geranylgeraniol reverses alendronate induced MC3T3 cell cytotoxicity and
   alteration of osteoblast function via cell cytoskeletal maintenance
SO JOURNAL OF ORAL PATHOLOGY & MEDICINE
LA English
DT Article
DE alendronate; cell cycle; cytoskeleton; geranylgeraniol; viability
ID ZOLEDRONIC ACID; OSTEOCLAST FORMATION; BONE RESORPTION; BISPHOSPHONATES;
   ACTIN; MECHANISM; DIFFERENTIATION; MINERALIZATION; PATHWAY
AB Background: Alendronate (ALN) is a bisphosphonate, which is prescribed as an anti osteoporotic drug. ALN has been shown to increase osteoblast cell death and decrease bone mineralization. ALN inhibits a key regulatory enzyme in the mevalonate pathway, consequently reducing geranylgeranyl pyrophosphate (GGPP). Geranylgeraniol (GGOH) can be converted to GGPP. The aim of this study was to investigate the effects of exogenous GGOH on MC3T3 cell viability, cell cycle, osteoblast function, and cell cytoskeleton under ALN treatment.
   Methods: MC3T3 cells and osteoblast precursors, were incubated with ALN (0 50 mu mol/L) and GGOH (0 50 mu mol/L). After treatment, cells were evaluated for cell viability, cell cycle, osteoblast function, and cell cytoskeleton by MTT, flow cytometry, alizarin red S assay, and fluorescent microscopy, respectively.
   Results: ALN reduced cell viability and bone nodule formation in a dose dependent manner. GGOH partially inhibited the negative effects of ALN on cell viability and function. ALN increased the percentages of cell apoptosis and necrosis and arrested cells in G2M phase. Co incubation with GGOH partially reduced late cell apoptosis and rescued cell cycle arrest. Furthermore, ALN altered MC3T3 morphology and decreased cell area, actin stress fiber density as well as nuclear area. GGOH abolished the effect of ALN on cell area, actin stress fiber density, and nuclear area.
   Conclusions: GGOH partially inhibited negative effects of ALN on cell viability, cell cycle, function, and cell cytoskeleton. It might be an additional option for increasing osteoblast function and reducing apoptosis of osteoblasts in the condition treated with low bisphosphonate concentration.
C1 [Patntirapong, Somying; Korjai, Nareerat; Matchimapiro, Monticha; Sungkaruk, Paphada; Suthamporn, Yauwaluk] Thammasat Univ, Fac Dent, Rangsit Campus,99 Moo 18 Pahonyothin Rd, Klongluang 12120, Pathumthani, Thailand.
C3 Thammasat University
RP Patntirapong, S (通讯作者)，Thammasat Univ, Fac Dent, Rangsit Campus,99 Moo 18 Pahonyothin Rd, Klongluang 12120, Pathumthani, Thailand.
EM p_somying@hotmail.com
FU Thammasat University [2/11/2562]
FX The authors gratefully thank Prof. Prasit Pavasant, Faculty of
   Dentistry, Chulalongkorn University, for providing MC3T3 cells. The
   authors acknowledge the financial support provided by Thammasat
   University Research Fund under the TU Research Scholar, Contract No.
   2/11/2562.
CR Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Chen L, 2015, STEM CELL RES, V15, P281, DOI 10.1016/j.scr.2015.06.009
   Coleman ML, 2002, CELL DEATH DIFFER, V9, P493, DOI 10.1038/sj.cdd.4400987
   Colnot C, 2009, J BONE MINER RES, V24, P274, DOI 10.1359/JBMR.081003
   Crick DC, 1997, BIOCHEM BIOPH RES CO, V237, P483, DOI 10.1006/bbrc.1997.7145
   Drabek K, 2011, J BONE MINER RES, V26, P2045, DOI 10.1002/jbmr.435
   Filippi Chiela EC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042522
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Huang X, 2016, MOL MED REP, V13, P613, DOI 10.3892/mmr.2015.4627
   Iwata K, 2006, BONE, V39, P1053, DOI 10.1016/j.bone.2006.05.006
   Kazmers NH, 2009, BONE, V45, P52, DOI 10.1016/j.bone.2009.03.675
   Korichneva I, 1999, J CELL SCI, V112, P2521
   Lee KG, 2007, CELL CYCLE, V6, P1487
   Lee YJ, 2005, MOL BIOTECHNOL, V31, P1, DOI 10.1385/MB:31:1:001
   Marx RE, 2012, INT J ORAL MAX SURG, V41, P283, DOI 10.1016/j.ijom.2011.12.016
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Moreau MF, 2007, BIOCHEM PHARMACOL, V73, P718, DOI 10.1016/j.bcp.2006.09.031
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Patntirapong S, 2014, J CLIN PHARM THER, V39, P349, DOI 10.1111/jcpt.12149
   Patntirapong S, 2012, J ORAL PATHOL MED, V41, P713, DOI 10.1111/j.1600 0714.2012.01154.x
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Tu Kristie N, 2018, P T, V43, P92
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Zafar S, 2016, CLIN ORAL INVEST, V20, P2023, DOI 10.1007/s00784 015 1706 y
   Ziebart T, 2011, ORAL ONCOL, V47, P195, DOI 10.1016/j.oraloncology.2010.12.003
NR 27
TC 6
Z9 6
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0904 2512
EI 1600 0714
J9 J ORAL PATHOL MED
JI J. Oral Pathol. Med.
PD FEB
PY 2021
VL 50
IS 2
BP 191
EP 199
DI 10.1111/jop.13120
EA JAN 2021
PG 9
WC Dentistry, Oral Surgery & Medicine; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine; Pathology
GA QF5BQ
UT WOS:000605613200001
PM 33164239
DA 2025 08 17
ER

PT J
AU Lee, SY
   Park, KH
   Lee, G
   Kim, SJ
   Song, WH
   Kwon, SH
   Koh, JT
   Huh, YH
   Ryu, JH
AF Lee, Sun Young
   Park, Ka Hyon
   Lee, Gyuseok
   Kim, Su Jin
   Song, Won Hyun
   Kwon, Seung Hee
   Koh, Jeong Tae
   Huh, Yun Hyun
   Ryu, Je Hwang
TI Hypoxia inducible factor 2α mediates senescence associated intrinsic
   mechanisms of age related bone loss
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; OSTEOCLAST DIFFERENTIATION; VITAMIN D; CELL;
   APOPTOSIS; SWITCH; MASS; OSTEOGENESIS; HOMEOSTASIS; EXPRESSION
AB Aging is associated with cellular senescence followed by bone loss leading to bone fragility in humans. However, the regulators associated with cellular senescence in aged bones need to be identified. Hypoxia inducible factor (HIF) 2 alpha regulates bone remodeling via the differentiation of osteoblasts and osteoclasts. Here, we report that HIF 2 alpha expression was highly upregulated in aged bones. HIF 2 alpha depletion in male mice reversed age induced bone loss, as evidenced by an increase in the number of osteoblasts and a decrease in the number of osteoclasts. In an in vitro model of doxorubicin mediated senescence, the expression of Hif 2 alpha and p21, a senescence marker gene, was enhanced, and osteoblastic differentiation of primary mouse calvarial preosteoblast cells was inhibited. Inhibition of senescence induced upregulation of HIF 2 alpha expression during matrix maturation, but not during the proliferation stage of osteoblast differentiation, reversed the age related decrease in Runx2 and Ocn expression. However, HIF 2 alpha knockdown did not affect p21 expression or senescence progression, indicating that HIF 2 alpha expression upregulation in senescent osteoblasts may be a result of aging rather than a cause of cellular senescence. Osteoclasts are known to induce a senescent phenotype during in vitro osteoclastogenesis. Consistent with increased HIF 2 alpha expression, the expression of p16 and p21 was upregulated during osteoclastogenesis of bone marrow macrophages. ChIP following overexpression or knockdown of HIF 2 alpha using adenovirus revealed that p16 and p21 are direct targets of HIF 2 alpha in osteoclasts. Osteoblast specific (Hif 2 alpha(fl/fl);Col1a1 Cre) or osteoclast specific (Hif 2 alpha(fl/fl);Ctsk Cre) conditional knockout of HIF 2 alpha in male mice reversed age related bone loss. Collectively, our results suggest that HIF 2 alpha acts as a senescence related intrinsic factor in age related dysfunction of bone homeostasis.
   Bone remodeling: Protein linked to age related bone loss Drugs directed at a protein called HIF 2 alpha may help combat cellular aging processes in bone. Je Hwang Ryu from Chonnam National University in Gwangju, South Korea, and colleagues have linked the expression of HIF 2 alpha, a known regulator of bone remodeling, to aging and senescence, a state of irreversible growth arrest in which cells remain metabolically active yet cease dividing. Experimentally targeting HIF 2 alpha in mice, either in bone forming osteoblast cells or in bone resorbing osteoclast cells, reversed the gradual and progressive decline of bone tissue associated with aging, showing that senescence induced HIF 2 alpha activity contributes to imbalances in bone cell turnover. HIF 2 alpha blockers are already in clinical testing for the treatment of cancer; these findings suggest that this class of drugs should now be considered for the treatment of osteoporosis and other bone diseases as well.
C1 [Lee, Sun Young; Park, Ka Hyon; Lee, Gyuseok; Kim, Su Jin; Song, Won Hyun; Kwon, Seung Hee; Koh, Jeong Tae; Ryu, Je Hwang] Chonnam Natl Univ, Sch Dent, Dept Pharmacol & Dent Therapeut, Gwangju 61186, South Korea.
   [Kim, Su Jin; Song, Won Hyun; Kwon, Seung Hee; Koh, Jeong Tae; Ryu, Je Hwang] Chonnam Natl Univ, Hard Tissue Biointerface Res Ctr, Sch Dent, Gwangju 61186, South Korea.
   [Huh, Yun Hyun] Gwangju Inst Sci & Technol GIST, Sch Life Sci, Gwangju 61005, South Korea.
C3 Chonnam National University; Chonnam National University; Gwangju
   Institute of Science & Technology (GIST)
RP Ryu, JH (通讯作者)，Chonnam Natl Univ, Sch Dent, Dept Pharmacol & Dent Therapeut, Gwangju 61186, South Korea.; Ryu, JH (通讯作者)，Chonnam Natl Univ, Hard Tissue Biointerface Res Ctr, Sch Dent, Gwangju 61186, South Korea.
EM jesryu@jnu.ac.kr
FU National Research Foundation of Korea (NRF) through the Korean
   government (MSIT) [2019R1A5A2027521, NRF 2018R1A2B2006033]; Bio &
   Medical Technology Development Program of the NRF   Korean government
   (MSIT) [2019M3A9A8065758]; Korea Health Technology R&D project through
   the Korea Health Industry Development Institute (KHIDI)   Ministry of
   Health Welfare [HI14C3484]
FX This work was supported by grants from the National Research Foundation
   of Korea (NRF) through the Korean government (MSIT) (2019R1A5A2027521
   and NRF 2018R1A2B2006033); the Bio & Medical Technology Development
   Program of the NRF, funded by the Korean government (MSIT)
   (2019M3A9A8065758); and the Korea Health Technology R&D project through
   the Korea Health Industry Development Institute (KHIDI), funded by the
   Ministry of Health & Welfare (HI14C3484).
CR Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   BOURRIN S, 1995, J BONE MINER RES, V10, P1745
   Cao JJ, 2009, BONE, V44, P1097, DOI 10.1016/j.bone.2009.02.017
   Carmeliet G, 2015, BEST PRACT RES CL EN, V29, P621, DOI 10.1016/j.beem.2015.06.001
   Center JR, 1999, LANCET, V353, P878, DOI 10.1016/S0140 6736(98)09075 8
   Chen W, 2007, HUM MOL GENET, V16, P410, DOI 10.1093/hmg/ddl474
   Choi WS, 2019, NATURE, V566, P254, DOI 10.1038/s41586 019 0920 1
   Cong Q, 2017, SCI REP UK, V7, DOI 10.1038/srep45964
   Coppé JP, 2010, ANNU REV PATHOL MECH, V5, P99, DOI 10.1146/annurev pathol 121808 102144
   Dengler VL, 2014, CRIT REV BIOCHEM MOL, V49, P1, DOI 10.3109/10409238.2013.838205
   Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097 0177(2000)9999:9999<::AID DVDY1074>3.0.CO;2 C
   Eastell R, 2011, BONE, V49, P82, DOI 10.1016/j.bone.2011.02.011
   Everts V, 2002, J BONE MINER RES, V17, P77, DOI 10.1359/jbmr.2002.17.1.77
   Farr JN, 2017, NAT MED, V23, P1072, DOI 10.1038/nm.4385
   Farr JN, 2016, J BONE MINER RES, V31, P1920, DOI 10.1002/jbmr.2892
   GLACKIN CA, 1992, BIOCHEM INT, V28, P67
   Henriksen K, 2011, ENDOCR REV, V32, P31, DOI 10.1210/er.2010 0006
   Hill TR, 2018, SUBCELL BIOCHEM, V90, P191, DOI 10.1007/978 981 13 2835 0_8
   Hu XR, 2019, MED SCI MONITOR, V25, P3617, DOI 10.12659/MSM.914295
   Hwang ES, 2009, CELL MOL LIFE SCI, V66, P2503, DOI 10.1007/s00018 009 0034 2
   Infante A, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0995 x
   Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817
   Iwamoto J, 2005, EXP ANIM TOKYO, V54, P1, DOI 10.1538/expanim.54.1
   Jonason JH, 2014, METHODS MOL BIOL, V1130, P295, DOI 10.1007/978 1 62703 989 5_22
   Karsenty G, 2010, J CLIN ENDOCR METAB, V95, P4795, DOI 10.1210/jc.2010 1030
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Kassem M, 2011, AGING CELL, V10, P191, DOI 10.1111/j.1474 9726.2011.00669.x
   Khan MP, 2015, DIABETES, V64, P2609, DOI 10.2337/db14 1611
   Kim HN, 2019, AGING CELL, V18, DOI 10.1111/acel.12923
   Kim HN, 2017, AGING CELL, V16, P693, DOI 10.1111/acel.12597
   Kronenberg HM, 2004, DEV CELL, V6, P317, DOI 10.1016/S1534 5807(04)00069 3
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Lee SY, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0054 y
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Li DH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11330
   López Otín C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Ma Y, 2018, AGING CELL, V17, DOI 10.1111/acel.12709
   Marie PJ, 2014, J BONE MINER RES, V29, P1311, DOI 10.1002/jbmr.2190
   Matsuoka K, 2014, J BONE MINER RES, V29, P1522, DOI 10.1002/jbmr.2187
   Mellis DJ, 2011, J ENDOCRINOL, V211, P131, DOI 10.1530/JOE 11 0212
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Nishikawa K, 2010, J CLIN INVEST, V120, P3455, DOI 10.1172/JCI42528
   Ott SM, 2018, AM J NEPHROL, V47, P373, DOI 10.1159/000489672
   Piemontese M, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93771
   Pietschmann P, 2007, EXP GERONTOL, V42, P1099, DOI 10.1016/j.exger.2007.08.008
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Ryu JH, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001881
   Saeed H, 2011, J BONE MINER RES, V26, P1494, DOI 10.1002/jbmr.349
   Schuit SCE, 2004, BONE, V34, P195, DOI 10.1016/j.bone.2003.10.001
   Shum LC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155709
   Taylor Sarah E B, 2014, Bonekey Rep, V3, P585, DOI 10.1038/bonekey.2014.80
   Vignery A, 2005, J EXP MED, V202, P337, DOI 10.1084/jem.20051123
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang L, 2015, CELL DEATH DIFFER, V22, P1654, DOI 10.1038/cdd.2015.14
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Yang S, 2010, NAT MED, V16, P687, DOI 10.1038/nm.2153
NR 60
TC 24
Z9 28
U1 0
U2 27
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1226 3613
EI 2092 6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD APR
PY 2021
VL 53
IS 4
BP 591
EP 604
DI 10.1038/s12276 021 00594 y
PG 14
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA RY2UO
UT WOS:000647772600010
PM 33811248
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zainabadi, K
   Liu, CJ
   Caldwell, ALM
   Guarente, L
AF Zainabadi, Kayvan
   Liu, Cassie J.
   Caldwell, Alison L. M.
   Guarente, Leonard
TI SIRT1 is a positive regulator of in vivo bone mass and a therapeutic
   target for osteoporosis
SO PLOS ONE
LA English
DT Article
ID EXTENDS LIFE SPAN; CALORIE RESTRICTION; GLYCERALDEHYDE 3 PHOSPHATE
   DEHYDROGENASE; HISTONE DEACETYLASE; IMPROVES HEALTH; STANDARD DIET;
   BETA CATENIN; MALE RATS; MICE; EXPRESSION
AB Overexpression or pharmacological activation of SIRT1 has been shown to extend the lifespan of mice and protect against aging related diseases. Here we show that pharmacological activation of SIRT1 protects in two models of osteoporosis. Ovariectomized female mice and aged male mice, models for post menopausal and aging related osteoporosis, respectively, show significant improvements in bone mass upon treatment with SIRT1 agonist, SRT1720. Further, we find that calorie restriction (CR) results in a two fold upregulation of sirt1 mRNA expression in bone tissue that is associated with increased bone mass in CR mice. Reciprocally, SIRT1 whole body knockout (KO) mice, as well as osteoblast and osteoclast specific KOs, show a low bone mass phenotype; though double knockout mice (containing SIRT1 deleted in both osteoblasts and osteoclasts) do not show a more severe phenotype. Altogether, these findings provide strong evidence that SIRT1 is a positive regulator of bone mass and a promising target for the development of novel therapeutics for osteoporosis.
C1 [Zainabadi, Kayvan; Liu, Cassie J.; Caldwell, Alison L. M.; Guarente, Leonard] MIT, Dept Biol, Koch Inst, Glenn Ctr Sci Aging, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
C3 Massachusetts Institute of Technology (MIT)
RP Zainabadi, K (通讯作者)，MIT, Dept Biol, Koch Inst, Glenn Ctr Sci Aging, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
EM kayvan@alum.mit.edu
RI Guarente, Luca/GYD 8942 2022
FU NIH; Glenn Foundation for Medical Research
FX This work was supported by grants from the NIH and The Glenn Foundation
   for Medical Research. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Artsi H, 2014, ENDOCRINOLOGY, V155, P3508, DOI 10.1210/en.2014 1334
   Baksi A, 2014, BRIT J CLIN PHARMACO, V78, P69, DOI 10.1111/bcp.12327
   Banks AS, 2008, CELL METAB, V8, P333, DOI 10.1016/j.cmet.2008.08.014
   Barger JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002264
   Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354
   Boily G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001759
   Bordone L, 2007, AGING CELL, V6, P759, DOI 10.1111/j.1474 9726.2007.00335.x
   Chang HC, 2013, CELL, V153, P1448, DOI 10.1016/j.cell.2013.05.027
   Chen D, 2005, SCIENCE, V310, P1641, DOI 10.1126/science.1118357
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   Cohen DE, 2009, GENE DEV, V23, P2812, DOI 10.1101/gad.1839209
   Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196
   Cohen Kfir E, 2011, ENDOCRINOLOGY, V152, P4514, DOI 10.1210/en.2011 1128
   Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100
   Edwards JR, 2013, J BONE MINER RES, V28, P960, DOI 10.1002/jbmr.1824
   Gong H, 2014, MOL MED REP, V10, P3296, DOI 10.3892/mmr.2014.2648
   Gräff J, 2013, J NEUROSCI, V33, P8951, DOI 10.1523/JNEUROSCI.5657 12.2013
   Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029
   Gurt I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134391
   Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506
   Herranz D, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1001
   Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622
   Iyer S, 2014, J BIOL CHEM, V289, P24069, DOI 10.1074/jbc.M114.561803
   KALU DN, 1984, MECH AGEING DEV, V26, P103, DOI 10.1016/0047 6374(84)90169 6
   Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092 8674(00)80219 6
   KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092 8674(95)90499 9
   Kim D, 2007, EMBO J, V26, P3169, DOI 10.1038/sj.emboj.7601758
   Kim HN, 2015, MOL ENDOCRINOL, V29, P1498, DOI 10.1210/me.2015 1133
   Kolthur Seetharam U, 2009, BIOL REPROD, V80, P384, DOI 10.1095/biolreprod.108.070193
   Koubova J, 2003, GENE DEV, V17, P313, DOI 10.1101/gad.1052903
   Krueger JG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142081
   Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013
   Lemieux ME, 2005, MECH AGEING DEV, V126, P1097, DOI 10.1016/j.mad.2005.04.006
   Liu F, 2004, INT J DEV BIOL, V48, P645, DOI 10.1387/ijdb.041816fl
   Lowe DA, 2000, J GERONTOL A BIOL, V55, pB160, DOI 10.1093/gerona/55.3.B160
   Maran A, 2004, CALCIFIED TISSUE INT, V74, P204, DOI 10.1007/s00223 002 1098 2
   Mercken EM, 2014, AGING CELL, V13, P787, DOI 10.1111/acel.12220
   Mercken EM, 2014, AGING CELL, V13, P193, DOI 10.1111/acel.12151
   Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261
   Mitchell SJ, 2014, CELL REP, V6, P836, DOI 10.1016/j.celrep.2014.01.031
   Mohelnikova Duchonova B, 2012, DIS MARKERS, V32, P203, DOI [10.1155/2012/582107, 10.3233/DMA 2011 0875]
   Mozdziak PE, 2003, NUTRITION, V19, P438, DOI 10.1016/S0899 9007(02)01006 7
   Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728
   Ornstrup MJ, 2014, J CLIN ENDOCR METAB, V99, P4720, DOI 10.1210/jc.2014 2799
   Pearson KJ, 2008, CELL METAB, V8, P157, DOI 10.1016/j.cmet.2008.06.011
   Redman LM, 2008, ARCH INTERN MED, V168, P1859, DOI 10.1001/archinte.168.17.1859
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101
   Sanderson JP, 1997, J GERONTOL A BIOL, V52, pB20, DOI 10.1093/gerona/52A.1.B20
   Sands BE, 2016, INFLAMM BOWEL DIS, V22, P607, DOI 10.1097/MIB.0000000000000597
   Satoh A, 2013, CELL METAB, V18, P416, DOI 10.1016/j.cmet.2013.07.013
   Simic P, 2013, EMBO MOL MED, V5, P430, DOI 10.1002/emmm.201201606
   Tatsumi S, 2008, ENDOCRINOLOGY, V149, P634, DOI 10.1210/en.2007 1089
   Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638
   Toorie AM, 2016, J BIOL CHEM, V291, P5844, DOI 10.1074/jbc.M115.675264
   Warren LA, 2007, AGING CELL, V6, P775, DOI 10.1111/j.1474 9726.2007.00337.x
   Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789
   Zainabadi K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178520
   Zhou LH, 2010, BMC GENOMICS, V11, DOI 10.1186/1471 2164 11 75
NR 59
TC 68
Z9 84
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD SEP 22
PY 2017
VL 12
IS 9
AR e0185236
DI 10.1371/journal.pone.0185236
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FH9IR
UT WOS:000411524700024
PM 28937996
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Matthews, BG
   Roeder, E
   Wang, X
   Aguila, HL
   Lee, SK
   Grcevic, D
   Kalajzic, I
AF Matthews, Brya G.
   Roeder, Emilie
   Wang, Xi
   Aguila, Hector Leonardo
   Lee, Sun Kyeong
   Grcevic, Danka
   Kalajzic, Ivo
TI Splenomegaly, myeloid lineage expansion and increased osteoclastogenesis
   in osteogenesis imperfecta murine
SO BONE
LA English
DT Article
DE Osteogenesis imperfecta; Osteoclast; Tumor necrosis factor alpha;
   Inflammation
ID TUMOR NECROSIS FACTOR; IMPROVES BONE MASS; MOUSE MODEL; SCLEROSTIN
   ANTIBODY; MICE; STRENGTH; CHILDREN; TNF; IDENTIFICATION; MACROPHAGES
AB Osteogenesis imperfecta (OI) is a disease caused by defects in type I collagen production that results in brittle bones. While the pathology is mainly caused by defects in the osteoblast lineage, there is also elevated bone resorption by osteoclasts resulting in high bone turnover in severe forms of the disease. Osteoclasts originate from hematopoietic myeloid cells, however changes in hematopoiesis have not been previously documented in OI. In this study, we evaluated hematopoietic lineage distribution and osteoclast progenitor cell frequency in bone marrow, spleen and peripheral blood of osteogenesis imperfecta murine (OIM) mice, a model of severeOI. We found splenomegaly in all ages examined, and expansion of myeloid lineage cells (CD11b(+)) in bone marrow and spleen of 7 9 week old male OIM animals. OIM spleens also showed an increased frequency of purified osteoclast progenitors. This phenotype is suggestive of chronic inflammation. Isolated osteoclast precursors from both spleen and bone marrow formed osteoclasts more rapidly than wild type controls. We found that serum TNF alpha levels were increased in OIM, as was IL1 alpha in OIM females. We targeted inflammation therapeutically by treating growing animals with murine TNFR2:Fc, a compound that blocks TNFa activity. Anti TNF alpha treatment marginally decreased spleen mass in OIM females, but failed to reduce bone resorption, or improve bone parameters or fracture rate in OIM animals. We have demonstrated that OIM mice have changes in their hematopoietic system, and form osteoclasts more rapidly even in the absence of OI osteoblast signals, however therapy targeting TNF alpha did not improve disease parameters. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Matthews, Brya G.; Roeder, Emilie; Wang, Xi; Kalajzic, Ivo] Univ Connecticut, Dept Reconstruct Sci, Farmington, CT 06030 USA.
   [Aguila, Hector Leonardo] Univ Connecticut, Dept Immunol, Farmington, CT 06030 USA.
   [Lee, Sun Kyeong] Univ Connecticut, Ctr Aging, Farmington, CT 06030 USA.
   [Grcevic, Danka] Univ Zagreb, Sch Med, Dept Physiol & Immunol, Zagreb 10000, Croatia.
C3 University of Connecticut; University of Connecticut; University of
   Connecticut; University of Zagreb
RP Matthews, BG (通讯作者)，Univ Connecticut, Sch Dent Med, Dept Reconstruct Sci, MC 3705,263 Farmington Ave, Farmington, CT 06030 USA.
EM brya.g.matthews@gmail.com; ikalaj@uchc.edu
RI ; Grcevic, Danka/AAS 1666 2021; Matthews, Brya/B 9812 2013
OI Roeder, Emilie/0000 0001 5992 6623; Grcevic, Danka/0000 0002 2365 8249;
   Matthews, Brya G./0000 0002 4145 4696
FU NIH/NIAMS [AR066218]; Michael Geissman Fellowship from the Osteogenesis
   Imperfecta Foundation
FX The authors thank Amgen for provision of murine TNFR2:Fc. We acknowledge
   Devin Shaheen for technical assistance. This work has been supported by
   NIH/NIAMS grant AR066218 to LK, and the Michael Geissman Fellowship from
   the Osteogenesis Imperfecta Foundation to BGM.
CR Bargman R, 2012, OSTEOPOROSIS INT, V23, P1141, DOI 10.1007/s00198 011 1742 7
   Boskey AL, 2015, CLIN ORTHOP RELAT R, V473, P2587, DOI 10.1007/s11999 015 4268 z
   Brunetti G., 2016, OSTEOPOROSIS INT, P1
   Camacho NP, 1999, J BONE MINER RES, V14, P264, DOI 10.1359/jbmr.1999.14.2.264
   CHIPMAN SD, 1993, P NATL ACAD SCI USA, V90, P1701, DOI 10.1073/pnas.90.5.1701
   D'Eufemia P, 2008, PEDIATR RES, V63, P203, DOI 10.1203/PDR.0b013e31815efd63
   DiGirolamo DJ, 2015, BONE RES, V3, DOI 10.1038/boneres.2014.42
   Ding Z, 2015, INT IMMUNOPHARMACOL, V28, P892, DOI 10.1016/j.intimp.2015.03.048
   Dwan K., 2016, COCHRANE DB SYST REV, V10
   Gilbert LC, 2013, BONE, V56, P174, DOI 10.1016/j.bone.2013.06.002
   Grafe I., 2014, NAT MED, V20, P670, DOI [DOI 10.1038/NM.3544, 10.1038/nm.3544]
   Grafe I, 2016, J BONE MINER RES, V31, P1030, DOI 10.1002/jbmr.2776
   Hoyer Kuhn H, 2016, J MUSCULOSKEL NEURON, V16, P24
   Jacobsen CM, 2016, BONE, V90, P127, DOI 10.1016/j.bone.2016.06.005
   Jacobsen CM, 2014, J BONE MINER RES, V29, P2297, DOI 10.1002/jbmr.2198
   Jacome Galarza CE, 2013, J BONE MINER RES, V28, P1203, DOI 10.1002/jbmr.1822
   Jacquin C, 2006, J BONE MINER RES, V21, P67, DOI 10.1359/JBMR.051007
   Kalajzic I, 2002, ENDOCRINOLOGY, V143, P1594, DOI 10.1210/en.143.5.1594
   Kawai VK, 2012, CURR OPIN RHEUMATOL, V24, P576, DOI 10.1097/BOR.0b013e328356d212
   KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460 2075.1991.tb04978.x
   Koulnis M, 2011, JOVE J VIS EXP, DOI 10.3791/2809
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Land C, 2006, J BONE MINER RES, V21, P374, DOI 10.1359/JBMR.051207
   Li HT, 2010, AM J PATHOL, V176, P2405, DOI 10.2353/ajpath.2010.090704
   Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419
   Lisse TS, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040007
   McBride DJ, 1998, CALCIFIED TISSUE INT, V62, P172, DOI 10.1007/s002239900412
   Munns CFJ, 2004, J BONE MINER RES, V19, P1779, DOI 10.1359/JBMR.040814
   Oakley Ingrid, 2010, AANA J, V78, P47
   Perosky JE, 2016, BONE, V93, P79, DOI 10.1016/j.bone.2016.09.013
   Rauch F, 2004, LANCET, V363, P1377, DOI 10.1016/S0140 6736(04)16051 0
   Reagan Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07 9574LSF
   Rijks EBG, 2015, HORM RES PAEDIAT, V84, P26, DOI 10.1159/000381713
   Saban J, 1996, BIOTECHNIQUES, V21, P190
   Schulz M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/675108
   Sinder BP, 2015, BONE, V71, P115, DOI 10.1016/j.bone.2014.10.012
   Sinder BP, 2013, J BONE MINER RES, V28, P73, DOI 10.1002/jbmr.1717
   Uveges TE, 2008, J BONE MINER RES, V23, P1983, DOI 10.1359/JBMR.080804
   Vanleene M, 2013, BONE, V53, P507, DOI 10.1016/j.bone.2013.01.023
   Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood 2003 11 4011
   Wekre Lena Lande, 2011, Arch Osteoporos, V6, P31, DOI 10.1007/s11657 011 0054 z
   Yao XM, 2013, ANN BIOMED ENG, V41, P1139, DOI 10.1007/s10439 013 0793 7
   Yi H, 2014, MOL MED REP, V9, P2301, DOI 10.3892/mmr.2014.2127
   Yoshitaka T, 2014, J BONE MINER RES, V29, P1170, DOI 10.1002/jbmr.2125
   Zanotti S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086757
   Zhang H, 2007, J CELL BIOCHEM, V102, P1011, DOI 10.1002/jcb.21337
NR 46
TC 19
Z9 21
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2017
VL 103
BP 1
EP 11
DI 10.1016/j.bone.2017.06.004
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FF0NY
UT WOS:000408599600001
PM 28600151
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Abuduwali, N
   Lossdörfer, S
   Winter, J
   Kraus, D
   Guhlke, S
   Wolf, M
   Jäger, A
AF Abuduwali, Nuersailike
   Lossdoerfer, Stefan
   Winter, Jochen
   Kraus, Dominik
   Guhlke, Stefan
   Wolf, Michael
   Jaeger, Andreas
TI Functional characterization of the parathyroid hormone 1 receptor in
   human periodontal ligament cells
SO CLINICAL ORAL INVESTIGATIONS
LA English
DT Article
DE Human PDL cells; Parathyroid hormone 1 receptor; Binding
   characteristics; Signal transduction; Subcellular distribution; In vitro
ID CHRONIC RENAL FAILURE; PTH PTHRP RECEPTOR; IN VITRO; OSTEOSARCOMA CELLS;
   PTH/PTHRP RECEPTOR; DOWN REGULATION; RAT TISSUES; KINASE C; EXPRESSION;
   PROTEIN
AB Intermittent parathyroid hormone (PTH) exerts anabolic effects on bone and has been approved for osteoporosis therapy. The dual actions of PTH are mediated primarily through the parathyroid hormone 1 receptor (PTH1R). Upon ligand binding, PTH1R activates diverse signaling pathways, including cAMP/protein kinase A (PKA)  and phospholipase C/protein kinase C (PLC/PKC) dependent pathways. PTH1R has been abundantly studied in bone cells. Knowledge on PTH1R characteristics and physiology in periodontal ligament (PDL) cells is still in its infancy.
   We characterized PTH1R in PDL cells in terms of its cellular localization, binding affinity, and signal transduction and compared these characteristics to those of MG63 osteoblast like cells.
   PTH1R mRNA/protein was identified in PDL and MG63 cells. PTH1R was mainly localized on the plasma membrane, in vesicular structures inside the cell, and, to some extent, in the nucleus of both cell types. Binding characteristics of PTH1R were cell type specific, with PDL cells demonstrating a lower binding affinity. The response of cAMP and active PKC production in MG63 cells was dose dependent with increasing PTH(1 34) concentration, whereas in PDL cells, it was regulated biphasically. However, we observed a cross talk between the cAMP/PKA and PLC/PKC signaling pathways, which were regulated diametrically opposed at a given concentration of PTH(1 34).
   These data indicate that, albeit the similarity in its subcellular distribution, PTH1R in PDL cells exhibits characteristics different from those in MG63 cells, pointing to the cell type specificity of this receptor.
   The findings further elucidate the characteristics of PTH action in dental tissues and widen the theoretical basis for the development of anabolic treatment strategies.
C1 [Abuduwali, Nuersailike; Lossdoerfer, Stefan; Wolf, Michael; Jaeger, Andreas] Univ Bonn, Dent Clin, Dept Orthodont, D 53111 Bonn, Germany.
   [Winter, Jochen] Univ Bonn, Dent Clin, Dept Periodontol Operat & Prevent Dent, D 53111 Bonn, Germany.
   [Kraus, Dominik] Univ Bonn, Dent Clin, Dept Prosthodont Preclin Educ & Mat Sci, D 53111 Bonn, Germany.
   [Guhlke, Stefan] Univ Bonn, Clin Nucl Med, Bonn, Germany.
C3 University of Bonn; University of Bonn; University of Bonn; University
   of Bonn
RP Lossdörfer, S (通讯作者)，Univ Bonn, Dent Clin, Dept Orthodont, Welschnonnenstr 17, D 53111 Bonn, Germany.
EM s.lossdoerfer@gmx.de
RI Kraus, Dominik/K 6481 2015
FU Deutsche Forschungsgemeinschaft [KFO 208, TP8, LO 1181/2 2]; Medical
   Faculty of the University of Bonn
FX This study was supported by the Deutsche Forschungsgemeinschaft (KFO
   208, TP8, LO 1181/2 2) and the Medical Faculty of the University of
   Bonn.
CR Alokail MS, 2008, CELL BIOCHEM FUNCT, V26, P522, DOI 10.1002/cbf.1475
   ARORA PD, 1994, J CELL PHYSIOL, V159, P161, DOI 10.1002/jcp.1041590120
   Avnet S, 2008, INT J ONCOL, V33, P1231, DOI 10.3892/ijo_00000113
   Barros SP, 2003, J DENT RES, V82, P791, DOI 10.1177/154405910308201006
   Bartold PM, 2000, PERIODONTOL 2000, V24, P253, DOI 10.1034/j.1600 0757.2000.2240113.x
   Basdra EK, 1997, EUR J ORTHODONT, V19, P615, DOI 10.1093/ejo/19.6.615
   Bashutski JD, 2010, NEW ENGL J MED, V363, P2396, DOI 10.1056/NEJMoa1005361
   BECK F, 1995, CELL TISSUE RES, V280, P283, DOI 10.1007/BF00307800
   Carpio L, 2001, AM J PHYSIOL ENDOC M, V281, pE489, DOI 10.1152/ajpendo.2001.281.3.E489
   Chauvin S, 2002, MOL ENDOCRINOL, V16, P2720, DOI 10.1210/me.2002 0049
   Chen LP, 2011, NEPHROL DIAL TRANSPL, V26, P4068, DOI 10.1093/ndt/gfr209
   CHO MI, 1992, CALCIFIED TISSUE INT, V50, P459, DOI 10.1007/BF00296778
   CIVITELLI R, 1988, AM J PHYSIOL, V255, pE660, DOI 10.1152/ajpendo.1988.255.5.E660
   Cole JA, 1997, J BONE MINER RES, V12, P1223, DOI 10.1359/jbmr.1997.12.8.1223
   de Gortázar AR, 2006, CALCIFIED TISSUE INT, V79, P360, DOI 10.1007/s00223 006 0099 y
   DEMAY M, 1985, AM J PHYSIOL, V249, pE437, DOI 10.1152/ajpendo.1985.249.5.E437
   ENOMOTO M, 1989, BIOCHEM BIOPH RES CO, V162, P1222, DOI 10.1016/0006 291X(89)90804 8
   Gentili C, 2003, J CELL BIOCHEM, V88, P1157, DOI 10.1002/jcb.10472
   Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239
   Isales CM, 2000, AM J PHYSIOL ENDOC M, V279, pE654, DOI 10.1152/ajpendo.2000.279.3.E654
   Jönsson D, 2011, J PERIODONTAL RES, V46, P153, DOI 10.1111/j.1600 0765.2010.01331.x
   KARIMBUX NY, 1992, J DENT RES, V71, P1355, DOI 10.1177/00220345920710070201
   Kato A, 2005, TOXICOL PATHOL, V33, P456, DOI 10.1080/01926230590959604
   Kebschull M, 2010, J DENT RES, V89, P879, DOI 10.1177/0022034510375281
   King GL, 2008, J PERIODONTOL, V79, P1527, DOI 10.1902/jop.2008.080246
   Konermann A, 2012, CELL IMMUNOL, V272, P137, DOI 10.1016/j.cellimm.2011.10.020
   Lekic P, 1996, ANAT REC, V245, P327
   Lekic P, 2001, J PERIODONTAL RES, V36, P71, DOI 10.1034/j.1600 0765.2001.360202.x
   Li HK, 2001, J BONE MINER RES, V16, P1068, DOI 10.1359/jbmr.2001.16.6.1068
   Lossdörfer S, 2011, CLIN ORAL INVEST, V15, P941, DOI 10.1007/s00784 010 0456 0
   Lossdörfer S, 2006, J PERIODONTAL RES, V41, P62, DOI 10.1111/j.1600 0765.2005.00838.x
   Lossdörfer S, 2005, J DENT RES, V84, P634, DOI 10.1177/154405910508400710
   Lossdörfer S, 2004, J BIOMED MATER RES A, V70A, P361, DOI 10.1002/jbm.a.30025
   LUKINMAA PL, 1992, J DENT RES, V71, P391, DOI 10.1177/00220345920710020801
   Malecz N, 1998, MOL ENDOCRINOL, V12, P1846, DOI 10.1210/me.12.12.1846
   Mannstadt M, 1999, AM J PHYSIOL RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665
   Massry SG, 1998, NEPHROL DIAL TRANSPL, V13, P50, DOI 10.1093/ndt/13.suppl_1.50
   NOJIMA N, 1990, J PERIODONTAL RES, V25, P179, DOI 10.1111/j.1600 0765.1990.tb01041.x
   Offenbacher S, 1996, J PERIODONTOL, V67, P1103, DOI 10.1902/jop.1996.67.10s.1103
   Ouyang HJ, 2000, ARCH ORAL BIOL, V45, P293, DOI 10.1016/S0003 9969(99)00142 9
   Pautke C, 2004, ANTICANCER RES, V24, P3743
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   PLIAM NB, 1982, P NATL ACAD SCI BIOL, V79, P2061, DOI 10.1073/pnas.79.6.2061
   Qiu T, 2010, NAT CELL BIOL, V12, P224, DOI 10.1038/ncb2022
   RAO LG, 1985, ENDOCRINOLOGY, V117, P1632, DOI 10.1210/endo 117 4 1632
   Rashid G, 2007, NEPHROL DIAL TRANSPL, V22, P2831, DOI 10.1093/ndt/gfm269
   SCHWARTZ Z, 1992, BONE, V13, P51, DOI 10.1016/8756 3282(92)90361 Y
   Seymour GJ, 2007, CLIN MICROBIOL INFEC, V13, P3, DOI 10.1111/j.1469 0691.2007.01798.x
   Smock SL, 2001, MOL BIOL REP, V28, P235, DOI 10.1023/A:1015716726452
   SUGIMOTO T, 1994, J CELL PHYSIOL, V158, P374, DOI 10.1002/jcp.1041580220
   Tawfeek HAW, 2002, MOL ENDOCRINOL, V16, P1, DOI 10.1210/me.16.1.1
   Tenorio D, 1996, ARCH ORAL BIOL, V41, P299, DOI 10.1016/0003 9969(95)00113 1
   Tenta R, 2006, ANTICANCER RES, V26, P283
   TIAN J, 1994, AM J NEPHROL, V14, P41, DOI 10.1159/000168684
   URENA P, 1993, ENDOCRINOLOGY, V133, P617, DOI 10.1210/en.133.2.617
   Vilardaga JP, 2011, CELL MOL LIFE SCI, V68, P1, DOI 10.1007/s00018 010 0465 9
   Wada N, 2001, J PERIODONTAL RES, V36, P56, DOI 10.1034/j.1600 0765.2001.00604.x
   Watson PH, 2000, J BONE MINER RES, V15, P1033, DOI 10.1359/jbmr.2000.15.6.1033
   YAMAMOTO I, 1988, ENDOCRINOLOGY, V122, P1208, DOI 10.1210/endo 122 4 1208
   YAMASHITA Y, 1987, ARCH ORAL BIOL, V32, P677, DOI 10.1016/0003 9969(87)90044 6
NR 60
TC 10
Z9 11
U1 0
U2 4
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1432 6981
EI 1436 3771
J9 CLIN ORAL INVEST
JI Clin. Oral Investig.
PD MAR
PY 2014
VL 18
IS 2
BP 461
EP 470
DI 10.1007/s00784 013 0985 4
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA AC2GL
UT WOS:000332317500016
PM 23604700
DA 2025 08 17
ER

PT J
AU Chen, XX
   Wu, HJ
   Ke, DS
   Zhu, YR
AF Chen, Xia xia
   Wu, Hao jie
   Ke, Dian shan
   Zhu, Yun rong
TI IL 17A inhibits the degradation of RANKL in osteoblasts by inhibiting
   BCL2 Beclin1 autophagy signaling
SO IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY ANIMAL
LA English
DT Article
DE IL 17A; Osteoblast; Osteoclastogenesis; RANKL; Autophagy; BCL2
ID OSTEOCLAST PRECURSORS; BONE LOSS; AUTOPHAGY; DIFFERENTIATION
AB The inflammatory cytokine IL 17A is known to have the capacity to promote osteoclastogenesis, thereby enhancing bone loss. Moreover, IL 17A can promote the expression of RANKL in osteoblasts, contributing to its pro osteoclastogenic effect. IL 17A is an autophagy regulator, which is also responsible for its regulation on RANKL expression. However, the specific role of autophagy in IL 17A regulated RANKL expression and the underlying mechanism of IL 17A regulated osteoblast autophagy remain unclear. IL 17A is known to inhibit autophagy by preventing BCL2 degradation. This study aimed to explore the significance of BCL2 dependent autophagy in IL 17A regulated RANKL expression. Our results showed that IL 17A at 50 ng/mL could inhibit autophagic activity and promote RANKL protein expression in MC3T3 E1 osteoblast line. Moreover, the corresponding concentration of IL 17A could enhance BCL2 protein expression and the protein interaction between BCL2 and Beclin1 in MC3T3 E1 cells. However, the protein expression of RANKL and BCL2 promoted by 50 ng/mL of IL 17A was blocked by autophagy activation with Beclin1 pharmacological upregulation. Furthermore, RANKL protein expression promoted by 50 ng/mL of IL 17A was also reversed by autophagy activation with BCL2 knockdown. Importantly, the supernatant from osteoblasts treated with 50 ng/mL of IL 17A made osteoclast precursors (OCPs) form larger osteoclasts, which was reversed by BCL2 knockdown in osteoblasts. In conclusion, high levels of IL 17A prevent the degradation of RANKL by inhibiting BCL2 Beclin1 autophagy activation signal transduction in osteoblasts, thereby indirectly promoting osteoclastogenesis.
C1 [Chen, Xia xia] Fujian Prov Geriatr Hosp, Dept Endocrinol, Fuzhou, Fujian, Peoples R China.
   [Wu, Hao jie] Xiamen Univ, Dept Endocrinol, Zhongshan Hosp, Xiamen, Fujian, Peoples R China.
   [Ke, Dian shan] Fujian Med Univ, Shengli Clin Med Coll, Fuzhou, Fujian, Peoples R China.
   [Ke, Dian shan] Fujian Prov Hosp, Dept Orthoped, Fuzhou, Fujian, Peoples R China.
   [Zhu, Yun rong] Nantong Univ, Dept Orthoped, Jiangyin Hosp, 163 Shoushan Rd, Jiangyin 214400, Jiangsu, Peoples R China.
C3 Xiamen University; Fujian Medical University; Fujian Provincial
   Hospital; Nantong University
RP Zhu, YR (通讯作者)，Nantong Univ, Dept Orthoped, Jiangyin Hosp, 163 Shoushan Rd, Jiangyin 214400, Jiangsu, Peoples R China.
EM 504390699@qq.com; haojiew2002@163.com; kds8810@163.com;
   ZYRsoutheast@163.com
RI ; Wu, HaoJie/GZL 0304 2022
OI Ke, Dianshan/0000 0003 0260 7191; Zhu, Yunrong/0000 0001 6271 4226
FU Fujian Provincial Natural Science Foundation [2019J01096]
FX This work was supported by Fujian Provincial Natural Science Foundation
   Projects (2019J01096).
CR Atwood DJ, 2020, CELL SIGNAL, V74, DOI 10.1016/j.cellsig.2020.109730
   Bhadricha H, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 95640 0
   Cong LH, 2020, J CELL MOL MED, V24, P8532, DOI 10.1111/jcmm.15475
   Fernandez Alvaro F, 2018, Nature, V558, P136, DOI 10.1038/s41586 018 0162 7
   Huang H, 2009, CELL DEATH DIFFER, V16, P1332, DOI 10.1038/cdd.2009.74
   Kang CR, 2017, INT J NANOMED, V12, P4323, DOI 10.2147/IJN.S136281
   Ke DS, 2018, BIOCHEM BIOPH RES CO, V497, P890, DOI 10.1016/j.bbrc.2018.02.164
   Kim HJ, 2020, BIOCHEM BIOPH RES CO, V524, P1044, DOI 10.1016/j.bbrc.2020.02.054
   Le Goff B, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/8659302
   Lei LH, 2021, INT IMMUNOPHARMACOL, V96, DOI 10.1016/j.intimp.2021.107781
   Li JY, 2019, J BONE MINER RES, V34, P349, DOI 10.1002/jbmr.3600
   Li JY, 2015, CELL METAB, V22, P799, DOI 10.1016/j.cmet.2015.09.012
   Li S, 2019, BIOCHEM BIOPH RES CO, V509, P194, DOI 10.1016/j.bbrc.2018.12.103
   Lian WS, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0970 6
   Tateosian NL, 2017, AUTOPHAGY, V13, P1191, DOI 10.1080/15548627.2017.1320636
   Liu H, 2013, AUTOPHAGY, V9, P730, DOI 10.4161/auto.24039
   Liu SC, 2022, J BONE MINER RES, V37, P1944, DOI 10.1002/jbmr.4661
   Liu T, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02952
   Roberts JL, 2022, BONE, V157, DOI 10.1016/j.bone.2021.116310
   Samarpita S, 2018, CELL IMMUNOL, V332, P39, DOI 10.1016/j.cellimm.2018.07.005
   Schmidt T, 2019, J HEPATOL, V70, P941, DOI 10.1016/j.jhep.2018.12.035
   Shi H, 2018, J NEUROIMMUNOL, V323, P143, DOI 10.1016/j.jneuroim.2017.07.015
   Shoji Kawata S, 2013, NATURE, V494, P201, DOI 10.1038/nature11866
   Sun YX, 2018, CIRCULATION, V138, P2247, DOI 10.1161/CIRCULATIONAHA.117.032821
   Uluçkan Ö, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8996
   Wang ZX, 2021, CONNECT TISSUE RES, V62, P411, DOI 10.1080/03008207.2020.1759562
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   Xue Y, 2019, BIOCHEM BIOPH RES CO, V508, P1088, DOI 10.1016/j.bbrc.2018.12.029
   Zhang JM, 2022, ARCH ORAL BIOL, V144, DOI 10.1016/j.archoralbio.2022.105555
   Zhong JH, 2022, INT IMMUNOPHARMACOL, V107, DOI 10.1016/j.intimp.2022.108631
NR 30
TC 4
Z9 4
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1071 2690
EI 1543 706X
J9 IN VITRO CELL DEV AN
JI In Vitro Cell. Dev. Biol. Anim.
PD APR
PY 2023
VL 59
IS 4
BP 300
EP 311
DI 10.1007/s11626 023 00761 7
EA MAR 2023
PG 12
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA H7FI4
UT WOS:000961181100001
PM 37002492
DA 2025 08 17
ER

PT J
AU Ma, HP
   Deng, X
   Chen, DY
   Zhu, D
   Tong, JL
   Zhao, T
   Ma, JH
   Liu, YQ
AF Ma, Hui Peng
   Deng, Xue
   Chen, Deng Yi
   Zhu, Di
   Tong, Jin Ling
   Zhao, Ting
   Ma, Jin Hui
   Liu, Yan Qiu
TI A microfluidic chip based co culture of fibroblast like synoviocytes
   with osteoblasts and osteoclasts to test bone erosion and drug
   evaluation
SO ROYAL SOCIETY OPEN SCIENCE
LA English
DT Article
DE microfluidic chip; fibroblast like synoviocytes; bone marrow mesenchymal
   stem cells; osteoclast; migration; bone erosion
ID RHEUMATOID ARTHRITIS; SIGNALING PATHWAY; ALGINATE SCAFFOLD; IN VITRO;
   CELLS; CADHERIN 11; MIGRATION; CELASTROL; DIFFERENTIATION; PROLIFERATION
AB Targeting fibroblast like synoviocyte (FLS) migration and invasion mediated bone erosion is a promising clinical strategy for the treatment of rheumatoid arthritis (RA). Drug sensitivity testing is fundamental to this scheme. We designed a microfluidic chip based, cell co cultured platform to mimic RA FLS mediated bone erasion and perform drug sensitive assay. Human synovium SW982 cells were cultured in the central channel and migrated to flow through matrigel coated side Channels towards cell culture chamber where RANKL stimulated osteoclastic RAW264.7 and osteogenic medium (OS) stimulated bone marrow mesenchymal stem cells (BMSC) were cultured in the microfluidic chip device, mimicking FLS migration and invasion mediated bone erosion in RA. These SW982 cells showed different migration potentials to osteoclasts and BMSC. The migration of SW982 cells with high expression of cadherin 11 was more potent when SW982 cells were connected with the co culture of RAW264.7 and BMSC. Simultaneously, in the co cultured chamber, tartrate resistant acid phosphatase (TRAP) activity of RANKL stimulated RAW264.7 cells was enhanced, but alkaline phosphatase (ALP) activity was decreased in comparison with mono cultured Chamber. Furthermore, it was confirmed that celastrol, a positive drug for the treatment of RA, inhibited SW982 cell migration as well as TRAP activity in the cell cultured microfluidic chips. Thus, the migration and invasion to bone related cells was reconstituted on the microfluidic model. It may provide an effective anti RA drug screen model for targeting FLS migration mediated bone erosion.
C1 [Ma, Hui Peng; Chen, Deng Yi] Dalian Med Univ, Coll Lab Med, Dalian 116044, Peoples R China.
   [Deng, Xue; Zhu, Di; Tong, Jin Ling; Zhao, Ting; Liu, Yan Qiu] Dalian Med Univ, Inst Coll Integrat Med, Dalian 116044, Peoples R China.
   [Ma, Jin Hui] Dalian Med Univ, Peoples Liberat Army Hosp 202, Dalian 116044, Peoples R China.
C3 Dalian Medical University; Dalian Medical University; Dalian Medical
   University
RP Liu, YQ (通讯作者)，Dalian Med Univ, Inst Coll Integrat Med, Dalian 116044, Peoples R China.
EM ygliu@dmu.edu.cn
OI liu, Yan Qiu/0000 0002 1905 7168
FU National Natural Science Foundation of China [81473545]; National
   Science Foundation of China [81601825]; Program for Science and
   Technology Project of Liaoning Province [201601237]; China Scholarship
   Fund [201808210086]; Liaoning province plans to support innovative
   talents in Colleges and Universities [LR2017050]
FX This work was financially supported by the projects of National Natural
   Science Foundation of China (no. 81473545), The National Science
   Foundation of China (grant no. 81601825), Program for Science and
   Technology Project of Liaoning Province (grant no. 201601237), China
   Scholarship Fund (no. 201808210086) and Liaoning province plans to
   support innovative talents in Colleges and Universities (no. LR2017050).
CR Akhavani MA, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2689
   Amin MA, 2017, SEMIN IMMUNOPATHOL, V39, P385, DOI 10.1007/s00281 017 0631 3
   Bersini S, 2014, BIOMATERIALS, V35, P2454, DOI 10.1016/j.biomaterials.2013.11.050
   Cascao R, 2017, RMD OPEN, V3, DOI 10.1136/rmdopen 2017 000438
   Chang SK, 2011, P NATL ACAD SCI USA, V108, P8402, DOI 10.1073/pnas.1019437108
   Chang SK, 2010, IMMUNOL REV, V233, P256, DOI 10.1111/j.0105 2896.2009.00854.x
   Chaw KC, 2007, BIOMED MICRODEVICES, V9, P597, DOI 10.1007/s10544 007 9071 5
   Choe JY, 2016, RHEUMATOLOGY, V55, P928, DOI 10.1093/rheumatology/kev422
   Ding XQ, 2015, INT IMMUNOPHARMACOL, V26, P153, DOI 10.1016/j.intimp.2015.03.024
   Fang Z, 2017, APPL SCI BASEL, V7, DOI 10.3390/app7010071
   Figueiredo CP, 2018, SEMIN ARTHRITIS RHEU, V47, P611, DOI 10.1016/j.semarthrit.2017.09.011
   Gan K, 2015, INT IMMUNOPHARMACOL, V24, P239, DOI 10.1016/j.intimp.2014.12.012
   Ganesan R, 2017, MOL IMMUNOL, V91, P134, DOI 10.1016/j.molimm.2017.09.003
   Hatch A, 2011, LANGMUIR, V27, P4257, DOI 10.1021/la105016a
   Heftdal LD, 2017, J MOL MED, V95, P779, DOI 10.1007/s00109 017 1528 2
   Hou HS, 2015, JOVE J VIS EXP, DOI 10.3791/53340
   Huang CF, 2010, CANCER RES, V70, P4580, DOI 10.1158/0008 5472.CAN 09 3016
   Huang CW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025928
   Krebsbach PH, 1999, CRIT REV ORAL BIOL M, V10, P165, DOI 10.1177/10454411990100020401
   Li GQ, 2013, INT IMMUNOPHARMACOL, V17, P1028, DOI 10.1016/j.intimp.2013.10.006
   Li GQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068905
   Li Wenjuan, 2012, Zhongguo Zhong Yao Za Zhi, V37, P2492
   Li YC, 2017, EXP THER MED, V14, P2657, DOI 10.3892/etm.2017.4808
   Liu KG, 2015, GENET MOL RES, V14, P6852, DOI 10.4238/2015.June.18.28
   Liu YQ, 2014, J ETHNOPHARMACOL, V157, P206, DOI 10.1016/j.jep.2014.09.033
   Maeda Y, 2017, J BONE MINER RES, V32, P461, DOI 10.1002/jbmr.3005
   Malysheva K, 2016, CROAT MED J, V57, P89, DOI 10.3325/cmj.2016.57.89
   Matuszewska A, 2014, POSTEP HIG MED DOSW, V68, P145, DOI 10.5604/17322693.1088339
   Miao CG, 2013, CELL SIGNAL, V25, P2069, DOI 10.1016/j.cellsig.2013.04.002
   Moshaverinia A, 2014, TISSUE ENG PT A, V20, P611, DOI 10.1089/ten.TEA.2013.0229
   Nikhil K, 2015, PHARMACOL REP, V67, P1264, DOI 10.1016/j.pharep.2015.05.009
   Rainville PD, 2015, ANALYST, V140, P5546, DOI 10.1039/c5an00646e
   Sfikakis PP, 2017, CLIN IMMUNOL, V176, P107, DOI 10.1016/j.clim.2017.01.008
   Tang BF, 2018, ANTI CANCER DRUG, V29, P530, DOI 10.1097/CAD.0000000000000621
   Torisawa YS, 2014, NAT METHODS, V11, P663, DOI [10.1038/NMETH.2938, 10.1038/nmeth.2938]
   Wang CC, 2011, BIOMATERIALS, V32, P7118, DOI 10.1016/j.biomaterials.2011.06.018
   Wu JH, 2017, J PHARMACOL SCI, V134, P22, DOI 10.1016/j.jphs.2016.12.007
   Zhang H, 2010, MOL CELL ENDOCRINOL, V330, P25, DOI 10.1016/j.mce.2010.07.022
   Zhang H, 2008, MATURITAS, V61, P334, DOI 10.1016/j.maturitas.2008.09.023
   Zhao C, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/137695
   Zhao YL, 2015, BIOMICROFLUIDICS, V9, DOI 10.1063/1.4917290
NR 41
TC 35
Z9 38
U1 0
U2 61
PU ROYAL SOC
PI LONDON
PA 6 9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 2054 5703
J9 ROY SOC OPEN SCI
JI R. Soc. Open Sci.
PD SEP
PY 2018
VL 5
IS 9
AR 180528
DI 10.1098/rsos.180528
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GV6WO
UT WOS:000446259700025
PM 30839692
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Rotherham, M
   Nahar, T
   Goodman, T
   Telling, N
   Gates, M
   El Haj, A
AF Rotherham, Michael
   Nahar, Tasmin
   Goodman, Timothy
   Telling, Neil
   Gates, Monte
   El Haj, Alicia
TI Magnetic Mechanoactivation of Wnt Signaling Augments Dopaminergic
   Differentiation of Neuronal Cells
SO ADVANCED BIOSYSTEMS
LA English
DT Article
DE magnetic nanoparticles; neuronal differentiation; SH SY5Y; Wnt signaling
ID PROTECTS SH SY5Y CELLS; WNT/BETA CATENIN PATHWAY; OSTEOGENIC
   DIFFERENTIATION; RETINOIC ACID; RECEPTOR; NANOPARTICLES; PROLIFERATION;
   NEUROGENESIS; ACTIVATION; RESPONSES
AB Wnt signaling is a key developmental pathway that regulates dopaminergic progenitor cell proliferation and differentiation during neuronal development. This makes Wnt signaling an important therapeutic target for neurodegenerative conditions such as Parkinson's disease. Wnt signaling can be modulated using peptides such as UM206, which bind to the Wnt receptor Frizzled. Previous work has demonstrated remote activation of the Wnt pathway through Frizzled using peptide functionalized magnetic nanoparticles (MNPs) with magnetic field stimulation. Using this technology, Wnt signaling is remotely activated in the neuronal cell line SH SY5Y, and the phenotypic response to stimulation is assessed. Results indicate beta catenin translocalization and activation of TCF/LEF responsive transcription in response to MNP and magnetic fields, which result in dopaminergic marker expression when synergistically combined with differentiation factors retinoic acid and the phorbol ester phorbol 12 myristate 13 acetate. This approach is translated into ex vivo postnatal rat brain slices modeling the developing nigrostriatal pathway. Dopaminergic marker expression is maintained in MNP labeled SH SY5Y cells after injection and magnetic stimulation. These results demonstrate the translational value of remote control of signal transduction for controlling neuronal precursor cell behavior and highlight the potential applications for controlled cell differentiation as part of cell therapies for neurodegenerative disease.
C1 [Rotherham, Michael; Nahar, Tasmin; Goodman, Timothy; Telling, Neil; Gates, Monte] Keele Univ, Inst Sci & Technol Med, Guy Hilton Res Ctr, Thornburrow Dr, Stoke On Trent ST4 7QB, Staffs, England.
   [El Haj, Alicia] Univ Birmingham, Inst Translat Med, Heritage Bldg,Mindelsohn Way, Birmingham B15 2TH, W Midlands, England.
C3 Keele University; University of Birmingham
RP Rotherham, M (通讯作者)，Keele Univ, Inst Sci & Technol Med, Guy Hilton Res Ctr, Thornburrow Dr, Stoke On Trent ST4 7QB, Staffs, England.
EM m.rotherham@keele.ac.uk
RI Rotherham, Michael/K 7275 2019; Haj, Alicia/B 3315 2012
OI Rotherham, Michael/0000 0002 9297 7681; El Haj,
   Alicia/0000 0003 3544 5678; Gates, Monte/0000 0002 2901 1083; Nahar,
   Tasmin/0000 0001 7377 2130
FU European Union's Horizon 2020 research and innovation program
   [686841 MAGNEURON]; EPSRC DTC in Regenerative medicine [EP/L015072/1]
FX The authors acknowledge Tim Hopkins and Karen Walker for their technical
   assistance. The authors also acknowledge the European Union's Horizon
   2020 research and innovation program (grant agreement no.
   686841 MAGNEURON) and EPSRC DTC in Regenerative medicine (grant funding
   number: EP/L015072/1) who funded this research.
CR Agholme L, 2010, J ALZHEIMERS DIS, V20, P1069, DOI 10.3233/JAD 2010 091363
   Andersson ER, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003517
   Armstrong VJ, 2007, J BIOL CHEM, V282, P20715, DOI 10.1074/jbc.M703224200
   Arnsdorf EJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005388
   Avola R, 2018, MOL CELL NEUROSCI, V88, P212, DOI 10.1016/j.mcn.2018.02.006
   Berry CC, 2003, J PHYS D APPL PHYS, V36, pR198, DOI 10.1088/0022 3727/36/13/203
   Blankesteijn W. M., 2010, [No title captured], Patent No. [EP2226080, 2226080]
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Brunt L, 2018, CELL MOL LIFE SCI, V75, P785, DOI 10.1007/s00018 017 2654 2
   Cadigan KM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007906
   Cartmell Sarah H, 2002, IEEE Trans Nanobioscience, V1, P92, DOI 10.1109/TNB.2002.806945
   Castelo Branco GA, 2003, P NATL ACAD SCI USA, V100, P12747, DOI 10.1073/pnas.1534900100
   Coudreuse D, 2007, DEVELOPMENT, V134, P3, DOI 10.1242/dev.02699
   de Jaime Soguero A, 2018, GENES BASEL, V9, DOI 10.3390/genes9020093
   Duffy DJ, 2017, GENOME MED, V9, DOI 10.1186/s13073 017 0407 3
   Encinas M, 2000, J NEUROCHEM, V75, P991, DOI 10.1046/j.1471 4159.2000.0750991.x
   Feng Q, 2015, J CELL PHYSIOL, V230, P1170, DOI 10.1002/jcp.24853
   Gibbs HC, 2017, FRONT NEUROANAT, V11, DOI 10.3389/fnana.2017.00064
   Goncalves AI, 2018, NANOMED NANOTECHNOL, V14, P1149, DOI 10.1016/j.nano.2018.02.008
   Henstock JR, 2018, J TISSUE ENG, V9, DOI 10.1177/2041731418808695
   Hirabayashi Y, 2004, DEVELOPMENT, V131, P2791, DOI 10.1242/dev.01165
   Hu B, 2014, NANOMED NANOTECHNOL, V10, P45, DOI 10.1016/j.nano.2013.06.014
   Hu B, 2013, INT J MOL SCI, V14, P19276, DOI 10.3390/ijms140919276
   Imura T, 2010, STEM CELLS, V28, P2053, DOI 10.1002/stem.524
   Jackson A, 2005, J NEUROCHEM, V95, P1387, DOI 10.1111/j.1471 4159.2005.03476.x
   Jasmin, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477 3155 9 4
   Joksimovic M, 2009, P NATL ACAD SCI USA, V106, P19185, DOI 10.1073/pnas.0904285106
   Joksimovic M, 2009, NAT NEUROSCI, V12, P125, DOI 10.1038/nn.2243
   Kléber M, 2004, CURR OPIN CELL BIOL, V16, P681, DOI 10.1016/j.ceb.2004.08.006
   Knaryan VH, 2014, J NEUROCHEM, V130, P280, DOI 10.1111/jnc.12629
   Kumar C.S.S.R., 2009, MAGNETIC NANOMATERIA, P672
   Kunz M, 2004, DEV BIOL, V273, P390, DOI 10.1016/j.ydbio.2004.06.015
   Lowndes M, 2016, STEM CELL REP, V7, P126, DOI 10.1016/j.stemcr.2016.06.004
   Machon O, 2007, DEV BIOL, V311, P223, DOI 10.1016/j.ydbio.2007.08.038
   Mahmoudi M, 2011, ADV DRUG DELIVER REV, V63, P24, DOI 10.1016/j.addr.2010.05.006
   Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100
   Markides H, 2018, NPJ REGEN MED, V3, DOI 10.1038/s41536 018 0048 1
   Niewiarowska Sendo A, 2015, ACTA BIOCHIM POL, V62, P435, DOI 10.18388/abp.2015_1039
   Norvell SM, 2004, CALCIFIED TISSUE INT, V75, P396, DOI 10.1007/s00223 004 0213 y
   PAHLMAN S, 1981, INT J CANCER, V28, P583, DOI 10.1002/ijc.2910280509
   Prakash N, 2006, DEVELOPMENT, V133, P89, DOI 10.1242/dev.02181
   Presgraves SP, 2004, NEUROTOX RES, V5, P579, DOI 10.1007/bf03033178
   Quarto N, 2010, TISSUE ENG PT A, V16, P3185, DOI 10.1089/ten.tea.2010.0133
   Rao TP, 2010, CIRC RES, V106, P1798, DOI 10.1161/CIRCRESAHA.110.219840
   Rotherham M, 2018, NANOMED NANOTECHNOL, V14, P173, DOI 10.1016/j.nano.2017.09.008
   Rotherham M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121761
   Schwarz Romond T, 2012, EMBO J, V31, P2664, DOI 10.1038/emboj.2012.159
   Singh N, 2010, NANO REV EXP, V1, DOI 10.3402/nano.v1i0.5358
   SPINELLI W, 1982, CANCER RES, V42, P5067
   STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165 0270(91)90128 M
   Suebsoonthron J, 2017, ANTI CANCER DRUG, V28, P469, DOI 10.1097/CAD.0000000000000478
   Szemes M, 2018, NEOPLASIA, V20, P335, DOI 10.1016/j.neo.2018.01.009
   Tang MZ, 2010, J NEUROSCI, V30, P9280, DOI 10.1523/JNEUROSCI.0860 10.2010
   Uemura K, 2003, J NEUROSCI RES, V73, P166, DOI 10.1002/jnr.10641
   Wei L, 2015, TRANSL NEURODEGENER, V4, DOI 10.1186/s40035 015 0033 1
   Wei L, 2013, J MOL NEUROSCI, V49, P105, DOI 10.1007/s12031 012 9900 8
   Willert K, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007864
   Yang JW, 2015, NEUROPEPTIDES, V54, P35, DOI 10.1016/j.npep.2015.08.005
NR 58
TC 20
Z9 20
U1 0
U2 5
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
EI 2366 7478
J9 ADV BIOSYST
JI Adv. Biosyst.
PD SEP
PY 2019
VL 3
IS 9
AR 1900091
DI 10.1002/adbi.201900091
EA AUG 2019
PG 13
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA IY2EY
UT WOS:000481885900001
PM 32648650
OA hybrid
DA 2025 08 17
ER

PT S
AU Whyte, MP
AF Whyte, Michael P.
BE Zaidi, M
TI Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF κB
   signaling
SO SKELETAL DEVELOPMENT AND REMODELING IN HEALTH, DISEASE, AND AGING
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT Conference on Skeletal Development and Remodeling in Health, Disease and
   Aging
CY MAY 18 21, 2005
CL New York, NY
SP NY Acad Sci, Alliance Better Bone Hlth, Procter & Gamble Pharmaceut, Sanofi Aventis, Novartis Pharmaceut Corp, Roche Pharmaceut, Merck & Co
DE alkaline phosphatase; bisphosphonate; bone resorption; familial
   expansile osteolysis; fracture; hyperostosis; hyperphosphatasia;
   juvenile Paget's disease; NF kappa B; osteoclast; osteolysis;
   osteoprotegerin; osteosarcoma; skeletal remodeling; tumor necrosis
   factor
ID FAMILIAL EXPANSILE OSTEOLYSIS; OSTEOCLAST DIFFERENTIATION FACTOR;
   IDIOPATHIC HYPERPHOSPHATASIA; OSTEOPROTEGERIN LIGAND; CHROMOSOME 18Q;
   TNFRSF11A GENE; MEASLES VIRUS; HEREDITARY HYPERPHOSPHATASIA; SKELETAL
   HYPERPHOSPHATASIA; TANDEM DUPLICATION
AB Identification of the RANKL/OPG/RANK/NF kB (receptor activator of nuclear factor K B ligand / osteoprotegerin) signaling pathway as the major regulatory system for osteoclastogenesis began with discovery of these ligands and receptors in the tumor necrosis factor (TNF) superfamily. Subsequently, genetically altered mice revealed physiologic roles for these proteins in bone biology. However, full appreciation of their significance for the human skeleton came from clinical characterization of several extremely rare, heritable disorders followed by discovery of their genetic bases. Familial expansile osteolysis (FEO) is an autosomal dominant disorder featuring constitutive activation of RANK due to an 18 bp tandem duplication in its gene (TNFRSF11A). A similar, 27 bp duplication causes what has been called a familial form of early onset Paget's disease of bone (PDB2). Expansile skeletal hyperphosphatasia (ESH) is allelic to FEO and PDB2 and involves a 15 bp tandem duplication in TNFRSF11A. Autosomal recessive inheritance of deactivating mutations of the gene encoding OPG (TNFRSF11B) causes most cases of juvenile Paget disease. These disorders feature high bone turnover, deafness during early childhood, "idiopathic external lysis" of adult teeth, and sometimes focal lesions in appendicular bones that mimic active PDB. Biochemical markers indicate rapid skeletal remodeling. In FEO, osteolysis progresses to fat filled bone rather than to osteosclerosis. Antiresorptive therapy with bisphosphonates can be effective for each disorder.
C1 Shriners Hosp Children, Ctr Metab Bone Dis & Mol Res, St Louis, MO 63131 USA.
   Washington Univ, Sch Med, Div Bone & Mineral Dis, St Louis, MO 63131 USA.
C3 Washington University (WUSTL)
RP Whyte, MP (通讯作者)，Shriners Hosp Children, Ctr Metab Bone Dis & Mol Res, 2001 S Lindbergh Blvd, St Louis, MO 63131 USA.
EM mwhyte@shrinenet.org
CR Altman RD, 2000, J BONE MINER RES, V15, P461, DOI 10.1359/jbmr.2000.15.3.461
   ALTMAN RD, 1992, DISORDERS BONE MINER, P1027
   [Anonymous], ARTICULAR DIS PHILAD
   [Anonymous], MOL BIOL PAGETS DIS
   APGET J, 1877, MED CHIR T, V60, P37
   Asai T, 2002, JPN J CANCER RES, V93, P296, DOI 10.1111/j.1349 7006.2002.tb02172.x
   BARR RJ, 1989, AM J MED GENET, V32, P556, DOI 10.1002/ajmg.1320320430
   BLANCO O, 1977, J BONE JOINT SURG BR, V59, P421, DOI 10.1302/0301 620X.59B4.562883
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   *BUR CENS, 1994, 1990 CENS POP HOUS C
   CAFFEY J, 1972, Bulletin of the Hospital for Joint Diseases, V33, P81
   CASSINELLI HR, 1992, BONE MINER, V19, P175, DOI 10.1016/0169 6009(92)90924 3
   Chong B, 2003, J BONE MINER RES, V18, P2095, DOI 10.1359/jbmr.2003.18.12.2095
   CHOSICH N, 1991, J ENDOCRINOL INVEST, V14, P591, DOI 10.1007/BF03346877
   Cody JD, 1997, AM J HUM GENET, V61, P1117, DOI 10.1086/301601
   Cole D.E.C., 1996, STUDIES STOMATOLOGY, P245
   CRONE MD, 1990, SKELETAL RADIOL, V19, P245
   Cundy T, 2002, HUM MOL GENET, V11, P2119, DOI 10.1093/hmg/11.18.2119
   Cundy T, 2005, NEW ENGL J MED, V353, P918, DOI 10.1056/NEJMoa050893
   DICKSON GR, 1991, BONE, V12, P331, DOI 10.1016/8756 3282(91)90019 F
   Dunstan CR, 2000, ENDOCRINOLOGIST, V10, P18, DOI 10.1097/00019616 200010010 00005
   ENDERLE A, 1979, PATHOL RES PRACT, V166, P131, DOI 10.1016/S0344 0338(79)80014 X
   ENDERLE A, 1979, ARCH ORTHOP TRAUM SU, V94, P127, DOI 10.1007/BF00433578
   Esselman GH, 1996, OTOLARYNG HEAD NECK, V114, P639, DOI 10.1016/S0194 5998(96)70260 7
   EYRING EJ, 1968, J BONE JOINT SURG AM, VA 50, P1099, DOI 10.2106/00004623 196850060 00002
   Falchetti A, 2004, J BONE MINER RES, V19, P1013, DOI 10.1359/JBMR.040203
   GIPIN L, 1968, ENDURING NAVAHO
   Golob DS, 1996, J BONE MINER RES, V11, P132
   Good D, 2001, J BONE MINER RES, V16, P33, DOI 10.1359/jbmr.2001.16.1.33
   Good DA, 2004, BONE, V35, P277, DOI 10.1016/j.bone.2004.01.010
   Good DA, 2002, AM J HUM GENET, V70, P517, DOI 10.1086/338658
   Hamdy RC, 1981, PAGETS DIS BONE ASSE
   Haslam SI, 1998, J BONE MINER RES, V13, P911, DOI 10.1359/jbmr.1998.13.6.911
   Hocking LJ, 2004, J BONE MINER RES, V19, P1122, DOI 10.1359/JBMR.0403015
   Hocking LJ, 2002, HUM MOL GENET, V11, P2735, DOI 10.1093/hmg/11.22.2735
   Hocking LJ, 2001, AM J HUM GENET, V69, P1055, DOI 10.1086/323798
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Hofbauer LC, 1998, EUR J ENDOCRINOL, V139, P152, DOI 10.1530/eje.0.1390152
   Hofbauer LC, 2000, J CLIN ENDOCR METAB, V85, P2355, DOI 10.1210/jc.85.7.2355
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   HUGHES AE, 1994, HUM MOL GENET, V3, P359, DOI 10.1093/hmg/3.2.359
   Hughes AE, 2000, NAT GENET, V24, P45, DOI 10.1038/71667
   IANCU TC, 1978, RADIOLOGY, V129, P669, DOI 10.1148/129.3.669
   Johnson Pais TL, 2003, J BONE MINER RES, V18, P1748, DOI 10.1359/jbmr.2003.18.10.1748
   Johnson Pais TL, 2003, J BONE MINER RES, V18, P376, DOI 10.1359/jbmr.2003.18.2.376
   Kanis JA., 1998, PATHOPHYSIOLOGY TREA, VSecond
   Kim GS, 1997, MEDICINE, V76, P157, DOI 10.1097/00005792 199705000 00002
   Kimonis VE, 2000, GENET MED, V2, P232, DOI 10.1097/00125817 200007000 00006
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Laurin N, 2002, AM J HUM GENET, V70, P1582, DOI 10.1086/340731
   Laurin N, 2001, AM J HUM GENET, V69, P528, DOI 10.1086/322975
   Leach RJ, 2001, J CLIN ENDOCR METAB, V86, P24, DOI 10.1210/jc.86.1.24
   Leach RJ, 1999, J BONE MINER RES, V14, P17, DOI 10.1002/jbmr.5650140205
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Lories RJU, 2001, CLIN RHEUMATOL, V20, P3, DOI 10.1007/s100670170095
   Lucas GJA, 2005, J BONE MINER RES, V20, P227, DOI 10.1359/JBMR.041106
   Martin T. J., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P243
   MCKUSICK VA, 1960, HERITABLE DIS CONNEC
   McKusick VA., 1998, Mendelian Inheritance in Man: A Catalog of Human Genes and Genetic Disorders, V12
   MEUNIER PJ, 1980, ARTHRITIS RHEUM US, V23, P1095, DOI 10.1002/art.1780231005
   MITCHELL CA, 1990, J ORAL PATHOL MED, V19, P65, DOI 10.1111/j.1600 0714.1990.tb00798.x
   MITCHELL CA, 1990, ORAL SURG ORAL MED O, V70, P301, DOI 10.1016/0030 4220(90)90145 I
   MITSUDO SM, 1971, J BONE JOINT SURG AM, VA 53, P303, DOI 10.2106/00004623 197153020 00010
   MORALESPIGA AA, 1995, J BONE MINER RES, V10, P663
   Mumm S, 2003, J BONE MINER RES, V18, pS388
   NAGER GT, 1975, ANN OTO RHINOL LARYN, V84, P1, DOI 10.1177/00034894750844S201
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Nakatsuka K, 2003, J BONE MINER RES, V18, P1381, DOI 10.1359/jbmr.2003.18.8.1381
   Nance MA, 2000, AM J MED GENET, V92, P303, DOI 10.1002/1096 8628(20000619)92:5<303::AID AJMG2>3.0.CO;2 E
   Olsen C. B., 1999, Pediatric Dentistry, V21, P363
   OSTERBERG PH, 1988, J BONE JOINT SURG BR, V70, P255, DOI 10.1302/0301 620X.70B2.3346299
   Osterberg PH, 1976, BONE DIS CALCITONIN, P181
   Palenzuela L, 2002, J MED GENET, V39, DOI 10.1136/jmg.39.10.e67
   PETTIFOR JM, 1996, J BONE MINER RES  S1, V11, pS254
   Reddy SV, 1996, J BONE MINER RES, V11, P1602
   Reddy SV, 1999, J BONE MINER RES, V14, P3, DOI 10.1002/jbmr.5650140203
   Reddy SV, 2001, ENDOCRINOLOGY, V142, P2898, DOI 10.1210/en.142.7.2898
   Roodman GD, 2005, J CLIN INVEST, V115, P200, DOI 10.1172/JCI200524281
   Ross FP, 2000, J CLIN INVEST, V105, P555, DOI 10.1172/JCI9557
   SILVE C, 1986, J CLIN ENDOCR METAB, V62, P583, DOI 10.1210/jcem 62 3 583
   Singer FR, 1999, J BONE MINER RES, V14, P29, DOI 10.1002/jbmr.5650140207
   Singer FR, 2000, GENETICS OF OSTEOPOROSIS AND METABOLIC BONE DISEASE, P309
   SMITH BJ, 1981, J ORAL PATHOL MED, V10, P233, DOI 10.1111/j.1600 0714.1981.tb01270.x
   Sparks AB, 2001, CALCIFIED TISSUE INT, V68, P151, DOI 10.1007/s002230001211
   STRICKBERGER SA, 1987, AM J MED, V82, P953, DOI 10.1016/0002 9343(87)90157 4
   Tintut Y, 2001, CURR OPIN LIPIDOL, V12, P555, DOI 10.1097/00041433 200110000 00012
   WALLACE R, 1988, J MED GENET, V25, P276
   Wallace R.G.H., 1987, A Study of Familial Bone Dysplasia
   WALLACE RGH, 1989, CLIN ORTHOP RELAT R, P265
   Wallin R, 2001, MED RES REV, V21, P274, DOI 10.1002/med.1010.abs
   WATTS GDJ, 2004, NAT GENET, V10, P1
   WENKERT D, IN PRESS J BONE MINE
   Whyte Michael P., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P254
   Whyte MP, 2002, MEDICINE, V81, P101, DOI 10.1097/00005792 200203000 00002
   Whyte MP, 2002, NEW ENGL J MED, V347, P175, DOI 10.1056/NEJMoa013096
   Whyte MP, 2002, NEW ENGL J MED, V347, P1622
   Whyte MP, 2002, J BONE MINER RES, V17, P26, DOI 10.1359/jbmr.2002.17.1.26
   Whyte MP, 1996, J BONE MINER RES, V11, P1041
   Whyte MP, 2000, J BONE MINER RES, V15, P2330, DOI 10.1359/jbmr.2000.15.12.2330
   WHYTE MP, 1981, CALCITONIN 1980 CHEM, P217
   Wuyts W, 2001, BONE, V28, P104, DOI 10.1016/S8756 3282(00)00411 7
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 102
TC 69
Z9 78
U1 1
U2 8
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER STREET, HOBOKEN, NJ, UNITED STATES
SN 0077 8923
BN 1 57331 583 4
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2006
VL 1068
BP 143
EP 164
DI 10.1196/annals.1346.016
PG 22
WC Multidisciplinary Sciences; Orthopedics
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Orthopedics
GA BFA92
UT WOS:000240548200015
PM 16831914
DA 2025 08 17
ER

PT J
AU Deng, W
   Li, HS
   Zhang, YY
   Lin, YW
   Chen, CW
   Chen, JC
   Huang, YB
   Zhou, Y
   Tang, YC
   Ding, JY
   Yuan, K
   Xu, LL
   Li, YX
   Zhang, SC
AF Deng, Wei
   Li, HaiShan
   Zhang, YaYa
   Lin, YueWei
   Chen, ChiWei
   Chen, JunChun
   Huang, YanBo
   Zhou, Yi
   Tang, YongChao
   Ding, JinYong
   Yuan, Kai
   Xu, LiangLiang
   Li, YongXian
   Zhang, ShunCong
TI Isoliensinine suppresses bone loss by targeted inhibition of RANKL RANK
   binding
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Isoliensinine; Osteoporosis; Osteoclastogenesis; SPR; ROS; Ca2+
ID OSTEOPOROSIS; OSTEOCLASTOGENESIS; RISK
AB Background: Osteoporosis, a systemic metabolic bone disease, is often caused by the disruption of dynamic equilibrium between osteoclasts and osteoblasts. Overactive bone resorption, in which osteoclasts play a major role, is one of the most common and major causes of osteoporosis. Less costly and more effective drug treatments for this disease are needed. Based on the combination of molecular docking techniques and in vitro cell assays, this study aimed to explore the mechanism by which Isoliensinine (ILS) protects the bone loss by inhibiting osteoclast differentiation.Methods: A virtual docking model based on molecular docking technology was used to investigate the in teractions between ILS and the Receptor Activator of Nuclear Kappa B (RANK)/Receptor Activator of Nuclear Kappa B Ligand (RANKL).In this study, we determined the effective dose of action of ILS to inhibit osteoclast differentiation in vitro and, using bone resorption experiments, RT CPR and Western Blot investigated the effects of ILS on bone resorption function and normal expression of osteoclast associated genes and proteins, and validated potential mechanistic pathways. In vivo experiments revealed that ILS could inhibit bone loss through Micro CT results. Finally, the molecular interaction between ILS and RANK/RANKL was investigated using biomolecular inter action experiments to verify the correctness and accuracy of the computational results.Results: ILS binds to RANK and RANKL proteins, respectively, through virtual molecular docking. The Surface Plasmon Resonance (SPR) experiment results revealed that phosphorylated JNK, ERK, P38, and P65 expression was significantly downregulated when ILS were targeted to inhibit RANKL/RANK binding. At the same time, the expression of IKB a was significantly increased under the stimulation of ILS, which rescued the degradation of IKB a. ILS can significantly inhibit the levels of Reactive Oxygen Species (ROS) and Ca2 + concentration in vitro. Finally, the results of Micro CT showed that ILS can significantly inhibit bone loss in vivo, indicating that ILS has a potential role in the treatment of osteoporosis.Conclusion: ILS inhibits osteoclast differentiation and bone loss by preventing the normal binding of RANKL/ RANK, affecting downstream signaling pathways, including MAPK.NF KB, ROS, Ca2+, genes, and proteins.
C1 [Deng, Wei; Li, HaiShan; Zhang, YaYa; Lin, YueWei; Huang, YanBo; Tang, YongChao; Ding, JinYong; Yuan, Kai; Xu, LiangLiang; Li, YongXian; Zhang, ShunCong] Guangzhou Univ Chinese Med, 12 Ji Chang Rd, Guangzhou 510405, Guangdong, Peoples R China.
   [Deng, Wei; Li, HaiShan; Zhang, YaYa; Lin, YueWei; Huang, YanBo; Tang, YongChao; Ding, JinYong; Yuan, Kai; Xu, LiangLiang; Li, YongXian; Zhang, ShunCong] Guangzhou Univ Chinese Med, Lingnan Med Res Ctr, Lab Orthopaed & Traumatol, 12 Jichang Rd, Guangzhou 510405, Peoples R China.
   [Deng, Wei; Li, HaiShan; Lin, YueWei; Chen, ChiWei; Huang, YanBo; Tang, YongChao; Yuan, Kai; Xu, LiangLiang; Li, YongXian; Zhang, ShunCong] Guangzhou Univ Tradit Chinese Med, Affiliated Hosp 1, 12 Airport Rd, Guangzhou 510405, Guangdong, Peoples R China.
   [Chen, JunChun] Guangxi Univ Chinese Med, 179 Mingxiu East Rd, Nanning 530200, Guangxi, Peoples R China.
   [Zhou, Yi] Guangxi Med Univ, 22 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.
   [Zhang, YaYa] Guangzhou Univ Chinese Med, Sch Basic Med Sci, Guangzhou 510405, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Guangzhou University of Chinese Medicine; Guangxi
   University of Chinese Medicine; Guangxi Medical University; Guangzhou
   University of Chinese Medicine
RP Xu, LL; Li, YX; Zhang, SC (通讯作者)，Guangzhou Univ Tradit Chinese Med, Affiliated Hosp 1, 12 Airport Rd, Guangzhou 510405, Guangdong, Peoples R China.
EM xull 2016@gzucm.edu.cn; spinelyx@126.com; spinezsc@126.com
RI ; Li, Haishan/NOE 7338 2025; Lin, Yuewei/D 9454 2017; XU,
   LIANGLIANG/AAZ 7935 2020
OI Zhang, Shuncong/0000 0002 3059 2487; Li, Haishan/0000 0002 2102 7021;
   Xu, Liangliang/0000 0002 5249 7480; Deng, Wei/0000 0002 1216 549X
FU Science and Technology Program of Guangzhou, China [202102021040]; Basic
   and Applied Basic Research Fund Project in Guangdong Province, China
   [2020A1515110948]; Natural Science Foundation of Guangdong Province,
   China [2021A1515012168]; Application and foundation research project of
   Guangzhou, China [202201020500]; Administration of Traditional Chinese
   Medicine of Guangdong Province, China [20203004, 20221146]; innovation
   and strength project of The First Affiliated Hospital of Guangzhou
   University of Chinese Medicine, China [2019QN29]
FX Science and Technology Program of Guangzhou, China (Number:
   202102021040) ; Basic and Applied Basic Research Fund Project in
   Guangdong Province, China (Number: 2020A1515110948) ; Natural Science
   Foundation of Guangdong Province, China (Number: 2021A1515012168) ;
   Application and foundation research project of Guangzhou, China (Number:
   202201020500) ; Administration of Traditional Chinese Medicine of
   Guangdong Province, China (Number: 20203004; 20221146) ; The innovation
   and strength project of The First Affiliated Hospital of Guangzhou
   University of Chinese Medicine, China (Number: 2019QN29) .
CR An Y., ELECTRONIC, P1530
   Arceo Mendoza R, 2021, ENDOCRIN METAB CLIN, V50, P167, DOI 10.1016/j.ecl.2021.03.009
   Asberg D, 2016, J PHARMACEUT BIOMED, V129, P273, DOI 10.1016/j.jpba.2016.06.018
   Chen HL, 2021, J ETHNOPHARMACOL, V276, DOI 10.1016/j.jep.2021.114195
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Chen YL, 2022, FRONT PHARMACOL, V13
   Cheng Y, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.630385
   Deng W., PRINT, P1663
   Ebina K, 2021, JOINT BONE SPINE, V88, DOI 10.1016/j.jbspin.2021.105219
   El Gazzar A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020625
   Fata J.E., OSTEOCLAST DIFFERENT, P0092
   Forssén P, 2018, ANAL CHEM, V90, P5366, DOI 10.1021/acs.analchem.8b00504
   FROST HM, 1990, ANAT RECORD, V226, P423, DOI 10.1002/ar.1092260404
   Guerrini M.M., HUMAN OSTEOCLAST POO, P1537
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   He JB, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.645140
   Icer MA, 2018, CLIN BIOCHEM, V59, P17, DOI 10.1016/j.clinbiochem.2018.07.003
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Infante M, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 018 1001 2
   Johnston CB, 2020, MED CLIN N AM, V104, P873, DOI 10.1016/j.mcna.2020.06.004
   Kerschan Schindl K, 2016, WIEN MED WOCHENSCHR, V166, P22, DOI 10.1007/s10354 015 0417 y
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Law BYK, 2014, SCI REP UK, V4, DOI 10.1038/srep05510
   Li JB, 2017, J BONE MINER RES, V32, P962, DOI 10.1002/jbmr.3059
   Li QY, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108651
   Li S, 2014, EVID BASED COMPL ALT, V2014, DOI 10.1155/2014/138460
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Liu Z., ISOLIENSININE ELIMIN, P1559
   Ma M., 2022, Front. Pharmacol, V13
   Mancini A, 1997, ONCOGENE, V15, P1565, DOI 10.1038/sj.onc.1201518
   Marchenkova L A, 2021, Vopr Kurortol Fizioter Lech Fiz Kult, V98, P55, DOI 10.17116/kurort20219802155
   Arceo Mendoza RM, 2015, WOMENS HEALTH, V11, P477, DOI [10.2217/whe.15.14, 10.2217/WHE.15.14]
   Nguyen TV, 2001, AM J EPIDEMIOL, V153, P587, DOI 10.1093/aje/153.6.587
   Pan LL, 2020, J ETHNOPHARMACOL, V258, DOI 10.1016/j.jep.2020.112842
   Sharma B.R., COMPREHENSIVE REV CH, P1099
   Tsubaki M, 2014, J BIOMED SCI, V21, DOI 10.1186/1423 0127 21 10
   Tsukasaki M, 2021, J BONE MINER METAB, V39, P82, DOI 10.1007/s00774 020 01165 3
   Wang H, 2023, BIOACT MATER, V21, P324, DOI 10.1016/j.bioactmat.2022.08.029
   Wang YD, 2009, J ETHNOPHARMACOL, V122, P221, DOI 10.1016/j.jep.2009.01.026
   Wright N.C., RECENT PREVALENCE OS, P1523
   Wyss Coray T, 2016, NATURE, V539, P180, DOI 10.1038/nature20411
   Xie Yan Ming, 2021, Zhongguo Zhong Yao Za Zhi, V46, P5992, DOI 10.19540/j.cnki.cjcmm.20210709.501
   Xie Y, 2013, MOLECULES, V18, P10285, DOI 10.3390/molecules180910285
   Yang LN, 2021, CHIN J INTEGR MED, V27, P919, DOI 10.1007/s11655 020 3422 y
   Yang X., ELECTRONIC, P1520
   Yasuda H, 2021, J BONE MINER METAB, V39, P2, DOI 10.1007/s00774 020 01175 1
   Zhang F., 2000, CHIN J PHARMACOL TOX, V14, P296
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
NR 48
TC 7
Z9 7
U1 4
U2 17
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD APR
PY 2023
VL 210
AR 115463
DI 10.1016/j.bcp.2023.115463
EA MAR 2023
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA A6GR3
UT WOS:000956090800001
PM 36849060
DA 2025 08 17
ER

PT J
AU Masi, L
   Agnusdei, D
   Bilezikian, J
   Chappard, D
   Chapurlat, R
   Cianferotti, L
   Devolgelaer, JP
   El Maghraoui, A
   Ferrari, S
   Javaid, MK
   Kaufman, JM
   Liberman, UA
   Lyritis, G
   Miller, P
   Napoli, N
   Roldan, E
   Papapoulos, S
   Watts, NB
   Brandi, ML
AF Masi, L.
   Agnusdei, D.
   Bilezikian, J.
   Chappard, D.
   Chapurlat, R.
   Cianferotti, L.
   Devolgelaer, J.  P.
   El Maghraoui, A.
   Ferrari, S.
   Javaid, M. K.
   Kaufman, J.  M.
   Liberman, U. A.
   Lyritis, G.
   Miller, P.
   Napoli, N.
   Roldan, E.
   Papapoulos, S.
   Watts, N. B.
   Brandi, M. L.
TI Taxonomy of rare genetic metabolic bone disorders
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Bone metabolism; Genetic bone diseases; Metabolic bone diseases; Rare
   bone diseases; Taxonomy
ID VACUOLAR PROTON PUMP; BIOCHEMICAL MARKERS; OSTEOPETROSIS; OSTEOCYTES;
   DISEASES; RESORPTION; OSTEOPOROSIS; MECHANISMS; OSTEOBLAST; MEMBRANE
AB The Summary This article reports a taxonomic classification of rare skeletal diseases based on metabolic phenotypes. It was prepared by The Skeletal Rare Diseases Working Group of the International Osteoporosis Foundation (IOF) and includes 116 OMIM phenotypes with 86 affected genes.
   Introduction Rare skeletal metabolic diseases comprise a group of diseases commonly associated with severe clinical consequences. In recent years, the description of the clinical phenotypes and radiographic features of several genetic bone disorders was paralleled by the discovery of key molecular pathways involved in the regulation of bone and mineral metabolism. Including this information in the description and classification of rare skeletal diseases may improve the recognition and management of affected patients.
   Methods IOF recognized this need and formed a Skeletal Rare Diseases Working Group (SRD WG) of basic and clinical scientists who developed a taxonomy of rare skeletal diseases based on their metabolic pathogenesis.
   Results This taxonomy of rare genetic metabolic bone disorders (RGMBDs) comprises 116 OMIM phenotypes, with 86 affected genes related to bone and mineral homeostasis. The diseases were divided into four major groups, namely, disorders due to altered osteoclast, osteoblast, or osteocyte activity; disorders due to altered bone matrix proteins; disorders due to altered bone microenvironmental regulators; and disorders due to deranged calciotropic hormonal activity.
   Conclusions This article provides the first comprehensive taxonomy of rare metabolic skeletal diseases based on deranged metabolic activity. This classification will help in the development of common and shared diagnostic and therapeutic pathways for these patients and also in the creation of international registries of rare skeletal diseases, the first step for the development of genetic tests based on next generation sequencing and for performing large intervention trials to assess efficacy of orphan drugs.
C1 [Masi, L.; Cianferotti, L.; Brandi, M. L.] Univ Florence, Univ Hosp Florence, Dept Surg & Translat Med, Metab Bone Dis Unit, Florence, Italy.
   [Agnusdei, D.] Eli Lilly & Co, Florence, Italy.
   [Bilezikian, J.] Columbia Univ, Coll Phys & Surg, New York, NY USA.
   [Chappard, D.] LUNAM Univ, IRIS IBS, GEROM Grp Etud Remodelage Osseux & BioMat LHEA, Angers, France.
   [Chapurlat, R.] Univ Lyon, Hosp Civils Lyon, Dept Rheumatol, INSERM UMR 1033, Lyon, France.
   [Devolgelaer, J.  P.] Clin Univ UCL St Luc, Dept Med Interne, Brussels, Belgium.
   [El Maghraoui, A.] Hop Militaire Mohammed V, Serv Rhumatol, Rabat, Morocco.
   [Ferrari, S.] Univ Hosp Geneva, Fac Med, Div Bone Dis, Geneva, Switzerland.
   [Javaid, M. K.] Univ Oxford, Oxford NIHR Musculoskeletal Biomed Res Unit, Oxford, England.
   [Kaufman, J.  M.] Ghent Univ Hosp, Dept Endocrinol, Ghent, Belgium.
   [Liberman, U. A.] Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL 69978 Tel Aviv, Israel.
   [Liberman, U. A.] Tel Aviv Univ, Sackler Sch Med, Felsenstein Med Res Ctr, IL 69978 Tel Aviv, Israel.
   [Lyritis, G.] Univ Athens, Lab Res Musculoskeletal Syst, Athens, Greece.
   [Miller, P.] Univ Colorado, Hlth Sci Ctr, Colorado Ctr Bone Res, Lakewood, CO USA.
   [Napoli, N.] Univ Campus Biomed Roma, Div Endocrinol & Diabet, Rome, Italy.
   [Roldan, E.] Gador SA, Dept Clin Pharmacol, Buenos Aires, DF, Argentina.
   [Papapoulos, S.] Leiden Univ, Med Ctr, Ctr Bone Qual, Leiden, Netherlands.
   [Watts, N. B.] Mercy Hlth Osteoporosis & Bone Hlth Serv, Cincinnati, OH USA.
C3 University of Florence; Azienda Ospedaliero Universitaria Careggi; Eli
   Lilly; Columbia University; CHU Lyon; Universite Claude Bernard Lyon 1;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Catholique Louvain; Cliniques Universitaires Saint Luc;
   Mohammed V University in Rabat; Ibn sina University Hospital Center of
   Rabat; University of Geneva; University of Oxford; Ghent University;
   Ghent University Hospital; Tel Aviv University; Sackler Faculty of
   Medicine; Tel Aviv University; Sackler Faculty of Medicine; National &
   Kapodistrian University of Athens; Colorado Center For Bone Research;
   University of Colorado System; University of Colorado Anschutz Medical
   Campus; University Campus Bio Medico   Rome Italy; Leiden University  
   Excl LUMC; Leiden University; Leiden University Medical Center (LUMC)
RP Brandi, ML (通讯作者)，Univ Florence, Univ Hosp Florence, Dept Surg & Translat Med, Metab Bone Dis Unit, Florence, Italy.
EM marialuisa.brandi@unifi.it
RI ; CIANFEROTTI, LUISELLA/LSK 2125 2024; Cianferotti,
   Luisella/LSK 2125 2024; Ferrari, Serge/ABD 2730 2020; Napoli,
   Nicola/K 8242 2016; CHAPURLAT, ROLAND/AAU 1165 2021
OI roldan, emilio/0000 0002 8472 617X; Javaid,
   Muhammad/0000 0001 7985 0048; CIANFEROTTI, LUISELLA/0000 0001 7424 6212;
   El Maghraoui, Abdellah/0000 0003 0668 5680; brandi, maria
   luisa/0000 0002 8741 0592; Napoli, Nicola/0000 0002 3091 8205; 
FU IOF
FX This paper was supported by the IOF.
CR Alfadda TI, 2014, AM J PHYSIOL CELL PH, V307, pC221, DOI 10.1152/ajpcell.00139.2014
   [Anonymous], 1971, PEDIATRICS, V47, P431
   [Anonymous], 1971, Radiology, V99, P699
   [Anonymous], 1971, Arch Fr Pediatr, V28, P553
   [Anonymous], 1971, J Pediatr, V78, P177
   [Anonymous], 2010, 5 EUR C RAR DIS EUR, P1
   [Anonymous], 2013, Reflection Paper on the Data Requirements for Intravenous Liposomal Products Developed with Reference to an Innovator Liposomal Product; EMA/CHMP/806058/2009/Rev. 02, P1
   [Anonymous], IBMS BONEKEY
   Arnett TR, 2008, J NUTR, V138, p415S, DOI 10.1093/jn/138.2.415S
   Aymé S, 2007, BUNDESGESUNDHEITSBLA, V50, P1477, DOI 10.1007/s00103 007 0381 9
   BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210
   Bergmann P, 2009, INT J CLIN PRACT, V63, P19, DOI 10.1111/j.1742 1241.2008.01911.x
   BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207
   BLAIR HC, 1991, AM J PHYSIOL, V260, pC1315, DOI 10.1152/ajpcell.1991.260.6.C1315
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   Bonewald LF, 2007, ANN NY ACAD SCI, V1116, P281, DOI 10.1196/annals.1402.018
   Boyce BF, 2009, CRIT REV EUKAR GENE, V19, P171, DOI 10.1615/CritRevEukarGeneExpr.v19.i3.10
   Braun MM, 2010, NAT REV DRUG DISCOV, V9, P519, DOI 10.1038/nrd3160
   Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239
   Burger EH, 1999, FASEB J, V13, pS101, DOI 10.1096/fasebj.13.9001.s101
   BURTIS WJ, 1987, J BIOL CHEM, V262, P7151
   Calvo MS, 1996, ENDOCR REV, V17, P333, DOI 10.1210/er.17.4.333
   Dallas SL, 2010, ANN NY ACAD SCI, V1192, P437, DOI 10.1111/j.1749 6632.2009.05246.x
   DELMAS PD, 1983, J CLIN ENDOCR METAB, V57, P1028, DOI 10.1210/jcem 57 5 1028
   ECONS MJ, 1994, NEW ENGL J MED, V330, P1679, DOI 10.1056/NEJM199406093302310
   FLEISCH H, 1980, FUNDAMENTAL CLIN BON, P268
   Forman J, 2012, ACTA PAEDIATR, V101, P805, DOI 10.1111/j.1651 2227.2012.02705.x
   Franz Odendaal TA, 2006, DEV DYNAM, V235, P176, DOI 10.1002/dvdy.20603
   Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131
   Fukuchi M, 2002, CANCER RES, V62, P7162
   Gentili C, 2009, CURR PHARM DESIGN, V15, P1334, DOI 10.2174/138161209787846739
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   Guo D, 2006, J BONE MINER RES, V21, pS168
   Haffner ME, 2002, NAT REV DRUG DISCOV, V1, P821, DOI 10.1038/nrd919
   Henriksen K, 2004, AM J PATHOL, V164, P1537, DOI 10.1016/S0002 9440(10)63712 1
   Henriksen K, 2011, ENDOCR REV, V32, P31, DOI 10.1210/er.2010 0006
   Hofbauer L. C., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P268
   Jansen IDC, 2009, FASEB J, V23, P3470, DOI 10.1096/fj.08 122598
   Josephsen K, 2009, P NATL ACAD SCI USA, V106, P1638, DOI 10.1073/pnas.0811682106
   Jüppner H, 2013, GENETICS OF BONE BIOLOGY AND SKELETAL DISEASE, P441, DOI 10.1016/B978 0 12 387829 8.00028 7
   Karsdal MA, 2005, AM J PATHOL, V166, P467, DOI 10.1016/S0002 9440(10)62269 9
   Keen RW, 2013, PRIMER METABOLIC BON, P767
   Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657
   KUMAR R, 1990, J AM SOC NEPHROL, V1, P30
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Li XF, 2005, NAT GENET, V37, P945, DOI 10.1038/ng1614
   Lian J. B., 2006, DYNAMICS BONE CARTIL, P221
   Macarthur D, 2011, ORPHAN DRUGS EUROPE
   Mäkitie O, 2011, ENDOCR DEV, V21, P78, DOI 10.1159/000328131
   MCKUSICK VA, 1971, J BONE JOINT SURG AM, VA 53, P978, DOI 10.2106/00004623 197153050 00012
   Moriishi T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040143
   Qin C, 2004, CRIT REV ORAL BIOL M, V15, P126, DOI 10.1177/154411130401500302
   Quarles LD, 2003, AM J PHYSIOL ENDOC M, V285, pE1, DOI 10.1152/ajpendo.00016.2003
   Robey PG, PRIMER BONE METABOLI, P32
   Roldan EJA, 2013, RARE J S1, VRare J 1, P1
   Ross F.P., 2013, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, P25
   Rossert Jerome, 1996, P127
   Schiavi SC, 2002, CURR OPIN NEPHROL HY, V11, P423, DOI 10.1097/00041552 200207000 00009
   Singer FR, 2008, CLEV CLIN J MED, V75, P739, DOI 10.3949/ccjm.75.10.739
   Suwanwalaikorn S, 1997, AM J PHYSIOL ENDOC M, V272, pE212, DOI 10.1152/ajpendo.1997.272.2.E212
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   Thorat C, 2012, PEDIATRICS, V129, P516, DOI 10.1542/peds.2011 1798
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   Villa S, 2009, INT J HEALTH PLAN M, V24, P27, DOI 10.1002/hpm.930
NR 65
TC 30
Z9 31
U1 0
U2 12
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD OCT
PY 2015
VL 26
IS 10
BP 2529
EP 2558
DI 10.1007/s00198 015 3188 9
PG 30
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CR8YF
UT WOS:000361639700015
PM 26070300
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Xu, D
   Lyu, Y
   Chen, XW
   Zhu, XY
   Feng, JQ
   Xu, YJ
AF Xu, Dan
   Lyu, Ying
   Chen, Xiaowen
   Zhu, Xiaoyu
   Feng, Jinqiu
   Xu, Yajun
TI Fructus Ligustri Lucidi ethanol extract inhibits
   osteoclastogenesis in RAW264.7 cells via the RANKL signaling pathway
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE Fructus ligustri Lucidi; oleanolic acid; ursolic acid; osteoclast;
   receptor activator of nuclear factor kappa B ligand
ID BONE MINERAL DENSITY; DIFFERENTIATION; OSTEOPOROSIS; EXPRESSION;
   IDENTIFICATION; INSIGHTS
AB Fructus ligustri Lucidi (FLL) is the fruit of Ligustrum lucidum Ait and a traditional Chinese medicine, primarily known for its role in osteoporosis prevention and treatment. The present study aimed to elucidate the effect and underlying mechanism of action of ethanol extract of FLL on osteoclast differentiation and bone resorption, and to identify the active compounds within it. RAW264.7 murine monocyte/macrophage cells were stimulated with the receptor activator of nuclear factor kappa B ligand (RANKL) to induce osteoclast differentiation in vitro. The present study demosntrated that FLL extract and its two primary components, oleanolic acid (OA) and ursolic acid (UA), significantly suppressed RANKL induced tartrate resistant acid phosphatase (TRAP) activity and multinucleate osteoclast formation without inducing cytotoxicity; however, no effect was observed on the apoptosis of mature osteoclasts. Additionally, RANKL induced mRNA expression levels of the key transcription factors, tumor necrosis factor receptor associated factor 6, nuclear factor of activated T cell c1 and c Fos, and the osteoclast markers, TRAP, cathepsin K and matrix metalloproteinase 9 were suppressed by FLL, OA and UA. However, no effect was observed on RANKL induced mRNA expression levels of Src. These results demonstrated that FLL may inhibit osteoclastogenesis in RAW264.7 cells via RANKL signaling pathways. OA and UA are active compounds in inducing this effect; however, their specific roles remain to be elucidated.
C1 [Xu, Dan; Lyu, Ying; Chen, Xiaowen; Zhu, Xiaoyu; Feng, Jinqiu; Xu, Yajun] Peking Univ, Sch Publ Hlth, Dept Nutr & Food Hyg, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
   [Xu, Yajun] Peking Univ, Beijing Key Lab Toxicol Res & Risk Assessment Foo, Beijing 100191, Peoples R China.
C3 Peking University; Peking University
RP Xu, YJ (通讯作者)，Peking Univ, Sch Publ Hlth, Dept Nutr & Food Hyg, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
EM xuyajun@bjmu.edu.cn
RI feng, jin/ISS 3921 2023; xu, yajun/E 9210 2011; ZHU,
   XIAOYU/HJY 7240 2023; Chen, Xiaowen/AIC 9330 2022
OI xu, yajun/0000 0001 5791 4629
FU special fund for cultivation and development of Beijing Science and
   Technology Innovation Base [Z151100001615035]
FX The present study was supported by the special fund for cultivation and
   development of Beijing Science and Technology Innovation Base (grant no.
   Z151100001615035).
CR Adami S, 2013, BONE RES, V1, P323, DOI 10.4248/BR201304003
   Alvarado HL, 2015, NANOMED NANOTECHNOL, V11, P521, DOI 10.1016/j.nano.2015.01.004
   [Anonymous], 2003, World Health Organ Tech Rep Ser, V921, P1
   Bian Q, 2012, MENOPAUSE, V19, P225, DOI 10.1097/gme.0b013e3182272ef1
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bruyère O, 2014, BEST PRACT RES CL EN, V28, P835, DOI 10.1016/j.beem.2014.07.001
   Chambers TJ, 2000, J PATHOL, V192, P4
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Feng X, 2014, CALCIFIED TISSUE INT, V94, P433, DOI 10.1007/s00223 013 9825 4
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Hou GQ, 2013, INT J MOL MED, V32, P503, DOI 10.3892/ijmm.2013.1406
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Lee EJ, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/680145
   Leung Ping Chung, 2013, J Tradit Complement Med, V3, P82, DOI 10.4103/2225 4110.110407
   Li F, 2012, FITOTERAPIA, V83, P1443, DOI 10.1016/j.fitote.2012.08.008
   Li G, 2010, PHYTOTHER RES, V24, P571, DOI 10.1002/ptr.2987
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lyu Y, 2014, J BONE MINER METAB, V32, P616, DOI 10.1007/s00774 013 0536 8
   Mizoguchi T, 2009, J CELL BIOL, V184, P541, DOI 10.1083/jcb.200806139
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Pang ZT, 2015, BIOMED RES INT UK, V2015, DOI 10.1155/2015/281873
   Pérez Sayáns M, 2010, ORAL SURG ORAL MED O, V109, P679, DOI 10.1016/j.tripleo.2009.10.042
   Putnam SE, 2007, PHYTOTHER RES, V21, P99, DOI 10.1002/ptr.2030
   Rahman MM, 2006, J LIPID RES, V47, P1739, DOI 10.1194/jlr.M600151 JLR200
   Recchia I, 2004, BONE, V34, P65, DOI 10.1016/j.bone.2003.06.004
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rufus P, 2013, CURR DRUG TARGETS, V14, P1689, DOI 10.2174/1389450114666131220160357
   Siddiqi MH, 2013, J GINSENG RES, V37, P261, DOI 10.5142/jgr.2013.37.261
   Suh KS, 2013, FOOD CHEM TOXICOL, V62, P99, DOI 10.1016/j.fct.2013.08.047
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Ullevig SL, 2014, REDOX BIOL, V2, P259, DOI 10.1016/j.redox.2014.01.003
   Winograd Katz SE, 2011, EUR J CELL BIOL, V90, P143, DOI 10.1016/j.ejcb.2010.07.006
   Wong RWK, 2006, J ORAL MAXIL SURG, V64, P828, DOI 10.1016/j.joms.2006.01.017
   Xiong JH, 2012, J BONE MINER RES, V27, P499, DOI 10.1002/jbmr.1547
   Yao WF, 2015, J SEP SCI, V38, P1822, DOI 10.1002/jssc.201500094
   Yasuda H, 2013, WORLD J ORTHOP, V4, P207, DOI 10.5312/wjo.v4.i4.207
   Zhang Y, 2008, BRIT J NUTR, V99, P494, DOI 10.1017/S0007114507801589
   Zhao Y, 2011, MENOPAUSE, V18, P690, DOI 10.1097/gme.0b013e3181fd7f4b
NR 44
TC 24
Z9 27
U1 1
U2 24
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD NOV
PY 2016
VL 14
IS 5
BP 4767
EP 4774
DI 10.3892/mmr.2016.5849
PG 8
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA EB3DD
UT WOS:000387241600097
PM 27748884
OA Bronze
DA 2025 08 17
ER

PT J
AU Nancollas, GH
   Tang, R
   Phipps, RJ
   Henneman, Z
   Gulde, S
   Wu, W
   Mangood, A
   Russell, RGG
   Ebetino, FH
AF Nancollas, G. H.
   Tang, R.
   Phipps, R. J.
   Henneman, Z.
   Gulde, S.
   Wu, W.
   Mangood, A.
   Russell, R. G. G.
   Ebetino, F. H.
TI Novel insights into actions of bisphosphonates on bone: Differences in
   interactions with hydroxyapatite
SO BONE
LA English
DT Article
DE bisphosphonates; osteoporosis; hydroxyapatite; zeta potential; bone
   binding affinity; risedronate
ID CRYSTAL GROWTH; IN VITRO; ZOLEDRONIC ACID; ELECTROKINETIC PROPERTIES;
   ANTIRESORPTIVE PROPERTIES; POSTMENOPAUSAL WOMEN; MECHANICAL STRENGTH;
   PARATHYROID HORMONE; CALCIUM PHOSPHATES; AQUEOUS SOLUTIONS
AB Bisphosphonates are now the most widely used drugs for diseases associated with increased bone resorption, such as osteoporosis. Although bisphosphonates act directly on osteoclasts, and interfere with specific biochemical processes such as protein prenylation, their ability to adsorb to bone mineral also contributes to their potency and duration of action.
   The aim of the present study was to compare the binding affinities for hydroxyapatite (HAP) of 6 bisphosphonates currently used clinically and to determine the effects of these bisphosphonates on other mineral surface properties including zeta potential and interfacial tension.
   Affinity constants (K L) for the adsorption of bisphosphonates were calculated from kinetic studies on HAP crystal growth using a constant composition method at 37 degrees C and at physiological ionic strength (0.15 M). Under conditions likely to simulate bisphosphonate binding onto bone, there were significant differences in K L among the bisphosphonates for HAP growth (pH 7.4) with a rank order of zoledronate > alendronate > ibandronate > risedronate > etidronate > clodronate. The measurements of zeta potential show that the crystal surface is modified by the adsorption of bisphosphonates in a manner best explained by molecular charges related to the protonation of their side chain moieties, with risedronate showing substantial differences from alendronate, ibandronate, and zoledronate. The studies of the solid/liquid interfacial properties show additional differences among the bisphosphonates that may influence their mechanisms for binding and inhibiting crystal growth and dissolution. The observed differences in kinetic binding affinities, HAP zeta potentials, and interfacial tension are likely to contribute to the biological properties of the various bisphosphonates. In particular, these binding properties may contribute to differences in uptake and persistence in bone and the reversibility of effects. These properties, therefore, have potential clinical implications that may be important in understanding differences among potent bisphosphonates, such as the apparently more prolonged duration of action of alendronate and zoledronate compared with the more readily reversible effects of etidronate and risedronate. (c) 2005 Elsevier Inc. All rights reserved.
C1 Procter & Gamble Co, Hlth Care Res Ctr, Mason, OH 45040 USA.
   SUNY Buffalo, Dept Chem, Buffalo, NY 14260 USA.
   Univ Oxford, Inst Musculoskeletal Sci, Botnar Res Ctr, Nuffield Dept Orthopaed Surg,Nuffield Orthopaed C, Oxford OX3 7LD, England.
C3 Procter & Gamble; State University of New York (SUNY) System; University
   at Buffalo, SUNY; Nuffield Orthopaedic Centre; University of Oxford
RP Ebetino, FH (通讯作者)，Procter & Gamble Co, Hlth Care Res Ctr, 8700 Mason Montgomery Rd, Mason, OH 45040 USA.
EM ebetino.fh@pg.com
RI ; Russell, R/JEF 5877 2023; Russell, Robert Graham G/JEF 5877 2023
OI Mangood, Ahmed/0000 0002 3588 6177; Russell, Robert Graham
   G/0000 0002 4136 1828
CR ARENDS J, 1979, J CRYST GROWTH, V46, P213, DOI 10.1016/0022 0248(79)90060 5
   BAGDA E, 1978, FARBE LACK, V84, P212
   BENEDICT JJ, 1990, S CEM CTR ET MAL OST, P7
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Cao L. C., 1996, Scanning Microscopy, V10, P401
   CARRINGTON A, 1989, J PHYS B AT MOL OPT, V22, P3551, DOI 10.1088/0953 4075/22/22/006
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   CHEN WC, 1986, J DENT RES, V65, P663, DOI 10.1177/00220345860650050601
   Christiansen C, 2003, OSTEOPOROSIS INT, V14, pS38
   CHRISTOFFERSEN J, 1978, J CRYST GROWTH, V43, P501, DOI 10.1016/0022 0248(78)90350 0
   Cook S.D., 1991, CLIN ORTHOP RELAT R, V265, P280
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Eastell R, 2003, J BONE MINER RES, V18, P1051, DOI 10.1359/jbmr.2003.18.6.1051
   Ebetino FH, 1998, REV CONTEMP PHARMACO, V9, P233
   Ebetino Frank H., 1995, P139
   Ebrahimpour Arman, 1995, P125
   Fairney A, 1998, BRIT J RHEUMATOL, V37, P51
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   FLEISCH H, 1966, NATURE, V212, P901, DOI 10.1038/212901a0
   Fleisch H., 2000, BISPHOSPHONATES BONE
   FLEISCH HA, 1970, EUR J CLIN INVEST, V1, P12, DOI 10.1111/j.1365 2362.1970.tb00591.x
   FOGELMAN I, 1978, J NUCL MED, V19, P270
   FRANCIS MD, 1980, ETIDRONATE, P33
   FUIERER TA, 1994, LANGMUIR, V10, P4721, DOI 10.1021/la00024a054
   GARNIER P, 1976, J BIOL BUCCALE, V4, P323
   GILMAN H, 1994, J INORG BIOCHEM, V55, P21, DOI 10.1016/0162 0134(94)85129 8
   Glatt M, 2004, OSTEOPOROSIS INT, V15, P707, DOI 10.1007/s00198 004 1588 3
   HEYWOOD BR, 1988, BIOCHEM SOC T, V16, P824, DOI 10.1042/bst0160824
   Hornby SB, 2003, CALCIFIED TISSUE INT, V72, P519, DOI 10.1007/s00223 002 2015 4
   HUNTER RJ, 1981, ZETA POTENTIAL COLLO
   Khan SA, 1997, J BONE MINER RES, V12, P1700, DOI 10.1359/jbmr.1997.12.10.1700
   Koutsopoulos S, 1997, J CHEM SOC FARADAY T, V93, P4183, DOI 10.1039/a704572g
   Koutsopoulos S, 2000, LANGMUIR, V16, P6739, DOI 10.1021/la000057z
   Koutsopoulos S, 2000, J CRYST GROWTH, V218, P353, DOI 10.1016/S0022 0248(00)00559 5
   KOUTSOUKOS P, 1980, J AM CHEM SOC, V102, P1553, DOI 10.1021/ja00525a015
   KOUTSOUKOS PG, 1981, J COLLOID INTERF SCI, V83, P599, DOI 10.1016/0021 9797(81)90354 4
   Leu CT, 2004, BONE, V34, pS62
   Liu Y, 1997, J CRYST GROWTH, V174, P386, DOI 10.1016/S0022 0248(96)01133 5
   LOWENSTAM HA, 1989, BIOMINERALIZATION
   MANIATIS C, 1991, LANGMUIR, V7, P1542, DOI 10.1021/la00055a043
   MANN S, 1986, J INORG BIOCHEM, V28, P363, DOI 10.1016/0162 0134(86)80101 5
   MASOUD MS, 1983, J CHEM ENG DATA, V28, P297, DOI 10.1021/je00033a004
   Mitchell DY, 2001, PHARMACEUT RES, V18, P166, DOI 10.1023/A:1011024200280
   Nancollas GH, 1998, J DISPER SCI TECHNOL, V19, P723, DOI 10.1080/01932699808913211
   Neilsen A.E., 1964, KINETICS PRECIPITATI
   PASCHALIS EP, 1994, J BIOMED MATER RES, V28, P1411, DOI 10.1002/jbm.820281205
   Ravn P, 2000, J CLIN ENDOCR METAB, V85, P1492, DOI 10.1210/jc.85.4.1492
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   RUSSELL RGG, 1970, CALC TISS RES, V6, P183, DOI 10.1007/BF02196199
   Sahin Ö, 2003, CRYST RES TECHNOL, V38, P56, DOI 10.1002/crat.200310007
   SCHENK R, 1973, CALC TISS RES, V11, P196, DOI 10.1007/BF02547219
   SEMENCHENKO VK, 1934, USP KHIM, V3, P710
   SOLOMONS TWG, 1994, FUNDAMENTALS ORGAIN, P100
   Stock JL, 1997, AM J MED, V103, P291, DOI 10.1016/S0002 9343(97)00130 7
   SUNBERG RJ, 1991, CHEMTECH, V21, P304
   Tang RK, 2003, J COLLOID INTERF SCI, V260, P379, DOI 10.1016/S0021 9797(03)00048 1
   Tonino RP, 2000, J CLIN ENDOCR METAB, V85, P3109, DOI 10.1210/jc.85.9.3109
   TRAUBE I, 1927, BER B, V60, P1808
   van Beek ER, 1998, BONE, V23, P437, DOI 10.1016/S8756 3282(98)00120 3
   van Oss C.J., 1994, Interfacial Forces in Aqueous Media
   VANBEEK E, 1994, J BONE MINER RES, V9, P1875, DOI 10.1002/jbmr.5650091206
   vanBeek E, 1996, J BONE MINER RES, V11, P1492
   VANOSS CJ, 1992, J ADHES SCI TECHNOL, V6, P413, DOI 10.1163/156856192X00755
   Vdovic N, 2000, COLLOID SURFACE A, V161, P499, DOI 10.1016/S0927 7757(99)00197 1
   Ware B. R., 1974, Advances in Colloid and Interface Science, V4, P1, DOI 10.1016/0001 8686(74)80001 1
   Washburn EW, 1921, PHYS REV, V17, P273, DOI 10.1103/PhysRev.17.273
   Watts N, 2004, BONE, V34, pS99
   Wu W, 1997, Adv Dent Res, V11, P566
   Wu WJ, 1999, J AM SOC NEPHROL, V10, pS355
   Wu WJ, 1996, J COLLOID INTERF SCI, V182, P365, DOI 10.1006/jcis.1996.0475
   Wu WJ, 1999, ADV COLLOID INTERFAC, V79, P229, DOI 10.1016/S0001 8686(98)00072 4
   Zieba A, 1996, LANGMUIR, V12, P2853, DOI 10.1021/la950842p
NR 75
TC 703
Z9 805
U1 1
U2 181
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAY
PY 2006
VL 38
IS 5
BP 617
EP 627
DI 10.1016/j.bone.2005.05.003
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 043PU
UT WOS:000237614400003
PM 16046206
DA 2025 08 17
ER

PT J
AU Badran, SA
   Atia tul Wahab
   Fayyaz, S
   Muhammad, BT
   Choudhary, MI
AF Badran, Serene Adnan
   Atia tul Wahab
   Fayyaz, Sharmeen
   Muhammad, Bushra Taj
   Choudhary, Muhammad Iqbal
TI Effect of Steroidal Hormone Pregnenolone on Proliferation and
   Differentiation of MC3T3 E1 Osteoblast like Cells
SO LETTERS IN DRUG DESIGN & DISCOVERY
LA English
DT Article
DE Bone fragility diseases; osteoblast cells; osteoclast cells; MC3T3 E1;
   pregnenolone; alkaline phosphatase
ID ANDROGEN DEPRIVATION THERAPY; OSTEOGENIC DIFFERENTIATION; RECEPTOR
   ACTIVATOR; OSTEOPOROSIS; PROMOTES
AB Background: Bone remodeling is a complex process that includes continuous resorption by osteoclast cells and bone formation by osteoblast cells. Bone fragility is a common health issue of the elderly population, particularly in postmenopausal women. It has been established that steroidal hormones have an important role in bone homeostasis. Therefore hormone replacement therapy could have beneficial effects on bone health as compared to other treatments.
   Objectives: An imbalance between the rate of bone formation and bone resorption leads to the fragility of bones. During the current study, we aimed to explore the ability of pregnenolone (1) (PRE), on proliferation and differentiation of MC3T3 E1 cells. We further aimed to investigate the underlying mechanism of action for the anabolic effect of PRE (1).
   Methods: The effects of pregnenolone (1) on proliferation, differentiation, and mineralization of MC3T3 osteoblast like cells were determined. Cell viability was analyzed using MU assay and flow cytometry. ALP activity and alizarin staining were employed to evaluate the effect of pregnenolone on osteoblast differentiation. Moreover, western blot for analysis of certain important proteins, crucial for the regulation of bone homeostasis, such as BMP2 and RANKL, was also performed.
   Results and Discussions: Our results showed that pregnenolone (1) at a concentration of 5 mu M caused a significant (p< 0.05) rise in the growth of MC3T3 E1 cells, whereas a comparable effect was observed in osteoblast differentiating assays. A significant decrease in RANKL expression was observed at (0.04  1 mu M). Our results, therefore, indicated the possible role of pregnenolone (1) in positive regulation of bone homeostasis by suppressing RANKL expression.
   Conclusion: Taken together, our results indicate that pregnenolone (1) has the potential to enhance osteoblast proliferation, as inferred from the increased number of cells. These results demonstrated that pregnenolone (1) could be a potential anabolic agent for the treatment of fragility related disorders.
C1 [Badran, Serene Adnan] Univ Jordan, Fac Dent, Dept Pediat Dent & Orthodont, Amman 11942, Jordan.
   [Atia tul Wahab; Muhammad, Bushra Taj; Choudhary, Muhammad Iqbal] Univ Karachi, Dr Panjwani Ctr Mol Med & Drug Res, Int Ctr Chem & Biol Sci, Karachi 75270, Pakistan.
   [Fayyaz, Sharmeen; Choudhary, Muhammad Iqbal] Univ Karachi, Int Ctr Chem & Biol Sci, HEJ Res Inst Chem, Karachi 75270, Pakistan.
   [Choudhary, Muhammad Iqbal] Univ Airlangga, Fac Sci & Technol, Dept Chem, Komplek Campus C, Surabaya 60115, Indonesia.
C3 University of Jordan; University of Karachi; University of Karachi;
   Airlangga University
RP Atia tul Wahab (通讯作者)，Univ Karachi, Dr Panjwani Ctr Mol Med & Drug Res, Int Ctr Chem & Biol Sci, Karachi 75270, Pakistan.; Choudhary, MI (通讯作者)，Univ Karachi, Int Ctr Chem & Biol Sci, HEJ Res Inst Chem, Karachi 75270, Pakistan.
EM atia.tulwahab@iccs.edu; iqbal.choudhary@iccs.edu
RI fayyaz, sharmeen/AAP 5124 2021; Choudhary, M./C 8633 2012; Badran,
   Serene/AAI 2458 2021; , Atia tul Wahab/C 5839 2018; Wahab,
   Atia tul /KCL 2242 2024
OI Badran, Serene/0000 0002 8528 7607; ,
   Atia tul Wahab/0000 0002 2730 5547; 
CR Chmielnicka M, 2014, POSTEP DERM ALERGOL, V31, P281, DOI 10.5114/pdia.2014.44016
   Daniell HW, 2000, J UROLOGY, V163, P181, DOI 10.1016/S0022 5347(05)68000 7
   Diamond TH, 2004, CANCER AM CANCER SOC, V100, P892, DOI 10.1002/cncr.20056
   Fang HM, 2017, INT J CLIN EXP MED, V10, P14876
   Grigoriou V, 2005, J BIOL CHEM, V280, P1733, DOI 10.1074/jbc.M402550200
   Hasan WNW, 2018, DRUG DES DEV THER, V12, P1715, DOI 10.2147/DDDT.S168935
   Heo SY, 2018, CELL BIOCHEM FUNCT, V36, P137, DOI 10.1002/cbf.3325
   Khan AH, 2018, ANN MED SURG, V29, P19, DOI 10.1016/j.amsu.2018.03.019
   Kim MK, 2017, BIOMACROMOLECULES, V18, P3099, DOI 10.1021/acs.biomac.7b00750
   Kwak EJ, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/829650
   LI H, 2018, SHANGHAI KOU QIANG Y, V27, P1, DOI DOI 10.1134/S1810232818010010
   Li SB, 2018, EXP THER MED, V16, P643, DOI 10.3892/etm.2018.6199
   Lo YC, 2010, J AGR FOOD CHEM, V58, P6643, DOI 10.1021/jf904158k
   Lu XL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176196
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   Maurya SW, 2017, BIOORG MED CHEM LETT, V27, P1390, DOI 10.1016/j.bmcl.2017.02.004
   Narla RR, 2018, KIDNEY INT, V94, P239, DOI 10.1016/j.kint.2018.03.021
   Onal M, 2012, J BIOL CHEM, V287, P29851, DOI 10.1074/jbc.M112.377945
   Park S, 2016, B KOREAN CHEM SOC, V37, P2058, DOI 10.1002/bkcs.10998
   Shan ZM, 2018, EXP THER MED, V15, P55, DOI 10.3892/etm.2017.5405
   Streicher C, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 06614 0
   Suh KS, 2018, CYTOTECHNOLOGY, V70, P215, DOI 10.1007/s10616 017 0135 y
   Thu HE, 2017, IRAN J BASIC MED SCI, V20, P894, DOI 10.22038/IJBMS.2017.9111
   Weinstein RS, 1997, ENDOCRINOLOGY, V138, P4013, DOI 10.1210/en.138.9.4013
   Wu RX, 2017, EVID BASED COMPL ALT, V2017, DOI 10.1155/2017/1693643
   Wu XC, 2018, EXP THER MED, V16, P4722, DOI 10.3892/etm.2018.6772
   Yan XF, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00007
   Yazid MD, 2010, CANCER CELL INT, V10, DOI 10.1186/1475 2867 10 42
   Zeng XW, 2018, PHYTOTHER RES, V32, P996, DOI 10.1002/ptr.6034
   Zhao H, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/3673295
NR 30
TC 2
Z9 2
U1 0
U2 7
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570 1808
EI 1875 628X
J9 LETT DRUG DES DISCOV
JI Lett. Drug Des. Discov.
PY 2020
VL 17
IS 9
BP 1139
EP 1145
DI 10.2174/1570180817666200204110859
PG 7
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA NN7HI
UT WOS:000568954400006
DA 2025 08 17
ER

PT J
AU Zhang, GJ
   Zhen, CX
   Yang, JC
   Zhang, ZY
   Wu, YD
   Che, JM
   Shang, P
AF Zhang, Gejing
   Zhen, Chenxiao
   Yang, Jiancheng
   Zhang, Zheyuan
   Wu, Youde
   Che, Jingmin
   Shang, Peng
TI 1 2 T static magnetic field combined with Ferumoxytol prevent
   unloading induced bone loss by regulating iron metabolism in
   osteoclastogenesis
SO JOURNAL OF ORTHOPAEDIC TRANSLATION
LA English
DT Article
DE Static magnetic field; Ferumoxytol; Bone loss; Iron metabolism;
   Osteoclastogenesis
ID SKELETAL CHANGES; DIFFERENTIATION; NANOPARTICLES; STIMULATION; PROMOTES
AB Objective: With the deepening of magnetic biomedical effects and electromagnetic technology, some medical instruments based on static magnetic field (SMF) have been used in orthopedic related diseases treatment. Studies have shown SMF could combat osteoporosis by regulating the differentiation of mesenchymal stem cells (MSCs), osteoblast and osteoclast. With the development of nanotechnology, iron oxide nanoparticles (IONPs) have been reported to regulate the process of bone anabolism. As for SMF combined with IONPs, studies indicated osteo genic differentiation of MSCs were promoted by the combination of SMF and IONPs. However, there are few reports on the effects of SMF combined with IONPs on osteoclast. Herein, the purpose of this study was to investigate the effects of high static magnetic field (HiSMF) combined with IONPs on unloading induced bone loss in vivo and osteoclastic formation in vitro, and elucidated the potential molecular mechanisms.Methods: In vivo, C57BL/6 J male mice were unloaded via tail suspension or housed normally. The hindlimb of mice were fixed and exposed to 1 2 T SMF for 1 h every day, 10 mg/kg of Ferumoxytol or saline were injected by tail vein once a week, last for 4 weeks. Bone microstructure, mechanical properties, and osteoclastogenesis were examined respectively. In vitro, the RAW264.7 cells were used to assess the effects of 1 2 T SMF combined with IONPs in osteoclastogenesis. The iron content was detected by atomic absorption spectrometry and Prussian blue staining. DCFH DA and MitoSOXTM fluorescence staining were used to assess oxidative stress levels. NF Kappa B and MAPK signaling pathways were examined by western blot assay.Results: In vivo, the results showed 1 2 T SMF and IONPs prevented the damage to bone microstructure and improved the mechanical properties, diminished the number of osteoclasts in unloaded mice, 1 2 T SMF com bined with IONPs was found more effective. The iron content in the liver and spleen was reduced by the com bination of 1 2 T SMF and IONPs, enhancing iron levels in the femur. In vitro, osteoclast formation was inhibited by 1 2 T SMF and IONPs treatment, and 1 2 T SMF combined with IONPs had a more pronounced effect. Moreover, iron uptake of IONPs in osteoclast was reduced to 1 2 T SMF exposure. Oxidative stress levels were decreased in osteoclast differentiation under 1 2 T SMF combined with IONPs treatment. Molecularly, the expression of NF Kappa B and MAPK signaling pathways were inhibited under 1 2 T SMF combined with IONPs in osteoclastogenesis.Conclusions: Synthetically, our research illustrated 1 2 T SMF combined with IONPs prevented unloading induced bone loss by regulating iron metabolism in osteoclastogenesis.Translational potential of this article: As a non invasive alternative therapy, some medical instruments based on SMF have been used for orthopedic related diseases treatment for their portability, cheapness and safety. Ferumoxytol (FerahemeTM), the first FDA approved IONP drug for the treatment of iron deficiency anemia, has been also adapted in translational research for osteoporosis. Based on the above mentioned two points, we found the synergistic effects of SMF and Ferumoxytol for treatment of experimental osteoporosis. These results show translational potentials for clinical application.
C1 [Zhang, Gejing; Zhen, Chenxiao; Zhang, Zheyuan; Wu, Youde; Che, Jingmin] Northwestern Polytech Univ, Sch Life Sci, Xian, Shaanxi, Peoples R China.
   [Zhang, Gejing; Zhen, Chenxiao; Zhang, Zheyuan; Wu, Youde; Che, Jingmin; Shang, Peng] Northwestern Polytech Univ, Res & Dev Inst, Shenzhen 518057, Peoples R China.
   [Yang, Jiancheng] Xi An Jiao Tong Univ, Honghui Hosp, Dept Osteoporosis, Xian 710054, Peoples R China.
   [Zhang, Gejing; Zhen, Chenxiao; Zhang, Zheyuan; Wu, Youde; Che, Jingmin; Shang, Peng] Northwestern Polytech Univ, Inst Special Environm Biophys, Key Lab Space Biosci & Biotechnol, Xian 710072, Shaanxi, Peoples R China.
C3 Northwestern Polytechnical University; Northwestern Polytechnical
   University; Xi'an Jiaotong University; Northwestern Polytechnical
   University
RP Shang, P (通讯作者)，Northwestern Polytech Univ, Res & Dev Inst, Shenzhen 518057, Peoples R China.
EM shangpeng@nwpu.edu.cn
RI 车, 景敏/GYA 3521 2022; Yang, Jiancheng/JPK 2205 2023
OI Yang, Jiancheng/0000 0003 0008 9036
FU National Natural Science Foundation of China;  [52037007]
FX This work was supported by the National Natural Science Foundation of
   China (52037007) , and ?Chong Ming Bird? Program of Heye Health
   Technology.
CR Alexandre C, 2011, JOINT BONE SPINE, V78, P572, DOI 10.1016/j.jbspin.2011.04.007
   Alphandéry E, 2019, NANOTOXICOLOGY, V13, P573, DOI 10.1080/17435390.2019.1572809
   Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   [Anonymous], 1994, World Health Organ Tech Rep Ser, V843, P1
   Balakrishnan VS, 2009, EUR J CLIN INVEST, V39, P489, DOI 10.1111/j.1365 2362.2009.02130.x
   Buettmann EG, 2022, J BONE MINER RES, V37, P1417, DOI 10.1002/jbmr.4643
   Callaway DA, 2015, J BONE MINER METAB, V33, P359, DOI 10.1007/s00774 015 0656 4
   Chen GL, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 02004 y
   Coyne DW, 2009, EXPERT OPIN PHARMACO, V10, P2563, DOI 10.1517/14656560903224998
   Dong DD, 2019, J TISSUE ENG REGEN M, V13, P2181, DOI 10.1002/term.2973
   Hendrickx G, 2015, NAT REV RHEUMATOL, V11, P462, DOI 10.1038/nrrheum.2015.48
   Jia B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105604
   Kim EC, 2018, BIOELECTROMAGNETICS, V39, P394, DOI 10.1002/bem.22126
   Kotani H, 2002, J BONE MINER RES, V17, P1814, DOI 10.1359/jbmr.2002.17.10.1814
   Liu L, 2020, ACTA BIOMATER, V103, P281, DOI 10.1016/j.actbio.2019.12.022
   Marycz K, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951 020 00590 w
   Miyazaki T, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.385369
   Mo WC, 2014, SCI CHINA LIFE SCI, V57, P726, DOI 10.1007/s11427 014 4662 x
   Morey Holton ER, 1998, BONE, V22, p83S, DOI 10.1016/S8756 3282(98)00019 2
   Nhiem T, 2011, ACTA BIOMATER, V7, P1298, DOI 10.1016/j.actbio.2010.10.004
   Pelaz B, 2017, ACS NANO, V11, P2313, DOI 10.1021/acsnano.6b06040
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Tautzenberger A, 2012, INT J NANOMED, V7, P4545, DOI 10.2147/IJN.S34127
   Vico L, 2018, NAT REV RHEUMATOL, V14, P229, DOI 10.1038/nrrheum.2018.37
   Wang BY, 2019, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01556
   Wang GK, 2019, MOL PHARMACEUT, V16, P4274, DOI 10.1021/acs.molpharmaceut.9b00632
   Wang X, 2018, METABOLISM, V83, P167, DOI 10.1016/j.metabol.2018.01.005
   Wu D, 2020, INT J NANOMED, V15, P7979, DOI 10.2147/IJN.S275650
   Xiao HT, 2015, INT J CLIN EXP MED, V8, P698
   Xue YR, 2020, J BONE MINER RES, V35, P1163, DOI 10.1002/jbmr.3949
   Yamamoto Y, 2003, J DENT RES, V82, P962, DOI 10.1177/154405910308201205
   Yang JC, 2021, INT J RADIAT BIOL, V97, P746, DOI 10.1080/09553002.2021.1900944
   Yang JC, 2021, BIOELECTROMAGNETICS, V42, P200, DOI 10.1002/bem.22324
   Yang JC, 2018, BONE, V114, P235, DOI 10.1016/j.bone.2018.06.012
   Yang JC, 2018, BIOL TRACE ELEM RES, V184, P214, DOI 10.1007/s12011 017 1161 5
   Yu PJ, 2020, INT J BIOL MACROMOL, V165, P1634, DOI 10.1016/j.ijbiomac.2020.10.016
   Yun HM, 2016, BIOMATERIALS, V85, P88, DOI 10.1016/j.biomaterials.2016.01.035
   Zhang J, 2017, ELECTROMAGN BIOL MED, V36, P8, DOI 10.3109/15368378.2016.1141362
   Zheng LM, 2022, BIOACT MATER, V14, P250, DOI 10.1016/j.bioactmat.2021.11.012
NR 39
TC 17
Z9 17
U1 4
U2 33
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2214 031X
J9 J ORTHOP TRANSL
JI J. Orthop. Transl.
PD JAN
PY 2023
VL 38
BP 126
EP 140
DI 10.1016/j.jot.2022.10.007
EA NOV 2022
PG 15
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 6I4EI
UT WOS:000886079800006
PM 36381248
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Seong, S
   Vijayan, V
   Kim, JH
   Kim, K
   Kim, I
   Cherukula, K
   Park, IK
   Kim, N
AF Seong, Semun
   Vijayan, Veena
   Kim, Jung Ha
   Kim, Kabsun
   Kim, Inyoung
   Cherukula, Kondareddy
   Park, In Kyu
   Kim, Nacksung
TI Nano formulations for bone specific delivery of siRNA for CrkII
   silencing induced regulation of bone formation and resorption to
   maximize therapeutic potential for bone related diseases
SO BIOMATERIALS SCIENCE
LA English
DT Article
ID DRUG DELIVERY; MESSENGER RNA; MECHANISMS; MIGRATION; DOMAINS; CELLS; SH2
AB CrkII, a member of the adaptor protein family, is known to participate in bone homeostasis via the regulation of osteoclasts and osteoblasts. Therefore, silencing CrkII would beneficially impact the bone microenvironment. In this study, CrkII siRNA encapsulated by a bone targeting peptide (AspSerSer)(6) liposome was evaluated for its therapeutic applications using a receptor activator of nuclear factor kappa B ligand (RANKL) induced bone loss model. (AspSerSer)(6) liposome siCrkII maintained its gene silencing ability in both osteoclasts and osteoblasts in vitro and significantly reduced osteoclast formation while increasing osteoblast differentiation in vitro. Fluorescence image analyses showed that the (AspSerSer)(6) liposome siCrkII was present largely in bone, where it remained present for up to 24 hours and was cleared by 48 hours, even when systemically administrated. Importantly, microcomputed tomography revealed that bone loss induced by RANKL administration was recovered by systemic administration of (AspSerSer)(6) liposome siCrkII. Collectively, the findings of this study suggest that (AspSerSer)(6) liposome siCrkII is a promising therapeutic strategy for the development of treatments for bone diseases, as it overcomes the adverse effects derived from ubiquitous expression via bone specific delivery of siRNA.
C1 [Seong, Semun; Kim, Jung Ha; Kim, Kabsun; Kim, Inyoung; Kim, Nacksung] Chonnam Natl Univ Med Sch, Dept Pharmacol, Gwangju 61469, South Korea.
   [Seong, Semun; Kim, Jung Ha; Kim, Nacksung] Chonnam Natl Univ, Hard Tissue Biointerface Res Ctr, Sch Dent, Gwangju 61186, South Korea.
   [Vijayan, Veena; Cherukula, Kondareddy; Park, In Kyu] Chonnam Natl Univ Med Sch, Dept Biomed Sci, Gwangju 61469, South Korea.
   [Vijayan, Veena; Cherukula, Kondareddy; Park, In Kyu] Chonnam Natl Univ, Chonnam Natl Univ Med Sch, Ctr Global Future Biomed Scientists, Gwangju 61469, South Korea.
C3 Chonnam National University; Chonnam National University; Chonnam
   National University; Chonnam National University
RP Kim, N (通讯作者)，Chonnam Natl Univ Med Sch, Dept Pharmacol, Gwangju 61469, South Korea.; Kim, N (通讯作者)，Chonnam Natl Univ, Hard Tissue Biointerface Res Ctr, Sch Dent, Gwangju 61186, South Korea.; Park, IK (通讯作者)，Chonnam Natl Univ Med Sch, Dept Biomed Sci, Gwangju 61469, South Korea.; Park, IK (通讯作者)，Chonnam Natl Univ, Chonnam Natl Univ Med Sch, Ctr Global Future Biomed Scientists, Gwangju 61469, South Korea.
EM pik96@jnu.ac.kr; nacksung@jnu.ac.kr
RI vijayan, veena/MFI 7575 2025; , 박인규/AGN 7088 2022; Cherukula,
   Kondareddy/AAF 6151 2021; Park, In Kyu/W 1613 2017
OI Vijayan, Veena/0000 0002 6415 0177; Park, In Kyu/0000 0002 8522 8236
FU National Research Foundation of Korea (NRF)   Korean government (MSIT)
   [NRF 2019R1A5A2027521, 2021R1I1A1A01040963]
FX This work was supported by National Research Foundation of Korea (NRF)
   grants funded by the Korean government (MSIT) (NRF 2019R1A5A2027521 and
   2021R1I1A1A01040963).
CR Almeida B, 2020, MOLECULES, V25, DOI 10.3390/molecules25235672
   Bertrand N, 2012, J CONTROL RELEASE, V161, P152, DOI 10.1016/j.jconrel.2011.09.098
   Buijs A, 2001, BLOOD, V98, P2856, DOI 10.1182/blood.V98.9.2856
   Coudert AE, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/372156
   Crane JL, 2014, J MOL MED, V92, P107, DOI 10.1007/s00109 013 1084 3
   Datta HK, 2008, J CLIN PATHOL, V61, P577, DOI 10.1136/jcp.2007.048868
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Duvvuri S, 2003, EXPERT OPIN BIOL TH, V3, P45, DOI 10.1517/eobt.3.1.45.20945
   Fang ZW, 2022, CHINESE CHEM LETT, V33, P1693, DOI 10.1016/j.cclet.2021.11.050
   Fathers KE, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3183
   Gelperina S, 2005, AM J RESP CRIT CARE, V172, P1487, DOI 10.1164/rccm.200504 613PP
   Guan SY, 2022, ISCIENCE, V25, DOI 10.1016/j.isci.2022.104807
   Ickenstein LM, 2003, BBA BIOMEMBRANES, V1614, P135, DOI 10.1016/S0005 2736(03)00196 2
   Jiao Y, 2007, BMC GENET, V8, DOI 10.1186/1471 2156 8 16
   Jilka RL, 2009, BONE, V44, P275, DOI 10.1016/j.bone.2008.10.037
   Kadam RS, 2012, DRUG METAB DISPOS, V40, P1380, DOI 10.1124/dmd.112.044925
   Kim Jinoh, 2019, Exp Mol Med, V51, P1, DOI 10.1038/s12276 019 0275 6
   Kim JH, 2016, J IMMUNOL, V196, P1123, DOI 10.4049/jimmunol.1501998
   Kim Sung Jin, 2019, International Journal of Oral Biology, V44, P1
   Koch FP, 2010, HEAD FACE MED, V6, DOI 10.1186/1746 160X 6 12
   Leng QP, 2020, THERANOSTICS, V10, P3190, DOI 10.7150/thno.42640
   Li CZ, 2022, ADV SCI, V9, DOI 10.1002/advs.202104134
   Li J, 2015, ASIAN J PHARM SCI, V10, P81, DOI 10.1016/j.ajps.2014.09.004
   Liu XL, 2016, J BIOMED RES, V30, P264, DOI 10.7555/JBR.30.20150110
   MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482
   Miller CT, 2003, ONCOGENE, V22, P7950, DOI 10.1038/sj.onc.1206529
   Mizokami A, 2017, BIOCHEM PHARMACOL, V132, P1, DOI 10.1016/j.bcp.2017.02.001
   Naidu A, 2008, ORAL SURG ORAL MED O, V106, P5, DOI 10.1016/j.tripleo.2008.03.036
   Nguyen MK, 2018, ACTA BIOMATER, V75, P105, DOI 10.1016/j.actbio.2018.06.007
   Ogawa K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084335
   Owen R, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00134
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451
   Rodrigues SP, 2005, MOL CANCER RES, V3, P183
   Russell G, 2001, Novartis Found Symp, V232, P251
   Saw PE, 2020, ANGEW CHEM INT EDIT, V59, P6249, DOI 10.1002/anie.201916574
   Schiller PC, 1999, J BONE MINER RES, V14, P1504, DOI 10.1359/jbmr.1999.14.9.1504
   Soukup AA, 2019, J CLIN INVEST, V129, P1180, DOI 10.1172/JCI122694
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tsuda Masumi, 2012, Genes Cancer, V3, P334, DOI 10.1177/1947601912458687
   Waksman Gabriel, 2004, Expert Reviews in Molecular Medicine, V6, P1, DOI 10.1017/S1462399404007331
   Wang D, 2007, BIOCONJUGATE CHEM, V18, P1375, DOI 10.1021/bc7002132
   Xu JZ, 2018, J ZHEJIANG UNIV SC B, V19, P739, DOI 10.1631/jzus.B1700594
   Yang K, 2018, BONE, V114, P40, DOI 10.1016/j.bone.2018.06.003
   Yarbrough DK, 2010, CALCIFIED TISSUE INT, V86, P58, DOI 10.1007/s00223 009 9312 0
   Youn H, 2015, EXPERT OPIN BIOL TH, V15, P1337, DOI 10.1517/14712598.2015.1057563
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhang HX, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2005191118
NR 49
TC 4
Z9 4
U1 0
U2 14
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2047 4830
EI 2047 4849
J9 BIOMATER SCI UK
JI Biomater. Sci.
PD MAR 28
PY 2023
VL 11
IS 7
BP 2581
EP 2589
DI 10.1039/d2bm02038f
EA FEB 2023
PG 9
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA A1ZL4
UT WOS:000937283700001
PM 36794531
DA 2025 08 17
ER

PT J
AU Mora Raimundo, P
   Lozano, D
   Benito, M
   Mulero, F
   Manzano, M
   Vallet Regí, M
AF Mora Raimundo, Patricia
   Lozano, Daniel
   Benito, Manuel
   Mulero, Francisca
   Manzano, Miguel
   Vallet Regi, Maria
TI Osteoporosis Remission and New Bone Formation with Mesoporous Silica
   Nanoparticles
SO ADVANCED SCIENCE
LA English
DT Article
DE combination therapy; mesoporous silica nanoparticles; osteoporosis;
   osteostatin; small interfering RNAs
ID DRUG DELIVERY; COMBINATION THERAPY; PARATHYROID HORMONE; SIGNALING
   PATHWAYS; MINERAL DENSITY; SIRNA DELIVERY; LINING CELLS; TERIPARATIDE;
   ALENDRONATE; WOMEN
AB Nanotechnology changed the concept of treatment for a variety of diseases, producing a huge impact regarding drug and gene delivery. Among the different targeted diseases, osteoporosis has devastating clinical and economic consequences. Since current osteoporosis treatments present several side effects, new treatment approaches are needed. Recently, the application of small interfering RNA (siRNA) has become a promising alternative. Wnt/beta catenin signaling pathway controls bone development and formation. This pathway is negatively regulated by sclerostin, which knock down through siRNA application would potentially promote bone formation. However, the major bottleneck for siRNA based treatments is the necessity of a delivery vector, bringing nanotechnology as a potential solution. Among the available nanocarriers, mesoporous silica nanoparticles (MSNs) have attracted great attention for intracellular delivery of si RNAs. The mesoporous structure of MSNs permits the delivery of siRNAs together with another biomolecule, achieving a combination therapy. Here, the effectiveness of a new potential osteoporosis treatment based on MSNs is evaluated. The proposed system is effective in delivering SOST siRNA and osteostatin through systemic injection to bone tissue. The nanoparticle administration produced an increase expression of osteogenic related genes improving the bone microarchitecture. The treated osteoporotic mice recovered values of a healthy situation approaching to osteoporosis remission.
C1 [Mora Raimundo, Patricia; Lozano, Daniel; Manzano, Miguel; Vallet Regi, Maria] Univ Complutense Madrid, Sch Pharm, Chem Pharmaceut Sci, Inst Invest Sanitaria,Hosp 12 Octubre I 12, Plaza Ramon y Cajal S N, E 28040 Madrid, Spain.
   [Mora Raimundo, Patricia; Lozano, Daniel; Manzano, Miguel; Vallet Regi, Maria] Networking Res Ctr Bioengn Biomat & Nanomed CIBER, E 28034 Madrid, Spain.
   [Benito, Manuel] Univ Complutense Madrid, Sch Pharm, Dept Biochem & Mol Biol, Plaza Ramon y Cajal S N, E 28040 Madrid, Spain.
   [Benito, Manuel] Inst Salud Carlos III, Spanish Biomed Res Ctr Diabet & Associated Metab, Madrid 28040, Spain.
   [Mulero, Francisca] Spanish Natl Canc Res Ctr CNIO, Mol Imaging Unit, E 28029 Madrid, Spain.
C3 Complutense University of Madrid; Hospital Universitario 12 de Octubre;
   CIBER   Centro de Investigacion Biomedica en Red; CIBERBBN; Complutense
   University of Madrid; Instituto de Salud Carlos III; Centro Nacional de
   Investigaciones Oncologicas (CNIO)
RP Manzano, M; Vallet Regí, M (通讯作者)，Univ Complutense Madrid, Sch Pharm, Chem Pharmaceut Sci, Inst Invest Sanitaria,Hosp 12 Octubre I 12, Plaza Ramon y Cajal S N, E 28040 Madrid, Spain.; Manzano, M; Vallet Regí, M (通讯作者)，Networking Res Ctr Bioengn Biomat & Nanomed CIBER, E 28034 Madrid, Spain.
EM mmanzano@ucm.es; vallet@ucm.es
RI Benito, Melissa/IAP 0513 2023; Vallet Regi, Maria/M 3378 2014;
   Vallet Regí, Maria/M 3378 2014; Mora Raimundo, Patricia/P 7671 2019;
   Lozano, Daniel/B 5081 2017; Mulero, Francisca/R 2387 2019; Mulero,
   Francisca/M 3289 2014; Manzano, Miguel/K 3719 2014
OI Vallet Regi, Maria/0000 0002 6104 4889; Mora,
   Patricia/0000 0001 5382 2743; Lozano, Daniel/0000 0001 5902 9201; Ceron,
   Ester/0000 0003 1449 1018; Mulero, Francisca/0000 0001 9584 4211; 
FU European Research Council [694160]; Spanish "Ministerio de Ciencia e
   Innovacion" [PID2019 106436RB I00]
FX This authors thank the financial support provided by European Research
   Council (Advanced Grant VERDI; ERC 2015 AdG proposal no. 694160) and the
   Spanish "Ministerio de Ciencia e Innovacion" through the project
   PID2019 106436RB I00.
CR Adir O, 2020, ADV MATER, V32, DOI 10.1002/adma.201901989
   Baeza A, 2016, BIOMATER SCI UK, V4, P803, DOI 10.1039/c6bm00039h
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Basha G, 2016, MOL THER NUCL ACIDS, V5, DOI 10.1038/mtna.2016.68
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Canalis E, 2010, J CLIN ENDOCR METAB, V95, P1496, DOI 10.1210/jc.2009 2677
   Clemens DL, 2019, ACS INFECT DIS, V5, P281, DOI 10.1021/acsinfecdis.8b00268
   Cosman F, 2011, J BONE MINER RES, V26, P503, DOI 10.1002/jbmr.238
   Delgado Calle J, 2017, J BONE MINER RES, V32, P889, DOI 10.1002/jbmr.3141
   Dong YZ, 2019, ADV DRUG DELIVER REV, V144, P133, DOI 10.1016/j.addr.2019.05.004
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Duan PP, 2016, INT J BIOCHEM CELL B, V77, P23, DOI 10.1016/j.biocel.2016.05.015
   Encinas N, 2019, ACTA BIOMATER, V84, P317, DOI 10.1016/j.actbio.2018.12.012
   Esbrit P, 2014, PLOS ONE, V9, P87536
   Gennari L, 2020, EXPERT OPIN THER TAR, V24, P115, DOI 10.1080/14728222.2020.1726889
   Ghisaidoobe ABT, 2014, INT J MOL SCI, V15, P22518, DOI 10.3390/ijms151222518
   Gisbert Garzarán M, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12010083
   Goyal R, 2012, NANOMED NANOTECHNOL, V8, P167, DOI 10.1016/j.nano.2011.06.001
   Grundt A, 2009, BIOCHEM BIOPH RES CO, V389, P550, DOI 10.1016/j.bbrc.2009.09.026
   Haas AV, 2018, J ENDOCR SOC, V2, P922, DOI 10.1210/js.2018 00118
   Han L, 2012, ACS NANO, V6, P7340, DOI 10.1021/nn3024688
   Harris ST, 2001, J CLIN ENDOCR METAB, V86, P1890, DOI 10.1210/jc.86.5.1890
   Hom C, 2010, SMALL, V6, P1185, DOI 10.1002/smll.200901966
   Iñiguez Ariza NM, 2015, MATURITAS, V82, P245, DOI 10.1016/j.maturitas.2015.07.003
   Johnell O, 2002, J CLIN ENDOCR METAB, V87, P985, DOI 10.1210/jc.87.3.985
   Keasberry NA, 2017, BIOCHEMISTRY MOSCOW+, V82, P655, DOI 10.1134/S0006297917060025
   Kelly JJ, 2019, CURR OPIN ENDOCRINOL, V26, P291, DOI 10.1097/MED.0000000000000507
   Kim SW, 2017, J BONE MINER RES, V32, P892, DOI 10.1002/jbmr.3038
   Komori T, 2015, EUR J PHARMACOL, V759, P287, DOI 10.1016/j.ejphar.2015.03.028
   Kyllönen L, 2015, ACTA BIOMATER, V11, P412, DOI 10.1016/j.actbio.2014.09.006
   Langdahl BL, 2021, BRIT J PHARMACOL, V178, P1891, DOI 10.1111/bph.15024
   Li XD, 2010, J BONE MINER RES, V25, P2371, DOI 10.1002/jbmr.182
   Liu J, 2019, J ENDOCRINOL INVEST, V42, P1149, DOI 10.1007/s40618 019 01041 6
   Luhmann T, 2012, J CONTROL RELEASE, V161, P198, DOI 10.1016/j.jconrel.2011.10.001
   Manzano M, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201902634
   Manzano M, 2018, J MATER SCI MATER M, V29, DOI 10.1007/s10856 018 6069 x
   Martínez Carmona M, 2017, NANOSCALE, V9, P15967, DOI 10.1039/c7nr05050j
   Meng HA, 2010, ACS NANO, V4, P4539, DOI 10.1021/nn100690m
   Moester MJC, 2010, CALCIFIED TISSUE INT, V87, P99, DOI 10.1007/s00223 010 9372 1
   Mora Raimundo P, 2017, AIMS BIOENG, V4, P259, DOI 10.3934/bioeng.2017.2.259
   Mora Raimundo P, 2019, ACS NANO, V13, P5451, DOI 10.1021/acsnano.9b00241
   Nácher Juan J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163845
   Paris JL, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12060526
   Paris JL, 2020, ACTA BIOMATER, V101, P459, DOI 10.1016/j.actbio.2019.11.004
   Paris JL, 2018, J MATER CHEM B, V6, P2785, DOI 10.1039/c8tb00444g
   Pelaz B, 2017, ACS NANO, V11, P2313, DOI 10.1021/acsnano.6b06040
   Pietrzyk B, 2017, ADV CLIN EXP MED, V26, P1283, DOI 10.17219/acem/68739
   Portal Núñez S, 2018, BONE JOINT RES, V7, P58, DOI 10.1302/2046 3758.71.BJR 2016 0242.R2
   Russow G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010083
   Saw PE, 2020, SCI CHINA LIFE SCI, V63, P485, DOI 10.1007/s11427 018 9438 y
   Schipani E, 2009, J BONE MINER RES, V24, P1347, DOI [10.1359/JBMR.090602, 10.1359/jbmr.090602]
   STOBER W, 1968, J COLLOID INTERF SCI, V26, P62, DOI 10.1016/0021 9797(68)90272 5
   Swami A, 2007, BIOCHEM BIOPH RES CO, V362, P835, DOI 10.1016/j.bbrc.2007.08.073
   Takayanagi Hiroshi, 2007, Clin Calcium, V17, P484
   Tibbitt MW, 2016, J AM CHEM SOC, V138, P704, DOI 10.1021/jacs.5b09974
   Tsai JN, 2013, LANCET, V382, P50, DOI 10.1016/S0140 6736(13)60856 9
   Vallet Regi M, 2001, CHEM MATER, V13, P308, DOI 10.1021/cm0011559
   Vallet Regí M, 2007, ANGEW CHEM INT EDIT, V46, P7548, DOI 10.1002/anie.200604488
   Vallet Regí M, 2018, MOLECULES, V23, DOI 10.3390/molecules23010047
   Vidal M, 2019, CLIN RHEUMATOL, V38, P385, DOI 10.1007/s10067 018 4370 1
   Villaverde G, 2017, CHEM EUR J, V23, P7174, DOI 10.1002/chem.201605947
   Walker MD, 2013, ENDOCRINE, V44, P237, DOI 10.1007/s12020 012 9819 4
   Wang YP, 2014, FRONT BIOSCI LANDMRK, V19, P379, DOI 10.2741/4214
   Weng YH, 2019, BIOTECHNOL ADV, V37, P801, DOI 10.1016/j.biotechadv.2019.04.012
   Yoon BK, 2017, J KOREAN MED SCI, V32, P992, DOI 10.3346/jkms.2017.32.6.992
   Zhang J, 2014, J CONTROL RELEASE, V190, P440, DOI 10.1016/j.jconrel.2014.05.037
   Zhou XJ, 2016, J PHYS CHEM C, V120, P22375, DOI 10.1021/acs.jpcc.6b06759
NR 68
TC 75
Z9 77
U1 8
U2 134
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2198 3844
J9 ADV SCI
JI Adv. Sci.
PD AUG
PY 2021
VL 8
IS 16
AR 2101107
DI 10.1002/advs.202101107
EA JUN 2021
PG 14
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA UB4HE
UT WOS:000658222500001
PM 34096198
OA Green Published, gold, Green Accepted
DA 2025 08 17
ER

PT J
AU Zheng, SY
   Ma, Y
   Guo, Y
   Wang, LN
   Pan, YL
AF Zheng, Suyang
   Ma, Yong
   Guo, Yang
   Wang, Lining
   Pan, Yalan
TI Osthole Promote Differentiation and Inhibit Proliferation of Osteoblast
   by Activating Wnt Signaling and Endoplasmic Reticulum Stress
SO PHARMACOGNOSY MAGAZINE
LA English
DT Article
DE Differentiation; endoplasmic reticulum stress; Osthole proliferation;
   Wnt/beta catenin signaling
ID OSTEOGENIC DIFFERENTIATION; CNIDIUM MONNIERI; BONE FORMATION;
   OSTEOPOROSIS; CELLS; COMPONENTS; REGULATORS; PATHWAY; FRUCTUS
AB Background: Osthole is extracted from Fructus Cnidii and is proved to be effective in the treatment of osteoporosis in rats. However, data are still scarce and the mechanism remains elusive. Objective: To investigate the effect of Osthole on proliferation and differentiation of osteoblast. Materials and Methods: Cells were divided into five groups: control group, beta estradiol group (10( 8) M), and Osthole groups (10( 6) M, 10( 5) M, and 10 4 M). Osteoblast proliferation was evaluated by Cell Counting Kit 8 (CCK 8) assay. Alkaline phosphatase (ALP) activity was detected by ALP staining and enzymatic measurement. Mineralization was detected by alizarin red staining. The level of osteocalcin was measured by enzyme linked immunosorbent assay (ELISA). The expression of key proteins of Wnt/beta catenin signaling pathway and endoplasmic reticulum stress (ERS) was analyzed by Western blot. Results: Cell proliferation was retarded in moderate dose and high dose Osthole group at 1d, 2d and 3d and in low dose Osthole group at 1d and 2d (P < 0.05). ALP activity was enhanced in high dose Osthole group from 1d to 3d and in moderate dose Osthole group at 2d (P < 0.05). Mineralization of bone matrix was promoted in high dose Osthole group at 21d (P < 0.05). The secretion of osteocalcin was promoted in Osthole groups at 21d (P < 0.05). Expression of CHOP, GRP78, PDI, Wnt1, and beta catenin was upregulated in high dose Osthole group at 2d, indicating that both of ERS and Wnt/beta catenin signaling pathway were activated. Conclusion: It can be concluded that the effect of Osthole on inhibition of proliferation is relevant with activation of ERS, and activation of Wnt/beta catenin signaling pathway is one of the mechanisms how Osthole promotes osteoblast differentiation. In summary, this study provided more evidence for Osthole as a potential anti osteoporosis medicine.
C1 [Zheng, Suyang; Ma, Yong; Guo, Yang; Wang, Lining; Pan, Yalan] Nanjing Univ Chinese Med, Inst Traumatol & Orthoped, Lab New Tech Restorat & Reconstruct Orthoped & Tr, Nanjing, Jiangsu, Peoples R China.
   [Ma, Yong] Nanjing Univ Chinese Med, Affiliated Hosp, Dept Traumatol & Orthoped, Nanjing 210029, Jiangsu, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine
RP Guo, Y (通讯作者)，138 Xianlin Rd, Nanjing 210023, Jiangsu, Peoples R China.
EM drguoyang@126.com
RI PAN, Misty/JRX 0528 2023; Zheng, Suyang/HNR 6545 2023
OI Zheng, Suyang/0000 0001 8517 6002
FU National Natural Science Foundation of China [81473692]; Science and
   Technology Project of Administration of traditional Chinese medicine in
   Jiangsu Province [YB2015135]; Natural Science Foundation for the Young
   of Jiangsu Province [BK20151007]
FX This work was partially supported by National Natural Science Foundation
   of China (81473692), Science and Technology Project of Administration of
   traditional Chinese medicine in Jiangsu Province (YB2015135) and Natural
   Science Foundation for the Young of Jiangsu Province (BK20151007).
CR Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Davidson G, 2010, TRENDS CELL BIOL, V20, P453, DOI 10.1016/j.tcb.2010.05.002
   de Villiers TJ, 2015, CLIMACTERIC, V18, P19, DOI 10.3109/13697137.2015.1099806
   Eghbali Fatourechi GZ, 2005, NEW ENGL J MED, V352, P1959, DOI 10.1056/NEJMoa044264
   Gao FY, 2013, FOOD CHEM, V141, P1962, DOI 10.1016/j.foodchem.2013.05.013
   Hagino H, 2014, BONE, V59, P44, DOI 10.1016/j.bone.2013.10.017
   Hessle L, 2002, P NATL ACAD SCI USA, V99, P9445, DOI 10.1073/pnas.142063399
   Jia M, 2016, CHIN J NAT MEDICINES, V14, P413, DOI 10.1016/S1875 5364(16)30037 1
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kobayashi Y, 2016, J BIOCHEM, V159, P387, DOI 10.1093/jb/mvv124
   Kuo PL, 2005, J PHARMACOL EXP THER, V314, P1290, DOI 10.1124/jpet.105.085092
   Li XX, 2002, BIOL PHARM BULL, V25, P738, DOI 10.1248/bpb.25.738
   Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704
   Ming LG, 2011, PHARMACOLOGY, V88, P33, DOI 10.1159/000328776
   Pan ZQ, 2015, J ETHNOPHARMACOL, V175, P456, DOI 10.1016/j.jep.2015.10.009
   Rauner M, 2016, NEW ENGL J MED, V375, P1902, DOI 10.1056/NEJMc1609768
   Costa CRR, 2016, PHYTOTHER RES, V30, P519, DOI 10.1002/ptr.5568
   Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593
   Tang DZ, 2010, J BONE MINER RES, V25, P1234, DOI 10.1002/jbmr.21
   VUKICEVIC S, 1990, CELL, V63, P437, DOI 10.1016/0092 8674(90)90176 F
   Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038
   Yang Y, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01612
   Yuan ZY, 2016, CURR STEM CELL RES T, V11, P216, DOI 10.2174/1574888X10666150519093429
   Zhai YK, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/921954
   Zhang QY, 2007, PLANTA MED, V73, P13, DOI 10.1055/s 2006 951724
   Zhang WP, 2010, J ACUPUNCT MERIDIAN, V3, P32, DOI 10.1016/S2005 2901(10)60005 2
   Zhang ZR, 2017, NUTRIENTS, V9, DOI 10.3390/nu9060588
NR 27
TC 7
Z9 7
U1 1
U2 20
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A 202, 2ND FLR, QUBE, C T S  NO 1498A 2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0973 1296
EI 0976 4062
J9 PHARMACOGN MAG
JI Pharmacogn. Mag.
PD OCT DEC
PY 2018
VL 14
IS 58
BP 641
EP 646
DI 10.4103/pm.pm_591_17
PG 6
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA HB6YS
UT WOS:000451220800027
DA 2025 08 17
ER

PT J
AU Lee, K
   Kim, H
   Kim, JM
   Kim, JR
   Kim, KJ
   Kim, YJ
   Park, SI
   Jeong, JH
   Moon, YM
   Lim, HS
   Bae, DW
   Kwon, J
   Ko, CY
   Kim, HS
   Shin, HI
   Jeong, D
AF Lee, Kyunghee
   Kim, Hyunsoo
   Kim, Jin Man
   Kim, Jae Ryong
   Kim, Keuk Jun
   Kim, Yong Jin
   Park, Se Il
   Jeong, Jae Ho
   Moon, Young mi
   Lim, Hyun Sook
   Bae, Dong Won
   Kwon, Joseph
   Ko, Chang Yong
   Kim, Han Sung
   Shin, Hong In
   Jeong, Daewon
TI Systemic transplantation of human adipose derived stem cells stimulates
   bone repair by promoting osteoblast and osteoclast function
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE adipose derived stem cell; osteoblast; osteoclast; osteoporosis;
   systemic transplantation
ID HEPATOCYTE GROWTH FACTOR; MARROW STROMAL CELLS; KAPPA B;
   1,25 DIHYDROXYVITAMIN D 3; IN VITRO; DIFFERENTIATION; TISSUE; BIOLOGY;
   MATRIX; MINERALIZATION
AB Systemic transplantation of adipose derived stem cells (ASCs) is emerging as a novel therapeutic option for functional recovery of diverse damaged tissues. This study investigated the effects of systemic transplantation of human ASCs (hASCs) on bone repair. We found that hASCs secrete various bone cell activating factors, including hepatocyte growth factor and extracellular matrix proteins. Systemic transplantation of hASCs into ovariectomized mice induced an increased number of both osteoblasts and osteoclasts in bone tissue and thereby prevented bone loss. We also observed that conditioned medium from hASCs is capable of stimulating proliferation and differentiation of osteoblasts via Smad/extracellular signal regulated kinase (ERK)/JNK (c jun NH2 terminal kinase) activation as well as survival and differentiation of osteoclasts via ERK/JNK/p38 activation in vitro. Overall, our findings suggest that paracrine factors secreted from hASCs improve bone repair and that hASCs can be a valuable tool for use in osteoporosis therapy.
C1 [Lee, Kyunghee; Kim, Hyunsoo; Kim, Jin Man; Jeong, Daewon] Yeungnam Univ, Coll Med, Dept Microbiol, Taegu 705717, South Korea.
   [Lee, Kyunghee; Kim, Hyunsoo; Kim, Jin Man; Kim, Jae Ryong; Jeong, Daewon] Yeungnam Univ, Coll Med, Aging Associated Vasc Dis Res Ctr, Taegu 705717, South Korea.
   [Kim, Jae Ryong] Yeungnam Univ, Coll Med, Dept Biochem & Mol Biol, Taegu 705717, South Korea.
   [Kim, Keuk Jun] Taekyeung Coll, Dept Clin Pathol, Gyeungsan, South Korea.
   [Kim, Yong Jin] Yeungnam Univ, Coll Med, Dept Pathol, Taegu 705717, South Korea.
   [Park, Se Il] Yeungnam Univ, Coll Med, Dept Orthoped Surg, Taegu 705717, South Korea.
   [Jeong, Jae Ho; Moon, Young mi] Noblesse Plast Surg & Stem Tec Korea, Taegu, South Korea.
   [Lim, Hyun Sook] Hanyang Womens Univ, Dept Publ Hlth Adm, Seoul, South Korea.
   [Bae, Dong Won] Gyeongsang Natl Univ, Cent Instrument Facil, Jinju, South Korea.
   [Kwon, Joseph] Korea Basic Sci Inst, Gwangju Ctr, Kwangju, South Korea.
   [Ko, Chang Yong; Kim, Han Sung] Yonsei Univ, Inst Med Engn, Coll Hlth Sci, Dept Biomed Engn, Wonju, South Korea.
   [Shin, Hong In] Kyungpook Natl Univ, Sch Dent, Dept Oral Pathol, IHBR, Taegu, South Korea.
C3 Yeungnam University; Yeungnam University; Yeungnam University; Yeungnam
   University; Yeungnam University; Gyeongsang National University; Korea
   Basic Science Institute (KBSI); Yonsei University; Kyungpook National
   University (KNU)
RP Jeong, D (通讯作者)，Yeungnam Univ, Coll Med, Dept Microbiol, Taegu 705717, South Korea.
EM dwjeong@ynu.ac.kr
RI Ko, Chang Yong/JHS 9349 2023; park, seil/KLD 0847 2024; Kim, Jin
   Man/HJO 8987 2023; Kim, Yong Jin/J 2745 2012; Kim, Eun/AAS 6706 2020;
   Kim, Hyunsoo/AAP 1689 2021
OI ko, chang yong/0000 0002 8164 5120; Park, seil/0000 0002 4949 8976; 
FU Ministry for Health, Welfare & Family Affairs, Republic of Korea
   [A084221]; Korea Science and Engineering Foundation [2010 0001240]
FX This work was supported, in part, by grants from the Korea Healthcare
   Technology R&D Project, Ministry for Health, Welfare & Family Affairs,
   Republic of Korea (A084221; to D.J.) and from the Korea Science and
   Engineering Foundation (No. 2010 0001240).
CR Adamopoulos IE, 2006, BIOCHEM BIOPH RES CO, V350, P478, DOI 10.1016/j.bbrc.2006.09.076
   Allen MR, 2004, BONE, V35, P1003, DOI 10.1016/j.bone.2004.07.014
   Cai LY, 2009, STEM CELLS, V27, P230, DOI 10.1634/stemcells.2008 0273
   Carron JA, 2000, BIOCHEM BIOPH RES CO, V270, P1124, DOI 10.1006/bbrc.2000.2574
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Corre J, 2006, J CELL PHYSIOL, V208, P282, DOI 10.1002/jcp.20655
   D'Ippolito G, 2002, BONE, V31, P269, DOI 10.1016/S8756 3282(02)00820 7
   Datta NS, 2009, CELL SIGNAL, V21, P1245, DOI 10.1016/j.cellsig.2009.02.012
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Delany AM, 2003, ENDOCRINOLOGY, V144, P2588, DOI 10.1210/en.2002 221044
   Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7
   Everts V, 2006, J BONE MINER RES, V21, P1399, DOI 10.1359/JBMR.060614
   Geoffroy V, 2004, J BONE MINER RES, V19, P811, DOI 10.1359/JBMR.040119
   Gimble JM, 2007, CIRC RES, V100, P1249, DOI 10.1161/01.RES.0000265074.83288.09
   Globus RK, 1998, J CELL SCI, V111, P1385
   Grano M, 1996, P NATL ACAD SCI USA, V93, P7644, DOI 10.1073/pnas.93.15.7644
   Hankenson KD, 2002, J BONE MINER RES, V17, P415, DOI 10.1359/jbmr.2002.17.3.415
   Hayami T, 2008, MATRIX BIOL, V27, P682, DOI 10.1016/j.matbio.2008.07.005
   HOWARD GA, 1981, J BIOL CHEM, V256, P7738
   Huh YJ, 2006, CELL DEATH DIFFER, V13, P1138, DOI 10.1038/sj.cdd.4401793
   Kilroy GE, 2007, J CELL PHYSIOL, V212, P702, DOI 10.1002/jcp.21068
   Kim H, 2009, J CLIN INVEST, V119, P813, DOI 10.1172/JCI36809
   Kim WS, 2007, J DERMATOL SCI, V48, P15, DOI 10.1016/j.jdermsci.2007.05.018
   Lee K, 2004, PROTEOMICS, V4, P3343, DOI 10.1002/pmic.200400960
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Li F, 2007, STEM CELLS, V25, P3183, DOI 10.1634/stemcells.2007 0466
   Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623 200206000 00022
   Lien CY, 2009, J BONE MINER RES, V24, P837, DOI [10.1359/JBMR.081257, 10.1359/jbmr.081257]
   LYNCH MP, 1995, EXP CELL RES, V216, P35, DOI 10.1006/excr.1995.1005
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsumoto N, 2005, AM J PHYSIOL ENDOC M, V289, pE123, DOI 10.1152/ajpendo.00562.2004
   Menaa C, 2008, KIDNEY INT, V73, P1275, DOI 10.1038/ki.2008.100
   Mimeault M, 2008, STEM CELL REV, V4, P27, DOI 10.1007/s12015 008 9008 2
   Mimeault M, 2006, STEM CELLS, V24, P2319, DOI 10.1634/stemcells.2006 0066
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Mosig RA, 2007, HUM MOL GENET, V16, P1113, DOI 10.1093/hmg/ddm060
   Nakagami H, 2005, ARTERIOSCL THROM VAS, V25, P2542, DOI 10.1161/01.ATV.0000190701.92007.6d
   Nordstrom SM, 2007, BONE, V41, P995, DOI 10.1016/j.bone.2007.08.020
   Ogasawara T, 2004, MOL CELL BIOL, V24, P6560, DOI 10.1128/mcb.24.15.6560 6568.2004
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Raouf A, 2002, MATRIX BIOL, V21, P361, DOI 10.1016/S0945 053X(02)00027 6
   Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1
   RICKARD DJ, 1995, BONE, V16, P671, DOI 10.1016/8756 3282(95)00099 Y
   SCUTT A, 1995, J BONE MINER RES, V10, P474
   SMITH JW, 1994, J BIOL CHEM, V269, P960
   Thapa N, 2005, BONE, V36, P232, DOI 10.1016/j.bone.2004.08.007
   Wei X, 2009, NEUROSCI LETT, V462, P76, DOI 10.1016/j.neulet.2009.06.054
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Xu K, 2007, J BIOL CHEM, V282, P11347, DOI 10.1074/jbc.M608744200
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zambuzzi WF, 2009, MOL CELL BIOCHEM, V322, P143, DOI 10.1007/s11010 008 9951 x
   Zhu SM, 2009, J CELL PHYSIOL, V218, P584, DOI 10.1002/jcp.21633
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
NR 53
TC 61
Z9 68
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD OCT
PY 2011
VL 15
IS 10
BP 2082
EP 2094
DI 10.1111/j.1582 4934.2010.01230.x
PG 13
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 824RD
UT WOS:000295218800007
PM 21159123
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Coxon, FP
   Thompson, K
   Roelofs, AJ
   Ebetino, FH
   Rogers, MJ
AF Coxon, Fraser P.
   Thompson, Keith
   Roelofs, Anke J.
   Ebetino, F. Hal
   Rogers, Michael J.
TI Visualizing mineral binding and uptake of bisphosphonate by osteoclasts
   and non resorbing cells
SO BONE
LA English
DT Article
DE bisphosphonate; osteoclast; bone resorption; bone mineral; transcyrosis
ID RAB GERANYLGERANYL TRANSFERASE; BONE RESORPTION; IN VITRO;
   MOLECULAR MECHANISMS; ZOLEDRONIC ACID; ALENDRONATE; APOPTOSIS;
   LOCALIZATION; OSTEOBLASTS; PRENYLATION
AB Bisphosphonates (BPs) target bone due to their high affinity for calcium ions. During osteoclastic resorption, these drugs are released from the acidified bone surface and taken up by osteoclasts, where they act by inhibiting the pretrylation of small GTPases essential for osteoclast function. However, it remains unclear exactly how osteoclasts intemalise BPs from bone and whether other cells in the bone microenvironment can also take up BPs from the bone surface. We have investigated. this using a novel fluorescently labelled alendronate analogue (FL ALN), and by examining changes in protein prenylation following treatment of cells with risedronate (RIS). Confocal microscopic analysis showed that FL ALN was efficiently internalised from solution or from the surface of dentine by resorbing osteoclasts into intracellular vesicles. Accordingly, unprenylated Rap] A accumulated to the same extent whether osteoclasts were cultured on RIS coated dentine or with RIS in solution. By contrast, J774 macrophages intemalised FL ALN and RIS from solution, but took up comparatively little from dentine, due to their inability to resorb the mineral. Calvarial osteoblasts and MCF 7 tumour cells internalised even less FL ALN and RIS, both from solution and from the surface of dentine. Accordingly, the viability of J774 and MCF 7 cells was drastically reduced when cultured with RIS in solution, but not when cultured on dentine pre coated with RIS. However, when J774 macrophages were co cultured with rabbit osteoclasts, J774 cells that were adjacent to resorbing osteoclasts frequently internalised more FL ALN than J774 cells more distant from osteoclasts. This was possibly a result of increased availability of BP to these J774 cells due to transcytosis through osteoclasts, since FL ALN partially co localised with trancytosed, resorbed matrix protein within osteoclasts. In addition, J774 cells occupying resorption pits internalised more FL ALN than those on unresorbed surfaces. These data demonstrate that osteoclasts are able to take up large amounts of BP, due to their ability to release the BP from the dentine surface during resorption. By contrast, non resorbing cells take up only small amounts of BP that becomes available due to natural desorption from the dentine surface. However, BP uptake by non resorbing cells can be increased when cultured in the presence of resorbing osteoclasts. (c) 2008 Elsevier Inc. All rights reserved.
C1 [Coxon, Fraser P.; Thompson, Keith; Roelofs, Anke J.; Rogers, Michael J.] Univ Aberdeen, Inst Med Sci, Bone & Musculoskeletal Programme, Aberdeen AB25 2ZD, Scotland.
   [Ebetino, F. Hal] Procter & Gamble Pharmaceut, Cincinnati, OH USA.
C3 University of Aberdeen; Procter & Gamble
RP Coxon, FP (通讯作者)，Univ Aberdeen, Inst Med Sci, Bone & Musculoskeletal Programme, Aberdeen AB25 2ZD, Scotland.
EM f.p.coxon@abdn.ac.uk
RI Roelofs, Anke/ABG 5019 2021
OI Rogers, Michael/0000 0002 1818 9249; Thompson, Keith/0000 0002 9167 5147
FU Arthritis Research UK Funding Source: Medline
CR Armour KE, 2001, ENDOCRINOLOGY, V142, P760, DOI 10.1210/en.142.2.760
   AZUMA Y, 1995, BONE, V16, P235, DOI 10.1016/8756 3282(94)00035 X
   Collin Osdoby P, 2003, METH MOLEC MED, V80, P65
   Coxon FP, 2001, J BIOL CHEM, V276, P48213, DOI 10.1074/jbc.M106473200
   Coxon FP, 2005, BONE, V37, P349, DOI 10.1016/j.bone.2005.04.021
   Coxon FP, 2003, METH MOLEC MED, V80, P89
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Ebetino FH, 1996, PHOSPHORUS SULFUR, V109, P217
   Ebetino FH, 1998, REV CONTEMP PHARMACO, V9, P233
   Everts V, 2002, J BONE MINER RES, V17, P77, DOI 10.1359/jbmr.2002.17.1.77
   FERRIS AL, 1987, J CELL BIOL, V105, P2703, DOI 10.1083/jcb.105.6.2703
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Iwata K, 2006, BONE, V39, P1053, DOI 10.1016/j.bone.2006.05.006
   Masarachia P, 1996, BONE, V19, P281, DOI 10.1016/8756 3282(96)00182 2
   Matczak Jon E, 2002, POLYHEDRON, V21, P321, DOI 10.1016/S0277 5387(01)00996 2
   MURAKAMI H, 1995, BONE, V17, P137, DOI 10.1016/S8756 3282(95)00150 6
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Nesbitt SA, 1997, SCIENCE, V276, P266, DOI 10.1126/science.276.5310.266
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   Reid IR, 2005, NEW ENGL J MED, V353, P898, DOI 10.1056/NEJMoa044241
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Russell RGG, 2007, BONE, V40, pS21, DOI 10.1016/j.bone.2007.03.002
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Schindeler A, 2005, BIOCHEM BIOPH RES CO, V338, P710, DOI 10.1016/j.bbrc.2005.09.198
   Schindeler A, 2007, J PHARM SCI US, V96, P1872, DOI 10.1002/jps.20904
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Staal A, 2003, J BONE MINER RES, V18, P88, DOI 10.1359/jbmr.2003.18.1.88
   Stenbeck G, 2000, J CELL SCI, V113, P1577
   SUNDQUIST K, 1990, BIOCHEM BIOPH RES CO, V168, P309, DOI 10.1016/0006 291X(90)91709 2
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   van Beek ER, 1998, BONE, V23, P437, DOI 10.1016/S8756 3282(98)00120 3
   Virtanen SS, 2002, CANCER RES, V62, P2708
NR 38
TC 184
Z9 206
U1 1
U2 28
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
J9 BONE
JI Bone
PD MAY
PY 2008
VL 42
IS 5
BP 848
EP 860
DI 10.1016/j.bone.2007.12.225
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 292IQ
UT WOS:000255260100004
PM 18325866
DA 2025 08 17
ER

PT J
AU Reed, MC
   Schiffer, C
   Heales, S
   Mehta, AB
   Hughes, DA
AF Reed, Matthew C.
   Schiffer, Capucine
   Heales, Simon
   Mehta, Atul B.
   Hughes, Derralynn A.
TI Impact of sphingolipids on osteoblast and osteoclast activity in Gaucher
   disease
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE Glucosylsphingosine; Glucosylceramide; Sphingosine; Plasma cells; Bone
   mineral density; Mesenchymal stem cells
ID BONE MARROW MICROENVIRONMENT; ENZYME REPLACEMENT THERAPY;
   COLONY STIMULATING FACTOR; MULTIPLE MYELOMA; GLUCOCEREBROSIDASE
   DEFICIENCY; CANCER; PLASMA; CELLS; CERAMIDE; GLUCOSYLSPHINGOSINE
AB Gaucher disease (GD) is an inherited disorder in which mutations in the GBA1 gene lead to deficient beta glucocerebrosidase activity and accumulation of its substrate glucosylceramide. Bone disease is present in around 84% of GD patients, ranging from bone loss including osteopenia and osteonecrosis to abnormal bone remodelling in the form of Erlenmeyer flask formation. The range of severity and variety of types of bone disease found in GD patients indicate the involvement of several mechanisms. Here we investigate the effects of exogenous sphingolipids on osteoclasts, osteoblasts, plasma cells and mesenchymal stem cells (MSC) and the interactions between these cell types. Osteoclasts were differentiated from the peripheral blood of Gaucher patients and control subjects. Osteoblasts were differentiated from mesenchymal stem cells isolated from bone marrow aspirates of Gaucher patients and control subjects. The human osteoblast cell line SaOS 2 was also investigated. Osteoclasts, osteoblasts and a human myeloma plasma cell line NCI H929 were cultured with relevant exogenous sphingolipids to assess effects on cellular viability and function. Calcium deposition by osteoblasts differentiated from Gaucher patient MSC's was on average only 11.4% of that deposited by control subject osteoblasts. Culture with glucosylsphingosine reduced control subject MSC viability by 10.4%, SaOS 2 viability by 17.4% and plasma cell number by 40%. Culture with glucosylceramide decreased calcium deposition by control MSC derived osteoblasts while increasing control subject osteoclast generation by 55.6%, Gaucher patient osteoclast generation by 37.6% and plasma cell numbers by up to 29.7%. Excessive osteoclast number and activity and reduced osteoblast activity may have the overall effect of an uncoupling between osteoclasts and osteoblasts in the GD bone microenvironment.
C1 [Reed, Matthew C.; Schiffer, Capucine; Mehta, Atul B.; Hughes, Derralynn A.] UCL, Sch Med, Royal Free Hosp, Lysosomal Storage Disorders Unit,Dept Haematol, Pond St, London NW3 2PF, England.
   [Heales, Simon] Inst Child Hlth, Ctr Translat Om, UCL eGreat Ormond St,30 Guilford St, London WC1N 1EH, England.
C3 University of London; University College London; UCL Medical School;
   Royal Free London NHS Foundation Trust; University of London; University
   College London
RP Hughes, DA (通讯作者)，Royal Free Hosp, Dept Haematol, Lysosomal Storage Disorders Unit, Pond St, London NW3 2PF, England.; Hughes, DA (通讯作者)，UCL, Pond St, London NW3 2PF, England.
EM rmgvdah@ucl.ac.uk
RI Hughes, Derralynn/J 8012 2013; Mehta, Atul/AFI 0044 2022
FU Genzyme Gaucher generation program [GZ 2011 10810]
FX This work was funded by the Genzyme Gaucher generation program [grant
   number GZ 2011 10810]. The funding source had no involvement in study
   design; in the collection, analysis and interpretation of data; in the
   writing of the report; or in the decision to submit the article for
   publication.
CR Abe M, 2006, LEUKEMIA, V20, P1313, DOI 10.1038/sj.leu.2404228
   Baris HN, 2014, PEDIATR ENDOCR REV P, V12, P72
   Barth BM, 2011, ANTI CANCER AGENT ME, V11, P911
   BATAILLE R, 1992, INT J CLIN LAB RES, V21, P283, DOI 10.1007/BF02591662
   Bondar C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010112
   BRADY RO, 1965, BIOCHEM BIOPH RES CO, V18, P221, DOI 10.1016/0006 291X(65)90743 6
   Byeon SK, 2015, J CHROMATOGR A, V1381, P132, DOI 10.1016/j.chroma.2015.01.004
   Charrow J, 2000, ARCH INTERN MED, V160, P2835, DOI 10.1001/archinte.160.18.2835
   Chipeaux C, 2017, J CHROMATOGR A, V1525, P116, DOI 10.1016/j.chroma.2017.10.038
   Clarke LA, 2015, BEST PRACT RES CL EN, V29, P219, DOI 10.1016/j.beem.2014.08.010
   Cox TM, 2010, BIOL TARGETS THER, V4, P299, DOI 10.2147/BTT.S7582
   de Fost M, 2006, BLOOD CELL MOL DIS, V36, P53, DOI 10.1016/j.bcmd.2005.08.004
   Deegan PB, 2011, MEDICINE, V90, P52, DOI 10.1097/MD.0b013e3182057be4
   Dekker N, 2011, BLOOD, V118, pE118, DOI 10.1182/blood 2011 05 352971
   Drake MT, 2014, J BONE MINER RES, V29, P2529, DOI 10.1002/jbmr.2387
   Fahy E, 2011, BBA MOL CELL BIOL L, V1811, P637, DOI 10.1016/j.bbalip.2011.06.009
   Ferraz MJ, 2014, BBA MOL CELL BIOL L, V1841, P811, DOI 10.1016/j.bbalip.2013.11.004
   Fu R, 2016, ANN HEMATOL, V95, P1099, DOI 10.1007/s00277 016 2657 3
   Fuller M, 2015, CLIN CHIM ACTA, V450, P6, DOI 10.1016/j.cca.2015.07.026
   Gadola SD, 2006, J EXP MED, V203, P2293, DOI 10.1084/jem.20060921
   Grabowski GA, 2015, AM J HEMATOL, V90, pS12, DOI 10.1002/ajh.24063
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Groener JEM, 2008, BBA MOL CELL BIOL L, V1781, P72, DOI 10.1016/j.bbalip.2007.11.004
   Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329
   Hulková H, 2005, VIRCHOWS ARCH, V447, P31, DOI 10.1007/s00428 005 1246 y
   Ishii M, 2010, J EXP MED, V207, P2793, DOI 10.1084/jem.20101474
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Iwamoto T, 2001, J BIOL CHEM, V276, P46031, DOI 10.1074/jbc.M104464200
   Josselin N, 2009, PATHOL ONCOL RES, V15, P65, DOI 10.1007/s12253 008 9092 2
   Kitatani K, 2009, J BIOL CHEM, V284, P12979, DOI 10.1074/jbc.M809500200
   Kyle RA, 2004, CANCER AM CANCER SOC, V101, P2667, DOI 10.1002/cncr.20652
   Lecourt S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069293
   Lecourt S, 2012, STEM CELLS DEV, V21, P239, DOI 10.1089/scd.2011.0365
   Maas M, 2002, BRIT J RADIOL, V75, pA13, DOI 10.1259/bjr.75.suppl_1.750013
   MARSH NL, 1995, J CLIN INVEST, V95, P2903, DOI 10.1172/JCI117997
   Mikosch P, 2008, CALCIFIED TISSUE INT, V83, P43, DOI 10.1007/s00223 008 9143 4
   Mirzaian M, 2015, BLOOD CELL MOL DIS, V54, P307, DOI 10.1016/j.bcmd.2015.01.006
   Mistry PK, 2011, BLOOD CELL MOL DIS, V46, P66, DOI 10.1016/j.bcmd.2010.10.011
   Mistry PK, 2010, P NATL ACAD SCI USA, V107, P19473, DOI 10.1073/pnas.1003308107
   Mucci JM, 2015, BLOOD CELL MOL DIS, V55, P134, DOI 10.1016/j.bcmd.2015.05.009
   Mucci JM, 2013, GENE, V532, P186, DOI 10.1016/j.gene.2013.09.072
   Noll JE, 2014, HAEMATOLOGICA, V99, P163, DOI 10.3324/haematol.2013.090977
   Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411
   Quint P, 2013, J BIOL CHEM, V288, P5398, DOI 10.1074/jbc.M112.413583
   Reed M, 2013, BLOOD CELL MOL DIS, V51, P185, DOI 10.1016/j.bcmd.2013.04.006
   Rosenbloom BE, 2005, BLOOD, V105, P4569, DOI 10.1182/blood 2004 12 4672
   Ryland LK, 2011, CANCER BIOL THER, V11, P138, DOI 10.4161/cbt.11.2.14624
   Sims KB, 2008, CLIN GENET, V73, P430, DOI 10.1111/j.1399 0004.2008.00978.x
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Takeda H, 1998, FEBS LETT, V422, P255, DOI 10.1016/S0014 5793(98)00005 2
   Whitfield PD, 2002, MOL GENET METAB, V75, P46, DOI 10.1006/mgme.2001.3269
   Yaccoby S, 2004, CANCER RES, V64, P2016, DOI 10.1158/0008 5472.CAN 03 1131
   Zancan I, 2015, HUM MOL GENET, V24, P1280, DOI 10.1093/hmg/ddu538
NR 53
TC 27
Z9 27
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 1096 7192
EI 1096 7206
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD AUG
PY 2018
VL 124
IS 4
BP 278
EP 286
DI 10.1016/j.ymgme.2018.06.007
PG 9
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
   Medicine
GA GQ1DY
UT WOS:000441367900007
PM 29934064
DA 2025 08 17
ER

PT J
AU Zhang, ST
   Huo, SC
   Li, H
   Tang, HZ
   Nie, BE
   Qu, XH
   Yue, B
AF Zhang, Shutao
   Huo, Shicheng
   Li, Hui
   Tang, Haozheng
   Nie, Bin'en
   Qu, Xinhua
   Yue, Bing
TI Flufenamic acid inhibits osteoclast formation and bone resorption and
   act against estrogen dependent bone loss in mice
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Flufenamic acid; Osteoclast differentiation; Osteoporosis; MAPK; RNA Seq
ID MINERAL DENSITY; POSTMENOPAUSAL WOMEN; KAPPA B; OSTEONECROSIS;
   FRACTURES; NSAIDS; DIFFERENTIATION; OSTEOPOROSIS; ASPIRIN; MODEL
AB Postmenopausal osteoporosis is one of the most common types of osteoporosis resulting from estrogen deficiency in elderly women. Nonsteroidal anti inflammatory drugs (NSAIDs) are important drugs for pain relief in patients with osteoporosis. In this study, we report for the first time that flufenamic acid, a clinically approved and widely used NSAID, not only has analgesic properties but also shows a significant effect in terms of preventing postmenopausal osteoporosis. Quantitative RT PCR analysis showed that treatment with flufenamic acid significantly downregulated the genes associated with osteoclast differentiation. Meanwhile, RNA sequencing and western blot analyses suggested that flufenamic acid could inhibit the bone resorption by suppressing the phosphorylation of MAPK pathways. Moreover, an ovariectomy (OVX) induced bone loss mouse model indicated that flufenamic acid might be a potent drug for preventing osteoporotic fractures, as verified by micro CT scanning and histological analysis. Therefore, this study proposes an attractive and potent drug with analgesic properties for the prevention of postmenopausal osteoporosis.
C1 [Zhang, Shutao; Huo, Shicheng; Li, Hui; Tang, Haozheng; Nie, Bin'en; Qu, Xinhua; Yue, Bing] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Bone & Joint Surg, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Qu, XH; Yue, B (通讯作者)，Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Bone & Joint Surg, Shanghai, Peoples R China.
EM xinhua_qu@126.com; advbmp2@163.com
RI ; Huo, Shicheng/HGU 2326 2022; Qu, Xinhua/Q 3950 2016
OI Huo, Shicheng/0000 0002 9047 8846; Qu, Xinhua/0000 0002 8889 0890
FU National Natural Science Foundation of China [81472119, 81672196];
   Shanghai "Rising Stars of Medical Talent" Youth Development Program
   (Youth Medical Talents   Specialist Program)
FX This work was supported by the National Natural Science Foundation of
   China (81472119 and 81672196) and Shanghai "Rising Stars of Medical
   Talent" Youth Development Program (Youth Medical Talents   Specialist
   Program).
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bauer DC, 1996, J BONE MINER RES, V11, P29
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Blackwell KA, 2010, TRENDS ENDOCRIN MET, V21, P294, DOI 10.1016/j.tem.2009.12.004
   Cappola AR, 2016, JAMA J AM MED ASSOC, V316, P715, DOI 10.1001/jama.2016.11032
   Carbone LD, 2003, J BONE MINER RES, V18, P1795, DOI 10.1359/jbmr.2003.18.10.1795
   Chambers TJ, 2000, J PATHOL, V192, P4
   Compston J, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 017 0324 5
   Drake MT, 2015, CLIN THER, V37, P1837, DOI 10.1016/j.clinthera.2015.06.006
   Eastell R, 1998, NEW ENGL J MED, V338, P736, DOI 10.1056/NEJM199803123381107
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Ge RL, 2013, INT J ONCOL, V42, P1945, DOI 10.3892/ijo.2013.1891
   Geusens P, 2013, CURR OPIN RHEUMATOL, V25, P524, DOI 10.1097/BOR.0b013e32836200b8
   Giannoudis PV, 2000, J BONE JOINT SURG BR, V82B, P655, DOI 10.1302/0301 620X.82B5.9899
   Green G A, 2001, Clin Cornerstone, V3, P50, DOI 10.1016/S1098 3597(01)90069 9
   Guinamard R, 2013, PHARMACOL THERAPEUT, V138, P272, DOI 10.1016/j.pharmthera.2013.01.012
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Hernandez RK, 2012, ACTA ORTHOP, V83, P653, DOI 10.3109/17453674.2012.747054
   Ishida M, 2019, BIOMED PHARMACOTHER, V109, P242, DOI 10.1016/j.biopha.2018.10.052
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P801, DOI [10.1007/s00198 018 4704 5, 10.1007/s00198 020 05303 5, 10.1007/s00223 018 00512 x]
   Kawashima M, 2009, MOD RHEUMATOL, V19, P192, DOI 10.1007/s10165 008 0149 6
   Kean Walter F., 2005, Inflammopharmacology, V13, P343, DOI 10.1163/156856005774415565
   Kellinsalmi M, 2007, EUR J PHARMACOL, V572, P102, DOI 10.1016/j.ejphar.2007.06.030
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kishikawa A, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00157
   Kitaura H, 2005, J CLIN INVEST, V115, P3418, DOI 10.1172/JCI26132
   Kurmis AP, 2012, J BONE JOINT SURG AM, V94A, P815, DOI 10.2106/JBJS.J.01743
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Li QA, 2011, SPINE, V36, pE461, DOI 10.1097/BRS.0b013e3181dfd163
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Marahleh A, 2019, JOVE J VIS EXP, DOI 10.3791/59089
   Meunier PJ, 2004, NEW ENGL J MED, V350, P2002
   Pongkorpsakol P, 2017, EUR J PHARMACOL, V798, P94, DOI 10.1016/j.ejphar.2017.01.026
   Reid IR, 2009, BONE, V44, P4, DOI 10.1016/j.bone.2008.09.012
   Richards JB, 2006, OSTEOPOROSIS INT, V17, P1410, DOI 10.1007/s00198 006 0142 x
   Ringe JD, 2002, RHEUMATOL INT, V22, P199, DOI 10.1007/s00296 002 0217 8
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Rosen CJ, 2005, NEW ENGL J MED, V353, P595, DOI 10.1056/NEJMcp043801
   Singer A, 2015, MAYO CLIN PROC, V90, P53, DOI 10.1016/j.mayocp.2014.09.011
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   van Esch RW, 2013, MED HYPOTHESES, V81, P343, DOI 10.1016/j.mehy.2013.03.042
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
NR 49
TC 16
Z9 16
U1 1
U2 20
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29a, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD JAN
PY 2020
VL 78
AR 106014
DI 10.1016/j.intimp.2019.106014
PG 10
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA KG6VC
UT WOS:000510086800065
PM 31776093
DA 2025 08 17
ER

PT J
AU Blacksburg, SR
   Witten, MR
   Haas, JA
AF Blacksburg, Seth R.
   Witten, Matthew R.
   Haas, Jonathan A.
TI Integrating Bone Targeting Radiopharmaceuticals Into the Management of
   Patients With Castrate Resistant Prostate Cancer With Symptomatic Bone
   Metastases
SO CURRENT TREATMENT OPTIONS IN ONCOLOGY
LA English
DT Article
DE Prostate cancer; Castrate resident prostate cancer; Radium 223; Xofigo;
   Radiopharmaceuticals; Alpha emitters
ID STEREOTACTIC BODY RADIOTHERAPY; VERTEBRAL COMPRESSION FRACTURE;
   SKELETAL RELATED EVENTS; PHASE III TRIAL; DOUBLE BLIND; ABIRATERONE
   ACETATE; INCREASED SURVIVAL; SPINE METASTASES; RADIOSURGERY; IRRADIATION
AB Metastatic castrate resistant prostate cancer (CRPC) refers to the disease state in which metastatic prostate cancer fails to respond to androgen deprivation therapy (ADT). This can be manifest as a rising PSA, increase in radiographically measurable disease, or progression of clinical disease. Roughly 90 % of men with metastatic prostate cancer have bone metastases, which is a predictor of both morbidity and mortality. Historically, treatment has been palliative, consisting of external beam radiation therapy (EBRT) and pharmacological analgesics for pain control and osteoclast inhibitors, such as bisphosphonates and denosumab to mitigate skeletal related events. Older radiopharmaceuticals, such as Strontium 89 and Samarium 153, are Beta emitting agents that were found to provide palliation but were without survival benefit and carried high risks of myelosuppression. Radium 223 is an Alpha emitting radiopharmaceutical that has demonstrated a significant overall survival benefit in men with metastatic CRPC, delay to symptomatic skeletal events (SSEs), and improvement in pain control, with a favorable toxicity profile compared with placebo. Unlike EBRT, Radium 223 has systemic uptake, with the potential to address several bone metastases concurrently and provides overall survival benefit. It is a simple administration with minimal complexity and shielding requirements in experienced hands. EBRT appears to provide a more rapid and dramatic palliative benefit to any given lesion. Because Radium 223 has limited myelosuppression, the two can be thoughtfully integrated, along with multiple agents, for the treatment of men with CRPC with symptomatic bone metastases. Given its excellent safety profile, there is interest and anecdotal safety combining Radium 223 with therapies, such as abiraterone and enzalutamide. Formal recommendations regarding combination therapies will require clinical trials. The use of Alpha emitting radiopharmaceuticals in castratesensitive disease, in metastatic asymptomatic CRPC, the categorical sequencing amongst other treatments for CRPC, as well as the application to other primary pathologies, such as metastatic breast cancer, is currently evolving.
C1 [Blacksburg, Seth R.; Witten, Matthew R.; Haas, Jonathan A.] Winthrop Univ Hosp, Mineola, NY 11501 USA.
C3 Winthrop University Hospital
RP Blacksburg, SR (通讯作者)，Winthrop Univ Hosp, 259 First St, Mineola, NY 11501 USA.
EM SBlacksburg@winthrop.org
CR [Anonymous], 1999, Radiother Oncol, V52, P111, DOI 10.1016/S0167 8140(99)00097 3
   [Anonymous], 2013, Prostate Cancer
   [Anonymous], 2014, NAT REV CLIN ONCOL, V11, P380
   [Anonymous], 2013, PROSTATE CANCER VERS
   [Anonymous], CLIN ADV HEMATOL S11
   [Anonymous], 2013, XOFIGO RADIUM RA 223
   Bruland OS, 2006, CLIN CANCER RES, V12, p6250S, DOI 10.1158/1078 0432.CCR 06 0841
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   D'Amico AV, 2014, J CLIN ONCOL, V32, P362, DOI 10.1200/JCO.2013.53.9528
   De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618
   Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470 2045(12)70379 0
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Gagnon GJ, 2007, CANCER AM CANCER SOC, V110, P1796, DOI 10.1002/cncr.22977
   Gerszten PC, 2007, SPINE, V32, P193, DOI 10.1097/01.brs.0000251863.76595.a2
   Hartsell WF, 2005, JNCI J NATL CANCER I, V97, P798, DOI 10.1093/jnci/dji139
   Hess KR, 2006, CANCER, V106, P1624, DOI 10.1002/cncr.21778
   James N, 2013, J CLIN ONCOL SUPPL L, V31
   Janjan N, 2009, J PALLIAT MED, V12, P417, DOI 10.1089/jpm.2009.9633
   Ki Y, 2011, INT J RADIAT ONCOL, V79, P220, DOI 10.1016/j.ijrobp.2009.10.033
   Lage MJ, 2008, AM J MANAG CARE, V14, P317
   Logothetis CJ, 2012, LANCET ONCOL, V13, P1210, DOI 10.1016/S1470 2045(12)70473 4
   Lutz S, 2011, INT J RADIAT ONCOL, V79, P965, DOI 10.1016/j.ijrobp.2010.11.026
   Nilsson S, 2014, J CLIN ONCOL SUPPL, V32, p5s
   Norgaard M, 2007, J UROLOGY, V184, P162, DOI DOI 10.1016/J.JUR0.2010.03.034
   Pandit Taskar N, 2004, J NUCL MED, V45, P1358
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   PORTER AT, 1993, INT J RADIAT ONCOL, V25, P805, DOI 10.1016/0360 3016(93)90309 J
   QUILTY PM, 1994, RADIOTHER ONCOL, V31, P33, DOI 10.1016/0167 8140(94)90411 1
   Rades D, 2007, NAT CLIN PRACT ONCOL, V4, P400, DOI 10.1038/ncponc0846
   Roach M, 2014, ONCOLOGY NY, V28, P297
   Roque M, 2003, COCHRANE DB SYST REV, V4
   Rose PS, 2009, J CLIN ONCOL, V27, P5075, DOI 10.1200/JCO.2008.19.3508
   Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096
   Ryu S, 2014, PRACT RADIAT ONCOL, V4, P76, DOI 10.1016/j.prro.2013.05.001
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Sahgal A, 2013, J CLIN ONCOL, V31, P3426, DOI 10.1200/JCO.2013.50.1411
   Sahgal A, 2013, LANCET ONCOL, V14, pE310, DOI 10.1016/S1470 2045(13)70101 3
   Sahgal A, 2009, INT J RADIAT ONCOL, V74, P723, DOI 10.1016/j.ijrobp.2008.09.020
   Salazar OM, 2001, INT J RADIAT ONCOL, V50, P765, DOI 10.1016/S0360 3016(01)01495 X
   Sartor O, 2004, UROLOGY, V63, P940, DOI 10.1016/j.urology.2004.01.034
   Sartor O, 2014, LANCET ONCOL, V15, P738, DOI 10.1016/S1470 2045(14)70183 4
   Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506
   Serafini AN, 1998, J CLIN ONCOL, V16, P1574, DOI 10.1200/JCO.1998.16.4.1574
   Steenland E, 1999, RADIOTHER ONCOL, V52, P101, DOI 10.1016/S0167 8140(99)00110 3
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175
   van der Linden YM, 2004, INT J RADIAT ONCOL, V59, P528, DOI 10.1016/j.ijrobp.2003.10.006
   Vapiwala N, 2013, NEW ENGL J MED, V369, P276, DOI 10.1056/NEJMe1304041
   Yamada Y, 2008, INT J RADIAT ONCOL, V71, P484, DOI 10.1016/j.ijrobp.2007.11.046
   Zorga P, 2011, ANN ACAD MED STETIN, V57, P53
   Zorga Piotr, 2011, Roczniki Pomorskiej Akademii Medycznej w Szczecinie, V57, P49
   Zustovich F, 2014, CRIT REV ONCOL HEMAT, V91, P197, DOI 10.1016/j.critrevonc.2014.01.003
NR 52
TC 9
Z9 9
U1 1
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1527 2729
EI 1534 6277
J9 CURR TREAT OPTION ON
JI Curr. Treat. Options Oncol.
PD MAR
PY 2015
VL 16
IS 3
AR 11
DI 10.1007/s11864 014 0325 1
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA CE0SV
UT WOS:000351517500001
PM 25777571
DA 2025 08 17
ER

PT J
AU Li, SY
   Zhou, HL
   Hu, C
   Yang, JB
   Ye, JF
   Zhou, YX
   Li, ZG
   Chen, LL
   Zhou, QS
AF Li, Shuyuan
   Zhou, Hongliang
   Hu, Cheng
   Yang, Jiabao
   Ye, Jinfei
   Zhou, Yuexi
   Li, Zige
   Chen, Leilei
   Zhou, Qishi
TI Total Flavonoids of Rhizoma Drynariae Promotes Differentiation of
   Osteoblasts and Growth of Bone Graft in Induced Membrane Partly by
   Activating Wnt/β Catenin Signaling Pathway
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE total flavonoids of rhizoma drynariae; inducedmembrane;
   Wnt/beta catenin; bone defect; osteogenic efficacy
ID WNT; CELLS; BMP 2; MECHANISMS; EXTRACTS; CANCER
AB Total flavonoids of Rhizoma drynariae (TFRD), a Chinese medicine, is widely used in the treatment of fracture, bone defect, osteoporosis and other orthopedic diseases, and has achieved good effects. Purpose of this trial was to explore efficacy of TFRD on bone graft's mineralization and osteoblasts' differentiation in Masquelet induced membrane technique in rats. Forty male Sprague Dawley rats were randomly divided into high dose group (H TFRD), middle dose group (M TFRD), low dose group (L TFRD) and control group (control). The critical size bone defect model of rats was established with 10 rats in each group. Polymethyl methacrylate (PMMA) spacer was implanted into the defect of right femur in rats. After the formation of the induced membrane, autogenous bone was implanted into the induced membrane. After 12 weeks of bone graft, bone tissues in the area of bone graft were examined by X ray, Micro CT, hematoxylin eosin (HE) and Masson trichrome staining to evaluate the growth of the bone graft. The beta catenin, c myc, COL1A1, BMP 2 and OPN in bone graft were quantitatively analyzed by Western blot and Immunohistostaining. Osteoblasts were cultured in the medium containing TFRD. Cell Counting Kit 8 (CCK 8) method, Alkaline phosphatase (ALP) and Alizarin Red S (ARS) staining, Western blot, RT PCR and other methods were used to detect the effects of TFRD on the proliferation of osteoblasts and the regulation of Wnt/beta catenin signaling pathway. In vivo experiments showed that the growth and mineralization of bone graft in TFRD group was better. Moreover, the expression of Wnt/beta catenin and osteogenesis related proteins in bone tissue of TFRD group was more than that in other groups. In vitro experiments indicated that osteoblasts proliferated faster, activity of ALP was higher, number of mineralized nodules and proteins related to osteogenesis were more in TFRD group. But blocking Wnt/beta catenin signaling pathway could limit these effects. Therefore, TFRD could promote mineralization of bone graft and differentiation of osteoblasts in a dose dependent manner during growing period of the bone graft of induced membrane technique, which is partly related to the activation of Wnt/beta catenin signaling pathway.
C1 [Li, Shuyuan; Zhou, Hongliang; Hu, Cheng; Yang, Jiabao; Ye, Jinfei; Zhou, Yuexi; Li, Zige] Guangzhou Univ Chinese Med, Guangzhou, Peoples R China.
   [Li, Shuyuan; Zhou, Hongliang; Hu, Cheng; Yang, Jiabao; Ye, Jinfei; Zhou, Yuexi; Li, Zige] Guangzhou Univ Chinese Med, Lingnan Med Res Ctr, Guangzhou, Peoples R China.
   [Chen, Leilei] Guangzhou Univ Chinese Med, Affiliated Hosp 3, Guangzhou, Peoples R China.
   [Zhou, Qishi] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou
   University of Chinese Medicine
RP Chen, LL (通讯作者)，Guangzhou Univ Chinese Med, Affiliated Hosp 3, Guangzhou, Peoples R China.; Zhou, QS (通讯作者)，Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Peoples R China.
EM yutian_1010@sina.com; zhouqishi@139.com
RI cheng, hu/GYE 0667 2022; ZHOU, YUE/IZE 6277 2023; Zhou,
   Hongliang/JBS 4810 2023
OI cheng, hu/0000 0001 7075 8616; 
FU National Natural Science Foundation of China [81674001]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81674001).
CR ARONSON J, 1989, CLIN ORTHOP RELAT R, P71
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Canalis E, 2013, NAT REV ENDOCRINOL, V9, P575, DOI 10.1038/nrendo.2013.154
   Chatakun P, 2014, CELL MOL LIFE SCI, V71, P113, DOI 10.1007/s00018 013 1326 0
   Chen LL, 2011, ARCH ORAL BIOL, V56, P1655, DOI 10.1016/j.archoralbio.2011.06.008
   Chen L, 2018, Z GERONTOL GERIATR, V51, P875, DOI 10.1007/s00391 017 1326 z
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Chenard KE, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/601549
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   Garnavos C, 2010, J ORTHOP TRAUMA, V24, P199, DOI 10.1097/BOT.0b013e3181b2b74d
   Giannoudis PV, 2008, INJURY, V39, pS5, DOI 10.1016/S0020 1383(08)70010 X
   Giannoudis PV, 2007, INJURY, V38, pS3, DOI 10.1016/S0020 1383(08)70003 2
   Glantschnig H, 2010, J BIOL CHEM, V285, P40135, DOI 10.1074/jbc.M110.166892
   Gouron R, 2017, J TISSUE ENG REGEN M, V11, P382, DOI 10.1002/term.1921
   Guo WJ, 2019, MED SCI MONITOR, V25, P3133, DOI 10.12659/MSM.914568
   Guo Y., 2012, J CHIN MED ASSOC, V92, P2288
   Heo SY, 2018, CELL BIOCHEM FUNCT, V36, P137, DOI 10.1002/cbf.3325
   Huang Y, 2012, J ORTHOP RES, V30, P304, DOI 10.1002/jor.21505
   Jeong JC, 2003, INT IMMUNOPHARMACOL, V3, P1685, DOI 10.1016/j.intimp.2003.08.003
   Jiang B., 2021, ANTICANCER AGENTS ME, V11, P1
   [姜自伟 Jiang Ziwei], 2018, [中华中医药杂志, China Journal of Traditional Chinese Medicine and Pharmacy], V33, P661
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kuo HC, 2014, FOOD FUNCT, V5, P1956, DOI 10.1039/c4fo00219a
   Li LJ, 2019, CHINESE MED J PEKING, V132, P145, DOI 10.1097/CM9.0000000000000013
   Liu H.X., 2010, ZHONGGUO KOUQIANG HE, V8, P531
   Liu XF, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046 021 01934 6
   Luyten FP, 2009, BONE, V44, P522, DOI 10.1016/j.bone.2008.12.006
   Lv WX, 2021, MOL MED REP, V23, DOI 10.3892/mmr.2021.11984
   Masquelet A C, 2000, Ann Chir Plast Esthet, V45, P346
   Masquelet AC, 2010, ORTHOP CLIN N AM, V41, P27, DOI 10.1016/j.ocl.2009.07.011
   Milat F, 2009, MOL CELL ENDOCRINOL, V310, P52, DOI 10.1016/j.mce.2009.06.002
   Monroe DG, 2012, GENE, V492, P1, DOI 10.1016/j.gene.2011.10.044
   Nguyen H, 2003, BIOCHEM BIOPH RES CO, V311, P179, DOI 10.1016/j.bbrc.2003.09.192
   Nishimura R, 2012, J BIOCHEM, V151, P247, DOI 10.1093/jb/mvs004
   OSTERMAN AL, 1984, ORTHOP CLIN N AM, V15, P131
   Palomo T, 2017, CURR OPIN ENDOCRINOL, V24, P381, DOI 10.1097/MED.0000000000000367
   Pelissier P, 2004, J ORTHOP RES, V22, P73, DOI 10.1016/S0736 0266(03)00165 7
   Pinzone JJ, 2009, BLOOD, V113, P517, DOI 10.1182/blood 2008 03 145169
   Qian Q, 2015, CHIN J BIOCH PHARM, V35, P186
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Shen Z, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.503524
   Song Shuang Hong, 2016, Bone Rep, V5, P262, DOI 10.1016/j.bonr.2016.09.001
   Song SH, 2017, MOLECULES, V22, DOI 10.3390/molecules22071033
   Sun Z, 2016, CHRONPATHEMATOL J, V17, P327
   Susperregui ARG, 2008, J CELL PHYSIOL, V216, P144, DOI 10.1002/jcp.21389
   Wiese A, 2010, ORTHOP CLIN N AM, V41, P1, DOI 10.1016/j.ocl.2009.07.003
   Wong R., 2007, CHIN MED UK, V2, P13, DOI [10.1186/1749 8546 2 13, DOI 10.1186/1749 8546 2 13]
   Yang F., 2017, CHINA J ORAL MAXILLO, V16, P34, DOI [10.19438/j.cjoms.2018.01.007, DOI 10.19438/J.CJOMS.2018.01.007]
   Yao WY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01251
   Zhang Jun, 2009, Zhong Yao Cai, V32, P1090
   Zhao J, 2020, CANCER SCI, V111, P994, DOI 10.1111/cas.14243
   Zhao YX, 2018, INT J BIOL MACROMOL, V120, P491, DOI 10.1016/j.ijbiomac.2018.08.079
   Zheng J, 2021, CANCER MANAG RES, V13, P3005, DOI 10.2147/CMAR.S295003
NR 54
TC 24
Z9 33
U1 1
U2 36
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAY 26
PY 2021
VL 12
AR 675470
DI 10.3389/fphar.2021.675470
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA SO6QR
UT WOS:000659096900001
PM 34122101
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Atkinson, EG
   Adaway, M
   Horan, DJ
   Korff, C
   Klunk, A
   Orr, AL
   Ratz, K
   Bellido, T
   Plotkin, LI
   Robling, AG
   Bidwell, JP
AF Atkinson, Emily G.
   Adaway, Michele
   Horan, Daniel J.
   Korff, Crystal
   Klunk, Angela
   Orr, Ashley L.
   Ratz, Katherine
   Bellido, Teresita
   Plotkin, Lilian I.
   Robling, Alexander G.
   Bidwell, Joseph P.
TI Conditional Loss of Nmp4 in Mesenchymal Stem Progenitor Cells
   Enhances PTH Induced Bone Formation
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE BONE ANABOLISM; OSTEOANABOLICS; OSTEOPOROSIS; TERIPARATIDE
ID UNFOLDED PROTEIN RESPONSE; PARATHYROID HORMONE; ANABOLIC ACTIVITY;
   IN VIVO; OSTEOBLAST DIFFERENTIATION; POSTMENOPAUSAL WOMEN; TRANSCRIPTION
   FACTOR; SCLEROSTIN ANTIBODY; FRACTURE PREVENTION; LINING CELLS
AB Activation of bone anabolic pathways is a fruitful approach for treating severe osteoporosis, yet FDA approved osteoanabolics, eg, parathyroid hormone (PTH), have limited efficacy. Improving their potency is a promising strategy for maximizing bone anabolic output. Nmp4 (Nuclear Matrix Protein 4) global knockout mice exhibit enhanced PTH induced increases in trabecular bone but display no overt baseline skeletal phenotype. Nmp4 is expressed in all tissues; therefore, to determine which cell type is responsible for driving the beneficial effects of Nmp4 inhibition, we conditionally removed this gene from cells at distinct stages of osteogenic differentiation. Nmp4 floxed (Nmp4(fl/fl)) mice were crossed with mice bearing one of three Cre drivers including (i) Prx1Cre(+) to remove Nmp4 from mesenchymal stem/progenitor cells (MSPCs) in long bones; (ii) BglapCre(+) targeting mature osteoblasts, and (iii) Dmp1Cre(+) to disable Nmp4 in osteocytes. Virgin female Cre(+) and Cre( ) mice (10 weeks of age) were sorted into cohorts by weight and genotype. Mice were administered daily injections of either human PTH 1 34 at 30 mu g/kg or vehicle for 4 weeks or 7 weeks. Skeletal response was assessed using dual energy X ray absorptiometry, micro computed tomography, bone histomorphometry, and serum analysis for remodeling markers. Nmp4(fl/fl);Prx1Cre(+) mice virtually phenocopied the global Nmp4( / ) skeleton in the femur, ie, a mild baseline phenotype but significantly enhanced PTH induced increase in femur trabecular bone volume/total volume (BV/TV) compared with their Nmp4(fl/fl);Prx1Cre( ) controls. This was not observed in the spine, where Prrx1 is not expressed. Heightened response to PTH was coincident with enhanced bone formation. Conditional loss of Nmp4 from the mature osteoblasts (Nmp4(fl/fl);BglapCre(+)) failed to increase BV/TV or enhance PTH response. However, conditional disabling of Nmp4 in osteocytes (Nmp4(fl/fl);Dmp1Cre(+)) increased BV/TV without boosting response to hormone under our experimental regimen. We conclude that Nmp4( / ) Prx1 expressing MSPCs drive the improved response to PTH therapy and that this gene has stage specific effects on osteoanabolism. (c) 2022 American Society for Bone and Mineral Research (ASBMR).
C1 [Atkinson, Emily G.; Adaway, Michele; Horan, Daniel J.; Klunk, Angela; Orr, Ashley L.; Ratz, Katherine; Plotkin, Lilian I.; Robling, Alexander G.; Bidwell, Joseph P.] Indiana Univ Sch Med IUSM, Dept Anat Cell Biol & Physiol, Indianapolis, IN USA.
   [Horan, Daniel J.; Robling, Alexander G.] Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN USA.
   [Korff, Crystal] Indiana Univ Sch Med IUSM, Dept Med & Mol Genet, Indianapolis, IN USA.
   [Bellido, Teresita] Univ Arkansas Med Sci UAMS, Dept Physiol & Cell Biol, Little Rock, AR USA.
   [Bellido, Teresita] Cent Arkansas Vet Healthcare Syst, Little Rock, AR USA.
   [Plotkin, Lilian I.; Robling, Alexander G.; Bidwell, Joseph P.] Indiana Univ Sch Med IUSM, Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN USA.
   [Bidwell, Joseph P.] Dept Anat Cell Biol & Physiol, VanNuys Med Sci Bldg 635 Barnhill Dr,MS 5035 India, Indianapolis, IN 46202 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Richard L. Roudebush VA Medical Center; University of Arkansas System;
   University of Arkansas Medical Sciences; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans
   Healthcare System
RP Bidwell, JP (通讯作者)，Dept Anat Cell Biol & Physiol, VanNuys Med Sci Bldg 635 Barnhill Dr,MS 5035 India, Indianapolis, IN 46202 USA.
EM jbidwell@iupui.edu
RI ; Orr, Ashley/HZM 5309 2023; Plotkin, Lilian/H 7188 2019
OI Bellido, Teresita/0000 0002 8203 7004; 
FU National Institutes of Health [R01 AR073739, R01 AR053237]; VA grants
   [I01 BX005861, IK6 BX 003783]; Veterans Research Administration Merit
   Award [1I0 1BX005154];  [T32 AR065971]
FX This work was supported by National Institutes of Health grants R01
   AR073739 to JPB and R01 AR053237 to AGR; VA grants I01 BX005861 and IK6
   BX 003783 to AGR; and support from T32 AR065971 to EGA and CK and
   Veterans Research Administration Merit Award 1I0 1BX005154 to LIP.
CR Abdelmagid SM, 2014, AM J PATHOL, V184, P697, DOI 10.1016/j.ajpath.2013.11.031
   Ajubi NE, 1996, BIOCHEM BIOPH RES CO, V225, P62, DOI 10.1006/bbrc.1996.1131
   Al Maskari M, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 32705 7
   Amin S, 2014, J BONE MINER RES, V29, P581, DOI 10.1002/jbmr.2072
   Anagnostis P, 2019, MATURITAS, V120, P1, DOI 10.1016/j.maturitas.2018.11.010
   Balani DH, 2021, J BONE MINER RES, V36, P757, DOI 10.1002/jbmr.4238
   Balani DH, 2017, J CLIN INVEST, V127, P3333, DOI 10.1172/JCI91699
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bedi B, 2012, P NATL ACAD SCI USA, V109, pE725, DOI 10.1073/pnas.1120735109
   Bidwell J, 2022, CALCIFIED TISSUE INT, V110, P244, DOI 10.1007/s00223 021 00903 7
   Bilic Curcic I, 2005, GENESIS, V43, P87, DOI 10.1002/gene.20156
   Bivi N, 2012, J BONE MINER RES, V27, P374, DOI 10.1002/jbmr.548
   Bockamp E, 2002, PHYSIOL GENOMICS, V11, P115, DOI 10.1152/physiolgenomics.00067.2002
   Böhm AM, 2019, DEV CELL, V51, P236, DOI 10.1016/j.devcel.2019.08.013
   Candeliere GA, 2001, BONE, V28, P351, DOI 10.1016/S8756 3282(01)00410 0
   Cao W, 2020, CURR OSTEOPOROS REP, V18, P541, DOI 10.1007/s11914 020 00610 6
   Capoccia BJ, 2011, PHYSIOL GENOMICS, V43, P174, DOI 10.1152/physiolgenomics.00084.2010
   Catalano A, 2017, DRUG AGING, V34, P755, DOI 10.1007/s40266 017 0492 4
   Childress P, 2015, MOL ENDOCRINOL, V29, P1269, DOI 10.1210/me.2014 1406
   Childress P, 2011, CALCIFIED TISSUE INT, V89, P74, DOI 10.1007/s00223 011 9496 y
   Cho CJ, 2022, AM J PHYSIOL GASTR L, V322, pG49, DOI 10.1152/ajpgi.00246.2021
   Conley RB, 2020, J BONE MINER RES, V35, P36, DOI 10.1002/jbmr.3877
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Couasnay G, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10128
   Creecy A, 2021, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.578477
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Dallas SL, 2018, CURR OSTEOPOROS REP, V16, P466, DOI 10.1007/s11914 018 0455 7
   Dallas SL, 2010, ANN NY ACAD SCI, V1192, P437, DOI 10.1111/j.1749 6632.2009.05246.x
   Dekaney CM, 2019, CELL MOL GASTROENTER, V8, P549, DOI 10.1016/j.jcmgh.2019.07.003
   Delgado Calle J, 2017, BONE, V96, P29, DOI 10.1016/j.bone.2016.10.007
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   DUDLEY HR, 1961, J BIOPHYS BIOCHEM CY, V11, P627, DOI 10.1083/jcb.11.3.627
   Esen E, 2015, J BONE MINER RES, V30, P1959, DOI 10.1002/jbmr.2556
   Fan Y, 2017, CELL METAB, V25, P661, DOI 10.1016/j.cmet.2017.01.001
   Fox Rebecca M, 2015, Front Biol (Beijing), V10, P28
   Gong Y, 2021, AGING US, V13, P20629, DOI 10.18632/aging.203452
   Han HS, 2018, J CELL BIOCHEM, V119, P3220, DOI 10.1002/jcb.26478
   He YZ, 2013, STEM CELLS DEV, V22, P492, DOI 10.1089/scd.2012.0308
   Hess DA, 2016, MOL CELL BIOL, V36, P2931, DOI 10.1128/MCB.00366 16
   Hetz C, 2011, PHYSIOL REV, V91, P1219, DOI 10.1152/physrev.00001.2011
   Holdsworth G, 2019, J MOL ENDOCRINOL, V62, pR167, DOI 10.1530/JME 18 0176
   Hongo H, 2020, J HISTOCHEM CYTOCHEM, V68, P651, DOI 10.1369/0022155420961375
   Hsiao EC, 2008, P NATL ACAD SCI USA, V105, P1209, DOI 10.1073/pnas.0707457105
   Huang CY, 2015, OSTEOPOROSIS INT, V26, P875, DOI 10.1007/s00198 014 2963 3
   Huh WJ, 2010, GASTROENTEROLOGY, V139, P2038, DOI 10.1053/j.gastro.2010.08.050
   International Osteoporosis Foundation, 2017, DIAGN OST
   Irie K, 2000, ACTA HISTOCHEM CYTOC, V33, P385, DOI 10.1267/ahc.33.385
   Irie K, 2008, J HISTOCHEM CYTOCHEM, V56, P561, DOI 10.1369/jhc.2008.950527
   Iwamoto R, 2021, J BONE MINER METAB, V39, P558, DOI 10.1007/s00774 021 01210 9
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793
   Joeng KS, 2017, J CLIN INVEST, V127, P2678, DOI 10.1172/JCI92617
   Ke H.Z., 2020, Principles of Bone Biology, P1711
   Kendler DL, 2018, LANCET, V391, P230, DOI 10.1016/S0140 6736(17)32137 2
   Khetchoumian K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 11894 3
   Kim SW, 2017, J BONE MINER RES, V32, P892, DOI 10.1002/jbmr.3038
   Kim SW, 2012, J BONE MINER RES, V27, P2075, DOI 10.1002/jbmr.1665
   Lee AH, 2005, EMBO J, V24, P4368, DOI 10.1038/sj.emboj.7600903
   Lewiecki EM, 2018, J CLIN ENDOCR METAB, V103, P3183, DOI 10.1210/jc.2017 02163
   Li C, 2016, J BIOSCI BIOENG, V121, P213, DOI 10.1016/j.jbiosc.2015.05.017
   Li JY, 2014, J BONE MINER RES, V29, P43, DOI 10.1002/jbmr.2044
   Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017
   Lippuner K, 2009, OSTEOPOROSIS INT, V20, P1131, DOI 10.1007/s00198 008 0779 8
   Liu F, 1997, EXP CELL RES, V232, P97, DOI 10.1006/excr.1997.3501
   Liu YD, 2013, PLANT SIGNAL BEHAV, V8, DOI [10.1371/journal.pone.0065361, 10.4161/psb.23864, 10.4161/psb.25079, 10.1371/journal.pone.0076105, 10.1371/journal.pone.0063447]
   Lo HYG, 2017, GENE DEV, V31, P154, DOI 10.1101/gad.285684.116
   Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092
   Ma YFL, 2003, ENDOCRINOLOGY, V144, P2008, DOI 10.1210/en.2002 221061
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Miao DS, 2005, J CLIN INVEST, V115, P2402, DOI 10.1172/JCI24918
   Mills JC, 2012, BIOESSAYS, V34, P10, DOI 10.1002/bies.201100089
   Mizoguchi T, 2021, J BONE MINER RES, V36, P1432, DOI 10.1002/jbmr.4410
   Mizoguchi T, 2014, DEV CELL, V29, P340, DOI 10.1016/j.devcel.2014.03.013
   Nakamoto T, 2016, J CELL BIOCHEM, V117, P970, DOI 10.1002/jcb.25382
   Ominsky MS, 2015, BONE, V81, P380, DOI 10.1016/j.bone.2015.08.007
   Oswald AJ, 2014, CALCIFIED TISSUE INT, V94, P176, DOI 10.1007/s00223 013 9788 5
   Pacifici R, 2016, ANN NY ACAD SCI, V1364, P11, DOI 10.1111/nyas.12969
   Piemontese M, 2016, SCI REP UK, V6, DOI 10.1038/srep24262
   Rizzoli R, 2018, BEST PRACT RES CL EN, V32, P739, DOI 10.1016/j.beem.2018.09.005
   Robling AG, 2011, ENDOCRINOLOGY, V152, P2963, DOI 10.1210/en.2011 0049
   Robling AG, 2009, J CELL PHYSIOL, V219, P734, DOI 10.1002/jcp.21717
   Russell LA, 2018, BEST PRACT RES CL RH, V32, P835, DOI 10.1016/j.berh.2019.04.002
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Schaffler MB, 2014, CALCIFIED TISSUE INT, V94, P5, DOI 10.1007/s00223 013 9790 y
   Shaffer AL, 2004, IMMUNITY, V21, P81, DOI 10.1016/j.immuni.2004.06.010
   Shao Y, 2019, AM J PHYSIOL ENDOC M, V316, pE749, DOI 10.1152/ajpendo.00343.2018
   Shao Y, 2017, ENDOCRINOLOGY, V158, P2722, DOI 10.1210/en.2017 00355
   Sims N.A., 2020, Principles of Bone Biology, VFourth, P89
   Stern AR, 2012, BIOTECHNIQUES, V52, P361, DOI 10.2144/0000113876
   Ström O, 2020, OSTEOPOROSIS INT, V31, P1525, DOI 10.1007/s00198 020 05380 6
   Strom O, 2011, Arch Osteoporos, V6, P59, DOI 10.1007/s11657 011 0060 1
   Tabacco G, 2019, BRIT J CLIN PHARMACO, V85, P1084, DOI 10.1111/bcp.13766
   Terauchi M, 2009, CELL METAB, V10, P229, DOI 10.1016/j.cmet.2009.07.010
   Thunyakitpisal P, 2001, J BONE MINER RES, V16, P10, DOI 10.1359/jbmr.2001.16.1.10
   Tian FM, 2018, J ORTHOP RES, V36, P576, DOI 10.1002/jor.23767
   Tu XL, 2012, BONE, V50, P209, DOI 10.1016/j.bone.2011.10.025
   Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038
   Wattanachanya L, 2015, EXP CELL RES, V333, P289, DOI 10.1016/j.yexcr.2015.02.009
   Wein MN, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031237
   Yang MY, 2019, J BONE MINER RES, V34, P1952, DOI 10.1002/jbmr.3811
   Yang SS, 2021, MUCOSAL IMMUNOL, V14, P209, DOI 10.1038/s41385 020 0280 z
   Young SK, 2016, J BIOL CHEM, V291, P13780, DOI 10.1074/jbc.M116.729830
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
   Zweifler LE, 2021, J BONE MINER RES, V36, P1979, DOI 10.1002/jbmr.4389
NR 104
TC 7
Z9 8
U1 1
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JAN
PY 2023
VL 38
IS 1
BP 70
EP 85
DI 10.1002/jbmr.4732
EA NOV 2022
PG 16
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 8L2LH
UT WOS:000888236000001
PM 36321253
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Kuroshima, S
   Elliott, KW
   Yamashita, J
AF Kuroshima, Shinichiro
   Elliott, Kirk William
   Yamashita, Junro
TI Effect of Zoledronate on the Responses of Osteocytes to Acute
   Parathyroid Hormone
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Zoledronate; Osteocyte; PTH; Endothelial progenitor cell; gamma delta T
   cell
ID DELTA T CELLS; BONE MARROW; IN VIVO; POSTMENOPAUSAL WOMEN; OSTEOCLAST
   FORMATION; ACID THERAPY; MICE; BISPHOSPHONATE; TERIPARATIDE; ALENDRONATE
AB The bone anabolic effect of parathyroid hormone (PTH) therapy is blunted when used in patients who were previously on bisphosphonate treatment. Osteocytes may play a role in the bisphosphonate silencing effect on PTH therapy since bisphosphonates have been shown to reach the lacunocanalicular system. In vivo osteocyte studies pose a significant challenge. For the current study, we developed a simple method to isolate RNA from cortical bone enriched with osteocytes. Our purpose was to investigate how zoledronate (ZA) treatment modulates the responses of osteocytes and the bone marrow (BM) to acute PTH treatment. Mice received ZA treatment for 3 months and a single PTH injection prior to death. Bone was histomorphometrically evaluated. Gene expression was assessed at the RNA level in osteocytes and BM. Endothelial progenitor cells (EPCs) and gamma delta T cells were analyzed in the BM and blood using flow cytometry. We found that ZA treatment altered bone responses to PTH. Expression of Sfrp4, a Wnt antagonist, was significantly increased in ZA affected osteocytes. BM EPCs were increased in response to acute PTH but not when treatment was combined with ZA. ZA treatment augmented EPCs in the BM but not in blood, which suggests that ZA treatment may have differential effects between the BM and blood. These findings indicate that osteocytes and BM EPCs in mice on ZA treatment respond differently to acute PTH from those not receiving ZA. This may partially explain the mechanisms of previous reports that ZA therapy attenuates the anabolic effect of PTH in bone.
C1 [Kuroshima, Shinichiro; Elliott, Kirk William; Yamashita, Junro] Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan
RP Yamashita, J (通讯作者)，Univ Michigan, Sch Dent, Dept Biol & Mat Sci, 1011 North Univ Ave, Ann Arbor, MI 48109 USA.
EM yamashit@umich.edu
RI ; Yamashita, Junro/D 4787 2019
OI Kuroshima, Shinichiro/0000 0001 9891 9987; Yamashita,
   Junro/0000 0002 5486 1362
FU NIH/NIDCR [R03DE018923]; NIH/NICRR [S10RR026475 01]; Grants in Aid for
   Scientific Research [25670824, 25870523] Funding Source: KAKEN
FX This study was supported by the NIH/NIDCR (grant R03DE018923). The
   micro CT core facility was funded partly by NIH/NICRR grant
   S10RR026475 01.
CR Allen MR, 2008, J ORAL MAXIL SURG, V66, P987, DOI 10.1016/j.joms.2008.01.038
   [Anonymous], 2005, Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers Pharmacology and Toxicology Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Bedi B, 2012, P NATL ACAD SCI USA, V109, pE725, DOI 10.1073/pnas.1120735109
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   Dempster DW, 2012, J CLIN ENDOCR METAB, V97, P2799, DOI 10.1210/jc.2012 1262
   Drake MT, 2011, BONE, V49, P349, DOI 10.1016/j.bone.2011.05.003
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Ferguson VL, 2003, BONE, V33, P387, DOI 10.1016/S8756 3282(03)00199 6
   Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087
   Halasy Nagy JM, 2001, BONE, V29, P553, DOI 10.1016/S8756 3282(01)00615 9
   Jacome Galarza CE, 2011, J BONE MINER RES, V26, P1207, DOI 10.1002/jbmr.324
   Kamiya N, 2008, DEVELOPMENT, V135, P3801, DOI 10.1242/dev.025825
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Kuroshima S, 2012, ENDOCRINOLOGY, V153, P17, DOI 10.1210/en.2011 1439
   Lai KA, 2005, J BONE JOINT SURG AM, V87A, P2155, DOI 10.2106/JBJS.D.02959
   Li X, 2007, J BIOL CHEM, V282, P33086, DOI 10.1074/jbc.M705194200
   Meraviglia S, 2010, CLIN EXP IMMUNOL, V161, P290, DOI 10.1111/j.1365 2249.2010.04167.x
   Nakanishi R, 2008, J BONE MINER RES, V23, P271, DOI 10.1359/JBMR.071007
   O'Brien CA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002942
   Obermayer Pietsch BM, 2008, J BONE MINER RES, V23, P1591, DOI 10.1359/JBMR.080506
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Plotkin LI, 2011, BONE, V49, P122, DOI 10.1016/j.bone.2010.08.011
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Qing H, 2012, J BONE MINER RES, V27, P1018, DOI 10.1002/jbmr.1567
   Roelofs AJ, 2010, J BONE MINER RES, V25, P606, DOI 10.1359/jbmr.091009
   Rossini M, 2012, CALCIFIED TISSUE INT, V91, P395, DOI 10.1007/s00223 012 9647 9
   Rossini M, 2012, J BONE MINER RES, V27, P227, DOI 10.1002/jbmr.521
   Weinstein RS, 2010, ENDOCRINOLOGY, V151, P2641, DOI 10.1210/en.2009 1488
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Weinstein RS, 2000, J CLIN ENDOCR METAB, V85, P2907, DOI 10.1210/jc.85.8.2907
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yaccoby S, 2002, BRIT J HAEMATOL, V116, P278, DOI 10.1046/j.1365 2141.2002.03257.x
   Yamashita J, 2011, CLIN CANCER RES, V17, P1405, DOI 10.1158/1078 0432.CCR 10 1614
NR 36
TC 1
Z9 2
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD JUN
PY 2013
VL 92
IS 6
BP 576
EP 585
DI 10.1007/s00223 013 9720 z
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 145MX
UT WOS:000319021400010
PM 23503790
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Wilson, C
AF Wilson, Caroline
TI Reproductive hormones in breast cancer bone metastasis: The role of
   inhibins
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Article
DE Breast cancer; Bisphosphonates; Inhibin; Activin; Follistatin
ID FOLLICLE STIMULATING HORMONE; DISSEMINATED TUMOR CELLS; ZOLEDRONIC ACID;
   NEOADJUVANT CHEMOTHERAPY; ACTIVIN; MARROW; GROWTH; BETA; RESORPTION;
   SURVIVAL
AB The spread of breast cancer cells to bone and survival in this new metastatic environment is influenced not only by the genetic signature of the cells, but also multiple host cells and soluble factors produced locally (paracrine) or from distant sites (endocrine). Disrupting this metastatic process has been evaluated in clinical trials of the bone targeted agents bisphosphonates and denosumab and have shown that these agents reduce the recurrence of breast cancer in postmenopausal women only, suggesting the efficacy of the drugs are influenced by levels of reproductive endocrine hormones. The molecular mechanism driving this differential effect has not been definitively identified, however, there is evidence that both reproductive hormones and bisphosphonates can affect similar paracrine factors and cellular components of the bone metastatic niche. This review focuses on how the ovarian endocrine hormone, inhibin, interacts with the paracrine factors activin and follistatin, abundant in the primary tumour and bone microenvironment, with subsequent effects on tumour cell survival. Inhibin also affects the cellular components of the bone microenvironment primarily the osteoblastic niche. Recent evidence has shown that bisphosphonates also alter this niche, which may represent a common mechanism by which inhibin and bisphosphonates interact to influence disease outcomes in early breast cancer. Further research is needed to fully elucidate these molecular mechanisms to enable understanding and future development of alternative bone targeted treatments with anti tumour efficacy in premenopausal women. (C) 2016 The Author. Published by Elsevier GmbH.
C1 [Wilson, Caroline] Weston Pk Hosp, Acad Unit Clin Oncol, Whitham Rd, Sheffield, S Yorkshire, England.
C3 Weston Park Hospital
RP Wilson, C (通讯作者)，Weston Pk Hosp, Acad Unit Clin Oncol, Whitham Rd, Sheffield, S Yorkshire, England.
EM C.wilson@sheffield.uk
OI wilson, caroline/0000 0003 1769 7169
CR Aft R, 2010, LANCET ONCOL, V11, P421, DOI 10.1016/S1470 2045(10)70054 1
   [Anonymous], 2015, Lancet
   [Anonymous], SAN ANT BREAST CANC
   Balic M, 2006, CLIN CANCER RES, V12, P5615, DOI 10.1158/1078 0432.CCR 06 0169
   Banys M, 2013, BMC CANCER, V13, DOI 10.1186/1471 2407 13 480
   Bierie B, 2010, CYTOKINE GROWTH F R, V21, P49, DOI 10.1016/j.cytogfr.2009.11.008
   Braun S, 2005, NEW ENGL J MED, V353, P793, DOI 10.1056/NEJMoa050434
   Chantry AD, 2010, J BONE MINER RES, V25, P2357, DOI 10.1002/jbmr.142
   Drake MT, 2010, J CLIN ENDOCR METAB, V95, P5063, DOI 10.1210/jc.2010 1103
   Haider MT, 2014, BONE, V66, P240, DOI 10.1016/j.bone.2014.06.023
   Harries M, 2014, CANCER EPIDEMIOL, V38, P427, DOI 10.1016/j.canep.2014.05.005
   Hoffmann O, 2011, ANTICANCER RES, V31, P3623
   Holen L, 2012, PATHOPHYSIOLOGY BONE
   Jeruss JS, 2003, CANCER RES, V63, P3783
   KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151
   Kim HJ, 2010, J CERAM PROCESS RES, V11, P11
   Kroep JR, 2016, EUR J CANCER, V54, P57, DOI 10.1016/j.ejca.2015.10.011
   Liu T, 2010, BIOCHEM J, V430, P191, DOI 10.1042/BJ20100427
   OGAWA Y, 1992, J BIOL CHEM, V267, P14233
   Pearsall RS, 2008, P NATL ACAD SCI USA, V105, P7082, DOI 10.1073/pnas.0711263105
   Perrien DS, 2007, ENDOCRINOLOGY, V148, P1654, DOI 10.1210/en.2006 0848
   Perrien DS, 2006, J CLIN ENDOCR METAB, V91, P1848, DOI 10.1210/jc.2005 2423
   Rack B, 2010, ANTICANCER RES, V30, P1807
   Razanajaona D, 2007, CANCER RES, V67, P7223, DOI 10.1158/0008 5472.CAN 07 0805
   Shiozawa Y, 2008, J CELL BIOCHEM, V105, P370, DOI 10.1002/jcb.21835
   Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414
   Wilson C, 2012, CANCER TREAT REV, V38, P877, DOI 10.1016/j.ctrv.2012.02.007
   Wilson C, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1066 7
   Winter MC, 2013, CLIN CANCER RES, V19, P2755, DOI 10.1158/1078 0432.CCR 12 3235
   Zhu LL, 2012, P NATL ACAD SCI USA, V109, P14574, DOI 10.1073/pnas.1212806109
   Zhu LL, 2012, BIOCHEM BIOPH RES CO, V422, P54, DOI 10.1016/j.bbrc.2012.04.104
NR 31
TC 5
Z9 5
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2212 1366
EI 2212 1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD SEP
PY 2016
VL 5
IS 3
BP 139
EP 142
DI 10.1016/j.jbo.2016.03.005
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA ED5LG
UT WOS:000388893000016
PM 27761376
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhai, ZJ
   Qu, XH
   Yan, W
   Li, HW
   Liu, GW
   Liu, XQ
   Tang, TT
   Qin, A
   Dai, KR
AF Zhai, Zanjing
   Qu, Xinhua
   Yan, Wei
   Li, Haowei
   Liu, Guangwang
   Liu, Xuqiang
   Tang, Tingting
   Qin, An
   Dai, Kerong
TI Andrographolide prevents human breast cancer induced osteoclastic bone
   loss via attenuated RANKL signaling
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Andrographolide; RANKL; Osteoclast; Breast cancer; Bone metastasis
ID NF KAPPA B; RECEPTOR ACTIVATOR; EXPRESSION; KINASE; INHIBITION;
   METASTASES; BISPHOSPHONATES; DIFFERENTIATION; NECROSIS; FAMILY
AB Bone metastasis is a common and serious complication in advanced cancers such as breast cancer, prostate cancer, and multiple myeloma. Agents that prevent bone loss could be used to develop an alternative therapy for bone metastasis. RANKL, a member of the tumor necrosis factor superfamily, has been shown to play a significant role in cancer associated bone loss. In this study, we examined the efficacy of the natural compound andrographolide (AP), a diterpenoid lactone isolated from the traditional Chinese and Indian medicinal plant Andrographis paniculata, in reducing breast cancer induced osteolysis. AP prevented human breast cancer induced bone loss by suppressing RANKL mediated and human breast cancer cell induced osteoclast differentiation. Molecular analysis revealed that AP prevented osteoclast function by inhibiting RANKL induced NF kappa B and ERK signaling pathway in lower dose (20 mu M), as well as inducing apoptosis at higher dose (40 mu M). Thus, AP is a potent inhibitor of breast cancer induced bone metastasis.
C1 [Zhai, Zanjing; Qu, Xinhua; Li, Haowei; Liu, Xuqiang; Tang, Tingting; Qin, An; Dai, Kerong] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Shanghai Key Lab Orthopaed Implants,Dept Orthopae, Shanghai 200030, Peoples R China.
   [Yan, Wei] Wendeng Zhenggu Hosp Shandong Prov, Wendeng, Shandong, Peoples R China.
   [Liu, Guangwang] Southeast Univ, Affiliated Hosp Med Collage, Cent Hosp Xuzhou, Dept Orthopaed Surg, Xuzhou, Jiangsu, Peoples R China.
C3 Shanghai Jiao Tong University; Southeast University   China
RP Qin, A (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Shanghai Key Lab Orthopaed Implants,Dept Orthopae, Shanghai 200030, Peoples R China.
EM dr.qinan@gmail.com; krdai@163.com
RI 田, 昊/T 9919 2019; zhang, xuyang/GQH 3712 2022; Tang,
   Tingting/B 1361 2013; Qin, An/J 2518 2019; Qu, Xinhua/Q 3950 2016
OI Tang, Tingting/0000 0002 1670 7452; Qu, Xinhua/0000 0002 8889 0890
FU Program for Innovative Research Team of Shanghai Municipal Education
   Commission (Phase I); Innovative Research from Shanghai Municipal
   Education Commission [13YZ031]; National Natural Science Foundation for
   the Youth of China [81201364]; scientific research foundation for
   returned overseas Chinese scholars from the state human resource
   ministry; Key National Basic Research Program of China [2012CB619101];
   scientific research grant for youth of Shanghai [ZZjdyx 2097]; 985
   project stem cell and regenerative medicine centre; Zhejiang National
   Science Foundation [Y2110653]; Major Basic Research of Science and
   Technology Commission of Shanghai Municipality [11DJ1400303]
FX This work was supported by the Program for Innovative Research Team of
   Shanghai Municipal Education Commission (Phase I), a grant from the
   Innovative Research from Shanghai Municipal Education Commission
   (13YZ031), a grant for scientific research from the National Natural
   Science Foundation for the Youth of China (No. 81201364), grant from the
   scientific research foundation for returned overseas Chinese scholars
   from the state human resource ministry, the Key National Basic Research
   Program of China (Grant No. 2012CB619101), a scientific research grant
   for youth of Shanghai (Grant No. ZZjdyx 2097), a scientific research
   grant from 985 project stem cell and regenerative medicine centre, a
   scientific research grant from Zhejiang National Science Foundation
   (Grant No. Y2110653), and the Major Basic Research of Science and
   Technology Commission of Shanghai Municipality (Grant No. 11DJ1400303).
CR Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795
   Ang E, 2011, J CELL BIOCHEM, V112, P89, DOI 10.1002/jcb.22800
   [Anonymous], 2007, Global Cancer Facts Figures 2007
   Bhatia P, 2005, CLIN CANCER RES, V11, P162
   Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101
   Body JJ, 2002, BONE, V30, p75S
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Canon J, 2010, BONE, V46, P1613, DOI 10.1016/j.bone.2010.03.001
   Canon JR, 2008, CLIN EXP METASTAS, V25, P119, DOI 10.1007/s10585 007 9127 1
   Chen CL, 2013, J IMMUNOL, V191, P1744, DOI 10.4049/jimmunol.1201976
   Chen HW, 2011, J NAT PROD, V74, P2408, DOI 10.1021/np200631v
   Chikatsu N, 2000, BIOCHEM BIOPH RES CO, V267, P632, DOI 10.1006/bbrc.1999.2008
   Chiou WF, 1998, BRIT J PHARMACOL, V125, P327, DOI 10.1038/sj.bjp.0702073
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Coleman RE, 1998, BRIT J CANCER, V77, P336, DOI 10.1038/bjc.1998.52
   Coon JT, 2004, PLANTA MED, V70, P293, DOI 10.1055/s 2004 818938
   Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883
   Costa L, 2009, NAT CLIN PRACT ONCOL, V6, P163, DOI 10.1038/ncponc1323
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   De Leenheer E, 2004, CURR OPIN PHARMACOL, V4, P340, DOI 10.1016/j.coph.2004.03.011
   DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493
   Eastell R, 1998, NEW ENGL J MED, V338, P736, DOI 10.1056/NEJM199803123381107
   Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460 2075.1995.tb00305.x
   Farrugia AN, 2003, CANCER RES, V63, P5438
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Gevorgyan A, 2008, CURR OPIN OTOLARYNGO, V16, P325, DOI 10.1097/MOO.0b013e328304b445
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092 8674(02)00703 1
   Guise Theresa A., 2000, Cancer, V88, P2892, DOI 10.1002/1097 0142(20000615)88:12+<2892::AID CNCR2>3.0.CO;2 Y
   HANDA SS, 1990, INDIAN J MED RES B, V92, P284
   Haskell SG, 2003, SOUTH MED J, V96, P469, DOI 10.1097/01.SMJ.0000051146.93190.4A
   Hillner BE, 2000, J CLIN ONCOL, V18, P1378, DOI 10.1200/JCO.2000.18.6.1378
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Jiang XJ, 2009, EUR J MED CHEM, V44, P2936, DOI 10.1016/j.ejmech.2008.12.014
   Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302 221
   Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kim HJ, 2007, MOL PHARMACOL, V72, P418, DOI 10.1124/mol.107.034173
   Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230
   Kurata T, 2012, JPN J CLIN ONCOL, V42, P663, DOI 10.1093/jjco/hys088
   Lee JH, 2010, MOL PHARMACOL, V77, P17, DOI 10.1124/mol.109.057877
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Lipton A, 2012, EXPERT REV CLIN PHAR, V5, P359, DOI [10.1586/ecp.12.35, 10.1586/ECP.12.35]
   Mackiewicz Wysocka M, 2012, EXPERT OPIN INV DRUG, V21, P785, DOI 10.1517/13543784.2012.679928
   Mariotti A, 2008, J DENT EDUC, V72, P919
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Melchior J, 1997, PHYTOMEDICINE, V3, P315, DOI 10.1016/S0944 7113(97)80002 5
   Miller FR, 2000, J NATL CANCER I, V92, P1185, DOI 10.1093/jnci/92.14.1185A
   Monje P, 2005, J BIOL CHEM, V280, P35081, DOI 10.1074/jbc.C500353200
   Morony S, 2001, CANCER RES, V61, P4432
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nangia Makker P, 2013, CANCER BIOL THER, V14, P1
   Nangia Makker P, 2007, INT J CANCER, V121, P884, DOI 10.1002/ijc.22733
   Negi AS, 2008, MED RES REV, V28, P746, DOI 10.1002/med.20115
   Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239
   Paller CJ, 2012, CLIN INTERV AGING, V7, P363, DOI 10.2147/CIA.S27930
   Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476
   PURI A, 1993, J NAT PROD, V56, P995, DOI 10.1021/np50097a002
   Puszynski K, 2009, IET SYST BIOL, V3, P356, DOI 10.1049/iet syb.2008.0172
   Qin A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034132
   Radhakrishnan SK, 2006, BBA REV CANCER, V1766, P53, DOI 10.1016/j.bbcan.2006.02.001
   Rajagopal Sriram, 2003, J Exp Ther Oncol, V3, P147, DOI 10.1046/j.1359 4117.2003.01090.x
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Roodman GD, 2008, CANCER TREAT REV, V34, P92, DOI 10.1016/j.ctrv.2007.09.002
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Roxas M, 2007, ALTERN MED REV, V12, P25
   Ruocco MG, 2007, ADV EXP MED BIOL, V602, P125
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Shen YC, 2002, BRIT J PHARMACOL, V135, P399, DOI 10.1038/sj.bjp.0704493
   Society A.C., 2007, Breast cancer facts figures. American Cancer Society
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   Steer JH, 2000, J BIOL CHEM, V275, P18432, DOI 10.1074/jbc.M906304199
   Tait LR, 2007, INT J CANCER, V120, P2127, DOI 10.1002/ijc.22572
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   THAMLIKITKUL V, 1991, Journal of the Medical Association of Thailand, V74, P437
   Trémollières F, 2002, PRESSE MED, V31, P1323
   Trivedi NP, 2009, INTEGR CANCER THER, V8, P177, DOI 10.1177/1534735409335606
   Wang C, 2003, J BONE MINER RES, V18, P2159, DOI 10.1359/jbmr.2003.18.12.2159
   Wang LJ, 2011, J DENT RES, V90, P1246, DOI 10.1177/0022034511418341
   Watts NB, 2003, CLIN GERIATR MED, V19, P395, DOI 10.1016/S0749 0690(02)00069 1
   Wedemeyer C, 2007, CALCIFIED TISSUE INT, V81, P394, DOI 10.1007/s00223 007 9077 2
   Xing LP, 2002, J BONE MINER RES, V17, P1200, DOI 10.1359/jbmr.2002.17.7.1200
   Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073
   Zhi ling G., 1995, J TONGJI MED U, V15, P205
NR 88
TC 25
Z9 26
U1 0
U2 25
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167 6806
EI 1573 7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD FEB
PY 2014
VL 144
IS 1
BP 33
EP 45
DI 10.1007/s10549 014 2844 7
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AB2VD
UT WOS:000331649300004
PM 24481680
DA 2025 08 17
ER

PT J
AU Huang, YF
   Li, LJ
   Gao, SQ
   Chu, Y
   Niu, J
   Geng, FN
   Shen, YM
   Peng, LH
AF Huang, Yan Fen
   Li, Long Jian
   Gao, Si Qian
   Chu, Yang
   Niu, Jie
   Geng, Fu Neng
   Shen, Yong Mei
   Peng, Li Hua
TI Evidence based anti osteoporosis effects of Periplaneta americana
   L on osteoblasts, osteoclasts, vascular endothelial cells and bone
   marrow derived mesenchymal stem cells
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE Periplaneta americana L; Anti osteoporosis; Osteoblasts; Osteoclasts;
   HUVECs; BMSCs
ID GENE DELIVERY; NANOPARTICLES; INCREASE
AB Background: Kangfuxin (KFX) is the ethanol extract of Periplaneta americana L, which has been widely used in the Traditional Chinese Medicine for the repair and regeneration of injured organ and tissues with long history. This study is to investigate the influence of KFX in the various cellular activities and evaluate the anti osteoporosis potential of KFX.
   Methods: The influence of the KFX in the cellular activities, including: 1) migration, osteocalcin secretion of osteoblasts; 2) apoptosis of osteoclasts; 3) migration and tube formation of human umbilical vein endothelial cell (HUVEC); and 4) proliferation, cell cycle regulation and migration of bone marrow mesenchymal stem cells (BMSCs), were investigated systematically.
   Results: KFX was shown to significantly 1) Promote of the migration of osteoblasts, HUVEC, and BMSCs; 2) Increase the secretion of osteocalcin and mineralization of osteoblasts; 3) Accelerate the apoptosis of osteoclasts; 4) Stimulate the proliferation and regulate the cell cycle of BMSCs.
   Conclusion: Taken together, these results provide the evidence for the osteogenesis, anti osteoporosis and angiogenesis effects of KFX, with the mechanism of activating the bone formation through stimulating the osteoblasts and HUVECs, as well as inhibiting the bone absorption by inhibiting the osteoclasts activities. The KFX was definitely shown a promising bone turnover agent with great potential for anti osteoporosis treatment.
C1 [Huang, Yan Fen; Li, Long Jian; Gao, Si Qian; Chu, Yang; Niu, Jie; Peng, Li Hua] Zhejiang Univ, Coll Pharmaceut Sci, Inst Pharmaceut, 866 Yuhangtang Rd, Hangzhou 310058, Zhejiang, Peoples R China.
   [Peng, Li Hua] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau, Peoples R China.
   [Li, Long Jian] Chinese Peoples Armed Police Forces, Zhejiang Prov Corps Hosp, Jiaxing, Zhejiang, Peoples R China.
   [Geng, Fu Neng] Sichuan Engn Res Ctr Med Anim, Yingmenkou Rd 88, Chengdu, Sichuan, Peoples R China.
   [Geng, Fu Neng; Shen, Yong Mei] GOODDOCTOR Pharmaceut Co, Yingmenkou Rd 88, Chengdu, Sichuan, Peoples R China.
C3 Zhejiang University; Macau University of Science & Technology
RP Peng, LH (通讯作者)，Zhejiang Univ, Coll Pharmaceut Sci, Inst Pharmaceut, 866 Yuhangtang Rd, Hangzhou 310058, Zhejiang, Peoples R China.; Peng, LH (通讯作者)，Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau, Peoples R China.
EM lhpeng@zju.edu.cn
FU National Natural Science Foundation of China [81473145]; Macao Science
   and Technology Development Fund, Macau Special Administrative Region,
   China (Open project of State Key Laboratory of Quality Research in
   Chinese Medicine, Macau University of Science and Technology)
   [MUST SKL 2016 11]
FX This study was supported in part by the National Natural Science
   Foundation of China (81473145) and The Macao Science and Technology
   Development Fund, Macau Special Administrative Region, China (Open
   project of State Key Laboratory of Quality Research in Chinese Medicine,
   Macau University of Science and Technology, Project No:
   MUST SKL 2016 11).
CR Abdallah BM, 2015, BONE, V70, P28, DOI 10.1016/j.bone.2014.07.028
   Abrahamsen B, 2010, CURR OPIN RHEUMATOL, V22, P404, DOI 10.1097/BOR.0b013e32833ad677
   BREIER G, 1995, DEV DYNAM, V204, P228, DOI 10.1002/aja.1002040303
   Campbell AJ, 1997, AGE AGEING, V26, P315, DOI 10.1093/ageing/26.4.315
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Das S, 2013, DRUG DES DEV THER, V7, P435, DOI 10.2147/DDDT.S31504
   Fong ELS, 2011, BIOMATERIALS, V32, P395, DOI 10.1016/j.biomaterials.2010.08.101
   Glynn ERA, 2013, J ANIM SCI BIOTECHNO, V4, DOI 10.1186/2049 1891 4 40
   Guan M, 2012, NAT MED, V18, P456, DOI 10.1038/nm.2665
   Ingle JN, 2013, BREAST, V22, pS180, DOI 10.1016/j.breast.2013.07.035
   Kelchtermans H, 2009, ANN RHEUM DIS, V68, P744, DOI 10.1136/ard.2007.086066
   KORTING HC, 1994, LIFE SCI, V55, P533, DOI 10.1016/0024 3205(94)00746 2
   Li HY, 2013, ACTA BIOMATER, V9, P5379, DOI 10.1016/j.actbio.2012.10.019
   Li HY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016767
   Loder EW, 2005, AM J OBSTET GYNECOL, V193, P636, DOI 10.1016/j.ajog.2004.12.089
   Logan PC, 2012, REPROD SCI, V19, P883, DOI 10.1177/1933719112438447
   Lou Hongying, 2009, Zhongguo Zhong Yao Za Zhi, V34, P2950
   Mukherjee S, 2014, THERANOSTICS, V4, P316, DOI 10.7150/thno.7819
   Neve A, 2013, REGUL PEPTIDES, V184, P81, DOI 10.1016/j.regpep.2013.03.014
   Nian H, 2009, PHYTOMEDICINE, V16, P320, DOI 10.1016/j.phymed.2008.12.006
   Peng LH, 2016, BIOMATERIALS, V103, P137, DOI 10.1016/j.biomaterials.2016.06.057
   Peng LH, 2013, MOL PHARMACEUT, V10, P3090, DOI 10.1021/mp400162k
   Peng SL, 2010, J ORTHOP RES, V28, P1208, DOI 10.1002/jor.21127
   Song HY, 2014, NANOSCALE, V6, P3206, DOI 10.1039/c3nr04363k
   Tang CH, 2007, J BIOL CHEM, V282, P2346, DOI 10.1074/jbc.M603070200
   Terman BI, 1996, CANCER METAST REV, V15, P159, DOI 10.1007/BF00437468
   TURNER RT, 1994, ENDOCR REV, V15, P275, DOI 10.1210/er.15.3.275
   Vanella L, 2012, INT J HYPERTENS, V2012, DOI 10.1155/2012/890671
   Verit Fatma Ferda, 2006, Archives of Gynecology and Obstetrics, V274, P133, DOI 10.1007/s00404 006 0148 9
   Xia BJ, 2014, J ETHNOPHARMACOL, V153, P133, DOI 10.1016/j.jep.2014.01.040
   Yang F, 2011, STEM CELLS, V29, P981, DOI 10.1002/stem.646
NR 32
TC 28
Z9 29
U1 1
U2 23
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1472 6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD AUG 18
PY 2017
VL 17
AR 413
DI 10.1186/s12906 017 1917 7
PG 12
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA FE0ZN
UT WOS:000407948300001
PM 28821253
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yu, HP
   Wang, YY
   Gao, JJ
   Gao, YS
   Zhong, C
   Chen, YX
AF Yu, Hongping
   Wang, Yanyi
   Gao, Junjie
   Gao, Youshui
   Zhong, Chao
   Chen, Yixuan
TI Application of the neuropeptide NPVF to enhance angiogenesis and
   osteogenesis in bone regeneration
SO COMMUNICATIONS BIOLOGY
LA English
DT Article
ID PHARMACOLOGICAL CHARACTERIZATION; MAMMALIAN NEUROPEPTIDE; FF; RECEPTORS;
   HYDROXYAPATITE; ACTIVATION; CELLS; ANTINOCICEPTION; TRANSPLANTATION;
   IDENTIFICATION
AB The brain bone regulatory system regulates skeletal homeostasis via bioactive neuropeptides, yet the underlying mechanism remains elusive. Here, we report the role of the neuropeptide VF (NPVF, VPNLPQRF NH2) in enhancing both angiogenesis and osteogenesis in a rat skeletal system and the potential pathways involved. An in vitro study revealed that NPVF not only promotes migration and angiogenesis of human umbilical vein endothelial cells (HUVECs) by activating NPFFR1, which leads to upregulation of miR 181c 3p and downregulation of Argonaute1 (AGO1), but also mediates osteogenic differentiation of bone mesenchymal stem cells (BMSCs) via the Wnt/beta catenin signaling pathway. To improve the stability and bioavailability and thus efficacy of NPVF as a promoter of in vivo bone regeneration, we genetically engineered amyloid NPVF fusion proteins and utilized them as self assembling nanofiber coatings to treat bone defects in a rat calvarial defect model. We found that a porous hydroxyapatite scaffold loaded with the NPVF peptide fused amyloid coating substantially enhanced angiogenesis and site specific fresh bone in growth when implanted in calvarial defects. Taken together, our work uncovered a previously undefined crosstalk between the brain and bone by unveiling the role of NPVF in bone tissue and demonstrated a viable method for promoting bone tissue repairs based upon self assembling NPVF containing protein coatings.
   The neuropeptide NPVF stimulates bone formation via the Wnt signaling pathway and hydroxyapatite scaffolds coated with NPVF stimulates angiogenesis and osteogenesis in a rat calvaria defect model.
C1 [Yu, Hongping] Xiamen Univ, Affiliated Hosp Xiamen Univ 1, Sch Med, Dept Orthoped Surg, Xiamen 361005, Fujian, Peoples R China.
   [Wang, Yanyi; Zhong, Chao] Chinese Acad Sci, Shenzhen Inst Synthet Biol, Shenzhen Inst Adv Technol, Ctr Mat Synthet Biol, Shenzhen 518055, Peoples R China.
   [Wang, Yanyi; Zhong, Chao] Chinese Acad Sci, Shenzhen Inst Synthet Biol, Shenzhen Inst Adv Technol, CAS Key Lab Quantitat Engn Biol, Shenzhen 518055, Peoples R China.
   [Gao, Junjie; Gao, Youshui; Chen, Yixuan] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Sch Med, Dept Orthoped Surg, Shanghai 200233, Peoples R China.
   [Gao, Junjie] Univ Chinese Acad Sci, Ningbo Inst Life & Hlth Ind, Ningbo, Zhejiang, Peoples R China.
C3 Xiamen University; Chinese Academy of Sciences; Shenzhen Institute of
   Advanced Technology, CAS; Chinese Academy of Sciences; Shenzhen
   Institute of Advanced Technology, CAS; Shanghai Jiao Tong University;
   Chinese Academy of Sciences; University of Chinese Academy of Sciences,
   CAS
RP Zhong, C (通讯作者)，Chinese Acad Sci, Shenzhen Inst Synthet Biol, Shenzhen Inst Adv Technol, Ctr Mat Synthet Biol, Shenzhen 518055, Peoples R China.; Zhong, C (通讯作者)，Chinese Acad Sci, Shenzhen Inst Synthet Biol, Shenzhen Inst Adv Technol, CAS Key Lab Quantitat Engn Biol, Shenzhen 518055, Peoples R China.; Gao, YS; Chen, YX (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Sch Med, Dept Orthoped Surg, Shanghai 200233, Peoples R China.
EM gaoyoushui@sjtu.edu.cn; chao.zhong@siat.ac.cn; yixuanchen_sjtu@163.com
RI chen, yixuan/KVC 2060 2024; Zhong, Chao/F 3484 2010; GAO,
   YOUSHUI/U 8349 2019
OI Zhong, Chao/0000 0002 6638 3652; Gao, Junjie/0000 0003 4820 8524; chen,
   yixuan/0000 0001 7390 0622
FU National Key Research and Development Program of China [2020YFA0908100];
   National Science Fund for Distinguished Young Scholars [32125023]; Joint
   Funds of the National Natural Science Foundation of China [81902237];
   China Postdoctoral Science Foundation [U1932204]; National Natural
   Science Foundation of China;  [2021M703380]
FX This project was partially funded by the National Key Research and
   Development Program of China (2020YFA0908100), the National Science Fund
   for Distinguished Young Scholars (Grant No. 32125023), the Joint Funds
   of the National Natural Science Foundation of China (Key Program No.
   U1932204), the National Natural Science Foundation of China (Grant No.
   81902237) and the China Postdoctoral Science Foundation (Grant No.
   2021M703380).
CR Appelt J, 2020, EBIOMEDICINE, V59, DOI 10.1016/j.ebiom.2020.102970
   Arcos D, 2020, J MATER CHEM B, V8, P1781, DOI 10.1039/c9tb02710f
   Baldock PA, 2002, J CLIN INVEST, V109, P915, DOI 10.1172/JCI200214588
   Bonini JA, 2000, J BIOL CHEM, V275, P39324, DOI 10.1074/jbc.M004385200
   Chen YX, 2020, FASEB J, V34, P5348, DOI 10.1096/fj.201902463RR
   Clancy JW, 2019, NAT CELL BIOL, V21, P856, DOI 10.1038/s41556 019 0345 y
   Cui MK, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax3155
   DeVeale B, 2021, NAT REV GENET, V22, P307, DOI 10.1038/s41576 020 00309 5
   DIEKMANN O, 1994, BRAZ J MED BIOL RES, V27, P1865
   Erak M, 2018, BIOORGAN MED CHEM, V26, P2759, DOI 10.1016/j.bmc.2018.01.012
   Fang Q, 2012, NEUROPHARMACOLOGY, V62, P855, DOI 10.1016/j.neuropharm.2011.09.013
   Fosgerau K, 2015, DRUG DISCOV TODAY, V20, P122, DOI 10.1016/j.drudis.2014.10.003
   Gao X, 2021, NATURE, V589, P591, DOI 10.1038/s41586 020 03057 y
   Han ZL, 2015, ANESTH ANALG, V121, P1360, DOI 10.1213/ANE.0000000000000921
   Hartgerink JD, 2001, SCIENCE, V294, P1684, DOI 10.1126/science.1063187
   Heid S, 2020, ACTA BIOMATER, V113, P1, DOI 10.1016/j.actbio.2020.06.040
   Hofmann A, 2020, J BONE JOINT SURG AM, V102, P179, DOI 10.2106/JBJS.19.00680
   Itkin T, 2016, NATURE, V532, P323, DOI 10.1038/nature17624
   Ji CB, 2019, NAT REV ENDOCRINOL, V15, P731, DOI 10.1038/s41574 019 0260 0
   Langen UH, 2017, NAT CELL BIOL, V19, P189, DOI 10.1038/ncb3476
   Li FXZ, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00077
   Li H, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.675503
   Li MM, 2021, ADV MATER, V33, DOI 10.1002/adma.202104829
   Li T, 2022, BIOACT MATER, V11, P268, DOI 10.1016/j.bioactmat.2021.09.029
   Li YF, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba1425
   Lin YT, 2019, CHINESE J PHYSIOL, V62, P47, DOI 10.4103/CJP.CJP_23_19
   Lin YT, 2017, EXP NEUROL, V291, P62, DOI 10.1016/j.expneurol.2017.02.003
   Liu QY, 2001, J BIOL CHEM, V276, P36961, DOI 10.1074/jbc.M105308200
   Liu SY, 2015, CELL METAB, V22, P606, DOI 10.1016/j.cmet.2015.08.018
   Liu YT, 2022, LANGMUIR, V38, P680, DOI 10.1021/acs.langmuir.1c02515
   McDermott AM, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav7756
   Molino G, 2020, BIOMED MATER, V15, DOI 10.1088/1748 605X/ab5f1a
   Mollereau C, 2002, EUR J PHARMACOL, V451, P245, DOI 10.1016/S0014 2999(02)02224 0
   Moulédous L, 2010, BIOFACTORS, V36, P423, DOI 10.1002/biof.116
   Muschter D, 2020, BONE, V133, DOI 10.1016/j.bone.2019.115181
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Negahdaripour M, 2019, EXPERT OPIN BIOL TH, V19, P1275, DOI 10.1080/14712598.2019.1652592
   Oliveira HL, 2017, CALCIFIED TISSUE INT, V101, P341, DOI 10.1007/s00223 017 0294 z
   Panula P, 1996, PROG NEUROBIOL, V48, P461, DOI 10.1016/0301 0082(96)00001 9
   Picardi P, 2014, TRANSL MED UNISA, V10, P8
   Praveschotinunt P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 13336 6
   Ramasamy SK, 2014, NATURE, V507, P376, DOI 10.1038/nature13146
   Ramesh N, 2018, J BIOMED MATER RES B, V106, P2046, DOI 10.1002/jbm.b.33950
   Schipani E, 2009, J BONE MINER RES, V24, P1347, DOI [10.1359/JBMR.090602, 10.1359/jbmr.090602]
   Siddiqui HA, 2018, MATERIALS, V11, DOI 10.3390/ma11101813
   Solorio LD, 2012, STEM CELL TRANSL MED, V1, P632, DOI 10.5966/sctm.2012 0039
   Sun F, 2011, ACTA BIOMATER, V7, P3813, DOI 10.1016/j.actbio.2011.07.002
   Sun XH, 2014, TRENDS CARDIOVAS MED, V24, P105, DOI 10.1016/j.tcm.2013.09.002
   Tuukkanen J, 2017, CURR PHARM DESIGN, V23, P3786, DOI [10.2174/1381612823666170615105454, 10.2174/1381612823666170609084016]
   Uyama H, 2022, STEM CELL REP, V17, P2392, DOI 10.1016/j.stemcr.2022.09.014
   Waqas SFH, 2017, J CLIN INVEST, V127, P2842, DOI 10.1172/JCI90152
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Yamamizu K, 2015, BRIT J PHARMACOL, V172, P268, DOI 10.1111/bph.12573
   YANG HYT, 1985, P NATL ACAD SCI USA, V82, P7757, DOI 10.1073/pnas.82.22.7757
   Yang M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16003
   Yang X, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201802730
   Yu HP, 2016, PEPTIDES, V86, P24, DOI 10.1016/j.peptides.2016.09.012
   Zengin A, 2010, TRENDS ENDOCRIN MET, V21, P411, DOI 10.1016/j.tem.2010.02.004
   Zhang Y, 2021, ADV SCI, V8, DOI 10.1002/advs.202100808
   Zitman Gal T, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/1475 2840 13 8
NR 60
TC 11
Z9 13
U1 4
U2 33
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2399 3642
J9 COMMUN BIOL
JI Commun. Biol.
PD FEB 20
PY 2023
VL 6
IS 1
AR 197
DI 10.1038/s42003 023 04567 x
PG 12
WC Biology; Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Science & Technology   Other
   Topics
GA 9E6RY
UT WOS:000936911500005
PM 36804475
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yang, YL
   Chung, MR
   Zhou, SR
   Gong, XY
   Xu, HY
   Hong, YY
   Jin, AT
   Huang, XR
   Zou, WG
   Dai, QG
   Jiang, LY
AF Yang, Yiling
   Chung, Mi Ri
   Zhou, Siru
   Gong, Xinyi
   Xu, Hongyuan
   Hong, Yueyang
   Jin, Anting
   Huang, Xiangru
   Zou, Weiguo
   Dai, Qinggang
   Jiang, Lingyong
TI STAT3 controls osteoclast differentiation and bone homeostasis by
   regulating NFATc1 transcription
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE bone; osteoporosis; STAT3; osteoclast; NFAT transcription factor;
   transgenic mice
ID MEDIATED OSTEOCLASTOGENESIS; T CELLS; ACTIVATION; PROTEIN; FAMILY;
   INACTIVATION; PRECURSORS; EXPRESSION; INDUCTION; ROLES
AB The transcription factor signal transducer and activator of transcription 3 (STAT3) plays a central role in cell survival and function. STAT3 has been demonstrated to participate in the maintenance of bone homeostasis in osteoblasts, but its role in osteoclasts in vivo remains poorly defined. Here, we generated a conditional knockout mouse model in which Stat3 was deleted in osteoclasts using a cathepsin K Cre (Ctsk Cre) driver. We observed that osteoclast specific Stat3 deficiency caused increased bone mass in mice, which we attributed to impaired bone catabolism by osteoclasts. Stat3 deficient bone marrow macrophages (BMMs) showed decreased expression of nuclear factor of activated T cells, cytoplasm 1 (NFATc1), and reduced osteoclast differentiation determined by decreases in osteoclast number, tartrate resistant acid phosphatase activity, and expression of osteoclast marker genes. Enforced expression of NFATc1 in Stat3 deficient BMMs rescued the impaired osteoclast differentiation. Mechanistically, we revealed that STAT3 could drive the transcription of NFATc1 by binding to its promoter. Furthermore, preventing STAT3 activation by using an inhibitor of upstream phosphorylases, AG490, also impaired osteoclast differentiation and formation in a similar way as gene deletion of Stat3. In summary, our data provide the first evidence that STAT3 is significant in osteoclast differentiation and bone homeostasis in vivo, and it may be identified as a potential pharmacological target for the treatment of bone metabolic diseases through regulation of osteoclast activity.
C1 [Yang, Yiling; Chung, Mi Ri; Zhou, Siru; Gong, Xinyi; Xu, Hongyuan; Hong, Yueyang; Jin, Anting; Huang, Xiangru; Jiang, Lingyong] Shanghai Jiao Tong Univ, Peoples Hosp 9, Shanghai Key Lab Stomatol,Sch Med, Ctr Craniofacial Orthodont,Dept Oral & Craniomaxi, Shanghai 200011, Peoples R China.
   [Yang, Yiling; Chung, Mi Ri; Zhou, Siru; Gong, Xinyi; Xu, Hongyuan; Hong, Yueyang; Jin, Anting; Huang, Xiangru; Dai, Qinggang; Jiang, Lingyong] Natl Clin Res Ctr Stomatol, Shanghai Res Inst Stomatol, Shanghai 200011, Peoples R China.
   [Zou, Weiguo] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Cell Biol,CAS Ctr Excellence Mol Ce, Shanghai 200031, Peoples R China.
   [Dai, Qinggang] Shanghai Jiao Tong Univ, Peoples Hosp 9, Dent Ctr 2, Shanghai Key Lab Stomatol,Sch Med, Shanghai 200011, Peoples R China.
C3 Shanghai Jiao Tong University; Chinese Academy of Sciences; Center for
   Excellence in Molecular Cell Science, CAS; Shanghai Jiao Tong University
RP Dai, QG (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dent Ctr 2, 639 Zhi Zao Ju Rd, Shanghai 200011, Peoples R China.; Jiang, LY (通讯作者)，Shanghai Jiao Tong Univ, Peoples Hosp 9, Dept Oral & Craniomaxillofacial Sci, Ctr Craniofacial Orthodont,Sch Med, 639 Zhi Zao Ju Rd, Shanghai 200011, Peoples R China.
EM daiqinggang@126.com; 247416218@qq.com
RI ; huang, xiangru/HJH 8638 2023; Qinggang, Dai/HLV 8212 2023
OI zou, weiguo/0000 0003 2516 0302; Dai, Qinggang/0000 0002 8177 2496;
   Yang, Yiling/0000 0001 9044 2897; Chung, Miri/0000 0002 1331 8574; 
FU National Natural Science Foundation of China (NSFC) [81570950, 81870740,
   81800949]; Shanghai Summit & Plateau Disciplines; SHIPM mu fund from
   Shanghai Institute of Precision Medicine, Shanghai Ninth People's
   Hospital, Shanghai Jiao Tong University School of Medicine [JC201809];
   Incentive Project of High level Innovation Team for Shanghai Jiao Tong
   University School of Medicine; Scholar of the Outstanding Youth Medical
   Talents from Shanghai Jiaotong University; "Chen Xing" project from
   Shanghai Jiaotong University; Shanghai "Rising Stars of Medical Talent"
   Youth Development Program from Shanghai Jiaotong University
FX This work was supported in part by National Natural Science Foundation
   of China (NSFC) Grants 81570950, 81870740, and 81800949; Shanghai Summit
   & Plateau Disciplines; the SHIPM mu fund from Shanghai Institute of
   Precision Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong
   University School of Medicine Grant JC201809; and the Incentive Project
   of High level Innovation Team for Shanghai Jiao Tong University School
   of Medicine. This work was also supported by Scholar of the Outstanding
   Youth Medical Talents, Shanghai "Rising Stars of Medical Talent" Youth
   Development Program and the "Chen Xing" project from Shanghai Jiaotong
   University. The authors declare that they have no conflicts of interest
   with the contents of this article.
CR Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Chuvpilo S, 2002, IMMUNITY, V16, P881, DOI 10.1016/S1074 7613(02)00329 1
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Dai QG, 2017, CELL DEATH DIFFER, V24, P1886, DOI 10.1038/cdd.2017.110
   Dai QG, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 04422 0
   Dai QG, 2017, J BIOL CHEM, V292, P196, DOI 10.1074/jbc.M116.764761
   Debnath S, 2018, NATURE, V562, P133, DOI 10.1038/s41586 018 0554 8
   Han YJ, 2019, J CLIN INVEST, V129, P1895, DOI 10.1172/JCI124590
   Harmer D, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00788
   Hikata T, 2009, BLOOD, V113, P2202, DOI 10.1182/blood 2008 06 162594
   Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Ikeda K, 2016, J BIOCHEM, V159, P1, DOI 10.1093/jb/mvv112
   Itoh S, 2006, BONE, V39, P505, DOI 10.1016/j.bone.2006.02.074
   Johnson RW, 2015, BONE, V81, P343, DOI 10.1016/j.bone.2015.08.005
   Joung YH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159891
   Kim K, 2007, J IMMUNOL, V178, P5588, DOI 10.4049/jimmunol.178.9.5588
   Li CH, 2013, BIOCHEM BIOPH RES CO, V435, P533, DOI 10.1016/j.bbrc.2013.04.084
   Li J., 2013, ECS ELECTROCHEMISTY, V2, pA25, DOI DOI 10.4161/JKST.23930
   Liu Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11149
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Mori T, 2011, INT IMMUNOL, V23, P701, DOI 10.1093/intimm/dxr077
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Sitara D, 2010, IMMUNOL REV, V233, P286, DOI 10.1111/j.0105 2896.2009.00849.x
   Sun J, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0015 x
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Wang G, 2016, ONCOGENE, V35, P4388, DOI 10.1038/onc.2015.446
   Wotton CJ, 2019, BONE, V124, P69, DOI 10.1016/j.bone.2019.04.003
   Wu Q, 2017, CELL PHYSIOL BIOCHEM, V41, P1360, DOI 10.1159/000465455
   Yang WL, 2018, J CELL PHYSIOL, V233, P4606, DOI 10.1002/jcp.26372
   Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818
   Zhou HK, 2011, BONE, V49, P404, DOI 10.1016/j.bone.2011.04.020
   Zou WG, 2013, J EXP MED, V210, P1793, DOI 10.1084/jem.20111790
NR 37
TC 86
Z9 92
U1 1
U2 33
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021 9258
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 18
PY 2019
VL 294
IS 42
BP 15395
EP 15407
DI 10.1074/jbc.RA119.010139
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA JQ9HM
UT WOS:000499248700017
PM 31462535
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Peng, Y
   Liu, QZ
   Xu, D
   Li, K
   Li, H
   Qiu, L
   Lin, JG
AF Peng, Ying
   Liu, Qingzhu
   Xu, Dong
   Li, Ke
   Li, Hang
   Qiu, Ling
   Lin, Jianguo
TI Inhibition of zoledronic acid derivatives with extended methylene
   linkers on osteoclastogenesis involve downregulation of JNK and Akt
   pathways
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Article
DE bone resorption; mechanism; osteoclast; RANKL; zoledronic acid
   derivative
ID FARNESYL PYROPHOSPHATE SYNTHASE; DIPHOSPHATE SYNTHASE; MEVALONATE
   PATHWAY; BONE RESORPTION; KAPPA B; C FOS; BISPHOSPHONATES;
   DIFFERENTIATION; ACTIVATION; BINDING
AB Bisphosphonates (BPs), especially zoledronic acid (ZOL), are clinically used to treat osteolytic bone lesions. However, serious side effects may be also induced during the therapeutic process. To improve the BPs drugs, here, we investigated the effects of a series of ZOL derivatives with increasing number of methylene linker between the imidazole ring and the P C P backbone named IPrDP, IBDP, IPeDP, and IHDP on cell viability and receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast differentiation, function and apoptosis induction in mouse bone marrow derived macrophages (BMMs). Our results suggested that IPeDP and IHDP, which contains 4 and 5 methylene linkers, respectively, exerted lower toxicity on BMMs compared with ZOL, IPrDP, and IBDP, which contains 1, 2, and 3 methylene linkers respectively. At concentrations below cytotoxicity threshold, IPeDP and IHDP possessed strong abilities of antiosteoclast formation, antibone absorption, and inducing osteoclast apoptosis, which were similar to ZOL and more powerful than IPrDP and IBDP. The mechanism behind these effects of IPeDP and IHDP might involve the interference of small GTPases prenylation through suppression of mevalonate pathway. The downregulation of JNK and Akt phosphorylation and subsequent inhibition of the expression of c Fos and NFATc1 might also be involved. Our results supported the potential usage of IPeDP and IHDP to treat bone related disorders involving increased osteoclastogenesis. Our attempt to extend the methylene linker between the imidazole ring and the P C P backbone of ZOL also reveals some regularities between the structure and properties of the BPs drugs.
C1 [Peng, Ying; Liu, Qingzhu; Xu, Dong; Li, Ke; Li, Hang; Qiu, Ling; Lin, Jianguo] Jiangsu Inst Nucl Med, NHC Key Lab Nucl Med, Jiangsu Key Lab Mol Nucl Med, Wuxi 214063, Jiangsu, Peoples R China.
   [Peng, Ying; Lin, Jianguo] Nanjing Med Univ, Sch Pharm, Dept Radiopharmaceut, Nanjing, Jiangsu, Peoples R China.
   [Li, Hang; Qiu, Ling] Jiangnan Univ, Sch Chem & Mat Engn, Wuxi, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Jiangnan University
RP Qiu, L; Lin, JG (通讯作者)，Jiangsu Inst Nucl Med, NHC Key Lab Nucl Med, Jiangsu Key Lab Mol Nucl Med, Wuxi 214063, Jiangsu, Peoples R China.
EM qiuling@jsinm.org; qiuling@jsinm.org
RI Peng, Ying/AHD 4440 2022
FU National Natural Science Foundation of China [81803586]; Jiangsu
   Provincial Medical Youth Talent [QNRC2016626, QNRC2016629]; 333 Project
   of Jiangsu Province [LGY2018086]
FX National Natural Science Foundation of China, Grant/Award Number:
   81803586; Jiangsu Provincial Medical Youth Talent, Grant/Award Numbers:
   QNRC2016626, QNRC2016629; 333 Project of Jiangsu Province, Grant/Award
   Number: LGY2018086
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Baykan EK, 2014, OSTEOPOROSIS INT, V25, P2221, DOI 10.1007/s00198 014 2752 z
   Boudot C, 2010, BONE, V46, P1416, DOI 10.1016/j.bone.2010.01.383
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   Gough A, 1998, J RHEUMATOL, V25, P1282
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Henneman ZJ, 2008, J BIOMED MATER RES A, V85A, P993, DOI 10.1002/jbm.a.31599
   Hoefert S, 2016, CLIN ORAL INVEST, V20, P1043, DOI 10.1007/s00784 015 1584 3
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Ikeda F, 2008, J BONE MINER RES, V23, P907, DOI 10.1359/JBMR.080211
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Knowles HJ, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00080
   Kong XY, 2015, J TRANSL MED, V13, DOI 10.1186/s12967 015 0440 1
   Krzeszinski JY, 2015, TRENDS PHARMACOL SCI, V36, P360, DOI [10.1016/J.tips.2015.04.006, 10.1016/j.tips.2015.04.006]
   Lawson MA, 2017, J BONE MINER RES, V32, P1860, DOI 10.1002/jbmr.3138
   Lee CYS, 2015, IMPLANT DENT, V24, P227, DOI 10.1097/ID.0000000000000227
   Li BJ, 2011, J CELL BIOCHEM, V112, P1229, DOI 10.1002/jcb.23049
   Lin JG, 2012, APPL RADIAT ISOTOPES, V70, P848, DOI 10.1016/j.apradiso.2011.12.019
   Lin JG, 2011, NUCL MED BIOL, V38, P619, DOI 10.1016/j.nucmedbio.2010.12.005
   Liu QZ, 2018, CHEM BIOL DRUG DES, V91, P735, DOI 10.1111/cbdd.13134
   Liu QZ, 2020, EUR J MED CHEM, V186, DOI 10.1016/j.ejmech.2019.111905
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Ohno K, 2011, CURR MED CHEM, V18, P220, DOI 10.2174/092986711794088335
   Pazianas M, 2011, JNCI J NATL CANCER I, V103, P232, DOI 10.1093/jnci/djq516
   Peng Y, 2017, LIFE SCI, V185, P63, DOI 10.1016/j.lfs.2017.07.024
   Polascik TJ, 2008, DRUG DES DEV THER, V3, P27
   Roelofs AJ, 2010, J BONE MINER RES, V25, P606, DOI 10.1359/jbmr.091009
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Ruza I, 2013, THER ADV MUSCULOSKEL, V5, P182, DOI 10.1177/1759720X13485829
   Schmidberger JW, 2015, ACTA CRYSTALLOGR D, V71, P721, DOI 10.1107/S1399004715001121
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Sun Y, 2015, J RECEPT SIG TRANSD, V35, P600, DOI 10.3109/10799893.2015.1030412
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2011, ANN NY ACAD SCI, V1240, P14, DOI 10.1111/j.1749 6632.2011.06283.x
   Touaitahuata Heiani, 2014, Small GTPases, V5, pe28119, DOI 10.4161/sgtp.28119
   Tsubaki M, 2013, BIOCHEM PHARMACOL, V85, P163, DOI 10.1016/j.bcp.2012.10.009
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   van Beek ER, 1998, BONE, V23, P437, DOI 10.1016/S8756 3282(98)00120 3
   Wagner EF, 2001, CURR OPIN GENET DEV, V11, P527, DOI 10.1016/S0959 437X(00)00228 8
   Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i
   Wiemer AJ, 2011, CLIN PHARMACOL THER, V90, P804, DOI 10.1038/clpt.2011.215
   Xu XJ, 2017, J HUM GENET, V62, P205, DOI 10.1038/jhg.2016.109
   Zgani I, 2004, J MED CHEM, V47, P4600, DOI 10.1021/jm049861z
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
NR 51
TC 3
Z9 4
U1 1
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1065 6995
EI 1095 8355
J9 CELL BIOL INT
JI Cell Biol. Int.
PD MAY
PY 2021
VL 45
IS 5
BP 1015
EP 1029
DI 10.1002/cbin.11546
EA JAN 2021
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA RN4DL
UT WOS:000609303000001
PM 33404170
DA 2025 08 17
ER

PT J
AU Zhu, MP
   Guo, Q
   Kang, HL
   Peng, RP
   Dong, YM
   Zhang, YY
   Wang, SB
   Liu, HY
   Zhao, HJ
   Dong, ZJ
   Song, KH
   Xu, SM
   Wang, PJ
   Chen, LX
   Liu, J
   Li, F
AF Zhu, Meipeng
   Guo, Qian
   Kang, Honglei
   Peng, Renpeng
   Dong, Yimin
   Zhang, Yayun
   Wang, Sibo
   Liu, Haiyang
   Zhao, Hongjian
   Dong, Zijian
   Song, Kehan
   Xu, Shimeng
   Wang, Pengju
   Chen, Liangxi
   Liu, Jian
   Li, Feng
TI Inhibition of FAAH suppresses RANKL induced osteoclastogenesis and
   attenuates ovariectomy induced bone loss partially through repressing
   the IL17 pathway
SO FASEB JOURNAL
LA English
DT Article
DE fatty amide hydrolase (FAAH); IL17; MAPK; NF kappa B; osteoclast;
   osteoporosis; PF 04457845
ID ACID AMIDE HYDROLASE; NF KAPPA B; ENDOCANNABINOID SYSTEM; IL 17
   RECEPTOR; RAT MODEL; DIFFERENTIATION; ACTIVATION; EXPRESSION;
   OSTEOPOROSIS; CELLS
AB Fatty amide hydrolase (FAAH) is a key degradation enzyme of the endocannabinoid system, mainly responsible for the hydrolysis of arachidonic acid ethanolamine (AEA). Previous investigations have shown that FAAH is involved in a series of biological processes, such as inflammation, immune regulation, and transmembrane signal transduction of neurons. Endogenous cannabinoids and cannabinoid receptors have been reported to participate in the regulation of bone homeostasis by regulating the differentiation of osteoblasts and osteoclasts. We hypothesized that FAAH may play an important role in osteoclastogenesis based on the above evidence. The present study found that the FAAH expression was increased at both mRNA and protein levels during RANKL induced osteoclastogenesis. Pharmacological and genetic inhibition of FAAH in bone marrow derived macrophages (BMMs) inhibited osteoclastogenesis, F actin ring formation, bone resorption, and osteoclast specific gene expression in vitro. Moreover, intragastric administration of the FAAH inhibitor PF 04457845(PF) ameliorated ovariectomy (OVX) induced bone loss in mice. Further investigation revealed that nuclear factor kappa B (NF kappa B) and mitogen activated protein kinase (MAPK) pathways were inhibited by PF treatment and FAAH knockdown. RNAseq indicated that the IL17 pathway was blocked by PF, and administration of recombinant murine IL17 protein could partially restore osteoclastogenesis and activate NF kappa B and MAPK pathways. To sum up, our findings demonstrate that targeting FAAH could be a promising candidate strategy for treating osteoclast related diseases, especially osteoporosis.
C1 [Zhu, Meipeng; Guo, Qian; Kang, Honglei; Peng, Renpeng; Dong, Yimin; Zhang, Yayun; Wang, Sibo; Liu, Haiyang; Zhao, Hongjian; Dong, Zijian; Song, Kehan; Xu, Shimeng; Wang, Pengju; Chen, Liangxi; Liu, Jian; Li, Feng] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Orthoped, Wuhan, Peoples R China.
   [Liu, Jian; Li, Feng] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Orthoped, Wuhan 430030, Hubei, Peoples R China.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology
RP Liu, J; Li, F (通讯作者)，Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Orthoped, Wuhan 430030, Hubei, Peoples R China.
EM jianliu1986@hust.edu.cn; lifengmd@hust.edu.cn
RI Guo, Qian/NPI 7671 2025; Wang, Sibo/HGD 1894 2022; pengju,
   wang/AAB 9642 2021
OI Li, Feng/0000 0002 7961 3728
FU National Natural Science Foundation of China; Wuhan Huanghe Talents
   Program; Hubei Province Key Research and Development Program; 
   [82072500];  [81874024];  [31800059];  [HHYC 201601];  [2020BCB049]
FX ACKNOWLEDGMENTS This work was funded by the National Natural Science
   Foundation of China (Grant no. 82072500, 81874024, 31800059), Wuhan
   Huanghe Talents Program (Grant no. HHYC 201601), and the Hubei Province
   Key Research and Development Program (Grant no. 2020BCB049).
CR Ahn K, 2011, J PHARMACOL EXP THER, V338, P114, DOI 10.1124/jpet.111.180257
   Amatya N, 2017, TRENDS IMMUNOL, V38, P310, DOI 10.1016/j.it.2017.01.006
   Amin A, 2021, IMMUNOBIOLOGY, V226, DOI 10.1016/j.imbio.2020.152045
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bab I, 2009, ANN MED, V41, P560, DOI 10.1080/07853890903121025
   Bortolato M, 2007, BIOL PSYCHIAT, V62, P1103, DOI 10.1016/j.biopsych.2006.12.001
   Cao HL, 2010, J CLIN INVEST, V120, P2755, DOI 10.1172/JCI42106
   Cencioni MT, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008688
   Chiang KP, 2004, HUM MOL GENET, V13, P2113, DOI 10.1093/hmg/ddh216
   Chiurchiù V, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11040502
   Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698
   Cravatt BF, 2003, CURR OPIN CHEM BIOL, V7, P469, DOI 10.1016/S1367 5931(03)00079 6
   Delaissé JM, 2003, MICROSC RES TECHNIQ, V61, P504, DOI 10.1002/jemt.10374
   DeSelm CJ, 2012, J CELL BIOCHEM, V113, P2895, DOI 10.1002/jcb.24165
   Guedes MCE, 2016, INDIAN J OPHTHALMOL, V64, P628, DOI 10.4103/0301 4738.194339
   Fabre JAS, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123880
   Gao B, 2013, BONE RES, V1, DOI 10.4248/BR201302006
   Geng DC, 2010, BIOMATERIALS, V31, P1996, DOI 10.1016/j.biomaterials.2009.11.069
   Grillo A, 2021, ACS CHEM NEUROSCI, V12, P1716, DOI 10.1021/acschemneuro.1c00192
   Guan HF, 2015, FASEB J, V29, P1092, DOI 10.1096/fj.14 262055
   Hagino H, 2021, OSTEOPOROSIS INT, V32, P2301, DOI 10.1007/s00198 021 05996 2
   Hariri AR, 2009, BIOL PSYCHIAT, V66, P9, DOI 10.1016/j.biopsych.2008.10.047
   Hill MN, 2010, J NEUROSCI, V30, P14980, DOI 10.1523/JNEUROSCI.4283 10.2010
   Idris AI, 2008, ENDOCRINOLOGY, V149, P5619, DOI 10.1210/en.2008 0150
   Idris Aymen I, 2012, Front Endocrinol (Lausanne), V3, P136, DOI 10.3389/fendo.2012.00136
   Idris AI, 2008, DRUG NEWS PERSPECT, V21, P533, DOI 10.1358/dnp.2008.21.10.1314055
   Idris AI, 2009, CELL METAB, V10, P139, DOI 10.1016/j.cmet.2009.07.006
   Jackson AR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093954
   Johnson DS, 2011, ACS MED CHEM LETT, V2, P91, DOI 10.1021/ml100190t
   Kameo Y, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax0938
   Kanakaris Nikolaos K, 2009, Injury, V40 Suppl 3, pS21, DOI 10.1016/S0020 1383(09)70007 5
   Kang HL, 2022, FASEB J, V36, DOI 10.1096/fj.202101205RR
   Kang L, 2008, PLANT J, V56, P336, DOI 10.1111/j.1365 313X.2008.03603.x
   Karsak M, 2005, HUM MOL GENET, V14, P3389, DOI 10.1093/hmg/ddi370
   Karsak M, 2007, SCIENCE, V316, P1494, DOI 10.1126/science.1142265
   Kearns Donovan G, 2021, J Clin Aesthet Dermatol, V14, P55
   Keupp K, 2013, AM J HUM GENET, V92, P565, DOI 10.1016/j.ajhg.2013.02.010
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Leutner M, 2019, ANN RHEUM DIS, V78, P1706, DOI 10.1136/annrheumdis 2019 215714
   Li CJ, 2018, J CLIN INVEST, V128, P5251, DOI 10.1172/JCI99044
   Li GL, 2012, BRIT J CLIN PHARMACO, V73, P706, DOI 10.1111/j.1365 2125.2011.04137.x
   Li JY, 2016, J CLIN INVEST, V126, P2049, DOI 10.1172/JCI86062
   Li XX, 2019, NAT IMMUNOL, V20, P1594, DOI 10.1038/s41590 019 0514 y
   Lunn CA, 2007, IMMUNOPHARM IMMUNOT, V29, P387, DOI 10.1080/08923970701674997
   Marazzi J, 2011, J IMMUNOL METHODS, V373, P219, DOI 10.1016/j.jim.2011.08.021
   Miossec P, 2012, NAT REV DRUG DISCOV, V11, P763, DOI 10.1038/nrd3794
   Mizoguchi T, 2009, J CELL BIOL, V184, P541, DOI 10.1083/jcb.200806139
   Monaco C, 2004, P NATL ACAD SCI USA, V101, P5634, DOI 10.1073/pnas.0401060101
   Naderi N, 2008, J NEURAL TRANSM, V115, P1501, DOI 10.1007/s00702 008 0076 x
   Nakamura Y, 2017, BONE RES, V5, DOI 10.1038/boneres.2016.55
   Nasirinezhad F, 2015, NEUROPHARMACOLOGY, V95, P100, DOI 10.1016/j.neuropharm.2014.11.024
   Nesmond S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02107
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2
   Piomelli D, 2006, CNS DRUG REV, V12, P21, DOI 10.1111/j.1527 3458.2006.00021.x
   Pisani P, 2016, WORLD J ORTHOP, V7, P171, DOI 10.5312/wjo.v7.i3.171
   Rackov G, 2016, J CLIN INVEST, V126, P3089, DOI 10.1172/JCI83404
   Richardson D, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2401
   Robert M, 2017, AUTOIMMUN REV, V16, P984, DOI 10.1016/j.autrev.2017.07.009
   Ross RA, 2009, TRENDS PHARMACOL SCI, V30, P156, DOI 10.1016/j.tips.2008.12.004
   Rossi F, 2009, BONE, V44, P476, DOI 10.1016/j.bone.2008.10.056
   Ruiz Pérez G, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974 021 02276 y
   Sankar U, 2004, J BONE MINER RES, V19, P1339, DOI 10.1359/JBMR.040321
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Sexton M, 2014, INFLAMMOPHARMACOLOGY, V22, P295, DOI 10.1007/s10787 014 0214 z
   Shen F, 2008, CYTOKINE, V41, P92, DOI 10.1016/j.cyto.2007.11.013
   Sido JM, 2015, INT REV IMMUNOL, V34, P403, DOI 10.3109/08830185.2014.921165
   Smoum R, 2015, P NATL ACAD SCI USA, V112, P8774, DOI 10.1073/pnas.1503395112
   Smoum R, 2010, P NATL ACAD SCI USA, V107, P17710, DOI 10.1073/pnas.0912479107
   Song L, 2019, MOL MED REP, V19, P4743, DOI 10.3892/mmr.2019.10155
   Sophocleous A, 2011, ENDOCRINOLOGY, V152, P2141, DOI 10.1210/en.2010 0930
   Tam J, 2008, FASEB J, V22, P285, DOI 10.1096/fj.06 7957com
   Tam J, 2006, MOL PHARMACOL, V70, P786, DOI 10.1124/mol.106.026435
   Tyagi AM, 2014, J BONE MINER RES, V29, P1981, DOI 10.1002/jbmr.2228
   van Egmond N, 2021, ANNU REV PHARMACOL, V61, P441, DOI 10.1146/annurev pharmtox 030220 112741
   Vazquez Roque MI, 2011, NEUROGASTROENT MOTIL, V23, P637, DOI 10.1111/j.1365 2982.2011.01711.x
   Wei W, 2010, CELL METAB, V11, P503, DOI 10.1016/j.cmet.2010.04.015
   Wen HT, 2010, J EXP MED, V207, P2943, DOI 10.1084/jem.20101138
   Whyte LS, 2012, BRIT J PHARMACOL, V165, P2584, DOI 10.1111/j.1476 5381.2011.01519.x
   Wu F, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/8494079
   Xiao E, 2017, CELL HOST MICROBE, V22, P120, DOI 10.1016/j.chom.2017.06.014
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Zaitone SA, 2012, BEHAV PHARMACOL, V23, P417, DOI 10.1097/FBP.0b013e3283566065
   Zeytinoglu M, 2021, ENDOCRIN METAB CLIN, V50, P205, DOI 10.1016/j.ecl.2021.03.004
   Zhang C, 2015, OSTEOPOROSIS INT, V26, P2803, DOI 10.1007/s00198 015 3195 x
   Zhu MP, 2020, BIOMED PHARMACOTHER, V123, DOI 10.1016/j.biopha.2019.109769
   Zrioual S, 2008, J IMMUNOL, V180, P655, DOI 10.4049/jimmunol.180.1.655
NR 88
TC 7
Z9 7
U1 1
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD JAN
PY 2023
VL 37
IS 1
AR e22690
DI 10.1096/fj.202200911R
PG 22
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA 6X6PH
UT WOS:000896533000001
PM 36468880
OA hybrid
DA 2025 08 17
ER

PT J
AU Juzeniene, A
   Stenberg, VY
   Bruland, OS
   Revheim, ME
   Larsen, RH
AF Juzeniene, Asta
   Stenberg, Vilde Yuli
   Bruland, Oyvind Sverre
   Revheim, Mona Elisabeth
   Larsen, Roy Hartvig
TI Dual targeting with <SUP>224</SUP>Ra/<SUP>212</SUP>Pb conjugates for
   targeted alpha therapy of disseminated cancers: A conceptual approach
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE cancer; lead 212; radiopharmaceutical; radium 224; radium 223; targeted
   radionuclide therapy (TRT); targeted alpha particle therapy (TAT)
ID BONE SEEKING; ANKYLOSING SPONDYLITIS; SKELETAL METASTASES; RADIUM 223
   DICHLORIDE; PROSTATE CANCER; DOSIMETRY; SURVIVAL; RA 223; RISK;
   DENOSUMAB
AB Metastases are the primary cause of death among cancer patients and efficacious new treatments are sorely needed. Targeted alpha emitting radiopharmaceuticals that are highly cytotoxic may fulfill this critical need. The focus of this paper is to describe and explore a novel technology that may improve the therapeutic effect of targeted alpha therapy by combining two radionuclides from the same decay chain in the same solution. We hypothesize that the dual targeting solution containing bone seeking Ra 224 and cell directed complexes of progeny Pb 212 is a promising approach to treat metastatic cancers with bone and soft tissue lesions as well as skeletal metastases of mixed lytic/osteoblastic nature. A novel liquid Ra 224/Pb 212 generator for rapid preparation of a dual targeting solution is described. Cancer cell targeting monoclonal antibodies, their fragments, synthetic proteins or peptides can all be radiolabeled with Pb 212 in the Ra 224 solution in transient equilibrium with daughter nuclides. Thus, Ra 224 targets stromal elements in sclerotic bone metastases and Pb 212 chelated conjugate targets tumor cells of metastatic prostate cancer or osteosarcoma. The dual targeting solution may also be explored to treat metastatic breast cancer or multiple myeloma after manipulation of bone metastases to a more osteoblastic phenotype by the use of bisphosphonates, denosumab, bortezomib or hormone therapy prior to treatment. This may improve targeting of bone seeking Ra 224 and render an augmented radiation dose deposited within metastases. Our preliminary preclinical studies provide conceptual evidence that the dual Ra 224 solution with bone or tumor targeted delivery of Pb 212 has potential to inhibit cancer metastases without significant toxicity. In some settings, the use of a booster dose of purified Pb 212 conjugate alone could be required to elevate the effect of this tumor cell directed component, if needed, e.g., in a fractionated treatment regimen, where the dual targeting solution will act as maintenance treatment.
C1 [Juzeniene, Asta; Stenberg, Vilde Yuli] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Radiat Biol, Oslo, Norway.
   [Juzeniene, Asta] Univ Oslo, Dept Phys, Oslo, Norway.
   [Stenberg, Vilde Yuli; Bruland, Oyvind Sverre; Revheim, Mona Elisabeth] Univ Oslo, Inst Clin Med, Oslo, Norway.
   [Stenberg, Vilde Yuli; Larsen, Roy Hartvig] ARTBIO, Oslo, Norway.
   [Bruland, Oyvind Sverre] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Oncol, Oslo, Norway.
   [Revheim, Mona Elisabeth] Oslo Univ Hosp, Div Radiol & Nucl Med, Oslo, Norway.
C3 University of Oslo; University of Oslo; University of Oslo; University
   of Oslo; University of Oslo
RP Juzeniene, A (通讯作者)，Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Radiat Biol, Oslo, Norway.; Juzeniene, A (通讯作者)，Univ Oslo, Dept Phys, Oslo, Norway.
EM astaj@rr research.no
FU Norwegian Research Council
FX Funding This research was funded by the Norwegian Research Council and
   Artbio AS [Industrial Ph.D. project number 260639 (Vilde Stenberg),
   Oslo, Norway], and the South Eastern Norway Regional Health Authority
   (project number 2020028, Oslo, Norway).
CR Abou DS, 2021, J NUCL MED, V62, P1751, DOI 10.2967/jnumed.121.261977
   Abou DS, 2021, CHEM SCI, V12, P3733, DOI 10.1039/d0sc06867e
   Aicher A, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14071466
   Altunay B, 2022, SEMIN NUCL MED, V52, P561, DOI 10.1053/j.semnuclmed.2022.04.003
   Arazi L, 2020, PHYS MED BIOL, V65, DOI 10.1088/1361 6560/ab5b73
   Badila AE, 2021, CANCERS, V13, DOI 10.3390/cancers13164229
   Bellia SR, 2019, J CONTEMP BRACHYTHER, V11, P449, DOI 10.5114/jcb.2019.88138
   Brechbiel MW, 2007, DALTON T, P4918, DOI 10.1039/b704726f
   Brozovich A, 2021, J BONE ONCOL, V31, DOI 10.1016/j.jbo.2021.100399
   Bruland OS, 2006, CLIN CANCER RES, V12, p6250S, DOI 10.1158/1078 0432.CCR 06 0841
   Bruland Oyvind S., 2008, P181, DOI 10.1007/978 1 4020 8696 0_10
   Carlsson J, 2013, ONCOL LETT, V5, P208, DOI 10.3892/ol.2012.996
   Coleman R, 2020, ANN ONCOL, V31, P1650, DOI 10.1016/j.annonc.2020.07.019
   Coleman R, 2014, BREAST CANCER RES TR, V145, P411, DOI 10.1007/s10549 014 2939 1
   Dahle J, 2008, CURR RADIOPHARM, V1, P209, DOI 10.2174/1874471010801030209
   Damiana TST, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13050674
   Day KC, 2017, CANCER RES, V77, P74, DOI 10.1158/0008 5472.CAN 16 1656
   Delpassand ES, 2022, J NUCL MED, V63, P1326, DOI 10.2967/jnumed.121.263230
   Dillekås H, 2019, CANCER MED US, V8, P5574, DOI 10.1002/cam4.2474
   Eda Homare, 2016, Cancer Treat Res, V169, P251
   Feliciani G, 2022, CANCERS, V14, DOI 10.3390/cancers14010240
   Frantellizzi V, 2020, CANCER BIOTHER RADIO, V35, P437, DOI 10.1089/cbr.2019.3105
   Gafita Andrei, 2022, Am Soc Clin Oncol Educ Book, V42, P1, DOI 10.1200/EDBK_350946
   Garcia Torralba E, 2021, CANCER TREAT REV, V94, DOI 10.1016/j.ctrv.2021.102168
   Gong LL, 2019, J BONE ONCOL, V19, DOI 10.1016/j.jbo.2019.100265
   Gott M, 2019, CHEM COMMUN, V55, P7631, DOI 10.1039/c9cc02587a
   Hagemann UB, 2020, CANCER BIOTHER RADIO, V35, P497, DOI 10.1089/cbr.2020.3568
   Hallqvist A, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9111570
   Hameed A, 2014, CANCER GROWTH METAST, V7, P33, DOI 10.4137/CGM.S16817
   Hanley DA, 2012, INT J CLIN PRACT, V66, P1139, DOI 10.1111/ijcp.12022
   Heider U, 2006, EUR J HAEMATOL, V77, P233, DOI 10.1111/j.1600 0609.2006.00692.x
   Hendriks LEL, 2016, J THORAC ONCOL, V11, P155, DOI 10.1016/j.jtho.2015.10.001
   Henriksen G, 2004, ANTICANCER RES, V24, P101
   Henriksen G, 2002, CANCER RES, V62, P3120
   Henriksen G, 2002, APPL RADIAT ISOTOPES, V56, P667, DOI 10.1016/S0969 8043(01)00282 2
   Herrmann K, 2020, LANCET ONCOL, V21, pE146, DOI 10.1016/S1470 2045(19)30821 6
   Huang JF, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.03.55
   Humm JL, 2015, INT J RADIAT ONCOL, V91, P898, DOI 10.1016/j.ijrobp.2014.12.061
   Jadvar H, 2021, EUR J NUCL MED MOL I, V49, P47, DOI 10.1007/s00259 021 05405 0
   Jiang W, 2018, NUCL MED BIOL, V62 63, P1, DOI 10.1016/j.nucmedbio.2018.05.003
   Juzeniene A, 2018, ANTICANCER RES, V38, P1947, DOI 10.21873/anticanres.12432
   Khreish F, 2020, EUR J NUCL MED MOL I, V47, P721, DOI 10.1007/s00259 019 04612 0
   Knapp BJ, 2022, J THORAC DIS, V14, P1696, DOI 10.21037/jtd 21 1502
   Kokov KV, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14010189
   Kratochwil C, 2016, J NUCL MED, V57, P1941, DOI 10.2967/jnumed.116.178673
   Larsen R., 2019, RADIOPHARMACEUTICAL
   Larsen RH, 2006, IN VIVO, V20, P325
   Lassmann M, 2002, RADIAT ENVIRON BIOPH, V41, P173, DOI 10.1007/s00411 002 0164 5
   Li RG, 2023, J NUCL MED, V64, P173, DOI 10.2967/jnumed.122.264009
   LLOYD RD, 1982, RADIAT RES, V92, P280, DOI 10.2307/3576005
   Lorusso Vito, 2012, Front Biosci (Schol Ed), V4, P31
   Ma J, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.796657
   Macedo F, 2017, ONCOL REV, V11, P43, DOI 10.4081/oncol.2017.321
   Maennling AE, 2019, CANCERS, V11, DOI 10.3390/cancers11121826
   Marcu L, 2018, CRIT REV ONCOL HEMAT, V123, P7, DOI 10.1016/j.critrevonc.2018.01.001
   Megyesfalvi Z, 2021, THORAC CANCER, V12, P914, DOI 10.1111/1759 7714.13854
   Meredith R, 2014, J NUCL MED, V55, P1636, DOI 10.2967/jnumed.114.143842
   Meredith RF, 2014, CANCER BIOTHER RADIO, V29, P12, DOI 10.1089/cbr.2013.1531
   Milenic DE, 2013, CANCER BIOTHER RADIO, V28, P441, DOI 10.1089/cbr.2012.1423
   Miyahira AK, 2022, J NUCL MED, V63, P331, DOI 10.2967/jnumed.121.262997
   Morgenstern A, 2020, SEMIN NUCL MED, V50, P119, DOI 10.1053/j.semnuclmed.2020.02.003
   Muggenburg BA, 1996, RADIAT RES, V146, P171, DOI 10.2307/3579589
   Napoli E, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248133
   Nekolla EA, 2000, RADIAT RES, V153, P93, DOI 10.1667/0033 7587(2000)153[0093:IOMBTI]2.0.CO;2
   Pandit Taskar N, 2014, J NUCL MED, V55, P268, DOI 10.2967/jnumed.112.112482
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Pouget JP, 2021, FRONT MED LAUSANNE, V8, DOI 10.3389/fmed.2021.692436
   Priest ND, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232597
   Reissig F, 2022, NUKLEARMED NUCL MED, V61, P325, DOI 10.1055/a 1759 1749
   Robertson AKH, 2018, CURR RADIOPHARM, V11, P156, DOI 10.2174/1874471011666180416161908
   Rosar F, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13050722
   Rosar F, 2021, THERANOSTICS, V11, P4050, DOI 10.7150/thno.56211
   Roudier MP, 2008, J UROLOGY, V180, P1154, DOI 10.1016/j.juro.2008.04.140
   Ruigrok EAM, 2022, EUR J NUCL MED MOL I, V49, P3627, DOI 10.1007/s00259 022 05821 w
   Sartor O, 2021, NEW ENGL J MED, V385, P1091, DOI 10.1056/NEJMoa2107322
   Sartor O, 2013, CANCER TREAT REV, V39, P18, DOI 10.1016/j.ctrv.2012.03.006
   Schumann S, 2018, EJNMMI RES, V8, DOI 10.1186/s13550 018 0422 4
   Sharma R, 2023, INT J RADIAT ONCOL, V115, P419, DOI 10.1016/j.ijrobp.2022.07.029
   Sheng GH, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.780264
   Solnes LB, 2021, SEMIN RADIAT ONCOL, V31, P83, DOI 10.1016/j.semradonc.2020.07.010
   Stenberg VY, 2020, CURR RADIOPHARM, V13, P130, DOI 10.2174/1874471013666200511000532
   Stenberg VY, 2022, CANCERS, V14, DOI 10.3390/cancers14112784
   Stenberg VY, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094815
   Stenberg VY, 2020, J LABELLED COMPD RAD, V63, P129, DOI 10.1002/jlcr.3825
   Suominen MI, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115570
   Suominen MI, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163899
   Suominen MI, 2013, JNCI J NATL CANCER I, V105, P908, DOI 10.1093/jnci/djt116
   Tagawa ST, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.5015
   Takalkar A, 2014, EXP HEMATOL ONCOL, V3, DOI 10.1186/2162 3619 3 23
   Thiele NA, 2018, CANCER BIOTHER RADIO, V33, P336, DOI 10.1089/cbr.2018.2494
   Tomblyn M, 2012, CANCER CONTROL, V19, P137, DOI 10.1177/107327481201900208
   Washiyama K, 2004, NUCL MED BIOL, V31, P901, DOI 10.1016/j.nucmedbio.2004.05.001
   Westrom S, 2017, NUCL MED BIOL, V51, P1, DOI 10.1016/j.nucmedbio.2017.04.005
   Wick RR, 2008, RHEUMATOLOGY, V47, P855, DOI 10.1093/rheumatology/ken060
   Wick RR, 1999, RADIAT RES, V152, pS8, DOI 10.2307/3580103
   Winter M, 2022, J BONE ONCOL, V35, DOI 10.1016/j.jbo.2022.100442
   Woodward E, 2011, BONE, V48, P160, DOI 10.1016/j.bone.2010.09.008
   Yordanova A, 2021, PHARMACEUTICALS BASE, V14, DOI 10.3390/ph14101005
   Zhang JJ, 2021, CLIN NUCL MED, V46, P1030, DOI 10.1097/RLU.0000000000003792
NR 99
TC 9
Z9 9
U1 4
U2 28
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 2296 858X
J9 FRONT MED LAUSANNE
JI Front. Med.
PD JAN 17
PY 2023
VL 9
AR 1051825
DI 10.3389/fmed.2022.1051825
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 8F1KP
UT WOS:000919427600001
PM 36733936
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kampfenkel, T
   Baraniskin, A
   Teschendorf, C
   Schmiegel, W
   Massenkeil, G
AF Kampfenkel, T.
   Baraniskin, A.
   Teschendorf, C.
   Schmiegel, W.
   Massenkeil, G.
TI A Rare Case of Chronic Lymphocytic Leukemia with Hypercalcemia Induced
   by Elevated Parathyroid Hormone Related Peptides
SO ACTA HAEMATOLOGICA
LA English
DT Article
DE Chronic lymphocytic leukemia; Hypercalcemia; Lymphoma; Malignancy;
   Parathyroid hormone related peptide
ID RESORPTION IN VITRO; PROTEIN PTHRP; MALIGNANCY; BONE; LYMPHOMA; DISEASE;
   VIVO
AB Hypercalcemia in malignancies is a frequent complication, mostly affecting patients with solid tumors or multiple myeloma. Calcium elevation is induced by direct bone infiltration of a tumor mass or through calcium liberation from the skeleton by a humoral mediator. The latter mechanism is referred to as humoral hypercalcemia of malignancy (HHM). Frequent mediators of HHM are parathyroid hormone related peptides (PTHrP). We report a patient with chronic lymphocytic leukemia and hypercalcemia induced by PTHrP. In contrast to solid tumors and myeloma, PTHrP induced HHM is very rare in low grad lymphoma including chronic lymphocytic leukemia. Therapeutical approaches consist of cytoreductive treatment and calcium lowering therapy with bisphosphonates. Copyright (C) 2010 S. Karger AG, Basel
C1 [Kampfenkel, T.; Baraniskin, A.; Teschendorf, C.; Schmiegel, W.; Massenkeil, G.] Ruhr Univ Bochum, Knappschaftskrankenhaus, Dept Internal Med, DE 44892 Bochum, Germany.
   [Massenkeil, G.] Hosp Guetersloh, Bochum, Germany.
C3 Ruhr University Bochum
RP Kampfenkel, T (通讯作者)，Ruhr Univ Bochum, Med Univ Klin, Knappschaftskrankenhaus Bochum Langendreer, Schornau 23 25, DE 44892 Bochum, Germany.
EM tobias.kampfenkel@rub.de
CR Beaudreuil J, 1997, CANCER AM CANCER SOC, V79, P1211, DOI 10.1002/(SICI)1097 0142(19970315)79:6<1211::AID CNCR21>3.0.CO;2 1
   Clines GA, 2005, ENDOCR RELAT CANCER, V12, P549, DOI 10.1677/erc.1.00543
   DAVIES SV, 1993, J CLIN PATHOL, V46, P188, DOI 10.1136/jcp.46.2.188 b
   FAIN O, 1994, BRIT J HAEMATOL, V87, P856, DOI 10.1111/j.1365 2141.1994.tb06752.x
   FIRKIN F, 1996, BRIT J HAEMATOL, V94, P468
   FUKUMOTO S, 1988, ARCH INTERN MED, V148, P921, DOI 10.1001/archinte.148.4.921
   Grill V, 2000, Rev Endocr Metab Disord, V1, P253, DOI 10.1023/A:1026597816193
   GUISE TA, 1993, J CLIN ENDOCR METAB, V77, P40, DOI 10.1210/jc.77.1.40
   LEMER D, 1994, LEUKEMIA LYMPHOMA, V12, P231
   Majumdar G, 2002, J CLIN PATHOL, V55, P637, DOI 10.1136/jcp.55.8.637 a
   Minina E, 2001, DEVELOPMENT, V128, P4523
   Mundy GR, 1997, AM J MED, V103, P134, DOI 10.1016/S0002 9343(97)80047 2
   Rankin W, 1997, CANCER, V80, P1564, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1564::AID CNCR6>3.3.CO;2 H
   Sato K, 2003, SEMIN ONCOL, V30, P167, DOI 10.1053/j.seminoncol.2003.08.019
   SATO K, 1989, ENDOCRINOLOGY, V124, P2172, DOI 10.1210/endo 124 5 2172
   SCHILLING T, 1993, J CLIN ENDOCR METAB, V76, P801, DOI 10.1210/jc.76.3.801
   Schoevaerdts D, 1999, ACTA CLIN BELG, V54, P217, DOI 10.1080/17843286.1999.11754235
   Schottker Bjorn, 2006, Haematologica, V91, pECR45
   SEYMOUR JF, 1993, BLOOD, V82, P1383
   SEYMOUR JF, 1995, BRIT J HAEMATOL, V89, P685, DOI 10.1111/j.1365 2141.1995.tb08394.x
   SOUTHBY J, 1990, CANCER RES, V50, P7710
   VASSILOPOULOUSE.R, 1991, P AN M AM SOC CLIN, V10, P131
   Vlasveld LT, 1999, NETH J MED, V54, P21, DOI 10.1016/S0300 2977(98)00099 0
   WATANABE T, 1993, BLOOD, V81, P1017
   Wysolmerski JJ, 1998, DEVELOPMENT, V125, P1285
   WYSOLMERSKI JJ, 1994, P NATL ACAD SCI USA, V91, P1133, DOI 10.1073/pnas.91.3.1133
NR 26
TC 7
Z9 8
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 0001 5792
J9 ACTA HAEMATOL BASEL
JI Acta Haematol.
PY 2010
VL 124
IS 1
BP 57
EP 60
DI 10.1159/000314646
PG 4
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 632XA
UT WOS:000280461600013
PM 20616540
DA 2025 08 17
ER

PT J
AU Mäkitie, RE
   Niinimäki, T
   Nieminen, MT
   Schalin Jäntti, C
   Niinimäki, J
   Mäkitie, O
AF Makitie, Riikka E.
   Niinimaki, Tuukka
   Nieminen, Miika T.
   Schalin Jantti, Camilla
   Niinimaki, Jaakko
   Makitie, Outi
TI Impaired WNT signaling and the spine Heterozygous WNT1 mutation
   causes severe age related spinal pathology
SO BONE
LA English
DT Article
DE WNT signaling; Magnetic resonance imaging; Vertebral compression
   fracture; Thoracic kyphosis; Schmorl node; Intervertebral disc
ID DEFORMITY INDEX SDI; DIFFERENTIATED OSTEOBLASTS; VERTEBRAL FRACTURE;
   SCHMORLS NODES; BONE DENSITY; LRP5; OSTEOPOROSIS; GENE; ASSOCIATION;
   PROGENITORS
AB Background: WNT signaling plays a major role in bone and cartilage metabolism. Impaired WNT/beta catenin signaling leads to early onset osteoporosis, but specific features in bone and other tissues remain inadequately characterized. We have identified two large Finnish families with early onset osteoporosis due to a heterozygous WNT1 mutation c.652T>G, p.C218G. This study evaluated the impact of impaired WNT/beta catenin signaling on spinal structures.
   Methods: Altogether 18 WNT1 mutation positive (age range 11 76 years, median 49 years) and 14 mutation negative subjects (10 77 years, median 43 years) underwent magnetic resonance imaging (MRI) of the spine. The images were reviewed for spinal alignment, vertebral compression fractures, intervertebral disc changes and possible endplate deterioration. The findings were correlated with clinical data.
   Results: Vertebral compression fractures were present in 78% (7/9) of those aged over 50 years but were not seen in younger mutation positive subjects. All those with fractures had several severely compressed vertebrae. Altogether spinal compression fractures were present in 39% of those with a WNT1 mutation. Only 14% (2/14) mutation  negative subjects had one mild compressed vertebra each. The mutation positive subjects had a higher mean spinal deformity index (4.0 +/  7.3 vs 0.0 +/  0.4) and more often increased thoracic kyphosis (Z score > + 2.0 in 33% vs 0%). Further, they had more often Schmorl nodes (61% vs 36%), already in adolescence, and their intervertebral discs were enlarged.
   Conclusion: Compromised WNT signaling introduces severe and progressive changes to the spinal structures. Schmorl nodes are prevalent even at an early age and increased thoracic kyphosis and compression fractures become evident after the age of 50 years. Therapies targeting the WNT pathway may be an effective way to prevent spinal pathology not only in those harboring a mutation but also in the general population with similar pathology. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Makitie, Riikka E.; Makitie, Outi] Univ Helsinki, Folkhalsan Inst Genet, POB 63, FI 00290 Helsinki, Finland.
   [Niinimaki, Tuukka] Oulu Univ Hosp, Dept Orthoped, FI 90220 Oulu, Finland.
   [Nieminen, Miika T.] Oulu Univ Hosp, Dept Diagnost Radiol, Res Unit Med Imaging Phys & Technol, FI 90220 Oulu, Finland.
   [Nieminen, Miika T.] Univ Oulu, Med Res Ctr, FI 90220 Oulu, Finland.
   [Nieminen, Miika T.] Oulu Univ Hosp, FI 90220 Oulu, Finland.
   [Schalin Jantti, Camilla] Univ Helsinki, Endocrinol, Abdominal Ctr, FI 00290 Helsinki, Finland.
   [Schalin Jantti, Camilla; Makitie, Outi] Helsinki Univ Hosp, FI 00290 Helsinki, Finland.
   [Makitie, Outi] Univ Helsinki, Childrens Hosp, FI 00290 Helsinki, Finland.
   [Makitie, Outi] Karolinska Univ Hosp, Ctr Mol Med, Karolinska Inst, SE 17176 Stockholm, Sweden.
   [Makitie, Outi] Karolinska Univ Hosp, Clin Genet, SE 17176 Stockholm, Sweden.
C3 University of Helsinki; University of Oulu; University of Oulu;
   University of Oulu; University of Oulu; University of Helsinki;
   University of Helsinki; Helsinki University Central Hospital; University
   of Helsinki; Karolinska Institutet; Karolinska University Hospital;
   Karolinska Institutet; Karolinska University Hospital
RP Mäkitie, RE (通讯作者)，Univ Helsinki, Folkhalsan Inst Genet, POB 63, FI 00290 Helsinki, Finland.
EM riikka.makitie@helsinki.fi; tuukka.niinimaki@oulu.fi;
   miika.nieminen@oulu.fi; camilla.schalin jantti@hus.fi;
   jaakko.niinimaki@oulu.fi; outi.makitie@helsinki.fi
RI Niinimäki, Jaakko/O 2186 2014; Nieminen, Miika/G 7798 2012; Pedersen,
   Ole/F 2476 2011
OI , Tuukka/0000 0002 5155 9918; Nieminen, Miika/0000 0002 2300 2848;
   Schalin Jantti, Camilla/0000 0002 2428 0161; Niinimaki,
   Jaakko/0000 0002 5591 3726; Makitie, Riikka/0000 0002 2907 3348;
   Makitie, Outi/0000 0002 4547 001X
FU Sigrid Juselius Foundation; Folkhalsan Research Foundation; Academy of
   Finland [277843]; Foundation for Pediatric Research; Helsinki University
   Research Funds; Swedish Research Council [2013 2603]; Novo Nordisk
   Foundation; European Society for Paediatric Endocrinology Research Unit;
   Swedish Childhood Cancer Foundation; Stockholm County Council;
   Karolinska Institutet; Academy of Finland (AKA) [277843] Funding Source:
   Academy of Finland (AKA); Novo Nordisk Fonden [NNF16OC0021322] Funding
   Source: researchfish
FX This study was supported by the Sigrid Juselius Foundation, the
   Folkhalsan Research Foundation, the Academy of Finland (277843), the
   Foundation for Pediatric Research, the Helsinki University Research
   Funds, the Swedish Research Council (2013 2603), the Novo Nordisk
   Foundation, the European Society for Paediatric Endocrinology Research
   Unit, the Swedish Childhood Cancer Foundation, and through the regional
   agreement on medical training and clinical research (ALF) between
   Stockholm County Council and Karolinska Institutet. The funders had no
   role in design and conduct of the study; collection, management,
   analysis, and interpretation of the data; and preparation, review, or
   approval of the manuscript.
CR Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Cobb J R, 1948, Instr Course Lect AAOS, V5, P261
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   FON GT, 1980, AM J ROENTGENOL, V134, P979, DOI 10.2214/ajr.134.5.979
   GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Hartikka H, 2005, J BONE MINER RES, V20, P783, DOI 10.1359/JBMR.050101
   Hasserius R, 2005, CALCIFIED TISSUE INT, V76, P235, DOI 10.1007/s00223 004 2222 2
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Hirabayashi Y, 1996, BRIT J ANAESTH, V76, P508, DOI 10.1093/bja/76.4.508
   Kerkeni S, 2009, OSTEOPOROSIS INT, V20, P1547, DOI 10.1007/s00198 008 0832 7
   Keupp K, 2013, AM J HUM GENET, V92, P565, DOI 10.1016/j.ajhg.2013.02.010
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Laine CM, 2011, EUR J HUM GENET, V19, P875, DOI 10.1038/ejhg.2011.42
   Laine CM, 2013, NEW ENGL J MED, V368, P1809, DOI 10.1056/NEJMoa1215458
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Loots GG, 2005, GENOME RES, V15, P928, DOI 10.1101/gr.3437105
   Luyten FP, 2009, BONE, V44, P522, DOI 10.1016/j.bone.2008.12.006
   Mäkitie RE, 2016, J BONE MINER RES, V31, P1734, DOI 10.1002/jbmr.2841
   MINNE HW, 1988, BONE MINER, V3, P335
   Pyott SM, 2013, AM J HUM GENET, V92, P590, DOI 10.1016/j.ajhg.2013.02.009
   Regard JB., 2012, Cold Spring Harb Perspect Biol, V4
   Saarinen A, 2007, BONE, V40, P1006, DOI 10.1016/j.bone.2006.11.010
   Saarinen A, 2010, CLIN ENDOCRINOL, V72, P481, DOI 10.1111/j.1365 2265.2009.03680.x
   Samartzis D, 2016, OSTEOARTHR CARTILAGE, V24, P1753, DOI 10.1016/j.joca.2016.04.020
   Usami Y, 2016, LAB INVEST, V96, P186, DOI 10.1038/labinvest.2015.142
   van Meurs JBJ, 2008, JAMA J AM MED ASSOC, V299, P1277, DOI 10.1001/jama.299.11.1277
   Williams FMK, 2007, ARTHRIT RHEUM ARTHR, V57, P855, DOI 10.1002/art.22789
   Zheng HF, 2015, NATURE, V526, P112, DOI 10.1038/nature14878
NR 32
TC 25
Z9 25
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD AUG
PY 2017
VL 101
BP 3
EP 9
DI 10.1016/j.bone.2017.04.001
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA EY9LE
UT WOS:000404319300002
PM 28411110
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Couturier, A
   Keller, J
   Most, E
   Ringseis, R
   Eder, K
AF Couturier, Aline
   Keller, Janine
   Most, Erika
   Ringseis, Robert
   Eder, Klaus
TI Niacin in Pharmacological Doses Alters MicroRNA Expression in Skeletal
   Muscle of Obese Zucker Rats
SO PLOS ONE
LA English
DT Article
ID NICOTINIC ACID; GENE EXPRESSION; FATTY ACIDS; PLASMA; SUPPLEMENTATION;
   ADIPONECTIN; CHOLESTEROL; TRANSITION; MECHANISM; PGC 1
AB Administration of pharmacological niacin doses was recently reported to have pronounced effects on skeletal muscle gene expression and phenotype in obese Zucker rats, with the molecular mechanisms underlying the alteration of gene expression being completely unknown. Since miRNAs have been shown to play a critical role for gene expression through inducing miRNA mRNA interactions which results in the degradation of specific mRNAs or the repression of protein translation, we herein aimed to investigate the influence of niacin at pharmacological doses on the miRNA expression profile in skeletal muscle of obese Zucker rats fed either a control diet with 30 mg supplemented niacin/kg diet or a high niacin diet with 780 mg supplemented niacin/kg diet for 4 wk. miRNA microarray analysis revealed that 42 out of a total of 259 miRNAs were differentially expressed (adjusted P value <0.05), 20 being down regulated and 22 being up regulated, between the niacin group and the control group. Using a biostatistics approach, we could demonstrate that the most strongly up regulated (log2 ratio >= 0.5) and down regulated (log2 ratio <= 0.5) miRNAs target approximately 1,800 mRNAs. Gene term enrichment analysis showed that many of the predicted target mRNAs from the most strongly regulated miRNAs were involved in molecular processes dealing with gene transcription such as DNA binding, transcription regulator activity, transcription factor binding and in important regulatory pathways such as Wnt signaling and MAPK signaling. In conclusion, the present study shows for the first time that pharmacological niacin doses alter the expression of miRNAs in skeletal muscle of obese Zucker rats and that the niacin regulated miRNAs target a large set of genes and pathways which are involved in gene regulatory activity indicating that at least some of the recently reported effects of niacin on skeletal muscle gene expression and phenotype in obese Zucker rats are mediated through miRNA mRNA interactions.
C1 [Couturier, Aline; Keller, Janine; Most, Erika; Ringseis, Robert; Eder, Klaus] Univ Giessen, Inst Anim Nutr & Nutr Physiol, D 35390 Giessen, Germany.
C3 Justus Liebig University Giessen
RP Couturier, A (通讯作者)，Univ Giessen, Inst Anim Nutr & Nutr Physiol, D 35390 Giessen, Germany.
EM aline.couturier@ernaehrung.uni giessen.de
RI Ringseis, Robert/AAH 1509 2021
FU Deutsche Forschungsgemeinschaft (DFG)
FX JK is financed by the Deutsche Forschungsgemeinschaft (DFG). The funder
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Bao BL, 2010, J NUTR, V140, P1546, DOI 10.3945/jn.110.126359
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Benyó Z, 2005, J CLIN INVEST, V115, P3634, DOI 10.1172/JCI23626
   Carlson LA, 2005, J INTERN MED, V258, P94, DOI 10.1111/j.1365 2796.2005.01528.x
   CISTERNAS P, 2013, MOL NEUROBIOL
   DISHAO LY, 2010, MITOCHONDRION, V10, P516
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Ganji SH, 2003, J NUTR BIOCHEM, V14, P298, DOI 10.1016/S0955 2863(02)00284 X
   Garzon R, 2007, ONCOGENE, V26, P4148, DOI 10.1038/sj.onc.1210186
   Ge Q, 2012, ENDOCRINOLOGY, V153, P5285, DOI 10.1210/en.2012 1623
   Gille A, 2008, ANNU REV PHARMACOL, V48, P79, DOI 10.1146/annurev.pharmtox.48.113006.094746
   Guyton JR, 1998, AM J CARDIOL, V82, p18U, DOI 10.1016/S0002 9149(98)00767 X
   Hemandez C, 2010, CELL METAB, V12, P411, DOI 10.1016/j.cmet.2010.09.001
   Hu Y, 2012, J ANIM SCI BIOTECHNO, V3, DOI 10.1186/2049 1891 3 16
   Humphreys DT, 2005, P NATL ACAD SCI USA, V102, P16961, DOI 10.1073/pnas.0506482102
   Hutvágner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827
   JUFFER P, 2014, CELL BIOCH BIOPHYS
   Kamanna VS, 2008, AM J CARDIOL, V101, p20B, DOI 10.1016/j.amjcard.2008.02.029
   Karere GM, 2012, BMC GENOMICS, V13, DOI 10.1186/1471 2164 13 320
   Keller J, 2012, ANIMAL, V6, P70, DOI 10.1017/S1751731111001327
   Khan M, 2013, ACTA VET SCAND, V55, DOI 10.1186/1751 0147 55 85
   Kirkland JB, 2009, CURR PHARM DESIGN, V15, P3, DOI 10.2174/138161209787185823
   Knutti D, 2001, P NATL ACAD SCI USA, V98, P9713, DOI 10.1073/pnas.171184698
   Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   Kwiterovich PO, 1998, AM J CARDIOL, V82, p39U, DOI 10.1016/S0002 9149(98)00958 8
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li D, 2013, BRIT J NUTR, V110, P2156, DOI 10.1017/S0007114513001815
   Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004
   Liu M, 2012, J CHROMATOGR B, V904, P107, DOI 10.1016/j.jchromb.2012.07.030
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   National Research Council, 1985, GUIDE CARE USE LAB A
   Parra P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013005
   Peng XJ, 2010, J CELL BIOCHEM, V110, P1324, DOI 10.1002/jcb.22646
   Plaisance EP, 2008, METABOLISM, V57, P404, DOI 10.1016/j.metabol.2007.10.018
   Pohl J, 2002, J LIPID RES, V43, P1390, DOI 10.1194/jlr.M100404 JLR200
   QUABBE HJ, 1983, J CLIN ENDOCR METAB, V57, P410, DOI 10.1210/jcem 57 2 410
   Ring A, 2006, BBA MOL CELL BIOL L, V1761, P416, DOI 10.1016/j.bbalip.2006.03.016
   Ringseis R, 2013, J NUTR, V143, P125, DOI 10.3945/jn.112.164038
   Ritchie ME, 2007, BIOINFORMATICS, V23, P2700, DOI 10.1093/bioinformatics/btm412
   Roepstorff C, 2004, AM J PHYSIOL ENDOC M, V287, pE696, DOI 10.1152/ajpendo.00001.2004
   Lipszyc PS, 2013, OPEN CARDIOVASC MED, V7, P90, DOI 10.2174/1874192401307010090
   Scholz K, 2014, EUR J NUTR, V53, P1229, DOI 10.1007/s00394 013 0624 5
   Schuler M, 2006, CELL METAB, V4, P407, DOI 10.1016/j.cmet.2006.10.003
   Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514
   Terao M, 2011, J BIOL CHEM, V286, P4027, DOI 10.1074/jbc.M110.184994
   Wanders D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071285
   Wang WLW, 2011, MOL CANCER, V10, DOI 10.1186/1476 4598 10 58
   Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294
   Watt MJ, 2004, J MOL ENDOCRINOL, V33, P533, DOI 10.1677/jme.1.01499
   Weijts BGMW, 2012, EMBO J, V31, P3871, DOI 10.1038/emboj.2012.231
   Westphal S, 2007, ATHEROSCLEROSIS, V193, P361, DOI 10.1016/j.atherosclerosis.2006.06.028
   Wu BJ, 2010, ARTERIOSCL THROM VAS, V30, P968, DOI 10.1161/ATVBAHA.109.201129
NR 52
TC 12
Z9 13
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAY 21
PY 2014
VL 9
IS 5
AR e98313
DI 10.1371/journal.pone.0098313
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AI3AL
UT WOS:000336730600108
PM 24847987
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Liu, DC
   He, SH
   Chen, SX
   Yang, L
   Yang, JZ
   Bao, QW
   Qin, H
   Zhao, YF
   Zong, ZW
AF Liu, Daocheng
   He, Sihao
   Chen, Sixu
   Yang, Lei
   Yang, Jiazhi
   Bao, Quanwei
   Qin, Hao
   Zhao, Yufeng
   Zong, Zhaowen
TI Different effects of Wnt/β catenin activation and parathyroid hormone on
   diaphyseal and metaphyseal in the early phase of femur bone healing of
   mice
SO CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
LA English
DT Article
DE bone healing; diaphysis; metaphysis; parathyroid hormone; Wnt;
   beta catenin
ID FRACTURE REPAIR; BETA CATENIN; POSTMENOPAUSAL WOMEN; TRABECULAR BONE;
   DENOSUMAB; TERIPARATIDE; ALENDRONATE
AB Parathyroid hormone (PTH) and agents related to the manipulation of Wnt/beta catenin signalling are two promising anabolic anti osteoporotic therapies that have been shown to promote the healing of bone fractures. Now, it is widely accepted that cortical bone and trabecular bone are two different compartments, and should be treated as separate compartments in pathological processes, such as fracture healing. It is currently unknown whether PTH and the activation of beta catenin signalling would demonstrate different effects on cortical bone and trabecular bone healing. In the current study, single 0.6 mm cortex holes were made in the femur metaphysis and diaphysis of mice, and then, PTH application and beta catenin activation were used to observe the promoting effect on bone healing. The effects of beta catenin and PTH signalling on fracture healing were observed by X ray and CT at 3, 6, and 14 days after fracture, and the levels of beta catenin were detected by RT PCR assay, and the number of specific antigen positive cells of BRDU, OCN, RUNX2 was counted by immunohistochemical staining. While beta catenin activation and PTH were found to demonstrate similar effects on accelerating metaphyseal bone healing, activation of beta catenin showed a more striking effect than PTH on promoting diaphyseal bone healing. These findings might be helpful for selecting proper medication to accelerate fracture healing of different bone compartments.
C1 [Liu, Daocheng; He, Sihao; Chen, Sixu; Yang, Lei; Yang, Jiazhi; Bao, Quanwei; Qin, Hao; Zhao, Yufeng; Zong, Zhaowen] Army Med Univ, Base Army Hlth Serv Training, Dept War Wound Rescue Skills Training, State Key Lab Trauma Burn & Combined injury, Chongqing, Peoples R China.
C3 Army Medical University
RP Zong, ZW (通讯作者)，Army Med Univ, Base Army Hlth Serv Training, Dept War Wound Rescue Skills Training, Chongqing, Peoples R China.
EM zongzhaowen@tmmu.edu.cn
RI Yang, Jiazhi/G 3659 2013
CR Agholme F, 2014, J ORTHOP RES, V32, P471, DOI 10.1002/jor.22525
   Agholme F, 2011, BONE, V48, P988, DOI 10.1016/j.bone.2011.02.008
   Agholme F, 2010, J BONE MINER RES, V25, P2412, DOI 10.1002/jbmr.135
   Alzahrani MM, 2016, CLIN ORTHOP RELAT R, V474, P1294, DOI 10.1007/s11999 015 4640 z
   An G, 2017, ANN ANAT, V210, P76, DOI 10.1016/j.aanat.2016.11.009
   Aspenberg P, 2010, J BONE MINER RES, V25, P404, DOI 10.1359/jbmr.090731
   Bao QW, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02705 0
   Bao QW, 2017, EXP CELL RES, V350, P123, DOI 10.1016/j.yexcr.2016.11.013
   Bernhardsson M, 2018, ACTA ORTHOP, V89, P674, DOI 10.1080/17453674.2018.1523771
   Cao YP, 2002, J BONE MINER RES, V17, P2237, DOI 10.1359/jbmr.2002.17.12.2237
   Chao EYS, 2004, CLIN ORTHOP RELAT R, P12, DOI 10.1097/01.blo.0000132263.14046.0c
   Chen HG, 2017, INT J BIOL SCI, V13, P1254, DOI 10.7150/ijbs.21258
   Chen SX, 2015, J BONE MINER RES, V30, P1184, DOI 10.1002/jbmr.2453
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Dayan MO, 2019, FOLIA MORPHOL WARSZ
   Giannotti S, 2013, CLIN CASES MINER BON, V10, P116, DOI 10.11138/ccmbm/2013.10.2.116
   Goldhahn J, 2012, CALCIFIED TISSUE INT, V90, P343, DOI 10.1007/s00223 012 9587 4
   Harding AK, 2011, ACTA ORTHOP, V82, P465, DOI 10.3109/17453674.2011.594231
   Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597
   Inoue S, 2018, BONE REP, V8, P652
   Jin HT, 2015, BONE, V71, P63, DOI 10.1016/j.bone.2014.07.039
   Kim JB, 2007, J BONE MINER RES, V22, P1913, DOI 10.1359/JBMR.070802
   Lenart BA, 2008, NEW ENGL J MED, V358, P1304, DOI 10.1056/NEJMc0707493
   Li JF, 2017, J ORTHOP RES, V35, P812, DOI 10.1002/jor.23339
   Liu AL, 2015, CALCIFIED TISSUE INT, V97, P581, DOI 10.1007/s00223 015 0041 2
   Loiselle AE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081399
   McGee Lawrence ME, 2013, BIOCHEM BIOPH RES CO, V441, P886, DOI 10.1016/j.bbrc.2013.10.155
   Montagnani A, 2014, WORLD J ORTHOP, V5, P247, DOI 10.5312/wjo.v5.i3.247
   Nakajima A, 2002, J BONE MINER RES, V17, P2038, DOI 10.1359/jbmr.2002.17.11.2038
   Nauth A, 2011, J ORTHOP TRAUMA, V25, pS51, DOI 10.1097/BOT.0b013e31821b8c52
   Ping ZC, 2017, ACTA BIOMATER, V51, P513, DOI 10.1016/j.actbio.2017.01.034
   Rizzoli R, 2011, OSTEOPOROSIS INT, V22, P373, DOI 10.1007/s00198 010 1453 5
   Sandberg O, 2014, BONE, V63, P15, DOI 10.1016/j.bone.2014.02.008
   Secreto Frank J, 2009, Curr Osteoporos Rep, V7, P64
   Seeman E, 2013, J GERONTOL A BIOL, V68, P1218, DOI 10.1093/gerona/glt071
   Seeman E, 2010, J BONE MINER RES, V25, P1886, DOI 10.1002/jbmr.81
   Sibai T, 2011, CLIN ORTHOP RELAT R, V469, P2215, DOI 10.1007/s11999 010 1722 9
   Skripitz R, 2001, CLIN ORTHOP RELAT R, P427
   Skripitz R, 2001, J BONE JOINT SURG BR, V83B, P437, DOI 10.1302/0301 620X.83B3.10256
   Tsai JN, 2015, J CLIN ENDOCR METAB, V100, P2718, DOI 10.1210/jc.2015 1541
   Wang MN, 2015, BONE, V81, P104, DOI 10.1016/j.bone.2015.07.008
   Wang P, 2017, INT J BIOL SCI, V13, P996, DOI 10.7150/ijbs.19986
   Wang QJ, 2011, J BONE MINER RES, V26, P1577, DOI 10.1002/jbmr.360
   Wang YH, 2013, CLIN EXP PHARMACOL P, V40, P715, DOI 10.1111/1440 1681.12161
   Weng SJ, 2019, CHEM BIOL INTERACT, V300, P101, DOI 10.1016/j.cbi.2019.01.012
   Xie YL, 2016, INT J BIOL SCI, V12, P990, DOI 10.7150/ijbs.14077
   Xue DT, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/1749 799X 9 45
   Yeh CH, 2008, CLIN ORTHOP RELAT R, V466, P1047, DOI 10.1007/s11999 008 0171 1
   Zebaze RM, 2014, BONE, V59, P173, DOI 10.1016/j.bone.2013.11.016
   Zebaze RMD, 2010, LANCET, V375, P1729, DOI 10.1016/S0140 6736(10)60320 0
   Zhang L X, 2018, Zhonghua Yi Xue Za Zhi, V98, P781, DOI 10.3760/cma.j.issn.0376 2491.2018.10.014
   Zhong ZDA, 2015, BONE, V81, P614, DOI 10.1016/j.bone.2015.07.034
   Zhu Q, 2013, J BONE MINER RES, V28, P1898, DOI 10.1002/jbmr.2000
NR 53
TC 5
Z9 5
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0305 1870
EI 1440 1681
J9 CLIN EXP PHARMACOL P
JI Clin. Exp. Pharmacol. Physiol.
PD JUL
PY 2019
VL 46
IS 7
BP 652
EP 663
DI 10.1111/1440 1681.13088
PG 12
WC Pharmacology & Pharmacy; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Physiology
GA IB1KW
UT WOS:000470025100005
PM 30908657
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Nielsen, JJ
   Low, SA
   Ramseier, NT
   Hadap, RV
   Young, NA
   Wang, MD
   Low, PS
AF Nielsen, Jeffery J.
   Low, Stewart A.
   Ramseier, Neal T.
   Hadap, Rahul, V
   Young, Nicholas A.
   Wang, Mingding
   Low, Philip S.
TI Analysis of the bone fracture targeting properties of osteotropic
   ligands
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Acidic oligopeptides; Bone fracture targeting ligands; Targeted drug
   delivery; Acceleration of fracture healing; Osteogenic therapies;
   Bisphosphonates
ID INHIBITOR LOADED MICELLES; BIOLOGICAL EVALUATION; PARATHYROID HORMONE;
   CRYSTAL FORMATION; CRYPTIC PEPTIDE; DELIVERY SYSTEM; BINDING; MODEL;
   HYDROXYAPATITE; BISPHOSPHONATES
AB Purpose: Although more than 18,000,000 fractures occur each year in the US, methods to promote fracture healing still rely primarily on fracture stabilization, with use of bone anabolic agents to accelerate fracture repair limited to rare occasions when the agent can be applied to the fracture surface. Because management of broken bones could be improved if bone anabolic agents could be continuously applied to a fracture over the entire course of the healing process, we undertook to identify strategies that would allow selective concentration of bone anabolic agents on a fracture surface following systemic administration. Moreover, because hydroxyapatite is uniquely exposed on a broken bone, we searched for molecules that would bind with high affinity and specificity for hydroxyapatite. We envisioned that by conjugating such osteotropic ligands to a bone anabolic agent, we could acquire the ability to continuously stimulate fracture healing.
   Results: Although bisphosphonates and tetracyclines were capable of localizing small amounts of peptidic pay loads to fracture surfaces 2 fold over healthy bone, their specificities and capacities for drug delivery were significantly inferior to subsequent other ligands, and were therefore considered no further. In contrast, short oligopeptides of acidic amino acids were found to localize a peptide payload to a bone fracture 91.9 times more than the control untargeted peptide payload. Furthermore acidic oligopeptides were observed to be capable of targeting all classes of peptides, including hydrophobic, neutral, cationic, anionic, short oligopeptides, and long polypeptides. We further found that highly specific bone fracture targeting of multiple peptidic cargoes can be achieved by subcutaneous injection of the construct.
   Conclusions: Using similar constructs, we anticipate that healing of bone fractures in humans that have relied on immobilization alone can be greately enhanced by continuous stimulation of bone growth using systemic administration of fracture targeted bone anabolic agents.
C1 [Nielsen, Jeffery J.; Young, Nicholas A.; Low, Philip S.] Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN USA.
   [Low, Stewart A.; Ramseier, Neal T.; Hadap, Rahul, V; Wang, Mingding; Low, Philip S.] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.
C3 Purdue University System; Purdue University; Purdue University System;
   Purdue University
RP Low, PS (通讯作者)，720 Clin Dr, W Lafayette, IN 47907 USA.
EM plow@purdue.edu
RI Low, Stewart/JTU 2123 2023
OI Low, Philip/0000 0001 9042 5528; Ramseier, Neal/0000 0001 8813 596X;
   Low, Stewart/0000 0002 7387 3545
FU National Institutes of Health [TL1 TR002531, UL1 TR002529, R44DE028713]
FX This work was supported in part by the National Institutes of Health
   [TL1 TR002531, UL1 TR002529, R44DE028713].
CR Agrawal V, 2011, TISSUE ENG PT A, V17, P2435, DOI [10.1089/ten.TEA.2011.0036, 10.1089/ten.tea.2011.0036]
   Agrawal V, 2011, TISSUE ENG PT A, V17, P3033, DOI [10.1089/ten.tea.2011.0257, 10.1089/ten.TEA.2011.0257]
   Amso Z, 2016, MED RES REV, V36, P579, DOI 10.1002/med.21388
   Antczak MI, 2017, J MED CHEM, V60, P3979, DOI 10.1021/acs.jmedchem.7b00271
   Arns S, 2012, BIOORGAN MED CHEM, V20, P2131, DOI 10.1016/j.bmc.2012.01.024
   Beachler DC, 2016, J BONE JOINT SURG AM, V98, P1064, DOI 10.2106/JBJS.15.01106
   Beaupre LA, 2005, J GEN INTERN MED, V20, P1019, DOI 10.1111/j.1525 1497.2005.00219.x
   Bednarek MA, 2000, J MED CHEM, V43, P4370, DOI 10.1021/jm0001727
   Bergeron E, 2012, TISSUE ENG PT A, V18, P342, DOI [10.1089/ten.tea.2011.0008, 10.1089/ten.TEA.2011.0008]
   Bergmann R, 2016, EJNMMI RES, V6, DOI 10.1186/s13550 016 0161 3
   Bone and Joint Initiative, 2012, NUMB MUSC INJ
   Brommage R, 1999, J CLIN ENDOCR METAB, V84, P3757, DOI 10.1210/jc.84.10.3757
   Brown JP, 2014, CAN FAM PHYSICIAN, V60, P324
   Campbell EJ, 2015, EXPERT OPIN BIOL TH, V15, P119, DOI 10.1517/14712598.2015.977249
   Carbone EJ, 2017, J NANOSCI NANOTECHNO, V17, P1747, DOI 10.1166/jnn.2017.12855
   Carpintero P, 2014, WORLD J ORTHOP, V5, P402, DOI 10.5312/wjo.v5.i4.402
   CHAUNCEY DM, 1976, J NUCL MED, V17, P274
   Choi SH, 2010, BIOCHEMISTRY US, V49, P9935, DOI 10.1021/bi1014437
   Chung AM, 2018, REV NEUROSCIENCE, V29, P369, DOI 10.1515/revneuro 2017 0060
   Cole LE, 2016, ADV DRUG DELIVER REV, V99, P12, DOI 10.1016/j.addr.2015.10.005
   Coleman CI, 2012, J MANAGE CARE PHARM, V18, P527, DOI 10.18553/jmcp.2012.18.7.527
   Cutbirth S.T, 2015, DENISTRY TODAY, P3
   Di Stasi R, 2018, CHEM EUR J, V24, P11461, DOI 10.1002/chem.201802117
   Elefteriou F, 2005, CELL MOL LIFE SCI, V62, P2339, DOI 10.1007/s00018 005 5175 3
   Farrell K.B., 2018, BISPHOSPHONATE CONJU, DOI [10.1016/j.bonr.2018.06.007, DOI 10.1016/J.BONR.2018.06.007]
   Farrell Kristen B, 2018, Bone Rep, V9, P47, DOI 10.1016/j.bonr.2018.06.007
   Gilsenan A, 2018, OSTEOPOROSIS INT, V29, P2335, DOI 10.1007/s00198 018 4604 8
   Grässel S, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075 014 0485 1
   Gruber R, 2006, EXP GERONTOL, V41, P1080, DOI 10.1016/j.exger.2006.09.008
   Haas AV, 2018, J ENDOCR SOC, V2, P922, DOI 10.1210/js.2018 00118
   Hacchou Y, 2007, J DENT RES, V86, P893, DOI 10.1177/154405910708600917
   Halling Sorensen B, 2002, ARCH ENVIRON CON TOX, V42, P263, DOI 10.1007/s00244 001 0017 2
   Hamed E, 2001, J CONTROL RELEASE, V73, P329, DOI 10.1016/S0168 3659(01)00356 X
   Health R., 2011, JAMA J AM MED ASSOC, DOI [10.1002/central/CN 01841784/full., DOI 10.1002/CENTRAL/CN 01841784/FULL]
   Helmerhorst GTT, 2014, J BONE JOINT SURG AM, V96A, P495, DOI 10.2106/JBJS.L.01406
   Hengst V, 2007, INT J PHARMACEUT, V331, P224, DOI 10.1016/j.ijpharm.2006.11.024
   Houghton TJ, 2008, J MED CHEM, V51, P6955, DOI 10.1021/jm801007z
   HUNTER GK, 1994, BIOCHEM J, V300, P723, DOI 10.1042/bj3000723
   HUNTER GK, 1994, BIOCHEM J, V302, P175, DOI 10.1042/bj3020175
   Ingersoll KS, 2008, J BEHAV MED, V31, P213, DOI 10.1007/s10865 007 9147 y
   Ishizaki J, 2009, J BONE MINER METAB, V27, P1, DOI 10.1007/s00774 008 0004 z
   James AW, 2016, TISSUE ENG PART B RE, V22, P284, DOI [10.1089/ten.TEB.2015.0357, 10.1089/ten.teb.2015.0357]
   Jeon OH, 2016, DRUG DELIV TRANSL RE, V6, P105, DOI 10.1007/s13346 015 0266 7
   Juhász T, 2014, J MOL NEUROSCI, V54, P555, DOI 10.1007/s12031 014 0389 1
   Jung T, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/7859184
   Kar M., 2014, J DRUG DELIV THER, V4, P60, DOI [10.22270/jddt.v4i3.836, DOI 10.22270/JDDT.V4I3.836]
   Kim CH, 1999, J ENDOCRINOL, V162, P371, DOI 10.1677/joe.0.1620371
   LANE TF, 1994, J CELL BIOL, V125, P929, DOI 10.1083/jcb.125.4.929
   Leamon CP, 2002, BIOCONJUGATE CHEM, V13, P1200, DOI 10.1021/bc0200430
   Lee JY, 2007, J BIOMED MATER RES A, V83A, P970, DOI 10.1002/jbm.a.31351
   Li MY, 2006, J BIOMED MATER RES A, V79A, P963, DOI 10.1002/jbm.a.30833
   Li Y, 2011, BIOPOLYMERS, V95, P94, DOI 10.1002/bip.21536
   Liu CC, 2015, J BONE MINER RES, V30, P670, DOI 10.1002/jbmr.2382
   Liu YZ, 2018, NANOMED NANOTECHNOL, V14, P2271, DOI 10.1016/j.nano.2018.07.011
   Low SA, 2017, NANOMEDICINE UK, V12, P185, DOI 10.2217/nnm 2016 0340
   Low SA, 2015, BIOMACROMOLECULES, V16, P3145, DOI 10.1021/acs.biomac.5b00777
   Low SA, 2012, ADV DRUG DELIVER REV, V64, P1189, DOI 10.1016/j.addr.2012.01.012
   Miller SC, 2008, PHARM RES DORDR, V25, P2889, DOI 10.1007/s11095 008 9706 0
   Morioka M, 2010, BIOORGAN MED CHEM, V18, P1143, DOI 10.1016/j.bmc.2009.12.041
   Neale JR, 2009, BIOORG MED CHEM LETT, V19, P680, DOI 10.1016/j.bmcl.2008.12.051
   Newman MR, 2018, BIOMACROMOLECULES, V19, P71, DOI 10.1021/acs.biomac.7b01193
   Nielsen JJ, 2020, CURR OSTEOPOROS REP, V18, P449, DOI 10.1007/s11914 020 00604 4
   Nieminen MS, 1996, EUR HEART J, V17, P1576
   Ogawa K, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14149 7
   Parashar Atul, 2013, Indian J Plast Surg, V46, P221, DOI 10.4103/0970 0358.118597
   PERRIN DD, 1965, NATURE, V208, P787, DOI 10.1038/208787a0
   Ponnapakkam T, 2014, DRUG DISCOV TODAY, V19, P204, DOI 10.1016/j.drudis.2013.07.015
   Ponnapakkam T, 2011, CALCIFIED TISSUE INT, V88, P511, DOI 10.1007/s00223 011 9485 1
   Poynton AR, 2002, SPINE, V27, pS40, DOI 10.1097/00007632 200208151 00010
   Rotman SG, 2018, J CONTROL RELEASE, V269, P88, DOI 10.1016/j.jconrel.2017.11.009
   Ruczynski J, 2008, J PEPT SCI, V14, P335, DOI 10.1002/psc.941
   SAVOIE JC, 1973, J CLIN INVEST, V52, P106, DOI 10.1172/JCI107153
   Sedghizadeh P.P, 2017, DESIGN SYNTHESIS ANT, DOI [10.1021/acs.jmedchem.6b01615, DOI 10.1021/ACS.JMEDCHEM.6B01615]
   Sekido T, 2001, J DRUG TARGET, V9, P111, DOI 10.3109/10611860108997922
   Senta H, 2011, CAN J CHEM ENG, V89, P227, DOI 10.1002/cjce.20453
   Shaikh N, 2010, BIOPOLYMERS, V94, P213, DOI 10.1002/bip.21336
   Shea JE, 2005, ADV DRUG DELIVER REV, V57, P945, DOI 10.1016/j.addr.2004.12.017
   Shin H, 2004, BIOMATERIALS, V25, P895, DOI 10.1016/S0142 9612(03)00602 1
   Sibai T, 2011, CLIN ORTHOP RELAT R, V469, P2215, DOI 10.1007/s11999 010 1722 9
   Soltero R, 2005, WILEY SER DRUG DISC, P189, DOI 10.1002/0471475734.ch10
   Srinivasarao M, 2017, CHEM REV, V117, P12133, DOI 10.1021/acs.chemrev.7b00013
   Stapleton M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071345
   Sun Y, 2016, ACS NANO, V10, P5759, DOI 10.1021/acsnano.5b07828
   Tahimic Candice G T, 2013, Front Endocrinol (Lausanne), V4, P6, DOI 10.3389/fendo.2013.00006
   Takahashi T, 2008, PHARM RES DORDR, V25, P2881, DOI 10.1007/s11095 008 9605 4
   TAM J P, 1988, Peptide Research, V1, P6
   Tavafoghi M, 2016, J R SOC INTERFACE, V13, DOI 10.1098/rsif.2016.0462
   The Bone and Joint Initative, 2019, BURDEN MUSCULOSKELET, VFourth
   UCHTMAN VA, 1972, J PHYS CHEM US, V76, P1304, DOI 10.1021/j100653a014
   Verheyen A, 2013, NEUROSCIENCE, V244, P77, DOI 10.1016/j.neuroscience.2013.03.050
   Vincent K, 2013, J MOL GRAPH MODEL, V39, P108, DOI 10.1016/j.jmgm.2012.10.007
   Visser R, 2016, J CONTROL RELEASE, V244, P122, DOI 10.1016/j.jconrel.2016.10.024
   Wang CY, 2017, REGEN BIOMATER, V4, P191, DOI 10.1093/rb/rbx011
   Wang D, 2007, BIOCONJUGATE CHEM, V18, P1375, DOI 10.1021/bc7002132
   Wang H, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10030154
   Wang H, 2015, INT J NANOMED, V10, P5671, DOI 10.2147/IJN.S88798
   Wang MD, 2018, BIOCONJUGATE CHEM, V29, P3800, DOI 10.1021/acs.bioconjchem.8b00660
   Wang YC, 2017, ACS NANO, V11, P9445, DOI 10.1021/acsnano.7b05103
   Xie H., 2017, DESIGN SYNTHESIS PHA, DOI [10.1021/acs.jmedchem.6b00951, DOI 10.1021/ACS.JMEDCHEM.6B00951]
   YOUNG MRA, 1988, INJURY, V19, P14, DOI 10.1016/0020 1383(88)90166 0
   Young RN, 2018, CURR OPIN PHARMACOL, V40, P87, DOI 10.1016/j.coph.2018.03.010
   Yu SM, 2011, SOFT MATTER, V7, P7927, DOI 10.1039/c1sm05329a
   Yuasa M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116462
   Zhang YY, 2015, SCIENCE, V348, DOI 10.1126/science.aaa2340
   Ziffra Jeffrey B Jr, 2018, BMJ Case Rep, V2018, DOI 10.1136/bcr 2017 223035
NR 105
TC 16
Z9 17
U1 0
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168 3659
EI 1873 4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD JAN 10
PY 2021
VL 329
BP 570
EP 584
DI 10.1016/j.jconrel.2020.09.047
EA FEB 2021
PG 15
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA QT1EB
UT WOS:000626334700040
PM 33031877
DA 2025 08 17
ER

PT J
AU Quarto, N
   Senarath Yapa, K
   Renda, A
   Longaker, MT
AF Quarto, Natalina
   Senarath Yapa, Kshemendra
   Renda, Andrea
   Longaker, Michael T.
TI TWIST1 Silencing Enhances In Vitro and In Vivo Osteogenic
   Differentiation of Human Adipose Derived Stem Cells by Triggering
   Activation of BMP ERK/FGF Signaling and TAZ Upregulation
SO STEM CELLS
LA English
DT Article
DE hASCs; Silencing; TWIST1; Activation; Signaling; Upregulation; TAZ;
   Osteogenesis
ID BONE MORPHOGENETIC PROTEIN; SAETHRE CHOTZEN SYNDROME; MARROW STROMAL
   CELLS; LOOP HELIX PROTEINS; OSTEOBLAST DIFFERENTIATION; TRANSCRIPTIONAL
   REGULATION; MOLECULAR MECHANISMS; CALVARIAL DEFECTS; RETINOIC ACID;
   TISSUE
AB Mesenchymal stem cells (MSCs) show promise for cellular therapy and regenerative medicine. Human adipose tissue derived stem cells (hASCs) represent an attractive source of seed cells in bone regeneration. How to effectively improve osteogenic differentiation of hASCs in the bone tissue engineering has become a very important question with profound translational implications. Numerous regulatory pathways dominate osteogenic differentiation of hASCs involving transcriptional factors and signaling molecules. However, how these factors combine with each other to regulate hASCs osteogenic differentiation still remains to be illustrated. The highly conserved developmental proteins TWIST play key roles for transcriptional regulation in mesenchymal cell lineages. This study investigates TWIST1 function in hASCs osteogenesis. Our results show that TWIST1 shRNA silencing increased the osteogenic potential of hASCs in vitro and their skeletal regenerative ability when applied in vivo. We demonstrate that the increased osteogenic capacity observed with TWIST1 knockdown in hASCs is mediated through endogenous activation of BMP and ERK/FGF signaling leading, in turn, to upregulation of TAZ, a transcriptional modulator of MSCs differentiation along the osteoblast lineage. Inhibition either of BMP or ERK/FGF signaling suppressed TAZ upregulation and the enhanced osteogenesis in shTWIST1 hASCs. Cosilencing of both TWIST1 and TAZ abrogated the effect elicited by TWIST1 knockdown thus, identifying TAZ as a downstream mediator through which TWIST1 knockdown enhanced osteogenic differentiation in hASCs. Our functional study contributes to a better knowledge of molecular mechanisms governing the osteogenic ability of hASCs, and highlights TWIST1 as a potential target to facilitate in vivo bone healing.
C1 [Quarto, Natalina; Senarath Yapa, Kshemendra; Longaker, Michael T.] Stanford Univ, Sch Med, Dept Surg, Hagey Lab Pediat Regenerat Med, Stanford, CA 94305 USA.
   [Quarto, Natalina; Renda, Andrea] Univ Naples Federico II, Dipartimento Sci Biomed Avanzate, Naples, Italy.
C3 Stanford University; University of Naples Federico II
RP Quarto, N (通讯作者)，Stanford Univ, Sch Med, Dept Surg, Hagey Lab Pediat Regenerat Med, 257 Campus Dr, Stanford, CA 94305 USA.
EM quarto@unina.it; longaker@stanford.edu
OI RENDA, Andrea/0000 0002 8402 2244
FU Oak Foundation; Hagey Laboratory for Pediatric Regenerative Medicine;
   National Institutes of Health NIH [R01 DE021683 01, R01 DE19434,
   U01HL099776]; "Transplant and Tissue Engineering Program Endowment
   Awards" Lucille Packard Children Hospital Translational
   Medicine/Transplant" Stanford University
FX This work was supported by the Oak Foundation, John and Cynthia Gunn,
   The Hagey Laboratory for Pediatric Regenerative Medicine, The National
   Institutes of Health NIH Grants R01 DE021683 01, R01 DE19434, and
   U01HL099776 to M.T.L., and "Transplant and Tissue Engineering Program
   Endowment Awards" Lucille Packard Children Hospital Translational
   Medicine/Transplant" Stanford University to N.Q. We are grateful to Dr.
   M. Lee and Dr. B. Wu at UCLA for providing with PLGA scaffolds.
CR Baylies MK, 1996, SCIENCE, V272, P1481, DOI 10.1126/science.272.5267.1481
   Behr B, 2012, TISSUE ENG PT A, V18, P1079, DOI [10.1089/ten.tea.2011.0537, 10.1089/ten.TEA.2011.0537]
   Behr B, 2011, STEM CELLS, V29, P286, DOI 10.1002/stem.581
   Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534 5807(04)00058 9
   Bildsoe H, 2009, DEV BIOL, V331, P176, DOI 10.1016/j.ydbio.2009.04.034
   Bohnenblust ME, 2009, J CRANIOFAC SURG, V20, P340, DOI 10.1097/SCS.0b013e3181992316
   Byun MR, 2014, BONE, V58, P72, DOI 10.1016/j.bone.2013.09.024
   CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27
   Chang J, 2013, P NATL ACAD SCI USA, V110, P9469, DOI 10.1073/pnas.1300532110
   Chang SCN, 2004, J SURG RES, V119, P85, DOI 10.1016/j.jss.2003.08.003
   Connerney J, 2006, DEV DYNAM, V235, P1345, DOI 10.1002/dvdy.20717
   Cowan CM, 2004, NAT BIOTECHNOL, V22, P560, DOI 10.1038/nbt958
   Cripps RM, 1998, DEV BIOL, V203, P106, DOI 10.1006/dbio.1998.9040
   Cui L, 2007, BIOMATERIALS, V28, P5477, DOI 10.1016/j.biomaterials.2007.08.042
   ElGhouzzi V, 1997, NAT GENET, V15, P42
   Gimble JM, 2007, CIRC RES, V100, P1249, DOI 10.1161/01.RES.0000265074.83288.09
   Gimble JM, 2003, CURR TOP DEV BIOL, V58, P137, DOI 10.1016/S0070 2153(03)58005 X
   Halvorsen YDC, 2001, TISSUE ENG, V7, P729, DOI 10.1089/107632701753337681
   Hattori H, 2004, CELLS TISSUES ORGANS, V178, P2, DOI 10.1159/000081088
   Hayashi M, 2007, J CELL SCI, V120, P1350, DOI 10.1242/jcs.000067
   Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959 437X(96)80064 5
   Hong JH, 2006, CELL CYCLE, V5, P176, DOI 10.4161/cc.5.2.2362
   Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   Isenmann S, 2009, STEM CELLS, V27, P2457, DOI 10.1002/stem.181
   Izadpanah R, 2006, J CELL BIOCHEM, V99, P1285, DOI 10.1002/jcb.20904
   Johnson D, 2000, MECH DEVELOP, V91, P341, DOI 10.1016/S0925 4773(99)00278 6
   KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49
   Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037
   Katz AJ, 1999, CLIN PLAST SURG, V26, P587
   Keibl C, 2011, INJURY, V42, P814, DOI 10.1016/j.injury.2011.03.007
   Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005 0342
   Kim Y, 2007, J CELL PHYSIOL, V211, P253, DOI 10.1002/jcp.20933
   Komaki M, 2007, J CELL BIOCHEM, V100, P303, DOI 10.1002/jcb.21038
   Kwan MD, 2011, J BIOL CHEM, V286, P11307, DOI 10.1074/jbc.M110.180042
   Laursen KB, 2007, J BIOL CHEM, V282, P34623, DOI 10.1074/jbc.M707085200
   Lee MS, 1999, J CELL BIOCHEM, V75, P566, DOI 10.1002/(SICI)1097 4644(19991215)75:4<566::AID JCB3>3.0.CO;2 0
   LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568
   Levi B, 2011, STEM CELLS, V29, P2018, DOI 10.1002/stem.757
   Levi B, 2011, STEM CELLS, V29, P576, DOI 10.1002/stem.612
   LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023
   Li SL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014033
   Marie PJ, 2012, GROWTH FACTORS, V30, P117, DOI 10.3109/08977194.2012.656761
   Marie Pierre J., 2008, V12, P144, DOI 10.1159/000115036
   Miraoui H, 2010, GENE, V468, P1, DOI 10.1016/j.gene.2010.07.013
   Miraoui H, 2010, J CELL BIOCHEM, V110, P1147, DOI 10.1002/jcb.22628
   Miraoui H, 2009, J BIOL CHEM, V284, P4897, DOI 10.1074/jbc.M805432200
   MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092 8674(89)90682 X
   MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092 8674(89)90434 0
   O'Rourke MP, 2002, DEV BIOL, V248, P143, DOI 10.1006/dbio.2002.0730
   O'Rourke MP, 2002, INT J DEV BIOL, V46, P401
   Oda H, 1998, DEV BIOL, V203, P435, DOI 10.1006/dbio.1998.9047
   Pan DN, 2009, CELL, V137, P73, DOI 10.1016/j.cell.2009.01.051
   Panetta NJ, 2010, PLAST RECONSTR SURG, V125, P483, DOI 10.1097/PRS.0b013e3181c82d75
   Pettersson AT, 2011, J CLIN ENDOCR METAB, V96, P133, DOI 10.1210/jc.2010 0929
   Pettersson AT, 2010, DIABETES, V59, P564, DOI 10.2337/db09 0997
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Qin Q, 2012, CELL RES, V22, P90, DOI 10.1038/cr.2011.144
   Quarto N, 2005, GENE, V356, P49, DOI 10.1016/j.gene.2005.05.014
   Quarto N, 2008, BONE, V42, P1040, DOI 10.1016/j.bone.2008.01.026
   Quarto N, 2006, TISSUE ENG, V12, P1405, DOI 10.1089/ten.2006.12.1405
   Quarto N, 2010, J BONE MINER RES, V25, P1680, DOI 10.1359/jbmr.091116
   Rice DPC, 2000, DEVELOPMENT, V127, P1845
   Rosen ED, 2000, GENE DEV, V14, P1293
   Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002 9440(10)64464 1
   SHISHIDO E, 1993, DEVELOPMENT, V117, P751
   Skillington J, 2002, J CELL BIOL, V159, P135, DOI 10.1083/jcb.200204060
   Tamura M, 1999, J CELL BIOCHEM, V72, P167, DOI 10.1002/(SICI)1097 4644(19990201)72:2<167::AID JCB1>3.0.CO;2 3
   Tavares AT, 2001, INT J DEV BIOL, V45, P707
   THISSE B, 1987, NUCLEIC ACIDS RES, V15, P3439, DOI 10.1093/nar/15.8.3439
   THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460 2075.1988.tb03056.x
   Vincentz JW, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003405
   Wan DC, 2006, P NATL ACAD SCI USA, V103, P12335, DOI 10.1073/pnas.0604849103
   Wu SY, 2008, DEV BIOL, V319, P406, DOI 10.1016/j.ydbio.2008.04.003
   Xue P, 2013, BIOCHEM BIOPH RES CO, V433, P226, DOI 10.1016/j.bbrc.2013.02.088
   Yang DC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027324
   Yang JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056585
   Yousfi M, 2001, J CLIN INVEST, V107, P1153, DOI 10.1172/JCI11846
   Yu WL, 2008, DEV DYNAM, V237, P2716, DOI 10.1002/dvdy.21627
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 80
TC 46
Z9 50
U1 0
U2 22
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD MAR
PY 2015
VL 33
IS 3
BP 833
EP 847
DI 10.1002/stem.1907
PG 15
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA CB7ZZ
UT WOS:000349849000018
PM 25446627
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Xie, GY
   Huang, C
   Jiang, SD
   Li, HZ
   Gao, YH
   Zhang, TW
   Zhang, QD
   Pavel, V
   Rahmati, M
   Li, YS
AF Xie, Guangyang
   Huang, Cheng
   Jiang, Shide
   Li, Hengzhen
   Gao, Yihan
   Zhang, Tingwei
   Zhang, Qidong
   Pavel, Volotovski
   Rahmati, Masoud
   Li, Yusheng
TI Smoking and osteoimmunology: Understanding the interplay between bone
   metabolism and immune homeostasis
SO JOURNAL OF ORTHOPAEDIC TRANSLATION
LA English
DT Article
DE Arthritis; Bone; Fractures; Mesenchymal stem cells; Osteoarthritis;
   Osteoclasts; Osteoblasts; Periodontitis; Rheumatoid; Smoking; Th17 cells
ID TUMOR NECROSIS FACTOR; NF KAPPA B; REGULATORY T CELLS; CIGARETTE SMOKE;
   RHEUMATOID ARTHRITIS; RECEPTOR ACTIVATOR; OSTEOCLAST DIFFERENTIATION;
   HUMAN OSTEOBLASTS; GENE EXPRESSION; CHONDROGENIC DIFFERENTIATION
AB Smoking continues to pose a global threat to morbidity and mortality in populations. The detrimental impact of smoking on health and disease includes bone destruction and immune disruption in various diseases. Osteoimmunology, which explores the communication between bone metabolism and immune homeostasis, aims to reveal the interaction between the osteoimmune systems in disease development. Smoking impairs the differentiation of mesenchymal stem cells and osteoblasts in bone formation while promoting osteoclast differentiation in bone resorption. Furthermore, smoking stimulates the Th17 response to increase inflammatory and osteoclastogenic cytokines that promote the receptor activator of NF kappa B ligand (RANKL) signaling in osteoclasts, thus exacerbating bone destruction in periodontitis and rheumatoid arthritis. The pro inflammatory role of smoking is also evident in delayed bone fracture healing and osteoarthritis development. The osteoimmunological therapies are promising in treating periodontitis and rheumatoid arthritis, but further research is still required to block the smoking induced aggravation in these diseases. Translational potential: This review summarizes the adverse effect of smoking on mesenchymal stem cells, osteoblasts, and osteoclasts and elucidates the smoking induced exacerbation of periodontitis, rheumatoid arthritis, bone fracture healing, and osteoarthritis from an osteoimmune perspective. We also propose the therapeutic potential of osteoimmunological therapies for bone destruction aggravated by smoking.
C1 [Xie, Guangyang; Li, Hengzhen; Gao, Yihan; Li, Yusheng] Cent South Univ, Xiangya Hosp, Deparment Orthoped, Changsha 410008, Hunan, Peoples R China.
   [Xie, Guangyang; Gao, Yihan] Cent South Univ, Xiangya Sch Med, Clin Med, Changsha 410083, Hunan, Peoples R China.
   [Huang, Cheng; Zhang, Qidong] China Japan Friendship Hosp, Dept Orthopead, Beijing 100029, Peoples R China.
   [Jiang, Shide] Cent Hosp Yongzhou, Yongzhou 425000, Peoples R China.
   [Li, Hengzhen; Li, Yusheng] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha 410008, Hunan, Peoples R China.
   [Zhang, Tingwei] Wendeng Orthopaed Hosp Shandong Prov, Dept Orthopaed, Weihai 264400, Peoples R China.
   [Pavel, Volotovski] Republican Sci & Pract Ctr Traumatol & Orthoped, Minsk 220024, BELARUS.
   [Rahmati, Masoud] Lorestan Univ, Fac Literature & Human Sci, Dept Phys Educ & Sport Sci, Khorramabad, Iran.
   [Rahmati, Masoud] Vali E Asr Univ Rafsanjan, Fac Literature & Humanities, Dept Phys Educ & Sport Sci, Rafsanjan, Iran.
C3 Central South University; Central South University; China Japan
   Friendship Hospital; Central South University; Lorestan University;
   Vali e Asr University of Rafsanjan
RP Li, YS (通讯作者)，Cent South Univ, Xiangya Hosp, Deparment Orthoped, Changsha 410008, Hunan, Peoples R China.
EM liyusheng@csu.edu.cn
RI ; Huang, Cheng/KUG 8355 2024; Volotovski, Pavel/AAL 2193 2020; Rahmati,
   Masoud/AAY 1843 2021; Xie, Guangyang/KJL 6403 2024; zhang,
   tingwei/AAX 6150 2021
OI Xie, Guangyang/0009 0000 9150 4981; Volotovski,
   Pavel/0000 0002 4455 035X; Huang, Cheng/0000 0002 8793 5946; Rahmati,
   Masoud/0000 0003 4792 027X; 
FU National Key R&D Program of China [2019YFA0111900]; National Natural
   Science Foundation of China [82072506, 92268115, 82372500]; Hunan
   Provincial Science Fund for Distinguished Young Scholars [2024JJ2089];
   Science and Technology Innovation Program of Hunan Province
   [2021RC3025]; Wu Jieping Medical Foundation [320.6750.2020 03 14];
   National Clinical Research Center for Geriatric Disorders (Xiangya
   Hospital) [2021KF02]; National High Level Hospital Clinical Research
   Funding [2022 NHLHCRF LX 02 0104]; Elite Medical Professionals Project
   of China  Japan Friendship Hospital [ZRJY2021 QM21]
FX This work was supported by the National Key R&D Program of China (No.
   2019YFA0111900) ; National Natural Science Foundation of China
   (No.82072506, 92268115, 82372500) ; Hunan Provincial Science Fund for
   Distinguished Young Scholars (No. 2024JJ2089) , Science and Technology
   Innovation Program of Hunan Province (No. 2021RC3025) ; Wu Jieping
   Medical Foundation (320.6750.2020 03 14) , National Clinical Research
   Center for Geriatric Disorders (Xiangya Hospital, No. 2021KF02) ;
   National High Level Hospital Clinical Research Funding (No.
   2022 NHLHCRF LX 02 0104) & Elite Medical Professionals Project of China
    Japan Friendship Hospital (ZRJY2021 QM21) .
CR Ahluwalia IB, 2018, MMWR MORBID MORTAL W, V67, P1072, DOI 10.15585/mmwr.mm6738a7
   Alghamdi B, 2023, CURR OSTEOPOROS REP, V21, P128, DOI 10.1007/s11914 023 00774 x
   Ammitzboll C, 2019, J AUTOIMMUN, V97, P114, DOI 10.1016/j.jaut.2018.09.005
   An LQ, 2020, ECOTOX ENVIRON SAFE, V203, DOI 10.1016/j.ecoenv.2020.110930
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Andreoli C, 2015, CLIN CHEM LAB MED, V53, P57, DOI 10.1515/cclm 2013 0290
   Apatzidou DA, 2022, PERIODONTOL 2000, V90, P45, DOI 10.1111/prd.12449
   Arnez Maya Fernanda Manfrin, 2022, Braz. Dent. J., V33, P99, DOI 10.1590/0103 6440202203966
   Aspera Werz RH, 2020, WORLD J STEM CELLS, V12, P841, DOI 10.4252/wjsc.v12.i8.841
   Aspera Werz RH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20122915
   Aspera Werz RH, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/3172480
   Baskara I, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 63613 4
   Bin Homran FM, 2022, SAUDI J BIOL SCI, V29, P2230, DOI 10.1016/j.sjbs.2021.11.038
   Braun KF, 2011, THESCIENTIFICWORLDJO, V11, P2348, DOI 10.1100/2011/471426
   Buchwald ZS, 2015, J BONE MINER RES, V30, P1508, DOI 10.1002/jbmr.2472
   Cai XY, 2019, J CLIN MED, V8, DOI 10.3390/jcm8101699
   Chan KH, 2022, LANCET PUBLIC HEALTH, V7, pE1014, DOI 10.1016/S2468 2667(22)00227 4
   Chen T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051901
   Chen Y, 2016, INT J MOL MED, V38, P585, DOI 10.3892/ijmm.2016.2629
   Chevalier N, 2016, J AUTOIMMUN, V73, P120, DOI 10.1016/j.jaut.2016.06.018
   Choi Y, 2001, EUR J IMMUNOL, V31, P2179, DOI 10.1002/1521 4141(200107)31:7<2179::AID IMMU2179>3.0.CO;2 X
   Costa Rodrigues J, 2018, J CELL PHYSIOL, V233, P1029, DOI 10.1002/jcp.25956
   Cruz T, 2019, AM J RESP CELL MOL, V61, P575, DOI 10.1165/rcmb.2018 0351OC
   Cyprus GN, 2018, ACTA BIOMATER, V76, P308, DOI 10.1016/j.actbio.2018.06.018
   Danks L, 2016, ANN RHEUM DIS, V75, P1187, DOI 10.1136/annrheumdis 2014 207137
   Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Deng JW, 2022, J PERIODONTAL RES, V57, P246, DOI 10.1111/jre.12958
   Donate PB, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2017120118
   El Zawawy HB, 2006, J ORTHOP RES, V24, P2150, DOI 10.1002/jor.20263
   Engler A, 2016, J MOL MED, V94, P173, DOI 10.1007/s00109 015 1332 9
   Engler A, 2014, J MOL MED, V92, P757, DOI 10.1007/s00109 014 1139 0
   FANG MA, 1991, BONE, V12, P283, DOI 10.1016/8756 3282(91)90077 V
   Fernández Torres J, 2023, EXP BIOL MED, V248, P1754, DOI 10.1177/15353702231199072
   Finckh A, 2022, NAT REV RHEUMATOL, V18, P591, DOI 10.1038/s41584 022 00827 y
   Fu JQ, 2018, P NATL ACAD SCI USA, V115, P4755, DOI 10.1073/pnas.1722124115
   Gazdic M, 2015, STEM CELL REV REP, V11, P280, DOI 10.1007/s12015 014 9583 3
   Genovese MC, 2018, RHEUMATOLOGY, V57, P1972, DOI 10.1093/rheumatology/key173
   Glyn Jones S, 2015, LANCET, V386, P376, DOI 10.1016/S0140 6736(14)60802 3
   González Osuna L, 2021, AGING DIS, V12, P1150, DOI 10.14336/AD.2021.0110
   Greenbaum A, 2013, NATURE, V495, P227, DOI 10.1038/nature11926
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Hao ZC, 2021, J BONE MINER RES, V36, P186, DOI 10.1002/jbmr.4175
   Harre U, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7651
   Harrell CR, 2022, HISTOL HISTOPATHOL, V37, P93, DOI 10.14670/HH 18 400
   He SY, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 85637 0
   Hedström AK, 2018, EUR J EPIDEMIOL, V33, P415, DOI 10.1007/s10654 018 0360 5
   Hirota K, 2007, J EXP MED, V204, P2803, DOI 10.1084/jem.20071397
   Holzer N, 2012, LANGENBECK ARCH SURG, V397, P467, DOI 10.1007/s00423 011 0882 8
   Hou J, 2013, THORAX, V68, P1131, DOI 10.1136/thoraxjnl 2012 201956
   Hu Y, 2017, BBA MOL BASIS DIS, V1863, P2149, DOI 10.1016/j.bbadis.2017.06.001
   Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140 6736(19)30417 9
   Ishida Kitagawa N, 2012, J BIOL CHEM, V287, P17493, DOI 10.1074/jbc.M111.324194
   Ishikawa Y, 2019, ANN RHEUM DIS, V78, P1480, DOI 10.1136/annrheumdis 2019 215463
   Iwamoto N, 2022, ARTHRITIS RES THER, V24, DOI 10.1186/s13075 022 02957 w
   Izawa T, 2016, J IMMUNOL, V197, P4639, DOI 10.4049/jimmunol.1600822
   Jaligama S, 2018, PART FIBRE TOXICOL, V15, DOI 10.1186/s12989 018 0255 3
   Javed F, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17207435
   Jin Y, 2014, INT IMMUNOPHARMACOL, V23, P537, DOI 10.1016/j.intimp.2014.10.003
   Jing W, 2019, PEDIATR RES, V85, P469, DOI 10.1038/s41390 019 0276 0
   Josien R, 1999, J IMMUNOL, V162, P2562
   Joyce Shaikh B, 2010, J EXP MED, V207, P579, DOI 10.1084/jem.20090516
   Kamer AR, 2006, INT J MOL MED, V17, P121
   Kang J, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230719
   Kelchtermans H, 2009, ANN RHEUM DIS, V68, P744, DOI 10.1136/ard.2007.086066
   Kharlamova N, 2016, ARTHRITIS RHEUMATOL, V68, P604, DOI 10.1002/art.39491
   Khatri A, 2019, RHEUMATOLOGY, V58, P352, DOI 10.1093/rheumatology/key312
   Kim BS, 2012, LIFE SCI, V90, P109, DOI 10.1016/j.lfs.2011.10.019
   Kim DH, 2013, J BONE MINER METAB, V31, P44, DOI 10.1007/s00774 012 0382 0
   Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200
   Kim N, 2002, J EXP MED, V195, P201, DOI 10.1084/jem.20011681
   Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978
   Kim YG, 2007, BIOCHEM BIOPH RES CO, V357, P1046, DOI 10.1016/j.bbrc.2007.04.042
   Kiyota Y, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 73789 4
   Ko CH, 2015, CALCIFIED TISSUE INT, V96, P389, DOI 10.1007/s00223 015 9966 8
   Kobayashi T, 2014, J PERIODONTOL, V85, P57, DOI 10.1902/jop.2013.120696
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Kohler JB, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 33965 8
   Kon T, 2001, J BONE MINER RES, V16, P1004, DOI 10.1359/jbmr.2001.16.6.1004
   Kubota M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155594
   Kung MH, 2012, J CELL PHYSIOL, V227, P1062, DOI 10.1002/jcp.22819
   Kwon HM, 2020, EXP GERONTOL, V133, DOI 10.1016/j.exger.2020.110873
   Lahoti TS, 2013, ANN RHEUM DIS, V72, P1708, DOI 10.1136/annrheumdis 2012 202639
   Larsson SC, 2022, EBIOMEDICINE, V82, DOI 10.1016/j.ebiom.2022.104154
   Lee J, 2013, JOINT BONE SPINE, V80, P621, DOI 10.1016/j.jbspin.2013.02.009
   Leite FRM, 2018, AM J PREV MED, V54, P831, DOI 10.1016/j.amepre.2018.02.014
   Li HJ, 2015, AM J MED SCI, V349, P392, DOI 10.1097/MAJ.0000000000000447
   Li Y, 2015, ACTA BIOCH BIOPH SIN, V47, DOI 10.1093/abbs/gmv013
   Liang D, 2018, MOL MED REP, V17, P8269, DOI 10.3892/mmr.2018.8884
   Liu HJ, 2018, INT J MOL MED, V42, P3404, DOI 10.3892/ijmm.2018.3919
   Lu Y, 2021, J TRANSL MED, V19, DOI 10.1186/s12967 021 02836 z
   Ma CW, 2021, LANCET CHILD ADOLESC, V5, P245, DOI 10.1016/S2352 4642(20)30390 4
   Mahajan A, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph181910228
   Mahdi H, 2009, NAT GENET, V41, P1319, DOI 10.1038/ng.480
   Mandl P, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 0961 x
   Marinucci L, 2018, FREE RADICAL BIO MED, V117, P6, DOI 10.1016/j.freeradbiomed.2018.01.017
   Marinucci L, 2014, J CELL PHYSIOL, V229, P2038, DOI 10.1002/jcp.24661
   Martel Pelletier J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.72
   Melnik BC, 2018, BRIT J DERMATOL, V179, P260, DOI 10.1111/bjd.16561
   Miranda TS, 2018, J CLIN PERIODONTOL, V45, P293, DOI 10.1111/jcpe.12854
   Miranda TS, 2019, CLIN ORAL INVEST, V23, P641, DOI 10.1007/s00784 018 2471 5
   Mito K, 2017, SCI REP UK, V7, DOI 10.1038/srep45597
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Mócsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101
   Moutsopoulos NM, 2017, NEW ENGL J MED, V376, P1141, DOI 10.1056/NEJMoa1612197
   Nagaie M, 2014, INT J MOL SCI, V15, P18610, DOI 10.3390/ijms151018610
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Negishi Koga T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7637
   Ng TK, 2015, SCI REP UK, V5, DOI 10.1038/srep07828
   Nielsen SF, 2012, BMJ BRIT MED J, V345, DOI 10.1136/bmj.e5244
   Nile CJ, 2013, J CLIN PERIODONTOL, V40, P875, DOI 10.1111/jcpe.12134
   Nishino K, 2021, J BONE JOINT SURG AM, V103, P2024, DOI 10.2106/JBJS.20.02227
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Ono T, 2017, CURR OSTEOPOROS REP, V15, P367, DOI 10.1007/s11914 017 0381 0
   Pacheco CMF, 2021, J IMMUNOL, V206, P2386, DOI 10.4049/jimmunol.2001432
   Pan WY, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368 019 0064 z
   Papaioannou KA, 2011, INT J ORAL MAX IMPL, V26, P509
   Pavlovic D, 2023, TOXICOL LETT, V385, P12, DOI 10.1016/j.toxlet.2023.08.006
   Peng XY, 2019, INT J RHEUM DIS, V22, P666, DOI 10.1111/1756 185X.13476
   Peruzzo DC, 2016, J PERIODONTAL RES, V51, P800, DOI 10.1111/jre.12363
   Pfeifle R, 2017, NAT IMMUNOL, V18, P104, DOI 10.1038/ni.3579
   Qin Y, 2021, J DENT RES, V100, P1378, DOI 10.1177/00220345211009471
   Qin Y, 2022, ANN RHEUM DIS, V81, P1504, DOI 10.1136/ard 2022 222605
   Qiu SL, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00553
   Reitsma MB, 2021, LANCET, V397, P2337, DOI 10.1016/S0140 6736(21)01169 7
   Ren BJ, 2021, BIOMED PHARMACOTHER, V134, DOI 10.1016/j.biopha.2020.111171
   Ren QZ, 2019, ECOTOX ENVIRON SAFE, V178, P211, DOI 10.1016/j.ecoenv.2019.04.029
   Ribeiro FV, 2017, J PERIODONTOL, V88, P788, DOI 10.1902/jop.2017.170025
   Rinderknecht H, 2022, BIOENGINEERING BASEL, V9, DOI 10.3390/bioengineering9050186
   Rivellese F, 2022, NAT MED, V28, P1256, DOI 10.1038/s41591 022 01789 0
   Rose BJ, 2021, HISTOL HISTOPATHOL, V36, P347, DOI 10.14670/HH 18 311
   Rothem DE, 2011, BONE, V48, P903, DOI 10.1016/j.bone.2010.12.007
   Rothem DE, 2009, J BONE MINER METAB, V27, P555, DOI 10.1007/s00774 009 0075 5
   Rouabhia M, 2019, J ORAL IMPLANTOL, V45, P2, DOI 10.1563/aaid joi D 18 00009
   Ruscitti P, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002901
   Santiago HAR, 2017, CLIN ORTHOP RELAT R, V475, P894, DOI 10.1007/s11999 016 5184 6
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Sato T, 2008, BIOCHEM BIOPH RES CO, V377, P126, DOI 10.1016/j.bbrc.2008.09.114
   Schwendicke F, 2018, J CLIN PERIODONTOL, V45, P2, DOI 10.1111/jcpe.12823
   Shaito A, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14634 z
   Shao Y, 2022, CELLS BASEL, V11, DOI 10.3390/cells11182810
   Shao Y, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.887681
   Shashkova EV, 2016, J IMMUNOL, V197, P726, DOI 10.4049/jimmunol.1600253
   Shen YL, 2018, PART FIBRE TOXICOL, V15, DOI 10.1186/s12989 018 0253 5
   Shinohara M, 2008, CELL, V132, P794, DOI 10.1016/j.cell.2007.12.037
   Shoji M, 2007, ACTA BIOCH BIOPH SIN, V39, P163, DOI 10.1111/j.1745 7270.2007.00271.x
   Silva LEF, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 72305 y
   Smolen JS, 2016, LANCET, V388, P1984
   So H, 2021, ANN RHEUM DIS, V80, P981, DOI 10.1136/annrheumdis 2021 219846
   Sun L, 2020, J IMMUNOL, V204, P2177, DOI 10.4049/jimmunol.1900532
   Svärd A, 2015, ARTHRITIS RHEUMATOL, V67, P2032, DOI 10.1002/art.39170
   Svensson B, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4438
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Talbot J, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1609 9
   Tanaka H, 2006, LIFE SCI, V78, P1733, DOI 10.1016/j.lfs.2005.08.017
   Tanaka H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059402
   Ternes S, 2015, INT IMMUNOPHARMACOL, V29, P215, DOI 10.1016/j.intimp.2015.09.013
   Thuller KABR, 2021, J ENDODONT, V47, P755, DOI 10.1016/j.joen.2021.01.010
   Torshabi M, 2017, EUR J ORAL SCI, V125, P426, DOI 10.1111/eos.12375
   Torshabi Maryam, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P595, DOI 10.1515/jbcpp 2015 0143
   Tsai KS, 2004, CHEM RES TOXICOL, V17, P679, DOI 10.1021/tx0499517
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Tsukasaki M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03147 6
   Tuttle J, 2023, NEW ENGL J MED, V388, P1853, DOI 10.1056/NEJMoa2209856
   Vasques AMV, 2023, INT ENDOD J, V56, P465, DOI 10.1111/iej.13883
   Vassallo R, 2014, CLIN IMMUNOL, V152, P25, DOI 10.1016/j.clim.2014.02.002
   Voronov I, 2008, BIOCHEM PHARMACOL, V75, P2034, DOI 10.1016/j.bcp.2008.02.025
   Wahl EA, 2016, SCI REP UK, V6, DOI 10.1038/srep22957
   Walsh MC, 2018, NAT REV RHEUMATOL, V14, P146, DOI 10.1038/nrrheum.2017.213
   Wang J, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.947341
   Wang J, 2020, INT J IMMUNOPATH PH, V34, DOI 10.1177/2058738420974893
   Wang LY, 2014, J PERIODONTOL, V85, P740, DOI 10.1902/jop.2013.130132
   Wasén C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01677
   Wasén C, 2017, J AUTOIMMUN, V78, P101, DOI 10.1016/j.jaut.2016.12.009
   Weng CH, 2016, MOL IMMUNOL, V71, P115, DOI 10.1016/j.molimm.2016.01.013
   Xiao H, 2019, FASEB J, V33, P12972, DOI 10.1096/fj.201901145RR
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Xu WH, 2019, BMC PULM MED, V19, DOI 10.1186/s12890 019 0899 2
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yang J, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/8759568
   Yang X, 2017, BIO MED MATER ENG, V28, pS217, DOI 10.3233/BME 171644
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Ying XZ, 2012, KNEE SURG SPORT TR A, V20, P2329, DOI 10.1007/s00167 012 1890 0
   Yoshikawa Y, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 94470 4
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010225
   Zhang JC, 2016, SCI REP UK, V6, DOI 10.1038/srep31911
   Zhang J, 2018, AM J TRANSL RES, V10, P2796
   Zhang XY, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 022 00887 2
   Zheng Y, 2019, J CELL PHYSIOL, V234, P20662, DOI 10.1002/jcp.28671
   Zheng YH, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03962 8
   Zhou YQ, 2017, SCI TOTAL ENVIRON, V587, P305, DOI 10.1016/j.scitotenv.2017.02.152
   Zhu SB, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 30644 6
   Zhu S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010053
NR 193
TC 5
Z9 6
U1 3
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2214 031X
J9 J ORTHOP TRANSL
JI J. Orthop. Transl.
PD MAY
PY 2024
VL 46
BP 33
EP 45
DI 10.1016/j.jot.2024.04.003
EA MAY 2024
PG 13
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA TK6L7
UT WOS:001241194800001
PM 38765605
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yano, A
   Tsutsumi, S
   Soga, S
   Lee, MJ
   Trepel, J
   Osada, H
   Neckers, L
AF Yano, Akihiro
   Tsutsumi, Shinji
   Soga, Shiro
   Lee, Min Jung
   Trepel, Jane
   Osada, Hiroyuki
   Neckers, Len
TI Inhibition of Hsp90 activates osteoclast c Src signaling and promotes
   growth of prostate carcinoma cells in bone
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE cancer; geldanamycin; heat shock protein 90; osteoclastogenesis
ID COLONY STIMULATING FACTOR; LUNG CANCER; TUMOR GROWTH;
   HEAT SHOCK PROTEIN 90 INHIBITOR; TARGETED DISRUPTION; ANDROGEN RECEPTOR;
   BREAST CANCER; IN VIVO; KINASE; RESISTANCE
AB Hsp90 inhibitors are being evaluated extensively in patients with advanced cancers. However, the impact of Hsp90 inhibition on signaling pathways in normal tissues and the effect that this may have on the antitumor activity of these molecularly targeted drugs have not been rigorously examined. Breast and prostate carcinomas are among those cancers that respond to Hsp90 inhibitors in animal xenograft models and in early studies in patients. Because these cancers frequently metastasize to bone, it is important to determine the impact of Hsp90 inhibitors in the bone environment. In the current study, we show that, in contrast to its activity against prostate cancer cells in vitro and its inhibition of s.c. prostate cancer xenografts, the Hsp90 inhibitor 17 AAG stimulates the intraosseous growth of PC 3M prostate carcinoma cells. This activity is mediated not by a direct effect on the tumor but by Hsp90 dependent stimulation of osteoclast maturation. Hsp90 inhibition transiently activates osteoclast Src kinase and promotes Src dependent Akt activation. Both kinases are key drivers of osteoclast maturation, and three agents that block osteoclastogenesis, the Src inhibitor dasatinib, the bisphosphonate alendronate, and the osteoclast specific apoptosis inducer reveromycin A, markedly reduced 17 AAG stimulated tumor growth in bone. These data emphasize the importance of understanding the complex role played by Hsp90 in regulating signal transduction pathways in normal tissues as well as in cancer cells, and they demonstrate that drug dependent modulation of the local tumor environment may profoundly affect the antitumor efficacy of Hsp90 directed therapy.
C1 [Yano, Akihiro; Tsutsumi, Shinji; Soga, Shiro; Neckers, Len] NCI, Urol Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
   [Lee, Min Jung; Trepel, Jane] NCI, Med Oncol Branch, Bethesda, MD 20892 USA.
   [Osada, Hiroyuki] RIKEN, Discovery Res Inst, Antibiot Lab, Wako, Saitama 3510198, Japan.
C3 National Institutes of Health (NIH)   USA; NIH National Cancer Institute
   (NCI); National Institutes of Health (NIH)   USA; NIH National Cancer
   Institute (NCI); RIKEN
RP Neckers, L (通讯作者)，NCI, Urol Oncol Branch, Ctr Canc Res, Bldg 10,Room 1 5940, Bethesda, MD 20892 USA.
EM neckersl@mail.nih.gov
RI Osada, Hiroyuki/AAY 6254 2020
FU National Institutes of Health, National Cancer Institute
FX Grant support was provided by funds from the Intramural Research Program
   of the National Institutes of Health, National Cancer Institute.
CR Bisht KS, 2003, CANCER RES, V63, P8984
   Boissy P, 1998, J CELL SCI, V111, P2563
   Boyce BF, 2003, KIDNEY INT, V63, pS2, DOI 10.1046/j.1523 1755.63.s85.2.x
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Citri A, 2004, EMBO REP, V5, P1165, DOI 10.1038/sj.embor.7400300
   Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111
   Datta A, 2002, J BIOL CHEM, V277, P3943, DOI 10.1074/jbc.M109536200
   Donzé O, 2001, EMBO J, V20, P3771, DOI 10.1093/emboj/20.14.3771
   Eccles SA, 2008, CANCER RES, V68, P2850, DOI 10.1158/0008 5472.CAN 07 5256
   Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478
   Faccio R, 2005, NAT MED, V11, P284, DOI 10.1038/nm1194
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Insogna KL, 1997, J CLIN INVEST, V100, P2476, DOI 10.1172/JCI119790
   Jemal A, 2008, CA CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Johnson FM, 2005, CLIN CANCER RES, V11, P6924, DOI 10.1158/1078 0432.CCR 05 0757
   Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662
   Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238
   Koga F, 2006, P NATL ACAD SCI USA, V103, P11318, DOI 10.1073/pnas.0604705103
   Lattouf JB, 2006, NAT CLIN PRACT UROL, V3, P590, DOI 10.1038/ncpuro0604
   Mishra S, 2006, CANCER RES, V66, P5387, DOI 10.1158/0008 5472.CAN 05 3058
   Mitsiades CS, 2006, BLOOD, V107, P1092, DOI 10.1182/blood 2005 03 1158
   Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200
   Modi S, 2007, J CLIN ONCOL, V25, P5410, DOI 10.1200/JCO.2007.11.7960
   Morgillo F, 2007, CLIN CANCER RES, V13, P2795, DOI 10.1158/1078 0432.CCR 06 2077
   Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471 4914(02)02316 X
   Niu G, 2008, MOL IMAGING BIOL, V10, P99, DOI 10.1007/s11307 007 0123 2
   Price JT, 2005, CANCER RES, V65, P4929, DOI 10.1158/0008 5472.CAN 04 4458
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Ross FP, 2005, IMMUNOL REV, V208, P88, DOI 10.1111/j.0105 2896.2005.00331.x
   Sakai H, 2006, BONE, V39, P1290, DOI 10.1016/j.bone.2006.06.012
   Saporita AJ, 2007, PROSTATE, V67, P509, DOI 10.1002/pros.20541
   Solit DB, 2006, CURR TOP MED CHEM, V6, P1205, DOI 10.2174/156802606777812068
   Solit DB, 2002, CLIN CANCER RES, V8, P986
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200
   von Bubnoff N, 2003, LEUKEMIA, V17, P829, DOI 10.1038/sj.leu.2402889
   Weisberg E, 2008, MOL CANCER THER, V7, P1121, DOI 10.1158/1535 7163.MCT 07 2331
   Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716
   Williams CR, 2007, J UROLOGY, V178, P1528, DOI 10.1016/j.juro.2007.05.120
   Woo JT, 2006, P NATL ACAD SCI USA, V103, P4729, DOI 10.1073/pnas.0505663103
   Workman P, 2007, ANN NY ACAD SCI, V1113, P202, DOI 10.1196/annals.1391.012
   Xu WP, 2007, CLIN CANCER RES, V13, P1625, DOI 10.1158/1078 0432.CCR 06 2966
   Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200
   Yang MH, 2006, BLOOD, V107, P2262, DOI 10.1182/blood 2005 08 3365
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
   Yun BG, 2005, CELL SIGNAL, V17, P1477, DOI 10.1016/j.cellsig.2005.03.006
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
NR 47
TC 74
Z9 85
U1 0
U2 5
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 7
PY 2008
VL 105
IS 40
BP 15541
EP 15546
DI 10.1073/pnas.0805354105
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 364UI
UT WOS:000260360500059
PM 18840695
OA Green Published
DA 2025 08 17
ER

PT J
AU AlQranei, MS
   Aljohani, H
   Majumdar, S
   Senbanjo, LT
   Chellaiah, MA
AF AlQranei, Mohammed S.
   Aljohani, Hanan
   Majumdar, Sunipa
   Senbanjo, Linda T.
   Chellaiah, Meenakshi A.
TI C phycocyanin attenuates RANKL induced osteoclastogenesis and bone
   resorption in vitro through inhibiting ROS levels, NFATc1 and NF κB
   activation
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RECEPTOR ACTIVATOR; RING FORMATION; DIFFERENTIATION; PODOSOMES;
   OSTEOPONTIN; EXPRESSION; LIGAND; ACTIN; MICE; FOS
AB Excessive bone loss occurs in inflammatory disorders such as periodontitis and osteoporosis. The underlying mechanism is related to the differentiation of macrophages into multinucleated giant osteoclasts and their bone resorptive activity. C Phycocyanin (C PC) is a phycobiliprotein extracted from the blue green algae, which has been shown to have various pharmacological effects. The role of C PC on bone metabolism needs revelation. In this study, we determined the effectiveness of C PC as an inhibitor of osteoclast differentiation, activity, and survival in vitro. We found that C PC strongly inhibited the differentiation of macrophages to TRAP positive osteoclasts, distinctive osteoclast specific podosomal organization, and dentine matrix resorption without any cytotoxicity. Also, it suppressed the expression of osteoclast specific markers, such as cathepsin K and integrin beta 3 at mRNA and protein levels. RANKL mediated signaling utilizes reactive oxygen species (ROS) for the differentiation of osteoclasts. C PC attenuated RANKL stimulated ROS. Mechanistic studies indicate that C PC has the potential to reduce osteoclast formation via blocking the degradation of cytosolic I kappa B alpha and hence, the activation of downstream markers such as c Fos and NFATc1. However, it does not have any effect on osteoblast mediated bone formation in vitro. Collectively, our data suggest that C PC may be utilized as a therapeutic agent that can target bone loss mediated by excessive osteoclastic bone resorption without affecting osteoblastic activity in bone.
C1 [AlQranei, Mohammed S.; Aljohani, Hanan; Majumdar, Sunipa; Senbanjo, Linda T.; Chellaiah, Meenakshi A.] Univ Maryland, Sch Dent, Dept Oncol & Diagnost Sci, Baltimore, MD 21201 USA.
   [AlQranei, Mohammed S.] Imam Abdulrahman Bin Faisal Univ, Sch Dent, Prevent Dent Sci Dept, Dammam, Saudi Arabia.
   [Aljohani, Hanan] King Saud Univ, Sch Dent, Dept Oral Med & Diagnost Sci, Riyadh, Saudi Arabia.
C3 University System of Maryland; University of Maryland Baltimore; Imam
   Abdulrahman Bin Faisal University; King Saud University
RP Chellaiah, MA (通讯作者)，Univ Maryland, Sch Dent, Dept Oncol & Diagnost Sci, Baltimore, MD 21201 USA.
EM mchellaiah@umaryland.edu
FU NIH   NIAMS [5R01AR066044]; University of Maryland, School of Dentistry;
   Imam Abdulrahman Bin Faisal University   College of Dentistry through
   the Saudi Arabian Cultural Mission (SACM)
FX This work was supported by a research grant from NIH   NIAMS
   (5R01AR066044) to M.C. and a student support funding from the University
   of Maryland, School of Dentistry. This work was also supported by the
   progress and development award to MA from Imam Abdulrahman Bin Faisal
   University   College of Dentistry through the Saudi Arabian Cultural
   Mission (SACM).
CR ABERCROMBIE M, 1980, PROC R SOC SER B BIO, V207, P129, DOI 10.1098/rspb.1980.0017
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bhat VB, 2000, BIOCHEM BIOPH RES CO, V275, P20, DOI 10.1006/bbrc.2000.3270
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chellaiah M, 2000, J CELL BIOL, V148, P665, DOI 10.1083/jcb.148.4.665
   Chellaiah M, 1996, MOL BIOL CELL, V7, P743, DOI 10.1091/mbc.7.5.743
   Chellaiah M, 1998, J BIOL CHEM, V273, P11908, DOI 10.1074/jbc.273.19.11908
   Chellaiah MA, 2003, MOL BIOL CELL, V14, P173, DOI 10.1091/mbc.E02 06 0354
   Chellaiah MA, 2000, J BIOL CHEM, V275, P11993, DOI 10.1074/jbc.275.16.11993
   Chellaiah MA, 2003, CALCIFIED TISSUE INT, V72, P197, DOI 10.1007/s00223 002 1025 6
   Chellaiah MA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204209
   Chellaiah MA, 2018, EXP CELL RES, V372, P73, DOI 10.1016/j.yexcr.2018.09.014
   Cheon YH, 2014, PHYTOTHER RES, V28, P586, DOI 10.1002/ptr.5034
   Cherng SC, 2007, LIFE SCI, V81, P1431, DOI 10.1016/j.lfs.2007.09.009
   Cuetara BLV, 2006, IN VITRO CELL DEV AN, V42, P182, DOI 10.1290/0510075.1
   Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02 07 0389
   Ea CK, 2004, P NATL ACAD SCI USA, V101, P15318, DOI 10.1073/pnas.0404132101
   Gimona M, 2008, CURR OPIN CELL BIOL, V20, P235, DOI 10.1016/j.ceb.2008.01.005
   Gough A, 1998, J RHEUMATOL, V25, P1282
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Grigoriadis AE, 2010, BLOOD, V115, P2769, DOI 10.1182/blood 2009 07 234690
   Gupta A, 2003, J BONE MINER RES, V18, P669, DOI 10.1359/jbmr.2003.18.4.669
   Gupta A, 2012, MOL CANCER, V11, DOI 10.1186/1476 4598 11 66
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Hayman AR, 2008, AUTOIMMUNITY, V41, P218, DOI 10.1080/08916930701694667
   Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200
   Ishida A, 2002, J BIOL CHEM, V277, P26217, DOI 10.1074/jbc.M111093200
   KANEHISA J, 1988, BONE, V9, P73, DOI 10.1016/8756 3282(88)90106 8
   KANEHISA J, 1990, BONE, V11, P287, DOI 10.1016/8756 3282(90)90082 A
   KAY RA, 1991, CRIT REV FOOD SCI, V30, P555, DOI 10.1080/10408399109527556
   Kim JH, 2016, INT J MOL MED, V37, P649, DOI 10.3892/ijmm.2016.2477
   Kim JH, 2016, SCI REP UK, V6, DOI 10.1038/srep38526
   Kim K, 2010, J IMMUNOL, V185, P7460, DOI 10.4049/jimmunol.1000885
   Kim MH, 2010, ARCH PHARM RES, V33, P457, DOI 10.1007/s12272 010 0316 0
   Kim WS, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 11246 5
   Linder S, 2000, J CELL SCI, V113, P4165
   Linder S, 2015, CELL MOL LIFE SCI, V72, P121, DOI 10.1007/s00018 014 1731 z
   Ma T, 2010, J BIOL CHEM, V285, P29911, DOI 10.1074/jbc.M109.099697
   Majumdar S., 2019, INT J CELL BIOL, V2019
   Mohanan S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00067
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Niu CG, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00626
   Reddy CM, 2000, BIOCHEM BIOPH RES CO, V277, P599, DOI 10.1006/bbrc.2000.3725
   Remirez D, 1999, DRUG DEVELOP RES, V48, P70, DOI 10.1002/(SICI)1098 2299(199910)48:2<70::AID DDR4>3.0.CO;2 N
   Romay C, 1998, INFLAMM RES, V47, P36, DOI 10.1007/s000110050256
   Romay C, 2000, ARZNEIMITTEL FORSCH, V50, P1106
   Romay C, 2001, ARZNEIMITTEL FORSCH, V51, P733
   Sambandam Y, 2010, J CELL BIOCHEM, V111, P1179, DOI 10.1002/jcb.22840
   Senbanjo LT, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964 019 0395 6
   Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304
   Song DZ, 2018, J CELL PHYSIOL, V233, P9674, DOI 10.1002/jcp.26882
   Soysa NS, 2016, BIOCHEM BIOPH RES CO, V476, P115, DOI 10.1016/j.bbrc.2016.05.019
   Srinivasan S, 2010, ANN NY ACAD SCI, V1192, P245, DOI 10.1111/j.1749 6632.2009.05377.x
   Sun ZW, 2002, SHOCK, V18, P99, DOI 10.1097/00024382 200208000 00001
   Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tan Z, 2017, MOL CELL ENDOCRINOL, V439, P369, DOI 10.1016/j.mce.2016.09.026
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tella SH, 2014, EUR J CLIN PHARMACOL, V70, P1291, DOI 10.1007/s00228 014 1735 5
   Udagawa N, 1999, BONE, V25, P517, DOI 10.1016/S8756 3282(99)00210 0
   Väänänen K, 2005, ADV DRUG DELIVER REV, V57, P959, DOI 10.1016/j.addr.2004.12.018
   Vadiraja BB, 1998, BIOCHEM BIOPH RES CO, V249, P428, DOI 10.1006/bbrc.1998.9149
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Winslow MM, 2006, DEV CELL, V10, P771, DOI 10.1016/j.devcel.2006.04.006
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yip KHM, 2005, J BONE MINER RES, V20, P1462, DOI 10.1359/JBMR.050324
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
NR 69
TC 28
Z9 32
U1 1
U2 19
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD FEB 13
PY 2020
VL 10
IS 1
AR 2513
DI 10.1038/s41598 020 59363 y
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA NE8XH
UT WOS:000562888000002
PM 32054921
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Xu, C
   Jin, SQ
   Jin, C
   Dai, ZH
   Wu, YH
   He, GL
   Ma, HW
   Xu, CY
   Fang, WL
AF Xu, Cong
   Jin, Shu Qing
   Jin, Chen
   Dai, Zi Han
   Wu, Yu Hao
   He, Gao Lu
   Ma, Hai Wei
   Xu, Chao Yi
   Fang, Wen Lai
TI Cedrol, a Ginger derived sesquiterpineol, suppresses estrogen deficient
   osteoporosis by intervening NFATc1 and reactive oxygen species
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Ginger; Cedrol; Osteoporosis; Osteoclast; RANKL; ROS
ID NF KAPPA B; INHIBITS OSTEOCLASTOGENESIS; DNA DAMAGE; DIFFERENTIATION;
   ACTIVATION; MICE; INFLAMMATION; ANTICANCER; ARTHRITIS; EFFICACY
AB Osteoporosis is a prevalent bone metabolic disease in menopause, and long term medication is accompanied by serious side effects. Ginger, a food spice and traditional medicine with ancient history, exhibits the potential to alleviate osteoporosis in preclinical experiments, whereas its complex composition leads to ambiguous pharmacological mechanisms. The purpose of this study was to investigate the effect and mechanism of Ced in estrogen deficient osteoporosis, a sesquiterpene alcohol recently discovered from Ginger with multiple pharmacological properties. RANKL was stimulated BMM (bone marrow macrophages) differentiation into osteoclasts in vitro. And the osteoclast activity and number were assessed by TRAcP and SEM. We found that Ced mitigated RANKL induced osteoclastogenesis by descending the ROS content and obstructing NFATc1, NF KB, and MAPK signaling. Also, Ced mediated anti osteolytic property was found in ovariectomized mice by Micro CT scanning and histological staining. Summarily, our works demonstrated the anti osteoporotic potential of Cedrol in Ginger for the first time, which also offered more pharmacological evidence for Ginger as food or medicine used for bone metabolic disease.
C1 [Xu, Cong; Jin, Shu Qing; Jin, Chen; Dai, Zi Han; Wu, Yu Hao; He, Gao Lu; Fang, Wen Lai] Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed, Key Lab Orthopaed Zhejiang Prov, 109 Xueyuan Rd, Wenzhou 325000, Zhejiang, Peoples R China.
   [Xu, Cong; Jin, Shu Qing; Jin, Chen; Dai, Zi Han; Wu, Yu Hao; He, Gao Lu; Fang, Wen Lai] Wenzhou Med Univ, Yuying Childrens Hosp, 109 Xueyuan Rd, Wenzhou 325000, Zhejiang, Peoples R China.
   [Ma, Hai Wei] Wenzhou Med Univ, Lishui Cent Hosp, Dept Orthopaed Surg, 289 Kuocang Rd, Lishui 323000, Zhejiang, Peoples R China.
   [Ma, Hai Wei] Wenzhou Med Univ, Affiliated Hosp 5, 289 Kuocang Rd, Lishui 323000, Zhejiang, Peoples R China.
   [Xu, Cong; Jin, Shu Qing; Jin, Chen; Dai, Zi Han; Wu, Yu Hao; He, Gao Lu; Fang, Wen Lai] Wenzhou Med Univ, Sch Med 2, 270 Xueyuan Rd, Wenzhou 325000, Zhejiang, Peoples R China.
   [Xu, Chao Yi] Wenzhou Med Univ, Dept Obstet & Gynecol, Affiliated Hosp 2, Wenzhou 325000, Zhejiang, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical
   University; Wenzhou Medical University; Wenzhou Medical University;
   Wenzhou Medical University
RP Fang, WL (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthopaed, Key Lab Orthopaed Zhejiang Prov, 109 Xueyuan Rd, Wenzhou 325000, Zhejiang, Peoples R China.; Fang, WL (通讯作者)，Wenzhou Med Univ, Yuying Childrens Hosp, 109 Xueyuan Rd, Wenzhou 325000, Zhejiang, Peoples R China.; Ma, HW (通讯作者)，Wenzhou Med Univ, Lishui Cent Hosp, Dept Orthopaed Surg, 289 Kuocang Rd, Lishui 323000, Zhejiang, Peoples R China.; Ma, HW (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 5, 289 Kuocang Rd, Lishui 323000, Zhejiang, Peoples R China.; Xu, CY (通讯作者)，Wenzhou Med Univ, Dept Obstet & Gynecol, Affiliated Hosp 2, Wenzhou 325000, Zhejiang, Peoples R China.
EM mhwwmu@163.com; wzpyxcy@126.com; feyfwl@yeah.net
RI He, Gaolu/IUQ 7491 2023; jin, chen/KBQ 8592 2024
FU National Natural Science Foundation of China [82102614]; Wenzhou Science
   and Technology Bureau Foun dation [2021Y1434, Y20190399]
FX Acknowledgements This study is supported by the National Natural Science
   Foundation of China (82102614) ; Wenzhou Science and Technology Bureau
   Foun dation (2021Y1434, Y20190399) .
CR Adler RA, 2016, J BONE MINER RES, V31, P16, DOI 10.1002/jbmr.2708
   Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Bhatia SP, 2008, FOOD CHEM TOXICOL, V46, pS100, DOI 10.1016/j.fct.2008.06.038
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031 10
   Chang KF, 2020, J NAT PROD, V83, P3021, DOI 10.1021/acs.jnatprod.0c00580
   Chang KF, 2020, CANCER LETT, V495, P180, DOI 10.1016/j.canlet.2020.09.007
   Chen D., PHARMACOL RES
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Chen X, 2020, FOOD FUNCT, V11, P4752, DOI [10.1039/d0fo00549e, 10.1039/D0FO00549E]
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Emami SA, 2011, IRAN J PHARM RES, V10, P799
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Forouzanfar F, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/4943965
   Funk JL, 2012, FASEB J, V26
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   Hodge JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021462
   Hou N, 2008, ENDOCRINOLOGY, V149, P1654, DOI 10.1210/en.2007 0988
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Ito S, 2016, BIOSCI BIOTECH BIOCH, V80, P779, DOI 10.1080/09168451.2015.1127133
   Jung YY, 2008, J BIOL CHEM, V283, P23863, DOI 10.1074/jbc.M803072200
   Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041
   Kang IS, 2016, SCI REP UK, V6, DOI 10.1038/srep38014
   Kanzaki H, 2016, REDOX BIOL, V8, P186, DOI 10.1016/j.redox.2016.01.006
   Kiyama R, 2020, J NUTR BIOCHEM, V86, DOI 10.1016/j.jnutbio.2020.108486
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Luo F, 2019, PHYTOCHEMISTRY, V162, P121, DOI 10.1016/j.phytochem.2019.03.009
   Mishra SK, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.571676
   Mlakar SJ, 2012, MATURITAS, V71, P180, DOI 10.1016/j.maturitas.2011.11.023
   Park JH, 2017, MOL CELLS, V40, P706
   Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092 8674(00)80344 X
   Ryter SW, 2021, CELLS BASEL, V10, DOI 10.3390/cells10030515
   Sahebkar A, 2011, WORLD J GASTROENTERO, V17, P271, DOI 10.3748/wjg.v17.i2.271
   Sasaki H, 2009, J MED INVESTIG, V56, P33, DOI 10.2152/jmi.56.33
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Su YC, 2012, NAT PROD COMMUN, V7, P1245
   Tai TW, 2017, SCI REP UK, V7, DOI 10.1038/srep44245
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Tantikanlayaporn D, 2013, PHYTOMEDICINE, V20, P676, DOI 10.1016/j.phymed.2013.02.008
   Tiwari AK, 2001, J AGR FOOD CHEM, V49, P4642, DOI 10.1021/jf010573a
   van der Kraan AGJ, 2013, BIOCHEM J, V451, P235, DOI 10.1042/BJ20121626
   Wang C, 2003, J BONE MINER RES, V18, P2159, DOI 10.1359/jbmr.2003.18.12.2159
   Wei LH, 2022, PHARMACOL RES, V184, DOI 10.1016/j.phrs.2022.106400
   Xian Y., BIOCHEM PHARMACOL, V193
   Xiao YL, 2017, BLOOD ADV, V1, P1993, DOI 10.1182/bloodadvances.2017008540
   Xu Q, 2016, J BIOL CHEM, V291, P20030, DOI 10.1074/jbc.M116.731216
   Zang LQ, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.588093
   Zhang YM, 2021, J AGR FOOD CHEM, V69, P5332, DOI 10.1021/acs.jafc.1c00284
   Zhao HY, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6345857
NR 53
TC 7
Z9 7
U1 1
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD APR
PY 2023
VL 117
AR 109893
DI 10.1016/j.intimp.2023.109893
EA FEB 2023
PG 11
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA C9DT9
UT WOS:000964848300001
PM 36842234
DA 2025 08 17
ER

PT J
AU Yang, K
   Miron, RJ
   Bian, Z
   Zhang, YF
AF Yang, K.
   Miron, R. J.
   Bian, Z.
   Zhang, Y. F.
TI A bone targeting drug delivery system based on Semaphorin 3A gene
   therapy ameliorates bone loss in osteoporotic ovariectomized mice
SO BONE
LA English
DT Article
DE Semaphorin3A; (AspSerSer)6; Bone targeting; Osteoporosis
ID POSTMENOPAUSAL WOMEN; MICROARCHITECTURE; SCAFFOLDS; STRENGTH;
   EXPRESSION; SEMA3A; REPAIR
AB Osteoporosis is a serious health problem worldwide. Semaphonns (Sema) have been described as key molecules involved in the cross talk between bone cells (osteoblasts/osteoclasts). In this study, we investigated whether plasmid containing Sema3a could ameliorate bone loss in an ovariectomized (OVX) mouse model via (AspSerSer)(6), a selectively bone targeting moiety. Plasmid pcDNA3.1(+) Sema3a GFP was fabricated and transfected cells with the plasmid demonstrated statistically higher levels of Sema3A in vitro (p < 0.001). Mice were ovariectomized and injected twice weekly with (AspSerSer)(6) (STR R8) + pcDNA3.1(+) Sema3a GFP for four weeks. The aim of the study was twofold: firstly to design an effective bone targeting drug delivery system (AspSerSer)(6). Secondly, the effects of Sem3A gene therapy on bone loss was investigated Here, the targeting selectivity of pcDNA3.1(+) Sema3a GFP via (AspSerSer)(6) to the trabecular bone surface was firstly verified by histological observation of frozen sections and immunofluorescence staining. Then, bone microstructure analysis by Micro CT indicated significantly less bone loss in mice treated with (AspSerSer)(6) (STR R8) + pcDNA3.1(+)Sema3a GFP compared to the control group (p < 0.05). Furthermore,H&E staining and Safranin O staining of the decalcified sections demonstrated statistically significantly higher bone area/total area in the mice that were injected with (AspSerSer)(6) (STR R8) + pcDNA3.1(+) Sema3a GFP (p < 0.001, p < 0.01,respectively). TRAP staining and immunohistochemistry staining of COL I demonstrated lower numbers of osteoclasts and significantly increased numbers of osteoblasts in the bone targeting moiety delivering pcDNA3.1(+) Sema3a GFP group, when compared to the control group (p < 0.01, p < 0.001,respectively). Together, our findings have identified that, (AspSerSer)(6), a bone targeting drug delivery system based on semaphorin3A gene therapy, ameliorated bone loss in osteoporotic ovariectomized mice, by suppressing osteoclastic bone resorption and simultaneously increasing osteoblastic bone formation. Gene therapy by local site specific Sema3A overexpression might be a potential new strategy for treating osteoporosis and bone defects.
C1 [Yang, K.; Miron, R. J.; Bian, Z.; Zhang, Y. F.] Wuhan Univ, Sch & Hosp Stomatol, Minist Educ, State Key Lab Breeding Base Basic Sci Stomatol Hu, Wuhan, Hubei, Peoples R China.
   [Yang, K.; Miron, R. J.; Bian, Z.; Zhang, Y. F.] Wuhan Univ, Sch & Hosp Stomatol, Minist Educ, Key Lab Oral Biomed, Wuhan, Hubei, Peoples R China.
   [Miron, R. J.] Nova Southeastern Univ, Coll Dent Med, Cell Therapy Inst, Dept Periodontol, Ft Lauderdale, FL 33314 USA.
   [Bian, Z.] Wuhan Univ, Sch & Hosp Stomatol, Dept Endodont, Wuhan, Hubei, Peoples R China.
   [Zhang, Y. F.] Wuhan Univ, Sch & Hosp Stomatol, Dept Dent Implantol, Wuhan, Hubei, Peoples R China.
C3 Wuhan University; Wuhan University; Nova Southeastern University; Wuhan
   University; Wuhan University
RP Bian, Z (通讯作者)，Wuhan Univ, Sch & Hosp Stomatol, Dept Endodont, Wuhan, Hubei, Peoples R China.; Zhang, YF (通讯作者)，Wuhan Univ, Sch & Hosp Stomatol, Dept Dent Implantol, Wuhan, Hubei, Peoples R China.
EM bianzhuan@whu.edu.cn; zyf@whu.edu.cn
RI Miron, Richard/J 4995 2012; Zhang, Yufeng/GZL 1973 2022
OI Zhang, Yufeng/0000 0001 8702 5291
FU National Natural Science Foundation of China [81570954, 81470727,
   81120108010]; Foreign Cooperation Projects in Science and Technology of
   Hubei Province [2017AHB046]; National key research and development
   program [2016YFC1000505]; Hubei Province's Outstanding Medical Academic
   Leader program [2013AB033]
FX This work was supported by the funds of the National Natural Science
   Foundation of China (81570954, 81470727, 81120108010 [International
   cooperation and exchange projects]), the Foreign Cooperation Projects in
   Science and Technology of Hubei Province (2017AHB046) and the National
   key research and development program (2016YFC1000505) and Hubei
   Province's Outstanding Medical Academic Leader program (2013AB033).
CR Akbar MA, 2017, HUM GENE THER, V28, P179, DOI 10.1089/hum.2016.069
   Akbar MA, 2016, HUM GENE THER, V27, P679, DOI 10.1089/hum.2016.029
   Becker David J, 2010, Curr Rheumatol Rep, V12, P186, DOI 10.1007/s11926 010 0097 y
   Chen WQ, 2015, P NATL ACAD SCI USA, V112, pE3893, DOI 10.1073/pnas.1501759112
   Cheng N, 2013, J MATER SCI MATER M, V24, P1963, DOI 10.1007/s10856 013 4945 y
   Corr A, 2017, TOXICOL PATHOL, V45, P894, DOI 10.1177/0192623317738708
   Crotti TN, 2004, BIOMATERIALS, V25, P565, DOI 10.1016/S0142 9612(03)00556 8
   Fukuda T, 2013, NATURE, V497, P490, DOI 10.1038/nature12115
   Genant HK, 1999, OSTEOPOROSIS INT, V10, P259, DOI 10.1007/s001980050224
   Hansen S, 2013, J BONE MINER RES, V28, P736, DOI 10.1002/jbmr.1784
   Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000
   Haynes D. R., 2006, Inflammopharmacology, V14, P193, DOI 10.1007/s10787 006 0006 1
   Henriksen K, 2014, CALCIFIED TISSUE INT, V94, P88, DOI 10.1007/s00223 013 9741 7
   Kofron MD, 2006, ADV DRUG DELIVER REV, V58, P555, DOI 10.1016/j.addr.2006.03.008
   Leder BZ, 2017, CURR OSTEOPOROS REP, V15, P110, DOI 10.1007/s11914 017 0353 4
   Lewiecki EM, 2011, NAT REV RHEUMATOL, V7, P631, DOI 10.1038/nrrheum.2011.130
   Li YF, 2017, J BIOMED MATER RES B, V105, P2060, DOI 10.1002/jbm.b.33730
   Liu DM, 2014, J CLIN ENDOCR METAB, V99, pE2504, DOI 10.1210/jc.2014 1443
   Liu WQ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12794
   Liu XW, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/2545214
   Ma RF, 2017, CELL PHYSIOL BIOCHEM, V41, P55, DOI 10.1159/000455936
   Macdonald HM, 2011, OSTEOPOROSIS INT, V22, P357, DOI 10.1007/s00198 010 1226 1
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Neufeld G, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006718
   Ohlsson C, 2013, NAT REV ENDOCRINOL, V9, P72, DOI 10.1038/nrendo.2012.252
   Ominsky MS, 2017, BONE, V96, P63, DOI 10.1016/j.bone.2016.10.019
   Phillips JE, 2007, BIOMATERIALS, V28, P211, DOI 10.1016/j.biomaterials.2006.07.032
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Reid IR, 2015, NAT REV ENDOCRINOL, V11, P418, DOI 10.1038/nrendo.2015.71
   Saad S, 2016, ACTA BIOMATER, V30, P311, DOI 10.1016/j.actbio.2015.11.025
   Saul D, 2017, BONE, V101, P134, DOI 10.1016/j.bone.2017.04.011
   Silva BC, 2011, ANNU REV MED, V62, P307, DOI 10.1146/annurev med 061709 145401
   Storrie H, 2006, ADV DRUG DELIVER REV, V58, P500, DOI 10.1016/j.addr.2006.03.004
   Takamatsu H, 2010, CELL MOL IMMUNOL, V7, P83, DOI 10.1038/cmi.2009.111
   Takeda S, 2008, J NEUROENDOCRINOL, V20, P802, DOI 10.1111/j.1365 2826.2008.01732.x
   Wang D, 2007, BIOCONJUGATE CHEM, V18, P1375, DOI 10.1021/bc7002132
   Wang DX, 2006, ANAL CHEM, V78, P3681, DOI 10.1021/ac051904b
   Yarbrough DK, 2010, CALCIFIED TISSUE INT, V86, P58, DOI 10.1007/s00223 009 9312 0
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhang Y, 2014, J DENT RES, V93, P1095, DOI 10.1177/0022034514552676
   Zhang YF, 2016, SCI REP UK, V6, DOI 10.1038/srep26925
   Zhang YF, 2015, J BONE MINER RES, V30, P286, DOI 10.1002/jbmr.2322
   Zhang YF, 2012, BIOMATERIALS, V33, P6698, DOI 10.1016/j.biomaterials.2012.06.021
NR 43
TC 30
Z9 33
U1 0
U2 38
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD SEP
PY 2018
VL 114
BP 40
EP 49
DI 10.1016/j.bone.2018.06.003
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA GQ1EJ
UT WOS:000441369000005
PM 29883786
DA 2025 08 17
ER

PT J
AU Hu, GL
   Yu, YL
   Ren, YS
   Tower, RJ
   Zhang, GF
   Karner, CM
AF Hu, Guoli
   Yu, Yilin
   Ren, Yinshi
   Tower, Robert J.
   Zhang, Guo Fang
   Karner, Courtney M.
TI Glutaminolysis provides nucleotides and amino acids to regulate
   osteoclast differentiation in mice
SO EMBO REPORTS
LA English
DT Article
DE Glutaminolysis; Amino Acids; Nucleotides; Osteoclast; Osteoporosis
ID MITOCHONDRIAL BIOGENESIS; THERAPEUTIC TARGETS; BONE; RANKL; METABOLISM;
   RECEPTOR; PROTEIN; NFATC1; CYTOKINES; CELLS
AB Osteoclasts are bone resorbing cells that are essential to maintain skeletal integrity and function. While many of the growth factors and molecular signals that govern osteoclastogenesis are well studied, how the metabolome changes during osteoclastogenesis is unknown. Using a multifaceted approach, we identified a metabolomic signature of osteoclast differentiation consisting of increased amino acid and nucleotide metabolism. Maintenance of the osteoclast metabolic signature is governed by elevated glutaminolysis. Mechanistically, glutaminolysis provides amino acids and nucleotides which are essential for osteoclast differentiation and bone resorption in vitro. Genetic experiments in mice found that glutaminolysis is essential for osteoclastogenesis and bone resorption in vivo. Highlighting the therapeutic implications of these findings, inhibiting glutaminolysis using CB 839 prevented ovariectomy induced bone loss in mice. Collectively, our data provide strong genetic and pharmacological evidence that glutaminolysis is essential to regulate osteoclast metabolism, promote osteoclastogenesis and modulate bone resorption in mice.
   Metabolic rewiring is essential for osteoclast differentiation and bone resorption. This study shows that glutaminolysis regulates osteoclast differentiation and bone resorption by maintaining amino acid and nucleotide abundance.Amino acid and nucleotide abundance increases during osteoclastogenesis.Glutaminolysis and glutamate transamination reactions provide amino acids and nucleotides that are essential for osteoclast differentiation and function.GLS deficiency in myeloid cells leads to reduced osteoclastogenesis and increased bone mass.Increasing glutaminolysis in myeloid cells enhances osteoclastogenesis and reduces bone mass.Pharmacological inhibition of glutaminolysis prevents estrogen deficiency induced osteoclast expansion and bone loss.
   Metabolic rewiring is essential for osteoclast differentiation and bone resorption. This study shows that glutaminolysis regulates osteoclast differentiation and bone resorption by maintaining amino acid and nucleotide abundance.
C1 [Hu, Guoli; Yu, Yilin; Karner, Courtney M.] Univ Texas Southwestern Med Ctr, Dept Internal Med, Dallas, TX 75390 USA.
   [Ren, Yinshi] Texas Scottish Rite Hosp Children, Ctr Excellence Hip Disorders, Dallas, TX 75219 USA.
   [Ren, Yinshi] Univ Texas Southwestern Med Ctr, Dept Orthoped Surg, Dallas, TX 75390 USA.
   [Tower, Robert J.] Univ Texas Southwestern Med Ctr, Dept Surg, Dallas, TX 75390 USA.
   [Tower, Robert J.; Karner, Courtney M.] Univ Texas Southwestern Med Ctr, Charles & Jane Pak Ctr Mineral Metab & Clin Res, Dallas, TX 75390 USA.
   [Zhang, Guo Fang] Duke Univ, Med Ctr, Dept Med, Div Endocrinol Metab Nutr, Durham, NC 27701 USA.
   [Zhang, Guo Fang] Duke Univ, Sch Med, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27701 USA.
   [Zhang, Guo Fang] Duke Univ, Duke Mol Physiol Inst, Sch Med, Durham, NC 27701 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center; Texas Scottish Rite Hospital for Children; University of Texas
   System; University of Texas Southwestern Medical Center; University of
   Texas System; University of Texas Southwestern Medical Center;
   University of Texas System; University of Texas Southwestern Medical
   Center; Duke University; Duke University; Duke University
RP Karner, CM (通讯作者)，Univ Texas Southwestern Med Ctr, Dept Internal Med, Dallas, TX 75390 USA.; Karner, CM (通讯作者)，Univ Texas Southwestern Med Ctr, Charles & Jane Pak Ctr Mineral Metab & Clin Res, Dallas, TX 75390 USA.
EM Courtney.Karner@UTSouthwestern.edu
RI ; Liu, Fang/HTN 2574 2023
OI Zhang, Guo Fang/0000 0003 3484 5864; Tower, Robert/0000 0001 5856 5758;
   Ren, Yinshi/0000 0003 3361 6015; Karner, Courtney/0000 0003 0387 4486
FU HHS | NIH | National Institute of Arthritis and Musculoskeletal and Skin
   Diseases (NIAMS) [AR076325, AR071967]; National Institute of Arthritis
   and Musculoskeletal and Skin Diseases (NIAMS)
FX We thank Sierra Root, Vishal Patel and Thomas J Carroll for helpful
   discussions; the CRI metabolomics Core for help with metabolomics and
   data analysis, the McDermott Center Sequencing Core for help with
   mRNA seq and data analysis. This work was supported by the National
   Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
   grants (AR076325 and AR071967) to CMK The funders had no role in study
   design, data acquisition, decision to publish, or preparation of the
   manuscript.
CR Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   An E, 2014, MOL CELL PROTEOMICS, V13, P2687, DOI 10.1074/mcp.M113.034371
   Arnett TR, 2018, BONE, V115, P25, DOI 10.1016/j.bone.2017.12.021
   Birsoy K, 2015, CELL, V162, P540, DOI 10.1016/j.cell.2015.07.016
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Choi Y, 2009, NAT REV RHEUMATOL, V5, P543, DOI 10.1038/nrrheum.2009.175
   Da WCL, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.675385
   DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104
   DeSelm CJ, 2011, DEV CELL, V21, P966, DOI 10.1016/j.devcel.2011.08.016
   Go M, 2022, EXP MOL MED, V54, P825, DOI 10.1038/s12276 022 00775 3
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Guo Q, 2025, AGING DIS, V16, P432, DOI 10.14336/AD.2024.0201
   HALL TJ, 1994, BIOCHEM BIOPH RES CO, V199, P1237, DOI 10.1006/bbrc.1994.1363
   Hamerman JA, 2006, J IMMUNOL, V177, P2051, DOI 10.4049/jimmunol.177.4.2051
   Harding JJ, 2021, CLIN CANCER RES, V27, P4994, DOI 10.1158/1078 0432.CCR 21 1204
   Hu GL, 2023, JCI INSIGHT, V8, DOI 10.1172/jci.insight.166888
   Humphrey MB, 2006, J BONE MINER RES, V21, P237, DOI 10.1359/JBMR.051016
   Indo Y, 2013, J BONE MINER RES, V28, P2392, DOI 10.1002/jbmr.1976
   Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910
   Karner CM, 2015, J CLIN INVEST, V125, P551, DOI 10.1172/JCI78470
   Kikuta J, 2013, RHEUMATOLOGY, V52, P226, DOI 10.1093/rheumatology/kes259
   Kim H, 2021, CELLS BASEL, V10, DOI 10.3390/cells10010089
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kim N, 2002, J EXP MED, V195, P201, DOI 10.1084/jem.20011681
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Kushwaha P, 2022, FRONT PHYSIOL, V13, DOI 10.3389/fphys.2022.997358
   Lee S, 2021, BONE, V145, DOI 10.1016/j.bone.2020.115836
   Lee SK, 2006, CURR OPIN RHEUMATOL, V18, P411, DOI 10.1097/01.bor.0000231911.42666.78
   Lemma S, 2016, INT J BIOCHEM CELL B, V79, P168, DOI 10.1016/j.biocel.2016.08.034
   Li BE, 2020, FASEB J, V34, P11058, DOI 10.1096/fj.202000771R
   López Ibáñez J, 2016, NUCLEIC ACIDS RES, V44, pW201, DOI 10.1093/nar/gkw253
   Macedo F, 2017, ONCOL REV, V11, P43, DOI 10.4081/oncol.2017.321
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Mi HY, 2019, NAT PROTOC, V14, P703, DOI 10.1038/s41596 019 0128 8
   Miyazaki T, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.385369
   Parker SJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 25228 9
   Peng RP, 2024, CELL DEATH DIS, V15, DOI 10.1038/s41419 024 06475 2
   Rohatgi N, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 41629 4
   Rose NR, 2011, CHEM SOC REV, V40, P4364, DOI 10.1039/c0cs00203h
   Sato K, 2006, CURR OPIN RHEUMATOL, V18, P419, DOI 10.1097/01.bor.0000231912.24740.a5
   Shaker JL, 2009, THER ADV MUSCULOSKEL, V1, P107, DOI 10.1177/1759720X09351779
   Sharma D, 2021, ELIFE, V10, DOI [10.7554/eLife.71595, 10.7554/eLife.71595.sa1, 10.7554/eLife.71595.sa2]
   Shen GS, 2018, CELL PHYSIOL BIOCHEM, V50, P1916, DOI 10.1159/000494872
   Song C, 2023, JCI INSIGHT, V8, DOI 10.1172/jci.insight.174293
   Stegen S, 2024, NAT METAB, V6, P141, DOI 10.1038/s42255 023 00948 y
   Stegen S, 2021, J BONE MINER RES, V36, P604, DOI 10.1002/jbmr.4219
   Stegen S, 2020, DEV CELL, V53, P530, DOI 10.1016/j.devcel.2020.05.001
   Stegen S, 2016, CELL METAB, V23, P265, DOI 10.1016/j.cmet.2016.01.002
   Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1857
   Tsukasaki M, 2020, NAT METAB, V2, DOI 10.1038/s42255 020 00318 y
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang Q, 2003, J CELL BIOL, V160, P565, DOI 10.1083/jcb.200207036
   Yu YL, 2019, CELL METAB, V29, P966, DOI 10.1016/j.cmet.2019.01.016
   Zeng R, 2015, J BONE MINER RES, V30, P2287, DOI 10.1002/jbmr.2584
   Zhang HY, 2022, J BONE MINER RES, V37, P983, DOI 10.1002/jbmr.4532
   Zhang Y, 2018, J BONE MINER RES, V33, P1114, DOI 10.1002/jbmr.3398
   Zhao BH, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3379
NR 60
TC 7
Z9 7
U1 5
U2 13
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1469 221X
EI 1469 3178
J9 EMBO REP
JI EMBO Rep.
PD OCT 10
PY 2024
VL 25
IS 10
BP 4515
EP 4541
DI 10.1038/s44319 024 00255 x
EA SEP 2024
PG 27
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA J4T5L
UT WOS:001312059200003
PM 39271775
OA gold
DA 2025 08 17
ER

PT J
AU Park, KR
   Lee, JY
   Cho, M
   Hong, JT
   Yun, HM
AF Park, Kyung Ran
   Lee, Joon Yeop
   Cho, Myounglae
   Hong, Jin Tae
   Yun, Hyung Mun
TI Paeonolide as a Novel Regulator of Core Binding Factor Subunit Alpha 1
   in Bone Forming Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE Paeonia suffruticosa; paeonolide; osteoblast differentiation; bone
   mineralization; ERK1; 2; RUNX2; Cbfa1
ID RANKL INDUCED OSTEOCLASTOGENESIS; OSTEOBLAST DIFFERENTIATION;
   OSTEOPOROSIS; MECHANISMS; OSTEOSARCOMA; APOPTOSIS; GLYCOSIDE; PATHWAYS;
   PRODUCTS; BMP
AB Paeonia suffruticosa has been extensively used as a traditional medicine with various beneficial effects; paeonolide (PALI) was isolated from its dried roots. This study aimed to investigate the novel effects and mechanisms of PALI in pre osteoblasts. Here, cell viability was evaluated using an MTT assay. Early and late osteoblast differentiation was examined by analyzing the activity of alkaline phosphatase (ALP) and by staining it with Alizarin red S (ARS). Cell migration was assessed using wound healing and Boyden chamber assays. Western blot and immunofluorescence analyses were used to examine the intracellular signaling pathways and differentiation proteins. PALI (0.1, 1, 10, 30, and 100 mu M) showed no cytotoxic or proliferative effects in pre osteoblasts. In the absence of cytotoxicity, PALI (1, 10, and 30 mu M) promoted wound healing and transmigration during osteoblast differentiation. ALP staining demonstrated that PALI (1, 10, and 30 mu M) promoted early osteoblast differentiation in a dose dependent manner, and ARS staining showed an enhanced mineralized nodule formation, a key indicator of late osteoblast differentiation. Additionally, low concentrations of PALI (1 and 10 mu M) increased the bone morphogenetic protein (BMP) Smad1/5/8 and Wnt beta catenin pathways in osteoblast differentiation. Particularly, PALI (1 and 10 mu M) increased the phosphorylation of ERK1/2 compared with BMP2 treatment, an FDA approved drug for bone diseases. Furthermore, PALI mediated early and late osteoblast differentiation was abolished in the presence of the ERK1/2 inhibitor U0126. PALI induced RUNX2 (Cbfa1) expression and nuclear localization were also attenuated by blocking the ERK1/2 pathway during osteoblast differentiation. We suggest that PALI has biologically novel activities, such as enhanced osteoblast differentiation and bone mineralization mainly through the intracellular ERK1/2 RUNX2 signaling pathway, suggesting that PALI might have therapeutic action and aid the treatment and prevention of bone diseases, such as osteoporosis and periodontitis.
C1 [Park, Kyung Ran; Yun, Hyung Mun] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, Seoul 02447, South Korea.
   [Lee, Joon Yeop; Cho, Myounglae] Natl Inst Korean Med Dev, Gyongsan 38540, South Korea.
   [Hong, Jin Tae] Chungbuk Natl Univ, Coll Pharm, Chungbuk 28160, South Korea.
   [Hong, Jin Tae] Chungbuk Natl Univ, Med Res Ctr, Chungbuk 28160, South Korea.
C3 Kyung Hee University; Chungbuk National University; Chungbuk National
   University
RP Yun, HM (通讯作者)，Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, Seoul 02447, South Korea.
EM rudfks282@naver.com; chool9090@nikom.or.kr; meanglae@nikom.or.kr;
   jinthong@chungbuk.ac.kr; yunhm@khu.ac.kr
OI Hong, Jin Tae/0000 0002 6534 9575
FU National Research Foundation of Korea (NRF)   Korea government (MSIP)
   (MRC) [2017R1A5A2015541, NRF 2018R1D1A1B07043282]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MSIP) (MRC,
   2017R1A5A2015541; NRF 2018R1D1A1B07043282).
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Artigas N, 2014, J BIOL CHEM, V289, P27105, DOI 10.1074/jbc.M114.576793
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Cai SQ, 2020, SKELETAL RADIOL, V49, P273, DOI 10.1007/s00256 019 03280 3
   Chen G, 2006, J PHARMACEUT BIOMED, V41, P129, DOI 10.1016/j.jpba.2005.11.001
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Esfahanian Vahid, 2012, J Dent (Tehran), V9, P256
   Fakhry Maya, 2013, World J Stem Cells, V5, P136, DOI 10.4252/wjsc.v5.i4.136
   Franceschi Renny T, 2017, Curr Mol Biol Rep, V3, P122, DOI 10.1007/s40610 017 0059 5
   Granero Moltó F, 2009, STEM CELLS, V27, P1887, DOI 10.1002/stem.103
   Guntur AR, 2011, J ENDOCRINOL, V211, P123, DOI 10.1530/JOE 11 0175
   Ichida M, 2011, FEBS LETT, V585, P4018, DOI 10.1016/j.febslet.2011.11.014
   Iguchi M, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/3979606
   Infante A, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0995 x
   Irfan U M, 2001, J Int Acad Periodontol, V3, P14
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Kawai M, 2011, NAT REV DRUG DISCOV, V10, P141, DOI 10.1038/nrd3299
   Kim MB, 2014, FITOTERAPIA, V98, P59, DOI 10.1016/j.fitote.2014.07.013
   Kuwajima H, 1996, PHYTOCHEMISTRY, V41, P289, DOI 10.1016/0031 9422(95)00525 0
   Lee HS, 2011, PHYTOTHER RES, V25, P716, DOI 10.1002/ptr.3328
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Li J, 2019, BIOCHIMIE, V156, P129, DOI 10.1016/j.biochi.2018.09.004
   Liang YX, 2020, BIOACT MATER, V5, P297, DOI 10.1016/j.bioactmat.2020.02.012
   Liu TM, 2013, TISSUE ENG PART B RE, V19, P254, DOI [10.1089/ten.TEB.2012.0527, 10.1089/ten.teb.2012.0527]
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Marie PJ, 2015, CELL MOL LIFE SCI, V72, P1347, DOI 10.1007/s00018 014 1801 2
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Numan MS, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S88845
   Park KR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249579
   Park KR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218059
   Park KR, 2020, PHYTOMEDICINE, V79, DOI 10.1016/j.phymed.2020.153347
   Park KR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155332
   Park KR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103700
   Park KR, 2020, INT J BIOL SCI, V16, P330, DOI 10.7150/ijbs.37781
   Park KR, 2019, TOXICOLOGY, V422, P95, DOI 10.1016/j.tox.2019.05.010
   Park KR, 2018, THERANOSTICS, V8, P3087, DOI 10.7150/thno.24426
   Park KR, 2017, ARCH PHARM RES, V40, P933, DOI 10.1007/s12272 017 0932 z
   Russow G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010083
   Ryu G, 2001, ARCH PHARM RES, V24, P105, DOI 10.1007/BF02976476
   Sciandra M, 2014, J BONE MINER RES, V29, P1295, DOI 10.1002/jbmr.2141
   Soelaiman IN, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/764701
   Tsai HY, 2008, EUR J PHARMACOL, V588, P124, DOI 10.1016/j.ejphar.2008.04.024
   Wang CW, 2016, CURR OSTEOPOROS REP, V14, P284, DOI 10.1007/s11914 016 0330 3
   Whelan AM, 2006, ANN PHARMACOTHER, V40, P836, DOI 10.1345/aph.1G226
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   Zhang L, 2019, INT IMMUNOPHARMACOL, V72, P413, DOI 10.1016/j.intimp.2019.04.033
   Zheng XG, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414 431X20187574, 10.1590/1414 431x20187574]
NR 49
TC 7
Z9 8
U1 0
U2 13
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAY
PY 2021
VL 22
IS 9
AR 4924
DI 10.3390/ijms22094924
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA SC1FW
UT WOS:000650427400001
PM 34066458
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Shim, KS
   Lee, CJ
   Yim, NH
   Ha, H
   Ma, JY
AF Shim, Ki Shuk
   Lee, Chung Jo
   Yim, Nam Hui
   Ha, Hyunil
   Ma, Jin Yeul
TI A water extract of Malva verticillata seeds suppresses
   osteoclastogenesis and bone resorption stimulated by RANK ligand
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE Malvaceae; Malva verticillata seeds; Receptor activator of nuclear
   factor kappa B ligand; Osteoclasts; Nuclear factor of activated T cells;
   cytoplasmic 1
ID INDUCED OSTEOPOROSIS; CATHEPSIN K; DIFFERENTIATION; CONSTITUENTS;
   OSTEOBLASTS; FORMULA; FRUITS
AB Background: Malva verticillata seeds are used as a therapeutic medicine to treat kidney dysfunction in traditional Chinese medicine (TCM). TCM has suggested that herbal medicine tonifying kidney function may have beneficial effect on bone metabolism.
   Methods: Osteoclastogenesis was examined in bone marrow macrophages by measuring tartrate resistant acid phosphatase (TRAP) activity and counting the number of TRAP stained multinuclear cells. The activation of receptor activator of nuclear factor kB (RANK) ligand signaling, and the expression of c Fos and nuclear factor of activated T cells, cytoplasmic 1 (NFATc1) were investigated by western blot analysis. Transcription factor and bone resorption marker mRNA levels were evaluated using real time quantitative polymerase chain reaction. The bone resorption activity of mature osteoclast was examined in osteoclasts cultured on a hydroxyapatite coated culture plate.
   Results: A water extract of M. verticillata seeds (WEMV) inhibited osteoclastogenesis stimulated by RANKL. WEMV also strongly inhibited expression of c Fos and NFATc1 as well as phosphorylation of c Jun N terminal kinase, p38, I kBa, and phospholipase.2. Furthermore, WEMV significantly attenuated osteoclast resorption activity and downregulated mRNA expression of resorption markers.
   Conclusion: These results demonstrate that WEMV inhibits osteoclastogenesis and bone resorption by suppressing the RANKL signaling pathway and suggest that M. verticillata seeds may be used as a therapeutic candidate in complementary alternative medicine to treat pathological bone diseases.
C1 [Shim, Ki Shuk; Lee, Chung Jo; Yim, Nam Hui; Ha, Hyunil; Ma, Jin Yeul] Korea Inst Oriental Med, KM Applicat Ctr, 70 Cheomdanro Dong Gu, Daegu 41062, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM)
RP Ma, JY (通讯作者)，Korea Inst Oriental Med, KM Applicat Ctr, 70 Cheomdanro Dong Gu, Daegu 41062, South Korea.
EM jyma@kiom.re.kr
FU Korea Institute of Oriental Medicine [K15280]
FX This research was supported by a grant (K15280) funded by the Korea
   Institute of Oriental Medicine. We were thankful to Dr. T. Kitamura and
   Dr. N.A. Clipstone (Northwestern University) for the reagents.
CR Bae K., 2000, The process of opening access to documents of, VVolume 260
   Bischoff Ferrari HA, 2004, AM J MED, V116, P634, DOI 10.1016/j.amjmed.2003.12.029
   Boyce BF, 2012, EUR J CLIN INVEST, V42, P1332, DOI 10.1111/j.1365 2362.2012.02717.x
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chan BCL, 2014, J PHARM PHARMACOL, V66, P437, DOI 10.1111/jphp.12166
   Cornish J, 2008, ENDOCRINOLOGY, V149, P5688, DOI 10.1210/en.2008 0111
   Das S, 2013, DRUG DES DEV THER, V7, P435, DOI 10.2147/DDDT.S31504
   GONDA R, 1990, PLANTA MED, V56, P73, DOI 10.1055/s 2006 960888
   Jeong JC, 2003, INT IMMUNOPHARMACOL, V3, P1685, DOI 10.1016/j.intimp.2003.08.003
   Ju DH, 2014, FRONT MED PRC, V8, P389, DOI 10.1007/s11684 014 0362 y
   Kim HN, 2011, J BONE MINER RES, V26, P2161, DOI 10.1002/jbmr.426
   Kim HJ, 2012, BONE, V51, P643, DOI 10.1016/j.bone.2012.07.015
   Kim JeongAh Kim JeongAh, 2011, Natural Product Sciences, V17, P350
   Kim T, 2009, J BIOL CHEM, V284, P15308, DOI 10.1074/jbc.M807722200
   Kishimoto T, 2012, J PERIODONTAL RES, V47, P446, DOI 10.1111/j.1600 0765.2011.01452.x
   Leung P, 2011, BONE, V49, P623, DOI 10.1016/j.bone.2011.06.014
   Leung Ping Chung, 2013, J Tradit Complement Med, V3, P82, DOI 10.4103/2225 4110.110407
   Liu YQ, 2014, J ETHNOPHARMACOL, V157, P206, DOI 10.1016/j.jep.2014.09.033
   Maurer T, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/171209
   Miyamoto Takeshi, 2011, Keio Journal of Medicine, V60, P101
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Ransjö M, 2003, BIOCHEM BIOPH RES CO, V303, P1179, DOI 10.1016/S0006 291X(03)00502 3
   Riggs BL, 1998, J BONE MINER RES, V13, P168, DOI 10.1359/jbmr.1998.13.2.168
   Seo B, 2002, J APPL ORI MED, V2, P33
   Shen CL, 2012, NUTR RES, V32, P897, DOI 10.1016/j.nutres.2012.09.018
   SHIMIZU N, 1988, CHEM PHARM BULL, V36, P2778
   SHIMIZU N, 1987, CHEM PHARM BULL, V35, P4981
   TOMODA M, 1990, PLANTA MED, V56, P168, DOI 10.1055/s 2006 960917
   WHO, 2013, Medicinal plants in Mongolia
   Yan XT, 2015, ARCH PHARM RES, V38, P186, DOI 10.1007/s12272 014 0389 2
   Yang F, 2011, TRIALS, V12, DOI 10.1186/1745 6215 12 187
   Yang LC, 2013, J FUNCT FOODS, V5, P1642, DOI 10.1016/j.jff.2013.07.006
   Zhang H, 2008, MATURITAS, V61, P334, DOI 10.1016/j.maturitas.2008.09.023
   Zhang WP, 2012, AM J CHINESE MED, V40, P735, DOI 10.1142/S0192415X12500553
   Zhao Gang, 2003, J Tradit Chin Med, V23, P103
   Zhao Y, 2007, J PHARM PHARMACOL, V59, P1167, DOI 10.1211/jpp.59.8.0016
NR 36
TC 7
Z9 7
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1472 6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD AUG 31
PY 2016
VL 16
AR 332
DI 10.1186/s12906 016 1295 6
PG 10
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA DU4UW
UT WOS:000382209100001
PM 27580958
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Xu, C
   Wang, ZD
   Liu, YJ
   Duan, KY
   Guan, JZ
AF Xu, Chen
   Wang, Zhaodong
   Liu, Ya Jun
   Duan, Keyou
   Guan, Jianzhong
TI Harnessing GMNP loaded BMSC derived EVs to target miR 3064 5p via MEG3
   overexpression: Implications for diabetic osteoporosis therapy in rats
SO CELLULAR SIGNALLING
LA English
DT Article
DE Diabetic osteoporosis; Magnetic nanoparticles; Bone marrow mesenchymal
   stem cells; Extracellular vesicles; MEG3
ID MESENCHYMAL STEM CELLS; EXTRACELLULAR VESICLES; NONCODING RNA; EXOSOMES;
   DIFFERENTIATION; OSTEOGENESIS
AB Diabetic osteoporosis (DO) is a significant complication of diabetes, characterized by a decrease in bone mineral density and an increase in fracture risk. Magnetic nanoparticles (GMNPs) have emerged as potential drug carriers for various therapeutic applications. This study investigated the molecular mechanism of GMNPs loaded with bone marrow mesenchymal stem cell (BMSC) derived extracellular vesicles (EVs) overexpressing MEG3 target miR 3064 5p to induce NR4A3 for treating DO in rats. Initial analysis was carried out on GEO datasets GSE7158 and GSE62589, revealing a notable downregulation of NR4A3 in osteoporotic samples. Subsequent in vitro studies demonstrated the effective uptake of BMSC EVs MEG3 by osteoblasts and its potential to inhibit miR3064 5p, activating the PINK1/Parkin signaling pathway and thus promoting mitochondrial autophagy, osteoblast proliferation, and differentiation. In vivo, experiments using DO rat models further substantiated the therapeutic efficacy of GMNPE EVs MEG3 in alleviating osteoporosis symptoms. In conclusion, GMNPs loaded with BMSC EVs, through the delivery of MEG3 targeting miR 3064 5p, can effectively promote NR4A3 expression, activate the PINK1/Parkin pathway, and thereby enhance osteoblast proliferation and differentiation, offering a promising treatment for DO.
C1 [Xu, Chen; Wang, Zhaodong; Liu, Ya Jun; Duan, Keyou; Guan, Jianzhong] Bengbu Med Univ, Hosp 1, Dept Orthoped, 2600 Donghai Ave,287 Changhuai Rd, Bengbu 233000, Anhui, Peoples R China.
   [Xu, Chen; Wang, Zhaodong; Liu, Ya Jun; Duan, Keyou; Guan, Jianzhong] Bengbu Med Coll, Anhui Prov Key Lab Tissue Transplantat, 2600 Donghai Ave, Bengbu 233030, Anhui, Peoples R China.
C3 Bengbu Medical University; Bengbu Medical University
RP Guan, JZ (通讯作者)，Bengbu Med Univ, Hosp 1, Dept Orthoped, 2600 Donghai Ave,287 Changhuai Rd, Bengbu 233000, Anhui, Peoples R China.
EM jianzhongguan2023@xs.ustb.edu.cn
FU Anhui Provincial Department of Edu cation Key Project [2022AH051493];
   Anhui Provincial Department Key Laboratory Open Subject General Project
   [AHTT2022B002]
FX <B>Funding</B> This study was supported by Anhui Provincial Department
   of Edu cation Key Project (2022AH051493) and Anhui Provincial Department
   Key Laboratory Open Subject General Project (AHTT2022B002) .
CR An YA, 2019, FASEB J, V33, P12515, DOI 10.1096/fj.201802805RR
   Baker N, 2015, BONE, V70, P37, DOI 10.1016/j.bone.2014.10.014
   Behera J, 2022, LIFE SCI, V301, DOI 10.1016/j.lfs.2022.120595
   Bezerra AF, 2022, VET RES COMMUN, V46, P1259, DOI 10.1007/s11259 022 09995 4
   Castellano JJ, 2021, METHODS MOL BIOL, V2348, P285, DOI 10.1007/978 1 0716 1581 2_20
   Chao X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040388
   Charbord P, 2010, HUM GENE THER, V21, P1045, DOI 10.1089/hum.2010.115
   Chen LQ, 2020, CELL MOL BIOL LETT, V25, DOI 10.1186/s11658 020 00241 w
   Chen S, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0935 9
   Chen TN, 2022, GENOMICS, V114, DOI 10.1016/j.ygeno.2022.110452
   Dong ZJ, 2021, J TRANSL MED, V19, DOI 10.1186/s12967 021 02903 5
   Farzin A, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.201901058
   Gao MQ, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.945310
   Guo ZJ, 2023, J BIOENERG BIOMEMBR, DOI 10.1007/s10863 023 09959 6
   Hofbauer LC, 2022, LANCET DIABETES ENDO, V10, P207, DOI 10.1016/S2213 8587(21)00347 8
   Hou XS, 2018, BIOMATER SCI UK, V6, DOI 10.1039/c8bm00673c
   Hu XY, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.871008
   Huang JJ, 2022, LANCET HAEMATOL, V9, pE670, DOI 10.1016/S2352 3026(22)00165 X
   Huang M, 2021, DIFFERENTIATION, V120, P19, DOI 10.1016/j.diff.2021.05.002
   Hunt JE, 2020, ELIFE, V9, DOI 10.7554/eLife.59285
   Kalra Sanjay, 2022, J Pak Med Assoc, V72, P1663, DOI 10.47391/JPMA.22 86
   Kurra S, 2014, ENDOCRIN METAB CLIN, V43, P233, DOI 10.1016/j.ecl.2013.09.004
   LeBoff MS, 2022, OSTEOPOROSIS INT, V33, P2049, DOI 10.1007/s00198 021 05900 y
   Li CJ, 2020, THERANOSTICS, V10, P7422, DOI 10.7150/thno.42167
   Li W, 2023, CELL DEATH DIS, V14, DOI 10.1038/s41419 023 05595 5
   Li WW, 2019, MOL MED REP, V19, P3676, DOI 10.3892/mmr.2019.10040
   Li X, 2019, LIFE SCI, V232, DOI 10.1016/j.lfs.2019.116602
   Li Y, 2020, CANCER LETT, V485, P38, DOI 10.1016/j.canlet.2020.04.023
   Li Z, 2017, MOL CELL BIOCHEM, V433, P51, DOI 10.1007/s11010 017 3015 z
   Liu SY, 2020, NAT BIOMED ENG, V4, P1063, DOI 10.1038/s41551 020 00637 1
   Lu J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046 018 0814 3
   Luo AP, 2019, ONCOGENE, V38, P4990, DOI 10.1038/s41388 019 0771 0
   Marzi M, 2022, BIOMED RES INT, V2022, DOI 10.1155/2022/2346941
   Matsuzaki K, 2017, ONCOTARGET, V8, P24668, DOI 10.18632/oncotarget.14969
   Mohsin S, 2019, EXPERT OPIN BIOL TH, V19, P937, DOI 10.1080/14712598.2019.1618266
   Mulcahy LA, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24641
   Pan W, 2023, SCI BULL, V68, P838, DOI 10.1016/j.scib.2023.03.043
   Qi X, 2016, INT J BIOL SCI, V12, P836, DOI 10.7150/ijbs.14809
   Qin X, 2018, J CELL BIOCHEM, V119, P1074, DOI 10.1002/jcb.26275
   Rui YF, 2012, KNEE SURG SPORT TR A, V20, P1409, DOI 10.1007/s00167 011 1685 8
   Shapiro IM, 2014, AUTOPHAGY, V10, P7, DOI 10.4161/auto.26679
   Tamura Hiroshi, 2019, J Phys Ther Sci, V31, P621, DOI 10.1589/jpts.31.621
   Tian WJ, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 04510 8
   Wang C, 2019, CELL CYCLE, V18, P932, DOI 10.1080/15384101.2019.1593645
   Wang N, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.937803
   Xu C, 2023, CELL BIOL TOXICOL, V39, P1257, DOI 10.1007/s10565 022 09744 y
   Yang R, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.607910
   Yang XC, 2019, AGING US, V11, P8777, DOI 10.18632/aging.102264
   Yang XM, 2021, BIOL PROCED ONLINE, V23, DOI 10.1186/s12575 020 00140 6
   Yang Y, 2020, BIOL RES, V53, DOI 10.1186/s40659 020 00309 z
   Yin HL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 21514 8
   Zhang R, 2017, BIOCHEM BIOPH RES CO, V490, P406, DOI 10.1016/j.bbrc.2017.06.055
   Zhou WY, 2019, AM J SPORT MED, V47, P1722, DOI 10.1177/0363546519848678
   Zhuang WZ, 2015, STEM CELLS, V33, P1985, DOI 10.1002/stem.1989
NR 54
TC 8
Z9 9
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0898 6568
EI 1873 3913
J9 CELL SIGNAL
JI Cell. Signal.
PD JUN
PY 2024
VL 118
AR 111055
DI 10.1016/j.cellsig.2024.111055
EA MAR 2024
PG 21
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA OH6F2
UT WOS:001206413200001
PM 38246512
DA 2025 08 17
ER

PT J
AU Bae, S
   Zeng, S
   Park Min, KH
AF Bae, Seyeon
   Zeng, Steven
   Park Min, Kyung Hyun
TI Nuclear receptors in osteoclasts
SO CURRENT OPINION IN PHARMACOLOGY
LA English
DT Article
ID LIVER X RECEPTOR; ESTROGEN RELATED RECEPTORS; SUPPRESS BONE FORMATION;
   GLUCOCORTICOID RECEPTOR; PPAR GAMMA; REGULATES OSTEOCLASTOGENESIS;
   OSTEOBLAST DIFFERENTIATION; BINDING PROTEIN; ACTIVATION; BETA
AB Osteoclasts are bone resorbing cells that play an essential role in the remodeling of bone under physiological conditions and numerous pathological conditions, such as osteoporosis, bone metastasis, and inflammatory bone erosion. Nuclear receptors are crucial to various physiological processes, including metabolism, development and inflammation, and function as transcription factors to activate target genes. Synthetic ligands of nuclear receptors are also available for the treatment of metabolic and inflammatory diseases. However, dysregulated bone phenotypes have been documented in patients who take synthetic nuclear receptor ligands as a therapy. Therefore, the effect of nuclear receptors on bone cells has become an important area of exploration; additionally, the molecular mechanisms underlying the action of nuclear receptors in osteoclasts have not been completely understood. Here, we cover the recent progress in our understanding of the roles of nuclear receptors in osteoclasts.
C1 [Bae, Seyeon; Zeng, Steven; Park Min, Kyung Hyun] Hosp Special Surg, David Z Rosensweig Genom Res Ctr, Arthrit & Tissue Degenerat Program, New York, NY 10021 USA.
   [Bae, Seyeon; Park Min, Kyung Hyun] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA.
   [Park Min, Kyung Hyun] Weill Cornell Grad Sch Med Sci, BCMB Allied Program, New York, NY 10021 USA.
C3 Cornell University; Weill Cornell Medicine; Cornell University
RP Park Min, KH (通讯作者)，Hosp Special Surg, David Z Rosensweig Genom Res Ctr, Arthrit & Tissue Degenerat Program, New York, NY 10021 USA.; Park Min, KH (通讯作者)，Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA.; Park Min, KH (通讯作者)，Weill Cornell Grad Sch Med Sci, BCMB Allied Program, New York, NY 10021 USA.
EM ParkminK@hss.edu
OI Zeng, Steven/0000 0001 7131 104X
FU National Institutes of Health5R01 [AR069562, 5R01 AR073156]
FX This work was supported by the National Institutes of Health5R01
   AR069562; 5R01 AR073156 (to P.M.K.H.). Figures were generated by
   www.biorender.com.
CR Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Auwerx J, 1999, CELL, V97, P161
   Bae S, 2017, J CLIN INVEST, V127, P2555, DOI 10.1172/JCI89935
   Bellini G, 2017, PHARMACOL RES, V115, P267, DOI 10.1016/j.phrs.2016.11.039
   Bennesch MA, 2015, MOL ENDOCRINOL, V29, P349, DOI 10.1210/me.2014 1315
   Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756 3282(02)00953 5
   Bouvard B, 2009, OSTEOPOROSIS INT, V20, P1089, DOI 10.1007/s00198 009 0864 7
   Buckley L, 2018, NEW ENGL J MED, V379, P2547, DOI 10.1056/NEJMcp1800214
   Butler JS, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 210
   Cain DW, 2017, NAT REV IMMUNOL, V17, P233, DOI 10.1038/nri.2017.1
   Cardelli M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109592
   Chen H, 2005, ENDOCRINOLOGY, V146, P4266, DOI 10.1210/en.2005 0160
   Chen H, 2011, J BONE MINER RES, V26, P2537, DOI 10.1002/jbmr.456
   Clemons M, 2001, NEW ENGL J MED, V344, P276, DOI 10.1056/NEJM200101253440407
   Conaway HH, 2016, BONE, V93, P43, DOI 10.1016/j.bone.2016.08.024
   Deblois G, 2013, NAT REV CANCER, V13, P27, DOI 10.1038/nrc3396
   Delhon I, 2009, ENDOCRINOLOGY, V150, P4463, DOI 10.1210/en.2009 0121
   Dhiman VK, 2018, NAT REV GENET, V19, P160, DOI 10.1038/nrg.2017.102
   Dupont S, 2000, DEVELOPMENT, V127, P4277
   Dyson HJ, 2016, J BIOL CHEM, V291, P6714, DOI 10.1074/jbc.R115.692020
   Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025
   Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200
   Germain P, 2006, PHARMACOL REV, V58, P685, DOI 10.1124/pr.58.4.2
   GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0
   Grey A, 2008, OSTEOPOROSIS INT, V19, P129, DOI 10.1007/s00198 007 0477 y
   Grygiel Górniak B, 2014, NUTR J, V13, DOI 10.1186/1475 2891 13 17
   Hamilton JA, 2008, NAT REV IMMUNOL, V8, P533, DOI 10.1038/nri2356
   Harman S Mitchell, 2006, Gend Med, V3, P254, DOI 10.1016/S1550 8579(06)80214 7
   Heitzer MD, 2007, REV ENDOCR METAB DIS, V8, P321, DOI 10.1007/s11154 007 9059 8
   Henneicke H, 2014, TRENDS ENDOCRIN MET, V25, P197, DOI 10.1016/j.tem.2013.12.006
   Huss JM, 2015, BBA MOL BASIS DIS, V1852, P1912, DOI 10.1016/j.bbadis.2015.06.016
   Imai Y, 2013, PHYSIOL REV, V93, P481, DOI 10.1152/physrev.00008.2012
   Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910
   Izawa N, 2019, J BONE MINER RES, V34, P1143, DOI 10.1002/jbmr.3689
   Izawa T, 2015, CELL REP, V11, P1625, DOI 10.1016/j.celrep.2015.05.019
   Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0
   Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006 0459
   Jin ZX, 2015, MOL ENDOCRINOL, V29, P172, DOI 10.1210/me.2014 1316
   Jozwik KM, 2012, NAT REV CANCER, V12, P381, DOI 10.1038/nrc3263
   Jurdic P, 2006, EUR J CELL BIOL, V85, P195, DOI 10.1016/j.ejcb.2005.09.008
   Kahn SE, 2006, NEW ENGL J MED, V355, P2427, DOI 10.1056/NEJMoa066224
   Kassel O, 2007, MOL CELL ENDOCRINOL, V275, P13, DOI 10.1016/j.mce.2007.07.003
   Kato S, 2011, TRENDS BIOCHEM SCI, V36, P272, DOI 10.1016/j.tibs.2011.01.001
   Kawai M, 2010, NAT REV ENDOCRINOL, V6, P629, DOI 10.1038/nrendo.2010.155
   Khosla S, 1998, J CLIN ENDOCR METAB, V83, P2266, DOI 10.1210/jc.83.7.2266
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084
   Kim HJ, 2019, J CELL PHYSIOL, V234, P1659, DOI 10.1002/jcp.27035
   Kim HJ, 2013, J LEUKOCYTE BIOL, V94, P99, DOI 10.1189/jlb.1112601
   Kleiner S, 2009, J BIOL CHEM, V284, P18624, DOI 10.1074/jbc.M109.008797
   Kleyer A, 2012, J BONE MINER RES, V27, P2442, DOI 10.1002/jbmr.1702
   Knowles HJ, 2015, HYPOXIA, V3, P73, DOI 10.2147/HP.S95960
   Lazarenko OP, 2007, ENDOCRINOLOGY, V148, P2669, DOI 10.1210/en.2006 1587
   Lecka Czernik B, 2002, ENDOCRINOLOGY, V143, P2376, DOI 10.1210/en.143.6.2376
   Lewis Tuffin LJ, 2006, ANN NY ACAD SCI, V1069, P1, DOI 10.1196/annals.1351.001
   Lorenzo J, 2008, ENDOCR REV, V29, P403, DOI 10.1210/er.2007 0038
   Lu NZ, 2005, MOL CELL, V18, P331, DOI 10.1016/j.molcel.2005.03.025
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092 8674(95)90199 X
   Martin Millan M, 2010, MOL ENDOCRINOL, V24, P323, DOI 10.1210/me.2009 0354
   Mauvais Jarvis F, 2013, ENDOCR REV, V34, P309, DOI 10.1210/er.2012 1055
   Menéndez Gutiérrez MP, 2015, J CLIN INVEST, V125, P809, DOI 10.1172/JCI77186
   Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110
   Moon YJ, 2019, CELL DEATH DIFFER, V26, P2358, DOI 10.1038/s41418 019 0306 9
   Morimoto E, 2017, J CELL PHYSIOL, V232, P145, DOI 10.1002/jcp.25399
   Morita M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165922
   Mullican SE, 2013, J MOL ENDOCRINOL, V51, pT115, DOI 10.1530/JME 13 0212
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Nelson HD, 2002, JAMA J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872
   Oikawa T, 2013, CELL MOL LIFE SCI, V70, P3341, DOI 10.1007/s00018 012 1238 4
   Park Min KH, 2018, CELL MOL LIFE SCI, V75, P2519, DOI 10.1007/s00018 018 2817 9
   Pico Michael J, 2016, Bone Rep, V5, P222, DOI 10.1016/j.bonr.2016.07.006
   Piemontese M, 2016, AM J PHYSIOL ENDOC M, V311, pE587, DOI 10.1152/ajpendo.00219.2016
   Pinkerton JV, 2014, J STEROID BIOCHEM, V142, P142, DOI 10.1016/j.jsbmb.2013.12.011
   Pott S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048102
   Prawitt J, 2011, BONE, V48, P339, DOI 10.1016/j.bone.2010.08.018
   Querfeldt C, 2006, EXPERT OPIN PHARMACO, V7, P907, DOI 10.1517/14656566.7.7.907
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Remen KMR, 2013, J LEUKOCYTE BIOL, V93, P71, DOI 10.1189/jlb.0712339
   Remen KMR, 2011, J BIOL CHEM, V286, P33084, DOI 10.1074/jbc.M111.235937
   Robertson KM, 2006, J BONE MINER RES, V21, P1276, DOI 10.1359/JBMR.060503
   Roszer T, 2013, TRENDS ENDOCRIN MET, V24, P460, DOI 10.1016/j.tem.2013.04.004
   Rzonca SO, 2004, ENDOCRINOLOGY, V145, P401, DOI 10.1210/en.2003 0746
   Schierle S, 2019, EXPERT OPIN THER PAT, V29, P605, DOI 10.1080/13543776.2019.1643322
   Scholtysek C, 2013, NAT MED, V19, P608, DOI 10.1038/nm.3146
   Schwartz AV, 2008, PPAR RES, V2008, DOI 10.1155/2008/297893
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sims NA, 2002, BONE, V30, P18, DOI 10.1016/S8756 3282(01)00643 3
   SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604
   Soe K, 2019, CALCIFIED TISSUE INT, V105, P430, DOI 10.1007/s00223 019 00575 4
   Sorocéanu MA, 2004, J ENDOCRINOL, V183, P203, DOI 10.1677/joe.1.05723
   Still K, 2008, CALCIFIED TISSUE INT, V83, P285, DOI 10.1007/s00223 008 9175 9
   Stunes AK, 2011, BMC ENDOCR DISORD, V11, DOI 10.1186/1472 6823 11 11
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Teitelbaum SL, 2015, CLIN EXP RHEUMATOL, V33, pS37
   Teyssier C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007942
   Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Unsworth AJ, 2018, CARDIOVASC RES, V114, P645, DOI 10.1093/cvr/cvy044
   Viccica G, 2010, J Endocrinol Invest, V33, P9
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Wang FS, 2005, ENDOCRINOLOGY, V146, P2415, DOI 10.1210/en.2004 1050
   Wei W, 2016, CELL METAB, V23, P479, DOI 10.1016/j.cmet.2015.12.010
   Wei W, 2010, CELL METAB, V11, P503, DOI 10.1016/j.cmet.2010.04.015
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Wilson Carol, 2010, Nat Rev Endocrinol, V6, P420, DOI 10.1038/nrendo.2010.83
   Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776
   Zelcer N, 2006, J CLIN INVEST, V116, P607, DOI 10.1172/JCI27883
   ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0
   Zhao LJ, 2020, TRENDS IMMUNOL, V41, P172, DOI 10.1016/j.it.2019.12.006
   Zou W, 2016, NAT MED, V22, P1203, DOI 10.1038/nm.4208
   Zuo H, 2017, CURR TOP DEV BIOL, V125, P71, DOI 10.1016/bs.ctdb.2017.01.002
NR 112
TC 4
Z9 7
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471 4892
EI 1471 4973
J9 CURR OPIN PHARMACOL
JI Curr. Opin. Pharmacol.
PD AUG
PY 2020
VL 53
SI SI
BP 8
EP 17
DI 10.1016/j.coph.2020.03.002
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA OU4MU
UT WOS:000591504200003
PM 32569976
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Mantyh, P
AF Mantyh, Patrick
TI The science behind metastatic bone pain
SO EJC SUPPLEMENTS
LA English
DT Article
DE cancer; pain; bone metastases; mouse model; bisphosphonates
ID PLACEBO CONTROLLED TRIAL; BREAST CANCER CELLS; QUALITY OF LIFE;
   BISPHOSPHONATES INHIBIT; SKELETAL COMPLICATIONS; IN VITRO; BREAKTHROUGH
   PAIN; ZOLEDRONIC ACID; TUMOR GROWTH; SPINAL CORD
AB Metastatic bone pain is a significant cause of morbidity in patients with advanced cancer and greatly reduces quality of life. Standard palliative treatments such as opioids may not provide effective relief of metastatic bone pain, particularly acute breakthrough pain, without unacceptable side effects at the high doses required. A mouse model of metastatic bone pain has been developed in which tumor cells are injected directly into the marrow space of mice femora. As the tumor cells proliferate, mice display reproducible behaviors associated with pain, such as flinching or guarding the affected limb, that increase as bone destruction progresses. The model also enables measurement of other endpoints, including tumor growth and migration, and monitoring of relevant cell types such as osteoclasts, macrophages, and neurons. Mouse studies have provided important information on the mechanisms behind metastatic bone pain and the specific effects of potential therapies. These studies have demonstrated that metastatic bone disease is caused by multiple factors and that osteoclasts are particularly important in pain generation through destruction of bone and nerve fibers and acidotic stimulation of pH sensitive receptors. Clinical studies with bisphosphonates demonstrate that these agents provide relief of metastatic bone pain, and preliminary experiments using the mouse model suggest that this may occur via multiple mechanisms. Further studies are under way. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Univ Minnesota, Neurosyst Ctr, Minneapolis, MN 55455 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities
RP Mantyh, P (通讯作者)，Univ Minnesota, Neurosyst Ctr, 515 Delaware St SE,18 208 Moos Tower, Minneapolis, MN 55455 USA.
EM manty001@umn.edu
CR Body JJ, 2004, ANN ONCOL, V15, P180, DOI 10.1093/annonc/mdh035
   Body JJ, 2003, ANN ONCOL, V14, P1399, DOI 10.1093/annonc/mdg367
   Body JJ, 2004, PAIN, V111, P306, DOI 10.1016/j.pain.2004.07.011
   Boissier S, 2000, CANCER RES, V60, P2949
   Boissier S, 1997, CANCER RES, V57, P3890
   BONICA JJ, 1982, ACTA ANAESTH SCAND, V74, P75
   Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542
   Coleman RE, 2005, J CLIN ONCOL, V23, P4925, DOI 10.1200/JCO.2005.06.091
   Conte PF, 1996, J CLIN ONCOL, V14, P2552, DOI 10.1200/JCO.1996.14.9.2552
   Diel IJ, 2004, EUR J CANCER, V40, P1704, DOI 10.1016/j.ejca.2004.03.025
   Dumon JC, 2004, EUR UROL, V45, P521, DOI 10.1016/j.eururo.2003.12.012
   Fournier P, 2002, CANCER RES, V62, P6538
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Heidenreich A., 2003, EJC Supplements, V1, pS270, DOI 10.1016/S1359 6349(03)90923 2
   Hiraga T, 2001, CANCER RES, V61, P4418
   Honore P, 2000, NAT MED, V6, P521, DOI 10.1038/74999
   Hortobagyi GN, 1998, J CLIN ONCOL, V16, P2038, DOI 10.1200/JCO.1998.16.6.2038
   Kohno N, 2005, J CLIN ONCOL, V23, P3314, DOI 10.1200/JCO.2005.05.116
   Luger NM, 2005, J PAIN SYMPTOM MANAG, V29, pS32, DOI 10.1016/j.jpainsymman.2005.01.008
   Luger NM, 2001, CANCER RES, V61, P4038
   Luger NM, 2002, PAIN, V99, P397, DOI 10.1016/S0304 3959(02)00102 1
   Mancini I, 2004, J CLIN ONCOL, V22, P3587, DOI 10.1200/JCO.2004.07.054
   Mantyh PW, 2002, NAT REV CANCER, V2, P201, DOI 10.1038/nrc747
   McNicol E, 2003, J PAIN, V4, P231, DOI 10.1016/S1526 5900(03)00556 X
   Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304 3959(96)03267 8
   Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249
   Mercadante S, 1998, CANCER TREAT REV, V24, P425, DOI 10.1016/S0305 7372(98)90005 6
   Mercadante S, 2005, ANN ONCOL, V16, P132, DOI 10.1093/annonc/mdi922
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Sabino MAC, 2002, CANCER RES, V62, P7343
   Sabino Mary Ann C, 2005, J Support Oncol, V3, P15
   Schwei MJ, 1999, J NEUROSCI, V19, P10886, DOI 10.1523/JNEUROSCI.19 24 10886.1999
   Sevcik MA, 2004, PAIN, V111, P169, DOI 10.1016/j.pain.2004.06.015
   Theriault RL, 1999, J CLIN ONCOL, V17, P846, DOI 10.1200/JCO.1999.17.3.846
   Urch C, 2004, PALLIATIVE MED, V18, P267, DOI 10.1191/0269216304pm887ra
   vanderPluijm G, 1996, J CLIN INVEST, V98, P698, DOI 10.1172/JCI118841
   ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304 3959(95)00017 M
NR 38
TC 11
Z9 13
U1 0
U2 1
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1359 6349
J9 EJC SUPPL
JI EJC Suppl.
PD SEP
PY 2006
VL 4
IS 8
BP 4
EP 8
DI 10.1016/j.ejcsup.2006.07.003
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 091WK
UT WOS:000241058800002
OA hybrid
DA 2025 08 17
ER

PT J
AU Wang, XW
   Wang, M
   Lin, QJ
   He, LX
   Zhang, BL
   Chen, X
   Chen, GH
   Du, H
   Lang, CD
   Peng, XS
   Dai, YH
AF Wang, Xinwen
   Wang, Min
   Lin, Qijun
   He, Lixin
   Zhang, Baolin
   Chen, Xin
   Chen, Guanhong
   Du, Hong
   Lang, Chuandong
   Peng, Xinsheng
   Dai, Yuhu
TI Osteoblast Derived ECM1 Promotes Anti Androgen Resistance in Bone
   Metastatic Prostate Cancer
SO ADVANCED SCIENCE
LA English
DT Article
DE ECM1; ENO1; enzalutamide resistance; osteoblast; prostate cancer
ID ANDROGEN RECEPTOR INHIBITORS; TUMOR MICROENVIRONMENT;
   CELL PROLIFERATION; PHOSPHORYLATION; MECHANISMS; ACTIVATION;
   TUMORIGENESIS; REGULATOR; DIAGNOSIS; ENOLASE 1
AB Acquired resistance to hormonal therapy, particularly enzalutamide (ENZ), remains a significant obstacle in the treatment of advanced bone metastatic prostate cancer. Here, it is demonstrated that under ENZ treatment, osteoblasts in the bone microenvironment secrete increased levels of extracellular matrix protein 1 (ECM1), which affects surrounding prostate cancer cells, promoting tumor cell proliferation and anti androgen resistance. Mechanistically, ECM1 interacts with the enolase 1 (ENO1) receptor on the prostate cancer cell membrane, leading to its phosphorylation at the Y189 site. This event further recruits adapter proteins including growth factor receptor bound protein 2 (GRB2) and son of sevenless homolog 1 (SOS1), which activates the downstream mitogen activated protein kinase (MAPK) signaling pathway to induce anti androgen resistance. Furthermore, inhibiting ECM1 or utilizing the ENO1 targeting inhibitor phosphonoacetohydroxamate (PhAH) significantly restores tumor cell sensitivity to ENZ. Taken together, a potential mechanism is identified through which osteoblast derived ECM1 drives resistance in bone metastatic prostate cancer under ENZ treatment. Additionally, the findings indicate that ECM1 and ENO1 may serve as potential targets for developing therapies for bone metastatic castration resistant prostate cancer.
C1 [Wang, Xinwen; Lin, Qijun; Zhang, Baolin; Chen, Xin; Chen, Guanhong; Peng, Xinsheng; Dai, Yuhu] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Orthoped Surg, Guangzhou 510080, Peoples R China.
   [Wang, Xinwen; Wang, Min; Lin, Qijun; Zhang, Baolin; Chen, Xin; Chen, Guanhong; Peng, Xinsheng; Dai, Yuhu] Guangdong Prov Key Lab Orthoped & Traumatol, Guangzhou 510080, Peoples R China.
   [Wang, Min; Du, Hong] Guangzhou First Peoples Hosp, Dept Pathol, Guangzhou 510080, Peoples R China.
   [He, Lixin] Sun Yat Sen Univ, Dept Expt Res, State Key Lab Oncol South China, Ctr Canc, Guangzhou 510060, Peoples R China.
   [Lang, Chuandong] Univ Sci & Technology China, Affiliated Hosp 1, Dept Orthoped, Div Life Sci & Med,USTC, Hefei 230001, Peoples R China.
C3 Sun Yat Sen University; South China University of Technology; State Key
   Lab Oncology South China; Sun Yat Sen University; Chinese Academy of
   Sciences; University of Science & Technology of China, CAS
RP Peng, XS; Dai, YH (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 1, Dept Orthoped Surg, Guangzhou 510080, Peoples R China.; Peng, XS; Dai, YH (通讯作者)，Guangdong Prov Key Lab Orthoped & Traumatol, Guangzhou 510080, Peoples R China.; Lang, CD (通讯作者)，Univ Sci & Technology China, Affiliated Hosp 1, Dept Orthoped, Div Life Sci & Med,USTC, Hefei 230001, Peoples R China.
EM langchd@ustc.edu.cn; pengxsh@mail.sysu.edu.cn; daiyh5@mail.sysu.edu.cn
RI peng, Xinsheng/Q 9115 2019; LANG, CHUANDONG/LZG 1940 2025
FU National Natural Science Foundation of China [82072973, 82373020,
   82203721]; Basic and Applied Basic Research Foundation of Guangdong
   province [2023A1515011580, 2024A1515030230, 2023A1515010581]; Natural
   Science Research Project of Anhui Provincial Department of Education
   [2023AH053409]; China Postdoctoral Science Foundation [2022M723045,
   GZC20233188]
FX The authors would like to thank Yue Li, Xinyu Jiang, Ying Ouyang, and
   Xiangfu Chen from the Department of Experimental Research, State Key
   Laboratory of Oncology in Southern China at the Sun Yat sen University
   Cancer Center for their advice and insights. This work was supported by
   grants from the National Natural Science Foundation of China (grant
   numbers 82072973, 82373020, 82203721), the Basic and Applied Basic
   Research Foundation of Guangdong province (grant numbers
   2023A1515011580, 2024A1515030230, 2023A1515010581), Natural Science
   Research Project of Anhui Provincial Department of Education (grant
   number 2023AH053409), China Postdoctoral Science Foundation (grant
   number 2022M723045) and State funded Postdoctoral Researchers Plan
   (grant number GZC20233188).
CR Ahmed Z, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8354
   Al Shareef Z, 2018, ONCOGENE, V37, P5305, DOI 10.1038/s41388 018 0294 0
   Almaguel FA, 2021, FRONT GENET, V11, DOI 10.3389/fgene.2020.614726
   Baldessari C, 2023, CANCERS, V15, DOI 10.3390/cancers15051518
   Blomme A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 16126 7
   Boukhechba F, 2009, J BONE MINER RES, V24, P1927, DOI [10.1359/JBMR.090517, 10.1359/jbmr.090517]
   Brizuela L, 2014, MOL ONCOL, V8, P1181, DOI 10.1016/j.molonc.2014.04.001
   Capello M, 2011, FEBS J, V278, P1064, DOI 10.1111/j.1742 4658.2011.08025.x
   Chen ML, 2022, MOL CANCER THER, V21, P1337, DOI 10.1158/1535 7163.MCT 21 0285
   Cheng CP, 2022, NAT CANCER, V3, P565, DOI 10.1038/s43018 022 00380 3
   Chng KR, 2012, EMBO J, V31, P2810, DOI 10.1038/emboj.2012.112
   Dai JL, 2014, CLIN CANCER RES, V20, P617, DOI 10.1158/1078 0432.CCR 13 0839
   Dai YH, 2017, BRIT J CANCER, V117, P685, DOI 10.1038/bjc.2017.212
   de Visser KE, 2023, CANCER CELL, V41, P374, DOI 10.1016/j.ccell.2023.02.016
   Didiasova M, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00061
   Elhanani O, 2023, CANCER CELL, V41, P404, DOI 10.1016/j.ccell.2023.01.010
   Francini E, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.16536
   Galletti G, 2017, CANCER TREAT REV, V57, P16, DOI 10.1016/j.ctrv.2017.04.008
   Gan L, 2018, ONCOGENE, V37, P744, DOI 10.1038/onc.2017.363
   Godier A, 2013, J THROMB HAEMOST, V11, P26, DOI 10.1111/jth.12064
   Hao XX, 2023, CELL STEM CELL, V30, P648, DOI 10.1016/j.stem.2023.04.005
   Hassan M, 2021, DARU, V29, P73, DOI 10.1007/s40199 020 00384 3
   He MX, 2021, NAT MED, V27, P426, DOI 10.1038/s41591 021 01244 6
   He YD, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 022 01042 7
   Huang CK, 2022, MOL THER ONCOLYTICS, V24, P288, DOI 10.1016/j.omto.2021.12.026
   Ihle CL, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425 019 0753 3
   Karantanos T, 2015, EUR UROL, V67, P470, DOI 10.1016/j.eururo.2014.09.049
   Kfoury Y, 2021, CANCER CELL, V39, P1464, DOI 10.1016/j.ccell.2021.09.005
   Kong L, 2010, MATRIX BIOL, V29, P276, DOI 10.1016/j.matbio.2010.01.007
   Lee JY, 2018, ANN RHEUM DIS, V77, P1480, DOI 10.1136/annrheumdis 2018 213444
   Lee KM, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058 014 0479 6
   Li HJ, 2021, CANCER RES, V81, P4094, DOI 10.1158/0008 5472.CAN 20 3543
   Li SZ, 2019, CANCER RES, V79, P2580, DOI 10.1158/0008 5472.CAN 18 2812
   Li YM, 2020, CLIN CANCER RES, V26, P1965, DOI 10.1158/1078 0432.CCR 19 3023
   Liao TJ, 2020, J AM CHEM SOC, V142, P3401, DOI 10.1021/jacs.9b10710
   Liao TJ, 2018, BIOPHYS J, V115, P629, DOI 10.1016/j.bpj.2018.07.016
   Litwin MS, 2017, JAMA J AM MED ASSOC, V317, P2532, DOI 10.1001/jama.2017.7248
   Liu JZ, 2022, CANCER LETT, V550, DOI 10.1016/j.canlet.2022.215927
   Loehr A, 2023, EUR UROL, V83, P200, DOI 10.1016/j.eururo.2022.09.010
   Lorente D, 2015, LANCET ONCOL, V16, pE279, DOI 10.1016/S1470 2045(15)70033 1
   Madan B, 2024, J CLIN INVEST, V134, DOI 10.1172/JCI171222
   Morris MJ, 2019, NAT REV UROL, V16, P745, DOI 10.1038/s41585 019 0251 x
   Mourkioti I, 2023, J EXP CLIN CANC RES, V42, DOI 10.1186/s13046 023 02769 z
   Muller FL, 2012, NATURE, V488, P337, DOI 10.1038/nature11331
   Navarro MVDS, 2007, FEBS J, V274, P5077, DOI 10.1111/j.1742 4658.2007.06027.x
   Ortega J, 2015, P NATL ACAD SCI USA, V112, P5667, DOI 10.1073/pnas.1417711112
   Pakula H, 2024, NAT COMMUN, V15, DOI 10.1038/s41467 023 44210 1
   Peng JM, 2022, CELL COMMUN SIGNAL, V20, DOI 10.1186/s12964 022 00950 z
   Qiao G, 2021, INT J BIOL SCI, V17, P3981, DOI 10.7150/ijbs.63556
   Ren D, 2019, J EXP MED, V216, P428, DOI 10.1084/jem.20180661
   de Porras VR, 2021, CANCER LETT, V523, P162, DOI 10.1016/j.canlet.2021.08.033
   Seidlitz T, 2022, EMBO MOL MED, V14, DOI 10.15252/emmm.202215705
   Sercu S, 2009, MATRIX BIOL, V28, P160, DOI 10.1016/j.matbio.2009.02.003
   Shi Q, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 1096 x
   Stalnecker CA, 2022, CANCER RES, V82, P586, DOI 10.1158/0008 5472.CAN 21 1443
   Stark C, 2006, NUCLEIC ACIDS RES, V34, pD535, DOI 10.1093/nar/gkj109
   Steinhaeuser SS, 2020, LAB INVEST, V100, P928, DOI 10.1038/s41374 020 0415 6
   Su S, 2022, CANCER LETT, V525, P170, DOI 10.1016/j.canlet.2021.10.042
   Sumanasuriya S, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a030635
   Sun FF, 2022, ONCOGENE, V41, P3239, DOI 10.1038/s41388 022 02332 8
   Sun LC, 2023, NAT CHEM BIOL, V19, P1492, DOI 10.1038/s41589 023 01391 6
   Thulin MH, 2016, MOL CELL ENDOCRINOL, V422, P182, DOI 10.1016/j.mce.2015.11.013
   Tu H, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 34080 4
   Wang HL, 2023, CANCER CELL, V41, P1345, DOI 10.1016/j.ccell.2023.05.016
   Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016
   Wei J, 2021, CANCER RES, V81, P4275, DOI 10.1158/0008 5472.CAN 21 0198
   Wu QW, 2018, CANCER LETT, V437, P44, DOI 10.1016/j.canlet.2018.08.022
   Wu QY, 2023, CELL RES, V33, P464, DOI 10.1038/s41422 023 00810 6
   Xiao Y, 2021, PHARMACOL THERAPEUT, V221, DOI 10.1016/j.pharmthera.2020.107753
   Xu WP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10463 y
   Yang Q, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 019 1374 x
   Yang T, 2024, CELL DEATH DIS, V15, DOI 10.1038/s41419 023 06362 2
   Yu Lee LY, 2018, CANCER RES, V78, P2911, DOI 10.1158/0008 5472.CAN 17 1051
   Zhang J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13732
   Zhang SX, 2022, ADV SCI, V9, DOI 10.1002/advs.202201974
   Zhang T, 2022, NAT CANCER, V3, P75, DOI 10.1038/s43018 021 00299 1
   Zhang X, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058 016 0785 2
   Zhang ZD, 2020, CANCER CELL, V38, P279, DOI 10.1016/j.ccell.2020.06.005
   Zhao JC, 2012, GENOME RES, V22, P322, DOI 10.1101/gr.131508.111
   Zheng HQ, 2017, CANCER CELL, V32, P731, DOI 10.1016/j.ccell.2017.11.002
   Zhu GM, 2021, MOL CANCER, V20, DOI 10.1186/s12943 021 01441 4
NR 81
TC 0
Z9 0
U1 6
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2198 3844
J9 ADV SCI
JI Adv. Sci.
PD JAN
PY 2025
VL 12
IS 2
AR 2407662
DI 10.1002/advs.202407662
EA NOV 2024
PG 22
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA U3A0H
UT WOS:001358372100001
PM 39563492
OA gold
DA 2025 08 17
ER

PT J
AU Vanderburgh, J
   Hill, JL
   Gupta, MK
   Kwakwa, KA
   Wang, SK
   Moyer, K
   Bedingfield, SK
   Merkel, AR
   d'Arcy, R
   Guelcher, SA
   Rhoades, JA
   Duvall, CL
AF Vanderburgh, Joseph
   Hill, Jordan L.
   Gupta, Mukesh K.
   Kwakwa, Kristin A.
   Wang, Sean K.
   Moyer, Kathleen
   Bedingfield, Sean K.
   Merkel, Alyssa R.
   d'Arcy, Richard
   Guelcher, Scott A.
   Rhoades, Julie A.
   Duvall, Craig L.
TI Tuning Ligand Density To Optimize Pharmacokinetics of Targeted
   Nanoparticles for Dual Protection against Tumor Induced Bone Destruction
SO ACS NANO
LA English
DT Article
DE polymer nanoparticles; bone targeting; bone metastasis; tumor delivery;
   bisphosphonate; pharmacokinetics; hedgehog pathway
ID HORMONE RELATED PROTEIN; BREAST CANCER CELLS; MINERAL AFFINITY;
   HYDROXYAPATITE BINDING; SURFACE CHEMISTRY; DELIVERY; METASTASIS;
   STABILITY; DENOSUMAB; MICELLES
AB Breast cancer patients are at high risk for bone metastasis. Metastatic bone disease is a major clinical problem that leads to a reduction in mobility, increased risk of pathologic fracture, severe bone pain, and other skeletal related events. The transcription factor Gli2 drives expression of parathyroid hormone related protein (PTHrP), which activates osteoclast mediated bone destruction, and previous studies showed that Gli2 genetic repression in bone metastatic tumor cells significantly reduces tumor induced bone destruction. Small molecule inhibitors of Gli2 have been identified; however, the lipophilicity and poor pharmacokinetic profile of these compounds have precluded their success in vivo. In this study, we designed a bone targeted nanoparticle (BTNP) comprising an amphiphilic diblock copolymer of poly [(propylene sulfide) block (alendronate acrylamide co N,N dimethylacrylamide)] [PPS b P(Aln co DMA)] to encapsulate and preferentially deliver a small molecule Gli2 inhibitor, GANT58, to boneassociated tumors. The mol % of the bisphosphonate Aln in the hydrophilic polymer block was varied in order to optimize BTNP targeting to tumor associated bone by a combination of nonspecific tumor accumulation (presumably through the enhanced permeation and retention effect) and active bone binding. Although 100% functionalization with Aln created BTNPs with strong bone binding, these BTNPs had highly negative zeta potential, resulting in shorter circulation time, greater liver uptake, and less distribution to metastatic tumors in bone. However, 10 mol % of Aln in the hydrophilic block generated a formulation with a favorable balance of systemic pharmacokinetics and bone binding, providing the highest bone/liver biodistribution ratio among formulations tested. In an intracardiac tumor cell injection model of breast cancer bone metastasis, treatment with the lead candidate GANTS8 BTNP formulation decreased tumor associated bone lesion area 3 fold and increased bone volume fraction in the tibiae of the mice 2.5 fold. Aln conferred bone targeting to the GANTS8 BTNPs, which increased GANT58 concentration in the tumor associated bone relative to untargeted NPs, and also provided benefit through the direct antiresorptive therapeutic function of Aln. The dual benefit of the Aln in the BTNPs was supported by the observations that drug free Aln containing BTNPs improved bone volume fraction in bone tumor bearing mice, while GANT58 BTNPs created better therapeutic outcomes than both unloaded BTNPs and GANT58 loaded untargeted NPs. These findings suggest GANTS8 BTNPs have potential to potently inhibit tumor driven osteoclast activation and resultant bone destruction in patients with bone associated tumor metastases.
C1 [Hill, Jordan L.; Gupta, Mukesh K.; Wang, Sean K.; Bedingfield, Sean K.; d'Arcy, Richard; Guelcher, Scott A.; Rhoades, Julie A.; Duvall, Craig L.] Vanderbilt Univ, Dept Biomed Engn, Nashville, TN 37235 USA.
   [Vanderburgh, Joseph; Guelcher, Scott A.] Vanderbilt Univ, Dept Chem & Biomol Engn, Nashville, TN 37235 USA.
   [Vanderburgh, Joseph; Kwakwa, Kristin A.; Merkel, Alyssa R.; Guelcher, Scott A.; Rhoades, Julie A.] Vanderbilt Univ, Med Ctr, Ctr Bone Biol, Nashville, TN 37232 USA.
   [Vanderburgh, Joseph; Kwakwa, Kristin A.; Merkel, Alyssa R.; Rhoades, Julie A.] Tennessee Valley Healthcare Syst, Dept Vet Affairs, Nashville, TN 37212 USA.
   [Kwakwa, Kristin A.] Vanderbilt Univ, Program Canc Biol, Nashville, TN 37232 USA.
   [Moyer, Kathleen] Vanderbilt Univ, Interdisciplinary Grad Program Mat, Nashville, TN 37232 USA.
   [Rhoades, Julie A.] Vanderbilt Univ, Med Ctr, Dept Med, Div Clin Pharmacol, Nashville, TN 37232 USA.
C3 Vanderbilt University; Vanderbilt University; Vanderbilt University; US
   Department of Veterans Affairs; Veterans Health Administration (VHA); VA
   Tennessee Valley Healthcare System; Vanderbilt University; Vanderbilt
   University; Vanderbilt University
RP Duvall, CL (通讯作者)，Vanderbilt Univ, Dept Biomed Engn, Nashville, TN 37235 USA.
EM craig.duvall@vanderbilt.edu
RI ; Gupta, Mukesh/B 4180 2016; D'Arcy, Richard/V 2293 2018; d'Arcy,
   Richard/V 2293 2018; Bedingfield, Sean/AAB 1181 2021; Rhoades,
   Julie/LNU 1104 2024
OI Guelcher, Scott/0000 0002 9871 8058; Gupta, Mukesh/0000 0002 9571 3454;
   D'Arcy, Richard/0000 0002 8567 368X; Wang, Sean K./0000 0002 1835 8962;
   Moyer, Kathleen/0000 0002 8179 8151; Hill, Jordan/0000 0001 7560 005X;
   Merkel, Alyssa/0000 0001 6498 4211; 
FU NIH [R01CA163499]; VA Merit Award [1I01BX001957]; DOD CDMRP
   [W81XWH 15 1 0627, W81XWH 15 1 0622]
FX This work was supported by NIH Grant No. R01CA163499 (S.A.G. and
   J.A.S.), VA Merit Award 1I01BX001957 (J.A.S.), and the DOD CDMRP awards
   W81XWH 15 1 0627 (C.L.D.) and W81XWH 15 1 0622 (J.A.S.).
CR Allen SD, 2018, NANO RES, V11, P5689, DOI 10.1007/s12274 018 2069 x
   Ansari N, 2018, J BONE MINER RES, V33, P137, DOI 10.1002/jbmr.3291
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Bansal G, 2005, J BIOMED MATER RES A, V74A, P618, DOI 10.1002/jbm.a.30334
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Bertrand N, 2012, J CONTROL RELEASE, V161, P152, DOI 10.1016/j.jconrel.2011.09.098
   Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598
   Cannonier SA, 2016, ONCOTARGET, V7, P76062, DOI 10.18632/oncotarget.12584
   Carbone EJ, 2017, NANOMED NANOTECHNOL, V13, P37, DOI 10.1016/j.nano.2016.08.015
   Chen F, 2013, PHARM RES DORDR, V30, P2808, DOI 10.1007/s11095 013 1105 5
   Clark AJ, 2016, P NATL ACAD SCI USA, V113, P3850, DOI 10.1073/pnas.1603018113
   Cole LE, 2016, ADV DRUG DELIVER REV, V99, P12, DOI 10.1016/j.addr.2015.10.005
   Coleman R, 2011, BREAST CANCER RES TR, V127, P429, DOI 10.1007/s10549 011 1429 y
   CORNS CM, 1987, ANN CLIN BIOCHEM, V24, P345, DOI 10.1177/000456328702400403
   Costa A, 2014, SEMIN CANCER BIOL, V25, P23, DOI 10.1016/j.semcancer.2013.12.007
   di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229
   Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995
   Du FF, 2017, CELL MOL BIOENG, V10, P357, DOI 10.1007/s12195 017 0486 7
   Elmalla SF, 2019, LUMINESCENCE, V34, P375, DOI 10.1002/bio.3622
   Fan CM, 2017, BREAST CANCER RES TR, V165, P41, DOI 10.1007/s10549 017 4308 3
   Gittens SA, 2004, J CONTROL RELEASE, V98, P255, DOI 10.1016/j.jconrel.2004.05.001
   Gnant M, 2015, LANCET, V386, P433, DOI 10.1016/S0140 6736(15)60995 3
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Guo R, 2016, J MATER CHEM B, V4, P3584, DOI 10.1039/c5tb02747k
   Gupta MK, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201704107
   Gupta MK, 2014, J AM CHEM SOC, V136, P14896, DOI 10.1021/ja507626y
   Gupta MK, 2012, J CONTROL RELEASE, V162, P591, DOI 10.1016/j.jconrel.2012.07.042
   He CB, 2010, BIOMATERIALS, V31, P3657, DOI 10.1016/j.biomaterials.2010.01.065
   He YC, 2018, RSC ADV, V8, P16762, DOI 10.1039/c8ra01872c
   Hengst V, 2007, INT J PHARMACEUT, V331, P224, DOI 10.1016/j.ijpharm.2006.11.024
   Jackson MA, 2017, ACS NANO, V11, P5680, DOI 10.1021/acsnano.7b01110
   Johnson RW, 2011, CANCER RES, V71, P822, DOI 10.1158/0008 5472.CAN 10 2993
   Kamaly N, 2012, CHEM SOC REV, V41, P2971, DOI 10.1039/c2cs15344k
   Kim S, 2010, EXPERT OPIN DRUG DEL, V7, P49, DOI 10.1517/17425240903380446
   Lam MHC, 2002, MOL ENDOCRINOL, V16, P390, DOI 10.1210/me.16.2.390
   Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104
   Leu CT, 2006, BONE, V38, P628, DOI 10.1016/j.bone.2005.07.023
   Li CY, 2017, ADV MATER, V29, DOI 10.1002/adma.201605754
   LIEDTKE RJ, 1981, CLIN CHEM, V27, P2025
   Liu P, 2015, SCI REP UK, V5, DOI 10.1038/srep17387
   Low SA, 2012, ADV DRUG DELIVER REV, V64, P1189, DOI 10.1016/j.addr.2012.01.012
   Lu Y, 2018, NANO RES, V11, P4985, DOI 10.1007/s12274 018 2152 3
   MBALAVIELE G, 1995, J CLIN INVEST, V95, P2757, DOI 10.1172/JCI117979
   Michigami T, 2000, BLOOD, V96, P1953, DOI 10.1182/blood.V96.5.1953.h8001953_1953_1960
   Mundy GR, 1997, CANCER AM CANCER SOC, V80, P1546, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1546::AID CNCR4>3.3.CO;2 R
   Murphy MB, 2007, BIOMACROMOLECULES, V8, P2237, DOI 10.1021/bm070121s
   Napoli A, 2004, NAT MATER, V3, P183, DOI 10.1038/nmat1081
   Onishi T, 2010, NAT REV CLIN ONCOL, V7, P641, DOI 10.1038/nrclinonc.2010.134
   Page JM, 2015, BIOMATERIALS, V64, P33, DOI 10.1016/j.biomaterials.2015.06.026
   Perry JL, 2012, NANO LETT, V12, P5304, DOI 10.1021/nl302638g
   Poole KM, 2015, BIOMATERIALS, V41, P166, DOI 10.1016/j.biomaterials.2014.11.016
   Pozzi S, 2009, CLIN CANCER RES, V15, P5829, DOI 10.1158/1078 0432.CCR 09 0426
   Qiao H, 2017, ACS NANO, V11, P7259, DOI 10.1021/acsnano.7b03197
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Ross RD, 2012, J NANOPART RES, V14, DOI 10.1007/s11051 012 1175 z
   Ross RD, 2011, J BIOMED MATER RES A, V99A, P58, DOI 10.1002/jbm.a.33165
   Ruppender NS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015451
   Saito H, 2005, ANTICANCER RES, V25, P3817
   Sinder BP, 2017, J BONE MINER RES, V32, P2116, DOI 10.1002/jbmr.3196
   Sprincl L, 1971, J Biomed Mater Res, V5, P197, DOI 10.1002/jbm.820050307
   Sterling JA, 2006, CANCER RES, V66, P7548, DOI 10.1158/0008 5472.CAN 06 0452
   Swami A, 2014, P NATL ACAD SCI USA, V111, P10287, DOI 10.1073/pnas.1401337111
   SZATROWSKI TP, 1991, CANCER RES, V51, P794
   Tatem AJ, 2011, LANCET, V377, P30, DOI 10.1016/S0140 6736(11)61226 9
   Thiyagarajan S, 2007, CANCER RES, V67, P10642, DOI 10.1158/0008 5472.CAN 07 2015
   Uddin MJ, 2016, BIOMATERIALS, V92, P71, DOI 10.1016/j.biomaterials.2016.03.028
   Ulbrich W, 2011, TALANTA, V84, P437, DOI 10.1016/j.talanta.2011.01.049
   Uludag H, 2002, BIOTECHNOL PROGR, V18, P604, DOI 10.1021/bp0200447
   Valencia PM, 2013, ACS NANO, V7, P10671, DOI 10.1021/nn403370e
   Wang D, 2007, BIOCONJUGATE CHEM, V18, P1375, DOI 10.1021/bc7002132
   Wang H, 2015, INT J NANOMED, V10, P5671, DOI 10.2147/IJN.S88798
   Wang J, 2014, BIOMATERIALS, V35, P866, DOI 10.1016/j.biomaterials.2013.10.028
   Wang L, 2007, MACROMOL BIOSCI, V7, P987, DOI 10.1002/mabi.200700109
   Werfel TA, 2017, J CONTROL RELEASE, V255, P12, DOI 10.1016/j.jconrel.2017.03.389
   Wright JEI, 2006, BIOMATERIALS, V27, P769, DOI 10.1016/j.biomaterials.2005.06.012
   Wright LE, 2016, BONEKEY REP, V5, DOI 10.1038/bonekey.2016.31
   Xiao K, 2011, BIOMATERIALS, V32, P3435, DOI 10.1016/j.biomaterials.2011.01.021
   Yamamoto Y, 2001, J CONTROL RELEASE, V77, P27, DOI 10.1016/S0168 3659(01)00451 5
   Yamashita S, 2018, BIOMATERIALS, V154, P74, DOI 10.1016/j.biomaterials.2017.10.053
   Yamashita S, 2017, J CONTROL RELEASE, V262, P10, DOI 10.1016/j.jconrel.2017.07.018
   Yang SP, 2017, ONCOLOGIST, V22, P438, DOI 10.1634/theoncologist.2016 0192
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Zhao YP, 2017, NANOSCALE, V9, P6264, DOI 10.1039/c7nr00962c
   Zhou ZJ, 2019, BIOMATERIALS, V194, P130, DOI 10.1016/j.biomaterials.2018.12.024
NR 84
TC 52
Z9 59
U1 3
U2 130
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936 0851
EI 1936 086X
J9 ACS NANO
JI ACS Nano
PD JAN
PY 2020
VL 14
IS 1
BP 311
EP 327
DI 10.1021/acsnano.9b04571
PG 17
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA KH3FI
UT WOS:000510531500024
PM 31894963
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Coxon, FP
   Ebetino, FH
   Mules, EH
   Seabra, MC
   McKenna, CE
   Rogers, MJ
AF Coxon, FP
   Ebetino, FH
   Mules, EH
   Seabra, MC
   McKenna, CE
   Rogers, MJ
TI Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase
   disrupt the prenylation and membrane localization of Rab proteins in
   osteoclasts in vitro and in vivo
SO BONE
LA English
DT Article
DE bisphosphonate; phosphonocarboxylate; osteoclast; protein prenylation;
   Rab GGTase
ID NITROGEN CONTAINING BISPHOSPHONATES; HETEROCYCLE CONTAINING
   BISPHOSPHONATES; FARNESYL DIPHOSPHATE SYNTHASE; GTP BINDING PROTEINS;
   BREAST CANCER CELLS; BONE RESORPTION; DICTYOSTELIUM DISCOIDEUM;
   MEVALONATE PATHWAY; ZOLEDRONIC ACID; ALENDRONATE
AB Nitrogen containing bisphosphonate drugs such as risedronate act by inhibiting farnesyl diphosphate synthase, thereby disrupting protein prenylation in osteoclasts. We recently found that an anti resorptive phosphonocarboxylate analogue of risedronate, 3 PEHPC (previously referred to as NE10790), selectively prevents prenylation of Rab GTPases in vitro by specifically inhibiting Rab geranylgeranyl transferase. In this study, we demonstrate that unprenylated Rab6 could be detected in J774 cells after treatment with 3 PEHPC or risedronate for as little as 4 h, and reached 50% after 24 h. Furthermore, treatment of J774 cells or osteoclasts with either 3 PEHPC or risedronate disrupted membrane association of several Rab family proteins. Like risedronate, the effects of 3 PEHPC are likely to be restricted to osteoclasts in vivo, since both risedronate and 3 PEHPC inhibited Rab prenylation in osteoclasts, but not in general bone marrow cells, when administered to rabbits in vivo. Analysis of two new phosphonocarboxylate analogues of 3 PEHPC (3 PEPC and 2 PEPC) revealed that, first, the geminal hydroxyl group is not essential for inhibition of Rab prenylation by phosphonocarboxylates, but does contribute to their anti resorptive potency, most likely by enhancing their affinity for bone mineral. Second, the position of the nitrogen in the side chain of phosphonocarboxylates is crucial for their ability to inhibit Rab prenylation and hence to inhibit bone resorption. In addition, there is a good correlation between the ability of the phosphonocarboxylates to inhibit Rab prenylation and to inhibit bone resorption in vitro, indicating that these compounds are a new class of pharmacological agents that inhibit bone resorption by specifically preventing prenylation of Rab proteins. Furthermore, although phosphonocarboxylates are analogues of bisphosphonates, the structure activity relationships of phosphonocarboxylates for inhibiting Rab geranylgeranyltransferase appear to differ from the structure activity relationships of bisphosphonates for inhibiting farnesyl diphosphate synthase. (c) 2005 Elsevier Inc. All rights reserved.
C1 Univ Aberdeen, Inst Med Sci, Aberdeen AB25 2ZD, Scotland.
   Procter & Gamble Pharmaceut, Cincinnati, OH 45250 USA.
   Univ London Imperial Coll Sci Technol & Med, Sch Med, Div Biomed Sci, London SW7 2AZ, England.
   Univ So Calif, Dept Chem, Los Angeles, CA 90007 USA.
C3 University of Aberdeen; Procter & Gamble; Imperial College London;
   University of Southern California
RP Coxon, FP (通讯作者)，Univ Aberdeen, Inst Med Sci, Foresterhill, Aberdeen AB25 2ZD, Scotland.
EM f.p.coxon@abdn.ac.uk
RI ; Seabra, Miguel/M 3280 2013
OI Rogers, Michael/0000 0002 1818 9249; Seabra, Miguel/0000 0002 6404 4892
CR ARMSTRONG SA, 1995, METHOD ENZYMOL, V257, P30
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   BORDIER C, 1981, J BIOL CHEM, V256, P1604
   Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289
   Coxon FP, 2001, J BIOL CHEM, V276, P48213, DOI 10.1074/jbc.M106473200
   Coxon FP, 2003, CALCIFIED TISSUE INT, V72, P80, DOI 10.1007/s00223 002 2017 2
   Coxon FP, 1998, MOL PHARMACOL, V54, P631
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Denoyelle C, 2003, BRIT J CANCER, V88, P1631, DOI 10.1038/sj.bjc.6600925
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Ebetino FH, 1996, PHOSPHORUS SULFUR, V109, P217
   Ebrahimpour Arman, 1995, P125
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Frith JC, 2001, ARTHRITIS RHEUM, V44, P2201, DOI 10.1002/1529 0131(200109)44:9<2201::AID ART374>3.0.CO;2 E
   Haklai R, 1998, BIOCHEMISTRY US, V37, P1306, DOI 10.1021/bi972032d
   Holstein SA, 2002, J BIOL CHEM, V277, P10678, DOI 10.1074/jbc.M111369200
   Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   Masarachia P, 1996, BONE, V19, P281, DOI 10.1016/8756 3282(96)00182 2
   Ren ZB, 1997, BIOCHEM PHARMACOL, V54, P113, DOI 10.1016/S0006 2952(97)00151 2
   REPKO EM, 1989, J BIOL CHEM, V264, P9945
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   ROGERS MJ, 1994, J BONE MINER RES, V9, P1029
   ROGERS MJ, 1995, MOL PHARMACOL, V47, P398
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   SEABRA MC, 1995, J BIOL CHEM, V270, P24420, DOI 10.1074/jbc.270.41.24420
   Seabra MC, 1998, CELL SIGNAL, V10, P167, DOI 10.1016/S0898 6568(97)00120 4
   Senaratne SG, 2002, BRIT J CANCER, V86, P1479, DOI 10.1038/sj.bjc.6600297
   SIETSEMA WK, 1989, DRUG EXP CLIN RES, V15, P389
   Staal A, 2003, J BONE MINER RES, V18, P88, DOI 10.1359/jbmr.2003.18.1.88
   Stenbeck G, 2000, J CELL SCI, V113, P1577
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   van Beek ER, 1998, BONE, V23, P437, DOI 10.1016/S8756 3282(98)00120 3
   Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055
NR 38
TC 86
Z9 102
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
J9 BONE
JI Bone
PD SEP
PY 2005
VL 37
IS 3
BP 349
EP 358
DI 10.1016/j.bone.2005.04.021
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 963CD
UT WOS:000231779600007
PM 16006204
DA 2025 08 17
ER

PT J
AU Zheng, H
   Li, YZ
   Deng, YS
   Li, HJ
   Shen, XY
   Lin, HK
   Yang, Y
   Tian, X
   Li, B
   Yuan, HW
   Sheng, WB
   Wang, W
   Yu, HH
AF Zheng, Hao
   Li, Yunzhe
   Deng, Yasi
   Li, Huanjie
   Shen, Xinyang
   Lin, Haokai
   Yang, Yong
   Tian, Xing
   Li, Bin
   Yuan, Hanwen
   Sheng, Wenbing
   Wang, Wei
   Yu, Huanghe
TI Xuetongsu attenuates bone destruction in collagen induced arthritis mice
   by inhibiting osteoclast differentiation and promoting osteoclast
   apoptosis
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE Tujia ethnomedicine; Xuetongsu; Rheumatoid arthritis; Osteoclast; Bone
   destruction; Apoptosis
ID OSTEOARTHRITIS; RESORPTION; SYNOVITIS
AB Tujia ethnomedicine Xuetong (the stems of Kadsura heteroclita) have been widely used in folk for rheumatoid arthritis (RA), which can alleviate rheumatic pain through liquor soaking in folk. In this study, we aimed to evaluate the pharmacological effects and underlying mechanism of Xuetongsu (a key chemical component of Xuetong) on bone destruction. In our previous study, it was found that Xuetong extract can reduce adjuvant arthritic rats paw swelling and inhibit inflammatory factors in serum. Furthermore, Xuetongsu has been demonstrated to inhibit the proliferation of fibroblast like synoviocytes, but its potential to inhibit bone destruction has not been explored. To address this, we employed the STRING database to predict protein interactions and utilized Autodock software to simulate the binding of Xuetongsu to target proteins. In this study, administration of Xuetongsu significantly alleviated paw swelling and bone destruction in C57BL/6 mice with collagen induced arthritis (CIA). Mechanistic studies have indicated that Xuetongsu promotes apoptosis of mature osteoclasts in joint tissues by activating Caspase 3 and Bax, while inhibiting Bcl 2. Additionally, Xuetongsu inhibits osteoclast differentiation by suppressing RANKL, RANK, P NF kappa B, and NFATc1, and reduces bone resorption activity by inhibiting MMP 9, CTSK, and TRAP. Importantly, Xuetongsu exhibits good biocompatibility in major organs of mice. In summary, Xuetongsu has the potential to treat bone destruction by promoting apoptosis of mature osteoclasts, inhibiting osteoclast differentiation, and reducing bone resorption. This study reveals the pharmacological effects of Xuetongsu and its mechanism of action, which may contribute to the development of novel approaches for treating RA.
C1 [Zheng, Hao; Li, Yunzhe; Deng, Yasi; Li, Huanjie; Shen, Xinyang; Lin, Haokai; Yang, Yong; Tian, Xing; Li, Bin; Yuan, Hanwen; Sheng, Wenbing; Wang, Wei; Yu, Huanghe] Hunan Univ Chinese Med, Innovat Mat Med Res Inst, Sch Pharm, TCM & Ethnomedicine Innovat & Dev Int Lab, Changsha 410208, Peoples R China.
C3 Hunan University of Chinese Medicine
RP Wang, W; Yu, HH (通讯作者)，Hunan Univ Chinese Med, Innovat Mat Med Res Inst, Sch Pharm, TCM & Ethnomedicine Innovat & Dev Int Lab, Changsha 410208, Peoples R China.
EM wangwei402@hotmail.com; yhh@hnucm.edu.cn
RI Yu, Haijun/ABG 1776 2021; Yuan, Hanwen/NMK 7675 2025; Li,
   Huanjie/ABE 2328 2021; Shen, Xinyang/IAR 3347 2023; Sheng,
   Wang/JPC 7385 2023
FU Innovation Experimental Program for College Students of Hunan Prov ince
   [S202210541050]; Postgraduate Innovation Project of Hunan University of
   Chinese Medicine [2022CX88]; Undergraduate Research and Innovation
   Foundation of Hunan University of Chinese Medicine [2023]
FX This work was financially supported by National Natural Science
   Foundation of China (82204766, 82174078, 82074122, 82304878) ; Natural
   Science Foundation of Hunan Province (2023JJ40490, 2023JJ30445,
   2022JJ40318, 2021JJ30502) ; Scientific research project of Hunan
   Provincial Education Department (21B0394, 21A0239) ; Changjiang Scholars
   Program in Ministry Education, People's Republic of China (T2019133) ;
   Xiaohe Sci Tech Talents Special <STRONG>Funding</STRONG>under Hunan
   Provincial Sci Tech Talents Sponsorship Program (2023TJ X71) ; Research
   Project of Hunan Administration of Traditional Chinese Medicine
   (2023B55) ; Outstanding Youth Program of Hunan University of Chinese
   Medicine (202202) ; The Scientific Research Fund of Hunan University of
   Chinese Medicine (2021XJJJ006) ; Hunan University of Chinese Medicine
   Pharmacy first class construction Discipline Project; Open Foundation
   Project of Hunan International Joint Laboratory of Traditional Chinese
   Medicine (2022GJSYS02) ; Research Learning andInnovation Experimental
   Program for College Students of Hunan Prov ince (S202210541050) .
   Postgraduate Innovation Project of Hunan University of Chinese Medicine
   (2022CX88) . Undergraduate Research and Innovation Foundation of Hunan
   University of Chinese Medicine (2023) .r Innovation Experimental Program
   for College Students of Hunan Prov ince (S202210541050) . Postgraduate
   Innovation Project of Hunan University of Chinese Medicine (2022CX88) .
   Undergraduate Research and Innovation Foundation of Hunan University of
   Chinese Medicine (2023) .
CR Anesi A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194925
   Anggreini Putri, 2023, J Exp Pharmacol, V15, P513, DOI 10.2147/JEP.S438435
   Blum A, 2019, AUTOIMMUN REV, V18, P679, DOI 10.1016/j.autrev.2019.05.005
   Burmester GR, 2017, LANCET, V389, P2338, DOI 10.1016/S0140 6736(17)31491 5
   Calisto Perez Carlos, 2012, Bol Asoc Med P R, V104, P34
   Cao L, 2020, FITOTERAPIA, V140, DOI 10.1016/j.fitote.2019.104441
   Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976 500X.119726
   Chen JR, 2017, AM J CASE REP, V18, DOI 10.12659/AJCR.904519
   Fang QH, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/3830212
   Festing MFW, 2006, ILAR J, V47, P5, DOI 10.1093/ilar.47.1.5
   Festing Michael F W, 2002, ILAR J, V43, P244
   Guo QY, 2023, J PHARM ANAL, V13, P908, DOI 10.1016/j.jpha.2023.03.004
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Komatsu N, 2022, NAT REV RHEUMATOL, V18, P415, DOI 10.1038/s41584 022 00793 5
   Kou YY, 2022, J MOL HISTOL, V53, P27, DOI 10.1007/s10735 021 10030 0
   Krenn V, 2006, HISTOPATHOLOGY, V49, P358, DOI 10.1111/j.1365 2559.2006.02508.x
   Krenn V, 2002, PATHOL RES PRACT, V198, P317, DOI 10.1078/0344 0338 5710261
   Li FB, 2014, BIOCHEM BIOPH RES CO, V452, P629, DOI 10.1016/j.bbrc.2014.08.117
   Li J, 2020, INT J RHEUM DIS, V23, P1627, DOI 10.1111/1756 185X.13958
   Li MB, 2022, DEV CELL, V57, P2365, DOI 10.1016/j.devcel.2022.09.013
   Liu HT, 2003, CURR OPIN PHARMACOL, V3, P317, DOI 10.1016/S1471 4892(03)00037 7
   Logar DB, 2007, J BONE MINER METAB, V25, P219, DOI 10.1007/s00774 007 0753 0
   Miyoshi M, 2018, METHODS MOL BIOL, V1868, P3, DOI 10.1007/978 1 4939 8802 0_1
   Pritzker KPH, 2006, OSTEOARTHR CARTILAGE, V14, P13, DOI 10.1016/j.joca.2005.07.014
   Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2110
   Shehla N, 2020, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00935
   Singh JA, 2022, RHEUM DIS CLIN N AM, V48, P679, DOI 10.1016/j.rdc.2022.03.005
   Smolen JS, 2016, LANCET, V388, P1984
   Spagnolo P, 2018, ARTHRITIS RHEUMATOL, V70, P1544, DOI 10.1002/art.40574
   Szklarczyk D, 2023, NUCLEIC ACIDS RES, V51, pD638, DOI 10.1093/nar/gkac1000
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Wang D, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.729909
   Wang MY, 2022, FRONT CHEM, V10, DOI 10.3389/fchem.2022.878811
   Wang MY, 2021, J ETHNOPHARMACOL, V268, DOI 10.1016/j.jep.2020.113567
   Wang W, 2006, CHROMATOGRAPHIA, V64, P297, DOI 10.1365/s10337 006 0031 7
   Yu HH, 2022, ACS NANO, V16, P502, DOI 10.1021/acsnano.1c07556
   Yu H, 2019, PHYTOMEDICINE, V58, DOI 10.1016/j.phymed.2019.152876
NR 38
TC 4
Z9 5
U1 8
U2 17
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357 2725
EI 1878 5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD APR
PY 2024
VL 169
AR 106550
DI 10.1016/j.biocel.2024.106550
EA FEB 2024
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA KN1Z3
UT WOS:001180565900001
PM 38340949
DA 2025 08 17
ER

PT J
AU Ruiz Lozano, R
   Calvo Gallego, JL
   Pivonka, P
   Mcdonald, MM
   Martínez Reina, J
AF Ruiz Lozano, Rocio
   Calvo Gallego, Jose Luis
   Pivonka, Peter
   Mcdonald, Michelle M.
   Martinez Reina, Javier
TI An in silico approach to elucidate the pathways leading to primary
   osteoporosis: age related vs. postmenopausal
SO BIOMECHANICS AND MODELING IN MECHANOBIOLOGY
LA English
DT Article
DE Age related osteoporosis; Postmenopausal osteoporosis; RANKL RANK OPG
   signalling pathway; Oestrogen deficiency; TGF beta
ID VIBRATION; FINGERTIP; SENSITIVITY; SKIN; HAND
AB Numerical models of bone remodelling have traditionally been used to perform in silico tests of bone loss in postmenopausal women and also to simulate the response to different drug treatments. These models simulate the menopausal oestrogen decline by altering certain signalling pathways. However, they do not consider the simultaneous effect that ageing can have on cell function and bone remodelling, and thus on bone loss. Considering ageing and oestrogen decline together is important for designing osteoporosis treatments that can selectively counteract one or the other disease mechanism. A previously developed bone cell population model was adapted to consider the effect of ageing through: (1) the decrease of TGF beta contained in the bone matrix and (2) an increased production of sclerostin by non skeletal cells. Oestrogen deficiency is simulated in three different ways: (a) an increase in RANKL expression, (b) a decrease in OPG production, and (c) an increase in the responsiveness of osteoclasts to RANKL. The effect of ageing was validated using the cross sectional study of (Riggs et al. in J Bone Miner Res 19: 1945 1954, 2004) on BMD of trabecular bone of the vertebral body of men. The joint effect of ageing and oestrogen deficiency was validated using these same clinical results but in women. In ageing, the effect of the increasing production of sclerostin is more important than the decrease of TGF beta, while the three mechanisms used to simulate the effect of oestrogen deficiency produce almost identical responses. The results show that an early menopause leads to a lower average density in the fifth decade, but after the sixth decade the average density is independent of the age at menopause. Treatment of osteoporosis with denosumab was also simulated to conclude that the drug is not very effective if started before 10 years after menopause or before age 60.
C1 [Ruiz Lozano, Rocio; Calvo Gallego, Jose Luis; Martinez Reina, Javier] Univ Seville, Dept Ingn Mecan & Fabricac, Seville 41092, Spain.
   [Pivonka, Peter] Queensland Univ Technol, Sch Mech Med & Proc Engn, Brisbane, Qld 4000, Australia.
   [Mcdonald, Michelle M.] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia.
C3 University of Sevilla; Queensland University of Technology (QUT);
   University of Sydney
RP Martínez Reina, J (通讯作者)，Univ Seville, Dept Ingn Mecan & Fabricac, Seville 41092, Spain.
EM rrlozano@us.es; joselucalvo@us.es; peter.pivonka@qut.edu.au;
   michelle.mcdonald@sydney.edu.au; jmreina@us.es
RI Pivonka, Peter/AAL 1053 2021; McDonald, Michelle/AAD 4760 2019;
   Martínez Reina, Javier/K 2806 2014; Calvo Gallego, Jose
   Luis/L 6118 2014; Calvo Gallego, Jose/L 6118 2014
OI McDonald, Michelle/0000 0002 3928 2506; Pivonka,
   Peter/0000 0001 9183 530X; Calvo Gallego, Jose Luis/0000 0002 3407 1582;
   
FU Spanish Government [PID2019 106969RB I00]; Australian Research Council
   (ARC) Industrial Transformation Training Centre for Joint Biomechanics
   [IC190100020]; Discovery Project [DP230101404]; The Ernest Heine Family
   Foundation
FX Funding was provided by MCIN /AEI /10.13039 /501100011033 of the Spanish
   Government through the research project PID2019 106969RB I00 entitled
   Modelos de Remodelacion Osea y su Aplicacion para Simular el Efecto de
   Tratamientos Antireabsortivos contra la Osteoporosis Postmenopausica for
   which this paper has been prepared. Dr. Pivonka would also like to
   gratefully acknowledge funding received through the Australian Research
   Council (ARC) Industrial Transformation Training Centre for Joint
   Biomechanics (IC190100020) and Discovery Project (DP230101404). Dr.
   McDonald was supported by The Ernest Heine Family Foundation.
CR Abdouni A, 2017, ROY SOC OPEN SCI, V4, DOI 10.1098/rsos.170321
   Bianchi M, 2011, IEEE ENG MED BIO, P3467, DOI 10.1109/IEMBS.2011.6090937
   Choi S, 2013, P IEEE, V101, P2093, DOI 10.1109/JPROC.2012.2221071
   Dalsgaard TS, 2022, INT J HUM COMPUT ST, V168, DOI 10.1016/j.ijhcs.2022.102920
   Gertler I, 2023, SOFT ROBOT, V10, P624, DOI 10.1089/soro.2021.0184
   Gescheider GA, 2002, SOMATOSENS MOT RES, V19, P114, DOI 10.1080/08990220220131505
   Harris C.M., 2002, Harris' Shock and Vibration Handbook
   Hoshi T, 2010, IEEE T HAPTICS, V3, P155, DOI [10.1109/ToH.2010.4, 10.1109/TOH.2010.4]
   JOHANSSON RS, 1979, J PHYSIOL LONDON, V286, P283, DOI 10.1113/jphysiol.1979.sp012619
   Liu G.R., 2003, The finite element method: A practical course, DOI 10.1016/B978 0 7506 5866 9.X5000 2
   LOFVENBERG J, 1984, BRAIN RES, V301, P65, DOI 10.1016/0006 8993(84)90403 7
   Long B, 2014, ACM T GRAPHIC, V33, DOI 10.1145/2661229.2661257
   Pawluk DTV, 1999, J BIOMECH ENG T ASME, V121, P178, DOI 10.1115/1.2835100
   Rakkolainen I, 2021, IEEE T HAPTICS, V14, P2, DOI 10.1109/TOH.2020.3018754
   Raza A, 2020, IEEE T IND ELECTRON, V67, P736, DOI 10.1109/TIE.2019.2910036
   Serhat Gokhan, 2022, PLoS One, V17, pe0269722, DOI 10.1371/journal.pone.0269722
   Serhat G, 2021, APPL SCI BASEL, V11, DOI 10.3390/app11125709
   Shao YT, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz1158
   Shao YT, 2016, P NATL ACAD SCI USA, V113, P4188, DOI 10.1073/pnas.1520866113
   Shultz C, 2022, IEEE HAPTICS SYM, DOI 10.1109/HAPTICS52432.2022.9765565
   Wiertlewski M, 2012, J BIOMECH, V45, P1869, DOI 10.1016/j.jbiomech.2012.05.045
   Wu JZ, 2007, MED ENG PHYS, V29, P718, DOI 10.1016/j.medengphy.2006.07.005
   Wu JZ, 2009, J BIOMECH, V42, P116, DOI 10.1016/j.jbiomech.2008.10.033
   Wu JZ, 2003, ANN BIOMED ENG, V31, P867, DOI 10.1114/1.1581290
   Yildiz MZ, 2013, SOMATOSENS MOT RES, V30, P37, DOI 10.3109/08990220.2012.754754
NR 25
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1617 7959
EI 1617 7940
J9 BIOMECH MODEL MECHAN
JI Biomech. Model. Mechanobiol.
PD AUG
PY 2024
VL 23
IS 4
BP 1393
EP 1409
DI 10.1007/s10237 024 01846 2
EA MAY 2024
PG 17
WC Biophysics; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Engineering
GA D4U5S
UT WOS:001214068800002
PM 38700787
OA hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU Baek, JM
   Kim, JY
   Lee, CH
   Yoon, KH
   Lee, MS
AF Baek, Jong Min
   Kim, Ju Young
   Lee, Chang Hoon
   Yoon, Kwon Ha
   Lee, Myeung Su
TI Methyl Gallate Inhibits Osteoclast Formation and Function by Suppressing
   Akt and Btk PLCγ2 Ca<SUP>2+</SUP> Signaling and Prevents
   Lipopolysaccharide Induced Bone Loss
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE methyl gallate; osteoclast; Akt; Ca2+ signaling; bone resorption;
   osteoporosis
ID POSTMENOPAUSAL WOMEN; RECEPTOR ACTIVATOR; IN VITRO; T CELLS;
   DIFFERENTIATION; OSTEOPOROSIS; RANKL; RESORPTION; PATHWAY; PROTEIN
AB In the field of bone research, various natural derivatives have emerged as candidates for osteoporosis treatment by targeting abnormally elevated osteoclastic activity. Methyl gallate, a plant derived phenolic compound, is known to have numerous pharmacological effects against inflammation, oxidation, and cancer. Our purpose was to explore the relation between methyl gallate and bone metabolism. Herein, we performed screening using methyl gallate by tartrate resistant acid phosphatase (TRAP) staining and revealed intracellular mechanisms responsible for methyl gallate mediated regulation of osteoclastogenesis by Western blotting and quantitative reverse transcription polymerase chain reaction (RT PCR). Furthermore, we assessed the effects of methyl gallate on the characteristics of mature osteoclasts. We found that methyl gallate significantly suppressed osteoclast formation through Akt and Btk PLC gamma 2 Ca2+ signaling. The blockade of these pathways was confirmed through transduction of cells with a CA Akt retrovirus and evaluation of Ca2+ influx intensity (staining with Fluo 3/AM). Indeed, methyl gallate downregulated the formation of actin ring positive osteoclasts and resorption pit areas. In agreement with in vitro results, we found that administration of methyl gallate restored osteoporotic phenotype stimulated by acute systemic injection of lipopolysaccharide in vivo according to micro computed tomography and histological analysis. Our data strongly indicate that methyl gallate may be useful for the development of a plant based antiosteoporotic agent.
C1 [Baek, Jong Min] Wonkwang Univ, Sch Med, Dept Anat, Iksan 570749, Jeonbuk, South Korea.
   [Kim, Ju Young; Lee, Chang Hoon; Yoon, Kwon Ha; Lee, Myeung Su] Wonkwang Univ, Imaging Sci Based Lung & Bone Dis Res Ctr, Iksan 570749, Jeonbuk, South Korea.
   [Yoon, Kwon Ha] Wonkwang Univ, Sch Med, Dept Radiol, Iksan 570749, Jeonbuk, South Korea.
   [Lee, Chang Hoon; Lee, Myeung Su] Wonkwang Univ, Dept Internal Med, Div Rheumatol, Iksan 570749, Jeonbuk, South Korea.
C3 Wonkwang University; Wonkwang University; Wonkwang University; Wonkwang
   University
RP Lee, MS (通讯作者)，Wonkwang Univ, Imaging Sci Based Lung & Bone Dis Res Ctr, Iksan 570749, Jeonbuk, South Korea.; Lee, MS (通讯作者)，Wonkwang Univ, Dept Internal Med, Div Rheumatol, Iksan 570749, Jeonbuk, South Korea.
EM phone8418@hanmail.net; kimjy1014@gmail.com; lch110@wku.ac.kr;
   khy1646@wku.ac.kr; ckhlms@wku.ac.kr
RI Lee, Sang Hoon/ABH 6210 2020
FU Korean Health Technology R&D Project, Ministry of Health & Welfare,
   Republic of Korea [HI12C0110]
FX This study was supported by a grant from the Korean Health Technology
   R&D Project, Ministry of Health & Welfare, Republic of Korea
   (HI12C0110).
CR Asnaashari M, 2014, FOOD CHEM, V159, P439, DOI 10.1016/j.foodchem.2014.03.038
   Baek JM, 2015, BIOCHEM BIOPH RES CO, V461, P334, DOI 10.1016/j.bbrc.2015.04.034
   Baek JM, 2015, PHYTOMEDICINE, V22, P27, DOI 10.1016/j.phymed.2014.10.008
   Ballestrem C, 1998, J CELL SCI, V111, P1649
   Block MR, 2008, EUR J CELL BIOL, V87, P491, DOI 10.1016/j.ejcb.2008.02.012
   Boyce Brendan F, 2007, Curr Osteoporos Rep, V5, P98
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Cao HL, 2013, J BIOL CHEM, V288, P30399, DOI 10.1074/jbc.M113.469973
   Chae HS, 2010, AM J CHINESE MED, V38, P973, DOI 10.1142/S0192415X10008391
   Chen JS, 2012, NAT REV ENDOCRINOL, V8, P81, DOI 10.1038/nrendo.2011.146
   Choi JG, 2008, J MICROBIOL BIOTECHN, V18, P1848, DOI 10.4014/jmb.0800.025
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   El Desoky AH, 2017, J NAT PROD, V80, P90, DOI 10.1021/acs.jnatprod.6b00725
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hwang SY, 2011, BBA MOL CELL RES, V1813, P979, DOI 10.1016/j.bbamcr.2010.11.002
   KATO T, 1994, J ANAT, V185, P599
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Kobayashi Y, 2009, CRIT REV EUKAR GENE, V19, P61, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.30
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Lee H, 2010, J IMMUNOL, V185, P6698, DOI 10.4049/jimmunol.1001373
   Lee SH, 2008, J BIOL CHEM, V283, P11526, DOI 10.1074/jbc.M708935200
   Luxenburg C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000179
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Palokangas H, 1997, J CELL SCI, V110, P1767
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403
   QUEVEDO L, 1981, PHARMACOLOGY, V23, P293, DOI 10.1159/000137563
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Raisz LG, 1999, CLIN CHEM, V45, P1353
   Roodman GD, 2006, ANN NY ACAD SCI, V1068, P100, DOI 10.1196/annals.1346.013
   Schlesinger PH, 1997, J BIOL CHEM, V272, P18636, DOI 10.1074/jbc.272.30.18636
   Shinohara M, 2008, CELL, V132, P794, DOI 10.1016/j.cell.2007.12.037
   Sibai T, 2011, CLIN ORTHOP RELAT R, V469, P2215, DOI 10.1007/s11999 010 1722 9
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   Toyosaki Maeda T, 2001, ARTHRITIS RES, V3, P306, DOI 10.1186/ar320
   VAANANEN HK, 1995, J CELL SCI, V108, P2729
   Watts NB, 2012, OSTEOPOROSIS INT, V23, P327, DOI 10.1007/s00198 011 1755 2
   Zhou YD, 2011, J CELL PHYSIOL, V226, P1082, DOI 10.1002/jcp.22423
   Zou W, 2007, J CELL BIOL, V176, P877, DOI 10.1083/jcb.200611083
NR 42
TC 32
Z9 33
U1 0
U2 7
PU MDPI AG
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2017
VL 18
IS 3
AR 581
DI 10.3390/ijms18030581
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA EN8ME
UT WOS:000396253700112
PM 28272351
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Tian, LL
   Ding, L
   Wang, GQ
   Guo, Y
   Zhao, YY
   Wei, YC
   Li, XQ
   Zhang, W
   Mi, J
   Li, XY
   Wang, ZY
   Wang, XG
AF Tian, Lulu
   Ding, Lu
   Wang, Guoqiang
   Guo, Yu
   Zhao, Yunyun
   Wei, Yuchi
   Li, Xingquan
   Zhang, Wei
   Mi, Jia
   Li, Xiangyan
   Wang, Zeyu
   Wang, Xiuge
TI Qizhi Kebitong Formula Ameliorates Streptozocin Induced Diabetic
   Osteoporosis through Regulating the PI3K/Akt/NF κB Pathway
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; BONE LOSS; INTERLEUKIN 6; INFLAMMATION;
   MEDIATION; BAICALEIN; CELLS
AB Background. Diabetic osteoporosis (DOP) is a progressive osteoblast dysfunction induced by high glucose, which has negative impacts on bone homeostasis. Qizhi Kebitong formula (QKF) is a traditional Chinese medicine (TCM) formula for treating DOP. However, its role in the protection of DOP has not been clarified yet. Here, we aimed to explore the potential mechanisms of QKF on DOP development via in vivo experiment. Methods. Network pharmacology was used to detect the key targets and signaling pathways of QKF on DOP. The effects of QKF on DOP were examined by the phenotypic characteristics, micro CT, and hematoxylin eosin (H&E) staining. The predicted targets and pathways were validated by a streptozocin  (STZ ) induced mouse model. Subsequently, the levels of the selected genes and proteins were analyzed using qRT PCR and Western blot. Finally, AutoDock and PyMOL were used for molecular docking. Results. In this study, 90 active compounds and 2970 related disease targets have been found through network pharmacology. And QKF could improve the microstructures of femur bone mass, reduce inflammatory cell infiltration, and downregulate the levels of TNF alpha, IKBKB, IL 6, and IL 1 beta. Moreover, the underlying effect of PI3K/Akt/NF kappa B pathways was also recommended in the treatment. Conclusion. Altogether, our findings suggested that QKF could markedly alleviate osteoblast dysfunction by modulating the key targets and PI3K/Akt/NF kappa B signaling pathway.
C1 [Tian, Lulu; Guo, Yu; Zhao, Yunyun; Wei, Yuchi; Li, Xingquan] Changchun Univ Chinese Med, Coll Chinese Med, Changchun 130117, Peoples R China.
   [Ding, Lu; Zhang, Wei; Li, Xiangyan] Changchun Univ Chinese Med, Jilin Ginseng Acad, Key Lab Act Subst & Biol Mech Ginseng Efficacy, Jilin Prov Key Lab Biomacromol Chinese Med,Minist, Changchun 130117, Jilin, Peoples R China.
   [Wang, Guoqiang; Mi, Jia; Wang, Xiuge] Affiliated Hosp Changchun Univ Chinese Med, Dept Endocrinol, Changchun 130021, Peoples R China.
   [Wang, Zeyu] Changchun Univ Chinese Med, Dept Sci Res, Changchun, Peoples R China.
C3 Changchun University of Chinese Medicine; Changchun University of
   Chinese Medicine; Changchun University of Chinese Medicine
RP Wang, XG (通讯作者)，Affiliated Hosp Changchun Univ Chinese Med, Dept Endocrinol, Changchun 130021, Peoples R China.; Wang, ZY (通讯作者)，Changchun Univ Chinese Med, Dept Sci Res, Changchun, Peoples R China.
EM tianll_ccucm@163.com; dl15904314460@163.com; 674263771@qq.com;
   guoy0828@163.com; yephely0204@163.com; davidway2021@163.com;
   1252780154@qq.com; weizcaas@126.com; mijia8201@126.com;
   xiangyan_li1981@163.com; zeyu781022@163.com; xiuge_w@163.com
RI Li, Xiangyan/JDW 4460 2023
FU National Key Research and Development Program of China; Jilin Scientific
   and Technological of Chinese Medicine Program;  [2019YFC1709904]; 
   [20160204010YY];  [2015ZFZC14]
FX AcknowledgmentsThis project was supported by grants from the National
   Key Research and Development Program of China (2019YFC1709904) and the
   Jilin Scientific and Technological of Chinese Medicine Program
   (20160204010YY and 2015ZFZC14).
CR Caffarelli C, 2022, AGING CLIN EXP RES, V34, P121, DOI 10.1007/s40520 021 01889 w
   Cai P, 2021, AGING US, V13, P17370, DOI 10.18632/aging.203227
   Dai JS, 2004, TOXICOLOGY, V203, P199, DOI 10.1016/j.tox.2004.06.009
   El Makawy AI, 2020, ENVIRON SCI POLLUT R, V27, P20950, DOI 10.1007/s11356 020 08540 7
   Gomes A, 2009, TOXICON, V53, P60, DOI 10.1016/j.toxicon.2008.10.011
   Gortázar AR, 2020, CURR OSTEOPOROS REP, V18, P796, DOI 10.1007/s11914 020 00641 z
   Guo CC, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/514063
   Guo C, 2017, CELL PHYSIOL BIOCHEM, V43, P1547, DOI 10.1159/000481978
   He CM, 2022, J BONE MINER METAB, V40, P208, DOI 10.1007/s00774 021 01280 9
   Hofbauer LC, 2022, LANCET DIABETES ENDO, V10, P207, DOI 10.1016/S2213 8587(21)00347 8
   Huan JM, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/5590743
   Jia Y, 2022, BIOENGINEERED, V13, P5581, DOI 10.1080/21655979.2022.2038941
   Jordan SC, 2017, TRANSPLANTATION, V101, P32, DOI 10.1097/TP.0000000000001452
   Karsenty G, 2003, NATURE, V423, P316, DOI 10.1038/nature01654
   Khosla S, 2021, NAT REV ENDOCRINOL, V17, P685, DOI 10.1038/s41574 021 00555 5
   Kim C, 2003, ARCH PHARM RES, V26, P917, DOI 10.1007/BF02980200
   Koromani F, 2021, CURR OSTEOPOROS REP, V19, P50, DOI 10.1007/s11914 020 00646 8
   Lee D, 2021, MOLECULES, V26, DOI 10.3390/molecules26216509
   Li HF, 2015, DRUG DES DEV THER, V9, P5169, DOI 10.2147/DDDT.S81578
   Li ZR, 2021, FOOD FUNCT, V12, P11898, DOI [10.1039/d1fo01838h, 10.1039/D1FO01838H]
   Liu P, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/2634431
   Ma C, 2018, PAK J PHARM SCI, V31, P1151
   Moseley KF, 2021, CURR OPIN ENDOCRINOL, V28, P360, DOI 10.1097/MED.0000000000000641
   Mukherjee A, 2012, MOL CELL BIOL, V32, P490, DOI 10.1128/MCB.06361 11
   Ning YM, 2016, PHARMAZIE, V71, P134, DOI 10.1691/ph.2016.5135
   Park YH, 2020, J ETHNOPHARMACOL, V251, DOI 10.1016/j.jep.2020.112542
   Peng YH, 2022, J DIABETES INVEST, V13, P236, DOI 10.1111/jdi.13695
   Pivodova V, 2013, INT J ORAL MAX IMPL, V28, P1386, DOI 10.11607/jomi.3039
   Poutoglidou F, 2022, CONNECT TISSUE RES, V63, P577, DOI 10.1080/03008207.2022.2042275
   Qi LN, 2022, J NUTR BIOCHEM, V104, DOI 10.1016/j.jnutbio.2022.108973
   Ren YF, 2022, MOL CELL ENDOCRINOL, V546, DOI 10.1016/j.mce.2022.111559
   Tang FY, 2022, EVID BASED COMPL ALT, V2022, DOI 10.1155/2022/6741995
   Tian HL, 2022, J CELL MOL MED, V26, P2163, DOI 10.1111/jcmm.17238
   Wang JJ, 2016, MOL BRAIN, V9, DOI 10.1186/s13041 016 0193 7
   Xie BC, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.697442
   Yang SL, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109102
   Ying XZ, 2015, EUR J PHARMACOL, V765, P394, DOI 10.1016/j.ejphar.2015.09.005
   Zhang H, 2008, MATURITAS, V61, P334, DOI 10.1016/j.maturitas.2008.09.023
   Zhang LL, 2022, EVID BASED COMPL ALT, V2022, DOI 10.1155/2022/4093138
   Zhang W, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/6480381
   Zhang ZX, 2019, J TRADIT CHIN MED, V39, P133
   Zhu GP, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.758829
NR 42
TC 3
Z9 5
U1 0
U2 28
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2314 6133
EI 2314 6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD AUG 21
PY 2022
VL 2022
AR 4469766
DI 10.1155/2022/4469766
PG 16
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 4F3KV
UT WOS:000848414000017
PM 36046447
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Sutherland, KA
   Rogers, HL
   Tosh, D
   Rogers, MJ
AF Sutherland, Karen A.
   Rogers, Helena L.
   Tosh, Denise
   Rogers, Michael J.
TI RANKL increases the level of Mcl 1 in osteoclasts and reduces
   bisphosphonate induced osteoclast apoptosis in vitro
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
ID BCL 2 FAMILY MEMBER; RHEUMATOID ARTHRITIS; ZOLEDRONIC ACID; PROTEIN
   GERANYLGERANYLATION; CELL DEATH; TNF ALPHA; SURVIVAL; DIFFERENTIATION;
   INHIBITION; MECHANISMS
AB Introduction Bisphosphonates are the most widely used class of drug for inhibiting osteoclast mediated bone loss, but their effectiveness at preventing joint destruction in rheumatoid arthritis has generally been disappointing. We examined whether the ability of bisphosphonates to induce osteoclast apoptosis and inhibit bone resorption in vitro is influenced by the cytokine receptor activator of nuclear factor kappa B ligand (RANKL), an important mediator of inflammation induced bone loss.
   Methods Rabbit osteoclasts were treated with the bisphosphonates clodronate or alendronate for up to 48 hours in the absence or presence of RANKL. Changes in cell morphology and induction of apoptosis were examined by scanning electron microscopy, whilst resorptive activity was determined by measuring the area of resorption cavities. Changes in the level of anti apoptotic proteins, including Mcl 1, Bcl 2, and Bcl x(>L), were determined in rabbit osteoclasts and in cytokine starved mouse osteoclasts by Western blotting.
   Results RANKL significantly attenuated the ability of both clodronate and alendronate to induce osteoclast apoptosis and inhibit bone resorption. Treatment of rabbit osteoclasts with RANKL was associated with an increase in the anti apoptotic protein Mcl 1 but not Bcl 2. A role for Mcl 1 in osteoclast survival was suggested using osteoclasts generated from mouse bone marrow macrophages in the presence of RANKL + macrophage colony stimulating factor (M CSF) since cytokine deprivation of mouse osteoclasts caused a rapid loss of Mcl 1 (but not Bcl 2 or Bcl x(L)), which preceded the biochemical and morphological changes associated with apoptosis. Loss of Mcl 1 from mouse osteoclasts could be prevented by factors known to promote osteoclast survival (RANKL, M CSF, tumour necrosis factor alpha [TNF alpha], or lipopolysaccharide [LPS]).
   Conclusions RANKL protects osteoclasts from the apoptosis inducing and anti resorptive effects of bisphosphonates in vitro. The ability of RANKL (and other pro inflammatory factors such as TNF alpha and LPS) to increase the level of Mcl 1 in osteoclasts may explain the lack of effectiveness of some bisphosphonates in preventing inflammation induced bone loss.
C1 [Sutherland, Karen A.; Rogers, Helena L.; Tosh, Denise; Rogers, Michael J.] Univ Aberdeen, Inst Med Sci, Sch Med & Dent, Bone & Musculoskeletal Res Programme, Aberdeen AB25 2ZD, Scotland.
C3 University of Aberdeen
RP Rogers, MJ (通讯作者)，Univ Aberdeen, Inst Med Sci, Sch Med & Dent, Bone & Musculoskeletal Res Programme, Aberdeen AB25 2ZD, Scotland.
EM m.j.rogers@abdn.ac.uk
OI Rogers, Michael/0000 0002 1818 9249
FU Arthritis Research Campaign
FX We are grateful to Debbie Marshall for technical assistance with
   scanning EM and to Ruth Craig (Dartmouth Medical School, Hanover, NH,
   USA) and Brendan Boyce (University of Rochester Medical Center,
   Rochester, NY, USA) for helpful discussions. This work was funded by a
   studentship to KAS from the Arthritis Research Campaign.
CR Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Benford HL, 2001, BONE, V28, P465, DOI 10.1016/S8756 3282(01)00412 4
   Bradley EW, 2008, J BIOL CHEM, V283, P8055, DOI 10.1074/jbc.M709500200
   Breuil V, 2006, JOINT BONE SPINE, V73, P349, DOI 10.1016/j.jbspin.2005.10.019
   Coxon FP, 2001, J BIOL CHEM, V276, P48213, DOI 10.1074/jbc.M106473200
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   COXON FP, 2003, BONE RES PROTOCOLS, P89
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416
   Domina AM, 2004, ONCOGENE, V23, P5301, DOI 10.1038/sj.onc.1207692
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795
   Eggelmeijer F, 1996, ARTHRITIS RHEUM, V39, P396, DOI 10.1002/art.1780390307
   Frith JC, 2001, ARTHRITIS RHEUM, V44, P2201, DOI 10.1002/1529 0131(200109)44:9<2201::AID ART374>3.0.CO;2 E
   Gélinas W, 2005, GENE DEV, V19, P1263, DOI 10.1101/gad.1326205
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Herrak P, 2004, ARTHRITIS RHEUM US, V50, P2327, DOI 10.1002/art.20384
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Jarrett SJ, 2006, ARTHRITIS RHEUM US, V54, P1410, DOI 10.1002/art.21824
   Kanaoka K, 2000, ENDOCRINOLOGY, V141, P2995, DOI 10.1210/en.141.8.2995
   Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302 221
   KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   Liu HT, 2006, ARTHRITIS RHEUM US, V54, P3174, DOI 10.1002/art.22132
   Liu HT, 2005, J IMMUNOL, V175, P8337, DOI 10.4049/jimmunol.175.12.8337
   Maksymowych WP, 2003, J RHEUMATOL, V30, P430
   Matsuo A, 2003, J RHEUMATOL, V30, P1280
   Mönkkönen H, 2001, PHARMACEUT RES, V18, P1550, DOI 10.1023/A:1013026313647
   Oursler MJ, 2005, AM J PHYSIOL CELL PH, V288, pC156, DOI 10.1152/ajpcell.00092.2004
   Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975
   Ritchlin C. T., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P276
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Schett G, 2005, NAT CLIN PRACT RHEUM, V1, P47, DOI 10.1038/ncprheum0036
   Sims NA, 2004, ARTHRITIS RHEUM US, V50, P2338, DOI 10.1002/art.20382
   Smolewska E, 2006, J RHEUMATOL, V33, P1684
   Suda K, 2002, J CELL PHYSIOL, V190, P101, DOI 10.1002/jcp.10041
   Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200
   Suyama K, 2007, ONCOL REP, V18, P1291
   Takayanagi Hiroshi, 2005, Mod Rheumatol, V15, P225
   Teitelbaum SL, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1857
   van de Donk NWCJ, 2003, BLOOD, V102, P3354, DOI 10.1182/blood 2003 03 0970
   van Delft MF, 2006, CELL RES, V16, P203, DOI 10.1038/sj.cr.7310028
   Xing LP, 2005, BIOCHEM BIOPH RES CO, V328, P709, DOI 10.1016/j.bbrc.2004.11.072
   Yang Yen HF, 2006, J BIOMED SCI, V13, P201, DOI 10.1007/s11373 005 9064 4
   Zhang Q, 2005, ARTHRITIS RHEUM US, V52, P2708, DOI 10.1002/art.21236
   Zhao HP, 2006, RHEUMATOL INT, V26, P732, DOI 10.1007/s00296 005 0061 8
   Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630
NR 50
TC 39
Z9 48
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1478 6354
EI 1478 6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PY 2009
VL 11
IS 2
AR R58
DI 10.1186/ar2681
PG 9
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 460CV
UT WOS:000267163900043
PM 19405951
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ohba, T
   Cole, HA
   Cates, JMM
   Slosky, DA
   Haro, H
   Ando, T
   Schwartz, HS
   Schoenecker, JG
AF Ohba, Tetsuro
   Cole, Heather A.
   Cates, Justin M. M.
   Slosky, David A.
   Haro, Hirotaka
   Ando, Takashi
   Schwartz, Herbert S.
   Schoenecker, Jonathan G.
TI Bisphosphonates Inhibit Osteosarcoma Mediated Osteolysis Via Attenuation
   of Tumor Expression of MCP 1 and RANKL
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOSARCOMA; RANKL; OPG; MCP 1; OSTEOCLAST; BISPHOSPHONATES
ID DIAGNOSED METASTATIC OSTEOSARCOMA; ZOLEDRONIC ACID; BREAST CANCER;
   OSTEOCLAST DIFFERENTIATION; ORTHOTOPIC MODEL; BONE METASTASIS;
   EWINGS SARCOMA; GROWTH; OSTEOPROTEGERIN; RECEPTOR
AB Osteosarcoma is the most common primary malignant tumor of bone and accounts for around 50% of all primary skeletal malignancies. In addition to novel chemotherapies, there is a need for adjuvant therapies designed to inhibit osteosarcoma proliferation and tumor induced osteolysis to attenuate tumor expansion and metastasis. As such, studies on the efficacy of bisphosphonates on human osteosarcoma are planned after feasibility studies determined that the bisphosphonate zoledronic acid (ZOL) can be safely combined with conventional chemotherapy. However, the molecular mechanisms responsible for, and means of inhibiting, osteosarcoma induced osteolysis are largely unknown. We establish that osteosarcoma growth directly correlates with tumor induced osteolysis and activation of osteoclasts in vivo. In vitro, tumor cells were determined to expresses surface, but not soluble, receptor activator of NF B ligand (RANKL) and stimulated osteoclastogenesis in a manner directly proportional to their malignant potential. In addition, an aggressive osteosarcoma cell line was shown to secrete monocyte chemoattractant protein 1 (MCP 1), resulting in robust monocyte migration. Because MCP 1 is a key cytokine for monocyte recruitment and surface bound RANKL strongly supports local osteoclastogenesis, we suggest that high levels of these signaling molecules are associated with the aggressive potential of osteosarcoma. Consistent with these findings, abundant expression of RANKL/MCP 1 was observed in tumor in vivo, and MCP 1 plasma levels strongly correlated with tumor progression and osteolysis. ZOL administration directly attenuates osteosarcoma production of RANKL/MCP 1, reducing tumor induced bone destruction. In vivo, these findings also correlated with significant reduction in osteosarcoma growth. ZOL attenuates tumor induced osteolysis, not only through direct inhibition of osteoclasts, but also through direct actions on tumor expression of osteoclast activators. These data provide insight regarding the effect of ZOL on osteosarcoma essential for designing the planned upcoming prospective randomized trials to determine the efficacy of bisphosphonates on osteosarcoma in humans. (c) 2014 American Society for Bone and Mineral Research.
C1 [Ohba, Tetsuro; Cole, Heather A.; Schwartz, Herbert S.; Schoenecker, Jonathan G.] Vanderbilt Univ, Med Ctr, Dept Orthopaed, Nashville, TN 37232 USA.
   [Cates, Justin M. M.; Schoenecker, Jonathan G.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA.
   [Slosky, David A.] Vanderbilt Univ, Med Ctr, Dept Cardiooncol, Nashville, TN 37232 USA.
   [Haro, Hirotaka; Ando, Takashi] Univ Yamanashi, Fac Med, Dept Orthopaed Surg, Yamanashi, Japan.
   [Schoenecker, Jonathan G.] Vanderbilt Univ, Med Ctr, Ctr Bone Biol, Nashville, TN 37232 USA.
   [Schoenecker, Jonathan G.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.
   [Schoenecker, Jonathan G.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA.
C3 Vanderbilt University; Vanderbilt University; Vanderbilt University;
   University of Yamanashi; Vanderbilt University; Vanderbilt University;
   Vanderbilt University
RP Schoenecker, JG (通讯作者)，Vanderbilt Univ, Med Ctr, 2200 Childrens Way, Nashville, TN 37232 USA.
EM jon.schoenecker@vanderbilt.edu
RI ; Cates, Justin/D 5927 2014
OI Schoenecker, Jonathan/0000 0002 3097 5496; Cates,
   Justin/0000 0002 7336 5196
FU Caitlin Lovejoy Fund
FX Funding for this project was provided by the Caitlin Lovejoy Fund. The
   authors thank JI for his development of the models used in this study.
CR Avnet S, 2008, INT J ONCOL, V33, P1231, DOI 10.3892/ijo_00000113
   Battaglia S, 2011, J BONE MINER RES, V26, P2439, DOI 10.1002/jbmr.453
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Brennecke P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074045
   Buddingh EP, 2011, CLIN CANCER RES, V17, P2110, DOI 10.1158/1078 0432.CCR 10 2047
   Bussard KM, 2010, J CELL BIOCHEM, V111, P1138, DOI 10.1002/jcb.22799
   Chou AJ, 2009, CANCER AM CANCER SOC, V115, P5339, DOI 10.1002/cncr.24566
   Cole HA, 2011, J ORTHOP RES, V29, P1957, DOI 10.1002/jor.21474
   Danks L, 2013, J BIOCHEM, V154, P29, DOI 10.1093/jb/mvt049
   Daubiné F, 2007, J NATL CANCER I, V99, P322, DOI 10.1093/jnci/djk054
   Dobnig H, 2006, OSTEOPOROSIS INT, V17, P693, DOI 10.1007/s00198 005 0035 4
   Endo Munoz L, 2012, BBA REV CANCER, V1826, P434, DOI 10.1016/j.bbcan.2012.07.003
   Endo Munoz L, 2010, CANCER RES, V70, P7063, DOI 10.1158/0008 5472.CAN 09 4291
   Fujita K, 2012, NAT MED, V18, P589, DOI 10.1038/nm.2659
   Gallo M, 2012, ANN ONCOL, V23, P597, DOI 10.1093/annonc/mdr159
   Goldsby RE, 2013, EUR J CANCER, V49, P2384, DOI 10.1016/j.ejca.2013.03.018
   Halleen JM, 2006, CLIN LAB, V52, P499
   Ichikawa J, 2012, CANCER AM CANCER SOC, V118, P2494, DOI 10.1002/cncr.26518
   Khanna C, 2000, CLIN EXP METASTAS, V18, P261, DOI 10.1023/A:1006767007547
   Kim JY, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4018
   Kim MS, 2005, J BIOL CHEM, V280, P16163, DOI 10.1074/jbc.M412713200
   Lau YS, 2007, BRIT J CANCER, V96, P1716, DOI 10.1038/sj.bjc.6603774
   Lee JA, 2011, PEDIATR BLOOD CANCER, V56, P738, DOI 10.1002/pbc.22720
   Lipton A, 2011, BONE, V48, P96, DOI 10.1016/j.bone.2010.10.161
   Luu HH, 2005, CLIN EXP METASTAS, V22, P319, DOI 10.1007/s10585 005 0365 9
   Lynch CC, 2005, CANCER CELL, V7, P485, DOI 10.1016/j.ccr.2005.04.013
   Mercatali L, 2013, INT J MOL SCI, V14, P10683, DOI 10.3390/ijms140610683
   Mizuno A, 2002, J BONE MINER METAB, V20, P337, DOI 10.1007/s007740200049
   Mizutani K, 2009, NEOPLASIA, V11, P1235, DOI 10.1593/neo.09988
   Murphey MD, 2004, RADIOLOGY, V233, P129, DOI 10.1148/radiol.2331030326
   New DC, 2003, ACTA BIOCH BIOPH SIN, V35, P779
   Odri GA, 2010, CANCER RES, V70, P7610, DOI 10.1158/0008 5472.CAN 09 4272
   Penno H, 2009, SCAND J CLIN LAB INV, V69, P151, DOI 10.1080/00365510802460466
   Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138
   Romano M, 2000, LAB INVEST, V80, P1095, DOI 10.1038/labinvest.3780115
   Rousseau J, 2011, J BONE MINER RES, V26, P2452, DOI 10.1002/jbmr.455
   SCHMIDT J, 1988, DIFFERENTIATION, V39, P151, DOI 10.1111/j.1432 0436.1988.tb00090.x
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Solinas G, 2009, J LEUKOCYTE BIOL, V86, P1065, DOI 10.1189/jlb.0609385
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Taylor R, 2011, J PATHOL, V225, P195, DOI 10.1002/path.2869
   Tsubaki M, 2012, MOL CELL ENDOCRINOL, V361, P219, DOI 10.1016/j.mce.2012.05.002
   Uppal R, 2012, INVEST RADIOL, V47, P553, DOI 10.1097/RLI.0b013e31825dddfb
   Van Poznak CH, 2011, J CLIN ONCOL, V29, P1221, DOI 10.1200/JCO.2010.32.5209
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
   Wang SW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035101
   Weiss KR, 2006, CLIN ORTHOP RELAT R, P111, DOI 10.1097/01.blo.0000229333.98781.56
   Wunder JS, 2007, LANCET ONCOL, V8, P513, DOI 10.1016/S1470 2045(07)70169 9
   Yarmish G, 2010, RADIOGRAPHICS, V30, P1653, DOI 10.1148/rg.306105524
   Yin DZ, 2008, INT J ONCOL, V33, P253, DOI 10.3892/ijo_00000004
NR 50
TC 65
Z9 67
U1 0
U2 22
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUN
PY 2014
VL 29
IS 6
BP 1431
EP 1445
DI 10.1002/jbmr.2182
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AH3DJ
UT WOS:000336001500016
PM 24443409
OA Bronze
DA 2025 08 17
ER

PT J
AU Chen, YZ
   Zhou, Y
   Chen, JL
   Luo, YP
   Feng, CZ
   Fan, XH
AF Chen, Yu zhou
   Zhou, Yi
   Chen, Jun long
   Luo, Yi ping
   Feng, Cheng zhi
   Fan, Xiao hong
TI Mechanism of modified danggui buxue decoction in glucocorticoid induced
   osteoporosis: A discussion based on network pharmacology and molecular
   docking
SO HELIYON
LA English
DT Article
DE Modified danggui buxue decoction; Glucocorticoid induced osteoporosis;
   Molecular docking; Network pharmacology
ID OSTEOBLAST DIFFERENTIATION; BONE; PREVENTION; QUERCETIN; PATHWAY; GROWTH
AB Objective: Glucocorticoid induced osteoporosis (GIOP) represents a major complication arising from the long term use of glucocorticoids, which are widely prescribed for various inflammatory and autoimmune conditions. Despite its prevalence, the current therapeutic options for GIOP are limited in terms of efficacy, safety profiles, and patient compliance. The Modified Danggui Buxue Decoction (DGBXD), a traditional Chinese herbal formulation, has shown promise in preliminary studies for its potential osteoprotective effects. The present study aimed to explore the mechanistic underpinnings of DGBXD's action on GIOP using network pharmacology and molecular docking approaches, bridging traditional medicine with modern pharmacological insights. Method: Network pharmacology is applied to screen drug active compounds and potential core target proteins for disease treatment and to explore the drugs' therapeutic mechanisms. Result: Altogether, 78 DGBXD active compounds and 223 DGBXD related, 146 component disease common, and 2168 GIOP associated target genes were obtained. The PPI network had 43 nodes and 462 edges, and a total of 10 core target genes, including TP53, JUN and MAPK3, were identified. The results of the GO enrichment analysis implied that DGBXD might participate in biological activities, including responses to oxidative stress and nutrient levels. The outcomes of the KEGG pathway enrichment analysis showed that DGBXD may treat GIOP through TNF, IL 17, and phosphatidylinositol 3 kinase (PI3K) Akt signaling pathways. Based on to the molecular docking results, biologically active compounds (beta carotene, formononetin, luteolin, and isorhamnetin) exhibited good binding to AKT1 and ESR1. Conclusion: DGBXD may aid in GIOP treatment by modulating multiple therapeutic targets and signaling pathways.
C1 [Chen, Yu zhou] Chengdu Univ TCM, Chengdu 610075, Peoples R China.
   [Chen, Yu zhou; Feng, Cheng zhi; Fan, Xiao hong] Hosp Chengdu Univ Tradit Chinese Med, Dept Orthoped, Chengdu 610075, Peoples R China.
   [Zhou, Yi] Tradit Chinese Med Hosp Wenjiang Dist, Dept Tradit Chinese Med, Chengdu 611130, Peoples R China.
   [Chen, Jun long] Tradit Chinese Med Hosp Wenjiang Dist, Dept Anorectal, Chengdu 611130, Peoples R China.
   [Luo, Yi ping] Hosp Chengdu Univ Tradit Chinese Med, Dept Gynecol, Chengdu 610075, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Chengdu University
   of Traditional Chinese Medicine; Chengdu University of Traditional
   Chinese Medicine
RP Fan, XH (通讯作者)，Hosp Chengdu Univ Tradit Chinese Med, Dept Orthoped, Chengdu 610075, Peoples R China.
EM doctorfanxiaohong@163.com
RI chen, junlong/KJL 8942 2024; 范, 晓红/GQA 8649 2022
FU Key R & D projects in Sichuan Province (Sichuan Provincial Department of
   Science and Technology) [2022YFS0418]
FX <BOLD>Funding</BOLD> This work was supported by Key R & D projects in
   Sichuan Province (Sichuan Provincial Department of Science and
   Technology, No: 2022YFS0418) .
CR Ang ESM, 2011, FEBS LETT, V585, P2755, DOI 10.1016/j.febslet.2011.07.046
   Bénard Laribière A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen 2017 015905
   Bocci G, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 06692 0
   Boutros T, 2008, PHARMACOL REV, V60, P261, DOI 10.1124/pr.107.00106
   Bozec A, 2010, J CELL BIOL, V190, P1093, DOI 10.1083/jcb.201002111
   Buckley L, 2017, ARTHRITIS RHEUMATOL, V69, P1521, DOI [10.1002/art.40137, 10.1002/acr.23279]
   Byun MR, 2012, BONE, V50, P364, DOI 10.1016/j.bone.2011.10.035
   C.R. Association, 2013, Chinese Journal of Rheumatology, V17, P363
   Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031 10
   Compston J, 2018, ENDOCRINE, V61, P7, DOI 10.1007/s12020 018 1588 2
   Derakhshanian H, 2013, CAN J PHYSIOL PHARM, V91, P380, DOI 10.1139/cjpp 2012 0190
   Ersahin T, 2015, MOL BIOSYST, V11, P1946, DOI 10.1039/c5mb00101c
   Goldring SR, 2000, ARTHRITIS RES, V2, P33, DOI 10.1186/ar67
   Hsin KY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083922
   Hu Y.Y., 2012, World Science and Technology Modernization of Traditional Chinese Medicine, V14, P1349
   Huang H, 2009, CELL DEATH DIFFER, V16, P1332, DOI 10.1038/cdd.2009.74
   Jing Z, 2019, J CELL PHYSIOL, V234, P4472, DOI 10.1002/jcp.27252
   Kan S, 2002, AM J HUM GENET, V70, P472, DOI 10.1086/338758
   Kim IR, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1320 9
   Komori T, 2005, J CELL BIOCHEM, V95, P445, DOI 10.1002/jcb.20420
   Lei G., 2016, Journal of New Chinese Medicine, V48, P218
   Lerbs T, 2020, STEM CELL REP, V14, P603, DOI 10.1016/j.stemcr.2020.02.009
   Li A.A., 2022, Chinese Journal of Tissue Engineering Research, V26, P197
   Li L.B, 2014, Chinese Journal of Clinical Rational Drug Use, V7, P187
   Li S, 2013, CHIN J NAT MEDICINES, V11, P110, DOI [10.3724/SP.J.1009.2013.00110, 10.1016/S1875 5364(13)60037 0]
   Li X, 2022, COMPUT BIOL MED, V144, DOI 10.1016/j.compbiomed.2022.105389
   Liu SH, 2015, DRUG SAFETY, V38, P117, DOI 10.1007/s40264 014 0250 z
   Liu WJ, 2015, AGING US, V7, P205, DOI 10.18632/aging.100728
   Liu ZC, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.594785
   Ma H., 2018, Journal of Ningxia Medical University, V40, P41
   Ma H., 2018, Journal of Ningxia Medical University, V40, P17
   Ma YG, 2021, SCI TOTAL ENVIRON, V750, DOI 10.1016/j.scitotenv.2020.141638
   Mu W, 2022, PHARMACEUTICALS BASE, V15, DOI 10.3390/ph15101274
   Mukherjee A, 2012, MOL CELL BIOL, V32, P490, DOI 10.1128/MCB.06361 11
   Osiri M, 2000, JCR J CLIN RHEUMATOL, V6, P117, DOI 10.1097/00124743 200006000 00001
   Overman RA, 2013, ARTHRIT CARE RES, V65, P294, DOI 10.1002/acr.21796
   Pang WY, 2010, BRIT J PHARMACOL, V159, P1693, DOI 10.1111/j.1476 5381.2010.00664.x
   Peng ZC, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.911326
   Qin Zhen, 2013, Chinese Pharmacological Bulletin, V29, P1320
   Schurman L, 2008, EXP CLIN ENDOCR DIAB, V116, P333, DOI 10.1055/s 2007 992786
   Sinha KM, 2013, J CELL BIOCHEM, V114, P975, DOI 10.1002/jcb.24439
   Venuturupalli SR, 2013, CURR OSTEOPOROS REP, V11, P357, DOI 10.1007/s11914 013 0170 3
   Wang Y.F., 2021, Lishizhen Medicine and Materia Medica Research, V32, P2794
   Wang YK, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012691
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Wong RWK, 2008, J ORTHOP RES, V26, P1061, DOI 10.1002/jor.20638
   Xiao P, 2008, J BONE MINER RES, V23, P644, DOI 10.1359/JBMR.080105
   Xie BC, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.739326
   Xie WG, 2015, MED SCI MONITOR, V21, P1333, DOI 10.12659/MSM.894111
   Yang Fei Xia, 2021, Zhongguo Zhong Yao Za Zhi, V46, P2677, DOI 10.19540/j.cnki.cjcmm.20200828.201
   [喻琴云 Yu Qinyun], 2017, [中国临床药理学与治疗学, Chinese Journal of Clinical Pharmacology and Therapeutics], V22, P1371
   Yu T, 2020, AGING US, V12, P10473, DOI 10.18632/aging.103271
   Zeng L., 2007, Herald of Medicine, P1258
   Zhang JH, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 18287 5
   Zhang X., 2017, Chin. J. Allergy Clin. Immunol, V11, P277
   Zhang X.Y., 2022, Chinese Journal of Tissue Engineering Research, V26, P245
   Zhou Y, 2023, CURR STEM CELL RES T, V18, P115, DOI 10.2174/1574888X17666220426120850
NR 57
TC 1
Z9 1
U1 4
U2 9
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2405 8440
J9 HELIYON
JI Heliyon
PD SEP 15
PY 2024
VL 10
IS 17
AR e37249
DI 10.1016/j.heliyon.2024.e37249
EA AUG 2024
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA F1X8A
UT WOS:001307825300001
PM 39286188
OA Green Published
DA 2025 08 17
ER

PT J
AU Gou, WL
   Wang, X
   Peng, J
   Lu, Q
   Wang, Y
   Wang, AY
   Guo, QY
   Gao, XP
   Xu, WJ
   Lu, SB
AF Gou, Wenlong
   Wang, Xin
   Peng, Jiang
   Lu, Qiang
   Wang, Yu
   Wang, Aiyuan
   Guo, Quanyi
   Gao, Xupeng
   Xu, Wenjing
   Lu, Shibi
TI Controlled Delivery of Zoledronate Improved Bone Formation Locally In
   Vivo
SO PLOS ONE
LA English
DT Article
ID BISPHOSPHONATE RELATED OSTEONECROSIS; OSTEOGENIC DIFFERENTIATION;
   PAMIDRONATE TREATMENT; OSTEOBLAST APOPTOSIS; MINERAL DENSITY; OSTEOCYTE;
   ALENDRONATE; MECHANISMS; INCREASES; CELLS
AB Bisphosphonates (BPs) have been widely used in clinical treatment of bone diseases with increased bone resorption because of their strong affinity for bone and their inhibition of bone resorption. Recently, there has been growing interest in their improvement of bone formation. However, the effect of local controlled delivery of BPs is unclear. We used polylactide acid glycolic acid copolymer (PLGA) as a drug carrier to deliver various doses of the bisphosphonate zoledronate (Zol) into the distal femur of 8 week old Sprague Dawley rats. After 6 weeks, samples were harvested and analyzed by micro CT and histology. The average bone mineral density and mineralized bone volume fraction were higher with medium and high dose PLGA Zol (30 and 300 mu g Zol, respectively) than control and low dose Zol (3 mu g PLGA Zol; p<0.05). Local controlled delivery of Zol decreased the numbers of osteoclast and increased the numbers of osteoblast. Moreover, local controlled delivery of medium and high dose Zol accelerated the expression of bone formation markers. PLGA used as a drug carrier for controlled delivery of Zol may promote local bone formation.
C1 [Gou, Wenlong; Wang, Xin; Peng, Jiang; Lu, Qiang; Wang, Yu; Wang, Aiyuan; Guo, Quanyi; Gao, Xupeng; Xu, Wenjing; Lu, Shibi] Chinese Peoples Liberat Army Gen Hosp, Inst Orthopaed, Beijing, Peoples R China.
C3 Chinese People's Liberation Army General Hospital
RP Peng, J (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Inst Orthopaed, Beijing, Peoples R China.
EM pengjiang301@126.com
RI Xu, Wenjing/N 6924 2018; WANG, Xinxin/MVW 1205 2025; Wang,
   Yu/IZE 9175 2023; guo, quanyi/JRY 6402 2023; wang, yu/IZE 9175 2023
OI wang, yu/0000 0001 7811 5834
FU National Technology Research and Development Program of China
   [2012AA020502, 2012CB518106]; National Science Foundation of China
   [30930092, 30973047, 31240048];  [BWS11J025]
FX This work was funded by a grant from the National Technology Research
   and Development Program of China (2012AA020502, 2012CB518106) and the
   National Science Foundation of China (30930092, 30973047, 31240048), and
   BWS11J025. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Aya Ay J, 2007, J BONE MINER RES, V22, P93, DOI 10.1359/JBMR.060817
   Belfrage O, 2011, ACTA ORTHOP, V82, P228, DOI 10.3109/17453674.2011.566138
   Bellido T, 2011, BONE, V49, P50, DOI 10.1016/j.bone.2010.08.008
   Bembi B, 1997, J PEDIATR US, V131, P622, DOI 10.1016/S0022 3476(97)70074 X
   Cenni E, 2008, BIOMATERIALS, V29, P1400, DOI 10.1016/j.biomaterials.2007.12.022
   Dai RC, 2008, J BONE MINER METAB, V26, P342, DOI 10.1007/s00774 007 0830 4
   EGGELMEIJER F, 1994, J RHEUMATOL, V21, P2016
   Freiberg S, 2004, INT J PHARMACEUT, V282, P1, DOI 10.1016/j.ijpharm.2004.04.013
   Gopferich A, 1996, BIOMATERIALS, V17, P103, DOI 10.1016/0142 9612(96)85755 3
   Gourion Arsiquaud S, 2010, BONE, V46, P666, DOI 10.1016/j.bone.2009.11.011
   Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128
   Greiner S, 2007, J BIOMED MATER RES A, V80A, P769, DOI 10.1002/jbm.a.30950
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Jeong HM, 2013, BIOCHEM BIOPH RES CO, V432, P152, DOI 10.1016/j.bbrc.2013.01.068
   Kim HK, 2009, CLIN ORTHOP RELAT R, V467, P3121, DOI 10.1007/s11999 008 0409 y
   Koch FP, 2011, J CRANIO MAXILL SURG, V39, P562, DOI 10.1016/j.jcms.2010.10.007
   KOST J, 1992, TRENDS BIOTECHNOL, V10, P127, DOI 10.1016/0167 7799(92)90194 Z
   Lala R, 2000, ACTA PAEDIATR, V89, P188, DOI 10.1080/080352500750028816
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Lu JG, 2011, J CANCER RES CLIN, V137, P1613, DOI 10.1007/s00432 011 1024 y
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Paccou J, 2010, JOINT BONE SPINE, V77, pS120, DOI 10.1016/S1297 319X(10)70007 5
   Pan BQ, 2004, BONE, V34, P112, DOI 10.1016/j.bone.2003.08.013
   Peter B, 2005, BONE, V36, P52, DOI 10.1016/j.bone.2004.10.004
   Plotkin LI, 2011, BONE, V49, P122, DOI 10.1016/j.bone.2010.08.011
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2008, J BONE MINER RES, V23, P1712, DOI [10.1359/jbmr.080617, 10.1359/JBMR.080617]
   Ponader S, 2008, COLLOID SURFACE B, V64, P275, DOI 10.1016/j.colsurfb.2008.02.002
   Pozzi S, 2009, CLIN CANCER RES, V15, P5829, DOI 10.1158/1078 0432.CCR 09 0426
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Roshan Ghias A, 2011, CLIN BIOMECH, V26, P1039, DOI 10.1016/j.clinbiomech.2011.06.004
   Ruggiero SL, 2009, AUST ENDOD J, V35, P119, DOI 10.1111/j.1747 4477.2009.00213.x
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Schindeler A, 2011, J BONE JOINT SURG BR, V93B, P1134, DOI 10.1302/0301 620X.93B8.25940
   Sharma D, 2013, VASC CELL, V5, DOI 10.1186/2045 824X 5 1
   Sinha VR, 2003, J CONTROL RELEASE, V90, P261, DOI 10.1016/S0168 3659(03)00194 9
   TENENBAUM HC, 1992, BONE, V13, P249, DOI 10.1016/8756 3282(92)90205 B
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Wang CZ, 2010, BIOMATERIALS, V31, P8674, DOI 10.1016/j.biomaterials.2010.07.096
   Xiong Y, 2009, J INT MED RES, V37, P407, DOI 10.1177/147323000903700216
   Xu XL, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 303
NR 44
TC 17
Z9 18
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAR 11
PY 2014
VL 9
IS 3
AR e91317
DI 10.1371/journal.pone.0091317
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AC9GM
UT WOS:000332842400073
PM 24618585
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Xu, C
   Dinh, VV
   Kruse, K
   Jeong, HW
   Watson, EC
   Adams, S
   Berkenfeld, F
   Stehling, M
   Rasouli, SJ
   Fan, R
   Chen, R
   Bedzhov, I
   Chen, Q
   Kato, K
   Pitulescu, ME
   Adams, RH
AF Xu, Cong
   Van Vuong Dinh
   Kruse, Kai
   Jeong, Hyun Woo
   Watson, Emma C.
   Adams, Susanne
   Berkenfeld, Frank
   Stehling, Martin
   Rasouli, Seyed Javad
   Fan, Rui
   Chen, Rui
   Bedzhov, Ivan
   Chen, Qi
   Kato, Katsuhiro
   Pitulescu, Mara E.
   Adams, Ralf H.
TI Induction of osteogenesis by bone targeted Notch activation
SO ELIFE
LA English
DT Article
DE bone; osteogenesis; Notch signaling; Mouse
ID DRUG DELIVERY SYSTEM; POSTMENOPAUSAL WOMEN; MESENCHYMAL PROGENITORS;
   CELLS; JAGGED1; PREVENTION; PROTEIN; DLL4; DIFFERENTIATION; OLIGOPEPTIDE
AB Declining bone mass is associated with aging and osteoporosis, a disease characterized by progressive weakening of the skeleton and increased fracture incidence. Growth and lifelong homeostasis of bone rely on interactions between different cell types including vascular cells and mesenchymal stromal cells (MSCs). As these interactions involve Notch signaling, we have explored whether treatment with secreted Notch ligand proteins can enhance osteogenesis in adult mice. We show that a bone targeting, high affinity version of the ligand Delta like 4, termed Dll4((E12)), induces bone formation in male mice without causing adverse effects in other organs, which are known to rely on intact Notch signaling. Due to lower bone surface and thereby reduced retention of Dll4((E12)), the same approach failed to promote osteogenesis in female and ovariectomized mice but strongly enhanced trabecular bone formation in combination with parathyroid hormone. Single cell analysis of stromal cells indicates that Dll4((E12)) primarily acts on MSCs and has comparably minor effects on osteoblasts, endothelial cells, or chondrocytes. We propose that activation of Notch signaling by bone targeted fusion proteins might be therapeutically useful and can avoid detrimental effects in Notch dependent processes in other organs.
C1 [Xu, Cong; Van Vuong Dinh; Kruse, Kai; Jeong, Hyun Woo; Watson, Emma C.; Adams, Susanne; Berkenfeld, Frank; Rasouli, Seyed Javad; Chen, Qi; Kato, Katsuhiro; Pitulescu, Mara E.; Adams, Ralf H.] Max Planck Inst Mol Biomed, Dept Tissue Morphogenesis, Munster, Germany.
   [Xu, Cong; Van Vuong Dinh; Kruse, Kai; Jeong, Hyun Woo; Watson, Emma C.; Adams, Susanne; Berkenfeld, Frank; Rasouli, Seyed Javad; Chen, Qi; Kato, Katsuhiro; Pitulescu, Mara E.; Adams, Ralf H.] Univ Munster, Fac Med, Munster, Germany.
   [Stehling, Martin] Max Planck Inst Mol Biomed, Flow Cytometry Unit, Munster, Germany.
   [Fan, Rui; Chen, Rui; Bedzhov, Ivan] Max Planck Inst Mol Biomed, Embryon Self Org Res Grp, Munster, Germany.
C3 Max Planck Society; University of Munster; Max Planck Society; Max
   Planck Society
RP Pitulescu, ME; Adams, RH (通讯作者)，Max Planck Inst Mol Biomed, Dept Tissue Morphogenesis, Munster, Germany.; Pitulescu, ME; Adams, RH (通讯作者)，Univ Munster, Fac Med, Munster, Germany.
EM mara.pitulescu@mpi muenster.mpg.de; ralf.adams@mpi muenster.mpg.de
RI ; Kato, Katsuhiro/AAV 8356 2020; Bedzhov, Ivan/Q 5214 2017
OI Bedzhov, Ivan/0000 0002 2122 6485; Jeong, Hyun Woo/0000 0002 6976 6739;
   Pitulescu, Mara E/0000 0001 5322 8146; Kruse, Kai/0000 0002 7951 7357;
   Watson, Emma/0000 0002 0986 5524; Chen, Qi/0000 0001 8485 6540
FU Max Planck Society; European Research Council [AdG 339409, AdG 786672];
   Leducq Foundation
FX Max Planck Society Ralf H Adams European Research Council AdG 339409
   AngioBone Ralf H Adams European Research Council AdG 786672 PROVEC Ralf
   H Adams Leducq Foundation Ralf H Adams
CR [Anonymous], 2001, South Med J, V94, P569
   Baryawno N, 2019, CELL, V177, P1915, DOI 10.1016/j.cell.2019.04.040
   Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025
   Bianco P, 2000, J CLIN INVEST, V105, P1663, DOI 10.1172/JCI10413
   Canalis E, 2013, ENDOCRINOLOGY, V154, P623, DOI 10.1210/en.2012 1732
   Chen LA, 2010, J BONE MINER RES, V25, P2447, DOI 10.1002/jbmr.133
   Chen S, 2013, J BONE MINER RES, V28, P649, DOI 10.1002/jbmr.1770
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Chesnut CH III, 2000, AM J MED, V109, P267, DOI 10.1016/S0002 9343(00)00490 3
   Clarke BL, 2014, MATURITAS, V78, P199, DOI 10.1016/j.maturitas.2014.04.016
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Dishowitz MI, 2014, J BIOMED MATER RES A, V102, P1558, DOI 10.1002/jbm.a.34825
   Eastell R, 2000, OSTEOPOROSIS INT, V11, P331, DOI 10.1007/s001980070122
   Engin FZ, 2008, NAT MED, V14, P299, DOI 10.1038/nm1712
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Fung E, 2007, CIRCULATION, V115, P2948, DOI 10.1161/CIRCULATIONAHA.106.675462
   Gil L, 1999, BIOORGAN MED CHEM, V7, P901, DOI 10.1016/S0968 0896(99)00045 0
   Golson ML, 2009, MECH DEVELOP, V126, P687, DOI 10.1016/j.mod.2009.05.005
   Hicks C, 2002, J NEUROSCI RES, V68, P655, DOI 10.1002/jnr.10263
   Hill CR, 2014, BONE, V62, P10, DOI 10.1016/j.bone.2014.01.019
   Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716
   Jiménez Alcázar M, 2017, SCIENCE, V358, P1202, DOI 10.1126/science.aam8897
   Kasugai S, 2000, J BONE MINER RES, V15, P936, DOI 10.1359/jbmr.2000.15.5.936
   Kato K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04913 2
   Katsumi H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135966
   Knowles HJ, 2010, FASEB J, V24, P4648, DOI 10.1096/fj.10 162230
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Kwan KM, 1997, J CELL BIOL, V136, P459, DOI 10.1083/jcb.136.2.459
   Langen UH, 2017, NAT CELL BIOL, V19, P189, DOI 10.1038/ncb3476
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Limbourg FP, 2005, CIRCULATION, V111, P1826, DOI 10.1161/01.CIR.0000160870.93058.DD
   Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947
   Liu P, 2016, P NATL ACAD SCI USA, V113, pE2152, DOI 10.1073/pnas.1603399113
   Luca VC, 2017, SCIENCE, V355, P1320, DOI 10.1126/science.aaf9739
   Luca VC, 2015, SCIENCE, V347, P847, DOI 10.1126/science.1261093
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Miller SC, 2008, PHARM RES DORDR, V25, P2889, DOI 10.1007/s11095 008 9706 0
   Mizoguchi T, 2014, DEV CELL, V29, P340, DOI 10.1016/j.devcel.2014.03.013
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Noguera Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355
   Nombela Arrieta C, 2011, NAT REV MOL CELL BIO, V12, P126, DOI 10.1038/nrm3049
   Novince CM, 2012, J BONE MINER RES, V27, P11, DOI 10.1002/jbmr.508
   Ono N, 2014, NAT CELL BIOL, V16, P1157, DOI 10.1038/ncb3067
   Ortinau LC, 2019, CELL STEM CELL, V25, P784, DOI 10.1016/j.stem.2019.11.003
   Osathanon T, 2013, J BIOMED MATER RES A, V101, P358, DOI 10.1002/jbm.a.34332
   Pinho S, 2019, NAT REV MOL CELL BIO, V20, P303, DOI 10.1038/s41580 019 0103 9
   Polacheck WJ, 2017, NATURE, V552, P258, DOI 10.1038/nature24998
   Porter A, 2017, SCI REP UK, V7, DOI 10.1038/srep42505
   Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074 7613(00)80054 0
   Ramasamy SK, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13601
   Ramasamy SK, 2014, NATURE, V507, P376, DOI 10.1038/nature13146
   Ross RD, 2014, J BONE MINER RES, V29, P1597, DOI 10.1002/jbmr.2188
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Sekido T, 2001, J DRUG TARGET, V9, P111, DOI 10.3109/10611860108997922
   Sivaraj KK, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109352
   Stapleton M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071345
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Wilson SS, 2015, J ORTHOP RES, V33, P1364, DOI 10.1002/jor.22898
   Wu Y, 2010, NATURE, V464, P1052, DOI 10.1038/nature08878
   Yagami K, 1999, J CELL BIOL, V147, P1097, DOI 10.1083/jcb.147.5.1097
   Yan MH, 2010, NATURE, V463, pE6, DOI 10.1038/nature08751
   Yokogawa K, 2001, ENDOCRINOLOGY, V142, P1228, DOI 10.1210/en.142.3.1228
   Youngstrom DW, 2016, BONE, V91, P64, DOI 10.1016/j.bone.2016.07.006
   Yu J, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115474
   Zanotti S, 2016, ENDOCR REV, V37, P223, DOI 10.1210/er.2016 1002
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
NR 71
TC 29
Z9 33
U1 2
U2 22
PU eLIFE SCIENCES PUBL LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050 084X
J9 ELIFE
JI eLife
PD FEB 4
PY 2022
VL 11
AR e60183
DI 10.7554/eLife.60183; 10.7554/eLife.60183.sa0; 10.7554/eLife.60183.sa1;
   10.7554/eLife.60183.sa2
PG 34
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA ZN7WJ
UT WOS:000765239400001
PM 35119364
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Chai, LJ
   Zhou, K
   Wang, SX
   Zhang, H
   Fan, N
   Li, J
   Tan, XF
   Hu, LM
   Fan, X
AF Chai, Lijuan
   Zhou, Kun
   Wang, Shaoxia
   Zhang, Han
   Fan, Na
   Li, Jie
   Tan, Xiaofeng
   Hu, Limin
   Fan, Xiang
TI Psoralen and Bakuchiol Ameliorate M CSF Plus RANKL Induced Osteoclast
   Differentiation and Bone Resorption Via Inhibition of AKT and AP 1
   Pathways in Vitro
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Psoralen; Bakuchiol; Osteoclast; Differentiation; Bone resorption
ID SIGNALING PATHWAYS; OSTEOPOROSIS; EXPRESSION; EXTRACT; MEN; OSTEOBLASTS;
   INDUCTION; FRACTURE; CELLS; OLDER
AB Background/Aims: Psoralen and bakuchiol are the main active compounds found in the traditional Chinese medicine Psoralea corylifolia L., and have been used to treat osteoporosis. This study aims to investigate the anti osteoporosis effects of these two compounds using osteoclasts precursor differentiation and bone absorption assays in vitro. Methods: Primary mouse osteoclasts precursor cells were induced by M CSF (macrophage colony stimulating factor) plus RANKL (receptor activator of nuclear factor kappa B ligand) in vitro. TRACP (tartrate resistant acid phosphatase) enzyme activity and toluidine blue staining were used to observe the effects of psoralen and bakuchiol on osteoclast differentiation and bone resorption, respectively. Gelatin zymography was used to assess MMP (matrix metalloproteinase) activity, and ELISA was performed to measure cathepsin K activity. Western blotting analysis for expression of phosphorylated AKT, ERK, NF kB, and c jun; and immunofluorescence analysis for c jun and p65 nuclear translocation in induced osteoclasts were then used to determine the mechanism of anti bone resorption of psoralen and bakuchiol. Results: Mature osteoclasts were induced by M CSF plus RANKL from primary bone marrow macrophages in vitro. Both psoralen and bakuchiol significantly inhibited TRACP enzyme activity and slightly decreased the number of TRACP(+) multinuclear osteoclasts induced by M CSF plus RANKL. Bakuchiol significantly decreased bone lacunae area and attenuated MMP 2 activity induced by M CSF plus RANKL in osteoclasts. Both psoralen and bakuchiol significantly decreased the expression and nuclear translocation of phosphorylated c jun stimulated by M CSF plus RANKL, but no significant effect on p65 translocation was observed in osteoclasts. Additionally, bakuchiol significantly attenuated the increased of M CSF plus RANKL induced phosphorylation of AKT in osteoclasts. Conclusions: Psoralen and bakuchiol ameliorated M CSF plus RANKL induced osteoclast differentiation and bone resorption via inhibition of AKT and AP 1 pathways activation in vitro. (C) 2018 The Author(s) Published by S. Karger AG, Basel
C1 [Chai, Lijuan; Wang, Shaoxia; Zhang, Han; Fan, Na; Tan, Xiaofeng; Hu, Limin; Fan, Xiang] Tianjin Univ Tradit Chinese Med, Minist Educ, Key Lab Pharmacol Tradit Chinese Med Formulae, Tianjin, Peoples R China.
   [Chai, Lijuan; Zhou, Kun; Zhang, Han; Fan, Na; Li, Jie; Tan, Xiaofeng; Hu, Limin; Fan, Xiang] Tianjin Univ Tradit Chinese Med, Tianjin Key Lab Tradit Chinese Med Pharmacol, Tianjin, Peoples R China.
   [Hu, Limin] Tianjin Univ Tradit Chinese Med, Changjiang Scholars & Innovat Res Team Univ, Tianjin, Peoples R China.
C3 Tianjin University of Traditional Chinese Medicine; Tianjin University
   of Traditional Chinese Medicine; Tianjin University of Traditional
   Chinese Medicine
RP Hu, LM; Fan, X (通讯作者)，Tianjin Univ Tradit Chinese Med, Inst Tradit Chinese Med, 312 Anshan Xi Rd, Tianjin 300193, Peoples R China.
EM huliminth@126.com; fanxiang_78@hotmail.com
RI zhou, kun/KRP 1631 2024; tan, xiao/GZL 0264 2022
OI Fan, Xiang/0000 0001 7697 0378
FU National Natural Science Foundation of China [81102860, 81202991,
   81001660]; Program for ChangJiang Scholars and Innovative Research Team
   in University IRT [14R41]
FX The authors declare to have no conflict of interests. This work was
   supported by the National Natural Science Foundation of China (No.
   81102860, 81202991, 81001660). And the Program for ChangJiang Scholars
   and Innovative Research Team in University IRT 14R41.
CR Boileau C, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2444
   [蔡玉霞 Cai Yu xia], 2009, [中国组织工程研究与临床康复, Journal of Clinical Rehabilitative Tissue Engineering Research], V13, P268
   Cauley JA, 2015, STEROIDS, V99, P11, DOI 10.1016/j.steroids.2014.12.010
   Constant SL, 2000, J IMMUNOL, V165, P2671, DOI 10.4049/jimmunol.165.5.2671
   Don MJ, 2012, PHYTOMEDICINE, V19, P551, DOI 10.1016/j.phymed.2012.01.006
   Franco GCN, 2011, EXP CELL RES, V317, P1454, DOI 10.1016/j.yexcr.2011.03.014
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   Kang Ju Hee, 2016, J Bone Metab, V23, P207, DOI 10.11005/jbm.2016.23.4.207
   Karst M, 2004, J CELL PHYSIOL, V200, P99, DOI 10.1002/jcp.20036
   Kim MH, 2011, AMINO ACIDS, V40, P1447, DOI 10.1007/s00726 010 0755 4
   Kong LB, 2017, CELL PHYSIOL BIOCHEM, V43, P1425, DOI 10.1159/000481874
   LeBlanc ES, 2009, J CLIN ENDOCR METAB, V94, P3337, DOI 10.1210/jc.2009 0206
   Lee JW, 2012, J NAT MED TOKYO, V66, P8, DOI 10.1007/s11418 011 0537 7
   Li Jin Ping, 2013, Zhongguo Zhong Yao Za Zhi, V38, P1816
   Li WD, 2014, PHYTOMEDICINE, V21, P400, DOI 10.1016/j.phymed.2013.09.015
   Lim SY, 2013, AM J MENS HEALTH, V7, P350, DOI 10.1177/1557988313478826
   Lim SH, 2009, BRIT J NUTR, V101, P1031, DOI 10.1017/S0007114508066750
   Ma Y, 2016, EVID BASED COMPL ALT, V2016, DOI 10.1155/2016/5815946
   Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110
   Mukherjee A, 2012, MOL CELL BIOL, V32, P490, DOI 10.1128/MCB.06361 11
   Park CK, 2008, BIOCHEM PHARMACOL, V75, P2175, DOI 10.1016/j.bcp.2008.03.007
   Roy DK, 2003, OSTEOPOROSIS INT, V14, P19, DOI 10.1007/s00198 002 1317 8
   Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197
   Shuid AN, 2011, J ETHNOPHARMACOL, V133, P538, DOI 10.1016/j.jep.2010.10.033
   Soysa NS, 2009, J BONE MINER METAB, V27, P131, DOI 10.1007/s00774 008 0026 6
   Tang CH, 2009, OSTEOPOROSIS INT, V20, P93, DOI 10.1007/s00198 008 0630 2
   Tang DZ, 2011, BIOCHEM BIOPH RES CO, V405, P256, DOI 10.1016/j.bbrc.2011.01.021
   Thiolloy S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029862
   Tsai MH, 2007, AM J CHINESE MED, V35, P669, DOI 10.1142/S0192415X07005168
   VANTHOF RJ, 1995, INT J EXP PATHOL, V76, P205
   Wei ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059171
   Wong RWK, 2010, PHYTOTHER RES, V24, P1578, DOI 10.1002/ptr.3184
   Wu Q, 2017, CELL PHYSIOL BIOCHEM, V41, P1360, DOI 10.1159/000465455
   Yang Z, 2012, MENOPAUSE, V19, P1156, DOI 10.1097/gme.0b013e3182507e18
   Yonezawa T, 2011, EUR J PHARMACOL, V650, P511, DOI 10.1016/j.ejphar.2010.10.048
   Yu MX, 2014, BIOCHEM BIOPH RES CO, V447, P364, DOI 10.1016/j.bbrc.2014.04.009
NR 36
TC 43
Z9 56
U1 0
U2 33
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1015 8987
EI 1421 9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2018
VL 48
IS 5
BP 2123
EP 2133
DI 10.1159/000492554
PG 11
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA GS5WQ
UT WOS:000443744900025
PM 30110702
OA gold
DA 2025 08 17
ER

PT J
AU Buranaphatthana, W
   Yavirach, A
   Leaf, EM
   Scatena, M
   Zhang, H
   An, JY
   Giachelli, CM
AF Buranaphatthana, Worakanya
   Yavirach, Apichai
   Leaf, Elizabeth M.
   Scatena, Marta
   Zhang, Hai
   An, Jonathan Y.
   Giachelli, Cecilia M.
TI Engineered osteoclasts resorb necrotic alveolar bone in anti RANKL
   antibody treated mice
SO BONE
LA English
DT Article
DE MRONJ; Osteonecrosis; Denosumab; Tooth extraction; Cell therapy
ID BISPHOSPHONATE RELATED OSTEONECROSIS; ZOLEDRONIC ACID; JAW; CELLS;
   RESORPTION; AGENTS; MECHANISMS; EXTRACTION; DENOSUMAB; APOPTOSIS
AB Medication related osteonecrosis of the jaw (MRONJ) is a serious side effect of antiresorptive medications such as denosumab (humanized anti RANKL antibody), yet its pathophysiology remains elusive. It has been posited that inhibition of osteoclastic bone resorption leads to the pathological sequelae of dead bone accumulation, impaired new bone formation, and poor wound healing in MRONJ, but this hypothesis has not been definitively tested. We previously engineered myeloid precursors with a conditional receptor activator of nuclear factor kappa B intracellular domain (iRANK cells), which differentiate into osteoclasts in response to a chemical inducer of dimerization (CID) independently of RANKL. In this study, we showed that CID treated iRANK cells differentiated into osteoclasts and robustly resorbed mineralized surfaces even in the presence of anti RANKL antibody in vitro. We then developed a tooth extraction triggered MRONJ model in nude mice using anti RANKL antibody to deplete osteoclasts. This model was used to determine whether reconstitution of engineered osteoclasts within sockets could prevent specific pathological features of MRONJ. Locally delivered iRANK cells successfully differentiated into multinucleated osteoclasts in response to CID treatment in vivo as measured by green fluorescent protein (GFP), tartrate resistant acid phosphatase (TRAP), carbonic anhydrase II, matrix metallopeptidase 9 (MMP 9), and cathepsin K staining. Sockets treated with iRANK cells + CID had significantly more osteoclasts and less necrotic bone than those receiving iRANK cells alone. These data support the hypothesis that osteoclast deficiency leads to accumulation of necrotic bone in MRONJ.
C1 [Buranaphatthana, Worakanya; Yavirach, Apichai; An, Jonathan Y.; Giachelli, Cecilia M.] Univ Washington, Sch Dent, Dept Oral Hlth Sci, Seattle, WA 98195 USA.
   [Buranaphatthana, Worakanya] Chiang Mai Univ, Fac Dent, Dept Oral Biol & Oral Diagnost Sci, Chiang Mai, Thailand.
   [Leaf, Elizabeth M.; Scatena, Marta; Giachelli, Cecilia M.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
   [Zhang, Hai] Univ Washington, Sch Dent, Dept Restorat Dent, Seattle, WA 98195 USA.
C3 University of Washington; University of Washington Seattle; Chiang Mai
   University; University of Washington; University of Washington Seattle;
   University of Washington; University of Washington Seattle
RP Giachelli, CM (通讯作者)，Univ Washington, Box 355061,Foege Hall,3720 15th Ave NE, Seattle, WA 98195 USA.
EM ceci@uw.edu
OI Yavirach, Apichai/0000 0003 3827 3963; Soberg,
   Elizabeth/0000 0002 5354 6010; Giachelli, Cecilia/0000 0002 6387 5993
FU SunStar Preventive Dentistry Award; Warren G. Magnuson Scholarship of
   University of Washington; Ananda Mahidol Foundation Scholarship of
   Thailand; United States Department of Defense Peer Reviewed Orthopaedic
   Research Program Award [OR120074]; National Institutes of Health [R01
   HL114611, HL081785, HL62329]
FX This work was supported by the SunStar Preventive Dentistry Award; the
   Warren G. Magnuson Scholarship of University of Washington; and the
   Ananda Mahidol Foundation Scholarship of Thailand to WB. United States
   Department of Defense Peer Reviewed Orthopaedic Research Program Award
   [OR120074]; and the National Institutes of Health [R01 HL114611,
   HL081785, HL62329] to CMG.
CR Allegra A, 2019, TOHOKU J EXP MED, V248, P27, DOI 10.1620/tjem.248.27
   Allen MR, 2014, INT J ORAL MAX IMPL, V29, pE45, DOI 10.11607/jomi.te41
   Cardoso L, 2009, J BONE MINER RES, V24, P597, DOI 10.1359/JBMR.081210
   Chen FM, 2012, BIOMATERIALS, V33, P6320, DOI 10.1016/j.biomaterials.2012.05.048
   Chrysanthakopoulos NA, 2011, INT DENT J, V61, P19, DOI 10.1111/j.1875 595X.2011.00004.x
   Colucci S, 1998, CALCIFIED TISSUE INT, V63, P230, DOI 10.1007/s002239900519
   Elsayed R, 2020, FASEB J, V34, P2595, DOI 10.1096/fj.201901819RR
   Fung PPL, 2017, ORAL DIS, V23, P477, DOI 10.1111/odi.12632
   GLICKMAN I, 1947, AM J ORTHOD ORAL SUR, V33, P263
   Gorski JP, 1998, CRIT REV ORAL BIOL M, V9, P201, DOI 10.1177/10454411980090020401
   Green JR, 2002, AM J CLIN ONCOL CANC, V25, pS3, DOI 10.1097/00000421 200212001 00002
   Harre U, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7651
   Hayano H, 2020, BONE, V135, DOI 10.1016/j.bone.2020.115308
   Heithersay GS, 2013, DENT TRAUMATOL, V29, P253, DOI 10.1111/edt.12029
   Heymann D, 2004, TRENDS MOL MED, V10, P337, DOI 10.1016/j.molmed.2004.05.007
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Katsarelis H, 2015, J DENT RES, V94, P534, DOI 10.1177/0022034515572021
   Khan A, 2016, OSTEOPOROSIS INT, V27, P853, DOI 10.1007/s00198 015 3335 3
   Kikuiri T, 2010, J BONE MINER RES, V25, P1668, DOI 10.1002/jbmr.37
   Kim Kyoung Min, 2015, J Bone Metab, V22, P151, DOI 10.11005/jbm.2015.22.4.151
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Kün Darbois JD, 2018, CLIN ORAL INVEST, V22, P2997, DOI 10.1007/s00784 018 2385 2
   Lewiecki EM, 2008, BIOL TARGETS THER, V2, P645
   Liu Y, 2019, OSTEOPOROSIS INT, V30, P1873, DOI 10.1007/s00198 019 05071 x
   Miller Paul D, 2009, Curr Osteoporos Rep, V7, P18
   Pan BQ, 2004, J BONE MINER RES, V19, P147, DOI 10.1359/jbmr.2004.19.1.147
   Park S, 2015, J BIOL CHEM, V290, P17349, DOI 10.1074/jbc.M115.652305
   Pelleitier M, 1975, Methods Achiev Exp Pathol, V7, P149
   Rementer CW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084465
   Rizzoli R, 2010, NAT REV DRUG DISCOV, V9, P591, DOI 10.1038/nrd3244
   Romano R, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/467101
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Russell RGG, 1999, J BONE MINER RES, V14, P53, DOI 10.1002/jbmr.5650140212
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Sehic E, 2021, SCAND J IMMUNOL, V93, DOI 10.1111/sji.13009
   Soares MQS, 2018, J ORAL MAXIL SURG, V76, P1893, DOI 10.1016/j.joms.2018.03.007
   Soundia A, 2018, J DENT RES, V97, P312, DOI 10.1177/0022034517732770
   Szadvari I, 2016, PHYSIOL RES, V65, pS441, DOI 10.33549/physiolres.933526
   Tamaki S, 2020, BONE, V141, DOI 10.1016/j.bone.2020.115560
   Trombelli L, 2008, J CLIN PERIODONTOL, V35, P630, DOI 10.1111/j.1600 051X.2008.01246.x
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
   Williams DW, 2014, AM J PATHOL, V184, P3084, DOI 10.1016/j.ajpath.2014.07.010
   Zhang QZ, 2013, CLIN CANCER RES, V19, P3176, DOI 10.1158/1078 0432.CCR 13 0042
   Zhu WW, 2019, FASEB J, V33, P5208, DOI 10.1096/fj.201801791RR
NR 44
TC 9
Z9 10
U1 0
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD DEC
PY 2021
VL 153
AR 116144
DI 10.1016/j.bone.2021.116144
EA AUG 2021
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA US3QH
UT WOS:000697347500031
PM 34375732
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Yan, BZ
   Luo, D
   Li, JC
   Liang, XZ
   Xu, B
   Li, G
AF Yan, Bo Zhao
   Luo, Di
   Li, Jia Cheng
   Liang, Xue Zhen
   Xu, Bo
   Li, Gang
TI Molecular mechanism of Wutou Decoction in the treatment of
   osteoarthritis: a bioinformatics and molecular docking study
SO ANNALS OF PALLIATIVE MEDICINE
LA English
DT Article
DE Osteoarthritis (OA); Wutou Decoction (WTD); bioinformatics; molecular
   docking
ID KNOWLEDGEBASE; CARTILAGE
AB Background: Osteoarthritis (OA) is a chronic joint disease characterized by cartilage destruction and periarticular osteophyte formation. One therapeutic option for this condition, the Wutou Decoction (WTD) Chinese medicine formula, is satisfactory in its efficacy. Here, we used bioinformatic and molecular docking techniques to investigate the mechanism of action of WTD in the treatment of OA.
   Methods: The active compounds (and their target proteins) of 5 Chinese herbs in WTD were obtained by searching the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform. The action targets of WTD for OA were obtained by searching the Therapeutic Target Database and by mining the microarray data in the Gene Expression Omnibus. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses were performed to identify key targets for OA treatment with the help of Database for Annotation, Visualization, and Integrated Discovery. Based on the Cytoscape software version 3.6.1, the visual networks of the "TCM drugs Active Compounds Targets Diseases" and protein protein interaction of the key targets of WTD for the treatment of OA were constructed. The core active compounds and the key targets obtained were molecularly docked and validated.
   Results: Analyses revealed 140 active compounds in WTD, 123 of which had a total of 163 corresponding targets. In addition, 331 differentially expressed genes and 227 OA related targets were obtained. The interaction networks among 32 key targets were identified. The biological processes of WTD in treating OA mainly involved regulation of inflammatory factors, transcription of genetic materials, cell cycle, angiogenesis, and endocrine regulation. The signaling pathways involved mainly included TNF signaling pathway, rheumatoid arthritis signaling pathway, cancer related signals, vascular endothelial growth factor signaling pathway, and osteoclast differentiation signaling pathways. Molecular docking showed that 7 core compounds including quercetin and kaempferol had strong affinities with key target proteins for the WTD treatment of OA.
   Conclusions: WTD with multi component can treats OA through multi pathway. Its active compounds, including quercetin and kaempferol, can exert their therapeutic effects on OA by acting on TNF, PTGS2, MMP2, IL 6, IL 1 beta, and other key targets to regulate inflammation, immunity, autophagy, and endocrine related signaling pathways.
C1 [Yan, Bo Zhao; Luo, Di; Li, Jia Cheng; Liang, Xue Zhen; Xu, Bo; Li, Gang] Shandong Univ Tradit Chinese Med, Clin Med Sch 1, Jinan, Peoples R China.
   [Luo, Di; Liang, Xue Zhen; Xu, Bo; Li, Gang] Shandong Univ Tradit Chinese Med, Dept Orthoped, Affiliated Hosp, Jinan, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Shandong University
   of Traditional Chinese Medicine
RP Li, G (通讯作者)，Shandong Univ Tradit Chinese Med, Affiliated Hosp, 16369 Jingshi Rd, Jinan, Peoples R China.
EM doctorlee808@163.com
RI LIANG, Xuezhen/HGA 4207 2022
FU National Natural Science Foundation of China [81774333, 82074453]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81774333 and 82074453) .
CR Aa LX, 2020, ACTA PHARMACOL SIN, V41, P73, DOI 10.1038/s41401 019 0279 8
   Ananth DA, 2016, BIOMED PHARMACOTHER, V80, P244, DOI 10.1016/j.biopha.2016.03.019
   Becker KG, 2004, NAT GENET, V36, P431, DOI 10.1038/ng0504 431
   Bonfante HD, 2017, INT J RHEUM DIS, V20, P1958, DOI 10.1111/1756 185X.12589
   Chen X, 2002, NUCLEIC ACIDS RES, V30, P412, DOI 10.1093/nar/30.1.412
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 9 r60
   [段爱霞 DUAN Ai xia], 2009, [分析科学学报, Journal of Analytical Science], V25, P473
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Fraysse F, 2016, J BIOMECH, V49, P3538, DOI 10.1016/j.jbiomech.2016.08.005
   Guo Q, 2021, EXP MOL PATHOL, V118, DOI 10.1016/j.yexmp.2020.104576
   Haleagrahara N, 2018, INFLAMMOPHARMACOLOGY, V26, P1219, DOI 10.1007/s10787 018 0464 2
   Hamilton JL, 2016, J BONE MINER RES, V31, P911, DOI 10.1002/jbmr.2828
   Hamosh A, 2005, NUCLEIC ACIDS RES, V33, pD514
   Hewett M, 2002, NUCLEIC ACIDS RES, V30, P163, DOI 10.1093/nar/30.1.163
   Hosnijeh FS, 2019, OSTEOARTHR CARTILAGE, V27, P412, DOI 10.1016/j.joca.2018.12.002
   Hu GL, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.522
   Huang XJ, 2018, MOL MED REP, V18, P2697, DOI 10.3892/mmr.2018.9280
   Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140 6736(19)30417 9
   Krasselt M, 2019, EXPERT OPIN PHARMACO, V20, P1689, DOI 10.1080/14656566.2019.1645123
   Le H., 2014, Mod. Diagn. Treat., V4, P763
   Lee YM, 2019, PHARM BIOL, V57, P74, DOI 10.1080/13880209.2018.1557700
   Li JS, 2015, SCI REP UK, V5, DOI 10.1038/srep15290
   Li Y, 2017, ONCOTARGET, V8, P90781, DOI 10.18632/oncotarget.21796
   Liu FE, 2020, INT IMMUNOPHARMACOL, V78, DOI 10.1016/j.intimp.2019.105954
   Liu H, 2013, J ETHNOPHARMACOL, V146, P773, DOI 10.1016/j.jep.2013.02.004
   Liu S.W., 2020, CHINESE J LUNG DIS E, V13, P104, DOI 10.3877/cma.j.issn.1674 6902.2020.01.026
   Liu Y, 2017, YUNNAN J TRADITIONAL, V38, P83
   Maes C, 2017, SEMIN CELL DEV BIOL, V62, P16, DOI 10.1016/j.semcdb.2016.05.007
   Mansoori MN, 2020, INT IMMUNOPHARMACOL, V82, DOI 10.1016/j.intimp.2020.106299
   Mei YY, 2016, RHEUMATISM ARTHRITIS, V5, P47
   Nagao M, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 13417 w
   Piñero J, 2015, DATABASE OXFORD, DOI 10.1093/database/bav028
   Ren JD, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930894
   Robinson PN, 2008, AM J HUM GENET, V83, P610, DOI 10.1016/j.ajhg.2008.09.017
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shao X, 2016, RHEUMATISM ARTHRITIS, V5, P62
   Shchetynsky K, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1220 5
   Sousa LH, 2016, J PERIODONTOL, V87, P1206, DOI 10.1902/jop.2016.160075
   Szklarczyk D, 2011, NUCLEIC ACIDS RES, V39, pD561, DOI 10.1093/nar/gkq973
   Tang X, 2016, ARTHRITIS RHEUMATOL, V68, P648, DOI 10.1002/art.39465
   Tong P. J., 2018, Natl. Med. J. China, V98, P3653, DOI [10.3760/cma.j.issn.0376 2491.2018.45.005, DOI 10.3760/CMA.J.ISSN.0376 2491.2018.45.005]
   Wang SL, 2017, ONCOTARGET, V8, P14549, DOI 10.18632/oncotarget.14675
   Wang WD, 2018, CHINESE J TRADITIONA, V26, P17
   Wang XW, 2015, INT J CLIN EXP MED, V8, P16536
   Wei HZ, 2013, MODERN DIAGNOSIS TRE, V24, P326
   Weiheng C, 2020, J Trad Chin Orthop Traumatol, V32, P1
   Wiczkowski W, 2008, J NUTR, V138, P885, DOI 10.1093/jn/138.5.885
   Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958
   [解静 Xie Jing], 2019, [中草药, Chinese Traditional and Herbal Drugs], V50, P2257
   Xu X, 2012, INT J MOL SCI, V13, P6964, DOI 10.3390/ijms13066964
   [于雅楠 Yu Yanan], 2018, [中草药, Chinese Traditional and Herbal Drugs], V49, P1640
   [袁小亮 Yuan Xiaoliang], 2016, [时珍国医国药, Lishizhen Medicine and Materia Medica Research], V27, P283
   Zhang X, 2016, OSTEOARTHR CARTILAGE, V24, P1970, DOI 10.1016/j.joca.2016.06.005
   Zhang Y, 2011, CHINESE J TISSUE ENG, V15, P8031
   Zhang YanQiong Zhang YanQiong, 2015, Chinese Journal of Pharmacology and Toxicology, V29, P883
   Zhao YP, 2016, INFLAMMATION, V39, P385, DOI 10.1007/s10753 015 0260 8
   Zhou LL, 2012, IMMUNOLOGICAL J, V28, P332
   Zhou Y, 2015, CHINESE J TISSUE ENG, V19, P8327
   [周庄 Zhou Zhuang], 2012, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V18, P78
NR 60
TC 10
Z9 11
U1 1
U2 50
PU AME PUBL CO
PI SHATIN
PA FLAT RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2224 5820
EI 2224 5839
J9 ANN PALLIAT MED
JI Ann. Pallliat. Med.
PD JUL
PY 2021
VL 10
IS 7
BP 7706
EP 7720
DI 10.21037/apm 21 1691
EA JUL 2021
PG 15
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI EXPANDED)
SC Health Care Sciences & Services
GA UJ8IF
UT WOS:000675776800001
PM 34353059
OA gold
DA 2025 08 17
ER

PT J
AU China, SP
   Pal, S
   Chattopadhyay, S
   Porwal, K
   Mittal, M
   Sanyal, S
   Chattopadhyay, N
AF China, Shyamsundar Pal
   Pal, Subhashis
   Chattopadhyay, Sourav
   Porwal, Konica
   Mittal, Monika
   Sanyal, Sabyasachi
   Chattopadhyay, Naibedya
TI The wakefulness promoting drug Modafinil causes adenosine
   receptor mediated upregulation of receptor activator of nuclear factor
   κB ligand in osteoblasts: Negative impact of the drug on peak bone
   accrual in rats
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE Skeletal toxicity; RANKL; cAMP; Peak bone mass; Cognition enhancer
ID MASS ACCUMULATION; DIFFERENTIATION; EXPRESSION; RANKL; A(2A);
   OSTEOCLASTOGENESIS; OSTEOPOROSIS; STIMULATION; ADOLESCENTS
AB Modafinil is primarily prescribed for treatment of narcolepsy and other sleep associated disorders. However, its off prescription use as a cognition enhancer increased considerably, specially among youths. Given its increasing use in young adults the effect of modafinil on peak bone accrual is an important issue but has never been investigated. Modafinil treatment to young male rats caused trabecular and cortical bone loss in tibia and femur, and reduction in biomechanical strength. Co treatment of modafinil with alendronate (a drug that suppresses bone resorption) reversed the trabecular bone loss but failed to prevent cortical loss. Modafinil increased serum type 1 pro collagen N terminal protein (P1NP) and collagen type 1 cross linked C telopeptide (CTX 1) indicating a high turnover bone loss. The drug also increased receptor activator of nuclear factor kappa B ligand (RANKL) to osteoprotegerin (OPG) ratio in serum which likely resulted in increased osteoclast number per bone surface. Furthermore, conditioned medium from modafinil treated osteoblasts increased the expression of osteoclastogenic genes in bone marrow derived macrophages and the effect was blocked by RANKL neutralizing antibody. In primary osteoblasts, modafinil stimulated cAMP production and using pharmacological approach, we showed that modafinil signalled via adenosine receptors (A(2A)R and A(2B)R) which resulted in increased RANKL expression. ZM 241,385 (an A(2A)R inhibitor) and MRS 1754 (an A(2B) R inhibitor) suppressed modafinil induced upregulation of RANKL/OPG ratio in the calvarium of new born rat pups. Our data suggests that by activating osteoblast adenosine receptors modafinil increases the production of osteoclastogenic cytokine, RANKL that in turn results in high turnover bone loss in young rats.
C1 [China, Shyamsundar Pal; Pal, Subhashis; Porwal, Konica; Mittal, Monika; Chattopadhyay, Naibedya] CSIR, CDRI, Ctr Res Anabol Skeletal Target Hlth & Illness AST, Div Endocrinol, Lucknow 226031, Uttar Pradesh, India.
   [China, Shyamsundar Pal; Chattopadhyay, Sourav; Mittal, Monika; Sanyal, Sabyasachi; Chattopadhyay, Naibedya] AcSIR, CSIR Cent Drug Res Inst Campus, Lucknow 226031, Uttar Pradesh, India.
   [Chattopadhyay, Sourav; Sanyal, Sabyasachi] CSIR, CDRI, Div Biochem, Lucknow 226031, Uttar Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); Academy of Scientific &
   Innovative Research (AcSIR); Council of Scientific & Industrial Research
   (CSIR)   India; CSIR   Central Drug Research Institute (CDRI)
RP Chattopadhyay, N (通讯作者)，Cent Drug Res Inst, CSIR, Endocrinol Div, Lucknow 226031, Uttar Pradesh, India.
EM n_chattopadhyay@cdri.res.in
RI ; Pal, Subhashis/IXD 3635 2023; Chattopadhyay, Sourav/GQY 9508 2022; Pal
   China, Shyamsundar/AAB 8041 2019; Chattopadhyay, Naibedya/AAF 2058 2019;
   Sanyal, Sabyasachi/E 8034 2010
OI Pal, Subhashis/0000 0002 3916 5545; Chattopadhyay,
   Sourav/0000 0003 0055 5818; Pal China, Shyamsundar/0000 0003 0062 3593;
   Mittal, Monika/0000 0002 3328 7787; Chattopadhyay,
   Naibedya/0000 0003 2473 0246; Sanyal, Sabyasachi/0000 0002 8603 3828
FU Council of Scientific and Industrial Research, Government of India
   [BSC0201]
FX Council of Scientific and Industrial Research, Government of India
   (BSC0201).
CR Costa MA, 2011, J CELL PHYSIOL, V226, P1353, DOI 10.1002/jcp.22458
   Bagi CM, 2011, COMPARATIVE MED, V61, P76
   Ballon JS, 2006, J CLIN PSYCHIAT, V67, P554, DOI 10.4088/JCP.v67n0406
   Battleday RM, 2015, EUR NEUROPSYCHOPHARM, V25, P1865, DOI 10.1016/j.euroneuro.2015.07.028
   Ben Awadh AN, 2014, ENDOCRINOLOGY, V155, P2797, DOI 10.1210/en.2014 1046
   Biederman J, 2005, PEDIATRICS, V116, pE777, DOI 10.1542/peds.2005 0617
   Carroll SH, 2012, J BIOL CHEM, V287, P15718, DOI 10.1074/jbc.M112.344994
   Chen MJZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132348
   China SP, 2017, BONE, V105, P75, DOI 10.1016/j.bone.2017.08.005
   Fournier PE, 1997, OSTEOPOROSIS INT, V7, P525, DOI 10.1007/BF02652557
   Gerrard Paul, 2007, Neuropsychiatr Dis Treat, V3, P349
   Ham Jack, 2012, Front Endocrinol (Lausanne), V3, P113
   Haney EM, 2010, BONE, V46, P13, DOI 10.1016/j.bone.2009.07.083
   Hannon JP, 2002, BRIT J PHARMACOL, V135, P685, DOI 10.1038/sj.bjp.0704516
   He WJ, 2013, FASEB J, V27, P3446, DOI 10.1096/fj.13 231233
   Katebi M, 2009, J LEUKOCYTE BIOL, V85, P438, DOI 10.1189/jlb.0908520
   Khan K, 2013, OSTEOPOROSIS INT, V24, P1455, DOI 10.1007/s00198 012 2121 8
   Khan K, 2015, J NUTR BIOCHEM, V26, P1491, DOI 10.1016/j.jnutbio.2015.07.021
   Khan K, 2012, MOL NUTR FOOD RES, V56, P1860, DOI 10.1002/mnfr.201200200
   Kim Dongsoo, 2012, Environ Health Toxicol, V27, pe2012007, DOI 10.5620/eht.2012.27.e2012007
   Kondo H, 2002, J BONE MINER RES, V17, P1667, DOI 10.1359/jbmr.2002.17.9.1667
   Lelovas PP, 2008, COMPARATIVE MED, V58, P424
   Lewiecki EM, 2013, J CLIN DENSITOM, V16, P28, DOI 10.1016/j.jocd.2012.11.013
   Lo Iacono N, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/412768
   Ma Y, 2011, ENDOCRINOLOGY, V152, P1412, DOI 10.1210/en.2010 0881
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976 0105.177703
   Pal S, 2016, TOXICOL APPL PHARM, V295, P12, DOI 10.1016/j.taap.2016.02.002
   Peñaloza RA, 2013, JAMA INTERN MED, V173, P704, DOI 10.1001/jamainternmed.2013.2807
   Poucher SM, 1996, J PHARM PHARMACOL, V48, P601, DOI 10.1111/j.2042 7158.1996.tb05981.x
   Rinotas V, 2014, J BONE MINER RES, V29, P1158, DOI 10.1002/jbmr.2112
   Rizzoli R, 2012, BONE, V51, P606, DOI 10.1016/j.bone.2012.05.018
   Robertson P, 2003, CLIN PHARMACOKINET, V42, P123, DOI 10.2165/00003088 200342020 00002
   Russell JM, 2007, CALCIFIED TISSUE INT, V81, P316, DOI 10.1007/s00223 007 9060 y
   Saggese G, 2002, BEST PRACT RES CL EN, V16, P53, DOI 10.1053/beem.2001.0180
   Saper CB, 2004, SLEEP, V27, P11
   Shibuya I, 2019, PATHOL ONCOL RES, V25, P409, DOI 10.1007/s12253 017 0362 8
   Takeuchi T, 2001, BIOCHEM PHARMACOL, V61, P579, DOI 10.1016/S0006 2952(00)00591 8
   THEINTZ G, 1992, J CLIN ENDOCR METAB, V75, P1060, DOI 10.1210/jc.75.4.1060
   Trincavelli ML, 2014, BBA MOL CELL RES, V1843, P2957, DOI 10.1016/j.bbamcr.2014.09.013
   Turner DC, 2003, PSYCHOPHARMACOLOGY, V165, P260, DOI 10.1007/s00213 002 1250 8
   US Food and Drug Administration, 2015, FDA MED GUID PROV
   Wang BL, 2006, J ENDOCRINOL INVEST, V29, P101, DOI 10.1007/BF03344081
NR 42
TC 12
Z9 12
U1 0
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0041 008X
EI 1096 0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD JUN 1
PY 2018
VL 348
BP 22
EP 31
DI 10.1016/j.taap.2018.04.006
PG 10
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA GG4AH
UT WOS:000432634300003
PM 29649498
DA 2025 08 17
ER

PT J
AU Aisa, MC
   Datti, A
   Orlacchio, A
   Di Renzo, GC
AF Aisa, Maria Cristina
   Datti, Alessandro
   Orlacchio, Antonio
   Di Renzo, Gian Carlo
TI COX inhibitors and bone: A safer impact on osteoblasts by NO releasing
   NSAIDs
SO LIFE SCIENCES
LA English
DT Article
ID NITRIC OXIDE SYNTHASE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS;
   GROWTH FACTOR BETA; MATRIX METALLOPROTEINASES; CELL GROWTH; CATHEPSIN B;
   EXPRESSION; ASPIRIN; RESORPTION; ACTIVATOR
AB Nonsteroidal anti inflammatory drugs (NSAIDs) are commonly prescribed for the treatment of pain and inflammation. Although it is well known that NSAIDs can suppress bone growth, remodelling and repair, they are largely used post operatively and post traumatically to achieve analgesia and reduce inflammation in bone tissue.
   Aims: The impact of two NO releasing, non selective NSAIDs, NCX 4016 and HCT 3012 (NO derivatives of Aspirin and Naproxen, respectively) on osteoblasts were evaluated and compared to the non selective, parent chemicals and to the COX 2 selective inhibitor Celecoxib.
   Main methods: Using MG 63 osteoblast like cells, we considered proliferation, the early and late stage of differentiation, and the activity of proteinases thought to be involved in osteoid degradation, a preliminary fundamental event of bone remodelling.
   Key findings: Unlike Aspirin, Naproxen and Celecoxib, the two NO NSAIDs did not alter proliferation and differentiation of osteoblasts. They also reduced the activity of plasminogen activator, metalloproteinases, and cathepsin B. Similar inhibitory effects against these proteinases were recapitulated by the NO donor sodium nitroprusside, thereby suggesting a NO mediated mechanism.
   Significance: Due to a differential effect on cell proliferation and differentiation, the two NO NSAIDs exhibit a safer impact on osteoblast metabolism compared to Celecoxib and their parent compounds. This suggests an advantageous option for these drugs in individuals with a need of COX inhibiting treatment, in general. In addition, their capability of modulating the proteinases involved in osteoid degradation may specifically suggest an additional safer use in comorbidity conditions of inflammation or pain with bone disorders characterized by high rate of remodelling, such as high turnover osteoporosis in post menopausal women.
C1 [Aisa, Maria Cristina; Di Renzo, Gian Carlo] Univ Perugia, Sect Obstet & Gynecol, Dept Surg & Biomed Sci, Perugia, Italy.
   [Datti, Alessandro] Univ Perugia, Sect Biochem & Mol Biol, Dept Agr Food & Environm Sci, Perugia, Italy.
   [Orlacchio, Antonio] Inst Res & Hlth Care IRCCS, European Ctr Brain Res CERC, Lab Neurogenet, Rome, Italy.
   [Orlacchio, Antonio] Univ Perugia, Sect Med Genet, Dept Surg & Biomed Sci, Perugia, Italy.
C3 University of Perugia; University of Perugia; University of Perugia
RP Aisa, MC (通讯作者)，Univ Perugia, Sect Obstet & Gynecol, Dept Surg & Biomed Sci, Perugia, Italy.; Aisa, MC (通讯作者)，Univ Perugia, Med Sch, I 06121 Perugia, Italy.
EM maria.aisa@unipg.it
RI ; Aisa, Maria/AAO 6144 2021; Orlacchio, Antonio/A 1968 2014; Datti,
   Alessandro/ABA 1108 2021
OI Datti, Alessandro/0000 0001 6824 7382; Orlacchio,
   Antonio/0000 0002 2602 3281; Aisa, Maria Cristina/0000 0002 8557 1253; 
FU Nicox France [NCX 4016, HCT 3012]
FX We thank Nicox France for supporting this study, providing NCX 4016 and
   HCT 3012.
CR Aguirre J, 2001, AM J PATHOL, V158, P247, DOI 10.1016/S0002 9440(10)63963 6
   Aisa MC, 1996, BBA GEN SUBJECTS, V1290, P29, DOI 10.1016/0304 4165(95)00182 4
   Aisa MC, 2003, BBA GEN SUBJECTS, V1621, P149, DOI 10.1016/S0304 4165(03)00054 0
   [Anonymous], 2007, Drugs R D, V8, P255
   [Anonymous], AM J PHYS
   Armour KE, 2001, ENDOCRINOLOGY, V142, P760, DOI 10.1210/en.142.2.760
   Beck A, 2003, ARCH ORTHOP TRAUM SU, V123, P327, DOI 10.1007/s00402 003 0537 5
   BLAVIER L, 1995, J CELL SCI, V108, P3649
   Bolla M, 2006, EUR J CLIN PHARMACOL, V62, P145, DOI 10.1007/s00228 005 0026 6
   Burgaud JL, 2002, CURR PHARM DESIGN, V8, P201, DOI 10.2174/1381612023396357
   Carini M, 2004, LIFE SCI, V74, P3291, DOI 10.1016/j.lfs.2003.11.018
   CHAMBERS TJ, 1985, J CELL SCI, V76, P155
   Chang JK, 2009, TOXICOLOGY, V258, P148, DOI 10.1016/j.tox.2009.01.016
   Chang JK, 2005, CONNECT TISSUE RES, V46, P200, DOI 10.1080/03008200500344025
   Chattopadhyay M, 2010, CANCER LETT, V298, P204, DOI 10.1016/j.canlet.2010.07.006
   Corazzi T, 2003, BIOCHEM BIOPH RES CO, V311, P897, DOI 10.1016/j.bbrc.2003.10.079
   Damiens C, 2000, CYTOKINE, V12, P1727, DOI 10.1006/cyto.2000.0765
   De Luna Bertos E, 2013, SCI WORLD J, DOI 10.1155/2013/809891
   De Luna Bertos E, 2012, SCI WORLD J, DOI 10.1100/2012/834246
   De Luna Bertos E, 2015, BIOL RES NURS, V17, P62, DOI 10.1177/1099800414527155
   Díaz Rodríguez L, 2010, ACTA PHARMACOL SIN, V31, P1495, DOI 10.1038/aps.2010.129
   Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063
   Evans CE, 2004, J BONE JOINT SURG BR, V86B, P444, DOI 10.1302/0301 620X.86B3.14592
   FAWTHROP FW, 1992, J BONE MINER RES, V7, P1363
   Fiorucci S, 2000, J IMMUNOL, V165, P5245, DOI 10.4049/jimmunol.165.9.5245
   FUKUMOTO S, 1992, J CELL PHYSIOL, V152, P346, DOI 10.1002/jcp.1041520216
   García Martínez O, 2015, LIFE SCI, V123, P72, DOI 10.1016/j.lfs.2015.01.009
   García Martínez O, 2011, ARCH ORAL BIOL, V56, P317, DOI 10.1016/j.archoralbio.2010.10.018
   Gerstenfeld LC, 2003, J ORTHOP RES, V21, P670, DOI 10.1016/S0736 0266(03)00003 2
   Gresele P, 2006, CARDIOVASC DRUG REV, V24, P148, DOI 10.1111/j.1527 3466.2006.00148.x
   Gresele P, 2012, J VASC SURG, V56, P1622, DOI 10.1016/j.jvs.2012.05.064
   Gresele P, 2010, DIABETES CARE, V33, P1262, DOI 10.2337/dc09 2013
   Helfrich MH, 1997, J BONE MINER RES, V12, P1108, DOI 10.1359/jbmr.1997.12.7.1108
   Hikita A, 2006, J BIOL CHEM, V281, P36846, DOI 10.1074/jbc.M606656200
   Holliday LS, 1997, J BIOL CHEM, V272, P22053, DOI 10.1074/jbc.272.35.22053
   Hukkanen MVJ, 1999, J BONE MINER RES, V14, P868, DOI 10.1359/jbmr.1999.14.6.868
   Karsdal MA, 2001, J BIOL CHEM, V276, P39350, DOI 10.1074/jbc.M008738200
   Kaspar D, 2005, UNFALLCHIRURG, V108, P18, DOI 10.1007/s00113 004 0858 z
   Katayama N, 2008, J PHARMACOL EXP THER, V325, P69, DOI 10.1124/jpet.107.132100
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014 5793(92)80300 6
   Krischak GD, 2007, ARCH ORTHOP TRAUM SU, V127, P453, DOI 10.1007/s00402 007 0288 9
   Lirani Galvao APR, 2010, CALCIFIED TISSUE INT, V87, P52, DOI 10.1007/s00223 010 9357 0
   Loveridge N, 2002, BONE, V30, P866, DOI 10.1016/S8756 3282(02)00732 9
   MCGLEW IC, 1991, ANAESTH INTENS CARE, V19, P40, DOI 10.1177/0310057X9101900107
   Mezzasoma AM, 1999, THROMB HAEMOSTASIS, P230
   Muscara Marcelo N., 2006, Cardiovascular & Hematological Agents in Medicinal Chemistry, V4, P155, DOI 10.2174/187152506776369917
   Pountos I, 2012, SCI WORLD J, DOI 10.1100/2012/606404
   RIANCHO JA, 1995, J BONE MINER RES, V10, P439
   RIANCHO JA, 1995, MOL CELL ENDOCRINOL, V107, P87, DOI 10.1016/0303 7207(94)03428 V
   Rigas B, 2004, TRENDS MOL MED, V10, P324, DOI 10.1016/j.molmed.2004.05.004
   Rowe PSN, 2006, BONE, V39, P773, DOI 10.1016/j.bone.2006.04.012
   Saura M, 2010, THESCIENTIFICWORLDJO, V10, P624, DOI 10.1100/tsw.2010.58
   STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157
   Tumber A, 2003, J ENDOCRINOL, V178, P437, DOI 10.1677/joe.0.1780437
   Turner CH, 1996, AM J PHYSIOL ENDOC M, V270, pE634, DOI 10.1152/ajpendo.1996.270.4.E634
   van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365 2567.2001.01261.x
   Vestergaard P, 2012, OSTEOPOROSIS INT, V23, P1255, DOI 10.1007/s00198 011 1692 0
   Wallace JL, 2003, FUND CLIN PHARMACOL, V17, P11, DOI 10.1046/j.1472 8206.2003.00125.x
   Whittle BJR, 2005, EXPERT OPIN INV DRUG, V14, P1347, DOI 10.1517/13543784.14.11.1347
   Wimalawansa SJ, 2007, ANN NY ACAD SCI, V1117, P283, DOI 10.1196/annals.1402.066
   Zaman G, 1999, J BONE MINER RES, V14, P1123, DOI 10.1359/jbmr.1999.14.7.1123
   Zhou X, 2015, EUR REV MED PHARMACO, V19, P4087
NR 63
TC 13
Z9 13
U1 1
U2 8
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
EI 1879 0631
J9 LIFE SCI
JI Life Sci.
PD SEP 1
PY 2018
VL 208
BP 10
EP 19
DI 10.1016/j.lfs.2018.07.011
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA GR3XZ
UT WOS:000442532700002
PM 29990484
DA 2025 08 17
ER

PT J
AU Motyl, KJ
   McCauley, LK
   McCabe, LR
AF Motyl, Katherine J.
   McCauley, Laurie K.
   McCabe, Laura R.
TI Amelioration of type I diabetes induced osteoporosis by parathyroid
   hormone is associated with improved osteoblast survival
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID BONE LOSS; INTERMITTENT PTH; OVARIECTOMIZED RATS; POSTMENOPAUSAL WOMEN;
   ALENDRONATE THERAPY; GENE EXPRESSION; ANABOLIC ACTION; FRACTURES;
   MELLITUS; INSULIN
AB Type 1 diabetic osteoporosis results from impaired osteoblast activity and death. Therefore, anti resorptive treatments may not effectively treat bone loss in this patient population. Intermittent parathyroid hormone (PTH) treatment stimulates bone remodeling and increases bone density in healthy subjects. However, PTH effects may be limited in patients with diseases that interfere with its signaling. Here, we examined the ability of 8 and 40 mu g/kg intermittent PTH to counteract diabetic bone loss. PTH treatment reduced fat pad mass and blood glucose levels in non diabetic PTH treated mice, consistent with PTH affecting glucose homeostasis. However, PTH treatment did not significantly affect general body parameters, including the blood glucose levels, of type 1 diabetic mice. We found that the high dose of PTH significantly increased tibial trabecular bone density parameters in control and diabetic mice, and the lower dose elevated trabecular bone parameters in diabetic mice. The increased bone density was due to increased mineral apposition and osteoblast surface, all of which are defective in type 1 diabetes. PTH treatment suppressed osteoblast apoptosis in diabetic bone, which could further contribute to the bone enhancing effects. In addition, PTH treatment (40 mu g/kg) reversed preexisting bone loss from diabetes. We conclude that intermittent PTH may increase type 1 diabetic trabecular bone volume through its anabolic effects on osteoblasts. J. Cell. Physiol. 227: 1326 1334, 2012. (C) 2011 Wiley Periodicals, Inc.
C1 [Motyl, Katherine J.; McCabe, Laura R.] Michigan State Univ, Dept Physiol, Biomed Imaging Res Ctr, E Lansing, MI 48824 USA.
   [Motyl, Katherine J.; McCabe, Laura R.] Michigan State Univ, Dept Radiol, Biomed Imaging Res Ctr, E Lansing, MI 48824 USA.
   [McCauley, Laurie K.] Univ Michigan, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.
   [McCauley, Laurie K.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
C3 Michigan State University; Michigan State University; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan
RP McCabe, LR (通讯作者)，Michigan State Univ, Dept Physiol, Biomed Imaging Res Ctr, 2201 Biomed Phys Sci Bldg, E Lansing, MI 48824 USA.
EM mccabel@msu.edu
RI ; McCauley, Laurie/G 4041 2012
OI McCabe, Laura/0000 0001 5407 162X; 
FU National Institutes of Health [RO1DK061184, DK53904]; American Diabetes
   Association [7 07 RA 105]
FX The authors thank Regina Irwin and Lindsay Coe for technical assistance
   and critical review of the article, and the MSU Investigative Histology
   Laboratory for technical assistance. This work was funded by grants from
   the National Institutes of Health (RO1DK061184 and DK53904) and the
   American Diabetes Association (7 07 RA 105) to LRM. The authors have no
   financial conflicts.
CR Abrahamsen B, 2009, J BONE MINER RES, V24, P1095, DOI [10.1359/JBMR.081247, 10.1359/jbmr.081247]
   Alkhiary YM, 2005, J BONE JOINT SURG AM, V87A, P731, DOI 10.2106/JBJS.D.02115
   AUWERX J, 1988, DIABETES, V37, P8, DOI 10.2337/diabetes.37.1.8
   Barnes GL, 2008, J BONE JOINT SURG AM, V90A, P120, DOI 10.2106/JBJS.G.01443
   Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   Botolin S, 2005, ENDOCRINOLOGY, V146, P3622, DOI 10.1210/en.2004 1677
   Botolin S, 2006, J CELL BIOCHEM, V99, P411, DOI 10.1002/jcb.20842
   Botolin S, 2007, ENDOCRINOLOGY, V148, P198, DOI 10.1210/en.2006 1006
   BOUILLON R, 1995, J CLIN ENDOCR METAB, V80, P1194, DOI 10.1210/jc.80.4.1194
   Burr DB, 2001, J BONE MINER RES, V16, P157, DOI 10.1359/jbmr.2001.16.1.157
   Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296
   Coe LM, 2011, J CELL PHYSIOL, V226, P477, DOI 10.1002/jcp.22357
   Danne T, 1997, DIABETES CARE, V20, P281, DOI 10.2337/diacare.20.3.281
   DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690
   Ferron M, 2010, CELL, V142, P296, DOI 10.1016/j.cell.2010.06.003
   Follak N, 2004, HISTOL HISTOPATHOL, V19, P473, DOI 10.14670/HH 19.473
   Fowlkes JL, 2008, ENDOCRINOLOGY, V149, P1697, DOI 10.1210/en.2007 1408
   Fox J, 2006, CALCIFIED TISSUE INT, V79, P262, DOI 10.1007/s00223 006 0108 1
   Gandhi A, 2005, BONE, V37, P482, DOI 10.1016/j.bone.2005.04.039
   Goh SK, 2007, J BONE JOINT SURG BR, V89B, P349, DOI 10.1302/0301 620X.89B3.18146
   GOODMAN WG, 1984, DIABETES, V33, P825, DOI 10.2337/diabetes.33.9.825
   Holl RW, 1998, EUR J PEDIATR, V157, P972, DOI 10.1007/s004310050980
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Jilka RL, 2010, J BONE MINER RES, V25, P2427, DOI 10.1002/jbmr.145
   Jilka RL, 2009, BONE, V44, P275, DOI 10.1016/j.bone.2008.10.037
   Kemink SAG, 2000, J ENDOCRINOL INVEST, V23, P295, DOI 10.1007/BF03343726
   Khamaisi M, 2007, J CLIN ENDOCR METAB, V92, P1172, DOI 10.1210/jc.2006 2036
   Krishnan V, 2003, MOL ENDOCRINOL, V17, P423, DOI 10.1210/me.2002 0225
   Kuchler U, 2011, CLIN ORAL IMPLAN RES, V22, P518, DOI 10.1111/j.1600 0501.2010.02047.x
   Kwek EBK, 2008, INJURY, V39, P224, DOI 10.1016/j.injury.2007.08.036
   Lenart BA, 2008, NEW ENGL J MED, V358, P1304, DOI 10.1056/NEJMc0707493
   LEVIN ME, 1976, NEW ENGL J MED, V294, P241, DOI 10.1056/NEJM197601292940502
   LIU CC, 1990, J BONE MINER RES, V5, P973
   LIU CC, 1991, J BONE MINER RES, V6, P1071
   Lozano D, 2009, ENDOCRINOLOGY, V150, P2027, DOI 10.1210/en.2008 1108
   Ma YFL, 2001, ENDOCRINOLOGY, V142, P4047, DOI 10.1210/en.142.9.4047
   Martin LM, 2007, HISTOCHEM CELL BIOL, V128, P125, DOI 10.1007/s00418 007 0308 4
   McCabe LR, 2007, J CELL BIOCHEM, V102, P1343, DOI 10.1002/jcb.21573
   Motyl K, 2009, BIOL PROCED ONLINE, V11, P296, DOI 10.1007/s12575 009 9000 5
   Motyl KJ, 2009, J CELL PHYSIOL, V218, P575, DOI 10.1002/jcp.21626
   Motyl KJ, 2009, J CELL PHYSIOL, V218, P376, DOI 10.1002/jcp.21608
   Nakajima A, 2002, J BONE MINER RES, V17, P2038, DOI 10.1359/jbmr.2002.17.11.2038
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Neviaser AS, 2008, J ORTHOP TRAUMA, V22, P346, DOI 10.1097/BOT.0b013e318172841c
   Niziolek PJ, 2009, J CELL PHYSIOL, V221, P579, DOI 10.1002/jcp.21887
   Ogita M, 2008, ENDOCRINOLOGY, V149, P5713, DOI 10.1210/en.2008 0369
   Ontiveros C, 2003, J CELL BIOCHEM, V88, P427, DOI 10.1002/jcb.10410
   Pettway GJ, 2008, BONE, V42, P806, DOI 10.1016/j.bone.2007.11.017
   Pierroz DD, 2006, BONE, V39, P260, DOI 10.1016/j.bone.2006.01.145
   Rotolin S, 2006, J CELL PHYSIOL, V209, P967, DOI 10.1002/jcp.20804
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Schnoke M, 2009, BONE, V45, P590, DOI 10.1016/j.bone.2009.05.006
   Sibonga JD, 2007, BONE, V40, P1013, DOI 10.1016/j.bone.2006.11.002
   Tanaka S, 2004, J BONE MINER RES, V19, P1813, DOI 10.1359/JBMR.040808
   Tashjian AH, 2006, J BONE MINER RES, V21, P354, DOI 10.1359/JBMR.051023
   Tsuchida T, 2000, CALCIFIED TISSUE INT, V66, P229, DOI 10.1007/PL00005838
   Turner RT, 1998, ENDOCRINOLOGY, V139, P4086, DOI 10.1210/en.139.10.4086
   Turner RT, 2007, J BONE MINER RES, V22, P64, DOI 10.1359/JBMR.061006
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Vahle JL, 2004, TOXICOL PATHOL, V32, P426, DOI 10.1080/01926230490462138
   Vengellur A, 2004, TOXICOL SCI, V82, P638, DOI 10.1093/toxsci/kfh278
   Wiren KM, 2004, ENDOCRINOLOGY, V145, P3507, DOI 10.1210/en.2003 1016
   Zhao S, 2002, J BONE MINER RES, V17, P2068, DOI 10.1359/jbmr.2002.17.11.2068
NR 64
TC 71
Z9 83
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD APR
PY 2012
VL 227
IS 4
BP 1326
EP 1334
DI 10.1002/jcp.22844
PG 9
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA 874VL
UT WOS:000298986100006
PM 21604269
OA Green Accepted, Green Submitted
DA 2025 08 17
ER

PT J
AU Chiu, HW
   Lu, KC
   Lin, YC
   Hou, YC
   Liao, MT
   Chen, YJ
   Chiu, YJ
   Zheng, CM
AF Chiu, Hui Wen
   Lu, Kuo Cheng
   Lin, Yen Chung
   Hou, Yi Chou
   Liao, Min Tser
   Chen, Yi Jie
   Chiu, Yu Jhe
   Zheng, Cai Mei
TI Etelcalcetide ameliorates bone loss in chronic kidney disease mineral
   and bone disorder by activation of IRF7 and necroptosis pathways
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Chronic kidney disease mineral and bone disorder; Etelcalcetide;
   Osteoclasts; IRF7; Necroptosis
ID RANKL INDUCED OSTEOCLAST; CELL DEATH; DIFFERENTIATION; MECHANISMS;
   APOPTOSIS; KINASE; RIP3
AB Chronic kidney disease mineral and bone disorder (CKD MBD) is a multifaceted clinical syndrome characterized by mineral imbalances, abnormalities in bone metabolism, chronic inflammation and vascular calcification. Etelcalcetide, a second generation intravenous calcimimetic agent, has been approved for treating high turnover renal osteodystrophy, effectively targeting the pathophysiological mechanisms underlying this condition. We investigate the impacts of etelcalcetide on osteoclast (OC) differentiation and functionality in CKD MBD via three critical mechanisms: inflammation initiated by interferon regulatory factor 7 (IRF7), receptor interacting protein (RIP) mediated necroptosis and apoptosis induced cell death. The low dose (CKD + L) or high dose (CKD + H) of etelcalcetide groups significantly improved biochemical markers compared to the CKD control mice. Additionally, etelcalcetide treated CKD mice significantly improved cortical and trabecular bone parameters. In an in vitro study, etelcalcetide was observed to bolster the IRF7 mediated IFN beta response in OC differentiation. Furthermore, it stimulated RIP mediated necroptosis via RIP and MLKL activation, inhibiting bone resorption. Moreover, the drug increased levels of caspases 3 and 9, inducing cell death in OCs. These findings suggest that etelcalcetide regulates bone metabolism and reduces skeletal issues in CKD MBD. Etelcalcetide likely enhances bone parameters in CKD MBD mice by regulating IRF7 pathways and inhibiting OC differentiation. It also improves bone health and promotes RIP mediated necroptosis and apoptosis pathways within OCs.
C1 [Chiu, Hui Wen; Chen, Yi Jie; Chiu, Yu Jhe] Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan.
   [Chiu, Hui Wen] Taipei Med Univ, Shuang Ho Hosp, Dept Med Res & Educ, New Taipei, Taiwan.
   [Chiu, Hui Wen] Taipei Med Univ, Coll Pharm, Ph D Program Drug Discovery & Dev Ind, Taipei, Taiwan.
   [Chiu, Hui Wen; Lin, Yen Chung; Zheng, Cai Mei] Taipei Med Univ, TMU Res Ctr Urol & Kidney, Taipei, Taiwan.
   [Lu, Kuo Cheng] Tzu Chi Univ, Buddhist Tzu Chi Med Fdn, Taipei Tzu Chi Hosp, Sch Med,Dept Med,Div Nephrol, Hualien, Taiwan.
   [Lu, Kuo Cheng] Fu Jen Catholic Univ, Fu Jen Catholic Univ Hosp, Sch Med, Dept Med,Div Nephrol, New Taipei, Taiwan.
   [Lu, Kuo Cheng] Triserv Gen Hosp, Natl Def Med Ctr, Dept Med, Div Nephrol, Taipei, Taiwan.
   [Lin, Yen Chung] Taipei Med Univ Hosp, Dept Internal Med, Div Nephrol, Taipei, Taiwan.
   [Lin, Yen Chung; Zheng, Cai Mei] Taipei Med Univ, Coll Med, Sch Med, Dept Internal Med,Div Nephrol, 250 Wu Hsing St, Taipei 110, Taiwan.
   [Hou, Yi Chou] Fu Jen Catholic Univ, Cardinal Tien Hosp, Sch Med, Dept Internal Med,Div Nephrol, New Taipei, Taiwan.
   [Liao, Min Tser] Taoyuan Armed Forces Gen Hosp, Dept Pediat, Taoyuan, Taiwan.
   [Zheng, Cai Mei] Triserv Gen Hosp, Natl Def Med Ctr, Dept Pediat, Taipei, Taiwan.
   [Zheng, Cai Mei] Taipei Med Univ, Shuang Ho Hosp, Dept Internal Med, Div Nephrol, New Taipei, Taiwan.
C3 Taipei Medical University; Taipei Medical University; Shuang Ho
   Hospital; Taipei Medical University; Taipei Medical University; Tzu Chi
   University; Fu Jen Catholic University; Fu Jen Catholic University
   Hospital; Tri Service General Hospital; National Defense Medical
   University; Taipei Medical University; Taipei Medical University
   Hospital; Taipei Medical University; Fu Jen Catholic University;
   National Defense Medical University; Tri Service General Hospital;
   Taipei Medical University; Shuang Ho Hospital
RP Zheng, CM (通讯作者)，Taipei Med Univ, Coll Med, Sch Med, Dept Internal Med,Div Nephrol, 250 Wu Hsing St, Taipei 110, Taiwan.
EM 11044@s.tmu.edu.tw
FU Taipei Medical University Shuang Ho Hospital [113TMU SHH 19]; National
   Science and Technology Council, Taiwan [MOST 110 2314 B 038 075 MY3,
   NSTC 112 2314 B 038 087, NSTC 112 2221 E 038 016, NSTC
   112 2314 B 303 018 MY3, NSTC 113 2314 B 038 084]
FX This study was supported by the Taipei Medical University Shuang Ho
   Hospital (113TMU SHH 19) and National Science and Technology Council,
   Taiwan (MOST 110 2314 B 038 075 MY3, NSTC 112 2314 B 038 087, NSTC
   112 2221 E 038 016, NSTC 112 2314 B 303 018 MY3 and NSTC
   113 2314 B 038 084).
CR Block GA, 2017, JAMA J AM MED ASSOC, V317, P156, DOI 10.1001/jama.2016.19468
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cafiero C, 2018, NEPHROL DIAL TRANSPL, V33, P65, DOI 10.1093/ndt/gfx222
   Chiu HW, 2022, J BONE MINER RES, V37, P215, DOI 10.1002/jbmr.4459
   D'Marco L, 2023, HEALTHCARE BASEL, V11, DOI 10.3390/healthcare11010072
   Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83
   Galluzzi L, 2017, ANNU REV PATHOL MECH, V12, P103, DOI 10.1146/annurev pathol 052016 100247
   Galluzzi L, 2014, SEMIN CELL DEV BIOL, V35, P24, DOI 10.1016/j.semcdb.2014.02.006
   Guo M, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/3027954
   Hoyland JA, 1999, KIDNEY INT, V56, pS8, DOI 10.1046/j.1523 1755.1999.07312.x
   Hu XL, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.1032614
   Huang FJ, 2019, EBIOMEDICINE, V48, P491, DOI 10.1016/j.ebiom.2019.09.002
   Iseme Rosebella A, 2017, Bone Rep, V7, P121, DOI 10.1016/j.bonr.2017.10.003
   Kamio N, 2013, CONNECT TISSUE RES, V54, P147, DOI 10.3109/03008207.2012.761978
   Kim MH, 2009, J CELL PHYSIOL, V221, P618, DOI 10.1002/jcp.21892
   Kumar G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205154
   Lamothe B, 2013, MOL CELL BIOL, V33, P582, DOI 10.1128/MCB.01225 12
   Li XD, 2017, BONE, V105, P163, DOI 10.1016/j.bone.2017.08.026
   Liu WC, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/5696686
   Ma XQ, 2018, EXP THER MED, V15, P182, DOI 10.3892/etm.2017.5381
   Mazzaferro S, 2021, CALCIFIED TISSUE INT, V108, P452, DOI 10.1007/s00223 020 00794 0
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   Moen IN, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420 021 00415 1
   Mullin BH, 2020, GENOME BIOL, V21, DOI 10.1186/s13059 020 01997 2
   NCBI, The RNA seq data were deposited in the GEO database of NCBI
   Seeliger C, 2015, EUR J MED RES, V20, DOI 10.1186/s40001 014 0074 4
   Song CC, 2019, J CELL PHYSIOL, V234, P11969, DOI 10.1002/jcp.27852
   Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031
   Tani T, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02351 6
   Xipell M, 2019, BLOOD PURIFICAT, V48, P106, DOI 10.1159/000496562
   Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308
   Zheng CM, 2022, BIOMED PHARMACOTHER, V154, DOI 10.1016/j.biopha.2022.113565
   Zheng CM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112800
NR 33
TC 0
Z9 0
U1 1
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141 8130
EI 1879 0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD NOV
PY 2024
VL 280
AR 135978
DI 10.1016/j.ijbiomac.2024.135978
EA SEP 2024
PN 3
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA I2D9P
UT WOS:001328425100001
PM 39322143
DA 2025 08 17
ER

PT J
AU Lin, CX
   Chen, Z
   Guo, D
   Zhou, LX
   Lin, SP
   Li, CC
   Li, SX
   Wang, XJ
   Lin, BD
   Ding, Y
AF Lin, Chuangxin
   Chen, Zhong
   Guo, Dong
   Zhou, Laixi
   Lin, Sipeng
   Li, Changchuan
   Li, Shixun
   Wang, Xinjia
   Lin, Bendan
   Ding, Yue
TI Increased expression of osteopontin in subchondral bone promotes bone
   turnover and remodeling, and accelerates the progression of OA in a
   mouse model
SO AGING US
LA English
DT Article
DE OA; subchondral bone; osteopontin; bone turnover; remodeling
ID OSTEOCLAST DIFFERENTIATION; IN VITRO; OSTEOARTHRITIS; OSTEOBLASTS;
   PROLIFERATION; RECOMMENDATIONS; CHONDROCYTES; NSAIDS; CELLS
AB Osteopontin (OPN) has been proved to be closely related to the pathogenesis of osteoarthritis (OA), but the role of OPN in the pathogenesis of OA has not been fully clarified. Current studies on OPN in OA mostly focus on articular cartilage, synovial membrane and articular fluid, while ignoring its role in OA subchondral bone turnover and remodeling. In this study, we used a destabilization OA mouse model to investigate the role of OPN in OA subchondral bone changes. Our results indicate that increased expression of OPN accelerates the turnover and remodeling of OA subchondral bone, promotes the formation of h type vessels in subchondral bone, and mediates articular cartilage degeneration induced by subchondral bone metabolism. In addition, our results confirmed that inhibition of PI3K/AKT signaling pathway inhibits OPN mediated OA subchondral bone remodeling and cartilage degeneration. This study revealed the role and mechanism of OPN in OA subchondral bone, which is of great significance for exploring specific biological indicators for early diagnosis of OA and monitoring disease progression, as well as for developing drugs to regulate the metabolism and turnover of subchondral bone and alleviate the subchondral bone sclerosis of OA.
C1 [Lin, Chuangxin; Chen, Zhong; Lin, Sipeng; Li, Changchuan; Li, Shixun; Ding, Yue] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Orthoped, Guangzhou 510120, Peoples R China.
   [Lin, Chuangxin; Zhou, Laixi; Lin, Bendan] Shantou Cent Hosp, Dept Orthoped Surg, Shantou 515000, Peoples R China.
   [Guo, Dong] Southern Med Univ, Ctr Orthoped Surg, Affiliated Hosp 3, Dept Joint Surg, Guangzhou 510515, Peoples R China.
   [Wang, Xinjia] Shantou Univ, Coll Med, Affiliated Canc Hosp, Dept Orthoped, Shantou 515041, Peoples R China.
C3 Sun Yat Sen University; Southern Medical University   China; Shantou
   University
RP Ding, Y (通讯作者)，Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Orthoped, Guangzhou 510120, Peoples R China.; Lin, BD (通讯作者)，Shantou Cent Hosp, Dept Orthoped Surg, Shantou 515000, Peoples R China.; Wang, XJ (通讯作者)，Shantou Univ, Coll Med, Affiliated Canc Hosp, Dept Orthoped, Shantou 515041, Peoples R China.
EM xj.wang2000@163.com; yyguyike@163.com; dingyue@mail.sysu.edu.cn
RI Li, Changchuan/GPX 7405 2022
OI Lin, Sipeng/0000 0001 8395 8561
FU National Natural Science Foundation of China [81902268]; Natural Science
   Foundation of Guangdong Province [2020A1515010207]; China Postdoctoral
   Science Foundation [2019TQ0385, 2019M663264]; medical and health
   projects of Shantou science and technology plan [190923175260442,
   190915165269567]
FX This work was supported by the National Natural Science Foundation of
   China (81902268); The Natural Science Foundation of Guangdong Province
   (2020A1515010207); the China Postdoctoral Science Foundation
   (2019TQ0385, 2019M663264); and the medical and health projects of
   Shantou science and technology plan (190923175260442, 190915165269567).
CR Abed E, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1365 2
   Aizah N, 2021, CARTILAGE, V13, p1322S, DOI 10.1177/1947603519878479
   Chen YY, 2019, ONCOL LETT, V17, P564, DOI 10.3892/ol.2018.9524
   Cheng C, 2014, RHEUMATOL INT, V34, P1627, DOI 10.1007/s00296 014 3036 9
   Clemente N, 2020, J CONTROL RELEASE, V320, P112, DOI 10.1016/j.jconrel.2020.01.030
   Couchourel D, 2009, ARTHRITIS RHEUM US, V60, P1438, DOI 10.1002/art.24489
   Dai QG, 2017, J BIOL CHEM, V292, P196, DOI 10.1074/jbc.M116.764761
   Dianzani C, 2010, J IMMUNOL, V185, P3970, DOI 10.4049/jimmunol.0903269
   DODDS RA, 1995, J BONE MINER RES, V10, P1666
   Geurts J, 2016, J ORTHOP RES, V34, P262, DOI 10.1002/jor.23009
   Gigliotti CL, 2016, J IMMUNOL, V197, P3905, DOI 10.4049/jimmunol.1600424
   Glasson SS, 2007, OSTEOARTHR CARTILAGE, V15, P1061, DOI 10.1016/j.joca.2007.03.006
   Glasson SS, 2010, OSTEOARTHR CARTILAGE, V18, pS17, DOI 10.1016/j.joca.2010.05.025
   Herndon Christopher M, 2012, J Pain Palliat Care Pharmacother, V26, P18, DOI 10.3109/15360288.2011.653600
   Honsawek S, 2009, CLIN BIOCHEM, V42, P808, DOI 10.1016/j.clinbiochem.2009.02.002
   Hou CH, 2015, CELL PHYSIOL BIOCHEM, V36, P1753, DOI 10.1159/000430148
   Hügle T, 2017, RHEUMATOLOGY, V56, P1461, DOI 10.1093/rheumatology/kew389
   Hunter DJ, 2020, LANCET, V396, P1711, DOI 10.1016/S0140 6736(20)32230 3
   Jiang A, 2021, CONNECT TISSUE RES, V62, P709, DOI 10.1080/03008207.2020.1870969
   Kiefer FW, 2010, DIABETES, V59, P935, DOI 10.2337/db09 0404
   Klose Jensen R, 2015, OSTEOARTHR CARTILAGE, V23, P2167, DOI 10.1016/j.joca.2015.06.001
   Lajeunesse D, 2003, BONE, V33, P703, DOI 10.1016/S8756 3282(03)00206 0
   Li GY, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4405
   Li L, 2020, J CELL PHYSIOL, V235, P281, DOI 10.1002/jcp.28968
   Li YH, 2015, SCI REP UK, V5, DOI 10.1038/srep16124
   Li YS, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6345656
   Li YS, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/9561058
   Liang J, 2018, J CELL BIOCHEM, V119, P431, DOI 10.1002/jcb.26200
   Lin CX, 2019, BONE RES, V7, DOI 10.1038/s41413 018 0041 8
   Lu JS, 2018, J BONE MINER RES, V33, P909, DOI 10.1002/jbmr.3388
   Naumov A V, 2019, Zh Nevrol Psikhiatr Im S S Korsakova, V119, P112, DOI 10.17116/jnevro2019119091112
   Pazolli E, 2009, CANCER RES, V69, P1230, DOI 10.1158/0008 5472.CAN 08 2970
   Pelletier JP, 2016, SEMIN ARTHRITIS RHEU, V45, pS22, DOI 10.1016/j.semarthrit.2015.11.009
   Peng Y, 2020, THERANOSTICS, V10, P426, DOI 10.7150/thno.34126
   Prasadam I, 2012, J RHEUMATOL, V39, P621, DOI 10.3899/jrheum.110777
   Rafanan BS, 2018, PAIN MANAG, V8, P115, DOI 10.2217/pmt 2017 0047
   Raineri D, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003 020 01333 1
   Sanchez C, 2005, OSTEOARTHR CARTILAGE, V13, P988, DOI 10.1016/j.joca.2005.07.012
   Sanchez C, 2008, ARTHRITIS RHEUM US, V58, P442, DOI 10.1002/art.23159
   Smith SR, 2016, OSTEOARTHR CARTILAGE, V24, P962, DOI 10.1016/j.joca.2016.01.135
   Sun PF, 2020, EUR REV MED PHARMACO, V24, P2836, DOI 10.26355/eurrev_202003_20647
   Suri S, 2012, BONE, V51, P204, DOI 10.1016/j.bone.2011.10.010
   Wan YP, 2019, LIFE SCI, V239, DOI 10.1016/j.lfs.2019.116980
   Wang QY, 2017, J CELL BIOCHEM, V118, P3775, DOI 10.1002/jcb.26025
   Wu LZ, 2015, INT J CLIN EXP PATHO, V8, P14121
   Yang Y, 2014, EUR REV MED PHARMACO, V18, P3580
   Yuan XL, 2014, OSTEOARTHR CARTILAGE, V22, P1077, DOI 10.1016/j.joca.2014.05.023
   Yumoto K, 2012, CARTILAGE, V3, P79, DOI 10.1177/1947603511421502
   Zhang FJ, 2013, RHEUMATOL INT, V33, P79, DOI 10.1007/s00296 011 2339 3
   Zhang JK, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12874
NR 50
TC 18
Z9 22
U1 3
U2 33
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945 4589
J9 AGING US
JI Aging US
PD JAN 15
PY 2022
VL 14
IS 1
BP 253
EP 271
PG 19
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA YJ1IW
UT WOS:000744292300002
PM 34982732
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zheng, C
   Shi, XM
AF Zheng, Chao
   Shi, Xiaoming
TI Cysteinyl leukotriene receptor 1 (cysLT1R) regulates osteoclast
   differentiation and bone resorption
SO ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
LA English
DT Article
DE Osteoclast differentiation; RANKL; osteoporosis; type 1 cysteinyl
   leukotriene receptor; montelukast
ID CRUCIAL ROLE; KAPPA B; RANKL; OSTEOIMMUNOLOGY; MECHANISMS; PATHWAYS;
   DISEASE; IMMUNE
AB Excessive bone resorption induced by abnormal osteoclast differentiation has been associated with bone microstructure damage and bone associated disorders, including osteoporosis. Here, we investigated the physiological roles of the type 1 cysteinyl leukotriene receptor (cysLTR 1) and the pharmacological functions of the specific cysLTR 1 antagonist montelukast on M CSF  and RANKL induced osteoclast differentiation. We showed that cysLTR 1 but not cysLTR 2 is expressed in osteoclast precursor cells: mouse bone marrow derived macrophages (BMMs). We also found that treatment with M CSF and RANKL significantly increased expression of cysLTR 1. Overexpression of cysLTR 1 promoted osteoclast differentiation of BMMs by increasing NFATc1 and TRAP. In contrast, treatment with montelukast prevented M CSF  and RANKL induced osteoclast differentiation of BMMs. Mechanically, our findings demonstrate that montelukast treatment attenuated activation of the ERK1/2, p38, JNK and NF kappa B signalling pathways. Additionally, we reported that montelukast treatment ameliorated the generation of ROS and calcium signalling. Importantly, the co immunoprecipitation assay displayed that montelukast treatment prevented the interaction of RANK and TRAF6. Finally, in vivo experiments indicated that montelukast rescued the reduction of bone volume as well as trabecular number in an ovariectomy mouse model.
C1 [Zheng, Chao] Linyi Peoples Hosp, Dept Reparat & Reconstruct Surg, Linyi, Shandong, Peoples R China.
   [Shi, Xiaoming] Linyi Peoples Hosp, Dept Stomatol, 27 Jiefang Rd East, Linyi 276003, Shandong, Peoples R China.
RP Shi, XM (通讯作者)，Linyi Peoples Hosp, Dept Stomatol, 27 Jiefang Rd East, Linyi 276003, Shandong, Peoples R China.
EM shixm085@yeah.net
CR Austen KF, 2008, NAT IMMUNOL, V9, P113, DOI 10.1038/ni0208 113
   Boehmler AM, 2009, J IMMUNOL, V182, P6789, DOI 10.4049/jimmunol.0801525
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Busse W, 2005, CHEST, V127, P1312, DOI 10.1378/chest.127.4.1312
   Chang EJ, 2008, NAT MED, V14, P966, DOI 10.1038/nm.1860
   Chen QB, 2014, CELL PHYSIOL BIOCHEM, V34, P1890, DOI 10.1159/000366387
   Currie GP, 2005, QJM INT J MED, V98, P171, DOI 10.1093/qjmed/hci024
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   Guo X, 2018, ARTIF CELL NANOMED B, V30, P1
   Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000
   Hayashi M, 2010, BIOCHEM BIOPH RES CO, V393, P432, DOI 10.1016/j.bbrc.2010.02.013
   Henderson WR, 2006, AM J RESP CRIT CARE, V173, P718, DOI 10.1164/rccm.200501 088OC
   Ihn HJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122635
   Kadono Y, 2005, EMBO REP, V6, P171, DOI 10.1038/sj.embor.7400345
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kim DC, 2006, J IMMUNOL, V176, P4440, DOI 10.4049/jimmunol.176.7.4440
   Kim MS, 2010, J BIOL CHEM, V285, P6913, DOI 10.1074/jbc.M109.051557
   Kim WS, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 11246 5
   Kim YG, 2015, J DENT RES, V94, P1243, DOI 10.1177/0022034515592592
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Liu M, 2015, ALLERGOL INT, V64, P17, DOI 10.1016/j.alit.2014.09.001
   Park JH, 2017, MOL CELLS, V40, P706
   Peters Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371
   Plotkin LI, 2006, BONE, V39, P443, DOI 10.1016/j.bone.2006.02.060
   Rezaei Sadabady R, 2016, ARTIF CELL NANOMED B, V44, P128, DOI 10.3109/21691401.2014.926456
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tsai M. K., 2017, J ASTHMA, V11, P1
   Walsh MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00511
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Xiong JH, 2012, J BONE MINER RES, V27, P499, DOI 10.1002/jbmr.1547
   Zhao R, 2011, J PHARM PHARMACOL, V63, P550, DOI 10.1111/j.2042 7158.2010.01238.x
NR 32
TC 17
Z9 17
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2169 1401
EI 2169 141X
J9 ARTIF CELL NANOMED B
JI Artif. Cell. Nanomed. Biotechnol.
PY 2018
VL 46
SU 3
BP S64
EP S70
DI 10.1080/21691401.2018.1489264
PG 7
WC Biotechnology & Applied Microbiology; Engineering, Biomedical; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering; Materials Science
GA HN4GH
UT WOS:000460141900006
PM 30183378
OA Bronze
DA 2025 08 17
ER

PT J
AU Zhao, M
   Ko, SY
   Garrett, IR
   Mundy, GR
   Gutierrez, GE
   Edwards, JR
AF Zhao, Ming
   Ko, Seon Yle
   Garrett, I. Ross
   Mundy, Gregory R.
   Gutierrez, Gloria E.
   Edwards, James R.
TI The polyphenol resveratrol promotes skeletal growth in mice through a
   sirtuin 1 bone morphogenic protein 2 longevity axis
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
ID NITRIC OXIDE SYNTHASE; BONE FORMATION; DONOR NITROGLYCERIN; EXPRESSION;
   ACTIVATION; TRANSCRIPTION; REGULATOR; ISOFORMS; PROTECTS; DEFECTS
AB BACKGROUND AND PURPOSE
   The polyphenol resveratrol (RSV) exists in high quantities in certain foods (e.g. grapes and nuts). However, the capacity of RSV to confer physiological health benefits and a biological mechanism through which this might occur remains unclear.
   EXPERIMENTAL APPROACH
   Aged, RSV treated (300 mg.kg( 1).day( 1)) and genetically modified [endothelial NOS (eNOS( / ))] female mice were assessed using histomorphometric and mu CT analysis. Alongside in vivo analysis, molecular siRNA knockdown and pharmacological manipulation of eNOS, BMP2 and sirtuin 1 (SIRT1) and functional cellular assays in an osteoblast cell line panel, explored the mechanism through which RSV might impact overall bone volume.
   KEY RESULTS
   RSV promoted osteoblast activity and bone growth in vivo. RSV dose dependently and simultaneously increased alkaline phosphatase (ALP) and eNOS levels. Similarly, NO donor treatment increased ALP, runt homology transcription factor 2, BMP2 and stimulated bone formation, whilst eNOS deficient mice displayed a bone loss phenotype. Moreover, RSV induced increase in ALP and BMP2 expression was blocked in eNOS( / ) osteoblasts and by BMP inhibitor noggin. The longevity linked SIRT1 enzyme was positively regulated by RSV and SIRT1 deletion reduced eNOS, BMP2 and ALP. Like eNOS deletion, loss of SIRT1 blocked RSV induced osteoblast activity; however, SIRT1 levels remained unchanged in eNOS( / ) mice, indicating RSV activation of SIRT1 stimulates BMP2 release via eNOS. This signalling axis is supported by decreased SIRT1, eNOS and BMP2 confirmed in old versus young bone.
   CONCLUSIONS AND IMPLICATIONS
   These findings suggest a new mechanism of action in bone remodelling and the ageing skeleton, where RSV positively impacts bone homeostasis via SIRT1 activation of BMP2.
C1 [Zhao, Ming] Tulane Univ, Sch Med, 1430 Tulane Ave, New Orleans, LA 70112 USA.
   [Ko, Seon Yle] Dankook Univ, Sch Dent, Cheonan, South Korea.
   [Garrett, I. Ross; Mundy, Gregory R.; Gutierrez, Gloria E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
   [Garrett, I. Ross; Mundy, Gregory R.; Gutierrez, Gloria E.] OsteoScreen Inc, San Antonio, TX USA.
   [Edwards, James R.] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Botnar Res Ctr, Oxford OX3 7LD, England.
C3 Tulane University; Dankook University; University of Texas System;
   University of Texas Health Science Center at San Antonio; University of
   Oxford
RP Edwards, JR (通讯作者)，Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Botnar Res Ctr, Oxford OX3 7LD, England.
EM james.edwards@ndorms.ox.ac.uk
RI Zhao, Mingduo/NMK 6268 2025
FU ERC Marie Sklodowska Curie Scheme (Ageing Skeleton Fellowship);
   Arthritis Research UK [20631]; National Centre for the Replacement,
   Refinement and Reduction of Animals in Research (NC3Rs) [NC/M000133/1]
   Funding Source: researchfish; Versus Arthritis [20631] Funding Source:
   researchfish
FX We are grateful to Dr Stephen Harris, University of Texas Health Science
   Centre at San Antonio, USA, for use of the 2T3 osteoblast cell line, and
   funding support to J.R.E. from the ERC Marie Sklodowska Curie Scheme
   (Ageing Skeleton Fellowship)
   (http://ec.europa.eu/research/mariecurieactions/) and Arthritis Research
   UK (20631) (http://www.arthritisresearchuk.org/) for their support of
   this work.
CR Aguirre J, 2001, AM J PATHOL, V158, P247, DOI 10.1016/S0002 9440(10)63963 6
   Alexander SPH, 2017, BRIT J PHARMACOL, V174, pS272, DOI [10.1111/bph.13882, 10.1111/bph.13877]
   [Anonymous], PRIMER METABOLIC BON
   Bartell SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4773
   Bellaver B, 2015, NEUROCHEM RES, V40, P1600, DOI 10.1007/s11064 015 1636 8
   Berman AY, 2017, NPJ PRECIS ONCOL, V1, DOI 10.1038/s41698 017 0038 6
   Boissy P, 2005, CANCER RES, V65, P9943, DOI 10.1158/0008 5472.CAN 05 0651
   Borra MT, 2005, J BIOL CHEM, V280, P17187, DOI 10.1074/jbc.M501250200
   Breen DM, 2012, ATHEROSCLEROSIS, V222, P375, DOI 10.1016/j.atherosclerosis.2012.03.021
   Chen MH, 2015, MOD RHEUMATOL, V25, P913, DOI 10.3109/14397595.2015.1029221
   Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100
   Cohen Kfir E, 2011, ENDOCRINOLOGY, V152, P4514, DOI 10.1210/en.2011 1128
   Conte E, 2015, HISTOL HISTOPATHOL, V30, P523, DOI 10.14670/HH 30.523
   Corbett SA, 1999, J BONE JOINT SURG BR, V81B, P531, DOI 10.1302/0301 620X.81B3.8852
   Csiszar A, 2006, AM J PATHOL, V168, P629, DOI 10.2353/ajpath.2006.050284
   Curtis MJ, 2015, BRIT J PHARMACOL, V172, P3461, DOI 10.1111/bph.12856
   Diwan AD, 2000, J BONE MINER RES, V15, P342, DOI 10.1359/jbmr.2000.15.2.342
   Edwards JR, 2013, J BONE MINER RES, V28, P960, DOI 10.1002/jbmr.1824
   Harding SD, 2018, NUCLEIC ACIDS RES, V46, pD1091, DOI 10.1093/nar/gkx1121
   Helfrich MH, 1997, J BONE MINER RES, V12, P1108, DOI 10.1359/jbmr.1997.12.7.1108
   Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960
   Huang TT, 2014, INNATE IMMUN LONDON, V20, P735, DOI 10.1177/1753425913507096
   Hukkanen M, 2003, BONE, V32, P142, DOI 10.1016/S8756 3282(02)00955 9
   Iyer S, 2014, J BIOL CHEM, V289, P24069, DOI 10.1074/jbc.M114.561803
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412
   Kim HN, 2015, MOL ENDOCRINOL, V29, P1498, DOI 10.1210/me.2015 1133
   Kupisiewicz K, 2010, CALCIFIED TISSUE INT, V87, P437, DOI 10.1007/s00223 010 9399 3
   Lin CH, 2018, J CELL MOL MED, V22, P786, DOI 10.1111/jcmm.13356
   MacPherson H, 1999, BONE, V24, P179, DOI 10.1016/S8756 3282(98)00173 2
   Mandal CC, 2011, BIOCHEM J, V433, P393, DOI 10.1042/BJ20100357
   Mattagajasingh I, 2007, P NATL ACAD SCI USA, V104, P14855, DOI 10.1073/pnas.0704329104
   Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728
   Ota H, 2007, J MOL CELL CARDIOL, V43, P571, DOI 10.1016/j.yjmcc.2007.08.008
   Sahni S, 2015, CURR OSTEOPOROS REP, V13, P245, DOI 10.1007/s11914 015 0272 1
   Salminen A, 2008, BIOESSAYS, V30, P939, DOI 10.1002/bies.20799
   Samuels A, 2001, BONE, V29, P24, DOI 10.1016/S8756 3282(01)00471 9
   Shakibaei M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035712
   Shakibaei M, 2011, J BIOL CHEM, V286, P11492, DOI 10.1074/jbc.M110.198713
   Sin TK, 2015, J PHYSIOL LONDON, V593, P1887, DOI 10.1113/jphysiol.2014.270101
   Sin TK, 2015, CELL PHYSIOL BIOCHEM, V35, P541, DOI 10.1159/000369718
   Smoliga JM, 2011, MOL NUTR FOOD RES, V55, P1129, DOI 10.1002/mnfr.201100143
   Su JL, 2007, J BIOL CHEM, V282, P19385, DOI 10.1074/jbc.M702452200
   Szkudelski T, 2015, BBA MOL BASIS DIS, V1852, P1145, DOI 10.1016/j.bbadis.2014.10.013
   Tomé Carneiro J, 2013, CURR PHARM DESIGN, V19, P6064, DOI 10.2174/13816128113199990407
   Truong VL, 2018, BIOFACTORS, V44, P36, DOI 10.1002/biof.1399
   Turner CH, 1996, AM J PHYSIOL ENDOC M, V270, pE634, DOI 10.1152/ajpendo.1996.270.4.E634
   Voronov I, 2005, BIOCHEM PHARMACOL, V70, P300, DOI 10.1016/j.bcp.2005.04.028
   Wallerath T, 2002, CIRCULATION, V106, P1652, DOI 10.1161/01.CIR.0000029925.18593.5C
   Wang XW, 2017, EXP THER MED, V14, P5032, DOI 10.3892/etm.2017.5147
   Wimalawansa SJ, 1997, BONE, V21, P275, DOI 10.1016/S8756 3282(97)00125 7
   Xia N, 2013, NITRIC OXIDE BIOL CH, V32, P29, DOI 10.1016/j.niox.2013.04.001
   Zayzafoon M, 2006, J CELL BIOCHEM, V97, P56, DOI 10.1002/jcb.20675
   Zhang JQ, 2013, J NUTR BIOCHEM, V24, P629, DOI 10.1016/j.jnutbio.2012.02.015
   Zhou HB, 2009, EXP CELL RES, V315, P2953, DOI 10.1016/j.yexcr.2009.07.030
NR 56
TC 30
Z9 33
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0007 1188
EI 1476 5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD NOV
PY 2018
VL 175
IS 21
SI SI
BP 4183
EP 4192
DI 10.1111/bph.14477
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GW3RH
UT WOS:000446824000015
PM 30125963
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Guo, L
   Zhen, QL
   Zhen, XY
   Cui, ZY
   Jiang, C
   Zhang, Q
   Gao, K
   Luan, DH
   Zhou, XC
AF Guo, Ling
   Zhen, Qingliu
   Zhen, Xiaoyue
   Cui, Zhaoyang
   Jiang, Chao
   Zhang, Qiang
   Gao, Kun
   Luan, Deheng
   Zhou, Xuanchen
TI A network pharmacology approach to explore and validate the potential
   targets of ginsenoside on osteoporosis
SO INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
LA English
DT Article
DE Ginsenoside; osteoporosis; network pharmacology; enrichment analysis;
   validation
ID DISEASE; DIFFERENTIATION; MECHANISMS; PATHWAY; GENES
AB Background: Osteoporosis (OP) is determined as a chronic systemic bone disorder to increase the susceptibility to fracture. Ginsenosides have been found the anti osteoporotic activity of in vivo and in vitro. However, its mechanism remains unknown.Methods: The potential mechanism of ginsenosides in anti osteoporotic activity was identified by using network phamacology analysis. The active compounds of ginsenosides and their targets associated to OP were retrieved from Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform, Drug Bank, Pharmmapper, and Cytoscape. The Gene ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis target genes were performed in String, Phenopedia, DisGeNET database, and Metascape software. The protein to protein interaction were created by String database and Cytoscape software. The molecular docking was used to investigate the interactions between active coumpounds and potential targets by utilizing SwissDock tool, UCSF Chimera, and Pymol software. Results: A total of eight important active ingredients and 17 potential targets related to OP treatment were subjected to analyze. GO analysis showed the anti osteoporosis targets of ginsenoside mainly play a role in the response to steroid hormone. KEGG enrichment analysis indicated that ginsenoside treats OP by osteoblast differentiation signal pathway. Lastly, the molecular docking outcomes indicated that ginsenoside rh2 had a good binding ability with four target proteins IL1B, TNF, IFNG, and NFKBIA. Conclusion: IL1B, TNF, IFNG, and NFKBIA are the most important targets and osteoblast differentiation is the most valuable signaling pathways in ginsenoside for the treatment of OP, which might be beneficial to elucidate the mechanism concerned to the action of ginsenoside and might supply a better understanding of its anti OP effects.
C1 [Guo, Ling; Cui, Zhaoyang; Jiang, Chao; Zhang, Qiang; Gao, Kun; Luan, Deheng; Zhou, Xuanchen] Shandong First Med Univ, Dept Otorhinolaryngol Head & Neck Surg, Shandong Prov Hosp, 324 Jingwu Rd, Jinan 250021, Peoples R China.
   [Zhen, Qingliu] Shandong First Med Univ, Dept Anesthesiol, Shandong Prov Hosp, Jinan, Peoples R China.
   [Zhen, Xiaoyue] Shandong First Med Univ, Minimally Invas Urol Ctr, Shandong Prov Hosp, Jinan, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical
   Sciences; Shandong First Medical University & Shandong Academy of
   Medical Sciences; Shandong First Medical University & Shandong Academy
   of Medical Sciences
RP Luan, DH; Zhou, XC (通讯作者)，Shandong First Med Univ, Dept Otorhinolaryngol Head & Neck Surg, Shandong Prov Hosp, 324 Jingwu Rd, Jinan 250021, Peoples R China.
EM rename2004@163.com; xuanchenzhou@163.com
RI Zhang, Qiang/GXF 3105 2022; cui, zhaoyang/AAH 7527 2019; Zhou,
   Xuanchen/GXG 0014 2022
FU Key Technology Research and Development Program of Shandong
   [2019GSF108257, 2018GSF118192]; Shandong Provincial Medical and Health
   Science and Technology Development Project [2019WS500]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This
   present study was supported by funds from the Key Technology Research
   and Development Program of Shandong (grant no. 2019GSF108257 and
   2018GSF118192) and Shandong Provincial Medical and Health Science and
   Technology Development Project (2019WS500). Funding agencies have no
   role in research design or manuscript writing.
CR An YA, 2019, FASEB J, V33, P12515, DOI 10.1096/fj.201802805RR
   Aouidate A, 2021, J BIOMOL STRUCT DYN, V39, P4522, DOI 10.1080/07391102.2020.1779130
   Bardou P, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471 2105 15 293
   Bitencourt Ferreira G, 2019, METHODS MOL BIOL, V2053, P189, DOI 10.1007/978 1 4939 9752 7_12
   Chen C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222313170
   Chen YQ, 2020, CURR MOL MED, V20, P220, DOI 10.2174/1566524019666191011160543
   Chen Y, 2020, J ETHNOPHARMACOL, V257, DOI 10.1016/j.jep.2020.112834
   Chotiyarnwong P, 2020, NAT REV ENDOCRINOL, V16, P437, DOI 10.1038/s41574 020 0341 0
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cong F, 2017, BIOMED PHARMACOTHER, V92, P927, DOI 10.1016/j.biopha.2017.05.115
   Gao B, 2015, STEM CELLS DEV, V24, P781, DOI 10.1089/scd.2014.0367
   Gore S, 2017, STRUCTURE, V25, P1916, DOI 10.1016/j.str.2017.10.009
   Huang CC, 2014, NUCLEIC ACIDS RES, V42, pW478, DOI 10.1093/nar/gku377
   Jin WQ, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109676
   Kar S, 2017, CURR DRUG METAB, V18, P1106, DOI 10.2174/1389200218666170607102104
   Kim YA, 2013, OSTEOPOROSIS INT, V24, P2603, DOI 10.1007/s00198 013 2354 1
   Liu L, 2020, HUM GENET, V139, P1023, DOI 10.1007/s00439 020 02155 1
   Liu WJ, 2020, J ETHNOPHARMACOL, V257, DOI 10.1016/j.jep.2020.112871
   Lu XJ, 2020, NUCLEIC ACIDS RES, V48, DOI 10.1093/nar/gkaa426
   Luo WJ, 2017, NUCLEIC ACIDS RES, V45, pW501, DOI 10.1093/nar/gkx372
   Manolagas SC, 2013, J CLIN INVEST, V123, P1919, DOI 10.1172/JCI68062
   Piñero J, 2020, NUCLEIC ACIDS RES, V48, pD845, DOI 10.1093/nar/gkz1021
   Reimand J, 2019, NAT PROTOC, V14, P482, DOI 10.1038/s41596 018 0103 9
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Schidlitzki A, 2020, NEUROBIOL DIS, V134, DOI 10.1016/j.nbd.2019.104664
   Schousboe JT, 2016, J CLIN DENSITOM, V19, P8, DOI 10.1016/j.jocd.2015.08.004
   Shehzad O, 2013, ANAL BIOANAL CHEM, V405, P4523, DOI 10.1007/s00216 012 6609 z
   Shen S, 2019, J CELL BIOCHEM, V120, P10069, DOI 10.1002/jcb.28290
   Song M, 2020, BIOL TRACE ELEM RES, V198, P557, DOI 10.1007/s12011 020 02089 9
   Sun B, 2016, HISTOL HISTOPATHOL, V31, P647, DOI 10.14670/HH 11 702
   Sun J, 2019, BIOMED PHARMACOTHER, V109, P254, DOI 10.1016/j.biopha.2018.09.002
   Sun MM, 2020, MOLECULES, V25, DOI 10.3390/molecules25204815
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Tang XY, 2020, J CHROMATOGR SCI, V58, P494, DOI 10.1093/chromsci/bmaa012
   Wen Y, 2016, OSTEOPOROSIS INT, V27, P1041, DOI 10.1007/s00198 015 3364 y
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Xu XX, 2018, DRUG DES DEV THER, V12, P967, DOI 10.2147/DDDT.S161904
   Yang LL, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20122974
   Yu W, 2010, BIOINFORMATICS, V26, P145, DOI 10.1093/bioinformatics/btp618
   Zeng ZZ, 2022, BIOMED PHARMACOTHER, V145, DOI 10.1016/j.biopha.2021.112086
   Zhai X, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00348
   Zhang J, 2020, CURR OPIN RHEUMATOL, V32, P387, DOI 10.1097/BOR.0000000000000722
   Zhang XN, 2016, CHEM BIOL INTERACT, V256, P188, DOI 10.1016/j.cbi.2016.07.003
   Zhou W, 2018, J GINSENG RES, V42, P199, DOI 10.1016/j.jgr.2017.03.004
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
NR 45
TC 3
Z9 3
U1 0
U2 22
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0394 6320
EI 2058 7384
J9 INT J IMMUNOPATH PH
JI Int. J. Immunopathol. Pharmacol.
PD JUN
PY 2022
VL 36
AR 03946320221107239
DI 10.1177/03946320221107239
PG 14
WC Immunology; Pathology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pathology; Pharmacology & Pharmacy
GA 3A8NK
UT WOS:000827510900001
PM 35791093
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Dishowitz, MI
   Zhu, FC
   Sundararaghavan, HG
   Ifkovits, JL
   Burdick, JA
   Hankenson, KD
AF Dishowitz, Michael I.
   Zhu, Fengchang
   Sundararaghavan, Harini G.
   Ifkovits, Jamie L.
   Burdick, Jason A.
   Hankenson, Kurt D.
TI Jagged1 immobilization to an osteoconductive polymer activates the Notch
   signaling pathway and induces osteogenesis
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE Notch signaling; osteoblast differentiation; Jagged1; osteoinduction;
   translational medicine
ID ALAGILLE SYNDROME; OSTEOBLAST DIFFERENTIATION; CELL DIFFERENTIATION;
   FUTURE DIRECTIONS; BONE REGENERATION; FRACTURES; PROLIFERATION;
   MUTATIONS; INTERFACE; CHILDREN
AB Treatment of nonunion fractures is a significant problem. Common therapeutics, including autologous bone grafts and bone morphogenetic proteins, show well established limitations. Therefore, a need persists for the identification of novel clinical therapies to promote healing. The Notch signaling pathway regulates bone development. Clinically, loss of function mutations to the Notch ligand Jagged1 decrease bone mass and increase fracture risk. Jagged1 is also the most highly upregulated ligand during fracture repair, identifying it as a potential target to promote bone formation. Therefore, the objective of this study was to develop a clinically translatable construct comprised of Jagged1 and an osteoconductive scaffold, and characterize its activity in human mesenchymal stem cells (hMSC). We first evaluated the effects of Jagged1 directly immobilized to a novel poly(beta amino ester) relative to indirect coupling via antibody. Direct was more effective at activating hMSC Notch target gene expression and osteogenic activity. We then found that directly immobilized Jagged1 constructs induced osteoblast differentiation. This is the first study to demonstrate that Jagged1 delivery transiently activates Notch signaling and increases osteogenesis. A positive correlation was found between Jagged1 induced Notch and osteogenic expression. Collectively, these results indicate that Jagged1 coupled to an osteogenic biomaterial could promote bone tissue formation during fracture healing. (c) 2013 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 102A: 1558 1567, 2014.
C1 [Dishowitz, Michael I.; Sundararaghavan, Harini G.; Ifkovits, Jamie L.; Burdick, Jason A.] Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA.
   [Zhu, Fengchang; Hankenson, Kurt D.] Univ Penn, Sch Vet Med, Dept Clin Studies, New Bolton Ctr, Philadelphia, PA 19104 USA.
   [Hankenson, Kurt D.] Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; University of Pennsylvania; University of
   Pennsylvania
RP Hankenson, KD (通讯作者)，311 Hill Pavilion,380 S Univ Ave, Philadelphia, PA 19103 USA.
EM kdhank@vet.upenn.edu
RI Burdick, Jason/JTD 2254 2023; Hankenson, Kurt/ABI 1547 2020
OI Hankenson, Kurt/0000 0001 6361 143X; 
FU Congressionally Directed Medical Research Program [W81XWH 10 1 0825];
   Osteosynthesis and Trauma Care Foundation, the Penn Center for
   Musculoskeletal Disorders [NIH/NIAMS P30 AR050950]; Ruth L. Kirschstein
   National Research Service Award [NIH/NIDCR F31DE020231]
FX Contract grant sponsor: Congressionally Directed Medical Research
   Program; contract grant number: W81XWH 10 1 0825Contract grant sponsor:
   Osteosynthesis and Trauma Care Foundation, the Penn Center for
   Musculoskeletal Disorders; contract grant number: NIH/NIAMS P30
   AR050950Contract grant sponsor: Ruth L. Kirschstein National Research
   Service Award; contract grant number: NIH/NIDCR F31DE020231
CR Anderson DG, 2006, ADV MATER, V18, P2614, DOI 10.1002/adma.200600529
   Audigé L, 2005, CLIN ORTHOP RELAT R, P221, DOI 10.1097/01.blo.0000163836.66906.74
   Bales CB, 2010, J PEDIATR GASTR NUTR, V51, P66, DOI 10.1097/MPG.0b013e3181cb9629
   Beckstead BL, 2006, J BIOMED MATER RES A, V79A, P94, DOI 10.1002/jbm.a.30760
   Beckstead BL, 2009, J BIOMED MATER RES A, V91A, P436, DOI 10.1002/jbm.a.32214
   Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025
   Braithwaite RS, 2003, J AM GERIATR SOC, V51, P364, DOI 10.1046/j.1532 5415.2003.51110.x
   Brey DM, 2010, J BIOMED MATER RES A, V93A, P807, DOI 10.1002/jbm.a.32769
   Carragee EJ, 2011, SPINE J, V11, P695, DOI 10.1016/j.spinee.2011.08.418
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Dishowitz MI, 2012, J ORTHOP RES, V30, P296, DOI 10.1002/jor.21518
   Dong YF, 2010, DEVELOPMENT, V137, P1461, DOI 10.1242/dev.042911
   Engin FZ, 2008, NAT MED, V14, P299, DOI 10.1038/nm1712
   Friedlaender GE, 2001, J BONE JOINT SURG AM, V83A, pS151
   Gonçalves RM, 2009, BIOMATERIALS, V30, P6879, DOI 10.1016/j.biomaterials.2009.09.010
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623 200212000 00001
   Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716
   Kohn A, 2012, DEVELOPMENT, V139, P1198, DOI 10.1242/dev.070649
   Kramer H, 2000, Sci STKE, V2000, ppe1, DOI 10.1126/stke.2000.29.pe1
   Kwon SM, 2008, CIRCULATION, V118, P157, DOI 10.1161/CIRCULATIONAHA.107.754978
   Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797 243
   Mead TJ, 2009, P NATL ACAD SCI USA, V106, P14420, DOI 10.1073/pnas.0902306106
   Nobta M, 2005, J BIOL CHEM, V280, P15842, DOI 10.1074/jbc.M412891200
   Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797 235
   Oldershaw RA, 2008, STEM CELLS, V26, P666, DOI 10.1634/stemcells.2007 0806
   Olsen IE, 2005, J PEDIATR GASTR NUTR, V40, P76, DOI 10.1097/00005176 200501000 00014
   Osathanon T, 2013, J BIOMED MATER RES A, V101, P358, DOI 10.1002/jbm.a.34332
   Salie R, 2010, BONE, V46, P680, DOI 10.1016/j.bone.2009.10.022
   Sekine C, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3758
   Tao JN, 2010, J BONE MINER RES, V25, P2175, DOI 10.1002/jbmr.115
   Tezuka K, 2002, J BONE MINER RES, V17, P231, DOI 10.1359/jbmr.2002.17.2.231
   Vas V, 2004, J LEUKOCYTE BIOL, V75, P714, DOI 10.1189/jlb.1003462
   Zanotti S, 2008, ENDOCRINOLOGY, V149, P3890, DOI 10.1210/en.2008 0140
   Zhu FC, 2013, STEM CELLS, V31, P1181, DOI 10.1002/stem.1353
NR 34
TC 50
Z9 57
U1 0
U2 17
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1549 3296
EI 1552 4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD MAY
PY 2014
VL 102
IS 5
BP 1558
EP 1567
DI 10.1002/jbm.a.34825
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA AD4JB
UT WOS:000333215600037
PM 23775982
DA 2025 08 17
ER

PT J
AU Yoon, HJ
   Seo, CR
   Kim, M
   Kim, YJ
   Song, NJ
   Jang, WS
   Kim, BJ
   Lee, J
   Hong, JW
   Nho, CW
   Park, KW
AF Yoon, Hyang Jin
   Seo, Cho Rong
   Kim, MiAe
   Kim, Young Jun
   Song, No Joon
   Jang, Woo Seok
   Kim, Byung Joon
   Lee, JaeHwan
   Hong, Joung Woo
   Nho, Chu Won
   Park, Kye Won
TI Dichloromethane extracts of Sophora japonica L. stimulate
   osteoblast differentiation in mesenchymal stem cells
SO NUTRITION RESEARCH
LA English
DT Article
DE Sophora japonica; Osteoclast; Osteoblast; Genistein; Alkaline
   phosphatase; Bone marrow cells
ID ESTROGEN RECEPTOR; HORMONE THERAPY; BREAST CANCER; BONE; GENISTEIN;
   FRUCTUS; OSTEOPOROSIS; ISOFLAVONES; INHIBITION; BIOLOGY
AB Sophora japonica L. fruit prevents bone loss by inhibiting osteoclast activity. We hypothesized that S japonica L. extracts could promote osteoblast differentiation. To test this hypothesis, we investigated the effect of S japonica L. on osteoblast differentiation and identified the bioactive compound(s) from S japonica L. The mature fruit of S japonica L. was partitioned with ethanol, hexane, dichloromethane (DCM), ethyl acetate, and butanol, and their effects were tested on osteoblast differentiation of C3H10T1/2 cells. DCM fractionated extracts were identified as the most osteogenic fractions. DCM fractionated extracts dose dependently stimulated alkaline phosphatase activity and matrix mineralization. The DCM fractions also induced expression of osteoblast markers such as alkaline phosphatase, osterix, and osteocalcin in C3H10T1/2 and primary bone marrow cells. Genistein was found abundantly in the DCM fractions. Furthermore, the genistein and DCM fractions similarly modulated the expression of estrogen target genes and were both active in transfection assays that measured estrogen agonistic activity. Finally, pharmacological inhibition by treatment with an estrogen receptor antagonist or specific inhibition of gene expression by small interference RNAs targeted to estrogen receptor p abolished the effects of the DCM extracts, further supporting the idea that the genistein in the DCM extracts mediated the pro osteogenic effects. Taken together, we identified genistein as the key phytoestrogen responsible for the effects of S japonica L. on osteoblast differentiation. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Yoon, Hyang Jin; Seo, Cho Rong; Song, No Joon; Jang, Woo Seok; Lee, JaeHwan; Park, Kye Won] Sungkyunkwan Univ, Dept Food Sci & Biotechnol, Suwon 440746, South Korea.
   [Kim, MiAe; Nho, Chu Won] Korea Inst Sci & Technol, Gangneung Inst, Funct Food Ctr, Gangwon Do 210340, South Korea.
   [Kim, Young Jun] Seoul Natl Univ, Dept Agr Biotechnol, WCU Biomodulat Major, Seoul 151921, South Korea.
   [Kim, Byung Joon] Gachon Univ Med & Sci, Grad Sch Med, Dept Internal Med, Inchon 406799, South Korea.
   [Hong, Joung Woo] Kyung Hee Univ, Grad Sch East West Med Sci, Yongin 446701, South Korea.
C3 Sungkyunkwan University (SKKU); Korea Institute of Science & Technology
   (KIST); Seoul National University (SNU); Gachon University; Kyung Hee
   University
RP Park, KW (通讯作者)，Sungkyunkwan Univ, Dept Food Sci & Biotechnol, Suwon 440746, South Korea.
EM kwpark@skku.edu
RI Hong, Joung Woo/AAG 1173 2021; Lee, JaeHwan/B 3223 2010
OI Hong, Joung Woo/0000 0001 6511 7881; Park, Kye Won/0000 0003 2771 249X; 
FU Korea Healthcare Technology R & D Project, Ministry for Health, Welfare,
   and Family Affairs, Republic of Korea [A101711]; High Value added Food
   Technology Development Program through the iPET (Korea Institute of
   Planning and Evaluation for Technology in Food, Agriculture, Forestry
   and Fisheries)
FX This study was supported by a grant from the Korea Healthcare Technology
   R & D Project, Ministry for Health, Welfare, and Family Affairs,
   Republic of Korea (A101711). This study was also supported by the High
   Value added Food Technology Development Program through the iPET (Korea
   Institute of Planning and Evaluation for Technology in Food,
   Agriculture, Forestry and Fisheries).
CR Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   Bums KA, 2012, ARCH TOXICOL, V86, P1491
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Chu QC, 2005, BIOMED CHROMATOGR, V19, P149, DOI 10.1002/bmc.431
   Clark James H, 2006, Nucl Recept Signal, V4, pe023
   El Halawany AM, 2010, PHARM BIOL, V48, P177, DOI 10.3109/13880200903062663
   Gao YH, 1999, BIOL PHARM BULL, V22, P805, DOI 10.1248/bpb.22.805
   Gimble JM, 2012, CLIN BIOCHEM, V45, P874, DOI 10.1016/j.clinbiochem.2012.03.006
   Heim M, 2004, ENDOCRINOLOGY, V145, P848, DOI 10.1210/en.2003 1014
   Heino TJ, 2008, CURR STEM CELL RES T, V3, P131, DOI 10.2174/157488808784223032
   Hsieh CY, 1998, CANCER RES, V58, P3833
   Ishimi Y, 2000, BIOCHEM BIOPH RES CO, V274, P697, DOI 10.1006/bbrc.2000.3175
   Jia TL, 2003, BIOCHEM PHARMACOL, V65, P709, DOI 10.1016/S0006 2952(02)01585 X
   Joo SS, 2004, ARCH PHARM RES, V27, P99, DOI 10.1007/BF02980054
   Joo SS, 2003, ARCH PHARM RES, V26, P1029, DOI 10.1007/BF02994754
   Jung SR, 2011, J MED FOOD, V14, P360, DOI 10.1089/jmf.2010.1324
   Karas RH, 2004, CLIN OBSTET GYNECOL, V47, P489, DOI 10.1097/00003081 200406000 00024
   Kite GC, 2009, PHYTOCHEMISTRY, V70, P785, DOI 10.1016/j.phytochem.2009.04.003
   Lecka Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097 4644(19990901)74:3<357::AID JCB5>3.0.CO;2 7
   Lee J, 2010, ARCH PHARM RES, V33, P523, DOI 10.1007/s12272 010 0405 0
   Lin CY, 2004, GENOME BIOL, V5, DOI 10.1186/gb 2004 5 9 r66
   Manolagas SC, 1998, AGING CLIN EXP RES, V10, P182, DOI 10.1007/BF03339652
   Park HJ, 2008, J MED FOOD, V11, P773, DOI 10.1089/jmf.2008.0077
   Park KW, 2009, MOL CELL BIOL, V29, P3905, DOI 10.1128/MCB.00002 09
   Park KW, 2008, CELL METAB, V8, P454, DOI 10.1016/j.cmet.2008.11.001
   Rayalam S, 2011, J NUTR BIOCHEM, V22, P1099, DOI 10.1016/j.jnutbio.2010.11.009
   Reid IR, 2008, SEMIN CELL DEV BIOL, V19, P473, DOI 10.1016/j.semcdb.2008.08.002
   Robertson JFR, 2001, J STEROID BIOCHEM, V79, P209, DOI 10.1016/S0960 0760(01)00138 8
   Shim JG, 2005, ARCH PHARM RES, V28, P106, DOI 10.1007/BF02975144
   Simons R, 2012, FOOD FUNCT, V3, P810, DOI 10.1039/c2fo10290k
   Sims NA, 2008, SEMIN CELL DEV BIOL, V19, P444, DOI 10.1016/j.semcdb.2008.07.016
   Soleimani S, 2009, J CONTAM HYDROL, V106, P39, DOI 10.1016/j.jconhyd.2008.12.007
   Sugimoto E, 2000, INT J MOL MED, V5, P515
   Tang Weici., 1992, CHINESE DRUGS PLANT
   Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829
   Turgeon JL, 2004, SCIENCE, V304, P1269, DOI 10.1126/science.1096725
   Umetani M, 2007, NAT MED, V13, P1185, DOI 10.1038/nm1641
   Veronesi F, 2011, CRIT REV EUKAR GENE, V21, P363, DOI 10.1615/CritRevEukarGeneExpr.v21.i4.60
   Wang TTY, 1996, CARCINOGENESIS, V17, P271, DOI 10.1093/carcin/17.2.271
   Zhang Y., 2008, Inflammopharmacology, V16, P213, DOI 10.1007/s10787 008 8018 7
NR 40
TC 28
Z9 29
U1 0
U2 24
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0271 5317
J9 NUTR RES
JI Nutr. Res.
PD DEC
PY 2013
VL 33
IS 12
BP 1053
EP 1062
DI 10.1016/j.nutres.2013.08.004
PG 10
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA 266GW
UT WOS:000328013100009
PM 24267045
DA 2025 08 17
ER

PT J
AU Canon, J
   Bryant, R
   Roudier, M
   Osgood, T
   Jones, J
   Miller, R
   Coxon, A
   Radinsky, R
   Dougall, WC
AF Canon, Jude
   Bryant, Rebecca
   Roudier, Martine
   Osgood, Tao
   Jones, Jon
   Miller, Robert
   Coxon, Angela
   Radinsky, Robert
   Dougall, William C.
TI Inhibition of RANKL increases the anti tumor effect of the EGFR
   inhibitor panitumumab in a murine model of bone metastasis
SO BONE
LA English
DT Article
DE RANK ligand; Panitumumab; Bone metastasis; Osteoprotegerin; Osteolysis
ID RECEPTOR MONOCLONAL ANTIBODY; SKELETAL TUMOR BURDEN; BREAST CANCER;
   OSTEOCLAST DIFFERENTIATION; ABX EGF; IMPROVES SURVIVAL; OSTEOPROTEGERIN;
   GROWTH; LIGAND; ACTIVATION
AB Bone metastases cause severe skeletal complications and are associated with osteoclast mediated bone destruction. RANKL is essential for osteoclast formation, function, and survival, and is the primary effector of tumor induced osteoclastogenesis and osteolysis. RANKL inhibition by its soluble decoy receptor osteoprotegerin (OPG) prevents tumor induced osteolysis and decreases skeletal tumor burden. Because osteoclast mediated bone resorption releases growth factors from the bone matrix, the host bone microenvironment induces a vicious cycle of bone destruction and tumor proliferation and survival. A prediction of this vicious cycle hypothesis is that targeting the host bone microenvironment by osteoclast inhibition would reduce tumor growth and survival and may enhance the anti tumor effects of targeted therapies. The epidermal growth factor receptor (EGER) pathway regulates critical processes such as cell growth and survival, and anti EGFR therapies can cause tumor cell arrest and apoptosis. We evaluated whether reduction of osteolysis by RANKL inhibition could enhance the anti tumor effects of an anti EGFR antibody (panitumumab) in a novel murine model of human A431 epidermoid carcinoma bone metastasis. Skeletal tumor progression was assessed longitudinally by bioluminescence imaging. RANKL inhibition by OPG Fc treatment resulted in a reduction in tumor progression in bony sites. OPG Fc treatment also caused a dose dependent reduction in tumor induced osteolysis, supporting the essential role of RANKL in this process. In combination, RANKL inhibition increased the anti tumor efficacy of an anti EGFR antibody, and completely blocked tumor induced bone breakdown, demonstrating that addition of the indirect anti tumor effect of RANKL inhibition increases the anti tumor efficacy of panitumumab, a targeted anti EGFR antibody. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Canon, Jude; Bryant, Rebecca; Osgood, Tao; Coxon, Angela; Radinsky, Robert] Amgen Inc, Dept Oncol Res, Thousand Oaks, CA 91320 USA.
   [Roudier, Martine] Amgen Inc, Dept Pathol, Seattle, WA USA.
   [Jones, Jon; Miller, Robert; Dougall, William C.] Amgen Inc, Dept Oncol Res, Seattle, WA USA.
C3 Amgen; Amgen; Amgen
RP Canon, J (通讯作者)，Amgen Inc, Dept Oncol Res, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.
EM jcanon@amgen.com
OI Dougall, William/0000 0001 9487 251X
CR Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bruns CJ, 2000, CLIN CANCER RES, V6, P1936
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Canon JR, 2008, CLIN EXP METASTAS, V25, P119, DOI 10.1007/s10585 007 9127 1
   Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463 8471.1998
   Feeley BT, 2006, J BONE MINER RES, V21, P1571, DOI 10.1359/JBMR.060706
   Foon KA, 2004, INT J RADIAT ONCOL, V58, P984, DOI 10.1016/j.ijrobp.2003.09.098
   Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18
   Hirata A, 2002, CANCER RES, V62, P2554
   Ignatoski KMW, 2008, PROSTATE, V68, P820, DOI 10.1002/pros.20744
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lynch DH, 2002, SEMIN ONCOL, V29, P47, DOI 10.1053/sonc.2002.31522
   MCDORMAN K, 2004, AACR 95 ANN M P S, V45
   Miller R, 2005, J BONE MINER RES, V20, pS117
   Miller RE, 2008, MOL CANCER THER, V7, P2160, DOI 10.1158/1535 7163.MCT 08 0046
   Morony S, 2000, J BONE MINER RES, V15, pS209
   Morony S, 2001, CANCER RES, V61, P4432
   Nemeth JA, 2002, J NATL CANCER I, V94, P17
   Normanno N, 2005, ENDOCR RELAT CANCER, V12, P471, DOI 10.1677/erc.1.00956
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Yang XD, 2001, CRIT REV ONCOL HEMAT, V38, P17, DOI 10.1016/S1040 8428(00)00134 7
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
   Zheng Y, 2007, CANCER RES, V67, P9542, DOI 10.1158/0008 5472.CAN 07 1046
   Zheng Y, 2007, BONE, V40, P471, DOI 10.1016/j.bone.2006.09.016
   Zhu J, 2007, J BIOL CHEM, V282, P26656, DOI 10.1074/jbc.M705064200
NR 28
TC 31
Z9 35
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
J9 BONE
JI Bone
PD JUN
PY 2010
VL 46
IS 6
BP 1613
EP 1619
DI 10.1016/j.bone.2010.03.001
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 607EF
UT WOS:000278481000017
PM 20215062
DA 2025 08 17
ER

PT J
AU Na, S
   TruongVo, T
   Jiang, FF
   Joll, JE
   Guo, YX
   Utreja, A
   Chen, J
AF Na, Sungsoo
   TruongVo, ThucNhi
   Jiang, Feifei
   Joll, Jeffery E.
   Guo, Yunxia
   Utreja, Achint
   Chen, Jie
TI Dose analysis of photobiomodulation therapy on osteoblast, osteoclast,
   and osteocyte
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE photobiomodulation; osteoblast; osteocyte; osteoclast; cell viability;
   proliferation; differentiation; light dose
ID LOW LEVEL LASER; ORTHODONTIC TOOTH MOVEMENT; RAPID MAXILLARY EXPANSION;
   IRRADIATION PROMOTES; SIGNALING PATHWAY; BONE REGENERATION; ROOT
   RESORPTION; PROLIFERATION; RATS; CELLS
AB The objective of this study was to evaluate the effects of varying light doses on the viability and cellular activity of osteoblasts, osteocytes, and osteoclasts. A light application device was developed to apply 940 nm wavelength light from light emitting diodes on three cultured cells, MC3T3 E1, MLO A5, and RANKL treated RAW264.7 cells. The doses (energy density) on cells were 0, 1, 5, and 7.5 J/cm(2). The corresponding light power densities at the cell site were 0, 1.67, 8.33, and 12.5 mW/cm(2), respectively, and the duration was 10 min. The results showed that the three cell types respond differently to light and their responses were dose dependent. Low dose treatment (1 J/cm(2)) enhanced osteoblast proliferation, osteoclast differentiation, and osteoclastic bone resorption activity. Osteocyte proliferation was not affected by both low  and high dose (5 J/cm(2)) treatments. While 1 J/cm(2) did not affect viability of all three cell types, 5 J/cm(2) significantly decreased viability of osteocytes and osteoclasts. Osteoblast viability was negatively impacted by the higher dose (7.5 J/cm(2)). The findings suggest that optimal doses exist for osteoblast and osteoclast, which can stimulate cell activities, and there is a safe dose range for each type of cell tested. (C) 2018 Society of Photo Optical Instrumentation Engineers (SPIE).
C1 [Na, Sungsoo; TruongVo, ThucNhi; Joll, Jeffery E.; Guo, Yunxia] Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.
   [Jiang, Feifei; Chen, Jie] Indiana Univ Purdue Univ, Dept Mech Engn, Indianapolis, IN 46202 USA.
   [Utreja, Achint; Chen, Jie] Indiana Univ Purdue Univ, Dept Orthodont & Oral Facial Genet, Indianapolis, IN 46202 USA.
C3 Purdue University System; Purdue University; Purdue University in
   Indianapolis; Purdue University System; Purdue University; Purdue
   University in Indianapolis; Purdue University System; Purdue University;
   Purdue University in Indianapolis
RP Chen, J (通讯作者)，Indiana Univ Purdue Univ, Dept Mech Engn, Indianapolis, IN 46202 USA.; Chen, J (通讯作者)，Indiana Univ Purdue Univ, Dept Orthodont & Oral Facial Genet, Indianapolis, IN 46202 USA.
EM jchen3@iupui.edu
RI Utreja, Achint/Q 9535 2019
FU Ormco, Orange County, California
FX This work was supported by the Ormco, Orange County, California. We
   thank Bo Sun for his technical assistance.
CR Aihara N, 2006, LASER MED SCI, V21, P24, DOI 10.1007/s10103 005 0368 4
   Altan BA, 2012, LASER MED SCI, V27, P131, DOI 10.1007/s10103 010 0853 2
   Angeletti P, 2010, ORAL SURG ORAL MED O, V109, pE38, DOI 10.1016/j.tripleo.2009.10.043
   Barbosa D, 2014, ACTA ORTOP BRAS, V22, P71, DOI 10.1590/1413 78522014220200438
   Bloise N, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.12.128006
   Cepera F, 2012, AM J ORTHOD DENTOFAC, V141, P444, DOI 10.1016/j.ajodo.2011.10.023
   Collin Osdoby P, 2012, METHODS MOL BIOL, V816, P187, DOI 10.1007/978 1 61779 415 5_13
   Sousa MVD, 2011, PHOTOMED LASER SURG, V29, P191, DOI 10.1089/pho.2009.2652
   Dickerson Todd E, 2017, J Clin Orthod, V51, P157
   Dogan GE, 2014, PHOTOMED LASER SURG, V32, P226, DOI 10.1089/pho.2013.3664
   Doshi Mehta G, 2012, AM J ORTHOD DENTOFAC, V141, P289, DOI 10.1016/j.ajodo.2011.09.009
   Ekizer A, 2016, LASER SURG MED, V48, P936, DOI 10.1002/lsm.22516
   Ekizer A, 2015, LASER MED SCI, V30, P779, DOI 10.1007/s10103 013 1405 3
   Fazilat F, 2014, PHOTOMED LASER SURG, V32, P315, DOI 10.1089/pho.2013.3559
   Fonseca PD, 2013, LASER MED SCI, V28, P49, DOI 10.1007/s10103 012 1061 z
   Franzen TJ, 2015, EUR J ORTHODONT, V37, P111, DOI 10.1093/ejo/cju053
   Gao XJ, 2006, J CELL PHYSIOL, V206, P441, DOI 10.1002/jcp.20484
   Gao XJ, 2009, J BIOMED SCI, V16, DOI 10.1186/1423 0127 16 4
   Han K. H., 2014, J ORAL MAXILLOFAC SU, V72
   Jawad MM, 2014, LASER MED SCI, V29, P367, DOI 10.1007/s10103 012 1199 8
   Kansal Ankur, 2014, Dent Res J (Isfahan), V11, P481
   Li QS, 2017, LASER MED SCI, V32, P1489, DOI 10.1007/s10103 017 2269 8
   Medina Huertas R, 2014, LASER MED SCI, V29, P1479, DOI 10.1007/s10103 014 1557 9
   Migliario M, 2014, LASER MED SCI, V29, P1463, DOI 10.1007/s10103 014 1556 x
   Milligan M, 2017, ARCH ORAL BIOL, V80, P62, DOI 10.1016/j.archoralbio.2017.03.016
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   Rosser J, 2012, METHODS MOL BIOL, V816, P67, DOI 10.1007/978 1 61779 415 5_6
   Seifi Massoud, 2014, Dent Res J (Isfahan), V11, P61
   Shefer G, 2001, J CELL PHYSIOL, V187, P73, DOI 10.1002/1097 4652(2001)9999:9999<::AID JCP1053>3.0.CO;2 9
   Shirazi M, 2015, LASER MED SCI, V30, P713, DOI 10.1007/s10103 013 1407 1
   Tim CR, 2014, LASER MED SCI, V29, P147, DOI 10.1007/s10103 013 1302 9
   Üretürk SE, 2017, LASER MED SCI, V32, P757, DOI 10.1007/s10103 017 2159 0
   Wu JY, 2013, INT J ORAL SCI, V5, P85, DOI 10.1038/ijos.2013.38
   Yi J, 2017, J ORAL REHABIL, V44, P636, DOI 10.1111/joor.12509
   Zhang JT, 2008, J CELL PHYSIOL, V217, P518, DOI 10.1002/jcp.21529
   Zhang LL, 2009, J CELL PHYSIOL, V219, P553, DOI 10.1002/jcp.21697
NR 36
TC 23
Z9 23
U1 1
U2 23
PU SPIE SOC PHOTO OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083 3668
EI 1560 2281
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD JUL
PY 2018
VL 23
IS 7
AR 075008
DI 10.1117/1.JBO.23.7.075008
PG 8
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA GP7FF
UT WOS:000441058300020
PM 30030913
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Drudge Coates, L
   Turner, B
AF Drudge Coates, Lawrence
   Turner, Bruce
TI Bone micro environment in prostate cancer: impact, treatment and
   implications for nursing practice
SO INTERNATIONAL JOURNAL OF UROLOGICAL NURSING
LA English
DT Article
DE Androgen deprivation therapy; Bone metastases; Denosumab; Prostate
   cancer; RANK ligand; Skeletal related events
ID ANDROGEN DEPRIVATION THERAPY; SKELETAL RELATED EVENTS; QUALITY OF LIFE;
   ZOLEDRONIC ACID; BREAST CANCER; SOLID TUMORS; LUNG CANCER; METASTASES;
   MEN; OSTEOPOROSIS
AB Prostate cancer is a substantial worldwide health care challenge. The disease is associated with detrimental effects on bone remodelling, mediated by the RANK/RANK ligand (RANKL) system. Androgen deprivation therapy (ADT) causes an imbalance in regular bone turnover, resulting in bone loss [cancer treatment induced bone loss (CTIBL)]. As prostate cancer progresses, bone metastases may develop, leading to a vicious cycle of increased bone turnover and tumour growth. In both cases, patients have reduced quality of life and an increased risk of fracture. However, data show that subcutaneous denosumab, a human monoclonal antibody that targets RANKL, is superior to the intravenous bisphosphonate zoledronic acid in delaying the onset of skeletal related events (SREs) and has a favourable safety profile in terms of nephrotoxicity and acute phase reactions. Urology nurse practitioners, as members of multidisciplinary teams, have an important role to play in assessing and helping to manage patients with bone related disease in prostate cancer. In this review, an overview of prostate cancer related bone disease is provided. Currently available pharmacological interventions for the different stages of the disease are discussed, and implications for urological nursing practice are suggested.
C1 [Drudge Coates, Lawrence] NHS Fdn Hosp Trust, Univ London Kings Coll Hosp, Dept Urol, London SE5 9RS, England.
   [Turner, Bruce] Homerton Univ Hosp, Dept Urol, London E9 6SR, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital;
   University of London; King's College London; University of London; Queen
   Mary University London
RP Drudge Coates, L (通讯作者)，NHS Fdn Hosp Trust, Univ London Kings Coll Hosp, Dept Urol, Denmark Hill, London SE5 9RS, England.
EM ldrudge coates@nhs.net
CR Alibhai SMH, 2010, J UROLOGY, V184, P918, DOI 10.1016/j.juro.2010.04.068
   Beheshti M, 2009, SEMIN NUCL MED, V39, P396, DOI 10.1053/j.semnuclmed.2009.05.003
   Beltran H, 2011, EUR UROL, V60, P279, DOI 10.1016/j.eururo.2011.04.038
   Benton MJ, 2006, J COMMUN HEALTH NURS, V23, P201, DOI 10.1207/s15327655jchn2304_1
   Berenson JR, 2006, CANCER BIOL THER, V5, P1078, DOI 10.4161/cbt.5.9.3306
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown JE, 2010, BJU INT, V105, P1042, DOI 10.1111/j.1464 410X.2010.09251.x
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Burkiewicz JS, 2009, ANN PHARMACOTHER, V43, P1445, DOI 10.1345/aph.1M102
   CANCERMondial, 2008, INT AG RES CANC WEB
   Cappuccio M, 2010, EUR REV MED PHARMACO, V14, P407
   Casimiro S, 2009, MOL CELL ENDOCRINOL, V310, P71, DOI 10.1016/j.mce.2009.07.004
   Coleman RE, 2008, CLIN CANCER RES, V14, P6387, DOI 10.1158/1078 0432.CCR 08 1572
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Daniell HW, 2000, J UROLOGY, V163, P181, DOI 10.1016/S0022 5347(05)68000 7
   Diamond T, 1998, CANCER, V83, P1561, DOI 10.1002/(SICI)1097 0142(19981015)83:8<1561::AID CNCR11>3.0.CO;2 Z
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Drudge Coates Lawrence, 2005, Br J Nurs, V14, P368
   Ebeling PR, 2008, NEW ENGL J MED, V358, P1474, DOI 10.1056/NEJMcp0707217
   European Association of Urology, 2010, GUID PROST CANC
   European Medicines Agency, 2010, PROL DEN SUMM PROD C
   European Medicines Agency, 2009, ZOM ZOL AC SUMM PROD
   Ferlay J, 2010, EUR J CANCER, V46, P765, DOI 10.1016/j.ejca.2009.12.014
   Fine Perry G, 2004, J Support Oncol, V2, P5
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Jemal A, 2009, CA CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Jimenez Andrade JM, 2010, ANN NY ACAD SCI, V1198, P173, DOI 10.1111/j.1749 6632.2009.05429.x
   Kanis JA, 2008, OSTEOPOROSIS INT, V19, P385, DOI 10.1007/s00198 007 0543 5
   Kim Howard S, 2010, Curr Opin Support Palliat Care, V4, P147, DOI 10.1097/SPC.0b013e32833bd913
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   Leder BZ, 2003, J CLIN ENDOCR METAB, V88, P204, DOI 10.1210/jc.2002 021036
   Lipton Allan, 2007, Support Cancer Ther, V4, P92, DOI 10.3816/SCT.2007.n.003
   Martin TJ, 2008, BEST PRACT RES CL EN, V22, P701, DOI 10.1016/j.beem.2008.07.006
   Michaelson MD, 2004, CLIN CANCER RES, V10, P2705, DOI 10.1158/1078 0432.CCR 03 0735
   Muir VJ, 2010, BIODRUGS, V24, P379, DOI 10.2165/11203310 000000000 00000
   Neville Webbe HL, 2010, EUR J CANCER, V46, P1211, DOI 10.1016/j.ejca.2010.02.041
   Novartis Pharmaceuticals Corporation, 2009, ZOM ZOL AC PRESCR IN
   Oades GM, 2002, PROSTATE CANCER P D, V5, P264, DOI 10.1038/sj.pcan.4500607
   Olson Karin, 2007, J Oncol Pharm Pract, V13, P223, DOI 10.1177/1078155207080806
   Ortega C, 2007, ACTA ONCOL, V46, P664, DOI 10.1080/02841860601185917
   Pinski J, 2005, EUR J CANCER, V41, P932, DOI 10.1016/j.ejca.2004.12.026
   Pockett RD, 2010, EUR J CANCER CARE, V19, P755, DOI 10.1111/j.1365 2354.2009.01135.x
   Polascik TJ, 2008, DRUG DES DEV THER, V3, P27
   Roato I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003627
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Ruggiero SL, 2011, ANN NY ACAD SCI, V1218, P38, DOI 10.1111/j.1749 6632.2010.05768.x
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Saylor PJ, 2010, PROSTATE CANCER P D, V13, P20, DOI 10.1038/pcan.2009.50
   Saylor PJ, 2010, J UROLOGY, V183, P2200, DOI 10.1016/j.juro.2010.02.022
   Saylor PJ, 2010, J NATL COMPR CANC NE, V8, P211, DOI 10.6004/jnccn.2010.0014
   Shahinian VB, 2005, NEW ENGL J MED, V352, P154, DOI 10.1056/NEJMoa041943
   Smith MR, 2009, J UROLOGY, V182, P2670, DOI 10.1016/j.juro.2009.08.048
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Sullivan PW, 2007, QUAL LIFE RES, V16, P571, DOI 10.1007/s11136 006 9156 2
   Tchekmedyian NS, 2010, CANCER INVEST, V28, P849, DOI 10.3109/07357907.2010.483508
   Terpos E, 2009, EXPERT OPIN BIOL TH, V9, P465, DOI [10.1517/14712590902845610, 10.1517/14712590902845610 ]
   Turner B, 2009, INT J UROL NURS, V3, P93, DOI 10.1111/j.1749 771X.2009.01078.x
   Wadhwa VK, 2009, BJU INT, V104, P800, DOI 10.1111/j.1464 410X.2009.08483.x
   Weinfurt KP, 2005, ANN ONCOL, V16, P579, DOI 10.1093/annonc/mdi122
   Wright HL, 2009, CURR REV MUSCULOSKE, V2, P56, DOI 10.1007/s12178 009 9046 7
   Yuen KK, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006250
NR 64
TC 0
Z9 0
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1749 7701
EI 1749 771X
J9 INT J UROL NURS
JI Int. J. Urol. Nurs.
PD JUL
PY 2012
VL 6
IS 2
BP 83
EP 90
DI 10.1111/j.1749 771X.2012.01148.x
PG 8
WC Nursing; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Nursing; Urology & Nephrology
GA 956ZV
UT WOS:000305129100007
DA 2025 08 17
ER

PT J
AU Van Camp, J
   Beckers, S
   Zegers, D
   Van Hul, W
AF Van Camp, J. K.
   Beckers, S.
   Zegers, D.
   Van Hul, W.
TI Wnt Signaling and the Control of Human Stem Cell Fate
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article
DE Wnt; Human; Embryonic stem cells; Adult stem cells; Canonical;
   Noncanonical
ID RECEPTOR RELATED PROTEIN 5; CANONICAL WNT/BETA CATENIN; GENE EXPRESSION
   SIGNATURE; TYROSINE KINASE ROR2; HUMAN ADIPOSE TISSUE; BETA CATENIN;
   SELF RENEWAL; MOLECULAR CLONING; BONE MASS; PROGENITOR CELLS
AB Wnt signaling determines major developmental processes in the embryonic state and regulates maintenance, self renewal and differentiation of adult mammalian tissue stem cells. Both beta catenin dependent and independent Wnt pathways exist, and both affect stem cell fate in developing and adult tissues. In this review, we debate the response to Wnt signal activation in embryonic stem cells and human, adult stem cells of mesenchymal, hematopoetic, intestinal, gastric, epidermal, mammary and neural lineages, and discuss the need for Wnt signaling in these cell types. Due to the vital actions of Wnt signaling in developmental and maintenance processes, deregulation of the pathway can culminate into a broad spectrum of developmental and genetic diseases, including cancer. The way in which Wnt signals can feed tumors and maintain cancer stem stells is discussed as well. Manipulation of Wnt signals both in vivo and in vitro thus carries potential for therapeutic approaches such as tissue engineering for regenerative medicine and anti cancer treatment. Although many questions remain regarding the complete Wnt signal cell type specific response and interplay of Wnt signaling with pathways such as BMP, Hedgehog and Notch, we hereby provide an overview of current knowledge on Wnt signaling and its control over human stem cell fate.
C1 [Van Camp, J. K.; Beckers, S.; Zegers, D.; Van Hul, W.] Univ Antwerp, Dept Med Genet, Prins Boudewijnlaan 43, B 2650 Antwerp, Belgium.
RP Van Hul, W (通讯作者)，Univ Antwerp, Dept Med Genet, Prins Boudewijnlaan 43, B 2650 Antwerp, Belgium.
EM wim.vanhul@uantwerpen.be
RI ; Beckers, Stefan/O 2943 2019
OI Van Hul, Wim/0000 0002 5065 7858; 
CR Abed É, 2011, ARTHRITIS RHEUM US, V63, P3865, DOI 10.1002/art.30625
   Adachi K, 2007, STEM CELLS, V25, P2827, DOI 10.1634/stemcells.2007 0177
   Adaimy L, 2007, AM J HUM GENET, V81, P821, DOI 10.1086/520064
   Agalliu D, 2009, NEURON, V61, P708, DOI 10.1016/j.neuron.2008.12.026
   Ahumada A, 2002, SCIENCE, V298, P2006, DOI 10.1126/science.1073776
   Ai M, 2005, MOL CELL BIOL, V25, P4946, DOI 10.1128/MCB.25.12.4946 4955.2005
   Alkelai A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029228
   Andreu P, 2005, DEVELOPMENT, V132, P1443, DOI 10.1242/dev.01700
   Andreu P, 2008, DEV BIOL, V324, P288, DOI 10.1016/j.ydbio.2008.09.027
   Anton R, 2007, FEBS LETT, V581, P5247, DOI 10.1016/j.febslet.2007.10.012
   Archbold HC, 2012, ACTA PHYSIOL, V204, P74, DOI 10.1111/j.1748 1716.2011.02293.x
   Assou S, 2007, STEM CELLS, V25, P961, DOI 10.1634/stemcells.2006 0352
   Baksh D, 2007, J CELL PHYSIOL, V212, P817, DOI 10.1002/jcp.21080
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Balemans W, 2008, CALCIFIED TISSUE INT, V82, P445, DOI 10.1007/s00223 008 9130 9
   Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013
   Barrilleaux B, 2006, TISSUE ENG, V12, P3007, DOI 10.1089/ten.2006.12.3007
   Bartscherer K, 2006, CELL, V125, P523, DOI 10.1016/j.cell.2006.04.009
   Bazhin AV, 2010, CELL MOL LIFE SCI, V67, P817, DOI 10.1007/s00018 009 0214 0
   Beattie GM, 2005, STEM CELLS, V23, P489, DOI 10.1634/stemcells.2004 0279
   Bejsovec A, 2000, CURR BIOL, V10, pR919, DOI 10.1016/S0960 9822(00)00852 6
   Ben Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200
   Bergstein I, 1997, GENOMICS, V46, P450, DOI 10.1006/geno.1997.5041
   Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0
   Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792
   Biason Lauber A, 2004, NEW ENGL J MED, V351, P792, DOI 10.1056/NEJMoa040533
   Binnerts ME, 2007, P NATL ACAD SCI USA, V104, P14700, DOI 10.1073/pnas.0702305104
   Blattner A, 2010, AM J MED GENET A, V152A, P2053, DOI 10.1002/ajmg.a.33504
   Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003 0498
   Bone HK, 2011, J CELL SCI, V124, P1992, DOI 10.1242/jcs.081679
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020
   Brack AS, 2008, CELL STEM CELL, V2, P50, DOI 10.1016/j.stem.2007.10.006
   Bradley EW, 2011, J CELL PHYSIOL, V226, P1683, DOI 10.1002/jcp.22499
   BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857
   Brantjes H, 2001, NUCLEIC ACIDS RES, V29, P1410, DOI 10.1093/nar/29.7.1410
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Brynczka C, 2008, DIFFERENTIATION, V76, P795, DOI 10.1111/j.1432 0436.2007.00261.x
   Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471 4914(01)02016 0
   Caricasole A, 2004, J NEUROSCI, V24, P6021, DOI 10.1523/JNEUROSCI.1381 04.2004
   Carmon KS, 2008, MOL CANCER RES, V6, P1017, DOI 10.1158/1541 7786.MCR 08 0039
   Carmon KS, 2008, BIOCHEM BIOPH RES CO, V368, P285, DOI 10.1016/j.bbrc.2008.01.088
   Carmon KS, 2010, ANAL BIOCHEM, V401, P288, DOI 10.1016/j.ab.2010.03.009
   Carroll TJ, 2005, DEV CELL, V9, P283, DOI 10.1016/j.devcel.2005.05.016
   Castelo Branco GA, 2003, P NATL ACAD SCI USA, V100, P12747, DOI 10.1073/pnas.1534900100
   Cawthorn WP, 2012, BONE, V50, P477, DOI 10.1016/j.bone.2011.08.010
   Choi HY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007930
   CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012 1606(91)90073 C
   CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13
   Christodoulides C, 2006, DIABETOLOGIA, V49, P678, DOI 10.1007/s00125 006 0144 4
   Christodoulides C, 2006, J CELL SCI, V119, P2613, DOI 10.1242/jcs.02975
   CLARK CC, 1993, GENOMICS, V18, P249, DOI 10.1006/geno.1993.1463
   Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008 5472.CAN 06 3126
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Costa AG, 2012, CURR OSTEOPOROS REP, V10, P64, DOI 10.1007/s11914 011 0089 5
   Cui DH, 2005, MOL PSYCHIATR, V10, P669, DOI 10.1038/sj.mp.4001653
   Dahéron L, 2004, STEM CELLS, V22, P770, DOI 10.1634/stemcells.22 5 770
   Dalton S, 2013, CURR OPIN CELL BIOL, V25, P241, DOI 10.1016/j.ceb.2012.09.005
   Davidson KC, 2012, P NATL ACAD SCI USA, V109, P4485, DOI 10.1073/pnas.1118777109
   de Lau W, 2011, NATURE, V476, P293, DOI 10.1038/nature10337
   DEOME KB, 1959, CANCER RES, V19, P515
   Dickins EM, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00162
   Dierick HA, 1998, DEVELOPMENT, V125, P4729
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Dunlap KA, 2011, BIOL REPROD, V85, P386, DOI 10.1095/biolreprod.111.091769
   Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101
   Etheridge SL, 2004, STEM CELLS, V22, P849, DOI 10.1634/stemcells.22 5 849
   Eyler CE, 2008, J CLIN ONCOL, V26, P2839, DOI 10.1200/JCO.2007.15.1829
   Fear MW, 2000, BIOCHEM BIOPH RES CO, V278, P814, DOI 10.1006/bbrc.2000.3852
   Fevr T, 2007, MOL CELL BIOL, V27, P7551, DOI 10.1128/MCB.01034 07
   Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770
   Fleming HE, 2008, CELL STEM CELL, V2, P274, DOI 10.1016/j.stem.2008.01.003
   Fotaki V, 2010, DEV DYNAM, V239, P284, DOI 10.1002/dvdy.22137
   Friedenstein AJ., 1988, CIBA F SYMP, P42
   Friedman MS, 2009, J BIOL CHEM, V284, P14117, DOI 10.1074/jbc.M808337200
   FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337
   Gang E.J., 2013, Oncogene
   Garlid KD, 1998, FEBS LETT, V438, P10, DOI 10.1016/S0014 5793(98)01246 0
   Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092 8674(00)81631 1
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gazit A, 1999, ONCOGENE, V18, P5959, DOI 10.1038/sj.onc.1202985
   Glinka A, 2011, EMBO REP, V12, P1055, DOI 10.1038/embor.2011.175
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Goss AM, 2009, DEV CELL, V17, P290, DOI 10.1016/j.devcel.2009.06.005
   Green D, 2003, TISSUE ENG, V9, P1159, DOI 10.1089/10763270360728062
   Gunhaga L, 2003, NAT NEUROSCI, V6, P701, DOI 10.1038/nn1068
   Hagen T, 2004, BIOCHEM J, V379, P471, DOI 10.1042/BJ20031749
   Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092 8674(00)80689 3
   Hansen T, 2011, BIOL PSYCHIAT, V70, P59, DOI 10.1016/j.biopsych.2011.01.031
   Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019
   Hardiman G, 1997, CYTOGENET CELL GENET, V77, P278, DOI 10.1159/000134597
   Hasegawa K, 2012, STEM CELL TRANSL MED, V1, P18, DOI 10.5966/sctm.2011 0033
   Hay DC, 2008, P NATL ACAD SCI USA, V105, P12301, DOI 10.1073/pnas.0806522105
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117
   He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652
   Herz J, 2009, J LIPID RES, V50, pS287, DOI 10.1194/jlr.R800077 JLR200
   Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Hong L, 2005, ANN BIOMED ENG, V33, P511, DOI 10.1007/s10439 005 2510 7
   Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899
   Hsu SY, 1998, MOL ENDOCRINOL, V12, P1830, DOI 10.1210/me.12.12.1830
   Hu WJ, 2013, J CLIN ENDOCR METAB, V98, P290, DOI 10.1210/jc.2012 2466
   Hu Z., 2013, DIABETES RESEARCH AN
   Hübner R, 2010, BIOCHEM BIOPH RES CO, V400, P358, DOI 10.1016/j.bbrc.2010.08.066
   Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567
   HUGUET EL, 1994, CANCER RES, V54, P2615
   Hwang YS, 2009, P NATL ACAD SCI USA, V106, P16978, DOI 10.1073/pnas.0905550106
   Ikegawa S, 1996, CYTOGENET CELL GENET, V74, P149, DOI 10.1159/000134404
   Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131 139.2003
   Jaks V, 2008, NAT GENET, V40, P1291, DOI 10.1038/ng.239
   Jeays Ward K, 2004, DEV BIOL, V276, P431, DOI 10.1016/j.ydbio.2004.08.049
   Kanazawa A, 2005, BIOCHEM BIOPH RES CO, V330, P505, DOI 10.1016/j.bbrc.2005.03.007
   Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200
   Karasawa T, 2002, J BIOL CHEM, V277, P37479, DOI 10.1074/jbc.M205658200
   Karner CM, 2009, NAT GENET, V41, P793, DOI 10.1038/ng.400
   Katoh M, 2001, BIOCHEM BIOPH RES CO, V289, P1093, DOI 10.1006/bbrc.2001.6076
   Katoh M, 1996, ONCOGENE, V13, P873
   Kawasaki A, 2007, CELL SIGNAL, V19, P2498, DOI 10.1016/j.cellsig.2007.07.023
   Kim KA, 2005, SCIENCE, V309, P1256, DOI 10.1126/science.1112521
   Kim KA, 2008, MOL BIOL CELL, V19, P2588, DOI 10.1091/mbc.E08 02 0187
   Kim M, 2008, J HEPATOL, V48, P780, DOI 10.1016/j.jhep.2007.12.020
   Kirikoshi H, 2001, INT J ONCOL, V19, P779
   Kirikoshi H, 2001, BIOCHEM BIOPH RES CO, V283, P798, DOI 10.1006/bbrc.2001.4855
   Kishimoto M, 2008, BEHAV BRAIN FUNCT, V4, DOI 10.1186/1744 9081 4 37
   Kobune M, 2007, MOL CANCER THER, V6, P1774, DOI 10.1158/1535 7163.MCT 06 0684
   Koch U, 2010, SEMIN CANCER BIOL, V20, P116, DOI 10.1016/j.semcancer.2010.02.003
   Köhler T, 1999, STEM CELLS, V17, P19, DOI 10.1002/stem.170019
   Kohn AD, 2005, CELL CALCIUM, V38, P439, DOI 10.1016/j.ceca.2005.06.022
   KOLLER MR, 1992, ANN NY ACAD SCI, V665, P105, DOI 10.1111/j.1749 6632.1992.tb42578.x
   Kongkanuntn R, 1999, ONCOGENE, V18, P7219, DOI 10.1038/sj.onc.1203181
   Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270
   Kosinski C, 2007, P NATL ACAD SCI USA, V104, P15418, DOI 10.1073/pnas.0707210104
   Kühl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701
   LaBarge MA, 2010, CLIN CANCER RES, V16, P3121, DOI 10.1158/1078 0432.CCR 09 2933
   Laine CM, 2013, NEW ENGL J MED, V368, P1809, DOI 10.1056/NEJMoa1215458
   Lako M, 1998, HUM MOL GENET, V7, P813, DOI 10.1093/hmg/7.5.813
   Lako M, 1998, GENE, V219, P101, DOI 10.1016/S0378 1119(98)00393 X
   Lathia JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024807
   Le Grand F, 2009, CELL STEM CELL, V4, P535, DOI 10.1016/j.stem.2009.03.013
   Lee HK, 2012, DEV CELL, V22, P183, DOI 10.1016/j.devcel.2011.10.025
   Lee SMK, 2000, DEVELOPMENT, V127, P457
   Leupin O, 2011, J BIOL CHEM, V286, P19489, DOI 10.1074/jbc.M110.190330
   Li FQ, 2008, J CELL BIOL, V181, P1141, DOI 10.1083/jcb.200709091
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XF, 2005, NAT GENET, V37, P945, DOI 10.1038/ng1614
   Li YH, 2011, CLIN EXP DERMATOL, V36, P534, DOI 10.1111/j.1365 2230.2011.04019.x
   Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108
   Lim XH, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008029
   Lin ZH, 2008, J BIOL CHEM, V283, P33053, DOI 10.1074/jbc.M804039200
   Lindvall C, 2006, J BIOL CHEM, V281, P35081, DOI 10.1074/jbc.M607571200
   Lindvall C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005813
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Liu GZ, 2009, J CELL BIOL, V185, P67, DOI 10.1083/jcb.200810137
   Liu PT, 1999, NAT GENET, V22, P361, DOI 10.1038/11932
   Liu Y, 2008, J CELL BIOCHEM, V105, P497, DOI 10.1002/jcb.21848
   Longo KA, 2004, J BIOL CHEM, V279, P35503, DOI 10.1074/jbc.M402937200
   Louis I, 2008, IMMUNITY, V29, P57, DOI 10.1016/j.immuni.2008.04.023
   Lu WG, 2004, CELL, V119, P97, DOI 10.1016/j.cell.2004.09.019
   Luo S., 2013, BIOMEDICINE PHARMACO
   Ma L, 2007, J BIOL CHEM, V282, P28980, DOI 10.1074/jbc.M702840200
   Majumdar A, 2003, DEVELOPMENT, V130, P3175, DOI 10.1242/dev.00520
   Mandel H, 2008, AM J HUM GENET, V82, P39, DOI 10.1016/j.ajhg.2007.08.005
   Mao BY, 2003, GENE, V302, P179, DOI 10.1016/S0378 1119(02)01106 X
   Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097 2765(01)00224 6
   Marinaro C, 2012, CEREB CORTEX, V22, P2415, DOI 10.1093/cercor/bhr320
   Martin BL, 2012, DEV CELL, V22, P223, DOI 10.1016/j.devcel.2011.11.001
   Marui T, 2010, INT J NEUROPSYCHOPH, V13, P443, DOI 10.1017/S1461145709990903
   MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521
   Mcdonald SAC, 2008, GASTROENTEROLOGY, V134, P500, DOI 10.1053/j.gastro.2007.11.035
   MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092 8674(92)90222 X
   MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092 8674(90)90385 R
   Medina Gomez C, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002718
   Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115
   Millar JBA, 2002, GENOME BIOL, V3
   Miller C, 1998, DEVELOPMENT, V125, P3201
   Mizutani K, 2005, TUMORI J, V91, P546, DOI 10.1177/030089160509100616
   Mokhtarzada S, 2011, BIOCHEMISTRY US, V50, P715, DOI 10.1021/bi101236z
   Monkley SJ, 1996, DEVELOPMENT, V122, P3343
   MOON RT, 1993, DEVELOPMENT, V119, P97
   Morioka K, 2009, CANCER SCI, V100, P1227, DOI 10.1111/j.1349 7006.2009.01165.x
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Nam JS, 2006, J BIOL CHEM, V281, P13247, DOI 10.1074/jbc.M508324200
   Nemeth MJ, 2007, P NATL ACAD SCI USA, V104, P15436, DOI 10.1073/pnas.0704747104
   Niemann S, 2004, AM J HUM GENET, V74, P558, DOI 10.1086/382196
   Nolta JA, 2002, LEUKEMIA, V16, P352, DOI 10.1038/sj.leu.2402371
   NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092 8674(92)90630 U
   NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092 8674(82)90409 3
   Nusse R, 2008, CELL RES, V18, P523, DOI 10.1038/cr.2008.47
   O'Connor KC, 2003, BIOTECHNOL LETT, V25, P1967, DOI 10.1023/B:BILE.0000004386.08923.ab
   Ogawa K, 2006, BIOCHEM BIOPH RES CO, V343, P159, DOI 10.1016/j.bbrc.2006.02.127
   Ohyama M, 2006, J CLIN INVEST, V116, P249, DOI 10.1172/JCI26043
   Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365 2443.2003.00662.x
   Okamura M, 2009, P NATL ACAD SCI USA, V106, P5819, DOI 10.1073/pnas.0901676106
   Okoye Ujunwa C, 2008, J Mol Signal, V3, P16, DOI 10.1186/1750 2187 3 16
   Ouko L, 2004, J BIOL CHEM, V279, P26707, DOI 10.1074/jbc.M402877200
   Papkoff J, 1996, MOL CELL BIOL, V16, P2128
   Papkoff J, 1998, BIOCHEM BIOPH RES CO, V247, P851, DOI 10.1006/bbrc.1998.8888
   Park JR, 2008, CELL PROLIFERAT, V41, P859, DOI 10.1111/j.1365 2184.2008.00565.x
   Park JS, 2007, DEVELOPMENT, V134, P2533, DOI 10.1242/dev.006155
   PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0
   Parr BA, 2001, DEV BIOL, V237, P324, DOI 10.1006/dbio.2001.0373
   Parr BA, 1998, NATURE, V395, P707, DOI 10.1038/27221
   Patthy L, 2000, TRENDS BIOCHEM SCI, V25, P12, DOI 10.1016/S0968 0004(99)01504 2
   Person AD, 2010, DEV DYNAM, V239, P327, DOI 10.1002/dvdy.22156
   Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103
   Piters E, 2010, HUM MUTAT, V31, pE1526, DOI 10.1002/humu.21274
   Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052
   PROCKOP DJ, 1997, SCIENCE, V276, P71, DOI [DOI 10.1126/SCIENCE.276.5309.71, 10.1126/science.276.5309.71]
   Proitsi P, 2008, BIOL PSYCHIAT, V63, P13, DOI 10.1016/j.biopsych.2007.03.014
   Purro SA, 2012, J NEUROSCI, V32, P3492, DOI 10.1523/JNEUROSCI.4562 11.2012
   Qiu WM, 2007, J BONE MINER RES, V22, P1720, DOI 10.1359/JBMR.070721
   Qiu WM, 2011, BIOCHEM BIOPH RES CO, V413, P98, DOI 10.1016/j.bbrc.2011.08.061
   Qu F, 2013, FRONT BIOSCI LANDMRK, V18, P493, DOI 10.2741/4116
   Qu Qiuhao, 2010, Nat Cell Biol, V12, P31, DOI 10.1038/ncb2001
   Qu QH, 2013, MOL CELL BIOL, V33, P2551, DOI 10.1128/MCB.00325 13
   Rebhan M, 1997, TRENDS GENET, V13, P163, DOI 10.1016/S0168 9525(97)01103 7
   Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819
   Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593
   Reyes M, 2001, ANN NY ACAD SCI, V938, P231
   Roarty K, 2007, DEVELOPMENT, V134, P3929, DOI 10.1242/dev.008250
   Rodríguez Carballo E, 2011, J BONE MINER RES, V26, P718, DOI 10.1002/jbmr.260
   Rosen ED, 2000, GENE DEV, V14, P1293
   Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066
   ROSS SE, 2000, SCIENCE, V289, P950, DOI DOI 10.1126/SCIENCE.289.5481.950
   Saitoh T, 2001, INT J ONCOL, V19, P347
   Saitoh T, 2001, BIOCHEM BIOPH RES CO, V284, P1168, DOI 10.1006/bbrc.2001.5105
   Saneyoshi T, 2002, NATURE, V417, P295, DOI 10.1038/417295a
   Santos A, 2010, CYTOTHERAPY, V12, P924, DOI 10.3109/14653241003774011
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Sato T, 2013, SCIENCE, V340, P1190, DOI 10.1126/science.1234852
   Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637
   Schepers A, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007989
   Schlessinger K, 2007, J CELL BIOL, V178, P355, DOI 10.1083/jcb.200701083
   Schulte DM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032437
   Schulte G, 2005, J NEUROCHEM, V92, P1550, DOI 10.1111/j.1471 4159.2004.03022.x
   Shan J, 2009, GENESIS, V47, P782, DOI 10.1002/dvg.20566
   Shang YC, 2007, CYTOTHERAPY, V9, P667, DOI 10.1080/14653240701508437
   Sharma AR, 2013, INDIAN J BIOCHEM BIO, V50, P19
   Sheldahl LC, 2003, J CELL BIOL, V161, P769, DOI 10.1083/jcb.200211094
   Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960 9822(99)80310 8
   Shen LX, 2011, EXP CELL RES, V317, P1796, DOI 10.1016/j.yexcr.2011.05.018
   Shimogori T, 2004, J COMP NEUROL, V473, P496, DOI 10.1002/cne.20135
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Shu WG, 2002, DEVELOPMENT, V129, P4831
   Singh AM, 2012, CELL STEM CELL, V10, P312, DOI 10.1016/j.stem.2012.01.014
   SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267
   Sokol SY, 2011, DEVELOPMENT, V138, P4341, DOI 10.1242/dev.066209
   Sousa KM, 2010, J BIOL CHEM, V285, P7246, DOI 10.1074/jbc.M109.079822
   Später D, 2006, DEVELOPMENT, V133, P3039, DOI 10.1242/dev.02471
   Spinsanti P, 2008, J NEUROCHEM, V104, P1588, DOI 10.1111/j.1471 4159.2007.05111.x
   STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0
   Steele BM, 2012, FEBS LETT, V586, P2267, DOI 10.1016/j.febslet.2012.05.060
   Sumi T, 2008, DEVELOPMENT, V135, P2969, DOI 10.1242/dev.021121
   Sustmann C, 2008, MOL CELL BIOL, V28, P3526, DOI 10.1128/MCB.01986 07
   Tago K, 2000, GENE DEV, V14, P1741
   Takada I, 2007, ANN NY ACAD SCI, V1116, P182, DOI 10.1196/annals.1402.034
   Takada I, 2007, NAT CELL BIOL, V9, P1273, DOI 10.1038/ncb1647
   TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174
   Takemaru KI, 2003, NATURE, V422, P905, DOI 10.1038/nature01570
   Tanaka K, 2002, J BIOL CHEM, V277, P12816, DOI 10.1074/jbc.M200187200
   Teh MT, 2007, J CELL SCI, V120, P330, DOI 10.1242/jcs.03329
   Teo JL, 2010, ADV DRUG DELIVER REV, V62, P1149, DOI 10.1016/j.addr.2010.09.012
   THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0
   Timmons JA, 2007, P NATL ACAD SCI USA, V104, P4401, DOI 10.1073/pnas.0610615104
   Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123
   Tran TH, 2009, STEM CELLS, V27, P1869, DOI 10.1002/stem.95
   Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436
   Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817
   Uematsu K, 2003, CANCER RES, V63, P4547
   Ugur SA, 2008, HUM MOL GENET, V17, P2644, DOI 10.1093/hmg/ddn164
   Vaes BLT, 2005, BONE, V36, P803, DOI 10.1016/j.bone.2005.02.001
   Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068
   Vallier L, 2009, DEVELOPMENT, V136, P1339, DOI 10.1242/dev.033951
   Van Camp JK, 2012, MOL GENET METAB, V105, P489, DOI 10.1016/j.ymgme.2011.11.197
   Van Camp J. K., 2013, ENDOCRINE
   Van Camp J. K., 2012, ENDOCRINE
   Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202
   van Tienen FHJ, 2009, BIOCHEM BIOPH RES CO, V387, P207, DOI 10.1016/j.bbrc.2009.07.004
   Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277
   Verkaar F, 2009, CELL SIGNAL, V21, P22, DOI 10.1016/j.cellsig.2008.09.008
   Vertino AM, 2005, MOL BIOL CELL, V16, P2039, DOI 10.1091/mbc.E04 08 0720
   Vijayaragavan K, 2009, CELL STEM CELL, V4, P248, DOI 10.1016/j.stem.2008.12.011
   Vivante A, 2013, J AM SOC NEPHROL, V24, P550, DOI 10.1681/ASN.2012010097
   von Maltzahn J, 2012, TRENDS CELL BIOL, V22, P602, DOI 10.1016/j.tcb.2012.07.008
   von Maltzahn J, 2012, NAT CELL BIOL, V14, P186, DOI 10.1038/ncb2404
   Voskas Daniel, 2010, F1000 Biol Rep, V2, P82, DOI 10.3410/B2 82
   WAINWRIGHT BJ, 1988, EMBO J, V7, P1743, DOI 10.1002/j.1460 2075.1988.tb03003.x
   WAKITANI S, 1995, MUSCLE NERVE, V18, P1417, DOI 10.1002/mus.880181212
   Wang Q, 2013, BIOL REPROD, V88, DOI 10.1095/biolreprod.112.104687
   Wang YS, 2007, DEVELOPMENT, V134, P647, DOI 10.1242/dev.02772
   Wang ZS, 2005, MOL CELL BIOL, V25, P5022, DOI 10.1128/MCB.25.12.5022 5030.2005
   Wassink TH, 2001, AM J MED GENET, V105, P406, DOI 10.1002/ajmg.1401
   Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535 6108(02)00045 4
   Wend P, 2010, SEMIN CELL DEV BIOL, V21, P855, DOI 10.1016/j.semcdb.2010.09.004
   Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611
   Wisniewska MB, 2013, NEUROCHEM RES, V38, P1144, DOI 10.1007/s11064 013 0980 9
   Wisniewska MB, 2010, J NEUROSCI, V30, P4957, DOI 10.1523/JNEUROSCI.1425 09.2010
   Woods CG, 2006, AM J HUM GENET, V79, P402, DOI 10.1086/506332
   Xu RH, 2008, CELL STEM CELL, V3, P196, DOI 10.1016/j.stem.2008.07.001
   Yamaguchi TP, 1999, DEVELOPMENT, V126, P1211
   Yan Y, 2009, J CELL SCI, V122, P3566, DOI 10.1242/jcs.051904
   Yanai I, 2005, BIOINFORMATICS, V21, P650, DOI 10.1093/bioinformatics/bti042
   Yang JZ, 2003, BIOL PSYCHIAT, V54, P1298, DOI 10.1016/S0006 3223(03)00291 9
   Ye X, 2011, DEVELOPMENT, V138, P1161, DOI 10.1242/dev.057620
   Yoshioka S, 2012, MOL CANCER RES, V10, P469, DOI 10.1158/1541 7786.MCR 11 0177
   YOUNG LJT, 1971, EXP GERONTOL, V6, P49, DOI 10.1016/0531 5565(71)90048 9
   Yu JM, 2006, MOL CELL BIOCHEM, V288, P17, DOI 10.1007/s11010 005 9113 3
   Zeng YA, 2010, CELL STEM CELL, V6, P568, DOI 10.1016/j.stem.2010.03.020
   Zhang P, 2012, J BIOL CHEM, V287, P21290, DOI 10.1074/jbc.M112.357202
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
NR 314
TC 141
Z9 157
U1 1
U2 67
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2629 3269
EI 2629 3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
PD APR
PY 2014
VL 10
IS 2
BP 207
EP 229
DI 10.1007/s12015 013 9486 8
PG 23
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA AE6CZ
UT WOS:000334077900006
PM 24323281
DA 2025 08 17
ER

PT J
AU Song, J
   Han, S
   Choi, S
   Lee, J
   Jeong, Y
   Lee, HM
   Son, J
   Jeong, DY
   Yu, SS
   Lee, W
AF Song, Jisun
   Han, Suhyun
   Choi, Sooyeon
   Lee, Jungkyu
   Jeong, Yoonseon
   Lee, Hyun Myung
   Son, JongDai
   Jeong, Dam Yeon
   Yu, Seung Shin
   Lee, Wonwoo
TI A mixture of Pueraria lobata and Platycodon grandiflorum extracts
   ameliorates RANKL induced osteoclast differentiation and
   ovariectomy induced bone loss by regulating Src PI3K AKT and JNK/p38
   signaling pathways
SO HELIYON
LA English
DT Article
DE Pueraria lobata; Platycodon grandiflorum; Herbal extracts; Osteoclast;
   Osteoporosis
ID HORMONE REPLACEMENT THERAPY; OSTEOBLAST DIFFERENTIATION;
   PHOSPHATIDYLINOSITOL 3 KINASE; ENDOMETRIAL CANCER; ESTROGEN; P38;
   SAPONINS; KINASE; METABOLISM; RADIX
AB Osteoporosis is caused by increased bone resorption due to the excessive activity of osteoclasts. Pueraria lobata has demonstrated the ability to improve bone density in ovariectomized mice, and Platycodon grandiflorum can suppress osteolysis biomarkers such as collagen content in cartilage and alkaline phosphatase activity. In this study, we examined whether HX112, a mixture of Pueraria lobata and Platycodon grandiflorum extracts, could inhibit the receptor activator of nuclear factor kappa B (NF kappa B) ligand (RANKL) induced osteoclast differentiation to alleviate osteoporosis. To induce the differentiation of osteoclasts, RAW 264.7 cell were cultured with RANKL and HX112. Osteoclasts differentiation was evaluated by TRAP activity and TRAP staining. Bone resorption as osteoclasts major function was assessed by pit formation assay. As a result, HX112 suppressed osteoclast differentiation and bone resorptive function. Additionally, HX112 reduced the expression of osteoclastogenic genes including NFATc1 and c Fos, and these effects of HX112 were mediated by inhibiting Src phosphoinositide 3 kinase (PI3K)  Protein kinase B (Akt) and cJun N terminal kinase (JNK)/p38 signaling pathways. Furthermore, ICR mice were ovariectomized to induce osteoporosis and bone mineral density of femur was measured using micro CT. Consequently, oral administration of HX112 to ovariectomized mice significantly improved bone microstructure and bone mineral density. Collectively, these findings indicate that the mixed extract of Pueraria lobata and Platycodon grandiflorum may be useful as therapeutics for osteoporosis.
C1 [Song, Jisun; Han, Suhyun; Choi, Sooyeon; Lee, Jungkyu; Jeong, Yoonseon; Lee, Hyun Myung; Son, JongDai; Jeong, Dam Yeon; Yu, Seung Shin; Lee, Wonwoo] Helixmith Co Ltd, R&D Ctr Innovat Med, Seoul 07794, South Korea.
   [Lee, Wonwoo] Helixmith Co Ltd, Seoul 07794, South Korea.
RP Lee, W (通讯作者)，Helixmith Co Ltd, Seoul 07794, South Korea.
EM summersnow97@snu.ac.kr
FU Korea Institute of Planning and Evaluation for Technology in Food,
   Agriculture and Forestry (IPET) through Technology Commercialization
   Support Program   Ministry of Agriculture, Food and Rural Affairs
   (MAFRA) [821058 03]
FX This work was supported by Korea Institute of Planning and Evaluation
   for Technology in Food, Agriculture and Forestry (IPET) through
   Technology Commercialization Support Program, funded by Ministry of
   Agriculture, Food and Rural Affairs (MAFRA, 821058 03) .
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Blair HC, 2017, TISSUE ENG PART B RE, V23, P268, DOI [10.1089/ten.teb.2016.0454, 10.1089/ten.TEB.2016.0454]
   Blonska M, 2007, IMMUNITY, V26, P55, DOI 10.1016/j.immuni.2006.11.008
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chambers TJ, 2000, J PATHOL, V192, P4
   Chen LR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092213
   Cho HJ, 2012, PHYTOTHER RES, V26, P1864, DOI 10.1002/ptr.4669
   Clynes MA, 2020, BRIT MED BULL, V133, P105, DOI 10.1093/bmb/ldaa005
   Cranney A, 2003, CLIN GERIATR MED, V19, P361, DOI 10.1016/S0749 0690(02)00078 2
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Gao YH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082436
   Ha YW, 2006, J CHROMATOGR A, V1135, P27, DOI 10.1016/j.chroma.2006.09.015
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   HALL TJ, 1995, CALCIFIED TISSUE INT, V56, P336, DOI 10.1007/BF00318056
   Han Y, 2019, J CELL BIOCHEM, V120, P13085, DOI 10.1002/jcb.28580
   Hayman AR, 2008, AUTOIMMUNITY, V41, P218, DOI 10.1080/08916930701694667
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Ikeda F, 2008, J BONE MINER RES, V23, P907, DOI 10.1359/JBMR.080211
   Jang KJ, 2013, INT J MOL MED, V31, P1357, DOI 10.3892/ijmm.2013.1330
   Jee W. S. S., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P193
   Jeong HM, 2010, FOOD CHEM TOXICOL, V48, P3362, DOI 10.1016/j.fct.2010.09.005
   Ji Meng Xia, 2015, Chronic Dis Transl Med, V1, P9, DOI 10.1016/j.cdtm.2015.02.006
   Ji MY, 2020, FOODS, V9, DOI 10.3390/foods9020142
   Jin SE, 2012, ARCH PHARM RES, V35, P823, DOI 10.1007/s12272 012 0508 x
   Kasoha M, 2020, J CANCER RES CLIN, V146, P315, DOI 10.1007/s00432 019 03114 8
   Keung WM, 1998, PHYTOCHEMISTRY, V47, P499, DOI 10.1016/S0031 9422(97)00723 1
   Komori T, 2015, EUR J PHARMACOL, V759, P287, DOI 10.1016/j.ejphar.2015.03.028
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Lee W, 2018, J NAT PROD, V81, P1343, DOI 10.1021/acs.jnatprod.7b00927
   Lewlecki EM, 2008, OBSTET GYN CLIN N AM, V35, P301, DOI 10.1016/j.ogc.2008.03.007
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Lien LL, 1996, J CLIN PHARM THER, V21, P101, DOI 10.1111/j.1365 2710.1996.tb00008.x
   Lin CY, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1667
   Lin J, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005867
   Lorentzon M, 2015, J INTERN MED, V277, P650, DOI 10.1111/joim.12369
   Lv HH, 2015, MOL MED REP, V12, P2283, DOI 10.3892/mmr.2015.3647
   Maciejewska Turska M, 2022, MOLECULES, V27, DOI 10.3390/molecules27196227
   Mal R, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.587386
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsumoto Y, 2013, STEROIDS, V78, P513, DOI 10.1016/j.steroids.2013.02.011
   Murphy LC, 2012, SEMIN REPROD MED, V30, P5, DOI 10.1055/s 0031 1299592
   NAKAMURA I, 1995, FEBS LETT, V361, P79, DOI 10.1016/0014 5793(95)00153 Z
   Oh JH, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110747
   Park KH, 2017, AM J CHINESE MED, V45, P1725, DOI 10.1142/S0192415X17500938
   Penetar DM, 2012, DRUG ALCOHOL DEPEN, V126, P251, DOI 10.1016/j.drugalcdep.2012.04.012
   Pilsáková L, 2010, PHYSIOL RES, V59, P651, DOI 10.33549/physiolres.931902
   Rafii F, 2015, METABOLITES, V5, P56, DOI 10.3390/metabo5010056
   Rodriguez AC, 2019, HORM CANCER US, V10, P51, DOI 10.1007/s12672 019 0358 9
   Ryu CS, 2012, FOOD CHEM, V132, P333, DOI 10.1016/j.foodchem.2011.10.086
   Salari N, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02772 0
   Sellitto A, 2020, CANCERS, V12, DOI 10.3390/cancers12061477
   Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197
   Shin KC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041207
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Streicher C, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 06614 0
   Sunita P, 2011, Pharmacogn Rev, V5, P41, DOI 10.4103/0973 7847.79098
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tian WY, 2019, CANCER BIOL MED, V16, P55, DOI 10.20892/j.issn.2095 3941.2018.0157
   Uehara M, 2013, J CLIN BIOCHEM NUTR, V52, P193, DOI 10.3164/jcbn.13 2
   Ulbricht Catherine, 2015, Journal of Dietary Supplements, V12, P36, DOI 10.3109/19390211.2014.904123
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   Wang BT, 2016, BIOMED PHARMACOTHER, V84, P1108, DOI 10.1016/j.biopha.2016.10.052
   Wang XX, 2003, J BONE MINER METAB, V21, P268, DOI 10.1007/s00774 003 0420 z
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Woo J, 2003, MENOPAUSE, V10, P352, DOI 10.1097/01.GME.0000054764.94658.33
   Xiao L, 2020, AGING US, V12, P21706, DOI 10.18632/aging.103976
   Xu X, 2022, FRONT NUTR, V9, DOI 10.3389/fnut.2022.868188
   Yamazaki K, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000387
   Yang JX, 2019, METHODS MOL BIOL, V1882, P143, DOI 10.1007/978 1 4939 8879 2_12
   Yang RJ, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.774440
   Zhang Z, 2013, J CLIN PHARMACOL, V53, P787, DOI 10.1002/jcph.96
   Zhang ZY, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21934
   Zhou YX, 2014, PHYTOTHER RES, V28, P961, DOI 10.1002/ptr.5083
NR 77
TC 1
Z9 3
U1 3
U2 16
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2405 8440
J9 HELIYON
JI Heliyon
PD JAN 30
PY 2024
VL 10
IS 2
AR e24842
DI 10.1016/j.heliyon.2024.e24842
EA JAN 2024
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA IP6N9
UT WOS:001167574000001
PM 38312605
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Grigson, ER
   Ozerova, M
   Pisklakova, A
   Liu, H
   Sullivan, DM
   Nefedova, Y
AF Grigson, Eileen R.
   Ozerova, Maria
   Pisklakova, Alexandra
   Liu, Hao
   Sullivan, Daniel M.
   Nefedova, Yulia
TI Canonical Wnt Pathway Inhibitor ICG 001 Induces Cytotoxicity of Multiple
   Myeloma Cells in Wnt Independent Manner
SO PLOS ONE
LA English
DT Article
ID NOVO DRUG RESISTANCE; APOPTOSIS; PROLIFERATION
AB Canonical Wnt signaling has been implicated in the regulation of multiple myeloma ( MM) growth. Here, we investigated whether the targeting of this pathway with a novel pharmacological inhibitor ICG 001 would result in an anti tumor effect and improvement of chemosensitivity in MM. As expected, ICG 001 specifically down regulated beta catenin/TCF mediated transcription in MM cells. Treatment with ICG 001 resulted in growth arrest and apoptosis in MM cell lines and primary MM cells. Moreover, ICG 001 enhanced the cytotoxic effects of doxorubicin and melphalan and abrogated chemoresistance of MM cells to these chemotherapeutics induced by bone marrow stroma. The cytotoxic effect of ICG 001 was caspase dependent and mediated through transcriptional up regulation of BH3 only proapoptotic members of the Bcl 2 family Noxa and Puma but not through inhibition of canonical Wnt signaling. ICG 001 selectively induced apoptosis in primary MM cells but did not affect non MM cells of the bone marrow microenvironment. Experiments using a xenograft model of MM showed substantial anti tumor effects of this compound in vivo. Thus, our study demonstrated that the small molecule inhibitor ICG 001 has strong anti MM effects and could be developed further for therapeutic intervention in this disease.
C1 [Grigson, Eileen R.; Pisklakova, Alexandra; Liu, Hao; Sullivan, Daniel M.; Nefedova, Yulia] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
   [Grigson, Eileen R.; Ozerova, Maria; Nefedova, Yulia] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA.
C3 State University System of Florida; University of South Florida; H Lee
   Moffitt Cancer Center & Research Institute; The Wistar Institute
RP Nefedova, Y (通讯作者)，Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
EM ynefedova@wistar.org
OI Nefedova, Yulia/0000 0002 5121 9294
FU Multiple Myeloma Research Foundation Senior Award; National Cancer
   Institute of the National Institutes of Health [R01CA130923]; Cancer
   Center Support Grant (CCSG) [P30 CA76292, CA010815]
FX Research reported in this publication was supported by the Multiple
   Myeloma Research Foundation (http://www.themmrf.org) Senior Award (to
   YN) and by the National Cancer Institute of the National Institutes of
   Health under award number R01CA130923 (to YN). Support for Shared
   Resources utilized in the study was provided by Cancer Center Support
   Grant (CCSG) P30 CA76292 to the Moffitt Cancer Center and Research
   Institute and CA010815 to The Wistar Institute. The content is solely
   the responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   Anderson KC, 2011, ANNU REV PATHOL MECH, V6, P249, DOI 10.1146/annurev pathol 011110 130249
   Ashihara E, 2009, CLIN CANCER RES, V15, P2731, DOI 10.1158/1078 0432.CCR 08 1350
   Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Colla S, 2007, BLOOD, V109, P4470, DOI 10.1182/blood 2006 11 056747
   Edwards CM, 2008, BLOOD, V111, P2833, DOI 10.1182/blood 2007 03 077685
   Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101
   Gang E.J., 2013, Oncogene
   Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432 1327.2001.02226.x
   Huang ML, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 221
   IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098
   Khin ZP, 2014, CANCER RES, V74, P56, DOI 10.1158/0008 5472.CAN 13 2397
   Lento W, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008011
   Mazieres J, 2005, ONCOGENE, V24, P5396, DOI 10.1038/sj.onc.1208568
   Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714
   Nefedova Y, 2004, BLOOD, V103, P3503, DOI 10.1182/blood 2003 07 2340
   Nefedova Y, 2003, LEUKEMIA, V17, P1175, DOI 10.1038/sj.leu.2402924
   Qiang YW, 2008, BLOOD, V112, P374, DOI 10.1182/blood 2007 10 120253
   Qiang YW, 2009, BLOOD, V113, P4319, DOI 10.1182/blood 2008 08 174300
   Qiang YW, 2005, BLOOD, V106, P1786, DOI 10.1182/blood 2005 01 0049
   Qiang YW, 2003, ONCOGENE, V22, P1536, DOI 10.1038/sj.onc.1206239
   Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074 7613(00)00004 2
   Shibue T, 2006, INT J CANC
   Sukhdeo K, 2007, P NATL ACAD SCI USA, V104, P7516, DOI 10.1073/pnas.0610299104
   Sun P, 2006, MOL PHARMACOL, V69, P520, DOI 10.1124/mol.105.019620
   Takahashi Yanaga F, 2010, CLIN CANCER RES, V16, P3153, DOI 10.1158/1078 0432.CCR 09 2943
   Veeramachaneni NK, 2004, J THORAC CARDIOV SUR, V127, P92, DOI 10.1016/j.jtcvs.2003.06.008
   Wend P, 2013, EMBO J, V32, P1977, DOI 10.1038/emboj.2013.127
   You L, 2004, CANCER RES, V64, P5385, DOI 10.1158/0008 5472.CAN 04 1227
   Zhao C, 2007, CANCER CELL, V12, P528, DOI 10.1016/j.ccr.2007.11.003
NR 31
TC 42
Z9 43
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JAN 30
PY 2015
VL 10
IS 1
AR e0117693
DI 10.1371/journal.pone.0117693
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CC9HX
UT WOS:000350680700097
PM 25635944
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Liu, J
   Cheng, QF
   Wu, XM
   Zhu, HF
   Deng, XY
   Wang, MR
   Yang, SY
   Xu, J
   Chen, Q
   Li, MX
   Liu, XJ
   Wang, CD
AF Liu, Jie
   Cheng, Qingfeng
   Wu, Xiangmei
   Zhu, Huifang
   Deng, Xiaoyan
   Wang, Maorong
   Yang, Shengyong
   Xu, Jie
   Chen, Qian
   Li, Mengxue
   Liu, Xianjun
   Wang, Changdong
TI Icariin Treatment Rescues Diabetes Induced Bone Loss via Scavenging ROS
   and Activating Primary Cilia/Gli2/Osteocalcin Signaling Pathway
SO CELLS
LA English
DT Article
DE diabetes; bone loss; primary cilia; Icariin; ROS
ID PRIMARY CILIA; RISK
AB Diabetes associated bone complications lead to fragile bone mechanical strength and osteoporosis, aggravating the disease burden of patients. Advanced evidence shows that chronic hyperglycemia and metabolic intermediates, such as inflammatory factor, reactive oxygen species (ROS), and advanced glycation end products (AGEs), are regarded as dominant hazardous factors of bone complications, whereas the pathophysiological mechanisms are complex and controversial. By establishing a diabetic Sprague Dawley (SD) rat model and diabetic bone loss cell model in vitro, we confirmed that diabetes impaired primary cilia and led to bone loss, while adding Icariin (ICA) could relieve the inhibitions. Mechanistically, ICA could scavenge ROS to maintain the mitochondrial and primary cilia homeostasis of osteoblasts. Intact primary cilia acted as anchoring and modifying sites of Gli2, thereby activating the primary cilia/Gli2/osteocalcin signaling pathway to promote osteoblast differentiation. All results suggest that ICA has potential as a therapeutic drug targeting bone loss induced by diabetes.
C1 [Liu, Jie; Zhu, Huifang; Deng, Xiaoyan; Yang, Shengyong; Xu, Jie; Chen, Qian; Li, Mengxue; Liu, Xianjun; Wang, Changdong] Chongqing Med Univ, Coll Basic Med, Mol Med & Canc Res Ctr, Dept Biochem & Mol Biol, Chongqing 400016, Peoples R China.
   [Cheng, Qingfeng] Chongqing Med Univ, Dept Endocrinol, Affiliated Hosp 1, Chongqing 401331, Peoples R China.
   [Wu, Xiangmei] Chongqing Med Univ, Coll Basic Med, Mol Med & Canc Res Ctr, Dept Physiol, Chongqing 400016, Peoples R China.
   [Wang, Maorong] Hubei Univ Nationalities, Dept Endocrinol, Affiliated Hosp, Enshi 445000, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University; Chongqing
   Medical University; Hubei Minzu University
RP Wang, CD (通讯作者)，Chongqing Med Univ, Coll Basic Med, Mol Med & Canc Res Ctr, Dept Biochem & Mol Biol, Chongqing 400016, Peoples R China.
EM wangchangdong@cqmu.edu.cn
RI Zhenmin, Fan/JZT 2394 2024; liu, xianjun/GZA 6168 2022
OI Yang, Jing/0009 0004 8274 9863; yang, sheng yong/0000 0001 7312 0255;
   wang, changdong/0000 0002 2595 1369; Wu, Xiangmei/0000 0002 6405 8346
CR Ahmad W, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929 017 0379 z
   An YA, 2019, FASEB J, V33, P12515, DOI 10.1096/fj.201802805RR
   [Anonymous], 2018, DIABETES RES CLIN PR, V135, P235, DOI 10.1016/j.diabres.2018.01.005
   Anvarian Z, 2019, NAT REV NEPHROL, V15, P199, DOI 10.1038/s41581 019 0116 9
   Bangs F, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a028175
   Bhatti JS, 2022, FREE RADICAL BIO MED, V184, P114, DOI 10.1016/j.freeradbiomed.2022.03.019
   Cheng KM, 2022, FRONT PUBLIC HEALTH, V10, DOI 10.3389/fpubh.2022.918483
   Cheng RX, 2019, THERANOSTICS, V9, P4287, DOI 10.7150/thno.36077
   Chinipardaz Z, 2022, J DENT RES, V101, P253, DOI 10.1177/00220345211046606
   Chinipardaz Z, 2021, BONE, V153, DOI 10.1016/j.bone.2021.116176
   Cho JH, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abq8486
   de Waard EAC, 2018, OSTEOPOROSIS INT, V29, P2725, DOI 10.1007/s00198 018 4678 3
   Ding XS, 2022, PHYTOMEDICINE, V99, DOI 10.1016/j.phymed.2022.154005
   Dugan LL, 2013, J CLIN INVEST, V123, P4888, DOI 10.1172/JCI66218
   Ebeling PR, 2022, ENDOCR REV, V43, P240, DOI 10.1210/endrev/bnab028
   Eftekharpour E, 2022, ANTIOXID REDOX SIGN, V37, P578, DOI 10.1089/ars.2021.0152
   Ehnert S, 2017, J MOL MED, V95, P653, DOI 10.1007/s00109 017 1526 4
   Esteves Monteiro M, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232113233
   Goodpaster BH, 2017, CELL METAB, V25, P1027, DOI 10.1016/j.cmet.2017.04.015
   Ho Shui Ling A, 2018, BIOMATERIALS, V180, P143, DOI 10.1016/j.biomaterials.2018.07.017
   Hofbauer LC, 2022, LANCET DIABETES ENDO, V10, P207, DOI 10.1016/S2213 8587(21)00347 8
   Hughes JW, 2020, P NATL ACAD SCI USA, V117, P8912, DOI 10.1073/pnas.2001936117
   Ji Y, 2019, ANTIOXID REDOX SIGN, V30, P1731, DOI 10.1089/ars.2018.7507
   Jiang YN, 2021, J TRANSL MED, V19, DOI 10.1186/s12967 021 02867 6
   Kawata K, 2021, BONE, V150, DOI 10.1016/j.bone.2021.116001
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group, 2020, Kidney Int, V98, pS1, DOI 10.1016/j.kint.2020.06.019
   Kim B, 2018, PHYTOMEDICINE, V51, P181, DOI 10.1016/j.phymed.2018.06.020
   Klein KR, 2020, NAT REV ENDOCRINOL, V16, P717, DOI 10.1038/s41574 020 00425 6
   Kluth O, 2019, CELL REP, V26, P3027, DOI 10.1016/j.celrep.2019.02.056
   Kong MJ, 2019, REDOX BIOL, V20, P38, DOI 10.1016/j.redox.2018.09.017
   Lee SY, 2018, J CLIN INVEST, V128, P5573, DOI 10.1172/JCI96221
   Li DZ, 2022, ADV MATER, V34, DOI 10.1002/adma.202108430
   Liu Y, 2015, DIABETES, V64, P36, DOI 10.2337/db14 0267
   Lu YJ, 2019, BONE, V123, P159, DOI 10.1016/j.bone.2019.03.026
   Ma HD, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/9067610
   Moore ER, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0930 1
   Morgan EF, 2018, ANNU REV BIOMED ENG, V20, P119, DOI [10.1146/annurev bioeng 062117 121139, 10.1146/annurev bioeng 062117121139]
   Moruzzi N, 2022, LIFE SCI ALLIANCE, V5, DOI 10.26508/lsa.202201505
   Napoli N, 2018, J BONE MINER RES, V33, P63, DOI 10.1002/jbmr.3287
   Napoli N, 2017, NAT REV ENDOCRINOL, V13, P208, DOI 10.1038/nrendo.2016.153
   Nielsen JJ, 2021, J CONTROL RELEASE, V329, P570, DOI 10.1016/j.jconrel.2020.09.047
   Ohba S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186665
   Panchapakesan U, 2020, INT J BIOCHEM CELL B, V122, DOI 10.1016/j.biocel.2020.105718
   Ruegsegger GN, 2018, J CLIN INVEST, V128, P3671, DOI 10.1172/JCI120843
   Santos N, 2014, J CELL SCI, V127, P1500, DOI 10.1242/jcs.139253
   Sewing L, 2022, J BONE MINER RES, V37, P837, DOI 10.1002/jbmr.4517
   Shahen VA, 2020, CYTOKINE GROWTH F R, V55, P109, DOI 10.1016/j.cytogfr.2020.04.001
   Sheu A, 2023, TRENDS ENDOCRIN MET, V34, P34, DOI 10.1016/j.tem.2022.11.003
   Shi WG, 2017, J BIOL CHEM, V292, P20883, DOI 10.1074/jbc.M117.809517
   Sun H, 2022, DIABETES RES CLIN PR, V183, DOI 10.1016/j.diabres.2021.109119
   Sun J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 24819 w
   Tao ZS, 2022, J MATER SCI MATER M, V33, DOI 10.1007/s10856 022 06684 1
   Tsushima K, 2018, CIRC RES, V122, P58, DOI 10.1161/CIRCRESAHA.117.311307
   Tu CX, 2022, BIOMATERIALS, V286, DOI 10.1016/j.biomaterials.2022.121597
   Volta F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12953 5
   Wang H, 2023, BIOACT MATER, V21, P324, DOI 10.1016/j.bioactmat.2022.08.029
   Wang YL, 2020, J DIABETES RES, V2020, DOI 10.1155/2020/3714704
   Wisanwattana W, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.636784
   Wu J, 2022, INT J BIOL SCI, V18, P956, DOI 10.7150/ijbs.65954
   Wu YQ, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 05392 z
   Xia J, 2022, PHYTOMEDICINE, V104, DOI 10.1016/j.phymed.2022.154331
   Xu DD, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.851956
   Xu J, 2021, AGING US, V13, P8989, DOI 10.18632/aging.202734
   Yang AF, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/5747298
   Yong EL, 2021, PHYTOMEDICINE, V91, DOI 10.1016/j.phymed.2021.153680
   Yuan X, 2015, ANN NY ACAD SCI, V1335, P78, DOI 10.1111/nyas.12463
   Zhang CT, 2019, J BONE MINER RES, V34, P547, DOI 10.1002/jbmr.3610
   Zhang JF, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368 019 0046 1
   Zhao HY, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 021 04435 8
   Zhou LP, 2021, PHYTOMEDICINE, V82, DOI 10.1016/j.phymed.2020.153413
   Zhu YF, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.755260
NR 72
TC 14
Z9 16
U1 2
U2 36
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD DEC
PY 2022
VL 11
IS 24
AR 4091
DI 10.3390/cells11244091
PG 20
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 7D5QQ
UT WOS:000900545200001
PM 36552853
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lumetti, S
   Ferrillo, S
   Mazzotta, S
   Macaluso, GM
   Bonanini, M
   Passeri, G
   Galli, C
AF Lumetti, S.
   Ferrillo, S.
   Mazzotta, S.
   Macaluso, G. M.
   Bonanini, M.
   Passeri, G.
   Galli, C.
TI PHARMACOLOGICAL GSK 3β INHIBITION IMPROVES OSTEOBLAST DIFFERENTIATION ON
   TITANIUM SURFACES
SO JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
LA English
DT Article
DE titanium; Wnt; BIO; osteoblast; implant
ID BONE MASS; MESENCHYMAL CELLS; BETA CATENIN; WNT; ACTIVATION;
   MAINTENANCE; TOPOGRAPHY; EXPRESSION; OSTEOCYTES; SCALE
AB Rough titanium surfaces enhance the activation of Wnt canonical signaling, a pathway required for osteoblast differentiation. The present study investigated the effects of GSK3b inhibitor (2'Z,3'E) 6 Bromoindirubin 3' oxime (BIO) on osteoblastic differentiation on titanium surfaces with different topography and wettability. C2C12 cells were plated on pickled, acid etched/sand blasted (SLA), modified hydrophilic SLA titanium discs (modSLA) and stimulated with increasing doses of BIO. Activation of Wnt canonical signaling was measured with a reporter system. Gene expression was measured in the same cell system by Real Time PCR. Osteoblastic MC3T3 cells were then plated on discs with or without BIO and the expression of osteoblast specific genes was assessed by Real Time PCR. One mM BIO activated Wnt canonical signaling in C2C12 cells on all surfaces, and the highest effect was on rough surfaces. BIO markedly increased the expression of Osteoprotegerin and Osteocalcin in MC3T3 cells on rough surfaces at the concentration of 100 nM, and on all surfaces at the concentration of 1 mM. BIO enhances Wnt signaling activation and the expression of osteoblastic genes on rough surfaces and could be a viable approach to improve cell response to implant surfaces.
C1 [Lumetti, S.; Macaluso, G. M.; Bonanini, M.; Galli, C.] Univ Parma, Dept Biomed Biotechnol & Translat Sci, I 43100 Parma, Italy.
   [Ferrillo, S.; Mazzotta, S.; Passeri, G.] Univ Parma, Dept Clin & Expt Med, I 43100 Parma, Italy.
C3 University of Parma; University of Parma; University Hospital of Parma
RP Macaluso, GM (通讯作者)，Univ Parma, Dept Biomed Biotechnol & Translat Sci, Via Gramsci 14, I 43100 Parma, Italy.
EM guidomaria.macaluso@unipr.it
RI ; Macaluso, Guido/D 5317 2013; Galli, Carlo/D 4728 2014
OI Passeri, Giovanni/0000 0002 4039 1160; Galli, Carlo/0000 0001 7476 7181;
   
FU ITI Foundation (Basel, Switzerland) [093_2010]; Fondazione Cariparma
FX The authors would like to thank Straumann Institut AG (and in particular
   Dr. Appert and Dr. Molenberg), Basel, Switzerland, for kindly providing
   the titanium surfaces used in the present study. The study was funded by
   grant 093_2010 from ITI Foundation (Basel, Switzerland) research grant
   from Fondazione Cariparma.
CR Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717
   BARAN DT, 1978, J CLIN INVEST, V61, P1691, DOI 10.1172/JCI109090
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Cselenyi CS, 2008, P NATL ACAD SCI USA, V105, P8032, DOI 10.1073/pnas.0803025105
   Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388
   Galli C, 2013, CLIN ORAL IMPLAN RES, V24, P921, DOI 10.1111/j.1600 0501.2012.02488.x
   Galli C, 2012, ACTA BIOMATER, V8, P2963, DOI 10.1016/j.actbio.2012.04.043
   Galli C, 2008, ENDOCRINOLOGY, V149, P146, DOI 10.1210/en.2007 0734
   Galli C, 2014, CLIN ORAL IMPLAN RES, V25, pE133, DOI 10.1111/clr.12075
   Galli C, 2010, J BIOMED MATER RES A, V95A, P682, DOI 10.1002/jbm.a.32887
   Galli C, 2009, J BIOL CHEM, V284, P12654, DOI 10.1074/jbc.M806628200
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Hyzy SL, 2013, ACTA BIOMATER, V9, P5821, DOI 10.1016/j.actbio.2012.10.030
   Ivanovski S, 2011, CLIN ORAL IMPLAN RES, V22, P373, DOI 10.1111/j.1600 0501.2010.02112.x
   Khandelwal N, 2013, CLIN ORAL IMPLAN RES, V24, P13, DOI 10.1111/j.1600 0501.2011.02369.x
   Klein MO, 2013, CLIN IMPLANT DENT R, V15, P166, DOI 10.1111/j.1708 8208.2011.00339.x
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kulkarni NH, 2006, J BONE MINER RES, V21, P910, DOI 10.1359/JBMR.060316
   Li JJ, 2011, BONE, V48, P321, DOI 10.1016/j.bone.2010.09.033
   LUMETTI S, 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/401859
   O'Brien CA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002942
   Onal M, 2012, MOL ENDOCRINOL, V26, P341, DOI 10.1210/me.2011 1149
   Rhee Y, 2011, J BONE MINER RES, V26, P1035, DOI 10.1002/jbmr.304
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Rokutanda S, 2009, DEV BIOL, V328, P78, DOI 10.1016/j.ydbio.2009.01.009
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Schwartz Z, 1999, Adv Dent Res, V13, P38
   Verheyen EM, 2010, DEV DYNAM, V239, P34, DOI 10.1002/dvdy.22019
   Wall I, 2009, BONE, V45, P17, DOI 10.1016/j.bone.2009.03.662
   Xu WQ, 2007, J CELL SCI, V120, P3337, DOI 10.1242/jcs.013771
   Zhao G, 2007, BIOMATERIALS, V28, P2821, DOI 10.1016/j.biomaterials.2007.02.024
NR 33
TC 8
Z9 9
U1 0
U2 4
PU BIOLIFE SAS
PI SILVA MARINA (TE)
PA VIA S STEFANO 39 BIS, 64029 SILVA MARINA (TE), ITALY
SN 0393 974X
EI 1724 6083
J9 J BIOL REG HOMEOS AG
JI J. Biol. Regul. Homeost. Agents
PD JUL SEP
PY 2014
VL 28
IS 3
BP 489
EP 495
PG 7
WC Endocrinology & Metabolism; Immunology; Medicine, Research &
   Experimental; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Immunology; Research & Experimental
   Medicine; Physiology
GA AR5EY
UT WOS:000343609200014
PM 25316136
DA 2025 08 17
ER

PT J
AU Lappin, KM
   Mills, KI
   Lappin, TR
AF Lappin, Katrina M.
   Mills, Ken I.
   Lappin, Terence R.
TI Erythropoietin in bone homeostasis Implications for efficacious anemia
   therapy
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Article
AB Bone homeostasis and hematopoiesis are irrevocably linked in the hypoxic environment of the bone marrow. Erythropoietin (Epo) regulates erythropoiesis by binding to its receptor, Epor, on erythroid progenitor cells. The continuous process of bone remodeling is achieved by the finely balanced activity of osteoblasts in bone synthesis and osteoclasts in bone resorption. Both osteoblasts and osteoclasts express functional Epors, but the underlying mechanism of Epo Epor signaling in bone homeostasis is incompletely understood. Two recent publications have provided new insights into the contribution of endogenous Epo to bone homeostasis. Suresh et al examined Epo Epor signaling in osteoblasts in bone formation in mice and Deshet Unger et al investigated osteoclastogenesis arising from transdifferentiation of B cells. Both groups also studied bone loss in mice caused by exogenous human recombinant EPO stimulated erythropoiesis. They found that either deletion of Epor in osteoblasts or conditional knockdown of Epor in B cells attenuates EPO driven bone loss. These findings have direct clinical implications because patients on long term treatment for anemia may have an increased risk of bone fractures. Phase 3 trials of small molecule inhibitors of the PHD enzymes (hypoxia inducible factor prolyl hydroxylase inhibitors [HIF PHIs]), such as Roxadustat, have shown improved iron metabolism and increased circulating Epo levels in a titratable manner, avoiding the supraphysiologic increases that often accompany intravenous EPO therapy. The new evidence presented by Suresh and Deshet Unger and their colleagues on the effects of EPO stimulated erythropoiesis on bone homeostasis seems likely to stimulate discussion on the relative merits and safety of EPO and HIF PHIs.
C1 [Lappin, Katrina M.; Mills, Ken I.; Lappin, Terence R.] Queens Univ Belfast, Patrick G Johnston Ctr Canc Res, 97 Lisburn Rd, Belfast BT9 7AE, Antrim, North Ireland.
C3 Queens University Belfast
RP Lappin, KM (通讯作者)，Queens Univ Belfast, Patrick G Johnston Ctr Canc Res, 97 Lisburn Rd, Belfast BT9 7AE, Antrim, North Ireland.
EM k.lappin@qub.ac.uk
RI ; Mills, Ken/A 8556 2012
OI Lappin, Terence/0000 0002 0648 0223; Lappin,
   Katrina/0000 0002 6463 5430; Mills, Ken/0000 0002 6362 4481
FU Leukaemia UK [R2569CNR]; Leukaemia Lymphoma NI (LLNI) [R2043HAE,
   R2029HAE, R2536CNR]; Leukaemia & Lymphoma NI [R2536CNR] Funding Source:
   researchfish
FX Leukaemia UK, Grant/Award Number: R2569CNR; Leukaemia Lymphoma NI
   (LLNI), Grant/Award Numbers: R2043HAE, R2029HAE, R2536CNR
CR Cantarelli C, 2019, AM J TRANSPLANT, V19, P2407, DOI 10.1111/ajt.15369
   Chen Z, 2010, J AM GERIATR SOC, V58, P2337, DOI 10.1111/j.1532 5415.2010.03183.x
   Deshet Unger N, 2020, THERANOSTICS, V10, P8744, DOI 10.7150/thno.45845
   Eggold JT, 2019, BONE, V119, P36, DOI 10.1016/j.bone.2018.03.014
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Gruber M, 2007, P NATL ACAD SCI USA, V104, P2301, DOI 10.1073/pnas.0608382104
   Guo LH, 2014, CLIN EXP MED, V14, P69, DOI 10.1007/s10238 012 0220 7
   Haase VH, 2017, HEMODIAL INT, V21, pS110, DOI 10.1111/hdi.12567
   Hiram Bab S, 2015, FASEB J, V29, P1890, DOI 10.1096/fj.14 259085
   Hirano I, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00451 16
   Hobeika E, 2006, P NATL ACAD SCI USA, V103, P13789, DOI 10.1073/pnas.0605944103
   Hodson E, 2020, AM J RESP CRIT CARE, V202, P917, DOI 10.1164/rccm.202006 2149ED
   Horowitz MC, 2010, BONE, V47, P472, DOI 10.1016/j.bone.2010.06.011
   James AW, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/684736
   Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009
   Kapitsinou PP, 2010, BLOOD, V116, P3039, DOI 10.1182/blood 2010 02 270322
   Koh MY, 2012, TRENDS BIOCHEM SCI, V37, P364, DOI 10.1016/j.tibs.2012.06.004
   Koury MJ, 2015, NAT REV NEPHROL, V11, P394, DOI 10.1038/nrneph.2015.82
   KOURY ST, 1988, BLOOD, V71, P524
   Kristjansdottir HL, 2020, J BONE MINER RES, V35, P298, DOI 10.1002/jbmr.3900
   LACOMBE C, 1988, J CLIN INVEST, V81, P620, DOI 10.1172/JCI113363
   Lappin TR, 2019, BLOOD REV, V37, DOI 10.1016/j.blre.2019.100590
   Lappin TR, 2002, STEM CELLS, V20, P485, DOI 10.1634/stemcells.20 6 485
   Lee FS, 2011, ANNU REV PATHOL MECH, V6, P165, DOI 10.1146/annurev pathol 011110 130321
   Li C, 2015, J DENT RES, V94, P455, DOI 10.1177/0022034514566431
   Li Yan, 2014, Open Bone J, V6, P8
   Li ZL, 2020, KIDNEY DIS BASEL, V6, P65, DOI 10.1159/000504850
   Lifshitz L, 2010, HAEMATOL HEMATOL J, V95, P1823, DOI 10.3324/haematol.2010.025015
   LORD B I, 1975, Blood, V46, P65
   Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022
   Maxwell PH, 2002, CLIN MED, V2, P356, DOI 10.7861/clinmedicine.2 4 356
   Mills TR., 2021, STEM CELL TRANSL MED, P1
   Minguell JJ, 2001, EXP BIOL MED, V226, P507, DOI 10.1177/153537020122600603
   Nair AM, 2013, BIOMATERIALS, V34, P7364, DOI 10.1016/j.biomaterials.2013.06.031
   Noguchi CT, 2020, EXP HEMATOL, V92, P32, DOI 10.1016/j.exphem.2020.09.190
   Oikonomidou PR, 2016, OSTEOPOROSIS INT, V27, P1559, DOI 10.1007/s00198 015 3412 7
   Pasupneti S, 2020, AM J RESP CRIT CARE, V202, P983, DOI 10.1164/rccm.202001 0078OC
   PATT HM, 1972, P SOC EXP BIOL MED, V140, P205
   Rankin EB, 2012, CELL, V149, P63, DOI 10.1016/j.cell.2012.01.051
   Ratcliffe PJ, 2002, BLOOD PURIFICAT, V20, P445, DOI 10.1159/000065201
   Rauner M, 2016, J BONE MINER RES, V31, P1877, DOI 10.1002/jbmr.2857
   Rölfing JHD, 2014, STEM CELL REV REP, V10, P69, DOI 10.1007/s12015 013 9476 x
   Sarrai M, 2007, BRIT J HAEMATOL, V136, P666, DOI 10.1111/j.1365 2141.2006.06487.x
   Scortegagna M, 2005, BLOOD, V105, P3133, DOI 10.1182/blood 2004 05 1695
   Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955 0674(00)00194 0
   Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471 4914(01)02090 1
   SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P8725, DOI 10.1073/pnas.88.19.8725
   Semenza GL, 2014, ANNU REV PATHOL MECH, V9, P47, DOI 10.1146/annurev pathol 012513 104720
   Shiozawa Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010853
   Siddiqui JA, 2016, PHYSIOLOGY, V31, P233, DOI 10.1152/physiol.00061.2014
   Singbrant S, 2011, BLOOD, V117, P5631, DOI 10.1182/blood 2010 11 320564
   Spencer JA, 2014, NATURE, V508, P269, DOI 10.1038/nature13034
   Storti F, 2014, HAEMATOLOGICA, V99, pE45, DOI 10.3324/haematol.2013.102707
   Suresh S, 2020, FASEB J, V34, P11685, DOI 10.1096/fj.202000888R
   Suresh S, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0060 0
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   Valderrábano RJ, 2017, J CLIN ENDOCR METAB, V102, P2199, DOI 10.1210/jc.2017 00266
   Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood 2003 11 4011
   Vogiatzi MG, 2009, J BONE MINER RES, V24, P543, DOI 10.1359/JBMR.080505
   Wang L, 2013, DIABETES, V62, P4122, DOI 10.2337/db13 0518
   Wang LY, 2018, INT J MOL MED, V41, P829, DOI 10.3892/ijmm.2017.3294
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   Wu DL, 2019, NAT CHEM BIOL, V15, P367, DOI 10.1038/s41589 019 0234 5
   Ye Lihua, 2010, Int J Stem Cells, V3, P175
   Zheng Fang, 2009, Int J Stem Cells, V2, P129
   Zubareva E.V., 2019, RES RESULTS PHARM, V55, P53, DOI [DOI 10.3897/RRPHARMACOLOGY.5.33457, 10.3897/rrpharmacology.5.33457]
NR 66
TC 11
Z9 11
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2157 6564
EI 2157 6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
PD JUN
PY 2021
VL 10
IS 6
BP 836
EP 843
DI 10.1002/sctm.20 0387
EA JAN 2021
PG 8
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA SE2OK
UT WOS:000609304300001
PM 33475252
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Huang, F
   Cao, YQ
   Wu, G
   Chen, JY
   Wang, CH
   Lin, WZ
   Lan, RL
   Wu, B
   Xie, XH
   Hong, JS
   Fu, LX
AF Huang, Fei
   Cao, Yaqiang
   Wu, Gui
   Chen, Junying
   CaihongWang
   Lin, Wanzun
   Lan, Ruilong
   Wu, Bing
   Xie, Xianhe
   Hong, Jinsheng
   Fu, Lengxi
TI BMP2 signalling activation enhances bone metastases of non small cell
   lung cancer
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE BMP2 signalling; bone metastases; NSCLC; osteoblastic mechanism;
   osteolytic mechanism
ID MORPHOGENETIC PROTEIN 2; CYTOKERATIN 18; CROSS TALK; TGF BETA; KAPPA B;
   TUMOR; PROSTATE; EXPRESSION; PROMOTES; RANKL
AB Distant metastases occur when non small cell lung cancer (NSCLC) is at late stages. Bone metastasis is one of the most frequent metastases of NSCLC and leads to poor prognosis. It has been reported that high expression of BMP2 in NSCLC correlates with poor survival, but whether BMP2 contributes to NSCLC bone metastasis remains largely unknown. The activation of BMP signalling is found in metastatic bone tumours of mice Lewis lung carcinoma and predicts poor survival in human NSCLC. BMP2 signalling activation can enhance bone metastasis of Lewis lung carcinoma. Moreover, BMP2 secreted by stroma fibroblasts can promote the migration and invasion of NSCLC cells. Besides, in combination with pre osteoblast and LLCs, BMP2 could enhance the differentiation of macrophages into osteoclasts to play roles in the osteolytic mechanism of NSCLC bone metastasis. Interestingly, NSCLC cells can also enrich BMP2 to pre osteoblasts to function in the osteoblastic mechanism. Our results firstly demonstrate the detailed mechanisms about what roles BMP2 signalling play in enhancing NSCLC bone metastases. These findings provide a new potential therapy choice for preventing bone metastases of NSCLC via the inhibition of BMP2 signalling.
C1 [Huang, Fei; Chen, Junying; Lan, Ruilong; Wu, Bing; Fu, Lengxi] Fujian Med Univ, Affiliated Hosp 1, Cent Lab, 20 Chazhong Rd, Fuzhou 350005, Peoples R China.
   [Huang, Fei; Chen, Junying; Lan, Ruilong; Wu, Bing; Fu, Lengxi] Fujian Med Univ, Affiliated Hosp 1, Fujian Platform Med Res, Fuzhou, Peoples R China.
   [Huang, Fei; Chen, Junying; Lan, Ruilong; Wu, Bing; Fu, Lengxi] Fujian Key Lab Individualized Act Immunotherapy, Fuzhou, Peoples R China.
   [Huang, Fei; Chen, Junying; CaihongWang; Lan, Ruilong; Wu, Bing; Hong, Jinsheng; Fu, Lengxi] Key Lab Radiat Biol Fujian Prov Univ, Fuzhou, Peoples R China.
   [Cao, Yaqiang] Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Inst Biol Sci,CAS Key Lab Computat Biol, CAS MPG Partner Inst Computat Biol,Shanghai Inst, Shanghai, Peoples R China.
   [Wu, Gui] Fujian Med Univ, Affiliated Hosp 1, Dept Orthoped, Fuzhou, Peoples R China.
   [CaihongWang; Hong, Jinsheng] Fujian Med Univ, Affiliated Hosp 1, Dept Radiat Oncol, Fuzhou, Peoples R China.
   [Lin, Wanzun; Xie, Xianhe] Fujian Med Univ, Affiliated Hosp 1, Dept Chemotherapy, Fuzhou, Peoples R China.
C3 Fujian Medical University; Fujian Medical University; Chinese Academy of
   Sciences; University of Chinese Academy of Sciences, CAS; Max Planck
   Society; Fujian Medical University; Fujian Medical University; Fujian
   Medical University
RP Huang, F (通讯作者)，Fujian Med Univ, Affiliated Hosp 1, Cent Lab, 20 Chazhong Rd, Fuzhou 350005, Peoples R China.
EM feifeigood2148@126.com
RI ; Cao, Yaqiang/ABC 3753 2021
OI Huang, Fei/0000 0001 9769 4798; Cao, Yaqiang/0000 0002 4665 1517
FU National Natural Science Foundation for Young Scholars of China
   [81702913]; Project for Distinguished Young Scholars in Fujian Province
   [2018B051]
FX We thank the grants from National Natural Science Foundation for Young
   Scholars of China (81702913) and Project for Distinguished Young
   Scholars in Fujian Province (2018B051).
CR Alexander C, 2011, DEVELOPMENT, V138, P5135, DOI 10.1242/dev.067801
   An HQ, 2016, CELL PHYSIOL BIOCHEM, V40, P1052, DOI 10.1159/000453161
   Ando T, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2038
   BERTRAM JS, 1980, CANCER LETT, V11, P63, DOI 10.1016/0304 3835(80)90130 5
   Bieniasz M, 2009, LUNG CANCER, V66, P319, DOI 10.1016/j.lungcan.2009.02.020
   Brady JJ, 2016, CANCER CELL, V29, P697, DOI 10.1016/j.ccell.2016.03.003
   Brunetti G, 2020, J BONE MINER RES, V35, P671, DOI 10.1002/jbmr.3942
   Chen JF, 2010, ANTICANCER RES, V30, P1113
   Chen Y, 2011, ONCOLOGY BASEL, V80, P333, DOI 10.1159/000329098
   Choi YJ, 2012, MED ONCOL, V29, P582, DOI 10.1007/s12032 011 9852 9
   Chu HY, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746 1596 9 123
   Coelho RM, 2016, J THEOR BIOL, V391, P1, DOI 10.1016/j.jtbi.2015.11.024
   Colden M, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.15
   Croucher PI, 2016, NAT REV CANCER, V16, P373, DOI 10.1038/nrc.2016.44
   Daniele S, 2015, SCI REP UK, V5, DOI 10.1038/srep18670
   De Castro J, 2015, CLIN LUNG CANCER, V16, P431, DOI 10.1016/j.cllc.2015.06.004
   De Petris L, 2011, EUR J CANCER, V47, P131, DOI 10.1016/j.ejca.2010.08.006
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Oliveira MBD, 2016, LUNG CANCER, V96, P19, DOI 10.1016/j.lungcan.2016.03.014
   Esposito M, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031252
   Fang WT, 2014, INT J CANCER, V135, P809, DOI 10.1002/ijc.28734
   Feeley BT, 2005, J BONE MINER RES, V20, P2189, DOI 10.1359/JBMR.050802
   Fei ZH, 2013, ASIAN PAC J CANCER P, V14, P5293, DOI 10.7314/APJCP.2013.14.9.5293
   Fu LJ, 2017, IMMUNOBIOLOGY, V222, P597, DOI 10.1016/j.imbio.2016.11.009
   Ganguly SS, 2020, ONCOGENE, V39, P204, DOI 10.1038/s41388 019 0977 1
   Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Herbst RS, 2018, NATURE, V553, P446, DOI 10.1038/nature25183
   Hsu YL, 2011, J BIOL CHEM, V286, P37335, DOI 10.1074/jbc.M111.256156
   Huang F, 2012, CELL BIOSCI, V2, DOI 10.1186/2045 3701 2 9
   Itoh T, 2012, J MOL HISTOL, V43, P509, DOI 10.1007/s10735 012 9415 1
   Juan O, 2017, CLIN LUNG CANCER, V18, P595, DOI 10.1016/j.cllc.2017.03.002
   Juárez P, 2011, BONE, V48, P23, DOI 10.1016/j.bone.2010.08.004
   Kanehisa M, 2012, NUCLEIC ACIDS RES, V40, pD109, DOI 10.1093/nar/gkr988
   Keller ET, 2001, CANCER METAST REV, V20, P333, DOI 10.1023/A:1015599831232
   Kim JS, 2015, MOL CANCER, V14, DOI 10.1186/s12943 015 0441 y
   Kir S, 2014, NATURE, V513, P100, DOI 10.1038/nature13528
   Kuo PL, 2013, BBA GEN SUBJECTS, V1830, P3756, DOI 10.1016/j.bbagen.2013.02.022
   Labelle M, 2011, CANCER CELL, V20, P576, DOI 10.1016/j.ccr.2011.09.009
   Langenfeld EM, 2005, ANN THORAC SURG, V80, P1028, DOI 10.1016/j.athoracsur.2005.03.094
   Langenfeld EM, 2003, CARCINOGENESIS, V24, P1445, DOI 10.1093/carcin/bgg100
   Larson SR, 2013, PROSTATE, V73, P932, DOI 10.1002/pros.22639
   Li LC, 2019, ONCOGENE, V38, P6241, DOI 10.1038/s41388 019 0873 8
   Lu HY, 2019, PHARMACOL RES, V148, DOI 10.1016/j.phrs.2019.104406
   Macedo F, 2017, ONCOL REV, V11, P43, DOI 10.4081/oncol.2017.321
   Mancino AT, 2001, J SURG RES, V100, P18, DOI 10.1006/jsre.2001.6204
   Maredziak M, 2015, IN VITRO CELL DEV AN, V51, P230, DOI 10.1007/s11626 014 9828 0
   Massagué J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038
   McAllister SS, 2014, NAT CELL BIOL, V16, P717, DOI 10.1038/ncb3015
   Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nakamura ES, 2006, CLIN EXP METASTAS, V23, P9, DOI 10.1007/s10585 006 9006 1
   Peters S, 2013, CURR OPIN ONCOL, V25, P137, DOI 10.1097/CCO.0b013e32835d720b
   Popper HH, 2016, CANCER METAST REV, V35, P75, DOI 10.1007/s10555 016 9618 0
   Quayle L, 2015, CURR CANCER DRUG TAR, V15, P469, DOI 10.2174/1568009615666150506092443
   Rajski M, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920 015 0090 4
   Räsänen K, 2010, EXP CELL RES, V316, P2713, DOI 10.1016/j.yexcr.2010.04.032
   Sathiakumar N, 2017, MED CARE, V55, pE144, DOI 10.1097/MLR.0000000000000539
   Selvaggi G, 2005, CRIT REV ONCOL HEMAT, V56, P365, DOI 10.1016/j.critrevonc.2005.03.011
   Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022
   Su YP, 2018, J CELL BIOCHEM, V119, P3716, DOI 10.1002/jcb.26593
   Suliman S, 2016, ADV HEALTHC MATER, V5, P730, DOI 10.1002/adhm.201500723
   Sun SX, 2014, BRAZ J MED BIOL RES, V47, P461
   Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016
   Usui M, 2008, J BONE MINER RES, V23, P314, DOI 10.1359/JBMR.071025
   Vargas AJ, 2016, NAT REV CANCER, V16, P525, DOI 10.1038/nrc.2016.56
   Wang CH, 2020, CELL REP, V30, P1780, DOI 10.1016/j.celrep.2020.01.037
   Wang H, 2018, CANCER CELL, V34, P823, DOI 10.1016/j.ccell.2018.10.002
   Wei F, 2018, TISSUE ENG PT A, V24, P584, DOI [10.1089/ten.TEA.2017.0232, 10.1089/ten.tea.2017.0232]
   Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764
   Wood SL, 2014, CANCER TREAT REV, V40, P558, DOI 10.1016/j.ctrv.2013.10.001
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Xiong W, 2019, ONCOL LETT, V17, P1946, DOI 10.3892/ol.2018.9781
   Xouri G, 2010, SEMIN CELL DEV BIOL, V21, P40, DOI 10.1016/j.semcdb.2009.11.017
   Zhang B, 2016, J CANCER RES CLIN, V142, P2479, DOI 10.1007/s00432 016 2253 x
   Zhang XX, 2020, BONE, V130, DOI 10.1016/j.bone.2019.115139
   Zhu Hong, 2018, React Oxyg Species (Apex), V5, P118, DOI 10.20455/ros.2018.813
NR 78
TC 30
Z9 34
U1 1
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD SEP
PY 2020
VL 24
IS 18
BP 10768
EP 10784
DI 10.1111/jcmm.15702
EA AUG 2020
PG 17
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA NT8EF
UT WOS:000555291600001
PM 32750747
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Pettway, GJ
   Meganck, JA
   Koh, AJ
   Keller, ET
   Goldstein, SA
   McCauley, LK
AF Pettway, Glenda J.
   Meganck, Jeffrey A.
   Koh, Amy J.
   Keller, Evan T.
   Goldstein, Steven A.
   McCauley, Laurie K.
TI Parathyroid hormone mediates bone growth through the regulation of
   osteoblast proliferation and differentiation
SO BONE
LA English
DT Article
DE parathyroid hormone; zoledronic acid; bone marrow stromal cells;
   proliferation; tissue engineering
ID ANABOLIC ACTIONS; INTERMITTENT TREATMENT; GENE EXPRESSION;
   BISPHOSPHONATES; CELLS; PTH; ALENDRONATE; ACTIVATION; RATS;
   OSTEOPROTEGERIN
AB PTH (1 34) is the only FDA approved anabolic agent for osteoporosis treatment in the U.S., but its mechanisms are not completely understood. This study investigated PTH effects on osteogenic cells at various stages of differentiation and proliferation using an engineered bone growth model in vivo. Ossicles were generated from bone marrow stromal cells (BMSCs) implanted in immunocompromised mice. Three weeks of PTH (40 mu g/kg/day) or vehicle treatment initiated I day, 1, 2, or 3 weeks after BMSC implantation resulted in an anabolic response in PTH treated implants (via histomorphometry and microCT) in all treatment groups. A novel in vivo tracking strategy with luciferase tagged BMSCs and weekly bioluminescent imaging of ossicles revealed increased donor cell proliferation in PTH treated ossicles. The greatest increase occurred during the first week, and the activity remained elevated in PTH treated implants over time. Zoledronic acid (ZA) was combined with PTH to delineate interactive mechanisms of these bone active agents. Combining ZA with PTH treatment reduced the PTH mediated increase in luciferase BMSC activity, serum osteocalcin, and serum tartrate resistant acid phosphotase 5b (TRAP 5b) but ZA did not reduce the PTH induced increase in total bone. Since zoledronic acid reduced PTH induced proliferation without reducing bone volume, these data suggest that combining PTH and bisphosphonate therapy warrants further investigation in the treatment of bone disorders. (c) 2007 Elsevier Inc. All rights reserved.
C1 [Pettway, Glenda J.; Koh, Amy J.; McCauley, Laurie K.] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.
   [Pettway, Glenda J.; Meganck, Jeffrey A.; Goldstein, Steven A.] Univ Michigan, Coll Engn, Dept Biomed Engn, Ann Arbor, MI 48109 USA.
   [Meganck, Jeffrey A.; Goldstein, Steven A.] Univ Michigan, Dept Orthopaed Surg, Orthopaed Res Labs, Ann Arbor, MI 48109 USA.
   [Keller, Evan T.] Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI 48109 USA.
   [Keller, Evan T.; McCauley, Laurie K.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; University of Michigan System; University of
   Michigan; University of Michigan System; University of Michigan
RP McCauley, LK (通讯作者)，Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Room 3343,1011 N Univ Ave, Ann Arbor, MI 48109 USA.
EM gpettway@gmail.com; meganckj@umich.edu; ajkoh@umich.edu;
   etkeller@umich.edu; stevegld@umich.edu; mccauley@umich.edu
RI McCauley, Laurie/G 4041 2012; Keller, Evan/M 1446 2016
FU National Cancer Institute [P01CA093900] Funding Source: NIH RePORTER;
   NCI NIH HHS [P01 CA093900] Funding Source: Medline; NIDDK NIH HHS [R01
   DK053904, DK53904, R56 DK053904] Funding Source: Medline
CR Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   Bikle DD, 2002, J BONE MINER RES, V17, P1570, DOI 10.1359/jbmr.2002.17.9.1570
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032
   CECCHINI MG, 1990, J BONE MINER RES, V5, P1019
   CECCHINI MG, 1987, J BONE MINER RES, V2, P135
   Chaudhary LR, 1998, MOL CELL BIOCHEM, V178, P59, DOI 10.1023/A:1006807221545
   Chen HL, 2002, J BIOL CHEM, V277, P19374, DOI 10.1074/jbc.M108913200
   Cosman F, 1998, J BONE MINER RES, V13, P1051, DOI 10.1359/jbmr.1998.13.6.1051
   Datta NS, 2007, J BONE MINER RES, V22, P951, DOI 10.1359/JBMR.070328
   Demiralp B, 2002, ENDOCRINOLOGY, V143, P4038, DOI 10.1210/en.2002 220221
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Giuliani N, 1998, BONE, V22, P455, DOI 10.1016/S8756 3282(98)00033 7
   HOCK JM, 2002, PRINCIPLES BONE BIOL, V1, P463
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Johnston S, 2007, ENDOCRINOLOGY, V148, P4466, DOI 10.1210/en.2007 0229
   Koh AJ, 1999, ENDOCRINOLOGY, V140, P3154, DOI 10.1210/en.140.7.3154
   Koh AJ, 2005, ENDOCRINOLOGY, V146, P4584, DOI 10.1210/en.2005 0333
   KOZLOFFK, 2004, 5 COMB M ORTH RES SO
   LEAFFER D, 1995, ENDOCRINOLOGY, V136, P3624, DOI 10.1210/en.136.8.3624
   Lindsay R, 2007, J BONE MINER RES, V22, P495, DOI 10.1359/JBMR.070104
   LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485
   Meng XW, 1996, J BONE MINER RES, V11, P421
   Nakazawa T, 2005, BONE, V37, P711, DOI 10.1016/j.bone.2005.06.013
   Onishi T, 1997, ENDOCRINOLOGY, V138, P1995, DOI 10.1210/en.138.5.1995
   Pettway GJ, 2005, BONE, V36, P959, DOI 10.1016/j.bone.2005.02.015
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Reszka Alfred A, 2003, Curr Osteoporos Rep, V1, P45, DOI 10.1007/s11914 003 0008 5
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Rodan Gideon A., 2002, Current Molecular Medicine (Hilversum), V2, P571, DOI 10.2174/1566524023362104
   SAMADFAM R, 2007, J BONE MINER RES, V148, P2778
   Samadfam R, 2007, J BONE MINER RES, V22, P55, DOI 10.1359/JBMR.060915
   SANSONI P, 1995, J BONE MINER RES, V10, P1719
   Sato M, 2002, ENDOCRINOLOGY, V143, P3230, DOI 10.1210/en.2002 220149
   Schiller PC, 1999, J BONE MINER RES, V14, P1504, DOI 10.1359/jbmr.1999.14.9.1504
   Schneider A, 2005, ENDOCRINOLOGY, V146, P1727, DOI 10.1210/en.2004 1211
   SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
NR 44
TC 97
Z9 125
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2008
VL 42
IS 4
BP 806
EP 818
DI 10.1016/j.bone.2007.11.017
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 283NQ
UT WOS:000254643500023
PM 18234576
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Park, KR
   Kim, B
   Lee, JY
   Moon, HJ
   Kwon, IK
   Yun, HM
AF Park, Kyung Ran
   Kim, Bomi
   Lee, Joon Yeop
   Moon, Ho Jin
   Kwon, Il Keun
   Yun, Hyung Mun
TI Effects of Scoparone on differentiation, adhesion, migration, autophagy
   and mineralization through the osteogenic signalling pathways
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE Artemisia capillaris; autophagy; differentiation; mineralization;
   osteoblast; SCOP
ID BONE MORPHOGENETIC PROTEIN 2; OSTEOBLAST DIFFERENTIATION; MC3T3 E1
   CELLS; EXPRESSION; OSTEOPOROSIS; ASSOCIATION; ACTIVATION; MECHANISMS;
   OSTERIX; DAMAGE
AB Scoparone (SCOP), an active and efficient coumarin compound derived from Artemisia capillaris Thunb, has been used as a traditional Chinese herbal medicine. Herein, we investigated the effects of SCOP on the osteogenic processes using MC3T3 E1 pre osteoblasts in in vitro cell systems. SCOP (C11H10O4, > 99.17%) was purified and identified from A. capillaries. SCOP (0.1 to 100 mu M concentrations) did not have cytotoxic effects in pre osteoblasts; however, it promoted alkaline phosphatase (ALP) staining and activity, and mineralized nodule formation under early and late osteogenic induction. SCOP elevated osteogenic signals through the bone morphogenetic protein 2 (BMP2) Smad1/5/8 pathway, leading to the increased expression of runt related transcription factor 2 (RUNX2) with its target protein, matrix metallopeptidase 13 (MMP13). SCOP also induced the non canonical BMP2 MAPKs pathway, but not the Wnt3a beta catenin pathway. Moreover, SCOP promoted autophagy, migration and adhesion under the osteogenic induction. Overall, the findings of this study demonstrated that SCOP has osteogenic effects associated with cell differentiation, adhesion, migration, autophagy and mineralization.
C1 [Park, Kyung Ran] Korea Basic Sci Inst KBSI, Gwangju Ctr, Gwangju, South Korea.
   [Kim, Bomi; Lee, Joon Yeop] Natl Dev Inst Korean Med, Gyongsan, South Korea.
   [Moon, Ho Jin; Kwon, Il Keun] Kyung Hee Univ, Sch Dent, Dept Dent Mat, 26 Kyungheedae Ro, Seoul 02447, South Korea.
   [Kwon, Il Keun] Kyung Hee Univ, Med Ctr, Med Sci Res Inst, Med Device Res Ctr, Seoul, South Korea.
   [Yun, Hyung Mun] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, 26 Kyungheedae Ro, Seoul 02447, South Korea.
C3 Korea Basic Science Institute (KBSI); Kyung Hee University; Kyung Hee
   University; Kyung Hee University
RP Kwon, IK (通讯作者)，Kyung Hee Univ, Sch Dent, Dept Dent Mat, 26 Kyungheedae Ro, Seoul 02447, South Korea.; Yun, HM (通讯作者)，Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, 26 Kyungheedae Ro, Seoul 02447, South Korea.
EM kwoni@khu.ac.kr; yunhm@khu.ac.kr
OI Yun, Hyung Mun/0000 0001 6504 1610; Moon, Ho Jin/0000 0002 8056 5313
FU National Research Foundation of Korea [NRF 2022R1C1C1003491,
   NRF 2020R1A2C2011937]
FX National Research Foundation of Korea, Grant/Award Number:
   NRF 2020R1A2C2011937; National Research Foundation of Korea, Grant/Award
   Number: NRF 2022R1C1C1003491
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Artigas N, 2014, J BIOL CHEM, V289, P27105, DOI 10.1074/jbc.M114.576793
   Cai BJ, 2019, EXP CELL RES, V385, DOI 10.1016/j.yexcr.2019.111647
   Cha JD, 2009, J FOOD SCI, V74, pT75, DOI 10.1111/j.1750 3841.2009.01355.x
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen Y, 2007, J BIOL CHEM, V282, P526, DOI 10.1074/jbc.M602700200
   Chu CY, 1999, ARCH TOXICOL, V73, P263, DOI 10.1007/s002040050615
   Darcy A, 2012, BONE, V50, P1294, DOI 10.1016/j.bone.2012.03.001
   di Giacomo V, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082789
   Fukuda T, 2010, DIFFERENTIATION, V80, P46, DOI 10.1016/j.diff.2010.05.002
   Guntur AR, 2011, J ENDOCRINOL, V211, P123, DOI 10.1530/JOE 11 0175
   Han JM, 2013, EXP TOXICOL PATHOL, V65, P837, DOI 10.1016/j.etp.2012.12.002
   He CS, 2012, EXP THER MED, V4, P645, DOI 10.3892/etm.2012.666
   HUANG HC, 1991, EUR J PHARMACOL, V198, P211
   HUANG HC, 1992, EUR J PHARMACOL, V218, P123, DOI 10.1016/0014 2999(92)90155 W
   Jung HA, 2004, FOOD SCI BIOTECHNOL, V13, P328
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Kawai M, 2011, NAT REV DRUG DISCOV, V10, P141, DOI 10.1038/nrd3299
   Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200
   Kim IR, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1320 9
   Kim MB, 2014, FITOTERAPIA, V98, P59, DOI 10.1016/j.fitote.2014.07.013
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Lee CJ, 2016, AM J CHINESE MED, V44, P1675, DOI 10.1142/S0192415X16500944
   Lee HS, 2008, NUTR RES, V28, P270, DOI 10.1016/j.nutres.2008.02.001
   Lee HS, 2011, PHYTOTHER RES, V25, P716, DOI 10.1002/ptr.3328
   Lee SH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020322
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Li HX, 2018, AUTOPHAGY, V14, P1726, DOI 10.1080/15548627.2018.1483807
   Li WW, 2019, MOL MED REP, V19, P3676, DOI 10.3892/mmr.2019.10040
   Liu YX, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005467.pub2
   Lu C, 2018, BIOMED PHARMACOTHER, V106, P1169, DOI 10.1016/j.biopha.2018.07.062
   Marie PJ, 2015, CELL MOL LIFE SCI, V72, P1347, DOI 10.1007/s00018 014 1801 2
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Nishimura R, 2012, J BIOL CHEM, V287, P33179, DOI 10.1074/jbc.M111.337063
   Park KR, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111362
   Park KR, 2022, AM J CHINESE MED, V50, P295, DOI 10.1142/S0192415X22500112
   Park KR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249579
   Park KR, 2020, PHYTOMEDICINE, V79, DOI 10.1016/j.phymed.2020.153347
   Park KR, 2019, TOXICOLOGY, V422, P95, DOI 10.1016/j.tox.2019.05.010
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Russow G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010083
   Sato MM, 2009, GENES CELLS, V14, P141, DOI 10.1111/j.1365 2443.2008.01258.x
   Shapiro IM, 2014, AUTOPHAGY, V10, P7, DOI 10.4161/auto.26679
   Smith M, 2017, ESSAYS BIOCHEM, V61, P625, DOI 10.1042/EBC20170092
   Toriseva M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042596
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   Wang NN, 2021, FREE RADICAL BIO MED, V171, P112, DOI 10.1016/j.freeradbiomed.2021.05.014
   Wei M, 2014, MOL MED REP, V9, P2309, DOI 10.3892/mmr.2014.2079
   Yamagiwa H, 1999, BONE, V25, P197, DOI 10.1016/S8756 3282(99)00157 X
   Zhang LS, 2010, J BONE MINER RES, V25, P1572, DOI 10.1002/jbmr.36
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
   Zhao X, 2021, AM J TRANSL RES, V13, P4233
   Zheng XG, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414 431X20187574, 10.1590/1414 431x20187574]
NR 54
TC 9
Z9 9
U1 1
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD AUG
PY 2022
VL 26
IS 16
BP 4520
EP 4529
DI 10.1111/jcmm.17476
EA JUL 2022
PG 10
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 3O6GI
UT WOS:000821501500001
PM 35796406
OA Green Published
DA 2025 08 17
ER

PT J
AU Conceiçao, F
   Sousa, DM
   Loessberg Zahl, J
   Vollertsen, AR
   Neto, E
   Soe, K
   Paredes, J
   Leferink, A
   Lamghari, M
AF Conceicao, Francisco
   Sousa, Daniela M.
   Loessberg Zahl, Joshua
   Vollertsen, Anke R.
   Neto, Estrela
   Soe, Kent
   Paredes, Joana
   Leferink, Anne
   Lamghari, Meriem
TI A metastasis on a chip approach to explore the sympathetic modulation of
   breast cancer bone metastasis
SO MATERIALS TODAY BIO
LA English
DT Article
DE Metastasis on a chip; Breast cancer; Bone metastasis; Sympathetic
   nervous system; Paracrine
ID MICROFLUIDIC COCULTURE; TUMOR GROWTH; TGF BETA; CELLS; OSTEOCLAST;
   EXPRESSION; MODEL; OSTEOBLASTS; ENHANCEMENT; SURVIVAL
AB Organ on a chip models have emerged as a powerful tool to model cancer metastasis and to decipher specific crosstalk between cancer cells and relevant regulators of this particular niche. Recently, the sympathetic nervous system (SNS) was proposed as an important modulator of breast cancer bone metastasis. However, epidemiological studies concerning the benefits of the SNS targeting drugs on breast cancer survival and recurrence remain controversial. Thus, the role of SNS signaling over bone metastatic cancer cellular processes still requires further clarification. Herein, we present a novel humanized organ on a chip model recapitulating neuro breast cancer crosstalk in a bone metastatic context. We developed and validated an innovative three dimensional printing based multi compartment microfluidic platform, allowing both selective and dynamic multicellular paracrine signaling between sympathetic neurons, bone tropic breast cancer cells and osteoclasts. The selective multicellular crosstalk in combination with biochemical, microscopic and proteomic profiling show that synergistic paracrine signaling from sympathetic neurons and osteoclasts increase breast cancer aggressiveness demonstrated by augmented levels of pro inflammatory cytokines (e.g. interleukin 6 and macrophage inflammatory protein 1 alpha). Overall, this work introduced a novel and versatile platform that could potentially be used to unravel new mechanisms involved in intracellular communication at the bone metastatic niche.
C1 [Conceicao, Francisco; Sousa, Daniela M.; Neto, Estrela; Paredes, Joana; Lamghari, Meriem] Univ Porto, Inst Invest & Inovacao Saude I3S, P 4200135 Porto, Portugal.
   [Conceicao, Francisco; Sousa, Daniela M.; Neto, Estrela; Lamghari, Meriem] Univ Porto, INEB Inst Nacl Engn Biomed, P 4200135 Porto, Portugal.
   [Conceicao, Francisco; Lamghari, Meriem] Univ Porto, ICBAS Inst Ciencias Biomed Abel Salazar, P 4050313 Porto, Portugal.
   [Paredes, Joana] Univ Porto, IPATIMUP Inst Patol & Imunol Mol, P 4200135 Porto, Portugal.
   [Paredes, Joana] Univ Porto, FMUP Fac Med, P 4200319 Porto, Portugal.
   [Loessberg Zahl, Joshua] Univ Twente, MESA Inst Nanotechnol, BIOS Lab Chip Grp, Max Planck Univ Twente Ctr Complex Fluid Dynam, POB 217, NL 7500 AE Enschede, Netherlands.
   [Vollertsen, Anke R.; Leferink, Anne] Univ Twente, TechMed Ctr, Appl Stem Cell Technol, POB 217, NL 7500 AE Enschede, Netherlands.
   [Soe, Kent] Univ Southern Denmark, Vejle Hosp, Dept Reg Hlth Res, Clin Cell Biol,Lillebaelt Hosp, DK 7100 Vejle, Denmark.
   [Soe, Kent] Univ Southern Denmark, Dept Clin Res, Pathol Res Unit, Clin Cell Biol, DK 5230 Odense, Denmark.
C3 Universidade do Porto; i3S   Instituto de Investigacao e Inovacao em
   Saude, Universidade do Porto; Universidade do Porto; Universidade do
   Porto; Universidade do Porto; Universidade do Porto; University of
   Twente; University of Twente; University of Southern Denmark; Lillebaelt
   Hospital; University of Southern Denmark
RP Lamghari, M (通讯作者)，Univ Porto, Inst Invest & Inovacao Saude I3S, P 4200135 Porto, Portugal.
EM lamghari@ineb.up.pt
RI Lamghari, Meriem/K 2159 2013; Soe, Kent/N 3618 2017; Conceição,
   Francisco/HCI 8740 2022; Sousa, Daniela/C 1485 2014; Paredes,
   Joana/F 8224 2011; Leferink, Ir./G 5024 2012; Neto, Estrela/M 2561 2013
OI Lamghari, Meriem/0000 0002 2500 4548; Soe, Kent/0000 0001 7402 314X;
   Sousa, Daniela/0000 0001 8498 0664; Paredes, Joana/0000 0002 1076 1343;
   Conceicao, Francisco/0000 0003 4587 2470; Neto,
   Estrela/0000 0003 2334 2292
FU i3S Scientific Platform Bioimaging [PPBI POCI 01 0145 FEDER 022122];
   FEDER Fundo Europeu de Desenvolvimento Regional funds through the
   COMPETE 2020 Operacional Programme for Competi tiveness and
   Internationalisation (POCI) , Portugal 2020; FCT/MCTES
   [POCI 01 0145 FEDER 030158, PTDC/MED PAT/30158/2017]; VESCEL ERC
   Advanced Grant [669768];  [SFRH/BD/128771/2017]; 
   [SFRH/BPD/115341/2016]; European Research Council (ERC) [669768] Funding
   Source: European Research Council (ERC); Fundação para a Ciência e a
   Tecnologia [SFRH/BPD/115341/2016, PTDC/MED PAT/30158/2017] Funding
   Source: FCT
FX The authors would like to acknowledge Inez Duursma for the first
   generation design of the three compartment microfluidic chip and Hugo
   Oso?rio and the I3S Scientific Platform Proteomics for the help with the
   proteomic screening of cancer conditioned medium. The authors also thank
   Pedro Sousa and Anabela Nunes from the I3S Communication Unit for their
   help in illustration design. The authors acknowledge the support of the
   i3S Scientific Platform Bioimaging, member of the national
   infrastructure PPBI Portuguese Platform of Bioimaging
   (PPBI POCI 01 0145 FEDER 022122) , for confocal imaging acquisition.
   This work was financed by FEDER Fundo Europeu de Desenvolvimento
   Regional funds through the COMPETE 2020 Operacional Programme for
   Competi tiveness and Internationalisation (POCI) , Portugal 2020, and
   Portuguese funds through FCT/MCTES in the framework of the project
   "SproutOC" (POCI 01 0145 FEDER 030158, PTDC/MED PAT/30158/2017) . F.C.
   is a recipient of the Ph.D. fellowship SFRH/BD/128771/2017. D.M.S. is a
   recipient of Post Doc fellowship SFRH/BPD/115341/2016. J.L. and A.R.V.
   were funded under the VESCEL ERC Advanced Grant to A. van der Berg
   (grant no. 669768) .
CR Ahn J, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00168
   Aleman J, 2019, SMALL, V15, DOI 10.1002/smll.201902971
   Andriessen AS, 2021, PAIN REP, V6, DOI 10.1097/PR9.0000000000000867
   Arai M, 2003, BBA MOL CELL RES, V1640, P137, DOI 10.1016/S0167 4889(03)00042 9
   Bersini S, 2014, BIOMATERIALS, V35, P2454, DOI 10.1016/j.biomaterials.2013.11.050
   Bischel LL, 2014, INTEGR BIOL UK, V6, P627, DOI 10.1039/c3ib40240a
   Brooks DLP, 2016, MOL CANCER, V15, DOI 10.1186/s12943 016 0510 x
   Cai WL, 2018, MOL CANCER, V17, DOI 10.1186/s12943 017 0746 0
   Campbell JP, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001363
   Cardwell CR, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058 016 0782 5
   Cardwell CR, 2013, INT J EPIDEMIOL, V42, P1852, DOI 10.1093/ije/dyt196
   Chiou AE, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf2283
   Chou DB, 2020, NAT BIOMED ENG, DOI 10.1038/s41551 019 0495 z
   Chramiec A, 2020, LAB CHIP, V20, P4357, DOI 10.1039/d0lc00424c
   Clément Demange L, 2018, J BONE ONCOL, V13, P1, DOI 10.1016/j.jbo.2018.09.002
   Coleman RE, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572 020 00216 3
   Comina G, 2014, LAB CHIP, V14, P2978, DOI 10.1039/c4lc00394b
   Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200
   Hao SJ, 2018, SMALL, V14, DOI 10.1002/smll.201702787
   Higgins DF, 2004, AM J PHYSIOL RENAL, V287, pF1223, DOI 10.1152/ajprenal.00245.2004
   Hiraga T, 2007, CANCER RES, V67, P4157, DOI 10.1158/0008 5472.CAN 06 2355
   Hughes CS, 2019, NAT PROTOC, V14, P68, DOI 10.1038/s41596 018 0082 x
   Hynes RO, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a004903
   Imamura Y, 2015, ONCOL REP, V33, P1837, DOI 10.3892/or.2015.3767
   Ishiguro T, 2017, CANCER SCI, V108, P283, DOI 10.1111/cas.13155
   Jeon JS, 2015, P NATL ACAD SCI USA, V112, P214, DOI 10.1073/pnas.1417115112
   Jiang X, 2021, SMALL, V17, DOI 10.1002/smll.202004282
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kim B, 2020, J BONE MINER RES, V35, P155, DOI 10.1002/jbmr.3869
   Kitson PJ, 2012, LAB CHIP, V12, P3267, DOI 10.1039/c2lc40761b
   Kong J, 2016, ONCOTARGET, V7, P78421, DOI 10.18632/oncotarget.9382
   Kovalevich J, 2013, METHODS MOL BIOL, V1078, P9, DOI 10.1007/978 1 62703 640 5_2
   Le Pape F, 2016, J BONE ONCOL, V5, P93, DOI 10.1016/j.jbo.2016.02.008
   Lee YS, 2018, LAB CHIP, V18, P1207, DOI [10.1039/c8lc00001h, 10.1039/C8LC00001H]
   Leitao L, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0096 1
   Li R, 2017, ANAL BIOCHEM, V539, P48, DOI 10.1016/j.ab.2017.10.008
   Madden KS, 2011, BREAST CANCER RES TR, V130, P747, DOI 10.1007/s10549 011 1348 y
   Marturano Kruik A, 2018, P NATL ACAD SCI USA, V115, P1256, DOI 10.1073/pnas.1714282115
   May JM, 2012, BIOCHEM BIOPH RES CO, V426, P148, DOI 10.1016/j.bbrc.2012.08.054
   Mei XT, 2019, INTEGR BIOL UK, V11, P119, DOI 10.1093/intbio/zyz008
   Merrild DMH, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.32
   Middleton K, 2017, J BIOMECH, V59, P35, DOI 10.1016/j.jbiomech.2017.05.012
   Mulcrone PL, 2017, J BONE MINER RES, V32, P1442, DOI 10.1002/jbmr.3133
   Neto E, 2014, INTEGR BIOL UK, V6, P586, DOI 10.1039/c4ib00035h
   Okui T, 2021, J BONE ONCOL, V26, DOI 10.1016/j.jbo.2020.100330
   Okuyama N, 2008, ONCOL REP, V20, P1497, DOI 10.3892/or_00000171
   Osório H, 2021, J CLIN MED, V10, DOI 10.3390/jcm10030407
   Piñero CP, 2012, BRIT J PHARMACOL, V166, P721, DOI 10.1111/j.1476 5381.2011.01791.x
   Powe DG, 2010, ONCOTARGET, V1, P628, DOI 10.18632/oncotarget.197
   Shiirevnyamba A, 2011, BRIT J CANCER, V104, P505, DOI 10.1038/sj.bjc.6606070
   Sloan EK, 2010, CANCER RES, V70, P7042, DOI 10.1158/0008 5472.CAN 10 0522
   Soe K, 2017, J CELL SCI, V130, P2026, DOI 10.1242/jcs.202036
   Soe K, 2013, BONE, V56, P191, DOI 10.1016/j.bone.2013.06.007
   Soe K, 2010, J BONE MINER RES, V25, P2184, DOI 10.1002/jbmr.113
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   Unger MA, 2000, SCIENCE, V288, P113, DOI 10.1126/science.288.5463.113
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Vanderoost J, 2013, CALCIFIED TISSUE INT, V92, P240, DOI 10.1007/s00223 012 9674 6
   Wakabayashi H, 2018, BREAST CANCER TOKYO, V25, P566, DOI 10.1007/s12282 018 0853 9
   Weber KL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040799
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Yang EV, 2009, BRAIN BEHAV IMMUN, V23, P267, DOI 10.1016/j.bbi.2008.10.005
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Yuan XX, 2021, THERANOSTICS, V11, P1429, DOI 10.7150/thno.45351
   Zeltner N, 2016, NAT MED, V22, P1421, DOI 10.1038/nm.4220
   Zhang WT, 2014, TISSUE ENG PART C ME, V20, P663, DOI [10.1089/ten.tec.2013.0490, 10.1089/ten.TEC.2013.0490]
   Zheng L, 2013, INT J BIOL SCI, V9, P830, DOI 10.7150/ijbs.7039
NR 67
TC 40
Z9 42
U1 2
U2 47
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2590 0064
J9 MATER TODAY BIO
JI Mater. Today Bio
PD JAN
PY 2022
VL 13
AR 100219
DI 10.1016/j.mtbio.2022.100219
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA ZH5WE
UT WOS:000761008100005
PM 35243294
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wang, N
   Robaye, B
   Agrawal, A
   Skerry, TM
   Boeynaems, JM
   Gartland, A
AF Wang, Ning
   Robaye, Bernard
   Agrawal, Ankita
   Skerry, Timothy M.
   Boeynaems, Jean Marie
   Gartland, Alison
TI Reduced Bone Turnover in Mice Lacking the P2Y13 Receptor of
   ADP
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID OSTEOCLASTS IN VITRO; NF KAPPA B; PHARMACOLOGICAL CHARACTERIZATION;
   EXTRACELLULAR NUCLEOTIDES; NORADRENALINE RELEASE; SIGNALING DOWNSTREAM;
   HDL ENDOCYTOSIS; RAT OSTEOBLASTS; TRABECULAR BONE; P2Y RECEPTORS
AB Osteoporosis is a condition of excessive and uncoupled bone turnover, in which osteoclastic resorption exceeds osteoblastic bone formation, resulting in an overall net bone loss, bone fragility, and morbidity. Although numerous treatments have been developed to inhibit bone loss by blocking osteoclastic bone resorption, understanding of the mechanisms behind bone loss is incomplete. The purinergic signaling system is emerging to be a pivotal regulator of bone homeostasis, and extracellular ADP has previously been shown to be a powerful osteolytic agent in vitro. We report here that deletion of the P2Y(13) receptor, a G protein coupled receptor for extracellular ADP, leads to a 40% reduction in trabecular bone mass, 50% reduction in osteoblast and osteoclast numbers in vivo, as well as activity in vitro, and an overall 50% reduction in the rate of bone remodeling in mice in vivo. Down regulation of RhoA/ROCK I signaling and a reduced ratio of receptor activator of nuclear factor kappa B ligand/osteoprotegerin observed in osteoblasts from P2Y(13)R( / ) mice might explain this bone phenotype. Furthermore, because one of the main causes of osteoporosis in older women is lack of estrogen, we examined the effect of ovariectomy of the P2Y(13)R( / ) mice and found them to be protected from ovariectomy induced bone loss by up to 65%. These data confirm a role of purinergic ADP signaling in the skeleton, whereby deletion of the P2Y(13) receptor leads to reduced bone turnover rates, which provide a protective advantage in conditions of accelerated bone turnover such as oestrogen deficiency induced osteoporosis. (Molecular Endocrinology 26: 142 152, 2012)
C1 [Wang, Ning; Agrawal, Ankita; Skerry, Timothy M.; Gartland, Alison] Univ Sheffield, Mellanby Ctr Bone Res, Dept Human Metab, Sheffield S10 2RX, S Yorkshire, England.
   [Robaye, Bernard; Boeynaems, Jean Marie] Univ Libre Bruxelles, Inst Rech Interdisciplinaire Biol Humaine & Mol, Inst Interdisciplinary Res, B 6041 Gosselies, Belgium.
   [Boeynaems, Jean Marie] Erasme Univ Hosp, Dept Med Chem, B 1070 Brussels, Belgium.
C3 University of Sheffield; Universite Libre de Bruxelles; Universite Libre
   de Bruxelles
RP Gartland, A (通讯作者)，Univ Sheffield, Mellanby Ctr Bone Res, Dept Human Metab, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
EM a.gartland@sheffield.ac.uk
RI ; Agrawal, Ankita/R 2437 2016; Gartland, Alison/A 2152 2012; Wang,
   Ning/HKO 8446 2023
OI WANG, NING/0000 0002 2663 7515; Gartland, Alison/0000 0002 3712 2437;
   Agrawal, Ankita/0000 0003 1055 9142; Skerry, Timothy/0000 0003 1319 5575
FU European Commission [202231]
FX This work was supported by the European Commission under the 7th
   Framework Program (proposal 202231) performed as a collaborative project
   among the members of the ATPBone Consortium (Copenhagen University,
   University College London, University of Maastricht, University of
   Ferrara, University of Liverpool, University of Sheffield, and
   Universite Libre de Bruxelles) and is a substudy under the main study
   "Fighting osteoporosis by blocking nucleotides: purinergic signaling in
   bone formation and homeostasis."
CR Agrawal A, 2010, PURINERG SIGNAL, V6, P307, DOI 10.1007/s11302 010 9181 z
   Alvarenga ÉC, 2010, BONE, V46, P355, DOI 10.1016/j.bone.2009.09.017
   [Anonymous], [No title captured]
   Arnett TR, 2003, J CELL PHYSIOL, V196, P2, DOI 10.1002/jcp.10321
   Blom D, 2010, BBA MOL CELL BIOL L, V1801, P1349, DOI 10.1016/j.bbalip.2010.08.013
   Buckley KA, 2002, BONE, V31, P582, DOI 10.1016/S8756 3282(02)00877 3
   Buckley KA, 2001, J BIOL CHEM, V276, P9565, DOI 10.1074/jbc.M005672200
   Burnstock G, 2007, CELL MOL LIFE SCI, V64, P1471, DOI 10.1007/s00018 007 6497 0
   Carrasquero LMG, 2009, J NEUROCHEM, V110, P879, DOI 10.1111/j.1471 4159.2009.06179.x
   CARRON JA, 1995, BIOCHEM BIOPH RES CO, V213, P1017, DOI 10.1006/bbrc.1995.2230
   Chu XY, 2006, J PHARMACOL EXP THER, V317, P579, DOI 10.1124/jpet.105.098665
   Communi D, 2001, J BIOL CHEM, V276, P41479, DOI 10.1074/jbc.M105912200
   Csölle C, 2008, J NEUROCHEM, V106, P347, DOI 10.1111/j.1471 4159.2008.05391.x
   Delmas PD, 2000, OSTEOPOROSIS INT, V11, P2, DOI 10.1007/s001980070002
   Dixon CJ, 1997, BRIT J PHARMACOL, V120, P777
   Fabre AC, 2010, HEPATOLOGY, V52, P1477, DOI 10.1002/hep.23897
   Fumagalli M, 2004, BIOCHEM PHARMACOL, V68, P113, DOI 10.1016/j.bcp.2004.02.038
   Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307
   Gartland A, 2003, CRIT REV EUKAR GENE, V13, P243, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.160
   Gartland A, 2003, CALCIFIED TISSUE INT, V73, P361, DOI 10.1007/s00223 002 2098 y
   Goodyear SR, 2009, BONE, V44, P899, DOI 10.1016/j.bone.2009.01.008
   Govoni KE, 2008, AM J PHYSIOL ENDOC M, V295, pE1172, DOI 10.1152/ajpendo.90507.2008
   Grimm I, 2009, J CELL SCI, V122, P2524, DOI 10.1242/jcs.044891
   HAHN M, 1992, BONE, V13, P327, DOI 10.1016/8756 3282(92)90078 B
   Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104
   Heinrich A, 2008, NEUROPHARMACOLOGY, V54, P375, DOI 10.1016/j.neuropharm.2007.10.013
   Hoebertz A, 2001, FASEB J, V15, P1139, DOI 10.1096/fj.00 0395com
   Idris A, 2008, BIOCHEM BIOPH RES CO, V371, P94, DOI 10.1016/j.bbrc.2008.04.014
   Iwaniec UT, 2006, J BONE MINER RES, V21, P1068, DOI 10.1359/JBMR.060402
   Jacquet S, 2005, CELL MOL LIFE SCI, V62, P2508, DOI 10.1007/s00018 005 5194 0
   Ke HZ, 2003, MOL ENDOCRINOL, V17, P1356, DOI 10.1210/me.2003 0021
   Khatiwala CB, 2009, J BONE MINER RES, V24, P886, DOI [10.1359/jbmr.081240, 10.1359/JBMR.081240]
   Korcok J, 2005, J BIOL CHEM, V280, P16909, DOI 10.1074/jbc.M410764200
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Malaval C, 2009, CELL SIGNAL, V21, P120, DOI 10.1016/j.cellsig.2008.09.016
   Marionneau C, 2005, J PHYSIOL LONDON, V562, P223, DOI 10.1113/jphysiol.2004.074047
   Marteau F, 2003, MOL PHARMACOL, V64, P104, DOI 10.1124/mol.64.1.104
   Morrison MS, 1998, J PHYSIOL LONDON, V511, P495, DOI 10.1111/j.1469 7793.1998.495bh.x
   Nakamura E, 2000, AM J PHYSIOL CELL PH, V279, pC510, DOI 10.1152/ajpcell.2000.279.2.C510
   Nakamura H, 2003, J BONE MINER RES, V18, P1198, DOI 10.1359/jbmr.2003.18.7.1198
   Odvina CV, CLIN ENDOCRINOL, p[72, 161]
   Orriss Isabel, 2011, Front Biosci (Schol Ed), V3, P1038
   Orriss IR, 2007, ENDOCRINOLOGY, V148, P4208, DOI 10.1210/en.2007 0066
   Orriss IR, 2006, BONE, V39, P300, DOI 10.1016/j.bone.2006.02.063
   Orriss IR, 2010, CURR OPIN PHARMACOL, V10, P322, DOI 10.1016/j.coph.2010.01.003
   Orriss IR, 2009, J CELL PHYSIOL, V220, P155, DOI 10.1002/jcp.21745
   Orriss IR, 2009, J CELL BIOCHEM, V106, P109, DOI 10.1002/jcb.21983
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   PAUL H, 1983, ARTHRITIS RHEUM, V26, P191, DOI 10.1002/art.1780260211
   Queiroz G, 2003, J PHARMACOL EXP THER, V307, P809, DOI 10.1124/jpet.103.054809
   Seeman E, 2003, J APPL PHYSIOL, V95, P2142, DOI 10.1152/japplphysiol.00564.2003
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   VANTHOF RJ, 1995, INT J EXP PATHOL, V76, P205
   WALSH CA, 1991, J BONE MINER RES, V6, P661
   Wang LW, 2005, CIRC RES, V96, P189, DOI 10.1161/01.RES.0000153670.07559.E4
   Wittenberger T, 2001, J MOL BIOL, V307, P799, DOI 10.1006/jmbi.2001.4520
   Zhang FL, 2002, J PHARMACOL EXP THER, V301, P705, DOI 10.1124/jpet.301.2.705
NR 57
TC 43
Z9 46
U1 1
U2 6
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815 5817 USA
SN 0888 8809
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD JAN
PY 2012
VL 26
IS 1
BP 142
EP 152
DI 10.1210/me.2011 1083
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 877RO
UT WOS:000299199800013
PM 22108801
OA Green Accepted, Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Voss, PJ
   Poxleitner, P
   Schmelzeisen, R
   Stricker, A
   Semper Hogg, W
AF Voss, P. J.
   Poxleitner, P.
   Schmelzeisen, R.
   Stricker, A.
   Semper Hogg, W.
TI Update MRONJ and perspectives of its treatment
SO JOURNAL OF STOMATOLOGY ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article; Proceedings Paper
CT 53rd SFSCMFCO Congress
CY OCT 04 07, 2017
CL Marseille, FRANCE
SP SFSCMFCO
DE Bisphosphonates; Osteonecrosis of the jaw; Denosumab; ARONJ
ID MEDICATION RELATED OSTEONECROSIS; SURGICAL TREATMENT; JAW; PREVENTION
AB Antiresorptive agents are widely used in catabolic bone diseases. Not only bisphosphonates but also new drugs like Denosumab may induce osteonecrosis of the jaw as a side effect. The present review describes the current effect mechanisms of commonly used antiresorptives, pathogenetic theories for the development of antiresorptive related osteonecrosis of the jaw (ARONJ), and potential risk factors. Furthermore, diagnostic modalities and treatment options as well as new and innovative strategies are discussed. The major key factor to avoid the occurrence of ARONJ still remains the implementation of throughout preventive measures. (C) 2017 Elsevier Masson SAS. All rights reserved.
C1 [Voss, P. J.; Poxleitner, P.; Schmelzeisen, R.; Stricker, A.; Semper Hogg, W.] Univ Med Ctr Freiburg, Ctr Dent Med, Dept Oral & Craniomaxillofacial Surg, Hugstetter Str 55, D 79106 Freiburg, Germany.
C3 University of Freiburg
RP Semper Hogg, W (通讯作者)，Univ Med Ctr Freiburg, Ctr Dent Med, Dept Oral & Craniomaxillofacial Surg, Hugstetter Str 55, D 79106 Freiburg, Germany.
EM wiebke.semper.hogg@uniklinik freiburg.de
RI Voss, Pit/ABE 5710 2020; Stricker, Andres/ABH 5800 2020
OI Semper, Wiebke/0000 0003 3255 3091; , Andres/0000 0003 4764 9563;
   Schmelzeisen, Rainer/0000 0002 9686 6989; Poxleitner,
   Philipp/0000 0003 1551 1797
CR Abdelsalam H, 2008, J CARDIOVASC SURG, V49, P187
   Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   Cardoso CL, 2017, INT J DENT, V2017, P1, DOI 10.1155/2017/3190301
   Ficarra G, 2005, J CLIN PERIODONTOL, V32, P1123, DOI 10.1111/j.1600 051X.2005.00842.x
   Gaudin E, 2015, J CLIN PERIODONTOL, V42, P922, DOI 10.1111/jcpe.12455
   Hamadeh IS, 2015, CANCER TREAT REV, V41, P455, DOI 10.1016/j.ctrv.2015.04.007
   Hines SL, 2009, BREAST CANCER RES TR, V117, P603, DOI 10.1007/s10549 009 0332 2
   Jeong HG, 2017, IMAGNG SCI DENT, V47, P41, DOI 10.5624/isd.2017.47.1.45
   Lemound J, 2012, CLIN ORAL INVEST, V16, P1143, DOI 10.1007/s00784 011 0596 x
   Liu J, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002014
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Matsumoto A, 2017, CLIN ORAL INVEST, V21, P127, DOI 10.1007/s00784 016 1762 y
   Nagaoka Y, 2015, J DENT RES, V94, P594, DOI 10.1177/0022034514564187
   Norholt SE, 2016, INT J ORAL MAX SURG, V45, P1256, DOI 10.1016/j.ijom.2016.04.010
   Pazianas M, 2011, BONE, V49, P103, DOI 10.1016/j.bone.2011.01.003
   Poxleitner P, 2017, DTSCH ARZTEBL INT, V114, P63, DOI 10.3238/arztebl.2017.0063
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Stockmann P, 2010, CLIN ORAL INVEST, V14, P311, DOI 10.1007/s00784 009 0293 1
   Treister NS, 2010, ORAL SURG ORAL MED O, V109, P753, DOI 10.1016/j.tripleo.2009.12.005
   Voss PJ, 2012, J CRANIO MAXILL SURG, V40, P719, DOI 10.1016/j.jcms.2012.01.005
   Walter C, 2016, INT J IMPLANT DENT, V2, DOI 10.1186/s40729 016 0041 7
   Walter C, 2010, HEAD FACE MED, V6, DOI 10.1186/1746 160X 6 11
NR 23
TC 25
Z9 29
U1 1
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2468 8509
EI 2468 7855
J9 J STOMATOL ORAL MAXI
JI J. Stomatol. Oral Maxillofac. Surg.
PD SEP
PY 2017
VL 118
IS 4
BP 232
EP 235
DI 10.1016/j.jormas.2017.06.012
PG 4
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Dentistry, Oral Surgery & Medicine
GA FW0QU
UT WOS:000425001000007
PM 28697987
DA 2025 08 17
ER

PT J
AU Keever, AL
   Collins, KM
   Clark, RA
   Framstad, AL
   Ashley, JW
AF Keever, Abigail L.
   Collins, Kathryn M.
   Clark, Rachel A.
   Framstad, Amber L.
   Ashley, Jason W.
TI RANK signaling in osteoclast precursors results in a more permissive
   epigenetic landscape and sexually divergent patterns of gene expression
SO PEERJ
LA English
DT Article
DE Osteoclasts; RANK signaling; RNA seq; ATAC seq; Sexual dimorphism;
   Macrophages
ID DIFFERENT SKELETAL SITES; SEX STEROID LEVELS; STRUCTURAL PARAMETERS;
   BONE; OSTEOPOROSIS; MECHANISM; AROMATASE; PATHWAY; HEALTH; LIGAND
AB Background: Sex is an important risk factor in the development of osteoporosis and other bone loss disorders, with women often demonstrating greater susceptibility than men. While variation in sex steroids, such as estradiol, accounts for much of the risk, there are likely additional non endocrine factors at transcriptional and epigenetic levels that result in a higher rate of bone loss in women. Identification of these factors could improve risk assessment and therapies to preserve and improve bone health.Methods: Osteoclast precursors were isolated male and female C57Bl/6 mice and cultured with either MCSF alone or MCSF and RANKL. Following the culture period RNA was isolated for RNA sequencing and DNA was isolated for tagmentation and ATAC sequencing. RNA Seq and ATAC seq were evaluated via pathway analysis to identify sex and RANKL differential transcription and chromatin accessibility.Results: Osteoclasts demonstrated significant alterations in gene expression compared to macrophages with both shared and differential pathways between the sexes. Transcriptional pathways differentially regulated between male and female cells were associated with immunological functions with evidence of greater sensitivity in male macrophages and female osteoclasts. ATAC Seq revealed a large increase in chromatin accessibility following RANKL treatment with few alterations attributable to sex. Comparison of RNA Seq and ATAC seq data revealed few common pathways suggesting that many of the transcriptional changes of osteoclastogenesis occur independently of chromatin remodeling.
C1 [Keever, Abigail L.] Washington State Univ, Elson S Floyd Coll Med, Spokane, WA USA.
   [Keever, Abigail L.; Collins, Kathryn M.; Clark, Rachel A.; Framstad, Amber L.; Ashley, Jason W.] Eastern Washington Univ, Dept Biol, Cheney, WA 99004 USA.
C3 Washington State University; Eastern Washington University
RP Ashley, JW (通讯作者)，Eastern Washington Univ, Dept Biol, Cheney, WA 99004 USA.
EM jashley6@ewu.edu
RI Ashley, Jason/S 9142 2019
OI Ashley, Jason/0000 0003 1064 542X
FU Faculty Grant in Research and Creative Works (FGRCW) from Eastern
   Washington University
FX This work was supported by a Faculty Grant in Research and Creative
   Works (FGRCW) from Eastern Washington University. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Ahsan S., 2017, Curr. Protoc. Bioinform, V57, P7, DOI [DOI 10.1002/CPBI.24, 10.1002/CPBI.24]
   Alswat Khaled A, 2017, J Clin Med Res, V9, P382, DOI 10.14740/jocmr2970w
   Astleford K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197080
   Barcena ML, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.758767
   Chen KHE, 2021, J IMMUNOL, V206, P141, DOI 10.4049/jimmunol.2000490
   Da WCL, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.675385
   Das P, 2018, P NATL ACAD SCI, P115
   de Villiers TJ, 2009, BEST PRACT RES CL OB, V23, P73, DOI 10.1016/j.bpobgyn.2008.10.009
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Gal Oz ST, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12348 6
   Gennari L, 2004, J CLIN ENDOCR METAB, V89, P5898, DOI 10.1210/jc.2004 1717
   Goel PN, 2019, J ORTHOP RES, V37, P2089, DOI 10.1002/jor.24384
   Hart SN, 2013, J COMPUT BIOL, V20, P970, DOI 10.1089/cmb.2012.0283
   Iki M, 2004, OSTEOPOROSIS INT, V15, P981, DOI 10.1007/s00198 004 1634 1
   Jiang LY, 2022, INT J BIOL SCI, V18, P1303, DOI 10.7150/ijbs.66931
   Kaur G, 2017, JOVE J VIS EXP, DOI 10.3791/55234
   Kelsey TW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109346
   Khosla S, 2005, J CLIN ENDOCR METAB, V90, P5096, DOI 10.1210/jc.2005 0396
   Khosla S, 2005, J BONE MINER RES, V20, P730, DOI 10.1359/JBMR.041228
   Kim BJ, 2018, J CLIN INVEST, V128, P1429, DOI 10.1172/JCI91086
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Krum SA, 2008, EMBO J, V27, P535, DOI 10.1038/sj.emboj.7601984
   Larsson J., 2020, EULERR AREA PROPORTI
   Li BE, 2020, FASEB J, V34, P11058, DOI 10.1096/fj.202000771R
   Li K, 2009, CIRC RES, V105, P353, DOI 10.1161/CIRCRESAHA.109.195230
   Liu JZ, 2009, J BIOL CHEM, V284, P12512, DOI 10.1074/jbc.M809789200
   Machado ABD, 1999, J BONE MINER RES, V14, P602
   Marriott I, 2006, J REPROD IMMUNOL, V71, P12, DOI 10.1016/j.jri.2006.01.004
   Matsuo K, 2012, CELL ADHES MIGR, V6, P148, DOI 10.4161/cam.20888
   Mun SH, 2021, J BONE MINER RES, V36, P1104, DOI 10.1002/jbmr.4270
   Recker R, 2004, J BONE MINER RES, V19, P1628, DOI 10.1359/JBMR.040710
   Rohatgi N, 2018, BLOOD ADV, V2, P2467, DOI 10.1182/bloodadvances.2018018309
   Sasano H, 1997, J BONE MINER RES, V12, P1416, DOI 10.1359/jbmr.1997.12.9.1416
   Sebbag E, 2019, ANN RHEUM DIS, V78, P844, DOI 10.1136/annrheumdis 2019 215142
   Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197
   Shin Y, 2019, EPIGENET CHROMATIN, V12, DOI 10.1186/s13072 019 0270 0
   Song MJ, 2022, PEERJ, V10, DOI 10.7717/peerj.13159
   St Laurent G, 2013, METHODS, V63, P18, DOI 10.1016/j.ymeth.2013.03.027
   Tarca AL, 2009, BIOINFORMATICS, V25, P75, DOI 10.1093/bioinformatics/btn577
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Therneau Terry M, 2017, Bioconductor, DOI 10.18129/B9.BIOC.RNASEQPOWER
   Watts NB, 2008, J CLIN DENSITOM, V11, P473, DOI 10.1016/j.jocd.2008.04.003
   Yelin E, 2016, SEMIN ARTHRITIS RHEU, V46, P259, DOI 10.1016/j.semarthrit.2016.07.013
   Zhu XZ, 2018, MOL MED REP, V17, P1561, DOI 10.3892/mmr.2017.8045
NR 45
TC 1
Z9 1
U1 0
U2 1
PU PEERJ INC
PI LONDON
PA 341 345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167 8359
J9 PEERJ
JI PeerJ
PD FEB 9
PY 2023
VL 11
AR e4814
DI 10.7717/peerj.14814
PG 27
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA P7TH4
UT WOS:001052655600003
PM 36788807
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Qi, GB
   Jiang, ZX
   Lu, W
   Li, DF
   Chen, WB
   Yang, XY
   Ding, L
   Yuan, HF
AF Qi, Guobin
   Jiang, Zengxin
   Lu, Wei
   Li, Defang
   Chen, Weibing
   Yang, Xiuying
   Ding, Lei
   Yuan, Hengfeng
TI Berbamine inhibits RANKL  and M CSF mediated osteoclastogenesis and
   alleviates ovariectomy induced bone loss
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE berbamine; osteoclastogenesis; osteoporosis; NF kappa B; MAPK
ID KAPPA B; DIFFERENTIATION; OSTEOPOROSIS; HOMEOSTASIS; GROWTH
AB Osteoporosis is a common public health problem characterized by decreased bone mass, increased bone brittleness and damage to the bone microstructure. Excessive bone resorption by osteoclasts is the main target of the currently used drugs or treatment for osteoporosis. Effective antiresorptive drugs without side effects following long term administration have become a major focus of anti osteoporotic drugs. In the present study, we investigated the effect of berbamine, a small molecule natural product from Berberis amurensis Rupr, a traditional Chinese medicine, on RANKL induced osteoclast differentiation in vitro and ovariectomy induced bone loss in vivo. The results demonstrated that berbamine at a safe and effective dose inhibited osteoclastogenesis and bone resorption function in vitro by suppressing the nuclear factor kappa B signaling pathway. In addition, berbamine protected against osteoporosis by inhibiting osteoclastogenesis and bone resorption function without affecting osteogenesis in the ovariectomy mouse model. These findings revealed that berbamine has a protective role against osteoporosis and may represent a novel promising treatment strategy for osteoporosis.
C1 [Qi, Guobin; Jiang, Zengxin; Yuan, Hengfeng] Shanghai Sixth Peoples Hosp, Dept Orthopaed, Shanghai, Peoples R China.
   [Qi, Guobin] Fudan Univ, Zhongshan Hosp, Dept Orthoped Surg, Shanghai, Peoples R China.
   [Lu, Wei] Shanghai Univ TCM, Dept Orthoped Surg, Shanghai TCM Integrated Hosp, Shanghai, Peoples R China.
   [Li, Defang; Chen, Weibing; Ding, Lei] Fudan Univ, Jinshan Hosp, Dept Orthoped Surg, Shanghai, Peoples R China.
   [Yang, Xiuying] Fudan Univ, Jinshan Hosp, Dept Radiol, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Fudan University; Shanghai University of
   Traditional Chinese Medicine; Fudan University; Fudan University
RP Yuan, HF (通讯作者)，Shanghai Sixth Peoples Hosp, Dept Orthopaed, Shanghai, Peoples R China.; Ding, L (通讯作者)，Fudan Univ, Jinshan Hosp, Dept Orthoped Surg, Shanghai, Peoples R China.; Yang, XY (通讯作者)，Fudan Univ, Jinshan Hosp, Dept Radiol, Shanghai, Peoples R China.
EM dryangyingzi@163.com; three_stones2008@163.com; yuanhf@shsmu.edu.cn
RI Qi, Guobin/IXD 9658 2023; chen, weibing/HCI 7370 2022
FU Shanghai Jinshan Health Commission; Jinshan Science and Technology
   Committee of Shanghai [JSZK 2019B01];  [2019 3 03]
FX This work was supported by the sixth key specialty construction project
   of Shanghai Jinshan Health Commission (grant numbers: JSZK 2019B01) and
   Jinshan Science and Technology Committee of Shanghai (grant number:
   2019 3 03).
CR Amend SR, 2015, J BONE MINER RES, V30, P106, DOI 10.1002/jbmr.2308
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Borggaard XG, 2022, BONE, V160, DOI 10.1016/j.bone.2022.116419
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Demontiero O, 2012, THER ADV MUSCULOSKEL, V4, P61, DOI 10.1177/1759720X11430858
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Farr JN, 2015, NAT REV ENDOCRINOL, V11, P513, DOI 10.1038/nrendo.2015.89
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Han CL, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/8851763
   Hu HY, 2020, J PHARMACOL SCI, V142, P131, DOI 10.1016/j.jphs.2019.12.008
   Jensen PR, 2021, BONE, V145, DOI 10.1016/j.bone.2021.115850
   Jia XJ, 2017, CELL PHYSIOL BIOCHEM, V41, P2307, DOI 10.1159/000475650
   Jung S, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 11615 9
   Kendler DL, 2022, ADV THER, V39, P58, DOI 10.1007/s12325 021 01936 y
   Levin VA, 2018, OSTEOPOROSIS INT, V29, P1049, DOI 10.1007/s00198 018 4414 z
   Li HX, 2021, CURR MED CHEM, V28, P1489, DOI 10.2174/0929867327666200330142432
   Li JB, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10677 0
   Li QW, 2020, J BONE MINER RES, V35, P1597, DOI 10.1002/jbmr.4015
   Liang Y, 2009, ACTA PHARMACOL SIN, V30, P1659, DOI 10.1038/aps.2009.167
   Liu XY, 2020, CHIN J NAT MEDICINES, V18, P186, DOI 10.1016/S1875 5364(20)30020 0
   Lotz EM, 2020, J BIOMED MATER RES A, V108, P1774, DOI 10.1002/jbm.a.36944
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Parekh HS, 2009, MOL CANCER, V8, DOI 10.1186/1476 4598 8 21
   Park JH, 2017, MOL CELLS, V40, P706
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Ren YP, 2008, J IMMUNOL, V181, P1491, DOI 10.4049/jimmunol.181.2.1491
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Salehi B, 2019, FOODS, V8, DOI 10.3390/foods8100522
   Seeman E, 2002, LANCET, V359, P1841, DOI 10.1016/S0140 6736(02)08706 8
   Suvarna V, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00981
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Tang LY, 2021, J BONE MINER RES, V36, P779, DOI 10.1002/jbmr.4230
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   Yang X, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.664697
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
NR 38
TC 7
Z9 8
U1 2
U2 11
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 2
PY 2022
VL 13
AR 1032866
DI 10.3389/fphar.2022.1032866
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 6I4NW
UT WOS:000886105200001
PM 36408260
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Eapen, A
   Sundivakkam, P
   Song, YQ
   Ravindran, S
   Ramachandran, A
   Tiruppathi, C
   George, A
AF Eapen, Asha
   Sundivakkam, Premanand
   Song, Yiqiang
   Ravindran, Sriram
   Ramachandran, Amsaveni
   Tiruppathi, Chinnaswammy
   George, Anne
TI Calcium mediated Stress Kinase Activation by DMP1 Promotes Osteoblast
   Differentiation
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID DENTIN MATRIX PROTEIN 1; ENDOPLASMIC RETICULUM STRESS; BONE FORMATION;
   TRANSCRIPTIONAL REGULATION; P38; CELLS; APOPTOSIS; OSTERIX; SIGNAL;
   RUNX2
AB Calcium signaling and calcium transport play a key role during osteoblast differentiation and bone formation. Here, we demonstrate that DMP1 mediated calcium signaling, and its downstream effectors play an essential role in the differentiation of preosteoblasts to fully functional osteoblasts. DMP1, a key regulatory bone matrix protein, can be endocytosed by preosteoblasts, triggering a rise in cytosolic levels of calcium that initiates a series of downstream events leading to cellular stress. These events include release of store operated calcium that facilitates the activation of stress induced p38 MAPK leading to osteoblast differentiation. However, chelation of intracellular calcium and inhibition of the p38 signaling pathway by specific pharmacological inhibitors and dominant negative plasmid suppressed this activation. Interestingly, activated p38 MAPK can translocate to the nucleus to phosphorylate transcription factors that coordinate the expression of downstream target genes such as Runx 2, a key modulator of osteoblast differentiation. These studies suggest a novel paradigm by which DMP1 mediated release of intracellular calcium activates p38 MAPK signaling cascade to regulate gene expression and osteoblast differentiation.
C1 [George, Anne] Univ Illinois, Brodie Tooth Dev Genet & Regenerat Med Res Lab, Chicago, IL 60612 USA.
   [Sundivakkam, Premanand; Tiruppathi, Chinnaswammy] Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital
RP George, A (通讯作者)，Univ Illinois, Brodie Tooth Dev Genet & Regenerat Med Res Lab, Chicago, IL 60612 USA.
EM anneg@uic.edu
OI GEORGE, ANNE/0000 0002 9008 7642
FU National Institutes of Health [DE 11657]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grant DE 11657.
CR Åberg T, 2004, J HISTOCHEM CYTOCHEM, V52, P131, DOI 10.1177/002215540405200113
   AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756 3282(95)00183 E
   Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097 4644(19970701)66:1<1::AID JCB1>3.0.CO;2 V
   BODEN SD, 1990, ORTHOP CLIN N AM, V21, P31
   CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968 0004(00)88978 1
   Davidson SM, 2000, DEV BIOL, V218, P146, DOI 10.1006/dbio.1999.9596
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025
   Dvorak MM, 2004, CELL CALCIUM, V35, P249, DOI 10.1016/j.ceca.2003.10.014
   Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111
   GEORGE A, 1993, J BIOL CHEM, V268, P12624
   Goodman SB, 2007, J BIOMED MATER RES A, V81A, P310, DOI 10.1002/jbm.a.30983
   GREEN J, 1992, AM J PHYSIOL, V263, pE1070
   Hamamura K, 2007, FEBS LETT, V581, P1769, DOI 10.1016/j.febslet.2007.03.063
   Hino S, 2010, J BONE MINER METAB, V28, P131, DOI 10.1007/s00774 009 0117 z
   Hu YY, 2003, ENDOCRINOLOGY, V144, P2068, DOI 10.1210/en.2002 220863
   Javed A, 2008, J BIOL CHEM, V283, P8412, DOI 10.1074/jbc.M705578200
   Kim IS, 2008, DEV GROWTH DIFFER, V50, P553, DOI 10.1111/j.1440 169X.2008.01052.x
   Kobayashi M, 2006, EMBO J, V25, P713, DOI 10.1038/sj.emboj.7600973
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Leonardi R, 2004, CALCIFIED TISSUE INT, V75, P509, DOI 10.1007/s00223 004 0077 1
   Liao JH, 2006, CANCER METAST REV, V25, P559, DOI 10.1007/s10555 006 9033 z
   Lien YC, 2008, HISTOL HISTOPATHOL, V23, P1299, DOI 10.14670/HH 23.1299
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   MUNDY GR, 1995, BONE, V17, pS71, DOI 10.1016/8756 3282(95)00182 D
   Murakami T, 2009, NAT CELL BIOL, V11, P1205, DOI 10.1038/ncb1963
   Narayanan K, 2004, J BIOL CHEM, V279, P44294, DOI 10.1074/jbc.M403511200
   Narayanan K, 2002, CONNECT TISSUE RES, V43, P365, DOI 10.1080/03008200290000592
   Narayanan K, 2001, P NATL ACAD SCI USA, V98, P4516, DOI 10.1073/pnas.081075198
   Nishihara A, 2003, BIOCHEM BIOPH RES CO, V301, P617, DOI 10.1016/S0006 291X(02)03068 1
   Nöth U, 2003, EXP CELL RES, V291, P201, DOI 10.1016/S0014 4827(03)00386 0
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Ravindran S, 2008, J BIOL CHEM, V283, P29658, DOI 10.1074/jbc.M800786200
   Reilly Gwendolen C, 2005, Cell Commun Signal, V3, P3, DOI 10.1186/1478 811X 3 3
   San Miguel SM, 2005, J BIOL CHEM, V280, P37495, DOI 10.1074/jbc.M503861200
   Seeman E, 2002, J BONE MINER RES, V17, P373, DOI 10.1359/jbmr.2002.17.3.373
   Seeman E, 2008, J BONE MINER METAB, V26, P1, DOI 10.1007/s00774 007 0793 5
   Sharan K, 2008, INDIAN J MED RES, V127, P274
   Srinivasan R, 1999, CONNECT TISSUE RES, V40, P251, DOI 10.3109/03008209909000703
   STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843
   STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014 5793(92)81216 9
   Sundivakkam PC, 2009, AM J PHYSIOL CELL PH, V296, pC403, DOI 10.1152/ajpcell.00470.2008
   Tindberg N, 2000, NEUROCHEM RES, V25, P527, DOI 10.1023/A:1007520311457
   Tuli R, 2002, ANN NY ACAD SCI, V961, P172, DOI 10.1111/j.1749 6632.2002.tb03077.x
   Ulsamer A, 2008, J BIOL CHEM, V283, P3816, DOI 10.1074/jbc.M704724200
   Walsh David, 1999, Environmental Medicine (Nagoya), V43, P79
   Wang XY, 2007, ENDOCRINOLOGY, V148, P1629, DOI 10.1210/en.2006 1000
   Ye L, 2005, J BIOL CHEM, V280, P6197, DOI 10.1074/jbc.M412911200
   Yeung BHY, 2008, ONCOGENE, V27, P6782, DOI 10.1038/onc.2008.290
   Zayzafoon M, 2002, J BIOL CHEM, V277, P37212, DOI 10.1074/jbc.M200129200
NR 51
TC 51
Z9 61
U1 0
U2 10
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 19
PY 2010
VL 285
IS 47
BP 36339
EP 36351
DI 10.1074/jbc.M110.145607
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 679FE
UT WOS:000284146100079
PM 20841352
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Fukui, T
   Terashima, A
   Omata, Y
   Chijimatsu, R
   Okamoto, K
   Tsukasaki, M
   Fukuda, Y
   Hayata, T
   Saitoh, A
   Toda, E
   Takayanagi, H
   Tanaka, S
   Terashima, Y
   Saito, T
AF Fukui, Tatsuyuki
   Terashima, Asuka
   Omata, Yasunori
   Chijimatsu, Ryota
   Okamoto, Kazuo
   Tsukasaki, Masayuki
   Fukuda, Yukiko
   Hayata, Tadayoshi
   Saitoh, Akiyoshi
   Toda, Etsuko
   Takayanagi, Hiroshi
   Tanaka, Sakae
   Terashima, Yuya
   Saito, Taku
TI Disulfiram ameliorates bone loss in ovariectomized mice by suppressing
   osteoclastogenesis
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Osteoporosis; DSF; Osteoclast precursor; Osteoclastogenesis; scRNA seq
   analysis
ID PATHWAYS; MASS; JAWS
AB IntroductionDisulfiram (DSF), known as an anti alcoholism drug, has been reported to suppress osteoclast differentiation in vitro; however, it remains uncertain whether DSF is effective in preventing osteoclastogenesis in vivo. This study aimed to investigate the effect of DSF administration in osteoporotic mice and its contribution to osteoclastogenesis in vivo.Materials and methodsThe bone phenotype of ovariectomized mice, both treated and untreated with DSF, was examined using microcomputed tomography analysis. Osteoclastic and osteoblastic parameters were assessed through bone morphometric analysis. The direct effect of DSF on osteoblastogenesis in vitro was evaluated via a primary osteoblast culture experiment. The expression of genes related to DSF targets (Nup85, Ccr2, and Ccr5) in osteoclast lineage cells was examined using scRNA seq analysis and flow cytometry analysis using the bone marrow cells from ovariectomized mice. The impact of DSF on osteoclast lineage cells was assessed using primary cultures of osteoclasts.ResultsDSF administration ameliorated ovariectomy induced bone loss and mitigated the increase of osteoclasts without affecting osteoblastogenesis. The scRNA seq data revealed that osteoclast precursor cells expressed Nup85, Ccr2, and Ccr5. CCR2 and CCR5 positive cells in osteoclast precursor cells within bone marrow increased following ovariectomy, and this increase was canceled by DSF administration. Finally, we found that DSF had a significant inhibitory effect on osteoclastogenesis in the early stage by suppressing Tnfrsf11a expression.ConclusionThis study demonstrates that DSF could be a candidate for osteoporosis therapies because it suppresses osteoclastogenesis from an early stage in vivo.
C1 [Fukui, Tatsuyuki; Omata, Yasunori; Tanaka, Sakae; Saito, Taku] Univ Tokyo, Grad Sch Med, Sensory & Motor Syst Med, 7 3 1 Hongo,Bunkyo Ku, Tokyo 1138655, Japan.
   [Terashima, Asuka; Omata, Yasunori; Chijimatsu, Ryota] Univ Tokyo Hosp, Bone & Cartilage Regenerat Med, 7 3 1 Hongo,Bunkyo Ku, Tokyo 1138655, Japan.
   [Chijimatsu, Ryota] Okayama Univ Hosp, Ctr Comprehens Genom Med, Shikata Cho,Kita Ku, Okayama 7008558, Japan.
   [Okamoto, Kazuo; Tsukasaki, Masayuki] Univ Tokyo, Grad Sch Med, Dept Osteoimmunol, 7 3 1 Hongo,Bunkyo Ku, Tokyo 1130033, Japan.
   [Okamoto, Kazuo] Kanazawa Univ, Canc Res Inst, Div Immune Environm Dynam, Kakuma Machi, Kanazawa 9201192, Japan.
   [Fukuda, Yukiko; Saitoh, Akiyoshi] Tokyo Univ Sci, Grad Sch Pharmaceut Sci, Lab Pharmacol, 2641 Yamazaki, Noda, Chiba 2788510, Japan.
   [Fukuda, Yukiko; Toda, Etsuko; Terashima, Yuya] Tokyo Univ Sci, Res Inst Biomed Sci, Div Mol Regulat Inflammatory & Immune Dis, 2641 Yamazaki, Noda, Chiba 2788510, Japan.
   [Hayata, Tadayoshi] Dept Mol Pharmacol, 2641 Yamazaki, Noda, Chiba 2788510, Japan.
   [Toda, Etsuko] Nippon Med Sch, Dept Analyt Human Pathol, 1 25 16 Nezu,Bunkyo Ku, Tokyo 1130031, Japan.
   [Takayanagi, Hiroshi] Univ Tokyo, Grad Sch Med, Dept Immunol, 7 3 1 Hongo,Bunkyo Ku, Tokyo, Japan.
   [Takayanagi, Hiroshi] Univ Tokyo, Fac Med, 7 3 1 Hongo,Bunkyo Ku, Tokyo, Japan.
C3 University of Tokyo; University of Tokyo; Okayama University; University
   of Tokyo; Kanazawa University; Tokyo University of Science; Tokyo
   University of Science; Nippon Medical School; University of Tokyo;
   University of Tokyo
RP Terashima, A (通讯作者)，Univ Tokyo Hosp, Bone & Cartilage Regenerat Med, 7 3 1 Hongo,Bunkyo Ku, Tokyo 1138655, Japan.
EM tera ort@m.u tokyo.ac.jp
RI Terashima, Angelica/ABD 7759 2021; Tanaka, Sakae/Y 3061 2019
OI Terashima, Asuka/0000 0001 5150 5656; 
FU Japan Society for the Promotion of Science
FX We thank Y. Arino and T. Tsubaki for their invaluable technical advice
   on scRNA seq analysis. We also thank J. Sugita, K. Kaneko, and R. Homma
   for their technical assistance.
CR Ann DG., 1994, MEDICINA, V57, P61
   BARRERA SE, 1950, AM J PSYCHIAT, V107, P8, DOI 10.1176/ajp.107.1.8
   Binder NB, 2009, NAT MED, V15, P417, DOI 10.1038/nm.1945
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Filipovic M, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.994035
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   Greenberg MS, 2004, ORAL SURG ORAL MED O, V98, P259, DOI 10.1016/j.tripleo.2004.08.001
   Hafemeister C, 2019, GENOME BIOL, V20, DOI 10.1186/s13059 019 1874 1
   Hernlund E., 2013, ARCH OSTEOPOROS, V8, P1, DOI DOI 10.1007/S11657 013 0136 1
   Ikebukuro T, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24010735
   Jacquin C, 2006, J BONE MINER RES, V21, P67, DOI 10.1359/JBMR.051007
   Jia YW, 2019, AGING US, V11, P8103, DOI 10.18632/aging.102279
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Lee JW, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 02368 5
   Li T, 2024, BRIT POULTRY SCI, V65, P44, DOI 10.1080/00071668.2023.2264792
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Mittal M, 2020, EUR J PHARMACOL, V886, DOI 10.1016/j.ejphar.2020.173541
   Mittal M, 2014, TOXICOL SCI, V139, P257, DOI 10.1093/toxsci/kfu020
   Muguruma Y, 1998, BLOOD, V91, P1272, DOI 10.1182/blood.V91.4.1272
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Nakashima T, 2009, J BONE MINER METAB, V27, P519, DOI 10.1007/s00774 009 0089 z
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Papapetrou PD, 2009, HORM INT J ENDOCRINO, V8, P96, DOI 10.14310/horm.2002.1226
   PERIS P, 1994, J BONE MINER RES, V9, P1607
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Ross FP, 2005, IMMUNOL REV, V208, P88, DOI 10.1111/j.0105 2896.2005.00331.x
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Saitoh A, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.826783
   Shakeel M, 2023, ANIM REPROD SCI, V256, DOI 10.1016/j.anireprosci.2023.107319
   Stubelius A, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 1315 1
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Terashima Y, 2005, NAT IMMUNOL, V6, P827, DOI 10.1038/ni1222
   Terashima Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 14338 5
   Toda E, 2022, KIDNEY INT, V102, P1276, DOI 10.1016/j.kint.2022.07.031
   Toda E, 2009, J IMMUNOL, V183, P6387, DOI 10.4049/jimmunol.0803469
   Tsukasaki M, 2020, NAT METAB, V2, DOI 10.1038/s42255 020 00318 y
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   Walker MD, 2023, NEW ENGL J MED, V389, P1979, DOI 10.1056/NEJMcp2307353
   Weivoda MM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14003 6
   Yasuda H, 2021, J BONE MINER METAB, V39, P2, DOI 10.1007/s00774 020 01175 1
   Ying H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125696
   Yip NC, 2011, BRIT J CANCER, V104, P1564, DOI 10.1038/bjc.2011.126
   Zappia L, 2018, GIGASCIENCE, V7, DOI 10.1093/gigascience/giy083
   Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007
NR 45
TC 1
Z9 1
U1 2
U2 4
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD MAR
PY 2025
VL 43
IS 2
BP 61
EP 73
DI 10.1007/s00774 024 01555 x
EA OCT 2024
PG 13
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA 1IB2R
UT WOS:001327582800001
PM 39373772
OA hybrid
DA 2025 08 17
ER

PT J
AU Kim, MK
   Kim, HD
   Park, JH
   Lim, JI
   Yang, JS
   Kwak, WY
   Sung, SY
   Kim, HJ
   Kim, SH
   Lee, CH
   Shim, JY
   Bae, MH
   Shin, YA
   Huh, Y
   Han, TD
   Chong, W
   Choi, H
   Ahn, BN
   Yang, SO
   Son, MH
AF Kim, M. K.
   Kim, H. D.
   Park, J. H.
   Lim, J. I.
   Yang, J. S.
   Kwak, W. Y.
   Sung, S. Y.
   Kim, H. J.
   Kim, S. H.
   Lee, C. H.
   Shim, J. Y.
   Bae, M. H.
   Shin, Y. A.
   Huh, Y.
   Han, T. D.
   Chong, W.
   Choi, H.
   Ahn, B. N.
   Yang, S. O.
   Son, M. H.
TI An orally active cathepsin K inhibitor, furan 2 carboxylic acid,
   1 {1 [4 fluoro 2 (2 oxo pyrrolidin 1 yl) phenyl] 3 oxopiperidin 4 ylcarb
   amoyl} cyclohexyl) amide (OST 4077), inhibits osteoclast activity in
   vitro and bone loss in ovariectomized rats
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID TRANSFORMING GROWTH FACTOR BETA 1; RESORPTION; EXPRESSION;
   PYCNODYSOSTOSIS; PURIFICATION; DEFICIENCY; ACTIVATION; POTENT; CELLS;
   LEADS
AB Human cathepsin K, a cysteine proteinase of the papain family, has been recognized as a potential drug target for the treatment of osteoporosis. The predominant expression of cathepsin K in osteoclasts has rendered the enzyme into a major target for the development of novel antiresorptive drugs. Now, we report the pharmacological properties of OST 4077 [furan 2 carboxylic acid (1 {1 [4 fluoro 2 (2 oxo pyrrolidin 1 yl) phenyl] 3 oxo piperidin 4 ylcarbamoyl} cyclohexyl) amide] as a novel selective cathepsin K inhibitor. Human and rat cathepsin K were inhibited in vitro by OST 4077 with the IC50 values of 11 and 427 nM, respectively. OST 4077 suppressed bone resorption induced by rabbit osteoclasts (IC50, 37 nM) but did not affect bone mineralization or cellular alkaline phosphatase activity in MC3T3 E1 cells. Parathyroid hormone induced bone resorption was inhibited in a dose dependent manner in thyroparathyroidectomized rats gavaged with a single dose of OST 4077 (ED50, 69 mg/kg). When given orally twice daily for 4 weeks to 3 month old ovariectomized (OVX) rats, OST 4077 dose dependently prevented bone loss, as monitored by bone densitometry, ash content, and urinary excretion of deoxypyridinoline. No change in serum osteocalcin in the OVX rats by OST 4077 suggested that bone formation might not be affected by the agent. In summary, OST 4077 selectively inhibited bone resorbing activities of osteoclasts and prevented bone loss induced by estrogen deficiency but did not affect bone formation. OST 4077, an orally active selective human cathepsin K inhibitor, may have the therapeutic potential for the treatment of diseases characterized by excessive bone loss including osteoporosis.
C1 Dong A Pharmaceut Co Ltd, Dong A Res Labs, Gyeonggi Do, South Korea.
   Yuhan Corp, Yuhan Res Inst, Gyeonggi Do, South Korea.
   Eulji Univ Hosp, Dept Radiol, Taejon, South Korea.
C3 Eulji University; Eulji University Hospital
RP Son, MH (通讯作者)，47 5 Sanggal Dong, Yongin 446905, Gyeonggi Do, South Korea.
EM ssonmh@donga.co.kr
CR Aibe K, 1996, BIOL PHARM BULL, V19, P1026
   Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517
   Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126
   Caselli G, 1997, J BONE MINER RES, V12, P972, DOI 10.1359/jbmr.1997.12.6.972
   Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511
   Einhorn Thomas A., 1996, P3
   Fujikawa Y, 2001, BONE, V28, P261, DOI 10.1016/S8756 3282(00)00453 1
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Hou WS, 1999, J CLIN INVEST, V103, P731, DOI 10.1172/JCI653
   Kamiya T, 1998, J BIOCHEM TOKYO, V123, P752
   Kaneko H, 2000, BONE, V27, P479, DOI 10.1016/S8756 3282(00)00358 6
   Lark MW, 2002, BONE, V30, P746, DOI 10.1016/S8756 3282(02)00675 0
   Linnevers CJ, 1997, PROTEIN SCI, V6, P919
   LittlewoodEvans AJ, 1997, CANCER RES, V57, P5386
   Massey HM, 2001, BONE, V28, P577, DOI 10.1016/S8756 3282(01)00432 X
   McQueney MS, 1998, PROTEIN EXPRES PURIF, V14, P387, DOI 10.1006/prep.1998.0965
   Mitsudo K, 2003, BIOCHEMISTRY US, V42, P3874, DOI 10.1021/bi027029v
   Pennypacker B, 2004, J BONE MINER RES, V19, pS444
   Pennypacker BL, 1999, J BONE MINER RES, V14, pS549
   Rodan GA, 1993, OSTEOPOROS INT S3, V3, P7
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Spinella Jaegle S, 2001, BONE, V29, P323, DOI 10.1016/S8756 3282(01)00580 4
   Stroup GB, 2001, J BONE MINER RES, V16, P1739, DOI 10.1359/jbmr.2001.16.10.1739
   Tepel C, 2000, J CELL SCI, V113, P4487
   Votta BJ, 1997, J BONE MINER RES, V12, P1396, DOI 10.1359/jbmr.1997.12.9.1396
   Yasuma T, 1998, J MED CHEM, V41, P4301, DOI 10.1021/jm9803065
NR 26
TC 31
Z9 36
U1 0
U2 1
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3995 USA
SN 0022 3565
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD AUG
PY 2006
VL 318
IS 2
BP 555
EP 562
DI 10.1124/jpet.106.102798
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 063MS
UT WOS:000239023100012
PM 16699068
DA 2025 08 17
ER

PT J
AU Joshua, J
   Schwaerzer, GK
   Kalyanaraman, H
   Cory, E
   Sah, RL
   Li, MF
   Vaida, F
   Boss, GR
   Pilz, RB
AF Joshua, Jisha
   Schwaerzer, Gerburg K.
   Kalyanaraman, Hema
   Cory, Esther
   Sah, Robert L.
   Li, Mofei
   Vaida, Florin
   Boss, Gerry R.
   Pilz, Renate B.
TI Soluble Guanylate Cyclase as a Novel Treatment Target for Osteoporosis
SO ENDOCRINOLOGY
LA English
DT Article
ID NITRIC OXIDE SYNTHASE; BONE MINERAL DENSITY; ESTROGEN RECEPTOR ALPHA;
   NF KAPPA B; ORGANIC NITRATES; POSTMENOPAUSAL WOMEN; ENDOTHELIAL
   FUNCTION; OVARIECTOMIZED MICE; ANABOLIC RESPONSE; CORTICAL BONE
AB Osteoporosis is a major health problem leading to fractures that cause substantial morbidity and mortality. Current osteoporosis therapies have significant drawbacks, creating a need for novel bone anabolic agents. We previously showed that the nitric oxide/cyclic GMP (cGMP)/protein kinase G pathway mediates some of the anabolic effects of estrogens and mechanical stimulation in osteoblasts and osteocytes, leading us to hypothesize that cGMP elevating agents may have bone protective effects. We tested cinaciguat, a prototype of a novel class of soluble guanylate cyclase activators, in a mouse model of estrogen deficiency induced osteoporosis. Compared with sham operated mice, ovariectomized mice had lower serum cGMP concentrations, which were largely restored to normal by treatment with cinaciguat or low dose 17 beta estradiol. Microcomputed tomography of tibiae showed that cinaciguat significantly improved trabecular bone microarchitecture in ovariectomized animals, with effect sizes similar to those obtained with estrogen replacement therapy. Cinaciguat reversed ovariectomy induced osteocyte apoptosis as efficiently as estradiol and enhanced bone formation parameters in vivo, consistent with in vitro effects on osteoblast proliferation, differentiation, and survival. Compared with 17 beta estradiol, which completely reversed the ovariectomy induced increase in osteoclast number, cinaciguat had little effect on osteoclasts. Direct guanylate cyclase stimulators have been extremely well tolerated in clinical trials of cardiovascular diseases, and our findings provide proof of concept for this new class of drugs as a novel, anabolic treatment strategy for postmenopausal osteoporosis, confirming an important role of nitric oxide/cGMP/protein kinase G signaling in bone.
C1 [Joshua, Jisha; Schwaerzer, Gerburg K.; Kalyanaraman, Hema; Boss, Gerry R.; Pilz, Renate B.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
   [Cory, Esther; Sah, Robert L.] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA.
   [Li, Mofei] Univ Calif San Diego, Dept Math, La Jolla, CA 92093 USA.
   [Vaida, Florin] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego
RP Pilz, RB (通讯作者)，Univ Calif San Diego, 9500 Gilman Dr, La Jolla, CA 92093 USA.
EM rpilz@ucsd.edu
OI Li, Mofei/0009 0007 2609 4219; Boss, Gerry/0000 0002 9758 8714
FU National Institutes of Health Grants [R01AR051300, P01AG007996,
   P30NS047101, P30AR04603]
FX This work was supported by National Institutes of Health Grants
   R01AR051300 (to R.B.P.), P01AG007996 (R.S.S., Micro CT core Grant),
   P30NS047101 (University of California, San Diego, Neuroscience
   Microscopy Shared Facility), and P30AR04603 (University of Alabama,
   Birmingham, Center for Metabolic Bone Disease).
CR Alexander JM, 2001, J BONE MINER RES, V16, P1665, DOI 10.1359/jbmr.2001.16.9.1665
   Alles N, 2010, ENDOCRINOLOGY, V151, P4626, DOI 10.1210/en.2010 0399
   Armour KE, 1998, ENDOCRINOLOGY, V139, P799, DOI 10.1210/en.139.2.799
   Armour KE, 2001, ENDOCRINOLOGY, V142, P760, DOI 10.1210/en.142.2.760
   Bakker A, 2003, METH MOLEC MED, V80, P19
   Bartell SM, 2013, MOL ENDOCRINOL, V27, P649, DOI 10.1210/me.2012 1368
   Bouxsein ML, 2005, J BONE MINER RES, V20, P1085, DOI 10.1359/JBMR.050307
   BRANDI ML, 1995, P NATL ACAD SCI USA, V92, P2954, DOI 10.1073/pnas.92.7.2954
   Cui R, 2009, J ATHEROSCLER THROMB, V16, P457, DOI 10.5551/jat.No083
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Duque G, 2011, J BONE MINER RES, V26, P1472, DOI 10.1002/jbmr.350
   Ghofrani HA, 2013, NEW ENGL J MED, V369, P330, DOI 10.1056/NEJMoa1209655
   Grassi F, 2006, ENDOCRINOLOGY, V147, P4392, DOI 10.1210/en.2006 0334
   Hagiwara H, 1996, AM J PHYSIOL CELL PH, V270, pC1311, DOI 10.1152/ajpcell.1996.270.5.C1311
   Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000
   Hayashi T, 2000, J GERONTOL A BIOL, V55, pB183, DOI 10.1093/gerona/55.4.B183
   Holliday LS, 1997, AM J PHYSIOL RENAL, V272, pF283, DOI 10.1152/ajprenal.1997.272.3.F283
   Hukkanen M, 2003, BONE, V32, P142, DOI 10.1016/S8756 3282(02)00955 9
   Jamal SA, 1998, J BONE MINER RES, V13, P1755, DOI 10.1359/jbmr.1998.13.11.1755
   Jamal SA, 2012, CURR OSTEOPOROS REP, V10, P86, DOI 10.1007/s11914 011 0087 7
   Jamal SA, 2011, JAMA J AM MED ASSOC, V305, P800, DOI 10.1001/jama.2011.176
   Kawai M, 2011, NAT REV DRUG DISCOV, V10, P141, DOI 10.1038/nrd3299
   Khosla S, 2011, J BONE MINER RES, V26, P441, DOI 10.1002/jbmr.262
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Levis S, 2012, J MANAG CARE PHAR SB, V18, pS3
   Mancini L, 2000, BIOCHEM BIOPH RES CO, V274, P477, DOI 10.1006/bbrc.2000.3164
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Marathe N, 2012, J BIOL CHEM, V287, P978, DOI 10.1074/jbc.M111.294959
   Martin Millan M, 2010, MOL ENDOCRINOL, V24, P323, DOI 10.1210/me.2009 0354
   Mendelsohn ME, 2010, J CLIN INVEST, V120, P2277, DOI 10.1172/JCI43756
   Mödder UIL, 2004, ENDOCRINOLOGY, V145, P913, DOI 10.1210/en.2003 1089
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Nakamura Y, 1999, AM HEART J, V138, P577, DOI 10.1016/S0002 8703(99)70163 8
   O'Shaughnessy MC, 2000, BIOCHEM BIOPH RES CO, V277, P604, DOI 10.1006/bbrc.2000.3714
   Parker JD, 2004, J CLIN INVEST, V113, P352, DOI 10.1172/JCI200421003
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Pierroz DD, 2010, J BIOL CHEM, V285, P28164, DOI 10.1074/jbc.M110.101964
   Pouwels S, 2010, J CLIN ENDOCR METAB, V95, P1924, DOI 10.1210/jc.2009 2342
   Ralston SH, 1996, BONE, V19, P29, DOI 10.1016/8756 3282(96)00101 9
   Rangaswami H, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001423
   Rangaswami H, 2009, J BIOL CHEM, V284, P14796, DOI 10.1074/jbc.M806486200
   Rejnmark L, 2006, J BONE MINER RES, V21, P1811, DOI 10.1359/JBMR.060804
   ROSSELLI M, 1995, HYPERTENSION, V25, P848, DOI 10.1161/01.HYP.25.4.848
   Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930
   Salloum FN, 2012, AM J PHYSIOL HEART C, V302, pH1347, DOI 10.1152/ajpheart.00544.2011
   Scutt A, 2003, METH MOLEC MED, V80, P29
   Seeger H, 2002, INT J CLIN PHARM TH, V40, P150
   Solomon DH, 2014, J BONE MINER RES, V29, P1929, DOI 10.1002/jbmr.2202
   Sophocleous A, 2011, ENDOCRINOLOGY, V152, P2141, DOI 10.1210/en.2010 0930
   Stacey E, 1998, J CLIN ENDOCR METAB, V83, P3056, DOI 10.1210/jc.83.9.3056
   Stasch JP, 2002, BRIT J PHARMACOL, V136, P773, DOI 10.1038/sj.bjp.0704778
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   Tomkinson A, 1997, J CLIN ENDOCR METAB, V82, P3128, DOI 10.1210/jc.82.9.3128
   van't Hof RJ, 2004, ENDOCRINOLOGY, V145, P5068, DOI 10.1210/en.2004 0205
   Watts Nelson B, 2010, Endocr Pract, V16 Suppl 3, P1
   Wimalawansa SJ, 1996, BONE, V18, P301, DOI 10.1016/8756 3282(96)00005 1
   Wimalawansa SJ, 2009, J CLIN ENDOCR METAB, V94, P3356, DOI 10.1210/jc.2008 2225
   Yadav VK, 2010, NAT MED, V16, P308, DOI 10.1038/nm.2098
   Yaroslavskiy BB, 2005, J CELL SCI, V118, P5479, DOI 10.1242/jcs.02655
   Yaroslavskiy BB, 2004, J CELL BIOCHEM, V91, P962, DOI 10.1002/jcb.20009
   Zheng H, 2006, J BIOL CHEM, V281, P15809, DOI 10.1074/jbc.M513225200
NR 62
TC 43
Z9 46
U1 0
U2 13
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD DEC
PY 2014
VL 155
IS 12
BP 4720
EP 4730
DI 10.1210/en.2014 1343
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AX0UN
UT WOS:000346668000013
PM 25188528
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Lin, X
   Xu, F
   Zhang, KW
   Qiu, WX
   Zhang, H
   Hao, Q
   Li, M
   Deng, XN
   Tian, Y
   Chen, ZH
   Qian, AR
AF Lin, Xiao
   Xu, Fang
   Zhang, Ke Wen
   Qiu, Wu Xia
   Zhang, Hui
   Hao, Qiang
   Li, Meng
   Deng, Xiao Ni
   Tian, Ye
   Chen, Zhi Hao
   Qian, Ai Rong
TI Acacetin Prevents Bone Loss by Disrupting Osteoclast Formation and
   Promoting Type H Vessel Formation in Ovariectomy Induced Osteoporosis
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE acacetin; osteoporosis; osteoclasts; type H vessel; Akt/GSK3 beta;
   NF kappa B
ID DIFFERENTIATION; ANGIOGENESIS; TARGET; WOMEN
AB Osteoporosis, characterized by the destruction of bone resorption and bone formation, is a serious disease that endangers human health. Osteoporosis prevention and treatment has become one of the important research contents in the field of medicine. Acacetin, a natural flavonoid compound, could promote osteoblast differentiation, and inhibit osteoclast formation in vitro. However, the mechanisms of acacetin on osteoclast differentiation and type H vessel formation, as well as the effect of preventing bone loss, remain unclear. Here, we firstly used primary bone marrow derived macrophages (BMMs), endothelial progenitor cells (EPCs), and ovariectomized (OVX) mice to explore the function of acacetin on bone remodeling and H type vessel formation. In this study, we found that acacetin inhibits osteoclast formation and bone resorption of BMMs induced by the macrophage colony stimulating factor (M CSF) and receptor activator of nuclear factor kappa B ligand (RANKL) in a concentration of 20 mu M without exerting cytotoxic effects. It was accompanied by downregulation of osteoclast differentiation marker genes (Ctsk, Acp5, and Mmp9) and cell fusion genes (CD9, CD47, Atp6v0d2, Dc stamp, and Oc stamp). Moreover, acacetin disrupted actin ring formation and extracellular acidification in osteoclasts. Mechanistic analysis revealed that acacetin not only inhibits the expression of the major transcription factor NFATc1 and NF kappa B during RANKL induced osteoclast formation, but also suppresses RANKL induced the phosphorylation of Akt, GSK3 beta, I kappa B alpha, and p65. Additionally, acacetin enhanced the ability of M CSF and RANKL stimulated BMMs to promote angiogenesis and migration of EPCs. We further established that, in vivo, acacetin increased trabecular bone mass, decreased the number of osteoclasts, and showed more type H vessels in OVX mice. These data demonstrate that acacetin prevents OVX induced bone loss in mice through inhibition of osteoclast function and promotion of type H vessel formation via Akt/GSK3 beta and NF kappa B signalling pathway, suggesting that acacetin may be a novel therapeutic agent for the treatment of osteoporosis.
EM tianye@nwpu.edu.cn; chenzhihao@nwpu.edu.cn; qianair@nwpu.edu.cn
RI Lin, Xiao/LYP 2289 2024; zhang, kewen/KXR 4680 2024; chen,
   zhihao/GXM 3816 2022; Chen, Zhihao/ACK 3514 2022
OI Chen, Zhihao/0000 0003 0128 1409
FU National Natural Science Foundation of China [81700784]; Key R&D
   Projects in Shaanxi Province [2021SF 242]; China Postdoctoral Science
   Foundation [2017M613196, 2020M683573]; Natural Science Basic Research
   Plan of Shaanxi Province of China [2021JQ 128, BKJ17J004]
FX Funding This work was supported by the National Natural Science
   Foundation of China (Grant number 81700784), the Key R&D Projects in
   Shaanxi Province (Grant number 2021SF 242), the China Postdoctoral
   Science Foundation (Grant numbers 2017M613196, 2020M683573), the Natural
   Science Basic Research Plan of Shaanxi Province of China (Grant number
   2021JQ 128), and the key grant BKJ17J004.
CR Akbar MA, 2017, MOL MED, V23, P57, DOI 10.2119/molmed.2016.00170
   Beekman KM, 2019, BONE, V118, P62, DOI 10.1016/j.bone.2017.10.011
   Bellavia D, 2021, TRENDS ENDOCRIN MET, V32, P76, DOI 10.1016/j.tem.2020.11.007
   Bhat TA, 2013, CANCER PREV RES, V6, P1128, DOI 10.1158/1940 6207.CAPR 13 0209
   Chen DL, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104944
   Chen J, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2328401
   Chen LR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092213
   Chen X, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00647
   Chen ZH, 2020, THERANOSTICS, V10, P12263, DOI 10.7150/thno.53009
   Dai QG, 2017, J BIOL CHEM, V292, P196, DOI 10.1074/jbc.M116.764761
   Gao B, 2019, J CLIN INVEST, V129, P2578, DOI 10.1172/JCI98857
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hardcastle AC, 2011, J BONE MINER RES, V26, P941, DOI 10.1002/jbmr.285
   Huang Q, 2015, BONE, V73, P132, DOI 10.1016/j.bone.2014.12.059
   Ilchovska D, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2020.102741
   Jung SK, 2014, CARCINOGENESIS, V35, P123, DOI 10.1093/carcin/bgt266
   Kim SI, 2020, PHYTOMEDICINE, V79, DOI 10.1016/j.phymed.2020.153351
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Leder BZ, 2020, J CLIN ENDOCR METAB, V105, P938, DOI 10.1210/clinem/dgz162
   Li J, 2016, EVID BASED COMPL ALT, V2016, DOI 10.1155/2016/2587201
   Li WT, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00265
   Li XQ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb7135
   Lin CJ, 2019, THERANOSTICS, V9, P3780, DOI 10.7150/thno.34493
   Lin X, 2019, MOL CELL ENDOCRINOL, V494, DOI 10.1016/j.mce.2019.110494
   Meng JH, 2020, BIOCHEM PHARMACOL, V171, DOI 10.1016/j.bcp.2019.113715
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Pan MH, 2006, BIOCHEM PHARMACOL, V72, P1293, DOI 10.1016/j.bcp.2006.07.039
   Ramasamy SK, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13601
   Ren JY, 2021, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.577237
   Shi YJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.561962
   Song CC, 2020, FASEB J, V34, P4798, DOI 10.1096/fj.201902551R
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tatangelo G, 2019, J BONE MINER RES, V34, P616, DOI 10.1002/jbmr.3640
   Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0
   Wang L, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.36
   Wang SB, 2020, DRUG DES DEV THER, V14, P5077, DOI 10.2147/DDDT.S275148
   Wei YX, 2020, MOL BIOL REP, V47, P6899, DOI 10.1007/s11033 020 05746 3
   Wu MR, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13700
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xu Q, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.682541
   Xu YX, 2021, PHYTOMEDICINE, V85, DOI 10.1016/j.phymed.2021.153485
   Yang P, 2018, BONE, V114, P1, DOI 10.1016/j.bone.2018.05.025
   Zhang ZQ, 2014, OSTEOPOROSIS INT, V25, P2417, DOI 10.1007/s00198 014 2763 9
   Zhu Y, 2019, J BONE MINER METAB, V37, P987, DOI 10.1007/s00774 019 01000 4
NR 45
TC 19
Z9 21
U1 3
U2 20
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD APR 19
PY 2022
VL 10
AR 796227
DI 10.3389/fcell.2022.796227
PG 16
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA 2A8QN
UT WOS:000809760400001
PM 35517504
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Tamma, R
   Colaianni, G
   Zhu, LL
   DiBenedetto, A
   Greco, G
   Montemurro, G
   Patano, N
   Strippoli, M
   Vergari, R
   Mancini, L
   Colucci, S
   Grano, M
   Faccio, R
   Liu, X
   Li, JH
   Usmani, S
   Bachar, M
   Bab, I
   Nishimori, K
   Younge, LJ
   Buettner, C
   Iqbal, J
   Sun, L
   Zaidi, M
   Zallone, A
AF Tamma, Roberto
   Colaianni, Graziana
   Zhu, Ling ling
   DiBenedetto, Adriana
   Greco, Giovanni
   Montemurro, Gabriella
   Patano, Nicola
   Strippoli, Maurizio
   Vergari, Rosaria
   Mancini, Lucia
   Colucci, Silvia
   Grano, Maria
   Faccio, Roberta
   Liu, Xuan
   Li, Jianhua
   Usmani, Sabah
   Bachar, Marilyn
   Bab, Itai
   Nishimori, Katsuhiko
   Younge, Larry J.
   Buettner, Christoph
   Iqbal, Jameel
   Sun, Li
   Zaidi, Mone
   Zallone, Alberta
TI Oxytocin is an anabolic bone hormone
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE osteoblast; osteoclast; osteoporosis; pituitary hormones; bone density
ID DEFICIENT MICE; NITRIC OXIDE; LACTATION; PREGNANCY; CALCIUM;
   OSTEOCLASTS; MASS; PARTURITION; RESORPTION; CALCITONIN
AB We report that oxytocin (OT), a primitive neurohypophyseal hormone, hitherto thought solely to modulate lactation and social bonding, is a direct regulator of bone mass. Deletion of OT or the OT receptor (Oxtr) in male or female mice causes osteoporosis resulting from reduced bone formation. Consistent with low bone formation, OT stimulates the differentiation of osteoblasts to a mineralizing phenotype by causing the up regulation of BMP 2, which in turn controls Schnurri 2 and 3, Osterix, and ATF 4 expression. In contrast, OT has dual effects on the osteoclast. It stimulates osteoclast formation both directly, by activating NF kappa B and MAP kinase signaling, and indirectly through the up regulation of RANK L. On the other hand, OT inhibits bone resorption by mature osteoclasts by triggering cytosolic Ca2+ release and NO synthesis. Together, the complementary genetic and pharmacologic approaches reveal OT as a novel anabolic regulator of bone mass, with potential implications for osteoporosis therapy.
C1 [Zhu, Ling ling; Liu, Xuan; Li, Jianhua; Usmani, Sabah; Buettner, Christoph; Iqbal, Jameel; Sun, Li; Zaidi, Mone] Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY 10029 USA.
   [Tamma, Roberto; Colaianni, Graziana; DiBenedetto, Adriana; Greco, Giovanni; Montemurro, Gabriella; Patano, Nicola; Strippoli, Maurizio; Vergari, Rosaria; Mancini, Lucia; Colucci, Silvia; Grano, Maria; Faccio, Roberta; Zallone, Alberta] Univ Bari, Dept Human Anat & Histol, I 70124 Bari, Italy.
   [Bachar, Marilyn; Bab, Itai] Hebrew Univ Jerusalem, Bone Lab, IL 91120 Jerusalem, Israel.
   [Nishimori, Katsuhiko] Tohoku Univ, Grad Sch Agr Sci, Aoba Ku, Sendai, Miyagi 9818555, Japan.
   [Younge, Larry J.] Emory Univ, Sch Med, Dept Psychiat, Ctr Behav Neurosci, Atlanta, GA 30322 USA.
C3 Icahn School of Medicine at Mount Sinai; Universita degli Studi di Bari
   Aldo Moro; Hebrew University of Jerusalem; Tohoku University; Emory
   University
RP Zaidi, M (通讯作者)，Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY 10029 USA.
EM mone.zaidi@mssm.edu; a.zallone@anatomia.uniba.it
RI ; tamma, roberto/C 3679 2016; Mancini, Lucia/JBJ 7422 2023; Buettner,
   Christoph/F 5793 2013
OI Colaianni, Graziana/0000 0001 8501 5399; TAMMA,
   Roberto/0000 0003 4623 5406; Zaidi, Mone/0000 0001 5911 9522; Grano,
   Maria/0000 0002 7121 5899; Colucci, Silvia/0000 0001 9970 3539; 
FU Italian Space Agency; European Space Agency; Ministero dell'Istruzione;
   dell'Universita e della Ricerca; National Institutes of Health
   [DK804590, AG23176, DK70526]
FX This work was supported by grants from the Italian Space Agency
   (Osteoporosis and Muscular Atrophy Project), European Space Agency
   (European Research In Space and Terrestrial Osteoporosis Microgravity
   Application Promotion project), Ministero dell'Istruzione,
   dell'Universita e della Ricerca (to A. Z.), and the National Institutes
   of Health Grants DK804590, AG23176, and DK70526 (to M. Z. and L. S.).
CR Abe E, 2003, CELL, V115, P151, DOI 10.1016/S0092 8674(03)00771 2
   Amico JA, 2004, J NEUROENDOCRINOL, V16, P319, DOI 10.1111/j.0953 8194.2004.01161.x
   Amico JA, 2008, NEUROSCI LETT, V442, P262, DOI 10.1016/j.neulet.2008.07.004
   Blair HC, 2007, TRENDS ENDOCRIN MET, V18, P227, DOI 10.1016/j.tem.2007.06.001
   Blevins JE, 2004, AM J PHYSIOL REG I, V287, pR87, DOI 10.1152/ajpregu.00604.2003
   Camerino C, 2008, J BONE MINER RES, V23, pS56
   Colucci S, 2002, BIOCHEM BIOPH RES CO, V297, P442, DOI 10.1016/S0006 291X(02)02009 0
   Copland JA, 1999, ENDOCRINOLOGY, V140, P4371, DOI 10.1210/en.140.9.4371
   DAWOOD MY, 1981, J CLIN ENDOCR METAB, V52, P678, DOI 10.1210/jcem 52 4 678
   DAWOOD MY, 1979, J CLIN ENDOCR METAB, V49, P429, DOI 10.1210/jcem 49 3 429
   Elabd C, 2008, STEM CELLS, V26, P2399, DOI 10.1634/stemcells.2008 0127
   Elabd S K, 2007, Endocr Regul, V41, P131
   Jones DC, 2006, SCIENCE, V312, P1223, DOI 10.1126/science.1126313
   Keverne EB, 2004, CURR OPIN NEUROBIOL, V14, P777, DOI 10.1016/j.conb.2004.10.006
   Kovacs CS, 2006, ENDOCRIN METAB CLIN, V35, P21, DOI 10.1016/j.ecl.2005.09.004
   MACINTYRE I, 1991, P NATL ACAD SCI USA, V88, P2936, DOI 10.1073/pnas.88.7.2936
   MALGAROLI A, 1989, J BIOL CHEM, V264, P14342
   Nishimori K, 1996, P NATL ACAD SCI USA, V93, P11699, DOI 10.1073/pnas.93.21.11699
   Nishiyama C, 2008, RESUSCITATION, V79, P90, DOI 10.1016/j.resuscitation.2008.05.009
   Pearson D, 2004, BONE, V34, P570, DOI 10.1016/j.bone.2003.11.005
   RALSTON SH, 1995, J BONE MINER RES, V10, P1040
   Saita Y, 2007, J BIOL CHEM, V282, P12907, DOI 10.1074/jbc.M611203200
   SCAFANI A, 2007, AM J PHYSIOL, V292, pR1828
   Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051
   Sun L, 2008, P NATL ACAD SCI USA, V105, P4289, DOI 10.1073/pnas.0712395105
   Takayanagi Y, 2005, P NATL ACAD SCI USA, V102, P16096, DOI 10.1073/pnas.0505312102
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Valassi E, 2008, NUTR METAB CARDIOVAS, V18, P158, DOI 10.1016/j.numecd.2007.06.004
   Vanhouten JN, 2003, ENDOCRINOLOGY, V144, P5521, DOI 10.1210/en.2003 0892
   VanHouten JN, 2003, J CLIN INVEST, V112, P1429, DOI 10.1172/JCI200319504
   WHITEHEAD M, 1981, BRIT MED J, V283, P10, DOI 10.1136/bmj.283.6283.10
   Wysolmerski JJ, 2002, J MAMMARY GLAND BIOL, V7, P267, DOI 10.1023/A:1022800716196
   Yao LC, 2006, DEVELOPMENT, V133, P4025, DOI 10.1242/dev.02561
   ZAIDI M, 1993, J BONE MINER RES, V8, P961
   ZAIDI M, 1988, Q J EXP PHYSIOL CMS, V73, P471, DOI 10.1113/expphysiol.1988.sp003168
NR 35
TC 193
Z9 212
U1 1
U2 15
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 28
PY 2009
VL 106
IS 17
BP 7149
EP 7154
DI 10.1073/pnas.0901890106
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 438VS
UT WOS:000265584500051
PM 19369205
OA Green Published
DA 2025 08 17
ER

PT J
AU Jia, LJ
   Shi, LY
   Li, JP
   Zeng, Y
   Tang, SY
   Liu, W
   Mo, XM
   Liu, X
AF Jia, Lujuan
   Shi, Liying
   Li, Jinping
   Zeng, Ying
   Tang, Siyuan
   Liu, Wei
   Mo, Xinmin
   Liu, Xin
TI Total flavonoids from celery suppresses RANKL induced osteoclast
   differentiation and bone resorption function via attenuating NF κB and
   p38 pathways in RAW264.7 cells
SO JOURNAL OF FUNCTIONAL FOODS
LA English
DT Article
DE Osteoclast; Total flavonoids; MAPKs; NF kappa B; Osteoporosis
ID APIUM GRAVEOLENS; LUTEOLIN; INHIBITION; ACTIVATION; GROWTH; MASS
AB Skeletal diseases caused by excessive activation of osteoclasts seriously affect elderly's health. Therefore, inhibiting excessive activation of osteoclasts become effective therapeutic strategy for osteoporosis. Celery, a traditional and popular Chinese vegetable with high nutritional value, is rich in flavonoids which have a variety of pharmacological activities. The present study aimed to determine the pharmacological effect of total flavonoids of celery (TFC) on osteoclastogenesis, and to explore the molecular mechanisms. Results showed that TFC inhibited osteoclast differentiation and bone resorption without significant toxic and side effect. Furthermore, the results of western blot analysis and qPCR indicated that TFC inhibited the degradation of I kappa B alpha, phosphorylation of NF kappa B and p38, and subsequently attenuated the expression levels of osteoclast specific genes. The results of this study may have a positive impact on the application of TFC as functional food ingredients, which has potential preventive and therapeutic effects on osteoclast related diseases.
C1 [Jia, Lujuan; Shi, Liying; Li, Jinping; Liu, Xin] Cent South Univ, Xiangya Sch Pharmaceut Sci, Dept Pharmachem, 172 Tong Zi Po Rd, Changsha 410013, Hunan, Peoples R China.
   [Zeng, Ying; Mo, Xinmin] Hunan Univ Tradit Chinese Med, Hosp 1, 105 Shao Shan Rd, Changsha, Hunan, Peoples R China.
   [Tang, Siyuan; Liu, Wei] Cent South Univ, Sch Nursing, 172 Tong Zi Po Rd, Changsha, Hunan, Peoples R China.
C3 Central South University; Hunan University of Chinese Medicine; Central
   South University
RP Li, JP (通讯作者)，Cent South Univ, Xiangya Sch Pharmaceut Sci, Dept Pharmachem, 172 Tong Zi Po Rd, Changsha 410013, Hunan, Peoples R China.
EM pjingli@163.com
FU National Natural Science Foundation of China [81273816, 81774379,
   81370974]; Fundamental Research Funds for the Central Universities of
   Central South University [1053320183583]; Fund for the Key Laboratory of
   Hunan Province, China [2017TP1004]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81273816, 81774379, 81370974); the Fundamental Research Funds
   for the Central Universities of Central South University
   (1053320183583); and the Fund for the Key Laboratory of Hunan Province,
   China (2017TP1004).
CR An J, 2016, INT IMMUNOPHARMACOL, V36, P118, DOI 10.1016/j.intimp.2016.04.024
   Ang ESM, 2011, FEBS LETT, V585, P2755, DOI 10.1016/j.febslet.2011.07.046
   Baek JM, 2016, MOLECULES, V21, DOI 10.3390/molecules21030295
   Bandyopadhyay S, 2006, BIOCHEM PHARMACOL, V72, P184, DOI 10.1016/j.bcp.2006.04.018
   Brown KD, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2457
   Choi EM, 2007, CELL BIOL INT, V31, P870, DOI 10.1016/j.cellbi.2007.01.038
   Choi JH, 2017, J CELL BIOCHEM, V118, P860, DOI 10.1002/jcb.25763
   Cong Q, 2017, SCI REP UK, V7, DOI 10.1038/srep45964
   Dang ZC, 2005, TRENDS ENDOCRIN MET, V16, P207, DOI 10.1016/j.tem.2005.05.001
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Goto T, 2015, CYTOTECHNOLOGY, V67, P357, DOI 10.1007/s10616 014 9694 3
   Guijarro Real C, 2019, FOOD RES INT, V121, P765, DOI 10.1016/j.foodres.2018.12.054
   Hayman AR, 2008, AUTOIMMUNITY, V41, P218, DOI 10.1080/08916930701694667
   He QF, 2016, CZECH J FOOD SCI, V34, P341, DOI 10.17221/266/2015 CJFS
   Huang XL, 2019, INT J MOL MED, V44, P582, DOI 10.3892/ijmm.2019.4207
   Ji X, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030349
   Karsenty G, 2016, CELL, V164, P1248, DOI 10.1016/j.cell.2016.02.043
   Kim B, 2018, PHYTOMEDICINE, V51, P181, DOI 10.1016/j.phymed.2018.06.020
   Kim JH, 2019, INT J MOL MED, V44, P913, DOI 10.3892/ijmm.2019.4269
   Kim MH, 2016, ARCH PHARM RES, V39, P1671, DOI 10.1007/s12272 016 0810 0
   Kim TH, 2011, J NUTR BIOCHEM, V22, P8, DOI 10.1016/j.jnutbio.2009.11.002
   Lee JW, 2009, CYTOTECHNOLOGY, V61, P125, DOI 10.1007/s10616 010 9253 5
   Li K, 2019, J CELL PHYSIOL, V234, P16263, DOI 10.1002/jcp.28289
   Li MY, 2018, CRIT REV BIOTECHNOL, V38, P172, DOI 10.1080/07388551.2017.1312275
   Lin X, 2019, MOL CELL ENDOCRINOL, V494, DOI 10.1016/j.mce.2019.110494
   Liu WQ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12794
   Ma XJ, 2014, BIOCHEM BIOPH RES CO, V445, P282, DOI 10.1016/j.bbrc.2014.01.145
   Matsuda H, 2003, BIOORGAN MED CHEM, V11, P1995, DOI 10.1016/S0968 0896(03)00067 1
   Middleton E, 2000, PHARMACOL REV, V52, P673
   Mousavinejad G, 2009, FOOD CHEM, V115, P1274, DOI 10.1016/j.foodchem.2009.01.044
   Nash LA, 2015, MOL NUTR FOOD RES, V59, P443, DOI 10.1002/mnfr.201400592
   Niu CG, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00626
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Raynaud Messina B, 2019, BONE, V127, P315, DOI 10.1016/j.bone.2019.06.023
   Shin DK, 2012, ACTA BIOMATER, V8, P3524, DOI 10.1016/j.actbio.2012.05.002
   Singh A, 1995, J ETHNOPHARMACOL, V49, P119, DOI 10.1016/0378 8741(95)01291 5
   Song SH, 2017, MOLECULES, V22, DOI 10.3390/molecules22071033
   Suvarna V, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00981
   Wang Q, 2018, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00966
   Weaver Connie M., 2012, Journal of Nutrition in Gerontology and Geriatrics, V31, P239, DOI 10.1080/21551197.2012.698220
   Wittrant Y, 2003, BIOCHEM BIOPH RES CO, V310, P774, DOI 10.1016/j.bbrc.2003.09.084
   Wu J, 2006, J BONE MINER RES, V21, P780, DOI 10.1359/JBMR.060208
   Yin F, 1999, ANTICANCER RES, V19, P4297
   Yin F, 2001, ANTICANCER RES, V21, P413
   Yin ZQ, 2019, EUR J PHARMACOL, V859, DOI 10.1016/j.ejphar.2019.172550
   Yu MX, 2014, BIOCHEM BIOPH RES CO, V447, P364, DOI 10.1016/j.bbrc.2014.04.009
   Zhang YL, 2017, DRUG DES DEV THER, V11, P1881, DOI 10.2147/DDDT.S139804
   Zheng X, 2018, INT J MOL MED, V41, P3137, DOI 10.3892/ijmm.2018.3515
   Zhu W, 2019, BIOCHEM BIOPH RES CO, V509, P294, DOI 10.1016/j.bbrc.2018.12.125
NR 49
TC 4
Z9 4
U1 0
U2 21
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1756 4646
J9 J FUNCT FOODS
JI J. Funct. Food.
PD JUN
PY 2020
VL 69
AR 103949
DI 10.1016/j.jff.2020.103949
PG 9
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA LU4FP
UT WOS:000537713200015
OA gold
DA 2025 08 17
ER

PT J
AU Son, HS
   Lee, J
   Lee, HI
   Kim, N
   Jo, YJ
   Lee, GR
   Hong, SE
   Kwon, M
   Kim, NY
   Kim, HJ
   Ha Park, J
   Lee, SY
   Jeong, W
AF Son, Han Saem
   Lee, Jiae
   Lee, Hye In
   Kim, Narae
   Jo, You Jin
   Lee, Gong Rak
   Hong, Seong Eun
   Kwon, Minjeong
   Kim, Nam Young
   Kim, Hyun Jin
   Ha Park, Jin
   Lee, Soo Young
   Jeong, Woojin
TI Benzydamine inhibits osteoclast differentiation and bone resorption
   via down regulation of interleukin 1β expression
SO ACTA PHARMACEUTICA SINICA B
LA English
DT Article
DE Benzydamine; Osteoclast; Bone; Interleukin 1 beta; Nuclear factor kappa
   B; Activator protein 1
ID NF KAPPA B; C FOS; TRANSCRIPTION; PATHWAYS; GENE; AP 1; P38; ERK;
   PHOSPHORYLATION; ACTIVATION
AB Bone diseases such as osteoporosis and periodontitis are induced by excessive osteoclastic activity, which is closely associated with inflammation. Benzydamine (BA) has been used as a cytokine suppressive or non steroidal anti inflammatory drug that inhibits the production of pro inflammatory cytokines or prostaglandins. However, its role in osteoclast differentiation and function remains unknown. Here, we explored the role of BA in regulating osteoclast differentiation and elucidated the underlying mechanism. BA inhibited osteoclast differentiation and strongly suppressed interleukin 1 beta (IL 1 beta) production. BA inhibited osteoclast formation and bone resorption when added to bone marrow derived macrophages and differentiated osteoclasts, and the inhibitory effect was reversed by IL 1 beta treatment. The reporter assay and the inhibitor study of IL 1 beta transcription suggested that BA inhibited nuclear factor kappa B and activator protein 1 by regulating I kappa B kinase, extracellular signal regulated kinase and P38, resulting in the down regulation of IL 1 beta expression. BA also promoted osteoblast differentiation. Furthermore, BA protected lipopolysaccharide and ovariectomy induced bone loss in mice, suggesting therapeutic potential against inflammation induced bone diseases and postmenopausal osteoporosis. (C) 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
C1 [Son, Han Saem; Lee, Jiae; Lee, Hye In; Kim, Narae; Jo, You Jin; Lee, Gong Rak; Hong, Seong Eun; Kwon, Minjeong; Kim, Nam Young; Kim, Hyun Jin; Ha Park, Jin; Lee, Soo Young; Jeong, Woojin] Ewha Womans Univ, Dept Life Sci, Seoul 03760, South Korea.
   [Son, Han Saem; Lee, Jiae; Lee, Hye In; Kim, Narae; Jo, You Jin; Lee, Gong Rak; Hong, Seong Eun; Kwon, Minjeong; Kim, Nam Young; Kim, Hyun Jin; Ha Park, Jin; Lee, Soo Young; Jeong, Woojin] Ewha Womans Univ, Res Ctr Cellular Homeostasis, Seoul 03760, South Korea.
C3 Ewha Womans University; Ewha Womans University
RP Jeong, W (通讯作者)，Ewha Womans Univ, Dept Life Sci, Seoul 03760, South Korea.
EM jeongw@ewha.ac.kr
OI LEE, GONG RAK/0009 0003 1287 0855
FU National Research Foundation (NRF) [2017R1A2B2012435, 2019R1C1C1011198,
   2019R1A5A6099645]; Korean Ministry of Science, ICT and future Planning
   (MSIP)
FX This work was supported by the National Research Foundation (NRF) (Grant
   Nos. 2017R1A2B2012435, 2019R1C1C1011198 and 2019R1A5A6099645, Korea)
   funded by the Korean Ministry of Science, ICT and future Planning
   (MSIP).
CR Abe T, 2014, J IMMUNOL, V193, P1383, DOI 10.4049/jimmunol.1400970
   Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821
   Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Boyce BF, 2005, J BONE MINER METAB, V23, P11, DOI 10.1007/BF03026317
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   CIOLI V, 1985, INT J TISSUE REACT, V7, P205
   COGSWELL JP, 1994, J IMMUNOL, V153, P712
   Dinarello CA, 2000, CHEST, V118, P503, DOI 10.1378/chest.118.2.503
   Eto K, 2010, MOL CELL BIOCHEM, V339, P119, DOI 10.1007/s11010 009 0375 z
   Fujioka S, 2004, MOL CELL BIOL, V24, P7806, DOI 10.1128/MCB.24.17.7806 7819.2004
   GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460 2075.1995.tb07076.x
   Guglielmotti A, 1997, INFLAMM RES, V46, P332, DOI 10.1007/s000110050197
   HANSEN HS, 1981, LIPIDS, V16, P849, DOI 10.1007/BF02535041
   Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715
   Hirayama T, 2002, RHEUMATOLOGY, V41, P1232, DOI 10.1093/rheumatology/41.11.1232
   Hong SE, 2017, FREE RADICAL BIO MED, V112, P191, DOI 10.1016/j.freeradbiomed.2017.07.030
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Jin SH, 2018, BMB REP, V51, P356, DOI 10.5483/BMBRep.2018.51.7.106
   Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682
   Kim H, 2013, J IMMUNOL, V190, P1312, DOI 10.4049/jimmunol.1202525
   Kobayashi Y, 2005, J BIOL CHEM, V280, P11395, DOI 10.1074/jbc.M411189200
   Lee HI, 2019, FASEB J, V33, P9685, DOI 10.1096/fj.201900862R
   Lee J, 2019, FASEB J, V33, P2026, DOI 10.1096/fj.201800866RR
   Lee YM, 2010, INT IMMUNOL, V22, P805, DOI 10.1093/intimm/dxq431
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200
   Nakamura I, 2006, VITAM HORM, V74, P357, DOI 10.1016/S0083 6729(06)74015 8
   Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239
   Phan TCA, 2004, HISTOL HISTOPATHOL, V19, P1325, DOI 10.14670/HH 19.1325
   Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449
   Ruscitti P, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/782382
   SEGRE G, 1985, INT J TISSUE REACT, V7, P187
   SERKKOLA E, 1993, EUR J BIOCHEM, V213, P243, DOI 10.1111/j.1432 1033.1993.tb17754.x
   Shiratori T, 2018, J IMMUNOL, V200, P218, DOI 10.4049/jimmunol.1602035
   Sironi M, 1997, INT J CLIN LAB RES, V27, P118, DOI 10.1007/BF02912445
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Tu YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080996
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   Wang Y, 2000, ONCOGENE, V19, P1379, DOI 10.1038/sj.onc.1203443
   WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106
   Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360
   Yamazaki Nishioka M, 2018, XENOBIOTICA, V48, P117, DOI 10.1080/00498254.2017.1288280
   ZHANG Y, 1993, MOL CELL BIOL, V13, P3831, DOI 10.1128/MCB.13.6.3831
NR 47
TC 50
Z9 57
U1 0
U2 21
PU INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
PI BEIJING
PA C/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST,
   BEIJING, 100050, PEOPLES R CHINA
SN 2211 3835
EI 2211 3843
J9 ACTA PHARM SIN B
JI Acta Pharm. Sin. B
PD MAR
PY 2020
VL 10
IS 3
BP 462
EP 474
DI 10.1016/j.apsb.2019.11.004
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA KS1AF
UT WOS:000518042300006
PM 32140392
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Kanno, C
   Kaneko, T
   Endo, M
   Kitabatake, T
   Sakuma, T
   Kanaya, Y
   Watanabe, Y
   Hasegawa, H
AF Kanno, Chihiro
   Kaneko, Tetsuharu
   Endo, Manabu
   Kitabatake, Takehiro
   Sakuma, Tomoko
   Kanaya, Yoshiaki
   Watanabe, Yuki
   Hasegawa, Hiroshi
TI Anti VEGFR therapy is one of the healing inhibitors of
   antiresorptive related osteonecrosis of the jaw
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Antiresorptive related osteonecrosis of the jaw; Vascular endothelial
   growth factor receptor; Endothelial growth factor receptor; Molecular
   targeting drug; Conservative therapy
ID ENDOTHELIAL GROWTH FACTOR; AGENT RELATED OSTEONECROSIS; OSTEOCLAST
   DIFFERENTIATION; BONE RESORPTION; CANCER PATIENTS; RISK FACTORS;
   BEVACIZUMAB; COMPLICATIONS; DENOSUMAB; MECHANISMS
AB Introduction Antiresorptive related osteonecrosis of the jaw (ARONJ) is a rare but serious adverse event associated with bone modifying agents (BMAs) and affects patients in the terminal stages of cancer. Molecular targeting drugs (MTDs), anti vascular endothelial growth factor receptor (VEGFR), and anti epidermal growth factor receptor (EGFR) drugs are essential in various cancer treatments, although MTDs are risk factors for ARONJ. However, the mechanism through which MTDs affect treatment prognosis of ARONJ remains unclear. Therefore, we investigated the potential inhibitory factors for healing in the conservative therapy of ARONJ with a focus on MTDs. Materials and methods Sixty patients who were administered BMAs for the treatment of malignancies and who underwent conservative treatment for ARONJ were assessed. The healing rate of ARONJ for each risk factor was retrospectively evaluated. Results Among the 60 patients, 27 were male and 33 were female. The median age was 67 years, and the median follow up period was 292 (range 91 1758) days. The healing rate was lower in those treated with both zoledronic acid (Za) and denosumab (Dmab) than in those treated with Za or Dmab alone (0% vs. 28.8%, p = 0.03). Regarding the administration of MTDs, the treatment rate with anti VEGFR drugs was 7.1% (p = 0.04), anti EGFR drugs was 12.5% (p = 0.18), and without MTDs was 36.8%. Conclusion In the conservative treatment of ARONJ, the administration of several BMAs and anti VEGFR drugs was the factor contributing to the inhibition of healing.
C1 [Kanno, Chihiro; Kaneko, Tetsuharu; Endo, Manabu; Kitabatake, Takehiro; Sakuma, Tomoko; Kanaya, Yoshiaki; Watanabe, Yuki; Hasegawa, Hiroshi] Fukushima Med Univ Hosp, Dept Oral & Maxillofacial Surg, 1 Hikarigaoka, Fukushima, Fukushima 9601295, Japan.
C3 Fukushima Medical University
RP Hasegawa, H (通讯作者)，Fukushima Med Univ Hosp, Dept Oral & Maxillofacial Surg, 1 Hikarigaoka, Fukushima, Fukushima 9601295, Japan.
EM hasehi@fmu.ac.jp
RI Hasegawa, Hiroshi/C 4261 2015
CR Ahn JW, 2019, INT WOUND J, V16, P1009, DOI 10.1111/iwj.13139
   Akita Y, 2018, J BONE MINER METAB, V36, P547, DOI 10.1007/s00774 017 0872 1
   Aldridge SE, 2005, BIOCHEM BIOPH RES CO, V335, P793, DOI 10.1016/j.bbrc.2005.07.145
   Allegra CJ, 2009, J CLIN ONCOL, V27, P3385, DOI 10.1200/JCO.2009.21.9220
   Beuselinck B, 2012, BRIT J CANCER, V107, P1665, DOI 10.1038/bjc.2012.385
   Birkenhauer E, 2015, INT J MOL SCI, V16, P7159, DOI 10.3390/ijms16047159
   Clark AJ, 2011, J NEUROSURG, V114, P1609, DOI 10.3171/2010.10.JNS101042
   El Rabbany M, 2019, J ORAL MAXIL SURG, V77, P1816, DOI 10.1016/j.joms.2019.03.040
   Fornaro L, 2014, WORLD J GASTROENTERO, V20, P6081, DOI 10.3748/wjg.v20.i20.6081
   Gnant M, 2015, LANCET, V386, P433, DOI 10.1016/S0140 6736(15)60995 3
   Golshan M, 2011, ANN SURG ONCOL, V18, P733, DOI 10.1245/s10434 010 1366 8
   Guo Z, 2020, INT J ORAL MAX SURG, V49, P298, DOI 10.1016/j.ijom.2019.07.016
   Hayashida S, 2020, J BONE MINER METAB, V38, P126, DOI 10.1007/s00774 019 01035 7
   Higuchi T, 2018, OR SURG OR MED OR PA, V125, P547, DOI 10.1016/j.oooo.2018.02.010
   Honnegowda T.M., 2015, PLAST AESTHET RES, V2, P243, DOI [DOI 10.4103/2347 9264.165438, 10.4103/2347 9264.165448, DOI 10.4103/2347 9264.165448]
   Ikeda T, 2015, BONE, V73, P217, DOI 10.1016/j.bone.2014.12.021
   Jonasch E, 2009, J CLIN ONCOL, V27, P4076, DOI 10.1200/JCO.2008.21.3660
   Lee HW, 2013, BBA REV CANCER, V1835, P170, DOI 10.1016/j.bbcan.2012.12.007
   Maeda H, 1995, JPN J STOMATOL, V44, P317
   Marx RE, 2007, J ORAL MAXIL SURG, V65, P2397, DOI 10.1016/j.joms.2007.08.003
   Nifosi AF, 2019, J KOR ASSOC ORAL MAX, V45, P3, DOI 10.5125/jkaoms.2019.45.1.3
   Owosho AA, 2016, J CRANIO MAXILL SURG, V44, P265, DOI 10.1016/j.jcms.2015.12.005
   Pastore S, 2008, J INVEST DERMATOL, V128, P1365, DOI 10.1038/sj.jid.5701184
   Repertinger SK, 2004, J INVEST DERMATOL, V123, P982, DOI 10.1111/j.0022 202X.2004.23478.x
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Scappaticci FA, 2005, J SURG ONCOL, V91, P173, DOI 10.1002/jso.20301
   Sharma K, 2013, ANN PLAS SURG, V71, P434, DOI 10.1097/SAP.0b013e31824e5e57
   Shibahara T, 2019, TOHOKU J EXP MED, V247, P75, DOI 10.1620/tjem.247.75
   Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006
   Sitohy B, 2012, CANCER RES, V72, P1909, DOI 10.1158/0008 5472.CAN 11 3406
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Soundia A, 2018, J DENT RES, V97, P312, DOI 10.1177/0022034517732770
   STAVRI GT, 1995, CIRCULATION, V92, P11, DOI 10.1161/01.CIR.92.1.11
   van Cann T, 2018, SUPPORT CARE CANCER, V26, P869, DOI 10.1007/s00520 017 3903 5
   Vokes Everett E, 2006, Oncology (Williston Park), V20, P15
   Voss PJ, 2018, ODONTOLOGY, V106, P469, DOI 10.1007/s10266 018 0362 5
   Yang QL, 2008, MATRIX BIOL, V27, P589, DOI 10.1016/j.matbio.2008.06.005
   Yang ZF, 2004, J IMMUNOL, V173, P2507, DOI 10.4049/jimmunol.173.4.2507
   Yarom N, 2019, J CLIN ONCOL, V37, P2270, DOI 10.1200/JCO.19.01186
   Yi T, 2008, J CELL PHYSIOL, V217, P409, DOI 10.1002/jcp.21511
   Yoneda T, 2017, J BONE MINER METAB, V35, P6, DOI 10.1007/s00774 016 0810 7
NR 41
TC 2
Z9 4
U1 1
U2 9
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD MAY
PY 2021
VL 39
IS 3
BP 423
EP 429
DI 10.1007/s00774 020 01170 6
EA NOV 2020
PG 7
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA RU3VD
UT WOS:000590334800001
PM 33196901
DA 2025 08 17
ER

PT J
AU Liu, YL
   Zhao, LY
   He, XYX
   Shen, Y
   Wang, N
   Hu, SJ
   Xu, JL
   Zhao, QM
   Zhang, QL
   Qin, LP
   Zhang, QY
AF Liu, Yuling
   Zhao, Luying
   He, Xinyunxi
   Shen, Yi
   Wang, Na
   Hu, Sijing
   Xu, Jinlong
   Zhao, Qiming
   Zhang, Quanlong
   Qin, Luping
   Zhang, Qiaoyan
TI Jintiange proteins promote osteogenesis and inhibit apoptosis of
   osteoblasts by enhancing autophagy via PI3K/AKT and ER stress pathways
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Jintiange capsule; Osteogenesis; Autophagy; PI3K; AKT pathway;
   Endoplasmic reticulum (ER) stress
ID OSTEOPOROSIS
AB Ethnopharmacological relevance: Tiger bone, which had long been used in traditional Chinese medicine, had the action of removing wind and alleviating pain, strengthening the sinews and bones, and often used to treat bone impediment, and atrophic debility of bones in TCM clinical practice. As a substitute of natural bone tiger, artificial tiger bone Jintiange (JTG), has been approved by the State Food and Drug Administration of China for relief the symptom of osteoporosis, such as lumbago and back pain, lassitude in loin and legs, flaccidity and weakness legs, and walk with difficulty based on TCM theory. JTG has similar chemical profile to natural tiger bone, and contains mineral substance, peptides and proteins, and has been shown to protect bone loss in ovariectomized mice and exert the regulatory effects on osteoblast and osteoclast activities. But how the peptides and proteins in JTG modulate bone formation remains unclear. Aim: To investigate the stimulating effects of JTG proteins on osteogenesis and explore the possible underlying mechanisms. Materials and methods: JTG proteins were prepared from JTG Capsules by extracting calcium, phosphorus and other inorganic elements using SEP PaktC18 desalting column. MC3T3 E1 cells were treated with JTG proteins to evaluate their effects and explore the underlying mechanisms. Osteoblast proliferation was detected by CCK 8 method. ALP activity was detected using a relevant assay kit, and bone mineralized nodules were stained with alizarin red Tris HCl solution. Cell apoptosis was analyzed by flow cytometry. Autophagy was observed by MDC staining, and autophagosomes were observed by TEM. Nuclear translocations of LC3 and CHOP were detected by immunofluorescence and observed under a laser confocal microscope. The expression of key proteins related to osteogenesis, apoptosis, autophagy and PI3K/AKT and ER stress pathways was analyzed by Western Blot analysis. Results: JTG proteins improved osteogenesis as evidenced by the alteration of proliferation, differentiation and mineralization of MC3T3 E1 osteoblasts, inhibited their apoptosis, and enhanced autophagosome formation and autophagy. They also regulated the expression of key proteins of PI3K/AKT and ER stress pathways. In addition, PI3K/AKT and ER stress pathway inhibitors could reverse the regulatory effects of JTG proteins on osteogenesis, apoptosis, autophagy and PI3K/AKT and ER stress pathways. Conclusion: JTG proteins increased the osteogenesis and inhibited osteoblast apoptosis by enhancing autophagy via PI3K/AKT and ER stress signaling pathways.
C1 [Liu, Yuling; Zhao, Luying; He, Xinyunxi; Shen, Yi; Hu, Sijing; Zhao, Qiming; Zhang, Quanlong; Qin, Luping; Zhang, Qiaoyan] Zhejiang Chinese Med Univ, Sch Pharmaceut Sci, Hangzhou 310053, Peoples R China.
   [Wang, Na] Ginwa Enterprise Grp INC, Xian 710069, Peoples R China.
   [Xu, Jinlong] 969th Hosp PLA Joint Logist Support Forces, Hohhot 010051, Peoples R China.
   [Zhang, Qiaoyan] Zhejiang Chinese Med Univ, Sch Pharmaceut Sci, Binwen Rd 584, Hangzhou 310053, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Chinese Medical University
RP Qin, LP; Zhang, QY (通讯作者)，Zhejiang Chinese Med Univ, Sch Pharmaceut Sci, Hangzhou 310053, Peoples R China.; Zhang, QY (通讯作者)，Zhejiang Chinese Med Univ, Sch Pharmaceut Sci, Binwen Rd 584, Hangzhou 310053, Peoples R China.
EM lpqin@zcmu.edu.cn; zqy1965@163.com
CR Amarasekara DS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062851
   Ambrose AJ, 2019, BIOORG MED CHEM LETT, V29, P1689, DOI 10.1016/j.bmcl.2019.05.041
   Arceo Mendoza R, 2021, ENDOCRIN METAB CLIN, V50, P167, DOI 10.1016/j.ecl.2021.03.009
   Behera J, 2022, LIFE SCI, V301, DOI 10.1016/j.lfs.2022.120595
   Bloise N, 2020, MATERIALS, V13, DOI 10.3390/ma13143052
   Chen YX, 2022, CRIT REV FOOD SCI, V62, P1187, DOI 10.1080/10408398.2020.1836606
   Chen YS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21144923
   Coleman OI, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02825
   Dadsena S, 2021, BIOCHEM SOC T, V49, P663, DOI 10.1042/BST20200522
   Dong K, 2021, INT J IMPLANT DENT, V7, DOI 10.1186/s40729 021 00357 4
   El Sayed KMF, 2014, J CRANIO MAXILL SURG, V42, P568, DOI 10.1016/j.jcms.2013.07.028
   Guo JC, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.13011
   Guo YF, 2021, J CELL PHYSIOL, V236, P4152, DOI 10.1002/jcp.30111
   Guo YS, 2021, MOL BIOL REP, V48, P7841, DOI 10.1007/s11033 021 06806 y
   He QT, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02623 z
   Huang R, 2015, MOL CELL, V57, P456, DOI 10.1016/j.molcel.2014.12.013
   Jaber FA, 2019, J CELL PHYSIOL, V234, P12105, DOI 10.1002/jcp.27071
   Ke DS, 2022, MOL BIOL REP, V49, P259, DOI 10.1007/s11033 021 06866 0
   Kemp K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071792
   Kong YP, 2022, CELL SIGNAL, V95, DOI 10.1016/j.cellsig.2022.110335
   Li J, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2159 z
   Li ZX, 2021, J ETHNOPHARMACOL, V280, DOI 10.1016/j.jep.2021.114481
   Liang HT, 2022, J ORTHOP TRANSL, V35, P53, DOI 10.1016/j.jot.2022.05.002
   Liang JQ, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/3635485
   Liao NN, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0249894
   刘铮, 2006, [中国中医骨伤科杂志, Chinese Journal of Traditional Medicine Traumatology and Orthopedics], V14, P73
   Mizoguchi T, 2021, J BONE MINER RES, V36, P1432, DOI 10.1002/jbmr.4410
   Nasiri Ansari N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020818
   Pal S, 2021, EUR J PHARMACOL, V913, DOI 10.1016/j.ejphar.2021.174634
   Park CS, 2018, BIOSENS BIOELECTRON, V105, P151, DOI 10.1016/j.bios.2018.01.018
   Park KR, 2022, AM J CHINESE MED, V50, P295, DOI 10.1142/S0192415X22500112
   Peng CH, 2022, J ETHNOPHARMACOL, V297, DOI 10.1016/j.jep.2022.115565
   Ren SS, 2022, BIOACT MATER, V7, P242, DOI 10.1016/j.bioactmat.2021.05.037
   Ru JY, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 03059 8
   Shakeri A, 2019, PHARMACOL RES, V146, DOI 10.1016/j.phrs.2019.104335
   Shen Y, 2022, CHIN MED UK, V17, DOI 10.1186/s13020 022 00627 2
   Sun K, 2020, OSTEOARTHR CARTILAGE, V28, P400, DOI 10.1016/j.joca.2020.02.027
   Touyama K., 2019, J CELL BIOCH
   Wang O., 2022, BONE MINER RES, V15, P142
   Wang XY, 2021, J INFLAMM RES, V14, P6685, DOI 10.2147/JIR.S338107
   Xu AH, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964 020 0512 6
   Yang Z, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/5338182
   Yin N, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658 019 0177 6
   Yun HM, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23158297
   Zahid MK, 2020, MOL CELL BIOCHEM, V463, P211, DOI 10.1007/s11010 019 03642 4
   Zhang D, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 02037 3
   Zhang YQ, 2021, EXP BIOL MED, V246, P1650, DOI 10.1177/15353702211002136
   Zhao BK, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.615191
   [赵岩 Zhao Yan], 2012, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V18, P95
   Zhong HM, 2022, CONTRAST MEDIA MOL I, V2022, DOI 10.1155/2022/8521051
   Zhou Y.M., 2012, J HOSP PHARM, V32, P1391
   Zhuang CY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.762543
NR 52
TC 17
Z9 19
U1 8
U2 40
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JUL 15
PY 2023
VL 311
AR 116399
DI 10.1016/j.jep.2023.116399
EA MAR 2023
PG 14
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA J3NQ9
UT WOS:001008716600001
PM 36997131
DA 2025 08 17
ER

PT J
AU Ha, H
   Shim, KS
   Ma, JY
AF Ha, Hyunil
   Shim, Ki Shulz
   Ma, Jin Yeul
TI Water extract of Uncaria sinensis suppresses RANKL induced bone
   loss by attenuating osteoclast differentiation and bone resorption
SO INTEGRATIVE MEDICINE RESEARCH
LA English
DT Article
DE Uncaria sinensis; Osteoclasts; Receptor activator for nuclear
   factor kappa B ligand; Nuclear factor of activated T cells; Cytoplasmic
   1
ID TRANSIENT FOREBRAIN ISCHEMIA; INDUCED NEURONAL DEATH; KAPPA B PATHWAY;
   NFATC1 INDUCTION; NUCLEAR FACTOR; CHOTO SAN; C FOS; HOOKS; STEMS;
   ACTIVATION
AB Background: The hooks and stems of Uncaria sinensis have been used to mitigate cardiovascular and central nervous system disorders in Asia traditional medicine. Regulation of osteoclast differentiation and activity is a major target for preventing and treating pathological bone diseases.
   Methods: Tartrate  resistant acid phosphatase (TRAP) activity and the number of TRAP stained multinucleated cells were used to examine receptor activator of nuclear factor KB ligand (RANKL) induced osteoclast differentiation. The activation of RANKL induced signaling pathways and the expression of transcription factors were investigated by western blot analysis and quantitative real time polymerase chain reaction. The bone resorption activity of osteoclast was studied using a plate coated with hydroxyl apatite. Trabecular bone destruction was investigated using a RANKL induced trabecular bone loss mouse model.
   Results: We found that water extract of the hooks and stems of U. sinensis (WEUS) inhibits RANKL induced differentiation of murine bone marrow macrophages and RAW264.7 cells into osteoclasts. WEUS inhibited the activation of NF KB and the expression of nuclear factor of activated T cells, cytoplasmic 1. In addition, WEUS suppressed the bone resorbing activity of mature osteoclasts without affecting their survival. Furthermore, oral administration of WEUS suppressed RANKL induced bone loss with a significant amelioration of trabecular bone micro structures. WEUS also reduced RANKL induced increase in serum TRAP5b activity and C terminal cross linked telopeptide of type I collagen levels.
   Conclusion: The present study demonstrates that WEUS has a pharmacological activity that inhibits osteoclast mediated bone destruction by suppressing osteoclast differentiation and function. These results suggest that U. sinensis could be a promising herbal candidate for preventing and treating bone diseases such as osteoporosis. (C) 2017 Korea Institute of Oriental Medicine. Published by Elsevier. This is an open access article under the CC BY NC ND license
C1 [Ha, Hyunil] Korea Inst Oriental Med, Div Clin Res, Daejeon, South Korea.
   [Shim, Ki Shulz; Ma, Jin Yeul] Korea Inst Oriental Med, Korean Med Applicat Ctr, 70 Cheomdan Ro, Daegu 41062, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM); Korea Institute of Oriental
   Medicine (KIOM)
RP Ma, JY (通讯作者)，Korea Inst Oriental Med, Korean Med Applicat Ctr, 70 Cheomdan Ro, Daegu 41062, South Korea.
EM jyma@kiom.re.kr
FU Ministry of Science, ICT and Future Planning, Korea [K17281]
FX This work was supported by a grant K17281 for the Korea Institute of
   Oriental Medicine from Ministry of Science, ICT and Future Planning,
   Korea. We thank to Chung Jo Lee for technical support.
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   Ha H, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472 6882 14 352
   Ha H, 2013, MOLECULES, V18, P7376, DOI 10.3390/molecules18077376
   Heitzman ME, 2005, PHYTOCHEMISTRY, V66, P5, DOI 10.1016/j.phytochem.2004.10.022
   Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Jang JY, 2012, INT J MOL MED, V30, P1465, DOI 10.3892/ijmm.2012.1134
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Park SH, 2011, J ETHNOPHARMACOL, V138, P774, DOI 10.1016/j.jep.2011.10.026
   Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Shimada Y, 1999, J PHARM PHARMACOL, V51, P715, DOI 10.1211/0022357991772853
   Shimada Y, 2001, AM J CHINESE MED, V29, P173, DOI 10.1142/S0192415X01000198
   Soysa NS, 2009, J BONE MINER METAB, V27, P131, DOI 10.1007/s00774 008 0026 6
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tan SN, 2011, TALANTA, V83, P891, DOI 10.1016/j.talanta.2010.10.048
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Tomimori Y, 2009, J BONE MINER RES, V24, P1194, DOI [10.1359/JBMR.090217, 10.1359/jbmr.090217]
   Walsh MC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004064
   Yokoyama K, 2004, J ETHNOPHARMACOL, V95, P335, DOI 10.1016/j.jep.2004.08.018
   Yokoyama K, 2004, PHYTOMEDICINE, V11, P478, DOI 10.1016/j.phymed.2003.04.001
NR 29
TC 4
Z9 5
U1 0
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213 4220
EI 2213 4239
J9 INTEGR MED RES
JI Integr. Med. Res.
PD DEC
PY 2017
VL 6
IS 4
BP 434
EP 442
DI 10.1016/j.imr.2017.09.004
PG 9
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA FO9MW
UT WOS:000417212600013
PM 29296571
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, ZY
   Yin, YJ
   Wang, Z
   Xie, L
   Deng, P
   Wang, DH
   Ji, N
   Zhao, H
   Han, XL
   Chen, QM
   Chung, CH
   Bai, D
   Zhao, XF
AF Liu, Zhongyu
   Yin, Yijia
   Wang, Zheng
   Xie, Liang
   Deng, Peng
   Wang, Donghui
   Ji, Ning
   Zhao, Hang
   Han, Xianglong
   Chen, Qianming
   Chung, Chun Hsi
   Bai, Ding
   Zhao, Xuefeng
TI RANKL inhibition halts lesion progression and promotes bone
   remineralization in mice with fibrous dysplasia
SO BONE
LA English
DT Article
DE RANKL; Small molecule inhibitor; GNAS(R201C); Fibrous dysplasia
ID STEM CELLS; EXPRESSION; ORIENTATION; DENOSUMAB; DENSITY
AB Fibrous dysplasia (FD) is a rare bone disease caused by GNAS mutation in skeletal stem cells, typically originating from and worsening in childhood. Till now, no cure for FD exists despite the well recognized etiology. Studies have demonstrated that osteoclastogenesis hyperactivity is caused by elevated RANKL expression, making RANKL inhibition a potential therapy. Although a human monoclonal anti RANKL antibody, denosumab, has been used in FD patients, the effects and mechanisms of RANKL inhibition for FD treatment require assessment. Denosumab is expensive and can only be injected. Therefore, formulating an oral administered, cost effective medicine is encouraged. In the current study, we evaluated the effects of a small molecule RANKL inhibitor, A52676293, on a transgenic FD mouse model. A52676293 effectively suppressed osteoclastogenesis and halted FD progression. The pre existing bone defects were primarily replaced by newly formed mineralized bone after two weeks of A52676293 administration. The potent RANKL inhibitory effect and easier route of delivery make A52676293 a promising target therapy of FD. Results from our study suggested that RANKL inhibition is effective in halting FD progression and promoting bone remineralization, which could benefit the patients with early onset of FD.
C1 [Liu, Zhongyu; Yin, Yijia; Wang, Zheng; Xie, Liang; Ji, Ning; Zhao, Hang; Han, Xianglong; Chen, Qianming; Bai, Ding; Zhao, Xuefeng] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis, Chengdu 610041, Peoples R China.
   [Deng, Peng] UCLA, Div Oral Biol & Med, Lab Mol Signaling, Sch Dent, Los Angeles, CA 90095 USA.
   [Wang, Donghui] Hebei Univ Technol, Sch Mat Sci & Engn, Tianjin 300130, Peoples R China.
   [Chung, Chun Hsi] Univ Penn, Sch Dent Med, Dept Orthodont, Philadelphia, PA 19104 USA.
C3 Sichuan University; University of California System; University of
   California Los Angeles; Hebei University of Technology; University of
   Pennsylvania
RP Bai, D; Zhao, XF (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis, Chengdu 610041, Peoples R China.
EM baiding@scu.edu.cn; xfzhao@scu.edu.cn
RI Wu, Fanglong/AAT 7998 2021; Wang, Donghui/HMP 1218 2023; Zhao,
   Xuefeng/ACK 5669 2022; chen, qian/HKE 2403 2023; zhao,
   hang/JVM 8270 2024; Wang, Donghui/A 8242 2019; Liu,
   Zhongyu/ABA 3216 2021; YIN, Yijia/KBB 9124 2024
OI Chen, Qianming/0000 0002 5371 4432; Wang, Donghui/0000 0002 1198 0978;
   Bai, Ding/0000 0002 5058 4329; Zhao, Xuefeng/0000 0001 6860 7739; 
FU National Natural Science Foundation of China [81970989, 82071146,
   81870804, 81870803, 81991500, 81991502]; Young Elite Scientist
   Sponsorship Program by China Association for Science and Technology
   [2019QNRC001]; Sichuan Science and Technology Program, China
   [19YYJC2613, 18H1134, 19H1134]; Sichuan University [18H1134, 19H1134]
FX We thank Dr. Ramiro Iglesias Bartolome and Dr. J. Silvio Gutkind for
   generously sharing Tet GasR201C mice with us. The authors would like to
   thank Dr. Li Chen from Analytical & Testing Center Sichuan University
   for her help with micro CT scanning and analysis. This project was
   supported by National Natural Science Foundation of China Grants
   (81970989, 82071146, 81870804, 81870803, 81991500 and 81991502); Young
   Elite Scientist Sponsorship Program by China Association for Science and
   Technology (2019QNRC001); Sichuan Science and Technology Program, China
   (19YYJC2613). We thank the continuous support from Mr. Mingxu Zhou and
   his family for fibrous dysplasiarelated research (Sichuan University
   internal grants 18H1134 and 19H1134).
CR Bhattacharyya N, 2012, J BONE MINER RES, V27, P1132, DOI 10.1002/jbmr.1546
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyce AM, 2020, ENDOCR REV, V41, P345, DOI 10.1210/endrev/bnz011
   Boyce AM, 2017, CURR OSTEOPOROS REP, V15, P283, DOI 10.1007/s11914 017 0380 1
   Boyce AM, 2013, CURR OSTEOPOROS REP, V11, P65, DOI 10.1007/s11914 013 0144 5
   Boyce AM, 2012, J BONE MINER RES, V27, P1462, DOI 10.1002/jbmr.1603
   Chon CS, 2017, APPL BIONICS BIOMECH, V2017, DOI 10.1155/2017/7201769
   Collins MT, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750 1172 7 S1 S4
   Corsi A, 2020, CALCIFIED TISSUE INT, V107, P603, DOI 10.1007/s00223 020 00752 w
   de Castro LF, 2019, J BONE MINER RES, V34, P2169, DOI 10.1002/jbmr.3904
   de Castro LF, 2019, J BONE MINER RES, V34, P290, DOI 10.1002/jbmr.3602
   Deodati A, 2022, J ENDOCRINOL INVEST, V45, P159, DOI 10.1007/s40618 021 01630 4
   DiCaprio MR, 2005, J BONE JOINT SURG AM, V87A, P1848, DOI 10.2106/JBJS.D.02942
   ENNEKING WF, 1986, J BONE JOINT SURG AM, V68A, P1415, DOI 10.2106/00004623 198668090 00015
   Florenzano P, 2019, J BONE MINER RES, V34, P653, DOI 10.1002/jbmr.3649
   Fratzl P, 2004, J MATER CHEM, V14, P2115, DOI 10.1039/b402005g
   Gehweiler D, 2022, ARCH ORTHOP TRAUM SU, V142, P1055, DOI 10.1007/s00402 021 03782 7
   Guerrini MM, 2015, IMMUNITY, V43, P1174, DOI 10.1016/j.immuni.2015.10.017
   Guille JT, 1998, J BONE JOINT SURG AM, V80A, P648, DOI 10.2106/00004623 199805000 00005
   Hakim DN, 2015, J BONE ONCOL, V4, P37, DOI 10.1016/j.jbo.2015.02.001
   Hart ES, 2007, J BONE MINER RES, V22, P1468, DOI 10.1359/JBMR.070511
   Iglesias Bartolome R, 2015, NAT CELL BIOL, V17, P793, DOI 10.1038/ncb3164
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Ippolito E, 2014, CLIN ORTHOP RELAT R, V472, P1558, DOI 10.1007/s11999 013 3380 1
   Javaid MK, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023 019 1102 9
   JUNQUEIRA LCU, 1979, HISTOCHEM J, V11, P447, DOI 10.1007/BF01002772
   Lattouf R, 2014, J HISTOCHEM CYTOCHEM, V62, P751, DOI 10.1369/0022155414545787
   Lederer E, 2014, J PHYSIOL LONDON, V592, P3985, DOI 10.1113/jphysiol.2014.273979
   Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092
   Majoor BCJ, 2019, J CLIN ENDOCR METAB, V104, P6069, DOI 10.1210/jc.2018 02543
   MARTIN RB, 1989, J BIOMECH, V22, P419, DOI 10.1016/0021 9290(89)90202 9
   Meier ME, 2021, J BONE MINER RES, V36, P1729, DOI 10.1002/jbmr.4380
   Meier ME, 2021, BONE REP, V14, DOI 10.1016/j.bonr.2021.101058
   Miedel EL, 2015, J ORTHOP RES, V33, P675, DOI 10.1002/jor.22838
   Miyata J, 2012, BIOORG MED CHEM LETT, V22, P5681, DOI 10.1016/j.bmcl.2012.06.087
   Mun SH, 2020, EXP MOL MED, V52, P1239
   Nakai Y, 2019, BONE RES, V7, DOI 10.1038/s41413 018 0036 5
   Palmisano B, 2019, J BONE MINER RES, V34, P2171, DOI 10.1002/jbmr.3828
   Piersanti S, 2010, J BONE MINER RES, V25, P1103, DOI 10.1359/jbmr.091036
   Raborn LN, 2021, OSTEOPOROSIS INT, V32, P1889, DOI 10.1007/s00198 021 05895 6
   Riminucci M, 1997, AM J PATHOL, V151, P1587
   Riminucci M, 2003, J CLIN INVEST, V112, P683, DOI 10.1172/JC120031899
   Saggio I, 2014, J BONE MINER RES, V29, P2357, DOI 10.1002/jbmr.2267
   SHENKER A, 1994, J CLIN ENDOCR METAB, V79, P750, DOI 10.1210/jc.79.3.750
   Stanton RP, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750 1172 7 S1 S1
   Tiefenboeck TM, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 42476 4
   Toyosawa S, 2007, MODERN PATHOL, V20, P389, DOI 10.1038/modpathol.3800753
   WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403
   Wu JY, 2011, J CLIN INVEST, V121, P3492, DOI 10.1172/JCI46406
   Zdravkovic V, 2020, J ORTHOP RES, V38, P1914, DOI 10.1002/jor.24633
   Zhao XF, 2018, P NATL ACAD SCI USA, V115, pE428, DOI 10.1073/pnas.1713710115
NR 51
TC 12
Z9 15
U1 3
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2022
VL 156
AR 116301
DI 10.1016/j.bone.2021.116301
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA ZZ8ZH
UT WOS:000773552400004
PM 34952228
OA hybrid
DA 2025 08 17
ER

PT J
AU Zhao, Y
   Li, J
   Liu, Y
   Yu, KQ
   Zhang, J
   Chen, XG
AF Zhao, Yi
   Li, Juan
   Liu, Yi
   Yu, Ke Qiang
   Zhang, Juan
   Chen, Xiao Guang
TI Gu Ling Pian a traditional Chinese medicine regulates, function and
   OPG/RANKL synthesis of osteoblasts via the p38 MAPK pathway
SO JOURNAL OF PHARMACY AND PHARMACOLOGY
LA English
DT Article
ID ACTIVATED PROTEIN KINASE; KAPPA B LIGAND; OSTEOCLAST DIFFERENTIATION;
   RECEPTOR ACTIVATOR; BONE RESORPTION; OSTEOPROTEGERIN; EXPRESSION;
   MINERALIZATION; CYTOKINES; COLLAGEN
AB Osteoporosis is a common disease that makes bones prone to fracture and can affect both men and women. Many traditional Chinese medicine formulations have the potential effect of preventing osteoporosis. Gu Ling Pian (GLP), a traditional Chinese medicine formulation, comprised of tonifying kidney herbal medicines, has been demonstrated to prevent osteoporosis by increasing bone mineral density, however the exact mechanism has not yet been elucidated. Osteoprotegerin (OPG), a receptor activator of NF kappa B (RANK), and RANK ligand (RANKL) play critical roles in bone remodelling by regulating the function of osteoclasts. In this study, we investigated the effect of GLP on osteoblasts, namely MG 63 cells. The cell proliferation and differentiation, synthesis of OPG/RANKL and p38 expression were tested on MG 63 cells exposed to serum from rats fed with GLP or not. The results showed that GLP significantly promoted MG 63 cell proliferation and differentiation. Upregulation of OPG and down regulation of RANKL at the protein and mRNA level were observed in GLP serum treated MG 63 cells using an enzyme linked immunosorbent assay and real time polymerase chain reaction. Further, treatment with GLP serum increased the level of p38 phosphorylation but did not affect the total p38 expression. These effects can be blocked by the p38 specific inhibitor SB203580. The results indicate that GLP can effectively promote the proliferation and differentiation of osteoblasts and regulate their OPG/RANKL expression, while the effects may be mediated via the p38 MAPK pathway. The findings suggest that GLP induces bone formation and may be beneficial for patients with osteoporosis.
C1 So Med Univ, Nanfang Hosp, Dept Tradit Chinese Med, Guangzhou 510515, Guangdong, Peoples R China.
   So Med Univ, Sch Publ Hlth & Trop Med, Lab Mol Pathogens, Guangzhou, Guangdong, Peoples R China.
   Luzhou Med Coll, Affiliated Hosp, Dept Rheumatol & Immunol, Luzhou, Sichuan, Peoples R China.
   So Med Univ, Dept Sci Res, Guangzhou, Guangdong, Peoples R China.
C3 Southern Medical University   China; Southern Medical University  
   China; Southwest Medical University; Southern Medical University   China
RP Li, J (通讯作者)，So Med Univ, Nanfang Hosp, Dept Tradit Chinese Med, Guangzhou 510515, Guangdong, Peoples R China.
EM lijuan4l675@hotmail.com
OI Li, Juan/0000 0002 2977 2966
CR Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756 3282(02)00953 5
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Hipskind Robert A., 1998, Frontiers in Bioscience, V3, pD804
   Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226
   Hu YY, 2003, ENDOCRINOLOGY, V144, P2068, DOI 10.1210/en.2002 220863
   Jeong JC, 2004, TOXICOL IN VITRO, V18, P829, DOI 10.1016/j.tiv.2004.05.002
   Kanno Y, 2004, MOL CELL ENDOCRINOL, V220, P89, DOI 10.1016/j.mce.2004.03.010
   Karsdal MA, 2001, J BIOL CHEM, V276, P39350, DOI 10.1074/jbc.M008738200
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kusumi A, 2005, J BONE MINER METAB, V23, P373, DOI 10.1007/s00774 005 0615 6
   LI J, 2005, NEW J TRADIT CHIN ME, V37, P17
   LI J, 1999, DI YI JUN YI DA XUE, V19, P242
   Lin Dong yun, 2005, Zhongguo Zhongyao Zazhi, V30, P851
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lovicu FJ, 2001, DEVELOPMENT, V128, P5075
   Luo XH, 2006, J BONE MINER RES, V21, P1648, DOI 10.1359/JBMR.060707
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Martini G, 2007, BONE, V40, P457, DOI 10.1016/j.bone.2006.08.003
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Pantouli E, 2005, BIOCHEM BIOPH RES CO, V329, P224, DOI 10.1016/j.bbrc.2005.01.122
   Qin DN, 2000, ASIAN J ANDROL, V2, P99
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   SHEN YG, 2006, CHIN J CLIN REHAB, V10, P42
   Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252
   Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309
   Tanabe N, 2004, LIFE SCI, V75, P2317, DOI 10.1016/j.lfs.2004.04.026
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tran QK, 2000, CARDIOVASC RES, V48, P13, DOI 10.1016/S0008 6363(00)00172 3
   Udagawa N, 2000, ENDOCRINOLOGY, V141, P3478, DOI 10.1210/en.141.9.3478
   Wang BC, 2005, COLLOID SURFACE B, V43, P194, DOI 10.1016/j.colsurfb.2005.04.013
NR 31
TC 11
Z9 16
U1 0
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0022 3573
EI 2042 7158
J9 J PHARM PHARMACOL
JI J. Pharm. Pharmacol.
PD AUG
PY 2007
VL 59
IS 8
BP 1167
EP 1173
DI 10.1211/jpp.59.8.0016
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 210SF
UT WOS:000249475200016
PM 17725861
OA Bronze
DA 2025 08 17
ER

PT J
AU Kim, SJ
   Uehara, H
   Yazici, S
   He, JQ
   Langley, RR
   Mathew, P
   Fan, D
   Fidler, IJ
AF Kim, SJ
   Uehara, H
   Yazici, S
   He, JQ
   Langley, RR
   Mathew, P
   Fan, D
   Fidler, IJ
TI Modulation of bone microenvironment with zoledronate enhances the
   therapeutic effects of STI571 and paclitaxel against experimental bone
   metastasis of human prostate cancer
SO CANCER RESEARCH
LA English
DT Article
ID BISPHOSPHONATES INDUCE APOPTOSIS; ANGIOGENESIS IN VITRO; GROWTH FACTOR;
   BREAST; CELLS; OSTEOCLASTS; SURVIVAL; ACID; MECHANISMS; HYPOTHESIS
AB Prostate cancer cells metastasize to the bone where their interaction with osteoclasts and osteoblasts can lead to alterations in the structure of the bone. We determined whether the systemic administration of the bisphosphonate, zoledronate, could prevent bone lysis and halt the proliferation of human prostate cancer cells injected into the tibia of nude mice. Zoledronate did not affect the in vitro proliferation of human prostate cancer PC 3MM2 cells. The in vivo administration of zoledronate produced significant bone preservation but did not inhibit the progressive growth of PC 3MM2 cells. The systemic administration of ST1571 (imatinib mesylate, Gleevec), an inhibitor of phosphorylation of the platelet derived growth factor receptor, in combination with paclitaxel, produced apoptosis of tumor cells and bone and tumor associated endothelial cells. The systemic administration of zoledronate with ST1571 and paclitaxel produced a significant preservation of bone structure, a decrease in tumor incidence and weight, and a decrease in incidence of lymph node metastasis. This therapeutic activity was correlated with inhibition of osteoclast function, inhibition of tumor cell proliferation, and induction of apoptosis in tumor associated endothelial cells and tumor cells. Cancer is a heterogeneous disease that requires multimodality therapy. The present data recommend the combination of a bisphosphonate agent with protein tyrosine kinase inhibitor and an anticycling drug for the treatment of prostate cancer bone metastasis.
C1 Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Unit 173, Houston, TX 77230 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77230 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center
RP Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Unit 173, POB 301429, Houston, TX 77230 USA.
EM ifidler@mdanderson.org
RI ; Yazici, Sertac/AAH 5296 2019
OI YAZICI, SERTAC/0000 0001 9616 3776; 
FU NCI NIH HHS [CA16672, P50 CA090270 050001, P30 CA016672 239014, CA90270]
   Funding Source: Medline
CR AIMAKAJORNBOON N, 2001, BRAIN RES, V895, P111
   BATTEGAY EJ, 1994, J CELL BIOL, V125, P917, DOI 10.1083/jcb.125.4.917
   Body JJ, 1998, J CLIN ONCOL, V16, P3890, DOI 10.1200/JCO.1998.16.12.3890
   Boissier S, 2000, CANCER RES, V60, P2949
   BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081
   Boyce BF, 1999, ENDOCR RELAT CANCER, V6, P333, DOI 10.1677/erc.0.0060333
   Chun L, 1999, J BIOMED MATER RES, V48, P899, DOI 10.1002/(SICI)1097 4636(1999)48:6<899::AID JBM20>3.0.CO;2 E
   CLARKE NW, 1991, BRIT J UROL, V68, P74, DOI 10.1111/j.1464 410X.1991.tb15260.x
   Coleman RE, 2002, AM J CLIN ONCOL CANC, V25, pS32, DOI 10.1097/00000421 200212001 00006
   Eberhard A, 2000, CANCER RES, V60, P1388
   Fidler IJ, 2002, LANCET ONCOL, V3, P53, DOI 10.1016/S1470 2045(01)00622 2
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   FIDLER IJ, 1990, CANCER RES, V50, P6130
   FLANAGAN AM, 1991, CALCIFIED TISSUE INT, V49, P407, DOI 10.1007/BF02555852
   Fleisch H, 1997, HORM METAB RES, V29, P145, DOI 10.1055/s 2007 979008
   Folkman J, 1992, Semin Cancer Biol, V3, P65
   Fournier P, 2002, CANCER RES, V62, P6538
   Fudge K, 1996, PROSTATE, V29, P282
   GREEN JR, 1994, J BONE MINER RES, V9, P745
   Heuchel R, 1999, P NATL ACAD SCI USA, V96, P11410, DOI 10.1073/pnas.96.20.11410
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Kim SJ, 2003, CLIN CANCER RES, V9, P1200
   Koeneman KS, 1999, PROSTATE, V39, P246
   KOUTSILIERIS M, 1993, ANTICANCER RES, V13, P443
   Lange PH, 1998, CANCER METAST REV, V17, P331, DOI 10.1023/A:1006106209527
   Langley RR, 2004, CANCER RES, V64, P3727, DOI 10.1158/0008 5472.CAN 03 3863
   Lee MV, 2001, CANCER RES, V61, P2602
   Lee Y, 2003, J ORTHOP RES, V21, P62, DOI 10.1016/S0736 0266(02)00095 5
   Liu YC, 1996, EXP CELL RES, V228, P206, DOI 10.1006/excr.1996.0318
   Mackle PS, 2001, BRIT J CANCER, V84, P951, DOI 10.1054/bjoc.2000.1679
   Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558
   Michigami T, 2001, CANCER RES, V61, P1637
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   MORTON AR, 1988, BRIT MED J, V297, P772, DOI 10.1136/bmj.297.6651.772
   OSIER LK, 1987, BONE MINER, V3, P35
   Pettaway CA, 1996, CLIN CANCER RES, V2, P1627
   Pietras K, 2001, CANCER RES, V61, P2929
   Rogers MJ, 1997, CANCER, V80, P1652, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1652::AID CNCR15>3.0.CO;2 Z
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Sohara Y, 2003, CANCER RES, V63, P3026
   Tenta R, 2004, PROSTATE, V59, P120, DOI 10.1002/pros.10363
   Uehara H, 2003, J NATL CANCER I, V95, P458, DOI 10.1093/jnci/95.6.458
   Xie JW, 2001, P NATL ACAD SCI USA, V98, P9255, DOI 10.1073/pnas.151173398
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
   Zhang SXL, 2003, FASEB J, V17, P1709, DOI 10.1096/fj.02 1111fje
NR 47
TC 50
Z9 57
U1 0
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 0008 5472
EI 1538 7445
J9 CANCER RES
JI Cancer Res.
PD MAY 1
PY 2005
VL 65
IS 9
BP 3707
EP 3715
DI 10.1158/0008 5472.CAN 04 3601
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 919ZH
UT WOS:000228656000030
PM 15867366
OA Bronze
DA 2025 08 17
ER

PT J
AU Elabd, C
   Basillais, A
   Beaupied, H
   Breuil, V
   Wagner, N
   Scheideler, M
   Zaragosi, LE
   Massiéra, F
   Lemichez, E
   Trajanoski, Z
   Carle, G
   Euller Ziegler, L
   Ailhaud, G
   Benhamou, CL
   Dani, C
   Amri, EZ
AF Elabd, Christian
   Basillais, Armelle
   Beaupied, Helene
   Breuil, Veronique
   Wagner, Nicole
   Scheideler, Marcel
   Zaragosi, Laure Emmanuelle
   Massiera, Florence
   Lemichez, Emmanuel
   Trajanoski, Zlatko
   Carle, Georges
   Euller Ziegler, Liana
   Ailhaud, Gerard
   Benhamou, Claude Laurent
   Dani, Christian
   Amri, Ez Zoubir
TI Oxytocin controls differentiation of human mesenchymal stem cells and
   reverses osteoporosis
SO STEM CELLS
LA English
DT Article
DE mesenchymal stem cells; osteoblast; adipocyte; differentiation;
   osteoporosis; oxytocin
ID HUMAN ADIPOSE TISSUE; GENE EXPRESSION; BONE FORMATION; ADIPOCYTE
   DIFFERENTIATION; OSTEOPROGENITOR CELLS; POSTMENOPAUSAL WOMEN;
   OVARIECTOMIZED RATS; IN VITRO; RECEPTOR; ADIPOGENESIS
AB Osteoporosis constitutes a major worldwide public health burden characterized by enhanced skeletal fragility. Bone metabolism is the combination of bone resorption by osteoclasts and bone formation by osteoblasts. Whereas increase in bone resorption is considered as the main contributor of bone loss that may lead to osteoporosis, this loss is accompanied by increased bone marrow adiposity. Osteoblasts and adipocytes share the same precursor cell and an inverse relationship exists between the two lineages. Therefore, identifying signaling pathways that stimulate mesenchymal stem cells osteogenesis at the expense of adipogenesis is of major importance for developing new therapeutic treatments. For this purpose, we identified by transcriptomic analysis the oxytocin receptor pathway as a potential regulator of the osteoblast/adipocyte balance of human multipotent adipose derived stem (hMADS) cells. Both oxytocin (OT) and carbetocin ( a stable OT analogue) negatively modulate adipogenesis while promoting osteogenesis in both hMADS cells and human bone marrow mesenchymal stromal cells. Consistent with these observations, ovariectomized (OVX) mice and rats, which become osteoporotic and exhibit disequilibrium of this balance, have significant decreased OT levels compared to sham operated controls. Subcutaneous OT injection reverses bone loss in OVX mice and reduces marrow adiposity. Clinically, plasma OT levels are significantly lower in postmenopausal women developing osteoporosis than in their healthy counterparts. Taken together, these results suggest that plasma OT levels represent a novel diagnostic marker for osteoporosis and that OT administration holds promise as a potential therapy for this disease.
C1 [Elabd, Christian; Zaragosi, Laure Emmanuelle; Massiera, Florence; Ailhaud, Gerard; Dani, Christian; Amri, Ez Zoubir] Univ Nice Sophia Antipolis, CNRS, ISBDC, F 06100 Nice, France.
   [Basillais, Armelle; Beaupied, Helene; Benhamou, Claude Laurent] IPROS Hop Porte Madeleine, INSERM, U658, Orleans, France.
   [Breuil, Veronique; Carle, Georges] Univ Nice Sophia Antipolis, CNRS, GEPITOS, F 06100 Nice, France.
   [Breuil, Veronique; Carle, Georges] Fac Med, IFR50, Nice, France.
   [Breuil, Veronique; Euller Ziegler, Liana] CHU Archet 1, Serv Rhumatol, Nice, France.
   [Wagner, Nicole; Trajanoski, Zlatko] Fac Med Nice, INSERM, U907, F 06034 Nice, France.
   [Scheideler, Marcel] Graz Univ Technol, Inst Genom & Bioinformat, A 8010 Graz, Austria.
   [Lemichez, Emmanuel] Fac Med Nice, INSERM, U627, F 06034 Nice, France.
C3 Universite Cote d'Azur; Centre National de la Recherche Scientifique
   (CNRS); Institut National de la Sante et de la Recherche Medicale
   (Inserm); Centre National de la Recherche Scientifique (CNRS);
   Universite Cote d'Azur; Universite Cote d'Azur; CHU Nice; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Universite
   Cote d'Azur; Graz University of Technology; Universite Cote d'Azur;
   Institut National de la Sante et de la Recherche Medicale (Inserm)
RP Amri, EZ (通讯作者)，Univ Nice Sophia Antipolis, CNRS, ISBDC, 28 Ave Valrose, F 06100 Nice, France.
EM amri@unice.fr
RI Carle, Georges/GWC 5240 2022; Trajanoski, Zlatko/AAT 6703 2021;
   zaragosi, laure emmanuelle/P 9887 2016; Zaragosi,
   Laure Emmanuelle/P 9887 2016; lemichez, emmanuel/G 3559 2013; Lemichez,
   Emmanuel/G 3559 2013; Scheideler, Marcel/B 3087 2015; DANI,
   Christian/G 3639 2014
OI zaragosi, laure emmanuelle/0000 0001 6747 7928; amri,
   Ez Zoubir/0000 0001 8426 5396; Carle, Georges/0000 0002 3901 1052;
   lemichez, emmanuel/0000 0001 9080 7761; Wagner,
   Nicole/0000 0002 2746 0707; Scheideler, Marcel/0000 0003 4650 7387;
   Ailhaud, Gerard/0000 0003 0596 2906; Dani,
   Christian/0000 0003 3228 0230; 
FU Centre National de la Recherche Scientifique; Equipe FRM, soutenue par
   la Fondation pour la Recherche Medicale; CHU de Nice "Programme
   Hospitalier de Recherche Clinique Regional"; CHR d'Orleans; Austrian
   Ministry for Science and Research; Fondation de France; Fondation pour
   la Recherche Medicale
FX This work was supported by the Centre National de la Recherche
   Scientifique, by a grant from "Equipe FRM, soutenue par la Fondation
   pour la Recherche Medicale", by CHU de Nice "Programme Hospitalier de
   Recherche Clinique Regional", by CHR d'Orleans, and by the GEN AU
   program from the Austrian Ministry for Science and Research (projects
   GOLD II and BIN II). We are grateful to Drs. R. Arkowitz and P. Follette
   for critical review of the manuscript, to Dr. N. Bonnet for providing
   rat plasma, and to O. Cochet and A. Doye for skilled technical
   assistance. N. W. is a fellow of Fondation de France; C. E. is a
   recipient of a fellowship from Fondation pour la Recherche Medicale.
CR Abdallah BM, 2006, BONE, V39, P181, DOI 10.1016/j.bone.2005.12.082
   Aguirre JI, 2007, J BONE MINER RES, V22, P877, DOI 10.1359/JBMR.070313
   Ahdjoudj S, 2004, HISTOL HISTOPATHOL, V19, P151, DOI 10.14670/HH 19.151
   [Anonymous], 1994, World Health Organ Tech Rep Ser, V843, P1
   BOLAND D, 1987, REGUL PEPTIDES, V18, P7, DOI 10.1016/0167 0115(87)90045 0
   Bonnet N, 2007, J APPL PHYSIOL, V103, P524, DOI 10.1152/japplphysiol.01319.2006
   Bonnet N, 2007, TOXICOL APPL PHARM, V221, P111, DOI 10.1016/j.taap.2007.02.005
   Colucci S, 2002, BIOCHEM BIOPH RES CO, V297, P442, DOI 10.1016/S0006 291X(02)02009 0
   Copland JA, 1999, ENDOCRINOLOGY, V140, P4371, DOI 10.1210/en.140.9.4371
   De Ugarte DA, 2003, CELLS TISSUES ORGANS, V174, P101, DOI 10.1159/000071150
   Delmas PD, 1999, B WORLD HEALTH ORGAN, V77, P416
   DiMasso RJ, 1997, BONE, V20, P539, DOI 10.1016/S8756 3282(97)00055 0
   Doye A, 2002, CELL, V111, P553, DOI 10.1016/S0092 8674(02)01132 7
   Elabd C, 2007, BIOCHEM BIOPH RES CO, V361, P342, DOI 10.1016/j.bbrc.2007.06.180
   Elabd S K, 2007, Endocr Regul, V41, P131
   Ferguson JN, 2000, NAT GENET, V25, P284, DOI 10.1038/77040
   Graham DY, 1999, ALIMENT PHARM THER, V13, P515
   Greenspan SL, 2007, ANN INTERN MED, V146, P326, DOI 10.7326/0003 4819 146 5 200703060 00005
   Gronthos S, 2001, J CELL PHYSIOL, V189, P54, DOI 10.1002/jcp.1138
   Halvorsen YDC, 2001, TISSUE ENG, V7, P729, DOI 10.1089/107632701753337681
   HANEJI T, 1983, J BIOCHEM, V94, P1127, DOI 10.1093/oxfordjournals.jbchem.a134456
   Hata K, 2005, MOL CELL BIOL, V25, P1971, DOI 10.1128/MCB.25.5.1971 1979.2005
   HUNTER DJS, 1992, CLIN PHARMACOL THER, V52, P60, DOI 10.1038/clpt.1992.103
   Jansson JO, 2006, EUR J ENDOCRINOL, V154, P349, DOI 10.1530/eje.1.02082
   Jee WSS, 1997, BONE, V21, P297, DOI 10.1016/S8756 3282(97)00147 6
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kasukawa Y, 2007, TOHOKU J EXP MED, V211, P275, DOI 10.1620/tjem.211.275
   Keen R, 2007, BEST PRACT RES CL RH, V21, P109, DOI 10.1016/j.berh.2006.10.004
   Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984 05.2005
   Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701
   Kulterer B, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 70
   Levasseur R, 2005, JOINT BONE SPINE, V72, P474, DOI 10.1016/j.jbspin.2005.10.002
   López FJ, 2000, CURR OPIN CHEM BIOL, V4, P383
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   McCormick RK, 2007, ALTERN MED REV, V12, P113
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   NEGREL R, 1978, P NATL ACAD SCI USA, V75, P6054, DOI 10.1073/pnas.75.12.6054
   Neumann ID, 2007, CELL METAB, V5, P231, DOI 10.1016/j.cmet.2007.03.008
   Nishimori K, 1996, P NATL ACAD SCI USA, V93, P11699, DOI 10.1073/pnas.93.21.11699
   Noël D, 2008, EXP CELL RES, V314, P1575, DOI 10.1016/j.yexcr.2007.12.022
   Nuttall ME, 2004, CURR OPIN PHARMACOL, V4, P290, DOI 10.1016/j.coph.2004.03.002
   Petersson M, 2005, BRAIN RES, V1049, P234, DOI 10.1016/j.brainres.2005.05.034
   Petersson M, 2005, MATURITAS, V51, P426, DOI 10.1016/j.maturitas.2004.10.005
   Petersson M, 2002, PEPTIDES, V23, P1121, DOI 10.1016/S0196 9781(02)00041 4
   PETERSSON M, 2008, REGUL PEPT IN PRESS
   Reginato MJ, 1998, J BIOL CHEM, V273, P1855, DOI 10.1074/jbc.273.4.1855
   Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578
   RICHARD S, 1990, J BIOL CHEM, V265, P6098
   Richter ON, 2004, MOL HUM REPROD, V10, P339, DOI 10.1093/molehr/gah039
   Rizzoli R, 2008, BONE, V42, P841, DOI 10.1016/j.bone.2008.01.003
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rodriguez AM, 2005, J EXP MED, V201, P1397, DOI 10.1084/jem.20042224
   Rodriguez AM, 2004, BIOCHEM BIOPH RES CO, V315, P255, DOI 10.1016/j.bbrc.2004.01.053
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Russell JA, 2003, FRONT NEUROENDOCRIN, V24, P27, DOI 10.1016/S0091 3022(02)00104 8
   Sakaguchi Y, 2005, ARTHRITIS RHEUM US, V52, P2521, DOI 10.1002/art.21212
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Seibel MJ, 2006, CELL, V127, P1079, DOI 10.1016/j.cell.2006.12.002
   Simic P, 2006, J BIOL CHEM, V281, P25509, DOI 10.1074/jbc.M513276200
   Smith JG, 2006, CLIN OBSTET GYNECOL, V49, P594, DOI 10.1097/00003081 200609000 00019
   Strakova Z, 1998, AM J PHYSIOL ENDOC M, V274, pE634, DOI 10.1152/ajpendo.1998.274.4.E634
   Stringer B, 2007, CALCIFIED TISSUE INT, V80, P233, DOI 10.1007/s00223 007 9016 2
   Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051
   Tahara M, 2002, ENDOCRINOLOGY, V143, P920, DOI 10.1210/en.143.3.920
   Takayanagi Y, 2005, P NATL ACAD SCI USA, V102, P16096, DOI 10.1073/pnas.0505312102
   Takeda S, 2005, BIOCHEM BIOPH RES CO, V328, P697, DOI 10.1016/j.bbrc.2004.11.071
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tsuboi H, 2004, BIOCHEM BIOPH RES CO, V322, P1066, DOI 10.1016/j.bbrc.2004.08.018
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   Wagner N, 2005, GENE DEV, V19, P2631, DOI 10.1101/gad.346405
   Wang FS, 2002, J BIOL CHEM, V277, P10931, DOI 10.1074/jbc.M104587200
   WRONSKI TJ, 1985, CALCIFIED TISSUE INT, V37, P324, DOI 10.1007/BF02554882
   Yeh JK, 1997, BONE, V20, P413, DOI 10.1016/S8756 3282(97)00027 6
   Yeh JK, 1996, BONE, V18, P443, DOI 10.1016/8756 3282(96)00045 2
   Yeung DKW, 2005, J MAGN RESON IMAGING, V22, P279, DOI 10.1002/jmri.20367
   Zaragosi LE, 2006, STEM CELLS, V24, P2412, DOI 10.1634/stemcells.2006 0006
   Zingg HH, 2003, TRENDS ENDOCRIN MET, V14, P222, DOI 10.1016/S1043 2760(03)00080 8
NR 78
TC 159
Z9 181
U1 0
U2 30
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD SEP
PY 2008
VL 26
IS 9
BP 2399
EP 2407
DI 10.1634/stemcells.2008 0127
PG 9
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 350PE
UT WOS:000259364800021
PM 18583541
OA Bronze
DA 2025 08 17
ER

PT J
AU Cai, MX
   Peng, HZ
   Liu, MY
   Huang, MH
   Zheng, W
   Zhang, GL
   Lai, WJ
   Liao, CF
   Cai, LZ
   Zhang, DM
   Liu, XN
AF Cai, Mingxiang
   Peng, Huizhen
   Liu, Minyi
   Huang, Maohua
   Zheng, Wen
   Zhang, Guilan
   Lai, Wenjia
   Liao, Chufang
   Cai, Lizhao
   Zhang, Dongmei
   Liu, Xiangning
TI Vascular Pericyte Derived Exosomes Inhibit Bone Resorption via Traf3
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE pericytes; exosomes; bone resorption; Traf3
ID NF KAPPA B; OSTEOCLAST DIFFERENTIATION; NG2 PROTEOGLYCAN; CELLS;
   OSTEOPROTEGERIN; OSTEOPOROSIS; ANGIOGENESIS; EXPRESSION
AB Purpose: Blood vessels distribute cells, oxygen, and nutrients throughout the body to support tissue growth and balance. Pericytes and endothelial cells form the inner wall of blood vessels, crucial for organ development and tissue homeostasis by producing paracrine signaling molecules. In the skeletal system, pericyte derived vascular factors along with angiogenic factors released by bone cells regulate angiogenesis and bone formation. Although the involvement of angiogenic factors and skeletal blood vessels in bone homeostasis is relatively clear, the role of pericytes and the underlying mechanisms remain unknown. Here, our objective was to elucidate the significance of pericytes in regulating osteoclast differentiation.Methods: We used tissue staining to detect the coverage of pericytes and osteoclasts in femoral tissues of osteoporotic mice and mice of different ages, analyzing their correlation. We developed mice with conditionally deleted pericytes, observing changes in bone mass and osteoclast activity using micro computer tomography and tissue staining to detect the regulatory effect of pericytes on osteoclasts. Pericytes derived exosomes (PC EVs) were collected and co cultured with monocytes that induce osteoclast differentiation to detect the effect of the former on the exosomes. Finally, the specific mechanism of PC EVs regulating osteoclast differentiation was verified using RNA sequencing and Western blotting.Results: Our study indicates a significant correlation between pericytes and age related bone resorption. Conditional deletion of pericytes activated bone resorption and led to osteopenia in vivo. We discovered that PC EVs inhibited the nuclear factor kappa light  chain enhancer of activated B cells (NF kappa B) pathway, which is mediated by tumor necrosis factor receptor associated factor 3 (Traf3), negatively regulating osteoclast development and bone resorption. Silencing Traf3 in PC EVs canceled their inhibitory effect on osteoclast differentiation.Conclusion: Our study provides a novel perspective into the regulatory role of pericytes on bone resorption and may provide potential strategies for developing novel anti bone resorption therapies.
C1 [Cai, Mingxiang; Peng, Huizhen; Liu, Minyi; Zheng, Wen; Zhang, Guilan; Lai, Wenjia; Liao, Chufang; Cai, Lizhao; Liu, Xiangning] Jinan Univ, Affiliated Hosp 1, Sch Stomatol, Clin Res Platform Interdiscipline Stomatol, Guangzhou 510630, Peoples R China.
   [Huang, Maohua; Zhang, Dongmei] Jinan Univ, Coll Pharm, Guangzhou 510632, Peoples R China.
   [Huang, Maohua; Zhang, Dongmei] Jinan Univ, Guangdong Prov Key Lab Pharmacodynam Constituents, Guangzhou 510632, Guangdong, Peoples R China.
C3 Jinan University; Jinan University; Jinan University
RP Liu, XN (通讯作者)，Jinan Univ, Affiliated Hosp 1, Sch Stomatol, Clin Res Platform Interdiscipline Stomatol, Guangzhou 510630, Peoples R China.; Zhang, DM (通讯作者)，Jinan Univ, Coll Pharm, Guangzhou 510632, Peoples R China.
EM dmzhang701@jnu.edu.cn; liuxiangning@jnu.edu.cn
RI cai, mingxiang/IYT 1913 2023; zhang, dongmei/B 8011 2013
OI Zheng, Wen/0000 0002 3686 5765
FU National Natural Science Foundation of China [82201001]; Natural Science
   Foundation Projects of Guangdong [2021A1515010882]; Science and
   Technology Projects in Guangzhou [202102010040, 202201010315,
   2023A03J1030]; Clinical Frontier Technology Program of the First
   Affiliated Hospital of Jinan University, China [JNU1AF CFTP 2022 a01210]
FX This work was generously supported by the National Natural Science
   Foundation of China (82201001) , the Natural Science Foundation Projects
   of Guangdong (2021A1515010882) , the Science and Technology Projects in
   Guangzhou (202102010040, 202201010315 and 2023A03J1030) , and the
   Clinical Frontier Technology Program of the First Affiliated Hospital of
   Jinan University, China (JNU1AF CFTP 2022 a01210) .
CR Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7
   Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001
   Boyce BF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02263
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cackowski FC, 2010, BLOOD, V115, P140, DOI 10.1182/blood 2009 08 237628
   Chim SM, 2013, CYTOKINE GROWTH F R, V24, P297, DOI 10.1016/j.cytogfr.2013.03.008
   Cooke VG, 2012, CANCER CELL, V21, P66, DOI 10.1016/j.ccr.2011.11.024
   Davaine JM, 2016, EUR J VASC ENDOVASC, V51, P259, DOI 10.1016/j.ejvs.2015.10.004
   Davaine JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107642
   Elsharkasy OM, 2020, ADV DRUG DELIVER REV, V159, P332, DOI 10.1016/j.addr.2020.04.004
   He JQ, 2007, J BIOL CHEM, V282, P3688, DOI 10.1074/jbc.M610271200
   He JQ, 2006, J EXP MED, V203, P2413, DOI 10.1084/jem.20061166
   Hu Y, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00147 z
   Huang MH, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12096
   Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977
   Ke DS, 2019, BIOCHIMIE, V167, P217, DOI 10.1016/j.biochi.2019.10.008
   Kenswil KJG, 2018, CELL REP, V22, P666, DOI 10.1016/j.celrep.2017.12.070
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Li JB, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10677 0
   Liu CH, 2001, BIOCHEM BIOPH RES CO, V288, P129, DOI 10.1006/bbrc.2001.5737
   Liu C, 2019, P NATL ACAD SCI USA, V116, P7455, DOI 10.1073/pnas.1814874116
   Mulcahy LA, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24641
   Murfee WL, 2005, MICROCIRCULATION, V12, P151, DOI 10.1080/10739680590904955
   Negri S, 2020, STEM CELL TRANSL MED, V9, P1617, DOI 10.1002/sctm.20 0152
   Ozerdem U, 2002, MICROVASC RES, V63, P129, DOI 10.1006/mvre.2001.2376
   Pegtel DM, 2019, ANNU REV BIOCHEM, V88, P487, DOI 10.1146/annurev biochem 013118 111902
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Ramasamy SK, 2014, NATURE, V507, P376, DOI 10.1038/nature13146
   SHEPRO D, 1993, FASEB J, V7, P1031, DOI 10.1096/fasebj.7.11.8370472
   Smith ZJ, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.28533
   Song H, 2019, NANO LETT, V19, P3040, DOI 10.1021/acs.nanolett.9b00287
   Suzuki N, 2008, INT J MOL MED, V21, P291
   Taverna S, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03460 y
   Teichert M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16106
   Wilson CL, 2018, AM J PHYSIOL LUNG C, V315, pL991, DOI 10.1152/ajplung.00289.2018
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xiu Y, 2014, J CLIN INVEST, V124, P297, DOI 10.1172/JCI66947
   Xu R, 2018, NAT MED, V24, P823, DOI 10.1038/s41591 018 0020 z
   Xu S, 2021, J BONE MINER RES, V36, P2053, DOI 10.1002/jbmr.4398
   Xue Y, 2019, BIOCHEM BIOPH RES CO, V508, P1088, DOI 10.1016/j.bbrc.2018.12.029
   Yang ZY, 2022, BIOMATERIALS, V283, DOI 10.1016/j.biomaterials.2022.121438
   Ye L, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/8833098
   Yuan XC, 2019, FRONT NEUROSCI SWITZ, V13, DOI 10.3389/fnins.2019.00319
   ZAIDI M, 1993, BONE, V14, P97, DOI 10.1016/8756 3282(93)90234 2
   Zeng XZ, 2016, ACTA PHARMACOL SIN, V37, P255, DOI 10.1038/aps.2015.85
   Zhang H, 2023, SCI ADV, V9, DOI 10.1126/sciadv.abo7868
   Zhang Y, 2011, P NATL ACAD SCI USA, V108, P9863, DOI 10.1073/pnas.1018493108
   Zhu SP, 2020, THERANOSTICS, V10, P5957, DOI 10.7150/thno.45422
NR 49
TC 7
Z9 8
U1 3
U2 13
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2023
VL 18
BP 7065
EP 7077
DI 10.2147/IJN.S438229
PG 13
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA Z5WS7
UT WOS:001112781200001
PM 38046234
OA gold
DA 2025 08 17
ER

PT J
AU Li, JKJ
   Lin, JCA
   Liu, HC
   Sun, JS
   Ruaan, RC
   Shih, C
   Chang, WHS
AF Li, JKJ
   Lin, JCA
   Liu, HC
   Sun, JS
   Ruaan, RC
   Shih, C
   Chang, WHS
TI Comparison of ultrasound and electromagnetic field effects on osteoblast
   growth
SO ULTRASOUND IN MEDICINE AND BIOLOGY
LA English
DT Article
DE Wistar rat calvaria; mechanism; NO synthase; protein kinase; inositol
   phosphate pathway; Ca2+ release; stretch activated ion channel;
   calmodulin; enhanced bone repair
ID NITRIC OXIDE SYNTHASE; PROTEIN KINASE C; BONE CELLS; PROLIFERATIVE
   RESPONSE; STIMULATION; DIFFERENTIATION; EXPRESSION; MECHANISM; REQUIRES;
   PATHWAY
AB This study compares the mechanisms of ultrasound (US) on osteoblast proliferation with those of pulsed electromagnetic field (PEMF), by different signal transduction pathway inhibitors. The cells were stimulated for 15 min under US or for 2 h under PEMF exposure. Twenty four h after the beginning of stimulation, the cells were harvested and used for mitochondrial activity test (MTT) analysis. The results showed that there are different transduction pathways for US and PEMF stimulation that lead to an upgrade of osteoblast proliferation, although their pathways all lead to an increase in cytocolic Ca2+ and activation of calmodulin. These findings offer a biochemical mechanism to support the process of ultrasound and PEMF induced enhanced healing of bone fractures. (E mail: whchang@cycu.edu.tw) (c) 2006 World Federation for Ultrasound in Medicine & Biology.
C1 Chung Yuan Christian Univ, Ctr Nano Bioengn, Dept Biomed Engn, Chungli 32023, Taiwan.
   Natl Taiwan Univ, Ctr Med, Dept Orthopaed Surg, Taipei 10764, Taiwan.
   Natl Cent Univ, Dept Chem & Mat Engn, Chungli 32054, Taiwan.
   Natl Def Med Ctr, Dept Biol & Anat, Taipei, Taiwan.
   Natl Yang Ming Univ, Inst Rehabil Sci & Technol, Taipei 112, Taiwan.
C3 Chung Yuan Christian University; National Taiwan University; National
   Central University; National Defense Medical University; National Yang
   Ming Chiao Tung University
RP Chang, WHS (通讯作者)，Chung Yuan Christian Univ, Ctr Nano Bioengn, Dept Biomed Engn, Chungli 32023, Taiwan.
EM whchang@cycu.edu.tw
RI ; SUN, Jus Sheng/ITU 1253 2023; Lin, Cheng An/AAS 6532 2021; Chang,
   Wen Hao/C 4906 2013
OI Lin, Cheng An/0000 0002 0452 1132; SUN, JUI SHENG/0000 0001 5142 8777;
   /0000 0003 3636 5506; Chang, Wen Hao/0000 0003 4880 6006
CR Brighton CT, 1996, J BONE JOINT SURG AM, V78A, P1337, DOI 10.2106/00004623 199609000 00007
   BRIGHTON CT, 1992, J ORTHOPAED RES, V10, P385, DOI 10.1002/jor.1100100311
   Brighton CT, 2001, J BONE JOINT SURG AM, V83A, P1514, DOI 10.2106/00004623 200110000 00009
   CARTER TD, 1989, BIOCHEM J, V262, P431, DOI 10.1042/bj2620431
   Chen NX, 2000, AM J PHYSIOL CELL PH, V278, pC989, DOI 10.1152/ajpcell.2000.278.5.C989
   CHIOU CY, 1975, BRIT J PHARMACOL, V53, P279, DOI 10.1111/j.1476 5381.1975.tb07359.x
   Diniz P, 2002, NITRIC OXIDE BIOL CH, V7, P18, DOI 10.1016/S1089 8603(02)00004 6
   HIDAKA H, 1984, BIOCHEMISTRY US, V23, P5036, DOI 10.1021/bi00316a032
   Ho Mei Ling, 1999, Kaohsiung Journal of Medical Sciences, V15, P248
   Hung CT, 1996, J BIOMECH, V29, P1411, DOI 10.1016/0021 9290(96)84536 2
   KONTUREK SJ, 1992, EUR J PHARMACOL, V229, P155, DOI 10.1016/0014 2999(92)90550 N
   LEIBOVICH SJ, 1994, P NATL ACAD SCI USA, V91, P4190, DOI 10.1073/pnas.91.10.4190
   Li J, 2003, ELECTROMAGN BIOL MED, V22, P87, DOI 10.1081/JBC 120024619
   Li JGR, 2002, ULTRASOUND MED BIOL, V28, P683, DOI 10.1016/S0301 5629(02)00485 4
   Li JK, 2003, BIOMATERIALS, V24, P2379, DOI 10.1016/S0142 9612(03)00033 4
   MacPherson H, 1999, BONE, V24, P179, DOI 10.1016/S8756 3282(98)00173 2
   Morbidelli L, 1996, AM J PHYSIOL HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411
   Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868
   Pavalko FM, 1998, AM J PHYSIOL CELL PH, V275, pC1591
   PEAD MJ, 1989, CALCIFIED TISSUE INT, V45, P34, DOI 10.1007/BF02556658
   RALSTON SH, 1995, J BONE MINER RES, V10, P1040
   RALSTON SH, 1994, ENDOCRINOLOGY, V135, P330, DOI 10.1210/en.135.1.330
   Reher P, 2002, BONE, V31, P236, DOI 10.1016/S8756 3282(02)00789 5
   Siggelkow H, 1999, J CELL BIOCHEM, V75, P22, DOI 10.1002/(SICI)1097 4644(19991001)75:1<22::AID JCB3>3.3.CO;2 Y
   YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333
NR 25
TC 67
Z9 77
U1 0
U2 23
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0301 5629
J9 ULTRASOUND MED BIOL
JI Ultrasound Med. Biol.
PD MAY
PY 2006
VL 32
IS 5
BP 769
EP 775
DI 10.1016/j.ultrasmedbio.2006.01.017
PG 7
WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
GA 044CN
UT WOS:000237650000018
PM 16677936
DA 2025 08 17
ER

PT J
AU Tanguay, AP
   Menon, NG
   Boudreau, MH
   Jastrzebski, S
   Woods, PS
   Doyle, EA
   Edwards, WB
   Jay, GD
   Deymier, AC
   Lorenzo, J
   Lee, SK
   Schmidt, TA
AF Tanguay, Adam P.
   Menon, Nikhil G.
   Boudreau, Margaret H.
   Jastrzebski, Sandra
   Woods, Paige S.
   Doyle, Erica A.
   Edwards, W. Brent
   Jay, Gregory D.
   Deymier, Alix C.
   Lorenzo, Joseph
   Lee, Sun Kyeong
   Schmidt, Tannin A.
TI PRG4 deficiency in mice alters skeletal structure, mechanics, and
   calvarial osteoclastogenesis, and rhPRG4 inhibits in vitro
   osteoclastogenesis
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE bone; lubricin; osteoclast; osteoporosis; PRG4
ID HUMAN PROTEOGLYCAN 4; PARATHYROID HORMONE; BONE LOSS; LUBRICIN;
   PATHOGENESIS; OSTEOPOROSIS
AB Osteoporosis is a chronic disease characterized by reduced bone mass and increased fracture risk, estimated to affect over 10 million people in the United States alone. Drugs used to treat bone loss often come with significant limitations and/or long term safety concerns. Proteoglycan 4 (PRG4, also known as lubricin) is a mucin like glycoprotein best known for its boundary lubricating function of articular cartilage. In more recent years, it has been shown that PRG4 has anti inflammatory properties, contributes to the maintenance of subchondral bone integrity, and patients with PRG4 mutations are osteopenic. However, it remains unknown how PRG4 impacts mechanical and material properties of bone. Therefore, our objective was to perform a phenotyping study of bone in a Prg4 gene trap (GT) mouse (PRG4 deficient). We found that femurs of Prg4 GT mice have altered mechanical, structural, and material properties relative to wildtype littermates. Additionally, Prg4 GT mice have a greater number of calvarial osteoclasts than wildtype mice, but do not have a notable inflammatory serum profile. Finally, Prg4 GT mice do not have an altered rate of bone formation, and exogenous recombinant human PRG4 (rhPRG4) administration inhibited osteoclastogenesis in vitro, suggesting that the skeletal phenotype may be due to changes in bone resorption. Overall, this work demonstrates that PRG4 deficiency affects several integral properties of bone structure, mechanics, and skeletal cell activity, and provides the foundation and insight toward future work evaluating PRG4 as a potential therapeutic target in treating bone loss.
C1 [Tanguay, Adam P.; Menon, Nikhil G.; Woods, Paige S.; Doyle, Erica A.; Deymier, Alix C.; Schmidt, Tannin A.] UConn Hlth, Dept Biomed Engn, Farmington, CT USA.
   [Boudreau, Margaret H.; Jastrzebski, Sandra; Lorenzo, Joseph] UConn Hlth, Dept Med, Farmington, CT USA.
   [Jastrzebski, Sandra; Lorenzo, Joseph] UConn Hlth, Dept Orthopaed Surg, Farmington, CT USA.
   [Edwards, W. Brent] Univ Calgary, Fac Kinesiol, Human Performance Lab, Calgary, AB, Canada.
   [Jay, Gregory D.] Brown Univ, Warren Alpert Med Sch, Dept Med, Providence, RI USA.
   [Jay, Gregory D.] Brown Univ, Dept Engn, Warren Alpert Med Sch, Providence, RI USA.
   [Lee, Sun Kyeong] Ctr Aging, UConn Hlth, Farmington, CT USA.
   [Schmidt, Tannin A.] UConn Hlth, Dept Biomed Engn, 263 Farmington Ave, Farmington, CT 06030 USA.
C3 University of Calgary; Brown University; Brown University
RP Schmidt, TA (通讯作者)，UConn Hlth, Dept Biomed Engn, 263 Farmington Ave, Farmington, CT 06030 USA.
EM tschmidt@uchc.edu
RI Deymier, Alix/AAY 4762 2021; Schmidt, Tannin/AAE 3830 2019; Edwards,
   Brent/AAI 2469 2020; Jay, Gregory/C 6346 2013
OI Tanguay, Adam/0000 0002 7152 7710; 
FU Convergence Grant through the Research Excellence Program at UConn
   Health; Biomedical Engineering Department startup funds (TAS), a
   Convergence Grant through the Research Excellence Program at UConn
   Health [5R01 AR077534 04]; National Institute of Arthritis and
   Musculoskeletal and Skin diseases (NIAMS) of NIH; University of
   Connecticut Health Research Program award (EAD)
FX This work was supported by Biomedical Engineering Department startup
   funds (TAS), a Convergence Grant through the Research Excellence Program
   at UConn Health (TAS, SKL, JL), the National Institute of Arthritis and
   Musculoskeletal and Skin diseases (NIAMS) of NIH under award number 5R01
   AR077534 04 (JL), and a University of Connecticut Health Research
   Program award (EAD). We also acknowledge UConn Health MicroCT Imaging
   Facility for aid with structural analysis. We would like to thank Dr.
   Ivo Kalajzic for providing access to equipment in addition to
   constructive feedback on the manuscript.
CR Abubacker S, 2019, J ORTHOP RES, V37, P2077, DOI 10.1002/jor.24378
   Alquraini A, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0877 x
   Anastasilakis AD, 2021, J CLIN MED, V10, DOI 10.3390/jcm10010152
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Cole JH, 2011, CLIN ORTHOP RELAT R, V469, P2139, DOI 10.1007/s11999 011 1784 3
   Das N, 2019, BIOESSAYS, V41, DOI 10.1002/bies.201800166
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Ghosh M, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 90271 x
   Gold T, 2019, J Drug Assess, V8, P175, DOI 10.1080/21556660.2019.1677674
   Hardy R, 2009, J ENDOCRINOL, V201, P309, DOI 10.1677/JOE 08 0568
   Hayes KN, 2021, J CLIN MED, V10, DOI 10.3390/jcm10051140
   Hill A, 2015, ARTHRITIS RHEUMATOL, V67, P3070, DOI 10.1002/art.39276
   Iqbal SM, 2016, SCI REP UK, V6, DOI 10.1038/srep18910
   Jastrzebski S, 2019, J IMMUNOL, V203, P105, DOI 10.4049/jimmunol.1801032
   Jay GD, 2014, MATRIX BIOL, V39, P17, DOI 10.1016/j.matbio.2014.08.008
   KELLER TS, 1994, J BIOMECH, V27, P1159, DOI 10.1016/0021 9290(94)90056 6
   Khosla S, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031211
   Lambiase A, 2017, OCUL SURF, V15, P77, DOI 10.1016/j.jtos.2016.08.004
   Liu SY, 2022, MOL MED REP, V25, DOI 10.3892/mmr.2022.12615
   Maniscalco V, 2022, FRONT PEDIATR, V10, DOI 10.3389/fped.2022.981938
   Marcelino J, 1999, NAT GENET, V23, P319, DOI 10.1038/15496
   Maresova KB, 2011, J OSTEOPOROS, V2011, DOI 10.4061/2011/569417
   Mayo Clinic Staff, 2023, OSTEOPOROSIS
   McDaniel JS, 2014, EUR J ORAL SCI, V122, P100, DOI 10.1111/eos.12119
   Menon NG, 2021, EXP EYE RES, V208, DOI 10.1016/j.exer.2021.108628
   Morgan EF, 2018, ANNU REV BIOMED ENG, V20, P119, DOI [10.1146/annurev bioeng 062117 121139, 10.1146/annurev bioeng 062117121139]
   Novince CM, 2013, J ORTHOP RES, V31, P183, DOI 10.1002/jor.22207
   Novince CM, 2012, J BONE MINER RES, V27, P11, DOI 10.1002/jbmr.508
   Novince CM, 2011, AM J PATHOL, V179, P2431, DOI 10.1016/j.ajpath.2011.07.032
   Offiah AC, 2005, AM J ROENTGENOL, V185, P522, DOI 10.2214/ajr.185.2.01850522
   Oftadeh R, 2015, J BIOMECH ENG T ASME, V137, DOI 10.1115/1.4029176
   Peters B, 2016, PEDIATR RHEUMATOL, V14, DOI 10.1186/s12969 016 0093 5
   Pouresmaeili F, 2018, THER CLIN RISK MANAG, V14, P2029, DOI 10.2147/TCRM.S138000
   Qadri M, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075 021 02621 9
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Rhee DK, 2005, J CLIN INVEST, V115, P622, DOI 10.1172/JCI200522263
   Samsom ML, 2014, EXP EYE RES, V127, P14, DOI 10.1016/j.exer.2014.06.015
   Sanchez Lopez E, 2022, NAT REV RHEUMATOL, V18, P258, DOI 10.1038/s41584 022 00749 9
   Sarkar A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219697
   Schmidt TA, 2013, JAMA OPHTHALMOL, V131, P766, DOI 10.1001/jamaophthalmol.2013.2385
   Sokolove J, 2013, THER ADV MUSCULOSKEL, V5, P77, DOI 10.1177/1759720X12467868
   Tu Kristie N, 2018, P T, V43, P92
   Ungethuem U, 2010, PHYSIOL GENOMICS, V42A, P267, DOI 10.1152/physiolgenomics.00004.2010
   Vardakastani V, 2014, BONE, V69, P61, DOI 10.1016/j.bone.2014.09.003
   Waller KA, 2017, AM J SPORT MED, V45, P1512, DOI 10.1177/0363546516686965
NR 45
TC 2
Z9 2
U1 4
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD JUN
PY 2024
VL 42
IS 6
BP 1231
EP 1243
DI 10.1002/jor.25772
EA JAN 2024
PG 13
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA OR4T3
UT WOS:001136449800001
PM 38111181
DA 2025 08 17
ER

PT J
AU Qu, H
   Zhang, YK
   He, RX
   Lin, N
   Wang, C
AF Qu, Hao
   Zhang, Yuankang
   He, Rongxin
   Lin, Nong
   Wang, Cong
TI Anethole inhibits RANKL induced osteoclastogenesis by downregulating
   ERK/AKT signaling and prevents ovariectomy induced bone loss in vivo
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Anethole; Osteoporosis; RANKL; Osteoclast; NFATc1
ID NF KAPPA B; OSTEOPOROSIS; AKT; MAPK; DIFFERENTIATION; ANTIBACTERIAL;
   CANCER
AB Postmenopausal osteoporosis is a chronic population health hazard systemic metabolic disease caused by excessive bone resorption and reduced bone formation. The activity between osteoblast and osteoclast, with their mutual effects, influence the procedure of normal bone remodeling. Over activated osteoclast differentiation and function play a crucial role in excessive bone resorption. Hence, therapy strategies targeting osteoclast activity may promote the bone mass preservation and delay the osteoporosis process. Natural compound (anethole) is emerging as potential therapeutics for various metabolic diseases. The purpose of this study is to investigate the potential effects of anethole on RANKL induced osteoclast formation and function in vitro and in vivo. Here, in vitro TRAP staining assay was performed to investigate the inhibitory effect of anethole on osteoclast differentiation. Bone pits resorption assay revealed that osteoclast mediated bone resorption was inhibited by anethole. At mRNA and protein levels, anethole significantly reduced the expression of osteoclast specific genes expression in a concentration  or time dependent manner, including NFATc1, MMP 9, DC STAMP, c F, TRAP, CTR, Cathepsin K, and V ATPase d2. Furthermore, intracellular signaling transduction assay indicated that anethole inhibited osteoclast formation via blocking ERK and AKT signaling. GSK3 beta, the downstream signal of AKT, is simultaneously suppressed with anethole treatment. Based on ovariectomized (OVX) mice model, micro CT and histological staining results suggested that anethole prevented estrogen deficiency induced bone mass loss and increased osteoclast activity in vivo. In conclusion, our results show significant indications that anethole exhibits an osteoprotective effect and may be potential for the treatment of osteoporosis.
C1 [Qu, Hao; He, Rongxin; Lin, Nong; Wang, Cong] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Orthoped Surg, Hangzhou, Zhejiang, Peoples R China.
   [Qu, Hao; He, Rongxin; Lin, Nong; Wang, Cong] Zhejiang Univ, Orthoped Res Inst, Hangzhou, Zhejiang, Peoples R China.
   [Qu, Hao; He, Rongxin; Lin, Nong; Wang, Cong] Key Lab Motor Syst Dis Res & Precis Therapy Zheji, Hangzhou, Zhejiang, Peoples R China.
   [Zhang, Yuankang] XinJian Dist Peoples Hosp Nanchang, Dept Orthoped, Nanchang, Jiangxi, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP He, RX; Lin, N; Wang, C (通讯作者)，Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Orthoped Surg, Hangzhou, Zhejiang, Peoples R China.
EM email@zju.edu.cn; zyk20080058@163.com; herongxin@zju.edu.cn;
   linnong@zju.edu.cn; 05wangcong@zju.edu.cn
RI He, Rongxin/NLN 8611 2025
FU Zhejiang Provincial Natural Science Foundation of China [LQ19H060003,
   LY19H060006, LQ20H060008]
FX This work was supported by grants from Zhejiang Provincial Natural
   Science Foundation of China (LQ19H060003, LY19H060006, LQ20H060008).
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Adamik J, 2020, J BONE MINER RES, V35, DOI 10.1002/jbmr.3863
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Aprotosoaie AC, 2016, ADV EXP MED BIOL, V929, P247, DOI 10.1007/978 3 319 41342 6_11
   Armas LAG, 2012, ENDOCRIN METAB CLIN, V41, P475, DOI 10.1016/j.ecl.2012.04.006
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Aspray Terry J, 2019, Subcell Biochem, V91, P453, DOI 10.1007/978 981 13 3681 2_16
   Aziziyeh R, 2019, J MED ECON, V22, P638, DOI 10.1080/13696998.2019.1590843
   Bhardwaj A, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010429.pub2
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Boonen S, 2008, BEST PRACT RES CL EN, V22, P765, DOI 10.1016/j.beem.2008.07.002
   Cao HL, 2013, J BIOL CHEM, V288, P30399, DOI 10.1074/jbc.M113.469973
   Chen CH, 2012, PHYTOMEDICINE, V19, P763, DOI 10.1016/j.phymed.2012.02.017
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Cotts KG, 2018, JAMA J AM MED ASSOC, V319, P1040, DOI 10.1001/jama.2017.21995
   De Vries TJ, 2015, J CELL PHYSIOL, V230, P210, DOI 10.1002/jcp.24702
   Diker Cohen T, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgz322
   Dunn KL, 2005, BIOCHEM CELL BIOL, V83, P1, DOI 10.1139/O04 121
   Eastell R, 2017, LANCET DIABETES ENDO, V5, P908, DOI 10.1016/S2213 8587(17)30184 5
   Fang QH, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/3830212
   Fujita KI, 2014, FEBS J, V281, P1304, DOI 10.1111/febs.12706
   Giustarini D, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/3562972
   Ivarsson KM, 2019, WORLD J SURG, V43, P1981, DOI 10.1007/s00268 019 05020 z
   Jeong HM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174270
   Kenkre JS, 2018, ANN CLIN BIOCHEM, V55, P308, DOI 10.1177/0004563218759371
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kikuta J, 2018, METHODS MOL BIOL, V1763, P1, DOI 10.1007/978 1 4939 7762 8_1
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Komori T, 2015, EUR J PHARMACOL, V759, P287, DOI 10.1016/j.ejphar.2015.03.028
   Ksouda G, 2019, FOOD CHEM, V288, P47, DOI 10.1016/j.foodchem.2019.02.103
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Li K, 2018, CLIN INTERV AGING, V13, P2443, DOI 10.2147/CIA.S157523
   Li L, 2017, EUR J PHARMACOL, V815, P202, DOI 10.1016/j.ejphar.2017.09.015
   Liu W, 2015, MINERVA MED, V106, P203
   Lu JW, 2020, J CELL MOL MED, V24, P10444, DOI 10.1111/jcmm.15657
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Park JH, 2017, MOL CELLS, V40, P706
   Pereira M, 2018, J CELL SCI, V131, DOI 10.1242/jcs.216267
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rhee YH, 2018, BMC CELL BIOL, V19, DOI 10.1186/s12860 018 0163 2
   Sá NAR, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414 431x20187129, 10.1590/1414 431X20187129]
   Sá NAR, 2020, REPROD SCI, V27, P1602, DOI 10.1007/s43032 020 00190 x
   Schultze SM, 2012, EXPERT REV MOL MED, V14, DOI 10.1017/S1462399411002109
   Soysa NS, 2016, BIOCHEM BIOPH RES CO, V476, P115, DOI 10.1016/j.bbrc.2016.05.019
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Ritter AMV, 2017, INFLAMM RES, V66, P725, DOI 10.1007/s00011 017 1053 3
   Wang B, 2018, NEUROCHEM RES, V43, P2404, DOI 10.1007/s11064 018 2668 7
   Wisniewski Rebecca ES, 2015, CHEM BIOL INTERACT, V242, P247, DOI 10.1016/j.cbi.2015.10.013
   Xu WF, 2020, J CELL PHYSIOL, V235, P3022, DOI 10.1002/jcp.29207
   Yang JF, 2010, J MED FOOD, V13, P1254, DOI 10.1089/jmf.2010.1086
   Yokota Kazuhiro, 2017, Nihon Rinsho Meneki Gakkai Kaishi, V40, P367, DOI 10.2177/jsci.40.367
   Zhi X, 2020, J CELL MOL MED, V24, P5122, DOI 10.1111/jcmm.15153
   Zhou CH, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00210
NR 53
TC 9
Z9 10
U1 0
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD NOV
PY 2021
VL 100
AR 108113
DI 10.1016/j.intimp.2021.108113
EA SEP 2021
PG 9
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA WE4ND
UT WOS:000705603500006
PM 34530203
DA 2025 08 17
ER

PT J
AU Colombo, M
   Thümmler, K
   Mirandola, L
   Garavelli, S
   Todoerti, K
   Apicella, L
   Lazzari, E
   Lancellotti, M
   Platonova, N
   Akbar, M
   Chiriva Internati, M
   Soutar, R
   Neri, A
   Goodyear, CS
   Chiaramonte, R
AF Colombo, Michela
   Thuemmler, Katja
   Mirandola, Leonardo
   Garavelli, Silvia
   Todoerti, Katia
   Apicella, Luana
   Lazzari, Elisa
   Lancellotti, Marialuigia
   Platonova, Natalia
   Akbar, Moeed
   Chiriva Internati, Maurizio
   Soutar, Richard
   Neri, Antonino
   Goodyear, Carl S.
   Chiaramonte, Raffaella
TI Notch signaling drives multiple myeloma induced osteoclastogenesis
SO ONCOTARGET
LA English
DT Article
DE Myeloma; Notch; Jagged; RANKL; bone disease
ID BONE MARROW MICROENVIRONMENT; KAPPA B LIGAND; T CELL; RECEPTOR
   ACTIVATOR; TUMOR PROGRESSION; PLASMA CELLS; IN VITRO; LEUKEMIA;
   OVEREXPRESSION; RESORPTION
AB Multiple myeloma (MM) is closely associated with bone destruction. Once migrated to the bone marrow, MM cells unbalance bone formation and resorption via the recruitment and maturation of osteoclast precursors.
   The Notch pathway plays a key role in different types of cancer and drives several biological processes relevant in MM, including cell localization within the bone marrow, proliferation, survival and pharmacological resistance.
   Here we present evidences that MM can efficiently drive osteoclastogenesis by contemporaneously activating Notch signaling on tumor cells and osteoclasts through the aberrant expression of Notch ligands belonging to the Jagged family. Active Notch signaling in MM cells induces the secretion of the key osteoclastogenic factor, RANKL, which can be boosted in the presence of stromal cells. In turn, MM cells derived RANKL causes the upregulation of its receptor, RANK, and Notch2 in pre osteoclasts. Notch2 stimulates osteoclast differentiation by promoting autocrine RANKL signaling. Finally, MM cells through Jagged ligands expression can also activate Notch signaling in pre osteoclast by direct contact.
   Such synergism between tumor cells and pre osteoclasts in MM induced osteoclastogenesis can be disrupted by silencing tumor derived Jagged1 and 2. These results make the Jagged ligands new promising therapeutic targets in MM to contrast bone disease and the associated co morbidities.
C1 [Colombo, Michela; Mirandola, Leonardo; Garavelli, Silvia; Apicella, Luana; Lazzari, Elisa; Lancellotti, Marialuigia; Platonova, Natalia; Chiaramonte, Raffaella] Univ Milan, Dept Hlth Sci, Milan, Italy.
   [Thuemmler, Katja; Akbar, Moeed; Goodyear, Carl S.] Univ Glasgow, Coll Med Vet & Life Sci, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland.
   [Neri, Antonino] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
   [Neri, Antonino] Fdn Ca Granda IRCCS Policlin, Milan, Italy.
   [Chiriva Internati, Maurizio] Texas Tech Univ, Div Hematol & Oncol, Hlth Sci Ctr, Lubbock, TX 79409 USA.
   [Chiriva Internati, Maurizio] Southwest Canc Treatment & Res Ctr, Milan, Italy.
   [Soutar, Richard] Gartnavel Royal Hosp, Haematooncol Serv, Beatson West Scotland Canc Ctr, Glasgow G12 0YN, Lanark, Scotland.
   [Todoerti, Katia] Referral Canc Ctr Basilicata, IRCCS CROB, Lab Preclin & Translat Res, Rionero In Vulture, Italy.
C3 University of Milan; University of Glasgow; University of Milan; IRCCS
   Ca Granda Ospedale Maggiore Policlinico; Texas Tech University System;
   Texas Tech University Health Sciences Center Lubbock; Beatson Oncology
   Centre; Gartnavel Royal Hospital; IRCCS CROB
RP Chiaramonte, R (通讯作者)，Univ Milan, Dept Hlth Sci, Milan, Italy.
EM antonino.neri@unimi.it; raffaella.chiaramonte@unimi.it
RI Neri, Antonino/I 9690 2014; Chiriva Internati, Maurizio/KCY 6778 2024;
   Garavelli, Silvia/Z 5510 2019; Chiaramonte, Raffaella/J 2173 2012;
   Colombo, Michela/K 7879 2016; Chiriva Internati, maurizio/KCY 6778 2024
OI Neri, Antonino/0000 0001 9047 5912; Goodyear, Carl/0000 0001 5926 5941;
   Chiriva Internati, Maurizio/0000 0002 4180 5046; Thummler,
   Katja/0000 0002 1681 2359; GARAVELLI, SILVIA/0000 0001 6105 1467;
   Chiaramonte, Raffaella/0000 0003 1078 1704; Colombo,
   Michela/0000 0003 2252 1424; Todoerti, Katia/0000 0001 6687 6871
FU MIUR [PRIN 2008 2008ZFYEY3_003]; Associazione Italiana Ricerca sul
   Cancro [IG 10136]; Dept. of Health Sciences, Universita degli Studi di
   Milano; Arthritis Research UK CP Fellowship [19701]; Medical Research
   Scotland Project; Association for International Cancer Research; DFG
   [TH1599/1 1]
FX We thank S. De Nevi and C. Paris for donation, Dr. A. Villa (Istituto di
   Ricerca Genetica e Biomedica, CNR, Humanitas, Milano) for Raw264.7
   cells. RC was supported from MIUR (PRIN 2008 2008ZFYEY3_003), AN from
   Associazione Italiana Ricerca sul Cancro (Grant IG 10136); NPand MC are
   is sponsored by Dept. of Health Sciences, Universita degli Studi di
   Milano (temporary research associate); EL and LA by the PhD program of
   the Doctorate School in Molecular Medicine (Universita degli Studi di
   Milano). CSG was supported by an Arthritis Research UK CP Fellowship
   (No. 19701), a Medical Research Scotland Project grant (Vipiana Award)
   and Association for International Cancer Research. KTh was supported by
   a DFG (postdoctoral fellowship TH1599/1 1).
CR Abe M, 2011, INT J HEMATOL, V94, P334, DOI 10.1007/s12185 011 0949 x
   Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Bai S, 2008, J BIOL CHEM, V283, P6509, DOI 10.1074/jbc.M707000200
   Chen F, 2011, CELL ONCOL, V34, P545, DOI 10.1007/s13402 011 0060 6
   Chiaramonte R, 2005, CANCER LETT, V219, P113, DOI 10.1016/j.canlet.2004.07.022
   Chiaramonte R, 2006, LEUKEMIA RES, V30, P1331, DOI 10.1016/j.leukres.2006.07.009
   Choi YH, 2013, BBA MOL CELL RES, V1833, P69, DOI 10.1016/j.bbamcr.2012.10.018
   Colombo M, 2013, LEUKEMIA, V27, P1009, DOI 10.1038/leu.2013.6
   Duan L, 2008, FRONT BIOSCI LANDMRK, V13, P7064, DOI 10.2741/3210
   Farrugia AN, 2003, CANCER RES, V63, P5438
   Fukushima H, 2008, MOL CELL BIOL, V28, P6402, DOI 10.1128/MCB.00299 08
   Ghoshal P, 2009, CANCER RES, V69, P4380, DOI 10.1158/0008 5472.CAN 08 3467
   Giuliani M, 2005, HAEMATOLOGICA, V90, P275
   Giuliani N, 2008, CANCER RES, V68, P6840, DOI 10.1158/0008 5472.CAN 08 0402
   Heider U, 2003, CLIN CANCER RES, V9, P1436
   Houde C, 2004, BLOOD, V104, P3697, DOI 10.1182/blood 2003 12 4114
   Hubmann R, 2002, BLOOD, V99, P3742, DOI 10.1182/blood.V99.10.3742
   Juárez P, 2011, BONE, V48, P23, DOI 10.1016/j.bone.2010.08.004
   Jundt F, 2004, BLOOD, V103, P3511, DOI 10.1182/blood 2003 07 2254
   Kyle RA, 2003, MAYO CLIN PROC, V78, P21, DOI 10.4065/78.1.21
   Lai FPL, 2004, BRIT J HAEMATOL, V126, P192, DOI 10.1111/j.1365 2141.2004.05018.x
   Lee SH, 2007, APMIS, V115, P1357, DOI 10.1111/j.1600 0463.2007.00751.x
   Mirandola L, 2013, LEUKEMIA, V27, P1558, DOI 10.1038/leu.2013.27
   Mirandola L, 2011, CANCER LETT, V308, P1, DOI 10.1016/j.canlet.2011.05.009
   Moreaux J, 2011, BLOOD, V117, P1280, DOI 10.1182/blood 2010 04 279760
   Nefedova Y, 2004, BLOOD, V103, P3503, DOI 10.1182/blood 2003 07 2340
   Nefedova Y, 2008, BLOOD, V111, P2220, DOI 10.1182/blood 2007 07 102632
   Oba Y, 2005, EXP HEMATOL, V33, P272, DOI 10.1016/j.exphem.2004.11.015
   Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442
   Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283
   Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498
   Ramakrishnan V, 2012, LEUKEMIA, V26, P340, DOI 10.1038/leu.2011.192
   Schwarzer R, 2008, LEUKEMIA, V22, P2273, DOI 10.1038/leu.2008.138
   Sekine C, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3758
   Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022
   Skrtic A, 2010, HUM PATHOL, V41, P1702, DOI 10.1016/j.humpath.2010.05.002
   Takeuchi T, 2005, AM J PATHOL, V166, P1817, DOI 10.1016/S0002 9440(10)62491 1
   Tanaka Y, 2007, CLIN CANCER RES, V13, P816, DOI 10.1158/1078 0432.CCR 06 2258
   Tchorz JS, 2009, HEPATOLOGY, V50, P871, DOI 10.1002/hep.23048
   Todoerti K, 2013, CLIN CANCER RES, V19, P3247, DOI 10.1158/1078 0432.CCR 12 3461
   Troen G, 2008, HAEMATOL HEMATOL J, V93, P1107, DOI 10.3324/haematol.11635
   Vallet S, 2007, BLOOD, V110, P3744, DOI 10.1182/blood 2007 05 093294
   Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160
   Xu D, 2012, LEUKEMIA, V26, P1402, DOI 10.1038/leu.2011.332
   Yaccoby S, 2002, BRIT J HAEMATOL, V116, P278, DOI 10.1046/j.1365 2141.2002.03257.x
   Yaccoby S, 2010, BRIT J HAEMATOL, V149, P311, DOI 10.1111/j.1365 2141.2010.08141.x
   Yin L, 2010, BIOCHEM PHARMACOL, V80, P690, DOI 10.1016/j.bcp.2010.03.026
NR 47
TC 42
Z9 51
U1 0
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 15
PY 2014
VL 5
IS 21
BP 10393
EP 10406
DI 10.18632/oncotarget.2084
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA AZ2AL
UT WOS:000348036900015
PM 25257302
OA Green Accepted, Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Gu, QH
   Chen, C
   Zhang, ZP
   Wu, ZG
   Fan, XL
   Zhang, ZY
   Di, WWL
   Shi, L
AF Gu, Qiuhan
   Chen, Chen
   Zhang, Zhengping
   Wu, Zhigang
   Fan, Xiangli
   Zhang, Zhenyu
   Di, Wuweilong
   Shi, Lei
TI Ginkgo biloba extract promotes osteogenic differentiation of human bone
   marrow mesenchymal stem cells in a pathway involving Wnt/β catenin
   signaling
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE Ginkgo biloba extract (GBE); Osteogenesis; Bone marrow derived
   mesenchymal stem cell (BM MSC); BMP signaling; Wnt signaling
ID PROGENITOR CELLS; TNF ALPHA; OSTEOBLAST; INFLAMMATION; PROLIFERATION;
   IMMUNE; TISSUE
AB Human bone marrow derived mesenchymal stem cells (BM MSCs) are a novel cell source used in stem cell therapy to treat bone diseases owing to their high potential to differentiate into osteoblasts. Effective induction of osteogenic differentiation from human BM MSCs is critical to fulfill their therapeutic potential. In this study, Ginkgo biloba extract (GBE), a traditional herbal medicine, was used to stimulate the proliferation and osteogenic differentiation of human BM MSCs. The present study revealed that GBE improved the proliferation and osteogenesis of human BM MSCs in a dose dependent manner in the range 25 75 mg/l, as indicated by alkaline phosphatase (ALP) activity and calcium content. However, such effect was decreased or inhibited at 100 mg/l or higher. The dose dependent improvement in osteogenesis of human BM MSCs by GBE was further confirmed by the dose dependent upregulation of marker genes, osteopontin (OPN) and Collagen I. The increased osteoprotegerin (OPG) expression and minimal expression of receptor activator of nuclear factor kappa B ligand (RANKL) suggested that GBE also inhibited osteoclastogenesis of human BM MSCs. Further mechanistic study demonstrated that the transcriptional levels of bone morphogenetic protein 4 (BMP4) and runt related transcription factor 2 (RUNX2) in the BMP signaling, p catenin and Cyclin D1 in the Wnt/beta catenin signaling, increased significantly during GBE promoted osteogenesis. Meanwhile, loss of function assay with the signaling inhibitor(s) confirmed that the BMP and Wnt/beta catenin signaling pathways were indispensable during the GBE promoted osteogenesis, suggesting that GBE improved osteogenesis via upregulation of the BMP and Wnt/beta catenin signaling. The present study proposed GBE to be used to upregulate the osteogenic differentiation of human BM MSCs for new bone formation in BM MSC based cell therapy, which could provide an attractive and promising treatment for bone disorders. (c) 2015 Elsevier Ltd. All rights reserved.
C1 [Gu, Qiuhan] Fourth Mil Med Univ, Xijing Hosp, Dept Anesthesiol, Xian 710032, Shanxi, Peoples R China.
   [Chen, Chen] PLA, Jinan Mil Gen Hosp, Dept Orthoped Surg, Jinan 250031, Shandong, Peoples R China.
   [Zhang, Zhengping] Xi An Jiao Tong Univ, Coll Med, Hong Hui Hosp, Xian 710054, Shanxi, Peoples R China.
   [Wu, Zhigang; Fan, Xiangli; Zhang, Zhenyu; Di, Wuweilong; Shi, Lei] Fourth Mil Med Univ, Xijing Hosp, Dept Orthoped, Xian 710032, Shanxi, Peoples R China.
C3 Air Force Medical University; Xi'an Jiaotong University; Air Force
   Medical University
RP Shi, L (通讯作者)，Fourth Mil Med Univ, Xijing Hosp, Dept Orthoped, Xian 710032, Shanxi, Peoples R China.
EM lshi12345@163.com
CR AMEDEE J, 1994, DIFFERENTIATION, V58, P157
   Baddoo M, 2003, J CELL BIOCHEM, V89, P1235, DOI 10.1002/jcb.10594
   Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006 291X(02)02951 0
   Baker LePain JC, 2011, CURR OPIN RHEUMATOL, V23, P389, DOI 10.1097/BOR.0b013e3283474dbe
   Bianco P, 2010, HUM GENE THER, V21, P1057, DOI 10.1089/hum.2010.136
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Dong XX, 2007, J CARDIOVASC PHARM, V49, P111, DOI 10.1097/FJC.0b013e31802ef519
   Franke AG, 2014, AGE, V36, P435, DOI 10.1007/s11357 013 9550 y
   Gambari L, 2014, PHARMACOL RES, V87, P99, DOI 10.1016/j.phrs.2014.06.014
   Heinonen T, 2015, TOXICOLOGY, V327, P95, DOI 10.1016/j.tox.2014.10.013
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Holmen SL, 2005, CANCER RES, V65, P8250, DOI 10.1158/0008 5472.CAN 05 1173
   HUGHES FJ, 1995, ENDOCRINOLOGY, V136, P2671, DOI 10.1210/en.136.6.2671
   Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388
   Jakab L, 2014, ORVOSI HETILAP, V155, P1575, DOI 10.1556/OH.2014.30015
   Jiao Ya bin, 2007, Yaoxue Xuebao, V42, P930
   Komatsu N, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00077
   Kosmacheva SM, 2014, B EXP BIOL MED+, V156, P560, DOI 10.1007/s10517 014 2396 1
   Kristjansson B, 2014, STEM CELLS INT, V2014, DOI 10.1155/2014/194318
   Lu CH, 2012, INDIAN J PHARMACOL, V44, P118, DOI 10.4103/0253 7613.91881
   Lu Wen Yi, 2012, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V34, P90
   Nguyen TTN, 2012, J AGR FOOD CHEM, V60, P2815, DOI 10.1021/jf204768d
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00048
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Ren M, 2013, ENDOCRINE, V43, P360, DOI 10.1007/s12020 012 9745 5
   Rodriguez Porcel M, 2010, MOL IMAGING BIOL, V12, P325, DOI 10.1007/s11307 009 0274 4
   Singh B, 2008, FITOTERAPIA, V79, P401, DOI 10.1016/j.fitote.2008.05.007
   Stanko P, 2014, BIOMED PAP, V158, P373, DOI 10.5507/bp.2013.078
   Stanojkovic I, 2013, CLIN BIOCHEM, V46, P1678, DOI 10.1016/j.clinbiochem.2013.08.003
   Thomas MV, 2011, J DENT RES, V90, P1052, DOI 10.1177/0022034510393967
   Tziridis K, 2014, NEURAL PLAST, V2014, DOI 10.1155/2014/427298
   Veronesi F, 2013, STEM CELLS DEV, V22, P181, DOI 10.1089/scd.2012.0373
   Wang JW, 2013, NEURAL REGEN RES, V8, P1655, DOI 10.3969/j.issn.1673 5374.2013.18.003
   Wang Xing Xiang, 2004, Yaoxue Xuebao, V39, P656
   Wang X, 2014, PAK J PHARM SCI, V27, P1099
   Wilson Carol, 2014, Nat Rev Endocrinol, V10, P3, DOI 10.1038/nrendo.2013.225
   Xiong XJ, 2014, PHYTOMEDICINE, V21, P1131, DOI 10.1016/j.phymed.2014.04.024
   Yang MM, 2014, AM J CHINESE MED, V42, P505, DOI 10.1142/S0192415X14500335
   Yang TH, 2011, J NUTR BIOCHEM, V22, P886, DOI 10.1016/j.jnutbio.2010.08.009
   Zhang JF, 2009, PHYTOMEDICINE, V16, P521, DOI 10.1016/j.phymed.2009.01.003
   Zhao M, 2014, GENET MOL RES, V13, P220, DOI 10.4238/2014.January.14.1
   Zhou YH, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/MI/2006/92642
NR 43
TC 47
Z9 50
U1 1
U2 55
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043 6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD JUL
PY 2015
VL 97
BP 70
EP 78
DI 10.1016/j.phrs.2015.04.004
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CM0DC
UT WOS:000357347600008
PM 25917209
DA 2025 08 17
ER

PT J
AU Kajizono, M
   Sada, H
   Sugiura, Y
   Soga, Y
   Kitamura, Y
   Matsuoka, J
   Sendo, T
AF Kajizono, Makoto
   Sada, Hikaru
   Sugiura, Yuhko
   Soga, Yoshihiko
   Kitamura, Yoshihisa
   Matsuoka, Junji
   Sendo, Toshiaki
TI Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced
   Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A
   Retrospective Cohort Study
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE medication related osteonecrosis of the jaw (MRONJ); zoledronic acid;
   denosumab; periodical dentistry maintenance
ID SKELETAL RELATED EVENTS; ANGIOGENESIS IN VITRO; MULTIPLE MYELOMA; BONE
   METASTASES; PREVENTIVE MEASURES; AMERICAN SOCIETY; BREAST CANCER; SOLID
   TUMORS; DOUBLE BLIND; BISPHOSPHONATES
AB Zoledronic acid and denosumab are two antiresorptive drugs currently in use for treating osteoporosis. They have different mechanisms of action, but both have been shown to delay the onset of skeletal related events in patients with advanced cancer. However, medication related osteonecrosis of the jaw (MRONJ) has been reported in cancer patients treated with zoledronic acid or denosumab. We studied 155 patients with several types of advanced cancer who were treated with zoledronic acid or denosumab in our hospital during the period from April 2010 through March 2013. Thirteen of these 155 patients (8.4%) developed MRONJ. MRONJ development was significantly associated with the number of zoledronic acid or denosumab infusions (p<0.001) and the duration of zoledronic acid or denosumab therapy (p<0.001). Logistic regression analysis showed that diabetes [odds ratio (OR)=6.699, 95% confidence interval (CI), 1.435 31.277, p=0.016], anemia [OR=14.559, 95% CI, 2.161 98.069, p=0.006], and pus discharge [OR=6.491, 95% CI, 1.514 27.835, p=0.012] significantly increased the risk of developing MRONJ. However, the risk of MRONJ was significantly lower [OR=0.137, 95% CI, 0.020 0.944, p=0.043] when patients received periodical dentistry maintenance. Diabetes, anemia, and pus discharge may also play roles in its development. These findings suggest that the active inclusion of dentistry maintenance in bisphosphonate or denosumab treatment of cancer patients can reduce MRONJ development.
C1 [Kajizono, Makoto; Sada, Hikaru; Kitamura, Yoshihisa; Sendo, Toshiaki] Okayama Univ Hosp, Dept Pharm, Kita Ku, Okayama 7008558, Japan.
   [Sugiura, Yuhko] Okayama Univ Hosp, Div Dent Hygienist, Kita Ku, Okayama 7008558, Japan.
   [Soga, Yoshihiko] Okayama Univ Hosp, Cent Clin Dept, Div Hosp Dent, Kita Ku, Okayama 7008558, Japan.
   [Matsuoka, Junji] Okayama Univ Hosp, Dept Palliat & Support Care, Kita Ku, Okayama 7008558, Japan.
C3 Okayama University; Okayama University; Okayama University; Okayama
   University
RP Kitamura, Y (通讯作者)，Okayama Univ Hosp, Dept Pharm, Kita Ku, 2 5 1 Shikata Cho, Okayama 7008558, Japan.
EM kitamu y@cc.okayama u.ac.jp
RI SOGA, Yoshihiko/A 7312 2010; KITAMURA, Yoshihisa/B 2036 2011; Kitamura,
   Yoshihisa/HCH 9498 2022
OI SOGA, Yoshihiko/0000 0001 5346 1474; KITAMURA,
   Yoshihisa/0000 0002 3652 3722; 
CR Aragon Ching JB, 2009, CANCER INVEST, V27, P221, DOI 10.1080/07357900802208608
   Assael LA, 2004, J ORAL MAXIL SURG, V62, P125, DOI 10.1016/j.joms.2003.11.009
   Badros A, 2006, J CLIN ONCOL, V24, P945, DOI 10.1200/JCO.2005.04.2465
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Berenson JR, 2002, J CLIN ONCOL, V20, P3719, DOI 10.1200/JCO.2002.06.037
   Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dimopoulos MA, 2009, ANN ONCOL, V20, P117, DOI 10.1093/annonc/mdn554
   Dimopoulos MA, 2006, HAEMATOL HEMATOL J, V91, P968
   Dunstan CR, 2007, NAT CLIN PRACT ONCOL, V4, P42, DOI 10.1038/ncponc0688
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   Fisher JE, 2000, ENDOCRINOLOGY, V141, P4793, DOI 10.1210/en.141.12.4793
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fournier P, 2002, CANCER RES, V62, P6538
   Greenberg MS, 2004, ORAL SURG ORAL MED O, V98, P259, DOI 10.1016/j.tripleo.2004.08.001
   Guarneri V, 2010, BREAST CANCER RES TR, V122, P181, DOI 10.1007/s10549 010 0866 3
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hillner BE, 2003, J CLIN ONCOL, V21, P4042, DOI 10.1200/JCO.2003.08.017
   Hoff AO, 2008, J BONE MINER RES, V23, P826, DOI [10.1359/JBMR.080205, 10.1359/jbmr.080205]
   Hortobagyi GN, 1998, J CLIN ONCOL, V16, P2038, DOI 10.1200/JCO.1998.16.6.2038
   Hortobagyi GN, 2014, J CLIN ONCOL, V32
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Migliorati CA, 2010, SUPPORT CARE CANCER, V18, P1099, DOI 10.1007/s00520 010 0882 1
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Otto S, 2013, J CRANIO MAXILL SURG, V41, P694, DOI 10.1016/j.jcms.2013.05.038
   Reszka Alfred A, 2003, Curr Osteoporos Rep, V1, P45, DOI 10.1007/s11914 003 0008 5
   Ribatti D, 2007, CLIN RHEUMATOL, V26, P1094, DOI 10.1007/s10067 006 0455 3
   Ripamonti CI, 2009, ANN ONCOL, V20, P137, DOI 10.1093/annonc/mdn526
   Robinson NA, 2004, ANN ACAD MED SINGAP, V33, P48
   Roodman G David, 2004, Discov Med, V4, P144
   Rosen LS, 2004, CANCER, V100, P2613, DOI 10.1002/cncr.20308
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Scott LJ, 2011, BIODRUGS, V25, P397, DOI 10.2165/11207650 000000000 00000
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Tarassoff P, 2003, J ORAL MAXIL SURG, V61, P1238, DOI 10.1016/j.joms.2003.09.001
   Vahtsevanos K, 2009, J CLIN ONCOL, V27, P5356, DOI 10.1200/JCO.2009.21.9584
   Van den Wyngaert T, 2006, ANN ONCOL, V17, P1197, DOI 10.1093/annonc/mdl294
   Vincenzi B, 2003, ANN ONCOL, V14, P806, DOI 10.1093/annonc/mdg194
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Zervas K, 2006, BRIT J HAEMATOL, V134, P620, DOI 10.1111/j.1365 2141.2006.06230.x
NR 46
TC 57
Z9 64
U1 0
U2 17
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2 12 15 SHIBUYA, SHIBUYA KU, TOKYO, 150 0002, JAPAN
SN 0918 6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD DEC
PY 2015
VL 38
IS 12
BP 1850
EP 1855
DI 10.1248/bpb.b15 00385
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CX4UC
UT WOS:000365694800004
PM 26632176
OA gold
DA 2025 08 17
ER

PT J
AU Gignac, SJ
   MacCharles, KR
   Fu, K
   Bonaparte, K
   Akarsu, G
   Barrett, TW
   Verheyen, EM
   Richman, JM
AF Gignac, Sarah J.
   MacCharles, Katja R.
   Fu, Katherine
   Bonaparte, Kywana
   Akarsu, Gamze
   Barrett, Thalia W.
   Verheyen, Esther M.
   Richman, Joy M.
TI Mechanistic studies in Drosophila and chicken give new insights into
   functions of DVL1 in dominant Robinow syndrome
SO DISEASE MODELS & MECHANISMS
LA English
DT Article
DE Wnt signaling; Dishevelled 1; Skeletogenesis; Planar cell polarity;
   Drosophila; Chicken embryo
ID PLANAR CELL POLARITY; DISHEVELLED PROTEIN; GROWTH PLATE; WINGLESS;
   MUTATIONS; GENE; PATHWAY; ARMADILLO; CATENIN; CLONING
AB The study of rare genetic diseases provides valuable insights into human gene function. The autosomal dominant or autosomal recessive forms of Robinow syndrome are genetically heterogeneous, and the common theme is that all the mutations lie in genes in Wnt signaling pathways. Cases diagnosed with Robinow syndrome do survive to adulthood with distinct skeletal phenotypes, including limb shortening and craniofacial abnormalities. Here, we focus on mutations in dishevelled 1 (DVL1), an intracellular adaptor protein that is required for both canonical (0 catenin dependent) or non canonical (requiring small GTPases and JNK) Wnt signaling. We expressed human wild type DVL1 or DVL1 variants alongside the endogenous genome of chicken and Drosophila. This design is strategically suited to test for functional differences between mutant and wild type human proteins in relevant developmental contexts. The expression of variant forms of DVL1 produced a major disorganization of cartilage and Drosophila wing morphology compared to expression of wild type DVL1. Moreover, the variants caused a loss of canonical and gain of non canonical Wnt signaling in several assays. Our data point to future therapies that might correct the levels of Wnt signaling, thus improving skeletal growth.
C1 [Gignac, Sarah J.; Fu, Katherine; Bonaparte, Kywana; Richman, Joy M.] Univ British Columbia, Life Sci Inst, Vancouver, BC V6T 1Z3, Canada.
   [Gignac, Sarah J.; Fu, Katherine; Bonaparte, Kywana; Richman, Joy M.] Univ British Columbia, Fac Dent, Vancouver, BC V6T 1Z3, Canada.
   [MacCharles, Katja R.; Barrett, Thalia W.; Verheyen, Esther M.] Simon Fraser Univ, Ctr Cell Biol Dev & Dis, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada.
C3 University of British Columbia; University of British Columbia; Simon
   Fraser University
RP Richman, JM (通讯作者)，Univ British Columbia, Life Sci Inst, Vancouver, BC V6T 1Z3, Canada.; Richman, JM (通讯作者)，Univ British Columbia, Fac Dent, Vancouver, BC V6T 1Z3, Canada.; Verheyen, EM (通讯作者)，Simon Fraser Univ, Ctr Cell Biol Dev & Dis, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada.
EM everheye@sfu.ca; richman@dentistry.ubc.ca
RI VERHEYEN, ERIK/E 5550 2013; Richman, Joy/AAD 9445 2020; Richman,
   Joy/C 3111 2018
OI Richman, Joy/0000 0002 1409 8163; Verheyen, Esther/0000 0002 9795 5094
FU Canadian Institutes of Health Research [PJT 166182]; University of
   British Columbia 4 year fellowship; Canada Graduate Scholarships
   Master's scholarship   Canadian Institutes of Health Research;
   University of British Columbia
FX This work was funded by the Canadian Institutes of Health Research
   (grant PJT 166182 to J.M.R. and E.M.V.). S.J.G. received a University of
   British Columbia 4 year fellowship and K.R.M. was the recipient of a
   Canada Graduate Scholarships Master's scholarship funded by the Canadian
   Institutes of Health Research. Open Access funding provided by the
   University of British Columbia. Deposited in PMC for immediate release.
CR Abu Ghname A, 2021, AM J MED GENET A, V185, P3584, DOI 10.1002/ajmg.a.61884
   Adler PN, 2012, CURR TOP DEV BIOL, V101, P1, DOI 10.1016/B978 0 12 394592 1.00001 6
   Afzal AR, 2000, NAT GENET, V25, P419, DOI 10.1038/78107
   Al Kaissi A, 2020, J INVEST MED HIGH IM, V8, DOI 10.1177/2324709620911771
   Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610
   BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460 2075.1987.tb02429.x
   BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0
   Bienz M, 2014, TRENDS BIOCHEM SCI, V39, P487, DOI 10.1016/j.tibs.2014.08.006
   Bond SR, 2012, NUCLEIC ACIDS RES, V40, pW209, DOI 10.1093/nar/gks396
   Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092 8674(00)81226 X
   Bunn KJ, 2015, AM J HUM GENET, V96, P623, DOI 10.1016/j.ajhg.2015.02.010
   Butler MT, 2017, NAT REV MOL CELL BIO, V18, P375, DOI 10.1038/nrm.2017.11
   Cantwell H, 2022, SEMIN CELL DEV BIOL, V130, P90, DOI 10.1016/j.semcdb.2021.10.013
   Conlon CJ, 2021, AM J MED GENET A, V185, P3606, DOI 10.1002/ajmg.a.61986
   Danescu A, 2015, J ANAT, V227, P474, DOI 10.1111/joa.12365
   Davey MG, 2018, INT J DEV BIOL, V62, P85, DOI 10.1387/ijdb.170315CT
   Duffy JB, 2002, GENESIS, V34, P1, DOI 10.1002/gene.10150
   Etheridge SL, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000259
   FAHMY OG, 1959, GENETICS, V44, P1149
   Furman DP, 2011, INT J DEV BIOL, V55, P133, DOI 10.1387/ijdb.103129df
   Geetha Loganathan P, 2014, J BIOL CHEM, V289, P24153, DOI 10.1074/jbc.M113.522003
   Gignac SJ, 2019, HUM MOL GENET, V28, P2395, DOI 10.1093/hmg/ddz071
   Habas Raymond, 2005, J Biol, V4, P2, DOI 10.1186/jbiol22
   Hall ET, 2017, BIOL OPEN, V6, P1165, DOI 10.1242/bio.025221
   HAMBURGER V, 1992, DEV DYNAM, V195, P231, DOI 10.1002/dvdy.1001950404
   HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104
   Hartmann C, 2000, DEVELOPMENT, V127, P3141
   Higashihori N, 2010, DEV DYNAM, V239, P458, DOI 10.1002/dvdy.22182
   Hosseini Farahabadi S, 2017, J DENT RES, V96, P1265, DOI 10.1177/0022034517716916
   Hu RL, 2022, MOL GENET GENOM MED, V10, DOI 10.1002/mgg3.1886
   Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131 139.2003
   Itoh Keiji, 2005, J Biol, V4, P3, DOI 10.1186/jbiol20
   Jenny A, 2003, EMBO J, V22, P4409, DOI 10.1093/emboj/cdg424
   Kalukula Y, 2022, NAT REV MOL CELL BIO, V23, P583, DOI 10.1038/s41580 022 00480 z
   KRASNOW RE, 1994, DEVELOPMENT, V120, P1883
   Kuss P, 2014, DEV BIOL, V385, P83, DOI 10.1016/j.ydbio.2013.10.013
   Lee HJ, 2015, ELIFE, V4, DOI 10.7554/eLife.08142
   Lee SH, 2001, NATURE, V414, P909, DOI 10.1038/414909a
   Li YW, 2017, ELIFE, V6, DOI 10.7554/eLife.23279
   Li YW, 2009, DEVELOPMENT, V136, P1083, DOI 10.1242/dev.023820
   Lijam N, 1997, CELL, V90, P895, DOI 10.1016/S0092 8674(00)80354 2
   Loftus SK, 2001, DNA RES, V8, P221, DOI 10.1093/dnares/8.5.221
   Logan Cairine, 2008, V461, P363, DOI 10.1007/978 1 60327 483 8_26
   Long JT, 2021, DEV CELL, V56, P156, DOI 10.1016/j.devcel.2021.01.002
   Martín Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557
   Mazzeu JF, 2020, AM J MED GENET A, V182, P2005, DOI 10.1002/ajmg.a.61756
   Mikels A, 2009, J BIOL CHEM, V284, P30167, DOI 10.1074/jbc.M109.041715
   Montanari MP, 2022, DEV DYNAM, V251, P198, DOI 10.1002/dvdy.397
   Niethammer P, 2021, ANNU REV CELL DEV BI, V37, P233, DOI 10.1146/annurev cellbio 120319 030049
   Nimmagadda S, 2015, DEV BIOL, V407, P275, DOI 10.1016/j.ydbio.2015.09.007
   Nishita M, 2010, MOL CELL BIOL, V30, P3610, DOI 10.1128/MCB.00177 10
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0
   NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156
   Ohkawara B, 2011, DEV DYNAM, V240, P188, DOI 10.1002/dvdy.22500
   PEIFER M, 1994, DEV BIOL, V166, P543, DOI 10.1006/dbio.1994.1336
   Person AD, 2010, DEV DYNAM, V239, P327, DOI 10.1002/dvdy.22156
   Qi J, 2017, J BIOL CHEM, V292, P5898, DOI 10.1074/jbc.M116.772509
   Rai A, 2021, AM J MED GENET A, V185, P1105, DOI 10.1002/ajmg.a.62082
   Roifman M, 2015, CLIN GENET, V87, P34, DOI 10.1111/cge.12401
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Schwartz DD, 2021, AM J MED GENET A, V185, P3576, DOI 10.1002/ajmg.a.61854
   Sharma Monica, 2021, Genes Cancer, V12, P77, DOI 10.18632/genesandcancer.217
   Sharma M, 2018, CELL SIGNAL, V47, P52, DOI 10.1016/j.cellsig.2018.03.004
   Shayota BJ, 2020, AM J MED GENET A, V182, P2632, DOI 10.1002/ajmg.a.61843
   Simons M, 2008, ANNU REV GENET, V42, P517, DOI 10.1146/annurev.genet.42.110807.091432
   Stricker S, 2006, DEV DYNAM, V235, P3456, DOI 10.1002/dvdy.20993
   Stricker S, 2017, CURR TOP DEV BIOL, V123, P105, DOI 10.1016/bs.ctdb.2016.09.003
   Swarup S, 2015, DEVELOPMENT, V142, P1502, DOI 10.1242/dev.116715
   Teufel S, 2019, CURR TOP DEV BIOL, V133, P235, DOI 10.1016/bs.ctdb.2018.11.010
   Tickle C, 2015, J ANAT, V227, P418, DOI 10.1111/joa.12361
   Tree DRP, 2002, CELL, V109, P371, DOI 10.1016/S0092 8674(02)00715 8
   van Bokhoven H, 2000, NAT GENET, V25, P423, DOI 10.1038/78113
   VINSON CR, 1987, NATURE, V329, P549, DOI 10.1038/329549a0
   Vlachos S, 2015, DEVELOPMENT, V142, P82, DOI 10.1242/dev.111039
   Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613
   Wallingford JB, 2005, DEVELOPMENT, V132, P4421, DOI 10.1242/dev.02068
   Wang HY, 2012, ACTA PHYSIOL, V204, P65, DOI 10.1111/j.1748 1716.2011.02291.x
   Weitzman Jonathan B, 2005, J Biol, V4, P1, DOI 10.1186/jbiol21
   White J, 2015, AM J HUM GENET, V96, P612, DOI 10.1016/j.ajhg.2015.02.015
   White JJ, 2018, AM J HUM GENET, V102, P27, DOI 10.1016/j.ajhg.2017.10.002
   White JJ, 2016, AM J HUM GENET, V98, P553, DOI 10.1016/j.ajhg.2016.01.005
   WONG LL, 1993, J CELL BIOL, V123, P209, DOI 10.1083/jcb.123.1.209
   Wynshaw Boris A, 2012, CURR TOP DEV BIOL, V101, P213, DOI 10.1016/B978 0 12 394592 1.00007 7
   Yamaguchi TP, 1999, DEVELOPMENT, V126, P1211
   Yanagawa S, 2002, EMBO J, V21, P1733, DOI 10.1093/emboj/21.7.1733
   YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087
   Yanagawa SI, 1997, J BIOL CHEM, V272, P25243, DOI 10.1074/jbc.272.40.25243
   Yu HM, 2010, DEVELOPMENT, V137, P3707, DOI 10.1242/dev.052001
   Zhang CF, 2022, HUM GENET GENOM ADV, V3, DOI 10.1016/j.xhgg.2021.100074
   Zhang CF, 2021, AM J MED GENET A, V185, P3593, DOI 10.1002/ajmg.a.61908
NR 92
TC 7
Z9 7
U1 0
U2 3
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 1754 8403
EI 1754 8411
J9 DIS MODEL MECH
JI Dis. Model. Mech.
PD APR
PY 2023
VL 16
IS 4
AR dmm049844
DI 10.1242/dmm.049844
PG 17
WC Cell Biology; Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine; Pathology
GA H1UH3
UT WOS:000993879600003
PM 36916233
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Geng, B
   Wang, CF
   Zhang, B
   Wang, J
   Jiang, J
   Tan, XY
   Chen, C
   Chen, YG
   An, LP
   Ma, JL
   Xia, YY
AF Geng Bin
   Wang Cuifang
   Zhang Bo
   Wang Jing
   Jiang Jin
   Tan Xiaoyi
   Chen Cong
   Chen Yonggang
   An Liping
   Ma Jinglin
   Xia Yayi
TI Fluid shear stress inhibits TNF α induced osteoblast apoptosis via ERK5
   signaling pathway
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Fluid shear stress; Osteoblast; Extracellular signal regulated kinase 5;
   Apoptosis; TNF alpha
ID REGULATED PROTEIN KINASES 5; DEPENDENT ACTIVATION; NEURONS CONTRIBUTES;
   OSTEOCYTE APOPTOSIS; SENSORY NEURONS; GROWTH FACTOR; CELLS;
   PROLIFERATION; STIMULATION; PROTEIN
AB Fluid shear stress (FSS) is a potent mechanical stimulus and prevents cells from TNF alpha induced apoptosis. Recently, Extracellular signal regulated kinase 5 (ERK5) has been found to be involved in regulation of cell survival. However, little is known about the role of ERK5 signaling pathway in FSS mediated antiapoptotic effects in osteoblast In this study, we show that FSS blocks TNF alpha induced apoptosis of MC3T3 E1 cells via ERK5 signaling pathway.
   We found that physiological FSS for 1 h significantly decreased TNF alpha induced MC3T3 E1 cells apoptosis. After inhibition of ERK5 activity by XMD8 92, a highly selective inhibitor of ERK5 activity, the ability of FSS to inhibit TNF alpha induced apoptosis was significantly decreased. Analysis of anti apoptotic mechanisms indicated that exposure of MC3T3 E1 cells to FSS for 1 h increased phosphorylation of Bad and inhibited caspase 3 activity. After treatment with XMD8 92, phosphorylation of Bad by FSS was significantly blocked, but caspase 3 activity was increased. In summary, these findings indicated that FSS inhibits INF cc mediated signaling events in osteoblast by a mechanism dependent on activation of ERK5, and Bad is a crucial downstream target for ERK5. Those results implied that ERK5 signaling pathway play a crucial role in FSS mediated anti apoptotic effect in osteoblast.
   Thus, ERK5 signaling pathway may be a new drug treatment target of osteoporosis and related bone wasting diseases. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Geng Bin; Wang Cuifang; Zhang Bo; Wang Jing; Jiang Jin; Tan Xiaoyi; Chen Cong; An Liping; Ma Jinglin] Lanzhou Univ, Hosp 2, Lanzhou 730000, Gansu, Peoples R China.
   [Geng Bin; Wang Cuifang; Zhang Bo; Wang Jing; Jiang Jin; Tan Xiaoyi; Chen Cong; An Liping; Ma Jinglin] Orthopaed Key Lab Gansu Prov, Lanzhou 730000, Gansu, Peoples R China.
   [Chen Yonggang; Xia Yayi] Lanzhou Univ, Hosp 2, Dept Orthopaed, Lanzhou 730000, Gansu, Peoples R China.
C3 Lanzhou University; Lanzhou University
RP Xia, YY (通讯作者)，Lanzhou Univ, Hosp 2, Dept Orthopaed, 82 Cuiyingmen, Lanzhou 730000, Gansu, Peoples R China.
EM xiayayildey@163.com
RI Jiang, Jin/ABD 8827 2021; Lin, Chen/AFV 2163 2022
FU National Natural Science Foundation of China [81450042, 81071478]
FX This work was supported by the National Natural Science Foundation of
   China (Grant Nos. 81450042 and 81071478).
CR FRANGOS JA, 1988, BIOTECHNOL BIOENG, V32, P1053, DOI 10.1002/bit.260320812
   Fritton SP, 2009, ANNU REV FLUID MECH, V41, P347, DOI 10.1146/annurev.fluid.010908.165136
   Hayashi M, 2004, J CLIN INVEST, V113, P1138, DOI 10.1172/JCI200419890
   HILLAM RA, 1995, J BONE MINER RES, V10, P683
   HILLSLEY MV, 1994, BIOTECHNOL BIOENG, V43, P573, DOI 10.1002/bit.260430706
   Jiang J, 2015, MOL CELL BIOCHEM, V406, P237, DOI 10.1007/s11010 015 2441 z
   Kapur S, 2005, J BIOL CHEM, V280, P20163, DOI 10.1074/jbc.M501460200
   Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234
   Katsura H, 2007, J NEUROCHEM, V102, P1614, DOI 10.1111/j.1471 4159.2007.04698.x
   Kitase Y, 2010, J BONE MINER RES, V25, P2381, DOI 10.1002/jbmr.168
   LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189
   Li P, 2012, MOL CELL BIOCHEM, V364, P321, DOI 10.1007/s11010 012 1233 y
   Li P, 2012, CELL BIOL INT, V36, P229, DOI 10.1042/CBI20110113
   Li XT, 2013, J ORTHOP RES, V31, P1959, DOI 10.1002/jor.22448
   Mai ZH, 2013, CHINESE MED J PEKING, V126, P1544, DOI 10.3760/cma.j.issn.0366 6999.20123137
   Mizushima T, 2007, J PHARMACOL EXP THER, V321, P28, DOI 10.1124/jpet.106.116749
   Nithianandarajah Jones GN, 2012, CELL SIGNAL, V24, P2187, DOI 10.1016/j.cellsig.2012.07.007
   Obata K, 2007, J NEUROCHEM, V102, P1569, DOI 10.1111/j.1471 4159.2007.04656.x
   Pavalko FM, 2003, J CELL PHYSIOL, V194, P194, DOI 10.1002/jcp.10221
   Pi XC, 2004, CIRC RES, V94, P362, DOI 10.1161/01.RES.0000112406.27800.6F
   Plotkin LI, 2005, AM J PHYSIOL CELL PH, V289, pC633, DOI 10.1152/ajpcell.00278.2004
   Tan SD, 2006, J DENT RES, V85, P905, DOI 10.1177/154405910608501006
   Wang HF, 2011, J CELL PHYSIOL, V226, P1044, DOI 10.1002/jcp.22427
   Wang YP, 2006, J BIOL CHEM, V281, P35965, DOI 10.1074/jbc.M605503200
   Yang QK, 2010, CANCER CELL, V18, P258, DOI 10.1016/j.ccr.2010.08.008
   Zhao LG, 2014, CONNECT TISSUE RES, V55, P96, DOI 10.3109/03008207.2013.853755
   ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665
NR 27
TC 11
Z9 14
U1 0
U2 18
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD OCT 9
PY 2015
VL 466
IS 1
BP 117
EP 123
DI 10.1016/j.bbrc.2015.08.117
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CS5YU
UT WOS:000362155000018
DA 2025 08 17
ER

PT J
AU Miao, MM
   Li, MY
   Sheng, YJ
   Tong, PJ
   Zhang, Y
   Shou, D
AF Miao, Maomao
   Li, Mengying
   Sheng, Yunjie
   Tong, Peijian
   Zhang, Yang
   Shou, Dan
TI Epimedium Curculigo herb pair enhances bone repair with infected bone
   defects and regulates osteoblasts through LncRNA MALAT1/miR 34a 5p/SMAD2
   axis
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE Epimedium Curculigo herb pair; infected bone defects; LncRNA MALAT1;
   miR 34a 5p; SMAD2
ID TGF BETA/SMADS; STEM CELLS; OSTEOPOROSIS; DIFFERENTIATION; RATS
AB Infected bone defects (IBDs) are the common condition in the clinical practice of orthopaedics. Although surgery and anti infective medicine are the firstly chosen treatments, in many cases, patients experience a prolonged bone union process after anti infective treatment. Epimedium Curculigo herb pair (ECP) has been proved to be effective for bone repair. However, the mechanisms of ECP in IBDs are insufficiency. In this study, Effect of ECP in IBDs was verified by micro CT and histological examination. Qualitative and quantitative analysis of the main components in ECP containing medicated serum (ECP CS) were performed. The network pharmacological approaches were then applied to predict potential pathways for ECP associated with bone repair. In addition, the mechanism of ECP regulating LncRNA MALAT1/miRNA 34a 5p/SMAD2 signalling axis was evaluated by molecular biology experiments. In vivo experiments indicated that ECP could significantly promote bone repair. The results of the chemical components analysis and the pathway identification revealed that TGF beta signalling pathway was related to ECP. The results of in vitro experiments indicated that ECP CS could reverse the damage caused by LPS through inhibiting the expressions of LncRNA MALAT1 and SMAD2, and improving the expressions of miR 34a 5p, ALP, RUNX2 and Collagen type & Iukcy; in osteoblasts significantly. This research showed that ECP could regulate the TGF beta/SMADs signalling pathway to promote bone repair. Meanwhile, ECP could alleviate LPS induced bone loss by modulating the signalling axis of LncRNA MALAT1/miRNA 34a 5p/ SMAD2 in IBDs.
C1 [Miao, Maomao; Li, Mengying; Sheng, Yunjie; Zhang, Yang; Shou, Dan] Zhejiang Chinese Med Univ, Sch Pharmaceut Sci, 260 Baichuan Rd, Hangzhou 311402, Peoples R China.
   [Tong, Peijian; Zhang, Yang] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Zhejiang Prov Hosp Chinese Med, Inst Orthopaed & Traumatol, 548 Binwen Rd, Hangzhou 310053, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Chinese Medical University
RP Zhang, Y; Shou, D (通讯作者)，Zhejiang Chinese Med Univ, Sch Pharmaceut Sci, 260 Baichuan Rd, Hangzhou 311402, Peoples R China.; Zhang, Y (通讯作者)，Zhejiang Chinese Med Univ, Affiliated Hosp 1, Zhejiang Prov Hosp Chinese Med, Inst Orthopaed & Traumatol, 548 Binwen Rd, Hangzhou 310053, Peoples R China.
EM zhangyang0310@163.com; shoudanok@163.com
RI ; Li, Mengying/IXD 5394 2023
OI Shou, Dan/0000 0003 3465 4072; 
FU Zhejiang Provincial Medical and Health Science and Technology Fund
FX Project of Chunyan Special Fund for Chinese Medicine Development of
   Zhejiang Chinese Medical University, Grant/Award Number: CY202305;
   Research Project of Zhejiang Chinese Medical University, Grant/Award
   Number: 2023JKZKTS34; Zhejiang Provincial Natural Science Foundation of
   China, Grant/Award Number: LD22C060002; Zhejiang Province "High level
   Talents Special Support Program" Science and Technology innovation
   Leading talents project, Grant/Award Number: 2022R52031; Zhejiang
   Provincial Traditional Chinese Medicine Science and Technology Fund,
   Grant/Award Number: 2021ZA033; Zhejiang Provincial Medical and Health
   Science and Technology Fund, Grant/Award Number: 2021KY112r No Statement
   Availabler No Statement Availabler No Statement Availabler No Statement
   Availabler No Statement Available
CR Aqin P., 2020, Mastercases studies in open tibial fracture and complication with cilincal practice
   Blair HC, 2017, TISSUE ENG PART B RE, V23, P268, DOI [10.1089/ten.teb.2016.0454, 10.1089/ten.TEB.2016.0454]
   Bost KL, 2000, INFECT IMMUN, V68, P5075, DOI 10.1128/IAI.68.9.5075 5083.2000
   Boyle KK, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222034
   Chen L, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.900816
   Chen ZY, 2021, J MATER CHEM B, V9, P2594, DOI 10.1039/d0tb02983a
   Dai RC, 2022, J EXP CLIN CANC RES, V41, DOI 10.1186/s13046 022 02520 0
   Diao XY, 2021, BASIC CLIN PHARMACOL, V129, P450, DOI 10.1111/bcpt.13657
   Dong M, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.615920
   Duan GC, 2019, INT J ONCOL, V54, P17, DOI 10.3892/ijo.2018.4600
   Gao Y, 2018, J CELL BIOCHEM, V119, P6986, DOI 10.1002/jcb.26907
   Gong W, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/5410377
   Han Y, 2020, PHARMACOL THERAPEUT, V216, DOI 10.1016/j.pharmthera.2020.107680
   Indran IR, 2016, PHARMACOL THERAPEUT, V162, P188, DOI 10.1016/j.pharmthera.2016.01.015
   Jia PZ, 2023, J ETHNOPHARMACOL, V317, DOI 10.1016/j.jep.2023.116768
   Jiao Y, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1077796
   Lan HY, 2011, INT J BIOL SCI, V7, P1056, DOI 10.7150/ijbs.7.1056
   Liu X, 2023, J ETHNOPHARMACOL, V310, DOI 10.1016/j.jep.2023.116395
   Liu Y, 2021, J MATER SCI MATER M, V32, DOI 10.1007/s10856 020 06472 9
   Lüthje FL, 2020, APMIS, V128, P275, DOI 10.1111/apm.13027
   Ma M, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.874952
   Mei YQ, 2021, J PHARMACEUT BIOMED, V194, DOI 10.1016/j.jpba.2020.113803
   Mühlberg E, 2020, CAN J MICROBIOL, V66, P11, DOI 10.1139/cjm 2019 0309
   Nagao M, 2017, J CELL PHYSIOL, V232, P3337, DOI 10.1002/jcp.25777
   Oliveira TC, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8111765
   Panir K, 2018, HUM REPROD UPDATE, V24, P497, DOI 10.1093/humupd/dmy014
   Quarto N, 2012, STEM CELLS, V30, P2709, DOI 10.1002/stem.1250
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   Roper PM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9102157
   Shi SH, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.782096
   Shou D, 2017, PHYTOTHER RES, V31, P330, DOI 10.1002/ptr.5755
   Silva AM, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0048 9
   Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676
   Tang RH, 2020, CHIN J TRAUMATOL, V23, P314, DOI 10.1016/j.cjtee.2020.05.009
   Tong X, 2022, EVID BASED COMPL ALT, V2022, DOI 10.1155/2022/1116923
   Wang L, 2017, FITOTERAPIA, V117, P109, DOI [10.1016/j.fitote.2017.01.009, 10.1016/j.fitot]
   Wang NN, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00988
   Wang NN, 2017, MED SCI MONITOR, V23, P5113, DOI 10.12659/MSM.904264
   Wang WZ, 2012, INT J BIOL SCI, V8, P1310, DOI 10.7150/ijbs.5136
   Wang XQ, 2019, CARBOHYD POLYM, V203, P292, DOI 10.1016/j.carbpol.2018.09.059
   Xi YH, 2019, BIOMED PHARMACOTHER, V115, DOI 10.1016/j.biopha.2019.108850
   Yang KD, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10751
   Yang XC, 2019, AGING US, V11, P8777, DOI 10.18632/aging.102264
   Yi JY, 2019, CELL TISSUE RES, V376, P113, DOI 10.1007/s00441 018 2963 2
   Yuan XQ, 2019, BONE, V127, P305, DOI 10.1016/j.bone.2019.06.019
   Zhang L, 2022, BIOENGINEERED, V13, P14339, DOI 10.1080/21655979.2022.2085388
   Zhang XY, 2021, PHARM BIOL, V59, P1245, DOI 10.1080/13880209.2021.1972121
   Zhao Y, 2024, NAT COMMUN, V15, DOI 10.1038/s41467 024 46602 3
   Zhu FB, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/5707242
NR 49
TC 2
Z9 2
U1 2
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JUL
PY 2024
VL 28
IS 13
AR e18527
DI 10.1111/jcmm.18527
PG 18
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA YM1Q0
UT WOS:001268817500001
PM 38984969
OA Green Published
DA 2025 08 17
ER

PT J
AU Balke, M
   Campanacci, L
   Gebert, C
   Picci, P
   Gibbons, M
   Taylor, R
   Hogendoorn, P
   Kroep, J
   Wass, J
   Athanasou, N
AF Balke, Maurice
   Campanacci, Laura
   Gebert, Carsten
   Picci, Piero
   Gibbons, Max
   Taylor, Richard
   Hogendoorn, Pancras
   Kroep, Judith
   Wass, John
   Athanasou, Nicholas
TI Bisphosphonate treatment of aggressive primary, recurrent and metastatic
   Giant Cell Tumour of Bone
SO BMC CANCER
LA English
DT Article
ID FIBROUS DYSPLASIA; MECHANISMS; APOPTOSIS; PAMIDRONATE; OSTEOCLASTS;
   RESORPTION; THERAPY
AB Background: Giant cell tumour of bone (GCTB) is an expansile osteolytic tumour which contains numerous osteoclast like giant cells. GCTB frequently recurs and can produce metastatic lesions in the lungs. Bisphosphonates are anti resorptive drugs which act mainly on osteoclasts.
   Method: In this study, we have examined clinical and radiological outcomes of treatment with aminobisphosphonates on 25 cases of aggressive primary, recurrent and metastatic GCTB derived from four European centres. We also analysed in vitro the inhibitory effect of zoledronic acid on osteoclasts isolated from GCTBs.
   Results: Treatment protocols differed with several different aminobisphosphonates being employed, but stabilisation of disease was achieved in most of these cases which were refractory to conventional treatment. Most inoperable sacral/pelvic tumours did not increase in size and no further recurrence was seen in GCTBs that had repeatedly recurred in bone and soft tissues. Lung metastases did not increase in size or number following treatment. Zoledronic acid markedly inhibited lacunar resorption by GCTB derived osteoclasts in vitro.
   Conclusion: Our findings suggest that bisphosphonates may be useful in controlling disease progression in GCTB and that these agents directly inhibit GCTB   derived osteoclast resorption. These studies highlight the need for the establishment of standardised protocols to assess the efficacy of bisphosphonate treatment of GCTB.
C1 [Gibbons, Max; Taylor, Richard; Wass, John; Athanasou, Nicholas] Univ Oxford, Nuffield Dept Orthopaed Surg, Dept Pathol, Nuffield Orthopaed Ctr, Oxford OX3 7LD, England.
   [Balke, Maurice; Gebert, Carsten] Univ Munster, Dept Orthopaed Surg, D 48149 Munster, Germany.
   [Campanacci, Laura; Picci, Piero] Orthopaed Inst Rizzoli, Lab Oncol Res, I 40136 Bologna, Italy.
   [Hogendoorn, Pancras; Kroep, Judith] Leiden Univ, Med Ctr, Dept Pathol, NL 2300 RC Leiden, Netherlands.
C3 Nuffield Orthopaedic Centre; University of Oxford; University of
   Munster; Leiden University; Leiden University Medical Center (LUMC);
   Leiden University   Excl LUMC
RP Athanasou, N (通讯作者)，Univ Oxford, Nuffield Dept Orthopaed Surg, Dept Pathol, Nuffield Orthopaed Ctr, Oxford OX3 7LD, England.
EM nick.athanasou@ndorms.ox.ac.uk
RI Picci, Piero/J 5979 2016; campanacci, laura/C 7539 2019; Hogendoorn,
   Pancras C W/H 5859 2015; Hogendoorn, Pancras/H 5859 2015
OI Picci, Piero/0000 0002 8519 4101; campanacci, laura/0000 0002 4734 6741;
   Hogendoorn, Pancras C W/0000 0002 1513 8104; Kroep,
   Judith/0000 0003 2671 1903; 
FU EU
FX The authors wish to thank Chris Lowe for typing the manuscript. This
   study was carried out by members of the EuroBoNet network of Excellence
   funded by the EU, to promote research into the pathology, biology and
   genetics of bone tumours in adults and children.
CR Arpornchayanon Olarn, 2008, Journal of the Medical Association of Thailand, V91, P1609
   ATHANASOU NA, J CLIN PATHOL, V43, P997
   Blackley HR, 1999, J BONE JOINT SURG AM, V81A, P811, DOI 10.2106/00004623 199906000 00008
   Broom R, 2009, J PAIN SYMPTOM MANAG, V38, P244, DOI 10.1016/j.jpainsymman.2008.08.005
   CAMPANACCI M, 1987, J BONE JOINT SURG AM, V69A, P106, DOI 10.2106/00004623 198769010 00018
   Chang SS, 2004, CLIN ORTHOP RELAT R, P103, DOI 10.1097/01.blo.0000141372.54456.80
   Chapurlat RD, 1997, J BONE MINER RES, V12, P1746, DOI 10.1359/jbmr.1997.12.10.1746
   Cheng YY, 2004, CALCIFIED TISSUE INT, V75, P71, DOI 10.1007/s00223 004 0120 2
   Cheng YY, 2003, ULTRASTRUCT PATHOL, V27, P385, DOI 10.1080/01913120390248629
   Clohisy DR, 2000, CLIN ORTHOP RELAT R, P104
   Farran RP, 2001, J PEDIAT HEMATOL ONC, V23, P54, DOI 10.1097/00043426 200101000 00013
   Hall EJ, 2004, POSTGRAD MED J, V80, P190, DOI 10.1136/pgmj.2003.015529
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Kimmel DB, 2007, J DENT RES, V86, P1022, DOI 10.1177/154405910708601102
   Lane JM, 2001, CLIN ORTHOP RELAT R, P6
   Lau YS, 2005, HUM PATHOL, V36, P945, DOI 10.1016/j.humpath.2005.07.005
   Mendenhall WM, 2006, AM J CLIN ONCOL CANC, V29, P96, DOI 10.1097/01.coc.0000195089.11620.b7
   Nishikawa M, 1996, BONE, V18, P9, DOI 10.1016/8756 3282(95)00426 2
   Pandey R, 1996, ACTA ORTHOP SCAND, V67, P221, DOI 10.3109/17453679608994677
   PETRA M, 2003, SARCOMA, V7, P35
   QUINN JMW, 1994, LAB INVEST, V71, P465
   Reid IR, 2009, SKELETAL RADIOL, V38, P5, DOI 10.1007/s00256 008 0549 x
   REID R, 2002, PATHOLOGY GENETICS T, P310
   Rodan GA, 1998, ANNU REV PHARMACOL, V38, P375, DOI 10.1146/annurev.pharmtox.38.1.375
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Tse LF, 2008, BONE, V42, P68, DOI 10.1016/j.bone.2007.08.038
   Turcotte RE, 2006, ORTHOP CLIN N AM, V37, P35, DOI 10.1016/j.ocl.2005.08.005
   UNNI KK, 2005, TUMOURS BONES JOINTS
NR 29
TC 109
Z9 121
U1 0
U2 15
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471 2407
J9 BMC CANCER
JI BMC Cancer
PD AUG 29
PY 2010
VL 10
AR 462
DI 10.1186/1471 2407 10 462
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 661IE
UT WOS:000282718700001
PM 20799989
OA Green Published, gold, Green Accepted
DA 2025 08 17
ER

PT J
AU Li, B
   Wu, Y
   Ying, LK
   Zhu, WW
   Yang, JY
   Zhou, LL
   Yi, LL
   Jiang, TL
   Jiang, HF
   Song, XR
   Xue, WW
   Liang, G
   Huang, SB
   Song, ZQ
AF Li, Bin
   Wu, Yao
   Ying, Linkun
   Zhu, Weiwei
   Yang, Jingyi
   Zhou, Lingling
   Yi, Lele
   Jiang, Tianle
   Jiang, Haofu
   Song, Xiangrui
   Xue, Weiwei
   Liang, Guang
   Huang, Shengbin
   Song, Zengqiang
TI Synthesis and Antiosteoporotic Characterization of Diselenyl Maleimides:
   Discovery of a Potent Agent for the Treatment of Osteoporosis by
   Targeting RANKL
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID OSTEOCLAST DIFFERENTIATION; BONE; SELENIUM
AB To discover new osteoclast targeting antiosteoporosis agents, we identified forty six diselenyl maleimides, which were efficiently prepared using a novel, simple, and metal free method at room temperature in a short reaction time. Among them, 3k showed the most marked inhibition of osteoclast differentiation with an IC50 value of 0.36 +/  0.03 mu M. Moreover, 3k significantly suppressed RANKL induced osteoclast formation, bone resorption, and osteoclast specific genes expression in vitro. Mechanistic studies revealed that 3k remarkably blocked the RANKL induced mitogen activated protein kinase (MAPK) and NF kappa B signaling pathways. In ovariectomized mice, intragastric administration of 3k significantly alleviated bone loss, exhibiting an effect similar to that of alendronate. Surface plasmon resonance assay and microscale thermophoresis assay results suggested that RANKL might be a potential molecular target for 3k. Collectively, the findings presented above provided a novel candidate for further development of bone antiresorptive drugs that target RANKL.
C1 [Li, Bin; Jiang, Tianle; Jiang, Haofu; Huang, Shengbin] Wenzhou Med Univ, Sch & Hosp Stomatol, Inst Stomatol, Wenzhou 325027, Peoples R China.
   [Wu, Yao; Ying, Linkun; Zhou, Lingling; Yi, Lele; Song, Xiangrui; Song, Zengqiang] Wenzhou Med Univ, Sch Pharmaceut Sci, Wenzhou 325035, Zhejiang, Peoples R China.
   [Wu, Yao; Ying, Linkun; Zhu, Weiwei; Zhou, Lingling; Yi, Lele; Song, Xiangrui; Liang, Guang; Song, Zengqiang] Wenzhou Med Univ, Sch Pharmaceut Sci, State Key Lab Macromol Drugs & Large Scale Mfg, Wenzhou 325035, Zhejiang, Peoples R China.
   [Yang, Jingyi; Xue, Weiwei] Chongqing Univ, Sch Pharmaceut Sci, Chongqing 401331, Peoples R China.
   [Liang, Guang] Hangzhou Med Coll, Sch Pharm, Hangzhou 311399, Zhejiang, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical
   University; Chongqing University; Hangzhou Medical College
RP Huang, SB (通讯作者)，Wenzhou Med Univ, Sch & Hosp Stomatol, Inst Stomatol, Wenzhou 325027, Peoples R China.; Song, ZQ (通讯作者)，Wenzhou Med Univ, Sch Pharmaceut Sci, Wenzhou 325035, Zhejiang, Peoples R China.; Liang, G; Song, ZQ (通讯作者)，Wenzhou Med Univ, Sch Pharmaceut Sci, State Key Lab Macromol Drugs & Large Scale Mfg, Wenzhou 325035, Zhejiang, Peoples R China.; Liang, G (通讯作者)，Hangzhou Med Coll, Sch Pharm, Hangzhou 311399, Zhejiang, Peoples R China.
EM zmcliangguang@163.com; huangsb003@wmu.edu.cn; songzengqiang09@163.com
RI Xue, Weiwei/C 7461 2016; jingyi, yang/JDW 7176 2023; li,
   bin/LYP 2970 2024
FU National Natural Science Foundation of China [22077096]; Natural Science
   Foundation of Zhejiang Province [LY23B020006]; Scientific Research
   Center of Wenzhou Medical University
FX This study was supported by the National Natural Science Foundation of
   China (22077096) and the Natural Science Foundation of Zhejiang Province
   (LY23B020006). We thank the Scientific Research Center of Wenzhou
   Medical University for the consultation and instrument availability that
   supported this work.
CR Ali W, 2021, DRUG DISCOV TODAY, V26, P256, DOI 10.1016/j.drudis.2020.10.014
   [Anonymous], 2024, J MED CHEM, V67, P7585
   Boonrungsiman S, 2012, P NATL ACAD SCI USA, V109, P14170, DOI 10.1073/pnas.1208916109
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Castañeda L, 2013, TETRAHEDRON LETT, V54, P3493, DOI 10.1016/j.tetlet.2013.04.088
   Chen Y, 2022, J ORG CHEM, V87, P16175, DOI 10.1021/acs.joc.2c01567
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Chuai HY, 2021, EUR J MED CHEM, V223, DOI 10.1016/j.ejmech.2021.113621
   Dana S, 2017, ORG LETT, V19, P1902, DOI 10.1021/acs.orglett.7b00674
   Dirckx N, 2019, NAT REV ENDOCRINOL, V15, P651, DOI 10.1038/s41574 019 0246 y
   Ferrari Lacraz S, 2011, OSTEOPOROSIS INT, V22, P435, DOI 10.1007/s00198 010 1326 y
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Gong LY, 2010, BIOORG MED CHEM LETT, V20, P1693, DOI 10.1016/j.bmcl.2010.01.038
   Hong GJ, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.392
   Hou W, 2022, J MED CHEM, V65, P4436, DOI 10.1021/acs.jmedchem.1c01859
   Huang D, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 33006 4
   Hwang YH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072068
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Li H, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00639
   Martinez A, 2005, J MED CHEM, V48, P7103, DOI 10.1021/jm040895g
   Modi A, 2014, INT J WOMENS HEALTH, V6, P759, DOI 10.2147/IJWH.S53489
   Morán Serradilla C, 2024, J MED CHEM, V67, P7759, DOI 10.1021/acs.jmedchem.3c02426
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Ono T, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232 019 0111 3
   Park JH, 2017, MOL CELLS, V40, P706
   Reich HJ, 2016, ACS CHEM BIOL, V11, P821, DOI 10.1021/acschembio.6b00031
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Salamanna F, 2021, NANOMATERIALS BASEL, V11, DOI 10.3390/nano11020530
   Salazar VS, 2016, NAT REV ENDOCRINOL, V12, P203, DOI 10.1038/nrendo.2016.12
   Sharma U, 2014, INDIAN J CLIN BIOCHE, V29, P269, DOI 10.1007/s12291 013 0408 y
   Song ZQ, 2020, CHEM COMMUN, V56, P1847, DOI 10.1039/c9cc09001k
   Szulc P., 2021, BIOCHEMICAL MARKERS, P1545
   Wagner J, 2009, J MED CHEM, V52, P6193, DOI 10.1021/jm901108b
   Walsh MC, 2021, J BONE MINER METAB, V39, P54, DOI 10.1007/s00774 020 01178 y
   Wang X, 2017, ACCOUNTS CHEM RES, V50, P1712, DOI 10.1021/acs.accounts.7b00148
   Wang YT, 2024, EUR J MED CHEM, V265, DOI 10.1016/j.ejmech.2024.116124
   Wu XX, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05522 9
   Yang YF, 2020, ADV SYNTH CATAL, V362, P2168, DOI 10.1002/adsc.202000015
   Zeng HW, 2013, NUTRIENTS, V5, P97, DOI 10.3390/nu5010097
   Zhang JY, 2023, EUR J MED CHEM, V259, DOI 10.1016/j.ejmech.2023.115654
   Zhang Y, 2020, CURR MED CHEM, V27, P1151, DOI 10.2174/0929867325666180801145614
   Zhou Q, 2023, REGEN BIOMATER, V10, DOI 10.1093/rb/rbad011
   Zou Z, 2020, BIOCHEM SOC T, V48, P1623, DOI 10.1042/BST20200005
NR 44
TC 1
Z9 2
U1 1
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD SEP 19
PY 2024
VL 67
IS 19
BP 17226
EP 17242
DI 10.1021/acs.jmedchem.4c01105
EA SEP 2024
PG 17
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR EXPANDED)
SC Pharmacology & Pharmacy
GA I4J1A
UT WOS:001318702300001
PM 39299698
DA 2025 08 17
ER

PT J
AU Helali, AM
   Iti, FM
   Mohamed, IN
AF Helali, Asadul Mazid
   Iti, Farhana Matin
   Mohamed, Isa Naina
TI Cathepsin K Inhibitors: A Novel Target but Promising Approach in the
   Treatment of Osteoporosis
SO CURRENT DRUG TARGETS
LA English
DT Article
DE Bone remodeling; bone resorption; bone turnover markers; cathepsin K;
   selective cathepsin K inhibitors; osteoporosis; osteoclast
ID POSTMENOPAUSAL WOMEN; BONE RESORPTION; MOLECULAR CLONING; IN VIVO;
   ODANACATIB; PROTEASE; COLLAGEN; THERAPY; FUTURE; BISPHOSPHONATES
AB Osteoporosis is a pathologic process characterized by low bone mass with skeletal fragility and an increased risk of fracture. It occurs due to an imbalance between bone resorption and formation. Although current antiresorptive therapy halts bone loss, it does not cure the condition as it also inhibits bone formation. Recent preclinical and clinical trials suggest that the inhibition of resorption by cathepsin K inhibitors increases bone formation. Cathepsin K is a papain like cysteine protease with high potent collagenase activity and predominantly expressed in osteoclasts. While allowing demineralization, cathepsin K inhibitors suppress the degradation of type I collagen (the major organic matrix of bone) and thus enhancing bone formation. Many of these inhibitors have passed preclinical studies and are presently in clinical trials at different stages of advancement. This review explores the promising role of cathepsin K as a novel antiresorptive for the treatment of osteoporosis.
C1 [Helali, Asadul Mazid] Gonoshasthya Samajvittik Med Coll & Hosp, Dept Pharmacol & Therapeut, Dhaka, Bangladesh.
   [Iti, Farhana Matin] Rajshahi Med Coll & Hosp, Dept Microbiol, Rajshahi, Bangladesh.
   [Mohamed, Isa Naina] Natl Univ Malaysia, Univ Kebangsaan Malaysia, Fac Med, Pharmacoepidemiol & Drug Safety Unit,Pharmacol De, Kuala Lumpur, Malaysia.
C3 Rajshahi Medical College; Universiti Kebangsaan Malaysia
RP Mohamed, IN (通讯作者)，Univ Kebangsaan Malaysia, Fac Med, Dept Pharmacol, Kuala Lumpur 50300, Malaysia.
EM isa@medic.ukm.my
OI Helali, Asadul/0000 0002 8481 1868
CR [Anonymous], NEW DEV HORM REPL TH
   [Anonymous], 2004, Bone Health and Osteoporosis: A report of the Surgeon General
   Atley LM, 2000, BONE, V26, P241, DOI 10.1016/S8756 3282(99)00270 7
   Balkan W, 2009, GENE, V446, P90, DOI 10.1016/j.gene.2009.06.013
   Bilezikian JP, 2006, NEW ENGL J MED, V355, P2278, DOI 10.1056/NEJMp068157
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Brömme D, 2011, BIOL EXTRACELL MATR, P23, DOI 10.1007/978 3 642 16861 1_2
   BROMME D, 1995, BIOL CHEM H S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379
   Brömme D, 2009, EXPERT OPIN INV DRUG, V18, P585, DOI [10.1517/13543780902832661, 10.1517/13543780902832661 ]
   Brubaker KD, 2003, J BONE MINER RES, V18, P222, DOI 10.1359/jbmr.2003.18.2.222
   Burr D. B., 2003, Journal of Musculoskeletal & Neuronal Interactions, V3, P408
   Chen W, 2007, HUM MOL GENET, V16, P410, DOI 10.1093/hmg/ddl474
   Clinical Trials, SERV US NAT I HLTH
   Costa AG, 2011, NAT REV RHEUMATOL, V7, P447, DOI 10.1038/nrrheum.2011.77
   Cusick T, 2009, P AM SOC BON MIN RES, V24
   Cusick T, 2012, J BONE MINER RES, V27, P524, DOI 10.1002/jbmr.1477
   Desmarais S, 2008, MOL PHARMACOL, V73, P147, DOI 10.1124/mol.107.039511
   Dickinson DP, 2002, CRIT REV ORAL BIOL M, V13, P238, DOI 10.1177/154411130201300304
   Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511
   Duong Le T, 2012, Bonekey Rep, V1, P67, DOI 10.1038/bonekey.2012.67
   Eastell R, 2011, J BONE MINER RES, V26, P1303, DOI 10.1002/jbmr.341
   Eisman J., 2009, P AM SOC BON MIN RES, V24
   Engelke K., 2010, 32 ANN M AM SOC BON
   Everts V, 2003, CALCIFIED TISSUE INT, V73, P380, DOI 10.1007/s00223 002 2092 4
   Falgueyret JP, 2005, J MED CHEM, V48, P7535, DOI 10.1021/jm0504961
   Fleming FF, 2010, J MED CHEM, V53, P7902, DOI 10.1021/jm100762r
   Fuller K, 2008, BONE, V42, P200, DOI 10.1016/j.bone.2007.09.044
   Gallagher JC, 2002, MENOPAUSE, V9, P84
   Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347
   Gauthier JY, 2008, BIOORG MED CHEM LETT, V18, P923, DOI 10.1016/j.bmcl.2007.12.047
   GELB BD, 2001, METABOLIC MOL BASES, P3453
   Gianoukakis AG Smith TJ, 2004, CAN J DIABETES, V28, P30
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   Grcevic D, 2001, CROAT MED J, V42, P384
   Hamwi A, 2001, CLIN CHEM LAB MED, V39, P414, DOI 10.1515/CCLM.2001.066
   Henriksen K, 2011, ENDOCR REV, V32, P31, DOI 10.1210/er.2010 0006
   Hodgson Stephen F, 2003, Endocr Pract, V9, P544
   Hou WS, 2001, AM J PATHOL, V159, P2167, DOI 10.1016/S0002 9440(10)63068 4
   Isabel E, 2010, BIOORG MED CHEM LETT, V20, P887, DOI 10.1016/j.bmcl.2009.12.083
   Jensen AB, 2010, CLIN BREAST CANCER, V10, P452, DOI 10.3816/CBC.2010.n.059
   Kafienah W, 1998, BIOCHEM J, V331, P727, DOI 10.1042/bj3310727
   Kalanjati VP, 2005, FOLIA MED INDONESIAN, V41, P313
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kumar S, 2007, BONE, V40, P122, DOI 10.1016/j.bone.2006.07.015
   Langdahl B, 2012, J BONE MINER RES, V27, P2251, DOI 10.1002/jbmr.1695
   Le Gall C, 2007, CANCER RES, V67, P9894, DOI 10.1158/0008 5472.CAN 06 3940
   Lecaille F, 2008, BIOCHIMIE, V90, P208, DOI 10.1016/j.biochi.2007.08.011
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   LittlewoodEvans AJ, 1997, CANCER RES, V57, P5386
   Marcus R, 2002, ENDOCR REV, V23, P16, DOI 10.1210/er.23.1.16
   *NAT OST FDN, PHYS GUID PREV TREAT
   Ng KW, 2012, CLIN INTERV AGING, V7, P235, DOI 10.2147/CIA.S26729
   Ochi Y, 2011, BONE, V49, P1351, DOI 10.1016/j.bone.2011.09.041
   Pathophysiology of Osteoporosis, 2004, OST MAN MOD 3 CME PR, P1
   Pennypacker B, 2009, BONE, V44, P199, DOI 10.1016/j.bone.2008.08.130
   Pennypacker BL, 2011, J BONE MINER RES, V26, P252, DOI 10.1002/jbmr.223
   Perez Castrillon J.L., 2010, J OSTEOPOROS, V2010, P1
   Perez Castrillon JL, 2009, OPEN BONE J, V1, P23
   Podgorski I, 2009, FUTURE MED CHEM, V1, P21, DOI 10.4155/FMC.09.4
   Quintanilla Dieck MJ, 2009, EXP DERMATOL, V18, P596, DOI 10.1111/j.1600 0625.2009.00855.x
   Reynolds J J, 1996, Oral Dis, V2, P70
   Rizzoli R, 2001, J MOL ENDOCRINOL, V26, P79, DOI 10.1677/jme.0.0260079
   Rodan S.B., 2008, IBMS BONEKEY, V5, P16
   Rothschild BM, 1998, AM J PHYS ANTHROPOL, V105, P241, DOI 10.1002/(SICI)1096 8644(199802)105:2<241::AID AJPA10>3.0.CO;2 0
   Rünger TM, 2012, J AM ACAD DERMATOL, V66, pE89, DOI 10.1016/j.jaad.2010.11.033
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Sato A, 2013, BIOORG MED CHEM LETT, V23, P3013, DOI 10.1016/j.bmcl.2013.03.024
   Seeman E., 2009, IBMS BONEKEY, V6, P496
   SHI GP, 1995, FEBS LETT, V357, P129, DOI 10.1016/0014 5793(94)01349 6
   Stephenson J, 2003, JAMA J AM MED ASSOC, V289, P537, DOI 10.1001/jama.289.5.537
   Stoch SA, 2008, CLIN PHARMACOL THER, V83, P172, DOI 10.1038/sj.clpt.6100450
   Stoch SA, 2009, CLIN PHARMACOL THER, V86, P175, DOI 10.1038/clpt.2009.60
   Turk B, 2006, NAT REV DRUG DISCOV, V5, P785, DOI 10.1038/nrd2092
   Van den Wyngaerta T, 2007, CURR OPIN ONCOL, V19, P315, DOI 10.1097/CCO.0b013e32819f820b
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Wells G, 2002, ENDOCR REV, V23, P529, DOI 10.1210/er.2001 5002
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Xue Y, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750 1172 6 20
   Yasuda Y, 2005, ADV DRUG DELIVER REV, V57, P973, DOI 10.1016/j.addr.2004.12.013
NR 80
TC 28
Z9 30
U1 0
U2 21
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389 4501
EI 1873 5592
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PD DEC
PY 2013
VL 14
IS 13
SI SI
BP 1591
EP 1600
DI 10.2174/13894501113149990202
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 258VA
UT WOS:000327485600009
PM 23957815
DA 2025 08 17
ER

PT J
AU Costa Rodrigues, J
   Carmo, SC
   Silva, JC
   Fernandes, MHR
AF Costa Rodrigues, J.
   Carmo, S. C.
   Silva, J. C.
   Fernandes, M. H. R.
TI Inhibition of human in vitro osteoclastogenesis by Equisetum
   arvense
SO CELL PROLIFERATION
LA English
DT Article
ID HYDROALCOHOLIC EXTRACT; TRICALCIUM PHOSPHATE; KINASE ACTIVATION; BONE
   SUBSTITUTE; PRECURSOR CELLS; DIFFERENTIATION; SILICON; L.;
   HYDROXYAPATITE; MODULATION
AB Objectives Equisetum arvense has long been used in traditional medicines to treat different disorders, including bone pathologies. In this study a hydromethanolic extract of E. arvense was assessed for its effects on human osteoclastogenesis.
   Materials and methods Osteoclast precursors were maintained in non stimulated and stimulated (presence of M CSF and RANKL) conditions, or in co cultures with osteoblasts. Cell cultures were treated with 0.00016 0.5 mg/ml of a hydromethanolic E. arvense extract.
   Results The extract did not affect spontaneous osteoclastogenesis. In osteoclast precursors committed to osteoclastogenesis (stimulated or co cultured with osteoblasts), E. arvense caused dose dependent inhibitory effect that became statistically significant at concentrations >= 0.004 mg/ml. This was observed using different osteoclast differentiation and activation markers. Cell response was associated with changes in relative contribution of MEK and NFkB signalling pathways, as well as PGE2 production. As there were differences in the response of osteoclast precursors maintained in the presence of inductive factors, or co cultured with osteoblastic cells, it seems that E. arvense extract had the ability to modulate osteoclastogenesis, either by acting directly on osteoclast precursor cells, and/or via osteoblasts.
   Conclusions Equisetum appeared to have a negative effect on human osteoclastogenesis, which is in line with its putative beneficial role in pathophysiological conditions associated with increased osteoclastic activity, and might suggest potential utility for treatment with bone regeneration strategies.
C1 [Costa Rodrigues, J.; Fernandes, M. H. R.] Univ Porto, Fac Med Dent, Lab Pharmacol & Cellular Biocompatibil, P 4200393 Oporto, Portugal.
C3 Universidade do Porto
RP Fernandes, MHR (通讯作者)，Univ Porto, Fac Med Dent, Lab Pharmacol & Cellular Biocompatibil, Rua Dr Manuel Pereira da Silva, P 4200393 Oporto, Portugal.
EM mhfernandes@fmd.up.pt
RI do Carmo, Carolina/AAE 4670 2021; Fernandes, Maria/K 6917 2014;
   Fernandes, Maria Helena/K 6917 2014; Costa Rodrigues, João/L 1058 2014;
   Silva, Júlio César/KBB 6705 2024
OI Costa Rodrigues, Joao/0000 0003 1375 8067; Fernandes, Maria
   Helena/0000 0001 9391 9574; 
FU Faculdade de Medicina Dentaria, Universidade do Porto, Portugal
FX Financial support was provided by Faculdade de Medicina Dentaria,
   Universidade do Porto, Portugal. CLSM observation was performed at
   Advanced Light Microscopy, IBMC, University of Porto (IBMC.INEB) under
   the responsibility of Dr Paula Sampaio.
CR Bandyopadhyay S, 2006, BIOCHEM PHARMACOL, V72, P184, DOI 10.1016/j.bcp.2006.04.018
   Pereira CB, 2012, CELL PROLIFERAT, V45, P386, DOI 10.1111/j.1365 2184.2012.00826.x
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bradford MM, 1976, ANAL BIOCHEM, V72, P2448
   Broudiscou LP, 2000, REPROD NUTR DEV, V40, P431, DOI 10.1051/rnd:2000110
   Cetojevic Simin DD, 2010, J MED FOOD, V13, P452, DOI 10.1089/jmf.2008.0159
   CHANH PH, 1986, PROSTAG LEUKOTR ESS, V22, P295, DOI 10.1016/0262 1746(86)90140 X
   Costa Rodrigues J, 2011, CELL PROLIFERAT, V44, P410, DOI 10.1111/j.1365 2184.2011.00768.x
   Costa Rodrigues J, 2011, CLIN EXP METASTAS, V28, P505, DOI 10.1007/s10585 011 9387 7
   Costa Rodrigues J, 2011, CELL PROLIFERAT, V44, P264, DOI 10.1111/j.1365 2184.2011.00751.x
   Costa Rodrigues J, 2012, ACTA BIOMATER, V8, P1137, DOI 10.1016/j.actbio.2011.11.032
   Costa Rodrigues J, 2012, J CELL BIOCHEM, V113, P1069, DOI 10.1002/jcb.23439
   Costa Rodrigues J, 2011, J CELL BIOCHEM, V112, P3704, DOI 10.1002/jcb.23295
   Costa Rodrigues J, 2010, J CELL BIOCHEM, V109, P205, DOI 10.1002/jcb.22398
   Currie HA, 2009, PHYTOCHEMISTRY, V70, P2089, DOI 10.1016/j.phytochem.2009.07.039
   D'AGOSTINO M, 1984, Bollettino Societa Italiana Biologia Sperimentale, V60, P2241
   Datta HK, 2008, J CLIN PATHOL, V61, P577, DOI 10.1136/jcp.2007.048868
   Dew TP, 2007, NUTR RES REV, V20, P89, DOI 10.1017/S0954422407738805
   DiCarlo EF, 2011, SEMIN DIAGN PATHOL, V28, P53, DOI 10.1053/j.semdp.2011.02.012
   Do Monte FHM, 2004, PHARMACOL RES, V49, P239, DOI 10.1016/j.phrs.2003.10.002
   Dong GC, 2008, J BIOMED MATER RES A, V84A, P167, DOI 10.1002/jbm.a.31261
   Dos Santos JG Jr, 2005, FITOTERAPIA, V76, P508, DOI 10.1016/j.fitote.2005.04.017
   Duke J., 2002, HDB MED HERBS, P391
   Gomes PS, 2010, J BIOMED MATER RES B, V94B, P337, DOI 10.1002/jbm.b.31656
   Graefe EU, 1999, PHYTOMEDICINE, V6, P239, DOI 10.1016/S0944 7113(99)80015 4
   HALL TJ, 1995, BIOCHEM BIOPH RES CO, V207, P280, DOI 10.1006/bbrc.1995.1184
   Hodson MJ, 2005, ANN BOT LONDON, V96, P1027, DOI 10.1093/aob/mci255
   Holzhüter G, 2003, ANAL BIOANAL CHEM, V376, P512, DOI 10.1007/s00216 003 1905 2
   Hotokezaka H, 2007, J CELL BIOCHEM, V101, P122, DOI 10.1002/jcb.21167
   Jeong JC, 2005, J ETHNOPHARMACOL, V96, P489, DOI 10.1016/j.jep.2004.09.038
   Jugdaohsingh R, 2007, J NUTR HEALTH AGING, V11, P99
   Kawashima M, 2009, MOD RHEUMATOL, V19, P192, DOI 10.1007/s10165 008 0149 6
   Kellinsalmi M, 2007, EUR J PHARMACOL, V572, P102, DOI 10.1016/j.ejphar.2007.06.030
   Milovanovic V, 2007, PLANT FOOD HUM NUTR, V62, P113, DOI 10.1007/s11130 007 0050 z
   Nian H, 2006, ACTA PHARMACOL SIN, V27, P728, DOI 10.1111/j.1745 7254.2006.00328.x
   Oh H, 2004, J ETHNOPHARMACOL, V95, P421, DOI 10.1016/j.jep.2004.08.015
   Park EK, 2004, BIOCHEM BIOPH RES CO, V325, P1472, DOI 10.1016/j.bbrc.2004.10.197
   Patel N, 2002, J MATER SCI MATER M, V13, P1199, DOI 10.1023/A:1021114710076
   Pietak AM, 2007, BIOMATERIALS, V28, P4023, DOI 10.1016/j.biomaterials.2007.05.003
   Putnam SE, 2007, PHYTOTHER RES, V21, P99, DOI 10.1002/ptr.2030
   Radulovic N, 2006, PHYTOTHER RES, V20, P85, DOI 10.1002/ptr.1815
   Shishodia S, 2006, ONCOGENE, V25, P1463, DOI 10.1038/sj.onc.1209194
   Stajner D, 2009, PHYTOTHER RES, V23, P546, DOI 10.1002/ptr.2682
   Sun JS, 2003, BIOMATERIALS, V24, P873, DOI 10.1016/S0142 9612(02)00372 1
   Van Wyk B., 2004, Medicinal plants of the world, P136
   Wichtl M., 2004, Herbal drugs and phytopharmaceuticals, V3, P195
   Yao CH, 2005, J BIOMED MATER RES B, V75B, P277, DOI 10.1002/jbm.b.30294
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhang Y, 2008, BRIT J NUTR, V99, P494, DOI 10.1017/S0007114507801589
   Zhao QX, 2007, FRONT BIOSCI LANDMRK, V12, P2519, DOI 10.2741/2252
NR 51
TC 19
Z9 23
U1 0
U2 24
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0960 7722
J9 CELL PROLIFERAT
JI Cell Prolif.
PD DEC
PY 2012
VL 45
IS 6
BP 566
EP 576
DI 10.1111/j.1365 2184.2012.00848.x
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 029HQ
UT WOS:000310485900009
PM 23106302
OA Green Published
DA 2025 08 17
ER

PT J
AU Zhao, JW
   Gao, ZL
   Mei, H
   Li, YL
   Wang, Y
AF Zhao, Jian Wu
   Gao, Zhong Li
   Mei, Hong
   Li, Yu Lin
   Wang, Yan
TI Differentiation of Human Mesenchymal Stem Cells: The Potential Mechanism
   for Estrogen Induced Preferential Osteoblast Versus Adipocyte
   Differentiation
SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES
LA English
DT Article
DE Mesenchymal stem cells; Osteoporosis; Estrogen; Osteoblasts; Adipocytes
ID MARROW; OSTEOPOROSIS; SLINGSHOT; TISSUE; PHOSPHATASES; PATHOGENESIS;
   EXPRESSION; PHENOTYPE; FAMILY
AB Introduction: Bone marrow derived mesenchymal stem cells (MSCs) are capable of differentiating into osteoblasts and adipocytes. This critical balance between osteoblast and adipocyte differentiation plays a significant role in maintaining normal bone homeostasis. In osteoporosis, a metabolic bone disease seen mainly in postmenopausal women because of estrogen deficiency, the concomitant occurrence of increased bone marrow adipocyte production with diminished production of osteoblasts, points to the potential role of estrogen in shifting the balance of MSC differentiation. Methods: We established an in vitro differentiation model of isolated human MSCs (hMSCs) and examined the role of distinct estrogen signaling pathways in regulating the differentiation of hMSCs. Results: Estrogen promoted the differentiation of hMSCs to osteoblasts in contrast to adipocytes, the former of which was mediated through the PI3K/SSH1L but not the mitogen activated protein kinase pathway. Conclusion: This study provides a novel mechanistic understanding of estrogen related osteoporosis and identifies potential targets for antiosteoporosis therapies.
C1 [Wang, Yan] Jilin Univ, China Japan Union Hosp, Res Ctr Gene Therapy, Changchun 130033, Peoples R China.
   [Zhao, Jian Wu; Gao, Zhong Li] Jilin Univ, China Japan Union Hosp, Dept Orthopaed, Changchun 130033, Peoples R China.
   [Mei, Hong; Li, Yu Lin] Jilin Univ, Minist Educ, Key Lab Pathobiol, Changchun 130033, Peoples R China.
C3 Jilin University; Jilin University; Jilin University
RP Wang, Y (通讯作者)，Jilin Univ, China Japan Union Hosp, Res Ctr Gene Therapy, Changchun 130033, Peoples R China.
EM wangy01@jlu.edu.cn
RI yan, wang/JRW 9981 2023; Li, yulin/AGZ 5611 2022
FU International Cooperation of Jilin Provincial Science & Technology
   Department [20080723]; NSFC [30772488]
FX This study was supported by Projects of International Cooperation of
   Jilin Provincial Science & Technology Department (No. 20080723), and
   NSFC (No. 30772488).
CR BERESFORD JN, 1992, J CELL SCI, V102, P341
   BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496
   Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007 0197
   CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   COELINGH BHJ, 2004, MATURITAS, V47, P269
   Ebeling PR, 1998, DRUG AGING, V13, P421, DOI 10.2165/00002512 199813060 00002
   FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843
   Garcia Olmo D, 2006, Clin Transl Oncol, V8, P301, DOI 10.1007/s12094 006 0173 y
   GIMBLE JM, 1995, J CELL BIOCHEM, V58, P393, DOI 10.1002/jcb.240580312
   Jilka RL, 1996, J CLIN INVEST, V97, P1732, DOI 10.1172/JCI118600
   Kadiyala S, 1997, CELL TRANSPLANT, V6, P125, DOI 10.1016/S0963 6897(96)00279 5
   Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627
   Lecka Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097 4644(19990901)74:3<357::AID JCB5>3.0.CO;2 7
   Lennon DP, 2006, EXP HEMATOL, V34, P1604, DOI 10.1016/j.exphem.2006.07.014
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   MEUNIER P, 1971, CLIN ORTHOP RELAT R, P147, DOI 10.1097/00003086 197110000 00021
   Mikami Y, 2010, J CELL PHYSIOL, V223, P123, DOI 10.1002/jcp.22017
   Moriarty K, 2006, ENDOCRINOLOGY, V147, P5557, DOI 10.1210/en.2006 0729
   Muruganandan S, 2009, CELL MOL LIFE SCI, V66, P236, DOI 10.1007/s00018 008 8429 z
   Nishita M, 2004, J BIOL CHEM, V279, P7193, DOI 10.1074/jbc.M312591200
   Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092 8674(01)00638 9
   OHTA H, 1992, BONE MINER, V19, P273, DOI 10.1016/0169 6009(92)90876 F
   Ohta Y, 2003, GENES CELLS, V8, P811, DOI 10.1046/j.1365 2443.2003.00678.x
   Okazaki R, 2002, ENDOCRINOLOGY, V143, P2349, DOI 10.1210/en.143.6.2349
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Robertson JFR, 2001, J STEROID BIOCHEM, V79, P209, DOI 10.1016/S0960 0760(01)00138 8
   Rodríguez JP, 1999, J CELL BIOCHEM, V75, P414, DOI 10.1002/(SICI)1097 4644(19991201)75:3<414::AID JCB7>3.3.CO;2 3
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Takada I, 2007, ANN NY ACAD SCI, V1116, P182, DOI 10.1196/annals.1402.034
   Wang Y, 2005, J BIOL CHEM, V280, P12683, DOI 10.1074/jbc.M411494200
NR 33
TC 48
Z9 55
U1 1
U2 36
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002 9629
EI 1538 2990
J9 AM J MED SCI
JI Am. J. Med. Sci.
PD JUN
PY 2011
VL 341
IS 6
BP 460
EP 468
DI 10.1097/MAJ.0b013e31820865d5
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 769IA
UT WOS:000291004900009
PM 21289500
DA 2025 08 17
ER

PT J
AU Maeda, K
   Yoshida, K
   Nishizawa, T
   Otani, K
   Yamashita, Y
   Okabe, H
   Hadano, Y
   Kayama, T
   Kurosaka, D
   Saito, M
AF Maeda, Kazuhiro
   Yoshida, Ken
   Nishizawa, Tetsuro
   Otani, Kazuhiro
   Yamashita, Yu
   Okabe, Hinako
   Hadano, Yuka
   Kayama, Tomohiro
   Kurosaka, Daitaro
   Saito, Mitsuru
TI Inflammation and Bone Metabolism in Rheumatoid Arthritis: Molecular
   Mechanisms of Joint Destruction and Pharmacological Treatments
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE rheumatoid arthritis; osteoporosis; osteoclast; fibroblast; RANKL;
   DKK 1; TNF alpha; IL 6; CTLA 4; JAK
ID COLLAGEN INDUCED ARTHRITIS; NECROSIS FACTOR RECEPTOR; LONG TERM
   TREATMENT; MINERAL DENSITY; PARATHYROID HORMONE; BETA CATENIN;
   SERUM LEVELS; TNF ALPHA; B CELLS; PRECLINICAL CHARACTERIZATION
AB Rheumatoid arthritis (RA) is an inflammatory disease characterized by a variety of symptoms and pathologies often presenting with polyarthritis. The primary symptom in the initial stage is joint swelling due to synovitis. With disease progression, cartilage and bone are affected to cause joint deformities. Advanced osteoarticular destruction and deformation can cause irreversible physical disabilities. Physical disabilities not only deteriorate patients' quality of life but also have substantial medical economic effects on society. Therefore, prevention of the progression of osteoarticular destruction and deformation is an important task. Recent studies have progressively improved our understanding of the molecular mechanism by which synovitis caused by immune disorders results in activation of osteoclasts; activated osteoclasts in turn cause bone destruction and para articular osteoporosis. In this paper, we review the mechanisms of bone metabolism under physiological and RA conditions, and we describe the effects of therapeutic intervention against RA on bone.
C1 [Maeda, Kazuhiro; Nishizawa, Tetsuro; Yamashita, Yu; Okabe, Hinako; Hadano, Yuka; Kayama, Tomohiro; Saito, Mitsuru] Jikei Univ, Sch Med, Dept Orthopaed Surg, Minato Ku, 3 25 8 Nishi Shimbashi, Tokyo 1058461, Japan.
   [Yoshida, Ken; Otani, Kazuhiro; Kurosaka, Daitaro] Jikei Univ, Sch Med, Dept Internal Med, Div Rheumatol,Minato Ku, 3 25 8 Nishi Shimbashi, Tokyo 1058461, Japan.
C3 Jikei University; Jikei University
RP Maeda, K (通讯作者)，Jikei Univ, Sch Med, Dept Orthopaed Surg, Minato Ku, 3 25 8 Nishi Shimbashi, Tokyo 1058461, Japan.
EM maeda@jikei.ac.jp; k.yoshida@jikei.ac.jp; nishizawatetsu@jikei.ac.jp;
   md11 otani@jikei.ac.jp; y.yamashita@jikei.ac.jp; hnnr316@gmail.com;
   yuka.momo@outlook.jp; tom_kayama@jikei.ac.jp; d_kurosaka@jikei.ac.jp;
   xlink67@gol.com
RI Kayama, Tomohiro/AAO 7094 2020; Maeda, Kazuhiro/ABD 5762 2020; Yoshida,
   Ken/LBH 5514 2024
OI Yoshida, Ken/0000 0002 5351 3227
FU Ministry of Education, Cultures, Sports, Science and Technology of Japan
   [18K16161]; Grants in Aid for Scientific Research [18K16161] Funding
   Source: KAKEN
FX This work was supported in part by Grants in Aid for Scientific Research
   (KAKEN) 18K16161 (K.M.) from the Ministry of Education, Cultures,
   Sports, Science and Technology of Japan.
CR Abu Shakra M, 2018, ISR MED ASSOC J, V20, P239
   Adam S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay4447
   Adami G, 2019, CURR RHEUMATOL REP, V21, DOI 10.1007/s11926 019 0836 7
   Axmann R, 2008, ANN RHEUM DIS, V67, P1603, DOI 10.1136/ard.2007.080713
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Berardi S, 2021, MOL BIOL REP, V48, P2843, DOI 10.1007/s11033 021 06288 y
   Bonnet N, 2012, P NATL ACAD SCI USA, V109, P15048, DOI 10.1073/pnas.1203085109
   Bonnet N, 2009, J BIOL CHEM, V284, P35939, DOI 10.1074/jbc.M109.060335
   Boyapati A, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 1132 9
   Bozec A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007764
   Briot K, 2015, JOINT BONE SPINE, V82, P109, DOI 10.1016/j.jbspin.2014.10.015
   Cawthorn WP, 2012, BONE, V50, P477, DOI 10.1016/j.bone.2011.08.010
   Charoenngam N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910659
   Chopin F, 2008, ANN RHEUM DIS, V67, P353, DOI 10.1136/ard.2007.076604
   Chotiyarnwong P, 2020, NAT REV ENDOCRINOL, V16, P437, DOI 10.1038/s41574 020 0341 0
   Cici D, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225552
   Colditz J, 2018, J BONE MINER RES, V33, P1698, DOI 10.1002/jbmr.3463
   Croft AP, 2019, NATURE, V570, P246, DOI 10.1038/s41586 019 1263 7
   Danks L, 2016, ANN RHEUM DIS, V75, P1187, DOI 10.1136/annrheumdis 2014 207137
   De Benedetti F, 2006, ARTHRITIS RHEUM, V54, P3551, DOI 10.1002/art.22175
   Delgado Calle J, 2017, J BONE MINER RES, V32, P522, DOI 10.1002/jbmr.3011
   Di Munno O, 2004, J RHEUMATOL, V31, P1305
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Edwards JCW, 2001, RHEUMATOLOGY, V40, P205, DOI 10.1093/rheumatology/40.2.205
   Eekman DA, 2011, ANN RHEUM DIS, V70, P389, DOI 10.1136/ard.2009.127787
   Emery P, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075 020 02379 6
   Emery P, 2016, RHEUMATOLOGY, V55, P1458, DOI 10.1093/rheumatology/kew056
   Finzel S, 2019, ANN RHEUM DIS, V78, P1186, DOI 10.1136/annrheumdis 2018 214894
   Fridman JS, 2010, J IMMUNOL, V184, P5298, DOI 10.4049/jimmunol.0902819
   FRIES JF, 1980, ARTHRITIS RHEUM US, V23, P137, DOI 10.1002/art.1780230202
   Gabay C, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 02163 6
   Gabay C, 2018, RMD OPEN, V4, DOI 10.1136/rmdopen 2017 000607
   Gaber T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030865
   Gao YG, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22158182
   Genovese MC, 2013, ANN RHEUM DIS, V72, P863, DOI 10.1136/annrheumdis 2012 201601
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Goldring SR, 2015, BONE, V80, P143, DOI 10.1016/j.bone.2015.05.024
   Gulyas K, 2020, CLIN RHEUMATOL, V39, P167, DOI 10.1007/s10067 019 04771 3
   Guo QY, 2018, BAMBOO SILK, V1, P1, DOI [10.1163/24689246 00101001, 10.1038/s41413 018 0016 9]
   Hamar A, 2021, OSTEOPOROSIS INT, V32, P1621, DOI 10.1007/s00198 021 05871 0
   Harre U, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7651
   Harre U, 2012, J CLIN INVEST, V122, P1791, DOI 10.1172/JCI60975
   Hasegawa T, 2019, NAT IMMUNOL, V20, P1631, DOI 10.1038/s41590 019 0526 7
   Hirota K, 2007, J EXP MED, V204, P2803, DOI 10.1084/jem.20071397
   Huybrechts Y, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00165
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Ito M, 2017, J PHARMACOL SCI, V133, P25, DOI 10.1016/j.jphs.2016.12.001
   Jann J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207597
   Jimi E, 2019, CELLS BASEL, V8, DOI 10.3390/cells8121636
   Jovanovic DV, 1998, J IMMUNOL, V160, P3513
   Kanagawa H, 2016, J BONE MINER METAB, V34, P526, DOI 10.1007/s00774 015 0702 2
   Kaste SC, 2001, LEUKEMIA, V15, P728, DOI 10.1038/sj.leu.2402078
   Katagiri T, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021899
   Kawai VK, 2013, ARTHRIT CARE RES, V65, P1085, DOI 10.1002/acr.21937
   Kim SY, 2012, J BONE MINER RES, V27, P789, DOI 10.1002/jbmr.1489
   Kochi Y, 2010, NAT GENET, V42, P515, DOI 10.1038/ng.583
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Koide M, 2019, J BONE MINER METAB, V37, P9, DOI 10.1007/s00774 018 0971 7
   Koide M, 2017, J BONE MINER RES, V32, P2074, DOI 10.1002/jbmr.3175
   Komatsu N, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI143060
   Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432
   Komori T, 2016, HORM METAB RES, V48, P755, DOI 10.1055/s 0042 110571
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2020, MOL CELLS, V43, P168, DOI 10.14348/molcells.2019.0244
   Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703
   Kremer JM, 2005, ARTHRITIS RHEUM, V52, P2263, DOI 10.1002/art.21201
   Krieckaert CLM, 2013, RHEUMATOLOGY, V52, P547, DOI 10.1093/rheumatology/kes320
   Kukita T, 2004, J EXP MED, V200, P941, DOI 10.1084/jem.20040518
   Kume K, 2014, RHEUMATOLOGY, V53, P900, DOI 10.1093/rheumatology/ket468
   LaBranche TP, 2012, ARTHRITIS RHEUM US, V64, P3531, DOI 10.1002/art.34649
   Lee JW, 2010, BIOCHEM PHARMACOL, V80, P352, DOI 10.1016/j.bcp.2010.04.014
   Lee YH, 2016, CLIN EXP RHEUMATOL, V34, P827
   Lin J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146351
   Liu HR, 2014, J HISTOCHEM CYTOCHEM, V62, P556, DOI 10.1369/0022155414537830
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Lubberts E, 2004, ARTHRITIS RHEUM US, V50, P650, DOI 10.1002/art.20001
   MacLauchlan S, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1375 0
   Maeda K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225525
   Maeda K, 2013, J MOL MED, V91, P15, DOI 10.1007/s00109 012 0974 0
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   Mageed RA, 1998, GENE THER, V5, P1584, DOI 10.1038/sj.gt.3300785
   Mahmoud DE, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.663683
   Malemud CJ, 2017, PROG MOL BIOL TRANSL, V148, P305, DOI 10.1016/bs.pmbts.2017.03.003
   Manolagas SC, 2010, TRENDS ENDOCRIN MET, V21, P369, DOI 10.1016/j.tem.2010.01.010
   Marotte H, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2219
   Matsuoka K, 2014, J BONE MINER RES, V29, P1522, DOI 10.1002/jbmr.2187
   Mease PJ, 2018, J RHEUMATOL, V45, P22, DOI 10.3899/jrheum.161238
   Meednu N, 2016, ARTHRITIS RHEUMATOL, V68, P805, DOI 10.1002/art.39489
   Michaud K, 2019, RHEUMATOL THER, V6, P409, DOI 10.1007/s40744 019 0164 4
   Mizoguchi F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 02892 y
   Mueller AL, 2021, CELLS BASEL, V10, DOI 10.3390/cells10113017
   Murakami K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181126
   Murray E, 2018, J COMP EFFECT RES, V7, P959, DOI 10.2217/cer 2017 0106
   Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365 2443.1999.00265.x
   Nakajima A, 2020, INT J RHEUM DIS, V23, P1676, DOI 10.1111/1756 185X.13974
   Nakamura M, 2003, ENDOCRINOLOGY, V144, P5441, DOI 10.1210/en.2003 0717
   Nakanishi R, 2008, J BONE MINER RES, V23, P271, DOI 10.1359/JBMR.071007
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Narisawa M, 2021, BONE, V142, DOI 10.1016/j.bone.2020.115616
   Negishi Koga T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7637
   Nishimura R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041340
   Nistala K, 2008, ARTHRITIS RHEUM US, V58, P875, DOI 10.1002/art.23291
   Ogura H, 2008, IMMUNITY, V29, P628, DOI 10.1016/j.immuni.2008.07.018
   Okada H, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010180
   Okada H, 2019, J BONE MINER RES, V34, P1744, DOI 10.1002/jbmr.3754
   Okada Y, 2014, NATURE, V506, P376, DOI 10.1038/nature12873
   Okamoto K, 2019, CSH PERSPECT MED, V9, DOI 10.1101/cshperspect.a031245
   Orsolini G, 2016, CALCIFIED TISSUE INT, V98, P580, DOI 10.1007/s00223 016 0114 x
   Ota K, 2013, ENDOCRINOLOGY, V154, P3745, DOI 10.1210/en.2013 1272
   Ota Y, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 0957 6
   Ozen G, 2019, ANN RHEUM DIS, V78, P1041, DOI 10.1136/annrheumdis 2019 215328
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Peruzzi B, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1651
   Poutoglidou F, 2021, INFLAMMOPHARMACOLOGY, V29, P661, DOI 10.1007/s10787 021 00815 w
   Powell WF, 2011, J ENDOCRINOL, V209, P21, DOI 10.1530/JOE 10 0308
   Purdue PE, 2014, SCI REP UK, V4, DOI 10.1038/srep07595
   Qin ZJ, 2015, J MOL HISTOL, V46, P409, DOI 10.1007/s10735 015 9630 7
   RANGES GE, 1985, J EXP MED, V162, P1105, DOI 10.1084/jem.162.3.1105
   Rao DA, 2017, NATURE, V542, P110, DOI 10.1038/nature20810
   Rauner M, 2012, J BONE MINER RES, V27, P575, DOI 10.1002/jbmr.1488
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Robling AG, 2020, ANNU REV PHYSIOL, V82, P485, DOI 10.1146/annurev physiol 021119 034332
   Rodriguez Trillo A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.555245
   Roser Page S, 2018, ANN NY ACAD SCI, V1415, P21, DOI 10.1111/nyas.13643
   Roser Page S, 2014, ARTHRITIS RHEUMATOL, V66, P990, DOI 10.1002/art.38319
   Rossini M, 2015, CLIN EXP RHEUMATOL, V33, P77
   Saidenberg Kermanac'h N, 2004, BONE, V35, P1200, DOI 10.1016/j.bone.2004.07.004
   Sakaguchi S, 2020, ANNU REV IMMUNOL, V38, P541, DOI 10.1146/annurev immunol 042718 041717
   Sanpaolo ER, 2020, MOL BIOL REP, V47, P9087, DOI 10.1007/s11033 020 05910 9
   Sasaki F, 2021, J BONE MINER METAB, V39, P34, DOI 10.1007/s00774 020 01145 7
   Sasaki F, 2020, BIOCHEM BIOPH RES CO, V521, P806, DOI 10.1016/j.bbrc.2019.10.174
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Segawa Y, 1997, BONE, V20, P457, DOI 10.1016/S8756 3282(97)00023 9
   Sen M, 2000, P NATL ACAD SCI USA, V97, P2791, DOI 10.1073/pnas.050574297
   Seror R, 2016, SCI REP UK, V6, DOI 10.1038/srep18421
   Shakibaei M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035712
   Shakibaei M, 2011, J BIOL CHEM, V286, P11492, DOI 10.1074/jbc.M110.198713
   Sims NA, 2020, ANNU REV PHYSIOL, V82, P507, DOI 10.1146/annurev physiol 021119 034425
   Singh A, 2019, DRUG DISCOV THER, V13, P22, DOI 10.5582/ddt.2019.01011
   Smolen JS, 2020, ANN RHEUM DIS, V79, P685, DOI 10.1136/annrheumdis 2019 216655
   Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1
   Smolen JS, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis 2016 209831
   Stach CM, 2010, ARTHRITIS RHEUM US, V62, P330, DOI 10.1002/art.27252
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Sun ZZ, 2021, J MOL HISTOL, V52, P1245, DOI 10.1007/s10735 020 09941 1
   Syversen SW, 2008, ANN RHEUM DIS, V67, P212, DOI 10.1136/ard.2006.068247
   Taams LS, 2020, J EXP MED, V217, DOI 10.1084/jem.20192048
   Tada M, 2018, RHEUMATOL INT, V38, P777, DOI 10.1007/s00296 017 3922 z
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo 123 5 2600
   Takashi Y, 2020, J ENDOCRINOL INVEST, V43, P877, DOI 10.1007/s40618 020 01205 9
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Takeshita S, 2013, J CLIN INVEST, V123, P3914, DOI 10.1172/JCI69493
   Takeuchi T, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2021.102884
   Takeuchi T, 2017, ADV THER, V34, P686, DOI 10.1007/s12325 017 0477 z
   Tanaka Y, 2021, J CLIN MED, V10, DOI 10.3390/jcm10061241
   Tanaka Y, 2022, MOD RHEUMATOL, V32, P1, DOI 10.1080/14397595.2021.1902617
   Tanaka Y, 2021, RHEUMATOL THER, V8, P729, DOI 10.1007/s40744 021 00284 1
   Tanaka Y, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1647 3
   Thudium CS, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 02340 7
   Tlustochowicz W, 2016, J RHEUMATOL, V43, P495, DOI 10.3899/jrheum.150117
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Tsukasaki M, 2011, BIOCHEM BIOPH RES CO, V410, P766, DOI 10.1016/j.bbrc.2011.06.048
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Uehara S, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aan0023
   Van Rompaey L, 2013, J IMMUNOL, V191, P3568, DOI 10.4049/jimmunol.1201348
   van Vollenhoven R, 2020, ARTHRITIS RHEUMATOL, V72, P1607, DOI 10.1002/art.41384
   VanderHeijde DMFM, 1996, BAILLIERE CLIN RHEUM, V10, P435, DOI 10.1016/S0950 3579(96)80043 4
   Vidal B, 2018, RHEUMATOLOGY, V57, P1461, DOI 10.1093/rheumatology/kex258
   Vis M, 2006, ANN RHEUM DIS, V65, P1495, DOI 10.1136/ard.2005.044198
   Vis M, 2005, ANN RHEUM DIS, V64, P336, DOI 10.1136/ard.2003.017780
   Walker EC, 2010, J CLIN INVEST, V120, P582, DOI 10.1172/JCI40568
   Walker EC, 2008, J BONE MINER RES, V23, P2025, DOI [10.1359/jbmr.080706, 10.1359/JBMR.080706]
   Walsh MC, 2015, IMMUNOL REV, V266, P72, DOI 10.1111/imr.12302
   Wang F, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115754
   Wang F, 2019, J BONE MINER RES, V34, P1129, DOI 10.1002/jbmr.3680
   Wang SY, 2011, J RHEUMATOL, V38, P821, DOI 10.3899/jrheum.100089
   Wang XH, 2014, MOL MED REP, V10, P241, DOI 10.3892/mmr.2014.2182
   Wei KV, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI149538
   Wei KV, 2020, NATURE, V582, P259, DOI 10.1038/s41586 020 2222 z
   Weivoda MM, 2016, J BONE MINER RES, V31, P76, DOI 10.1002/jbmr.2586
   Wijbrandts CA, 2009, ANN RHEUM DIS, V68, P373, DOI 10.1136/ard.2008.091611
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Xu S, 2016, J BONE MINER RES, V31, P1320, DOI 10.1002/jbmr.2800
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yago T, 2017, J CLIN MED, V6, DOI 10.3390/jcm6090081
   Yamada A, 2013, BIOMATERIALS, V34, P3270, DOI 10.1016/j.biomaterials.2013.01.066
   Yamanaka H, 2014, MOD RHEUMATOL, V24, P33, DOI 10.3109/14397595.2013.854059
   Yamaoka K, 2016, CURR OPIN CHEM BIOL, V32, P29, DOI 10.1016/j.cbpa.2016.03.006
   Yamashita T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085878
   Yao W, 2010, J BONE MINER RES, V25, P190, DOI 10.1359/jbmr.090719
   Yeo L, 2011, ANN RHEUM DIS, V70, P2022, DOI 10.1136/ard.2011.153312
   Yokota K, 2021, ARTHRITIS RHEUMATOL, V73, P1145, DOI 10.1002/art.41666
   Yoshida H, 2018, SCAND J RHEUMATOL, V47, P384, DOI 10.1080/03009742.2017.1416667
   Zeng HC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15000
   Zhang F, 2019, NAT IMMUNOL, V20, P928, DOI 10.1038/s41590 019 0378 1
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
   Zhou TF, 2020, ELIFE, V9, DOI 10.7554/eLife.52779
   Zhu TY, 2014, J BONE MINER RES, V29, P2118, DOI 10.1002/jbmr.2221
NR 208
TC 81
Z9 96
U1 5
U2 35
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2022
VL 23
IS 5
AR 2871
DI 10.3390/ijms23052871
PG 24
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 0A2YY
UT WOS:000773826900001
PM 35270012
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Hu, SJ
   Cheng, G
   Chen, GC
   Zhou, H
   Zhang, Q
   Zhao, QM
   Lian, CX
   Zhao, ZH
   Zhang, QL
   Han, T
   Zhang, QY
   Qin, LP
AF Hu, Si jing
   Cheng, Gang
   Chen, Gao ce
   Zhou, Hao
   Zhang, Qi
   Zhao, Qi ming
   Lian, Chen xia
   Zhao, Zi hui
   Zhang, Quan long
   Han, Ting
   Zhang, Qiao yan
   Qin, Lu ping
TI Cannabinoid receptors type 2: Function and development in agonist
   discovery from synthetic and natural sources with applications for the
   therapy of osteoporosis
SO ARABIAN JOURNAL OF CHEMISTRY
LA English
DT Article
DE Cannabinoid receptors type 2; Osteoporosis; CB2R agonist discovery;
   Osteoblasts; Osteoclasts
ID RUBUS COREANUS EXTRACTS; BONE LOSS; OSTEOCLAST DIFFERENTIATION;
   MOLECULAR MECHANISMS; ECHINACEA PURPUREA; BETA CARYOPHYLLENE; INDUCED
   APOPTOSIS; CB2 AGONISTS; AFFINITY; LIGAND
AB Type 2 cannabinoid receptor (CB2R) is a member of the G protein coupled receptor superfamily with various biological activities in pain regulation, anti inflammation, anti fibrosis, and bone metabolism regulation. CB2R modulators have been demonstrated to have significant regulatory effects on bone metabolism with no significant psychoactive adverse effects. In this article, we present a comprehensive review of the molecular mechanism of CB2R in regulating bone metabolism and summarize virtual screening and experimental screening methods for CB2R modulators from natural and synthetic products. Knowing that some botanical compounds are CB2R modulators involved in the regulation of bone metabolism, we also review the botanical and synthetic compounds currently known to be potential CB2R and summarize their regulatory effects on bone metabolism based on the results of animal, osteoblasts (OBs) and osteoclasts (OCs) experimental studies presently available, hoping that the findings and conclusions in this review could provide a scientific basis for the discovery of new CB2R regulators and the development of new anti osteoporosis drugs.
C1 [Hu, Si jing; Cheng, Gang; Chen, Gao ce; Zhou, Hao; Zhang, Qi; Zhao, Qi ming; Lian, Chen xia; Zhao, Zi hui; Zhang, Quan long; Han, Ting; Zhang, Qiao yan; Qin, Lu ping] Zhejiang Chinese Med Univ, Sch Pharmaceut Sci, Binwen Rd 584, Hangzhou 310053, Peoples R China.
   [Han, Ting; Zhang, Qiao yan] Naval Med Univ, Sch Pharm, Shanghai 200433, Peoples R China.
C3 Zhejiang Chinese Medical University; Naval Medical University
RP Han, T; Zhang, QY; Qin, LP (通讯作者)，Zhejiang Chinese Med Univ, Sch Pharmaceut Sci, Binwen Rd 584, Hangzhou 310053, Peoples R China.
EM hanting@smmu.edu.cn; zqy1965@163.com; lpqin@zcmu.edu.cn
RI Zhou, Hao/C 3442 2018
FU National Natural Science Foundation of China [82374098, 82374099,
   81974534]; Shanghai Municipal Science and Technology Commission
   [22S21901600]; Opening Project of Zhejiang Provincial Preponderant and
   Characteristic Subject of Key University (Traditional Chinese
   Pharmacology) and Zhejiang Chinese Medical University [ZYAOX2018018]
FX This work was supported by the National Natural Science Foundation of
   China (No. 82374098; 82374099; 81974534) ; the Shanghai Municipal
   Science and Technology Commission (No. 22S21901600) ; the Opening
   Project of Zhejiang Provincial Preponderant and Characteristic Subject
   of Key University (Traditional Chinese Pharmacology) and Zhejiang
   Chinese Medical University (No. ZYAOX2018018) .
CR Aguiar DD, 2022, LIFE SCI, V293, DOI 10.1016/j.lfs.2021.120279
   Akter Y, 2021, MINI REV MED CHEM, V21, P2799, DOI 10.2174/1389557521666210203153436
   Alexandre J, 2020, ADDICT BIOL, V25, DOI 10.1111/adb.12824
   Alharthi N, 2018, BBA MOL CELL BIOL L, V1863, P1433, DOI 10.1016/j.bbalip.2018.08.003
   Ansari Ramin, 2019, Current Drug Discovery Technologies, V16, P148, DOI 10.2174/1570163815666180521101136
   Apostu D, 2019, DRUG METAB REV, V51, P65, DOI 10.1080/03602532.2019.1574303
   Ashton JC, 2007, CURR OPIN INVEST DR, V8, P373
   Bab I, 2008, J NEUROENDOCRINOL, V20, P69, DOI 10.1111/j.1365 2826.2008.01675.x
   Bab I, 2009, ANN MED, V41, P560, DOI 10.1080/07853890903121025
   Bai JX, 2019, BIOMED PHARMACOTHER, V116, DOI 10.1016/j.biopha.2019.109025
   Bellini G, 2017, PHARMACOL RES, V115, P267, DOI 10.1016/j.phrs.2016.11.039
   Biersack B, 2020, CANCER DRUG RESIST, V3, P867, DOI 10.20517/cdr.2020.53
   Blázquez C, 2003, FASEB J, V17, P529, DOI 10.1096/fj.02 0795fje
   Bolognini D, 2012, BRIT J PHARMACOL, V165, P2561, DOI 10.1111/j.1476 5381.2011.01503.x
   Brown C, 2017, NATURE, V550, pS15, DOI 10.1038/550S15a
   Bruni N, 2018, MOLECULES, V23, DOI 10.3390/molecules23102478
   Bryant HU, 1999, J STEROID BIOCHEM, V69, P37, DOI 10.1016/S0960 0760(98)00147 2
   Chang BY, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 67890 x
   Chen FL, 2019, NUTR METAB, V16, DOI 10.1186/s12986 019 0393 0
   Chen H, 2015, MED MOL MORPHOL, V48, P61, DOI 10.1007/s00795 015 0099 y
   Chen JZ, 2007, J CHEM INF MODEL, V47, P1626, DOI 10.1021/ci7000814
   Chen SN, 2019, J CELL PHYSIOL, V234, P22960, DOI 10.1002/jcp.28857
   Chicca A, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974 015 0307 7
   Chicca A, 2009, INT IMMUNOPHARMACOL, V9, P850, DOI 10.1016/j.intimp.2009.03.006
   Choi C, 2012, MENOPAUSE, V19, P1043, DOI 10.1097/gme.0b013e31824b1cc5
   Choi H, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929 016 0260 5
   Choi SI, 2022, FOODS, V11, DOI 10.3390/foods11131925
   Cichero E, 2011, EUR J MED CHEM, V46, P4489, DOI 10.1016/j.ejmech.2011.07.023
   Aarland RC, 2017, PHARM BIOL, V55, P649, DOI 10.1080/13880209.2016.1265989
   Coughlan T, 2014, CLIN MED, V14, P187, DOI 10.7861/clinmedicine.14 2 187
   Maíra DCD, 2018, NUTRITION, V49, P48, DOI 10.1016/j.nut.2017.11.025
   De Petrocellis L, 2017, ADV PHARMACOL, V80, P249, DOI 10.1016/bs.apha.2017.04.001
   Dhopeshwarkar A, 2016, J PHARMACOL EXP THER, V358, P342, DOI 10.1124/jpet.116.232561
   Do SH, 2008, MENOPAUSE, V15, P676, DOI 10.1097/gme.0b013e31815bb687
   Dong W, 2022, BONE JOINT RES, V11, P528, DOI 10.1302/2046 3758.118.BJR 2021 0392.R1
   Dossou KSS, 2013, J NAT PROD, V76, P2060, DOI 10.1021/np400478c
   Du YH, 2009, J RECEPT SIG TRANSD, V29, P182, DOI 10.1080/10799890902976933
   Dutra RC, 2012, NEUROPHARMACOLOGY, V63, P593, DOI 10.1016/j.neuropharm.2012.05.008
   Ettinger B, 2006, MENOPAUSE, V13, P340, DOI 10.1097/01.gme.0000222475.93345.b3
   Fei WY, 2019, INT J MOL MED, V43, P1669, DOI 10.3892/ijmm.2019.4099
   Floresta G, 2018, MOLECULES, V23, DOI 10.3390/molecules23092183
   Franks LN, 2018, TOXICOL APPL PHARM, V353, P31, DOI 10.1016/j.taap.2018.06.009
   Fuchs A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077739
   GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432 1033.1995.tb20780.x
   Gan K, 2015, INT IMMUNOPHARMACOL, V24, P239, DOI 10.1016/j.intimp.2014.12.012
   Geng DC, 2011, CHINESE MED J PEKING, V124, P586, DOI 10.3760/cma.j.issn.0366 6999.2011.04.019
   George KL, 2008, J CELL PHYSIOL, V214, P714, DOI 10.1002/jcp.21263
   Gertsch J, 2008, P NATL ACAD SCI USA, V105, P9099, DOI 10.1073/pnas.0803601105
   Gonzalez Salitre L, 2023, FOOD CHEM, V405, DOI 10.1016/j.foodchem.2022.134959
   Grabon W, 2023, NEUROSCI BIOBEHAV R, V150, DOI 10.1016/j.neubiorev.2023.105226
   Hanus L, 1999, P NATL ACAD SCI USA, V96, P14228, DOI 10.1073/pnas.96.25.14228
   Hashiesh HM, 2021, BIOMED PHARMACOTHER, V140, DOI 10.1016/j.biopha.2021.111639
   Herrera B, 2005, FEBS LETT, V579, P5084, DOI 10.1016/j.febslet.2005.08.021
   Hickey ER, 2015, BIOORG MED CHEM LETT, V25, P575, DOI 10.1016/j.bmcl.2014.12.033
   Hou W, 2020, EUR J MED CHEM, V189, DOI 10.1016/j.ejmech.2020.112081
   Hu SJ, 2022, MOLECULES, V27, DOI 10.3390/molecules27030702
   Hua T, 2020, CELL, V180, P655, DOI 10.1016/j.cell.2020.01.008
   Huang ZB, 2016, SCI REP UK, V6, DOI 10.1038/srep29757
   Huffman JW, 1999, BIOORGAN MED CHEM, V7, P2905, DOI 10.1016/S0968 0896(99)00219 9
   Hussain S, 2016, INT J STEM CELLS, V9, P221, DOI 10.15283/ijsc16024
   Hwang YH, 2018, MOLECULES, V23, DOI 10.3390/molecules23071598
   Idris AI, 2008, ENDOCRINOLOGY, V149, P5619, DOI 10.1210/en.2008 0150
   Jiang XW, 2020, PHYTOMEDICINE, V67, DOI 10.1016/j.phymed.2019.153160
   Jüttler E, 2004, NEUROPHARMACOLOGY, V47, P580, DOI 10.1016/j.neuropharm.2004.05.009
   Kaneda T, 2019, J NAT MED TOKYO, V73, P504, DOI 10.1007/s11418 019 01292 w
   Kang EJ, 2017, EVID BASED COMPL ALT, V2017, DOI 10.1155/2017/1583185
   Kim SK, 2013, KOREAN J PHYSIOL PHA, V17, P73, DOI 10.4196/kjpp.2013.17.1.73
   Kim Y, 2011, NUTRITION, V27, P1101, DOI 10.1016/j.nut.2011.05.012
   Korte G, 2009, J MED FOOD, V12, P1407, DOI 10.1089/jmf.2008.0243
   Kostrzewa M, 2021, CELLS BASEL, V10, DOI 10.3390/cells10051199
   Kumar HC, 2022, INTEGR CANCER THER, V21, DOI 10.1177/15347354221132848
   Kumarihamy M, 2015, J ETHNOPHARMACOL, V174, P57, DOI 10.1016/j.jep.2015.08.006
   KUNTZ ID, 1982, J MOL BIOL, V161, P269, DOI 10.1016/0022 2836(82)90153 X
   Kwak EJ, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/829650
   LaBuda CJ, 2005, EUR J PHARMACOL, V527, P172, DOI 10.1016/j.ejphar.2005.10.020
   Lee JE, 2011, NUTR RES PRACT, V5, P429, DOI 10.4162/nrp.2011.5.5.429
   Lee YJ, 2011, PHARMACOL THERAPEUT, V130, P157, DOI 10.1016/j.pharmthera.2011.01.010
   Li L, 2020, AGING US, V12, P16887, DOI 10.18632/aging.103590
   Li L, 2022, INT J STEM CELLS, V15, P405, DOI 10.15283/ijsc21152
   Li T, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/s13018 014 0056 9
   Li W, 2020, REGEN THER, V14, P191, DOI 10.1016/j.reth.2020.02.001
   Li XT, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 37112 9
   Li XT, 2019, CELL, V176, P459, DOI 10.1016/j.cell.2018.12.011
   Li Y, 2014, CHIN J NAT MEDICINES, V12, P204, DOI 10.1016/S1875 5364(14)60034 0
   Li YW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033011
   Lim HK, 2015, AGING MALE, V18, P124, DOI 10.3109/13685538.2014.949661
   Liu XD, 2016, J PHARMACOL SCI, V130, P204, DOI 10.1016/j.jphs.2016.02.001
   Liu XY, 2012, MOL CANCER THER, V11, P1421, DOI 10.1158/1535 7163.MCT 12 0026
   Liu Yuan, 2012, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V28, P194
   Lu SH, 2015, J NAT PROD, V78, P61, DOI 10.1021/np500663y
   Ríos JL, 2018, PLANTA MED, V84, P8, DOI 10.1055/s 0043 123472
   Ma C, 2013, J CHEM INF MODEL, V53, P11, DOI 10.1021/ci3003914
   Maier MLV, 2021, DRUG METAB DISPOS, V49, P694, DOI 10.1124/dmd.120.000346
   Mao YT, 2019, MOL MED REP, V20, P5100, DOI 10.3892/mmr.2019.10772
   MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0
   Melough MM, 2017, NUTRIENTS, V9, DOI 10.3390/nu9070789
   Moaddel R, 2011, ANAL BIOCHEM, V412, P85, DOI 10.1016/j.ab.2010.12.034
   Moore TJ, 2018, JAMA INTERN MED, V178, P1451, DOI 10.1001/jamainternmed.2018.3931
   Morales P, 2022, FRONT MOL BIOSCI, V9, DOI 10.3389/fmolb.2022.841190
   Morales P, 2016, EXPERT OPIN THER PAT, V26, P843, DOI 10.1080/13543776.2016.1193157
   MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0
   Ndong C, 2011, EUR J PHARMACOL, V669, P24, DOI 10.1016/j.ejphar.2011.08.002
   Nunes Alves C, 2015, NAT REV MICROBIOL, V13, P68, DOI 10.1038/nrmicro3421
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   Ofek O, 2011, J BONE MINER RES, V26, P308, DOI 10.1002/jbmr.228
   Ossola CA, 2016, J PERIODONTOL, V87, P725, DOI 10.1902/jop.2016.150612
   Palu AK, 2008, J ETHNOPHARMACOL, V115, P502, DOI 10.1016/j.jep.2007.10.023
   Panchal SK, 2022, NUTRIENTS, V14, DOI 10.3390/nu14102161
   Paoletta M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221810158
   Park KR, 2017, ARCH PHARM RES, V40, P933, DOI 10.1007/s12272 017 0932 z
   Peng Y, 2020, PHYTOMEDICINE, V68, DOI 10.1016/j.phymed.2019.153151
   Piomelli D, 2014, NEUROPHARMACOLOGY, V76, P228, DOI 10.1016/j.neuropharm.2013.07.026
   Qian H, 2010, J PERIODONTAL RES, V45, P504, DOI 10.1111/j.1600 0765.2009.01265.x
   Qian HY, 2017, EUR J MED CHEM, V137, P598, DOI 10.1016/j.ejmech.2017.05.060
   Qiu S, 2015, MOL CELL BIOCHEM, V399, P131, DOI 10.1007/s11010 014 2240 y
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Raphael Mizrahi B, 2020, CURR OSTEOPOROS REP, V18, P433, DOI 10.1007/s11914 020 00607 1
   Raterman HG, 2019, DRUGS, V79, P1065, DOI 10.1007/s40265 019 01145 6
   Rempel V, 2013, ACS MED CHEM LETT, V4, P41, DOI 10.1021/ml300235q
   Ribeiro DC, 2017, LIPIDS, V52, P327, DOI 10.1007/s11745 017 4245 2
   Rollinger JM, 2009, PLANTA MED, V75, P195, DOI 10.1055/s 0028 1088397
   Romero Parra J, 2016, EUR J MED CHEM, V124, P17, DOI 10.1016/j.ejmech.2016.08.005
   Ross RA, 1999, BRIT J PHARMACOL, V126, P665, DOI 10.1038/sj.bjp.0702351
   Rossi F, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0271730
   Rossi F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081919
   Rossi F, 2013, PHARMACOL RES, V68, P7, DOI 10.1016/j.phrs.2012.10.017
   Sadybekov AA, 2022, NATURE, V601, P452, DOI 10.1038/s41586 021 04220 9
   Saponaro F, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222212374
   Sarfraz A, 2020, SCI TOTAL ENVIRON, V722, DOI 10.1016/j.scitotenv.2020.137907
   Schuehly W, 2011, CHEM BIOL, V18, P1053, DOI 10.1016/j.chembiol.2011.05.012
   Shan JH, 2017, IUBMB LIFE, V69, P22, DOI 10.1002/iub.1584
   Sharma G, 2024, SEMIN CELL DEV BIOL, V154, P275, DOI 10.1016/j.semcdb.2022.11.002
   Shayan M, 2020, COMB CHEM HIGH T SCR, V23, P699, DOI 10.2174/1386207323666200521121708
   Shen YB, 2019, FOOD SCI NUTR, V7, P3062, DOI 10.1002/fsn3.1165
   Smoum R, 2015, P NATL ACAD SCI USA, V112, P8774, DOI 10.1073/pnas.1503395112
   Sophocleous A, 2017, AGING CELL, V16, P1051, DOI 10.1111/acel.12638
   Starowicz K, 2017, ADV PHARMACOL, V80, P437, DOI 10.1016/bs.apha.2017.05.003
   Steinmüller SAM, 2023, ANGEW CHEM INT EDIT, V62, DOI 10.1002/anie.202306176
   Styrczewska M, 2012, CELL MOL BIOL LETT, V17, P479, DOI 10.2478/s11658 012 0023 6
   Su SJ, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/594857
   Thors L, 2010, BRIT J PHARMACOL, V160, P549, DOI 10.1111/j.1476 5381.2010.00716.x
   Tonelli M, 2018, MEDCHEMCOMM, V9, P2045, DOI 10.1039/c8md00461g
   Tortora C, 2020, J PEDIATR GASTR NUTR, V71, P633, DOI 10.1097/MPG.0000000000002863
   Tuccinardi T, 2006, J MED CHEM, V49, P984, DOI 10.1021/jm050875u
   UGI I, 1990, CONCEPTS AND APPLICATIONS OF MOLECULAR SIMILARITY, P239
   Velusami CC, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/145925
   Vijayakumar S, 2019, COMPUT BIOL CHEM, V78, P95, DOI 10.1016/j.compbiolchem.2018.11.013
   Viscomi MT, 2009, J NEUROSCI, V29, P4564, DOI 10.1523/JNEUROSCI.0786 09.2009
   Walji R, 2007, SUPPORT CARE CANCER, V15, P913, DOI 10.1007/s00520 007 0286 z
   Wang MK, 2021, MOLECULES, V26, DOI 10.3390/molecules26216679
   Wang MY, 2002, ACTA PHARMACOL SIN, V23, P1127
   Wang ZY, 2023, CRIT REV FOOD SCI, V63, P4867, DOI 10.1080/10408398.2021.2009436
   Wattanathorn J, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/1039364
   Wei JY, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01025
   Xi JC, 2018, MOL MED REP, V18, P4753, DOI 10.3892/mmr.2018.9436
   Xing CR, 2020, CELL, V180, P645, DOI 10.1016/j.cell.2020.01.007
   Xu AH, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964 020 0512 6
   Xu Q, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.682541
   Xu SH, 2021, PHARMACOL RES, V167, DOI 10.1016/j.phrs.2021.105572
   Xu WQ, 2021, PHYTOMEDICINE, V87, DOI 10.1016/j.phymed.2021.153572
   Yamaguchi M, 2016, EXP THER MED, V12, P3602, DOI 10.3892/etm.2016.3818
   Yang JF, 2020, ACS CHEM NEUROSCI, V11, P3455, DOI 10.1021/acschemneuro.0c00551
   Yin H, 2009, J BIOL CHEM, V284, P12328, DOI 10.1074/jbc.M806516200
   Yu TY, 2015, J PHARMACOL SCI, V127, P75, DOI 10.1016/j.jphs.2014.11.006
   Yuan JY, 2022, MOLECULES, V27, DOI 10.3390/molecules27020453
   Zhang JH, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/1847130
   Zhou H, 2020, J ETHNOPHARMACOL, V246, DOI 10.1016/j.jep.2019.112218
   Zhou H, 2023, COMPUT BIOL MED, V152, DOI 10.1016/j.compbiomed.2022.106379
   Zou SL, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030833
NR 169
TC 1
Z9 1
U1 2
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1878 5352
EI 1878 5379
J9 ARAB J CHEM
JI Arab. J. Chem.
PD FEB
PY 2024
VL 17
IS 2
AR 105536
DI 10.1016/j.arabjc.2023.105536
EA DEC 2023
PG 19
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA EF6D8
UT WOS:001137538600001
OA gold
DA 2025 08 17
ER

PT J
AU Bermúdez Bejarano, EB
   Serrera Figallo, MA
   Gutiérrez Corrales, A
   Romero Ruiz, MM
   Castillo de Oyagüe, R
   Gutiérrez Pérez, JL
   Machuca Portillo, G
   Torres Lagares, D
AF Bermudez Bejarano, Elena Beatriz
   Serrera Figallo, Maria Angeles
   Gutierrez Corrales, Aida
   Romero Ruiz, Manuel Maria
   Castillo de Oyaguee, Raquel
   Gutierrez Perez, Jose Luis
   Machuca Portillo, Guillermo
   Torres Lagares, Daniel
TI Analysis of different therapeutic protocols for osteonecrosis of the jaw
   associated with oral and intravenous bisphosphonates
SO MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL
LA English
DT Article
DE Bisphosphonates; bronj; therapeutic protocol; clinical result
ID MEDICATION RELATED OSTEONECROSIS; CASE SERIES REPORT;
   SURGICAL TREATMENT; CANCER PATIENTS; FLAP RECONSTRUCTION;
   PARATHYROID HORMONE; MANAGEMENT; OUTCOMES; RICH; EXPERIENCE
AB Introduction: Chemotherapy associated osteonecrosis of the jaw caused by bisphosphonates is an exposure of necrotic bone with more than eight weeks of evolution that is attributable to bisphosphonates and no prior radiation therapy. Its etiopathogenesis remains unknown, although there are two hypotheses that may explain it: the drug's mechanism of action, and the risk factors that can lead to osteonecrosis. There is a wide range of treatment options for managing chemotherapy associated osteonecrosis of the jaw, from conservative treatments to surgical procedures of varying levels of invasiveness, which are sometimes supplemented with adjuvant therapies.
   Objectives: The objective of this article is to group the therapeutic options for osteonecrosis of the jaw (ONJ) into seven different protocols and to evaluate their effectiveness in relation to stage of ONJ.
   Material and Methods: A literature review was carried out in PubMed following the PRISMA criteria. A total of 47 were collected after compiling a series of variables that define ONJ, applied treatments, and the clinical results obtained.
   Results and Discussion: The 47 articles selected have a low to average estimated risk of bias and are of moderate to good quality. According to the data obtained, Protocol 3 (conservative treatment, clinical and radiological follow up, minimally invasive surgical treatment, and adjuvant therapies) is the most favorable approach for ONJ lesions caused by oral bisphosphonates. For lesions caused by intravenous bisphosphonates, Protocol 2 (conservative treatment, clinical and radiological follow up, minimally invasive surgical treatment, and no adjuvant therapies) is the best approach. When comparing the different stages of ONJ, Protocol 1 (conservative treatment, clinical and radiological follow up) promotes better healing of Stage 1 ONJ lesions caused by orally administered bisphosphonates, and Protocol 3 is recommended for Stage II. For ONJ lesions attributable to intravenous bisphosphonates, Protocol 7 (conservative treatment, clinical and radiological follow up, and adjuvant therapies) provides the best results in Stage 0; in Stages I, II, and III, Protocol 1 gives better results.
C1 [Bermudez Bejarano, Elena Beatriz; Gutierrez Corrales, Aida; Romero Ruiz, Manuel Maria; Gutierrez Perez, Jose Luis; Torres Lagares, Daniel] Univ Seville, Sch Dent, Oral Surg, Seville, Spain.
   [Serrera Figallo, Maria Angeles; Machuca Portillo, Guillermo] Univ Seville, Sch Dent, Integrated Dent & Patients Special Dis, Seville, Spain.
   [Castillo de Oyaguee, Raquel] Univ Complutense Madrid, Sch Dent, Dept Stomatol, E 28040 Madrid, Spain.
C3 University of Sevilla; University of Sevilla; Complutense University of
   Madrid
RP Torres Lagares, D (通讯作者)，Univ Seville, Sch Dent, C Avicena S N, E 41009 Seville, Spain.
EM danieltl@us.es
RI Torres Lagares, Daniel/A 5524 2008; Serrera Figallo, Maria
   Angeles/W 8982 2018; Castillo, Raquel/AAH 3983 2019; Serrera Figallo,
   Maria Angeles/W 8982 2018; Machuca Portillo, Guillermo/L 2511 2016
OI Gutierrez Corrales, Aida/0000 0002 2362 8285; Serrera Figallo, Maria
   Angeles/0000 0002 1279 4237; Gutierrez Perez, Jose
   Luis/0000 0003 2624 1454; CASTILLO DE OYAGUE,
   RAQUEL/0000 0002 7955 3323; Machuca Portillo,
   Guillermo/0000 0003 1605 8699
CR Alons K, 2009, ORAL SURG ORAL MED O, V107, pE1, DOI 10.1016/j.tripleo.2008.09.021
   Anavi Lev K, 2013, OR SURG OR MED OR PA, V115, P660, DOI 10.1016/j.oooo.2013.03.001
   Angiero F, 2009, LASER MED SCI, V24, P849, DOI 10.1007/s10103 009 0654 7
   Atalay B, 2011, LASER MED SCI, V26, P815, DOI 10.1007/s10103 011 0974 2
   Badros A, 2006, J CLIN ONCOL, V24, P945, DOI 10.1200/JCO.2005.04.2465
   Bagan J, 2009, ORAL ONCOL, V45, P551, DOI 10.1016/j.oraloncology.2009.01.002
   Bedogni A, 2011, ORAL ONCOL, V47, P420, DOI 10.1016/j.oraloncology.2011.02.024
   Beninati F, 2013, MED ORAL PATOL ORAL, V18, pE752, DOI 10.4317/medoral.18076
   Blus C, 2013, OPEN DENT J, V7, P94, DOI 10.2174/1874210601307010094
   Bocanegra Pérez S, 2012, INT J ORAL MAX SURG, V41, P1410, DOI 10.1016/j.ijom.2012.04.020
   Colella G, 2009, J ORAL MAXIL SURG, V67, P2698, DOI 10.1016/j.joms.2009.07.097
   Curi MM, 2011, J ORAL MAXIL SURG, V69, P2465, DOI 10.1016/j.joms.2011.02.078
   Epstein MS, 2010, ORAL SURG ORAL MED O, V110, P593, DOI 10.1016/j.tripleo.2010.05.067
   Ferlito S, 2011, J ORAL MAXIL SURG, V69, pE1, DOI 10.1016/j.joms.2010.10.055
   Ferlito S, 2012, BRIT J ORAL MAX SURG, V50, P425, DOI 10.1016/j.bjoms.2011.08.004
   Fliefel R, 2015, INT J ORAL MAX SURG, V44, P568, DOI 10.1016/j.ijom.2015.01.026
   Freiberger JJ, 2007, J ORAL MAXIL SURG, V65, P1321, DOI 10.1016/j.joms.2007.03.019
   Gavaldá C, 2016, MED ORAL PATOL ORAL, V21, pE260, DOI 10.4317/medoral.21001
   Hanasono MM, 2013, JAMA OTOLARYNGOL, V139, P1135, DOI 10.1001/jamaoto.2013.4474
   Hoefert S, 2011, J ORAL MAXIL SURG, V69, P362, DOI 10.1016/j.joms.2010.06.200
   Holzinger D, 2013, ORAL ONCOL, V49, P66, DOI 10.1016/j.oraloncology.2012.07.008
   Jabbour Z, 2012, INT J ORAL MAX SURG, V41, P1404, DOI 10.1016/j.ijom.2012.05.012
   Junquera L, 2009, AM J OTOLARYNG, V30, P390, DOI 10.1016/j.amjoto.2008.07.014
   Kos M, 2010, INT J ORAL MAX SURG, V39, P1097, DOI 10.1016/j.ijom.2010.04.054
   Leizaola Cardesa IO, 2016, MED ORAL PATOL ORAL, V21, pE236, DOI 10.4317/medoral.20927
   Longo F, 2014, INT J DENT, V2014, DOI 10.1155/2014/298945
   Longobardi G, 2007, J CRANIOFAC SURG, V18, P1012, DOI 10.1097/scs.0b013e3180f611ef
   Manfredi M, 2011, INT J ORAL MAX SURG, V40, P277, DOI 10.1016/j.ijom.2010.11.002
   Markose G, 2009, BRIT J ORAL MAX SURG, V47, P294, DOI 10.1016/j.bjoms.2009.01.007
   Martins MAT, 2012, ORAL ONCOL, V48, P79, DOI 10.1016/j.oraloncology.2011.08.010
   Melea PI, 2014, INT J DENT, V2014, DOI 10.1155/2014/427273
   Mozzati M, 2012, ORAL ONCOL, V48, P817, DOI 10.1016/j.oraloncology.2012.03.009
   Nocini PF, 2009, EJSO EUR J SURG ONC, V35, P373, DOI 10.1016/j.ejso.2008.05.002
   Pelaz A, 2014, MED ORAL PATOL ORAL, V19, pE320, DOI 10.4317/medoral.19458
   Ripamonti CI, 2011, ORAL ONCOL, V47, P185, DOI 10.1016/j.oraloncology.2011.01.002
   Rugani P, 2015, CLIN ORAL INVEST, V19, P1329, DOI 10.1007/s00784 014 1384 1
   Rugani P, 2010, ORAL SURG ORAL MED O, V110, pE1, DOI 10.1016/j.tripleo.2010.08.013
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Saussez S, 2009, LARYNGOSCOPE, V119, P323, DOI 10.1002/lary.20076
   Schafer AL, 2012, J CLIN ENDOCR METAB, V97, P3522, DOI 10.1210/jc.2012 1844
   Schubert M, 2012, ORAL ONCOL, V48, P349, DOI 10.1016/j.oraloncology.2011.11.004
   Scoletta M, 2013, J ORAL MAXIL SURG, V71, P994, DOI 10.1016/j.joms.2013.01.006
   Seth R, 2010, LARYNGOSCOPE, V120, P2165, DOI 10.1002/lary.21062
   Stanton DC, 2009, J ORAL MAXIL SURG, V67, P943, DOI 10.1016/j.joms.2008.12.057
   Stockmann P, 2010, SUPPORT CARE CANCER, V18, P449, DOI 10.1007/s00520 009 0688 1
   Stübinger S, 2009, LASER SURG MED, V41, P26, DOI 10.1002/lsm.20730
   Thumbigere Math V, 2012, AM J CLIN ONCOL CANC, V35, P386, DOI 10.1097/COC.0b013e3182155fcb
   Van den Wyngaert T, 2009, ANN ONCOL, V20, P331, DOI 10.1093/annonc/mdn630
   Vescovi P, 2007, BRIT J ORAL MAX SURG, V45, P628, DOI 10.1016/j.bjoms.2007.03.016
   Vescovi P, 2012, J ORAL PATHOL MED, V41, P214, DOI 10.1111/j.1600 0714.2011.01091.x
   Vescovi P, 2011, ORAL ONCOL, V47, P191, DOI 10.1016/j.oraloncology.2010.11.007
   Vidal Real C, 2015, MED ORAL PATOL ORAL, V20, pE267, DOI 10.4317/medoral.20092
   Williamson RA, 2010, INT J ORAL MAX SURG, V39, P251, DOI 10.1016/j.ijom.2009.11.014
   Wutzl A, 2012, HEAD NECK J SCI SPEC, V34, P194, DOI 10.1002/hed.21708
NR 54
TC 13
Z9 14
U1 0
U2 5
PU MEDICINA ORAL S L
PI VALENCIA
PA CALLE DANIEL BALACIART N 4 PTA 17, VALENCIA, 46020, SPAIN
SN 1698 6946
J9 MED ORAL PATOL ORAL
JI Med. Oral Patol. Oral Cir. Bucal
PD JAN 1
PY 2017
VL 22
IS 1
BP E43
EP E57
DI 10.4317/medoral.21477
PG 15
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA EN9YZ
UT WOS:000396356800007
PM 27918742
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Kang, H
   Chang, W
   Hurley, M
   Vignery, A
   Wu, DQ
AF Kang, Heeseog
   Chang, Woochul
   Hurley, Marja
   Vignery, Agnes
   Wu, Dianqing
TI Important roles of PI3Kγ in osteoclastogenesis and bone homeostasis
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE chemokine; signaling; apoptosis
ID KAPPA B LIGAND; RESISTANT ACID PHOSPHATASE; RECEPTOR ACTIVATOR;
   CALCITONIN RECEPTOR; DIFFERENTIATION; FUSION; 3 KINASE GAMMA;
   INFLAMMATION; MIP 1 GAMMA; INHIBITION
AB G protein coupled receptor regulated PI3K gamma is abundantly expressed in myeloid cells and has been implicated as a promising drug target to treat various inflammatory diseases. However, its role in bone homeostasis has not been investigated, despite the fact that osteoclasts are derived from myeloid lineage. We therefore carried out thorough bone phenotypic characterization of a PI3K gamma deficient mouse line and found that PI3K gamma deficient mice had high bone mass. Our analyses further revealed that PI3K gamma deficiency did not affect bone formation because no significant changes in osteoblast number and bone formation rate were observed. Instead, the lack of PI3K gamma was associated with decreased bone resorption, as evidenced by decreased osteoclast number in vivo and impaired osteoclast formation in vitro. The decreased osteoclast formation was accompanied by down regulated expression of osteoclastogenic genes, compromised chemokine receptor signaling, and an increase in apoptosis during osteoclast differentiation. Together, these data suggest that PI3K gamma regulates bone homeostasis by modulating osteoclastogenesis. Our study also suggests that inhibition of PI3K gamma, which is being considered as a potential therapeutic strategy for treating chronic inflammatory disorders, may result in an increase in bone mass.
C1 [Kang, Heeseog; Chang, Woochul; Wu, Dianqing] Yale Univ, Sch Med, Vasc Biol & Therapeut Program, New Haven, CT 06520 USA.
   [Kang, Heeseog; Chang, Woochul; Wu, Dianqing] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA.
   [Hurley, Marja] Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT 06030 USA.
   [Vignery, Agnes] Yale Univ, Sch Med, Dept Med & Cell Biol, New Haven, CT 06520 USA.
C3 Yale University; Yale University; University of Connecticut; Yale
   University
RP Wu, DQ (通讯作者)，Yale Univ, Sch Med, Vasc Biol & Therapeut Program, 333 Cedar St, New Haven, CT 06520 USA.
EM dan.wu@yale.edu
RI ; Kang, Heeseog/LJL 5469 2024
OI Chang, Woochul/0000 0001 7367 2586; 
FU National Institutes of Health [AR051476]; Yale Core Center for
   Musculoskeletal Diseases [P30 AR04603211]
FX We thank Michelle Orsulak for technical assistance and the Yale Core
   Center for Musculoskeletal Diseases for bone analyses. This work is
   supported by National Institutes of Health Grant AR051476 (to D.W.) and
   Pilot Grant P30 AR04603211 from the Yale Core Center for Musculoskeletal
   Diseases.
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Barber DF, 2005, NAT MED, V11, P933, DOI 10.1038/nm1291
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bozec A, 2008, NATURE, V454, P221, DOI 10.1038/nature07019
   Brock C, 2003, J CELL BIOL, V160, P89, DOI 10.1083/jcb.200210115
   Camps M, 2005, NAT MED, V11, P936, DOI 10.1038/nm1284
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   Hildebrand TOR, 1997, Comput Methods Biomech Biomed Engin, V1, P15, DOI 10.1080/01495739708936692
   Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049
   Jones GE, 2003, EXP CELL RES, V290, P120, DOI 10.1016/S0014 4827(03)00318 5
   Kim MS, 2006, J BIOL CHEM, V281, P1274, DOI 10.1074/jbc.M510156200
   Kim MS, 2005, J BIOL CHEM, V280, P16163, DOI 10.1074/jbc.M412713200
   Kim N, 2002, J EXP MED, V195, P201, DOI 10.1084/jem.20011681
   Laffargue M, 2002, IMMUNITY, V16, P441, DOI 10.1016/S1074 7613(02)00282 0
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046
   MARTIN TJ, 1995, J NUTR, V125, pS2009, DOI 10.1093/jn/125.suppl_7.2009S
   Munugalavadla V, 2008, MOL CELL BIOL, V28, P7182, DOI 10.1128/MCB.00920 08
   NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0
   Oddie GW, 2000, BONE, V27, P575, DOI 10.1016/S8756 3282(00)00368 9
   Okamatsu Y, 2004, J IMMUNOL, V173, P2084, DOI 10.4049/jimmunol.173.3.2084
   Ravindran C, 2010, CELL IMMUNOL, V260, P113, DOI 10.1016/j.cellimm.2009.10.001
   Roodman GD, 2006, ANN NY ACAD SCI, V1068, P100, DOI 10.1196/annals.1346.013
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567
   Suda T, 1997, J BONE MINER RES, V12, P869, DOI 10.1359/jbmr.1997.12.6.869
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yang MH, 2006, BLOOD, V107, P2262, DOI 10.1182/blood 2005 08 3365
   Yavropoulou M. P., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P204
   Yu XF, 2003, J BONE MINER RES, V18, P1404, DOI 10.1359/jbmr.2003.18.8.1404
NR 32
TC 29
Z9 32
U1 0
U2 3
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 20
PY 2010
VL 107
IS 29
BP 12901
EP 12906
DI 10.1073/pnas.1001499107
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 628TJ
UT WOS:000280144500037
PM 20616072
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Voskaridou, E
   Christoulas, D
   Xirakia, C
   Varvagiannis, K
   Boutsikas, G
   Bilalis, A
   Kastritis, E
   Papatheodorou, A
   Terpos, E
AF Voskaridou, Ersi
   Christoulas, Dimitrios
   Xirakia, Charoula
   Varvagiannis, Konstantinos
   Boutsikas, Georgios
   Bilalis, Antonios
   Kastritis, Efstathios
   Papatheodorou, Athanasios
   Terpos, Evangelos
TI Serum Dickkopf 1 is increased and correlates with reduced bone mineral
   density in patients with thalassemia induced osteoporosis. Reduction
   post zoledronic acid administration
SO HAEMATOLOGICA THE HEMATOLOGY JOURNAL
LA English
DT Article; Proceedings Paper
CT 13th Congress of the European Hematology Association
CY JUN 12 15, 2008
CL Copenhagen, DENMARK
SP European Hematol Assoc
DE thalassemia; osteoporosis; Dickkopf 1; osteoblast; zoledronic acid
ID OSTEOPROTEGERIN; EXPRESSION; MYELOMA; MASS
AB Dickkopf 1 is an inhibitor of Wnt signaling, which is crucial for osteoblast differentiation. We evaluated serum levels of Dickkopf 1 in 66 patients with thalassemia induced osteoporosis who received therapy with zoledronic acid in a placebo controlled, randomized trial. At baseline, thalassemia patients had increased serum levels of Dickkopf 1 that correlated with reduced bone mineral density of the lumbar spine and the distal radius. High Dickkopf 1 also correlated with increased bone resorption and reduced bone formation markets. Zoledronic acid produced a reduction in serum Dickkopf 1, which was associated with bone mineral density increase after 12 months of therapy. On the contrary, placebo group showed a borderline increase of Dickkopf 1, which was higher in patients who showed deterioration in pain scores. These results suggest that Dickkopf 1 is implicated in the pathogenesis of osteoporosis in thalassemia and reveal Dickkopf 1 as a possible target for the development of novel agents for the management of thalassemia induced osteoporosis (ClinicalTrials. got., Identifier: NCT00346242).
C1 252 Gen AF Hosp, Dept Med Res, GR 11526 Athens, Greece.
   [Kastritis, Efstathios] Univ Athens, Sch Med, Dept Clin Therapeut, GR 11527 Athens, Greece.
   [Voskaridou, Ersi; Xirakia, Charoula; Varvagiannis, Konstantinos; Bilalis, Antonios] Laikon Gen Hosp, Thalassemia Ctr, Athens, Greece.
C3 National & Kapodistrian University of Athens; Laiko General Hospital
RP Terpos, E (通讯作者)，252 Gen AF Hosp, Dept Med Res, 3 Kanellopoulou St, GR 11526 Athens, Greece.
EM eterpos@hotmail.com
RI ; Terpos, Evangelos/AAD 3667 2019; Kastritis, Efstathios/AAD 3656 2019
OI Kastritis, Efstathios/0000 0001 8191 5832; Terpos,
   Evangelos/0000 0001 5133 1422; 
CR Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Gilfillan CP, 2006, CALCIFIED TISSUE INT, V79, P138, DOI 10.1007/s00223 006 0314 x
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Lala R, 1998, J PEDIATR ENDOCR MET, V11, P785
   MacDonald BT, 2007, BONE, V41, P331, DOI 10.1016/j.bone.2007.05.009
   Morabito N, 2007, BONE, V40, P1588, DOI 10.1016/j.bone.2007.02.020
   Perifanis V, 2007, ANN HEMATOL, V86, P23, DOI 10.1007/s00277 006 0180 7
   Pinzone JJ, 2009, BLOOD, V113, P517, DOI 10.1182/blood 2008 03 145169
   Politou MC, 2006, INT J CANCER, V119, P1728, DOI 10.1002/ijc.22033
   Qiang YW, 2008, BLOOD, V112, P196, DOI 10.1182/blood 2008 01 132134
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Voorzanger Rousselot N, 2007, BRIT J CANCER, V97, P964, DOI 10.1038/sj.bjc.6603959
   Voskaridou E, 2005, EUR J HAEMATOL, V74, P359, DOI 10.1111/j.1600 0609.2004.00395.x
   Voskaridou E, 2004, BRIT J HAEMATOL, V127, P127, DOI 10.1111/j.1365 2141.2004.05143.x
   Voskaridou E, 2003, BRIT J HAEMATOL, V123, P730, DOI 10.1046/j.1365 2141.2003.04657.x
   Voskaridou E, 2001, BRIT J HAEMATOL, V112, P36, DOI 10.1046/j.1365 2141.2001.02549.x
   Voskaridou E, 2008, HAEMATOL HEMATOL J, V93, P1588, DOI 10.3324/haematol.12849
   Voskaridou E, 2006, HAEMATOLOGICA, V91, P1193
   Wang FS, 2007, BONE, V40, P485, DOI 10.1016/j.bone.2006.09.004
   Zhang YH, 2004, MOL CELL BIOL, V24, P4677, DOI 10.1128/MCB.24.11.4677 4684.2004
NR 20
TC 47
Z9 48
U1 0
U2 1
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390 6078
EI 1592 8721
J9 HAEMATOL HEMATOL J
JI Haematol Hematol. J.
PD MAY
PY 2009
VL 94
IS 5
BP 725
EP 728
DI 10.3324/haematol.2008.000893
PG 4
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Hematology
GA 445JH
UT WOS:000266046600019
PM 19407319
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Savino, S
   Toscano, A
   Purgatorio, R
   Profilo, E
   Laghezza, A
   Tortorella, P
   Angelelli, M
   Cellamare, S
   Scala, R
   Tricarico, D
   Marobbio, CMT
   Perna, F
   Vitale, P
   Agamennone, M
   Dimiccoli, V
   Tolomeo, A
   Scilimati, A
AF Savino, Salvatore
   Toscano, Annamaria
   Purgatorio, Rosa
   Profilo, Emanuela
   Laghezza, Antonio
   Tortorella, Paolo
   Angelelli, Mariacristina
   Cellamare, Saverio
   Scala, Rosa
   Tricarico, Domenico
   Marobbio, Carlo Marya Thomas
   Perna, Filippo
   Vitale, Paola
   Agamennone, Mariangela
   Dimiccoli, Vincenzo
   Tolomeo, Anna
   Scilimati, Antonio
TI Novel bisphosphonates with antiresorptive effect in bone mineralization
   and osteoclastogenesis
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Bisphosphonates; Cancer; Bone mineralization; Human farnesyl diphosphate
   synthase; Human geranylgeranyl diphosphate synthase; Cell lines;
   Hydroxyapatite
ID FARNESYL DIPHOSPHATE SYNTHASE; NITROGEN CONTAINING BISPHOSPHONATES;
   GERANYLGERANYL PYROPHOSPHATE SYNTHASE; IN VITRO;
   DICTYOSTELIUM DISCOIDEUM; CLINICAL EFFICACY; CRYSTAL STRUCTURE;
   STRUCTURAL BASIS; INHIBITION; MECHANISMS
AB Bisphosphonates such as zoledronic, alendronic and risedronic acids are a class of drugs clinically used to prevent bone density loss and osteoporosis. Novel P C P bisphosphonates were synthesized for targeting human farnesyl pyrophosphate synthase (hFPPS) and human geranylgeranyl pyrophosphate synthase (hGGPPS), key enzymes of the mevalonate pathway, and capable of anti proliferative action on a number of cell lines (PC3, MG63, MC3T3, RAW 264.7, J774A.1, bone marrow cells and their co colture with PC3) involved in bone homeostasis, bone formation and death. Among sixteen compounds, [1 hydroxy 2 (pyrimidin 2 ylamino)ethane 1,1 diyl]bis(phosphonic acid) (10) was effective in reducing PC3 and RAW 264.7 cell number in crystal violet and cell dehydrogenase activity assays at 100 mu M concentration. 10 reduced differentiated osteoclasts number similarly with zoledronic acid in osteoclastogenesis assay. At nanomolar concentrations, 10 was more effective than zoledronic acid in inducing mineralization in MC3T3 and murine bone marrow cells. Further, 10 significantly inhibited the activity of hFPPS showing an IC50 of 0.31 mu M and a remarkable hydroxyapatite binding of 90%. Docking calculations were performed identifying putative interactions between some representative novel bisphosphonates and both hFPPS and hGGPPS. Then, 10 was found to behave similarly or even better than zoledronic acid as a anti resorptive agent. (C) 2018 Elsevier Masson SAS. All rights reserved.
C1 [Savino, Salvatore; Toscano, Annamaria; Purgatorio, Rosa; Profilo, Emanuela; Laghezza, Antonio; Tortorella, Paolo; Angelelli, Mariacristina; Cellamare, Saverio; Scala, Rosa; Tricarico, Domenico; Perna, Filippo; Vitale, Paola; Scilimati, Antonio] Univ Bari A Moro, Dept Pharm Pharmaceut Sci, Via E Orabona 4,70125, I 70125 Bari, Italy.
   [Marobbio, Carlo Marya Thomas] Univ Bari A Moro, Dept Biosci Biotechnol & Biopharmaceut, Via E Orabona 4,70125, I 70125 Bari, Italy.
   [Agamennone, Mariangela] Univ Chieti Gabriele Annunzio, Dept Pharm, Via Vestini 31, I 66100 Chieti, Italy.
   [Dimiccoli, Vincenzo; Tolomeo, Anna] ITEL Telecomun Sr1, Via A Labriola, I 70037 Bari, Italy.
C3 Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari
   Aldo Moro; G d'Annunzio University of Chieti Pescara
RP Scilimati, A (通讯作者)，Univ Bari A Moro, Dept Pharm Pharmaceut Sci, Via E Orabona 4,70125, I 70125 Bari, Italy.
EM antonio.scilimati@uniba.it
RI Purgatorio, Rosa/ABH 3216 2020; VITALE, PAOLA/A 3370 2014; vitale,
   paola/A 3370 2014; MAROBBIO, Carlo/G 5775 2015; Perna,
   Filippo/I 4336 2019; Laghezza, Antonio/F 7420 2014; Agamennone,
   Mariangela/J 2916 2012
OI Purgatorio, Rosa/0000 0003 1002 5087; vitale, paola/0000 0001 8132 2893;
   Agamennone, Mariangela/0000 0001 5198 0051; Scilimati,
   Antonio/0000 0003 2740 6425; Laghezza, Antonio/0000 0001 6221 6155; 
FU University of Bari; Programma Regione Puglia Italy: Avviso Regionale  
   Cluster Tecnologici Regionali per l'Innovazione 2015 2017, Project
   "Cluster in Bioimaging" [QZYCUM0]
FX This work was supported by research funds through the University of Bari
   and Programma Regione Puglia Italy: Avviso Regionale   Cluster
   Tecnologici Regionali per l'Innovazione 2015 2017, Project "Cluster in
   Bioimaging" code QZYCUM0.
CR Ankush M. T., 2010, Novel Process for Preparing Risedronic Acid, Patent No. [US012066, 012066]
   [Anonymous], 2014, BONEKEY REP, DOI [10.1038/bonekey.2014.24, DOI 10.1038/BONEKEY.2014.24]
   Bellido T, 2011, BONE, V49, P50, DOI 10.1016/j.bone.2010.08.008
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Bigi A, 2018, J FUNCT BIOMATER, V9, DOI 10.3390/jfb9010006
   Burridge K, 2006, NAT CELL BIOL, V8, P781, DOI 10.1038/ncb0806 781
   Cao R, 2008, PROTEINS, V73, P431, DOI 10.1002/prot.22066
   Cecchini MG., 2005, EAU Update Series, V3, P214
   Chen CKM, 2008, J MED CHEM, V51, P5594, DOI 10.1021/jm800325y
   Clézardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008 5472.CAN 05 0264
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Curci A., 2016, CURR TOP PHARMACOL, V20, P113
   Dozier JK, 2012, ANAL BIOCHEM, V421, P158, DOI 10.1016/j.ab.2011.10.038
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Dunford JE, 2008, J MED CHEM, V51, P2187, DOI 10.1021/jm7015733
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Ebetino FH, 1998, REV CONTEMP PHARMACO, V9, P233
   Feoktistova Maria, 2016, Cold Spring Harb Protoc, V2016, DOI 10.1101/pdb.prot087379
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Frith JC, 1997, J BONE MINER RES, V12, P1358, DOI 10.1359/jbmr.1997.12.9.1358
   Gao JB, 2010, CHEM COMMUN, V46, P5340, DOI 10.1039/c0cc00992j
   Giannuzzi G, 2014, MOL BIOTECHNOL, V56, P157, DOI 10.1007/s12033 013 9691 3
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Grove JE, 2000, J BONE MINER RES, V15, P971, DOI 10.1359/jbmr.2000.15.5.971
   Hosfield DJ, 2004, J BIOL CHEM, V279, P8526, DOI 10.1074/jbc.C300511200
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Ito M, 1999, BONE, V25, P447, DOI 10.1016/S8756 3282(99)00197 0
   Jung Yoon C., 2017, INT J MOL MED, V39, P539
   Kas M., 2013, Process for Making Zoledronic Acid, Patent No. [EP2192126B1, 2192126]
   Kavanagh KL, 2006, J BIOL CHEM, V281, P22004, DOI 10.1074/jbc.M602603200
   Kieczykowski GR, 1995, J ORG CHEM, V60, P8310, DOI 10.1021/jo00130a036
   Macedo F, 2017, ONCOL REV, V11, P43, DOI 10.4081/oncol.2017.321
   Maisano R, 2001, CRIT REV ONCOL HEMAT, V40, P239, DOI 10.1016/S1040 8428(01)00092 0
   Mao JH, 2006, J AM CHEM SOC, V128, P14485, DOI 10.1021/ja061737c
   Meyer D., 1998, Polyaminated Ligands and Metal Complexes Thereof, Patent No. [US5712389, 5712389]
   Ohno K, 2011, CURR MED CHEM, V18, P220, DOI 10.2174/092986711794088335
   PELORGEAS S, 1992, BIOCHEM PHARMACOL, V44, P2157, DOI 10.1016/0006 2952(92)90342 G
   Puljula E, 2015, ACS MED CHEM LETT, V6, P397, DOI 10.1021/ml5004603
   Ragavendran JV, 2007, EUR J MED CHEM, V42, P146, DOI 10.1016/j.ejmech.2006.08.010
   Rodan GA, 1998, ANNU REV PHARMACOL, V38, P375, DOI 10.1146/annurev.pharmtox.38.1.375
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rogers MJ, 1997, PHARMACEUT RES, V14, P625, DOI 10.1023/A:1012157212793
   Rogers MJ, 1997, CANCER, V80, P1652, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1652::AID CNCR15>3.0.CO;2 Z
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Rubino MT, 2011, CHEMMEDCHEM, V6, P1258, DOI 10.1002/cmdc.201000540
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Russell RGG, 1999, J BONE MINER RES, V14, P53, DOI 10.1002/jbmr.5650140212
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Schrodinger Release 2017 4, 2017, SCHROD REL 2017 4 MA
   Selander KS, 1996, MOL PHARMACOL, V50, P1127
   Selvaggi G, 2005, CRIT REV ONCOL HEMAT, V56, P365, DOI 10.1016/j.critrevonc.2005.03.011
   Sen SE, 2007, INSECT BIOCHEM MOLEC, V37, P819, DOI 10.1016/j.ibmb.2007.05.012
   Stefanucci A, 2015, MED CHEM, V11, P417, DOI 10.2174/1573406410666141226132630
   Sun XL, 2017, HUM CELL, V30, P216, DOI 10.1007/s13577 017 0167 9
   Szabo CM, 2002, J MED CHEM, V45, P2185, DOI 10.1021/jm010412y
   Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153
   TARSHIS LC, 1994, BIOCHEMISTRY US, V33, P10871, DOI 10.1021/bi00202a004
   Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018
   Tauro M, 2013, BIOORGAN MED CHEM, V21, P6456, DOI 10.1016/j.bmc.2013.08.054
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Wiemer AJ, 2007, BIOCHEM BIOPH RES CO, V353, P921, DOI 10.1016/j.bbrc.2006.12.094
   Yin FL, 2006, J AM CHEM SOC, V128, P3524, DOI 10.1021/ja0601639
   Yu TS, 2016, DIS MODEL MECH, V9, P155, DOI 10.1242/dmm.019091
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
NR 67
TC 23
Z9 24
U1 0
U2 30
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0223 5234
EI 1768 3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD OCT 5
PY 2018
VL 158
BP 184
EP 200
DI 10.1016/j.ejmech.2018.08.044
PG 17
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA GX9BR
UT WOS:000448094000014
PM 30216851
DA 2025 08 17
ER

PT J
AU Kuchuk, M
   Addison, CL
   Clemons, M
   Kuchuk, I
   Wheatley Price, P
AF Kuchuk, Michael
   Addison, Christina L.
   Clemons, Mark
   Kuchuk, Iryna
   Wheatley Price, Paul
TI Incidence and consequences of bone metastases in lung cancer patients
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Article
DE Non small cell lung cancer; Bone metastasis; Skeletal related event;
   Bisphosphonates and denosumab
ID SKELETAL RELATED EVENTS; LONG TERM EFFICACY; ZOLEDRONIC ACID;
   DOUBLE BLIND; BREAST CANCER; PALLIATIVE RADIOTHERAPY; 1ST LINE
   TREATMENT; PROSTATE CANCER; SOLID TUMORS; OPEN LABEL
AB Background: Bone metastases (BM) are common in NSCLC patients. Despite some potential positive effects of bone targeted therapies, their use in NSCLC is infrequent, which may relate to the overall poor prognosis of advanced lung cancer. We reviewed the literature to evaluate the incidence, consequences and use of bone targeting agents in lung cancer patients with BM in both the trial and non trial clinical setting.
   Methods: Published prospective and retrospective papers investigating lung cancer and BM, in trial and non trial settings, were identified and are discussed in this review.
   Results: BM are common in patients with advanced lung cancer and often present symptomatically with pain and skeletal related events (SREs). Patients with high bone turnover marker levels, multiple BM, and history of pathological fractures have shorter overall survival. In randomized studies bone targeted therapies reduced the risk of SREs and prolonged the time to first SRE. The use of bonetargeted agents may also be associated with a survival benefit.
   Conclusion: BM are a common problem in advanced lung cancer. While the benefits of bone targeted therapies have been demonstrated, their use is limited in non trial populations. If better predictive markers of individual risk were available this might increase the appropriate use of bone targeted agents. (C) 2012 Elsevier GmbH. All rights reserved.
C1 [Kuchuk, Michael; Clemons, Mark; Kuchuk, Iryna; Wheatley Price, Paul] Univ Ottawa, Div Med Oncol, Ottawa, ON, Canada.
   [Kuchuk, Michael; Clemons, Mark; Kuchuk, Iryna; Wheatley Price, Paul] Ottawa Hosp Canc Ctr, Ottawa, ON K1H 8L6, Canada.
   [Addison, Christina L.; Clemons, Mark] Ottawa Hosp Res Inst, Program Canc Therapeut, Ottawa, ON, Canada.
   [Addison, Christina L.] Univ Ottawa, Dept Med & Biochem, Ottawa, ON, Canada.
   [Addison, Christina L.] Univ Ottawa, Dept Microbiol & Immunol, Ottawa, ON, Canada.
C3 University of Ottawa; University of Ottawa; Ottawa Hospital Research
   Institute; University of Ottawa; Ottawa Hospital Research Institute;
   University of Ottawa; University of Ottawa
RP Wheatley Price, P (通讯作者)，Ottawa Hosp Canc Ctr, Div Med Oncol, Dept Med, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.
EM pwheatleyprice@toh.on.ca
OI Wheatley Price, Paul/0000 0002 3725 9767
CR Ali SM, 2004, ANN ONCOL, V15, P455, DOI 10.1093/annonc/mdh089
   [Anonymous], J CLIN ONCOLOGY OFFI
   [Anonymous], J CLIN ONCOLOGY OFFI
   [Anonymous], J CLIN ONCOLOGY OFFI
   [Anonymous], LUNG CANC AMSTERDAM
   [Anonymous], SUPPORTIVE CARE CANC
   Chow E, 2012, CLIN ONCOL UK, V24, P112, DOI 10.1016/j.clon.2011.11.004
   Clines GA, 2011, CURR OPIN ENDOCRINOL, V18, P339, DOI 10.1097/MED.0b013e32834b4401
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   De Marinis F, 2009, J THORAC ONCOL, V4, P1280, DOI 10.1097/JTO.0b013e3181b68e5a
   Decroisette C, 2011, J THORAC ONCOL, V6, P576, DOI 10.1097/JTO.0b013e318206a1e3
   Delea T, 2004, ONCOLOGY BASEL, V67, P390, DOI 10.1159/000082923
   Delea TE, 2006, J THORAC ONCOL, V1, P571, DOI 10.1097/01243894 200607000 00012
   Haddad P, 2005, CLIN ONCOL UK, V17, P430, DOI 10.1016/j.clon.2005.03.012
   Hatoum HT, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.8106
   Henk Henry J, 2012, J Med Econ, V15, P195, DOI 10.3111/13696998.2011.650489
   Henk Henry J, 2012, J Med Econ, V15, P185, DOI 10.3111/13696998.2011.649324
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Heras P, 2011, AM J THER, V18, P340, DOI 10.1097/MJT.0b013e3181e70c38
   Hirsh V, 2008, J THORAC ONCOL, V3, P228, DOI 10.1097/JTO.0b013e3181651c0e
   Hirsh Vera, 2004, Clin Lung Cancer, V6, P170, DOI 10.3816/CLC.2004.n.030
   Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401
   Jemal A, 2007, CA CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Kagohashi K, 2003, INT J CLIN PRACT, V57, P184
   Kiagia M, 2006, ANTICANCER RES, V26, P3133
   Kosteva J, 2004, LUNG CANCER J IASLC, V46, pS45
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530
   Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558
   Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304 3959(96)03267 8
   MICHEL F, 1991, THORAX, V46, P469, DOI 10.1136/thx.46.7.469
   Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470 2045(09)70364 X
   Mystakidou K, 2008, J CANCER RES CLIN, V134, P1303, DOI 10.1007/s00432 008 0419 x
   Nieder C, 2010, BMC UROL, V10, DOI 10.1186/1471 2490 10 23
   Niikura N, 2011, ONCOLOGIST, V16, P155, DOI 10.1634/theoncologist.2010 0350
   NOTTEBAERT M, 1989, INT ORTHOP, V13, P119, DOI 10.1007/BF00266372
   Oefelein MG, 2002, J UROLOGY, V168, P1005, DOI 10.1016/S0022 5347(05)64561 2
   OSADA H, 1987, JPN J SURG, V17, P362, DOI 10.1007/BF02470635
   Pandya KJ, 2010, LUNG CANCER, V67, P330, DOI 10.1016/j.lungcan.2009.04.020
   Piga A, 1998, J EXP CLIN CANC RES, V17, P213
   Pockett RD, 2010, EUR J CANCER CARE, V19, P755, DOI 10.1111/j.1365 2354.2009.01135.x
   Quint LE, 1996, ANN THORAC SURG, V62, P246, DOI 10.1016/0003 4975(96)00220 2
   Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470 2045(11)70393 X
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Rosen LS, 2004, CANCER, V100, P2613, DOI 10.1002/cncr.20308
   Saad F, 2007, CANCER AM CANCER SOC, V110, P1860, DOI 10.1002/cncr.22991
   SALVATIERRA A, 1990, CHEST, V97, P1052, DOI 10.1378/chest.97.5.1052
   Scagliotti GV, 2012, J THORAC ONCOL, V7, P1823, DOI 10.1097/JTO.0b013e31826aec2b
   Sekine I, 2009, LUNG CANCER, V65, P219, DOI 10.1016/j.lungcan.2008.10.026
   Siegel R, 2012, CA CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Soo RA, 2011, J THORAC ONCOL, V6, P1030, DOI 10.1097/JTO.0b013e3182199c03
   Spizzo G, 2009, ANTICANCER RES, V29, P5245
   Stenbygaard LE, 1997, ACTA ONCOL, V36, P301, DOI 10.3109/02841869709001267
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Sugiura H, 2008, CLIN ORTHOP RELAT R, V466, P729, DOI 10.1007/s11999 007 0051 0
   Sun JM, 2011, LUNG CANCER, V71, P89, DOI 10.1016/j.lungcan.2010.04.003
   TORNYOS K, 1991, CLIN NUCL MED, V16, P107, DOI 10.1097/00003072 199102000 00009
   Tsuya A, 2007, LUNG CANCER, V57, P229, DOI 10.1016/j.lungcan.2007.03.013
   von Minckwitz G, 2005, BREAST CANCER RES TR, V89, P165, DOI 10.1007/s10549 004 1720 2
   Wu JSY, 2003, INT J RADIAT ONCOL, V55, P594, DOI 10.1016/S0360 3016(02)04147 0
   Yong M, 2011, BREAST CANCER RES TR, V129, P495, DOI 10.1007/s10549 011 1475 5
   Yu JL, 2011, ONCOLOGIST, V16, P1307, DOI 10.1634/theoncologist.2011 0079
   Zampa G, 2008, LUNG CANCER, V60, P452, DOI 10.1016/j.lungcan.2007.11.002
   Zarogoulidis K, 2009, INT J CANCER, V125, P1705, DOI 10.1002/ijc.24470
   Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470 2045(11)70184 X
NR 66
TC 74
Z9 79
U1 1
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2212 1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD FEB
PY 2013
VL 2
IS 1
BP 22
EP 29
DI 10.1016/j.jbo.2012.12.004
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA V37LM
UT WOS:000209277300004
PM 26909268
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Guerra, JM
   Hanes, MA
   Rasa, C
   Loganathan, N
   Innis Whitehouse, W
   Gutierrez, E
   Nair, S
   Banu, J
AF Guerra, Juan M.
   Hanes, Martha A.
   Rasa, Cordelia
   Loganathan, Nagarajan
   Innis Whitehouse, Wendy
   Gutierrez, Ednia
   Nair, Saraswathy
   Banu, Jameela
TI Modulation of bone turnover by Cissus quadrangularis after
   ovariectomy in rats
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Cissus quadrangularis; Postmenopausal bone loss; Static histomorphometry
   and bone strength; Bone biochemical markers; miRNA and qPCR
ID PETROLEUM ETHER EXTRACT; ANTIOSTEOPOROTIC ACTIVITY; POSTMENOPAUSAL
   WOMEN; ADIPOSE TISSUE; OSTEOPOROSIS; ADIPONECTIN; THERAPY; HORMONE;
   CONSTITUENTS; FLUCTUATION
AB In women, age related bone loss is associated with increased risk of bone fracture. Existing therapies are associated with severe side effects; thus, there is a need to find alternative medicines with less or optimal side effects. Cissus quadrangularis (CQ), an Ayurvedic medicine used to enhance fracture healing, was tested for its bone protective properties and studied to discern the mechanism by which it is beneficial to bone. Female Sprague Dawley rats were either sham operated or ovariectomized and were fed CQ for 3 months. Several biochemical markers, cytokines and hormones were assayed. Femur, tibia and lumbar vertebrae were subjected to pQCT and mu CT densitometry. MC3T3 cells were cultured, treated with CQ and used to analyze miRNA content and subjected to qPCR for gene expression analysis related to bone metabolism. CQO rats showed protected bone mass and microarchitecture of trabecular bone in the distal femoral metaphysis and the proximal tibial metaphysis. The lumbar vertebrae, however, showed no significant changes. Serum protein expression levels of P1NP increased and Trap5b and CTX levels decreased with in vivo CQ treatment. Some influence on the anti  and pro inflammatory markers was also observed. Significantly high level of estradiol in the CQO rats was observed. In vitro expression of a few genes related to bone metabolism showed that osteocalcin increased significantly. The other genes collagen I expression, SPP1, BMP2, DCAT1 decreased significantly. Certain miRNA that regulate bone turnover using the BMP pathway and Wnt signaling pathways were upregulated by CQ. qPCR after acute treatment with CQ showed significantly increased levels of osteocalcin and decreased levels of Wnt/beta catenin antagonist DCAT1. Overall, CQ protected the microarchitecture of the long bones from ovariectomy induced bone loss. This may be because of decreased inflammation and modulation through the BMP and Wnt signaling pathways. We conclude that CQ is a potential therapeutic agent to treat postmenopausal osteoporosis with no side effects.
C1 [Guerra, Juan M.; Gutierrez, Ednia; Nair, Saraswathy; Banu, Jameela] Univ Texas Rio Grande Valley, Dept Hlth & Biomed Sci, 1201 W Univ Dr, Edinburg, TX 78539 USA.
   [Guerra, Juan M.; Banu, Jameela] Univ Texas Rio Grande Valley, Dept Biol, 1201 W Univ Dr, Edinburg, TX 78539 USA.
   [Hanes, Martha A.] Univ Texas Hlth San Antonio, Dept Lab Anim Resources, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
   [Rasa, Cordelia] Univ Texas Rio Grande Valley, Dept Lab Anim Resources, 1201 W Univ Dr, Edinburg, TX 78539 USA.
   [Loganathan, Nagarajan] Poorveegam Res Trust, Pondicherry, India.
   [Innis Whitehouse, Wendy] Univ Texas Rio Grande Valley, Sch Med, 1201 W Univ Dr, Edinburg, TX 78539 USA.
C3 University of Texas System; University of Texas Rio Grande Valley;
   University of Texas System; University of Texas Rio Grande Valley;
   University of Texas System; University of Texas Health Science Center at
   San Antonio; University of Texas System; University of Texas Rio Grande
   Valley; University of Texas System; University of Texas Rio Grande
   Valley
RP Banu, J (通讯作者)，Univ Texas Rio Grande Valley, Dept Hlth & Biomed Sci, 1201 W Univ Dr, Edinburg, TX 78539 USA.; Banu, J (通讯作者)，Univ Texas Rio Grande Valley, Dept Biol, 1201 W Univ Dr, Edinburg, TX 78539 USA.
EM Jameela.banu@utrgv.edu
CR Abbott MJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134290
   Adesanya SA, 1999, J NAT PROD, V62, P1694, DOI 10.1021/np9902744
   [Anonymous], 2013, Using multivariate statistics
   Araneta MRG, 2009, J BONE MINER RES, V24, P2016, DOI [10.1359/JBMR.090519, 10.1359/jbmr.090519]
   Aswar UM, 2012, INDIAN J PHARMACOL, V44, P345, DOI 10.4103/0253 7613.96310
   Aswar UM, 2010, PHARMACOGN RES, V2, P138, DOI 10.4103/0974 8490.65507
   Banu J, 2013, HDB NUTR DIET MENOPA
   Banu J, 2012, J OSTEOPOROS, V2012, DOI 10.1155/2012/101206
   Bent S, 2004, AM J MED, V116, P478, DOI 10.1016/j.amjmed.2003.10.036
   Bhujade AM, 2012, J ETHNOPHARMACOL, V141, P989, DOI 10.1016/j.jep.2012.03.044
   BHUTANI KK, 1984, PHYTOCHEMISTRY, V23, P407, DOI 10.1016/S0031 9422(00)80341 6
   Blick SKA, 2008, DRUGS, V68, P2709, DOI 10.2165/0003495 200868180 00012
   Boyle RA, 2006, J THEOR BIOL, V242, P832, DOI 10.1016/j.jtbi.2006.05.003
   Casabiell X, 1998, J CLIN ENDOCR METAB, V83, P2149, DOI 10.1210/jc.83.6.2149
   Cheyette BNR, 2002, DEV CELL, V2, P449, DOI 10.1016/S1534 5807(02)00140 5
   Chu SC, 1999, LIFE SCI, V64, P2299, DOI 10.1016/S0024 3205(99)00181 2
   Combs TP, 2014, REV ENDOCR METAB DIS, V15, P137, DOI 10.1007/s11154 013 9280 6
   Das K, 2013, TUBERCULOSIS, V93, pS47, DOI 10.1016/S1472 9792(13)70010 6
   Debreczeni DE, 2011, J VIROL METHODS, V176, P32, DOI 10.1016/j.jviromet.2011.05.027
   Fratzl P, 1996, J CLIN INVEST, V97, P396, DOI 10.1172/JCI118428
   Gimble JM, 2012, CLIN BIOCHEM, V45, P874, DOI 10.1016/j.clinbiochem.2012.03.006
   GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003 4819 117 12 1016
   GUPTA MM, 1991, PHYTOCHEMISTRY, V30, P875, DOI 10.1016/0031 9422(91)85270 A
   Hair J. F., 2009, Multivariate data analysis, V7th ed.
   HAUSCHKA PV, 1989, ANAT REC, V224, P180, DOI 10.1002/ar.1092240208
   Hauser G, 1981, Harefuah, V100, P438
   ISHIMI Y, 1990, J IMMUNOL, V145, P3297
   Jainu M, 2010, PHARMACOGN MAG, V6, P225, DOI 10.4103/0973 1296.66941
   Jainu M, 2006, CHEM BIOL INTERACT, V161, P262, DOI 10.1016/j.cbi.2006.04.011
   JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100
   Kanazawa I, 2009, EUR J ENDOCRINOL, V160, P265, DOI 10.1530/EJE 08 0642
   Kothari SC, 2011, FOOD CHEM TOXICOL, V49, P3343, DOI 10.1016/j.fct.2011.09.029
   Lombardi G, 2015, ENDOCRINE, V48, P394, DOI 10.1007/s12020 014 0401 0
   McGarry KA, 2000, POSTGRAD MED, V108, P79, DOI 10.3810/pgm.2000.09.1.1206
   Mertler CARR, 2017, ADVANCED AND MULTIVA
   Meyers L., 2006, APPL MULTIVARIATE RE
   Montero M, 2012, J OSTEOPOROS, V2012, DOI 10.1155/2012/639427
   Mundy GR, 2007, NUTR REV, V65, pS147, DOI [10.1111/j.1753 4887.2007.tb00353.x, 10.1301/nr.2007.dec.S147 S151]
   Muthusami S, 2011, J CELL BIOCHEM, V112, P1035, DOI 10.1002/jcb.23016
   Nagani KV, 2011, INT J PHARM SCI RES, V2, P2856, DOI 10.13040/IJPSR.0975 8232.2(11).2856 62
   Naot D, 2017, CALCIFIED TISSUE INT, V100, P486, DOI 10.1007/s00223 016 0216 5
   National Osteoporosis Foundation, TYP OST MED
   NBJ, 2000, CALIFORNIA NUTR BUS, V2000, P1
   Panthong A, 2007, J ETHNOPHARMACOL, V110, P264, DOI 10.1016/j.jep.2006.09.018
   POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460 2075.1994.tb06368.x
   Potu BK, 2009, UPSALA J MED SCI, V114, P140, DOI 10.1080/03009730902891784
   Potu BK, 2009, CLINICS, V64, P993, DOI 10.1590/S1807 59322009001000010
   QUIGLEY MET, 1987, AM J OBSTET GYNECOL, V156, P1516
   Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763
   Rizzoli R, 2011, CALCIFIED TISSUE INT, V89, P91, DOI 10.1007/s00223 011 9499 8
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Rubin MR, 2005, DRUGS, V65, P2481, DOI 10.2165/00003495 200565170 00005
   Schepeler T, 2012, ONCOGENE, V31, P2750, DOI 10.1038/onc.2011.453
   Sharma U, 2014, INDIAN J CLIN BIOCHE, V29, P269, DOI 10.1007/s12291 013 0408 y
   Singh G, 2007, NAT PROD RES, V21, P522, DOI 10.1080/14786410601130471
   SINGH L M, 1962, Indian J Med Sci, V16, P926
   Srivastava AK, 2011, INT J PHARN RES DEV, V3, P207
   Stohs SJ, 2013, PHYTOTHER RES, V27, P1107, DOI 10.1002/ptr.4846
   Torgerson DJ, 2001, JAMA J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891
   Udayakumar R, 2004, Anc Sci Life, V24, P79
   UDUPA K. N., 1961, INDIAN JOUR MED SCI, V15, P551
   Wei JW, 2015, CURR OSTEOPOROS REP, V13, P180, DOI 10.1007/s11914 015 0267 y
   Williamson EM., 2002, Major Herbs of Ayurveda
   Williamson EM, 2004, ANC SCI LIFE, VXXIII, P33
   Zhang L, 2006, J BIOL CHEM, V281, P8607, DOI 10.1074/jbc.M600274200
   Zhu Qi, 2007, V382, P287, DOI 10.1007/978 1 59745 304 2_19
NR 66
TC 10
Z9 11
U1 0
U2 5
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD SEP
PY 2019
VL 37
IS 5
BP 780
EP 795
DI 10.1007/s00774 018 0983 3
PG 16
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA IT5NH
UT WOS:000482909800004
PM 30756174
DA 2025 08 17
ER

PT J
AU Addison, CL
   Simos, D
   Wang, Z
   Pond, G
   Smith, S
   Robertson, S
   Mazzarello, S
   Singh, G
   Vandermeer, L
   Fernandes, R
   Iyengar, A
   Verma, S
   Clemons, M
AF Addison, C. L.
   Simos, D.
   Wang, Z.
   Pond, G.
   Smith, S.
   Robertson, S.
   Mazzarello, S.
   Singh, G.
   Vandermeer, L.
   Fernandes, R.
   Iyengar, A.
   Verma, S.
   Clemons, M.
TI A phase 2 trial exploring the clinical and correlative effects of
   combining doxycycline with bone targeted therapy in patients with
   metastatic breast cancer
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Article
DE Doxycycline; Bisphosphonate; Breast cancer; Biomarkers; Bone metastasis
ID ESCALATED BISPHOSPHONATE THERAPY; SKELETAL RELATED EVENTS; ZOLEDRONIC
   ACID; FUNCTIONAL ASSESSMENT; PALLIATIVE BENEFIT; OCOG ZAMBONEY; TUMOR
   BURDEN; PLACEBO; PREDOMINANT; FULVESTRANT
AB Background: Bone targeting agents (BTAs), such as bisphosphonates and denosumab, have demonstrated no discernable effects on tumour response or disease free/overall survival in patients with bone metastases from breast cancer. Doxycycline is both osteotropic and has anti cancer effects. When combined with zoledronate in animal models, doxycycline showed significantly increased inhibition of tumour burden and increased bone formation. We evaluated the effects of adding doxycycline to ongoing anti cancer therapy in patients with metastatic breast cancer.
   Methods: Breast cancer patients with bone metastases and >= 3 months of BTA use, entered this single arm study. Patients received doxycycline 100 mg orally, twice a day for 12 weeks. The co primary endpoints were; effect on validated pain scores (FACT Bone pain and Brief Pain Inventory) and bone resorption markers (serum C telopeptide, [sCTx]). All endpoints (pain scores, sCTx, bone specific alkaline phosphatase, skeletal related events, toxicity) were evaluated at baseline, 4, 8 and 12 weeks. Bone marrow was sampled at baseline and week 12 for exploratory biomarker analysis.
   Results: Out of 37 enroled patients, 27 (73%) completed 12 weeks of therapy. No significant changes were seen in pain scores or bone turnover markers. Failure to complete treatment: drug toxicity (70%) and disease progression (30%). Sixteen (43%) patients had GI adverse events.
   Conclusions: Doxycycline 100 mg twice daily for 12 weeks had no significant effects on either bone pain or bone turnover markers. Its toxicity profile in this patient population would make further evaluation challenging. (C) 2016 The Authors. Published by Elsevier GmbH.
C1 [Addison, C. L.; Mazzarello, S.; Vandermeer, L.; Clemons, M.] Ottawa Hosp Res Inst, Ottawa, ON, Canada.
   [Addison, C. L.; Mazzarello, S.; Vandermeer, L.; Clemons, M.] Univ Ottawa, Dept Med, Ottawa, ON, Canada.
   [Simos, D.; Wang, Z.; Smith, S.; Fernandes, R.; Verma, S.; Clemons, M.] Ottawa Hosp, Ctr Canc, Div Med Oncol, Ottawa, ON, Canada.
   [Simos, D.; Wang, Z.; Smith, S.; Fernandes, R.; Verma, S.; Clemons, M.] Univ Ottawa, Dept Med, Ottawa, ON, Canada.
   [Pond, G.] McMaster Univ, Dept Oncol, Hamilton, ON, Canada.
   [Robertson, S.] Ottawa Hosp, Dept Pathol, Ottawa, ON, Canada.
   [Robertson, S.] Univ Ottawa, Ottawa, ON, Canada.
   [Singh, G.] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada.
   [Iyengar, A.] Ottawa Hosp, Div Hematol, Ottawa, ON, Canada.
C3 University of Ottawa; Ottawa Hospital Research Institute; University of
   Ottawa; University of Ottawa; Ottawa Hospital Research Institute;
   University of Ottawa; McMaster University; University of Ottawa; Ottawa
   Hospital Research Institute; University of Ottawa; McMaster University;
   University of Ottawa; Ottawa Hospital Research Institute
RP Clemons, M (通讯作者)，Ottawa Hosp, Ctr Canc, Div Med Oncol, Ottawa, ON, Canada.; Clemons, M (通讯作者)，Univ Ottawa, Dept Med, Ottawa, ON, Canada.
EM mclemons@toh.on.ca
RI Pond, Gregory/JOZ 2926 2023; Singh, Gurmit/C 6744 2014
OI Mazzarello, Sasha/0000 0003 1299 5132; Pond,
   Gregory/0000 0003 1033 0882; 
FU Canadian Breast Cancer Foundation   Ontario Chapter [07938]
FX We are grateful to the Canadian Breast Cancer Foundation (application ID
   07938)   Ontario Chapter for peer reviewed funding for this study. Bone
   biopsies were performed by Drs Abhinav lyengar and Fernandes. Patients
   were accrued by Drs Clemons, Verma, Dent, Sulpher, Gertler and
   Wheatley Price. Data monitoring committee consisted of Drs Asmis
   (Ottawa), Nicholas (Ottawa) and Rayson (Halifax, Nova Scotia). We are,
   as always, grateful to patients and their families for all their help in
   enabling the successful completion of this study.
CR Addison CL, 2015, J BONE ONCOL, V4, P47, DOI 10.1016/j.jbo.2015.04.001
   Addison CL, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193 1801 3 577
   Addison CL, 2014, BREAST CANCER RES TR, V144, P615, DOI 10.1007/s10549 014 2906 x
   Ali SM, 2004, ANN ONCOL, V15, P455, DOI 10.1093/annonc/mdh089
   Amir E., 2012, AM J CLIN ONCOL
   Amir E, 2010, CANCER AM CANCER SOC, V116, P284, DOI 10.1002/cncr.24749
   Broom R, 2009, J PAIN SYMPTOM MANAG, V38, P244, DOI 10.1016/j.jpainsymman.2008.08.005
   CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570
   Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129
   Clemons M, 2012, CURR ONCOL, V19, P259, DOI 10.3747/co.19.1011
   Clemons M, 2008, BREAST CANCER RES TR, V108, P79, DOI 10.1007/s10549 007 9583 y
   Clemons MJ, 2006, J CLIN ONCOL, V24, P4895, DOI 10.1200/JCO.2006.05.9212
   Clemons MJ, 2014, BREAST CANCER RES TR, V146, P153, DOI 10.1007/s10549 014 3015 6
   Coleman RE, 2005, J CLIN ONCOL, V23, P4925, DOI 10.1200/JCO.2005.06.091
   Coleman RE, 2011, BONE, V49, P71, DOI 10.1016/j.bone.2011.02.003
   Dhesy Thind S.K., 2005, J CLIN ONCOL, V23, P3198, DOI [10.1200/jco.2005.23.16_suppl.3198, DOI 10.1200/JCO.2005.23.16_SUPPL.3198]
   Duivenvoorden WCM, 2007, BRIT J CANCER, V96, P1526, DOI 10.1038/sj.bjc.6603740
   Duivenvoorden WCM, 2002, CANCER RES, V62, P1588
   FERRERI AJ, 2006, A J, V98, P1375, DOI DOI 10.1093/JNCI/DJJ373
   FIFE RS, 1995, J LAB CLIN MED, V125, P407
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Gordon M.S., 1997, P AN M AM SOC CLIN, VII, P794
   Holen I, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2769
   Jacobs C., 2015, BREAST CANC RES TREA
   Kimmel DB, 2007, J DENT RES, V86, P1022, DOI 10.1177/154405910708601102
   Kuchuk I, 2012, CURR ONCOL, V19, pE303, DOI 10.3747/co.19.1009
   Kuchuk I.B.J., 2013, J BONE ONCOL, V2
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   Russell K, 2012, J BONE ONCOL, V1, P12, DOI 10.1016/j.jbo.2012.04.003
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Vinholes J, 1999, BRIT J CANCER, V80, P221, DOI 10.1038/sj.bjc.6690506
   Wu W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089841
NR 32
TC 11
Z9 12
U1 2
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2212 1366
EI 2212 1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD NOV
PY 2016
VL 5
IS 4
BP 173
EP 179
DI 10.1016/j.jbo.2016.06.003
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA EJ0RK
UT WOS:000392917800006
PM 28008379
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Jagiello Wieczorek, E
   Pienkowski, A
   Rutkowski, P
AF Jagiello Wieczorek, Ewelina
   Pienkowski, Andrzej
   Rutkowski, Piotr
TI Denosumab for treating giant cell tumor of bone
SO EXPERT OPINION ON ORPHAN DRUGS
LA English
DT Article
DE denosumab; giant cell tumor of bone; RANKL; receptor activator of NF B
   ligand
ID MEGAVOLTAGE RADIATION THERAPY; FACTOR KAPPA B; RECEPTOR ACTIVATOR;
   OSTEOCLAST PRECURSORS; LOCAL RECURRENCE; RANK LIGAND; LONG BONES;
   RADIOTHERAPY; METASTASES; EXPRESSION
AB Introduction: Giant cell tumor of bone (GCTB) is usually a locally aggressive tumor with low metastatic potential. Giant cells are known to express receptor activator of NF B ligand (RANKL) and are responsible for its aggressive osteolytic nature. Overexpression of RANKL by mononuclear neoplastic stromal cells promotes recruitment of numerous reactive multinucleated giant cells.Areas covered: In patients with high risk or locally advanced/surgically unsalvageable GCTB or in rare cases of metastatic disease, systemic targeted therapy with the RANKL inhibitor   monoclonal antibody denosumab   is highly effective and may lead to long term responses or down staging facilitating resection of the tumor. Several studies with denosumab in patients with advanced or unresectable GCTB have shown objective reductions of bone destruction and clinical benefits. The literature focusing on denosumab and GCTB is reviewed here and the most important questions related to the future management of GCTB are discussed.Expert opinion: Denosumab, which inhibits RANK   RANKL interaction, is a new promising actor among molecular targeted therapeutic agents for GCTB. Ideally, all patients should be treated with local/intralesional excision followed by adjuvant treatment or preceded by neoadjuvant denosumab in selected cases, achieving joint salvage and optimal function outcome.
C1 [Rutkowski, Piotr] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland.
   Inst Oncol, Dept Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland.
C3 Maria Sklodowska Curie National Research Institute of Oncology; Maria
   Sklodowska Curie National Research Institute of Oncology
RP Rutkowski, P (通讯作者)，Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland.
EM rutkowskip@coi.waw.pl
RI ; Rutkowski, Piotr/B 3907 2013
OI Rutkowski, Piotr/0000 0002 8920 5429; Pienkowski,
   Andrzej/0000 0002 6714 6237; 
FU Amgen
FX P Rutkowski has served as a member of an advisory board for Amgen and
   received honoraria for lectures for Amgen. A Pienkowski has received a
   travel grant from Amgen. The authors have no other relevant affiliations
   or financial involvement with any organization or entity with a
   financial interest in or financial conflict with the subject matter or
   materials discussed in the manuscript. This includes employment,
   consultancies, honoraria, stock ownership or options, expert testimony,
   grants or patents received or pending, or royalties.
CR Adler RA, 2011, CLIN INTERV AGING, V6, P119, DOI 10.2147/CIA.S14565
   Akiyama T, 2010, CLIN EXP METASTAS, V27, P207, DOI 10.1007/s10585 010 9319 y
   Akiyama T, 2010, J PHARM PHARMACOL, V62, P470, DOI 10.1211/jpp.62.04.0009
   Algawahmed H., 2010, Sarcoma, V2010, P586090, DOI 10.1155/2010/586090
   Antal I, 1999, INT ORTHOP, V23, P315, DOI 10.1007/s002640050381
   Aponte Tinao LA, 2015, CLIN ORTHOP RELAT RE
   Athanassou NA, 2013, GIANT CELL TUMOR BON, P321
   Atkins GJ, 2006, J BONE MINER RES, V21, P1339, DOI 10.1359/JBMR.060604
   Balke M, 2008, J CANCER RES CLIN, V134, P969, DOI 10.1007/s00432 008 0370 x
   Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814
   BENNETT CJ, 1993, INT J RADIAT ONCOL, V26, P299, DOI 10.1016/0360 3016(93)90210 M
   Bhatia S, 2011, RARE TUMORS, V3, P150, DOI 10.4081/rt.2011.e48
   BIDWELL JK, 1987, J COMPUT ASSIST TOMO, V11, P909, DOI 10.1097/00004728 198709000 00035
   Biermann JS, 2013, J NATL COMPR CANC NE, V11, P681, DOI 10.6004/jnccn.2013.0200
   Blackley HR, 1999, J BONE JOINT SURG AM, V81A, P811, DOI 10.2106/00004623 199906000 00008
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Boons HW, 2002, ARCH ORTHOP TRAUM SU, V122, P17, DOI 10.1007/s004020100317
   Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078 0432.CCR 12 0578
   CAMPANACCI M, 1987, J BONE JOINT SURG AM, V69A, P106, DOI 10.2106/00004623 198769010 00018
   Caudell JJ, 2003, INT J RADIAT ONCOL, V57, P158, DOI 10.1016/S0360 3016(03)00416 4
   Cavalli L, 2012, THER CLIN RISK MANAG, V8, P253, DOI 10.2147/TCRM.S7688
   Chakarun CJ, 2013, RADIOGRAPHICS, V33, P197, DOI 10.1148/rg.331125089
   Chakravarti A, 1999, J BONE JOINT SURG AM, V81A, P1566, DOI 10.2106/00004623 199911000 00008
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   Clézardin P, 2011, B CANCER, V98, P837, DOI 10.1684/bdc.2011.1398
   Dominkus M, 2006, INT ORTHOP, V30, P499, DOI 10.1007/s00264 006 0204 x
   Dufresne Armelle, 2012, Bonekey Rep, V1, P149, DOI 10.1038/bonekey.2012.149
   Errani C, 2010, CANCER TREAT REV, V36, P1, DOI 10.1016/j.ctrv.2009.09.002
   ESMO European Sarcoma Network Work, 2012, ANN ONCOL, V23, P100, DOI 10.1093/annonc/mds254
   ESMO/European Sarcoma Network Working Group, 2014, ANN ONCOL
   Feigenberg SJ, 2003, CLIN ORTHOP RELAT R, P207, DOI 10.1097/01.blo.0000069890.31220.b4
   Forsyth R, 2008, J PATHOL, V214, P555, DOI 10.1002/path.2301
   Forsyth RG, 2009, J BONE MINER RES, V24, P70, DOI [10.1359/jbmr.080905, 10.1359/JBMR.080905]
   Ghert MA, 2002, CLIN ORTHOP RELAT R, P201
   Goldschlager T, 2015, J NEUROSURG SPINE, V22, P526, DOI 10.3171/2014.10.SPINE13937
   Gorunova L, 2009, GENE CHROMOSOME CANC, V48, P583, DOI 10.1002/gcc.20667
   Hemingway F, 2012, VIRCHOWS ARCH, V460, P525, DOI 10.1007/s00428 012 1235 x
   Hemingway F, 2011, BONE, V48, P938, DOI 10.1016/j.bone.2010.12.023
   Henderson ER, 2011, J BONE JOINT SURG AM, V93A, P418, DOI 10.2106/JBJS.J.00834
   Huang L, 2000, AM J PATHOL, V156, P761, DOI 10.1016/S0002 9440(10)64942 5
   Jeys LM, 2006, INT ORTHOP, V30, P135, DOI 10.1007/s00264 005 0061 z
   Kaban LB, 2002, J ORAL MAXIL SURG, V60, P1103, DOI 10.1053/joms.2002.34975
   Karras NA, 2013, J CLIN ONCOL, V31, pE200, DOI 10.1200/JCO.2012.46.4255
   Kay RM, 1994, CLIN ORTHOP RELAT R, V219, P230
   Kitazawa S, 2002, J PATHOL, V198, P228, DOI 10.1002/path.1199
   Kivioja AH, 2008, ACTA ORTHOP, V79, P86, DOI 10.1080/17453670710014815
   Klenke FM, 2011, CLIN ORTHOP RELAT R, V469, P591, DOI 10.1007/s11999 010 1501 7
   Knochentumoren A, 2008, J BONE JOINT SURG AM, V90A, P1060, DOI 10.2106/JBJS.D.02771
   Liao TS, 2005, J ORTHOP RES, V23, P203, DOI 10.1016/j.orthres.2004.06.018
   Maggiani F, 2011, J CLIN PATHOL, V64, P701, DOI 10.1136/jcp.2011.090852
   Mak IWY, 2014, J BONE JOINT SURG AM, V96A, DOI 10.2106/JBJS.M.01332
   MALONE S, 1995, INT J RADIAT ONCOL, V33, P689, DOI 10.1016/0360 3016(95)00159 V
   Mankin HJ, 2005, CLIN ORTHOP RELAT R, P144, DOI 10.1097/01.blo.0000174684.85250.b5
   Martin Broto J, 2014, ACTA ONCOL, V53, P1173, DOI 10.3109/0284186X.2014.910313
   Matcuk GR, 2015, SKELETAL RADIOL, V44, P1027, DOI 10.1007/s00256 015 2117 5
   Mattei TA, 2014, SPINE J, V14, pE15, DOI 10.1016/j.spinee.2014.02.019
   MCDONALD DJ, 1986, J BONE JOINT SURG AM, V68A, P235, DOI 10.2106/00004623 198668020 00009
   MILLER G, 1990, Chirurgia degli Organi di Movimento, V75, P203
   Miszczyk L, 2001, INT J RADIAT ONCOL, V49, P1239, DOI 10.1016/S0360 3016(00)01520 0
   Mittal Srabani, 2007, J Cancer Res Ther, V3, P96, DOI 10.4103/0973 1482.34687
   Morgan T, 2005, AM J PATHOL, V167, P117, DOI 10.1016/S0002 9440(10)62959 8
   Moskovszky L, 2009, GENE CHROMOSOME CANC, V48, P468, DOI 10.1002/gcc.20656
   Muheremu A, 2015, ONCOL LETT, V9, P1321, DOI 10.3892/ol.2014.2837
   Muheremu A, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477 7819 12 261
   Murphey MD, 2001, RADIOGRAPHICS, V21, P1283, DOI 10.1148/radiographics.21.5.g01se251283
   Nair MK, 1999, INT J RADIAT ONCOL, V43, P1065, DOI 10.1016/S0360 3016(98)00526 4
   Oda Y, 2001, HISTOPATHOLOGY, V39, P629, DOI 10.1046/j.1365 2559.2001.01275.x
   Panagopoulos I, 2001, INT J CANCER, V93, P769, DOI 10.1002/ijc.1415
   Rao UNM, 2005, CANCER GENET CYTOGEN, V158, P126, DOI 10.1016/j.cancergencyto.2004.09.015
   Raskin KA, 2013, J AM ACAD ORTHOP SUR, V21, P118, DOI 10.5435/JAAOS 21 02 118
   ROCK MG, 1984, J BONE JOINT SURG AM, V66A, P269, DOI 10.2106/00004623 198466020 00014
   Roux S, 2002, AM J CLIN PATHOL, V117, P210
   Ruka W, 2010, INT J RADIAT ONCOL, V78, P494, DOI 10.1016/j.ijrobp.2009.07.1704
   Rutkowski P, 2015, ANN SURG ONCOL
   Saito T, 2011, HUM PATHOL, V42, P727, DOI 10.1016/j.humpath.2010.08.008
   SCHWARTZ HS, 1993, CANCER GENET CYTOGEN, V71, P132, DOI 10.1016/0165 4608(93)90018 H
   SCHWARTZ LH, 1989, INT J RADIAT ONCOL, V17, P1085, DOI 10.1016/0360 3016(89)90160 0
   Shehadeh A, 2010, CLIN ORTHOP RELAT R, V468, P2885, DOI 10.1007/s11999 010 1454 x
   Shi WY, 2013, AM J CLIN ONCOL CANC, V36, P505, DOI 10.1097/COC.0b013e3182568fb6
   Siebenrock KA, 1998, J BONE JOINT SURG BR, V80B, P43, DOI 10.1302/0301 620X.80B1.7875
   Stadler N, 2015, CLINICS PRACT, V5, DOI 10.4081/cp.2015.697
   Szendröi M, 2004, J BONE JOINT SURG BR, V86B, P5, DOI 10.1302/0301 620X.86B1.14053
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Thomas DM, 2012, CURR OPIN ONCOL, V24, P397, DOI 10.1097/CCO.0b013e328354c129
   Tse LF, 2008, BONE, V42, P68, DOI 10.1016/j.bone.2007.08.038
   TUBBS WS, 1992, AM J ROENTGENOL, V158, P331, DOI 10.2214/ajr.158.2.1729794
   Turcotte RE, 2002, CLIN ORTHOP RELAT R, P248
   Ulas A, 2015, J BUON, V20, P666
   van der Heijden L, 2014, ONCOLOGIST, V19, P550, DOI 10.1634/theoncologist.2013 0432
   van der Heijden L, 2012, ACTA ORTHOP, V83, P401, DOI 10.3109/17453674.2012.711193
   Wang H, 2012, INT ORTHOP, V36, P2521, DOI 10.1007/s00264 012 1664 9
   Ward WG, 2002, CLIN ORTHOP RELAT R, P259
   Wu PF, 2015, TUMOR BIOL, V36, P495, DOI 10.1007/s13277 015 3094 y
NR 93
TC 5
Z9 5
U1 0
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2167 8707
J9 EXPERT OPIN ORPHAN D
JI Exp. Opin. Orphan Drugs
PD OCT 3
PY 2015
VL 3
IS 10
BP 1219
EP 1229
DI 10.1517/21678707.2015.1086336
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA DC7KZ
UT WOS:000369400100002
DA 2025 08 17
ER

PT J
AU Paese, CLB
   Chang, CF
   Kristeková, D
   Brugmann, SA
AF Paese, Christian Louis Bonatto
   Chang, Ching Fang
   Kristekova, Daniela
   Brugmann, Samantha A.
TI Pharmacological intervention of the FGF PTH axis as a potential
   therapeutic for craniofacial ciliopathies
SO DISEASE MODELS & MECHANISMS
LA English
DT Article
DE Primary cilia; Ciliopathies; FGF; C2CD3; Micrognathia; talpid(2)
ID MANDIBULAR DISTRACTION OSTEOGENESIS; PRIMARY CILIA; PARATHYROID HORMONE;
   CHICK EMBRYO; HEDGEHOG PATHWAY; GENE EXPRESSION; JAW NECROSIS;
   FOLIC ACID; CALCIUM; CHILDREN
AB Ciliopathies represent a disease class characterized by a broad range of phenotypes including polycystic kidneys and skeletal anomalies. Ciliopathic skeletal phenotypes are among the most common and most difficult to treat due to a poor understanding of the pathological mechanisms leading to disease. Using an avian model (talpid(2)) for a human ciliopathy with both kidney and skeletal anomalies (orofaciodigital syndrome 14), we identified disruptions in the FGF23 PTH axis that resulted in reduced calcium uptake in the developing mandible and subsequent micrognathia. Although pharmacological intervention with the U.S. Food and Drug Administration (FDA) approved pan FGFR inhibitor AZD4547 alone rescued expression of the FGF target SPRY2, it did not significantly rescue micrognathia. In contrast, treatment with a cocktail of AZD4547 and teriparatide acetate, a PTH agonist and FDA approved treatment for osteoporosis, resulted in molecular, cellular and phenotypic rescue of ciliopathic micrognathia in talpid(2) mutants. Together, these data provide novel insight into pathological molecular mechanisms associated with ciliopathic skeletal phenotypes and a potential therapeutic strategy for a pleiotropic disease class with limited to no treatment options.
C1 [Paese, Christian Louis Bonatto; Chang, Ching Fang; Brugmann, Samantha A.] Cincinnati Childrens Hosp Med Ctr, Div Dev Biol, Cincinnati, OH 45229 USA.
   [Paese, Christian Louis Bonatto; Chang, Ching Fang; Brugmann, Samantha A.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45229 USA.
   [Kristekova, Daniela] Czech Acad Sci, Vvi, Inst Anim Physiol & Genet, Lab Mol Morphogenesis, Brno 60200, Czech Republic.
   [Kristekova, Daniela] Masaryk Univ, Fac Sci, Dept Expt Biol, Brno 62500, Czech Republic.
   [Brugmann, Samantha A.] Cincinnati Childrens Hosp Med Ctr, Dept Surg, Div Plast Surg, Cincinnati, OH 45229 USA.
   [Paese, Christian Louis Bonatto] Seattle Childrens Hosp, Ben Towne Ctr Childhood Canc Res, Seattle, WA 98105 USA.
C3 Cincinnati Children's Hospital Medical Center; University System of
   Ohio; University of Cincinnati; Czech Academy of Sciences; Institute of
   Animal Physiology & Genetics of the Czech Academy of Sciences; Masaryk
   University Brno; Cincinnati Children's Hospital Medical Center; Seattle
   Children's Hospital
RP Paese, CLB; Brugmann, SA (通讯作者)，Cincinnati Childrens Hosp Med Ctr, Div Dev Biol, Cincinnati, OH 45229 USA.; Paese, CLB; Brugmann, SA (通讯作者)，Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45229 USA.; Brugmann, SA (通讯作者)，Cincinnati Childrens Hosp Med Ctr, Dept Surg, Div Plast Surg, Cincinnati, OH 45229 USA.; Paese, CLB (通讯作者)，Seattle Childrens Hosp, Ben Towne Ctr Childhood Canc Res, Seattle, WA 98105 USA.
EM christian.bonattopaese@seattlechildrens.org; samantha.brugmann@cchmc.gov
RI ; Paese, Christian/AAX 8098 2020
OI Kristekova, Daniela/0000 0001 9242 1096; Chang,
   Ching Fang/0000 0001 6754 2769
FU National Institute of Dental and Craniofacial Research [R35 DE027557];
   Cincinnati Children's Hospital Medical Center; Cincinnati Children's
   Hospital Medical Center
FX This study was funded by the National Institute of Dental and
   Craniofacial Research (R35 DE027557 to S.A.B.) and a Cincinnati
   Children's Hospital Medical Center internal grant to C.L.B.P. (Arnold W.
   Strauss Fellowship). Open Access funding provided by Cincinnati
   Children's Hospital Medical Center. Deposited in PMC for immediate
   release.
CR Abbott U. K., 1960, Journal of Heredity, V51, P194
   ABBOTT UK, 1959, POULTRY SCI, V38, P1185
   Abramson ZR, 2013, J ORAL MAXIL SURG, V71, P90, DOI 10.1016/j.joms.2012.03.014
   Al lami HA, 2016, BIOCHEM SOC T, V44, P1753, DOI 10.1042/BST20160241
   Blau JE, 2015, REV ENDOCR METAB DIS, V16, P165, DOI 10.1007/s11154 015 9318 z
   Bodenner D, 2007, CLIN INTERV AGING, V2, P499
   Bosakova MK, 2019, P NATL ACAD SCI USA, V116, P4316, DOI 10.1073/pnas.1800338116
   Bosakova MK, 2018, HUM MOL GENET, V27, P1093, DOI 10.1093/hmg/ddy031
   Breik O, 2016, INT J PEDIATR OTORHI, V85, P128, DOI 10.1016/j.ijporl.2016.03.033
   Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598
   BUEKER ED, 1956, P SOC EXP BIOL MED, V91, P539
   Chang CF, 2014, DEVELOPMENT, V141, P3003, DOI 10.1242/dev.105924
   Chopra K, 2021, AM J THER, V28, pE469, DOI 10.1097/MJT.0000000000001182
   Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117
   Cordido A, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1008337
   Delaine Smith RM, 2014, FASEB J, V28, P430, DOI 10.1096/fj.13 231894
   Delling M, 2016, NATURE, V531, P656, DOI 10.1038/nature17426
   Delling M, 2013, NATURE, V504, P311, DOI 10.1038/nature12833
   Ferreira LD, 2021, OSTEOPOROSIS INT, V32, P2449, DOI 10.1007/s00198 021 06078 z
   Ealba EL, 2015, DEV BIOL, V408, P151, DOI 10.1016/j.ydbio.2015.10.001
   Eckert AW, 2007, CANCER TREAT REV, V33, P58, DOI 10.1016/j.ctrv.2006.09.003
   ELBADAWI A, 1981, AM J CLIN PATHOL, V75, P355
   Elliott KH, 2018, DEV DYNAM, V247, P818, DOI 10.1002/dvdy.24627
   Gutiérrez Cerecedo LE, 2016, GAC MED MEX, V152, P322
   Gal Moscovici A, 2007, SEMIN DIALYSIS, V20, P423, DOI 10.1111/j.1525 139X.2007.00319.x
   Goetz SC, 2010, NAT REV GENET, V11, P331, DOI 10.1038/nrg2774
   Grau L, 2020, KIDNEY360, V1, P648, DOI 10.34067/KID.0001692020
   HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104
   Hebert K, 2005, POULTRY SCI, V84, P1533, DOI 10.1093/ps/84.10.1533
   HODGES JH, 1946, SCIENCE, V104, P460, DOI 10.1126/science.104.2707.460
   Hoey David A, 2012, Front Endocrinol (Lausanne), V3, P75, DOI 10.3389/fendo.2012.00075
   Holloway JL, 2014, J CONTROL RELEASE, V191, P63, DOI 10.1016/j.jconrel.2014.05.053
   Horner VL, 2011, DEV BIOL, V355, P43, DOI 10.1016/j.ydbio.2011.04.019
   Iwasaki Ishizuka Y, 2005, NEPHROL DIAL TRANSPL, V20, P1904, DOI 10.1093/ndt/gfh876
   Jevon M, 2003, SCAND J RHEUMATOL, V32, P95, DOI 10.1080/03009740310000102
   Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233
   Karnofsky D A, 1964, Clin Orthop Relat Res, V33, P59
   Kawane T, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 31853 0
   Kawata K, 2021, BONE, V150, DOI 10.1016/j.bone.2021.116001
   Kue CS, 2015, EXP ANIM TOKYO, V64, P129, DOI 10.1538/expanim.14 0059
   Kwon Yong Dae, 2016, Dent J (Basel), V4, DOI 10.3390/dj4040041
   Leder BZ, 2017, CURR OSTEOPOROS REP, V15, P110, DOI 10.1007/s11914 017 0353 4
   Lee Kristen L, 2015, Cilia, V4, P7, DOI 10.1186/s13630 015 0016 y
   LIEVREMONT M, 1982, ACTA ANAT, V114, P268
   Lin TL, 2012, ONCOTARGETS THER, V5, P47, DOI 10.2147/OTT.S21957
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu Yongbo, 2011, Curr Osteoporos Rep, V9, P103, DOI 10.1007/s11914 011 0053 4
   Malone AMD, 2007, P NATL ACAD SCI USA, V104, P13325, DOI 10.1073/pnas.0700636104
   Millington G, 2017, DEV BIOL, V424, P124, DOI 10.1016/j.ydbio.2017.02.021
   Mina M, 2007, ORTHOD CRANIOFAC RES, V10, P59, DOI 10.1111/j.1601 6343.2007.00385.x
   MONSEN ER, 1989, J AM DIET ASSOC, V89, P1748
   Neugebauer JM, 2009, NATURE, V458, P651, DOI 10.1038/nature07753
   Paese CLB, 2021, DEVELOPMENT, V148, DOI 10.1242/dev.194175
   Paul J, 2019, BMJ CASE REP, V12, DOI 10.1136/bcr 2018 228375
   Perlyn CA, 2002, PLAST RECONSTR SURG, V109, P1809, DOI 10.1097/00006534 200205000 00005
   Perrine SMM, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.038513
   Plotnikova OV, 2009, METHOD CELL BIOL, V94, P137, DOI 10.1016/S0091 679X(08)94007 3
   Rayman S, 2009, INT J DENT HYG, V7, P90, DOI 10.1111/j.1601 5037.2008.00331.x
   Reiter JF, 2017, NAT REV MOL CELL BIO, V18, P533, DOI 10.1038/nrm.2017.60
   ROBEL EJ, 1993, POULTRY SCI, V72, P546, DOI 10.3382/ps.0720546
   RYLEY JF, 1968, PARASITOLOGY, V58, P215, DOI 10.1017/S0031182000073558
   Sasai N, 2012, WIRES DEV BIOL, V1, P753, DOI 10.1002/wdev.43
   Saternos H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197109
   Satterwhite J, 2010, CALCIFIED TISSUE INT, V87, P485, DOI 10.1007/s00223 010 9424 6
   Scales SJ, 2009, TRENDS PHARMACOL SCI, V30, P303, DOI 10.1016/j.tips.2009.03.007
   Schock EN, 2015, DIS MODEL MECH, V8, P855, DOI 10.1242/dmm.020222
   Shigetani Y, 2000, DEV BIOL, V228, P73, DOI 10.1006/dbio.2000.9932
   Silva BC, 2015, CURR OPIN PHARMACOL, V22, P41, DOI 10.1016/j.coph.2015.03.005
   Sim IW, 2020, J CLIN ONCOL, V38, P2971, DOI 10.1200/JCO.19.02192
   Tabler JM, 2013, DEV CELL, V25, P623, DOI 10.1016/j.devcel.2013.05.021
   Takashi Y, 2021, BIOCHEM BIOPHYS REP, V27, DOI 10.1016/j.bbrep.2021.101107
   Tanaka S, 2001, Clin Calcium, V11, P598
   Tasnim N, 2021, CUREUS J MED SCIENCE, V13, DOI 10.7759/cureus.18488
   Teitelbaum SL, 1996, MT SINAI J MED, V63, P399
   Terao F, 2011, DEV BIOL, V350, P337, DOI 10.1016/j.ydbio.2010.11.029
   Tomonari H, 2017, HEAD FACE MED, V13, DOI 10.1186/s13005 017 0150 4
   Tsai JN, 2019, LANCET DIABETES ENDO, V7, P767, DOI 10.1016/S2213 8587(19)30255 4
   VIDAL A, 1953, Ann Endocrinol (Paris), V14, P437
   Wallingford JB, 2011, GENE DEV, V25, P201, DOI 10.1101/gad.2008011
   Waters AM, 2011, PEDIATR NEPHROL, V26, P1039, DOI 10.1007/s00467 010 1731 7
   Xiao ZS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104154
   Xie YL, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392 020 00222 7
   Yu WL, 2020, ORAL DIS, V26, P609, DOI 10.1111/odi.13275
   Yuan X, 2019, INT J BIOL SCI, V15, P2087, DOI 10.7150/ijbs.27231
   Zhang ZC, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0024608, 10.1371/journal.pone.0028817]
   Zhou X, 2013, AM J MED GENET A, V161A, P983, DOI 10.1002/ajmg.a.35824
   Zosen D, 2021, J PHARMACOL TOX MET, V112, DOI 10.1016/j.vascn.2021.107105
   Zúñiga J, 2003, BIOL RES, V36, P233
NR 88
TC 3
Z9 3
U1 1
U2 5
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 1754 8403
EI 1754 8411
J9 DIS MODEL MECH
JI Dis. Model. Mech.
PD AUG
PY 2022
VL 15
IS 8
AR dmm049611
DI 10.1242/dmm.049611
PG 10
WC Cell Biology; Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine; Pathology
GA 5C2EK
UT WOS:000864078600001
PM 35818799
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhou, Y
   Li, X
   Wang, JC
   He, R
   Ng, L
   Li, DP
   Mortimer, J
   Varma, SN
   Hu, JH
   Zhao, Q
   Peng, ZY
   Liu, CZ
   Su, SC
AF Zhou, Yu
   Li, Xin
   Wang, Jinchao
   He, Rong
   Ng, Liqi
   Li, Dapeng
   Mortimer, Jeremy
   Varma, Swastina Nath
   Hu, Jinhua
   Zhao, Qing
   Peng, Zeyu
   Liu, Chaozong
   Su, Songchuan
TI Prediction of the Molecular Mechanism of Corni Fructus Epimedii
   Folium Rehmanniae Radix Praeparata in the Treatment of Postmenopausal
   Osteoporosis based on Network Pharmacology and Molecular Docking
SO CURRENT COMPUTER AIDED DRUG DESIGN
LA English
DT Article
DE Corni fructus; epimedii folium; rehmanniae radix praeparata; data
   mining; network pharmacology; postmenopausal osteoporosis
ID GROWTH FACTOR RECEPTOR; OSTEOCLAST DIFFERENTIATION; THYROID HORMONE;
   BONE FORMATION; BIG DATA; AKT1; TRANSACTIVATION; OSTEOARTHRITIS;
   OSTEOGENESIS; ASSOCIATION
AB Introduction: In this study, core drugs of clinical postmenopausal osteoporosis were retrieved using data mining, the drug molecular action target was predicted through network pharmacology, the key nodes of interaction were identified by combining postmenopausal osteoporosis related targets, and the pharmacological mechanism of Traditional Chinese Medicine (TCM) against postmenopausal osteoporosis and other action mechanisms was explored.Methods: TCMISS V2.5 was used to collect TCM prescriptions of postmenopausal osteoporosis from databases, including Zhiwang, Wanfang, PubMed, etc., for selecting the highest confidence drugs. TCMSP and SwissTargetPrediction databases were selected to screen the main active ingredients of the highest confidence drugs and their targets. Relevant targets for postmenopausal osteoporosis were retrieved from GeneCards and GEO databases, PPI network diagrams construction and selection of core nodes in the network, GO and KEGG enrichment analysis, and molecular docking validation.Results: Correlation analysis identified core drug pairs as 'Corni Fructus Epimedii Folium Rehmanniae Radix Praeparata' (SZY YYH SDH). After TCMSP co screening and de weighting, 36 major active ingredients and 305 potential targets were selected. PPI network graph was built from the 153 disease targets and 24 TCM disease intersection targets obtained. GO, KEGG enrichment results showed that the intersectional targets were enriched in the PI3K Akt signalling pathway, etc. The target organs were mainly distributed in the thyroid, liver, CD33+_Myeloid, etc. Molecular docking results showed that the core active ingredients of the 'SZY YYH SDH' were able to bind to the pair core nodes and PTEN and EGFR.Conclusion: The results showed that 'SZY YYH SDH' can provide the basis for clinical application and treat postmenopausal osteoporosis through multi component, multi pathway, and multi target effects.
C1 [Zhou, Yu; Su, Songchuan] Chongqing Orthoped Hosp Tradit Chinese Med, Chongqing 400012, Peoples R China.
   [Zhou, Yu; Ng, Liqi; Mortimer, Jeremy; Varma, Swastina Nath; Liu, Chaozong] UCL, Royal Natl Orthopaed Hosp, Inst Orthopaed & Musculoskeletal Sci, London HA7 4LP, England.
   [Zhou, Yu; Li, Xin; He, Rong; Hu, Jinhua; Peng, Zeyu] Changchun Univ Chinese Med, Changchun 130117, Peoples R China.
   [Wang, Jinchao; Li, Dapeng] Yantai Hosp Shandong Wendeng Osteopath & Traumatol, Yantai 264009, Peoples R China.
   [Mortimer, Jeremy] Univ Bristol, Sch Anat, Southwell St, Bristol BS2 8EJ, England.
   [Zhao, Qing] Tianjin Univ Tradit Chinese Med, Tianjin 301617, Peoples R China.
C3 University of London; University College London; Royal National
   Orthopaedic Hospital NHS Trust; Changchun University of Chinese
   Medicine; University of Bristol; Tianjin University of Traditional
   Chinese Medicine
RP Su, SC (通讯作者)，Chongqing Orthoped Hosp Tradit Chinese Med, Chongqing 400012, Peoples R China.; Liu, CZ (通讯作者)，UCL, Royal Natl Orthopaed Hosp, Inst Orthopaed & Musculoskeletal Sci, London HA7 4LP, England.
EM chaozong.liu@ucl.ac.uk; su_songchuan@sohu.com
RI ; WANG, Jinchao/ABB 1608 2020; Hu, Jinhua/C 6516 2015; Mortimer,
   Jeremy/IZP 6410 2023; Zhou, Yu/HLW 4073 2023; Su,
   Songchuan/JCP 3261 2023
OI Nath Varma, Swastina/0000 0002 9449 8772; Zhou, Yu/0000 0002 3065 4625;
   jin hua, hu/0000 0003 3736 0790; 
FU Declared none.
FX Declared none.
CR Alzahrani AS, 2019, SEMIN CANCER BIOL, V59, P125, DOI 10.1016/j.semcancer.2019.07.009
   Arranz A, 2012, P NATL ACAD SCI USA, V109, P9517, DOI 10.1073/pnas.1119038109
   Aziz N, 2018, J ETHNOPHARMACOL, V225, P342, DOI 10.1016/j.jep.2018.05.019
   Baliram R, 2012, J CLIN INVEST, V122, P3737, DOI 10.1172/JCI63948
   Bassett JHD, 2003, TRENDS ENDOCRIN MET, V14, P356, DOI 10.1016/S1043 2760(03)00144 90
   Buettmann EG, 2019, J BONE MINER RES, V34, P1690, DOI 10.1002/jbmr.3755
   Bui HT, 2009, J ASIAN NAT PROD RES, V11, P817, DOI 10.1080/10286020903117317
   Chandra A, 2013, J BIOL CHEM, V288, P20488, DOI 10.1074/jbc.M112.447250
   Chen RB, 2021, CHIN MED UK, V16, DOI 10.1186/s13020 021 00503 5
   Christiansen BA, 2015, CARTILAGE, V6, P30, DOI 10.1177/1947603514554992
   Faltas CL, 2020, ENDOCRINOLOGY, V161, DOI 10.1210/endocr/bqaa030
   Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649
   Fischer V, 2022, SEMIN CELL DEV BIOL, V123, P14, DOI 10.1016/j.semcdb.2021.05.014
   Ghafouri Fard S, 2021, BIOMED PHARMACOTHER, V133, DOI 10.1016/j.biopha.2020.110986
   Gong W, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.727808
   Guo K, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/7144529
   Hamad M, 2020, EXP CLIN ENDOCR DIAB, V128, P270, DOI 10.1055/a 0885 1677
   Hsu E, 2018, CALCIFIED TISSUE INT, V102, P512, DOI 10.1007/s00223 017 0321 0
   Imran M, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108612
   Jia HR, 2016, P NATL ACAD SCI USA, V113, P14360, DOI 10.1073/pnas.1608938113
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P801, DOI [10.1007/s00198 018 4704 5, 10.1007/s00198 020 05303 5, 10.1007/s00223 018 00512 x]
   Kaur Tejinder, 2019, Current Drug Discovery Technologies, V16, P30, DOI 10.2174/1570163815666180219112421
   Kim HY, 2013, BONE RES, V1, DOI 10.4248/BR201302004
   Kim TH, 2011, J NUTR BIOCHEM, V22, P8, DOI 10.1016/j.jnutbio.2009.11.002
   Liu P, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/2634431
   Luo TT, 2020, CHIN J INTEGR MED, V26, P72, DOI 10.1007/s11655 019 3064 0
   Marahatha R, 2021, PHYTOTHER RES, V35, P5103, DOI 10.1002/ptr.7138
   Morgan LV, 2021, BEHAV PHARMACOL, V32, P640, DOI 10.1097/FBP.0000000000000658
   Mukherjee A, 2012, MOL CELL BIOL, V32, P490, DOI 10.1128/MCB.06361 11
   Qin L, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0099 y
   Rajandran SN, 2020, FRONT MED LAUSANNE, V7, DOI 10.3389/fmed.2020.554669
   Sampath SJP, 2021, INFLAMMOPHARMACOLOGY, V29, P1701, DOI 10.1007/s10787 021 00874 z
   Sharma N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222212255
   Shuai YM, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/7049812
   Sun G, 2019, BIOSCIENCE REP, V39, DOI [10.1042/bsr20181346, 10.1042/BSR20181346]
   Tang SH, 2019, CHIN J INTEGR MED, V25, P861, DOI 10.1007/s11655 017 2957 z
   Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285
   Wang T, 2022, ALTERN THER HEALTH M, V28, P18
   Wang YJ, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.878433
   Wang Z, 2022, BIOENGINEERED, V13, P5064, DOI 10.1080/21655979.2022.2036893
   Wu CM, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472 6882 13 277
   Wu D, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687551
   Wu WT, 2021, MILITARY MED RES, V8, DOI 10.1186/s40779 021 00338 z
   Xiao L, 2020, AGING US, V12, P21706, DOI 10.18632/aging.103976
   Yang F, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 43518 7
   Yang J, 2020, J EVID BASED MED, V13, P57, DOI 10.1111/jebm.12373
   Yang KD, 2022, FRONT PHYSIOL, V13, DOI 10.3389/fphys.2022.840293
   Yang M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16003
   Yoon HS, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10150
   Yu B, 2022, PERIODONTOL 2000, V89, P99, DOI 10.1111/prd.12422
   Yu T, 2020, AGING US, V12, P10473, DOI 10.18632/aging.103271
   Yu T, 2020, AGING US, V12, P9500, DOI 10.18632/aging.103223
   Yuan Z, 2018, AM J TRANSL RES, V10, P4313
   Zhang XR, 2011, J BONE MINER RES, V26, P1022, DOI 10.1002/jbmr.295
   Zintzaras E, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 9
NR 55
TC 2
Z9 3
U1 4
U2 45
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1573 4099
EI 1875 6697
J9 CURR COMPUT AID DRUG
JI Curr. Comput. Aided Drug Des.
PY 2024
VL 20
IS 2
BP 87
EP 103
DI 10.2174/1573409919666230605123129
PG 17
WC Chemistry, Medicinal; Computer Science, Interdisciplinary Applications
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Computer Science
GA U7JT6
UT WOS:001086539600001
PM 37317909
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Nakatsu, Y
   Nakagawa, F
   Higashi, S
   Ohsumi, T
   Shiiba, S
   Watanabe, S
   Takeuchi, H
AF Nakatsu, Yoshihiro
   Nakagawa, Fumio
   Higashi, Sen
   Ohsumi, Tomoko
   Shiiba, Shunji
   Watanabe, Seiji
   Takeuchi, Hiroshi
TI Effect of acetaminophen on osteoblastic differentiation and migration of
   MC3T3 E1 cells
SO PHARMACOLOGICAL REPORTS
LA English
DT Article
DE Acetaminophen; Migration; Osteoblast; Cyclooxygenase; Transient receptor
   potential
ID PARACETAMOL ACETAMINOPHEN; TRPV4 CHANNELS; BONE; RECEPTORS; FRACTURE;
   DENSITY; SYSTEM; DRUGS
AB Background: N acetyl p aminophenol (APAP, acetaminophen, paracetamol) is a widely used analgesic/antipyretic with weak inhibitory effects on cyclooxygenase (COX) compared to non steroidal anti inflammatory drugs (NSAIDs). The mechanism of action of APAP is mediated by its metabolite that activates transient receptor potential channels, including transient receptor potential vanilloid 1 (TRPV1) and TRP ankyrin 1 (TRPA1) or the cannabinoid receptor type 1 (CB1). However, the exact molecular mechanism and target underlying the cellular actions of APAP remain unclear. Therefore, we investigated the effect of APAP on osteoblastic differentiation and cell migration, with a particular focus on TRP channels and CB1.
   Methods: Effects of APAP on osteoblastic differentiation and cell migration of MC3T3 E1, a mouse pre osteoblast cell line, were assessed by the increase in alkaline phosphatase (ALP) activity, and both wound healing and transwell migration assays, respectively.
   Results: APAP dose dependently inhibited osteoblastic differentiation, which was well correlated with the effects on COX activity compared with other NSAIDs. In contrast, cell migration was promoted by APAP, and this effect was not correlated with COX inhibition. None of the agonists or antagonists of TRP channels and the CB receptor affected the APAP induced cell migration, while the effect of APAP on cell migration was abolished by down regulating TRPV4 gene expression.
   Conclusion: APAP inhibited osteoblastic differentiation via COX inactivation while it promoted cell migration independently of previously known targets such as COX, TRPV1, TRPA1 channels, and CB receptors, but through the mechanism involving TRPV4. APAP may have still unidentified molecular targets that modify cellular functions. (c) 2017 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Sp. z o.o. All rights reserved.
C1 [Nakatsu, Yoshihiro; Nakagawa, Fumio; Shiiba, Shunji; Watanabe, Seiji] Kyushu Dent Univ, Dept Control Phys Funct, Div Dent Anesthesiol, Kitakyushu, Fukuoka, Japan.
   [Nakatsu, Yoshihiro; Nakagawa, Fumio; Higashi, Sen; Ohsumi, Tomoko; Takeuchi, Hiroshi] Kyushu Dent Univ, Dept Hlth Promot, Div Appl Pharmacol, Kitakyushu, Fukuoka, Japan.
C3 Kyushu Dental University; Kyushu Dental University
RP Takeuchi, H (通讯作者)，Kyushu Dent Univ, Dept Hlth Promot, Div Appl Pharmacol, Kitakyushu, Fukuoka, Japan.
EM r12takeuchi@fa.kyu dent.ac.jp
RI Takeuchi, Hiroshi/I 8849 2019
OI Takeuchi, Hiroshi/0000 0003 0033 2913
FU Kyushu Dental University Internal Grants; Grants in Aid for Scientific
   Research [17K11649] Funding Source: KAKEN
FX The present study was supported by a grant in aid from Kyushu Dental
   University Internal Grants (to HT).
CR Abed E, 2009, MOL MEMBR BIOL, V26, P146, DOI 10.1080/09687680802612721
   Bertolini A, 2006, CNS DRUG REV, V12, P250, DOI 10.1111/j.1527 3458.2006.00250.x
   Díaz Rodríguez L, 2010, ACTA PHARMACOL SIN, V31, P1495, DOI 10.1038/aps.2010.129
   Fracon RN, 2010, J APPL ORAL SCI, V18, P630, DOI 10.1590/S1678 77572010000600016
   García Martínez O, 2011, ARCH ORAL BIOL, V56, P317, DOI 10.1016/j.archoralbio.2010.10.018
   Gentry C, 2015, SCI REP UK, V5, DOI 10.1038/srep12771
   Högestätt ED, 2005, J BIOL CHEM, V280, P31405, DOI 10.1074/jbc.M501489200
   Mallet C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012748
   Martin E, 2012, PFLUG ARCH EUR J PHY, V464, P261, DOI 10.1007/s00424 012 1136 5
   Masuyama R, 2008, CELL METAB, V8, P257, DOI 10.1016/j.cmet.2008.08.002
   Menter DG, INT J CELL BIOL
   Miller AM, 2008, BRIT J PHARMACOL, V153, P299, DOI 10.1038/sj.bjp.0707523
   Miyazaki A, 2015, BIOCHEM BIOPH RES CO, V458, P161, DOI 10.1016/j.bbrc.2015.01.086
   Mizoguchi F, 2008, J CELL PHYSIOL, V216, P47, DOI 10.1002/jcp.21374
   Ong CKS, 2010, ANESTH ANALG, V110, P1170, DOI 10.1213/ANE.0b013e3181cf9281
   Ottani A, 2006, EUR J PHARMACOL, V531, P280, DOI 10.1016/j.ejphar.2005.12.015
   Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165 6147(00)01482 6
   Robertson G, 2006, BONE, V39, P767, DOI 10.1016/j.bone.2006.04.006
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Szallasi A, 1999, PHARMACOL REV, V51, P159
   van Esch RW, 2013, MED HYPOTHESES, V81, P343, DOI 10.1016/j.mehy.2013.03.042
   Williams LJ, 2011, BONE, V48, P1277, DOI 10.1016/j.bone.2011.03.435
   Zaninetti R, 2011, J NEUROCHEM, V116, P606, DOI 10.1111/j.1471 4159.2010.07144.x
NR 23
TC 12
Z9 14
U1 0
U2 14
PU POLISH ACAD SCIENCES INST PHARMACOLOGY
PI KRAKOW
PA SMETNA 12, 31 343 KRAKOW, POLAND
SN 1734 1140
J9 PHARMACOL REP
JI Pharmacol. Rep.
PD FEB
PY 2018
VL 70
IS 1
BP 29
EP 36
DI 10.1016/j.pharep.2017.07.006
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GA2QQ
UT WOS:000428169000005
PM 29306760
DA 2025 08 17
ER

PT J
AU Gong, W
   Zhang, ND
   Cheng, G
   Zhang, QL
   He, YQ
   Shen, Y
   Zhang, Q
   Zhu, B
   Zhang, QY
   Qin, LP
AF Gong, Wan
   Zhang, Naidan
   Cheng, Gang
   Zhang, Quanlong
   He, Yuqiong
   Shen, Yi
   Zhang, Qi
   Zhu, Bo
   Zhang, Qiaoyan
   Qin, Luping
TI Rehmannia glutinosa Libosch Extracts Prevent Bone Loss and
   Architectural Deterioration and Enhance Osteoblastic Bone Formation by
   Regulating the IGF 1/PI3K/mTOR Pathway in Streptozotocin Induced
   Diabetic Rats
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE Rehmannia glutinosa Libosch; diabetic osteoporosis; osteoblast; BMP
   pathway; IGF 1; PI3K; mTOR signaling pathways
ID GENE EXPRESSION; DIFFERENTIATION; OSTEOPOROSIS; MELLITUS; TYPE 1; RUNX2;
   HYPERGLYCEMIA; STRENGTH; CATENIN; OSTERIX
AB Rehmanniae Radix Praeparata (RR, named as Shudihuang in traditional Chinese medicine), the steamed roots of Rehmannia glutinosa Libosch (Scrophulariaceae), has been demonstrated to have anti diabetic and anti osteoporotic activities. This study aimed to explore the protective effect and underlying mechanism of RR on diabetes induced bone loss. It was found that RR regulated the alkaline phosphatase activity and osteocalcin level, enhanced bone mineral density, and improved the bone microarchitecture in diabetic rats. The catalpol (CAT), acteoside (ACT), and echinacoside (ECH) from RR increased the proliferation and differentiation of osteoblastic MC3T3 E1 cells injured by high glucose and promoted the production of IGF 1 and expression of related proteins in BMP and IGF 1/PI3K/mammalian target of rapamycin complex 1 (mTOR) signaling pathways. The verifying tests of inhibitors of BMP pathway (noggin) and IGF 1/PI3K/mTOR pathway (picropodophyllin) and molecular docking of IGF 1R further indicated that CAT, ACT, and ECH extracted from RR enhanced bone formation by regulating IGF 1/PI3K/mTOR signaling pathways. These findings suggest that RR may prove to be a promising candidate drug for the prevention and treatment of diabetes induced osteoporosis.
C1 [Gong, Wan; Cheng, Gang; Zhang, Quanlong; Zhu, Bo; Zhang, Qiaoyan; Qin, Luping] Zhejiang Chinese Med Univ, Coll Pharmaceut Sci, Hangzhou 311402, Zhejiang, Peoples R China.
   [Gong, Wan] Zhejiang Chinese Med Univ, Coll Basic Med Sci, Hangzhou 310053, Zhejiang, Peoples R China.
   [Zhang, Naidan; He, Yuqiong; Zhang, Qiaoyan; Qin, Luping] Second Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R China.
   [Shen, Yi; Zhang, Qi] Fujian Univ Tradit Chinese Med, Sch Pharm, Fuzhou 350108, Fujian, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Chinese Medical
   University; Naval Medical University; Fujian University of Traditional
   Chinese Medicine
RP Zhang, QY; Qin, LP (通讯作者)，Zhejiang Chinese Med Univ, Coll Pharmaceut Sci, Hangzhou 311402, Zhejiang, Peoples R China.; Zhang, QY; Qin, LP (通讯作者)，Second Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R China.
EM zqy1965@163.com; lpqin@zcmu.edu.cn
RI ; Zhu, Bo/GOG 4717 2022
OI Cheng, Gang/0000 0002 1760 9539; Zhu, Bo/0000 0003 0281 3585
FU National Natural Science Foundation of China [U1505226, U1603283];
   Project of High level Innovation Team of Zhejiang Province, China
FX This study was supported by the National Natural Science Foundation of
   China (Grant No. U1505226 and U1603283), and the Project of High level
   Innovation Team of Zhejiang Province, China.
CR Anagnostis P, 2018, ENDOCRINE, V60, P373, DOI 10.1007/s12020 018 1548 x
   Bagi CM, 2018, CALCIFIED TISSUE INT, V102, P683, DOI 10.1007/s00223 017 0367 z
   Bakker AD, 2016, J CELL PHYSIOL, V231, P1283, DOI 10.1002/jcp.25228
   Bakker AD, 2015, CURR OSTEOPOROS REP, V13, P131, DOI 10.1007/s11914 015 0264 1
   Botolin S, 2006, J CELL BIOCHEM, V99, P411, DOI 10.1002/jcb.20842
   Brandao Burch A, 2005, CALCIFIED TISSUE INT, V77, P167, DOI 10.1007/s00223 004 0285 8
   Chen YA, 2019, J INT MED RES, V47, P1740, DOI 10.1177/0300060519830212
   Cheng AX, 2010, J BONE MINER RES, V25, P2404, DOI 10.1002/jbmr.174
   Choi C, 2012, MENOPAUSE, V19, P1043, DOI 10.1097/gme.0b013e31824b1cc5
   [傅淑平 Fu Shuping], 2014, [中国病理生理杂志, Chinese Journal of Pathophysiology], V30, P1656
   Ghodsi M, 2016, J DIABETES METAB DIS, V15, DOI 10.1186/s40200 016 0275 1
   Janghorbani M, 2007, AM J EPIDEMIOL, V166, P495, DOI 10.1093/aje/kwm106
   Jensen ED, 2010, BIOFACTORS, V36, P25, DOI 10.1002/biof.72
   Kanazawa I, 2018, INTERNAL MED, V57, P2773, DOI 10.2169/internalmedicine.0905 18
   Kanazawa I, 2017, ENDOCR J, V64, P1043, DOI 10.1507/endocrj.EJ17 0323
   Kawai M, 2012, ENDOCRIN METAB CLIN, V41, P323, DOI 10.1016/j.ecl.2012.04.013
   Kemink SAG, 2000, J ENDOCRINOL INVEST, V23, P295, DOI 10.1007/BF03343726
   Komori T, 2005, J CELL BIOCHEM, V95, P445, DOI 10.1002/jcb.20420
   Lee ST, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057708
   Li JJ, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 11090 7
   Lim DW, 2013, MOLECULES, V18, P5804, DOI 10.3390/molecules18055804
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Liu CY, 2017, J ETHNOPHARMACOL, V198, P351, DOI 10.1016/j.jep.2017.01.021
   Ma RF, 2017, CELL PHYSIOL BIOCHEM, V41, P55, DOI 10.1159/000455936
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nishimura R, 2002, BONE, V31, P303, DOI 10.1016/S8756 3282(02)00826 8
   Niu TH, 2005, GENE, V361, P38, DOI 10.1016/j.gene.2005.07.016
   Oh KO, 2003, CLIN CHIM ACTA, V334, P185, DOI 10.1016/S0009 8981(03)00238 9
   Räkel A, 2008, DIABETES METAB, V34, P193, DOI 10.1016/j.diabet.2007.10.008
   Schrodinger, 2017, SCHROD MAESTR VERS 1
   Schrodinger LLC., 2017, PYMOL MOL GRAPHICS S
   Sheng Matilda H C, 2014, J Bone Metab, V21, P41, DOI 10.11005/jbm.2014.21.1.41
   Starup Linde J, 2016, BONE, V82, P69, DOI 10.1016/j.bone.2015.02.019
   Stauffer F, 2016, BIOORG MED CHEM LETT, V26, P2065, DOI 10.1016/j.bmcl.2016.02.074
   Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676
   Tell Lebanon Osnat, 2016, Harefuah, V155, P697
   Wang R, 2017, J STEROID BIOCHEM, V174, P276, DOI 10.1016/j.jsbmb.2017.10.008
   Wu Mi shan, 2010, Zhongguo Yaolixue Tongbao, V26, P509
   Xia BJ, 2014, J ETHNOPHARMACOL, V153, P133, DOI 10.1016/j.jep.2014.01.040
   Xiao L, 2015, CELL BIOCHEM BIOPHYS, V71, P437, DOI 10.1007/s12013 014 0220 1
   Xie HG, 2018, BIOMED PHARMACOTHER, V108, P280, DOI 10.1016/j.biopha.2018.08.131
   Xue P, 2013, BIOCHEM BIOPH RES CO, V433, P226, DOI 10.1016/j.bbrc.2013.02.088
   Zhang H, 2018, BONE, V107, P36, DOI 10.1016/j.bone.2017.10.024
   Zhang RX, 2008, J ETHNOPHARMACOL, V117, P199, DOI 10.1016/j.jep.2008.02.018
   Zhou J, 2015, J ETHNOPHARMACOL, V164, P229, DOI 10.1016/j.jep.2015.02.026
   Zhu HF, 2016, CHIN MED UK, V11, DOI 10.1186/s13020 016 0096 7
   Zuo C, 2012, OSTEOPOROSIS INT, V23, P1653, DOI 10.1007/s00198 012 1909 x
NR 48
TC 91
Z9 112
U1 5
U2 75
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG 2
PY 2019
VL 20
IS 16
AR 3964
DI 10.3390/ijms20163964
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA IV6XM
UT WOS:000484411100121
PM 31443143
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Kimura, H
   Ng, JMY
   Curran, T
AF Kimura, Hiromichi
   Ng, Jessica M. Y.
   Curran, Tom
TI Transient inhibition of the hedgehog pathway in young mice causes
   permanent defects in bone structure
SO CANCER CELL
LA English
DT Article
ID SMALL MOLECULE INHIBITOR; CELL LUNG CANCER; INDIAN HEDGEHOG; STEM CELLS;
   VERATRUM CALIFORNICUM; SIGNALING PATHWAY; TARGETED THERAPY;
   PROSTATE CANCER; SONIC HEDGEHOG; IN VITRO
AB The Hedgehog (Hh) pathway plays critical roles in normal development and in tumorigenesis. We generated Gli luciferase transgenic mice to evaluate the Smo inhibitor, HhAntag, by whole animal functional imaging. HhAntag rapidly reduced systemic luciferase activity in 10  to 14 day old mice following oral dosing. Although pathway activity was restored 2 days after drug removal, brief inhibition caused permanent defects in bone growth. HhAntag inhibited proliferation and promoted differentiation of chondrocytes, leading to dramatic expansion of the hypertrophic zone. After drug removal, osteoblasts invaded the cartilage plate, mineralization occurred, and there was premature fusion of the growth plate resulting in permanent disruption of bone epiphyses.
C1 [Ng, Jessica M. Y.; Curran, Tom] Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Dept Pathol & Lab Med, Abramson Res Ctr 517, Philadelphia, PA 19104 USA.
   [Kimura, Hiromichi] St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of
   Philadelphia; St Jude Children's Research Hospital
RP Curran, T (通讯作者)，Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Dept Pathol & Lab Med, Abramson Res Ctr 517, 3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM currant@chop.edu
RI Curran, Tom/AAE 7631 2019; Curran, Tom/C 1164 2008
OI Curran, Tom/0000 0003 1444 7551
FU NCI NIH HHS [CA096832] Funding Source: Medline
CR Ahn S, 2005, NATURE, V437, P894, DOI 10.1038/nature03994
   Athar M, 2004, CANCER RES, V64, P7545, DOI 10.1158/0008 5472.CAN 04 1393
   Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733
   Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972
   BINNS W, 1965, J AM VET MED ASSOC, V147, P839
   BINNS W, 1963, AM J VET RES, V24, P1164
   Callahan CA, 2001, CURR OPIN GENET DEV, V11, P541, DOI 10.1016/S0959 437X(00)00230 6
   Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302
   Colnot C, 2005, DEVELOPMENT, V132, P1057, DOI 10.1242/dev.01649
   Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603
   Dellovade T, 2006, ANNU REV NEUROSCI, V29, P539, DOI 10.1146/annurev.neuro.29.051605.112858
   Ehlen Harald W. A., 2006, Birth Defects Research, V78, P267, DOI 10.1002/bdrc.20076
   Evangelista M, 2006, CLIN CANCER RES, V12, P5924, DOI 10.1158/1078 0432.CCR 06 1736
   Fogarty MP, 2005, J NEUROBIOL, V64, P458, DOI 10.1002/neu.20166
   Fuchs E, 2007, NATURE, V445, P834, DOI 10.1038/nature05659
   Gabay L, 2003, NEURON, V40, P485, DOI 10.1016/S0896 6273(03)00637 8
   Gilbertson RJ, 2004, LANCET ONCOL, V5, P209, DOI 10.1016/S1470 2045(04)01424 X
   Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109
   GORLIN RJ, 1995, DERMATOL CLIN, V13, P113, DOI 10.1016/S0733 8635(18)30114 1
   Hellemans J, 2003, AM J HUM GENET, V72, P1040, DOI 10.1086/374318
   KAMACHI Y, 1993, MOL CELL BIOL, V13, P5206, DOI 10.1128/MCB.13.9.5206
   Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962
   Keeler R F, 1972, Adv Exp Med Biol, V27, P107
   Kimura H, 2005, ONCOGENE, V24, P4026, DOI 10.1038/sj.onc.1208567
   Lai LP, 2005, J CELL BIOCHEM, V96, P1163, DOI 10.1002/jcb.20635
   Maeda Y, 2007, P NATL ACAD SCI USA, V104, P6382, DOI 10.1073/pnas.0608449104
   MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306
   McMahon AP, 2003, CURR TOP DEV BIOL, V53, P1, DOI 10.1016/S0070 2153(03)53002 2
   Mimeault M, 2006, STEM CELLS, V24, P2319, DOI 10.1634/stemcells.2006 0066
   Razzaque MS, 2005, J PATHOL, V207, P453, DOI 10.1002/path.1870
   Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019
   Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086
   Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101
   Sanchez P, 2005, CANCER RES, V65, P2990, DOI 10.1158/0008 5472.CAN 05 0439
   Sanchez P, 2005, MECH DEVELOP, V122, P223, DOI 10.1016/j.mod.2004.10.002
   Sasai K, 2006, CANCER RES, V66, P4215, DOI 10.1158/0008 5472.CAN 05 4505
   Sasai K, 2007, CANCER RES, V67, P3871, DOI 10.1158/0008 5472.CAN 07 0493
   Sasaki H, 1997, DEVELOPMENT, V124, P1313
   Savage DG, 2002, NEW ENGL J MED, V346, P683, DOI 10.1056/NEJMra013339
   Shibata K, 2000, HISTOCHEM CELL BIOL, V113, P153, DOI 10.1007/s004180050434
   Silvestri GA, 2005, CHEST, V128, P3975, DOI 10.1378/chest.128.6.3975
   St Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072
   Thompson MC, 2006, J CLIN ONCOL, V24, P1924, DOI 10.1200/JCO.2005.04.4974
   Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493
   Wetmore C, 2000, CANCER RES, V60, P2239
   Wetmore C, 2001, CANCER RES, V61, P513
   Williams JA, 2003, P NATL ACAD SCI USA, V100, P4616, DOI 10.1073/pnas.0732813100
NR 47
TC 189
Z9 216
U1 0
U2 9
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1535 6108
EI 1878 3686
J9 CANCER CELL
JI Cancer Cell
PD MAR
PY 2008
VL 13
IS 3
BP 249
EP 260
DI 10.1016/j.ccr.2008.01.027
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA 273LO
UT WOS:000253932300009
PM 18328428
OA Bronze
DA 2025 08 17
ER

PT J
AU Zeng, XH
   He, H
   Zhang, L
   Wu, YY
   Wang, YY
   Gong, P
AF Zeng, Xiaohua
   He, Hao
   Zhang, Liang
   Wu, Yingying
   Wang, Yanying
   Gong, Ping
TI A potential therapeutic approach to overload induced bone loss around
   implant: Parathyroid hormone (PTH)
SO MEDICAL HYPOTHESES
LA English
DT Article
ID OSSEOINTEGRATED ORAL IMPLANTS; DENTAL IMPLANTS; POSTMENOPAUSAL WOMEN;
   AUTOGENOUS BONE; MINERAL DENSITY; CORTICAL BONE; REGENERATION;
   OSTEOPOROSIS; TERIPARATIDE; MEN
AB The clinical use of dental implants has a high success rate, but overload induced bone loss around implant is not uncommon in patients with implant supported denture especially those with long cantilever designs and greatly harmful to the long term implant success. The mechanism underlying the bone loss is thought to be the imbalance of bone remodeling involving a detrimental positive feedback activated by overloading. While surgical regenerative treatments may be useful in promoting bone regeneration, extra suffering and risk of infection have to be fully recognized. To date, no optimal method is available to solve this problem. We hereby propose a novel therapy that may potentially improve this condition. Many studies have shown that parathyroid hormone (PTH), an anabolic agent targeting bone, is effective in reversing bone loss caused by osteoporosis with negative bone remodeling in clinical studies. Moreover, PTH has the potential to accelerate the bone healing in patients with fracture and fracture nonunion and improve osseointegration of implant inserted in pre existed bone defect via its anabolic effect to increase bone formation in animal model studies. Specifically for alveolar bone, PTH is associated with effective bone regeneration in patients with severe periodontitis. What is more, PTH and mechanical loading has a synergistic effect on bone formation, which is in favor of bone healing under physiological loading. The mechanisms underlying its anabolic effect may involve increased osteoblasts activity, prolonged osteoblasts life span and recruitment of new osteoblasts from marrow stromal cells. Furthermore, PTH could activate resting lining cells to initial de novo bone formation. Considering these actions of PTH, we hypothesize that PTH may be a potential treatment for overload induced bone loss around implant. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Zeng, Xiaohua; He, Hao; Zhang, Liang; Wu, Yingying; Wang, Yanying; Gong, Ping] Sichuan Univ, Dept Dent Implants, W China Sch Stomatol, Chengdu 610041, Sichuan, Peoples R China.
   [Zeng, Xiaohua; He, Hao; Zhang, Liang; Wu, Yingying; Wang, Yanying; Gong, Ping] State Key Lab Oral Dis, Chengdu 610041, Sichuan, Peoples R China.
C3 Sichuan University; Sichuan University
RP Gong, P (通讯作者)，Sichuan Univ, Dept Dent Implants, W China Sch Stomatol, Chengdu 610041, Sichuan, Peoples R China.
EM dentistgong@hotmail.com
RI Zhang, Liang/HPD 4165 2023
CR Alkhiary YM, 2005, J BONE JOINT SURG AM, V87A, P731, DOI 10.2106/JBJS.D.02115
   Aspenberg P, 2010, J BONE MINER RES, V25, P404, DOI 10.1359/jbmr.090731
   Aubin J. E., 2002, PRINCIPLES BONE BIOL, V1, P59, DOI [10.1016/B978 012098652 1.50106 2, DOI 10.1016/B978 012098652 1.50106 2]
   Bashutski JD, 2010, NEW ENGL J MED, V363, P2396, DOI 10.1056/NEJMoa1005361
   Brunski J B, 1999, Adv Dent Res, V13, P99
   Büchter A, 2004, BRIT J ORAL MAX SURG, V42, P454, DOI 10.1016/j.bjoms.2004.06.008
   Burr DB, 2002, BONE, V30, P2, DOI 10.1016/S8756 3282(01)00619 6
   Chintamaneni S, 2010, OSTEOPOROSIS INT, V21, P1059, DOI 10.1007/s00198 009 1061 4
   Daugaard H, 2011, CALCIFIED TISSUE INT, V88, P294, DOI 10.1007/s00223 010 9458 9
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Esposito M, 1998, EUR J ORAL SCI, V106, P721, DOI 10.1046/j.0909 8836..t01 6 .x
   Esposito M, 1998, EUR J ORAL SCI, V106, P527, DOI 10.1046/j.0909 8836..t01 2 .x
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Garetto L P, 1995, Implant Dent, V4, P235, DOI 10.1097/00008505 199500440 00002
   Grey A, 2003, ENDOCRINOLOGY, V144, P4886, DOI 10.1210/en.2003 0350
   Hagino H, 2001, J BONE MINER METAB, V19, P244, DOI 10.1007/s007740170027
   Heydenrijk K, 2002, INT J ORAL MAX IMPL, V17, P829
   Huja SS, 1999, BONE, V25, P217, DOI 10.1016/S8756 3282(99)00151 9
   Huja SS, 2004, SEMIN ORTHOD, V10, P162
   Isidor F, 1996, CLIN ORAL IMPLAN RES, V7, P143, DOI 10.1034/j.1600 0501.1996.070208.x
   Isidor F, 1997, CLIN ORAL IMPLAN RES, V8, P1, DOI 10.1111/j.1600 0501.1997.tb00001.x
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Jovanovi J. D., 2004, Medical Biology, V11, P35
   Jung RE, 2007, CLIN ORAL IMPLAN RES, V18, P319, DOI 10.1111/j.1600 0501.2007.01342.x
   Khoury F, 2001, J PERIODONTOL, V72, P1498, DOI 10.1902/jop.2001.72.11.1498
   Kim CH, 2003, J BONE MINER RES, V18, P2116, DOI 10.1359/jbmr.2003.18.12.2116
   Knecht Thomas P, 2004, Endocr Pract, V10, P293
   Kurland ES, 2000, J CLIN ENDOCR METAB, V85, P3069, DOI 10.1210/jc.85.9.3069
   Lane NE, 2000, J BONE MINER RES, V15, P944, DOI 10.1359/jbmr.2000.15.5.944
   Leucht P, 2007, BONE, V40, P919, DOI 10.1016/j.bone.2006.10.027
   Li J, 2003, ENDOCRINOLOGY, V144, P1226, DOI 10.1210/en.2002 220821
   Ma YF, 1999, J BONE MINER RES, V14, P439, DOI 10.1359/jbmr.1999.14.3.439
   Misch Carl E, 2005, Implant Dent, V14, P108, DOI 10.1097/01.id.0000165033.34294.db
   Misch CE, 2001, J PERIODONTOL, V72, P1276, DOI 10.1902/jop.2000.72.9.1276
   Misiorowski W, 2011, ENDOKRYNOL POL, V62, P73
   Morley P, 1999, CURR MED CHEM, V6, P1095
   Muhlbradt L, 1989, Int J Oral Maxillofac Implants, V4, P125
   NAERT I, 1992, J PROSTHET DENT, V68, P949, DOI 10.1016/0022 3913(92)90557 Q
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9
   Oteo Alvaro A., 2010, Journal of shoulder and elbow surgery / American Shoulder and Elbow Surgeons ... [et al.], V19, pe22, DOI [DOI 10.1016/J.JSE.2010.05.005, 10.1016/j.jse.2010.05.005]
   Parfitt AM, 2002, BONE, V30, P5, DOI 10.1016/S8756 3282(01)00642 1
   Piattelli A, 2003, J PERIODONTOL, V74, P385, DOI 10.1902/jop.2003.74.3.385
   Piattelli A, 1998, J PERIODONTOL, V69, P178, DOI 10.1902/jop.1998.69.2.178
   Puzas J Edward, 2006, J Am Acad Orthop Surg, V14, pS145
   Quirynen M, 1992, Clin Oral Implants Res, V3, P104, DOI 10.1034/j.1600 0501.1992.030302.x
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Roberts MD, 2009, J BIOMECH, V42, P2431, DOI 10.1016/j.jbiomech.2009.08.030
   Rotenberg SA, 2011, J PERIODONTOL   0114
   Rubery PT, 2010, J SPINAL DISORD TECH, V23, P151, DOI 10.1097/BSD.0b013e31819a8b7a
   Sugiyama T, 2008, BONE, V43, P238, DOI 10.1016/j.bone.2008.04.012
   Tomson PLM, 2004, J PROSTHET DENT, V92, P12, DOI 10.1016/j.prosdent.2004.04.016
   Valderrama P, 2010, J PERIODONTOL, V81, P737, DOI 10.1902/jop.2010.090562
   von Arx T, 1997, CLIN ORAL IMPLAN RES, V8, P517, DOI 10.1034/j.1600 0501.1997.080611.x
NR 54
TC 10
Z9 13
U1 0
U2 15
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306 9877
EI 1532 2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD NOV
PY 2011
VL 77
IS 5
BP 701
EP 704
DI 10.1016/j.mehy.2011.06.016
PG 4
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 843PN
UT WOS:000296684500001
PM 21908105
DA 2025 08 17
ER

PT J
AU Chen, XY
   Wei, YL
   Li, ZC
   Zhou, CC
   Fan, Y
AF Chen, Xinyu
   Wei, Yali
   Li, Zucen
   Zhou, Chenchen
   Fan, Yi
TI Distinct role of Klotho in long bone and craniofacial bone: skeletal
   development, repair and regeneration
SO PEERJ
LA English
DT Article
DE Klotho protein; Bone remodeling; Maxillofacial bone; Appendicular
   skeleton; Clinical therapy
ID GROWTH FACTOR 23; TRANSCRIPTS ENCODING MEMBRANE; LINEAGE FATE
   DETERMINATION; MESENCHYMAL STEM CELLS; TNF ALPHA; OSTEOCLAST
   DIFFERENTIATION; KIDNEY DISEASE; IN VITRO; EXPRESSION; PROTEIN
AB Bone defects are highly prevalent diseases caused by trauma, tumors, inflammation, congenital malformations and endocrine abnormalities. Ideally effective and side effect free approach to dealing with bone defects remains a clinical conundrum. Klotho is an important protein, which plays an essential role in regulating aging and mineral ion homeostasis. More recently, research revealed the function of Klotho in regulating skeleton development and regeneration. Klotho has been identified in mesenchymal stem cells, osteoblasts, osteocytes and osteoclasts in different skeleton regions. The specific function and regulatory mechanisms of Klotho in long bone and craniofacial bone vary due to their different embryonic development, ossification and cell types, which remain unclear and without conclusion. Moreover, studies have confirmed that Klotho is a multifunctional protein that can inhibit inflammation, resist cancer and regulate the endocrine system, which may further accentuate the potential of Klotho to be the ideal molecule in inducing bone restoration clinically. Besides, as an endogenous protein, Klotho has a promising potential for clinical therapy without side effects. In the current review, we summarized the specific function of Klotho in long bone and craniofacial skeleton from phenotype to cellular alternation and signaling pathway. Moreover, we illustrated the possible future clinical application for Klotho. Further research on Klotho might help to solve the existing clinical difficulties in bone healing and increase the life quality of patients with bone injury and the elderly.
C1 [Chen, Xinyu; Wei, Yali; Li, Zucen; Zhou, Chenchen; Fan, Yi] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Peoples R China.
   [Chen, Xinyu; Wei, Yali; Li, Zucen; Zhou, Chenchen; Fan, Yi] Sichuan Univ, West China Hosp Stomatol, Natl Ctr Stomatol, Chengdu, Peoples R China.
   [Chen, Xinyu; Wei, Yali; Li, Zucen; Zhou, Chenchen; Fan, Yi] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Chengdu, Peoples R China.
   [Wei, Yali; Li, Zucen; Fan, Yi] Sichuan Univ, West China Hosp Stomatol, Dept Operat Dent & Endodont, Chengdu, Peoples R China.
   [Zhou, Chenchen] Sichuan Univ, West China Hosp Stomatol, Dept Pediat Dent, Chengdu, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University; Sichuan
   University; Sichuan University
RP Zhou, CC; Fan, Y (通讯作者)，Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Peoples R China.; Zhou, CC; Fan, Y (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Ctr Stomatol, Chengdu, Peoples R China.; Zhou, CC; Fan, Y (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Chengdu, Peoples R China.; Fan, Y (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Dept Operat Dent & Endodont, Chengdu, Peoples R China.; Zhou, CC (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Dept Pediat Dent, Chengdu, Peoples R China.
EM chenchenzhou5510@scu.edu.cn; yifan@scu.edu.cn
RI Chen, Xinyu/JKJ 1847 2023; Zhou, Chenchen/LKJ 8704 2024
FU National Natural Science Foundation of China (NSFC) [82370945, 82171001,
   82222015]; State Key Laboratory of Oral Diseases Open Funding Grant
   Sichuan University [SKLOD R016]; West China School/Hospital of
   Stomatology, Sichuan University [RCDWJS2024  (4)]; Natural Science
   Foundation of Sichuan Province [2024NSFSC0545]
FX This work was supported by grants from the National Natural Science
   Foundation of China (NSFC) (82370945, 82171001 and 82222015) ; the State
   Key Laboratory of Oral Diseases Open Funding Grant Sichuan University
   (SKLOD R016) ; the Research Funding from West China School/Hospital of
   Stomatology, Sichuan University (RCDWJS2024  (4) ) ; and the Natural
   Science Foundation of Sichuan Province (2024NSFSC0545) . The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Abolghasemi M, 2019, J CELL BIOCHEM, V120, P14306, DOI 10.1002/jcb.29022
   Aldhaher A, 2023, HELIYON, V9, DOI 10.1016/j.heliyon.2023.e17050
   Amaro Gahete FJ, 2019, REJUV RES, V22, P478, DOI 10.1089/rej.2018.2092
   Andrukhova O, 2017, J BONE MINER RES, V32, P2049, DOI 10.1002/jbmr.3195
   Bacakova L, 2018, BIOTECHNOL ADV, V36, P1111, DOI 10.1016/j.biotechadv.2018.03.011
   Balkwill F, 2006, CANCER METAST REV, V25, P409, DOI 10.1007/s10555 006 9005 3
   Bilha SC, 2021, ENDOKRYNOL POL, V72, P202, DOI 10.5603/EP.a2021.0028
   Bonewald LF, 2008, OSTEOPOROSIS, VOLS I AND II, 3RD EDITION, P169
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brenchley L, 2024, J CLIN PERIODONTOL, V51, P464, DOI 10.1111/jcpe.13940
   Brownstein CA, 2008, P NATL ACAD SCI USA, V105, P3455, DOI 10.1073/pnas.0712361105
   Buendía P, 2016, VITAM HORM, V101, P119, DOI 10.1016/bs.vh.2016.02.005
   Carrillo López N, 2016, KIDNEY INT, V90, P77, DOI 10.1016/j.kint.2016.01.024
   Castner SA, 2023, NATURE AGING, V3, P931, DOI 10.1038/s43587 023 00441 x
   Chen CD, 2007, P NATL ACAD SCI USA, V104, P19796, DOI 10.1073/pnas.0709805104
   Chen GZ, 2018, NATURE, V553, P461, DOI 10.1038/nature25451
   Chen GQ, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.970575
   Chen H, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9261565
   Chen Q, 2019, INFLAMMATION, V42, P221, DOI 10.1007/s10753 018 0886 4
   Chen XW, 2022, KIDNEY INT, V102, P506, DOI 10.1016/j.kint.2022.04.028
   Choo KB, 2014, INT J MED SCI, V11, P1201, DOI 10.7150/ijms.8356
   Christov M, 2018, BEST PRACT RES CL EN, V32, P685, DOI 10.1016/j.beem.2018.06.004
   Clinkenbeard E, 2023, CALCIFIED TISSUE INT, V113, P4, DOI 10.1007/s00223 023 01092 1
   Junho CVC, 2022, BIOMED PHARMACOTHER, V153, DOI 10.1016/j.biopha.2022.113515
   Danisovic L, 2017, J PHYSIOL PHARMACOL, V68, P149
   Doi K, 2013, J TISSUE ENG REGEN M, V7, P864, DOI 10.1002/term.1478
   Donadelli M, 2014, CELL MOL LIFE SCI, V71, P1171, DOI 10.1007/s00018 013 1407 0
   Dong W, 2022, BONE JOINT RES, V11, P528, DOI 10.1302/2046 3758.118.BJR 2021 0392.R1
   Eleuterio E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071101
   Erben RG, 2017, TOXICOL PATHOL, V45, P904, DOI 10.1177/0192623317737469
   Fan J, 2016, STEM CELLS, V34, P1615, DOI 10.1002/stem.2305
   Fan Y, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 022 00957 5
   Fang B, 2022, CYTOTECHNOLOGY, V74, P65, DOI 10.1007/s10616 021 00507 x
   Feng R, 2023, STEM CELLS DEV, V32, P331, DOI 10.1089/scd.2022.0243
   Ferreira AC, 2021, TRANSPL INT, V34, P1065, DOI 10.1111/tri.13888
   Fu XR, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080784
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Gharibi B, 2014, STEM CELLS, V32, P2256, DOI 10.1002/stem.1709
   Gu YQ, 2019, AGING US, V11, P12793, DOI 10.18632/aging.102603
   Guo R, 1997, J BONE MINER RES, V12, P1009, DOI 10.1359/jbmr.1997.12.7.1009
   Hamdy M, 2022, J PEDIAT HEMATOL ONC, V44, pE40, DOI 10.1097/MPH.0000000000002231
   Han W, 2019, MENOPAUSE, V26, P546, DOI 10.1097/GME.0000000000001276
   Han XB, 2016, CURR OPIN NEPHROL HY, V25, P333, DOI 10.1097/MNH.0000000000000240
   Hikone K, 2017, J HISTOCHEM CYTOCHEM, V65, P207, DOI 10.1369/0022155416689670
   Ito S, 2000, MECH DEVELOP, V98, P115, DOI 10.1016/S0925 4773(00)00439 1
   Ito S, 2002, BBA GENE STRUCT EXPR, V1576, P341, DOI 10.1016/S0167 4781(02)00281 6
   Jiang JL, 2023, BMC ENDOCR DISORD, V23, DOI 10.1186/s12902 023 01380 9
   Kaludjerovic J, 2017, FASEB J, V31, P2050, DOI 10.1096/fj.201601036R
   Kaszubowska L, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24098393
   Katsaounis PV, 2023, SCAND J GASTROENTERO, V58, P185, DOI 10.1080/00365521.2022.2114813
   Kawaguchi H, 1999, J CLIN INVEST, V104, P229, DOI 10.1172/JCI5705
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   King MD, 2013, NEUROSCI LETT, V542, P92, DOI 10.1016/j.neulet.2013.02.051
   Komaba H, 2018, CURR OPIN NEPHROL HY, V27, P298, DOI 10.1097/MNH.0000000000000423
   Komaba H, 2017, KIDNEY INT, V92, P599, DOI 10.1016/j.kint.2017.02.014
   Kono SJ, 2007, BONE, V40, P68, DOI 10.1016/j.bone.2006.07.024
   Krick S, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00236 2018
   Kuro o M, 2006, CURR OPIN NEPHROL HY, V15, P437, DOI 10.1097/01.mnh.0000232885.81142.83
   Kuro O M, 2011, KIDNEY INT, V79, pS20, DOI 10.1038/ki.2011.26
   Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285
   Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766
   Kuzmova Z, 2021, PHYSIOL RES, V70, pS43, DOI 10.33549/physiolres.934773
   Kyono A, 2012, J BONE MINER METAB, V30, P19, DOI 10.1007/s00774 011 0288 2
   Laird NZ, 2021, ADV DRUG DELIVER REV, V174, P613, DOI 10.1016/j.addr.2021.05.009
   Lee J, 2021, BIOCHEM BIOPH RES CO, V534, P1040, DOI 10.1016/j.bbrc.2020.10.040
   Li Y, 2013, CALCIFIED TISSUE INT, V93, P556, DOI 10.1007/s00223 013 9795 6
   Li Y, 2011, J BONE MINER RES, V26, P2656, DOI 10.1002/jbmr.480
   Liang X, 2018, BIOCHEM BIOPH RES CO, V507, P355, DOI 10.1016/j.bbrc.2018.11.040
   Liu HJ, 2007, SCIENCE, V317, P803, DOI 10.1126/science.1143578
   Liu Q, 2024, ORAL DIS, V30, P2463, DOI 10.1111/odi.14703
   López Otín C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Lu Yongbo, 2011, Curr Osteoporos Rep, V9, P103, DOI 10.1007/s11914 011 0053 4
   Luo XT, 2022, FRONT CELL INFECT MI, V12, DOI 10.3389/fcimb.2022.908859
   Ma Y, 2018, AGING CELL, V17, DOI 10.1111/acel.12709
   Manabe N, 2001, J IMMUNOL, V167, P2625, DOI 10.4049/jimmunol.167.5.2625
   Marini F, 2023, OSTEOPOROSIS INT, V34, P213, DOI 10.1007/s00198 022 06523 7
   Matei A, 2022, J NEPHROL, V35, P293, DOI [10.1007/s40620 021 00972 9, 10.1162/jocn_a_01695]
   Matsumura Y, 1998, BIOCHEM BIOPH RES CO, V242, P626, DOI 10.1006/bbrc.1997.8019
   Matsuura T, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/769414
   Miao DS, 2001, ENDOCRINOLOGY, V142, P926, DOI 10.1210/en.142.2.926
   Minamizaki T, 2018, J ENDOCRINOL, V237, P285, DOI 10.1530/JOE 17 0683
   Murali SK, 2016, J BONE MINER RES, V31, P129, DOI 10.1002/jbmr.2606
   Nakatani T, 2009, FASEB J, V23, P433, DOI 10.1096/fj.08 114397
   Neyra JA, 2021, CLIN J AM SOC NEPHRO, V16, P162, DOI 10.2215/CJN.02840320
   Toan NK, 2020, FEBS LETT, V594, P290, DOI 10.1002/1873 3468.13613
   Niu QR, 2023, J ORTHOP SURG RES, V18, DOI 10.1186/s13018 023 03849 8
   Olauson H, 2017, BONE, V100, P19, DOI 10.1016/j.bone.2017.03.043
   Olejnik A, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 47686 5
   Ou QM, 2019, BIOMATER SCI UK, V7, P1973, DOI 10.1039/c8bm01653d
   Ponzetti M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136651
   Prud'homme GJ, 2022, FRONT AGING LAUSANNE, V3, DOI 10.3389/fragi.2022.931331
   Quarles LD, 2019, CURR OPIN NEPHROL HY, V28, P16, DOI 10.1097/MNH.0000000000000467
   Raimann A, 2013, CONNECT TISSUE RES, V54, P108, DOI 10.3109/03008207.2012.753879
   Rani S, 2010, J CELL PHYSIOL, V225, P152, DOI 10.1002/jcp.22208
   Rhee Y, 2011, BONE, V49, P636, DOI 10.1016/j.bone.2011.06.025
   Roberts W.E., 2004, SEMIN ORTHOD, V10, P100, DOI DOI 10.1053/J.SODO.2004.01.001
   Rodgers JT, 2014, NATURE, V510, P393, DOI 10.1038/nature13255
   Roig Soriano J, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 31117 6
   Salamanna F, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25115879
   Sariboyaci AE, 2022, MED ONCOL, V39, DOI 10.1007/s12032 022 01793 x
   Shalhoub V, 2011, CALCIFIED TISSUE INT, V89, P140, DOI 10.1007/s00223 011 9501 5
   Shan HJ, 2022, BIOMATERIALS, V284, DOI 10.1016/j.biomaterials.2022.121482
   Shen FK, 2024, PHYTOMEDICINE, V125, DOI 10.1016/j.phymed.2024.155356
   Shimada T, 2004, J BONE MINER RES, V19, P429, DOI 10.1359/JBMR.0301264
   Shiraki Iida T, 1998, FEBS LETT, V424, P6, DOI 10.1016/S0014 5793(98)00127 6
   Smolinska V, 2023, CELL TRANSPLANT, V32, DOI 10.1177/09636897231183530
   Suzuki H, 2008, ANAT REC, V291, P183, DOI 10.1002/ar.20630
   Tan BW, 2021, INT J ORAL SCI, V13, DOI 10.1038/s41368 021 00113 9
   Tang XW, 2016, LAB INVEST, V96, P197, DOI 10.1038/labinvest.2015.86
   Tibúrcio Machado CS, 2021, INT ENDOD J, V54, P712, DOI 10.1111/iej.13467
   Tozer L, 2023, NATURE, V619, P234, DOI 10.1038/d41586 023 02214 3
   Tresguerres FGF, 2020, ANN ANAT, V227, DOI 10.1016/j.aanat.2019.151422
   Trubiani O, 2019, STEM CELLS DEV, V28, P995, DOI 10.1089/scd.2019.0025
   Tsai CL, 2014, BONE, V60, P186, DOI 10.1016/j.bone.2013.12.014
   Tsou HK, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15071965
   Ullah M, 2019, J GERONTOL A BIOL, V74, P1396, DOI 10.1093/gerona/gly261
   Vozna IV, 2021, ZAPOROZHYE MED J, V23, P274, DOI 10.14739/2310 1210.2021.2.228787
   Wang YJ, 2020, BIOMED PHARMACOTHER, V131, DOI 10.1016/j.biopha.2020.110660
   Wang ZF, 2024, J GERONTOL A BIOL, V79, DOI 10.1093/gerona/glae172
   Wu Y, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1109296
   Xiao ZS, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.132820
   Xing LP, 2005, IMMUNOL REV, V208, P19, DOI 10.1111/j.0105 2896.2005.00336.x
   Yamashita T, 2000, J ENDOCRINOL, V164, P239, DOI 10.1677/joe.0.1640239
   Yang Y, 2021, INT IMMUNOPHARMACOL, V101, DOI 10.1016/j.intimp.2021.108299
   Yao ZQ, 2022, CELLS BASEL, V11, DOI 10.3390/cells11010132
   Yook Jong In, 2020, [The Korean Journal of Oral and Maxillofacial Pathology, 대한구강악안면병리학회지], V44, P103
   Yu T, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm 21 4332
   Yuan Q, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 28096 z
   Yuan Q, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002726
   Zhang W, 2015, GROWTH FACTORS, V33, P356, DOI 10.3109/08977194.2015.1108313
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
   Zhao BH, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.583561
   Zhao BH, 2017, CURR OSTEOPOROS REP, V15, P126, DOI 10.1007/s11914 017 0358 z
   Zhao TT, 2024, RSC ADV, V14, P2016, DOI 10.1039/d3ra05046g
   Zhu ZW, 2021, CELL MOL LIFE SCI, V78, P7831, DOI 10.1007/s00018 021 03972 x
NR 136
TC 3
Z9 3
U1 5
U2 6
PU PEERJ INC
PI LONDON
PA 341 345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167 8359
J9 PEERJ
JI PeerJ
PD OCT 21
PY 2024
VL 12
AR 18269
DI 10.7717/peerj.18269
PG 33
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA T8J3F
UT WOS:001407396000001
PM 39465174
OA gold
DA 2025 08 17
ER

PT J
AU Al Hadi, H
   Smerdon, GR
   Fox, SW
AF Al Hadi, Hadil
   Smerdon, Gary R.
   Fox, Simon W.
TI Hyperbaric Oxygen Therapy Suppresses Osteoclast Formation and Bone
   Resorption
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE osteoclast; hyperbaric oxygen therapy; osteonecrosis; hypoxia
ID HYPOXIA INDUCIBLE FACTOR; DIFFERENTIATION; EXPRESSION; PROLIFERATION;
   OSTEOBLASTS; INHIBITOR; PRESSURE; STRESS; GROWTH; CELLS
AB The cellular and molecular mechanism through which hyperbaric oxygen therapy (HBO) improves osteonecrosis (ON) is unclear. The present study therefore examined the effect of HBO, pressure and hyperoxia on RANKL induced osteoclast formation in RAW 264.7 cells and human peripheral blood monocytes (PBMC). Daily exposure to HBO (2.4 ATA, 97% O 2, 90min), hyperbaric pressure (2.4 ATA, 8.8% O 2, 90min) or normobaric hyperoxia (1 ATA, 95% O 2, 90min) significantly decreased RANKL induced osteoclast formation and bone resorption in normoxic conditions. HBO had a more pronounced anti osteoclastic effect than hyperoxia or pressure alone and also directly inhibited osteoclast formation and resorption in hypoxic conditions a hallmark of many osteolytic skeletal disorders. The suppressive action of HBO was at least in part mediated through a reduction in RANK, NFATc1, and Dc STAMP expression and inhibition of hypoxia induced HIF 1 mRNA and protein expression. This data provides mechanistic evidence supporting the use of HBO as an adjunctive therapy to prevent osteoclast formation and bone loss associated with low oxygen partial pressure. (c) 2013 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 31:1839 1844, 2013
C1 [Al Hadi, Hadil; Fox, Simon W.] Univ Plymouth, Sch Biomed & Biol Sci, Plymouth PL4 8AA, Devon, England.
   [Smerdon, Gary R.] Diving Dis Res Ctr, Plymouth PL6 8BU, Devon, England.
C3 University of Plymouth
RP Fox, SW (通讯作者)，Univ Plymouth, Sch Biomed & Biol Sci, Plymouth PL4 8AA, Devon, England.
EM simon.fox@plymouth.ac.uk
RI Smerdon, Gary/W 2035 2019; fox, simon/D 8119 2014
OI Fox, Simon/0000 0002 4862 5363; 
FU Iraqi Government; Diving Diseases Research Centre
FX Grant sponsor: Iraqi Government and the Diving Diseases Research Centre.
CR Arnett TR, 2003, J CELL PHYSIOL, V196, P2, DOI 10.1002/jcp.10321
   Bejar J, 2005, THEOR BIOL MED MODEL, V2, DOI 10.1186/1742 4682 2 24
   Benson RM, 2003, CLIN EXP IMMUNOL, V134, P57, DOI 10.1046/j.1365 2249.2003.02248.x
   BURSTONE MS, 1958, JNCI J NATL CANCER I, V21, P523
   Chen YC, 2007, LEUKEMIA RES, V31, P805, DOI 10.1016/j.leukres.2006.09.016
   Fukuoka H, 2005, BIOCHEM BIOPH RES CO, V328, P885, DOI 10.1016/j.bbrc.2005.01.042
   GRAY DH, 1976, CLIN ORTHOP RELAT R, P225
   Hiraga T, 2007, CANCER RES, V67, P4157, DOI 10.1158/0008 5472.CAN 06 2355
   Hsieh CP, 2010, CONNECT TISSUE RES, V51, P497, DOI 10.3109/03008201003746679
   Jan AMA, 2006, ORAL SURG ORAL MED O, V101, P146, DOI 10.1016/j.tripleo.2005.08.032
   Karieb S, 2011, J CELL BIOCHEM, V112, P476, DOI 10.1002/jcb.22935
   Katz J, 2011, INT J ORAL MAX SURG, V40, P605, DOI 10.1016/j.ijom.2011.02.002
   Kim HJ, 2006, FREE RADICAL BIO MED, V40, P1483, DOI 10.1016/j.freeradbiomed.2005.10.066
   Knowles HJ, 2008, J PATHOL, V215, P56, DOI 10.1002/path.2319
   Knowles HJ, 2010, FASEB J, V24, P4648, DOI 10.1096/fj.10 162230
   Knowles HJ, 2009, J PATHOL, V218, P256, DOI 10.1002/path.2534
   Kurowska Stolarska M, 2009, ARTHRITIS RHEUM US, V60, P3663, DOI 10.1002/art.25001
   Leger AJ, 2010, J BONE MINER METAB, V28, P510, DOI 10.1007/s00774 010 0171 6
   Maurer P, 2006, INT J ORAL MAX SURG, V35, P231, DOI 10.1016/j.ijom.2005.07.016
   Muhonen A, 2004, INT J ORAL MAX SURG, V33, P173, DOI 10.1054/ijom.2003.0489
   Muzylak M, 2006, CALCIFIED TISSUE INT, V79, P301, DOI 10.1007/s00223 006 0082 7
   Rubin J, 1997, J CELL PHYSIOL, V170, P81, DOI 10.1002/(SICI)1097 4652(199701)170:1<81::AID JCP9>3.0.CO;2 H
   Srinivasan S, 2007, ANN NY ACAD SCI, V1117, P51, DOI 10.1196/annals.1402.067
   Tang ZN, 2011, BIOCHEM BIOPH RES CO, V408, P411, DOI 10.1016/j.bbrc.2011.04.035
   Utting JC, 2010, CELL BIOCHEM FUNCT, V28, P374, DOI 10.1002/cbf.1660
   Vescovi P, 2010, Minerva Stomatol, V59, P181
   Walmsley SR, 2005, J EXP MED, V201, P105, DOI 10.1084/jem.20040624
   Wong AK, 2008, J CRANIOFAC SURG, V19, P757, DOI 10.1097/SCS.0b013e31816aac19
   Wu D, 2007, CONNECT TISSUE RES, V48, P206, DOI 10.1080/03008200701458749
   Yu X, 2009, EUR SURG RES, V42, P130, DOI 10.1159/000196164
   Zhao Y, 2012, J CELL PHYSIOL, V227, P639, DOI 10.1002/jcp.22768
NR 31
TC 44
Z9 44
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD NOV
PY 2013
VL 31
IS 11
BP 1839
EP 1844
DI 10.1002/jor.22443
PG 6
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 224YX
UT WOS:000324930500023
PM 23878004
DA 2025 08 17
ER

PT J
AU Littman, J
   Gil, H
   Aaron, R
AF Littman, Jake
   Gil, Holly
   Aaron, Roy
TI Spontaneous Bone Marrow Edema: Perfusion Abnormalities and Treatment
   with Surgical Decompression
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE MRI; pathophysiology; venous stasis; bone pain; surgical decompression;
   intraosseous hypertension
ID INTRAOSSEOUS PRESSURE; TRANSIENT OSTEOPOROSIS; CORE DECOMPRESSION;
   AVASCULAR NECROSIS; VENOUS CONGESTION; BLOOD FLOW; OSTEOARTHRITIS; HIP;
   OXYGEN; PAIN
AB Bone marrow edema (BME), also termed bone marrow lesions, is a syndrome characterized by bone pain and the appearance of high signal intensity on T2 fat suppressed and short tau inversion recovery (STIR) MRI sequences. BME can be related to trauma or a variety of non traumatic diseases, and current treatment modalities include non steroidal anti inflammatory drugs (NSAIDS), bisphosphonates, denosumab, extracorporeal shockwave therapy (ESWT), the vasoactive prostacyclin analogue iloprost, and surgical decompression. Spontaneous BME is a subset that has been observed with no apparent causative conditions. It is most likely caused by venous outflow obstruction and intraosseous hypertension. These are mechanistically related to impaired perfusion and ischemia in several models of BME and are related to bone remodeling. The association of perfusion abnormalities and bone pain provides the pathophysiological rationale for surgical decompression. We present a case of spontaneous BME and a second case of spontaneous migratory BME treated with surgical decompression and demonstrate resolution of pain and the high signal intensity on MRI. This report provides an integration of the clinical syndrome, MR imaging characteristics, circulatory pathophysiology, and treatment. It draws upon several studies to suggest that both the bone pain and the MRI characteristics are related to venous stasis, and when circulatory pathologies are relieved by decompression or fenestration, both the bone pain and the MRI signal abnormalities resolve.
C1 [Littman, Jake; Aaron, Roy] Brown Univ, Warren Alpert Med Sch, Dept Orthoped Surg, Providence, RI 02903 USA.
   [Gil, Holly] Brown Univ, Warren Alpert Med Sch, Dept Radiol, Providence, RI 02903 USA.
C3 Brown University; Brown University
RP Aaron, R (通讯作者)，Brown Univ, Warren Alpert Med Sch, Dept Orthoped Surg, Providence, RI 02903 USA.
EM roy_aaron@brown.edu
OI Aaron, Roy/0000 0002 0745 2267; Littman, Jake/0000 0002 7122 2423
FU Miriam Hospital
FX This study was funded by a research grant from The Miriam Hospital.
CR Aaron RK, 2018, OSTEOARTHR CARTILAGE, V26, P940, DOI 10.1016/j.joca.2018.04.003
   Aaron RK, 2007, ANN NY ACAD SCI, V1117, P124, DOI 10.1196/annals.1402.069
   Aigner N, 2005, WIEN KLIN WOCHENSCHR, V117, P130, DOI 10.1007/s00508 005 321 3
   ARNOLDI C C, 1972, Journal of Bone and Joint Surgery British Volume, V54B, P409
   ARNOLDI CC, 1975, J BONE JOINT SURG BR, V57, P360, DOI 10.1302/0301 620X.57B3.360
   ARNOLDI CC, 1980, ACTA ORTHOP SCAND, V51, P19, DOI 10.3109/17453678008990764
   ARNOLDI CC, 1994, ACTA ORTHOP SCAND, V65, P5
   Baumbach SF, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020551
   Berger CE, 2006, ARTHROSCOPY, V22, P866, DOI 10.1016/j.arthro.2006.04.095
   BJORKSTROM S, 1980, ARCH ORTHOP TRAUM SU, V97, P81, DOI 10.1007/BF00450927
   Cahir JG, 2008, EUR J RADIOL, V67, P2, DOI 10.1016/j.ejrad.2008.01.051
   Disch AC, 2005, J BONE JOINT SURG BR, V87B, P560, DOI 10.1302/0301 620X.87B4.15658
   Eriksen EF, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.124
   Foti G, 2021, TOMOGRAPHY, V7, P387, DOI 10.3390/tomography7030034
   Gil HC, 2006, SEMIN MUSCULOSKEL R, V10, P177, DOI 10.1055/s 2006 957171
   Guardiano SA, 2004, JCR J CLIN RHEUMATOL, V10, P269, DOI 10.1097/01.rhu.0000141509.18395.3c
   GUERRA JJ, 1995, J BONE JOINT SURG AM, V77A, P616, DOI 10.2106/00004623 199504000 00017
   HOFMANN S, 1993, J BONE JOINT SURG BR, V75, P210, DOI 10.1302/0301 620X.75B2.8444939
   Jäger M, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2526
   KIAER T, 1993, J ORTHOPAED RES, V11, P28, DOI 10.1002/jor.1100110105
   KIAER T, 1992, J ORTHOPAED RES, V10, P807, DOI 10.1002/jor.1100100609
   KIAER T, 1990, J BONE JOINT SURG BR, V72, P1023, DOI 10.1302/0301 620X.72B6.2246284
   KIAER T, 1988, CLIN ORTHOP RELAT R, P149
   LEMPERG RK, 1978, CLIN ORTHOP RELAT R, P143
   Maraghelli D, 2021, SKELETAL RADIOL, V50, P645, DOI 10.1007/s00256 020 03632 4
   Meizer R, 2005, WIEN KLIN WOCHENSCHR, V117, P278, DOI 10.1007/s00508 005 0326 y
   Moosikasuwan JB, 2004, SKELETAL RADIOL, V33, P380, DOI 10.1007/s00256 004 0783 9
   Paraskevopoulos K, 2023, OSTEOPOROSIS INT, V34, P269, DOI 10.1007/s00198 022 06584 8
   PEDERSEN NW, 1989, ACTA ORTHOP SCAND, V60, P415, DOI 10.3109/17453678909149309
   Radke S, 2003, ARCH ORTHOP TRAUM SU, V123, P223, DOI 10.1007/s00402 003 0506 z
   Simkin Peter A, 2004, Novartis Found Symp, V260, P179
   Starr AM, 2008, ACTA RADIOL, V49, P771, DOI 10.1080/02841850802161023
   Thiryayi WA, 2008, EUR J RADIOL, V67, P62, DOI 10.1016/j.ejrad.2008.01.056
   Tosun HB, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.10547
   Ververidis AN, 2020, J ORTHOP, V17, P30, DOI 10.1016/j.jor.2019.08.025
NR 35
TC 1
Z9 1
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD APR
PY 2023
VL 24
IS 7
AR 6761
DI 10.3390/ijms24076761
PG 7
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA D6WH0
UT WOS:000970106900001
PM 37047734
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Sato, K
   Suematsu, A
   Nakashima, T
   Takemoto Kimura, S
   Aoki, K
   Morishita, Y
   Asahara, H
   Ohya, K
   Yamaguchi, A
   Takai, T
   Kodama, T
   Chatila, TA
   Bito, H
   Takayanagi, H
AF Sato, Kojiro
   Suematsu, Ayako
   Nakashima, Tomoki
   Takemoto Kimura, Sayaka
   Aoki, Kazuhiro
   Morishita, Yasuyuki
   Asahara, Hiroshi
   Ohya, Keiichi
   Yamaguchi, Akira
   Takai, Toshiyuki
   Kodama, Tatsuhiko
   Chatila, Talal A.
   Bito, Haruhiko
   Takayanagi, Hiroshi
TI Regulation of osteoclast differentiation and function by the CaMK CREB
   pathway
SO NATURE MEDICINE
LA English
DT Article
ID PROTEIN KINASE IV; T CELLS; C FOS; BONE HOMEOSTASIS; NUCLEAR FACTOR;
   TRANSCRIPTION; CALMODULIN; RANKL; EXPRESSION; INHIBITOR
AB Calcium (Ca2+) signaling is essential for a variety of cellular responses and higher biological functions. Ca2+/calmodulin dependent kinases (CaMKs) and the phosphatase calcineurin activate distinct downstream pathways that are mediated by the transcription factors cAMP response element (CRE) binding protein ( CREB) and nuclear factor of activated T cells ( NFAT), respectively(1). The importance of the calcineurin NFAT pathway in bone metabolism has been demonstrated in osteoclasts, osteoblasts and chondrocytes(2 5). However, the contribution of the CaMK CREB pathway is poorly understood, partly because of the difficulty of dissecting the functions of homologous family members(6 8). Here we show that the CaMKIV CREB pathway is crucial for osteoclast differentiation and function. Pharmacological inhibition of CaMKs as well as the genetic ablation of Camk4 reduced CREB phosphorylation and downregulated the expression of c Fos, which is required for the induction of NFATc1 ( the master transcription factor for osteoclastogenesis(2,3)) that is activated by receptor activator of NF kappa B ligand ( RANKL). Furthermore, CREB together with NFATc1 induced the expression of specific genes expressed by differentiated osteoclasts. Thus, the CaMK CREB pathway biphasically functions to regulate the transcriptional program of osteoclastic bone resorption, by not only enhancing induction of NFATc1 but also facilitating NFATc1 dependent gene regulation once its expression is induced. This provides a molecular basis for a new therapeutic strategy for bone diseases.
C1 Tokyo Med & Dent Univ, Grad Sch, Dept Cell Signaling, Bunkyo Ku, Tokyo 1138549, Japan.
   Ctr Excellence Program Frontier Res Mol Destruct, Tokyo 1138549, Japan.
   Univ Tokyo, Grad Sch Med, Dept Neurochem, Bunkyo Ku, Tokyo 1130033, Japan.
   Tokyo Med & Dent Univ, Dept Hard Tissue Engn, Pharmacol Sect, Grad Sch,Bunkyo Ku, Tokyo 1138549, Japan.
   Univ Tokyo, Grad Sch Med, Dept Human Pathol, Bunkyo Ku, Tokyo 1130033, Japan.
   Natl Ctr Child Hlth & Dev, Dept Innovat Surg, Setagaya Ku, Tokyo 1578535, Japan.
   Tokyo Med & Dent Univ, Grad Sch, Dept Oral Pathol, Bunkyo Ku, Tokyo 1138549, Japan.
   Tohoku Univ, Dept Expt Immunol, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi 9808575, Japan.
   Univ Tokyo, Dept Mol Biol & Med, Adv Sci & Technol Res Ctr, Meguro Ku, Tokyo 1538904, Japan.
   Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Rheumatol Allergy & Immunol, Los Angeles, CA 90095 USA.
   Japan Sci & Technol Agcy JST, SORST, Kawaguchi, Saitama 3320012, Japan.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   University of Tokyo; Institute of Science Tokyo; Tokyo Medical & Dental
   University (TMDU); University of Tokyo; National Center for Child Health
   & Development   Japan; Institute of Science Tokyo; Tokyo Medical &
   Dental University (TMDU); Tohoku University; University of Tokyo;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; Japan Science & Technology Agency (JST)
RP Takayanagi, H (通讯作者)，Tokyo Med & Dent Univ, Grad Sch, Dept Cell Signaling, Bunkyo Ku, Yushima 1 5 45, Tokyo 1138549, Japan.
EM taka.csi@tmd.ac.jp
RI AOKI, Kazuhiro/G 2258 2016; Bito, Haruhiko/A 8635 2008; Yamaguchi,
   Akira/AAX 9286 2020
OI AOKI, Kazuhiro/0000 0001 6643 6315; Sato, Kojiro/0000 0003 4105 3726;
   Chatila, Talal/0000 0001 7439 2762; Bito, Haruhiko/0000 0001 6315 9594; 
CR Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967
   Anderson KA, 2002, MOL CELL BIOL, V22, P23, DOI 10.1128/MCB.22.1.23 29.2002
   Aoki K, 2006, J CLIN INVEST, V116, P1525, DOI 10.1172/JCI22513
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035
   Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092 8674(00)81816 4
   García Rodríguez C, 1998, J EXP MED, V187, P2031, DOI 10.1084/jem.187.12.2031
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131
   Ho N, 2000, J NEUROSCI, V20, P6459, DOI 10.1523/JNEUROSCI.20 17 06459.2000
   Kang HJ, 2001, CELL, V106, P771, DOI 10.1016/S0092 8674(01)00497 4
   Kim Y, 2005, J BIOL CHEM, V280, P32905, DOI 10.1074/jbc.M505820200
   Kitsos CM, 2005, J BIOL CHEM, V280, P33101, DOI 10.1074/jbc.M505208200
   Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Long FX, 2001, DEVELOPMENT, V128, P541
   Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9
   Seales EC, 2006, J CELL BIOCHEM, V97, P45, DOI 10.1002/jcb.20659
   Sée V, 2001, FASEB J, V15, P134, DOI 10.1096/fj.00 0106com
   Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821
   SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896 6273(90)90106 P
   SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648
   Soderling TR, 2001, CHEM REV, V101, P2341, DOI 10.1021/cr0002386
   SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006 291X(91)92031 E
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Tokumitsu H, 2004, J BIOL CHEM, V279, P40296, DOI 10.1074/jbc.M406534200
   Tokumitsu H, 2002, J BIOL CHEM, V277, P15813, DOI 10.1074/jbc.M201075200
   Zayzafoon M, 2005, J BIOL CHEM, V280, P7049, DOI 10.1074/jbc.M412680200
NR 30
TC 294
Z9 329
U1 1
U2 52
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1078 8956
EI 1546 170X
J9 NAT MED
JI Nat. Med.
PD DEC
PY 2006
VL 12
IS 12
BP 1410
EP 1416
DI 10.1038/nm1515
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 113SS
UT WOS:000242618200022
PM 17128269
DA 2025 08 17
ER

PT J
AU Long, ZY
   Wu, JM
   Xiang, W
   Yuan, MX
   Wu, YH
   Li, J
   Yu, GP
   Yang, TJ
AF Long, Zhi yong
   Wu, Jia min
   Xiang, Wang
   Yuan, Meng xia
   Wu, Yong he
   Li, Jun
   Yu, Gan peng
   Yang, Tiejun
TI Research on the Mechanism of Liuwei Dihuang Decoction for Osteoporosis
   Based on Systematic Biological Strategies
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID INHIBITS BONE LOSS; OSTEOCLAST DIFFERENTIATION; POSTMENOPAUSAL
   OSTEOPOROSIS; CELL DIFFERENTIATION; OVARIECTOMIZED RATS; FERULIC ACID;
   PATHWAY; RANKL; OSTEOBLASTS; DIOSGENIN
AB Background. Osteoporosis is an important health problem worldwide. Liuwei Dihuang Decoction (LDD) and its main ingredients may have a good clinical effect on osteoporosis. Meanwhile, its mechanism for treating osteoporosis needs to be further revealed in order to provide a basis for future drug development. Methods. A systematic biological methodology was utilized to construct and analyze the LDD osteoporosis network. After that, the human transcription data of LDD intervention in patients with osteoporosis and protein arrays data of LDD intervention in osteoporosis rats were collected. The human transcription data analysis, protein arrays data analysis, and molecular docking were performed to validate the findings of the prediction network (LDD osteoporosis PPI network). Finally, animal experiments were conducted to verify the prediction results of systematic pharmacology. Results. (1) LDD osteoporosis PPI network shows the potential compounds, potential targets (such as ALB, IGF1, SRC, and ESR1), clusters, biological processes (such as positive regulation of calmodulin 1 monooxygenase activity, estrogen metabolism, and endothelial cell proliferation), and signaling and Reactome pathways (such as JAK STAT signaling pathway, osteoclast differentiation, and degradation of the extracellular matrix) of LDD intervention in osteoporosis. (2) Human transcriptomics data and protein arrays data validated the findings of the LDD osteoporosis PPI network. (3) The animal experiments showed that LDD can improve bone mineral density (BMD), increase serum estradiol (E2) and alkaline phosphatase (ALP) levels, and upregulate Wnt3a and beta catenin mRNA expression (P < 0.05). (4) Molecular docking results showed that alisol A, dioscin, loganin, oleanolic acid, pachymic acid, and ursolic acid may stably bind to JAK2, ESR1, and CTNNB1. Conclusion. LDD may have a therapeutic effect on osteoporosis through regulating the targets (such as ALB, IGF1, SRC, and ESR1), biological processes (such as positive regulation of calmodulin 1 monooxygenase activity, estrogen metabolism, and endothelial cell proliferation), and pathways (such as JAK STAT signaling pathway, osteoclast differentiation, and degradation of the extracellular matrix) found in this research.
C1 [Long, Zhi yong] Guangzhou Panyu Cent Hosp, Dept Rehabil Med, Guangzhou, Peoples R China.
   [Wu, Jia min; Xiang, Wang; Yuan, Meng xia; Wu, Yong he] Hunan Univ Chinese Med, Changsha, Hunan, Peoples R China.
   [Li, Jun; Yu, Gan peng; Yang, Tiejun] Peoples Hosp Ningxiang City, Ningxiang 410600, Hunan, Peoples R China.
C3 Hunan University of Chinese Medicine
RP Long, ZY (通讯作者)，Guangzhou Panyu Cent Hosp, Dept Rehabil Med, Guangzhou, Peoples R China.
EM 2212471438@qq.com; 769520635@qq.com; 609834551@qq.com; yuanmx14@163.com;
   923489595@qq.com; lijun.guke@hotmail.com; yuganpeng.guke@hotmail.com;
   yangtiejun321@outlook.com
RI 李, 绍纯/GVR 8874 2022; xiang, wang/JKH 6962 2023
CR Adhikary S, 2018, NUTRITION, V53, P64, DOI 10.1016/j.nut.2017.12.003
   Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bai J., 2018, LIAONING U TRADITION
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Boran ADW, 2010, CURR OPIN DRUG DISC, V13, P297
   Bover J, 2017, J NEPHROL, V30, P677, DOI 10.1007/s40620 017 0404 z
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown C, 2017, NATURE, V550, pS15, DOI 10.1038/550S15a
   Burley SK, 2017, METHODS MOL BIOL, V1606, P627, DOI 10.1007/978 1 4939 7000 1_26
   Byun MR, 2012, BONE, V50, P364, DOI 10.1016/j.bone.2011.10.035
   Cao SS, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01435
   Che CT, 2016, MOLECULES, V21, DOI 10.3390/molecules21030239
   Che N, 2019, EUR REV MED PHARMACO, V23, P3183, DOI 10.26355/eurrev_201904_17676
   Chen FP, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472 6882 14 91
   Chen Juan Chen Juan, 2017, China Journal of Traditional Chinese Medicine and Pharmacy, V32, P1747
   Chen Lin Lin, 2011, Chinese Journal of Natural Medicines, V9, P363, DOI 10.3724/SP.J.1009.2011.00363
   Chen ST, 2019, MOLECULES, V24, DOI 10.3390/molecules24010156
   Chen WD, 2019, AGING DIS, V10, P578, DOI 10.14336/AD.2018.0604
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Cheng M, 2019, CHIN J INTEGR MED, V25, P210, DOI 10.1007/s11655 018 3050 y
   Choi EM, 2011, FOOD CHEM TOXICOL, V49, P1800, DOI 10.1016/j.fct.2011.04.031
   Choi HK, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030506
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Eastell R, 2017, LANCET DIABETES ENDO, V5, P908, DOI 10.1016/S2213 8587(17)30184 5
   Fabregat A, 2018, NUCLEIC ACIDS RES, V46, pD649, DOI 10.1093/nar/gkx1132
   Folwarczna J, 2016, ACTA BIOCHIM POL, V63, P287, DOI 10.18388/abp.2015_1095
   Fontalis A, 2019, EXPERT OPIN PHARMACO, V20, P1123, DOI 10.1080/14656566.2019.1594772
   Ge JR, 2018, CHIN J INTEGR MED, V24, P415, DOI 10.1007/s11655 016 2744 2
   Gong W, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163964
   Guo YC, 2019, ACS SYNTH BIOL, V8, P482, DOI 10.1021/acssynbio.8b00237
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huiying L., 2014, EVID BASED COMPL ALT, V4, P1
   Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kanehisa M, 2019, NUCLEIC ACIDS RES, V47, pD590, DOI 10.1093/nar/gky962
   Kawabata T, 2018, BIOMED REP, V9, P318, DOI 10.3892/br.2018.1140
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kim CJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010125
   Kim KJ, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/132436
   Lai NN, 2015, AM J REPROD IMMUNOL, V74, P487, DOI 10.1111/aji.12423
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Lee JW, 2010, BIOCHEM PHARMACOL, V80, P352, DOI 10.1016/j.bcp.2010.04.014
   Lee JH, 2010, MOL PHARMACOL, V77, P17, DOI 10.1124/mol.109.057877
   Lee SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080873
   Lee SU, 2008, PHARMACOL RES, V58, P290, DOI 10.1016/j.phrs.2008.08.008
   Li CR, 2014, AM J CHINESE MED, V42, P1, DOI 10.1142/S0192415X14500013
   Li H. W., 2015, DRUG EVALUATION RES, V38, P218
   Li MY, 2010, MOLECULES, V15, P7403, DOI 10.3390/molecules15107403
   Li XJ, 2016, PROG BIOPHYS MOL BIO, V122, P101, DOI 10.1016/j.pbiomolbio.2016.05.008
   Li Y, 2018, CURR STEM CELL RES T, V13, P185, DOI 10.2174/1574888X12666171012141908
   Li ZH, 2017, MOL MED REP, V16, P8380, DOI 10.3892/mmr.2017.7625
   Liang W, 2011, EUR J PHARMACOL, V670, P317, DOI 10.1016/j.ejphar.2011.08.014
   Liu F.H., 2017, CHINA PHARMACY, V28, P2182, DOI [10.6039/j.issn.1001 0408.2017.16.0610.1002/cav.1776, DOI 10.6039/j.issn.1001 0408.2017.16.06]
   Liu XF, 2010, NUCLEIC ACIDS RES, V38, pW609, DOI 10.1093/nar/gkq300
   Liu Y. F., 2013, PEKING UNION MED COL
   Liu Y, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015282
   Lu D. P., 2004, STRAIT PHARM J, V3, P23
   Ma G., 2015, ZHEJIANG CHINESE MED
   Martín Saavedra F, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 15036 x
   Messer JG, 2015, J CELL BIOCHEM, V116, P1857, DOI 10.1002/jcb.25141
   Metodiewa D, 1997, BIOCHEM MOL BIOL INT, V41, P1067
   Misiorowski W, 2011, ENDOKRYNOL POL, V62, P73
   Missiuro PV, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000350
   Miyamoto Takeshi, 2015, Keio Journal of Medicine, V64, P44, DOI 10.2302/kjm.2015 0003 RE
   Nagy V, 2015, GERONTOLOGY, V61, P534, DOI 10.1159/000371845
   Nowak B, 2017, PHARMACOL REP, V69, P1113, DOI 10.1016/j.pharep.2017.05.002
   Orchard S, 2014, NUCLEIC ACIDS RES, V42, pD358, DOI 10.1093/nar/gkt1115
   Park JH, 2017, MOL CELLS, V40, P706
   Plotkin LI, 2019, ADV PROTEIN CHEM STR, V116, P237, DOI 10.1016/bs.apcsb.2019.01.002
   Qu XH, 2014, BIOCHEM BIOPH RES CO, V443, P658, DOI 10.1016/j.bbrc.2013.12.029
   Raut N, 2019, PHARMACOL RES, V147, DOI 10.1016/j.phrs.2019.104350
   Rharass T, 2018, EUR J ENDOCRINOL, V179, pR165, DOI 10.1530/EJE 18 0182
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P121, DOI 10.1007/s00223 013 9749 z
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Russell RGG, 2015, CURR OPIN PHARMACOL, V22, P115, DOI 10.1016/j.coph.2015.05.005
   Sagar T, 2016, CYTOTECHNOLOGY, V68, P1963, DOI 10.1007/s10616 016 0009 8
   Sánchez Duffhues G, 2015, BONE, V80, P43, DOI 10.1016/j.bone.2015.05.025
   Sassa S, 2003, IN VIVO, V17, P277
   Shen GY, 2018, J CELL PHYSIOL, V233, P3929, DOI 10.1002/jcp.26161
   Solling ASK, 2019, DRUG AGING, V36, P625, DOI 10.1007/s40266 019 00675 8
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Tan H, 2019, J AGR FOOD CHEM, V67, P3333, DOI 10.1021/acs.jafc.8b06954
   Tao XF, 2016, PHARMACOL RES, V108, P90, DOI 10.1016/j.phrs.2016.05.003
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Testini V, 2021, MINERVA OBSTET GYNEC, V73, P730, DOI 10.23736/S2724 606X.20.04674 2
   Tsai CH, 2018, EUR J PHARMACOL, V832, P104, DOI 10.1016/j.ejphar.2018.05.024
   Tsai HY, 2008, EUR J PHARMACOL, V588, P124, DOI 10.1016/j.ejphar.2008.04.024
   Tsubaki M, 2012, MOL CELL ENDOCRINOL, V361, P219, DOI 10.1016/j.mce.2012.05.002
   Wagner D, 2010, WIEN MED WOCHENSCHR, V160, P452, DOI 10.1007/s10354 010 0818 x
   Wang Y., 2018, ONCOTARGET, V9, p7372 7388, DOI DOI 10.18632/ONCOTARGET.23677
   [王洋 Wang Yang], 2020, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V26, P663
   Wang YM, 2018, BIOCHEM BIOPH RES CO, V498, P981, DOI 10.1016/j.bbrc.2018.03.093
   Xia BJ, 2014, J ETHNOPHARMACOL, V153, P133, DOI 10.1016/j.jep.2014.01.040
   Xie BG, 2015, PHYTOTHER RES, V29, P1054, DOI 10.1002/ptr.5346
   Xie L., 2015, CHINESE J OSTEOPOROS, V20, P741
   Xing LZ, 2017, BIOMED PHARMACOTHER, V89, P1136, DOI 10.1016/j.biopha.2017.02.073
   Xu LJ, 2018, J CELL BIOCHEM, V119, P3819, DOI 10.1002/jcb.26332
   Xu S., 2017, GUANGZHOU U CHINESE
   [徐森楠 Xu Sennan], 2018, [中国药学杂志, Chinese Pharmaceutical Journal], V53, P1913
   Yadav BS, 2018, CURR TOP MED CHEM, V18, P1737, DOI 10.2174/1568026618666181025112344
   Yang KL, 2018, EVID BASED COMPL ALT, V2018, DOI 10.1155/2018/5059743
   Yang LL, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20122974
   Yao ChenGuang Yao ChenGuang, 2017, Zhongguo Bingyuan Shengwuxue Zazhi / Journal of Pathogen Biology, V12, P722
   Ye J, 2009, J PHARMACEUT BIOMED, V49, P638, DOI 10.1016/j.jpba.2008.12.009
   Zanotti S, 2013, EUR J ENDOCRINOL, V168, pR95, DOI 10.1530/EJE 13 0115
   Zeng LT, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 17139 x
   Zhang ZG, 2018, EXP THER MED, V16, P3939, DOI 10.3892/etm.2018.6681
   Zhang ZG, 2014, INT J MOL SCI, V15, P17130, DOI 10.3390/ijms150917130
   Zhao JG, 2017, JAMA J AM MED ASSOC, V318, P2466, DOI 10.1001/jama.2017.19344
   Zhao S, 2016, IRISH J MED SCI, V185, P581, DOI 10.1007/s11845 015 1309 2
   Zhu Y, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1143 y
NR 115
TC 4
Z9 6
U1 2
U2 21
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PD SEP 22
PY 2022
VL 2022
AR 7017610
DI 10.1155/2022/7017610
PG 22
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA 6R6WD
UT WOS:000892440300010
PM 36185080
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wang, GX
   Li, HL
   Zhao, HX
   Liu, DL
   Chu, SF
   Lee, MS
   Fang, ZB
AF Wang, Gaoxiang
   Li, Huilin
   Zhao, Hengxia
   Liu, Deliang
   Chu, Shufang
   Lee, Maosheng
   Fang, Zebin
TI Network Pharmacology Study to Reveal the Mechanism of Zuogui Pill for
   Treating Osteoporosis
SO CURRENT COMPUTER AIDED DRUG DESIGN
LA English
DT Article
DE Bioassays; natural products; network pharmacology; molecular docking;
   osteoporosis; Zuogui pill
ID CYTOSCAPE; IMPROVES; RATS
AB Background :To our knowledge, there is still a lack of scientific reports on the pharmacological mechanism of the Zuogui Pill (ZGP) for treating osteoporosis (OP).Aims :This study aimed to explore it via network pharmacology and molecular docking.Methods: We identified active compounds and associated targets in ZGP via two drug databases. Disease targets of OP were obtained utilizing five disease databases. Networks were established and analyzed through the Cytoscape software and STRING databases. Enrichment analyses were performed using the DAVID online tools. Molecular docking was performed using Maestro, PyMOL, and Discovery Studio software.Results :89 drug active compounds, 365 drug targets, 2514 disease targets, and 163 drug disease common targets were obtained. Quercetin, kaempferol, phenylalanine, isorhamnetin, betavulgarin, and glycitein may be the crucial compounds of ZGP in treating OP. AKT1, MAPK14, RELA, TNF, and JUN may be the most important therapeutic targets. Osteoclast differentiation, TNF, MAPK, and thyroid hormone signaling pathways may be the critical therapeutic signaling pathways. The potential therapeutic mechanism mainly relates to osteoblastic or osteoclastic differentiation, oxidative stress, and osteoclastic apoptosis.Conclusion: This study has revealed the anti OP mechanism of ZGP, which offers objective evidence for relevant clinical application and further basic research.
C1 [Wang, Gaoxiang] Nanjing Univ Chinese Med, Dept Endocrinol, Shenzhen Tradit Chinese Med Hosp, Shenzhen, Guangdong, Peoples R China.
   [Wang, Gaoxiang; Li, Huilin; Zhao, Hengxia; Liu, Deliang; Chu, Shufang; Lee, Maosheng] Shenzhen Tradit Chinese Med Hosp, Dept Endocrinol, Shenzhen, Guangdong, Peoples R China.
   [Fang, Zebin] Guangzhou Univ Chinese Med, Clin Med Coll 4, Dept Endocrinol, Shenzhen, Guangdong, Peoples R China.
C3 Nanjing University of Chinese Medicine; Shenzhen Traditional Chinese
   Medicine Hospital; Shenzhen Traditional Chinese Medicine Hospital;
   Guangzhou University of Chinese Medicine
RP Li, HL (通讯作者)，Shenzhen Tradit Chinese Med Hosp, Dept Endocrinol, Shenzhen, Guangdong, Peoples R China.
EM sztcmlhl@163.com
RI Li, Huilin/E 6850 2018; Liu, Deliang/JFJ 1644 2023
FU Declared none.
FX Declared none.
CR Al Mamun MA, 2020, J CELL MOL MED, V24, P2542, DOI 10.1111/jcmm.14948
   Amberger Joanna S, 2017, Curr Protoc Bioinformatics, V58, DOI 10.1002/cpbi.27
   [Anonymous], 2021, LANCET DIABETES ENDO, V9, P1, DOI 10.1016/S2213 8587(20)30408 3
   Bardou P, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471 2105 15 293
   Bellavia D, 2021, TRENDS ENDOCRIN MET, V32, P76, DOI 10.1016/j.tem.2020.11.007
   Beringer A, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03170
   Boezio B, 2017, MOL INFORM, V36, DOI 10.1002/minf.201700048
   Cao B, 2015, IUBMB LIFE, V67, P928, DOI 10.1002/iub.1436
   Chen GM, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000013936
   Chen SJ, 2020, AGING DIS, V11, P1058, DOI 10.14336/AD.2019.0724
   Cole HA, 2014, ARTHRITIS RHEUMATOL, V66, P2222, DOI 10.1002/art.38639
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Delitala AP, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041034
   Ensrud Kristine E, 2021, JAMA, V325, P96, DOI 10.1001/jama.2020.2923
   Estell EG, 2021, NAT REV ENDOCRINOL, V17, P31, DOI 10.1038/s41574 020 00426 5
   Fuggle NR, 2019, NAT REV ENDOCRINOL, V15, P535, DOI 10.1038/s41574 019 0220 8
   He Q, 2021, J ETHNOPHARMACOL, V273, DOI 10.1016/j.jep.2021.113946
   Hopkins AL, 2007, NAT BIOTECHNOL, V25, P1110, DOI 10.1038/nbt1007 1110
   Huang JH, 2017, MOL MED REP, V16, P4583, DOI 10.3892/mmr.2017.7149
   Jeong YH, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/1927017
   Jia XL, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10124
   Jiao XL, 2012, BIOINFORMATICS, V28, P1805, DOI 10.1093/bioinformatics/bts251
   Kim S, 2021, NUCLEIC ACIDS RES, V49, pD1388, DOI 10.1093/nar/gkaa971
   Koura HM, 2011, ARCH MED SCI, V7, P493, DOI 10.5114/aoms.2011.23417
   Kouranov A, 2006, NUCLEIC ACIDS RES, V34, pD302, DOI 10.1093/nar/gkj120
   Krízová L, 2019, MOLECULES, V24, DOI 10.3390/molecules24061076
   Langdahl BL, 2021, BRIT J PHARMACOL, V178, P1891, DOI 10.1111/bph.15024
   Lerbs T, 2020, STEM CELL REP, V14, P603, DOI 10.1016/j.stemcr.2020.02.009
   Li C, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/5196302
   Li JB, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10677 0
   Li JY, 2021, PHYTOTHER RES, V35, P1754, DOI 10.1002/ptr.6908
   Li WX, 2018, J TRADIT CHIN MED, V38, P33
   Li YH, 2018, NUCLEIC ACIDS RES, V46, pD1121, DOI 10.1093/nar/gkx1076
   Liu FX, 2021, J TRADIT CHIN MED, V41, P927, DOI 10.19852/j.cnki.jtcm.20210903.001
   Liu H, 2021, MOL CELL ENDOCRINOL, V520, DOI 10.1016/j.mce.2020.111074
   Liu MJ, 2011, J TRADIT CHIN MED, V31, P98, DOI 10.1016/S0254 6272(11)60020 4
   Liu SH, 2015, DRUG SAFETY, V38, P117, DOI 10.1007/s40264 014 0250 z
   Liu ZY, 2016, SCI REP UK, V6, DOI 10.1038/srep21146
   Liu ZC, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.594785
   Mazurek AH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176411
   Messer JG, 2015, J CELL BIOCHEM, V116, P1857, DOI 10.1002/jcb.25141
   Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110
   Mullard A, 2019, NAT REV DRUG DISCOV, V18, P411, DOI 10.1038/d41573 019 00083 y
   Neugebauer J, 2018, HUM MOL GENET, V27, P4249, DOI 10.1093/hmg/ddy318
   Ning K, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/7573904
   Pagnotti GM, 2019, NAT REV ENDOCRINOL, V15, P339, DOI 10.1038/s41574 019 0170 1
   Pandit AP, 2020, DRUG DELIV TRANSL RE, V10, P1495, DOI 10.1007/s13346 020 00708 5
   Piñero J, 2020, NUCLEIC ACIDS RES, V48, pD845, DOI 10.1093/nar/gkz1021
   Qin XY, 2021, J ETHNOPHARMACOL, V270, DOI 10.1016/j.jep.2021.113815
   Renaux A, 2018, NUCLEIC ACIDS RES, V46, P2699, DOI 10.1093/nar/gky092
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Safran M, 2010, DATABASE OXFORD, DOI 10.1093/database/baq020
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Tang Y, 2015, BIOSYSTEMS, V127, P67, DOI 10.1016/j.biosystems.2014.11.005
   Vakili S, 2021, J CELL PHYSIOL, V236, P3495, DOI 10.1002/jcp.30087
   Wang N, 2021, PHYTOTHER RES, V35, P2639, DOI 10.1002/ptr.7010
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wong SK, 2019, DRUG DES DEV THER, V13, P3497, DOI 10.2147/DDDT.S227738
   Wu DY, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/8245071
   Wu HB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0540 y
   Wu LL, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1500 x
   Yang AF, 2018, EVID BASED COMPL ALT, V2018, DOI 10.1155/2018/3717391
   Yang FH, 2020, EXP THER MED, V20, P309, DOI 10.3892/etm.2020.8689
   Yin H, 2018, BIOMED PHARMACOTHER, V97, P995, DOI 10.1016/j.biopha.2017.11.029
   Zantut Wittmann DE, 2020, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00890
   Zha JP, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018 020 01775 7
   Zhang LL, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20203520
   Zhang M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092333
   Zhang Y, 2016, EUR REV MED PHARMACO, V20, P433
   Zhou W, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020246
NR 72
TC 3
Z9 3
U1 4
U2 31
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1573 4099
EI 1875 6697
J9 CURR COMPUT AID DRUG
JI Curr. Comput. Aided Drug Des.
PY 2024
VL 20
IS 1
BP 2
EP 15
DI 10.2174/1573409919666230302111951
PG 14
WC Chemistry, Medicinal; Computer Science, Interdisciplinary Applications
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Computer Science
GA W7RA2
UT WOS:001093549600002
PM 36861803
DA 2025 08 17
ER

PT J
AU Räikkönen, J
   Crockett, JC
   Rogers, MJ
   Mönkkönen, H
   Auriola, S
   Mönkkönen, J
AF Raikkonen, Johanna
   Crockett, Julie C.
   Rogers, Michael J.
   Monkkonen, Hannu
   Auriola, Seppo
   Monkkonen, Jukka
TI Zoledronic acid induces formation of a pro apoptotic ATP analogue and
   isopentenyl pyrophosphate in osteoclasts in vivo and in MCF 7
   cells in vitro
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE AppCCl(2)p; ApppI; bisphosphonate; cellular uptake; clodronate; IPP;
   osteoclast; zoledronic acid
ID NITROGEN CONTAINING BISPHOSPHONATES; HMG COA REDUCTASE; BONE RESORPTION;
   BREAST CANCER; INHIBITION; CLODRONATE; PRENYLATION; MECHANISM; DRUGS;
   LOCALIZATION
AB Bisphosphonates (BPs) are highly effective inhibitors of bone resorption. Nitrogen containing bisphosphonates (N BPs), such as zoledronic acid, induce the formation of a novel ATP analogue (1 adenosin 5' yl ester 3 (3 methylbut 3 enyl) ester triphosphoric acid; ApppI), as a consequence of the inhibition of farnesyl pyrophosphate synthase and the accumulation of isopentenyl pyrophosphate (IPP). ApppI induces apoptosis, as do comparable metabolites of non nitrogen containing bisphosphonates (non N BPs). In order to further evaluate a pharmacological role for ApppI, we obtained more detailed data on IPP/ApppI formation in vivo and in vitro. Additionally, zoledronic acid induced ApppI formation from IPP was compared with the metabolism of clodronate (a non N BP) to adenosine 5'(beta,gamma dichloromethylene) triphosphate (AppCCl(2)p).
   After giving zoledronic acid in vivo to rabbits, IPP/ApppI formation and accumulation was assessed in isolated osteoclasts. The formation of ApppI from IPP was compared with the metabolism of clodronate in MCF 7 cells in vitro. IPP/ApppI and AppCCl(2)p levels in cell extracts were analysed by mass spectrometry.
   Isopentenyl pyrophosphate/ApppI were formed in osteoclasts in vivo, after a single, clinically relevant dose of zoledronic acid. Furthermore, exposure of MCF 7 cells in vitro to zoledronic acid at varying times and concentrations induced time  and dose dependent accumulation of IPP/ApppI. One hour pulse treatment was sufficient to cause IPP accumulation and subsequent ApppI formation, or the metabolism of clodronate into AppCCl(2)p.
   This study provided the first conclusive evidence that pro apoptotic ApppI is a biologically significant molecule, and demonstrated that IPP/ApppI analysis is a sensitive tool for investigating pathways involved in BP action.
C1 [Raikkonen, Johanna; Monkkonen, Hannu; Monkkonen, Jukka] Univ Kuopio, Dept Pharmaceut, FIN 70211 Kuopio, Finland.
   [Crockett, Julie C.; Rogers, Michael J.] Univ Aberdeen, Bone & Musculoskeletal Res Programme, Inst Med Sci, Aberdeen, Scotland.
   [Monkkonen, Hannu] Fac Med Laennec, INSERM, Res Unit, UMR 664, Lyon, France.
   [Auriola, Seppo] Univ Kuopio, Dept Pharmaceut Chem, FIN 70211 Kuopio, Finland.
C3 University of Eastern Finland; University of Aberdeen; Institut National
   de la Sante et de la Recherche Medicale (Inserm); Universite Claude
   Bernard Lyon 1; University of Eastern Finland
RP Räikkönen, J (通讯作者)，Univ Kuopio, Dept Pharmaceut, Yliopistonranta 1 B,POB 1627, FIN 70211 Kuopio, Finland.
EM Johanna.Raikkonen@uku.fi
OI Rogers, Michael/0000 0002 1818 9249
FU Academy of Finland; Finnish Cultural Foundation; Oskar Huttunen
   Foundation
FX This work was financially supported by the Academy of Finland, Finnish
   Cultural Foundation and Oskar Huttunen Foundation. The skilful technical
   assistance Mrs Lea Pirskanen is gratefully acknowledged. We thank
   Novartis Pharma AG (Switzerland) and Schering AG (Germany) for their
   kind gift of zoledronic acid and clodronate, respectively.
CR AMIN D, 1992, J LIPID RES, V33, P1657
   Auriola S, 1997, J CHROMATOGR B, V704, P187, DOI 10.1016/S0378 4347(97)00490 8
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   BROWN MS, 1980, J LIPID RES, V21, P505
   Coleman RE, 2004, BREAST, V13, pS19, DOI 10.1016/j.breast.2004.09.004
   Coxon FP, 2005, BONE, V37, P349, DOI 10.1016/j.bone.2005.04.021
   Daubiné F, 2007, J NATL CANCER I, V99, P322, DOI 10.1093/jnci/djk054
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   Dunford JE, 2008, J MED CHEM, V51, P2187, DOI 10.1021/jm7015733
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   EDMOND J, 1974, J BIOL CHEM, V249, P66
   Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157
   FLANAGAN AM, 1991, CALCIFIED TISSUE INT, V49, P407, DOI 10.1007/BF02555852
   Frith JC, 1997, J BONE MINER RES, V12, P1358, DOI 10.1359/jbmr.1997.12.9.1358
   Frith JC, 2001, ARTHRITIS RHEUM, V44, P2201, DOI 10.1002/1529 0131(200109)44:9<2201::AID ART374>3.0.CO;2 E
   Goffinet M, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 60
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Mönkkönen H, 2003, EUR J PHARM SCI, V19, P23, DOI 10.1016/S0928 0987(03)00039 3
   Mönkkönen H, 2008, ANTI CANCER DRUG, V19, P391, DOI 10.1097/CAD.0b013e3282f632bf
   Mönkkönen H, 2007, LIFE SCI, V81, P1066, DOI 10.1016/j.lfs.2007.08.007
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rogers MJ, 1996, BIOCHEM BIOPH RES CO, V224, P863, DOI 10.1006/bbrc.1996.1113
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Roux C, 1999, DRUGS, V58, P823, DOI 10.2165/00003495 199958050 00005
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Staal A, 2003, J BONE MINER RES, V18, P88, DOI 10.1359/jbmr.2003.18.1.88
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
NR 30
TC 65
Z9 70
U1 0
U2 2
PU WILEY BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0007 1188
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD JUN
PY 2009
VL 157
IS 3
BP 427
EP 435
DI 10.1111/j.1476 5381.2009.00160.x
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 448MV
UT WOS:000266267600010
PM 19371349
OA Green Published
DA 2025 08 17
ER

PT J
AU Shibamoto, A
   Ogawa, T
   Duyck, J
   Vandamme, K
   Naert, I
   Sasaki, K
AF Shibamoto, Aya
   Ogawa, Toru
   Duyck, Joke
   Vandamme, Katleen
   Naert, Ignace
   Sasaki, Keiichi
TI Effect of high frequency loading and parathyroid hormone administration
   on peri implant bone healing and osseointegration
SO INTERNATIONAL JOURNAL OF ORAL SCIENCE
LA English
DT Article
ID WHOLE BODY VIBRATION; ORAL BISPHOSPHONATES; LOW MAGNITUDE;
   POSTMENOPAUSAL WOMEN; MINERAL DENSITY; MECHANICAL SIGNALS; TITANIUM
   IMPLANTS; DENTAL IMPLANTS; TERIPARATIDE; OSTEOPOROSIS
AB The objective of this study is to examine the effect of low magnitude, high frequency (LMHF) loading, and anti osteoporosis medications such as parathyroid hormone (PTH) and bisphosphonates on peri implant bone healing in an osteoporosis model, and to assess their combined effects on these processes. Thirteen week old ovariectomized rats (n = 44) were divided into three groups: PTH, alendronate, and saline. After 3 weeks of drug administration, titanium implants were inserted into the tibiae. Each group was subdivided into two groups: with or without LMHF loading via whole body vibration (50 Hz at 0.5 g, 15 min per day, 5 days per week). Rats were killed 4 weeks following implantation. Removal torque test, micro CT analyses (relative gray (RG) value, water = 0, and implant = 100), and histomorphometric analyses (bone to implant contact (BIC) and peri implant bone formation (bone volume/tissue volume (BV/TV))) were performed. Removal torque values and BIC were significantly differed by loading and drug administration (ANOVA). Post hoc analysis showed that PTH treated groups were significantly higher than the other drug treated groups. BV/TV was significantly enhanced by PTH administration. In cortical bone, RG values were significantly increased by loading. In trabecular bone, however, RG values were significantly increased by PTH administration. These findings suggest that LMHF loading and PTH can act locally and additively on the bone healing process, improving the condition of implant osseointegration.
C1 [Shibamoto, Aya; Ogawa, Toru; Sasaki, Keiichi] Tohoku Univ, Grad Sch Dent, Div Adv Prosthet Dent, Sendai, Miyagi, Japan.
   [Duyck, Joke; Vandamme, Katleen; Naert, Ignace] Katholieke Univ Leuven, BIOMAT Biomat, Dept Oral Hlth Sci, Prosthet Dent, Leuven, Belgium.
C3 Tohoku University; KU Leuven
RP Ogawa, T (通讯作者)，Tohoku Univ, Grad Sch Dent, Div Adv Prosthet Dent, Sendai, Miyagi, Japan.
EM ogat thk@umin.ac.jp
RI Duyck, Joke/AGN 7677 2022
OI Duyck, Joke/0000 0002 8698 1692; OGAWA, Toru/0000 0002 5578 7766
FU Ministry of Education, Culture, Sports, Science and Technology, Japan
   [15K11147, 26670830, 26861620]; Grants in Aid for Scientific Research
   [26670830, 26861620, 15K11147, 15K11148] Funding Source: KAKEN
FX This study was partially supported by a Grant in Aid for Scientific
   Research (C) (15K11147), a Grant in Aid for Challenging Exploratory
   Research (26670830), and a Grant in Aid for Young Scientists (B)
   (26861620) from the Ministry of Education, Culture, Sports, Science and
   Technology, Japan. We thank Dr. Masahiro Iikubo, Department of Oral
   Diagnosis, Tohoku University Graduate School of Dentistry, for providing
   assistance with the micro CT analysis.
CR Akca Kivanc, 2007, Head Face Med, V3, P28, DOI 10.1186/1746 160X 3 28
   Aspenberg P, 2010, J BONE MINER RES, V25, P404, DOI 10.1359/jbmr.090731
   Bell BM, 2008, J ORAL MAXIL SURG, V66, P1022, DOI 10.1016/j.joms.2007.12.040
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Brown JP, 2014, CAN FAM PHYSICIAN, V60, P324
   Campbell GM, 2011, BONE, V49, P225, DOI 10.1016/j.bone.2011.04.008
   Chan HL, 2013, J DENT RES, V92, P18, DOI 10.1177/0022034512464779
   Chatterjee M, 2015, OSTEOPOROSIS INT, V26, P281, DOI 10.1007/s00198 014 2824 0
   Chen BL, 2012, J ORTHOP RES, V30, P733, DOI 10.1002/jor.22004
   Chintamaneni S, 2010, OSTEOPOROSIS INT, V21, P1059, DOI 10.1007/s00198 009 1061 4
   Fuchs RK, 2007, BONE, V41, P290, DOI 10.1016/j.bone.2007.04.179
   Fugazzotto PA, 2007, J PERIODONTOL, V78, P1664, DOI 10.1902/jop.2007.060514
   Grant BT, 2008, J ORAL MAXIL SURG, V66, P223, DOI 10.1016/j.joms.2007.09.019
   Gusi N, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471 2474 7 92
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Hodsman AB, 2000, BONE, V27, P311, DOI 10.1016/S8756 3282(00)00316 1
   Hwang Debby, 2006, Implant Dent, V15, P353, DOI 10.1097/01.id.0000247855.75691.03
   Hwang D, 2007, IMPLANT DENT, V16, P13, DOI 10.1097/ID.0b013e31803276c8
   Hwang SJ, 2009, CLIN ORTHOP RELAT R, V467, P1083, DOI 10.1007/s11999 008 0552 5
   Almagro MI, 2013, CLIN ORAL IMPLAN RES, V24, P1027, DOI 10.1111/j.1600 0501.2012.02495.x
   Iwamoto J, 2005, AGING CLIN EXP RES, V17, P157
   Iwamoto J, 2006, CURR MED RES OPIN, V22, P919, DOI 10.1185/030079906X100276
   Jeffcoat MK, 2006, INT J ORAL MAX IMPL, V21, P349
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Judex S, 2009, ORTHOD CRANIOFAC RES, V12, P94, DOI 10.1111/j.1601 6343.2009.01442.x
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Kneissel M, 2001, BONE, V28, P237, DOI 10.1016/S8756 3282(00)00448 8
   Kuchler U, 2011, J DENT RES, V90, P1001, DOI 10.1177/0022034511407920
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Ogawa T, 2014, CALCIFIED TISSUE INT, V95, P467, DOI 10.1007/s00223 014 9896 x
   Ogawa T, 2011, CLIN ORAL IMPLAN RES, V22, P302, DOI 10.1111/j.1600 0501.2010.02020.x
   Ogawa T, 2011, J CLIN PERIODONTOL, V38, P180, DOI 10.1111/j.1600 051X.2010.01637.x
   Ohtori S, 2012, SPINE, V37, pE1464, DOI 10.1097/BRS.0b013e31826ca2a8
   Omar H, 2008, J ORAL MAXIL SURG, V66, P1104, DOI 10.1016/j.joms.2008.01.048
   RODAN GA, 1993, OSTEOPOROSIS INT, V3, pS7
   Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122
   Rubin C, 2004, J BONE MINER RES, V19, P343, DOI 10.1359/JBMR.0301251
   Russo CR, 2003, ARCH PHYS MED REHAB, V84, P1854, DOI 10.1016/S0003 9993(03)00357 5
   Sehmisch S, 2009, OSTEOPOROSIS INT, V20, P1999, DOI 10.1007/s00198 009 0892 3
   Shi HF, 2010, BONE, V46, P1299, DOI 10.1016/j.bone.2009.11.028
   Shirota T, 2003, J ORAL MAXIL SURG, V61, P471, DOI 10.1053/joms.2003.50093
   Skripitz R, 2004, ACTA ORTHOP SCAND, V75, P654, DOI 10.1080/00016470410004012
   Tashjian AH, 2002, J BONE MINER RES, V17, P1151, DOI 10.1359/jbmr.2002.17.7.1151
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Verschueren SMP, 2004, J BONE MINER RES, V19, P352, DOI 10.1359/JBMR.0301245
   Vohra F, 2014, ARCH ORAL BIOL, V59, P912, DOI 10.1016/j.archoralbio.2014.05.016
   von Stengel S, 2011, OSTEOPOROSIS INT, V22, P317, DOI 10.1007/s00198 010 1215 4
   Zahid TM, 2011, J ORAL IMPLANTOL, V37, P335, DOI 10.1563/AAID JOI D 09 00114
   Zhang X, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0042529, 10.1371/journal.pone.0035700]
NR 49
TC 28
Z9 30
U1 1
U2 12
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1674 2818
EI 2049 3169
J9 INT J ORAL SCI
JI Int. J. Oral Sci.
PD MAR 13
PY 2018
VL 10
AR 61
DI 10.1038/s41368 018 0009 y
PG 7
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA GF2TP
UT WOS:000431792900001
PM 29531334
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Jaschke, N
   Kleymann, A
   Hofbauer, LC
   Göbel, A
   Rachner, TD
AF Jaschke, Nikolai
   Kleymann, Alexander
   Hofbauer, Lorenz C.
   Goebel, Andy
   Rachner, Tilman D.
TI Dorsomorphin: A novel inhibitor of Dickkopf 1 in breast cancer
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Breast cancer; Dickkopf 1; Dorsomorphin; Bone metastases
AB Advanced stages of breast cancer are frequently complicated by bone metastases which cause substantial cancer related morbidity and mortality. The Wnt signaling antagonist Dickkopf 1 (DKK 1) has emerged as a crucial factor in the development and progression of osteolytic bone metastases. Although several signaling pathways have been implicated in promoting DKK 1 production in breast cancer cells, pharmacological interventions that interfere with tumor DKK 1 synthesis still remain scarce.
   In the current study, using an unbiased approach, we identified the small molecule Dorsomorphin as a potent suppressor of DKK 1 in several breast cancer cell lines (MDA MB 231, MDA Bone, MDA MET and MCF7, respectively). Here, Dorsomorphin suppressed DKK 1 mRNA and protein production by 70 and 90%, respectively (p <0.001). Whereas bone morphogenic protein (BMP) and AMP activated protein kinase (AMPK) signaling are two well established targets of Dorsomorphin, we show that neither pathway is essentially involved in facilitating its inhibitory effects on DKK 1.
   In summary, we identified Dorsomorphin as a potent pharmacological inhibitor of DKK 1 production in breast cancer cells. Whether Dorsomorphin reflects a valuable therapeutic agent in breast cancer warrants further investigations. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Jaschke, Nikolai; Hofbauer, Lorenz C.; Goebel, Andy; Rachner, Tilman D.] Tech Univ Dresden, Dept Med 3, Div Endocrinol & Metab Bone Dis, Dresden, Germany.
   [Jaschke, Nikolai; Hofbauer, Lorenz C.; Goebel, Andy; Rachner, Tilman D.] Tech Univ Dresden, Ctr Hlth Ageing, Dept Med 3, Dresden, Germany.
   [Jaschke, Nikolai] Med Univ Innsbruck, Dept Internal Med Gastroenterol Hepatol Endocrino, Innsbruck, Austria.
   [Kleymann, Alexander] Tech Univ Dresden, Dept Med 3, Div Rheumatol, Dresden, Germany.
   [Hofbauer, Lorenz C.; Goebel, Andy; Rachner, Tilman D.] Dresden & German Canc Res Ctr DKFZ, German Canc Consortium DKTK, Heidelberg, Germany.
C3 Technische Universitat Dresden; Technische Universitat Dresden; Medical
   University of Innsbruck; Technische Universitat Dresden; Helmholtz
   Association; German Cancer Research Center (DKFZ)
RP Rachner, TD (通讯作者)，Div Endocrinol Diabet & Bone Dis, Fetscherstr 74, D 01037 Dresden, Germany.; Rachner, TD (通讯作者)，Hlth Aging Dept Med 3, Fetscherstr 74, D 01037 Dresden, Germany.
EM tilman.rachner@uniklinikum dresden.de
RI Hofbauer, Lorenz C./G 2490 2010; Hofbauer, Lorenz/G 2490 2010
OI Hofbauer, Lorenz C./0000 0002 8691 8423; 
FU Deutsche Forschungsgemeinschaft [GO 3055/1 1, RA 2151/3 1, RA 2151/4 1,
   HO 1875/15 1, HO 1875/16 1]; German Academic Exchange Service (Deutscher
   Akademischer Austauschdienst)
FX The authors would like to thank Josefa Hotzel for her excellent
   technical assistance and Ms. Theresa Reiche for her secretarial
   assistance. The work was funded by the Deutsche Forschungsgemeinschaft
   to AG (GO 3055/1 1), TDR (RA 2151/3 1, and 4 1), and to LCH (HO
   1875/15 1 and 16 1) as part of the DFG Research group SKELMET and the
   Schwerpunktprogramm 2084 mBone. Further funding was provided by the
   German Academic Exchange Service (Deutscher Akademischer
   Austauschdienst) to NJ.
CR Boergermann JH, 2010, INT J BIOCHEM CELL B, V42, P1802, DOI 10.1016/j.biocel.2010.07.018
   Brook N, 2018, INT J BIOCHEM CELL B, V96, P63, DOI 10.1016/j.biocel.2018.01.003
   Dasgupta B, 2018, METHODS MOL BIOL, V1732, P195, DOI 10.1007/978 1 4939 7598 3_12
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Garulli C, 2014, CELL SIGNAL, V26, P352, DOI 10.1016/j.cellsig.2013.11.022
   Hofbauer LC, 2014, LANCET DIABETES ENDO, V2, P500, DOI 10.1016/S2213 8587(13)70203 1
   Huang Y, 2018, LIFE SCI, V209, P249, DOI 10.1016/j.lfs.2018.08.019
   Isakovic A, 2007, CELL MOL LIFE SCI, V64, P1290, DOI 10.1007/s00018 007 7080 4
   Kaiser M, 2008, EUR J HAEMATOL, V80, P490, DOI 10.1111/j.1600 0609.2008.01065.x
   Liu XN, 2014, MOL CANCER THER, V13, P596, DOI 10.1158/1535 7163.MCT 13 0579
   Pinzone JJ, 2009, BLOOD, V113, P517, DOI 10.1182/blood 2008 03 145169
   Rachner TD, 2015, BIOCHEM BIOPH RES CO, V466, P728, DOI 10.1016/j.bbrc.2015.09.101
   Rachner TD, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3616
   Rachner TD, 2014, CANCER LETT, V346, P172, DOI 10.1016/j.canlet.2014.01.010
   Ríos M, 2013, CANCER RES, V73, P2628, DOI 10.1158/0008 5472.CAN 12 0861
   Siegel RL, 2020, CA CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Thiele S, 2015, J BONE MINER RES, V30, P488, DOI 10.1002/jbmr.2362
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Vogt J, 2011, CELL SIGNAL, V23, P1831, DOI 10.1016/j.cellsig.2011.06.019
   Voorzanger Rousselot N, 2007, BRIT J CANCER, V97, P964, DOI 10.1038/sj.bjc.6603959
   Voorzanger Rousselot N, 2009, CALCIFIED TISSUE INT, V84, P348, DOI 10.1007/s00223 009 9225 y
   Wilke M., 2014, J Bone Oncol, V3, P10, DOI [10.1016/j.jbo.2014.02.001, DOI 10.1016/J.JBO.2014.02.001]
   Yui PB, 2008, NAT CHEM BIOL, V4, P33, DOI 10.1038/nchembio.2007.54
   Zhou SJ, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000 014 0161 4
NR 24
TC 6
Z9 8
U1 0
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 2
PY 2020
VL 524
IS 2
BP 360
EP 365
DI 10.1016/j.bbrc.2020.01.106
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA LE5VZ
UT WOS:000526790200013
PM 32001001
DA 2025 08 17
ER

PT J
AU Kim, JY
   Oh, HM
   Kwak, SC
   Cheon, YH
   Lee, MS
   Rho, MC
   Oh, J
AF Kim, Ju Young
   Oh, Hyun Mee
   Kwak, Sung Chul
   Cheon, Yoon Hee
   Lee, Myeung Su
   Rho, Mun Chual
   Oh, Jaemin
TI Purslane Suppresses Osteoclast Differentiation and Bone Resorbing
   Activity via Inhibition of Akt/GSK3β c Fos NFATc1 Signaling in
   Vitro and Prevents Lipopolysaccharide Induced Bone Loss in
   Vivo
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE purslane (Portulaca oleracea); osteoclast; bone loss; osteoporosis;
   natural medicine
ID KEY REGULATOR; C FOS; PROTEIN; RANKL; RECEPTOR; LIGAND
AB Purslane (Portulaca oleracea L.) is popular as a potherb in many areas of Europe, Asia, and the Mediterranean region and is widely distributed around the globe. It has a wide range of pharmacological effects, such as antibacterial, anti aging, anti inflammatory, and anti oxidative properties. Although the extract of purslane has numerous beneficial pharmacological effects, its effect on osteoclasts remains unknown. We aimed to investigate the anti osteoclastogenic activity in vitro and in vivo and to elucidate the underlying mechanism. The effect of purslane on the differentiation and function of bone marrow derived macrophages (BMMs) into osteoclasts was examined using a phenotype assay such as tartrate resistant acid phosphatase (TRAP) staining, F actin staining, and pit assay and followed by confirmation by real time reverse transcription polymerase chain reaction (RT PCR) and Western blot analysis. To address the effect of purslane in vivo, the inflammatory, lipopolysaccharide (LPS) induced osteolysis mouse model was chosen. Bone volume and bone microarchitecture were evaluated by microcomputed tomography and histologic analysis. Purslane inhibited receptor activator of nuclear factor kappa B ligand (RANKL) stimulated osteoclast differentiation accompanied by inhibition of Akt/glycogen synthase kinase 3 beta (GSK3 beta) signaling, which could underlie purslane induced downregulation of c Fos and nuclear factor of activated T cells 1 (NFATc1) expression levels, transcription factors that regulate osteoclast specific genes, as well as osteoclast fusion and resorption related molecules. Moreover, in vivo studies further verified the bone protection activity of purslane in the LPS induced osteolysis animal model. Purslane could exhibit its anti osteoclastogenic activity by inhibiting Akt/GSK3 beta c Fos NFATc1 signaling cascades. Therefore, purslane is a potential natural medicine for the treatment of osteoclast related diseases.
C1 [Kim, Ju Young; Oh, Jaemin] Wonkwang Univ, Imaging Sci Lung & Bone Dis Res Ctr, Iksan 570749, Jeonbuk, South Korea.
   [Oh, Hyun Mee; Rho, Mun Chual] Korea Res Inst Biosci & Biotechnol, Biomat Res Inst, Bioind Proc Res Ctr, Jeongeup 580185, Jeonbuk, South Korea.
   [Kwak, Sung Chul] NeuMed Inc, KISTEM, Seoul 130701, South Korea.
   [Cheon, Yoon Hee; Oh, Jaemin] Wonkwang Univ, Sch Med, Dept Anat, Iksan 570749, Jeonbuk, South Korea.
   [Cheon, Yoon Hee; Oh, Jaemin] Wonkwang Univ, Grad Sch, Program BK21plus, Iksan 570749, Jeonbuk, South Korea.
   [Cheon, Yoon Hee; Oh, Jaemin] Wonkwang Univ, Grad Sch, Dept Smart Life Care Convergence, Iksan 570749, Jeonbuk, South Korea.
   [Lee, Myeung Su] Wonkwang Univ, Dept Internal Med, Div Rheumatol, Iksan 570749, Jeonbuk, South Korea.
C3 Wonkwang University; Korea Research Institute of Bioscience &
   Biotechnology (KRIBB); Wonkwang University; Wonkwang University;
   Wonkwang University; Wonkwang University
RP Rho, MC (通讯作者)，Korea Res Inst Biosci & Biotechnol, Biomat Res Inst, Bioind Proc Res Ctr, Jeongeup 580185, Jeonbuk, South Korea.
EM rho m@kribb.re.kr; jmoh@wku.ac.kr
RI Lee, Sang Hoon/ABH 6210 2020
FU Wonkwang University; Korean Health Technology R&D Project, Ministry of
   Health & Welfare, Republic of Korea [HI11C1602]
FX This study was supported by a Grant from the Wonkwang University in 2013
   and the Korean Health Technology R&D Project, Ministry of Health &
   Welfare, Republic of Korea (HI11C1602).
CR Angel NZ, 2000, J BONE MINER RES, V15, P103, DOI 10.1359/jbmr.2000.15.1.103
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cao HL, 2013, J BIOL CHEM, V288, P30399, DOI 10.1074/jbc.M113.469973
   Chan K, 2000, J ETHNOPHARMACOL, V73, P445, DOI 10.1016/S0378 8741(00)00318 4
   Delaissé JM, 2003, MICROSC RES TECHNIQ, V61, P504, DOI 10.1002/jemt.10374
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Jurdic P, 2006, EUR J CELL BIOL, V85, P195, DOI 10.1016/j.ejcb.2005.09.008
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Liu LX, 2000, J CHROMATOGR A, V893, P207, DOI 10.1016/S0021 9673(00)00747 0
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Nakamura I, 2007, J BONE MINER METAB, V25, P337, DOI 10.1007/s00774 007 0773 9
   Nemeth K, 2011, J IMMUNOL, V186, P13, DOI 10.4049/jimmunol.1002483
   Rashed AN, 2003, J ETHNOPHARMACOL, V88, P131, DOI 10.1016/S0378 8741(03)00194 6
   Silva R, 2014, NAT PROD COMMUN, V9, P45
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Uddin MK, 2014, SCI WORLD J, DOI 10.1155/2014/951019
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Xiang L, 2005, PHYTOCHEMISTRY, V66, P2595, DOI 10.1016/j.phytochem.2005.08.011
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yang M, 2008, J CELL PHYSIOL, V215, P497, DOI 10.1002/jcp.21331
NR 26
TC 30
Z9 31
U1 0
U2 15
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2 12 15 SHIBUYA, SHIBUYA KU, TOKYO, 150 0002, JAPAN
SN 0918 6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD JAN
PY 2015
VL 38
IS 1
BP 66
EP 74
DI 10.1248/bpb.b14 00567
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AX5FF
UT WOS:000346951500010
PM 25744460
OA gold
DA 2025 08 17
ER

PT J
AU Chen, LL
   Lei, LH
   Ding, PH
   Tang, Q
   Wu, YM
AF Chen, Li li
   Lei, Li hong
   Ding, Pei hui
   Tang, Qi
   Wu, Yan min
TI Osteogenic effect of Drynariae rhizoma extracts and
   Naringin on MC3T3 E1 cells and an induced rat alveolar bone
   resorption model
SO ARCHIVES OF ORAL BIOLOGY
LA English
DT Article
DE Drynariae rhizoma [Drynaria fortunei (kunze) J. Smith]; Naringin;
   Periodontal disease; Osteoblast; Alveolar bone loss
ID MORPHOGENETIC PROTEIN 2 EXPRESSION; DIFFERENTIATION; PROLIFERATION;
   SUPPLEMENTATION; MINERALIZATION; OSTEOBLASTS; PATHWAY
AB Objective: To investigate if Drynariae rhizoma (DR) and its main ingredient Naringin could reduce alveolar bone loss by stimulating the proliferation and differentiation of osteoblasts.
   Materials and methods: The effect of DR water (DRWE), ethanolic extract (DREE), and Naringin on MC3T3 E1 cells was evaluated respectively by MTT method and by measuring the activity of alkaline phosphatase (ALP activity) as well as the level of osteocalcin in medium. Bone mineral density (BMD) detection, osteoclast counting by tartrate resistant acid phosphatase staining, and histopathological analysis were performed in an induced rat model of alveolar bone resorption after gastric perfusion with DR extracts or Naringin.
   Results: DRWE and Naringin effectively increased the proliferation of MC3T3 E1 cells, whilst DREE and Naringin enhanced the differentiation of osteoblastic cells. The in vivo study indicated an elevated BMD value in the tooth periodontal tissues from DRWE, DREE and Naringin treated groups after 10, 20 and 30 days of perfusion (P < 0.05). In DRWE treated group, the number of osteoclasts at days 10, 20 and 30 decreased remarkably as compared to the corresponding negative controls (P < 0.05), and no osteoclast could be found at day 30. New non calcified bone like matrix attached by osteoblasts at the root furcation was also shown.
   Conclusions: DR could be a supplementary medicine for periodontal therapy as it could reduce bone resorption in rat model of alveolar bone resorption and exert osteogenic effect on osteoblasts. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Chen, Li li; Lei, Li hong; Ding, Pei hui; Wu, Yan min] Zhejiang Univ, Sch Med, Dept Oral Med, Affiliated Hosp 2, Hangzhou 310009, Zhejiang, Peoples R China.
   [Tang, Qi] Hosp Stomatol Hangzhou, Dept Periodont, Hangzhou 310006, Zhejiang, Peoples R China.
C3 Zhejiang University
RP Wu, YM (通讯作者)，88 Jiefang Rd, Hangzhou, Zhejiang, Peoples R China.
EM wym731128@126.com
RI Ding, Pei Hui/CAG 8041 2022; Tang, Qi/KSL 8607 2024
FU National Natural Science Foundation of China [30872884]; Natural Science
   Foundation of Zhejiang Province [Y2090060]
FX Project was supported by research programme from National Natural
   Science Foundation of China (project number: 30872884) for Prof. Li li
   Chen and Natural Science Foundation of Zhejiang Province for Dr. Yan min
   Wu (project number: Y2090060).
CR Benavente García O, 2008, J AGR FOOD CHEM, V56, P6185, DOI 10.1021/jf8006568
   Chen FM, 2010, BIOMATERIALS, V31, P7892, DOI 10.1016/j.biomaterials.2010.07.019
   Cirelli JA, 2009, GENE THER, V16, P426, DOI 10.1038/gt.2008.174
   Fujita T, 2008, BIOL PHARM BULL, V31, P925, DOI 10.1248/bpb.31.925
   Goltzman D, 2002, NAT REV DRUG DISCOV, V1, P784, DOI 10.1038/nrd916
   HUANG K, 1994, CHINESE MAT MED ENGL, P469
   Janckila AJ, 2009, CALCIFIED TISSUE INT, V85, P465, DOI 10.1007/s00223 009 9309 8
   Jeong JC, 2005, J ETHNOPHARMACOL, V96, P489, DOI 10.1016/j.jep.2004.09.038
   Jeong JC, 2005, PHARMACOL RES, V51, P125, DOI 10.1016/j.phrs.2004.06.005
   Jonarta AL, 2002, ORAL DIS, V8, P261, DOI 10.1034/j.1601 0825.2002.01797.x
   Kim KW, 2008, J ETHNOPHARMACOL, V115, P42, DOI 10.1016/j.jep.2007.09.003
   Kozuka Y, 2006, CALCIFIED TISSUE INT, V78, P125, DOI 10.1007/s00223 005 0149 x
   Lin XP, 2011, INFECT IMMUN, V79, P911, DOI 10.1128/IAI.00944 10
   Pereira CT, 2009, PLAST RECONSTR SURG, V124, P2199, DOI 10.1097/PRS.0b013e3181bcf5ff
   Robling AG, 2009, CRIT REV EUKAR GENE, V19, P319, DOI 10.1615/CritRevEukarGeneExpr.v19.i4.50
   Singh D, 2004, TOXICOLOGY, V201, P1, DOI 10.1016/j.tox.2004.03.028
   Tang CH, 2008, EUR J PHARMACOL, V579, P40, DOI 10.1016/j.ejphar.2007.10.013
   Tsutsumimoto T, 2002, BONE, V31, P396, DOI 10.1016/S8756 3282(02)00839 6
   Ukai T, 1996, J PERIODONTAL RES, V31, P414, DOI 10.1111/j.1600 0765.1996.tb00510.x
   UMEZU A, 1989, J PERIODONTAL RES, V24, P378, DOI 10.1111/j.1600 0765.1989.tb00886.x
   van Lenthe GH, 2008, J ORTHOP TRAUMA, V22, pS66, DOI 10.1097/BOT.0b013e31815e9fe1
   Vignesh RC, 2006, TOXICOLOGY, V220, P63, DOI 10.1016/j.tox.2005.11.026
   Von Böhl M, 2004, ANGLE ORTHOD, V74, P16
   Wang XL, 2008, CHEM PHARM BULL, V56, P46, DOI 10.1248/cpb.56.46
   Wei M, 2007, AM J CHINESE MED, V35, P663, DOI 10.1142/S0192415X07005156
   Wong R., 2007, CHIN MED UK, V2, P13, DOI [10.1186/1749 8546 2 13, DOI 10.1186/1749 8546 2 13]
   Wong RWK, 2006, BIOMATERIALS, V27, P1824, DOI 10.1016/j.biomaterials.2005.11.009
   Wood N, 2004, J MED FOOD, V7, P192, DOI 10.1089/1096620041224049
   Wu JB, 2008, EUR J PHARMACOL, V588, P333, DOI 10.1016/j.ejphar.2008.04.030
   Wu YM, 2007, ACTA PHARMACOL SIN, V28, P1015, DOI 10.1111/j.1745 7254.2007.00599.x
   Xie Yan ming, 2004, Zhongguo Zhong Yao Za Zhi, V29, P343
NR 31
TC 59
Z9 68
U1 1
U2 43
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0003 9969
EI 1879 1506
J9 ARCH ORAL BIOL
JI Arch. Oral Biol.
PD DEC
PY 2011
VL 56
IS 12
BP 1655
EP 1662
DI 10.1016/j.archoralbio.2011.06.008
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 863XP
UT WOS:000298201900026
PM 21764032
DA 2025 08 17
ER

PT J
AU Appelman Dijkstra, NM
   Papapoulos, SE
AF Appelman Dijkstra, Natasha M.
   Papapoulos, Socrates E.
TI Novel approaches to the treatment of osteoporosis
SO BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE bone formation; bone resorption; osteoporosis; cathepsin K; PTHrP;
   sclerostin
ID BONE MINERAL DENSITY; CATHEPSIN K INHIBITOR; PARATHYROID HORMONE 1 34;
   VAN BUCHEM DISEASE; POSTMENOPAUSAL WOMEN; SCLEROSTIN ANTIBODY;
   BIOCHEMICAL MARKERS; VERTEBRAL FRACTURE; SOST GENE; ODANACATIB
AB Despite the availability of efficacious treatments for fracture reduction in patients with osteoporosis, there are still unmet needs requiring a broader range of therapeutics. In particular, agents that are capable of replacing already lost bone and that also drastically reduce the risk of non vertebral fractures are needed. Studies of rare bone diseases in humans and animal genetics have identified targets in bone cells for the development of therapies for osteoporosis with novel mechanisms of action. Here, we review these new developments, with emphasis on inhibitors of cathepsin K in osteoclasts and sclerostin in osteocytes, which are currently studied in phase 3 clinical trials. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Appelman Dijkstra, Natasha M.; Papapoulos, Socrates E.] Leiden Univ, Med Ctr, Ctr Bone Qual, NL 2333 ZA Leiden, Netherlands.
C3 Leiden University; Leiden University Medical Center (LUMC); Leiden
   University   Excl LUMC
RP Papapoulos, SE (通讯作者)，Leiden Univ, Med Ctr, Ctr Bone Qual, Albinusdreef 2, NL 2333 ZA Leiden, Netherlands.
EM m.v.iken@lumc.nl
RI ; Appelman Dijkstra, Natasha/V 7322 2018
OI Appelman Dijkstra, Natasha/0000 0001 5035 127X; 
FU Amgen; Eli Lilly; GSK; Merck Co; Novartis
FX Dr Appelman has none. Dr Papapoulos has received speaking/consulting
   fees from Amgen, Eli Lilly, GSK, Merck & Co and Novartis.
CR Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Binkley N, 2012, J BONE MINER RES, V27, P1821, DOI 10.1002/jbmr.1602
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Bonnick S, 2013, J CLIN ENDOCR METAB, V98, P4727, DOI 10.1210/jc.2013 2020
   Boonen S, 2012, CURR OSTEOPOROS REP, V10, P73, DOI 10.1007/s11914 011 0085 9
   Bouxsein ML, 2005, BEST PRACT RES CL RH, V19, P897, DOI 10.1016/j.berh.2005.07.004
   Brixen K, 2013, J CLIN ENDOCR METAB, V98, P571, DOI 10.1210/jc.2012 2972
   Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Cabal A, 2013, BONE, V56, P497, DOI 10.1016/j.bone.2013.06.011
   Chambers TJ, 2013, J CLIN ENDOCR METAB, V98, P4329, DOI 10.1210/jc.2013 2630
   Cheung AM, 2014, J BONE MINER RES, V29, P1786, DOI 10.1002/jbmr.2194
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Compston JE, 2007, BONE, V40, P1447, DOI 10.1016/j.bone.2006.09.008
   Cosman F, 2011, J BONE MINER RES, V26, P503, DOI 10.1002/jbmr.238
   Cosman F, 2010, J CLIN ENDOCR METAB, V95, P151, DOI 10.1210/jc.2009 0358
   Cusick T, 2012, J BONE MINER RES, V27, P524, DOI 10.1002/jbmr.1477
   Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511
   Duong Le T, 2012, Bonekey Rep, V1, P67, DOI 10.1038/bonekey.2012.67
   Eastell R, 2014, J BONE MINER RES, V29, P458, DOI 10.1002/jbmr.2047
   Eastell R, 2011, J BONE MINER RES, V26, P1303, DOI 10.1002/jbmr.341
   Eisman JA, 2011, J BONE MINER RES, V26, P242, DOI 10.1002/jbmr.212
   Felsenberg D, 2005, CLIN THER, V27, P1, DOI 10.1016/j.clinthera.2004.12.020
   Fitzpatrick LA, 2011, J CLIN ENDOCR METAB, V96, P2441, DOI 10.1210/jc.2010 2855
   Fujita T, 2014, CALCIFIED TISSUE INT, V94, P170, DOI 10.1007/s00223 013 9777 8
   Gardner JC, 2005, J CLIN ENDOCR METAB, V90, P6392, DOI 10.1210/jc.2005 1235
   Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   Greenspan SL, 2007, ANN INTERN MED, V146, P326, DOI 10.7326/0003 4819 146 5 200703060 00005
   Hamersma H, 2003, CLIN GENET, V63, P192, DOI 10.1034/j.1399 0004.2003.00036.x
   Hassler N, 2014, J BONE MIN IN PRESS
   Henriksen K, 2013, BONE, V53, P160, DOI 10.1016/j.bone.2012.11.045
   Horwitz MJ, 2013, J BONE MINER RES, V28, P2266, DOI 10.1002/jbmr.1978
   Jamal SA, 2011, JAMA J AM MED ASSOC, V305, P800, DOI 10.1001/jama.2011.176
   Jerome C, 2012, OSTEOPOROSIS INT, V23, P339, DOI 10.1007/s00198 011 1593 2
   Ke HZ, 2012, ENDOCR REV, V33, P747, DOI 10.1210/er.2011 1060
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Kiviranta R, 2001, J BONE MINER RES, V16, P1444, DOI 10.1359/jbmr.2001.16.8.1444
   Kulkarni NH, 2006, J BONE MINER RES, V21, P910, DOI 10.1359/JBMR.060316
   Langdahl B, 2012, J BONE MINER RES, V27, P2251, DOI 10.1002/jbmr.1695
   Lecaille F, 2008, BIOCHIMIE, V90, P208, DOI 10.1016/j.biochi.2007.08.011
   Leder BZ, 2014, J CLIN ENDOCR METAB, V99, P1694, DOI 10.1210/jc.2013 4440
   Leupin O, 2011, J BIOL CHEM, V286, P19489, DOI 10.1074/jbc.M110.190330
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Lotinun Sutada, 2012, Curr Mol Pharmacol, V5, P195
   Lotinun S, 2010, BONE, V46, P1082, DOI 10.1016/j.bone.2010.01.370
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Masarachia PJ, 2012, J BONE MINER RES, V27, P509, DOI 10.1002/jbmr.1475
   Matsumoto T, 2006, OSTEOPOROSIS INT, V17, P1532, DOI 10.1007/s00198 006 0159 1
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   McColm J, 2014, J BONE MINER RES, V29, P935, DOI 10.1002/jbmr.2092
   Moester MJC, 2010, CALCIFIED TISSUE INT, V87, P99, DOI 10.1007/s00223 010 9372 1
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Ochi Y, 2014, BONE, V65, P1, DOI 10.1016/j.bone.2014.04.023
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Padhi D, 2014, J CLIN PHARMACOL, V54, P168, DOI 10.1002/jcph.239
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Papapoulos Socrates E, 2014, Bonekey Rep, V3, P523, DOI 10.1038/bonekey.2014.18
   Parfitt AM., 2001, Osteoporosis, V2rd, P433
   Pearsall RS, 2008, P NATL ACAD SCI USA, V105, P7082, DOI 10.1073/pnas.0711263105
   Pennypacker B, 2009, BONE, V44, P199, DOI 10.1016/j.bone.2008.08.130
   Pennypacker BL, 2014, J BONE MINER RES, V29, P1847, DOI 10.1002/jbmr.2211
   Pennypacker BL, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471 2474 14 344
   Pennypacker BL, 2011, J BONE MINER RES, V26, P252, DOI 10.1002/jbmr.223
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Recker R, 2004, J BONE MINER RES, V19, P1628, DOI 10.1359/JBMR.040710
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Ruckle J, 2009, J BONE MINER RES, V24, P744, DOI 10.1359/JBMR.081208
   Rünger TM, 2012, J AM ACAD DERMATOL, V66, pE89, DOI 10.1016/j.jaad.2010.11.033
   Saini V, 2013, J BIOL CHEM, V288, P20122, DOI 10.1074/jbc.M112.441360
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Segovia Silvestre T, 2009, HUM GENET, V124, P561, DOI 10.1007/s00439 008 0583 8
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Staehling Hampton K, 2002, AM J MED GENET, V110, P144, DOI 10.1002/ajmg.10401
   Stroup GB, 2009, CALCIFIED TISSUE INT, V85, P344, DOI 10.1007/s00223 009 9279 x
   Tsai JN, 2013, LANCET, V382, P50, DOI 10.1016/S0140 6736(13)60856 9
   van Bezooijen RL, 2009, J DENT RES, V88, P569, DOI 10.1177/0022034509338340
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   van Bezooijen RL, 2007, J BONE MINER RES, V22, P19, DOI 10.1359/JBMR.061002
   van Lierop AH, 2012, CLIN REV BONE MINER, V10, P108, DOI 10.1007/s12018 011 9123 5
   van Lierop AH, 2013, J BONE MINER RES, V28, P848, DOI 10.1002/jbmr.1794
   van Lierop AH, 2011, J BONE MINER RES, V26, P2804, DOI 10.1002/jbmr.474
   VANBUCHE.FS, 1971, ACTA MED SCAND, V189, P257
   Wijenayaka AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025900
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Yasuda Y, 2005, ADV DRUG DELIVER REV, V57, P973, DOI 10.1016/j.addr.2004.12.013
   Yavropoulou MP, 2010, EXPERT REV ENDOCRINO, V5, P711, DOI 10.1586/EEM.10.48
NR 95
TC 22
Z9 24
U1 0
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1521 690X
EI 1532 1908
J9 BEST PRACT RES CL EN
JI Best Pract. Res. Clin. Endoc. Metab.
PD DEC
PY 2014
VL 28
IS 6
BP 843
EP 857
DI 10.1016/j.beem.2014.07.003
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AY5CI
UT WOS:000347590500007
PM 25432356
DA 2025 08 17
ER

PT J
AU Nihashi, Y
   Miyoshi, M
   Umezawa, K
   Shimosato, T
   Takaya, T
AF Nihashi, Yuma
   Miyoshi, Mana
   Umezawa, Koji
   Shimosato, Takeshi
   Takaya, Tomohide
TI Identification of a Novel Osteogenetic Oligodeoxynucleotide (osteoDN)
   That Promotes Osteoblast Differentiation in a TLR9 Independent Manner
SO NANOMATERIALS
LA English
DT Article
DE osteogenetic oligodeoxynucleotide (osteoDN); osteoblast; bone
   differentiation; calcification; mineralization; Toll like receptor 9
   (TLR9)
ID IN VITRO; BONE; ACTIVATION; PROLIFERATION; OSTEOPOROSIS; EXPRESSION;
   DENOSUMAB; OSTERIX; CELLS; RUNX2
AB Dysfunction of bone forming cells, osteoblasts, is one of the causes of osteoporosis. Accumulating evidence has indicated that oligodeoxynucleotides (ODNs) designed from genome sequences have the potential to regulate osteogenic cell fate. Such osteogenetic ODNs (osteoDNs) targeting and activating osteoblasts can be the candidates of nucleic acid drugs for osteoporosis. In this study, the ODN library derived from the Lacticaseibacillus rhamnosus GG genome was screened to determine its osteogenetic effect on murine osteoblast cell line MC3T3 E1. An 18 base ODN, iSN40, was identified to enhance alkaline phosphatase activity of osteoblasts within 48 h. iSN40 also induced the expression of osteogenic genes such as Msx2, osterix, collagen type 1 alpha, osteopontin, and osteocalcin. Eventually, iSN40 facilitated calcium deposition on osteoblasts at the late stage of differentiation. Intriguingly, the CpG motif within iSN40 was not required for its osteogenetic activity, indicating that iSN40 functions in a TLR9 independent manner. These data demonstrate that iSN40 serves as a novel osteogenetic ODN (osteoDN) that promotes osteoblast differentiation. iSN40 provides a potential seed of the nucleic acid drug that activating osteoblasts for osteoporosis therapy.
C1 [Nihashi, Yuma; Shimosato, Takeshi; Takaya, Tomohide] Shinshu Univ, Grad Sch Med Sci & Technol, Dept Sci & Technol, 8304 Minami Minowa, Nagano 3994598, Japan.
   [Miyoshi, Mana; Shimosato, Takeshi; Takaya, Tomohide] Shinshu Univ, Grad Sch Sci & Technol, Dept Agr, 8304 Minami Minowa, Nagano 3994598, Japan.
   [Umezawa, Koji; Shimosato, Takeshi; Takaya, Tomohide] Shinshu Univ, Fac Agr, Dept Agr & Life Sci, 8304 Minami Minowa, Nagano 3994598, Japan.
   [Umezawa, Koji; Shimosato, Takeshi; Takaya, Tomohide] Shinshu Univ, Inst Biomed Sci, Dept Biomol Innovat, 8304 Minami Minowa, Nagano 3994598, Japan.
C3 Shinshu University; Shinshu University; Shinshu University; Shinshu
   University
RP Takaya, T (通讯作者)，Shinshu Univ, Grad Sch Med Sci & Technol, Dept Sci & Technol, 8304 Minami Minowa, Nagano 3994598, Japan.; Takaya, T (通讯作者)，Shinshu Univ, Grad Sch Sci & Technol, Dept Agr, 8304 Minami Minowa, Nagano 3994598, Japan.; Takaya, T (通讯作者)，Shinshu Univ, Fac Agr, Dept Agr & Life Sci, 8304 Minami Minowa, Nagano 3994598, Japan.; Takaya, T (通讯作者)，Shinshu Univ, Inst Biomed Sci, Dept Biomol Innovat, 8304 Minami Minowa, Nagano 3994598, Japan.
EM 19hs504f@shinshu u.ac.jp; 21as121c@shinshu u.ac.jp;
   koume@shinshu u.ac.jp; shimot@shinshu u.ac.jp; ttakaya@shinshu u.ac.jp
RI ; Shimosato, Takeshi/ABA 1499 2020; Takaya, Tomohide/D 6372 2012
OI Shimosato, Takeshi/0000 0001 8132 1911; Takaya,
   Tomohide/0000 0002 3610 0906; Nihashi, Yuma/0000 0002 5689 116X
FU Japan Society for the Promotion of Science [19K05948, 22K05554];
   Grants in Aid for Scientific Research [19K05948] Funding Source: KAKEN
FX This research was funded by The Japan Society for the Promotion of
   Science, grant numbers 19K05948 and 22K05554.
CR Amcheslavsky A, 2007, J BONE MINER RES, V22, P1301, DOI 10.1359/JBMR.070501
   Artigas N, 2014, J BIOL CHEM, V289, P27105, DOI 10.1074/jbc.M114.576793
   Awasthi H, 2018, MED RES REV, V38, P2024, DOI 10.1002/med.21504
   Becerikli M, 2017, J CELL MOL MED, V21, P2773, DOI 10.1111/jcmm.13192
   Boros K, 2017, BEST PRACT RES CL RH, V31, P203, DOI 10.1016/j.berh.2017.09.003
   Canalis E, 2013, NAT REV ENDOCRINOL, V9, P575, DOI 10.1038/nrendo.2013.154
   Charles JF, 2014, CURR OSTEOPOROS REP, V12, P1, DOI 10.1007/s11914 014 0195 2
   Corrado A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103679
   Corrado A, 2017, POSTGRAD MED, V129, P858, DOI 10.1080/00325481.2017.1362312
   Deng HD, 2017, ONCOTARGET, V8, P114428, DOI 10.18632/oncotarget.22826
   Diedhiou D, 2015, ANN ENDOCRINOL PARIS, V76, P650, DOI 10.1016/j.ando.2015.10.009
   El Sayed KMF, 2017, J CRANIO MAXILL SURG, V45, P2054, DOI 10.1016/j.jcms.2017.09.007
   Eriksen CG, 2010, CALCIFIED TISSUE INT, V87, P414, DOI 10.1007/s00223 010 9412 x
   Feng ZY, 2011, INT J MOL SCI, V12, P2543, DOI 10.3390/ijms12042543
   Gao J, 2018, CELL DEATH DIFFER, V25, P229, DOI 10.1038/cdd.2017.144
   Hou X, 2012, INT J MOL SCI, V13, P7902, DOI 10.3390/ijms13077902
   Ikebe J, 2011, J COMPUT CHEM, V32, P1286, DOI 10.1002/jcc.21710
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Lee DJ, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.20
   Liu TM, 2013, TISSUE ENG PART B RE, V19, P254, DOI [10.1089/ten.TEB.2012.0527, 10.1089/ten.teb.2012.0527]
   Macke TJ, 1998, ACS SYM SER, V682, P379
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Miller SA, 2021, J PHARM TECHNOL, V37, P45, DOI 10.1177/8755122520967632
   Moser SC, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00794
   Nakamura S, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.679152
   Nemoto E, 2008, J PERIODONTAL RES, V43, P585, DOI 10.1111/j.1600 0765.2008.01096.x
   Nigar S, 2017, BMC IMMUNOL, V18, DOI 10.1186/s12865 017 0227 7
   Niger S, 2019, FRONT NUTR, V6, DOI 10.3389/fnut.2019.00140
   Nihashi Y, 2022, bioRxiv, DOI [10.1101/2022.03.21.485101, 10.1101/2022.03.21.485101, DOI 10.1101/2022.03.21.485101]
   Nihashi Y., 2021, BIORXIV, DOI [10.1101/2021.11.17.469038, DOI 10.1101/2021.11.17.469038]
   Nihashi Y, 2021, ANIM SCI J, V92, DOI 10.1111/asj.13597
   Nohira N., 2021, BIORXIV, DOI DOI 10.1101/2021.10.18.464889
   Pisani P, 2016, WORLD J ORTHOP, V7, P171, DOI 10.5312/wjo.v7.i3.171
   Pohar J, 2015, J IMMUNOL, V195, P4396, DOI 10.4049/jimmunol.1500600
   Quemener AM, 2020, WIRES RNA, V11, DOI 10.1002/wrna.1594
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Sackesen C, 2013, ALLERGY, V68, P593, DOI 10.1111/all.12133
   Shen YQ, 2012, INT J MOL SCI, V13, P2877, DOI 10.3390/ijms13032877
   Shinji S, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.616706
   Takayama T, 2017, J BIOMATER APPL, V31, P1049, DOI 10.1177/0885328216686727
   Tian Y, 2012, CELL BIOCHEM BIOPHYS, V64, P169, DOI 10.1007/s12013 012 9369 7
   Tsui V, 2001, BIOPOLYMERS, V56, P275, DOI 10.1002/1097 0282(2000)56:4<275::AID BIP10024>3.0.CO;2 E
   Veazey KJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027592
   Vimalraj S, 2015, INT J BIOL MACROMOL, V78, P202, DOI 10.1016/j.ijbiomac.2015.04.008
   Vollmer J, 2009, ADV DRUG DELIVER REV, V61, P195, DOI 10.1016/j.addr.2008.12.008
   Wang T, 2019, BIOTECHNOL ADV, V37, P28, DOI 10.1016/j.biotechadv.2018.11.001
   Yang GA, 2010, IMMUNOLOGY, V131, P501, DOI 10.1111/j.1365 2567.2010.03322.x
   Yang XY, 2019, J CELL MOL MED, V23, P2149, DOI 10.1111/jcmm.14126
   Yu WW, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018 020 01844 x
   Zhang X, 2018, BIOCHEM BIOPH RES CO, V504, P771, DOI 10.1016/j.bbrc.2018.08.094
NR 51
TC 8
Z9 8
U1 0
U2 8
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2079 4991
J9 NANOMATERIALS BASEL
JI Nanomaterials
PD MAY
PY 2022
VL 12
IS 10
AR 1680
DI 10.3390/nano12101680
PG 11
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA 1R7HW
UT WOS:000803538000001
PM 35630904
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Xu, HH
   Chen, F
   Liu, TT
   Xu, J
   Li, J
   Jiang, L
   Wang, XJ
   Sheng, J
AF Xu, Huanhuan
   Chen, Fei
   Liu, Titi
   Xu, Jing
   Li, Jin
   Jiang, Li
   Wang, Xuanjun
   Sheng, Jun
TI Ellagic acid blocks RANKL RANK interaction and suppresses RANKL induced
   osteoclastogenesis by inhibiting RANK signaling pathways
SO CHEMICO BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Ellagic acid; RANKL RANK interaction; Osteoclastogenesis; RANK signaling
   Pathways
ID INDUCED BONE LOSS; DIFFERENTIATION; ELLAGITANNINS; OSTEOPOROSIS;
   PROTECTS; NFATC1; L.
AB Ellagic acid (EA) is a naturally occurring polyphenolic compound that has been shown to exhibit diverse beneficial pharmacological activities including anti osteoclastogenesis effect. However, the molecular mechanism by which EA inhibits osteoclastogenesis remains to be elucidated. The protein protein interaction between receptor activator of nuclear factor (NF) kappa B ligand (RANKL) and its receptor RANK contributes to osteoclast differentiation and activation in bone remodeling, and is regarded as an important therapeutic target for the treatment of osteoporosis. The current study is focused on investigating whether EA can directly bind to RANKL and/or RANK and block the interaction between RANKL and RANK, thereby inhibiting downstream signaling pathways. Interestingly, we found that EA had strong affinities to RANK and RANKL, with the estimated equilibrium dissociation constants (K D) of 2.485 x 10( 11) and 1.688 x 10( 9) M, respectively, and could disrupt the interaction between RANKL and RANK, thereby inhibiting RANKL induced canonical RANK signaling pathways (p65, JNK, ERK, and p38) and expression of downstream master transcriptional factors (NFATc1 and c Fos) and osteoclast specific genes and proteins (TRAP, c Src, and cathepsin K), which could ultimately suppress RANKL induced osteoclast differentiation and F actin ring formation. Taken together, our results revealed that EA could block RANKL RANK interaction and suppress RANKL induced osteoclastogenesis by inhibiting RANK signaling pathways in RAW 264.7 murine macrophages.
C1 [Xu, Huanhuan; Chen, Fei; Liu, Titi; Xu, Jing; Li, Jin; Jiang, Li; Wang, Xuanjun; Sheng, Jun] Yunnan Agr Univ, Key Lab Pu Er Tea Sci, Minist Educ, 452 Fengyuan Rd, Kunming 650201, Yunnan, Peoples R China.
   [Xu, Huanhuan; Liu, Titi; Wang, Xuanjun] Yunnan Agr Univ, Coll Sci, Kunming 650201, Yunnan, Peoples R China.
   [Chen, Fei; Li, Jin; Jiang, Li] Yunnan Agr Univ, Coll Food Sci & Technol, Kunming 650201, Yunnan, Peoples R China.
   [Wang, Xuanjun; Sheng, Jun] State Key Lab Conservat & Utilizat Bioresources Y, Kunming 650201, Yunnan, Peoples R China.
C3 Yunnan Agricultural University; Yunnan Agricultural University; Yunnan
   Agricultural University
RP Wang, XJ; Sheng, J (通讯作者)，Yunnan Agr Univ, Key Lab Pu Er Tea Sci, Minist Educ, 452 Fengyuan Rd, Kunming 650201, Yunnan, Peoples R China.
EM jwang@ynau.edu.cn
RI jin, li/IWU 4648 2023
FU Major Scientific and Technological Special Project of Yunnan Province
   [2017ZF003, 2018ZG010, 2018ZG013]; Yunnan Provincial Key Programs of
   Yunnan Eco friendly Food International Cooperation Research Center
   Project [2019ZG00904, 2019ZG00909]; Science and Technology Plan Project
   of Yunnan Province [2018IA060]
FX This work was supported by grants from the Major Scientific and
   Technological Special Project of Yunnan Province (2017ZF003, 2018ZG010,
   and 2018ZG013), the Yunnan Provincial Key Programs of Yunnan
   Eco friendly Food International Cooperation Research Center Project
   (2019ZG00904 and 2019ZG00909), and the Science and Technology Plan
   Project of Yunnan Province (2018IA060).
CR Rosillo MA, 2020, FOOD FUNCT, V11, P4038, DOI [10.1039/d0fo00433b, 10.1039/D0FO00433B]
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Chen WX, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1914 5
   Cui J, 2020, J CELL MOL MED, V24, P6149, DOI 10.1111/jcmm.15229
   Derosa G, 2016, ADV EXP MED BIOL, V928, P473, DOI 10.1007/978 3 319 41334 1_20
   Du TS, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2548 3
   Elendran S, 2019, FOOD FUNCT, V10, P602, DOI [10.1039/C8FO01927D, 10.1039/c8fo01927d]
   Feeley BT, 2006, J BONE MINER RES, V21, P1571, DOI 10.1359/JBMR.060706
   Guo S, 2020, FOOD FUNCT, V11, P1560, DOI [10.1039/c9fo03091c, 10.1039/C9FO03091C]
   Han SY, 2019, AM J CHINESE MED, V47, P439, DOI [10.1142/S0192415X19500228, 10.1142/s0192415x19500228]
   Hou HH, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01696
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Iglesias DE, 2020, FREE RADICAL BIO MED, V152, P776, DOI 10.1016/j.freeradbiomed.2020.01.022
   Kawabata K, 2019, MOLECULES, V24, DOI 10.3390/molecules24020370
   Kim K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020601
   Ko Y, 2020, OSTEOPOROSIS INT, V31, P983, DOI 10.1007/s00198 019 05200 6
   Langdahl B, 2016, THER ADV MUSCULOSKEL, V8, P225, DOI 10.1177/1759720X16670154
   Lee HI, 2019, FASEB J, V33, P9685, DOI 10.1096/fj.201900862R
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   Li ZX, 2019, J BONE MINER RES, V34, P765, DOI 10.1002/jbmr.3652
   Lin XX, 2020, J CELL PHYSIOL, V235, P5951, DOI 10.1002/jcp.29520
   Liu C, 2018, EUR J MED CHEM, V145, P661, DOI 10.1016/j.ejmech.2018.01.022
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Lu D, 2018, J BONE MINER RES, V33, P1773, DOI 10.1002/jbmr.3469
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Mansouri Z, 2020, INFLAMMATION, V43, P1143, DOI 10.1007/s10753 020 01201 4
   Moosa S, 2018, FOOD FUNCT, V9, P3301, DOI 10.1039/c7fo01497j
   Nagy V, 2015, GERONTOLOGY, V61, P534, DOI 10.1159/000371845
   Nakai Y, 2019, BONE RES, V7, DOI 10.1038/s41413 018 0036 5
   Papoutsi Z, 2008, BRIT J NUTR, V99, P715, DOI 10.1017/S0007114507837421
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rantlha M, 2017, ARCH PHARM RES, V40, P79, DOI 10.1007/s12272 016 0790 0
   Raut N, 2019, PHARMACOL RES, V147, DOI 10.1016/j.phrs.2019.104350
   Seeram NP, 2004, CLIN CHIM ACTA, V348, P63, DOI 10.1016/j.cccn.2004.04.029
   Sun XW, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101309
   Tan H, 2019, J AGR FOOD CHEM, V67, P3333, DOI 10.1021/acs.jafc.8b06954
   Wang QQ, 2020, J BONE MINER RES, V35, P1582, DOI 10.1002/jbmr.4025
   Wang YZ, 2019, J CANCER, V10, P3303, DOI 10.7150/jca.29738
   Warren JT, 2015, J CELL BIOCHEM, V116, P2476, DOI 10.1002/jcb.25191
   Yao N, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01111
   Zhou L, 2020, INT J BIOL SCI, V16, P309, DOI 10.7150/ijbs.37162
   Zhou L, 2019, FASEB J, V33, P6726, DOI 10.1096/fj.201800883RRR
NR 42
TC 27
Z9 28
U1 0
U2 15
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009 2797
EI 1872 7786
J9 CHEM BIOL INTERACT
JI Chem. Biol. Interact.
PD NOV 1
PY 2020
VL 331
AR 109235
DI 10.1016/j.cbi.2020.109235
PG 9
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA OH7TD
UT WOS:000582795500007
PM 32971123
DA 2025 08 17
ER

PT J
AU Wang, SJ
   Zhu, SW
   Li, XC
   Yang, Z
AF Wang, Shujun
   Zhu, Shaowen
   Li, Xincheng
   Yang, Zhao
TI Study on the Mechanism of Action of the Traditional Chinese Medical
   Prescription Gushukang in Treating Osteoporosis Based on Network
   Pharmacology and Experimental Verification
SO CURRENT COMPUTER AIDED DRUG DESIGN
LA English
DT Article; Early Access
DE Gushukang; osteoporosis; network pharmacology; molecular docking;
   experimental verification; polypharmacology; pharmacodynamic
ID DIFFERENTIATION
AB Background Gushukang (GSK), a traditional Chinese medical prescription, has made a great and extensive contribution to the treatment of different forms of osteoporosis, but polypharmacology studies of its mechanism of action are lacking. This study investigatesthe pharmacological mechanism of osteoporosis using network pharmacology and molecular docking. Experimental verification was carried out to confirm the efficacy of GSK on RANKL induced osteoclast differentiation in RAW264.7 cells to verify the network pharmacology studies.Methods The effective chemical components and corresponding targets of osteoporosiswith oral bioavailability of more than 30% and drug like properties greater than 0.18 were searched in the TCMSP and TCM ID databases. DrugBank, GeneCards, OMIM, TTD, andother databases were examined for targets related to osteoporosis. Using Cytoscape software,a network of possible TCM active ingredient osteoporosis targets was created. STRINGsoftware was used to create the networks of protein protein interactions. The DAVID program was carried out to conduct GO and KEGG pathway enrichment analyses of thetargets. Molecular docking and pattern of action analysis were carried out using softwarelike AutoDock Vina and Discovery Studio Visualizer. The growth media for RAW264.7cells contained varying doses of GSK serum and 50 ng/mL RANKL. The activity of TRAPwas altered. Additionally, genes related to osteoclasts were examined using an RT PCRassay.Results Network pharmacological analysis revealed that the primary efficacy targets of osteoporosis were PTGS2, PTGS1, HSP90AA1, NCOA2, ADRB2, ESR1, NCOA1, and AR. The pharmacological targets of osteoporosis may be mediated by substances including quercetin, kaempferol, luteolin, naringenin, icariin, anthocyanin, tanshinone IIA, and cryptotanshinone. GSK markedly inhibited RANKL induced TRAP activity. qRT PCR results revealed decreased expression of the PTGS2 and ADRB2 genes upon GSK treatment.Conclusion The findings of network pharmacology, molecular docking, as well as experimental verification provide a new further study for elucidating the pharmacodynamic substance basis and polypharmacology mechanism of GSK in treating osteoporosis.
C1 [Wang, Shujun; Zhu, Shaowen] Tianjin Hosp, Dept Orthoped, Beijing, Peoples R China.
   [Li, Xincheng] Beijing Chao Yang Hosp, Dept Thorac Surg, Beijing, Peoples R China.
   [Yang, Zhao] Tianjin Hosp, Dept Emergency, Beijing, Peoples R China.
C3 Capital Medical University
RP Yang, Z (通讯作者)，Tianjin Hosp, Dept Emergency, Beijing, Peoples R China.
EM anny.allan@126.com
RI zhu, shaowen/U 8777 2019; li, xincheng/HCH 9713 2022
CR Amberger JS, 2015, NUCLEIC ACIDS RES, V43, pD789, DOI 10.1093/nar/gku1205
   [Anonymous], 2023, Drug Standards of China, V24, P476
   Bardou P, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471 2105 15 293
   Borchers A, 2010, GENES BASEL, V1, P413, DOI 10.3390/genes1030413
   Chai S, 2019, PHYTOMEDICINE, V64, DOI 10.1016/j.phymed.2019.153063
   Deng W, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1015693
   Huang YY, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/6080597
   Jin HL, 2023, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1116257
   Jing Z, 2019, J CELL PHYSIOL, V234, P4472, DOI 10.1002/jcp.27252
   Kaczmarczyk Sedlak I, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/457052
   Li CX, 2024, PHYTOMEDICINE, V122, DOI 10.1016/j.phymed.2023.155137
   Li XL, 2020, AM J CHINESE MED, V48, P1671, DOI 10.1142/S0192415X20500834
   Lin RH, 2022, BMC COMPLEMENT MED, V22, DOI 10.1186/s12906 022 03807 7
   Liu H, 2021, MOL CELL ENDOCRINOL, V520, DOI 10.1016/j.mce.2020.111074
   NQ, 2018, Zhongguo Shiyan Fangjixue Zazhi, V24, P42
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758 2946 3 33
   Ryszkiewicz P, 2023, PHARMACOL REP, V75, P755, DOI 10.1007/s43440 023 00501 4
   [侍方 Shi Fang], 2020, [中成药, Chinese Traditional Patent Medicine], V42, P3188
   Song Shuang hong, 2015, Yaoxue Xuebao, V50, P154
   Stelzer Gil, 2016, Curr Protoc Bioinformatics, V54, DOI 10.1002/cpbi.5
   Suh KS, 2018, CHEM BIOL INTERACT, V296, P18, DOI 10.1016/j.cbi.2018.09.005
   SZ, 2019, Yaowu Fenxi Zazhi, V39, P1086
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tsukamoto S, 2014, BIOORG MED CHEM LETT, V24, P5315, DOI 10.1016/j.bmcl.2014.09.043
   Wang JF, 2005, CLIN PHARMACOL THER, V78, P92, DOI 10.1016/j.clpt.2005.03.010
   Wang JB, 2023, MEDICINE, V102, DOI 10.1097/MD.0000000000036292
   Wang Ru, 2023, Progress in Modern Biomedicine, V23, P193, DOI 10.13241/j.cnki.pmb.2023.01.038
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Xiao JC, 2023, LIFE SCI, V322, DOI 10.1016/j.lfs.2022.121326
   Zhao YJ, 2019, JOVE J VIS EXP, DOI 10.3791/59171
   Zheng ZG, 2017, EUR J PHARMACOL, V809, P156, DOI 10.1016/j.ejphar.2017.05.017
   Zhou Xue Hong, 2020, Drugs and Clinic, V35, P1821, DOI 10.7501/j.issn.1674 5515.2020.09.019
   Zhou Y, 2022, NUCLEIC ACIDS RES, V50, pD1398, DOI 10.1093/nar/gkab953
   Zhu SW, 2018, MOL MED REP, V17, P6969, DOI 10.3892/mmr.2018.8741
NR 34
TC 1
Z9 1
U1 1
U2 13
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1573 4099
EI 1875 6697
J9 CURR COMPUT AID DRUG
JI Curr. Comput. Aided Drug Des.
PD 2024 MAY 28
PY 2024
DI 10.2174/0115734099282620240521102006
EA MAY 2024
PG 13
WC Chemistry, Medicinal; Computer Science, Interdisciplinary Applications
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Computer Science
GA TC8O6
UT WOS:001239154900001
PM 38808725
DA 2025 08 17
ER

PT J
AU Nakamichi, Y
   Udagawa, N
   Suda, T
   Takahashi, N
AF Nakamichi, Yuko
   Udagawa, Nobuyuki
   Suda, Tatsuo
   Takahashi, Naoyuki
TI Mechanisms involved in bone resorption regulated by vitamin D
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article; Proceedings Paper
CT 20th Workshop on Vitamin D
CY MAR 28 31, 2017
CL Orlando, FL
SP Pfizer, DiaSorin, OPKO Hlth, Bio Tech Pharmacal Inc, DIAsource Immunoassays SA, Cerbios, Teijin, Grassroots Hlth
DE Vitamin D; Osteoclasts; Pro resorptive; Anti resorptive; Osteoblast
   lineage specific VDR cKO; Osteoclast specific VDR cKO; FGF23
ID OSTEOCLASTOGENESIS INHIBITORY FACTOR; D RECEPTOR; POSTMENOPAUSAL
   OSTEOPOROSIS; OSTEOBLASTIC CELLS; MINERAL DENSITY; KNOCKOUT MICE;
   STROMAL CELLS; IN VITRO; D ANALOG; C FOS
AB Active forms of vitamin D enhance osteoclastogenesis in vitro and in vivo through the vitamin D receptor (VDR) in osteoblast lineage cells consisting of osteoblasts and osteocytes. This pro resorptive activity was evident basically with higher concentrations of active vitamin D than those expected in physiological conditions. Nevertheless, vitamin D compounds have been used in Japan for treating osteoporosis to increase bone mineral density (BMD). Of note, the increase in BMD by long term treatment with pharmacological ( = near physiological) doses of vitamin D compounds was caused by the suppression of bone resorption. Therefore, whether vitamin D expresses pro resorptive or anti resorptive properties seems to be dependent on the treatment protocols. We established osteoblast lineage specific and osteoclast specific VDR conditional knockout (cKO) mice using Osterix Cre transgenic mice and Cathepsin K Cre knock in mice, respectively. According to our observation using these cKO mouse lines, neither VDR in osteoblast lineage cells nor that in osteoclasts played important roles for osteoclastogenesis and bone resorption at homeostasis. However, using our cKO lines, we observed that VDR in osteoblast lineage cells, but not osteoclasts, was involved in the anti resorptive properties of pharmacological doses of vitamin D compounds in vivo. Two different osteoblast lineage VDR cKO mouse lines were reported. One is a VDR cKO mouse line using alpha 1, type I collagen (Colla 1) Cre transgenic mice (here we call Collal VDR cKO mice) and the other is that using dentin matrix protein 1 (Dmpl) Cre transgenic mice (Dmpl VDR cKO mice). Collal VDR cKO mice exhibited slightly increased bone mass due to lowered bone resorption. In contrast, Dmpl VDR cKO mice exhibited no difference in BMD in agreement with our results regarding ObVDR cKO mice. Here we discuss contradictory results and multiple modes of actions of vitamin D in bone resorption in detail. (279 words)
C1 [Nakamichi, Yuko; Takahashi, Naoyuki] Matsumoto Dent Univ, Inst Oral Sci, Shiojiri, Nagano 3990781, Japan.
   [Udagawa, Nobuyuki] Matsumoto Dent Univ, Dept Biochem, Shiojiri, Nagano 3990781, Japan.
   [Suda, Tatsuo] Saitama Med Univ, Res Ctr Genom Med, Saitama 3501241, Japan.
C3 Matsumoto Dental University; Matsumoto Dental University; Saitama
   Medical University
RP Nakamichi, Y (通讯作者)，Matsumoto Dent Univ, Inst Oral Sci, Shiojiri, Nagano 3990781, Japan.
EM nakamichi@po.mdu.ac.jp
FU Japan Society for the Promotion of Science (JSPS) [16K11493, 16H05508,
   16H05144]; Grants in Aid for Scientific Research [16H05508, 16K11493,
   16H05144, 15KK0356] Funding Source: KAKEN
FX This work was supported in part by Grants in Aid from Japan Society for
   the Promotion of Science (JSPS) [16K11493 (YN), 16H05508 (NU), and
   16H05144 (NT)]
CR Amling M, 1999, ENDOCRINOLOGY, V140, P4982, DOI 10.1210/en.140.11.4982
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hagino H, 2013, EXPERT OPIN PHARMACO, V14, P817, DOI 10.1517/14656566.2013.778825
   Harada S, 2012, J BONE MINER RES, V27, P461, DOI 10.1002/jbmr.555
   HOLTROP ME, 1986, AM J PHYSIOL, V251, pE234, DOI 10.1152/ajpendo.1986.251.2.E234
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Kikuta J, 2013, P NATL ACAD SCI USA, V110, P7009, DOI 10.1073/pnas.1218799110
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Lieben L, 2012, J CLIN INVEST, V122, P1803, DOI 10.1172/JCI45890
   Lips P, 2007, J BONE MINER RES, V22, P1668, DOI 10.1359/JBMR.070716
   Matsumoto Toshio, 2014, Bonekey Rep, V3, P513, DOI 10.1038/bonekey.2014.8
   Matsumoto T, 2011, BONE, V49, P605, DOI 10.1016/j.bone.2011.07.011
   Miedlich SU, 2010, ENDOCRINOLOGY, V151, P4607, DOI 10.1210/en.2010 0354
   Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110
   Mizoguchi T, 2014, DEV CELL, V29, P340, DOI 10.1016/j.devcel.2014.03.013
   Mizoguchi T, 2009, J CELL BIOL, V184, P541, DOI 10.1083/jcb.200806139
   Muto A, 2011, J BONE MINER RES, V26, P2978, DOI 10.1002/jbmr.490
   Nakamichi Y, 2017, J BONE MINER RES, V32, P1297, DOI 10.1002/jbmr.3096
   Nakamichi Y, 2012, P NATL ACAD SCI USA, V109, P10006, DOI 10.1073/pnas.1207361109
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Nicholson GC, 2000, CLIN SCI, V99, P133, DOI 10.1042/CS19990355
   ORIMO H, 1994, CALCIFIED TISSUE INT, V54, P370, DOI 10.1007/BF00305521
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Sakai S, 2009, J BONE MINER METAB, V27, P643, DOI 10.1007/s00774 009 0084 4
   Sato M, 2007, BONE, V40, P293, DOI 10.1016/j.bone.2006.09.007
   Sato Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111845
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Starczak Y., 2016, J BONE MINER RES, V31, pS20
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo 123 5 2600
   Takasu H, 2006, J CLIN INVEST, V116, P528, DOI 10.1172/JCI24742
   Takeda S, 1999, ENDOCRINOLOGY, V140, P1005, DOI 10.1210/en.140.2.1005
   TILYARD MW, 1992, NEW ENGL J MED, V326, P357, DOI 10.1056/NEJM199202063260601
   Uchiyama Y, 2002, BONE, V30, P582, DOI 10.1016/S8756 3282(02)00682 8
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   Wang YJ, 2014, J BONE MINER RES, V29, P685, DOI 10.1002/jbmr.2081
   Winkeler CL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042005
   Xue YB, 2009, GASTROENTEROLOGY, V136, P1317, DOI 10.1053/j.gastro.2008.12.051
   Yagishita N, 2001, ENDOCRINOLOGY, V142, P5332, DOI 10.1210/en.142.12.5332
   Yamamoto Y, 2013, ENDOCRINOLOGY, V154, P1008, DOI 10.1210/en.2012 1542
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
   Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897 391
   Zarei A, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.30
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
NR 51
TC 49
Z9 53
U1 1
U2 17
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960 0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD MAR
PY 2018
VL 177
SI SI
BP 70
EP 76
DI 10.1016/j.jsbmb.2017.11.005
PG 7
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA FZ1KG
UT WOS:000427334900011
PM 29146302
DA 2025 08 17
ER

PT J
AU Petranova, T
   Sheytanov, I
   Monov, S
   Rashkov, R
   Kinov, P
AF Petranova, Tsvetanka
   Sheytanov, Ivan
   Monov, Simeon
   Rashkov, Rasho
   Kinov, Plamen
TI EFFICACY OF DENOSUMAB FOR CONTROL OF BONE MINERAL DENSITY AND
   MICROARCHITECTURE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: A ONE YEAR
   EXPERIENCE
SO BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT
LA English
DT Article; Proceedings Paper
CT 2nd International Conference on Biomedical Engineering and Biotechnology
   (iCBEB)
CY OCT 11 13, 2013
CL Wuhan Sci & Technol Convent & Exhibit Ctr, Wuhan, PEOPLES R CHINA
SP Sci & Engn Inst Hong Kong, Wuhan Univ, Huazhong Univ Sci & Technol, Wuhan Univ Technol, Central China Normal Univ, Inspirees Int BV The Netherlands
HO Wuhan Sci & Technol Convent & Exhibit Ctr
DE denosumab; postmenopausal osteoporosis; treatment; BMD; TBS
ID OSTEOCLAST DIFFERENTIATION; FRACTURES; TURNOVER; OSTEOPROTEGERIN;
   ALENDRONATE; RISK; MASS
AB Denosumab is a fully human monoclonal antibody targeting the receptor activator of nuclear factor kappa B ligand (RANKL) and thus, inhibiting the osteoclast differentiation, activation and survival. Due to its specific mode of action, denosumab is already successfully used as a new targeted therapy of women with low bone mineral density (BMD) resulting from postmenopausal osteoporosis (PMO). The aim of this one year clinical observational study was to evaluate the therapeutic efficacy and safety profile of denosumab in 36 women with PMO. Denosumab was, administered as a subcutaneous injection of 60 mg once per 6 months. The therapeutic efficacy of denosumab was assessed on the basis of BMD, trabecular bone score (TBS) and fracture risk based on FRAX (R) (WHO Fracture Risk Assessment tool). Treatment with denosumab resulted in an increase in BMD by 3.9% at the lumbar spine and by 1.3% at the total hip (as compared to the baseline BMD values) with corresponding improvement of the T score of the lumbar spine of 13.8% and 4.5% of total hip, respectively TBS is a new texture measurement that correlates with the quality of bone microarchitecture. At month 12, the TBS appeared to be significantly increased by 1.7% as compared to its baseline mean value. The risk of major osteoporotic fracture and hip fracture assessed by FRAX (R) was reduced by 13.3% and 38.4%, respectively These data, representing the local clinical experience, suggest that denosumab might be used as an effective treatment of PMO.
C1 [Petranova, Tsvetanka; Sheytanov, Ivan; Monov, Simeon; Rashkov, Rasho] Med Univ Sofia, Univ Hosp Sv Ivan Rilski, Sofia, Bulgaria.
   [Kinov, Plamen] Med Univ Sofia, Univ Hosp Tsaritsa Yoanna, Sofia, Bulgaria.
C3 Medical University Sofia; Medical University Sofia
RP Petranova, T (通讯作者)，Med Univ Sofia, Univ Hosp Sv Ivan Rilski, Sofia, Bulgaria.
EM dr_petranova@yahoo.com
RI ; Kinov, Plamen/AIB 3491 2022; Monov, Simeon/ABE 5806 2021
OI Kinov, Plamen/0000 0002 1652 1463; 
CR [Anonymous], 1994, World Health Organ Tech Rep Ser, V843, P1
   Bone HG, 2008, J CLIN ENDOCR METAB, V93, P2149, DOI 10.1210/jc.2007 2814
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Delmas PD, 2008, J CLIN DENSITOM, V11, P325, DOI 10.1016/j.jocd.2008.02.002
   European Medicines Agency, 2012, PROL
   Hans D, 2011, J BONE MINER RES, V26, P2762, DOI 10.1002/jbmr.499
   Hans D, 2011, J CLIN DENSITOM, V14, P302, DOI 10.1016/j.jocd.2011.05.005
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Link Thomas M, 2004, Curr Osteoporos Rep, V2, P47, DOI 10.1007/s11914 004 0003 5
   McClung MR, 2012, J BONE MINER RES, V27, P211, DOI 10.1002/jbmr.536
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Papapoulos S, 2012, J BONE MINER RES, V27, P694, DOI 10.1002/jbmr.1479
   Rubin CD, 2005, CURR MED RES OPIN, V21, P1049, DOI 10.1185/030079905X50525
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sornay Rendu E, 2005, J BONE MINER RES, V20, P1929, DOI 10.1359/JBMR.050704
   von Keyserlingk C, 2011, SEMIN ARTHRITIS RHEU, V41, P178, DOI 10.1016/j.semarthrit.2011.03.005
NR 20
TC 3
Z9 3
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1310 2818
EI 1314 3530
J9 BIOTECHNOL BIOTEC EQ
JI Biotechnol. Biotechnol. Equip.
PD AUG
PY 2013
VL 27
IS 4
BP 3977
EP 3981
DI 10.5504/BBEQ.2013.0045
PG 5
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Biotechnology & Applied Microbiology
GA 206OV
UT WOS:000323532900013
OA Bronze
DA 2025 08 17
ER

PT J
AU Li, CR
   Li, Y
   Zhang, LX
   Zhang, S
   Yao, WY
   Zuo, Z
AF Li, Chenrui
   Li, Yu
   Zhang, Lixiu
   Zhang, Shu
   Yao, Weiyun
   Zuo, Zhong
TI The protective effect of piperine on ovariectomy induced bone loss in
   female mice and its enhancement effect of osteogenic differentiation via
   Wnt/β catenin signaling pathway
SO JOURNAL OF FUNCTIONAL FOODS
LA English
DT Article
DE Piperine; Ovariectomized mice; Wnt/beta catenin; Osteoblast; Bone
   remodeling
ID MINERAL DENSITY; OSTEOBLAST DIFFERENTIATION; OSTEOPOROSIS; SEROTONIN;
   RECEPTOR; EXPRESSION; DISEASE; CELLS
AB Piperine (PIP) demonstrates extensive pharmacological effects. Recent studies reported that PIP enhanced osteogenic differentiation and inhibited osteoclast functions. Nevertheless, its effect has not been evaluated in vivo. In the current study, ovariectomised female mice and MC3T3 E1 cells were used to examine its effect on osteoblastogenesis. Oral administration of PIP significantly elevated bone mineral density and suppressed bone remodeling without dose dependence. The deterioration of trabecula and biomechanical properties were significantly improved. Moreover, new bone formation was also accelerated with increased mineral apposition rate. At the presence of PIP, the cell proliferation and alkaline phosphatase as well as mineralized nodules formation were significantly enhanced. The expression of osteogenic markers and Wnt/beta catenin signals were significantly up regulated by the treatment of PIP. Conclusively, as an alternative supplement or functional food ingredient, PIP has the potential to treat osteoporosis induced by estrogen deficiency by enhancing osteogenic differentiation via Wnt/beta catenin signaling.
C1 [Li, Chenrui; Li, Yu; Zhang, Lixiu; Zhang, Shu; Yao, Weiyun] Northwestern Polytech Univ, Sch Life Sci, Xian, Shaanxi, Peoples R China.
   [Zuo, Zhong] Chinese Univ Hong Kong, Sch Pharm, Hong Kong, Peoples R China.
C3 Northwestern Polytechnical University; Chinese University of Hong Kong
RP Zuo, Z (通讯作者)，Chinese Univ Hong Kong, Sch Pharm, Fac Med, Shatin, Hong Kong, Peoples R China.
EM joanzuo@cuhk.edu.hk
RI Li, Xiang/AEW 7546 2022; Li, Chenrui/D 9013 2011; Zuo, Zhong/B 6884 2008
OI Zuo, Zhong/0000 0002 6976 6157; 
FU National Natural Science Foundation of China, China [81502980]; Graduate
   Creative Innovation Seed Fund of Northwestern Polytechnical University,
   Xi'an, China [ZZ2017233]
FX The work was supported by the National Natural Science Foundation of
   China, China (No. 81502980) and the Graduate Creative Innovation Seed
   Fund of Northwestern Polytechnical University, Xi'an, China (No.
   ZZ2017233).
CR Ak E, 2015, OSTEOPOROSIS INT, V26, P273, DOI 10.1007/s00198 014 2859 2
   Alkhamees OA, 2017, BIOMED PHARMACOTHER, V87, P575, DOI 10.1016/j.biopha.2017.01.008
   Blaber E, 2010, ASTROBIOLOGY, V10, P463, DOI 10.1089/ast.2009.0415
   Borre YE, 2014, NEUROPHARMACOLOGY, V79, P738, DOI 10.1016/j.neuropharm.2013.11.009
   Bradaschia Correa V, 2017, J BONE MINER RES, V32, P821, DOI 10.1002/jbmr.3045
   Chen CY, 2013, EUR J PHARMACOL, V714, P288, DOI 10.1016/j.ejphar.2013.07.041
   Cremers S, 2011, BONE, V49, P42, DOI 10.1016/j.bone.2011.01.014
   Deepak V, 2015, BIOFACTORS, V41, P403, DOI 10.1002/biof.1241
   Deng RX, 2018, J FUNCT FOODS, V40, P229, DOI 10.1016/j.jff.2017.10.044
   Ducy P, 2010, J CELL BIOL, V191, P7, DOI 10.1083/jcb.201006123
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Gates BJ, 2009, AM J GERIATR PHARMAC, V7, P293, DOI 10.1016/j.amjopharm.2009.12.004
   Hou XF, 2015, INFLAMMATION, V38, P1093, DOI 10.1007/s10753 014 0075 z
   Hu DH, 2015, J ETHNOPHARMACOL, V169, P109, DOI 10.1016/j.jep.2015.04.006
   Hwang JH, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.115
   Kanis JA, 2002, LANCET, V359, P1929, DOI 10.1016/S0140 6736(02)08761 5
   Kastner M, 2018, OSTEOPOROSIS INT, V29, P5, DOI 10.1007/s00198 017 4248 0
   Kim DY, 2018, BIOCHEM BIOPH RES CO, V495, P1497, DOI 10.1016/j.bbrc.2017.11.200
   Kuda T, 2017, J FUNCT FOODS, V35, P605, DOI 10.1016/j.jff.2017.06.030
   Lavoie B, 2017, ADV EXP MED BIOL, V1033, P35, DOI 10.1007/978 3 319 66653 2_3
   Leder BZ, 2015, LANCET, V386, P1147, DOI 10.1016/S0140 6736(15)61120 5
   Lee DH, 2016, J FUNCT FOODS, V23, P105, DOI 10.1016/j.jff.2016.02.008
   Li CR, 2016, J PHARMACEUT BIOMED, V128, P286, DOI 10.1016/j.jpba.2016.05.041
   Li S, 2007, LIFE SCI, V80, P1373, DOI 10.1016/j.lfs.2006.12.027
   Liu HL, 2015, FOOD CHEM, V177, P191, DOI 10.1016/j.foodchem.2015.01.033
   Mao QQ, 2014, NEUROCHEM INT, V74, P36, DOI 10.1016/j.neuint.2014.04.017
   Mao QQ, 2014, BEHAV BRAIN RES, V261, P140, DOI 10.1016/j.bbr.2013.12.020
   Mao QQ, 2011, NEUROSCI LETT, V504, P181, DOI 10.1016/j.neulet.2011.09.038
   Mao QQ, 2011, PROG NEURO PSYCHOPH, V35, P1144, DOI 10.1016/j.pnpbp.2011.03.017
   Maraka S, 2015, BMJ BRIT MED J, V351, DOI 10.1136/bmj.h3783
   Peng SL, 2013, BONE, V55, P230, DOI 10.1016/j.bone.2013.02.012
   Petronijevic M, 2008, BONE, V42, P582, DOI 10.1016/j.bone.2007.11.010
   PIYACHATURAWAT P, 1983, TOXICOL LETT, V16, P351, DOI 10.1016/0378 4274(83)90198 4
   Pongkorpsakol P, 2015, PHARMACOL RES, V100, P271, DOI 10.1016/j.phrs.2015.08.012
   Rauma PH, 2016, BONE, V89, P25, DOI 10.1016/j.bone.2016.05.003
   Ren T. J., 2017, XENOBIOTICA, V28, P1
   Rizzoli R, 2012, BONE, V51, P606, DOI 10.1016/j.bone.2012.05.018
   Schweiger JU, 2016, BRAIN BEHAV, V6, DOI 10.1002/brb3.489
   Sunila ES, 2004, J ETHNOPHARMACOL, V90, P339, DOI 10.1016/j.jep.2003.10.016
   Wu Q, 2009, OSTEOPOROSIS INT, V20, P1309, DOI 10.1007/s00198 009 0918 x
   Xie CL, 2018, J FUNCT FOODS, V43, P165, DOI 10.1016/j.jff.2018.02.014
   Yang JH, 2017, J FUNCT FOODS, V38, P529, DOI 10.1016/j.jff.2017.09.053
   Yirmiya R, 2009, BIOL PSYCHIAT, V66, P423, DOI 10.1016/j.biopsych.2009.03.016
   Zhang GW, 2017, MOLECULES, V22, DOI 10.3390/molecules22071044
NR 44
TC 9
Z9 11
U1 2
U2 49
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1756 4646
J9 J FUNCT FOODS
JI J. Funct. Food.
PD JUL
PY 2019
VL 58
BP 138
EP 150
DI 10.1016/j.jff.2019.04.048
PG 13
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA IC8EG
UT WOS:000471208500016
DA 2025 08 17
ER

PT J
AU Zhang, XY
   Hamadeh, IS
   Song, S
   Katz, J
   Moreb, JS
   Langaee, TY
   Lesko, LJ
   Gong, Y
AF Zhang, Xiaoyan
   Hamadeh, Issam S.
   Song, Shuang
   Katz, Joseph
   Moreb, Jan S.
   Langaee, Taimour Y.
   Lesko, Lawrence J.
   Gong, Yan
TI Osteonecrosis of the Jaw in the United States Food and Drug
   Administration's Adverse Event Reporting System (FAERS)
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEONECROSIS OF THE JAW; FAERS; BISPHOSPHONATES; RANKL INHIBITORS;
   ANTIANGIOGENIC AGENTS
ID ZOLEDRONIC ACID; SIGNAL DETECTION; DOUBLE BLIND; METASTASES; CANCER
AB Osteonecrosis of the jaw (ONJ) is a serious adverse drug event that was initially reported with intravenous bisphosphonates (BPs) and more recently with other classes of drugs such as receptor activator of NF B ligand (RANKL) inhibitor, antiangiogenic agents, and mammalian target of rapamycin (m TOR) inhibitors. The purpose of this study is to analyze the ONJ cases and the associated drugs in the US Food and Drug Administration's adverse event reporting system (FAERS). The FAERS database was queried for the adverse drug events reported from the first quarter of 2010 to the first quarter of 2014. The reporting odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for each queried drug. A total of 17,119 unique ONJ cases were identified. In the overall analysis, the drugs with the highest reporting ORs were BPs: pamidronate (OR=498.9), zoledronate (OR=171.7), and alendronate (OR=63.6), whereas denosumab had lower ORs than all the BPs except for etidronate. The antiangiogenic and m TOR inhibitors had the lowest ORs. In cancer patients who were treated for prevention of skeletal related events (SREs), the reporting ORs for zoledronate and denosumab were 125.2 and 4.9, respectively. In patients with osteoporosis, the ORs were 1.1 (1.0 1.18) for zoledronate and 0.63 (0.56 0.70) for denosumab, respectively. Our analysis of the FAERS database showed that the intravenous BPs were associated with the highest risk for ONJ, RANKL inhibitor was associated with risk comparable to BPs used for osteoporosis such as etidronate, and the antiangiogenic agents and m TOR inhibitors were associated with the lowest risk for ONJ. The high risk for ONJ with zoledronate and denosumab was mainly observed in those who were treated for prevention of SREs, whereas there was limited evidence for such risk in those who were treated for osteoporosis. (c) 2015 American Society for Bone and Mineral Research.
C1 [Zhang, Xiaoyan; Lesko, Lawrence J.] Univ Florida, Coll Pharm, Dept Pharmaceut, Orlando, FL USA.
   [Zhang, Xiaoyan; Lesko, Lawrence J.] Univ Florida, Coll Pharm, Ctr Pharmacometr & Syst Pharmacol, Orlando, FL USA.
   [Hamadeh, Issam S.; Song, Shuang; Langaee, Taimour Y.; Gong, Yan] Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, Gainesville, FL USA.
   [Hamadeh, Issam S.; Langaee, Taimour Y.; Gong, Yan] Univ Florida, Coll Pharm, Ctr Pharmacogen, Gainesville, FL USA.
   [Katz, Joseph] Univ Florida, Coll Dent, Dept Oral Med, Gainesville, FL USA.
   [Moreb, Jan S.] Univ Florida, Coll Med, Dept Med, Gainesville, FL USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida; State University
   System of Florida; University of Florida; State University System of
   Florida; University of Florida; State University System of Florida;
   University of Florida; State University System of Florida; University of
   Florida
RP Gong, Y (通讯作者)，Univ Florida, Dept Pharmacotherapy & Translat Res, POB 100486,1600 SW Archer Rd, Gainesville, FL 32610 USA.
EM gong@cop.ufl.edu
RI Katz, Joseph/A 7624 2010; Moreb, Jan/HJG 6455 2022; Gong,
   Yan/LBH 7198 2024
OI katz, joseph/0000 0002 0741 8149; 
CR AAOMS, 2007, J ORAL MAXIL SURG, V65, P369, DOI 10.1016/j.joms.2006.11.003
   [Anonymous], 2013, ISRN ONCOL
   Bate A, 2009, PHARMACOEPIDEM DR S, V18, P427, DOI 10.1002/pds.1742
   Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097 0142(20010401)91:7<1191::AID CNCR1119>3.0.CO;2 0
   Center M., 2011, GLOBAL CANC FACTS FI, V2nd
   Diz P, 2012, J AM DENT ASSOC, V143, P981, DOI 10.14219/jada.archive.2012.0323
   Fusco V, 2010, BREAST, V19, P432, DOI 10.1016/j.breast.2010.03.008
   Grbic JT, 2010, J AM DENT ASSOC, V141, P1365, DOI 10.14219/jada.archive.2010.0082
   Hamadeh IS, 2015, CANCER TREAT REV, V41, P455, DOI 10.1016/j.ctrv.2015.04.007
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hoff AO, 2008, J BONE MINER RES, V23, P826, DOI [10.1359/JBMR.080205, 10.1359/jbmr.080205]
   Kim DW, 2013, BRIT J ORAL MAX SURG, V51, pE302, DOI 10.1016/j.bjoms.2013.09.008
   Lo JC, 2010, J ORAL MAXIL SURG, V68, P243, DOI 10.1016/j.joms.2009.03.050
   Malden N, 2012, J BONE MINER METAB, V30, P171, DOI 10.1007/s00774 011 0299 z
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Migliorati CA, 2009, J TENN DENT ASS, V89, P38
   Migliorati Cesar A, 2009, J Tenn Dent Assoc, V89, P36
   Reszka Alfred A, 2003, Curr Rheumatol Rep, V5, P65, DOI 10.1007/s11926 003 0085 6
   Rogers MJ, 2004, CALCIFIED TISSUE INT, V75, P451, DOI 10.1007/s00223 004 0024 1
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Taylor KH, 2010, BRIT J ORAL MAX SURG, V48, P221, DOI 10.1016/j.bjoms.2009.08.030
   van Puijenbroek EP, 2002, PHARMACOEPIDEM DR S, V11, P3, DOI 10.1002/pds.668
   Wilkinson GS, 2007, JNCI J NATL CANCER I, V99, P1016, DOI 10.1093/jnci/djm025
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
NR 26
TC 77
Z9 78
U1 2
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD FEB
PY 2016
VL 31
IS 2
BP 336
EP 340
DI 10.1002/jbmr.2693
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DD8NE
UT WOS:000370182900011
PM 26288087
OA Bronze
DA 2025 08 17
ER

PT J
AU Zhao, DF
   Wang, CL
   Zhao, YJ
   Shu, B
   Jia, YJ
   Liu, SF
   Wang, HS
   Chang, JL
   Dai, WW
   Lu, S
   Shi, Q
   Yang, YP
   Zhang, Y
   Wang, YJ
AF Zhao, Dongfeng
   Wang, Chenglong
   Zhao, Yongjian
   Shu, Bing
   Jia, Youji
   Liu, Shufen
   Wang, Hongshen
   Chang, Junli
   Dai, Weiwei
   Lu, Sheng
   Shi, Qi
   Yang, Yanping
   Zhang, Yan
   Wang, Yongjun
TI Cyclophosphamide causes osteoporosis in C57BL/6 male mice: suppressive
   effects of cyclophosphamide on osteoblastogenesis and osteoclastogenesis
SO ONCOTARGET
LA English
DT Article
DE cyclophosphamide; chemotherapy; osteoporosis; osteoblastogenesis;
   osteoclastogenesis
ID INDUCED BONE LOSS; BREAST CANCER PATIENTS; ADJUVANT CHEMOTHERAPY;
   MESENCHYMAL PROGENITORS; MARROW ADIPOSITY; RECEPTIVE MICROENVIRONMENT;
   SIGNALING PATHWAYS; IN VIVO; DIFFERENTIATION; METHOTREXATE
AB The clinical evidence indicated that cyclophosphamide (CPD), one of the chemotherapy drugs, caused severe deteriorations in bones of cancer patients. However, the exact mechanisms by which CPD exerts effects on bone remodeling is not yet fully elucidated. Therefore, this study was performed to investigate the role and potential mechanism of CPD in osteoblastogenesis and osteoclastogenesis. Here it was found that CPD treatment (100mg/kg/day) for 7 days led to osteoporosis phenotype in male mice. CPD inhibited osteoblastogenesis as shown by decreasing the number and differentiation of bone mesenchymal stem cells (MSCs) and reducing the formation and activity of osteoblasts. Moreover, CPD suppressed the osteoclastogenesis mediated by receptor activator for nuclear factor kappa B ligand (RANKL) as shown by reducing the maturation and activity of osteoclasts. At the molecular level, CPD exerted inhibitory effect on the expression of components (Cyclin D1, beta catenin, Wnt 1, Wnt10b) of Wnt/beta catenin signaling pathway in MSCs and osteoblasts specific factors (alkaline phosphatase, Runx2, and osteocalcin). CPD also down regulated the expression of the components (tumor necrosis factor receptorassociated factor 6, nuclear factor of activated T cells cytoplasm 1, c Fos and NF kappa B) of RANKL signaling pathway and the factors (matrix metalloproteinase 9, cathepsin K, tartrate resistant acid phosphates and carbonic anhydrase II) for osteoclastic activity. Taken together, this study demonstrated that the short term treatment of CPD induced osteoporosis in mice and the underlying mechanism might be attributed to its marked suppression on osteoblastogenesis and osteoclastogenesis, especially the effect of CPD on bone formation might play a dominant role in its detrimental effects on bone remodeling.
C1 [Zhao, Dongfeng; Wang, Chenglong; Zhao, Yongjian; Shu, Bing; Jia, Youji; Liu, Shufen; Wang, Hongshen; Chang, Junli; Dai, Weiwei; Lu, Sheng; Shi, Qi; Yang, Yanping; Zhang, Yan; Wang, Yongjun] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Shanghai, Peoples R China.
   [Zhao, Dongfeng; Wang, Chenglong; Zhao, Yongjian; Shu, Bing; Jia, Youji; Liu, Shufen; Wang, Hongshen; Chang, Junli; Lu, Sheng; Shi, Qi; Yang, Yanping; Zhang, Yan; Wang, Yongjun] Shanghai Univ Tradit Chinese Med, Spine Dis Res Inst, Shanghai, Peoples R China.
   [Zhao, Dongfeng; Zhao, Yongjian; Shu, Bing; Liu, Shufen; Wang, Hongshen; Chang, Junli; Shi, Qi; Yang, Yanping; Zhang, Yan; Wang, Yongjun] Shanghai Univ Tradit Chinese Med, Key Lab Theory & Therapy Muscles & Bones, Minist Educ, Shanghai, Peoples R China.
   [Wang, Chenglong; Dai, Weiwei] Longhua Hosp, Cent Lab Res, Shanghai, Peoples R China.
   [Wang, Yongjun] Shanghai Univ Tradit Chinese Med, Sch Rehabil Sci, Shanghai, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University
   of Traditional Chinese Medicine; Shanghai University of Traditional
   Chinese Medicine; Shanghai University of Traditional Chinese Medicine
RP Yang, YP; Zhang, Y; Wang, YJ (通讯作者)，Shanghai Univ Tradit Chinese Med, Longhua Hosp, Shanghai, Peoples R China.; Yang, YP; Zhang, Y; Wang, YJ (通讯作者)，Shanghai Univ Tradit Chinese Med, Spine Dis Res Inst, Shanghai, Peoples R China.; Yang, YP; Zhang, Y; Wang, YJ (通讯作者)，Shanghai Univ Tradit Chinese Med, Key Lab Theory & Therapy Muscles & Bones, Minist Educ, Shanghai, Peoples R China.; Wang, YJ (通讯作者)，Shanghai Univ Tradit Chinese Med, Sch Rehabil Sci, Shanghai, Peoples R China.
EM yanpingyangks@163.com; medicineyan@aliyun.com; yjwang8888@126.com
RI wang, chenglong/GQQ 2852 2022; Dai, Weiwei/AAE 4581 2022; Wang,
   Lan/JGM 3426 2023
FU Shanghai Sailing Program [15YF1412200]; program for the National Natural
   Science foundation of China [81220108027, 81373667, 81202708, 81774329];
   Longhua Medical Innovation Team Program [LYCX 01]; Innovative Research
   Team of Ministry of Science and Technology of China [2015RA4002];
   Natural Science Foundation of Shanghai [17ZR1430800]
FX The authors wish to acknowledge that research reported in this
   publication was supported by grants from Shanghai Sailing Program
   (15YF1412200), the program for the National Natural Science foundation
   of China (81220108027, 81373667, 81202708, 81774329), Longhua Medical
   Innovation Team Program (LYCX 01), Innovative Research Team of Ministry
   of Science and Technology of China (2015RA4002) and Natural Science
   Foundation of Shanghai (17ZR1430800).
CR Ackland SP, 2001, J CLIN ONCOL, V19, P943, DOI 10.1200/JCO.2001.19.4.943
   Aksnes LH, 2007, ACTA ONCOL, V46, P490, DOI 10.1080/02841860701218642
   Albers J, 2013, J CELL BIOL, V200, P537, DOI 10.1083/jcb.201207142
   Arioka M, 2013, BIOCHEM BIOPH RES CO, V440, P677, DOI 10.1016/j.bbrc.2013.09.126
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brufsky AM, 2008, ONCOLOGIST, V13, P187, DOI 10.1634/theoncologist.2007 0152
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Cappellen D, 2002, J BIOL CHEM, V277, P21971, DOI 10.1074/jbc.M200434200
   Cegiela Urszula, 2003, Przegl Lek, V60, P329
   Coleman RE, 2003, CANCER AM CANCER SOC, V97, P880, DOI 10.1002/cncr.11124
   D'Oronzo S, 2015, CANCER TREAT REV, V41, P798, DOI 10.1016/j.ctrv.2015.09.003
   Darnay BG, 2007, ADV EXP MED BIOL, V597, P152
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   DeLeve LD, 1996, HEPATOLOGY, V24, P830, DOI 10.1002/hep.510240414
   Dupuis LL, 2017, SUPPORT CARE CANCER, V25, P317, DOI 10.1007/s00520 016 3330 z
   Fan CM, 2016, J BONE MINER METAB, V34, P277, DOI 10.1007/s00774 015 0679 x
   Feng X, 2005, GENE, V350, P1, DOI 10.1016/j.gene.2005.01.014
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Fogelman I, 2003, OSTEOPOROSIS INT, V14, P1001, DOI 10.1007/s00198 003 1508 y
   Gambardella A, 2011, J BONE MINER RES, V26, P811, DOI 10.1002/jbmr.266
   Georgiou KR, 2012, AM J STEM CELLS, V1, P205
   Georgiou KR, 2012, BONE, V50, P1223, DOI 10.1016/j.bone.2012.03.027
   Goss PE, 2008, CLIN BREAST CANCER, V8, P411, DOI 10.3816/CBC.2008.n.049
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Gunjal PM, 2015, J OVARIAN RES, V8, DOI 10.1186/s13048 015 0141 7
   Han DD, 2016, J ETHNOPHARMACOL, V192, P406, DOI 10.1016/j.jep.2016.09.018
   Jonat W, 2002, J CLIN ONCOL, V20, P4628, DOI 10.1200/JCO.2002.05.042
   JORDAN VC, 1987, CANCER RES, V47, P624
   Jules J, 2010, J BIOL CHEM, V285, P37427, DOI 10.1074/jbc.M110.149484
   Kailajärvi MEH, 2004, ANTICANCER RES, V24, P1271
   Kim JH, 2013, THER ADV MUSCULOSKEL, V5, P13, DOI 10.1177/1759720X12466608
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Le Pape F, 2016, J BONE ONCOL, V5, P93, DOI 10.1016/j.jbo.2016.02.008
   Lee Jae Mok, 2010, J Periodontal Implant Sci, V40, P39, DOI 10.5051/jpis.2010.40.1.39
   Li Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062363
   Liu CC, 2009, J BIOCHEM MOL TOXIC, V23, P349, DOI 10.1002/jbt.20298
   Liu JZ, 2009, J BIOL CHEM, V284, P12512, DOI 10.1074/jbc.M809789200
   Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613
   Mabilleau G, 2010, DIABETIC MED, V27, P925, DOI 10.1111/j.1464 5491.2010.03048.x
   Macsai CE, 2008, J CELL PHYSIOL, V215, P578, DOI 10.1002/jcp.21342
   Martin M, 2003, ANN ONCOL, V14, P833, DOI 10.1093/annonc/mdg260
   MATTISON DR, 1981, RES COMMUN CHEM PATH, V31, P155
   Meier W, 2009, GYNECOL ONCOL, V114, P199, DOI 10.1016/j.ygyno.2009.04.026
   Michaud LB, 2006, AM J HEALTH SYST PH, V63, P419, DOI 10.2146/ajhp050045.p1
   Motawi TMK, 2010, FOOD CHEM TOXICOL, V48, P2326, DOI 10.1016/j.fct.2010.05.067
   Mundy P, 2012, VET MICROBIOL, V159, P230, DOI 10.1016/j.vetmic.2012.03.019
   Nacamuli RP, 2003, PLAST RECONSTR SURG, V112, P1328, DOI 10.1097/01.PRS.0000079826.24086.CD
   Newton HB, 2012, HAND CLINIC, V105, P903, DOI 10.1016/B978 0 444 53502 3.00031 8
   Norton L, 1999, SEMIN ONCOL, V26, P1
   Oostra DR, 2015, MOL CELL ENDOCRINOL, V402, P51, DOI 10.1016/j.mce.2014.12.028
   Park SI, 2012, CANCER RES, V72, P2522, DOI 10.1158/0008 5472.CAN 11 2928
   PLOWCHALK DR, 1992, REPROD TOXICOL, V6, P411, DOI 10.1016/0890 6238(92)90004 D
   PLOWCHALK DR, 1991, TOXICOL APPL PHARM, V107, P472, DOI 10.1016/0041 008X(91)90310 B
   Ponnapakkam T, 2011, J ENDOCRINOL INVEST, V34, pE392, DOI 10.3275/7864
   Quach JM, 2015, J BONE MINER RES, V30, P886, DOI 10.1002/jbmr.2415
   RABELLOGAY MN, 1985, MUTAT RES, V158, P181
   Rao TP, 2010, CIRC RES, V106, P1798, DOI 10.1161/CIRCRESAHA.110.219840
   Rehman MU, 2012, MOL CELL BIOCHEM, V365, P119, DOI 10.1007/s11010 012 1250 x
   Rho J, 2002, DNA CELL BIOL, V21, P541, DOI 10.1089/104454902320308915
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P121, DOI 10.1007/s00223 013 9749 z
   Russell HV, 2011, PEDIATR BLOOD CANCER, V57, P275, DOI 10.1002/pbc.22821
   Saarto T, 1997, J CLIN ONCOL, V15, P1341, DOI 10.1200/JCO.1997.15.4.1341
   Salas Ramirez KY, 2015, BEHAV BRAIN RES, V292, P133, DOI 10.1016/j.bbr.2015.06.028
   SALLAY K, 1982, J PERIODONTAL RES, V17, P263, DOI 10.1111/j.1600 0765.1982.tb01153.x
   Schoeman MAE, 2015, J CELL BIOCHEM, V116, P2938, DOI 10.1002/jcb.25241
   Shapiro CL, 2001, J CLIN ONCOL, V19, P3306, DOI 10.1200/JCO.2001.19.14.3306
   Snoeks TJA, 2011, MOL CANCER THER, V10, P874, DOI 10.1158/1535 7163.MCT 10 0997
   Sorocéanu MA, 2004, J ENDOCRINOL, V183, P203, DOI 10.1677/joe.1.05723
   Stretz Christoph, 2016, Conn Med, V80, P163
   Sun SK, 2003, STEM CELLS, V21, P527, DOI 10.1634/stemcells.21 5 527
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   WANG TM, 1986, ACTA ANAT, V127, P93
   Wu J, 2009, NEOPLASIA, V11, P187, DOI 10.1593/neo.81352
   Xiao JH, 2017, EXP BIOL MED, V242, P214, DOI 10.1177/1535370216668051
   Yamauchi K, 2008, CANCER RES, V68, P516, DOI 10.1158/0008 5472.CAN 07 3063
   Yang YY, 2011, EXP BIOL MED, V236, P729, DOI 10.1258/ebm.2011.010369
   Zhao DF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102706
NR 80
TC 19
Z9 22
U1 1
U2 18
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 17
PY 2017
VL 8
IS 58
BP 98163
EP 98183
DI 10.18632/oncotarget.21000
PG 21
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA FR9KJ
UT WOS:000419392300038
PM 29228681
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Center, JR
   Lyles, KW
   Bliuc, D
AF Center, Jacqueline R.
   Lyles, Kenneth W.
   Bliuc, Dana
TI Bisphosphonates and lifespan
SO BONE
LA English
DT Article
DE Bisphosphonates; Mortality; Survival; Osteoporosis
ID ZOLEDRONIC ACID; MORTALITY RISK; HIP FRACTURE; BONE LOSS; OSTEOPOROTIC
   FRACTURE; MYOCARDIAL INFARCTION; REDUCED MORTALITY; MULTIPLE MYELOMA;
   CANCER; THERAPY
AB Bisphosphonates are first line agents used to treat osteoporosis and reduce fracture rate. They bind to areas of exposed calcium in the skeleton and cause osteoclast apoptosis, thereby leading to a reduction in remodelling rates. They are also used to decrease skeletal complications of some cancers including a reduction in bone metastases.
   Following the landmark randomised controlled trial of zoledronate post hip fracture (HORIZON) in which an unexpected survival benefit was found, there has been increasing interest in their potential ability to increase lifespan. This review will consider the clinical evidence for their effect on mortality in both the osteoporosis and non osteoporosis settings, the latter including studies in intensive care, cancer and cardiovascular disease. Where evidence exists, this review will briefly discuss some of the postulated mechanisms for this survival benefit.
C1 [Center, Jacqueline R.; Bliuc, Dana] Garvan Inst Med Res, Bone Biol, Sydney, NSW, Australia.
   [Center, Jacqueline R.; Bliuc, Dana] UNSW Sydney, Fac Med, Clin Sch, St Vincents Hosp, Sydney, NSW, Australia.
   [Lyles, Kenneth W.] Duke Univ, Durham, NC USA.
   VA Med Ctr, Durham, NC USA.
C3 Garvan Institute of Medical Research; University of New South Wales
   Sydney; NSW Health; St Vincents Hospital Sydney; Duke University
RP Center, JR (通讯作者)，UNSW Sydney, Fac Med, Clin Sch, St Vincents Hosp, Sydney, NSW, Australia.
EM j.center@garvan.org.au
RI Bliuc, Dana/Y 7240 2018; Center, Jacqueline/AAY 8712 2021
OI Bliuc, Dana/0000 0001 9682 2313; Center, Jacqueline/0000 0002 5278 4527;
   
FU National Health Medical Research Council Australia [1070187, 1008219,
   1073430]; Mrs. Gibson and Ernst Heine Family Foundation; Osteoporosis
   Australia Amgen; National Health and Medical Research Council of
   Australia [1070187, 1073430] Funding Source: NHMRC
FX This work was supported by the National Health Medical Research Council
   Australia Projects 1070187, 1008219, and 1073430. Other funding bodies
   were an Osteoporosis Australia Amgen grant and the Mrs. Gibson and Ernst
   Heine Family Foundation.
CR Abtahi S, 2020, J AM MED DIR ASSOC, V21, P811, DOI 10.1016/j.jamda.2019.11.003
   Alarkawi D, 2018, JBMR PLUS, V2, P187, DOI 10.1002/jbm4.10051
   Beaupre LA, 2011, OSTEOPOROSIS INT, V22, P983, DOI 10.1007/s00198 010 1411 2
   Behanova M, 2019, CALCIFIED TISSUE INT, V105, P630, DOI 10.1007/s00223 019 00611 3
   Bergman J, 2019, OSTEOPOROSIS INT, V30, P1973, DOI 10.1007/s00198 019 05097 1
   Bilezikian JP, 2016, AM J RESP CRIT CARE, V193, P706, DOI 10.1164/rccm.201511 2253ED
   Bliuc D, 2019, OSTEOPOROSIS INT, V30, P817, DOI 10.1007/s00198 018 4806 0
   Bliuc D, 2015, OSTEOPOROSIS INT, V26, P1331, DOI 10.1007/s00198 014 3014 9
   Bliuc D., 2019, OSTEOPOROSIS INT, V29, P2725
   Bliuc D, 2009, JAMA J AM MED ASSOC, V301, P513, DOI 10.1001/jama.2009.50
   Bliuc D, 2019, J BONE MINER RES, V34, P2001, DOI 10.1002/jbmr.3816
   Bolland MJ, 2010, J CLIN ENDOCR METAB, V95, P1174, DOI 10.1210/jc.2009 0852
   Bondo L, 2013, OSTEOPOROSIS INT, V24, P245, DOI 10.1007/s00198 012 2024 8
   Brozek W, 2016, OSTEOPOROSIS INT, V27, P387, DOI 10.1007/s00198 015 3415 4
   Brozek W, 2014, CALCIFIED TISSUE INT, V95, P257, DOI 10.1007/s00223 014 9889 9
   Byrne A.J., 2015, THORAX, V70
   Center JR, 2011, J CLIN ENDOCR METAB, V96, P1006, DOI 10.1210/jc.2010 2730
   Chen WW, 2018, J BONE MINER RES, V33, P795, DOI 10.1002/jbmr.3374
   Chen YC, 2016, J BONE MINER METAB, V34, P325, DOI 10.1007/s00774 015 0672 4
   Coleman R, 2015, LANCET, V386, P1353, DOI 10.1016/S0140 6736(15)60908 4
   Coleman RE, 2018, J BONE ONCOL, V13, P123, DOI 10.1016/j.jbo.2018.09.008
   Coleman R, 2014, LANCET ONCOL, V15, P997, DOI 10.1016/S1470 2045(14)70302 X
   Colón Emeric CS, 2010, J BONE MINER RES, V25, P91, DOI 10.1359/jbmr.090704
   Cree MW, 2003, OSTEOPOROSIS INT, V14, P722, DOI 10.1007/s00198 003 1430 3
   Cremers S, 2019, BRIT J CLIN PHARMACO, V85, P1052, DOI 10.1111/bcp.13867
   Cummings SR, 2019, JAMA INTERN MED, V179, P1491, DOI 10.1001/jamainternmed.2019.2779
   Curtis JR, 2011, J BONE MINER RES, V26, P683, DOI 10.1002/jbmr.274
   den Uyl D, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3224
   Green J, 2010, BMJ BRIT MED J, V341, DOI 10.1136/bmj.c4444
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hue TF, 2014, JAMA INTERN MED, V174, P1550, DOI 10.1001/jamainternmed.2014.3634
   Huntjens Kirsten M B, 2014, J Bone Joint Surg Am, V96, pe29, DOI 10.2106/JBJS.L.00223
   Kanazawa I, 2010, AM J MED SCI, V339, P519, DOI 10.1097/MAJ.0b013e3181db6dfe
   Kang J.H., 2013, OSTEOPOROS INT, V24
   Kim DH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122646
   Koshiyama H, 2000, J CLIN ENDOCR METAB, V85, P2793, DOI 10.1210/jc.85.8.2793
   Kranenburg G, 2016, ATHEROSCLEROSIS, V252, P106, DOI 10.1016/j.atherosclerosis.2016.06.039
   Kremer R, 2014, JNCI J NATL CANCER I, V106, DOI 10.1093/jnci/dju264
   Leder BZ, 2020, J BONE MINER RES, V35, P18, DOI 10.1002/jbmr.3880
   Lee P, 2016, J CLIN ENDOCR METAB, V101, P1945, DOI 10.1210/jc.2015 3467
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Melton LJ, 2013, OSTEOPOROSIS INT, V24, P1689, DOI 10.1007/s00198 012 2225 1
   Mhaskar R., 2012, COCHRANE DB SYST REV
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Newcomb PA, 2015, J CLIN ONCOL, V33, P1186, DOI 10.1200/JCO.2014.58.6842
   Nguyen ND, 2007, J BONE MINER RES, V22, P1147, DOI [10.1359/jbmr.070412, 10.1359/JBMR.070412]
   Nurmi Lüthje I, 2011, J BONE MINER RES, V26, P1845, DOI 10.1002/jbmr.375
   Parihar SP, 2019, NAT REV IMMUNOL, V19, P104, DOI 10.1038/s41577 018 0094 3
   Pazianas M, 2012, OSTEOPOROSIS INT, V23, P2693, DOI 10.1007/s00198 012 1902 4
   Raje N, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2015.96
   Raje N, 2018, LANCET ONCOL, V19, P370, DOI 10.1016/S1470 2045(18)30072 X
   Reid IR, 2020, J BONE MINER RES, V35, P20, DOI 10.1002/jbmr.3860
   Reid IR, 2018, NEW ENGL J MED, V379, P2407, DOI 10.1056/NEJMoa1808082
   Rennert G, 2011, J CLIN ONCOL, V29, P1146, DOI 10.1200/JCO.2010.33.7485
   Rogers MJ, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115493
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sambrook PN, 2011, OSTEOPOROSIS INT, V22, P2551, DOI 10.1007/s00198 010 1444 6
   Schulman RC, 2016, ENDOCR PRACT, V22, P799, DOI 10.4158/EP151050.OR
   Schulz E., 2004, J CLIN ENDOCRINOL ME, V89
   Sing C W, J BONE MINER RES
   Sing CW, 2018, J BONE MINER RES, V33, P1422, DOI 10.1002/jbmr.3448
   Steinbuch M, 2002, REGUL TOXICOL PHARM, V35, P320, DOI 10.1006/rtph.2002.1550
   Tran T, 2017, J BONE MINER RES, V32, P1802, DOI 10.1002/jbmr.3118
   Tran T, 2018, J CLIN ENDOCR METAB, V103, P3205, DOI 10.1210/jc.2017 02656
   Van Acker HH, 2016, PHARMACOL THERAPEUT, V158, P24, DOI 10.1016/j.pharmthera.2015.11.008
   van Geel TACM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198006
   Varela I, 2008, NAT MED, V14, P767, DOI 10.1038/nm1786
   Vestergaard P, 2012, CALCIFIED TISSUE INT, V90, P22, DOI 10.1007/s00223 011 9549 2
   Wolfe F, 2013, J BONE MINER RES, V28, P984, DOI 10.1002/jbmr.1792
   Yu SF, 2019, BMC GERIATR, V19, DOI 10.1186/s12877 019 1278 9
NR 71
TC 37
Z9 40
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD DEC
PY 2020
VL 141
AR 115566
DI 10.1016/j.bone.2020.115566
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA PK3CN
UT WOS:000602327700011
PM 32745686
DA 2025 08 17
ER

PT J
AU Wu, YK
   Liu, M
   Li, JW
   Gao, RR
   Hu, QY
   Xie, YF
   Zhou, HL
   Li, HJ
   He, X
   Li, L
AF Wu, Yeke
   Liu, Min
   Li, Jiawei
   Gao, Ranran
   Hu, Qiongying
   Xie, Yunfei
   Zhou, Hongling
   Li, Huijing
   He, Xiang
   Li, Li
TI Kouqiangjie formula alleviates diabetic periodontitis by regulating
   alveolar bone homeostasis via miR 29a 3p mediated Dkk 1/Wnt/(3 catenin
   signaling pathway
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Kouqiangjie formula; Diabetic periodontitis; Dkk 1/wnt/(3 catenin
   signaling pathway; miR 29a 3p; Bone homeostasis
ID OSTEOGENIC DIFFERENTIATION; CATENIN
AB Ethnopharmacological relevance: Diabetic periodontitis (DP) is a commonly co occurring complication in diabetes patients characterized by advanced gum disease and bone resorption. Conventional treatment modalities often fail to adequately address the underlying biological disruptions caused by diabetes. The use of traditional medicinal formulas Kouqiangjie Formula (KQJF) potentially offers novel therapeutic approaches for DP, but its detailed regulatory mechanisms remain unclear. Aim of the study: This study aims to investigate the impacts of KQJF on osteoblastic activity and inflammatory responses in a rat model and in vitro pre osteoblast cultures under conditions mimicking DP, focusing on the involvement of the miR 29a 3p Dkk 1/Wnt/(3 catenin signaling pathway. Materials and methods: Using network pharmacological analysis, micro CT, histological staining, and an array of molecular biology methodologies including Western blotting, RT qPCR, and immunofluorescence, we investigated the systemic and cellular responses to KQJF treatment. Both in vivo (rat model) and in vitro (MC3T3 E1 preosteoblasts) models subjected to high glucose and lipopolysaccharide (HG + LPS) stress were used to simulate DP conditions. Results: Network pharmacological analyses, incorporating protein protein interactions and pathway enrichment, disclosed that KQJF interacts with pathways crucial for inflammation and bone metabolism. Experimentally, KQJF significantly preserved alveolar bone architecture, reduced osteoclast activity, and dampened inflammatory cytokine production in DP rats. In pre osteoblasts, KQJF enhanced cell viability, promoted cell cycle progression, and decreased apoptosis. At the molecular level, KQJF treatment upregulated miR 29a 3p and downregulated Dkk 1, thereby activating the Wnt/(3 catenin pathway. The interventional studies with miR 29a3p antagonists and Dkk 1 knockdown further confirmed the regulatory role of the miR 29a 3p/Dkk 1 axis in mediating the effects of KQJF. Conclusion: KQJF mitigates the deleterious effects of DP by enhancing osteoblastic activity and reducing inflammatory responses, predominantly through the modulation of the miR 29a 3p Dkk 1/Wnt/(3 catenin signaling pathway. These discoveries underscore the therapeutic promise of KQJF in managing bone and inflammatory complications of DP, offering insights into its mechanism, and supporting its use in clinical settings.
C1 [Wu, Yeke] Hosp Chengdu Univ Tradit Chinese Med, Dept Stomatol, Chengdu 610072, Peoples R China.
   [Liu, Min] Hosp Chengdu Univ Tradit Chinese Med, Dept Gynaecol, Chengdu 610072, Peoples R China.
   [Li, Jiawei] Chengdu Univ Tradit Chinese Med, Sch Basic Med Sci, Chengdu 610072, Peoples R China.
   [Gao, Ranran] Henan Prov Peoples Hosp, Dept Gynaecol, Zhengzhou 450000, Peoples R China.
   [Hu, Qiongying] Hosp Chengdu Univ Tradit Chinese Med, Dept Lab Med, Chengdu 610072, Peoples R China.
   [Xie, Yunfei] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Dept Nucl Med, Chengdu 610072, Peoples R China.
   [Zhou, Hongling] Sichuan Univ, Ctr Stomatol, West China Xiamen Hosp, Xiamen 361021, Peoples R China.
   [Li, Huijing; He, Xiang] Chengdu Univ Tradit Chinese Med, Coll Clin Med, Chengdu 610072, Peoples R China.
   [Li, Li] Hosp Chengdu Univ Tradit Chinese Med, Dept Radiol, 39 Shierqiao Rd, Chengdu 610072, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Chengdu University
   of Traditional Chinese Medicine; Chengdu University of Traditional
   Chinese Medicine; Zhengzhou University; Chengdu University of
   Traditional Chinese Medicine; Sichuan Provincial People's Hospital;
   University of Electronic Science & Technology of China; Sichuan
   University; Chengdu University of Traditional Chinese Medicine; Chengdu
   University of Traditional Chinese Medicine
RP Li, L (通讯作者)，Hosp Chengdu Univ Tradit Chinese Med, Dept Radiol, 39 Shierqiao Rd, Chengdu 610072, Peoples R China.
EM wuyeke@cdutcm.edu.cn; 739879384@qq.com; 974225085@qq.com;
   377435416@qq.com; qiongyinghu@163.com; xyfsub@126.com;
   2907571940@qq.com; 2272051760@qq.com; 1151045092@qq.com;
   cddrlili@hotmail.com
RI Zhou, hongling/HCG 9805 2022
FU National Natural Science Foundation of China [82074303, 81973684];
   Natural Science Foundation of Sichuan Province [2023NSFSC1760]
FX This research received financial support from several sources, including
   the National Natural Science Foundation of China (82074303, 81973684) ,
   the Natural Science Foundation of Sichuan Province (2023NSFSC1760) .
CR Abdolahinia ED, 2023, ORAL DIS, V29, P2468, DOI 10.1111/odi.14276
   Cheng CH, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031376
   Dong L, 2021, J TRADIT CHIN MED, V41, P608, DOI [10.19852/j.cnki.jtcm.2021.03.013, 10.19852/j.cnki.jtcm.2021.04.010]
   Elashiry M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126459
   Feng GJ, 2016, IN VITRO CELL DEV AN, V52, P1001, DOI 10.1007/s11626 016 0070 9
   Fernández Rojas B, 2018, LIFE SCI, V209, P435, DOI 10.1016/j.lfs.2018.08.029
   Graves DT, 2020, PERIODONTOL 2000, V82, P214, DOI 10.1111/prd.12318
   Grover Harpreet Singh, 2013, J Indian Soc Periodontol, V17, P292, DOI 10.4103/0972 124X.115642
   Guo AJY, 2011, J BIOL CHEM, V286, P27882, DOI 10.1074/jbc.M111.236281
   [何翔 He Xiang], 2023, [中药新药与临床药理, Traditional Chinese Drug Research and Clinical Plarmacology], V34, P691
   Horita M, 2021, J CELL BIOCHEM, V122, P696, DOI 10.1002/jcb.29896
   Hrdlicka HC, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115779
   Hsu YC, 2016, SCI REP UK, V6, DOI 10.1038/srep30575
   Hu XP, 2021, STEM CELLS DEV, V30, P641, DOI 10.1089/scd.2020.0193
   Jiang H, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241411294
   Kapinas K, 2009, J CELL BIOCHEM, V108, P216, DOI 10.1002/jcb.22243
   Karadeniz F, 2020, PHYTOMEDICINE, V71, DOI 10.1016/j.phymed.2020.153225
   Kitaura H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145169
   Lan Q, 2023, FRONT CELL DEV BIOL, V11, DOI 10.3389/fcell.2023.1225449
   Li Y, 2023, NUTRIENTS, V15, DOI 10.3390/nu15092115
   Lima SMF, 2013, INT ENDOD J, V46, P700, DOI 10.1111/iej.12072
   Liu F, 2018, CELL BIOSCI, V8, DOI 10.1186/s13578 018 0254 y
   Liu JQ, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 021 00762 6
   Loh HY, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24076423
   Ma RCW, 2018, DIABETOLOGIA, V61, P1249, DOI 10.1007/s00125 018 4557 7
   Marini F, 2023, OSTEOPOROSIS INT, V34, P213, DOI 10.1007/s00198 022 06523 7
   Miranda TS, 2018, J CLIN PERIODONTOL, V45, P293, DOI 10.1111/jcpe.12854
   Ni LJ, 2016, J ETHNOPHARMACOL, V179, P420, DOI 10.1016/j.jep.2015.12.052
   Qin J, 2024, ARAB J CHEM, V17, DOI 10.1016/j.arabjc.2023.105504
   Qin MZ, 2021, MOL THER NUCL ACIDS, V25, P37, DOI 10.1016/j.omtn.2021.04.016
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P121, DOI 10.1007/s00223 013 9749 z
   Sang CL, 2016, BONE, V84, P78, DOI 10.1016/j.bone.2015.12.012
   Santonocito S, 2022, MEDIAT INFLAMM, V2022, DOI 10.1155/2022/4955277
   Steinhart Z, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.146589
   Thouvenot K, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12030378
   Tian S, 2023, J ETHNOPHARMACOL, V312, DOI 10.1016/j.jep.2023.116433
   Wu YK, 2024, AUTOIMMUNITY, V57, DOI 10.1080/08916934.2024.2312927
   Wu YK, 2024, J ETHNOPHARMACOL, V323, DOI 10.1016/j.jep.2024.117738
   Wu YK, 2023, MOL CELL BIOCHEM, V478, P2191, DOI 10.1007/s11010 022 04645 4
   Xiang GL, 2024, HELIYON, V10, DOI 10.1016/j.heliyon.2024.e30983
   Xing N, 2023, J ETHNOPHARMACOL, V314, DOI 10.1016/j.jep.2023.116572
   Xu D, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.1066089
   Yuan SY, 2023, CELLS BASEL, V12, DOI 10.3390/cells12232695
   Zhang FW, 2019, ADV CLIN EXP MED, V28, P1293, DOI 10.17219/acem/104533
   Zhang LN, 2019, MOL MED REP, V19, P5440, DOI 10.3892/mmr.2019.10193
   Zhao BH, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.583561
   Zhao L, 2023, J ETHNOPHARMACOL, V309, DOI 10.1016/j.jep.2023.116306
   Zhao XD, 2022, BIOMATERIALS, V282, DOI 10.1016/j.biomaterials.2022.121387
NR 48
TC 1
Z9 1
U1 5
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JAN 31
PY 2025
VL 340
AR 119270
DI 10.1016/j.jep.2024.119270
EA DEC 2024
PG 17
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA R7K3D
UT WOS:001393187700001
PM 39706357
DA 2025 08 17
ER

PT J
AU Li, FB
   Sun, XL
   Ma, JX
   Ma, XL
   Zhao, B
   Zhang, Y
   Tian, P
   Li, YJ
   Han, Z
AF Li, Fengbo
   Sun, Xiaolei
   Ma, Jianxiong
   Ma, Xinlong
   Zhao, Bin
   Zhang, Yang
   Tian, Peng
   Li, Yanjun
   Han, Zhe
TI Naringin prevents ovariectomy induced osteoporosis and promotes
   osteoclasts apoptosis through the mitochondria mediated apoptosis
   pathway
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Naringin; Osteoporosis; Apoptosis; Osteoclast
ID DISUSE OSTEOPOROSIS; BONE; RATS; DIFFERENTIATION
AB Naringin, the primary active compound of the traditional Chinese medicine Rhizoma drynariae, possesses many pharmacological activities. The present study is an effort to explore the anti osteoporosis potential of naringin in vivo and in vitro. In vivo, we used ovariectomized rats to clarify the mechanisms by which naringin anti osteoporosis. In vitro, we used osteoclasts to investigate naringin promotes osteoclasts apoptosis. Naringin was effective at enhancing BMD, trabecular thickness, bone mineralization, and mechanical strength in a dose dependent manner. The result of RT PCR analysis revealed that naringin down regulated the mRNA expression levels of BCL 2 and up regulated BAX, caspase 3 and cytochrome C. In addition, naringin significantly reduced the bone resorption area in vitro. These findings suggest that naringin promotes the apoptosis of osteoclasts by regulating the activity of the mitochondrial apoptosis pathway and prevents OVX induced osteoporosis in rats. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Li, Fengbo; Sun, Xiaolei; Ma, Jianxiong; Ma, Xinlong; Zhao, Bin; Zhang, Yang; Tian, Peng; Han, Zhe] Tianjin Inst Orthoped Tradit Chinese & Western Me, Tianjin Tj 300050, Peoples R China.
   [Li, Fengbo; Li, Yanjun] Tianjin Med Univ, Grad Sch, Tianjin 300070, Peoples R China.
C3 Tianjin Medical University
RP Ma, XL (通讯作者)，Tianjin Hosp, Tianjin Inst Orthoped Tradit Chinese & Western Me, 155 Munan Rd, Tianjin Tj 300050, Peoples R China.
EM gengxiao502@163.com
RI Zhao, Bin/AAO 2287 2021; Li, Boshu/JPX 6598 2023
FU Public Health Bureau of Science and Technology of Tianjin, China
   [2011KZ57]; Traditional Chinese Medicine Administration of Tianjin,
   China [13123]
FX This study was funded by the Public Health Bureau of Science and
   Technology of Tianjin, China (No. 2011KZ57) and the Traditional Chinese
   Medicine Administration of Tianjin, China (No. 13123).
CR Abe K, 2012, INT J MOL MED, V29, P1007, DOI 10.3892/ijmm.2012.952
   Adams JM, 2007, CURR OPIN IMMUNOL, V19, P488, DOI 10.1016/j.coi.2007.05.004
   Akhter MP, 2011, BIOMECH MODEL MECHAN, V10, P423, DOI 10.1007/s10237 010 0244 4
   Berecki Gisolf J, 2010, OSTEOPOROSIS INT, V21, P479, DOI 10.1007/s00198 009 0987 x
   Boyd SK, 2006, BONE, V39, P854, DOI 10.1016/j.bone.2006.04.017
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brincat S D, 2014, Minerva Ginecol, V66, P391
   Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027
   Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551
   Debatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558
   Eslami B, 2011, CALCIFIED TISSUE INT, V88, P272, DOI 10.1007/s00223 011 9473 5
   Hellebrand EE, 2010, DRUG DISCOV THER, V4, P54
   Jilka RL, 2013, BONE, V54, P264, DOI 10.1016/j.bone.2012.11.038
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   Li CY, 2005, J BONE MINER RES, V20, P117, DOI 10.1359/JBMR.041010
   Li LN, 2011, PHYTOMEDICINE, V18, P985, DOI 10.1016/j.phymed.2011.03.002
   Li NH, 2013, J ORTHOP SCI, V18, P478, DOI 10.1007/s00776 013 0362 9
   Ma ZJ, 2010, BIOL TRACE ELEM RES, V134, P280, DOI 10.1007/s12011 009 8472 0
   McNamara LM, 2010, J R SOC INTERFACE, V7, P353, DOI 10.1098/rsif.2009.0282
   Miyazaki Tsuyoshi, 2013, Clin Calcium, V23, P1577, DOI CliCa131115771583
   Pang WY, 2010, BRIT J PHARMACOL, V159, P1693, DOI 10.1111/j.1476 5381.2010.00664.x
   Peng Zhang, 2009, EUR J PHARMACOL, V607, P1, DOI 10.1016/j.ejphar.2009.01.035
   Qi W, 2012, OSTEOPOROSIS INT, V23, P2347, DOI 10.1007/s00198 011 1842 4
   Quinn JMW, 2005, BIOCHEM BIOPH RES CO, V328, P739, DOI 10.1016/j.bbrc.2004.11.076
   REVELL PA, 1983, J CLIN PATHOL, V36, P1323, DOI 10.1136/jcp.36.12.1323
   Soda Tetsuji, 2013, Hinyokika Kiyo, V59, P587
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Turgeon R. D., 2012, NEW ENGL J MED, V367, P1714
   Wei M, 2007, AM J CHINESE MED, V35, P663, DOI 10.1142/S0192415X07005156
   Yin XM, 2006, GENE, V369, P7, DOI 10.1016/j.gene.2005.10.038
   Yoon KH, 2012, J KOREAN NEUROSURG S, V51, P323, DOI 10.3340/jkns.2012.51.6.323
   Zimmermann EA, 2011, P NATL ACAD SCI USA, V108, P14416, DOI 10.1073/pnas.1107966108
NR 32
TC 66
Z9 78
U1 1
U2 42
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 26
PY 2014
VL 452
IS 3
BP 629
EP 635
DI 10.1016/j.bbrc.2014.08.117
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA AQ7UE
UT WOS:000343023900052
PM 25181344
DA 2025 08 17
ER

PT J
AU Miraoui, H
   Ringe, J
   Häupl, T
   Marie, PJ
AF Miraoui, Hichem
   Ringe, Jochen
   Haeupl, Thomas
   Marie, Pierre J.
TI Increased EFG  and PDGFα receptor signaling by mutant FGF receptor 2
   contributes to osteoblast dysfunction in Apert craniosynostosis
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID GROWTH FACTOR RECEPTOR; LIGAND BINDING SPECIFICITY; PROTEIN KINASE C;
   ENRICHED CULTURES; TYROSINE KINASES; BONE DEVELOPMENT; GENE EXPRESSION;
   CBL; MUTATIONS; PATHWAY
AB Dysregulations of osteoblast function induced by gain of function genetic mutations in fibroblast growth factor receptors (FGFRs) cause premature fusion of cranial sutures in syndromic craniosynostosis. The pathogenic signaling mechanisms induced by FGFR genetic mutations in human craniosynostosis remain largely unknown. In this study, we have used microarray analysis to investigate the signaling pathways that are activated by FGFR2 mutations in Apert craniosynostosis. Transcriptomic analysis revealed that EGFR and PDGFR alpha expression is abnormally increased in human Apert calvaria osteoblasts compared with wild type cells. Quantitative RT PCR and western blot analyses in Apert osteoblasts and immunohistochemical analysis of Apert sutures confirmed the increased EGFR and PDGFR alpha expression in vitro and in vivo. We demonstrate that pharmacological inhibition of EGFR and PDGFR reduces the pathological upregulation of phenotypic osteoblast genes and in vitro matrix mineralization in Apert osteoblasts. Investigation of the underlying molecular mechanisms revealed that activated FGFR2 enhances EGFR and PDGFR alpha mRNA expression via activation of PKC alpha dependent AP 1 transcriptional activity. We also show that the increased EGFR protein expression in Apert osteoblasts results in part from a post transcriptional mechanism involving increased Sprouty2 Cbl interaction, leading to Cbl sequestration and reduced EGFR ubiquitination. These data reveal novel molecular crosstalks between activated FGFR2, EGFR and PDGFR alpha that functionally contribute to the osteoblastic dysfunction in Apert craniosynostosis, which may provide a molecular basis for novel therapeutic approaches in this severe skeletal disorder.
C1 [Marie, Pierre J.] Hop Lariboisiere, INSERM, U606, Lab Osteoblast Biol & Pathol, F 75475 Paris 10, France.
   [Ringe, Jochen; Haeupl, Thomas] Charite, Berlin, Germany.
   [Miraoui, Hichem; Marie, Pierre J.] Univ Paris Diderot, Paris, France.
C3 Universite Paris Cite; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Lariboisiere Fernand Widal   APHP; Free University of
   Berlin; Humboldt University of Berlin; Charite Universitatsmedizin
   Berlin; Universite Paris Cite
RP Marie, PJ (通讯作者)，Hop Lariboisiere, INSERM, U606, Lab Osteoblast Biol & Pathol, 2 Rue Ambroise Pare, F 75475 Paris 10, France.
EM pierre.marie@inserm.fr
FU European Commission [LSHB CT 2003 503161]; Ministere de la Recherche
   (Paris, France)
FX This work was supported in part by Inserm and the Integrated Project of
   the European Commission FP6 research funding programme (Contract
   LSHB CT 2003 503161 Genostem). H. M. is a recipient of a PhD Award from
   the Ministere de la Recherche (Paris, France).
CR Anderson J, 1998, HUM MOL GENET, V7, P1475, DOI 10.1093/hmg/7.9.1475
   ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304 419X(91)90011 9
   Baron R, 2006, CURR TOP DEV BIOL, V76, P103, DOI 10.1016/S0070 2153(06)76004 5
   Bonello MR, 2004, J BIOL CHEM, V279, P2377, DOI 10.1074/jbc.M308254200
   CENTRELLA M, 1989, ENDOCRINOLOGY, V125, P13, DOI 10.1210/endo 125 1 13
   CENTRELLA M, 1992, J CLIN INVEST, V89, P1076, DOI 10.1172/JCI115687
   Cohen MM Jr, 2005, AM J MED GENET A, V136A, P313, DOI 10.1002/ajmg.a.30757
   Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007
   Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955 0674(03)00004 8
   Edwin F, 2008, J BIOL CHEM, V283, P3181, DOI 10.1074/jbc.M706567200
   Eswarakumar VP, 2006, P NATL ACAD SCI USA, V103, P18603, DOI 10.1073/pnas.0609157103
   Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001
   Fitter S, 2008, BLOOD, V111, P2538, DOI 10.1182/blood 2007 07 104281
   Fong CW, 2003, J BIOL CHEM, V278, P33456, DOI 10.1074/jbc.M301317200
   Glass DA, 2006, CURR TOP DEV BIOL, V73, P43, DOI 10.1016/S0070 2153(05)73002 7
   Häupl T, 2007, J BIOMOL SCREEN, V12, P328, DOI 10.1177/1087057107299261
   Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867
   Ibrahimi OA, 2001, P NATL ACAD SCI USA, V98, P7182, DOI 10.1073/pnas.121183798
   Jabs EW, 1998, CLIN GENET, V53, P79
   Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309
   Johnson AC, 2000, MOL MED, V6, P17, DOI 10.1007/BF03401931
   Kaabeche K, 2004, J BIOL CHEM, V279, P36259, DOI 10.1074/jbc.M402469200
   KAWAGISHI J, 1995, GENOMICS, V30, P224, DOI 10.1006/geno.1995.9883
   Kim HJ, 2003, DEV DYNAM, V227, P335, DOI 10.1002/dvdy.10319
   Lemonnier J, 2001, J BONE MINER RES, V16, P832, DOI 10.1359/jbmr.2001.16.5.832
   Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Lomri A, 1998, J CLIN INVEST, V101, P1310
   Lomri A, 2001, J BONE MINER RES, V16, P705, DOI 10.1359/jbmr.2001.16.4.705
   Mansukhani A, 2005, J CELL BIOL, V168, P1065, DOI 10.1083/jcb.200409182
   Marie Pierre J., 2008, V12, P144, DOI 10.1159/000115036
   MARIE PJ, 1990, AM J PHYSIOL, V258, pE275, DOI 10.1152/ajpendo.1990.258.2.E275
   MARTINEAUDOIZE B, 1988, ENDOCRINOLOGY, V123, P841, DOI 10.1210/endo 123 2 841
   Mason JM, 2006, TRENDS CELL BIOL, V16, P45, DOI 10.1016/j.tcb.2005.11.004
   Miin Wong Esther Sook, 2006, V327, P61
   Miraoui H, 2009, J BIOL CHEM, V284, P4897, DOI 10.1074/jbc.M805432200
   Mitlak BH, 1996, J BONE MINER RES, V11, P238
   Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927
   Moenning A, 2009, MOL CELL BIOL, V29, P881, DOI 10.1128/MCB.00885 08
   O'Sullivan S, 2007, J BONE MINER RES, V22, P1679, DOI 10.1359/JBMR.070719
   Opperman LA, 2000, DEV DYNAM, V219, P472, DOI 10.1002/1097 0177(2000)9999:9999<::AID DVDY1073>3.0.CO;2 F
   Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702
   Perlyn CA, 2006, NEUROSURGERY, V59, P210, DOI 10.1227/01.NEU.0000224323.53866.1E
   Schlessinger J, 2004, SCIENCE, V306, P1506, DOI 10.1126/science.1105396
   Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/S0092 8674(00)00114 8
   Schneider MR, 2009, J BONE MINER RES, V24, P455, DOI [10.1359/jbmr.081202, 10.1359/JBMR.081202]
   Shukla V, 2007, NAT GENET, V39, P1145, DOI 10.1038/ng2096
   Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100
   Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781
   Wagner EF, 2002, ANN RHEUM DIS, V61, P40, DOI 10.1136/ard.61.suppl_2.ii40
   Wilkie AOM, 2007, NAT GENET, V39, P1057, DOI 10.1038/ng0907 1057
   Wilkie AOM, 2005, CYTOKINE GROWTH F R, V16, P187, DOI 10.1016/j.cytogfr.2005.03.001
   Wilkie AOM, 1997, HUM MOL GENET, V6, P1647, DOI 10.1093/hmg/6.10.1647
   Wong A, 2002, P NATL ACAD SCI USA, V99, P6684, DOI 10.1073/pnas.052138899
   Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493
   Yu K, 2001, P NATL ACAD SCI USA, V98, P3641, DOI 10.1073/pnas.081082498
   Yu K, 2000, P NATL ACAD SCI USA, V97, P14536, DOI 10.1073/pnas.97.26.14536
   Yu XH, 1997, AM J PHYSIOL CELL PH, V272, pC1709, DOI 10.1152/ajpcell.1997.272.5.C1709
NR 58
TC 32
Z9 34
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964 6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAY 1
PY 2010
VL 19
IS 9
BP 1678
EP 1689
DI 10.1093/hmg/ddq045
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 581MF
UT WOS:000276526700004
PM 20124286
OA Bronze
DA 2025 08 17
ER

PT J
AU Bataille, C
   Mauprivez, C
   Hay, E
   Baroukh, B
   Brun, A
   Chaussain, C
   Marie, PJ
   Saffar, JL
   Cherruau, M
AF Bataille, Caroline
   Mauprivez, Cedric
   Hay, Eric
   Baroukh, Brigitte
   Brun, Adrian
   Chaussain, Catherine
   Marie, Pierre J.
   Saffar, Jean Louis
   Cherruau, Marc
TI Different sympathetic pathways control the metabolism of distinct bone
   envelopes
SO BONE
LA English
DT Article
DE Catecholaminergic pathway; Cholinergic pathway; Vasoactive Intestinal
   Peptide; Periosteum; Trabecular bone; Osteoclast precursors;
   Sympathectomy
ID VASOACTIVE INTESTINAL PEPTIDE; BETA ADRENERGIC RECEPTORS;
   OSTEOBLAST LIKE CELLS; NERVOUS SYSTEM; CALVARIAL OSTEOBLASTS;
   IMMUNOREACTIVE NERVES; MAST CELLS; IN VIVO; EXPRESSION; RESORPTION
AB Bone remodeling, the mechanism that modulates bone mass adaptation, is controlled by the sympathetic nervous system through the catecholaminergic pathway. However, resorption in the mandible periosteum envelope is associated with cholinergic Vasoactive Intestinal Peptide (VIP) positive nerve fibers sensitive to sympathetic neurotoxics, suggesting that different sympathetic pathways may control distinct bone envelopes. In this study, we assessed the role of distinct sympathetic pathways on rat femur and mandible envelopes. To this goal, adult male Wistar rats were chemically sympathectomized or treated with agonists/antagonists of the catecholaminergic and cholinergic pathways; femora and mandibles were sampled. Histomorphometric analysis showed that sympathectomy decreased the number of preosteoclasts and RANKL expressing osteoblasts in mandible periosteum but had no effect on femur trabecular bone. In contrast, pharmacological stimulation or repression of the catecholaminergic cell receptors impacted the femur trabecular bone and mandible endosteal retromolar zone. VIP treatment of sympathectomized rats rescued the disturbances of the mandible periosteum and alveolar wall whereas the cholinergic pathway had no effect on the catecholaminergic dependent envelopes. We also found that VIP receptor 1 was weakly expressed in periosteal osteoblasts in the mandible and was increased by VIP treatment, whereas osteoblasts of the retromolar envelope that was innervated only by tyrosine hydroxylase immunoreactive fibers, constitutively expressed beta 2 adrenergic receptors. These data highlight the complexity of the sympathetic control of bone metabolism. Both the embryological origin of the bone (endochondral for the femur, membranous for the mandibular periosteum and the socket wall) and environmental factors specific to the innervated envelope may influence the phenotype of the sympathetic innervation. We suggest that an origin dependent imprint of bone cells through osteoblast nerve interactions determines the type of autonomous system innervating a particular bone envelope. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Bataille, Caroline; Mauprivez, Cedric; Baroukh, Brigitte; Brun, Adrian; Chaussain, Catherine; Saffar, Jean Louis; Cherruau, Marc] Univ Paris 05, Fac Chirurg Dent, Lab Pathol & Biotherapies Organe Dent, EA2496, F 92120 Montrouge, France.
   [Hay, Eric; Marie, Pierre J.] Univ Paris 05, Hop Lariboisiere, F 75475 Paris 10, France.
   [Hay, Eric; Marie, Pierre J.] INSERM, UMR606, F 75475 Paris 10, France.
   [Bataille, Caroline; Mauprivez, Cedric; Chaussain, Catherine; Saffar, Jean Louis; Cherruau, Marc] AP HP, Paris, France.
C3 Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP);
   Universite Paris Cite; Hopital Universitaire Lariboisiere Fernand Widal
     APHP; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Assistance Publique Hopitaux Paris (APHP)
RP Saffar, JL (通讯作者)，Univ Paris 05, Fac Chirurg Dent, Lab Pathol & Biotherapies Organe Dent, EA2496, 1 Rue Maurice Arnoux, F 92120 Montrouge, France.
EM caroline.bataille@parisdescartes.fr; mauprivez.cedric@free.fr;
   eric.hay@inserm.fr; maya.baroukh@parisdescartes.fr;
   adrian.brun@etu.parisdescartes.fr;
   catherine.chaussain@parisdescartes.fr; pierre.marie@inserm.fr;
   jean louis.saffar@parisdescartes.fr; marc.cherruau@parisdescartes.fr
RI ; Haÿ, Eric/HNS 9912 2023; BRUN, Adrian/B 5328 2016; Chaussain,
   Catherine/HLX 0868 2023
OI Hay, Eric/0000 0002 0131 9983; Chaussain, Catherine/0000 0002 3463 3936;
   BRUN, Adrian/0000 0002 5934 9501; Saffar, Jean Louis/0000 0001 6288 9325
FU INSERM Programme National de Recherche sur les Maladies
   Osteo Articulaires PRO A; Societe Francaise de Rhumatologie [PRO A0604,
   AO7063SP]
FX This study was supported by a Grant from INSERM Programme National de
   Recherche sur les Maladies Osteo Articulaires PRO A 2006 and the Societe
   Francaise de Rhumatologie (PRO A0604; #AO7063SP).
CR Adam C, 2000, EXP PHYSIOL, V85, P61, DOI 10.1111/j.1469 445X.2000.01930.x
   Asmus SE, 2000, J NEUROSCI, V20, P1495
   Asmus SE, 2001, DEV BIOL, V235, P1, DOI 10.1006/dbio.2001.0282
   Baroukh B, 2000, BONE, V27, P627, DOI 10.1016/S8756 3282(00)00372 0
   BERGENDORFF A, 1975, ACTA PHYSIOL SCAND, V95, P133, DOI 10.1111/j.1748 1716.1975.tb10035.x
   Biosse Duplan M, 2009, AM J PATHOL, V174, P1426, DOI 10.2353/ajpath.2009.080871
   BJURHOLM A, 1992, J BONE MINER RES, V7, P1011
   BJURHOLM A, 1988, PEPTIDES, V9, P165, DOI 10.1016/0196 9781(88)90023 X
   Bonnet N, 2008, J CELL PHYSIOL, V217, P819, DOI 10.1002/jcp.21564
   Bouxsein ML, 2009, ENDOCRINOLOGY, V150, P144, DOI 10.1210/en.2008 0843
   Cherruau M, 1999, BONE, V25, P545, DOI 10.1016/S8756 3282(99)00211 2
   Cherruau M, 2003, J CELL PHYSIOL, V194, P341, DOI 10.1002/jcp.10209
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Feuerbach D, 1997, FEBS LETT, V402, P21, DOI 10.1016/S0014 5793(96)01495 0
   Fouilloux I, 2006, BONE, V38, P59, DOI 10.1016/j.bone.2005.07.026
   Freeman JG, 2001, J NEUROIMMUNOL, V119, P231, DOI 10.1016/S0165 5728(01)00384 8
   HILL EL, 1991, NEUROSCIENCE, V44, P747, DOI 10.1016/0306 4522(91)90094 5
   HILL EL, 1991, CELL TISSUE RES, V264, P469, DOI 10.1007/BF00319037
   HOHMANN EL, 1986, SCIENCE, V232, P868, DOI 10.1126/science.3518059
   Inoue H, 2003, NEUROSCI LETT, V338, P37, DOI 10.1016/S0304 3940(02)01352 6
   JOHNSON EM, 1984, INT REV NEUROBIOL, V25, P1, DOI 10.1016/S0074 7742(08)60676 5
   Kandere Grzybowska K, 2003, BRAIN RES, V980, P213, DOI 10.1016/S0006 8993(03)02975 5
   Kingery WS, 2000, PAIN, V85, P345, DOI 10.1016/S0304 3959(99)00286 9
   Kondo H, 2005, J BIOL CHEM, V280, P30192, DOI 10.1074/jbc.M504179200
   Kulka M, 2008, IMMUNOLOGY, V123, P398, DOI 10.1111/j.1365 2567.2007.02705.x
   LANDIS SC, 1988, DEV BIOL, V126, P129, DOI 10.1016/0012 1606(88)90246 1
   Lerner UH, 2000, ENDOCRINOLOGIST, V10, P377, DOI 10.1097/00019616 200010060 00003
   Levick SP, 2010, HYPERTENSION, V55, P270, DOI 10.1161/HYPERTENSIONAHA.109.142042
   Lundberg P, 2000, BONE, V27, P803, DOI 10.1016/S8756 3282(00)00394 X
   Lundberg P, 2001, ENDOCRINOLOGY, V142, P339, DOI 10.1210/en.142.1.339
   MAKRIS GP, 1982, ARCH ORAL BIOL, V27, P965, DOI 10.1016/0003 9969(82)90104 2
   Marenzana M, 2007, BONE, V41, P206, DOI 10.1016/j.bone.2007.04.184
   Merle B, 2003, J CELL BIOCHEM, V90, P424, DOI 10.1002/jcb.10625
   MIONE MC, 1992, CELL TISSUE RES, V268, P491, DOI 10.1007/BF00319156
   Moon DE, 1999, PAIN, V80, P589, DOI 10.1016/S0304 3959(98)00252 8
   MOORE RE, 1993, BONE MINER, V23, P301, DOI 10.1016/S0169 6009(08)80105 5
   Persson E, 2005, BIOCHEM BIOPH RES CO, V335, P705, DOI 10.1016/j.bbrc.2005.07.135
   RAHMAN S, 1992, REGUL PEPTIDES, V37, P111, DOI 10.1016/0167 0115(92)90660 M
   Ransjö M, 2000, BIOCHEM BIOPH RES CO, V274, P400, DOI 10.1006/bbrc.2000.3151
   Rifas L, 2003, J CELL BIOCHEM, V89, P213, DOI 10.1002/jcb.10531
   Saffar JL, 1997, PERIODONTOL 2000, V13, P76, DOI 10.1111/j.1600 0757.1997.tb00096.x
   Sato T, 2010, J PHARMACOL EXP THER, V334, P99, DOI 10.1124/jpet.110.167643
   SCHOTZINGER RJ, 1990, NEURON, V5, P91, DOI 10.1016/0896 6273(90)90037 G
   Serre CM, 1999, BONE, V25, P623, DOI 10.1016/S8756 3282(99)00215 X
   Sherman BE, 2000, J BONE MINER RES, V15, P1354, DOI 10.1359/jbmr.2000.15.7.1354
   Siebenhaar F, 2008, J ALLERGY CLIN IMMUN, V121, P955, DOI 10.1016/j.jaci.2007.11.013
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Takeuchi T, 2001, BIOCHEM PHARMACOL, V61, P579, DOI 10.1016/S0006 2952(00)00591 8
   Tam J, 2006, MOL PHARMACOL, V70, P786, DOI 10.1124/mol.106.026435
   Togari A, 2002, MICROSC RES TECHNIQ, V58, P77, DOI 10.1002/jemt.10121
   Trebec DP, 2007, J CELL BIOCHEM, V101, P205, DOI 10.1002/jcb.21171
NR 52
TC 38
Z9 45
U1 1
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAY
PY 2012
VL 50
IS 5
BP 1162
EP 1172
DI 10.1016/j.bone.2012.01.023
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 932EY
UT WOS:000303274400020
PM 22326888
DA 2025 08 17
ER

PT J
AU Bahner, U
   Brandl, M
   Nies, C
   Schmidt Gayk, H
AF Bahner, Udo
   Brandl, Margit
   Nies, Christoph
   Schmidt Gayk, Heinrich
TI Use of cinacalcet HCl to achieve the recommended targets of bone
   metabolism in a patient with therapy resistant renal hyperparathyroidism
SO JOURNAL OF RENAL NUTRITION
LA English
DT Article
ID SECONDARY HYPERPARATHYROIDISM; PARATHYROID HORMONE; HEMODIALYSIS;
   CALCIUM; DISEASE
AB We report on a patient with end stage renal disease and severe progressive secondary hyperparathyroidism, whose condition failed to respond to conventional pharmacologic or surgical interventions. Although immunotherapy produced a partial response, it failed to decrease serum parathyroid hormone to the levels recommended by the National Kidney Foundation Kidney Disease Outcomes Quality Initiative clinical practice guidelines. Treatment with a new calcimimetic agent, cinacalcet HCI (Mimpara, Amgen, Munich, Germany), resulted in a rapid decline in elevated parathyroid hormone levels, near normalization of other laboratory markers of bone metabolism, improvement in mobility and skeletal pain caused by renal osteodystrophy, and an increase in body weight. (C) 2008 by the National Kidney Foundation, Inc. All rights reserved.
C1 [Bahner, Udo; Brandl, Margit] KFH Nierenzentrum Wuerzburg, Dialysis Unit, D 97080 Wurzburg, Germany.
   [Nies, Christoph] Marien Hosp, Osnabruck, Germany.
   [Schmidt Gayk, Heinrich] Dept Osteol, Lab Limbach, Heidelberg, Germany.
C3 St. Marien Hospital
RP Bahner, U (通讯作者)，KFH Nierenzentrum Wuerzburg, Dialysis Unit, D 97080 Wurzburg, Germany.
EM udo.bahner@kfh dialyse.de
CR Betea D, 2004, J CLIN ENDOCR METAB, V89, P3413, DOI 10.1210/jc.2003 031911
   Blacher J, 2001, HYPERTENSION, V38, P938, DOI 10.1161/hy1001.096358
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Bradwell AR, 1999, LANCET, V353, P370, DOI 10.1016/S0140 6736(98)06469 1
   Brown EM, 1997, BONE, V20, P303, DOI 10.1016/S8756 3282(97)00002 1
   Colloton M, 2005, KIDNEY INT, V67, P467, DOI 10.1111/j.1523 1755.2005.67103.x
   Cunningham J, 2005, KIDNEY INT, V68, P1793, DOI 10.1111/j.1523 1755.2005.00596.x
   Cuppari L, 2004, J AM SOC NEPHROL, V15, P2933, DOI 10.1097/01.ASN.0000141961.49723.BC
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
   HENRY JFR, 1990, WORLD J SURG, V14, P303, DOI 10.1007/BF01658510
   HOERL WH, 2004, NEPHROL DIAL TRANSPL, V19, pV2
   Lindberg JS, 2005, J AM SOC NEPHROL, V16, P800, DOI 10.1681/ASN.2004060512
   Moe SM, 2005, NEPHROL DIAL TRANSPL, V20, P2186, DOI 10.1093/ndt/gfh966
   Moe SM, 2005, KIDNEY INT, V67, P760, DOI 10.1111/j.1523 1755.2005.67139.x
   Quarles LD, 2003, J AM SOC NEPHROL, V14, P575, DOI 10.1097/01.ASN.0000050224.03126.AD
   Schlosser K, 2004, WORLD J SURG, V28, P583, DOI 10.1007/s00268 004 7321 8
   Strózecki P, 2001, RENAL FAILURE, V23, P115, DOI 10.1081/JDI 100001291
NR 18
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 1051 2276
EI 1532 8503
J9 J RENAL NUTR
JI J. Renal Nutr.
PD JUL
PY 2008
VL 18
IS 4
BP 383
EP 388
DI 10.1053/j.jrn.2008.05.001
PG 6
WC Nutrition & Dietetics; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics; Urology & Nephrology
GA 326DI
UT WOS:000257637800009
PM 18558304
DA 2025 08 17
ER

PT J
AU Park, KR
   Lee, JY
   Cho, M
   Yun, HM
AF Park, Kyung Ran
   Lee, Joon Yeop
   Cho, MyoungLae
   Yun, Hyung Mun
TI Ziyuglycoside I Upregulates RUNX2 through ERK1/2 in Promoting Osteoblast
   Differentiation and Bone Mineralization
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Sanguisorba officinalis L.; Ziyuglycoside I; Osteoblast; ERK1/2; RUNX2
ID SANGUISORBA OFFICINALIS L.; POSTMENOPAUSAL WOMEN; PARATHYROID HORMONE;
   CELLS; OSTEOPOROSIS; MECHANISMS; OSTEOSARCOMA; PATHWAYS; ACTIVATE; BMP
AB Sanguisorba officinalis L. (Rosaceae) is a perennial herbaceous plant and its roots have been used as an important traditional medicine for over 2000 years. Ziyuglycoside I (Ziyu), an active compound isolated from the roots of S. officinalis L., has shown biological effects such as anti oxidant, antiviral, and antiwrinkle activities. This study aimed to elucidate the underlying mechanisms of action of Ziyu on cytotoxicity, migration, and differentiation of pre osteoblasts. Herein, at concentrations ranging from 1 to 100 mu M, Ziyu was not cytotoxic against pre osteoblasts. Alkaline phosphatase activity assay and staining, and migration assay showed that Ziyu increased cell migration and promoted early osteoblast differentiation, followed by the enhancement of mineralized nodule formation in a dose dependent manner, as indicated by Alizarin Red S staining. In addition, Ziyu increased the protein levels of runt related transcription factor 2 (RUNX2) during osteoblast differentiation, whereas it did not affect the phosphorylation of Smad1/5/8 and GSK3b and expression of beta catenin. Ziyu also activated ERK1/2 and mitogen activated protein kinase during osteoblast differentiation, and ERK1/2 inhibitor attenuated Ziyu mediated RUNX2 expression and nuclear accumulation. Furthermore, Ziyu mediated early and late osteoblast differentiation was significantly suppressed by the inhibition of ERK1/2, which was accompanied by attenuation in the mRNA levels of osteoblast related genes including bone sialoprotein, osteopontin, and osteocalcin. Taken together, the findings of this study provide evidence that Ziyu promotes cell migration, osteoblast differentiation, and bone mineralization and suggest a potential role for Ziyu in the treatment of bone diseases.
C1 [Park, Kyung Ran; Yun, Hyung Mun] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, 1 Heogi Dong, Seoul 02453, South Korea.
   [Lee, Joon Yeop; Cho, MyoungLae] Natl Inst Korean Med Dev, Gyongsan 38540, South Korea.
C3 Kyung Hee University
RP Yun, HM (通讯作者)，Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, 1 Heogi Dong, Seoul 02453, South Korea.
EM yunhm@khu.ac.kr
FU National Research Foundation of Korea [NRF]   Korean government (MSIP)
   [NRF 2018R1D1A1B07043282]
FX We thank the Bioevaluation Center (Korea Research Institute of
   Bioscience and Biotechnology, Republic of Korea) for experimental
   assistance. This work was supported by the National Research Foundation
   of Korea [NRF] grant funded by the Korean government (MSIP)
   (NRF 2018R1D1A1B07043282).
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Artigas N, 2014, J BIOL CHEM, V289, P27105, DOI 10.1074/jbc.M114.576793
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Fakhry Maya, 2013, World J Stem Cells, V5, P136, DOI 10.4252/wjsc.v5.i4.136
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Franceschi Renny T, 2017, Curr Mol Biol Rep, V3, P122, DOI 10.1007/s40610 017 0059 5
   GRIGORIADIS AE, 1988, J CELL BIOL, V106, P2139, DOI 10.1083/jcb.106.6.2139
   Guntur AR, 2011, J ENDOCRINOL, V211, P123, DOI 10.1530/JOE 11 0175
   Histing T, 2012, J SURG RES, V175, P271, DOI 10.1016/j.jss.2011.03.052
   Iguchi M, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/3979606
   Ji H, 2018, BIOCHEM BIOPH RES CO, V504, P352, DOI 10.1016/j.bbrc.2018.08.196
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Kawai M, 2011, NAT REV DRUG DISCOV, V10, P141, DOI 10.1038/nrd3299
   Kim MB, 2014, FITOTERAPIA, V98, P59, DOI 10.1016/j.fitote.2014.07.013
   Kim YH, 2008, BIOSCI BIOTECH BIOCH, V72, P303, DOI 10.1271/bbb.70268
   Lee HS, 2011, PHYTOTHER RES, V25, P716, DOI 10.1002/ptr.3328
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Liu TM, 2013, TISSUE ENG PART B RE, V19, P254, DOI [10.1089/ten.TEB.2012.0527, 10.1089/ten.teb.2012.0527]
   Liu YX, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005467.pub2
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Marie PJ, 2015, CELL MOL LIFE SCI, V72, P1347, DOI 10.1007/s00018 014 1801 2
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Miller Paul D, 2008, Curr Osteoporos Rep, V6, P12, DOI 10.1007/s11914 008 0003 y
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Numan MS, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S88845
   Park KR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103700
   Park KR, 2020, INT J BIOL SCI, V16, P330, DOI 10.7150/ijbs.37781
   Park KR, 2019, TOXICOLOGY, V422, P95, DOI 10.1016/j.tox.2019.05.010
   Park KR, 2018, THERANOSTICS, V8, P3087, DOI 10.7150/thno.24426
   Park KR, 2017, ARCH PHARM RES, V40, P933, DOI 10.1007/s12272 017 0932 z
   Ponnapakkam T, 2014, DRUG DISCOV TODAY, V19, P204, DOI 10.1016/j.drudis.2013.07.015
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Rucci N, 2008, CLIN CASES MINER BON, V5, P49
   Russow G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010083
   Sciandra M, 2014, J BONE MINER RES, V29, P1295, DOI 10.1002/jbmr.2141
   Shin TY, 2002, IMMUNOPHARM IMMUNOT, V24, P455, DOI 10.1081/IPH 120014729
   Sun W, 2012, MOLECULES, V17, P7629, DOI 10.3390/molecules17077629
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   Yoshida H, 2019, INT J COSMETIC SCI, V41, P12, DOI 10.1111/ics.12505
   Yun HM, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.185
   Yun HM, 2015, ONCOTARGET, V6, P20875, DOI 10.18632/oncotarget.5205
   Zhao ZF, 2017, AM J CHINESE MED, V45, P199, DOI 10.1142/S0192415X17500136
   Zheng XG, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414 431X20187574, 10.1590/1414 431x20187574]
   Zhu X, 2018, J BIOCHEM MOL TOXIC, V32, DOI 10.1002/jbt.22001
   Zhu X, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111903
NR 47
TC 11
Z9 11
U1 1
U2 14
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192 415X
EI 1793 6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PY 2021
VL 49
IS 04
BP 883
EP 900
DI 10.1142/S0192415X21500427
PG 18
WC Integrative & Complementary Medicine; Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; General & Internal Medicine
GA RX8QO
UT WOS:000647483500006
PM 33829967
DA 2025 08 17
ER

PT J
AU Wu, ZX
   Li, XD
   Chen, XH
   He, XM
   Chen, Y
   Zhang, L
   Li, Z
   Yang, MY
   Yuan, GX
   Shi, BH
   Chen, N
   Li, N
   Feng, HT
   Zhou, MY
   Rui, G
   Xu, F
   Xu, R
AF Wu, Zuoxing
   Li, Xuedong
   Chen, Xiaohui
   He, Xuemei
   Chen, Yu
   Zhang, Long
   Li, Zan
   Yang, Mengyu
   Yuan, Guixin
   Shi, Baohong
   Chen, Ning
   Li, Na
   Feng, Haotian
   Zhou, Mengyu
   Rui, Gang
   Xu, Feng
   Xu, Ren
TI Phosphatidyl Inositol 3 Kinase (PI3K) Inhibitor CDZ173 protects against
   LPS induced osteolysis
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE Osteoclast; CDZ173; Osteolysis; PI3K; MAPK
ID OSTEOCLAST DIFFERENTIATION; BONE RESORPTION; ACTIVATION
AB A major complication of a joint replacement is prosthesis loosening caused by inflammatory osteolysis, leading to the revision of the operation. This is due to the abnormal activation of osteoclast differentiation and function caused by periprosthetic infection. Therefore, targeting abnormally activated osteoclasts is still effective for treating osteolytic inflammatory diseases. CDZ173 is a selective PI3K inhibitor widely used in autoimmune related diseases and inflammatory diseases and is currently under clinical development. However, the role and mechanism of CDZ173 in osteoclast related bone metabolism remain unclear. The possibility for treating aseptic prosthesis loosening brought on by inflammatory osteolysis illness can be assessed using an LPS induced mouse cranial calcium osteolysis model. In this study, we report for the first time that CDZ173 has a protective effect on LPS induced osteolysis. The data show that this protective effect is due to CDZ173 inhibiting the activation of osteoclasts in vivo. Meanwhile, our result demonstrated that CDZ173 had a significant inhibitory effect on RANKL induced osteoclasts. Furthermore, using the hydroxyapatite resorption pit assay and podosol actin belt staining, respectively, the inhibitory impact of CDZ173 on bone resorption and osteoclast fusion of pre OC was determined. In addition, staining with alkaline phosphatase (ALP) and alizarin red (AR) revealed that CDZ173 had no effect on osteoblast development in vitro. Lastly, CDZ173 inhibited the differentiation and function of osteoclasts by weakening the signal axis of PI3K AKT/MAPK NFATc1 in osteoclasts. In conclusion, our results highlight the potential pharmacological role of CDZ173 in preventing osteoclast mediated inflammatory osteolysis and its potential clinical application.
C1 [Wu, Zuoxing; Chen, Xiaohui; Li, Na; Rui, Gang; Xu, Ren] Xiamen Univ, Affiliated Hosp 1, Sch Med, Dept Orthoped Surg, Xiamen, Peoples R China.
   [Wu, Zuoxing; Chen, Xiaohui; He, Xuemei; Chen, Yu; Zhang, Long; Yang, Mengyu; Yuan, Guixin; Shi, Baohong; Li, Na; Xu, Ren] Xiamen Univ, Affiliated Hosp 1, ICMRS Collaborating Ctr Skeletal Stem Cell, Sch Med, Xiamen, Peoples R China.
   [Wu, Zuoxing; Chen, Xiaohui; Li, Na; Xu, Ren] Xiamen Univ, Sch Med, Fujian Prov Key Lab Organ & Tissue Regenerat, Xiamen, Peoples R China.
   [Li, Xuedong] Guangxi Med Univ, Affiliated Hosp 4, Dept Med Lab, Liuzhou, Peoples R China.
   [Li, Zan] Cent South Univ, Xiangya Hosp, Dept Sports Med, Changsha, Peoples R China.
   [Chen, Ning] Fudan Univ, Zhongshan Hosp Xiamen, Dept Endocrinol, Xiamen, Peoples R China.
   [Feng, Haotian] Inner Mongolia Dairy Technol Res Inst Co Ltd, Hohhot, Peoples R China.
   [Zhou, Mengyu] Guangxi Med Univ, Dept Dent, Affiliated Hosp 1, Nanning, Peoples R China.
   [Xu, Feng] Jiaotong Univ, Ninth Peoples Hosp Shanghai, Sch Med, Dept Subject Planning, Shanghai, Peoples R China.
   [Xu, Ren] Guangxi Med Univ, Res Ctr Regenerat Med, Guangxi Key Lab Regenerat Med, Nanning, Peoples R China.
C3 Xiamen University; Xiamen University; Xiamen University; Guangxi Medical
   University; Central South University; Fudan University; Guangxi Medical
   University; Shanghai Jiao Tong University; Guangxi Medical University
RP Rui, G; Xu, R (通讯作者)，Xiamen Univ, Affiliated Hosp 1, Sch Med, Dept Orthoped Surg, Xiamen, Peoples R China.; Xu, R (通讯作者)，Xiamen Univ, Affiliated Hosp 1, ICMRS Collaborating Ctr Skeletal Stem Cell, Sch Med, Xiamen, Peoples R China.; Xu, R (通讯作者)，Xiamen Univ, Sch Med, Fujian Prov Key Lab Organ & Tissue Regenerat, Xiamen, Peoples R China.; Zhou, MY (通讯作者)，Guangxi Med Univ, Dept Dent, Affiliated Hosp 1, Nanning, Peoples R China.; Xu, F (通讯作者)，Jiaotong Univ, Ninth Peoples Hosp Shanghai, Sch Med, Dept Subject Planning, Shanghai, Peoples R China.; Xu, R (通讯作者)，Guangxi Med Univ, Res Ctr Regenerat Med, Guangxi Key Lab Regenerat Med, Nanning, Peoples R China.
EM xuren526@xmu.edu.cn; xufenghhou@163.com; reigang@163.com;
   zhoumengyu@gxmu.edu.cn
RI xu, ren/G 6907 2015; li, xuedong/JYP 4367 2024; wu,
   zuoxing/JCN 5560 2023; Xu, Feng/H 4468 2011
OI xu, ren/0000 0001 6578 4553; 
FU National Key R&D Program of China [2020YFA0112900]; National Natural
   Science Foundation of China [81972034, 92068104, 82002262]; Natural
   Science Foundation of Fujian Province [2022J06003]
FX This work was supported in part by National Key R & D Program of China
   (2020YFA0112900 to RX), National Natural Science Foundation of China
   (81972034, 92068104 to RX and 82002262 to NL) and Natural Science
   Foundation of Fujian Province (2022J06003 to RX).
CR An YA, 2019, FASEB J, V33, P12515, DOI 10.1096/fj.201802805RR
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Fang CH, 2021, CELL SIGNAL, V85, DOI 10.1016/j.cellsig.2021.110060
   Fang QH, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/3830212
   Gao XR, 2022, CELL SIGNAL, V95, DOI 10.1016/j.cellsig.2022.110353
   Guo JC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 03046 z
   Han B, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/j.biopha.2020.110305
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Hoegenauer K, 2017, ACS MED CHEM LETT, V8, P975, DOI 10.1021/acsmedchemlett.7b00293
   Honma M, 2021, J BONE MINER METAB, V39, P27, DOI 10.1007/s00774 020 01157 3
   Jamee M, 2020, CLIN REV ALLERG IMMU, V59, P323, DOI 10.1007/s12016 019 08738 9
   Kandahari AM, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.14
   Kim I, 2021, BMB REP, V54, P482, DOI 10.5483/BMBRep.2021.54.9.070
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Krieger NS, 2020, JBMR PLUS, V4, DOI 10.1002/jbm4.10350
   Kuritani M, 2018, BIOL PHARM BULL, V41, P637, DOI 10.1248/bpb.b18 00026
   Li SF, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 02947 3
   Lin Yifan, 2020, Nan Fang Yi Ke Da Xue Xue Bao, V40, P1439, DOI 10.12122/j.issn.1673 4254.2020.10.09
   Liu X, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23052868
   Ma YG, 2021, SCI TOTAL ENVIRON, V750, DOI 10.1016/j.scitotenv.2020.141638
   Mbalaviele G, 2017, J CLIN INVEST, V127, P2030, DOI 10.1172/JCI93356
   Mediero A, 2013, TRENDS ENDOCRIN MET, V24, P290, DOI 10.1016/j.tem.2013.02.001
   Meng XC, 2022, J ORTHOP TRANSL, V34, P1, DOI 10.1016/j.jot.2022.04.001
   Miller Paul D, 2009, Curr Osteoporos Rep, V7, P18
   Qiu ZC, 2022, J ORTHOP TRANSL, V33, P55, DOI 10.1016/j.jot.2022.01.003
   Rao VK, 2017, BLOOD, V130, P2307, DOI 10.1182/blood 2017 08 801191
   Ren PG, 2011, CLIN ORTHOP RELAT R, V469, P113, DOI 10.1007/s11999 010 1645 5
   ROODMAN GD, 1991, CRIT REV ORAL BIOL M, V2, P389, DOI 10.1177/10454411910020030601
   Rossi F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081919
   Sadangi S, 2020, J FISH BIOL, V96, P580, DOI 10.1111/jfb.14244
   Shao SY, 2019, J CELL PHYSIOL, V234, P12701, DOI 10.1002/jcp.27887
   Takayanagi H, 2021, J BONE MINER METAB, V39, P13, DOI 10.1007/s00774 020 01191 1
   Tan Z, 2017, MOL CELL ENDOCRINOL, V439, P369, DOI 10.1016/j.mce.2016.09.026
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Wang J, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01188
   Wu ZX, 2019, J CELL PHYSIOL, V234, P17812, DOI 10.1002/jcp.28408
   Xin YJ, 2020, CALCIFIED TISSUE INT, V106, P553, DOI 10.1007/s00223 020 00666 7
   Xing Q, 2011, J DENT RES, V90, P157, DOI 10.1177/0022034510379019
   Yan Z, 2018, MOL MED, V24, DOI 10.1186/s10020 018 0013 x
   Yang YL, 2019, J BIOL CHEM, V294, P15395, DOI 10.1074/jbc.RA119.010139
   Yu W, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI140214
   Zhan YF, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01587
   Zhao HY, 2020, J CELL PHYSIOL, V235, P2997, DOI 10.1002/jcp.29205
   Zhou L, 2015, INT J MOL SCI, V16, P27087, DOI 10.3390/ijms161125998
   Zhou ZH, 2020, EXP CELL RES, V388, DOI 10.1016/j.yexcr.2020.111857
   Zhu FB, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/5707242
   Zhu X, 2016, J BONE MINER RES, V31, P560, DOI 10.1002/jbmr.2710
NR 47
TC 3
Z9 4
U1 2
U2 23
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JAN 6
PY 2023
VL 13
AR 1021714
DI 10.3389/fphar.2022.1021714
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 8F2QC
UT WOS:000919510900001
PM 36686650
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Posritong, S
   Chavez, RF
   Chu, TMG
   Bruzzaniti, A
AF Posritong, Sumana
   Chavez, Regina Flores
   Chu, Tien Min Gabriel
   Bruzzaniti, Angela
TI A Pyk2 inhibitor incorporated into a PEGDA gelatin hydrogel promotes
   osteoblast activity and mineral deposition
SO BIOMEDICAL MATERIALS
LA English
DT Article
DE osteoblast; mineralization; tyrosine kinase; alkaline phosphatase; bone
   formation; bone regeneration
ID BONE MORPHOGENETIC PROTEIN 2; CONTROLLED DRUG DELIVERY; FOCAL ADHESION
   KINASE; RELEASE; PHOSPHORYLATION; DIFFERENTIATION; DEGRADATION;
   SCAFFOLDS; INCREASES; DENSITY
AB Pyk2 is a non receptor tyrosine kinase that belongs to the family of focal adhesion kinases. Studies from our laboratory and others demonstrated that mice lacking the Pyk2 gene (Ptk2B) have high bone mass, which was due to increased osteoblast activity, as well as decreased osteoclast activity. It was previously reported that a chemical inhibitor that targets both Pyk2 and its homolog FAK, led to increased bone formation in ovariectomized rats. In the current study, we developed a hydrogel containing poly(ethylene glycol) diacrylate (PEGDA) and gelatin which was curable by visible light and was suitable for the delivery of small molecules, including a Pyk2 targeted chemical inhibitor. We characterized several critical properties of the hydrogel, including viscosity, gelation time, swelling, degradation, and drug release behavior. We found that a hydrogel composed of PEGDA1000 plus 10% gelatin (P1000:G10) exhibited Bingham fluid behavior that can resist free flowing before in situ polymerization, making it suitable for use as an injectable carrier in open wound applications. The P1000:G10 hydrogel was cytocompatible and displayed a more delayed drug release behavior than other hydrogels we tested. Importantly, the Pyk2 inhibitor hydrogel retained its inhibitory activity against the Pyk2 tyrosine kinase, and promoted osteoblast activity and mineral deposition in vitro. Overall, our findings suggest that a Pyk2 inhibitor based hydrogel may be suitable for the treatment of craniofacial and appendicular skeletal defects and targeted bone regeneration.
C1 [Posritong, Sumana; Chavez, Regina Flores; Chu, Tien Min Gabriel; Bruzzaniti, Angela] Indiana Univ, Sch Dent, Dept Biomed & Appl Sci, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Indianapolis
RP Bruzzaniti, A (通讯作者)，Indiana Univ, Sch Dent, Dept Biomed & Appl Sci, Indianapolis, IN 46202 USA.
EM abruzzan@iu.edu
RI Bruzzaniti, Angela/AAP 2225 2020; Chu, Tien Min/W 1009 2019
OI Bruzzaniti, ANGELA/0000 0003 0389 4604; Chu, Tien Min
   Gabriel/0000 0002 7190 837X
FU National Institutes of Health, NIAMS [R01 AR060332]; Indiana Clinical
   and Translational Science Institute, Collaboration in
   Biomedical/Translational Research (CBR/CTR) Pilot Program Grants
   [RR025761, TR000006]; IUPUI Office of the Vice Chancellor for Research
   (OVCR) Research Support Funds Grant (RSFG); IUPUI Biomechanics and
   Biomaterials Research Center (BBRC); Indiana University School of
   Dentistry
FX National Institutes of Health, NIAMS R01 AR060332; Indiana Clinical and
   Translational Science Institute, Collaboration in
   Biomedical/Translational Research (CBR/CTR) Pilot Program Grants,
   RR025761, TR000006; IUPUI Office of the Vice Chancellor for Research
   (OVCR) Research Support Funds Grant (RSFG); IUPUI Biomechanics and
   Biomaterials Research Center (BBRC) Grant and funds from Indiana
   University School of Dentistry. The authors would like to thank Dr Marco
   Bottino, Indiana University School of Dentistry, for helpful suggestions
   and discussions. In addition, we thank Dr Chien Chi Lin and Tanja
   Greene, IUPUI School of Engineering and Technology, for guidance and
   assistance with the rheometry experiments.
CR Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
   [Anonymous], ISO1099351993
   Asghar W, 2012, IEEE T NANOTECHNOL, V11, P546, DOI 10.1109/TNANO.2012.2183004
   Bae JW, 2015, J TISSUE ENG REGEN M, V9, P1225, DOI 10.1002/term.1917
   Boutahar N, 2004, J BIOL CHEM, V279, P30588, DOI 10.1074/jbc.M313244200
   Bruzzaniti A, 2009, MOL CELL BIOL, V29, P3644, DOI 10.1128/MCB.00851 08
   Buckbinder L, 2007, P NATL ACAD SCI USA, V104, P10619, DOI 10.1073/pnas.0701421104
   Chattopadhyay S, 2014, BIOPOLYMERS, V101, P821, DOI 10.1002/bip.22486
   Cheng YH, 2013, J BONE MINER RES, V28, P1434, DOI 10.1002/jbmr.1876
   Choi B., 2015, IN SITU GELLING POLY, P5
   Chu TMG, 2007, BIOMATERIALS, V28, P459, DOI 10.1016/j.biomaterials.2006.09.004
   Dash S, 2010, ACTA POL PHARM, V67, P217
   de Oliveira GS, 2013, AUST DENT J, V58, P326, DOI 10.1111/adj.12088
   Eley JG, 2003, J MICROENCAPSUL, V20, P653, DOI 10.1080/0265204031000150876
   Emmakah AM, 2017, BIOMED MATER, V12, DOI 10.1088/1748 605X/aa5f3e
   Freitas F, 2002, BONE, V30, P99, DOI 10.1016/S8756 3282(01)00625 1
   Fu RW, 2013, ANN INTERN MED, V158, P890, DOI 10.7326/0003 4819 158 12 201306180 00006
   Fu Y, 2012, BIOMATERIALS, V33, P48, DOI 10.1016/j.biomaterials.2011.09.031
   Fu Y, 2009, PHARM RES DORDR, V26, P2115, DOI 10.1007/s11095 009 9923 1
   Gil Henn H, 2007, J CELL BIOL, V178, P1053, DOI 10.1083/jcb.200701148
   Glowacki J, 2008, BIOPOLYMERS, V89, P338, DOI 10.1002/bip.20871
   GOLUB EE, 1992, BONE MINER, V17, P273, DOI 10.1016/0169 6009(92)90750 8
   Grassi Mario, 2005, Current Drug Delivery, V2, P97, DOI 10.2174/1567201052772906
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Guignandon A, 2006, BIOCHEM BIOPH RES CO, V343, P407, DOI 10.1016/j.bbrc.2006.02.162
   Han S, 2009, J BIOL CHEM, V284, P13193, DOI 10.1074/jbc.M809038200
   Hao YT, 2014, J BIOMED MATER RES A, V102, P3813, DOI 10.1002/jbm.a.35044
   Hudalla GA, 2008, BIOMACROMOLECULES, V9, P842, DOI 10.1021/bm701179s
   Hutson CB, 2011, TISSUE ENG PT A, V17, P1713, DOI 10.1089/ten.tea.2010.0666
   Kacena MA, 2012, J BIOL CHEM, V287, P17257, DOI 10.1074/jbc.M111.309880
   Lemon JC, 2003, J PROSTHET DENT, V90, P276, DOI 10.1016/S0022 3913(03)00366 4
   Lin CC, 2015, J APPL POLYM SCI, V132, DOI 10.1002/app.41563
   Lin CC, 2011, BIOMATERIALS, V32, P9685, DOI 10.1016/j.biomaterials.2011.08.083
   Lin CC, 2009, PHARM RES DORDR, V26, P631, DOI 10.1007/s11095 008 9801 2
   Liu B A, 2014, CURRENT STATE ART PE, V1
   Liu WC, 2017, J APPL BIOMATER FUNC, V15, pE347, DOI 10.5301/jabfm.5000374
   Mesfin A, 2013, J BONE JOINT SURG AM, V95A, P1546, DOI 10.2106/JBJS.L.01730
   Metz J, 2006, BIOMED SCI INSTRUM, V42, P389
   Meyers VE, 2004, J CELL BIOCHEM, V93, P697, DOI 10.1002/jcb.20229
   Moller P, 2009, PHILOS T R SOC A, V367, P5139, DOI 10.1098/rsta.2009.0194
   Mont MA, 2004, J BONE JOINT SURG AM, V86A, P41, DOI 10.2106/00004623 200412002 00008
   Mouriño V, 2010, J R SOC INTERFACE, V7, P209, DOI 10.1098/rsif.2009.0379
   Murata H, 2004, J ORAL REHABIL, V31, P1115, DOI 10.1111/j.1365 2842.2004.01343.x
   Oryan A, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/1749 799X 9 18
   Parlato M, 2014, MACROMOL BIOSCI, V14, P687, DOI 10.1002/mabi.201300418
   Posritong S, 2018, MOL CELL ENDOCRINOL, V474, P35, DOI 10.1016/j.mce.2018.02.005
   Ratko TA., 2010, Bone Morphogenetic Protein: The State of the Evidence of On Label and Off Label Use
   Rodgers MA, 2013, BMJ BRIT MED J, V346, DOI 10.1136/bmj.f3981
   Romagnoli C, 2013, CLIN CASES MINER BON, V10, P155, DOI 10.11138/ccmbm/2013.10.3.155
   Salasznyk RM, 2007, EXP CELL RES, V313, P22, DOI 10.1016/j.yexcr.2006.09.013
   Santoro M, 2014, J CONTROL RELEASE, V190, P210, DOI 10.1016/j.jconrel.2014.04.014
   Simmonds MC, 2013, ANN INTERN MED, V158, P877, DOI 10.7326/0003 4819 158 12 201306180 00005
NR 52
TC 13
Z9 14
U1 0
U2 40
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1748 6041
EI 1748 605X
J9 BIOMED MATER
JI Biomed. Mater.
PD MAR
PY 2019
VL 14
IS 2
AR 025015
DI 10.1088/1748 605X/aafffa
PG 16
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA HN2CG
UT WOS:000459992700001
PM 30658347
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Lamandé, SR
   Ng, ES
   Cameron, TL
   Kung, LHW
   Sampurno, L
   Rowley, L
   Lilianty, J
   Patria, YN
   Stenta, T
   Hanssen, E
   Bell, KM
   Saxena, R
   Stok, KS
   Stanley, EG
   Elefanty, AG
   Bateman, JF
AF Lamande, Shireen R.
   Ng, Elizabeth S.
   Cameron, Trevor L.
   Kung, Louise H. W.
   Sampurno, Lisa
   Rowley, Lynn
   Lilianty, Jinia
   Patria, Yudha Nur
   Stenta, Tayla
   Hanssen, Eric
   Bell, Katrina M.
   Saxena, Ritika
   Stok, Kathryn S.
   Stanley, Edouard G.
   Elefanty, Andrew G.
   Bateman, John F.
TI Modeling human skeletal development using human pluripotent stem cells
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE cartilage; bone; iPSC; genetic skeletal disorder
ID CHONDROCYTE DIFFERENTIATION; TRANSCRIPTION FACTOR; CHONDROGENIC
   DIFFERENTIATION; HYPERTROPHIC CHONDROCYTES; I PROCOLLAGEN; BONE;
   CARTILAGE; OSTEOBLASTS; EXPRESSION; MUTATIONS
AB Chondrocytes and osteoblasts differentiated from induced pluripotent stem cells (iPSCs) will provide insights into skeletal development and genetic skeletal disorders and will generate cells for regenerative medicine applications. Here, we describe a method that directs iPSC derived sclerotome to chondroprogenitors in 3D pellet culture then to articular chondrocytes or, alternatively, along the growth plate cartilage pathway to become hypertrophic chondrocytes that can transition to osteoblasts. Osteogenic organoids deposit and mineralize a collagen I extracellular matrix (ECM), mirroring in vivo endochondral bone formation. We have identified gene expression signatures at key developmental stages including chondrocyte maturation, hypertrophy, and transition to osteoblasts and show that this system can be used to model genetic cartilage and bone disorders.
C1 [Lamande, Shireen R.; Ng, Elizabeth S.; Cameron, Trevor L.; Kung, Louise H. W.; Sampurno, Lisa; Rowley, Lynn; Lilianty, Jinia; Patria, Yudha Nur; Stenta, Tayla; Bell, Katrina M.; Saxena, Ritika; Stanley, Edouard G.; Elefanty, Andrew G.; Bateman, John F.] Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia.
   [Lamande, Shireen R.; Ng, Elizabeth S.; Lilianty, Jinia; Patria, Yudha Nur; Saxena, Ritika; Stanley, Edouard G.; Elefanty, Andrew G.; Bateman, John F.] Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia.
   [Lamande, Shireen R.; Ng, Elizabeth S.; Stanley, Edouard G.; Elefanty, Andrew G.] Murdoch Childrens Res Inst, Ctr Stem Cell Med reNEW, Novo Nordisk Fdn, Parkville, Vic 3052, Australia.
   [Patria, Yudha Nur] Univ Gadjah Mada, Dept Child Hlth, Yogyakarta 55281, Indonesia.
   [Hanssen, Eric] Univ Melbourne, Bio21 Inst, Ian Holmes Imaging Ctr, Parkville, Vic 3010, Australia.
   [Hanssen, Eric] Univ Melbourne, Bio21 Inst, Dept Biochem & Pharmacol, Parkville, Vic 3010, Australia.
   [Stok, Kathryn S.] Univ Melbourne, Dept Biomed Engn, Parkville, Vic 3010, Australia.
C3 Murdoch Children's Research Institute; University of Melbourne; Murdoch
   Children's Research Institute; Gadjah Mada University; University of
   Melbourne; University of Melbourne; University of Melbourne
RP Lamandé, SR (通讯作者)，Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia.; Lamandé, SR (通讯作者)，Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia.; Lamandé, SR (通讯作者)，Murdoch Childrens Res Inst, Ctr Stem Cell Med reNEW, Novo Nordisk Fdn, Parkville, Vic 3052, Australia.
EM shireen.lamande@mcri.edu.au
RI Hanssen, Eric/A 7217 2013; Patria, Yudha Nur/N 8871 2016; Saxena,
   Ritika/JQW 3422 2023; Patria, Yudha/N 8871 2016; Elefanty,
   Andrew/A 6066 2008; Stanley, Ed/A 2985 2013; Stok, Kathryn/AAA 2667 2021
OI Hanssen, Eric/0000 0002 4064 1844; Saxena, Ritika/0000 0001 5412 2255;
   Patria, Yudha Nur/0000 0002 4802 2685; Stenta,
   Tayla/0000 0003 4794 030X; Lamande, Shireen/0000 0003 2938 2711;
   Stanley, Ed/0000 0002 6389 3665; Lilianty, Jinia/0000 0001 8333 9744
FU National Health and Medical Research Council of Australia [GNT2003393,
   GNT1144807, GNT1146952, GNT1068866, GNT1129861, GNT1164577, GNT1117596,
   GNT1079004]; Australian Research Council Special Research Initiative in
   Stem Cells (Stem Cells Australia); Stafford Fox Medical Research
   Foundation; Australian Government National Health and Medical Research
   Council Independent Research Institute Infrastructure Support Scheme;
   Victorian Government's Operational Infrastructure Support Program; Novo
   Nordisk Foundation [NNF21CC0073729]
FX We would like to thank Zlatan Trifunovic, from the Bio21 Institute Ian
   Holmes Imaging Center, for technical assistance. This work was supported
   by the National Health and Medical Research Council of Australia through
   project grants awarded to S.R.L. and J.F.B. (GNT2003393) ; S.R.L.,
   A.G.E., and J.F.B. (GNT1144807 and GNT1146952) ; E.G.S. and A.G.E.
   (GNT1068866, GNT1129861) ; S.R.L. and E.S.N. (GNT1164577) ; and research
   fellowships awarded to A.G.E. (GNT1117596) and E.G.S. (GNT1079004) and
   project grants awarded by the Australian Research Council Special
   Research Initiative in Stem Cells (Stem Cells Australia) and by the
   Stafford Fox Medical Research Foundation. Additional infrastructure
   funding to the Murdoch Children's Research Institute was provided by the
   Australian Government National Health and Medical Research Council
   Independent Research Institute Infrastructure Support Scheme and the
   Victorian Government's Operational Infrastructure Support Program. Work
   in the laboratories of E.S.N., E.G.S, and A.G.E. in the Novo Nordisk
   Foundation Center for Stem Cell Medicine is supported by Novo Nordisk
   Foundation grants (NNF21CC0073729) .
CR Adkar SS, 2019, STEM CELLS, V37, P65, DOI 10.1002/stem.2931
   Aghajanian P, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 11050 1
   Alagha MA, 2021, CARTILAGE, V13, p53S, DOI 10.1177/1947603520903425
   Ayadi A, 2001, MECH DEVELOP, V102, P205, DOI 10.1016/S0925 4773(01)00289 1
   Ayturk UM, 2020, J BONE MINER RES, V35, P1981, DOI 10.1002/jbmr.4052
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Bonnard C, 2012, NAT GENET, V44, P709, DOI 10.1038/ng.2259
   Boyanich R, 2019, J MICROSC OXFORD, V275, P159, DOI 10.1111/jmi.12824
   Cameron TL, 2015, OSTEOARTHR CARTILAGE, V23, P661, DOI 10.1016/j.joca.2015.01.001
   Chan WCW, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115445
   Cole WG, 1996, J MED GENET, V33, P965, DOI 10.1136/jmg.33.11.965
   Craft AM, 2015, NAT BIOTECHNOL, V33, P638, DOI [10.1038/nbt.3210, 10.10.38/nbt.3210]
   Craft AM, 2013, DEVELOPMENT, V140, P2597, DOI 10.1242/dev.087890
   De Kinderen P, 2022, J BONE MINER RES, V37, P397, DOI 10.1002/jbmr.4524
   Decker RS, 2014, MATRIX BIOL, V39, P5, DOI 10.1016/j.matbio.2014.08.006
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Dobreva G, 2006, CELL, V125, P971, DOI 10.1016/j.cell.2006.05.012
   Dreher SI, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00081
   Dudek M, 2016, J CLIN INVEST, V126, P365, DOI 10.1172/JCI82755
   Ecke A, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080934
   Ewels P, 2016, BIOINFORMATICS, V32, P3047, DOI 10.1093/bioinformatics/btw354
   Fell HB, 1925, J MORPHOL PHYSIOL, V40, P417, DOI 10.1002/jmor.1050400302
   FREISINGER P, 1994, J BIOL CHEM, V269, P13663
   Galeano Garces C, 2017, CARTILAGE, V8, P283, DOI 10.1177/1947603516659344
   Hall BK, 2000, BIOESSAYS, V22, P138, DOI 10.1002/(SICI)1521 1878(200002)22:2<138::AID BIES5>3.0.CO;2 4
   Hanssen E, 2013, CELL MICROBIOL, V15, P1457, DOI 10.1111/cmi.12132
   Haseeb A, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2019152118
   Hirao M, 2006, J BIOL CHEM, V281, P31079, DOI 10.1074/jbc.M602296200
   Howden S, 2019, STEM CELL RES, V38, DOI 10.1016/j.scr.2019.101453
   Iwamoto M, 2007, DEV BIOL, V305, P40, DOI 10.1016/j.ydbio.2007.01.037
   Kao T, 2016, STEM CELL REP, V7, P518, DOI 10.1016/j.stemcr.2016.07.015
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Kawata M, 2019, STEM CELL REP, V13, P530, DOI 10.1016/j.stemcr.2019.07.012
   Kim J, 2010, PHYSIOL GENOMICS, V40, P100, DOI 10.1152/physiolgenomics.00105.2009
   Kimura M, 2015, BIOCHEM BIOPH RES CO, V468, P86, DOI 10.1016/j.bbrc.2015.10.160
   Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657
   Kung LHW, 2020, STEM CELL RES, V48, DOI 10.1016/j.scr.2020.101962
   Lamande S. R., HUMAN IPSC CAN BE DI
   LAMANDE SR, 1995, J BIOL CHEM, V270, P8642, DOI 10.1074/jbc.270.15.8642
   Lambert SA, 2018, CELL, V172, P650, DOI 10.1016/j.cell.2018.01.029
   Langenbach F, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt328
   Law Charity W, 2016, F1000Res, V5, DOI 10.12688/f1000research.9005.3
   Lee HH, 2013, SCI REP UK, V3, DOI 10.1038/srep02683
   Leupin O, 2007, J BONE MINER RES, V22, P1957, DOI 10.1359/JBMR.070804
   Li XH, 2021, CURR OSTEOPOROS REP, V19, P101, DOI 10.1007/s11914 020 00650 y
   Liang GY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086894
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Lilianty J, 2021, STEM CELL RES, V56, DOI 10.1016/j.scr.2021.102515
   Limraksasin P, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 72038 y
   Lin X, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00757
   Liu N, 2018, HUM MOL GENET, V27, P2454, DOI 10.1093/hmg/ddy146
   Loh KM, 2016, CELL, V166, P451, DOI 10.1016/j.cell.2016.06.011
   Long FX, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008334
   Long JT, 2022, ELIFE, V11, DOI 10.7554/eLife.76932
   Ma ZM, 2019, CELL CYCLE, V18, P1473, DOI 10.1080/15384101.2019.1620572
   McIntosh BE, 2015, STEM CELL REP, V4, P171, DOI 10.1016/j.stemcr.2014.12.005
   Naba A, 2016, MATRIX BIOL, V49, P10, DOI 10.1016/j.matbio.2015.06.003
   Nakajima T, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.165431
   Napierala D, 2008, HUM MOL GENET, V17, P2244, DOI 10.1093/hmg/ddn125
   Ohta Y, 2015, ARTHRITIS RHEUMATOL, V67, P2679, DOI 10.1002/art.39243
   Okuma T, 2015, BIOMED RES TOKYO, V36, P21, DOI 10.2220/biomedres.36.21
   Oldershaw RA, 2010, NAT BIOTECHNOL, V28, P1221, DOI 10.1038/nbt.1683
   Pang LP, 2020, PEERJ, V8, DOI 10.7717/peerj.8515
   Park J, 2015, BIOL OPEN, V4, P608, DOI 10.1242/bio.201411031
   Patria YN, 2020, STEM CELL RES, V42, DOI 10.1016/j.scr.2019.101689
   Pretemer Y, 2021, STEM CELL REP, V16, P610, DOI 10.1016/j.stemcr.2021.01.014
   Price JA, 1998, HUM MOL GENET, V7, P563, DOI 10.1093/hmg/7.3.563
   Raouf A, 2000, ONCOGENE, V19, P6455, DOI 10.1038/sj.onc.1204037
   Reijntjes S, 2007, INT J DEV BIOL, V51, P753, DOI 10.1387/ijdb.072332sr
   Robins JC, 2005, BONE, V37, P313, DOI 10.1016/j.bone.2005.04.040
   Sadedin SP, 2012, BIOINFORMATICS, V28, P1525, DOI 10.1093/bioinformatics/bts167
   Salinas EY, 2020, BIOFABRICATION, V12, DOI 10.1088/1758 5090/aba412
   Shang J, 2014, CURR STEM CELL RES T, V9, P141, DOI 10.2174/1574888X09666131230142459
   Shimo T, 2019, IN VIVO, V33, P85, DOI 10.21873/invivo.11443
   Snelling SJB, 2016, CHRONOBIOL INT, V33, P574, DOI 10.3109/07420528.2016.1158183
   Soeda T, 2010, GENESIS, V48, P635, DOI 10.1002/dvg.20667
   Suehiro F, 2011, STEM CELLS DEV, V20, P1540, DOI 10.1089/scd.2010.0279
   Symoens Sofie, 2013, Orphanet J Rare Dis, V8, P154, DOI 10.1186/1750 1172 8 154
   Tan ZJ, 2020, J BONE MINER RES, V35, P2444, DOI 10.1002/jbmr.4132
   Tan ZJ, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007346
   Tani S, 2020, EXP MOL MED, V52, P1166, DOI 10.1038/s12276 020 0482 1
   ten Berge D, 1998, DEVELOPMENT, V125, P3831
   Tohmonda T, 2011, EMBO REP, V12, P451, DOI 10.1038/embor.2011.34
   Tsang KY, 2014, BIRTH DEFECTS RES C, V102, P52, DOI 10.1002/bdrc.21060
   Tsuda T, 2004, DEV DYNAM, V229, P340, DOI 10.1002/dvdy.10439
   Umeda K, 2012, SCI REP UK, V2, DOI 10.1038/srep00455
   Vágó J, 2022, J PINEAL RES, V73, DOI 10.1111/jpi.12827
   Varrault A, 2006, DEV CELL, V11, P711, DOI 10.1016/j.devcel.2006.09.003
   Vlahos K, 2019, STEM CELL RES, V34, DOI 10.1016/j.scr.2018.101380
   Wagner EF, 2002, ANN RHEUM DIS, V61, P40, DOI 10.1136/ard.61.suppl_2.ii40
   Wu CL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 020 20598 y
   Xi HB, 2017, CELL REP, V18, P1573, DOI 10.1016/j.celrep.2017.01.040
   Yang L, 2014, P NATL ACAD SCI USA, V111, P12097, DOI 10.1073/pnas.1302703111
   Youlten SE, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22517 1
   Zankl A, 2012, AM J HUM GENET, V90, P494, DOI 10.1016/j.ajhg.2012.01.003
   Zhang Q, 2020, J CELL PHYSIOL, V235, P8601, DOI 10.1002/jcp.29704
   Zhang QY, 2011, GENESIS, V49, P75, DOI 10.1002/dvg.20702
   Zhou X, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004820
NR 98
TC 31
Z9 31
U1 6
U2 29
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
EI 1091 6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 1
PY 2023
VL 120
IS 19
AR e2211510120
DI 10.1073/pnas.2211510120
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA N6JY6
UT WOS:001038063500001
PM 37126720
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Wei, X
   Qi, BY
   Ma, RY
   Zhang, YL
   Liu, N
   Fang, SJ
   Zhu, YN
   Xie, YM
   Dai, JY
   Zhu, LG
AF Wei, Xu
   Qi, Baoyu
   Ma, Ruyun
   Zhang, Yili
   Liu, Ning
   Fang, Shengjie
   Zhu, Yanning
   Xie, Yanming
   Dai, Jianye
   Zhu, Liguo
TI Quantitative Proteomics Revealed the Pharmacodynamic Network of Bugu
   Shengsui Decoction Promoting Osteoblast Proliferation
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE Bugu Shengsui Decoction; PI3K AKT pathway; osteoporosis; stable isotope
   dimethyl labeled proteomics; bone formation
ID RHIZOMA DRYNARIAE; OSTEOPOROSIS; PREVENTION; THERAPIES
AB Background and ObjectiveWith high morbidity and disability, osteoporosis is a worldwide bone metabolism disease, regulated by complex pathological processes. Insufficient osteogenesis is greatly essential to osteoporosis. Traditional Chinese Medicine, a complex natural herbal medicine system, has increasingly attracted attention all over the world. Bugu Shengsui Decoction, a compound formula for osteoporosis, has significant clinical effects in the treatment of osteoporosis. Yet the detailed mechanisms are unclear. Thus, we investigated the effects and mechanism of Bugu Shengsui Decoction on osteoporotic rats and osteoblasts in vitro. MethodsIn this study, we evaluated the effect of Bugu Shengsui Decoction in an animal model of orchiectomy. Multi pharmacology indexes revealed that Bugu Shengsui Decoction obviously improved bone metabolism, bone mineral density, bone morphology, and biomechanics in the castrated rats. Then, serum pharmacology was employed to unveil that Bugu Shengsui Decoction promoted the proliferation and differentiation of osteoblasts. Moreover, quantitative proteomics combined with RNA interference assay was used to analyze and verify the pathway and key targets in pro proliferation of MC3T3 E1 cells. ResultsBugu Shengsui Decoction obviously improved the worse parameters of bone metabolism, bone mineral density, bone morphology, and biomechanics in a castrated rat model. In vitro, Bugu Shengsui Decoction exerted proliferation  and differentiation promoting effects of osteoblasts induced by serum starvation. Moreover, quantitative proteomics analysis combined with RNA interfere assay illustrated that Bugu Shengsui Decoction promoted osteogenesis via the PI3K AKT pathway. ConclusionSummarily, our discoveries certify that Bugu Shengsui Decoction is an effective treatment for osteoporosis via PI3K AKT. This study is not only a beneficial attempt to explore the detailed mechanism of Traditional Chinese formula but also will provide inspiration for the treatment strategy of osteoporosis.
C1 [Wei, Xu; Qi, Baoyu; Liu, Ning; Fang, Shengjie; Zhu, Liguo] China Acad Chinese Med Sci, Wangjing Hosp, Beijing, Peoples R China.
   [Ma, Ruyun; Zhu, Yanning; Dai, Jianye] Lanzhou Univ, Sch Pharm, Lanzhou, Peoples R China.
   [Zhang, Yili] Nanjing Univ Chinese Med, Sch Tradit Chinese Med, Nanjing, Peoples R China.
   [Zhang, Yili] Nanjing Univ Chinese Med, Sch Integrated Chinese & Western Med, Nanjing, Peoples R China.
   [Xie, Yanming] China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing, Peoples R China.
   [Dai, Jianye] Lanzhou Univ, Collaborat Innovat Ctr Northwestern Chinese Med, Lanzhou, Peoples R China.
C3 China Academy of Chinese Medical Sciences; Wang Jing Hospital, CACMS;
   Lanzhou University; Nanjing University of Chinese Medicine; Nanjing
   University of Chinese Medicine; Institute of Basic Research In Clinical
   Medicine, CACMS; China Academy of Chinese Medical Sciences; Lanzhou
   University
RP Zhu, LG (通讯作者)，China Acad Chinese Med Sci, Wangjing Hosp, Beijing, Peoples R China.; Dai, JY (通讯作者)，Lanzhou Univ, Sch Pharm, Lanzhou, Peoples R China.; Xie, YM (通讯作者)，China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing, Peoples R China.; Dai, JY (通讯作者)，Lanzhou Univ, Collaborat Innovat Ctr Northwestern Chinese Med, Lanzhou, Peoples R China.
EM ktzu2018@163.com; daijy@lzu.edu.cn; tcmspine@163.com
RI Li, Ying/U 4004 2017; liu, yang/HHZ 8976 2022
FU National Natural Science Foundation of China (NSFC) Youth Program
   [81704102]; Fundamental Research Funds for the Central Public Welfare
   Research Institutes [ZZ15 XY CT 06, ZZ13 YQ 039]; Inheritance and
   Innovation Team Project of National Traditional Chinese Medicine
   [ZYYCXTD C 202003]; National Key Research and Development Program of
   China [2018YFC17063005]; Science and Technology Planning Project of
   Gansu Province [20JR10RA586]; Fundamental Research Funds for the Central
   Universities [lzujbky 2021 kb40]; Project for Longyuan Youth Innovation
   and Entrepreneurship Talent
FX This work was supported by the National Natural Science Foundation of
   China (NSFC) Youth Program (81704102), the Fundamental Research Funds
   for the Central Public Welfare Research Institutes (ZZ15 XY CT 06,
   ZZ13 YQ 039), the Inheritance and Innovation Team Project of National
   Traditional Chinese Medicine (ZYYCXTD C 202003), National Key Research
   and Development Program of China (2018YFC17063005), the Science and
   Technology Planning Project of Gansu Province (20JR10RA586), the
   Fundamental Research Funds for the Central Universities
   (lzujbky 2021 kb40), and the Project for Longyuan Youth Innovation and
   Entrepreneurship Talent.
CR Banu J, 2012, NUTR REV, V70, P22, DOI 10.1111/j.1753 4887.2011.00451.x
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Boersema PJ, 2009, NAT PROTOC, V4, P484, DOI 10.1038/nprot.2009.21
   Canalis E, 2005, J Endocrinol Invest, V28, P3
   Chen Y, 2021, LIFE SCI, V269, DOI 10.1016/j.lfs.2021.119041
   Cheng YH, 2019, WORLD J STEM CELLS, V11, P1084, DOI 10.4252/wjsc.v11.i12.1084
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Guo DY, 2011, J ETHNOPHARMACOL, V138, P451, DOI 10.1016/j.jep.2011.09.034
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   IWAMA H, 1987, J ETHNOPHARMACOL, V21, P45
   Iyer S, 2013, ANN NY ACAD SCI, V1280, P11, DOI 10.1111/nyas.12091
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Komm BS, 2015, EXPERT REV CLIN PHAR, V8, P769, DOI 10.1586/17512433.2015.1099432
   Lane JM, 2000, CLIN ORTHOP RELAT R, P139
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Langdahl B, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115516
   Lau HT, 2014, J PROTEOME RES, V13, P4164, DOI 10.1021/pr500630a
   Li CR, 2014, AM J CHINESE MED, V42, P1, DOI 10.1142/S0192415X14500013
   Li JY, 2021, PHYTOTHER RES, V35, P1754, DOI 10.1002/ptr.6908
   Li T, 2019, J PINEAL RES, V66, DOI 10.1111/jpi.12548
   Liao HH, 2015, J ETHNOPHARMACOL, V173, P11, DOI 10.1016/j.jep.2015.07.014
   Liu J., 2004, CHIN J EXP TRADITION, V4, P31, DOI [10.13422/j.cnki.syfjx.2004.05.014, DOI 10.13422/J.CNKI.SYFJX.2004.05.014]
   Liu J., 1997, J INTEGR TRADITIONAL, V4, P255
   Liu J., 2006, CHIN J OSTEOPOROSIS, V4, P46
   Liu XY, 2012, J ETHNOPHARMACOL, V139, P311, DOI 10.1016/j.jep.2011.11.017
   Liu YX, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005467.pub2
   Luo CL, 2019, FREE RADICAL BIO MED, V130, P215, DOI 10.1016/j.freeradbiomed.2018.10.402
   Marie PJ, 2012, CURR OSTEOPOROS REP, V10, P190, DOI 10.1007/s11914 012 0109 0
   Mediero A, 2013, TRENDS ENDOCRIN MET, V24, P290, DOI 10.1016/j.tem.2013.02.001
   Miller PD, 2016, EXPERT OPIN PHARMACO, V17, P473, DOI 10.1517/14656566.2016.1124856
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Shao S, 2020, AGING MALE, V23, P1259, DOI 10.1080/13685538.2020.1762074
   [孙凯 Sun Kai], 2019, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V25, P1556
   Wang JG, 2016, PHARMACOL THERAPEUT, V162, P10, DOI 10.1016/j.pharmthera.2016.01.010
   Wang T, 2017, J CELL PHYSIOL, V232, P913, DOI 10.1002/jcp.25641
   Wei X, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906 017 1617 3
   Wu X, 2020, CHEM BIOL INTERACT, V316, DOI 10.1016/j.cbi.2019.108923
   Xie Y., 2004, CHINA J CHIN MAT MED, V4, P59
   Xie Y M, 1997, Zhongguo Zhong Xi Yi Jie He Za Zhi, V17, P526
   Xie Yan ming, 2005, Zhongguo Zhongyao Zazhi, V30, P1092
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
NR 42
TC 3
Z9 4
U1 3
U2 36
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD JAN 25
PY 2022
VL 12
AR 833474
DI 10.3389/fendo.2021.833474
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA ZG4XE
UT WOS:000760261900001
PM 35145485
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Li, ZW
   Zhang, J
   Ren, XS
   Liu, QY
   Yang, XY
AF Li, Zhengwei
   Zhang, Jun
   Ren, Xiansheng
   Liu, Qinyi
   Yang, Xiaoyu
TI The mechanism of quercetin in regulating osteoclast activation and the
   PAR2/TRPV1 signaling pathway in the treatment of bone cancer pain
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Bone cancer pain; quercetin; RANKL/RANK/OPG signaling pathway;
   PAR2/TRPV1 signaling pathway
ID RECEPTOR 2; PATHOPHYSIOLOGY; INVOLVEMENT; NEURONS
AB Objective: The present paper aimed to investigate the therapeutic effect of quercetin in a rat model of bone cancer pain, and to further explore the molecular mechanism of quercetin in the treatment of bone cancer pain. Methods: The activation status of the osteoblasts in each group of rats was detected by anti tartaric acid phosphatase (TRAP) immunohistochemistry, while the activation status of the osteoclasts was detected by alkaline phosphatase (BAP) immunohistochemistry. An ELISA assay was used to detect the levels of serum type I collagen carboxy terminal pro peptide (CDC), tartrate resistant acid phosphatase (TRAP5b), and osteocalcin in each group, as well as the expressions of the main inflammatory mediator membrane protease (trypsin), TNF alpha, and IL 1 beta in the PAR2/TRPV1 pathway in serum. Taking CD68 as a marker, immunohistochemistry was used to detect the positive proportion of macrophages in the left tibia of each group. Western blot was applied to analyze the expressions of the RANKL, OPG, RANK, PTHrP and IGF 1 proteins in rat bone tissue, the inflammatory mediators IL 8, M CSF and TNF alpha, and the PAR2/TRPV1 pathway related molecules PAR2, TRPV1, PKC Y and PKA in rat DRG neurons, as well as the neurotransmitters c Fos, GFAP, PKR, and CGRP in the spinal cord. Results: Quercetin significantly reduces serum CTX, TRAP and osteocalcin expressions in a rat model of bone cancer pain and also significantly reduces the proportion of TRAP positive cells. The drug can significantly reduce the positive proportion of local bone tissue macrophages in rats with bone cancer pain. It can significantly decrease the expressions of RANKL, RANK, PTHrP and IGF 1 proteins and the inflammatory mediators such as IL 8, M CSF and TNF alpha, significantly increase the expressions of OPG and further significantly inhibit the expressions of the PAR2/TRPV1 pathway related molecules PAR2, TRPV1, PKC gamma and PKA in DRG neurons, as well as significantly reduce the levels of major inflammatory mediators (trypsin), TNF alpha, and IL 1 beta in the PAR2/TRPV1 pathway. Conclusion: Quercetin can inhibit osteoclast activation and reduce bone destruction in the bone cancer pain model by regulatingthe RANKL/RANK/OPG signaling pathway and the inflammatory response. It can inhibit peripheral sensitization and central sensitization in bone cancer pain by regulating the PAR2/TRPV1 signaling pathway.
C1 [Li, Zhengwei; Zhang, Jun; Ren, Xiansheng; Liu, Qinyi; Yang, Xiaoyu] Jilin Univ, Hosp 2, Dept Orthoped, 218 Zi Qiang St, Changchun 130041, Jilin, Peoples R China.
C3 Jilin University
RP Ren, XS (通讯作者)，Jilin Univ, Hosp 2, Dept Orthoped, 218 Zi Qiang St, Changchun 130041, Jilin, Peoples R China.
EM renxiansheng506609@163.com
RI Li, Zhengwei/AAH 3558 2019; Zhang, Donglei/AAB 7572 2022
OI Liu, Qinyi/0000 0001 8012 3147
FU National Natural Science Foundation of China [31572217]
FX This work was supported by the National Natural Science Foundation of
   China, No. 31572217.
CR Bao Y, 2014, MOL PAIN, V10, DOI 10.1186/1744 8069 10 28
   Bao YJ, 2014, J MOL NEUROSCI, V52, P566, DOI 10.1007/s12031 013 0112 7
   Bao YJ, 2014, EXPERT OPIN THER TAR, V18, P15, DOI 10.1517/14728222.2014.844792
   Chen Y, 2011, NEUROSCIENCE, V193, P440, DOI 10.1016/j.neuroscience.2011.06.085
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Garcia PS, 2010, THROMB HAEMOSTASIS, V103, P1145, DOI 10.1160/TH09 12 0848
   Jimenez Andrade JM, 2010, ANN NY ACAD SCI, V1198, P173, DOI 10.1111/j.1749 6632.2009.05429.x
   Kanke T, 2005, J PHARMACOL SCI, V97, P38, DOI 10.1254/jphs.FMJ04005X7
   Ke CB, 2012, NEUROSCIENCE, V227, P80, DOI 10.1016/j.neuroscience.2012.09.046
   Marie N, 2013, SUPPORT CARE CANCER, V21, P3529, DOI 10.1007/s00520 013 1995 0
   Middlemiss T, 2011, CLIN ONCOL UK, V23, P387, DOI 10.1016/j.clon.2011.03.003
   Running A, 2012, CURR PAIN HEADACHE R, V16, P325, DOI 10.1007/s11916 012 0275 x
   Swarm RA, 2013, J NATL COMPR CANC NE, V11, P992, DOI 10.6004/jnccn.2013.0119
   Vergnolle N, 2001, NAT MED, V7, P821, DOI 10.1038/89945
   Villiere V, 1996, J NEUROPHYSIOL, V76, P1924, DOI 10.1152/jn.1996.76.3.1924
   Yoneda T, 2011, BONE, V48, P100, DOI 10.1016/j.bone.2010.07.009
   Zheng Q, 2012, MOL PAIN, V8, DOI 10.1186/1744 8069 8 24
NR 17
TC 24
Z9 27
U1 0
U2 7
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936 2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2018
VL 11
IS 11
BP 5149
EP 5156
PG 8
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pathology
GA HC5PV
UT WOS:000451855800001
PM 31949595
DA 2025 08 17
ER

PT J
AU Hamidouche, Z
   Haÿ, E
   Vaudin, P
   Charbord, P
   Schüle, R
   Marie, PJ
   Fromigué, O
AF Hamidouche, Zahia
   Haye, Eric
   Vaudin, Pascal
   Charbord, Pierre
   Schuele, Roland
   Marie, Pierre J.
   Fromigue, Olivia
TI FHL2 mediates dexamethasone induced mesenchymal cell differentiation
   into osteoblasts by activating Wnt/β catenin signaling dependent Runx2
   expression
SO FASEB JOURNAL
LA English
DT Article
DE osteogenesis; signaling; cell therapy
ID LIM ONLY PROTEIN; OSTEOGENIC DIFFERENTIATION; STEM CELLS;
   GLUCOCORTICOIDS INHIBIT; STROMAL CELLS; BONE MASS; MARROW; COACTIVATOR;
   DISRUPTION; INTERACTS
AB The differentiation of bone marrow mesenchymal stem cells (MSCs) into osteoblasts is a crucial step in bone formation. However, the mechanisms involved in the early stages of osteogenic differentiation are not well understood. In this study, we identified FHL2, a member of the LIM only subclass of the LIM protein superfamily, that is up regulated during early osteoblast differentiation induced by dexamethasone in murine and human MSCs. Gain of function studies showed that FHL2 promotes the expression of the osteoblast transcription factor Runx2, alkaline phosphatase, type I collagen, as well as in vitro extracellular matrix mineralization in murine and human mesenchymal cells. Knocking down FHL2 using sh RNA reduces basal and dexamethasone induced osteoblast marker gene expression in MSCs. We demonstrate that FHL2 interacts with beta catenin, a key player involved in bone formation induced by Wnt signaling. FHL2 beta catenin interaction potentiates beta catenin nuclear translocation and TCF/LEF transcription, resulting in increased Runx2 and alkaline phosphatase expression, which was inhibited by the Wnt inhibitor DKK1. Reduction of Runx2 transcriptional activity using a mutant Runx2 results in inhibition of FHL2 induced alkaline phosphatase expression in MSCs. These findings reveal that FHL2 acts as an endogenous activator of mesenchymal cell differentiation into osteoblasts and mediates osteogenic differentiation induced by dexamethasone in MSCs through activation of Wnt/beta catenin signaling dependent Runx2 expression. Hamidouche, Z., Hay, E., Vaudin, P., Charbord, P., Schule, R., Marie, P. J., and Fromigue, O. FHL2 mediates dexamethasone induced mesenchymal cell differentiation into osteoblasts by activating Wnt/beta catenin signaling dependent Runx2 expression. FASEB J. 22, 3813 3822 (2008)
C1 [Marie, Pierre J.] Hop Lariboisiere, INSERM, U606, F 75475 Paris 10, France.
   [Hamidouche, Zahia; Haye, Eric; Marie, Pierre J.; Fromigue, Olivia] Univ Paris 07, Paris, France.
   [Vaudin, Pascal] Univ Tours, Tours, France.
   [Charbord, Pierre] INSERM ESPRI, Tours, France.
   [Schuele, Roland] Univ Frauenklin, Freiburg, Germany.
   [Schuele, Roland] Zentrum Klin Forsch, Freiburg, Germany.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Lariboisiere Fernand Widal   APHP; Universite
   Paris Cite; Universite de Tours; Institut National de la Sante et de la
   Recherche Medicale (Inserm); University of Freiburg
RP Marie, PJ (通讯作者)，Hop Lariboisiere, INSERM, U606, 2 Rue Ambroise Pare, F 75475 Paris 10, France.
EM pierre.marie@inserm.fr
RI Schüle, Rebecca/B 5763 2019; Haÿ, Eric/HNS 9912 2023; Vaudin,
   Pascal/J 1870 2014; Fromigue, Olivia/B 8225 2013
OI charbord, pierre/0000 0002 2254 3300; Fromigue,
   Olivia/0000 0002 3050 6155; Hay, Eric/0000 0002 0131 9983
FU INSERM; Etablissement Francais du Sang, France [2004 08, 2005.11];
   Integrated Project of the European Commission FP6 [LSHB CT 2003 503161];
   Association Rhumatisme et Travail, Hopital Lariboisiere, Paris, France
FX The authors thank Dr. J. Dennis (Case Western Reserve University,
   Cleveland, OH, USA) for providing the BMC10 cell line, Biopredic
   (Rennes, France) for the hMSCs, and Dr. G. Karsenty (Department of
   Genetics and Development, Columbia University, New York, NY, USA) for
   the gift of mutant Runx2 cDNA. This work was funded in part by INSERM,
   the Etablissement Francais du Sang (EFS, Scientific Council No. 2004 08
   and 2005.11, France), the Integrated Project of the European Commission
   FP6 research funding program (contract LSHB CT 2003 503161 GENOSTEM) and
   Association Rhumatisme et Travail, Hopital Lariboisiere, Paris, France.
CR Aubin J E, 1998, J Cell Biochem Suppl, V30 31, P73
   Baksh D, 2007, J CELL PHYSIOL, V212, P817, DOI 10.1002/jcp.21080
   Baron R, 2006, CURR TOP DEV BIOL, V76, P103, DOI 10.1016/S0070 2153(06)76004 5
   BELLOWS CG, 1987, ENDOCRINOLOGY, V121, P1985, DOI 10.1210/endo 121 6 1985
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bianco P, 2000, J CLIN INVEST, V105, P1663, DOI 10.1172/JCI10413
   Bodine PVN, 2006, REV ENDOCR METAB DIS, V7, P33, DOI 10.1007/s11154 006 9002 4
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Caplan AI, 2007, J CELL PHYSIOL, V213, P341, DOI 10.1002/jcp.21200
   CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277
   de Boer J, 2004, BONE, V34, P818, DOI 10.1016/j.bone.2004.01.016
   Delorme Bruno, 2007, V140, P67
   Dennis JE, 1999, J BONE MINER RES, V14, P700, DOI 10.1359/jbmr.1999.14.5.700
   Eijken M, 2008, J CELL BIOCHEM, V104, P568, DOI 10.1002/jcb.21651
   Etheridge SL, 2004, STEM CELLS, V22, P849, DOI 10.1634/stemcells.22 5 849
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Fromigué O, 2006, CELL DEATH DIFFER, V13, P1845, DOI 10.1038/sj.cdd.4401873
   Fromigue O, 1997, CYTOKINE, V9, P613, DOI 10.1006/cyto.1997.0209
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Genini M, 1997, DNA CELL BIOL, V16, P433, DOI 10.1089/dna.1997.16.433
   Glass DA, 2007, ENDOCRINOLOGY, V148, P2630, DOI 10.1210/en.2006 1372
   Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200
   Govoni KE, 2006, CALCIFIED TISSUE INT, V79, P112, DOI 10.1007/s00223 006 0074 7
   Günther T, 2005, EMBO J, V24, P3049, DOI 10.1038/sj.emboj.7600773
   Johannessen M, 2006, CELL MOL LIFE SCI, V63, P268, DOI 10.1007/s00018 005 5438 z
   Karsenty G, 2000, SEMIN CELL DEV BIOL, V11, P343, DOI 10.1006/scdb.2000.0188
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kassem M, 2008, CELL TISSUE RES, V331, P157, DOI 10.1007/s00441 007 0509 0
   Kimelman N, 2006, REGEN MED, V1, P549, DOI 10.2217/17460751.1.4.549
   Komori T, 2008, FRONT BIOSCI LANDMRK, V13, P898, DOI 10.2741/2730
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lai CF, 2006, J BONE MINER RES, V21, P17, DOI 10.1359/JBMR.050915
   Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797 307
   Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i12.10
   Lian JB, 2003, CALCIFIED TISSUE INT, V72, P631, DOI 10.1007/s00223 002 1058 x
   Lian JB, 1998, BIOCHEM SOC T, V26, P14, DOI 10.1042/bst0260014
   Luppen CA, 2003, J BONE MINER RES, V18, P1186, DOI 10.1359/jbmr.2003.18.7.1186
   Marie PJ, 2006, REGEN MED, V1, P539, DOI 10.2217/17460751.1.4.539
   Martin B, 2002, J CELL BIOL, V159, P113, DOI 10.1083/jcb.200202075
   McLoughlin P, 2002, J BIOL CHEM, V277, P37045, DOI 10.1074/jbc.M203336200
   Morlon A, 2003, P NATL ACAD SCI USA, V100, P3977, DOI 10.1073/pnas.0735923100
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Ohnaka K, 2004, BIOCHEM BIOPH RES CO, V318, P259, DOI 10.1016/j.bbrc.2004.04.025
   OWEN M, 1988, J CELL SCI, P63
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007 0637
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Sher LB, 2006, CALCIFIED TISSUE INT, V79, P118, DOI 10.1007/s00223 005 0297 z
   Sher LB, 2004, ENDOCRINOLOGY, V145, P922, DOI 10.1210/en.2003 0655
   Shibamoto S, 1998, GENES CELLS, V3, P659
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Smith E, 2000, J BIOL CHEM, V275, P19992, DOI 10.1074/jbc.M001758200
   Smith E, 2005, J BIOL CHEM, V280, P2388, DOI 10.1074/jbc.M406294200
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   Wang FS, 2005, ENDOCRINOLOGY, V146, P2415, DOI 10.1210/en.2004 1050
   Wei Y, 2003, J BIOL CHEM, V278, P5188, DOI 10.1074/jbc.M207216200
   Zhou H, 2008, J BIOL CHEM, V283, P1936, DOI 10.1074/jbc.M702687200
NR 56
TC 158
Z9 181
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD NOV
PY 2008
VL 22
IS 11
BP 3813
EP 3822
DI 10.1096/fj.08 106302
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA 366SF
UT WOS:000260503000010
PM 18653765
DA 2025 08 17
ER

PT J
AU Xu, LM
   Xu, X
   Liang, YJ
   Wen, CN
   Ouyang, K
   Huang, JD
   Xiao, Y
   Deng, X
   Xia, J
   Duan, L
AF Xu, Limei
   Xu, Xiao
   Liang, Yujie
   Wen, Caining
   Ouyang, Kan
   Huang, Jiadai
   Xiao, Yin
   Deng, Xin
   Xia, Jiang
   Duan, Li
TI Osteoclast targeted delivery of anti miRNA oligonucleotides by red blood
   cell extracellular vesicles
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Administrative Region; Osteoporosis; Red blood cells; Extracellular
   vesicles; Targeted delivery; Anti miR 214
ID EXOSOMES; OSTEOPOROSIS
AB Osteoporosis (OP) affects millions worldwide but currently cannot be cured. Suppressing the level of miR 214 in osteoclasts by the anti miRNA oligonucleotide (AMO) anti miR 214 reverses bone absorption and provides a potential treatment. Here we report a peptide guided delivery strategy using red blood cell extracellular vesicles (RBCEVs) as the vehicle to realize osteoclast targeted delivery of anti miR 214. A bi functional peptide, TBP CP05, which binds to both the CD63 on RBCEVs and receptors on osteoclasts, acts as the guide. TBP CP05 binds with RBCEVs through CP05, displays the TRAP binding peptide (TBP) on the surface of EVs, and en dows RBCEVs with osteoclast targeting capability both in vitro and in vivo. Intravenous injection of the osteoclast targeting RBCEVs (OT RBCEVs) led to the enrichment of EVs in the bone skeleton, significant inhibition of the osteoclast activity, elevated osteoblast activity, and improved bone density in osteoporotic mice. Altogether, this work demonstrates efficient guidance of drug loaded EVs to the targeted cells in vivo using bi functional fusion peptides, and showcases that targeted delivery of anti miR 214 by OT RBCEVs may be a viable method for OP treatment.SIGNIFICANCE STATEMENT. Surface functionalization of EVs endows these nanovesicles cell specific targeting property which guides the drug cargos to specific tissues and cells with higher accuracy, longer retention, and minimal off target effects. Methods to functionalize EVs with minimal procedures are highly desired for clinical applications. Here we present a facile method using a bifunctional fusion peptide to guide RBCEVs to osteoclasts. A simple incubation of the bifunctional peptide and RBCEVs results in osteoclast targeting RBCEVs (OT RBCEVs) that effectively deliver anti miR 214 to osteoclasts in vivo in a mouse model of osteoporosis, bringing a potential therapy to osteoporotic patients. This is, to our knowledge, the first report on peptide functionalization of RBCEVs and osteoclast targeted delivery using RBCEVs.
C1 [Xu, Limei; Xu, Xiao; Liang, Yujie; Wen, Caining; Ouyang, Kan; Duan, Li] Shenzhen Univ, Shenzhen Peoples Hosp 2, Dept Orthoped, Shenzhen Intelligent Orthopaed & Biomed Innovat Pl, Shenzhen, Peoples R China.
   [Xu, Limei; Xu, Xiao] Chinese Acad Sci, Shenzhen Inst Adv Technol, Shenzhen 518055, Guangdong, Peoples R China.
   [Xu, Limei; Xu, Xiao; Wen, Caining] Jining Med Univ, Affiliated Hosp, Jining 272029, Shandong, Peoples R China.
   [Liang, Yujie] Shenzhen Kangning Hosp, Shenzhen Mental Hlth Ctr, Dept Child & Adolescent Psychiat, Shenzhen 518020, Guangdong, Peoples R China.
   [Liang, Yujie; Xia, Jiang] Chinese Univ Hong Kong, Dept Chem, Shatin, Hong Kong, Peoples R China.
   [Liang, Yujie; Xia, Jiang] Chinese Univ Hong Kong, Ctr Cell & Dev Biol, Sch Life Sci, Shatin, Hong Kong, Peoples R China.
   [Xiao, Yin] Queensland Univ Technol, Ctr Biomed Technol, Kelvin Grove, Qld 4059, Australia.
   [Xiao, Yin] Queensland Univ Technol, Fac Engn, Australia China Ctr Tissue Engn & Regenerat Med, Kelvin Grove, Qld 4059, Australia.
   [Huang, Jiadai; Deng, Xin] City Univ Hong Kong, Dept Biomed Sci, Hong Kong, Peoples R China.
C3 Shenzhen University; Chinese Academy of Sciences; Shenzhen Institute of
   Advanced Technology, CAS; Jining Medical University; Shenzhen Institute
   of Mental Health & Shenzhen Kangning Hospital; Chinese University of
   Hong Kong; Chinese University of Hong Kong; Queensland University of
   Technology (QUT); Queensland University of Technology (QUT); City
   University of Hong Kong
RP Duan, L (通讯作者)，Shenzhen Univ, Shenzhen Peoples Hosp 2, Dept Orthoped, Shenzhen Intelligent Orthopaed & Biomed Innovat Pl, Shenzhen, Peoples R China.; Xia, J (通讯作者)，Chinese Univ Hong Kong, Dept Chem, Shatin, Hong Kong, Peoples R China.; Xia, J (通讯作者)，Chinese Univ Hong Kong, Ctr Cell & Dev Biol, Sch Life Sci, Shatin, Hong Kong, Peoples R China.
EM jiangxia@cuhk.edu.hk; duanl@szu.edu.cn
RI ; Xu, Limei/A 4848 2010; Yujie, Liang/GLQ 6360 2022; Duan,
   Li/IUO 1967 2023; Xiao, Yin/AAM 4033 2020
OI Liang, Yujie/0000 0002 0860 4859; HUANG, Jiadai/0000 0002 4104 6836;
   Xiao, Yin/0000 0003 1785 3491; Xu, Limei/0000 0003 0391 7327; LIANG,
   Yujie/0000 0002 0036 2453
FU National Natural Science Foundation of China [81972116, 81772394,
   82102607]; Shenzhen Science and Technology Projects
   [SGDX20201103095800003, GJHZ20200731095606019, JCYJ20170817172023838];
   Guangdong International Cooperation Project [2021A0505030011]; China
   Postdoctoral Science Foundation [2020M682907, 2021M702286]; PhD Research
   Foundation of Affiliated Hospital of Jining Medical University
   [2022 BS 03, 2022 BS 04]; Research Grants Council of Hong Kong
   [R5013 19]
FX National Natural Science Foundation of China (81972116, 81772394, and
   82102607) , Shenzhen Science and Technology Projects
   (SGDX20201103095800003, GJHZ20200731095606019, and
   JCYJ20170817172023838) ; Guangdong International Cooperation Project
   (2021A0505030011) ; China Postdoctoral Science Foundation (2020M682907
   and 2021M702286) ; PhD Research Foundation of Affiliated Hospital of
   Jining Medical University (2022 BS 03, 2022 BS 04) ; Research Grants
   Council of Hong Kong (Research Impact Fund R5013 19).
CR Bae S, 2017, J CLIN INVEST, V127, P2555, DOI 10.1172/JCI89935
   Batra N, 2012, BBA BIOMEMBRANES, V1818, P1909, DOI 10.1016/j.bbamem.2011.09.018
   Bi HD, 2017, FRONT MED LAUSANNE, V4, DOI 10.3389/fmed.2017.00234
   Borgheti Cardoso L.N., INT J TORONTO
   Bottani M, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.01044
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Campaner S, 2010, NAT CELL BIOL, V12, P54, DOI 10.1038/ncb2004
   Chen H, 2021, BIOENGINEERED, V12, P12677, DOI 10.1080/21655979.2021.2008666
   Chen K, 2019, P NATL ACAD SCI USA, V116, P14138, DOI 10.1073/pnas.1900881116
   Cocozza F, 2020, CELL, V182, P262, DOI 10.1016/j.cell.2020.04.054
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Danesh A, 2014, BLOOD, V123, P687, DOI 10.1182/blood 2013 10 530469
   Duan L, 2021, NANOSCALE, V13, DOI 10.1039/d0nr07622h
   Duan L, 2021, CURR MED CHEM, V28, P6458, DOI 10.2174/0929867327666201118161232
   EJIRI S, 1983, ARCH HISTOL JAPON, V46, P533, DOI 10.1679/aohc.46.533
   Filippo JS, 2008, ANNU REV BIOCHEM, V77, P229, DOI 10.1146/annurev.biochem.77.061306.125255
   Gao XJ, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat0195
   Gao Y, 2019, CELL ADHES MIGR, V13, P183, DOI 10.1080/19336918.2019.1619433
   Gao Y, 2019, BIOMECH MODEL MECHAN, V18, P1731, DOI 10.1007/s10237 019 01171 z
   Gao YH, 2020, J LEUKOCYTE BIOL, V108, P1765, DOI 10.1002/JLB.1A0220 666R
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gu CY, 2021, MOL CANCER, V20, DOI 10.1186/s12943 021 01380 0
   Kauffman KJ, 2015, NANO LETT, V15, P7300, DOI 10.1021/acs.nanolett.5b02497
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Li HX, 2021, CURR MED CHEM, V28, P1489, DOI 10.2174/0929867327666200330142432
   Li XX, 2021, THERANOSTICS, V11, P9821, DOI 10.7150/thno.62187
   Liang YJ, 2023, MOL THER, V31, P1207, DOI 10.1016/j.ymthe.2022.10.008
   Liang YJ, 2021, THERANOSTICS, V11, P3183, DOI 10.7150/thno.52570
   Liang YJ, 2020, ACS APPL MATER INTER, V12, P36938, DOI 10.1021/acsami.0c10458
   Lorenzo J, 2007, ADV EXP MED BIOL, V602, P77
   Maeda K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225525
   Martin TJ, 2009, CRIT REV EUKAR GENE, V19, P73, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.40
   Mashel TV, 2020, BIOMATERIALS, V258, DOI 10.1016/j.biomaterials.2020.120282
   Misiewicz Krzeminska I., HAEMATOLOGICA, V98
   Mohamad N, 2019, J CELL BIOCHEM, V120, P15518, DOI 10.1002/jcb.28818
   Mora Raimundo P, 2021, ADV SCI, V8, DOI 10.1002/advs.202101107
   Pham TC, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12057
   Ryu J, 2006, EMBO J, V25, P5840, DOI 10.1038/sj.emboj.7601430
   Sender R, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002533
   Shafiey SI, 2018, LIFE SCI, V212, P109, DOI 10.1016/j.lfs.2018.09.046
   Sheu TJ, 2002, J BONE MINER RES, V17, P915, DOI 10.1359/jbmr.2002.17.5.915
   Shi JH, 2014, P NATL ACAD SCI USA, V111, P10131, DOI 10.1073/pnas.1409861111
   Smyth T, 2014, BIOCONJUGATE CHEM, V25, P1777, DOI 10.1021/bc500291r
   Sun WJ, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.15
   Sun YQ, 2019, J CELL PHYSIOL, V234, P231, DOI 10.1002/jcp.26856
   Tang DE, 2020, AGING US, V12, P13297, DOI 10.18632/aging.103434
   Tao S, 2021, J CONTROL RELEASE, V329, P121, DOI 10.1016/j.jconrel.2020.11.059
   Tu Kristie N, 2018, P T, V43, P92
   Usman W.M., NAT COMMUN
   Wang C, 2019, MOL THER NUCL ACIDS, V18, P841, DOI 10.1016/j.omtn.2019.09.030
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Weivoda MM, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115757
   Weivoda MM, 2019, J BONE MINER RES, V34, P1546, DOI 10.1002/jbmr.3740
   Wu KR, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 25473 y
   Xing LP, 2005, IMMUNOL REV, V208, P19, DOI 10.1111/j.0105 2896.2005.00336.x
   Xu LM, 2021, BIOENGINEERED, V12, P7929, DOI 10.1080/21655979.2021.1982320
   Xu X, 2021, BIOMATERIALS, V269, DOI 10.1016/j.biomaterials.2020.120539
   Yang TS, 2013, CANCER CELL INT, V13, DOI 10.1186/1475 2867 13 68
   Ye ZL, 2018, ACS APPL MATER INTER, V10, P12341, DOI 10.1021/acsami.7b18135
   Zhang BS, 2022, BIOMATER SCI UK, V10, P1821, DOI 10.1039/d2bm00076h
   Zhao BH, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3379
   Zhao CY, 2015, RNA BIOL, V12, P343, DOI 10.1080/15476286.2015.1017205
   Zhou Y, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abl6432
NR 63
TC 46
Z9 47
U1 15
U2 81
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168 3659
EI 1873 4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD JUN
PY 2023
VL 358
BP 259
EP 272
DI 10.1016/j.jconrel.2023.04.043
EA MAY 2023
PG 14
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA H9JR4
UT WOS:000999044200001
PM 37121514
DA 2025 08 17
ER

PT J
AU Tower, RJ
   Campbell, GM
   Müller, M
   Will, O
   Glüer, CC
   Tiwari, S
AF Tower, Robert J.
   Campbell, Graeme M.
   Mueller, Marc
   Will, Olga
   Glueer, Claus C.
   Tiwari, Sanjay
TI Binding Kinetics of a Fluorescently Labeled Bisphosphonate as a Tool for
   Dynamic Monitoring of Bone Mineral Deposition In Vivo
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE BISPHOSPHONATES; MOLECULAR IMAGING; BONE TURNOVER; BONE MINERALIZATION;
   OSTEOPOROSIS
ID TC 99M METHYLENE DIPHOSPHONATE; MOLECULAR TOMOGRAPHY; F 18 FLUORIDE;
   ACTIVATION; RESORPTION; INHIBITION; RETENTION; MECHANISM; PROTEIN;
   LESIONS
AB Bone mineral deposition during the modeling of new bone and remodeling of old bone can be perturbed by several pathological conditions, including osteoporosis and skeletal metastases. A site specific marker depicting the dynamics of bone mineral deposition would provide insight into skeletal disease location and severity, and prove useful in evaluating the efficacy of pharmacological interventions. Fluorescent labels may combine advantages of both radioisotope imaging and detailed microscopic analyses. The purpose of this study was to determine if the fluorescent bisphosphonate OsteoSense could detect localized changes in bone mineral deposition in established mouse models of accelerated bone loss (ovariectomy) (OVX) and anabolic bone gain resulting from parathyroid hormone (PTH) treatment. We hypothesized that the early rate of binding, as well as the total amount of bisphosphonate, which binds over long periods of time, could be useful in evaluating changes in bone metabolism. Evaluation of the kinetic uptake of bisphosphonates revealed a significant reduction in both the rate constant and plateau binding after OVX, whereas treatment with PTH resulted in a 36 fold increase in the bisphosphonate binding rate constant compared with untreated OVX controls. Localization of bisphosphonate binding revealed initial binding at sites of ossification adjacent to the growth plate and, to a lesser extent, along more distal trabecular and cortical elements. Micro computed tomography (CT) was used to confirm that initial bisphosphonate binding is localized to sites of low tissue mineral density, associated with new bone mineral deposition. Our results suggest monitoring binding kinetics based on fluorescently labeled bisphosphonates represents a highly sensitive, site specific method for monitoring changes in bone mineral deposition with the potential for translation into human applications in osteoporosis and bone metastatic processes and their treatment. (C) 2014 American Society for Bone and Mineral Research.
C1 [Tower, Robert J.; Campbell, Graeme M.; Mueller, Marc; Will, Olga; Glueer, Claus C.; Tiwari, Sanjay] Univ Hosp Schleswig Holstein, Dept Diagnost Radiol, Sect Biomed Imaging, D 24118 Kiel, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital
RP Tiwari, S (通讯作者)，Univ Hosp Schleswig Holstein, Dept Diagnost Radiol, Sect Biomed Imaging, Campus Kiel,Botanischen Garten 14, D 24118 Kiel, Germany.
EM stiwari@email.uni kiel.de
RI Campbell, Graeme/JPX 2238 2023; Tiwari, Sanjay/Q 1853 2016; Glüer,
   Claus Christian/C 9752 2010
OI Tower, Robert/0000 0001 5856 5758; Tiwari, Sanjay/0000 0002 3804 3300; 
FU Deutsche Forschungsgemeinschaft (DFG) [forschergruppe 1586 SKELMET];
   state of Schleswig Holstein; European Union ERDF European Regional
   Development Fund; PerkinElmer
FX Financial support was provided by the Deutsche Forschungsgemeinschaft
   (DFG) through the forschergruppe 1586 SKELMET and by the research grant
   from the state of Schleswig Holstein and the European Union
   ERDF European Regional Development Fund (MOIN CC, Zukunftsprogramm
   Wirtschaft). Research support was provided by PerkinElmer in the form of
   discounted reagents.
CR Al Nakouzi N, 2012, NEOPLASIA, V14, P376, DOI 10.1593/neo.12308
   Blake GM, 2012, NUCL MED COMMUN, V33, P881, DOI 10.1097/MNM.0b013e3283550275
   Blake GM, 2001, SEMIN NUCL MED, V31, P28, DOI 10.1053/snuc.2001.18742
   Boivin G, 2002, CALCIFIED TISSUE INT, V70, P503, DOI 10.1007/s00223 001 2048 0
   Buenzli PR, 2014, BIOMECH MODEL MECHAN, V13, P185, DOI 10.1007/s10237 013 0495 y
   Buie HR, 2007, BONE, V41, P505, DOI 10.1016/j.bone.2007.07.007
   Campbell GM, 2014, CALCIFIED TISSUE INT, V94, P282, DOI 10.1007/s00223 013 9809 4
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   DELMAS PD, 1993, J BONE MINER RES, V8, pS549
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   FOGELMAN I, 1978, J NUCL MED, V19, P270
   FRANCIS MD, 1980, J NUCL MED, V21, P1185
   Frost ML, 2011, J BONE MINER RES, V26, P1002, DOI 10.1002/jbmr.305
   Graves EE, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1993427
   HALPERN SE, 1980, EUR J NUCL MED, V5, P515
   Hsu WK, 2008, J NUCL MED, V49, P414, DOI 10.2967/jnumed.107.045666
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kozloff KM, 2007, J BONE MINER RES, V22, P1208, DOI 10.1359/JBMR.070504
   Kozloff KM, 2010, J BONE MINER RES, V25, P1748, DOI 10.1002/jbmr.66
   Lambers FM, 2013, BONE, V52, P587, DOI 10.1016/j.bone.2012.11.001
   Leu CT, 2006, BONE, V38, P628, DOI 10.1016/j.bone.2005.07.023
   Mackie EJ, 2011, J ENDOCRINOL, V211, P109, DOI 10.1530/JOE 11 0048
   Martin A, 2008, MOL IMAGING, V7, P157, DOI 10.2310/7290.2008.00016
   Meganck JA, 2009, BONE, V45, P1104, DOI 10.1016/j.bone.2009.07.078
   Moore AEB, 2008, J NUCL MED, V49, P375, DOI 10.2967/jnumed.107.048595
   Ntziachristos V, 2002, NAT MED, V8, P757, DOI 10.1038/nm729
   Pacifici R, 2012, J BONE MINER RES, V27, P231, DOI 10.1002/jbmr.1500
   Park Holohan SJ, 2001, NUCL MED COMMUN, V22, P1037, DOI 10.1097/00006231 200109000 00014
   Roche B, 2013, BONE, V55, P418, DOI 10.1016/j.bone.2013.03.022
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Roelofs AJ, 2012, J BONE MINER RES, V27, P835, DOI 10.1002/jbmr.1543
   Roelofs AJ, 2010, J BONE MINER RES, V25, P606, DOI 10.1359/jbmr.091009
   Siddique M, 2012, EUR J NUCL MED MOL I, V39, P337, DOI 10.1007/s00259 011 1966 y
   Snoeks TJA, 2011, BONE, V48, P106, DOI 10.1016/j.bone.2010.07.027
   Uveges TE, 2009, J BONE MINER RES, V24, P849, DOI [10.1359/jbmr.081238, 10.1359/JBMR.081238]
   Wythe SE, 2014, CALCIFIED TISSUE INT, V94, P98, DOI 10.1007/s00223 013 9764 0
   Yamaza T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002615
   Yoshimasu T, 2003, CANCER SCI, V94, P741, DOI 10.1111/j.1349 7006.2003.tb01512.x
   Zaheer A, 2001, NAT BIOTECHNOL, V19, P1148, DOI 10.1038/nbt1201 1148
NR 40
TC 16
Z9 18
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD SEP
PY 2014
VL 29
IS 9
BP 1993
EP 2003
DI 10.1002/jbmr.2224
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AN8HV
UT WOS:000340846000009
PM 24644087
OA Bronze
DA 2025 08 17
ER

PT J
AU Peris, P
   Monegal, A
   Guañabens, N
AF Peris, Pilar
   Monegal, Ana
   Guanabens, Nuria
TI Bisphosphonates in inflammatory rheumatic diseases
SO BONE
LA English
DT Article
DE Nitrogen containing bisphosphonates; Experimental arthritis; Rheumatoid
   arthritis; Ankylosing spondylitis; SAPHO; Spondyloarthropathies
ID ACUTE PHASE RESPONSE; SAPHO SYNDROME; DOUBLE BLIND; BONE LOSS; IN VITRO;
   ANKYLOSING SPONDYLITIS; ZOLEDRONIC ACID; INTRAVENOUS PAMIDRONATE;
   ALENDRONATE CONJUGATE; TARGETING OSTEOCLASTS
AB The main well recognized action of bisphosphonates (BPs) is their antiresorptive capacity, making them first line drugs in the treatment of osteoporosis and other metabolic bone diseases. In this review we have compiled other possible actions of BPs, particularly in the areas of immunomodulation, anti inflammatory capacity and in the prevention of structural joint damage in inflammatory rheumatic diseases. The immunomodulatory capacity of BPs has been focused on the mechanisms involved in the acute phase response associated with the administration of nitrogen containing BPs (N BPs), with the stimulus of pro inflammatory cytokines, through the mevalonate pathway, activation of T cells and the decrease in the cytotoxic T lymphocyte antigen 4 (CTLA 4). In relation to their anti inflammatory capacity, special attention has been given to their effect on preventing structural damage in inflammatory joint diseases and on the differential immune response in bone lesions of the most common and representative inflammatory rheumatic diseases, i.e. rheumatoid arthritis and spondyloarthropathies. The present data indicate that more studies are needed to improve the knowledge on the effect of BPs on inflammatory mediated diseases and particularly on the prevention and/or treatment of the structural damage in these disorders, since these agents could be a potential useful concomitant therapy.
C1 [Peris, Pilar; Monegal, Ana; Guanabens, Nuria] Univ Barcelona, Dept Rheumatol, Hosp Clin, CIBERehd,IDIBAPS, Barcelona, Spain.
C3 University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; CIBER  
   Centro de Investigacion Biomedica en Red; CIBEREHD
RP Guañabens, N (通讯作者)，Hosp Clin Barcelona, Dept Rheumatol, C Villarroel 170, Barcelona 08036, Spain.
EM nguanabens@ub.edu
CR ADAMI S, 1987, CALCIFIED TISSUE INT, V41, P326, DOI 10.1007/BF02556671
   Amital H, 2004, RHEUMATOLOGY, V43, P658, DOI 10.1093/rheumatology/keh149
   [Anonymous], 2020, MED CLIN BARC, V8, P358
   Bruyn GA, 2019, J RHEUMATOL, V46, P1388, DOI 10.3899/jrheum.181095
   Bugatti S, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 1116 9
   Cantatore FP, 1999, J RHEUMATOL, V26, P2318
   Clunie GPR, 2014, ANN RHEUM DIS, V73, P1273, DOI 10.1136/annrheumdis 2013 204938
   Coates L, 2017, CLIN EXP RHEUMATOL, V35, P445
   Colina M, 2009, CLIN EXP RHEUMATOL, V27, P112
   Confavreux CB, 2009, MOL CELL ENDOCRINOL, V310, P21, DOI 10.1016/j.mce.2009.04.004
   Corrado A, 2017, POSTGRAD MED, V129, P858, DOI 10.1080/00325481.2017.1362312
   Depasquale R, 2012, CLIN RADIOL, V67, P195, DOI 10.1016/j.crad.2011.08.014
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Dohn UM, 2009, ANN RHEUM DIS, V68, P1585, DOI 10.1136/ard.2008.097048
   Dohn UM, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1995
   Dong AS, 2016, CLIN NUCL MED, V41, pE211, DOI 10.1097/RLU.0000000000000983
   Eggelmeijer F, 1996, ARTHRITIS RHEUM, V39, P396, DOI 10.1002/art.1780390307
   EGGELMEIJER F, 1994, J RHEUMATOL, V21, P2016
   Eriksen EF, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115352
   Ferron M, 2010, CELL, V142, P296, DOI 10.1016/j.cell.2010.06.003
   Fioravanti A, 2008, JCR J CLIN RHEUMATOL, V14, P183, DOI 10.1097/RHU.0b013e318177a64f
   Fiore C E, 2009, J Endocrinol Invest, V32, P38
   FRANCIS MD, 1972, CALC TISS RES, V9, P109, DOI 10.1007/BF02061949
   Giollo A, 2019, J RHEUMATOL, V46, P318, DOI 10.3899/jrheum.180324
   Giuliani N, 1998, BONE, V22, P455, DOI 10.1016/S8756 3282(98)00033 7
   Giusti A, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115512
   Gong X, 2019, RHEUMATOLOGY, V58, P1443, DOI 10.1093/rheumatology/kez042
   Gorecki P, 2015, J MED HYPOTHESES IDE, V9, P72, DOI 10.1016/j.jmhi.2015.04.002
   Harre U, 2012, J CLIN INVEST, V122, P1791, DOI 10.1172/JCI60975
   Hasegawa J, 2003, J RHEUMATOL, V30, P474
   Ideguchi H, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1943
   Jarrett SJ, 2006, ARTHRITIS RHEUM US, V54, P1410, DOI 10.1002/art.21824
   Jensen TW, 2014, ANN RHEUM DIS, V73, P1123, DOI 10.1136/annrheumdis 2012 203171
   Jung K, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106534
   Kastbom A, 2004, ANN RHEUM DIS, V63, P1085, DOI 10.1136/ard.2003.016808
   Kawahara T, 2013, CIRCULATION, V127, P2327, DOI 10.1161/CIRCULATIONAHA.113.001534
   Kim DH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122646
   Kinne RW, 1995, ARTHRITIS RHEUM US, V38, P1777, DOI 10.1002/art.1780381211
   Kleyer A, 2014, ANN RHEUM DIS, V73, P854, DOI 10.1136/annrheumdis 2012 202958
   Kopterides P, 2004, ARTHRITIS RHEUM US, V50, P2970, DOI 10.1002/art.20464
   Koshiyama H, 2000, J CLIN ENDOCR METAB, V85, P2793, DOI 10.1210/jc.85.8.2793
   Laloux L, 2001, ANN RHEUM DIS, V60, P316, DOI 10.1136/ard.60.4.316
   Le Goff B, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2877
   Lee H, 2017, BIOCONJUGATE CHEM, V28, P1084, DOI 10.1021/acs.bioconjchem.7b00008
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Li C, 2019, CLIN EXP RHEUMATOL, V37, P663
   Lodder MC, 2003, J RHEUMATOL, V30, P2080
   Lukas C, 2010, ANN RHEUM DIS, V69, P851, DOI 10.1136/ard.2009.119156
   Maksymowych Walter P., 2002, Current Medicinal Chemistry   Anti Inflammatory & Anti Allergy Agents, V1, P15, DOI 10.2174/1568014024606539
   Maksymowych WP, 2003, J RHEUMATOL, V30, P430
   Maksymowych WP, 2002, ARTHRITIS RHEUM, V46, P766, DOI 10.1002/art.10139
   Fernández Real JM, 2011, DIABETES, V60, P2179, DOI 10.2337/db10 1210
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   Meyer O, 2003, ANN RHEUM DIS, V62, P120, DOI 10.1136/ard.62.2.120
   Nguyen MT, 2012, SEMIN ARTHRITIS RHEU, V42, P254, DOI 10.1016/j.semarthrit.2012.05.006
   Mok CC, 2015, SCAND J RHEUMATOL, V44, P480, DOI 10.3109/03009742.2015.1038300
   Mönkkönen J, 1998, LIFE SCI, V62, pPL95, DOI 10.1016/S0024 3205(97)01178 8
   García JAN, 2010, REUMATOL CLIN, V6, P111, DOI 10.1016/j.reuma.2009.03.002
   Olivieri I, 2006, EXPERT OPIN INV DRUG, V15, P1229, DOI 10.1517/13543784.15.10.1229
   Orriss IR, 2009, J CELL BIOCHEM, V106, P109, DOI 10.1002/jcb.21983
   Ostergaard M, 2003, J RHEUMATOL, V30, P1385
   Panagiotakou A, 2020, METABOLISM, V110, DOI 10.1016/j.metabol.2020.154264
   Papapoulos SE, 2008, BEST PRACT RES CL EN, V22, P831, DOI 10.1016/j.beem.2008.07.001
   Patntirapong S, 2018, ORAL DIS, V24, P1294, DOI 10.1111/odi.12908
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2006, BONE, V39, P443, DOI 10.1016/j.bone.2006.02.060
   RALSTON SH, 1989, ANN RHEUM DIS, V48, P396, DOI 10.1136/ard.48.5.396
   Redlich K, 2002, ARTHRITIS RHEUM, V46, P785, DOI 10.1002/art.10097
   Richards PJ, 1999, RHEUMATOLOGY, V38, P818, DOI 10.1093/rheumatology/38.9.818
   Rodriguez García SC, 2020, JCR J CLIN RHEUMATOL, V26, pE155, DOI 10.1097/RHU.0000000000001025
   Roelofs AJ, 2010, CURR PHARM DESIGN, V16, P2950
   Roelofs AJ, 2010, J BONE MINER RES, V25, P606, DOI 10.1359/jbmr.091009
   Roelofs AJ, 2009, BRIT J HAEMATOL, V144, P245, DOI 10.1111/j.1365 2141.2008.07435.x
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Russell RGG, 1999, OSTEOPOROSIS INT, V9, P66, DOI 10.1007/PL00004164
   Sambataro G, 2017, THER ADV CHRONIC DIS, V8, P97, DOI 10.1177/2040622317702363
   SANSONI P, 1995, J BONE MINER RES, V10, P1719
   Santra G, 2010, SINGAP MED J, V51, P883
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Schwartz AV, 2013, J BONE MINER RES, V28, P1348, DOI 10.1002/jbmr.1865
   SCHWEITZER DH, 1995, J BONE MINER RES, V10, P956
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   Senolt L., 2019, F1000RES, V8
   SHARP JT, 1971, ARTHRITIS RHEUM US, V14, P706, DOI 10.1002/art.1780140605
   Shi J, 2011, P NATL ACAD SCI USA, V108, P17372, DOI 10.1073/pnas.1114465108
   Simone R, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/215763
   Sims NA, 2004, ARTHRITIS RHEUM US, V50, P2338, DOI 10.1002/art.20382
   Singh JA, 2016, ARTHRITIS RHEUMATOL, V68, P1, DOI 10.1002/art.39480
   Smolen JS, 2017, ANN RHEUM DIS, V76, P960, DOI 10.1136/annrheumdis 2016 210715
   Solomon DH, 2009, ARTHRITIS RHEUM, V60, P1624, DOI 10.1002/art.24551
   Soyfoo MS, 2010, JCR J CLIN RHEUMATOL, V16, P253, DOI 10.1097/RHU.0b013e3181e9be89
   Stach CM, 2010, ARTHRITIS RHEUM US, V62, P330, DOI 10.1002/art.27252
   Sulko J, 2019, JOINT BONE SPINE, V86, P783, DOI 10.1016/j.jbspin.2019.06.005
   Sun XC, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018 018 0795 0
   Suzuki K, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9060503
   Takeuchi T, 2019, ANN RHEUM DIS, V78, P899, DOI 10.1136/annrheumdis 2018 214827
   Thiebaud D, 1997, CALCIFIED TISSUE INT, V61, P386, DOI 10.1007/s002239900353
   Toussirot É, 2007, CURR OPIN RHEUMATOL, V19, P340
   Tzschentke TM, 2021, BRIT J PHARMACOL, V178, P1973, DOI 10.1111/bph.14799
   Valleala H, 2003, J RHEUMATOL, V30, P468
   van der Heijde D, 2013, ANN RHEUM DIS, V72, P479, DOI 10.1136/annrheumdis 2012 202779
   van der Heijde DMFM, 2000, RHEUMATOLOGY, V39, P9, DOI 10.1093/oxfordjournals.rheumatology.a031496
   van der Linden MPM, 2010, ANN RHEUM DIS, V69, P727, DOI 10.1136/ard.2009.108332
   VANDERHEIJDE DM, 1989, LANCET, V1, P1036, DOI 10.1016/S0140 6736(89)92442 2
   Vestergaard P, 2011, CALCIFIED TISSUE INT, V89, P265, DOI 10.1007/s00223 011 9515 z
   Viapiana O, 2014, RHEUMATOLOGY, V53, P90, DOI 10.1093/rheumatology/ket321
   Xie Z, 2018, DRUG DELIV, V25, P187, DOI 10.1080/10717544.2017.1422295
   Yang S, 2016, DIABETES OBES METAB, V18, P875, DOI 10.1111/dom.12678
   Yue J, 2017, ARTHRIT CARE RES, V69, P1156, DOI 10.1002/acr.23133
NR 110
TC 22
Z9 22
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAY
PY 2021
VL 146
AR 115887
DI 10.1016/j.bone.2021.115887
EA FEB 2021
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA RF4DW
UT WOS:000634791000004
PM 33592328
DA 2025 08 17
ER

PT J
AU Xu, CD
   Hu, XY
   Fan, YT
   Zhang, L
   Gao, ZL
   Cai, CH
AF Xu, Congdi
   Hu, Xinyu
   Fan, Yantao
   Zhang, Ling
   Gao, Zhengliang
   Cai, Chunhui
TI Wif1 Mediates Coordination of Bone Morphogenetic Protein and Wnt
   Signaling in Neural and Glioma Stem Cells
SO CELL TRANSPLANTATION
LA English
DT Article
DE BMP4; Wif1; neural stem cells; GBM; Wnt signaling pathway
ID NEURONAL DIFFERENTIATION; PATHWAY; HYPERMETHYLATION; GLIOBLASTOMA;
   GROWTH
AB Wnts, bone morphogenetic protein (BMP), and fibroblast growth factor (FGF) are paracrine signaling pathways implicated in the niche control of stem cell fate decisions. BMP on and Wnt off are the dominant quiescent niche signaling pathways in many cell types, including neural stem cells (NSCs). However, among the multiple inhibitory family members of the Wnt pathway, those with direct action after BMP4 stimulation in NSCs remain unclear. We examined 11 Wnt inhibitors in NSCs after BMP4 treatment. Wnt inhibitory factor 1 (Wif1) has been identified as the main factor reacting to BMP4 stimuli. RNA sequencing confirmed that Wif1 was markedly upregulated after BMP4 treatment in different gene expression analyses. Similar to the functional role of BMP4, Wif1 significantly decreased the cell cycle of NSCs and significantly inhibited cell proliferation (P < 0.05). Combined treatment with BMP4 and Wif1 significantly enhanced the inhibition of cell growth compared with the single treatment (P < 0.05). Wif1 expression was clearly lower in glioblastoma and low grade glioma samples than in normal samples (P < 0.05). A functional analysis revealed that both BMP4 and Wif1 could decrease glioma cell growth. These effects were abrogated by the BMP inhibitor Noggin. The collective findings demonstrate that Wif1 plays a key role in quiescent NSC homeostasis and glioma cell growth downstream of BMP on signaling. The functional roles of Wif1/BMP4 in glioma cells may provide a technical basis for regenerative medicine, drug discovery, and personal molecular therapy in future clinical treatments.
C1 [Xu, Congdi; Hu, Xinyu; Fan, Yantao; Gao, Zhengliang; Cai, Chunhui] Tongji Univ, Shanghai YangZhi Rehabil Hosp, Fundamental Res Ctr, Sch Med,Shanghai Sunshine Rehabil Ctr, Shanghai 200001, Peoples R China.
   [Hu, Xinyu] Radboud Univ Nijmegen, Inst Mol & Mat, Nijmegen, Netherlands.
   [Fan, Yantao; Gao, Zhengliang; Cai, Chunhui] Shanghai Univ, Affiliated Nantong Hosp, Inst Geriatr, Sch Med,Peoples Hosp Nantong 6, Nantong, Peoples R China.
   [Zhang, Ling] Tongji Univ, Rehabil Hosp Shanghai 1, Sch Med, Shanghai 200001, Peoples R China.
C3 Tongji University; Radboud University Nijmegen; Shanghai University;
   Tongji University
RP Gao, ZL; Cai, CH (通讯作者)，Tongji Univ, Shanghai YangZhi Rehabil Hosp, Fundamental Res Ctr, Sch Med,Shanghai Sunshine Rehabil Ctr, Shanghai 200001, Peoples R China.; Zhang, L (通讯作者)，Tongji Univ, Rehabil Hosp Shanghai 1, Sch Med, Shanghai 200001, Peoples R China.
EM lzhang0808@tongji.edu.cn; zhengliang_gao@shu.edu.cn;
   pattycaich@tongji.edu.cn
RI ; hu, xinyu/GYU 4240 2022
OI Cai, Chunhui/0000 0002 8700 4383; 
CR Almario RU, 2015, HORM METAB RES, V47, P152, DOI 10.1055/s 0034 1384521
   Armenteros T, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 27581 0
   Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192
   Choe Y, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a018887
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Couturier CP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 17186 5
   Cui Y, 2016, SCI REP UK, V6, DOI 10.1038/srep23300
   Cunningham TJ, 2015, DEV DYNAM, V244, P797, DOI 10.1002/dvdy.24275
   Deng XC, 2017, MOL MED REP, V16, P7497, DOI 10.3892/mmr.2017.7564
   Ding SL, 2015, WORLD J GASTROENTERO, V21, P6317, DOI 10.3748/wjg.v21.i20.6317
   Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302
   Han XX, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.639858
   Hirabayashi Y, 2004, DEVELOPMENT, V131, P2791, DOI 10.1242/dev.01165
   Hunter DD, 2004, MOL CELL NEUROSCI, V27, P477, DOI 10.1016/j.mcn.2004.08.003
   Jain R, 2015, SCIENCE, V348, DOI 10.1126/science.aaa6071
   Jang MH, 2013, CELL STEM CELL, V12, P215, DOI 10.1016/j.stem.2012.11.021
   Kalies S, 2014, J BIOPHOTONICS, V7, P825, DOI 10.1002/jbio.201300056
   Kandyba E, 2013, P NATL ACAD SCI USA, V110, P1351, DOI 10.1073/pnas.1121312110
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Kühl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/S0168 9525(00)02028 X
   Lambiv WL, 2011, NEURO ONCOLOGY, V13, P736, DOI 10.1093/neuonc/nor036
   Li LH, 2010, SCIENCE, V327, P542, DOI 10.1126/science.1180794
   Lim FT, 2017, ZEBRAFISH, V14, P10, DOI 10.1089/zeb.2016.1319
   Liu AM, 2005, NAT REV NEUROSCI, V6, P945, DOI 10.1038/nrn1805
   Liu ZY, 2006, J BIOL CHEM, V281, P17156, DOI 10.1074/jbc.M513812200
   Mao YW, 2009, CELL, V136, P1017, DOI 10.1016/j.cell.2008.12.044
   Mimura S, 2016, INT J DEV BIOL, V60, P21, DOI 10.1387/ijdb.160040mk
   Mira H, 2010, CELL STEM CELL, V7, P78, DOI 10.1016/j.stem.2010.04.016
   Muroyama Y, 2004, BIOCHEM BIOPH RES CO, V313, P915, DOI 10.1016/j.bbrc.2003.12.023
   Nakaya N, 2008, J NEUROSCI, V28, P7900, DOI 10.1523/JNEUROSCI.0617 08.2008
   Nayak S, 2020, CANCERS, V12, DOI 10.3390/cancers12020516
   Neftel C, 2019, CELL, V178, P835, DOI 10.1016/j.cell.2019.06.024
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Queimado L, 2008, ARCH OTOLARYNGOL, V134, P94, DOI 10.1001/archotol.134.1.94
   Shen EH, 2012, TRENDS NEUROSCI, V35, P711, DOI 10.1016/j.tins.2012.09.005
   Szopa W, 2017, BIOMED RES INT UK, V2017, DOI 10.1155/2017/8013575
   Tai D, 2015, ONCOLOGIST, V20, P1189, DOI 10.1634/theoncologist.2015 0057
   Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430
   ten Berge D, 2008, DEVELOPMENT, V135, P3247, DOI 10.1242/dev.023176
   Urbán N, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00396
   Varela Nallar L, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00100
   Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449
   Wu SH, 2020, CANCER CELL, V38, P311, DOI 10.1016/j.ccell.2020.08.012
   Xu B, 2011, DEVELOPMENT, V138, P925, DOI 10.1242/dev.062687
   Yang ZAY, 2010, ACTA BIOCH BIOPH SIN, V42, P418, DOI 10.1093/abbs/gmq037
   Zhu Z, 2020, CELL STEM CELL, V26, P187, DOI 10.1016/j.stem.2019.11.016
NR 46
TC 2
Z9 2
U1 0
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0963 6897
EI 1555 3892
J9 CELL TRANSPLANT
JI Cell Transplant.
PD NOV
PY 2022
VL 31
AR 09636897221134540
DI 10.1177/09636897221134540
PG 13
WC Cell & Tissue Engineering; Medicine, Research & Experimental;
   Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine; Transplantation
GA 6I1JJ
UT WOS:000885882100001
PM 36324293
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Shao, CY
   Liu, Y
   Li, JC
   Liu, ZY
   Zhao, YX
   Jing, YQ
   Lv, Z
   Fu, T
   Wang, ZH
   Li, G
AF Shao, Chenyi
   Liu, Yi
   Li, Jiaci
   Liu, Ziyun
   Zhao, Yuxia
   Jing, Yaqing
   Lv, Zhe
   Fu, Ting
   Wang, Zihan
   Li, Guang
TI Up regulated IL 17 and Tnf signaling in bone marrow cells of young male
   osteogenesis imperfecta mice
SO PEERJ
LA English
DT Article
DE Osteogenesis imperfecta; Bone resorption; RNA sequencing; Bone marrow;
   Inflammation
ID OSTEOCLAST DIFFERENTIATION; INTERFERON; RESORPTION; MUTATION; RANKL
AB Osteogenesis imperfecta (OI) is a congenital bone dysplasia mainly caused by either defective production or assembly of type I collagen. The skeletal phenotypes especially fractures are often seen in OI adolescents. Studies have found that an increased number of osteoclasts and excessive bone resorption existed in collagen related OI, which has not been well understood. Emerging evidence has suggested that inflammation may be associated with OI. We speculated that the bone marrow (BM) niche had similar inflammatory changes and performed RNA sequencing (RNA seq) in BM cells derived from young male mice to analyze the related differentially expressed genes (DEGs) and pathways. Data showed that there were 117 shared DEGs (Q <= 0.05, vertical bar loga2FC vertical bar >= 1) in BM cells isolated from two types of OI murine models that respectively simulate different OI types. Gene Ontology (GO) (Q <= 0.05) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) (Q <= 0.05) analysis and real time PCR validation indicated the dysregulated biology process of cellular response to interferon (Ifn) together with upregulated IL17 signaling, tumor necrosis factor (Tnf) signaling and osteoclast differentiation in OI BM niche. Either defective collagen production or abnormal collagen assembly shared similar alterations in gene profiles and pathways involving inflammation and osteoclast activation. Data presented here not only contributed to understanding of the mechanism of the enhanced bone absorption in the bones of OI, but also provided more evidence to develop potential anti inflammation therapies.
C1 [Shao, Chenyi; Liu, Yi; Liu, Ziyun; Zhao, Yuxia; Jing, Yaqing; Lv, Zhe; Fu, Ting; Wang, Zihan; Li, Guang] Tianjin Med Univ, Tianjin, Peoples R China.
   [Li, Jiaci] Tianjin Childrens Hosp, Tianjin Pediat Res Inst, Longyan Rd, Tianjin, Peoples R China.
C3 Tianjin Medical University
RP Li, G (通讯作者)，Tianjin Med Univ, Tianjin, Peoples R China.
EM lig@tmu.edu.cn
RI Zhang, Yunjiao/AAG 4482 2020; Shao, Chenyi/MHR 1330 2025; Wang,
   Zihan/EZP 6684 2022
OI wang, zi han/0000 0001 8193 7054; 
FU National Key R&D Program of China [2017YFC1001904]
FX The present study was supported by grants from the National Key R&D
   Program of China (2017YFC1001904). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Berg S, 2021, RADIOLOGE, V61, P87, DOI 10.1007/s00117 020 00792 1
   Biros E, 2022, CYTOKINE GROWTH F R, V64, P7, DOI 10.1016/j.cytogfr.2022.01.005
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brunetti G, 2016, OSTEOPOROSIS INT, V27, P2355, DOI 10.1007/s00198 016 3501 2
   CHIPMAN SD, 1993, P NATL ACAD SCI USA, V90, P1701, DOI 10.1073/pnas.90.5.1701
   Ciucci T, 2015, GUT, V64, P1072, DOI 10.1136/gutjnl 2014 306947
   Feng W, 2019, J ORAL BIOSCI, V61, P16, DOI 10.1016/j.job.2019.01.001
   Forlino A, 2011, NAT REV ENDOCRINOL, V7, P540, DOI 10.1038/nrendo.2011.81
   Franco GEL, 2005, BONE, V36, P1039, DOI 10.1016/j.bone.2005.03.004
   Grafel I, 2014, NAT MED, V20, P670, DOI 10.1038/nm.3544
   Herrmann M, 2019, CURR STEM CELL RES T, V14, P305, DOI 10.2174/1574888X14666190123161447
   Hoyer Kuhn H, 2015, WIEN MED WOCHENSCHR, V165, P278, DOI 10.1007/s10354 015 0361 x
   Iwamoto J, 2002, J BONE MINER METAB, V20, P174, DOI 10.1007/s007740200025
   Liu Y, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/j.biopha.2020.110235
   Liu Y, 2019, BONE, V127, P646, DOI 10.1016/j.bone.2019.07.021
   Marom R, 2020, EUR J ENDOCRINOL, V183, pR95, DOI 10.1530/EJE 20 0299
   Matthews BG, 2017, BONE, V103, P1, DOI 10.1016/j.bone.2017.06.004
   McBride DJ, 1998, CALCIFIED TISSUE INT, V62, P172, DOI 10.1007/s002239900412
   Michalska A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01135
   Nijhuis WH, 2019, J CHILD ORTHOP, V13, P1, DOI 10.1302/1863 2548.13.180190
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   PATERSON CR, 1984, NEW ENGL J MED, V310, P1694, DOI 10.1056/NEJM198406283102602
   Saban J, 1996, BONE, V19, P575, DOI 10.1016/S8756 3282(96)00305 5
   Saito M, 2015, CALCIFIED TISSUE INT, V97, P242, DOI 10.1007/s00223 015 9985 5
   Takayanagi H, 2005, IMMUNOL REV, V208, P181, DOI 10.1111/j.0105 2896.2005.00337.x
   Takeyari S, 2021, J BIOL CHEM, V296, DOI 10.1074/jbc.RA120.014709
   Tilg H, 2008, GUT, V57, P684, DOI 10.1136/gut.2006.117382
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Weitzmann MN, 2017, TOXICOL PATHOL, V45, P911, DOI 10.1177/0192623317735316
   Weyand CM, 2021, NAT IMMUNOL, V22, P10, DOI 10.1038/s41590 020 00816 x
   Yao WL, 2021, CLIN EXP IMMUNOL, V203, P137, DOI 10.1111/cei.13531
   Zhao BH, 2012, J EXP MED, V209, P319, DOI 10.1084/jem.20111566
   Zhytnik L, 2020, BMC MED GENOMICS, V13, DOI 10.1186/s12920 020 00825 7
NR 33
TC 2
Z9 2
U1 0
U2 4
PU PEERJ INC
PI LONDON
PA 341 345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167 8359
J9 PEERJ
JI PeerJ
PD AUG 23
PY 2022
VL 10
AR e13963
DI 10.7717/peerj.13963
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 4M3IH
UT WOS:000853218100014
PM 36032950
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wu, DJ
   Dixit, N
   Suzuki, E
   Nguyen, T
   Shin, HS
   Davis, J
   Maverakis, E
   Adamopoulos, IE
AF Wu, Dennis J.
   Dixit, Neha
   Suzuki, Erika
   Thanh Nguyen
   Shin, Hyun Seock
   Davis, Jack
   Maverakis, Emanual
   Adamopoulos, Iannis E.
TI A Novel in vivo Gene Transfer Technique and in vitro Cell
   Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
SO JOVE JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Medicine; Issue 88; osteoclast; arthritis; minicircle DNA; macrophages;
   cell culture; hydrodynamic delivery
ID MINICIRCLE DNA VECTORS; OSTEOCLAST DIFFERENTIATION; OSTEOPOROSIS;
   EXPRESSION; RESORPTION; ARTHRITIS; ESTROGEN; MICE; OSTEOIMMUNOLOGY;
   PERSISTENT
AB Differentiation and activation of osteoclasts play a key role in the development of musculoskeletal diseases as these cells are primarily involved in bone resorption. Osteoclasts can be generated in vitro from monocyte/macrophage precursor cells in the presence of certain cytokines, which promote survival and differentiation. Here, both in vivo and in vitro techniques are demonstrated, which allow scientists to study different cytokine contributions towards osteoclast differentiation, signaling, and activation. The minicircle DNA delivery gene transfer system provides an alternative method to establish an osteoporosis related model is particularly useful to study the efficacy of various pharmacological inhibitors in vivo. Similarly, in vitro culturing protocols for producing osteoclasts from human precursor cells in the presence of specific cytokines enables scientists to study osteoclastogenesis in human cells for translational applications. Combined, these techniques have the potential to accelerate drug discovery efforts for osteoclast specific targeted therapeutics, which may benefit millions of osteoporosis and arthritis patients worldwide.
C1 [Wu, Dennis J.; Dixit, Neha; Suzuki, Erika; Shin, Hyun Seock; Adamopoulos, Iannis E.] Univ Calif Davis, Div Rheumatol Allergy & Clin Immunol, Davis, CA 95616 USA.
   [Thanh Nguyen; Davis, Jack; Adamopoulos, Iannis E.] Shriners Hosp Children Northern California, Inst Pediat Regenerat Med, Sacramento, CA 95817 USA.
   [Maverakis, Emanual] Univ Calif Davis, Dept Dermatol, Davis, CA 95616 USA.
C3 University of California System; University of California Davis;
   University of California System; University of California Davis
RP Adamopoulos, IE (通讯作者)，Univ Calif Davis, Div Rheumatol Allergy & Clin Immunol, Davis, CA 95616 USA.
EM iannis@ucdavis.edu
RI Maverakis, Emanual/JWP 9408 2024; Adamopoulos, Iannis/AAE 5624 2022
OI Adamopoulos, Iannis/0000 0002 3708 2965; Maverakis,
   Emanual/0000 0002 6294 6294
FU NIH [R01 AR062173, SHC 250862]; NIH T32 CTSC predoctoral fellowship
FX Research was partly supported by NIH research grants R01 AR062173 and
   SHC 250862 to IEA. ES is the recipient of NIH T32 CTSC predoctoral
   fellowship.
CR Adamopoulos IE, 2011, J IMMUNOL, V187, P951, DOI 10.4049/jimmunol.1003986
   Adamopoulos IE, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2936
   Adamopoulos IE, 2006, J PATHOL, V208, P35, DOI 10.1002/path.1891
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Boyce BF, 2012, EUR J CLIN INVEST, V42, P1332, DOI 10.1111/j.1365 2362.2012.02717.x
   Bradley Elizabeth W., 2008, V455, P19, DOI 10.1007/978 1 59745 104 8_2
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Chen ZY, 2005, HUM GENE THER, V16, P126, DOI 10.1089/hum.2005.16.126
   Chen ZY, 2003, MOL THER, V8, P495, DOI 10.1016/S1525 0016(03)00168 0
   Das S, 2013, DRUG DES DEV THER, V7, P435, DOI 10.2147/DDDT.S31504
   Edwards JR, 2011, NAT REV RHEUMATOL, V7, P235, DOI 10.1038/nrrheum.2011.23
   FULLER K, 1993, J EXP MED, V178, P1733, DOI 10.1084/jem.178.5.1733
   Halleen JM, 2000, J BONE MINER RES, V15, P1337, DOI 10.1359/jbmr.2000.15.7.1337
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   Jones D, 2011, J CLIN INVEST, V121, P2534, DOI 10.1172/JCI46262
   Kay MA, 2010, NAT BIOTECHNOL, V28, P1287, DOI 10.1038/nbt.1708
   KITAZAWA R, 1994, J CLIN INVEST, V94, P2397, DOI 10.1172/JCI117606
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lelovas PP, 2008, COMPARATIVE MED, V58, P424
   Matsuzaki K, 1998, BIOCHEM BIOPH RES CO, V246, P199, DOI 10.1006/bbrc.1998.8586
   Mizuno A, 2002, J BONE MINER METAB, V20, P337, DOI 10.1007/s007740200049
   Ominsky MS, 2008, J BONE MINER RES, V23, P672, DOI 10.1359/JBMR.080109
   Sato K, 2006, CURR OPIN RHEUMATOL, V18, P419, DOI 10.1097/01.bor.0000231912.24740.a5
   Seto H, 1999, BONE, V25, P687, DOI 10.1016/S8756 3282(99)00229 X
   SHERMAN BM, 1976, J CLIN ENDOCR METAB, V42, P629, DOI 10.1210/jcem 42 4 629
   SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66
   Suda T, 1997, J BONE MINER RES, V12, P869, DOI 10.1359/jbmr.1997.12.6.869
   Suda T, 2007, MOL THER, V15, P2063, DOI 10.1038/sj.mt.6300314
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo 123 5 2600
   Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   WRONSKI TJ, 1989, CALCIFIED TISSUE INT, V45, P360, DOI 10.1007/BF02556007
   Yelin E, 2003, J RHEUMATOL, V30, P8
NR 35
TC 4
Z9 5
U1 0
U2 4
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940 087X
J9 JOVE J VIS EXP
JI J. Vis. Exp.
PD JUN
PY 2014
IS 88
AR e51810
DI 10.3791/51810
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CB0BQ
UT WOS:000349290100080
PM 24961167
OA Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Muthukrishnan, A
   Al Ismail, S
   Bertelli, G
   Browne, P
AF Muthukrishnan, A.
   Al Ismail, S.
   Bertelli, G.
   Browne, P.
TI MRONJ risk reduction pathway 360 degree survey
SO BRITISH DENTAL JOURNAL
LA English
DT Article
ID MEDICATION RELATED OSTEONECROSIS; POSTMENOPAUSAL WOMEN; BREAST CANCER;
   BISPHOSPHONATES; OSTEOPOROSIS; JAWS; ASSOCIATION; PREVENTION; DENOSUMAB;
   UPDATE
AB Introduction Bisphosphonates and denosumab reduce the risk of skeletal events in some malignancies (for example, breast, myeloma). These drugs carry a significant risk of a difficult to manage side effect of medication related osteonecrosis of the jaw (MRONJ). Preventive dental screening and treatment reduces the incidence of MRONJ. A managed clinical network (MCN) has been used to provide a MRONJ risk reduction pathway. A 360 degree survey was undertaken to assess the effectiveness of the pathway. Aim The aim of the 360 degree survey was to evaluate if this preventive pathway fulfilled its aims based on patient and stakeholder responses. Method A multidisciplinary, cross service, cross health board MRONJ preventive pathway has been developed. A 360 degree feedback survey of patients and other stakeholders was undertaken. Results Overall, this survey revealed high levels of satisfaction across patients, oncologists, community dental services, general dental services, and hospital managers. Conclusion Alternative ways of delivering MRONJ preventive pathways can be developed and assessed using iterative stakeholder feedback aided by a robust clinical governance framework.
C1 [Muthukrishnan, A.; Browne, P.] ABM Univ Hlth Board, Morriston Hosp, Swansea SA6 6NL, W Glam, Wales.
   [Al Ismail, S.] ABM Univ Hlth Board, Singleton Hosp, Dept Haematol & Haemato Oncol, Swansea SA2 8QA, W Glam, Wales.
   [Bertelli, G.] ABM Univ Hlth Board, Singleton Hosp, Dept Oncol, Swansea SA2 8QA, W Glam, Wales.
C3 Morriston Hospital; Singleton Hospital; Singleton Hospital
RP Muthukrishnan, A (通讯作者)，ABM Univ Hlth Board, Morriston Hosp, Swansea SA6 6NL, W Glam, Wales.
EM akhila.muthukrishnan@wales.nhs.uk
CR [Anonymous], 2013, SIMPL PRUD HELATHC
   [Anonymous], 2011, OR HLTH MAN PAT PRES
   Baker CD, 2000, BRIT MED J, V321, P1152, DOI 10.1136/bmj.321.7269.1152
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Boonyapakorn T, 2008, ORAL ONCOL, V44, P857, DOI 10.1016/j.oraloncology.2007.11.012
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Day Mary Rose, 2009, Nurs Older People, V21, P26
   Graziani F, 2012, J ORAL MAXIL SURG, V70, P2501, DOI 10.1016/j.joms.2012.05.019
   Hellstein JW, 2011, J AM DENT ASSOC, V142, P1243, DOI 10.14219/jada.archive.2011.0108
   Hillner BE, 2003, J CLIN ONCOL, V21, P4042, DOI 10.1200/JCO.2003.08.017
   Ibrahim T, 2008, ONCOLOGIST, V13, P330, DOI 10.1634/theoncologist.2007 0159
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Patel D, 2015, J DISABIL ORAL HLTH, V16, P54
   Ramaswamy Bhuvaneswari, 2003, Oncology (Williston Park), V17, P1261
   Ripamonti CI, 2009, ANN ONCOL, V20, P137, DOI 10.1093/annonc/mdn526
   Ristow O, 2015, J CRANIO MAXILL SURG, V43, P290, DOI 10.1016/j.jcms.2014.11.014
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Spears J., 2014, Cancer Nursing Practice, V13, P21
   Stopeck A, 2009, EJC SUPPL, V7, P2, DOI 10.1016/S1359 6349(09)72028 2
   Tait T., 2002, NT RES, V7, P19
   Taylor T, 2013, BRIT DENT J, V214, DOI 10.1038/sj.bdj.2013.327
   Watts NB, 2003, CONT ENDOCRINOL, P459
NR 23
TC 5
Z9 5
U1 1
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007 0610
EI 1476 5373
J9 BRIT DENT J
JI Br. Dent. J.
PD MAR
PY 2017
VL 222
IS 5
BP 386
EP 390
DI 10.1038/sj.bdj.2017.225
PG 5
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA EN8AB
UT WOS:000396222200020
PM 28281587
DA 2025 08 17
ER

PT J
AU Li, YL
   Zhang, J
   Yan, CP
   Chen, Q
   Xiang, C
   Zhang, QY
   Wang, XK
   Jiang, K
AF Li, Yuling
   Zhang, Jing
   Yan, Caiping
   Chen, Qian
   Xiang, Chao
   Zhang, Qingyan
   Wang, Xingkuan
   Jiang, Ke
TI Marein Prevented LPS Induced Osteoclastogenesis by Regulating the NF κB
   Pathway In Vitro
SO JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY
LA English
DT Article
DE Marein; LPS; inflammation; RAW264; 7; NF KB
ID LIPOPOLYSACCHARIDE; DIFFERENTIATION; OSTEOMYELITIS; MECHANISMS
AB Many bone diseases such as osteolysis, osteomyelitis, and septic arthritis are caused by gram negative bacterial infection, and lipopolysaccharide (LPS), a bacterial product, plays an essential role in this process. Drugs that inhibit LPS induced osteoclastogenesis are urgently needed to prevent bone destruction in infective bone diseases. Marein, a major bioactive compound of Coreopsis tinctoria, possesses anti oxidative, anti inflammatory, anti hypertensive, antihyperlipidemic, and anti diabetic effects. In this study, we measured the effect of marein on RAW264.7 cells by CCK 8 assay and used TRAP staining to determine osteoclastogenesis. The levels of osteoclast related genes and NF kappa B related proteins were then analyzed by western blot, and the levels of pro inflammatory cytokines were quantified by ELISA. Our results showed that marein inhibited LPS induced osteoclast formation by osteoclast precursor RAW264.7 cells. The effect of marein was related to its inhibitory function on expressions of pro inflammatory cytokines and osteoclast related genes containing RANK, TRAF6, MMP 9, CK, and CAII. Additionally, marein leads to markedly inhibited NF kappa B signaling pathway activation in LPS induced RAW264.7 cells. Concurrently, when the NF kappa B signaling pathway was inhibited, osteoclast formation and pro inflammatory cytokine expression were decreased. Collectively, marein could inhibit LPS induced osteoclast formation in RAW264.7 cells via regulating the NF kappa B signaling pathway. Our data demonstrate that marein might be a potential drug for bacteria induced bone destruction disease. Our findings provide new insights into LPS induced bone disease.
C1 [Li, Yuling; Yan, Caiping; Chen, Qian; Xiang, Chao; Zhang, Qingyan; Wang, Xingkuan; Jiang, Ke] North Sichuan Med Coll, Affiliated Hosp, Dept Orthopaed, 63 Wenhua Rd, Nanchong City 637000, Sichuan, Peoples R China.
   [Zhang, Jing] North Sichuan Med Coll, Affiliated Hosp, Dept Gastroenterol, 63 Wenhua Rd, Nanchong City 637000, Sichuan, Peoples R China.
C3 North Sichuan Medical University; North Sichuan Medical University
RP Jiang, K (通讯作者)，North Sichuan Med Coll, Affiliated Hosp, Dept Orthopaed, 63 Wenhua Rd, Nanchong City 637000, Sichuan, Peoples R China.
EM jiangke2010@ymail.com
RI ZHANG, qingyan/LBK 6809 2024
OI li, yu ling/0000 0003 4659 1013
FU Foundation for Young Scientist of the Medical Association of Sichuan
   Province [Q19069]; Research Foundation of Science and Technology Bureau
   of Nanchong City [18SXHZ0147]; Major Program of Science Foundation of
   Affiliated Hospital of North Sichuan Medical College [2019ZD008];
   Applied Basic Research Programs of the Science and Technology Department
   of Sichuan Province [2021YJ0467]; National Natural Science Foundation of
   China [82102578]; Research Project of the Affiliated Hospital of North
   Sichuan Medical College [2021ZK001]
FX This study was supported by the Foundation for Young Scientist of the
   Medical Association of Sichuan Province (Q19069), the Research
   Foundation of Science and Technology Bureau of Nanchong City
   (18SXHZ0147), Major Program of Science Foundation of Affiliated Hospital
   of North Sichuan Medical College (2019ZD008), the Research Project of
   the Affiliated Hospital of North Sichuan Medical College (2021ZK001),
   the Applied Basic Research Programs of the Science and Technology
   Department of Sichuan Province (2021YJ0467), and the National Natural
   Science Foundation of China (82102578).
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649
   Cao Y, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112794
   Chang MK, 2014, P NATL ACAD SCI USA, V111, pE5187, DOI 10.1073/pnas.1413828111
   Díaz Muñoz MD, 2010, CELL SIGNAL, V22, P1427, DOI 10.1016/j.cellsig.2010.05.011
   He PD, 2018, J AGR FOOD CHEM, V66, P10205, DOI 10.1021/acs.jafc.8b03731
   Hotokezaka H, 2007, J CELL BIOCHEM, V101, P122, DOI 10.1002/jcb.21167
   Hou GQ, 2013, INT J MOL MED, V32, P503, DOI 10.3892/ijmm.2013.1406
   Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092 8674(00)81699 2
   Islam S, 2007, BIOCHEM BIOPH RES CO, V360, P346, DOI 10.1016/j.bbrc.2007.06.023
   Jiang BP, 2016, FREE RADICAL RES, V50, P1173, DOI 10.1080/10715762.2016.1222374
   Karieb S, 2012, BRIT J NUTR, V108, P1736, DOI 10.1017/S0007114511007355
   Karieb S, 2011, J CELL BIOCHEM, V112, P476, DOI 10.1002/jcb.22935
   Khurana N, 2018, CANCERS, V10, DOI 10.3390/cancers10100352
   Kong LB, 2019, J CELL MOL MED, V23, P3077, DOI 10.1111/jcmm.14277
   Liu D, 2019, ANN ROY COLL SURG, V101, P328, DOI 10.1308/rcsann.2019.0021
   Maffulli N, 2016, SURG J R COLL SURG E, V14, P345, DOI 10.1016/j.surge.2015.12.005
   Maldonado RF, 2016, FEMS MICROBIOL REV, V40, P480, DOI 10.1093/femsre/fuw007
   Marcoline FV, 2016, BONE, V93, P167, DOI 10.1016/j.bone.2016.09.007
   Mizutani H, 2013, J PERIODONTAL RES, V48, P748, DOI 10.1111/jre.12065
   Nason R, 2009, JARO J ASSOC RES OTO, V10, P151, DOI 10.1007/s10162 008 0153 8
   OHANIAN SH, 1967, J EXP MED, V125, P1137, DOI 10.1084/jem.125.6.1137
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Park JH, 2017, MOL CELLS, V40, P706
   Peng A, 2019, FOOD RES INT, V123, P64, DOI 10.1016/j.foodres.2019.04.046
   Tran PT, 2018, INT J MOL MED, V42, P569, DOI 10.3892/ijmm.2018.3627
   Satpathy Swaha, 2015, J Complement Integr Med, V12, P251, DOI 10.1515/jcim 2015 0034
   Wang W, 2015, J AGR FOOD CHEM, V63, P200, DOI 10.1021/jf504289g
   Yang J, 2019, FASEB J, V33, P7261, DOI 10.1096/fj.201802172R
   Yao MY, 2020, INT IMMUNOPHARMACOL, V80, DOI 10.1016/j.intimp.2019.106126
   Zeng XZ, 2020, ACTA PHARMACOL SIN, V41, P229, DOI 10.1038/s41401 019 0289 6
   Zhang Y, 2016, BIOL PHARM BULL, V39, P2028, DOI 10.1248/bpb.b16 00522
   Zhao G, 2019, INFLAMMATION, V42, P650, DOI 10.1007/s10753 018 0922 4
   Zheng MX, 2014, INT ORTHOP, V38, P627, DOI 10.1007/s00264 013 2184 y
NR 35
TC 9
Z9 10
U1 2
U2 27
PU KOREAN SOC MICROBIOLOGY & BIOTECHNOLOGY
PI SEOUL
PA KOREA SCI TECHNOL CENTER #507,  635 4 YEOGSAM DONG, KANGNAM GU, SEOUL
   135 703, SOUTH KOREA
SN 1017 7825
EI 1738 8872
J9 J MICROBIOL BIOTECHN
JI J. Microbiol. Biotechnol.
PD FEB
PY 2022
VL 32
IS 2
BP 141
EP 148
DI 10.4014/jmb.2109.09033
PG 8
WC Biotechnology & Applied Microbiology; Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Microbiology
GA ZQ8ME
UT WOS:000767351500001
PM 35001005
OA Bronze, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Indo, Y
   Takeshita, S
   Ishii, KA
   Hoshii, T
   Aburatani, H
   Hirao, A
   Ikeda, K
AF Indo, Yoriko
   Takeshita, Sunao
   Ishii, Kiyo Aki
   Hoshii, Takayuki
   Aburatani, Hiroyuki
   Hirao, Atsushi
   Ikeda, Kyoji
TI Metabolic Regulation of Osteoclast Differentiation and Function
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOCLAST; BIOSYNTHESIS; BIOENERGETICS; GLYCOLYSIS; GLUTAMINOLYSIS
ID MITOCHONDRIAL PYRUVATE CARRIER; BONE RESORPTION; C MYC; SKELETAL
   DEVELOPMENT; MAMMALIAN TARGET; AMINO ACIDS; RAG GTPASES; HYPOXIA;
   ACTIVATION; EXPRESSION
AB The osteoclast is a giant cell that resorbs calcified matrix by secreting acids and collagenolytic enzymes. The molecular mechanisms underlying metabolic adaptation to the increased biomass and energetic demands of osteoclastic bone resorption remain elusive. Here we show that during osteoclastogenesis the expression of both glucose transporter 1 (Glut1) and glycolytic genes is increased, whereas the knockdown of hypoxia inducible factor 1 alpha (Hif1), as well as glucose deprivation, inhibits the bone resorbing function of osteoclasts, along with a suppression of Glut1 and glycolytic gene expression. Furthermore, the expression of the glutamine transporter solute carrier family 1 (neutral amino acid transporter), member 5 (Slc1a5) and glutaminase 1 was increased early in differentiation, and a depletion of L glutamine or pharmacological inhibition of the Slc1a5 transporter suppressed osteoclast differentiation and function. Inhibition of c Myc function abrogated osteoclast differentiation and function, along with a suppression of Slc1a5 and glutaminase 1 gene expression. Genetic and pharmacological inhibition of mammalian target of rapamycin (mTOR), as well as the activation of adenosine monophosphate (AMP) activated protein kinase (AMPK), inhibited osteoclastogenesis. Thus, the uptake of glucose and glutamine and utilization of the carbon sources derived from them, coordinated by HIF1 and c Myc, are essential for osteoclast development and bone resorbing activity through a balanced regulation of the nutrient and energy sensors, mTOR and AMPK. (c) 2013 American Society for Bone and Mineral Research
C1 [Indo, Yoriko; Takeshita, Sunao; Ishii, Kiyo Aki; Ikeda, Kyoji] Natl Ctr Geriatr & Gerontol, Dept Bone & Joint Dis, Obu, Aichi 4748511, Japan.
   [Hoshii, Takayuki; Hirao, Atsushi] Kanazawa Univ, Canc Res Inst, Div Mol Genet, Kanazawa, Ishikawa 920, Japan.
   [Aburatani, Hiroyuki] Univ Tokyo, Sch Med, Genomesci Div, Ctr Adv Sci & Technol, Tokyo 113, Japan.
C3 National Center for Geriatrics & Gerontology; Kanazawa University;
   University of Tokyo
RP Ikeda, K (通讯作者)，Natl Ctr Geriatr & Gerontol, Dept Bone & Joint Dis, 35 Gengo, Obu, Aichi 4748511, Japan.
EM kikeda@ncgg.go.jp
RI ; Ishii, Kiyoaki/MGS 9352 2025; Hoshii, Takayuki/HZL 9690 2023
OI Hoshii, Takayuki/0000 0002 5418 1981; Ishii,
   Kiyo aki/0000 0001 9846 5575
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [22118007]; Grants in Aid for Scientific Research [22590330, 22118007,
   25118710, 24790967, 22390064] Funding Source: KAKEN
FX This work was supported by a Grant in Aid for Scientific Research on
   Innovative Areas (22118007 to K. Ikeda) from the Ministry of Education,
   Culture, Sports, Science and Technology of Japan.
CR Arnett TR, 2003, J CELL PHYSIOL, V196, P2, DOI 10.1002/jcp.10321
   Battaglino R, 2002, J BONE MINER RES, V17, P763, DOI 10.1359/jbmr.2002.17.5.763
   Benjamin D, 2011, NAT REV DRUG DISCOV, V10, P868, DOI 10.1038/nrd3531
   Bland ML, 2011, SCIENCE, V332, P1387, DOI 10.1126/science.1208444
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bozec A, 2008, NATURE, V454, P221, DOI 10.1038/nature07019
   Bricker DK, 2012, SCIENCE, V337, P96, DOI 10.1126/science.1218099
   Cejka D, 2010, ARTHRITIS RHEUM US, V62, P2294, DOI 10.1002/art.27504
   Chow DC, 2001, BIOPHYS J, V81, P685, DOI 10.1016/S0006 3495(01)75733 5
   Daumer KM, 2002, J BONE MINER RES, V17, P1701, DOI 10.1359/jbmr.2002.17.9.1701
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002
   Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Herzig S, 2012, SCIENCE, V337, P93, DOI 10.1126/science.1218530
   Hoshii T, 2012, J CLIN INVEST, V122, P2114, DOI 10.1172/JCI62279
   Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910
   Jones RG, 2007, IMMUNITY, V27, P173, DOI 10.1016/j.immuni.2007.07.008
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kim E, 2008, NAT CELL BIOL, V10, P935, DOI 10.1038/ncb1753
   Kim JM, 2007, CELL PHYSIOL BIOCHEM, V20, P935, DOI 10.1159/000110454
   Kneissel M, 2004, BONE, V35, P1144, DOI 10.1016/j.bone.2004.07.013
   Knowles HJ, 2009, J PATHOL, V218, P256, DOI 10.1002/path.2534
   Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044
   Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097 2765(00)00066 6
   Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535
   Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024
   Schipani E, 2001, GENE DEV, V15, P2865
   Smink JJ, 2010, J MOL MED, V88, P227, DOI 10.1007/s00109 009 0567 8
   Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200
   UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   WARBURG O, 1956, SCIENCE, V124, P269
   Williams JP, 1997, BIOCHEM BIOPH RES CO, V235, P646, DOI 10.1006/bbrc.1997.6795
   Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 42
TC 186
Z9 219
U1 1
U2 75
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD NOV
PY 2013
VL 28
IS 11
BP 2392
EP 2399
DI 10.1002/jbmr.1976
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 239KZ
UT WOS:000326024000017
PM 23661628
DA 2025 08 17
ER

PT J
AU Chen, K
   Yuan, Y
   Wang, ZY
   Song, DZ
   Zhao, JM
   Cao, Z
   Chen, JH
   Guo, Q
   Chen, L
   Tickner, J
   Xu, JK
AF Chen, Kai
   Yuan, Yu
   Wang, Ziyi
   Song, Dezhi
   Zhao, Jinmin
   Cao, Zhen
   Chen, Junhao
   Guo, Qiang
   Chen, Li
   Tickner, Jennifer
   Xu, Jiake
TI Helvolic acid attenuates osteoclast formation and function via
   suppressing RANKL induced NFATc1 activation
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE helvolic acid (HA); nuclear factor of activated T cells 1 (NFATc1);
   osteoclast; reactive oxygen species (ROS)
ID NUCLEAR FACTOR; RECEPTOR ACTIVATOR; GENE EXPRESSION; INDUCED
   OSTEOPOROSIS; CATHEPSIN K; BONE; DIFFERENTIATION; LIGAND; CELLS;
   INHIBITION
AB Excessive osteoclast formation and function are considered as the main causes of bone lytic disorders such as osteoporosis and osteolysis. Therefore, the osteoclast is a potential therapeutic target for the treatment of osteoporosis or other osteoclast related diseases. Helvolic acid (HA), a mycotoxin originally isolated from Aspergillus fumigatus , has been discovered as an effective broad spectrum antibacterial agent and has a wide range of pharmacological properties. Herein, for the first time, HA was demonstrated to be capable of significantly inhibiting receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclastogenesis and bone resorption in vitro by suppressing nuclear factor of activated T cells 1 (NFATc1) activation. This inhibition was followed by the dramatically decreased expression of NFATc1 targeted genes including Ctr (encoding calcitonin receptor), Acp5 (encoding tartrate resistant acid phosphatase [TRAcP]), Ctsk (encoding cathepsin K), Atp6v0d2 (encoding the vacuolar H+ ATPase V0 subunit d2 [V ATPase d2]) and Mmp9 (encoding matrix metallopeptidase 9) which are osteoclastic specific genes required for osteoclast formation and function. Mechanistically, HA was shown to greatly attenuate multiple upstream pathways including extracellular signal regulated kinase (ERK) phosphorylation, c Fos signaling, and intracellular Ca2+ oscillation, but had little effect on nuclear factor kappa B (NF kappa B) activation. In addition, HA also diminished the RANKL induced generation of intracellular reactive oxygen species. Taken together, our study indicated HA effectively suppressed RANKL induced osteoclast formation and function. Thus, we propose that HA can be potentially used in the development of a novel drug for osteoclast related bone diseases.
C1 [Chen, Kai; Yuan, Yu; Wang, Ziyi; Song, Dezhi; Cao, Zhen; Chen, Junhao; Guo, Qiang; Chen, Li; Tickner, Jennifer; Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.
   [Yuan, Yu] South China Normal Univ, Sch Phys Educ & Sports Sci, Guangzhou, Guangdong, Peoples R China.
   [Song, Dezhi; Zhao, Jinmin] Guangxi Med Univ, Res Ctr Regenerat Med, Nanning, Guangxi, Peoples R China.
   [Zhao, Jinmin] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Guangxi, Peoples R China.
   [Zhao, Jinmin] Guangxi Med Univ, Int Joint Lab Regenerat Bone & Soft Tissues, Guangxi, Peoples R China.
   [Cao, Zhen] Third Mil Med Univ, Dept Biomed Mat Sci, Chongqing, Peoples R China.
   [Guo, Qiang] Cent S Univ, Xiangya Hosp, Dept Spine Surg, Changsha, Hunan, Peoples R China.
   [Chen, Li] Univ Melbourne, Melbourne Med Sch, Parkville, Vic, Australia.
C3 University of Western Australia; South China Normal University; Guangxi
   Medical University; Guangxi Medical University; Guangxi Medical
   University; Army Medical University; Central South University;
   University of Melbourne
RP Xu, JK (通讯作者)，Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.
EM jiake.xu@uwa.edu.au
RI zhao, jin/LBH 0351 2024; Song, Dezhi/AAL 9799 2020; Chen,
   Junhao/LCD 2351 2024; Chen, KaiJie/A 1743 2016; Tickner,
   Jennifer/H 5965 2014; guo, qiang/IXD 7450 2023; Yuan, Yu/HKN 3214 2023
OI CHEN, LI/0000 0002 6717 5708; Zhao, Jinmin/0000 0001 8423 0425; Xu,
   Jiake/0000 0003 2021 8309; Chen, Kai/0000 0001 6850 1723; Wang,
   Ziyi/0000 0002 1334 7287; Zhao, Jinmin/0000 0002 1047 8820; Tickner,
   Jennifer/0000 0002 5020 0671; Yuan, Yu/0000 0003 1032 6330
FU National Natural Science Foundation of China [81702186, 81501910];
   National Health and Medical Research Council [1107828, 1027932];
   Australian Government Research Training Program Scholarship;
   Co innovation Center for Bio Medicine, Innovation Team of Tissue Repair
   and Reconstruction; National Health and Medical Research Council of
   Australia [1107828] Funding Source: NHMRC
FX National Natural Science Foundation of China, Grant/Award Numbers:
   81702186, 81501910; National Health and Medical Research Council,
   Grant/Award Numbers: 1107828, 1027932; Co innovation Center for
   Bio Medicine, Innovation Team of Tissue Repair and Reconstruction;
   Australian Government Research Training Program Scholarship
CR Abu Amer Y, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2170
   Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Bartell SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4773
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Cheng JW, 2018, J CELL PHYSIOL, V233, P2502, DOI 10.1002/jcp.26126
   Crotti TN, 2006, GENE, V372, P92, DOI 10.1016/j.gene.2005.12.012
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   HOROWITZ MC, 1993, SCIENCE, V260, P626, DOI 10.1126/science.8480174
   Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910
   Ke QD, 2006, AM J PHYSIOL LUNG C, V291, pL257, DOI 10.1152/ajplung.00007.2006
   Kim H, 2017, J BONE MINER RES, V32, P397, DOI 10.1002/jbmr.2974
   Kim HJ, 2006, FREE RADICAL BIO MED, V40, P1483, DOI 10.1016/j.freeradbiomed.2005.10.066
   Kim H, 2013, CELL METAB, V17, P249, DOI 10.1016/j.cmet.2013.01.002
   Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Lee MS, 2009, J IMMUNOL, V183, P3390, DOI 10.4049/jimmunol.0804314
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Luo XW, 2017, NAT PROD RES, V31, P1958, DOI 10.1080/14786419.2016.1266353
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Qin L, 2009, NAT PROD RES, V23, P309, DOI 10.1080/14786410801972813
   Rana T, 2012, FREE RADICAL BIO MED, V53, P2298, DOI 10.1016/j.freeradbiomed.2012.10.536
   Ratnaweera Pamoda B, 2014, Mycology, V5, P23
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Shiao MS, 2008, BIOFACTORS, V34, P147, DOI 10.1002/biof.5520340206
   SHINOHARA C, 1993, BIOCHIM BIOPHYS ACTA, V1167, P303, DOI 10.1016/0005 2760(93)90233 Y
   Song FM, 2016, J CELL PHYSIOL, V231, P1983, DOI 10.1002/jcp.25304
   Sundaram K, 2007, EXP CELL RES, V313, P168, DOI 10.1016/j.yexcr.2006.10.001
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Troen BR, 2004, DRUG NEWS PERSPECT, V17, P19, DOI 10.1358/dnp.2004.17.1.829022
   Tsunawaki S, 2004, INFECT IMMUN, V72, P3373, DOI 10.1128/IAI.72.6.3373 3382.2004
   van der Kraan AGJ, 2013, BIOCHEM J, V451, P235, DOI 10.1042/BJ20121626
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   Wauquier F, 2009, TRENDS MOL MED, V15, P468, DOI 10.1016/j.molmed.2009.08.004
   Xiao JH, 2017, EXP BIOL MED, V242, P214, DOI 10.1177/1535370216668051
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Yip KHM, 2005, J BONE MINER RES, V20, P1462, DOI 10.1359/JBMR.050324
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
NR 49
TC 16
Z9 17
U1 0
U2 38
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD MAY
PY 2019
VL 234
IS 5
BP 6477
EP 6488
DI 10.1002/jcp.27385
PG 12
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA HK7AQ
UT WOS:000458138600097
PM 30341897
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Watanabe, R
   Fujita, N
   Takeda, S
   Sato, Y
   Kobayashi, T
   Morita, M
   Oike, T
   Miyamoto, K
   Matsumoto, Y
   Matsumoto, M
   Nakamura, M
   Miyamoto, T
AF Watanabe, Ryuichi
   Fujita, Nobuyuki
   Takeda, Satoshi
   Sato, Yuiko
   Kobayashi, Tami
   Morita, Mayu
   Oike, Takatsugu
   Miyamoto, Kana
   Matsumoto, Yoshihiro
   Matsumoto, Mono
   Nakamura, Masaya
   Miyamoto, Takeshi
TI Ibandronate concomitantly blocks immobilization induced bone and muscle
   atrophy
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Ibandronate; Muscle atrophy; Bisphosphonate; Immobilization; Osteoclast;
   Bone loss
ID SCIATIC NEURECTOMY; SPACE FLIGHT; OSTEOPOROSIS; FALLS; PREDICTORS;
   ACTIVATION; MECHANISMS; STRATEGIES
AB Both bone and muscle volume is concomitantly reduced under immobilization conditions; however, no single drug is currently available to block these outcomes simultaneously. Bisphosphonates are utilized clinically to inhibit osteoclast dependent bone resorption, but their effects on muscle are largely unknown. Here we show that skeletal muscle is a direct target of the bisphosphonate ibandronate (IBN) and that reduced muscle volume and induction of Atrogin 1 and MuRF1, both atrogenes, are significantly inhibited by IBN administration in vivo using a mouse model of muscle atrophy. IBN treatment also significantly blocked immobilization induced bone loss in vivo. We also report that expression of Atrogin 1 and MuRF1 and accumulation of Smad2/3 proteins, which are upstream of atrogines, occurred following serum starvation of myogenic C2C12 cells in vitro, effects significantly inhibited by IBN treatment. Interestingly, IBN effects on C2C12 cells were abrogated by MG132, an ubiquitin/proteasome inhibitor, suggesting that IBN functions via the ubiquitin proteasome system. Our findings lend new insight into the role of IBN in preventing muscle atrophy. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Watanabe, Ryuichi; Fujita, Nobuyuki; Sato, Yuiko; Kobayashi, Tami; Oike, Takatsugu; Miyamoto, Kana; Matsumoto, Mono; Nakamura, Masaya; Miyamoto, Takeshi] Keio Univ, Sch Med, Dept Orthoped Surg, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.
   [Sato, Yuiko; Miyamoto, Takeshi] Keio Univ, Sch Med, Dept Adv Therapy Musculoskeletal Disorders, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.
   [Kobayashi, Tami] Keio Univ, Sch Med, Dept Musculoskeletal Reconstruct & Regenerat Surg, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.
   [Morita, Mayu] Keio Univ, Sch Med, Dept Dent & Oral Surg, Div Oral & Maxillofacial Surg,Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.
   [Matsumoto, Yoshihiro] Chugai Pharmaceut Co Ltd, Fuji Gotemba Res Labs, Prod Res Dept, 1 135 Komakado, Gotemba, Shizuoka S, Japan.
C3 Keio University; Keio University; Keio University; Keio University;
   Chugai Pharmaceutical Co., Ltd.; Roche Holding; Roche Holding Japan
RP Miyamoto, T (通讯作者)，Keio Univ, Sch Med, Dept Orthoped Surg, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.
EM miyamoto@z5.keio.jp
RI ; Nakamura, Masaya/K 4111 2013; Matsumoto, Yoichiro/M 4093 2014
OI Morita, Mayu/0009 0003 8092 0762; Matsumoto,
   Yoshihiro/0009 0005 2276 9341
FU Japan Agency for Medical Research and Development in Japan;
   Translational Research Network Program; Chugai pharmaceutical company;
   Grants in Aid for Scientific Research [16K10917, 15H04963, 15K10490]
   Funding Source: KAKEN
FX Y. Sato, K. Miyamoto and T. Miyamoto were supported by a grant in aid
   for Scientific Research in Japan. T. Miyamoto was also supported by a
   grant from Japan Agency for Medical Research and Development in Japan.
   This study was supported in part by a Grant in aid for Scientific
   Research, the Translational Research Network Program and Chugai
   pharmaceutical company.
CR Abrahamsen B, 2009, OSTEOPOROSIS INT, V20, P1633, DOI 10.1007/s00198 009 0920 3
   Bauss F, 2004, OSTEOPOROSIS INT, V15, P423, DOI 10.1007/s00198 004 1612 7
   Bikle DD, 2015, BONE, V80, P79, DOI 10.1016/j.bone.2015.04.036
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874
   Boström P, 2012, NATURE, V481, P463, DOI 10.1038/nature10777
   BRIGHTON CT, 1988, J ORTHOP RES, V6, P676, DOI 10.1002/jor.1100060509
   Brocca L, 2012, J PHYSIOL LONDON, V590, P5211, DOI 10.1113/jphysiol.2012.240267
   Caillot Augusseau A, 1998, CLIN CHEM, V44, P578
   Cooper C, 2013, CALCIFIED TISSUE INT, V93, P201, DOI 10.1007/s00223 013 9757 z
   Corrado A, 2007, JOINT BONE SPINE, V74, P32, DOI 10.1016/j.jbspin.2006.06.005
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   Cruz Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034
   Dutt V, 2015, PHARMACOL RES, V99, P86, DOI 10.1016/j.phrs.2015.05.010
   Ettinger MP, 2003, ARCH INTERN MED, V163, P2237, DOI 10.1001/archinte.163.18.2237
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Guenther A, 2010, INT J CANCER, V126, P239, DOI 10.1002/ijc.24758
   Hiraga T, 2001, CANCER RES, V61, P4418
   Janssen I, 2004, AM J EPIDEMIOL, V159, P413, DOI 10.1093/aje/kwh058
   JUNG A, 1973, CALC TISS RES, V11, P269, DOI 10.1007/BF02547227
   Kodama Y, 1999, BONE, V25, P183, DOI 10.1016/S8756 3282(99)00155 6
   KU Z, 1994, AM J PHYSIOL, V267, pC115, DOI 10.1152/ajpcell.1994.267.1.C115
   Lee SW, 2004, J AM SOC NEPHROL, V15, P1537, DOI 10.1097/01.ASN.0000127211.86206.E1
   Maki BE, 1997, J AM GERIATR SOC, V45, P313, DOI 10.1111/j.1532 5415.1997.tb00946.x
   Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110
   Muscaritoli M, 2006, EUR J CANCER, V42, P31, DOI 10.1016/j.ejca.2005.07.026
   NIHPanel, 2001, JAMA J AM MED ASSOC, V285, P785, DOI DOI 10.1001/JAMA.285.6.785
   Relizani K, 2014, MOL THER, V22, P1423, DOI 10.1038/mt.2014.90
   ROBBINS AS, 1989, ARCH INTERN MED, V149, P1628, DOI 10.1001/archinte.149.7.1628
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Schakman O, 2013, INT J BIOCHEM CELL B, V45, P2163, DOI 10.1016/j.biocel.2013.05.036
   Siris E, 2014, OSTEOPOROSIS INT, V25, P1439, DOI 10.1007/s00198 014 2655 z
   Skelton DA, 2002, AGE AGEING, V31, P119, DOI 10.1093/ageing/31.2.119
   Smith SM, 1998, J CLIN ENDOCR METAB, V83, P3584, DOI 10.1210/jc.83.10.3584
   Suetta C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051238
   Tanaka K, 2012, J BIOL CHEM, V287, P11616, DOI 10.1074/jbc.M111.292193
   Tanaka K, 2012, BIOCHEM BIOPH RES CO, V418, P134, DOI 10.1016/j.bbrc.2011.12.147
   Tando T, 2016, J BIOL CHEM, V291, P12184, DOI 10.1074/jbc.M115.680579
   Tipton KD, 2013, NESTLE NUTR WORKS SE, V75, P51, DOI 10.1159/000345818
   WHIPPLE RH, 1987, J AM GERIATR SOC, V35, P13, DOI 10.1111/j.1532 5415.1987.tb01313.x
   WHITE MJ, 1984, Q J EXP PHYSIOL CMS, V69, P685, DOI 10.1113/expphysiol.1984.sp002860
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   Youm T, 1999, Am J Orthop (Belle Mead NJ), V28, P190
   Zeng QQ, 1996, BONE, V19, P13, DOI 10.1016/8756 3282(96)00112 3
NR 44
TC 17
Z9 17
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD NOV 25
PY 2016
VL 480
IS 4
BP 662
EP 668
DI 10.1016/j.bbrc.2016.10.112
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA ED7DH
UT WOS:000389015400026
PM 27983979
DA 2025 08 17
ER

PT J
AU Choi, BY
   Park, CH
   Na, YH
   Bai, HW
   Cho, JY
   Chung, BY
AF Choi, Bo Yun
   Park, Chul Hong
   Na, Yun Hee
   Bai, Hyoung Woo
   Cho, Jae Young
   Chung, Byung Yeoup
TI Inhibition of RANKL induced osteoclast differentiation through the
   downregulation of c Fos and NFATc1 by Eremochloa ophiuroides
   (centipedegrass) extract
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE osteoclast; osteoclastogenesis; Eremochloa ophiuroides; centipedegrass;
   receptor activator of nuclear factor kappa B ligand; bone
ID NF KAPPA B; RAW 264.7 CELLS; BONE RESORPTION; GIANT CELLS; DC STAMP;
   EXPRESSION; INDUCTION; PATHWAYS; FUSION
AB Osteoclasts, derived from hematopoietic stem cells, are specialized macrophages and have a homeostatic role in skeletal modeling and remodeling with bone forming osteoblasts. However, excessive osteoclast activity induces bone diseases, including osteoporosis, periodontitis and rheumatoid arthritis. Natural substances have received attention as therapeutic drugs in human diseases. In the current study, cells isolated from mouse bone marrow, and a mouse model, were used to determine the effect of centipedegrass extract (CGE) on osteoclasts. Multiple concentrations of CGE were administered to bone marrow cells for 24 72 hours and, for the in vivo study, mice were treated with CGE for 8 days. The effects of CGE on transcription and translation of osteoclast associated molecules were then determined using reverse transcription polymerase chain reaction and immunoblotting, respectively. In the present study it was shown that CGE extracted from Eremochloa ophiuroides (centipedegrass) inhibited receptor activator of nuclear factor. B ligand (RANKL) mediated osteoclast differentiation in bone marrow macrophages, without cytotoxicity, in a dose dependent manner. CGE decreased the expression levels of osteoclast specific genes, including matrix metalloproteinase 9, osteoclast associated immunoglobulin like receptor and cathepsin K, however, CGE had no inhibitory effect on the expression levels of mitogen activated protein kinases, nuclear factor kappa B and Akt. Furthermore, the protein and RNA levels of RANKL induced c Fos and nuclear factor of activated T cell cytoplasmic 1 were suppressed by CGE. These results indicated that CGE may serve as a useful drug in the prevention of bone loss.
C1 [Choi, Bo Yun; Park, Chul Hong; Na, Yun Hee; Bai, Hyoung Woo; Chung, Byung Yeoup] Korea Atom Energy Res Inst, Res Div Biotechnol, Adv Radiat Technol Inst, 1266 Sinjeong Dong, Jeongeup 580185, North Jeolla, South Korea.
   [Park, Chul Hong] Chonnam Natl Univ, Sch Biol Sci & Biotechnol, Kwangju 500757, South Korea.
   [Na, Yun Hee] Chonnam Natl Univ, Interdisciplinary Grad Program Mol Med, Kwangju 500757, South Korea.
   [Cho, Jae Young] Chonbuk Natl Univ, Dept Appl Life Sci, Jeonju 561756, North Jeolla, South Korea.
C3 Korea Atomic Energy Research Institute (KAERI); Chonnam National
   University; Chonnam National University; Jeonbuk National University
RP Chung, BY (通讯作者)，Korea Atom Energy Res Inst, Res Div Biotechnol, Adv Radiat Technol Inst, 1266 Sinjeong Dong, Jeongeup 580185, North Jeolla, South Korea.
EM bychung@kaeri.re.kr
RI Cho, Jae Young/A 7013 2013
FU National Research Foundation of Korea; Korean Ministry of Science, ICT
   and Future Planning
FX This study was supported by the National Research Foundation of Korea,
   funded by the Korean Ministry of Science, ICT and Future Planning.
CR Badaboina S, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472 6882 13 350
   Barampuram S, 2009, IN VITRO CELL DEV PL, V45, P155, DOI 10.1007/s11627 009 9199 5
   Choi HJ, 2010, EUR J PHARMACOL, V636, P28, DOI 10.1016/j.ejphar.2010.03.023
   Choi J, 2013, CELL SIGNAL, V25, P1222, DOI 10.1016/j.cellsig.2013.02.015
   Fumimoto R, 2012, J PHARMACOL SCI, V118, P479, DOI 10.1254/jphs.11212FP
   Ghayor C, 2011, J BIOL CHEM, V286, P24458, DOI 10.1074/jbc.M111.223297
   Han KY, 2007, BIOCHEM PHARMACOL, V74, P911, DOI 10.1016/j.bcp.2007.06.044
   Kim BG, 2010, ANAT CELL BIOL, V43, P310, DOI 10.5115/acb.2010.43.4.310
   Kim HH, 2004, BIOCHEM PHARMACOL, V67, P1647, DOI 10.1016/j.bcp.2003.12.031
   Kim HJ, 2012, LIFE SCI, V91, P928, DOI 10.1016/j.lfs.2012.09.009
   Kwak HB, 2006, EXP MOL MED, V38, P256, DOI 10.1038/emm.2006.31
   Kwak HB, 2010, BONE, V46, P724, DOI 10.1016/j.bone.2009.10.042
   Mochizuki A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048795
   National Research Council (US), 2011, NAT RES COUNC US COM
   Nepal M, 2013, EUR J PHARMACOL, V715, P96, DOI 10.1016/j.ejphar.2013.06.002
   Park HJ, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472 6882 12 230
   Park YR, 2009, KOREAN J PHYSIOL PHA, V13, P417, DOI 10.4196/kjpp.2009.13.6.417
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   WISEMAN BR, 1990, J CHEM ECOL, V16, P2677, DOI 10.1007/BF00988078
   Yagi M, 2005, J EXP MED, V202, P345
   Yagi M, 2006, J BONE MINER METAB, V24, P355, DOI 10.1007/s00774 006 0697 9
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
NR 22
TC 11
Z9 18
U1 0
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD MAY
PY 2016
VL 13
IS 5
BP 4014
EP 4022
DI 10.3892/mmr.2016.5015
PG 9
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA DI6BA
UT WOS:000373583000038
PM 27035226
OA Bronze
DA 2025 08 17
ER

PT J
AU Kim, KJ
   Lee, J
   Wang, W
   Lee, Y
   Oh, E
   Park, KH
   Park, C
   Woo, GE
   Son, YJ
   Kang, H
AF Kim, Kwang Jin
   Lee, Jusung
   Wang, Weihong
   Lee, Yongjin
   Oh, Eunseok
   Park, Kyu Hyung
   Park, Chanyoon
   Woo, Gee Eun
   Son, Young Jin
   Kang, Heonjoong
TI Austalide K from the Fungus Penicillium rudallense Prevents
   LPS Induced Bone Loss in Mice by Inhibiting Osteoclast Differentiation
   and Promoting Osteoblast Differentiation
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE marine fungus; osteoporosis; bone diseases; bone remodeling
ID POSTMENOPAUSAL WOMEN; STEM CELLS; IN VITRO; OSTEOPOROSIS; MECHANISMS;
   INSIGHTS; BIOLOGY
AB Osteoporosis is a chronic disease that has become a serious public health problem due to the associated reduction in quality of life and its increasing financial burden. It is known that inhibiting osteoclast differentiation and promoting osteoblast formation prevents osteoporosis. As there is no drug with this dual activity without clinical side effects, new alternatives are needed. Here, we demonstrate that austalide K, isolated from the marine fungus Penicillium rudallenes, has dual activities in bone remodeling. Austalide K inhibits the receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast differentiation and improves bone morphogenetic protein (BMP) 2 mediated osteoblast differentiation in vitro without cytotoxicity. The nuclear factor of activated T cells c1 (NFATc1), tartrate resistant acid phosphatase (TRAP), dendritic cell specific transmembrane protein (DC STAMP), and cathepsin K (CTSK) osteoclast formation related genes were reduced and alkaline phosphatase (ALP), runt related transcription factor 2 (Runx2), osteocalcin (OCN), and osteopontin (OPN) (osteoblast activation related genes) were simultaneously upregulated by treatment with austalide K. Furthermore, austalide K showed good efficacy in an LPS induced bone loss in vivo model. Bone volume, trabecular separation, trabecular thickness, and bone mineral density were recovered by austalide K. On the basis of these results, austalide K may lead to new drug treatments for bone diseases such as osteoporosis.
C1 [Kim, Kwang Jin; Lee, Yongjin; Son, Young Jin] Sunchon Natl Univ, Dept Pharm, 315 Maegok Dong, Sunchon 57922, South Korea.
   [Lee, Jusung; Wang, Weihong; Oh, Eunseok; Park, Kyu Hyung; Woo, Gee Eun; Kang, Heonjoong] Seoul Natl Univ, Sch Earth & Environm Sci, Lab Marine Drugs, NS 80, Seoul 08826, South Korea.
   [Wang, Weihong; Park, Chanyoon; Kang, Heonjoong] Seoul Natl Univ, Interdisciplinary Grad Program Genet Engn, NS 80, Seoul 08826, South Korea.
   [Kang, Heonjoong] Seoul Natl Univ, Res Inst Oceanog, NS 80, Seoul 08826, South Korea.
C3 Sunchon National University; Seoul National University (SNU); Seoul
   National University (SNU); Seoul National University (SNU)
RP Son, YJ (通讯作者)，Sunchon Natl Univ, Dept Pharm, 315 Maegok Dong, Sunchon 57922, South Korea.; Kang, H (通讯作者)，Seoul Natl Univ, Sch Earth & Environm Sci, Lab Marine Drugs, NS 80, Seoul 08826, South Korea.; Kang, H (通讯作者)，Seoul Natl Univ, Interdisciplinary Grad Program Genet Engn, NS 80, Seoul 08826, South Korea.; Kang, H (通讯作者)，Seoul Natl Univ, Res Inst Oceanog, NS 80, Seoul 08826, South Korea.
EM mastiffk@naver.com; leejusung@snu.ac.kr; pharmacy2007@naver.com;
   yojilee@gmail.com; dmstjr0130@snu.ac.kr; grekhp@snu.ac.kr;
   chanyoon0126@snu.ac.kr; tddok7953@naver.com; sony@scnu.ac.kr;
   hjkang@snu.ac.kr
RI Jin Ho, Seo/B 3621 2014
FU Basic Science Research Program   Ministry of Science, ICT & Future
   Planning [NRF 2015M1A5A1037572]; National Research Foundation of Korea
   (NRF); Center for Women in Science, Engineering and Technology (WISET)  
   Ministry of Science and ICT under the Program for Returners into RD;
   Ministry of Science, ICT & Future Planning [NRF 2019R1A2C2005492]
FX This work was supported by the Basic Science Research Program funded by
   the Ministry of Science, ICT & Future Planning (NRF 2015M1A5A1037572)
   and by the Ministry of Science and ICT (NRF 2019R1A2C2005492). This work
   was also in part supported by the National Research Foundation of Korea
   (NRF) and the Center for Women in Science, Engineering and Technology
   (WISET) Grant funded by the Ministry of Science and ICT under the
   Program for Returners into R&D.
CR Blunt JW, 2015, NAT PROD REP, V32, P116, DOI 10.1039/c4np00144c
   Carson MA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207303
   Chung HJ, 2017, J NAT PROD, V80, P434, DOI 10.1021/acs.jnatprod.6b00964
   Eastell R, 2019, J CLIN ENDOCR METAB, V104, P1595, DOI 10.1210/jc.2019 00221
   Edwards JR, 2011, NAT REV RHEUMATOL, V7, P235, DOI 10.1038/nrrheum.2011.23
   Fleisch H, 2003, AGING SPINE, V12, P60
   French DL, 2008, PHYTOMEDICINE, V15, P1069, DOI 10.1016/j.phymed.2008.06.007
   Fuller K, 2008, BONE, V42, P200, DOI 10.1016/j.bone.2007.09.044
   Gallagher JC, 2010, MATURITAS, V65, P301, DOI 10.1016/j.maturitas.2010.01.002
   Hayman AR, 2000, J HISTOCHEM CYTOCHEM, V48, P219, DOI 10.1177/002215540004800207
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Jönsson S, 2012, J BONE MINER METAB, V30, P119, DOI 10.1007/s00774 011 0323 3
   JonvilleBera A.P., 2011, Presse Med, V40, P453
   Karsenty G, 2000, SEMIN CELL DEV BIOL, V11, P343, DOI 10.1006/scdb.2000.0188
   Kessenich C R, 1997, Rehabil Nurs, V22, P192
   Kim H, 2014, MAR DRUGS, V12, P2054, DOI 10.3390/md12042054
   Koyama T, 2011, ADV FOOD NUTR RES, V64, P443, DOI 10.1016/B978 0 12 387669 0.00034 X
   Li J, 2015, SCI REP UK, V5, DOI 10.1038/srep17605
   Ohara N, 2004, BIOMATERIALS, V25, P1749, DOI 10.1016/j.biomaterials.2003.08.022
   Papapetrou PD, 2009, HORM INT J ENDOCRINO, V8, P96, DOI 10.14310/horm.2002.1226
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Shikov AN, 2020, MAR DRUGS, V18, DOI 10.3390/md18110557
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Welton JL, 2013, J BONE MINER RES, V28, P464, DOI 10.1002/jbmr.1797
   Yagi M, 2007, J BONE MINER RES, V22, P992, DOI 10.1359/JBMR.070401
   Yeon JT, 2016, J NAT PROD, V79, P1730, DOI 10.1021/acs.jnatprod.6b00004
   Yeon JT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088974
   Zhang X, 2006, CALCIFIED TISSUE INT, V79, P169, DOI 10.1007/s00223 006 0083 6
   Zhou YM, 2014, TETRAHEDRON LETT, V55, P2789, DOI 10.1016/j.tetlet.2014.02.062
   Zhuravleva OI, 2014, J NAT PROD, V77, P1390, DOI 10.1021/np500151b
NR 32
TC 12
Z9 15
U1 0
U2 17
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUN
PY 2021
VL 22
IS 11
AR 5493
DI 10.3390/ijms22115493
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA SQ2QU
UT WOS:000660203000001
PM 34071042
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU István, G
   Nikolette, S
AF Istvan, Gera
   Nikolette, Szucs
TI The recombinant human parathyroid hormone, teriparatide as an
   alternative remedy for the medication related osteonecrosis of the jaw
SO ORVOSI HETILAP
LA English
DT Article
DE osteoporosis; anabolic pharmacological effect of human parathyroid
   hormone; antiresorptive drug thera py; medication related osteonecrosis
   of the jaw
ID BISPHOSPHONATE RELATED OSTEONECROSIS; BONE MINERAL DENSITY;
   GLUCOCORTICOID INDUCED OSTEOPOROSIS; POSTMENOPAUSAL WOMEN; OSSEOUS
   REGENERATION; VERTEBRAL FRACTURE; HUMAN PTH(1 34); DOUBLE BLIND; MASS;
   THERAPY
AB In developed countries, osteoporosis is one of the most common debilitating conditions in the population over the age of 50. Unfortunately, the pathomechanism of the disease is still not fully understood. Nowadays, the administration of antiresorptive drugs blocking osteoclastic activity is the most commonly used medication to slow down the speed of the bone loss. One of the uncommon side effects of such drugs is the medication related osteonecrosis of the jaw (MRONJ). Recently, a number of alternative therapeutic approaches has been tested and published, amongst them the recombinant human parathyroid hormone (rhPTH, teriparatide) use, which is turning into a promising treatment modality. According to certain meta analyses, its pharmacological effect on increasing bone mineral density and controlling pathological vertebral fractures is superior to antiresorptive drugs; however, the so called "off label" application of teriparatide remains controversial. As intermittent administration of teriparatide stimulates bone for mation, several animal and clinical studies indicated that systemic application of teriparatide shortened fracture healing time and improved quality of the callus and the newly formed bone. Furthermore, recently several clinical studies showed the beneficial effect of the intermittent rhPTH administration in the management of MRONJ. This article reviews the history of the anabolic effect of the low dose rhPTH discovery, provides evidence based data from animal and human studies, summarizes its biological mechanisms and the clinical benefits of the anabolic therapy and also their possible role in the management of MRONJ. The majority of the clinical data indicates that, in the case of therapy resistant osteonecrosis, it may be worthwhile to apply short term intermittent teriparatide therapy. Notwithstanding, more randomized clinical trials are necessary in order to confirm the efficacy and the safety of the use of teriparatide in the treatment of MRONJ.
C1 [Istvan, Gera] Semmelweis Egyet, Fogorvostud Kar, Parodontol Klin, Budapest, Hungary.
   [Nikolette, Szucs] Semmelweis Egyet, Altalanos Orvostud Kar, Belgyogyaszati & Hematol Klin, Budapest, Hungary.
   [Istvan, Gera] Szentkiralyi U 47, H 1088 Budapest, Hungary.
C3 Semmelweis University; Semmelweis University
RP István, G (通讯作者)，Szentkiralyi U 47, H 1088 Budapest, Hungary.
EM gera.istvan@dent.semmelweis univ.hu
CR Alkhiary YM, 2005, J BONE JOINT SURG AM, V87A, P731, DOI 10.2106/JBJS.D.02115
   Anabtawi M, 2021, INT J ORAL MAX SURG, V50, P501, DOI 10.1016/j.ijom.2020.07.021
   Aspenberg P, 2010, J BONE MINER RES, V25, P404, DOI 10.1359/jbmr.090731
   Bashutski JD, 2012, CLIN ADV PERIODONTIC, V2, P66, DOI 10.1902/cap.2012.110043
   Bashutski JD, 2010, NEW ENGL J MED, V363, P2396, DOI 10.1056/NEJMoa1005361
   Bhandari M, 2016, CLIN ORTHOP RELAT R, V474, P1234, DOI 10.1007/s11999 015 4669 z
   Bouxsein ML, 2009, J BONE JOINT SURG AM, V91A, P1329, DOI 10.2106/JBJS.H.01030
   Brommage R, 1999, J CLIN ENDOCR METAB, V84, P3757, DOI 10.1210/jc.84.10.3757
   Burr DB, 2001, J BONE MINER RES, V16, P157, DOI 10.1359/jbmr.2001.16.1.157
   Campbell EJ, 2015, EXPERT OPIN BIOL TH, V15, P119, DOI 10.1517/14712598.2015.977249
   Chan HL, 2013, J DENT RES, V92, P18, DOI 10.1177/0022034512464779
   Chopra K, 2021, AM J THER, V28, pE469, DOI 10.1097/MJT.0000000000001182
   Collinge C, 2016, INJURY, V47, pS36, DOI 10.1016/S0020 1383(16)30009 2
   Cosman F, 2001, J BONE MINER RES, V16, P925, DOI 10.1359/jbmr.2001.16.5.925
   Dayisoylu EH, 2013, INT J ORAL MAX SURG, V42, P1475, DOI 10.1016/j.ijom.2013.05.001
   Díez Pérez A, 2019, BONE, V120, P1, DOI 10.1016/j.bone.2018.09.020
   Dobnig H, 2009, J BONE MINER RES, V24, P1998, DOI [10.1359/JBMR.090527, 10.1359/jbmr.090527]
   Ferreira LD, 2021, OSTEOPOROSIS INT, V32, P2449, DOI 10.1007/s00198 021 06078 z
   Ebeling PR, 2003, INT J CLIN PRACT, V57, P710
   Fung PPL, 2017, ORAL DIS, V23, P477, DOI 10.1111/odi.12632
   GERA I, 1987, CALCIFIED TISSUE INT, V40, P206, DOI 10.1007/BF02556623
   Gera I, 1989, J Bone Miner Res, V4, pS744
   Geusens P, 2018, J BONE MINER RES, V33, P783, DOI 10.1002/jbmr.3384
   Greenspan SL, 2007, ANN INTERN MED, V146, P326, DOI 10.7326/0003 4819 146 5 200703060 00005
   Grover HS, 2013, J CLIN DIAGN RES, V7, P1820, DOI 10.7860/JCDR/2013/5893.3280
   GUNNESSHEY M, 1986, CALCIFIED TISSUE INT, V38, P234, DOI 10.1007/BF02556716
   GUNNESSHEY M, 1988, CALCIFIED TISSUE INT, V43, P284, DOI 10.1007/BF02556637
   Han SL, 2012, INT J CLIN PRACT, V66, P199, DOI 10.1111/j.1742 1241.2011.02837.x
   Harper RP, 2007, J ORAL MAXIL SURG, V65, P573, DOI 10.1016/j.joms.2006.10.076
   Haseman JK, 1998, TOXICOL PATHOL, V26, P428, DOI 10.1177/019262339802600318
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Hock J. M., 2001, Journal of Musculoskeletal & Neuronal Interactions, V2, P33
   HOCK JM, 1992, J BONE MINER RES, V7, P65, DOI 10.1002/jbmr.5650070110
   HOCK JM, 1988, ENDOCRINOLOGY, V122, P2899, DOI 10.1210/endo 122 6 2899
   HOCK JM, 1989, J BONE MINER RES, V4, P449
   Hodsman AB, 1997, J CLIN ENDOCR METAB, V82, P620, DOI 10.1210/jc.82.2.620
   JEROME CP, 1995, BONE, V17, pS415, DOI 10.1016/8756 3282(95)00320 D
   Jerome CP, 2001, BONE, V28, P150, DOI 10.1016/S8756 3282(00)00430 0
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Jung J, 2017, J BONE MINER RES, V32, P2445, DOI 10.1002/jbmr.3237
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P801, DOI [10.1007/s00198 018 4704 5, 10.1007/s00198 020 05303 5, 10.1007/s00223 018 00512 x]
   Keskinruzgar A, 2016, J ORAL MAXIL SURG, V74, P68, DOI 10.1016/j.joms.2015.07.005
   Kim KM, 2014, OSTEOPOROSIS INT, V25, P1625, DOI 10.1007/s00198 014 2622 8
   Kim WJ, 2021, BIOMOL THER, V29, P263
   Kwon Yong Dae, 2016, Dent J (Basel), V4, DOI 10.3390/dj4040041
   Lane NE, 2000, J BONE MINER RES, V15, P944, DOI 10.1359/jbmr.2000.15.5.944
   Langdahl B, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115516
   Lou SH, 2016, BIOMED RES INT UK, V2016, DOI 10.1155/2016/6040379
   Morishita K, 2020, J ORTHOP SCI, V25, P1079, DOI 10.1016/j.jos.2020.01.012
   Nakajima A, 2002, J BONE MINER RES, V17, P2038, DOI 10.1359/jbmr.2002.17.11.2038
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   On SW, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10050680
   Pelaz A, 2014, MED ORAL PATOL ORAL, V19, pE320, DOI 10.4317/medoral.19458
   POTTS JT, 1976, CLIN ENDOCRINOL, V5, pS307, DOI 10.1111/j.1365 2265.1976.tb03839.x
   Pugsley LI, 1933, J PHYSIOL LONDON, V79, P113, DOI 10.1113/jphysiol.1933.sp003032
   Quattrocchi E, 2004, CLIN THER, V26, P841, DOI 10.1016/S0149 2918(04)90128 2
   Reeve J, 2001, J BONE MINER METAB, V19, P102, DOI 10.1007/s007740170048
   Ruggiero SL, 2006, ORAL SURG ORAL MED O, V102, P433, DOI 10.1016/j.tripleo.2006.06.004
   Saag KG, 2009, ARTHRITIS RHEUM US, V60, P3346, DOI 10.1002/art.24879
   Selye H, 1932, ENDOCRINOLOGY, V16, P547, DOI 10.1210/endo 16 5 547
   Shen LX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026267
   Shi ZJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168691
   Sibai T, 2011, CLIN ORTHOP RELAT R, V469, P2215, DOI 10.1007/s11999 010 1722 9
   Sim IW, 2020, J CLIN ONCOL, V38, P2971, DOI 10.1200/JCO.19.02192
   Song JF, 2014, MED SCI MONITOR, V20, P2624, DOI 10.12659/MSM.892581
   Spanou A, 2015, ORAL DIS, V21, P927, DOI 10.1111/odi.12333
   Steen Hacket L, 1987, J Bone Miner Res, V2, P57
   Subramanian G, 2011, ORAL SURG ORAL MED O, V112, P744, DOI 10.1016/j.tripleo.2011.04.020
   Szentpéteri S, 2020, ORVOSI HETILAP, V161, P283, DOI 10.1556/650.2019.31621
   Tashjian AH, 2006, J BONE MINER RES, V21, P354, DOI 10.1359/JBMR.051023
   Tsai JN, 2019, LANCET DIABETES ENDO, V7, P767, DOI 10.1016/S2213 8587(19)30255 4
   Tsai JN, 2013, LANCET, V382, P50, DOI 10.1016/S0140 6736(13)60856 9
   Wang YK, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006970
   Zandi M, 2017, J CRANIO MAXILL SURG, V45, P275, DOI 10.1016/j.jcms.2016.12.010
   Zhang L, 1997, BONE, V21, P501, DOI 10.1016/S8756 3282(97)00198 1
NR 75
TC 3
Z9 3
U1 2
U2 5
PU AKADEMIAI KIADO ZRT
PI BUDAPEST
PA BUDAFOKI UT 187 189 A 3, H 1117 BUDAPEST, HUNGARY
SN 0030 6002
EI 1788 6120
J9 ORVOSI HETILAP
JI Orvosi Hetilap
PD SEP
PY 2023
VL 164
IS 36
BP 1406
EP 1415
DI 10.1556/650.2023.32861
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA U1WF1
UT WOS:001082766500001
PM 37695713
OA hybrid
DA 2025 08 17
ER

PT J
AU Alvarez, MB
   Childress, P
   Philip, BK
   Gerard O'Riley, R
   Hanlon, M
   Herbert, BS
   Robling, AG
   Pavalko, FM
   Bidwell, JP
AF Alvarez, Marta B.
   Childress, Paul
   Philip, Binu K.
   Gerard O'Riley, Rita
   Hanlon, Michael
   Herbert, Brittney Shea
   Robling, Alexander G.
   Pavalko, Fredrick M.
   Bidwell, Joseph P.
TI Immortalization and characterization of osteoblast cell lines generated
   from wild type and Nmp4 null mouse bone marrow stromal cells using
   murine telomerase reverse transcriptase (mTERT)
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID MESENCHYMAL STEM CELLS; ZINC FINGER PROTEIN; PARATHYROID HORMONE;
   TRABECULAR BONE; PTH; DIFFERENTIATION; EXPRESSION; PROLIFERATION;
   NETWORKS; CULTURES
AB Intermittent parathyroid hormone (PTH) adds new bone to the osteoporotic skeleton; the transcription factor Nmp4/CIZ represses PTH induced bone formation in mice and as a consequence is a potential drug target for improving hormone clinical efficacy. To explore the impact of Nmp4/CIZ on osteoblast phenotype, we immortalized bone marrow stromal cells from wildtype (WT) and Nmp4 knockout (KO) mice using murine telomerase reverse transcriptase. Clonal lines were initially chosen based on their positive staining for alkaline phosphatase and capacity for mineralization. Disabling Nmp4/CIZ had no gross impact on osteoblast phenotype development. WT and KO clones exhibited identical sustained growth, reduced population doubling times, extended maintenance of the mature osteoblast phenotype, and competency for differentiating toward the osteoblast and adipocyte lineages. Additional screening of the immortalized cells for PTH responsiveness permitted further studies with single WT and KO clones. We recently demonstrated that PTH induced c fos femoral mRNA expression is enhanced in Nmp4 KO mice and in the present study we observed that hormone stimulated either an equivalent or modestly enhanced increase in c fos mRNA expression in both primary null and KO clone cells depending on PTH concentration. The null primary osteoblasts and KO clone cells exhibited a transiently enhanced response to bone morphogenetic protein 2 (BMP2). The clones exhibited lower and higher expressions of the PTH receptor (Pthr1) and the BMP2 receptor (Bmpr1a, Alk3), respectively, as compared to primary cells. These immortalized cell lines will provide a valuable tool for disentangling the complex functional roles underlying Nmp4/CIZ regulation of bone anabolism. J. Cell. Physiol. 227: 18731882, 2012. (C) 2011 Wiley Periodicals, Inc.
C1 [Alvarez, Marta B.; Childress, Paul; Hanlon, Michael; Robling, Alexander G.; Bidwell, Joseph P.] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
   [Philip, Binu K.] Bristol Myers Squibb, Drug Safety & Evaluat, Mt Vernon, IA USA.
   [Gerard O'Riley, Rita; Pavalko, Fredrick M.] Indiana Univ Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA.
   [Herbert, Brittney Shea] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.
   [Robling, Alexander G.] Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington; Bristol Myers
   Squibb; Indiana University System; Indiana University Bloomington;
   Indiana University System; Indiana University Bloomington; Purdue
   University System; Purdue University; Purdue University in Indianapolis
RP Bidwell, JP (通讯作者)，Indiana Univ Sch Med, Dept Anat & Cell Biol, Med Sci Bldg 5035,635 Barnhill Dr, Indianapolis, IN 46202 USA.
EM fpavalko@iupui.edu; jbidwell@iupui.edu
RI Childress, Paul/AAD 4684 2020
FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
   [DK053796]; National Institute of Arthritis and Musculoskeletal and Skin
   Diseases (NIAMS) [AR052682]; NIH National Institute of Diabetes and
   Digestive and Kidney Diseases (NIDDK) [DK053796]; NIH The National
   Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
   [AR052682]
FX Contract grant sponsor: National Institute of Diabetes and Digestive and
   Kidney Diseases (NIDDK);Contract grant number: DK053796.Contract grant
   sponsor: The National Institute of Arthritis and Musculoskeletal and
   Skin Diseases (NIAMS);Contract grant number: AR052682.This work was
   supported by a grant from NIH National Institute of Diabetes and
   Digestive and Kidney Diseases (NIDDK), contract grant number DK053796
   (JPB) and from NIH The National Institute of Arthritis and
   Musculoskeletal and Skin Diseases (NIAMS), AR052682 (FMP).
CR Abdallah BM, 2005, BIOCHEM BIOPH RES CO, V326, P527, DOI 10.1016/j.bbrc.2004.11.059
   Allan EH, 2008, J BONE MINER RES, V23, P1170, DOI 10.1359/JBMR.080324
   Alvarez M, 1998, J CELL BIOCHEM, V69, P336, DOI 10.1002/(SICI)1097 4644(19980601)69:3<336::AID JCB11>3.0.CO;2 A
   Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717
   Bianco P, 1999, CRIT REV EUKAR GENE, V9, P159, DOI 10.1615/CritRevEukarGeneExpr.v9.i2.30
   Birge RB, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478 811X 7 13
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097 4644(199702)64:2<278::AID JCB11>3.0.CO;2 F
   BRYANT JC, 1958, JNCI J NATL CANCER I, V21, P331
   Childress P, 2011, CALCIFIED TISSUE INT, V89, P74, DOI 10.1007/s00223 011 9496 y
   Childress P, 2010, BONE, V46, P259, DOI 10.1016/j.bone.2009.09.014
   Datta NS, 2009, CELL SIGNAL, V21, P1245, DOI 10.1016/j.cellsig.2009.02.012
   de Freitas PHL, 2009, J BONE MINER RES, V24, P1586, DOI [10.1359/JBMR.090413, 10.1359/jbmr.090413]
   de Paula FJA, 2010, HORM METAB RES, V42, P299, DOI 10.1055/s 0030 1248255
   Delany AM, 2003, ENDOCRINOLOGY, V144, P2588, DOI 10.1210/en.2002 221044
   Horiuchi H, 2004, J BONE MINER METAB, V22, P329, DOI 10.1007/s00774 003 0490 y
   Huang GP, 2008, J CELL BIOCHEM, V103, P1256, DOI 10.1002/jcb.21502
   Huang JC, 2004, J BONE MINER RES, V19, P235, DOI 10.1359/JBMR.0301226
   Irie N, 2009, J BIOL CHEM, V284, P14637, DOI 10.1074/jbc.M807598200
   Kempen DHR, 2010, TISSUE ENG PT A, V16, P3769, DOI [10.1089/ten.tea.2010.0173, 10.1089/ten.TEA.2010.0173]
   Koh AJ, 2005, ENDOCRINOLOGY, V146, P4584, DOI 10.1210/en.2005 0333
   Lecka Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097 4644(19990901)74:3<357::AID JCB5>3.0.CO;2 7
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Mödder UI, 2008, J CELL BIOCHEM, V103, P393, DOI 10.1002/jcb.21423
   Morinobu M, 2005, J EXP MED, V201, P961, DOI 10.1084/jem.20041097
   Nakamoto T, 2000, MOL CELL BIOL, V20, P1649, DOI 10.1128/MCB.20.5.1649 1658.2000
   Nakao Y, 2009, BONE, V44, P872, DOI 10.1016/j.bone.2009.01.370
   Philip BK, 2010, AM J PHYSIOL ENDOC M, V298, pE714, DOI 10.1152/ajpendo.00564.2009
   Robling AG, 2009, J CELL PHYSIOL, V219, P734, DOI 10.1002/jcp.21717
   Sawada Y, 2006, CELL, V127, P1015, DOI 10.1016/j.cell.2006.09.044
   Shah R, 2004, AM J PHYSIOL ENDOC M, V287, pE289, DOI 10.1152/ajpendo.00517.2003
   Shen ZJ, 2002, J BIOL CHEM, V277, P29840, DOI 10.1074/jbc.M203157200
   Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602 592
   Wagner EF, 2010, ANN RHEUM DIS, V69, P86, DOI 10.1136/ard.2009.119396
   Wang YH, 2007, AM J PHYSIOL ENDOC M, V292, pE594, DOI 10.1152/ajpendo.00216.2006
   Yang ZQ, 2010, J CELL PHYSIOL, V223, P435, DOI 10.1002/jcp.22057
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
NR 37
TC 13
Z9 20
U1 0
U2 5
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD MAY
PY 2012
VL 227
IS 5
BP 1873
EP 1882
DI 10.1002/jcp.22915
PG 10
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA 879ZS
UT WOS:000299373900011
PM 21732358
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Nanke, Y
   Kotake, S
   Ninomiya, T
   Furuya, T
   Ozawa, H
   Kamatani, N
AF Nanke, Y
   Kotake, S
   Ninomiya, T
   Furuya, T
   Ozawa, H
   Kamatani, N
TI Geranylgeranylacetone inhibits formation and function of human
   osteoclasts and prevents bone loss in tail suspended rats and
   ovariectomized rats
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE osteoclast; bone mineral density; osteoporosis; space flight;
   bisphosphonate
ID NITROGEN CONTAINING BISPHOSPHONATES; MEVALONATE PATHWAY; PROTEIN
   GERANYLGERANYLATION; T CELLS; RESORPTION; DIFFERENTIATION;
   MENATETRENONE; EXPRESSION; KINASE; LIGAND
AB Vitamin K is used for protecting against osteoporosis. Recently, it has been reported that the inhibitory effect of vitamin K 2 (menatetrenone) on bone resorption may be related to its side chain. Geranylgeranylacetone (GGA), known as teprenone, an antiulcer drug, has almost the same chemical structure as that of the side chain of menatetrenone. We hypothesized that GGA also has an inhibitory effect on osteoclastogenesis both in vitro and in vivo. GGA in pharmacological concentrations directly inhibited osteoclastogenesis from human monocytes induced by soluble receptor activator of nuclear factor kappa B ligand. In addition, GGA induced degradation of actin rings in mature osteoclasts, which was reversed by adding geranylgeranylpyrophosphatase. Moreover, GGA increased the bone mineral density of total femur, proximal metaphysis, and diaphysis of femur in ovariectomized rats. GGA also prevented bone loss induced by hindlimb unloading in tail suspended rats. These results indicate that GGA prevents bone loss by maintaining a positive balance of bone turnover through suppression of both the formation and the activity of osteoclasts. Thus, GGA could be used to prevent and improve osteoporosis.
C1 Tokyo Womens Med Univ, Inst Rheumatol, Shinjuku Ku, Tokyo 1620054, Japan.
   Mastumoto Dent Univ, Inst Oral Sci, Div Hard Tissue Res, Nagano 399078, Japan.
C3 Tokyo Women's Medical University
RP Nanke, Y (通讯作者)，Tokyo Womens Med Univ, Inst Rheumatol, Shinjuku Ku, 10 22 Kawada Cho, Tokyo 1620054, Japan.
EM ynn@ior.twmu.ac.jp
CR AKIYAMA Y, 1994, EUR J PHARMACOL, V263, P181, DOI 10.1016/0014 2999(94)90539 8
   AKIYAMA Y, 1993, JPN J PHARMACOL, V62, P145, DOI 10.1254/jjp.62.145
   Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Garrett IR, 2001, CURR PHARM DESIGN, V7, P715, DOI 10.2174/1381612013397762
   Halasy Nagy JM, 2001, BONE, V29, P553, DOI 10.1016/S8756 3282(01)00615 9
   HARA K, 1993, BONE, V14, P813, DOI 10.1016/8756 3282(93)90309 X
   HARA K, 1993, J BONE MINER RES, V8, P535
   HARA K, 1995, BONE, V16, P179, DOI 10.1016/8756 3282(94)00027 W
   Heer M, 2002, NUTRITION, V18, P853, DOI 10.1016/S0899 9007(02)00905 X
   Hirakawa T, 1996, GASTROENTEROLOGY, V111, P345, DOI 10.1053/gast.1996.v111.pm8690199
   Hirota K, 2000, BIOCHEM BIOPH RES CO, V275, P825, DOI 10.1006/bbrc.2000.3392
   Horwood NJ, 1999, BIOCHEM BIOPH RES CO, V265, P144, DOI 10.1006/bbrc.1999.1623
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703
   Kotake S, 2001, ARTHRITIS RHEUM, V44, P1003, DOI 10.1002/1529 0131(200105)44:5<1003::AID ANR179>3.3.CO;2 R
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Ohnaka K, 2001, BIOCHEM BIOPH RES CO, V287, P337, DOI 10.1006/bbrc.2001.5597
   Okada S, 1999, CELL STRUCT FUNCT, V24, P161, DOI 10.1247/csf.24.161
   Okahashi N, 1997, J BONE MINER RES, V12, P1116, DOI 10.1359/jbmr.1997.12.7.1116
   Ooie T, 2001, CIRCULATION, V104, P1837, DOI 10.1161/hc3901.095771
   Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967
   Rogers MJ, 1999, BONE, V24, p73S, DOI 10.1016/S8756 3282(99)00070 8
   Rokutan K, 2000, J GASTROENTEROL, V35, P673, DOI 10.1007/s005350070046
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Takeuchi Y, 2000, BONE, V27, P769, DOI 10.1016/S8756 3282(00)00396 3
   TETSUYA H, 1999, GASTROENTEROLOGY, V111, P345
   Van Beek ER, 2002, BONE, V30, P64, DOI 10.1016/S8756 3282(01)00655 X
   Vermeer C, 1998, J Gravit Physiol, V5, P65
   Wang XX, 2002, J BONE MINER RES, V17, P91, DOI 10.1359/jbmr.2002.17.1.91
   Woo JT, 2000, J BONE MINER RES, V15, P650, DOI 10.1359/jbmr.2000.15.4.650
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 35
TC 16
Z9 16
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD DEC
PY 2005
VL 77
IS 6
BP 376
EP 385
DI 10.1007/s00223 005 0123 7
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 995ZL
UT WOS:000234144100006
PM 16362462
DA 2025 08 17
ER

PT J
AU Noh, ALSM
   Yang, M
   Lee, JM
   Park, H
   Lee, DS
   Yim, M
AF Noh, A. Long Sae Mi
   Yang, Mihye
   Lee, Jung Min
   Park, Hyojung
   Lee, Dong Seok
   Yim, Mijung
TI Phosphodiesterase 3 and 4 Negatively Regulate Receptor Activator of
   Nuclear Factor κB Ligand Mediated Osteoclast Formation by Prostaglandin
   E2
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE prostaglandin E 2; phosphodiesterase; osteoblast, osteoclast
ID NECROSIS FACTOR RECEPTOR; BONE RESORPTION; OSTEOBLASTIC CELLS;
   PROTEIN KINASE; DIFFERENTIATION; TRANCE/RANKL; INVOLVEMENT; EXPRESSION;
   INHIBITOR; AGONISTS
AB Prostaglandin E 2 (PGE(2)) stimulates osteoclast formation by increasing receptor activator of nuclear factor (NF) kappa B ligand (RANKL) mRNA expression via cAMP protein kinase A (PKA) pathways in osteoblasts. Since phosphodiesterases (PDEs) balance the concentration of intracellular cAMP stimulated by PGE(2), we investigated the role of PDEs in PGE(2) mediated osteoclast formation using various cAMP specific PDEs inhibitors. In the presence of PGE(2), PDE3 and 4 inhibitors were shown to dose dependently increase the osteoclast formation in cocultures of mouse bone marrow cells and calvarial osteoblasts. In agreement with this finding, they stimulated PGE(2) induced cAMP production followed by increased RANKL mRNA expression in osteoblasts, suggesting that PDE3 and 4 negatively regulate PGE(2) mediated RANKL expression in osteoblasts. RT PCR analysis revealed that PDE3A, 3B, 4A, 4B and 4D are expressed in osteoblasts. The PDE8 inhibitor did not increase osteoclast formation, although it stimulated PGE(2) induced RANKL mRNA expression in osteoblasts. The four subtypes of PGE receptors are designated EP1, EP2, EP3 and EP4, PDE3 and 4 inhibitors were found to increase EP1/3, EP4 and/or EP2 agonist stimulated RANKL expression, indicating that PDE3 and PDE4 negatively regulate PGE(2) induced RANKL mRNA expression through four EPs. Taken together, these data suggest that PDE3 and PDE4 could have important pharmacological and clinical implications in hone related diseases.
C1 [Noh, A. Long Sae Mi; Lee, Jung Min; Park, Hyojung; Yim, Mijung] Sookmyung Womens Univ, Coll Pharm, Yongsan Ku, Seoul 140742, South Korea.
   [Yang, Mihye; Lee, Dong Seok] Kyungpook Natl Univ, Coll Nat Sci, Taegu 702701, South Korea.
C3 Sookmyung Women's University; Kyungpook National University (KNU)
RP Yim, M (通讯作者)，Sookmyung Womens Univ, Coll Pharm, Yongsan Ku, Hyochangwongil 52, Seoul 140742, South Korea.
EM myim@sm.ackr
OI Lee, Dong Seok/0000 0001 6348 8937
CR Alander CB, 2006, PROSTAG OTH LIPID M, V81, P178, DOI 10.1016/j.prostaglandins.2006.09.005
   Gardner CR, 2001, PROSTAG LEUKOTR ESS, V64, P117, DOI 10.1054/plef.2001.0250
   Kaji H, 1996, J BONE MINER RES, V11, P62
   Kobayashi Y, 2005, J BIOL CHEM, V280, P11395, DOI 10.1074/jbc.M411189200
   Lugnier C, 2006, PHARMACOL THERAPEUT, V109, P366, DOI 10.1016/j.pharmthera.2005.07.003
   Park H, 2007, BIOCHEM BIOPH RES CO, V354, P178, DOI 10.1016/j.bbrc.2006.12.174
   Richter W, 2008, EMBO J, V27, P384, DOI 10.1038/sj.emboj.7601968
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200
   Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo 123 5 2600
   Takami M, 2005, FEBS LETT, V579, P832, DOI 10.1016/j.febslet.2004.12.066
   Tian XY, 2008, BONE, V42, P914, DOI 10.1016/j.bone.2007.12.228
   Väänänen HK, 2000, J CELL SCI, V113, P377
   Wakabayashi S, 2002, J BONE MINER RES, V17, P249, DOI 10.1359/jbmr.2002.17.2.249
   Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190
   Yao W., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P119
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 18
TC 21
Z9 23
U1 0
U2 2
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2 12 15 SHIBUYA, SHIBUYA KU, TOKYO, 150 0002, JAPAN
SN 0918 6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD NOV
PY 2009
VL 32
IS 11
BP 1844
EP 1848
DI 10.1248/bpb.32.1844
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 512MG
UT WOS:000271252900006
PM 19881295
OA Bronze
DA 2025 08 17
ER

PT J
AU Sun, Y
   Cai, MX
   Zhong, JY
   Yang, L
   Xiao, J
   Jin, FJ
   Xue, H
   Liu, XN
   Liu, HS
   Zhang, YB
   Jiang, D
   Hong, A
   Ji, XM
   Wang, ZL
   Zhang, G
   Wang, XG
AF Sun, Yao
   Cai, Mingxiang
   Zhong, Jiayong
   Yang, Li
   Xiao, Jia
   Jin, Fujun
   Xue, Hui
   Liu, Xiangning
   Liu, Huisheng
   Zhang, Yongbiao
   Jiang, Dong
   Hong, An
   Ji, Xunming
   Wang, Zuolin
   Zhang, Gong
   Wang, Xiaogang
TI The long noncoding RNA lnc ob1 facilitates bone formation by
   upregulating Osterix in osteoblasts
SO NATURE METABOLISM
LA English
DT Article
ID DIFFERENTIATION; MECHANISMS; EXPRESSION; HORMONE
AB Long noncoding RNAs (lncRNAs) have emerged as integral regulators of physiology and disease, but specific roles of lncRNAs in bone disease remain largely unknown. Here, we show that lnc ob1 regulates osteoblast activity and bone formation in mice by upregulating the osteogenic transcription factor Osterix. Expression of lnc ob1 is enriched in osteoblasts and upregulated during osteoblastogenesis. We demonstrate that osteoblast specific knock in of lnc ob1 enhances bone formation and increases bone mass. Pharmacological overexpression of lnc ob1 specifically in osteoblasts confers resistance to ovariectomy induced osteoporosis in mice. In humans, expression of the homologue, lnc OB1, decreases with age in osteoblasts of patients with osteoporosis. Mechanistically, lnc ob1 upregulates the expression of Osterix in mouse and human osteoblasts, probably via inhibition of H3K27me3 methylation. Our data indicate that lnc OB1 regulates bone formation and might be a drug target for the treatment of osteoporosis.
C1 [Sun, Yao; Cai, Mingxiang; Xue, Hui; Wang, Zuolin] Tongji Univ, Shanghai Engn Res Ctr Tooth Restorat & Regenerat, Sch Stomatol, Dept Oral Implantol, Shanghai, Peoples R China.
   [Zhong, Jiayong; Liu, Huisheng; Zhang, Yongbiao; Ji, Xunming; Wang, Xiaogang] Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Beijing, Peoples R China.
   [Zhong, Jiayong; Liu, Huisheng; Zhang, Yongbiao; Ji, Xunming; Wang, Xiaogang] Beihang Univ, Sch Biol Sci & Med Engn, Beijing, Peoples R China.
   [Zhong, Jiayong; Yang, Li; Jin, Fujun; Hong, An; Wang, Xiaogang] Jinan Univ, Coll Life Sci & Technol, Dept Cell Biol, Guangzhou, Guangdong, Peoples R China.
   [Zhong, Jiayong; Yang, Li; Jin, Fujun; Hong, An; Wang, Xiaogang] Jinan Univ, Coll Life Sci & Technol, Inst Biomed, Guangzhou, Guangdong, Peoples R China.
   [Zhong, Jiayong; Zhang, Gong] Jinan Univ, Inst Life & Hlth Engn, Guangdong Higher Educ Inst, Key Lab Funct Prot Res, Guangzhou, Guangdong, Peoples R China.
   [Zhong, Jiayong] Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Inst Pediat, Guangzhou, Guangdong, Peoples R China.
   [Xiao, Jia; Liu, Xiangning; Wang, Xiaogang] Jinan Univ, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
   [Jiang, Dong] Peking Univ, Hosp 3, Inst Sports Med, Beijing Key Lab Sports Injuries, Beijing, Peoples R China.
   [Ji, Xunming] Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Ji, Xunming] Capital Med Univ, Xuanwu Hosp, China Amer Inst Neurosci, Beijing, Peoples R China.
C3 Tongji University; Beihang University; Beihang University; Jinan
   University; Jinan University; Jinan University; Guangzhou Medical
   University; Jinan University; Peking University; Capital Medical
   University; Capital Medical University
RP Sun, Y; Wang, ZL (通讯作者)，Tongji Univ, Shanghai Engn Res Ctr Tooth Restorat & Regenerat, Sch Stomatol, Dept Oral Implantol, Shanghai, Peoples R China.; Wang, XG (通讯作者)，Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Beijing, Peoples R China.; Wang, XG (通讯作者)，Beihang Univ, Sch Biol Sci & Med Engn, Beijing, Peoples R China.; Wang, XG (通讯作者)，Jinan Univ, Coll Life Sci & Technol, Dept Cell Biol, Guangzhou, Guangdong, Peoples R China.; Wang, XG (通讯作者)，Jinan Univ, Coll Life Sci & Technol, Inst Biomed, Guangzhou, Guangdong, Peoples R China.; Zhang, G (通讯作者)，Jinan Univ, Inst Life & Hlth Engn, Guangdong Higher Educ Inst, Key Lab Funct Prot Res, Guangzhou, Guangdong, Peoples R China.; Wang, XG (通讯作者)，Jinan Univ, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
EM yaosun@tongji.edu.cn; zuolin@tongji.edu.cn; zhanggong@jnu.edu.cn;
   xiaogangwang@buaa.edu.cn
RI Ji, Xunming/AAN 3370 2021; sun, yao/MEP 9275 2025; cai,
   mingxiang/IYT 1913 2023; Zhang, Gong/Q 7419 2017; Zhang,
   Yongbiao/KLB 9206 2024; wang, Xiaogang/J 5003 2017; Liu,
   Huisheng/D 2917 2011
OI Zhang, Gong/0000 0003 0418 3433; Wang, Xiaogang/0000 0001 9798 834X;
   sun, yao/0000 0002 4323 0506; Ji, Xunming/0000 0003 0293 2744; Jin,
   Fujun/0000 0002 7314 0085; Zhong, Jiayong/0000 0001 9357 1117
FU National key research and development program
   [2016YFC102705/2017YFA0505001/2018YFC0910200]; National Natural Science
   Foundation [81822012, 81770873, 81722031, 81470715, 81771043, 31671312,
   3137134]; Guangdong Natural Science Funds [2014A030313358]; Major
   Project in Guangdong Province of Science [2014KZDXM011]; Guangdong
   Natural Science Funds for Distinguished Young Scholars [S2013050013880];
    [2017BR009];  [2014BAI04B07];  [Kx0200020173386]
FX This research was supported by grants from the National key research and
   development program (2016YFC102705/2017YFA0505001/2018YFC0910200);
   National Natural Science Foundation Projects (No. 81822012, 81771043,
   81770873, 81722031, 81470715, 81771043, 31671312, 3137134); 2017BR009,
   2014BAI04B07 and Kx0200020173386, Guangdong Natural Science Funds (no.
   2014A030313358), the Major Project in Guangdong Province of Science (no.
   2014KZDXM011) and Guangdong Natural Science Funds for Distinguished
   Young Scholars (no. S2013050013880). We thank C. Qin for providing the
   DMP1 antibody as a gift. We thank Y. Zhang and S. Gao at Tongji
   University for providing critical comments and technical support. We
   thank J. Li for help with the style of the manuscript.
CR Atianand MK, 2014, TRENDS MOL MED, V20, P623, DOI 10.1016/j.molmed.2014.09.002
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Canalis E, 2010, ENDOCR PRACT, V16, P855, DOI 10.4158/EP10048.RA
   Cheloha RW, 2015, NAT REV ENDOCRINOL, V11, P712, DOI 10.1038/nrendo.2015.139
   Crandall C, 2002, ARCH INTERN MED, V162, P2297, DOI 10.1001/archinte.162.20.2297
   Ettinger MP, 2003, ARCH INTERN MED, V163, P2237, DOI 10.1001/archinte.163.18.2237
   Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606
   Flynn RA, 2014, CELL STEM CELL, V14, P752, DOI 10.1016/j.stem.2014.05.014
   Gong CG, 2015, DEV CELL, V34, P181, DOI 10.1016/j.devcel.2015.05.009
   Hojo H, 2016, DEV CELL, V37, P238, DOI 10.1016/j.devcel.2016.04.002
   Huang YP, 2015, STEM CELLS, V33, P3481, DOI 10.1002/stem.2225
   Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981
   Knoll M, 2015, NAT REV ENDOCRINOL, V11, P151, DOI 10.1038/nrendo.2014.229
   Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270
   Lee JT, 2012, SCIENCE, V338, P1435, DOI 10.1126/science.1231776
   Li CJ, 2018, J CLIN INVEST, V128, P5251, DOI 10.1172/JCI99044
   Liu WQ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12794
   Liu Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11149
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Morlan JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042882
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nakashima K, 2003, TRENDS GENET, V19, P458, DOI 10.1016/S0168 9525(03)00176 8
   Necsulea A, 2014, NATURE, V505, P635, DOI 10.1038/nature12943
   Ng SY, 2013, MOL CELL, V51, P349, DOI 10.1016/j.molcel.2013.07.017
   Nikitovic D, 2016, ONCOL REP, V36, P1787, DOI 10.3892/or.2016.4986
   Ramos AD, 2015, CELL STEM CELL, V16, P439, DOI 10.1016/j.stem.2015.02.007
   Redis RS, 2016, MOL CELL, V61, P520, DOI 10.1016/j.molcel.2016.01.015
   Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev biochem 051410 092902
   Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010
   Simon JA, 2013, MOL CELL, V49, P808, DOI 10.1016/j.molcel.2013.02.013
   Sun M, 2015, ENDOCR REV, V36, P25, DOI 10.1210/er.2014 1034
   Sun Y, 2016, ACS NANO, V10, P5759, DOI 10.1021/acsnano.5b07828
   Thum T, 2014, NAT REV CARDIOL, V11, P655, DOI 10.1038/nrcardio.2014.125
   Uchida S, 2015, CIRC RES, V116, P737, DOI 10.1161/CIRCRESAHA.116.302521
   Wahlestedt C, 2013, NAT REV DRUG DISCOV, V12, P433, DOI 10.1038/nrd4018
   Yang L, 2014, TRENDS BIOCHEM SCI, V39, P35, DOI 10.1016/j.tibs.2013.10.002
   Zeng HC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15000
   Zhao XY, 2015, TRENDS BIOCHEM SCI, V40, P586, DOI 10.1016/j.tibs.2015.08.002
   Zhou X, 2010, P NATL ACAD SCI USA, V107, P12919, DOI 10.1073/pnas.0912855107
   Zhu L, 2013, BIOCHEM BIOPH RES CO, V432, P612, DOI 10.1016/j.bbrc.2013.02.036
   Zhuang WZ, 2015, STEM CELLS, V33, P1985, DOI 10.1002/stem.1989
NR 42
TC 51
Z9 56
U1 6
U2 92
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2522 5812
J9 NAT METAB
JI Nat. Metab.
PD APR
PY 2019
VL 1
IS 4
BP 485
EP 496
DI 10.1038/s42255 019 0053 8
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA JT1CY
UT WOS:000500737300009
PM 32694877
DA 2025 08 17
ER

PT J
AU Wang, JH
   Li, Y
   Yang, YF
   Du, J
   Zhao, MQ
   Lin, F
   Zhang, SW
   Wang, B
AF Wang, Jinghui
   Li, Yan
   Yang, Yinfeng
   Du, Jian
   Zhao, Miaoqing
   Lin, Feng
   Zhang, Shuwei
   Wang, Bin
TI Systems Pharmacology Dissection of Multiscale Mechanisms of Action for
   Herbal Medicines in Treating Rheumatoid Arthritis
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE Rheumatoid arthritis; TCM; Systems Pharmacology; MD; MM PBSA
ID WILFORDII HOOK F; RADIX PAEONIAE ALBA; PERFORMANCE
   LIQUID CHROMATOGRAPHY; OSTEOCLAST DIFFERENTIATION FACTOR; NF KAPPA B;
   CHINESE MEDICINE; DOUBLE BLIND; RAT PLASMA; ANTIINFLAMMATORY ACTIVITY;
   RHIZOMA ANEMARRHENAE
AB As a chronic inflammatory and angiogenic disease with increased morbidity and mortality, rheumatoid arthritis (RA) is characterized by the proliferation of synovial tissue and the accumulation of excessive mononuclear infiltration, which always results in the joint deformity, disability, and eventually the destruction of the bone and cartilage. Traditional Chinese Medicine (TCM), with rich history of proper effectiveness in treating the inflammatory joint disease containing RA, has long combated such illness from, actually, an integrative and holistic point of view. However, its "multi components" and "multi targets" features make it very difficult to decipher the molecular mechanisms of RA from a systematic perspective if employing only routine methods. Presently, an innovative systems pharmacology approach was introduced, which combined the ADME screening model, drug targeting, and network pharmacology, to explore the action mechanisms of botanic herbs for the treatment of RA. As a result, we uncovered 117 active compounds and 85 key molecular targets from seven RA related herbs, which are mainly implicated in four signaling pathways, that is, vascular endothelial growth factor, PI3K Akt, Toll like receptor, and T cell receptor pathways. Additionally, the network relationships among the active components, target proteins, and pathways were further built to uncover the pharmacological characters of these herbs. Besides, molecular dynamics (MD) simulations and molecular mechanics Poisson Boltzmann surface area calculations were carried out to explore the binding interactions between the compounds and their receptors as well as to investigate the binding affinity of the ligand to their protein targets. In vitro experiments by ligand binding assays validate the reliability of the drug target interactions as well as the MD results. The high binding affinities and good inhibitions of the active compounds indicate that the potential therapeutic effects of these herbal medicines for treating RA are exerted probably through the modulation of these relevant proteins, which further validates the rationality and reliability of the drug target interactions as well as our the network based analytical methods. This work may be of help for not only understanding the action mechanisms of TCM and for discovering new drugs from plants for the treatment of RA, but also providing a novel potential method for modern medicine in treating complex diseases.
C1 [Wang, Jinghui; Li, Yan; Yang, Yinfeng; Du, Jian; Zhao, Miaoqing; Lin, Feng; Zhang, Shuwei] Dalian Univ Technol, Key Lab Ind Ecol & Environm Engn MOE, Dept Mat Sci & Chem Engn, Dalian 116024, Liaoning, Peoples R China.
   [Wang, Jinghui; Li, Yan; Du, Jian] Dalian Univ Technol, Inst Chem Proc Syst Engn, Dalian 116024, Liaoning, Peoples R China.
   [Wang, Bin] Dalian Ocean Univ, Dalian 116023, Liaoning, Peoples R China.
C3 Dalian University of Technology; Dalian University of Technology; Dalian
   Ocean University
RP Li, Y; Du, J (通讯作者)，Dalian Univ Technol, Key Lab Ind Ecol & Environm Engn MOE, Dept Mat Sci & Chem Engn, Dalian 116024, Liaoning, Peoples R China.; Li, Y; Du, J (通讯作者)，Dalian Univ Technol, Inst Chem Proc Syst Engn, Dalian 116024, Liaoning, Peoples R China.
EM yanli@dlut.edu.cn; dujian@dlut.edu.cn
RI ; bin, wang/X 9166 2019; Du, Jian/IXD 1367 2023
OI Li, Yan/0000 0001 8295 530X; 
FU Key Program of National Natural Science Foundation of China [81530100,
   21576036]
FX We are grateful for the Oasis Scholar Fund of Shihezi University. The
   Project was also supported by the Key Program of National Natural
   Science Foundation of China (Grant Nos. 81530100, 21576036).
CR González DA, 2010, IMMUNOL LETT, V133, P6, DOI 10.1016/j.imlet.2010.07.001
   ANAYA JM, 1995, SEMIN ARTHRITIS RHEU, V24, P242, DOI 10.1016/S0049 0172(95)80034 4
   Banham Hall Edward, 2012, Open Rheumatol J, V6, P245, DOI 10.2174/1874312901206010245
   Begovich AB, 2004, AM J HUM GENET, V75, P330, DOI 10.1086/422827
   Brennan FM, 2008, J CLIN INVEST, V118, P3537, DOI 10.1172/JCI36389
   Cai YM, 2013, J ETHNOPHARMACOL, V147, P349, DOI 10.1016/j.jep.2013.03.017
   Chae S, 2011, BIOSCI BIOTECH BIOCH, V75, P2321, DOI 10.1271/bbb.110465
   Chang YX, 2011, CHROMATOGRAPHIA, V74, P639, DOI 10.1007/s10337 011 2109 0
   Chen YF, 2006, HEALTH TECHNOL ASSES, V10, P1, DOI 10.3310/hta10420
   Chen Yung Hsiang, 2014, Evid Based Complement Alternat Med, V2014, P280204, DOI 10.1155/2014/280204
   Cheng K. F., 2012, OPEN J SAF SCI TECHN, V02, P32, DOI [10.4236/ojsst.2012.21005, DOI 10.4236/OJSST.2012.21005]
   Cohen S, 2002, ARTHRITIS RHEUM, V46, P614, DOI 10.1002/art.10141
   Cope Andrew P, 2008, Arthritis Res Ther, V10 Suppl 1, pS1, DOI 10.1186/ar2412
   Coulthard LR, 2011, ANN RHEUM DIS, V70, P98, DOI 10.1136/ard.2010.133249
   CUVELIER C, 1987, GUT, V28, P394, DOI 10.1136/gut.28.4.394
   Date AA, 2011, MOL PHARMACEUT, V8, P716, DOI 10.1021/mp100305h
   DeBusk LM, 2003, ARTHRITIS RHEUM US, V48, P2461, DOI 10.1002/art.11213
   Do Kwon Y, 2012, P NATL ACAD SCI USA, V109, P5663, DOI 10.1073/pnas.1112391109
   Duke J.A., 2002, HDB MED HERBS, P27
   Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397
   Feng C, 2010, J ETHNOPHARMACOL, V130, P407, DOI 10.1016/j.jep.2010.05.028
   FIRESTEIN GS, 1990, J IMMUNOL, V144, P3347
   Goldbach Mansky R, 2009, ANN INTERN MED, V151, P229, DOI 10.7326/0003 4819 151 4 200908180 00005
   Goodson N, 2002, CURR OPIN RHEUMATOL, V14, P115, DOI 10.1097/00002281 200203000 00007
   He XH, 2004, J CHROMATOGR B, V802, P277, DOI 10.1016/j.jchromb.2003.11.040
   Huang C, 2014, BRIEF BIOINFORM, V15, P710, DOI 10.1093/bib/bbt035
   Huse M, 2009, J CELL SCI, V122, P1269, DOI 10.1242/jcs.042762
   Hwang SH, 2009, GENE, V443, P83, DOI 10.1016/j.gene.2009.04.024
   Ichiki H, 2007, J NAT MED TOKYO, V61, P146, DOI 10.1007/s11418 006 0111 x
   Islander U, 2011, MOL CELL ENDOCRINOL, V335, P14, DOI 10.1016/j.mce.2010.05.018
   Jiang FJ, 2012, FITOTERAPIA, V83, P415, DOI 10.1016/j.fitote.2011.12.009
   Jin S. E., 2016, BMC COMPLEM ALTERN M, V16, P1
   Jung J, 2011, YAKUGAKU ZASSHI, V131, P1103, DOI 10.1248/yakushi.131.1103
   Kaga S, 2006, J MOL CELL CARDIOL, V40, P138, DOI 10.1016/j.yjmcc.2005.09.009
   Kim JY, 2009, FOOD CHEM TOXICOL, V47, P1610, DOI 10.1016/j.fct.2009.04.009
   Klareskog L, 2004, LANCET, V363, P675, DOI 10.1016/S0140 6736(04)15640 7
   Koch AE, 2003, ANN RHEUM DIS, V62, P60, DOI 10.1136/ard.62.suppl_2.ii60
   Koenders MI, 2015, TRENDS PHARMACOL SCI, V36, P189, DOI 10.1016/j.tips.2015.02.001
   Kowanetz M, 2006, CLIN CANCER RES, V12, P5018, DOI 10.1158/1078 0432.CCR 06 1520
   Kramer PR, 2004, ARTHRITIS RHEUM, V50, P1967, DOI 10.1002/art.20309
   Kremer JM, 2003, NEW ENGL J MED, V349, P1907, DOI 10.1056/NEJMoa035075
   Lao LX, 2006, AM J CHINESE MED, V34, P833, DOI 10.1142/S0192415X06004326
   Leopoldini M, 2004, J PHYS CHEM A, V108, P92, DOI 10.1021/jp035901j
   Li DD, 2014, CHROMATOGRAPHIA, V77, P853, DOI 10.1007/s10337 014 2681 1
   Li Y, 2015, J ETHNOPHARMACOL, V175, P301, DOI 10.1016/j.jep.2015.09.016
   Lin JH, 2002, J AM CHEM SOC, V124, P5632, DOI 10.1021/ja0260162
   Liu J, 2011, CHIN J INTEGR MED, V17, P735, DOI 10.1007/s11655 011 0872 2
   Liu JL, 2016, SCI REP UK, V6, DOI 10.1038/srep19809
   Loizou S, 2010, MOL NUTR FOOD RES, V54, P551, DOI 10.1002/mnfr.200900012
   Lv QW, 2015, ANN RHEUM DIS, V74, P1078, DOI 10.1136/annrheumdis 2013 204807
   Ma CH, 2008, BIOMED CHROMATOGR, V22, P1066, DOI 10.1002/bmc.1026
   Malemud CJ, 2007, CLIN CHIM ACTA, V375, P10, DOI 10.1016/j.cca.2006.06.033
   Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131
   Moudgil KD, 2014, EXPERT REV CLIN IMMU, V10, P819, DOI 10.1586/1744666X.2014.917963
   Murakami M, 2006, BLOOD, V108, P1849, DOI 10.1182/blood 2006 04 016030
   Nirmal Sunil A., 2012, Inflammopharmacology, V20, P219, DOI 10.1007/s10787 011 0110 8
   Romas E, 2000, ARTHRITIS RHEUM, V43, P821, DOI 10.1002/1529 0131(200004)43:4<821::AID ANR12>3.0.CO;2 T
   Saito T., 2002, AM J PHYSIOL HEART C, V283, P1
   Sakaguchi S, 2012, IMMUNOL CELL BIOL, V90, P277, DOI 10.1038/icb.2012.4
   Sarzi Puttini P, 2005, AUTOIMMUN REV, V4, P153, DOI 10.1016/j.autrev.2004.09.004
   Seibl R, 2003, AM J PATHOL, V162, P1221, DOI 10.1016/S0002 9440(10)63918 1
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shigeyama Y, 2000, ARTHRITIS RHEUM, V43, P2523, DOI 10.1002/1529 0131(200011)43:11<2523::AID ANR20>3.0.CO;2 Z
   Shin JiSun Shin JiSun, 2008, Natural Product Sciences, V14, P206
   Smolen JS, 2008, LANCET, V371, P987, DOI 10.1016/S0140 6736(08)60453 5
   Straub RH, 2007, ENDOCR REV, V28, P521, DOI 10.1210/er.2007 0001
   Sun QH, 2006, J CHROMATOGR A, V1104, P69, DOI 10.1016/j.chroma.2005.11.046
   Tao XL, 2002, ARTHRITIS RHEUM, V46, P1735, DOI 10.1002/art.10411
   Tarner IH, 2007, NAT CLIN PRACT RHEUM, V3, P336, DOI 10.1038/ncprheum0506
   Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343
   Taylor PC, 2000, ARTHRITIS RHEUM US, V43, P38, DOI 10.1002/1529 0131(200001)43:1<38::AID ANR6>3.0.CO;2 L
   Tong L, 2010, BIOMED CHROMATOGR, V24, P1324, DOI 10.1002/bmc.1443
   Wang GJ, 2002, LIFE SCI, V71, P1081, DOI 10.1016/S0024 3205(02)01794 0
   Wang JH, 2016, J AGR FOOD CHEM, V64, P5941, DOI 10.1021/acs.jafc.6b01067
   Wang JH, 2013, CURR MED CHEM, V20, P2032, DOI 10.2174/0929867311320150008
   Wang JJ, 2017, SCI REP UK, V7, DOI 10.1038/srep41850
   Wang YH, 2006, J BIOMED SCI, V13, P127, DOI 10.1007/s11373 005 9031 0
   Willett P, 1998, J CHEM INF COMP SCI, V38, P983, DOI 10.1021/ci9800211
   Wolfe F, 2004, AM J MED, V116, P305, DOI 10.1016/j.amjmed.2003.09.039
   Woods JM, 2003, EXP MOL PATHOL, V74, P282, DOI 10.1016/S0014 4800(03)00019 4
   Wu XX, 2014, J SEP SCI, V37, P2490, DOI 10.1002/jssc.201400494
   Xiao HB, 2004, J CHROMATOGR A, V1032, P117, DOI 10.1016/j.chroma.2003.09.032
   Xu H, 2007, RHEUMATOLOGY, V46, P920, DOI 10.1093/rheumatology/kem014
   Xu SJ, 2008, CHROMATOGRAPHIA, V68, P459, DOI 10.1365/s10337 008 0693 4
   Xu X, 2012, INT J MOL SCI, V13, P6964, DOI 10.3390/ijms13066964
   Yan Y, 2014, J PHARMACEUT BIOMED, V95, P76, DOI 10.1016/j.jpba.2014.02.013
   Yu H., 2013, EVID BASED COMPL ALT, V2013
   Yu H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037608
   Yun H. K., 2012, EVID BASED COMPL ALT, V2011
   Zhang HG, 2001, ARTHRITIS RHEUM US, V44, P1555, DOI 10.1002/1529 0131(200107)44:7<1555::AID ART279>3.0.CO;2 M
   Zhang J, 2013, PHARM BIOL, V51, P455, DOI 10.3109/13880209.2012.739177
   Zhang RX, 2009, J ETHNOPHARMACOL, V121, P366, DOI 10.1016/j.jep.2008.11.018
   Zhang Yanqiong, 2013, Evid Based Complement Alternat Med, V2013, P548498, DOI 10.1155/2013/548498
   Zhao FL, 2015, J ETHNOPHARMACOL, V168, P1, DOI 10.1016/j.jep.2015.03.035
   Zhao YX, 2008, PROTEINS, V72, P635, DOI 10.1002/prot.21955
   Zheng YQ, 2007, INFLAMM RES, V56, P182, DOI 10.1007/s00011 006 6002 5
   Zhou ZG, 2005, J AM CHEM SOC, V127, P17253, DOI 10.1021/ja053973d
NR 97
TC 29
Z9 32
U1 0
U2 65
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543 8384
EI 1543 8392
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD SEP
PY 2017
VL 14
IS 9
BP 3201
EP 3217
DI 10.1021/acs.molpharmaceut.7b00505
PG 17
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FG2ZT
UT WOS:000410005100032
PM 28771010
DA 2025 08 17
ER

PT J
AU Cheng, X
   Tian, WZ
   Yang, JH
   Wang, JM
   Zhang, Y
AF Cheng, Xin
   Tian, Wenzhi
   Yang, Jianhua
   Wang, Jiamian
   Zhang, Yang
TI Engineering approaches to manipulate osteoclast behavior for bone
   regeneration
SO MATERIALS TODAY BIO
LA English
DT Article
DE Osteoclasts; Drug delivery; Biomaterials; Bone coupling; Bone
   regeneration
ID MESENCHYMAL STEM CELLS; IN VITRO; INHIBIT OSTEOCLASTOGENESIS; TERMINAL
   DIFFERENTIATION; ZOLEDRONIC ACID; RAT OSTEOCLASTS; DRUG DELIVERY;
   CALCIUM; RESORPTION; RANKL
AB Extensive research has delved into the multifaceted roles of osteoclasts beyond their traditional function in bone resorption in recent years, uncovering their significant influence on bone formation. This shift in understanding has spurred investigations into engineering strategies aimed at leveraging osteoclasts to not only inhibit bone resorption but also facilitate bone regeneration. This review seeks to comprehensively examine the mechanisms by which osteoclasts impact bone metabolism. Additionally, it explores various engineering methodologies, including the modification of bioactive material properties, localized drug delivery, and the introduction of exogenous cells, assessing their potential and mechanisms in aiding bone repair by targeting osteoclasts. Finally, the review proposes current limitations and future routes for manipulating osteoclasts through biological and material cues to facilitate bone repair.
C1 [Cheng, Xin] Shenzhen Univ, Clin Med Acad, Dept Stomatol, Gen Hosp, 1098 Xueyuan Rd, Shenzhen 518055, Guangdong, Peoples R China.
   [Tian, Wenzhi] Jilin Univ, Sch & Hosp Stomatol, Dept Oral Pathol, Jilin Prov Key Lab Tooth Dev & Bone Remodeling, Changchun 130041, Jilin, Peoples R China.
   [Yang, Jianhua] Chinese Univ Hong Kong, Longgang Dist Peoples Hosp Shenzhen, Shenzhen 518172, Guangdong, Peoples R China.
   [Yang, Jianhua] Chinese Univ Hong Kong, Affiliated Hosp 2, Shenzhen 518172, Guangdong, Peoples R China.
   [Wang, Jiamian] Natl Innovat Ctr Adv Med Devices, Shenzhen 518000, Guangdong, Peoples R China.
   [Zhang, Yang] Shenzhen Univ, Sch Dent, Med Sch, 1088 Xueyuan Rd, Shenzhen 518055, Guangdong, Peoples R China.
   [Zhang, Yang] Shenzhen Univ, Med Sch, Sch Biomed Engn, 1088 Xueyuan Rd, Shenzhen 518055, Guangdong, Peoples R China.
C3 Shenzhen University; Jilin University; The Chinese University of Hong
   Kong, Shenzhen; Longgang District People's Hospital, Shenzhen; The
   Chinese University of Hong Kong, Shenzhen; Shenzhen University; Shenzhen
   University
RP Zhang, Y (通讯作者)，Shenzhen Univ, Sch Dent, Med Sch, 1088 Xueyuan Rd, Shenzhen 518055, Guangdong, Peoples R China.
EM yang.zhang@szu.edu.cn
RI Yang, Jianhua/ABG 2962 2021; Zhang, Yang/A 7911 2016; Zhang,
   Yang/N 4600 2019
OI Zhang, Yang/0000 0002 7864 1452; 
FU National Natural Science Foundation of China [82301041, 31900966];
   Guangdong Basic and Applied Basic Research Foundation [2020A1515110880,
   2019A1515110415]; Shenzhen Science and Technology Program
   [JCYJ20220530162206012]; Shenzhen Medical Academy of Research and
   Translation [A2303069]; Medicine Plus Program of Shenzhen University
FX This work was supported by the National Natural Science Foundation of
   China (No. 82301041 & 31900966) and Guangdong Basic and Applied Basic
   Research Foundation (2020A1515110880 & 2019A1515110415) , Shenzhen
   Science and Technology Program (JCYJ20220530162206012) , Shenzhen
   Medical Academy of Research and Translation (A2303069) , and Medicine
   Plus Program of Shenzhen University.
CR AARDEN EM, 1994, J CELL BIOCHEM, V55, P287, DOI 10.1002/jcb.240550304
   Al Baadani MA, 2022, MATER DESIGN, V217, DOI 10.1016/j.matdes.2022.110596
   Andersen TL, 2009, AM J PATHOL, V174, P239, DOI 10.2353/ajpath.2009.080627
   Arnett TR, 2008, J NUTR, V138, p415S, DOI 10.1093/jn/138.2.415S
   Bai HT, 2020, MATER DESIGN, V189, DOI 10.1016/j.matdes.2020.108513
   Bai YP, 2018, MATERIALS, V11, DOI 10.3390/ma11102047
   Bang SM, 2014, CLIN ORAL IMPLAN RES, V25, P831, DOI 10.1111/clr.12146
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brinkmann J, 2012, BIOINTERPHASES, V7, DOI 10.1007/s13758 012 0034 x
   Cackowski FC, 2010, BLOOD, V115, P140, DOI 10.1182/blood 2009 08 237628
   Chung PL, 2014, J CELL BIOCHEM, V115, P1412, DOI 10.1002/jcb.24792
   Córdoba A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113319
   Costa DO, 2013, BIOMATERIALS, V34, P7215, DOI 10.1016/j.biomaterials.2013.06.014
   Crane JL, 2014, J CLIN INVEST, V124, P466, DOI 10.1172/JCI70050
   Cui YG, 2018, CELL PHYSIOL BIOCHEM, V49, P555, DOI 10.1159/000492993
   Detsch R, 2010, ACTA BIOMATER, V6, P3223, DOI 10.1016/j.actbio.2010.03.003
   Dou C, 2018, ADV SCI, V5, DOI 10.1002/advs.201700578
   Dubon MJ, 2018, J CELL PHYSIOL, V233, P201, DOI 10.1002/jcp.25863
   Durdan MM, 2022, SEMIN CELL DEV BIOL, V123, P4, DOI 10.1016/j.semcdb.2021.10.008
   Feng MX, 2016, SCI REP UK, V6, DOI 10.1038/srep19074
   Fernández González FJ, 2016, ORTHOD CRANIOFAC RES, V19, P54, DOI 10.1111/ocr.12115
   Galow Anne Marie, 2017, Biochem Biophys Rep, V10, P17, DOI 10.1016/j.bbrep.2017.02.001
   Gamblin AL, 2014, BIOMATERIALS, V35, P9660, DOI 10.1016/j.biomaterials.2014.08.018
   Geljic IS, 2018, J TISSUE ENG REGEN M, V12, pE854, DOI 10.1002/term.2396
   Gou WL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091317
   Goya M, 2006, PROSTATE, V66, P1573, DOI 10.1002/pros.20375
   Green Jacob, 1995, American Journal of Physiology, V268, pC1090
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hayakawa T, 2015, MOL MED REP, V12, P5879, DOI 10.3892/mmr.2015.4141
   HELFRICH MH, 1992, J BONE MINER RES, V7, P335
   Helfrich MH, 1996, BONE, V19, P317, DOI 10.1016/S8756 3282(96)00223 2
   Henriksen K, 2014, CALCIFIED TISSUE INT, V94, P88, DOI 10.1007/s00223 013 9741 7
   Hu CH, 2017, SCI REP UK, V7, DOI 10.1038/srep43191
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Ikeda M, 2016, MOL MED REP, V14, P4699, DOI 10.3892/mmr.2016.5801
   Ippolito JA, 2017, J ORTHOP RES, V35, P2174, DOI 10.1002/jor.23521
   Ishikawa K, 2018, MATERIALS, V11, DOI 10.3390/ma11101993
   James AW, 2016, TISSUE ENG PART B RE, V22, P284, DOI [10.1089/ten.TEB.2015.0357, 10.1089/ten.teb.2015.0357]
   Jansen IDC, 2012, CALCIFIED TISSUE INT, V90, P515, DOI 10.1007/s00223 012 9600 y
   Jensen PR, 2021, BONE, V145, DOI 10.1016/j.bone.2021.115850
   Jiao K, 2015, ACTA BIOMATER, V19, P23, DOI 10.1016/j.actbio.2015.03.012
   Jie S, 2019, INT J NANOMED, V14, P7353, DOI 10.2147/IJN.S217974
   Jin SE, 2022, BIOACT MATER, V8, P559, DOI 10.1016/j.bioactmat.2021.06.028
   Jin YQ, 2023, BASIC CLIN PHARMACOL, V132, P144, DOI 10.1111/bcpt.13817
   Limirio PHJO, 2016, AAPS PHARMSCITECH, V17, P872, DOI 10.1208/s12249 015 0411 0
   Kajiya H, 2012, ADV EXP MED BIOL, V740, P917, DOI 10.1007/978 94 007 2888 2_41
   Kajiya H, 2010, CELL CALCIUM, V48, P260, DOI 10.1016/j.ceca.2010.09.010
   Kameda T, 1998, BIOCHEM BIOPH RES CO, V245, P419, DOI 10.1006/bbrc.1998.8448
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kim BJ, 2012, BONE, V51, P431, DOI 10.1016/j.bone.2012.06.015
   Kim HD, 2017, BIOMATERIALS, V112, P31, DOI 10.1016/j.biomaterials.2016.10.009
   Kubota K, 2002, J BONE MINER RES, V17, P257, DOI 10.1359/jbmr.2002.17.2.257
   Lee KS, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12152
   Lee K, 2011, J CELL MOL MED, V15, P2082, DOI 10.1111/j.1582 4934.2010.01230.x
   Lee SK, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 17427 6
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Li GY, 2018, ACTA BIOMATER, V65, P486, DOI 10.1016/j.actbio.2017.10.033
   Li H, 2021, FRONT MED LAUSANNE, V8, DOI 10.3389/fmed.2021.781449
   Li JM, 2021, BIOACT MATER, V6, P3839, DOI 10.1016/j.bioactmat.2021.03.039
   Li P, 2018, CELL CALCIUM, V71, P45, DOI 10.1016/j.ceca.2017.12.001
   Li XQ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb7135
   Li ZP, 2006, BIOCHEM BIOPH RES CO, V343, P345, DOI 10.1016/j.bbrc.2006.02.147
   Lian WS, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1942 1
   Lien CY, 2009, J BONE MINER RES, V24, P837, DOI [10.1359/JBMR.081257, 10.1359/jbmr.081257]
   Lin TH, 2016, ACTA BIOMATER, V41, P273, DOI 10.1016/j.actbio.2016.05.038
   Liu WL, 2019, ACS APPL MATER INTER, V11, P9557, DOI 10.1021/acsami.8b20580
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Ma CW, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.918370
   Makihira S, 2007, DENT MATER J, V26, P739, DOI 10.4012/dmj.26.739
   Mamalis AA, 2011, CLIN ORAL IMPLAN RES, V22, DOI 10.1111/j.1600 0501.2010.02027.x
   Mandal CC, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00165
   Masuyama R, 2008, CELL METAB, V8, P257, DOI 10.1016/j.cmet.2008.08.002
   Mayr Wohlfart U, 2002, BONE, V30, P472, DOI 10.1016/S8756 3282(01)00690 1
   Miao QJ, 2023, MATER TODAY BIO, V23, DOI 10.1016/j.mtbio.2023.100871
   MILLER SC, 1989, SCANNING MICROSCOPY, V3, P953
   Nabeshima A, 2017, BIOMATERIALS, V117, P1, DOI 10.1016/j.biomaterials.2016.11.039
   Nakamachi Y, 2016, ANN RHEUM DIS, V75, P601, DOI 10.1136/annrheumdis 2014 206417
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Negri S, 2020, STEM CELL TRANSL MED, V9, P1617, DOI 10.1002/sctm.20 0152
   Nilsson A, 2012, J CELL BIOCHEM, V113, P1224, DOI 10.1002/jcb.23456
   Ong EC, 2013, J BIOL CHEM, V288, P22219, DOI 10.1074/jbc.M113.459826
   Oshita K, 2011, ARTHRITIS RHEUM US, V63, P1658, DOI 10.1002/art.30309
   Ota K, 2013, BONE, V57, P68, DOI 10.1016/j.bone.2013.07.023
   Pang H, 2013, BIOCHEM BIOPH RES CO, V430, P729, DOI 10.1016/j.bbrc.2012.11.081
   Park D, 2016, BIOMATERIALS, V98, P131, DOI 10.1016/j.biomaterials.2016.05.007
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rothe M, 2014, CURR GENE THER, V14, P429, DOI 10.2174/1566523214666140918110905
   Sheng X, 2023, MATER TODAY BIO, V20, DOI 10.1016/j.mtbio.2023.100636
   Shinohara Masahiro, 2007, Curr Osteoporos Rep, V5, P67
   Shirai Y, 1999, BIOCHEM BIOPH RES CO, V265, P484, DOI 10.1006/bbrc.1999.1664
   Siddiqui JA, 2016, PHYSIOLOGY, V31, P233, DOI 10.1152/physiol.00061.2014
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Song H, 2019, NANO LETT, V19, P3040, DOI 10.1021/acs.nanolett.9b00287
   Song R, 2018, DRUG DES DEV THER, V12, P3117, DOI 10.2147/DDDT.S165440
   Sumi K, 2018, J ORAL SCI, V60, P221, DOI 10.2334/josnusd.17 0187
   Sun WJ, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 30625 9
   Sun WT, 2016, LANGMUIR, V32, P9237, DOI 10.1021/acs.langmuir.6b02228
   Sun XY, 2019, THERANOSTICS, V9, P5183, DOI 10.7150/thno.33376
   Sydorak I, 2019, EUR J ORTHODONT, V41, P1, DOI 10.1093/ejo/cjy017
   Takahashi N, 2011, FRONT BIOSCI LANDMRK, V16, P21, DOI 10.2741/3673
   Takami M, 1997, BIOCHEM BIOPH RES CO, V237, P111, DOI 10.1006/bbrc.1997.7090
   Takano T, 2014, LAB INVEST, V94, P286, DOI 10.1038/labinvest.2013.152
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Vinay R, 2016, DRUG DELIV, V23, P21, DOI 10.3109/10717544.2014.913325
   Wang QQ, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abn3333
   Wang QX, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13172
   Wang XG, 2021, BIOACT MATER, V6, P4517, DOI 10.1016/j.bioactmat.2021.05.003
   Wang YF, 2019, J CELL PHYSIOL, V234, P12685, DOI 10.1002/jcp.27879
   Wornham DP, 2014, OSTEOPOROSIS INT, V25, P2477, DOI 10.1007/s00198 014 2791 5
   Wu YQ, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 05392 z
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xie YL, 2019, INT J NANOMED, V14, P6019, DOI 10.2147/IJN.S203859
   Xu RY, 2018, AGING CELL, V17, DOI 10.1111/acel.12794
   Xu RY, 2018, J TISSUE ENG REGEN M, V12, P1209, DOI 10.1002/term.2652
   Xu YM, 2021, BIOMATERIALS, V275, DOI 10.1016/j.biomaterials.2021.120890
   Xu YT, 2021, PHARMACOL RES, V165, DOI 10.1016/j.phrs.2021.105458
   Yang K, 2018, BONE, V114, P40, DOI 10.1016/j.bone.2018.06.003
   Yang WB, 2021, INFECT IMMUN, V89, DOI 10.1128/IAI.00436 20
   Yang XJ, 2020, BIOMED MATER, V15, DOI 10.1088/1748 605X/ab8720
   YU HS, 1993, BIOCHEM BIOPH RES CO, V191, P357, DOI 10.1006/bbrc.1993.1225
   Yu NYC, 2017, J BIOMED MATER RES B, V105, P136, DOI 10.1002/jbm.b.33481
   Yuan Y, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12693
   Zaidi M, 1999, J BONE MINER RES, V14, P669, DOI 10.1359/jbmr.1999.14.5.669
   ZAIDI M, 1991, J CELL PHYSIOL, V149, P422, DOI 10.1002/jcp.1041490310
   Zeng JK, 2020, BIOACT MATER, V5, P435, DOI 10.1016/j.bioactmat.2020.03.008
   Zeng YY, 2020, BIOACT MATER, V5, P859, DOI 10.1016/j.bioactmat.2020.06.010
   Zhang Y, 2018, ACS APPL MATER INTER, V10, P36652, DOI 10.1021/acsami.8b10992
   Zhang Z., 2023, SCI ADV, V9, DOI [10.1126/sciadv.ade7379, DOI 10.1126/SCIADV.ADE7379, 10.1126]
   Zhao ZY, 2021, ACS NANO, V15, P13041, DOI 10.1021/acsnano.1c02147
   Zhou XF, 2016, ACTA BIOMATER, V39, P192, DOI 10.1016/j.actbio.2016.05.007
   Zhu H, 2009, STEM CELLS DEV, V18, P1473, DOI 10.1089/scd.2009.0021
   Zhuang Y, 2023, MATER DESIGN, V234, DOI 10.1016/j.matdes.2023.112313
   Zou W, 2008, MOL CELL, V31, P422, DOI 10.1016/j.molcel.2008.06.023
NR 139
TC 3
Z9 3
U1 3
U2 27
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2590 0064
J9 MATER TODAY BIO
JI Mater. Today Bio
PD JUN
PY 2024
VL 26
AR 101043
DI 10.1016/j.mtbio.2024.101043
EA APR 2024
PG 16
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA QX8H4
UT WOS:001224253400001
PM 38600918
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Gunson, MJ
   Arnett, GW
   Milam, SB
AF Gunson, Michael J.
   Arnett, G. William
   Milam, Stephen B.
TI Pathophysiology and Pharmacologic Control of Osseous Mandibular Condylar
   Resorption
SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
ID TUMOR NECROSIS FACTOR; HUMAN TEMPOROMANDIBULAR JOINT;
   RHEUMATOID ARTHRITIS PATIENTS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS;
   INTERLEUKIN 6 RECEPTOR INHIBITION; MATRIX METALLOPROTEINASE ACTIVITY;
   MAGNETIC RESONANCE IMAGES; PLACEBO CONTROLLED TRIAL; FLUID MEDIATOR
   LEVEL; BONE MINERAL DENSITY
AB Purpose: When osseous mandibular condylar resorption occurs there can be many different diagnoses: inflammatory arthritis, TMJ compression, trauma, hormone imbalances, and others. While each diagnosis has its own original inciting event, the pathophysiological pathway for articular bone loss is the same. The aim of this article is to review the relevant literature on condylar resorption and the use of pharmacotherapy to control arthritic erosions and resorption.
   Materials and Methods: The literature search was performed using PubMed database with various combinations of related keywords. Preference was given to clinical trials when reviewing articles.
   Results: The literature reveals that common cellular level events associated with articular resorption include the activation of osteoblasts by cytokines, free radicals, hormone imbalances and/or potent phospholipid catabolites. The osteoblast then activates the recruitment of osteoclasts and promotes the release of matrix degrading enzymes from the osteoclast. Research into articular erosions has focused on elucidating the important steps in the bone destructive pathways and interfering with them by pharmacological means. The use of antioxidants, tetracyclines, omega 3 fatty acids, non steroidal anti inflammatories and inflammatory cytokine inhibitors to aid in preventing and controlling articular bone loss including osseous mandibular condylar resorption has been successful.
   Conclusion: By understanding the known pathways that lead to condylar resorption and the individual patient's susceptibilities, targeted pharmacotherapy might be able to disturb these pathways and prevent further condylar resorption. Basic clinical investigations and randomized clinical trials are still required, but the present science is encouraging. (C) 2012 American Association of Oral and Maxillofacial Surgeons J Oral Maxillofac Surg 70:1918 1934, 2012
C1 [Gunson, Michael J.; Arnett, G. William] Arnett & Gunson Facial Reconstruct, Santa Barbara, CA USA.
   [Milam, Stephen B.] Univ Texas Hlth Sci Ctr San Antonio, Oral & Maxillofacial Surg Dept, San Antonio, TX 78229 USA.
C3 University of Texas System; University of Texas Health Science Center at
   San Antonio
RP Gunson, MJ (通讯作者)，9 E Pedregosa St, Santa Barbara, CA 93101 USA.
EM gunson@arnettgunson.com
OI Gunson, Michael/0000 0001 7210 6910
CR Abate A, 2000, FREE RADICAL BIO MED, V29, P1135, DOI 10.1016/S0891 5849(00)00425 1
   Abramson SB, 2006, ADV DRUG DELIVER REV, V58, P212, DOI 10.1016/j.addr.2006.01.008
   ABUBAKER AO, 1993, J ORAL MAXIL SURG, V51, P1096
   Abud Mendoza C, 2003, LUPUS, V12, P607, DOI 10.1191/0961203303lu429oa
   Aghabeigi B, 2003, INT J ORAL MAX SURG, V32, P401, DOI 10.1054/ijom.2002.0368
   Aghaloo TL, 2010, J ORAL MAXIL SURG, V68, P959, DOI 10.1016/j.joms.2009.10.010
   Ahn IE, 2010, CLIN RHEUMATOL, V29, P211, DOI 10.1007/s10067 009 1293 x
   Alstergren P, 2008, SCAND J RHEUMATOL, V37, P155, DOI 10.1080/03009740701675635
   Alstergren P, 1999, ACTA ODONTOL SCAND, V57, P16, DOI 10.1080/000163599429057
   Alstergren P, 2003, J ORAL MAXIL SURG, V61, P1171, DOI 10.1016/S0278 2391(03)00678 5
   Alstergren P, 1998, J ORAL MAXIL SURG, V56, P1059, DOI 10.1016/S0278 2391(98)90256 7
   Alstergren P, 2000, J ORAL MAXIL SURG, V58, P180, DOI 10.1016/S0278 2391(00)90335 5
   Alstergren P, 2006, J RHEUMATOL, V33, P1734
   Amin AR, 1996, P NATL ACAD SCI USA, V93, P14014, DOI 10.1073/pnas.93.24.14014
   Arinci A, 2005, ORAL SURG ORAL MED O, V99, P666, DOI 10.1016/j.tripleo.2004.08.029
   Arner EC, 1998, OSTEOARTHR CARTILAGE, V6, P214, DOI 10.1053/joca.1998.0114
   Arnett G., 1992, MODERN PRACTICE ORTH, P522
   Arnett GW, 1996, AM J ORTHOD DENTOFAC, V110, P117, DOI 10.1016/S0889 5406(96)70099 9
   Arnett GW, 1996, AM J ORTHOD DENTOFAC, V110, P8, DOI 10.1016/S0889 5406(96)70081 1
   ARNETT GW, 1993, AM J ORTHOD DENTOFAC, V104, P506, DOI 10.1016/0889 5406(93)70076 Z
   ARNETT GW, 1988, J ORAL MAXIL SURG, V46, P625
   Arnett GW, 1997, COMPLICATIONS ORAL M, P265
   Arnett GW., 1990, ORAL MAXILLOFAC SURG, V2, P699
   Arnett GW, 2000, ORAL MAXILLOFACIAL S, P245
   AUFDEMORTE TB, 1986, ORAL SURG ORAL MED O, V61, P307, DOI 10.1016/0030 4220(86)90407 X
   Ayral X, 2003, OSTEOARTHR CARTILAGE, V11, P198, DOI 10.1016/S1063 4584(02)00353 9
   Bae SC, 2003, J AM COLL NUTR, V22, P311, DOI 10.1080/07315724.2003.10719309
   Barracchini A, 1998, J PHARM PHARMACOL, V50, P1417, DOI 10.1111/j.2042 7158.1998.tb03369.x
   Barsante MM, 2005, EUR J PHARMACOL, V516, P282, DOI 10.1016/j.ejphar.2005.05.005
   Berbert AA, 2005, NUTRITION, V21, P131, DOI 10.1016/j.nut.2004.03.023
   Bergink AP, 2009, JCR J CLIN RHEUMATOL, V15, P230, DOI 10.1097/RHU.0b013e3181b08f20
   Bettany J T, 1998, Adv Dent Res, V12, P136
   Bettany JT, 2000, BONE, V27, P75, DOI 10.1016/S8756 3282(00)00297 0
   Blanco FJ, 1999, J RHEUMATOL, V26, P1366
   Borderie D, 2001, INFLAMM RES, V50, P409, DOI 10.1007/PL00000263
   BOUWMAN JPB, 1994, ORAL SURG ORAL MED O, V78, P138, DOI 10.1016/0030 4220(94)90135 X
   Brandt KD, 2005, ARTHRITIS RHEUM US, V52, P2015, DOI 10.1002/art.21122
   Cai HX, 2006, J OROFAC PAIN, V20, P53
   Campese VA, 2005, CURR HYPERTENS REP, V7, P337, DOI 10.1007/s11906 005 0066 4
   Canter PH, 2007, RHEUMATOLOGY, V46, P1223, DOI 10.1093/rheumatology/kem116
   CHANDRA H, 1987, NATURE, V328, P833, DOI 10.1038/328833a0
   Cutbirth M, 1998, J ORAL MAXIL SURG, V56, P178, DOI 10.1016/S0278 2391(98)90863 1
   Darlington LG, 2001, BRIT J NUTR, V85, P251, DOI 10.1079/BJN2000239
   De Clercq C A, 1994, Int J Adult Orthodon Orthognath Surg, V9, P233
   Deodhar A, 2010, ARTHRIT CARE RES, V62, P569, DOI 10.1002/acr.20004
   Dingle JT, 1999, Z RHEUMATOL, V58, P125, DOI 10.1007/s003930050161
   Dohn UM, 2009, ANN RHEUM DIS, V68, P1585, DOI 10.1136/ard.2008.097048
   Dohn UM, 2007, CLIN RHEUMATOL, V26, P1857, DOI 10.1007/s10067 007 0589 y
   Edmonds SE, 1997, ANN RHEUM DIS, V56, P649, DOI 10.1136/ard.56.11.649
   ELDIN AAK, 1992, PHARMACOL RES, V26, P357, DOI 10.1016/1043 6618(92)90234 3
   ELLIS E, 1991, J ORAL MAXIL SURG, V49, P1316, DOI 10.1016/0278 2391(91)90311 9
   ELLIS E, 1989, CLIN PLAST SURG, V16, P133
   Emery P, 2008, ANN RHEUM DIS, V67, P1516, DOI 10.1136/ard.2008.092932
   Emshoff R, 2000, ORAL SURG ORAL MED O, V90, P442, DOI 10.1067/moe.2000.108801
   Emshoff R, 2000, INT J ORAL MAX SURG, V29, P176, DOI 10.1016/S0901 5027(00)80088 0
   FU KY, 1995, J ORAL MAXIL SURG, V53, P424, DOI 10.1016/0278 2391(95)90717 3
   Galal N, 2008, INT J MOL MED, V21, P785
   Genovese MC, 2008, ARTHRITIS RHEUM US, V58, P2968, DOI 10.1002/art.23940
   Goldberg RJ, 2007, PAIN, V129, P210, DOI 10.1016/j.pain.2007.01.020
   Golub LM, 1997, INFLAMM RES, V46, P310, DOI 10.1007/s000110050193
   Güler N, 2003, DENTOMAXILLOFAC RAD, V32, P304, DOI 10.1259/dmfr/24534480
   Gunson MJ, 2009, AM J ORTHOD DENTOFAC, V136, P772, DOI 10.1016/j.ajodo.2009.07.011
   Hajati AK, 2009, J ORAL MAXIL SURG, V67, P1895, DOI 10.1016/j.joms.2009.04.056
   Hamada Y, 2006, ORAL SURG ORAL MED O, V102, P596, DOI 10.1016/j.tripleo.2005.11.010
   Heidari B., 2011, Rheumatol Int
   Heidari B, 2010, INT ORTHOP
   Helgeland M, 2000, CLIN EXP RHEUMATOL, V18, P637
   Helmy M, 2001, ARZNEIMITTELFORSCH, V51, P293
   Hernández JL, 2008, ARTHRITIS RHEUM, V58, P1696, DOI 10.1002/art.23500
   Holick MF, 2005, J NUTR, V135, p2739S, DOI 10.1093/jn/135.11.2739S
   Holmes SG, 2004, BONE, V35, P471, DOI 10.1016/j.bone.2004.02.028
   Hoppenreijs TJM, 1998, INT J ORAL MAX SURG, V27, P81, DOI 10.1016/S0901 5027(98)80301 9
   Ijima Y, 2001, EUR J ORAL SCI, V109, P50, DOI 10.1034/j.1600 0722.2001.00939.x
   Israel H A, 1998, Adv Dent Res, V12, P51
   Jones G, 2010, ANN RHEUM DIS, V69, P88, DOI 10.1136/ard.2008.105197
   Kaneyama K, 2005, ORAL SURG ORAL MED O, V99, P411, DOI 10.1016/j.tripleo.2004.08.012
   Kaneyama K, 2002, BRIT J ORAL MAX SURG, V40, P418, DOI 10.1016/S0266 4356(02)00215 2
   Kanyama M, 2000, J OROFAC PAIN, V14, P20
   Kapila S, 2009, ANN NY ACAD SCI, V1160, P322, DOI 10.1111/j.1749 6632.2009.03830.x
   Kirkwood K, 2003, BIOCHEM PHARMACOL, V66, P1809, DOI 10.1016/S0006 2952(03)00450 7
   Kloppenburg M, 1996, IMMUNOPHARMACOLOGY, V31, P163, DOI 10.1016/0162 3109(95)00041 0
   KREMER JM, 1995, ARTHRITIS RHEUM, V38, P1107, DOI 10.1002/art.1780380813
   Kubota E, 1997, J ORAL MAXIL SURG, V55, P20, DOI 10.1016/S0278 2391(97)90438 9
   Kubota E, 1998, J ORAL MAXIL SURG, V56, P192, DOI 10.1016/S0278 2391(98)90868 0
   Kubota T, 1998, EUR J ORAL SCI, V106, P992, DOI 10.1046/j.0909 8836.1998.eos106603.x
   Lai YC, 2006, ARTHRITIS RHEUM US, V54, P1184, DOI 10.1002/art.21771
   Lane NE, 1999, ARTHRITIS RHEUM US, V42, P854, DOI 10.1002/1529 0131(199905)42:5<854::AID ANR3>3.0.CO;2 I
   LAUHIO A, 1994, ANTIMICROB AGENTS CH, V38, P400, DOI 10.1128/AAC.38.2.400
   Lazzerini PE, 2004, ANN RHEUM DIS, V63, P867, DOI 10.1136/ard.2003.009746
   Lee MC, 2004, REDOX REP, V9, P331, DOI 10.1179/135100004225006830
   Leung BP, 2003, J IMMUNOL, V170, P1524, DOI 10.4049/jimmunol.170.3.1524
   Liang L, 2008, J PERIODONTOL, V79, P1745, DOI [10.1902/jop.2008.070437, 10.1902/jop.2008.070437 ]
   Mahmud Z, 1992, Bangladesh Med Res Counc Bull, V18, P47
   Marchetti C, 1999, ARCH ORAL BIOL, V44, P297, DOI 10.1016/S0003 9969(98)00107 1
   Matsumoto K, 2006, DENTOMAXILLOFAC RAD, V35, P432, DOI 10.1259/dmfr/77288976
   McAlindon TE, 1996, ARTHRITIS RHEUM US, V39, P648, DOI 10.1002/art.1780390417
   McCarey DW, 2004, LANCET, V363, P2015, DOI 10.1016/S0140 6736(04)16449 0
   McCarey DW, 2001, NEW ENGL J MED, V345, P1209
   Mease P, 2011, ARTHRITIS RHEUM US, V63, P939, DOI 10.1002/art.30176
   Mercuri Louis G, 2008, Oral Maxillofac Surg Clin North Am, V20, P169, DOI 10.1016/j.coms.2007.12.007
   MERKX MAW, 1994, J CRANIO MAXILL SURG, V22, P53, DOI 10.1016/S1010 5182(05)80297 5
   MILAM SB, 1995, J ORAL MAXIL SURG, V53, P1448, DOI 10.1016/0278 2391(95)90675 4
   Milam SB, 1998, J ORAL MAXIL SURG, V56, P214, DOI 10.1016/S0278 2391(98)90872 2
   Milner JM, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2034
   Mitani M, 2005, INT J MOL MED, V15, P827
   Miyamoto K, 2002, J ORAL MAXIL SURG, V60, P66, DOI 10.1053/joms.2002.29077
   Mizui T, 2001, BRIT J ORAL MAX SURG, V39, P310, DOI 10.1054/bjom.2001.0634
   Moen K, 2005, ORAL SURG ORAL MED O, V100, P433, DOI 10.1016/j.tripleo.2005.05.060
   MOORE KE, 1991, J ORAL MAXIL SURG, V49, P448, DOI 10.1016/0278 2391(91)90166 J
   Mouithys Mickalad AML, 2000, FREE RADICAL RES, V33, P607, DOI 10.1080/10715760000301131
   Muroi Y, 2007, J DENT RES, V86, P786, DOI 10.1177/154405910708600819
   Naidu BV, 2003, J THORAC CARDIOV SUR, V126, P482, DOI 10.1016/S0022 5223(03)00699 8
   Nishimura M, 2004, J ORAL MAXIL SURG, V62, P284, DOI 10.1016/j.joms.2003.08.012
   Nishimura M, 2002, ORAL SURG ORAL MED O, V94, P328, DOI 10.1067/moe.2002.124106
   Nishimura M, 2002, BRIT J ORAL MAX SURG, V40, P68, DOI 10.1054/bjom.2001.0742
   Nordahl S, 1998, EUR J ORAL SCI, V106, P559, DOI 10.1046/j.0909 8836.1998.eos106104.x
   Novack V, 2009, INTENS CARE MED, V35, P1255, DOI 10.1007/s00134 009 1429 0
   Ogura N, 2005, J ORAL PATHOL MED, V34, P357, DOI 10.1111/j.1600 0714.2005.00302.x
   Ogura N, 2004, J ORAL PATHOL MED, V33, P629, DOI 10.1111/j.1600 0714.2004.00260.x
   Ogura N, 2002, J ORAL PATHOL MED, V31, P353, DOI 10.1034/j.1600 0714.2002.310606.x
   Paredes S, 2002, J RHEUMATOL, V29, P2271
   Peterson CA, 2008, J INFLAMM LOND, V5, DOI 10.1186/1476 9255 5 10
   Planello AC, 2011, EUR J ORAL SCI, V119, P1, DOI 10.1111/j.1600 0722.2010.00803.x
   Puzas JE, 2001, CELLS TISSUES ORGANS, V169, P248, DOI 10.1159/000047888
   Ravaud P, 1998, J RHEUMATOL, V25, P2425
   Riancho JA, 2010, OSTEOARTHR CARTILAGE, V18, P927, DOI 10.1016/j.joca.2010.04.002
   Sandler NA, 1998, J ORAL MAXIL SURG, V56, P534, DOI 10.1016/S0278 2391(98)90446 3
   Sano H, 2009, MOD RHEUMATOL, V19, P390, DOI 10.1007/s10165 009 0177 x
   Sato J, 2003, BRIT J ORAL MAX SURG, V41, P95, DOI 10.1016/S0266 4356(02)00294 2
   Sato J, 2007, ORAL SURG ORAL MED O, V103, P467, DOI 10.1016/j.tripleo.2006.06.058
   SCHLONDORFF D, 1985, BIOCHEM PHARMACOL, V34, P3391, DOI 10.1016/0006 2952(85)90366 1
   Segami N, 2002, ORAL SURG ORAL MED O, V94, P515, DOI 10.1067/moe.2002.126697
   SHAFER DM, 1994, J ORAL MAXIL SURG, V52, P786, DOI 10.1016/0278 2391(94)90217 8
   Shinoda C, 2000, Oral Dis, V6, P383
   Shlopov BV, 2001, J RHEUMATOL, V28, P835
   Simopoulos AP, 2002, J AM COLL NUTR, V21, P495, DOI 10.1080/07315724.2002.10719248
   Sindelar BJ, 2002, ANAT RECORD, V266, P167, DOI 10.1002/ar.10050
   Smith GN, 1999, ARTHRITIS RHEUM, V42, P1140, DOI 10.1002/1529 0131(199906)42:6<1140::AID ANR10>3.0.CO;2 7
   Smolen JS, 2008, LANCET, V371, P987, DOI 10.1016/S0140 6736(08)60453 5
   Sreekanth V R, 2000, J Assoc Physicians India, V48, P804
   Srinivas R, 2001, ORAL SURG ORAL MED O, V91, P517, DOI 10.1067/moe.2001.115136
   Stone M, 2003, J RHEUMATOL, V30, P2112
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Suenaga S, 2001, DENTOMAXILLOFAC RAD, V30, P214, DOI 10.1038/sj.dmfr.4600610
   Sundrarjun T, 2004, J INT MED RES, V32, P443, DOI 10.1177/147323000403200501
   Suzuki T, 2002, J ORAL PATHOL MED, V31, P549, DOI 10.1034/j.1600 0714.2002.00022.x
   Suzuki T, 1999, ORAL SURG ORAL MED O, V88, P670, DOI 10.1016/S1079 2104(99)70007 7
   SYMONS MCR, 1988, FREE RADICAL RES COM, V5, P131, DOI 10.3109/10715768809066922
   Tak PP, 2011, ANN RHEUM DIS, V70, P39, DOI 10.1136/ard.2010.137703
   Takahashi T, 1999, ORAL SURG ORAL MED O, V88, P129, DOI 10.1016/S1079 2104(99)70105 8
   Tanaka A, 2001, J ORAL PATHOL MED, V30, P59, DOI 10.1034/j.1600 0714.2001.300110.x
   Tanaka A, 2000, J ORAL PATHOL MED, V29, P314, DOI 10.1034/j.1600 0714.2000.290705.x
   TARP U, 1992, ANN RHEUM DIS, V51, P1044, DOI 10.1136/ard.51.9.1044
   Thunyakitpisal PD, 2004, J PHARMACOL SCI, V94, P403, DOI 10.1254/jphs.94.403
   Tiilikainen P, 2005, J ORAL PATHOL MED, V34, P39, DOI 10.1111/j.1600 0714.2004.00262.x
   Tiku ML, 2000, J BIOL CHEM, V275, P20069, DOI 10.1074/jbc.M907604199
   Tobe M, 2002, J ORAL MAXIL SURG, V60, P741, DOI 10.1053/joms.2002.33239
   Tomida M., 2004, British Journal of Oral & Maxillofacial Surgery, V42, P405, DOI 10.1016/j.bjoms.2004.06.003
   Tominaga K, 2004, ARCH ORAL BIOL, V49, P493, DOI 10.1016/j.archoralbio.2003.12.008
   Venkatraman JT, 1999, J AM COLL NUTR, V18, P602, DOI 10.1080/07315724.1999.10718895
   Voog Ü, 2004, ACTA ODONTOL SCAND, V62, P7, DOI 10.1080/00016350310007860
   Voog Ü, 2003, ACTA ODONTOL SCAND, V61, P57, DOI 10.1080/ode.61.1.57.64
   Wakita T, 2006, J DENT RES, V85, P627, DOI 10.1177/154405910608500709
   Wall R, 2010, NUTR REV, V68, P280, DOI 10.1111/j.1753 4887.2010.00287.x
   Wang Yanhong, 2007, Marine Science Bulletin (Beijing), V9, P66
   WEBSTER GF, 1994, ARCH DERMATOL, V130, P748, DOI 10.1001/archderm.130.6.748
   Weinblatt ME, 2010, ARTHRITIS CARE RES H
   Wolford L M, 2001, Proc (Bayl Univ Med Cent), V14, P246
   Yamada K, 2001, ORAL SURG ORAL MED O, V92, P265, DOI 10.1067/moe.2001.117558
   Yamaguchi A, 2005, ARCH ORAL BIOL, V50, P81, DOI 10.1016/j.archoralbio.2004.06.006
   Yamashiro T, 1998, ARCH ORAL BIOL, V43, P191, DOI 10.1016/S0003 9969(98)00008 9
   Yoshida K, 2006, ORAL SURG ORAL MED O, V102, P22, DOI 10.1016/j.tripleo.2005.07.013
   Zardeneta G, 1998, INT J ORAL MAX SURG, V27, P397, DOI 10.1016/S0901 5027(98)80072 6
   Zardeneta G, 2000, J ORAL MAXIL SURG, V58, P302, DOI 10.1016/S0278 2391(00)90060 0
NR 174
TC 100
Z9 107
U1 0
U2 18
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0278 2391
EI 1531 5053
J9 J ORAL MAXIL SURG
JI J. Oral Maxillofac. Surg.
PD AUG
PY 2012
VL 70
IS 8
BP 1918
EP 1934
DI 10.1016/j.joms.2011.07.018
PG 17
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 981UJ
UT WOS:000306996100033
PM 22014941
DA 2025 08 17
ER

PT J
AU Wan, YH
   Chong, LW
   Evans, RM
AF Wan, Yihong
   Chong, Ling Wa
   Evans, Ronald M.
TI PPAR γ regulates osteoclastogenesis in mice
SO NATURE MEDICINE
LA English
DT Article
ID ACTIVATED RECEPTOR GAMMA; BONE RESORPTION; INSULIN RESISTANCE; IN VIVO;
   C FOS; ROSIGLITAZONE; DIFFERENTIATION; AGONIST; HEMATOPOIESIS; DISEASE
AB Osteoclasts are bone resorbing cells derived from hematopoietic precursors of the monocyte macrophage lineage. Regulation of osteoclast function is central to the understanding of bone diseases such as osteoporosis, rheumatoid arthritis and osteopetrosis(1). Although peroxisome proliferator activated receptor gamma (PPAR gamma) has been shown to inhibit osteoblast differentiation(2,3), its role, if any, in osteoclasts is unknown. This is a clinically crucial question because PPAR gamma agonists, ''such as thiazolidinediones '' a class of insulin sensitizing drugs, have been reported to cause a higher rate of fractures in human patients(4,5). Here we have uncovered a pro osteoclastogenic effect of PPAR gamma by using a Tie2Cre/flox mouse model in which PPAR gamma is deleted in osteoclasts but not in osteoblasts. These mice develop osteopetrosis characterized by increased bone mass, reduced medullary cavity space and extramedullary hematopoiesis in the spleen. These defects are the result of impaired osteoclast differentiation and compromised receptor activator of nuclear factor kappa B ligand signaling and can be rescued by bone marrow transplantation. Moreover, ligand activation of PPAR gamma by rosiglitazone exacerbates osteoclast differentiation in a receptor dependent manner. Our examination of the underlying mechanisms suggested that PPAR gamma functions as a direct regulator of c fos expression, an essential mediator of osteoclastogenesis(6). Therefore, PPAR gamma and its ligands have a previously unrecognized role in promoting osteoclast differentiation and bone resorption.
C1 Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, La Jolla, CA 92037 USA.
C3 Salk Institute; Howard Hughes Medical Institute
RP Evans, RM (通讯作者)，Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, La Jolla, CA 92037 USA.
EM evans@salk.edu
RI Evans, Ronald/AAF 4001 2019; Wan, Yihong/J 8681 2012
OI Evans, Ronald/0000 0002 9986 5965
FU NHLBI NIH HHS [HL07770, HL569898] Funding Source: Medline; NIDDK NIH HHS
   [DK57978] Funding Source: Medline
CR Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004 0735
   Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097 2765(00)80209 9
   Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326
   Chui PC, 2005, J CLIN INVEST, V115, P2244, DOI 10.1172/JCI24130
   Cock TA, 2004, EMBO REP, V5, P1007, DOI 10.1038/sj.embor.7400254
   Constien R, 2001, GENESIS, V30, P36, DOI 10.1002/gene.1030
   GREY A, 2007, OSTEOPOROS INT  0928
   Grey A, 2007, J CLIN ENDOCR METAB, V92, P1305, DOI 10.1210/jc.2006 2646
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   He WM, 2003, P NATL ACAD SCI USA, V100, P15712, DOI 10.1073/pnas.2536828100
   Kahn SE, 2006, NEW ENGL J MED, V355, P2427, DOI 10.1056/NEJMoa066224
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kawano H, 2003, P NATL ACAD SCI USA, V100, P9416, DOI 10.1073/pnas.1533500100
   Kisanuki YY, 2001, DEV BIOL, V230, P230, DOI 10.1006/dbio.2000.0106
   Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097 2765(00)80210 5
   Lee G, 2002, J BIOL CHEM, V277, P19649, DOI 10.1074/jbc.M200743200
   Leesnitzer LM, 2002, BIOCHEMISTRY US, V41, P6640, DOI 10.1021/bi0159581
   Li M, 2006, BONE, V39, P796, DOI 10.1016/j.bone.2006.04.008
   Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855
   Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178
   Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097 2765(00)80211 7
   Rzonca SO, 2004, ENDOCRINOLOGY, V145, P401, DOI 10.1210/en.2003 0746
   Sottile V, 2004, CALCIFIED TISSUE INT, V75, P329, DOI 10.1007/s00223 004 0224 8
   Taichman RS, 2005, BLOOD, V105, P2631, DOI 10.1182/blood 2004 06 2480
   Takakura N, 1998, IMMUNITY, V9, P677, DOI 10.1016/S1074 7613(00)80665 2
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wan YH, 2007, GENE DEV, V21, P1895, DOI 10.1101/gad.1567207
NR 30
TC 449
Z9 504
U1 0
U2 37
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013 1917 USA
SN 1078 8956
J9 NAT MED
JI Nat. Med.
PD DEC
PY 2007
VL 13
IS 12
BP 1496
EP 1503
DI 10.1038/nm1672
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 238KB
UT WOS:000251445400025
PM 18059282
DA 2025 08 17
ER

PT J
AU Lei, SG
   Ding, M
   Wang, YC
   Xu, H
   Liao, BH
AF Lei, Shangguan
   Ding, Ming
   Wang, Yingchun
   Xu, Hu
   Liao, Binghui
TI Denosumab ameliorates osteoarthritis by protecting cartilage against
   degradation and modulating subchondral bone remodeling
SO REGENERATIVE THERAPY
LA English
DT Article
DE Osteoarthritis; Denosumab; Osteoclast; Chondrocyte
ID CHONDROCYTE APOPTOSIS; DIFFERENTIATION; OSTEOPOROSIS; PATHOGENESIS;
   TERIPARATIDE; MICE
AB Osteoarthritis (OA) is the most prevalent degenerative joint disease worldwide. Effective management for early stage OA is crucial. Denosumab (DS) has been widely used to treat osteoporosis (OP) and rheumatoid arthritis, but its potential for managing OA remains clear. We assessed the effects of DS on osteoclast activity and chondrocyte apoptosis using tartrate resistant acid phosphatase (TRAP) assay, quantitative real time polymerase chain reaction (qRT PCR), flow cytometry, and TUNEL staining. To assess the impact of DS on the NF kB pathway, we performed Western blot and immunofluorescence staining. Additionally, we used an OA model to explore the influence of DS on subchondral bone remodeling and cartilage degeneration in vivo. We found that DS hindered receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclastogenesis by inhibiting the activity of the NF kB pathway. Besides, DS alleviated reactive oxygen species (ROS) induced apoptosis in chondrocytes by regulating the expression of genes related to apoptosis. Moreover, we observed an attenuation of OArelated subchondral bone remodeling and cartilage degeneration in vivo. Our findings indicate that DS could effectively suppress osteoclast activity and chondrocyte apoptosis, thereby mitigating OA related subchondral bone remodeling and cartilage degeneration. These results provide a mechanistic basis for using DS to treat OA. (c) 2024, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
C1 [Lei, Shangguan; Ding, Ming; Wang, Yingchun; Xu, Hu; Liao, Binghui] Fourth Mil Med Univ, Xijing Hosp, Dept Orthoped Surg, Xian, Peoples R China.
C3 Air Force Medical University
RP Liao, BH (通讯作者)，Fourth Mil Med Univ, Xijing Hosp, Dept Orthoped Surg, Xian, Peoples R China.
EM sky_0821@163.com
CR Allen KD, 2022, OSTEOARTHR CARTILAGE, V30, P184, DOI 10.1016/j.joca.2021.04.020
   Arden NK, 2021, NAT REV RHEUMATOL, V17, P59, DOI 10.1038/s41584 020 00523 9
   Arnold JB, 2022, OSTEOARTHR CARTILAGE, V30, P945, DOI 10.1016/j.joca.2022.02.603
   Bodic B, 2022, OSTEOARTHR CARTILAGE, V30, P875, DOI 10.1016/j.joca.2022.02.620
   Bolduc JA, 2019, FREE RADICAL BIO MED, V132, P73, DOI 10.1016/j.freeradbiomed.2018.08.038
   Bonnet N, 2019, J CLIN INVEST, V129, P3214, DOI 10.1172/JCI125915
   Chen TH, 2021, BIOCHEM PHARMACOL, V192, DOI 10.1016/j.bcp.2021.114669
   Englund M, 2012, NAT REV RHEUMATOL, V8, P412, DOI 10.1038/nrrheum.2012.69
   Fuksa L, 2015, CURR MED RES OPIN, V31, P1645, DOI 10.1185/03007995.2015.1065241
   Goldring MB, 2010, ANN NY ACAD SCI, V1192, P230, DOI 10.1111/j.1749 6632.2009.05240.x
   Goldring SR, 2009, MED CLIN N AM, V93, P25, DOI 10.1016/j.mcna.2008.09.006
   Guo Q, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 020 03341 9
   Hu QW, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.799575
   Hu WH, 2021, ANN RHEUM DIS, V80, P413, DOI 10.1136/annrheumdis 2020 218089
   Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140 6736(19)30417 9
   Hwang HS, 2015, INT J MOL SCI, V16, P26035, DOI 10.3390/ijms161125943
   Kim H, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22565 7
   Kim K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020601
   Kobayakawa T, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 91248 6
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Krenn V, 2006, HISTOPATHOLOGY, V49, P358, DOI 10.1111/j.1365 2559.2006.02508.x
   Lepetsos P, 2016, BBA MOL BASIS DIS, V1862, P576, DOI 10.1016/j.bbadis.2016.01.003
   Liang X, 2023, CONNECT TISSUE RES, V64, P274, DOI 10.1080/03008207.2022.2157723
   Lin CX, 2022, AGING US, V14, P253, DOI 10.18632/aging.203707
   Lin L, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.1011246
   Lindsay R, 2016, OSTEOPOROSIS INT, V27, P2395, DOI 10.1007/s00198 016 3534 6
   Litwic A, 2013, BRIT MED BULL, V105, P185, DOI 10.1093/bmb/lds038
   Matsubara T, 2017, BIOCHEM BIOPH RES CO, V489, P472, DOI 10.1016/j.bbrc.2017.05.174
   MEACHIM G, 1965, ANN RHEUM DIS, V24, P23, DOI 10.1136/ard.24.1.23
   Musumeci G, 2015, INT J MOL SCI, V16, P20560, DOI 10.3390/ijms160920560
   Recknor C, 2011, EXPERT OPIN PHARMACO, V12, P807, DOI 10.1517/14656566.2011.562201
   Reid IR, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115390
   Rendina Ruedy E, 2022, MOL METAB, V60, DOI 10.1016/j.molmet.2022.101480
   Rim YA, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072358
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Stamenkovic BN, 2022, MEDICINA LITHUANIA, V58, DOI 10.3390/medicina58091207
   Tanaka S, 2021, J BONE MINER METAB, V39, P106, DOI 10.1007/s00774 020 01159 1
   Tao HQ, 2021, PHARMACOL RES, V174, DOI 10.1016/j.phrs.2021.105967
   Tsokanos A, 2021, MEDICINA LITHUANIA, V57, DOI 10.3390/medicina57070696
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Wang BW, 2019, DRUG DES DEV THER, V13, P3529, DOI 10.2147/DDDT.S210220
   Xin YQ, 2022, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.793750
   Xu L, 2023, BONE, V167, DOI 10.1016/j.bone.2022.116638
   Zhang M, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt139
   Zhou F, 2019, ACTA PHARM SIN B, V9, P973, DOI 10.1016/j.apsb.2019.01.015
NR 45
TC 7
Z9 7
U1 1
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352 3204
J9 REGEN THER
JI Regen. Ther.
PD DEC
PY 2024
VL 27
BP 181
EP 190
DI 10.1016/j.reth.2024.03.019
EA MAR 2024
PG 10
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering
GA T8C3T
UT WOS:001407215200001
PM 38840731
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Qiu, ZC
   Tang, XY
   Wu, QC
   Tang, ZL
   Wong, MS
   Chen, JX
   Yao, XS
   Dai, Y
AF Qiu, Zuo chengy
   Tang, Xi yang
   Wu, Qing chang
   Tang, Zi ling
   Wong, Man sau
   Chen, Jia xu
   Yao, Xin sheng
   Dai, Yi
TI A new strategy for discovering effective substances and mechanisms of
   traditional Chinese medicine based on standardized drug containing
   plasma and the absorbed ingredients composition, a case study of
   Xian Ling Gu Bao capsules
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Traditional Chinese medicine formula; Mechanism of action;
   Xian Ling Gu Bao capsule; Transcriptome sequencing; Standardized
   drug containing plasma
ID ER ALPHA; IDENTIFICATION; ESTROGEN; FORMULA; METABOLITES; DISSECTION;
   FUFANG; GENE
AB Ethnopharmacological relevance: The overall therapeutic effect of traditional Chinese medicine formulae (TCMF) was achieved by the interactions of multiple components with multiple targets. However, current pharmacology research strategies have struggled to identify effective substance groups and encountered challenges in elucidating the underlying mechanisms of TCMF. Aim: In this study, a comprehensive strategy was proposed and applied to elucidate the interactions of the multiple components that underlie the functions of the famous TCMF: Xian Ling Gu Bao (XLGB) capsule on bone metabolism in vivo and to elucidate the molecular mechanisms underlying the effects of XLGB on bone cells, especially on osteoblasts. Methods: The efficacy of XLGB in the protection against bones loss in ovariectomized (OVX) rats was confirmed by Micro CT analysis. The anti osteoporosis mechanism involved in the systemic regulatory actions of XLGB was elucidated by transcriptome sequencing analysis on bone marrow mesenchymal stem cells isolated from OVX rats. Moreover, the components absorbed in XLGB treated plasma were characterized by mass spectrometry analysis, and subsequently, a standardized preparation process of drug containing plasma was established. The synergistic osteogenic effect of the multiple components in plasma was investigated by a combination and then knockout of components using pre osteoblast MC3T3 E1 cells. In order to decipher the underlying mechanism of XLGB, the targets of the absorbed components on bone were predicted by target prediction and network pharmacology analysis, then several interactions were validated by biochemical and cell based assay. Results: A total of 18 genes, including HDC, CXCL1/2, TNF, IL6 and Il1b, were newly found to be the major target genes regulated by XLGB. Interestingly, we found that a combination of the three absorbed components, i.e. MSP, rather than their single form at the same concentration, stimulated the formation of calcified nodules in MC3T3E1 cells, suggesting a synergistic effect of these components. Besides, target prediction and experimental validation confirmed the binding affinity of corylin and icaritin for estrogen receptor alpha and beta, the inhibitory activity of isobavachin and isobavachalcone on glycogen synthase kinase 3 beta, and the inhibitory activity of isobavachalcone on cathepsin K. The cell based assay further confirmed the result of the biochemical assay. A network that integrated absorbed components of XLGB targets perturbation genes pathways against osteoporosis was established. Conclusion: Our current study provides a new systemic strategy for discovering active ingredient groups of TCM formulae and understanding their underlying mechanisms.
C1 [Qiu, Zuo chengy; Tang, Zi ling; Chen, Jia xu] Jinan Univ, Sch Tradit Chinese Med, Formula Pattern Res Ctr, Guangzhou Key Lab Formula Pattern Tradit Chinese, Guangzhou 510632, Peoples R China.
   [Tang, Xi yang; Wu, Qing chang; Yao, Xin sheng] Jinan Univ, Coll Pharm, Guangzhou 510632, Peoples R China.
   [Tang, Xi yang; Wu, Qing chang; Yao, Xin sheng] Jinan Univ, Int Cooperat Lab Tradit Chinese Med Modernizat &, Chinese Minist Educ, Guangzhou 510632, Peoples R China.
   [Wong, Man sau] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Kowloon, Hung Hom, Hong Kong, Peoples R China.
C3 Jinan University; Jinan University; Jinan University; Hong Kong
   Polytechnic University
RP Yao, XS; Dai, Y (通讯作者)，Jinan Univ, Inst Tradit Chinese Med & Nat Prod, Coll Pharm, Guangzhou, Peoples R China.; Chen, JX (通讯作者)，Jinan Univ, Sch Tradit Chinese Med, Formula Pattern Res Ctr, Guangzhou, Peoples R China.
EM chenjiaxu@hotmail.com; tyaoxs@jnu.edu.cn; daiyi1004@163.com
RI Wong, Man Sau/F 2059 2015; chen, jiaojiao/KII 6749 2024; Dai,
   Yi/AAC 1336 2019
OI Wong, Man Sau/0000 0002 0729 8618; 
FU Shenzhen Key Laboratory of Food Biological Safety; State Key Laboratory
   of Chinese Medicine and Molecular Pharmacology (Incubation); National
   Natural Science Foundation of China [81903618]; Major Project for
   International Cooperation and Exchange of the National Natural Science
   Foundation of China [81220108028]; Project of the Science Foundation for
   Distinguished Young Scholars of Guangdong Province [2014A030306043];
   Guangzhou Basic and Applied Basic Research Foundation [202102021160];
   National Innovation and Entrepreneurship Training Program for
   Undergraduate [202110559094]; Huang Zhendong Research Fund for
   Traditional Chinese Medicine of Jinan University
FX We thank the Shenzhen Key Laboratory of Food Biological Safety and the
   State Key Laboratory of Chinese Medicine and Molecular Pharmacology
   (Incubation) for their support. This work was supported by National
   Natural Science Foundation of China (81903618) and Major Project for
   International Cooperation and Exchange of the National Natural Science
   Foundation of China (81220108028) , Project of the Science Foundation
   for Distinguished Young Scholars of Guangdong Province (2014A030306043)
   , Huang Zhendong Research Fund for Traditional Chinese Medicine of Jinan
   University, Guangzhou Basic and Applied Basic Research Foundation
   (202102021160) , National Innovation and Entrepreneurship Training
   Program for Undergraduate (202110559094) .
CR Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471 2105 4 2
   Bao HS, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906 020 03007 1
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Buriani A, 2012, J ETHNOPHARMACOL, V140, P535, DOI 10.1016/j.jep.2012.01.055
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Dai Y, 2013, AM J CHINESE MED, V41, P1181, DOI 10.1142/S0192415X13500808
   Ding Y, 2019, J CELL BIOCHEM, V120, P16025, DOI 10.1002/jcb.28882
   Duong Le T, 2012, Bonekey Rep, V1, P67, DOI 10.1038/bonekey.2012.67
   Fitzpatrick LA, 2003, P NATL ACAD SCI USA, V100, P6027, DOI 10.1073/pnas.0934373100
   Geng JL, 2014, J PHARMACEUT BIOMED, V96, P90, DOI 10.1016/j.jpba.2014.03.024
   Guo R, 2020, PHARMACOL RES, V152, DOI 10.1016/j.phrs.2020.104627
   Guo SZ, 2016, PHARMACOL RES, V114, P196, DOI 10.1016/j.phrs.2016.10.026
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   IWAMA H, 1987, J ETHNOPHARMACOL, V21, P45
   Knox C, 2011, NUCLEIC ACIDS RES, V39, pD1035, DOI 10.1093/nar/gkq1126
   Li FM, 2017, EXP THER MED, V14, P2385, DOI 10.3892/etm.2017.4771
   Lim SH, 2011, PHYTOMEDICINE, V18, P425, DOI 10.1016/j.phymed.2011.02.002
   Liu X, 2014, BIOORG MED CHEM LETT, V24, P1403, DOI 10.1016/j.bmcl.2014.01.029
   Qin L, 2005, J BONE MINER METAB, V23, P55, DOI 10.1007/BF03026324
   Qiu ZC, 2020, EXP CELL RES, V395, DOI 10.1016/j.yexcr.2020.112186
   Qiu ZC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122116
   Sánchez Vidaña DI, 2017, EVID BASED COMPL ALT, V2017, DOI 10.1155/2017/6359730
   Sheng YJ, 2018, IET SYST BIOL, V12, P118, DOI 10.1049/iet syb.2017.0043
   Suo TC, 2017, SCI REP UK, V7, DOI 10.1038/srep40529
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Tang XY, 2020, J PHARMACEUT BIOMED, V177, DOI 10.1016/j.jpba.2019.112836
   Vidal D, 2010, MOL INFORM, V29, P543, DOI 10.1002/minf.201000055
   Wang L, 2008, P NATL ACAD SCI USA, V105, P4826, DOI 10.1073/pnas.0712365105
   Wang PL, 2016, FITOTERAPIA, V109, P31, DOI 10.1016/j.fitote.2015.11.006
   Wang XJ, 2016, SCI REP UK, V6, DOI 10.1038/srep18997
   Wang XL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118184
   Wei QS, 2016, BIOMED PHARMACOTHER, V84, P931, DOI 10.1016/j.biopha.2016.09.107
   Wu H, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00273
   Wu QC, 2020, PHYTOMEDICINE, V68, DOI 10.1016/j.phymed.2019.153146
   Xiao HH, 2014, J STEROID BIOCHEM, V143, P141, DOI 10.1016/j.jsbmb.2014.02.019
   Xu YP, 2016, BIOSCI TRENDS, V10, P433, DOI 10.5582/bst.2016.01072
   Yao Y, 2013, J ETHNOPHARMACOL, V150, P619, DOI 10.1016/j.jep.2013.09.018
   Yao ZH, 2017, J CHROMATOGR B, V1041, P104, DOI 10.1016/j.jchromb.2016.12.026
   Zhang TH, 2018, J PHARMACEUT BIOMED, V161, P129, DOI 10.1016/j.jpba.2018.08.040
   Zhang Y., Oncotarget
   Zhou LP, 2021, PHYTOMEDICINE, V82, DOI 10.1016/j.phymed.2020.153413
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
   Zhu F, 2012, NUCLEIC ACIDS RES, V40, pD1128, DOI 10.1093/nar/gkr797
   Zhu HM, 2012, OSTEOPOROSIS INT, V23, P1317, DOI 10.1007/s00198 011 1577 2
NR 44
TC 17
Z9 20
U1 11
U2 84
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD OCT 28
PY 2021
VL 279
AR 114396
DI 10.1016/j.jep.2021.114396
EA JUL 2021
PG 16
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA UA4GN
UT WOS:000685119400009
PM 34246738
DA 2025 08 17
ER

PT J
AU Dong, W
   Qi, MC
   Wang, YR
   Feng, XJ
   Liu, HC
AF Dong, Wei
   Qi, Mengchun
   Wang, Yirui
   Feng, Xiaojie
   Liu, Hongchen
TI Zoledronate and high glucose levels influence osteoclast differentiation
   and bone absorption via the AMPK pathway
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Zoledronate; Osteoclast; High glucose; AMPK
ID ACTIVATED PROTEIN KINASE; KAPPA B LIGAND; IN VITRO; RECEPTOR ACTIVATOR;
   TRANSMEMBRANE PROTEIN; NEGATIVE REGULATOR; RANKL; MICE; OSTEOPROTEGERIN;
   SUPPRESSION
AB Bisphosphonates, the main drugs to treat osteoporosis, have been shown to protect against bone loss in diabetic osteoporosis. However, the effects of the bisphosphonate zoledronate (ZOL) on osteoclast differentiation and function in a high glucose environment as well as the involvement of the adenosine activated protein kinase (AMPK) pathway remain unclear. In the current study, RAW264.7 cells were induced into osteoclasts, divided into low glucose, high glucose, low glucose + ZOL, and high glucose + ZOL groups, which were tested for cell proliferation, cell migration, integrity of the osteoclast sealing zone, osteoclast differentiation, bone absorption, and protein and mRNA expression of genes in the AMPK pathway. We demonstrated that high glucose promoted the expression of AMPK, p AMPK, while inhibited nuclear factor of activated T cells 1 (NFATc1), spleen tyrosine kinase (SYK), cathepsin K (CTSK), and tartrate resistant acid phosphatase (TRAP), which influenced osteoclast differentiation and bone absorption. Upon addition of ZOL to high glucose, the expression of AMPK, p AMPK increased and the expression of NFATc1, SYK, CTSK, TRAP decreased, while osteoclast differentiation and bone absorption were further inhibited. Further more, when added Compound C (AMPK antagonist), we found the expression of AMPK, p AMPK, decreased, whereas NFATc1, SYK, and TRAP increased. In contrast, AMPK and p AMPK increased and NFATc1, SYK, CTSK and TRAP decreased upon addition of AICAR, an AMPK agonist. In conclusion, the results suggest AMPK has potential as a new target for the treatment of osteoporosis, the high glucose environment promoted RAW264.7 cell migration, but suppressed osteoclast differentiation and bone absorption, and ZOL suppressed osteoclast migration, differentiation, and bone absorption via the AMPK pathway. (C) 2018 The Authors. Published by Elsevier Inc.
C1 [Dong, Wei; Liu, Hongchen] Chinese Peoples Liberat Army Gen Hosp, Inst Stomatol, Fuxing Lu 28, Beijing 100853, Peoples R China.
   [Qi, Mengchun; Wang, Yirui; Feng, Xiaojie] North China Univ Sci & Technol, Sch Stomatol, Tangshan City 063210, Hebei, Peoples R China.
C3 Chinese People's Liberation Army General Hospital; North China
   University of Science & Technology
RP Liu, HC (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Inst Stomatol, Fuxing Lu 28, Beijing 100853, Peoples R China.
EM liu hc301@hotmail.com
RI ; Feng, Xiaojie/NIV 1861 2025; dong, wei/KVA 6898 2024
OI Dong, Wei/0000 0002 0997 8983; 
FU National High Technology Research and Development Program of China
   [2015AA033502]; Natural Science Foundation of Hebei Province
   [H2017209114]
FX The study is partly supported by the National High Technology Research
   and Development Program of China (grant numbers 2015AA033502); and the
   Natural Science Foundation of Hebei Province (grant numbers
   H2017209114).
CR Coe LM, 2015, J CELL PHYSIOL, V230, P1944, DOI 10.1002/jcp.24929
   Duarte PM, 2005, J PERIODONTOL, V76, P107, DOI 10.1902/jop.2005.76.1.107
   Foretz M, 2011, J HEPATOL, V54, P827, DOI 10.1016/j.jhep.2010.09.014
   Gandhi A, 2006, BONE, V38, P540, DOI 10.1016/j.bone.2005.10.019
   Gong X, 2017, SCI REP UK, V7, DOI 10.1038/srep36129
   Hsieh TP, 2011, PHYTOMEDICINE, V18, P176, DOI 10.1016/j.phymed.2010.04.003
   Iwamoto J, 2011, DIABETES RES CLIN PR, V93, P166, DOI 10.1016/j.diabres.2011.03.033
   Jeyabalan J, 2012, J ENDOCRINOL, V214, P349, DOI 10.1530/JOE 12 0184
   Jeyabalan J, 2012, J ENDOCRINOL, V212, P277, DOI 10.1530/JOE 11 0306
   Kang H, 2013, J BIOL CHEM, V288, P12187, DOI 10.1074/jbc.M112.430389
   Kasai T, 2009, J CELL PHYSIOL, V221, P740, DOI 10.1002/jcp.21917
   Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968 0004(98)01340 1
   Kim JY, 2015, BONE, V79, P242, DOI 10.1016/j.bone.2015.06.011
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kitamura K, 2017, COMP BIOCHEM PHYS A, V203, P152, DOI 10.1016/j.cbpa.2016.09.010
   Lee YS, 2010, BONE, V47, P926, DOI 10.1016/j.bone.2010.08.001
   Mai QG, 2011, J CELL BIOCHEM, V112, P2902, DOI 10.1002/jcb.23206
   Maycas M, 2017, J CELL PHYSIOL, V232, P3611, DOI 10.1002/jcp.25829
   Shah M, 2010, BONE, V47, P309, DOI 10.1016/j.bone.2010.04.596
   Singh DK, 2010, ACTA DIABETOL, V47, pS105, DOI 10.1007/s00592 009 0146 z
   Väänänen HK, 2008, ARCH BIOCHEM BIOPHYS, V473, P132, DOI 10.1016/j.abb.2008.03.037
   Wittrant Y, 2008, BONE, V42, P1122, DOI 10.1016/j.bone.2008.02.006
   Wittrant Y, 2004, EXP CELL RES, V293, P292, DOI 10.1016/j.yexcr.2003.10.016
   Xu F, 2013, J HUAZHONG U SCI MED, V33, P244, DOI 10.1007/s11596 013 1105 z
   Xu J, 2015, MOL MED REP, V11, P865, DOI 10.3892/mmr.2014.2807
   Yavropoulou M. P., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P204
   Yokomoto Umakoshi M, 2016, BIOCHEM BIOPH RES CO, V469, P791, DOI 10.1016/j.bbrc.2015.12.072
NR 27
TC 28
Z9 38
U1 1
U2 40
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD NOV 10
PY 2018
VL 505
IS 4
BP 1195
EP 1202
DI 10.1016/j.bbrc.2018.10.059
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA HA1WR
UT WOS:000450019400038
PM 30322621
OA hybrid
DA 2025 08 17
ER

PT J
AU Bellanger, A
   Donini, CF
   Vendrell, JA
   Lavaud, J
   Machuca Gayet, I
   Ruel, M
   Vollaire, J
   Grisard, E
   Gyorffy, B
   Bièche, I
   Peyruchaud, O
   Coll, JL
   Treilleux, I
   Maguer Satta, V
   Josserand, V
   Cohen, PA
AF Bellanger, Aurelie
   Donini, Caterina F.
   Vendrell, Julie A.
   Lavaud, Jonathan
   Machuca Gayet, Irma
   Ruel, Maeva
   Vollaire, Julien
   Grisard, Evelyne
   Gyorffy, Balazs
   Bieche, Ivan
   Peyruchaud, Olivier
   Coll, Jean Luc
   Treilleux, Isabelle
   Maguer Satta, Veronique
   Josserand, Veronique
   Cohen, Pascale A.
TI The critical role of the ZNF217 oncogene in promoting breast cancer
   metastasis to the bone
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE ZNF217; oncogene; breast cancer; bone metastasis; BMP pathway
ID INTERNATIONAL EXPERT CONSENSUS; OSTEOCLAST PROGENITOR CELLS; MAMMARY
   EPITHELIAL CELLS; MORPHOGENETIC PROTEIN; PROSTATE CANCER; OSTEOBLAST
   DIFFERENTIATION; TGF BETA; SIGNALING PATHWAYS; THERAPEUTIC TARGET;
   TUMOR SUPPRESSOR
AB Bone metastasis affects > 70% of patients with advanced breast cancer. However, the molecular mechanisms underlying this process remain unclear. On the basis of analysis of clinical datasets, and in vitro and in vivo experiments, we report that the ZNF217 oncogene is a crucial mediator and indicator of bone metastasis. Patients with high ZNF217 mRNA expression levels in primary breast tumours had a higher risk of developing bone metastases. MDA MB 231 breast cancer cells stably transfected with ZNF217 (MDA MB 231 ZNF217) showed the dysregulated expression of a set of genes with bone homing and metastasis characteristics, which overlapped with two previously described 'osteolytic bone metastasis' gene signatures, while also highlighting the bone morphogenetic protein (BMP) pathway. The latter was activated in MDA MB 231 ZNF217 cells, and its silencing by inhibitors (Noggin and LDN 193189) was sufficient to rescue ZNF217 dependent cell migration, invasion or chemotaxis towards the bone environment. Finally, by using non invasive multimodal in vivo imaging, we found that ZNF217 increases the metastatic growth rate in the bone and accelerates the development of severe osteolytic lesions. Altogether, the findings of this study highlight ZNF217 as an indicator of the emergence of breast cancer bone metastasis; future therapies targeting ZNF217 and/or the BMP signalling pathway may be beneficial by preventing the development of bone metastases. Copyright (C) 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
C1 [Bellanger, Aurelie; Donini, Caterina F.; Vendrell, Julie A.; Ruel, Maeva; Grisard, Evelyne; Maguer Satta, Veronique; Cohen, Pascale A.] Univ Claude Bernard Lyon 1, Ctr Leon Berard, CNRS 5286, Ctr Rech Cancerol Lyon,INSERM,U1052, Lyon, France.
   [Bellanger, Aurelie; Donini, Caterina F.; Vendrell, Julie A.; Machuca Gayet, Irma; Ruel, Maeva; Grisard, Evelyne; Peyruchaud, Olivier; Cohen, Pascale A.] Univ Claude Bernard Lyon 1, Lyon, France.
   [Donini, Caterina F.] Ctr Leon Berard, Unite Canc & Environm, Lyon, France.
   [Lavaud, Jonathan; Vollaire, Julien; Coll, Jean Luc; Josserand, Veronique] INSERM, Inst Albert Bonniot, U1209, Grenoble, France.
   [Lavaud, Jonathan; Vollaire, Julien; Coll, Jean Luc; Josserand, Veronique] Univ Grenoble Alpes, Inst Albert Bonniot, Grenoble, France.
   [Machuca Gayet, Irma; Peyruchaud, Olivier] INSERM, Fac Med Lyon Est, Unit 1033, Lyon, France.
   [Gyorffy, Balazs] MTA TTK Lendulet Canc Biomarker Res Grp, Budapest, Hungary.
   [Gyorffy, Balazs] Semmelweis Univ, Dept Pediat 2, Budapest, Hungary.
   [Bieche, Ivan] Inst Curie, Dept Genet, Unit Pharmacogenet, Paris, France.
   [Treilleux, Isabelle] Ctr Leon Berard, Dept Biopathol, Lyon, France.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS   National
   Institute for Biology (INSB); UNICANCER; Centre Leon Berard; Universite
   Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Universite Claude Bernard Lyon 1; UNICANCER; Centre
   Leon Berard; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Communaute Universite Grenoble Alpes; Universite Grenoble
   Alpes (UGA); Communaute Universite Grenoble Alpes; Universite Grenoble
   Alpes (UGA); Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite Claude Bernard Lyon 1; HUN REN; HUN REN Research
   Centre for Natural Sciences; Semmelweis University; UNICANCER;
   Universite PSL; Institut Curie; UNICANCER; Centre Leon Berard
RP Cohen, PA (通讯作者)，Fac Pharm Lyon, ISPBL, 8 Ave Rockefeller, F 69373 Lyon 08, France.
EM pascale.cohen@univ lyon1.fr
RI vollaire, julien/E 9272 2019; josserand, veronique/F 1773 2019; Gyorffy,
   Balazs/AAA 9135 2021; Bieche, Ivan/O 7399 2017; cohen,
   pascale/I 5875 2012; Maguer Satta, Veronique/U 8857 2019; Vendrell,
   Julie/I 5867 2012; Lavaud, Jonathan/F 1685 2019; Cohen,
   Pascale/I 5875 2012; Bièche, Ivan/O 7399 2017; Josserand,
   Veronique/F 1773 2019; julien, vollaire/E 9272 2019; Coll,
   Jean Luc/G 2520 2013
OI Bellanger, Aurelie/0000 0002 7573 7416; Maguer Satta,
   Veronique/0000 0002 1556 068X; Peyruchaud, Olivier/0000 0002 5393 4945;
   Machuca  Gayet, irma/0000 0002 3010 9774; Bieche,
   Ivan/0000 0002 2430 5429; cohen, pascale/0000 0001 7016 9598; Gyorffy,
   Balazs/0000 0002 5772 3766; Donini, Caterina
   Francesca/0000 0001 8976 1524; Coll, Jean Luc/0000 0002 2453 3552;
   Lavaud, Jonathan/0000 0002 7540 6975; Josserand,
   Veronique/0000 0001 6733 3801; julien, vollaire/0000 0001 7001 4190; 
FU Ligue Nationale Contre le Cancer (LNCC); ANR (Agence Nationale de la
   Recherche, France) [2011 ANR CESA 018 01]; Region Rhone Alpes
   [CMIRA COOPERA 12 004945 01, CMIRA 2014 COOPERA 14007020 02]; LNCC
   Comite 71; INSERM; University of Lyon; Comite Departemental de la Loire
   de la Ligue Contre le Cancer; French Foundation pour la Recherche sur le
   Cancer (ARC) [PJA20151203151]; ANR grant LYSBONE [ANR 15 CE14 0010 01];
   ANR [2011 ANR CESA 018 01]; Agence Nationale de la Recherche (ANR)
   [ANR 15 CE14 0010] Funding Source: Agence Nationale de la Recherche
   (ANR)
FX The authors thank the Centre de Ressources Biologiques of the Centre
   Leon Berard, S. Leon Goddard and A. Colombe for technical support, and
   B. Manship for editing. AB was supported by a PhD grant from the Ligue
   Nationale Contre le Cancer (LNCC) and CFD was partly funded by the ANR
   (2011 ANR CESA 018 01, Agence Nationale de la Recherche, France). VMS
   part of the project was funded by ANR (2011 ANR CESA 018 01) and Region
   Rhone Alpes (CMIRA COOPERA 12 004945 01, CMIRA
   2014 COOPERA 14007020 02). This work was supported by grants from the
   LNCC Comite 71 (PC), 2011 ANR CESA 018 01 (CFD), INSERM and the
   University of Lyon (OP, IM), the Comite Departemental de la Loire de la
   Ligue Contre le Cancer (OP), the French Foundation pour la Recherche sur
   le Cancer (ARC, Grant no. PJA20151203151), and the ANR grant LYSBONE
   (OP) (Grant no. ANR 15 CE14 0010 01).
CR Abe Y, 2004, J BONE MINER RES, V19, P1302, DOI 10.1359/JBMR.040408
   Alarmo EL, 2013, MODERN PATHOL, V26, P10, DOI 10.1038/modpathol.2012.128
   Alarmo EL, 2010, ENDOCR RELAT CANCER, V17, pR123, DOI 10.1677/ERC 09 0273
   Ampuja M, 2016, CANCER LETT, V375, P238, DOI 10.1016/j.canlet.2016.03.008
   Arnold SF, 1999, CYTOKINE, V11, P1031, DOI 10.1006/cyto.1999.0508
   Atallah I., 2014, HEAD NECK S1, V38, pE246
   Balboni AL, 2013, CANCER RES, V73, P1020, DOI 10.1158/0008 5472.CAN 12 2862
   Baniwal SK, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 258
   Barnes GL, 2004, CANCER RES, V64, P4506, DOI 10.1158/0008 5472.CAN 03 3851
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Beck GR, 2001, CELL GROWTH DIFFER, V12, P61
   Bellahcène A, 2007, BREAST CANCER RES TR, V101, P135, DOI 10.1007/s10549 006 9279 8
   Bendre MS, 2005, CANCER RES, V65, P11001, DOI 10.1158/0008 5472.CAN 05 2630
   Blake ML, 2014, CLIN EXP METASTAS, V31, P233, DOI 10.1007/s10585 013 9624 3
   Bondareva A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005620
   Cai DQ, 2009, BMC CANCER, V9, DOI 10.1186/1471 2407 9 102
   Canfield AE, 1996, J CELL SCI, V109, P343
   Chapellier M, 2015, STEM CELL REP, V4, P239, DOI 10.1016/j.stemcr.2014.12.007
   Chen C, 2012, J CELL BIOCHEM, V113, P3672, DOI 10.1002/jcb.24240
   Cohen PA, 2015, ONCOTARGET, V6, P41566, DOI 10.18632/oncotarget.5893
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Colucci S, 2007, APOPTOSIS, V12, P1623, DOI 10.1007/s10495 007 0095 3
   Cuny GD, 2008, BIOORG MED CHEM LETT, V18, P4388, DOI 10.1016/j.bmcl.2008.06.052
   David M, 2014, J BIOL CHEM, V289, P6551, DOI 10.1074/jbc.M113.533232
   Davies Simon R, 2008, J Exp Ther Oncol, V7, P327
   Delorme G, 2005, BIOL CELL, V97, P589
   Demirkan B, 2013, J CLIN MED, V2, P264, DOI 10.3390/jcm2040264
   Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078 0432.CCR 06 2765
   Di Benedetto A, 2010, J CELL SCI, V123, P2640, DOI 10.1242/jcs.067777
   Dougall WC, 2006, CANCER METAST REV, V25, P541, DOI 10.1007/s10555 006 9021 3
   Dumont B, 2012, J PROTEOME RES, V11, P2247, DOI 10.1021/pr201022n
   Egusa H, 2011, BONE, V49, P264, DOI 10.1016/j.bone.2011.04.003
   Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933
   Feeley BT, 2006, BONE, V38, P154, DOI 10.1016/j.bone.2005.07.015
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Frietze S, 2014, BMC GENOMICS, V15, DOI 10.1186/1471 2164 15 520
   Furushima K, 2002, J BONE MINER RES, V17, P128, DOI 10.1359/jbmr.2002.17.1.128
   Garcia T, 2008, CLIN EXP METASTAS, V25, P33, DOI 10.1007/s10585 007 9099 1
   Gatza CE, 2014, NEOPLASIA, V16, P489, DOI 10.1016/j.neo.2014.05.008
   Gazzerro E, 2007, CURR OPIN PHARMACOL, V7, P325, DOI 10.1016/j.coph.2007.01.003
   Gnant M, 2011, BREAST CARE, V6, P136, DOI 10.1159/000328054
   Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303
   Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304
   Groppe J, 2002, NATURE, V420, P636, DOI 10.1038/nature01245
   Ha BG, 2008, PROTEOMICS, V8, P2625, DOI 10.1002/pmic.200701192
   Hellawell GO, 2002, CANCER RES, V62, P2942
   Herschkowitz JI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2142
   Javed A, 2005, P NATL ACAD SCI USA, V102, P1454, DOI 10.1073/pnas.0409121102
   Jernberg E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077407
   Jiramongkolchai P, 2016, BIOCHEM SOC T, V44, P1117, DOI 10.1042/BST20160069
   Josserand V, 2016, J CONTROL RELEASE, V233, P81, DOI 10.1016/j.jconrel.2016.05.003
   Käkönen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Katsuno Y, 2008, ONCOGENE, V27, P6322, DOI 10.1038/onc.2008.232
   Keller ET, 2001, CANCER METAST REV, V20, P333, DOI 10.1023/A:1015599831232
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   Koblinski JE, 2005, CANCER RES, V65, P7370, DOI 10.1158/0008 5472.CAN 05 0807
   Koenig A, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3309738
   Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200
   Krig SR, 2007, J BIOL CHEM, V282, P9703, DOI 10.1074/jbc.M611752200
   Kudo O, 2003, BONE, V32, P1, DOI 10.1016/S8756 3282(02)00915 8
   Kudo Saito C, 2013, CANCER RES, V73, P6185, DOI 10.1158/0008 5472.CAN 13 1364
   Kuiperij HB, 2009, EXP HEMATOL, V37, P641, DOI 10.1016/j.exphem.2009.02.004
   Lee J, 2006, BLOOD, V107, P2686, DOI 10.1182/blood 2005 07 2798
   Lee MJ, 2016, J CELL PHYSIOL, V231, P449, DOI 10.1002/jcp.25091
   Lee SJ, 2011, CANCER RES TREAT, V43, P89, DOI 10.4143/crt.2011.43.2.89
   Leto G, 2010, J CELL PHYSIOL, V225, P302, DOI 10.1002/jcp.22272
   Li XQ, 2015, CANCER RES, V75, P3302, DOI 10.1158/0008 5472.CAN 15 0240
   Lin CQ, 2000, CANCER RES, V60, P1332
   Littlepage LE, 2012, CANCER DISCOV, V2, P638, DOI 10.1158/2159 8290.CD 12 0093
   Liu F, 2003, J CELL SCI, V116, P1787, DOI 10.1242/jcs.00376
   Liu QX, 2013, CANCER RES, V73, P3297, DOI 10.1158/0008 5472.CAN 12 3970
   Lowery JW, 2015, J CELL SCI, V128, P1308, DOI 10.1242/jcs.156737
   Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002
   Lu X, 2010, CELL RES, V20, P1012, DOI 10.1038/cr.2010.93
   Lu X, 2009, GENE DEV, V23, P1882, DOI 10.1101/gad.1824809
   Matsushita K, 2014, J CELL BIOCHEM, V115, P1262, DOI 10.1002/jcb.24777
   Mccoy EM, 2013, BMC CANCER, V13, DOI 10.1186/1471 2407 13 16
   Mihály Z, 2013, BREAST CANCER RES TR, V140, P219, DOI 10.1007/s10549 013 2622 y
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320
   Mock K, 2015, ONCOTARGET, V6, P14399, DOI 10.18632/oncotarget.3882
   Muff Roman, 2012, Sarcoma, V2012, P937506, DOI 10.1155/2012/937506
   Munoz Sanjuan I, 1999, DEVELOPMENT, V126, P409
   Nam J, 2015, BONE, V78, P62, DOI 10.1016/j.bone.2015.04.038
   Nguyen NT, 2014, MOL ONCOL, V8, P1441, DOI 10.1016/j.molonc.2014.05.013
   NobleTopham SE, 1996, J ORTHOPAED RES, V14, P700, DOI 10.1002/jor.1100140504
   Owens P, 2015, ONCOGENE, V34, P2437, DOI 10.1038/onc.2014.189
   Pickup MW, 2015, ONCOTARGET, V6, P22890, DOI 10.18632/oncotarget.4413
   Pratap J, 2006, CANCER METAST REV, V25, P589, DOI 10.1007/s10555 006 9032 0
   Rove KO, 2011, ONCOLOGY WILLISTON P, V25, P1375
   Rove KO, 2011, ONCOLOGY WILLISTON P, V25, P1387
   Rove KO, 2011, ONCOLOGY NY, V25, P1362
   Sabatier R, 2011, BREAST CANCER RES TR, V126, P407, DOI 10.1007/s10549 010 0897 9
   Sanches PG, 2015, BONE, V75, P62, DOI 10.1016/j.bone.2015.02.002
   Savci Heijink CD, 2015, BREAST CANCER RES TR, V150, P547, DOI 10.1007/s10549 015 3352 0
   Schulze J, 2012, CANCER LETT, V317, P106, DOI 10.1016/j.canlet.2011.11.016
   Sethi N, 2011, BONE, V48, P16, DOI 10.1016/j.bone.2010.07.005
   Smid M, 2006, J CLIN ONCOL, V24, P2261, DOI 10.1200/JCO.2005.03.8802
   Sotiriou C, 2006, JNCI J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052
   Sun M, 2014, ONCOGENE, V33, P3528, DOI 10.1038/onc.2013.328
   Suzuki H, 2003, BIOSCI BIOTECH BIOCH, V67, P1737, DOI 10.1271/bbb.67.1737
   Tao K, 2008, BMC CANCER, V8, DOI 10.1186/1471 2407 8 228
   Theriault RL, 2012, CANCER CONTROL, V19, P92, DOI 10.1177/107327481201900203
   Thillainadesan G, 2008, MOL CELL BIOL, V28, P6066, DOI 10.1128/MCB.00246 08
   Thollet A, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 291
   Trojan L, 2005, ANTICANCER RES, V25, P183
   van der Pluijm G, 2011, BONE, V48, P37, DOI 10.1016/j.bone.2010.07.023
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Vendrell JA, 2012, CANCER RES, V72, P3593, DOI 10.1158/0008 5472.CAN 11 3095
   Vendrell JA, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2158
   Vicent S, 2008, CANCER RES, V68, P2275, DOI 10.1158/0008 5472.CAN 07 6493
   Vogt J, 2011, CELL SIGNAL, V23, P1831, DOI 10.1016/j.cellsig.2011.06.019
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Woelfle U, 2003, CANCER RES, V63, P5679
   Wongdee K, 2008, HISTOCHEM CELL BIOL, V130, P79, DOI 10.1007/s00418 008 0419 6
   Wu XB, 2003, J CLIN INVEST, V112, P924, DOI 10.1172/JCI200315543
   Xia TS, 2012, BREAST CANCER RES TR, V132, P471, DOI 10.1007/s10549 011 1496 0
   YAMASHITA JI, 1992, INT J ONCOL, V1, P683
   Ye L, 2011, FRONT BIOSCI LANDMRK, V16, P865, DOI 10.2741/3725
   Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070
   Yuen HF, 2010, BRIT J CANCER, V102, P332, DOI 10.1038/sj.bjc.6605480
NR 122
TC 41
Z9 43
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3417
EI 1096 9896
J9 J PATHOL
JI J. Pathol.
PD MAY
PY 2017
VL 242
IS 1
BP 73
EP 89
DI 10.1002/path.4882
PG 17
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pathology
GA ES6QT
UT WOS:000399674800009
PM 28207159
DA 2025 08 17
ER

PT J
AU Rizzoli, R
AF Rizzoli, Rene
TI Long term outcome of weekly bisphosphonates
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID BONE MINERAL DENSITY; POSTMENOPAUSAL OSTEOPOROSIS; VERTEBRAL FRACTURES;
   RANDOMIZED TRIAL; ANTIRESORPTIVE AGENTS; HIP FRACTURE; DOUBLE BLIND;
   ALENDRONATE; WOMEN; RISEDRONATE
AB Bisphosphonates currently are the preferred therapy for treating osteoporosis. Treatment with potent bisphosphonates such as alendronate or risedronate decreases biochemical markers of bone turnover and increases bone mineral density. These changes are associated with significant reductions in vertebral and nonvertebral fracture risk. Clinical trial data with up to 10 years of followup shows these agents are effective and well tolerated for long term periods. Daily administration is effective and generally well tolerated. However, once weekly doses are more convenient, which may enhance long term compliance and lead to more successful outcomes. The pharmacokinetics and mechanism of action predict the short term and long term skeletal effects and safety profile of once weekly doses of bisphosphonates are similar to daily doses. These predictions are supported by authors of trials of up to 2 years who report once weekly doses are therapeutically equivalent to daily doses in terms of BMD and biochemical markers of bone remodeling. Once weekly bisphosphonate doses have safety and tolerability profiles as good as daily doses and are comparable with the placebo.
C1 Univ Hosp, Dept Rehabil & Geriatr, Serv Bone Dis,Div Bone Dis, WHO Collaborating Ctr Osteoporosis Prevent, CH 1211 Geneva 14, Switzerland.
C3 University of Geneva
RP Rizzoli, R (通讯作者)，Univ Hosp, Dept Rehabil & Geriatr, Serv Bone Dis,Div Bone Dis, WHO Collaborating Ctr Osteoporosis Prevent, CH 1211 Geneva 14, Switzerland.
EM Rene.Rizzoli@medecine.unige.ch
CR Black D, 2004, J BONE MINER RES, V19, pS45
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Bone HG, 2000, CLIN THER, V22, P15, DOI 10.1016/S0149 2918(00)87974 6
   Bone HG, 2000, J CLIN ENDOCR METAB, V85, P720, DOI 10.1210/jc.85.2.720
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Brown JP, 2002, CALCIFIED TISSUE INT, V71, P103, DOI 10.1007/s00223 002 2011 8
   Claxton AJ, 2001, CLIN THER, V23, P1296, DOI 10.1016/S0149 2918(01)80109 0
   Cranney A, 2002, ENDOCR REV, V23, P570, DOI 10.1210/er.2001 9002
   Cryer B, 2002, MAYO CLIN PROC, V77, P1031, DOI 10.4065/77.10.1031
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Eisman JA, 2004, CURR MED RES OPIN, V20, P699, DOI 10.1185/030079904125003548
   Ensrud KE, 2000, J AM GERIATR SOC, V48, P241, DOI 10.1111/j.1532 5415.2000.tb02641.x
   Greenspan S, 2002, MAYO CLIN PROC, V77, P1044, DOI 10.4065/77.10.1044
   Harris ST, 2004, CURR MED RES OPIN, V20, P757, DOI 10.1185/030079904125003566
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Hochberg M, 2000, DRUG AGING, V17, P317, DOI 10.2165/00002512 200017040 00007
   JONES G, 1994, OSTEOPOROSIS INT, V4, P277, DOI 10.1007/BF01623352
   Kendler D, 2004, MATURITAS, V48, P243, DOI 10.1016/j.maturitas.2003.12.012
   Klotzbuecher CM, 2000, J BONE MINER RES, V15, P721, DOI 10.1359/jbmr.2000.15.4.721
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Lindsay R, 2001, JAMA J AM MED ASSOC, V285, P320, DOI 10.1001/jama.285.3.320
   McClung M R, 2000, Expert Opin Pharmacother, V1, P225, DOI 10.1517/14656566.1.2.225
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   Mellström DD, 2004, CALCIFIED TISSUE INT, V75, P462, DOI 10.1007/s00223 004 0286 7
   Melton LJ, 1999, OSTEOPOROSIS INT, V10, P214, DOI 10.1007/s001980050218
   *MERCK CO INC, 2005, FOS PRESCR INF PACK
   *NIH CONS DEV PAN, 2001, JAMA J AM MED ASSOC, V2285, P785
   Papapoulos SE, 2005, OSTEOPOROSIS INT, V16, P468, DOI 10.1007/s00198 004 1725 z
   Pols HAP, 1999, OSTEOPOROSIS INT, V9, P461, DOI 10.1007/PL00004171
   Porras AG, 1999, CLIN PHARMACOKINET, V36, P315, DOI 10.2165/00003088 199936050 00002
   *PROCT GAMBL PHARM, 2002, ACT PRESCR INF PACK
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Rodan G, 2004, CURR MED RES OPIN, V20, P1291, DOI 10.1185/030079904125004475
   Rosen CJ, 2005, J BONE MINER RES, V20, P141, DOI 10.1359/jbmr.2005.20.1.141
   Schnitzer T, 2000, AGING CLIN EXP RES, V12, P1
   Schurch MA, 1996, J BONE MINER RES, V11, P1935
   Simon JA, 2002, CLIN THER, V24, P1871, DOI 10.1016/S0149 2918(02)80085 6
   Tonino RP, 2000, J CLIN ENDOCR METAB, V85, P3109, DOI 10.1210/jc.85.9.3109
   *US C OOTA, 1994, OTABPH120 US C
   van Balen R, 2001, CLIN ORTHOP RELAT R, P232
   Watts N B, 1999, Obstet Gynecol Surv, V54, P532, DOI 10.1097/00006254 199908000 00024
   Wehren LE, 2004, CURR MED RES OPIN, V20, P525, DOI 10.1185/030079904125003269
NR 42
TC 14
Z9 14
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009 921X
EI 1528 1132
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD FEB
PY 2006
IS 443
BP 61
EP 65
DI 10.1097/01.blo.0000200249.12006.6e
PG 5
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA 119NV
UT WOS:000243019900015
PM 16462427
DA 2025 08 17
ER

PT J
AU Chapurlat, RD
   Gensburger, D
   Jimenez Andrade, JM
   Ghilardi, JR
   Kelly, M
   Mantyh, P
AF Chapurlat, Roland D.
   Gensburger, Deborah
   Jimenez Andrade, Juan M.
   Ghilardi, Joseph R.
   Kelly, Marilyn
   Mantyh, Patrick
TI Pathophysiology and medical treatment of pain in fibrous dysplasia of
   bone
SO ORPHANET JOURNAL OF RARE DISEASES
LA English
DT Article
ID MCCUNE ALBRIGHT SYNDROME; NERVE GROWTH FACTOR; QUALITY OF LIFE;
   INTRAVENOUS PAMIDRONATE; CELLS; CHILDREN; OSTEOARTHRITIS; EXPRESSION;
   TURNOVER; THERAPY
AB One of the most common complications of fibrous dysplasia of bone (FD) is bone pain. Usual pain killers are often of inadequate efficacy to control this bone pain. The mechanism of bone pain in FD remains uncertain, but by analogy with bone tumors one may consider that ectopic sprouting and formation of neuroma like structures by sensory and sympathetic nerve fibers also occur in the dysplastic skeleton. Bone pain has been reported in up to 81% of adults and 49% of children. It affects predominantly the lower limbs and the spine. The degree of pain is highly variable and adults reports more pain than children. Bisphosphonates have been shown to reduce bone pain in uncontrolled studies. Their influence on bone strength remains unknown. In a randomized trial testing alendronate, bone pain was not significantly improved. Another trial assessing the effect of risedronate is ongoing. Possible future therapies include tocilizumab, denosumab and drugs targeting nerve growth factor and its receptor TrkA.
C1 [Chapurlat, Roland D.; Gensburger, Deborah] Univ Lyon, Hosp Civils Lyon, Hop E Herriot, INSERM UMR 1033, F 69437 Lyon, France.
   [Chapurlat, Roland D.; Gensburger, Deborah] Hop Edouard Herriot, Natl Reference Ctr Fibrous Dysplasia Bone, F 69437 Lyon, France.
   [Jimenez Andrade, Juan M.; Mantyh, Patrick] Univ Arizona, Coll Med, Dept Pharmacol, Tucson, AZ 85724 USA.
   [Ghilardi, Joseph R.; Mantyh, Patrick] Vet Adm Med Ctr, Res Serv, Minneapolis, MN 55417 USA.
   [Kelly, Marilyn] Natl Inst Dent & Craniofacial Res, Skeletal Clin Studies Unit, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD USA.
   [Mantyh, Patrick] Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Claude Bernard Lyon 1; CHU Lyon; CHU Lyon; University of
   Arizona; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Minneapolis VA Health Care System; National
   Institutes of Health (NIH)   USA; NIH National Institute of Dental &
   Craniofacial Research (NIDCR); Arizona Center Cancer Care; University of
   Arizona
RP Chapurlat, RD (通讯作者)，Univ Lyon, Hosp Civils Lyon, Hop E Herriot, INSERM UMR 1033, F 69437 Lyon, France.
RI CHAPURLAT, ROLAND/AAU 1165 2021; ANDRADE, JUAN/C 1416 2016
OI Jimenez Andrade, Juan Miguel/0000 0002 2703 9736; 
FU Fibrous Dysplasia Foundation; Zimmer
FX This article has been published as part of Orphanet Journal of Rare
   Diseases Volume 7 Supplement 1, 2012: International Meeting on Fibrous
   Dysplasia/McCune Albright Syndrome and Cherubism. The full contents of
   the supplement are available online at
   http://www.ojrd.com/supplements/7/S1. Publication of the proceedings was
   funded by the Fibrous Dysplasia Foundation and an unrestricted grant
   from Zimmer.
CR Ashraf S, 2011, ANN RHEUM DIS, V70, P523, DOI 10.1136/ard.2010.137844
   Chapurlat R, 1999, REV RHUM, V66, P1
   Chapurlat RD, 1997, J BONE MINER RES, V12, P1746, DOI 10.1359/jbmr.1997.12.10.1746
   Chapurlat RD, 2004, BONE, V35, P235, DOI 10.1016/j.bone.2004.03.004
   Chapurlat RD, 2006, J BONE MINER RES, V21, pP114, DOI 10.1359/JBMR.06S222
   Collins MT, 2005, J BONE MINER RES, V20, P219, DOI 10.1359/JBMR.041111
   DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304 3959(83)90143 4
   EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P10984, DOI 10.1073/pnas.90.23.10984
   FIRAT D, 1968, AM J MED, V44, P421, DOI 10.1016/0002 9343(68)90112 5
   Freemont AJ, 2002, J PATHOL, V197, P286, DOI 10.1002/path.1108
   Garnero P, 2010, ARTHRITIS RHEUM US, V62, P33, DOI 10.1002/art.25053
   Halvorson KG, 2005, CANCER RES, V65, P9426, DOI 10.1158/0008 5472.CAN 05 0826
   Isaia GC, 2002, CALCIFIED TISSUE INT, V71, P121, DOI 10.1007/s00223 001 1098 7
   Jimenez Andrade JM, 2011, BONE, V46, P523
   Jimenez Andrade JM, 2012, NEUROBIOL AGING, V33, P921, DOI 10.1016/j.neurobiolaging.2010.08.008
   Jimenez Andrade JM, 2010, J NEUROSCI, V30, P14649, DOI 10.1523/JNEUROSCI.3300 10.2010
   Kelly MH, 2008, OSTEOPOROSIS INT, V19, P57, DOI 10.1007/s00198 007 0425 x
   Kelly MH, 2005, BONE, V37, P388, DOI 10.1016/j.bone.2005.04.026
   Kitagawa Y, 2004, J ORTHOP SCI, V9, P521, DOI 10.1007/s00776 004 0809 0
   Kuznetsov SA, 2008, J BONE MINER RES, V23, P1731, DOI 10.1359/JBMR.080609
   Lala R, 2000, ACTA PAEDIATR, V89, P188, DOI 10.1080/080352500750028816
   LANE JM, 2001, CLIN ORTHOP RELAT R, V382, P6
   Lane NE, 2010, NEW ENGL J MED, V363, P1521, DOI 10.1056/NEJMoa0901510
   LIENS D, 1994, LANCET, V343, P953, DOI 10.1016/S0140 6736(94)90069 8
   Mantyh PW, 2006, NAT REV NEUROSCI, V7, P797, DOI 10.1038/nrn1914
   Mantyh WG, 2010, NEUROSCIENCE, V171, P588, DOI 10.1016/j.neuroscience.2010.08.056
   Parisi MS, 2003, BONE, V33, P582, DOI 10.1016/S8756 3282(03)00221 7
   Plotkin H, 2003, J CLIN ENDOCR METAB, V88, P4569, DOI 10.1210/jc.2003 030050
   Riminucci A, 2003, BONE, V33, P434, DOI 10.1016/S8756 3282(03)00064 4
   Skaper SD, 2001, MOL BRAIN RES, V97, P177, DOI 10.1016/S0169 328X(01)00314 X
   Suri S, 2007, ANN RHEUM DIS, V66, P1423, DOI 10.1136/ard.2006.063354
   Weinstein RS, 1997, J BONE MINER RES, V12, P1314, DOI 10.1359/jbmr.1997.12.8.1314
   Wu Z, 2002, HISTOCHEM CELL BIOL, V118, P213, DOI 10.1007/s00418 002 0443 x
   Yamamoto T, 1996, J CLIN INVEST, V98, P30, DOI 10.1172/JCI118773
   Zacharin M, 2000, J PEDIATR US, V137, P403, DOI 10.1067/mpd.2000.107836
   Zylka MJ, 2005, NEURON, V45, P17, DOI 10.1016/j.neuron.2004.12.015
NR 36
TC 80
Z9 88
U1 0
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1750 1172
J9 ORPHANET J RARE DIS
JI Orphanet J. Rare Dis.
PD MAY 24
PY 2012
VL 7
SU 1
AR S3
DI 10.1186/1750 1172 7 S1 S3
PG 9
WC Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity; Research & Experimental Medicine
GA 951YJ
UT WOS:000304756300003
PM 22640953
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Geng, QH
   Heng, K
   Li, J
   Wang, S
   Sun, HB
   Sha, LW
   Guo, YL
   Nie, XF
   Wang, QJ
   Dai, L
   Zhu, XZ
   Kang, JJ
   Shao, LW
   Zhai, J
   Miao, S
   Lin, Q
   Guo, KJ
   Wang, J
AF Geng, Qinghe
   Heng, Ke
   Li, Jie
   Wang, Shen
   Sun, Huabei
   Sha, Liangwei
   Guo, Yilong
   Nie, Xinfa
   Wang, Qingjun
   Dai, Lei
   Zhu, Xianzhong
   Kang, Jiujie
   Shao, Liwu
   Zhai, Juan
   Miao, Sheng
   Lin, Qiang
   Guo, Kaijin
   Wang, Jin
TI A soluble bone morphogenetic protein type 1A receptor fusion protein
   treatment prevents glucocorticoid Induced bone loss in mice
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Murine BMP receptor type 1A fusion protein (mBMPR1A mFc);
   glucocorticoid induced osteoporosis (GIOP); Wnt/beta catenin signaling;
   RANK/RANKL/OPG
ID INDUCED OSTEOPOROSIS; IA RECEPTOR; OSTEOCLAST FORMATION; IN VIVO; BETA;
   OSTEOBLASTS; MECHANISMS; EXPRESSION; APOPTOSIS; DIFFERENTIATION
AB Glucocorticoid induced osteoporosis (GIOP) is a frequent complication of systemic glucocorticoid (GC) therapy, is the most common form of secondary osteoporosis, and is associated with skeletal fragility and increased fracture risk. A soluble form of BMP receptor type 1A fusion protein (mBMPR1A mFc) acts as an antagonist to endogenous BMPR1A and could increase bone mass in both ovariectomized and ovary intact mice, but its effects in GIOP mice remained unclear. The aim of this study was to evaluate the effects of mBMPR1A mFc on the skeleton in experimental models of GIOP. mBMPR1A mFc treatment could increase the bone mineral density (BMD), trabecular bone volume, thickness, and number, and cortical thickness, and reduce the structure model index and trabecular separation in GIOP mice. mBMPR1A mFc treatment could also prevent bone loss and enhance biomechanical strength in GIOP mice by promoting osteoblastic bone formation and inhibiting osteoclastic bone resorption. Mechanistic studies revealed that mBMPR1A mFc treatment increased murine osteoblastogenesis by activating the Wnt/beta catenin signaling pathway while decreasing osteoclastogenesis by inhibiting the RANK/RANKL/osteoprotegerin (OPG) signaling pathway. These findings demonstrate that mBMPR1A mFc treatment in GIOP mice improves bone mass, microarchitecture, and strength by enhancing osteoblastic bone formation and inhibiting osteoclastic bone resorption in GIOP mice and offers a promising novel alternative for the treatment of GIOP.
C1 [Geng, Qinghe; Sun, Huabei; Sha, Liangwei; Guo, Yilong; Nie, Xinfa; Wang, Qingjun; Dai, Lei; Zhu, Xianzhong; Kang, Jiujie; Shao, Liwu; Zhai, Juan; Wang, Jin] Xuzhou Med Univ, Affiliated Pizhou Hosp, Lab Bone & Mineral Res, Xuzhou 221300, Jiangsu, Peoples R China.
   [Heng, Ke] Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Dept Orthoped, Changzhou 213003, Peoples R China.
   [Li, Jie] Southeast Univ, Xuzhou Cent Hosp, Dept Orthoped, Xuzhou 221006, Jiangsu, Peoples R China.
   [Wang, Shen] Guangxi Med Univ, Dept Acupuncture, Nanning 530000, Peoples R China.
   [Miao, Sheng] Nanjing Med Univ, Hosp Suqian 1, Jiangsu Prov Hosp, Dept Orthoped, Suqian 223899, Peoples R China.
   [Lin, Qiang; Guo, Kaijin] Xuzhou Med Univ, Affiliated Hosp, Dept Orthoped, Xuzhou 221004, Jiangsu, Peoples R China.
C3 Xuzhou Medical University; Nanjing Medical University; Southeast
   University   China; Guangxi Medical University; Nanjing Medical
   University; Xuzhou Medical University
RP Wang, J (通讯作者)，Xuzhou Med Univ, Affiliated Pizhou Hosp, Lab Bone & Mineral Res, Xuzhou 221300, Jiangsu, Peoples R China.
EM wangjin221300@163.com
RI Wang, Jianming/HGA 5239 2022; Guo, Yilong/LZH 0891 2025; wang,
   shuqing/JRX 7812 2023; wang, yihan/HTN 8802 2023
FU Research Funding Project of Xuzhou Medical University [2018KJ23]
FX This study was supported by the Research Funding Project of Xuzhou
   Medical University (Grant No. 2018KJ23).
CR Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Baud'huin M, 2012, P NATL ACAD SCI USA, V109, P12207, DOI 10.1073/pnas.1204929109
   Belaya ZE, 2018, OSTEOPOROSIS INT, V29, P211, DOI 10.1007/s00198 017 4241 7
   Brott BK, 2002, MOL CELL BIOL, V22, P6100, DOI 10.1128/MCB.22.17.6100 6110.2002
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Dai WW, 2015, BONE, V74, P48, DOI 10.1016/j.bone.2015.01.001
   de Vries F, 2007, J INTERN MED, V261, P170, DOI 10.1111/j.1365 2796.2006.01754.x
   DEMPSTER DW, 1989, J BONE MINER RES, V4, P137
   Fujita K, 2007, MOL CANCER, V6, DOI 10.1186/1476 4598 6 71
   Geng QH, 2019, INT J BIOL SCI, V15, P58, DOI 10.7150/ijbs.25783
   Gifre L, 2013, BONE, V57, P272, DOI 10.1016/j.bone.2013.08.016
   Giusti A, 2010, BONE, V47, P169, DOI 10.1016/j.bone.2010.05.019
   Hatta T, 2000, BIOPOLYMERS, V55, P399, DOI 10.1002/1097 0282(2000)55:5<399::AID BIP1014>3.0.CO;2 9
   Jackson A, 2005, BONE, V36, P585, DOI 10.1016/j.bone.2005.01.007
   Jin HO, 2009, FREE RADICAL BIO MED, V46, P1158, DOI 10.1016/j.freeradbiomed.2009.01.015
   Jing D, 2016, J BONE MINER RES, V31, P1713, DOI 10.1002/jbmr.2837
   Kamiya N, 2010, J BONE MINER RES, V25, P200, DOI 10.1359/jbmr.090806
   Kamiya N, 2008, J BONE MINER RES, V23, P2007, DOI 10.1359/JBMR.080809
   Karunaratne A, 2016, BONE, V84, P15, DOI 10.1016/j.bone.2015.11.019
   Kawai M, 2011, NAT REV DRUG DISCOV, V10, P141, DOI 10.1038/nrd3299
   Keller S, 2004, NAT STRUCT MOL BIOL, V11, P481, DOI 10.1038/nsmb756
   Ko FC, 2017, JBMR PLUS, V1, P66, DOI [10.1002/jbmr.10012, 10.1002/jbm4.10012]
   Ko JY, 2015, BONE, V81, P80, DOI 10.1016/j.bone.2015.06.022
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Liu K, 2017, BONE, V97, P130, DOI 10.1016/j.bone.2017.01.014
   Lui PPY, 2013, RHEUMATOLOGY, V52, P1609, DOI 10.1093/rheumatology/ket214
   Manolagas SC, 2013, J CLIN INVEST, V123, P1919, DOI 10.1172/JCI68062
   Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108
   MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092 8674(92)90627 O
   Mazziotti G, 2006, TRENDS ENDOCRIN MET, V17, P144, DOI 10.1016/j.tem.2006.03.009
   Miao DS, 2004, ENDOCRINOLOGY, V145, P2046, DOI 10.1210/en.2003 1097
   Miao DS, 2002, BMC MUSCULOSKELET DI, V3, DOI 10.1186/1471 2474 3 16
   Mishina Y, 2004, J BIOL CHEM, V279, P27560, DOI 10.1074/jbc.M404222200
   Mok CC, 2015, BONE, V75, P222, DOI 10.1016/j.bone.2015.03.002
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Overman RA, 2014, ARTHRIT CARE RES, V66, P1644, DOI 10.1002/acr.22346
   PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303
   Pearsall RS, 2008, P NATL ACAD SCI USA, V105, P7082, DOI 10.1073/pnas.0711263105
   Reid IR, 1997, EUR J ENDOCRINOL, V137, P209, DOI 10.1530/eje.0.1370209
   Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541
   Rizzoli R, 2012, CALCIFIED TISSUE INT, V91, P225, DOI 10.1007/s00223 012 9630 5
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P121, DOI 10.1007/s00223 013 9749 z
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502
   Sato AY, 2016, J BONE MINER RES, V31, P1791, DOI 10.1002/jbmr.2869
   Sato AY, 2015, BONE, V73, P60, DOI 10.1016/j.bone.2014.12.012
   Seibel MJ, 2013, LANCET DIABETES ENDO, V1, P59, DOI 10.1016/S2213 8587(13)70045 7
   Shi J, 2015, BONE, V79, P222, DOI 10.1016/j.bone.2015.06.014
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Takuma A, 2003, J BIOL CHEM, V278, P44667, DOI 10.1074/jbc.M300213200
   Taut AD, 2013, J BONE MINER RES, V28, P2347, DOI 10.1002/jbmr.1984
   Thiele S, 2012, J BONE MINER RES, V27, P2242, DOI 10.1002/jbmr.1688
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   Weinstein R S, 2001, Rev Endocr Metab Disord, V2, P65, DOI 10.1023/A:1010007108155
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   WOZNEY JM, 1992, MOL REPROD DEV, V32, P160, DOI 10.1002/mrd.1080320212
   Xue YB, 2005, J BONE MINER RES, V20, P1766, DOI 10.1359/JBMR.050608
   Xue YB, 2005, HUM MOL GENET, V14, P1515, DOI 10.1093/hmg/ddi160
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 60
TC 7
Z9 12
U1 2
U2 8
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943 8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2019
VL 11
IS 7
BP 4232
EP 4247
PG 16
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA IM3DV
UT WOS:000477873300023
PM 31396331
DA 2025 08 17
ER

PT J
AU Demir, SA
   Seyrantepe, V
AF Demir, Secil Akyildiz
   Seyrantepe, Volkan
TI Abnormally accumulated GM2 ganglioside contributes to skeletal deformity
   in Tay Sachs mice
SO JOURNAL OF MOLECULAR MEDICINE JMM
LA English
DT Article
DE Tay Sachs Disease; Osteoporosis; Bone; Micro CT; Osteoclasts;
   Osteoblasts
ID MOUSE MODEL; BONE; DEFICIENCY; THERAPY
AB Tay Sachs Disease is a rare lysosomal storage disorder caused by mutations in the HEXA gene, responsible for the degradation of ganglioside GM2. In addition to progressive neurodegeneration, Tay Sachs patients display bone anomalies, including kyphosis. Tay Sachs disease mouse model (Hexa / Neu3 / ) shows both neuropathological and clinical abnormalities of the infantile onset disease phenotype. In this study, we investigated the effects of GM2 accumulation on bone remodeling activity. Here, we evaluated the bone phenotype of 5 month old Hexa / Neu3 /  mice with age matched control groups using gene expression analysis, bone plasma biomarker analysis, and micro computed tomography. We demonstrated lower plasma alkaline phosphatase activity and calcium levels with increased tartrate resistant acid phosphatase levels, indicating reduced bone remodeling activity in mice. Consistently, gene expression analysis confirmed osteoblast reduction and osteoclast induction in the femur of mice. Micro computed tomography and analysis show reduced trabecular bone volume, mineral density, number, and thickness in Hexa / Neu3 /  mice. In conclusion, we demonstrated that abnormal GM2 ganglioside accumulation significantly triggers skeletal abnormality in Tay Sachs mice. We suggest that further investigation of the molecular basis of bone structure anomalies is necessary to elucidate new therapeutic targets that prevent the progression of bone symptoms and improve the life standards of Tay Sachs patients.
C1 [Demir, Secil Akyildiz; Seyrantepe, Volkan] IYTEDEHAM, Izmir Inst Technol, Urla, Izmir, Turkiye.
   [Seyrantepe, Volkan] Izmir Inst Technol, Dept Mol Biol & Genet, Urla, Izmir, Turkiye.
C3 Izmir Institute of Technology; Izmir Institute of Technology
RP Seyrantepe, V (通讯作者)，IYTEDEHAM, Izmir Inst Technol, Urla, Izmir, Turkiye.; Seyrantepe, V (通讯作者)，Izmir Inst Technol, Dept Mol Biol & Genet, Urla, Izmir, Turkiye.
EM volkanseyrantepe@iyte.edu.tr
RI demir, seçil/HGE 7242 2022
OI akyildiz demir, secil/0000 0002 8528 4801
FU IYTEBAP
FX We thank Ege University Central Research Test and Analysis Laboratory
   (Ege MATAL) for Micro computed tomography (micro CT) analysis.
CR ADAMS C, 1986, DEV MED CHILD NEUROL, V28, P236
   Beranger GE, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00081
   Blanque R, 1998, GEN PHARMACOL, V30, P51, DOI 10.1016/S0306 3623(97)00067 0
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Chung HJ, 2017, J NAT PROD, V80, P434, DOI 10.1021/acs.jnatprod.6b00964
   Clarke LA, 2015, BEST PRACT RES CL EN, V29, P219, DOI 10.1016/j.beem.2014.08.010
   Dahl M, 2021, MOL THER METH CLIN D, V20, P312, DOI 10.1016/j.omtm.2020.11.018
   Ferreira CR, 2017, METABOLIC DISEASES: FOUNDATIONS OF CLINICAL MANAGEMENT, GENETICS, AND PATHOLOGY, 2ND EDITION, P367, DOI [10.3233/978 1 61499 718 4 367, 10.3233/TRD 160005]
   Hölzer HT, 2021, J NEUROL, V268, P2259, DOI 10.1007/s00415 021 10492 y
   Hwang YH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030912
   Jeyakumar M, 2002, NEUROBIOL DIS, V10, P201, DOI 10.1006/nbdi.2002.0511
   JOHNSON WG, 1982, ANN NEUROL, V11, P11, DOI 10.1002/ana.410110103
   Kelly RR, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.612366
   Kim SJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092554
   Ko AR, 2016, MOL GENET METAB, V117, P447, DOI 10.1016/j.ymgme.2016.02.001
   Konukoglu D., 2019, Int. J. Med. Biochem, V2, P65, DOI DOI 10.14744/IJMB.2019.60362
   Kuehn SC, 2015, HUM MOL GENET, V24, P7075, DOI 10.1093/hmg/ddv407
   Kuiper GA, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023 019 0997 5
   Kuo TR, 2017, BIOMARK RES, V5, DOI 10.1186/s40364 017 0097 4
   Kushwaha P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.350
   Lebel E, 2004, J BONE MINER METAB, V22, P597, DOI 10.1007/s00774 004 0529 8
   Malatt C, 2015, J RADIOL CASE REP, V9, P30, DOI 10.3941/jrcr.v9i5.2149
   Mucci JM, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/192761
   Mikosch P, 2010, WIEN MED WOCHENSCHR, V160, P609, DOI 10.1007/s10354 010 0841 y
   NARDOCCI N, 1992, MOVEMENT DISORD, V7, P64, DOI 10.1002/mds.870070113
   Ng PY, 2019, BIOCHEM SOC T, V47, P639, DOI 10.1042/BST20180445
   Nordin BEC, 1997, NUTRITION, V13, P664, DOI 10.1016/S0899 9007(97)00136 6
   Oussoren E, 2011, BBA MOL BASIS DIS, V1812, P1542, DOI 10.1016/j.bbadis.2011.07.013
   Prost S, 2021, ORTHOP TRAUMATOL SUR, V107, DOI 10.1016/j.otsr.2020.102779
   RAPIN I, 1976, ARCH NEUROL CHICAGO, V33, P120, DOI 10.1001/archneur.1976.00500020048008
   Seyrantepe V, 2018, EXP NEUROL, V299, P26, DOI 10.1016/j.expneurol.2017.09.012
   Shetty Sahana, 2016, Indian J Endocrinol Metab, V20, P846
   Solovyeva VV, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01663
   Sromová V, 2023, CELLS BASEL, V12, DOI 10.3390/cells12212576
   TOMA L, 1990, J INHERIT METAB DIS, V13, P721, DOI 10.1007/BF01799575
   Tsukuba T, 2017, J ORAL BIOSCI, V59, P92, DOI 10.1016/j.job.2017.01.004
   Vijayalekha A, 2023, APPL BIOCHEM BIOTECH, V195, P4617, DOI 10.1007/s12010 023 04318 y
   YAMANAKA S, 1994, P NATL ACAD SCI USA, V91, P9975, DOI 10.1073/pnas.91.21.9975
NR 38
TC 0
Z9 0
U1 3
U2 5
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 0946 2716
EI 1432 1440
J9 J MOL MED
JI J. Mol. Med.
PD DEC
PY 2024
VL 102
IS 12
BP 1517
EP 1526
DI 10.1007/s00109 024 02498 6
EA NOV 2024
PG 10
WC Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity; Research & Experimental Medicine
GA M8F3U
UT WOS:001350169200001
PM 39514043
DA 2025 08 17
ER

PT J
AU Baldock, P
AF Baldock, Paul
TI Reciprocal Regulation of Bone and Energy Metabolism
SO HORMONE RESEARCH IN PAEDIATRICS
LA English
DT Article
DE Bone; Energy metabolism; Regulation
ID NEUROPEPTIDE Y; MINERAL DENSITY; FAT MASS; MESSENGER RNA; KNOCKOUT MICE;
   ELDERLY MEN; OB/OB MICE; LEPTIN; WOMEN; RECEPTOR
AB Background: The primary relationship affecting skeletal tissue involves the association between fat mass and bone mass. However, there is some complexity in this relationship that may be explained by endocrine and neural pathways representing direct, reciprocal signalling between fat and bone tissue. For example, leptin signalling can directly stimulate osteoblastic differentiation and osteoblast proliferation and mineralization, but it also has central signalling actions in that it decreases cancellous bone volume. A novel regulatory loop between bone and adipose tissue suggests that uncarboxylated osteocalcin may affect energy homeostasis and afford a pathway by which fat mass can be regulated by bone mass. Conclusions: The multilayered and complex signals between fat and bone tissue involve both direct and indirect pathways. The endocrinologic nature of these signals highlights an emerging trend in medicine: identification of organ based endocrine signals. Copyright (C) 2011 S. Karger AG, Basel
C1 Garvan Inst Med Res, Osteoporosis & Bone Biol & Neurosci Program, Sydney, NSW 2010, Australia.
C3 Garvan Institute of Medical Research
RP Baldock, P (通讯作者)，Garvan Inst Med Res, Osteoporosis & Bone Biol & Neurosci Program, 384 Victoria St, Sydney, NSW 2010, Australia.
EM p.baldock@garvan.org.au
RI Baldock, Paul/B 3840 2012
FU Pfizer
FX P.B. declares no conflict of interest. He received an honorarium from
   Pfizer in association with his presentation and resulting manuscript for
   the proceedings for the 41st International Symposium sponsored by
   Pfizer.
CR Baldock PA, 2005, J BONE MINER RES, V20, P1851, DOI 10.1359/JBMR.050523
   Baldock PA, 2006, J BONE MINER RES, V21, P1600, DOI 10.1359/JBMR.060705
   Baldock PA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008415
   Baskin DG, 1999, DIABETES, V48, P828, DOI 10.2337/diabetes.48.4.828
   Basurto L, 2009, EUR J ENDOCRINOL, V160, P289, DOI 10.1530/EJE 08 0569
   Cornish J, 2002, J ENDOCRINOL, V175, P405, DOI 10.1677/joe.0.1750405
   Dennison EM, 2004, CALCIFIED TISSUE INT, V74, P401, DOI 10.1007/s00223 002 0017 x
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Ferron M, 2008, P NATL ACAD SCI USA, V105, P5266, DOI 10.1073/pnas.0711119105
   Hsu YH, 2006, AM J CLIN NUTR, V83, P146
   Huang KC, 2004, CLIN ENDOCRINOL, V61, P204, DOI 10.1111/j.1365 2265.2004.02081.x
   Iwaniec UT, 2007, PEPTIDES, V28, P1012, DOI 10.1016/j.peptides.2007.02.001
   Jürimäe J, 2006, EXP BIOL MED, V231, P1673
   Kontogianni MD, 2004, J BONE MINER RES, V19, P546, DOI 10.1359/JBMR.040107
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Lundberg P, 2007, J BIOL CHEM, V282, P19082, DOI 10.1074/jbc.M609629200
   Reid IR, 2008, OSTEOPOROSIS INT, V19, P595, DOI 10.1007/s00198 007 0492 z
   STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0
   Steppan CM, 2000, REGUL PEPTIDES, V92, P73, DOI 10.1016/S0167 0115(00)00152 X
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Thomas T, 1999, ENDOCRINOLOGY, V140, P1630, DOI 10.1210/en.140.4.1630
   Thomas T, 2001, BONE, V29, P114, DOI 10.1016/S8756 3282(01)00487 2
   Weiss LA, 2006, J BONE MINER RES, V21, P758, DOI 10.1359/JBMR.060206
   WILDING JPH, 1993, ENDOCRINOLOGY, V132, P1939, DOI 10.1210/en.132.5.1939
NR 24
TC 5
Z9 6
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1663 2818
J9 HORM RES PAEDIAT
JI Horm. Res. Paediatr.
PY 2011
VL 76
SU 1
BP 7
EP 11
DI 10.1159/000329134
PG 5
WC Endocrinology & Metabolism; Pediatrics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Pediatrics
GA 796UI
UT WOS:000293077900003
PM 21778741
DA 2025 08 17
ER

PT J
AU Kang, H
   Jha, S
   Ivovic, A
   Fratzl Zelman, N
   Deng, ZM
   Mitra, A
   Cabral, WA
   Hanson, EP
   Lange, E
   Cowen, EW
   Katz, J
   Roschger, P
   Klaushofer, K
   Dale, RK
   Siegel, RM
   Bhattacharyya, T
   Marini, JC
AF Kang, Heeseog
   Jha, Smita
   Ivovic, Aleksandra
   Fratzl Zelman, Nadja
   Deng, Zuoming
   Mitra, Apratim
   Cabral, Wayne A.
   Hanson, Eric P.
   Lange, Eileen
   Cowen, Edward W.
   Katz, James
   Roschger, Paul
   Klaushofer, Klaus
   Dale, Ryan K.
   Siegel, Richard M.
   Bhattacharyya, Timothy
   Marini, Joan C.
TI Somatic SMAD3 activating mutations cause melorheostosis by
   up regulating the TGF β/SMAD pathway
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID BUSCHKE OLLENDORFF SYNDROME; OSTEOBLAST DIFFERENTIATION; DENSITY
   DISTRIBUTION; MAMMALIAN TARGET; BONE FORMATION; BETA; GROWTH; SMAD3;
   TRANSCRIPTION; MSX2
AB Melorheostosis is a rare sclerosing dysostosis characterized by asymmetric exuberant bone formation. Recently, we reported that somatic mosaicism for MAP2K1 activating mutations causes radiographical "dripping candle wax" melorheostosis. We now report somatic SMAD3 mutations in bone lesions of four unrelated patients with endosteal pattern melorheostosis. In vitro, the SMAD3 mutations stimulated the TGF beta pathway in osteoblasts, enhanced nuclear translocation and target gene expression, and inhibited proliferation. Osteoblast differentiation and mineralization were stimulated by the SMAD3 mutation, consistent with higher mineralization in affected than in unaffected bone, but differing from MAP2K1 mutation positive melorheostosis. Conversely, osteoblast differentiation and mineralization were inhibited when osteogenesis of affected osteoblasts was driven in the presence of BMP2. Transcriptome profiling displayed that TGF beta pathway activation and ossification related processes were significantly influenced by the SMAD3 mutation. Co expression clustering illuminated melorheostosis pathophysiology, including alterations in ECM organization, cell growth, and interferon signaling. These data reveal antagonism of TGF beta/SMAD3 activation by BMP signaling in SMAD3 mutation positive endosteal melorheostosis, which may guide future therapies.
C1 [Kang, Heeseog; Cabral, Wayne A.; Marini, Joan C.] NICHHD, Sect Heritable Disorders Bone & Extraceadar Matri, NIH, Bethesda, MD 20892 USA.
   [Jha, Smita] NIAMSD, Clin & Invest Orthoped Surg Unit, NIH, Bethesda, MD 20892 USA.
   [Jha, Smita] NICHHD, Program Reprod & Adult Endocrinol, NIH, Bethesda, MD 20892 USA.
   [Ivovic, Aleksandra; Siegel, Richard M.] NIAMSD, ImmunoreguLat Sect, Autoimmun Branch, NIH, Bethesda, MD 20892 USA.
   [Fratzl Zelman, Nadja; Roschger, Paul; Klaushofer, Klaus] Hanusch Hosp Wiener Gebietskrankenkasse, Ludwig Boltzmann Inst Osteol, Vienna, Austria.
   [Fratzl Zelman, Nadja; Roschger, Paul; Klaushofer, Klaus] Hanusch Hosp, Allgemeine Unfahversicherungsanstalt Trauma Ctr M, Med Dept 1, Vienna, Austria.
   [Deng, Zuoming] NIAMSD, Biodata Min & Discovery Sect, Off Sci & Technol, NIH, Bethesda, MD 20892 USA.
   [Mitra, Apratim; Dale, Ryan K.] NICHHD, Bioinformat & Sci Programming Core, NIH, Bethesda, MD 20892 USA.
   [Hanson, Eric P.] NIAMSD, Immunodeficiency & Inflammat Unit, Autoimmun Branch, NIH, Bethesda, MD 20892 USA.
   [Lange, Eileen; Katz, James] NIAMSD, Off Clin Director, NIH, Bethesda, MD 20892 USA.
   [Cowen, Edward W.] NIAMSD, Dermatol Branch, NIH, Bethesda, MD 20892 USA.
   [Jha, Smita; Bhattacharyya, Timothy] NIH, Sect Congenital Disorders, Clin Ctr, Bldg 10, Bethesda, MD 20892 USA.
   [Ivovic, Aleksandra] Wellcome Sanger Inst, Canc Ageing & Somat Mutat, Hinxton, Cambs, England.
   [Cabral, Wayne A.] NHGRI, Mol Genet Sect, Med Genom & Metab Genet Branch, NIH, Bethesda, MD 20892 USA.
   [Siegel, Richard M.] Novartis Inst Biomed Res, Basel, Switzerland.
C3 National Institutes of Health (NIH)   USA; NIH Eunice Kennedy Shriver
   National Institute of Child Health & Human Development (NICHD); National
   Institutes of Health (NIH)   USA; NIH National Institute of Arthritis &
   Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health
   (NIH)   USA; NIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD); National Institutes of Health (NIH)
     USA; NIH National Institute of Arthritis & Musculoskeletal & Skin
   Diseases (NIAMS); WGKK   Hanusch Hospital; Ludwig Boltzmann Institute;
   Ludwig Boltzmann Institute for Osteology; WGKK   Hanusch Hospital;
   National Institutes of Health (NIH)   USA; NIH National Institute of
   Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes
   of Health (NIH)   USA; NIH Eunice Kennedy Shriver National Institute of
   Child Health & Human Development (NICHD); National Institutes of Health
   (NIH)   USA; NIH National Institute of Arthritis & Musculoskeletal &
   Skin Diseases (NIAMS); National Institutes of Health (NIH)   USA; NIH
   National Institute of Arthritis & Musculoskeletal & Skin Diseases
   (NIAMS); National Institutes of Health (NIH)   USA; NIH National
   Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS);
   National Institutes of Health (NIH)   USA; NIH Clinical Center (CC);
   Wellcome Trust Sanger Institute; National Institutes of Health (NIH)  
   USA; NIH National Human Genome Research Institute (NHGRI); Novartis
RP Marini, JC (通讯作者)，NICHHD, Sect Heritable Disorders Bone & Extraceadar Matri, NIH, Bethesda, MD 20892 USA.
EM oidoc@helix.nih.gov
RI Hanson, Eric/AAE 5511 2022; Siegel, Richard/C 7592 2009; Cowen,
   Edward/AGI 2397 2022; Katz, James/ABB 8247 2020; Kang,
   Heeseog/LJL 5469 2024; Siegel, Richard/AAX 1779 2020
OI Siegel, Richard/0000 0001 5953 9893; Katz, James/0000 0002 2098 8883; 
FU National Institutes of Health [1ZIAHD008973 02, AR041173 11,
   AR041207 03, AR041180 11, 1ZIDAR041180 09]; Allgemeine
   Unfallversicherungsanstalt (research funds of the Austrian Workers'
   Compensation Board); Wiener Gebietskrankenkasse (Vienna Regional Health
   Insurance Fund); National Institutes of Health Oxford Cambridge PhD
   Scholars Program; Eunice Kennedy Shriver National Institute of Child
   Health and Human Development [ZICHD008986] Funding Source: NIH RePORTER;
   National Institute of Arthritis and Musculoskeletal and Skin Diseases
   [ZIDAR041180, ZIHAR041173] Funding Source: NIH RePORTER
FX This work was supported by National Institutes of Health intramural
   funds to J.C. Marini (National Institute of Child Health and Human
   Development, 1ZIAHD008973 02), R.M. Siegel (National Institute of
   Arthritis and Musculoskeletal and Skin Diseases, AR041173 11,
   AR041207 03, and AR041180 11), and T. Bhattacharyya (National Institute
   of Arthritis and Musculoskeletal and Skin Diseases, 1ZIDAR041180 09),
   and the Allgemeine Unfallversicherungsanstalt (research funds of the
   Austrian Workers' Compensation Board) and Wiener Gebietskrankenkasse
   (Vienna Regional Health Insurance Fund) to N. Fratzl Zelman. A. Ivovic
   was supported by the National Institutes of Health Oxford Cambridge PhD
   Scholars Program.
CR Bisseret D, 2015, SKELETAL RADIOL, V44, P321, DOI 10.1007/s00256 014 1976 5
   Borton AJ, 2001, J BONE MINER RES, V16, P1754, DOI 10.1359/jbmr.2001.16.10.1754
   Bourgeois B, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003411
   Chabanon A, 2008, STEM CELLS, V26, P3150, DOI 10.1634/stemcells.2008 0219
   Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Choi H, 2016, SCI REP UK, V6, DOI 10.1038/srep26046
   Couto JA, 2017, AM J HUM GENET, V100, P546, DOI 10.1016/j.ajhg.2017.01.018
   David CJ, 2018, NAT REV MOL CELL BIO, V19, P419, DOI 10.1038/s41580 018 0007 0
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Duque G, 2011, J BONE MINER RES, V26, P1472, DOI 10.1002/jbmr.350
   Fleming NI, 2013, CANCER RES, V73, P725, DOI 10.1158/0008 5472.CAN 12 2706
   Fratzl Zelman N, 2019, J BONE MINER RES, V34, P883, DOI 10.1002/jbmr.3656
   Freyschmidt J, 2001, EUR RADIOL, V11, P474, DOI 10.1007/s003300000562
   Glorieux FH, 2000, BONE, V26, P103, DOI 10.1016/S8756 3282(99)00257 4
   Grönroos E, 2012, MOL CELL BIOL, V32, P2904, DOI 10.1128/MCB.00231 12
   Hellemans J, 2004, NAT GENET, V36, P1213, DOI 10.1038/ng1453
   Hellemans Jan, 2006, Hum Mutat, V27, P290, DOI 10.1002/humu.9403
   Ho NC, 2000, J BONE MINER RES, V15, P2095, DOI 10.1359/jbmr.2000.15.11.2095
   Holm TM, 2011, SCIENCE, V332, P358, DOI 10.1126/science.1192149
   Janssens K, 2000, NAT GENET, V26, P273, DOI 10.1038/81563
   Jha S, 2019, J BONE MINER RES, V34, P145, DOI 10.1002/jbmr.3577
   Kaji H, 2006, HORM METAB RES, V38, P740, DOI 10.1055/s 2006 955085
   Kang H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03720 z
   Kinoshita A, 2000, NAT GENET, V26, P19, DOI 10.1038/79128
   Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984
   Leri A., 1922, B SOC MED HOP PARIS, V46, P1141
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Lin HT, 2019, INT J MOL MED, V43, P1085, DOI 10.3892/ijmm.2018.4001
   Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044
   Loeys B.L., 1993, Loeys Dietz Syndrome GeneReviews NCBI Bookshelf
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Ma L, 1996, HUM MOL GENET, V5, P1915, DOI 10.1093/hmg/5.12.1915
   Maguire BA, 2001, CELL, V104, P813, DOI 10.1016/S0092 8674(01)00278 1
   Massagué J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051
   Miyazono K, 2018, NUCLEIC ACIDS RES, V46, P12139, DOI 10.1093/nar/gky925
   Mumm S, 2007, J BONE MINER RES, V22, P243, DOI 10.1359/JBMR.061102
   Muñoz NM, 2008, GROWTH FACTORS, V26, P254, DOI 10.1080/08977190802291667
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Naora H, 1999, IMMUNOL CELL BIOL, V77, P197, DOI 10.1046/j.1440 1711.1999.00816.x
   Pezzini A, 2012, CURR MED CHEM, V19, P454, DOI 10.2174/092986712803414286
   Qing J, 2004, MOL CELL BIOL, V24, P1411, DOI 10.1128/MCB.24.3.1411 1425.2004
   Rahimi RA, 2009, CANCER RES, V69, P84, DOI 10.1158/0008 5472.CAN 08 2146
   Roschger P, 1998, BONE, V23, P319, DOI 10.1016/S8756 3282(98)00112 4
   Roschger P, 2008, BONE, V42, P456, DOI 10.1016/j.bone.2007.10.021
   Sartori R, 2009, AM J PHYSIOL CELL PH, V296, pC1248, DOI 10.1152/ajpcell.00104.2009
   Schepers D, 2018, HUM MUTAT, V39, P621, DOI 10.1002/humu.23407
   Shirakabe K, 2001, GENES CELLS, V6, P851, DOI 10.1046/j.1365 2443.2001.00466.x
   Soltanoff CS, 2009, CRIT REV EUKAR GENE, V19, P1, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.10
   Sowa H, 2002, J BONE MINER RES, V17, P1190, DOI 10.1359/jbmr.2002.17.7.1190
   Steinbaugh MJ., 2018, F1000RESEARCH, V6, P1976, DOI [DOI 10.12688/F1000RESEARCH.12093.2, 10.12688/F1000RESEARCH.12093.2]
   van de Laar IMBH, 2011, NAT GENET, V43, P121, DOI 10.1038/ng.744
   van der Pluijm I, 2016, EBIOMEDICINE, V12, P280, DOI 10.1016/j.ebiom.2016.09.006
   Whyte MP, 2017, BONE, V101, P145, DOI 10.1016/j.bone.2017.04.010
   Wilkie AOM, 2000, NAT GENET, V24, P387, DOI 10.1038/74224
   Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097 2765(01)00421 X
   Wu LY, 2009, DEV CELL, V17, P35, DOI 10.1016/j.devcel.2009.05.010
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Yao Yihong, 2009, Hum Genomics Proteomics, V2009, DOI 10.4061/2009/374312
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zimmermann RA, 2003, CELL, V115, P130, DOI 10.1016/S0092 8674(03)00804 3
NR 61
TC 32
Z9 32
U1 0
U2 4
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0022 1007
EI 1540 9538
J9 J EXP MED
JI J. Exp. Med.
PD MAY
PY 2020
VL 217
IS 5
AR e20191499
DI 10.1084/jem.20191499
PG 23
WC Immunology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Research & Experimental Medicine
GA LK7FU
UT WOS:000531028800014
PM 32232430
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Kyriazoglou, A
   Ntanasis Stathopoulos, I
   Terpos, E
   Fotiou, D
   Kastritis, E
   Dimopoulos, MA
   Gavriatopoulou, M
AF Kyriazoglou, Anastasios
   Ntanasis Stathopoulos, Ioannis
   Terpos, Evangelos
   Fotiou, Despina
   Kastritis, Efstathios
   Dimopoulos, Meletios A.
   Gavriatopoulou, Maria
TI Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma
   and Associated Bone Disease
SO CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
LA English
DT Article
DE Microenvironment; Plasma cell; Targeted; TAZ; YAP
ID SIGNALING PATHWAY; CLINICAL IMPLICATIONS; CELL PROLIFERATION; YAP
   PATHWAY; TAZ; TRANSCRIPTION; PROTEIN; BIOGENESIS; EXPRESSION; BORTEZOMIB
AB Multiple myeloma (MM) is an incurable plasma cell dyscrasia with numerous treatment options currently available; however, drug resistance is usually inevitable, so there is a constant need for novel treatment approaches. The Hippo pathway has emerged as an important mediator of oncogenesis in solid tumors. More recently, its key role in regulating apoptosis and mediating resistance in MM and other hematologic malignancies has been demonstrated in preclinical studies, which provides a strong basis for further clinical investigation. The Hippo pathway is also implicated in the pathogenesis of MM induced bone disease, as it regulates both osteoblast and osteoclast function. We provide an overview of the available data regarding the role of the Hippo signaling components in the pathophysiology of MM. A better understanding of the underlying interactions at the molecular and cellular levels will lead to novel and promising treatment approaches. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Kyriazoglou, Anastasios; Ntanasis Stathopoulos, Ioannis; Terpos, Evangelos; Fotiou, Despina; Kastritis, Efstathios; Dimopoulos, Meletios A.; Gavriatopoulou, Maria] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Sch Med, Athens, Greece.
C3 National & Kapodistrian University of Athens
RP Gavriatopoulou, M (通讯作者)，Natl & Kapodistrian Univ Athens, Sch Med, Alexandra Gen Hosp, Dept Clin Therapeut, 80 Vas Sofias Ave, Athens 11528, Greece.
EM mgavria@med.uoa.gr
RI Terpos, Evangelos/AAD 3667 2019; Kastritis, Efstathios/AAD 3656 2019;
   Ntanasis Stathopoulos, Ioannis/AAD 3692 2019; Gavriatopoulou,
   Maria/AAD 3698 2019; Dimopoulos, Meletios/AAD 4130 2019; Fotiou,
   Despina/AAD 7499 2019
OI Gavriatopoulou, Maria/0000 0002 6244 1229; Terpos,
   Evangelos/0000 0001 5133 1422; Fotiou, Despina/0000 0002 0618 8900; 
CR Ailawadhi S, 2016, CANCER AM CANCER SOC, V122, P618, DOI 10.1002/cncr.29771
   Avruch J, 2006, METHOD ENZYMOL, V407, P290, DOI 10.1016/S0076 6879(05)07025 4
   Calura E, 2016, ONCOTARGET, V7, P2367, DOI 10.18632/oncotarget.6151
   Cottini F, 2014, MOL CELL ONCOL, V1, DOI 10.4161/23723548.2014.970055
   Cottini F, 2014, NAT MED, V20, P599, DOI 10.1038/nm.3562
   Delgado Calle J, 2017, LEUKEMIA, V31, P2686, DOI 10.1038/leu.2017.152
   Delgado Calle J, 2016, CANCER RES, V76, P1089, DOI 10.1158/0008 5472.CAN 15 1703
   Dimopoulos MA, 2016, NEW ENGL J MED, V375, P1319, DOI 10.1056/NEJMoa1607751
   Eda H, 2010, EUR J HAEMATOL, V85, P68, DOI 10.1111/j.1600 0609.2010.01435.x
   Ehmer U, 2016, MOL CANCER RES, V14, P127, DOI 10.1158/1541 7786.MCR 15 0305
   Errani C, 2011, GENE CHROMOSOME CANC, V50, P644, DOI 10.1002/gcc.20886
   Fan R, 2013, P NATL ACAD SCI USA, V110, P2569, DOI 10.1073/pnas.1216462110
   Federico C, 2019, NON CODING RNA, V5, DOI 10.3390/ncrna5020037
   Fenske TS, 2015, CANCER AM CANCER SOC, V121, P3465, DOI 10.1002/cncr.29502
   Frassanito MA, 2019, J PATHOL, V247, P241, DOI 10.1002/path.5187
   Giuliani N, 2012, LEUKEMIA, V26, P1391, DOI 10.1038/leu.2011.381
   Halder G, 2012, NAT REV MOL CELL BIO, V13, P591, DOI 10.1038/nrm3416
   Hsu PC, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6040114
   Huang W, 2012, J BIOL CHEM, V287, P26245, DOI 10.1074/jbc.M112.382036
   Huggett MT, 2014, BRIT J CANCER, V110, P1698, DOI 10.1038/bjc.2014.95
   Ibata Soushi, 2018, Oncotarget, V9, P25127, DOI 10.18632/oncotarget.25350
   Kalinski P, 2012, J IMMUNOL, V188, P21, DOI 10.4049/jimmunol.1101029
   Kim HB, 2018, BMB REP, V51, P119, DOI 10.5483/BMBRep.2018.51.3.018
   Kim MH, 2018, CANCER IMMUNOL RES, V6, P255, DOI 10.1158/2326 6066.CIR 17 0320
   Kim S, 2016, BMB REP, V49, P357, DOI 10.5483/BMBRep.2016.49.7.104
   Kumar SK, 2017, LEUKEMIA, V31, P2443, DOI 10.1038/leu.2017.138
   Lai D, 2011, CANCER RES, V71, P2728, DOI 10.1158/0008 5472.CAN 10 2711
   Lamar JM, 2018, CANCERS BASEL, V10
   Lee BS, 2017, BIOCHEM BIOPH RES CO, V491, P493, DOI 10.1016/j.bbrc.2017.07.007
   Li BZ, 2007, STEM CELLS DEV, V16, P921, DOI 10.1089/scd.2007.0074
   Lin CH, 2015, MOL BIOL CELL, V26, P3946, DOI 10.1091/mbc.E15 07 0456
   Lin LP, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1021441
   Lin LP, 2015, NAT GENET, V47, P250, DOI 10.1038/ng.3218
   Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932
   Liu XF, 2016, CELL REP, V14, P1169, DOI 10.1016/j.celrep.2015.12.104
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Lonial S, 2015, NEW ENGL J MED, V373, P621, DOI 10.1056/NEJMoa1505654
   Maruyama J, 2018, MOL CANCER RES, V16, P197, DOI 10.1158/1541 7786.MCR 17 0382
   Matsumoto Y, 2016, J CLIN INVEST, V126, P4482, DOI 10.1172/JCI87802
   Maugeri Saccà M, 2015, EXPERT REV MOL MED, V17, DOI 10.1017/erm.2015.12
   McGray AJR, 2017, ADV EXP MED BIOL, V1036, P213, DOI 10.1007/978 3 319 67577 0_14
   Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638
   Moreau P, 2017, ANN ONCOL, V28, P52, DOI 10.1093/annonc/mdx096
   Mori M, 2014, CELL, V156, P893, DOI 10.1016/j.cell.2013.12.043
   Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876
   Motz GT, 2014, NAT MED, V20, P607, DOI 10.1038/nm.3541
   Oancea M, 2004, INT J HEMATOL, V80, P224, DOI 10.1532/IJH97.04107
   Pan JX, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0018 7
   Park HW, 2015, CELL, V162, P780, DOI 10.1016/j.cell.2015.07.013
   Park HW, 2013, TRENDS PHARMACOL SCI, V34, P581, DOI 10.1016/j.tips.2013.08.006
   Piersma B, 2015, FRONT MED, V2, DOI 10.3389/fmed.2015.00059
   Rauskolb C, 2014, CELL, V158, P143, DOI 10.1016/j.cell.2014.05.035
   Rui HB, 2018, EUR REV MED PHARMACO, V22, P6880, DOI 10.26355/eurrev_201810_16157
   Seo E, 2013, CELL REP, V3, P2075, DOI 10.1016/j.celrep.2013.05.029
   Sohn BH, 2016, CLIN CANCER RES, V22, P1256, DOI 10.1158/1078 0432.CCR 15 1447
   Song J, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12453
   Spaan I, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045 018 0615 3
   Stein C, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005465
   Stewart TJ, 2011, CANCER METAST REV, V30, P125, DOI 10.1007/s10555 011 9280 5
   Sun GP, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004324
   Terpos E, 2019, CL LYMPH MYELOM LEUK, V19, pE324, DOI 10.1016/j.clml.2019.03.008
   Terpos E, 2019, BLOOD, V133, P1534, DOI 10.1182/blood 2018 11 852459
   Terpos E, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408 017 0037 4
   van Rensburg HJJ, 2018, CANCER RES, V78, P1457, DOI 10.1158/0008 5472.CAN 17 3139
   Varelas X, 2014, DEVELOPMENT, V141, P1614, DOI 10.1242/dev.102376
   Varelas X, 2010, DEV CELL, V18, P579, DOI 10.1016/j.devcel.2010.03.007
   Wang LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065539
   Yang BN, 2017, INT J BIOCHEM CELL B, V87, P104, DOI 10.1016/j.biocel.2017.04.007
   Yang WL, 2018, J CELL PHYSIOL, V233, P4606, DOI 10.1002/jcp.26372
   Ye S, 2016, PHARMACOL RES, V103, P270, DOI 10.1016/j.phrs.2015.11.025
   Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037
   Yu JZ, 2010, DEV CELL, V18, P288, DOI 10.1016/j.devcel.2009.12.012
   Zagouri F, 2016, EXPERT OPIN EMERG DR, V21, P225, DOI 10.1080/14728214.2016.1186644
   Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216
   Zhang K, 2015, BIOCHEMISTRY US, V54, P6555, DOI 10.1021/acs.biochem.5b01014
   Zhuang Y, 2017, LEUKEMIA RES, V59, P97, DOI 10.1016/j.leukres.2017.06.002
NR 76
TC 10
Z9 11
U1 0
U2 6
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219 3931 USA
SN 2152 2650
EI 2152 2669
J9 CL LYMPH MYELOM LEUK
JI Clin. Lymphoma Myeloma Leuk.
PD FEB
PY 2020
VL 20
IS 2
BP 57
EP 62
DI 10.1016/j.clml.2019.09.620
PG 6
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Hematology
GA KM1YZ
UT WOS:000513918800012
PM 31734019
DA 2025 08 17
ER

PT J
AU Su, ZK
   Chen, D
   Huang, JY
   Liang, ZT
   Ren, W
   Zhang, ZY
   Jiang, QZ
   Luo, T
   Guo, L
AF Su, Zhikang
   Chen, Ding
   Huang, Jiangyon
   Liang, Zitian
   Ren, Wen
   Zhang, Zeyu
   Jiang, Qianzhou
   Luo, Tao
   Guo, Lvhua
TI Isoliquiritin treatment of osteoporosis by promoting osteogenic
   differentiation and autophagy of bone marrow mesenchymal stem cells
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE autophagy; bone marrow mesenchymal stem cells; isoliquiritin; MAPK;
   osteoporosis
AB Osteoporosis is a chronic progressive bone disease characterized by the decreased osteogenic ability of osteoblasts coupled with increased osteoclast activity. Natural products showing promising therapeutic potential for postmenopausal osteoporosis remain underexplored. In this study, we aimed to analyze the therapeutic effects of isoliquiritin (ISL) on osteoporosis in mice and its possible mechanism of action. An ovariectomy induced osteoporosis mouse model and bone marrow mesenchymal stem cells (BMSCs) were used to analyze the effects of ISL on bone regeneration in vivo and in vitro, respectively. Mitogen activated protein kinase (MAPK) and autophagy inhibitors were used, to investigate whether the MAPK signaling pathway and autophagy affect the osteogenic differentiation of BMSCs. ISL significantly improved bone formation and reduced bone resorption in mouse femurs without inducing any detectable toxicity in critical organs such as the liver, kidney, brain, heart, and spleen. In vitro experiments showed that ISL enhanced the proliferation and osteogenic differentiation of BMSCs and that its osteogenic effect was attenuated by p38/extracellular regulated protein kinase (ERK) and autophagy inhibitors. Further studies showed that the inhibition of phosphorylated p38/ERK blocked ISL autophagy in BMSCs. ISL promoted the osteogenic differentiation of BMSCs through the p38/ERK autophagy pathway and was therapeutically effective in treating osteoporosis in ovariectomized mice without any observed toxicity to vital organs. These results strongly suggest the promising potential of ISL as a safe and efficacious candidate drug for the treatment of osteoporosis.
C1 [Su, Zhikang; Chen, Ding; Huang, Jiangyon; Ren, Wen; Luo, Tao; Guo, Lvhua] Guangzhou Med Univ, Sch & Hosp Stomatol, Guangdong Engn Res Ctr Oral Restorat & Reconstruct, Dept Prosthodont, Guangzhou, Guangdong, Peoples R China.
   [Su, Zhikang; Chen, Ding; Huang, Jiangyon; Liang, Zitian; Ren, Wen; Zhang, Zeyu; Jiang, Qianzhou; Luo, Tao; Guo, Lvhua] Guangzhou Med Univ, Guangzhou Key Lab Basic & Appl Res Oral Regenerat, Guangzhou, Guangdong, Peoples R China.
   [Liang, Zitian; Zhang, Zeyu; Jiang, Qianzhou] Guangzhou Med Univ, Sch & Hosp Stomatol, Guangdong Engn Res Ctr Oral Restorat & Reconstruct, Guangzhou, Guangdong, Peoples R China.
   [Jiang, Qianzhou; Luo, Tao; Guo, Lvhua] Guangzhou Med Univ, Sch & Hosp Stomatol, Guangzhou 510000, Guangdong, Peoples R China.
C3 Guangzhou Medical University; Guangzhou Medical University; Guangzhou
   Medical University; Guangzhou Medical University
RP Jiang, QZ; Luo, T; Guo, L (通讯作者)，Guangzhou Med Univ, Sch & Hosp Stomatol, Guangzhou 510000, Guangdong, Peoples R China.
EM jqianzhou@gzhmu.edu.cn; 2011686028@gzhmu.edu.cn; 2010686002@gzhmu.edu.cn
RI ; Liang, Zitian/OAJ 9738 2025
OI Chen, Ding/0009 0000 4430 555X; Guo, Lvhua/0009 0001 5152 5611; 
FU This research was supported by the Guangdong Provincial Science and
   Technology Plan Project (2021A0505030079), the Key Projects of Science
   and Technology Plan of Liwan District of Guangzhou City (2201006), the
   Research and Development Plan of Key Areas of [2021A0505030079];
   Guangdong Provincial Science and Technology Plan Project [2201006]; Key
   Projects of Science and Technology Plan of Liwan District of Guangzhou
   City [2020B1111490004]; Research and Development Plan of Key Areas of
   Scientific Research Institutions in Guangdong Province
FX This research was supported by the Guangdong Provincial Science and
   Technology Plan Project (2021A0505030079), the Key Projects of Science
   and Technology Plan of Liwan District of Guangzhou City (2201006), the
   Research and Development Plan of Key Areas of Scientific Research
   Institutions in Guangdong Province, and the Key Technology Research and
   Development of Oral High Performance Implantable Medical Devices
   (2020B1111490004).
CR Bellavia D, 2021, TRENDS ENDOCRIN MET, V32, P846, DOI 10.1016/j.tem.2021.07.011
   Boya P, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.146506
   Ceccariglia S, 2020, AUTOPHAGY, V16, P28, DOI 10.1080/15548627.2019.1630223
   Cheng CH, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031376
   Dong X, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.296
   Fleming A, 2022, NEURON, V110, P935, DOI 10.1016/j.neuron.2022.01.017
   Gu HW, 2023, PHYTOTHER RES, V37, P2841, DOI 10.1002/ptr.7780
   Ho TT, 2017, NATURE, V543, P205, DOI 10.1038/nature21388
   Hou Y, 2013, FOOD FUNCT, V4, P1727, DOI 10.1039/c3fo60295h
   Isbrucker RA, 2006, REGUL TOXICOL PHARM, V46, P167, DOI 10.1016/j.yrtph.2006.06.002
   Jiang YX, 2022, CELL TRANSPLANT, V31, DOI 10.1177/09636897221107636
   Jin X, 2017, NUTR RES, V42, P20, DOI 10.1016/j.nutres.2017.04.009
   Lee JY, 2021, PHYTOTHER RES, V35, P2119, DOI 10.1002/ptr.6960
   Lei G, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/8889731
   Li X, 2020, AGEING RES REV, V62, DOI 10.1016/j.arr.2020.101098
   Li Y, 2022, J NAT FIBERS, V19, P10979, DOI 10.1080/15440478.2021.2002785
   Liang TT, 2021, J BIOMED MATER RES A, V109, P219, DOI 10.1002/jbm.a.37018
   Liu GF, 2022, PHYTOTHER RES, V36, P4230, DOI 10.1002/ptr.7558
   Liu YY, 2020, FISH SHELLFISH IMMUN, V100, P238, DOI 10.1016/j.fsi.2020.02.071
   Lu JM, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1345 3
   Luo Y, 2022, BONE, V162, DOI 10.1016/j.bone.2022.116444
   Ma Y, 2018, AGING CELL, V17, DOI 10.1111/acel.12709
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976 0105.177703
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Nuschke A, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt530
   Oliver L, 2012, STEM CELLS DEV, V21, P2779, DOI 10.1089/scd.2012.0124
   Sahani MH, 2014, AUTOPHAGY, V10, P431, DOI 10.4161/auto.27344
   Shi HY, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.13114
   Song SS, 2022, PHARMACOL THERAPEUT, V237, DOI 10.1016/j.pharmthera.2022.108168
   Pham TH, 2022, PHYTOTHER RES, V36, P3601, DOI 10.1002/ptr.7526
   Vidoni C, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964 019 0414 7
   Wang TM, 2016, BIOMED CHROMATOGR, V30, P1166, DOI 10.1002/bmc.3662
   Wang YH, 2021, PHYTOMEDICINE, V84, DOI 10.1016/j.phymed.2021.153513
   Wang YQ, 2018, J CELL PHYSIOL, V233, P2386, DOI 10.1002/jcp.26110
   Wang YP, 2022, J DIABETES RES, V2022, DOI 10.1155/2022/4067812
   Xu N, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.823341
   Yang S, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0869 2
   Yin X, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0058 7
   Yu C, 2020, EUR J PHARMACOL, V881, DOI 10.1016/j.ejphar.2020.173184
   Yuan SJ, 2023, J ETHNOPHARMACOL, V308, DOI 10.1016/j.jep.2023.116174
   Zeng WF, 2013, PROTEIN CELL, V4, P539, DOI 10.1007/s13238 013 3003 3
   Zhang XH, 2021, PHYTOMEDICINE, V83, DOI 10.1016/j.phymed.2021.153469
   Zhang XH, 2019, LIFE SCI, V223, P128, DOI 10.1016/j.lfs.2019.03.026
   Zhou J, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 02958 1
   Zhou YZ, 2017, FOOD FUNCT, V8, P1235, DOI [10.1039/c6fo01503d, 10.1039/C6FO01503D]
   Zhu SP, 2020, STEM CELL TRANSL MED, V9, P603, DOI 10.1002/sctm.19 0282
   Zhu Y, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1143 y
NR 47
TC 4
Z9 7
U1 5
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0951 418X
EI 1099 1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD JAN
PY 2024
VL 38
IS 1
BP 214
EP 230
DI 10.1002/ptr.8032
EA OCT 2023
PG 17
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GP7Q2
UT WOS:001085877900001
PM 37859562
DA 2025 08 17
ER

PT J
AU Vu, AA
   Bose, S
AF Vu, Ashley A.
   Bose, Susmita
TI Natural Antibiotic Oregano in Hydroxyapatite Coated Titanium Reduces
   Osteoclastic Bone Resorption for Orthopedic and Dental Applications
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE carvacrol; thymol; oregano; plasma spray hydroxyapatite coating;
   osteoclast
ID RESISTANT ACID PHOSPHATASE; IN VITRO; ESCHERICHIA COLI; DRUG RELEASE;
   CARVACROL; ANTIOXIDANT; DELIVERY; THYMOL; CEMENT; STABILITY
AB Traditional infection prevention and treatment methods include synthetic antibiotics, which can cause severe adverse side effects. Carvacrol and thymol are biologically active monoterpenoid extractants from oregano leaves with antibiotic capabilities; however, little is known regarding their effects on bone tissue engineering. The objective of this work is to understand their effects on osteogenesis, specifically with osteoblast and osteoclast cells, from surface modified Ti6Al4V with plasma sprayed hydroxyapatite (HA) coatings. This system is an alternative to cemented implants to aid in bone healing. Results reveal that full carvacrol release from the HA matrix is successful in aqueous environments and modulation of release kinetics can also be made using polycaprolactone (PCL) and polyethylene glycol (PEG) polymers. From HA pressed disc samples in physiological pH, full carvacrol release is achieved in 10 days using PCL/PEG, about 95% release in 50 days using no polymer, and 60% in 50 days when using a PCL coating. Without polymer, full carvacrol release is achieved after 3 days from HA coatings in both physiological pH and acidic pH, mimicking the post surgery environment. The release is assessed as a diffusion based mechanism in phosphate buffered saline but degradation based mechanism in acetate buffer solution. Carvacrol and thymol show bacterial inhibition of Staphylococcus epidermidis and no cytotoxic effects on osteoblast proliferation in vitro. Carvacrol and thymol also induce a significant 7% reduction in osteoclast tartrate resistant acid phosphatase (TRAP) activity, caused by poorly attached cellular morphologies, leading to an approximately 65% reduction in osteoclast resorption pit formation. Our goal is to demonstrate a natural medicinal system that can support bone healing while providing infection prevention and reducing costly revision surgeries for orthopedic and dental applications.
C1 [Vu, Ashley A.; Bose, Susmita] Washington State Univ, WM Keck Biomed Mat Res Lab, Sch Mech & Mat Engn, Pullman, WA 99164 USA.
C3 Washington State University
RP Bose, S (通讯作者)，Washington State Univ, WM Keck Biomed Mat Res Lab, Sch Mech & Mat Engn, Pullman, WA 99164 USA.
EM sbose@wsu.edu
OI Vu, Ashley/0000 0003 4336 8342
FU National Institutes of Health [R01 AR066361, R01 DE029204 01]
FX The authors would like to acknowledge financial support from the
   National Institutes of Health under grant numbers R01 AR066361 and R01
   DE029204 01. The authors would like to thank the Franceschi Microscopy &
   Imaging Center at Washington State University. The authors specially
   thank Naboneeta Sarkar for her help in imaging. This content is solely
   the responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health.
CR Abraham R. J, 2008, MODELLING 1H NMR SPE, P79
   [Anonymous], 2009, 10993 ISO
   Astle M. J., 1985, CRC HDB DATA ORGANIC, VI, P454
   Bohner M, 1997, J PHARM SCI US, V86, P565, DOI 10.1021/js960405a
   Bose S, 2018, MATER TODAY CHEM, V8, P110, DOI 10.1016/j.mtchem.2018.03.005
   Bose S, 2018, MAT SCI ENG C MATER, V88, P166, DOI 10.1016/j.msec.2018.02.019
   Bose S, 2009, J AM CERAM SOC, V92, P323, DOI 10.1111/j.1551 2916.2008.02881.x
   BURSTONE MS, 1959, J HISTOCHEM CYTOCHEM, V7, P39, DOI 10.1177/7.1.39
   Burt SA, 2005, J FOOD PROTECT, V68, P919, DOI 10.4315/0362 028X 68.5.919
   Chakraborty J, 2013, MAT SCI ENG C MATER, V33, P2168, DOI 10.1016/j.msec.2013.01.047
   Chemical Abstracts Services, CAS REG NUMB 499 75
   Deepak V, 2016, BIOL PHARM BULL, V39, P1150, DOI 10.1248/bpb.b16 00117
   Deng LL, 2016, SCI REP UK, V6, DOI 10.1038/srep38160
   Di Giacomo G., 2019, Management of Bone Metastases, P183
   Dorman HJD, 2000, J APPL MICROBIOL, V88, P308, DOI 10.1046/j.1365 2672.2000.00969.x
   Frieden T., 2013, Antibiotic resistance threats in the United States
   Ghosh S, 2016, ACS APPL MATER INTER, V8, P7691, DOI 10.1021/acsami.6b01160
   Griffin SG, 1999, FLAVOUR FRAG J, V14, P322, DOI [10.1002/(SICI)1099 1026(199909/10)14:5<322::AID FFJ837>3.0.CO;2 4, 10.1002/(SICI)1099 1026(199909/10)14:5<322::AID FFJ837>3.3.CO;2 W]
   Hajimehdipoor H, 2010, PHARMACOGN MAG, V6, P154, DOI 10.4103/0973 1296.66927
   Hayman AR, 2008, AUTOIMMUNITY, V41, P218, DOI 10.1080/08916930701694667
   Karakaya S, 2004, CRIT REV FOOD SCI, V44, P453, DOI 10.1080/10408690490886683
   Ke DX, 2019, ACTA BIOMATER, V84, P414, DOI 10.1016/j.actbio.2018.11.041
   Ke DX, 2017, ACS APPL MATER INTER, V9, P25731, DOI 10.1021/acsami.7b05574
   Keawchaoon L, 2011, COLLOID SURFACE B, V84, P163, DOI 10.1016/j.colsurfb.2010.12.031
   Kirstein B, 2006, J CELL BIOCHEM, V98, P1085, DOI 10.1002/jcb.20835
   Knobloch K., 1988, BIOFLAVOUR, V87, P287, DOI DOI 10.1515/9783110867121 022
   Knobloch K., 1986, Progress in essential oil research, P429
   Landa P, 2009, ARCH PHARM RES, V32, P75, DOI 10.1007/s12272 009 1120 6
   Lide D.R., 1994, Handbook of Data on Organic Compounds, VI, P4082
   Love C, 2016, CLIN RADIOL, V71, P632, DOI 10.1016/j.crad.2016.01.003
   Matluobi D, 2018, MICROVASC RES, V115, P20, DOI 10.1016/j.mvr.2017.08.003
   Pei RS, 2009, J FOOD SCI, V74, pM379, DOI 10.1111/j.1750 3841.2009.01287.x
   Perni S, 2019, ACS APPL BIO MATER, V2, P1850, DOI 10.1021/acsabm.8b00752
   Pizzale L, 2002, J SCI FOOD AGR, V82, P1645, DOI 10.1002/jsfa.1240
   Rauschmann MA, 2005, BIOMATERIALS, V26, P2677, DOI 10.1016/j.biomaterials.2004.06.045
   Roy M, 2012, J BIOMED MATER RES A, V100A, P2450, DOI 10.1002/jbm.a.34181
   Roy M, 2012, ACS APPL MATER INTER, V4, P1341, DOI 10.1021/am201610q
   Roy M, 2011, SURF COAT TECH, V205, P2785, DOI 10.1016/j.surfcoat.2010.10.042
   Rubió L, 2013, CRIT REV FOOD SCI, V53, P943, DOI 10.1080/10408398.2011.574802
   Schnieders J, 2011, J BIOMED MATER RES B, V99B, P391, DOI 10.1002/jbm.b.31910
   SOBALLE K, 1992, J ORTHOPAED RES, V10, P285, DOI 10.1002/jor.1100100216
   Vahabzadeh S, 2015, ACTA BIOMATER, V17, P47, DOI 10.1016/j.actbio.2015.01.022
   Vu AA, 2020, ANN BIOMED ENG, V48, P1025, DOI 10.1007/s10439 019 02292 3
   Vu AA, 2019, ACTA BIOMATER, V92, P325, DOI 10.1016/j.actbio.2019.05.020
   Weast R.C., 1985, CRC handbook of data on organic compounds
   Weast R. C., 1985, CRC HDB DATA ORGANIC, VII, P454
   WESTPHAL JF, 1994, J ANTIMICROB CHEMOTH, V33, P387, DOI 10.1093/jac/33.3.387
   Wolff K., 2010, Encyclopedia of Psychopharmacology
   Yildiz ZI, 2018, J MATER SCI, V53, P15837, DOI 10.1007/s10853 018 2750 1
NR 49
TC 23
Z9 27
U1 0
U2 30
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD NOV 25
PY 2020
VL 12
IS 47
BP 52383
EP 52392
DI 10.1021/acsami.0c14993
PG 10
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA PA3OK
UT WOS:000595547400013
PM 33181015
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Fang, J
   Xu, Q
AF Fang, J.
   Xu, Q.
TI Differences of osteoblastic bone metastases and osteolytic bone
   metastases in clinical features and molecular characteristics
SO CLINICAL & TRANSLATIONAL ONCOLOGY
LA English
DT Article
DE Bone metastases; Differences; Clinical features; Molecular
   characteristics; Bone targets
ID HORMONE RELATED PROTEIN; BREAST CANCER CELLS; RESISTANT PROSTATE CANCER;
   SKELETAL RELATED EVENTS; ZOLEDRONIC ACID; TGF BETA; ENDOTHELIN 1
   PRODUCTION; RANDOMIZED PHASE 3; ADJUVANT TREATMENT; ZIBOTENTAN ZD4054
AB Several cancers tend to metastasize to bone, leading to osteolytic or osteoblastic bone lesions. The respective phenotypes of bone destruction and bone formation vary in clinical features, including incidence, prognosis, skeletal related events and bone biomarkers. In addition, different molecular mechanisms explain the difference in phenotype. For example, molecules involved in osteolytic bone metastases (represented with breast cancer) include parathyroid hormone related protein, transforming growth factor beta, while in osteoblastic lesions (represented with prostate cancer), endothelin 1 and morphogenetic proteins, etc. play a more important role in bone formation. It is important for us to understand the differences of bone metastases between two phenotypes to help clinicians to understand the underlying mechanisms, behaviors and therapies in development and currently available for bone metastases.
C1 [Fang, J.; Xu, Q.] Tongji Univ, Dept Med Oncol, Shanghai Peoples Hosp 10, Sch Med, Shanghai 200072, Peoples R China.
C3 Tongji University
RP Xu, Q (通讯作者)，Tongji Univ, Dept Med Oncol, Shanghai Peoples Hosp 10, Sch Med, 301 Yanchang Rd, Shanghai 200072, Peoples R China.
EM fjmholmes@163.com; xuqingmd@gmail.com
FU National Natural Science Foundation of China [30872591, 81372749]
FX This work was supported by National Natural Science Foundation of China
   (Grant Nos. 30872591 and 81372749).
CR Aapro M, 2008, ANN ONCOL, V19, P420, DOI 10.1093/annonc/mdm442
   Autzen P, 1998, BRIT J CANCER, V78, P1219, DOI 10.1038/bjc.1998.658
   BAYLINK DJ, 1993, J BONE MINER RES, V8, pS565
   Bendre MS, 2005, CANCER RES, V65, P11001, DOI 10.1158/0008 5472.CAN 05 2630
   Brown JE, 2005, JNCI J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002
   Buijs JT, 2011, CANCER MICROENVIRON, V4, P261, DOI 10.1007/s12307 011 0075 6
   Chen YC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2781
   Clines Gregory A., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000616
   Clines GA, 2007, MOL ENDOCRINOL, V21, P486, DOI 10.1210/me.2006 0346
   Coleman RE, 2005, J CLIN ONCOL, V23, P4925, DOI 10.1200/JCO.2005.06.091
   Coleman RE, 2004, ONCOLOGIST, V9, P14, DOI 10.1634/theoncologist.9 90004 14
   Coleman R, 2008, CANCER TREAT REV, V34, P629, DOI 10.1016/j.ctrv.2008.05.001
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Connolly EC, 2012, INT J BIOL SCI, V8, P964, DOI 10.7150/ijbs.4564
   Dai JL, 2004, CANCER RES, V64, P994, DOI 10.1158/0008 5472.CAN 03 1382
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Dearnaley DP, 2009, LANCET ONCOL, V10, P872, DOI 10.1016/S1470 2045(09)70201 3
   Drabsch Y, 2011, J MAMMARY GLAND BIOL, V16, P97, DOI 10.1007/s10911 011 9217 1
   Drzymalski DM, 2010, J NEUROSURG SPINE, V13, P789, DOI 10.3171/2010.6.SPINE10167
   Falzon M, 2000, ENDOCRINOLOGY, V141, P1882, DOI 10.1210/en.141.5.1882
   Fang YZ, 2013, JNCI J NATL CANCER I, V105, P47, DOI 10.1093/jnci/djs485
   Feeley BT, 2006, BONE, V38, P154, DOI 10.1016/j.bone.2005.07.015
   Fizazi KS, 2013, J CLIN ONCOL, V31, P1740, DOI 10.1200/JCO.2012.46.4149
   Ganapathy V, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 122
   Granchi S, 2001, PROSTATE, V49, P267, DOI 10.1002/pros.10022
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Guise TA, 1997, CANCER AM CANCER SOC, V80, P1572, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1572::AID CNCR7>3.3.CO;2 D
   Guise T, 2010, SEMIN ONCOL, V37, pS2, DOI 10.1053/j.seminoncol.2010.10.007
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008 5472.CAN 05 1317
   Haudenschild DR, 2004, CANCER RES, V64, P8276, DOI 10.1158/0008 5472.CAN 04 2251
   Henderson MA, 2006, CANCER RES, V66, P2250, DOI 10.1158/0008 5472.CAN 05 2814
   Henry D, 2014, SUPPORT CARE CANCER, V22, P679, DOI 10.1007/s00520 013 2022 1
   HIRAGA T, 2004, J BONE MINER RES, V19, pS129
   Hiraga T, 2007, CANCER RES, V67, P4157, DOI 10.1158/0008 5472.CAN 06 2355
   Isowa S, 2010, ANTICANCER RES, V30, P2755
   James ND, 2010, BJU INT, V106, P966, DOI 10.1111/j.1464 410X.2010.09638.x
   Käkönen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kataoka M, 2012, ACTA MED OKAYAMA, V66, P213
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   Kohno N, 2005, J CLIN ONCOL, V23, P3314, DOI 10.1200/JCO.2005.05.116
   Kyle RA, 2007, J CLIN ONCOL, V25, P2464, DOI 10.1200/JCO.2007.12.1269
   Lee YC, 2011, CANCER RES, V71, P5194, DOI 10.1158/0008 5472.CAN 10 4374
   Linforth R, 2002, CLIN CANCER RES, V8, P3172
   Lipton A, 2008, CANCER AM CANCER SOC, V113, P193, DOI 10.1002/cncr.23529
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   Llombart A, 2012, CLIN BREAST CANCER, V12, P40, DOI 10.1016/j.clbc.2011.08.002
   Maroni P, 2011, BREAST CANCER RES TR, V129, P433, DOI 10.1007/s10549 010 1240 1
   McMahon S, 2006, J BIOL CHEM, V281, P24171, DOI 10.1074/jbc.M604507200
   Mehrotra M, 2004, J CELL BIOCHEM, V93, P741, DOI 10.1002/jcb.20138
   Menezes ME, 2012, INT J CANCER, V130, P1477, DOI 10.1002/ijc.26449
   Mohammad KS, 2003, CLIN ORTHOP RELAT R, pS67, DOI 10.1097/01.blo.0000093047.96273.4e
   Mourskaia AA, 2009, ONCOGENE, V28, P1005, DOI 10.1038/onc.2008.454
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990
   Nelson JB, 1996, CANCER RES, V56, P663
   Nelson JB, 2008, CANCER AM CANCER SOC, V113, P2478, DOI 10.1002/cncr.23864
   Nelson JB, 2012, CANCER AM CANCER SOC, V118, P5709, DOI 10.1002/cncr.27674
   Nuzzo F, 2012, ANN ONCOL, V23, P2027, DOI 10.1093/annonc/mdr600
   Ohshiba T, 2003, BIOCHEM BIOPH RES CO, V300, P957, DOI 10.1016/S0006 291X(02)02937 6
   Ortiz A, 2012, RECENT RESULTS CANC, V192, P225, DOI 10.1007/978 3 642 21892 7_11
   Palmieri C, 2013, CLIN CANCER RES, V19, P6863, DOI 10.1158/1078 0432.CCR 13 2275
   Paterson AHG, 2012, LANCET ONCOL, V13, P734, DOI 10.1016/S1470 2045(12)70226 7
   Qiang YW, 2008, BLOOD, V112, P196, DOI 10.1182/blood 2008 01 132134
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saad Fred, 2010, Curr Opin Support Palliat Care, V4, P127, DOI 10.1097/SPC.0b013e32833ac6d6
   Saito H, 2005, ANTICANCER RES, V25, P3817
   Schlüter KD, 2001, BRIT J PHARMACOL, V132, P427, DOI 10.1038/sj.bjp.0703830
   Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022
   Small EJ, 2003, J CLIN ONCOL, V21, P4277, DOI 10.1200/JCO.2003.05.147
   Sugiura H, 2008, CLIN ORTHOP RELAT R, V466, P729, DOI 10.1007/s11999 007 0051 0
   Thudi NK, 2011, PROSTATE, V71, P615, DOI 10.1002/pros.21277
   Virk MS, 2011, BONE, V48, P578, DOI 10.1016/j.bone.2010.11.003
   Voorzanger Rousselot N, 2007, BRIT J CANCER, V97, P964, DOI 10.1038/sj.bjc.6603959
   Winter MC, 2013, CLIN ONCOL UK, V25, P135, DOI 10.1016/j.clon.2012.10.010
   Yavas O, 2007, TUMORI, V93, P580
   Yin JJ, 2003, P NATL ACAD SCI USA, V100, P10954, DOI 10.1073/pnas.1830978100
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Zi XL, 2005, CANCER RES, V65, P9762, DOI 10.1158/0008 5472.CAN 05 0103
NR 81
TC 40
Z9 44
U1 1
U2 13
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH 6330, SWITZERLAND
SN 1699 048X
EI 1699 3055
J9 CLIN TRANSL ONCOL
JI Clin. Transl. Oncol.
PD MAR
PY 2015
VL 17
IS 3
BP 173
EP 179
DI 10.1007/s12094 014 1247 x
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA CB1AW
UT WOS:000349359800001
PM 25351174
DA 2025 08 17
ER

PT S
AU Faccio, R
AF Faccio, Roberta
GP Annals NY Acad Sci
TI Immune regulation of the tumor/bone vicious cycle
SO SKELETAL BIOLOGY AND MEDICINE I
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT 4th New York Skeletal Biology and Medicine Conference
CY APR 27 30, 2011
CL Mt Sinai Sch Med, New York, NY
HO Mt Sinai Sch Med
DE osteoclasts; T cells; bone metastases; vicious cycle; cancer
ID BREAST CANCER; PHOSPHOLIPASE C GAMMA 2; IFN GAMMA; DENDRITIC CELL;
   MYELOID CELLS; BONE MARROW; T CELLS; NK CELL; B CELL; LYN
AB The bone destruction attending skeletal metastasis is mediated by tumor recruited osteoclasts (OCs). Hence, OCs are principal therapeutic targets in afflicted individuals. On the other hand, one third of patients develop further skeletal related events within two years of initiating antiresorptive therapies, suggesting that additional cells modulate bone tumor growth. Previous studies showing amelioration of bone metastases by targeting the OCs were performed in immune compromised animals injected with human breast cancer cells. Consequently, the contribution of the immune system to bone tumor growth was unclear. Using genetic models of immune and OC modulation (PLC gamma 2 and Lyn), as well as pharmacological inhibition of OCs and T cells, we now demonstrate that a condition of immune deficiency can interfere with the antitumor effects of OC blockade. Thus, our findings expand the current tumor/bone vicious cycle model to include T cells as additional regulators of bone tumor growth, regardless of the OC status.
C1 Washington Univ, Sch Med, Dept Orthoped, St Louis, MO 63110 USA.
C3 Washington University (WUSTL)
RP Faccio, R (通讯作者)，Washington Univ, Sch Med, Dept Orthoped, Campus Box 8233,660 S Euclid, St Louis, MO 63110 USA.
EM faccior@wustl.edu
FU NIH [RO1 AR52921]; ARRA [63181]
FX This work was supported by NIH to R. F. (RO1 AR52921) and ARRA to R. F.
   (63181).
CR Aki D, 2008, GENES CELLS, V13, P199, DOI 10.1111/j.1365 2443.2007.01159.x
   Almand B, 2001, J IMMUNOL, V166, P678, DOI 10.4049/jimmunol.166.1.678
   [Anonymous], COCHRANE DATABASE SY
   Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673
   Canon JR, 2008, CLIN EXP METASTAS, V25, P119, DOI 10.1007/s10585 007 9127 1
   Chirgwin JM, 2007, J CELL BIOCHEM, V102, P1333, DOI 10.1002/jcb.21556
   Chu CL, 2005, J IMMUNOL, V175, P2880, DOI 10.4049/jimmunol.175.5.2880
   Cremasco V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008909
   Dieli F, 2003, BLOOD, V102, P2310, DOI 10.1182/blood 2003 05 1655
   Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102 991
   Epple H, 2008, MOL CELL BIOL, V28, P3610, DOI 10.1128/MCB.00259 08
   Feuerer M, 2001, INT J CANCER, V92, P96, DOI 10.1002/1097 0215(200102)9999:9999<::AID IJC1152>3.0.CO;2 Q
   Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506
   Gerosa F, 2002, J EXP MED, V195, P327, DOI 10.1084/jem.20010938
   Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18
   Harder KW, 2004, BLOOD, V104, P3901, DOI 10.1182/blood 2003 12 4396
   Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401
   HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904
   Käkönen SM, 2003, CANCER AM CANCER SOC, V97, P834, DOI 10.1002/cncr.11132
   Kim HJ, 2009, P NATL ACAD SCI USA, V106, P2325, DOI 10.1073/pnas.0806963106
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   Kumar S, 1997, CELL DEATH DIFFER, V4, P2, DOI 10.1038/sj.cdd.4400208
   Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471 4906(02)02302 5
   Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009
   Mao DL, 2006, J CLIN INVEST, V116, P2869, DOI 10.1172/JCI28775
   Marigo I, 2008, IMMUNOL REV, V222, P162, DOI 10.1111/j.1600 065X.2008.00602.x
   Morony S, 2001, CANCER RES, V61, P4432
   Mozaffari F, 2007, BRIT J CANCER, V97, P105, DOI 10.1038/sj.bjc.6603840
   MUNDY GR, 1991, BONE, V12, pS1, DOI 10.1016/8756 3282(91)90057 P
   Nagaraj S, 2008, CANCER RES, V68, P2561, DOI 10.1158/0008 5472.CAN 07 6229
   Nishizumi H, 1998, J EXP MED, V187, P1343, DOI 10.1084/jem.187.8.1343
   NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074 7613(95)90126 4
   Qin ZH, 2000, IMMUNITY, V12, P677, DOI 10.1016/S1074 7613(00)80218 6
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Ross JR, 2003, BMJ BRIT MED J, V327, P469, DOI 10.1136/bmj.327.7413.469
   Sallusto F, 2000, IMMUNOL REV, V177, P134, DOI 10.1034/j.1600 065X.2000.17717.x
   Scapini P, 2010, J EXP MED, V207, P1757, DOI 10.1084/jem.20100086
   Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122
   Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208
   Siveen KS, 2009, IMMUNOL LETT, V123, P97, DOI 10.1016/j.imlet.2009.02.011
   Smith KGC, 1998, J EXP MED, V187, P807, DOI 10.1084/jem.187.5.807
   Smyth MJ, 2006, ADV IMMUNOL, V90, P1, DOI 10.1016/S0065 2776(06)90001 7
   Tassi I, 2005, J IMMUNOL, V175, P749, DOI 10.4049/jimmunol.175.2.749
   Tassi I, 2009, EUR J IMMUNOL, V39, P1369, DOI 10.1002/eji.200839313
   Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074 7613(00)00005 4
   Yoon SH, 2009, FEBS LETT, V583, P1164, DOI 10.1016/j.febslet.2009.03.005
   Zhang KH, 2011, CANCER RES, V71, P4799, DOI 10.1158/0008 5472.CAN 10 3922
NR 47
TC 22
Z9 26
U1 0
U2 9
PU BLACKWELL SCIENCE PUBL
PI OXFORD
PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND
SN 0077 8923
BN 978 1 57331 846 4
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2011
VL 1237
BP 71
EP 78
DI 10.1111/j.1749 6632.2011.06244.x
PG 8
WC Multidisciplinary Sciences; Physiology
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Physiology
GA BZE87
UT WOS:000301292200011
PM 22082368
DA 2025 08 17
ER

PT J
AU Lazar, AC
   Pacurar, M
   Campian, RS
AF Lazar, Adela Cristina
   Pacurar, Mariana
   Campian, Radu Septimiu
TI Bisphosphonates in Bone Diseases Treatment
SO REVISTA DE CHIMIE
LA English
DT Article
DE bisphosphonates; nitrogen atoms; ATP; osteoporosis; treatment
ID ZOLEDRONIC ACID; ALENDRONATE; PAMIDRONATE; OSTEOCLAST; RESORPTION;
   MECHANISMS
AB Bisphosphonates are the most frequently used drugs in the treatment of various bone and cancer diseases. They are complex chemical compounds, having a structure similar to that of pyrophosphates, but with certain differences: i.e., bisphosphonates have P C P in their composition; instead of an oxygen atom, a carbon atom is present. The R1 and R2 chains bind to the carbon atom and thus, the antiresorptive capacity of bisphosphonates on the one hand, and their bone binding capacity on the other hand are stimulated. Through their action, they favor the treatment of diseases for which they have been prescribed, but they can also favor a number of undesired side effects.
C1 [Lazar, Adela Cristina; Campian, Radu Septimiu] Iuliu Hatieganu Univ Med & Pharm, Dept Oral Rehabil Oral Hlth & Dent Off Management, 15 Victor Babes, Cluj Napoca 400012, Romania.
   [Pacurar, Mariana] Univ Med & Pharm, Fac Med Dent, 38 Gh Marinescu Str, Targu Mures 540139, Romania.
C3 Iuliu Hatieganu University of Medicine & Pharmacy; George Emil Palade
   University of Medicine, Pharmacy, Science, & Technology of Targu Mures
RP Lazar, AC (通讯作者)，Iuliu Hatieganu Univ Med & Pharm, Dept Oral Rehabil Oral Hlth & Dent Off Management, 15 Victor Babes, Cluj Napoca 400012, Romania.
EM lazar_adela@yahoo.ro
RI Pacurar, Mariana/ABR 5190 2022; Lazar, ADELA/AAO 8270 2021
CR Berenson JR, 2002, J CLIN ONCOL, V20, P3719, DOI 10.1200/JCO.2002.06.037
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Coxon JP, 2004, PROSTATE CANCER P D, V7, P99, DOI 10.1038/sj.pcan.4500705
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   FLEISCH H, 1999, BISPHOSPHONATE BONE
   Frith JC, 2001, ARTHRITIS RHEUM, V44, P2201, DOI 10.1002/1529 0131(200109)44:9<2201::AID ART374>3.0.CO;2 E
   GRAHAM R., BISPHOSPHONATES MODE
   LAZAR AC, 2016, THESIS
   Lipton A, 2004, ONCOLOGIST, V9, P38, DOI 10.1634/theoncologist.9 90004 38
   Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558
   Malden NJ, 2007, BRIT DENT J, V203, P93, DOI 10.1038/bdj.2007.636
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902
   PAPAPOULOS SE, 1989, J BONE MINER RES, V4, P775
   RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092 8674(92)90164 8
   RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092 8674(92)90163 7
   ROGERS MJ, 1992, BIOCHEM BIOPH RES CO, V189, P414, DOI 10.1016/0006 291X(92)91574 A
   Rosen LS, 2004, CANCER, V100, P2613, DOI 10.1002/cncr.20308
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   SAHNI M, 1992, J BONE MINER RES, V17, P189
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   SCHENK R, 1973, CALC TISS RES, V11, P196, DOI 10.1007/BF02547219
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Takagi Y, 2009, J PROSTHET DENT, V101, P289, DOI 10.1016/S0022 3913(09)00049 3
   VANBREUKELEN FJM, 1982, CALCIFIED TISSUE INT, V34, P321, DOI 10.1007/BF02411261
   ZHANY FL, 1996, ANNU REV BIOCHEM, V65, P241
NR 29
TC 3
Z9 3
U1 1
U2 5
PU CHIMINFORM DATA S A
PI BUCHAREST
PA CALEA PLEVNEI NR 139, SECTOR 6, BUCHAREST R 77131, ROMANIA
SN 0034 7752
J9 REV CHIM BUCHAREST
JI Rev. Chim.
PD FEB
PY 2017
VL 68
IS 2
BP 246
EP 249
PG 4
WC Chemistry, Multidisciplinary; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Engineering
GA EO9YD
UT WOS:000397043100011
DA 2025 08 17
ER

PT J
AU Yoon, DS
   Oh, SE
   Lee, KM
   Jung, SJ
   Ko, EA
   Kim, TG
   Park, KH
   Lee, JW
AF Yoon, Dong Suk
   Oh, Seung Eun
   Lee, Kyoung Mi
   Jung, Sujin
   Ko, Eun Ae
   Kim, Tae Gyun
   Park, Kwang Hwan
   Lee, Jin Woo
TI Age Related Decrease in Pellino 1 Expression Contributes to
   Osteoclast Mediated Bone Loss
SO ADVANCED BIOLOGY
LA English
DT Article
DE aging; bone; osteoclast; osteoclastogenesis; Pellino 1; skeletal aging
ID STERILE INSECT TECHNIQUE; SUZUKII DIPTERA DROSOPHILIDAE; IRRADIATION;
   INVASION; IMPACT
AB Aging related bone loss is driven by various biological factors, such as imbalanced bone metabolism from decreased osteoblast and increased osteoclast activities. Various transcriptional and post transcriptional factors increase osteoclast activity with aging; however, studies regarding the post translational regulators of osteoclast activity are still limited. The ubiquitin E3 ligase Pellino 1 is a well known post translational regulator of inflammation. However, how Pellino 1 expression regulation affects osteoclast differentiation remains unclear. This study determined that Pellino 1 levels are reduced in bone marrow monocytes (BMMs) from 40 week old mice compared to 4 week old mice. Interestingly, conditional Knockout (cKO) of Pellino 1 in 6 week old mice resulted in decreased bone mass, reduced body size, and lower weight than in Pellino 1 floxed mice; however, these differences are not observed in 20 week old mice. The increased number of tartrate resistant acid phosphatase (TRAP) positive cells and serum levels of C terminal telopeptides of type I collagen, a marker of bone resorption, in 6 week old Pellino 1 cKO mice implied a connection between Pellino 1 and the osteoclast population. Enhanced TRAP activity and upregulation of osteoclast genes in BMMs from the cKO mice indicate that Pellino 1 deletion affects osteoclast differentiation, leading to decreased bone mass and heightened osteoclast activity. Thus, targeting Pellino 1 could be a potential gene therapy for managing and preventing osteoporosis.
C1 [Yoon, Dong Suk] Hwasung Med Sci Univ, Dept Biomed Sci, Hwasung 18274, Gyeonggi Do, South Korea.
   [Yoon, Dong Suk] Hwasung Med Sci Univ, Inst HSMU Med Sci, Stem Cell & Aging Lab, Hwaseong 18274, Gyeonggi Do, South Korea.
   [Oh, Seung Eun; Lee, Kyoung Mi; Jung, Sujin; Ko, Eun Ae; Park, Kwang Hwan; Lee, Jin Woo] Yonsei Univ, Coll Med, Dept Orthopaed Surg, Seoul 03722, South Korea.
   [Oh, Seung Eun; Lee, Kyoung Mi; Jung, Sujin; Lee, Jin Woo] Yonsei Univ Coll Med, Grad Sch Med Sci, Dept Orthopaed Surg, Brain Korea Project 21, Seoul 03722, South Korea.
   [Kim, Tae Gyun] Yonsei Univ, Coll Med, Inst Immunol & Immunol Dis, Seoul 03722, South Korea.
   [Kim, Tae Gyun] Yonsei Univ, Severance Hosp, Coll Med, Cutaneous Biol Res Inst,Dept Dermatol, Seoul 03722, South Korea.
C3 Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System; Yonsei University; Yonsei University
   Health System; Yonsei University; Yonsei University Health System
RP Park, KH; Lee, JW (通讯作者)，Yonsei Univ, Coll Med, Dept Orthopaed Surg, Seoul 03722, South Korea.; Lee, JW (通讯作者)，Yonsei Univ Coll Med, Grad Sch Med Sci, Dept Orthopaed Surg, Brain Korea Project 21, Seoul 03722, South Korea.
EM khpark@yuhs.ac; ljwos@yuhs.ac
RI ; LEE, JIN/Q 3108 2018; Kim, TaeHeon/KIC 2380 2024; Yoon,
   Dong/K 1077 2019
OI Kim, Tae Gyun/0000 0002 2116 4579; Lee, Jin Woo/0000 0002 0293 9017;
   Park, Kwang Hwan/0000 0002 2110 0559; 
FU National Research Foundation of Korea [NRF 2021R1A2C2006556,
   NRF 2021R1C1C2093717]; National Research Foundation of Korea (NRF)  
   Korean Government (MSIT) [6 2022 0167]; Yonsei University College of
   Medicine
FX The authors would like to thank Dr. Takashi Nakamura (University of
   Tokyo) for providing the Ctsk Cre mouse and for allowing the authors to
   use it in this project. This work was supported by the National Research
   Foundation of Korea (NRF) grant funded by the Korean Government (MSIT)
   (No. NRF 2020R1I1A1A01054892 to K. M.L., NRF 2021R1A2C2006556 to J.W.L.,
   and NRF 2021R1C1C2093717 to D.S.Y.) and by a faculty research grant from
   the Yonsei University College of Medicine (6 2022 0167).
CR Almeida M, 2013, J GERONTOL A BIOL, V68, P1197, DOI 10.1093/gerona/glt079
   Arias CF, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204171
   Chung PL, 2014, J CELL BIOCHEM, V115, P1412, DOI 10.1002/jcb.24792
   Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551
   Hughes BM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01721
   Jiang ZF, 2003, J BIOL CHEM, V278, P10952, DOI 10.1074/jbc.M212112200
   Kim JH, 2011, MOL CELLS, V31, P85, DOI 10.1007/s10059 011 0006 x
   Kim S, 2020, EXP MOL MED, V52, P1537, DOI 10.1038/s12276 020 00489 4
   Li HX, 2021, CURR MED CHEM, V28, P1489, DOI 10.2174/0929867327666200330142432
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Moynagh PN, 2014, NAT REV IMMUNOL, V14, P122, DOI 10.1038/nri3599
   Moynagh PN, 2009, TRENDS IMMUNOL, V30, P33, DOI 10.1016/j.it.2008.10.001
   Nakajima A, 2009, J BONE MINER RES, V24, P1162, DOI [10.1359/jbmr.090205, 10.1359/JBMR.090205]
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Shen JL, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.706395
   Shu B, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0104 5
   Wang G, 2021, DIABET METAB SYND OB, V14, P671, DOI 10.2147/DMSO.S288338
   Weivoda MM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14003 6
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
NR 20
TC 2
Z9 2
U1 0
U2 3
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 2701 0198
J9 ADV BIOL GER
JI Adv. Biol.
PD JUL
PY 2024
VL 8
IS 7
DI 10.1002/adbi.202400210
EA MAY 2024
PG 6
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA ZC6E7
UT WOS:001214895300001
PM 38712476
OA hybrid
DA 2025 08 17
ER

PT J
AU Dieudonné, FX
   Marion, A
   Hay, E
   Marie, PJ
   Modrowski, D
AF Dieudonne, Francois Xavier
   Marion, Allison
   Hay, Eric
   Marie, Pierre Jacques
   Modrowski, Dominique
TI High Wnt Signaling Represses the Proapoptotic Proteoglycan
   syndecan 2 in Osteosarcoma Cells
SO CANCER RESEARCH
LA English
DT Article
ID INCREASED BONE FORMATION; HIGH GRADE OSTEOSARCOMA; DRUG REGULATED GENES;
   BETA CATENIN; INDUCED APOPTOSIS; CHEMOTHERAPY; OSTEOBLASTS; PATHWAY;
   PROTEIN; IDENTIFICATION
AB Osteosarcoma is characterized by frequent relapse and metastatic disease associated with resistance to chemotherapy. We previously showed that syndecan 2 is a mediator of the antioncogenic effect of chemotherapeutic drugs. The purpose of this work was to elucidate molecular mechanisms responsible for the low expression of syndecan 2 in osteosarcoma. We compared the regulatory activity of cis acting DNA sequences of the syndecan 2 gene in osteosarcoma and osteoblastic cell lines. We identified a DNA region that negatively regulates syndecan 2 transcription in the osteosarcoma cells. T cell factors (TCF) bind to this sequence in vivo. Wnt3a stimulation, beta catenin activation, and TCF overexpression resulted in syndecan 2 repression, whereas Wnt inhibition using sFRP 1 increased syndecan 2 expression in U2OS cells. RhoA activation blunted the stimulatory effect of sFRP 1 on syndecan 2 transcription, whereas RhoA inhibition enhanced syndecan 2 expression. These results indicate that Wnt/beta catenin and Wnt/RhoA signaling contribute to syndecan 2 repression. The alteration of syndecan 2 expression in osteosarcoma cell lines also seemed to be related to a higher shedding, controlled by Wnt/RhoA. Conversely, syndecan 2 was found to activate its own expression in U2OS cells through RhoA inhibition. These data identify a molecular network that may contribute to the low expression of the proapoptotic proteoglycan syndecan 2 in osteosarcoma cells. The high activity of the canonical Wnt pathway in the different osteosarcoma cells induces a constitutive repression of syndecan 2 transcription, whereas Wnt/RhoA signaling blocks the amplification loop of syndecan 2 expression. Our results identify syndecan 2 as a Wnt target and bring new insights into a possible pathologic role of Wnt signaling in osteosarcoma. Cancer Res; 70(13); 5399 408. (C) 2010 AACR.
C1 [Modrowski, Dominique] Hop Lariboisiere, INSERM, U606, Lab Osteoblast Biol & Pathol,UMR 606, F 75475 Paris 10, France.
   Univ Paris Diderot, Paris, France.
C3 Universite Paris Cite; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Lariboisiere Fernand Widal   APHP; Universite Paris Cite
RP Modrowski, D (通讯作者)，Hop Lariboisiere, INSERM, U606, Lab Osteoblast Biol & Pathol,UMR 606, 2 Rue Ambroise Pare, F 75475 Paris 10, France.
EM dominique.modrowski@inserm.fr
RI Modrowski, Dominique/N 6578 2018; Haÿ, Eric/HNS 9912 2023
OI Modrowski, Dominique/0000 0003 1103 7127; Hay, Eric/0000 0002 0131 9983;
   
FU European Calcified Tissue Society; Association pour la Recherche contre
   le Cancer; Ligue Nationale Contre le Cancer
FX F X. Dieudonne was supported by a Ph.D. studentship from the European
   Calcified Tissue Society. This work was supported by grants from
   Association pour la Recherche contre le Cancer and the Ligue Nationale
   Contre le Cancer.
CR Alexander CM, 2000, NAT GENET, V25, P329, DOI 10.1038/77108
   Alexopoulou AN, 2007, INT J BIOCHEM CELL B, V39, P505, DOI 10.1016/j.biocel.2006.10.014
   Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Cai YP, 2010, J PATHOL, V220, P24, DOI 10.1002/path.2628
   Chou AJ, 2006, EXPERT REV ANTICANC, V6, P1075, DOI 10.1586/14737140.6.7.1075
   DePollack C, 1996, J BONE MINER RES, V11, P401
   Enomoto M, 2009, ONCOGENE, V28, P3197, DOI 10.1038/onc.2009.175
   Entz Werle N, 2007, NEOPLASIA, V9, P678, DOI 10.1593/neo.07367
   Essner JJ, 2006, INT J BIOCHEM CELL B, V38, P152, DOI 10.1016/j.biocel.2005.08.012
   Fears CY, 2006, J BIOL CHEM, V281, P14533, DOI 10.1074/jbc.C600075200
   Fellenberg J, 2003, INT J CANCER, V105, P636, DOI 10.1002/ijc.11135
   Fellenberg J, 2007, MODERN PATHOL, V20, P1085, DOI 10.1038/modpathol.3800937
   Fromigué O, 2006, CELL DEATH DIFFER, V13, P1845, DOI 10.1038/sj.cdd.4401873
   Fromigué O, 2001, J BONE MINER RES, V16, P1600, DOI 10.1359/jbmr.2001.16.9.1600
   Fromigué O, 2008, J BIOL CHEM, V283, P30549, DOI 10.1074/jbc.M801436200
   Guo Y, 2008, CLIN ORTHOP RELAT R, V466, P2039, DOI 10.1007/s11999 008 0344 y
   Guo Y, 2007, J ORTHOP RES, V25, P964, DOI 10.1002/jor.20356
   Haydon RC, 2002, INT J CANCER, V102, P338, DOI 10.1002/ijc.10719
   Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008 5472.CAN 03 1952
   Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175
   Khyrul WAKM, 2004, J BIOL CHEM, V279, P54131, DOI 10.1074/jbc.M410051200
   LEOW PC, 2010, INVEST NEW IN PRESS
   Marina N, 2004, ONCOLOGIST, V9, P422, DOI 10.1634/theoncologist.9 4 422
   Matushansky I, 2007, J CLIN INVEST, V117, P3248, DOI 10.1172/JCI31377
   Modrowski D, 2005, BONE, V37, P180, DOI 10.1016/j.bone.2005.04.010
   Morioka K, 2009, CANCER SCI, V100, P1227, DOI 10.1111/j.1349 7006.2009.01165.x
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Munesue S, 2007, J BIOL CHEM, V282, P28164, DOI 10.1074/jbc.M609812200
   Muñoz R, 2006, NAT CELL BIOL, V8, P492, DOI 10.1038/ncb1399
   Obama H, 1997, J BIOL CHEM, V272, P11017
   Orosco A, 2007, CANCER RES, V67, P3708, DOI 10.1158/0008 5472.CAN 06 4164
   Orosco A, 2006, J CELL BIOCHEM, V98, P838, DOI 10.1002/jcb.20826
   Shibamoto S, 1998, GENES CELLS, V3, P659
   TABONE MD, 1994, J CLIN ONCOL, V12, P2614, DOI 10.1200/JCO.1994.12.12.2614
   Villena J, 2006, APOPTOSIS, V11, P2065, DOI 10.1007/s10495 006 0193 7
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Yousfi M, 2001, J CLIN INVEST, V107, P1153, DOI 10.1172/JCI11846
NR 38
TC 42
Z9 51
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 0008 5472
EI 1538 7445
J9 CANCER RES
JI Cancer Res.
PD JUL 1
PY 2010
VL 70
IS 13
BP 5399
EP 5408
DI 10.1158/0008 5472.CAN 10 0090
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 618ZY
UT WOS:000279396800022
PM 20530678
OA Bronze
DA 2025 08 17
ER

PT J
AU Cenni, E
   Avnet, S
   Granchi, D
   Fotia, C
   Salerno, M
   Micieli, D
   Sarpietro, MG
   Pignatello, R
   Castelli, F
   Baldini, N
AF Cenni, Elisabetta
   Avnet, Sofia
   Granchi, Donatella
   Fotia, Caterina
   Salerno, Manuela
   Micieli, Dorotea
   Sarpietro, Maria Grazia
   Pignatello, Rosario
   Castelli, Francesco
   Baldini, Nicola
TI The Effect of Poly(D,L Lactide co Glycolide) Alendronate
   Conjugate Nanoparticles on Human Osteoclast Precursors
SO JOURNAL OF BIOMATERIALS SCIENCE POLYMER EDITION
LA English
DT Article
DE Nanoparticle; bisphosphonate; poly(D,L lactide co glycolide); bone
   targeting; osteoclast
ID LOADED NANOPARTICLES; BONE RESORPTION; DRUG DELIVERY; IN VITRO;
   BISPHOSPHONATE; ALENDRONATE; APOPTOSIS; CELLS; DIFFERENTIATION;
   MACROPHAGES
AB Nanoparticles (NPs) formed from polymers conjugated with bisphosphonates (BPs) allow the bone targeting of loaded drugs, such as doxorubicin, for the treatment of skeletal tumours. The additional antiosteoclastic effect of the conjugated BP could contribute to the inhibition of tumour associated bone degradation. With this aim, we have produced NPs made of poly(D,L lactide co glycolide) (PLGA) conjugated with alendronate (ALE). To show if ALE retained the antiosteoclastic properties after the conjugation with PLGA and the production of NPs, we treated human osteoclasts, derived from circulating precursors, with PLGA ALE NPs and compared the effects on actin ring generation, apoptosis and type I collagen degradation with those of free ALE and with NPs made of pure PLGA. PLGA ALE NPs disrupted actin ring, induced apoptosis and inhibited collagen degradation. Unexpectedly, also NPs made of pure PLGA showed similar effects. Therefore, we cannot exclude that in addition to the observed antiosteoclastic activity dependent on ALE in PLGA ALE NPs, there was also an effect due to pure PLGA. Still, as PLGA ALE NPs are intended for the loading with drugs for the treatment of osteolytic bone metastases, the additional antiosteoclastic effect of PLGA ALE NPs, and even of PLGA, may contribute to the inhibition of the disease associated bone degradation. (C) Koninklijke Brill NV, Leiden, 2011
C1 [Cenni, Elisabetta; Avnet, Sofia; Granchi, Donatella; Fotia, Caterina; Salerno, Manuela; Baldini, Nicola] Ist Ortoped Rizzoli, Lab Fisiopatol Ortoped & Med Rigenerat, I 40136 Bologna, Italy.
   [Micieli, Dorotea; Sarpietro, Maria Grazia; Castelli, Francesco] Univ Catania, Dipartimento Sci Chim, I 95125 Catania, Italy.
   [Pignatello, Rosario] Univ Catania, Dipartimento Sci Farmaco, I 95125 Catania, Italy.
   [Baldini, Nicola] Univ Bologna, Dipartimento Sci Anat Umane & Fisiopatol Apparat, I 40126 Bologna, Italy.
C3 IRCCS Istituto Ortopedico Rizzoli; University of Catania; University of
   Catania; University of Bologna
RP Salerno, M (通讯作者)，Ist Ortoped Rizzoli, Lab Fisiopatol Ortoped & Med Rigenerat, Via Barbiano 1 10, I 40136 Bologna, Italy.
EM manuela.salerno@ior.it
RI Granchi, Donatella/J 3647 2016; Castelli, Fabio/M 1177 2013; Pignatello,
   Rosario/G 3176 2010; Baldini, Nicola/J 4806 2016; pignatello,
   rosario/G 3176 2010; Avnet, Sofia/B 3220 2018
OI Granchi, Donatella/0000 0001 7225 0023; CASTELLI,
   Francesco/0000 0002 1982 8065; Pignatello, Rosario/0000 0002 5937 4192;
   Baldini, Nicola/0000 0003 2228 3833; Avnet, Sofia/0000 0002 7843 0591
FU Italian Association for Cancer Research (AIRC); Italian Ministry of
   Education, University and Research; Istituto Ortopedico Rizzoli,
   'Ricerca corrente'
FX This work was supported by grants from the Italian Association for
   Cancer Research (AIRC), from the Italian Ministry of Education,
   University and Research, and from the Istituto Ortopedico Rizzoli,
   'Ricerca corrente'. The authors thank Ms Lucy Scioscia for her help in
   editing the English.
CR Albini A, 2010, JNCI J NATL CANCER I, V102, P14, DOI 10.1093/jnci/djp440
   Bala I, 2004, CRIT REV THER DRUG, V21, P387, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.i5.20
   Blanco Prieto MJ, 2004, J CONTROL RELEASE, V96, P437, DOI 10.1016/j.jconrel.2004.02.015
   Cenni E, 2008, BIOMATERIALS, V29, P1400, DOI 10.1016/j.biomaterials.2007.12.022
   Chellaiah MA, 2000, J BIOL CHEM, V275, P11993, DOI 10.1074/jbc.275.16.11993
   Choi SW, 2007, J CONTROL RELEASE, V122, P24, DOI 10.1016/j.jconrel.2007.06.003
   Clark JCM, 2008, EXPERT OPIN EMERG DR, V13, P609, DOI 10.1517/14728210802584217 
   Cohen Sela E, 2006, J CONTROL RELEASE, V113, P23, DOI 10.1016/j.jconrel.2006.03.010
   Coleman RE, 2010, CANCER TREAT REV, V36, P615, DOI 10.1016/j.ctrv.2010.04.003
   Danenberg HD, 2003, J CARDIOVASC PHARM, V42, P671, DOI 10.1097/00005344 200311000 00014
   Dempster DW, 2005, J CELL BIOCHEM, V95, P139, DOI 10.1002/jcb.20388
   Doschak MR, 2009, MOL PHARMACEUT, V6, P634, DOI 10.1021/mp8002368
   Fang C, 2006, EUR J PHARM SCI, V27, P27, DOI 10.1016/j.ejps.2005.08.002
   Granchi D, 2005, BIOMATERIALS, V26, P2371, DOI 10.1016/j.biomaterials.2004.07.045
   Gryparis EC, 2007, EUR J PHARM BIOPHARM, V67, P1, DOI 10.1016/j.ejpb.2006.12.017
   Halasy Nagy JM, 2001, BONE, V29, P553, DOI 10.1016/S8756 3282(01)00615 9
   Holmes S, 2008, BIOCHEM BIOPH RES CO, V365, P840, DOI 10.1016/j.bbrc.2007.11.054
   Houghton TJ, 2008, J MED CHEM, V51, P6955, DOI 10.1021/jm801007z
   Iino G, 2008, INT J ORAL MAX IMPL, V23, P835
   Ito M, 1999, BONE, V25, P447, DOI 10.1016/S8756 3282(99)00197 0
   Jain KK, 2010, BMC MED, V8, DOI 10.1186/1741 7015 8 83
   James DE, 2010, J IMMUNOL, V185, P1265, DOI 10.4049/jimmunol.0902808
   Knowles HJ, 2009, J PATHOL, V218, P256, DOI 10.1002/path.2534
   Lakkakorpi PT, 1996, MICROSC RES TECHNIQ, V33, P171, DOI 10.1002/(SICI)1097 0029(19960201)33:2<171::AID JEMT7>3.0.CO;2 W
   Lee JW, 2010, BIOL PHARM BULL, V33, P1733, DOI 10.1248/bpb.33.1733
   Liu XM, 2008, BIOMATERIALS, V29, P1686, DOI 10.1016/j.biomaterials.2007.12.023
   Loi M, 2010, J CONTROL RELEASE, V145, P66, DOI 10.1016/j.jconrel.2010.03.015
   Martin MB, 1999, BIOCHEM BIOPH RES CO, V263, P754, DOI 10.1006/bbrc.1999.1404
   Ogawa K, 2006, J NUCL MED, V47, P2042
   Oursler MJ, 2010, J CELL BIOCHEM, V110, P1058, DOI 10.1002/jcb.22640
   Pignatello R, 2009, NANOMEDICINE UK, V4, P161, DOI 10.2217/17435889.4.2.161
   Rai S, 2011, J BIOMED NANOTECHNOL, V7, P121, DOI 10.1166/jbn.2011.1231
   Ruoslahti E, 2010, J CELL BIOL, V188, P759, DOI 10.1083/jcb.200910104
   Salerno M, 2010, CURR CANCER DRUG TAR, V10, P649, DOI 10.2174/156800910793605767
   Sharma G, 2010, J CONTROL RELEASE, V147, P408, DOI 10.1016/j.jconrel.2010.07.116
   Shi C, 2008, BLOOD, V112, P4699, DOI 10.1182/blood 2008 01 137018
   Shi XT, 2009, BIOMATERIALS, V30, P3996, DOI 10.1016/j.biomaterials.2009.04.021
   Shi XT, 2009, PHARM RES DORDR, V26, P422, DOI 10.1007/s11095 008 9759 0
   Su K, 2011, EXPERT OPIN DRUG DEL, V8, P113, DOI 10.1517/17425247.2011.541438
   Sun J, 2009, J BIOMED MATER RES A, V88A, P673, DOI 10.1002/jbm.a.31892
   Sutherland KA, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2681
   Suzuki K, 2006, J PHARMACOL SCI, V100, P189, DOI 10.1254/jphs.FMJ05004X2
   Väänänen HK, 2008, ARCH BIOCHEM BIOPHYS, V473, P132, DOI 10.1016/j.abb.2008.03.037
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Wang GL, 2010, J DRUG TARGET, V18, P611, DOI 10.3109/10611861003622560
   Watari F, 2009, J R SOC INTERFACE, V6, pS371, DOI 10.1098/rsif.2008.0488.focus
   Zhang Q, 2005, ARTHRITIS RHEUM US, V52, P2708, DOI 10.1002/art.21236
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
NR 48
TC 19
Z9 20
U1 0
U2 32
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0920 5063
EI 1568 5624
J9 J BIOMAT SCI POLYM E
JI J. Biomater. Sci. Polym. Ed.
PY 2012
VL 23
IS 10
BP 1285
EP 1300
DI 10.1163/092050611X580373
PG 16
WC Engineering, Biomedical; Materials Science, Biomaterials; Polymer
   Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science; Polymer Science
GA 987VL
UT WOS:000307445800003
PM 21781381
DA 2025 08 17
ER

PT J
AU Landgraf, M
   Lahr, CA
   Sanchez Herrero, A
   Meinert, C
   Shokoohmand, A
   Pollock, PM
   Hutmacher, DW
   Shafiee, A
   McGovern, JA
AF Landgraf, Marietta
   Lahr, Christoph A.
   Sanchez Herrero, Alvaro
   Meinert, Christoph
   Shokoohmand, Ali
   Pollock, Pamela M.
   Hutmacher, Dietmar W.
   Shafiee, Abbas
   McGovern, Jacqui A.
TI Humanized bone facilitates prostate cancer metastasis and recapitulates
   therapeutic effects of zoledronic acid in vivo
SO BONE RESEARCH
LA English
DT Article
ID BREAST CANCER; MOUSE MODEL; DENOSUMAB; CELLS; TUMOR; MICE;
   MICROENVIRONMENT; BISPHOSPHONATES; MECHANISMS; PREVENTION
AB Advanced prostate cancer (PCa) is known for its high prevalence to metastasize to bone, at which point it is considered incurable. Despite significant effort, there is no animal model capable of recapitulating the complexity of PCa bone metastasis. The humanized mouse model for PCa bone metastasis used in this study aims to provide a platform for the assessment of new drugs by recapitulating the human human cell interactions relevant for disease development and progression. The humanized tissue engineered bone construct (hTEBC) was created within NOD scid IL2rg(null) (NSG) mice and was used for the study of experimental PC3 Luc bone metastases. It was confirmed that PC3 Luc cells preferentially grew in the hTEBC compared with murine bone. The translational potential of the humanized mouse model for PCa bone metastasis was evaluated with two clinically approved osteoprotective therapies, the non species specific bisphosphonate zoledronic acid (ZA) or the human specific antibody Denosumab, both targeting Receptor Activator of Nuclear Factor Kappa B Ligand. ZA, but not Denosumab, significantly decreased metastases in hTEBCs, but not murine femora. These results highlight the importance of humanized models for the preclinical research on PCa bone metastasis and indicate the potential of the bioengineered mouse model to closely mimic the metastatic cascade of PCa cells to human bone. Eventually, it will enable the development of new effective antimetastatic treatments.
C1 [Landgraf, Marietta; Lahr, Christoph A.; Sanchez Herrero, Alvaro; Meinert, Christoph; Shokoohmand, Ali; Hutmacher, Dietmar W.; Shafiee, Abbas; McGovern, Jacqui A.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Ctr Regenerat Med, Brisbane, Qld, Australia.
   [Pollock, Pamela M.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Translat Res Inst, Sch Biomed Sci, Brisbane, Qld, Australia.
   [Hutmacher, Dietmar W.] Queensland Univ Technol, ARC, Training Ctr Addit Biomfg, Brisbane, Qld, Australia.
   [Shafiee, Abbas] Univ Queensland, UQ Diamantina Inst, Translat Res Inst, Brisbane, Qld, Australia.
C3 Queensland University of Technology (QUT); University of Queensland;
   Queensland University of Technology (QUT); Queensland University of
   Technology (QUT); University of Queensland
RP Shafiee, A; McGovern, JA (通讯作者)，Queensland Univ Technol, Inst Hlth & Biomed Innovat, Ctr Regenerat Med, Brisbane, Qld, Australia.; Shafiee, A (通讯作者)，Univ Queensland, UQ Diamantina Inst, Translat Res Inst, Brisbane, Qld, Australia.
EM a.shafiee@uq.edu.au; jacqui.mcgovern@qut.edu.au
RI ; Hutmacher, Dietmar/AEO 9578 2022; Shafiee, Abbas/H 9230 2019; shafiee,
   Abbas/H 9230 2019
OI Hutmacher, Dietmar Werner/0000 0001 5678 2134; Shokoohmand,
   Ali/0009 0005 9182 2054; Shafiee, Abbas/0000 0002 8885 9025; Landgraf,
   Marietta/0000 0003 3443 4256; McGovern, Jacqui/0000 0002 4993 6745;
   Pollock, Pamela/0000 0001 8420 1026
FU Institute of Health and Biomedical Innovation Histology Facility;
   Australian Government; Cell Analysis Facility at QUT
FX The authors would like to thank the Australian Research Council (ARC)
   Training Centre in Additive Biomanufacturing for providing the
   scaffolds. We thank Dr Thomas Kryza and A/Prof Sally Ann Stephenson for
   their assistance with hOB cell culture. We would also like to
   acknowledge the contribution and support of the team from the Institute
   of Health and Biomedical Innovation Histology Facility, as well as the
   Cell Analysis Facility at QUT. The authors also thank the TRI for
   providing an excellent research environment and core facilities that
   enabled this research. We particularly thank the staff from the
   Biological Resources, the Microscopy, and the Preclinical Imaging Core
   Facility. TRI is supported by a grant from the Australian Government.
CR Aguado BA, 2017, NAT BIOMED ENG, V1, DOI 10.1038/s41551 017 0077
   [Anonymous], 2007, PUBLISHING HOUSE ROM
   [Anonymous], NAT REV CLIN ONCOL
   Barcellos Hoff MH, 2013, NAT REV CANCER, V13, P511, DOI 10.1038/nrc3536
   Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096
   Bray F, 2018, CA CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Brown TD, 2012, BIOINTERPHASES, V7, DOI 10.1007/s13758 011 0013 7
   Chen QF, 2009, P NATL ACAD SCI USA, V106, P21783, DOI 10.1073/pnas.0912274106
   Chirgwin JM, 2007, J CELL BIOCHEM, V102, P1333, DOI 10.1002/jcb.21556
   Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541 7786.MCR 08 0077
   Cleeland CS, 2013, CANCER AM CANCER SOC, V119, P832, DOI 10.1002/cncr.27789
   Deng XY, 2014, CANCER TREAT REV, V40, P730, DOI 10.1016/j.ctrv.2014.04.003
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   FLANAGAN AM, 1991, CALCIFIED TISSUE INT, V49, P407, DOI 10.1007/BF02555852
   Ganguly SS, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00364
   Green J, 2010, CANCER INVEST, V28, P944, DOI 10.3109/07357907.2010.512598
   Green JR, 2004, EUR UROL SUPPL, V3, P16, DOI 10.1016/j.eursup.2004.08.008
   Hanley DA, 2012, INT J CLIN PRACT, V66, P1139, DOI 10.1111/ijcp.12022
   Havens A, 2008, NEOPLASIA, V10, P371, DOI 10.1593/neo.08154
   Hayman AR, 2008, AUTOIMMUNITY, V41, P218, DOI 10.1080/08916930701694667
   Hegemann M, 2017, THER ADV UROL, V9, P81, DOI 10.1177/1756287216686018
   Hesami P, 2014, CLIN EXP METASTAS, V31, P435, DOI 10.1007/s10585 014 9638 5
   Holzapfel BM, 2014, BIOMATERIALS, V35, P4108, DOI 10.1016/j.biomaterials.2014.01.062
   Holzapfel BM, 2013, CANCER METAST REV, V32, P129, DOI 10.1007/s10555 013 9437 5
   Horas K, 2019, J BONE MINER RES, V34, P1721, DOI 10.1002/jbmr.3744
   Ibrahim A, 2003, CLIN CANCER RES, V9, P2394
   Jo Y, 2018, THERANOSTICS, V8, P5259, DOI 10.7150/thno.29098
   Joyce MH, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00337
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Landgraf M, 2018, TRENDS BIOTECHNOL, V36, P242, DOI 10.1016/j.tibtech.2017.12.001
   Little DG, 2009, J BONE MINER RES, V24, P179, DOI 10.1359/JBMR.081221
   Loessner D, 2016, NAT PROTOC, V11, P727, DOI 10.1038/nprot.2016.037
   Martine LC, 2017, NAT PROTOC, V12, P639, DOI 10.1038/nprot.2017.002
   McGovern JA, 2018, CANCERS, V10, DOI 10.3390/cancers10110438
   Miller KD, 2016, CA CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Norman G.R., 2003, PDQ STAT PDQ SERIES, V3rd
   O'Neill K, 2010, J PATHOL, V220, P317, DOI 10.1002/path.2656
   Oades GM, 2002, PROSTATE CANCER P D, V5, P264, DOI 10.1038/sj.pcan.4500607
   Ortiz A, 2012, RECENT RESULTS CANC, V192, P225, DOI 10.1007/978 3 642 21892 7_11
   Paget S., LANCET, V1, P571, DOI DOI 10.1016/S0140 6736(00)49915 0
   Paindelli C, 2019, BIOMATERIALS, V197, P296, DOI 10.1016/j.biomaterials.2019.01.027
   Qiao H, 2017, ACS NANO, V11, P7259, DOI 10.1021/acsnano.7b03197
   Reichert JC, 2010, BIOMATERIALS, V31, P7928, DOI 10.1016/j.biomaterials.2010.06.055
   Reinisch A, 2017, NAT PROTOC, V12, P2169, DOI 10.1038/nprot.2017.088
   Rizzoli R, 2010, THER ADV MUSCULOSKEL, V2, P3, DOI 10.1177/1759720X09352920
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Scher HI, 2003, CANCER AM CANCER SOC, V97, P758, DOI 10.1002/cncr.11151
   Shafiee A, 2018, INT J CANCER, V143, P1470, DOI 10.1002/ijc.31528
   Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414
   Simmons J. K., 2014, Veterinary Sciences, V1, P16
   Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25
   Sturge J, 2011, NAT REV CLIN ONCOL, V8, P357, DOI 10.1038/nrclinonc.2011.67
   Tannehill Gregg SH, 2006, CLIN EXP METASTAS, V23, P19, DOI 10.1007/s10585 006 9008 z
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   Thakur SS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0188983
   Thibaudeau L, 2015, CELL CYCLE, V14, P2191, DOI 10.1080/15384101.2015.1062327
   Thibaudeau L, 2014, CANCER METAST REV, V33, P721, DOI 10.1007/s10555 014 9499 z
   Thudi NK, 2008, PROSTATE, V68, P1116, DOI 10.1002/pros.20776
   TUKEY JW, 1977, EXPLORATORY DATA ANA
   Turner CJ, 2016, CURR OSTEOPOROS REP, V14, P170, DOI 10.1007/s11914 016 0323 2
   Vaquette C, 2013, BIOMATERIALS, V34, P5538, DOI 10.1016/j.biomaterials.2013.03.088
   Wagner F, 2016, J BONE JOINT SURG AM, V98, P916, DOI 10.2106/JBJS.15.00920
   Zekri J, 2014, J BONE ONCOL, V3, P25, DOI 10.1016/j.jbo.2013.12.001
NR 64
TC 20
Z9 21
U1 1
U2 10
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2095 4700
EI 2095 6231
J9 BONE RES
JI Bone Res.
PD OCT 21
PY 2019
VL 7
AR 31
DI 10.1038/s41413 019 0072 9
PG 11
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA JF6IY
UT WOS:000491492700001
PM 31646018
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Duque, G
   Troen, BR
AF Duque, Gustavo
   Troen, Bruce R.
TI Understanding the mechanisms of senile osteoporosis: New facts for a
   major geriatric syndrome
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE osteoporosis; osteoblast; osteoclast; bone formation and resorption;
   adipogenesis
ID BONE MINERAL DENSITY; ESTROGEN RECEPTOR MODULATORS; VITAMIN D;
   POSTMENOPAUSAL WOMEN; SECONDARY HYPERPARATHYROIDISM; STRONTIUM RANELATE;
   ZOLEDRONIC ACID; ELDERLY WOMEN; DRUG INSIGHT; FRACTURES
AB Knowledge of the underlying mechanisms of osteoporosis in older adults has significantly advanced in recent years. There is an acute loss of bone mineral density in the peri menopausal period, followed by a more gradual and progressive decline, which is also seen in men. Markedly increased bone resorption leads to the initial fall in bone mineral density. With increasing age, there is also a significant reduction in bone formation. This is mostly due to a shift from osteoblastogenesis to predominant adipogenesis in the bone marrow. This study reviews new evidence on the pathophysiology of senile osteoporosis, with emphasis upon the mechanism of action of current osteoporosis treatments. New potential treatments are also considered, including therapeutic approaches to osteoporosis in elderly people that focus on the pathophysiology and potential reversal of the adipogenic shift in bone.
C1 [Duque, Gustavo] Univ Sydney, Nepean Clin Sch, Aging Bone Res Program, Penrith, NSW, Australia.
   [Troen, Bruce R.] Miami Vet Affairs Med Ctr, Res Serv, Ctr Geriatr Res Educ & Clin, Miami, FL USA.
   [Troen, Bruce R.] Univ Miami, Miller Sch Med, Geriatr Inst, Dept Med,Div Gerontol & Geriatr Med, Miami, FL 33152 USA.
C3 University of Sydney; Geriatric Research Education & Clinical Center;
   University of Miami
RP Troen, BR (通讯作者)，Miami VAMC, 11 GRC,1201 NW 16th St, Miami, FL 33125 USA.
EM troen@miami.edu
RI Troen, Bruce/ABB 4959 2021; Duque, Gustavo/G 6656 2015; Duque,
   Gustavo/HDO 1243 2022
OI Duque, Gustavo/0000 0001 8126 0637; Troen, Bruce/0000 0002 3699 0021
CR Adler Robert A, 2006, Curr Osteoporos Rep, V4, P110, DOI 10.1007/BF02686955
   Bäckesjö CM, 2006, J BONE MINER RES, V21, P993, DOI 10.1359/JBMR.060415
   Behre HM, 1997, J CLIN ENDOCR METAB, V82, P2386, DOI 10.1210/jc.82.8.2386
   Bergo MO, 2002, P NATL ACAD SCI USA, V99, P13049, DOI 10.1073/pnas.192460799
   Bischoff Ferrari HA, 2005, JAMA J AM MED ASSOC, V293, P2257, DOI 10.1001/jama.293.18.2257
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   BOONEN S, 2007, OSTEOPOROSIS OLDER P
   Boonen S, 2006, J AM GERIATR SOC, V54, P782, DOI 10.1111/j.1532 5415.2006.00695.x
   BOTOLIN S, 2007, BONEKEY OSTEOVISION, V4, P129
   Brown LB, 2005, OSTEOPOROSIS INT, V16, P1849, DOI 10.1007/s00198 005 1948 7
   Burger HG, 2006, AUST NZ J OBSTET GYN, V46, P84, DOI 10.1111/j.1479 828X.2006.00533.x
   Chan GK, 2002, GERONTOLOGY, V48, P62, DOI 10.1159/000048929
   Chapurlat RD, 2006, NAT CLIN PRACT ENDOC, V2, P211, DOI 10.1038/ncpendmet0121
   Chen PQ, 2006, J BONE MINER RES, V21, P1785, DOI 10.1359/JBMR.060802
   Colón Emeric CS, 2006, BEST PRACT RES CL RH, V20, P695, DOI 10.1016/j.berh.2006.04.004
   David V, 2007, ENDOCRINOLOGY, V148, P2553, DOI 10.1210/en.2006 1704
   de Boer J, 2002, SCIENCE, V296, P1276, DOI 10.1126/science.1070174
   De Sandre Giovannoli A, 2003, SCIENCE, V300, P2055, DOI 10.1126/science.1084125
   Dempster DW, 2003, OSTEOPOROSIS INT, V14, pS54, DOI 10.1007/s00198 003 1474 4
   Docheva D, 2007, J CELL MOL MED, V11, P21, DOI 10.1111/j.1582 4934.2007.00001.x
   Duque G, 2006, MECH AGEING DEV, V127, P378, DOI 10.1016/j.mad.2005.12.007
   Duque G, 2005, AM J PHYSIOL ENDOC M, V288, pE723, DOI 10.1152/ajpendo.00180.2004
   Duque G, 2004, BIOGERONTOLOGY, V5, P421, DOI 10.1007/s10522 004 3192 5
   Duque G, 2004, BONE, V35, P57, DOI 10.1016/j.bone.2004.03.005
   Duque G, 2003, DRUG NEWS PERSPECT, V16, P341, DOI 10.1358/dnp.2003.16.6.829305
   Duque G, 2007, J BONE MINER RES, V22, P1603, DOI 10.1359/JBMR.070701
   Ellies DL, 2006, CELL, V125, P840, DOI 10.1016/j.cell.2006.05.022
   GARN SM, 1966, RELATIONS DEV AGING, P41
   Gimble JM, 2006, J CELL BIOCHEM, V98, P251, DOI 10.1002/jcb.20777
   GLOTH FM, 1999, AGING SKELETON
   Gusi N, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471 2474 7 92
   Hamann KL, 2006, RHEUM DIS CLIN N AM, V32, P703, DOI 10.1016/j.rdc.2006.07.005
   Hampton T, 2007, JAMA J AM MED ASSOC, V297, P1645, DOI 10.1001/jama.297.15.1645
   Hutchison CJ, 2004, NAT CELL BIOL, V6, P1062, DOI 10.1038/ncb1104 1062
   Karinkanta S, 2007, OSTEOPOROSIS INT, V18, P453, DOI 10.1007/s00198 006 0256 1
   Kim CH, 2003, J BONE MINER RES, V18, P2116, DOI 10.1359/jbmr.2003.18.12.2116
   Kira M, 2003, J DERMATOL, V30, P429, DOI 10.1111/j.1346 8138.2003.tb00412.x
   Leifke E, 1998, EUR J ENDOCRINOL, V138, P51, DOI 10.1530/eje.0.1380051
   Lin JT, 2006, CLIN GERIATR MED, V22, P435, DOI 10.1016/j.cger.2005.12.010
   Lips P, 2007, J STEROID BIOCHEM, V103, P620, DOI 10.1016/j.jsbmb.2006.12.076
   Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Mann V, 2007, BONE, V40, P674, DOI 10.1016/j.bone.2006.10.014
   Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385
   Manuele S, 2007, ARCH GERONTOL GERIAT, V44, P249, DOI 10.1016/j.archger.2007.01.034
   Marie PJ, 2007, BONE, V40, pS5, DOI 10.1016/j.bone.2007.02.003
   Maurin AC, 2000, BONE, V26, P485, DOI 10.1016/S8756 3282(00)00252 0
   McCauley LK, 2003, CONNECT TISSUE RES, V44, P250, DOI 10.1080/03008200390181744
   Michael H, 2007, BRIT J PHARMACOL, V151, P384, DOI 10.1038/sj.bjp.0707232
   Mitsui A, 2002, ANTIOXID REDOX SIGN, V4, P693, DOI 10.1089/15230860260220201
   Mulder JE, 2006, NAT CLIN PRACT ENDOC, V2, P670, DOI 10.1038/ncpendmet0325
   Mundy GR, 2006, CELL, V126, P441, DOI 10.1016/j.cell.2006.07.015
   Musacchio E, 2007, CONNECT TISSUE RES, V48, P34, DOI 10.1080/03008200601056528
   O'Donnell S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005326.pub2
   Pendás AM, 2002, NAT GENET, V31, P94, DOI 10.1038/ng871
   Perrien DS, 2007, AM J PHYSIOL REG I, V292, pR988, DOI 10.1152/ajpregu.00302.2006
   Prestwood KM, 2003, JAMA J AM MED ASSOC, V290, P1042, DOI 10.1001/jama.290.8.1042
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Raisz LG, 2003, ENDOCRIN METAB CLIN, V32, P15, DOI 10.1016/S0889 8529(02)00055 5
   Rauch F, 2007, BONE, V40, P274, DOI 10.1016/j.bone.2006.09.012
   Rickard DJ, 2006, BONE, V39, P1361, DOI 10.1016/j.bone.2006.06.010
   Rodrigues GHD, 2002, ANN GENET PARIS, V45, P151, DOI 10.1016/S0003 3995(02)01119 X
   Roodman GD, 2006, ANN NY ACAD SCI, V1068, P100, DOI 10.1196/annals.1346.013
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Rubin J, 2006, GENE, V367, P1, DOI 10.1016/j.gene.2005.10.028
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Schwartz AV, 2006, J CLIN ENDOCR METAB, V91, P3349, DOI 10.1210/jc.2005 2226
   Seeman E, 2006, J BONE MINER RES, V21, P1113, DOI 10.1359/JBMR.060404
   Selander KS, 1996, MOL CELL ENDOCRINOL, V122, P119, DOI 10.1016/0303 7207(96)03870 1
   Steidle Christopher P, 2003, Rev Urol, V5 Suppl 1, pS34
   Suda T, 2003, J CELL BIOCHEM, V88, P259, DOI 10.1002/jcb.10331
   Szulc P, 2005, J BONE MINER RES, V20, P721, DOI 10.1359/JBMR.041230
   Tenenhouse A, 2000, OSTEOPOROSIS INT, V11, P897, DOI 10.1007/s001980070050
   Troen BR, 2003, EXP GERONTOL, V38, P605, DOI 10.1016/S0531 5565(03)00069 X
   Troen BR, 2006, ANN NY ACAD SCI, V1068, P165, DOI 10.1196/annals.1346.018
   Tromp AM, 2006, CALCIFIED TISSUE INT, V79, P404, DOI 10.1007/s00223 006 0045 z
   Uusi Rasi K, 2003, BONE, V33, P132, DOI 10.1016/S8756 3282(03)00082 6
   Vanderschueren D, 2004, ENDOCR REV, V25, P389, DOI 10.1210/er.2003 0003
   Verschueren SMP, 2004, J BONE MINER RES, V19, P352, DOI 10.1359/JBMR.0301245
   Weinstein RS, 2000, AM J MED, V108, P153, DOI 10.1016/S0002 9343(99)00420 9
   Yeung RSM, 2004, J RHEUMATOL, V31, P844
   Yudoh K, 2004, GENE THER, V11, P909, DOI 10.1038/sj.gt.3302234
   Zaidi M, 2003, J BONE MINER RES, V18, P599, DOI 10.1359/jbmr.2003.18.4.599
   Zhang Y, 2007, AM J PHYSIOL ENDOC M, V292, pE723, DOI 10.1152/ajpendo.00445.2006
NR 84
TC 109
Z9 140
U1 0
U2 27
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0002 8614
EI 1532 5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2008
VL 56
IS 5
BP 935
EP 941
DI 10.1111/j.1532 5415.2008.01764.x
PG 7
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA 295PI
UT WOS:000255486000022
PM 18454751
DA 2025 08 17
ER

PT J
AU Takahashi, N
AF Takahashi, Naoyuki
TI Mechanism of inhibitory action of Eldecalcitol, an active vitamin D
   analog, on bone resorption in vivo
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article; Proceedings Paper
CT 15th Vitamin D Workshop
CY JUN 20 22, 2012
CL Houston, TX
DE Eldecalcitol; Osteoclasts; RANKL; Osteoclast precursors; Bone resorption
ID OSTEOCLAST PRECURSORS; OVARIECTOMIZED RATS; MINERAL DENSITY; TRABECULAR
   BONE; D 3 ED 71; DIFFERENTIATION; EXPRESSION;
   1 ALPHA,25 DIHYDROXYVITAMIN D3; ALFACALCIDOL; OSTEOPOROSIS
AB Bone resorbing osteoclasts differentiate from hematopoietic precursors under the strict regulation of bone forming osteoblasts. Osteoblasts express two cytokines essentially required for osteoclastogenesis; macrophage colony stimulating factor (M CSF) and receptor activator of nuclear factor kappa B ligand (RANKL). Osteoblasts express constitutively M CSF, and inducibly RANKL in response to bone resorption stimulating factors. The active form of vitamin D3, 1 alpha,25 dihydroxyvitamin D3 [1 alpha,25(OH)(2)D 3], is known to be a hormone which enhances RANKL expression in vitro. Nevertheless, Calcitoriol [1 alpha,25(OH)(2)D 3] and its prodrug, Alfacalcidol (1 alpha hydroxyvitamin D 3) have been taken as therapeutic drugs in osteoporotic patients in Japan. In addition, Eldecalcitol [2 beta (3 hydroxypropoxy) 1 alpha,25(OH)(2)D 3], a new analog of 1 alpha,25(OH)(2)D 3, was approved as a therapeutic agent for osteoporosis in Japan in 2011. Interestingly, those vitamin D compounds increased bone mineral density due to the suppression of bone resorption in vivo. We previously showed that cycle arrested quiescent osteoclast precursors (QOPs) were the direct osteoclasts precursors in vivo. We then investigated effects of daily administration of Eldecalcitol on bone resorption in mice. Bone mineral density was increased through the suppression of RANKL expression in osteoblasts in mice treated with Eldecalcito. The number of QOPs remained unchanged in bone. These results suggest that a long term exposure of osteoblasts to vitamin D compounds down regulate RANKL expression. This article is part of a Special Issue entitled '15th Vitamin D Workshop'. (C) 2012 Elsevier Ltd. All rights reserved.
C1 Matsumoto Dent Univ, Inst Oral Sci, Shiojiri, Nagano 3990781, Japan.
C3 Matsumoto Dental University
RP Takahashi, N (通讯作者)，Matsumoto Dent Univ, Inst Oral Sci, 1780 Hiro Oka Gobara, Shiojiri, Nagano 3990781, Japan.
EM takahashinao@po.mdu.ac.jp
FU Chugai Pharmaceutical Co., Ltd.
FX Some of the present studies were financially supported by Chugai
   Pharmaceutical Co., Ltd.
CR Arai A, 2012, J CELL SCI, V125, P2910, DOI 10.1242/jcs.099986
   BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376
   FUKUSHIMA M, 1978, BIOCHEM J, V170, P495, DOI 10.1042/bj1700495
   Harada S, 2012, J BONE MINER RES, V27, P461, DOI 10.1002/jbmr.555
   Harada S, 2010, J STEROID BIOCHEM, V121, P281, DOI 10.1016/j.jsbmb.2010.04.001
   Hatakeyama S, 2007, J STEROID BIOCHEM, V103, P222, DOI 10.1016/j.jsbmb.2006.12.025
   de Freitas PHL, 2011, BONE, V49, P335, DOI 10.1016/j.bone.2011.05.022
   Matsumoto T, 2005, J CLIN ENDOCR METAB, V90, P5031, DOI 10.1210/jc.2004 2552
   Matsumoto T, 2007, J STEROID BIOCHEM, V103, P584, DOI 10.1016/j.jsbmb.2006.12.088
   Matsumoto T, 2010, J STEROID BIOCHEM, V121, P261, DOI 10.1016/j.jsbmb.2010.03.035
   MIYAMOTO K, 1993, CHEM PHARM BULL, V41, P1111
   Mizoguchi T, 2009, J CELL BIOL, V184, P541, DOI 10.1083/jcb.200806139
   MORIMOTO S, 1989, BIOCHEM INT, V19, P1143
   Muto A, 2011, J BONE MINER RES, V26, P2978, DOI 10.1002/jbmr.490
   Nakamichi Y, 2012, P NATL ACAD SCI USA, V109, P10006, DOI 10.1073/pnas.1207361109
   OKANO T, 1989, J NUTR SCI VITAMINOL, V35, P529, DOI 10.3177/jnsv.35.529
   RAISZ LG, 1972, SCIENCE, V175, P768, DOI 10.1126/science.175.4023.768
   Shiraki M, 2004, J BONE MINER METAB, V22, P352, DOI 10.1007/s00774 004 0494 2
   SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Suda T, 2012, ARCH BIOCHEM BIOPHYS, V523, P22, DOI 10.1016/j.abb.2011.11.011
   Tanaka Y, 1996, J BONE MINER RES, V11, P325
   TSURUKAMI H, 1994, CALCIFIED TISSUE INT, V54, P142, DOI 10.1007/BF00296065
   Uchiyama Y, 2002, BONE, V30, P582, DOI 10.1016/S8756 3282(02)00682 8
NR 26
TC 18
Z9 18
U1 0
U2 14
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960 0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD JUL
PY 2013
VL 136
SI SI
BP 171
EP 174
DI 10.1016/j.jsbmb.2012.11.010
PG 4
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 177WJ
UT WOS:000321405800034
PM 23220095
DA 2025 08 17
ER

PT J
AU McClung, MR
   Wagman, RB
   Miller, PD
   Wang, A
   Lewiecki, EM
AF McClung, M. R.
   Wagman, R. B.
   Miller, P. D.
   Wang, A.
   Lewiecki, E. M.
TI Observations following discontinuation of long term denosumab therapy
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Denosumab; Discontinuation; Osteoporosis; Treatment cessation
ID BONE MINERAL DENSITY; OSTEOPOROSIS RISK ASSESSMENT; PHASE 2
   CLINICAL TRIAL; POSTMENOPAUSAL WOMEN; FREEDOM EXTENSION; FRACTURE RISK;
   VERTEBRAL FRACTURES; HORMONE THERAPY; TURNOVER; ALENDRONATE
AB Stopping denosumab after 8 years of continued treatment was associated with bone loss during a 1 year observation study in patients who were not prescribed osteoporosis treatment. Bone loss was attenuated in patients who began another osteoporosis therapy. Treatment to prevent bone loss upon stopping denosumab should be considered.
   This study aimed to understand osteoporosis management strategies during a 1 year observational follow up after up to 8 years of denosumab treatment in a phase 2 study.
   During the observational year, patients received osteoporosis management at the discretion of their physician and returned to the clinic for BMD assessment and completion of an osteoporosis management questionnaire. Incidence of serious adverse events and fractures was collected. Analyses were descriptive.
   Of 138 eligible patients, 82 enrolled in and completed the observation study. Most (65 [79%]) did not receive prescription osteoporosis medication, with "my doctor felt I no longer needed a medication" being the most common reason (23 [35%]). Of the 17 patients who took osteoporosis medications, 8 discontinued therapy during the observation study. In patients treated with denosumab for 8 years (N = 52), BMD decreased during the 1 year observation study (6.7% [lumbar spine], 6.6% [total hip]). Those who took osteoporosis medication during the observation study showed a smaller decline in BMD than those who did not. No new safety concerns were identified. Eight patients (9.8%), all of whom had at least one predisposing risk factor, experienced 17 fractures. This included seven patients who experienced one or more vertebral fractures.
   Consistent with denosumab's mechanism of action, treatment cessation led to reversal of the drug's effect on BMD and perhaps fracture risk. For patients who took osteoporosis therapy, bone loss was attenuated. For patients at high fracture risk, switching to another osteoporosis therapy if denosumab is discontinued seems appropriate.
C1 [McClung, M. R.] Oregon Osteoporosis Ctr, 2881 NW Cumberland Rd, Portland, OR 97210 USA.
   [McClung, M. R.] Australian Catholic Univ, Melbourne, Vic, Australia.
   [Wagman, R. B.; Wang, A.] Amgen Inc, Thousand Oaks, CA 91320 USA.
   [Miller, P. D.] Colorado Ctr Bone Res, Lakewood, CO USA.
   [Lewiecki, E. M.] New Mexico Clin Res & Osteoporosis Ctr, Albuquerque, NM USA.
C3 Oregon Osteoporosis Center; Australian Catholic University; Australian
   Catholic University   Melbourne Campus; Amgen; Colorado Center For Bone
   Research; New Mexico Clinical Research & Osteoporosis Center
RP McClung, MR (通讯作者)，Oregon Osteoporosis Ctr, 2881 NW Cumberland Rd, Portland, OR 97210 USA.; McClung, MR (通讯作者)，Australian Catholic Univ, Melbourne, Vic, Australia.
EM mmcclung.ooc@gmail.com; rwagman@amgen.com; MillerCCBR@aol.com;
   awang@amgen.com; mlewiecki@gmail.com
RI Lewiecki, E./B 3706 2018; McClung, Michael/ABA 4100 2021
FU Amgen Inc., Thousand Oaks, CA, USA
FX This study was sponsored by Amgen Inc., Thousand Oaks, CA, USA.
CR Adler RA, 2016, J BONE MINER RES, V31, P16, DOI 10.1002/jbmr.2708
   Anastasilakis AD, 2016, OSTEOPOROSIS INT, V27, P1929, DOI 10.1007/s00198 015 3459 5
   Ascott Evans BH, 2003, ARCH INTERN MED, V163, P789, DOI 10.1001/archinte.163.7.789
   Banks E, 2004, JAMA J AM MED ASSOC, V291, P2212, DOI 10.1001/jama.291.18.2212
   Barrett Connor E, 2003, MENOPAUSE, V10, P412, DOI 10.1097/01.GME.0000086467.82759.DA
   Black DM, 2016, NEW ENGL J MED, V374, P2096, DOI 10.1056/NEJMc1602599
   Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336
   Bone HG, 2013, J CLIN ENDOCR METAB, V98, P4483, DOI 10.1210/jc.2013 1597
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Bone HG, 2015, J Bone Miner Res, V30, pS471
   Boonen S, 2012, J BONE MINER RES, V27, P963, DOI 10.1002/jbmr.1570
   Brown JP, 2013, J BONE MINER RES, V28, P746, DOI 10.1002/jbmr.1808
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Diab DL, 2014, MENOPAUSE, V21, P195, DOI 10.1097/GME.0b013e31829ef343
   Egerdie BR, 2015, CAN UROL ASS J S2, V9, pS91
   Eisman JA, 2011, J BONE MINER RES, V26, P242, DOI 10.1002/jbmr.212
   Freemantle N, 2012, OSTEOPOROSIS INT, V23, P317, DOI 10.1007/s00198 011 1780 1
   Greenspan SL, 2002, ANN INTERN MED, V137, P875, DOI 10.7326/0003 4819 137 11 200212030 00008
   Heiss G, 2008, JAMA J AM MED ASSOC, V299, P1036, DOI 10.1001/jama.299.9.1036
   Ivaska KK, 2010, J BONE MINER RES, V25, P393, DOI 10.1359/jbmr.091006
   Lewiecki EM, 2007, J BONE MINER RES, V22, P1832, DOI 10.1359/JBMR.070809
   McClung MR, 2013, OSTEOPOROSIS INT, V24, P227, DOI 10.1007/s00198 012 2052 4
   McClung M, 2013, AM J MED, V126, P13, DOI 10.1016/j.amjmed.2012.06.023
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Miller PD, 2011, J CLIN ENDOCR METAB, V96, P394, DOI 10.1210/jc.2010 1805
   Papapoulos S, 2015, OSTEOPOROSIS INT, V26, P2773, DOI 10.1007/s00198 015 3234 7
   Papapoulos S, 2012, J BONE MINER RES, V27, P694, DOI 10.1002/jbmr.1479
   Popp AW, 2016, OSTEOPOROSIS INT, V27, P1917, DOI 10.1007/s00198 015 3458 6
   Prince R, 2005, J BONE MINER RES, V20, P1507, DOI 10.1359/JBMR.050501
   Wasnich Richard D, 2004, Menopause, V11, P622
   Whitaker M, 2012, NEW ENGL J MED, V366, P2048, DOI 10.1056/NEJMp1202619
   Yates J, 2004, OBSTET GYNECOL, V103, P440, DOI 10.1097/01.AOG.0000114986.14806.37
NR 33
TC 160
Z9 167
U1 0
U2 5
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD MAY
PY 2017
VL 28
IS 5
BP 1723
EP 1732
DI 10.1007/s00198 017 3919 1
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA ES3QH
UT WOS:000399443600023
PM 28144701
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Moon, MH
   Seol, JW
   Seo, JS
   Jeong, JK
   Lee, YJ
   Kim, IS
   Jackson, C
   Sambrook, P
   Park, SY
AF Moon, Myung Hee
   Seol, Jae Won
   Seo, Jae Suk
   Jeong, Jae Kyo
   Lee, You Jin
   Kim, In Shik
   Jackson, Chris
   Sambrook, Philip
   Park, Sang Youel
TI Protective effect of hypoxia on bisphosphonate related bone cell damage
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE hypoxia; bisphosphonate; apoptosis; osteoporosis
ID NITROGEN CONTAINING BISPHOSPHONATES; MEVALONATE PATHWAY; IN VITRO;
   OSTEOCLAST FORMATION; PROTEIN PRENYLATION; KINASE ACTIVATION; MECHANISM;
   ALENDRONATE; INHIBITION; APOPTOSIS
AB Bisphosphonates (BPs) are widely used for the prevention and treatment of osteoporosis. However, there have been numerous reports of side effects of BPs, including osteonecrosis of the jaw. In the present study, we investigated whether hypoxia inhibits BP induced apoptosis, and examined the mechanisms of this inhibition. The cell viability of the MG 63 human osteoblast like cell line treated with the nitrogen containing (N) BPs alendronate, risedronate and zoledronate was investigated, and hypoxia was assessed by crystal violet staining and the MTT assay, and by observing cell morphology. The effect of N BPs and hypoxia on apoptotic cell signaling was evaluated using Western blotting, immunocytochemistry and the TUNEL assay. The results of crystal violet staining and the MTT and TUNEL assays showed that the N BPs inhibited proliferation and induced apoptosis in MG 63 cells. Hypoxia significantly prevented N BP induced MG 63 cell apoptosis, and also attenuated BP induced c Jun N terminal kinase (INK) phosphorylation and BCL xL reduction. Hypoxia prevented BP induced cell damage by blocking JNK phosphorylation and by regulating the BCL xL protein. Thus, hypoxia or hypoxia related genes, including hypoxia inducible factor la, may be a potential therapy for BP related side effects such as osteonecrosis of the jaw.
C1 [Moon, Myung Hee; Seo, Jae Suk; Jeong, Jae Kyo; Lee, You Jin; Kim, In Shik; Park, Sang Youel] Chonbuk Natl Univ, Ctr Healthcare Technol Dev, Biosafety Res Inst, Coll Vet Med, Jeonju 561756, Jeonbuk, South Korea.
   [Seol, Jae Won; Jackson, Chris; Sambrook, Philip] Univ Sydney, Royal N Shore Hosp, Kolling Inst, Inst Bone & Joint Res, St Leonards, NSW 2065, Australia.
C3 Jeonbuk National University; University of Sydney; Kolling Institute of
   Medical Research; Royal North Shore Hospital
RP Park, SY (通讯作者)，Chonbuk Natl Univ, Ctr Healthcare Technol Dev, Biosafety Res Inst, Coll Vet Med, Jeonju 561756, Jeonbuk, South Korea.
EM sypark@chonbuk.ac.kr
RI Park, Sang Youel/D 5966 2012; kim, jeeyoung/AFK 5620 2022; Kim, Pyeong
   Hwa/KGM 1468 2024
OI Jackson, Christopher/0000 0002 9234 9116; 
FU Korean Government [2009 65822]; Regional Research Universities Program;
   Center for Healthcare Technology Development
FX This study was supported by the National Research Foundation of the
   Korea Grant funded by the Korean Government (2009 65822) and by the
   Regional Research Universities Program and the Center for Healthcare
   Technology Development.
CR Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   Boyle Robert George, 2006, Anti Cancer Agents in Medicinal Chemistry, V6, P281
   Brizel DM, 1996, CANCER RES, V56, P941
   Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743 2754.2001
   CASEY PJ, 1992, J LIPID RES, V33, P1731
   Chen N, 2009, J BIOL CHEM, V284, P10004, DOI 10.1074/jbc.M805997200
   Cheng WH, 2003, BIOCHEM J, V370, P927, DOI 10.1042/BJ20021870
   Cosse JPJ, 2009, NEOPLASIA, V11, P976, DOI 10.1593/neo.09632
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092 8674(00)00116 1
   Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200
   Dong Z, 2004, J BIOL CHEM, V279, P9215, DOI 10.1074/jbc.M312225200
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Geddes A.D., 1994, J BONE MINER RES, V8, P265
   Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0
   Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   Inoue R, 2005, BRIT J PHARMACOL, V146, P633, DOI 10.1038/sj.bjp.0706373
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Lu PZ, 2008, INT J MOL SCI, V9, P698, DOI 10.3390/ijms9050698
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   McAteer JA., 1994, BASIC CELL CULTURE, P93
   Mizukami Y, 1997, J BIOL CHEM, V272, P16657, DOI 10.1074/jbc.272.26.16657
   Papapetrou PD, 2009, HORM INT J ENDOCRINO, V8, P96, DOI 10.14310/horm.2002.1226
   Perkins GL, 2005, DIFFERENTIATION, V73, P199, DOI 10.1111/j.1432 0436.2005.00024.x
   Pouysségur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Roux C, 1999, DRUGS, V58, P823, DOI 10.2165/00003495 199958050 00005
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Seol JW, 2007, ONCOL REP, V18, P523
   Shipman CM, 1998, CANCER RES, V58, P5294
   Silverman SL, 2009, AM J MED, V122, P33, DOI 10.1016/j.amjmed.2008.12.005
   TOBIAS JH, 1993, BONE, V14, P619, DOI 10.1016/8756 3282(93)90083 M
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Virtanen SS, 2002, CANCER RES, V62, P2708
NR 42
TC 4
Z9 4
U1 0
U2 9
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD SEP OCT
PY 2010
VL 3
IS 5
BP 869
EP 875
DI 10.3892/mmr.2010.344
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA 635RE
UT WOS:000280673000022
PM 21472328
OA Bronze
DA 2025 08 17
ER

PT J
AU Krishnacoumar, B
   Stenzel, M
   Garibagaoglu, H
   Omata, Y
   Sworn, RL
   Hofmann, T
   Ipseiz, N
   Czubala, MA
   Steffen, U
   Maccataio, A
   Stoll, C
   Boehm, C
   Herrmann, M
   Uderhardt, S
   Jenkins, RH
   Taylor, PR
   Grüneboom, A
   Zaiss, MM
   Schett, G
   Krönke, G
   Scholtysek, C
AF Krishnacoumar, Brenda
   Stenzel, Martin
   Garibagaoglu, Hilal
   Omata, Yasunori
   Sworn, Rachel L.
   Hofmann, Thea
   Ipseiz, Natacha
   Czubala, Magdalena A.
   Steffen, Ulrike
   Maccataio, Antonio
   Stoll, Cornelia
   Boehm, Christina
   Herrmann, Martin
   Uderhardt, Stefan
   Jenkins, Robert H.
   Taylor, Philip R.
   Grueneboom, Anika
   Zaiss, Mario M.
   Schett, Georg
   Kroenke, Gerhard
   Scholtysek, Carina
TI Caspase 8 promotes scramblase mediated phosphatidylserine exposure and
   fusion of osteoclast precursors
SO BONE RESEARCH
LA English
DT Article
ID APOPTOTIC CELLS; RECOGNITION; FLIPPASE; SIGNALS; ME
AB Efficient cellular fusion of mononuclear precursors is the prerequisite for the generation of fully functional multinucleated bone resorbing osteoclasts. However, the exact molecular factors and mechanisms controlling osteoclast fusion remain incompletely understood. Here we identify RANKL mediated activation of caspase 8 as early key event during osteoclast fusion. Single cell RNA sequencing based analyses suggested that activation of parts of the apoptotic machinery accompanied the differentiation of osteoclast precursors into mature multinucleated osteoclasts. A subsequent characterization of osteoclast precursors confirmed that RANKL mediated activation of caspase 8 promoted the non apoptotic cleavage and activation of downstream effector caspases that translocated to the plasma membrane where they triggered activation of the phospholipid scramblase Xkr8. Xkr8 mediated exposure of phosphatidylserine, in turn, aided cellular fusion of osteoclast precursors and thereby allowed generation of functional multinucleated osteoclast syncytia and initiation of bone resorption. Pharmacological blockage or genetic deletion of caspase 8 accordingly interfered with fusion of osteoclasts and bone resorption resulting in increased bone mass in mice carrying a conditional deletion of caspase 8 in mononuclear osteoclast precursors. These data identify a novel pathway controlling osteoclast biology and bone turnover with the potential to serve as target for therapeutic intervention during diseases characterized by pathologic osteoclast mediated bone loss.Proposed model of osteoclast fusion regulated by caspase 8 activation and PS exposure. RANK/RANK L interaction. Activation of procaspase 8 into caspase 8. Caspase 8 activates caspase 3. Active capase 3 cleaves Xkr8. Local PS exposure is induced. Exposed PS is recognized by the fusion partner. FUSION. PS is re internalized.
C1 [Krishnacoumar, Brenda; Stenzel, Martin; Garibagaoglu, Hilal; Omata, Yasunori; Sworn, Rachel L.; Hofmann, Thea; Steffen, Ulrike; Maccataio, Antonio; Stoll, Cornelia; Boehm, Christina; Herrmann, Martin; Uderhardt, Stefan; Zaiss, Mario M.; Schett, Georg; Kroenke, Gerhard; Scholtysek, Carina] Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Internal Med Rheumatol & Immunol 3, D 91054 Erlangen, Germany.
   [Krishnacoumar, Brenda; Stenzel, Martin; Garibagaoglu, Hilal; Omata, Yasunori; Sworn, Rachel L.; Hofmann, Thea; Steffen, Ulrike; Maccataio, Antonio; Stoll, Cornelia; Boehm, Christina; Herrmann, Martin; Uderhardt, Stefan; Zaiss, Mario M.; Schett, Georg; Kroenke, Gerhard; Scholtysek, Carina] Univ Klinikum Erlangen, D 91054 Erlangen, Germany.
   [Krishnacoumar, Brenda; Stenzel, Martin; Garibagaoglu, Hilal; Omata, Yasunori; Sworn, Rachel L.; Hofmann, Thea; Steffen, Ulrike; Maccataio, Antonio; Stoll, Cornelia; Boehm, Christina; Herrmann, Martin; Uderhardt, Stefan; Zaiss, Mario M.; Schett, Georg; Kroenke, Gerhard; Scholtysek, Carina] Friedrich Alexander Univ Erlangen Nurnberg FAU, Deutsch Zent Immuntherapie DZI, D 91054 Erlangen, Germany.
   [Krishnacoumar, Brenda; Stenzel, Martin; Grueneboom, Anika] Leibniz Inst Analyt Wissensch ISAS E V, Dept Biopsectroscopy, Bunsen Kirchhoff Str 11, D 44227 Dortmund, Germany.
   [Krishnacoumar, Brenda; Grueneboom, Anika] Univ Hosp, Univ Duisburg Essen, Med Fac, D 45147 Essen, Germany.
   [Ipseiz, Natacha; Czubala, Magdalena A.; Taylor, Philip R.] Cardiff Univ, Syst Immun Res Inst, Heath Pk, Cardiff CF14 4XN, Wales.
   [Uderhardt, Stefan] Friedrich Alexander Univ Erlangen Nurnberg FAU, Opt Imaging Competence Ctr FAU OICE, Exploratory Res Unit, Erlangen, Germany.
   [Jenkins, Robert H.] Cardiff Univ, Div Infect & Immun, Sch Med, Heath Pk, Cardiff CF14 4XN, Wales.
   [Kroenke, Gerhard] Deutsch Rheuma Forschungszentrum Julich Berlin, Berlin, Germany.
   [Kroenke, Gerhard] Charite Univ Med Berlin, Dept Radiooncol, Berlin, Germany.
C3 University of Erlangen Nuremberg; University of Erlangen Nuremberg;
   University of Erlangen Nuremberg; Dortmund University of Technology;
   Leibniz Association; Leibniz Institut fur Analytische Wissenschaften
   (ISAS); University of Duisburg Essen; Cardiff University; University of
   Erlangen Nuremberg; Cardiff University; Free University of Berlin;
   Humboldt University of Berlin; Charite Universitatsmedizin Berlin
RP Krishnacoumar, B; Scholtysek, C (通讯作者)，Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Internal Med Rheumatol & Immunol 3, D 91054 Erlangen, Germany.; Krishnacoumar, B; Scholtysek, C (通讯作者)，Univ Klinikum Erlangen, D 91054 Erlangen, Germany.; Krishnacoumar, B; Scholtysek, C (通讯作者)，Friedrich Alexander Univ Erlangen Nurnberg FAU, Deutsch Zent Immuntherapie DZI, D 91054 Erlangen, Germany.; Krishnacoumar, B (通讯作者)，Leibniz Inst Analyt Wissensch ISAS E V, Dept Biopsectroscopy, Bunsen Kirchhoff Str 11, D 44227 Dortmund, Germany.; Krishnacoumar, B (通讯作者)，Univ Hosp, Univ Duisburg Essen, Med Fac, D 45147 Essen, Germany.
EM Brenda.Krishnacoumar@uk essen.de; carina.scholtysek@uk erlangen.de
RI ; Krishnacoumar, Brenda/MDT 4452 2025; Herrmann, Martin/HTN 8390 2023;
   Scholtysek, Carina/LXA 1619 2024; Krönke, Gerhard/C 6615 2014; Kronke,
   Gerhard/C 6615 2014; Uderhardt, Stefan/AAA 5224 2022; Zaiss,
   Mario/ABE 7125 2021
OI Schett, Georg/0000 0001 8740 9615; Jenkins, Robert/0000 0001 8500 9044;
   Scholtysek, Carina/0009 0001 2197 5179; Stenzel,
   Martin/0000 0002 1378 2529; Kronke, Gerhard/0000 0002 7566 4325;
   Czubala, Magdalena/0000 0001 9881 1095; 
FU Bayerische Forschungsstiftung (Bavarian Research Foundation) [CRC1181,
   SCHE 2062/1 1]; Wellcome Trust Investigator Award [107964/Z/15/Z]; UK
   Dementia Research Institute; BBSRC Discovery Fellowship [BB/T009543/1];
   Wellcome Trust [107964/Z/15/Z] Funding Source: researchfish; Wellcome
   Trust [107964/Z/15/Z] Funding Source: Wellcome Trust
FX We thank the Optical Imaging Center Erlangen (OICE), IMCES (Imaging
   Center Essen), Daniela Weidner, Alexandra Correa Zamora, Monica Pascual
   Mate and Rita Weinkam for their excellent technical assistance. We thank
   Prof. Dr. Julio Vera Gonzalez and Martin Eberhardt for providing us with
   the bioinformatical infrastructure. We thank Prof. Dr. Shigekazu Nagata
   and Dr. Jean Philippe Auger for their careful and critical reading of
   our manuscript and their input; Prof. Joachim Fandrey for his support.
   This work was supported by the Bayerische Forschungsstiftung to B.K. and
   the Deutsche Forschungsgemeinschaft (CRC1181 to G.K. and G.S.; SCHE
   2062/1 1 to C.S.). P.R.T was funded by the Wellcome Trust Investigator
   Award (107964/Z/15/Z) and the UK Dementia Research Institute. M.A.C was
   funded by BBSRC Discovery Fellowship (BB/T009543/1).
CR Fadok VA, 2001, J CLIN INVEST, V108, P957, DOI 10.1172/JCI200114122
   Günther C, 2011, NATURE, V477, P335, DOI 10.1038/nature10400
   Hochreiter Hufford AE, 2015, METHODS MOL BIOL, P141, DOI 10.1007/978 1 4939 2703 6_10
   Hochreiter Hufford AE, 2013, NATURE, V497, P263, DOI 10.1038/nature12135
   Jacome Galarza CE, 2019, NATURE, V568, P541, DOI 10.1038/s41586 019 1105 7
   Kang JH, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2712 9
   Kearney CJ, 2013, J BIOL CHEM, V288, P4878, DOI 10.1074/jbc.M112.422410
   Kim GW, 2016, BMB REP, V49, P303, DOI 10.5483/BMBRep.2016.49.6.078
   Klöditz K, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420 019 0146 x
   Koizumi K, 2009, J IMMUNOL, V183, P7825, DOI 10.4049/jimmunol.0803627
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Li J, 2008, ONCOGENE, V27, P6194, DOI 10.1038/onc.2008.297
   Miyamoto H, 2012, J BONE MINER RES, V27, P1289, DOI 10.1002/jbmr.1575
   Mukherjee A, 2017, CELL DEATH DIFFER, V24, P1411, DOI 10.1038/cdd.2017.64
   Nagata S, 2016, CELL DEATH DIFFER, V23, P952, DOI 10.1038/cdd.2016.7
   Nagata S, 2020, CURR OPIN IMMUNOL, V62, P31, DOI 10.1016/j.coi.2019.11.009
   Ravichandran KS, 2007, NAT REV IMMUNOL, V7, P964, DOI 10.1038/nri2214
   Ravichandran KS, 2010, J EXP MED, V207, P1807, DOI 10.1084/jem.20101157
   Rosas M, 2011, EUR J IMMUNOL, V41, P356, DOI 10.1002/eji.201040962
   Segawa K, 2015, TRENDS CELL BIOL, V25, P639, DOI 10.1016/j.tcb.2015.08.003
   Segawa K, 2014, SCIENCE, V344, P1164, DOI 10.1126/science.1252809
   Svandova E, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00174
   Szymczyk KH, 2006, J CELL PHYSIOL, V209, P836, DOI 10.1002/jcp.20770
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tsuchiya M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04436 w
   Verma SK, 2018, J BIOL CHEM, V293, P254, DOI 10.1074/jbc.M117.809681
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Witwicka H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128275
   Wu Y, 2006, TRENDS CELL BIOL, V16, P189, DOI 10.1016/j.tcb.2006.02.003
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
NR 30
TC 8
Z9 8
U1 1
U2 5
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2095 4700
EI 2095 6231
J9 BONE RES
JI Bone Res.
PD JUL 11
PY 2024
VL 12
IS 1
AR 40
DI 10.1038/s41413 024 00338 4
PG 10
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA YA4Q4
UT WOS:001265754700001
PM 38987568
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Xu, J
   Li, ZX
   Luo, J
   Yang, F
   Liu, T
   Liu, MY
   Qiu, WW
   Tang, J
AF Xu, Jun
   Li, Zhenxi
   Luo, Jian
   Yang, Fan
   Liu, Ting
   Liu, Mingyao
   Qiu, Wen Wei
   Tang, Jie
TI Synthesis and Biological Evaluation of Heterocyclic Ring Fused Betulinic
   Acid Derivatives as Novel Inhibitors of Osteoclast Differentiation and
   Bone Resorption
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID NF KAPPA B; PARATHYROID HORMONE; NATURAL PRODUCTS; ESTROGEN; THERAPY;
   OSTEOPOROSIS; BISPHOSPHONATES; MECHANISMS; STRENGTH; BENEFITS
AB A series of betulinic acid (BA) derivatives were designed and synthesized by introducing various fused heterocyclic rings at C 2 and C 3 positions. Their inhibitory effects of RANKL induced osteoclastogenesis were evaluated by using a cell based tartrate resistant acid phosphatase (TRAP) activity assay. To our delight, most of these compounds exhibited a dramatic increase in inhibitory potency, compared with BA. The most potent compound, 20, showed 66.9% inhibition even at the low concentration of 0.1 mu M, which was about 200 fold more potent than the lead compound BA. What's more, the cytotoxicity assay on RAW264.7 suggested that the inhibition of 20 on osteoclast differentiation did not result from its cytotoxicity. The primary mechanistic study indicated that 20 could inhibit osteoclastogenesis related marker gene expression levels of cathepsin K and TRAP. More importantly, 20 could attenuate bone loss of ovariectomy mouse in vivo. Therefore, these BA derivatives could be used as potential leads for the development of a new type of antiosteoporosis agent.
C1 [Xu, Jun; Yang, Fan; Liu, Ting; Tang, Jie] E China Normal Univ, Shanghai Engn Res Ctr Mol Therapeut & New Drug De, Shanghai 200062, Peoples R China.
   [Qiu, Wen Wei] E China Normal Univ, Inst Med Chem, Shanghai 200062, Peoples R China.
   [Qiu, Wen Wei] E China Normal Univ, Dept Chem, Shanghai 200062, Peoples R China.
   [Li, Zhenxi; Luo, Jian; Liu, Mingyao] E China Normal Univ, Shanghai Key Lab Regulatory Biol, Inst Biomed Sci, Shanghai 200241, Peoples R China.
   [Li, Zhenxi; Luo, Jian; Liu, Mingyao] E China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China.
C3 East China Normal University; East China Normal University; East China
   Normal University; East China Normal University; East China Normal
   University
RP Liu, MY (通讯作者)，E China Normal Univ, Shanghai Engn Res Ctr Mol Therapeut & New Drug De, Shanghai 200062, Peoples R China.
EM myliu@bio.ecnu.edu.cn; wwqiu@chem.ecnu.edu.cn; jtang@chem.ecnu.edu.cn
RI Luo, Jian/H 3362 2016; tang, jie/KIE 8633 2024; Yang, Fan/GYU 4249 2022
OI Luo, Jian/0000 0003 3583 0154; Qiu, Wen Wei/0000 0002 1666 8844; Li,
   Zhenxi/0000 0002 7220 6177; Liu, Mingyao/0000 0001 7339 5048
FU National Natural Science Foundation of China [20802020, 30800653,
   81071437]; Shanghai Science and Technology Council [10142200802]; Ph.D.
   Program Foundation of Ministry of Education of China [200802691039]; 973
   Program [2012CB910400]; "Lab of Organic Functional Molecules, the
   Sino French Institute of ECNU"
FX The National Natural Science Foundation of China (Grant 20802020),
   Shanghai Science and Technology Council (Grant 10142200802), Ph.D.
   Program Foundation of Ministry of Education of China (Grant
   200802691039), 973 Program (Grant 2012CB910400), and National Natural
   Science Foundation of China (Grants 30800653 and 81071437) are
   appreciated for their financial support. We also thank "Lab of Organic
   Functional Molecules, the Sino French Institute of ECNU" for support.
CR Abrahamsen B, 2010, CURR OPIN RHEUMATOL, V22, P404, DOI 10.1097/BOR.0b013e32833ad677
   Arantes HP, 2010, ARQ BRAS ENDOCRINOL, V54, P206, DOI 10.1590/S0004 27302010000200017
   Body JJ, 2005, ONCOLOGIST, V10, P317, DOI 10.1634/theoncologist.10 5 317
   Boyce Brendan F., 2005, Keio Journal of Medicine, V54, P127, DOI 10.2302/kjm.54.127
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Canderelli R, 2007, J AM ACAD NURSE PRAC, V19, P635, DOI 10.1111/j.1745 7599.2007.00269.x
   Canonico M, 2009, CLIMACTERIC, V12, P76, DOI 10.1080/13697130903006837
   Cappuzzo KA, 2004, ANN PHARMACOTHER, V38, P294, DOI 10.1345/aph.1D353
   Çetinkaya MB, 2002, J BONE MINER METAB, V20, P44, DOI 10.1007/s774 002 8446 8
   Conte P, 2004, ONCOLOGIST, V9, P28, DOI 10.1634/theoncologist.9 90004 28
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   ERNSTER VL, 1988, PREV MED, V17, P201, DOI 10.1016/0091 7435(88)90064 3
   Filleul O, 2010, J CANCER RES CLIN, V136, P1117, DOI 10.1007/s00432 010 0907 7
   Fulda S, 2009, MOL NUTR FOOD RES, V53, P140, DOI 10.1002/mnfr.200700491
   Furuyama N, 2000, STEROIDS, V65, P371, DOI 10.1016/S0039 128X(00)00097 0
   Hayman AR, 1996, DEVELOPMENT, V122, P3151
   Hollberg K, 2002, EXP CELL RES, V279, P227, DOI 10.1006/excr.2002.5612
   Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389
   Kashiwada Y, 1996, J MED CHEM, V39, P1016, DOI 10.1021/jm950922q
   Keller KB, 2005, AM J CRIT CARE, V14, P157, DOI 10.4037/ajcc2005.14.2.157
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   Li JF, 2009, EUR J MED CHEM, V44, P2796, DOI 10.1016/j.ejmech.2008.12.024
   Li JF, 2009, CARBOHYD RES, V344, P599, DOI 10.1016/j.carres.2009.01.019
   Lipton Allan, 2008, Curr Opin Support Palliat Care, V2, P197, DOI 10.1097/SPC.0b013e32830baac2
   Liu J, 2009, BIOORG MED CHEM LETT, V19, P2154, DOI 10.1016/j.bmcl.2009.02.119
   Lo YC, 2010, J AGR FOOD CHEM, V58, P6643, DOI 10.1021/jf904158k
   Miller Paul D, 2008, Curr Osteoporos Rep, V6, P12, DOI 10.1007/s11914 008 0003 y
   Miyahara T, 1996, BIOORG MED CHEM LETT, V6, P1037, DOI 10.1016/0960 894X(96)00173 4
   MOSEKILDE L, 1995, BONE, V16, P223, DOI 10.1016/8756 3282(94)00033 V
   Mukherjee PK, 1997, PLANTA MED, V63, P367, DOI 10.1055/s 2006 957705
   Mullauer FB, 2010, ANTI CANCER DRUG, V21, P215, DOI 10.1097/CAD.0b013e3283357c62
   Mundy GR, 2007, NUTR REV, V65, pS147, DOI [10.1111/j.1753 4887.2007.tb00353.x, 10.1301/nr.2007.dec.S147 S151]
   Neuprez A, 2008, BEST PRACT RES CL EN, V22, P869, DOI 10.1016/j.beem.2008.06.003
   Newman DJ, 2000, NAT PROD REP, V17, P215, DOI 10.1039/a902202c
   Newman DJ, 2003, J NAT PROD, V66, P1022, DOI 10.1021/np030096l
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Pacifici R, 1998, ENDOCRINOLOGY, V139, P2659, DOI 10.1210/en.139.6.2659
   Pietschmann P, 2009, GERONTOLOGY, V55, P3, DOI 10.1159/000166209
   Qiu SX, 2007, CHEM BIOL, V14, P860, DOI 10.1016/j.chembiol.2007.06.010
   Qiu WW, 2009, BIOORG MED CHEM LETT, V19, P6618, DOI 10.1016/j.bmcl.2009.10.017
   Rantakokko J, 1999, J BONE MINER RES, V14, P1934, DOI 10.1359/jbmr.1999.14.11.1934
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561
   Steinkamp Fenske K, 2007, J PHARMACOL EXP THER, V322, P836, DOI 10.1124/jpet.107.123356
   Studd J, 2009, CLIMACTERIC, V12, P206, DOI 10.1080/13697130902721873
   Takada Y, 2006, J IMMUNOL, V176, P3127, DOI 10.4049/jimmunol.176.5.3127
   Teitelbaum SL, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1857
   Terpos E, 2009, EXPERT OPIN BIOL TH, V9, P465, DOI [10.1517/14712590902845610, 10.1517/14712590902845610 ]
   Urban M, 2007, J NAT PROD, V70, P526, DOI 10.1021/np060436d
   Vääräniemi J, 2004, J BONE MINER RES, V19, P1432, DOI 10.1359/JBMR.040603
   van de Weijer PHM, 2008, MATURITAS, V60, P59, DOI 10.1016/j.maturitas.2008.04.010
   Walsh NC, 2004, CURR OPIN RHEUMATOL, V16, P419, DOI 10.1097/01.bor.0000127824.42507.68
   Weitzmann MN, 2006, ANN NY ACAD SCI, V1068, P256, DOI 10.1196/annals.1346.030
   Xia LH, 1999, BIOL CHEM, V380, P679, DOI 10.1515/BC.1999.084
   Xie F, 2005, BIOL PHARM BULL, V28, P1879, DOI 10.1248/bpb.28.1879
NR 57
TC 88
Z9 91
U1 0
U2 55
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD APR 12
PY 2012
VL 55
IS 7
BP 3122
EP 3134
DI 10.1021/jm201540h
PG 13
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA 923AT
UT WOS:000302591100022
PM 22435650
DA 2025 08 17
ER

PT J
AU Sato, AY
   Richardson, D
   Cregor, M
   Davis, HM
   Au, ED
   McAndrews, K
   Zimmers, TA
   Organ, JM
   Peacock, M
   Plotkin, LI
   Bellido, T
AF Sato, Amy Y.
   Richardson, Danielle
   Cregor, Meloney
   Davis, Hannah M.
   Au, Ernie D.
   McAndrews, Kevin
   Zimmers, Teresa A.
   Organ, Jason M.
   Peacock, Munro
   Plotkin, Lilian I.
   Bellido, Teresita
TI Glucocorticoids Induce Bone and Muscle Atrophy by Tissue Specific
   Mechanisms Upstream of E3 Ubiquitin Ligases
SO ENDOCRINOLOGY
LA English
DT Article
ID 1 NULL MICE; SKELETAL MUSCLE; INDUCED OSTEOPOROSIS; OXIDATIVE STRESS;
   OSTEOBLASTS; OSTEOCYTES; NOTCH; DEXAMETHASONE; PREVENTION; EXPRESSION
AB Glucocorticoid excess, either endogenous with diseases of the adrenal gland, stress, or aging or when administered for immunosuppression, induces bone and muscle loss, leading to osteopenia and sarcopenia. Muscle weakness increases the propensity for falling, which, combined with the lower bone mass, increases the fracture risk. The mechanisms underlying glucocorticoid induced bone and muscle atrophy are not completely understood. We have demonstrated that the loss of bone and muscle mass, decreased bone formation, and reduced muscle strength, hallmarks of glucocorticoid excess, are accompanied by upregulation in both tissues in vivo of the atrophy related genes atrogin1, MuRF1, and MUSA1. These are E3 ubiquitin ligases traditionally considered muscle specific. Glucocorticoids also upregulated atrophy genes in cultured osteoblastic/osteocytic cells, in ex vivo bone organ cultures, and in muscle organ cultures and C2C12 myoblasts/myotubes. Furthermore, glucocorticoids markedly increased the expression of components of the Notch signaling pathway in muscle in vivo, ex vivo, and in vitro. In contrast, glucocorticoids did not increase Notch signaling in bone or bone cells. Moreover, the increased expression of atrophy related genes in muscle, but not in bone, and the decreased myotube diameter induced by glucocorticoids were prevented by inhibiting Notch signaling. Thus, glucocorticoids activate different mechanisms in bone and muscle that upregulate atrophy related genes. However, the role of these genes in the effects of glucocorticoids in bone is unknown. Nevertheless, these findings advance our knowledge of the mechanism of action of glucocorticoids in the musculoskeletal system and provide the basis for novel therapies to prevent glucocorticoid induced atrophy of bone and muscle.
C1 [Sato, Amy Y.; Richardson, Danielle; Cregor, Meloney; Davis, Hannah M.; McAndrews, Kevin; Zimmers, Teresa A.; Organ, Jason M.; Plotkin, Lilian I.; Bellido, Teresita] Indiana Univ Sch Med, Dept Anat & Cell Biol, 635 Barnhill Dr,MS5045A, Indianapolis, IN 46202 USA.
   [Peacock, Munro; Bellido, Teresita] Indiana Univ Sch Med, Dept Med, Div Endocrinol, Indianapolis, IN 46202 USA.
   [Au, Ernie D.; Zimmers, Teresa A.] Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA.
   [McAndrews, Kevin; Zimmers, Teresa A.; Plotkin, Lilian I.; Bellido, Teresita] Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA.
   [Organ, Jason M.] Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.
   [Sato, Amy Y.; Davis, Hannah M.; Au, Ernie D.; Zimmers, Teresa A.; Organ, Jason M.; Peacock, Munro; Plotkin, Lilian I.; Bellido, Teresita] Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; Indiana University
   System; Indiana University Bloomington; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA
   Medical Center; Purdue University System; Purdue University; Purdue
   University in Indianapolis
RP Bellido, T (通讯作者)，Indiana Univ Sch Med, Dept Anat & Cell Biol, 635 Barnhill Dr,MS5045A, Indianapolis, IN 46202 USA.; Bellido, T (通讯作者)，Indiana Univ Sch Med, Div Endocrinol, Dept Internal Med, 635 Barnhill Dr,MS5045A, Indianapolis, IN 46202 USA.
EM tbel lido@iupui.edu
RI ; Organ, Jason/I 1548 2019; Plotkin, Lilian/H 7188 2019; Zimmers,
   Teresa/AAD 5461 2019
OI Zimmers, Teresa/0000 0001 7872 0540; Bellido,
   Teresita/0000 0002 8203 7004; Plotkin, Lilian/0000 0002 9537 4544; Sato,
   Amy/0000 0001 5061 1369; Organ, Jason/0000 0001 8462 0271; Au,
   Ernie/0000 0002 8782 4488
FU National Institutes of Health [R01 AR059357, T32  AR065971]; NHLBI [T35
   HL110854 01]; Department of Veterans Affairs [1 I01 BX002104  01]
FX This research was supported by the National Institutes of Health Grant
   R01 AR059357 to T.B., Grant T32  AR065971 to A.Y.S., and Grant NHLBI T35
   HL110854 01 and the Department of Veterans Affairs Grant 1 I01 BX002104 
   01 to T.B.
CR Almeida M, 2011, J BIOL CHEM, V286, P44326, DOI 10.1074/jbc.M111.283481
   Ambrogini E, 2010, CELL METAB, V11, P136, DOI 10.1016/j.cmet.2009.12.009
   [Anonymous], THESIS
   Baehr LM, 2011, J PHYSIOL LONDON, V589, P4759, DOI 10.1113/jphysiol.2011.212845
   Bivi N, 2012, J BONE MINER RES, V27, P374, DOI 10.1002/jbmr.548
   Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874
   Bonaldo P, 2013, DIS MODEL MECH, V6, P25, DOI 10.1242/dmm.010389
   Bonetto A, 2012, AM J PHYSIOL ENDOC M, V303, pE410, DOI 10.1152/ajpendo.00039.2012
   Buas MF, 2010, J BIOL CHEM, V285, P1249, DOI 10.1074/jbc.M109.046441
   BURKHOLDER TJ, 1994, J MORPHOL, V221, P177, DOI 10.1002/jmor.1052210207
   DEKHUIJZEN PNR, 1995, J APPL PHYSIOL, V78, P629, DOI 10.1152/jappl.1995.78.2.629
   FALDUTO MT, 1990, J APPL PHYSIOL, V69, P1058, DOI 10.1152/jappl.1990.69.3.1058
   Fournier M, 2003, AM J PHYSIOL REG I, V285, pR34, DOI 10.1152/ajpregu.00177.2002
   Furlow JD, 2013, PHYSIOL GENOMICS, V45, P1168, DOI 10.1152/physiolgenomics.00022.2013
   Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198
   Hauge E, 1999, BONE, V25, P389, DOI 10.1016/S8756 3282(99)00194 5
   Kondo H, 2011, J CELL BIOCHEM, V112, P3525, DOI 10.1002/jcb.23327
   KOPAN R, 1994, DEVELOPMENT, V120, P2385
   Lecka Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097 4644(19990901)74:3<357::AID JCB5>3.0.CO;2 7
   Menconi M, 2008, J CELL BIOCHEM, V105, P353, DOI 10.1002/jcb.21833
   Milan G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7670
   Minetto MA, 2010, J CLIN ENDOCR METAB, V95, P1663, DOI 10.1210/jc.2009 2161
   Minetto MA, 2015, MUSCLE NERVE, V52, P631, DOI 10.1002/mus.24572
   Moorwood C, 2013, JOVE J VIS EXP, DOI 10.3791/50036
   Mourikis P, 2012, STEM CELLS, V30, P243, DOI 10.1002/stem.775
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   O'Brien CA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002942
   Organ JM, 2006, J HUM EVOL, V51, P113, DOI 10.1016/j.jhevol.2006.01.007
   Organ JM, 2016, NEPHROL DIAL TRANSPL, V31, P223, DOI 10.1093/ndt/gfv352
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pereira RMR, 2002, J CELL BIOCHEM, V85, P252, DOI 10.1002/jcb.10125
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotnick RoyE., 1989, APPL BOOTSTRAP METHO, P144
   Reid IR, 1997, EUR J ENDOCRINOL, V137, P209, DOI 10.1530/eje.0.1370209
   Rhee Y, 2011, J BONE MINER RES, V26, P1035, DOI 10.1002/jbmr.304
   Rizzoli R, 2012, CALCIFIED TISSUE INT, V91, P225, DOI 10.1007/s00223 012 9630 5
   ROSENBLATT JD, 1992, J APPL PHYSIOL, V73, P2538, DOI 10.1152/jappl.1992.73.6.2538
   Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092 8674(04)00400 3
   Sandri M, 2006, P NATL ACAD SCI USA, V103, P16260, DOI 10.1073/pnas.0607795103
   Sartori R, 2013, NAT GENET, V45, P1309, DOI 10.1038/ng.2772
   Sato AY, 2016, J BONE MINER RES, V31, P1791, DOI 10.1002/jbmr.2869
   Sato AY, 2015, BONE, V73, P60, DOI 10.1016/j.bone.2014.12.012
   Schakman O, 2008, J ENDOCRINOL, V197, P1, DOI 10.1677/JOE 07 0606
   Schakman O, 2013, INT J BIOCHEM CELL B, V45, P2163, DOI 10.1016/j.biocel.2013.05.036
   Shimizu N, 2011, CELL METAB, V13, P170, DOI 10.1016/j.cmet.2011.01.001
   Suzuki Y, 2014, J BONE MINER METAB, V32, P337, DOI 10.1007/s00774 014 0586 6
   Tu XL, 2015, P NATL ACAD SCI USA, V112, pE478, DOI 10.1073/pnas.1409857112
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
   Waning DL, 2015, NAT MED, V21, P1262, DOI 10.1038/nm.3961
   Watson ML, 2012, AM J PHYSIOL ENDOC M, V302, pE1210, DOI 10.1152/ajpendo.00512.2011
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Wen YF, 2012, MOL CELL BIOL, V32, P2300, DOI 10.1128/MCB.06753 11
   Xu J, 2012, INT J PHOTOENERGY, V2012, DOI 10.1155/2012/425735
NR 53
TC 107
Z9 120
U1 2
U2 24
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD MAR
PY 2017
VL 158
IS 3
BP 664
EP 677
DI 10.1210/en.2016 1779
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA EP0VG
UT WOS:000397104200023
PM 28359087
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Chen, FQ
   Xie, L
   Kang, R
   Deng, RR
   Xi, ZP
   Sun, DX
   Zhu, J
   Wang, LM
AF Chen, Fangqing
   Xie, Lin
   Kang, Ran
   Deng, Rongrong
   Xi, Zhipeng
   Sun, Daoxi
   Zhu, Jin
   Wang, Liming
TI Gentiopicroside inhibits RANKL induced osteoclastogenesis by regulating
   NF κB and JNK signaling pathways
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Gentiopicroside; Osteoporosis; RANKL; JNK pathway; NF kappa B pathway
ID BONE RESORPTION; DIFFERENTIATION; ACTIVATION; MICE; INDUCTION; NFATC1;
   INJURY
AB Gentiopicroside, a main active component from the traditional Chinese herb medicine Gentiana manshurica Kitag, has been shown to possess anti arthritis effect. However, the molecular mechanism of gentiopicroside on the osteoclast formation remains unclear. The present study was designed to investigate the effects and mechanisms of gentiopicroside on receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclastogenesis. The results showed that pre treatment with gentiopicroside significantly inhibited RANKL induced osteoclast formation from mouse bone marrow macrophages (BMMs). In addition, we observed that gentiopicroside efficiently suppressed osteoclastogenesis related marker genes expression in RANKL stimulated BMMs. Mechanistically, gentiopicroside suppressed RANKL induced the activation of JNK and NF kappa B signaling pathways in BMMs. Taken together, the present study demonstrated that gentiopicroside inhibits RANKL induced osteoclastogenesis through the inactivation of JNK and NF kappa B signaling pathways. Thus, gentiopicroside may be a promising agent for the treatment of osteoporosis.
C1 [Chen, Fangqing; Wang, Liming] Nanjing Med Univ, Clin Med Coll 3, Nanjing 210029, Jiangsu, Peoples R China.
   [Chen, Fangqing; Xie, Lin; Kang, Ran; Deng, Rongrong; Xi, Zhipeng; Sun, Daoxi] Nanjing Univ Chinese Med, Affiliated Hosp Integrated Tradit Chinese & Weste, Dept Orthoped, Nanjing 210028, Jiangsu, Peoples R China.
   [Zhu, Jin] Nanjing Med Univ, Sch Basic Med, Nanjing 210029, Jiangsu, Peoples R China.
   [Wang, Liming] Nanjing Med Univ, Dept Orthoped, Affiliated Nanjing Hosp, Nanjing 210006, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing University of Chinese Medicine;
   Nanjing Medical University; Nanjing Medical University
RP Zhu, J (通讯作者)，Nanjing Med Univ, Sch Basic Med, Nanjing 210029, Jiangsu, Peoples R China.; Wang, LM (通讯作者)，Nanjing Med Univ, Dept Orthoped, Affiliated Nanjing Hosp, Nanjing 210006, Jiangsu, Peoples R China.; Wang, LM (通讯作者)，Nanjing Med Univ, Clin Med Coll 3, Nanjing 210006, Jiangsu, Peoples R China.
EM zhujinnj@163.com; wang_liming3@126.com
RI Wang, Liming/AAD 7697 2020; XI, ZHIPENG/JCD 4264 2023
CR Ang E, 2011, J CELL BIOCHEM, V112, P89, DOI 10.1002/jcb.22800
   BISKOBING DM, 1995, J BONE MINER RES, V10, P1025
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chaisson ML, 2004, J BIOL CHEM, V279, P54841, DOI 10.1074/jbc.M406392200
   Chang EJ, 2007, J CELL SCI, V120, P166, DOI 10.1242/jcs.03310
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Drake MT, 2015, CLIN THER, V37, P1837, DOI 10.1016/j.clinthera.2015.06.006
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Kim K, 2010, J IMMUNOL, V185, P7460, DOI 10.4049/jimmunol.1000885
   Kobayashi Y, 2009, CRIT REV EUKAR GENE, V19, P61, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.30
   Lee JH, 2010, MOL PHARMACOL, V77, P17, DOI 10.1124/mol.109.057877
   Lee SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080873
   Liu N, 2016, CAN J PHYSIOL PHARM, V94, P769, DOI 10.1139/cjpp 2015 0462
   Lv J, 2015, FITOTERAPIA, V102, P127, DOI 10.1016/j.fitote.2015.03.002
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Saftig P, 2000, ADV EXP MED BIOL, V477, P293
   Shinohara M, 2014, METHODS MOL BIOL, V1164, P171, DOI 10.1007/978 1 4939 0805 9_14
   Srivastava S, 2001, J BIOL CHEM, V276, P8836, DOI 10.1074/jbc.M010764200
   Takahashi N, 2011, FRONT BIOSCI LANDMRK, V16, P21, DOI 10.2741/3673
   Tang XW, 2016, J ETHNOPHARMACOL, V194, P63, DOI 10.1016/j.jep.2016.08.049
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Yamaguchi M, 2014, CURR MOL MED, V14, P783
   Zhao L, 2015, J ETHNOPHARMACOL, V172, P100, DOI 10.1016/j.jep.2015.06.031
NR 25
TC 27
Z9 33
U1 1
U2 26
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD APR
PY 2018
VL 100
BP 142
EP 146
DI 10.1016/j.biopha.2018.02.014
PG 5
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FZ5PZ
UT WOS:000427649200018
PM 29428661
DA 2025 08 17
ER

PT J
AU Jeon, H
   Yu, J
   Hwang, JM
   Park, HW
   Yu, J
   Lee, ZW
   Kim, T
   Rho, J
AF Jeon, Hyoeun
   Yu, Jungeun
   Hwang, Jung Me
   Park, Hye Won
   Yu, Jiyeon
   Lee, Zee Won
   Kim, Taesoo
   Rho, Jaerang
TI 1,3 Dibenzyl 5 Fluorouracil Prevents Ovariectomy Induced Bone Loss by
   Suppressing Osteoclast Differentiation
SO IMMUNE NETWORK
LA English
DT Article
DE Osteoclasts; Osteoclastogenesis; 1,3 Dibenzyl 5 fluorouracil;
   Ovariectomy; Osteoporosis
ID ESTROGEN RECEPTOR MODULATORS; FACTOR 6 TRAF6; GENE EXPRESSION; MINERAL
   DENSITY; NUCLEAR FACTOR; M CSF; PHOSPHORYLATION; ACTIVATOR; PATHWAY;
   OSTEOPETROSIS
AB Osteoclasts (OCs) are clinically important cells that resorb bone matrix. Accelerated bone destruction by OCs is closely linked to the development of metabolic bone diseases. In this study, we screened novel chemical inhibitors targeting OC differentiation to identify drug candidates for metabolic bone diseases. We identified that 1,3 dibenzyl 5 fluorouracil, also named OCI 101, is a novel inhibitor of osteoclastogenesis. The formation of multinucleated OCs is reduced by treatment with OCI 101 in a dose dependent manner. OCI 101 inhibited the expression of OC markers via downregulation of receptor activator of NF .B ligand and M  CSF signaling pathways. Finally, we showed that OCI 101 prevents ovariectomy induced bone loss by suppressing OC differentiation in mice. Hence, these results demonstrated that OCI 101 is a good drug candidate for treating metabolic bone diseases.
C1 [Jeon, Hyoeun; Yu, Jungeun; Park, Hye Won; Yu, Jiyeon; Rho, Jaerang] Chungnam Natl Univ, Dept Microbiol & Mol Biol, 99 Daehak Ro, Daejeon 34134, South Korea.
   [Hwang, Jung Me] Inst Basic Sci, Ctr Genom Integr, Ulsan 44919, South Korea.
   [Lee, Zee Won] bHLBIO, Cheongju 28119, South Korea.
   [Kim, Taesoo] Korea Inst Oriental Med, Herbal Med Res Div, Daejeon 34054, South Korea.
C3 Chungnam National University; Institute for Basic Science   Korea (IBS);
   Korea Institute of Oriental Medicine (KIOM)
RP Rho, J (通讯作者)，Chungnam Natl Univ, Dept Microbiol & Mol Biol, 99 Daehak Ro, Daejeon 34134, South Korea.
EM jrrho@cnu.ac.kr
RI ; Jeon, Hyoeun/KEI 6978 2024
OI Yu, Jungeun/0000 0002 4036 4867; Jeon, hyoeun/0000 0002 2141 6123; Kim,
   Taesoo/0000 0001 7503 9725; Yu, Jiyeon/0000 0001 5368 3093; Park,
   Hye Won/0000 0002 0566 0636; Jung Me, Hwang/0000 0001 7246 4646; 
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Education [NRF2019R1A2C1084311,
   2019M3F6A1109486, 2022R1A2C1004076]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) and was funded
   by the Ministry of Education (NRF2019R1A2C1084311, 2019M3F6A1109486 and
   2022R1A2C1004076).
CR Amarasekara DS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062851
   Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Amarasekara DS, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/832127
   Anastasilakis AD, 2018, EUR J ENDOCRINOL, V179, pR31, DOI 10.1530/EJE 18 0056
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Bone HG, 2008, J CLIN ENDOCR METAB, V93, P2149, DOI 10.1210/jc.2007 2814
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Bradley EW, 2008, J CELL BIOCHEM, V104, P1439, DOI 10.1002/jcb.21719
   Chandran T, 2019, SINGAP MED J, V60, P364, DOI 10.11622/smedj.2019028
   Darnay BG, 2007, ADV EXP MED BIOL, V597, P152
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Ha H, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472 6882 13 112
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Ji Meng Xia, 2015, Chronic Dis Transl Med, V1, P9, DOI 10.1016/j.cdtm.2015.02.006
   Khosla S, 2012, J CLIN ENDOCR METAB, V97, P2272, DOI 10.1210/jc.2012 1027
   Kim B, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10815
   Kim H, 2009, J CLIN INVEST, V119, P813, DOI 10.1172/JCI36809
   Kim N, 2002, J EXP MED, V195, P201, DOI 10.1084/jem.20011681
   Kim T, 2010, BIOCHEM BIOPH RES CO, V403, P73, DOI 10.1016/j.bbrc.2010.10.117
   Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Lorentzon M, 2019, J INTERN MED, V285, P381, DOI 10.1111/joim.12873
   Ma S, 2017, SCI REP UK, V7, DOI 10.1038/srep43399
   Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Meissner JD, 2011, NUCLEIC ACIDS RES, V39, P5907, DOI 10.1093/nar/gkr162
   Migliaccio S, 2007, CLIN INTERV AGING, V2, P55, DOI 10.2147/ciia.2007.2.1.55
   Nakamura H, 2003, J BONE MINER RES, V18, P1198, DOI 10.1359/jbmr.2003.18.7.1198
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Pfeilschifter J, 2001, ORTHOPADE, V30, P462, DOI 10.1007/s001320170079
   Rho J, 2002, DNA CELL BIOL, V21, P541, DOI 10.1089/104454902320308915
   Riggs BL, 2000, J CLIN INVEST, V106, P1203, DOI 10.1172/JCI11468
   Ross FP, 2006, ANN NY ACAD SCI, V1068, P110, DOI 10.1196/annals.1346.014
   Shin B, 2014, J BIOL CHEM, V289, P35868, DOI 10.1074/jbc.M114.589614
   Sundaram K, 2007, EXP CELL RES, V313, P168, DOI 10.1016/j.yexcr.2006.10.001
   Wagner EF, 2003, ANN RHEUM DIS, V62, P83, DOI 10.1136/ard.62.suppl_2.ii83
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Wu JQ, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018 018 0865 3
   Xing LP, 2002, J BONE MINER RES, V17, P1200, DOI 10.1359/jbmr.2002.17.7.1200
   Yamamoto M, 2021, P JPN ACAD B PHYS, V97, P145, DOI 10.2183/pjab.97.009
   Yu J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042097
   Yu J, 2016, J BIOL CHEM, V291, P20643, DOI 10.1074/jbc.M116.728303
   Zhang N, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00325
   Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097 2765(00)80066 0
NR 49
TC 0
Z9 0
U1 0
U2 0
PU KOREA ASSOC IMMUNOLOGISTS
PI SEOUL
PA KOREA SCIENCE & TECHNOLOGY CENTER, RM 701, 7 GIL 22, TEHERAN RO, (635 4
   YEOKSAM DONG) GANGMAN GU, SEOUL, 06130, SOUTH KOREA
SN 1598 2629
EI 2092 6685
J9 IMMUNE NETW
PD OCT
PY 2022
VL 22
IS 5
AR e43
DI 10.4110/in.2022.22.e43
PG 12
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA 8O6JZ
UT WOS:000925942500007
PM 36381956
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, ZY
   Li, ZJ
   Wang, GJ
   Sun, Y
   Yuan, YY
   Nie, H
AF Wang, Ziyu
   Li, Zijian
   Wang, Guojue
   Sun, Ying
   Yuan, Yuanyang
   Nie, Hong
TI Salubrinal Alleviates Collagen Induced Arthritis through Promoting P65
   Degradation in Osteoclastogenesis
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE Salubrinal; collagen induced arthritis; osteoclast; NF &#954; B
   signaling pathway; P65
AB Rheumatoid arthritis (RA) is a complex systemic autoimmune disorder that primarily involves joints, further affects the life quality of patients, and has increased mortality. The pathogenesis of RA involves multiple pathways, resulting in some patients showing resistance to the existing drugs. Salubrinal is a small molecule compound that has recently been shown to exert multiple beneficial effects on bone tissue. However, the effect of Salubrinal in RA has not been clearly confirmed. Hence, we induced collagen induced arthritis (CIA) in DBA/1J mice and found that Salubrinal treatment decreased the clinical score of CIA mice, inhibiting joint damage and bone destruction. Furthermore, Salubrinal treatment downregulated osteoclast number in knee joint of CIA in mice, and suppressed bone marrow derived osteoclast formation and function, downregulated osteoclast related gene expression. Moreover, Salubrinal treatment inhibited RANKL induced NF kappa B signaling pathway, and promoted P65 degradation through the ubiquitin proteasome system, further restrained RANKL induced osteoclastogenesis. This study explains the mechanism by which Salubrinal ameliorates arthritis of CIA in mice, indicating that Salubrinal may be a potential drug for RA, and expands the potential uses of Salubrinal in the treatment of bone destruction related diseases.
C1 [Wang, Ziyu; Li, Zijian; Wang, Guojue; Sun, Ying; Yuan, Yuanyang; Nie, Hong] Shanghai Jiao Tong Univ, Shanghai Inst Immunol, Dept Immunol & Microbiol, Sch Med, Shanghai 200025, Peoples R China.
C3 Shanghai Jiao Tong University; Chinese Academy of Sciences
RP Yuan, YY; Nie, H (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Inst Immunol, Dept Immunol & Microbiol, Sch Med, Shanghai 200025, Peoples R China.
EM ziyuwang@sjtu.edu.cn; lizijian0706@163.com; gjwang0422@sjtu.edu.cn;
   sunyingying@sjtu.edu.cn; yuanyangy@sjtu.edu.cn; hine@sjtu.edu.cn
OI Sun, Ying/0000 0002 4947 9783
FU National Natural Science Foundation of China [81671590]; National Key
   R&D Program of China [2019YFA0111000]; Shanghai Science and Technology
   Committee [20ZR1448900]; Shanghai Municipal Health Commission
   [202040121]; Innovative research team of high level local universities
   in Shanghai
FX This work was supported by grants from National Natural Science
   Foundation of China (No. 81671590), National Key R&D Program of China
   (2019YFA0111000), Shanghai Science and Technology Committee
   (20ZR1448900), Shanghai Municipal Health Commission (202040121) and
   Innovative research team of high level local universities in Shanghai.
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Buch MH, 2018, ANN RHEUM DIS, V77, P966, DOI 10.1136/annrheumdis 2017 212862
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Giridharan S, 2018, J INFLAMM RES, V11, P407, DOI 10.2147/JIR.S140188
   Grey A, 2000, ENDOCRINOLOGY, V141, P2129, DOI 10.1210/en.141.6.2129
   Hamamura K, 2015, BONE JOINT RES, V4, P84, DOI 10.1302/2046 3758.45.2000378
   Hamamura K., 2015, RECEPT CLIN INVESTIG, V2, P2
   Hamamura K, 2015, CELL SIGNAL, V27, P828, DOI 10.1016/j.cellsig.2015.01.010
   Hamamura K, 2015, CELL SIGNAL, V27, P353, DOI 10.1016/j.cellsig.2014.11.020
   Hamamura K, 2013, J BONE MINER METAB, V31, P618, DOI 10.1007/s00774 013 0450 0
   Hayman AR, 2008, AUTOIMMUNITY, V41, P218, DOI 10.1080/08916930701694667
   Insogna KL, 1997, J CLIN INVEST, V100, P2476, DOI 10.1172/JCI119790
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Kerrigan SA, 2020, NAT REV RHEUMATOL, V16, P179, DOI 10.1038/s41584 020 0375 7
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lin TH, 2017, ADV PROTEIN CHEM STR, V107, P117, DOI 10.1016/bs.apcsb.2016.11.002
   Massalska M, 2020, CELLS BASEL, V9, DOI 10.3390/cells9081876
   Matsuoka M, 2015, INT J MOL SCI, V16, P16275, DOI 10.3390/ijms160716275
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Park JH, 2017, MOL CELLS, V40, P706
   Raynaud Messina B, 2019, BONE, V127, P315, DOI 10.1016/j.bone.2019.06.023
   RODNAN GP, 1970, ARTHRITIS RHEUM US, V13, P145, DOI 10.1002/art.1780130207
   Saccani S, 2004, J EXP MED, V200, P107, DOI 10.1084/jem.20040196
   Schwartz DM, 2017, NAT REV DRUG DISCOV, V16, P843, DOI 10.1038/nrd.2017.201
   Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140 6736(16)30173 8
   Steffen U, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01483
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
NR 32
TC 7
Z9 9
U1 0
U2 10
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD APR
PY 2021
VL 22
IS 7
AR 3501
DI 10.3390/ijms22073501
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA RK9OJ
UT WOS:000638615800001
PM 33800699
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Huang, R
   Liao, XW
   Wang, XK
   Li, QC
AF Huang, Rui
   Liao, Xiwen
   Wang, Xiangkun
   Li, Qiaochuan
TI Comprehensive investigation of the clinical significance of long
   non coding RNA HOXA AS2 in acute myeloid leukemia using genome wide RNA
   sequencing dataset
SO JOURNAL OF CANCER
LA English
DT Article
DE HOXA AS2; acute myeloid leukemia; The Cancer Genome Atlas; molecular
   mechanism; drug prediction
ID FALSE DISCOVERY RATE; MEGESTROL ACETATE; GENE EXPRESSION; INTERACTION
   NETWORKS; LNCRNA HOXA AS2; CONNECTIVITY MAP; PROLIFERATION; CANCER;
   CARMUSTINE; CELLS
AB Objective: The present study aimed to determine the prognostic value of HOXA cluster antisense RNA2 (HOXA AS2) in acute myeloid leukemia (AML), and to explore its potential molecular mechanisms. We also screening of potential drugs targeting HOXA AS2 in AML.
   Methods: The level 3 raw genome wide RNA sequencing dataset of AML was download from The Cancer Genome Atlas (TCGA) Data Portal, and the potential molecular mechanisms and drugs prediction of HOXA AS2 in AML were explored using multiple bioinformatics analysis approaches.
   Results: TCGA AML cohort dataset indicated that HOXA AS2 was significantly up regulated in AML bone marrow tissues, and high HOXA AS2 expression was related to poor overall survival (log rank P=0.0284, hazard ratio 1.640, 95% confidence interval 1.046 2.573). Functional enrichment of differentially expressed genes (DEGs) suggested that the difference in prognosis between AML patients with high  and low HOXA AS2 expression may be due to differences in biological processes and pathways, including cell adhesion, angiogenesis, mitogen activated protein kinase, cell differentiation, and other biological processes, and phosphatidylinositol 3 kinase protein kinase B and Wnt signaling pathways. We also screened out three potential HOXA AS2 targeted therapeutic drugs for AML, megestrol, carmustine, and cefoxitin, based on these DEGs. Functional enrichment analysis of HOXA AS2 co expressed genes revealed that HOXA AS2 may act a part in AML by regulating nuclear factor KB transcription factor activity, DNA methylation, angiogenesis, apoptosis, cell migration, Toll like receptor 4, and Wnt signaling pathways.
   Conclusion: Our findings suggest that HOXA AS2 is up regulated in the bone marrow in patients with AML, and may serve as a novel prognostic biomarker for AML.
C1 [Huang, Rui; Li, Qiaochuan] Guangxi Med Univ, Dept Hematol, Affiliated Hosp 1, Shuang Yong Rd 6, Nanning 530021, Guangxi Zhuang, Peoples R China.
   [Liao, Xiwen; Wang, Xiangkun] Guangxi Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Nanning 530021, Guangxi Zhuang, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University
RP Li, QC (通讯作者)，Guangxi Med Univ, Dept Hematol, Affiliated Hosp 1, Shuang Yong Rd 6, Nanning 530021, Guangxi Zhuang, Peoples R China.
EM liqiaochuart@gxmu.edu.cn
RI Wang, Xiang Kun/HNQ 5335 2023
FU National Natural Science Foundation of China [81160075]; Natural Science
   Foundation of Guangxi [0728124]; Self raised Scientific Research Fund of
   the Ministry of Health of Guangxi Province [Z2014035]
FX This work was supported in part by the National Natural Science
   Foundation of China (No.81160075); Natural Science Foundation of Guangxi
   (No.0728124); Self raised Scientific Research Fund of the Ministry of
   Health of Guangxi Province (Z2014035). The authors thank the
   contributors of The Cancer Genome Atlas (https://portal.gdc.cancer.gov/)
   for their contribution to share the AML dataset on open access. In
   addition, we also would like to acknowledge the helpful comments on this
   paper received from reviewers.
CR Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood 2016 03 643544
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Collichio FA, 1998, AM J CLIN ONCOL CANC, V21, P209, DOI 10.1097/00000421 199804000 00024
   Coombs CC, 2016, NAT REV CLIN ONCOL, V13, P305, DOI 10.1038/nrclinonc.2015.210
   De Kouchkovsky I, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.50
   Ding J, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2016.84
   Dong XY, 2018, CELL PHYSIOL BIOCHEM, V51, P886, DOI 10.1159/000495387
   Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140 6736(06)69780 8
   Ewend MG, 2007, CLIN CANCER RES, V13, P3637, DOI 10.1158/1078 0432.CCR 06 2095
   Fang Y, 2017, ONCOTARGET, V8, P46090, DOI 10.18632/oncotarget.17552
   Gao Yana, 2018, Cell Physiol Biochem, V45, P131, DOI 10.1159/000486253
   HAHN RG, 1979, CANCER TREAT REP, V63, P513
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang R, 2019, ONCOL REP, V41, P2876, DOI 10.3892/or.2019.7075
   Huang R, 2017, ONCOTARGETS THER, V10, P5243, DOI 10.2147/OTT.S147717
   Jacot W, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 257
   Jatoi A, 2002, J CLIN ONCOL, V20, P567, DOI 10.1200/JCO.20.2.567
   Jiang LF, 2019, HUM GENE THER, V30, P618, DOI 10.1089/hum.2018.109
   Jiao XL, 2012, BIOINFORMATICS, V28, P1805, DOI 10.1093/bioinformatics/bts251
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Kouchaki B, 2018, SUPPORT CARE CANCER, V26, P2479, DOI 10.1007/s00520 018 4047 y
   Kuhn M, 2008, NUCLEIC ACIDS RES, V36, pD684, DOI 10.1093/nar/gkm795
   Kuo YC, 2019, MAT SCI ENG C MATER, V96, P114, DOI 10.1016/j.msec.2018.10.094
   Lamb J, 2007, NAT REV CANCER, V7, P54, DOI 10.1038/nrc2044
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689
   Li Q, 2016, NEOPLASMA, V63, P977, DOI 10.4149/neo_2016_617
   Lian YF, 2017, AM J TRANSL RES, V9, P5496
   Liao XW, 2018, CELL PHYSIOL BIOCHEM, V48, P1854, DOI 10.1159/000492507
   Liao XW, 2018, J CANCER, V9, P2357, DOI 10.7150/jca.25221
   Liao XW, 2017, ONCOTARGETS THER, V10, P4493, DOI 10.2147/OTT.S142557
   Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551
   Mostafavi S, 2008, GENOME BIOL, V9, DOI 10.1186/gb 2008 9 s1 s4
   Nabissi M, 2015, INT J CANCER, V137, P1855, DOI 10.1002/ijc.29573
   Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192
   Pautier P, 2017, INT J GYNECOL CANCER, V27, P258, DOI 10.1097/IGC.0000000000000862
   Prada Arismendy J, 2017, BLOOD REV, V31, P63, DOI 10.1016/j.blre.2016.08.005
   Raguz S, 2013, BIOCHEM PHARMACOL, V85, P186, DOI 10.1016/j.bcp.2012.10.020
   Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Sakellari I, 2019, BONE MARROW TRANSPL, V54, P921, DOI 10.1038/s41409 018 0395 y
   Shields CED, 2016, J INFECT DIS, V214, P122, DOI 10.1093/infdis/jiw069
   Short NJ, 2018, LANCET, V392, P593, DOI 10.1016/S0140 6736(18)31041 9
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Szklarczyk D, 2016, NUCLEIC ACIDS RES, V44, pD380, DOI 10.1093/nar/gkv1277
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247
   Tong GL, 2017, AM J TRANSL RES, V9, P4545
   von Mering C, 2005, NUCLEIC ACIDS RES, V33, pD433, DOI 10.1093/nar/gki005
   Voravud Narin, 2000, Journal of the Medical Association of Thailand, V83, P123
   Wais V, 2018, BONE MARROW TRANSPL, V53, P94, DOI 10.1038/bmt.2017.211
   Wang F, 2019, EXP CELL RES, V375, P1, DOI 10.1016/j.yexcr.2018.11.005
   Wang FQ, 2016, CELL PHYSIOL BIOCHEM, V40, P287, DOI 10.1159/000452545
   Wang JC, 2018, CLIN CHIM ACTA, V485, P229, DOI 10.1016/j.cca.2018.07.004
   Wang YL, 2009, NUCLEIC ACIDS RES, V37, pW623, DOI 10.1093/nar/gkp456
   Wang YH, 2018, CELL CYCLE, V17, P1637, DOI 10.1080/15384101.2018.1489174
   Warde Farley D, 2010, NUCLEIC ACIDS RES, V38, pW214, DOI 10.1093/nar/gkq537
   Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764
   Wheeler C, 2001, LEUKEMIA LYMPHOMA, V40, P499, DOI 10.3109/10428190109097649
   Wu J, 2019, J CELL BIOCHEM, V120, P14465, DOI 10.1002/jcb.28706
   Xia FD, 2018, CELL PHYSIOL BIOCHEM, V50, P1659, DOI 10.1159/000494786
   Xie M, 2015, ONCOTARGET, V6, P33587, DOI 10.18632/oncotarget.5599
   Yoav Benjamini Yoav Benjamini, 2001, Behavioural Brain Research, V125, P279, DOI 10.1016/S0166 4328(01)00297 2
   Zhang P, 2017, ONCOTARGET, V8, P33137, DOI 10.18632/oncotarget.16561
   Zhang Y, 2018, CELL PHYSIOL BIOCHEM, V50, P2124, DOI 10.1159/000495056
   Zhao QJ, 2019, BIOMED PHARMACOTHER, V109, P1640, DOI 10.1016/j.biopha.2018.10.046
   Zhong ZR, 2012, PHARM RES DORDR, V29, P145, DOI 10.1007/s11095 011 0521 7
   Zhu XX, 2019, J CELL MOL MED, V23, P1325, DOI 10.1111/jcmm.14034
   Zhu XX, 2019, ATHEROSCLEROSIS, V281, P38, DOI 10.1016/j.atherosclerosis.2018.12.012
NR 70
TC 7
Z9 8
U1 0
U2 3
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1837 9664
J9 J CANCER
JI J. Cancer
PY 2021
VL 12
IS 7
BP 2151
EP 2164
DI 10.7150/jca.48045
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA QO3UN
UT WOS:000623069400030
PM 33754013
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ebeling, PR
AF Ebeling, Peter R.
TI Androgens and osteoporosis
SO CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY
LA English
DT Article
DE bone modeling; bone remodelling; oestradiol; osteoporosis in men;
   testosterone
ID BONE MINERAL DENSITY; HORMONE BINDING GLOBULIN; IDIOPATHIC
   HYPOGONADOTROPIC HYPOGONADISM; ENDOGENOUS SEX HORMONES; ELDERLY MEN;
   OLDER MEN; VERTEBRAL FRACTURES; FREE TESTOSTERONE; HIP FRACTURE;
   EXOGENOUS TESTOSTERONE
AB Purpose of review
   The review is timely given recent advances regarding mechanisms of androgen action on bone cells and in humans. Osteoporosis in men is an important public health problem. An improved understanding of the role of androgens in the pathophysiology of bone loss will lead to new treatments.
   Recent findings
   Androgen receptors are present in most bone cells. Testosterone acts on bone both directly via the androgen receptor and indirectly, following aromatization, via the oestrogen receptor. During skeletal modelling, ER alpha is critical for longitudinal bone growth. For periosteal growth and bone expansion, androgen receptor activation has a positive effect, whereas ER alpha activation is inhibitory. During skeletal remodelling, both receptor pathways generate similar and additive effects on bone. Androgen deficiency is a common secondary cause of osteoporosis in men and should be treated with testosterone, particularly in symptomatic men. However, lack of efficacy data for testosterone in osteoporosis means it is less useful as a first line treatment in men with age related declines in testosterone and osteoporosis, when other agents such as bisphosphonates and parathyroid hormone are effective.
   Summary
   Randomized, placebo controlled trials of testosterone therapy in men with age related declines in testosterone and osteoporosis are needed, and should carefully evaluate potential risks, as well as its efficacy in reducing fractures and other health benefits.
C1 [Ebeling, Peter R.] Univ Melbourne, Western Hosp, Dept Med RMH WH, Footscray, Vic, Australia.
   [Ebeling, Peter R.] Univ Melbourne, Western Hosp, Dept Endocrinol, Footscray, Vic, Australia.
C3 University of Melbourne; Western Health; Western Hospital; Western
   Health; Western Hospital; University of Melbourne
RP Ebeling, PR (通讯作者)，Western Hosp, Dept Med RMH WH & Endocrinol, Gordon St, Footscray, Vic 3011, Australia.
EM peterre@unimelb.edu.au
RI ; Ebeling, Peter/A 9129 2012
OI Ebeling, Peter/0000 0002 2921 3742; 
FU Novartis; Amgen; Servier; Merck; University of Melbourne; National
   Health and Medical Research Council of Australia
FX Dr Ebeling reports having received honoraria from Merck, Amgen, GSK and
   Eli Lilly, and having received research funding from Novartis, Amgen,
   Servier and Merck. Funded by The University of Melbourne and, in part,
   by National Health and Medical Research Council of Australia.
CR ABBASI AA, 1995, AM J MED SCI, V310, P229
   Abu EO, 1997, J CLIN ENDOCR METAB, V82, P3493, DOI 10.1210/jcem.82.10.4319
   Amin S, 2006, AM J MED, V119, P426, DOI 10.1016/j.amjmed.2005.10.048
   Aminorroaya A, 2005, EUR J ENDOCRINOL, V152, P881, DOI 10.1530/eje.1.01920
   Amory JK, 2004, J CLIN ENDOCR METAB, V89, P503, DOI 10.1210/jc.2003 031110
   Anderson FH, 1997, J BONE MINER RES, V12, P472, DOI 10.1359/jbmr.1997.12.3.472
   Anderson FH, 1996, BONE, V18, P171, DOI 10.1016/8756 3282(95)00441 6
   Arts J, 1997, ENDOCRINOLOGY, V138, P5067, DOI 10.1210/en.138.11.5067
   BAILLIE SP, 1992, AGE AGEING, V21, P139, DOI 10.1093/ageing/21.2.139
   Barrett Connor E, 2000, J CLIN ENDOCR METAB, V85, P219, DOI 10.1210/jc.85.1.219
   Behre HM, 1997, J CLIN ENDOCR METAB, V82, P2386, DOI 10.1210/jc.82.8.2386
   Benito M, 2005, J BONE MINER RES, V20, P1785, DOI 10.1359/JBMR.050606
   Bertelloni S, 1998, HORM RES, V50, P309, DOI 10.1159/000023296
   Bjornerem Å, 2007, EUR J ENDOCRINOL, V157, P119, DOI 10.1530/EJE 07 0032
   Bliuc D, 2009, JAMA J AM MED ASSOC, V301, P513, DOI 10.1001/jama.2009.50
   Burnett Bowie SAM, 2009, J CLIN ENDOCR METAB, V94, P4785, DOI 10.1210/jc.2009 0739
   CALLEWAERT F, 2009, TRENDS ENDOCRINOL ME
   Chang KP, 2004, J BONE MINER RES, V19, P532, DOI 10.1359/JBMR.040109
   Chiang C, 2009, J BONE MINER RES, V24, P621, DOI [10.1359/jbmr.081217, 10.1359/JBMR.081217]
   Clarke BL, 1996, J CLIN ENDOCR METAB, V81, P2264, DOI 10.1210/jc.81.6.2264
   COOPER C, 1992, J BONE MINER RES, V7, P221, DOI 10.1002/jbmr.5650070214
   Ebeling PR, 2008, NEW ENGL J MED, V358, P1474, DOI 10.1056/NEJMcp0707217
   Ebeling PR, 1998, DRUG AGING, V13, P421, DOI 10.2165/00002512 199813060 00002
   Erbas B, 2007, CLIN ENDOCRINOL, V66, P78, DOI 10.1111/j.1365 2265.2006.02690.x
   Falahati Nini A, 2000, J CLIN INVEST, V106, P1553, DOI 10.1172/JCI10942
   Fink HA, 2006, J CLIN ENDOCR METAB, V91, P3908, DOI 10.1210/jc.2006 0173
   FINKELSTEIN JS, 1987, ANN INTERN MED, V106, P354, DOI 10.7326/0003 4819 106 3
   Finkelstein JS, 1996, J CLIN ENDOCR METAB, V81, P1152, DOI 10.1210/jc.81.3.1152
   FINKELSTEIN JS, 1989, J CLIN ENDOCR METAB, V69, P776, DOI 10.1210/jcem 69 4 776
   FINKELSTEIN JS, 1992, NEW ENGL J MED, V326, P600, DOI 10.1056/NEJM199202273260904
   Goderie Plomp HW, 2004, J CLIN ENDOCR METAB, V89, P3261, DOI 10.1210/jc.2002 022041
   Greendale GA, 1997, J BONE MINER RES, V12, P1833, DOI 10.1359/jbmr.1997.12.11.1833
   Huber DM, 2001, ENDOCRINOLOGY, V142, P3800, DOI 10.1210/en.142.9.3800
   Jiang HX, 2005, J BONE MINER RES, V20, P494, DOI 10.1359/JBMR.041133
   Jones G, 1996, OSTEOPOROSIS INT, V6, P233, DOI 10.1007/BF01622740
   Kasperk C, 1997, CALCIFIED TISSUE INT, V61, P464, DOI 10.1007/s002239900369
   Kaufman JM, 2005, OSTEOPOROSIS INT, V16, P510, DOI 10.1007/s00198 004 1713 3
   Khosla S, 2006, J BONE MINER RES, V21, P124, DOI 10.1359/JBMR.050916
   KHOSLA S, 1994, BONE, V15, P551, DOI 10.1016/8756 3282(94)90280 1
   Khosla S, 2001, J CLIN ENDOCR METAB, V86, P3555, DOI 10.1210/jc.86.8.3555
   Khosla S, 1998, J CLIN ENDOCR METAB, V83, P2266, DOI 10.1210/jc.83.7.2266
   LeBlanc ES, 2009, J CLIN ENDOCR METAB, V94, P3337, DOI 10.1210/jc.2009 0206
   Leder BZ, 2003, J CLIN ENDOCR METAB, V88, P204, DOI 10.1210/jc.2002 021036
   Leifke E, 1998, EUR J ENDOCRINOL, V138, P51, DOI 10.1530/eje.0.1380051
   Looker AC, 2008, J BONE MINER RES, V23, P143, DOI [10.1359/jbmr.071003, 10.1359/JBMR.071003]
   Lorentzon M, 2005, J BONE MINER RES, V20, P1334, DOI 10.1359/JBMR.050404
   Meier C, 2008, ARCH INTERN MED, V168, P47, DOI 10.1001/archinternmed.2007.2
   Mellström D, 2008, J BONE MINER RES, V23, P1552, DOI 10.1359/JBMR.080518
   Mellström D, 2006, J BONE MINER RES, V21, P529, DOI 10.1359/JBMR.060110
   MORISHIMA A, 1995, J CLIN ENDOCR METAB, V80, P3689, DOI 10.1210/jc.80.12.3689
   MUNOZTORRES M, 1995, CALCIFIED TISSUE INT, V57, P94, DOI 10.1007/BF00298426
   Notini AJ, 2005, J MOL ENDOCRINOL, V35, P547, DOI 10.1677/jme.1.01884
   ONeill TW, 1996, J BONE MINER RES, V11, P1010
   Onoe Y, 1997, ENDOCRINOLOGY, V138, P4509, DOI 10.1210/en.138.10.4509
   Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9
   Orwoll E, 2006, J CLIN ENDOCR METAB, V91, P1336, DOI 10.1210/jc.2005 1830
   Orwoll E, 2000, NEW ENGL J MED, V343, P604, DOI 10.1056/NEJM200008313430902
   Page ST, 2005, J CLIN ENDOCR METAB, V90, P1502, DOI 10.1210/jc.2004 1933
   Pederson L, 1999, P NATL ACAD SCI USA, V96, P505, DOI 10.1073/pnas.96.2.505
   Riggs B L., 2007, J Bone Miner Res
   Ringe JD, 2006, RHEUMATOL INT, V26, P427, DOI 10.1007/s00296 005 0004 4
   Sartorius G, 2009, ANN CLIN BIOCHEM, V46, P137, DOI 10.1258/acb.2008.008171
   Seeman E, 2006, OSTEOPOROSIS INT, V17, P1577, DOI 10.1007/s00198 006 0160 8
   Sims NA, 2006, AM J PHYSIOL ENDOC M, V290, pE456, DOI 10.1152/ajpendo.00311.2005
   SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Snyder PJ, 1999, J CLIN ENDOCR METAB, V84, P1966, DOI 10.1210/jc.84.6.1966
   STANLEY HL, 1991, J AM GERIATR SOC, V39, P766, DOI 10.1111/j.1532 5415.1991.tb02698.x
   Szulc P, 2001, CALCIFIED TISSUE INT, V69, P229, DOI 10.1007/s00223 001 1059 1
   Tang BMP, 2007, LANCET, V370, P657, DOI 10.1016/S0140 6736(07)61342 7
   TURNER RT, 1990, J ORTHOP RES, V8, P612, DOI 10.1002/jor.1100080418
   Vandenput L, 2002, J BONE MINER RES, V17, P2080, DOI 10.1359/jbmr.2002.17.11.2080
   Vandenput L, 2002, CALCIFIED TISSUE INT, V70, P170, DOI 10.1007/s00223 001 2065 z
   Vanderschueren D, 2006, J CLIN ENDOCR METAB, V91, P378, DOI 10.1210/jc.2005 1766
   Vanderschueren D, 2004, ENDOCR REV, V25, P389, DOI 10.1210/er.2003 0003
   Vieth R, 2001, AM J CLIN NUTR, V73, P288
NR 76
TC 24
Z9 29
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1752 296X
EI 1752 2978
J9 CURR OPIN ENDOCRINOL
JI Curr. Opin. Endocrinol. Diabetes Obes.
PD JUN
PY 2010
VL 17
IS 3
BP 284
EP 292
DI 10.1097/MED.0b013e328339658c
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 691EL
UT WOS:000285063000016
PM 20375885
DA 2025 08 17
ER

PT J
AU Shang, YC
   Zhang, C
   Wang, SH
   Xiong, F
   Zhao, CP
   Pengi, FN
   Fengi, SW
   Yu, MJ
   Li, MS
   Zhang, YN
   Li, Y
AF Shang, Y. C.
   Zhang, C.
   Wang, S. H.
   Xiong, F.
   Zhao, C. P.
   Pengi, F. N.
   Fengi, S. W.
   Yu, M. J.
   Li, M. S.
   Zhang, Y. N.
   Li, Y.
TI Activated β catenin induces myogenesis and inhibits adipogenesis in
   BM derived mesenchymal stromal cells
SO CYTOTHERAPY
LA English
DT Article
DE adipogenic differentiation; beta catenin; mesenchymal stromal cells;
   myogenic differentiation; Wnt
ID STEM CELLS; SKELETAL MUSCLE; OSTEOBLAST DIFFERENTIATION; PARAXIAL
   MESODERM; PATHWAYS; PROLIFERATION; SPECIFICATION; DYSTROPHIN; RECEPTORS;
   THERAPIES
AB Background
   Mesenchymal stromal cells (MSC) have been thought to be attractive candidates for the treatment of degenerative muscle diseases. However, little is known about the molecular mechanisms governing the myogenic differentiation in MSC. As the Wnt signaling pathway has been associated with myogenesis in embryogenesis and post natal muscle regeneration, we hypothesized that the Wnt signaling pathway may be involved in governing the myogenic differentiation in MSC.
   Methods
   Primary MSC were isolated from Sprague Dawley rats and expanded in proliferation medium. The rMSC were transfected with a constitutively active h beta catenin (S37A) plasmid or control vector by Lipofectamine followed by G418 selection. The transfected rMSC were grown to 80% confluence and then cultured in myogenic or adipogenic differentiation medium. Cells were characterized by light microscopy, immunofluorescence and RT PCR at different time points after myogenic or adipogenic introduction.
   Results
   Ectopic expression of activated beta catenin located primarily in the nucleus and activated transcription in rMSC. Overexpression of stabilized beta catenin induced 27.1 +/  3.91 % rMSC forming long multinucleated cells expressing MyoD), myogenin, desmin and myosin heavy chain (MHC via evoking the expression of skeletal muscle specific transcription factors. In addition, overexpression of activated beta catenin inhibited the adipogenic differentiation in rMSC through down regulated expressions of C/EBP alpha and PPAR gamma.
   Discussion
   To our knowledge, this is the first evidence that activated beta catenin can induce myogenic differentiation in rMSC. The ability of stabilized beta catenin to induce myogenic differentiation in rMSC may allow for its therapeutic application.
RP Zhang, C (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 1, Dept Neurol, Guangzhou 510080, Peoples R China.
EM zhangch6@inail.sysu.edu.cn
RI Shang, Chang/IUM 4429 2023; Li, miaosheng/AAI 5732 2021; Shang,
   Yanchang/B 2910 2008
OI shang, yanchang/0000 0003 3285 6746; 
CR Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797
   Armand AS, 2005, J CELL PHYSIOL, V204, P297, DOI 10.1002/jcp.20302
   Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006 291X(02)02951 0
   Bedada FB, 2005, MOL CELL BIOL, V25, P9509, DOI 10.1128/MCB.25.21.9509 9519.2005
   Bhagavati S, 2005, BIOCHEM BIOPH RES CO, V333, P644, DOI 10.1016/j.bbrc.2005.05.135
   Borello U, 1999, DEVELOPMENT, V126, P4247
   Chakkalakal JV, 2005, FASEB J, V19, P880, DOI 10.1096/fj.04 1956rev
   Christodoulides C, 2006, J CELL SCI, V119, P2613, DOI 10.1242/jcs.02975
   Cossu G, 2000, J CLIN INVEST, V105, P1669, DOI 10.1172/JCI10376
   De Bari C, 2003, J CELL BIOL, V160, P909, DOI 10.1083/jcb.200212064
   De Boer J, 2004, TISSUE ENG, V10, P393, DOI 10.1089/107632704323061753
   Dezawa M, 2005, SCIENCE, V309, P314, DOI 10.1126/science.1110364
   FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267
   Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200
   Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood 2003 05 1664
   HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327
   Hyatt JPK, 2003, AM J PHYSIOL CELL PH, V285, pC1161, DOI 10.1152/ajpcell.00128.2003
   Ikeya M, 1998, DEVELOPMENT, V125, P4969
   Jian HY, 2006, GENE DEV, V20, P666, DOI 10.1101/gad.1388806
   Kléber M, 2004, CURR OPIN CELL BIOL, V16, P681, DOI 10.1016/j.ceb.2004.08.006
   Le Blanc K, 2005, CYTOTHERAPY, V7, P36, DOI 10.1080/14653240510018118
   Lee JM, 2006, NEUROLOGY, V66, P6, DOI 10.1212/01.wnl.0000196863.43951.44
   Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129
   Luo JY, 2007, LAB INVEST, V87, P97, DOI 10.1038/labinvest.3700509
   Mbalaviele G, 2005, J CELL BIOCHEM, V94, P403, DOI 10.1002/jcb.20253
   Moon Randall T, 2004, Nat Rev Genet, V5, P691, DOI 10.1038/nrg1427
   MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911
   Neth P, 2006, STEM CELLS, V24, P1892, DOI 10.1634/stemcells.2005 0503
   Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283
   Parker MH, 2003, NAT REV GENET, V4, P497, DOI 10.1038/nrg1109
   Payne TR, 2005, GENE THER, V12, P1264, DOI 10.1038/sj.gt.3302521
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092 8674(03)00437 9
   Price FD, 2007, BBA MOL BASIS DIS, V1772, P272, DOI 10.1016/j.bbadis.2006.08.011
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Reyes M, 2001, BLOOD, V98, P2615, DOI 10.1182/blood.V98.9.2615
   ROSS SE, 2000, SCIENCE, V289, P950, DOI DOI 10.1126/SCIENCE.289.5481.950
   Ryu JH, 2002, DEVELOPMENT, V129, P5541, DOI 10.1242/dev.00110
   Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092 8674(00)00066 0
   Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200
   Tajbakhsh S, 1998, DEVELOPMENT, V125, P4155
   Torrente Y, 2001, J CELL BIOL, V152, P335, DOI 10.1083/jcb.152.2.335
   Vertino AM, 2005, MOL BIOL CELL, V16, P2039, DOI 10.1091/mbc.E04 08 0720
   WAKITANI S, 1995, MUSCLE NERVE, V18, P1417, DOI 10.1002/mus.880181212
   Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959 437X(98)80068 3
   Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443
   Yu JM, 2006, MOL CELL BIOCHEM, V288, P17, DOI 10.1007/s11010 005 9113 3
NR 47
TC 63
Z9 73
U1 0
U2 29
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1465 3249
EI 1477 2566
J9 CYTOTHERAPY
JI Cytotherapy
PY 2007
VL 9
IS 7
BP 667
EP 681
DI 10.1080/14653240701508437
PG 15
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Hematology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research
   & Experimental Medicine
GA 233JM
UT WOS:000251087200008
PM 17917885
DA 2025 08 17
ER

PT J
AU Musolino, C
   Oteri, G
   Allegra, A
   Mania, M
   D'Ascola, A
   Avenoso, A
   Innao, V
   Allegra, AG
   Campo, S
AF Musolino, Caterina
   Oteri, Giacomo
   Allegra, Alessandro
   Mania, Manuela
   D'Ascola, Angela
   Avenoso, Angela
   Innao, Vanessa
   Allegra, Andrea Gaetano
   Campo, Salvatore
TI Altered microRNA expression profile in the peripheral lymphoid
   compartment of multiple myeloma patients with bisphosphonate induced
   osteonecrosis of the jaw
SO ANNALS OF HEMATOLOGY
LA English
DT Article
DE miRNAs; Osteonecrosis of the jaw; Multiple myeloma; Zoledronic acid;
   Bone; Osteoclast
ID CIRCULATING ENDOTHELIAL CELLS; ZOLEDRONIC ACID; OSTEOCLAST
   DIFFERENTIATION; BREAST CANCER; IN VITRO; FEMORAL HEAD; C FOS; BONE;
   POLYMORPHISM; OSTEOPOROSIS
AB Bisphosphonates are formidable inhibitors of osteoclast mediated bone resorption employed for therapy of multiple myeloma (MM) subjects with osteolytic lesions. Osteonecrosis of the jaw (ONJ) is an uncommon drug induced adverse event of these agents. MicroRNAs (miRNAs) are a group of small, noncoding RNAs nucleotides, which are essential post transcriptional controllers of gene expression. They have a central role in the normal bone development. The goal of our study was to investigate 18 miRNAs, whose targets were previously validated and described in MM subjects without ONJ, in peripheral lymphocytes of MM subjects with bisphosphonate induced ONJ. Utilizing reverse transcription quantitative polymerase chain reaction, we evaluated miRNAs in five healthy subjects and in five MM patients with ONJ. Our experimental data revealed that a diverse miRNA signature for ONJ subjects emerged with respect to control subjects. Using the filter for in silico analysis, among the 18 miRNAs, we recognized 14 dysregulated miRNAs. All these miRNAs were significantly over expressed in patients vs controls (MIR 16 1, MIR 21, MIR 23A, MIR 28, MIR 101 1, MIR 124 1, MIR 129, MIR 139, MIR 145, MIR 149, MIR 202, MIR 221, MIR 424, MIR 520). Among them, six were strongly upregulated (fourfold upregulated and more). These miRNAs target numerous pathways and genes implicated in calcium ion binding, bone resorption, mineralization of bone matrix, and differentiation and maintenance of bone tissue. A modified microRNA expression profile after zoledronate therapy could participate to the onset of ONJ. Targeting these miRNAs could provide a new opportunity for the prevention or treatment of ONJ.
C1 [Musolino, Caterina; Allegra, Alessandro; Innao, Vanessa; Allegra, Andrea Gaetano] Univ Messina, Div Hematol, Dept Patol Umana Adulto & Eta Evolut, Via Consolare Valeria, I 98125 Messina, Italy.
   [Oteri, Giacomo; Mania, Manuela; D'Ascola, Angela; Avenoso, Angela; Campo, Salvatore] Sch Dent, Dept Biomed Dent Sci & Morphol & Funct Images, Messina, Italy.
C3 University of Messina
RP Allegra, A (通讯作者)，Univ Messina, Div Hematol, Dept Patol Umana Adulto & Eta Evolut, Via Consolare Valeria, I 98125 Messina, Italy.
EM aallegra@unime.it
RI ; Mania, Manuela/E 5738 2018; Innao, Vanessa/AAS 7720 2020; Innao,
   Vanessa/K 6906 2017; Allegra, Alessandro/LRT 2739 2024
OI Allegra, Andrea Gaetano/0000 0001 6109 4563; Mania,
   Manuela/0000 0001 5144 8719; Allegra, Alessandro/0000 0001 6156 8239;
   Innao, Vanessa/0000 0001 7596 1912; Oteri, Giacomo/0000 0002 0941 1645;
   d'ascola, angela/0000 0001 7530 1316
FU University of Messina
FX This study was supported by funds from the University of Messina.
CR Adapala NS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153174
   Allegra A, 2007, HEMATOL ONCOL, V25, P164, DOI 10.1002/hon.819
   Allegra A, 2014, J CRANIO MAXILL SURG, V42, P279, DOI 10.1016/j.jcms.2013.05.014
   Allegra A, 2012, INT J ONCOL, V41, P1897, DOI 10.3892/ijo.2012.1647
   Allegra A, 2010, ACTA HAEMATOL BASEL, V124, P79, DOI 10.1159/000313787
   Alonci A, 2007, LEUKEMIA LYMPHOMA, V48, P1852, DOI 10.1080/10428190701509806
   Arduino PG, 2011, J ORAL PATHOL MED, V40, P510, DOI 10.1111/j.1600 0714.2010.01004.x
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Cai CK, 2012, ONCOL REP, V28, P1764, DOI 10.3892/or.2012.1995
   Campo S, 2014, BRIT J HAEMATOL, V165, P801, DOI 10.1111/bjh.12828
   Cassoni A, 2016, CASE REP DENT, V2016, DOI 10.1155/2016/2856926
   Cheng P, 2013, J BONE MINER RES, V28, P1180, DOI 10.1002/jbmr.1845
   Cheung A, 2010, NEW ENGL J MED, V363, P2473, DOI 10.1056/NEJMc1002684
   Chhabra R, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 232
   Cornish J, 2011, BONE, V49, P710, DOI 10.1016/j.bone.2011.07.020
   Coxon FP, 2003, CALCIFIED TISSUE INT, V72, P80, DOI 10.1007/s00223 002 2017 2
   Deng ZM, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/496193
   Dhillon S, 2016, DRUGS, V76, P1683, DOI 10.1007/s40265 016 0662 4
   Di Martino MT, 2011, BRIT J HAEMATOL, V154, P529, DOI 10.1111/j.1365 2141.2011.08622.x
   Dole NS, 2016, BONE, V84, P57, DOI 10.1016/j.bone.2015.12.016
   Dou C, 2014, BBA GENE REGUL MECH, V1839, P1084, DOI 10.1016/j.bbagrm.2014.08.002
   Ell Brian, 2014, Bonekey Rep, V3, P549, DOI 10.1038/bonekey.2014.44
   Fanale D, 2016, ONCOTARGET, V7, P29321, DOI 10.18632/oncotarget.8722
   Filleul O, 2010, J CANCER RES CLIN, V136, P1117, DOI 10.1007/s00432 010 0907 7
   Fournier P, 2002, CANCER RES, V62, P6538
   Franceschetti T, 2013, J BIOL CHEM, V288, P33347, DOI 10.1074/jbc.M113.484568
   Ge C, 2017, BONE, V26, P1
   Hamadeh IS, 2015, CANCER TREAT REV, V41, P455, DOI 10.1016/j.ctrv.2015.04.007
   Hao C, 2016, SCI REP UK, V6, DOI 10.1038/srep22599
   Hwang S, 2014, FEBS LETT, V588, P2957, DOI 10.1016/j.febslet.2014.05.048
   Jia J, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.43
   Kagiya T, 2013, J PERIODONTAL RES, V48, P373, DOI 10.1111/jre.12017
   Katz J, 2011, INT J ORAL MAX SURG, V40, P605, DOI 10.1016/j.ijom.2011.02.002
   Kopecka J, 2015, ONCOTARGET, V6, P31461, DOI 10.18632/oncotarget.5058
   Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375
   Kyrgidis A, 2017, OSTEOPOROSIS INT, V28, P991, DOI 10.1007/s00198 016 3807 0
   Kyrgidis A, 2010, BONE, V46, P556, DOI 10.1016/j.bone.2009.09.026
   La Ferla F, 2012, BIOMARK MED, V6, P201, DOI [10.2217/BMM.12.14, 10.2217/bmm.12.14]
   Larsson E, 2009, GENOME MED, V1, DOI 10.1186/gm108
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li BA, 2012, ACTA PHARMACOL SIN, V33, P3, DOI 10.1038/aps.2011.198
   Maes OC, 2008, MECH AGEING DEV, V129, P534, DOI 10.1016/j.mad.2008.05.004
   Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855
   Misso G, 2012, CANCER BIOL THER, V13, P1491, DOI 10.4161/cbt.22274
   Mizoguchi F, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4282
   Mooney SM, 2010, BIOCHEMISTRY US, V49, P1, DOI 10.1021/bi901263m
   Nastro E, 2007, ACTA HAEMATOL BASEL, V117, P181, DOI 10.1159/000097876
   Nastro E, 2009, J ORAL MAXIL SURG, V67, P2701, DOI 10.1016/j.joms.2008.05.369
   Nicoletti P, 2012, ONCOLOGIST, V17, P279, DOI 10.1634/theoncologist.2011 0202
   Nussbaumer O, 2011, BLOOD, V118, P2743, DOI 10.1182/blood 2011 01 328526
   Oteri G, 2008, CYTOKINE, V43, P103, DOI 10.1016/j.cyto.2008.05.010
   Pazianas M, 2011, JNCI J NATL CANCER I, V103, P232, DOI 10.1093/jnci/djq516
   Perrotta I, 2010, ULTRASTRUCT PATHOL, V34, P207, DOI 10.3109/01913121003729806
   Poliseno L, 2006, BLOOD, V108, P3068, DOI 10.1182/blood 2006 01 012369
   Reddy S, 1998, J CELL PHYSIOL, V177, P636, DOI 10.1002/(SICI)1097 4652(199812)177:4<636::AID JCP14>3.0.CO;2 H
   Rietkötter E, 2013, ONCOTARGET, V4, P1449, DOI 10.18632/oncotarget.1201
   Robubi A, 2014, BONE JOINT RES, V3, P236, DOI 10.1302/2046 3758.37.2000231
   Roelofs AJ, 2009, BRIT J HAEMATOL, V144, P245, DOI 10.1111/j.1365 2141.2008.07435.x
   Rosset EM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173209
   Rossi M, 2013, J CELL PHYSIOL, V228, P1506, DOI 10.1002/jcp.24306
   Ruggiero SL, 2009, AUST ENDOD J, V35, P119, DOI 10.1111/j.1747 4477.2009.00213.x
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   Sarasquete ME, 2008, BLOOD, V112, P2709, DOI 10.1182/blood 2008 04 147884
   Siniscalchi EN, 2010, ONCOL REP, V24, P129, DOI 10.3892/or_00000837
   Stockmann P, 2013, J CRANIO MAXILL SURG, V41, P71, DOI 10.1016/j.jcms.2012.10.018
   Stucke VM, 2008, CELL CYCLE, V7, P830, DOI 10.4161/cc.7.6.5614
   Sugatani T, 2007, J CELL BIOCHEM, V101, P996, DOI 10.1002/jcb.21335
   Sugatani T, 2009, J BIOL CHEM, V284, P4667, DOI 10.1074/jbc.M805777200
   Sun JN, 2015, ONCOTARGETS THER, V8, P2681, DOI 10.2147/OTT.S88463
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tashima T, 2015, BIOCHEM BIOPH RES CO, V463, P292, DOI 10.1016/j.bbrc.2015.05.053
   Wagner EF, 2003, ANN RHEUM DIS, V62, P83, DOI 10.1136/ard.62.suppl_2.ii83
   Xu JF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114627
   Yuan HF, 2016, SCI REP UK, V6, DOI 10.1038/srep20046
   Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745
   Zhang Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182678
   Zhao CY, 2015, RNA BIOL, V12, P343, DOI 10.1080/15476286.2015.1017205
NR 77
TC 48
Z9 50
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0939 5555
EI 1432 0584
J9 ANN HEMATOL
JI Ann. Hematol.
PD JUL
PY 2018
VL 97
IS 7
BP 1259
EP 1269
DI 10.1007/s00277 018 3296 7
PG 11
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA GH5UK
UT WOS:000433502600011
PM 29546453
DA 2025 08 17
ER

PT J
AU Wu, PT
   Lv, QG
   Wang, S
   Feng, XQ
   Zhang, KY
   Li, CN
   Li, YS
   Gao, XC
   Sun, JM
AF Wu, Peitong
   Lv, Qingguo
   Wang, Shuo
   Feng, Xueqin
   Zhang, Kaiyue
   Li, Chunnan
   Li, Yishan
   Gao, Xiaochen
   Sun, Jiaming
TI Using a Dual Disease Target Mapping Network Pharmacology Approach,
   Verbascoside Ameliorates Osteoporosis by Activating Estrogen Signaling
   to Alleviate Oxidative Stress
SO COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING
LA English
DT Article; Early Access
DE Verbascoside; network pharmacology; oxidative stress; osteoporosis;
   zebrafish
ID HEPATOCELLULAR CARCINOMA
AB Background Verbascoside, a compound classified as a phenylethanol glycoside in Dihuang, has been the subject of modern pharmacological investigations. These studies have revealed its noteworthy antioxidant, anti inflammatory, memory enhancing, neuroprotective, anti tumor, and various other pharmacological properties. While verbascoside exhibits favorable antioxidant effects, its precise mechanism of action in ameliorating osteoporosis through the treatment of oxidative stress remains unclear.Methods This study employed CCK8, ALP, ELISA, and ROS staining techniques to examine the osteoporotic effects of verbascoside on zebrafish and MC3T3 E1 cells. Additionally, this study aimed to investigate the molecular mechanism by which verbascoside improves osteoporosis by mitigating oxidative stress. To identify the common targets of verbascoside in relation to oxidative stress and osteoporosis, network pharmacology and molecular dynamics simulation were employed. The construction of the verbascoside   oxidative stress   osteoporosis   potential target gene network aimed to identify the core targets, while the mechanism of action was elucidated through KEGG analysis, and the accuracy was confirmed by assessing the mRNA expression of the targets.Results In vivo experiments demonstrated that verbascoside exhibited therapeutic effects on osteoporosis and reduced ROS production in zebrafish. In vitro experiments further revealed that verbascoside enhanced the proliferation and differentiation of MC3T3 E1 cells, thereby improving the oxidative stress status of osteoblasts. Thirteen core targets and estrogen signaling pathways were identified through the application of network pharmacology. The pivotal role of the estrogen signaling pathway in facilitating the ability of verbascoside to mitigate oxidative stress induced osteoporosis was substantiated by the modulation of target protein mRNA expression.Conclusion The findings underscore the considerable therapeutic potential of verbascoside in ameliorating osteoporosis through the alleviation of oxidative stress, thus establishing it as a promising compound for the treatment of this condition.
C1 [Wu, Peitong; Wang, Shuo; Feng, Xueqin; Zhang, Kaiyue; Li, Chunnan; Li, Yishan; Gao, Xiaochen; Sun, Jiaming] Changchun Univ Chinese Med, Jilin Inst Ginseng Sci, Changchun 130117, Peoples R China.
   [Lv, Qingguo] Changchun Univ Chinese Med, Affiliated Hosp, Jilin Ginseng Acad, Changchun 130117, Peoples R China.
C3 Changchun University of Chinese Medicine; Changchun University of
   Chinese Medicine
RP Gao, XC; Sun, JM (通讯作者)，Changchun Univ Chinese Med, Jilin Inst Ginseng Sci, Changchun 130117, Peoples R China.
EM Sun_jiaming2000@163.com; gao_xiaochen@hotmail.com
RI gao, xiaochen/HJG 8077 2022; Zhang, kaiyue/KGK 4161 2024
FU National Natural Science Foundation of China [82074127]; Jilin Province
   Development and Reform Commission [2023C027 2]; Scientific Research
   Program Project of the Administration of Traditional Chinese Medicine of
   Jilin Province [2023034]
FX This work was financially supported by the National Natural Science
   Foundation of China (No. 82074127), the Jilin Province Development and
   Reform Commission (No.2023C027 2), and the Scientific Research Program
   Project of the Administration of Traditional Chinese Medicine of Jilin
   Province (No. 2023034).
CR Adami G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235867
   Aparicio Bautista DI, 2024, GEROSCIENCE, V46, P2177, DOI 10.1007/s11357 023 00977 1
   Bellavia D, 2021, TRENDS ENDOCRIN MET, V32, P76, DOI 10.1016/j.tem.2020.11.007
   Chen CY, 2022, LIFE SCI, V308, DOI 10.1016/j.lfs.2022.120950
   Chen K, 2022, AM J PATHOL, V192, P1648, DOI 10.1016/j.ajpath.2022.09.003
   Da WCL, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.675385
   Dama A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22084254
   Dowsett L, 2020, J CLIN MED, V9, DOI 10.3390/jcm9093026
   Gibreel S, 2021, Current Concepts in Dental Implantology From Science to Clinical Research
   Hajam YA, 2022, CELLS BASEL, V11, DOI 10.3390/cells11030552
   Li X, 2023, CHIN J NAT MEDICINES, V21, P323, DOI 10.1016/S1875 5364(23)60429 7
   Liu C, 2019, OSTEOPOROSIS INT, V30, P1537, DOI 10.1007/s00198 019 05028 0
   Liu C, 2019, OSTEOPOROSIS INT, V30, P491, DOI 10.1007/s00198 018 4670 y
   Liu Min, 2019, Nan Fang Yi Ke Da Xue Xue Bao, V39, P134, DOI 10.12122/j.issn.1673 4254.2019.09.02
   Liu Y, 2022, J AGR FOOD CHEM, V70, P1148, DOI 10.1021/acs.jafc.1c07583
   Luhata LP, 2022, BIOORG MED CHEM LETT, V59, DOI 10.1016/j.bmcl.2022.128528
   Luo LY, 2023, MOL MED, V29, DOI 10.1186/s10020 023 00625 6
   Mohamad NV, 2020, ENDOCR METAB IMMUNE, V20, P1478, DOI 10.2174/1871530320666200604160614
   Nigro O, 2020, ANTI CANCER DRUG, V31, P1, DOI 10.1097/CAD.0000000000000818
   Orea Soufi A, 2022, TRENDS PHARMACOL SCI, V43, P1070, DOI 10.1016/j.tips.2022.09.010
   Park JH, 2020, BIOMOL THER, V28, P549, DOI 10.4062/biomolther.2020.007
   Park OJ, 2023, J PATHOL, DOI 10.1002/path.6069
   Reid IR, 2021, LANCET DIABETES ENDO, V9, P805, DOI 10.1016/S2213 8587(21)00283 7
   Song ZJ, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.941098
   Sun X, 2019, INT J BIOL MACROMOL, V129, P579, DOI 10.1016/j.ijbiomac.2019.02.022
   Tao ZS, 2022, MOL MED, V28, DOI 10.1186/s10020 022 00503 7
   Tesfamariam B, 2020, DRUG DISCOV TODAY, V25, P422, DOI 10.1016/j.drudis.2019.12.004
   Wang NN, 2021, FREE RADICAL BIO MED, V171, P112, DOI 10.1016/j.freeradbiomed.2021.05.014
   Wei Z, 2021, PHYTOTHER RES, V35, P1546, DOI 10.1002/ptr.6921
   Wen J, 2020, THERANOSTICS, V10, P5322, DOI 10.7150/thno.42371
   Yu B, 2022, PERIODONTOL 2000, V89, P99, DOI 10.1111/prd.12422
   Zhang D, 2022, PHYTOMEDICINE, V104, DOI 10.1016/j.phymed.2022.154205
   Zhao FL, 2021, ARCH OSTEOPOROS, V16, DOI 10.1007/s11657 020 00854 w
   Zhao G, 2021, ACTA BIOCH BIOPH SIN, V53, P1602, DOI 10.1093/abbs/gmab143
   Zhu CY, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.898634
NR 35
TC 0
Z9 0
U1 7
U2 17
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1386 2073
EI 1875 5402
J9 COMB CHEM HIGH T SCR
JI Comb. Chem. High Throughput Screen
PD 2024 SEP 6
PY 2024
DI 10.2174/0113862073312956240826053228
EA SEP 2024
PG 16
WC Biochemical Research Methods; Chemistry, Applied; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy
GA F9E1Y
UT WOS:001312754500001
PM 39248060
DA 2025 08 17
ER

PT J
AU Miyamoto, DT
   Zheng, Y
   Wittner, BS
   Lee, RJ
   Zhu, HL
   Broderick, KT
   Desai, R
   Fox, DB
   Brannigan, BW
   Trautwein, J
   Arora, KS
   Desai, N
   Dahl, DM
   Sequist, LV
   Smith, MR
   Kapur, R
   Wu, CL
   Shioda, T
   Ramaswamy, S
   Ting, DT
   Toner, M
   Maheswaran, S
   Haber, DA
AF Miyamoto, David T.
   Zheng, Yu
   Wittner, Ben S.
   Lee, Richard J.
   Zhu, Huili
   Broderick, Katherine T.
   Desai, Rushil
   Fox, Douglas B.
   Brannigan, Brian W.
   Trautwein, Julie
   Arora, Kshitij S.
   Desai, Niyati
   Dahl, Douglas M.
   Sequist, Lecia V.
   Smith, Matthew R.
   Kapur, Ravi
   Wu, Chin Lee
   Shioda, Toshi
   Ramaswamy, Sridhar
   Ting, David T.
   Toner, Mehmet
   Maheswaran, Shyamala
   Haber, Daniel A.
TI RNA Seq of single prostate CTCs implicates noncanonical Wnt signaling in
   antiandrogen resistance
SO SCIENCE
LA English
DT Article
ID CIRCULATING TUMOR CELLS; CANCER; PATHWAY; ENZALUTAMIDE
AB Prostate cancer is initially responsive to androgen deprivation, but the effectiveness of androgen receptor (AR) inhibitors in recurrent disease is variable. Biopsy of bone metastases is challenging; hence, sampling circulating tumor cells (CTCs) may reveal drug resistance mechanisms. We established single cell RNA sequencing (RNA Seq) profiles of 77 intact CTCs isolated from 13 patients (mean six CTCs per patient), by using microfluidic enrichment. Single CTCs from each individual display considerable heterogeneity, including expression of AR gene mutations and splicing variants. Retrospective analysis of CTCs from patients progressing under treatment with an AR inhibitor, compared with untreated cases, indicates activation of noncanonical Wnt signaling (P = 0.0064). Ectopic expression of Wnt5a in prostate cancer cells attenuates the antiproliferative effect of AR inhibition, whereas its suppression in drug resistant cells restores partial sensitivity, a correlation also evident in an established mouse model. Thus, single cell analysis of prostate CTCs reveals heterogeneity in signaling pathways that could contribute to treatment failure.
C1 [Miyamoto, David T.; Zheng, Yu; Wittner, Ben S.; Lee, Richard J.; Zhu, Huili; Broderick, Katherine T.; Desai, Rushil; Fox, Douglas B.; Brannigan, Brian W.; Trautwein, Julie; Arora, Kshitij S.; Desai, Niyati; Dahl, Douglas M.; Sequist, Lecia V.; Smith, Matthew R.; Wu, Chin Lee; Shioda, Toshi; Ramaswamy, Sridhar; Ting, David T.; Maheswaran, Shyamala; Haber, Daniel A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Massachusetts Gen Canc Ctr, Charlestown, MA 02129 USA.
   [Miyamoto, David T.] Harvard Univ, Massachusetts Gen Hosp, Dept Radiat Oncol, Sch Med, Charlestown, MA 02129 USA.
   [Zheng, Yu; Haber, Daniel A.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
   [Wittner, Ben S.; Lee, Richard J.; Sequist, Lecia V.; Smith, Matthew R.; Ramaswamy, Sridhar; Ting, David T.; Haber, Daniel A.] Harvard Univ, Massachusetts Gen Hosp, Dept Med, Sch Med, Charlestown, MA 02129 USA.
   [Arora, Kshitij S.; Desai, Niyati; Wu, Chin Lee] Harvard Univ, Massachusetts Gen Hosp, Dept Pathol, Sch Med, Charlestown, MA 02129 USA.
   [Dahl, Douglas M.] Harvard Univ, Massachusetts Gen Hosp, Dept Urol, Sch Med, Charlestown, MA 02129 USA.
   [Kapur, Ravi; Toner, Mehmet] Harvard Univ, Massachusetts Gen Hosp, Ctr Bioengn Med, Sch Med, Charlestown, MA 02129 USA.
   [Maheswaran, Shyamala] Harvard Univ, Massachusetts Gen Hosp, Dept Surg, Sch Med, Charlestown, MA 02129 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard University; Harvard University Medical
   Affiliates; Massachusetts General Hospital; Howard Hughes Medical
   Institute; Harvard University; Harvard University Medical Affiliates;
   Massachusetts General Hospital; Harvard University; Harvard University
   Medical Affiliates; Massachusetts General Hospital; Harvard University;
   Harvard University Medical Affiliates; Massachusetts General Hospital;
   Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard University; Harvard University Medical
   Affiliates; Massachusetts General Hospital
RP Haber, DA (通讯作者)，Harvard Univ, Massachusetts Gen Hosp, Sch Med, Massachusetts Gen Canc Ctr, Charlestown, MA 02129 USA.
EM haber@helix.mgh.harvard.edu; smaheswaran@mgh.harvard.edu
RI Ting, David/F 4389 2017; Arora, Kshitij/AEZ 5478 2022
OI Ting, David/0000 0002 3261 2322; 
FU Prostate Cancer Foundation; Charles Evans Foundation; Department of
   Defense; Stand Up to Cancer; Howard Hughes Medical Institute; National
   Institute of Biomedical Imaging and Bioengineering (NIBIB); NIH
   [EB008047]; NCI [2RO1CA129933]; National Cancer Institute, NCI; Federal
   Share Program and Income; Affymetrix, Inc.; Mazzone Program Dana Farber
   Harvard Cancer Center; Burroughs Wellcome Fund; Massachusetts General
   Hospital Johnson & Johnson Center for Excellence in CTC Technologies;
   Janssen LLC.
FX We thank C. Sawyers for helpful discussions; A. McGovern, E.
   Stadtmueller, and B. Abebe for clinical trial support; and L. Libby and
   L. Nieman for technical assistance. This work was supported by grants
   from the Prostate Cancer Foundation (D.A.H., S.M., M.T., M.R.S., and
   R.J.L.), Charles Evans Foundation (D.A.H.), Department of Defense
   (D.T.M., R.J.L., and D.T.T.), Stand Up to Cancer (D.A.H., M.T., S.M.,
   and L.V.S.), Howard Hughes Medical Institute (D.A.H.), National
   Institute of Biomedical Imaging and Bioengineering (NIBIB), NIH,
   EB008047 (M.T.), NCI 2RO1CA129933 (D.A.H.), National Cancer Institute,
   NCI, Federal Share Program and Income (S.M. and D.T.M.), Affymetrix,
   Inc. (D.T.T., K.A., and N.D.), Mazzone Program Dana Farber Harvard
   Cancer Center (D.T.M.), Burroughs Wellcome Fund (D.T.T.), and the
   Massachusetts General Hospital Johnson & Johnson Center for Excellence
   in CTC Technologies (D.A.H., M.T., and S.M.). D.T.T. is a paid
   consultant for Affymetrix, Inc.; R.J.L. is a paid consultant for Janssen
   LLC. The Massachusetts General Hospital has filed for patent protection
   for the CTC iChip technology. RNA sequencing data have been deposited in
   GEO under accession number GSE67980.
CR Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013
   Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815
   Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012
   Balbas MD, 2013, ELIFE, V2, DOI 10.7554/eLife.00499
   Carreira S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009448
   Egan A, 2014, CANCER TREAT REV, V40, P426, DOI 10.1016/j.ctrv.2013.09.011
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Gottlieb B, 2012, HUM MUTAT, V33, P887, DOI 10.1002/humu.22046
   Gujral TS, 2014, CELL, V159, P844, DOI 10.1016/j.cell.2014.10.032
   Gutschner T, 2013, J MOL MED, V91, P791, DOI 10.1007/s00109 013 1028 y
   Joseph JD, 2013, CANCER DISCOV, V3, DOI 10.1158/2159 8290.CD 13 0226
   Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078 0432.CCR 06 2316
   Kurlender L, 2005, BBA REV CANCER, V1755, P1, DOI 10.1016/j.bbcan.2005.02.001
   Lohr JG, 2014, NAT BIOTECHNOL, V32, P479, DOI 10.1038/nbt.2892
   Lu CX, 2013, TRANSL ANDROL UROL, V2, P178, DOI 10.3978/j.issn.2223 4683.2013.09.08
   Miyamoto DT, 2012, CANCER DISCOV, V2, P995, DOI 10.1158/2159 8290.CD 12 0222
   Ozkumur E, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005616
   Ramsköld D, 2012, NAT BIOTECHNOL, V30, P777, DOI 10.1038/nbt.2282
   Rath N, 2012, EMBO REP, V13, P900, DOI 10.1038/embor.2012.127
   Robinson D, 2015, CELL, V161, P1215, DOI [10.1016/j.cell.2015.06.053, 10.1016/j.cell.2015.05.001]
   Schaefer CF, 2009, NUCLEIC ACIDS RES, V37, pD674, DOI 10.1093/nar/gkn653
   Scher HI, 2013, NAT REV CLIN ONCOL, V10, P225, DOI 10.1038/nrclinonc.2013.30
   Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506
   Sharpe B, 2013, STEM CELL REV REP, V9, P721, DOI 10.1007/s12015 013 9453 4
   Takahashi S, 2011, P NATL ACAD SCI USA, V108, P4938, DOI 10.1073/pnas.1014850108
   Tang FC, 2009, NAT METHODS, V6, P377, DOI [10.1038/NMETH.1315, 10.1038/nmeth.1315]
   Ting DT, 2014, CELL REP, V8, P1905, DOI 10.1016/j.celrep.2014.08.029
   Trepel J, 2010, NAT REV CANCER, V10, P537, DOI 10.1038/nrc2887
   Zhang J, 2013, CANCER DISCOV, V3, P1228, DOI 10.1158/2159 8290.CD 13 0253
   Zheng DL, 2013, MOL CANCER RES, V11, P482, DOI 10.1158/1541 7786.MCR 12 0520
NR 30
TC 576
Z9 645
U1 4
U2 208
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036 8075
EI 1095 9203
J9 SCIENCE
JI Science
PD SEP 18
PY 2015
VL 349
IS 6254
BP 1351
EP 1356
DI 10.1126/science.aab0917
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CR5CR
UT WOS:000361357700052
PM 26383955
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Ramírez Salazar, EG
   Almeraya, EV
   López Perez, TV
   Jiménez Salas, Z
   Patiño, N
   Velázquez Cruz, R
AF Gustavo Ramirez Salazar, Eric
   Victoria Almeraya, Erika
   Valentina Lopez Perez, Tania
   Jimenez Salas, Zacarias
   Patino, Nelly
   Velazquez Cruz, Rafael
TI MicroRNA 1270 Inhibits Cell Proliferation, Migration, and Invasion via
   Targeting IRF8 in Osteoblast like Cell Lines
SO CURRENT ISSUES IN MOLECULAR BIOLOGY
LA English
DT Article
DE bone metabolism; gene regulation; microRNA; osteoblast; osteoclast;
   osteoporosis
ID OSTEOPOROSIS; OSTEOCLASTS; PREVENTION
AB Osteoporosis (OP) is the most common bone disease affecting elderly individuals. The diagnosis of this pathology is most commonly made on the basis of bone fractures. Several microRNAs (miRNAs/miRs) have been identified as possible biomarkers for the diagnosis and treatment of OP. miRNAs can regulate gene expression, and determining their functions can provide potential pharmacological targets for treating OP. A previous study showed that miR 1270 was upregulated in monocytes derived from postmenopausal women with OP. Therefore, the present study aimed to uncover the role of miR 1270 in regulating bone metabolism. To reveal the mechanism underlying the regulatory effect of miR 1270 on interferon regulatory factor 8 (IRF8) expression, luciferase assay, reverse transcription quantitative PCR, and Western blot analysis were performed. The results suggest that miR 1270 could regulate the mRNA and protein expression levels of IRF8 by directly binding to its 3 ' untranslated region. The effects of miR 1270 overexpression and IRF8 silencing on cell proliferation, migration, and invasion were also evaluated. To the best of our knowledge, the current study was the first to support the crucial role of miR 1270 in bone metabolism via modulation of IRF8 expression. In addition, miR 1270 overexpression could attenuate human osteoblast like cells' proliferation and migration ability.
C1 [Gustavo Ramirez Salazar, Eric] Inst Nacl Med Genom INMEGEN, Consejo Nacl Ciencia & Tecnol CONACYT, Mexico City 14610, DF, Mexico.
   [Victoria Almeraya, Erika; Valentina Lopez Perez, Tania; Velazquez Cruz, Rafael] Inst Nacl Med Genom INMEGEN, Lab Genom Metabol Oseo, Mexico City 14610, DF, Mexico.
   [Jimenez Salas, Zacarias] Univ Autonoma Nuevo Leon, Ctr Invest Nutr & Salud Publ, Monterrey 64460, Mexico.
   [Patino, Nelly] Inst Nacl Med Genom INMEGEN, Unidad Citometria Flujo UCiF, Mexico City 14610, DF, Mexico.
   [Gustavo Ramirez Salazar, Eric; Victoria Almeraya, Erika] Wistar Inst Anat & Biol, Melanoma Res Ctr, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA.
   [Valentina Lopez Perez, Tania] Hosp Infantil Mexico Dr Federico Gomez, CONACYT Unidad Invest Enfermedades Oncol, Mexico City 06720, DF, Mexico.
C3 Consejo Nacional de Ciencia y Tecnologia (CONACyT); Instituto Nacional
   de Medicina Genomica; Instituto Nacional de Medicina Genomica;
   Universidad Autonoma de Nuevo Leon; Instituto Nacional de Medicina
   Genomica; The Wistar Institute; Hospital Infantil de Mexico Federico
   Gomez
RP Velázquez Cruz, R (通讯作者)，Inst Nacl Med Genom INMEGEN, Lab Genom Metabol Oseo, Mexico City 14610, DF, Mexico.
EM eramirez@inmegen.gob.mx; erikaalmeraya@yahoo.com.mx;
   valecita_vale@hotmail.com; zacarias.jimeners@uanl.mx;
   lnpatino@inmegen.gob.mx; rvelazquez@inmegen.gob.mx
RI Velazquez Cruz, Rafael/AAC 3710 2021; López Pérez, Tania/AAR 2631 2021;
   Ramirez Salazar, Eric Gustavo/P 6580 2018; Ramirez Salazar,
   Eric/P 6580 2018
OI Jimenez Salas, Zacarias/0000 0002 1544 0899; Almeraya, Erika
   V./0000 0002 5071 2423; Ramirez Salazar, Eric
   Gustavo/0000 0002 0767 9357; Velazquez Cruz, Rafael/0000 0003 4515 0777
FU Consejo Nacional de Ciencia y Tecnologia [INFR 2016 01 270405,
   CB 2013 1 221628]; Instituto Nacional de Medicina Genomica (INMEGEN)
   [217 14/2015/I]; Consejo Nacional de Ciencia y Tecnologia (CONACYT)
   [CB 2013 01 221628]
FX This research was partially supported by Consejo Nacional de Ciencia y
   Tecnologia (grant nos. INFR 2016 01 270405 and CB 2013 1 221628) and the
   Instituto Nacional de Medicina Genomica (INMEGEN; grant no.
   217 14/2015/I). T.V.L P. and E.V.A. were supported by a Postdoctoral
   Fellowship from the Consejo Nacional de Ciencia y Tecnologia (CONACYT;
   grant no. CB 2013 01 221628).
CR Adams NM, 2018, IMMUNITY, V48, P1172, DOI 10.1016/j.immuni.2018.04.018
   Al Bari AA, 2020, FASEB BIOADV, V2, P668, DOI 10.1096/fba.2020 00058
   Arceo Mendoza R, 2021, ENDOCRIN METAB CLIN, V50, P167, DOI 10.1016/j.ecl.2021.03.009
   Bernhardt A, 2010, J BIOMED MATER RES A, V95A, P848, DOI 10.1002/jbm.a.32856
   Borciani G, 2020, ACTA BIOMATER, V108, P22, DOI 10.1016/j.actbio.2020.03.043
   Cao Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097098
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Cheng P, 2013, J BONE MINER RES, V28, P1180, DOI 10.1002/jbmr.1845
   Clark P., 2010, ARCH OSTEOPOROS, V5, P9, DOI [DOI 10.1007/S11657 010 0042 8, 10.1007/s11657 010 0042 8]
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Corrado A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103679
   De La Cruz Montoya AH, 2018, EXP BIOL MED, V243, P1027, DOI 10.1177/1535370218806828
   Drake MT, 2015, CLIN THER, V37, P1837, DOI 10.1016/j.clinthera.2015.06.006
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Feng QY, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180453
   Ferbebouh M, 2021, INFLAMM RES, V70, P859, DOI 10.1007/s00011 021 01484 9
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Jiménez Ortega RF, 2017, EXP THER MED, V14, P5464, DOI 10.3892/etm.2017.5260
   Kartsogiannis V, 2004, MOL CELL ENDOCRINOL, V228, P79, DOI 10.1016/j.mce.2003.06.002
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kimura T, 2015, CELL MOL LIFE SCI, V72, P2749, DOI 10.1007/s00018 015 1875 5
   Kumar G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205154
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Lorentzon M, 2022, CLIMACTERIC, V25, P4, DOI 10.1080/13697137.2021.1951206
   Mohseny AB, 2011, LAB INVEST, V91, P1195, DOI 10.1038/labinvest.2011.72
   O'Connell MB, 1999, PHARMACOTHERAPY, V19, p7S, DOI 10.1592/phco.19.2.7S.30910
   Pautke C, 2004, ANTICANCER RES, V24, P3743
   Peng SL, 2011, BONE, V49, P1290, DOI 10.1016/j.bone.2011.08.031
   Phetfong J, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658 016 0013 1
   Ponzetti M, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00236
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Salem S, 2020, HUM GENET, V139, P707, DOI 10.1007/s00439 020 02154 2
   Shiwaku Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132903
   Srivastava M, 2002, CLIN GERIATR MED, V18, P529, DOI 10.1016/S0749 0690(02)00022 8
   Sun WJ, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.15
   Tang PF, 2014, RNA BIOL, V11, P1355, DOI 10.1080/15476286.2014.996462
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Wei L, 2019, ONCOTARGETS THER, V12, P4839, DOI 10.2147/OTT.S192521
   Yuan WB, 2019, MOL ONCOL, V13, P1559, DOI 10.1002/1878 0261.12523
   Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007
NR 40
TC 6
Z9 6
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1467 3037
EI 1467 3045
J9 CURR ISSUES MOL BIOL
JI Curr. Issues Mol. Biol.
PD MAR
PY 2022
VL 44
IS 3
BP 1182
EP 1190
DI 10.3390/cimb44030077
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 0D2RD
UT WOS:000775847100001
PM 35723300
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Duan, LJ
   Zhao, H
   Xiong, Y
   Tang, XS
   Yang, YD
   Hu, ZG
   Li, CH
   Chen, SX
   Yu, X
AF Duan, Lijun
   Zhao, He
   Xiong, Yang
   Tang, Xiangsheng
   Yang, Yongdong
   Hu, Zhenguo
   Li, Chuanhong
   Chen, Sixue
   Yu, Xing
TI miR 16 2*Interferes with WNT5A to Regulate Osteogenesis of Mesenchymal
   Stem Cells
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Mesenchymal stem cells; miR 16 2*; Osteoporosis; Osteogenesis; Bone
   formation; WNT5A
ID BONE FORMATION; OSTEOBLAST DIFFERENTIATION; MICRORNAS; ROLES;
   PROLIFERATION; DECISIONS; BALANCE; BETA; BMP
AB Background/Aims: Osteoporosis is a bone metabolic disease characterized by a systemic impairment of bone mass, which results in increased propensity of fragility fractures. A reduction in the differentiation of MSCs into osteoblasts contributes to the impaired bone formation observed in osteoporosis. Mesenchymal stem cells (MSCs) are induced to differentiate into preosteoblasts, which are regulated by the signaling cascades initiated by the various signals, including miRNAs. miR 16 2* is a newly discovered miRNA that participates in diagnosis and prognosis of hepatocellular carcinoma, cervical cancer and chronic lymphocytic leukemia. However, the effect of miR 16 2* on the regulation of osteoblast differentiation and the mechanism responsible are still unclear. Here we discuss the contribution of miR 162* to osteoporosis, osteoblast differentiation and mineralization. Methods: The expression pattern of miR 16 2* during osteogenesis or in osteoporosis bone samples was validated by quantitative real time PCR (qRT PCR). The human bone marrow mesenchymal stem cells (hBMSCs) were induced to differentiate into osteoblasts by osteogenic induced medium containing dexamethasone, ascorbate 2 phosphat, beta glycerophosphate and vitamin D3. The target genes of miR 16 2* were predicted by TargetScan and PicTar. The mRNA and protein levels of osteogenic key markers were detected using qRT PCR or western blot respectively. The WNT signal activity was analyzed by TOP/FOP reporter assay. Results: The expression of miR 16 2* in patient bone tissue with osteoporosis was negatively correlated with bone formation related genes. During osteoblast differentiation process, the expression of miR 162* was significantly decreased. Upregulation of miR 16 2* in hBMSCs impaired the osteogenic differentiation while the downregulation of miR 16 2* increased this process. Upregulation the expression of miR 16 2* could also block the WNT signal pathway by directly target WNT5A. Furthermore, knockdown of miR 16 2* could promote the activation of RUNX2, possibly by lifting the inhibitory effect of miR 16 2* on WNT pathway. Conclusion: Taken together, we report a novel biological role of miR 16 2* in osteogenesis through regulating WNT5A response for the first time. Our data support the potential utilization of miRNA based therapies in regenerative medicine. (C) 2018 The Author(s) Published by S. Karger AG, Basel
C1 [Duan, Lijun; Zhao, He; Xiong, Yang; Yang, Yongdong; Hu, Zhenguo; Li, Chuanhong; Chen, Sixue; Yu, Xing] Beijing Univ Chinese Med, Dongzhimen Hosp, Dept Orthoped, 5 Haiyuncang St, Beijing 100700, Peoples R China.
   [Duan, Lijun] Bayannaoer City Hosp, Dept Orthoped, Bayannaoer City, Peoples R China.
   [Tang, Xiangsheng] Beijing Univ Chinese Med, Dept Orthoped, China Japan Friendship Hosp, Beijing, Peoples R China.
C3 Beijing University of Chinese Medicine; Beijing University of Chinese
   Medicine; China Japan Friendship Hospital
RP Yu, X (通讯作者)，Beijing Univ Chinese Med, Dongzhimen Hosp, Dept Orthoped, 5 Haiyuncang St, Beijing 100700, Peoples R China.
EM yuxingbucm@sina.com
RI zhao, he/JEO 8161 2023
CR [Anonymous], SCI REP UK
   Aqeilan RI, 2010, CELL DEATH DIFFER, V17, P215, DOI 10.1038/cdd.2009.69
   Bae YJ, 2012, HUM MOL GENET, V21, P2991, DOI 10.1093/hmg/dds129
   Bandyopadhyay A, 2006, PLOS GENET, V2, P2116, DOI 10.1371/journal.pgen.0020216
   Baschant U, 2016, HAEMATOLOGICA, V101, P1499, DOI 10.3324/haematol.2016.144808
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995
   Cao FD, 2017, MOL MED REP, V16, P9301, DOI 10.3892/mmr.2017.7821
   Chang HG, 2017, CELL DEATH DIS, V8, DOI 10.1038/s41419 017 0078 4
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen JY, 2015, DRUG DEVELOP RES, V76, P235, DOI 10.1002/ddr.21260
   Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102
   Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388
   Cui Y, 2016, SCI REP UK, V6, DOI 10.1038/srep23300
   Davis LA, 2008, CELL MOL LIFE SCI, V65, P2658, DOI 10.1007/s00018 008 8042 1
   EKSTROM JE, 1990, J COMPUT ASSIST TOMO, V14, P239, DOI 10.1097/00004728 199003000 00015
   El Tawdi AHF, 2016, MOL DIAGN THER, V20, P265, DOI 10.1007/s40291 016 0200 9
   Fang SJ, 2015, INT J MOL SCI, V16, P8227, DOI 10.3390/ijms16048227
   Feng ZL, 2012, HEALTH AFFAIR, V31, P2764, DOI 10.1377/hlthaff.2012.0535
   Gao YP, 2016, ONCOTARGET, V7, P27613, DOI 10.18632/oncotarget.8376
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Guntur AR, 2011, J ENDOCRINOL, V211, P123, DOI 10.1530/JOE 11 0175
   Hashimoto Y, 2016, CELL BIOL INT, V40, P1129, DOI 10.1002/cbin.10652
   Hassan MQ, 2015, BONE, V81, P746, DOI 10.1016/j.bone.2015.05.026
   Heinrich EM, 2012, CIRC RES, V110, P1014, DOI 10.1161/CIRCRESAHA.111.243394
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Hyun J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10993
   Keller KC, 2016, STEM CELLS DEV, V25, P1020, DOI 10.1089/scd.2015.0367
   Kureel J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.4
   Kureel J, 2018, J CELL BIOCHEM, V119, P3293, DOI 10.1002/jcb.26490
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Li H, 2015, CELL DEATH DIFFER, V22, P1935, DOI 10.1038/cdd.2015.99
   Li HL, 2013, STEM CELL RES, V10, P313, DOI 10.1016/j.scr.2012.11.007
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Long HT, 2017, DNA CELL BIOL, V36, P715, DOI 10.1089/dna.2017.3657
   Lovat F, 2015, P NATL ACAD SCI USA, V112, P11636, DOI 10.1073/pnas.1514954112
   Ma L, 2016, CANCER MED US, V5, P684, DOI 10.1002/cam4.623
   Okamoto M, 2014, SCI REP UK, V4, DOI 10.1038/srep04493
   Parchem RJ, 2014, CELL STEM CELL, V14, P617, DOI 10.1016/j.stem.2014.01.021
   Qiu WM, 2007, J BONE MINER RES, V22, P1720, DOI 10.1359/JBMR.070721
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Small EM, 2011, NATURE, V469, P336, DOI 10.1038/nature09783
   Su X, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.221
   Sun YX, 2017, ONCOTARGET, V8, P89913, DOI 10.18632/oncotarget.20984
   Takada I, 2007, NAT CELL BIOL, V9, P1273, DOI 10.1038/ncb1647
   van Rooij E, 2011, CIRC RES, V108, P219, DOI 10.1161/CIRCRESAHA.110.227496
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Xiao CC, 2007, CELL, V131, P146, DOI 10.1016/j.cell.2007.07.021
   Xie Y, 2015, MOLECULES, V20, P19433, DOI 10.3390/molecules201019433
   Yoon BS, 2005, P NATL ACAD SCI USA, V102, P5062, DOI 10.1073/pnas.0500031102
   Zhang BL, 2017, CELL PHYSIOL BIOCHEM, V44, P1923, DOI 10.1159/000485883
   Zhang L, 2017, J BONE MINER RES, V32, P2466, DOI 10.1002/jbmr.3230
NR 55
TC 33
Z9 36
U1 0
U2 19
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1015 8987
EI 1421 9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2018
VL 51
IS 3
BP 1087
EP 1102
DI 10.1159/000495489
PG 16
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA HF3WM
UT WOS:000454165200007
PM 30476907
OA gold
DA 2025 08 17
ER

PT J
AU Wessel, LE
   Strike, SA
   Singh, A
   Bernthal, NM
   Athanasian, EA
AF Wessel, Lauren Elisabeth
   Strike, Sophia A.
   Singh, Arun
   Bernthal, Nicholas M.
   Athanasian, Edward A.
TI The Role of Denosumab in the Treatment of Primary Tumors of Bone
SO JOURNAL OF HAND SURGERY AMERICAN VOLUME
LA English
DT Article
DE bone tumor; denosumab; giant cell tumor; hand tumor; RANK
ID GIANT CELL TUMOR; OPEN LABEL; RECURRENCE; SARCOMA; CYSTS; RANKL
AB Many hand surgeons treat benign bone tumors without referral to orthopedic oncologists. However, there have been considerable advances in medical therapy for some of these tumors, with which hand surgeons may not be as familiar. This review focuses on the mechanism and uses of denosumab in the treatment of benign tumors of bone. Although the hand surgeon may not be directly prescribing this therapy, they are often the only physician treating the patient for these conditions. As such, awareness regarding the use of this therapy in reducing pain, decreasing tumor volume, and treatment of potential lung metastases is critical to those taking on these cases without the support of an orthopedic oncologist. This article aims to familiarize hand surgeons with denosumab to help promote knowledge of this therapeutic option and the potential role of this medication in the treatment of primary bone tumors in the hand. (J Hand Surg Am. 2023;48(9):923 930.Copyright & COPY; 2023 by the American Society for Surgery of the Hand. All rights reserved.)
C1 [Wessel, Lauren Elisabeth; Bernthal, Nicholas M.] Univ Calif Los Angeles, Dept Orthopaed Surg, Los Angeles, CA USA.
   [Strike, Sophia A.] Johns Hopkins Univ, Dept Orthopaed Surg, Baltimore, MD USA.
   [Singh, Arun] Univ Calif Los Angeles, Sarcoma & Connect Tissue Med Oncol, Los Angeles, CA USA.
   [Athanasian, Edward A.] Mem Sloan Kettering Canc Ctr, Dept Orthopaed Surg, New York, NY USA.
   [Athanasian, Edward A.] Hosp Special Surg, Div Hand Surg, New York, NY USA.
   [Wessel, Lauren Elisabeth] Univ Calif Los Angeles, Dept Orthopaed Surg, 1225 15th St,Suite 3145, Santa Monica, CA 90404 USA.
C3 University of California System; University of California Los Angeles;
   Johns Hopkins University; University of California System; University of
   California Los Angeles; Memorial Sloan Kettering Cancer Center;
   University of California System; University of California Los Angeles
RP Wessel, LE (通讯作者)，Univ Calif Los Angeles, Dept Orthopaed Surg, 1225 15th St,Suite 3145, Santa Monica, CA 90404 USA.
EM lwessel@mednet.ucla.edu
OI Wessel, Lauren/0000 0002 6240 5981
CR Aponte Tinao LA, 2015, CLIN ORTHOP RELAT R, V473, P3050, DOI 10.1007/s11999 015 4249 2
   Athanasian EA, 1997, J HAND SURG AM, V22A, P91, DOI 10.1016/S0363 5023(05)80187 X
   Averill R M, 1980, J Hand Surg Am, V5, P39
   Borkowska A, 2016, ONCOL LETT, V12, P4312, DOI 10.3892/ol.2016.5246
   Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078 0432.CCR 12 0578
   Broehm CJ, 2015, CASE REP MED, V2015, DOI 10.1155/2015/767198
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   Dubory A, 2016, SPINE, V41, pE654, DOI 10.1097/BRS.0000000000001350
   Errani C, 2018, J BONE JOINT SURG AM, V100, P496, DOI 10.2106/JBJS.17.00057
   Errani C, 2017, INT ORTHOP, V41, P2397, DOI 10.1007/s00264 017 3536 9
   Errani C, 2010, CANCER TREAT REV, V36, P1, DOI 10.1016/j.ctrv.2009.09.002
   Federman N, 2014, PEDIATR DRUGS, V16, P21, DOI 10.1007/s40272 013 0051 3
   Fuhs S E, 1979, J Hand Surg Am, V4, P152
   Gaston CL, 2016, CLIN SARCOMA RES, V6, DOI 10.1186/s13569 016 0056 0
   Gerrand CH, 2003, CANCER, V97, P485, DOI 10.1002/cncr.11076
   Jamshidi K, 2018, ARCH BONE JT SURG AB, V6, P260
   Kremen TJ, 2012, CLIN ORTHOP RELAT R, V470, P677, DOI 10.1007/s11999 011 2172 8
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lamy O, 2019, CURR OSTEOPOROS REP, V17, P8, DOI 10.1007/s11914 019 00502 4
   Li HY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.580605
   Mak IWY, 2014, J BONE JOINT SURG AM, V96A, DOI 10.2106/JBJS.M.01332
   Palmerini E, 2017, EUR J CANCER, V76, P118, DOI 10.1016/j.ejca.2017.01.028
   Palmerini E, 2020, CURR TREAT OPTION ON, V21, DOI 10.1007/s11864 020 00766 4
   Pan KS, 2021, CURR OSTEOPOROS REP, V19, P141, DOI 10.1007/s11914 021 00657 z
   Pelle DW, 2014, TRANSL RES, V164, P139, DOI 10.1016/j.trsl.2014.03.005
   Rutkowski P, 2015, ANN SURG ONCOL, V22, P2860, DOI 10.1245/s10434 015 4634 9
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Thomas DM, 2012, CURR OPIN ONCOL, V24, P397, DOI 10.1097/CCO.0b013e328354c129
   Traub F, 2016, EUR J CANCER, V59, P1, DOI 10.1016/j.ejca.2016.01.006
   Tsukamoto S, 2020, CLIN ORTHOP RELAT R, V478, P1076, DOI 10.1097/CORR.0000000000001074
   van der Heijden L, 2017, EUR J CANCER, V77, P75, DOI 10.1016/j.ejca.2017.02.021
   Wong K, 2021, RARE TUMORS, V13, DOI 10.1177/20363613211034710
   Xu RW, 2022, ANZ J SURG, V92, P691, DOI 10.1111/ans.17520
   Yamagishi T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154680
NR 34
TC 1
Z9 1
U1 0
U2 1
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0363 5023
EI 1531 6564
J9 J HAND SURG AM
JI J. Hand Surg. Am. Vol.
PD SEP
PY 2023
VL 48
IS 9
BP 923
EP 930
DI 10.1016/j.jhsa.2023.02.013
EA SEP 2023
PG 8
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA S9JP6
UT WOS:001074258900001
PM 37032292
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Bortolini, O
   Fantin, G
   Fogagnolo, M
   Rossetti, S
   Maiuolo, L
   Di Pompo, G
   Avnet, S
   Granchi, D
AF Bortolini, Olga
   Fantin, Giancarlo
   Fogagnolo, Marco
   Rossetti, Stefano
   Maiuolo, Loredana
   Di Pompo, Gemma
   Avnet, Sofia
   Granchi, Donatella
TI Synthesis, characterization and biological activity of
   hydroxyl bisphosphonic analogs of bile acids
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Hydroxy bisphosphonates; Bile acids; Hydroxyapatite affinity; Biological
   activity
ID NITROGEN CONTAINING BISPHOSPHONATES; IN VITRO; BONE RESORPTION; TISSUE
   CULTURE; DRUG DELIVERY; HYDROXYAPATITE; DISSOLUTION; INHIBITION;
   MECHANISMS; PYROPHOSPHATE
AB Bisphosphonates (BPs) are now the most widely used drugs for diseases associated with increased bone resorption, such as osteoporosis, and tumor bone diseases. A significant drawback of the BPs is their poor oral absorption that is enhanced by the presence of bile acid substituents in the bisphosphonate framework, with no toxic effects. A straightforward synthesis of bile acid containing hydroxy bisphosphonates and a full characterization of these pharmaceutically important molecules, including an evaluation of affinity and the mechanism of binding to hydroxyapatite, is presented. The biological activity of bile acid containing bisphosphonate salts was determined using the neutral red assay on the L929 cell line and primary cultures of osteoclasts. The bioactivity of the new compounds was found superior than bisphosphonates of established activity. (C) 2012 Elsevier Masson SAS. All rights reserved.
C1 [Bortolini, Olga; Fantin, Giancarlo; Fogagnolo, Marco; Rossetti, Stefano] Univ Ferrara, Dipartimento Chim, I 44121 Ferrara, Italy.
   [Bortolini, Olga; Fantin, Giancarlo; Fogagnolo, Marco; Rossetti, Stefano] Univ Ferrara, SOF CNR Sez Ferrara, I 44121 Ferrara, Italy.
   [Maiuolo, Loredana] Univ Calabria, Dipartimento Chim, I 87036 Arcavacata Di Rende, CS, Italy.
   [Di Pompo, Gemma; Avnet, Sofia; Granchi, Donatella] Ist Ortoped Rizzoli, Lab Fisiopatol Ortoped & Med Rigenerat, I 40136 Bologna, Italy.
C3 University of Ferrara; University of Ferrara; University of Calabria;
   IRCCS Istituto Ortopedico Rizzoli
RP Bortolini, O (通讯作者)，Univ Ferrara, Dipartimento Chim, Via Borsari 46, I 44121 Ferrara, Italy.
EM olga.bortolini@unife.it; giancarlo.fantin@unife.it;
   donatella.granchi@ior.it
RI Granchi, Donatella/J 3647 2016; Bortolini, Olga/D 8058 2014; Avnet,
   Sofia/B 3220 2018; Di Pompo, Gemma/J 5317 2018
OI Granchi, Donatella/0000 0001 7225 0023; MAIUOLO,
   Loredana/0000 0002 8936 4454; Bortolini, Olga/0000 0002 8428 2310;
   Avnet, Sofia/0000 0002 7843 0591; Di Pompo, Gemma/0000 0001 5121 4330; 
FU Italian Ministry of Research and University (MIUR)
FX This project was supported by Italian Ministry of Research and
   University (MIUR), PRIN 2008 "New catalytic strategies for the synthesis
   of bisphosphonate based bioactive molecules for the therapy and
   diagnosis of osteolytic diseases". We thank Mr. P. Formaglio and Dr. T.
   Bernardi, Department of Chemistry. University of Ferrara, for running
   NMRand HRMS experiments.
CR Babu P, 2005, STEROIDS, V70, P681, DOI 10.1016/j.steroids.2005.03.008
   Breuil V, 1998, J BONE MINER RES, V13, P1721, DOI 10.1359/jbmr.1998.13.11.1721
   Ciapetti G, 1996, BIOMATERIALS, V17, P1259, DOI 10.1016/0142 9612(96)88670 4
   Csizmadia F, 1997, J PHARM SCI US, V86, P865, DOI 10.1021/js960177k
   Dissette V, 2010, EUR J PHARM SCI, V41, P328, DOI 10.1016/j.ejps.2010.06.020
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Dunford JE, 2008, J MED CHEM, V51, P2187, DOI 10.1021/jm7015733
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Ebetino FH, 1998, REV CONTEMP PHARMACO, V9, P233
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Enhsen A, 1998, DRUG DISCOV TODAY, V3, P409, DOI 10.1016/S1359 6446(96)10046 5
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Filipponi P, 1998, BONE, V23, P543, DOI 10.1016/S8756 3282(98)00133 1
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   Frediani B, 2004, BONE, V35, P859, DOI 10.1016/j.bone.2004.06.001
   Fujisaki J, 1997, BIOL PHARM BULL, V20, P1183
   Gallagher J. A., 1998, PCT Int. Appl., Patent No. [9800438, WO98/00438]
   Granchi D, 2005, BIOMATERIALS, V26, P2371, DOI 10.1016/j.biomaterials.2004.07.045
   Granchi D, 2004, INT J CANCER, V111, P829, DOI 10.1002/ijc.20308
   GUERVENOU J, 1994, PHOSPHORUS SULFUR, V88, P1, DOI 10.1080/10426509408036901
   HOFMANN A F, 1985, Journal of Controlled Release, V2, P3, DOI 10.1016/0168 3659(85)90028 8
   HOFMANN AF, 1994, SCAND J GASTROENTERO, V29, P1, DOI 10.3109/00365529409103618
   Jahnke W, 2010, CHEMMEDCHEM, V5, P770, DOI 10.1002/cmdc.201000016
   Josse S, 2005, BIOMATERIALS, V26, P2073, DOI 10.1016/j.biomaterials.2004.05.019
   Kim ND, 2002, J BIOCHEM MOL BIOL, V35, P134, DOI 10.5483/BMBRep.2002.35.1.134
   Kritchevsky D., 1971, BILE ACIDS CHEM PHYS, V1, P3
   Lawson MA., 2009, J BIOMED MATER RES B, P149
   Lecouvey M, 2001, TETRAHEDRON LETT, V42, P8475, DOI 10.1016/S0040 4039(01)01844 5
   Lenevich S, 2011, ANAL BIOCHEM, V408, P316, DOI 10.1016/j.ab.2010.08.030
   Lin Julie T, 2003, J Am Acad Orthop Surg, V11, P1
   Lolli ML, 2010, BIOORGAN MED CHEM, V18, P2428, DOI 10.1016/j.bmc.2010.02.058
   Mukherjee S, 2008, J AM CHEM SOC, V130, P1264, DOI 10.1021/ja0759949
   Mukhopadhyay S, 2004, CURR SCI INDIA, V87, P1666
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Robinson J, 2006, J MOL STRUCT, V825, P134, DOI 10.1016/j.molstruc.2006.04.032
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   RUSSELL RGG, 1970, CALC TISS RES, V6, P183, DOI 10.1007/BF02196199
   Shmeeda H, 2010, J CONTROL RELEASE, V146, P76, DOI 10.1016/j.jconrel.2010.04.028
   Virtanen E, 2004, EUR J ORG CHEM, V2004, P3385, DOI 10.1002/ejoc.200300699
   Westphal GA, 2010, TOXICOLOGY, V268, P198, DOI 10.1016/j.tox.2009.12.016
   Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i
   Wiemer AJ, 2008, BIOORGAN MED CHEM, V16, P3652, DOI 10.1016/j.bmc.2008.02.016
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
NR 45
TC 22
Z9 25
U1 0
U2 28
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223 5234
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD JUN
PY 2012
VL 52
BP 221
EP 229
DI 10.1016/j.ejmech.2012.03.020
PG 9
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA 945QR
UT WOS:000304291600021
PM 22483634
DA 2025 08 17
ER

PT J
AU Kubi, JA
   Brah, AS
   Cheung, KMC
   Chen, ACH
   Lee, YL
   Lee, KF
   Qiao, W
   Feng, YB
   Yeung, KWK
AF Kubi, John Akrofi
   Brah, Augustine Suurinobah
   Cheung, Kenneth Man Chee
   Chen, Andy Chun Hang
   Lee, Yin Lau
   Lee, Kai Fai
   Qiao, Wei
   Feng, Yibin
   Yeung, Kelvin Wai Kwok
TI Low molecular weight estrogenic phytoprotein suppresses osteoporosis
   development through positive modulation of skeletal estrogen receptors
SO BIOACTIVE MATERIALS
LA English
DT Article
DE Ovariectomy (OVX); Osteoporosis; Osteoblast functions; Estrogen
   receptors (ERs); HKUOT S2 protein
ID MESENCHYMAL STEM CELLS; OSTEOBLAST DIFFERENTIATION; POSTMENOPAUSAL
   WOMEN; OSTEOGENIC ACTIVITY; BONE; ALPHA; EXPRESSION; FRACTURES; BETA;
   BAZEDOXIFENE
AB Age related osteoporosis is a metabolic skeletal disorder caused by estrogen deficiency in postmenopausal women. Prolonged use of anti osteoporotic drugs such as bisphosphonates and FDA approved anti resorptive selective estrogen receptor modulators (SERMs) has been associated with various clinical drawbacks. We recently discovered a low molecular weight biocompatible and osteoanabolic phytoprotein, called HKUOT S2 protein (32 kDa), from Dioscorea opposita Thunb that can accelerate bone defect healing. Here, we demonstrated that the HKUOT S2 protein treatment can enhance osteoblasts induced ossification and suppress osteoporosis development by upregulating skeletal estrogen receptors (ERs) ER alpha, ER beta, and GPR30 expressions in vivo. Also, HKUOTS2 protein estrogenic activities promoted hMSCs osteoblasts differentiation and functions by increasing osteogenic markers, ALP, and RUNX2 expressions, ALP activity, and osteoblast biomineralization in vitro. Fulvestrant treatment impaired the HKUOT S2 protein induced ERs expressions, osteoblasts differentiation, and functions. Finally, we demonstrated that the HKUOT S2 protein could bind to ERs to exert osteogenic and osteoanabolic properties. Our results showed that the biocompatible HKUOT S2 protein can exert estrogenic and osteoanabolic properties by positively modulating skeletal estrogen receptor signaling to promote ossification and suppress osteoporosis. Currently, there is no or limited data if any, on osteoanabolic SERMs. The HKUOT S2 protein can be applied as a new osteoanabolic SERM for osteoporosis treatment.
C1 [Kubi, John Akrofi; Brah, Augustine Suurinobah; Cheung, Kenneth Man Chee; Yeung, Kelvin Wai Kwok] Univ Hong Kong HKU, Li Ka Shing Fac Med, Dept Orthopaed & Traumatol, Hong Kong, Peoples R China.
   [Kubi, John Akrofi; Brah, Augustine Suurinobah; Cheung, Kenneth Man Chee; Yeung, Kelvin Wai Kwok] HKU Shenzhen Hosp, Shenzhen Key Lab Innovat Technol Orthopaed Trauma, Shenzhen 518053, Peoples R China.
   [Chen, Andy Chun Hang; Lee, Yin Lau; Lee, Kai Fai] HKU, Li Ka Shing Fac Med, Dept Obstet & Gynaecol, 21 Sassoon Rd, Hong Kong, Peoples R China.
   [Chen, Andy Chun Hang; Lee, Yin Lau; Lee, Kai Fai] HKU Shenzhen Hosp, Reprod Med Ctr, Shenzhen Key Lab Fertil Regulat, Shenzhen, Peoples R China.
   [Qiao, Wei] Fac Dent, Appl Oral Sci & Community Dent Care, Hong Kong, Peoples R China.
   [Feng, Yibin] HKU, Li Ka Shing Fac Med, Sch Chinese Med, Hong Kong, Peoples R China.
C3 University of Hong Kong; University of Hong Kong; University of Hong
   Kong
RP Yeung, KWK (通讯作者)，Univ Hong Kong HKU, Li Ka Shing Fac Med, Dept Orthopaed & Traumatol, Hong Kong, Peoples R China.
EM wkkyeung@hku.hk
RI Yeung, Kelvin/JPA 1366 2023; Feng, Yibin/I 5245 2012; Chen,
   Andy/KFS 9464 2024; Lee, Kai Fai/IQS 1019 2023
OI Yeung, Kelvin/0000 0003 0887 088X; Brah, Augustine
   S./0000 0002 1018 1496; 
FU University Research Committee (URC), The University of Hong Kong (HKU),
   Hong Kong China [:201910160024, 202010160009]
FX This research was supported by the Seed Fund for Translational and
   Applied Research from the University Research Committee (URC), The
   University of Hong Kong (HKU), Hong Kong China (Project Codes:
   201910160024 and 202010160009).
CR Aguirre Cruz G, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9020181
   Akkawi Ibrahim, 2018, Joints, V6, P122, DOI 10.1055/s 0038 1660790
   Almeida M, 2017, PHYSIOL REV, V97, P135, DOI 10.1152/physrev.00033.2015
   Almeida M, 2013, J CLIN INVEST, V123, P394, DOI 10.1172/JCI65910
   Bord S, 2003, BONE, V32, P136, DOI 10.1016/S8756 3282(02)00953 5
   Börjesson AE, 2013, CELL MOL LIFE SCI, V70, P4023, DOI 10.1007/s00018 013 1317 1
   Bryant HU, 1999, J STEROID BIOCHEM, V69, P37, DOI 10.1016/S0960 0760(98)00147 2
   Chakrabarti S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052357
   Chen FP, 2013, CLIMACTERIC, V16, P154, DOI 10.3109/13697137.2012.672496
   Chen Fang Ping, 2004, Chang Gung Med J, V27, P107
   Chen P, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.839005
   Cheng CH, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031376
   Coughlan T, 2014, CLIN MED, V14, P187, DOI 10.7861/clinmedicine.14 2 187
   D'Amelio P, 2013, EXPERT OPIN PHARMACO, V14, P949, DOI 10.1517/14656566.2013.782002
   De Martinis M, 2021, WORLD J MENS HEALTH, V39, P750, DOI 10.5534/wjmh.200099
   Denger S, 2008, STEROIDS, V73, P765, DOI 10.1016/j.steroids.2008.02.013
   Diamond T, 1996, OSTEOPOROSIS INT, V6, P329, DOI 10.1007/BF01623394
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Ettinger B, 2006, MENOPAUSE, V13, P340, DOI 10.1097/01.gme.0000222475.93345.b3
   Florencio Silva R, 2018, BIOMED PHARMACOTHER, V98, P406, DOI 10.1016/j.biopha.2017.12.089
   Föger Samwald U, 2020, EXCLI J, V19, P1017, DOI 10.17179/excli2020 2591
   Foessl I, 2023, NAT REV ENDOCRINOL, V19, P520, DOI 10.1038/s41574 023 00866 9
   Gao F, 2011, ENDOCRINOLOGY, V152, P1434, DOI 10.1210/en.2010 1368
   Gavali S, 2019, BBA MOL CELL RES, V1866, P1498, DOI 10.1016/j.bbamcr.2019.06.014
   Goldstein SR, 2022, CLIMACTERIC, V25, P56, DOI 10.1080/13697137.2021.1936485
   Hamilton KJ, 2017, CURR TOP DEV BIOL, V125, P109, DOI 10.1016/bs.ctdb.2016.12.005
   Heino TJ, 2008, J ENDOCRINOL, V197, pR1, DOI 10.1677/JOE 07 0629
   Huang L, 2021, BIOACT MATER, V6, P3074, DOI 10.1016/j.bioactmat.2021.02.015
   Ikedo A, 2021, BIOCHEM BIOPH RES CO, V559, P238, DOI 10.1016/j.bbrc.2021.04.112
   Kang WB, 2015, J STEROID BIOCHEM, V154, P237, DOI 10.1016/j.jsbmb.2015.07.002
   Kanis JA, 2013, OSTEOPOROSIS INT, V24, P23, DOI 10.1007/s00198 012 2074 y
   Kawate H, 2011, CLIN INTERV AGING, V6, P151, DOI 10.2147/CIA.S15711
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Khalid AB, 2016, BONE, V87, P130, DOI 10.1016/j.bone.2016.03.016
   Khan MZI, 2022, EUR J MED CHEM, V241, DOI 10.1016/j.ejmech.2022.114658
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Kim B, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10815
   Kim HN, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 68890 7
   Kim MY, 2021, EXP MOL MED, V53, P103, DOI 10.1038/s12276 020 00548 w
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Kubi JA, 2023, BIOACT MATER, V27, P429, DOI 10.1016/j.bioactmat.2023.04.018
   Kulak J, 2010, ARQ BRAS ENDOCRINOL, V54, P200, DOI 10.1590/S0004 27302010000200016
   Kwon JS, 2014, BIOMATERIALS, V35, P5337, DOI 10.1016/j.biomaterials.2014.03.045
   Lems WF, 2021, OSTEOPOROSIS INT, V32, P399, DOI 10.1007/s00198 020 05804 3
   Levin VA, 2018, OSTEOPOROSIS INT, V29, P1049, DOI 10.1007/s00198 018 4414 z
   Lewiecki EM, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10192
   Li J, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2159 z
   Li LY, 2018, ADV EXP MED BIOL, V1086, P199, DOI 10.1007/978 981 13 1117 8_13
   Li NN, 2023, PHARMACOECONOMICS, DOI 10.1007/s40273 022 01239 2
   Martin Millan M, 2010, MOL ENDOCRINOL, V24, P323, DOI 10.1210/me.2009 0354
   Matsumoto Y, 2013, STEROIDS, V78, P513, DOI 10.1016/j.steroids.2013.02.011
   Miller PD, 2008, J BONE MINER RES, V23, P525, DOI 10.1359/JBMR.071206
   Okazaki R, 2002, ENDOCRINOLOGY, V143, P2349, DOI 10.1210/en.143.6.2349
   Oreffo ROC, 1999, HISTOCHEM CELL BIOL, V111, P125, DOI 10.1007/s004180050342
   Osborne CK, 2004, BRIT J CANCER, V90, pS2, DOI 10.1038/sj.bjc.6601629
   Raina PM, 2023, Bazedoxifene
   Rinonapoli G, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042105
   Ru JY, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 03059 8
   Salamanna F, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23168904
   Salari N, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02821 8
   Sfeir JG, 2022, MAYO CLIN PROC, V97, P1194, DOI 10.1016/j.mayocp.2022.03.011
   Sharma D, 2018, CHEM CENT J, V12, DOI 10.1186/s13065 018 0472 8
   Shen GY, 2017, ONCOTARGET, V8, P73559, DOI 10.18632/oncotarget.20611
   Shen YY, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.882241
   Si L, 2015, OSTEOPOROSIS INT, V26, P1929, DOI 10.1007/s00198 015 3093 2
   Sims NA, 2002, BONE, V30, P18, DOI 10.1016/S8756 3282(01)00643 3
   Singer A, 2023, ARCH OSTEOPOROS, V18, DOI 10.1007/s11657 023 01229 7
   Skjodt MK, 2019, BRIT J CLIN PHARMACO, V85, P1063, DOI 10.1111/bcp.13759
   Sun XQ, 2018, MED SCI MONITOR, V24, P903, DOI 10.12659/MSM.908705
   Tang CH, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222312725
   Torgerson DJ, 2001, JAMA J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891
   Tsukune N, 2017, BIOCHEM BIOPH RES CO, V488, P664, DOI 10.1016/j.bbrc.2017.02.110
   Uehara IA, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117921
   Vassilopoulou Sellin R, 1994, J Natl Cancer Inst Monogr, P153
   Wang C, 2016, MED SCI MONITOR, V22, P226, DOI 10.12659/MSM.897044
   Wang LT, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24065814
   Wang Y, 2023, BIOACT MATER, V25, P13, DOI 10.1016/j.bioactmat.2023.01.009
   Warriner AH, 2011, J CLIN EPIDEMIOL, V64, P46, DOI 10.1016/j.jclinepi.2010.07.007
   Wend Korinna, 2012, Front Endocrinol (Lausanne), V3, P19, DOI 10.3389/fendo.2012.00019
   Wu T, 2020, BIOACT MATER, V5, P348, DOI 10.1016/j.bioactmat.2020.03.004
   Xiao PL, 2022, OSTEOPOROSIS INT, V33, P2137, DOI 10.1007/s00198 022 06454 3
   Xiao ZF, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1701 1
   Xu XY, 2023, J BONE MINER RES, V38, P186, DOI 10.1002/jbmr.4731
   Xu ZY, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.1011725
   Yang XS, 2021, BIOACT MATER, V6, P3150, DOI 10.1016/j.bioactmat.2021.02.034
   Yang YL, 2024, BIOACT MATER, V41, P336, DOI 10.1016/j.bioactmat.2024.07.024
   Zhang GY, 2024, BIOACT MATER, V39, P354, DOI 10.1016/j.bioactmat.2024.05.037
   Zhang ZL, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974 018 1246 x
   Zheng LM, 2022, BIOACT MATER, V14, P250, DOI 10.1016/j.bioactmat.2021.11.012
   Zhou S, 2001, J CELL BIOCHEM, P144
   Zhou S, 2018, EXP THER MED, V15, P3623, DOI 10.3892/etm.2018.5839
NR 92
TC 1
Z9 1
U1 4
U2 12
PU KEAI PUBLISHING LTD
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, Building 5, Room 411, BEIJING, DONGCHENG
   DISTRICT 100009, PEOPLES R CHINA
EI 2452 199X
J9 BIOACT MATER
JI Bioact. Mater.
PD DEC
PY 2024
VL 42
BP 299
EP 315
DI 10.1016/j.bioactmat.2024.08.045
PG 17
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA F3R5U
UT WOS:001309030500001
PM 39290337
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Mohamedali, KA
   Li, ZG
   Starbuck, MW
   Wan, XH
   Yang, J
   Kim, S
   Zhang, WD
   Rosenblum, MG
   Navone, NM
AF Mohamedali, Khalid A.
   Li, Zhi Gang
   Starbuck, Michael W.
   Wan, Xinhai
   Yang, Jun
   Kim, Sehoon
   Zhang, Wendy
   Rosenblum, Michael G.
   Navone, Nora M.
TI Inhibition of Prostate Cancer Osteoblastic Progression with
   VEGF121/rGel, a Single Agent Targeting Osteoblasts,
   Osteoclasts, and Tumor Neovasculature
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID ENDOTHELIAL GROWTH FACTOR; FUSION TOXIN VEGF(121)/RGEL; ENDOCHONDRAL
   BONE FORMATION; COLONY STIMULATING FACTOR; FACTOR CONTRIBUTES; FACTOR
   VEGF; CELLS; METASTASIS; DIFFERENTIATION; MECHANISMS
AB Purpose: A hallmark of prostate cancer (PCa) progression is the development of osteoblastic bone metastases, which respond poorly to available therapies. We previously reported that VEGF(121)/rGel targets osteoclast precursors and tumor neovasculature. Here we tested the hypothesis that targeting nontumor cells expressing these receptors can inhibit tumor progression in a clinically relevant model of osteoblastic PCa.
   Experimental Design: Cells from MDA PCa 118b, a PCa xenograft obtained from a bone metastasis in a patient with castrate resistant PCa, were injected into the femurs of mice. Osteoblastic progression was monitored following systemic administration of VEGF(121)/rGel.
   Results: VEGF(121)/rGel was cytotoxic in vitro to osteoblast precursor cells. This cytotoxicity was specific as VEGF(121)/rGel internalization into osteoblasts was VEGF(121) receptor driven. Furthermore, VEGF(121)/rGel significantly inhibited PCa induced bone formation in a mouse calvaria culture assay. In vivo, VEGF(121)/rGel significantly inhibited the osteoblastic progression of PCa cells in the femurs of nude mice. Microcomputed tomographic analysis revealed that VEGF(121)/rGel restored the bone volume fraction of tumor bearing femurs to values similar to those of the contralateral (non tumor bearing) femurs. VEGF(121)/rGel significantly reduced the number of tumor associated osteoclasts but did not change the numbers of peritumoral osteoblasts. Importantly, VEGF(121)/rGel treated mice had significantly less tumor burden than control mice. Our results thus indicate that VEGF(121)/rGel inhibits osteoblastic tumor progression by targeting angiogenesis, osteoclastogenesis, and bone formation.
   Conclusions: Targeting VEGF receptor (VEGFR) 1 or VEGFR 2 expressing cells is effective in controlling the osteoblastic progression of PCa in bone. These findings provide the basis for an effective multitargeted approach for metastatic PCa. Clin Cancer Res; 17(8); 2328 38. (C) 2011 AACR.
C1 [Mohamedali, Khalid A.; Kim, Sehoon; Zhang, Wendy; Rosenblum, Michael G.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA.
   [Li, Zhi Gang; Starbuck, Michael W.; Wan, Xinhai; Yang, Jun; Navone, Nora M.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center
RP Mohamedali, KA (通讯作者)，1515 Holcombe Blvd,Unit 1950, Houston, TX 77030 USA.
EM kmohamed@mdanderson.org
RI ; Kim, Sehoon/B 7330 2014; Yao, Jun/JAC 5608 2023
OI Mohamedali, Khalid/0000 0002 8249 5304; 
FU Clayton Foundation; NIH [R01 CA96797, CA016672]; Prostate Cancer
   Foundatio
FX This research was conducted in part by the Clayton Foundation for
   Research (M. G. Rosenblum) and was supported by grants from the NIH (R01
   CA96797) and the Prostate Cancer Foundation (both to N.M. Navone) and in
   part by the NIH through MD Anderson Cancer Center's support grant
   (CA016672).
CR Blanchard F, 2009, CYTOKINE GROWTH F R, V20, P19, DOI 10.1016/j.cytogfr.2008.11.004
   Carlevaro MF, 2000, J CELL SCI, V113, P59
   Casimiro S, 2009, MOL CELL ENDOCRINOL, V310, P71, DOI 10.1016/j.mce.2009.07.004
   Chen JH, 2004, CELL COMMUN ADHES, V11, P1, DOI 10.1080/15419060490471739
   Dai JL, 2004, CANCER RES, V64, P994, DOI 10.1158/0008 5472.CAN 03 1382
   Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012
   GALASKO CSB, 1982, CLIN ORTHOP RELAT R, P20
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200
   Goltzman D, 1997, CANCER, V80, P1581, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1581::AID CNCR8>3.0.CO;2 N
   Horner A, 1999, J ANAT, V194, P519, DOI 10.1046/j.1469 7580.1999.19440519.x
   Hotz B, 2010, NEOPLASIA, V12, P797, DOI 10.1593/neo.10418
   Hsu AR, 2007, J NUCL MED, V48, P445
   Ismail A Hazem, 2004, Can J Urol, V11, P2146
   Jemal A, 2009, CA CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186
   Kitagawa Y, 2005, CANCER RES, V65, P10921, DOI 10.1158/0008 5472.CAN 05 1809
   Koeneman KS, 1999, PROSTATE, V39, P246
   KOUTSILIERIS M, 1993, ANTICANCER RES, V13, P443
   Kroll J, 1999, BIOCHEM BIOPH RES CO, V265, P636, DOI 10.1006/bbrc.1999.1729
   Lange PH, 1998, CANCER METAST REV, V17, P331, DOI 10.1023/A:1006106209527
   Langley RR, 2007, ENDOCR REV, V28, P297, DOI 10.1210/er.2006 0027
   Lee RJ, 2011, BONE, V48, P88, DOI 10.1016/j.bone.2010.05.038
   Lee YP, 2002, CANCER RES, V62, P5564
   Li ZG, 2008, J CLIN INVEST, V118, P2697, DOI 10.1172/JCI33093
   Matsumoto Y, 2002, J IMMUNOL, V168, P5824, DOI 10.4049/jimmunol.168.11.5824
   Mayr Wohlfart U, 2002, BONE, V30, P472, DOI 10.1016/S8756 3282(01)00690 1
   McMahon G, 2000, Oncologist, V5 Suppl 1, P3
   Mohamedali KA, 2005, NEOPLASIA, V7, P912, DOI 10.1593/neo.05292
   Mohamedali KA, 2006, CANCER RES, V66, P10919, DOI 10.1158/0008 5472.CAN 06 0459
   Navone NM, 1997, CLIN CANCER RES, V3, P2493
   Niida S, 1999, J EXP MED, V190, P293, DOI 10.1084/jem.190.2.293
   Niida S, 2005, P NATL ACAD SCI USA, V102, P14016, DOI 10.1073/pnas.0503544102
   Otsuka S, 2009, ONCOL RES, V17, P581, DOI 10.3727/096504009789745511
   Qian BZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006562
   Ran S, 2005, NEOPLASIA, V7, P486, DOI 10.1593/neo.04631
   Shariat SF, 2004, J CLIN ONCOL, V22, P1655, DOI 10.1200/JCO.2004.09.142
   Shibuya M, 1995, ADV CANCER RES, V67, P281, DOI 10.1016/S0065 230X(08)60716 2
   Smagur A, 2009, ACTA BIOCHIM POL, V56, P115
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Veenendaal LM, 2002, P NATL ACAD SCI USA, V99, P10941, DOI 10.1073/pnas.162346299
   Vessella RL, 2006, CLIN CANCER RES, V12, p6285S, DOI 10.1158/1078 0432.CCR 06 0813
   WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988
   Yamauchi M, 2005, AM J PHYSIOL ENDOC M, V288, pE608, DOI 10.1152/ajpendo.00229.2004
   Yang J, 2001, CANCER RES, V61, P5652
   Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004
   Zelzer E, 2002, DEVELOPMENT, V129, P1893
   Zelzer E, 2004, DEVELOPMENT, V131, P2161, DOI 10.1242/dev.01053
   Zeng YP, 2004, CLIN CANCER RES, V10, P5137, DOI 10.1158/1078 0432.CCR 03 0434
NR 49
TC 21
Z9 22
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1078 0432
EI 1557 3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD APR 15
PY 2011
VL 17
IS 8
BP 2328
EP 2338
DI 10.1158/1078 0432.CCR 10 2943
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 750NP
UT WOS:000289555500026
PM 21343372
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Appelt, J
   Baranowsky, A
   Jahn, D
   Yorgan, T
   Köhli, P
   Otto, E
   Farahani, SK
   Graef, F
   Fuchs, M
   Herrera, A
   Amling, M
   Schinke, T
   Frosch, KH
   Duda, GN
   Tsitsilonis, S
   Keller, J
AF Appelt, Jessika
   Baranowsky, Anke
   Jahn, Denise
   Yorgan, Timur
   Koehli, Paul
   Otto, Ellen
   Farahani, Saeed Khomeijani
   Graef, Frank
   Fuchs, Melanie
   Herrera, Aaron
   Amling, Michael
   Schinke, Thorsten
   Frosch, Karl Heinz
   Duda, Georg N.
   Tsitsilonis, Serafeim
   Keller, Johannes
TI The neuropeptide calcitonin gene related peptide alpha is essential for
   bone healing
SO EBIOMEDICINE
LA English
DT Article
DE Fracture; Bone regeneration; Osteoblasts; Osteoclasts; Neuropeptides;
   alpha CGRP; CRLR; Olcegepant
ID TRAUMATIC BRAIN INJURY; EXTRACEREBRAL CIRCULATION; CGRP;
   DIFFERENTIATION; OSTEOBLASTS; MIGRAINE; EXPRESSION; PLASMA; FAMILY; RAT
AB Background: Impaired fracture healing represents an ongoing clinical challenge, as treatment options remain limited. Calcitonin gene related peptide (CGRP), a neuropeptide targeted by emerging anti migraine drugs, is also expressed in sensory nerve fibres innervating bone tissue.
   Method: Bone healing following a femoral osteotomy stabilized with an external fixator was analysed over 21 days in alpha CGRP deficient and WT mice. Bone regeneration was evaluated by serum analysis, mu CT analysis, histomorphometry and genome wide expression analysis. Bone marrow derived osteoblasts and osteoclasts, as well as the CGRP antagonist olcegepant were employed for mechanistic studies.
   Findings: WT mice with a femoral fracture display increased CGRP serum levels. alpha CGRP mRNA expression after skeletal injury is exclusively induced in callus tissue, but not in other organs. On protein level, CGRP and its receptor, calcitonin receptor like receptor (CRLR) complexing with RAMP1, are differentially expressed in the callus during bone regeneration. On the other hand, alpha CGRP deficient mice display pro foundly impaired bone regeneration characterised by a striking reduction in the number of bone forming osteoblasts and a high rate of incomplete callus bridging and non union. As assessed by genome wide expression analysis, CGRP induces the expression of specific genes linked to ossification, bone remodeling and adipogenesis. This suggests that CGRP receptor dependent PPAR gamma signaling plays a central role in fracture healing.
   Interpretation: This study demonstrates an essential role of alpha CGRP in orchestrating callus formation and identifies CGRP receptor agonism as a potential approach to stimulate bone regeneration. Moreover, as novel agents blocking CGRP or its receptor CRLR are currently introduced clinically for the treatment of migraine disorders, their potential negative impact on bone regeneration warrants clinical investigation. (C) 2020 The Author(s). Published by Elsevier B.V.
C1 [Appelt, Jessika; Jahn, Denise; Koehli, Paul; Otto, Ellen; Graef, Frank; Fuchs, Melanie; Tsitsilonis, Serafeim] Charite Univ Med Berlin, Ctr Musculoskeletal Surg, D 13353 Berlin, Germany.
   [Appelt, Jessika; Jahn, Denise; Farahani, Saeed Khomeijani; Herrera, Aaron; Duda, Georg N.; Tsitsilonis, Serafeim] Charite Univ Med Berlin, Julius Wolff Inst Biomech & Musculoskeletal Regen, D 13353 Berlin, Germany.
   [Baranowsky, Anke; Frosch, Karl Heinz; Keller, Johannes] Univ Med Ctr Hamburg Eppendorf, Dept Trauma & Orthoped Surg, D 20246 Hamburg, Germany.
   [Baranowsky, Anke; Yorgan, Timur; Amling, Michael; Schinke, Thorsten] Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, D 20246 Hamburg, Germany.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin; University of
   Hamburg; University Medical Center Hamburg Eppendorf; University of
   Hamburg; University Medical Center Hamburg Eppendorf
RP Keller, J (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Dept Trauma & Orthoped Surg, D 20246 Hamburg, Germany.
EM j.keller@uke.de
RI Jahn, Denise/KRP 8864 2024; Duda, Georg/H 2085 2016; Otto,
   Ellen/KIG 8274 2024
OI Graef, Frank/0000 0002 0435 9059; Duda, Georg/0000 0001 7605 3908;
   Keller, Johannes/0000 0002 8925 7288; Herrera Martin, Aaron
   Xerach/0000 0002 9780 1562; Khomeijani Farahani,
   Saeed/0000 0003 4113 3021; Jahn, Denise/0000 0001 8912 5851; Otto,
   Ellen/0000 0001 9394 0066; Kohli, Paul/0000 0001 7473 6553
FU Else Kroner Fresenius Stiftung [EKFS 2017_A22]; Deutsche
   Forschungsgemeinschaft [DFG KE 2179/2 1, TS 303/2 1]; Berlin Institute
   of Health (BIH)
FX This study was funded by grants to JK and ST by the
   Else Kroner Fresenius Stiftung (EKFS 2017_A22), the Deutsche
   Forschungsgemeinschaft (DFG KE 2179/2 1; TS 303/2 1) and the Berlin
   Institute of Health (BIH).
CR Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Aubdool AA, 2017, CIRCULATION, V136, P367, DOI 10.1161/CIRCULATIONAHA.117.028388
   Ballica R, 1999, J BONE MINER RES, V14, P1067, DOI 10.1359/jbmr.1999.14.7.1067
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Bussiere JL, 2019, REGUL TOXICOL PHARM, V106, P224, DOI 10.1016/j.yrtph.2019.05.013
   BUZZI MG, 1991, NEUROPHARMACOLOGY, V30, P1193, DOI 10.1016/0028 3908(91)90165 8
   Ceriani CEJ, 2019, HEADACHE, V59, P1597, DOI 10.1111/head.13661
   Charles A, 2019, LANCET, V394, P1765, DOI 10.1016/S0140 6736(19)32504 8
   Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1
   Deen M, 2017, J HEADACHE PAIN, V18, DOI 10.1186/s10194 017 0807 1
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Edvinsson L, 2018, NAT REV NEUROL, V14, P338, DOI 10.1038/s41582 018 0003 1
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0
   EMESON RB, 1992, ANN NY ACAD SCI, V657, P18
   ESCOTT KJ, 1995, BRAIN RES, V669, P93, DOI 10.1016/0006 8993(94)01247 F
   Finlay DB, 2020, BRIT J PHARMACOL, V177, P1472, DOI 10.1111/bph.14988
   GALLAI V, 1995, CEPHALALGIA, V15, P384, DOI 10.1046/j.1468 2982.1995.1505384.x
   GOADSBY PJ, 1988, ANN NEUROL, V23, P193, DOI 10.1002/ana.410230214
   GOADSBY PJ, 1990, ANN NEUROL, V28, P183, DOI 10.1002/ana.410280213
   Hak DJ, 2014, INJURY, V45, pS3, DOI 10.1016/j.injury.2014.04.002
   Hankenson KD, 2015, ADV DRUG DELIVER REV, V94, P3, DOI 10.1016/j.addr.2015.09.008
   Hay DL, 2018, BRIT J PHARMACOL, V175, P3, DOI 10.1111/bph.14075
   Hildebrand TOR, 1997, Comput Methods Biomech Biomed Engin, V1, P15, DOI 10.1080/01495739708936692
   Huebner AK, 2008, ARCH BIOCHEM BIOPHYS, V473, P210, DOI 10.1016/j.abb.2008.02.013
   Irie K, 2002, MICROSC RES TECHNIQ, V58, P85, DOI 10.1002/jemt.10122
   Keller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6215
   Kim SP, 2010, BIOCHEM BIOPH RES CO, V399, P55, DOI 10.1016/j.bbrc.2010.07.038
   Kitase Y, 2014, J DENT RES, V93, P1108, DOI 10.1177/0022034514553008
   Kosaki N, 2007, BIOCHEM BIOPH RES CO, V354, P846, DOI 10.1016/j.bbrc.2006.12.234
   Lee HW, 2009, STEM CELLS, V27, P2254, DOI 10.1002/stem.144
   Li L, 2007, J ORTHOP RES, V25, P1204, DOI 10.1002/jor.20406
   Lipton RB, 2019, JAMA J AM MED ASSOC, V322, P1887, DOI 10.1001/jama.2019.16711
   Lu JT, 1999, MOL CELL NEUROSCI, V14, P99, DOI 10.1006/mcne.1999.0767
   MACDONALD NJ, 1989, BRIT J CLIN PHARMACO, V28, P257, DOI 10.1111/j.1365 2125.1989.tb05424.x
   Mrak E, 2010, J CELL PHYSIOL, V225, P701, DOI 10.1002/jcp.22266
   Mumme M, 2012, EUR CELLS MATER, V24, P224, DOI 10.22203/eCM.v024a16
   Naot D, 2019, PHYSIOL REV, V99, P781, DOI 10.1152/physrev.00066.2017
   Neagu TP, 2016, ROM J MORPHOL EMBRYO, V57, P1215
   Negishi Koga T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7637
   Niedermair T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020405
   Nilsson C, 2016, EUR J PHARMACOL, V773, P24, DOI 10.1016/j.ejphar.2016.01.003
   Oni O O, 1990, J Orthop Trauma, V4, P441
   Onuoha GN, 2001, PEPTIDES, V22, P1107, DOI 10.1016/S0196 9781(01)00434 X
   Onuoha GN, 2000, NEUROPEPTIDES, V34, P116, DOI 10.1054/npep.2000.0803
   Russow G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010083
   Schinke T, 2004, J BONE MINER RES, V19, P2049, DOI 10.1359/JBMR.040915
   Scott LJ, 2020, DRUGS, V80, P323, DOI 10.1007/s40265 020 01264 5
   Seeling M, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305 5839.2015.06.26
   Seemann R, 2018, J MUSCULOSKEL NEURON, V18, P32
   Sexton PM, 2008, CRIT CARE MED, V36, P1637, DOI 10.1097/CCM.0b013e318170a554
   Sinder BP, 2017, J BONE MINER RES, V32, P2116, DOI 10.1002/jbmr.3196
   Sonomoto K, 2012, ARTHRITIS RHEUM US, V64, P3355, DOI 10.1002/art.34555
   Staines KA, 2014, J BONE MINER METAB, V32, P240, DOI 10.1007/s00774 013 0493 2
   Tepper SJ, 2018, HEADACHE, V58, P238, DOI 10.1111/head.13379
   Tian G, 2013, ACTA PHARMACOL SIN, V34, P1467, DOI 10.1038/aps.2013.41
   Tsitsilonis S, 2015, INJURY, V46, P661, DOI 10.1016/j.injury.2015.01.044
   Tzioupis C, 2007, INJURY, V38, pS3, DOI 10.1016/S0020 1383(07)80003 9
   Wang CC, 2019, AM J PATHOL, V189, P648, DOI 10.1016/j.ajpath.2018.11.019
   Wang LP, 2010, BONE, V46, P1369, DOI 10.1016/j.bone.2009.11.029
   Wang YY, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03899 z
   Williams GA, 2009, ENDOCRINOLOGY, V150, P3603, DOI 10.1210/en.2008 1639
   Yuan H, 2019, HEADACHE, V59, P20, DOI 10.1111/head.13583
   Zhang YF, 2016, NAT MED, V22, P1160, DOI 10.1038/nm.4162
   Zhou R, 2016, MOL MED REP, V13, P4689, DOI 10.3892/mmr.2016.5117
   Zou R, 2010, ACTA PHARMACOL SIN, V31, P43, DOI 10.1038/aps.2009.174
NR 66
TC 53
Z9 61
U1 1
U2 34
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352 3964
J9 EBIOMEDICINE
JI EBioMedicine
PD SEP
PY 2020
VL 59
AR 102970
DI 10.1016/j.ebiom.2020.102970
PG 14
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA NX1AN
UT WOS:000575450100013
PM 32853990
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhao, HY
   Xu, HH
   Qiao, SY
   Lu, C
   Wang, G
   Liu, MJ
   Guo, BS
   Tan, Y
   Ju, DH
   Xiao, C
AF Zhao, Hongyan
   Xu, Huihui
   Qiao, Senyan
   Lu, Cheng
   Wang, Gui
   Liu, Meijie
   Guo, Baosheng
   Tan, Yong
   Ju, Dahong
   Xiao, Cheng
TI Boldine isolated from Litsea cubeba inhibits bone resorption by
   suppressing the osteoclast differentiation in collagen induced arthritis
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Boldine; OPG/RANKL/RANK signaling pathway; Collagen induced arthritis;
   Osteoclast; Bone resorption; Litsea cubeba
ID RHEUMATOID ARTHRITIS; ANTIOXIDANT; DAMAGE; OSTEOPOROSIS; RANKL;
   MICROSTRUCTURE; INFLAMMATION; MECHANISMS; EXPRESSION; THERAPIES
AB Objective: To investigate the effect of boldine isolated from Litsea cubeba on collagen induced arthritis (CIA) rats and explore the molecular mechanism predicted by network pharmacology.
   Material and methods: CIA rats were orally administered with boldine. The bone destruction of paws was analyzed by histologic examination, tartrate resistant acid phosphatase (TRACP) staining and micro computed tomography. Prediction of signal pathway associated with boldine network molecules and CIA genes was applied by the network pharmacology analysis. The expressions of osteoprotegerin (OPG), receptor activator of nuclear factor kappa B (RANK) and its ligand (RANKL) in the ankle were detected by immunohistochemistry. In vitro osteoclasts were cultured in the presence of variable doses of boldine and the RANK expressions were evaluated using Real time polymerase chain reaction and western blot.
   Results: Boldine reduced ankle swelling, alleviated pathological damage and significantly prevented bone destruction in CIA rats. Consistent with this, enzyme linked immunosorbent assay revealed boldine decreased serum TRACP5b levels and osteoclast number in the ankle region by TRACP staining from CIA rats. The network pharmacology analysis indicated that RANK signaling in osteoclasts was the most significant canonical pathway associated with boldine network molecules and CIA genes, which was verified by the increased expression of OPG, reduced expression of RANK, RANKL and RANKL/OPG in boldine treated CIA rats. The in vitro study further confirmed that boldine inhibited osteoclastogenesis by inhibiting the RANKL/RANK signaling pathway.
   Conclusion: Taken together, our study first indicates that boldine from Litsea cubeba suppresses osteoclastogenesis, improves bone destruction by down regulating the OPG/RANKL/RANK signal pathway and may be a potential therapeutic agent for rheumatoid arthritis.
C1 [Zhao, Hongyan; Liu, Meijie; Ju, Dahong] China Acad Chinese Med Sci, Expt Res Ctr, Beijing, Peoples R China.
   [Zhao, Hongyan; Liu, Meijie; Ju, Dahong] China Acad Chinese Med Sci, Inst Basic Theory Chinese Med, Beijing, Peoples R China.
   [Xu, Huihui; Wang, Gui; Xiao, Cheng] China Japan Friendship Hosp, Inst Clin Med, Beijing, Peoples R China.
   [Xu, Huihui; Wang, Gui] Beijing Univ Chinese Med, Beijing, Peoples R China.
   [Qiao, Senyan] Third Peoples Hosp Zhengzhou, Dept Pathol, Zhengzhou, Henan, Peoples R China.
   [Lu, Cheng; Tan, Yong] China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing, Peoples R China.
   [Guo, Baosheng] Hong Kong Baptist Univ, Sch Chinese Med, Inst Adv Translat Med Bone & Joint Dis, Hong Kong, Peoples R China.
C3 China Academy of Chinese Medical Sciences; Experimental Research Center,
   CACMS; Institute of Basic Theory for Chinese Medicine, CACMS; China
   Academy of Chinese Medical Sciences; China Japan Friendship Hospital;
   Beijing University of Chinese Medicine; China Academy of Chinese Medical
   Sciences; Institute of Basic Research In Clinical Medicine, CACMS; Hong
   Kong Baptist University
RP Xiao, C (通讯作者)，China Japan Friendship Hosp, Inst Clin Med, Beijing, Peoples R China.
EM xc2002812@126.com
RI Xiao, Cheng/AAM 7764 2020; Guo, Baosheng/ABD 4800 2021
OI xiao, Cheng/0000 0002 5601 9670; Guo, Baosheng/0000 0002 4510 5418
FU National Natural Science Foundation of China [81373773, 81573845,
   81673844]; Beijing Natural Science Foundation [7142144]; Ministry of
   Science and Technology [2014DFA31490]; National Nonprofit Institute
   Research Grant for Institute of Basic Theory for Chinese Medicine, CACMS
   [YZ 1405]; State Administration of Traditional Chinese Medicine
   [GZYYGJ2017014]
FX This work was supported by the National Natural Science Foundation of
   China [grant numbers 81373773, 81573845, 81673844]; Beijing Natural
   Science Foundation [grant numbers 7142144]; International Cooperation
   Project of the Ministry of Science and Technology[grant number
   2014DFA31490]; National Nonprofit Institute Research Grant for Institute
   of Basic Theory for Chinese Medicine, CACMS [grant numbers YZ 1405];
   International Cooperation Project of the State Administration of
   Traditional Chinese Medicine (grant number GZYYGJ2017014).
CR Ainola M, 2008, CLIN EXP RHEUMATOL, V26, P240
   Bannach R, 1996, CELL BIOL TOXICOL, V12, P89, DOI 10.1007/BF00143359
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Camps M, 2005, NAT MED, V11, P936, DOI 10.1038/nm1284
   Colmegna I, 2012, CLIN PHARMACOL THER, V91, P607, DOI 10.1038/clpt.2011.325
   Danks L, 2002, ANN RHEUM DIS, V61, P916, DOI 10.1136/ard.61.10.916
   Durand M, 2011, BONE, V48, P588, DOI 10.1016/j.bone.2010.10.167
   Filipovic I, 2011, RHEUMATOLOGY, V50, P1083, DOI 10.1093/rheumatology/keq399
   Hou JM, 2012, ACTA PHARMACOL SIN, V33, P1277, DOI 10.1038/aps.2012.83
   Hwang JK, 2005, FITOTERAPIA, V76, P684, DOI 10.1016/j.fitote.2005.05.007
   Jang YY, 2000, PHARMACOL RES, V42, P361, DOI 10.1006/phrs.2000.0705
   Jung SM, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/263625
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Li S, 2014, EVID BASED COMPL ALT, V2014, DOI 10.1155/2014/138460
   Lin B, 2013, J ETHNOPHARMACOL, V147, P327, DOI 10.1016/j.jep.2013.03.011
   Ma B, 2012, ACTA PHARMACOL SIN, V33, P479, DOI 10.1038/aps.2011.177
   Marenzana M, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4305
   Matuszewska A, 2014, POSTEP HIG MED DOSW, V68, P145, DOI 10.5604/17322693.1088339
   McHugh KP, 2010, ANN RHEUM DIS, V69, P83, DOI 10.1136/ard.2009.120188
   Mellado M, 2015, BIOINORG CHEM APPL, V2015, DOI 10.1155/2015/920143
   Mulherin D, 1996, ARTHRITIS RHEUM, V39, P115, DOI 10.1002/art.1780390116
   Mun SH, 2014, ARTHRITIS RHEUMATOL, V66, P2482, DOI 10.1002/art.38723
   Murariu RV, 2013, MED SURG J, V117, P394
   Muthna D, 2013, NAT PROD COMMUN, V8, P1797
   Nanau RM, 2014, J PHARM PHARM SCI, V17, P324, DOI 10.18433/J3WP4F
   O'Brien P, 2006, CHEM BIOL INTERACT, V159, P1, DOI 10.1016/j.cbi.2005.09.002
   Pathak JL, 2014, OSTEOPOROSIS INT, V25, P2453, DOI 10.1007/s00198 014 2779 1
   Paydar M, 2014, DRUG DES DEV THER, V8, P719, DOI 10.2147/DDDT.S58178
   Qiao S., 2015, J CHINA JPN FRIENDSH, V29, P99
   Sardar S, 2016, IMMUNOPHARM IMMUNOT, V38, P2, DOI 10.3109/08923973.2015.1125917
   SHARP JT, 1991, ARTHRITIS RHEUM, V34, P660, DOI 10.1002/art.1780340606
   Smolen JS, 2007, LANCET, V370, P1861, DOI 10.1016/S0140 6736(07)60784 3
   Sokolove J, 2016, ANN RHEUM DIS, V75, P637, DOI 10.1136/annrheumdis 2015 208308
   Walsh NC, 2004, CURR OPIN RHEUMATOL, V16, P419, DOI 10.1097/01.bor.0000127824.42507.68
   Wang HW, 2010, CHEM BIODIVERS, V7, P229, DOI 10.1002/cbdv.200800349
   Xuan WH, 2017, CELL BIOCHEM FUNCT, V35, P171, DOI 10.1002/cbf.3260
   Yang X., 2017, PLANTA MED
   Zhang Shui Ying, 2014, Zhongguo Zhong Yao Za Zhi, V39, P3964
   Zhang XZ, 2014, MOL BIOSYST, V10, P2517, DOI 10.1039/c4mb00164h
   Zhao HY, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/102641
NR 41
TC 25
Z9 31
U1 2
U2 26
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD OCT
PY 2017
VL 51
BP 114
EP 123
DI 10.1016/j.intimp.2017.08.013
PG 10
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA FI2MC
UT WOS:000411772000015
PM 28826044
DA 2025 08 17
ER

PT J
AU Gutta, R
   Louis, PJ
AF Gutta, Rajesh
   Louis, Patrick J.
TI Bisphosphonates and osteonecrosis of the jaws: Science and rationale
SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND
   ENDODONTOLOGY
LA English
DT Article
ID CALCIUM PHOSPHATE CRYSTALS; MULTIPLE MYELOMA; ZOLEDRONIC ACID;
   RISK FACTORS; IN VITRO; BONE RESORPTION; BREAST CANCER;
   MOLECULAR MECHANISMS; DIPHOSPHONATES; RAT
AB Bisphosphonates as a group of drugs were introduced for the management of various conditions such as osteoporosis, Paget's disease, multiple myeloma, hypercalcemia of malignancy, breast cancer, prostate cancer, and other tumors. This group of drugs has improved the quality of life in many patients with proven efficacy in limiting pain and skeletal related events. The controversy of osteonecrosis of the jaws and bisphosphonates is a recent and growing problem. Osteonecrosis of the jaws is recognized as a serious complication of bisphosphonate therapy, more commonly with the intravenous form of the drugs. However, there is limited scientific understanding about the association between osteonecrosis of the jaws and bisphosphonates. In the present article we discuss various mechanisms of action of bisphosphonates, the rationale for occurrence of osteonecrosis in the jaws, and treatment guidelines for the condition.
C1 Univ Alabama, Oral & Maxillofacial Residency Program, Tuscaloosa, AL 35487 USA.
C3 University of Alabama System; University of Alabama Tuscaloosa
RP Gutta, R (通讯作者)，419 Sch Dent Bldg 1919,7th Ave S, Birmingham, AL 35294 USA.
EM rajeshg@uab.edu
CR Alatli I, 1996, ACTA ODONTOL SCAND, V54, P59, DOI 10.3109/00016359609003511
   American Association of Oral and Maxillofacial Surgeons (AAOMS), POS PAP BISPH REL OS
   Assouline Dayan Y, 2002, SEMIN ARTHRITIS RHEU, V32, P94, DOI 10.1053/sarh.2002.33724
   Badros A, 2006, J CLIN ONCOL, V24, P945, DOI 10.1200/JCO.2005.04.2465
   BALENA R, 1993, J CLIN INVEST, V92, P2577, DOI 10.1172/JCI116872
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   BASSETT CAL, 1969, LANCET, V2, P845
   BIJVOET O, 1995, BISPOSPHONATES BONE
   BISAZ S, 1978, CLIN SCI MOL MED, V54, P265, DOI 10.1042/cs0540265
   Body JJ, 2003, BREAST, V12, pS37, DOI 10.1016/S0960 9776(03)80162 5
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Bouquot JE, 2000, J ORAL MAXIL SURG, V58, P1003, DOI 10.1053/joms.2000.8744
   BRINER W W, 1971, International Dental Journal, V21, P61
   Caraglia M, 2006, ENDOCR RELAT CANCER, V13, P7, DOI 10.1677/erc.1.01094
   CARAGLIA M, 2005, CANCER CHEMOTH PHARM, V12, P1
   CECCHINI MG, 1987, J BONE MINER RES, V2, P135
   Coleman RE, 2005, J CLIN ONCOL, V23, P4925, DOI 10.1200/JCO.2005.06.091
   Conte P, 2004, ONCOLOGIST, V9, P28, DOI 10.1634/theoncologist.9 90004 28
   Coxon FP, 2001, J BIOL CHEM, V276, P48213, DOI 10.1074/jbc.M106473200
   David P, 1996, J BONE MINER RES, V11, P1498, DOI 10.1002/jbmr.5650111017
   Delmas PD, 1997, NEW ENGL J MED, V336, P558, DOI 10.1056/NEJM199702203360807
   FELIX R, 1976, BIOCHIM BIOPHYS ACTA, V429, P429, DOI 10.1016/0005 2744(76)90291 6
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   FLEISCH H, 1966, NATURE, V212, P901, DOI 10.1038/212901a0
   FLEISCH HA, 1970, EUR J CLIN INVEST, V1, P12, DOI 10.1111/j.1365 2362.1970.tb00591.x
   Flora L., 1980, METAB BONE DIS RELAT, V2S, P389
   Fournier P, 2002, CANCER RES, V62, P6538
   FRANCIS MD, 1969, SCIENCE, V165, P1264, DOI 10.1126/science.165.3899.1264
   Gruppo R, 1996, J LAB CLIN MED, V127, P481, DOI 10.1016/S0022 2143(96)90065 7
   Guarneri V, 2005, ONCOLOGIST, V10, P842, DOI 10.1634/theoncologist.10 10 842
   Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509
   Hellstein JW, 2005, J ORAL MAXIL SURG, V63, P682, DOI 10.1016/j.joms.2005.01.010
   Hillner BE, 2003, J CLIN ONCOL, V21, P4042, DOI 10.1200/JCO.2003.08.017
   John Anitha, 2001, Pathology and Oncology Research, V7, P14
   KASTING GB, 1992, J BONE MINER RES, V7, P513
   Keen RW, 1996, BRIT J CLIN PRACT, V50, P211
   KRAMSCH DM, 1978, CIRC RES, V42, P562, DOI 10.1161/01.RES.42.4.562
   LARSSON A, 1974, CALC TISS RES, V16, P109, DOI 10.1007/BF02008217
   Legge T., 1934, IND MALADIES
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   McCloskey EV, 1998, BRIT J HAEMATOL, V100, P317
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Menschutkin N., 1865, ANN CHEM PHARM, V133, P317
   MUHLEMANN HR, 1970, HELV ODONTOL ACTA, V14, P31
   Mundy GR, 1998, NEW ENGL J MED, V339, P398, DOI 10.1056/NEJM199808063390609
   Mundy GR, 2001, SEMIN ONCOL, V28, P35, DOI 10.1053/sonc.2001.24158
   MURAKAMI H, 1995, BONE, V17, P137, DOI 10.1016/S8756 3282(95)00150 6
   NISKIKAWA M, 1996, BONE, V18, P9
   *NOV PHARM CO, 2004, UPD SAF POSS REL AR
   RALSTON SH, 1989, LANCET, V2, P1180
   REGINSTER JY, 1989, LANCET, V2, P1469
   REITSMA PH, 1980, CALCIFIED TISSUE INT, V32, P145, DOI 10.1007/BF02408534
   Reszka Alfred A, 2003, Curr Osteoporos Rep, V1, P45, DOI 10.1007/s11914 003 0008 5
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   SCHENK R, 1986, CALCIFIED TISSUE INT, V38, P342, DOI 10.1007/BF02555748
   Senaratne SG, 2002, BRIT J CANCER, V86, P1479, DOI 10.1038/sj.bjc.6600297
   Starck W J, 1995, Int J Oral Maxillofac Implants, V10, P74
   STORM T, 1993, J BONE MINER RES, V8, P199
   STURZENBERGER OP, 1971, J PERIODONTOL, V42, P416, DOI 10.1902/jop.1971.42.7.416
   Suda T, 1997, J BONE MINER RES, V12, P869, DOI 10.1359/jbmr.1997.12.6.869
   Tarassoff P, 2003, J ORAL MAXIL SURG, V61, P1238, DOI 10.1016/j.joms.2003.09.001
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   Twiss IM, 1999, J BONE MINER RES, V14, P784, DOI 10.1359/jbmr.1999.14.5.784
   WEILE V, 1990, ARCH ORAL BIOL, V35, P857, DOI 10.1016/0003 9969(90)90064 H
   Zervas K, 2006, BRIT J HAEMATOL, V134, P620, DOI 10.1111/j.1365 2141.2006.06230.x
   Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325
   ZIGIC TM, 1985, AM J MED, V79, P596
   1944, BR DENT J, V76, P343
NR 69
TC 62
Z9 73
U1 0
U2 3
PU MOSBY ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010 1710 USA
SN 1079 2104
J9 ORAL SURG ORAL MED O
JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.
PD AUG
PY 2007
VL 104
IS 2
BP 186
EP 193
DI 10.1016/j.tripleo.2006.12.004
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 198CP
UT WOS:000248604900008
PM 17448709
DA 2025 08 17
ER

PT J
AU Yao, YC
   Wang, X
   Lin, LC
   Zhang, XL
   Wang, Y
AF Yao, Yichen
   Wang, Xin
   Lin, Lichieh
   Zhang, Xiaolei
   Wang, Yan
TI ROR2 Related Skeletal Dysplasia Reveals Disrupted Chondrocyte Polarity
   through Modulation of BMP/TGF β Signaling
SO AGING AND DISEASE
LA English
DT Article
DE Robinow syndrome; Ror2; skeletal development; BMP/TGF beta signaling
ID PLANAR CELL POLARITY; TYROSINE KINASE ROR2; VANGL2 PHOSPHORYLATION;
   ROBINOW SYNDROME; WNT; GROWTH; FK506; MUTATION; DIFFERENTIATION;
   MECHANISM
AB Genetic studies have shown that Robinow syndrome (RS), a rare skeletal dysplasia, is caused by ROR2 mutation. However, the cell origin and molecular mechanisms underlying this disease remain elusive. We established a conditional knockout system by crossing Prx1cre and Osxcre with Ror2(flox/flox) mice. and conducted histological and immunofluorescence analyses to investigate the phenotypes during skeletal development. In the Prx1cre line, we observed RS like skeletal abnormities, including short stature and an arched skull. Additionally, we found inhibition of chondrocyte differentiation and proliferation. In the Osxcre line, loss of ROR2 in osteoblast lineage cells led to reduced osteoblast differentiation during both embryonic and postnatal stages. Furthermore, ROR2 mutant mice exhibited increased adipogenesis in the bone marrow compared to their littermate controls. To further explore the underlying mechanisms, bulk RNA seq analysis of Prx1cre; Ror2(flox/flox) embryos was performed, results revealed decreased BMP/TGF beta signaling. Immunofluorescence analysis further confirmed the decreased expression of p smad1/5/8, accompanied by disrupted cell polarity in the developing growth plate. Pharmacological treatment using FK506 partially rescued the skeletal dysplasia and resulted in increased mineralization and osteoblast differentiation. By modeling the phenotype of RS in mice, our findings provide evidence for the involvement of mesenchymal progenitors as the cell origin and highlight the molecular mechanism of BMP/TGF beta signaling in skeletal dysplasia.
C1 [Yao, Yichen; Lin, Lichieh; Wang, Yan] Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Guangzhou, Peoples R China.
   [Yao, Yichen; Lin, Lichieh; Wang, Yan] Guangdong Prov Key Lab Stomatol, Guangzhou, Peoples R China.
   [Wang, Xin] Harvard Med Sch, Dept Med, Boston, MA USA.
   [Wang, Xin] Brigham & Womens Hosp, Jeff & Penny Vinik Ctr Translat Immunol Res, Div Allergy & Clin Immunol, Boston, MA USA.
   [Zhang, Xiaolei] Sun Yat Sen Univ, Affiliated Hosp 8, Dept Stomatol, Shen Zhen, Guangdong, Peoples R China.
   [Zhang, Xiaolei] Sun Yat sen Univ, Affiliated Hosp 8, Shen Zhen, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Harvard University; Harvard Medical School;
   Harvard University; Harvard University Medical Affiliates; Brigham &
   Women's Hospital; Sun Yat Sen University; Sun Yat Sen University
RP Wang, Y (通讯作者)，Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Guangzhou, Peoples R China.; Zhang, XL (通讯作者)，Sun Yat sen Univ, Affiliated Hosp 8, Shen Zhen, Guangdong, Peoples R China.
EM zhangxl35@mail.sysu.edu.cn; wangyan9@mail.sysu.edu.cn
RI ; Yao, Yichen/HNP 1789 2023; Zhang, Xiaolei/HNQ 5651 2023
OI Wang, Xin/0000 0003 1269 3943; 
FU Shenzhen Municipal Science and Technology Innovation Council, Shenzhen
   Science and Technology Innovation Program [JCYJ2022 0530144410023];
   National Natural Science Foundation of China (NSFC) [81470731]; Science
   and Technology Projects in Guangzhou [2023A04J2151]
FX & nbsp;This work was supported by the Shenzhen Municipal Science and
   Technology Innovation Council, Shenzhen Science and Technology
   Innovation Program: JCYJ2022 0530144410023 to Zhang. National Natural
   Science Foundation of China (NSFC) : 81470731 to Zhang. Funding by
   Science and Technology Projects in Guangzhou (2023A04J2151) to Yao
CR Afzal AR, 2000, NAT GENET, V25, P419, DOI 10.1038/78107
   Beederman Maureen, 2013, J Biomed Sci Eng, V6, P32
   Bernatik O, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00047
   Conlon CJ, 2021, AM J MED GENET A, V185, P3606, DOI 10.1002/ajmg.a.61986
   Dale RM, 2009, ZEBRAFISH, V6, P9, DOI 10.1089/zeb.2008.0563
   Dathe K, 2009, AM J HUM GENET, V84, P483, DOI 10.1016/j.ajhg.2009.03.001
   DeChiara TM, 2000, NAT GENET, V24, P271, DOI 10.1038/73488
   Feng D, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abg2099
   Feng JF, 2017, DEVELOPMENT, V144, P2560, DOI 10.1242/dev.150136
   Gao B, 2011, DEV CELL, V20, P163, DOI 10.1016/j.devcel.2011.01.001
   Gros J, 2010, CURR BIOL, V20, P1993, DOI 10.1016/j.cub.2010.09.063
   Ho S, 1996, CLIN IMMUNOL IMMUNOP, V80, pS40, DOI 10.1006/clin.1996.0140
   Humphries AC, 2018, CURR OPIN CELL BIOL, V51, P110, DOI 10.1016/j.ceb.2017.12.005
   Jain PS, 2017, CONTEMP CLIN DENT, V8, P479, DOI 10.4103/ccd.ccd_622_17
   Kugimiya F, 2005, BIOCHEM BIOPH RES CO, V338, P872, DOI 10.1016/j.bbrc.2005.10.024
   Lehmann K, 2006, EUR J HUM GENET, V14, P1248, DOI 10.1038/sj.ejhg.5201708
   Lei LZ, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01646 2
   Lin MK, 2011, DEV DYNAM, V240, P432, DOI 10.1002/dvdy.22550
   Ling L, 2009, GENE, V433, P1, DOI 10.1016/j.gene.2008.12.008
   Liu XD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094201
   Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092
   Ma YY, 2021, DEVELOPMENT, V148, DOI 10.1242/dev.196360
   Maeda K, 2013, J MOL MED, V91, P15, DOI 10.1007/s00109 012 0974 0
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   Marzin P, 2020, THER ADV ENDOCRINOL, V11, DOI 10.1177/2042018820904016
   Newman B, 2003, CLIN GENET, V63, P241, DOI 10.1034/j.1399 0004.2003.00046.x
   Nishita M, 2006, J CELL BIOL, V175, P555, DOI 10.1083/jcb.200607127
   Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365 2443.2003.00662.x
   Qi R, 2014, RENAL FAILURE, V36, P589, DOI 10.3109/0886022X.2014.882713
   Quarto N, 2010, J BONE MINER RES, V25, P1680, DOI 10.1359/jbmr.091116
   Randall RM, 2012, J ORTHOP RES, V30, P1906, DOI 10.1002/jor.22152
   Robinow M, 1993, Clin Dysmorphol, V2, P189
   Rosen V, 2017, BONE MORPHOGENETIC P
   Sammar M, 2004, GENES CELLS, V9, P1227, DOI 10.1111/j.1365 2443.2004.00799.x
   Sammar M, 2009, BIOCHEM BIOPH RES CO, V381, P1, DOI 10.1016/j.bbrc.2008.12.162
   Schwabe GC, 2000, AM J HUM GENET, V67, P822, DOI 10.1086/303084
   Spiekerkoetter E, 2013, J CLIN INVEST, V123, P3600, DOI 10.1172/JCI65592
   Strate I, 2015, DEVELOPMENT, V142, P1767, DOI 10.1242/dev.113894
   THOMSON AW, 1995, THER DRUG MONIT, V17, P584, DOI 10.1097/00007691 199512000 00007
   Thorup AS, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax3063
   Tsang KY, 2014, BIRTH DEFECTS RES C, V102, P52, DOI 10.1002/bdrc.21060
   van Bokhoven H, 2000, NAT GENET, V25, P423, DOI 10.1038/78113
   Wang YP, 2014, FRONT BIOSCI LANDMRK, V19, P379, DOI 10.2741/4214
   Witte F, 2010, P NATL ACAD SCI USA, V107, P14211, DOI 10.1073/pnas.1009314107
   Yamamoto S, 2008, DEV CELL, V15, P23, DOI 10.1016/j.devcel.2008.05.007
   Yang K, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23074
   Yang W, 2017, CELL RES, V27, P1466, DOI 10.1038/cr.2017.127
   Zhang CF, 2022, HUM GENET GENOM ADV, V3, DOI 10.1016/j.xhgg.2021.100074
NR 48
TC 1
Z9 1
U1 1
U2 15
PU INT SOC AGING & DISEASE
PI FORT WORTH
PA EDITORIAL OFF, 3400 CAMP BOWIE BLVD, FORT WORTH, TX 76106 USA
SN 2152 5250
J9 AGING DIS
JI Aging Dis.
PD FEB
PY 2024
VL 15
IS 1
BP 282
EP 294
DI 10.14336/AD.2023.0531
EA JUN 2023
PG 13
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology
GA HA9V2
UT WOS:001012646800001
PM 37307827
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Asai, M
   Lee, JW
   Itakura, Y
   Choi, BK
   Yonezawa, T
   Teruya, T
   Cha, BY
   Ohnishi, M
   Yamaguchi, A
   Woo, JT
AF Asai, Midori
   Lee, Ji Won
   Itakura, Yasunori
   Choi, Bong Keun
   Yonezawa, Takayuki
   Teruya, Toshiaki
   Cha, Byung Yoon
   Ohnishi, Motoko
   Yamaguchi, Akira
   Woo, Je Tae
TI Effects of veraguensin and galgravin on osteoclast differentiation and
   function
SO CYTOTECHNOLOGY
LA English
DT Article; Proceedings Paper
CT 23rd Annual and International Meeting of the
   Japanese Association for Animal Cell Technology (JAACT) on Animal Cell
   Technology from Asia to World
CY SEP 01 04, 2010
CL Hokkaido Univ, Sapporo, JAPAN
SP Japanese Assoc Anim Cell Technol (JAACT)
HO Hokkaido Univ
DE Veraguensin.; Galgravin; RANKL; Osteoclast; p38; c Fos
ID NECTANDRA MEGAPOTAMICA LAURACEAE; NATURAL PRODUCTS; DRUG DISCOVERY;
   IN VITRO; LIGAND; ACTIVATION
AB The dried flower buds of Magnolia sp. are widely used as herbal medicines because of their anti inflammatory, anti malarial and anti platelet activities. Here, we found that veraguensin and galgravin, lignan compounds derived from Magnolia sp., dose dependently inhibited osteoclast formation in co cultures of bone marrow cells and osteoblastic cells. These compounds also inhibited receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast differentiation in RAW264.7 cells and bone marrow macrophages. In the RANKL induced signaling pathway, veraguensin and galgravin reduced p38 phosphorylation and suppressed the expression of c Fos, a key transcription factor for osteoclastogenesis. Veraguensin and galgravin also inhibited osteoclastic pit formation, which was accompanied by decreased mature osteoclast viability. In conclusion, these results indicate that veraguensin and galgravin can inhibit bone resorption and may offer novel compounds for the development of drugs to treat bone destructive diseases such as osteoporosis.
C1 [Asai, Midori; Itakura, Yasunori; Choi, Bong Keun; Ohnishi, Motoko; Woo, Je Tae] Chubu Univ, Dept Biol Chem, Kasugai, Aichi 4878501, Japan.
   [Lee, Ji Won; Yamaguchi, Akira] Tokyo Med & Dent Univ, Sect Oral Pathol, Grad Sch Med & Dent Sci, Bunkyo Ku, Tokyo 1138549, Japan.
   [Yonezawa, Takayuki; Teruya, Toshiaki; Cha, Byung Yoon; Ohnishi, Motoko; Woo, Je Tae] Chubu Univ, Res Inst Biol Funct, Kasugai, Aichi 4878501, Japan.
C3 Chubu University; Institute of Science Tokyo; Tokyo Medical & Dental
   University (TMDU); Chubu University
RP Woo, JT (通讯作者)，Chubu Univ, Dept Biol Chem, 1200 Matsumoto, Kasugai, Aichi 4878501, Japan.
EM jwoo@isc.chubu.ac.jp
RI YONEZAWA, Takayuki/O 3047 2019; Lee, Jiwon/CAJ 1171 2022; Yamaguchi,
   Akinobu/E 4265 2016
OI YONEZAWA, Takayuki/0000 0001 8060 0839; 
CR Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen Zenai, 1993, China Journal of Chinese Materia Medica, V18, P292
   da Silva AA, 2004, J PHARM PHARMACOL, V56, P1179, DOI 10.1211/0022357044058
   da Silva AA, 2008, PHYTOTHER RES, V22, P1307, DOI 10.1002/ptr.2486
   Feng X, 2005, GENE, V350, P1, DOI 10.1016/j.gene.2005.01.014
   Harvey AL, 2008, DRUG DISCOV TODAY, V13, P894, DOI 10.1016/j.drudis.2008.07.004
   Hasegawa S, 2010, BIOL PHARM BULL, V33, P487, DOI 10.1248/bpb.33.487
   Kim SN, 2009, PHYTOTHER RES, V23, P185, DOI 10.1002/ptr.2581
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lam KS, 2007, TRENDS MICROBIOL, V15, P279, DOI 10.1016/j.tim.2007.04.001
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Lim H, 2009, PHYTOTHER RES, V23, P1489, DOI 10.1002/ptr.2783
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Suda T, 1997, J BONE MINER RES, V12, P869, DOI 10.1359/jbmr.1997.12.6.869
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252
NR 16
TC 5
Z9 6
U1 0
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0920 9069
EI 1573 0778
J9 CYTOTECHNOLOGY
JI Cytotechnology
PD MAY
PY 2012
VL 64
IS 3
SI SI
BP 315
EP 322
DI 10.1007/s10616 011 9416 z
PG 8
WC Biotechnology & Applied Microbiology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Biotechnology & Applied Microbiology; Cell Biology
GA 966JU
UT WOS:000305834700010
PM 22526488
OA Green Published
DA 2025 08 17
ER

PT J
AU Qiao, H
   Cui, ZW
   Yang, SB
   Ji, DK
   Wang, YG
   Yang, Y
   Han, XG
   Fan, QM
   Qin, A
   Wang, TY
   He, XP
   Bu, WB
   Tanet, TT
AF Qiao, Han
   Cui, Zhaowen
   Yang, Shengbing
   Ji, Dingkun
   Wang, Yugang
   Yang, Ying
   Han, Xiuguo
   Fan, Qiming
   Qin, An
   Wang, Tingyu
   He, Xiao Peng
   Bu, Wenbo
   Tang, Tingting
TI Targeting Osteocytes to Attenuate Early Breast Cancer Bone Metastasis by
   Theranostic Upconversion Nanoparticles with Responsive Plumbagin Release
SO ACS NANO
LA English
DT Article
DE upconversion nanoparticle; breast cancer bone metasatasis; theranostic;
   osteocyte targeting; ATP competitiveness; plumbagin; zoledronic acid
ID OSTEOCLAST FORMATION; IN VIVO; CELLS; BISPHOSPHONATES; DELIVERY; SYSTEM;
   NANOMATERIALS; MECHANISMS; MIGRATION; PHOSPHATE
AB The early detection and thus treatment of breast cancer bone metastasis remain a big challenge clinically. As the most abundant cells within bone tissue, osteocytes have been found to manipulate the activity of early cancer bone metastasis by its crosstalk with cancer cells and osteoclasts. However, conventional bone targeting nanomedicine has limited bone lesion specificity and ignores the vital role of osteocytes during breast cancer bone metastasis. Also, it lacks detailed insight into the therapeutic mechanisms, which hinders the following translational practice. Previously, we have shown that a combination of zoledronic acid (ZA) and plumbagin (PL) synergistically alleviates cancer induced bone destruction. Herein, we further develop a pH responsive bone targeting drug delivery system, i.e., the ZA anchored bimodal mesoporous slica covered gadolinium(III) upconversion nanoparticles loaded with PL, to detect and treat bone metastasis sensitively and specifically at an early stage. This multifunctional nanosystem can target osteocytes to release PL as controlled by pH, decreasing osteocytic RANKL expression synergistically through the structural simulation of adenosine phosphate, which competitively inhibits the phosphorylation of osteocytic protein kinase a, cAMP response element binding protein, extracellular regulated protein kinase, and c Jun N terminal kinase. More importantly, by establishing a breast cancer bone metastasis mice model via intracardiac injection, we show that tumoriogenesis and osteoclastogenesis can both be attenuated significantly. We thereby realize the effective theranostics of tiny bone metastasis in breast cancer bone metastasis. Our work highlights the significance of theranostic nanomedicine and osteocyte targeting therapy in the treatment of early bone metastasis, which could be applied in achieving efficient theranostic effects for other bone diseases.
C1 [Qiao, Han; Yang, Shengbing; Wang, Yugang; Yang, Ying; Han, Xiuguo; Fan, Qiming; Qin, An; Tang, Tingting] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Orthopaed Implants, Dept Orthopaed Surg,Shanghai Peoples Hosp 9, Shanghai 200011, Peoples R China.
   [Cui, Zhaowen; Bu, Wenbo] Chinese Acad Sci, Shanghai Inst Ceram, State Key Lab High Performance Ceram & Superfine, Shanghai 200050, Peoples R China.
   [Ji, Dingkun; He, Xiao Peng] East China Univ Sci & Technol, Key Lab Adv Mat, Shanghai 200237, Peoples R China.
   [Ji, Dingkun; He, Xiao Peng] East China Univ Sci & Technol, Inst Fine Chem, Sch Chem & Mol Engn, Shanghai 200237, Peoples R China.
   [Wang, Tingyu] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Pharm, Shanghai 200011, Peoples R China.
   [Bu, Wenbo] East China Normal Univ, Sch Chem & Mol Engn, Shanghai Key Lab Green Chem & Chem Proc, Shanghai 200062, Peoples R China.
C3 Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai
   Institute of Ceramics, CAS; East China University of Science &
   Technology; East China University of Science & Technology; Shanghai Jiao
   Tong University; East China Normal University
RP Tanet, TT (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Orthopaed Implants, Dept Orthopaed Surg,Shanghai Peoples Hosp 9, Shanghai 200011, Peoples R China.; Bu, WB (通讯作者)，Chinese Acad Sci, Shanghai Inst Ceram, State Key Lab High Performance Ceram & Superfine, Shanghai 200050, Peoples R China.; Bu, WB (通讯作者)，East China Normal Univ, Sch Chem & Mol Engn, Shanghai Key Lab Green Chem & Chem Proc, Shanghai 200062, Peoples R China.
EM wbbu@chem.ecnu.edu.cn; ttt@sjtu.edu.cn
RI ; Bu, Wenbo/G 1715 2012; He, Xiao Peng/O 4330 2014; Yang,
   Ying/KDP 1488 2024; Tang, Tingting/B 1361 2013; Qin, An/J 2518 2019
OI Yang, Ying/0000 0001 5433 1399; Tang, Tingting/0000 0002 1670 7452; 
FU National Key RD Plan [2016YFC1102100]; National Natural Science
   Foundation of China [81672205]; Innovation Program for Ph.D. students in
   Shanghai Jiaotong University School of Medicine [BXJ201729]
FX This work was funded by the National Key R&D Plan (2016YFC1102100),
   National Natural Science Foundation of China (81672205), and the
   Innovation Program for Ph.D. students in Shanghai Jiaotong University
   School of Medicine (BXJ201729). We thank Prof. Lynda Bonewald
   (University of Missouri, USA) and Prof. Jiake Xu (University of Western
   Australia, Australia) for their kindness in providing MLOY 4 and
   MDA MB 231SArfp cells.
CR Albain KS, 2009, LANCET, V374, P379, DOI 10.1016/S0140 6736(09)60737 6
   Bhattacharyya S, 2012, ACTA BIOMATER, V8, P3429, DOI 10.1016/j.actbio.2012.06.003
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Bultynck G, 2016, BBA REV CANCER, V1866, P121, DOI 10.1016/j.bbcan.2016.07.003
   Cenni E, 2012, J BIOMAT SCI POLYM E, V23, P1285, DOI 10.1163/092050611X580373
   Chaudhari KR, 2012, ADV FUNCT MATER, V22, P4101, DOI 10.1002/adfm.201102357
   Chaudhari KR, 2012, J CONTROL RELEASE, V158, P470, DOI 10.1016/j.jconrel.2011.11.020
   Chu WJ, 2017, INT J PHARMACEUT, V516, P352, DOI 10.1016/j.ijpharm.2016.11.051
   Cong YY, 2015, J BIOMAT SCI POLYM E, V26, P629, DOI 10.1080/09205063.2015.1053170
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   Cui YX, 2016, ANTICANCER RES, V36, P1193
   Fan L, 2014, LANCET ONCOL, V15, pE279, DOI 10.1016/S1470 2045(13)70567 9
   Fan WP, 2016, ADV MATER, V28, P3987, DOI 10.1002/adma.201505678
   Fan WP, 2015, BIOMATERIALS, V69, P89, DOI 10.1016/j.biomaterials.2015.08.017
   Fan WP, 2014, BIOMATERIALS, V35, P8992, DOI 10.1016/j.biomaterials.2014.07.024
   Fan WP, 2013, J AM CHEM SOC, V135, P6494, DOI 10.1021/ja312225b
   Feng W, 2013, ADV MATER, V25, P5287, DOI 10.1002/adma.201301946
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Gai SL, 2014, CHEM REV, V114, P2343, DOI 10.1021/cr4001594
   Hu Y, 2015, ACS APPL MATER INTER, V7, P15803, DOI 10.1021/acsami.5b02831
   Hubbell JA, 2012, SCIENCE, V337, P303, DOI 10.1126/science.1219657
   JUNG A, 1973, CALC TISS RES, V11, P269, DOI 10.1007/BF02547227
   Käkönen SM, 2003, CANCER AM CANCER SOC, V97, P834, DOI 10.1002/cncr.11132
   Lai JP, 2015, ACS NANO, V9, P5234, DOI 10.1021/acsnano.5b00641
   Li C., 2017, ADV MATER, V29, P1
   Li X, 2017, MAT SCI ENG C MATER, V71, P594, DOI 10.1016/j.msec.2016.10.037
   Mundy G, 2001, SEMIN ONCOL, V28, P2, DOI 10.1053/sonc.2001.25441
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nango N, 2016, BONE, V84, P279, DOI 10.1016/j.bone.2015.12.006
   O'Brien CA, 2013, BONE, V54, P258, DOI 10.1016/j.bone.2012.08.121
   Park YI, 2015, CHEM SOC REV, V44, P1302, DOI 10.1039/c4cs00173g
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Price JT, 2005, CANCER RES, V65, P4929, DOI 10.1158/0008 5472.CAN 04 4458
   Qiao H, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.11
   Qiao H, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.255
   Qiao H, 2015, ACTA PHARMACOL SIN, V36, P1085, DOI 10.1038/aps.2015.42
   Renema N, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20160150
   Roelofs AJ, 2010, J BONE MINER RES, V25, P606, DOI 10.1359/jbmr.091009
   Schroeder A, 2012, NAT REV CANCER, V12, P39, DOI 10.1038/nrc3180
   Singh T, 2015, J DRUG TARGET, V23, P1, DOI 10.3109/1061186X.2014.950668
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   Wang H, 2015, INT J NANOMED, V10, P5671, DOI 10.2147/IJN.S88798
   Xing HY, 2012, BIOMATERIALS, V33, P1079, DOI 10.1016/j.biomaterials.2011.10.039
   Xiong JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138189
   Yan W, 2013, BONE RES, V1, P362, DOI 10.4248/BR201304007
   Yang DM, 2015, CHEM SOC REV, V44, P1416, DOI 10.1039/c4cs00155a
   Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486
   Zhao QX, 2007, FRONT BIOSCI LANDMRK, V12, P2519, DOI 10.2741/2252
   Zhao S, 2002, J BONE MINER RES, V17, P2068, DOI 10.1359/jbmr.2002.17.11.2068
   Zhou JZ, 2016, ONCOGENE, V35, P5597, DOI 10.1038/onc.2016.101
   Zhou JZ, 2015, ONCOGENE, V34, P1831, DOI 10.1038/onc.2014.113
   Zhu W., 2016, NAT COMMUN, V7, P1, DOI DOI 10.1038/NCOMMS11495
NR 52
TC 107
Z9 113
U1 4
U2 199
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936 0851
EI 1936 086X
J9 ACS NANO
JI ACS Nano
PD JUL
PY 2017
VL 11
IS 7
BP 7259
EP 7273
DI 10.1021/acsnano.7b03197
PG 15
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA FC2EI
UT WOS:000406649700075
PM 28692257
DA 2025 08 17
ER

PT J
AU Kong, YH
   Zhang, HY
   Chen, X
   Zhang, WW
   Zhao, C
   Wang, N
   Wu, NN
   He, YF
   Nan, GX
   Zhang, HM
   Wen, S
   Deng, F
   Liao, Z
   Wu, D
   Zhang, JH
   Qin, XY
   Haydon, RC
   Luu, HH
   He, TC
   Zhou, L
AF Kong, Yuhan
   Zhang, Hongyu
   Chen, Xian
   Zhang, Wenwen
   Zhao, Chen
   Wang, Ning
   Wu, Ningning
   He, Yunfeng
   Nan, Guoxin
   Zhang, Hongmei
   Wen, Sheng
   Deng, Fang
   Liao, Zhan
   Wu, Di
   Zhang, Junhui
   Qin, Xinyue
   Haydon, Rex C.
   Luu, Hue H.
   He, Tong Chuan
   Zhou, Lan
TI Destabilization of Heterologous Proteins Mediated by the GSK3β
   Phosphorylation Domain of the β Catenin Protein
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE beta catenin; Wnt signal; Human cancer; Protein degradation; Green
   fluorescent protein; Destabilized GFP; Chimeric proteins
ID SUPPRESSES TUMOR GROWTH; WNT SIGNALING PATHWAY; OSTEOGENIC
   DIFFERENTIATION; OSTEOBLAST DIFFERENTIATION; CYCLIN D1; GENE;
   INHIBITION; MUTATIONS; TARGET; STEM
AB Background and Aims: Wnt/beta catenin signaling plays important roles in development and cellular processes. The hallmark of canonical Wnt signaling activation is the stabilization of beta catenin protein in cytoplasm and/or nucleus. The stability of beta catenin is the key to its biological functions and is controlled by the phosphorylation of its amino terminal degradation domain. Aberrant activation of beta catenin signaling has been implicated in the development of human cancers. It has been recently suggested that GSK3 beta may play an essential role in regulating global protein turnover. Here, we investigate if the GSK3 beta phosphorylation site containing degradation domain of beta catenin is sufficient to destabilize heterologous proteins.
   Methods and Results: We engineer chimeric proteins by fusing beta catenin degradation domain at the N  and/or C termini of the enhanced green fluorescent protein (eGFP). In both transient and stable expression experiments, the chimeric GFP proteins exhibit a significantly decreased stability, which can be effectively antagonized by lithium and Wnt1. An activating mutation in the destruction domain significantly stabilizes the fusion protein. Furthermore, GSK3 inhibitor SB 216763 effectively increases the GFP signal of the fusion protein. Conversely, the inhibition of Wnt signaling with tankyrase inhibitor XAV939 results in a decrease in GFP signal of the fusion proteins, while these small molecules have no significant effects on the mutant destruction domain GFP fusion protein.
   Conclusion: Our findings strongly suggest that the beta catenin degradation domain may be sufficient to destabilize heterologous proteins in Wnt signaling dependent manner. It is conceivable that the chimeric GFP proteins may be used as a functional reporter to measure the dynamic status of beta catenin signaling, and to identify potential anticancer drugs that target beta catenin signaling. Copyright (C) 2013 S. Karger AG, Basel
C1 [Kong, Yuhan; Zhang, Hongyu; He, Yunfeng; Zhang, Junhui; Qin, Xinyue] Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China.
   [Kong, Yuhan; Zhang, Hongyu; Chen, Xian; Zhang, Wenwen; Zhao, Chen; Wang, Ning; Wu, Ningning; He, Yunfeng; Nan, Guoxin; Zhang, Hongmei; Wen, Sheng; Deng, Fang; Liao, Zhan; Wu, Di; Zhang, Junhui; Haydon, Rex C.; Luu, Hue H.; He, Tong Chuan; Zhou, Lan] Univ Chicago, Med Ctr, Mol Oncol Lab, Dept Orthopaed Surg, Chicago, IL 60637 USA.
   [Chen, Xian; Zhang, Wenwen; Wu, Ningning; Zhang, Hongmei; He, Tong Chuan; Zhou, Lan] Chongqing Med Univ, Minist Educ, Key Lab Diagnost Med, Chongqing, Peoples R China.
   [Zhao, Chen; Wang, Ning; Deng, Fang] Third Mil Med Univ, Dept Cell Biol, Chongqing, Peoples R China.
   [Zhao, Chen; Wang, Ning; Deng, Fang] Third Mil Med Univ, Dept Clin Hematol, Chongqing, Peoples R China.
   [Zhao, Chen; Wang, Ning; Deng, Fang] Third Mil Med Univ, Dept Oncol, Chongqing, Peoples R China.
   [Nan, Guoxin; Wen, Sheng; He, Tong Chuan] Chongqing Med Univ, Childrens Hosp, Minist Educ, Stem Cell Biol & Therapy Lab,Key Lab Pediat, Chongqing, Peoples R China.
   [Liao, Zhan] Cent South Univ, Dept Orthoped Surg, Xiang Ya Hosp, Changsha, Peoples R China.
C3 Chongqing Medical University; University of Chicago; University of
   Chicago Medical Center; Chongqing Medical University; Army Medical
   University; Army Medical University; Army Medical University; Chongqing
   Medical University; Central South University
RP He, TC (通讯作者)，Univ Chicago, Med Ctr, Mol Oncol Lab, 5841 S Maryland Ave,MC 3079, Chicago, IL 60637 USA.
EM tche@uchicago.edu
RI Wu, Di/L 2437 2015; he, yun/JMB 6362 2023; zhang, junhui/HDN 6783 2022
FU National Institutes of Health [CA106569, AT004418, AR50142, AR054381];
   973 Program of Ministry of Science and Technology (MOST) of China
   [2011CB707900]
FX The reported work was supported in part by research grants from the
   National Institutes of Health (CA106569, AT004418, AR50142, and AR054381
   to TCH, RCH and HHL), and the 973 Program of Ministry of Science and
   Technology (MOST) of China (# 2011CB707900 to TCH and LZ).
CR Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935
   Bi Y, 2009, J CELL BIOCHEM, V108, P295, DOI 10.1002/jcb.22254
   Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622 199801000 00013
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074 5521(00)00025 9
   Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092 8674(00)81631 1
   Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931
   Haydon RC, 2002, INT J CANCER, V102, P338, DOI 10.1002/ijc.10719
   He BC, 2011, MOL PHARMACOL, V79, P211, DOI 10.1124/mol.110.068668
   He BC, 2010, CLIN CANCER RES, V16, P2235, DOI 10.1158/1078 0432.CCR 09 2499
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092 8674(00)81664 5
   He X, 2003, DEV CELL, V4, P791, DOI 10.1016/S1534 5807(03)00165 5
   Hino SI, 2001, MOL CELL BIOL, V21, P330, DOI 10.1128/MCB.21.1.330 342.2001
   Holland JD, 2013, CURR OPIN CELL BIOL, V25, P254, DOI 10.1016/j.ceb.2013.01.004
   Hu N, 2013, J CELL SCI, V126, P532, DOI 10.1242/jcs.114231
   Huang EY, 2012, J BONE MINER RES, V27, P1566, DOI 10.1002/jbmr.1622
   Huang EY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032428
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Jiang W, 2001, J BIOL CHEM, V276, P45168, DOI 10.1074/jbc.M106924200
   Kadoya T, 2000, J BIOL CHEM, V275, P37030, DOI 10.1074/jbc.M005984200
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092 8674(00)81333 1
   Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455
   Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590
   Luo J, 2007, NAT PROTOC, V2, P1236, DOI 10.1038/nprot.2007.135
   Luo JY, 2007, LAB INVEST, V87, P97, DOI 10.1038/labinvest.3700509
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   MENG X, 2001, J BIOL CHEM, V26, P26
   Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521 1878(199912)22:1<1021::AID BIES6>3.0.CO;2 P
   Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787
   Nusse R, 2008, COLD SH Q B, V73, P59, DOI 10.1101/sqb.2008.73.035
   Polakis P, 2000, GENE DEV, V14, P1837
   Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002 9440(10)65278 9
   Roose J, 1999, BBA REV CANCER, V1424, pM23, DOI 10.1016/S0304 419X(99)00026 8
   Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790
   RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518
   Sakamoto I, 2000, J BIOL CHEM, V275, P32871, DOI 10.1074/jbc.M004089200
   Sampson EM, 2001, EMBO J, V20, P4500, DOI 10.1093/emboj/20.16.4500
   Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Shui W, 2013, J BIOMED MATER RES A, V101, P3542, DOI 10.1002/jbm.a.34661
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785
   Sparks AB, 1998, CANCER RES, V58, P1130
   Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960 9822(02)70790 2
   Stambolic V, 1997, CURR BIOL, V7, pR196
   SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519
   Su Y, 2011, ONCOGENE, V30, P3907, DOI 10.1038/onc.2011.97
   Taelman VF, 2010, CELL, V143, P1136, DOI 10.1016/j.cell.2010.11.034
   Tago K, 2000, GENE DEV, V14, P1741
   Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582 4934.2008.00569.x
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Tsujiuchi T, 2000, CANCER RES, V60, P6611
   Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959 437X(98)80068 3
   Yang K, 2012, J INVEST DERMATOL, V132, P2479, DOI 10.1038/jid.2012.145
   Zhou L, 2002, BIOTECHNIQUES, V33, P1126, DOI 10.2144/02335dd07
NR 57
TC 30
Z9 31
U1 0
U2 7
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1015 8987
EI 1421 9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2013
VL 32
IS 5
BP 1187
EP 1199
DI 10.1159/000354518
PG 13
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA 275TD
UT WOS:000328699600006
PM 24335169
OA Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Sharma, K
   Awasthi, P
   Prakash, R
   Khanka, S
   Bajpai, R
   Sahasrabuddhe, AA
   Goel, A
   Singh, D
AF Sharma, Kriti
   Awasthi, Pallavi
   Prakash, Ravi
   Khanka, Sonu
   Bajpai, Ranju
   Sahasrabuddhe, Amogh A.
   Goel, Atul
   Singh, Divya
TI Maintenance of increased bone mass after PTH withdrawal by sequential
   medicarpin treatment via augmentation of cAMP PKA pathway
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE bone strength; cell viability; differentiation; mineralization;
   osteoblast cells; sequential therapies
ID PARATHYROID HORMONE; DISCONTINUATION; MEN
AB Osteoporosis is a metabolic bone disorder associated with impaired bone microarchitecture leading to fragility fractures. Long term usage of parathyroid hormone (PTH) enhances bone resorption and leads to osteosarcoma in rats which limits its exposure to maximum 2 years in human. Notably, the anabolic effects of PTH do not endure in the absence of sustained administration. Studies in our lab identified osteogenic and antiresorptive activity in medicarpin, a phytoestrogen belonging to the pterocarpan class. Considering dual acting property of medicarpin and limitations of PTH therapy, we envisaged that medicarpin sequential treatment after PTH withdrawal could serve as promising therapeutic approach for osteoporosis treatment. As PTH exerts its bone anabolic effect by increasing osteoblast survival, our study aims to determine whether medicarpin amplifies this effect of PTH. Our results show that PTH withdrawal led to reduced bone mineral density and bone parameters, while sequential treatment of medicarpin after PTH withdrawal significantly enhanced these parameters. Remarkably, these effects were more pronounced than 8 week PTH treatment. Sequential therapy also significantly increased P1NP levels and decreased CTX levels and TRAP positive cells compared to PTH 8W group where CTX levels were quite high due to bone resorptive action of PTH. Protein expression studies revealed that medicarpin along with PTH betters the antiapoptotic potential compared to PTH alone, through augmentation of cyclic adenosine monophosphate PKA CREB pathway. These results proclaim that medicarpin sequential treatment prevented the reduction in bone accrual and strength accompanying PTH withdrawal and also aided in antiapoptotic role of PTH. The study points toward the potential use of medicarpin as a replacement therapeutic option postdiscontinuation of PTH.
C1 [Sharma, Kriti; Prakash, Ravi; Khanka, Sonu; Singh, Divya] CSIR Cent Drug Res Inst, Div Endocrinol, Lucknow 226031, Uttar Pradesh, India.
   [Sharma, Kriti; Awasthi, Pallavi; Khanka, Sonu; Sahasrabuddhe, Amogh A.; Goel, Atul; Singh, Divya] Acad Sci & Innovat Res AcSIR, Ghaziabad, Uttar Pradesh, India.
   [Awasthi, Pallavi; Goel, Atul] CSIR Cent Drug Res Inst, Div Med & Proc Chem, Lucknow 226031, Uttar Pradesh, India.
   [Bajpai, Ranju; Sahasrabuddhe, Amogh A.] CSIR Cent Drug Res Inst, Div Biochem & Struct Biol, Lucknow, Uttar Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); Academy of Scientific &
   Innovative Research (AcSIR); Council of Scientific & Industrial Research
   (CSIR)   India; CSIR   Central Drug Research Institute (CDRI); Council
   of Scientific & Industrial Research (CSIR)   India; CSIR   Central Drug
   Research Institute (CDRI)
RP Singh, D (通讯作者)，CSIR Cent Drug Res Inst, Div Endocrinol, Lucknow 226031, Uttar Pradesh, India.; Goel, A (通讯作者)，CSIR Cent Drug Res Inst, Div Med & Proc Chem, Lucknow 226031, Uttar Pradesh, India.
EM atul_goel@cdri.res.in; divya_singh@cdri.res.in
RI Prakash, Ravi/JYP 0200 2024; Awasthi, Pallavi/NZO 0914 2025; Singh,
   Divya/IUM 7944 2023
OI Goel, Atul/0000 0003 2758 2461; 
FU Council of Scientific and Industrial Research, India [FBR MLP 2028];
   Department of Science and Technology, Ministry of Science and
   Technology, India [GAP303]
FX Council of Scientific and Industrial Research, India, Grant/Award
   Number: FBR MLP 2028; Department of Science and Technology, Ministry of
   Science and Technology, India, Grant/Award Number: GAP303
CR Amugongo SK, 2014, BONE, V67, P257, DOI 10.1016/j.bone.2014.04.033
   Augustine M, 2013, CURR OSTEOPOROS REP, V11, P400, DOI 10.1007/s11914 013 0171 2
   Bellido T, 2003, J BIOL CHEM, V278, P50259, DOI 10.1074/jbc.M307444200
   Bhargavan B, 2012, J NUTR BIOCHEM, V23, P27, DOI 10.1016/j.jnutbio.2010.11.002
   Boonrungsiman S, 2012, P NATL ACAD SCI USA, V109, P14170, DOI 10.1073/pnas.1208916109
   Chen BL, 2016, EXP THER MED, V11, P2399, DOI 10.3892/etm.2016.3177
   Dixit M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144541
   Ejersted C, 1998, BONE, V23, P43, DOI 10.1016/S8756 3282(98)00072 6
   Finkelstein JS, 2009, J CLIN ENDOCR METAB, V94, P2495, DOI 10.1210/jc.2009 0154
   Goel, Substituted benzofurochromenes and related compounds for the prevention and treatment of bone related disorders, Patent No. [US 8686028, 8686028]
   Goel A, 2012, ORG BIOMOL CHEM, V10, P9583, DOI 10.1039/c2ob25722j
   GUNNESSHEY M, 1989, BONE, V10, P447, DOI 10.1016/8756 3282(89)90077 X
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Kaufman JM, 2005, OSTEOPOROSIS INT, V16, P510, DOI 10.1007/s00198 004 1713 3
   Kureel J, 2018, J CELL BIOCHEM, V119, P3293, DOI 10.1002/jcb.26490
   Kureel J, 2016, MOL CELL BIOCHEM, V418, P71, DOI 10.1007/s11010 016 2734 x
   Leder BZ, 2009, J CLIN ENDOCR METAB, V94, P2915, DOI 10.1210/jc.2008 2630
   Li GF, 2012, MOL CELL BIOCHEM, V366, P169, DOI 10.1007/s11010 012 1294 y
   Mansoori MN, 2017, BONE, V105, P226, DOI 10.1016/j.bone.2017.09.010
   Meier C, 2014, SWISS MED WKLY, V144, DOI 10.4414/smw.2014.13952
   Pal S, 2019, BONE, V123, P28, DOI 10.1016/j.bone.2019.03.010
   Pandey R, 2010, MENOPAUSE, V17, P602, DOI 10.1097/gme.0b013e3181d0f7f0
   Park CH, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891 020 03771 8
   Prakash R, 2021, CALCIFIED TISSUE INT, V109, P32, DOI 10.1007/s00223 021 00818 3
   Prakash R, 2019, J CELL PHYSIOL, V234, P23507, DOI 10.1002/jcp.28919
   Sakai S, 2019, CALCIFIED TISSUE INT, V104, P251, DOI 10.1007/s00223 018 0497 y
   Seeman E, 2019, NAT REV RHEUMATOL, V15, P225, DOI 10.1038/s41584 019 0172 3
   Tashjian AH, 2008, J BONE MINER RES, V23, P803, DOI 10.1359/JBMR.080208
   Tyagi AM, 2012, OSTEOPOROSIS INT, V23, P1151, DOI 10.1007/s00198 011 1650 x
   Tyagi AM, 2010, MOL CELL ENDOCRINOL, V325, P101, DOI 10.1016/j.mce.2010.05.016
   Zayzafoon M, 2006, J CELL BIOCHEM, V97, P56, DOI 10.1002/jcb.20675
   Zhang RR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020780
NR 32
TC 8
Z9 8
U1 3
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD NOV
PY 2022
VL 123
IS 11
BP 1762
EP 1779
DI 10.1002/jcb.30313
EA AUG 2022
PG 18
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 6L5GW
UT WOS:000839502500001
PM 35959633
DA 2025 08 17
ER

PT J
AU Zhao, B
   Zhao, WQ
   Wang, YQ
   Zhao, Z
   Zhao, CF
   Wang, S
   Gao, CZ
AF Zhao, Bin
   Zhao, Wenqian
   Wang, Yiqiang
   Zhao, Zhao
   Zhao, Changfeng
   Wang, Shue
   Gao, Chunzheng
TI Prior administration of vitamin K2 improves the therapeutic
   effects of zoledronic acid in ovariectomized rats by antagonizing
   zoledronic acid induced inhibition of osteoblasts proliferation and
   mineralization
SO PLOS ONE
LA English
DT Article
ID BONE METABOLISM; IN VITRO; CELLS; OSTEOPOROSIS; SOST; DIFFERENTIATION;
   SCLEROSTEOSIS; CBFA1/RUNX2; EXPRESSION; APOPTOSIS
AB Zoledronic acid (ZA) exerts complex influence on bone by suppressing bone resorption, mostly due to the direct osteoclasts inhibition and uncertain influence on osteoblasts. Vitamin K 2 (VK2, Menaquinone 4) as an anabolic agent stimulates bone formation via anti apoptosis in osteoblasts and mild osteoclasts inhibition. Based on these knowledge, the therapeutic effect of the combined or sequential therapy of VK2 and ZA depends on the influence on the osteoblasts, since both cases exert similar inhibitory effect on osteoclasts. In a series of in vitro studies, we confirmed the protective effect of VK2 in osteoblasts culture, especially when followed by exposure to ZA, and the proliferation and mineralization inhibition induced by ZA towards osteoblasts. For mechanism study, expression of bcl 2/bax, Runx2 and Sost in cells were examined. For in vivo studies, an osteoporosis animal model was established in rats via ovariectomy (OVX) and subjected to sequential treatment, namely VK2 followed by ZA. Bone mineral density (BMD) was measured by Dual energy X ray absorptionmetry (DEXA), morphology and mechanical parameters by micro computed tomography (micro CT), mechanical strength by an electro hydraulic fatigue testing machine. The bone calcium, hydroxyproline content, blood lipids were evaluated using microplate technique, and the bone surface turnover was evaluated using the fluorescence in corporation method. It was found that VK2 pretreatment partially prevented the inhibition of bone formation caused by ZA, which was reflected by indices like BMD, bone calcium content and bone strength. The underling mechanisms for protection of VK2 pretreatment, mainly demonstrated via in vitro studies, included inhibiting apoptosis and depressing Sost expression in osteoblasts, which in turn improved the osteoporosis therapeutic effects of ZA. These findings suggested that pretreatment with VK2 before ZA therapy might serve a new long term therapy protocol for osteoporosis.
C1 [Zhao, Bin; Gao, Chunzheng] Shandong Univ, Hosp 2, Dept Orthoped, Jinan, Shandong, Peoples R China.
   [Zhao, Bin] Shouguang Hosp Tradit Chinese Med, Dept Orthoped, Shouguang, Shandong, Peoples R China.
   [Zhao, Wenqian] Peoples Hosp Shouguang, Dept Tradit Chinese Med & Dermatol, Shouguang, Shandong, Peoples R China.
   [Wang, Yiqiang] Soochow Univ, Jiangsu Inst Hematol, MOH Key Lab Thrombosis & Hemostasis, Affiliated Hosp 1, Suzhou, Peoples R China.
   [Zhao, Zhao] Shandong Univ, Qilu Hosp, Dept Cytol, Jinan, Shandong, Peoples R China.
   [Zhao, Changfeng; Wang, Shue] Shandong Univ, Sch Publ Hlth, Dept Nutr, Jinan, Shandong, Peoples R China.
C3 Shandong University; Soochow University   China; Shandong University;
   Shandong University
RP Gao, CZ (通讯作者)，Shandong Univ, Hosp 2, Dept Orthoped, Jinan, Shandong, Peoples R China.
EM gaochunzheng2016@163.com
RI zhao, bin/GWC 4839 2022
OI gao, chunzheng/0000 0002 2375 7626; Wang, Yiqiang/0000 0003 1552 7529
CR Ataoglu B, 2016, EKLEM HAST CERRAHISI, V27, P54, DOI 10.5606/ehc.2016.11
   Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537
   Basso FG, 2013, GERONTOLOGY, V59, P534, DOI 10.1159/000351194
   Belfrage O, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 240
   Borba VZC, 2007, INT J CLIN PRACT, V61, P1058, DOI 10.1111/j.1742 1241.2007.01392.x
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065 2571(84)90007 4
   Datta N, 2005, BIOMATERIALS, V26, P971, DOI 10.1016/j.biomaterials.2004.04.001
   FROST HM, 1991, BONE, V12, P429, DOI 10.1016/8756 3282(91)90032 E
   Geoffroy V, 2002, MOL CELL BIOL, V22, P6222, DOI 10.1128/MCB.22.17.6222 6233.2002
   Hao Y, 2015, BONE, V81, P702, DOI 10.1016/j.bone.2015.09.018
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Ichikawa T, 2007, J MOL ENDOCRINOL, V39, P239, DOI 10.1677/JME 07 0048
   Iwamoto J, 2014, NUTRIENTS, V6, P1971, DOI 10.3390/nu6051971
   Iwamoto J, 2011, BONE, V48, P1015, DOI 10.1016/j.bone.2011.02.015
   Katsuyama H, 2015, EXP THER MED, V10, P843, DOI 10.3892/etm.2015.2621
   Kishimoto Hideaki, 2009, Nihon Rinsho, V67, P975
   Knapen MHJ, 2007, OSTEOPOROSIS INT, V18, P963, DOI 10.1007/s00198 007 0337 9
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kopecka J, 2015, ONCOTARGET, V6, P31461, DOI 10.18632/oncotarget.5058
   Mattinzoli D, 2014, JOVE J VIS EXP, DOI 10.3791/51465
   Myneni V, 2017, ORAL DIS, V23, P1021, DOI 10.1111/odi.12624
   Olejnik C, 2016, BONE, V89, P32, DOI 10.1016/j.bone.2016.05.002
   Patntirapong S, 2012, J ORAL PATHOL MED, V41, P713, DOI 10.1111/j.1600 0714.2012.01154.x
   Rubin MR, 2003, ENDOCRIN METAB CLIN, V32, P285, DOI 10.1016/S0889 8529(02)00056 7
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Schwalfenberg GK, 2017, J NUTR METAB, V2017, DOI 10.1155/2017/6254836
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Sevetson B, 2004, J BIOL CHEM, V279, P13849, DOI 10.1074/jbc.M306249200
   SHEARER MJ, 1995, LANCET, V345, P229, DOI 10.1016/S0140 6736(95)90227 9
   Shiraki M, 2017, J BONE MINER METAB, V35, P675, DOI 10.1007/s00774 016 0806 3
   Talukdar Y, 2014, BIOMATERIALS, V35, P4863, DOI 10.1016/j.biomaterials.2014.02.054
   Urayama S, 2000, J LAB CLIN MED, V136, P181, DOI 10.1067/mlc.2000.108754
   VERMEER C, 1995, ANNU REV NUTR, V15, P1, DOI 10.1146/annurev.nutr.15.1.1
   Yamaguchi M, 2011, INT J MOL MED, V27, P3, DOI 10.3892/ijmm.2010.562
   Yang XM, 2013, INTRACTABLE RARE DIS, V2, P18, DOI 10.5582/irdr.2013.v2.1.18
NR 35
TC 12
Z9 13
U1 1
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD AUG 20
PY 2018
VL 13
IS 8
AR e0202269
DI 10.1371/journal.pone.0202269
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GR0JS
UT WOS:000442202100023
PM 30125322
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Geryk Hall, M
   Hughes, DPM
AF Geryk Hall, Mandy
   Hughes, Dennis P. M.
TI Critical Signaling Pathways in Bone Sarcoma: Candidates for Therapeutic
   Interventions
SO CURRENT ONCOLOGY REPORTS
LA English
DT Article
ID GROWTH FACTOR I; TUMOR GROWTH; OSTEOSARCOMA CELLS; GENE EXPRESSION;
   FACTOR RECEPTOR; FAS PATHWAY; METASTASIS; INHIBITION; P53; ACTIVATION
AB Bone sarcomas cause disproportionate morbidity and mortality and desperately need new therapies as there has been little improvement in outcomes in 20 years. Identification of critical signaling pathways, including type 1 insulin like growth factor receptor (IGF 1R) for Ewing sarcoma and possibly osteosarcoma, and the ERBB and the Wnt signaling pathways for osteosarcoma, have emerged as receptors mediating vital signals for bone sarcoma. Akt, mammalian target of rapamycin ( mTOR), phosphoinositide 3 kinases, mitogen activated protein kinase kinase, extracellular signal regulated kinases, and Ras pathway play key roles in at least some tumors, and inhibition of mTOR in particular will likely lead to improved survival, although clinical trials are still underway. The Notch pathway and ezrin are essential for osteosarcoma metastasis, and Fas down regulation is necessary for survival of metastases in lungs. As little is known about chondrosarcoma signaling, more preclinical work is needed. By defining vital signaling pathways in bone sarcomas, small molecule inhibitors can be applied rationally, leading to longer survival and reducing morbidity and late effects from intensive chemotherapy.
C1 [Hughes, Dennis P. M.] Univ Texas MD Anderson Canc Ctr, Childrens Canc Hosp, Dept Pediat Res, Unit 853, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center
RP Hughes, DPM (通讯作者)，Univ Texas MD Anderson Canc Ctr, Childrens Canc Hosp, Dept Pediat Res, Unit 853, POB 301402, Houston, TX 77030 USA.
EM dphughes@mdanderson.org
RI Hughes, Dennis/LPP 7849 2024
CR ATZORI F, 2008, ASCO M, V26, P3519
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Bovée JVMG, 2005, LANCET ONCOL, V6, P599, DOI 10.1016/S1470 2045(05)70282 5
   Britten CD, 2004, MOL CANCER THER, V3, P1335
   Chen K, 2008, PEDIATR BLOOD CANCER, V51, P349, DOI 10.1002/pbc.21595
   Dalal S, 2005, CLIN CANCER RES, V11, P2364, DOI 10.1158/1078 0432.CCR 04 1201
   Engin F, 2009, HUM MOL GENET, V18, P1464, DOI 10.1093/hmg/ddp057
   Ferrari S, 2007, CURR OPIN ONCOL, V19, P341, DOI 10.1097/CCO.0b013e328122d73f
   Garcia JA, 2008, MOL CANCER THER, V7, P1347, DOI 10.1158/1535 7163.MCT 07 2408
   Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300
   Gordon N, 2005, J PEDIAT HEMATOL ONC, V27, P611, DOI 10.1097/01.mph.0000188112.42576.df
   Gordon N, 2007, CLIN CANCER RES, V13, P4503, DOI 10.1158/1078 0432.CCR 07 0313
   Greil R, 2003, J LEUKOCYTE BIOL, V74, P311, DOI 10.1189/jlb.0802416
   Guan H, 2008, MOL CANCER THER, V7, P1807, DOI 10.1158/1535 7163.MCT 08 0058
   HALLGERYK MYY, 2008, 99 ANN M AM ASS CANC
   Hingorani P, 2009, CLIN CANCER RES, V15, P3416, DOI 10.1158/1078 0432.CCR 08 1657
   Hoang BH, 2004, INT J CANCER, V109, P106, DOI 10.1002/ijc.11677
   Hou P, 2006, CANCER AM CANCER SOC, V106, P1602, DOI 10.1002/cncr.21762
   Hughes DPM, 2004, CANCER RES, V64, P2047, DOI 10.1158/0008 5472.CAN 03 3096
   Kang HG, 2007, CANCER RES, V67, P3094, DOI 10.1158/0008 5472.CAN 06 3259
   KAPPEL CC, 1994, CANCER RES, V54, P2803
   Kikuchi A, 2000, BIOCHEM BIOPH RES CO, V268, P243, DOI 10.1006/bbrc.1999.1860
   Kim SY, 2009, ONCOLOGIST, V14, P83, DOI 10.1634/theoncologist.2008 0189
   Kolb EA, 2008, PEDIATR BLOOD CANCER, V50, P1190, DOI 10.1002/pbc.21450
   Koshkina NV, 2007, MOL CANCER RES, V5, P991, DOI 10.1158/1541 7786.MCR 07 0007
   Lee N, 2007, BRIT J CANCER, V97, P1552, DOI 10.1038/sj.bjc.6604069
   Lim S, 2003, ONCOL REP, V10, P897
   Marina N, 2004, ONCOLOGIST, V9, P422, DOI 10.1634/theoncologist.9 4 422
   Messerschmitt PJ, 2008, CLIN ORTHOP RELAT R, V466, P2168, DOI 10.1007/s11999 008 0338 9
   Ory B, 2007, MOL PHARMACOL, V71, P333, DOI 10.1124/mol.106.028837
   Ory B, 2007, CURR MED CHEM, V14, P1381, DOI 10.2174/092986707780831159
   Pompetti F, 1996, J CELL BIOCHEM, V63, P37
   Reddy K, 2008, INT J CANCER, V123, P831, DOI 10.1002/ijc.23582
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Ren L, 2009, ONCOGENE, V28, P792, DOI 10.1038/onc.2008.437
   Schaefer KL, 2008, EUR J CANCER, V44, P699, DOI 10.1016/j.ejca.2008.01.020
   Scotlandi K, 2005, CANCER RES, V65, P3868, DOI 10.1158/0008 5472.CAN 04 3192
   Shih IM, 2007, CANCER RES, V67, P1879, DOI 10.1158/0008 5472.CAN 06 3958
   Tanaka M, 2009, BRIT J CANCER, V100, P1957, DOI 10.1038/sj.bjc.6605060
   TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001
   Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822
   Üren A, 2004, PEDIATR BLOOD CANCER, V43, P243, DOI 10.1002/pbc.20124
   Wan XL, 2007, ONCOLOGIST, V12, P1007, DOI 10.1634/theoncologist.12 8 1007
   Wan XL, 2005, CANCER RES, V65, P2406, DOI 10.1158/0008 5472.CAN 04 3135
   Wen YH, 2007, HUM PATHOL, V38, P1184, DOI 10.1016/j.humpath.2007.01.002
   Woessmann W, 2002, CANCER CHEMOTH PHARM, V50, P397, DOI 10.1007/s00280 002 0502 y
   Yang R, 2008, CLIN CANCER RES, V14, P6396, DOI 10.1158/1078 0432.CCR 07 5113
   Yokoyama R, 1998, PATHOL RES PRACT, V194, P615, DOI 10.1016/S0344 0338(98)80096 4
   Zhang PY, 2008, CLIN CANCER RES, V14, P2962, DOI 10.1158/1078 0432.CCR 07 1992
   Zhou ZC, 2007, CLIN CANCER RES, V13, P4867, DOI 10.1158/1078 0432.CCR 07 0133
NR 50
TC 17
Z9 24
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523 3790
EI 1534 6269
J9 CURR ONCOL REP
JI Curr. Oncol. Rep.
PD NOV
PY 2009
VL 11
IS 6
BP 446
EP 453
DI 10.1007/s11912 009 0061 z
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA V16BL
UT WOS:000207845000007
PM 19840522
DA 2025 08 17
ER

PT J
AU Riccitiello, F
   De Luise, A
   Conte, R
   D'Aniello, S
   Vittoria, V
   Di Salle, A
   Calarco, A
   Peluso, G
AF Riccitiello, Francesco
   De Luise, Adriana
   Conte, Raffaele
   D'Aniello, Sharon
   Vittoria, Vittoria
   Di Salle, Anna
   Calarco, Anna
   Peluso, Gianfranco
TI Effect of resveratrol release kinetic from electrospun nanofibers on
   osteoblast and osteoclast differentiation
SO EUROPEAN POLYMER JOURNAL
LA English
DT Article
DE Electrospinning; Resveratrol; Osteoblast differentiation; Osteoblast
   differentiation; Alveolar bone defect
ID BONE MORPHOGENETIC PROTEIN 2; MESENCHYMAL STEM CELLS; OSTEOGENIC
   DIFFERENTIATION; MOLECULAR MECHANISMS; GENE EXPRESSION; IN VITRO;
   FABRICATION; SCAFFOLDS; DELIVERY; FIBERS
AB Resveratrol (RSV) has been shown to exhibit many biological properties that can influence bone osteogenesis. However, RSV oral clinical treatment is limited due to its poor pharmacokinetics, low water solubility, and rapid metabolism. Therefore, it is necessary to develop a valid delivery system to release RSV directly into the target site. Electrospun drug eluting fibers have gained great attention in the regenerative dentistry due to the ease of fabrication, the high surface to volume ratio and the drug loading efficiency. The post extraction preservation of the alveolar socket requires to operate on the bone remodeling processes both by stimulation of bone formation by osteoblasts and inhibition of osteoclast mediated bone resorption. In this work, uniform defect free fibers of poly(e caprolactone) PCL and poly(lactic) acid (PLA) loading resveratrol were synthetized and characterized. In vitro assay demonstrated that the two membranes were able to release RSV in a tunable and sustained manner with different kinetic: PCL RSV membrane showed an initial burst followed by a slow release, while PLA RSV presented a much slower and continuous release over the time. Although both RSV loaded materials showed similar in vitro osteoinductive capacity on human dental pulp stem cells, the differences on RSV release kinetic affected RANKL induced osteoclastogenesis Indeed, only the lower resveratrol releasing membrane (PLA RSV) was able both to induce osteoblast and to inhibit osteoclast differentiation, suggesting that this bioactive membrane could be used to preserve post extraction alveolar ridge volume acting simultaneously on two fronts: first counteract bone resorption, second allows new bone formation.
C1 [Riccitiello, Francesco] Univ Naples Federico II, Med Sch, Dept Neurosci Reprod & Odontostomatol Sci, Via Pansini 5, I 80131 Naples, Italy.
   [De Luise, Adriana; Conte, Raffaele; Di Salle, Anna; Calarco, Anna; Peluso, Gianfranco] CNR, IBAF, Inst Agroenvironm & Forest Biol, Natl Res Council, Via Castellino 111, I 80131 Naples, Italy.
   [D'Aniello, Sharon; Vittoria, Vittoria] Univ Salerno, Dept Ind Engn, Via Giovanni Paolo II, I 84084 Fisciano, SA, Italy.
C3 University of Naples Federico II; Consiglio Nazionale delle Ricerche
   (CNR); Istituto di Biologia Agroambientale e Forestale (IBAF CNR);
   University of Salerno
RP Calarco, A (通讯作者)，CNR, IBAF, Inst Agroenvironm & Forest Biol, Natl Res Council, Via Castellino 111, I 80131 Naples, Italy.
EM anna.calarco@ibaf.cnr.it
RI ; Conte, Raffaele/LDG 6490 2024; Di Salle, A/AAF 5416 2019; Calarco,
   Anna/P 2568 2019
OI Di Salle, Anna/0000 0001 6763 3636; Conte, Raffaele/0000 0002 6266 4991;
   Calarco, Anna/0000 0002 1441 7662; Vittoria,
   Vittoria/0000 0001 6978 3523
FU Ministero dell'Istruzione, dell'Universita e della Ricerca of Italy
   [PON01_01802, PON01_02512]
FX This work was supported from Ministero dell'Istruzione, dell'Universita
   e della Ricerca of Italy, Progetto PON   'Ricerca e Competitivita
   2007 2013' PON01_01802: 'Sviluppo di molecole capaci di modulare vie
   metaboliche intracellulari redox sensibili per la prevenzione e la cura
   di patologie infettive, tumorali, neurodegenerative e loro delivery
   mediante piattaforme nano tecnologiche', and PON01_02512: 'Ricerca e
   sviluppo di bioregolatori attivi sui meccanismi epigenetici dei processi
   infiammatori nelle malattie croniche e degenerative'.
CR Abrigo M, 2014, MACROMOL BIOSCI, V14, P772, DOI 10.1002/mabi.201300561
   Ahmed FE, 2015, DESALINATION, V356, P15, DOI 10.1016/j.desal.2014.09.033
   de la Lastral CA, 2007, BIOCHEM SOC T, V35, P1156, DOI 10.1042/BST0351156
   Avila Ortiz G, 2014, J DENT RES, V93, P950, DOI 10.1177/0022034514541127
   Badami AS, 2006, BIOMATERIALS, V27, P596, DOI 10.1016/j.biomaterials.2005.05.084
   Boissy P, 2005, CANCER RES, V65, P9943, DOI 10.1158/0008 5472.CAN 05 0651
   Bradamante S, 2004, CARDIOVASC DRUG REV, V22, P169
   Calarco A, 2015, J DENT RES, V94, P1099, DOI 10.1177/0022034515584615
   Canullo L, 2016, ANN ANAT, V206, P73, DOI 10.1016/j.aanat.2015.05.007
   Carragee EJ, 2013, J BONE JOINT SURG AM, V95A, P1537, DOI 10.2106/JBJS.L.01483
   Casarin RC, 2014, INT J ORAL MAX SURG, V43, P900, DOI 10.1016/j.ijom.2014.01.009
   Chen JP, 2011, COLLOID SURFACE B, V86, P169, DOI 10.1016/j.colsurfb.2011.03.038
   Chiara G, 2012, INT J MOL SCI, V13, P737, DOI 10.3390/ijms13010737
   Dai Z, 2007, PHYTOMEDICINE, V14, P806, DOI 10.1016/j.phymed.2007.04.003
   de la Lastra CA, 2005, MOL NUTR FOOD RES, V49, P405
   De Luca I, 2016, STEM CELL RES, V17, P248, DOI 10.1016/j.scr.2016.07.005
   Dosier CR, 2012, J MECH BEHAV BIOMED, V11, P112, DOI 10.1016/j.jmbbm.2011.08.014
   Faghihi F, 2014, BIOMED PAP, V158, P5, DOI 10.5507/bp.2013.013
   Fee L, 2017, BRIT DENT J, V222, P579, DOI 10.1038/sj.bdj.2017.355
   Fiorellini JP, 2005, J PERIODONTOL, V76, P605, DOI 10.1902/jop.2005.76.4.605
   Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138
   He X, 2010, BIOCHEM BIOPH RES CO, V401, P356, DOI 10.1016/j.bbrc.2010.09.053
   Horváth A, 2013, CLIN ORAL INVEST, V17, P341, DOI 10.1007/s00784 012 0758 5
   Huang ZM, 2006, J BIOMED MATER RES A, V77A, P169, DOI 10.1002/jbm.a.30564
   Kjær TN, 2017, J CLIN ENDOCR METAB, V102, P1642, DOI 10.1210/jc.2016 2160
   Krause U, 2011, METHODS MOL BIOL, V698, P215, DOI 10.1007/978 1 60761 999 4_17
   Kupisiewicz K, 2010, CALCIFIED TISSUE INT, V87, P437, DOI 10.1007/s00223 010 9399 3
   Lutolf MP, 2005, NAT BIOTECHNOL, V23, P47, DOI 10.1038/nbt1055
   Lyu S, 2013, J ORTHOP RES, V31, P1382, DOI 10.1002/jor.22367
   Manuel C. B. J., 2016, ELECTROSPINNING MAT
   Mei L, 2016, EXPERT OPIN DRUG DEL, V13, P741, DOI 10.1517/17425247.2016.1142525
   Nevins ML, 2011, INT J PERIODONT REST, V31, P481
   Ngadiman NHA, 2017, P I MECH ENG H, V231, P597, DOI 10.1177/0954411917699021
   Omar JM, 2014, J AGR FOOD CHEM, V62, P5812, DOI 10.1021/jf5001277
   Pérez Sayáns M, 2010, ORAL SURG ORAL MED O, V109, P679, DOI 10.1016/j.tripleo.2009.10.042
   Pillay V, 2013, J NANOMATER, V2013, DOI 10.1155/2013/789289
   Poornima B, 2017, CARBOHYD POLYM, V157, P1741, DOI 10.1016/j.carbpol.2016.11.056
   Poulsen MM, 2014, J FUNCT FOODS, V6, P305, DOI 10.1016/j.jff.2013.10.019
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Reneker DH, 1996, NANOTECHNOLOGY, V7, P216, DOI 10.1088/0957 4484/7/3/009
   Salifu AA, 2017, J BIOMED MATER RES A, V105, P1911, DOI 10.1002/jbm.a.36058
   Schliephake H, 2015, CLIN IMPLANT DENT R, V17, P247, DOI 10.1111/cid.12114
   Shakibaei M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035712
   Singh H, 2012, J BIOMATER TISS ENG, V2, P228, DOI 10.1166/jbt.2012.1049
   Tammaro L, 2014, J DENT, V42, P60, DOI 10.1016/j.jdent.2013.10.019
   Terranova L, 2016, ACTA BIOMATER, V29, P380, DOI 10.1016/j.actbio.2015.10.042
   Nguyen TH, 2013, J BIOMED MATER RES A, V101, P797, DOI 10.1002/jbm.a.34382
   Tou JC, 2015, BBA MOL BASIS DIS, V1852, P1186, DOI 10.1016/j.bbadis.2014.10.003
   Tseng PC, 2011, J BONE MINER RES, V26, P2552, DOI 10.1002/jbmr.460
   Ulrich S, 2005, MOL NUTR FOOD RES, V49, P452, DOI 10.1002/mnfr.200400081
   Valarezo E, 2015, J NANOSCI NANOTECHNO, V15, P4706, DOI 10.1166/jnn.2015.9726
   Venugopal J, 2008, J BIOMED MATER RES A, V85A, P408, DOI 10.1002/jbm.a.31538
   Wang J, 2010, ACTA BIOMATER, V6, P3856, DOI 10.1016/j.actbio.2010.04.009
   Wang XF, 2016, CURR OPIN CHEM ENG, V12, P62, DOI 10.1016/j.coche.2016.03.001
   Wang ZH, 2017, ACS APPL MATER INTER, V9, P19541, DOI 10.1021/acsami.6b16573
   Williams GR, 2012, THER DELIV, V3, P515, DOI 10.4155/tde.12.17
   Xiaowei Hu, 2014, Mathematical Problems in Engineering, DOI 10.1155/2014/708482
   Zupancic S, 2015, J DRUG DELIV SCI TEC, V30, P408, DOI 10.1016/j.jddst.2015.07.009
   Zupancic S, 2015, EUR J PHARM BIOPHARM, V93, P196, DOI 10.1016/j.ejpb.2015.04.002
NR 59
TC 42
Z9 42
U1 1
U2 57
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0014 3057
EI 1873 1945
J9 EUR POLYM J
JI Eur. Polym. J.
PD FEB
PY 2018
VL 99
BP 289
EP 297
DI 10.1016/j.eurpolymj.2017.12.035
PG 9
WC Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Polymer Science
GA FZ1LM
UT WOS:000427338100032
DA 2025 08 17
ER

PT J
AU Gagiannis, S
   Müller, M
   Uhlemann, S
   Koch, A
   Melino, G
   Krammer, PH
   Nawroth, PP
   Brune, M
   Schilling, T
AF Gagiannis, Sarah
   Mueller, Martina
   Uhlemann, Sebastian
   Koch, Andreas
   Melino, Gerry
   Krammer, Peter H.
   Nawroth, Peter P.
   Brune, Maik
   Schilling, Tobias
TI Parathyroid hormone related protein confers chemoresistance by blocking
   apoptosis signaling via death receptors and mitochondria
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE apoptosis; chemosensitivity; p53 family; PTHrP; PTH
ID BREAST CANCER CELLS; PTHRP; PEPTIDE; BCL 2; MCF7; P53
AB Parathyroid hormone (PTH) has a central role in the regulation of serum calcium and phosphate, whereas parathyroid hormone related peptide (PTHrP) has important developmental roles. In addition, PTHrP has been discovered as a causative agent of hypercalcemia of malignancy. PTHrP is also expressed in many tumors, and expression often correlates with unfavorable prognosis. We have investigated the effects of PTHrP on apoptosis signaling pathways initiated by DNA damaging chemotherapeutic drugs. Stimulation experiments of the CD95 , the TNF R , and the TRAIL R death receptor systems in Saos human osteosarcoma cells revealed that PTHrP can block signaling via each of these death receptors. Furthermore, our findings demonstrate a link between PTHrP and the mitochondrial apoptosis pathway. PTHrP down regulates expression of pro apoptotic Bcl 2 family members like Bax and PUMA and up regulates expression of antiapoptotic molecules like Bcl 2 and Bcl xl. It is of clinical relevance that PTHrP and anticancer drugs show opposing interactions on death receptor triggered as well as on mitochondrial apoptosis pathways. In addition, PTHrP induces chemoresistance by interference with p53 family dependent apoptosis signaling pathways and p53 mediated transactivation of apoptosis target genes. Inhibition of CD95  and Bax gene transactivation is a mechanism by which PTHrP reduced the apoptosis response and treatment sensitivity of tumor cells. Our data indicate that PTHrP inhibits major apoptosis signaling pathways by blocking signaling via p53, death receptors and mitochondria and, consequently, confers chemoresistance of cancer cells. Thus, beyond its importance in development and differentiation, we describe an important role for PTHrP in tumorigenesis. (C) 2009 UICC
C1 [Gagiannis, Sarah; Uhlemann, Sebastian; Nawroth, Peter P.; Brune, Maik; Schilling, Tobias] Univ Heidelberg Hosp, Dept Internal Med & Clin Chem 1, D 69120 Heidelberg, Germany.
   [Mueller, Martina; Koch, Andreas] Univ Heidelberg Hosp, Dept Internal Med Hepatol & Gastroenterol 4, D 69120 Heidelberg, Germany.
   [Melino, Gerry] Univ Rome, Biochem Lab, Dept Expt Med & Biochem Sci, IDI IRCCS, Rome, Italy.
   [Melino, Gerry] Univ Leicester, Toxicol Unit, MRC, Leicester, Leics, England.
   [Krammer, Peter H.] German Canc Res Ctr, Tumor Immunol Program, Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg; Ruprecht Karls University
   Heidelberg; Sapienza University Rome; IRCCS Istituto Dermopatico
   dell'Immacolata (IDI); University of Leicester; Helmholtz Association;
   German Cancer Research Center (DKFZ)
RP Schilling, T (通讯作者)，Univ Heidelberg Hosp, Dept Internal Med & Clin Chem 1, Neuenheimer Feld 410, D 69120 Heidelberg, Germany.
EM Tobias_Schilling@med.uni heidelberg.de
RI ; Martina, Mueller Schilling/R 4162 2016; Meier, Ute/N 6891 2018
OI Muller Schilling, Martina/0000 0002 8520 4568; 
FU Tumorzentrum Heidelberg/Mannheim; Helmholtz Alliance of Immunotherapy;
   Forschungsschwerpunktprogramm Baden Wurttemberg; Hopp Stiftung; MRC
   [MC_U132670600] Funding Source: UKRI; Medical Research Council
   [MC_U132670600] Funding Source: researchfish
FX This work was supported by grants of the Tumorzentrum
   Heidelberg/Mannheim (to M.M., T.S. and P.H.K.), the Helmholtz Alliance
   of Immunotherapy (to M.M. and P.H.K.), the Forschungsschwerpunktprogramm
   Baden Wurttemberg (to M.M.) and the Hopp Stiftung "Altern   Mobilitat
   erhalten, Regeneration ermoglichen" (to T.S. and P.P.N.). We thank
   Gisela Schwalm, Katja Lorenz and Petra Hill for expert technical
   assistance.
CR Alokail MS, 2008, CELL BIOCHEM FUNCT, V26, P522, DOI 10.1002/cbf.1475
   Alokail MS, 2007, CELL BIOCHEM FUNCT, V25, P139, DOI 10.1002/cbf.1280
   Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097 2765(01)00320 3
   Dittmer A, 2006, J BIOL CHEM, V281, P14563, DOI 10.1074/jbc.M510527200
   Falzon M, 2000, ENDOCRINOLOGY, V141, P1882, DOI 10.1210/en.141.5.1882
   Gensure RC, 2005, BIOCHEM BIOPH RES CO, V328, P666, DOI 10.1016/j.bbrc.2004.11.069
   Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320
   Gressner O, 2005, EMBO J, V24, P2458, DOI 10.1038/sj.emboj.7600708
   Hemann MT, 2004, P NATL ACAD SCI USA, V101, P9333, DOI 10.1073/pnas.0403286101
   Kern MA, 2006, CANCER RES, V66, P7059, DOI 10.1158/0008 5472.CAN 06 0325
   Linforth R, 2002, CLIN CANCER RES, V8, P3172
   Lund PK, 2001, J IMMUNOL METHODS, V252, P45, DOI 10.1016/S0022 1759(01)00330 1
   Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200
   MIYASHITA T, 1995, CELL, V80, P293
   Müller M, 2005, CELL DEATH DIFFER, V12, P1564, DOI 10.1038/sj.cdd.4401774
   Müller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033
   Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174
   Murray TM, 2005, ENDOCR REV, V26, P78, DOI 10.1210/er.2003 0024
   NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022 1759(91)90198 O
   Okoumassoun L, 2007, J CELL PHYSIOL, V210, P507, DOI 10.1002/jcp.20892
   Okoumassoun LE, 2007, J CELL PHYSIOL, V212, P591, DOI 10.1002/jcp.21055
   PECHERSTORFER M, 1994, J CLIN ENDOCR METAB, V78, P1268, DOI 10.1210/jc.78.5.1268
   SCHILLING T, 1993, J CLIN ENDOCR METAB, V76, P801, DOI 10.1210/jc.76.3.801
   Strewler GJ, 2000, NEW ENGL J MED, V342, P177, DOI 10.1056/NEJM200001203420306
   TOVAR SV, 2002, ENDOCRINOLOGY, V143, P596
   Zuliani T, 2003, CYTOM PART A, V54A, P100, DOI 10.1002/cyto.a.10059
NR 26
TC 23
Z9 29
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0020 7136
EI 1097 0215
J9 INT J CANCER
JI Int. J. Cancer
PD OCT 1
PY 2009
VL 125
IS 7
BP 1551
EP 1557
DI 10.1002/ijc.24471
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 491GB
UT WOS:000269565400007
PM 19507249
DA 2025 08 17
ER

PT J
AU Zhang, L
   Mager, DE
AF Zhang, Li
   Mager, Donald E.
TI Systems Modeling of Bortezomib and Dexamethasone Combinatorial Effects
   on Bone Homeostasis in Multiple Myeloma Patients
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE cancer cancer chemotherapy; drug drug interaction; in silico modeling;
   mechanistic modeling; PK/PD modeling; systems pharmacology
ID PROTEASOME INHIBITION; SERUM CONCENTRATIONS; OSTEOBLAST ACTIVITY;
   DISEASE; OSTEOPOROSIS; CELLS
AB Osteolytic bone disease is one of the most debilitating manifestations of multiple myeloma (MM). Bortezomib is a proteasome inhibitor that shows both anticancer and bone anabolic properties and is being evaluated for its positive effects in MM patients with skeletal complications. Dexamethasone is a potent corticosteroid that is often given in combination with bortezomib for its antineoplastic effects; however, bone loss and osteoporosis are major adverse effects of long term steroid based therapies. In this study, a small systems pharmacological model was developed to integrate the bone anabolic effects of bortezomib with the osteolytic activity of dexamethasone in MM patients with bone disease. The final model parameters were all estimated with good precision. The interaction model is based on codifying multiple regulatory mechanisms of drug action and provides a platform for probing optimized bortezomib and dexamethasone combination dosing regimens to minimize skeletal side effects during myeloma therapy. (C) 2019 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
C1 [Zhang, Li; Mager, Donald E.] SUNY Buffalo, Dept Pharmaceut Sci, Buffalo, NY 14260 USA.
C3 State University of New York (SUNY) System; University at Buffalo, SUNY
RP Mager, DE (通讯作者)，SUNY Buffalo, Dept Pharmaceut Sci, Buffalo, NY 14260 USA.
EM dmager@buffalo.edu
FU National Institutes of Health [GM57980]
FX This study was supported by the grant from National Institutes of Health
   (grant: GM57980).
CR Betts AM, 2010, J PHARMACOL EXP THER, V333, P2, DOI 10.1124/jpet.109.164129
   Bross PF, 2004, CLIN CANCER RES, V10, P3954, DOI 10.1158/1078 0432.CCR 03 0781
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253
   D'Argenio DZ., 2009, ADAPT 5 User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software
   Dick LR, 2010, DRUG DISCOV TODAY, V15, P243, DOI 10.1016/j.drudis.2010.01.008
   Edwards CM, 2009, AM J HEMATOL, V84, P268, DOI 10.1002/ajh.21374
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   Gibiansky E, 2014, CPT PHARMACOMET SYST, V3, DOI 10.1038/psp.2014.42
   Heider U, 2006, EUR J HAEMATOL, V77, P233, DOI 10.1111/j.1600 0609.2006.00692.x
   Heider U, 2009, EUR J HAEMATOL, V82, P31, DOI 10.1111/j.1600 0609.2008.01164.x
   Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952
   Iyengar R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003563
   Kaiser M, 2008, EUR J HAEMATOL, V80, P490, DOI 10.1111/j.1600 0609.2008.01065.x
   Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084
   Kyle RA, 2009, LEUKEMIA, V23, P3, DOI 10.1038/leu.2008.291
   Laubach J, 2011, ANNU REV MED, V62, P249, DOI 10.1146/annurev med 070209 175325
   Leclerc N, 2004, J MOL ENDOCRINOL, V33, P175, DOI 10.1677/jme.0.0330175
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Lund T, 2010, EUR J HAEMATOL, V85, P290, DOI 10.1111/j.1600 0609.2010.01485.x
   Mager DE, 2003, DRUG METAB DISPOS, V31, P510, DOI 10.1124/dmd.31.5.510
   Mager DE, 2003, J CLIN PHARMACOL, V43, P1216, DOI 10.1177/0091270003258651
   Mager DE, 2001, J PHARMACOKINET PHAR, V28, P507, DOI 10.1023/A:1014414520282
   Mager DE, 2001, CLIN PHARMACOL THER, V70, P210, DOI 10.1067/mcp.2001.118244
   Marathe A, 2008, J PHARMACOL EXP THER, V326, P555, DOI 10.1124/jpet.108.137703
   Ogawa Y, 2008, CANCER SCI, V99, P140, DOI 10.1111/j.1349 7006.2007.00638.x
   Oyajobi BO, 2007, BRIT J HAEMATOL, V139, P434, DOI 10.1111/j.1365 2141.2007.06829.x
   Peterson MC, 2010, BONE, V46, P49, DOI 10.1016/j.bone.2009.08.053
   Pinzone JJ, 2009, BLOOD, V113, P517, DOI 10.1182/blood 2008 03 145169
   Post TM, 2013, J PHARMACOKINET PHAR, V40, P143, DOI 10.1007/s10928 012 9294 9
   Reece DE, 2011, CANCER CHEMOTH PHARM, V67, P57, DOI 10.1007/s00280 010 1283 3
   Richardson PG, 2006, ANNU REV MED, V57, P33, DOI 10.1146/annurev.med.57.042905.122625
   Rosiñol L, 2007, J CLIN ONCOL, V25, P4452, DOI 10.1200/JCO.2007.12.3323
   Sacco JJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008933
   Terpos E, 2007, BLOOD, V110, P1098, DOI 10.1182/blood 2007 03 067710
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Vallet S, 2010, CLIN CANCER RES, V16, P4084, DOI 10.1158/1078 0432.CCR 10 0600
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Zangari M, 2005, BRIT J HAEMATOL, V131, P71, DOI 10.1111/j.1365 2141.2005.05733.x
   Zhang L, 2015, J PHARMACOKINET PHAR, V42, P541, DOI 10.1007/s10928 015 9445 x
NR 40
TC 3
Z9 5
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0022 3549
EI 1520 6017
J9 J PHARM SCI US
JI J. Pharm. Sci.
PD JAN
PY 2019
VL 108
IS 1
BP 732
EP 740
DI 10.1016/j.xphs.2018.11.024
PG 9
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Chemistry
GA HJ1BY
UT WOS:000456898100075
PM 30472266
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Silbermann, R
   Roodman, GD
AF Silbermann, Rebecca
   Roodman, G. David
TI Myeloma bone disease: Pathophysiology and management
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Article
DE Myeloma; Osteoblast; Osteoclast; Myeloma bone disease; Angiogenesis;
   Bone marrow microenvironment
ID KAPPA B LIGAND; MACROPHAGE INFLAMMATORY PROTEIN 1 ALPHA; OSTEOCLAST
   DIFFERENTIATION FACTOR; MESENCHYMAL STEM CELLS; HUMAN MULTIPLE MYELOMA;
   NECROSIS FACTOR ALPHA; MARROW STROMAL CELLS; REDUCES TUMOR BURDEN;
   RECEPTOR ACTIVATOR; OSTEOLYTIC LESIONS
AB Multiple myeloma bone disease is marked by severe dysfunction of both bone formation and resorption and serves as a model for understanding the regulation of osteoblasts (OBL) and osteoclasts (OCL) in cancer. Myeloma bone lesions are purely osteolytic and are associated with severe and debilitating bone pain, pathologic fractures, hypercalcemia, and spinal cord compression, as well as increased mortality. Interactions within the bone marrow microenvironment in myeloma are responsible for the abnormal bone remodeling in myeloma bone disease. Myeloma cells drive bone destruction that increases tumor growth, directly stimulates the OCL formation, and induces cells in the marrow microenvironment to produce factors that drive OCL formation and suppress OBL formation. Factors produced by marrow stromal cells and OCL promote tumor growth through direct action on myeloma cells and by increasing angiogenesis. Current therapies targeting MMBD focus on preventing osteoclastic bone destruction; however regulators of OBL inhibition in MMBD have also been identified, and targeted agents with a potential anabolic effect in MMBD are under investigation. This review will discuss the mechanisms responsible for MMBD and therapeutic approaches currently in use and in development for the management of MMBD. (C) 2013 Elsevier GmbH All rights reserved.
C1 [Silbermann, Rebecca; Roodman, G. David] Indiana Univ Sch Med, Dept Med, Div Hematol Oncol, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington
RP Silbermann, R (通讯作者)，Indiana Univ Sch Med, Dept Med, 980 West Walnut St,R3 C310, Indianapolis, IN 46202 USA.
EM rsilberm@iu.edu
CR Abe M, 2006, LEUKEMIA, V20, P1313, DOI 10.1038/sj.leu.2404228
   Abe M, 2004, BLOOD, V104, P2484, DOI 10.1182/blood 2003 11 3839
   Abe M, 2002, BLOOD, V100, P2195, DOI 10.1182/blood.V100.6.2195.h81802002195_2195_2202
   Alsina M, 1996, BLOOD, V87, P1495, DOI 10.1182/blood.V87.4.1495.bloodjournal8741495
   Anderson G, 2006, BLOOD, V107, P3098, DOI 10.1182/blood 2005 08 3450
   [Anonymous], BLOOD
   Aparicio A, 1998, LEUKEMIA, V12, P220, DOI 10.1038/sj.leu.2400892
   Avcu F, 2005, EUR J HAEMATOL, V74, P496, DOI 10.1111/j.1600 0609.2005.00427.x
   Badros A, 2006, J CLIN ONCOL, V24, P945, DOI 10.1200/JCO.2005.04.2465
   Badros A, 2007, BLOOD, V110, p1030A, DOI 10.1182/blood.V110.11.3519.3519
   Bao HY, 2009, INT J HEMATOL, V90, P177, DOI 10.1007/s12185 009 0356 8
   BATAILLE R, 1989, J CLIN ONCOL, V7, P1909, DOI 10.1200/JCO.1989.7.12.1909
   Berenson JR, 2010, BRIT J HAEMATOL, V150, P28, DOI 10.1111/j.1365 2141.2010.08207.x
   Berenson JR, 1998, J CLIN ONCOL, V16, P593, DOI 10.1200/JCO.1998.16.2.593
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Breitkreutz I, 2008, LEUKEMIA, V22, P1925, DOI 10.1038/leu.2008.174
   Brunetti G, 2011, ANN NY ACAD SCI, V1237, P19, DOI 10.1111/j.1749 6632.2011.06196.x
   Bruni Cardoso A, 2010, MOL CANCER RES, V8, P459, DOI 10.1158/1541 7786.MCR 09 0445
   Cackowski FC, 2010, BLOOD, V115, P140, DOI 10.1182/blood 2009 08 237628
   Chantry AD, 2010, J BONE MINER RES, V25, P2357, DOI 10.1002/jbmr.142
   Choi SJ, 2001, J CLIN INVEST, V108, P1833, DOI 10.1172/JCI13116
   Choi SJ, 2000, BLOOD, V96, P671
   Clarke BM, 2007, OTOLARYNG HEAD NECK, V136, P396, DOI 10.1016/j.otohns.2006.11.008
   Claudio JO, 2002, BLOOD, V100, P2175, DOI 10.1182/blood 2002 01 0008
   Costa AG, 2012, CURR OSTEOPOROS REP, V10, P64, DOI 10.1007/s11914 011 0089 5
   Croucher PI, 2001, BLOOD, V98, P3534, DOI 10.1182/blood.V98.13.3534
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   D'Souza S, 2010, 32 ANN M AM SOC BON, p742A
   D'Souza S, 2012, BLOOD, V119, P1888, DOI 10.1182/blood 2011 11 393348
   D'Souza S, 2011, BLOOD, V118, P6871, DOI 10.1182/blood 2011 04 346775
   Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200
   Dhodapkar MV, 1998, LEUKEMIA LYMPHOMA, V32, P121, DOI 10.3109/10428199809059252
   Diamond T, 1997, BRIT J HAEMATOL, V97, P641, DOI 10.1046/j.1365 2141.1997.1042920.x
   Dimopoulos M, 2009, LEUKEMIA, V23, P1545, DOI 10.1038/leu.2009.89
   DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097 0142(197509)36:3<842::AID CNCR2820360303>3.0.CO;2 U
   Edwards CM, 2008, BONE, V42, P1007, DOI 10.1016/j.bone.2008.01.027
   Edwards CM, 2008, BLOOD, V111, P2833, DOI 10.1182/blood 2007 03 077685
   Ehrlich LA, 2005, IMMUNOL REV, V208, P252, DOI 10.1111/j.0105 2896.2005.00323.x
   Ehrlich LA, 2005, BLOOD, V106, P1407, DOI 10.1182/blood 2005 03 1080
   Ellis GK, 2008, J CLIN ONCOL, V26, P4875, DOI 10.1200/JCO.2008.16.3832
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Fowler JA, 2011, BLOOD, V118, P5872, DOI 10.1182/blood 2011 01 330407
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   Fuller K, 2000, BIOCHEM BIOPH RES CO, V268, P2, DOI 10.1006/bbrc.2000.2075
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Ge Y, 2006, BRIT J HAEMATOL, V133, P83, DOI 10.1111/j.1365 2141.2006.05976.x
   Giuliani N, 2005, BLOOD, V106, P2472, DOI 10.1182/blood 2004 12 4986
   Giuliani N, 2004, EXP HEMATOL, V32, P685, DOI 10.1016/j.exphem.2004.03.015
   Giuliani N, 2012, LEUKEMIA, V26, P1391, DOI 10.1038/leu.2011.381
   Giuliani N, 2002, BLOOD, V100, P4615, DOI 10.1182/blood 2002 04 1121
   Giuliani N, 2007, LEUKEMIA LYMPHOMA, V48, P2323, DOI 10.1080/10428190701648281
   Giuliani N, 2007, BLOOD, V110, P334, DOI 10.1182/blood 2006 11 059188
   Giuliani N, 2006, BLOOD, V108, P3992, DOI 10.1182/blood 2006 05 026112
   Giuliani N, 2009, EXP HEMATOL, V37, P879, DOI 10.1016/j.exphem.2009.04.004
   Gladue RP, 2010, CURR TOP MED CHEM, V10, P1268
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gunn WG, 2006, STEM CELLS, V24, P986, DOI 10.1634/stemcells.2005 0220
   Han JH, 2001, BLOOD, V97, P3349, DOI 10.1182/blood.V97.11.3349
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623
   Hideshima T, 2001, SEMIN ONCOL, V28, P607, DOI 10.1053/sonc.2001.28608
   Hofbauer LC, 1998, EUR J ENDOCRINOL, V139, P152, DOI 10.1530/eje.0.1390152
   Howlader N., 2011, SEER cancer statistics review, 1975 2008
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Jin JM, 2006, EUR J IMMUNOL, V36, P421, DOI 10.1002/eji.200535155
   JOSSE RG, 1981, J CLIN INVEST, V67, P1472, DOI 10.1172/JCI110177
   Kaiser M, 2008, EUR J HAEMATOL, V80, P490, DOI 10.1111/j.1600 0609.2008.01065.x
   Kastritis E, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.1860.1860
   Khamaisi M, 2007, J CLIN ENDOCR METAB, V92, P1172, DOI 10.1210/jc.2006 2036
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kobayashi T, 2005, ENDOCRINOLOGY, V146, P1012, DOI 10.1210/en.2004 1343
   Kobayashi Y, 2009, CRIT REV EUKAR GENE, V19, P61, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.30
   Kukreja A, 2009, BLOOD, V114, P3413, DOI 10.1182/blood 2009 03 211920
   Kumar S, 2006, EUR J CANCER, V42, P1612, DOI 10.1016/j.ejca.2006.04.004
   KYLE RA, 1975, MAYO CLIN PROC, V50, P29
   Kyle RA, 2003, MAYO CLIN PROC, V78, P21, DOI 10.4065/78.1.21
   Kyle RA, 2007, J CLIN ONCOL, V25, P2464, DOI 10.1200/JCO.2007.12.1269
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lee JW, 2004, BLOOD, V103, P2308, DOI 10.1182/blood 2003 06 1992
   Lentzsch S, 2003, BLOOD, V101, P3568, DOI 10.1182/blood 2002 08 2383
   Li BZ, 2007, STEM CELLS DEV, V16, P921, DOI 10.1089/scd.2007.0074
   Li X, 2008, BLOOD, V112, P159, DOI 10.1182/blood 2007 11 124164
   Li X, 2007, BLOOD, V110, p250A, DOI 10.1182/blood.V110.11.815.815
   Limited AM, 2013, XGEVA US PRESCRIBING
   Lipton Allan, 2011, Curr Opin Support Palliat Care, V5, P258, DOI 10.1097/SPC.0b013e328349731c
   Lund T, 2010, EUR J HAEMATOL, V85, P290, DOI 10.1111/j.1600 0609.2010.01485.x
   Magrangeas F, 2003, BLOOD, V101, P4998, DOI 10.1182/blood 2002 11 3385
   Masih Khan E, 2006, BLOOD, V108, P3465, DOI 10.1182/blood 2006 04 017087
   McCloskey EV, 1998, BRIT J HAEMATOL, V100, P317
   Melton LJ, 2005, J BONE MINER RES, V20, P487, DOI 10.1359/JBMR.041131
   Menu E, 2006, CLIN EXP METASTAS, V23, P291, DOI 10.1007/s10585 006 9038 6
   Minter AR, 2011, SEMIN HEMATOL, V48, P55, DOI 10.1053/j.seminhematol.2010.11.001
   Mitsiades CS, 2007, HEMATOL ONCOL CLIN N, V21, P1007, DOI 10.1016/j.hoc.2007.08.007
   Mitsiades CS, 2006, EUR J CANCER, V42, P1564, DOI 10.1016/j.ejca.2005.12.025
   Morgan GJ, 2012, BLOOD, V119, P5374, DOI 10.1182/blood 2011 11 392522
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Mori Y, 2004, BLOOD, V104, P2149, DOI 10.1182/blood 2004 01 0236
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nefedova Y, 2004, BLOOD, V103, P3503, DOI 10.1182/blood 2003 07 2340
   Ng AC, 2011, BLOOD, V118, P6529, DOI 10.1182/blood 2011 04 351437
   Nguyen AN, 2006, EXP CELL RES, V312, P1909, DOI 10.1016/j.yexcr.2006.02.026
   NILSSONEHLE H, 1982, ACTA MED SCAND, V211, P427
   Nimmanapalli R, 2008, BRIT J HAEMATOL, V142, P551, DOI 10.1111/j.1365 2141.2008.07217.x
   Oshima T, 2005, BLOOD, V106, P3160, DOI 10.1182/blood 2004 12 4940
   Oyajobi BO, 2003, BLOOD, V102, P311, DOI 10.1182/blood 2002 12 3905
   Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498
   Pennisi A, 2009, BLOOD, V114, P1803, DOI 10.1182/blood 2009 01 201954
   Prabhala RH, 2010, BLOOD, V115, P5385, DOI 10.1182/blood 2009 10 246660
   Qiang YW, 2008, BLOOD, V112, P196, DOI 10.1182/blood 2008 01 132134
   Roodman GD, 2008, TREATMENT OF MULTIPLE MYELOMA AND RELATED DISORDERS, P64, DOI 10.1017/CBO9780511551901.006
   Roodman GD, 2011, BONE, V48, P135, DOI 10.1016/j.bone.2010.06.016
   Roodman G David, 2008, Hematology Am Soc Hematol Educ Program, P313, DOI 10.1182/asheducation 2008.1.313
   Roodman GD, 2010, J CELL BIOCHEM, V109, P283, DOI 10.1002/jcb.22403
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rosen LS, 2001, CANCER J, V7, P377
   Ruckle J, 2009, J BONE MINER RES, V24, P744, DOI 10.1359/JBMR.081208
   Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011
   Saad F, 2007, CANCER AM CANCER SOC, V110, P1860, DOI 10.1002/cncr.22991
   Shiozawa Y, 2008, J CELL BIOCHEM, V105, P370, DOI 10.1002/jcb.21835
   Siegel R, 2012, CA CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Silbermann R, 2011, BLOOD, V118, P1681, DOI 10.1182/blood.V118.21.3933.3933
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Standal T, 2007, BLOOD, V109, P3024, DOI 10.1182/blood 2006 07 034884
   Takada I, 2007, NAT CELL BIOL, V9, P1273, DOI 10.1038/ncb1647
   Takeuchi K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009870
   Tanaka Y, 2007, CLIN CANCER RES, V13, P816, DOI 10.1158/1078 0432.CCR 06 2258
   TAUBE T, 1992, EUR J HAEMATOL, V49, P192
   Terpos E, 2003, BLOOD, V102, P1064, DOI 10.1182/blood 2003 02 0380
   Terpos E, 2010, LEUKEMIA, V24, P1043, DOI 10.1038/leu.2010.62
   Terpos E, 2009, ANN ONCOL, V20, P1303, DOI 10.1093/annonc/mdn796
   Terpos E, 2010, ASH ANN M, V116, P2967
   Terpos E, 2006, BRIT J HAEMATOL, V135, P688, DOI 10.1111/j.1365 2141.2006.06356.x
   Terpos E, 2012, INT J CANCER, V131, P1466, DOI 10.1002/ijc.27342
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   VALENTINOPRAN A, 1982, BRIT J HAEMATOL, V52, P601, DOI 10.1111/j.1365 2141.1982.tb03936.x
   Vallet S, 2011, LEUKEMIA, V25, P1174, DOI 10.1038/leu.2011.43
   Vallet S, 2007, BLOOD, V110, P3744, DOI 10.1182/blood 2007 05 093294
   Vallet S, 2010, P NATL ACAD SCI USA, V107, P5124, DOI 10.1073/pnas.0911929107
   Vallet S, 2008, BLOOD, V112, P240
   Van den Wyngaerta T, 2007, CURR OPIN ONCOL, V19, P315, DOI 10.1097/CCO.0b013e32819f820b
   Vanderkerken K, 2006, BLOOD, V108, p981A, DOI 10.1182/blood.V108.11.3436.3436
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Yaccoby S, 2002, BRIT J HAEMATOL, V116, P278, DOI 10.1046/j.1365 2141.2002.03257.x
   Yaccoby S, 2006, HAEMATOL HEMATOL J, V91, P192
   YAMAMOTO I, 1989, CANCER RES, V49, P4242
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zangari M, 2005, BRIT J HAEMATOL, V131, P71, DOI 10.1111/j.1365 2141.2005.05733.x
   Zangari M, 2011, HAEMATOL HEMATOL J, V96, P333, DOI 10.3324/haematol.2010.031302
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
   Zheng YH, 2009, BLOOD, V114, P3625, DOI 10.1182/blood 2009 05 220285
NR 154
TC 91
Z9 96
U1 0
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2212 1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD JUN
PY 2013
VL 2
IS 2
BP 59
EP 69
DI 10.1016/j.jbo.2013.04.001
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA V37LN
UT WOS:000209277400001
PM 26909272
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Duque, G
   Huang, DC
   Dion, N
   Macoritto, M
   Rivas, D
   Li, W
   Yang, XF
   Li, JR
   Lian, J
   Marino, FT
   Barralet, J
   Lascau, V
   Deschênes, C
   Ste Marie, LG
   Kremer, R
AF Duque, Gustavo
   Huang, Dao Chao
   Dion, Natalie
   Macoritto, Michael
   Rivas, Daniel
   Li, Wei
   Yang, Xian Fang
   Li, Jiarong
   Lian, Jing
   Marino, Faleh Tamim
   Barralet, Jake
   Lascau, Viorica
   Deschenes, Claire
   Ste Marie, Louis Georges
   Kremer, Richard
TI Interferon γ Plays a Role in Bone Formation In Vivo and Rescues
   Osteoporosis in Ovariectomized Mice
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOBLASTOGENESIS; OSTEOPOROSIS; BONE TURNOVER; MESENCHYMAL STEM CELLS;
   INTERFERON gamma; RUNX2
ID NITRIC OXIDE; PARATHYROID HORMONE; REPLACEMENT THERAPY; ESTROGEN; CELLS;
   OSTEOCLASTOGENESIS; DECREASE; VOLUME; MASS
AB Interferon gamma (IFN gamma) is a cytokine produced locally in the bone microenvironment by cells of immune origin as well as mesenchymal stem cells. However, its role in normal bone remodeling is still poorly understood. In this study we first examined the consequences of IFN gamma ablation in vivo in C57BL/6 mice expressing the IFN gamma receptor knockout phenotype (IFN gamma R1( / )). Compared with their wild type littermates (IFN gamma R1(+/+)), IFN gamma R1( / ) mice exhibit a reduction in bone volume associated with significant changes in cortical and trabecular structural parameters characteristic of an osteoporotic phenotype. Bone histomorphometry of IFN gamma R1( / ) mice showed a low bone turnover pattern with a decrease in bone formation, a significant reduction in osteoblast and osteoclast numbers, and a reduction in circulating levels of bone formation and bone resorption markers. Furthermore, administration of IFN gamma (2000 and 10,000 units) to wildtype C57BL/6 sham operated (SHAM) and ovariectomized (OVX) female mice significantly improved bone mass and microarchitecture, mechanical properties of bone, and the ratio between bone formation and bone resorption in SHAM mice and rescued osteoporosis in OVX mice. These data therefore support an important physiologic role for IFN gamma signaling as a potential new anabolic therapeutic target for osteoporosis. (C) 2011 American Society for Bone and Mineral Research.
C1 [Duque, Gustavo; Li, Wei] Univ Sydney, Sydney Med Sch, Ageing Bone Res Program, Penrith, NSW 2750, Australia.
   [Huang, Dao Chao; Macoritto, Michael; Yang, Xian Fang; Li, Jiarong; Lian, Jing; Kremer, Richard] McGill Univ, Dept Med, Montreal, PQ, Canada.
   [Huang, Dao Chao; Macoritto, Michael; Yang, Xian Fang; Li, Jiarong; Lian, Jing; Kremer, Richard] McGill Univ, Ctr Bone & Periodontal Res, Montreal, PQ, Canada.
   [Dion, Natalie; Lascau, Viorica; Deschenes, Claire; Ste Marie, Louis Georges] Univ Montreal, Hop St Luc, Res Ctr, Ctr Hosp Univ Montreal, Montreal, PQ, Canada.
   [Rivas, Daniel] McGill Univ, Lady Davis Inst Med Res, Montreal, PQ, Canada.
   [Marino, Faleh Tamim; Barralet, Jake] McGill Univ, Fac Dent, Montreal, PQ, Canada.
C3 University of Sydney; McGill University; McGill University; Universite
   de Montreal; McGill University; Lady Davis Institute; McGill University
RP Duque, G (通讯作者)，Univ Sydney, Sydney Med Sch, Ageing Bone Res Program, Nepean Campus,POB 63, Penrith, NSW 2750, Australia.
EM gustavo.duque@sydney.edu.au
RI ; Barralet, Jake/K 2253 2019; Duque, Gustavo/G 6656 2015; Duque,
   Gustavo/HDO 1243 2022
OI Barralet, jake/0000 0003 3543 6042; Kremer, Richard/0000 0002 7053 2139;
   Duque, Gustavo/0000 0001 8126 0637; Tamimi, Faleh/0000 0002 4618 8374; 
FU University of Sydney Medical Research Foundation; Fond de la Recherche
   en Sante du Quebec; Canadian Institutes for Health Research (CIHR) [MOP
   10839]; Australian National Health and Medical Research Council (NHMRC)
   [632767]; Dairy Farmers of Canada; NSERC
FX GD holds a fellowship from The University of Sydney Medical Research
   Foundation. RK holds a Chercheur National Award from the Fond de la
   Recherche en Sante du Quebec. This study was supported by the Canadian
   Institutes for Health Research (CIHR MOP 10839), the Australian National
   Health and Medical Research Council (NHMRC 632767 to GD), the Dairy
   Farmers of Canada, and NSERC (to RK). We thank Pat Hales for preparation
   of the manuscript.
CR Aguirre J, 2001, AM J PATHOL, V158, P247, DOI 10.1016/S0002 9440(10)63963 6
   Andersson N, 2001, J ENDOCRINOL, V170, P529, DOI 10.1677/joe.0.1700529
   Armour KE, 2001, ENDOCRINOLOGY, V142, P760, DOI 10.1210/en.142.2.760
   Borah B, 2001, ANAT RECORD, V265, P101, DOI 10.1002/ar.1060
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Cenci S, 2003, P NATL ACAD SCI USA, V100, P10405, DOI 10.1073/pnas.1533207100
   Cuzzocrea S, 2003, ENDOCRINOLOGY, V144, P1098, DOI 10.1210/en.2002 220597
   Duque G, 2008, J AM GERIATR SOC, V56, P935, DOI 10.1111/j.1532 5415.2008.01764.x
   Duque G, 2009, STEM CELLS, V27, P550, DOI 10.1634/stemcells.2008 0886
   FERRARILACRAZ S, 2007, BONEKEY OSTEOVISION, V4, P83
   Franco GEL, 2004, J CLIN DENSITOM, V7, P326
   Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074
   García Pérez MA, 2006, HUM REPROD, V21, P880, DOI 10.1093/humrep/dei413
   Grewal TS, 2000, FASEB J, V14, P523, DOI 10.1096/fasebj.14.3.523
   Horwood NJ, 1998, J CLIN INVEST, V101, P595, DOI 10.1172/JCI1333
   HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301
   Ji JD, 2009, J IMMUNOL, V183, P7223, DOI 10.4049/jimmunol.0900072
   KEY LL, 1995, NEW ENGL J MED, V332, P1594, DOI 10.1056/NEJM199506153322402
   Kim S, 2003, GENE DEV, V17, P1979, DOI 10.1101/gad.1119303
   Komarova SV, 2005, ENDOCRINOLOGY, V146, P3589, DOI 10.1210/en.2004 1642
   Kumru S, 2004, J REPROD IMMUNOL, V63, P31, DOI 10.1016/j.jri.2004.02.001
   Lorenzo J, 2008, ENDOCR REV, V29, P403, DOI 10.1210/er.2007 0038
   MANN GN, 1994, ENDOCRINOLOGY, V135, P1077, DOI 10.1210/en.135.3.1077
   Nakashima T, 2009, J CLIN IMMUNOL, V29, P555, DOI 10.1007/s10875 009 9316 6
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Park YG, 2009, CELL BIOL INT, V33, P92, DOI 10.1016/j.cellbi.2008.09.012
   Pierroz DD, 2006, BONE, V39, P260, DOI 10.1016/j.bone.2006.01.145
   Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006
   Raisz LG, 2003, ENDOCRIN METAB CLIN, V32, P15, DOI 10.1016/S0889 8529(02)00055 5
   RALSTON SH, 1994, ENDOCRINOLOGY, V135, P330, DOI 10.1210/en.135.1.330
   Rifas L, 2006, J CELL BIOCHEM, V98, P706, DOI 10.1002/jcb.20933
   Rivas D, 2009, J GERONTOL A BIOL, V64, P1015, DOI 10.1093/gerona/glp089
   Sato K, 2006, CURR OPIN RHEUMATOL, V18, P419, DOI 10.1097/01.bor.0000231912.24740.a5
   Sun DX, 2003, J BONE MINER RES, V18, P1206, DOI 10.1359/jbmr.2003.18.7.1206
   SYKES M, 1990, J IMMUNOL, V145, P3209
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Takayanagi H, 2005, IMMUNOL REV, V208, P181, DOI 10.1111/j.0105 2896.2005.00337.x
   TOHKIN M, 1994, CANCER IMMUNOL IMMUN, V39, P155, DOI 10.1007/BF01533380
   van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365 2567.2001.01261.x
   vandenBroek MF, 1995, IMMUNOL REV, V148, P5
   Weitzmann MN, 2005, IMMUNOL REV, V208, P154, DOI 10.1111/j.0105 2896.2005.00324.x
   Xiao LP, 2004, J BIOL CHEM, V279, P27743, DOI 10.1074/jbc.M314323200
   Xu ZQ, 2009, J BIOL CHEM, V284, P4658, DOI 10.1074/jbc.M804812200
   Yang JH, 2000, FERTIL STERIL, V74, P261, DOI 10.1016/S0015 0282(00)00622 1
   Yoshida K, 2009, EXP CELL RES, V315, P2105, DOI 10.1016/j.yexcr.2009.02.003
NR 45
TC 133
Z9 154
U1 1
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUL
PY 2011
VL 26
IS 7
BP 1472
EP 1483
DI 10.1002/jbmr.350
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 783DJ
UT WOS:000292061400010
PM 21308779
OA Bronze
DA 2025 08 17
ER

PT J
AU Malwal, SR
   O'Dowd, B
   Feng, XX
   Turhanen, P
   Shin, C
   Yao, JQ
   Kim, BK
   Baig, N
   Zhou, TH
   Bansal, S
   Khade, RL
   Zhang, Y
   Oldfield, E
AF Malwal, Satish R.
   O'Dowd, Bing
   Feng, Xinxin
   Turhanen, Petri
   Shin, Christopher
   Yao, Jiaqi
   Kim, Boo Kyung
   Baig, Noman
   Zhou, Tianhui
   Bansal, Sandhya
   Khade, Rahul L.
   Zhang, Yong
   Oldfield, Eric
TI Bisphosphonate Generated ATP Analogs Inhibit Cell Signaling Pathways
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID NITROGEN CONTAINING BISPHOSPHONATES; MOLD DICTYOSTELIUM DISCOIDEUM;
   FARNESYL DIPHOSPHATE SYNTHASE; TUMOR ASSOCIATED MACROPHAGES;
   GROWTH FACTOR RECEPTOR; LUNG CANCER CELLS; IN VITRO; BONE RESORPTION;
   BREAST CANCER; ADENOSINE TRIPHOSPHATE
AB Bisphosphonates are a major class of drugs used to treat osteoporosis, Paget's disease, and cancer. They have been proposed to act by inhibiting one or more targets including protein prenylation, the epidermal growth factor receptor, or the adenine nucleotide translocase. Inhibition of the latter is due to formation in cells of analogs of ATP: the isopentenyl ester of ATP (ApppI) or an AppXp type analog of ATP, such as AMP clodronate (AppCCl(2)p). We screened both ApppI as well as AppCCl(2)p against a panel of 369 kinases finding potent inhibition of some tyrosine kinases by AppCCl(2)p, attributable to formation of a strong hydrogen bond between tyrosine and the terminal phosphonate. We then synthesized bisphosphonate preprodrugs that are converted in cells to other ATP analogs, finding low nM kinase inhibitors that inhibited cell signaling pathways. These results help clarify our understanding of the mechanisms of action of bisphosphonates, potentially opening up new routes resorption, anticancer, and anti inflammatory drug leads.
C1 [Malwal, Satish R.; O'Dowd, Bing; Feng, Xinxin; Shin, Christopher; Yao, Jiaqi; Kim, Boo Kyung; Baig, Noman; Zhou, Tianhui; Bansal, Sandhya; Oldfield, Eric] Univ Illinois, Dept Chem, Urbana, IL 61801 USA.
   [Turhanen, Petri] Univ Eastern Finland, Bioctr Kuopio, Sch Pharm, POB 1627, FIN 70211 Kuopio, Finland.
   [Khade, Rahul L.; Zhang, Yong] Stevens Inst Technol, Dept Chem & Chem Biol, 1 Castle Point Terrace, Hoboken, NJ 07030 USA.
   [Feng, Xinxin] Hunan Univ, Coll Chem & Chem Engn, State Key Lab Chemo Biosensing & Chemometr, Inst Chem Biol & Nanomed, Changsha 410082, Hunan, Peoples R China.
C3 University of Illinois System; University of Illinois Urbana Champaign;
   University of Eastern Finland; Stevens Institute of Technology; Hunan
   University
RP Malwal, SR; Oldfield, E (通讯作者)，Univ Illinois, Dept Chem, Urbana, IL 61801 USA.
EM satishm@illinois.edu; eo@chad.scs.uiuc.edu
RI ; Turhanen, Petri/L 4522 2019; Khade, Rahul/T 5664 2019; Feng,
   Xinixn/HPD 6503 2023; Bansal, Sandhya/LCJ 0658 2024; Shin,
   Christopher/KPY 2523 2024; Baig, Noman/NNG 1462 2025; Zhang,
   Yong/K 2395 2014; zhou, Tian/JRX 2651 2023
OI ZHOU, TIANHUI/0000 0002 2290 9632; Khade, Rahul/0000 0003 3212 7949;
   Turhanen, Petri/0000 0002 7546 8906; Malwal, Satish/0000 0001 7606 1932;
   
FU United States Public Health Service (National Institutes of Health)
   [GM065307, CA158191, GM085774]; Harriet A. Harlin Professorship;
   University of Illinois Foundation/Oldfield Research Fund; Academy of
   Finland [292574]
FX We thank Jouko Vepsalainen, Yoshimasa Tanaka, Eric Champagne, Javier
   Alguacil, and Suzanne Peyrottes for providing Apppl samples; Yang Wang
   and Guodong Rao for helpful advice; Robert Gennis and Jefferson Chan for
   providing access to instrumentation; and Hong Chen for providing cells.
   This work was supported in part by the United States Public Health
   Service (National Institutes of Health Grants GM065307 and CA158191 to
   E.O. and GM085774 to Y.Z.), by a Harriet A. Harlin Professorship, by the
   University of Illinois Foundation/Oldfield Research Fund, and by the
   Academy of Finland (Decision No. 292574 to P.T.).
CR Arnold WD, 2000, J AM CHEM SOC, V122, P12835, DOI 10.1021/ja0025705
   Bader R., 1994, J MOL STRUCT THEOCHE
   Bader RFW, 1998, J PHYS CHEM A, V102, P7314, DOI 10.1021/jp981794v
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027
   BLACKBURN GM, 1981, J CHEM SOC CHEM COMM, P1188, DOI 10.1039/c39810001188
   Chen CKM, 2008, J MED CHEM, V51, P5594, DOI 10.1021/jm800325y
   Cocco R, 1999, Boll Soc Ital Biol Sper, V75, P71
   Coleman R, 2015, LANCET, V386, P1353, DOI 10.1016/S0140 6736(15)60908 4
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Cromartie TH, 1999, PESTIC BIOCHEM PHYS, V63, P114, DOI 10.1006/pest.1999.2397
   Eid S, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859 016 1433 7
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   FLEISCH H, 1969, NATURE, V223, P211, DOI 10.1038/223211a0
   FLEISCH H, 1966, NATURE, V212, P901, DOI 10.1038/212901a0
   Garza RM, 2009, J BIOL CHEM, V284, P35368, DOI 10.1074/jbc.M109.023994
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Goetz M, 2010, GASTROENTEROLOGY, V138, P435, DOI 10.1053/j.gastro.2009.10.032
   Goffinet M, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 60
   Grove JE, 2000, J BONE MINER RES, V15, P971, DOI 10.1359/jbmr.2000.15.5.971
   Hadji P, 2016, ANN ONCOL, V27, P379, DOI 10.1093/annonc/mdv617
   Hinson DD, 1997, J LIPID RES, V38, P2216
   Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618
   Junankar S, 2015, CANCER DISCOV, V5, P35, DOI 10.1158/2159 8290.CD 14 0621
   Keller RK, 1999, BIOCHEM BIOPH RES CO, V266, P560, DOI 10.1006/bbrc.1999.1849
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   Li JK, 2016, CHEM EUR J, V22, P264, DOI 10.1002/chem.201503942
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   Martin MB, 1999, BIOCHEM BIOPH RES CO, V263, P754, DOI 10.1006/bbrc.1999.1404
   Mitrofan LM, 2009, BONE, V45, P1153, DOI 10.1016/j.bone.2009.08.010
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Mönkkönen H, 2001, PHARMACEUT RES, V18, P1550, DOI 10.1023/A:1013026313647
   Mönkkönen H, 2008, ANTI CANCER DRUG, V19, P391, DOI 10.1097/CAD.0b013e3282f632bf
   Mönkkönen J, 1998, LIFE SCI, V62, pPL95, DOI 10.1016/S0024 3205(97)01178 8
   Ni F, 2017, J AM CHEM SOC, V139, P7701, DOI 10.1021/jacs.7b03266
   Oizumi T, 2009, BASIC CLIN PHARMACOL, V104, P384, DOI 10.1111/j.1742 7843.2008.00374.x
   PELORGEAS S, 1992, BIOCHEM PHARMACOL, V44, P2157, DOI 10.1016/0006 2952(92)90342 G
   Puljula E, 2017, J CHROMATOGR B, V1063, P180, DOI 10.1016/j.jchromb.2017.08.038
   Räikkönen J, 2009, BRIT J PHARMACOL, V157, P427, DOI 10.1111/j.1476 5381.2009.00160.x
   Reuben JS, 2011, ORAL SURG ORAL MED O, V111, P196, DOI 10.1016/j.tripleo.2010.09.068
   ROGERS MJ, 1992, BIOCHEM BIOPH RES CO, V189, P414, DOI 10.1016/0006 291X(92)91574 A
   Rose K, 2011, BIOMED PHARMACOTHER, V65, P46, DOI 10.1016/j.biopha.2010.10.002
   Rossini M, 2009, RHEUMATOLOGY, V48, P773, DOI 10.1093/rheumatology/kep084
   Rovetta G, 2003, Minerva Med, V94, P353
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Saviola G, 2012, MOD RHEUMATOL, V22, P256, DOI 10.1007/s10165 011 0506 8
   Sever N, 2003, J BIOL CHEM, V278, P52479, DOI 10.1074/jbc.M310053200
   Shima K, 2017, BIOL PHARM BULL, V40, P25, DOI 10.1248/bpb.b16 00521
   Stachnik A, 2014, P NATL ACAD SCI USA, V111, P17995, DOI 10.1073/pnas.1421422111
   Turhanen PA, 2017, ACS OMEGA, V2, P2835, DOI 10.1021/acsomega.7b00531
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
   Van Schaeybroeck S, 2006, MOL CANCER THER, V5, P1154, DOI 10.1158/1535 7163.MCT 05 0446
   Wang CH, 2006, J ENDOCRINOL, V190, P415, DOI 10.1677/joe.1.06490
   Wang R, 2003, ARCH BIOCHEM BIOPHYS, V410, P7, DOI 10.1016/S0003 9861(02)00637 9
   Webster MR, 2014, MOL CANCER THER, V13, P297, DOI 10.1158/1535 7163.MCT 13 0315
   Webster MR, 2011, J MED CHEM, V54, P6647, DOI 10.1021/jm200521a
   Winthrop KL, 2017, NAT REV RHEUMATOL, V13, P234, DOI 10.1038/nrrheum.2017.23
   Xia YF, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3010382
   Yamaoka K, 2016, CURR OPIN CHEM BIOL, V32, P29, DOI 10.1016/j.cbpa.2016.03.006
   Yuen T, 2014, P NATL ACAD SCI USA, V111, P17989, DOI 10.1073/pnas.1421410111
   Yun CH, 2008, P NATL ACAD SCI USA, V105, P2070, DOI 10.1073/pnas.0709662105
   Zhang GH, 2013, BIOCHEM PHARMACOL, V86, P1721, DOI 10.1016/j.bcp.2013.10.013
   Zhang XT, 2011, ONCOGENE, V30, P770, DOI 10.1038/onc.2010.458
   Zhang Y, 2006, J MED CHEM, V49, P5804, DOI 10.1021/jm060280e
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
NR 68
TC 28
Z9 30
U1 0
U2 38
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002 7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD JUN 20
PY 2018
VL 140
IS 24
BP 7568
EP 7578
DI 10.1021/jacs.8b02363
PG 11
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Chemistry
GA GK5JO
UT WOS:000436211600035
PM 29787268
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Xing, LZ
   Ni, HJ
   Wang, YL
AF Xing, Li zhi
   Ni, Huai jun
   Wang, Yu ling
TI Quercitrin attenuates osteoporosis in ovariectomized rats by regulating
   mitogen activated protein kinase (MAPK) signaling pathways
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Quercitrin; MAPK; Osteoporosis
ID MESENCHYMAL STEM CELLS; ESTROGEN DEFICIENCY; MC3T3 E1 CELLS; BONE;
   OSTEOCLASTOGENESIS; DIFFERENTIATION; OSTEOBLASTS; MICE
AB MAPK signaling pathways are crucial in regulating osteogenesis, a genetic disorder affecting the bones. Quercitrin, a type of flavonoid, is widely distributed in nature and involved in many pharmacological activities. But its osteoprotective functions and mechanism in osteoporosis are far from being understood clearly. In this paper, the MAPK upregulation was observed in the ovariectomy  induced bone loss. Quercitrin was found to downregulate MAPK signaling pathways and prevent the ovariectomy induced deterioration of bone mineral density (BMD), trabecular microstructure, and bone mechanical characteristics. In this study, quercitrin was seen to prevent the progression of the postmenopausal osteoporosis among the rats, which may be mediated by the downregulated MAPK signaling pathways. (C) 2017 Elsevier Masson SAS. All rights reserved.
C1 [Xing, Li zhi] Linyi Peoples Hosp, Dept Endocrinolog, Linyi 276000, Shandong, Peoples R China.
   [Ni, Huai jun] Linyi Chest Hosp, Dept Surg, Linyi 276000, Shandong, Peoples R China.
   [Wang, Yu ling] Linyi Peoples Hosp, Dept Rheumatol & Immunol, 48 Jiefang Rd, Linyi 276003, Shandong, Peoples R China.
RP Wang, YL (通讯作者)，Linyi Peoples Hosp, Dept Rheumatol & Immunol, 48 Jiefang Rd, Linyi 276003, Shandong, Peoples R China.
EM scitougao007@qq.com
CR Babujanarthanam R, 2011, MOL CELL BIOCHEM, V358, P121, DOI 10.1007/s11010 011 0927 x
   Caverzasio J, 2008, J BONE MINER RES, V23, P1389, DOI 10.1359/JBMR.080410
   Choi EM, 2012, EXP TOXICOL PATHOL, V64, P211, DOI 10.1016/j.etp.2010.08.008
   Cruz EA, 2008, INT IMMUNOPHARMACOL, V8, P1616, DOI 10.1016/j.intimp.2008.07.006
   Ding M, 2010, INT J ONCOL, V36, P59, DOI 10.3892/ijo_00000475
   Fakhry Maya, 2013, World J Stem Cells, V5, P136, DOI 10.4252/wjsc.v5.i4.136
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   Kim JA, 2011, PHYTOTHER RES, V25, P1612, DOI 10.1002/ptr.3465
   Kim JY, 2014, J BONE MINER RES, V29, P1541, DOI 10.1002/jbmr.2183
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kwon HS, 2013, J BIOL CHEM, V288, P16882, DOI 10.1074/jbc.M112.422972
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Nishio Y, 2006, GENE, V372, P62, DOI 10.1016/j.gene.2005.12.022
   Redlich K, 2002, ARTHRITIS RHEUM, V46, P785, DOI 10.1002/art.10097
   Sandhu SK, 2011, J CLIN PATHOL, V64, P1042, DOI 10.1136/jcp.2010.077842
   Satue M, 2013, BIOCHEM PHARMACOL, V86, P1476, DOI 10.1016/j.bcp.2013.09.009
   Stires H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162662
   Suthon S, 2016, J NAT MED TOKYO, V70, P225, DOI 10.1007/s11418 016 0965 5
   Thouverey C, 2015, ENDOCRINOLOGY, V156, P4377, DOI 10.1210/en.2015 1669
   Thouverey C, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.80
   Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668
   Zha X, 2016, J NAT MED TOKYO, V70, P634, DOI 10.1007/s11418 016 0993 1
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
NR 24
TC 55
Z9 57
U1 1
U2 44
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD MAY
PY 2017
VL 89
BP 1136
EP 1141
DI 10.1016/j.biopha.2017.02.073
PG 6
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA EW4JQ
UT WOS:000402468200128
PM 28314242
DA 2025 08 17
ER

PT J
AU Price, JT
   Quinn, JMW
   Sims, NA
   Vieusseux, J
   Waldeck, K
   Docherty, SE
   Myers, D
   Nakamura, A
   Waltham, MC
   Gillespie, MT
   Thompson, EW
AF Price, JT
   Quinn, JMW
   Sims, NA
   Vieusseux, J
   Waldeck, K
   Docherty, SE
   Myers, D
   Nakamura, A
   Waltham, MC
   Gillespie, MT
   Thompson, EW
TI The heat shock protein 90 inhibitor,
   17 allylamino 17 demethoxygeldanamycin, enhances osteoclast formation
   and potentiates bone metastasis of a human breast cancer cell line
SO CANCER RESEARCH
LA English
DT Article
ID HSP90 MOLECULAR CHAPERONE; NUDE MICE; IN VITRO; MATRIX
   METALLOPROTEINASE 2; THERAPEUTIC IMPLICATIONS; ANTITUMOR ACTIVITY;
   GROWTH; EXPRESSION; RECEPTOR; MECHANISMS
AB Breast cancer metastasis to the bone occurs frequently, causing numerous complications including severe pain, fracture, hypercalcemia, and paralysis. Despite its prevalence and severity, few effective therapies exist. To address this, we examined whether the heat shock protein 90 (Hsp90) inhibitor, 17 allylamino 17 demethoxygeldanamycin (17 AAG), would be efficacious in inhibiting breast cancer metastasis to bone. Utilizing the human breast cancer subline, MDA MB 231SA, previously in vivo selected for its enhanced ability to generate osteolytic bone lesions, we determined that 17 AAG potently inhibited its in vitro proliferation and migration. Moreover, 17 AAG significantly reduced MDA MB 231SA tumor growth in the mammary fat pad of nude mice. Despite these findings, 17 AAG enhanced the incidence of bone metastasis and osteolytic lesions following intracardiac inoculation in the nude mouse. Consistent with these findings, 17 AAG enhanced osteoclast formation 2  to 4 fold in mouse bone marrow/osteoblast cocultures, receptor activator of nuclear factor kappa B ligand (RANKL) stimulated bone marrow, and RAW264.7 cell models of in vitro osteoclastogenesis. Moreover, the drug enhanced osteoclastogenesis in human cord blood progenitor cells, demonstrating that its effects were not limited to mouse models. In addition to 17 AAG, other Hsp90 inhibitors, such as radicicol and herbimycin A, also enhanced osteoclastogenesis. A pro osteolytic action of 17 AAG independent of tumor presence was also determined in vivo, in which 17 AAG treated tumor naive mice had reduced trabecular bone volume with an associated increase in osteoclast number. Thus, HSP90 inhibitors can stimulate osteoclast formation, which may underlie the increased incidence of osteolysis and skeletal tumor incidence causedby 17 AAG in vivo. These data suggest an important contraindication to the Hsp90 targeted cancer therapy currently undergoing clinical trial.
C1 St Vincents Inst Med Res, Tumour Cell Migrat & Metastasis Lab, Melbourne, Vic 3065, Australia.
   St Vincents Inst Med Res, Bone Joint & Canc Lab, Melbourne, Vic 3065, Australia.
   St Vincents Inst Med Res, Pharmacogenom Lab, Melbourne, Vic 3065, Australia.
   St Vincents Inst Med Res, Victorian Breast Res Consortium Invas, Melbourne, Vic 3065, Australia.
   St Vincents Inst Med Res, Metastasis Lab, Melbourne, Vic 3065, Australia.
   Univ Melbourne, Dept Med, Melbourne, Vic, Australia.
   Univ Melbourne, Dept Physiol, Melbourne, Vic, Australia.
   Univ Melbourne, Dept Surg, Melbourne, Vic, Australia.
C3 St. Vincent's Institute of Medical Research; St. Vincent's Institute of
   Medical Research; St. Vincent's Institute of Medical Research; St.
   Vincent's Institute of Medical Research; St. Vincent's Institute of
   Medical Research; University of Melbourne; University of Melbourne;
   University of Melbourne
RP Price, JT (通讯作者)，St Vincents Inst Med Res, Tumour Cell Migrat & Metastasis Lab, 41 Victoria Parade, Melbourne, Vic 3065, Australia.
EM jprice@svi.edu.au
RI Sims, Natalie/A 7192 2012; Thompson, Erik Walter/A 1425 2009; Myers,
   Damian/L 5302 2013; Price, Jack/G 9510 2011; Thompson, Erik/A 1425 2009
OI Sims, Natalie/0000 0003 1421 8468; Myers, Damian/0000 0002 7569 9907;
   Thompson, Erik Walter/0000 0002 9723 4924; Gillespie,
   Matthew/0000 0001 6543 8909; Price, John/0000 0002 8244 1023
CR Bagatell R, 2004, MOL CANCER THER, V3, P1021
   Bagatell R, 2000, CLIN CANCER RES, V6, P3312
   Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184
   Beliakoff J, 2003, CLIN CANCER RES, V9, P4961
   Bendre MS, 2002, CANCER RES, V62, P5571
   Boyce BF, 1999, ENDOCR RELAT CANCER, V6, P333, DOI 10.1677/erc.0.0060333
   Burger AM, 2004, ANTI CANCER DRUG, V15, P377, DOI 10.1097/00001813 200404000 00011
   Chung LWK, 2003, CANCER AM CANCER SOC, V97, P772, DOI 10.1002/cncr.11140
   Clarke PA, 2000, ONCOGENE, V19, P4125, DOI 10.1038/sj.onc.1203753
   Coleman R E, 2000, Oncologist, V5, P463, DOI 10.1634/theoncologist.5 6 463
   Diel IJ, 2000, DRUGS, V59, P391, DOI 10.2165/00003495 200059030 00001
   Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443
   Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131
   GU B, 2004, CARCINOGENESIS
   Hart I R, 1982, Cancer Metastasis Rev, V1, P5, DOI 10.1007/BF00049477
   Hillner BE, 2000, J CLIN ONCOL, V18, P1378, DOI 10.1200/JCO.2000.18.6.1378
   Hodge JM, 2004, J BONE MINER RES, V19, P190, DOI 10.1359/JBMR.0301232
   Horwood NJ, 1998, ENDOCRINOLOGY, V139, P4743, DOI 10.1210/en.139.11.4743
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535 6108(03)00029 1
   JacquierSarlin MR, 1996, BIOCHEM J, V318, P187, DOI 10.1042/bj3180187
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kelland LR, 1999, J NATL CANCER I, V91, P1940, DOI 10.1093/jnci/91.22.1940
   Lean J, 2004, BIOCHEM BIOPH RES CO, V321, P845, DOI 10.1016/j.bbrc.2004.07.035
   Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241
   Malozemoff A.P., 1990, HIGH TEMPERATURE SUP, P3
   Mirosavljevic D, 2003, J BONE MINER RES, V18, P984, DOI 10.1359/jbmr.2003.18.6.984
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Münster PN, 2002, CANCER RES, V62, P3132
   Myoui A, 2003, CANCER RES, V63, P5028
   Neckers Len, 2003, Current Opinion in Oncology, V15, P419, DOI 10.1097/00001622 200311000 00003
   Nielsen TO, 2004, CANCER RES, V64, P286, DOI 10.1158/0008 5472.CAN 03 1242
   O'Keefe RJ, 2003, CLIN ORTHOP RELAT R, pS100, DOI 10.1097/01.blo.0000093847.72468.2f
   Piper P W, 2001, Curr Opin Investig Drugs, V2, P1606
   Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201
   Price JT, 1999, CANCER RES, V59, P5475
   Price JT, 1997, CRIT REV BIOCHEM MOL, V32, P175, DOI 10.3109/10409239709082573
   Quinn JMW, 2003, J BONE MINER RES, V18, pS348
   Quinn JMW, 2001, J BONE MINER RES, V16, P1787, DOI 10.1359/jbmr.2001.16.10.1787
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   SASAKI A, 1995, CANCER RES, V55, P3551
   Sausville EA, 2003, CURR CANCER DRUG TAR, V3, P377, DOI 10.2174/1568009033481831
   Sharp JA, 2004, CLIN EXP METASTAS, V21, P19, DOI 10.1023/B:CLIN.0000017167.17065.61
   Sims NA, 2000, J CLIN INVEST, V106, P1095, DOI 10.1172/JCI10753
   SKEHAN P, 1990, JNCI J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Soga S, 1999, CANCER RES, V59, P2931
   Soga S, 2003, CURR CANCER DRUG TAR, V3, P359, DOI 10.2174/1568009033481859
   Solit DB, 2003, CANCER RES, V63, P2139
   Solit DB, 2002, CLIN CANCER RES, V8, P986
   STANLEY ER, 1981, J IMMUNOL METHODS, V42, P253, DOI 10.1016/0022 1759(81)90156 3
   Tester AM, 2004, CANCER RES, V64, P652, DOI 10.1158/0008 5472.CAN 0384 2
   Weber KL, 2003, CANCER RES, V63, P2940
   Woodhouse EC, 1997, CANCER AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1529::AID CNCR2>3.0.CO;2 F
   Workman P, 2004, CANCER LETT, V206, P149, DOI 10.1016/j.canlet.2003.08.032
   Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486
   Yoneda T, 1997, J CLIN INVEST, V99, P2509, DOI 10.1172/JCI119435
   Young JC, 2003, TRENDS BIOCHEM SCI, V28, P541, DOI 10.1016/j.tibs.2003.08.009
NR 57
TC 119
Z9 132
U1 0
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 0008 5472
J9 CANCER RES
JI Cancer Res.
PD JUN 1
PY 2005
VL 65
IS 11
BP 4929
EP 4938
DI 10.1158/0008 5472.CAN 04 4458
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 930HZ
UT WOS:000229407800056
PM 15930315
DA 2025 08 17
ER

PT J
AU Grigsby, IF
   Pham, L
   Mansky, LM
   Gopalakrishnan, R
   Carlson, AE
   Mansky, KC
AF Grigsby, Iwen F.
   Pham, Lan
   Mansky, Louis M.
   Gopalakrishnan, Raj
   Carlson, Ann E.
   Mansky, Kim C.
TI Tenofovir treatment of primary osteoblasts alters gene expression
   profiles: Implications for bone mineral density loss
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Bone; Nucleotide; Metabolism; HIV; Osteoclast; Cell cycle; Signaling
ID DISOPROXIL FUMARATE; DIFFERENTIATION; SAFETY; THERAPY
AB There is strong clinical evidence that implicates tenofovir in the loss of bone mineral density during treatment of human immunodeficiency virus infection. In this study, we sought to test the hypothesis that tenofovir treatment of osteoblasts causes changes in the gene expression profile that would impact osteoblast function during bone formation. Primary osteoblasts were isolated and then treated with the tenofovir prodrug, tenofovir disoproxil fumarate (TDF). Total RNA from TDF treated and untreated osteoblasts were extracted and used for microarray analysis to assess TDF associated changes in the gene expression profile. Strikingly, the changes in gene expression profiles involved in cell signaling, cell cycle and amino acid metabolism, which would likely impact osteoblast function in bone formation. Our findings demonstrate for the first time that tenofovir treatment of primary osteoblasts results in gene expression changes that implicate loss of osteoblast function in tenofovir associated bone mineral density loss. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Grigsby, Iwen F.; Pham, Lan; Mansky, Kim C.] Univ Minnesota, Sch Dent, Div Orthodont, Minneapolis, MN 55455 USA.
   [Grigsby, Iwen F.; Pham, Lan; Mansky, Kim C.] Univ Minnesota, Sch Dent, Dept Dev & Surg Sci, Minneapolis, MN 55455 USA.
   [Grigsby, Iwen F.; Mansky, Louis M.; Gopalakrishnan, Raj; Carlson, Ann E.] Univ Minnesota, Sch Dent, Dept Diagnost & Biol Sci, Minneapolis, MN 55455 USA.
   [Grigsby, Iwen F.; Pham, Lan; Mansky, Louis M.; Gopalakrishnan, Raj; Carlson, Ann E.; Mansky, Kim C.] Univ Minnesota, Sch Dent, MinnCResT Program, Minneapolis, MN 55455 USA.
   [Grigsby, Iwen F.; Mansky, Louis M.] Univ Minnesota, Acad Hlth Ctr, Inst Mol Virol, Minneapolis, MN 55455 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities
RP Mansky, KC (通讯作者)，Univ Minnesota, Sch Dent, Div Orthodont, 16 146 Moos Tower,515 Delaware St SE, Minneapolis, MN 55455 USA.
EM kmansky@umn.edu
RI ; Mansky, Kim/AAB 3592 2022
OI Mansky, Kim/0000 0002 2826 5030; 
FU NIH [AR53946, DE16093, GM56615];  [T32DE07288]
FX The following reagent was obtained through the NIH AIDS Research and
   Reference Reagent program, Division of AIDS, NIAID, NIH: Tenofovir
   disoproxil fumarate, Catalog Number 10198. We thank Andy Kaplan for
   stimulating discussions, and David Largaespada and Raha Allaei for
   assistance with mice. Supported by NIH grants AR53946 (to K.C.M.),
   DE16093 (to R.G.), and GM56615 (to L.M.M.). I.F.G. and L.P. were
   supported by T32DE07288.
CR Ambrosetti D, 2008, MOL CELL BIOL, V28, P4759, DOI 10.1128/MCB.01849 07
   Arpadi SM, 2002, J ACQ IMMUN DEF SYND, V29, P450, DOI 10.1097/00126334 200204150 00004
   Barditch Crovo P, 2001, ANTIMICROB AGENTS CH, V45, P2733, DOI 10.1128/AAC.45.10.2733 2739.2001
   Bodine PVN, 2009, BONE, V44, P1063, DOI 10.1016/j.bone.2009.02.013
   Boffito M, 2005, ANTIMICROB AGENTS CH, V49, P4386, DOI 10.1128/AAC.49.10.4386 4389.2005
   Castillo AB, 2002, J ORTHOPAED RES, V20, P1185, DOI 10.1016/S0736 0266(02)00074 8
   Cihlar T, 2002, ANTIVIR RES, V54, P37, DOI 10.1016/S0166 3542(01)00210 8
   Dennis JE, 1999, J BONE MINER RES, V14, P700, DOI 10.1359/jbmr.1999.14.5.700
   Erlebacher A, 1998, MOL BIOL CELL, V9, P1903, DOI 10.1091/mbc.9.7.1903
   Gafni RI, 2006, PEDIATRICS, V118, pE711, DOI 10.1542/peds.2005 2525
   Gallant JE, 2004, JAMA J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191
   Grigsby IF, 2010, THER CLIN RISK MANAG, V6, P41
   Grigsby IF, 2010, BIOCHEM BIOPH RES CO, V391, P1324, DOI 10.1016/j.bbrc.2009.12.039
   Hazra R, 2005, PEDIATRICS, V116, pE846, DOI 10.1542/peds.2005 0975
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Madeddu G, 2004, Q J NUCL MED MOL IM, V48, P39
   McCauley LK, 1996, J CELL BIOCHEM, V61, P638, DOI 10.1002/(SICI)1097 4644(19960616)61:4<638::AID JCB18>3.3.CO;2 9
   Purdy JB, 2008, J PEDIATR, V152, P582, DOI 10.1016/j.jpeds.2007.12.020
   Suzawa M, 1999, ENDOCRINOLOGY, V140, P2125, DOI 10.1210/en.140.5.2125
   Tarantal AF, 1999, J ACQ IMMUN DEF SYND, V20, P323, DOI 10.1097/00042560 199904010 00001
   Tebas P, 2000, AIDS, V14, pF63, DOI 10.1097/00002030 200003100 00005
   Van Rompay KKA, 2004, ANTIMICROB AGENTS CH, V48, P1469, DOI 10.1128/AAC.48.5.1469 1487.2004
   VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663
   Vigano Alessandra, 2004, Expert Opin Drug Saf, V3, P199
   YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681
NR 25
TC 62
Z9 65
U1 0
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAR 26
PY 2010
VL 394
IS 1
BP 48
EP 53
DI 10.1016/j.bbrc.2010.02.080
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 580UB
UT WOS:000276474800009
PM 20171173
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Mattingly, BT
   Kambrath, AV
   Ding, XC
   Thompson, WR
   Sankar, U
AF Mattingly, Brett T.
   Kambrath, Anuradha Valiya
   Ding, Xinchun
   Thompson, William R.
   Sankar, Uma
TI Conditional loss of CaMKK2 in Osterix positive osteoprogenitors enhances
   osteoblast function in a sex divergent manner
SO BONE
LA English
DT Article
DE CaMKK2; Osterix; Osteoprogenitors; Trabecular bone; Cortical bone;
   Osteoblasts
ID MOUSE MODELS; BONE; DIFFERENTIATION; TETRACYCLINES; OSTEOPOROSIS;
   INHIBITION; GUIDELINES; MECHANISMS
AB Ca2+/calmodulin dependent protein kinase kinase 2 (CaMKK2) is a multi functional, serine/threonine protein kinase with predominant roles in inflammation, systemic energy metabolism, and bone remodeling. We previously reported that global ablation of CaMKK2 or its systemic pharmacological inhibition led to bone mass accrual in mice by stimulating osteoblasts and inhibiting osteoclasts. However, a direct, cell intrinsic role for the kinase in the osteoblast lineage has not been established. Here we report that conditional deletion of CaMKK2 from osteoprogenitors, using the Osterix 1 (Osx1)   GFP::Cre (tetracycline off) mouse line, resulted in increased trabecular bone mass due to an acute stimulation of osteoblast function in male and female mice. The acute simulation of osteoblasts and bone formation following conditional ablation of osteoprogenitor derived CaMKK2 was sustained only in female mice. Periosteal bone formation at the cortical bone was enhanced only in male conditional knockout mice without altering cortical bone mass or strength. Prolonged deletion of CaMKK2 in early osteoblasts was accompanied by a stimulation of osteoclasts in both sexes, indicating a coupling effect. Notably, alterations in trabecular and cortical bone mass were absent in the doxycycline removed "Cre only" Osx1 GFP::Cre mice. Thus, the increase in osteoblast function at the trabecular and cortical bone surfaces following the conditional deletion of CaMKK2 in osteoprogenitors is indicative of a direct but sex divergent role for the kinase in osteoblasts.
C1 [Mattingly, Brett T.; Kambrath, Anuradha Valiya; Ding, Xinchun; Thompson, William R.; Sankar, Uma] Indiana Univ Sch Med, Dept Anat Cell Biol & Physiol, 635 Barnhill Dr,MS 5035, Indianapolis, IN 46202 USA.
   [Mattingly, Brett T.; Kambrath, Anuradha Valiya; Ding, Xinchun; Thompson, William R.; Sankar, Uma] Indiana Univ Sch Med, Indiana Ctr Musculoskeletal Hlth, 635 Barnhill Dr,MS 5035, Indianapolis, IN 46202 USA.
   [Thompson, William R.] Sch Hlth & Human Sci, Dept Phys Therapy, 635 Barnhill Dr,MS 5045, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington
RP Sankar, U (通讯作者)，Indiana Univ Sch Med, Dept Anat Cell Biol & Physiol, 635 Barnhill Dr,MS 5035, Indianapolis, IN 46202 USA.
EM btmattin@iu.edu; anvaliya@iupui.edu; xinding@iupui.edu; thompwil@iu.edu;
   usankar@iu.edu
RI ding, xinchun/P 5490 2017; Thompson, William/G 6027 2016
FU NIAMS/NIH [R01AR068332, R01AR076477, 1R01AR074473 01]
FX The authors thank Drew M. Brown and the staff at the Musculoskeletal
   Histology Core Facility of the Indiana Center for Musculoskeletal Health
   and the Bone and Body Composition Core of the Indiana Clinical
   Translational Sciences Institute (CTSI) for bone histology. This study
   supported in part by NIAMS/NIH awards R01AR068332 and R01AR076477 (both
   to US) and 1R01AR074473 01 (to WRT) . The study sponsors were not
   involved in any aspects of this study including study design,
   collection, analysis, and interpretation of data; or in the writing of
   the manuscript, and in the decision to submit the manuscript for
   publication. The content is solely the responsibility of the authors and
   does not necessarily represent the official views of the NIH.
CR Allen M.R., 2019, BASIC APPL BONE BIOL, P141
   Allen MR, 2014, BASIC AND APPLIED BONE BIOLOGY, P75, DOI 10.1016/B978 0 12 416015 6.00004 6
   Amin U, 2023, WOMENS HEALTH, V19, DOI 10.1177/17455057231176655
   Anagnostis P, 2019, MATURITAS, V120, P1, DOI 10.1016/j.maturitas.2018.11.010
   Anderson KA, 2008, CELL METAB, V7, P377, DOI 10.1016/j.cmet.2008.02.011
   Bellido T., 2019, Basic and Applied Bone Biology, VSecond, P37, DOI DOI 10.1016/B978 0 12 813259 3.00003 8
   Bellido T, 2014, BASIC AND APPLIED BONE BIOLOGY, P299, DOI 10.1016/B978 0 12 416015 6.00015 0
   Bettany JT, 2000, BONE, V27, P75, DOI 10.1016/S8756 3282(00)00297 0
   Bezerra MM, 2002, BRAZ J MED BIOL RES, V35, P613, DOI 10.1590/S0100 879X2002000500015
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Burr DB, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115518
   Byun Ji Hye, 2017, J Bone Metab, V24, P37
   Cary RL, 2013, J BONE MINER RES, V28, P1599, DOI 10.1002/jbmr.1890
   Zhang C, 2007, ACTA PHARMACOL SIN, V28, P1603, DOI 10.1111/j.1745 7254.2007.00638.x
   Compston J, 2020, BONE, V136, DOI 10.1016/j.bone.2020.115330
   Couasnay G, 2021, J BONE MINER RES, V36, P1661, DOI 10.1002/jbmr.4415
   Davey RA, 2012, TRANSGENIC RES, V21, P885, DOI 10.1007/s11248 011 9581 z
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Hong N, 2023, OSTEOPOROSIS INT, V34, P2059, DOI 10.1007/s00198 023 06889 2
   Jepsen KJ, 2015, J BONE MINER RES, V30, P951, DOI 10.1002/jbmr.2539
   Jilka RL, 2013, J GERONTOL A BIOL, V68, P1209, DOI 10.1093/gerona/glt046
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kambrath AV, 2020, J HISTOCHEM CYTOCHEM, V68, P199, DOI 10.1369/0022155419900915
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Lewiecki EM, 2018, OSTEOPOROSIS INT, V29, P717, DOI 10.1007/s00198 017 4345 0
   Liu YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071318
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Martin TJ, 2009, CRIT REV EUKAR GENE, V19, P73, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.40
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Odén A, 2015, OSTEOPOROSIS INT, V26, P2243, DOI 10.1007/s00198 015 3154 6
   Ponnapakkam T, 2014, DRUG DISCOV TODAY, V19, P204, DOI 10.1016/j.drudis.2013.07.015
   Prather C, 2020, AM J HEALTH SYST PH, V77, P1949, DOI 10.1093/ajhp/zxaa285
   Pritchard ZJ, 2015, BONE, V75, P120, DOI 10.1016/j.bone.2015.01.021
   Rawal SY, 2001, W INDIAN MED J, V50, P105
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Sims NA, 2020, ANNU REV PHYSIOL, V82, P507, DOI 10.1146/annurev physiol 021119 034425
   Tabacco G, 2019, BRIT J CLIN PHARMACO, V85, P1084, DOI 10.1111/bcp.13766
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   Vernillo A T, 1994, Curr Opin Periodontol, P111
   Wang L, 2015, CALCIFIED TISSUE INT, V96, P129, DOI 10.1007/s00223 014 9945 5
   Williams JN, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24054718
   Williams JN, 2019, CURR OSTEOPOROS REP, V17, P169, DOI 10.1007/s11914 019 00518 w
   Williams JN, 2018, J BONE MINER RES, V33, P930, DOI 10.1002/jbmr.3379
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Wu D, 2023, J TRANSL MED, V21, DOI 10.1186/s12967 023 04563 z
   Zannit HM, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10227
NR 47
TC 2
Z9 2
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUL
PY 2024
VL 184
AR 117113
DI 10.1016/j.bone.2024.117113
EA MAY 2024
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA A9V3C
UT WOS:001285937900001
PM 38703937
DA 2025 08 17
ER

PT J
AU Xu, LQ
   Luo, J
   Jin, RR
   Yue, ZY
   Sun, P
   Yang, ZF
   Yang, XH
   Wan, W
   Zhang, JS
   Li, SC
   Liu, MY
   Xiao, JR
AF Xu, Leqin
   Luo, Jian
   Jin, Rongrong
   Yue, Zhiying
   Sun, Peng
   Yang, Zhengfeng
   Yang, Xinghai
   Wan, Wei
   Zhang, Jishen
   Li, Shichang
   Liu, Mingyao
   Xiao, Jianru
TI Bortezomib Inhibits Giant Cell Tumor of Bone through Induction of Cell
   Apoptosis and Inhibition of Osteoclast Recruitment, Giant Cell
   Formation, and Bone Resorption
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID NF KAPPA B; STROMAL CELL; PROTEASOME INHIBITOR; RECEPTOR ACTIVATOR;
   UP REGULATION; IN VIVO; DENOSUMAB; LIGAND; BISPHOSPHONATES; RECURRENCE
AB Giant cell tumor of bone (GCTB) is a rare and highly osteolytic bone tumor that usually leads to an extensive bone lesion. The purpose of this study was to discover novel therapeutic targets and identify potential agents for treating GCTB. After screening the serum cytokine profiles in 52 GCTB patients and 10 normal individuals using the ELISA assay, we found that NF kappa B signaling related cytokines, including TNF alpha, MCP 1, IL1 alpha, and IL17A, were significantly increased in GCTB patients. The results were confirmed by IHC that the expression and activity of p65 were significantly increased in GCTB patients. Moreover, all of the NF kappa B inhibitors tested suppressed GCTB cell growth, and bortezomib (Velcade), a well known proteasome inhibitor, was the most potent inhibitor in blocking GCTB cells growth. Our results showed that bortezomib not only induced GCTB neoplastic stromal cell (NSC) apoptosis, but also suppressed GCTB NSC induced giant cell differentiation, formation, and resorption. Moreover, bortezomib specifically suppressed GCTB NSC induced preosteoclast recruitment. Furthermore, bortezomib ameliorated GCTB cell induced bone destruction in vivo. As a result, bortezomib suppressed NF kappa B regulated gene expression in GCTB NSC apoptosis, monocyte migration, angiogenesis, and osteoclastogenesis. Particularly, the inhibitory effects of bortezomib were much better than zoledronic acid, a drug currently used in treating GCTB, in our in vitro experimental paradigms. Together, our results demonstrated that NF kappa B signaling pathway is highly activated in GCTB, and bortezomib could suppress GCTB and osteolysis in vivo and in vitro, indicating that bortezomib is a potential agent in the treatment of GCTB. (C) 2016 AACR.
C1 [Xu, Leqin; Luo, Jian; Jin, Rongrong; Yue, Zhiying; Sun, Peng; Yang, Zhengfeng; Liu, Mingyao; Xiao, Jianru] E China Normal Univ, Shanghai Changzheng Hosp, Shanghai Key Lab Regulatory Biol, Shanghai 200062, Peoples R China.
   [Xu, Leqin; Luo, Jian; Jin, Rongrong; Yue, Zhiying; Sun, Peng; Yang, Zhengfeng; Liu, Mingyao; Xiao, Jianru] E China Normal Univ, Inst Biomed Sci, East China Normal Univ Joint Res Ctr Orthoped Onc, Shanghai 200062, Peoples R China.
   [Xu, Leqin; Luo, Jian; Jin, Rongrong; Yue, Zhiying; Sun, Peng; Yang, Zhengfeng; Liu, Mingyao; Xiao, Jianru] E China Normal Univ, Sch Life Sci, Shanghai 200062, Peoples R China.
   [Xu, Leqin; Luo, Jian; Yang, Xinghai; Wan, Wei; Zhang, Jishen; Liu, Mingyao; Xiao, Jianru] Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Orthoped Oncol, 415 Fengyang Rd, Shanghai 200003, Peoples R China.
   [Xu, Leqin; Luo, Jian; Yang, Xinghai; Wan, Wei; Zhang, Jishen; Liu, Mingyao; Xiao, Jianru] Second Mil Med Univ, Shanghai Changzheng Hosp, East China Normal Univ Joint Res Ctr Orthoped Onc, Shanghai 200003, Peoples R China.
   [Xu, Leqin] Fujian Univ Tradit Chinese Med, Xiamen Hosp Tradit Chinese Med, Xiamen, Peoples R China.
   [Sun, Peng; Li, Shichang] E China Normal Univ, Minist Educ, Key Lab Adolescent Hlth Assessment & Exercise Int, Shanghai 200062, Peoples R China.
   [Liu, Mingyao] Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Dept Mol & Cellular Med, Houston, TX USA.
C3 East China Normal University; Naval Medical University; East China
   Normal University; East China Normal University; Naval Medical
   University; Naval Medical University; Fujian University of Traditional
   Chinese Medicine; East China Normal University; University of Texas
   System; University of Texas Health Science Center Houston; Texas A&M
   University System; Texas A&M University College Station; Texas A&M
   Health Science Center
RP Luo, J; Xiao, JR (通讯作者)，Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Orthoped Oncol, 415 Fengyang Rd, Shanghai 200003, Peoples R China.; Luo, J (通讯作者)，E China Normal Univ, 500 Dong Chuan Rd, Shanghai 200241, Peoples R China.
EM jluo@bio.ecnu.edu.cn; jianruxiao83@163.com
RI Luo, Jian/H 3362 2016; Yue, Zhiying/JTV 1750 2023; zhang,
   jishen/AAQ 3092 2021; Yang, Zhengfeng/AAA 7014 2020
OI Luo, Jian/0000 0003 3583 0154; Sun, Peng/0000 0002 0615 2510; jishen,
   zhang/0000 0002 8305 9846; Liu, Mingyao/0000 0001 7339 5048; 
FU National Basic Research Program of China [2012CB910402]; National
   Natural Science Foundation of China [81272911, 81472048, 81330059,
   81330049]; Innovation Program of Shanghai Municipal Education Commission
   [14ZZ051]; Science and Technology Commission of Shanghai Municipality
   [15140903600, 09411950500, 12R21418300]
FX This work is supported by grants from the National Basic Research
   Program of China 2012CB910402 (to M. Liu and J. Luo), the National
   Natural Science Foundation of China 81272911 (to J. Luo), 81472048 (to
   J. Luo), 81330059 (to J. Xiao), and 81330049 (to M. Liu), Innovation
   Program of Shanghai Municipal Education Commission 14ZZ051 (to J. Luo),
   and the Science and Technology Commission of Shanghai Municipality
   15140903600 (to J. Luo), 09411950500 (to J. Xiao), and 12R21418300 (to
   J. Xiao).
CR Agarwal S, 2010, ACTA ORTHOP BELG, V76, P567
   Balke M, 2011, BMC CANCER, V11, DOI 10.1186/1471 2407 11 241
   Bhatia S, 2011, RARE TUMORS, V3, P150, DOI 10.4081/rt.2011.e48
   Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078 0432.CCR 12 0578
   CAMPANACCI M, 1987, J BONE JOINT SURG AM, V69A, P106, DOI 10.2106/00004623 198769010 00018
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   Chen D, 2011, CURR CANCER DRUG TAR, V11, P239, DOI 10.2174/156800911794519752
   Codony Servat J, 2006, MOL CANCER THER, V5, P665, DOI 10.1158/1535 7163.MCT 05 0147
   Cornelis F, 2014, BONE, V58, P11, DOI 10.1016/j.bone.2013.10.004
   Cowan RW, 2013, BONE, V52, P238, DOI 10.1016/j.bone.2012.10.002
   Craig MJ, 2006, CANCER METAST REV, V25, P611, DOI 10.1007/s10555 006 9027 x
   ENNEKING WF, 1980, CLIN ORTHOP RELAT R, P106
   Ghert M, 2007, CLIN ORTHOP RELAT R, P8, DOI 10.1097/BLO.0b013e31804856a1
   Gupta SC, 2011, EXP BIOL MED, V236, P658, DOI 10.1258/ebm.2011.011028
   Gupta SC, 2010, BBA GENE REGUL MECH, V1799, P775, DOI 10.1016/j.bbagrm.2010.05.004
   Huang L, 2000, AM J PATHOL, V156, P761, DOI 10.1016/S0002 9440(10)64942 5
   James IE, 1996, J BONE MINER RES, V11, P1453
   Jones MD, 2010, CLIN CANCER RES, V16, P4978, DOI 10.1158/1078 0432.CCR 09 3293
   Kane RC, 2003, ONCOLOGIST, V8, P508, DOI 10.1634/theoncologist.8 6 508
   Kim Y, 2012, CLIN ORTHOP SURG, V4, P107, DOI 10.4055/cios.2012.4.2.107
   Klenke FM, 2011, CLIN ORTHOP RELAT R, V469, P591, DOI 10.1007/s11999 010 1501 7
   Kouroukis TC, 2014, CURR ONCOL, V21, pE573, DOI 10.3747/co.21.1798
   Lau CPY, 2013, CONNECT TISSUE RES, V54, P439, DOI 10.3109/03008207.2013.848202
   Lewin J, 2013, DRUG TODAY, V49, P693, DOI 10.1358/dot.2013.49.11.2064725
   Li CY, 2008, MOL CANCER THER, V7, P1647, DOI 10.1158/1535 7163.MCT 07 2444
   Liao TS, 2005, J ORTHOP RES, V23, P203, DOI 10.1016/j.orthres.2004.06.018
   Liu L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.440
   Mak IWY, 2010, HUM PATHOL, V41, P1320, DOI 10.1016/j.humpath.2010.03.001
   Mak IWY, 2009, BONE, V45, P377, DOI 10.1016/j.bone.2009.04.253
   Niu XH, 2012, J BONE JOINT SURG AM, V94A, P461, DOI 10.2106/JBJS.J.01922
   OREFFO ROC, 1993, CLIN ORTHOP RELAT R, P229
   Park Serk In, 2010, Curr Protoc Pharmacol, VChapter 14, DOI 10.1002/0471141755.ph1415s51
   PRANDO A, 1979, RADIOLOGY, V130, P323, DOI 10.1148/130.2.323
   Roux S, 2002, AM J CLIN PATHOL, V117, P210
   Roux S, 2010, LANCET ONCOL, V11, P514, DOI 10.1016/S1470 2045(10)70076 0
   SANERKIN NG, 1980, CANCER AM CANCER SOC, V46, P1641, DOI 10.1002/1097 0142(19801001)46:7<1641::AID CNCR2820460725>3.0.CO;2 Z
   Schilcher J, 2014, ACTA ORTHOP, V85, P6, DOI 10.3109/17453674.2014.885355
   Shah MA, 2011, INVEST NEW DRUG, V29, P1475, DOI 10.1007/s10637 010 9474 7
   Singh S, 2013, Open Orthop J, V7, P109, DOI 10.2174/1874325001307010109
   Tang QL, 2012, JNCI J NATL CANCER I, V104, P749, DOI 10.1093/jnci/djs210
   Tang XL, 2013, CANCER RES, V73, P6206, DOI 10.1158/0008 5472.CAN 13 1049
   Taylor RM, 2012, LAB INVEST, V92, P1398, DOI 10.1038/labinvest.2012.108
   Thapa RJ, 2013, MOL CANCER THER, V12, P1568, DOI 10.1158/1535 7163.MCT 12 1010
   Tse LF, 2008, BONE, V42, P68, DOI 10.1016/j.bone.2007.08.038
   van der Heijden L, 2014, ONCOLOGIST, V19, P550, DOI 10.1634/theoncologist.2013 0432
   Wu X, 2012, J BONE MINER RES, V27, P1298, DOI 10.1002/jbmr.1576
   Wülling M, 2003, HUM PATHOL, V34, P983, DOI 10.1053/S0046 8177(03)00413 1
   Yu XC, 2013, ONCOL LETT, V5, P447, DOI 10.3892/ol.2012.1036
   Zheng MH, 2001, HISTOL HISTOPATHOL, V16, P297, DOI 10.14670/HH 16.297
   Zhou W, 2014, BONE, V66, P267, DOI 10.1016/j.bone.2014.06.021
NR 50
TC 17
Z9 18
U1 1
U2 29
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1535 7163
EI 1538 8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD MAY
PY 2016
VL 15
IS 5
BP 854
EP 865
DI 10.1158/1535 7163.MCT 15 0669
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA DL7YX
UT WOS:000375857400009
PM 26861247
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Zheng, PM
   Xie, YQ
   Lin, SF
   Zou, L
   Huang, ZH
   Zhang, ZP
AF Zheng, Pei min
   Xie, Yu qing
   Lin, Shi fan
   Zou, Le
   Huang, Zhi hua
   Zhang, Zhi ping
TI HIV patients' bone loss before and after antiretroviral treatment and
   its possible mechanisms
SO AIDS REVIEWS
LA English
DT Article
DE Osteoporosis; Antiretroviral therapy; Immune system; Bone inflammation
ID KAPPA B LIGAND; MINERAL DENSITY; OSTEOBLAST DIFFERENTIATION; INFECTED
   INDIVIDUALS; RECEPTOR ACTIVATOR; VITAMIN D; CELLS; EXPRESSION;
   EXPANSION; TENOFOVIR
AB HIV infection has been reported to cause bone loss and a higher risk of fracture. Under normal conditions, bone metabolism is regulated by mesenchymal cells, osteoclasts differentiated from mononuclear macrophages, osteoblasts, and their expression of regulatory factors, such as receptor activator of nuclear factor kappa B ligand (RANKL), M SCF, and transforming growth factor beta. The balance between bone resorption and osteogenesis depends on the balance between osteoclasts and osteoblasts. In addition, some immune cells, such as B cells, T cells, and other non immune cells expressing RANKL, can contribute to osteoporosis under inflammatory conditions. HIV proteins consist of three types: regulatory proteins, accessory proteins, and structural proteins, which contribute to HIV mediated bone loss partly by upregulating NF .B expression, tumor necrosis factor alpha content, and release of inflammatory cytokines. Even worse, although antiretroviral therapy has reduced HIV infection mortality and successfully transformed acquired immunodeficiency syndrome into a chronic disease, its impact on bone loss should not be overlooked, especially when the drug contains tenofovir. This review analyzes some reports focusing on the overall osteolytic situation due to imbalances in osteogenesis and bone resorption due to HIV infection and antiviral therapy. The intrinsic mechanism of bone loss provides a reference for researchers to analyze the risk factors for HIV patients complicated with bone loss and helps clinicians to provide ideas for the intervention and prevention of bone loss during clinical treatment and chronic disease management of HIV patients.
C1 [Zheng, Pei min; Xie, Yu qing; Lin, Shi fan; Zou, Le; Zhang, Zhi ping] Nanchang Univ, Nanchang Key Lab Orthopaed, Affiliated Hosp 3, Nanchang, Jiangxi, Peoples R China.
   [Zheng, Pei min; Lin, Shi fan; Zou, Le; Zhang, Zhi ping] Nanchang Univ, Affiliated Hosp 3, Dept Orthoped, Hosp Nanchang 1, Nanchang, Jiangxi, Peoples R China.
   [Zheng, Pei min; Huang, Zhi hua; Zhang, Zhi ping] Nanchang Univ, Huankui Acad, Nanchang, Jiangxi, Peoples R China.
   [Xie, Yu qing] Nanchang Univ, Sch Publ Hlth, Nanchang, Jiangxi, Peoples R China.
   [Huang, Zhi hua] Ninth Hosp Nanchang City, Dept Radiol, Nanchang, Jiangxi, Peoples R China.
C3 Nanchang University; Nanchang University; Nanchang University; Nanchang
   University
RP Huang, ZH (通讯作者)，Nanchang Univ, Huankui Acad, Nanchang, Jiangxi, Peoples R China.; Huang, ZH (通讯作者)，Ninth Hosp Nanchang City, Dept Radiol, Nanchang, Jiangxi, Peoples R China.
EM 8278424@qq.com
RI Huang, Zhihua/LRC 4904 2024; xie, yuqing/KBB 5708 2024
FU Health Commission of Jiangxi Province [202211611]; Nanchang Science and
   Technology Bureau [2019 258 5, 2021 129 4]
FX Health Commission of Jiangxi Province (grant numbers 202211611 to
   Z.P.Z); Nanchang Science and Technology Bureau (grant numbers 2019 258 5
   and 2021 129 4 to Z.P.Z).
CR Adamopoulos IE, 2018, CURR OPIN RHEUMATOL, V30, P59, DOI 10.1097/BOR.0000000000000449
   Ahmad Aamir N, 2017, Open Orthop J, V11, P777, DOI 10.2174/1874325001711010777
   Alvarez Barco E, 2021, CURR OPIN HIV AIDS, V16, P186, DOI 10.1097/COH.0000000000000682
   Amarasekara DS, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/832127
   Andersson J, 1998, AIDS, V12, pF123, DOI 10.1097/00002030 199811000 00004
   Beaupere C, 2015, AGING CELL, V14, P534, DOI 10.1111/acel.12308
   Bedimo R, 2012, AIDS, V26, P825, DOI 10.1097/QAD.0b013e32835192ae
   Birabaharan M, 2021, OPEN FORUM INFECT DI, V8, DOI 10.1093/ofid/ofab081
   Bolland MJ, 2015, LANCET DIABETES ENDO, V3, P63, DOI 10.1016/S2213 8587(13)70181 5
   Braun T, 2012, CURR OSTEOPOROS REP, V10, P101, DOI 10.1007/s11914 012 0104 5
   Braun T, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3380
   Brown TT, 2015, J INFECT DIS, V212, P1241, DOI 10.1093/infdis/jiv194
   Brown TT, 2015, CLIN INFECT DIS, V60, P1242, DOI 10.1093/cid/civ010
   Butler JS, 2013, J ORTHOP RES, V31, P218, DOI 10.1002/jor.22196
   Carr A, 2020, HIV MED, V21, P64, DOI 10.1111/hiv.12796
   Chang CJ, 2021, ARCH OSTEOPOROS, V16, DOI 10.1007/s11657 021 00903 y
   Charumbira MY, 2021, BMC HEALTH SERV RES, V21, DOI 10.1186/s12913 021 06343 1
   Chew N, 2014, J INT AIDS SOC, V17, P145, DOI 10.7448/IAS.17.4.19724
   Chisati EM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227893
   Christoph F, 2018, WORLD J UROL, V36, P187, DOI 10.1007/s00345 017 2145 y
   Cook PP, 2016, SOUTH MED J, V109, P712, DOI 10.14423/SMJ.0000000000000560
   Cotter EJ, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471 2474 9 33
   Coury F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00679
   Delpino MV, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00502
   Erlandson KM, 2015, AIDS RES HUM RETROV, V31, P731, DOI [10.1089/aid.2015.0052, 10.1089/AID.2015.0052]
   Fakruddin JM, 2004, CLIN EXP IMMUNOL, V137, P538, DOI 10.1111/j.1365 2249.2004.02568.x
   Freeman ML, 2016, J INFECT DIS, V214, pS51, DOI 10.1093/infdis/jiw287
   Gibellini D, 2008, J MED VIROL, V80, P1507, DOI 10.1002/jmv.21266
   Glesby MJ, 2003, CLIN INFECT DIS, V37, pS91, DOI 10.1086/375884
   Goh SSL, 2018, OSTEOPOROSIS INT, V29, P595, DOI 10.1007/s00198 017 4305 8
   Grant PM, 2016, CURR OPIN HIV AIDS, V11, P326, DOI 10.1097/COH.0000000000000248
   Han X, 2009, ORAL MICROBIOL IMMUN, V24, P190, DOI 10.1111/j.1399 302X.2008.00494.x
   Heiland GR, 2010, ANN RHEUM DIS, V69, P2152, DOI 10.1136/ard.2010.132852
   Hileman CO, 2016, CURR OPIN HIV AIDS, V11, P277, DOI 10.1097/COH.0000000000000272
   Kalayjian RC, 2018, AIDS, V32, P2517, DOI [10.1097/QAD.0000000000001995, 10.1097/qad.0000000000001995]
   Keating SM, 2011, AIDS, V25, P1823, DOI 10.1097/QAD.0b013e3283489d1f
   Lafferty MK, 2014, PATHOG DIS, V71, P81, DOI 10.1111/2049 632X.12117
   Le NT, 2020, AIDS Care, V32
   Li L, 2018, BBA GEN SUBJECTS, V1862, P1790, DOI 10.1016/j.bbagen.2018.05.001
   Liao TQ, 2018, CELL PHYSIOL BIOCHEM, V50, P1084, DOI 10.1159/000494533
   Lu MC, 2010, ARTHRITIS RHEUM US, V62, P1213, DOI 10.1002/art.27386
   Mallon PWG, 2014, CURR OPIN HIV AIDS, V9, P428, DOI 10.1097/COH.0000000000000080
   Metzger CE, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00285
   Mondy K, 2003, CLIN INFECT DIS, V36, pS101, DOI 10.1086/367566
   Moran Caitlin A, 2017, Curr Treat Options Infect Dis, V9, P52, DOI 10.1007/s40506 017 0109 9
   Nasi M, 2017, CLIN EXP IMMUNOL, V187, P44, DOI 10.1111/cei.12814
   Ofotokun I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9282
   Paccou J, 2018, MED MALADIES INFECT, V48, P442, DOI 10.1016/j.medmal.2018.02.009
   Poorolajal J, 2016, PUBLIC HEALTH, V139, P3, DOI 10.1016/j.puhe.2016.05.004
   Pramukti I, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233501
   Raynaud Messina B, 2018, P NATL ACAD SCI USA, V115, pE2556, DOI 10.1073/pnas.1713370115
   Rothman MS, 2012, CURR OSTEOPOROS REP, V10, P270, DOI 10.1007/s11914 012 0125 0
   Santiago F, 2012, BIOCHEM BIOPH RES CO, V417, P223, DOI 10.1016/j.bbrc.2011.11.089
   Stacey AR, 2009, J VIROL, V83, P3719, DOI 10.1128/JVI.01844 08
   Titanji K, 2020, AIDS, V34, P1475, DOI 10.1097/QAD.0000000000002563
   Titanji K, 2018, AIDS, V32, P885, DOI [10.1097/QAD.0000000000001764, 10.1097/qad.0000000000001764]
   Titanji K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004497
   Triant VA, 2008, J CLIN ENDOCR METAB, V93, P3499, DOI 10.1210/jc.2008 0828
   Tsukasaki M, 2011, BIOCHEM BIOPH RES CO, V410, P766, DOI 10.1016/j.bbrc.2011.06.048
   Turner MD, 2014, BBA MOL CELL RES, V1843, P2563, DOI 10.1016/j.bbamcr.2014.05.014
   Uluçkan Ö, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8996
   Van Welzen BJ, 2019, AIDS, V33, P1531, DOI 10.1097/QAD.0000000000002238
   Vega D, 2007, J CLIN ENDOCR METAB, V92, P4514, DOI 10.1210/jc.2007 0646
   Wattanachanya L, 2020, AIDS CARE, V32, P984, DOI 10.1080/09540121.2019.1622631
   Weitzmann MN, 2017, J INFECT DIS, V216, P1070, DOI 10.1093/infdis/jix444
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Yoshimura K, 2017, J INFECT CHEMOTHER, V23, P12, DOI 10.1016/j.jiac.2016.10.002
   Yuan YH, 2017, CELL BIOL INT, V41, P969, DOI 10.1002/cbin.10791
NR 68
TC 2
Z9 2
U1 3
U2 5
PU PERMANYER PUBL
PI BARCELONA
PA MALLORCA, 310, BARCELONA, 08037, SPAIN
SN 1139 6121
EI 1698 6997
J9 AIDS REV
JI Aids Rev.
PD APR JUN
PY 2023
VL 25
IS 2
BP 67
EP 76
DI 10.24875/AIDSRev.22000028
PG 10
WC Immunology; Infectious Diseases
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Infectious Diseases
GA JZ7N5
UT WOS:001177046300001
PM 37585363
DA 2025 08 17
ER

PT J
AU Chow, SKH
   Gao, Q
   Pius, A
   Morita, M
   Ergul, Y
   Murayama, M
   Shinohara, I
   Cekuc, MS
   Ma, C
   Susuki, Y
   Goodman, SB
AF Chow, Simon Kwoon Ho
   Gao, Qi
   Pius, Alexa
   Morita, Mayu
   Ergul, Yasemin
   Murayama, Masatoshi
   Shinohara, Issei
   Cekuc, Mehmet Sertac
   Ma, Chao
   Susuki, Yosuke
   Goodman, Stuart B.
TI The Advantages and Shortcomings of Stem Cell Therapy for Enhanced Bone
   Healing
SO TISSUE ENGINEERING PART C METHODS
LA English
DT Article
DE cell therapy; bone regeneration; stem cells; stem cell delivery method;
   induced pluripotent stem cells
ID EXTRACELLULAR MATRIX SCAFFOLDS; MESENCHYMAL STROMAL CELLS; FEMORAL HEAD;
   GENE THERAPY; OSTEOGENIC DIFFERENTIATION; MONOCYTE RECRUITMENT;
   PROTEOMIC ANALYSIS; ENDOTHELIAL CELLS; ADIPOSE TISSUE; T CELLS
AB This review explores the regenerative potential of key progenitor cell types and therapeutic strategies to improve healing of complex fractures and bone defects. We define, summarize, and discuss the differentiation potential of totipotent, pluripotent, and multipotent stem cells, emphasizing the advantages and shortcomings of cell therapy for bone repair and regeneration. The fundamental role of mesenchymal stem cells is highlighted due to their multipotency to differentiate into the key lineage cells including osteoblasts, osteocytes, and chondrocytes, which are crucial for bone formation and remodeling. Hematopoietic stem cells (HSCs) also play a significant role; immune cells such as macrophages and T cells modulate inflammation and tissue repair. Osteoclasts are multinucleated cells that are important to bone remodeling. Vascular progenitor (VP) cells are critical to oxygen and nutrient supply. The dynamic interplay among these lineages and their microenvironment is essential for effective bone restoration. Therapies involving cells that are more than "minimally manipulated" are controversial and include embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). ESCs, derived from early stage embryos, possess pluripotent capabilities and have shown promise in preclinical studies for bone healing. iPSCs, reprogrammed from somatic cells, offer personalized medicine applications and can differentiate into various tissue specific cell lines. Minimally manipulative cell therapy approaches such as the use of bone marrow aspirate concentrate (BMAC), exosomes, and various biomaterials for local delivery are explored for their effectiveness in bone regeneration. BMAC, which contains mostly immune cells but few mesenchymal and VPs, probably improves bone healing by facilitating paracrine mediated intercellular communication. Exosome isolation harnesses the biological signals and cellular by products that are a primary source for cell crosstalk and activation. Safe, efficacious, and cost effective strategies to enhance bone healing using novel cellular therapies are part of a changing paradigm to modulate the inflammatory, repair, and regenerative pathways to achieve earlier more robust tissue healing and improved physical function.
   Impact Statement Stem cell therapy holds immense potential for bone healing due to its ability to regenerate damaged tissue. Nonmanipulated bone marrow aspirate contains mesenchymal stem cells that promote bone repair and reduce healing time. Induced pluripotent stem cells offer the advantage of creating patient specific cells that can differentiate into osteoblasts, aiding in bone regeneration. Other delivery methods, such as scaffold based techniques, enhance stem cell integration and function. Collectively, these approaches can improve treatment outcomes, reduce recovery periods, and advance our understanding of bone healing mechanisms, making them pivotal in orthopedic research and regenerative medicine.
C1 [Chow, Simon Kwoon Ho; Gao, Qi; Pius, Alexa; Morita, Mayu; Ergul, Yasemin; Murayama, Masatoshi; Shinohara, Issei; Cekuc, Mehmet Sertac; Ma, Chao; Susuki, Yosuke; Goodman, Stuart B.] Stanford Univ, Dept Orthopaed Surg, 0200 BMI Bldg,240 Pasteur Dr, Stanford, CA 94305 USA.
   [Goodman, Stuart B.] Stanford Univ, Dept Bioengn, Stanford, CA USA.
C3 Stanford University; Stanford University
RP Chow, SKH; Goodman, SB (通讯作者)，Stanford Univ, Dept Orthopaed Surg, 0200 BMI Bldg,240 Pasteur Dr, Stanford, CA 94305 USA.; Goodman, SB (通讯作者)，Stanford Univ, Dept Orthopaed Surg, 450 Broadway St,Pavil A 1st Fl MC 6110, Redwood City, CA 94063 USA.
EM skhchow@stanford.edu; goodbone@stanford.edu
RI ; Shinohara, Issei/MBH 8634 2025; Goodman, Stuart/AAZ 7499 2020; Chow,
   Simon/AAG 7330 2020; Chow, Simon Kwoon ho/J 1554 2018
OI Goodman, Stuart/0000 0002 1919 3717; Morita, Mayu/0009 0003 8092 0762;
   Shinohara, Issei/0000 0002 4122 7119; Murayama,
   Masatoshi/0009 0000 1228 482X; Ma, Chao/0000 0002 1049 6172; ,
   Qi/0000 0003 0175 566X; Cekuc, Mehmet Sertac/0000 0002 8068 7820; Chow,
   Simon Kwoon ho/0000 0003 1742 980X
FU Robert L. and Mary Ellenburg Professorship of Surgery
FX This review was partially supported by the Robert L. and Mary Ellenburg
   Professorship of Surgery.
CR Almeida Porada G, 2020, MOL THER METH CLIN D, V16, P204, DOI 10.1016/j.omtm.2020.01.005
   Ambrosi TH, 2021, NATURE, V597, P256, DOI 10.1038/s41586 021 03795 7
   Ambrosi TH, 2020, AGING CELL, V19, DOI 10.1111/acel.13164
   Ambrosi TH, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00189
   Ankrum JA, 2014, NAT BIOTECHNOL, V32, P252, DOI 10.1038/nbt.2816
   Aoki T, 2010, TISSUE ENG PT A, V16, P2197, DOI 10.1089/ten.TEA.2009.0747
   Arpornmaeklong P, 2009, STEM CELLS DEV, V18, P955, DOI 10.1089/scd.2008.0310
   Atasoy Zeybek A, 2018, ADV EXP MED BIOL, V1119, P85, DOI 10.1007/5584_2018_253
   Bahney CS, 2019, J ORTHOP RES, V37, P35, DOI 10.1002/jor.24170
   Baker CE, 2018, CLIN REV BONE MINER, V16, P142, DOI 10.1007/s12018 018 9256 x
   Balmayor ER, 2015, FRONT BIOENG BIOTECH, V3, DOI 10.3389/fbioe.2015.00009
   Bastian O, 2011, J LEUKOCYTE BIOL, V89, P669, DOI 10.1189/jlb.0810446
   Benavides Castellanos Maria Paula, 2020, Cell Regen, V9, P5, DOI 10.1186/s13619 020 00047 3
   Berglund AK, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0742 8
   Betz VM, 2018, J GENE MED, V20, DOI 10.1002/jgm.3018
   Bruveris FF, 2021, EXP HEMATOL, V103, P30, DOI 10.1016/j.exphem.2021.08.006
   Caplan AI, 2007, J CELL PHYSIOL, V213, P341, DOI 10.1002/jcp.21200
   Caplan H, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01645
   Carter DR, 1998, CLIN ORTHOP RELAT R, pS41
   Cevallos RR., 2021, EVALUATING REPROGRAM
   Chan CKF, 2018, CELL, V175, P43, DOI 10.1016/j.cell.2018.07.029
   Chan CKF, 2015, CELL, V160, P285, DOI 10.1016/j.cell.2014.12.002
   Chan CKF., 2018, IDENTIFICATION HUMAN
   Chen JY, 2020, J BONE MINER RES, V35, P2103, DOI 10.1002/jbmr.4171
   Cheung WH, 2016, INJURY, V47, pS21, DOI 10.1016/S0020 1383(16)47004 X
   Chow SKH, 2019, EUR CELLS MATER, V38, P228, DOI 10.22203/eCM.v038a16
   Chow SKH, 2022, J ORTHOP TRANSL, V36, P83, DOI 10.1016/j.jot.2022.05.004
   Chu WX, 2019, REGEN MED, V14, P555, DOI 10.2217/rme 2018 0047
   Clark D, 2020, AGING CELL, V19, DOI 10.1111/acel.13112
   CONNOLLY J, 1989, J BONE JOINT SURG AM, V71A, P684, DOI 10.2106/00004623 198971050 00007
   Connolly J F, 1989, J Orthop Trauma, V3, P276, DOI 10.1097/00005131 198912000 00002
   Craft AM, 2013, DEVELOPMENT, V140, P2597, DOI 10.1242/dev.087890
   Croes M, 2016, BONE, V84, P262, DOI 10.1016/j.bone.2016.01.010
   Cui YZ, 2016, FEBS LETT, V590, P185, DOI 10.1002/1873 3468.12024
   de Girolamo L, 2010, INJURY, V41, P1172, DOI 10.1016/j.injury.2010.09.027
   De la Vega R, 2020, EUR CELLS MATER, V40, P160, DOI 10.22203/eCM.v040a10
   de la Vega R, 2021, TRANSL RES, V236, P1, DOI 10.1016/j.trsl.2021.04.009
   de Lageneste OD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03124 z
   Delclós LO, 2024, J TRANSL MED, V22, DOI 10.1186/s12967 024 05280 x
   Dong SW, 2009, BIOSCI BIOTECH BIOCH, V73, P2226, DOI 10.1271/bbb.90329
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Fan SY, 2023, FRONT CELL DEV BIOL, V11, DOI 10.3389/fcell.2023.1193765
   Felice HDR., 2024, AM ACAD ORTHOPAEDIC
   Friedlaender GE, 2013, CURR PHARM DESIGN, V19, P3384, DOI 10.2174/1381612811319190005
   Frisch J, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt491
   Fu TS, 2015, SPINE J, V15, P2036, DOI 10.1016/j.spinee.2014.11.002
   Fu XR, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080784
   Gao CD, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.59
   Gao MH, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0039 2
   García Sánchez D, 2019, WORLD J STEM CELLS, V11, P748, DOI 10.4252/wjsc.v11.i10.748
   Ge M, 2015, BIOCHEM BIOPH RES CO, V467, P27, DOI 10.1016/j.bbrc.2015.09.135
   Ghiasi MS, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891 019 2854 z
   Ghorbani Dalini S, 2020, 3 BIOTECH, V10, DOI 10.1007/s13205 020 02215 3
   Gianakos A, 2016, J ORTHOP TRAUMA, V30, P1, DOI 10.1097/BOT.0000000000000453
   Gibon E, 2017, J ORTHOP TRANSL, V10, P28, DOI 10.1016/j.jot.2017.04.002
   Gibon E, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0300 9
   Gomez JC, 2015, CELL MOL BIOENG, V8, P307, DOI 10.1007/s12195 015 0401 z
   Goodman SB, 2003, INT J IMMUNOPATH PH, V16, P201, DOI 10.1177/039463200301600303
   Goodman Stuart B, 2021, Biomater Biosyst, V2, P100017, DOI 10.1016/j.bbiosy.2021.100017
   Goodman SB, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00641
   Goodman SB, 2017, J ORTHOP TRANSL, V10, pA1, DOI 10.1016/j.jot.2017.07.001
   Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007
   Guan JY, 2022, NATURE, V605, P325, DOI 10.1038/s41586 022 04593 5
   Guihard P, 2012, STEM CELLS, V30, P762, DOI 10.1002/stem.1040
   Guo X, 2006, BIOMED MATER, V1, P93, DOI 10.1088/1748 6041/1/3/001
   Guzman RA, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02572 7
   Hernigou P, 2002, CLIN ORTHOP RELAT R, P14, DOI 10.1097/01.blo.0000038472.05771.79
   Hernigou P, 2005, J BONE JOINT SURG AM, V87A, P1430, DOI 10.2106/JBJS.D.02215
   Hernigou P, 2013, INT ORTHOP, V37, P2279, DOI 10.1007/s00264 013 2017 z
   Hirata H, 2022, IMMUN AGEING, V19, DOI 10.1186/s12979 022 00272 1
   Hoang DM, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 022 01134 4
   Hoover MY, 2023, NAT PROTOC, V18, P2256, DOI 10.1038/s41596 023 00836 5
   Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234
   Huang S, 2015, CELL TRANSPLANT, V24, P2643, DOI 10.3727/096368915X687219
   Hussey GS, 2018, NAT REV MATER, V3, P159, DOI 10.1038/s41578 018 0023 x
   Hutmacher DW, 2000, BIOMATERIALS, V21, P2529, DOI 10.1016/S0142 9612(00)00121 6
   Imai T, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.26238
   Ishikawa M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104954
   Ismail HD, 2016, BONE JOINT RES, V5, P287, DOI 10.1302/2046 3758.57.2000587
   Ji XF, 2020, THERANOSTICS, V10, P725, DOI 10.7150/thno.39167
   Jia Z., 2020, IDENTIFICATION DIFFE
   Jiang W., 2020, IMMUNE MODULATION ME
   Jiang YL, 1999, J PERIODONTOL, V70, P1472, DOI 10.1902/jop.1999.70.12.1472
   Jin YZ, 2018, CLIN ORTHOP SURG, V10, P271, DOI 10.4055/cios.2018.10.3.271
   JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412
   Kaigler D, 2015, J BONE MINER RES, V30, P1206, DOI 10.1002/jbmr.2464
   Kang MY, 2020, BONE, V141, DOI 10.1016/j.bone.2020.115627
   Kean TJ, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/732742
   Kessler F, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25105555
   Kim I, 2014, STEM CELL TRANSL MED, V3, P1312, DOI 10.5966/sctm.2014 0109
   Kim K, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030827
   Kim MS, 2022, WORLD J STEM CELLS, V14, P839, DOI 10.4252/wjsc.v14.i12.839
   Kogut I., 2018, NATURE
   Komura S, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 61063 6
   Koob S, 2011, TISSUE ENG PT A, V17, P311, DOI [10.1089/ten.tea.2010.0338, 10.1089/ten.TEA.2010.0338]
   Kovach TK, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/752510
   Kumar LP, 2019, CYTOKINE GROWTH F R, V46, P1, DOI 10.1016/j.cytogfr.2019.04.002
   Kurtz Andreas, 2008, Int J Stem Cells, V1, P1
   Kushioka J, 2023, INFLAMM REGEN, V43, DOI 10.1186/s41232 023 00279 1
   Kwong FNK, 2008, J AM ACAD ORTHOP SUR, V16, P619, DOI 10.5435/00124635 200811000 00001
   Lamandé SR, 2023, P NATL ACAD SCI USA, V120, DOI 10.1073/pnas.2211510120
   Laurent M, 2024, CELLS BASEL, V13, DOI 10.3390/cells13100800
   Lee DJ, 2020, J TISSUE ENG, V11, DOI 10.1177/2041731420981672
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Li Q, 2022, ONCOL LETT, V24, DOI 10.3892/ol.2022.13360
   Li Y, 2018, CURR STEM CELL RES T, V13, P362, DOI 10.2174/1574888X13666180403163456
   Liang HX, 2014, SPINE J, V14, P445, DOI 10.1016/j.spinee.2013.09.045
   Lin H, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1350 6
   Liu F, 2024, CYTOTHERAPY, V26, P686, DOI 10.1016/j.jcyt.2024.04.067
   Liu HH, 2024, BIOMATERIALS, V304, DOI 10.1016/j.biomaterials.2023.122406
   Liu HC, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02410 w
   Liu K, 2022, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.801432
   Liu S, 2023, MILITARY MED RES, V10, DOI 10.1186/s40779 023 00448 w
   Liu XL, 2017, INT J BIOL SCI, V13, P232, DOI 10.7150/ijbs.16951
   Liu YC, 2015, J TISSUE ENG REGEN M, V9, P85, DOI 10.1002/term.1617
   Liu ZQ, 2020, J TISSUE ENG REGEN M, V14, P1403, DOI 10.1002/term.3106
   Lo B, 2009, ENDOCR REV, V30, P204, DOI 10.1210/er.2008 0031
   Loh YH, 2010, CELL STEM CELL, V7, P15, DOI 10.1016/j.stem.2010.06.004
   Lohan P, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01626
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Lu LY, 2017, J ORTHOP RES, V35, P2378, DOI 10.1002/jor.23553
   Lu Y, 2023, STEM CELL RES THER, V14, DOI 10.1186/s13287 023 03275 x
   Marsell R, 2011, INJURY, V42, P551, DOI 10.1016/j.injury.2011.03.031
   Martínez Alvarez S, 2023, SCI PROGRESS UK, V106, DOI 10.1177/00368504231179790
   Maruyama M, 2021, BIOMATERIALS, V275, DOI 10.1016/j.biomaterials.2021.120972
   Maruyama M, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00386
   Mizuhashi K, 2018, NATURE, V563, P254, DOI 10.1038/s41586 018 0662 5
   Mountziaris PM, 2011, TISSUE ENG PART B RE, V17, P393, DOI [10.1089/ten.teb.2011.0182, 10.1089/ten.TEB.2011.0182]
   Müller CW, 2017, J TISSUE ENG REGEN M, V11, P1122, DOI 10.1002/term.2015
   Murayama M, 2024, J BIOMED MATER RES A, DOI 10.1002/jbm.a.37771
   Nagasaka R, 2017, REGEN THER, V6, P41, DOI 10.1016/j.reth.2016.12.003
   Nethercott HE., 2011, DERIVATION INDUCED P
   Omar OM, 2011, BIOMATERIALS, V32, P8190, DOI 10.1016/j.biomaterials.2011.07.055
   Otrock ZK, 2007, BLOOD CELL MOL DIS, V39, P212, DOI 10.1016/j.bcmd.2007.04.001
   Paduano F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148225
   Pajarinen J, 2019, BIOMATERIALS, V196, P80, DOI 10.1016/j.biomaterials.2017.12.025
   Palombella S, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/3715964
   Pan Q, 2021, CYTOTHERAPY, V23, P590, DOI 10.1016/j.jcyt.2020.12.005
   Park SH, 2011, J BIOMED MATER RES B, V97B, P235, DOI 10.1002/jbm.b.31805
   Perez JR, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00105
   Phinney DG, 2017, STEM CELLS, V35, P851, DOI 10.1002/stem.2575
   Pilquil C, 2020, J BIOL CHEM, V295, P6861, DOI 10.1074/jbc.RA119.011029
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Posner LJ, 1997, BONE, V21, P321, DOI 10.1016/S8756 3282(97)00154 3
   Qin YH, 2014, POSTGRAD MED J, V90, P643, DOI 10.1136/postgradmedj 2013 132387
   Ragipoglu D, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.883707
   RAHIMI P, 1995, ENDOCRINOLOGY, V136, P2752, DOI 10.1210/en.136.6.2752
   Robb KP, 2018, ACS BIOMATER SCI ENG, V4, P3627, DOI 10.1021/acsbiomaterials.7b00619
   Schlundt C, 2024, CELLS BASEL, V13, DOI 10.3390/cells13010040
   Schlundt C, 2021, ACTA BIOMATER, V133, P46, DOI 10.1016/j.actbio.2021.04.052
   Schlundt C, 2018, BONE, V106, P78, DOI 10.1016/j.bone.2015.10.019
   Schmidt Bleek K, 2012, CELL TISSUE RES, V347, P567, DOI 10.1007/s00441 011 1205 7
   Schreml S, 2009, CYTOTHERAPY, V11, P947, DOI 10.3109/14653240903204322
   Shinohara I, 2023, BIOMOLECULES, V13, DOI 10.3390/biom13111665
   Smith EL, 2014, ACTA BIOMATER, V10, P4186, DOI 10.1016/j.actbio.2014.06.011
   Sponer P, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/2076061
   Stanko P, 2014, BIOMED PAP, V158, P373, DOI 10.5507/bp.2013.078
   Steeg R, 2021, STEM CELL REP, V16, P1853, DOI 10.1016/j.stemcr.2021.07.009
   Stefanowski J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02588
   Tabatabaee RM, 2015, J ARTHROPLASTY, V30, P11, DOI 10.1016/j.arth.2015.06.022
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tevlin R, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag2809
   Théry C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309
   Thibault RA, 2010, TISSUE ENG PT A, V16, P431, DOI [10.1089/ten.tea.2009.0583, 10.1089/ten.TEA.2009.0583]
   Toya M, 2023, FRONT CELL DEV BIOL, V11, DOI 10.3389/fcell.2023.1213641
   Tsubosaka M, 2021, BIOENGINEERING BASEL, V8, DOI 10.3390/bioengineering8110165
   U.S. Department of Health and Human Services FaDA Center for Biologics Evaluation and Research CfDaRH Office of Combination Products, 2020, REGULATORY CONSIDERA
   Ueno M, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.755964
   Ueno M, 2020, J BIOMED MATER RES A, V108, P2240, DOI 10.1002/jbm.a.36982
   Vallés G, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 1578 1
   van Brakel F, 2024, BONE REP, V21, DOI 10.1016/j.bonr.2024.101757
   Vlahos K, 2019, STEM CELL RES, V34, DOI 10.1016/j.scr.2018.101380
   Vlassov AV, 2012, BBA GEN SUBJECTS, V1820, P940, DOI 10.1016/j.bbagen.2012.03.017
   Wagner DR, 2019, WORLD J STEM CELLS, V11, P281, DOI 10.4252/wjsc.v11.i6.281
   Wang AYL, 2019, CELL TRANSPLANT, V28, p112S, DOI 10.1177/0963689719886534
   Wang YH, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 03199 y
   Xie J, 2016, ACTA BIOMATER, V29, P365, DOI 10.1016/j.actbio.2015.10.007
   Xie XD, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.594247
   Xing ZQ, 2010, DIS MODEL MECH, V3, P451, DOI 10.1242/dmm.003186
   Xu F, 2020, J PINEAL RES, V68, DOI 10.1111/jpi.12631
   Xu LL, 2015, FASEB J, V29, P1143, DOI 10.1096/fj.14 254169
   Xue DT, 2017, ONCOTARGET, V8, P42098, DOI 10.18632/oncotarget.16887
   Yamasaki T, 2010, J BONE JOINT SURG BR, V92B, P337, DOI 10.1302/0301 620X.92B3.22483
   Yang BC, 2020, BIOCHEM BIOPH RES CO, V524, P883, DOI 10.1016/j.bbrc.2020.02.001
   Yang ZM, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.679914
   Yu HL, 2020, ACTA BIOMATER, V106, P328, DOI 10.1016/j.actbio.2020.01.051
   Yusa K, 2009, NAT METHODS, V6, P363, DOI [10.1038/NMETH.1323, 10.1038/nmeth.1323]
   Zhang D, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0592 4
   Zhang L, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 1562 9
   Zhang N, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 020 02086 8
   Zhang XW, 2022, BIOACT MATER, V10, P15, DOI 10.1016/j.bioactmat.2021.09.014
   Zhou ML, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02249 1
   Zhou T, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045 021 01037 x
   Zhu MT, 2023, STEM CELL TRANSL MED, V12, P576, DOI 10.1093/stcltm/szad043
   Zhu SP, 2020, THERANOSTICS, V10, P5957, DOI 10.7150/thno.45422
   Zou JX, 2023, J NANOBIOTECHNOL, V21, DOI 10.1186/s12951 023 01778 6
NR 197
TC 3
Z9 3
U1 3
U2 9
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3384
EI 1937 3392
J9 TISSUE ENG PART C ME
JI Tissue Eng. Part C Methods
PD OCT 1
PY 2024
VL 30
IS 10
BP 415
EP 430
DI 10.1089/ten.tec.2024.0252
EA OCT 2024
PG 16
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA J7P5K
UT WOS:001325811000001
PM 39311464
DA 2025 08 17
ER

PT J
AU Heo, J
   Kim, M
   Kim, JH
   Shin, H
   Lim, SE
   Jung, HS
   Sohn, Y
   Ku, J
AF Heo, Jun
   Kim, Minsun
   Kim, Jae Hyun
   Shin, Hwajeong
   Lim, Seo Eun
   Jung, Hyuk Sang
   Sohn, Youngjoo
   Ku, Jaseung
TI Effect of Taraxaci Herba on Bone Loss in an OVX Induced Model
   through the Regulation of Osteoclast Differentiation
SO NUTRIENTS
LA English
DT Article
DE Taraxaci Herba; osteoclast; RANKL; NFATc1; c Fos; ovariectomized
ID INDUCED INFLAMMATORY RESPONSES; OVARIECTOMIZED RAT MODEL; RECEPTOR
   ACTIVATOR; CHLOROGENIC ACID; NUCLEAR FACTOR; FRACTURE RISK; CAFFEIC
   ACID; OSTEOPOROSIS; RESORPTION; OFFICINALE
AB Bone is a dynamic tissue that maintains homeostasis with a balance of osteoclasts for bone resorption and osteoblasts for bone formation. Women are deficient in estrogen after menopause, which promotes bone resorption due to excessive activity of osteoclasts, leading to osteoporosis. TH (also known as dandelion) is native to warm regions and has traditionally been used to treat gynecological diseases and inflammation. Menopause is a major cause of osteoporosis as it causes abnormal activity of osteoclasts, and various studies have shown that anti inflammatory drugs have the potential to treat osteoporosis. We analyzed the effect of TH on osteoclast differentiation and the relevant mechanisms using RANKL. After administration of TH in a menopause like rat model in which ovariectomy of the was rats carried out, changes in bone microstructure were analyzed via micro CT, and the antiosteoporosis effect of TH was verified by a histological analysis. In addition, the pharmacological effects of TH in an animal model of osteoporosis were compared and analyzed with osteoporosis medications (17 beta estradiol (E 2) and alendronate (ALN)). TH significantly inhibited the initial osteoclast differentiation via the NFATc1/c Fos mechanism. In addition, bone density in the femur of osteoporotic rats was increased, and the expression of osteoclast related factors in the serum and tissues was controlled. The results of this study provide objective evidence of the inhibitory effect of TH on osteoclastogenesis and OVX induced bone loss.
C1 [Heo, Jun; Kim, Minsun; Kim, Jae Hyun; Shin, Hwajeong; Lim, Seo Eun; Jung, Hyuk Sang; Sohn, Youngjoo] Kyung Hee Univ, Coll Korean Med, Dept Anat, 26 Kyunghee Dae Ro, Seoul 02447, South Korea.
   [Ku, Jaseung] Bogwang Korean Med Clin 236, 236 Gucheonmyeon Ro, Seoul 05334, South Korea.
C3 Kyung Hee University
RP Sohn, Y (通讯作者)，Kyung Hee Univ, Coll Korean Med, Dept Anat, 26 Kyunghee Dae Ro, Seoul 02447, South Korea.; Ku, J (通讯作者)，Bogwang Korean Med Clin 236, 236 Gucheonmyeon Ro, Seoul 05334, South Korea.
EM youngjoos@khu.ac.kr; elfnlove@gmail.com
OI Jung, Hyuk Sang/0000 0002 7256 9672; Kim, Jae hyun/0000 0003 3593 3049
FU National Research Foundation of Korea (NRF)   Korean Government (MSIT)
   [2020R1A2C1007836]; Basic Science Research Program through the National
   Research Foundation of Korea (NRF)   Ministry of Education
   [2021R1A6A3A1303978212]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korean Government (MSIT) (grant number:
   2020R1A2C1007836) and the Basic Science Research Program through the
   National Research Foundation of Korea (NRF) funded by the Ministry of
   Education (grant number: 2021R1A6A3A1303978212).
CR BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0
   Black DM, 2020, NEW ENGL J MED, V383, P743, DOI 10.1056/NEJMoa1916525
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Camassa JA, 2017, BMC VET RES, V13, DOI 10.1186/s12917 017 1170 9
   Campbell Graeme M, 2014, Bonekey Rep, V3, P564, DOI 10.1038/bonekey.2014.59
   Caplan L, 2010, MAYO CLIN PROC, V85, P341, DOI 10.4065/mcp.2009.0492
   Carbonare LD, 2005, MICRON, V36, P609, DOI 10.1016/j.micron.2005.07.007
   Cha M, 2021, INTEGR MED RES, V10, DOI 10.1016/j.imr.2021.100720
   Chen LR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092213
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Collin Osdoby P, 2012, METHODS MOL BIOL, V816, P187, DOI 10.1007/978 1 61779 415 5_13
   Dobbs M B, 1999, Iowa Orthop J, V19, P43
   Ekeuku SO, 2021, DRUG DES DEV THER, V15, P259, DOI 10.2147/DDDT.S287280
   Ginaldi Lia, 2005, Immun Ageing, V2, P14, DOI 10.1186/1742 4933 2 14
   Hwang SJ, 2014, INFLAMM RES, V63, P81, DOI 10.1007/s00011 013 0674 4
   Ji Meng Xia, 2015, Chronic Dis Transl Med, V1, P9, DOI 10.1016/j.cdtm.2015.02.006
   Jiang YB, 1997, J BONE MINER RES, V12, P820, DOI 10.1359/jbmr.1997.12.5.820
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200
   Kim B, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10815
   Kim EY, 2020, J ETHNOPHARMACOL, V257, DOI 10.1016/j.jep.2020.112828
   Kim Jinhyun, 2016, Value Health Reg Issues, V9, P36, DOI 10.1016/j.vhri.2015.09.007
   Kim M, 2021, MOL MED REP, V24, DOI 10.3892/mmr.2021.12248
   Kim TH, 2011, J NUTR BIOCHEM, V22, P8, DOI 10.1016/j.jnutbio.2009.11.002
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Koh YJ, 2010, J MED FOOD, V13, P870, DOI 10.1089/jmf.2009.1249
   Komarova SV, 2005, P NATL ACAD SCI USA, V102, P2643, DOI 10.1073/pnas.0406874102
   Kuo TR, 2017, BIOMARK RES, V5, DOI 10.1186/s40364 017 0097 4
   Kwak SC, 2013, BIOL PHARM BULL, V36, P1779
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Lewiecki EM, 2010, THER ADV CHRONIC DIS, V1, P115, DOI 10.1177/2040622310374783
   Li YN, 2022, J ETHNOPHARMACOL, V293, DOI 10.1016/j.jep.2022.115272
   Liu TH, 2012, BIOMARK INSIGHTS, V7, P105, DOI 10.4137/BMI.S10009
   Liu W, 2015, MOL MED REP, V11, P3212, DOI 10.3892/mmr.2015.3152
   Luo G, 2018, MOL MED REP, V17, P6605, DOI 10.3892/mmr.2018.8698
   Magaki S, 2019, METHODS MOL BIOL, V1897, P289, DOI 10.1007/978 1 4939 8935 5_25
   Martinez M, 2015, J ETHNOPHARMACOL, V169, P244, DOI 10.1016/j.jep.2015.03.067
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976 0105.177703
   Nedeva IR, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.641162
   Omi M, 2021, ORAL SCI INT, V18, P14, DOI 10.1002/osi2.1078
   Ozer J, 2008, TOXICOLOGY, V245, P194, DOI 10.1016/j.tox.2007.11.021
   Painter Stephanie E, 2006, Endocr Pract, V12, P436
   Park CM, 2013, NUTR RES PRACT, V7, P423, DOI 10.4162/nrp.2013.7.6.423
   Pfingstgraf IO, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10040504
   Qiu YY, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891 019 2861 0
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Schütz K, 2006, J ETHNOPHARMACOL, V107, P313, DOI 10.1016/j.jep.2006.07.021
   Seo SW, 2005, WORLD J GASTROENTERO, V11, P597, DOI 10.3748/wjg.v11.i4.597
   Stournaras E, 2015, WORLD J HEPATOL, V7, P2189, DOI 10.4254/wjh.v7.i19.2189
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takito J, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19040984
   Thurston RC, 2016, STROKE, V47, P2910, DOI 10.1161/STROKEAHA.116.014674
   Tschöp MH, 2012, NAT METHODS, V9, P57, DOI [10.1038/nmeth.1806, 10.1038/NMETH.1806]
   Turner A. Simon, 2001, European Cells & Materials, V1, P66
   Vincent C, 2009, J BONE MINER METAB, V27, P114, DOI 10.1007/s00774 008 0018 6
   Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092 8674(00)81169 1
   Weitzmann MN, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/125705
   Williams CA, 1996, PHYTOCHEMISTRY, V42, P121, DOI 10.1016/0031 9422(95)00865 9
   Yoon Hyun Koo, 2017, J Bone Metab, V24, P59, DOI 10.11005/jbm.2017.24.1.59
   Yousefzadeh N, 2020, EXCLI J, V19, P89, DOI 10.17179/excli2019 1990
   Zhang MJ, 2014, BIOL PHARM BULL, V37, P347, DOI 10.1248/bpb.b13 00459
   Zhao XF, 2018, MOL MED REP, V18, P1718, DOI 10.3892/mmr.2018.9080
NR 67
TC 5
Z9 5
U1 0
U2 7
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6643
J9 NUTRIENTS
JI Nutrients
PD OCT
PY 2022
VL 14
IS 20
AR 4354
DI 10.3390/nu14204354
PG 20
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA 5P9LJ
UT WOS:000873463700001
PM 36297038
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Reagan, MR
   Mishima, Y
   Glavey, SV
   Zhang, Y
   Manier, S
   Lu, ZN
   Memarzadeh, M
   Zhang, Y
   Sacco, A
   Aljawai, Y
   Shi, JT
   Tai, YT
   Ready, JE
   Kaplan, DL
   Roccaro, AM
   Ghobrial, IM
AF Reagan, Michaela R.
   Mishima, Yuji
   Glavey, Siobhan V.
   Zhang, Yong
   Manier, Salomon
   Lu, Zhi Ning
   Memarzadeh, Masoumeh
   Zhang, Yu
   Sacco, Antonio
   Aljawai, Yosra
   Shi, Jiantao
   Tai, Yu Tzu
   Ready, John E.
   Kaplan, David L.
   Roccaro, Aldo M.
   Ghobrial, Irene M.
TI Investigating osteogenic differentiation in multiple myeloma using a
   novel 3D bone marrow niche model
SO BLOOD
LA English
DT Article
ID MESENCHYMAL STEM CELLS; OSTEOBLAST DIFFERENTIATION; STROMAL CELLS;
   EXPRESSION; DISEASE; MICROENVIRONMENT; BISPHOSPHONATES; MECHANISMS;
   ADHESION; THERAPY
AB Clonal proliferation of plasma cells within the bone marrow (BM) affects local cells, such as mesenchymal stromal cells (MSCs), leading to osteolysis and fatality in multiple myeloma (MM). Consequently, there is an urgent need to find better mechanisms of inhibiting myeloma growth and osteolytic lesion development. To meet this need and accelerate clinical translation, better models of myeloma within the BM are required. Herein we have developed a clinically relevant, three dimensional (3D) myeloma BM coculture model that mimics bone cell/cancer cell interactions within the bone microenvironment. The coculture model and clinical samples were used to investigate myeloma growth, osteogenesis inhibition, and myeloma induced abnormalities in MM MSCs. This platform demonstrated myeloma support of capillarylike assembly of endothelial cells and cell adhesion mediated drug resistance (CAM DR). Also, distinct normal donor (ND)and MM MSC miRNA (miR) signatures were identified and used to uncover osteogenic miRs of interest for osteoblast differentiation. More broadly, our 3D platform provides a simple, clinically relevant tool to model cancer growth within the bone useful for investigating skeletal cancer biology, screening compounds, and exploring osteogenesis. Our identification and efficacy validation of novel bone anabolic miRs in MM opens more opportunities for novel approaches to cancer therapy via stromal miR modulation.
C1 [Reagan, Michaela R.; Mishima, Yuji; Glavey, Siobhan V.; Zhang, Yong; Manier, Salomon; Lu, Zhi Ning; Memarzadeh, Masoumeh; Zhang, Yu; Sacco, Antonio; Aljawai, Yosra; Tai, Yu Tzu; Ready, John E.; Roccaro, Aldo M.; Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Shi, Jiantao] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   [Ready, John E.] Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Kaplan, David L.] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA.
C3 Harvard University; Harvard Medical School; Harvard University Medical
   Affiliates; Dana Farber Cancer Institute; Harvard University; Harvard
   T.H. Chan School of Public Health; Harvard University; Harvard
   University Medical Affiliates; Brigham & Women's Hospital; Tufts
   University
RP Ghobrial, IM (通讯作者)，Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA.
EM Irene_ghobrial@dfci.harvard.edu
RI ; Sacco, Antonio/K 4681 2016; Manier, Salomon/N 5976 2017; Roccaro,
   Aldo/AAA 8957 2022; Reagan, Michaela/E 3549 2017
OI Ghobrial, Irene/0000 0001 7361 3092; Kaplan, David/0000 0002 9245 7774;
   Roccaro, Aldo/0000 0002 1872 5128; Sacco, Antonio/0000 0003 2945 9416;
   Reagan, Michaela/0000 0003 2884 6481; Li, pengcheng/0009 0004 6334 051X;
   
FU Department of Defense, Peer review Cancer Research Program
   [W81WH 13 1 0390]; National Institutes of Health P41 Center [EB002520];
   National Cancer Institute [R01CA154648]
FX This study was supported by the Department of Defense, Peer review
   Cancer Research Program (W81WH 13 1 0390), the National Institutes of
   Health P41 Center (EB002520) and National Cancer Institute grant
   R01CA154648.
CR Azab AK, 2012, BLOOD, V119, P1468, DOI 10.1182/blood 2011 07 368050
   Azab AK, 2009, BLOOD, V113, P4341, DOI 10.1182/blood 2008 10 186668
   Baker BM, 2012, J CELL SCI, V125, P3015, DOI 10.1242/jcs.079509
   Corre J, 2007, LEUKEMIA, V21, P1079, DOI 10.1038/sj.leu.2404621
   Croucher PI, 2001, BLOOD, V98, P3534, DOI 10.1182/blood.V98.13.3534
   Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Ferrarini M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071613
   Fuhler GM, 2010, EXP CELL RES, V316, P1816, DOI 10.1016/j.yexcr.2010.03.013
   Gonsalves CS, 2010, J IMMUNOL, V184, P3878, DOI 10.4049/jimmunol.0902594
   Gu S, 2013, 63 ANN M AM SOC HUM
   Gu S, 2012, INT J MOL SCI, V13, P8449, DOI 10.3390/ijms13078449
   Gu ZJ, 2000, LEUKEMIA, V14, P188, DOI 10.1038/sj.leu.2401632
   Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000
   Hughes V, 2011, NATURE, V480, pS48, DOI 10.1038/480S48a
   Jullien N, 2012, J CELL BIOCHEM, V113, P2047, DOI 10.1002/jcb.24076
   Kirshner J, 2008, BLOOD, V112, P2935, DOI 10.1182/blood 2008 02 142430
   Lau E, 2011, J ORTHOP RES, V29, P1075, DOI 10.1002/jor.21334
   Lee DY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004527
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li BJ, 2013, SCI REP UK, V3, DOI 10.1038/srep02425
   Lin EA, 2009, J BIOL CHEM, V284, P11326, DOI 10.1074/jbc.M807709200
   Mandal BB, 2012, P NATL ACAD SCI USA, V109, P7699, DOI 10.1073/pnas.1119474109
   Marcucci G, 2013, J CLIN ONCOL, V31, P2086, DOI 10.1200/JCO.2012.45.6228
   Markovina S, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 176
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Oskowitz AZ, 2008, P NATL ACAD SCI USA, V105, P18372, DOI 10.1073/pnas.0809807105
   Pennisi A, 2009, BLOOD, V114, P1803, DOI 10.1182/blood 2009 01 201954
   Pozzi S, 2011, ONCOLOGIST, V16, P651, DOI 10.1634/theoncologist.2010 0225
   Reagan MR, 2012, J BREAST CANCER, V15, P273, DOI 10.4048/jbc.2012.15.3.273
   Reagan MR, 2012, CLIN CANCER RES, V18, P342, DOI 10.1158/1078 0432.CCR 11 2212
   Roccaro AM, 2013, J CLIN INVEST, V123, P1542, DOI 10.1172/JCI66517
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   SPIRA G, 1994, INT J CLIN LAB RES, V24, P1, DOI 10.1007/BF02592402
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Takeuchi K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009870
   Tamama K, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/795385
   Vallet S, 2011, CANCER MICROENVIRON, V4, P339, DOI 10.1007/s12307 011 0090 7
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   Wada N, 2014, STEM CELLS DEV
   Xu S, 2012, LEUKEMIA, V26, P2546, DOI 10.1038/leu.2012.126
   Xu S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079752
   Yaccoby S, 2006, HAEMATOL HEMATOL J, V91, P192
   Zangari M, 2012, CANCER TREAT REV, V38, P968, DOI 10.1016/j.ctrv.2011.12.007
   Zdzisinska B, 2009, FOLIA HISTOCHEM CYTO, V47, P69, DOI 10.2478/v10042 009 0015 1
NR 46
TC 94
Z9 101
U1 0
U2 22
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006 4971
EI 1528 0020
J9 BLOOD
JI Blood
PD NOV 20
PY 2014
VL 124
IS 22
BP 3250
EP 3259
DI 10.1182/blood 2014 02 558007
PG 10
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA AY3CW
UT WOS:000347463100014
PM 25205118
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Rossi, F
   Bellini, G
   Tortora, C
   Bernardo, ME
   Luongo, L
   Conforti, A
   Starc, N
   Manzo, I
   Nobili, B
   Locatelli, F
   Maione, S
AF Rossi, Francesca
   Bellini, Giulia
   Tortora, Chiara
   Bernardo, Maria Ester
   Luongo, Livio
   Conforti, Antonella
   Starc, Nadia
   Manzo, Iolanda
   Nobili, Bruno
   Locatelli, Franco
   Maione, Sabatino
TI CB2 and TRPV1 receptors oppositely modulate in
   vitro human osteoblast activity
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE Human osteoblast culture; Endocannabinoid/endovanilloid system; TRPV1
   receptor; CB2 receptor; Osteoblast activity markers
ID NECROSIS FACTOR RECEPTOR; MESENCHYMAL STEM CELLS; CANNABINOID RECEPTOR;
   BONE MASS; OSTEOCLAST DIFFERENTIATION; OSTEOPROTEGERIN LIGAND; STROMAL
   CELLS; OSTEOPOROSIS; METABOLISM; RESORPTION
AB In the current study, we have investigated the effect of CB2 and TRPV1 receptor ligands on in vitro osteoblasts from bone marrow of human healthy donors.
   A pivotal role for the endocannabinoid/endovanilloid system in bone metabolism has been highlighted. We have demonstrated a functional cross talk between CB2 and TRPV1 in human osteoclasts, suggesting these receptors as new pharmacological target for the treatment of bone resorption disease as osteoporosis. Moreover, we have shown the presence of these receptors on human mesenchimal stem cells, hMSCs.
   Osteoblasts are mononucleated cells originated from hMSCs by the essential transcription factor runt related transcription factor 2 and involved in bone formation via the synthesis and release of macrophage colony stimulating factor, receptor activator of nuclear factor kappa B ligand and osteoprotegerin.
   For the first time, we show that CB2 and TRPV1 receptors are both expressed on human osteoblasts together with enzymes synthesizing and degrading endocannabinoids/endovanilloids, and oppositely modulate human osteoblast activity in culture in a way that the CB2 receptor stimulation improves the osteogenesis whereas TRPV1 receptor stimulation inhibits it. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Rossi, Francesca; Manzo, Iolanda; Nobili, Bruno] Univ Naples 2, Dept Women Child & Gen & Specialist Surg, I 80138 Naples, Italy.
   [Bellini, Giulia; Tortora, Chiara; Luongo, Livio; Maione, Sabatino] Univ Naples 2, Div Pharmacol, Dept Expt Med, I 80138 Naples, Italy.
   [Bernardo, Maria Ester; Conforti, Antonella; Starc, Nadia; Locatelli, Franco] IRCCS Bambino Gesu Children Hosp, Dept Oncohaematol, Rome, Italy.
C3 Universita della Campania Vanvitelli; Universita della Campania
   Vanvitelli; IRCCS Bambino Gesu
RP Rossi, F (通讯作者)，Univ Naples 2, Dept Women Child & Gen & Specialist Surg, Via Luigi De Crecchio 4, I 80138 Naples, Italy.
EM francesca.rossi@unina2.it
RI Rossi, Francesca/HTP 5870 2023; Luongo, Livio/GXV 1993 2022; Locatelli,
   Franco/K 6734 2016; Conforti, Antonella/H 2209 2012; maione,
   sabatino/HTM 5113 2023
OI Rossi, Francesca/0000 0003 2879 6277; Conforti,
   Antonella/0000 0001 8524 5936; Luongo, Livio/0000 0002 1949 2039;
   Maione, Sabatino/0000 0003 3850 6704; 
FU FIRB "Futuro in Ricerca"
FX This work was supported in part by FIRB 2012 "Futuro in Ricerca" of Dr
   Livio Luongo.
CR Andersen TL, 2009, AM J PATHOL, V174, P239, DOI 10.2353/ajpath.2009.080627
   Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064
   Bab I, 2008, J NEUROENDOCRINOL, V20, P69, DOI 10.1111/j.1365 2826.2008.01675.x
   Bab I, 2008, BRIT J PHARMACOL, V153, P182, DOI 10.1038/sj.bjp.0707593
   Bab I, 2011, BRIT J PHARMACOL, V163, P1441, DOI 10.1111/j.1476 5381.2011.01474.x
   Bab I, 2009, ANN MED, V41, P560, DOI 10.1080/07853890903121025
   Bernabei R, 2014, CLIN CASES MINER BON, V11, P201, DOI 10.11138/ccmbm/2014.11.3.201
   Bernardo ME, 2009, ANN NY ACAD SCI, V1176, P101, DOI 10.1111/j.1749 6632.2009.04607.x
   Bernardo ME, 2011, BEST PRACT RES CL HA, V24, P73, DOI 10.1016/j.beha.2010.11.002
   Bifulco M, 2009, PHARMACOL RES, V60, P75, DOI 10.1016/j.phrs.2009.04.015
   Brodsky B, 2005, ADV PROTEIN CHEM, V70, P301, DOI 10.1016/S0065 3233(05)70009 7
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Di Daniele N, 2004, PHARMACOL RES, V50, P637, DOI [10.1016/S1043 6618(04)00145 8, 10.1016/j.phrs.2004.05.010]
   Di Marzo V, 2009, PHARMACOL RES, V60, P77, DOI 10.1016/j.phrs.2009.02.010
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Fattore L, 2007, PHARMACOL RES, V56, P418, DOI 10.1016/j.phrs.2007.09.004
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255
   Idris AI, 2008, ENDOCRINOLOGY, V149, P5619, DOI 10.1210/en.2008 0150
   Idris AI, 2010, CURR NEUROPHARMACOL, V8, P243, DOI 10.2174/157015910792246173
   Idris AI, 2010, BONE, V46, P1089, DOI 10.1016/j.bone.2010.01.368
   Idris AI, 2009, CELL METAB, V10, P139, DOI 10.1016/j.cmet.2009.07.006
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee SU, 2008, PHARMACOL RES, V58, P290, DOI 10.1016/j.phrs.2008.08.008
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   Palumbo S, 2013, TISSUE ENG PT A, V19, P2176, DOI [10.1089/ten.tea.2012.0550, 10.1089/ten.TEA.2012.0550]
   Pandey R, 2009, PHARMACOL RES, V60, P85, DOI 10.1016/j.phrs.2009.03.019
   Payne JB, 2011, PHARMACOL RES, V63, P121, DOI 10.1016/j.phrs.2010.10.006
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rossi F, 2014, BRIT J PHARMACOL, V171, P2621, DOI 10.1111/bph.12542
   Rossi F, 2009, BONE, V44, P476, DOI 10.1016/j.bone.2008.10.056
   Rossi F, 2014, HAEMATOLOGICA, V99, P1876, DOI 10.3324/haematol.2014.104463
   Rossi F, 2013, PHARMACOL RES, V68, P7, DOI 10.1016/j.phrs.2012.10.017
   Rossi F, 2012, PHARMACOL RES, V66, P88, DOI 10.1016/j.phrs.2012.03.011
   Rossi F, 2011, BONE, V48, P997, DOI 10.1016/j.bone.2011.01.001
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Scutt A, 2007, CALCIFIED TISSUE INT, V80, P50, DOI 10.1007/s00223 006 0171 7
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Szallasi A, 2007, NAT REV DRUG DISCOV, V6, P357, DOI 10.1038/nrd2280
   Udagawa N, 2000, ENDOCRINOLOGY, V141, P3478, DOI 10.1210/en.141.9.3478
   Zhang YJ, 2014, PHARMACOL RES, V88, P53, DOI 10.1016/j.phrs.2013.12.009
NR 45
TC 36
Z9 40
U1 1
U2 12
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043 6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD SEP
PY 2015
VL 99
BP 194
EP 201
DI 10.1016/j.phrs.2015.06.010
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CR8DA
UT WOS:000361580100021
PM 26117426
DA 2025 08 17
ER

PT J
AU Zhu, H
   Wang, M
   Zhao, CJ
   Li, RS
   Yang, J
   Pei, GC
   Ye, T
   Zuo, XZ
   Liu, L
   Shin, OLSCL
   Zhu, FM
   Sun, J
   Xu, HZ
   Zhao, Z
   Cao, CJ
   Wang, YX
   Yang, Q
   Xu, G
   Zeng, R
   Yao, Y
AF Zhu, Han
   Wang, Meng
   Zhao, Chengjun
   Li, Ruosong
   Yang, Juan
   Pei, Guangchang
   Ye, Ting
   Zuo, Xuezhi
   Liu, Liu
   Shin, Octavia L. S. Chong Lee
   Zhu, Fengming
   Sun, Jie
   Xu, Huzi
   Zhao, Zhi
   Cao, Chujin
   Wang, Yuxi
   Yang, Qian
   Xu, Gang
   Zeng, Rui
   Yao, Ying
TI GAG and collagen II attenuate glucocorticoid induced osteoporosis by
   regulating NF κB and MAPK signaling
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Glucocorticoids; osteoporosis; GAG and collagen II; NF kappa B and MAPK
   pathways
ID SUPPRESS BONE FORMATION; CHRONIC KIDNEY DISEASE; OSTEOCLAST
   DIFFERENTIATION; OSTEOBLAST DIFFERENTIATION; CATHEPSIN K; RECEPTOR;
   ACTIVATION; OSTEOCYTES; THERAPY; PATHWAY
AB As a component of collagen II, glycosaminoglycan (GAG) has a relatively close relationship with bone metabolism. GAG and collagen II have been proven to promote connection of the bone trabecular structure. However, the exact mechanism remains unknown. In this study, we aimed to determine the concrete effect and the mechanism of GAG and collagen II on glucocorticoid induced osteoporosis. We implanted prednisolone pellets subcutaneously in mice to mimic glucocorticoid induced osteoporosis. GAG was administered intragastrically every day for 60 days. The results demonstrated a protective effect of GAG and collagen II on glucocorticoid induced osteoporosis. Trabecular number and connection density increased after treatment with GAG and collagen II. We generated bone marrow derived macrophages to explore the effect of GAG and collagen II on osteoclast differentiation. We collected cell protein and RNA in the presence of macrophage colony stimulating factor (M CSF) and receptor activator for nuclear factor kappa B ligand (RANKL) and found that GAG and collagen II inhibited the NF kappa B and MAPK pathways, thereby down regulating osteoclast differentiation molecules such as matrix metallopeptidase 9 (MMP 9) and nuclear factor of activated T cells, cytoplasmic 1 (NFATc 1). Our findings suggest that GAG and collagen II may have therapeutic potential of patients with glucocorticoid induced osteoporosis in clinical settings.
C1 [Zhu, Han; Wang, Meng; Yang, Juan; Pei, Guangchang; Liu, Liu; Shin, Octavia L. S. Chong Lee; Zhu, Fengming; Xu, Huzi; Zhao, Zhi; Cao, Chujin; Wang, Yuxi; Yang, Qian; Xu, Gang; Zeng, Rui; Yao, Ying] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Nephrol, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.
   [Ye, Ting; Zuo, Xuezhi; Sun, Jie; Yao, Ying] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Nutr, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.
   [Zhao, Chengjun; Li, Ruosong] Wuhan Huge Biotechnol Co Ltd, 630 Hanyang Ave, Wuhan, Hubei, Peoples R China.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology
RP Zeng, R; Yao, Y (通讯作者)，Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Nephrol, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.
EM zengrui@tjh.tjmu.edu.cn; yaoyingkk@126.com
RI Wang, Meng/KLD 7672 2024; ye, ting/HGC 5924 2022; Yang,
   Juan/ABF 4433 2021; Xu, Gang/HNI 9325 2023; Zeng, RUI/AAF 7238 2019
FU National Natural Science Foundation of China [81570669, 81200521,
   81570615]; Wuhan health and family planning commission [2016whzqnyxgg02]
FX This work was supported by the National Natural Science Foundation of
   China (grants 81570669, 81200521, 81570615) and the Wuhan health and
   family planning commission (grants 2016whzqnyxgg02).
CR Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Buehring B, 2013, J ALLERGY CLIN IMMUN, V132, P1019, DOI 10.1016/j.jaci.2013.08.040
   Cooper MS, 2012, J BONE MINER RES, V27, P2238, DOI 10.1002/jbmr.1753
   de Vrieze E, 2011, BONE, V48, P704, DOI 10.1016/j.bone.2010.12.017
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Gao JJ, 2016, ONCOTARGET, V7, P26966, DOI 10.18632/oncotarget.9034
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Hartmann K, 2016, PHYSIOL REV, V96, P409, DOI 10.1152/physrev.00011.2015
   Henneicke H, 2014, TRENDS ENDOCRIN MET, V25, P197, DOI 10.1016/j.tem.2013.12.006
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Hofbauer LC, 2009, MOL ENDOCRINOL, V23, P1525, DOI 10.1210/me.2009 0069
   Hou WS, 2001, AM J PATHOL, V159, P2167, DOI 10.1016/S0002 9440(10)63068 4
   Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084
   Kondegowda NG, 2015, CELL METAB, V22, P77, DOI 10.1016/j.cmet.2015.05.021
   Li GW, 2015, INT J CLIN EXP PATHO, V8, P15684
   Li H, 2015, CELL DEATH DIFFER, V22, P1935, DOI 10.1038/cdd.2015.99
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Piemontese M, 2015, BONE, V75, P18, DOI 10.1016/j.bone.2015.02.005
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Salazar VS, 2016, DEVELOPMENT, V143, P4352, DOI 10.1242/dev.136879
   Saunders MR, 2015, JAMA J AM MED ASSOC, V314, P615, DOI 10.1001/jama.2015.9425
   Sundaram K, 2007, EXP CELL RES, V313, P168, DOI 10.1016/j.yexcr.2006.10.001
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Yin YR, 2017, AM J TRANSL RES, V9, P5743
   Zhang LX, 2012, LANCET, V379, P815, DOI 10.1016/S0140 6736(12)60033 6
   Zhang YH, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006481
   Zhou H, 2008, J BIOL CHEM, V283, P1936, DOI 10.1074/jbc.M702687200
NR 30
TC 8
Z9 11
U1 0
U2 14
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943 8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2018
VL 10
IS 6
BP 1762
EP 1772
PG 11
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA GL8HJ
UT WOS:000437458800017
PM 30018717
DA 2025 08 17
ER

PT J
AU Chen, K
   Lv, ZT
   Cheng, P
   Zhu, WT
   Liang, S
   Yang, Q
   Parkman, VJA
   Zhou, CH
   Jing, XZ
   Liu, H
   Wang, YT
   Lin, H
   Liao, H
   Chen, AM
AF Chen, Kun
   Lv, Zheng tao
   Cheng, Peng
   Zhu, Wen tao
   Liang, Shuang
   Yang, Qing
   Parkman, Virginia Jeni Akila
   Zhou, Chen he
   Jing, Xing zhi
   Liu, Hui
   Wang, Yu ting
   Lin, Hui
   Liao, Hui
   Chen, An min
TI Boldine Ameliorates Estrogen Deficiency Induced Bone Loss via Inhibiting
   Bone Resorption
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE boldine; osteoporosis; teoclast; osteoblast; AKT
ID KAPPA B LIGAND; OSTEOCLAST DIFFERENTIATION; RECEPTOR ACTIVATOR;
   POSTMENOPAUSAL WOMEN; LITSEA CUBEBA; OSTEOPOROSIS; ABALOPARATIDE;
   EPIDEMIOLOGY; MECHANISMS; FRACTURES
AB Osteoporosis is an enormous health problem caused by the imbalance between bone resorption and bone formation. The current therapeutic strategies for osteoporosis still have some limitations. Boldine, an alkaloid isolated from Peumus boldus, has been shown to have antioxidant and anti inflammatory effects in vivo. For the first time, we discover that boldine has a protective effect for the estrogen deficiency induced bone loss in mice. According to the Micro CT and histomorphometry assays, boldine conducts this protective effect through inhibiting bone resorption without affecting bone formation in vivo. Moreover, we showed that boldine can inhibit receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast formation via impairing the AKT signaling pathways, while SC79 (an AKT agonist) partially rescue this effect. In conclusion, our results suggest that boldine can prevent estrogen deficiency induced osteoporosis by inhibiting osteoclastogenesis. Thus, boldine may be served as a novel therapeutic agent for anti osteoporotic therapy.
C1 [Chen, Kun; Lv, Zheng tao; Cheng, Peng; Zhu, Wen tao; Liang, Shuang; Yang, Qing; Jing, Xing zhi; Liu, Hui; Wang, Yu ting; Liao, Hui; Chen, An min] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Orthoped, Wuhan, Hubei, Peoples R China.
   [Chen, Kun; Cheng, Peng; Liang, Shuang; Liu, Hui; Wang, Yu ting; Chen, An min] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Biol Engn & Regenerat Med Ctr, Wuhan, Hubei, Peoples R China.
   [Chen, Kun; Parkman, Virginia Jeni Akila] Harvard Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA USA.
   [Zhou, Chen he] Zhejiang Univ, Dept Orthopaed Surg, Sch Med, Affiliated Hosp 2, Hangzhou, Zhejiang, Peoples R China.
   [Lin, Hui] Huazhong Univ Sci & Technol, Dept Orthopaed Surg, Wuhan Union Hosp, Tongi Med Coll, Wuhan, Hubei, Peoples R China.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology; Harvard University; Harvard School of Dental
   Medicine; Zhejiang University; Huazhong University of Science &
   Technology
RP Liao, H; Chen, AM (通讯作者)，Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Orthoped, Wuhan, Hubei, Peoples R China.; Chen, AM (通讯作者)，Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Biol Engn & Regenerat Med Ctr, Wuhan, Hubei, Peoples R China.
EM liaohui0001@yahoo.com; anminchen@hust.edu
RI Zhou, Chenhe/AAI 9226 2020; CHENG, PENG/HNP 4206 2023; Chen,
   Kun/AAG 9227 2021; liang, shuang/JOK 5869 2023; liao, hui/GSE 5758 2022
OI Chen, Kun/0000 0003 0507 7640; 
FU National Nature Science Foundation of China [81672168, 81472082];
   Natural Science Foundation of Hubei Province of China [2018CFB714]
FX This study was supported by research grants from the National Nature
   Science Foundation of China (Grant No. 81672168 and 81472082 to A mC)
   and the Natural Science Foundation of Hubei Province of China
   (2018CFB714 to W tZ).
CR [Anonymous], UROL ONCOL, DOI [10.1016/j.urolonc.2013.02.012, DOI 10.1016/J.UROLONC.2013.02.012]
   Bannach R, 1996, CELL BIOL TOXICOL, V12, P89, DOI 10.1007/BF00143359
   Bernabei R, 2014, CLIN CASES MINER BON, V11, P201, DOI 10.11138/ccmbm/2014.11.3.201
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Cauley JA, 2017, CURR OPIN RHEUMATOL, V29, P150, DOI 10.1097/BOR.0000000000000365
   Clohisy JC, 2004, J ORTHOPAED RES, V22, P13, DOI 10.1016/S0736 0266(03)00156 6
   D'Amelio P, 2008, BONE, V43, P92, DOI 10.1016/j.bone.2008.02.017
   Ghayor C, 2011, J BIOL CHEM, V286, P24458, DOI 10.1074/jbc.M111.223297
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   Jang YY, 2000, PHARMACOL RES, V42, P361, DOI 10.1006/phrs.2000.0705
   Ji Meng Xia, 2015, Chronic Dis Transl Med, V1, P9, DOI 10.1016/j.cdtm.2015.02.006
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Khosla S, 2012, J CLIN ENDOCR METAB, V97, P2272, DOI 10.1210/jc.2012 1027
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   KRINGSTEIN P, 1995, FREE RADICAL BIO MED, V18, P559, DOI 10.1016/0891 5849(94)E0138 9
   Lau YS, 2015, J CARDIOVASC PHARM, V65, P522, DOI 10.1097/FJC.0000000000000185
   Lee JW, 2010, BIOL PHARM BULL, V33, P1733, DOI 10.1248/bpb.33.1733
   Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Mori G, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/108451
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Pandurangan AK, 2016, BIOFACTORS, V42, P247, DOI 10.1002/biof.1267
   Pavone V, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00803
   Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219
   Rosen HN, 2000, CALCIFIED TISSUE INT, V66, P100, DOI 10.1007/PL00005830
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Shirley M, 2017, DRUGS, V77, P1363, DOI 10.1007/s40265 017 0780 7
   Tabatabaei Malazy O, 2017, DARU, V25, DOI 10.1186/s40199 017 0167 z
   Takahashi T, 2012, BIOL PHARM BULL, V35, P1765, DOI 10.1248/bpb.b12 00445
   Thurairaja R, 2006, UROL INT, V76, P67, DOI 10.1159/000089738
   Vahle JL, 2004, TOXICOL PATHOL, V32, P426, DOI 10.1080/01926230490462138
   Wang XP, 2018, PHYTOTHER RES, V32, P1354, DOI 10.1002/ptr.6069
   Whitaker M, 2012, NEW ENGL J MED, V366, P2048, DOI 10.1056/NEJMp1202619
   Willson T, 2015, CLIN EPIDEMIOL, V7, P65, DOI 10.2147/CLEP.S40966
   Yang XY, 2018, PLANTA MED, V84, P20, DOI 10.1055/s 0043 113447
   Zhao HY, 2017, INT IMMUNOPHARMACOL, V51, P114, DOI 10.1016/j.intimp.2017.08.013
   Zhou CH, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00210
NR 43
TC 18
Z9 19
U1 1
U2 26
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD SEP 13
PY 2018
VL 9
AR 1046
DI 10.3389/fphar.2018.01046
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GT3WT
UT WOS:000444435500001
PM 30271347
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Eun, SY
   Park, GD
   Cheon, YH
   Lee, MS
   Cho, HJ
   Kim, JY
AF Eun, So Young
   Park, Gyeong Do
   Cheon, Yoon Hee
   Lee, Myeung Su
   Cho, Hae Joong
   Kim, Ju Young
TI Inhibition of receptor activator of nuclear factor kappa B
   ligand mediated osteoclast differentiation and bone resorption by
   Gryllus bimaculatus extract: An in vitro study
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE bone disease; bone resorption; functional food; Gryllus bimaculatus
   extract; osteoclast
ID GRYLLODES SIGILLATUS; EDIBLE INSECTS; PROTEIN; CRICKET
AB Excessive bone resorbing osteoclast activity during bone remodeling is a major feature of bone diseases, such as osteoporosis. Therefore, the inhibition of osteoclast formation and bone resorption can be an effective therapeutic target for various bone diseases. Gryllus biomaculatus (GB) has recently been approved as an alternative food source because of its high nutritional value and environmental sustainability. Traditionally, GB has been known to have various pharmacological properties, including antipyretic and blood pressure lowering activity, and it has recently been reported to have various biological activities, including protective effects against inflammation, oxidative stress, insulin resistance, and alcohol induced liver injury. However, the effect of GB on osteoclast differentiation and bone metabolism has not yet been demonstrated. In this study, we confirmed the inhibitory effect of GB extract (GBE) on the receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast formation. To determine the effect of GBE on RANKL induced osteoclast differentiation and function, we performed TRAP and F actin staining, as well as a bone resorbing assay. The intracellular mechanisms of GBE responsible for the regulation of osteoclastogenesis were revealed by Western blot analysis and quantitative real time polymerase chain reaction. We investigated the relationship between GBE and expression of osteoclast specific molecules to further elucidate the underlying mechanisms. It was found that GBE significantly suppressed osteoclastogenesis by decreasing the phosphorylation of Akt, p38, JNK, and ERK, as well as Btk PLC gamma 2 signaling, in pathways involved in early osteoclastogenesis as well as through the subsequent suppression of c Fos, NFATc1, and osteoclastogenesis specific marker genes. Additionally, GBE inhibited the formation of F actin ring positive osteoclasts and bone resorption activity of mature osteoclasts. Our findings suggest that GBE is a potential functional food and therapeutic candidate for bone diseases involving osteoclasts.
C1 [Eun, So Young; Park, Gyeong Do; Cheon, Yoon Hee; Lee, Myeung Su; Cho, Hae Joong; Kim, Ju Young] Wonkwang Univ, Musculoskeletal & Immune Dis Res Inst, Sch Med, 460 Iksandae Ro, Iksan 54538, South Korea.
   [Lee, Myeung Su] Wonkwang Univ Hosp, Dept Internal Med, Div Rheumatol, Iksan, South Korea.
   [Cho, Hae Joong] Wonkwang Univ Hosp, Dept Obstet & Gynecol, 460 Iksandae Ro, Iksan 54538, South Korea.
C3 Wonkwang University; Wonkwang University; Wonkwang University
RP Cho, HJ; Kim, JY (通讯作者)，Wonkwang Univ, Musculoskeletal & Immune Dis Res Inst, Sch Med, 460 Iksandae Ro, Iksan 54538, South Korea.; Cho, HJ (通讯作者)，Wonkwang Univ Hosp, Dept Obstet & Gynecol, 460 Iksandae Ro, Iksan 54538, South Korea.
EM chohj69@hanmail.net; kimjy1014@gmail.com
RI ; Lee, Sang Hoon/ABH 6210 2020
OI Kim, Ju Young/0000 0002 4493 0264; 
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) funded by the Ministry of Education; Inventor
   [NRF 2021R1I1A1A01050411, NRF 2022R1C1C2010740]; Basic Science Research
   Program through the National Research Foundation of Korea (NRF)  
   Ministry of Education
FX "GBE" is a commercial Gryllus bimarculatus powder under the name "D&D"
   (Diabetes & Dietary). Inventor and patentee: Dr. Lee Sam Goo, South
   Korea. The authors would like to thank Dr. Lee Sam Goo for providing
   "GBE" powder. This study was supported by a grant from the Basic Science
   Research Program through the National Research Foundation of Korea (NRF)
   funded by the Ministry of Education (NRF 2021R1I1A1A01050411 and
   NRF 2022R1C1C2010740).
CR Acosta Estrada BA, 2021, FRONT NUTR, V8, DOI 10.3389/fnut.2021.687712
   Aguilar Toalá JE, 2022, INSECTS, V13, DOI 10.3390/insects13111007
   Ahn MY, 2014, J TOXICOL ENV HEAL A, V77, P1332, DOI 10.1080/15287394.2014.951591
   Akisaka T, 2001, J BONE MINER RES, V16, P1248, DOI 10.1359/jbmr.2001.16.7.1248
   [Anonymous], 2016, N Engl J Med, V374, P1797, DOI 10.1056/NEJMx160008
   BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cao HL, 2013, J BIOL CHEM, V288, P30399, DOI 10.1074/jbc.M113.469973
   Cao X, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0040 9
   Chen X, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00647
   Cito A, 2017, J INSECTS FOOD FEED, V3, P231, DOI [10.3920/JIFF2017.0017, 10.3920/jiff2017.0017]
   Cong Q, 2017, SCI REP UK, V7, DOI 10.1038/srep45964
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Dobermann D, 2017, NUTR BULL, V42, P293, DOI 10.1111/nbu.12291
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Escobar Ortiz A, 2022, J FOOD BIOCHEM, V46, DOI 10.1111/jfbc.14269
   FAO, 2021, Looking at edible insects from a food safety perspective: challenges and opportunities for the sector, P108, DOI [10.4060/cb4094 n, DOI 10.4060/CB4094 N]
   Fashakin OO, 2023, INSECTS, V14, DOI 10.3390/insects14080674
   Ganguly K, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0249291
   Hall F, 2020, NUTRIENTS, V12, DOI 10.3390/nu12113588
   Hall FG, 2017, FOOD CHEM, V224, P414, DOI 10.1016/j.foodchem.2016.11.138
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Kertész Z, 2012, EUR J CLIN INVEST, V42, P49, DOI 10.1111/j.1365 2362.2011.02556.x
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Lee JH, 2021, FOOD SCI BIOTECHNOL, V30, P1003, DOI 10.1007/s10068 021 00942 8
   Lee SH, 2008, J BIOL CHEM, V283, P11526, DOI 10.1074/jbc.M708935200
   Meunier PJ, 2009, OSTEOPOROSIS INT, V20, P1663, DOI 10.1007/s00198 008 0825 6
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Nemeth K, 2011, J IMMUNOL, V186, P13, DOI 10.4049/jimmunol.1002483
   Omata Y, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 45909 3
   Park SA, 2020, FOOD SCI NUTR, V8, P402, DOI 10.1002/fsn3.1323
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403
   Raheem D, 2019, FOOD RES INT, V126, DOI 10.1016/j.foodres.2019.108672
   Sigl V, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160230
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Väänänen HK, 2000, J CELL SCI, V113, P377
   Zielinska E, 2018, INT J FOOD SCI TECH, V53, P2542, DOI 10.1111/ijfs.13848
NR 39
TC 2
Z9 2
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD FEB
PY 2024
VL 125
IS 2
DI 10.1002/jcb.30518
EA JAN 2024
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA HR4D6
UT WOS:001143171500001
PM 38224182
DA 2025 08 17
ER

PT J
AU Sheehan, MT
   Wermers, RA
   Jatoi, A
   Loprinzi, CL
   Onitilo, AA
AF Sheehan, Michael T.
   Wermers, Robert A.
   Jatoi, Aminah
   Loprinzi, Charles L.
   Onitilo, Adedayo A.
TI Oral cinacalcet responsiveness in non parathyroid hormone mediated
   hypercalcemia of malignancy
SO MEDICAL HYPOTHESES
LA English
DT Article
ID CALCIUM SENSING RECEPTOR; 1,25 DIHYDROXYVITAMIN D; CALCITRIOL;
   METABOLISM; MECHANISMS; DIAGNOSIS; PATIENT; CA2+
AB Hypercalcemia of malignancy develops in approximately 20 30% of patients with advanced cancer and is an ominous sign. This condition is subdivided into three categories: i) humoral hypercalcemia of malignancy (80% of cases), mediated by systemic parathyroid hormone related protein; ii) osteolytic metastases (20% of cases), mediated by inflammatory cytokines locally released by tumor cells and/or peri tumor macrophages; and iii) ectopic production of 1,25 dihydroxyvitamin D (< 1% of cases), leading to intestinal hyperabsorption of calcium and increased osteoclastic bone resorption. Humoral hypercalcemia of malignancy is seen in a variety of solid tumors, while osteolytic metastases are most common in breast cancer and multiple myeloma. Hypercalcemia of malignancy mediated by 1,25 dihydroxyvitamin D is primarily seen in lymphomas, having only rarely been reported in solid tumors. Pharmacologic management of humoral hypercalcemia of malignancy and osteolytic metastases mainly involves inhibition of bone resorption with intravenous bisphosphonates, subcutaneous denosumab, and subcutaneous calcitonin. Glucocorticoid therapy is the mainstay for management of increased 1,25 dihydroxyvitamin D. Unfortunately, management of hypercalcemia of malignancy often requires inpatient admission in the acute setting, and loss of effectiveness of antiresorptive therapy is common. We propose oral cinacalcet may be an efficacious therapy for hypercalcemia of malignancy related to elevated 1,25 dihydroxyvitamin D, and we present supporting data from two cases involving solid tumors. Furthermore, we hypothesize that this effect is primarily mediated by cinacalcet's interaction with the calcium sensing receptor in the intestine with lesser effects at bone and kidney. Lastly, the role of 1,25 dihydroxyvitamin D in hypercalcemia malignancy may be underappreciated in solid tumors.
C1 [Sheehan, Michael T.] Weston Ctr, Dept Endocrinol, Marshfield Clin Hlth Syst, 3501 Cranberry Blvd, Weston, WI 54476 USA.
   [Wermers, Robert A.] Mayo Clin Rochester, Div Endocrinol Diabet Metab & Nutr, Dept Med, Rochester, MN USA.
   [Jatoi, Aminah; Loprinzi, Charles L.] Mayo Clin Rochester, Dept Oncol, Rochester, MN USA.
   [Onitilo, Adedayo A.] Weston Ctr, Dept Hematol & Oncol, Marshfield Clin Hlth Syst, Weston, WI USA.
C3 Mayo Clinic; Mayo Clinic
RP Sheehan, MT (通讯作者)，Weston Ctr, Dept Endocrinol, Marshfield Clin Hlth Syst, 3501 Cranberry Blvd, Weston, WI 54476 USA.
EM sheehan.michael@marshfieldclinic.org
CR AKAI PS, 1989, CLIN INVEST MED, V12, P212
   Asonitis Nikolaos, 2017, Endocrinol Diabetes Metab Case Rep, V2017, DOI 10.1530/EDM 17 0118
   Bech A, 2012, CASE REP ONCOL, V5, P1, DOI 10.1159/000335676
   Campbell SR, 2013, J AM SOC NEPHROL, V24
   Chukir T, 2020, J CLIN ENDOCR METAB, V105, P1
   Cianferotti L, 2015, OSTEOPOROSIS INT, V26, P2055, DOI 10.1007/s00198 015 3203 1
   DAVIES M, 1985, LANCET, V1, P1186
   Donovan PJ, 2013, J CLIN ENDOCR METAB, V98, P4023, DOI 10.1210/jc.2013 2016
   Evans KN, 2004, AM J PATHOL, V165, P807, DOI 10.1016/S0002 9440(10)63343 3
   Felsenfeld A, 2013, CURR OPIN NEPHROL HY, V22, P371, DOI 10.1097/MNH.0b013e328362141e
   Goltzman D, 2015, NAT REV ENDOCRINOL, V11, P298, DOI 10.1038/nrendo.2015.30
   Haussler MR, 2013, CALCIFIED TISSUE INT, V92, P77, DOI 10.1007/s00223 012 9619 0
   Hewison M, 2003, J BONE MINER RES, V18, P579, DOI 10.1359/jbmr.2003.18.3.579
   HOEKMAN K, 1991, CANCER, V68, P642, DOI 10.1002/1097 0142(19910801)68:3<642::AID CNCR2820680334>3.0.CO;2 A
   Hu MI, 2014, J CLIN ENDOCR METAB, V99, P3144, DOI 10.1210/jc.2014 1001
   Jeon Un Sil, 2008, Electrolyte Blood Press, V6, P68, DOI 10.5049/EBP.2008.6.2.68
   Lee JJ, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.128013
   Moorthi RN, 2013, KIDNEY INT, V84, P886, DOI 10.1038/ki.2013.254
   Osorio JC, 2017, BMJ CASE REP, V23017
   Sheehan M, 2020, CASE REP ONCOL, V13, P321, DOI 10.1159/000506100
   Shivnani SB, 2009, ENDOCR PRACT, V15, P234, DOI 10.4158/EP.15.3.234
   Sternlicht H, 2015, THER CLIN RISK MANAG, V11, P1779, DOI 10.2147/TCRM.S83681
   Stewart AF, 2005, NEW ENGL J MED, V352, P373, DOI 10.1056/NEJMcp042806
   Tebben PJ, 2016, ENDOCR REV, V37, P521, DOI 10.1210/er.2016 1070
   Tennakoon S, 2016, BBA MOL CELL RES, V1863, P1398, DOI 10.1016/j.bbamcr.2015.11.017
   van de Graaf SFJ, 2004, J STEROID BIOCHEM, V89 90, P303, DOI 10.1016/j.jsbmb.2004.03.029
   Van Den Eynden GG, 2007, BONE, V40, P1166, DOI 10.1016/j.bone.2006.11.009
   Vezzoli G, 2009, CURR PHARM BIOTECHNO, V10, P302, DOI 10.2174/138920109787847475
   Wein MN, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031237
   Wongdee K, 2018, ARCH BIOCHEM BIOPHYS, V657, P15, DOI 10.1016/j.abb.2018.09.004
   Woudenberg Vrenken TE, 2012, AM J PHYSIOL GASTR L, V303, pG879, DOI 10.1152/ajpgi.00089.2012
   Wright JD, 2015, CANCER INVEST, V33, P331, DOI 10.3109/07357907.2015.1047506
   YERGEY AL, 1994, J NUTR, V124, P674, DOI 10.1093/jn/124.5.674
   Zagzag J, 2018, CA CANCER J CLIN, V68, P377, DOI 10.3322/caac.21489
NR 34
TC 7
Z9 7
U1 0
U2 3
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306 9877
EI 1532 2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 110149
DI 10.1016/j.mehy.2020.110149
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800102
PM 32763659
DA 2025 08 17
ER

PT J
AU Tat, SK
   Pelletier, JP
   Amiable, N
   Boileau, C
   Lajeunesse, D
   Duval, N
   Martel Pelletier, J
AF Tat, Steeve Kwan
   Pelletier, Jean Pierre
   Amiable, Nathalie
   Boileau, Christelle
   Lajeunesse, Daniel
   Duval, Nicolas
   Martel Pelletier, Johanne
TI Activation of the Receptor EphB4 by Its Specific Ligand Ephrin B2 in
   Human Osteoarthritic Subchondral Bone Osteoblasts
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID GROWTH FACTOR BETA; NF KAPPA B; CYTOSKELETAL ORGANIZATION; COLLAGEN
   METABOLISM; ILIAC CREST; INTERLEUKIN 6; OSTEOCLASTS; EXPRESSION; RANKL;
   RESORPTION
AB Objective. Abnormal subchondral bone metabolism is involved in osteoarthritis (OA). It has been suggested that ephrin 132 and its specific receptor EphB4 participate in bone homeostasis. We previously reported that human OA subchondral bone osteoblasts could be classified into 2 subpopulations: low (L), having proresorption properties, and high (H), having proformation properties. The purpose of this study was to investigate the importance of the ephrin system in OA subchondral bone osteoblasts.
   Methods. The presence of the EphB4 receptor was determined by immunohistochemistry, and its expression level, modulation upon treatment, and consequences of activation by ephrin B2 were determined by quantitative polymerase chain reaction. The effects of ephrin 132 activation of the EphB4 receptor on bone resorption activity were also determined. EphB4 receptor activation signaling pathways were investigated by specific enzyme linked immunosorbent assay.
   Results. EphB4 receptors were present in subchondral bone osteoblasts and osteocytes. Compared with normal and H OA osteoblasts, EphB4 receptor expression levels were significantly increased in L OA osteoblasts, with no difference between normal and H OA osteoblasts. EphB4 receptor levels in L OA osteoblasts were significantly up regulated by prostaglandin E 2(PGE(2)) and interleukin 17 (IL 17). Ephrin B2, PGE(2), and IL 17 significantly inhibited bone resorption activity in these cells. EphB4 activation by ephrin B2 significantly inhibited the expression of IL 1 beta, IL 6, matrix metalloproteinase 1 (MMP 1), MMP 9, MMP 13, and RANK L, but not MMP 2 and osteoprotegerin. EphB4 receptor activation significantly inhibited the phosphatidylinositol 3 kinase/Akt pathway.
   Conclusion. This study is the first to provide evidence that EphB4 receptor activation by ephrin B2 in OA subchondral bone could affect abnormal metabolism in this tissue by inhibiting resorption factors and their activities. Ephrin B2 could be targeted as a specific therapeutic approach in the development of a disease modifying OA drug.
C1 [Martel Pelletier, Johanne] Univ Montreal, Ctr Hosp, Osteoarthrit Res Unit, Notre Dame Hosp, Montreal, PQ H2L 4M1, Canada.
   [Duval, Nicolas] Ctr Convalescence Pavillon Charmilles, Vimont, PQ, Canada.
C3 Universite de Montreal
RP Martel Pelletier, J (通讯作者)，Univ Montreal, Ctr Hosp, Osteoarthrit Res Unit, Notre Dame Hosp, 1560 Sherbrooke St E, Montreal, PQ H2L 4M1, Canada.
EM jm@martelpelletier.ca
RI Martel Pelletier, Johanne/AAG 2928 2019; boileau, catherine/M 4482 2017;
   Pelletier, Jean Pierre/AAG 2896 2019; Lajeunesse, Daniel/U 2223 2019
OI Lajeunesse, Daniel/0000 0001 6958 5906; 
FU ESCEO/Amgen; Mentor/Canadian Institutes of Health Research
FX Dr. Kwan Tat is recipient of Fellowship awards from ESCEO/Amgen and
   Mentor/Canadian Institutes of Health Research.
CR ALTMAN R, 1986, ARTHRITIS RHEUM US, V29, P1039, DOI 10.1002/art.1780290816
   Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200
   Bailey AJ, 1997, GERONTOLOGY, V43, P296
   Bettica P, 2002, ARTHRITIS RHEUM, V46, P3178, DOI 10.1002/art.10630
   Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551
   Delaissé JM, 2003, MICROSC RES TECHNIQ, V61, P504, DOI 10.1002/jemt.10374
   Dempster DW, 2005, J CELL BIOCHEM, V95, P139, DOI 10.1002/jcb.20388
   DEQUEKER J, 1993, ARTHRITIS RHEUM, V36, P1702, DOI 10.1002/art.1780361209
   DIEPPE P, 1993, ANN RHEUM DIS, V52, P557, DOI 10.1136/ard.52.8.557
   El Mabrouk M, 2007, BBA MOL CELL RES, V1773, P309, DOI 10.1016/j.bbamcr.2006.11.018
   Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309
   GEVERS G, 1989, J RHEUMATOL, V16, P660
   Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360
   Himanen JP, 2003, INT J BIOCHEM CELL B, V35, P130, DOI 10.1016/S1357 2725(02)00096 1
   Himanen JP, 2007, CURR OPIN CELL BIOL, V19, P534, DOI 10.1016/j.ceb.2007.08.004
   Iqbal J, 2005, BIOCHEM BIOPH RES CO, V328, P751, DOI 10.1016/j.bbrc.2004.12.087
   Ishibashi O, 2006, LIFE SCI, V79, P1657, DOI 10.1016/j.lfs.2006.05.024
   Itoh T, 2002, J IMMUNOL, V169, P2643, DOI 10.4049/jimmunol.169.5.2643
   Jimi E, 1999, EXP CELL RES, V247, P84, DOI 10.1006/excr.1998.4320
   Jimi E, 1999, J IMMUNOL, V163, P434
   Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Kudo O, 2003, BONE, V32, P1, DOI 10.1016/S8756 3282(02)00915 8
   Kusano K, 1998, ENDOCRINOLOGY, V139, P1338, DOI 10.1210/en.139.3.1338
   Laboux O, 2003, J HISTOCHEM CYTOCHEM, V51, P61, DOI 10.1177/002215540305100108
   Lajeunesse D, 2003, Mod Rheumatol, V13, P7, DOI 10.3109/s101650300001
   Lee SK, 2006, BONE, V38, P678, DOI 10.1016/j.bone.2005.10.011
   Mansell JP, 1997, BRIT J RHEUMATOL, V36, P16
   Mansell JP, 1998, J CLIN INVEST, V101, P1596, DOI 10.1172/JCI867
   Martel Pelletier J, 2001, BEST PRACT RES CL RH, V15, P805, DOI 10.1053/berh.2001.0195
   Massicotte F, 2006, BONE, V38, P333, DOI 10.1016/j.bone.2005.09.007
   Massicotte F, 2002, OSTEOARTHR CARTILAGE, V10, P491, DOI 10.1053/joca.2002.0528
   Mundy GR, 2006, CELL, V126, P441, DOI 10.1016/j.cell.2006.07.015
   Nakamura I, 2002, J IMMUNOL, V168, P5103, DOI 10.4049/jimmunol.168.10.5103
   Pelletier JP, 2004, BONE, V34, P527, DOI 10.1016/j.bone.2003.11.021
   Ra HJ, 2007, MATRIX BIOL, V26, P587, DOI 10.1016/j.matbio.2007.07.001
   RADIN EL, 1986, CLIN ORTHOP RELAT R, P34
   RADIN EL, 1972, LANCET, V1, P519
   RADIN EL, 1970, ARTHRITIS RHEUM, V13, P400, DOI 10.1002/art.1780130406
   Shakibaei M, 2007, BIOCHEM PHARMACOL, V73, P1434, DOI 10.1016/j.bcp.2007.01.005
   Stephen LJ, 2007, DEV BIOL, V302, P66, DOI 10.1016/j.ydbio.2006.08.058
   Takai S, 2006, HORM METAB RES, V38, P563, DOI 10.1055/s 2006 950502
   Take I, 2005, ENDOCRINOLOGY, V146, P5204, DOI 10.1210/en.2005 0451
   Tardif G, 2004, ARTHRITIS RHEUM US, V50, P2521, DOI 10.1002/art.20441
   Tat SK, 2008, CLIN EXP RHEUMATOL, V26, P295
   Tat SK, 2008, BONE, V43, P284, DOI 10.1016/j.bone.2008.04.006
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Zamora DO, 2006, CELL IMMUNOL, V242, P99, DOI 10.1016/j.cellimm.2006.10.001
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
NR 50
TC 49
Z9 51
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0004 3591
EI 1529 0131
J9 ARTHRITIS RHEUM US
JI Arthritis Rheum.
PD DEC
PY 2008
VL 58
IS 12
BP 3820
EP 3830
DI 10.1002/art.24029
PG 11
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 382EI
UT WOS:000261587500021
PM 19035475
DA 2025 08 17
ER

PT J
AU Iqbal, J
   Sun, L
   Cao, J
   Yuen, T
   Lu, P
   Bab, I
   Leu, NA
   Srinivasan, S
   Wagage, S
   Hunter, CA
   Nebert, DW
   Zaidi, M
   Avadhani, NG
AF Iqbal, Jameel
   Sun, Li
   Cao, Jay
   Yuen, Tony
   Lu, Ping
   Bab, Itai
   Leu, N. Adrian
   Srinivasan, Satish
   Wagage, Sagie
   Hunter, Christopher A.
   Nebert, Daniel W.
   Zaidi, Mone
   Avadhani, Narayan G.
TI Smoke carcinogens cause bone loss through the aryl hydrocarbon receptor
   and induction of Cyp1 enzymes
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE skeletal remodeling; bone formation; toxicology; osteoblast
ID OSTEOCLAST DIFFERENTIATION; CIGARETTE SMOKE; IN VITRO; METABOLISM;
   INHIBITION; AHR; RESORPTION; HEALTH; TARGET; CANCER
AB Smoking is a major risk factor for osteoporosis and fracture, but the mechanism through which smoke causes bone loss remains unclear. Here, we show that the smoke toxins benzo(a) pyrene (BaP) and 2,3,7,8 tetrachlorodibenzo p dioxin (TCDD) interact with the aryl hydrocarbon receptor (Ahr) to induce osteoclastic bone resorption through the activation of cytochrome P450 1a/1b (Cyp1) enzymes. BaP and TCDD enhanced osteoclast formation in bone marrow cell cultures and gavage with BaP stimulated bone resorption and osteoclastogenesis in vivo. The osteoclastogenesis triggered by BaP or RANK L was reduced in Ahr( / ) cells, consistent with the high bone mass noted in Ahr( / ) male mice. The receptor activator of NF kappa B ligand (RANK L) also failed to induce the expression of Cyp1 enzymes in Ahr( / ) cells. Furthermore, the osteoclastogenesis induced by TCDD was lower in Cyp1a1/1a2( / ) and Cyp1a1/1a2/1b1( / ) cultures, indicating that Ahr was upstream of the Cyp enzymes. Likewise, the pharmacological inhibition of the Cyp1 enzymes with tetramethylsilane or proadifen reduced osteoclastogenesis. Finally, deletion of the Cyp1a1, Cyp1a2, and Cyp1b1 in triple knockout mice resulted in reduced bone resorption and recapitulated the high bone mass phenotype of Ahr( / ) mice. Overall, the data identify the Ahr and Cyp1 enzymes not only in the pathophysiology of smoke induced osteoporosis, but also as potential targets for selective modulation by new therapeutics.
C1 [Iqbal, Jameel; Leu, N. Adrian; Srinivasan, Satish; Avadhani, Narayan G.] Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19147 USA.
   [Wagage, Sagie; Hunter, Christopher A.] Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19147 USA.
   [Iqbal, Jameel] Univ Penn, Perelman Sch Med, Dept Pathol, Philadelphia, PA 19147 USA.
   [Iqbal, Jameel; Sun, Li; Yuen, Tony; Lu, Ping; Zaidi, Mone] Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY 10029 USA.
   [Cao, Jay] USDA, Human Nutr Res Ctr, Grand Forks, ND 58201 USA.
   [Bab, Itai] Hebrew Univ Jerusalem, Bone Lab, IL 76100 Jerusalem, Israel.
   [Nebert, Daniel W.] Univ Cincinnati, Med Ctr, Dept Environm Hlth, Cincinnati, OH 45267 USA.
C3 University of Pennsylvania; University of Pennsylvania; University of
   Pennsylvania; Icahn School of Medicine at Mount Sinai; United States
   Department of Agriculture (USDA); Hebrew University of Jerusalem;
   University System of Ohio; University of Cincinnati
RP Zaidi, M (通讯作者)，Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY 10029 USA.
EM mone.zaidi@mssm.edu; nar ayan@vet.upenn.edu
RI ; NEBERT, Daniel W/JNS 0645 2023
OI Yuen, Tony/0009 0001 6000 8827; Zaidi, Mone/0000 0001 5911 9522
FU National Institutes of Health [DK80459, AG23176, AG40132, GM34883,
   CA22763, ES08147, ES014403, P30 ES06096]; US Department of Agriculture
   Agricultural Research Service Current Research Information System
   Program [5450 51000 046 00D]; Harriet Ellison Woodward Trust
FX This work was supported by National Institutes of Health Grants DK80459
   (to M.Z. and L. S.), AG23176 (to M.Z.), AG40132 (to M.Z.), GM34883 (to
   N.G.A.), CA22763 (to N.G.A.), and ES08147, ES014403, and P30 ES06096 (to
   D.W.N.). J.C. is supported by the US Department of Agriculture
   Agricultural Research Service Current Research Information System
   Program (5450 51000 046 00D). N.G.A. is supported by an endowment from
   the Harriet Ellison Woodward Trust.
CR Abe E, 2003, CELL, V115, P151, DOI 10.1016/S0092 8674(03)00771 2
   Bruno RD, 2007, BIOORGAN MED CHEM, V15, P5047, DOI 10.1016/j.bmc.2007.05.046
   DiNatale BC, 2011, MOL CARCINOGEN, V50, P173, DOI 10.1002/mc.20702
   Galván N, 2005, TOXICOL APPL PHARM, V202, P244, DOI 10.1016/j.taap.2004.06.026
   Galván N, 2003, TOXICOL APPL PHARM, V193, P84, DOI 10.1016/S0041 008X(03)00338 7
   Ilvesaro J, 2005, LIFE SCI, V77, P1351, DOI 10.1016/j.lfs.2005.01.027
   Jefcoate C R, 2000, J Natl Cancer Inst Monogr, P95
   Kagan R, 2012, J WOMENS HEALTH, V21, P975, DOI 10.1089/jwh.2011.3448
   Kanis JA, 2005, OSTEOPOROSIS INT, V16, P737, DOI 10.1007/s00198 004 1734 y
   Kasai A, 2006, CANCER RES, V66, P7143, DOI 10.1158/0008 5472.CAN 05 4541
   Kung MH, 2012, J CELL PHYSIOL, V227, P1062, DOI 10.1002/jcp.22819
   Labrecque MP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029545
   Lees RL, 2001, BONE, V28, P187, DOI 10.1016/S8756 3282(00)00433 6
   Lindsey S, 2012, STEM CELL REV REP, V8, P1223, DOI 10.1007/s12015 012 9384 5
   N'jai AU, 2011, MOL PHARMACOL, V79, P724, DOI 10.1124/mol.110.070631
   Naruse M, 2004, BIOCHEM PHARMACOL, V67, P119, DOI 10.1016/j.bcp.2003.08.038
   Nebert DW, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0431
   Nebert DW, 2008, J BIOL CHEM, V283, P36061, DOI 10.1074/jbc.R800053200
   Rapuri PB, 2000, BONE, V27, P429, DOI 10.1016/S8756 3282(00)00341 0
   Singh SUN, 2000, J ENDOCRINOL, V167, P183, DOI 10.1677/joe.0.1670183
   Sissung TM, 2006, MOL CANCER RES, V4, P135, DOI 10.1158/1541 7786.MCR 05 0101
   Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051
   Szulc P, 2002, J CLIN ENDOCR METAB, V87, P666, DOI 10.1210/jc.87.2.666
   Tsuchiya Y, 2005, CANCER LETT, V227, P115, DOI 10.1016/j.canlet.2004.10.007
   Uno S, 2006, MOL PHARMACOL, V69, P1103, DOI 10.1124/mol.105.021501
   Vogel CFA, 2009, BIOCHEM PHARMACOL, V77, P734, DOI 10.1016/j.bcp.2008.09.036
   Vogel CFA, 2011, ARCH BIOCHEM BIOPHYS, V512, P78, DOI 10.1016/j.abb.2011.05.011
   Voronov I, 2008, BIOCHEM PHARMACOL, V75, P2034, DOI 10.1016/j.bcp.2008.02.025
   Voronov I, 2005, BIOCHEM PHARMACOL, V70, P300, DOI 10.1016/j.bcp.2005.04.028
   Ward KD, 2001, CALCIFIED TISSUE INT, V68, P259, DOI 10.1007/BF02390832
   Wejheden C, 2010, TOXICOL SCI, V114, P48, DOI 10.1093/toxsci/kfp284
   Wipfli H, 2009, CLIN PHARMACOL THER, V86, P263, DOI 10.1038/clpt.2009.93
   World Health Organization Collaborating Centre for Metabolic Bone Disease, 2013, FRAX
   Yin XF, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756 9966 31 46
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
NR 35
TC 96
Z9 113
U1 0
U2 21
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 2
PY 2013
VL 110
IS 27
BP 11115
EP 11120
DI 10.1073/pnas.1220919110
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 185OF
UT WOS:000321978000059
PM 23776235
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Marie, PJ
AF Marie, PJ
TI Strontium ranelate: A physiological approach for optimizing bone
   formation and resorption
SO BONE
LA English
DT Article; Proceedings Paper
CT 2nd Joint Meeting of the
   European Calcified Tissue Society/International Bone and Mineral Society
CY JUN 25 29, 2005
CL Geneva, SWITZERLAND
SP European Calcified Tissue Soc, Int Bone & Mineral Soc, Eli Lilly & Co, Elsevier, Merck, Novartis, Nycomed, GlaxoSmithKline, Servier, Alliance Better Bone Hlth, Roche
DE bone resorption; bone formation; strontium ranelate
ID MICRODAMAGE ACCUMULATION; BIOMECHANICAL PROPERTIES; EXTRACELLULAR
   CALCIUM; MOLECULAR TARGET; TURNOVER; OSTEOBLASTS; S12911 2; RECEPTOR;
   WOMEN; MASS
AB Osteoporosis associated with estrogen deficiency results from an imbalance between bone resorption and formation, causing deterioration of bone architecture and decreased bone mass. Anti osteoporotic therapies that have been developed so far include either anticatabolic or anabolic drugs. Strontium ranelate is a newly developed drug that induces opposite effects on bone resorption and formation. This dual original mode of action was demonstrated in experimental studies on bone cells and pharmacological studies in animals. In vitro, strontium ranelate was shown to decrease bone resorption. This effect resulted from a decreased differentiation and resorbing activity of osteoclasts and increased osteoclast apoptosis. In contrast, strontium ranelate was shown to enhance preosteoblastic cell replication and collagen synthesis in culture without affecting bone mineralization. In vivo, strontium ranelate promoted bone formation and reduced bone resorption in intact mice, an effect which resulted in increased vertebral bone mass. Additionally, strontium ranelate was found to reduce resorption and long bone loss induced by hind limb immobilization in rats. Finally, strontium ranelate administration decreased bone resorption and maintained bone formation in adult ovariectomized rats, which resulted in prevention of bone loss. In clinical trials (Spinal Osteoporosis Therapeutic Intervention [SOTI]), bone alkaline phosphatase levels increased, whereas C cross linking telopeptide of type I collagen (CTX) levels decreased in patients treated with strontium ranelate compared with placebo at all time points. These pharmacological and clinical studies suggest that strontium ranelate acts by increasing bone formation and decreasing bone resorption and that these effects result in improved bone mass in vivo. (c) 2006 Elsevier Inc. All rights reserved.
C1 Univ Paris 07, Lariboisiere Hosp, F 75475 Paris 10, France.
C3 Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP);
   Hopital Universitaire Lariboisiere Fernand Widal   APHP
RP INSERM, U606, 2,Rue Ambroise Pare, F 75475 Paris 10, France.
EM pierre.marie@larib.inserm.fr
CR Ammann P, 2004, J BONE MINER RES, V19, P2012, DOI 10.1359/JBMR.040906
   Barbara A, 2004, METABOLISM, V53, P532, DOI 10.1016/j.metabol.2003.10.022
   Baron R, 2002, EUR J PHARMACOL, V450, P11, DOI 10.1016/S0014 2999(02)02040 X
   Brown EM, 2003, OSTEOPOROSIS INT, V14, pS25, DOI 10.1007/s00198 002 1343 6
   Buehler J, 2001, BONE, V29, P176, DOI 10.1016/S8756 3282(01)00484 7
   Canalis E, 1996, BONE, V18, P517, DOI 10.1016/8756 3282(96)00080 4
   Choudhary S, 2003, J BONE MINER RES, V18, P1813, DOI 10.1359/jbmr.2003.18.10.1813
   Coulombe J, 2004, BIOCHEM BIOPH RES CO, V323, P1184, DOI 10.1016/j.bbrc.2004.08.209
   Dahl SG, 2001, BONE, V28, P446, DOI 10.1016/S8756 3282(01)00419 7
   Delannoy P, 2002, METABOLISM, V51, P906, DOI 10.1053/meta.2002.33360
   Häuselmann HJ, 2003, OSTEOPOROSIS INT, V14, P2, DOI 10.1007/s00198 002 1301 3
   Hott M, 2003, BONE, V33, P115, DOI 10.1016/S8756 3282(03)00115 7
   Hurtel Lemaire A, 2005, BONE, V36, pS401
   Komatsubara S, 2004, J BONE MINER RES, V19, P999, DOI 10.1359/JBMR.040126
   Marie PJ, 2001, CALCIFIED TISSUE INT, V69, P121, DOI 10.1007/s002230010055
   MARIE PJ, 1993, J BONE MINER RES, V8, P607
   Marie PJ, 2005, OSTEOPOROSIS INT, V16, pS7, DOI 10.1007/s00198 004 1753 8
   Marie PJ, 1996, THERAPEUTICS USES OF TRACE ELEMENTS, P277
   Mashiba T, 2001, BONE, V28, P524, DOI 10.1016/S8756 3282(01)00414 8
   Mashiba T, 2001, BONE, V29, P271, DOI 10.1016/S8756 3282(01)00575 0
   Mentaverri R, 2005, BONE, V36, pS403
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   MODROWSKI D, 1993, AM J PHYSIOL, V264, pE190, DOI 10.1152/ajpendo.1993.264.2.E190
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Pi M, 2004, J BONE MINER RES, V19, P862, DOI 10.1359/JBMR.040114
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Takahashi N, 2003, J BONE MINER RES, V18, P1082, DOI 10.1359/jbmr.2003.18.6.1082
   Wattel A, 2005, BONE, V36, pS400
NR 30
TC 137
Z9 151
U1 0
U2 27
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD FEB
PY 2006
VL 38
IS 2
SU 1
BP 10
EP 14
DI 10.1016/j.bone.2005.07.029
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Endocrinology & Metabolism
GA 017JB
UT WOS:000235688800004
DA 2025 08 17
ER

PT J
AU Yang, DS
   Liu, T
   Jiang, GY
   Hu, XT
   Zheng, T
   Li, T
   Gao, Z
   Ouyang, ZX
   Zhu, BY
AF Yang, Daishui
   Liu, Tang
   Jiang, Guangyao
   Hu, Xuantao
   Zheng, Tao
   Li, Tao
   Gao, Zhi
   Ouyang, Zhengxiao
   Zhu, Baoyu
TI Senkyunolide H attenuates osteoclastogenesis and postmenopausal
   osteoporosis by regulating the NF κB, JNK and ERK signaling pathways
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Senkyunolide H; Osteoclast; NF kappa B; JNK; ERK; Osteoporosis
ID LIGUSTILIDE; PREVENTION; CHUANXIONG
AB Osteoporosis is a common disease characterized by reduced bone mineral density and impaired bone strength and is currently one of the leading causes of fracture and morbidity among the elderly worldwide. The pathological generation of osteoclasts is an important event in the development of extensive bone resorption. Thus, the development of a drug that targets osteoclasts may be beneficial in treating osteoporosis. Accordingly, in this study, we investigated the effects of senkyunolide H (SNH), an active component extracted from ligusticum chuanxiong Hort, on osteoporosis through a series of in vivo and in vitro experiments. First, we found that SNH had a therapeutic effect in ovariectomized mice by inhibiting osteoclast formation. Then, the inhibitory effect on osteoclast differentiation was confirmed in vitro. Further western blotting analysis revealed that SNH downregulated receptor activator of nuclear factor (NF) kappa B ligand induced NF kappa B signaling activation, c Jun N terminal kinase (JNK) in the mitogen activated protein kinase and extracellular signal regulated kinase (ERK) signaling pathway. These data indicated that SNH may be a potential treatment for postmenopausal osteoporosis. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Yang, Daishui; Liu, Tang; Jiang, Guangyao; Hu, Xuantao; Zheng, Tao; Li, Tao; Gao, Zhi; Ouyang, Zhengxiao] Cent South Univ, Dept Orthoped, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.
   [Zhu, Baoyu] Cent South Univ, Affiliated Zhuzhou Hosp, Dept Orthoped, Xiangya Med Coll, Zhuzhou 412007, Hunan, Peoples R China.
C3 Central South University; Central South University
RP Ouyang, ZX (通讯作者)，Cent South Univ, Dept Orthoped, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.; Zhu, BY (通讯作者)，Cent South Univ, Affiliated Zhuzhou Hosp, Dept Orthoped, Xiangya Med Coll, Zhuzhou 412007, Hunan, Peoples R China.
EM ouyangzhengxiao@csu.edu.cn; zhubaoyu101@163.com
RI Chen, Qinghao/AEC 9185 2022
FU National Natural Science Foundation of China for Youths [81702670];
   Natural Science Foundation of Hunan Province for Youth, China
   [2019JJ50883]
FX This work was supported by the National Natural Science Foundation of
   China for Youths (Grant No. 81702670), the Natural Science Foundation of
   Hunan Province for Youth, China (Grant No.2019JJ50883).
CR Anastasilakis AD, 2009, HORM METAB RES, V41, P721, DOI 10.1055/s 0029 1224109
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Casas A, 2013, BREAST, V22, P585, DOI 10.1016/j.breast.2013.05.007
   Chan SSK, 2007, J ETHNOPHARMACOL, V111, P677, DOI 10.1016/j.jep.2006.12.018
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Gambacciani M, 2014, PANMINERVA MED, V56, P115
   Han L, 2018, INT IMMUNOPHARMACOL, V63, P43, DOI 10.1016/j.intimp.2018.06.045
   He Y, 2014, BIOCHEM BIOPH RES CO, V449, P344, DOI 10.1016/j.bbrc.2014.05.034
   Hu XT, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00385
   Koga Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061346
   Li FS, 2017, NAT PLANTS, V3, DOI 10.1038/nplants.2017.109
   Luo YY, 2019, ENVIRON TOXICOL PHAR, V65, P73, DOI 10.1016/j.etap.2018.12.007
   Mohamed SGK, 2007, BONE, V41, P592, DOI 10.1016/j.bone.2007.05.016
   Rizzoli R, 2018, BEST PRACT RES CL EN, V32, P739, DOI 10.1016/j.beem.2018.09.005
   Rizzoli R, 2011, CALCIFIED TISSUE INT, V89, P91, DOI 10.1007/s00223 011 9499 8
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Tao XF, 2018, PHARMACOL RES, V137, P259, DOI 10.1016/j.phrs.2018.09.022
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Wang XY, 2020, FITOTERAPIA, V142, DOI 10.1016/j.fitote.2020.104482
   Wei Y, 2011, J SEP SCI, V34, P3426, DOI 10.1002/jssc.201100547
   Yin ZQ, 2019, EUR J PHARMACOL, V859, DOI 10.1016/j.ejphar.2019.172550
   Yu J, 2018, J CELL BIOCHEM, V119, P9334, DOI 10.1002/jcb.27212
   Zhang Q, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01028
   Zhu W, 2019, BIOCHEM BIOPH RES CO, V509, P294, DOI 10.1016/j.bbrc.2018.12.125
NR 25
TC 15
Z9 22
U1 0
U2 25
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD DEC 10
PY 2020
VL 533
IS 3
BP 510
EP 518
DI 10.1016/j.bbrc.2020.09.054
PG 9
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA OP7LW
UT WOS:000588268300037
PM 32977943
DA 2025 08 17
ER

PT J
AU Liu, BS
   Wang, AF
   Cao, ZH
   Li, JJ
   Zheng, M
   Xu, YJ
AF Liu, Baoshan
   Wang, Aifei
   Cao, Zihou
   Li, Junjie
   Zheng, Miao
   Xu, Youjia
TI 被撤回的出版物: Mechanism of Pilose Antler in Treatment of Osteoporosis Based
   on Network Pharmacology (Retracted Article)
SO JOURNAL OF HEALTHCARE ENGINEERING
LA English
DT Article; Retracted Publication
ID LIPID PROFILES; BONE LOSS; PEPTIDE; DIFFERENTIATION; OSTEOBLASTS; GENES;
   OSTEOCLASTOGENESIS; ASSOCIATION; ESTROGEN; WOMEN
AB Background. The purpose of this study was to demonstrate the pharmacodynamic material basis and molecular mechanism of pilose antler (PA) in the prevention and treatment of osteoporosis (OP) by the method of network pharmacology. Methods. First, the active components of PA were screened by BATMAN TCM database, and the component targets were obtained from the SwissTargetPrediction online tool. Moreover, the relevant target genes of OP were obtained by searching the DisGeNET database. Second, the Venn diagram was drawn to obtain the PA OP common targets, and the protein protein interaction (PPI) network and drug component target (D C T) network were constructed by Cytoscape software. Finally, the GO functional annotation and KEGG pathway enrichment analysis of common targets were performed using the Metascape online tool. Results. 82 common targets were identified by generating a Venn diagram. The PPI network of 82 common targets indicated that the top 5 nodal targets, including PIK3CA, MAPK1, ESR1, AKT1, and SRC, were strongly associated with other proteins. The D C T network suggested that the active components with high degree of connectivity include Prostaglandin E1, 17 Beta Estradiol, Alpha Estradiol, and Estrone. Furthermore, the GO enrichment analysis revealed that the biological process categories were dominated by response to peptide, cellular response to lipid, regulation of MAPK cascade, and so on. Additionally, the KEGG pathway analysis indicated the estrogen signaling pathway, osteoclast differentiation, and HIF 1 signaling pathway might have critical effects on the development of OP. Conclusion. The study shows that PA has the characteristics of multi component, multi target, and multi pathway in treating osteoporosis.
C1 [Liu, Baoshan; Wang, Aifei; Cao, Zihou; Li, Junjie; Xu, Youjia] Soochow Univ, Dept Orthopaed, Affiliated Hosp 2, Suzhou 215004, Peoples R China.
   [Liu, Baoshan; Wang, Aifei; Cao, Zihou; Li, Junjie; Xu, Youjia] Soochow Univ, Inst Osteoporosis Diag & Treatments, Suzhou 215004, Peoples R China.
   [Zheng, Miao; Xu, Youjia] Soochow Univ, Osteoporosis Clin Ctr, Affiliated Hosp 2, Suzhou 215004, Peoples R China.
C3 Soochow University   China; Soochow University   China; Soochow
   University   China
RP Xu, YJ (通讯作者)，Soochow Univ, Dept Orthopaed, Affiliated Hosp 2, Suzhou 215004, Peoples R China.; Xu, YJ (通讯作者)，Soochow Univ, Inst Osteoporosis Diag & Treatments, Suzhou 215004, Peoples R China.; Xu, YJ (通讯作者)，Soochow Univ, Osteoporosis Clin Ctr, Affiliated Hosp 2, Suzhou 215004, Peoples R China.
EM xuyj1232021@163.com
RI ; li, junjie/Y 7018 2018; liu, shaoqing/AAV 6981 2021; Wang,
   Aifei/GRR 8071 2022
OI Cao, Zihou/0000 0001 5423 6842; 
FU Health Leading Talents of Gusu City [GSWS2019004]; Clinical Medicine
   Technology Project of Jiangsu Province [BE2019661]; Natural Science
   Foundation of China [81874018]; Postgraduate Research & Practice
   Innovation Program of Jiangsu Province [KYCX21_2976]
FX This study was supported by grants from Health Leading Talents of Gusu
   City (GSWS2019004), Clinical Medicine Technology Project of Jiangsu
   Province (BE2019661), Natural Science Foundation of China (81874018),
   and Postgraduate Research & Practice Innovation Program of Jiangsu
   Province (KYCX21_2976).
CR [Anonymous], 1999, NUTR REV, V57, P192
   Carina V, 2020, CALCIFIED TISSUE INT, V107, P301, DOI 10.1007/s00223 020 00724 0
   Chen YY, 2018, EUR REV MED PHARMACO, V22, P1, DOI 10.26355/eurrev_201801_14093
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cui LH, 2005, OSTEOPOROSIS INT, V16, P1975, DOI 10.1007/s00198 005 1977 2
   Gfeller D, 2014, NUCLEIC ACIDS RES, V42, pW32, DOI 10.1093/nar/gku293
   Hidalgo Bravo A, 2019, CLIMACTERIC, V22, P97, DOI 10.1080/13697137.2018.1538339
   Hommann M, 2007, TRANSPL P, V39, P540, DOI 10.1016/j.transproceed.2006.12.016
   Hopkins AL, 2007, NAT BIOTECHNOL, V25, P1110, DOI 10.1038/nbt1007 1110
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Kierdorf U, 2011, GERONTOLOGY, V57, P53, DOI 10.1159/000300565
   Kim KW, 2008, J ETHNOPHARMACOL, V118, P280, DOI 10.1016/j.jep.2008.04.010
   Kim SB, 2021, NUTR RES PRACT, V15, P541, DOI 10.4162/nrp.2021.15.5.541
   Kim S, 2016, NUCLEIC ACIDS RES, V44, pD1202, DOI 10.1093/nar/gkv951
   Klein Nulend J, 2015, J BIOMECH, V48, P855, DOI 10.1016/j.jbiomech.2014.12.007
   Krela Kazmierczak I, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091306
   Krishnan A, 2017, J ENDOCRINOL, V232, pR99, DOI 10.1530/JOE 16 0405
   Landete Castillejos T, 2019, BONE, V128, DOI 10.1016/j.bone.2019.115046
   Li JB, 2017, J BONE MINER RES, V32, P962, DOI 10.1002/jbmr.3059
   Li R, 2021, BRIEF BIOINFORM, V22, P1279, DOI 10.1093/bib/bbaa300
   Li Y, 2018, CURR STEM CELL RES T, V13, P185, DOI 10.2174/1574888X12666171012141908
   Lin JH, 2011, J OCCUP MED TOXICOL, V6, DOI 10.1186/1745 6673 6 27
   Liu GW, 2017, BIOCHEM BIOPH RES CO, V491, P388, DOI 10.1016/j.bbrc.2017.07.091
   Liu N, 2022, MOL BIOL REP, V49, P577, DOI 10.1007/s11033 021 06794 z
   Liu ZY, 2016, SCI REP UK, V6, DOI 10.1038/srep21146
   Ma CH, 2017, INFLAMMATION, V40, P904, DOI 10.1007/s10753 017 0535 3
   Ma YG, 2021, SCI TOTAL ENVIRON, V750, DOI 10.1016/j.scitotenv.2020.141638
   Maggio D, 2006, BONE, V38, P244, DOI 10.1016/j.bone.2005.08.003
   Nakai S, 2020, J NUTR SCI VITAMINOL, V66, P502, DOI 10.3177/jnsv.66.502
   Piñero J, 2017, NUCLEIC ACIDS RES, V45, pD833, DOI 10.1093/nar/gkw943
   Ren C, 2019, CELL MOL BIOL, V65, P24, DOI 10.14715/cmb/2019.65.5.4
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034
   Wang Y, 2019, SCIENCE, V364, P1153, DOI 10.1126/science.aav6335
   WatanabeTomita Y, 1997, CELL SIGNAL, V9, P105, DOI 10.1016/S0898 6568(96)00114 3
   Xiao Y, 2019, EXP THER MED, V17, P2529, DOI 10.3892/etm.2019.7225
   Yamamoto N, 2015, PROSTAG OTH LIPID M, V116, P57, DOI 10.1016/j.prostaglandins.2015.01.003
   Yang CH, 2017, INT J BIOL MACROMOL, V99, P15, DOI 10.1016/j.ijbiomac.2017.02.056
   Yang TL, 2020, NAT REV ENDOCRINOL, V16, P91, DOI 10.1038/s41574 019 0282 7
   Yun CJ, 2020, EXP THER MED, V19, P923, DOI 10.3892/etm.2019.8286
   Zheng HY, 2020, TOXICOL APPL PHARM, V409, DOI 10.1016/j.taap.2020.115271
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
NR 42
TC 4
Z9 5
U1 0
U2 21
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2040 2295
EI 2040 2309
J9 J HEALTHC ENG
JI J. Healthc. Eng.
PD MAR 30
PY 2022
VL 2022
AR 5298892
DI 10.1155/2022/5298892
PG 7
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI EXPANDED)
SC Health Care Sciences & Services
GA 2Q1JL
UT WOS:000820184200003
PM 35399830
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Oh, Y
   Ahn, CB
   Je, JY
AF Oh, Yunok
   Ahn, Chang Bum
   Je, Jae Young
TI Blue Mussel Derived Peptides PIISVYWK and FSVVPSPK Trigger Wnt/β Catenin
   Signaling Mediated Osteogenesis in Human Bone Marrow Mesenchymal Stem
   Cells
SO MARINE DRUGS
LA English
DT Article
DE osteogenic peptides; osteoblast differentiation; Wnt/beta catenin
   signaling; human mesenchymal stem cells
ID BIOACTIVE PEPTIDES; OSTEOBLAST DIFFERENTIATION; WNT; PROTEIN;
   ANTIOXIDANT; PURIFICATION; HYDROLYSATE; METABOLISM; ACTIVATION; PATHWAYS
AB Marine derived bioactive peptides have shown potential bone health promoting effects. Although various marine derived bioactive peptides have potential nutraceutical or pharmaceutical properties, only a few of them are commercially available. This study presented an osteogenic mechanism of blue mussel derived peptides PIISVYWK and FSVVPSPK as potential bone health promoting agents in human bone marrow derived mesenchymal stem cells (hBMMSCs). Alkaline phosphatase (ALP) activity and mineralization were stimulated using PIISVYWK and FSVVPSPK as early and late markers of osteogenesis in a concentration dependent manner. Western blot and RT qPCR results revealed that PIISVYWK and FSVVPSPK increased osteoblast differentiation of hBMMSCs by activating canonical Wnt/beta catenin signaling related proteins and mRNAs. Immunofluorescence images confirmed nuclear translocation of beta catenin in osteogenic differentiation. Treatment with the pharmacological inhibitor DKK 1 blocked PIISVYWK  and FSVVPSPK induced ALP activity and mineralization, as well as mRNA expression of the canonical Wnt/beta catenin signaling pathway in hBMMSC differentiation into osteoblasts. These findings suggested that PIISVYWK and FSVVPSPK promoted the canonical Wnt/beta catenin signaling pathway in osteogenesis of hBMMSCs. Blue mussel derived PIISVYWK and FSVVPSPK might help develop peptide based therapeutic agents for bone related diseases.
C1 [Oh, Yunok] Pukyong Natl Univ, Inst Marine Life Sci, Busan 48613, South Korea.
   [Ahn, Chang Bum] Chonnam Natl Univ, Div Food & Nutr, Gwangju 61186, South Korea.
   [Je, Jae Young] Pukyong Natl Univ, Dept Marine Bio Convergence Sci, Busan 48547, South Korea.
C3 Pukyong National University; Chonnam National University; Pukyong
   National University
RP Je, JY (通讯作者)，Pukyong Natl Univ, Dept Marine Bio Convergence Sci, Busan 48547, South Korea.
EM si565@daum.net; a321@jnu.ac.kr; jjy1915@pknu.ac.kr
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Education [NRF 2016R1A2B4016004]
FX This study was supported by the Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education (NRF 2016R1A2B4016004).
CR Ahn CB, 2019, J FOOD BIOCHEM, V43, DOI 10.1111/jfbc.12529
   Blair HC, 2017, TISSUE ENG PART B RE, V23, P268, DOI [10.1089/ten.teb.2016.0454, 10.1089/ten.TEB.2016.0454]
   Ngo DH, 2012, INT J BIOL MACROMOL, V51, P378, DOI 10.1016/j.ijbiomac.2012.06.001
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Elango J, 2019, CELLS BASEL, V8, DOI 10.3390/cells8050446
   Fan XD, 2014, J AGR FOOD CHEM, V62, P9211, DOI 10.1021/jf502420h
   Funck Brentano T, 2014, ARTHRITIS RHEUMATOL, V66, P3028, DOI 10.1002/art.38799
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   박삼국, 2016, [journal of korean foot and ankle society, 대한족부족관절학회지], V20, P88
   Hyung JH, 2018, FOOD CHEM, V242, P156, DOI 10.1016/j.foodchem.2017.09.043
   Hyung JH, 2017, RSC ADV, V7, P6223, DOI 10.1039/c6ra24995g
   Hyung JH, 2016, RSC ADV, V6, P29365, DOI 10.1039/c6ra00898d
   Karner CM, 2017, CELL MOL LIFE SCI, V74, P1649, DOI 10.1007/s00018 016 2425 5
   Kim SS, 2018, FOOD BIOSCI, V25, P128, DOI 10.1016/j.fbio.2018.08.010
   Kobayashi Y, 2008, JPN DENT SCI REV, V44, P76, DOI 10.1016/j.jdsr.2007.11.002
   Lee HW, 2008, J BONE MINER RES, V23, P1227, DOI 10.1359/JBMR.080325
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Majidinia M, 2018, J CELL PHYSIOL, V233, P2937, DOI 10.1002/jcp.26042
   Majumdar MK, 1998, J CELL PHYSIOL, V176, P57, DOI 10.1002/(SICI)1097 4652(199807)176:1<57::AID JCP7>3.0.CO;2 7
   Moorer MC, 2018, ENDOCRINOL METAB, V33, P318, DOI 10.3803/EnM.2018.33.3.318
   Oh Y, 2020, J FOOD BIOCHEM, V44, DOI 10.1111/jfbc.13440
   Oh Y, 2019, TOXICOL APPL PHARM, V385, DOI 10.1016/j.taap.2019.114779
   Oh Y, 2019, NUTR CANCER, V71, P118, DOI 10.1080/01635581.2018.1540717
   Oh Y, 2019, MAR DRUGS, V17, DOI 10.3390/md17020135
   Oh Y, 2018, BIOMED PHARMACOTHER, V108, P103, DOI 10.1016/j.biopha.2018.08.143
   Park SY, 2016, J AQUAT FOOD PROD T, V25, P1266, DOI 10.1080/10498850.2015.1054539
   Peng SL, 2009, CELL PHYSIOL BIOCHEM, V23, P165, DOI 10.1159/000204105
   Pérez MJ, 2016, MAR DRUGS, V14, DOI 10.3390/md14030052
   Reid IR, 2008, SEMIN CELL DEV BIOL, V19, P473, DOI 10.1016/j.semcdb.2008.08.002
   Ruiz Ruiz F, 2017, PROTEIN PEPTIDE LETT, V24, P109, DOI 10.2174/0929866523666160802155347
   Sanna G, 2005, ANN ONCOL, V16, P1207, DOI 10.1093/annonc/mdi206
   Tao K, 2016, TOXICOL LETT, V240, P68, DOI 10.1016/j.toxlet.2015.10.007
   Xia GH, 2015, J FUNCT FOODS, V15, P137, DOI 10.1016/j.jff.2015.03.021
   Yun HM, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.185
   Zhang JF, 2010, MOL CELL ENDOCRINOL, V314, P70, DOI 10.1016/j.mce.2009.08.012
   Zhang M, 2018, EUR REV MED PHARMACO, V22, P2896, DOI 10.26355/eurrev_201805_14992
NR 36
TC 24
Z9 25
U1 3
U2 18
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1660 3397
J9 MAR DRUGS
JI Mar. Drugs
PD OCT
PY 2020
VL 18
IS 10
AR 510
DI 10.3390/md18100510
PG 12
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA OM6MR
UT WOS:000586136800001
PM 33050263
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Weinstein, RS
   Roberson, PK
   Manolagas, SC
AF Weinstein, Robert S.
   Roberson, Paula K.
   Manolagas, Stavros C.
TI Giant Osteoclast Formation and Long Term Oral Bisphosphonate Therapy
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID AUTOSOMAL DOMINANT OSTEOPETROSIS; BONE LOSS; ALENDRONATE; OSTEOPOROSIS;
   METABOLISM; HISTOMORPHOMETRY; OSTEOCALCIN; RISEDRONATE
AB Background Bisphosphonates decrease bone resorption and are commonly used to treat or prevent osteoporosis. However, the effect of bisphosphonates on their target cells remains enigmatic, since in patients benefiting from therapy, little change, if any, has been observed in the number of osteoclasts, which are the cells responsible for bone resorption.
   Methods We examined 51 bone  biopsy specimens obtained after a 3  year, double  blind, randomized, placebo  controlled, dose  ranging trial of oral alendronate to prevent bone resorption among healthy postmenopausal women 40 through 59 years of age. The patients were assigned to one of five groups: those receiving placebo for 3 years; alendronate at a dose of 1, 5, or 10 mg per day for 3 years; or alendronate at a dose of 20 mg per day for 2 years, followed by placebo for 1 year. Formalin  fixed, undecalcified planar sections were assessed by bone histomorphometric methods.
   Results The number of osteoclasts was increased by a factor of 2.6 in patients receiving 10 mg of alendronate per day for 3 years as compared with the placebo group ( P< 0.01). Moreover, the number of osteoclasts increased as the cumulative dose of the drug increased ( r = 0.50, P< 0.001). Twenty  seven percent of these osteoclasts were giant cells with pyknotic nuclei that were adjacent to superficial resorption cavities. Furthermore, giant, hypernucleated, detached osteoclasts with 20 to 40 nuclei were found after alendronate treatment had been discontinued for 1 year. Of these large cells, 20 to 37% were apoptotic, according to both their morphologic features and positive findings from in situ end labeling.
   Conclusions Long  term alendronate treatment is associated with an increase in the number of osteoclasts, which include distinctive giant, hypernucleated, detached osteoclasts that are undergoing protracted apoptosis.
C1 [Weinstein, Robert S.; Manolagas, Stavros C.] Univ Arkansas Med Sci, Div Endocrinol & Metab, Little Rock, AR 72205 USA.
   [Weinstein, Robert S.; Roberson, Paula K.; Manolagas, Stavros C.] Univ Arkansas Med Sci, Ctr Osteoporosis & Metab Bone Dis, Little Rock, AR 72205 USA.
   [Weinstein, Robert S.; Manolagas, Stavros C.] Univ Arkansas Med Sci, Dept Internal Med, Little Rock, AR 72205 USA.
   [Roberson, Paula K.] Univ Arkansas Med Sci, Dept Biostat, Little Rock, AR 72205 USA.
   [Weinstein, Robert S.; Manolagas, Stavros C.] Univ Arkansas Med Sci, Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences;
   University of Arkansas System; University of Arkansas Medical Sciences;
   University of Arkansas System; University of Arkansas Medical Sciences;
   University of Arkansas System; University of Arkansas Medical Sciences;
   US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Central Arkansas Veterans Healthcare System; University of Arkansas
   System; University of Arkansas Medical Sciences
RP Weinstein, RS (通讯作者)，Univ Arkansas Med Sci, Div Endocrinol & Metab, 4301 W Markham St,Slot 587, Little Rock, AR 72205 USA.
EM weinsteinroberts@uams.edu
FU Department of Veterans Affairs Merit Review Grants; National Institutes
   of Health, and Tobacco Settlement Funds [P01 AG13918]; College of
   Medicine of the University of Arkansas for Medical Sciences
FX Supported by the Department of Veterans Affairs Merit Review Grants, a
   grant (P01 AG13918) from the National Institutes of Health, and Tobacco
   Settlement Funds provided by the College of Medicine of the University
   of Arkansas for Medical Sciences. The original clinical trial, which
   included transilial bone biopsy specimens, was supported by Merck.No
   potential conflict of interest relevant to this article was reported.We
   thank Tony Chambers, Erin Hogan, William Webb, and Chester Wicker III
   for their technical support; Michael Parfitt for helpful discussions;
   and Charles O'Brien and Robert Jilka for their careful reading of an
   earlier version of the manuscript.
CR Balemans W, 2005, CALCIFIED TISSUE INT, V77, P263, DOI 10.1007/s00223 005 0027 6
   BALENA R, 1993, J CLIN INVEST, V92, P2577, DOI 10.1172/JCI116872
   Boissy P, 2002, ENDOCRINOLOGY, V143, P1913, DOI 10.1210/en.143.5.1913
   BOLLERSLEV J, 1989, ENDOCR REV, V10, P45, DOI 10.1210/edrv 10 1 45
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Bone HG, 1997, J CLIN ENDOCR METAB, V82, P265, DOI 10.1210/jc.82.1.265
   Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668
   Dempster DW, 2007, J BONE MINER RES, V22, pS29
   FALLON MD, 1983, LAB INVEST, V49, P159
   Fisher JE, 2000, ENDOCRINOLOGY, V141, P4793, DOI 10.1210/en.141.12.4793
   Fleisch H, 2000, BISPHOSPHONATES BONE, P42
   GUNDBERG CM, 1986, J CLIN INVEST, V77, P1762, DOI 10.1172/JCI112499
   Halasy Nagy JM, 2001, BONE, V29, P553, DOI 10.1016/S8756 3282(01)00615 9
   Jilka RL, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 1, 3RD EDITION, P237, DOI 10.1016/B978 0 12 373884 4.00032 X
   KANIS JA, 1991, PATHOPHYSIOLOGY TREA, P26
   Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935
   KOUSTENI S, 2003, SCIENCE, V299, P1184
   Li CY, 2005, BONE, V37, P287, DOI 10.1016/j.bone.2005.04.041
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Lorget F, 2000, BIOCHEM BIOPH RES CO, V268, P899, DOI 10.1006/bbrc.2000.2229
   McClung M, 1998, ANN INTERN MED, V128, P253, DOI 10.7326/0003 4819 128 4 199802150 00001
   MILLER SC, 1977, CALC TISS RES, V22, P243, DOI 10.1007/BF02010363
   Muche B, 2003, J BONE MINER RES, V18, pS371
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Nielsen RH, 2007, BIOCHEM BIOPH RES CO, V360, P834, DOI 10.1016/j.bbrc.2007.06.145
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Orwoll E, 2000, NEW ENGL J MED, V343, P604, DOI 10.1056/NEJM200008313430902
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Rauch F, 2002, J CLIN INVEST, V110, P1293, DOI 10.1172/JCI200215952
   Recker R R, 2004, Osteoporos Int, V15, P231, DOI 10.1007/s00198 003 1530 0
   REITSMA PH, 1980, CALCIFIED TISSUE INT, V32, P145, DOI 10.1007/BF02408534
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502
   *SAS I, 2002, SAS STAT VERS 9 1
   Semba I, 2000, BONE, V27, P389, DOI 10.1016/S8756 3282(00)00330 6
   SPJUT HJ, 1971, ATLAS TUMOR PATHOLOG
   *STAT CORP, 2005, STATCORP STAT STAT S
   Weinstein RS, 2007, J BONE MINER RES, V22, pS17
   Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538
   WEINSTEIN RS, 1988, NEW ENGL J MED, V319, P1698, DOI 10.1056/NEJM198812293192603
   Weinstein RS, 2004, ENDOCRINOLOGY, V145, P1980, DOI 10.1210/en.2003 1133
   WEINSTEIN RS, 1982, CALCIFIED TISSUE INT, V34, P224, DOI 10.1007/BF02411241
   Whyte MP, 2003, NEW ENGL J MED, V349, P457, DOI 10.1056/NEJMoa023110
   Woo SB, 2006, ANN INTERN MED, V145, P235, DOI 10.7326/0003 4819 145 10 200611210 00023
NR 45
TC 294
Z9 329
U1 1
U2 26
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451 1413 USA
SN 0028 4793
EI 1533 4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JAN 1
PY 2009
VL 360
IS 1
BP 53
EP 62
DI 10.1056/NEJMoa0802633
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 389MI
UT WOS:000262096800007
PM 19118304
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Dong, X
   Bi, L
   He, S
   Meng, GL
   Wei, BY
   Jia, SJ
   Liu, J
AF Dong, Xin
   Bi, Long
   He, Shu
   Meng, Guolin
   Wei, Boyuan
   Jia, Shuaijun
   Liu, Jian
TI FFAs ROS ERK/P38 pathway plays a key role in adipocyte lipotoxicity on
   osteoblasts in co culture
SO BIOCHIMIE
LA English
DT Article
DE Adipocyte; Osteoblast; Lipotoxicity; Reactive oxygen species; Free fatty
   acids; Extracellular signal regulated kinase; P38
ID ANTIDIABETIC DRUG METFORMIN; ACTIVATED PROTEIN KINASE; FATTY ACIDS;
   INDUCED OSTEOPOROSIS; ADIPOSE TISSUE; BONE; DIFFERENTIATION; LIPOLYSIS;
   CELLS; MARROW
AB The accumulation of adipocytes in bone marrow is common in a variety of pathophysiological conditions, including obesity, insulin resistance, type 2 diabetes, and aging. Adipocytes in bone marrow exhibit severe adverse effect on osteoblast differentiation, proliferation, and function. However, the molecular mechanism of adipocytes lipotoxicity on osteoblasts is still far from completely understood. The present study was designed to investigate the signaling pathway responsible for adipocytes lipotoxicity on osteoblasts. Using a co culture system, we have identified that free fatty acids (FFAs) released by the adipocytes inhibited osteoblasts proliferation and function and induced osteoblasts apoptosis, evidenced by decreased cell viability/proliferation, ALP activity, expression of runt related transcription factor 2 (RunX2), type I collagen (ColA1) and osteocalcin and alizarin red staining. Dexamethasone (Dex) promoted the inhibitory effect of adipocytes on osteoblasts through stimulating FFAs release. Dexexacerbated FFAs release from adipocytes contributes to reactive oxygen species (ROS) production. In the co culture system, the phosphorylation of extracellular signal regulated kinase (ERK)/P38 was increased and inhibition of ERK/P38 significantly suppressed adipocytes lipotoxicity. FFAs generated ROS was responsible for adipocytes induced activation of ERK/P38 signaling. In conclusion, FFAs ROS ERK/ P38 pathway plays a key role in adipocyte lipotoxicity on osteoblasts in co culture. The evidence provides new insights into the mechanisms underlying the lipotoxic effect of adipocytes on bone within the marrow microenvironment and prevention of lipotoxicity on bone metabolism. (c) 2014 Elsevier Masson SAS. All rights reserved.
C1 [Dong, Xin; Bi, Long; He, Shu; Meng, Guolin; Wei, Boyuan; Jia, Shuaijun; Liu, Jian] Fourth Mil Med Univ, Xijing Hosp, Inst Orthoped Surg, Xian 710032, Shaanxi, Peoples R China.
C3 Air Force Medical University
RP Liu, J (通讯作者)，Fourth Mil Med Univ, Xijing Hosp, Inst Orthoped Surg, 15 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.
EM ljreny@fmmu.edu.cn
FU 863 High Tech Project [2012AA020502 6]
FX This work was supported by 863 High Tech Project (No. 2012AA020502 6)
CR Almeida M, 2010, MOL ENDOCRINOL, V24, P2030, DOI 10.1210/me.2010 0189
   Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073
   Bredella MA, 2009, J CLIN ENDOCR METAB, V94, P2129, DOI 10.1210/jc.2008 2532
   BURKHARDT R, 1987, BONE, V8, P157, DOI 10.1016/8756 3282(87)90015 9
   Cartwright MJ, 2007, EXP GERONTOL, V42, P463, DOI 10.1016/j.exger.2007.03.003
   Cnop M, 2001, DIABETES, V50, P1771, DOI 10.2337/diabetes.50.8.1771
   Cortizo AM, 2006, EUR J PHARMACOL, V536, P38, DOI 10.1016/j.ejphar.2006.02.030
   Corwin RL, 2006, J NUTR, V136, P159, DOI 10.1093/jn/136.1.159
   DIVERTIE GD, 1991, DIABETES, V40, P1228, DOI 10.2337/diabetes.40.10.1228
   Duque G, 2008, CURR OPIN RHEUMATOL, V20, P429, DOI 10.1097/BOR.0b013e3283025e9c
   Elbaz A, 2010, J CELL MOL MED, V14, P982, DOI 10.1111/j.1582 4934.2009.00751.x
   Flechtner Mors M, 1999, DIABETIC MED, V16, P1000, DOI 10.1046/j.1464 5491.1999.00189.x
   Gao Y, 2010, EUR J PHARMACOL, V635, P231, DOI 10.1016/j.ejphar.2010.02.051
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Gunstone F.D., 2007, The Lipid Handbook With CD ROM
   He J, 2012, CANCER RES, V72, P6393, DOI 10.1158/0008 5472.CAN 12 2664
   Hu YY, 2003, ENDOCRINOLOGY, V144, P2068, DOI 10.1210/en.2002 220863
   Kanazawa I, 2008, BIOCHEM BIOPH RES CO, V375, P414, DOI 10.1016/j.bbrc.2008.08.034
   Kirchgatterer A, 2000, ACTA MED AUST, V27, P23, DOI 10.1046/j.1563 2571.2000.00105.x
   Koo KH, 1999, CLIN ORTHOP RELAT R, P159
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Lecka Czernik B, 2002, ENDOCRINOLOGY, V143, P2376, DOI 10.1210/en.143.6.2376
   Macfarlane DP, 2008, J ENDOCRINOL, V197, P189, DOI 10.1677/JOE 08 0054
   Mai QG, 2011, J CELL BIOCHEM, V112, P2902, DOI 10.1002/jcb.23206
   MANISCALCO WM, 1985, PEDIATR RES, V19, P1272, DOI 10.1203/00006450 198512000 00010
   Maurin AC, 2002, BONE, V31, P260, DOI 10.1016/S8756 3282(02)00805 0
   Maurin AC, 2000, BONE, V26, P485, DOI 10.1016/S8756 3282(00)00252 0
   MAYOSMITH W, 1989, RADIOLOGY, V170, P835, DOI 10.1148/radiology.170.3.2916039
   MEUNIER P, 1971, CLIN ORTHOP RELAT R, P147, DOI 10.1097/00003086 197110000 00021
   Mu YM, 2001, ENDOCRINOLOGY, V142, P3590, DOI 10.1210/en.142.8.3590
   Ren TT, 2006, J MOL ENDOCRINOL, V37, P175, DOI 10.1677/jme.1.02061
   Rosca MG, 2012, DIABETES, V61, P2074, DOI 10.2337/db11 1437
   Sheng Hui H, 2007, J Orthop Surg Res, V2, P15, DOI 10.1186/1749 799X 2 15
   SOLOMON L, 1981, CAN J SURG, V24, P573
   Tang DG, 2002, BIOL CHEM, V383, P425, DOI 10.1515/BC.2002.046
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
   Wang DQ, 2013, BONE, V53, P520, DOI 10.1016/j.bone.2013.01.009
   Wang X, 2010, J ETHNOPHARMACOL, V127, P424, DOI 10.1016/j.jep.2009.10.022
   Wang X, 2013, CARCINOGENESIS, V34, P1323, DOI 10.1093/carcin/bgt058
   Wang X, 2012, BIOCHIMIE, V94, P1705, DOI 10.1016/j.biochi.2012.03.024
   Wang XY, 2007, ENDOCRINOLOGY, V148, P1629, DOI 10.1210/en.2006 1000
   Xu C, 2009, MOL ENDOCRINOL, V23, P1161, DOI 10.1210/me.2008 0464
   Zhang TT, 2009, J MOL ENDOCRINOL, V42, P57, DOI 10.1677/JME 08 0130
   Zhao LJ, 2008, J BONE MINER RES, V23, P17, DOI 10.1359/JBMR.070813
   Zhao LJ, 2007, J CLIN ENDOCR METAB, V92, P1640, DOI 10.1210/jc.2006 0572
NR 45
TC 43
Z9 51
U1 1
U2 23
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0300 9084
EI 1638 6183
J9 BIOCHIMIE
JI Biochimie
PD JUN
PY 2014
VL 101
BP 123
EP 131
DI 10.1016/j.biochi.2014.01.002
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA AH4PD
UT WOS:000336109600014
PM 24424405
DA 2025 08 17
ER

PT J
AU Ha, H
   Shim, KS
   Kim, T
   An, H
   Ma, JY
AF Ha, Hyunil
   Shim, Ki Shuk
   Kim, Taesoo
   An, Hyosun
   Ma, Jin Yeul
TI Water Extract of Dryopteris crassirhizoma Attenuates Bone Loss by
   Suppressing Osteoclast Differentiation and Function
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID NF KAPPA B; NFATC1 INDUCTION; C FOS; RANKL; ACTIVATION; PHOSPHORYLATION;
   TRANSACTIVATION; CONSTITUENTS; SERINE 536; PATHWAYS
AB The rhizome of Dryopteris crassirhizoma has been used as a traditional herbal medicine for treating various inflammatory and infectious diseases such as tapeworm infestation and mumps. In the present study, we investigated the bone protective effect of water extract of the rhizome of Dryopteris crassirhizoma (WEDC). We found that WEDC inhibits osteoclast differentiation via directly acting on osteoclast precursors. In osteoclast precursors, WEDC inhibited receptor activator of nuclear factor kappa B ligand( RANKL ) induced expression of c Fos and nuclear factor of activated T cells cytoplasmic 1, a key downstream target of c Fos during osteoclast differentiation. We found that WEDC inhibits RNAKL induced activation of extracellular regulated kinase and NF kappa B that mediates c Fos expression and osteoclast differentiation. In addition to the inhibitory effect of osteoclast differentiation, WEDC markedly suppressed bon resorbing activity of mature osteoclasts, which was accompanied by disruption of actin ring structure. Furthermore, administration of WEDC suppressed RANKL induced trabecular bone loss in mice. Collectively, our results demonstrate that WEDC inhibits not only osteoclast differentiation by inhibiting RANK signaling pathways in osteoclast precursors but also bone resorption by disrupting actin ring in mature osteoclasts, thereby contributing to its protective effect on bone loss.
C1 [Ha, Hyunil; Shim, Ki Shuk; Kim, Taesoo; An, Hyosun; Ma, Jin Yeul] Korea Inst Oriental Med, KM Based Herbal Drug Res Grp, Taejon 305811, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM)
RP Ma, JY (通讯作者)，Korea Inst Oriental Med, KM Based Herbal Drug Res Grp, Taejon 305811, South Korea.
EM jyma@kiom.re.kr
FU Korea Institute of Oriental Medicine, Ministry of Education, Science,
   and Technology, Republic of Korea [K13050]
FX This work was supported by a grant (K13050) from the Korea Institute of
   Oriental Medicine, Ministry of Education, Science, and Technology,
   Republic of Korea.
CR Bae K. H., 2008, MED PLANTS KOREA
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chang SH, 2010, J ETHNOPHARMACOL, V130, P248, DOI 10.1016/j.jep.2010.04.038
   Chang X, 2006, CHEM PHARM BULL, V54, P748, DOI 10.1248/cpb.54.748
   Doyle SL, 2005, J BIOL CHEM, V280, P23496, DOI 10.1074/jbc.C500053200
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111
   Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Kapadia GJ, 1996, CANCER LETT, V105, P161, DOI 10.1016/0304 3835(96)04275 9
   Kim HJ, 2007, MOL PHARMACOL, V72, P418, DOI 10.1124/mol.107.034173
   Kwon DY, 2007, FITOTERAPIA, V78, P430, DOI 10.1016/j.fitote.2007.03.026
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee HB, 2009, ARCH PHARM RES, V32, P655, DOI 10.1007/s12272 009 1502 9
   Lee JS, 2008, CHEM PHARM BULL, V56, P711, DOI 10.1248/cpb.56.711
   Lee JH, 2009, J BIOL CHEM, V284, P13725, DOI 10.1074/jbc.M806941200
   Lee SY, 2003, J IND ENG CHEM, V9, P9
   Min BS, 2001, CHEM PHARM BULL, V49, P546, DOI 10.1248/cpb.49.546
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Na M, 2006, BIOORG MED CHEM LETT, V16, P4738, DOI 10.1016/j.bmcl.2006.07.018
   Soysa NS, 2009, J BONE MINER METAB, V27, P131, DOI 10.1007/s00774 008 0026 6
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1857
   Tomimori Y, 2009, J BONE MINER RES, V24, P1194, DOI [10.1359/JBMR.090217, 10.1359/jbmr.090217]
   Walsh MC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004064
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630
   Yang Y, 2013, J ETHNOPHARMACOL, V145, P499, DOI 10.1016/j.jep.2012.11.019
NR 30
TC 8
Z9 9
U1 0
U2 6
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PY 2013
VL 2013
AR 852648
DI 10.1155/2013/852648
PG 10
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA 158HM
UT WOS:000319960100001
PM 23762163
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Khor, EC
   Abel, T
   Tickner, J
   Chim, SM
   Wang, C
   Cheng, T
   Ng, B
   Ng, PY
   Teguh, DA
   Kenny, J
   Yang, XH
   Chen, HH
   Nakayama, KI
   Nakayama, K
   Pavlos, N
   Zheng, MH
   Xu, JK
AF Khor, Ee Cheng
   Abel, Tamara
   Tickner, Jennifer
   Chim, Shek Man
   Wang, Cathy
   Cheng, Taksum
   Benjamin Ng
   Pei Ying Ng
   Teguh, Dian Astari
   Kenny, Jacob
   Yang, Xiaohong
   Chen, Honghui
   Nakayama, Keiichi I.
   Nakayama, Keiko
   Pavlos, Nathan
   Zheng, Ming H.
   Xu, Jiake
TI Loss of Protein Kinase C δ Protects against LPS Induced Osteolysis Owing
   to an Intrinsic Defect in Osteoclastic Bone Resorption
SO PLOS ONE
LA English
DT Article
ID NF KAPPA B; TYROSINE PHOSPHATASE; SRC KINASE; RECEPTOR ACTIVATOR;
   GENE EXPRESSION; INHIBITS OSTEOCLASTOGENESIS; ALPHA(V)BETA(3) INTEGRIN;
   OSTEOPROTEGERIN LIGAND; DIFFERENTIATION FACTOR; TARGETED DISRUPTION
AB Bone remodeling is intrinsically regulated by cell signaling molecules. The Protein Kinase C (PKC) family of serine/threonine kinases is involved in multiple signaling pathways including cell proliferation, differentiation, apoptosis and osteoclast biology. However, the precise involvement of individual PKC isoforms in the regulation of osteoclast formation and bone homeostasis remains unclear. Here, we identify PKC delta as the major PKC isoform expressed among all PKCs in osteoclasts; including classical PKCs ( alpha,  beta and  gamma), novel PKCs ( delta,  epsilon,  eta and  theta) and atypical PKCs ( iota/lambda and  lambda). Interestingly, pharmacological inhibition and genetic ablation of PKC delta impairs osteoclastic bone resorption in vitro. Moreover, disruption of PKC delta activity protects against LPS induced osteolysis in mice, with osteoclasts accumulating on the bone surface failing to resorb bone. Treatment with the PKC delta inhibitor Rottlerin, blocks LPS induced bone resorption in mice. Consistently, PKC delta deficient mice exhibit increased trabeculae bone containing residual cartilage matrix, indicative of an osteoclast rich osteopetrosis phenotype. Cultured ex vivo osteoclasts derived from PKC delta null mice exhibit decreased CTX 1 levels and MARKS phosphorylation, with enhanced formation rates. This is accompanied by elevated gene expression levels of cathepsin K and PKC  alpha,  gamma,  epsilon, as well as altered signaling of pERK and pcSrc416/527 upon RANKL induction, possibly to compensate for the defects in bone resorption. Collectively, our data indicate that PKC delta is an intrinsic regulator of osteoclast formation and bone resorption and thus is a potential therapeutic target for pathological osteolysis.
C1 [Khor, Ee Cheng; Wang, Cathy; Cheng, Taksum; Pei Ying Ng; Pavlos, Nathan; Zheng, Ming H.] Univ Western Australia, Sch Surg, Ctr Orthopaed Res, Nedlands, WA 6009, Australia.
   [Khor, Ee Cheng; Tickner, Jennifer; Chim, Shek Man; Benjamin Ng; Teguh, Dian Astari; Kenny, Jacob; Xu, Jiake] Univ Western Australia, Sch Pathol & Lab Med, Nedlands, WA 6009, Australia.
   [Abel, Tamara] Univ Western Australia, Ctr Microscopy Characterisat & Anal, Nedlands, WA 6009, Australia.
   [Yang, Xiaohong; Chen, Honghui] Jinan Univ, Affiliated Hosp 4, Coll Med, Guangzhou Inst Traumat Surg, Guangzhou, Guangdong, Peoples R China.
   [Nakayama, Keiichi I.] Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 812, Japan.
   [Nakayama, Keiko] Kyushu Univ, Med Inst Bioregulat, Dept Mol Genet, Fukuoka 812, Japan.
C3 University of Western Australia; University of Western Australia;
   University of Western Australia; Jinan University; Kyushu University;
   Kyushu University
RP Zheng, MH (通讯作者)，Univ Western Australia, Sch Surg, Ctr Orthopaed Res, Nedlands, WA 6009, Australia.
EM minghao.zheng@uwa.edu.au; jiake.xu@uwa.edu.au
RI ; Chim, Shek/AAK 6809 2020; Tickner, Jennifer/H 5965 2014; Nakayama,
   Keiichi/N 1527 2014; Ng, Ben/IZE 4541 2023
OI Pavlos, Nathan/0000 0001 7003 188X; Xu, Jiake/0000 0003 2021 8309;
   /0000 0002 2151 3433; Tickner, Jennifer/0000 0002 5020 0671; Zheng,
   Minghao/0000 0003 1185 4768; Kenny, Jacob/0000 0001 8169 9842
FU National Health and Medical Research Council [5138323]; National Natural
   Science Foundation of China (NSFC) [81228013]
FX This work was funded in part by grants from the National Health and
   Medical Research Council (number 5138323). This study was also supported
   by a grant from the National Natural Science Foundation of China (NSFC)
   (number 81228013). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Adapala NS, 2010, J BIOL CHEM, V285, P36745, DOI 10.1074/jbc.M110.124628
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Bakker A, 2003, METH MOLEC MED, V80, P19
   BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032
   Brandt DT, 2003, J BIOL CHEM, V278, P34073, DOI 10.1074/jbc.M211650200
   Buitrago C, 2011, MOL CELL ENDOCRINOL, V339, P81, DOI 10.1016/j.mce.2011.03.022
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Chiang CY, 1999, INFECT IMMUN, V67, P4231, DOI 10.1128/IAI.67.8.4231 4236.1999
   Cremasco V, 2012, J BONE MINER RES, V27, P2452, DOI 10.1002/jbmr.1701
   Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264 6021:3510095
   Gil Henn H, 2007, J CELL BIOL, V178, P1053, DOI 10.1083/jcb.200701148
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199
   Gutcher I, 2003, CELL MOL LIFE SCI, V60, P1061, DOI 10.1007/s00018 003 2281 y
   Ha J, 2011, CYTOKINE, V55, P48, DOI 10.1016/j.cyto.2011.03.026
   HELFRICH MH, 1991, BONE, V12, P411, DOI 10.1016/8756 3282(91)90030 M
   Horne WC, 2005, IMMUNOL REV, V208, P106, DOI 10.1111/j.0105 2896.2005.00335.x
   Huang L, 2000, AM J PATHOL, V156, P761, DOI 10.1016/S0002 9440(10)64942 5
   Humphries MJ, 2006, J BIOL CHEM, V281, P9728, DOI 10.1074/jbc.M507851200
   Jacquin C, 2006, J BONE MINER RES, V21, P67, DOI 10.1359/JBMR.051007
   Kikuchi T, 2001, J IMMUNOL, V166, P3574, DOI 10.4049/jimmunol.166.5.3574
   Kozuka Y, 2006, CALCIFIED TISSUE INT, V78, P125, DOI 10.1007/s00223 005 0149 x
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lampasso JD, 2002, J BONE MINER RES, V17, P1968, DOI 10.1359/jbmr.2002.17.11.1968
   Lee SW, 2003, BONE, V32, P217, DOI 10.1016/S8756 3282(02)00976 6
   Leitges M, 2001, J CLIN INVEST, V108, P1505
   Li Y, 2007, BLOOD, V109, P3839, DOI 10.1182/blood 2006 07 037994
   Lima F, 2009, MOL BIOL CELL, V20, P2697, DOI 10.1091/mbc.E08 10 1079
   Liu J, 2006, MOL CELL, V21, P467, DOI 10.1016/j.molcel.2005.12.020
   Margolis D, 2008, CALCIFIED TISSUE INT, V82, P66276
   Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200
   Moonga BS, 1996, CALCIFIED TISSUE INT, V59, P105, DOI 10.1007/s002239900095
   Moonga BS, 1998, EXP PHYSIOL, V83, P717, DOI 10.1113/expphysiol.1998.sp004153
   NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571
   Ozaki Y, 2009, BONE, V44, P1169, DOI 10.1016/j.bone.2009.01.375
   Pavlos NJ, 2011, MOL CELL BIOL, V31, P1551, DOI 10.1128/MCB.00834 10
   Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960 9822(99)80238 3
   Qin A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034132
   Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554 5565.2001
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rucci N, 2005, J CELL SCI, V118, P3263, DOI 10.1242/jcs.02436
   Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181
   Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835
   Shinohara M, 2012, J BONE MINER RES, V27, P2464, DOI 10.1002/jbmr.1703
   SISMEYDURRANT HJ, 1991, ORAL MICROBIOL IMMUN, V6, P378, DOI 10.1111/j.1399 302X.1991.tb00510.x
   Soltoff SP, 2007, TRENDS PHARMACOL SCI, V28, P453, DOI 10.1016/j.tips.2007.07.003
   Sorensen MG, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 250
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   SU YJ, 1992, ENDOCRINOLOGY, V131, P1497, DOI 10.1210/en.131.3.1497
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   TRACY S, 1995, J BIOL CHEM, V270, P10587, DOI 10.1074/jbc.270.18.10587
   Tu XL, 2007, DEV CELL, V12, P113, DOI 10.1016/j.devcel.2006.11.003
   WALKER DG, 1973, SCIENCE, V180, P875, DOI 10.1126/science.180.4088.875
   Wang C, 2003, J BONE MINER RES, V18, P2159, DOI 10.1359/jbmr.2003.18.12.2159
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yoshida K, 2002, J BIOL CHEM, V277, P48372, DOI 10.1074/jbc.M205485200
   Zheng XM, 2002, J BIOL CHEM, V277, P21922, DOI 10.1074/jbc.M201394200
   Zhuang L, 2007, LARYNGOSCOPE, V117, P841, DOI 10.1097/MLG.0b013e318033783a
   Zou W, 2002, J BONE MINER RES, V17, P1211, DOI 10.1359/jbmr.2002.17.7.1211
NR 68
TC 25
Z9 26
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD AUG 8
PY 2013
VL 8
IS 8
AR e70815
DI 10.1371/journal.pone.0070815
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 201ER
UT WOS:000323124000028
PM 23951014
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Meng, JH
   Hong, JQ
   Zhao, CC
   Zhou, CH
   Hu, B
   Yang, YT
   Jiang, GY
   Li, SH
   Shi, ZL
   Cai, XZ
   Yan, SG
AF Meng, Jiahong
   Hong, Jianqiao
   Zhao, Chenchen
   Zhou, Chenhe
   Hu, Bin
   Yang, Yute
   Jiang, Guangyao
   Li, Sihao
   Shi, Zhongli
   Cai, Xunzi
   Yan, Shigui
TI Low intensity pulsed ultrasound inhibits RANKL induced osteoclast
   formation via modulating ERK c Fos NFATc1 signaling cascades
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE LIPUS; osteoclast; ERK; c Fos; NFATc1
ID C FOS; MESENCHYMAL STEM; BONE FORMATION; FISH SCALES; DIFFERENTIATION;
   OSTEOBLAST; MODEL; LIPUS; STIMULATION; OSTEOLYSIS
AB Low intensity pulsed ultrasound (LIPUS), which is a noninvasive form of mechanical energy, has been utilized as a clinical therapy for bone fracture healing. However, the mechanism how LIPUS affects osteoclast formation and osteoclast activity, has not been fully detailed. Here we found that LIPUS inhibited RANKL induced osteoclast differentiation in vitro, characterized by decreased number and area of tartrate resistant acid phosphatase (TRAP) positive cells. Moreover, the expression levels of osteoclast specific gene were also suppressed by LIPUS treatment. Interestingly, F actin staining and resorption pit assay showed that LIPUS did not affect the bone resorptive activity of mature osteoclasts. Mechanistically, LIPUS achieved these inhibitory effects by disrupting the phosphorylation of ERK and subsequent activation of the osteoclastic transcription factors, c Fos and NFATc1. Collectively, our results demonstrated that LIPUS effectively suppresses osteoclast differentiation and osteoclast specific gene expression through the inhibition of ERK c Fos NFATC1 cascades.
C1 [Meng, Jiahong; Hong, Jianqiao; Zhao, Chenchen; Zhou, Chenhe; Hu, Bin; Yang, Yute; Jiang, Guangyao; Li, Sihao; Shi, Zhongli; Cai, Xunzi; Yan, Shigui] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Orthoped Surg, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.
   [Meng, Jiahong; Hong, Jianqiao; Zhao, Chenchen; Zhou, Chenhe; Hu, Bin; Yang, Yute; Jiang, Guangyao; Li, Sihao; Shi, Zhongli; Cai, Xunzi; Yan, Shigui] Zhejiang Univ, Orthoped Res Inst, Hangzhou 310009, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP Cai, XZ; Yan, SG (通讯作者)，Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Orthoped Surg, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.
EM 2506053@zju.edu.cn; zrjwsj@zju.edu.cn
RI ; Zhou, Chenhe/AAI 9226 2020
OI Yan, Shigui/0000 0001 9096 2868; 
FU National Natural Science Foundation of China [81772360, 31771106,
   81472113]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 81772360, No. 31771106 and No. 81472113). The
   authors have no conflicts of interest to declare.
CR Akisaka T, 2001, J BONE MINER RES, V16, P1248, DOI 10.1359/jbmr.2001.16.7.1248
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bandow K, 2007, J CELL PHYSIOL, V211, P392, DOI 10.1002/jcp.20944
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen SH, 2012, IEEE INT ULTRA SYM, P607, DOI 10.1109/ULTSYM.2012.0151
   Cheung WH, 2011, ULTRASOUND MED BIOL, V37, P231, DOI 10.1016/j.ultrasmedbio.2010.11.016
   Chiou WF, 2010, BRIT J PHARMACOL, V161, P321, DOI 10.1111/j.1476 5381.2010.00823.x
   Coskun ME, 2018, PHOTOMED LASER SURG, V36, P246, DOI 10.1089/pho.2017.4354
   Costa V, 2018, J CELL PHYSIOL, V233, P1558, DOI 10.1002/jcp.26058
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Feres MFN, 2016, ARCH ORAL BIOL, V70, P73, DOI 10.1016/j.archoralbio.2016.06.007
   Hanmoto T, 2017, BIOMED RES TOKYO, V38, P71, DOI 10.2220/biomedres.38.71
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hu XY, 2017, ACTA BIOMATER, V48, P479, DOI 10.1016/j.actbio.2016.11.022
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Inubushi T, 2013, BONE, V53, P497, DOI 10.1016/j.bone.2013.01.021
   Jingushi S, 2007, J ORTHOP SCI, V12, P35, DOI 10.1007/s00776 006 1080 3
   Jurdic P, 2006, EUR J CELL BIOL, V85, P195, DOI 10.1016/j.ejcb.2005.09.008
   Kusuyama J, 2014, J BIOL CHEM, V289, P10330, DOI 10.1074/jbc.M113.546382
   Liu Y, 2003, J BIOL CHEM, V278, P20603, DOI 10.1074/jbc.M212093200
   Liu ZF, 2012, ANGLE ORTHOD, V82, P48, DOI 10.2319/030711 164.1
   Manaka S, 2015, FEBS LETT, V589, P310, DOI 10.1016/j.febslet.2014.12.013
   Monici M, 2007, ACTA ASTRONAUT, V60, P383, DOI 10.1016/j.actaastro.2006.09.023
   Nakao J, 2014, BONE, V58, P17, DOI 10.1016/j.bone.2013.09.018
   Naruse K, 2003, J BONE MINER RES, V18, P360, DOI 10.1359/jbmr.2003.18.2.360
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Romano CL, 2009, ULTRASOUND MED BIOL, V35, P529, DOI 10.1016/j.ultrasmedbio.2008.09.029
   Stevenson DA, 2011, CLIN GENET, V80, P566, DOI 10.1111/j.1399 0004.2010.01619.x
   Suzuki N, 2016, COMP BIOCHEM PHYS A, V195, P26, DOI 10.1016/j.cbpa.2016.01.022
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Uddin SMZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073914
   Unsworth J, 2007, ULTRASOUND MED BIOL, V33, P1468, DOI 10.1016/j.ultrasmedbio.2006.12.003
   WANG SJ, 1994, J ORTHOP RES, V12, P40, DOI 10.1002/jor.1100120106
   Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143
   Wu SL, 2009, PATHOBIOLOGY, V76, P99, DOI 10.1159/000209387
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhao X, 2012, ULTRASOUND MED BIOL, V38, P238, DOI 10.1016/j.ultrasmedbio.2011.11.005
   Zhu HX, 2015, CLIN ORTHOP RELAT R, V473, P1830, DOI 10.1007/s11999 015 4154 8
NR 39
TC 22
Z9 25
U1 1
U2 11
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943 8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2018
VL 10
IS 9
BP 2901
EP 2910
PG 10
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA GY6EP
UT WOS:000448678900013
PM 30323876
DA 2025 08 17
ER

PT J
AU Siddiqui, JA
   Le Henaff, C
   Johnson, J
   He, ZM
   Rifkin, DB
   Partridge, NC
AF Siddiqui, Jawed A.
   Le Henaff, Carole
   Johnson, Joshua
   He, Zhiming
   Rifkin, Daniel B.
   Partridge, Nicola C.
TI Osteoblastic monocyte chemoattractant protein 1 (MCP 1) mediation of
   parathyroid hormone's anabolic actions in bone implicates TGF β
   signaling
SO BONE
LA English
DT Article
DE Osteoporosis; PTH; Bone; Chemokines; Monocyte chemoattractant protein 1
ID GROWTH FACTOR BETA; KAPPA B LIGAND; OSTEOCLAST DIFFERENTIATION; RECEPTOR
   ACTIVATOR; EXPRESSION; ALENDRONATE; CELLS; RECRUITMENT; FUSION; CCR2
AB Parathyroid hormone (PTH) is necessary for the regulation of calcium homeostasis and PTH (1 34) was the first approved osteoanabolic therapy for osteoporosis. It is well established that intermittent PTH increases bone formation and that bone remodeling and several cytokines and chemokines play an essential role in this process. Earlier, we had established that the chemokine, monocyte chemoattractant protein 1 (MCP 1/CCL2), was the most highly stimulated gene in rat bone after intermittent PTH injections. Nevertheless, MCP 1 function in bone appears to be complicated. To identify the primary cells expressing MCP 1 in response to PTH, we performed in situ hybridization of rat bone sections after hPTH (1 34) injections and showed that bone lining osteoblasts are the primary cells that express MCP 1 after PTH treatment. We previously demonstrated MCP 1's importance by showing that PTH's anabolic effects are abolished in MCP 1 null mice, further implicating a role for the chemokine in this process. To establish whether rhMCP 1 peptide treatment could rescue the anabolic effect of PTH in MCP 1 null mice, we treated 4 month old wild type (WT) mice with hPTH (1 34) and MCP  1 /mice with rhMCP 1 and/or hPTH (1 34) for 6 weeks. Micro computed tomography (mu CT) analysis of trabecular and cortical bone showed that MCP 1 injections for 6 weeks rescued the PTH anabolic effect in MCP  1 /mice. In fact, the combination of rhMCP 1 and hPTH (1 34) has a synergistic anabolic effect compared with monotherapies. Mechanistically, PTH enhanced transforming growth factor beta (TGF beta) signaling is abolished in the absence of MCP 1, while MCP 1 peptide treatment restores TGF beta signaling in the bone marrow. Here, we have shown that PTH regulates the transcription of the chemokine MCP 1 in osteoblasts and determined how MCP 1 affects bone cell function in PTH's anabolic actions. Taken together, our current work indicates that intermittent PTH stimulates osteoblastic secretion of MCP 1, which leads to increased TGF beta signaling, implicating it in PTH's anabolic actions.
C1 [Siddiqui, Jawed A.; Le Henaff, Carole; Johnson, Joshua; He, Zhiming; Partridge, Nicola C.] NYU, Coll Dent, Dept Mol Pathobiol, 345 East 24th St, New York, NY 10010 USA.
   [Rifkin, Daniel B.] NYU, Dept Cell Biol, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA.
   [Siddiqui, Jawed A.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.
C3 New York University; New York University; University of Nebraska System;
   University of Nebraska Medical Center
RP Partridge, NC (通讯作者)，NYU, Coll Dent, Dept Mol Pathobiol, 345 East 24th St, New York, NY 10010 USA.
EM ncp234@nyu.edu
RI ; Siddiqui, Jawed/G 9258 2017
OI Partridge, Nicola/0000 0002 5406 4814; Siddiqui,
   Jawed/0000 0003 1287 3004
FU National Institutes of Health CTSA [UL1 TR001445]; National Center for
   Advancing Translational Sciences [S10 OD010751]
FX This work was supported in part by the National Institutes of Health
   CTSA grant UL1 TR001445 from the National Center for Advancing
   Translational Sciences and by S10 OD010751 (to N.C.P.).
CR Balooch G, 2005, P NATL ACAD SCI USA, V102, P18813, DOI 10.1073/pnas.0507417102
   Binder NB, 2009, NAT MED, V15, P417, DOI 10.1038/nm.1945
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   CENTRELLA M, 1989, ENDOCRINOLOGY, V125, P199, DOI 10.1210/endo 125 1 199
   CENTRELLA M, 1988, P NATL ACAD SCI USA, V85, P5889, DOI 10.1073/pnas.85.16.5889
   Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Gilchrist A, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00386
   Gong XQ, 1997, J BIOL CHEM, V272, P11682, DOI 10.1074/jbc.272.18.11682
   Hopwood B, 2009, BONE, V44, P87, DOI 10.1016/j.bone.2008.08.120
   Khan UA, 2016, J CELL BIOCHEM, V117, P382, DOI 10.1002/jcb.25282
   Kim MS, 2006, J BIOL CHEM, V281, P1274, DOI 10.1074/jbc.M510156200
   Kim MS, 2005, J BIOL CHEM, V280, P16163, DOI 10.1074/jbc.M412713200
   Koh AJ, 2005, ENDOCRINOLOGY, V146, P4584, DOI 10.1210/en.2005 0333
   Kuo SW, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102221
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Le Henaff C, 2020, J BONE MINER RES, V35, P714, DOI 10.1002/jbmr.3930
   Li X, 2007, J BIOL CHEM, V282, P33098, DOI 10.1074/jbc.M611781200
   Li X, 2007, J BIOL CHEM, V282, P33086, DOI 10.1074/jbc.M705194200
   Lu Y, 2007, J CELL BIOCHEM, V101, P676, DOI 10.1002/jcb.21220
   Lu Y, 2007, CANCER RES, V67, P3646, DOI 10.1158/0008 5472.CAN 06 1210
   Miyamoto K, 2009, BIOCHEM BIOPH RES CO, V383, P373, DOI 10.1016/j.bbrc.2009.04.020
   Nakatani T, 2018, J BONE MINER RES, V33, P1362, DOI 10.1002/jbmr.3422
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   OREFFO ROC, 1989, BIOCHEM BIOPH RES CO, V158, P817, DOI 10.1016/0006 291X(89)92795 2
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Patel H, 2014, ENDOCR PRACT, V20, P1165, DOI 10.4158/EP14104.OR
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   RAHIMI P, 1995, ENDOCRINOLOGY, V136, P2752, DOI 10.1210/en.136.6.2752
   Siddiqui JA, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 15563 7
   Siddiqui JA, 2016, PHYSIOLOGY, V31, P233, DOI 10.1152/physiol.00061.2014
   Siddiqui JA, 2010, MOL CELL ENDOCRINOL, V323, P256, DOI 10.1016/j.mce.2010.03.024
   Siddiqui JA, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00049
   Silva BC, 2011, J ENDOCRINOL INVEST, V34, P801, DOI 10.3275/7925
   Tamasi JA, 2013, J BONE MINER RES, V28, P1975, DOI 10.1002/jbmr.1933
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   THOMPSON DD, 1988, P NATL ACAD SCI USA, V85, P5673, DOI 10.1073/pnas.85.15.5673
   Wain JH, 2002, CLIN EXP IMMUNOL, V127, P436, DOI 10.1046/j.1365 2249.2002.01764.x
   Wu XW, 2010, CELL STEM CELL, V7, P571, DOI 10.1016/j.stem.2010.09.012
   Wu YH, 2000, J BONE MINER RES, V15, P879, DOI 10.1359/jbmr.2000.15.5.879
   Yang XW, 2016, CLIN LAB, V62, P2173, DOI 10.7754/Clin.Lab.2016.160408
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zheng LW, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0027 6
NR 46
TC 14
Z9 15
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD FEB
PY 2021
VL 143
AR 115762
DI 10.1016/j.bone.2020.115762
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA PN8QB
UT WOS:000604736100012
PM 33212319
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Yewle, JN
   Puleo, DA
   Bachas, LG
AF Yewle, Jivan N.
   Puleo, David A.
   Bachas, Leonidas G.
TI Enhanced Affinity Bifunctional Bisphosphonates for Targeted Delivery of
   Therapeutic Agents to Bone
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID DRUG DELIVERY; PHARMACEUTICAL NANOCARRIERS; BIOMEDICAL APPLICATIONS;
   OSTEOPOROSIS; MECHANISMS; PH; SYSTEMS; HYDROXYAPATITE; INTELLIGENT;
   DERIVATIVES
AB Skeletal diseases have a major impact on the worldwide population and economy. Although several therapeutic agents and treatments are available for addressing bone diseases, they are not being fully utilized because of their uptake in nontargeted sites and related side effects. Active targeting with controlled delivery is an ideal approach for treatment of such diseases. Because bisphosphonates are known to have high affinity to bone and are being widely used in treatment of osteoporosis, they are well suited for drug targeting to bone. In this study, a targeted delivery of therapeutic agent to resorption sites and wound healing sites of bone was explored. Toward this goal, bifunctional hydrazine bisphosphonates (HBPs), with spacers of various lengths, were synthesized and studied for their enhanced affinity to bone. Crystal growth inhibition studies showed that these HBPs have high affinity to hydroxyapatite, and HBPs with shorter spacers bind more strongly than alendronate to hydroxyapatite. The HBPs did not affect proliferation of MC3T3 E1 preosteoblasts, did not induce apoptosis, and were not cytotoxic at the concentration range tested (10( 6) 10( 4) M). Furthermore, drugs can be linked to the HBPs through a hydrazone linkage that is cleavable at the low pH of bone resorption and wound healing sites, leading to release of the drug. This was demonstrated using hydroxyapatite as a model material of bone and 4 nitrobenzaldehyde as a model drug. This study suggests that these HBPs could be used for targeted delivery of therapeutic agents to bone.
C1 [Bachas, Leonidas G.] Univ Miami, Dept Chem, Coral Gables, FL 33146 USA.
   [Yewle, Jivan N.] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.
   [Puleo, David A.] Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA.
C3 University of Miami; University of Kentucky; University of Kentucky
RP Bachas, LG (通讯作者)，Univ Miami, Dept Chem, 1301 Mem Dr, Coral Gables, FL 33146 USA.
EM bachas@miami.edu
RI Bachas, Leonidas/G 2479 2015
OI Bachas, Leonidas/0000 0002 3308 6264
FU US Army Medical Research and Materiel Command [W81XWH 09 1 0461];
   National Institutes of Health [AR048700]; University of Kentucky for a
   Research Challenge Trust
FX This research was supported by the US Army Medical Research and Materiel
   Command (W81XWH 09 1 0461) and the National Institutes of Health
   (AR048700). J.Y. thanks the University of Kentucky for a Research
   Challenge Trust Fund fellowship supporting this research. We thank Drs.
   M. Watson, A. Cammers, Y. Wei, E. Dikici, and E. Zahran for useful
   discussions.
CR Årstad E, 2003, J MED CHEM, V46, P3021, DOI 10.1021/jm021107v
   Betre H, 2006, J CONTROL RELEASE, V115, P175, DOI 10.1016/j.jconrel.2006.07.022
   Blower P, 2006, DALTON T, P1705, DOI 10.1039/b516860k
   Chapurlat RD, 2006, NAT CLIN PRACT ENDOC, V2, P211, DOI 10.1038/ncpendmet0121
   Chebbi I, 2010, INT J PHARMACEUT, V383, P116, DOI 10.1016/j.ijpharm.2009.09.011
   de Rosales RTM, 2010, BIOCONJUGATE CHEM, V21, P811, DOI 10.1021/bc100071k
   Deal C, 2009, CURR OPIN RHEUMATOL, V21, P380, DOI 10.1097/BOR.0b013e32832cbc2a
   Doschak MR, 2009, MOL PHARMACEUT, V6, P634, DOI 10.1021/mp8002368
   Ehrick RS, 2008, BIOCONJUGATE CHEM, V19, P315, DOI 10.1021/bc700196q
   El Mabhouh A, 2004, CANCER BIOTHER RADIO, V19, P627, DOI 10.1089/cbr.2004.19.627
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Gil L, 1999, BIOORGAN MED CHEM, V7, P901, DOI 10.1016/S0968 0896(99)00045 0
   Goltzman D, 2002, NAT REV DRUG DISCOV, V1, P784, DOI 10.1038/nrd916
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Herczegh P, 2002, J MED CHEM, V45, P2338, DOI 10.1021/jm0105326
   Hirabayashi H, 2001, J CONTROL RELEASE, V70, P183, DOI 10.1016/S0168 3659(00)00355 2
   Kale AA, 2007, BIOCONJUGATE CHEM, V18, P363, DOI 10.1021/bc060228x
   Kieczykowski GR, 1995, J ORG CHEM, V60, P8310, DOI 10.1021/jo00130a036
   KOUTSOUKOS P, 1980, J AM CHEM SOC, V102, P1553, DOI 10.1021/ja00525a015
   Langer R, 2003, AICHE J, V49, P2990, DOI 10.1002/aic.690491202
   Langer R, 2001, SCIENCE, V293, P58, DOI 10.1126/science.1063273
   LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0
   Lumachi F, 2008, CURR MED CHEM, V15, P415, DOI 10.2174/092986708783497346
   MacEwan SR, 2010, BIOPOLYMERS, V94, P60, DOI 10.1002/bip.21327
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Ogawa K, 2006, J NUCL MED, V47, P2042
   Oh YK, 2009, BIOCONJUGATE CHEM, V20, P1813, DOI 10.1021/bc900260x
   Ora M, 2008, J ORG CHEM, V73, P4123, DOI 10.1021/jo800317e
   ORME MW, 1994, BIOORG MED CHEM LETT, V4, P1375, DOI 10.1016/S0960 894X(01)80365 6
   Pan HZ, 2006, J DRUG TARGET, V14, P425, DOI 10.1080/10611860600834219
   Peppas N.  A., 2006, Annales Pharmaceutiques Francaises, V64, P260
   Peppas NA, 2004, ADV DRUG DELIVER REV, V56, P1529, DOI 10.1016/j.addr.2004.07.001
   Polascik TJ, 2008, DRUG DES DEV THER, V3, P27
   Prommer EE, 2009, J PALLIAT MED, V12, P1061, DOI 10.1089/jpm.2009.9936
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Rodan GA, 1998, ANNU REV PHARMACOL, V38, P375, DOI 10.1146/annurev.pharmtox.38.1.375
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270
   Sawant RM, 2006, BIOCONJUGATE CHEM, V17, P943, DOI 10.1021/bc060080h
   Schneider LA, 2007, ARCH DERMATOL RES, V298, P413, DOI 10.1007/s00403 006 0713 x
   Segal E, 2011, BIOMATERIALS, V32, P4450, DOI 10.1016/j.biomaterials.2011.02.059
   Segal E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005233
   SUNBERG RJ, 1991, CHEMTECH, V21, P304
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Thompson W.J., 1989, Patent No. [EP0341961, 0341961]
   Uludag H, 2002, CURR PHARM DESIGN, V8, P1929, DOI 10.2174/1381612023393585
   vanBeek E, 1996, J BONE MINER RES, V11, P1492
   Vondracek SF, 2009, CLIN INTERV AGING, V4, P121
   Wang D, 2007, BIOCONJUGATE CHEM, V18, P1375, DOI 10.1021/bc7002132
   Wang D, 2006, MOL PHARMACEUT, V3, P717, DOI 10.1021/mp0600539
   Wang JB, 2005, CHINESE CHEM LETT, V16, P859
   Xu SJ, 2006, J DRUG TARGET, V14, P367, DOI 10.1080/10611860600834011
   Zaheer A, 2001, NAT BIOTECHNOL, V19, P1148, DOI 10.1038/nbt1201 1148
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
   ZHENG H, 1997, Patent No. 5698542
NR 56
TC 33
Z9 42
U1 0
U2 32
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043 1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD DEC
PY 2011
VL 22
IS 12
BP 2496
EP 2506
DI 10.1021/bc2003132
PG 11
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 864FL
UT WOS:000298222300016
PM 22073906
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Datta, NS
   Pettway, GJ
   Chen, C
   Koh, AJ
   McCauley, LK
AF Datta, Nabanita S.
   Pettway, Glenda J.
   Chen, Chen
   Koh, Amy J.
   McCauley, Laurie K.
TI Cyclin D1 as a target for the proliferative effects of PTH and PTHrP in
   early osteoblastic cells
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE PTH; PTH related peptide; osteoblasts; cyclin D1; proliferation
ID HORMONE RELATED PROTEIN; OSTEOGENESIS IN VITRO; PARATHYROID HORMONE;
   DNA SYNTHESIS; SIGNAL TRANSDUCTION; OSTEOSARCOMA CELLS; ANABOLIC
   ACTIONS; MESSENGER RNA; SAOS 2 CELLS; BONE CELLS
AB PTHrP induced a proliferative cyclin D1 activation in low density osteoblastic cells. The process was PKA and MAPK dependent and involved both AP 1 and CRE sites. In ectopic ossicles generated from implanted bone marrow stromal cells, PTH unpregulated cyclin D1 after acute or intermittent anabolic treatment. These data suggest a positive role of PTH and PTHrP in the cell cycle of early osteoblasts.
   Introduction: The mechanisms underlying the actions of PTH and its related protein (PTHrP) in osteoblast proliferation.. differentiation, and bone remodeling remain unclear. The action of PTH or PTHrP on the cell cycle during osteoblast proliferation was studied.
   Materials and Methods: Mouse calvarial MC3T3 E1 clone 4 cells were synchronized by serum starvation and induced with 100 nM PTHrP for 2 24 h under defined low serum conditions. Western blot, real time PCR, EMSAs, and promoter/luciferase assays were performed to evaluate cyclin D1 expression. Pharmacological inhibitors were used to determine the relevant signaling pathways. Ectopic ossicles generated from implanted bone marrow stromal cells were treated with acute (a single 8  or 12 h injection) or intermittent anabolic PTH treatment for 7 days, and RNA and histologic analysis were performed.
   Results: PTHrP upregulated cyclin D1 and CDK1 and decreased p27 expression. Cyclin D1 promoter/ luciferase assays showed that the PTHrP regulation involved both activator protein 1 (AP 1) and cyclic AMP response element binding protein (CRE) sites. AP 1 and CRE double mutants completely abolished the PTHrP effect of cyclin D1 transcription. Upregulation of cyclin D1. was found to be protein kinase A (PKA) and mitogen activated protein kinase (MAPK) dependent in proliferating MC3T3 E1 cells. In vivo expression of cyclin D1 in ectopic ossicles was upregulated after a single 12 h PTH injection or intermittent anabolic PTH treatment for 7 days in early developing ossicles.
   Conclusions: These data indicate that PTH and PTHrP induce cyclin D1 expression in early osteoblastic cells and their action is developmental stage specific.
C1 Univ Michigan, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.
   Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA.
   Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan
RP Datta, NS (通讯作者)，Univ Michigan, Dept Periodont & Oral Med, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.
EM nsdatta@umich.edu
RI McCauley, Laurie/G 4041 2012
FU NIDCR NIH HHS [DE016865, DE14073] Funding Source: Medline; NIDDK NIH HHS
   [DK53904] Funding Source: Medline
CR ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732
   Albanese C, 2003, MOL BIOL CELL, V14, P585, DOI 10.1091/mbc.02 06 0101
   AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611
   AUBIN JE, 2002, PRINCIPLES BONE BIOL, P1
   Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056
   Beck GR, 2001, CELL GROWTH DIFFER, V12, P61
   Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433
   Beier F, 2002, MOL ENDOCRINOL, V16, P2163, DOI 10.1210/me.2001 0103
   Beier F, 2001, MOL BIOL CELL, V12, P3852, DOI 10.1091/mbc.12.12.3852
   BELLOWS CG, 1990, ENDOCRINOLOGY, V127, P3111, DOI 10.1210/endo 127 6 3111
   Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609
   Chen C, 2004, J BIOL CHEM, V279, P29121, DOI 10.1074/jbc.M313000200
   Chen HL, 2002, J BIOL CHEM, V277, P19374, DOI 10.1074/jbc.M108913200
   Cole JA, 1999, ENDOCRINOLOGY, V140, P5771, DOI 10.1210/en.140.12.5771
   Cornish J, 1999, J BONE MINER RES, V14, P915, DOI 10.1359/jbmr.1999.14.6.915
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0
   Datta NS, 2005, J BONE MINER RES, V20, P1051, DOI 10.1359/JBMR.050106
   Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499
   Drissi H, 1999, CANCER RES, V59, P3705
   Du P, 2000, BONE, V26, P429, DOI 10.1016/S8756 3282(00)00264 7
   Freitas PHL, 2006, J BONE MINER RES, V21, pS321
   FUKAYAMA S, 1994, ENDOCRINOLOGY, V134, P1851, DOI 10.1210/en.134.4.1851
   Galindo M, 2005, J BIOL CHEM, V280, P20274, DOI 10.1074/jbc.M413665200
   HARRIS SA, 1995, J BONE MINER RES, V10, P178
   Higuchi C, 2002, J BONE MINER RES, V17, P1785, DOI 10.1359/jbmr.2002.17.10.1785
   KANO J, 1993, J BONE MINER RES, V8, P323
   KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277
   KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092 8674(94)90257 7
   Lanske B, 1998, CRIT REV EUKAR GENE, V8, P297, DOI 10.1615/CritRevEukarGeneExpr.v8.i3 4.40
   Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663
   LING Q, 2004, TRENDS ENDOCRIN MET, V15, P60
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Mashiba T, 2001, BONE, V28, P538, DOI 10.1016/S8756 3282(01)00433 1
   MCCALL MN, 2001, P SOC PHOTO OPT INS, V2, P142
   MCDONALD BR, 1986, ENDOCRINOLOGY, V118, P2445
   MCSHEEHY PMJ, 1986, ENDOCRINOLOGY, V118, P824, DOI 10.1210/endo 118 2 824
   MIAO D, 2005, J CLIN INVEST, V115, P2322
   Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200
   NAKAMURA T, 1983, J BIOCHEM, V94, P1029, DOI 10.1093/oxfordjournals.jbchem.a134444
   Nasu M, 2000, J ENDOCRINOL, V167, P305, DOI 10.1677/joe.0.1670305
   Onishi T, 1997, J BONE MINER RES, V12, P1596, DOI 10.1359/jbmr.1997.12.10.1596
   Onishi T, 1997, ENDOCRINOLOGY, V138, P1995, DOI 10.1210/en.138.5.1995
   Onyia JE, 1997, BONE, V20, P93, DOI 10.1016/S8756 3282(96)00350 X
   Parfitt AM, 1990, BONE, P351
   PARTRIDGE NC, 1985, CALCIFIED TISSUE INT, V37, P519, DOI 10.1007/BF02557835
   Peterson WJ, 2004, CELL PROLIFERAT, V37, P325, DOI 10.1111/j.1365 2184.2004.00316.x
   Peterson WJ, 1996, CELL PROLIFERAT, V29, P665, DOI 10.1111/j.1365 2184.1996.tb00980.x
   Pettway GJ, 2006, J BONE MINER RES, V21, pS114
   Pettway GJ, 2005, BONE, V36, P959, DOI 10.1016/j.bone.2005.02.015
   PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092 8674(89)90936 7
   Pines Jonathon, 1994, Seminars in Cell Biology, V5, P399, DOI 10.1006/scel.1994.1047
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Pratap J, 2003, CANCER RES, V63, P5357
   RAINALDI G, 1991, IN VITRO CELL DEV B, V27, P949
   Rajakumar RA, 1996, MOL ENDOCRINOL, V10, P867, DOI 10.1210/me.10.7.867
   Scheffrahn I, 2005, EXP CELL RES, V307, P427, DOI 10.1016/j.yexcr.2005.03.030
   Schneider A, 2003, J ORTHOP RES, V21, P859, DOI 10.1016/S0736 0266(03)00042 1
   SCUTT A, 1994, CALCIFIED TISSUE INT, V55, P208, DOI 10.1007/BF00425877
   Serra R, 1997, J CELL BIOL, V139, P541, DOI 10.1083/jcb.139.2.541
   Shen R, 2006, J BIOL CHEM, V281, P16347, DOI 10.1074/jbc.M603439200
   Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501
   Smith E, 2000, J BIOL CHEM, V275, P19992, DOI 10.1074/jbc.M001758200
   SMITH E, 1995, CANCER RES, V55, P5019
   Sowa H, 2002, J BIOL CHEM, V277, P36024, DOI 10.1074/jbc.M206030200
   Stewart AF, 2000, J BONE MINER RES, V15, P1517, DOI 10.1359/jbmr.2000.15.8.1517
   Sunters A, 1998, DEV GENET, V22, P386, DOI 10.1002/(SICI)1520 6408(1998)22:4<386::AID DVG8>3.0.CO;2 2
   Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378 1119(01)00798 3
   Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200
   WALSH CA, 1995, J BONE MINER RES, V10, P17
NR 69
TC 89
Z9 104
U1 1
U2 9
PU AMER SOC BONE & MINERAL RES
PI WASHINGTON
PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036 3309 USA
SN 0884 0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUL
PY 2007
VL 22
IS 7
BP 951
EP 964
DI 10.1359/JBMR.070328
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 181QQ
UT WOS:000247451600001
PM 17501623
OA Bronze
DA 2025 08 17
ER

EF